PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Fontemaggi, G; Gurtner, A; Damalas, A; Costanzo, A; Higashi, Y; Sacchi, A; Strano, S; Piaggio, G; Blandino, G				Fontemaggi, G; Gurtner, A; Damalas, A; Costanzo, A; Higashi, Y; Sacchi, A; Strano, S; Piaggio, G; Blandino, G			delta EF1 repressor controls selectively p53 family members during differentiation	ONCOGENE			English	Article						p73; p63; p53 family; delta EF1 transcriptional repressor	DROSOPHILA ZFH-1; ZINC-FINGER; P73; P63; EXPRESSION; PROLIFERATION; KERATINOCYTES; REGULATOR; PROTEINS; HOMOLOG	The discovery of two new p53 homologs, p73 and p63, has defined a family of transcription factors heavily involved in the control of growth suppression, apoptosis, differentiation and development. While p53-deficient mice undergo spontaneous tumors, p73 and p63 knockout mice exhibit severe developmental defects. We demonstrate here that p73 gene is an in vivo transcriptional target of the muscle regulatory factors MyoD, myogenin, Myf5 and Myf6. Ectopic expression of the transcriptional repressor delta EF1/ZEB/ zfhx1a counteracts MyoD/ Myf5-or MyoD/ Myf6- mediated transcriptional activation of p73. A distinct pattern of in vivo recruitment of muscle regulatory factors and delta EF1 on p73 regulatory regions was found between proliferating and differentiating muscle cells. We also found that dEF1 plays a role in the transcriptional regulation of p53 family members during keratinocytic differentiation. Mouse embryo. fibroblasts derived from delta EF1-deficient mice exhibit unbalanced expression of DNp63, TAp73 and Delta Np73 but not of TAp63 and p53. The analysis of tissues derived from delta EF1+/- mice exhibit a selective enrichment of DNp63 in skin.	Regina Elena Inst Canc Res, Dept Expt Oncol, I-00158 Rome, Italy; Rome Oncogenom Ctr, I-00158 Rome, Italy; Univ Roma Tor Vergata, Dept Dermatol, I-00133 Rome, Italy; Osaka Univ, Inst Mol & Cellular Biol, Suita, Osaka 5650871, Japan	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; University of Rome Tor Vergata; Osaka University	Blandino, G (corresponding author), Regina Elena Inst Canc Res, Dept Expt Oncol, Via Messi Oro,156, I-00158 Rome, Italy.	blandino@ifo.it	Costanzo, Antonio/D-3896-2012; Gurtner, Aymone/J-7217-2018; Fontemaggi, Giulia/K-9702-2016; gurtner, aymone/AAB-8843-2020; strano, sabrina/B-6743-2013; Piaggio, Giulia/J-7214-2018; Piaggio, Giulia/AAD-7336-2022; Costanzo, Antonio/GZG-2433-2022; Higashi, Yukihito/G-5343-2019; Blandino, Giovanni/B-1137-2013; Strano, Sabrina/K-9654-2016	Gurtner, Aymone/0000-0002-7661-9059; Fontemaggi, Giulia/0000-0001-8332-8842; gurtner, aymone/0000-0002-7661-9059; strano, sabrina/0000-0002-6341-4230; Piaggio, Giulia/0000-0003-2114-1892; Costanzo, Antonio/0000-0001-9697-2557; Blandino, Giovanni/0000-0002-6970-2241; 	Telethon [GGP030358] Funding Source: Medline	Telethon(Fondazione Telethon)		Bamberger C, 2002, J INVEST DERMATOL, V118, P133, DOI 10.1046/j.0022-202x.2001.01649.x; Blandino G, 2004, CELL CYCLE, V3, P886; De Laurenzi V, 2000, BIOCHEM BIOPH RES CO, V273, P342, DOI 10.1006/bbrc.2000.2932; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Fontemaggi G, 2001, MOL CELL BIOL, V21, P8461, DOI 10.1128/MCB.21.24.8461-8470.2001; FORTINI ME, 1991, MECH DEVELOP, V34, P113, DOI 10.1016/0925-4773(91)90048-B; GENETTA T, 1994, MOL CELL BIOL, V14, P6153, DOI 10.1128/MCB.14.9.6153; Higashi Y, 1997, J EXP MED, V185, P1467, DOI 10.1084/jem.185.8.1467; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; LAI ZC, 1993, P NATL ACAD SCI USA, V90, P4122, DOI 10.1073/pnas.90.9.4122; LUNDELL MJ, 1992, DEV BIOL, V154, P84, DOI 10.1016/0012-1606(92)90050-Q; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Morena A, 2002, BLOOD, V100, P96, DOI 10.1182/blood.V100.1.96; Postigo AA, 1997, EMBO J, V16, P3935, DOI 10.1093/emboj/16.13.3935; Takagi T, 1998, DEVELOPMENT, V125, P21; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607	19	40	41	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2005	24	49					7273	7280		10.1038/sj.onc.1208891	http://dx.doi.org/10.1038/sj.onc.1208891			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	982FA	16007124				2022-12-25	WOS:000233142100003
J	Takada, Y; Murakami, A; Aggarwal, BB				Takada, Y; Murakami, A; Aggarwal, BB			Zerumbone abolishes NF-kappa B and I kappa B alpha kinase activation leading to suppression of antiapoptotic and metastatic gene expression, upregulation of apoptosis, and downregulation of invasion	ONCOGENE			English	Article						carcinogens; NF-kappa B; TNF; IKK; inflammation; apoptosis; metastasis	TUMOR-NECROSIS-FACTOR; SIGNAL-TRANSDUCTION; P65 PHOSPHORYLATION; TRANSCRIPTIONAL REGULATION; GINGER SESQUITERPENE; DEPENDENT INDUCTION; SUBTROPICAL GINGER; ENDOTHELIAL-CELLS; CYCLIN D1; INHIBITOR	Zerumbone found in subtropical ginger Zingiber zerumbet Smith exhibits antiproliferative and antiinflammatory activityies but underlying molecular mechanisms are poorly understood. As several genes that regulate proliferation and apoptosis are regulated by nuclear factor (NF)-kappa B, we hypothesized that zerumbone mediates its activity through the modulation of NF-kappa B activation. We found that zerumbone suppressed NF-kappa B activation induced by tumor necrosis factor (TNF), okadaic acid, cigarette smoke condensate, phorbol myristate acetate, and H2O2 and that the suppression was not cell type specific. Interestingly, alpha-humulene, a structural analogue of zerumbone lacking the carbonyl group, was completely inactive. Besides being inducible, constitutively active NF-kappa B was also inhibited. NF-kappa B inhibition by zerumbone correlated with sequential suppression of the I kappa B alpha kinase activity, I kappa B alpha phosphorylation, I kappa B alpha degradation, p65 phosphorylation, p65 nuclear translocation, and p65 acylation. Zerumbone also inhibited the NF-kappa B-dependent reporter gene expression activated by TNF, TNFR1, TRADD, TRAF2, NIK, and IKK but not that activated by the p65 subunit of NF-kappa B. NF-kappa B regulated gene products, such as cyclin D1, COX-2, MMP-9 ICAM-1, c-Myc, survivin, IAP1, IAP2, XIAP, Bcl-2, Bcl-x(L), Bfl-1/A1, TRAF1 and FLIP, were all downregulated by zerumbone. This downregulation led to the potentiation of apoptosis induced by cytokines and chemotherapeutic agents. Zerumbone's inhibition of expression of these NF-kappa B regulated genes also correlated with the suppression of TNF-induced invasion activity. Overall, our results indicated that zerumbone inhibits the activation of NF-kappa B and NF-kappa B regulated gene expression induced by carcinogens and that this inhibition may provide a molecular basis for the prevention and treatment of cancer by zerumbone.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Cytokine Res Lab, Houston, TX 77030 USA; Kyoto Univ, Grad Sch Agr, Div Food Sci & Biotechnol, Kyoto 6068502, Japan	University of Texas System; UTMD Anderson Cancer Center; Kyoto University	Aggarwal, BB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Cytokine Res Lab, 1515 Holcombe Blvd,Box 143, Houston, TX 77030 USA.	aggarwal@mdanderson.org	Aggarwal, Bharat B/G-3388-2013		NATIONAL CANCER INSTITUTE [P01CA091844, P50CA097007] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA91844, P50 CA97007] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anto RJ, 2002, CARCINOGENESIS, V23, P1511, DOI 10.1093/carcin/23.9.1511; Bonizzi G, 1997, J IMMUNOL, V159, P5264; Catz SD, 2001, ONCOGENE, V20, P7342, DOI 10.1038/sj.onc.1204926; CHATURVEDI MM, 1994, J BIOL CHEM, V269, P14575; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; DEV S, 1956, CHEM IND-LONDON, P1051; DUYAO MP, 1992, J BIOL CHEM, V267, P16288; Garg A, 2002, LEUKEMIA, V16, P1053, DOI 10.1038/sj.leu.2402482; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Giri DK, 1998, J BIOL CHEM, V273, P14008, DOI 10.1074/jbc.273.22.14008; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; HIGUCHI M, 1995, BLOOD, V86, P2248, DOI 10.1182/blood.V86.6.2248.bloodjournal8662248; Hirschowitz E, 2002, GENE THER, V9, P81, DOI 10.1038/sj.gt.3301621; HISCOTT J, 1993, MOL CELL BIOL, V13, P6231, DOI 10.1128/MCB.13.10.6231; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Kirana C, 2003, NUTR CANCER, V45, P218, DOI 10.1207/S15327914NC4502_12; Kitayama T, 1999, J ORG CHEM, V64, P2667, DOI 10.1021/jo981593n; Kreuz S, 2001, MOL CELL BIOL, V21, P3964, DOI 10.1128/MCB.21.12.3964-3973.2001; Liotta L A, 1982, Cancer Metastasis Rev, V1, P277, DOI 10.1007/BF00124213; MAHON TM, 1995, J BIOL CHEM, V270, P28557, DOI 10.1074/jbc.270.48.28557; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Morris KR, 2003, INFECT IMMUN, V71, P1442, DOI 10.1128/IAI.71.3.1442-1452.2003; Mukhopadhyay A, 2002, ONCOGENE, V21, P8852, DOI 10.1038/sj.onc.1206048; Murakami A, 2004, INT J CANCER, V110, P481, DOI 10.1002/ijc.20175; Murakami A, 2003, BIOCHEM PHARMACOL, V66, P1253, DOI 10.1016/S0006-2952(03)00446-5; Murakami A, 2003, CANCER LETT, V195, P17, DOI 10.1016/S0304-3835(03)00058-2; Murakami A, 2003, MUTAT RES-FUND MOL M, V523, P151, DOI 10.1016/S0027-5107(02)00331-7; Murakami A, 2002, CARCINOGENESIS, V23, P795, DOI 10.1093/carcin/23.5.795; Murakami A, 1999, BIOSCI BIOTECH BIOCH, V63, P1811, DOI 10.1271/bbb.63.1811; Nasuhara Y, 1999, J BIOL CHEM, V274, P19965, DOI 10.1074/jbc.274.28.19965; Natarajan K, 1996, P NATL ACAD SCI USA, V93, P9090, DOI 10.1073/pnas.93.17.9090; Newman DJ, 2003, J NAT PROD, V66, P1022, DOI 10.1021/np030096l; OZAKI Y, 1991, CHEM PHARM BULL, V39, P2353, DOI 10.1248/cpb.39.2353; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Pomerantz JL, 2000, NATURE, V406, P26, DOI 10.1038/35017673; Schwenzer R, 1999, J BIOL CHEM, V274, P19368, DOI 10.1074/jbc.274.27.19368; SHAKHOV AN, 1990, J EXP MED, V171, P35, DOI 10.1084/jem.171.1.35; Shiraga M, 2002, CANCER RES, V62, P5967; Shishodia S, 2003, CANCER RES, V63, P4375; Simeonidis S, 1999, P NATL ACAD SCI USA, V96, P49, DOI 10.1073/pnas.96.1.49; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; STEVE PO, 2002, J BIOL CHEM, V277, P35150; Takada Y, 2004, J BIOL CHEM, V279, P26287, DOI 10.1074/jbc.M400963200; Takada Y, 2004, J BIOL CHEM, V279, P4750, DOI 10.1074/jbc.M304546200; Takada Y, 2003, J IMMUNOL, V171, P3278, DOI 10.4049/jimmunol.171.6.3278; Takada Y, 2003, J BIOL CHEM, V278, P24233, DOI 10.1074/jbc.M212389200; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531; Tanaka T, 2001, LIFE SCI, V69, P1935, DOI 10.1016/S0024-3205(01)01277-2; VANDESTOLPE A, 1994, J BIOL CHEM, V269, P6185; Verma IM, 1997, P NATL ACAD SCI USA, V94, P11758, DOI 10.1073/pnas.94.22.11758; VINITSKY A, 1992, BIOCHEMISTRY-US, V31, P9421, DOI 10.1021/bi00154a014; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Weinstein IB, 2000, CARCINOGENESIS, V21, P857, DOI 10.1093/carcin/21.5.857; Xu P, 1996, GENOMICS, V34, P173, DOI 10.1006/geno.1996.0262; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315; You MJ, 1997, MOL CELL BIOL, V17, P7328, DOI 10.1128/MCB.17.12.7328; Zhu L, 2001, FEBS LETT, V508, P369, DOI 10.1016/S0014-5793(01)03084-8; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	61	153	168	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2005	24	46					6957	6969		10.1038/sj.onc.1208845	http://dx.doi.org/10.1038/sj.onc.1208845			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	975ZD	16007145				2022-12-25	WOS:000232701700010
J	Kronblad, A; Hedenfalk, I; Nilsson, E; Pahlmann, S; Landberg, G				Kronblad, A; Hedenfalk, I; Nilsson, E; Pahlmann, S; Landberg, G			ERK1/2 inhibition increases antiestrogen treatment efficacy by interfering with hypoxia-induced downregulation of ER alpha: a combination therapy potentially targeting hypoxic and dormant tumor cells	ONCOGENE			English	Article						breast cancer; ERK1/2; MAPK; ER alpha; hypoxia; tamoxifen	HUMAN BREAST-CANCER; ACTIVATED PROTEIN-KINASE; ESTROGEN-RECEPTOR-ALPHA; POOR RESPONSE; BONE-MARROW; RT-PCR; EXPRESSION; GROWTH; RESISTANCE; PATHWAYS	Tumor hypoxia is associated with cancer invasiveness, metastasis and treatment failure. Recent data suggest that the major target for endocrine treatment in breast cancer, ER alpha, is downregulated during hypoxia, but the mechanism behind this remains unknown. MAPK signaling as well as ER alpha regulation has earlier been independently linked to hypoxia and we now demonstrate HIF-1 alpha and ERK1/2-activation in vivo towards the necrotic zone in DCIS of the breast, parallel with ER alpha downregulation. Hypoxia further caused transcriptional downregulation of ER alpha via activation of ERK1/2 in cell lines and, importantly, MEK1/2 inhibitors (U0126 or PD184352) or ERK1/2 suppression by siRNA partially restored the ERa expression. U0126 combined with tamoxifen accordingly produced an increased efficacy of the anti-estrogens during hypoxia. Base don these findings, we suggest a promising novel therapy for ER alpha-positive breast cancer where a combination of endocrine treatment and ERK1/2 inhibitors may increase treatment response by improved targeting of dormant hypoxic tumor cells.	Lund Univ, Malmo Univ Hosp, Dept Lab Med, Div Pathol, S-20502 Malmo, Sweden; Lund Univ, Malmo Univ Hosp, Dept Lab Med, Div Mol Med, S-20502 Malmo, Sweden	Lund University; Skane University Hospital; Lund University; Skane University Hospital	Landberg, G (corresponding author), Lund Univ, Malmo Univ Hosp, Dept Lab Med, Div Pathol, S-20502 Malmo, Sweden.	goran.landberg@pat.mas.lu.se		Hedenfalk, Ingrid/0000-0002-6840-3397				Ali S, 2002, NAT REV CANCER, V2, P101, DOI 10.1038/nrc721; Bhat-Nakshatri P, 2004, BRIT J CANCER, V90, P853, DOI 10.1038/sj.bjc.6601541; Brunnberg S, 2003, P NATL ACAD SCI USA, V100, P6517, DOI 10.1073/pnas.1136688100; Chen DS, 2002, ONCOGENE, V21, P4921, DOI 10.1038/sj.onc.1205420; Cho JY, 2005, MOL ENDOCRINOL, V19, P1191, DOI 10.1210/me.2004-0162; Clarke M, 1998, LANCET, V351, P1451; Cooper C, 2004, CLIN CANCER RES, V10, P8720, DOI 10.1158/1078-0432.CCR-04-1235; Coutts AS, 1998, CANCER RES, V58, P4071; Dokladda K, 2005, FEBS LETT, V579, P236, DOI 10.1016/j.febslet.2004.11.084; Duncia JV, 1998, BIOORG MED CHEM LETT, V8, P2839, DOI 10.1016/S0960-894X(98)00522-8; Gee JMW, 2003, ENDOCRINOLOGY, V144, P5105, DOI 10.1210/en.2003-0705; Gee JMW, 2001, INT J CANCER, V95, P247, DOI 10.1002/1097-0215(20010720)95:4<247::AID-IJC1042>3.0.CO;2-S; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Harrison JS, 2002, BLOOD, V99, P394, DOI 10.1182/blood.V99.1.394; Hedenfalk Ingrid, 2005, Cancer Genomics & Proteomics, V2, P83; Helczynska K, 2003, CANCER RES, V63, P1441; Holloway JN, 2004, MOL ENDOCRINOL, V18, P1396, DOI 10.1210/me.2004-0048; Hutcheson IR, 2003, BREAST CANCER RES TR, V81, P81, DOI 10.1023/A:1025484908380; Jogi A, 2004, EXP CELL RES, V295, P469, DOI 10.1016/j.yexcr.2004.01.013; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Johnston SRD, 2003, NAT REV CANCER, V3, P821, DOI 10.1038/nrc1211; Kronblad A, 2003, IN VIVO, V17, P311; Kurebayashi J, 2001, JPN J CANCER RES, V92, P1093, DOI 10.1111/j.1349-7006.2001.tb01064.x; Kuukasjarvi T, 1996, J CLIN ONCOL, V14, P2584, DOI 10.1200/JCO.1996.14.9.2584; LICHTMAN MA, 1981, EXP HEMATOL, V9, P391; Minet E, 2000, FEBS LETT, V468, P53, DOI 10.1016/S0014-5793(00)01181-9; Nicholson RI, 2004, CLIN CANCER RES, V10, p346S, DOI 10.1158/1078-0432.CCR-031206; Oh AS, 2001, MOL ENDOCRINOL, V15, P1344, DOI 10.1210/me.15.8.1344; Rostagno P, 1996, BREAST CANCER RES TR, V37, P77, DOI 10.1007/BF01806634; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Shawver LK, 2002, CANCER CELL, V1, P117, DOI 10.1016/S1535-6108(02)00039-9; Shim WS, 2000, ENDOCRINOLOGY, V141, P396, DOI 10.1210/en.141.1.396; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; SPATARO V, 1992, ANN ONCOL, V3, P733, DOI 10.1093/oxfordjournals.annonc.a058330; Stoner M, 2002, MOL ENDOCRINOL, V16, P2231, DOI 10.1210/me.2001-0347; Vandesompele J, 2002, ANAL BIOCHEM, V303, P95, DOI 10.1006/abio.2001.5564; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; VAUPEL P, 1989, CANCER RES, V49, P6449; Woelfle U, 2003, CANCER RES, V63, P5679; Yang ZB, 2004, CLIN CANCER RES, V10, P3621, DOI 10.1158/1078-0432.CCR-0740-3	40	37	39	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 13	2005	24	45					6835	6841		10.1038/sj.onc.1208830	http://dx.doi.org/10.1038/sj.onc.1208830			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	973MV	16007158				2022-12-25	WOS:000232527800011
J	Bradley, PJ; Ward, C; Cheng, SJ; Alexander, DL; Coller, S; Coombs, GH; Dunn, JD; Ferguson, DJ; Sanderson, SJ; Wastling, JM; Boothroyd, JC				Bradley, PJ; Ward, C; Cheng, SJ; Alexander, DL; Coller, S; Coombs, GH; Dunn, JD; Ferguson, DJ; Sanderson, SJ; Wastling, JM; Boothroyd, JC			Proteomic analysis of rhoptry organelles reveals many novel constituents for host-parasite interactions in Toxoplasma gondii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARASITOPHOROUS VACUOLE MEMBRANE; CELL INVASION; PLASMODIUM-FALCIPARUM; MICRONEME PROTEINS; APICAL ORGANELLES; DENSE GRANULES; IDENTIFICATION; GENE; ROP1; EXPRESSION	Rhoptries are specialized secretory organelles that are uniquely present within protozoan parasites of the phylum Apicomplexa. These obligate intracellular parasites comprise some of the most important parasites of humans and animals, including the causative agents of malaria ( Plasmodium spp.) and chicken coccidiosis ( Eimeria spp.). The contents of the rhoptries are released into the nascent parasitophorous vacuole during invasion into the host cell, and the resulting proteins often represent the literal interface between host and pathogen. We have developed a method for highly efficient purification of rhoptries from one of the best studied Apicomplexa, Toxoplasma gondii, and we carried out a detailed proteomic analysis using mass spectrometry that has identified 38 novel proteins. To confirm their rhoptry origin, antibodies were raised to synthetic peptides and/or recombinant protein. Eleven of 12 of these yielded antibody that showed strong rhoptry staining by immunofluorescence within the rhoptry necks and/or their bulbous base. Hemagglutinin epitope tagging confirmed one additional novel protein as from the rhoptry bulb. Previously identified rhoptry proteins from Toxoplasma and Plasmodium were unique to one or the other organism, but our elucidation of the Toxoplasma rhoptry proteome revealed homologues that are common to both. This study also identified the first Toxoplasma genes encoding rhoptry neck proteins, which we named RONs, demonstrated that toxofilin and Rab11 are rhoptry proteins, and identified novel kinases, phosphatases, and proteases that are likely to play a key role in the ability of the parasite to invade and co-opt the host cell for its own survival and growth.	Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA; Univ Calif Los Angeles, Dept Microbiol Mol Genet & Immunol, Los Angeles, CA 90095 USA; Univ Glasgow, Inst Biomed & Life Sci, Div Infect & Immun, Glasgow G12 8QQ, Lanark, Scotland; Univ Liverpool, Dept Preclin Vet Sci, Liverpool L69 7ZJ, Merseyside, England; Univ Liverpool, Dept Vet Pathol, Liverpool L69 7ZJ, Merseyside, England; Univ Oxford, John Radcliffe Hosp, Nuffield Dept Pathol, Oxford OX3 9DU, England	Stanford University; University of California System; University of California Los Angeles; University of Glasgow; University of Liverpool; University of Liverpool; University of Oxford	Boothroyd, JC (corresponding author), Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA.	john.boothroyd@stanford.edu		Dunn, Joe Dan/0000-0002-5091-4527; Ferguson, David/0000-0001-5045-819X; Boothroyd, John C./0000-0001-9719-745X	NIAID NIH HHS [F32AI10552, R01AI45057, R01AI 21423] Funding Source: Medline; NIGMS NIH HHS [T32GM07276] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI010552, R01AI045057, R01AI021423] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007276] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIKAWA M, 1990, EXP PARASITOL, V71, P326, DOI 10.1016/0014-4894(90)90037-D; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Anthony RN, 2000, J EUKARYOT MICROBIOL, V47, P319, DOI 10.1111/j.1550-7408.2000.tb00053.x; ASAI T, 1983, J BIOL CHEM, V258, P6816; Baldi DL, 2002, INFECT IMMUN, V70, P5236, DOI 10.1128/IAI.70.9.5236-5245.2002; Bannister LH, 2003, J CELL SCI, V116, P3825, DOI 10.1242/jcs.00665; BECKERS CJM, 1994, J CELL BIOL, V127, P947, DOI 10.1083/jcb.127.4.947; Beckers CJM, 1997, MOL BIOCHEM PARASIT, V89, P209, DOI 10.1016/S0166-6851(97)00120-5; Bendtsen JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028; Blackman MJ, 2001, MOL BIOCHEM PARASIT, V117, P11, DOI 10.1016/S0166-6851(01)00328-0; Bradley PJ, 2002, MOL BIOCHEM PARASIT, V125, P189, DOI 10.1016/S0166-6851(02)00162-7; Bradley PJ, 2001, INT J PARASITOL, V31, P1177, DOI 10.1016/S0020-7519(01)00242-9; Bradley PJ, 1999, MOL BIOCHEM PARASIT, V100, P103, DOI 10.1016/S0166-6851(99)00035-3; Brossier F, 2005, P NATL ACAD SCI USA, V102, P4146, DOI 10.1073/pnas.0407918102; Carey KL, 2004, EUKARYOT CELL, V3, P1320, DOI 10.1128/EC.3.5.1320-1330.2004; Carruthers VB, 1997, EUR J CELL BIOL, V73, P114; Carruthers Vern B., 1999, Parasitology International, V48, P1; CAVALIERSMITH T, 1993, MICROBIOL REV, V57, P953, DOI 10.1128/MMBR.57.4.953-994.1993; Conseil V, 1999, ANTIMICROB AGENTS CH, V43, P1358, DOI 10.1128/AAC.43.6.1358; Coppens I, 2003, MOL BIOL CELL, V14, P3804, DOI 10.1091/mbc.E02-12-0830; Coppens I, 2000, J CELL BIOL, V149, P167, DOI 10.1083/jcb.149.1.167; Cowman A F, 1984, Mol Biol Med, V2, P207; Delorme V, 2003, MOL BIOL CELL, V14, P1900, DOI 10.1091/mbc.E02-08-0462; DESOUZA W, 1978, Z PARASITENKD, V56, P123; Donald RGK, 1996, J BIOL CHEM, V271, P14010, DOI 10.1074/jbc.271.24.14010; Dubey J. P., 1977, PARASITIC PROTOZOA, V3, P101; Dubremetz JF, 1998, INT J PARASITOL, V28, P1007, DOI 10.1016/S0020-7519(98)00076-9; Ferguson DJP, 1999, EXP PARASITOL, V91, P203, DOI 10.1006/expr.1998.4384; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Gardiner DL, 2004, PARASITOL RES, V93, P590, DOI 10.1007/s00436-004-1098-4; Gromov P, 1998, ELECTROPHORESIS, V19, P1803, DOI 10.1002/elps.1150191043; Hakansson S, 2001, EMBO J, V20, P3132, DOI 10.1093/emboj/20.12.3132; He XL, 2002, NAT STRUCT BIOL, V9, P606, DOI 10.1038/nsb819; Hehl AB, 2000, INFECT IMMUN, V68, P7078, DOI 10.1128/IAI.68.12.7078-7086.2000; HOFMANN K, 1993, BIOL CHEM HOPPESEYLE, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; HOLDER AA, 1992, MEM I OSWALDO CRUZ, V87, P37, DOI 10.1590/S0074-02761992000700004; Holtta-Vuori M, 2002, MOL BIOL CELL, V13, P3107, DOI 10.1091/mbc.E02-01-0025; Hoppe HC, 2000, NAT CELL BIOL, V2, P449, DOI 10.1038/35017090; Kaneko O, 2001, MOL BIOCHEM PARASIT, V118, P223, DOI 10.1016/S0166-6851(01)00391-7; Karasov AO, 2005, INT J PARASITOL, V35, P285, DOI 10.1016/j.ijpara.2004.11.015; KASPER LH, 1983, J IMMUNOL, V130, P2407; Khan SM, 2001, MOL BIOCHEM PARASIT, V117, P1, DOI 10.1016/S0166-6851(01)00333-4; Kim K, 2004, INT J PARASITOL, V34, P423, DOI 10.1016/j.ijpara.2003.12.009; Kohler S, 1997, SCIENCE, V275, P1485, DOI 10.1126/science.275.5305.1485; Kong JT, 2003, J INFECT DIS, V187, P1484, DOI 10.1086/374647; LERICHE MA, 1991, MOL BIOCHEM PARASIT, V45, P249, DOI 10.1016/0166-6851(91)90092-K; LEVINE ND, 1988, J PROTOZOOL, V35, P518, DOI 10.1111/j.1550-7408.1988.tb04141.x; Lobo CA, 2003, MOL BIOCHEM PARASIT, V128, P59, DOI 10.1016/S0166-6851(03)00050-1; Meissner M, 2002, J CELL SCI, V115, P563; Miller SA, 2003, MOL MICROBIOL, V49, P883, DOI 10.1046/j.1365-2958.2003.03604.x; Miller SA, 2001, J BIOL CHEM, V276, P45341, DOI 10.1074/jbc.M106665200; Mohrmann K, 1999, MOL MEMBR BIOL, V16, P81, DOI 10.1080/096876899294797; Molestina RE, 2005, CELL MICROBIOL, V7, P351, DOI 10.1111/j.1462-5822.2004.00463.x; MORRISSETTE NS, 1994, EXP PARASITOL, V79, P445, DOI 10.1006/expr.1994.1106; Ngo HM, 2004, MOL MICROBIOL, V52, P1531, DOI 10.1111/j.1365-2958.2004.04056.x; NICHOLS BA, 1983, J ULTRA MOL STRUCT R, V83, P85, DOI 10.1016/S0022-5320(83)90067-9; Opitz C, 2002, MOL MICROBIOL, V45, P597, DOI 10.1046/j.1365-2958.2002.03056.x; OSSORIO PN, 1992, MOL BIOCHEM PARASIT, V50, P1, DOI 10.1016/0166-6851(92)90239-G; Poupel O, 2000, MOL BIOL CELL, V11, P355, DOI 10.1091/mbc.11.1.355; Que XC, 2002, J BIOL CHEM, V277, P25791, DOI 10.1074/jbc.M202659200; Reichmann G, 2002, MOL BIOCHEM PARASIT, V119, P43, DOI 10.1016/S0166-6851(01)00397-8; SADAK A, 1988, MOL BIOCHEM PARASIT, V29, P203, DOI 10.1016/0166-6851(88)90075-8; Sam-Yellowe TY, 2004, J PROTEOME RES, V3, P995, DOI 10.1021/pr049926m; SamYellowe TY, 1996, PARASITOL TODAY, V12, P308, DOI 10.1016/0169-4758(96)10030-2; Savina A, 2005, TRAFFIC, V6, P131, DOI 10.1111/j.1600-0854.2004.00257.x; SCHOFIELD L, 1991, PARASITOL TODAY, V7, P99, DOI 10.1016/0169-4758(91)90166-L; SCHWAB JC, 1994, P NATL ACAD SCI USA, V91, P509, DOI 10.1073/pnas.91.2.509; SCHWARTZMAN JD, 1986, INFECT IMMUN, V51, P760, DOI 10.1128/IAI.51.3.760-764.1986; Seabra MC, 1998, CELL SIGNAL, V10, P167, DOI 10.1016/S0898-6568(97)00120-4; Sinai AP, 2001, J CELL BIOL, V154, P95, DOI 10.1083/jcb.200101073; Soldati D, 1998, MOL BIOCHEM PARASIT, V96, P37, DOI 10.1016/S0166-6851(98)00090-5; Soldati D, 2001, INT J PARASITOL, V31, P1293, DOI 10.1016/S0020-7519(01)00257-0; Stenmark H, 2001, GENOME BIOL, V2; Striepen B, 2001, MOL BIOCHEM PARASIT, V113, P45, DOI 10.1016/S0166-6851(00)00379-0; Topolska AE, 2004, J BIOL CHEM, V279, P4648, DOI 10.1074/jbc.M307859200; WALLIS AE, 1994, EXP PARASITOL, V78, P161, DOI 10.1006/expr.1994.1016; Weiss LM, 2000, FRONT BIOSCI-LANDMRK, V5, pD391, DOI 10.2741/Weiss; Zhou XW, 2005, J BIOL CHEM, V280, P34233, DOI 10.1074/jbc.M504160200	78	293	325	0	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					34245	34258		10.1074/jbc.M504158200	http://dx.doi.org/10.1074/jbc.M504158200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16002398	hybrid			2022-12-25	WOS:000232229700067
J	Lucas, B; Grigo, K; Erdmann, S; Lausen, J; Klein-Hitpass, L; Ryffel, GU				Lucas, B; Grigo, K; Erdmann, S; Lausen, J; Klein-Hitpass, L; Ryffel, GU			HNF4 alpha reduces proliferation of kidney cells and affects genes deregulated in renal cell carcinoma	ONCOGENE			English	Article						HNF4 alpha; proliferation; microarray; renal cell carcinoma	TRANSCRIPTION FACTORS; C/EBP-ALPHA; EXPRESSION; LIVER; DIFFERENTIATION; CLASSIFICATION; HNF-4-ALPHA; INHIBITION; MUTATIONS; DISCOVERY	Hepatocyte nuclear factor 4 alpha (HNF4 alpha) is a tissue-specific transcription factor known to regulate a large number of genes in hepatocytes and pancreatic beta cells. Although HNF4 alpha is highly expressed in some sections of the kidney, little is known about its role in this organ and about HNF4 alpha-regulated genes in the kidney cells. The abundance and activity of HNF4 alpha are frequently reduced in renal cell carcinoma (RCC) indicating some tumor suppressing function of HNF4 alpha in renal cells. To determine the potential role of HNF4 alpha in RCC, we used Flp recombinase-mediated gene integration to generate human embryonic kidney cells (HEK293) that conditionally express wild-type or mutated HNF4a. Expression of wild-type HNF4 alpha but not of the mutants led to reduction of proliferation and alterations of cell morphology. These effects were reversible and induced at physiological concentrations of HNF4 alpha. Using gene expression pro. ling by microarrays, we determined genes regulated by HNF4 alpha. Interestingly, many of the genes regulated by HNF4 alpha have been shown to be deregulated in RCC microarray studies. These genes (ACY1, WT1, SELENBP1, COBL, EFHD1, AGXT2L1, ALDH5A1, THEM2, ABCB1, FLJ14146, CSPG2, TRIM9 and HEY1) are good candidates for genes whose activity is changed upon the decrease of HNF4 alpha in RCC.	Univ Klinikum Essen, Inst Zellbiol, D-45122 Essen, Germany	University of Duisburg Essen	Ryffel, GU (corresponding author), Univ Klinikum Essen, Inst Zellbiol, D-45122 Essen, Germany.	gerhart.ryffel@uni-essen.de						[Anonymous], 2001, NUCL RECEPTORS GENET; Berasain C, 2003, HEPATOLOGY, V38, P148, DOI 10.1053/jhep.2003.50269; Blondeau F, 2000, HUM MOL GENET, V9, P2223, DOI 10.1093/oxfordjournals.hmg.a018913; Boer JM, 2001, GENOME RES, V11, P1861, DOI 10.1101/gr.184501; Chabardes-Garonne D, 2003, P NATL ACAD SCI USA, V100, P13710, DOI 10.1073/pnas.2234604100; CHEN WS, 1994, GENE DEV, V8, P2466, DOI 10.1101/gad.8.20.2466; Chiba H, 2005, EXP CELL RES, V302, P11, DOI 10.1016/j.yexcr.2004.08.014; Choi JK, 2004, FEBS LETT, V565, P93, DOI 10.1016/j.febslet.2004.03.081; DELSAL G, 1994, P NATL ACAD SCI USA, V91, P1848, DOI 10.1073/pnas.91.5.1848; Drewes T, 1996, MOL CELL BIOL, V16, P925; Gieseg MA, 2002, BMC BIOINFORMATICS, V3, DOI 10.1186/1471-2105-3-26; Grewal JS, 2005, BIOCHEM J, V387, P609, DOI 10.1042/BJ20041465; Gupta RK, 2004, TRENDS MOL MED, V10, P521, DOI 10.1016/j.molmed.2004.09.004; Hattersley AT, 1998, DIABETIC MED, V15, P15, DOI 10.1002/(SICI)1096-9136(199801)15:1<15::AID-DIA562>3.0.CO;2-M; Hayhurst GP, 2001, MOL CELL BIOL, V21, P1393, DOI 10.1128/MCB.21.4.1393-1403.2001; Higgins JPT, 2003, AM J PATHOL, V162, P925, DOI 10.1016/S0002-9440(10)63887-4; HILL KE, 1993, P NATL ACAD SCI USA, V90, P537, DOI 10.1073/pnas.90.2.537; Ishiyama T, 2003, CANCER SCI, V94, P757, DOI 10.1111/j.1349-7006.2003.tb01515.x; Jiang Shuying, 2003, Nucl Recept, V1, P5, DOI 10.1186/1478-1336-1-5; KOWALCZYK AP, 1994, J BIOL CHEM, V269, P31214; Laine B, 2000, FEBS LETT, V479, P41, DOI 10.1016/S0014-5793(00)01864-0; Lausen J, 2000, NUCLEIC ACIDS RES, V28, P430, DOI 10.1093/nar/28.2.430; Lazarevich N, 2004, HEPATOLOGY, V39, P1038, DOI 10.1002/hep.20155; Lenburg ME, 2003, BMC CANCER, V3, DOI 10.1186/1471-2407-3-31; Li JX, 2000, GENE DEV, V14, P464; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Linehan WM, 2004, CANCER CELL, V6, P223, DOI 10.1016/j.ccr.2004.09.006; Naiki T, 2002, J BIOL CHEM, V277, P14011, DOI 10.1074/jbc.M105403200; Odom DT, 2004, SCIENCE, V303, P1378, DOI 10.1126/science.1089769; Parviz F, 2003, NAT GENET, V34, P292, DOI 10.1038/ng1175; Ryffel GU, 2000, MECH DEVELOP, V90, P65, DOI 10.1016/S0925-4773(99)00230-0; Ryffel GU, 2001, J MOL ENDOCRINOL, V27, P11, DOI 10.1677/jme.0.0270011; Sel S, 1996, CANCER LETT, V101, P205, DOI 10.1016/0304-3835(96)04136-5; Silacci P, 2004, CELL MOL LIFE SCI, V61, P2614, DOI 10.1007/s00018-004-4225-6; STUMPF H, 1995, CARCINOGENESIS, V16, P143, DOI 10.1093/carcin/16.1.143; Takahashi M, 2003, ONCOGENE, V22, P6810, DOI 10.1038/sj.onc.1206869; Taylor DG, 1996, NUCLEIC ACIDS RES, V24, P2930, DOI 10.1093/nar/24.15.2930; Thomas H, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh144; Torban E, 1998, BBA-MOL CELL RES, V1401, P53, DOI 10.1016/S0167-4889(97)00119-5; Wagner KD, 2003, J CELL SCI, V116, P1653, DOI 10.1242/jcs.00405; Wang HM, 2001, MOL CELL, V8, P817, DOI 10.1016/S1097-2765(01)00366-5; Wang HY, 2000, J BIOL CHEM, V275, P35953, DOI 10.1074/jbc.M006612200; Werdien D, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.11.e53; Xu L, 2001, CANCER RES, V61, P3176; Young AN, 2001, AM J PATHOL, V158, P1639, DOI 10.1016/S0002-9440(10)64120-X	45	74	77	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 22	2005	24	42					6418	6431		10.1038/sj.onc.1208794	http://dx.doi.org/10.1038/sj.onc.1208794			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	966RI	16007190				2022-12-25	WOS:000232038200009
J	Bredeston, LM; Caffaro, CE; Samuelson, J; Hirschberg, CB				Bredeston, LM; Caffaro, CE; Samuelson, J; Hirschberg, CB			Golgi and endoplasmic reticulum functions take place in different subcellular compartments of Entamoeba histolytica	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED GLYCANS; PROTEIN; DIPHOSPHATASE; TROPHOZOITES; TRANSPORT; VESICLES; YEAST; GLYCOSYLATION; TOPOGRAPHY; EXPRESSION	Entamoeba histolytica is a protozoan parasite that causes dysentery in developing countries of Africa, Asia, and Latin America. The lack of a defined Golgi apparatus in E. histolytica as well as in other protists led to the hypothesis that they had evolved prior to the acquisition of such organelle even though glycoproteins, glycolipids, and antigens have been detected, the latter of which react with antibodies against Golgi apparatus proteins of higher eukaryotes. We here provide direct evidence for Golgi apparatus-like functions in E. histolytica as well as for components of glycoprotein folding quality control. Using a combination of bioinformatic, cell biological, and biochemical approaches we have ( a) cloned and expressed the E. histolytica UDP-galactose transporter in Saccharomyces cerevisiae; its Km for UDP-galactose is 2.9 mu M; (b) characterized vesicles in an extract of the above protist, which transport UDPgalactose into their lumen with a Km of 2.7 mu M; ( c) detected galactosyltransferase activity(ies) in the lumen of the above vesicles with the Km for UDP-galactose, using endogenous acceptors, being 93 mu M; (d) measured latent apyrase activities in the above vesicles, suggesting they are in the lumen; ( e) characterized UDP-glucose transport activities in Golgi apparatus and endoplasmic reticulum-like vesicles with K(m)s for UDP-glucose of similar to 2-4 mu M. Although the endoplasmic reticulum-like fraction showed UDP-glucose: glycoprotein glucosyltransferase activity, the Golgi apparatus-like fraction did not. This fraction contained other glucosyltransferases. Together, these studies demonstrate that E. histolytica has different vesicles that play a role in protein glycosylation and folding quality control, analogous to the above organellar functions of higher eukaryotes.	Boston Univ, Goldman Sch Dent Med, Dept Mol & Cell Biol, Boston, MA 02118 USA	Boston University	Hirschberg, CB (corresponding author), Boston Univ, Goldman Sch Dent Med, Dept Mol & Cell Biol, 715 Albany St,Evans 437, Boston, MA 02118 USA.	chirschb@bu.edu		Samuelson, John/0000-0001-9533-3040; Hirschberg, Carlos/0000-0003-2299-7721	NIAID NIH HHS [AI 44070] Funding Source: Medline; NIGMS NIH HHS [GM 30365] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044070] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030365, R01GM030365] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEIJON C, 1989, P NATL ACAD SCI USA, V86, P6935, DOI 10.1073/pnas.86.18.6935; Arya R, 2003, MOL BIOCHEM PARASIT, V126, P1, DOI 10.1016/S0166-6851(02)00252-9; BAKKERGRUNWALD T, 1993, PARASITOL TODAY, V9, P27, DOI 10.1016/0169-4758(93)90161-8; Berninsone P, 2001, P NATL ACAD SCI USA, V98, P3738, DOI 10.1073/pnas.061593098; Berninsone P, 1997, J BIOL CHEM, V272, P12616, DOI 10.1074/jbc.272.19.12616; Berninsone PM, 2000, CURR OPIN STRUC BIOL, V10, P542, DOI 10.1016/S0959-440X(00)00128-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chavez-Munguia B, 2000, ARCH MED RES, V31, pS165, DOI 10.1016/S0188-4409(00)00158-2; D'Alessio C, 2003, J BIOL CHEM, V278, P22379, DOI 10.1074/jbc.M300892200; DACKS JB, 2003, P R SOC LOND B S, V270, P168; Dai JY, 2004, CELL, V116, P649, DOI 10.1016/S0092-8674(04)00172-2; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; ENYEDI A, 1993, J BIOL CHEM, V268, P10621; Ghosh SK, 1999, INFECT IMMUN, V67, P3073, DOI 10.1128/IAI.67.6.3073-3081.1999; Guillen E, 1998, P NATL ACAD SCI USA, V95, P7888, DOI 10.1073/pnas.95.14.7888; Helenius A, 2004, ANNU REV BIOCHEM, V73, P1019, DOI 10.1146/annurev.biochem.73.011303.073752; Hirschberg CB, 2001, J CLIN INVEST, V108, P3; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; Hirschberg CB, 1998, ANNU REV BIOCHEM, V67, P49, DOI 10.1146/annurev.biochem.67.1.49; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Loftus B, 2005, NATURE, V433, P865, DOI 10.1038/nature03291; Manning-Cela R, 2003, CELL MICROBIOL, V5, P921, DOI 10.1046/j.1462-5822.2003.00332.x; Mazzuco A, 1997, MICRON, V28, P241, DOI 10.1016/S0968-4328(97)00024-3; Moody-Haupt S, 2000, J MOL BIOL, V297, P409, DOI 10.1006/jmbi.2000.3577; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; PEREZ M, 1987, METHOD ENZYMOL, V138, P709; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Samuelson J, 2005, P NATL ACAD SCI USA, V102, P1548, DOI 10.1073/pnas.0409460102; STANLEY SL, 1995, J BIOL CHEM, V270, P4121, DOI 10.1074/jbc.270.8.4121; Stanley SL, 2003, LANCET, V361, P1025, DOI 10.1016/S0140-6736(03)12830-9; STANLEY SL, 1995, VACCINE, V13, P947, DOI 10.1016/0264-410X(95)00001-H; Trombetta ES, 2003, ANNU REV CELL DEV BI, V19, P649, DOI 10.1146/annurev.cellbio.19.110701.153949; TROMBETTA SE, 1989, BIOCHEMISTRY-US, V28, P8108, DOI 10.1021/bi00446a022; Uccelletti D, 2004, J BIOL CHEM, V279, P27390, DOI 10.1074/jbc.M402624200; YANAGISAWA K, 1990, J BIOL CHEM, V265, P19351	37	33	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	2005	280	37					32168	32176		10.1074/jbc.M507035200	http://dx.doi.org/10.1074/jbc.M507035200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	963HM	16027148	hybrid			2022-12-25	WOS:000231794800017
J	Kubo, S; Nemani, VM; Chalkley, RJ; Anthony, MD; Hattori, N; Mizuno, Y; Edwards, RH; Fortin, DL				Kubo, S; Nemani, VM; Chalkley, RJ; Anthony, MD; Hattori, N; Mizuno, Y; Edwards, RH; Fortin, DL			A combinatorial code for the interaction of alpha-synuclein with membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEWY BODY DEMENTIA; PARKINSONS-DISEASE; LIPID RAFTS; FATTY-ACIDS; HIPPOCAMPAL-NEURONS; SRC-FAMILY; PROTEIN; CELLS; MUTATION; BINDING	Considerable genetic and pathological evidence has implicated the small, soluble protein alpha-synuclein in the pathogenesis of familial and sporadic forms of Parkinsons disease (PD). However, the precise role of alpha-synuclein in the disease process as well as its normal function remain poorly understood. We recently found that an interaction with lipid rafts is crucial for the normal, pre-synaptic localization of alpha-synuclein. To understand how alpha-synuclein interacts with lipid rafts, we have now developed an in vitro binding assay to rafts purified from native membranes. Recapitulating the specificity observed in vivo, recombinant wild type but not PD-associated A30P mutant alpha-synuclein binds to lipid rafts isolated from cultured cells and purified synaptic vesicles. Proteolytic digestion of the rafts does not disrupt the binding of alpha-synuclein, indicating an interaction with lipid rather than protein components of these membranes. We have also found that alpha-synuclein binds directly to artificial membranes whose lipid composition mimics that of lipid rafts. The binding of alpha-synuclein to these raft-like liposomes requires acidic phospholipids, with a preference for phosphatidylserine ( PS). Interestingly, a variety of synthetic PS with defined acyl chains do not support binding when used individually. Rather, the interaction with alpha-synuclein requires a combination of PS with oleic ( 18: 1) and polyunsaturated ( either 20: 4 or 22: 6) fatty acyl chains, suggesting a role for phase separation within the membrane. Furthermore, alpha-synuclein binds with higher affinity to artificial membranes with the PS head group on the polyunsaturated fatty acyl chain rather than on the oleoyl side chain, indicating a stringent combinatorial code for the interaction of alpha-synuclein with membranes.	Univ Calif San Francisco, Sch Med, Dept Neurol & Physiol, Grad Program Biomed Sci, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, Dept Neurol & Physiol, Grad Program Cell Biol & Neurosci, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pharmaceut Chem, Mass Spectrometry Facil, San Francisco, CA 94143 USA; Juntendo Univ, Sch Med, Dept Neurol, Tokyo 1138421, Japan	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Juntendo University	Edwards, RH (corresponding author), Univ Calif San Francisco, Sch Med, Dept Neurol & Physiol, Grad Program Biomed Sci, 600 16th St,GH-N272B, San Francisco, CA 94143 USA.	edwards@itsa.ucsf.edu		Nemani, Venu/0000-0001-8895-7090; Chalkley, Robert/0000-0002-9757-7302	NCRR NIH HHS [RR014606] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR014606] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Abeliovich A, 2000, NEURON, V25, P239, DOI 10.1016/S0896-6273(00)80886-7; Ahn BH, 2002, J BIOL CHEM, V277, P12334, DOI 10.1074/jbc.M110414200; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Bussell R, 2005, PROTEIN SCI, V14, P862, DOI 10.1110/ps.041255905; Cabin DE, 2002, J NEUROSCI, V22, P8797; Chandra S, 2003, J BIOL CHEM, V278, P15313, DOI 10.1074/jbc.M213128200; Cole NB, 2002, J BIOL CHEM, V277, P6344, DOI 10.1074/jbc.M108414200; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; Edidin M, 2003, ANNU REV BIOPH BIOM, V32, P257, DOI 10.1146/annurev.biophys.32.110601.142439; Eliezer D, 2001, J MOL BIOL, V307, P1061, DOI 10.1006/jmbi.2001.4538; Ellis CE, 2001, J BIOL CHEM, V276, P3879, DOI 10.1074/jbc.M010316200; FIELD KA, 1995, P NATL ACAD SCI USA, V92, P9201, DOI 10.1073/pnas.92.20.9201; Fortin DL, 2004, J NEUROSCI, V24, P6715, DOI 10.1523/JNEUROSCI.1594-04.2004; Fridriksson EK, 1999, BIOCHEMISTRY-US, V38, P8056, DOI 10.1021/bi9828324; Galvin JE, 1999, P NATL ACAD SCI USA, V96, P13450, DOI 10.1073/pnas.96.23.13450; GEORGE JM, 1995, NEURON, V15, P361, DOI 10.1016/0896-6273(95)90040-3; Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001; Hell J. W, 1994, CELL BIOL LAB HDB, P567; Higgins D., 1998, CULTURING NERVE CELL, P37; Hirono M, 2004, NEURON, V44, P309, DOI 10.1016/j.neuron.2004.09.020; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; IWAI A, 1995, NEURON, V14, P467, DOI 10.1016/0896-6273(95)90302-X; Jensen PH, 1998, J BIOL CHEM, V273, P26292, DOI 10.1074/jbc.273.41.26292; Jo EJ, 2000, J BIOL CHEM, V275, P34328, DOI 10.1074/jbc.M004345200; Jo EJ, 2002, J MOL BIOL, V315, P799, DOI 10.1006/jmbi.2001.5269; Kahle PJ, 2000, J NEUROSCI, V20, P6365, DOI 10.1523/JNEUROSCI.20-17-06365.2000; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; MAROTEAUX L, 1988, J NEUROSCI, V8, P2804; Murphy DD, 2000, J NEUROSCI, V20, P3214, DOI 10.1523/JNEUROSCI.20-09-03214.2000; Nakamura T, 2002, FEBS LETT, V521, P190, DOI 10.1016/S0014-5793(02)02861-2; Nakamura T, 2001, BIOCHEM BIOPH RES CO, V280, P1085, DOI 10.1006/bbrc.2000.4253; Okochi M, 2000, J BIOL CHEM, V275, P390, DOI 10.1074/jbc.275.1.390; Outeiro TF, 2003, SCIENCE, V302, P1772, DOI 10.1126/science.1090439; Perrin RJ, 2000, J BIOL CHEM, V275, P34393, DOI 10.1074/jbc.M004851200; Perrin RJ, 2001, J BIOL CHEM, V276, P41958, DOI 10.1074/jbc.M105022200; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Pronin AN, 2000, J BIOL CHEM, V275, P26515, DOI 10.1074/jbc.M003542200; Sharon R, 2001, P NATL ACAD SCI USA, V98, P9110, DOI 10.1073/pnas.171300598; Sharon R, 2003, NEURON, V37, P583, DOI 10.1016/S0896-6273(03)00024-2; Sharon R, 2003, J BIOL CHEM, V278, P49874, DOI 10.1074/jbc.M309127200; Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627; Singleton AB, 2003, SCIENCE, V302, P841, DOI 10.1126/science.1090278; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1998, NEUROSCI LETT, V251, P205, DOI 10.1016/s0304-3940(98)00504-7; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282; Veatch SL, 2003, BIOPHYS J, V84, P725, DOI 10.1016/S0006-3495(03)74891-7; Veatch SL, 2003, BIOPHYS J, V85, P3074, DOI 10.1016/S0006-3495(03)74726-2; Withers GS, 1997, DEV BRAIN RES, V99, P87, DOI 10.1016/S0165-3806(96)00210-6; Zarranz JJ, 2004, ANN NEUROL, V55, P164, DOI 10.1002/ana.10795	49	155	156	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	2005	280	36					31664	31672		10.1074/jbc.M504894200	http://dx.doi.org/10.1074/jbc.M504894200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	961LZ	16020543	hybrid			2022-12-25	WOS:000231665200042
J	Lee, ER; Kang, YJ; Kim, JH; Lee, HT; Cho, SG				Lee, ER; Kang, YJ; Kim, JH; Lee, HT; Cho, SG			Modulation of apoptosis in HaCaT keratinocytes via differential regulation of ERK signaling pathway by flavonoids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; TRANSDUCTION PATHWAYS; CASPASE-3 CASCADE; DEPENDENT KINASE; OXIDATIVE STRESS; MAPK PATHWAYS; CYTOCHROME-C; CANCER CELLS; ACTIVATION; INHIBITION	The exact molecular mechanisms underlying the cellular effects associated with various flavonoids have yet to be fully explained. In the present study, we have administered several flavonoids to human HaCaT keratinocytes and determined that 3,4'-dihydroxy flavone (3,4'-DHF) exerts a slight stimulatory effect on cell growth, although other flavonoids, including kaempferol, quercetin, and isorhamnetin, exhibited growth inhibitory properties. 3,4'-DHF was found to exert an anti-apoptotic effect on etoposide-induced cell death of HaCaT keratinocytes. We were also able to determine that sustained ERK activation was intimately associated with the etoposide-induced apoptosis of HaCaT cells, and treatment with 3,4'-DHF induced a significant suppression of etoposide-induced ERK activation, concomitant with the repression of poly(ADP-ribose) polymerase or the cleavage of pro-caspase 3. ERK overexpression significantly overrode the anti-apoptotic function of 3,4'-DHF, but this was not true of ERK-DN. Moreover, treatment with 3,4'-DHF resulted in the protection of cells from H2O2-induced cell death and exerted an apparent suppressive effect on the stress-induced generation of reactive oxygen species (ROS). Finally, we showed that 3,4'-DHF almost completely abolished kaempferol-induced apoptosis, coupled with a concomitant suppression of both intracellular ROS generation and the activation of ERK. Taken together, our data clearly indicate that a host of phytochemicals, including etoposide and a variety of flavonoids, differentially regulate the apoptosis of human HaCaT keratinocytes via the differential modulation of intracellular ROS production, coupled with the concomitant activation of the ERK signaling pathway. According to these results, we are able to conclude the distinct structure-activity relationship between several flavonoids.	Konkuk Univ, Dept Anim Biotechnol, Biomol Informat Ctr, Seoul 143701, South Korea; Konkuk Univ, Inst Biomed Sci & Technol, Seoul 143701, South Korea	Konkuk University; Konkuk University	Cho, SG (corresponding author), Konkuk Univ, Dept Anim Biotechnol, Biomol Informat Ctr, Seoul 143701, South Korea.	ssangoo@konkuk.ac.kr	Kim, Jung-Hyun/AAK-8795-2021	Kim, Jung-Hyun/0000-0001-7176-409X; Cho, Ssang-Goo/0000-0002-0968-7932				Aligiannis N, 2001, PLANTA MED, V67, P468, DOI 10.1055/s-2001-15807; Areias FM, 2001, BIOCHEM PHARMACOL, V62, P111, DOI 10.1016/S0006-2952(01)00621-9; Basu S, 1998, J BIOL CHEM, V273, P30419, DOI 10.1074/jbc.273.46.30419; Boldt S, 2002, CARCINOGENESIS, V23, P1831, DOI 10.1093/carcin/23.11.1831; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; Cemeli E, 2004, ENVIRON MOL MUTAGEN, V44, P420, DOI 10.1002/em.20071; Chen YC, 2002, ARCH TOXICOL, V76, P351, DOI 10.1007/s00204-002-0346-6; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; Cho SG, 2003, J CELL BIOL, V163, P71, DOI 10.1083/jcb.200303003; Cody V, 1988, Prog Clin Biol Res, V280, P29; Diker-Cohen T, 2003, ANN NY ACAD SCI, V1010, P350, DOI 10.1196/annals.1299.064; FIALKOW L, 1994, J BIOL CHEM, V269, P31234; Fu Y, 2004, BIOCHEM BIOPH RES CO, V322, P263, DOI 10.1016/j.bbrc.2004.07.094; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Havsteen BH, 2002, PHARMACOL THERAPEUT, V96, P67, DOI 10.1016/S0163-7258(02)00298-X; Hendriks JJA, 2003, BIOCHEM PHARMACOL, V65, P877, DOI 10.1016/S0006-2952(02)01609-X; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; HERTOG MGL, 1993, NUTR CANCER, V20, P21, DOI 10.1080/01635589309514267; Hsu YL, 2004, BIOCHEM PHARMACOL, V67, P823, DOI 10.1016/j.bcp.2003.09.042; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Impey S, 1999, NEURON, V23, P11, DOI 10.1016/S0896-6273(00)80747-3; Ko CH, 2005, BIOCHEM PHARMACOL, V69, P913, DOI 10.1016/j.bcp.2004.12.005; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lee K, 2002, FREE RADICAL BIO MED, V33, P1121, DOI 10.1016/S0891-5849(02)01000-6; LEE SH, 1995, BIOCHEM BIOPH RES CO, V213, P837, DOI 10.1006/bbrc.1995.2205; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; Lenferink AEG, 2001, CANCER RES, V61, P6583; MacKeigan JP, 2000, J BIOL CHEM, V275, P38953, DOI 10.1074/jbc.C000684200; Marshall C, 1999, CURR OPIN CELL BIOL, V11, P732, DOI 10.1016/S0955-0674(99)00044-7; MOODIE SA, 1994, TRENDS GENET, V10, P44, DOI 10.1016/0168-9525(94)90147-3; Myhre O, 2003, BIOCHEM PHARMACOL, V65, P1575, DOI 10.1016/S0006-2952(03)00083-2; Nguyen TTT, 2003, J CELL PHYSIOL, V197, P110, DOI 10.1002/jcp.10340; PLOTKIN LI, 2005, IN PRESS AM J PHYSL; ROYALL JA, 1993, ARCH BIOCHEM BIOPHYS, V302, P348, DOI 10.1006/abbi.1993.1222; Ryoo K, 2004, J BIOL CHEM, V279, P43589, DOI 10.1074/jbc.M404359200; Rytomaa M, 2000, ONCOGENE, V19, P4461, DOI 10.1038/sj.onc.1203805; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Shen SC, 2004, INT J CANCER, V108, P502, DOI 10.1002/ijc.11581; Shen SC, 2003, J CELL BIOCHEM, V89, P1044, DOI 10.1002/jcb.10559; Sheppard BC, 1999, CANCER, V85, P1454, DOI 10.1002/(SICI)1097-0142(19990401)85:7<1454::AID-CNCR5>3.3.CO;2-R; Studzinski GP, 1999, INT REV CYTOL, V189, P1, DOI 10.1016/S0074-7696(08)61384-4; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; Tantini B, 2004, AMINO ACIDS, V27, P207, DOI 10.1007/s00726-004-0101-9; Townsend KJ, 1998, ONCOGENE, V17, P1223, DOI 10.1038/sj.onc.1202035; Tran SEF, 2001, J BIOL CHEM, V276, P16484, DOI 10.1074/jbc.M010384200; van den Brink MRM, 1999, J BIOL CHEM, V274, P11178, DOI 10.1074/jbc.274.16.11178; Wang XT, 2000, J BIOL CHEM, V275, P39435, DOI 10.1074/jbc.M004583200; WARD NE, 1995, J BIOL CHEM, V270, P8056, DOI 10.1074/jbc.270.14.8056; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang YL, 2000, CELL RES, V10, P169, DOI 10.1038/sj.cr.7290046; Zhou B, 2002, J BIOL CHEM, V277, P31818, DOI 10.1074/jbc.M203969200	54	93	96	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	2005	280	36					31498	31507		10.1074/jbc.M505537200	http://dx.doi.org/10.1074/jbc.M505537200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	961LZ	16014620	hybrid			2022-12-25	WOS:000231665200021
J	Bilton, R; Mazure, N; Trottier, E; Hattab, M; Dery, MA; Richard, DE; Pouyssegur, J; Brahimi-Horn, MC				Bilton, R; Mazure, N; Trottier, E; Hattab, M; Dery, MA; Richard, DE; Pouyssegur, J; Brahimi-Horn, MC			Arrest-defective-1 protein, an acetyltransferase, does not alter stability of hypoxia-inducible factor (HIF)-1 alpha and is not induced by hypoxia or HIF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL ACETYLTRANSFERASE; FACTOR-L-ALPHA; GENE-EXPRESSION; HIF-1-ALPHA; FACTOR-1-ALPHA; IDENTIFICATION; TUBEDOWN-1; ARD1; HIF-2-ALPHA; INDUCTION	The hypoxia-inducible factor (HIF) is a key player in a transcriptional pathway that controls the hypoxic response of mammalian cells. Post-translational modification of the alpha subunit of HIF determines its half-life and activity. Among the multiple reported modifications, acetylation, by an acetyltransferase termed arrest-defective-1 protein (ARD1), has been reported to decrease HIF-1 alpha stability and therefore impact on hypoxic gene expression. In contrast, we report that both overexpression and silencing of ARD1 had no impact on the stability of HIF-1 alpha or -2 alpha and that cells silenced for ARD1 maintained hypoxic nuclear localization of HIF-1 alpha. In addition, we show that the ARD1 mRNA and protein levels are not regulated by hypoxia in several human tumor cell lines, including cervical adenocarcinoma HeLa cells, fibrosarcoma HT1080 cells, adenovirus-transformed human kidney HEK293 cells, and human breast cancer MCF-7 cells. Using two model systems ((a) wild-type and HIF-1 alpha-null mouse embryo fibroblasts and (b) HeLa cells silenced for HIF-1 alpha or -2 alpha by RNA interference), we demonstrate that the level of expression of the ARD1 protein is independent of HIF-1 alpha and -2 alpha. We also demonstrate that ARD1 is a stable, predominantly cytoplasmic protein expressed in a broad range of tissues, tumor cell lines, and endothelial cells. Taken together, our findings demonstrate that ARD1 has limited, if any, impact on the HIF signaling pathway.	CNRS, Inst Signal Dev Biol & Canc Res, UMR 6543, Ctr Antoine Lacassagne, F-06189 Nice, France; Hop Hotel Dieu, Ctr Rech, Quebec City, PQ G1R 2J6, Canada	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; UNICANCER; Centre Antoine Lacassagne	Brahimi-Horn, MC (corresponding author), CNRS, Inst Signal Dev Biol & Canc Res, UMR 6543, Ctr Antoine Lacassagne, 33 Ave Valombrose, F-06189 Nice, France.	brahimi@unice.fr	Richard, Darren E./K-6760-2019	Mazure, Nathalie/0000-0003-1350-7161; Richard, Darren/0000-0003-2690-0480; Bilton, Rebecca/0000-0003-1932-8957				Arnesen T, 2005, BIOCHEM J, V386, P433, DOI 10.1042/BJ20041071; Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392; Brahimi-Horn C, 2005, CELL SIGNAL, V17, P1, DOI 10.1016/j.cellsig.2004.04.010; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chun YS, 2003, CANCER RES, V63, P8700; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Fisher TS, 2005, J BIOL CHEM, V280, P17749, DOI 10.1074/jbc.M412055200; Fluge O, 2002, ONCOGENE, V21, P5056, DOI 10.1038/sj.onc.1205687; Gendron RL, 2000, DEV DYNAM, V218, P300, DOI 10.1002/(SICI)1097-0177(200006)218:2<300::AID-DVDY5>3.0.CO;2-K; Gendron RL, 2001, INVEST OPHTH VIS SCI, V42, P3000; Hockel M, 2001, JNCI-J NATL CANCER I, V93, P266, DOI 10.1093/jnci/93.4.266; Hu CJ, 2003, MOL CELL BIOL, V23, P9361, DOI 10.1128/MCB.23.24.9361-9374.2003; Ivan M, 2002, P NATL ACAD SCI USA, V99, P13459, DOI 10.1073/pnas.192342099; Jeong JW, 2002, CELL, V111, P709, DOI 10.1016/S0092-8674(02)01085-1; Kim JH, 2001, COMPOS INTERFACE, V7, P443, DOI 10.1163/156855400750262932; Kim W, 2003, CURR OPIN GENET DEV, V13, P55, DOI 10.1016/S0959-437X(02)00010-2; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Lin SK, 2004, MOL PHARMACOL, V66, P612; Line A, 2002, BRIT J CANCER, V86, P1824, DOI 10.1038/sj.bjc.6600321; Manalo DJ, 2005, BLOOD, V105, P659, DOI 10.1182/blood-2004-07-2958; Metzen E, 2003, J CELL SCI, V116, P1319, DOI 10.1242/jcs.00318; MULLEN JR, 1989, EMBO J, V8, P2067, DOI 10.1002/j.1460-2075.1989.tb03615.x; Neuwald AF, 1997, TRENDS BIOCHEM SCI, V22, P154, DOI 10.1016/S0968-0004(97)01034-7; Onesto C, 2004, J BIOL CHEM, V279, P34217, DOI 10.1074/jbc.M400219200; Paradis H, 2002, DEV BIOL, V249, P140, DOI 10.1006/dbio.2002.0757; PARK EC, 1992, EMBO J, V11, P2087, DOI 10.1002/j.1460-2075.1992.tb05267.x; Park SK, 2003, MOL CELL BIOL, V23, P4959, DOI 10.1128/MCB.23.14.4959-4971.2003; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; Ryan HE, 2000, CANCER RES, V60, P4010; Schofield CJ, 1999, CURR OPIN STRUC BIOL, V9, P722, DOI 10.1016/S0959-440X(99)00036-6; Schofield CJ, 2004, NAT REV MOL CELL BIO, V5, P343, DOI 10.1038/nrm1366; Sheta EA, 2001, ONCOGENE, V20, P7624, DOI 10.1038/sj.onc.1204972; Sowter HM, 2003, CANCER RES, V63, P6130; Sugiura N, 2003, J BIOL CHEM, V278, P40113, DOI 10.1074/jbc.M301218200; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Vouret-Craviari V, 2002, J CELL SCI, V115, P2475; WHITEWAY M, 1985, CELL, V43, P483, DOI 10.1016/0092-8674(85)90178-3; Willis DM, 2002, J BIOL CHEM, V277, P37280, DOI 10.1074/jbc.M206482200	38	86	94	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	2005	280	35					31132	31140		10.1074/jbc.M504482200	http://dx.doi.org/10.1074/jbc.M504482200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	958ZX	15994306	hybrid			2022-12-25	WOS:000231487800059
J	Christen, M; Christen, B; Folcher, M; Schauerte, A; Jenal, U				Christen, M; Christen, B; Folcher, M; Schauerte, A; Jenal, U			Identification and characterization of a cyclic di-GMP-specific phosphodiesterase and its allosteric control by GTP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETOBACTER-XYLINUM; CELLULOSE SYNTHESIS; BACILLUS-SUBTILIS; STRINGENT RESPONSE; BIOFILM FORMATION; DIGUANYLATE; PROTEIN; GGDEF; SPORULATION; REGULATOR	Cyclic diguanylic acid (c-di-GMP) is a global second messenger controlling motility and adhesion in bacterial cells. Synthesis and degradation of c-di-GMP is catalyzed by diguanylate cyclases (DGC) and c-di-GMP-specific phosphodiesterases (PDE), respectively. Whereas the DGC activity has recently been assigned to the widespread GGDEF domain, the enzymatic activity responsible for c-di-GMP cleavage has been associated with proteins containing an EAL domain. Here we show biochemically that CC3396, a GGDEF-EAL composite protein from Caulobacter crescentus is a soluble PDE. The PDE activity, which rapidly converts c-di-GMP into the linear dinucleotide pGpG, is confined to the C-terminal EAL domain of CC3396, depends on the presence of Mg2+ ions, and is strongly inhibited by Ca2+ ions. Remarkably, the associated GGDEF domain, which contains an altered active site motif (GEDEF), lacks detectable DGC activity. Instead, this domain is able to bind GTP and in response activates the PDE activity in the neighboring EAL domain. PDE activation is specific for GTP (K-D 4 mu M) and operates by lowering the K-m for c-di-GMP of the EAL domain to a physiologically significant level (420 nM). Mutational analysis suggested that the substrate-binding site (A-site) of the GGDEF domain is involved in the GTP-dependent regulatory function, arguing that a catalytically inactive GGDEF domain has retained the ability to bind GTP and in response can activate the neighboring EAL domain. Based on this we propose that the c-di-GMP-specific PDE activity is confined to the EAL domain, that GGDEF domains can either catalyze the formation of c-di-GMP or can serve as regulatory domains, and that c-di-GMP-specific phosphodiesterase activity is coupled to the cellular GTP level in bacteria.	Univ Basel, Biozentrum, Div Mol Microbiol, CH-4056 Basel, Switzerland	University of Basel	Jenal, U (corresponding author), Univ Basel, Biozentrum, Div Mol Microbiol, Klingelbergstr 70, CH-4056 Basel, Switzerland.	urs.jenal@unibas.ch	Christen, Beat/AAC-2974-2021	Christen, Beat/0000-0002-9528-3685; Christen, Matthias/0000-0001-7724-4562				Aldridge P, 2003, MOL MICROBIOL, V47, P1695, DOI 10.1046/j.1365-2958.2003.03401.x; Bergara F, 2003, J BACTERIOL, V185, P3118, DOI 10.1128/JB.185.10.3118-3126.2003; BOCHNER BR, 1982, J BIOL CHEM, V257, P9759; Bomchil N, 2003, J BACTERIOL, V185, P1384, DOI 10.1128/JB.185.4.1384-1390.2003; Chan C, 2004, P NATL ACAD SCI USA, V101, P17084, DOI 10.1073/pnas.0406134101; Chang AL, 2001, BIOCHEMISTRY-US, V40, P3420, DOI 10.1021/bi0100236; CHIAVEROTTI TA, 1981, J BACTERIOL, V145, P1463, DOI 10.1128/JB.145.3.1463-1465.1981; Choy WK, 2004, J BACTERIOL, V186, P7221, DOI 10.1128/JB.186.21.7221-7228.2004; Conti M, 2000, PROG NUCLEIC ACID RE, V63, P1; Corbin JD, 1999, J BIOL CHEM, V274, P13729, DOI 10.1074/jbc.274.20.13729; D'Argenio DA, 2004, MICROBIOL-SGM, V150, P2497, DOI 10.1099/mic.0.27099-0; Drenkard E, 2002, NATURE, V416, P740, DOI 10.1038/416740a; ELY B, 1991, METHOD ENZYMOL, V204, P372; Essayan DM, 2001, J ALLERGY CLIN IMMUN, V108, P671, DOI 10.1067/mai.2001.119555; FREESE E, 1979, J GEN MICROBIOL, V115, P193, DOI 10.1099/00221287-115-1-193; Galperin Michael Y., 1999, Journal of Molecular Microbiology and Biotechnology, V1, P303; Galperin MY, 2001, FEMS MICROBIOL LETT, V203, P11, DOI 10.1111/j.1574-6968.2001.tb10814.x; Galperin MY, 2004, ENVIRON MICROBIOL, V6, P543, DOI 10.1111/j.1462-2920.2004.00652.x; Garcia B, 2004, MOL MICROBIOL, V54, P264, DOI 10.1111/j.1365-2958.2004.04269.x; Guvener ZT, 2003, J BACTERIOL, V185, P5431, DOI 10.1128/JB.185.18.5431-5441.2003; Houslay MD, 1997, TRENDS BIOCHEM SCI, V22, P217, DOI 10.1016/S0968-0004(97)01050-5; Huang BX, 2003, J BACTERIOL, V185, P7068, DOI 10.1128/JB.185.24.7068-7076.2003; Jenal U, 2004, CURR OPIN MICROBIOL, V7, P185, DOI 10.1016/j.mib.2004.02.007; Johnson MR, 2005, MOL MICROBIOL, V55, P664, DOI 10.1111/j.1365-2958.2004.04419.x; Kaupp UB, 2002, PHYSIOL REV, V82, P769, DOI 10.1152/physrev.00008.2002; Kirillina O, 2004, MOL MICROBIOL, V54, P75, DOI 10.1111/j.1365-2958.2004.04253.x; LOPEZ JM, 1979, BIOCHIM BIOPHYS ACTA, V587, P238, DOI 10.1016/0304-4165(79)90357-X; Lucas KA, 2000, PHARMACOL REV, V52, P375; OCHI K, 1987, J BACTERIOL, V169, P3608, DOI 10.1128/jb.169.8.3608-3616.1987; OCHI K, 1982, J BACTERIOL, V151, P1062, DOI 10.1128/JB.151.2.1062-1065.1982; Paul R, 2004, GENE DEV, V18, P715, DOI 10.1101/gad.289504; Ratnayake-Lecamwasam M, 2001, GENE DEV, V15, P1093, DOI 10.1101/gad.874201; ROSS P, 1987, NATURE, V325, P279, DOI 10.1038/325279a0; ROSS P, 1991, MICROBIOL REV, V55, P35, DOI 10.1128/MMBR.55.1.35-58.1991; Ryjenkov DA, 2005, J BACTERIOL, V187, P1792, DOI 10.1128/JB.187.5.1792-1798.2005; Simm R, 2004, MOL MICROBIOL, V53, P1123, DOI 10.1111/j.1365-2958.2004.04206.x; Spiers AJ, 2002, GENETICS, V161, P33; Tal R, 1998, J BACTERIOL, V180, P4416, DOI 10.1128/JB.180.17.4416-4425.1998; Thomas C, 2004, MICROBIOL-SGM, V150, P1031, DOI 10.1099/mic.0.26915-0; Tischler AD, 2004, MOL MICROBIOL, V53, P857, DOI 10.1111/j.1365-2958.2004.04155.x; Weinhouse H, 1997, FEBS LETT, V416, P207, DOI 10.1016/S0014-5793(97)01202-7	41	358	372	2	54	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	2005	280	35					30829	30837		10.1074/jbc.M504429200	http://dx.doi.org/10.1074/jbc.M504429200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	958ZX	15994307	hybrid			2022-12-25	WOS:000231487800023
J	Keilhack, H; David, FS; McGregor, M; Cantley, LC; Neel, BG				Keilhack, H; David, FS; McGregor, M; Cantley, LC; Neel, BG			Diverse biochemical properties of Shp2 mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; GROWTH-FACTOR RECEPTOR; GENOTYPE-PHENOTYPE CORRELATION; NOONAN-SYNDROME; PTPN11 MUTATIONS; FUNCTIONAL-ANALYSIS; INSULIN-RECEPTOR; SH2 DOMAIN; ACTIVATION; LEUKEMIA	Mutations in the Src homology 2 ( SH2)- containing protein- tyrosine phosphatase Shp2 ( PTPN11) underlie half of the cases of the autosomal dominant genetic disorder Noonan syndrome, and somatic Shp2 mutations are found in several hematologic and solid malignancies. Earlier studies of small numbers of mutants suggested that disease- associated mutations cause constitutive ( SH2 binding- independent) activation and that cancer- associated mutants are more active than those associated with Noonan syndrome. We have characterized a larger panel of Shp2 mutants and find that this " activity- centric" model cannot explain the behaviors of all pathogenic Shp2 mutations. Instead, enzymatic, structural, and mathematical modeling analyses show that these mutants can affect basal activation, SH2 domain phosphopeptide affinity, and/ or substrate specificity to varying degrees. Furthermore, there is no absolute correlation between the mutants' extents of basal activation and the diseases they induce. We propose that activated mutants of Shp2 modulate signaling from specific stimuli to a subset of effectors and provide a theoretical framework for understanding the complex relationship between Shp2 activation, intracellular signaling, and pathology.	Beth Israel Deaconess Med Ctr, Canc Biol Program, Dept Med, Boston, MA 02215 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Serono Reprod Biol Res Inst, Rockland, MA 02370 USA; Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Div Signal Transduct, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center	Neel, BG (corresponding author), Beth Israel Deaconess Med Ctr, Canc Biol Program, Dept Med, 330 Brookline Ave, Boston, MA 02215 USA.	bneel@bidmc.harvard.edu	Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653; David, Frank/0000-0002-8025-4427	NCI NIH HHS [R37CA49152] Funding Source: Medline; NHLBI NIH HHS [T32HL07627] Funding Source: Medline; NIGMS NIH HHS [R01GM56203] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA049152] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007627] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056203] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; Araki T, 2003, J BIOL CHEM, V278, P41677, DOI 10.1074/jbc.M306461200; Bentires-Alj M, 2004, CANCER RES, V64, P8816, DOI 10.1158/0008-5472.CAN-04-1923; Cheng A, 2001, J BIOL CHEM, V276, P25848, DOI 10.1074/jbc.M009734200; Eck MJ, 1996, NATURE, V379, P277, DOI 10.1038/379277a0; Ernst M, 2004, TRENDS GENET, V20, P23, DOI 10.1016/j.tig.2003.11.003; Fragale A, 2004, HUM MUTAT, V23, P267, DOI 10.1002/humu.20005; Gu HH, 2003, TRENDS CELL BIOL, V13, P122, DOI 10.1016/S0962-8924(03)00002-3; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; JOHANNES JM, 1995, PEDIATR HEMAT ONCOL, V12, P571, DOI 10.3109/08880019509030771; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; Keilhack H, 1998, J BIOL CHEM, V273, P24839, DOI 10.1074/jbc.273.38.24839; Kosaki K, 2002, J CLIN ENDOCR METAB, V87, P3529, DOI 10.1210/jc.87.8.3529; KRATZ CP, 2005, IN PRESS BLOOD; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LEE CH, 1994, STRUCTURE, V2, P423, DOI 10.1016/S0969-2126(00)00044-7; Loh ML, 2004, LEUKEMIA, V18, P1831, DOI 10.1038/sj.leu.2403492; Loh ML, 2004, BLOOD, V103, P2325, DOI 10.1182/blood-2003-09-3287; Maheshwari M, 2002, HUM MUTAT, V20, P298, DOI 10.1002/humu.10129; Manke IA, 2003, SCIENCE, V302, P636, DOI 10.1126/science.1088877; Marino B, 1999, J PEDIATR-US, V135, P703, DOI 10.1016/S0022-3476(99)70088-0; Mohi MG, 2005, CANCER CELL, V7, P179, DOI 10.1016/j.ccr.2005.01.010; Musante L, 2003, EUR J HUM GENET, V11, P201, DOI 10.1038/sj.ejhg.5200935; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Niihori T, 2005, J HUM GENET, V50, P192, DOI 10.1007/s10038-005-0239-7; Noonan JA, 1999, J PEDIATR-US, V135, P667, DOI 10.1016/S0022-3476(99)70082-X; O'Reilly AM, 2000, MOL CELL BIOL, V20, P299, DOI 10.1128/MCB.20.1.299-311.2000; Pannifer ADB, 1998, J BIOL CHEM, V273, P10454, DOI 10.1074/jbc.273.17.10454; Piao XH, 1996, P NATL ACAD SCI USA, V93, P14665, DOI 10.1073/pnas.93.25.14665; PLUSKEY S, 1995, J BIOL CHEM, V270, P2897, DOI 10.1074/jbc.270.7.2897; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; Ponniah S, 1999, CURR BIOL, V9, P535, DOI 10.1016/S0960-9822(99)80238-3; Salmeen A, 2000, MOL CELL, V6, P1401, DOI 10.1016/S1097-2765(00)00137-4; Sarkozy A, 2003, J MED GENET, V40, P704, DOI 10.1136/jmg.40.9.704; Schubbert S, 2005, BLOOD, V106, P311, DOI 10.1182/blood-2004-11-4207; Shimada H, 2004, LEUKEMIA, V18, P1142, DOI 10.1038/sj.leu.2403374; Side LE, 1997, J PEDIATR-US, V130, P857; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; Su J, 1999, CURR BIOL, V9, P505, DOI 10.1016/S0960-9822(99)80234-6; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; SUGIMOTO S, 1993, J BIOL CHEM, V268, P22771; Tartaglia M, 2004, CURR OPIN HEMATOL, V11, P44, DOI 10.1097/00062752-200401000-00007; Tartaglia M, 2004, BLOOD, V104, P307, DOI 10.1182/blood-2003-11-3876; Tartaglia M, 2001, NAT GENET, V29, P465, DOI 10.1038/ng772; Tartaglia M, 2003, NAT GENET, V34, P148, DOI 10.1038/ng1156; Tartaglia M, 2002, AM J HUM GENET, V70, P1555, DOI 10.1086/340847; WEISMANN CG, 2005, IN PRESS AM J MED GE; White MF, 2002, AM J PHYSIOL-ENDOC M, V283, pE413, DOI 10.1152/ajpendo.00514.2001; Yoshida R, 2004, J CLIN ENDOCR METAB, V89, P3359, DOI 10.1210/jc.2003-032091; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	51	215	227	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	2005	280	35					30984	30993		10.1074/jbc.M504699200	http://dx.doi.org/10.1074/jbc.M504699200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	958ZX	15987685	hybrid			2022-12-25	WOS:000231487800041
J	Zhang, YW; Rudnick, G				Zhang, YW; Rudnick, G			Cysteine-scanning mutagenesis of serotonin transporter intracellular loop 2 suggests an alpha-helical conformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REUPTAKE INHIBITORS; EXTERNAL LOOP; RAT-BRAIN; BINDING; CLONING; EXPRESSION; RECEPTORS; MECHANISM; DEPENDENCE; COMPLEX	Like other proteins involved in neurotransmitter transport, serotonin transporter (SERT) activity is regulated by multiple intracellular signal transduction pathways. The second intracellular loop (IL2) of SERT contains consensus sequences for cGMP-dependent protein kinase and protein kinase C. A 24-residue region of SERT including IL2, from Ile-270 through Ser-293, was analyzed by cysteine-scanning mutagenesis and chemical modification. 2-(Aminoethyl)methanethiosulfonate hydrobromide ( MTSEA) failed to inhibit serotonin transport or binding of the cocaine analog 2 beta-carbomethoxy-3 beta-(4-[I-125]iodophenyl)tropane (beta-CIT) in intact cells expressing these mutants, but it inactivated beta-CIT binding in membrane preparations. From the pattern of sensitivity, IL2 appears to extend from Trp-271 through Ile-290, a significantly longer region than that initially predicted by hydropathy analysis. Six mutants reacted with MTSEA much faster than the others, and the pattern of the more reactive mutations suggested that IL2 is in an alpha-helical conformation. Some of the mutants had significantly elevated transport rates, suggesting a possible mechanism for the regulation of SERT activity.	Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA	Yale University	Rudnick, G (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, 333 Cedar St, New Haven, CT 06520 USA.	gary.rudnick@yale.edu		ZHANG, YUAN-WEI/0000-0002-4276-9251				Androutsellis-Theotokis A, 2001, J BIOL CHEM, V276, P45933, DOI 10.1074/jbc.M107462200; BLAKELY RD, 1991, ANAL BIOCHEM, V194, P302, DOI 10.1016/0003-2697(91)90233-J; BLAKELY RD, 1991, NATURE, V354, P66, DOI 10.1038/354066a0; Chen JG, 1998, J BIOL CHEM, V273, P12675, DOI 10.1074/jbc.273.20.12675; Hansra N, 2004, J NEUROSCI, V24, P4082, DOI 10.1523/JNEUROSCI.0664-04.2004; HOFFMAN BJ, 1991, SCIENCE, V254, P579, DOI 10.1126/science.1948036; HUMPHREYS CJ, 1994, BIOCHEMISTRY-US, V33, P9118, DOI 10.1021/bi00197a014; Javitch JA, 1996, MOL PHARMACOL, V49, P692; Jones BJ, 2002, PHARMACOL BIOCHEM BE, V71, P555, DOI 10.1016/S0091-3057(01)00745-6; Keller PC, 2004, BIOCHEMISTRY-US, V43, P8510, DOI 10.1021/bi035971g; Kilic F, 2003, MOL PHARMACOL, V64, P440, DOI 10.1124/mol.64.2.440; Lacroix E, 1998, J MOL BIOL, V284, P173, DOI 10.1006/jmbi.1998.2145; Lesch KP, 1996, SCIENCE, V274, P1527, DOI 10.1126/science.274.5292.1527; MILLER KJ, 1994, J BIOL CHEM, V269, P27351; Mitchell SM, 2004, J BIOL CHEM, V279, P24089, DOI 10.1074/jbc.M311173200; Murphy DL, 1998, J CLIN PSYCHIAT, V59, P4; Ozaki N, 2003, MOL PSYCHIATR, V8, P933, DOI 10.1038/sj.mp.4001365; Pebay-Peyroula E, 2003, NATURE, V426, P39, DOI 10.1038/nature02056; RAMAMOORTHY S, 1993, P NATL ACAD SCI USA, V90, P2542, DOI 10.1073/pnas.90.6.2542; Rost B, 2004, NUCLEIC ACIDS RES, V32, pW321, DOI 10.1093/nar/gkh377; RUDNICK G, 1991, MOL PHARMACOL, V40, P421; RUDNICK G, 1992, P NATL ACAD SCI USA, V89, P1817, DOI 10.1073/pnas.89.5.1817; Rudnick G., 2002, TRANSMEMBRANE TRANSP, P125; Rudnick Gary, 2002, P25; Sato Y, 2004, J BIOL CHEM, V279, P22926, DOI 10.1074/jbc.M312194200; Sher L, 1999, J AFFECT DISORDERS, V53, P203, DOI 10.1016/S0165-0327(98)00194-3; Smits KM, 2004, MOL PSYCHIATR, V9, P433, DOI 10.1038/sj.mp.4001488; Stahl SM, 1998, J AFFECT DISORDERS, V51, P215, DOI 10.1016/S0165-0327(98)00221-3; Stephan MM, 1997, BIOCHEMISTRY-US, V36, P1322, DOI 10.1021/bi962150l; TATE CG, 1994, J BIOL CHEM, V269, P26303; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; WALL SC, 1993, MOL PHARMACOL, V43, P264; WALL SC, 1995, MOL PHARMACOL, V47, P544; Weizman A, 2000, Pharmacogenomics, V1, P335, DOI 10.1517/14622416.1.3.335; Yernool D, 2004, NATURE, V431, P811, DOI 10.1038/nature03018	35	39	39	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	2005	280	35					30807	30813		10.1074/jbc.M504087200	http://dx.doi.org/10.1074/jbc.M504087200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	958ZX	15994310	hybrid			2022-12-25	WOS:000231487800021
J	Wang, J; Zhang, X; Thomas, SM; Grandis, JR; Wells, A; Chen, Z; Ferris, RL				Wang, J; Zhang, X; Thomas, SM; Grandis, JR; Wells, A; Chen, Z; Ferris, RL			Chemokine receptor 7 activates phosphoinositide-3 kinase-mediated invasive and prosurvival pathways in head and neck cancer cells independent of EGFR	ONCOGENE			English	Article						CCR7; EGFR; PI3K; Akt; PLC gamma-1	GASTRIN-RELEASING-PEPTIDE; GROWTH-FACTOR RECEPTOR; UP-REGULATION; DENDRITIC CELLS; CARCINOMA; PROTEIN; 3-KINASE; SIGNAL; EXPRESSION; AKT	Chemokine receptor 7 (CCR7) upregulation, which mediates immune cell survival and migration to lymph nodes, has recently been associated with nodal metastasis of squamous cell carcinoma of the head and neck (SCCHN). However, the mechanism of CCR7 in tumor progression, its downstream signaling mediators, and interactions with other pathways contributing to metastasis of SCCHN have not been determined. We hypothesized that inflammatory chemokine-mediated signals could also promote tumor proliferation and mitogenic effects. Functional assays showed that chemotaxis and invasion of metastatic SCCHN cells were dependent on phosphoinositide-3 kinase (PI3K) and its substrate, activated phospholipase C gamma-1. In addition, treatment of CCR7(+) metastatic SCCHN cells with CCL19 (MIP-3 beta) showed rapid activation of the prosurvival, PI3K/Akt pathway. Transactivation of EGFR-mediated and mitogen-activated protein kinase signaling pathways, which can promote migration and survival in parallel, did not appear to contribute to the functional or biochemical effects of CCR7 stimulation. Thus, proinflammatory chemokine signals that mediate activation, trafficking and survival of tumor-infiltrating immune cells in the tumor microenvironment actually appear to induce signals for progression of cancer cells. The CCR7-mediated pathway in metastatic SCCHN cells functions independently of EGFR signal transduction and therefore may represent an additional target for therapeutic intervention to prevent tumor progression and metastasis.	Univ Pittsburgh, Inst Canc, Dept Otolaryngol, Sch Med, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Inst Canc, Dept Immunol, Sch Med, Pittsburgh, PA 15213 USA; Emory Univ, Winship Canc Ctr, Dept Hematol & Oncol, Atlanta, GA 30332 USA; Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Emory University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Ferris, RL (corresponding author), Univ Pittsburgh, Inst Canc, Dept Otolaryngol, Sch Med, Res Wing,Room 1-19D,5117 Ctr Ave, Pittsburgh, PA 15213 USA.	ferrisrl@upmc.edu	Thomas, Sufi/O-1487-2018; Thomas, Sufi Mary/AFR-1642-2022	Thomas, Sufi/0000-0001-5370-0842; Thomas, Sufi Mary/0000-0001-5370-0842; Wells, Alan/0000-0002-1637-8150				Amornphimoltham P, 2004, CLIN CANCER RES, V10, P4029, DOI 10.1158/1078-0432.CCR-03-0249; Benistant C, 2000, ONCOGENE, V19, P5083, DOI 10.1038/sj.onc.1203871; Beraud C, 1999, P NATL ACAD SCI USA, V96, P429, DOI 10.1073/pnas.96.2.429; Biswas SK, 2002, J INTERF CYTOK RES, V22, P527, DOI 10.1089/10799900252982007; Curnock AP, 2003, J IMMUNOL METHODS, V273, P29, DOI 10.1016/S0022-1759(02)00416-7; Curnock AP, 2002, IMMUNOLOGY, V105, P125, DOI 10.1046/j.1365-2567.2002.01345.x; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Ellis CA, 1999, J BIOL CHEM, V274, P13718, DOI 10.1074/jbc.274.19.13718; Ganju RK, 1998, J BIOL CHEM, V273, P23169, DOI 10.1074/jbc.273.36.23169; Grandis JR, 1998, J CELL BIOCHEM, V69, P55, DOI 10.1002/(SICI)1097-4644(19980401)69:1<55::AID-JCB6>3.0.CO;2-U; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; HEO DS, 1989, CANCER RES, V49, P5167; Kane LP, 2001, NAT IMMUNOL, V2, P37, DOI 10.1038/83144; Lango MN, 2002, J NATL CANCER I, V94, P375; Li XX, 2000, P NATL ACAD SCI USA, V97, P10489, DOI 10.1073/pnas.160265197; Li YM, 2004, CANCER CELL, V6, P459, DOI 10.1016/j.ccr.2004.09.027; Lui VWY, 2003, ONCOGENE, V22, P6183, DOI 10.1038/sj.onc.1206720; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Mailliard RB, 2004, CANCER RES, V64, P5934, DOI 10.1158/0008-5472.CAN-04-1261; Mills GB, 2001, SEMIN ONCOL, V28, P125, DOI 10.1053/sonc.2001.28554; Murakami T, 2003, J EXP MED, V198, P1337, DOI 10.1084/jem.20030593; Pilkington KR, 2004, J BIOL CHEM, V279, P40276, DOI 10.1074/jbc.M405808200; Sanchez-Sanchez N, 2004, BLOOD, V104, P619, DOI 10.1182/blood-2003-11-3943; Sotsios Y, 2000, IMMUNOL REV, V177, P217, DOI 10.1034/j.1600-065X.2000.17712.x; Thomas SM, 2003, CANCER RES, V63, P5629; Tosi L, 2005, HEAD NECK-J SCI SPEC, V27, P130, DOI 10.1002/hed.20120; Uchida D, 2003, EXP CELL RES, V290, P289, DOI 10.1016/S0014-4827(03)00344-6; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; Wang H, 2002, AM J PHYSIOL-CELL PH, V283, pC1351, DOI 10.1152/ajpcell.00001.2002; Wang J, 2004, CANCER RES, V64, P1861, DOI 10.1158/0008-5472.CAN-03-2968; WELLS A, 2004, SCI STKE, V253, P47	31	84	91	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	38					5897	5904		10.1038/sj.onc.1208740	http://dx.doi.org/10.1038/sj.onc.1208740			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960KW	16007209				2022-12-25	WOS:000231590400012
J	Bykov, VJN; Issaeva, N; Zache, N; Shilov, A; Hultcrantz, M; Bergman, J; Selivanova, G; Wiman, KG				Bykov, VJN; Issaeva, N; Zache, N; Shilov, A; Hultcrantz, M; Bergman, J; Selivanova, G; Wiman, KG			Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPROTECTIVE AMINOTHIOL WR1065; DNA-BINDING; PHOSPHATIDYLSERINE EXTERNALIZATION; CLINICAL-IMPLICATIONS; REDOX CONTROL; CANCER CELLS; LUNG-CANCER; IN-VITRO; MUTATIONS; RESTORATION	Reactivation of mutant p53 is likely to provide important benefits for treatment of chemotherapy- and radio-therapy-resistant tumors. We demonstrate here that the maleimide-derived molecule MIRA-1 can reactivate DNA binding and preserve the active conformation of mutant p53 protein in vitro and restore transcriptional transactivation to mutant p53 in living cells. MIRA-1 induced mutant p53-dependent cell death in different human tumor cells carrying tetracycline-regulated mutant p53. The structural analog MIRA-3 showed antitumor activity in vivo against human mutant p53-carrying tumor xenografts in SCID mice. The MIRA scaffold is a novel lead for the development of anticancer drugs specifically targeting mutant p53.	Karolinska Univ Hosp, Dept Oncol Pathol, Ctr Canc, Stockholm, Sweden; Karolinska Inst, MTC, SE-17177 Stockholm, Sweden; Inst Cytol & Genet, Novosibirsk 630090, Russia; Karolinska Inst, Dept Biosci, SE-14157 Huddinge, Sweden	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Russian Academy of Sciences; Institute of Cytology & Genetics ICG SB RAS; Karolinska Institutet	Selivanova, G (corresponding author), Karolinska Univ Hosp, Dept Oncol Pathol, Ctr Canc, Stockholm, Sweden.	Galina.Selivanova@mtc.ki.se; Wiman@cck.ki.se	Wiman, Klas/AAB-8399-2021; Issaeva, Natalia/K-4577-2019	Wiman, Klas/0000-0002-7113-524X; Issaeva, Natalia/0000-0001-5483-6610; Selivanova, Galina/0000-0002-8698-4332; Nakade Bykov, Vladimir/0000-0002-7199-8942				BARTEK J, 1991, ONCOGENE, V6, P1699; Beroud C, 1998, NUCLEIC ACIDS RES, V26, P200, DOI 10.1093/nar/26.1.200; Bhanoori M, 2003, ONCOGENE, V22, P117, DOI 10.1038/sj.onc.1206065; Bullock AN, 2001, NAT REV CANCER, V1, P68, DOI 10.1038/35094077; Buzek J, 2002, NUCLEIC ACIDS RES, V30, P2340, DOI 10.1093/nar/30.11.2340; Bykov VJN, 2003, EUR J CANCER, V39, P1828, DOI 10.1016/S0959-8049(03)00454-4; Bykov VJN, 2002, CARCINOGENESIS, V23, P2011, DOI 10.1093/carcin/23.12.2011; Bykov VJN, 2002, NAT MED, V8, P282, DOI 10.1038/nm0302-282; Campling Barbara G, 2003, Methods Mol Med, V75, P53; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Dornan D, 2004, NATURE, V429, P86, DOI 10.1038/nature02514; Elnemr A, 2000, INT J ONCOL, V16, P1111; Forsberg AJ, 2004, ANTIOXID REDOX SIGN, V6, P203, DOI 10.1089/152308604322899279; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; Gadducci A, 2002, EUR J GYNAECOL ONCOL, V23, P390; Geisler S, 2003, CLIN CANCER RES, V9, P5582; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Hainaut P, 2001, ANTIOXID REDOX SIGN, V3, P611, DOI 10.1089/15230860152542961; Hamilton David, 2004, Curr Oncol Rep, V6, P116, DOI 10.1007/s11912-004-0023-4; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Honda T, 2004, CANCER GENE THER, V11, P249, DOI 10.1038/sj.cgt.7700684; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Leng RP, 2003, CELL, V112, P779, DOI 10.1016/S0092-8674(03)00193-4; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; Nikolova PV, 2000, EMBO J, V19, P370, DOI 10.1093/emboj/19.3.370; North S, 2002, MOL CARCINOGEN, V33, P181, DOI 10.1002/mc.10038; Pluquet O, 2003, BIOCHEM PHARMACOL, V65, P1129, DOI 10.1016/S0006-2952(02)01655-6; RAINWATER R, 1995, MOL CELL BIOL, V15, P3892; Selivanova G, 1996, NUCLEIC ACIDS RES, V24, P3560, DOI 10.1093/nar/24.18.3560; Selivanova G, 1997, NAT MED, V3, P632, DOI 10.1038/nm0697-632; Seo YR, 2002, P NATL ACAD SCI USA, V99, P14548, DOI 10.1073/pnas.212319799; Sherr C J, 2000, Harvey Lect, V96, P73; Sun XZ, 2003, ANTIOXID REDOX SIGN, V5, P655, DOI 10.1089/152308603770310338; Ueda S, 2002, ANTIOXID REDOX SIGN, V4, P405, DOI 10.1089/15230860260196209; Wang JJ, 1997, CHEMOTHERAPY, V43, P182, DOI 10.1159/000239557; Wang JJ, 2002, ANTI-CANCER DRUG, V13, P533, DOI 10.1097/00001813-200206000-00012	36	177	187	0	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	2005	280	34					30384	30391		10.1074/jbc.M501664200	http://dx.doi.org/10.1074/jbc.M501664200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	957IC	15998635	hybrid			2022-12-25	WOS:000231362500050
J	Cain, SA; Baldock, C; Gallagher, J; Morgan, A; Bax, DV; Weiss, AS; Shuttleworth, CA; Kielty, CM				Cain, SA; Baldock, C; Gallagher, J; Morgan, A; Bax, DV; Weiss, AS; Shuttleworth, CA; Kielty, CM			Fibrillin-1 interactions with heparin - Implications for microfibril and elastic fiber assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN TROPOELASTIN; DIVALENT-CATIONS; INTEGRIN BINDING; TERNARY COMPLEX; MARFAN-SYNDROME; CELL-ADHESION; IN-VIVO; SULFATE; PROTEIN; DOMAIN	Fibrillin-1 assembly into microfibrils and elastic fiber formation involves interactions with glycosaminoglycans. We have used BIAcore technology to investigate fibrillin-1 interactions with heparin and with heparin saccharides that are analogous to S-domains of heparan sulfate. We have identified four high affinity heparin-binding sites on fibrillin-1, localized three of these sites, and defined their binding kinetics. Heparin binding to the fibrillin-1 N terminus has particularly rapid kinetics. Hyaluronan and chondroitin sulfate did not interact significantly with fibrillin-1. Heparin saccharides with more than 12 monosaccharide units bound strongly to all four fibrillin-1 sites. Heparin did not inhibit fibrillin-1 N- and C-terminal interactions or RGD-dependent cell attachment, but heparin and MAGP-1 competed for binding to the fibrillin-1 N terminus, and heparin and tropoelastin competed for binding to a central fibrillin-1 sequence. By regulating these key interactions, heparin can profoundly influence microfibril and elastic fiber assembly.	Univ Manchester, Fac Life Sci, UK Ctr Tissue Engn, Manchester M13 9PT, Lancs, England; Univ Manchester, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England; Christie Hosp NHS Trust, Canc Res UK, Manchester M20 4BX, Lancs, England; Univ Manchester, Christie Hosp NHS Trust, Dept Med Oncol, Manchester M20 4BX, Lancs, England; Univ Sydney, Sch Mol & Microbial Biosci G08, Sydney, NSW 2006, Australia	University of Manchester; University of Manchester; Cancer Research UK; Christie NHS Foundation Trust; Christie Hospital; University of Manchester; Christie NHS Foundation Trust; Christie Hospital; University of Manchester; University of Sydney	Kielty, CM (corresponding author), Univ Manchester, Fac Life Sci, UK Ctr Tissue Engn, Michael Smith Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	cay.kielty@manchester.ac.uk	Weiss, Anthony S/F-8103-2010; Weiss, Anthony S/GYV-0157-2022; Cain, Stuart A/G-2836-2017	Weiss, Anthony S/0000-0002-8106-4836; McGovern, Amanda/0000-0001-7727-3283; Cain, Stuart/0000-0001-8417-1058; Baldock, Clair/0000-0003-3497-1959				Baldock C, 2001, J CELL BIOL, V152, P1045, DOI 10.1083/jcb.152.5.1045; Bax DV, 2003, J BIOL CHEM, V278, P34605, DOI 10.1074/jbc.M303159200; Blackhall FH, 2003, BIOCHEM J, V375, P131, DOI 10.1042/BJ20030730; Buczek-Thomas JA, 2002, J CELL PHYSIOL, V192, P294, DOI 10.1002/jcp.10135; Clarke AW, 2004, EUR J BIOCHEM, V271, P3085, DOI 10.1111/j.1432-1033.2004.04246.x; Gallagher JT, 2000, PROTEOGLYCANS STRUCT, P27; IMBERTY A, 1999, PERSPECTIVES STRUCTU, P392; Isogai Z, 2002, J BIOL CHEM, V277, P4565, DOI 10.1074/jbc.M110583200; Isogai Z, 2003, J BIOL CHEM, V278, P2750, DOI 10.1074/jbc.M209256200; Jemth P, 2002, J BIOL CHEM, V277, P30567, DOI 10.1074/jbc.M203404200; Jensen SA, 2001, J BIOL CHEM, V276, P39661, DOI 10.1074/jbc.M104533200; Kielty CM, 1996, FEBS LETT, V386, P169, DOI 10.1016/0014-5793(96)00423-1; Kielty CM, 2002, J CELL SCI, V115, P2817; Kozel BA, 2004, MATRIX BIOL, V23, P23, DOI 10.1016/j.matbio.2004.02.004; Kramer KL, 2003, ANNU REV GENET, V37, P461, DOI 10.1146/annurev.genet.37.061103.090226; Kreuger J, 2002, EMBO J, V21, P6303, DOI 10.1093/emboj/cdf638; Lee SSJ, 2004, STRUCTURE, V12, P717, DOI 10.1016/j.str.2004.02.023; Lin GQ, 2002, J BIOL CHEM, V277, P50795, DOI 10.1074/jbc.M210611200; LINHARDT RJ, 1990, BIOCHEMISTRY-US, V29, P2611, DOI 10.1021/bi00462a026; Marson A, 2005, J BIOL CHEM, V280, P5013, DOI 10.1074/jbc.M409029200; MARTIN SL, 1995, GENE, V154, P159, DOI 10.1016/0378-1119(94)00848-M; Mecham R. P., 1994, EXTRACELLULAR MATRIX, P281; Mochizuki S, 2002, J BIOL CHEM, V277, P44854, DOI 10.1074/jbc.M205630200; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; MULLOY B, 1993, BIOCHEM J, V293, P849, DOI 10.1042/bj2930849; Murphy KJ, 2004, J BIOL CHEM, V279, P27239, DOI 10.1074/jbc.M401774200; Nakamura T, 2002, NATURE, V415, P171, DOI 10.1038/415171a; Nardella C, 2004, ANAL BIOCHEM, V332, P368, DOI 10.1016/j.ab.2004.05.050; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Oh ES, 2004, MOL CELLS, V17, P181; Osmond RIW, 2002, ANAL BIOCHEM, V310, P199, DOI 10.1016/S0003-2697(02)00396-2; PEREIRA L, 1993, HUM MOL GENET, V2, P961, DOI 10.1093/hmg/2.7.961; Pfaff M, 1996, FEBS LETT, V384, P247, DOI 10.1016/0014-5793(96)00325-0; Quondamatteo F, 2002, MATRIX BIOL, V21, P637, DOI 10.1016/S0945-053X(02)00100-2; Reinboth B, 2002, J BIOL CHEM, V277, P3950, DOI 10.1074/jbc.M109540200; Reinhardt DP, 2000, J BIOL CHEM, V275, P2205, DOI 10.1074/jbc.275.3.2205; Ricard-Blum S, 2004, J BIOL CHEM, V279, P2927, DOI 10.1074/jbc.M309868200; Ritty TM, 2003, BIOCHEM J, V375, P425, DOI 10.1042/BJ20030649; Robinson PN, 2001, CELL MOL LIFE SCI, V58, P1698, DOI 10.1007/PL00000807; Rock MJ, 2004, J BIOL CHEM, V279, P23748, DOI 10.1074/jbc.M400212200; Rodgers UR, 2004, BIOCHIMIE, V86, P173, DOI 10.1016/j.biochi.2004.03.002; Sakamoto H, 1996, J BIOL CHEM, V271, P4916; Segade F, 2002, J BIOL CHEM, V277, P11050, DOI 10.1074/jbc.M110347200; Smallridge RS, 2003, J BIOL CHEM, V278, P12199, DOI 10.1074/jbc.M208266200; Spillmann D, 1998, J BIOL CHEM, V273, P15487, DOI 10.1074/jbc.273.25.15487; Tiedemann K, 2001, J BIOL CHEM, V276, P36035, DOI 10.1074/jbc.M104985200; Toonkool P, 2001, J BIOL CHEM, V276, P44575, DOI 10.1074/jbc.M107920200; Trask BC, 2000, MOL BIOL CELL, V11, P1499, DOI 10.1091/mbc.11.5.1499; Wallis DD, 2003, J CELL BIOCHEM, V90, P641, DOI 10.1002/jcb.10657; Yanagisawa H, 2002, NATURE, V415, P168, DOI 10.1038/415168a	50	79	83	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	2005	280	34					30526	30537		10.1074/jbc.M501390200	http://dx.doi.org/10.1074/jbc.M501390200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	957IC	15980072	hybrid			2022-12-25	WOS:000231362500067
J	Iitaka, C; Miyazaki, K; Akaike, T; Ishida, N				Iitaka, C; Miyazaki, K; Akaike, T; Ishida, N			A role for glycogen synthase kinase-3 beta in the mammalian circadian clock	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-I-EPSILON; MOLECULAR-MECHANISM; PERIPHERAL-TISSUES; GENE-EXPRESSION; NUCLEAR ENTRY; INTACT-CELLS; RHYTHMS; PROTEIN; LITHIUM; PHOSPHORYLATION	The Drosophila shaggy gene product is a mammalian glycogen synthase kinase-3 beta (GSK-3 beta) homologue that contributes to the circadian clock of the Drosophila through TIMELESS phosphorylation, and it regulates nuclear translocation of the PERIOD/TIMELESS heterodimer. We found that mammalian GSK-3 beta is expressed in the suprachiasmatic nucleus and liver of mice and that GSK-3 beta phosphorylation exhibits robust circadian oscillation. Rhythmic GSK-3 beta phosphorylation is also observed in serum-shocked NIH3T3 cells. Exposing serum-shocked NIH3T3 cells to lithium chloride, a specific inhibitor of GSK-3 beta, increases GSK-3 beta phosphorylation and delays the phase of rhythmic clock gene expression. On the other hand, GSK-3 beta overexpression advances the phase of clock gene expression. We also found that GSK-3 beta interacts with PERIOD2 (PER2) in vitro and in vivo. Recombinant GSK-3 beta can phosphorylate PER2 in vitro. GSK-3 beta promotes the nuclear translocation of PER2 in COS1 cells. The present data suggest that GSK-3 beta plays important roles in mammalian circadian clock.	Natl Inst Adv Ind Sci & Technol, Inst Biol Resource & Funct, Clock Cell Biol Res Grp, Tsukuba, Ibaraki 3058566, Japan; Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Dept Biomol Engn, Midori Ku, Yokohama, Kanagawa 2268501, Japan; Univ Tsukuba, Inst Appl Biochem, Tsukuba, Ibaraki 3058502, Japan	National Institute of Advanced Industrial Science & Technology (AIST); Tokyo Institute of Technology; University of Tsukuba	Ishida, N (corresponding author), Natl Inst Adv Ind Sci & Technol, Inst Biol Resource & Funct, Clock Cell Biol Res Grp, Cent 6,1-1-1 Higashi, Tsukuba, Ibaraki 3058566, Japan.	n.ishida@aist.go.jp	Kinoshita, Chisato/AAW-5116-2020; Miyazaki, Koyomi/L-6539-2018	Kinoshita, Chisato/0000-0001-5877-0196; Miyazaki, Koyomi/0000-0002-5464-1095				Akashi M, 2000, GENE DEV, V14, P645; Balsalobre A, 2000, SCIENCE, V289, P2344, DOI 10.1126/science.289.5488.2344; Balsalobre A, 1998, CELL, V93, P929, DOI 10.1016/S0092-8674(00)81199-X; Chang DC, 2001, NEURON, V29, P555, DOI 10.1016/S0896-6273(01)00230-6; De Sarno P, 2002, NEUROPHARMACOLOGY, V43, P1158, DOI 10.1016/S0028-3908(02)00215-0; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Edery I, 2000, PHYSIOL GENOMICS, V3, P59, DOI 10.1152/physiolgenomics.2000.3.2.59; Eide EJ, 2002, J BIOL CHEM, V277, P17248, DOI 10.1074/jbc.M111466200; ENGELMANN W, 1973, Z NATURFORSCH C, VC 28, P733; Field MD, 2000, NEURON, V25, P437, DOI 10.1016/S0896-6273(00)80906-X; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; Glossop NRJ, 2002, J CELL SCI, V115, P3369; Harwood AJ, 2001, CELL, V105, P821, DOI 10.1016/S0092-8674(01)00412-3; Hogenesch JB, 1998, P NATL ACAD SCI USA, V95, P5474, DOI 10.1073/pnas.95.10.5474; Ishida N, 1999, P NATL ACAD SCI USA, V96, P8819, DOI 10.1073/pnas.96.16.8819; Ishida N, 2001, BIOCHEM BIOPH RES CO, V286, P1, DOI 10.1006/bbrc.2001.5207; Jin XW, 1999, CELL, V96, P57, DOI 10.1016/S0092-8674(00)80959-9; Keesler GA, 2000, NEUROREPORT, V11, P951, DOI 10.1097/00001756-200004070-00011; King DP, 2000, ANNU REV NEUROSCI, V23, P713, DOI 10.1146/annurev.neuro.23.1.713; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Kume K, 1999, CELL, V98, P193, DOI 10.1016/S0092-8674(00)81014-4; Lee C, 2001, CELL, V107, P855, DOI 10.1016/S0092-8674(01)00610-9; Lowrey PL, 2000, SCIENCE, V288, P483, DOI 10.1126/science.288.5465.483; Martinek S, 2001, CELL, V105, P769, DOI 10.1016/S0092-8674(01)00383-X; McNamara P, 2001, CELL, V105, P877, DOI 10.1016/S0092-8674(01)00401-9; Miyazaki K, 2001, MOL CELL BIOL, V21, P6651, DOI 10.1128/MCB.21.19.6651-6659.2001; Oishi K, 1998, NEUROSCI LETT, V256, P117, DOI 10.1016/S0304-3940(98)00765-4; Panda S, 2002, NATURE, V417, P329, DOI 10.1038/417329a; PITTENDRIGH CS, 1993, ANNU REV PHYSIOL, V55, P16; Planel E, 2001, J BIOL CHEM, V276, P34298, DOI 10.1074/jbc.M102780200; Ripperger JA, 2000, GENE DEV, V14, P679; STAMBOLIC V, 1994, BIOCHEM J, V303, P701, DOI 10.1042/bj3030701; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; Takano A, 2000, FEBS LETT, V477, P106, DOI 10.1016/S0014-5793(00)01755-5; Terazono H, 2003, P NATL ACAD SCI USA, V100, P6795, DOI 10.1073/pnas.0936797100; Vielhaber E, 2000, MOL CELL BIOL, V20, P4888, DOI 10.1128/MCB.20.13.4888-4899.2000; Wager-Smith K, 2000, NAT GENET, V26, P23, DOI 10.1038/79134; Weston CR, 2001, SCIENCE, V292, P2439, DOI 10.1126/science.1063279; WOODGETT JR, 2001, SCI STKE, pRE12; Yagita K, 2002, EMBO J, V21, P1301, DOI 10.1093/emboj/21.6.1301; Yamaguchi S, 2000, MOL CELL BIOL, V20, P4773, DOI 10.1128/MCB.20.13.4773-4781.2000; Young MW, 2000, SCIENCE, V288, P451, DOI 10.1126/science.288.5465.451; Zhang F, 2003, J BIOL CHEM, V278, P33067, DOI 10.1074/jbc.M212635200	44	273	280	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	2005	280	33					29397	29402		10.1074/jbc.M503526200	http://dx.doi.org/10.1074/jbc.M503526200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	954SX	15972822	hybrid			2022-12-25	WOS:000231176200003
J	Obeng, EA; Boise, LH				Obeng, EA; Boise, LH			Caspase-12 and caspase-4 are not required for caspase-dependent endoplasmic reticulum stress-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNFOLDED PROTEIN RESPONSE; PLASMA-CELL DIFFERENTIATION; TRANSCRIPTION FACTOR XBP-1; CYTOCHROME-C RELEASE; DEATH PROGRAM; ALZHEIMERS-DISEASE; PROAPOPTOTIC BAX; CARCINOMA-CELLS; MYELOMA CELLS; ER STRESS	Alterations in cellular homeostasis that affect protein folding in the endoplasmic reticulum (ER) trigger a signaling pathway known as the unfolded protein response (UPR). The initially cytoprotective UPR will trigger an apoptotic cascade if the cellular insult is not corrected; however, the proteins required to initiate this cell death pathway are poorly understood. In this study, we show that UPR gene expression is induced in cells treated with ER stress agents in the presence or absence of murine caspase-12 or human caspase-4 expression and in cells that overexpress Bcl-x(L) or a dominant negative caspase-9. We further demonstrate that ER stress-induced apoptosis is a caspase-dependent process that does not require the expression of caspase-12 or caspase-4 but can be inhibited by overexpression of Bcl-x(L) or a dominant negative caspase-9. Additionally, treatment of human and murine cells with ER stress agents led to the cleavage of the caspase-4 fluorogenic substrate, LEVD-7-amino-4-trifluoromethylcoumarin, in the presence or absence of caspase-12 or caspase-4 expression, whereas Bcl-x(L) or a dominant negative caspase-9 overexpression inhibited LEVD-7-amino-4-trifluoromethylcoumarin cleavage. These data suggest that caspase-12 and caspase-4 are not required for the induction of ER stress-induced apoptosis and that caspase-4-like activity is not always associated with an initiating event.	Univ Miami, Miller Sch Med, Dept Microbiol & Immunol, Miami, FL 33101 USA; Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL 33101 USA	University of Miami; University of Miami	Boise, LH (corresponding author), Univ Miami, Miller Sch Med, Dept Microbiol & Immunol, POB 016960,R-138, Miami, FL 33101 USA.	lboise@med.miami.edu	Obeng, Esther/N-8088-2018; Boise, Lawrence/AAD-2314-2019	Boise, Lawrence/0000-0001-9436-8815	NIGMS NIH HHS [R0-1 GM68513] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bassik MC, 2004, EMBO J, V23, P1207, DOI 10.1038/sj.emboj.7600104; Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0; BOISE LH, 1995, IMMUNITY, V3, P87, DOI 10.1016/1074-7613(95)90161-2; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; CEPERO E, 2005, IN PRESS ONCOGENE; Chatterjee S, 1997, CANCER RES, V57, P5112; DeGracia DJ, 2004, J NEUROCHEM, V91, P1, DOI 10.1111/j.1471-4159.2004.02703.x; Donepudi M, 2003, MOL CELL, V11, P543, DOI 10.1016/S1097-2765(03)00059-5; DRUMMOND IAS, 1987, J BIOL CHEM, V262, P12801; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; Fribley A, 2004, MOL CELL BIOL, V24, P9695, DOI 10.1128/MCB.24.22.9695-9704.2004; Gass JN, 2002, J BIOL CHEM, V277, P49047, DOI 10.1074/jbc.M205011200; Grad JM, 2001, BLOOD, V98, P805, DOI 10.1182/blood.V98.3.805; Hacki J, 2000, ONCOGENE, V19, P2286, DOI 10.1038/sj.onc.1203592; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Hitomi J, 2004, J CELL BIOL, V165, P347, DOI 10.1083/jcb.200310015; Imaizumi K, 2001, BBA-MOL BASIS DIS, V1536, P85, DOI 10.1016/S0925-4439(01)00049-7; Iwakoshi NN, 2003, NAT IMMUNOL, V4, P321, DOI 10.1038/ni907; Iwakoshi NN, 2003, IMMUNOL REV, V194, P29, DOI 10.1034/j.1600-065X.2003.00057.x; Johnson BW, 1999, J BIOL CHEM, V274, P18552, DOI 10.1074/jbc.274.26.18552; Kalai M, 2003, J CELL BIOL, V162, P457, DOI 10.1083/jcb.200303157; Katayama T, 2004, J CHEM NEUROANAT, V28, P67, DOI 10.1016/j.jchemneu.2003.12.004; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kheradpezhouh M, 2003, NEUROSIGNALS, V12, P315, DOI 10.1159/000075314; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; LEE AS, 1983, J BIOL CHEM, V258, P597; Lee K, 2002, GENE DEV, V16, P452, DOI 10.1101/gad.964702; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Mandic A, 2003, J BIOL CHEM, V278, P9100, DOI 10.1074/jbc.M210284200; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; Morishima N, 2004, J BIOL CHEM, V279, P50375, DOI 10.1074/jbc.M408493200; Morishima N, 2002, J BIOL CHEM, V277, P34287, DOI 10.1074/jbc.M204973200; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Paroni G, 2002, J BIOL CHEM, V277, P15147, DOI 10.1074/jbc.M112338200; Patil C, 2001, CURR OPIN CELL BIOL, V13, P349, DOI 10.1016/S0955-0674(00)00219-2; Rao RV, 2002, FEBS LETT, V514, P122, DOI 10.1016/S0014-5793(02)02289-5; Rao RV, 2002, J BIOL CHEM, V277, P21836, DOI 10.1074/jbc.M202726200; Rao RV, 2001, J BIOL CHEM, V276, P33869, DOI 10.1074/jbc.M102225200; Reimold AM, 2000, GENE DEV, V14, P152; Reimold AM, 2001, NATURE, V412, P300, DOI 10.1038/35085509; Robertson JD, 2002, J BIOL CHEM, V277, P29803, DOI 10.1074/jbc.M204185200; Ruiz-Vela A, 2005, EMBO REP, V6, P379, DOI 10.1038/sj.embor.7400375; Saleh M, 2004, NATURE, V429, P75, DOI 10.1038/nature02451; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Shaffer AL, 2004, IMMUNITY, V21, P81, DOI 10.1016/j.immuni.2004.06.010; Stennicke HR, 1999, J BIOL CHEM, V274, P8359, DOI 10.1074/jbc.274.13.8359; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Yamaguchi H, 2004, J BIOL CHEM, V279, P45495, DOI 10.1074/jbc.M406933200; Yamaguchi H, 2003, CANCER RES, V63, P1483; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982; Zong WX, 2003, J CELL BIOL, V162, P59, DOI 10.1083/jcb.200302084; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	60	146	152	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	2005	280	33					29578	29587		10.1074/jbc.M502685200	http://dx.doi.org/10.1074/jbc.M502685200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	954SX	15975932	hybrid			2022-12-25	WOS:000231176200025
J	Twizere, JC; Lefebvre, L; Collete, D; Debacq, C; Urbain, P; Heremans, H; Jauniaux, JC; Burny, A; Willems, L; Kettmann, R				Twizere, JC; Lefebvre, L; Collete, D; Debacq, C; Urbain, P; Heremans, H; Jauniaux, JC; Burny, A; Willems, L; Kettmann, R			The homeobox protein MSX2 interacts with tax oncoproteins and represses their transactivation activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL LEUKEMIA-VIRUS; LONG TERMINAL REPEAT; TRANS-ACTING FACTOR; RAS ONCOGENE; TYPE-1 TAX; IN-VITRO; EXPRESSION; GENE; TRANSFORMATION; ACTIVATION	Bovine leukemia virus (BLV) tax is an essential gene involved in the transcriptional activation of viral expression. Tax is also believed to be implicated in leuke-mogenesis because of its ability to immortalize primary cells in vitro. To gain insight into the molecular pathways mediating the activities of this important gene, we identified cellular proteins interacting with Tax. By means of a two-hybrid approach, we show that Tax specifically interacts with MSX2, a general repressor of gene expression. GST pull-down experiments and coimmunoprecipitation assays further confirmed binding specificity. Furthermore, the N-terminal residues 1-79 of MSX2 are required for binding, whereas the C-terminal residues 201-267 of MSX2 do not play a critical role. Whereas the oncogenic potential of Tax in primary cells was only slightly affected by overexpression of MSX2, the other function of Tax, namely LTR-dependent transcriptional activation, was inhibited by MSX2 in human HeLa and bovine B-lymphoblastoid (BL3) cell lines. This MSX2 repression function can be counteracted by overexpression of transcription factors CREB2 and RAP74. The Tax/MSX2 interplay thus results in repression of viral transcriptional activation possibly acting as a regulatory feedback loop. Importantly, this viral gene silencing is not strictly associated with a concomitant loss of Tax oncogenicity as measured by its ability to immortalize primary cells. And interestingly, MSX2 also interacts with and inhibits the transactivation function of the related Tax1 protein encoded by the Human T-cell leukemia virus type 1 (HTLV-1).	Fac Agron, B-5030 Gembloux, Belgium; Katholieke Univ Leuven, Rega Inst, B-3000 Louvain, Belgium; Deutsch Krebsforschungszentrum, D-69120 Heidelberg, Germany	KU Leuven; Helmholtz Association; German Cancer Research Center (DKFZ)	Willems, L (corresponding author), Fac Agron, 13 Ave Marechal Juin, B-5030 Gembloux, Belgium.	willems.1@fsagx.ac.be	Twizere, Jean-Claude/AAG-3706-2019	Willems, Luc/0000-0002-0563-2213; TWIZERE, Jean-Claude/0000-0002-8683-705X				Adam E, 1996, J VIROL, V70, P1990, DOI 10.1128/JVI.70.3.1990-1999.1996; Blattner WA, 1999, P ASSOC AM PHYSICIAN, V111, P563, DOI 10.1046/j.1525-1381.1999.99210.x; BOROS IM, 1995, VIROLOGY, V214, P207, DOI 10.1006/viro.1995.9939; BRADY J, 1987, J VIROL, V61, P2175, DOI 10.1128/JVI.61.7.2175-2181.1987; Catron KM, 1996, MECH DEVELOP, V55, P185, DOI 10.1016/0925-4773(96)00503-5; Chu ZL, 1999, J BIOL CHEM, V274, P15297, DOI 10.1074/jbc.274.22.15297; COELHO CND, 1991, DEVELOPMENT, V113, P1487; DAVIDSON D, 1995, TRENDS GENET, V11, P405, DOI 10.1016/S0168-9525(00)89124-6; DERSE D, 1987, J VIROL, V61, P2462, DOI 10.1128/JVI.61.8.2462-2471.1987; FRANCHINI G, 1995, BAILLIERE CLIN HAEM, V1, P131; FUJISAWA J, 1985, P NATL ACAD SCI USA, V82, P2277, DOI 10.1073/pnas.82.8.2277; Geoffroy V, 1995, J BIOL CHEM, V270, P30973, DOI 10.1074/jbc.270.52.30973; Haller K, 2002, MOL CELL BIOL, V22, P3327, DOI 10.1128/MCB.22.10.3327-3338.2002; HOFFMANN HM, 1994, P NATL ACAD SCI USA, V91, P12887, DOI 10.1073/pnas.91.26.12887; JABS EW, 1993, CELL, V75, P443, DOI 10.1016/0092-8674(93)90379-5; Jeang KT, 2004, J BIOL CHEM, V279, P31991, DOI 10.1074/jbc.R400009200; JEANG KT, 1988, J VIROL, V62, P4499, DOI 10.1128/JVI.62.12.4499-4509.1988; Jiang H, 1999, MOL CELL BIOL, V19, P8136; Jiang TX, 1999, J INVEST DERMATOL, V113, P230, DOI 10.1046/j.1523-1747.1999.00680.x; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; Kettmann R., 1994, RETROVIRIDAE, V3, P39, DOI DOI 10.1007/978-1-4899-1730-0_2; KRITZIK MR, 1999, J ENDOCRINOL, V163, P523; LIU YH, 1995, P NATL ACAD SCI USA, V92, P6137, DOI 10.1073/pnas.92.13.6137; MCGUIRE KL, 1993, J VIROL, V67, P1590, DOI 10.1128/JVI.67.3.1590-1599.1993; Mina M, 1996, CONNECT TISSUE RES, V35, P79, DOI 10.3109/03008209609029177; Newberry EP, 1997, BIOCHEMISTRY-US, V36, P10451, DOI 10.1021/bi971008x; POZZATTI R, 1990, MOL CELL BIOL, V10, P413, DOI 10.1128/MCB.10.1.413; SIEKEVITZ M, 1987, P NATL ACAD SCI USA, V84, P5389, DOI 10.1073/pnas.84.15.5389; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; SONG KN, 1992, NATURE, V360, P477, DOI 10.1038/360477a0; SUZUKI M, 1993, BIOCHEM BIOPH RES CO, V194, P187, DOI 10.1006/bbrc.1993.1802; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; Takahashi C, 1996, ONCOGENE, V12, P2137; Twizere JC, 2000, J VIROL, V74, P9895, DOI 10.1128/JVI.74.21.9895-9902.2000; Twizere JC, 2003, J NATL CANCER I, V95, P1846, DOI 10.1093/jnci/djg118; WILLEMS L, 1991, ONCOGENE, V6, P159; WILLEMS L, 1987, EMBO J, V6, P3385, DOI 10.1002/j.1460-2075.1987.tb02661.x; WILLEMS L, 1992, P NATL ACAD SCI USA, V89, P3957, DOI 10.1073/pnas.89.9.3957; WILLEMS L, 1992, J VIROL, V66, P766, DOI 10.1128/JVI.66.2.766-772.1992; Willems L, 1998, ONCOGENE, V16, P2165, DOI 10.1038/sj.onc.1201765; WILLEMS L, 1993, J VIROL, V67, P4078, DOI 10.1128/JVI.67.7.4078-4085.1993; WILLEMS L, 1990, EMBO J, V9, P1577, DOI 10.1002/j.1460-2075.1990.tb08277.x; Willems L, 2000, AIDS RES HUM RETROV, V16, P1787, DOI 10.1089/08892220050193326; WOLOSHIN P, 1995, CELL, V82, P611, DOI 10.1016/0092-8674(95)90033-0; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6	46	9	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	2005	280	33					29804	29811		10.1074/jbc.M503674200	http://dx.doi.org/10.1074/jbc.M503674200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	954SX	15970589	hybrid, Green Published			2022-12-25	WOS:000231176200051
J	Carny, O; Gazit, E				Carny, O; Gazit, E			A model for the role of short self-assembled peptides in the very early stages of the origin of life	FASEB JOURNAL			English	Article						aromatic interactions; closed-cage nanostructures; molecular recognition; origin of life; peptides; self-association; pi-pi stacking	AMYLOID FIBRIL FORMATION; SURFACTANT-LIKE PEPTIDES; FORM NANOTUBES; AMINO-ACIDS; RNA; RECOGNITION; STACKING; ATP; EVOLUTION; STATE	The molecular basis of the origin of life is one of the most fundamental questions in modern biology. While the "RNA world" hypothesis offers a very sensible model for the evolvement of the current biochemical networks, there is a lack of knowledge about the early steps that led to the formation of the first RNA molecules. This issue is essential as it is practically impossible that complex molecules as functional RNA oligonucleotides had evolved spontaneously. It was recently demonstrated that peptide molecules as simple as dipeptides can self-assemble into well-ordered tubular, fibrilar, and closed-cage structures. Other studies have confirmed the ability of dipeptides to act as catalysts and the capability of other peptides, as short as tripeptides, to serve as a template for nucleotide binding and orientation. Unlike complex RNA molecules, the spontaneous formation of functional short peptides in the primordial earth conditions is very likely. We suggest a novel mechanism for the origin of life that is based on the ability of short peptides to form encapsulated structures, catalyst chemical reaction, and serve as highly ordered template for the assembly of nucleotides. This model may explain the early events that led to the formation of the current biochemical machinery that combines the elaborated and coordinated interaction between nucleic acids and proteins to allow the function of living systems.	Tel Aviv Univ, Dept Mol Microbiol & Biotechnol, George S Wise Fac Life Sci, IL-69978 Tel Aviv, Israel	Tel Aviv University	Gazit, E (corresponding author), Tel Aviv Univ, Dept Mol Microbiol & Biotechnol, George S Wise Fac Life Sci, IL-69978 Tel Aviv, Israel.		Gazit, Ehud/C-3715-2011; Gazit, Ehud/M-8026-2019; Gazit, Ehud/AHE-9332-2022	Gazit, Ehud/0000-0001-5764-1720; Gazit, Ehud/0000-0001-5764-1720; 				ANDERS E, 1989, NATURE, V342, P255, DOI 10.1038/342255a0; Arrhenius G, 2000, CHEM GEOL, V169, P69, DOI 10.1016/S0009-2541(00)00333-8; BAHADUR K, 1958, NATURE, V182, P1668, DOI 10.1038/1821668a0; Blakaj DM, 2001, J AM CHEM SOC, V123, P2548, DOI 10.1021/ja005538j; BOHLER C, 2002, NATURE, V376, P578; Butterfield SM, 2004, ANGEW CHEM INT EDIT, V43, P724, DOI 10.1002/anie.200352527; Butterfield SM, 2003, J AM CHEM SOC, V125, P9580, DOI 10.1021/ja0359254; Chiti F, 2001, PROTEIN SCI, V10, P2541, DOI 10.1110/ps.ps.10201; DEAMER DW, 1993, ORIGINS LIFE CTR CON, P9; Dobson CM, 2003, NATURE, V426, P884, DOI 10.1038/nature02261; GABRIELE V, 1998, ANNU REV BIOPH BIOM, V27, P407; Gazit E, 2002, FASEB J, V16, P77, DOI 10.1096/fj.01-0442hyp; Gazit E, 2002, ANGEW CHEM INT EDIT, V41, P257, DOI 10.1002/1521-3773(20020118)41:2<257::AID-ANIE257>3.0.CO;2-M; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; Kochavi E, 1997, J MOL EVOL, V45, P342, DOI 10.1007/PL00006239; Lai J, 2003, CURR OPIN NEUROBIOL, V13, P291, DOI 10.1016/S0959-4388(03)00074-6; LARRALDE R, 1995, P NATL ACAD SCI USA, V92, P8158, DOI 10.1073/pnas.92.18.8158; LAZCANO A, 1988, J MOL EVOL, V27, P283, DOI 10.1007/BF02101189; LAZCANO A, 1988, J MOL EVOL, V27, P365, DOI 10.1007/BF02101199; Levy M, 1998, P NATL ACAD SCI USA, V95, P7933, DOI 10.1073/pnas.95.14.7933; Lilley DMJ, 2003, TRENDS BIOCHEM SCI, V28, P495, DOI 10.1016/S0968-0004(03)00191-9; Lu K, 2003, J AM CHEM SOC, V125, P6391, DOI 10.1021/ja0341642; MAHER KA, 1988, NATURE, V331, P612, DOI 10.1038/331612a0; MAJI SK, 2001, CHEM COMMUN CAMBRIDG; McCleskey SC, 2003, J AM CHEM SOC, V125, P1114, DOI 10.1021/ja021230b; Meierhenrich UJ, 2004, P NATL ACAD SCI USA, V101, P9182, DOI 10.1073/pnas.0403043101; Mojzsis SJ, 1996, NATURE, V384, P55, DOI 10.1038/384055a0; Naito A, 2004, MAGN RESON CHEM, V42, P247, DOI 10.1002/mrc.1323; NORBERG J, 1995, J AM CHEM SOC, V117, P10832, DOI 10.1021/ja00149a006; Orgel LE, 2004, CRIT REV BIOCHEM MOL, V39, P99, DOI 10.1080/10409230490460765; Pizzarello S, 2004, ORIGINS LIFE EVOL B, V34, P25, DOI 10.1023/B:ORIG.0000009826.76353.de; Plankensteiner K, 2004, ANGEW CHEM INT EDIT, V43, P1886, DOI 10.1002/anie.200353135; Reches M, 2004, NANO LETT, V4, P581, DOI 10.1021/nl035159z; Reches M, 2003, SCIENCE, V300, P625, DOI 10.1126/science.1082387; Reches M, 2002, J BIOL CHEM, V277, P35475, DOI 10.1074/jbc.M206039200; Rochet JC, 2000, CURR OPIN STRUC BIOL, V10, P60, DOI 10.1016/S0959-440X(99)00049-4; Rode BM, 1999, COORDIN CHEM REV, V190, P1085, DOI 10.1016/S0010-8545(99)00159-9; Rode BM, 1999, PEPTIDES, V20, P773, DOI 10.1016/S0196-9781(99)00062-5; Rode BM, 1999, PEPTIDES, V20, P1513, DOI 10.1016/S0196-9781(99)00163-1; Santoso S, 2002, NANO LETT, V2, P687, DOI 10.1021/n1025563i; Sazani PL, 2004, J AM CHEM SOC, V126, P8370, DOI 10.1021/ja049171k; Schneider SE, 2000, J AM CHEM SOC, V122, P542, DOI 10.1021/ja9935153; Shiels JC, 2002, NUCLEIC ACIDS RES, V30, P550, DOI 10.1093/nar/30.2.550; Song YJ, 2004, CHEM COMMUN, P1044, DOI 10.1039/b402126f; Sun LL, 2002, CHEM BIOL, V9, P619, DOI 10.1016/S1074-5521(02)00141-2; Takahashi Y, 2004, BIOORGAN MED CHEM, V12, P693, DOI 10.1016/j.bmc.2003.11.022; Tartaglia GG, 2004, PROTEIN SCI, V13, P1939, DOI 10.1110/ps.04663504; Tjernberg L, 2002, J BIOL CHEM, V277, P43243, DOI 10.1074/jbc.M205570200; Vauthey S, 2002, P NATL ACAD SCI USA, V99, P5355, DOI 10.1073/pnas.072089599; Zaychikov E, 1996, SCIENCE, V273, P107, DOI 10.1126/science.273.5271.107	51	83	82	0	37	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2005	19	9					1051	1055		10.1096/fj.04-3256hyp	http://dx.doi.org/10.1096/fj.04-3256hyp			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	951IO	15985527				2022-12-25	WOS:000230923000032
J	Pietri, M; Scheider, B; Mouillet-Richard, S; Ermonval, M; Mutel, V; Launay, JM; Kellermann, O				Pietri, M; Scheider, B; Mouillet-Richard, S; Ermonval, M; Mutel, V; Launay, JM; Kellermann, O			Reactive oxygen species-dependent TNF-alpha converting enzyme activation through stimulation of 5-HT2B and alpha(1D) autoreceptors in neuronal cells	FASEB JOURNAL			English	Article							TUMOR-NECROSIS-FACTOR; NADPH OXIDASE; SIGNAL-TRANSDUCTION; ALZHEIMERS-DISEASE; MYRISTATE ACETATE; RECEPTOR SUBTYPES; OXIDATIVE STRESS; LIPID RAFTS; EXPRESSION; SEROTONIN	A major determinant of neuronal homeostasis is the proper integration of cell signaling pathways recruited by a variety of neuronal and non-neuronal factors. By taking advantage of a neuroectodermal cell line (1C11) endowed with the capacity to differentiate into serotonergic (1C11(5-HT)) or noradrenergic (1C11(NE)) neurons, we identified serotonin (5-hydroxytryptamine, 5-HT)- and norepinephrine (NE)-dependent signaling cascades possibly involved in neuronal functions. First, we establish that 5-HT2B receptors and alpha(1D) adrenoceptors are functionally coupled to reactive oxygen species (ROS) synthesis through NADPH oxidase activation in 1C11(5-HT) and 1C11(NE) cells. This observation constitutes the prime evidence that bioaminergic autoreceptors take part in the control of the cellular redox equilibrium in a neuronal context. Second, our data identify TACE (TNF-alpha Converting Enzyme), a member of a disintegrin and metalloproteinase (ADAM) family, as a downstream target of the 5-HT2B and alpha(1D) receptor-NADPH oxidase signaling pathways. Upon 5-HT2B or alpha(1D) receptor stimulation, ROS fully govern TNF-alpha shedding in the surrounding milieu of 1C11(5-HT) or 1C11(NE) cells. Third, 5-HT2B and alpha(1D) receptor couplings to the NADPH oxidase-TACE cascade are strictly restricted to 1C11-derived progenies that have implemented a complete serotonergic or noradrenergic phenotype. Overall, these observations suggest that 5-HT2B and alpha(1D) autoreceptors may play a role in the maintenance of neuron- and neurotransmitter-associated functions. Eventually, our study may have implications regarding the origin of oxidative stress as well as upregulated expression of proinflammatory cytokines in neurodegenerative disorders, which may relate to the deviation of normal signaling pathways.	CNRS, Inst Andre Lwoff, UPR 1983, Inst Pasteur,Lab Differenciat Cellulaire & Pr, F-94801 Villejuif, France; F Hoffmann La Roche & Co Ltd, Pharma Res Dept, CH-4002 Basel, Switzerland; Univ Paris 05, Serv Biochim, Fac Pharm, Hop Lariboisiere EA3621, Paris, France	Centre National de la Recherche Scientifique (CNRS); Roche Holding; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite	Scheider, B (corresponding author), CNRS, Inst Andre Lwoff, UPR 1983, Inst Pasteur,Lab Differenciat Cellulaire & Pr, 7 Rue Guy Moquet, F-94801 Villejuif, France.	bschneid@vjf.cnrs.fr	Mouillet, Sophie/E-4960-2017; Schneider, Benoit/AAF-3850-2019	Mouillet, Sophie/0000-0002-8950-1949; PIETRI, Mathea/0000-0002-1819-2878; Ermonval, Myriam/0000-0002-9685-9826; Schneider, Benoit/0000-0002-1377-2670				Alonso MA, 2001, J CELL SCI, V114, P3957; Amin JK, 2001, J MOL CELL CARDIOL, V33, P131, DOI 10.1006/jmcc.2000.1285; Andersen JK, 2004, NAT MED, V10, pS18, DOI 10.1038/nrn1434; Anderson RGW, 2002, SCIENCE, V296, P1821, DOI 10.1126/science.1068886; Audia JE, 1996, J MED CHEM, V39, P2773, DOI 10.1021/jm960062t; Barnham KJ, 2004, NAT REV DRUG DISCOV, V3, P205, DOI 10.1038/nrd1330; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Black RA, 2002, INT J BIOCHEM CELL B, V34, P1, DOI 10.1016/S1357-2725(01)00097-8; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Choi DS, 1996, FEBS LETT, V391, P45, DOI 10.1016/0014-5793(96)00695-3; Cussac D, 2002, N-S ARCH PHARMACOL, V365, P242, DOI 10.1007/s00210-001-0505-y; DUSI S, 1993, BIOCHEM J, V290, P173, DOI 10.1042/bj2900173; Duxon MS, 1997, NEUROSCIENCE, V76, P323, DOI 10.1016/S0306-4522(96)00480-0; Friedman JI, 1999, BIOL PSYCHIAT, V46, P1243, DOI 10.1016/S0006-3223(99)00232-2; Gaspar P, 2003, NAT REV NEUROSCI, V4, P1002, DOI 10.1038/nrn1256; Gaur U, 2003, BIOCHEM PHARMACOL, V66, P1403, DOI 10.1016/S0006-2952(03)00490-8; Goridis C, 2002, NAT REV NEUROSCI, V3, P531, DOI 10.1038/nrn871; Hayley S, 1999, J NEUROSCI, V19, P5654; HIGUCHI M, 1994, J IMMUNOL, V152, P3550; Hoyer D, 2002, PHARMACOL BIOCHEM BE, V71, P533, DOI 10.1016/S0091-3057(01)00746-8; Ignatowski TA, 1997, J NEUROIMMUNOL, V79, P84, DOI 10.1016/S0165-5728(97)00107-0; Jaffre F, 2004, CIRCULATION, V110, P969, DOI 10.1161/01.CIR.0000139856.20505.57; Jerman JC, 2001, EUR J PHARMACOL, V414, P23, DOI 10.1016/S0014-2999(01)00775-0; Kamata H, 1999, CELL SIGNAL, V11, P1, DOI 10.1016/S0898-6568(98)00037-0; Kawakami N, 2000, BIOL PHARM BULL, V23, P1100; Kellermann O, 1996, BRIT J PHARMACOL, V118, P1161, DOI 10.1111/j.1476-5381.1996.tb15519.x; Kordek R, 1996, P NATL ACAD SCI USA, V93, P9754, DOI 10.1073/pnas.93.18.9754; Lee SL, 2001, AM J PHYSIOL-LUNG C, V281, pL646, DOI 10.1152/ajplung.2001.281.3.L646; LEE SL, 1994, AM J PHYSIOL, V266, pL46, DOI 10.1152/ajplung.1994.266.1.L46; LORIC S, 1995, MOL PHARMACOL, V47, P458; MacEwan DJ, 2002, CELL SIGNAL, V14, P477, DOI 10.1016/S0898-6568(01)00262-5; Manivet P, 2000, J BIOL CHEM, V275, P9324, DOI 10.1074/jbc.275.13.9324; Mattson MP, 2003, NEUROMOL MED, V4, P109, DOI 10.1385/NMM:4:1-2:109; MERRILL JE, 1992, DEV NEUROSCI-BASEL, V14, P1, DOI 10.1159/000111642; Mhatre M, 2004, J ALZHEIMERS DIS, V6, P147; Mouillet-Richard S, 2000, J BIOL CHEM, V275, P9186, DOI 10.1074/jbc.275.13.9186; Osborne PB, 2002, BRIT J PHARMACOL, V135, P226, DOI 10.1038/sj.bjp.0704453; Philipp M, 2004, PHARMACOL THERAPEUT, V101, P65, DOI 10.1016/j.pharmthera.2003.10.004; Porter RHP, 1999, BRIT J PHARMACOL, V128, P13, DOI 10.1038/sj.bjp.0702751; QUINN MT, 1993, J BIOL CHEM, V268, P20983; Scherzer JA, 1997, J IMMUNOL, V158, P913; Schneider B, 2003, P NATL ACAD SCI USA, V100, P13326, DOI 10.1073/pnas.2235648100; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531; Thannickal VJ, 2000, AM J PHYSIOL-LUNG C, V279, pL1005; Tournois C, 1998, J BIOL CHEM, V273, P17498, DOI 10.1074/jbc.273.28.17498; Vilhardt F, 2004, EMBO J, V23, P739, DOI 10.1038/sj.emboj.7600066; Viviani B, 2004, TOXICOL LETT, V149, P85, DOI 10.1016/j.toxlet.2003.12.022; Volgin DV, 2001, J CHEM NEUROANAT, V22, P157, DOI 10.1016/S0891-0618(01)00124-7; Williams A, 1997, BRAIN RES, V754, P171, DOI 10.1016/S0006-8993(97)00067-X; Xiao L, 2002, AM J PHYSIOL-CELL PH, V282, pC926, DOI 10.1152/ajpcell.00254.2001; Zhang ZL, 2001, FASEB J, V15, P303	51	36	37	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2005	19	9					1078	1087		10.1096/fj.04-3631com	http://dx.doi.org/10.1096/fj.04-3631com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	951IO	15985531				2022-12-25	WOS:000230923000036
J	Miccadei, S; Provenzano, C; Mojzisek, M; Natali, PG; Civitareale, D				Miccadei, S; Provenzano, C; Mojzisek, M; Natali, PG; Civitareale, D			Retinoblastoma protein acts as Pax 8 transcriptional coactivator	ONCOGENE			English	Article						Pax 8; retinoblastoma protein; thyroid; transcription; coactivator	CELL-CYCLE; EPITHELIAL-CELLS; FAMILY PROTEINS; RB/E2F PATHWAY; DNA-BINDING; GENE; DIFFERENTIATION; PROMOTER; RB; PRB	Control of cell proliferation and differentiation by the retinoblastoma protein (pRb) depends on its interactions with key cellular substrates. Available data indicate that pRb and the transcription factor Pax 8 play a crucial role in the differentiation of thyroid follicular cells. In this study, we show that pRb takes part in the complex assembled on the thyroperoxidase gene promoter acting as a transcriptional coactivator of Pax 8. Accordingly, pRb interacts with and potentiates Pax 8 transcriptional activity. In addition, we show that the downregulation of pRb gene expression, in thyrocytes, through RNA interference results in a reduction of the thyroperoxidase gene promoter activity mediated by the Pax 8-binding site. In agreement with these results and with the ability of the adenoviral protein E1A to bind pRb, we show that E1A downregulates Pax 8 activity and that such inhibition requires the E1A-Rb interaction. Furthermore, we show that the Pax 8/pRb synergy plays a role on the sodium/iodide symporter gene expression as well.	Italian Natl Council Res, Inst Neurobiol & Mol Med, I-00133 Rome, Italy; Regina Elena Inst Canc Res, Mol Pathol Lab, I-00158 Rome, Italy; Charles Univ Prague, Fac Med Hradec Kralove, Dept Med Biol & Genet, Hradec Kralove 50001, Czech Republic	Consiglio Nazionale delle Ricerche (CNR); IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Charles University Prague; University Hospital Hradec Kralove	Civitareale, D (corresponding author), Italian Natl Council Res, Inst Neurobiol & Mol Med, Via Fosso Cavaliere 100, I-00133 Rome, Italy.	dciv@yahoo.com	, stefaniamiccadei/J-2640-2017; Civitareale, Donato/B-4889-2015	, stefaniamiccadei/0000-0001-8890-6998; Civitareale, Donato/0000-0001-5719-9098				Adams PD, 2001, BBA-REV CANCER, V1471, pM123, DOI 10.1016/S0304-419X(01)00019-1; AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455; BERLINGIERI MT, 1993, ONCOGENE, V8, P249; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; Chen PL, 1996, P NATL ACAD SCI USA, V93, P465, DOI 10.1073/pnas.93.1.465; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; CIVITAREALE D, 1989, EMBO J, V8, P2537, DOI 10.1002/j.1460-2075.1989.tb08391.x; CIVITAREALE D, 1993, MOL ENDOCRINOL, V7, P1589, DOI 10.1210/me.7.12.1589; De Leo R, 2000, J BIOL CHEM, V275, P34100, DOI 10.1074/jbc.M003043200; Decary S, 2002, MOL CELL BIOL, V22, P7877, DOI 10.1128/MCB.22.22.7877-7888.2002; Decesse JT, 2001, ONCOGENE, V20, P962, DOI 10.1038/sj.onc.1204169; Di Palma T, 2003, J BIOL CHEM, V278, P3395, DOI 10.1074/jbc.M205977200; DIMAGLIANO P, 2000, P NATL ACAD SCI USA, V93, P465; Dorfler P, 1996, EMBO J, V15, P1971, DOI 10.1002/j.1460-2075.1996.tb00548.x; Eberhard D, 1999, CANCER RES, V59, p1716S; Esposito C, 1998, BIOCHEM J, V331, P37, DOI 10.1042/bj3310037; Fabbro D, 1998, J MOL ENDOCRINOL, V21, P347, DOI 10.1677/jme.0.0210347; Ferreira R, 2001, EMBO REP, V2, P794, DOI 10.1093/embo-reports/kve173; Goodman RH, 2000, GENE DEV, V14, P1553; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Iuliano R, 2000, EXP CELL RES, V260, P257, DOI 10.1006/excr.2000.5023; Klenova E, 2002, METHODS, V26, P254, DOI 10.1016/S1046-2023(02)00029-4; Lasorella A, 1996, MOL CELL BIOL, V16, P2570; Lipinski MM, 1999, ONCOGENE, V18, P7873, DOI 10.1038/sj.onc.1203244; Lukas J, 1999, ONCOGENE, V18, P3930, DOI 10.1038/sj.onc.1202777; Macchia PE, 1998, NAT GENET, V19, P83, DOI 10.1038/ng0598-83; MacLellan WR, 2000, MOL CELL BIOL, V20, P8903, DOI 10.1128/MCB.20.23.8903-8915.2000; Mansouri A, 1998, NAT GENET, V19, P87, DOI 10.1038/ng0598-87; Miccadei S, 2002, MOL ENDOCRINOL, V16, P837, DOI 10.1210/me.16.4.837; Miyake S, 2000, MOL CELL BIOL, V20, P8889, DOI 10.1128/MCB.20.23.8889-8902.2000; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; MUSTI AM, 1987, NUCLEIC ACIDS RES, V15, P8149, DOI 10.1093/nar/15.20.8149; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Ohno M, 1999, MOL CELL BIOL, V19, P2051; Perrone L, 2000, BIOCHEM BIOPH RES CO, V275, P203, DOI 10.1006/bbrc.2000.3232; Puri PL, 2000, J CELL PHYSIOL, V185, P155, DOI 10.1002/1097-4652(200011)185:2<155::AID-JCP1>3.0.CO;2-Z; Roberts EC, 2001, MOL CELL BIOL, V21, P524, DOI 10.1128/MCB.21.2.524-533.2001; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; Sharp PA, 1999, GENE DEV, V13, P139, DOI 10.1101/gad.13.2.139; Sierra J, 2003, MOL CELL BIOL, V23, P3339, DOI 10.1128/MCB.23.9.3339-3351.2003; Suzuki K, 1998, MOL CELL BIOL, V18, P7410, DOI 10.1128/MCB.18.12.7410; Thomas DM, 2001, MOL CELL, V8, P303, DOI 10.1016/S1097-2765(01)00327-6; Wang XC, 1997, T NONFERR METAL SOC, V7, P45; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; Wiggan O, 1998, ONCOGENE, V16, P227, DOI 10.1038/sj.onc.1201534; Yuan SSF, 2002, BIOCHEM BIOPH RES CO, V296, P1019, DOI 10.1016/S0006-291X(02)02032-6; ZANNINI M, 1992, MOL CELL BIOL, V12, P4230, DOI 10.1128/MCB.12.9.4230	52	24	24	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 27	2005	24	47					6993	7001		10.1038/sj.onc.1208861	http://dx.doi.org/10.1038/sj.onc.1208861			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	977WC	16007137				2022-12-25	WOS:000232833200001
J	Xie, YX; Bezard, E; Zhao, BL				Xie, YX; Bezard, E; Zhao, BL			Investigating the receptor-independent neuroprotective mechanisms of nicotine in mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILITY TRANSITION PORE; CYTOCHROME-C RELEASE; COMPLEX-I; ELECTRON-TRANSPORT; RESPIRATORY-CHAIN; CELL-DEATH; OXIDATIVE STRESS; RAT-BRAIN; PYRIDINE-NUCLEOTIDES; DISTINCT MECHANISMS	Although nicotine has been associated with a decreased risk of developing Parkinson disease, the underlying mechanisms are still unclear. By using isolated brain mitochondria, we found that nicotine inhibited N-methyl-4-phenylpyridine (MPP+) and calcium-induced mitochondria high amplitude swelling and cytochrome c release from intact mitochondria. Intra-mitochondria redox state was also maintained by nicotine, which could be attributed to an attenuation of mitochondria permeability transition. Further investigation revealed that nicotine did not prevent MPP+- or calcium-induced mitochondria membrane potential loss, but instead decreased the electron leak at the site of respiratory chain complex I. In the presence of mecamylamine hydrochloride, a nonselective nicotinic acetylcholine receptor inhibitor, nicotine significantly postponed mitochondria swelling and cytochrome c release induced by a mixture of neurotoxins (MPP+ and 6- hydroxydopamine) in SH-SY5Y cells, suggesting that there is a receptor-independent nicotine-mediated neuroprotective effect of nicotine. These results show that interaction of nicotine with mitochondria respiratory chain together with its antioxidant effects should be considered in the neuroprotective effects of nicotine.	Acad Sinica, Inst Biophys, State Key Lab Brain & Cognit Sci, Beijing 100101, Peoples R China; Univ Bordeaux 2, CNRS, UMR5543, F-33076 Bordeaux, France; Chinese Acad Sci, Grad Sch, Beijing 100049, Peoples R China	Chinese Academy of Sciences; Institute of Biophysics, CAS; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS	Zhao, BL (corresponding author), Acad Sinica, Inst Biophys, State Key Lab Brain & Cognit Sci, Beijing 100101, Peoples R China.	zhaobl@sun5.ibp.ac.cn	Bezard, Erwan/A-8173-2008; Bezard, Erwan/ABD-5153-2021	Xie, Yuxiang/0000-0002-8559-1967; Bezard, Erwan/0000-0002-0410-4638				Allam MF, 2002, REV NEUROLOGIA, V34, P686, DOI 10.33588/rn.3407.2001480; Alves G, 2004, MOVEMENT DISORD, V19, P1087, DOI 10.1002/mds.20117; Armstrong JS, 2003, J BIOL CHEM, V278, P49079, DOI 10.1074/jbc.M307841200; Armstrong JS, 2002, FASEB J, V16, P1263, DOI 10.1096/fj.02-0097fje; Aronis A, 2002, ANTIOXID REDOX SIGN, V4, P647, DOI 10.1089/15230860260220157; Batandier C, 2004, J BIOL CHEM, V279, P17197, DOI 10.1074/jbc.M310329200; BEHMAND RA, 1992, J NEUROCHEM, V58, P776, DOI 10.1111/j.1471-4159.1992.tb09786.x; BENOWITZ NL, 1982, CLIN PHARMACOL THER, V32, P758, DOI 10.1038/clpt.1982.233; Brand MD, 2004, FREE RADICAL BIO MED, V37, P755, DOI 10.1016/j.freeradbiomed.2004.05.034; Broekemeier KM, 1998, BIOCHEMISTRY-US, V37, P13059, DOI 10.1021/bi980820c; Brunner M, 2001, COMP BIOCHEM PHYS B, V128, P31, DOI 10.1016/S1096-4959(00)00315-8; Cassarino DS, 1999, BBA-MOL BASIS DIS, V1453, P49, DOI 10.1016/S0925-4439(98)00083-0; Chan TS, 2002, FREE RADICAL RES, V36, P421, DOI 10.1080/10715760290021270; Chauvin C, 2001, J BIOL CHEM, V276, P41394, DOI 10.1074/jbc.M106417200; Chavez E, 1997, BIOCHEM MOL BIOL INT, V41, P961; Chernyak BV, 1996, EUR J BIOCHEM, V238, P623, DOI 10.1111/j.1432-1033.1996.0623w.x; Chernyak BV, 1997, BIOSCIENCE REP, V17, P293, DOI 10.1023/A:1027384628678; Choi WS, 1999, J NEUROSCI RES, V57, P86, DOI 10.1002/(SICI)1097-4547(19990701)57:1<86::AID-JNR9>3.0.CO;2-E; Clarke SJ, 2002, J BIOL CHEM, V277, P34793, DOI 10.1074/jbc.M202191200; Cormier A, 2003, NEUROPHARMACOLOGY, V44, P642, DOI 10.1016/S0028-3908(03)00041-8; Cormier A, 2001, BRAIN RES, V900, P72, DOI 10.1016/S0006-8993(01)02254-5; DALE LC, 1995, JAMA-J AM MED ASSOC, V274, P1353, DOI 10.1001/jama.274.17.1353; Dawson TM, 2003, SCIENCE, V302, P819, DOI 10.1126/science.1087753; EHRINGER H, 1960, KLIN WOCHENSCHR, V38, P1236, DOI 10.1007/BF01485901; Fonck C, 2003, BRAIN RES, V975, P214, DOI 10.1016/S0006-8993(03)02675-1; Fonck C, 2001, BRAIN RES, V905, P199, DOI 10.1016/S0006-8993(01)02551-3; Fontaine E, 1999, J BIOENERG BIOMEMBR, V31, P335, DOI 10.1023/A:1005475802350; Fontaine E, 1998, J BIOL CHEM, V273, P12662, DOI 10.1074/jbc.273.20.12662; Gao WH, 2001, J CELL SCI, V114, P2855; Greenamyre JT, 2001, IUBMB LIFE, V52, P135, DOI 10.1080/15216540152845939; Hirsch T, 1997, BIOSCIENCE REP, V17, P67, DOI 10.1023/A:1027339418683; Huang XX, 2001, MOL CELL BIOCHEM, V224, P1, DOI 10.1023/A:1011990300114; Jarvik ME, 2000, PHARMACOL BIOCHEM BE, V66, P553, DOI 10.1016/S0091-3057(00)00261-6; Lambert AJ, 2004, J BIOL CHEM, V279, P39414, DOI 10.1074/jbc.M406576200; Lemasters JJ, 1997, BIOSCIENCE REP, V17, P281, DOI 10.1023/A:1027332611839; Leverve XM, 2001, IUBMB LIFE, V52, P221; Linert W, 1999, BBA-MOL BASIS DIS, V1454, P143, DOI 10.1016/S0925-4439(99)00029-0; Liu Q, 2003, APPL MAGN RESON, V24, P105, DOI 10.1007/BF03166682; Lotharius J, 1999, J NEUROSCI, V19, P1284; Maciel EN, 2004, J NEUROCHEM, V90, P1025, DOI 10.1111/j.1471-4159.2004.02565.x; Mazzio EA, 2004, BRAIN RES, V1004, P29, DOI 10.1016/j.brainres.2003.12.034; MIZUNO Y, 1989, BIOCHEM BIOPH RES CO, V163, P1450, DOI 10.1016/0006-291X(89)91141-8; Newhouse P, 2004, CURR TOP MED CHEM, V4, P267, DOI 10.2174/1568026043451401; O'Neill MJ, 2002, CNS NEUROL DISORD-DR, V1, P399, DOI 10.2174/1568007023339166; PRYOR WA, 1992, FREE RADICAL BIO MED, V12, P365, DOI 10.1016/0891-5849(92)90085-U; Przedborski S, 2004, J BIOENERG BIOMEMBR, V36, P375, DOI 10.1023/B:JOBB.0000041771.66775.d5; Quik M, 2002, NEUROTOXICOLOGY, V23, P581, DOI 10.1016/S0161-813X(02)00036-0; REED DJ, 1995, BBA-MOL BASIS DIS, V1271, P43, DOI 10.1016/0925-4439(95)00008-R; Ross GW, 2001, DRUG AGING, V18, P797, DOI 10.2165/00002512-200118110-00001; Salvi M, 2002, BBA-BIOENERGETICS, V1556, P187, DOI 10.1016/S0005-2728(02)00361-4; SAVAGE MK, 1994, BIOCHEM BIOPH RES CO, V200, P1615, DOI 10.1006/bbrc.1994.1636; Scarlett JL, 1996, BIOCHEM PHARMACOL, V52, P1047, DOI 10.1016/0006-2952(96)99426-5; SCHAPIRA AHV, 1989, LANCET, V1, P1269, DOI 10.1016/S0140-6736(89)92366-0; SERSHEN H, 1986, NEUROPHARMACOLOGY, V25, P1231, DOI 10.1016/0028-3908(86)90140-1; Seyfried J, 2000, NEUROCHEM INT, V36, P489, DOI 10.1016/S0197-0186(99)00156-4; SIMS NR, 1990, J NEUROCHEM, V55, P698, DOI 10.1111/j.1471-4159.1990.tb04189.x; Soto-Otero R, 2002, BIOCHEM PHARMACOL, V64, P125, DOI 10.1016/S0006-2952(02)01070-5; Stoltz M, 1996, J BIOL CHEM, V271, P25208, DOI 10.1074/jbc.271.41.25208; Yang CF, 2000, ARCH BIOCHEM BIOPHYS, V380, P319, DOI 10.1006/abbi.2000.1939; Zhao YG, 2003, J BIOL CHEM, V278, P2356, DOI 10.1074/jbc.M209681200	60	43	48	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	2005	280	37					32405	32412		10.1074/jbc.M504664200	http://dx.doi.org/10.1074/jbc.M504664200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	963HM	15985439	hybrid			2022-12-25	WOS:000231794800046
J	Kuznetsova, SA; Day, AJ; Mahoney, DJ; Rugg, MS; Mosher, DF; Roberts, DD				Kuznetsova, SA; Day, AJ; Mahoney, DJ; Rugg, MS; Mosher, DF; Roberts, DD			The n-terminal module of thrombospondin-1 interacts with the link domain of TSG-6 and enhances its covalent association with the heavy chains of inter-alpha-trypsin inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-STIMULATED GENE-6; NECROSIS-FACTOR-ALPHA; BINDING PROTEIN TSG-6; SMOOTH-MUSCLE CELLS; COLLAGEN-INDUCED ARTHRITIS; INFLAMMATORY T-CELLS; HYALURONAN-BINDING; EXTRACELLULAR-MATRIX; IN-VIVO; HEPARIN-BINDING	We recently found that leukocytes from thrombospondin-1 (TSP1)-deficient mice exhibit significant reductions in cell surface CD44 relative to those from wild type mice. Because TSG-6 modulates CD44-mediated cellular interactions with hyaluronan, we examined the possibility that TSP1 interacts with TSG-6. We showed that recombinant full-length human TSG-6 (TSG-6Q) and the Link module of TSG-6 (Link_TSG6) bind I-125-TSP1 with comparable affinities. Trimeric recombinant constructs containing the N-modules of TSP1 or TSP2 inhibit binding of TSP1 to TSG-6Q and Link_TSG6, but other recombinant regions of TSP1 do not. Therefore, the N-modules of both TSP1 and TSP2 specifically recognize the Link module of TSG-6. Heparin, which binds to these domains of both proteins, strongly inhibits binding of TSP1 to Link_TSG6 and TSG-6Q, but hyaluronan does not. Inhibition by heparin results from its binding to TSP1, because heparin also inhibits TSP1 binding to Link_TSG6 mutants deficient in heparin binding. Removal of bound Ca2+ from TSP1 reduces its binding to full-length TSG-6. Binding of TSP1 to Link_TSG6, however, is enhanced by chelating divalent cations. In contrast, divalent cations do not influence binding of the N-terminal region of TSP1 to TSG-6Q. This implies that divalent cation dependence is due to conformational effects of calcium-binding to the C-terminal domains of TSP1. TSP1 enhances covalent modification of the inter-alpha-trypsin inhibitor by TSG-6 and transfer of its heavy chains to hyaluronan, suggesting a physiological function of TSP1 binding to TSG-6 in regulation of hyaluronan metabolism at sites of inflammation.	NCI, Pathol Lab, NIH, Bethesda, MD 20892 USA; Univ Oxford, Dept Biochem, MRC, Immunochem Unit, Oxford OX1 3QU, England; Univ Wisconsin, Dept Med, Madison, WI 53706 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Oxford; University of Wisconsin System; University of Wisconsin Madison	Roberts, DD (corresponding author), NCI, Pathol Lab, NIH, Bldg 10 Rm 2A33,10 Ctr Dr,MSC1500, Bethesda, MD 20892 USA.	droberts@helix.nih.gov	Roberts, David D./A-9699-2008; Day, Anthony/O-1658-2015	Roberts, David D./0000-0002-2481-2981; Day, Anthony/0000-0002-1415-3134	MRC [MC_U138274352] Funding Source: UKRI; NATIONAL CANCER INSTITUTE [ZIASC009174, Z01SC009174, Z01SC009172, ZIASC009172] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; Medical Research Council [MC_U138274352] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Agah A, 2002, AM J PATHOL, V161, P831, DOI 10.1016/S0002-9440(10)64243-5; Anilkumar N, 2002, J CELL SCI, V115, P2357; Bagavandoss P, 1998, J HISTOCHEM CYTOCHEM, V46, P1043, DOI 10.1177/002215549804600908; Barazi HO, 2002, J BIOL CHEM, V277, P42859, DOI 10.1074/jbc.M206849200; Bardos T, 2001, AM J PATHOL, V159, P1711, DOI 10.1016/S0002-9440(10)63018-0; Bayliss MT, 2001, OSTEOARTHR CARTILAGE, V9, P42, DOI 10.1053/joca.2000.0348; Beckmann G, 1998, J MOL BIOL, V275, P725, DOI 10.1006/jmbi.1997.1510; Blundell CD, 2005, J BIOL CHEM, V280, P18189, DOI 10.1074/jbc.M414343200; Blundell CD, 2003, J BIOL CHEM, V278, P49261, DOI 10.1074/jbc.M309623200; Bornstein P, 2004, INT J BIOCHEM CELL B, V36, P1115, DOI 10.1016/j.biocel.2004.01.012; BORNSTEIN P, 1992, FASEB J, V6, P3290, DOI 10.1096/fasebj.6.14.1426766; Calzada MJ, 2004, J BIOL CHEM, V279, P41734, DOI 10.1074/jbc.M406267200; Calzada MJ, 2003, J BIOL CHEM, V278, P40679, DOI 10.1074/jbc.M302014200; Cao TV, 2004, MICROCIRCULATION, V11, P615, DOI 10.1080/10739680490503438; Crawford SE, 1998, CELL, V93, P1159, DOI 10.1016/S0092-8674(00)81460-9; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DAY A, 2005, IN PRESS HYALURONAN; Day AJ, 1996, PROTEIN EXPRES PURIF, V8, P1, DOI 10.1006/prep.1996.0068; Day AJ, 2002, J BIOL CHEM, V277, P4585, DOI 10.1074/jbc.R100036200; DIXIT VM, 1984, J BIOL CHEM, V259, P100; Doyen V, 2003, J EXP MED, V198, P1277, DOI 10.1084/jem.20030705; Engel MFM, 2002, J BIOL CHEM, V277, P10922, DOI 10.1074/jbc.M106005200; Flahaut C, 1998, BIOCHEM J, V333, P749, DOI 10.1042/bj3330749; Friedl P, 2000, Dev Immunol, V7, P249, DOI 10.1155/2000/56473; Fujimoto T, 2002, AM J PATHOL, V160, P1495, DOI 10.1016/S0002-9440(10)62575-8; Fulop C, 2003, DEVELOPMENT, V130, P2253, DOI 10.1242/dev.00422; Getting SJ, 2002, J BIOL CHEM, V277, P51068, DOI 10.1074/jbc.M205121200; Glant TT, 2002, ARTHRITIS RHEUM-US, V46, P2207, DOI 10.1002/art.10555; Goicoechea S, 2000, J BIOL CHEM, V275, P36358, DOI 10.1074/jbc.M005951200; GotisGraham I, 1997, ARTHRITIS RHEUM, V40, P1780, DOI 10.1002/art.1780401009; GUO NH, 1992, P NATL ACAD SCI USA, V89, P3040, DOI 10.1073/pnas.89.7.3040; Hannah BLA, 2003, J BIOL CHEM, V278, P8929, DOI 10.1074/jbc.M211185200; HOLLANDER Z, 1986, MOL IMMUNOL, V23, P927, DOI 10.1016/0161-5890(86)90122-7; HUANG SW, 1993, ALLERGY PROC, V14, P357, DOI 10.2500/108854193778774074; Hugo C, 2003, NEPHROL DIAL TRANSPL, V18, P1241, DOI 10.1093/ndt/gfg159; Jessen TE, 2004, OSTEOARTHR CARTILAGE, V12, P142, DOI 10.1016/j.joca.2003.10.004; Jessen TE, 2003, REPRODUCTION, V125, P27, DOI 10.1530/rep.0.1250027; Kahmann JD, 1997, PROTEIN EXPRES PURIF, V9, P315, DOI 10.1006/prep.1996.0694; Kehlen A, 2003, ARTHRITIS RES THER, V5, pR186, DOI 10.1186/ar762; Koch AE, 1998, CLIN IMMUNOL IMMUNOP, V86, P199, DOI 10.1006/clin.1997.4480; KOCH AE, 1993, PATHOBIOLOGY, V61, P1, DOI 10.1159/000163752; Kohda D, 1996, CELL, V86, P767, DOI 10.1016/S0092-8674(00)80151-8; Krutzsch HC, 1999, J BIOL CHEM, V274, P24080, DOI 10.1074/jbc.274.34.24080; Kuznetsova SA, 2004, INT J BIOCHEM CELL B, V36, P1126, DOI 10.1016/j.biocel.2003.12.006; KUZNETSOVA SA, 2005, HYALURONAN ITS STRUC; Kvansakul M, 2004, EMBO J, V23, P1223, DOI 10.1038/sj.emboj.7600166; Lange-Asschenfeldt B, 2002, BLOOD, V99, P538, DOI 10.1182/blood.V99.2.538; Lawler J, 2004, INT J BIOCHEM CELL B, V36, P1038, DOI 10.1016/j.biocel.2004.01.008; Lawler J, 1998, J CLIN INVEST, V101, P982, DOI 10.1172/JCI1684; Lee RT, 2001, J BIOL CHEM, V276, P13847, DOI 10.1074/jbc.M010556200; Lesley J, 2004, J BIOL CHEM, V279, P25745, DOI 10.1074/jbc.M313319200; Lesley J, 2002, J BIOL CHEM, V277, P26600, DOI 10.1074/jbc.M201068200; Li ZQ, 2002, J CELL BIOL, V157, P509, DOI 10.1083/jcb.200109098; Li ZQ, 2001, J IMMUNOL, V166, P2427, DOI 10.4049/jimmunol.166.4.2427; Mahoney DJ, 2005, J BIOL CHEM, V280, P27044, DOI 10.1074/jbc.M502068200; Mahoney DJ, 2004, ANAL BIOCHEM, V330, P123, DOI 10.1016/j.ab.2004.03.055; Mahoney DJ, 2001, J BIOL CHEM, V276, P22764, DOI 10.1074/jbc.M100666200; MANSFIELD PJ, 1994, J IMMUNOL, V153, P4219; Milner CM, 2003, J CELL SCI, V116, P1863, DOI 10.1242/jcs.00407; Mindrescu C, 2002, ARTHRITIS RHEUM, V46, P2453, DOI 10.1002/art.10503; Mindrescu C, 2000, ARTHRITIS RHEUM, V43, P2668, DOI 10.1002/1529-0131(200012)43:12<2668::AID-ANR6>3.0.CO;2-E; MISENHEIMER TM, 1995, J BIOL CHEM, V270, P1729, DOI 10.1074/jbc.270.4.1729; Misenheimer TM, 2000, J BIOL CHEM, V275, P40938, DOI 10.1074/jbc.M007022200; Mukhopadhyay D, 2004, J BIOL CHEM, V279, P11119, DOI 10.1074/jbc.M313471200; Mukhopadhyay D, 2001, ARCH BIOCHEM BIOPHYS, V394, P173, DOI 10.1006/abbi.2001.2552; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Nentwich HA, 2002, J BIOL CHEM, V277, P15354, DOI 10.1074/jbc.M110765200; Ochsner SA, 2003, ENDOCRINOLOGY, V144, P4376, DOI 10.1210/en.2003-0487; Parkar AA, 1998, FEBS LETT, V428, P171, DOI 10.1016/S0014-5793(98)00523-7; Parkar AA, 1997, FEBS LETT, V410, P413, DOI 10.1016/S0014-5793(97)00621-2; Petrik JJ, 2002, BIOL REPROD, V67, P1522, DOI 10.1095/biolreprod.102.007153; Pierson BA, 1996, BLOOD, V87, P180, DOI 10.1182/blood.V87.1.180.bloodjournal871180; Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004; Riessen R, 1998, AM HEART J, V135, P357, DOI 10.1016/S0002-8703(98)70105-X; Roberts David D., 1994, Journal of Tissue Culture Methods, V16, P217, DOI 10.1007/BF01540654; Roberts DD, 1996, FASEB J, V10, P1183, DOI 10.1096/fasebj.10.10.8751720; Rodrigues RG, 2001, J BIOL CHEM, V276, P27913, DOI 10.1074/jbc.M009518200; Rugg MS, 2005, J BIOL CHEM, V280, P25674, DOI 10.1074/jbc.M501332200; Salustri A, 2004, DEVELOPMENT, V131, P1577, DOI 10.1242/dev.01056; Sato H, 2001, BIOCHEM BIOPH RES CO, V281, P1154, DOI 10.1006/bbrc.2001.4475; Savill J, 1997, BRIT MED BULL, V53, P491; Savino W, 2002, TRENDS IMMUNOL, V23, P305, DOI 10.1016/S1471-4906(02)02224-X; Schor H, 2000, Dev Immunol, V7, P227, DOI 10.1155/2000/51902; Seidita G, 2000, CARCINOGENESIS, V21, P2203, DOI 10.1093/carcin/21.12.2203; Stenina OI, 2004, INT J BIOCHEM CELL B, V36, P1013, DOI 10.1016/j.biocel.2004.01.005; SUCHARD SJ, 1991, J IMMUNOL, V147, P651; Szanto S, 2004, ARTHRITIS RHEUM-US, V50, P3012, DOI 10.1002/art.20655; Teder P, 2002, SCIENCE, V296, P155, DOI 10.1126/science.1069659; Vallejo AN, 2000, J IMMUNOL, V164, P2947, DOI 10.4049/jimmunol.164.6.2947; Vallejo AN, 2003, J IMMUNOL, V171, P1732, DOI 10.4049/jimmunol.171.4.1732; Vanguri VK, 2000, BIOCHEM J, V347, P469, DOI 10.1042/0264-6021:3470469; Varani S, 2002, MOL ENDOCRINOL, V16, P1154, DOI 10.1210/me.16.6.1154; Wang Q, 2002, AM J PATHOL, V161, P2219, DOI 10.1016/S0002-9440(10)64498-7; Wisniewski Hans-Georg, 1996, Pfluegers Archiv European Journal of Physiology, V431, pR225, DOI 10.1007/BF02346350; WISNIEWSKI HG, 1993, J IMMUNOL, V151, P6593; Wisniewski HG, 1996, J IMMUNOL, V156, P1609; Ye L, 1997, CIRC RES, V81, P289, DOI 10.1161/01.RES.81.3.289; Yu HN, 2000, ARCH BIOCHEM BIOPHYS, V374, P13, DOI 10.1006/abbi.1999.1597; Zhuo LS, 2001, J BIOL CHEM, V276, P7693, DOI 10.1074/jbc.C000899200	99	29	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	2005	280	35					30899	30908		10.1074/jbc.M500701200	http://dx.doi.org/10.1074/jbc.M500701200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	958ZX	16006654	Green Accepted, hybrid			2022-12-25	WOS:000231487800031
J	Nomikos, M; Blayney, LM; Larman, MG; Campbell, K; Rossbach, A; Saunders, CM; Swann, K; Lai, FA				Nomikos, M; Blayney, LM; Larman, MG; Campbell, K; Rossbach, A; Saunders, CM; Swann, K; Lai, FA			Role of phospholipase C-zeta domains in Ca2+-dependent phosphatidylinositol 4,5-bisphosphate hydrolysis and cytoplasmic Ca2+ oscillations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; CYTOSOLIC SPERM FACTOR; MOUSE EGGS; SPATIOTEMPORAL DYNAMICS; CALCIUM OSCILLATIONS; PLC-ZETA; PARTHENOGENETIC ACTIVATION; INTRACELLULAR CALCIUM; MAMMALIAN EGGS; HAMSTER EGGS	The sperm- specific phospholipase C- xi( PLC xi) elicits fertilization-like Ca2+ oscillations and activation of embryo development when microinjected into mammalian eggs ( Saunders, C. M., Larman, M. G., Parrington, J., Cox, L. J., Royse, J., Blayney, L. M., Swann, K., and Lai, F. A. ( 2002) Development ( Camb.) 129, 3533 - 3544; Cox, L. J., Larman, M. G., Saunders, C. M., Hashimoto, K., Swann, K., and Lai, F. A. ( 2002) Reproduction 124, 611 - 623). PLC xi may represent the physiological stimulus for egg activation and development at mammalian fertilization. PLC xi is the smallest known mammalian PLC isozyme, comprising two EF hand domains, a C2 domain, and the catalytic X and Y core domains. To gain insight into PLC xi structure- function, we assessed the ability of PLC xi and a series of domain-deletion constructs to cause phosphatidylinositol 4,5- bisphosphate hydrolysis in vitro and also to generate cytoplasmic Ca2+ changes in intact mouse eggs. PLC xi and the closely related PLC xi 1 had similar Km values for phosphatidylinositol 4,5- bisphosphate, but PLC xi was around 100 times more sensitive to Ca2+ than was PLC delta 1. Notably, specific phosphatidylinositol 4,5- bisphosphate hydrolysis activity was retained in PLC xi constructs that had either EF hand domains or the C2 domain removed, or both. In contrast, Ca2+ sensitivity was greatly reduced when either one, or both, of the EF hand domains were absent, and the Hill coefficient was reduced upon deletion of the C2 domain. Microinjection into intact mouse eggs revealed that all domain- deletion constructs were ineffective at initiating Ca2+ oscillations. These data suggest that the exquisite Ca2+ - dependent features of PLC xi regulation are essential for it to generate inositol 1,4,5-trisphosphate and Ca2+ oscillations in intact mouse eggs.	Cardiff Univ, Sch Med, Wales Heart Res Inst, Cell Signalling Lab, Cardiff CF14 4XN, Wales; UCL, Dept Anat & Dev Biol, London WC1E 6BT, England; Cardiff Univ, Sch Med, Dept Obstet & Gynaecol, Cardiff CF14 4XN, Wales	Cardiff University; University of London; University College London; Cardiff University	Lai, FA (corresponding author), Cardiff Univ, Sch Med, Wales Heart Res Inst, Cell Signalling Lab, Cardiff CF14 4XN, Wales.	lait@cf.ac.uk		Nomikos, Michail/0000-0001-9761-6327; Lai, Tony/0000-0003-2852-8547; Rossbach, Andreas/0000-0002-6041-7348; Swann, Karl/0000-0002-4355-1449	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Allen V, 1997, BIOCHEM J, V327, P545, DOI 10.1042/bj3270545; Allue I, 1996, BIOCHEM J, V319, P463, DOI 10.1042/bj3190463; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Cox LJ, 2002, REPRODUCTION, V124, P611, DOI 10.1530/rep.0.1240611; DEYOUNG GW, 1992, P NATL ACAD SCI USA, V89, P9895, DOI 10.1073/pnas.89.20.9895; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; FABIATO A, 1981, J GEN PHYSIOL, V78, P457, DOI 10.1085/jgp.78.5.457; Fujimoto S, 2004, DEV BIOL, V274, P370, DOI 10.1016/j.ydbio.2004.07.025; Hirose K, 1999, SCIENCE, V284, P1527, DOI 10.1126/science.284.5419.1527; IGUSA Y, 1983, J PHYSIOL-LONDON, V340, P611, DOI 10.1113/jphysiol.1983.sp014783; Jellerette T, 2000, DEV BIOL, V223, P238, DOI 10.1006/dbio.2000.9675; Jones KT, 2000, BIOCHEM J, V346, P743, DOI 10.1042/0264-6021:3460743; Jones KT, 2000, DEV BIOL, V225, P1, DOI 10.1006/dbio.2000.9826; KATAN M, 1987, EUR J BIOCHEM, V168, P413, DOI 10.1111/j.1432-1033.1987.tb13435.x; Katan M, 1998, BBA-MOL CELL BIOL L, V1436, P5, DOI 10.1016/S0005-2760(98)00125-8; Katan M, 1997, SEMIN CELL DEV BIOL, V8, P287, DOI 10.1006/scdb.1997.0150; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; Kouchi Z, 2005, J BIOL CHEM, V280, P21015, DOI 10.1074/jbc.M412123200; Kouchi Z, 2004, J BIOL CHEM, V279, P10408, DOI 10.1074/jbc.M313801200; Kyozuka K, 1998, DEVELOPMENT, V125, P4099; Larman MG, 2004, J CELL SCI, V117, P2513, DOI 10.1242/jcs.01109; Lawrence Y, 1998, BIOCHEM J, V335, P335, DOI 10.1042/bj3350335; Mehlmann LM, 2001, DEV BIOL, V236, P492, DOI 10.1006/dbio.2001.0329; MIYAZAKI S, 1992, SCIENCE, V257, P251, DOI 10.1126/science.1321497; MIYAZAKI S, 1993, DEV BIOL, V158, P62, DOI 10.1006/dbio.1993.1168; Nakano Y, 1997, MOL HUM REPROD, V3, P1087, DOI 10.1093/molehr/3.12.1087; Nalefski EA, 2001, BIOCHEMISTRY-US, V40, P3089, DOI 10.1021/bi001968a; Parrington J, 2002, REPRODUCTION, V123, P31, DOI 10.1530/rep.0.1230031; Parrington J, 1998, DEV BIOL, V203, P451, DOI 10.1006/dbio.1998.9071; Pawelczyk T, 1997, ACTA BIOCHIM POL, V44, P221; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Rice A, 2000, DEV BIOL, V228, P125, DOI 10.1006/dbio.2000.9929; Rogers NT, 2004, REPRODUCTION, V128, P697, DOI 10.1530/rep.1.00484; Runft LL, 2002, DEV BIOL, V245, P237, DOI 10.1006/dbio.2002.0600; Saunders CM, 2002, DEVELOPMENT, V129, P3533; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; Stricker SA, 1999, DEV BIOL, V211, P157, DOI 10.1006/dbio.1999.9340; Stricker SA, 1997, DEV BIOL, V186, P185, DOI 10.1006/dbio.1997.8594; Summers MC, 2000, HUM REPROD, V15, P1791, DOI 10.1093/humrep/15.8.1791; Swann K, 2004, REPRODUCTION, V127, P431, DOI 10.1530/rep.1.00169; SWANN K, 1990, DEVELOPMENT, V110, P1295; SWANN K, 1994, CELL CALCIUM, V15, P331, DOI 10.1016/0143-4160(94)90072-8; SWANN K, 1994, INT REV CYTOL, V152, P183, DOI 10.1016/S0074-7696(08)62557-7; Tang TS, 2000, DEVELOPMENT, V127, P1141; Williams RL, 1999, BBA-MOL CELL BIOL L, V1441, P255, DOI 10.1016/S1388-1981(99)00150-X; Wu H, 1998, DEV BIOL, V203, P369, DOI 10.1006/dbio.1998.9070; Wu H, 1997, MOL REPROD DEV, V46, P176, DOI 10.1002/(SICI)1098-2795(199702)46:2&lt;176::AID-MRD8&gt;3.0.CO;2-N; Wu H, 2001, BIOL REPROD, V64, P1338, DOI 10.1095/biolreprod64.5.1338; Yoda A, 2004, DEV BIOL, V268, P245, DOI 10.1016/j.ydbio.2003.12.028	49	102	110	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	2005	280	35					31011	31018		10.1074/jbc.M500629200	http://dx.doi.org/10.1074/jbc.M500629200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	958ZX	16000311	hybrid			2022-12-25	WOS:000231487800044
J	Rave-Harel, N; Miller, NLG; Givens, ML; Mellon, PL				Rave-Harel, N; Miller, NLG; Givens, ML; Mellon, PL			The groucho-related gene family regulates the gonadotropin-releasing hormone gene through interaction with the homeodomain proteins MSX1 and OCT1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURON-SPECIFIC EXPRESSION; CELL-SPECIFIC EXPRESSION; BINDING TRANSCRIPTION FACTORS; GNRH GENE; GLUCOCORTICOID-RECEPTOR; DNA-BINDING; DROSOPHILA-ENHANCER; COREPRESSOR GROUCHO; PROMOTER ELEMENTS; TRANSGENIC MICE	Gonadotropin- releasing hormone ( GnRH) is exclusively expressed in a unique population of hypothalamic neurons that controls reproductive function. GnRH gene expression is highly dynamic. Its transcriptional activity is regulated in a complex spatiotemporal manner during embryonic development and postnatal life. Although a variety of transcription factors have been identified as regulators of GnRH transcription, most are promiscuous in their DNA- binding requirements, and none are solely expressed in GnRH neurons. Their specific activity is probably determined by interactions with distinct cofactors. Here we find that the Grouchorelated gene ( GRG) family of co- repressors is expressed in a model cell line for the GnRH neuron and co- expresses with GnRH during prenatal development. GRG proteins associate in vivo with the GnRH promoter. Furthermore, GRG proteins interact with two regulators of GnRH transcription, the homeodomain proteins MSX1 and OCT1. Co- transfection experiments indicate that GRG proteins regulate GnRH promoter activity. The long GRG forms enhance MSX1 repression and counteract OCT1 activation of the GnRH gene. In contrast, the short form, GRG5, has a dominant- negative effect on MSX1- dependent repression. Taken together, these data suggest that the dynamic switch between activation and repression of GnRH transcription is mediated by recruitment of the GRG co- regulators.	Univ Calif San Diego, Dept Reprod Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Mellon, PL (corresponding author), Univ Calif San Diego, Dept Reprod Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.	pmellon@ucsd.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD072754, P50HD012303] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044838] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008666] Funding Source: NIH RePORTER; NICHD NIH HHS [P50 HD012303, R01 HD072754] Funding Source: Medline; NIDA NIH HHS [DA07315] Funding Source: Medline; NIDDK NIH HHS [R01 DK044838-14, R01 DK044838-16, R01 DK044838-15, R01 DK44838, R01 DK044838] Funding Source: Medline; NIGMS NIH HHS [GM08666] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aronson BD, 1997, MOL CELL BIOL, V17, P5581, DOI 10.1128/MCB.17.9.5581; Belsham DD, 2000, MOL ENDOCRINOL, V14, P212, DOI 10.1210/me.14.2.212; Biggin MD, 1997, DEVELOPMENT, V124, P4425; Brantjes H, 2001, NUCLEIC ACIDS RES, V29, P1410, DOI 10.1093/nar/29.7.1410; Brinkmeier ML, 2003, MOL ENDOCRINOL, V17, P2152, DOI 10.1210/me.2003-0225; CATRON KM, 1995, MOL CELL BIOL, V15, P861; Chandran UR, 1999, J BIOL CHEM, V274, P2372, DOI 10.1074/jbc.274.4.2372; Chandran UR, 1996, J BIOL CHEM, V271, P20412, DOI 10.1074/jbc.271.34.20412; Chandran UR, 1999, BEHAV BRAIN RES, V105, P29, DOI 10.1016/S0166-4328(99)00080-7; Chen GQ, 2000, GENE, V249, P1, DOI 10.1016/S0378-1119(00)00161-X; Chen GQ, 1999, GENE DEV, V13, P2218, DOI 10.1101/gad.13.17.2218; Choi CY, 1999, J BIOL CHEM, V274, P31543, DOI 10.1074/jbc.274.44.31543; CLARK ME, 1995, MOL CELL BIOL, V15, P6169; Coss D, 2004, J BIOL CHEM, V279, P152, DOI 10.1074/jbc.M304697200; COUREY AJ, 1995, BBA-GENE STRUCT EXPR, V1261, P1, DOI 10.1016/0167-4781(94)00234-T; Courey AJ, 2001, GENE DEV, V15, P2786; Dasen JS, 2001, GENE DEV, V15, P3193, DOI 10.1101/gad.932601; DEHNI G, 1995, MECH DEVELOP, V53, P369, DOI 10.1016/0925-4773(95)00452-1; Dintilhac A, 2002, J BIOL CHEM, V277, P7021, DOI 10.1074/jbc.M108417200; Dubnicoff T, 1997, GENE DEV, V11, P2952, DOI 10.1101/gad.11.22.2952; Eberhard D, 2000, EMBO J, V19, P2292, DOI 10.1093/emboj/19.10.2292; Ebling FJP, 2000, NEUROREPORT, V11, pR23, DOI 10.1097/00001756-200011090-00002; ERALY SA, 1995, MOL ENDOCRINOL, V9, P848, DOI 10.1210/me.9.7.848; Eraly SA, 1998, MOL ENDOCRINOL, V12, P469, DOI 10.1210/me.12.4.469; Fisher AL, 1998, GENE DEV, V12, P1931, DOI 10.1101/gad.12.13.1931; Fisher AL, 1996, MOL CELL BIOL, V16, P2670; Flores-Saaib RD, 2001, DEVELOPMENT, V128, P1869; Givens ML, 2005, J BIOL CHEM, V280, P19156, DOI 10.1074/jbc.M502004200; Givens ML, 2004, MOL ENDOCRINOL, V18, P2950, DOI 10.1210/me.2003-0437; Grbavec D, 1996, BIOCHEM BIOPH RES CO, V223, P701, DOI 10.1006/bbrc.1996.0959; Jacobs SBR, 2003, MOL ENDOCRINOL, V17, P1470, DOI 10.1210/me.2002-0286; Jimenez G, 1999, MOL CELL BIOL, V19, P2080; Jimenez G, 1997, GENE DEV, V11, P3072, DOI 10.1101/gad.11.22.3072; Kelley CG, 2000, MOL ENDOCRINOL, V14, P1246, DOI 10.1210/me.14.8.1246; Kelley CG, 2002, MOL ENDOCRINOL, V16, P2413, DOI 10.1210/me.2002-0189; Kepa JK, 1996, NUCLEIC ACIDS RES, V24, P3614, DOI 10.1093/nar/24.18.3614; Lawson MA, 1996, MOL CELL BIOL, V16, P3596; Lawson MA, 2002, ENDOCRINOLOGY, V143, P1404, DOI 10.1210/en.143.4.1404; Leon C, 1997, DEV DYNAM, V208, P11, DOI 10.1002/(SICI)1097-0177(199701)208:1<11::AID-AJA2>3.0.CO;2-4; MALLO M, 1995, DEV DYNAM, V204, P338, DOI 10.1002/aja.1002040311; MALLO M, 1993, MECH DEVELOP, V42, P67, DOI 10.1016/0925-4773(93)90099-J; McLarren KW, 2000, J BIOL CHEM, V275, P530, DOI 10.1074/jbc.275.1.530; MELLON PL, 1990, NEURON, V5, P1, DOI 10.1016/0896-6273(90)90028-E; MONICA K, 1991, MOL CELL BIOL, V11, P6149, DOI 10.1128/MCB.11.12.6149; Muhr J, 2001, CELL, V104, P861, DOI 10.1016/S0092-8674(01)00283-5; Nelson SB, 2000, MOL ENDOCRINOL, V14, P1509, DOI 10.1210/me.14.9.1509; Palaparti A, 1997, J BIOL CHEM, V272, P26604, DOI 10.1074/jbc.272.42.26604; Pape JR, 1999, MOL ENDOCRINOL, V13, P2203, DOI 10.1210/me.13.12.2203; PAROUSH Z, 1994, CELL, V79, P805, DOI 10.1016/0092-8674(94)90070-1; Prefontaine GG, 1998, MOL CELL BIOL, V18, P3416, DOI 10.1128/MCB.18.6.3416; RADOVICK S, 1991, P NATL ACAD SCI USA, V88, P3402, DOI 10.1073/pnas.88.8.3402; Rave-Harel N, 2004, J BIOL CHEM, V279, P30287, DOI 10.1074/jbc.M402960200; Ren B, 1999, GENE DEV, V13, P125, DOI 10.1101/gad.13.1.125; ROBZYK K, 1992, NUCLEIC ACIDS RES, V20, P3790, DOI 10.1093/nar/20.14.3790; Roose J, 1998, NATURE, V395, P608, DOI 10.1038/26989; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHREIBER E, 1994, NEUROSURGERY, V34, P129; Simonian SX, 2001, NEUROENDOCRINOLOGY, V73, P149, DOI 10.1159/000054631; Skynner MJ, 1999, J NEUROSCI, V19, P5955, DOI 10.1523/JNEUROSCI.19-14-05955.1999; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; STRUBIN M, 1995, CELL, V80, P497, DOI 10.1016/0092-8674(95)90500-6; Suter KJ, 2000, ENDOCRINOLOGY, V141, P412, DOI 10.1210/en.141.1.412; TANAKA M, 1994, MOL CELL BIOL, V14, P6046, DOI 10.1128/MCB.14.9.6046; Tolkunova EN, 1998, MOL CELL BIOL, V18, P2804, DOI 10.1128/MCB.18.5.2804; VALE W, 1977, ANNU REV PHYSIOL, V39, P473, DOI 10.1146/annurev.ph.39.030177.002353; VERRIJZER CP, 1992, MOL CELL BIOL, V12, P542, DOI 10.1128/MCB.12.2.542; Welting TJM, 2004, NUCLEIC ACIDS RES, V32, P2138, DOI 10.1093/nar/gkh539; WHYTE DB, 1995, MOL ENDOCRINOL, V9, P467, DOI 10.1210/me.9.4.467; Wolberger C, 1998, CURR OPIN GENET DEV, V8, P552, DOI 10.1016/S0959-437X(98)80010-5; Wolfe A, 2002, MOL ENDOCRINOL, V16, P435, DOI 10.1210/me.16.3.435; Wolfe AM, 1996, J BIOL CHEM, V271, P20018, DOI 10.1074/jbc.271.33.20018; Wong MW, 1998, MOL CELL BIOL, V18, P368, DOI 10.1128/MCB.18.1.368; WRAY S, 1989, P NATL ACAD SCI USA, V86, P8132, DOI 10.1073/pnas.86.20.8132; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0; Yao J, 2001, MOL CELL BIOL, V21, P1962, DOI 10.1128/MCB.21.6.1962-1972.2001; Yao J, 2000, MECH DEVELOP, V93, P105, DOI 10.1016/S0925-4773(00)00278-1; Yu X, 2001, MOL CELL BIOL, V21, P4614, DOI 10.1128/MCB.21.14.4614-4625.2001; ZAPPAVIGNA V, 1994, GENE DEV, V8, P732, DOI 10.1101/gad.8.6.732; Zhang HL, 1997, MOL CELL BIOL, V17, P2920, DOI 10.1128/MCB.17.5.2920; Zhu CQC, 2002, DEVELOPMENT, V129, P2835	80	39	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	2005	280	35					30975	30983		10.1074/jbc.M502315200	http://dx.doi.org/10.1074/jbc.M502315200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	958ZX	16002402	Green Accepted, hybrid			2022-12-25	WOS:000231487800040
J	Schwimmer, C; Lefebvre-Legendre, L; Rak, M; Devin, A; Slonimski, PP; di Rago, JP; Rigoulet, M				Schwimmer, C; Lefebvre-Legendre, L; Rak, M; Devin, A; Slonimski, PP; di Rago, JP; Rigoulet, M			Increasing mitochondrial substrate-level phosphorylation can rescue respiratory growth of an ATP synthase-deficient yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; BETA-SUBUNIT; ALPHA-SUBUNIT; IDENTIFICATION; METABOLISM; DEFECTS; GENES; F-1-ATPASE; MECHANISM; PROTEASES	In a previous study we have identified Fmc1p, a mitochondrial protein involved in the assembly/stability of the yeast F0F1-ATP synthase at elevated temperatures. The Delta fmc1 mutant was shown to exhibit a severe phenotype of very slow growth on respiratory substrates at 37 degrees C. We have isolated ODC1 as a multicopy suppressor of the fmc1 deletion restoring a good respiratory growth. Odc1p expression level was estimated to be at least 10 times higher in mitochondria isolated from the Delta fmc1/ODC1 transformant as compared with wild type mitochondria. Interestingly, ODC1 encodes an oxodicarboxylate carrier, which transports alpha-ketoglutarate and alpha-ketoadipate or any other transported tricarboxylic acid cycle intermediate in a counter-exchange through the inner mitochondrial membrane. We show that the suppression of the respiratory-growth-deficient fmc1 by the overexpressed Odc1p was not due to a restored stable ATP synthase. Instead, the rescuing mechanism involves an increase in the flux of tricarboxylic acid cycle intermediate from the cytosol into the mitochondria, leading to an increase in the alpha-ketoglutarate oxidative decarboxylation, resulting in an increase in mitochondrial substrate-level-dependent ATP synthesis. This mechanism of metabolic bypass of a defective ATP synthase unravels the physiological importance of intramitochondrial substrate-level phosphorylations. This unexpected result might be of interest for the development of therapeutic solutions in pathologies associated with defects in the oxidative phosphorylation system.	Univ Bordeaux 2, CNRS, Inst Biochim & Genet Cellulaires, F-33077 Bordeaux, France; Univ Paris 06, Lab Propre Associe, CNRS, Ctr Genet Mol, F-91190 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay	Schwimmer, C (corresponding author), Univ Bordeaux 2, CNRS, Inst Biochim & Genet Cellulaires, 1 Rue Camille St Saens, F-33077 Bordeaux, France.	christine.schwimmer@ibgc.u-bordeaux2.fr						ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ACKERMAN SH, 1990, P NATL ACAD SCI USA, V87, P4986, DOI 10.1073/pnas.87.13.4986; Arnold I, 2002, BBA-MOL CELL RES, V1592, P89, DOI 10.1016/S0167-4889(02)00267-7; Arselin G, 1996, J BIOL CHEM, V271, P20284, DOI 10.1074/jbc.271.34.20284; Averet N, 1998, MOL CELL BIOCHEM, V184, P67, DOI 10.1023/A:1006830810440; Baumann F, 2000, FEBS LETT, V487, P307, DOI 10.1016/S0014-5793(00)02364-4; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; Butow RA, 2004, MOL CELL, V14, P1, DOI 10.1016/S1097-2765(04)00179-0; Dejean L, 2000, BBA-BIOENERGETICS, V1457, P45, DOI 10.1016/S0005-2728(00)00053-0; EMAUS RK, 1986, BIOCHIM BIOPHYS ACTA, V850, P436, DOI 10.1016/0005-2728(86)90112-X; Epstein CB, 2001, MOL BIOL CELL, V12, P297, DOI 10.1091/mbc.12.2.297; FITTON V, 1994, BIOCHEMISTRY-US, V33, P9692, DOI 10.1021/bi00198a039; Garland SA, 1999, J MOL BIOL, V294, P897, DOI 10.1006/jmbi.1999.3294; Guerin B, 1979, Methods Enzymol, V55, P149; Houstek J, 2004, BBA-BIOENERGETICS, V1658, P115, DOI 10.1016/j.bbabio.2004.04.012; Jia YK, 1997, MOL CELL BIOL, V17, P1110, DOI 10.1128/MCB.17.3.1110; Lefebvre-Legendre L, 2005, J BIOL CHEM, V280, P18386, DOI 10.1074/jbc.M410789200; Lefebvre-Legendre L, 2003, MOL MICROBIOL, V47, P1329, DOI 10.1046/j.1365-2958.2003.03371.x; Lefebvre-Legendre L, 2001, J BIOL CHEM, V276, P6789, DOI 10.1074/jbc.M009557200; Liang YL, 1996, J BIOL CHEM, V271, P26522, DOI 10.1074/jbc.271.43.26522; LIAO XS, 1993, CELL, V72, P61, DOI 10.1016/0092-8674(93)90050-Z; Liu ZC, 1999, MOL CELL BIOL, V19, P6720; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lutz T, 2001, J MOL BIOL, V307, P815, DOI 10.1006/jmbi.2001.4527; Palmieri L, 2001, J BIOL CHEM, V276, P1916, DOI 10.1074/jbc.M004332200; Pedersen PL, 1996, J BIOENERG BIOMEMBR, V28, P389, DOI 10.1007/BF02113979; RIGOULET M, 1985, EUR J BIOCHEM, V153, P601, DOI 10.1111/j.1432-1033.1985.tb09343.x; RIGOULET M, 1979, FEBS LETT, V102, P18, DOI 10.1016/0014-5793(79)80919-9; Schilke B, 1999, P NATL ACAD SCI USA, V96, P10206, DOI 10.1073/pnas.96.18.10206; Schouppe C, 1999, J BIOENERG BIOMEMBR, V31, P105, DOI 10.1023/A:1005495626823; SOMLO M, 1968, EUR J BIOCHEM, V5, P276, DOI 10.1111/j.1432-1033.1968.tb00368.x; Truscott KN, 2003, CURR BIOL, V13, pR326, DOI 10.1016/S0960-9822(03)00239-2; TZAGOLOFF A, 1975, J BIOL CHEM, V250, P8228; Van Dyck L, 1999, CELL MOL LIFE SCI, V56, P825, DOI 10.1007/s000180050029; Voos W, 2002, BBA-MOL CELL RES, V1592, P51, DOI 10.1016/S0167-4889(02)00264-1; Wang ZG, 2000, EMBO J, V19, P1486, DOI 10.1093/emboj/19.7.1486; Wang ZG, 2000, J BIOL CHEM, V275, P5767, DOI 10.1074/jbc.275.8.5767; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1; Weinberg JM, 2000, P NATL ACAD SCI USA, V97, P2826, DOI 10.1073/pnas.97.6.2826	39	38	40	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	2005	280	35					30751	30759		10.1074/jbc.M501831200	http://dx.doi.org/10.1074/jbc.M501831200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	958ZX	15975925	hybrid			2022-12-25	WOS:000231487800014
J	Turner, JH; Raymond, JR				Turner, JH; Raymond, JR			Interaction of calmodulin with the serotonin 5-hydroxytryptamine(2A) receptor - A putative regulator of G protein coupling and receptor phosphorylation by protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2ND INTRACELLULAR LOOP; MEDIATED ERK ACTIVATION; GROWTH-FACTOR RECEPTOR; 5-HT2A RECEPTOR; PHOSPHOLIPASE-C; MESANGIAL CELLS; SIGNAL-TRANSDUCTION; CYTOPLASMIC TAIL; INNER LOOP; BINDING	The 5-hydroxytryptamine(2A) (5-HT2A) receptor is a G(q/11)-coupled serotonin receptor that activates phospholipase C and increases diacylglycerol formation. In this report, we demonstrated that calmodulin (CaM) co-immunoprecipitates with the 5-HT2A receptor in NIH-3T3 fibroblasts in an agonist-dependent manner and that the receptor contains two putative CaM binding regions. The putative CaM binding regions of the 5-HT2A receptor are localized to the second intracellular loop and carboxyl terminus. In an in vitro binding assay peptides encompassing the putative second intracellular loop (i2) and carboxyl-terminal (ct) CaM binding regions bound CaM in a Ca2+-dependent manner. The i2 peptide bound with apparent higher affinity and shifted the mobility of CaM in a nondenaturing gel shift assay. Fluorescence emission spectral analyses of dansyl-CaM showed apparent K-D values of 65 +/- 30 nM for the i2 peptide and 168 +/- 38 nM for the ct peptide. The ct CaM-binding domain overlaps with a putative protein kinase C (PKC) site, which was readily phosphorylated by PKC in vitro. CaM binding and phosphorylation of the ct peptide were found to be antagonistic, suggesting a putative role for CaM in the regulation of 5-HT2A receptor phosphorylation and desensitization. Finally, we showed that CaM decreases 5-HT2A receptor-mediated [S-35]GTP gamma S binding to NIH-3T3 cell membranes, supporting a possible role for CaM in regulating receptor-G protein coupling. These data indicate that the serotonin 5-HT2A receptor contains two high affinity CaM-binding domains that may play important roles in signaling and function.	Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Ctr, Med & Res Serv, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Med, Div Nephrol, Charleston, SC 29425 USA	Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center; Medical University of South Carolina	Raymond, JR (corresponding author), Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Ctr, Med & Res Serv, 96 Jonathan Lucas St,Rm 829 CSB,POB 250623, Charleston, SC 29425 USA.	raymondj@musc.edu	Turner, Justin/AAD-8607-2020	Turner, Justin/0000-0002-5501-9900	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052448, R56DK052448] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063909] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK52448] Funding Source: Medline; NIGMS NIH HHS [GM08716, GM63909] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adlersberg M, 2000, J NEUROSCI RES, V61, P674, DOI 10.1002/1097-4547(20000915)61:6<674::AID-JNR11>3.3.CO;2-6; Airas JM, 2001, FEBS LETT, V494, P60, DOI 10.1016/S0014-5793(01)02311-0; Andrews RK, 2002, BLOOD, V99, P4219, DOI 10.1182/blood-2001-11-0008; BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; Bavec A, 2003, REGUL PEPTIDES, V111, P137, DOI 10.1016/S0167-0115(02)00282-3; Belcheva MM, 2001, J BIOL CHEM, V276, P33847, DOI 10.1074/jbc.M101535200; BERG KA, 1994, MOL PHARMACOL, V45, P826; Berg KA, 1998, ANN NY ACAD SCI, V861, P104, DOI 10.1111/j.1749-6632.1998.tb10180.x; Berg KA, 2001, J PHARMACOL EXP THER, V299, P593; Berg KA, 2001, BRIT J PHARMACOL, V134, P386, DOI 10.1038/sj.bjp.0704255; Berg KA, 1996, MOL PHARMACOL, V50, P1017; BERTRAND B, 1994, J BIOL CHEM, V269, P13703; Bhattacharyya S, 2002, P NATL ACAD SCI USA, V99, P14470, DOI 10.1073/pnas.212517999; BOESS FG, 1994, NEUROPHARMACOLOGY, V33, P275, DOI 10.1016/0028-3908(94)90059-0; Bofill-Cardona E, 2000, J BIOL CHEM, V275, P32672, DOI 10.1074/jbc.M002780200; Bohm SK, 1997, J BIOL CHEM, V272, P2363; Burstein ES, 1998, J BIOL CHEM, V273, P24322, DOI 10.1074/jbc.273.38.24322; Chung DA, 2002, BIOCHEM BIOPH RES CO, V293, P1233, DOI 10.1016/S0006-291X(02)00357-1; CONN PJ, 1984, NEUROPHARMACOLOGY, V23, P993, DOI 10.1016/0028-3908(84)90017-0; COOK EH, 1994, J NEUROCHEM, V63, P465; Cussac D, 2002, MOL PHARMACOL, V62, P578, DOI 10.1124/mol.62.3.578; Della Rocca GJ, 1999, J BIOL CHEM, V274, P4749, DOI 10.1074/jbc.274.8.4749; EBERLEWANG K, 1994, AM J PHYSIOL, V266, pR284, DOI 10.1152/ajpregu.1994.266.1.R284; El Far O, 2001, J BIOL CHEM, V276, P30662, DOI 10.1074/jbc.M102573200; Enrich C, 1996, Z Gastroenterol, V34 Suppl 3, P83; ERICKSONVIITANEN S, 1987, METHOD ENZYMOL, V139, P455; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; GARNOVSKAYA MN, 1995, MOL PHARMACOL, V48, P230; Garnovskaya MN, 2003, BIOCHEMISTRY-US, V42, P7178, DOI 10.1021/bi034563+; Goppelt-Struebe M, 1999, BIOCHEM J, V339, P329, DOI 10.1042/0264-6021:3390329; Gray JA, 2003, BIOCHEMISTRY-US, V42, P10853, DOI 10.1021/bi035061z; Greene EL, 2000, AM J PHYSIOL-RENAL, V278, pF650, DOI 10.1152/ajprenal.2000.278.4.F650; Grewal JS, 1999, AM J PHYSIOL-RENAL, V276, pF922, DOI 10.1152/ajprenal.1999.276.6.F922; GuilletDeniau I, 1997, J BIOL CHEM, V272, P14825, DOI 10.1074/jbc.272.23.14825; Hajduch E, 1999, BIOCHEM BIOPH RES CO, V257, P369, DOI 10.1006/bbrc.1999.0471; Havlickova M, 2003, J BIOL CHEM, V278, P35063, DOI 10.1074/jbc.M306555200; HOYER D, 1994, PHARMACOL REV, V46, P157; HUANG ZM, 1995, J BIOL CHEM, V270, P151, DOI 10.1074/jbc.270.1.151; IKEN K, 1995, CELL IMMUNOL, V163, P1, DOI 10.1006/cimm.1995.1092; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; Jalonen TO, 1997, BRAIN RES, V758, P69, DOI 10.1016/S0006-8993(97)00163-7; KUBLER E, 1994, EMBO J, V13, P5539, DOI 10.1002/j.1460-2075.1994.tb06891.x; KURSCHEIDREICH D, 1995, AM J PHYSIOL-RENAL, V268, pF997, DOI 10.1152/ajprenal.1995.268.6.F997; Li HB, 2002, BIOCHEM J, V362, P499, DOI 10.1042/bj3620499; Liu B, 2003, J BIOL CHEM, V278, P2384, DOI 10.1074/jbc.M208683200; MALEK D, 1993, FEBS LETT, V325, P215; MANN JJ, 1989, BRIT J PSYCHIAT, V155, P7, DOI 10.1192/S000712500029171X; Matsuda H, 2000, LIFE SCI, V66, P2233, DOI 10.1016/S0024-3205(00)00551-8; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; Melien O, 2002, BMC CELL BIOL, V3, DOI 10.1186/1471-2121-3-5; Minakami R, 1997, J BIOL CHEM, V272, P20291, DOI 10.1074/jbc.272.32.20291; Nakajima Y, 1999, J BIOL CHEM, V274, P27573, DOI 10.1074/jbc.274.39.27573; NEBIGIL CG, 1995, BIOCHEMISTRY-US, V34, P11954, DOI 10.1021/bi00037a037; Nickols HH, 2004, J BIOL CHEM, V279, P46969, DOI 10.1074/jbc.M407351200; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; Pankevych H, 2003, J BIOL CHEM, V278, P30283, DOI 10.1074/jbc.M212918200; Prado GN, 1998, J BIOL CHEM, V273, P33548, DOI 10.1074/jbc.273.50.33548; Quinn JC, 2002, J PHARMACOL EXP THER, V303, P746, DOI 10.1124/jpet.102.038083; ROTH BL, 1984, NEUROPHARMACOLOGY, V23, P1223, DOI 10.1016/0028-3908(84)90244-2; ROTH BL, 1986, J PHARMACOL EXP THER, V238, P480; Saimi Y, 2002, ANNU REV PHYSIOL, V64, P289, DOI 10.1146/annurev.physiol.64.100301.111649; Sano T, 1997, J BIOL CHEM, V272, P23631, DOI 10.1074/jbc.272.38.23631; SAXENA R, 1993, AM J PHYSIOL, V265, pF53, DOI 10.1152/ajprenal.1993.265.1.F53; STROEBEL M, 1994, J BIOL CHEM, V269, P22952; TAMIR H, 1992, SYNAPSE, V12, P155, DOI 10.1002/syn.890120209; Tebar F, 2002, MOL BIOL CELL, V13, P2057, DOI 10.1091/mbc.01-12-0571; THOMAS WG, 1995, J BIOL CHEM, V270, P22153, DOI 10.1074/jbc.270.38.22153; Tournois C, 1998, J BIOL CHEM, V273, P17498, DOI 10.1074/jbc.273.28.17498; Turner JH, 2004, J BIOL CHEM, V279, P17027, DOI 10.1074/jbc.M313919200; Wang DX, 1999, J BIOL CHEM, V274, P22081, DOI 10.1074/jbc.274.31.22081; Watts SW, 1996, J VASC RES, V33, P288, DOI 10.1159/000159156; Watts SW, 1998, ANN NY ACAD SCI, V861, P162; Wriggers W, 1998, BIOPHYS J, V74, P1622, DOI 10.1016/S0006-3495(98)77876-2; Yap Kyoko L., 2000, Journal of Structural and Functional Genomics, V1, P8, DOI 10.1023/A:1011320027914; ZIFA E, 1992, PHARMACOL REV, V44, P401	75	54	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	2005	280	35					30741	30750		10.1074/jbc.M501696200	http://dx.doi.org/10.1074/jbc.M501696200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	958ZX	15970592	hybrid			2022-12-25	WOS:000231487800013
J	Cherny, I; Rockah, L; Gazit, E				Cherny, I; Rockah, L; Gazit, E			The YoeB toxin is a folded protein that forms a physical complex with the unfolded YefM antitoxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; DNA-BINDING; PLASMID MAINTENANCE; SECONDARY STRUCTURE; ADDICTION MODULE; STABILITY SYSTEM; MESSENGER-RNAS; LON PROTEASE	The chromosomal YoeB-YefM toxin-antitoxin module common to numerous strains of bacteria is presumed to have a significant role in survival under stringent conditions. Recently we showed that the purified YefM antitoxin is a natively unfolded protein, as we previously reported for the Phd antitoxin in the P1 phage Doc-Phd toxin-antitoxin system. Here we report the purification and structural properties of the YoeB toxin and present physical evidence for the existence of a tight YoeB (.) YefM polypeptide complex in solution. YoeB and YefM proteins co-eluted as single peaks in sequential Ni-affinity FPLC and Q-Sepharose ion-exchange chromatography implying the formation of a YoeB (.) YefM complex. The unstable antitoxin was removed from the mixture by natural proteolysis, and the residual YoeB protein was purified using ion exchange chromatography. Fluorescence anisotropy studies of the purified YoeB and YefM proteins showed a 2:1 stoichiometry of the complex, providing direct evidence for a physical complex between the proteins. Near-and far-UV circular dichroism spectroscopy of the purified toxin revealed that, similar to the Doc toxin, YoeB is a well-folded protein. Thermal denaturation experiments confirmed the conformational stability of the YoeB toxin, which underwent reversible thermal unfolding at temperatures up to 56 degrees C. The thermodynamic features of the toxin-antitoxin complex were similar. Taken together, our results support the notion of a correlation between differential physiological and structural stability in toxin-antitoxin modules.	Tel Aviv Univ, Dept Mol Microbiol & Biotechnol, George S Wise Fac Life Sci, IL-69978 Tel Aviv, Israel	Tel Aviv University	Gazit, E (corresponding author), Tel Aviv Univ, Dept Mol Microbiol & Biotechnol, George S Wise Fac Life Sci, IL-69978 Tel Aviv, Israel.	ehudg@post.tau.ac.il	Gazit, Ehud/C-3715-2011; Gazit, Ehud/M-8026-2019; Gazit, Ehud/AHE-9332-2022	Gazit, Ehud/0000-0001-5764-1720; Gazit, Ehud/0000-0001-5764-1720; 				Aizenman E, 1996, P NATL ACAD SCI USA, V93, P6059, DOI 10.1073/pnas.93.12.6059; ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; Bandow JE, 2003, PROTEOMICS, V3, P299, DOI 10.1002/pmic.200390043; BECH FW, 1985, EMBO J, V4, P1059, DOI 10.1002/j.1460-2075.1985.tb03739.x; BERNARD P, 1992, J MOL BIOL, V226, P735, DOI 10.1016/0022-2836(92)90629-X; Bishop RE, 1998, J MOL BIOL, V280, P583, DOI 10.1006/jmbi.1998.1894; BRAVO A, 1987, MOL GEN GENET, V210, P101, DOI 10.1007/BF00337764; Brown JM, 2003, J BACTERIOL, V185, P6600, DOI 10.1128/JB.185.22.6600-6608.2003; Camacho AG, 2002, BIOL CHEM, V383, P1701, DOI 10.1515/BC.2002.191; Cherny I, 2004, J BIOL CHEM, V279, P8252, DOI 10.1074/jbc.M308263200; Christensen SK, 2004, MOL MICROBIOL, V51, P1705, DOI 10.1046/j.1365-2958.2003.03941.x; Christensen SK, 2003, J MOL BIOL, V332, P809, DOI 10.1016/S0022-2836(03)00922-7; Christensen SK, 2003, MOL MICROBIOL, V48, P1389, DOI 10.1046/j.1365-2958.2003.03512.x; Christensen SK, 2001, P NATL ACAD SCI USA, V98, P14328, DOI 10.1073/pnas.251327898; Dao-Thi MH, 2000, J MOL BIOL, V299, P1373, DOI 10.1006/jmbi.2000.3815; Dunker AK, 2002, BIOCHEMISTRY-US, V41, P6573, DOI 10.1021/bi012159+; Engelberg-Kulka H, 1999, ANNU REV MICROBIOL, V53, P43, DOI 10.1146/annurev.micro.53.1.43; Engelberg-Kulka H, 2004, TRENDS MICROBIOL, V12, P66, DOI 10.1016/j.tim.2003.12.008; Gazit E, 1999, J BIOL CHEM, V274, P2652, DOI 10.1074/jbc.274.5.2652; Gazit E, 1999, J BIOL CHEM, V274, P16813, DOI 10.1074/jbc.274.24.16813; Gerdes K, 2000, J BACTERIOL, V182, P561, DOI 10.1128/JB.182.3.561-572.2000; Gotfredsen M, 1998, MOL MICROBIOL, V29, P1065, DOI 10.1046/j.1365-2958.1998.00993.x; Grady R, 2003, MOL MICROBIOL, V47, P1419, DOI 10.1046/j.1365-2958.2003.03387.x; Hargreaves D, 2002, STRUCTURE, V10, P1425, DOI 10.1016/S0969-2126(02)00856-0; Hayes F, 2003, SCIENCE, V301, P1496, DOI 10.1126/science.1088157; Hazan R, 2004, J BACTERIOL, V186, P3663, DOI 10.1128/JB.186.11.3663-3669.2004; Ivanova N, 2004, J MOL BIOL, V338, P33, DOI 10.1016/j.jmb.2004.02.043; JAFFE A, 1985, J BACTERIOL, V163, P841; Jiang Y, 2002, MOL MICROBIOL, V44, P971, DOI 10.1046/j.1365-2958.2002.02921.x; Kamada K, 2003, MOL CELL, V11, P875, DOI 10.1016/S1097-2765(03)00097-2; Karzai AW, 2000, NAT STRUCT BIOL, V7, P449; Lah J, 2003, J BIOL CHEM, V278, P14101, DOI 10.1074/jbc.M209855200; LEHNHERR H, 1995, P NATL ACAD SCI USA, V92, P3274, DOI 10.1073/pnas.92.8.3274; LEHNHERR H, 1993, J MOL BIOL, V233, P414, DOI 10.1006/jmbi.1993.1521; Loris R, 2003, J BIOL CHEM, V278, P28252, DOI 10.1074/jbc.M302336200; Loris R, 1999, J MOL BIOL, V285, P1667, DOI 10.1006/jmbi.1998.2395; MASUDA YJ, 1993, J BACTERIOL, V175, P6850, DOI 10.1128/jb.175.21.6850-6856.1993; Meinhart A, 2003, P NATL ACAD SCI USA, V100, P1661, DOI 10.1073/pnas.0434325100; Munoz-Gomez AJ, 2004, FEBS LETT, V567, P316, DOI 10.1016/j.febslet.2004.05.005; Oberer M, 2002, BIOCHEM J, V361, P41, DOI 10.1042/0264-6021:3610041; Oberer M, 1999, BIOL CHEM, V380, P1413, DOI 10.1515/BC.1999.181; Pedersen K, 2003, CELL, V112, P131, DOI 10.1016/S0092-8674(02)01248-5; Pomerantsev AP, 2001, PLASMID, V46, P210, DOI 10.1006/plas.2001.1548; RUIZECHEVARRIA MJ, 1995, J MOL BIOL, V247, P568, DOI 10.1006/jmbi.1995.0163; RUIZECHEVARRIA MJ, 1991, MOL GEN GENET, V225, P355, DOI 10.1007/BF00261674; Takagi H, 2005, NAT STRUCT MOL BIOL, V12, P327, DOI 10.1038/nsmb911; Uversky VN, 2002, EUR J BIOCHEM, V269, P2, DOI 10.1046/j.0014-2956.2001.02649.x; Uversky VN, 2002, PROTEIN SCI, V11, P739, DOI 10.1110/ps.4210102; VanMelderen L, 1996, J BIOL CHEM, V271, P27730, DOI 10.1074/jbc.271.44.27730; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n; Zeev-Ben-Mordehai T, 2003, PROTEINS, V53, P758, DOI 10.1002/prot.10471; Zhang JJ, 2004, J BIOL CHEM, V279, P20678, DOI 10.1074/jbc.M314284200; Zhang JJ, 2003, J BIOL CHEM, V278, P32300, DOI 10.1074/jbc.M304767200; Zhang YL, 2003, MOL CELL, V12, P913, DOI 10.1016/S1097-2765(03)00402-7; Zhang YL, 2005, J BIOL CHEM, V280, P3143, DOI 10.1074/jbc.M411811200	55	28	32	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	2005	280	34					30063	30072		10.1074/jbc.M506220200	http://dx.doi.org/10.1074/jbc.M506220200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	957IC	15980067	hybrid			2022-12-25	WOS:000231362500011
J	Nadauld, LD; Shelton, DN; Chidester, S; Yost, HJ; Jones, DA				Nadauld, LD; Shelton, DN; Chidester, S; Yost, HJ; Jones, DA			The zebrafish retinol dehydrogenase, rdh1l, is essential for intestinal development and is regulated by the tumor suppressor adenomatous polyposis coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITAMIN-A-DEFICIENCY; ABERRANT CRYPT FOCI; CELL-PROLIFERATION; ALCOHOL-DEHYDROGENASE; ACID SYNTHESIS; VISCERAL ENDODERM; SODIUM-BUTYRATE; MOUSE EMBRYO; MUTANT MICE; RAT	Retinoic acid ( RA) is a potent signaling molecule that plays important roles in multiple and diverse developmental processes. The contribution of retinoic acid to promoting the development and differentiation of the vertebrate intestine and the factors that regulate RA production in the gut remain poorly defined. Herein, we report that the novel retinol dehydrogenase, rdh1l, is required for proper gut development and differentiation. rdh1l is expressed ubiquitously during early development but becomes restricted to the gut by 3 days postfertilization. Knockdown of rdh1l results in a robust RA-deficient phenotype including lack of intestinal differentiation, which can be rescued by the addition of exogenous retinoic acid. We report that adenomatous polyposis coli (APC) mutant zebrafish harbor an RA-deficient phenotype including aberrant intestinal differentiation and that these mutants can be rescued by treatment with retinoic acid or injection of rdh1l mRNA. Further, we have found that although APC mutants are deficient in rdh1l expression, they harbor increased expression of raldh2 suggesting the control of RA production by APC is via retinol dehydrogenase activity. These results provide genetic evidence that retinoic acid is required for vertebrate gut development and that the tumor suppressor APC controls the production of RA in the gut by regulating the expression of the retinol dehydrogenase, rdh1l.	Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA; Univ Utah, Dept Oncol Sci, Salt Lake City, UT 84112 USA; Univ Utah, Dept Med Chem, Salt Lake City, UT 84112 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Jones, DA (corresponding author), Univ Utah, Huntsman Canc Inst, 2000 Circle Hope, Salt Lake City, UT 84112 USA.	david.jones@hci.utah.edu		Chidester, Stephanie/0000-0003-4163-3480				Adachi Y, 2001, TUMOR BIOL, V22, P247, DOI 10.1159/000050623; Begemann G, 2001, DEVELOPMENT, V128, P3081; Chetyrkin SV, 2001, J BIOL CHEM, V276, P22278, DOI 10.1074/jbc.M102076200; Coffinier C, 1999, DEVELOPMENT, V126, P4785; Deltour L, 1999, DEV GENET, V25, P1, DOI 10.1002/(SICI)1520-6408(1999)25:1<1::AID-DVG1>3.0.CO;2-W; Deltour L, 1999, J BIOL CHEM, V274, P16796, DOI 10.1074/jbc.274.24.16796; Duester G, 2003, CHEM-BIOL INTERACT, V143, P201, DOI 10.1016/S0009-2797(02)00204-1; Duester G, 1998, J NUTR, V128, p459S, DOI 10.1093/jn/128.2.459S; Godsave SF, 1998, DEV DYNAM, V213, P39, DOI 10.1002/(SICI)1097-0177(199809)213:1<39::AID-AJA4>3.0.CO;2-Z; Grandel H, 2002, DEVELOPMENT, V129, P2851; Guan KM, 2001, CELL TISSUE RES, V305, P171, DOI 10.1007/s004410100416; Hurlstone AFL, 2003, NATURE, V425, P633, DOI 10.1038/nature02028; Jette C, 2004, J BIOL CHEM, V279, P34397, DOI 10.1074/jbc.M314021200; Keegan BR, 2005, SCIENCE, V307, P247, DOI 10.1126/science.1101573; Li XH, 2004, ENDOCRINOLOGY, V145, P4756, DOI 10.1210/en.2004-0514; Morrisey EE, 1998, GENE DEV, V12, P3579, DOI 10.1101/gad.12.22.3579; Nadauld LD, 2004, J BIOL CHEM, V279, P51581, DOI 10.1074/jbc.M408830200; NARISAWA T, 1976, CANCER RES, V36, P1379; Nicke B, 1999, BIOCHEM BIOPH RES CO, V261, P572, DOI 10.1006/bbrc.1999.1086; Niederreither K, 2001, DEVELOPMENT, V128, P1019; NILES RM, 1988, CANCER INVEST, V6, P39, DOI 10.3109/07357908809077027; NZEGWU H, 1991, GUT, V32, P1324, DOI 10.1136/gut.32.11.1324; NZEGWU HC, 1992, GUT, V33, P794, DOI 10.1136/gut.33.6.794; Pereira MA, 1999, ADV EXP MED BIOL, V470, P55; Perrault I, 2004, AM J HUM GENET, V75, P639, DOI 10.1086/424889; PERUMAL AS, 1968, BIOCHIM BIOPHYS ACTA, V170, P399, DOI 10.1016/0304-4165(68)90019-6; PERUMAL AS, 1966, BIOCHIM BIOPHYS ACTA, V124, P95, DOI 10.1016/0304-4165(66)90316-3; Polakis P, 2000, GENE DEV, V14, P1837; Purton LE, 2000, BLOOD, V95, P470, DOI 10.1182/blood.V95.2.470; Reynolds S, 1998, CANCER LETT, V134, P53, DOI 10.1016/S0304-3835(98)00242-0; Soref CM, 2001, J BIOL CHEM, V276, P24194, DOI 10.1074/jbc.M100332200; Stafford D, 2002, CURR BIOL, V12, P1215, DOI 10.1016/S0960-9822(02)00929-6; SUCOV HM, 1995, MOL NEUROBIOL, V10, P169, DOI 10.1007/BF02740674; Swartz-Basile DA, 2003, AM J PHYSIOL-GASTR L, V285, pG424, DOI 10.1152/ajpgi.00524.2002; Wallace KN, 2003, DEV BIOL, V255, P12, DOI 10.1016/S0012-1606(02)00034-9; Wargovich MJ, 2000, CARCINOGENESIS, V21, P1149, DOI 10.1093/carcin/21.6.1149; Westerfield M., 1995, ZEBRAFISH BOOK GUIDE; Wohl CA, 1998, J NEUROBIOL, V37, P281, DOI 10.1002/(SICI)1097-4695(19981105)37:2<281::AID-NEU7>3.0.CO;2-J; Yamamoto H, 1999, NAT GENET, V22, P188, DOI 10.1038/9707; Yashiro K, 2004, DEV CELL, V6, P411, DOI 10.1016/S1534-5807(04)00062-0; Zheng Y, 1997, CARCINOGENESIS, V18, P2119, DOI 10.1093/carcin/18.11.2119; Zheng Y, 1999, CARCINOGENESIS, V20, P255, DOI 10.1093/carcin/20.2.255; ZILE M, 1977, J NUTR, V107, P552, DOI 10.1093/jn/107.4.552; ZILE M, 1970, ARCH BIOCHEM BIOPHYS, V140, P210, DOI 10.1016/0003-9861(70)90024-X	44	36	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	2005	280	34					30490	30495		10.1074/jbc.M504973200	http://dx.doi.org/10.1074/jbc.M504973200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	957IC	15967793	hybrid			2022-12-25	WOS:000231362500062
J	Toth, J; Kovacs, M; Wang, F; Nyitray, L; Sellers, JR				Toth, J; Kovacs, M; Wang, F; Nyitray, L; Sellers, JR			Myosin V from Drosophila reveals diversity of motor mechanisms within the myosin V family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINETIC MECHANISM; 50/20-KDA JUNCTION; NUCLEOTIDE-BINDING; FLUORESCENT-PROBE; MOLECULAR MOTOR; ATPASE ACTIVITY; REAL-TIME; ACTIN; ACTOMYOSIN; DOMAIN	Myosin V is the best characterized vesicle transporter in vertebrates, but it has been unknown as to whether all members of the myosin V family share a common, evolutionarily conserved mechanism of action. Here we show that myosin V from Drosophila has a strikingly different motor mechanism from that of vertebrate myosin Va, and it is a nonprocessive, ensemble motor. Our steady-state and transient kinetic measurements on single-headed constructs reveal that a single Drosophila myosin V molecule spends most of its mechanochemical cycle time detached from actin, therefore it has to function in processive units that comprise several molecules. Accordingly, in in vitro motility assays, double-headed Drosophila myosin V requires high surface concentrations to exhibit a continuous translocation of actin filaments. Our comparison between vertebrate and fly myosin V demonstrates that the well preserved function of myosin V motors in cytoplasmic transport can be accomplished by markedly different underlying mechanisms.	NHLBI, Lab Mol Physiol, NIH, Bethesda, MD 20892 USA; Eotvos Lorand Univ, Dept Biochem, H-1117 Budapest, Hungary	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Eotvos Lorand University	Sellers, JR (corresponding author), NHLBI, Lab Mol Physiol, NIH, 9000 Rockville Pike,Bldg 10,Rm 8N202,MSC 1762, Bethesda, MD 20892 USA.	sellersj@nhlbi.nih.gov	Nyitray, László/AAE-5910-2020; Kovacs, Mihaly/A-6841-2011	Nyitray, László/0000-0003-4717-5994; Kovacs, Mihaly/0000-0002-1200-4741	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL004227, Z01HL004227] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baker JE, 2004, P NATL ACAD SCI USA, V101, P5542, DOI 10.1073/pnas.0307247101; Batra R, 1999, BIOL CHEM, V380, P1017, DOI 10.1515/BC.1999.126; Bonafe N, 1998, J MUSCLE RES CELL M, V19, P129, DOI 10.1023/A:1005356511634; BRUNE M, 1994, BIOCHEMISTRY-US, V33, P8262, DOI 10.1021/bi00193a013; Brune M, 2001, BIOCHEMISTRY-US, V40, P5087, DOI 10.1021/bi002484h; Catlett NL, 1998, P NATL ACAD SCI USA, V95, P14799, DOI 10.1073/pnas.95.25.14799; CHENEY RE, 1993, CELL, V75, P13, DOI 10.1016/0092-8674(93)90675-G; COOPER JA, 1983, J MUSCLE RES CELL M, V4, P253, DOI 10.1007/BF00712034; Coureux PD, 2004, EMBO J, V23, P4527, DOI 10.1038/sj.emboj.7600458; Coureux PD, 2003, NATURE, V425, P419, DOI 10.1038/nature01927; Cuda G, 1997, BIOPHYS J, V72, P1767, DOI 10.1016/S0006-3495(97)78823-4; De la Cruz EM, 2000, BIOPHYS J, V79, P1524, DOI 10.1016/S0006-3495(00)76403-4; De La Cruz EM, 1999, P NATL ACAD SCI USA, V96, P13726, DOI 10.1073/pnas.96.24.13726; De la Cruz EM, 2001, J BIOL CHEM, V276, P32373, DOI 10.1074/jbc.M104136200; Furch M, 1998, BIOCHEMISTRY-US, V37, P6317, DOI 10.1021/bi972851y; HOMSHER E, 1992, AM J PHYSIOL, V262, P714; Hu AH, 2002, J BIOL CHEM, V277, P46512, DOI 10.1074/jbc.M208506200; Joel PB, 2001, J BIOL CHEM, V276, P2998, DOI 10.1074/jbc.M006930200; Knetsch MLW, 1999, J BIOL CHEM, V274, P20133, DOI 10.1074/jbc.274.29.20133; Kovacs M, 2003, J BIOL CHEM, V278, P38132, DOI 10.1074/jbc.M305453200; Kovacs M, 2005, J BIOL CHEM, V280, P15071, DOI 10.1074/jbc.M500616200; Krementsov DN, 2004, J CELL BIOL, V164, P877, DOI 10.1083/jcb.200310065; Lapierre LA, 2001, MOL BIOL CELL, V12, P1843, DOI 10.1091/mbc.12.6.1843; Malnasi-Csizmadia A, 2001, BIOCHEMISTRY-US, V40, P12727, DOI 10.1021/bi010963q; Malnasi-Csizmadia A, 2000, BIOCHEMISTRY-US, V39, P16135, DOI 10.1021/bi001125j; Mehta AD, 1999, NATURE, V400, P590, DOI 10.1038/23072; Mendes P, 1997, TRENDS BIOCHEM SCI, V22, P361, DOI 10.1016/S0968-0004(97)01103-1; Murphy CT, 1999, BIOCHEMISTRY-US, V38, P3785, DOI 10.1021/bi9826815; Park S, 2000, BIOCHEMISTRY-US, V39, P11732, DOI 10.1021/bi000945t; Reck-Peterson SL, 2000, BBA-MOL CELL RES, V1496, P36, DOI 10.1016/S0167-4889(00)00007-0; Reck-Peterson SL, 2001, J CELL BIOL, V153, P1121, DOI 10.1083/jcb.153.5.1121; Robblee JP, 2004, J BIOL CHEM, V279, P38608, DOI 10.1074/jbc.M403504200; Rodriguez OC, 2002, J CELL SCI, V115, P991; Rosenfeld SS, 2004, J BIOL CHEM, V279, P40100, DOI 10.1074/jbc.M402583200; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Urbanke C, 2001, BIOCHEM J, V358, P165, DOI 10.1042/0264-6021:3580165; UYEDA TQP, 1994, NATURE, V368, P567, DOI 10.1038/368567a0; Vale RD, 2003, J CELL BIOL, V163, P445, DOI 10.1083/jcb.200308093; Veigel C, 2002, NAT CELL BIOL, V4, P59, DOI 10.1038/ncb732; Wang F, 2003, J BIOL CHEM, V278, P27439, DOI 10.1074/jbc.M302510200; Wang F, 2004, J BIOL CHEM, V279, P2333, DOI 10.1074/jbc.C300488200; White HD, 1997, BIOCHEMISTRY-US, V36, P11828, DOI 10.1021/bi970540h; Wu XF, 2002, MOL BIOL CELL, V13, P1735, DOI 10.1091/mbc.01-12-0595; Yamashita RA, 2000, J MUSCLE RES CELL M, V21, P491, DOI 10.1023/A:1026589626422; Yengo CM, 2000, J BIOL CHEM, V275, P25481, DOI 10.1074/jbc.M002910200; Yengo CM, 2004, BIOCHEMISTRY-US, V43, P2605, DOI 10.1021/bi035510v; Yengo CM, 2002, BIOCHEMISTRY-US, V41, P8508, DOI 10.1021/bi015969u; Yin HW, 2000, NATURE, V406, P1013, DOI 10.1038/35023024	48	38	38	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	2005	280	34					30594	30603		10.1074/jbc.M505209200	http://dx.doi.org/10.1074/jbc.M505209200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	957IC	15980429	hybrid			2022-12-25	WOS:000231362500076
J	Ungermannova, D; Gao, YF; Liu, XD				Ungermannova, D; Gao, YF; Liu, XD			Ubiquitination of p27(Kip1) requires physical interaction with cyclin E and probable phosphate recognition by SKP2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT-KINASE INHIBITOR; CDK INHIBITOR; DEGRADATION; BINDING; CKS1; SCF; P27; PHOSPHORYLATION; LIGASE; SCFSKP2	p27(Kip1) is an essential cell cycle inhibitor of Cyclin-dependent kinases. Ubiquitin- mediated proteolysis of p27(Kip1) is an important mechanism for activation of Cyclin E-Cdk2 and facilitates G(1)/S transition. Ubiquitination of p27 is primarily catalyzed by a multisubunit E3 ubiquitin ligase, SCFSkp2, and requires an adapter protein Cks1. In addition, phosphorylation of p27 at Thr(187) by Cyclin E and Cdk2 is also essential for triggering substrate ubiquitination. Here we investigate the molecular mechanism of p27 ubiquitination. We show that Cyclin E-Cdk2 is essential for targeting the p27 substrate to SCFSkp2. Direct physical contact between Cyclin E but not Cdk2 and p27 is required for p27 recruitment to SCFSkp2. In a search for positively charged amino acid residues that may be involved in recognition of the Thr187 phosphate group, we found that Arg(306) of Skp2 is required for association and ubiquitination of phosphorylated p27 but dispensable for ubiquitination of unphosphorylated p21. Thus, our data unravel the molecular organization of the ubiquitination complex that catalyzes p27 ubiquitination and provide unique insights into the specificity of substrate recognition by SCFSkp2.	Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Boulder	Liu, XD (corresponding author), Univ Colorado, Dept Chem & Biochem, UCB 215, Boulder, CO 80309 USA.	Xuedong.Liu@colorado.edu		LIU, XUEDONG/0000-0001-7209-4964	NCI NIH HHS [CA107098-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA107098] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bornstein G, 2003, J BIOL CHEM, V278, P25752, DOI 10.1074/jbc.M301774200; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Ganoth D, 2001, NAT CELL BIOL, V3, P321, DOI 10.1038/35060126; HADWIGER JA, 1989, MOL CELL BIOL, V9, P2034, DOI 10.1128/MCB.9.5.2034; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hsiung YG, 2001, MOL CELL BIOL, V21, P2506, DOI 10.1128/MCB.21.7.2506-2520.2001; Keyomarsi K, 2002, NEW ENGL J MED, V347, P1566, DOI 10.1056/NEJMoa021153; Keyomarsi K, 2003, NAT MED, V9, P152, DOI 10.1038/nm0203-152; Kipreos ET, 2000, GENOME BIOL, V1, DOI 10.1186/gb-2000-1-5-reviews3002; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Orlicky S, 2003, CELL, V112, P243, DOI 10.1016/S0092-8674(03)00034-5; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Patton EE, 1998, TRENDS GENET, V14, P236, DOI 10.1016/S0168-9525(98)01473-5; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; Schulman BA, 2000, NATURE, V408, P381, DOI 10.1038/35042620; Seeliger MA, 2003, NAT STRUCT BIOL, V10, P718, DOI 10.1038/nsb962; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sitry D, 2002, J BIOL CHEM, V277, P42233, DOI 10.1074/jbc.M205254200; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; Spruck C, 2001, MOL CELL, V7, P639, DOI 10.1016/S1097-2765(01)00210-6; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Wang W, 2004, J BIOL CHEM, V279, P51362, DOI 10.1074/jbc.M405944200; Wang W, 2003, J BIOL CHEM, V278, P32390, DOI 10.1074/jbc.M305241200; Winston JT, 1999, CURR BIOL, V9, P1180, DOI 10.1016/S0960-9822(00)80021-4; Wu G, 2003, MOL CELL, V11, P1445, DOI 10.1016/S1097-2765(03)00234-X; Xu K, 2003, BIOCHEM J, V371, P957, DOI 10.1042/BJ20021722; Yaffe MB, 2002, NAT REV MOL CELL BIO, V3, P177, DOI 10.1038/nrm759; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a; Zhu XH, 2004, MOL CELL BIOL, V24, P6058, DOI 10.1128/MCB.24.13.6058-6066.2004	39	30	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	2005	280	34					30301	30309		10.1074/jbc.M411103200	http://dx.doi.org/10.1074/jbc.M411103200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	957IC	15980415	hybrid			2022-12-25	WOS:000231362500039
J	Valverde, RHF; Tortelote, GG; Lemos, T; Mintz, E; Vieyra, A				Valverde, RHF; Tortelote, GG; Lemos, T; Mintz, E; Vieyra, A			Ca2+/calmodulin-dependent protein kinase II is an essential mediator in the coordinated regulation of electrocyte Ca2+-ATPase by calmodulin and protein kinase A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE CA2+ PUMP; PLASMA-MEMBRANE; ELECTROPHORUS-ELECTRICUS; SARCOPLASMIC-RETICULUM; CALCIUM-BINDING; ATPASE; PHOSPHORYLATION; ACTIVATION; INHIBITION; TRANSPORT	The aim of this study was to investigate ( a) whether Ca2+/calmodulin-dependent protein kinase II ( CaM kinase II) participates in the regulation of plasma membrane Ca2+-ATPase and ( b) its possible cross-talk with other kinase-mediated modulatory pathways of the pump. Using isolated innervated membranes of the electrocytes from Electrophorus electricus L., we found that stimulation of endogenous protein kinase A ( PKA) strongly phosphorylated membrane-bound CaM kinase II with simultaneous substantial activation of the Ca2+ pump ( approximate to 2-fold). The addition of cAMP ( 5-50 pM), forskolin ( 10 nM), or cholera toxin ( 10 or 100 nM) stimulated both CaM kinase II phosphorylation and Ca2+-ATPase activity, whereas these activation processes were cancelled by an inhibitor of the PKA alpha-catalytic subunit. When CaM kinase II was blocked by its specific inhibitor KN-93, the Ca2+-ATPase activity decreased to the levels measured in the absence of calmodulin; the unusually high Ca2+ affinity dropped 2-fold; and the PKA-mediated stimulation of Ca2+-ATPase was no longer seen. Hydroxylamine-resistant phosphorylation of the Ca2+-ATPase strongly increased when the PKA pathway was activated, and this phosphorylation was suppressed by inhibition of CaM kinase II. We conclude that CaM kinase II is an intermediate in a complex regulatory network of the electrocyte Ca2+ pump, which also involves calmodulin and PKA.	Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, BR-21941590 Rio De Janeiro, Brazil; Univ Grenoble 1, Lab Biophys Mol & Cellulaire, UMR 5090, CEA,CNRS, F-38054 Grenoble, France	Universidade Federal do Rio de Janeiro; CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Vieyra, A (corresponding author), Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, BR-21941590 Rio De Janeiro, Brazil.	avieyra@biof.ufrj.br	Lemos, Thiago/Q-9518-2017; Valverde, Rafael H.F./K-6567-2012	Lemos, Thiago/0000-0002-6657-5689; Valverde, Rafael H.F./0000-0002-1244-814X; Tortelote, Giovane/0000-0002-9312-3442				ALMEIDA DF, 1963, EXP CELL RES, V29, P42; AMENDE LM, 1983, J NEUROCHEM, V40, P1040, DOI 10.1111/j.1471-4159.1983.tb08090.x; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; BENAIM G, 1984, J BIOL CHEM, V259, P8471; BORKE JL, 1989, AM J PHYSIOL, V257, pF842, DOI 10.1152/ajprenal.1989.257.5.F842; BOUMENDILPODEVIN EF, 1983, BIOCHIM BIOPHYS ACTA, V735, P86, DOI 10.1016/0005-2736(83)90263-8; Bruce JIE, 2002, J BIOL CHEM, V277, P48172, DOI 10.1074/jbc.M208393200; Carafoli E, 2001, CRIT REV BIOCHEM MOL, V36, P107, DOI 10.1080/20014091074183; CARAFOLI E, 1991, PHYSIOL REV, V71, P129, DOI 10.1152/physrev.1991.71.1.129; CARAFOLI E, 1994, FASEB J, V8, P993, DOI 10.1096/fasebj.8.13.7926378; Carafoli E, 2000, CURR OPIN CHEM BIOL, V4, P152, DOI 10.1016/S1367-5931(99)00069-1; Caruso-Neves C, 2000, BBA-BIOMEMBRANES, V1468, P107, DOI 10.1016/S0005-2736(00)00248-0; CHAGAS C, 1972, CR ACAD SCI D NAT, V274, P1526; COELHOSAMPAIO T, 1991, J BIOL CHEM, V266, P22266; EMERICK MC, 1989, BIOCHEMISTRY-US, V28, P8367, DOI 10.1021/bi00447a016; ERONDU NE, 1985, J NEUROSCI, V5, P3270; ESQUIBEL MA, 1970, THESIS FEDERAL U RIO; FILOTEO AG, 1992, J BIOL CHEM, V267, P11800; Gotter AL, 1998, COMP BIOCHEM PHYS A, V119, P225, DOI 10.1016/S1095-6433(97)00414-5; Gotter AL, 1997, COMP BIOCHEM PHYS A, V118, P81, DOI 10.1016/S0300-9629(96)00411-2; GRAF E, 1981, J BIOL CHEM, V256, P1587; Gromadzinska E, 2001, BBA-PROTEIN STRUCT M, V1549, P19, DOI 10.1016/S0167-4838(01)00244-8; Guerini D, 1998, CELL TISSUE RES, V292, P191, DOI 10.1007/s004410051050; HAO LN, 1994, J BIOL CHEM, V269, P14268; HOFMANN F, 1994, J BIOL CHEM, V269, P24298; Hook SS, 2001, ANNU REV PHARMACOL, V41, P471, DOI 10.1146/annurev.pharmtox.41.1.471; Hudmon A, 2002, BIOCHEM J, V364, P593, DOI 10.1042/BJ20020228; INESI G, 1980, J BIOL CHEM, V255, P3025; Isshiki M, 1999, CELL CALCIUM, V26, P201, DOI 10.1054/ceca.1999.0073; Isshiki M, 1998, P NATL ACAD SCI USA, V95, P5009, DOI 10.1073/pnas.95.9.5009; KEYNES RD, 1953, J PHYSIOL-LONDON, V119, P315, DOI 10.1113/jphysiol.1953.sp004849; Lowe J, 2004, BBA-BIOMEMBRANES, V1661, P40, DOI 10.1016/j.bbamem.2003.11.020; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; Means AR, 2000, MOL ENDOCRINOL, V14, P4, DOI 10.1210/me.14.1.4; MUNJAAL RP, 1986, MOL CELL BIOL, V6, P950, DOI 10.1128/MCB.6.3.950; NIGGLI V, 1981, J BIOL CHEM, V256, P395; OLIVEIRA MM, 1978, COMP BIOCHEM PHYS C, V61, P17, DOI 10.1016/0306-4492(78)90104-1; Penniston JT, 1998, J MEMBRANE BIOL, V165, P101, DOI 10.1007/s002329900424; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; SAITOH T, 1985, J CELL BIOL, V100, P835, DOI 10.1083/jcb.100.3.835; Schoffeniels E., 1961, BIOELECTROGENESIS, P147; Shull GE, 2000, EUR J BIOCHEM, V267, P5284, DOI 10.1046/j.1432-1327.2000.01568.x; SORENSON MM, 1986, J MEMBRANE BIOL, V90, P219, DOI 10.1007/BF01870128; SOUZA WD, 1979, CELL TISSUE RES, V202, P275, DOI 10.1007/BF00232241; Strehler EE, 2001, PHYSIOL REV, V81, P21, DOI 10.1152/physrev.2001.81.1.21; SUMI M, 1991, BIOCHEM BIOPH RES CO, V181, P968, DOI 10.1016/0006-291X(91)92031-E; TAFFAREL M, 1989, J HISTOCHEM CYTOCHEM, V37, P953, DOI 10.1177/37.7.2525141; TAUSSKY HH, 1953, J BIOL CHEM, V202, P675; Tortelote GG, 2004, FEBS LETT, V576, P31, DOI 10.1016/j.febslet.2004.08.055; VIEYRA A, 1986, J BIOL CHEM, V261, P4247; Wang K K, 1992, Trends Cell Biol, V2, P46, DOI 10.1016/0962-8924(92)90162-G; Xu A, 1997, J MOL CELL CARDIOL, V29, P405, DOI 10.1006/jmcc.1996.0284; Yamaotsu N, 2001, BIOPOLYMERS, V58, P410, DOI 10.1002/1097-0282(20010405)58:4<410::AID-BIP1017>3.0.CO;2-0; Yao YH, 1996, BIOCHEMISTRY-US, V35, P2767, DOI 10.1021/bi951712i; Yin D, 1999, BIOCHEMISTRY-US, V38, P13654, DOI 10.1021/bi991152d; Yue CP, 2001, MOL CELL ENDOCRINOL, V175, P149, DOI 10.1016/S0303-7207(01)00383-5	57	13	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	2005	280	34					30611	30618		10.1074/jbc.M501880200	http://dx.doi.org/10.1074/jbc.M501880200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	957IC	15987689	hybrid			2022-12-25	WOS:000231362500078
J	Matsuda, S; Giliberto, L; Matsuda, Y; Davies, P; McGowan, E; Pickford, F; Ghiso, J; Frangione, B; D'Adamio, L				Matsuda, S; Giliberto, L; Matsuda, Y; Davies, P; McGowan, E; Pickford, F; Ghiso, J; Frangione, B; D'Adamio, L			The familial dementia BRI2 gene binds the Alzheimer gene amyloid-beta precursor protein and inhibits amyloid-beta production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-SECRETASE; MISSENSE MUTATIONS; A-BETA; DISEASE; EXPRESSION; NOTCH; CDNA; CLEAVAGE; SEQUENCE; CLONING	Alzheimer disease (AD), the most common senile dementia, is characterized by amyloid plaques, vascular amyloid, neurofibrillary tangles, and progressive neurodegeneration. Amyloid is mainly composed by amyloid-beta (A beta) peptides, which are derive from processing of the beta-amyloid precursor protein (APP), better named amyloid-beta precursor protein (A beta PP), by secretases. The (A) under bar beta PP intracellular domain (AID), which is released together with A beta, has signaling function, since it modulates apoptosis and transcription. Despite its biological and pathological importance, the mechanisms regulating A beta PP processing are poorly understood. As cleavage of other gamma-secretase substrates is regulated by membrane bound proteins, we have postulated the existence of integral membrane proteins that bind A beta PP and regulate its processing. Here, we show that BRI2, a type II membrane protein, interacts with A beta PP. Interestingly, 17 amino acids corresponding to the NH2-terminal portion of A beta are necessary for this interaction. Moreover, BRI2 expression regulates A beta PP processing resulting in reduced A beta and AID levels. Altogether, these findings characterize the BRI2-A beta PP interaction as a regulatory mechanism of A beta PP processing that inhibits A beta production. Notably, BRI2 mutations cause familial British (FBD) and Danish dementias (FDD) that are clinically and pathologically similar to AD. Finding that BRI2 pathogenic mutations alter the regulatory function of BRI2 on A beta PP processing would define dysregulation of A beta PP cleavage as a pathogenic mechanism common to AD, FDD, and FBD.	Albert Einstein Coll Med, Bronx, NY 10461 USA; Mayo Clin, Jacksonville, FL 32224 USA; NYU, Sch Med, New York, NY 10016 USA	Yeshiva University; Albert Einstein College of Medicine; Mayo Clinic; New York University	D'Adamio, L (corresponding author), Albert Einstein Coll Med, Bronx, NY 10461 USA.	ldadamio@aecom.yu.edu		D'Adamio, Luciano/0000-0002-9820-4882; D'Adamio, Luciano/0000-0002-2204-9441	NIA NIH HHS [R01 AG21588, R01 AG022595, R01AG05891, R01 AG08721, R01 AG22024] Funding Source: Medline; NINDS NIH HHS [R01NS38777] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038777] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG005891, R01AG022595, R01AG008721, R01AG022024, R01AG021588] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Cupers P, 2001, J NEUROCHEM, V78, P1168, DOI 10.1046/j.1471-4159.2001.00516.x; Deleersnijder W, 1996, J BIOL CHEM, V271, P19475, DOI 10.1074/jbc.271.32.19475; Gandy S, 2005, J CLIN INVEST, V115, P1121, DOI 10.1172/JCI200525100; Gianni D, 2003, J BIOL CHEM, V278, P9290, DOI 10.1074/jbc.M211899200; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; Holton JL, 2002, J NEUROPATH EXP NEUR, V61, P254, DOI 10.1093/jnen/61.3.254; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kim SH, 1999, NAT NEUROSCI, V2, P984, DOI 10.1038/14783; Kopan R, 2002, J CELL SCI, V115, P1095; LEVYLAHAD E, 1995, SCIENCE, V269, P970, DOI 10.1126/science.7638621; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Matsuda S, 2003, J BIOL CHEM, V278, P38601, DOI 10.1074/jbc.M304379200; Passer Brent, 2000, Journal of Alzheimer's Disease, V2, P289; Pickford F, 2003, NEUROSCI LETT, V338, P95, DOI 10.1016/S0304-3940(02)01356-3; Pittois K, 1998, GENE, V217, P141, DOI 10.1016/S0378-1119(98)00354-0; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; ROSTAGNO A, 2005, IN PRESS CELL MOL LI; Sanchez-Pulido L, 2002, TRENDS BIOCHEM SCI, V27, P329, DOI 10.1016/S0968-0004(02)02134-5; Scheinfeld MH, 2003, J BIOL CHEM, V278, P42058, DOI 10.1074/jbc.M304853200; Scheinfeld MH, 2002, J BIOL CHEM, V277, P44195, DOI 10.1074/jbc.M208110200; Selkoe D, 2003, ANNU REV NEUROSCI, V26, P565, DOI 10.1146/annurev.neuro.26.041002.131334; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Sisodia SS, 2002, NAT REV NEUROSCI, V3, P281, DOI 10.1038/nrn785; Stagljar I, 1998, P NATL ACAD SCI USA, V95, P5187, DOI 10.1073/pnas.95.9.5187; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Vidal R, 2000, P NATL ACAD SCI USA, V97, P4920, DOI 10.1073/pnas.080076097; Vidal R, 1999, NATURE, V399, P776; Vidal R, 2001, GENE, V266, P95, DOI 10.1016/S0378-1119(01)00374-2; Zambrano N, 1997, J BIOL CHEM, V272, P6399, DOI 10.1074/jbc.272.10.6399	31	110	117	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	2005	280	32					28912	28916		10.1074/jbc.C500217200	http://dx.doi.org/10.1074/jbc.C500217200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	952QT	15983050	hybrid			2022-12-25	WOS:000231021300011
J	Marimpietri, D; Nico, B; Vacca, A; Mangieri, D; Catarsi, P; Ponzoni, M; Ribatti, D				Marimpietri, D; Nico, B; Vacca, A; Mangieri, D; Catarsi, P; Ponzoni, M; Ribatti, D			Synergistic inhibition of human neuroblastoma-related angiogenesis by vinblastine and rapamycin	ONCOGENE			English	Article						angiogenesis; cytostatic; mTOR inhibitor; neuroblastoma; tumor progression; vessel growth	ENDOTHELIAL GROWTH-FACTOR; ANTIANGIOGENIC DRUGS; CELL PROLIFERATION; TUMOR ANGIOGENESIS; IN-VIVO; THERAPY; CANCER; TUMORIGENESIS; COMBINATION; EXPRESSION	The aim of this study was to evaluate the synergistic antiangiogenic effect of low dose of vinblastine (VBL) and rapamycin (RAP) in neuroblastoma (NB). Both in vitro (endothelial cells proliferation assay; TUNEL assay; phosphatidylserine exposure and cell cycle analysis) and in vivo (chick embryo chorioallantoic membrane, CAM) assays were used. Each compound alone was able to induce a significant dose- and time-response inhibition of in vitro endothelial cells (EC) growth. Interaction index evaluation indicates that a synergistic effect was found when both drugs were combined at very low doses. Comparable effects were obtained when EC were preincubated with conditioned medium (CM) derived from the human NB cell line HTLA-230. Morphological changes were induced by each drug, and their combination resulted in a clear and stronger effect. Apoptosis was demonstrated by the TUNEL assay and confirmed by Annexin V-FITC staining of EC treated with VBL, showing an increase in the percentage of cells with a G2-M and sub-G1 DNA content, whereas in those treated with RAP a block in the G1 cell fraction and inhibition of progression to the S phase were observed. Here too, the combination resulted in a synergistic cell cycle arrest and induction of apoptosis. Similar results were obtained in vivo with the CAM assay. The angiogenic responses induced by HTLA-230-derived CM, NB tumor xenografts, and human NB biopsy specimens were inhibited by each drug and more significantly by their combination. The observation that these well-known drugs display synergistic effects as antiangiogenics when administered frequently at very low dose may be of significance in the designing of new ways of treating NB.	Univ Bari, Sch Med, Dept Human Anat & Histol, Policlin, I-70124 Bari, Italy; G Gaslini Childrens Hosp, Differentiat Therapy Unit, Lab Oncol, I-16148 Genoa, Italy; Univ Bari, Sch Med, Dept Internal Med & Clin Oncol, I-70125 Bari, Italy; G Gaslini Childrens Hosp, Lab Pathophysiol Uremia, I-16148 Genoa, Italy	Universita degli Studi di Bari Aldo Moro; Universita degli Studi di Bari Aldo Moro	Ribatti, D (corresponding author), Univ Bari, Sch Med, Dept Human Anat & Histol, Policlin, Piazza G Cesare 11, I-70124 Bari, Italy.	ribatti@anatomia.uniba.it	Vacca, Angelo/AAC-9558-2022; Marimpietri, Danilo/J-5975-2016; Marimpietri, Danilo/AAA-7283-2020; Catarsi, Paolo/J-4463-2016; Ponzoni, Mirco/J-7713-2016	Vacca, Angelo/0000-0002-4567-8216; Marimpietri, Danilo/0000-0001-6360-1661; Catarsi, Paolo/0000-0002-1862-8168; Ponzoni, Mirco/0000-0002-6164-4286; Mangieri, Domenica/0000-0003-4871-1701; Mangieri, Domenica/0000-0001-7350-9383				Abdollahi A, 2003, CANCER RES, V63, P8890; Baker CH, 2002, CANCER RES, V62, P1996; Bayless KJ, 2004, J BIOL CHEM, V279, P11686, DOI 10.1074/jbc.M308373200; Beppu K, 2004, JNCI-J NATL CANCER I, V96, P46, DOI 10.1093/jnci/djh004; Bergers G, 2003, J CLIN INVEST, V111, P1287, DOI 10.1172/JCI200317929; Bogenmann E, 1996, INT J CANCER, V67, P379, DOI 10.1002/(SICI)1097-0215(19960729)67:3<379::AID-IJC12>3.0.CO;2-3; BRODEUR GM, 1993, J CLIN ONCOL, V11, P1466, DOI 10.1200/JCO.1993.11.8.1466; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; Eggert A, 2000, CLIN CANCER RES, V6, P1900; FIDLER IJ, 1994, CELL, V79, P185, DOI 10.1016/0092-8674(94)90187-2; FOLKMAN J, 1971, J EXP MED, V133, P275, DOI 10.1084/jem.133.2.275; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Folkman J, 1996, EUR J CANCER, V32A, P2534, DOI 10.1016/S0959-8049(96)00423-6; Fukazawa H, 2002, MOL CANCER THER, V1, P303; Guba M, 2002, NAT MED, V8, P128, DOI 10.1038/nm0202-128; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Kaicker S, 2003, INT J ONCOL, V23, P1651; Kerbel RS, 2001, J CLIN ONCOL, V19, p45S; Kerbel RS, 2000, EUR J CANCER, V36, P1248, DOI 10.1016/S0959-8049(00)00092-7; Keselman HJ, 2004, PSYCHOL SCI, V15, P47, DOI 10.1111/j.0963-7214.2004.01501008.x; Kim ES, 2002, J PEDIATR SURG, V37, P518, DOI 10.1053/jpsu.2002.30855; Klement G, 2000, J CLIN INVEST, V105, pR15, DOI 10.1172/JCI8829; KUENG W, 1989, ANAL BIOCHEM, V182, P16, DOI 10.1016/0003-2697(89)90710-0; Maris JM, 1999, J CLIN ONCOL, V17, P2264, DOI 10.1200/JCO.1999.17.7.2264; Meredith JE, 1997, TRENDS CELL BIOL, V7, P146, DOI 10.1016/S0962-8924(97)01002-7; Misawa A, 2003, INT J CANCER, V104, P233, DOI 10.1002/ijc.10914; Nagabuchi E, 1997, J PEDIATR SURG, V32, P287, DOI 10.1016/S0022-3468(97)90196-2; Page AM, 1999, ANNU REV BIOCHEM, V68, P583, DOI 10.1146/annurev.biochem.68.1.583; Pastorino F, 2003, CANCER RES, V63, P86; PHILLIPS P, 1976, INT J CANCER, V17, P549, DOI 10.1002/ijc.2910170502; PONZONI M, 1995, CANCER RES, V55, P853; Ribatti D, 2002, EUR J CANCER, V38, P750, DOI 10.1016/S0959-8049(01)00337-9; Ribatti D, 1998, INT J CANCER, V77, P449; Ribatti D, 1997, J VASC RES, V34, P455, DOI 10.1159/000159256; Svensson A, 2002, PEDIATR RES, V51, P607, DOI 10.1203/01.PDR.0000013688.03134.5A; Tallarida RJ, 2001, J PHARMACOL EXP THER, V298, P865; Tallarida RJ, 2002, PAIN, V98, P163, DOI 10.1016/S0304-3959(02)00041-6; Vacca A, 1999, BLOOD, V94, P4143, DOI 10.1182/blood.V94.12.4143.424k26_4143_4155; Velde EAT, 2002, BRIT J SURG, V89, P1302, DOI 10.1046/j.1365-2168.2002.02183.x; Vinals F, 1999, J BIOL CHEM, V274, P26776, DOI 10.1074/jbc.274.38.26776; Wassberg E, 1997, PEDIATR RES, V41, P327, DOI 10.1203/00006450-199703000-00004; WASSBERG E, 1997, AM J PATHOL, V1154, P395; Yokoyama Y, 2000, CANCER RES, V60, P2190	43	52	56	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 13	2005	24	45					6785	6795		10.1038/sj.onc.1208829	http://dx.doi.org/10.1038/sj.onc.1208829			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	973MV	16007159				2022-12-25	WOS:000232527800006
J	Goettig, P; Brandstetter, H; Groll, M; Gohring, W; Konarev, PV; Svergun, DI; Huber, R; Kim, JS				Goettig, P; Brandstetter, H; Groll, M; Gohring, W; Konarev, PV; Svergun, DI; Huber, R; Kim, JS			X-ray snapshots of peptide processing in mutants of tricorn-interacting factor F1 from Thermoplasma acidophilum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; PROTEASE; AMINOPEPTIDASE; SCATTERING; DIFFRACTION; REVEALS; SYSTEMS; FAMILY	The tricorn-interacting factor F1 of the archaeon Thermoplasma acidophilum cleaves small hydrophobic peptide products of the proteasome and tricorn protease. F1 mutants of the active site residues that are involved in substrate recognition and catalysis displayed distinct activity patterns toward fluorogenic test substrates. Crystal structures of the mutant proteins complexed with peptides Phe-Leu, Pro-Pro, or Pro-Leu-Gly-Gly showed interaction of glutamates 213 and 245 with the N termini of the peptides and defined the S1 and S1' sites and the role of the catalytic residues. Evidence was found for processive peptide cleavage in the N-to-C direction, whereby the P1' product is translocated into the S1 site. A functional interaction of F1 with the tricorn protease was observed with the inactive F1 mutant G37A. Moreover, small angle x-ray scattering measurements for tricorn and inhibited F1 have been interpreted as formation of transient and substrate-induced complexes.	Max Planck Inst Biochem, Abt Strukturforsch, D-82152 Martinsried, Germany; Max Planck Inst Biochem, Abt Mol Med, D-82152 Martinsried, Germany; Salzburg Univ, Dept Nat Sci, A-5020 Salzburg, Austria; Adolf Butenandt Inst Gebaude B, D-81377 Munich, Germany; Russian Acad Sci, Inst Crystallog, Moscow 117333, Russia; Deutsch Elekt Synchrotron, European Mol Biol Lab Hamburg, D-22603 Hamburg, Germany; Korea Res Inst Biosci & Biotechnol, Taejon 305333, South Korea	Max Planck Society; Max Planck Society; Salzburg University; University of Munich; Russian Academy of Sciences; FSRC Crystallography & Photonics RAS; European Molecular Biology Laboratory (EMBL); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); Korea Research Institute of Bioscience & Biotechnology (KRIBB)	Goettig, P (corresponding author), Max Planck Inst Biochem, Abt Strukturforsch, Klopferspitz 18, D-82152 Martinsried, Germany.	goettig@biochem.mpg.de; jsunkim@kribb.re.kr	Konarev, Petr V/W-1380-2017; Goettig, Peter/K-4508-2019; Goettig, Peter/R-7996-2017; Groll, Michael/F-5572-2015; Groll, Michael/C-1174-2010; Brandstetter, Hans/E-6754-2011	Goettig, Peter/0000-0002-2430-1970; Goettig, Peter/0000-0002-2430-1970; Brandstetter, Hans/0000-0002-6089-3045; Konarev, Petr/0000-0002-5606-1596; Svergun, Dmitri/0000-0003-0830-5696				Bochtler M, 1999, ANNU REV BIOPH BIOM, V28, P295, DOI 10.1146/annurev.biophys.28.1.295; BOULIN CJ, 1988, NUCL INSTRUM METH A, V269, P312, DOI 10.1016/0168-9002(88)90895-9; Brandstetter H, 2002, BIOL CHEM, V383, P1157, DOI 10.1515/BC.2002.127; Brandstetter H, 2001, NATURE, V414, P466, DOI 10.1038/35106609; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chandu D, 2003, J BIOL CHEM, V278, P5548, DOI 10.1074/jbc.M207926200; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Dunn BM, 2002, CHEM REV, V102, P4431, DOI 10.1021/cr010167q; Engel M, 2003, P NATL ACAD SCI USA, V100, P5063, DOI 10.1073/pnas.0230620100; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Fulop V, 1998, CELL, V94, P161, DOI 10.1016/S0092-8674(00)81416-6; Gabb HA, 1997, J MOL BIOL, V272, P106, DOI 10.1006/jmbi.1997.1203; GABRIEL A, 1982, NUCL INSTRUM METHODS, V201, P223, DOI 10.1016/0167-5087(82)90031-X; Goettig P, 2002, EMBO J, V21, P5343, DOI 10.1093/emboj/cdf552; GOETTIG P, 2003, APPL GENOMICS PROTEO, V2, P239; Groll M, 2005, CHEMBIOCHEM, V6, P222, DOI 10.1002/cbic.200400313; Guinier A., 1939, ANN PHYS-LEIPZIG, DOI DOI 10.1051/ANPHYS/193911120161; Gustchina A, 2002, BIOCHEM BIOPH RES CO, V295, P1020, DOI 10.1016/S0006-291X(02)00742-8; Ishikawa T, 2001, P NATL ACAD SCI USA, V98, P4328, DOI 10.1073/pnas.081543698; Kim JS, 2002, J MOL BIOL, V324, P1041, DOI 10.1016/S0022-2836(02)01153-1; KOCH MHJ, 1983, NUCL INSTRUM METHODS, V208, P461, DOI 10.1016/0167-5087(83)91169-9; Konarev PV, 2003, J APPL CRYSTALLOGR, V36, P1277, DOI 10.1107/S0021889803012779; Kyrieleis OJP, 2005, J MOL BIOL, V349, P787, DOI 10.1016/j.jmb.2005.03.070; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESLIE AGW, 1991, CRYSTALLOGRAPHIC COM, V5, P27; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; Medrano FJ, 1998, EMBO J, V17, P1, DOI 10.1093/emboj/17.1.1; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHOEPFER R, 1993, GENE, V124, P83, DOI 10.1016/0378-1119(93)90764-T; Stoltze L, 2000, NAT IMMUNOL, V1, P413, DOI 10.1038/80852; Svergun D, 1995, J APPL CRYSTALLOGR, V28, P768, DOI 10.1107/S0021889895007047; SVERGUN DI, 1992, J APPL CRYSTALLOGR, V25, P495, DOI 10.1107/S0021889892001663; SVERGUN DI, 1993, J APPL CRYSTALLOGR, V26, P258, DOI 10.1107/S0021889892011828; Tamura N, 1998, CELL, V95, P637, DOI 10.1016/S0092-8674(00)81634-7; Tamura T, 1996, FEBS LETT, V398, P101, DOI 10.1016/S0014-5793(96)01163-5; Tamura T, 1996, SCIENCE, V274, P1385, DOI 10.1126/science.274.5291.1385; TURK D, 1992, THESIS TU MUNCHEN MU; Vaguine AA, 1999, ACTA CRYSTALLOGR D, V55, P191, DOI 10.1107/S0907444998006684; VANHOOF G, 1995, FASEB J, V9, P736, DOI 10.1096/fasebj.9.9.7601338; Walz J, 1997, MOL CELL, V1, P59, DOI 10.1016/S1097-2765(00)80007-6; Yoshimoto T, 1999, J BIOCHEM, V126, P559, DOI 10.1093/oxfordjournals.jbchem.a022486	42	22	22	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	2005	280	39					33387	33396		10.1074/jbc.M505030200	http://dx.doi.org/10.1074/jbc.M505030200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	966YG	15994304	hybrid			2022-12-25	WOS:000232058100036
J	Hahn-Windgassen, A; Nogueira, V; Chen, CC; Skeen, JE; Sonenberg, N; Hay, N				Hahn-Windgassen, A; Nogueira, V; Chen, CC; Skeen, JE; Sonenberg, N; Hay, N			Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; TUBEROUS SCLEROSIS COMPLEX; SERINE THREONINE KINASE; JEGHERS CANCER SYNDROME; TUMOR-SUPPRESSOR GENE; SIGNALING PATHWAY; PHOSPHORYLATION SITES; SKELETAL-MUSCLE; MTOR; TSC2	The serine/threonine kinase Akt is an upstream positive regulator of the mammalian target of rapamycin ( mTOR). However, the mechanism by which Akt activates mTOR is not fully understood. The known pathway by which Akt activates mTOR is via direct phosphorylation and inhibition of tuberous sclerosis complex 2 (TSC2), which is a negative regulator of mTOR. Here we establish an additional pathway by which Akt inhibits TSC2 and activates mTOR. We provide for the first time genetic evidence that Akt regulates intracellular ATP level and demonstrate that Akt is a negative regulator of the AMP-activated protein kinase ( AMPK), which is an activator of TSC2. We show that in Akt1/Akt2 DKO cells AMP/ATP ratio is markedly elevated with concomitant increase in AMPK activity, whereas in cells expressing activated Akt there is a dramatic decrease in AMP/ATP ratio and a decline in AMPK activity. Currently, the Akt-mediated phosphorylation of TSC2 and the inhibition of AMPK-mediated phosphorylation of TSC2 are viewed as two separate pathways, which activate mTOR. Our results demonstrate that Akt lies upstream of these two pathways and induces full inhibition of TSC2 and activation of mTOR both through direct phosphorylation and by inhibition of AMPK-mediated phosphorylation of TSC2. We propose that the activation of mTOR by Akt-mediated cellular energy and inhibition of AMPK is the predominant pathway by which Akt activates mTOR in vivo.	Univ Illinois, Coll Med, Dept Biochem & Mol Genet MC 669, Chicago, IL 60607 USA; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Ctr Canc, Montreal, PQ H3G 1Y6, Canada	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; McGill University; McGill University	Hay, N (corresponding author), Univ Illinois, Coll Med, Dept Biochem & Mol Genet MC 669, 900 S Ashland Ave, Chicago, IL 60607 USA.	nhay@uic.edu			NATIONAL CANCER INSTITUTE [R01CA090764] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007739] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG016927] Funding Source: NIH RePORTER; NCI NIH HHS [CA090764] Funding Source: Medline; NIA NIH HHS [AG016927] Funding Source: Medline; NIDDK NIH HHS [T32DK007739] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barthel A, 1999, J BIOL CHEM, V274, P20281, DOI 10.1074/jbc.274.29.20281; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Carling D, 2004, TRENDS BIOCHEM SCI, V29, P18, DOI 10.1016/j.tibs.2003.11.005; Castro AF, 2003, J BIOL CHEM, V278, P32493, DOI 10.1074/jbc.C300226200; Cheadle JP, 2000, HUM GENET, V107, P97, DOI 10.1007/s004390000348; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; Cheng SWY, 2004, J BIOL CHEM, V279, P15719, DOI 10.1074/jbc.C300534200; Corradetti MN, 2004, GENE DEV, V18, P1533, DOI 10.1101/gad.1199104; Dennis PB, 2001, SCIENCE, V294, P1102, DOI 10.1126/science.1063518; Deprez J, 1997, J BIOL CHEM, V272, P17269, DOI 10.1074/jbc.272.28.17269; Eves EM, 1998, MOL CELL BIOL, V18, P2143, DOI 10.1128/MCB.18.4.2143; Gao XS, 2002, NAT CELL BIOL, V4, P699, DOI 10.1038/ncb847; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; Goncharova EA, 2002, J BIOL CHEM, V277, P30958, DOI 10.1074/jbc.M202678200; Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901; HA J, 1994, J BIOL CHEM, V269, P22162; Hajduch E, 1998, DIABETES, V47, P1006, DOI 10.2337/diabetes.47.7.1006; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Hawley SA, 1996, J BIOL CHEM, V271, P27879, DOI 10.1074/jbc.271.44.27879; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Jaeschke A, 2002, J CELL BIOL, V159, P217, DOI 10.1083/jcb.jcb.200206108; Jenne DE, 1998, NAT GENET, V18, P38, DOI 10.1038/ng0198-38; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; Kemp BE, 1999, TRENDS BIOCHEM SCI, V24, P22, DOI 10.1016/S0968-0004(98)01340-1; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; Kimura N, 2003, GENES CELLS, V8, P65, DOI 10.1046/j.1365-2443.2003.00615.x; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Majumder PK, 2004, NAT MED, V10, P594, DOI 10.1038/nm1052; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Mu J, 2001, MOL CELL, V7, P1085, DOI 10.1016/S1097-2765(01)00251-9; Ossovskaya VS, 1996, P NATL ACAD SCI USA, V93, P10309, DOI 10.1073/pnas.93.19.10309; Parsons Ramon, 2003, Methods Mol Biol, V222, P147; Peng XD, 2003, GENE DEV, V17, P1352, DOI 10.1101/gad.1089403; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Rathmell JC, 2003, MOL CELL BIOL, V23, P7315, DOI 10.1128/MCB.23.20.7315-7328.2003; Sapkota GP, 2002, BIOCHEM J, V362, P481, DOI 10.1042/0264-6021:3620481; Sapkota GP, 2001, J BIOL CHEM, V276, P19469, DOI 10.1074/jbc.M009953200; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Sekulic A, 2000, CANCER RES, V60, P3504; Shaw RJ, 2004, CANCER CELL, V6, P91, DOI 10.1016/j.ccr.2004.06.007; Woods A, 2000, MOL CELL BIOL, V20, P6704, DOI 10.1128/MCB.20.18.6704-6711.2000; Zhang HB, 2003, J CLIN INVEST, V112, P1223, DOI 10.1172/JCI200317222	48	427	443	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	2005	280	37					32081	32089		10.1074/jbc.M502876200	http://dx.doi.org/10.1074/jbc.M502876200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	963HM	16027121	hybrid, Green Published			2022-12-25	WOS:000231794800007
J	Rilla, K; Siiskonen, H; Spicer, AP; Hyttinen, JMT; Tammi, MI; Tammi, RH				Rilla, K; Siiskonen, H; Spicer, AP; Hyttinen, JMT; Tammi, MI; Tammi, RH			Plasma membrane residence of hyaluronan synthase is coupled to its enzymatic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; PROTEIN-KINASE-C; BREFELDIN-A; IN-VIVO; ACTIVATION; BIOSYNTHESIS; CELLS; KERATINOCYTES; CD44; GENE	Hyaluronan is a multifunctional glycosaminoglycan up to 10(7) Da molecular mass produced by the integral membrane glycosyltransferase, hyaluronan synthase ( HAS). When expressed in keratinocytes, N-terminally tagged green fluorescent protein-HAS2 and -HAS3 isoenzymes were found to travel through endoplasmic reticulum ( ER), Golgi, plasma membrane, and endocytic vesicles. A distinct enrichment of plasma membrane HAS was found in cell protrusions. The total turnover time of HAS3 was 4 - 5 h as judged by the green fluorescent protein signal decay and hyaluronan synthesis inhibition in cycloheximide-treated cells. The transfer from ER to Golgi took about 1 h, and the dwell time on the plasma membrane was less than 2 h in experiments with a relief and introduction, respectively, of brefeldin A. Constructs of HAS3 with 16- and 45-amino-acid C-terminal deletions mostly stayed within the ER, whereas a D216A missense mutant was localized within the Golgi complex but not the plasma membrane. Both types of mutations were almost or completely inactive, similar to the wild type enzyme that had its entry to the plasma membrane experimentally blocked by brefeldin A. Inhibition of hyaluronan synthesis by UDP-glucuronic acid starvation using 4-methyl-umbelliferone also prevented HAS access to the plasma membrane. The results demonstrate that 1) a latent pool of HAS exists within the ER-Golgi pathway; 2) this pool can be rapidly mobilized and activated by insertion into the plasma membrane; and 3) inhibition of HAS activity through mutation or substrate starvation results in exclusion of HAS from the plasma membrane.	Univ Kuopio, Dept Anat, FIN-70211 Kuopio, Finland; Texas A&M Univ, Syst Hlth Sci Ctr, Inst Biosci & Technol, Houston, TX 77030 USA	University of Eastern Finland; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Rilla, K (corresponding author), Univ Kuopio, Dept Anat, POB 1627, FIN-70211 Kuopio, Finland.	kirsi.rilla@uku.fi	Tammi, Markku/AAQ-7878-2021	Rilla, Kirsi/0000-0002-7862-5727; Hyttinen, Juha/0000-0002-3414-4032				Anggiansah CL, 2003, J PHYSIOL-LONDON, V550, P631, DOI 10.1113/jphysiol.2003.038943; BADEN HP, 1983, J INVEST DERMATOL, V80, P124, DOI 10.1111/1523-1747.ep12532899; BANSAL MK, 1986, BIOCHEM J, V236, P515, DOI 10.1042/bj2360515; Bodevin-Authelet S, 2005, J BIOL CHEM, V280, P8813, DOI 10.1074/jbc.M412803200; Brinck J, 1999, EXP CELL RES, V252, P342, DOI 10.1006/excr.1999.4645; CALABRO A, 1994, J BIOL CHEM, V269, P22764; Camenisch TD, 2000, J CLIN INVEST, V106, P349, DOI 10.1172/JCI10272; DeAngelis PL, 2002, ANAT RECORD, V268, P317, DOI 10.1002/ar.10163; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; Heldermon C, 2001, J BIOL CHEM, V276, P2037, DOI 10.1074/jbc.M002276200; HELDIN P, 1992, BIOCHEM J, V283, P165, DOI 10.1042/bj2830165; Hiltunen ELJ, 2002, CANCER RES, V62, P6410; Itano N, 1999, J BIOL CHEM, V274, P25085, DOI 10.1074/jbc.274.35.25085; Kakizaki I, 2004, J BIOL CHEM, V279, P33281, DOI 10.1074/jbc.M405918200; Karvinen S, 2003, J BIOL CHEM, V278, P49495, DOI 10.1074/jbc.M310445200; KITCHEN JR, 1995, BIOCHEM J, V309, P649, DOI 10.1042/bj3090649; Koprunner M, 2000, MECH DEVELOP, V90, P275, DOI 10.1016/S0925-4773(99)00238-5; Mullegger J, 2003, BIOL CHEM, V384, P175, DOI 10.1515/BC.2003.019; NG CK, 1989, BIOCHEM J, V263, P761, DOI 10.1042/bj2630761; Pienimaki JP, 2001, J BIOL CHEM, V276, P20428, DOI 10.1074/jbc.M007601200; PRYDZ K, 1992, J CELL BIOL, V119, P259, DOI 10.1083/jcb.119.2.259; Pummill PE, 2003, J BIOL CHEM, V278, P19808, DOI 10.1074/jbc.M301097200; Rilla K, 2004, J INVEST DERMATOL, V123, P708, DOI 10.1111/j.0022-202X.2004.23409.x; Semino CE, 1996, P NATL ACAD SCI USA, V93, P4548, DOI 10.1073/pnas.93.10.4548; SMITH TJ, 1995, AM J PHYSIOL-CELL PH, V268, pC382, DOI 10.1152/ajpcell.1995.268.2.C382; Spicer AP, 1999, BIOCHEM SOC T, V27, P109, DOI 10.1042/bst0270109; Spicer AP, 1998, J BIOL CHEM, V273, P1923, DOI 10.1074/jbc.273.4.1923; SUZUKI M, 1995, BIOCHEM J, V307, P817, DOI 10.1042/bj3070817; Tammi R, 1998, J BIOL CHEM, V273, P28878, DOI 10.1074/jbc.273.44.28878; Tlapak-Simmons VL, 2005, J BIOL CHEM, V280, P13012, DOI 10.1074/jbc.M409788200; WANG C, 1992, HISTOCHEMISTRY, V98, P105, DOI 10.1007/BF00717001; Weigel PH, 1997, J BIOL CHEM, V272, P13997, DOI 10.1074/jbc.272.22.13997; WONGPALMS S, 1995, ARCH BIOCHEM BIOPHYS, V319, P383, DOI 10.1006/abbi.1995.1308; Yoshida M, 2000, J BIOL CHEM, V275, P497, DOI 10.1074/jbc.275.1.497; YUSPA SH, 1980, BIOCHEM BIOPH RES CO, V97, P700, DOI 10.1016/0006-291X(80)90321-6	36	79	82	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	2005	280	36					31890	31897		10.1074/jbc.M504736200	http://dx.doi.org/10.1074/jbc.M504736200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	961LZ	16014622	hybrid			2022-12-25	WOS:000231665200068
J	Thimmaiah, KN; Easton, JB; Germain, GS; Morton, CL; Kamath, S; Buolamwini, JK; Houghton, PJ				Thimmaiah, KN; Easton, JB; Germain, GS; Morton, CL; Kamath, S; Buolamwini, JK; Houghton, PJ			Identification of N-10-substituted phenoxazines as potent and specific inhibitors of Akt signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; FORKHEAD TRANSCRIPTION FACTOR; PLECKSTRIN HOMOLOGY DOMAIN; VINCA ALKALOID RESISTANCE; PHOSPHOINOSITIDE 3-KINASE; CANCER-CELLS; TUMOR-SUPPRESSOR; PHOSPHATIDYLINOSITOL; PATHWAY; SURVIVAL	A series of 30 N-10-substituted phenoxazines were synthesized and screened as potential inhibitors of Akt. In cellular assays at 5 mu M, 17 compounds inhibited insulin-like growth factor 1 (IGF-I)-stimulated phosphorylation of Akt (Ser-473) by at least 50% but did not inhibit IGF-I-stimulated phosphorylation of Erk-1/2 (Thr-202/Tyr-204). Substitutions at the 2-position (Cl or CF3) did not alter inhibitory activity, whereas N-10-substitutions with derivatives having acetyl (20B) or morpholino (12B) side chain lost activity compared with propyl or butyl substituents ( 7B and 14B). Inhibition of Akt phosphorylation was associated with the inhibition of IGF-I stimulation of the mammalian target of rapamycin phosphorylation (Ser-2448 and Ser-2481), phosphorylation of p70 S6 kinase (Thr-389), and ribosomal protein S6 (Ser-235/ 236) in Rh1, Rh18, and Rh30 cell lines. The two most potent compounds 10-[4'-(N- diethylamino) butyl]-2-chlorophenoxazine (10B) and 10-[4'-[(beta-hydroxyethyl) piperazino]-butyl]2-chlorophenoxazine (15B) ( in vitro, IC50 similar to 1-2 mu M) were studied further. Inhibition of Akt phosphorylation correlated with inhibition of its kinase activity as determined in vitro after immunoprecipitation. Akt inhibitory phenoxazines did not inhibit the activity of recombinant phosphatidylinositol 3'-kinase, PDK1, or SGK1 but potently inhibited the kinase activity of recombinant Akt and Akt Delta PH, a mutant lacking the pleckstrin homology domain. Akt inhibitory phenoxazines blocked IGF-I-stimulated nuclear translocation of Akt in Rh1 cells and suppressed growth of Rh1, Rh18, and Rh30 cells (IC50 2-5 mu M), whereas " inactive" derivatives were >= 10-fold less potent inhibitors of cell growth. In contrast to rapamycin analogs, Akt inhibitory phenoxazines induced significant levels of apoptosis under serum-containing culture conditions at concentrations of agent consistent with Akt inhibition. Thus, the cellular responses to phenoxazine inhibitors of Akt appear qualitatively different from the rapamycin analogs. Modeling studies suggest inhibitory phenoxazines may bind in the ATP-binding site, although ATP competition studies were unable to distinguish between competitive and noncompetitive inhibition.	St Jude Childrens Res Hosp, Dept Mol Pharmacol, Memphis, TN 38105 USA; Western Illinois Univ, Dept Chem, Macomb, IL 61455 USA; Univ Tennessee, Ctr Hlth Sci, Coll Pharm, Dept Pharmaceut Sci, Memphis, TN 38163 USA	St Jude Children's Research Hospital; Western Illinois University; University of Tennessee System; University of Tennessee Health Science Center	Houghton, PJ (corresponding author), St Jude Childrens Res Hosp, Dept Mol Pharmacol, 332 N Lauderdale St, Memphis, TN 38105 USA.	peter.houghton@stjude.org	Houghton, Peter/E-3265-2011	Easton, John/0000-0003-4503-6608	NATIONAL CANCER INSTITUTE [P01CA023099, R01CA077776, R01CA100202] Funding Source: NIH RePORTER; NCI NIH HHS [CA100202, CA77776, CA96996, CA23099, CA21675] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham RT, 2002, CELL, V111, P9, DOI 10.1016/S0092-8674(02)01009-7; Barrett SF, 2005, BIOCHEM J, V385, P399; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Bjornsti MA, 2004, NAT REV CANCER, V4, P335, DOI 10.1038/nrc1362; Breitenlechner CB, 2004, J MED CHEM, V47, P1375, DOI 10.1021/jm0310479; Brownawell AM, 2001, MOL CELL BIOL, V21, P3534, DOI 10.1128/MCB.21.10.3534-3546.2001; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; Cheng JQ, 2001, ENCY REFERENCE CANC, P35; Coffer PJ, 1998, BIOCHEM J, V335, P1; CZARNECKI JJ, 1984, BIOCHIM BIOPHYS ACTA, V800, P41, DOI 10.1016/0304-4165(84)90092-8; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Eregowda GB, 1999, ASIAN J CHEM, V11, P878; Eregowda GB, 2000, INDIAN J CHEM B, V39, P243; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; HORTON JK, 1993, MOL PHARMACOL, V44, P552; Hosoi H, 1999, CANCER RES, V59, P886; Hu YH, 2000, J MED CHEM, V43, P3045, DOI 10.1021/jm000117y; Hu YH, 2001, BIOORG MED CHEM LETT, V11, P173, DOI 10.1016/S0960-894X(00)00640-5; Jacinto E, 2003, NAT REV MOL CELL BIO, V4, P117, DOI 10.1038/nrm1018; James SR, 1996, BIOCHEM J, V315, P709, DOI 10.1042/bj3150709; Jones G, 1997, J MOL BIOL, V267, P727, DOI 10.1006/jmbi.1996.0897; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; Kau TR, 2003, CANCER CELL, V4, P463, DOI 10.1016/S1535-6108(03)00303-9; Kozikowski AP, 2003, J AM CHEM SOC, V125, P1144, DOI 10.1021/ja0285159; Krasilnikov MA, 2000, BIOCHEMISTRY-MOSCOW+, V65, P59; Leevers SJ, 1999, CURR OPIN CELL BIOL, V11, P219, DOI 10.1016/S0955-0674(99)80029-5; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Luo Y, 2004, BIOCHEMISTRY-US, V43, P1254, DOI 10.1021/bi034515p; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; McIlroy J, 1997, MOL CELL BIOL, V17, P248, DOI 10.1128/MCB.17.1.248; Meuillet EJ, 2003, MOL CANCER THER, V2, P389; Moore SM, 1998, CANCER RES, V58, P5239; Nakatani K, 1999, J BIOL CHEM, V274, P21528, DOI 10.1074/jbc.274.31.21528; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; Reuveni H, 2002, BIOCHEMISTRY-US, V41, P10304, DOI 10.1021/bi0202530; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; SHAYRESIEH L, 1999, NAT GENET, V2, P99; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; STEPHENS L, 1994, CURR BIOL, V4, P203, DOI 10.1016/S0960-9822(00)00049-X; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998; THIMMAIAH KN, 1992, J MED CHEM, V35, P3358, DOI 10.1021/jm00096a009; THIMMAIAH KN, 1990, CANCER COMMUN, V2, P249, DOI 10.3727/095535490820874308; Thompson FH, 1996, CANCER GENET CYTOGEN, V87, P55, DOI 10.1016/0165-4608(95)00248-0; VANHAESEBROECK B, 1997, TRENDS BIOCHEM SCI, V276, P1848; VARTICOVSKI L, 1994, BBA-MOL BASIS DIS, V1226, P1, DOI 10.1016/0925-4439(94)90051-5; VAZQUEZ E, 2000, BIOCHIM BIOPHYS ACTA, V1470, pM21; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; West KA, 2002, DRUG RESIST UPDATE, V5, P234, DOI 10.1016/S1368-7646(02)00120-6; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587; Yang L, 2004, CANCER RES, V64, P4394, DOI 10.1158/0008-5472.CAN-04-0343; Yu JH, 1998, J BIOL CHEM, V273, P30199, DOI 10.1074/jbc.273.46.30199	57	91	94	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	2005	280	36					31924	31935		10.1074/jbc.M507057200	http://dx.doi.org/10.1074/jbc.M507057200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	961LZ	16009706	hybrid			2022-12-25	WOS:000231665200072
J	Vullhorst, D; Buonanno, A				Vullhorst, D; Buonanno, A			Multiple GTF2I-like repeats of general transcription factor 3 exhibit DNA binding properties - Evidence for a common origin as a sequence-specific dna interaction module	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILLIAMS-BEUREN-SYNDROME; TFII-I FAMILY; PROMOTER ACTIVITY; PROTEIN; RECOGNITION; EXPRESSION; DOMAIN	A hallmark of general transcription factor 3 (GTF3) is the presence of multiple GTF2I-like repeats that were suggested to mediate protein-protein interactions. However, we have recently demonstrated that repeat 4 is necessary and sufficient for binding of GTF3 to the bicoid-like motif of the Troponin I slow enhancer. Given the sequence similarity between different GTF2I-like repeats we hypothesized that DNA binding might be a common property of this domain type. We subjected five repeats of GTF3 to random oligonucleotide selection (SELEX) to assess their DNA binding potentials. We delineated the consensus sequence G(TC)G(A)GATTA(G)BG(A) for repeat 4 and showed that binding sites for GTF3 in enhancers for Troponin I and homeobox c8 (HOXc8) are in very good agreement with this motif. SELEX selections for repeats 5 and 2 enriched for oligonucleotides that were also bound by R4, suggesting that they share common sequence preferences, whereas repeat 3 exhibited relaxed sequence requirements for DNA binding. No binding was observed for repeat 1. We also show that GTF2I-like repeats 4 and 6 of transcription factor II-I (TFII- I) exhibit modest DNA binding properties. Lastly, we identified several amino acids of GTF3 repeat 4 required for high affinity protein-DNA interaction. Based on the ability of many repeats to bind DNA in vitro, we suggest that GTF2I-like domains evolved by duplication and diversification of a prototypic DNA-binding ancestor.	NICHD, Mol Neurobiol Sect, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Vullhorst, D (corresponding author), NICHD, Mol Neurobiol Sect, NIH, 35 Lincoln Dr, Bethesda, MD 20892 USA.	vullhord@mail.nih.gov		Vullhorst, Detlef/0000-0002-7947-8044	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000711] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000711] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Bayarsaihan D, 2000, P NATL ACAD SCI USA, V97, P7342, DOI 10.1073/pnas.97.13.7342; Calvo S, 2001, MOL CELL BIOL, V21, P8490, DOI 10.1128/MCB.21.24.8490-8503.2001; Cheriyath V, 2001, J BIOL CHEM, V276, P8377, DOI 10.1074/jbc.M008411200; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; Feledy JA, 1999, NUCLEIC ACIDS RES, V27, P764, DOI 10.1093/nar/27.3.764; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; Hinsley TA, 2004, PROTEIN SCI, V13, P2588, DOI 10.1110/ps.04747604; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Nakayama M, 1996, MOL CELL BIOL, V16, P2408; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; O'Mahoney JV, 1998, MOL CELL BIOL, V18, P6641, DOI 10.1128/MCB.18.11.6641; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; Roy AL, 1997, EMBO J, V16, P7091, DOI 10.1093/emboj/16.23.7091; Roy AL, 2001, GENE, V274, P1, DOI 10.1016/S0378-1119(01)00625-4; Tantin D, 2004, J BIOL CHEM, V279, P5460, DOI 10.1074/jbc.M311177200; Tassabehji M, 2003, HUM MOL GENET, V12, pR229, DOI 10.1093/hmg/ddg299; Tay ESE, 2003, BIOCHEM J, V374, P359, DOI 10.1042/BJ20030189; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Tussie-Luna MI, 2002, P NATL ACAD SCI USA, V99, P12807, DOI 10.1073/pnas.192464499; Vullhorst D, 2003, J BIOL CHEM, V278, P8370, DOI 10.1074/jbc.M209361200; Yan XM, 2000, BIOCHEM J, V345, P749, DOI 10.1042/0264-6021:3450749	22	24	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	2005	280	36					31722	31731		10.1074/jbc.M500593200	http://dx.doi.org/10.1074/jbc.M500593200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	961LZ	15987678	hybrid			2022-12-25	WOS:000231665200049
J	Maloney, G; Schroder, M; Bowie, AG				Maloney, G; Schroder, M; Bowie, AG			Vaccinia virus protein A52R activates p38 mitogen-activated protein kinase and potentiates lipopolysaccharide-induced interleukin-10	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TOLL-LIKE RECEPTOR-2; IL-10 GENE-EXPRESSION; REGULATORY T-CELLS; HOST-DEFENSE; STRANDED-RNA; ADAPTERS; PATHWAY; TARGETS; DOMAIN	Vaccinia virus (VV) has many mechanisms to suppress and modulate the host immune response. The VV protein A52R was previously shown to act as an intracellular inhibitor of nuclear factor kappa B (NF kappa B) signaling by Toll-like receptors (TLRs). Co-immunoprecipitation studies revealed that A52R interacted with both tumor necrosis factor receptor-associated factor 6 (TRAF6) and interleukin-1 receptor-associated kinase 2 (IRAK2). The effect of A52R on signals other than NF kappa B was not determined. Here, we show that A52R does not inhibit TLR-induced p38 or c-Jun amino N-terminal kinase (JNK) mitogen activating protein (MAP) kinase activation. Rather, A52R could drive activation of these kinases. Two lines of evidence suggested that the A52R/TRAF6 interaction was critical for these effects. First, A52R-induced p38 MAP kinase activation was inhibited by overexpression of the TRAF domain of TRAF6, which sequestered A52R and inhibited its interaction with endogenous TRAF6. Second, a truncated version of A52R, which interacted with IRAK2 and not TRAF6, was unable to activate p38. Because interleukin 10 (IL-10) production is strongly p38-dependent, we examined the effect of A52R on IL-10 gene induction. A52R was found to be capable of inducing the IL-10 promoter through a TRAF6-dependent mechanism. Furthermore, A52R enhanced lipopolysaccharide/TLR4-induced IL-10 production, while inhibiting the TLR-induced NF kappa B-dependent genes IL-8 and RANTES. These results show that although A52R inhibits NF kappa B activation by multiple TLRs it can simultaneously activate MAP kinases. A52R-mediated enhancement of TLR-induced IL-10 may be important to virulence, given the role of IL-10 in immunoregulation.	Trinity Coll Dublin, Dept Biochem, Sch Biochem & Immunol, Viral Immune Evas Grp, Dublin 2, Ireland	Trinity College Dublin	Bowie, AG (corresponding author), Trinity Coll Dublin, Dept Biochem, Sch Biochem & Immunol, Viral Immune Evas Grp, Dublin 2, Ireland.	agbowie@tcd.ie	Schroder, Martina/E-5493-2010	Schroeder, Martina/0000-0003-1899-6048; Bowie, Andrew/0000-0001-5316-4373				Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Akira S, 2003, BIOCHEM SOC T, V31, P637, DOI 10.1042/BST0310637; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Bartlett N, 2002, J GEN VIROL, V83, P1965, DOI 10.1099/0022-1317-83-8-1965; Baud V, 1999, GENE DEV, V13, P1297, DOI 10.1101/gad.13.10.1297; Benkhart EM, 2000, J IMMUNOL, V165, P1612, DOI 10.4049/jimmunol.165.3.1612; Bieback K, 2002, J VIROL, V76, P8729, DOI 10.1128/JVI.76.17.8729-8736.2002; Bowie A, 2000, P NATL ACAD SCI USA, V97, P10162, DOI 10.1073/pnas.160027697; Compton T, 2003, J VIROL, V77, P4588, DOI 10.1128/JVI.77.8.4588-4596.2003; Dean JLE, 2004, CELL SIGNAL, V16, P1113, DOI 10.1016/j.cellsig.2004.04.006; Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616; DiPerna G, 2004, J BIOL CHEM, V279, P36570, DOI 10.1074/jbc.M400567200; Fitzgerald KA, 2003, J EXP MED, V198, P1043, DOI 10.1084/jem.20031023; Fleming SB, 1997, J VIROL, V71, P4857, DOI 10.1128/JVI.71.6.4857-4861.1997; Foey AD, 1998, J IMMUNOL, V160, P920; Genin P, 2000, J IMMUNOL, V164, P5352, DOI 10.4049/jimmunol.164.10.5352; Harte MT, 2003, J EXP MED, V197, P343, DOI 10.1084/jem.20021652; Haynes LM, 2001, J VIROL, V75, P10730, DOI 10.1128/JVI.75.22.10730-10737.2001; Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620; Higgins SC, 2003, J IMMUNOL, V171, P3119, DOI 10.4049/jimmunol.171.6.3119; Hoebe K, 2003, NATURE, V424, P743, DOI 10.1038/nature01889; Huang YS, 2004, J BIOL CHEM, V279, P51697, DOI 10.1074/jbc.M410369200; Janssens S, 2002, TRENDS BIOCHEM SCI, V27, P474, DOI 10.1016/S0968-0004(02)02145-X; Jung YD, 2002, CYTOKINE, V18, P206, DOI 10.1006/cyto.2002.1034; Krug A, 2004, BLOOD, V103, P1433, DOI 10.1182/blood-2003-08-2674; LaMonica R, 2001, J BIOL CHEM, V276, P19889, DOI 10.1074/jbc.M100499200; Lund JM, 2004, P NATL ACAD SCI USA, V101, P5598, DOI 10.1073/pnas.0400937101; Ma W, 2001, J BIOL CHEM, V276, P13664, DOI 10.1074/jbc.M011157200; McCoy SL, 2005, J IMMUNOL, V174, P3006, DOI 10.4049/jimmunol.174.5.3006; MOORE KW, 1990, SCIENCE, V248, P1230, DOI 10.1126/science.2161559; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; Moss B, 2001, FIELDS VIROLOGY, P2849; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; Netea MG, 2004, TRENDS MICROBIOL, V12, P484, DOI 10.1016/j.tim.2004.09.004; Netea MG, 2004, J IMMUNOL, V172, P3712, DOI 10.4049/jimmunol.172.6.3712; Park KJ, 2003, J BIOL CHEM, V278, P30711, DOI 10.1074/jbc.M209623200; Powell MJ, 2000, J IMMUNOL, V165, P292, DOI 10.4049/jimmunol.165.1.292; Rassa JC, 2003, MICROBES INFECT, V5, P961, DOI 10.1016/S1286-4579(03)00193-X; Schultheiss U, 2001, EMBO J, V20, P5678, DOI 10.1093/emboj/20.20.5678; Sing A, 2002, J IMMUNOL, V168, P1315, DOI 10.4049/jimmunol.168.3.1315; Sing A, 2002, J EXP MED, V196, P1017, DOI 10.1084/jem.20020908; Slezak K, 2000, CYTOKINE, V12, P900, DOI 10.1006/cyto.1999.0646; Stack J, 2005, J EXP MED, V201, P1007, DOI 10.1084/jem.20041442; Tortorella D, 2000, ANNU REV IMMUNOL, V18, P861, DOI 10.1146/annurev.immunol.18.1.861; van den Broek M, 2000, J IMMUNOL, V164, P371, DOI 10.4049/jimmunol.164.1.371; Vockerodt M, 2001, VIROLOGY, V280, P183, DOI 10.1006/viro.2000.0768; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Yamamoto M, 2004, MOL IMMUNOL, V40, P861, DOI 10.1016/j.molimm.2003.10.006; Yamamoto M, 2002, J IMMUNOL, V169, P6668, DOI 10.4049/jimmunol.169.12.6668	49	62	64	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	2005	280	35					30838	30844		10.1074/jbc.M501917200	http://dx.doi.org/10.1074/jbc.M501917200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	958ZX	15998638	hybrid, Green Accepted			2022-12-25	WOS:000231487800024
J	Swarthout, JT; Lobo, S; Farh, L; Croke, MR; Greentree, WK; Deschenes, RJ; Linder, ME				Swarthout, JT; Lobo, S; Farh, L; Croke, MR; Greentree, WK; Deschenes, RJ; Linder, ME			DHHC9 and GCP16 constitute a human protein fatty acyltransferase with specificity for H- and N-Ras	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE LOCALIZATION; ZINC-FINGER DOMAIN; GOLGI-APPARATUS; PALMITOYLTRANSFERASE ACTIVITY; SACCHAROMYCES-CEREVISIAE; PALMITOYL TRANSFERASE; ENDOPLASMIC-RETICULUM; GENE-PRODUCT; IDENTIFICATION; TRAFFICKING	Covalent lipid modifications mediate the membrane attachment and biological activity of Ras proteins. All Ras isoforms are farnesylated and carboxyl-methylated at the terminal cysteine; H-Ras and N-Ras are further modified by palmitoylation. Yeast Ras is palmitoylated by the DHHC cysteine-rich domain-containing protein Erf2 in a complex with Erf4. Here we report that H- and N-Ras are palmitoylated by a human protein palmitoyltransferase encoded by the ZDHHC9 and GCP16 genes. DHHC9 is an integral membrane protein that contains a DHHC cysteine-rich domain. GCP16 encodes a Golgi-localized membrane protein that has limited sequence similarity to yeast Erf4. DHHC9 and GCP16 codistribute in the Golgi apparatus, a location consistent with the site of mammalian Ras palmitoylation in vivo. Like yeast Erf2(.)Erf4, DHHC9 and GCP16 form a protein complex, and DHHC9 requires GCP16 for protein fatty acyltransferase activity and protein stability. Purified DHHC9(.)GCP16 exhibits substrate specificity, palmitoylating H- and N-Ras but not myristoylated G(alpha i1) or GAP-43, proteins with N-terminal palmitoylation motifs. Hence, DHHC9(.)GCP16 displays the properties of a functional human ortholog of the yeast Ras palmitoyltransferase.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA; Univ Iowa, Genet Program, Iowa City, IA 52242 USA; Natl Pingtung Teachers Coll, Dept Nat Sci Educ, Pingtung 900, Taiwan	Washington University (WUSTL); University of Iowa; University of Iowa	Linder, ME (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, Campus Box 8228,660 S Euclid Ave, St Louis, MO 63110 USA.	mlinder@cellbiology.wustl.edu	Deschenes, Robert J/E-4926-2010; Linder, Maurine/AAU-9999-2021	Deschenes, Robert J/0000-0001-8325-4257; Linder, Maurine/0000-0003-2202-9712; Swarthout, John/0000-0002-3043-9386	NATIONAL CANCER INSTITUTE [R01CA050211] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051466] Funding Source: NIH RePORTER; NCI NIH HHS [CA050211, R01 CA050211, R01 CA050211-15A2] Funding Source: Medline; NIGMS NIH HHS [GM51466] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ANDREASEN TJ, 1983, BIOCHEMISTRY-US, V22, P4615, DOI 10.1021/bi00289a001; Apolloni A, 2000, MOL CELL BIOL, V20, P2475, DOI 10.1128/MCB.20.7.2475-2487.2000; Barr FA, 2003, CURR OPIN CELL BIOL, V15, P405, DOI 10.1016/S0955-0674(03)00054-1; Bartels DJ, 1999, MOL CELL BIOL, V19, P6775, DOI 10.1128/mcb.19.10.6775; Bivona TG, 2003, CURR OPIN CELL BIOL, V15, P136, DOI 10.1016/S0955-0674(03)00016-4; BOS JL, 1989, CANCER RES, V49, P4682; CAMP LA, 1993, J BIOL CHEM, V268, P22566; Chaudhary J, 2002, ENDOCRINOLOGY, V143, P426, DOI 10.1210/en.143.2.426; Chiu VK, 2002, NAT CELL BIOL, V4, P343, DOI 10.1038/ncb783; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; Colicelli John, 2004, Sci STKE, V2004, pRE13, DOI 10.1126/stke.2502004re13; Ducker CE, 2004, ONCOGENE, V23, P9230, DOI 10.1038/sj.onc.1208171; Dudler T, 1996, J BIOL CHEM, V271, P11541, DOI 10.1074/jbc.271.19.11541; Dunphy JT, 1996, J BIOL CHEM, V271, P7154, DOI 10.1074/jbc.271.12.7154; Dunphy JT, 2001, J BIOL CHEM, V276, P43300, DOI 10.1074/jbc.M104275200; Fons RD, 2003, J CELL BIOL, V160, P529, DOI 10.1083/jcb.200210095; Fukata M, 2004, NEURON, V44, P987, DOI 10.1016/j.neuron.2004.12.005; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; Hancock JF, 2003, NAT REV MOL CELL BIO, V4, P373, DOI 10.1038/nrm1105; Huang K, 2004, NEURON, V44, P977, DOI 10.1016/j.neuron.2004.11.027; Li BJ, 2002, J BIOL CHEM, V277, P28870, DOI 10.1074/jbc.M202388200; Linder ME, 2003, BIOCHEMISTRY-US, V42, P4311, DOI 10.1021/bi034159a; Lobo S, 2002, J BIOL CHEM, V277, P41268, DOI 10.1074/JBC.M206573200; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; MUMBY SM, 1994, METHOD ENZYMOL, V237, P254; Ohta E, 2003, J BIOL CHEM, V278, P51957, DOI 10.1074/jbc.M310014200; Perez de Castro I, 2004, MOL CELL BIOL, V24, P3485, DOI 10.1128/MCB.24.8.3485-3496.2004; Rocks O, 2005, SCIENCE, V307, P1746, DOI 10.1126/science.1105654; Roth AF, 2002, J CELL BIOL, V159, P23, DOI 10.1083/jcb.200206120; SCHAFER WR, 1992, ANNU REV GENET, V26, P209, DOI 10.1146/annurev.ge.26.120192.001233; SCHUH SM, 1991, BRAIN RES, V565, P85, DOI 10.1016/0006-8993(91)91739-N; Seedorf M, 1999, MOL CELL BIOL, V19, P1547; Singaraja RR, 2002, HUM MOL GENET, V11, P2815, DOI 10.1093/hmg/11.23.2815; Smotrys JE, 2004, ANNU REV BIOCHEM, V73, P559, DOI 10.1146/annurev.biochem.73.011303.073954; Uemura T, 2002, BIOCHEM BIOPH RES CO, V296, P492, DOI 10.1016/S0006-291X(02)00900-2; Washbourne P, 2004, NEURON, V44, P901, DOI 10.1016/S0896-6273(04)00799-8; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0; Willumsen BM, 1996, ONCOGENE, V13, P1901; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; Zhao LH, 2002, J BIOL CHEM, V277, P49352, DOI 10.1074/jbc.M209760200	41	240	249	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	2005	280	35					31141	31148		10.1074/jbc.M504113200	http://dx.doi.org/10.1074/jbc.M504113200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	958ZX	16000296	hybrid			2022-12-25	WOS:000231487800060
J	Botte, C; Jeanneau, C; Snajdrova, L; Bastien, O; Imberty, A; Breton, C; Marechal, E				Botte, C; Jeanneau, C; Snajdrova, L; Bastien, O; Imberty, A; Breton, C; Marechal, E			Molecular modeling and site-directed mutagenesis of plant chloroplast monogalactosyldiacylglycerol synthase reveal critical residues for activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATE DEPRIVATION; PAIRWISE ALIGNMENTS; ENVELOPE MEMBRANES; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; GALACTOLIPIDS; BIOSYNTHESIS; MGDG; PURIFICATION; INFORMATION	Monogalactosyldiacylglycerol ( MGDG), the major lipid of plant and algal plastids, is synthesized by MGD ( or MGDG synthase), a dimeric and membrane-bound glycosyltransferase of the plastid envelope that catalyzes the transfer of a galactosyl group from a UDP-galactose donor onto a diacylglycerol acceptor. Although this enzyme is essential for biogenesis, and therefore an interesting target for herbicide design, no structural information is available. MGD monomers share sequence similarity with MURG, a bacterial glycosyltransferase catalyzing the transfer of N-acetyl-glucosamine on Lipid 1. Using the x-ray structure of Escherichia coli MURG as a template, we computed a model for the fold of Spinacia oleracea MGD. This structural prediction was supported by site-directed mutagenesis analyses. The predicted monomer architecture is a double Rossmann fold. The binding site for UDP-galactose was predicted in the cleft separating the two Rossmann folds. Two short segments of MGD ([beta 2-alpha 2] and [beta 6-beta 7] loops) have no counterparts in MURG, and their structure could not be determined. Combining the obtained model with phylogenetic and biochemical information, we collected evidence supporting the [beta 2-alpha 2] loop in the N-domain as likely to be involved in diacylglycerol binding. Additionally, the monotopic insertion of MGD in one membrane leaflet of the plastid envelope occurs very likely at the level of hydrophobic amino acids of the N-terminal domain.	Univ Grenoble 1, INRA, CEA,CNRS,UMR 5168, Dept Response & Dynam Cellulaires, F-38054 Grenoble, France; CNRS, Ctr Rech Macromol Vegetales, F-38041 Grenoble, France; Gene IT, F-92500 Rueil Malmaison, France	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); CNRS - National Institute for Biology (INSB); INRAE; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Marechal, E (corresponding author), Univ Grenoble 1, INRA, CEA,CNRS,UMR 5168, Dept Response & Dynam Cellulaires, 17 Rue Martyrs, F-38054 Grenoble, France.	emarechal@cea.fr	Botte, Cyrille/G-1972-2014; Bastien, Olivier/B-9723-2008; Imberty, Anne/P-6451-2018	Botte, Cyrille/0000-0002-2245-536X; Imberty, Anne/0000-0001-6825-9527				Andersson MX, 2003, FEBS LETT, V537, P128, DOI 10.1016/S0014-5793(03)00109-1; Archibald JM, 2002, TRENDS GENET, V18, P577, DOI 10.1016/S0168-9525(02)02777-4; Awai K, 2001, P NATL ACAD SCI USA, V98, P10960, DOI 10.1073/pnas.181331498; BAKER PJ, 1992, J MOL BIOL, V228, P662, DOI 10.1016/0022-2836(92)90848-E; Bastien O, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-49; Bastien O, 2004, BIOINFORMATICS, V20, P534, DOI 10.1093/bioinformatics/btg440; Benning C, 2005, J BIOL CHEM, V280, P2397, DOI 10.1074/jbc.R400032200; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BLOCK MA, 1983, J BIOL CHEM, V258, P3281; BLUNDELL T, 1988, EUR J BIOCHEM, V172, P513, DOI 10.1111/j.1432-1033.1988.tb13917.x; Breton C, 1999, CURR OPIN STRUC BIOL, V9, P563, DOI 10.1016/S0959-440X(99)00006-8; Callebaut I, 1997, CELL MOL LIFE SCI, V53, P621, DOI 10.1007/s000180050082; CLARK M, 1989, J COMPUT CHEM, V10, P982, DOI 10.1002/jcc.540100804; CLINE K, 1983, PLANT PHYSIOL, V85, P780; Codani JJ, 1999, METHOD MICROBIOL, V28, P229; Cohen Z, 2000, BIOCHEM SOC T, V28, P740, DOI 10.1042/BST0280740; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; Comet JP, 1999, COMPUT CHEM, V23, P317, DOI 10.1016/S0097-8485(99)00008-X; Coutinho Pedro M., 1999, Journal of Molecular Microbiology and Biotechnology, V1, P307; Coutinho PM, 2003, J MOL BIOL, V328, P307, DOI 10.1016/S0022-2836(03)00307-3; Crouvoisier M, 1999, FEBS LETT, V449, P289, DOI 10.1016/S0014-5793(99)00412-3; Dormann P, 1999, SCIENCE, V284, P2181, DOI 10.1126/science.284.5423.2181; Douce, 1987, BIOCH PLANTS, P215, DOI 10.1016/B978-0-12-675409-4.50015-0; DOUCE R, 1974, SCIENCE, V183, P852, DOI 10.1126/science.183.4127.852; DOUCE R, 1973, J BIOL CHEM, V248, P7215; Edman M, 2003, J BIOL CHEM, V278, P8420, DOI 10.1074/jbc.M211492200; Feige G, 1980, BIOGENESIS FUNCTION, P135; Felsenstein J., 1989, CLADISTICS, V5, P164, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; FERRARI RA, 1961, ARCH BIOCHEM BIOPHYS, V93, P185, DOI 10.1016/0003-9861(61)90248-X; GOUNARIS K, 1983, TRENDS BIOCHEM SCI, V8, P378, DOI 10.1016/0968-0004(83)90366-3; Ha S, 2000, PROTEIN SCI, V9, P1045, DOI 10.1110/ps.9.6.1045; Hartel H, 2000, P NATL ACAD SCI USA, V97, P10649, DOI 10.1073/pnas.180320497; Hartel H, 2000, BIOCHEM SOC T, V28, P729, DOI 10.1042/BST0280729; Heinz E., 1977, Lipids and lipid polymers in higher plants., P102; Hu YN, 2003, P NATL ACAD SCI USA, V100, P845, DOI 10.1073/pnas.0235749100; IMBERTY A, 1999, PERSPECTIVES STRUCTU, P392; JANERO DR, 1981, J LIPID RES, V22, P1119; JONES D, 1993, J COMPUT AID MOL DES, V7, P439, DOI 10.1007/BF02337560; Jouhet J, 2004, J CELL BIOL, V167, P863, DOI 10.1083/jcb.200407022; Joyard Jacques, 1993, P231; Keeling Patrick J, 2004, Science, V306, P2191; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MARECHAL E, 1995, J BIOL CHEM, V270, P5714, DOI 10.1074/jbc.270.11.5714; MARECHAL E, 1994, J BIOL CHEM, V269, P5788; Marechal E, 2002, EUKARYOT CELL, V1, P653, DOI 10.1128/EC.1.4.653-656.2002; Marechal E, 2000, BIOCHEM SOC T, V28, P732, DOI 10.1042/BST0280732; MARECHAL E, 1991, CR ACAD SCI III-VIE, V313, P521; MATSON RS, 1970, PLANT PHYSIOL, V45, P531, DOI 10.1104/pp.45.4.531; Miege C, 1999, EUR J BIOCHEM, V265, P990, DOI 10.1046/j.1432-1327.1999.00801.x; MURATA N, 1982, BIOCH METABOLISM PLA, P165; NEUFELD EF, 1964, BIOCHEM BIOPH RES CO, V14, P503, DOI 10.1016/0006-291X(64)90259-1; Nishiyama Y, 2003, PROTEIN EXPRES PURIF, V31, P79, DOI 10.1016/S1046-5928(03)00158-X; Pali T, 2003, CELL MOL LIFE SCI, V60, P1591, DOI 10.1007/s00018-003-3173-x; Petrova P, 1999, J AM CHEM SOC, V121, P5535, DOI 10.1021/ja983854g; Qi YH, 2004, PLANTA, V219, P450, DOI 10.1007/s00425-004-1245-2; Sanina NM, 2004, PHYTOCHEMISTRY, V65, P721, DOI 10.1016/j.phytochem.2004.01.013; Sato N, 2003, BBA-MOL CELL BIOL L, V1633, P27, DOI 10.1016/S1388-1981(03)00069-6; Shimojima M, 1997, P NATL ACAD SCI USA, V94, P333, DOI 10.1073/pnas.94.1.333	59	32	33	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34691	34701		10.1074/jbc.M505622200	http://dx.doi.org/10.1074/jbc.M505622200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16009708	Green Published, hybrid			2022-12-25	WOS:000232403900039
J	Zimina, EP; Bruckner-Tuderman, L; Franzke, CW				Zimina, EP; Bruckner-Tuderman, L; Franzke, CW			Shedding of collagen XVII ectodomain depends on plasma membrane microenvironment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BULLOUS-PEMPHIGOID ANTIGEN; LIPID RAFTS; CHOLESTEROL DEPLETION; CELLULAR CHOLESTEROL; EPIDERMAL-KERATINOCYTES; PROTEIN; MICRODOMAINS; INHIBITION; ACTIVATION; MECHANISMS	Collagen XVII, a hemidesmosomal component, mediates the adhesion of epidermal keratinocytes to the underlying basement membrane. It exists as a full-length transmembrane protein and a soluble ectodomain that is proteolytically released from the cell surface by sheddases of a disintegrin and metalloproteinase ( ADAM) family; TACE, the tumor necrosis factor-alpha-converting enzyme, is the major physiological proteinase. Because both collagen XVII and the ADAMs are transmembrane proteins, their plasma membrane microenvironment can influence shedding. Lipid rafts, assemblies of sphingolipids and cholesterol within the plasma membrane, are responsible for the separation of membrane proteins and are thought to regulate shedding of cell surface proteins. In this study we analyzed the influence of the cholesterol-depleting agent methyl-beta-cyclodextrin ( M beta CD), which disintegrates lipid rafts, on the shedding of collagen XVII in HaCaT keratinocytes and in transfected COS-7 cells. Increasing concentrations of M beta CD led to a dose-dependent decrease of membrane cholesterol levels and to stimulation of collagen XVII shedding. The stimulation was completely inhibited by sheddase inhibitors, and experiments with COS-7 cells co-transfected with TACE and collagen XVII demonstrated that TACE mediated the low cholesterol-dependent shedding. Co-patching analysis by double immunofluorescence staining revealed co-localization of collagen XVII with the raft resident phosphatidylinositol-linked placental alkaline phosphatase and segregation from the non-raft protein human transferrin receptor, indicating that a majority of collagen XVII molecules was incorporated into lipid rafts. These data deliver the first evidence for the role of plasma membrane lipid organization in the regulation of collagen XVII shedding and, therefore, in the regulation of keratinocyte migration and differentiation.	Univ Freiburg, Dept Dermatol, D-79104 Freiburg, Germany	University of Freiburg	Zimina, EP (corresponding author), Univ Freiburg, Dept Dermatol, Hauptstr 7, D-79104 Freiburg, Germany.	zimina@haut.ukl.uni-freiburg.de; claus_franzke@haut.ukl.uni-freiburg.de						Diatchuk V, 1997, J BIOL CHEM, V272, P13292, DOI 10.1074/jbc.272.20.13292; Ehehalt R, 2003, J CELL BIOL, V160, P113, DOI 10.1083/jcb.200207113; Franzke CW, 2002, EMBO J, V21, P5026, DOI 10.1093/emboj/cdf532; Franzke CW, 2004, J BIOL CHEM, V279, P24521, DOI 10.1074/jbc.M308835200; Franzke CW, 2005, J BIOL CHEM, V280, P4005, DOI 10.1074/jbc.R400034200; Gagnoux-Palacios L, 2003, J CELL BIOL, V162, P1189, DOI 10.1083/jcb.200305006; GIUDICE GJ, 1992, J INVEST DERMATOL, V99, P243, DOI 10.1111/1523-1747.ep12616580; Gniadecki R, 2002, J INVEST DERMATOL, V118, P582, DOI 10.1046/j.1523-1747.2002.01716.x; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; Hirako Y, 1998, J BIOL CHEM, V273, P9711, DOI 10.1074/jbc.273.16.9711; Ilangumaran S, 1998, BIOCHEM J, V335, P433, DOI 10.1042/bj3350433; Jans R, 2004, J INVEST DERMATOL, V123, P564, DOI 10.1111/j.0022-202X.2004.23221.x; KATUNUMA N, 1995, METHOD ENZYMOL, V251, P382, DOI 10.1016/0076-6879(95)51142-3; Kojro E, 2001, P NATL ACAD SCI USA, V98, P5815, DOI 10.1073/pnas.081612998; Matthews V, 2003, J BIOL CHEM, V278, P38829, DOI 10.1074/jbc.M210584200; MCGRATH JA, 1995, NAT GENET, V11, P83, DOI 10.1038/ng0995-83; MENON GK, 1992, J INVEST DERMATOL, V98, P209, DOI 10.1111/1523-1747.ep12555880; Murphy MP, 1999, J BIOL CHEM, V274, P11914, DOI 10.1074/jbc.274.17.11914; NISHIZAWA Y, 1993, J BIOCHEM-TOKYO, V113, P493, DOI 10.1093/oxfordjournals.jbchem.a124072; Phong MC, 2003, BIOCHEM BIOPH RES CO, V300, P563, DOI 10.1016/S0006-291X(02)02886-3; Saslowsky DE, 2002, J BIOL CHEM, V277, P26966, DOI 10.1074/jbc.M204669200; Schacke H, 1998, J BIOL CHEM, V273, P25937, DOI 10.1074/jbc.273.40.25937; SCHMIDT R, 1991, J INVEST DERMATOL, V97, P771, DOI 10.1111/1523-1747.ep12486720; Schumann H, 2000, AM J PATHOL, V156, P685, DOI 10.1016/S0002-9440(10)64772-4; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Tasanen K, 2004, AM J PATHOL, V164, P2027, DOI 10.1016/S0002-9440(10)63762-5; von Tresckow B, 2004, J IMMUNOL, V172, P4324, DOI 10.4049/jimmunol.172.7.4324; Wakatsuki S, 2004, J NEUROCHEM, V89, P119, DOI 10.1046/j.1471-4159.2003.02303.x; Zheng XJ, 2003, J INVEST DERMATOL, V121, P1487, DOI 10.1111/j.1523-1747.2003.12614.x	30	44	46	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					34019	34024		10.1074/jbc.M503751200	http://dx.doi.org/10.1074/jbc.M503751200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16020548	hybrid			2022-12-25	WOS:000232229700040
J	Rouet, V; Hamma-Kourbali, Y; Petit, E; Panagopoulou, P; Katsoris, P; Barritault, D; Caruelle, JP; Courty, J				Rouet, V; Hamma-Kourbali, Y; Petit, E; Panagopoulou, P; Katsoris, P; Barritault, D; Caruelle, JP; Courty, J			A synthetic glycosaminoglycan mimetic binds vascular endothelial growth factor and modulates angiogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE; SUBSTITUTED DEXTRAN; TYROSINE KINASE; FACTOR FAMILY; RECEPTOR; REPAIR; EXPRESSION; CELLS; VASCULOGENESIS; IDENTIFICATION	In a previous study, we showed that in situ injection of glycosaminoglycan mimetics called RGTAs (R) (ReGeneraTing Agents) enhanced neovascularization after skeletal muscular ischemia ( Desgranges, P., Barbaud, C., Caruelle, J. P., Barritault, D., and Gautron, J. ( 1999) FASEB J. 13, 761 - 766). In the present study, we showed that the RGTA (R) OTR4120 modulated angiogenesis in the chicken embryo chorioallantoic membrane assay, in a dose-dependent manner. We therefore investigated the effect of OTR4120 on one of the most specific angiogenesis-regulating heparin-binding growth factors, vascular endothelial growth factor 165 ( VEGF(165)). OTR4120 showed high affinity binding to VEGF(165) (K-d = 2.2 nM), as compared with heparin (K-d = 15 nM), and potentiated the affinity of VEGF(165) for VEGF receptor-1 and -2 and for neuropilin-1. In vitro, OTR4120 potentiated VEGF(165)-induced proliferation and migration of human umbilical vein endothelial cells. In the in vivo Matrigel (TM) plug angiogenesis assay, OTR4120 in a concentration as low as 3 ng/ml caused a 6-fold increase in VEGF(165)-induced angiogenesis. Immunohistochemical staining showed a larger number of well differentiated VEGFR-2-expressing-cells in Matrigel (TM) sections of OTR4120-treated plug than in control sections. These findings indicate that OTR4120 enhances the VEGF(165)-induced angiogenesis and therefore may hold promise for treating disorders characterized by deficient angiogenesis.	Univ Paris 12, Lab Rech Croissance Cellulaire Reparat & Regenera, CNRS, UMR 7149, F-94010 Creteil, France; SAS, Organes Tissus Regenerat Reparat Remplacement, OTR3, F-75001 Paris, France; Univ Patras, Div Genet Cell & Dev Biol, Dept Biol, GR-26504 Patras, Greece	Centre National de la Recherche Scientifique (CNRS); Universite Gustave-Eiffel; Universite Paris-Est-Creteil-Val-de-Marne (UPEC); University of Patras	Courty, J (corresponding author), Univ Paris 12, Lab Rech Croissance Cellulaire Reparat & Regenera, CNRS, UMR 7149, Ave Gen de Gaulle, F-94010 Creteil, France.	courty@univ-paris12.fr	Hamma-Kourbali, Yamina/R-3692-2018; Courty, Jose/Q-3702-2018	Hamma-Kourbali, Yamina/0000-0002-2754-8928; 				AAMIRI A, 1995, CR ACAD SCI III-VIE, V318, P1037; Alexakis C, 2004, FASEB J, V18, P1147, DOI 10.1096/fj.03-1126fje; Alexakis C, 2001, FASEB J, V15, P1546, DOI 10.1096/fj.00-0756com; Barbosa I, 2005, J CELL SCI, V118, P253, DOI 10.1242/jcs.01607; Bechard D, 2001, J BIOL CHEM, V276, P48341, DOI 10.1074/jbc.M108395200; Bernard-Pierrot I, 2001, J BIOL CHEM, V276, P12228, DOI 10.1074/jbc.M010913200; Blanquaert F, 1995, BONE, V17, P499, DOI 10.1016/8756-3282(95)00402-5; Cochran S, 2003, J MED CHEM, V46, P4601, DOI 10.1021/jm030180y; Desgranges P, 1999, FASEB J, V13, P761, DOI 10.1096/fasebj.13.6.761; Desgranges P, 2001, J BIOMED MATER RES, V58, P1, DOI 10.1002/1097-4636(2001)58:1<1::AID-JBM10>3.0.CO;2-8; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; Escartin Q, 2003, FASEB J, V17, P644, DOI 10.1096/fj.02-0708com; Fannon M, 2003, FASEB J, V17, P902, DOI 10.1096/fj.02-0935fje; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18; Francis DJ, 2003, CIRC RES, V92, pE70, DOI 10.1161/01.RES.0000071345.76095.07; FREDJREYGROBELLET D, 1994, OPHTHALMIC RES, V26, P325, DOI 10.1159/000267497; Gengrinovitch S, 1999, J BIOL CHEM, V274, P10816, DOI 10.1074/jbc.274.16.10816; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Hamma-Kourbali Y, 2001, J BIOL CHEM, V276, P39748, DOI 10.1074/jbc.M101117200; Hattori K, 2002, NAT MED, V8, P841, DOI 10.1038/nm740; Hayashi T, 1998, J CEREBR BLOOD F MET, V18, P887, DOI 10.1097/00004647-199808000-00009; Hiratsuka S, 2001, CANCER RES, V61, P1207; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; Iivanainen E, 2003, MICROSC RES TECHNIQ, V60, P13, DOI 10.1002/jemt.10238; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; Ito N, 1999, Angiogenesis, V3, P159, DOI 10.1023/A:1009008926710; Li J, 2003, MICROSC RES TECHNIQ, V60, P107, DOI 10.1002/jemt.10249; Meddahi A, 2002, J BIOMED MATER RES, V60, P497, DOI 10.1002/jbm.1293; Meddahi A, 2002, J BIOMED MATER RES, V62, P525, DOI 10.1002/jbm.10283; Meddahi A, 1996, DIABETES METAB, V22, P274; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MUNSON PJ, 1983, METHOD ENZYMOL, V92, P543; Nangia-Makker P, 2000, CANCER METAST REV, V19, P51, DOI 10.1023/A:1026540129688; Pacini S, 2002, BIOCHEM BIOPH RES CO, V290, P820, DOI 10.1006/bbrc.2001.6254; Papadimitriou E, 2001, BIOCHEM BIOPH RES CO, V282, P306, DOI 10.1006/bbrc.2001.4574; PAPYGARCIA D, 2005, IN PRESS MACROMOLECU; PERETZ D, 1992, BIOCHEM BIOPH RES CO, V182, P1340, DOI 10.1016/0006-291X(92)91880-Y; PETERS KG, 1993, P NATL ACAD SCI USA, V90, P8915, DOI 10.1073/pnas.90.19.8915; Phongkitkarun S, 2004, ACAD RADIOL, V11, P573, DOI 10.1016/S1076-6332(03)00728-1; Plouet J, 1997, J BIOL CHEM, V272, P13390, DOI 10.1074/jbc.272.20.13390; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; Ribatti D, 2002, CYTOKINE, V17, P262, DOI 10.1006/cyto.2002.1002; RIBATTI D, 1987, ACTA ANAT, V130, P257; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; SASISEKHARAN R, 1994, P NATL ACAD SCI USA, V91, P1524, DOI 10.1073/pnas.91.4.1524; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Soulie P, 2002, J IMMUNOASS IMMUNOCH, V23, P33, DOI 10.1081/IAS-120002273; TARDIEU M, 1992, J CELL PHYSIOL, V150, P194, DOI 10.1002/jcp.1041500126; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TESSLER S, 1994, J BIOL CHEM, V269, P12456; Tonnesen MG, 2000, J INVEST DERM SYMP P, V5, P40, DOI 10.1046/j.1087-0024.2000.00014.x; Tuomisto TT, 2004, ATHEROSCLEROSIS, V174, P111, DOI 10.1016/j.atherosclerosis.2004.01.015; Vives RR, 1999, BIOCHEM J, V339, P767, DOI 10.1042/0264-6021:3390767; Yamauchi H, 2000, FASEB J, V14, P2133; Zakine G, 2003, ANN THORAC SURG, V75, P549, DOI 10.1016/S0003-4975(02)04332-1	57	62	65	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	2005	280	38					32792	32800		10.1074/jbc.M504492200	http://dx.doi.org/10.1074/jbc.M504492200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	964ZU	16014624	hybrid			2022-12-25	WOS:000231920300031
J	Wegiel, B; Bjartell, A; Ekberg, J; Gadaleanu, V; Brunhoff, C; Persson, JL				Wegiel, B; Bjartell, A; Ekberg, J; Gadaleanu, V; Brunhoff, C; Persson, JL			A role for cyclin A1 in mediating the autocrine expression of vascular endothelial growth factor in prostate cancer	ONCOGENE			English	Article						cyclin A1; VEGF; androgen; androgen receptor; Rb; prostate cancer	TUMOR-GROWTH; FACTOR VEGF; ANDROGEN; ANGIOGENESIS; PROGRESSION; RECEPTORS; PROTEIN; CELLS	Elevated levels of cyclin A1 expression have been implicated in acute myeloid leukemia and in male germ cell tumors. However, a role of cyclin A1 in tumorigenesis of prostate cancer has not been reported. In the present study, expression of cyclin A1 in patients with prostate cancer and a role of cyclin A1 in mediating expression of vascular endothelial growth factor ( VEGF) were investigated. Cyclin A1 was highly expressed in aggressive tumors and was significantly correlated with VEGF expression in 96 patients with prostate cancer. Treatment of LNCaP cells with R1881, a synthetic androgen resulted in increased cyclin A1 expression. Induction of cyclin A1 expression in LNCaP cells led to an increase in VEGF expression and this effect was manifested upon the R1881 treatment. Cyclin A1 failed to mediate VEGF activation in DU-145 cells lacking a functional Rb and an androgen receptor (AR). Although AR expression was induced into DU-145 cells, cyclin A1 was unable to mediate VEGF expression. However, induced coexpression of cyclin A1, Rb and AR in DU-145 cells in the presence of R1881 greatly promoted VEGF promoter activity. This suggests that cyclin A1 mediates VEGF expression in cooperation with Rb- and androgen-dependent pathways in prostate cancer.	Lund Univ, Univ Hosp, Div Pathol, Dept Lab Med, S-20502 Malmo, Sweden; Lund Univ, Univ Hosp, Dept Urol, Malmo, Sweden	Lund University; Skane University Hospital; Lund University; Skane University Hospital	Persson, JL (corresponding author), Lund Univ, Univ Hosp, Div Pathol, Dept Lab Med, S-20502 Malmo, Sweden.	jenny.persson@pat.mas.lu.se		Persson, Jenny/0000-0001-7682-7678				Ali IU, 2001, UROLOGY, V57, P143, DOI 10.1016/S0090-4295(00)00961-4; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Borre M, 2000, CLIN CANCER RES, V6, P1882; Chevalier S, 2002, MOL CELL ENDOCRINOL, V189, P169, DOI 10.1016/S0303-7207(01)00728-6; Coffey RNT, 2002, PROSTATE, V53, P300, DOI 10.1002/pros.10159; Coletta RD, 2004, P NATL ACAD SCI USA, V101, P6478, DOI 10.1073/pnas.0401139101; Culig Z, 2002, MOL CELL ENDOCRINOL, V197, P231, DOI 10.1016/S0303-7207(02)00263-0; Dasgupta P, 2004, MOL CELL BIOL, V24, P9527, DOI 10.1128/MCB.24.21.9527-9541.2004; Ekberg J, 2004, ONCOGENE, V23, P9082, DOI 10.1038/sj.onc.1208090; Ferrer FA, 1997, J UROLOGY, V157, P2329, DOI 10.1016/S0022-5347(01)64775-X; Finkenzeller G, 1997, ONCOGENE, V15, P669, DOI 10.1038/sj.onc.1201219; Haggstrom S, 1999, J UROLOGY, V161, P1620, DOI 10.1016/S0022-5347(05)68994-X; Hicklin DJ, 2005, J CLIN ONCOL, V23, P1011, DOI 10.1200/JCO.2005.06.081; Hrouda D, 2003, UROL RES, V30, P347, DOI 10.1007/s00240-002-0287-9; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Jackson MW, 2002, CANCER RES, V62, P854; Jozkowicz A, 2004, BIOCHEM BIOPH RES CO, V314, P31, DOI 10.1016/j.bbrc.2003.12.059; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; Kimura K, 2001, CANCER RES, V61, P5611; Klocker H, 1999, EUR UROL, V35, P413, DOI 10.1159/000019918; Liao C, 2004, INT J CANCER, V108, P654, DOI 10.1002/ijc.11573; Liao C, 2001, P NATL ACAD SCI USA, V98, P6853, DOI 10.1073/pnas.121540098; LILJA H, 1991, CLIN CHEM, V37, P1618; Liu D, 1998, NAT GENET, V20, P377, DOI 10.1038/3855; Lu JM, 1998, J BIOL CHEM, V273, P31528, DOI 10.1074/jbc.273.47.31528; Marker PC, 2003, DEV BIOL, V253, P165, DOI 10.1016/S0012-1606(02)00031-3; Muller-Tidow C, 2003, CANCER LETT, V190, P89, DOI 10.1016/S0304-3835(02)00582-7; Nicholson B, 2004, J CELL BIOCHEM, V91, P125, DOI 10.1002/jcb.10772; Porkka KP, 2004, EUR UROL, V45, P683, DOI 10.1016/j.eururo.2004.01.012; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Strohmeyer D, 2000, PROSTATE, V45, P216, DOI 10.1002/1097-0045(20001101)45:3<216::AID-PROS3>3.0.CO;2-C; Suzuki H, 2003, ENDOCR-RELAT CANCER, V10, P209, DOI 10.1677/erc.0.0100209; Sweeney C, 1996, DEVELOPMENT, V122, P53; Taneja SS, 2002, J CELL BIOCHEM, V84, P188, DOI 10.1002/jcb.1278; Tokumaru Y, 2004, CANCER RES, V64, P5982, DOI 10.1158/0008-5472.CAN-04-0993; van Moorselaar RJA, 2002, MOL CELL ENDOCRINOL, V197, P239, DOI 10.1016/S0303-7207(02)00262-9; Yang R, 1999, MOL CELL BIOL, V19, P2400; Yang R, 1997, CANCER RES, V57, P913	39	46	47	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 22	2005	24	42					6385	6393		10.1038/sj.onc.1208795	http://dx.doi.org/10.1038/sj.onc.1208795			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	966RI	16007189				2022-12-25	WOS:000232038200006
J	Jamieson, E; Chong, MMW; Steinberg, GR; Jovanovska, V; Fam, BC; Bullen, DVR; Chen, Y; Kemp, BE; Proietto, J; Kay, TWH; Andrikopoulos, S				Jamieson, E; Chong, MMW; Steinberg, GR; Jovanovska, V; Fam, BC; Bullen, DVR; Chen, Y; Kemp, BE; Proietto, J; Kay, TWH; Andrikopoulos, S			Socs1 deficiency enhances hepatic insulin signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; HUMAN SKELETAL-MUSCLE; METABOLISM IN-VIVO; CYTOKINE SIGNALING-1; RECEPTOR SUBSTRATE-2; INTERFERON-GAMMA; ISLET NEOGENESIS; MICE LACKING; BETA-CELLS; RESISTANCE	Suppressor of cytokine signaling 1 (SOCS1) is an intracellular inhibitor of cytokine, growth factor, and hormone signaling. Socs1(-/-) mice die before weaning from a multiorgan inflammatory disease. Neonatal Socs1(-/-) mice display severe hypoglycemia and hypoinsulinemia. Concurrent interferon gamma gene deletion (Ifng(-/-)) prevented inflammation and corrected the hypoglycemia. In hyperinsulinemic clamp studies, however, Socs1(-/-) Ifng(-/-) mice had enhanced hepatic insulin sensitivity demonstrated by greater suppression of endogenous glucose production compared with controls with no difference in glucose disposal. Socs1(-/-) Ifng(-/-) mice had elevated liver insulin receptor substrate 2 expression (IRS-2) and IRS-2 tyrosine phosphorylation. This was associated with lower phosphoenolpyruvate carboxykinase mRNA expression. These effects were not associated with elevated hepatic AMP-activated protein kinase activity. Hepatic insulin sensitivity and IRS-2 levels play central roles in the pathogenesis of type 2 diabetes. Socs1 deficiency increases IRS-2 expression and enhances hepatic insulin sensitivity in vivo indicating that inhibition of SOCS1 may be a logical strategy in type 2 diabetes.	St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia; Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia; Univ Melbourne, Heidelberg Repatriat Hosp, Dept Med, Heidelberg, Vic 3081, Australia; CSIRO Sci & Nutr, Parkville, Vic 3052, Australia	St. Vincent's Institute of Medical Research; Walter & Eliza Hall Institute; Florey Institute of Neuroscience & Mental Health; University of Melbourne; Commonwealth Scientific & Industrial Research Organisation (CSIRO)	Kay, TWH (corresponding author), St Vincents Inst Med Res, 41 Victria Parade, Fitzroy, Vic 3065, Australia.	tkay@svi.edu.au	Proietto, Joe/B-3780-2012; Kemp, Bruce E/L-2633-2014; Kemp, Bruce/G-9602-2019; Chong, Mark/H-6684-2016	Kemp, Bruce E/0000-0001-6735-5082; Kemp, Bruce/0000-0001-6735-5082; Chong, Mark/0000-0002-3701-7397; Jamieson, Emma/0000-0002-5549-6459; Steinberg, Gregory/0000-0001-5425-8275				Alexander WS, 1999, J LEUKOCYTE BIOL, V66, P588, DOI 10.1002/jlb.66.4.588; Alexander WS, 1999, CELL, V98, P597, DOI 10.1016/S0092-8674(00)80047-1; Brady MJ, 2004, J CLIN INVEST, V114, P886, DOI 10.1172/JC1200423108; Bullen DVR, 2001, IMMUNOLOGY, V104, P92, DOI 10.1046/j.1365-2567.2001.01294.x; Chen Y, 2004, AM J PATHOL, V165, P913, DOI 10.1016/S0002-9440(10)63353-6; Chen ZP, 2000, AM J PHYSIOL-ENDOC M, V279, pE1202, DOI 10.1152/ajpendo.2000.279.5.E1202; GU DL, 1993, DEVELOPMENT, V118, P33; Inoue H, 2004, NAT MED, V10, P168, DOI 10.1038/nm980; Johnston AM, 2003, FEBS LETT, V546, P32, DOI 10.1016/S0014-5793(03)00438-1; Kawazoe Y, 2001, J EXP MED, V193, P263, DOI 10.1084/jem.193.2.263; Kemp BE, 2003, BIOCHEM SOC T, V31, P162; Kido Y, 2000, J CLIN INVEST, V105, P199, DOI 10.1172/JCI7917; Kooptiwut S, 2002, ENDOCRINOLOGY, V143, P2085, DOI 10.1210/en.143.6.2085; Krebs DL, 2002, MOL CELL BIOL, V22, P4567, DOI 10.1128/MCB.22.13.4567-4578.2002; KREBS DL, 2003, SCI STKE, pPE6; Kubota N, 2004, J CLIN INVEST, V114, P917, DOI 10.1172/JCI200421484; Kubota N, 2000, DIABETES, V49, P1880, DOI 10.2337/diabetes.49.11.1880; Lamont BJ, 2003, DIABETOLOGIA, V46, P1338, DOI 10.1007/s00125-003-1180-y; Lauro D, 1998, NAT GENET, V20, P294, DOI 10.1038/3112; Lin XY, 2004, J CLIN INVEST, V114, P908, DOI [10.1172/JCI22217, 10.1172/JCI200422217]; Metcalf D, 2000, P NATL ACAD SCI USA, V97, P9174, DOI 10.1073/pnas.160255197; Michael MD, 2000, MOL CELL, V6, P87, DOI 10.1016/S1097-2765(00)00010-1; Mooney RA, 2001, J BIOL CHEM, V276, P25889, DOI 10.1074/jbc.M010579200; Previs SF, 2000, J BIOL CHEM, V275, P38990, DOI 10.1074/jbc.M006490200; Rui LY, 2002, J BIOL CHEM, V277, P42394, DOI 10.1074/jbc.C200444200; Starr R, 1998, P NATL ACAD SCI USA, V95, P14395, DOI 10.1073/pnas.95.24.14395; Starr R, 1998, INT J BIOCHEM CELL B, V30, P1081, DOI 10.1016/S1357-2725(98)00067-3; Steinberg GR, 2004, J CLIN ENDOCR METAB, V89, P4575, DOI 10.1210/jc.2004-0308; Ueki K, 2004, MOL CELL BIOL, V24, P5434, DOI 10.1128/MCB.24.12.5434-5446.2004; Ueki K, 2004, P NATL ACAD SCI USA, V101, P10422, DOI 10.1073/pnas.0402511101; Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788; Zang MW, 2004, J BIOL CHEM, V279, P47898, DOI 10.1074/jbc.M408149200; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI200113505	33	33	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	2005	280	36					31516	31521		10.1074/jbc.M502163200	http://dx.doi.org/10.1074/jbc.M502163200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	961LZ	15983045	hybrid			2022-12-25	WOS:000231665200023
J	Reininger, L; Billker, O; Tewari, R; Mukhopadhyay, A; Fennell, C; Dorin-Semblat, D; Doerig, C; Goldring, D; Harmse, L; Ranford-Cartwright, L; Packer, J; Doerig, C				Reininger, L; Billker, O; Tewari, R; Mukhopadhyay, A; Fennell, C; Dorin-Semblat, D; Doerig, C; Goldring, D; Harmse, L; Ranford-Cartwright, L; Packer, J; Doerig, C			A NIMA-related protein kinase is essential for completion of the sexual cycle of malaria parasites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMODIUM-FALCIPARUM; DNA-SYNTHESIS; IDENTIFICATION; GENE; ZYGOTES; BERGHEI; TRANSMISSION; GALLINACEUM; GAMETOCYTES; INTERPHASE	The molecular mechanisms regulating the sexual development of malaria parasites from gametocytes to oocysts in their mosquito vector are still largely unexplored. In other eukaryotes, NIMA-related kinases (Neks) regulate cell cycle progression and have been implicated in the regulation of meiosis. Here, we demonstrate that Nek-4, a new Plasmodium member of the Nek family, is essential for completion of the sexual cycle of the parasite. Recombinant Plasmodium falciparum Nek-4 possesses protein kinase activity and displays substrate preferences similar to those of other Neks. Nek-4 is highly expressed in gametocytes, yet disruption of the nek-4 gene in the rodent malaria parasite P. berghei has no effect on gamete formation and subsequent fertilization. However, further differentiation of zygotes into ookinetes is abolished. Measurements of nuclear DNA content indicate that zygotes lacking Nek-4 fail to undergo the genome replication to the tetraploid level that precedes meiosis. Cell cycle progression in the zygote is identified as a likely precondition for its morphological transition to the ookinete and for the successful establishment of a malaria infection in the mosquito.	Univ Glasgow, INSERM, U609, Wellcome Ctr Mol Parasitol, Glasgow G11 6NU, Lanark, Scotland; Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, London SW7 2AZ, England; Univ Kwazulu Natal, Sch Mol & Cellular Biosci, Dept Biochem, ZA-3209 Scottsville, South Africa; Univ Witwatersrand, Dept Pharm & Pharmacol, ZA-2193 Parktown, South Africa; Univ Glasgow, Inst Biol & Life Sci, Glasgow G12 8QQ, Lanark, Scotland; Abbott Labs, Abbott Pk, IL 60064 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); University of Glasgow; Imperial College London; University of Kwazulu Natal; University of Witwatersrand; University of Glasgow; Abbott Laboratories	Billker, O (corresponding author), Univ Glasgow, INSERM, U609, Wellcome Ctr Mol Parasitol, 56 Dumbarton Rd, Glasgow G11 6NU, Lanark, Scotland.	o.billker@imperial.ac.uk	Doerig, Christian/Q-9900-2019; Tewari, Rita/M-5698-2014; Reininger, Luc/O-5301-2015; Ranford-Cartwright, Lisa C/H-4701-2013; Dorin-Semblat, Dominique/P-5845-2017	Ranford-Cartwright, Lisa C/0000-0003-1992-3940; Dorin-Semblat, Dominique/0000-0002-8162-4573; Goldring, James Philip Dean/0000-0001-6713-9515; Billker, Oliver/0000-0003-1716-168X; Doerig, Christian/0000-0002-3188-094X; Tewari, Rita/0000-0003-3943-1847; REININGER, LUC/0000-0002-7014-7783	MRC [G120/746] Funding Source: UKRI; Medical Research Council [G120/746] Funding Source: Medline; Wellcome Trust Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		ALANO P, 1995, EXP PARASITOL, V81, P227, DOI 10.1006/expr.1995.1112; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Anamika, 2005, PROTEINS, V58, P180, DOI 10.1002/prot.20278; BAIROCH A, 1988, NATURE, V331, P22, DOI 10.1038/331022a0; Baldauf SL, 2003, SCIENCE, V300, P1703, DOI 10.1126/science.1085544; Billker O, 1998, NATURE, V392, P289, DOI 10.1038/32667; Billker O, 2004, CELL, V117, P503, DOI 10.1016/S0092-8674(04)00449-0; Billker O, 1997, PARASITOLOGY, V115, P1, DOI 10.1017/S0031182097008895; Bowers AJ, 2004, GENE, V328, P135, DOI 10.1016/j.gene.2003.12.002; Bozdech Z, 2003, PLOS BIOL, V1, P85, DOI 10.1371/journal.pbio.0000005; Carter R, 1993, Methods Mol Biol, V21, P67; Chen A, 1999, GENE, V234, P127, DOI 10.1016/S0378-1119(99)00165-1; Cohen P, 2002, NAT REV DRUG DISCOV, V1, P309, DOI 10.1038/nrd773; DOERIG C, 2004, BIOCHIM BIOPHYS ACTA, P155; Dorin D, 1999, J BIOL CHEM, V274, P29912, DOI 10.1074/jbc.274.42.29912; Dorin D, 2001, EUR J BIOCHEM, V268, P2600, DOI 10.1046/j.1432-1327.2001.02151.x; Eddy SR, 1998, BIOINFORMATICS, V14, P755, DOI 10.1093/bioinformatics/14.9.755; Felsenstein J., 1989, CLADISTICS, V5, P164, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; Fry AM, 1998, EMBO J, V17, P470, DOI 10.1093/emboj/17.2.470; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hunter T, 1997, TRENDS BIOCHEM SCI, V22, P18, DOI 10.1016/S0968-0004(96)10068-2; JANSE CJ, 1988, PARASITOLOGY, V96, P1, DOI 10.1017/S0031182000081609; JANSE CJ, 1986, T ROY SOC TROP MED H, V80, P154, DOI 10.1016/0035-9203(86)90219-1; JANSE CJ, 1986, MOL BIOCHEM PARASIT, V20, P173, DOI 10.1016/0166-6851(86)90029-0; Kissinger JC, 2002, NATURE, V419, P490, DOI 10.1038/419490a; KUMAR N, 1985, EXP PARASITOL, V59, P239, DOI 10.1016/0014-4894(85)90078-5; Le Roch KG, 2003, SCIENCE, V301, P1503, DOI 10.1126/science.1087025; Mahjoub MR, 2004, MOL BIOL CELL, V15, P5172, DOI 10.1091/mbc.E04-07-0571; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Menard R, 1997, METHODS, V13, P148, DOI 10.1006/meth.1997.0507; Merckx A, 2003, J BIOL CHEM, V278, P39839, DOI 10.1074/jbc.M301625200; O'Connell MJ, 2003, TRENDS CELL BIOL, V13, P221, DOI 10.1016/S0962-8924(03)00056-4; OAKLEY BR, 1983, J CELL BIOL, V96, P1155, DOI 10.1083/jcb.96.4.1155; OSMANI SA, 1988, CELL, V53, P237, DOI 10.1016/0092-8674(88)90385-6; PATON MG, 1993, MOL BIOCHEM PARASIT, V59, P263, DOI 10.1016/0166-6851(93)90224-L; Pruitt KD, 2005, NUCLEIC ACIDS RES, V33, pD501, DOI 10.1093/nar/gki025; Ridley RG, 2002, MICROBES INFECT, V4, P155, DOI 10.1016/S1286-4579(01)01536-2; Silva-Neto MAC, 2002, J BIOL CHEM, V277, P14085, DOI 10.1074/jbc.M107903200; SINDEN RE, 1985, J PROTOZOOL, V32, P742, DOI 10.1111/j.1550-7408.1985.tb03113.x; Tan BCM, 2004, J BIOL CHEM, V279, P9321, DOI 10.1074/jbc.M311477200; THOMPSON J, 1994, MOL BIOCHEM PARASIT, V68, P189, DOI 10.1016/0166-6851(94)90164-3; WALLIKER D, 1987, SCIENCE, V236, P1661, DOI 10.1126/science.3299700; Ward P, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-79; WINGER LA, 1988, PARASITE IMMUNOL, V10, P193, DOI 10.1111/j.1365-3024.1988.tb00214.x	45	111	114	0	37	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	2005	280	36					31957	31964		10.1074/jbc.M504523200	http://dx.doi.org/10.1074/jbc.M504523200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	961LZ	15970588	hybrid, Green Published			2022-12-25	WOS:000231665200075
J	Roca, H; Phimphilai, M; Gopalakrishnan, R; Xiao, GZ; Franceschi, RT				Roca, H; Phimphilai, M; Gopalakrishnan, R; Xiao, GZ; Franceschi, RT			Cooperative interactions between RUNX2 and homeodomain protein-binding sites are critical for the osteoblast-specific expression of the bone sialoprotein gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; OSTEOCALCIN GENE; TRANSGENIC MICE; IN-VITRO; DIFFERENTIATION; PROMOTER; CELLS; DLX5; MSX2; CBFA1	The bone sialoprotein (Bsp) gene provides an excellent model for studying mechanisms controlling osteoblast-specific gene expression. Although the RUNX2 transcription factor directly regulates many osteoblast-related genes, its function in Bsp expression remains uncertain. By using chromatin immunoprecipitation (ChIP) analysis in MC3T3-E1 (clone MC-4) preosteoblast cells, RUNX2 was shown to bind a chromatin fragment containing the proximal Bsp promoter. Two putative RUNX2-binding sites (R1 and R2) were identified within this region of the mouse, rat, and human genes and were shown to bind RUNX2 in vitro and in vivo (by ChIP assay). Site-specific mutagenesis established that both sites act as osteoblast-specific transcriptional enhancers and together account for nearly two-thirds of the total promoter activity. In addition, functional cooperativity was observed between the R2 site and an adjacent homeodomain protein-binding site previously characterized by this laboratory (the C site). All three sites (R1, R2, and C) are necessary for maximal promoter activity in osteoblasts. DLX5 in MC-4 cell nuclear extracts binds to the C site in vitro. Furthermore, ChIP assays revealed that DLX5 is selectively associated with chromatin in the vicinity of the C site only when Bsp is transcriptionally active. Finally, co-immunoprecipitation assays detected a physical complex containing DLX5 and RUNX2. Taken together, our data show that RUNX2 is a direct regulator of Bsp in osteoblasts and that it functions in cooperation with DLX5 or a related factor to activate osteoblast-specific gene expression.	Univ Michigan, Dept Periodont Prevent & Geriatr, Sch Dent, Ann Arbor, MI 48109 USA; Univ Michigan, Ctr Craniofacial Regenerat, Sch Dent, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol Chem, Sch Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Franceschi, RT (corresponding author), Univ Michigan, Dept Periodont Prevent & Geriatr, Sch Dent, 1011 N Univ Ave, Ann Arbor, MI 48109 USA.	rennyf@umich.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR046024] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE011723] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R56DE011723, R01DE012211] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR46024] Funding Source: Medline; NIDCR NIH HHS [DE 12211, DE 11723] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Acampora D, 1999, DEVELOPMENT, V126, P3795; Barnes GL, 2003, CANCER RES, V63, P2631; Barnes GL, 2002, J CELL BIOCHEM, V87, P458, DOI 10.1002/jcb.10351; Benson MD, 2000, J BIOL CHEM, V275, P13907, DOI 10.1074/jbc.275.18.13907; Benson MD, 1999, J BONE MINER RES, V14, P396, DOI 10.1359/jbmr.1999.14.3.396; Chen JK, 1996, J BONE MINER RES, V11, P654; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; Cowles EA, 1998, CALCIFIED TISSUE INT, V62, P74, DOI 10.1007/s002239900397; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Ducy P, 1999, GENE DEV, V13, P1025, DOI 10.1101/gad.13.8.1025; Franceschi RT, 2003, CALCIFIED TISSUE INT, V72, P638, DOI 10.1007/s00223-002-1053-2; FRANCESCHI RT, 1992, J BONE MINER RES, V7, P235; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; Gopalakrishnan R, 2003, CONNECT TISSUE RES, V44, P154, DOI 10.1080/03008200390152250; Hassan MQ, 2004, MOL CELL BIOL, V24, P9248, DOI 10.1128/MCB.24.20.9248-9261.2004; Hoshi K, 1999, BONE, V25, P639, DOI 10.1016/S8756-3282(99)00223-9; KAMACHI Y, 1990, J VIROL, V64, P4808, DOI 10.1128/JVI.64.10.4808-4819.1990; Kern B, 2001, J BIOL CHEM, V276, P7101, DOI 10.1074/jbc.M006215200; Kim YJ, 2004, J BIOL CHEM, V279, P50773, DOI 10.1074/jbc.M404145200; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Lee MH, 2003, J BIOL CHEM, V278, P34387, DOI 10.1074/jbc.M211386200; Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092-8674(01)00622-5; Newberry EP, 1999, BIOCHEMISTRY-US, V38, P10678, DOI 10.1021/bi990967j; Newberry EP, 1998, BIOCHEMISTRY-US, V37, P16360, DOI 10.1021/bi981878u; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Ryoo HM, 1997, MOL ENDOCRINOL, V11, P1681, DOI 10.1210/me.11.11.1681; Shirakabe K, 2001, GENES CELLS, V6, P851, DOI 10.1046/j.1365-2443.2001.00466.x; Tadic T, 2002, J BONE MINER RES, V17, P1008, DOI 10.1359/jbmr.2002.17.6.1008; Takeuchi Y, 1997, J BIOL CHEM, V272, P29309, DOI 10.1074/jbc.272.46.29309; Thirunavukkarasu K, 1998, MOL CELL BIOL, V18, P4197, DOI 10.1128/MCB.18.7.4197; Wang D, 1999, J BONE MINER RES, V14, P893, DOI 10.1359/jbmr.1999.14.6.893; Willis DM, 2002, J BIOL CHEM, V277, P37280, DOI 10.1074/jbc.M206482200; Xiao GZ, 1998, J BIOL CHEM, V273, P32988, DOI 10.1074/jbc.273.49.32988; Xiao GZ, 1997, MOL ENDOCRINOL, V11, P1103, DOI 10.1210/me.11.8.1103; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; Yang RJ, 1997, J CELL BIOCHEM, V64, P77, DOI 10.1002/(SICI)1097-4644(199701)64:1<77::AID-JCB11>3.0.CO;2-H; Yang SY, 2003, J BONE MINER RES, V18, P705, DOI 10.1359/jbmr.2003.18.4.705; Yang XG, 2004, CELL, V117, P387, DOI 10.1016/S0092-8674(04)00344-7; Zhou YG, 2002, EMBO J, V21, P4632, DOI 10.1093/emboj/cdf460; Zimmerman D, 2000, DEV BIOL, V220, P2, DOI 10.1006/dbio.2000.9633	41	82	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	2005	280	35					30845	30855		10.1074/jbc.M503942200	http://dx.doi.org/10.1074/jbc.M503942200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	958ZX	16000302	hybrid			2022-12-25	WOS:000231487800025
J	Xiao, GZ; Jiang, D; Ge, CX; Zhao, ZR; Lai, YM; Boules, H; Phimphilai, M; Yang, XL; Karsenty, G; Franceschi, RT				Xiao, GZ; Jiang, D; Ge, CX; Zhao, ZR; Lai, YM; Boules, H; Phimphilai, M; Yang, XL; Karsenty, G; Franceschi, RT			Cooperative interactions between activating transcription factor 4 and Runx2/Cbfa1 stimulate osteoblast-specific osteocalcin gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEIN-2; SIGNALING PATHWAYS; MC3T3-E1 CELLS; IN-VIVO; CLEIDOCRANIAL DYSPLASIA; DEPENDENT ACTIVATION; RESPONSE ELEMENT; ASCORBIC-ACID; CBF-BETA; DIFFERENTIATION	The role of ATF4 ( activating transcription factor 4) in osteoblast differentiation and bone formation was recently described using ATF4- deficient mice ( Yang, X., Matsuda, K., Bialek, P., Jacquot, S., Masuoka, H. C., Schinke, T., Li, L., Brancorsini, S., Sassone- Corsi, P., Townes, T. M., Hanauer, A., and Karsenty, G. ( 2004) Cell 117, 387 - 398). However, the mechanisms of ATF4 in bone cells are still not clear. In this study, we determined the molecular mechanisms through which ATF4 activates the mouse osteocalcin ( Ocn) gene 2 ( mOG2) expression and mOG2 promoter activity. ATF4 increased the levels of Ocn mRNA and mOG2 promoter activity in Runx2- containing osteoblasts but not in non- osteoblastic cells that lack detectable Runx2 protein. However, ATF4 increased Ocn mRNA and mOG2 promoter activity in non- osteoblastic cells when Runx2 was co- expressed. Mutational analysis of the OSE1 ( ATF4- binding site) and the two OSE2s ( Runx2-binding sites) in the 657- bp mOG2 promoter demonstrated that ATF4 and Runx2 activate Ocn via cooperative interactions with these sites. Pull- down assays using nuclear extracts from osteoblasts or COS- 7 cells overexpressing ATF4 and Runx2 showed that both factors are present in either anti- ATF4 and anti- Runx2 immunoprecipitates. In contrast, pull- down assays using purified glutathione S- transferase fusion proteins were unable to demonstrate a direct physical interaction between ATF4 and Runx2. Thus, accessory factors are likely involved in stabilizing interactions between these two molecules. Regions within Runx2 required for ATF4 complex formation and activation were identified. Deletion analysis showed that the leucine zipper domain of ATF4 is critical for Runx2 activation. This study is the first demonstration that cooperative interactions between ATF4 and Runx2/ Cbfa1 stimulate osteoblast- specific Ocn expression and suggests that this regulation may represent a novel intramolecular mechanism regulating Runx2 activity and, thereby, osteoblast differentiation and bone formation.	Univ Michigan, Sch Dent, Dept Periodont Prevent & Geriatr, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Surg, Ann Arbor, MI 48109 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Baylor College of Medicine	Xiao, GZ (corresponding author), Univ Michigan, Sch Dent, Dept Periodont Prevent & Geriatr, 1011 N Univ Ave, Ann Arbor, MI 48109 USA.	xiaogz@umich.edu			NIDCR NIH HHS [DE12211, DE11723, DE13386, DE14454] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE011723] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R03DE014454, R01DE013386, R56DE011723, R01DE012211] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Aslam F, 1999, ENDOCRINOLOGY, V140, P63, DOI 10.1210/en.140.1.63; Bialek P, 2004, DEV CELL, V6, P423, DOI 10.1016/S1534-5807(04)00058-9; Brindle PK, 1992, CURR OPIN GENET DEV, V2, P199, DOI 10.1016/S0959-437X(05)80274-6; CELESTE AJ, 1986, EMBO J, V5, P1885, DOI 10.1002/j.1460-2075.1986.tb04440.x; D'Alonzo RC, 2002, J BIOL CHEM, V277, P24788, DOI 10.1074/jbc.M202604200; DUCY P, 1995, MOL CELL BIOL, V15, P1858; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Ducy P, 1999, GENE DEV, V13, P1025, DOI 10.1101/gad.13.8.1025; Franceschi RT, 2003, CALCIFIED TISSUE INT, V72, P638, DOI 10.1007/s00223-002-1053-2; FRANCESCHI RT, 1994, J BONE MINER RES, V9, P843; Frendo JL, 1998, J BIOL CHEM, V273, P30509, DOI 10.1074/jbc.273.46.30509; Gilbert L, 2002, J BIOL CHEM, V277, P2695, DOI 10.1074/jbc.M106339200; Hai T, 1999, GENE EXPRESSION, V7, P321; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; Hess J, 2001, J BIOL CHEM, V276, P20029, DOI 10.1074/jbc.M010601200; Javed A, 2000, J CELL SCI, V113, P2221; Jiang D, 2004, J BIOL CHEM, V279, P5329, DOI 10.1074/jbc.M311547200; Kahler RA, 2003, J BIOL CHEM, V278, P11937, DOI 10.1074/jbc.M211443200; KARPINSKI BA, 1992, P NATL ACAD SCI USA, V89, P4820, DOI 10.1073/pnas.89.11.4820; Kim S, 2003, GENE DEV, V17, P1979, DOI 10.1101/gad.1119303; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Krebsbach PH, 1997, TRANSPLANTATION, V63, P1059, DOI 10.1097/00007890-199704270-00003; Krishnan V, 2003, MOL ENDOCRINOL, V17, P423, DOI 10.1210/me.2002-0225; Kundu M, 2002, NAT GENET, V32, P639, DOI 10.1038/ng1050; Lee DH, 1996, J BIOL CHEM, V271, P27280, DOI 10.1074/jbc.271.44.27280; Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783-8792.2000; McLarrent FW, 2001, J BIOL CHEM, V276, P1578, DOI 10.1074/jbc.M007629200; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; Miller J, 2002, NAT GENET, V32, P645, DOI 10.1038/ng1049; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SASSONECORSI P, 1994, EMBO J, V13, P4717, DOI 10.1002/j.1460-2075.1994.tb06797.x; Schinke T, 1999, J BIOL CHEM, V274, P30182, DOI 10.1074/jbc.274.42.30182; Selvamurugan N, 1998, J BIOL CHEM, V273, P10647, DOI 10.1074/jbc.273.17.10647; Thirunavukkarasu K, 1998, MOL CELL BIOL, V18, P4197, DOI 10.1128/MCB.18.7.4197; Thomas DM, 2001, MOL CELL, V8, P303, DOI 10.1016/S1097-2765(01)00327-6; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; Xiao GZ, 1998, J BIOL CHEM, V273, P32988, DOI 10.1074/jbc.273.49.32988; Xiao GZ, 1997, MOL ENDOCRINOL, V11, P1103, DOI 10.1210/me.11.8.1103; Xiao GZ, 2002, J BIOL CHEM, V277, P36181, DOI 10.1074/JBC.m206057200; Xiao GZ, 2002, J BONE MINER RES, V17, P101, DOI 10.1359/jbmr.2002.17.1.101; Yang SY, 2003, J BONE MINER RES, V18, P705, DOI 10.1359/jbmr.2003.18.4.705; Yang XG, 2004, CELL, V117, P387, DOI 10.1016/S0092-8674(04)00344-7; Yang XL, 2004, J BIOL CHEM, V279, P47109, DOI 10.1074/jbc.M410010200; Yoshida CA, 2002, NAT GENET, V32, P633, DOI 10.1038/ng1015; Zhang YW, 2000, P NATL ACAD SCI USA, V97, P10549, DOI 10.1073/pnas.180309597; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G	47	186	202	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	2005	280	35					30689	30696		10.1074/jbc.M500750200	http://dx.doi.org/10.1074/jbc.M500750200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	958ZX	16000305	hybrid			2022-12-25	WOS:000231487800007
J	Kim, H; Laing, M; Muller, W				Kim, H; Laing, M; Muller, W			c-Src-null mice exhibit defects in normal mammary gland development and ER alpha signaling	ONCOGENE			English	Article						estrogen receptor; c-Src; mammary gland	ESTROGEN-RECEPTOR-ALPHA; GROWTH-FACTOR RECEPTOR; BREAST-CANCER; ESTRADIOL-RECEPTOR; INDEPENDENT ACTIVATION; TARGETED DISRUPTION; SURVIVAL SIGNAL; KINASE PATHWAY; PHOSPHORYLATION; TYROSINE	The c-Src tyrosine kinase has been implicated to play an integral role in modulating growth factor receptor, integrin and steroid receptor function. One class of steroid receptors that c-Src modulates is the estrogen receptor a (ER alpha). Although there is strong biochemical evidence supporting a role for c-Src in ER alpha signaling, the consequence of this association is unclear at the biological level. To explore the significance of c-Src in ER alpha signaling, we studied the development of various reproductive organs that are dependent on ER alpha in c-Srcdeficient mice. We show that the loss of the c-Src tyrosine kinase correlates with defects in ductal development as well as in uterine and ovarian development. Genetic and biochemical analyses of c-Src-deficient mammary epithelial cells also revealed defects in the ability of mammary epithelial cells to activate a number of signaling pathways in response to exogenous estrogen stimulation. Taken together, these studies demonstrate that c-Src plays a role in ER alpha signaling in vivo.	McMaster Univ, Dept Med Sci, Hamilton, ON L8S 4K1, Canada; McMaster Univ, Dept Biol, Hamilton, ON L8S 4K1, Canada; McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON L8S 4K1, Canada	McMaster University; McMaster University; McMaster University	Muller, W (corresponding author), McGill Univ, Royal Victoria Hosp, Dept Med, Mol Oncol Grp, Room H5-63A,687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	william.muller@mcgill.ca						Arnold SF, 1997, MOL ENDOCRINOL, V11, P48, DOI 10.1210/me.11.1.48; ARNOLD SF, 1995, MOL ENDOCRINOL, V9, P24, DOI 10.1210/me.9.1.24; ARNOLD SF, 1995, J BIOL CHEM, V270, P30205; BISWAS R, 1987, CANCER RES, V47, P3509; Brisken C, 2000, GENE DEV, V14, P650; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; Campbell RA, 2001, J BIOL CHEM, V276, P9817, DOI 10.1074/jbc.M010840200; Carlomagno C, 1996, J CLIN ONCOL, V14, P2702, DOI 10.1200/JCO.1996.14.10.2702; Castoria G, 2001, EMBO J, V20, P6050, DOI 10.1093/emboj/20.21.6050; Castoria G, 1999, EMBO J, V18, P2500, DOI 10.1093/emboj/18.9.2500; Chan TO, 2002, CANCER CELL, V1, P181, DOI 10.1016/S1535-6108(02)00033-8; Cunha GR, 1997, J MAMMARY GLAND BIOL, V2, P393, DOI 10.1023/A:1026303630843; Dankort DL, 1997, MOL CELL BIOL, V17, P5410, DOI 10.1128/MCB.17.9.5410; Datta K, 1996, J BIOL CHEM, V271, P30835, DOI 10.1074/jbc.271.48.30835; De Placido S, 1998, BREAST CANCER RES TR, V52, P55, DOI 10.1023/A:1006159001039; DENTON RR, 1992, J BIOL CHEM, V267, P7263; DiDomenico M, 1996, CANCER RES, V56, P4516; Fan MY, 2004, MOL ENDOCRINOL, V18, P2603, DOI 10.1210/me.2004-0164; Frame S, 2001, MOL CELL, V7, P1321, DOI 10.1016/S1097-2765(01)00253-2; GRUNT TW, 1995, INT J CANCER, V63, P560, DOI 10.1002/ijc.2910630417; GULLICK WJ, 1991, BRIT J CANCER, V63, P434, DOI 10.1038/bjc.1991.100; Hisamoto K, 2001, J BIOL CHEM, V276, P3459, DOI 10.1074/jbc.M005036200; Houston SJ, 1999, BRIT J CANCER, V79, P1220, DOI 10.1038/sj.bjc.6690196; Hutchinson J, 2001, MOL CELL BIOL, V21, P2203, DOI 10.1128/MCB.21.6.2203-2212.2001; Jackson D, 1997, J CELL SCI, V110, P1261; Jackson-Fisher AJ, 2004, P NATL ACAD SCI USA, V101, P17138, DOI 10.1073/pnas.0407057101; Joel PB, 1998, J BIOL CHEM, V273, P13317, DOI 10.1074/jbc.273.21.13317; JOEL PB, 1995, MOL ENDOCRINOL, V9, P1041, DOI 10.1210/me.9.8.1041; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Korach KS, 1996, RECENT PROG HORM RES, V51, P159; KORACH KS, 1994, SCIENCE, V266, P1524, DOI 10.1126/science.7985022; Lahooti H, 1995, J STEROID BIOCHEM, V55, P305, DOI 10.1016/0960-0760(95)00188-3; LAHOOTI H, 1994, MOL ENDOCRINOL, V8, P182, DOI 10.1210/me.8.2.182; LEGOFF P, 1994, J BIOL CHEM, V269, P4458; LIPPMAN M, 1976, CANCER RES, V36, P4595; Lonard DM, 2000, MOL CELL, V5, P939, DOI 10.1016/S1097-2765(00)80259-2; LUBAHN DB, 1993, P NATL ACAD SCI USA, V90, P11162, DOI 10.1073/pnas.90.23.11162; MIGLIACCIO A, 1993, ONCOGENE, V8, P2183; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Migliaccio A, 2000, EMBO J, V19, P5406, DOI 10.1093/emboj/19.20.5406; MIGLIACCIO A, 1986, EMBO J, V5, P2867, DOI 10.1002/j.1460-2075.1986.tb04581.x; Migliaccio A, 1998, EMBO J, V17, P2008, DOI 10.1093/emboj/17.7.2008; Montagna C, 2002, ONCOGENE, V21, P890, DOI 10.1038/sj.onc.1205146; Morelli C, 2003, ONCOGENE, V22, P4007, DOI 10.1038/sj.onc.1206436; Nawaz Z, 1999, P NATL ACAD SCI USA, V96, P1858, DOI 10.1073/pnas.96.5.1858; Newman SP, 2000, ONCOGENE, V19, P490, DOI 10.1038/sj.onc.1203416; PIETRAS RJ, 1995, ONCOGENE, V10, P2435; Prall OWJ, 1998, MOL CELL BIOL, V18, P4499, DOI 10.1128/MCB.18.8.4499; Prall OWJ, 1997, J BIOL CHEM, V272, P10882; Reid G, 2002, CELL MOL LIFE SCI, V59, P821, DOI 10.1007/s00018-002-8470-2; Reid G, 2003, MOL CELL, V11, P695, DOI 10.1016/S1097-2765(03)00090-X; Schomberg DW, 1999, ENDOCRINOLOGY, V140, P2733, DOI 10.1210/en.140.6.2733; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STAMBOLIC V, 1994, BIOCHEM J, V303, P701, DOI 10.1042/bj3030701; Tepera SB, 2003, J CELL SCI, V116, P1137, DOI 10.1242/jcs.00334; WEBSTER MA, 1995, P NATL ACAD SCI USA, V92, P7849, DOI 10.1073/pnas.92.17.7849; White R, 1997, EMBO J, V16, P1427, DOI 10.1093/emboj/16.6.1427; Wiesen JF, 1999, DEVELOPMENT, V126, P335; Yudt MR, 1999, BIOCHEMISTRY-US, V38, P14146, DOI 10.1021/bi9911132; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6; Zwijsen RML, 1998, GENE DEV, V12, P3488, DOI 10.1101/gad.12.22.3488	64	49	50	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 25	2005	24	36					5629	5636		10.1038/sj.onc.1208718	http://dx.doi.org/10.1038/sj.onc.1208718			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	956JN	16007215				2022-12-25	WOS:000231296100009
J	Kuninaka, S; Nomura, M; Hirota, T; Iida, SI; Hara, T; Honda, S; Kunitoku, N; Sasayama, T; Arima, Y; Marumoto, T; Koja, K; Yonehara, S; Saya, H				Kuninaka, S; Nomura, M; Hirota, T; Iida, SI; Hara, T; Honda, S; Kunitoku, N; Sasayama, T; Arima, Y; Marumoto, T; Koja, K; Yonehara, S; Saya, H			The tumor suppressor WARTS activates the Omi/HtrA2-dependent pathway of cell death	ONCOGENE			English	Article						mitotic kinases; mitochondria; apoptosis; PDZ domain; IAPs; caspases; cancer	SERINE-PROTEASE OMI/HTRA2; ANTI-APOPTOTIC PROTEIN; PROMOTES APOPTOSIS; HUMAN HOMOLOG; MITOTIC APPARATUS; CASPASE ACTIVITY; MAMMALIAN-CELLS; IAP PROTEINS; CYCLE EXIT; DROSOPHILA	Drosophila tumor suppressor WARTS (Wts) is an evolutionally conserved serine/threonine kinase and participates in a signaling complex that regulates both proliferation and apoptosis to ensure the proper size and shape of the fly. Human counterparts of this complex have been found to be frequently downregulated or mutated in cancers. WARTS, a human homolog of Wts, is also known as tumor suppressor and mitotic regulator, but its molecular implications in tumorigenesis are still obscure. Here, we show that WARTS binds via its C-terminus to the PDZ domain of a proapoptotic serine protease Omi/HtrA2. Depletion of WARTS inhibited Omi/HtrA2-mediated cell death, whereas overexpression of WARTS promoted this process. Furthermore, WARTS can enhance the protease activity of Omi/HtrA2 both in vivo and in vitro. Activation of Omi/HtrA2-mediated cell death is thus a potential mechanism for the tumor suppressive activity of WARTS.	Kumamoto Univ, Grad Sch Med Sci, Dept Tumor Genet & Biol, Kumamoto 8608556, Japan; Univ Ryukyus, Sch Med, Dept Surg 2, Okinawa 9030215, Japan; Kyoto Univ, Inst Virus Res, Kyoto 6068507, Japan	Kumamoto University; University of the Ryukyus; Kyoto University	Saya, H (corresponding author), Kumamoto Univ, Grad Sch Med Sci, Dept Tumor Genet & Biol, 1-1-1 Honjo, Kumamoto 8608556, Japan.	hsaya@gpo.kumamoto-u.ac.jp	Arima, Yoshimi/J-8057-2013; Kuninaka, Shinji/J-7158-2013; Saya, Hideyuki/J-4325-2013	Sasayama, Takashi/0000-0002-5593-9045; Arima, Yoshimi/0000-0002-2384-1406				Abrams JM, 2002, CELL, V110, P403, DOI 10.1016/S0092-8674(02)00904-2; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Cilenti L, 2004, J BIOL CHEM, V279, P50295, DOI 10.1074/jbc.M406006200; Conlon I, 1999, CELL, V96, P235, DOI 10.1016/S0092-8674(00)80563-2; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; EVAN GI, 1995, CURR OPIN CELL BIOL, V7, P825, DOI 10.1016/0955-0674(95)80066-2; Faccio L, 2000, J BIOL CHEM, V275, P2581, DOI 10.1074/jbc.275.4.2581; Gray CW, 2000, EUR J BIOCHEM, V267, P5699, DOI 10.1046/j.1432-1327.2000.01589.x; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Harvey KF, 2003, CELL, V114, P457, DOI 10.1016/S0092-8674(03)00557-9; Harvey KJ, 2000, J CELL BIOL, V148, P59, DOI 10.1083/jcb.148.1.59; Hegde R, 2002, J BIOL CHEM, V277, P432, DOI 10.1074/jbc.M109721200; Hirota T, 2000, J CELL BIOL, V149, P1073, DOI 10.1083/jcb.149.5.1073; Hisaoka M, 2002, LAB INVEST, V82, P1427, DOI 10.1097/01.LAB.0000032381.68634.CA; Holley CL, 2002, NAT CELL BIOL, V4, P439, DOI 10.1038/ncb798; Huse M, 2002, CELL, V109, P275, DOI 10.1016/S0092-8674(02)00741-9; Iida S, 2004, ONCOGENE, V23, P5266, DOI 10.1038/sj.onc.1207623; Jones JM, 2003, NATURE, V425, P721, DOI 10.1038/nature02052; JUSTICE RW, 1995, GENE DEV, V9, P534, DOI 10.1101/gad.9.5.534; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Li WY, 2002, NAT STRUCT BIOL, V9, P436, DOI 10.1038/nsb795; Makino K, 1997, ONCOGENE, V14, P2425, DOI 10.1038/sj.onc.1201087; Martins LM, 2002, J BIOL CHEM, V277, P439, DOI 10.1074/jbc.M109784200; Martins LM, 2003, J BIOL CHEM, V278, P49417, DOI 10.1074/jbc.M308659200; Morisaki T, 2002, FEBS LETT, V529, P319, DOI 10.1016/S0014-5793(02)03360-4; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Nishiyama Y, 1999, FEBS LETT, V459, P159, DOI 10.1016/S0014-5793(99)01224-7; Pantalacci S, 2003, NAT CELL BIOL, V5, P921, DOI 10.1038/ncb1051; Ryoo HD, 2002, NAT CELL BIOL, V4, P432, DOI 10.1038/ncb795; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Schmitt CA, 1999, J PATHOL, V187, P127; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Srinivasula SM, 2003, J BIOL CHEM, V278, P31469, DOI 10.1074/jbc.C300240200; St John MAR, 1999, NAT GENET, V21, P182, DOI 10.1038/5965; Sudo T, 2001, EMBO J, V20, P6499, DOI 10.1093/emboj/20.22.6499; Suzuki Y, 2004, CELL DEATH DIFFER, V11, P208, DOI 10.1038/sj.cdd.4401343; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Tao WF, 1999, NAT GENET, V21, P177, DOI 10.1038/5960; Tapon N, 2002, CELL, V110, P467, DOI 10.1016/S0092-8674(02)00824-3; Trencia A, 2004, J BIOL CHEM, V279, P46566, DOI 10.1074/jbc.M406317200; Tsuruta F, 2002, J BIOL CHEM, V277, P14040, DOI 10.1074/jbc.M108975200; Udan RS, 2003, NAT CELL BIOL, V5, P914, DOI 10.1038/ncb1050; Verhagen AM, 2002, J BIOL CHEM, V277, P445, DOI 10.1074/jbc.M109891200; Wang XD, 2001, GENE DEV, V15, P2922; Wu S, 2003, CELL, V114, P445, DOI 10.1016/S0092-8674(03)00549-X; XU TA, 1995, DEVELOPMENT, V121, P1053; Yang QH, 2003, GENE DEV, V17, P1487, DOI 10.1101/gad.1097903; Yang XL, 2004, NAT CELL BIOL, V6, P609, DOI 10.1038/ncb1140; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Yoo SJ, 2002, NAT CELL BIOL, V4, P416, DOI 10.1038/ncb793	51	38	40	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 11	2005	24	34					5287	5298		10.1038/sj.onc.1208682	http://dx.doi.org/10.1038/sj.onc.1208682			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	954MF	16007220				2022-12-25	WOS:000231158500003
J	Oliveira, C; Velho, R; Domingo, E; Preto, A; Hofstra, RMW; Hamelin, R; Yamamoto, H; Seruca, R; Schwartz, S				Oliveira, C; Velho, R; Domingo, E; Preto, A; Hofstra, RMW; Hamelin, R; Yamamoto, H; Seruca, R; Schwartz, S			Concomitant RASSF1A hypermethylation and KRAS/BRAF mutations occur preferentially in MSI sporadic colorectal cancer	ONCOGENE			English	Article						RASSF1A promoter methylation; KRAS; BRAF; colorectal cancer; gastric cancer; MSI	MISMATCH REPAIR DEFICIENCY; EPIGENETIC INACTIVATION; PROMOTER METHYLATION; KRAS MUTATIONS; RAS MUTATIONS; BRAF MUTATION; HMLH1; TUMORIGENESIS; CARCINOMAS; PATTERNS	Methylation-associated inactivation of RASSF1A has frequently been observed in several human malignancies including sporadic colorectal and gastric cancer. However, nothing is known about the RASSF1A methylation status in the setting of MMR-deficient gastrointestinal tumours. In this study, we analysed systematically alterations in KRAS, BRAF and RASSF1A, in order to de. ne the frequency and the pattern of these genetic/epigenetic alterations in three distinct subsets of MSI gastrointestinal tumours. Further, an association study was performed between RASSF1A methylation and the clinicopathological parameters in order to determine the pro. le of tumours harbouring this epigenetic event. A total of 56 MSI sporadic gastrointestinal tumours (31 colorectal and 25 gastric) and 20 MSI HNPCC analysed for KRAS/BRAF were analysed for RASSF1A promoter hypermethylation by MSP and DNA sequencing. No significant differences were found between the frequency of RASSF1A methylation in sporadic MSI colorectal and gastric carcinomas and HNPCC carcinomas (P = 0.31). Methylation of RASSF1A was present in 16 of 31 (52%) sporadic MSI colorectal and 11 of 25 (44%) MSI gastric carcinomas, and in six of 20 (30%) HNPCC carcinomas. Nearly 36% of MSI sporadic colorectal carcinomas (CRCs) had RASSF1A methylation and activating mutations at KRAS and/or BRAF. In contrast, only 10 and 8% of HNPCC and sporadic gastric carcinomas, respectively, had concomitant KRAS mutations and RASSF1A methylation. The MSI sporadic gastric and CRCs with RASSF1A methylation were preferentially poorly differentiated (P = 0.03, 0.05, respectively). We show that the pro. le of alterations RASSF1A, KRAS/BRAF is different among the three groups of MSI gastrointestinal tumours. Further, we demonstrate that MSI sporadic CRCs accumulated significantly more epigenetic/genetic alterations in RASSF1A, KRAS/BRAF than MSI sporadic gastric or HNPCC carcinomas (P = 0.016). These results are likely to have therapeutic implications in the near future, due to the possibilities of using specific kinase inhibitors alone or in association with demethylating agents in MSI tumour types harbouring KRAS or BRAF mutations and RASSF1A methylation.	Univ Porto, Inst Mol Pathol & Immunol, IPATIMUP, P-4200465 Oporto, Portugal; Hosp Univ Vall Hebron, Ctr Invest Bioquim & Biol Mol, Barcelona 08035, Spain; Univ Groningen, Dept Med Genet, NL-9713 AW Groningen, Netherlands; Ctr Etud Polymorphisme Humain, INSERM, U434, F-75010 Paris, France; Sapporo Med Univ, Dept Internal Med 1, Sapporo, Hokkaido 0608543, Japan; Univ Porto, Fac Med, P-4100 Oporto, Portugal	Universidade do Porto; Hospital Universitari Vall d'Hebron; University of Groningen; Institut National de la Sante et de la Recherche Medicale (Inserm); Sapporo Medical University; Universidade do Porto	Seruca, R (corresponding author), Univ Porto, Inst Mol Pathol & Immunol, IPATIMUP, Rua Roberto Frias S-N, P-4200465 Oporto, Portugal.	rseruca@ipatimup.pt	seruca, raquel/F-8187-2011; Schwartz, Simo/H-7776-2012; Oliveira, Carla/F-8188-2011; Velho, Sérgia/B-8501-2013; Preto, Ana/H-8112-2012; Domingo, Enric/A-9099-2018	Oliveira, Carla/0000-0001-8340-2264; Velho, Sérgia/0000-0002-7104-8234; Preto, Ana/0000-0002-7302-0630; Domingo, Enric/0000-0003-4390-8767; Seruca, Raquel/0000-0002-8851-4166; Schwartz, Simo/0000-0001-8297-7971; Hofstra, Robert/0000-0001-7498-3829				Brennetot C, 2003, GASTROENTEROLOGY, V125, P1282, DOI 10.1016/j.gastro.2003.02.002; BYUN D, 2002, CANCER RES, V61, P7034; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dammann R, 2003, HISTOL HISTOPATHOL, V18, P665, DOI 10.14670/HH-18.665; Deng GR, 2004, CLIN CANCER RES, V10, P191, DOI 10.1158/1078-0432.CCR-1118-3; Domingo E, 2004, J MED GENET, V41, P664, DOI 10.1136/jmg.2004.020651; Domingo E, 2004, GENE CHROMOSOME CANC, V39, P138, DOI 10.1002/gcc.10310; Ibanez de Caceres I, 2004, CANCER RES, V64, P6476; Koinuma K, 2004, INT J CANCER, V108, P237, DOI 10.1002/ijc.11523; Lerman MI, 2000, CANCER RES, V60, P6116; McGivern A, 2004, Fam Cancer, V3, P101; Oliveira C, 2003, ONCOGENE, V22, P9192, DOI 10.1038/sj.onc.1207061; Oliveira C, 2004, HUM MOL GENET, V13, P2303, DOI 10.1093/hmg/ddh238; Ortiz-Vega S, 2002, ONCOGENE, V21, P1381, DOI 10.1038/sj.onc.1205192; Pfeifer GP, 2002, BIOL CHEM, V383, P907, DOI 10.1515/BC.2002.097; Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a; Reifenberger J, 2004, INT J CANCER, V109, P377, DOI 10.1002/ijc.11722; Shivakumar L, 2002, MOL CELL BIOL, V22, P4309, DOI 10.1128/MCB.22.12.4309-4318.2002; Umar A, 2004, NAT REV CANCER, V4, P153, DOI 10.1038/nrc1278; van Engeland M, 2002, ONCOGENE, V21, P3792, DOI 10.1038/sj.onc.1205466; Vos MD, 2000, J BIOL CHEM, V275, P35669, DOI 10.1074/jbc.C000463200; Williams JG, 2000, J BIOL CHEM, V275, P22172, DOI 10.1074/jbc.M000397200; Xing MZ, 2004, CANCER RES, V64, P1664, DOI 10.1158/0008-5472.CAN-03-3242; Yuen ST, 2002, CANCER RES, V62, P6451	24	41	44	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 17	2005	24	51					7630	7634		10.1038/sj.onc.1208906	http://dx.doi.org/10.1038/sj.onc.1208906			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	984VQ	16007118				2022-12-25	WOS:000233333800013
J	Kanda, A; Kawai, H; Suto, S; Kitajima, S; Sato, S; Takata, T; Tatsuka, M				Kanda, A; Kawai, H; Suto, S; Kitajima, S; Sato, S; Takata, T; Tatsuka, M			Aurora-B/AIM-1 kinase activity is involved in Ras-mediated cell transformation	ONCOGENE			English	Article						transformation susceptibility; Ras; Src; Raf; Aurora; kinase	AURORA-B KINASE; CHROMOSOMAL PASSENGER COMPLEX; HAMSTER EMBRYO CELLS; HISTONE H3; NEOPLASTIC TRANSFORMATION; ONCOGENIC TRANSFORMATION; MITOTIC PHOSPHORYLATION; CLEAVAGE FURROW; CYTOKINESIS; SURVIVIN	Aurora-B, previously known as AIM-1, is a conserved eukaryotic mitotic protein kinase. In mammals, this kinase plays an essential role in chromosomal segregation processes, including chromosome condensation, alignment, control of spindle checkpoints, chromosome segregation, and cytokinesis. Aurora-B is overexpressed in various cancer cells, suggesting that the kinase activity perturbs chromosomal segregation processes. Its forced overexpression induces chromosomal number instability and progressive tumorigenicity in rodent cells in vitro and in vivo. Nevertheless, based on focus formation in BALB/c 3T3 A31-1-1 cells, Aurora-B is not oncogenic. Here, we show that Aurora- B kinase activity augments Ras-mediated cell transformation. RNA interference with short hairpin RNA inhibits transformation by Ras and its upstream oncogene Src, but not by the downstream oncogene Raf. In addition, the inner centromere protein, which is a passenger protein associated with Aurora-B, has a similar ability to potentiate the activity of oncogenic Ras. These data indicate that elevated Aurora-B activity promotes transformation by oncogenic Ras by enhancing oncogenic signaling and by converting chromosome number-stable cells to aneuploid cells.	Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Regulatory Radiobiol, Minami Ku, Hiroshima 7348553, Japan; Hiroshima Univ, Grad Sch Biomed Sci, Div Genome Biol, Dept Mol Radiobiol,Minami Ku, Hiroshima 734, Japan; Hiroshima Univ, Grad Sch Biomed Sci, Div Frontier Med Sci, Dept Oral & Maxillofacial Pathobiol,Minami Ku, Hiroshima 734, Japan	Hiroshima University; Hiroshima University; Hiroshima University	Tatsuka, M (corresponding author), Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Regulatory Radiobiol, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348553, Japan.	haruo@hiroshima-u.ac.jp		Kawai, Hidehiko/0000-0003-2213-7166; Kitajima, Shojiro/0000-0002-4000-0473				Adams RR, 2001, J CELL BIOL, V153, P865, DOI 10.1083/jcb.153.4.865; Adams RR, 2001, CHROMOSOMA, V110, P65, DOI 10.1007/s004120100130; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Andrews PD, 2003, CURR OPIN CELL BIOL, V15, P672, DOI 10.1016/j.ceb.2003.10.013; Andrews PD, 2004, DEV CELL, V6, P253, DOI 10.1016/S1534-5807(04)00025-5; Carmena M, 2003, NAT REV MOL CELL BIO, V4, P842, DOI 10.1038/nrm1245; Chen J, 2003, J BIOL CHEM, V278, P486, DOI 10.1074/jbc.M211119200; Chen JG, 2002, CANCER RES, V62, P1935; Ditchfield C, 2003, J CELL BIOL, V161, P267, DOI 10.1083/jcb.200208091; Fukuda S, 2004, BIOCHEM BIOPH RES CO, V323, P636, DOI 10.1016/j.bbrc.2004.08.149; Gassmann R, 2004, J CELL BIOL, V166, P179, DOI 10.1083/jcb.200404001; Gigoux V, 2002, J BIOL CHEM, V277, P23742, DOI 10.1074/jbc.C200121200; Goto H, 2002, GENES CELLS, V7, P11, DOI 10.1046/j.1356-9597.2001.00498.x; Goto H, 2003, J BIOL CHEM, V278, P8526, DOI 10.1074/jbc.M210892200; Hauf S, 2003, J CELL BIOL, V161, P281, DOI 10.1083/jcb.200208092; HEI TK, 1993, CANCER RES, V53, P1368; Honda R, 2003, MOL BIOL CELL, V14, P3325, DOI 10.1091/mbc.E02-11-0769; Hsu JY, 2000, CELL, V102, P279, DOI 10.1016/S0092-8674(00)00034-9; KAKUNAGA T, 1980, SCIENCE, V209, P505, DOI 10.1126/science.7394516; KAKUNAGA T, 1985, TRANSFORMATION ASSAY; Katayama H, 1999, J NATL CANCER I, V91, P1160, DOI 10.1093/jnci/91.13.1160; Kawajiri A, 2003, MOL BIOL CELL, V14, P1489, DOI 10.1091/mbc.E02-09-0612; KIZAKA S, 1989, MOL CELL BIOL, V9, P5669, DOI 10.1128/MCB.9.12.5669; Lampson MA, 2004, NAT CELL BIOL, V6, P232, DOI 10.1038/ncb1102; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Minoshima Y, 2003, DEV CELL, V4, P549, DOI 10.1016/S1534-5807(03)00089-3; Murata-Hori M, 2000, J BIOCHEM-TOKYO, V128, P903, DOI 10.1093/oxfordjournals.jbchem.a022840; Murata-Hori M, 2002, MOL BIOL CELL, V13, P1099, DOI 10.1091/mbc.01-09-0467; Ota T, 2002, CANCER RES, V62, P5168; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; Sampath SC, 2004, CELL, V118, P187, DOI 10.1016/j.cell.2004.06.026; Sasai K, 2004, CELL MOTIL CYTOSKEL, V59, P249, DOI 10.1002/cm.20039; Schumacher JM, 1998, J CELL BIOL, V143, P1635, DOI 10.1083/jcb.143.6.1635; SHIMIZU T, 1995, JPN J CANCER RES, V86, P546, DOI 10.1111/j.1349-7006.1995.tb02433.x; Sommer KW, 2003, ONCOGENE, V22, P4266, DOI 10.1038/sj.onc.1206509; Tatsuka M, 2005, ONCOGENE, V24, P1122, DOI 10.1038/sj.onc.1208293; Tatsuka M, 1996, MOL CARCINOGEN, V15, P300, DOI 10.1002/(SICI)1098-2744(199604)15:4<300::AID-MC7>3.0.CO;2-J; Tatsuka M, 1998, CANCER RES, V58, P4811; TATSUKA M, 1992, NATURE, V359, P333, DOI 10.1038/359333a0; TATSUKA M, 2005, SIGNAL TRANSDUCTION; Temme A, 2005, BIOCHEM BIOPH RES CO, V327, P765, DOI 10.1016/j.bbrc.2004.12.075; Temme A, 2003, MOL BIOL CELL, V14, P78, DOI 10.1091/mbc.E02-04-0182; Terada Y, 1998, EMBO J, V17, P667, DOI 10.1093/emboj/17.3.667; Terada Y, 2001, CELL STRUCT FUNCT, V26, P653, DOI 10.1247/csf.26.653; TSUTSUI T, 1984, CARCINOGENESIS, V5, P89, DOI 10.1093/carcin/5.1.89; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; Wu JC, 2005, J BIOL CHEM, V280, P9013, DOI 10.1074/jbc.M411068200; YAGI T, 1989, MOL CARCINOGEN, V1, P222, DOI 10.1002/mc.2940010404; Yasui Y, 2004, J BIOL CHEM, V279, P12997, DOI 10.1074/jbc.M311128200; Zeitlin SG, 2001, J CELL BIOL, V155, P1147, DOI 10.1083/jcb.200108125	50	66	70	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2005	24	49					7266	7272		10.1038/sj.onc.1208884	http://dx.doi.org/10.1038/sj.onc.1208884			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	982FA	16027732				2022-12-25	WOS:000233142100002
J	Schwerk, C; Schulze-Osthoff, K				Schwerk, C; Schulze-Osthoff, K			Methyltransferase inhibition induces p53-dependent apoptosis and a novel form of cell death	ONCOGENE			English	Article						adenosine dialdehyde; apoptosis; actin; methyltransferases; p53	DNA-DAMAGE RESPONSE; ACTIN DEPOLYMERIZATION; MEDIATED CYTOTOXICITY; UNDERGO APOPTOSIS; EPITHELIAL-CELLS; IN-VIVO; ROCK-I; METHYLATION; ACTIVATION; P53	We have analysed the importance of proper substrate methylation by S-adenosylmethionine-dependent methyl-transferases for cell survival and cell cycle progression. We show that treatment of cells with the methyltransferase inhibitor adenosine dialdehyde (AdOx) causes cell cycle arrest and death in different cell types. The phenotypical outcome and form of cell death was strikingly dependent on the AdOx concentration. Lower AdOx concentrations led to a G2 arrest and predominantly caused apoptosis, as judged by biochemical and morphological criteria. Apoptotic cell death was largely dependent on the presence of the tumour suppressor p53, but did not require the Bcl-2 family member Bax. Interestingly, higher concentrations of AdOx led to a novel and so far undescribed form of cell death, which was characterized by distinct, caspase-independent alterations of the cell shape including a marked protuberation of the nucleus, cytoplasmic extensions, actin aggregation, and incomplete chromatin condensation. Although this latter form of cell death was clearly distinguishable from apoptosis, early apoptotic features such as Bax activation were detected, indicating a commitment but incomplete execution of apoptosis. Altogether, these data show that methylation reactions play a distinct role in cell survival, which might influence the decision between different phenotypic forms of cell death.	Univ Dusseldorf, Inst Mol Med, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf	Schwerk, C (corresponding author), Univ Dusseldorf, Inst Mol Med, Bldg 23-12,Univ Str 1, D-40225 Dusseldorf, Germany.	Christian.Scherk@uni-duesseldorf.de	Schwerk, Christian/GNP-5375-2022; Schulze-Osthoff, Klaus/N-9025-2013	Schulze-Osthoff, Klaus/0000-0003-1443-2720				BARTEL RL, 1984, MOL PHARMACOL, V25, P418; BERGMANN S, 1994, J IMMUNOL, V153, P1736; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Bursch W, 2000, J CELL SCI, V113, P1189; Chen TP, 2004, CURR TOP DEV BIOL, V60, P55; Chipuk JE, 2005, NAT REV MOL CELL BIO, V6, P268, DOI [10.1038/nrm1573, 10.1038/nrm2239]; Chuikov S, 2004, NATURE, V432, P353, DOI 10.1038/nature03117; Coleman ML, 2001, NAT CELL BIOL, V3, P339, DOI 10.1038/35070009; Croft DR, 2005, J CELL BIOL, V168, P245, DOI 10.1083/jcb.200409049; Cuervo AM, 2004, MOL CELL BIOCHEM, V263, P55, DOI 10.1023/B:MCBI.0000041848.57020.57; Di Simone N, 2003, BIOL REPROD, V69, P1129, DOI 10.1095/biolreprod.103.015800; Finkelstein JD, 1998, EUR J PEDIATR, V157, pS40, DOI 10.1007/PL00014300; Grzanka A, 2003, BIOCHEM PHARMACOL, V66, P1611, DOI 10.1016/S0006-2952(03)00532-X; HENNESSEY ES, 1993, BIOCHEM J, V291, P657, DOI 10.1042/bj2910657; Jackson-Grusby L, 2001, NAT GENET, V27, P31, DOI 10.1038/83730; Jamison JM, 2002, BIOCHEM PHARMACOL, V63, P1773, DOI 10.1016/S0006-2952(02)00904-8; Karpf AR, 2001, MOL PHARMACOL, V59, P751, DOI 10.1124/mol.59.4.751; Kruman II, 2004, NEURON, V41, P549, DOI 10.1016/S0896-6273(04)00017-0; Kruman II, 2000, J NEUROSCI, V20, P6920, DOI 10.1523/JNEUROSCI.20-18-06920.2000; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Martin S, 2001, MOL CELL BIOL, V21, P6529, DOI 10.1128/MCB.21.19.6529-6536.2001; Mehlhorn H, 1999, PARASITOL RES, V85, P625, DOI 10.1007/s004360050607; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Proskuryakov SY, 2003, EXP CELL RES, V283, P1, DOI 10.1016/S0014-4827(02)00027-7; Rao JY, 1999, J CELL BIOCHEM, V75, P686, DOI 10.1002/(SICI)1097-4644(19991215)75:4<686::AID-JCB14>3.0.CO;2-F; Ratter F, 1999, INT IMMUNOL, V11, P519, DOI 10.1093/intimm/11.4.519; Rice JC, 2003, MOL CELL, V12, P1591, DOI 10.1016/S1097-2765(03)00479-9; Schneider-Stock R, 2005, J PHARMACOL EXP THER, V312, P525, DOI 10.1124/jpet.104.074195; Schubert HL, 2003, TRENDS BIOCHEM SCI, V28, P329, DOI 10.1016/S0968-0004(03)00090-2; Schwerk C, 2003, MOL CELL BIOL, V23, P2981, DOI 10.1128/MCB.23.8.2981-2990.2003; Sebbagh M, 2001, NAT CELL BIOL, V3, P346, DOI 10.1038/35070019; Sgarra R, 2003, CELL DEATH DIFFER, V10, P386, DOI 10.1038/sj.cdd.4401184; Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993; Song ZY, 2004, HEPATOLOGY, V40, P989, DOI 10.1002/hep.20412; Sperandio S, 2000, P NATL ACAD SCI USA, V97, P14376, DOI 10.1073/pnas.97.26.14376; Stancheva I, 2001, EMBO J, V20, P1963, DOI 10.1093/emboj/20.8.1963; Suarez-Huerta N, 2000, J CELL PHYSIOL, V184, P239, DOI 10.1002/1097-4652(200008)184:2<239::AID-JCP12>3.0.CO;2-R; White SR, 2001, AM J RESP CELL MOL, V24, P282, DOI 10.1165/ajrcmb.24.3.3995; Wyllie AH, 2001, P NATL ACAD SCI USA, V98, P11, DOI 10.1073/pnas.98.1.11; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301; Zong WX, 2004, GENE DEV, V18, P1272, DOI 10.1101/gad.1199904	42	24	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 27	2005	24	47					7002	7011		10.1038/sj.onc.1208855	http://dx.doi.org/10.1038/sj.onc.1208855			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	977WC	16007140				2022-12-25	WOS:000232833200002
J	Bernassola, F; Oberst, A; Melino, G; Pandolfi, PP				Bernassola, F; Oberst, A; Melino, G; Pandolfi, PP			The promyelocytic leukaemia protein tumour suppressor functions as a transcriptional regulator of p63	ONCOGENE			English	Article						p63; PML; nuclear body; transcription	PREMATURE SENESCENCE; ONCOGENIC RAS; P53 HOMOLOG; PML; EXPRESSION; P73; CANCER; DELTA-NP63-ALPHA; CARCINOMAS; ENCODES	p63 plays unique developmental roles in epidermal morphogenesis, despite its structural similarity with p53. The p63 gene has two distinct promoters, coding for proteins containing an N-terminal transactivation domain ( TA isoforms) and for proteins lacking this region (Delta N isoforms). The full-length transcriptionally active TAp63 isoforms are capable of transactivating the majority of the p53 target promoters thus inducing cell cycle arrest and apoptosis. On the contrary, the Delta Np63 isoforms seem to counteract the transactivation activities of p53 and TAp63 proteins, thus possibly conferring a proliferative advantage to cancer cells. However, the molecular mechanisms controlling the transcriptional activity of p63 remain largely unclear. Here we present data indicating that (i) the promyelocytic leukaemia protein ( PML) physically interacts with p63, (ii) p63 is localized into the PML nuclear-bodies ( PML-NBs) in vivo, and (iii) PML regulates p63 transcriptional activity. We show that the interaction of p63 with PML increases the levels of p63 in cultured cells as well as its ability to transactivate the p53-responsive elements of the GADD45, p21 and bax promoters. These data are consistent with a general role for PML as a functional modulator of all the p53 family members. Our findings strengthen the relevance of the cross talk between PML and the p53 family members, imply a new tumour suppressive function of PML and unveil a possible role for PML in epidermal morphogenesis and differentiation.	Mem Sloan Kettering Canc Ctr, Dept Pathol, Canc Biol & Genet Program, New York, NY 10021 USA; Univ Roma Tor Vergata, Dept Expt Med, IDI, IRCCS,Biochem Lab, I-00133 Rome, Italy; Univ Leicester, MRC, Toxicol Unit, Leicester LE1 9HN, Leics, England	Memorial Sloan Kettering Cancer Center; IRCCS Istituto Dermopatico dell'Immacolata (IDI); University of Rome Tor Vergata; University of Leicester	Pandolfi, PP (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Pathol, Canc Biol & Genet Program, 1275 York Ave, New York, NY 10021 USA.	p-pandolfi@ski.mskcc.org			NCI NIH HHS [CA-71692] Funding Source: Medline; Telethon [GGP04110] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA071692, R01CA071692] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Telethon(Fondazione Telethon); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bernardi R, 2004, NAT CELL BIOL, V6, P665, DOI 10.1038/ncb1147; Bernassola F, 2004, J EXP MED, V199, P1545, DOI 10.1084/jem.20031943; Crook T, 2000, ONCOGENE, V19, P3439, DOI 10.1038/sj.onc.1203656; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Duijf PHG, 2002, HUM MOL GENET, V11, P799, DOI 10.1093/hmg/11.7.799; Ferbeyre G, 2000, GENE DEV, V14, P2015; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; Gurrieri C, 2004, JNCI-J NATL CANCER I, V96, P269, DOI 10.1093/jnci/djh043; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Melino G, 2003, TRENDS BIOCHEM SCI, V28, P663, DOI 10.1016/j.tibs.2003.10.004; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Nylander K, 2002, J PATHOL, V198, P417, DOI 10.1002/path.1231; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; Park BJ, 2000, CANCER RES, V60, P3370; Parsa R, 1999, J INVEST DERMATOL, V113, P1099, DOI 10.1046/j.1523-1747.1999.00780.x; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Piazza F, 2001, ONCOGENE, V20, P7216, DOI 10.1038/sj.onc.1204855; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Urist MJ, 2002, AM J PATHOL, V161, P1199, DOI 10.1016/S0002-9440(10)64396-9; Weber A, 2002, VIRCHOWS ARCH, V441, P428, DOI 10.1007/s00428-002-0705-y; Weber A, 2002, INT J CANCER, V99, P22, DOI 10.1002/ijc.10296; Westfall MD, 2003, MOL CELL BIOL, V23, P2264, DOI 10.1128/MCB.23.7.2264-2276.2003; Wu GJ, 2003, CANCER RES, V63, P2351; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583	29	39	39	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2005	24	46					6982	6986		10.1038/sj.onc.1208843	http://dx.doi.org/10.1038/sj.onc.1208843			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	975ZD	16007146				2022-12-25	WOS:000232701700013
J	Kim, EH; Kim, HS; Kim, SU; Noh, EJ; Lee, JS; Choi, KS				Kim, EH; Kim, HS; Kim, SU; Noh, EJ; Lee, JS; Choi, KS			Sodium butyrate sensitizes human glioma cells to TRAIL-mediated apoptosis through inhibition of Cdc2 and the subsequent downregulation of survivin and XIAP	ONCOGENE			English	Article						TRAIL; sodium butyrate; apoptosis; glioma	HISTONE DEACETYLASE INHIBITORS; X-LINKED INHIBITOR; COLON-CANCER CELLS; LIGAND TRAIL; ANTITUMOR-ACTIVITY; EPITHELIAL-CELLS; DEATH RECEPTORS; TRICHOSTATIN-A; LEUKEMIA-CELLS; TUMOR-CELLS	In TNF-related apoptosis-inducing ligand (TRAIL)-resistant glioma cells, co-treatment with nontoxic doses of sodium butyrate and TRAIL resulted in a marked increase of TRAIL-induced apoptosis. This combined treatment was also cytotoxic to glioma cells overexpressing Bcl-2 or Bcl-xL, but not to normal human astrocytes, thus offering an attractive strategy for safely treating resistant gliomas. Cotreatment with sodium butyrate facilitated completion of proteolytic processing of procaspase-3 that was partially blocked by treatment with TRAIL alone. We also found that treatment with sodium butyrate significantly decreased the protein levels of survivin and X-linked inhibitor of apoptosis protein (XIAP), two major caspase inhibitors. Overexpression of survivin and XIAP attenuated sodium butyratestimulated TRAIL-induced apoptosis, suggesting its involvement in conferring TRAIL resistance to glioma cells. Furthermore, the kinase activities of Cdc2 and Cdk2 were significantly decreased following sodium butyrate treatment, accompanying downregulation of cyclin A and cyclin B, as well as upregulation of p21. Forced expression of Cdc2 plus cyclin B, but not Cdk2 plus cyclin A, attenuated sodium butyrate/TRAIL-induced apoptosis, overriding sodium butyrate-mediated downregulation of survivin and XIAP. Therefore, Cdc2-mediated downregulation of survivin and XIAP by sodium butyrate may contribute to the recovery of TRAIL sensitivity in glioma cells.	Ajou Univ, Sch Med, Inst Med Sci, Suwon 442749, South Korea; Ajou Univ, Sch Med, Brain Dis Res Ctr, Suwon 442749, South Korea; Univ British Columbia, UBC Hosp, Div Neurol, Vancouver, BC V5Z 1M9, Canada	Ajou University; Ajou University; University of British Columbia	Choi, KS (corresponding author), Ajou Univ, Sch Med, Inst Med Sci, San 5,Wonchon Dong, Suwon 442749, South Korea.	kschoi@ajou.ac.kr	Kim, Eunhee/AAK-3650-2020; Kim, Eunhee/Q-9162-2016	Kim, Eunhee/0000-0001-7143-7769; Choi, Kyeong Sook/0000-0003-2331-0856				Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Atadja P, 2004, CANCER RES, V64, P689, DOI 10.1158/0008-5472.CAN-03-2043; Bernhard D, 1999, FASEB J, V13, P1991, DOI 10.1096/fasebj.13.14.1991; Boatright KM, 2003, CURR OPIN CELL BIOL, V15, P725, DOI 10.1016/j.ceb.2003.10.009; Brugarolas J, 1999, P NATL ACAD SCI USA, V96, P1002, DOI 10.1073/pnas.96.3.1002; Chakravarti A, 2002, J CLIN ONCOL, V20, P1063, DOI 10.1200/JCO.20.4.1063; Chen JS, 2003, CURR CANCER DRUG TAR, V3, P219, DOI 10.2174/1568009033481994; Chopin V, 2004, EXP CELL RES, V298, P560, DOI 10.1016/j.yexcr.2004.04.038; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Gui CY, 2004, P NATL ACAD SCI USA, V101, P1241, DOI 10.1073/pnas.0307708100; Guo F, 2004, CANCER RES, V64, P2580, DOI 10.1158/0008-5472.CAN-03-2629; Han ZY, 1997, J BIOL CHEM, V272, P13432, DOI 10.1074/jbc.272.20.13432; Heerdt BG, 1997, CELL GROWTH DIFFER, V8, P523; HEERDT BG, 1994, CANCER RES, V54, P3288; Hernandez A, 2001, SURGERY, V130, P265, DOI 10.1067/msy.2001.115897; Huang DCS, 1997, ONCOGENE, V14, P405, DOI 10.1038/sj.onc.1200848; Ito N, 2001, NEUROSURGERY, V49, P430, DOI 10.1097/00006123-200108000-00031; Kamitani H, 2002, NEURO-ONCOLOGY, V4, P95, DOI 10.1093/neuonc/4.2.95; Katula KS, 1997, CELL GROWTH DIFFER, V8, P811; Kim EH, 2004, ONCOGENE, V23, P446, DOI 10.1038/sj.onc.1207025; KIM SU, 1986, J NEUROSCI RES, V15, P303, DOI 10.1002/jnr.490150303; KIM SU, 1985, J NEUROIMMUNOL, V8, P255, DOI 10.1016/S0165-5728(85)80066-7; Kim YH, 2004, CARCINOGENESIS, V25, P1813, DOI 10.1093/carcin/bgh188; Kirsch DG, 1999, J BIOL CHEM, V274, P21155, DOI 10.1074/jbc.274.30.21155; Knight MJ, 2001, ONCOGENE, V20, P5789, DOI 10.1038/sj.onc.1204810; Kobayashi K, 1999, P NATL ACAD SCI USA, V96, P1457, DOI 10.1073/pnas.96.4.1457; Kramer A, 1997, CANCER RES, V57, P5117; KRUH J, 1982, MOL CELL BIOCHEM, V42, P65; Legler JM, 1999, JNCI-J NATL CANCER I, V91, P1382, DOI 10.1093/jnci/91.16.1382; Lipinski CA, 2003, MOL CANCER RES, V1, P323; Marks PA, 2001, CURR OPIN ONCOL, V13, P477, DOI 10.1097/00001622-200111000-00010; Misra A, 2000, J NEURO-ONCOL, V48, P1, DOI 10.1023/A:1006435201961; Nair AR, 2001, CANCER LETT, V166, P55, DOI 10.1016/S0304-3835(01)00418-9; Nakata S, 2004, ONCOGENE, V23, P6261, DOI 10.1038/sj.onc.1207830; Neuzil H, 2004, BIOCHEM BIOPH RES CO, V314, P186, DOI 10.1016/j.bbrc.2003.12.074; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nomura T, 2003, UROL RES, V31, P37, DOI 10.1007/s00240-003-0300-y; Pellizzaro C, 2001, INT J CANCER, V91, P654, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1117>3.0.CO;2-I; Piekarz R, 2004, CURR PHARM DESIGN, V10, P2289, DOI 10.2174/1381612043383980; Rokudai S, 2000, J CELL PHYSIOL, V182, P290, DOI 10.1002/(SICI)1097-4652(200002)182:2<290::AID-JCP18>3.0.CO;2-8; Rosato RR, 2003, MOL CANCER THER, V2, P1273; Sawa Hiroki, 2002, Brain Tumor Pathol, V19, P77, DOI 10.1007/BF02478931; Seol DW, 2001, CANCER RES, V61, P1138; Shankar S, 2004, DRUG RESIST UPDATE, V7, P139, DOI 10.1016/j.drup.2004.03.002; Siavoshian S, 2000, GUT, V46, P507, DOI 10.1136/gut.46.4.507; Suliman A, 2001, ONCOGENE, V20, P2122, DOI 10.1038/sj.onc.1204282; Sun XM, 2002, J BIOL CHEM, V277, P11345, DOI 10.1074/jbc.M109893200; Suzuki Y, 2001, P NATL ACAD SCI USA, V98, P8662, DOI 10.1073/pnas.161506698; TEWARI M, 1995, J BIOL CHEM, V270, P18738, DOI 10.1074/jbc.270.32.18738; Vigushin DM, 2001, CLIN CANCER RES, V7, P971; Vigushin DM, 2002, ANTI-CANCER DRUG, V13, P1, DOI 10.1097/00001813-200201000-00001; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang SL, 2003, ONCOGENE, V22, P8628, DOI 10.1038/sj.onc.1207232; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Yokota T, 2004, ONCOGENE, V23, P5340, DOI 10.1038/sj.onc.1207689; Zaffaroni N, 2002, DRUG RESIST UPDATE, V5, P65, DOI 10.1016/S1368-7646(02)00049-3; Zhang XD, 2003, BIOCHEM PHARMACOL, V66, P1537, DOI 10.1016/S0006-2952(03)00509-4; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	60	66	70	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2005	24	46					6877	6889		10.1038/sj.onc.1208851	http://dx.doi.org/10.1038/sj.onc.1208851			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	975ZD	16007142				2022-12-25	WOS:000232701700003
J	Mainou, BA; Everly, DN; Raab-Traub, N				Mainou, BA; Everly, DN; Raab-Traub, N			Epstein-Barr virus latent membrane protein 1 CTAR1 mediates rodent and human fibroblast transformation through activation of PI3K	ONCOGENE			English	Article						EBV; LMP1; CTAR; Rat-1; PI3K; transformation	NF-KAPPA-B; MEMBRANE-PROTEIN 1; SYNTHASE KINASE 3-BETA; GROWTH-FACTOR RECEPTOR; TRAF-BINDING-SITE; LYMPHOCYTE TRANSFORMATION; SIGNALING PATHWAYS; EPITHELIAL-CELLS; BETA-CATENIN; LMP1	Epstein-Barr virus (EBV) is a ubiquitous herpesvirus associated with a variety of malignancies including nasopharyngeal carcinoma. The EBV-encoded latent membrane protein 1 (LMP1) is considered the EBV oncogene as it is necessary for EBV-induced B-lymphocyte transformation and has been shown to transform rodent fibroblasts. LMP1 contains two signaling domains, the carboxy-terminal activating region 1 and 2 (CTAR1 and CTAR2), by which NF-kappa B, phosphatidylinositol 3-kinase (PI3K), mitogen- activated protein kinase, and c-Jun N-terminal kinase are activated. In this study, the role of CTAR1 and CTAR2 in LMP1-mediated transformation of rodent fibroblasts was analysed. CTAR1 was found to be necessary for rodent. broblast transformation, whereas CTAR2 was dispensable. The activation of the PI3K pathway in Rat-1 cells by LMP1 and LMP1-CTAR1 in transformed cells resulted in phosphorylated Akt and phosphorylated glycogen synthase kinase 3 beta. The role of PI3K and NF-kappa B activation in LMP1-mediated transformation was further analysed using the chemical inhibitors LY294002 and BAY 11-7085. LY294002 inhibited CTAR1-induced focus formation and anchorage independent growth, whereas BAY 11-7085 did not inhibit focus formation or anchorage-independent growth. Similar studies in human fibroblasts confirmed that LMP1-CTAR1 also mediates aberrant growth, phosphorylation of Akt, and decreased levels of p27. These findings indicate that LMP1-mediated rodent. broblast transformation is dependent upon activation of PI3K and Akt and is independent of activation of NF-kappa B.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Microbiol Immunol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Raab-Traub, N (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.	nrt@med.unc.edu	Mainou, Bernardo A./H-4164-2019	Mainou, Bernardo A./0000-0002-7721-183X	NATIONAL CANCER INSTITUTE [P01CA019014, R01CA032979] Funding Source: NIH RePORTER; NCI NIH HHS [CA 32979, CA 19014] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Atkinson PGP, 2003, J BIOL CHEM, V278, P51134, DOI 10.1074/jbc.M304771200; BAICHWAL VR, 1988, ONCOGENE, V2, P461; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dawson CW, 2003, J BIOL CHEM, V278, P3694, DOI 10.1074/jbc.M209840200; Devergne O, 1996, MOL CELL BIOL, V16, P7098; Devergne O, 1998, J VIROL, V72, P7900, DOI 10.1128/JVI.72.10.7900-7908.1998; Ding VW, 2000, J BIOL CHEM, V275, P32475, DOI 10.1074/jbc.M005342200; Eliopoulos AG, 1998, ONCOGENE, V16, P1731, DOI 10.1038/sj.onc.1201694; Everly DN, 2004, J VIROL, V78, P13470, DOI 10.1128/JVI.78.24.13470-13478.2004; Everly DN, 2004, J VIROL, V78, P11648, DOI 10.1128/JVI.78.21.11648-11655.2004; FAHRAEUS R, 1988, INT J CANCER, V42, P329, DOI 10.1002/ijc.2910420305; He ZM, 2000, CANCER RES, V60, P1845; Higuchi M, 2001, P NATL ACAD SCI USA, V98, P4675, DOI 10.1073/pnas.081075298; Izumi KM, 1999, MOL CELL BIOL, V19, P5759; Izumi KM, 1997, P NATL ACAD SCI USA, V94, P1447, DOI 10.1073/pnas.94.4.1447; Izumi KM, 1997, P NATL ACAD SCI USA, V94, P12592, DOI 10.1073/pnas.94.23.12592; KAYE KM, 1995, J VIROL, V69, P675, DOI 10.1128/JVI.69.2.675-683.1995; Kaye KM, 1996, P NATL ACAD SCI USA, V93, P11085, DOI 10.1073/pnas.93.20.11085; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; KIEFF E, 2001, FIELDS VIROLOGY, P2511; LIEBOWITZ D, 1989, J VIROL, V63, P4051, DOI 10.1128/JVI.63.9.4051-4054.1989; Luftig M, 2004, P NATL ACAD SCI USA, V101, P141, DOI 10.1073/pnas.2237183100; Mehl AM, 2001, J BIOL CHEM, V276, P984, DOI 10.1074/jbc.M003758200; Meng FY, 2002, J BIOL CHEM, V277, P29674, DOI 10.1074/jbc.M112464200; MILLER WE, 1995, J VIROL, V69, P4390, DOI 10.1128/JVI.69.7.4390-4398.1995; Miller WE, 1998, ONCOGENE, V16, P1869, DOI 10.1038/sj.onc.1201696; Miller WE, 1998, MOL CELL BIOL, V18, P2835, DOI 10.1128/MCB.18.5.2835; Miller WE, 1997, J VIROL, V71, P586, DOI 10.1128/JVI.71.1.586-594.1997; Morrison JA, 2004, CANCER RES, V64, P5251, DOI 10.1158/0008-5472.CAN-04-0538; Morrison JA, 2003, J VIROL, V77, P12276, DOI 10.1128/JVI.77.22.12276-12284.2003; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; PAINE E, 1995, J VIROL, V69, P4572, DOI 10.1128/JVI.69.7.4572-4576.1995; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; Puls A, 1999, J CELL SCI, V112, P2983; Raab-Traub N, 2002, SEMIN CANCER BIOL, V12, P431, DOI 10.1016/S1044579X0200086X; REYNOLDS VL, 1987, CANCER RES, V47, P6384; Roberts ML, 1998, VIROLOGY, V240, P93, DOI 10.1006/viro.1997.8901; ROWE M, 1994, J VIROL, V68, P5602, DOI 10.1128/JVI.68.9.5602-5612.1994; Saito N, 2003, J BIOL CHEM, V278, P46565, DOI 10.1074/jbc.M302549200; Scholle F, 2000, J VIROL, V74, P10681, DOI 10.1128/JVI.74.22.10681-10689.2000; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Thornburg NJ, 2003, CANCER RES, V63, P8293; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; YOUNG L, 1989, NEW ENGL J MED, V321, P1080, DOI 10.1056/NEJM198910193211604	44	101	105	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2005	24	46					6917	6924		10.1038/sj.onc.1208846	http://dx.doi.org/10.1038/sj.onc.1208846			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	975ZD	16007144				2022-12-25	WOS:000232701700006
J	Tynan, JA; Wen, F; Muller, WJ; Oshima, RG				Tynan, JA; Wen, F; Muller, WJ; Oshima, RG			Ets2-dependent microenvironmental support of mouse mammary tumors	ONCOGENE			English	Article						Ets2; breast cancer; Cre recombinase; stroma	EXPRESSION; ONCOGENE; MODEL; ETS2; MICE	Decreasing the amount of active mouse Ets2 transcription factor by half in mice or use of a MAP kinase insensitive hypomorphic targeted Ets2 allele restricts the appearance of transgenic mammary tumors caused by either Polyoma middle T antigen (PyMT) or activated Neu/ErbB2. In addition, the early growth of transplanted mammary tumors is limited by restricted Ets2 activity of the host. Here we have tested genetically, with the use of a conditional Ets2(flox) allele and tissue specific Cre recombinase expression, whether Ets2 also functions within tumor cells by inactivating Ets2 within mammary luminal epithelial cells from which transgenic PyMTY315/(322F) tumors arise. We find that inactivation of Ets2 within tumor cells has no effect on tumor appearance or growth. By contrast, complete inactivation of Ets2 in both epithelial and stromal cells moderates the early hyperplastic phase of tumor development and the time of tumor appearance but does not prevent tumor occurrence and has no detectable effect on tumor growth. Thus, Ets2 supports mammary tumors exclusively through their microenvironment.	Burnham Inst, Canc Res Ctr, Oncodev Biol Program, La Jolla, CA 92037 USA; Univ Calif San Diego, Grad Program Mol Pathol, La Jolla, CA 92093 USA; McGill Univ, Mol Oncol Grp, Montreal, PQ H3A 1A1, Canada	Sanford Burnham Prebys Medical Discovery Institute; University of California System; University of California San Diego; McGill University	Oshima, RG (corresponding author), Burnham Inst, Canc Res Ctr, Oncodev Biol Program, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	rgoshima@burnham.org			NCI NIH HHS [1T32CA77109-04, CA098778, CA74547] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA074547, T32CA077109, R01CA098778] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andrechek ER, 2000, P NATL ACAD SCI USA, V97, P3444, DOI 10.1073/pnas.050408497; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Hayakawa T, 2001, J STAT PLAN INFER, V97, P101, DOI 10.1016/S0378-3758(00)00348-7; Hever A, 2003, EXP CELL RES, V290, P132, DOI 10.1016/S0014-4827(03)00315-X; Lelievre E, 2001, INT J BIOCHEM CELL B, V33, P391, DOI 10.1016/S1357-2725(01)00025-5; Man AK, 2003, MOL CELL BIOL, V23, P8614, DOI 10.1128/MCB.23.23.8614-8625.2003; Neznanov N, 1999, CANCER RES, V59, P4242; Oshima RG, 2004, CANCER RES, V64, P169, DOI 10.1158/0008-5472.CAN-03-1944; Sapi E, 1998, CANCER RES, V58, P1027; Sato Y, 2001, CELL STRUCT FUNCT, V26, P19, DOI 10.1247/csf.26.19; Tallquist MD, 2000, GENESIS, V26, P113, DOI 10.1002/(SICI)1526-968X(200002)26:2<113::AID-GENE3>3.0.CO;2-2; Webster MA, 1998, MOL CELL BIOL, V18, P2344, DOI 10.1128/MCB.18.4.2344; Wei G, 2004, J IMMUNOL, V173, P1374, DOI 10.4049/jimmunol.173.2.1374; WERNERT N, 1992, AM J PATHOL, V140, P119; Yamamoto H, 1998, GENE DEV, V12, P1315, DOI 10.1101/gad.12.9.1315	15	15	15	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2005	24	46					6870	6876		10.1038/sj.onc.1208856	http://dx.doi.org/10.1038/sj.onc.1208856			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	975ZD	16007139	Green Submitted			2022-12-25	WOS:000232701700002
J	Yu, CR; Bruzek, LM; Meng, XW; Gores, GJ; Carter, CA; Kaufmann, SH; Adjei, AA				Yu, CR; Bruzek, LM; Meng, XW; Gores, GJ; Carter, CA; Kaufmann, SH; Adjei, AA			The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006	ONCOGENE			English	Article						Mcl-1; apoptosis; BAY 43-9006 (sorafenib); MEK; Raf; adaphostin	CHRONIC LYMPHOCYTIC-LEUKEMIA; CELLS IN-VITRO; B-RAF; KINASE ACTIVATION; SIGNALING PATHWAY; HUMAN CANCER; BRAF GENE; APOPTOSIS; MUTATIONS; EXPRESSION	BAY 43-9006, a multikinase inhibitor that targets Raf, prevents tumor cell proliferation in vitro and inhibits diverse human tumor xenografts in vivo. The mechanism of action of BAY 43-9006 remains incompletely defined. In the present study, the effects of BAY 43-9006 on the antiapoptotic Bcl-2 family member Mcl-1 were examined. Treatment of A549 lung cancer cells with BAY 43-9006 diminished Mcl-1 levels in a time- and dose-dependent manner without affecting other Bcl-2 family members. Similar BAY 43-9006-induced Mcl-1 downregulation was observed in ACHN (renal cell), HT-29 (colon), MDA-MB-231 (breast), KMCH (cholangiocarcinoma), Jurkat (acute T-cell leukemia), K562 (chronic myelogenous leukemia) and MEC-2 ( chronic lymphocytic leukemia) cells. Mcl-1 mRNA levels did not change in BAY 43-9006-treated cells. Instead, BAY 43-9006 enhanced proteasome-mediated Mcl-1 degradation. This Mcl-1 downregulation was followed by mitochondrail cytochrome c release and caspase activation as well as enhanced sensitivity to other proapoptotic agents. The caspase inhibitor Boc-D-fmk inhibited BAY 43-9006-induced caspase activation but not cytochrome c release. In contrast, Mcl-1 overexpression inhibited cytochrome c release and other features of BAY 43-9006-induced apoptosis. Conversely, Mcl-1 downregulation by short hairpin RNA enhanced BAY 43-9006-induced apoptosis. Collectively, these findings demonstrate that drug-induced Mcl-1 downregulation contributes to the proapoptotic effects of BAY 43-9006.	Mayo Clin & Mayo Fdn, Div Med Oncol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Med, Rochester, MN 55905 USA; Bayer Healthcare, West Haven, CT 06516 USA	Mayo Clinic; Mayo Clinic; Bayer AG; Bayer Healthcare Pharmaceuticals	Adjei, AA (corresponding author), Mayo Clin & Mayo Fdn, Div Med Oncol, 200 1st St SW, Rochester, MN 55905 USA.	adjei.alex@mayo.edu		Kaufmann, Scott/0000-0002-4900-7145	NCI NIH HHS [R01 CA69008] Funding Source: Medline; NIDDK NIH HHS [R01 DK59427] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adjei AA, 2001, CLIN CANCER RES, V7, P1438; Ahmad T, 2004, CLIN CANCER RES, V10, p6388S, DOI 10.1158/1078-0432.CCR-040028; Aichberger KJ, 2005, BLOOD, V105, P3303, DOI 10.1182/blood-2004-02-0749; Boucher MJ, 2000, J CELL BIOCHEM, V79, P355, DOI 10.1002/1097-4644(20001201)79:3<355::AID-JCB20>3.3.CO;2-S; Chandra J, 2003, BLOOD, V102, P4512, DOI 10.1182/blood-2003-02-0562; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Cohen J, 2003, J NATL CANCER I, V95, P625, DOI 10.1093/jnci/95.8.625; Craig RW, 2002, LEUKEMIA, V16, P444, DOI 10.1038/sj.leu.2402416; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dhillon AS, 2003, MOL CELL BIOL, V23, P1983, DOI 10.1128/MCB.23.6.1983-1993.2003; Domina AM, 2000, J BIOL CHEM, V275, P21688, DOI 10.1074/jbc.M000915200; Domina AM, 2004, ONCOGENE, V23, P5301, DOI 10.1038/sj.onc.1207692; FLAHERTY KT, 2004, P AM SOC CLIN ONCOL, V23; Gojo I, 2002, CLIN CANCER RES, V8, P3527; Inoshita S, 2002, J BIOL CHEM, V277, P43730, DOI 10.1074/jbc.M207951200; Karasarides M, 2004, ONCOGENE, V23, P6292, DOI 10.1038/sj.onc.1207785; Kaufmann SH, 1998, BLOOD, V91, P991, DOI 10.1182/blood.V91.3.991.991_991_1000; Kitada S, 1998, BLOOD, V91, P3379, DOI 10.1182/blood.V91.9.3379; KOBAYASHI S, 2005, IN PRESS GASTROENTER; Meng XW, 2003, J BIOL CHEM, V278, P47326, DOI 10.1074/jbc.M304793200; Mercer KE, 2003, BBA-REV CANCER, V1653, P25, DOI 10.1016/S0304-419X(03)00016-7; Milella M, 2001, J CLIN INVEST, V108, P851, DOI 10.1172/JCI200112807; Moshynska O, 2004, JNCI-J NATL CANCER I, V96, P673, DOI 10.1093/jnci/djh122; Opferman JT, 2003, NATURE, V426, P671, DOI 10.1038/nature02067; Opferman JT, 2005, SCIENCE, V307, P1101, DOI 10.1126/science.1106114; Pollock PM, 2002, CANCER CELL, V2, P5, DOI 10.1016/S1535-6108(02)00089-2; Ratain MJ, 2004, J CLIN ONCOL, V22, p382S; Singer G, 2003, J NATL CANCER I, V95, P484, DOI 10.1093/jnci/95.6.484; Strumberg D, 2005, J CLIN ONCOL, V23, P965, DOI 10.1200/JCO.2005.06.124; STRUMBERG D, 2004, J CLIN ONCOL, V21, P21; Svingen PA, 2000, CLIN CANCER RES, V6, P237; Taniai M, 2004, CANCER RES, V64, P3517, DOI 10.1158/0008-5472.CAN-03-2770; Tannapfel A, 2003, GUT, V52, P706, DOI 10.1136/gut.52.5.706; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443; Yu CR, 2004, ONCOGENE, V23, P1364, DOI 10.1038/sj.onc.1207248; Yu CR, 2003, BLOOD, V102, P3765, DOI 10.1182/blood-2003-03-0737	37	234	241	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2005	24	46					6861	6869		10.1038/sj.onc.1208841	http://dx.doi.org/10.1038/sj.onc.1208841			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	975ZD	16007148				2022-12-25	WOS:000232701700001
J	Bloor, AJC; Kotsopoulou, E; Hayward, P; Champion, BR; Green, AR				Bloor, AJC; Kotsopoulou, E; Hayward, P; Champion, BR; Green, AR			RFP represses transcriptional activation by bHLH transcription factors	ONCOGENE			English	Article						RFP; SCL; bHLH; transcription factor; repression	RET FINGER PROTEIN; LOOP-HELIX PROTEINS; ACUTE PROMYELOCYTIC LEUKEMIA; TRIPARTITE MOTIF; NUCLEAR-BODIES; FUSION PROTEIN; SCL GENE; MYOD; EXPRESSION; INTERACTS	Basic helix-loop-helix (bHLH) transcription factors play a pivotal role in the regulation of tumorigenesis, and also in a wide range of other developmental processes in diverse species from yeast to humans. Here we demonstrate for the first time that Ret finger protein (RFP), a member of the TRIM family of proteins initially identified as a recombined transforming gene from a human lymphoma, is a novel interaction partner for four different bHLH proteins (SCL, E47, MyoD and mASH-1), but does not interact with GATA-1 or PU.1. Interaction with SCL required the B-box and first coiled-coil region of RFP together with the bHLH domain of SCL. RFP was able to repress transcriptional activation by E47, MyoD and mASH-1, but not by members of several other transcription factor families. Transcriptional repression by RFP was trichostatin A sensitive and did not involve an Id-like mechanism or ubiquitination with subsequent degradation of bHLH proteins. Instead, our results suggest that bHLH transcription factors are regulated by a previously undescribed interaction with RFP, which functions to recruit HDAC and/or Polycomb proteins and thus repress target genes of bHLH proteins. These results reveal an unexpected link between the bHLH and TRIM protein families.	Univ Cambridge, Dept Haematol, Cambridge Inst Met Res, Cambridge CB2 2XY, England; Lorantis Ltd, Cambridge CB4 0WG, England; Univ Cambridge, Dept Genet, Cambridge CB2 3EH, England	University of Cambridge; University of Cambridge	Green, AR (corresponding author), Univ Cambridge, Dept Haematol, Cambridge Inst Met Res, Hills Rd, Cambridge CB2 2XY, England.	arg1000@cam.ac.uk		Green, Anthony/0000-0002-9795-0218	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Bailey P, 1999, MOL ENDOCRINOL, V13, P1155, DOI 10.1210/me.13.7.1155; Begley CG, 1999, BLOOD, V93, P2760; Bloor AJC, 2002, J HEMATOTH STEM CELL, V11, P195, DOI 10.1089/152581602753658402; BOCKAMP EO, 1995, BLOOD, V86, P1502, DOI 10.1182/blood.V86.4.1502.bloodjournal8641502; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; Cao TY, 1998, J CELL SCI, V111, P1319; Cao TY, 1997, J CELL SCI, V110, P1563; CHANG KS, 1992, MOL CELL BIOL, V12, P800, DOI 10.1128/MCB.12.2.800; Engel I, 1999, P NATL ACAD SCI USA, V96, P996, DOI 10.1073/pnas.96.3.996; Farah MH, 2000, DEVELOPMENT, V127, P693; Gould A, 1997, CURR OPIN GENET DEV, V7, P488, DOI 10.1016/S0959-437X(97)80075-5; Hall MA, 2003, P NATL ACAD SCI USA, V100, P992, DOI 10.1073/pnas.0237324100; HSU HL, 1994, P NATL ACAD SCI USA, V91, P5947, DOI 10.1073/pnas.91.13.5947; HSU HL, 1991, MOL CELL BIOL, V11, P3037, DOI 10.1128/MCB.11.6.3037; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; KERR LD, 1993, NATURE, V365, P412, DOI 10.1038/365412a0; Kho CJ, 1997, J BIOL CHEM, V272, P3845, DOI 10.1074/jbc.272.6.3845; Klugbauer S, 1999, ONCOGENE, V18, P4388, DOI 10.1038/sj.onc.1202824; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; Mikkola HKA, 2003, NATURE, V421, P547, DOI 10.1038/nature01345; Morris-Desbois C, 1999, J CELL SCI, V112, P3331; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NEUHOLD LA, 1993, CELL, V74, P1033, DOI 10.1016/0092-8674(93)90725-6; O'Neil J, 2004, CANCER CELL, V5, P587, DOI 10.1016/j.ccr.2004.05.023; Reymond A, 2001, EMBO J, V20, P2140, DOI 10.1093/emboj/20.9.2140; Sartorelli V, 1999, MOL CELL, V4, P725, DOI 10.1016/S1097-2765(00)80383-4; Shimono Y, 2003, J BIOL CHEM, V278, P51638, DOI 10.1074/jbc.M309198200; Shimono Y, 2000, J BIOL CHEM, V275, P39411, DOI 10.1074/jbc.M006585200; Sikder HA, 2003, CANCER CELL, V3, P525, DOI 10.1016/S1535-6108(03)00141-7; Sinclair AM, 2002, BLOOD, V99, P3931, DOI 10.1182/blood.V99.11.3931; Song A, 1998, MOL CELL BIOL, V18, P4994, DOI 10.1128/MCB.18.9.4994; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TANIGAWA T, 1994, CELL GROWTH DIFFER, V5, P557; Tezel G, 1999, PATHOL INT, V49, P881, DOI 10.1046/j.1440-1827.1999.00957.x; Wu WS, 2001, MOL CELL BIOL, V21, P2259, DOI 10.1128/MCB.21.7.2259-2268.2001; Yan W, 1997, MOL CELL BIOL, V17, P7317, DOI 10.1128/MCB.17.12.7317; Yokota Y, 2002, J CELL PHYSIOL, V190, P21, DOI 10.1002/jcp.10042; Zhang JS, 2004, SCIENCE, V305, P1286, DOI 10.1126/science.1097937	39	10	10	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 13	2005	24	45					6729	6736		10.1038/sj.onc.1208828	http://dx.doi.org/10.1038/sj.onc.1208828			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	973MV	16007160				2022-12-25	WOS:000232527800001
J	Ni, HH; Dydensborg, AB; Herring, FE; Basora, N; Gagne, D; Vachon, PH; Beaulieu, JF				Ni, HH; Dydensborg, AB; Herring, FE; Basora, N; Gagne, D; Vachon, PH; Beaulieu, JF			Upregulation of a functional form of the beta(4) integrin subunit in colorectal cancers correlates with c-Myc expression	ONCOGENE			English	Article						laminin receptor; integrin; colon; adenocarcinoma cells; epithelial cells	SUCRASE-ISOMALTASE EXPRESSION; HUMAN-COLON CARCINOMA; CRYPT-VILLUS AXIS; DIFFERENTIAL EXPRESSION; CYTOPLASMIC DOMAIN; ALPHA(6)BETA(4) INTEGRIN; ADHESION; LAMININ-5; MECHANISM; SEQUENCE	The integrin beta(4) subunit has been shown to be involved in various aspects of cancer progression. The aim of the present work was to evaluate the expression of beta(4) in primary colon cancers and to investigate the occurrence of a previously identified intestinal nonfunctional variant of beta(4) (beta(ctd-)(4)) for adhesion to laminin. Immunodetection of beta(4) using a panel of antibodies and RT-PCR analyses were performed on series of paired primary colon tumors and corresponding resection margins. The beta(4) subunit was found to be significantly overexpressed in cancer specimens at both the protein and transcript levels. Surprisingly, beta(4) levels of expression were closely correlated with those of the oncogene c-Myc in individual specimens. In vitro studies of c-Myc overexpression showed an upregulation of beta(4) promoter activity. Finally, the beta(ctd-)(4) form was identified in the normal proliferative colonic cells but was found to be predominantly absent in colon cancer cells, both in situ and in vitro. We concluded that the beta(ctd-)(4) form is lost from colon cancer cells, while the level of the wildtype form of beta(4), which is functional for adhesion to laminin, is increased in primary tumors in relation with the expression of c-Myc.	Univ Sherbrooke, CIHR Grp Funct Dev & Physiopathol Digest Tract, Dept Anat & Biol Cellulaire, Fac Med, Sherbrooke, PQ J1H 5N4, Canada; Univ Sherbrooke, Fac Med, Dept Physiol & Biophys, Sherbrooke, PQ J1H 5N4, Canada	University of Sherbrooke; University of Sherbrooke	Beaulieu, JF (corresponding author), Univ Sherbrooke, CIHR Grp Funct Dev & Physiopathol Digest Tract, Dept Anat & Biol Cellulaire, Fac Med, Sherbrooke, PQ J1H 5N4, Canada.	Jean-Francois.Beaulieu@USherbrooke.ca	Beaulieu, Jean-Francois/D-2054-2010					ASTLER VB, 1954, ANN SURG, V139, P846, DOI 10.1097/00000658-195406000-00015; Basora N, 1999, J BIOL CHEM, V274, P29819, DOI 10.1074/jbc.274.42.29819; BEAULIEU JF, 1989, J BIOL CHEM, V264, P20000; BEAULIEU JF, 1991, BIOCHEM J, V280, P599, DOI 10.1042/bj2800599; BEAULIEU JF, 1994, GASTROENTEROLOGY, V106, P829, DOI 10.1016/0016-5085(94)90740-4; BEAULIEU JF, 1992, J CELL SCI, V102, P427; BEAULIEU JF, 1990, GASTROENTEROLOGY, V98, P1467, DOI 10.1016/0016-5085(90)91077-J; BEAULIEU JF, 1999, FRONT BIOSCI, V4, P310; Borradori L, 1999, J INVEST DERMATOL, V112, P411, DOI 10.1046/j.1523-1747.1999.00546.x; CHANTRET I, 1988, CANCER RES, V48, P1936; CLARKE AS, 1994, CELL ADHES COMMUN, V2, P1, DOI 10.3109/15419069409014197; Dajee M, 2003, NATURE, V421, P639, DOI 10.1038/nature01283; Dans M, 2001, J BIOL CHEM, V276, P1494, DOI 10.1074/jbc.M008663200; de Melker AA, 1999, BIOESSAYS, V21, P499, DOI 10.1002/(SICI)1521-1878(199906)21:6<499::AID-BIES6>3.0.CO;2-D; DIKE LE, 1988, P NATL ACAD SCI USA, V85, P6792, DOI 10.1073/pnas.85.18.6792; DON RH, 1991, NUCLEIC ACIDS RES, V19, P4008, DOI 10.1093/nar/19.14.4008; Eisenman RN, 2001, GENE DEV, V15, P2023, DOI 10.1101/gad928101; ERISMAN MD, 1985, MOL CELL BIOL, V5, P1969, DOI 10.1128/MCB.5.8.1969; Escaffit F, 2005, J CELL PHYSIOL, V203, P15, DOI 10.1002/jcp.20189; FALCIONI R, 1994, INT J ONCOL, V5, P573; Gauthier R, 2001, AM J PHYSIOL-CELL PH, V280, pC1540, DOI 10.1152/ajpcell.2001.280.6.C1540; GIANCOTTI FG, 1992, J CELL BIOL, V118, P951, DOI 10.1083/jcb.118.4.951; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; HESSLE H, 1984, DIFFERENTIATION, V26, P49, DOI 10.1111/j.1432-0436.1984.tb01372.x; HOGERVORST F, 1990, EMBO J, V9, P765, DOI 10.1002/j.1460-2075.1990.tb08171.x; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Kim SY, 2003, MOL CELL, V11, P1177, DOI 10.1016/S1097-2765(03)00173-4; LaFlamme SE, 1997, MATRIX BIOL, V16, P153, DOI 10.1016/S0945-053X(97)90003-2; Lavigne P, 1998, J MOL BIOL, V281, P165, DOI 10.1006/jmbi.1998.1914; Levens D, 2002, P NATL ACAD SCI USA, V99, P5757, DOI 10.1073/pnas.102173199; Liu SC, 2000, J CELL SCI, V113, P3563; Lohi J, 2000, APMIS, V108, P161, DOI 10.1034/j.1600-0463.2000.d01-40.x; Mainiero F, 1997, EMBO J, V16, P2365, DOI 10.1093/emboj/16.9.2365; Mercurio AM, 2001, SEMIN CANCER BIOL, V11, P129, DOI 10.1006/scbi.2000.0364; Mercurio AM, 2001, CURR OPIN CELL BIOL, V13, P541, DOI 10.1016/S0955-0674(00)00249-0; Miranti CK, 2002, NAT CELL BIOL, V4, pE83, DOI 10.1038/ncb0402-e83; Nikolopoulos SN, 2004, CANCER CELL, V6, P471, DOI 10.1016/j.ccr.2004.09.029; Nishida K, 1997, BIOCHEM BIOPH RES CO, V241, P258, DOI 10.1006/bbrc.1997.7808; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Sanders RJ, 1998, CANCER INVEST, V16, P329, DOI 10.3109/07357909809084653; SCHUG J, 1997, ISMB, V5, P268; SMITH DR, 1993, BRIT J CANCER, V68, P407, DOI 10.1038/bjc.1993.350; Sordat I, 1998, J PATHOL, V185, P44, DOI 10.1002/(SICI)1096-9896(199805)185:1<44::AID-PATH46>3.0.CO;2-A; STALLMACH A, 1992, GUT, V33, P342, DOI 10.1136/gut.33.3.342; SUZUKI S, 1990, EMBO J, V9, P757, DOI 10.1002/j.1460-2075.1990.tb08170.x; Takaoka AS, 1998, J BIOL CHEM, V273, P33848, DOI 10.1074/jbc.273.50.33848; TAMURA RN, 1990, J CELL BIOL, V111, P1593, DOI 10.1083/jcb.111.4.1593; Tani T, 1997, AM J PATHOL, V151, P1289; Tani T, 1996, AM J PATHOL, V149, P781; VACHON PH, 1995, AM J PHYSIOL-GASTR L, V268, pG857, DOI 10.1152/ajpgi.1995.268.5.G857; VACHON PH, 1992, GASTROENTEROLOGY, V103, P414, DOI 10.1016/0016-5085(92)90829-N; vanLeusden MR, 1997, BIOCHEM BIOPH RES CO, V235, P826, DOI 10.1006/bbrc.1997.6892; Wanzel M, 2003, TRENDS CELL BIOL, V13, P146, DOI 10.1016/S0962-8924(03)00003-5; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; Watt FM, 2002, EMBO J, V21, P3919, DOI 10.1093/emboj/cdf399; WATT R, 1983, NATURE, V303, P725, DOI 10.1038/303725a0	58	44	46	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 13	2005	24	45					6820	6829		10.1038/sj.onc.1208848	http://dx.doi.org/10.1038/sj.onc.1208848			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	973MV	16007143				2022-12-25	WOS:000232527800009
J	Rho, SB; Lee, KW; Chun, T; Lee, SH; Park, K; Lee, JH				Rho, SB; Lee, KW; Chun, T; Lee, SH; Park, K; Lee, JH			The identification of apoptosis-related residues in human thymosin beta-10 by mutational analysis and computational modeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN-BINDING-SITE; XENOPUS-LAEVIS; EXPRESSION; PROTEINS; CANCER; CELLS; GENE; OVEREXPRESSION; METASTASIS; INHIBITION	Thymosin beta-10 (TB10) is an actin monomer-sequestering peptide that consists of 43 amino acid residues and that tends to form alpha-helical structures. Previously, we showed that the overexpression of TB10 dramatically increases the frequency of apoptosis in human ovarian cancer cells. To identify the critical residues responsible for TB10-mediated apoptosis, we used a series of computational methods. First, a three-dimensional structure of human TB10 was constructed using the homology modeling method with the calf thymosin beta-9 NMR structure as a template. Although the sequences of both of these structures are almost identical, 200-ps molecular dynamics simulation results showed that their secondary structures differ. Analyses of molecular dynamics snapshot structures suggested that the TB10 structure is conformationally more complicated than the TB9 structure. The conserved (LKKTET22)-L-17 motif region of TB10 was tested by Ala and Ser scanning mutagenesis using computational and biochemical methods, and 12 mutants were transfected into cancer cell lines and tested for their effects on growth arrest. Of the 12 mutants examined, only the Thr(20) to Ser(20) mutation showed reduced growth arrest. These results strongly suggest that Thr(20) is specifically required for actin sequestration by TB10 in ovarian cancer cells. These results may provide useful information for the development of a new ovarian cancer therapy.	Sungkyunkwan Univ, Samsung Med Ctr, Mol Therapy Res Ctr, Seoul 135710, South Korea; Sungkyunkwan Univ, Samsung Med Ctr, Dept Obstet & Gynecol, Div Gynecol Oncol, Seoul 135710, South Korea; Gyeongsang Natl Univ, Env Biotech Natl Core Res Ctr, Div Appl Life Sci, Jinju 660701, South Korea; Hanyang Univ, Sch Med, Dept Microbiol & Immunol, Seoul 133791, South Korea	Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan University (SKKU); Samsung Medical Center; Gyeongsang National University; Hanyang University	Lee, JH (corresponding author), Sungkyunkwan Univ, Samsung Med Ctr, Mol Therapy Res Ctr, Annex 8F,50 Ilwon Dong, Seoul 135710, South Korea.	jeholee@unitel.co.kr	Chun, Taehoon/F-2052-2013					Califano D, 1998, CANCER RES, V58, P823; Carpintero P, 1996, FEBS LETT, V394, P103, DOI 10.1016/0014-5793(96)00888-5; DAUBEROSGUTHORPE P, 1988, PROTEINS, V4, P31, DOI 10.1002/prot.340040106; Devineni N, 1999, BRAIN RES, V823, P129, DOI 10.1016/S0006-8993(99)01147-6; Eadie JS, 2000, J CELL BIOCHEM, V77, P277, DOI 10.1002/(SICI)1097-4644(20000501)77:2<277::AID-JCB10>3.0.CO;2-Q; Fidler I J, 1978, Adv Cancer Res, V28, P149, DOI 10.1016/S0065-230X(08)60648-X; Gutierrez-Pabello JA, 2002, INFECT IMMUN, V70, P2121, DOI 10.1128/IAI.70.4.2121-2127.2002; HALL AK, 1995, CELL MOL BIOL RES, V41, P167; HANNAPPEL E, 1993, BIOL CHEM H-S, V374, P117, DOI 10.1515/bchm3.1993.374.1-6.117; HANNAPPEL E, 1988, ARCH BIOCHEM BIOPHYS, V260, P546, DOI 10.1016/0003-9861(88)90480-8; HEINTZ D, 1993, FEBS LETT, V329, P9, DOI 10.1016/0014-5793(93)80181-S; HORECKER BL, 1984, LYMPHOKINES, V9, P15; Huff T, 2001, INT J BIOCHEM CELL B, V33, P205, DOI 10.1016/S1357-2725(00)00087-X; Huff T, 1997, FEBS LETT, V414, P39, DOI 10.1016/S0014-5793(97)00946-0; HUFF T, 1995, EUR J BIOCHEM, V230, P650; JEAN C, 1994, J MUSCLE RES CELL M, V15, P278; Lee SH, 2001, ONCOGENE, V20, P6700, DOI 10.1038/sj.onc.1204683; LIN SC, 1990, J MOL NEUROSCI, V2, P35, DOI 10.1007/BF02896924; LOW TLK, 1981, P NATL ACAD SCI-BIOL, V78, P1162, DOI 10.1073/pnas.78.2.1162; Philp D, 2003, FASEB J, V17, P2103, DOI 10.1096/fj.03-0121fje; Rho SB, 1996, P NATL ACAD SCI USA, V93, P10128, DOI 10.1073/pnas.93.19.10128; RUGGIERI S, 1983, ARCH BIOCHEM BIOPHYS, V226, P388, DOI 10.1016/0003-9861(83)90305-3; Stoll R, 1997, BIOPOLYMERS, V41, P623, DOI 10.1002/(SICI)1097-0282(199705)41:6<623::AID-BIP3>3.0.CO;2-S; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; VANCOMPERNOLLE K, 1992, EMBO J, V11, P4739, DOI 10.1002/j.1460-2075.1992.tb05579.x; VANCOMPERNOLLE K, 1991, J BIOL CHEM, V266, P15427; VanTroys M, 1996, EMBO J, V15, P201, DOI 10.1002/j.1460-2075.1996.tb00350.x; VergheseNikolakaki S, 1996, BRIT J CANCER, V74, P1441, DOI 10.1038/bjc.1996.562; YAMAMOTO M, 1992, BIOCHEM BIOPH RES CO, V184, P93, DOI 10.1016/0006-291X(92)91162-J; YU FX, 1993, J BIOL CHEM, V268, P502; ZETTER BR, 1990, NEW ENGL J MED, V322, P605	31	10	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					34003	34007		10.1074/jbc.M501629200	http://dx.doi.org/10.1074/jbc.M501629200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16012174	hybrid			2022-12-25	WOS:000232229700038
J	Umar, S; Wang, Y; Sellin, JH				Umar, S; Wang, Y; Sellin, JH			Epithelial proliferation induces novel changes in APC expression	ONCOGENE			English	Article						APC; colon; in vivo	POLYPOSIS-COLI PROTEIN; TUMOR-SUPPRESSOR PROTEIN; COLONIC-MUCOSA HYPERPROLIFERATION; BETA-CATENIN; NUCLEAR EXPORT; SUBCELLULAR-LOCALIZATION; GENE-PRODUCT; IN-VIVO; DOWN-REGULATION; ASSOCIATION	The role of wild-type adenomatous polyposis coli (APC) protein in native epithelia is poorly understood. The present study examined the relationships between wildtype APC and beta-catenin expression in an established model of hyperproliferation, transmissible murine colonic hyperplasia (TMCH). Distal colonic crypts isolated from normal or TMCH mice were: (i) fractionated into cytosolic and nuclear components for Western blotting and immunoprecipitation (IP),( ii) extracted for total RNA isolation for Northern blotting and,(iii) analysed immunohistochemically by confocal microscopy. Western blots performed sequentially through day 12 TMCH with N-terminal APC antibodies revealed increased abundance of similar to 312 kDa (p312) protein by day 6 (4.0 +/- 0.75-fold, n = 6) that peaked by day 9, before declining by day 12. A similar to 130 kDa ( p130) band appeared at day 9 and increased by day 12 (1.5 +/- 0.11-fold, n = 6). A C-terminal antibody detected only p312. APC mRNA level did not change during TMCH and appearance of p130 was not due to alternative splicing. Co-IP with N-terminal anti-APC antibodies, revealed APC's association with b-catenin both at day 6 and day 12. p130, but not p312, associated predominantly with beta-catenin at day 12 during co-IP with anti-beta-catenin. p130 also selectively accumulated in the nucleus, bound to nuclear beta-catenin at day 12. Immunocytochemistry with N-terminal antibodies revealed an increasing crypt base : surface gradient of APC within the apical pole/apical-lateral membranes at day 6. At day 12, intense apical/cytoplasmic and occasional nuclear staining along the longitudinal crypt axis was observed. Full-length APC increases during epithelial hyperproliferation and may represent a homoeostatic response. The dramatic increase in cytoplasmic and sporadic nuclear APC staining at day 12 with N-terminal antibodies may represent p130. The nuclear accumulation of p130 may be a novel mechanism regulating nuclear beta-catenin function during TMCH.	Univ Texas, Med Branch, Dept Internal Med, Div Gastroenterol & Hepatol, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Umar, S (corresponding author), Univ Texas, Med Branch, Dept Internal Med, Div Gastroenterol & Hepatol, 301 Univ Blvd,1108 Strand, Galveston, TX 77555 USA.	shumar@utmb.edu			NCI NIH HHS [CA 099121] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R03CA099121] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAEG GH, 1995, EMBO J, V14, P5618, DOI 10.1002/j.1460-2075.1995.tb00249.x; BARTHOLD SW, 1979, CANCER RES, V39, P24; BARTHOLD SW, 1977, LAB ANIM SCI, V27, P938; BARTHOLD SW, 1978, VET PATHOL, V15, P223, DOI 10.1177/030098587801500209; BARTHOLD SW, 1977, CANCER RES, V37, P4352; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Brocardo M, 2005, EMBO REP, V6, P184, DOI 10.1038/sj.embor.7400329; Browne SJ, 1998, CELL DEATH DIFFER, V5, P206, DOI 10.1038/sj.cdd.4400331; Deka J, 1999, ONCOGENE, V18, P5654, DOI 10.1038/sj.onc.1202944; Efstathiou JA, 1998, P NATL ACAD SCI USA, V95, P3122, DOI 10.1073/pnas.95.6.3122; Eleftheriou A, 2001, J BIOL CHEM, V276, P25883, DOI 10.1074/jbc.M102656200; Fagotto F, 1998, CURR BIOL, V8, P181, DOI 10.1016/S0960-9822(98)70082-X; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Galea MA, 2001, J BIOL CHEM, V276, P45833, DOI 10.1074/jbc.M107149200; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; Henderson BR, 2000, NAT CELL BIOL, V2, P653, DOI 10.1038/35023605; HORII A, 1993, HUM MOL GENET, V2, P283, DOI 10.1093/hmg/2.3.283; Iwamoto M, 2000, CARCINOGENESIS, V21, P1935, DOI 10.1093/carcin/21.11.1935; McCartney BM, 2000, NAT CELL BIOL, V2, pE58, DOI 10.1038/35008685; MIYASHIRO I, 1995, ONCOGENE, V11, P89; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; MUNEMITSU S, 1994, CANCER RES, V54, P3676; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Nakamura T, 1998, GENES CELLS, V3, P395, DOI 10.1046/j.1365-2443.1998.00198.x; Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165; Neufeld KL, 2000, P NATL ACAD SCI USA, V97, P12085, DOI 10.1073/pnas.220401797; Neufeld KL, 1997, P NATL ACAD SCI USA, V94, P3034, DOI 10.1073/pnas.94.7.3034; Neufeld KL, 2000, EMBO REP, V1, P519; Newman JV, 2001, J INFECT DIS, V184, P227, DOI 10.1086/321998; OSHIMA M, 1993, CANCER RES, V53, P5589; Reinacher-Schick A, 2001, J CELL BIOL, V152, P491, DOI 10.1083/jcb.152.3.491; Rosin-Arbesfeld R, 2000, NATURE, V406, P1009, DOI 10.1038/35023016; Roura S, 2003, BIOCHEM BIOPH RES CO, V309, P830, DOI 10.1016/j.bbrc.2003.08.075; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; RUBINFELD B, 1995, J BIOL CHEM, V270, P5549, DOI 10.1074/jbc.270.10.5549; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Sansom OJ, 2004, GENE DEV, V18, P1385, DOI 10.1101/gad.287404; Santoro IM, 1997, CANCER RES, V57, P488; Sellin JH, 2001, CANCER RES, V61, P2899; Smits R, 1999, GENE DEV, V13, P1309, DOI 10.1101/gad.13.10.1309; Spink KE, 2001, EMBO J, V20, P6203, DOI 10.1093/emboj/20.22.6203; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; THLIVERIS A, 1994, CANCER RES, V54, P2991; Umar S, 2003, CELL PROLIFERAT, V36, P361, DOI 10.1046/j.1365-2184.2003.00291.x; Umar S, 2000, AM J PHYSIOL-GASTR L, V278, pG765, DOI 10.1152/ajpgi.2000.278.5.G765; Umar S, 2000, AM J PHYSIOL-GASTR L, V278, pG753, DOI 10.1152/ajpgi.2000.278.5.G753; Umar S, 2000, AM J PHYSIOL-GASTR L, V279, pG223, DOI 10.1152/ajpgi.2000.279.1.G223; VOGELSTEIN B, 1994, COLD SPRING HARB SYM, V59, P517, DOI 10.1101/SQB.1994.059.01.057; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Webb SJ, 1999, FASEB J, V13, P339, DOI 10.1096/fasebj.13.2.339; White RL, 1997, PATHOL BIOL, V45, P240; Wiechens N, 2001, CURR BIOL, V11, P18, DOI 10.1016/S0960-9822(00)00045-2; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3; Wong MH, 1996, P NATL ACAD SCI USA, V93, P9588, DOI 10.1073/pnas.93.18.9588; Zhang F, 2000, P NATL ACAD SCI USA, V97, P12577, DOI 10.1073/pnas.230435597; Zhang F, 2001, MOL CELL BIOL, V21, P8143, DOI 10.1128/MCB.21.23.8143-8156.2001	56	11	11	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 6	2005	24	44					6709	6718		10.1038/sj.onc.1208820	http://dx.doi.org/10.1038/sj.onc.1208820			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	971FL	16007167	Bronze			2022-12-25	WOS:000232367800012
J	Kitsos, CM; Sankar, U; Illario, M; Colomer-Font, JM; Duncan, AW; Ribr, TJ; Reya, T; Means, AR				Kitsos, CM; Sankar, U; Illario, M; Colomer-Font, JM; Duncan, AW; Ribr, TJ; Reya, T; Means, AR			Calmodulin-dependent protein kinase IV regulates hematopoietic stem cell maintenance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREB-BINDING PROTEIN; TRANSCRIPTION FACTOR; SELF-RENEWAL; GENE-EXPRESSION; DEFICIENT MICE; CYCLE ENTRY; ACTIVATION; CBP; APOPTOSIS; SURVIVAL	The hematopoietic stem cell (HSC) gives rise to all mature, terminally differentiated cells of the blood. Here we show that calmodulin-dependent protein kinase IV (CaMKIV) is present in c-Kit(+) ScaI(+) Lin(-/low) hematopoietic progenitor cells (KLS cells) and that its absence results in hematopoietic failure, characterized by a diminished KLS cell population and by an inability of these cells to reconstitute blood cells upon serial transplantation. KLS cell failure in the absence of CaMKIV is correlated with increased apoptosis and proliferation of these cells in vivo and in vitro. In turn, these cell biological defects are correlated with decreases in CREB-serine 133 phosphorylation as well as in CREB-binding protein (CBP) and Bcl-2 levels. Re-expression of CaMKIV in Camk4(-/-) KLS cells results in the rescue of the proliferation defects in vitro as well as in the restoration of CBP and Bcl-2 to wild type levels. These studies show that CaMKIV is a regulator of HSC homeostasis and suggest that its effects may be in part mediated via regulation of CBP and Bcl-2.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27715 USA; Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy; Transform Pharmaceut, Emerging Sci & Technol Div, Lexington, MA 02421 USA	Duke University; University of Naples Federico II	Means, AR (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27715 USA.	means001@mc.duke.edu	Sankar, Uma/AHE-2383-2022	Duncan, Andrew/0000-0003-4962-4191; Illario, Maddalena/0000-0001-9834-6517				Alarcon JM, 2004, NEURON, V42, P947, DOI 10.1016/j.neuron.2004.05.021; Anderson KA, 2002, MOL CELL BIOL, V22, P23, DOI 10.1128/MCB.22.1.23-29.2002; Anderson KA, 1997, MOL ENDOCRINOL, V11, P725, DOI 10.1210/me.11.6.725; Apati A, 2003, J BIOL CHEM, V278, P9235, DOI 10.1074/jbc.M205528200; Blaeser F, 2000, J BIOL CHEM, V275, P197, DOI 10.1074/jbc.275.1.197; Chawla S, 1998, SCIENCE, V281, P1505, DOI 10.1126/science.281.5382.1505; Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Corcoran EE, 2001, J BIOL CHEM, V276, P2975, DOI 10.1074/jbc.R000027200; Domen J, 2000, J EXP MED, V191, P253, DOI 10.1084/jem.191.2.253; Domen J, 1999, MOL MED TODAY, V5, P201, DOI 10.1016/S1357-4310(99)01464-1; Greider C, 2002, ONCOGENE, V21, P7765, DOI 10.1038/sj.onc.1205928; Ho N, 2000, J NEUROSCI, V20, P6459, DOI 10.1523/JNEUROSCI.20-17-06459.2000; Hock H, 2004, NATURE, V431, P1002, DOI 10.1038/nature02994; Impey S, 2002, NEURON, V34, P235, DOI 10.1016/S0896-6273(02)00654-2; Janumyan YM, 2003, EMBO J, V22, P5459, DOI 10.1093/emboj/cdg533; Jiang HB, 2003, HUM MOL GENET, V12, P1, DOI 10.1093/hmg/ddg002; Kane CD, 2000, EMBO J, V19, P691, DOI 10.1093/emboj/19.4.691; Kondo M, 2003, ANNU REV IMMUNOL, V21, P759, DOI 10.1146/annurev.immunol.21.120601.141007; Kung AL, 2000, GENE DEV, V14, P272; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Lawson ND, 1999, EXP HEMATOL, V27, P1682, DOI 10.1016/S0301-472X(99)00108-3; Lemischka IR, 1997, STEM CELLS, V15, P63, DOI 10.1002/stem.5530150810; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; MORRISON SJ, 1994, IMMUNITY, V1, P661, DOI 10.1016/1074-7613(94)90037-X; Morrison SJ, 1995, ANNU REV CELL DEV BI, V11, P35, DOI 10.1146/annurev.cb.11.110195.000343; Morrison SJ, 1997, DEVELOPMENT, V124, P1929; Rebel VI, 2002, P NATL ACAD SCI USA, V99, P14789, DOI 10.1073/pnas.232568499; Ribar TJ, 2000, J NEUROSCI, V20, DOI 10.1523/JNEUROSCI.20-22-j0004.2000; Riccio A, 1999, SCIENCE, V286, P2358, DOI 10.1126/science.286.5448.2358; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; Wagers AJ, 2004, CELL, V116, P639, DOI 10.1016/S0092-8674(04)00208-9; Wang SL, 2001, CELL GROWTH DIFFER, V12, P351; Wei F, 2002, NAT NEUROSCI, V5, P573, DOI 10.1038/nn0602-855; Wilson BE, 1996, MOL CELL BIOL, V16, P5546; Wu JY, 2000, J BIOL CHEM, V275, P7994, DOI 10.1074/jbc.275.11.7994; Wu JY, 2000, NAT GENET, V25, P448, DOI 10.1038/78153; Yuan YZ, 2004, NAT CELL BIOL, V6, P436, DOI 10.1038/ncb1126; Zeng H, 2004, EMBO J, V23, P4116, DOI 10.1038/sj.emboj.7600419	39	59	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	2005	280	39					33101	33108		10.1074/jbc.M505208200	http://dx.doi.org/10.1074/jbc.M505208200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	966YG	16020540	hybrid			2022-12-25	WOS:000232058100003
J	Cepero, E; King, AM; Coffey, LM; Perez, RG; Boise, LH				Cepero, E; King, AM; Coffey, LM; Perez, RG; Boise, LH			Caspase-9 and effector caspases have sequential and distinct effects on mitochondria	ONCOGENE			English	Article						mitochondria; apoptosis; caspase; ROS	CYTOCHROME-C RELEASE; PERMEABILITY TRANSITION PORE; BCL-2 FAMILY-MEMBERS; INDUCED APOPTOSIS; COMPLEX-I; MEMBRANE; NECROSIS; DEATH; BAX; INHIBITION	Proapoptotic Bcl-2 family members alter mitochondrial permeability resulting in the release of apoptogenic factors that initiate a caspase cascade. These changes are well described; however, the effects of caspases on mitochondrial function are less well characterized. Here we describe the consequence of caspase-9 and effector caspase inhibition on mitochondrial physiology during intrinsic cell death. Caspase inhibition prevents the complete loss of mitochondrial membrane potential without affecting cytochrome c release. When effector caspases are inhibited, mitochondria become uncoupled and produce reactive oxygen species. Interestingly, the effector caspase-mediated depolarization of the mitochondria occurs independent of the activity of complexes I-IV of the electron transport chain. In contrast, caspase-9 inhibition prevents mitochondrial uncoupling and ROS production and allows for continued electron transport despite the release of cytochrome c. Taken together, these data suggest that activated caspase-9 prevents the accessibility of cytochrome c to complex III, resulting in the production of reactive oxygen species, and that effector caspases may depolarize mitochondria to terminate ROS production and preserve an apoptotic phenotype.	Univ Miami, Sch Med, Dept Microbiol & Immunol, Miami, FL 33101 USA	University of Miami	Boise, LH (corresponding author), Univ Miami, Sch Med, Dept Microbiol & Immunol, POB 016960 R-138,RMSB Room 3045A,1600 NW 10th Ave, Miami, FL 33101 USA.	lboise@med.miami.edu	Perez, Ruth G./AAK-9844-2020; Boise, Lawrence/AAD-2314-2019	Boise, Lawrence/0000-0001-9436-8815	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065813, F31GM020435] Funding Source: NIH RePORTER; NIGMS NIH HHS [F31 GM20435, R01 GM65813] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barrientos A, 1998, J BIOL CHEM, V273, P14210, DOI 10.1074/jbc.273.23.14210; Borner C, 1999, CELL DEATH DIFFER, V6, P497, DOI 10.1038/sj.cdd.4400525; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Bratton SB, 2001, CELL DEATH DIFFER, V8, P425, DOI 10.1038/sj.cdd.4400834; Burlacu A, 2001, CELL TISSUE RES, V306, P409, DOI 10.1007/s004410100424; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; Chandel NS, 1999, FEBS LETT, V454, P173, DOI 10.1016/S0014-5793(99)00783-8; Chandra J, 2000, FREE RADICAL BIO MED, V29, P323, DOI 10.1016/S0891-5849(00)00302-6; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Deshmukh M, 2000, J CELL BIOL, V150, P131, DOI 10.1083/jcb.150.1.131; Fearnhead HO, 1997, GENE DEV, V11, P1266, DOI 10.1101/gad.11.10.1266; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Higuchi M, 1998, ONCOGENE, V17, P2753, DOI 10.1038/sj.onc.1202211; Higuchi Y, 2002, ARCH BIOCHEM BIOPHYS, V400, P133, DOI 10.1006/abbi.2002.2784; Johnson BW, 2000, J BIOL CHEM, V275, P31546, DOI 10.1074/jbc.M001363200; Kim TH, 2000, J BIOL CHEM, V275, P39474, DOI 10.1074/jbc.M003370200; Kluck RM, 1999, J CELL BIOL, V147, P809, DOI 10.1083/jcb.147.4.809; Kokoszka JE, 2004, NATURE, V427, P461, DOI 10.1038/nature02229; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Martinou I, 1999, J CELL BIOL, V144, P883, DOI 10.1083/jcb.144.5.883; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; Marzo I, 1998, FEBS LETT, V427, P198, DOI 10.1016/S0014-5793(98)00424-4; Mootha VK, 2001, EMBO J, V20, P661, DOI 10.1093/emboj/20.4.661; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Raha S, 2001, AM J MED GENET, V106, P62, DOI 10.1002/ajmg.1398; Rathmell JC, 2000, MOL CELL, V6, P683, DOI 10.1016/S1097-2765(00)00066-6; Rego AC, 2001, CELL DEATH DIFFER, V8, P995, DOI 10.1038/sj.cdd.4400916; Ricci JE, 2004, CELL, V117, P773, DOI 10.1016/j.cell.2004.05.008; Ricci JE, 2003, J CELL BIOL, V160, P65, DOI 10.1083/jcb.200208089; Ryan CA, 2002, BIOCHEM J, V366, P595, DOI 10.1042/BJ20020863; Samali A, 1999, BIOCHEM BIOPH RES CO, V255, P6, DOI 10.1006/bbrc.1998.0139; Saraste M, 1999, SCIENCE, V283, P1488, DOI 10.1126/science.283.5407.1488; Scorrano L, 2002, DEV CELL, V2, P55, DOI 10.1016/S1534-5807(01)00116-2; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P577, DOI 10.1073/pnas.97.2.577; Vander Heiden MG, 2001, MOL CELL BIOL, V21, P5899, DOI 10.1128/MCB.21.17.5899-5912.2001; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; von Ahsen O, 2000, J CELL BIOL, V150, P1027, DOI 10.1083/jcb.150.5.1027; Waterhouse NJ, 2001, J CELL BIOL, V153, P319, DOI 10.1083/jcb.153.2.319; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X	47	33	37	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 22	2005	24	42					6354	6366		10.1038/sj.onc.1208793	http://dx.doi.org/10.1038/sj.onc.1208793			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	966RI	16007191				2022-12-25	WOS:000232038200003
J	Lingbeck, JM; Trausch-Azar, JS; Ciechanover, A; Schwartz, AL				Lingbeck, JM; Trausch-Azar, JS; Ciechanover, A; Schwartz, AL			E12 and E47 modulate cellular localization and proteasome-mediated degradation of MyoD and Id1	ONCOGENE			English	Article						E12; E47; Id1; MyoD; ubiquitin proteasome degradation	KAPPA-B-ALPHA; NUCLEAR-LOCALIZATION; DNA-BINDING; PROTEINS; PHOSPHORYLATION	Programs of tissue differentiation are likely controlled by factors regulating gene expression and protein degradation. In muscle, the degradation of the muscle transcription factor MyoD and its inhibitor Id1 occurs via the ubiquitin-proteasome system. E12 and E47, splice products of the E2A gene, interact with MyoD to activate transcription of the muscle program and are also degraded by the ubiquitin-proteasome system (t(1/2) = similar to 6 h). E12 and E47 each contain two regions of basic amino acids, which, when mutated, lead to cytoplasmic accumulation of the proteins. These NLS mutants ( E12(NLS), E47(NLS)) are degraded with a half-life similar to the wild-type proteins. In nonmuscle cells, cotransfection of either E12 or E47 with MyoD extended MyoD's half-life from similar to 1 to similar to 4h. In addition, cotransfection of either E12 or E47 with Id1 led to a marked reduction in Id1's degradation rate from t(1/2) of similar to 1 to similar to 8 h. Furthermore, the cotransfection of NLS deficient mutants of MyoD or Id1 with E12 or E47 resulted in altered intracellular localization of the proteins largely dependent upon the E12 or E47 moiety. Cotransfection of wild-type MyoD or Id1 with NLS deficient mutants of E12 or E47 also led to an altered intracellular localization of MyoD and Id1. These results demonstrate in vivo that E12 and E47 modulate both MyoD and Id1 degradation and may have implications for the physiological regulation of muscle development.	Washington Univ, Sch Med, Edward Mallinckrodt Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; St Louis Childrens Hosp, St Louis, MO 63110 USA; Technion Israel Inst Technol, Fac Med, Dept Biochem, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Fac Med, Rappaport Inst Res Med Sci, IL-31096 Haifa, Israel	Washington University (WUSTL); Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL); Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Schwartz, AL (corresponding author), Washington Univ, Sch Med, Edward Mallinckrodt Dept Pediat, 660 S Euclid Ave,CB 8116, St Louis, MO 63110 USA.	schwartz@kids.wustl.edu	Ciechanover, Aaron J/C-9166-2017					BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Breitschopf K, 1998, EMBO J, V17, P5964, DOI 10.1093/emboj/17.20.5964; Collavoli A, 2003, J MOL CELL CARDIOL, V35, P1191, DOI 10.1016/S0022-2828(03)00231-1; Deed RW, 1996, J BIOL CHEM, V271, P23603, DOI 10.1074/jbc.271.39.23603; Floyd ZE, 2001, J BIOL CHEM, V276, P22468, DOI 10.1074/jbc.M009388200; Fukuchi M, 2001, MOL BIOL CELL, V12, P1431, DOI 10.1091/mbc.12.5.1431; Huggins GS, 1999, J BIOL CHEM, V274, P28690, DOI 10.1074/jbc.274.40.28690; Kho CJ, 1997, J BIOL CHEM, V272, P3845, DOI 10.1074/jbc.272.6.3845; Langlands K, 1997, J BIOL CHEM, V272, P19785, DOI 10.1074/jbc.272.32.19785; Lingbeck JM, 2003, J BIOL CHEM, V278, P1817, DOI 10.1074/jbc.M208815200; NAGATA Y, 1995, BIOCHEM BIOPH RES CO, V207, P916, DOI 10.1006/bbrc.1995.1273; Rodriguez MS, 1999, J BIOL CHEM, V274, P9108, DOI 10.1074/jbc.274.13.9108; Sachdev S, 2000, MOL CELL BIOL, V20, P1571, DOI 10.1128/MCB.20.5.1571-1582.2000; Song A, 1998, MOL CELL BIOL, V18, P4994, DOI 10.1128/MCB.18.9.4994; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; Tintignac LA, 2005, J BIOL CHEM, V280, P2847, DOI 10.1074/jbc.M411346200; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Trausch-Azar JS, 2004, J BIOL CHEM, V279, P32614, DOI 10.1074/jbc.M403794200; Yagita K, 2002, EMBO J, V21, P1301, DOI 10.1093/emboj/21.6.1301	19	43	48	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 22	2005	24	42					6376	6384		10.1038/sj.onc.1208789	http://dx.doi.org/10.1038/sj.onc.1208789			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	966RI	16007194				2022-12-25	WOS:000232038200005
J	Celil, AB; Campbell, PG				Celil, AB; Campbell, PG			BMP-2 and insulin-like growth factor-I mediate osterix (Osx) expression in human mesenchymal stem cells via the MAPK and protein kinase D signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-MU; OSTEOBLAST DIFFERENTIATION; TRANSCRIPTION FACTOR; ENDOTHELIAL-CELLS; GENE-EXPRESSION; HOMOLOGY DOMAIN; KAPPA-B; ACTIVATION; BINDING; RAS	Genetic studies place the transcription factor Osterix (Osx) downstream of Runx2, but limited information is available about Osx regulation during osteoblastic differentiation. An important role for bone morphogenetic protein-2 (BMP-2) and insulin-like growth factor-I (IGF-I) on Osx expression and the requirement for p38 for the BMP-2-mediated effect was reported previously by our group. In this study, we continued to investigate the molecular mechanisms by which BMP-2 and IGF-1 regulate Osx expression during osteoblast lineage progression. IGF-I-mediated Osx expression required all three MAPK components (Erk, p38, and JNK), whereas BMP-2 required p38 and JNK signaling. As a common mediator of growth factor signaling, we also investigated the involvement of protein kinase C/D (PKC/D) signaling. BMP-2- and IGF-I-mediated Osx expression was blocked in response to a PKD inhibitor. A selective inhibitor of conventional PKCs had no effect on the BMP-2-mediated Osx expression. BMP-2 and IGF-I induced a selective phosphorylation of PKD, and PKD was required for mineralization. PKC/D and MAPK signaling also mediate Runx2 activity. Therefore, to document the implication for Runx2 in Osx regulation, we blocked Runx2 activity using a dominant negative Runx2 construct and an ubiquitination mediator for Runx2 degradation. We showed that blocking Runx2 activity inhibited the BMP-2-mediated induction of Osx. These studies implicated that multiple signaling pathways mediate Osx, a critical gene for osteoblast differentiation and bone formation. In addition to Runx2, other signaling components may be necessary to regulate Osx during osteoblast lineage progression.	Carnegie Mellon Univ, Inst Complex Engineered Syst, Pittsburgh, PA 15213 USA; Carnegie Mellon Univ, Dept Biol Sci, Pittsburgh, PA 15213 USA	Carnegie Mellon University; Carnegie Mellon University	Campbell, PG (corresponding author), Carnegie Mellon Univ, Inst Complex Engineered Syst, 1213 Hamburg Hall,5000 Forbes Ave, Pittsburgh, PA 15213 USA.	pcampbel@cs.cmu.edu						Akiyama H, 1999, J CELL PHYSIOL, V181, P169, DOI 10.1002/(SICI)1097-4652(199910)181:1<169::AID-JCP18>3.0.CO;2-5; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Brandlin I, 2002, J BIOL CHEM, V277, P45451, DOI 10.1074/jbc.M205299200; Cai H, 1997, MOL CELL BIOL, V17, P732, DOI 10.1128/MCB.17.2.732; Celil AB, 2005, J CELL BIOCHEM, V95, P518, DOI 10.1002/jcb.20429; Chang MS, 2005, CELL SIGNAL, V17, P299, DOI 10.1016/j.cellsig.2004.07.008; Cheng JJ, 2001, J BIOL CHEM, V276, P31368, DOI 10.1074/jbc.M011317200; Cheng SL, 2003, J BIOL CHEM, V278, P45969, DOI 10.1074/jbc.M306972200; Cook SJ, 1997, J BIOL CHEM, V272, P13309, DOI 10.1074/jbc.272.20.13309; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Gschwendt M, 1997, J BIOL CHEM, V272, P20742, DOI 10.1074/jbc.272.33.20742; Guicheux J, 2003, J BONE MINER RES, V18, P2060, DOI 10.1359/jbmr.2003.18.11.2060; HEIDENREICH KA, 1993, J BIOL CHEM, V268, P14663; Jadlowiec J, 2004, J BIOL CHEM, V279, P53323, DOI 10.1074/jbc.M404934200; Johannes FJ, 1998, EUR J BIOCHEM, V257, P47, DOI 10.1046/j.1432-1327.1998.2570047.x; Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; Kim HJ, 2003, J BIOL CHEM, V278, P319, DOI 10.1074/jbc.M203750200; Kooijman R, 2003, CELL SIGNAL, V15, P1091, DOI 10.1016/S0898-6568(03)00069-X; Kuriyama M, 1996, J BIOL CHEM, V271, P607, DOI 10.1074/jbc.271.2.607; Lee MH, 2003, BIOCHEM BIOPH RES CO, V309, P689, DOI 10.1016/j.bbrc.2003.08.058; Lemonnier J, 2004, J BIOL CHEM, V279, P259, DOI 10.1074/jbc.M308665200; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Linnemann T, 1999, J BIOL CHEM, V274, P13556, DOI 10.1074/jbc.274.19.13556; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; Matthews SA, 1999, J BIOL CHEM, V274, P26543, DOI 10.1074/jbc.274.37.26543; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; Milona M, 2003, BMC GENOMICS, V4, DOI 10.1186/1471-2164-4-43; Murakami G, 2003, MOL BIOL CELL, V14, P2809, DOI 10.1091/mbc.E02-07-0441; Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092-8674(01)00622-5; Nakashima K, 2003, TRENDS GENET, V19, P458, DOI 10.1016/S0168-9525(03)00176-8; Peron P, 2001, J BIOL CHEM, V276, P10524, DOI 10.1074/jbc.M005919200; Prestle J, 1996, J CELL BIOL, V134, P1401, DOI 10.1083/jcb.134.6.1401; Qiang YW, 2004, BLOOD, V103, P301, DOI 10.1182/blood-2003-06-2066; Qiao M, 2004, J BIOL CHEM, V279, P42709, DOI 10.1074/jbc.M404480200; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Rykx A, 2003, FEBS LETT, V546, P81, DOI 10.1016/S0014-5793(03)00487-3; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Selvamurugan N, 2004, J BIOL CHEM, V279, P19327, DOI 10.1074/jbc.M314048200; Sudhakar S, 2001, BIOCHEM BIOPH RES CO, V289, P616, DOI 10.1006/bbrc.2001.6033; Thomas T, 1999, ENDOCRINOLOGY, V140, P5036, DOI 10.1210/en.140.11.5036; Tintut Y, 1999, J BIOL CHEM, V274, P28875, DOI 10.1074/jbc.274.41.28875; TRANQUE PA, 1992, ENDOCRINOLOGY, V131, P1948, DOI 10.1210/en.131.4.1948; Umayahara Y, 2002, J BIOL CHEM, V277, P15261, DOI 10.1074/jbc.M110827200; Van Lint J, 2002, INT J BIOCHEM CELL B, V34, P577, DOI 10.1016/S1357-2725(01)00163-7; VANLINT J, 1995, J BIOL CHEM, V270, P1455, DOI 10.1074/jbc.270.3.1455; Waldron RT, 1999, J BIOL CHEM, V274, P9224, DOI 10.1074/jbc.274.14.9224; Waldron RT, 2003, J BIOL CHEM, V278, P154, DOI 10.1074/jbc.M208075200; Walsh PT, 2002, IMMUNOLOGY, V107, P461, DOI 10.1046/j.1365-2567.2002.01525.x; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; Xiao GZ, 2000, J BIOL CHEM, V275, P4453, DOI 10.1074/jbc.275.6.4453; Yagi K, 2003, J CELL BIOCHEM, V88, P1077, DOI 10.1002/jcb.10467; Yamamoto T, 1999, J BIOCHEM-TOKYO, V126, P799, DOI 10.1093/oxfordjournals.jbchem.a022519; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhao M, 2004, J BIOL CHEM, V279, P12854, DOI 10.1074/jbc.M313294200; Zhao M, 2003, J BIOL CHEM, V278, P27939, DOI 10.1074/jbc.M304132200	57	251	270	3	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	2005	280	36					31353	31359		10.1074/jbc.M503845200	http://dx.doi.org/10.1074/jbc.M503845200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	961LZ	16000303	hybrid			2022-12-25	WOS:000231665200004
J	Durand, E; Michel, G; Voulhoux, R; Kurner, J; Bernadac, A; Filloux, A				Durand, E; Michel, G; Voulhoux, R; Kurner, J; Bernadac, A; Filloux, A			XcpX controls biogenesis of the Pseudomonas aeruginosa XcpT-containing pseudopilus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-SECRETION; IDENTIFICATION; GENES; APPARATUS; PILI; COMPONENTS; MEMBRANE; CLONING; LOCALIZATION; TRANSPORT	Pseudomonas aeruginosa is an opportunistic Gram-negative pathogen equipped with multiple secretion systems. The type II secretion machinery (Xcp secreton) is involved in the release of toxins and enzymes. The Xcp secreton is a multiprotein complex, and most of its components share homology with proteins involved in type IV pili biogenesis. Among them, the XcpT-X pseudopilins possess characteristics of the major constituent of the type IV pili, the pilin PilA. We have shown previously that XcpT can be assembled in a multifibrillar structure that was called the pseudopilus. By using two different microscopic approaches, we show here that the pseudopili are preferentially isolated fibers rather than tight bundles. Moreover, none of the other four pseudopilins are able to form a pseudopilus, suggesting that the assembly of such a structure is a unique property of XcpT. Moreover, we show that 5 of the 12 Xcp proteins are not required for pseudopilus biogenesis, whereas they are for type II secretion. Most interestingly, we showed that one pseudopilin, XcpX, controls the assembly of XcpT into a pseudopilus. Indeed, when the number of XcpX subunits increases, the length of the pseudopilus decreases. Conversely, in the absence of XcpX, the pseudopilus length is abnormally long. Our results indicate that XcpT and XcpX directly interact with each other. Furthermore, this interaction induces a clear destabilization of XcpT. The interaction between XcpT and XcpX could be part of the molecular mechanism underlying the dynamic control of pseudopilus elongation, which could be crucial for type II-dependent protein secretion.	CNRS, IBSM, UPR9027, Lab Ingn Syst Macromol, F-13402 Marseille, France; Max Planck Inst Biochem, Dept Struct Biol, D-82152 Martinsried, Germany	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Max Planck Society	Filloux, A (corresponding author), CNRS, IBSM, UPR9027, Lab Ingn Syst Macromol, 31 Chem Joseph Aiguier, F-13402 Marseille, France.	filloux@ibsm.cnrs-mrs.fr	Voulhoux, Rome/AAT-5333-2021; Durand, Eric/E-6739-2017	Durand, Eric/0000-0002-0577-8220				Alm RA, 1996, MOL MICROBIOL, V22, P161; Ball G, 2002, MOL MICROBIOL, V43, P475, DOI 10.1046/j.1365-2958.2002.02759.x; Ball G, 1999, J BACTERIOL, V181, P382, DOI 10.1128/JB.181.2.382-388.1999; BALLY M, 1992, MOL MICROBIOL, V6, P1121, DOI 10.1111/j.1365-2958.1992.tb01550.x; Bitter W, 1998, MOL MICROBIOL, V27, P209, DOI 10.1046/j.1365-2958.1998.00677.x; Bleves S, 1996, J BACTERIOL, V178, P4297, DOI 10.1128/jb.178.14.4297-4300.1996; Bleves S, 1998, MOL MICROBIOL, V27, P31, DOI 10.1046/j.1365-2958.1998.00653.x; DUBOCHET J, 1988, Q REV BIOPHYS, V21, P129, DOI 10.1017/S0033583500004297; Durand E, 2003, J BACTERIOL, V185, P2749, DOI 10.1128/JB.185.9.2749-2758.2003; Duthy TG, 2002, J BACTERIOL, V184, P1065, DOI 10.1128/jb.184.4.1065-1077.2002; FIGURSKI DH, 1979, P NATL ACAD SCI USA, V76, P1648, DOI 10.1073/pnas.76.4.1648; Filloux A, 2004, BBA-MOL CELL RES, V1694, P163, DOI 10.1016/j.bbamcr.2004.05.003; FURSTE JP, 1986, GENE, V48, P119, DOI 10.1016/0378-1119(86)90358-6; GEBHART W, 1979, BRIT J VENER DIS, V55, P83; Govan JRW, 1996, MICROBIOL REV, V60, P539, DOI 10.1128/MMBR.60.3.539-574.1996; HERRERO M, 1990, J BACTERIOL, V172, P6557, DOI 10.1128/jb.172.11.6557-6567.1990; KANIGA K, 1991, GENE, V109, P137, DOI 10.1016/0378-1119(91)90599-7; Kohler R, 2004, MOL MICROBIOL, V54, P647, DOI 10.1111/j.1365-2958.2004.04307.x; KOVACH ME, 1994, BIOTECHNIQUES, V16, P800; Lee MS, 2005, J BIOL CHEM, V280, P4585, DOI 10.1074/jbc.M409362200; Ludtke SJ, 1999, J STRUCT BIOL, V128, P82, DOI 10.1006/jsbi.1999.4174; Martinez A, 1998, MOL MICROBIOL, V28, P1235, DOI 10.1046/j.1365-2958.1998.00888.x; Merz AJ, 2000, NATURE, V407, P98, DOI 10.1038/35024105; Michel G, 1998, MICROBIOL-SGM, V144, P3379, DOI 10.1099/00221287-144-12-3379; MORALES VM, 1991, GENE, V97, P39, DOI 10.1016/0378-1119(91)90007-X; NUNN DN, 1991, P NATL ACAD SCI USA, V88, P3281, DOI 10.1073/pnas.88.8.3281; NUNN DN, 1993, J BACTERIOL, V175, P4375, DOI 10.1128/JB.175.14.4375-4382.1993; PARGE HE, 1995, NATURE, V378, P32, DOI 10.1038/378032a0; Planet PJ, 2001, P NATL ACAD SCI USA, V98, P2503, DOI 10.1073/pnas.051436598; Resch GP, 2002, J CELL SCI, V115, P1877; Robert V, 2002, J BACTERIOL, V184, P1779, DOI 10.1128/JB.184.6.1779-1782.2002; Sambrook J, 1989, MOL CLONING; Sauer FG, 2004, BBA-MOL CELL RES, V1694, P259, DOI 10.1016/j.bbamcr.2004.02.010; Sauer FG, 2002, CELL, V111, P543, DOI 10.1016/S0092-8674(02)01050-4; Sauvonnet N, 2000, EMBO J, V19, P2221, DOI 10.1093/emboj/19.10.2221; SIMPSON DA, 1992, INFECT IMMUN, V60, P3771, DOI 10.1128/IAI.60.9.3771-3779.1992; Stover CK, 2000, NATURE, V406, P959, DOI 10.1038/35023079; SWANSON J, 1971, J EXP MED, V134, P886, DOI 10.1084/jem.134.4.886; TODD WJ, 1984, J BACTERIOL, V159, P312, DOI 10.1128/JB.159.1.312-320.1984; Vasseur P, 2005, MICROBIOL-SGM, V151, P985, DOI 10.1099/mic.0.27410-0; Vignon G, 2003, J BACTERIOL, V185, P3416, DOI 10.1128/JB.185.11.3416-3428.2003; Voulhoux R, 2001, EMBO J, V20, P6735, DOI 10.1093/emboj/20.23.6735; Wolfgang M, 2000, EMBO J, V19, P6408, DOI 10.1093/emboj/19.23.6408	43	65	66	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	2005	280	36					31378	31389		10.1074/jbc.M505812200	http://dx.doi.org/10.1074/jbc.M505812200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	961LZ	16012171	hybrid			2022-12-25	WOS:000231665200007
J	Gu, PL; Morgan, DH; Sattar, M; Xu, XP; Wagner, R; Raviscioni, M; Lichtarge, O; Cooney, AJ				Gu, PL; Morgan, DH; Sattar, M; Xu, XP; Wagner, R; Raviscioni, M; Lichtarge, O; Cooney, AJ			Evolutionary trace-based peptides identify a novel asymmetric interaction that mediates oligomerization in nuclear receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING DOMAIN; RETINOID-X-RECEPTOR; DNA-BINDING; CRYSTAL-STRUCTURE; HORMONE-RECEPTORS; MOLECULAR-BASIS; DIFFERENTIAL EXPRESSION; RESPONSE ELEMENTS; STRUCTURAL BASIS; RXR TETRAMERS	Germ cell nuclear factor ( GCNF) is an orphan nuclear receptor that plays important roles in development and reproduction, by repressing the expression of essential genes such as Oct4, GDF9, and BMP15, through binding to DR0 elements. Surprisingly, whereas recombinant GCNF binds to DR0 sequences as a homodimer, endogenous GCNF does not exist as a homodimer but rather as part of a large complex termed the transiently retinoid-induced factor ( TRIF). Here, we use evolutionary trace ( ET) analysis to design mutations and peptides that probe the molecular basis for the formation of this unusual complex. We find that GCNF homodimerization and TRIF complex formation are DNA-dependent, and ET suggests that dimerization involves key functional sites on both helix 3 and helix 11, which are located on opposing surfaces of the ligand binding domain. Targeted mutations in either helix of GCNF disrupt the formation of both the homodimer and the endogenous TRIF complex. Moreover, peptide mimetics of both of these ET-determined sites inhibit dimerization and TRIF complex formation. This suggests that a novel helix 3-helix 11 heterotypic interaction mediates GCNF interaction and would facilitate oligomerization. Indeed, it was determined that the endogenous TRIF complex is composed of a GCNF oligomer. These findings shed light on an evolutionarily selected mechanism that reveals the unusual DNA-binding, dimerization, and oligomerization properties of GCNF.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Grad Program Struct & Computat Biol & Mol Biophys, Houston, TX 77030 USA; Baylor Coll Med, WM Keck Ctr Computat & Struct Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Cooney, AJ (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza, Houston, TX 77030 USA.	acooney@bcm.tmc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066099] Funding Source: NIH RePORTER; NIDDK NIH HHS [U19DK6234-01] Funding Source: Medline; NIGMS NIH HHS [R01 GM066099] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aarnisalo P, 2002, J BIOL CHEM, V277, P35118, DOI 10.1074/jbc.M201707200; ALLAN GF, 1992, J BIOL CHEM, V267, P19513; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269; Barnea E, 2000, J BIOL CHEM, V275, P6608, DOI 10.1074/jbc.275.9.6608; Bauer UM, 1998, FEBS LETT, V439, P208, DOI 10.1016/S0014-5793(98)01327-1; Bledsoe RK, 2002, CELL, V110, P93, DOI 10.1016/S0092-8674(02)00817-6; Bogan AA, 2000, J MOL BIOL, V302, P831, DOI 10.1006/jmbi.2000.4099; Borgmeyer U, 1997, EUR J BIOCHEM, V244, P120, DOI 10.1111/j.1432-1033.1997.00120.x; Bourguet W, 2000, MOL CELL, V5, P289, DOI 10.1016/S1097-2765(00)80424-4; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; BURBACH JPH, 1994, J BIOL CHEM, V269, P15046; BUTLER AJ, 1995, NUCLEIC ACIDS RES, V23, P4143, DOI 10.1093/nar/23.20.4143; CHEN F, 1994, MOL ENDOCRINOL, V8, P1434, DOI 10.1210/me.8.10.1434; Chen ZP, 1998, J MOL BIOL, V275, P55, DOI 10.1006/jmbi.1997.1413; Cooney AJ, 1998, BIOCHEM BIOPH RES CO, V245, P94, DOI 10.1006/bbrc.1998.8391; COONEY AJ, 1992, MOL CELL BIOL, V12, P4153, DOI 10.1128/MCB.12.9.4153; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Dhe-Paganon S, 2002, J BIOL CHEM, V277, P37973, DOI 10.1074/jbc.C200420200; Egea PF, 2000, EMBO J, V19, P2592, DOI 10.1093/emboj/19.11.2592; Fuhrmann G, 2001, DEV CELL, V1, P377, DOI 10.1016/S1534-5807(01)00038-7; Fuhrmann G, 1999, CELL MOL BIOL, V45, P717; Gampe RT, 2000, MOL CELL, V5, P545, DOI 10.1016/S1097-2765(00)80448-7; Gampe RT, 2000, GENE DEV, V14, P2229, DOI 10.1101/gad.802300; Greschik H, 1999, MOL CELL BIOL, V19, P690; Greschik I, 2003, CURR TOP MED CHEM, V3, P1573, DOI 10.2174/1568026033451736; Gronemeyer H, 2004, NAT REV DRUG DISCOV, V3, P950, DOI 10.1038/nrd1551; Heinzer C, 1998, BIOL CHEM, V379, P349, DOI 10.1515/bchm.1998.379.3.349; Hentschke M, 2002, EUR J BIOCHEM, V269, P4086, DOI 10.1046/j.1432-1033.2002.03102.x; Hummelke GC, 1998, MOL REPROD DEV, V50, P396, DOI 10.1002/(SICI)1098-2795(199808)50:4<396::AID-MRD3>3.0.CO;2-D; Ikeda Y, 1996, ACTA PAEDIATR JAPON, V38, P412; KERSTEN S, 1995, P NATL ACAD SCI USA, V92, P8645, DOI 10.1073/pnas.92.19.8645; Kersten S, 1997, J BIOL CHEM, V272, P29759, DOI 10.1074/jbc.272.47.29759; Khorasanizadeh S, 2001, TRENDS BIOCHEM SCI, V26, P384, DOI 10.1016/S0968-0004(01)01800-X; Kumar R, 1999, STEROIDS, V64, P310, DOI 10.1016/S0039-128X(99)00014-8; Lan ZJ, 2003, EMBO J, V22, P4070, DOI 10.1093/emboj/cdg405; Lee WY, 2002, BIOCHEMISTRY-US, V41, P2500, DOI 10.1021/bi011764+; Lichtarge O, 1997, J MOL BIOL, V274, P325, DOI 10.1006/jmbi.1997.1395; Lichtarge O, 1996, J MOL BIOL, V257, P342, DOI 10.1006/jmbi.1996.0167; Madabushi S, 2004, J BIOL CHEM, V279, P8126, DOI 10.1074/jbc.M312671200; Madabushi S, 2002, J MOL BIOL, V316, P139, DOI 10.1006/jmbi.2001.5327; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Mihalek I, 2004, J MOL BIOL, V336, P1265, DOI 10.1016/j.jmb.2003.12.078; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; Munoz V, 1997, BIOPOLYMERS, V41, P495, DOI 10.1002/(SICI)1097-0282(19970415)41:5<495::AID-BIP2>3.3.CO;2-6; Quan XJ, 2004, DEVELOPMENT, V131, P1679, DOI 10.1242/dev.01055; RIBEIRO RCJ, 1995, ANNU REV MED, V46, P443, DOI 10.1146/annurev.med.46.1.443; Robinson-Rechavi M, 2003, J CELL SCI, V116, P585, DOI 10.1242/jcs.00247; Schmitz TP, 1999, BBA-GENE STRUCT EXPR, V1446, P173, DOI 10.1016/S0167-4781(99)00079-2; Seol W, 1997, MOL CELL BIOL, V17, P7126, DOI 10.1128/MCB.17.12.7126; Shan L, 2004, MOL CELL, V16, P907, DOI 10.1016/S1097-2765(04)00728-2; Suino K, 2004, MOL CELL, V16, P893, DOI 10.1016/j.molcel.2004.11.036; Susens U, 1997, DEV NEUROSCI-BASEL, V19, P410, DOI 10.1159/000111238; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Whitfield GK, 1999, J CELL BIOCHEM, P110; Xu RX, 2004, MOL CELL, V16, P919, DOI 10.1016/j.molcel.2004.11.042; Yan ZH, 1997, J BIOL CHEM, V272, P10565; Yan ZJ, 2000, J BIOL CHEM, V275, P35077, DOI 10.1074/jbc.M005566200; Yao H, 2003, J MOL BIOL, V326, P255, DOI 10.1016/S0022-2836(02)01336-0; Yasmin R, 2004, J MOL BIOL, V343, P327, DOI 10.1016/j.jmb.2004.08.070; ZENG ZM, 1994, ENDOCRINOLOGY, V135, P248, DOI 10.1210/en.135.1.248; Zhang YL, 1998, MOL REPROD DEV, V50, P93, DOI 10.1002/(SICI)1098-2795(199805)50:1&lt;93::AID-MRD12&gt;3.0.CO;2-Z; Zhang ZD, 2004, GENOME RES, V14, P580, DOI 10.1101/gr.2160004	63	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	2005	280	36					31818	31829		10.1074/jbc.M501924200	http://dx.doi.org/10.1074/jbc.M501924200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	961LZ	15994320	Green Published, hybrid			2022-12-25	WOS:000231665200061
J	Koyanagi, M; Baguet, A; Martens, J; Margueron, R; Jenuwein, T; Bix, M				Koyanagi, M; Baguet, A; Martens, J; Margueron, R; Jenuwein, T; Bix, M			EZH2 and histone 3 trimethyl lysine 27 associated with Il4 and Il13 gene silencing in T(H)1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IL-4 GENE; METHYLATION; H3; CHROMATIN; DIFFERENTIATION; EXPRESSION; STATES; LOCUS	Differentiation of naive CD4 T cells toward the T helper 1 (T(H)1) and T helper 2 (T(H)2) fates involves the transcriptional repression and enhancement, respectively, of Il4 and Il13, adjacent chromosome 11 genes encoding the canonical T(H)2 cytokines interleukin-4 and interleukin-13. Proper execution of this developmental fate choice during immune responses is critical to host defense and, when misregulated, leads to susceptibility to infectious microbes and to allergic and autoimmune diseases. Here, using chromatin immunoprecipitation and real time reverse transcription PCR we identify the Polycomb family histone methyltransferase EZH2 as the enzyme responsible for methylating lysine 27 of histone H3 at the Il4-Il13 locus of T(H)1 but not T(H)2 cells, implicating EZH2 in the mechanism of Il4 and Il13 transcriptional silencing.	Univ Washington, Dept Immunol, Seattle, WA 98195 USA; Res Inst Mol Pathol, A-1030 Vienna, Austria; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Div Nucl Acids Enzymol, Piscataway, NJ 08854 USA	University of Washington; University of Washington Seattle; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Rutgers State University New Brunswick; Rutgers State University Medical Center	Bix, M (corresponding author), Univ Washington, Dept Immunol, 1959 NE Pacific St,HSC 16071, Seattle, WA 98195 USA.	mbix@u.washington.edu	Martens, Joost/D-4966-2012; Margueron, Raphael F/B-9996-2015	Martens, Joost/0000-0003-2008-6537; Margueron, Raphael F/0000-0002-9093-7977; Bix, Mark/0000-0003-4617-0497	NIAID NIH HHS [AI48636] Funding Source: Medline; NIGMS NIH HHS [GM37120] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI048636, R01AI048636] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM037120, R01GM037120] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agarwal S, 1998, IMMUNITY, V9, P765, DOI 10.1016/S1074-7613(00)80642-1; Ansel KM, 2004, NAT IMMUNOL, V5, P1251, DOI 10.1038/ni1135; Baguet A, 2004, P NATL ACAD SCI USA, V101, P11410, DOI 10.1073/pnas.0403334101; Cao BH, 2003, NAT CELL BIOL, V5, P640, DOI 10.1038/ncb1008; Cao R, 2004, CURR OPIN GENET DEV, V14, P155, DOI 10.1016/j.gde.2004.02.001; Chen H, 2005, J BIOL CHEM, V280, P22437, DOI 10.1074/jbc.M501379200; Grogan JL, 2003, J IMMUNOL, V171, P6672, DOI 10.4049/jimmunol.171.12.6672; Khorasanizadeh S, 2004, CELL, V116, P259, DOI 10.1016/S0092-8674(04)00044-3; Kirmizis A, 2004, GENE DEV, V18, P1592, DOI 10.1101/gad.1200204; Kuzmichev A, 2005, P NATL ACAD SCI USA, V102, P1859, DOI 10.1073/pnas.0409875102; Kuzmichev A, 2004, MOL CELL, V14, P183, DOI 10.1016/S1097-2765(04)00185-6; Loots GG, 2000, SCIENCE, V288, P136, DOI 10.1126/science.288.5463.136; Margueron R, 2005, CURR OPIN GENET DEV, V15, P163, DOI 10.1016/j.gde.2005.01.005; Moss RB, 2004, EXPERT OPIN BIOL TH, V4, P1887, DOI 10.1517/14712598.4.12.1887; Perez-Burgos L, 2004, METHOD ENZYMOL, V376, P234; Peters AHFM, 2003, MOL CELL, V12, P1577, DOI 10.1016/S1097-2765(03)00477-5; Plath K, 2003, SCIENCE, V300, P131, DOI 10.1126/science.1084274; Schotta G, 2002, EMBO J, V21, P1121, DOI 10.1093/emboj/21.5.1121; Schotta Gunnar, 2004, Novartis Found Symp, V259, P22; Solymar DC, 2002, IMMUNITY, V17, P41, DOI 10.1016/S1074-7613(02)00334-5; Spilianakis CG, 2004, NAT IMMUNOL, V5, P1017, DOI 10.1038/ni1115; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Su IH, 2003, NAT IMMUNOL, V4, P124, DOI 10.1038/ni876; Takemoto N, 1998, INT IMMUNOL, V10, P1981, DOI 10.1093/intimm/10.12.1981; Wang Y., 2004, NOVART FDN SYMP, V259, P3; Wang Yanming, 2004, Novartis Found Symp, V259, P3	26	112	115	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	2005	280	36					31470	31477		10.1074/jbc.M504766200	http://dx.doi.org/10.1074/jbc.M504766200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	961LZ	16009709	hybrid			2022-12-25	WOS:000231665200018
J	Ludemann, N; Clement, A; Hans, VH; Leschik, J; Behl, C; Brandt, R				Ludemann, N; Clement, A; Hans, VH; Leschik, J; Behl, C; Brandt, R			O-glycosylation of the tail domain of neurofilament protein M in human neurons and in spinal cord tissue of a rat model of amyotrophic lateral sclerosis (ALS)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUTATIONAL HOT-SPOT; DYNAMIC INTERPLAY; NF-H; PHOSPHORYLATION SITES; LINKED GLYCOSYLATION; NERVOUS-SYSTEM; AXONAL CALIBER; RADIAL GROWTH; HEAVY SUBUNIT; C-MYC	Mammalian neurofilaments ( NFs) are modified by post-translational modifications that are thought to regulate NF assembly and organization. Whereas phosphorylation has been intensely studied, the role of another common modification, the attachment of O-linked N-acetylglucosamine ( GlcNAc) to individual serine and threonine residues, is hardly understood. We generated a novel monoclonal antibody that specifically recognizes an O-glycosylated epitope in the tail domain of NF-M and allows determination of the glycosylation state at this residue. The antibody displays strong species preference for human NF-M, shows some reactivity with rat but not with mouse or bovine NF-M. By immunohistochemistry and Western blot analysis of biopsy-derived human temporal lobe tissue we show that immunoreactivity is highly enriched in axons parallel to hyperphosphorylated NFs. Treatment of cultured neurons with the GlcNAcase inhibitor PUGNAc causes a 40% increase in immunoreactivity within 1 h, which is completely reversible and parallels the total increase in cellular O-GlcNAc modification. Treatment with the mitogen-activated protein kinase kinase inhibitor PD-98059 leads to a similar increase in immunoreactivity. In spinal cord tissue of a transgenic rat model for amyotrophic lateral sclerosis, immunoreactivity is strongly decreased compared with wild-type animals while phosphorylation is increased. The data suggest that hyper-phosphorylation and tail domain O-glycosylation of NFs are synchronously regulated in axons of human neurons in situ and that O-glycosylation of NF-M is highly dynamic and closely interweaved with phosphorylation cascades and may have a pathophysiological role.	Univ Osnabruck, Dept Neurobiol, D-49076 Osnabruck, Germany; Heidelberg Univ, IZN, Dept Neurobiol, D-69120 Heidelberg, Germany; Johannes Gutenberg Univ Mainz, Inst Physiol Chem & Pathobiochem, D-55099 Mainz, Germany; Univ Hosp Bonn, Inst Neuropathol, D-53105 Bonn, Germany	University Osnabruck; Ruprecht Karls University Heidelberg; Johannes Gutenberg University of Mainz; University of Bonn	Brandt, R (corresponding author), Univ Osnabruck, Dept Neurobiol, Barbarastr 11, D-49076 Osnabruck, Germany.	Brandt@biologie.uni-osnabrueck.de		Behl, Christian/0000-0001-8453-2378; Brandt, Roland/0000-0003-0101-1257				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ANDO S, 1989, BIOCHEMISTRY-US, V28, P2974, DOI 10.1021/bi00433a035; BIEDLER JL, 1978, CANCER RES, V38, P3751; Blom N, 2004, PROTEOMICS, V4, P1633, DOI 10.1002/pmic.200300771; BRANDT R, 1993, J BIOL CHEM, V268, P3414; CHIN SSM, 1991, J CELL SCI, V99, P335; CHOU CF, 1992, J BIOL CHEM, V267, P3901; CHOU TY, 1995, J BIOL CHEM, V270, P18961, DOI 10.1074/jbc.270.32.18961; COLE JS, 1994, J NEUROSCI, V14, P6956; Comer FI, 2001, ANAL BIOCHEM, V293, P169, DOI 10.1006/abio.2001.5132; Comer FI, 2000, J BIOL CHEM, V275, P29179, DOI 10.1074/jbc.R000010200; DEWAEGH SM, 1992, CELL, V68, P451, DOI 10.1016/0092-8674(92)90183-D; Dong DLY, 1996, J BIOL CHEM, V271, P20845, DOI 10.1074/jbc.271.34.20845; DONG DLY, 1993, J BIOL CHEM, V268, P16679; Duk M, 1997, ANAL BIOCHEM, V253, P98, DOI 10.1006/abio.1997.9994; ELHANANY E, 1994, J NEUROCHEM, V63, P2324; FAISSNER A, 1990, NEURON, V5, P627, DOI 10.1016/0896-6273(90)90217-4; Garcia ML, 2003, J CELL BIOL, V163, P1011, DOI 10.1083/jcb.200308159; GRIFFITH LS, 1995, BIOCHEM BIOPH RES CO, V213, P424, DOI 10.1006/bbrc.1995.2149; Haltiwanger RS, 1998, J BIOL CHEM, V273, P3611, DOI 10.1074/jbc.273.6.3611; Haltiwanger RS, 1997, BIOCHEM BIOPH RES CO, V231, P237, DOI 10.1006/bbrc.1997.6110; Harlow E., 1988, ANTIBODIES LAB MANUA; Hart GW, 1997, ANNU REV BIOCHEM, V66, P315, DOI 10.1146/annurev.biochem.66.1.315; HIROKAWA N, 1984, J CELL BIOL, V98, P1523, DOI 10.1083/jcb.98.4.1523; Hollander BA, 1996, J NEUROCHEM, V66, P412; HOLT GD, 1987, J CELL BIOL, V104, P1157, DOI 10.1083/jcb.104.5.1157; Howland DS, 2002, P NATL ACAD SCI USA, V99, P1604, DOI 10.1073/pnas.032539299; INAGAKI M, 1987, NATURE, V328, P649, DOI 10.1038/328649a0; JULIEN JP, 1983, J BIOL CHEM, V258, P4019; Julien JP, 1997, TRENDS CELL BIOL, V7, P243, DOI 10.1016/S0962-8924(97)01049-0; Kamemura K, 2002, J BIOL CHEM, V277, P19229, DOI 10.1074/jbc.M201729200; KEARSE KP, 1991, P NATL ACAD SCI USA, V88, P1701, DOI 10.1073/pnas.88.5.1701; KELLY WG, 1993, J BIOL CHEM, V268, P10416; Kempf M, 1996, J NEUROSCI, V16, P5583; Kikuchi S, 2003, BRAIN RES REV, V41, P306, DOI 10.1016/S0165-0173(02)00273-4; Lee MK, 1996, ANNU REV NEUROSCI, V19, P187, DOI 10.1146/annurev.ne.19.030196.001155; LEE VMY, 1987, J NEUROSCI, V7, P3474; LEE VMY, 1988, P NATL ACAD SCI USA, V85, P1998, DOI 10.1073/pnas.85.6.1998; MANETTO V, 1988, J NEUROPATH EXP NEUR, V47, P642, DOI 10.1097/00005072-198811000-00007; Nagai M, 2001, J NEUROSCI, V21, P9246, DOI 10.1523/JNEUROSCI.21-23-09246.2001; NIXON RA, 1991, TRENDS NEUROSCI, V14, P501, DOI 10.1016/0166-2236(91)90062-Y; OLMSTED JB, 1970, P NATL ACAD SCI USA, V65, P129, DOI 10.1073/pnas.65.1.129; Piontek J, 2003, J BIOL CHEM, V278, P38970, DOI 10.1074/jbc.M306749200; Piontek J, 1999, J NEUROCHEM, V73, P139, DOI 10.1046/j.1471-4159.1999.0730139.x; PLEASURE SJ, 1992, J NEUROSCI, V12, P1802; Rao MV, 2002, J CELL BIOL, V158, P681, DOI 10.1083/jcb.200202037; Rao MV, 1998, J CELL BIOL, V143, P171, DOI 10.1083/jcb.143.1.171; Rao MV, 2003, J CELL BIOL, V163, P1021, DOI 10.1083/jcb.200308076; Rao MV, 2003, NEUROCHEM RES, V28, P1041, DOI 10.1023/A:1023259207015; Riederer BM, 1996, J COMP NEUROL, V364, P704, DOI 10.1002/(SICI)1096-9861(19960122)364:4<704::AID-CNE8>3.0.CO;2-7; RIEDERER BM, 1993, J HISTOCHEM CYTOCHEM, V41, P609, DOI 10.1177/41.4.8450200; Roquemore EP, 1996, BIOCHEMISTRY-US, V35, P3578, DOI 10.1021/bi951918j; SCHERER WF, 1953, J EXP MED, V97, P695, DOI 10.1084/jem.97.5.695; Shafi R, 2000, P NATL ACAD SCI USA, V97, P5735, DOI 10.1073/pnas.100471497; SIHAG RK, 1991, J BIOL CHEM, V266, P18861; SIHAG RK, 1990, J BIOL CHEM, V265, P4166; Slawson C, 2003, CURR OPIN STRUC BIOL, V13, P631, DOI 10.1016/j.sbi.2003.08.003; SNOW CM, 1987, J CELL BIOL, V104, P1143, DOI 10.1083/jcb.104.5.1143; Song J, 1997, NEUROBIOL AGING, V18, P475, DOI 10.1016/S0197-4580(97)00043-2; Sun DM, 1996, J BIOL CHEM, V271, P14245, DOI 10.1074/jbc.271.24.14245; TODARO GJ, 1965, VIROLOGY, V27, P179, DOI 10.1016/0042-6822(65)90157-1; TURNER JR, 1990, P NATL ACAD SCI USA, V87, P5608, DOI 10.1073/pnas.87.15.5608; Veeranna, 1998, J NEUROSCI, V18, P4008; Vosseller K, 2002, CURR OPIN CHEM BIOL, V6, P851, DOI 10.1016/S1367-5931(02)00384-8; WONG PC, 1995, NEURON, V14, P1105, DOI 10.1016/0896-6273(95)90259-7; XU ZS, 1992, J BIOL CHEM, V267, P4467	66	62	66	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	2005	280	36					31648	31658		10.1074/jbc.M504395200	http://dx.doi.org/10.1074/jbc.M504395200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	961LZ	16006557	hybrid			2022-12-25	WOS:000231665200040
J	Merkley, N; Barber, KR; Shaw, GS				Merkley, N; Barber, KR; Shaw, GS			Ubiquitin manipulation by an E2 conjugating enzyme using a novel covalent intermediate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYUBIQUITIN CHAINS; BINDING INTERFACE; UBA DOMAINS; YEAST UBC4; PROTEIN; INSIGHTS; COMPLEX; TAIL; IDENTIFICATION; UBIQUITYLATION	Degradation of misfolded and damaged proteins by the 26 S proteasome requires the substrate to be tagged with a polyubiquitin chain. Assembly of polyubiquitin chains and subsequent substrate labeling potentially involves three enzymes, an E1, E2, and E3. E2 proteins are key enzymes and form a thioester intermediate through their catalytic cysteine with the C-terminal glycine (Gly(76)) of ubiquitin. This thioester intermediate is easily hydrolyzed in vitro and has eluded structural characterization. To overcome this, we have engineered a novel ubiquitin-E2 disulfide-linked complex by mutating Gly76 to Cys(76) in ubiquitin. Reaction of Ubc1, an E2 from Saccharomyces cerevisiae, with this mutant ubiquitin resulted in an ubiquitin-E2 disulfide that could be purified and was stable for several weeks. Chemical shift perturbation analysis of the disulfide ubiquitin- Ubc1 complex by NMR spectroscopy reveals an ubiquitin- Ubc1 interface similar to that for the ubiquitin- E2 thioester. In addition to the typical E2 catalytic domain, Ubc1 contains an ubiquitin- associated (UBA) domain, and we have utilized NMR spectroscopy to demonstrate that in this disulfide complex the UBA domain is freely accessible to non-covalently bind a second molecule of ubiquitin. The ability of the Ubc1 to bind two ubiquitin molecules suggests that the UBA domain does not interact with the thioester-bound ubiquitin during polyubiquitin chain formation. Thus, construction of this novel ubiquitin- E2 disulfide provides a method to characterize structurally the first step in polyubiquitin chain assembly by Ubc1 and its related class II enzymes.	Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada	Western University (University of Western Ontario)	Shaw, GS (corresponding author), Univ Western Ontario, Dept Biochem, Med Sci Bldg, London, ON N6A 5C1, Canada.	gshaw1@uwo.ca	Shaw, Gary S./C-7656-2009	Shaw, Gary S./0000-0002-4685-9625				Chen L, 2001, EMBO REP, V2, P933, DOI 10.1093/embo-reports/kve203; CHEN ZJ, 1990, J BIOL CHEM, V265, P21835; COOK WJ, 1993, BIOCHEMISTRY-US, V32, P13809, DOI 10.1021/bi00213a009; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Fang S, 2004, CELL MOL LIFE SCI, V61, P1546, DOI 10.1007/s00018-004-4129-5; Goto NK, 1999, J BIOMOL NMR, V13, P369, DOI 10.1023/A:1008393201236; GRZESIEK S, 1992, J MAGN RESON, V99, P201, DOI 10.1016/0022-2364(92)90169-8; GWOZD CS, 1995, BIOCHEMISTRY-US, V34, P6296, DOI 10.1021/bi00019a006; Haldeman MT, 1997, BIOCHEMISTRY-US, V36, P10526, DOI 10.1021/bi970750u; Hamilton KS, 2000, J BIOMOL NMR, V18, P319, DOI 10.1023/A:1026773008237; Hamilton KS, 2001, STRUCTURE, V9, P897, DOI 10.1016/S0969-2126(01)00657-8; Hodgins R, 1996, J BIOL CHEM, V271, P28766, DOI 10.1074/jbc.271.46.28766; Hofmann K, 1996, TRENDS BIOCHEM SCI, V21, P172, DOI 10.1016/0968-0004(96)30015-7; Huang DT, 2005, MOL CELL, V17, P341, DOI 10.1016/j.molcel.2004.12.020; Huang L, 1999, SCIENCE, V286, P1321, DOI 10.1126/science.286.5443.1321; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Lois LM, 2005, EMBO J, V24, P439, DOI 10.1038/sj.emboj.7600552; McKenna S, 2003, BIOCHEMISTRY-US, V42, P7922, DOI 10.1021/bi034480t; Merkley N, 2004, J BIOL CHEM, V279, P47139, DOI 10.1074/jbc.M409576200; Merkley N, 2003, J BIOMOL NMR, V26, P147, DOI 10.1023/A:1023571703783; Miura T, 1999, J MOL BIOL, V290, P213, DOI 10.1006/jmbi.1999.2859; Mueller TD, 2004, J BIOL CHEM, V279, P11926, DOI 10.1074/jbc.M312865200; Passmore LA, 2004, BIOCHEM J, V379, P513, DOI 10.1042/BJ20040198; Pickart CM, 2000, TRENDS BIOCHEM SCI, V25, P544, DOI 10.1016/S0968-0004(00)01681-9; Pickart CM, 2004, BBA-MOL CELL RES, V1695, P55, DOI 10.1016/j.bbamcr.2004.09.019; Raasi S, 2004, J MOL BIOL, V341, P1367, DOI 10.1016/j.jmb.2004.06.057; Raasi S, 2003, J BIOL CHEM, V278, P8951, DOI 10.1074/jbc.M212841200; Rajesh S, 1999, BIOCHEMISTRY-US, V38, P9242, DOI 10.1021/bi9903953; Ryu KS, 2003, J BIOL CHEM, V278, P36621, DOI 10.1074/jbc.M304628200; SULLIVAN ML, 1993, J BIOL CHEM, V268, P8777; SUNG P, 1991, J MOL BIOL, V221, P745, DOI 10.1016/0022-2836(91)80169-U; Varelas X, 2003, MOL CELL BIOL, V23, P5388, DOI 10.1128/MCB.23.15.5388-5400.2003; Walden H, 2003, NATURE, V422, P330, DOI 10.1038/nature01456; Winn PJ, 2005, PROTEINS, V58, P367, DOI 10.1002/prot.20318; WISHART DS, 1994, J BIOMOL NMR, V4, P171; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	37	34	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	2005	280	36					31732	31738		10.1074/jbc.M505205200	http://dx.doi.org/10.1074/jbc.M505205200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	961LZ	16014632	hybrid			2022-12-25	WOS:000231665200050
J	Weng, Y; DiRusso, CC; Reilly, AA; Black, PN; Ding, XX				Weng, Y; DiRusso, CC; Reilly, AA; Black, PN; Ding, XX			Hepatic gene expression changes in mouse models with liver-specific deletion or global suppression of the NADPH-cytochrome P450 reductase gene - Mechanistic implications for the regulation of microsomal cytochrome P450 and the fatty liver phenotype	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED RECEPTOR-ALPHA; CONSTITUTIVE ANDROSTANE RECEPTOR; PREGNANE-X RECEPTOR; BILE-ACID SYNTHESIS; COA DESATURASE 1; P450 OXIDOREDUCTASE; NUCLEAR RECEPTOR; MICROARRAY DATA; FEEDBACK-REGULATION; LIPOPROTEIN-LIPASE	NADPH-cytochrome P450 reductase (CPR) is an essential component for the function of many enzymes, including microsomal cytochrome P450 ( P450) monooxygenases and heme oxygenases. In liver-Cpr-null ( with liver-specific Cpr deletion) and Cpr-low ( with reduced CPR expression in all organs examined) mouse models, a reduced serum cholesterol level and an induction of hepatic P450s were observed, whereas hepatomegaly and fatty liver were only observed in the liver-Cpr- null model. Our goal was to identify hepatic gene expression changes related to these phenotypes. Cpr-lox mice ( with a floxed Cpr gene and normal CPR expression) were used as the control. Through microarray analysis, we identified many genes that were differentially expressed among the three groups of mice. We also recognized the 12 gene ontology terms that contained the most significantly changed gene expression in at least one of the two mouse models. We further uncovered potential mechanisms, such as an increased activation of constitutive androstane receptor and a decreased activation of peroxisomal proliferatoractivated receptor-alpha by precursors of cholesterol biosynthesis, that underlie common changes ( e. g. induction of multiple P450s and suppression of genes for fatty acid metabolism) in response to CPR loss in the two mouse models. Additionally, we observed model-specific gene expression changes, such as the induction of a fatty-acid translocase (Cd36 antigen) and the suppression of carnitine O-palmitoyltransferase 1 (Cpt1a) and acyl-CoA synthetase long chain family member 1 (Acsl1), that are potentially responsible for the severe hepatic lipidosis and an altered fatty acid profile observed in liver-Cpr-null mice.	New York State Dept Hlth, Wadsworth Ctr, Albany, NY 12201 USA; SUNY Albany, Albany, NY 12201 USA; Ordway Res Inst Inc, Albany, NY 12208 USA	State University of New York (SUNY) System; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany; Ordway Research Institute	Ding, XX (corresponding author), New York State Dept Hlth, Wadsworth Ctr, Empire State Plaza,Box 509, Albany, NY 12201 USA.	xding@wadsworth.org	DiRusso, Concetta C/M-1884-2014	Black, Paul/0000-0002-6272-6881	NCI NIH HHS [CA092596] Funding Source: Medline; NIEHS NIH HHS [ES07462] Funding Source: Medline; NIGMS NIH HHS [GM5685] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA092596] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007462] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Anderson SP, 2004, MOL PHARMACOL, V66, P1440, DOI 10.1124/mol.104.005496; Aoyama T, 1998, J BIOL CHEM, V273, P5678, DOI 10.1074/jbc.273.10.5678; Bae YJ, 2004, DNA CELL BIOL, V23, P81, DOI 10.1089/104454904322759894; CASTILLOOLIVARE.A, 2001, NUCLEIC ACIDS RES, V29, P4035; CASTILLOOLIVARE.A, 2004, J BIOL CHEM, V279, P16813; Chiang JYL, 2002, ENDOCR REV, V23, P443, DOI 10.1210/er.2000-0035; Coon M J, 1978, Methods Enzymol, V52, P109; Coort SLM, 2004, DIABETES, V53, P1655, DOI 10.2337/diabetes.53.7.1655; Dahlquist KD, 2002, NAT GENET, V31, P19, DOI 10.1038/ng0502-19; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Doniger SW, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-1-r7; Dussault I, 2003, P NATL ACAD SCI USA, V100, P833, DOI 10.1073/pnas.0336235100; ENOCH HG, 1979, J BIOL CHEM, V254, P8976; Febbraio M, 1999, J BIOL CHEM, V274, P19055, DOI 10.1074/jbc.274.27.19055; Ferguson SS, 2002, MOL PHARMACOL, V62, P737, DOI 10.1124/mol.62.3.737; Fiske CH, 1925, J BIOL CHEM, V66, P375; Fluck CE, 2004, NAT GENET, V36, P228, DOI 10.1038/ng1300; FOLCH J, 1957, J BIOL CHEM, V226, P497; Glatz JFC, 2002, MOL CELL BIOCHEM, V239, P3, DOI 10.1023/A:1020529918782; Goldberg IJ, 1996, J LIPID RES, V37, P693; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Goodwin B, 2003, P NATL ACAD SCI USA, V100, P223, DOI 10.1073/pnas.0237082100; Gu J, 1998, J PHARMACOL EXP THER, V285, P1287; Gu J, 2005, MOL PHARMACOL, V67, P623, DOI 10.1124/mol.104.007898; Gu J, 2003, J BIOL CHEM, V278, P25895, DOI 10.1074/jbc.M303125200; Harmon SD, 2003, LIPIDS, V38, P469, DOI 10.1007/s11745-003-1086-9; Henderson CJ, 2003, J BIOL CHEM, V278, P13480, DOI 10.1074/jbc.M212087200; Horton JD, 2003, P NATL ACAD SCI USA, V100, P12027, DOI 10.1073/pnas.1534923100; Hua XX, 1996, J BIOL CHEM, V271, P10379, DOI 10.1074/jbc.271.17.10379; Huang NW, 2005, AM J HUM GENET, V76, P729, DOI 10.1086/429417; Huebert RC, 2002, J BIOL CHEM, V277, P22710, DOI 10.1074/jbc.M202394200; Ibrahimi A, 1999, J BIOL CHEM, V274, P26761, DOI 10.1074/jbc.274.38.26761; Inoue I, 2002, BIOCHEM BIOPH RES CO, V290, P131, DOI 10.1006/bbrc.2001.6141; Ishida H, 1999, J BIOCHEM-TOKYO, V126, P19, DOI 10.1093/oxfordjournals.jbchem.a022422; JELINEK DF, 1990, BIOCHEMISTRY-US, V29, P7781, DOI 10.1021/bi00486a001; Kocarek TA, 1998, MOL PHARMACOL, V54, P474, DOI 10.1124/mol.54.3.474; Kocarek TA, 2002, MOL PHARMACOL, V62, P1177, DOI 10.1124/mol.62.5.1177; Landrier JF, 2004, J BIOL CHEM, V279, P45512, DOI 10.1074/jbc.M407461200; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Li-Hawkins J, 2002, J CLIN INVEST, V110, P1191, DOI 10.1172/JCI200216309; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Maglich JM, 2002, MOL PHARMACOL, V62, P638, DOI 10.1124/mol.62.3.638; Martin G, 2001, J CLIN INVEST, V107, P1423, DOI 10.1172/JCI10852; Martin GG, 2003, BIOCHEMISTRY-US, V42, P11520, DOI 10.1021/bi0346749; Mascaro C, 1998, J BIOL CHEM, V273, P8560, DOI 10.1074/jbc.273.15.8560; Meier PJ, 2002, ANNU REV PHYSIOL, V64, P635, DOI 10.1146/annurev.physiol.64.082201.100300; Miller CW, 1996, P NATL ACAD SCI USA, V93, P9443, DOI 10.1073/pnas.93.18.9443; Nishino H, 2000, ARCH BIOCHEM BIOPHYS, V374, P293, DOI 10.1006/abbi.1999.1602; Norlin M, 2004, BIOCHEM BIOPH RES CO, V316, P158, DOI 10.1016/j.bbrc.2004.02.029; Obukowicz M, 1999, LIPIDS, V34, pS149, DOI 10.1007/BF02562269; ONO T, 1975, J BIOL CHEM, V250, P1571; Otto DME, 2003, MOL CELL BIOL, V23, P6103, DOI 10.1128/MCB.23.17.6103-6116.2003; Pereira SL, 2003, PROSTAG LEUKOTR ESS, V68, P97, DOI 10.1016/S0952-3278(02)00259-4; Porter TD, 2002, J BIOCHEM MOL TOXIC, V16, P311, DOI 10.1002/jbt.10052; PORTER TD, 1991, J BIOL CHEM, V266, P13469; Roglans N, 2002, J PHARMACOL EXP THER, V302, P232, DOI 10.1124/jpet.302.1.232; Rosenfeld JM, 2003, MOL ENDOCRINOL, V17, P1268, DOI 10.1210/me.2002-0421; Russell DW, 2003, ANNU REV BIOCHEM, V72, P137, DOI 10.1146/annurev.biochem.72.121801.161712; Sampath H, 2004, NUTR REV, V62, P333, DOI [10.1301/nr.2004.sept.333-339, 10.1111/j.1753-4887.2004.tb00058.x]; SCHACTER BA, 1972, J BIOL CHEM, V247, P3601; SCHOONJANS K, 1995, J BIOL CHEM, V270, P19269, DOI 10.1074/jbc.270.33.19269; Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x; Shen AL, 2002, J BIOL CHEM, V277, P6536, DOI 10.1074/jbc.M111408200; Simpson AECM, 1997, GEN PHARMACOL-VASC S, V28, P351, DOI 10.1016/S0306-3623(96)00246-7; Sprecher H, 2000, BBA-MOL CELL BIOL L, V1486, P219, DOI 10.1016/S1388-1981(00)00077-9; Stith BJ, 2000, J LIPID RES, V41, P1448; Szczesna-Skorupa E, 2004, J BIOL CHEM, V279, P13953, DOI 10.1074/jbc.M312170200; Tabor DE, 1999, J BIOL CHEM, V274, P20603, DOI 10.1074/jbc.274.29.20603; Wang XJ, 2005, BIOCHEM J, V388, P857, DOI 10.1042/BJ20042087; Waxman DJ, 1999, ARCH BIOCHEM BIOPHYS, V369, P11, DOI 10.1006/abbi.1999.1351; Wu L, 2005, J PHARMACOL EXP THER, V312, P35, DOI 10.1124/jpet.104.073353; Wu L, 2003, GENESIS, V36, P177, DOI 10.1002/gene.10214; Xie W, 2000, NATURE, V406, P435, DOI 10.1038/35019116; Yu ST, 2003, J BIOL CHEM, V278, P498, DOI 10.1074/jbc.M210062200; ZHANG QY, 1989, P NATL ACAD SCI USA, V86, P8294, DOI 10.1073/pnas.86.21.8294; Zou ZY, 2002, J BIOL CHEM, V277, P31062, DOI 10.1074/jbc.M205034200	76	56	59	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	2005	280	36					31686	31698		10.1074/jbc.M504447200	http://dx.doi.org/10.1074/jbc.M504447200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	961LZ	16006652	hybrid			2022-12-25	WOS:000231665200045
J	Kota, RS; Ramana, CV; Tenorio, FA; Enelow, RI; Rutledge, JC				Kota, RS; Ramana, CV; Tenorio, FA; Enelow, RI; Rutledge, JC			Differential effects of lipoprotein lipase on tumor necrosis factor-alpha and interferon-gamma-mediated gene expression in human endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED RECEPTOR-GAMMA; NF-KAPPA-B; TRIGLYCERIDE-RICH LIPOPROTEINS; INTESTINAL POLYP FORMATION; C-REACTIVE PROTEIN; LIPID RAFTS; MACROPHAGE; ROLES; ATHEROSCLEROSIS; LIPOLYSIS	Lipoprotein lipase ( LPL) is a key enzyme in the hydrolysis of triglyceride- rich lipoproteins. In vascular diseases, such as atherosclerosis, inflammation plays an important role in the pathogenesis of the disease. We examined the role of LPL in modulating tumor necrosis factor-alpha ( TNF-alpha)- and interferon-gamma ( IFN-gamma)- mediated inflammatory cytokine signal transduction pathways in human aortic endothelial cells ( HAECs). LPL significantly suppressed TNF-alpha- induced gene expression, and this suppression was reversed by tetrahydrolipstatin and heparinase. In contrast, LPL synergistically enhanced IFN-gamma- induced gene expression in HAECs. To elucidate the molecular mechanisms of LPL action, we investigated the role of transcription factors nuclear factor kappa B ( NF- kappa B) and signal transducer and activator of transcription factor 1 ( Stat1). The anti- inflammatory response of LPL in suppressing TNF-alpha- induced gene expression was a result of its inhibition of NF- kappa B activity by the abrogation of I kappa B-alpha degradation and phosphorylation of the p65 subunit. Although LPL alone had no effect on Stat1 activation, LPL enhanced IFN-gamma-induced phosphorylation of Stat1 on tyrosine 701 and serine 727, as well as Stat1- mediated transactivation. The synergistic effect of LPL on IFN-gamma-induced Stat1 activation was mediated by enhanced activation of the tyrosine kinase JAK2 and was abrogated by LY294002, a specific inhibitor of the phosphatidylinositol 3 '- kinase pathway. Our studies indicate that LPL has differential effects on several inflammatory pathways known to be important in atherosclerosis.	Univ Calif Davis, Sch Med,Dept Internal Med, Genome & Biomed Sci Facil 5303, Div Endocrinol Clin Nutr & Vasc Med, Davis, CA 95616 USA; Yale Univ, Sch Med, Dept Med, New Haven, CT 06520 USA	University of California System; University of California Davis; Yale University	Kota, RS (corresponding author), Univ Calif Davis, Sch Med,Dept Internal Med, Genome & Biomed Sci Facil 5303, Div Endocrinol Clin Nutr & Vasc Med, 451 E Hlth Sci Dr, Davis, CA 95616 USA.	rskota@ucdavis.edu		chilakamarti, ramana/0000-0002-5153-8252	NHLBI NIH HHS [HL78615, HL70816, HL58660, HL55667] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055667, R29HL058660, R01HL058660, R01HL078615] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Agnoletti L, 1999, CIRCULATION, V100, P1983, DOI 10.1161/01.CIR.100.19.1983; Agrawal A, 2001, J IMMUNOL, V166, P2378, DOI 10.4049/jimmunol.166.4.2378; Augustus AS, 2003, AM J PHYSIOL-ENDOC M, V284, pE331, DOI 10.1152/ajpendo.00298.2002; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BEISIEGEL U, 1995, CURR OPIN LIPIDOL, V6, P117, DOI 10.1097/00041433-199506000-00002; BENNION SD, 1995, J INVEST DERMATOL, V105, pS71, DOI 10.1111/1523-1747.ep12316107; Bruce WR, 2000, NUTR CANCER, V37, P19, DOI 10.1207/S15327914NC3701_2; Brunzell J.D., 1995, METABOLIC MOL BASES, P1913; Castrillo A, 2001, J BIOL CHEM, V276, P34082, DOI 10.1074/jbc.M102472200; Cha-Molstad H, 2000, J IMMUNOL, V165, P4592, DOI 10.4049/jimmunol.165.8.4592; Cherukuri A, 2001, IMMUNITY, V14, P657, DOI 10.1016/S1074-7613(01)00156-X; ECKEL RH, 1989, NEW ENGL J MED, V320, P1060; Fichtlscherer S, 2001, CIRCULATION, V104, P3023, DOI 10.1161/hc5001.101749; Glass CK, 2001, J ENDOCRINOL, V169, P461, DOI 10.1677/joe.0.1690461; Goldberg IJ, 2001, FRONT BIOSCI-LANDMRK, V6, pD388, DOI 10.2741/Goldberg; Goldberg IJ, 1996, J LIPID RES, V37, P693; Gupta S, 1997, J CLIN INVEST, V99, P2752, DOI 10.1172/JCI119465; HOU JZ, 1994, P NATL ACAD SCI USA, V91, P11641, DOI 10.1073/pnas.91.24.11641; Ichikawa T, 2004, LAB INVEST, V84, P715, DOI 10.1038/labinvest.3700102; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Khovidhunkit W, 2004, J LIPID RES, V45, P1169, DOI 10.1194/jlr.R300019-JLR200; Kuvin JT, 2002, AM HEART J, V144, P165, DOI 10.1067/mhj.2002.123145; Legler DF, 2003, IMMUNITY, V18, P655, DOI 10.1016/S1074-7613(03)00092-X; LOOKENE A, 1994, EUR J BIOCHEM, V222, P395, DOI 10.1111/j.1432-1033.1994.tb18878.x; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; Makowski L, 2005, J BIOL CHEM, V280, P12888, DOI 10.1074/jbc.M413788200; Maziere C, 2001, FREE RADICAL BIO MED, V31, P1334, DOI 10.1016/S0891-5849(01)00649-9; Mead JR, 2002, J MOL MED, V80, P753, DOI 10.1007/s00109-002-0384-9; MEDH JD, 1995, J BIOL CHEM, V270, P536, DOI 10.1074/jbc.270.2.536; Nguyen H, 2001, J BIOL CHEM, V276, P33361, DOI 10.1074/jbc.M105070200; Niho N, 2005, P NATL ACAD SCI USA, V102, P2970, DOI 10.1073/pnas.0500153102; Niho N, 2003, CANCER RES, V63, P6090; Pober JS, 2002, ARTHRITIS RES THER, V4, pS109, DOI 10.1186/ar576; Ramana CV, 2002, TRENDS IMMUNOL, V23, P96, DOI 10.1016/S1471-4906(01)02118-4; Ramana CV, 2000, ONCOGENE, V19, P2619, DOI 10.1038/sj.onc.1203525; RENIER G, 1995, ARTERIOSCL THROM VAS, V15, P392, DOI 10.1161/01.ATV.15.3.392; REYMER PWA, 1995, NAT GENET, V10, P28, DOI 10.1038/ng0595-28; Ricote M, 2004, ARTERIOSCL THROM VAS, V24, P230, DOI 10.1161/01.ATV.0000103951.67680.B1; ROJAS C, 1991, EUR J BIOCHEM, V197, P315, DOI 10.1111/j.1432-1033.1991.tb15913.x; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; SHIMADA K, 1981, J CLIN INVEST, V68, P995, DOI 10.1172/JCI110354; Shimada M, 1996, P NATL ACAD SCI USA, V93, P7242, DOI 10.1073/pnas.93.14.7242; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Takaoka A, 2000, SCIENCE, V288, P2357, DOI 10.1126/science.288.5475.2357; Tellides G, 2000, NATURE, V403, P207, DOI 10.1038/35003221; Yagyu H, 1999, J LIPID RES, V40, P1677; Yin BY, 1997, J CLIN INVEST, V100, P649, DOI 10.1172/JCI119576; Ziouzenkova O, 2003, J BIOL CHEM, V278, P39874, DOI 10.1074/jbc.M306786200; Ziouzenkova O, 2003, P NATL ACAD SCI USA, V100, P2730, DOI 10.1073/pnas.0538015100; Zohlnhofer D, 2001, MOL CELL, V7, P1059, DOI 10.1016/S1097-2765(01)00239-8	53	32	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	2005	280	35					31076	31084		10.1074/jbc.M412189200	http://dx.doi.org/10.1074/jbc.M412189200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	958ZX	15994321	hybrid			2022-12-25	WOS:000231487800052
J	Sauvage, E; Herman, R; Petrella, S; Duez, C; Bouillenne, F; Frere, JM; Charlier, P				Sauvage, E; Herman, R; Petrella, S; Duez, C; Bouillenne, F; Frere, JM; Charlier, P			Crystal structure of the Actinomadura R39 DD-peptidase reveals new domains in penicillin-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STREPTOMYCES-ALBUS G; ESCHERICHIA-COLI; STREPTOCOCCUS-PNEUMONIAE; ENZYME; LOCALIZATION; DEACYLATION; PRECURSOR; PROGRAM; COMPLEX; ROLES	Actinomadura sp. R39 produces an exocellular DD-peptidase/penicillin- binding protein (PBP) whose primary structure is similar to that of Escherichia coli PBP4. It is characterized by a high alpha-lactam-binding activity ( second order rate constant for the acylation of the active site serine by benzylpenicillin: k(2)/K = 300 mM(-1)s(-1)). The crystal structure of the DD-peptidase from Actinomadura R39 was solved at a resolution of 1.8 angstrom by single anomalous dispersion at the cobalt resonance wavelength. The structure is composed of three domains: a penicillin-binding domain similar to the penicillin-binding domain of E. coli PBP5 and two domains of unknown function. In most multimodular PBPs, additional domains are generally located at the C or N termini of the penicillin-binding domain. In R39, the other two domains are inserted in the penicillin-binding domain, between the SXXK and SXN motifs, in a manner similar to "Matryoshka dolls." One of these domains is composed of a five-stranded beta-sheet with two helices on one side, and the other domain is a double three-stranded beta-sheet inserted in the previous domain. Additionally, the 2.4-angstrom structure of the acyl-enzyme complex of R39 with nitrocefin reveals the absence of active site conformational change upon binding the beta-lactams.	Univ Liege, Inst Phys, Ctr Ingn Prot, B-4000 Sart Tilman Par Liege, Belgium	University of Liege	Sauvage, E (corresponding author), Univ Liege, Inst Phys, Ctr Ingn Prot, B5, B-4000 Sart Tilman Par Liege, Belgium.	eric.sauvage@ulg.ac.be		Petrella, Stephanie/0000-0001-6641-5901				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BURMAN LG, 1984, P NATL ACAD SCI-BIOL, V81, P1844, DOI 10.1073/pnas.81.6.1844; Cordell SC, 2001, EMBO J, V20, P2454, DOI 10.1093/emboj/20.10.2454; Davies C, 2001, J BIOL CHEM, V276, P616, DOI 10.1074/jbc.M004471200; DIDEBERG O, 1987, BIOCHEM J, V245, P911, DOI 10.1042/bj2450911; Dive G, 1999, INT J QUANTUM CHEM, V73, P161, DOI 10.1002/(SICI)1097-461X(1999)73:2<161::AID-QUA10>3.0.CO;2-E; Duez C, 2001, J BACTERIOL, V183, P1595, DOI 10.1128/JB.183.5.1595-1599.2001; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FANUEL L, 1994, FEBS LETT, V351, P49, DOI 10.1016/0014-5793(94)00822-1; Ferri-Fioni ML, 2001, J BIOL CHEM, V276, P47285, DOI 10.1074/jbc.M106550200; Fonze E, 1999, J BIOL CHEM, V274, P21853, DOI 10.1074/jbc.274.31.21853; FRERE JM, 1985, CRC CR REV MICROBIOL, V11, P299; GHUYSEN JM, 1991, ANNU REV MICROBIOL, V45, P37, DOI 10.1146/annurev.mi.45.100191.000345; Gordon E, 2000, J MOL BIOL, V299, P477, DOI 10.1006/jmbi.2000.3740; GRANIER B, 1992, BIOCHEM J, V282, P781, DOI 10.1042/bj2820781; Harris F, 2002, EUR J BIOCHEM, V269, P5821, DOI 10.1046/j.1432-1033.2002.03295.x; Hoch J.A., 2001, BACILLUS SUBTILIS IT, P21, DOI 10.1128/9781555817992.ch4; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; Inagaki N, 2001, FEBS LETT, V509, P197, DOI 10.1016/S0014-5793(01)03180-5; JACOBDUBUISSON F, 1991, PROTEIN ENG, V4, P811, DOI 10.1093/protein/4.7.811; KELLY JA, 1995, J MOL BIOL, V254, P223, DOI 10.1006/jmbi.1995.0613; KORAT B, 1991, MOL MICROBIOL, V5, P675, DOI 10.1111/j.1365-2958.1991.tb00739.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUZIN AP, 1995, BIOCHEMISTRY-US, V34, P9532, DOI 10.1021/bi00029a030; LESLIE AGW, 1991, CRYSTALLOGRAPHIC COM, V5, P50; Lim D, 2002, NAT STRUCT BIOL, V9, P870, DOI 10.1038/nsb858; Massova I, 1998, ANTIMICROB AGENTS CH, V42, P1; McDonough MA, 2002, J MOL BIOL, V322, P111, DOI 10.1016/S0022-2836(02)00742-8; Meberg BM, 2004, J BACTERIOL, V186, P8326, DOI 10.1128/JB.186.24.8326-8336.2004; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MOTTL H, 1992, J BACTERIOL, V174, P3261, DOI 10.1128/jb.174.10.3261-3269.1992; Muller JJ, 1998, J BIOL CHEM, V273, P3438, DOI 10.1074/jbc.273.6.3438; NAGASAWA H, 1989, J BACTERIOL, V171, P5890, DOI 10.1128/jb.171.11.5890-5893.1989; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; Nicholas RA, 2003, J BIOL CHEM, V278, P52826, DOI 10.1074/jbc.M310177200; Nicolet Y, 1999, STRUCTURE, V7, P13, DOI 10.1016/S0969-2126(99)80005-7; Pares S, 1996, NAT STRUCT BIOL, V3, P284, DOI 10.1038/nsb0396-284; Pedersen LB, 1998, J BACTERIOL, V180, P4967, DOI 10.1128/JB.180.18.4967-4973.1998; Popham DL, 1999, J BACTERIOL, V181, P126, DOI 10.1128/JB.181.1.126-132.1999; Rico AI, 2004, MOL MICROBIOL, V53, P1359, DOI 10.1111/j.1365-2958.2004.04245.x; Roussel A., 1989, SILICON GRAPHICS GEO; Sauvage E, 2002, CELL MOL LIFE SCI, V59, P1223, DOI 10.1007/s00018-002-8500-0; Scheffers DJ, 2004, MOL MICROBIOL, V51, P749, DOI 10.1046/j.1365-2958.2003.03854.x; Silvaggi NR, 2005, J MOL BIOL, V345, P521, DOI 10.1016/j.jmb.2004.10.076; Stefanova ME, 2003, BIOCHEMISTRY-US, V42, P14614, DOI 10.1021/bi0350607; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Varma A, 2004, J BACTERIOL, V186, P6768, DOI 10.1128/JB.186.20.6768-6774.2004	50	45	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	2005	280	35					31249	31256		10.1074/jbc.M503271200	http://dx.doi.org/10.1074/jbc.M503271200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	958ZX	15987687	Green Published, hybrid			2022-12-25	WOS:000231487800072
J	Wang, HC; Liu, YD; Chen, YX; Robinson, H; Ke, HM				Wang, HC; Liu, YD; Chen, YX; Robinson, H; Ke, HM			Multiple elements jointly determine inhibitor selectivity of cyclic nucleotide phosphodiesterases 4 and 7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; CATALYTIC DOMAIN; MESSENGER-RNA; CAMP; MECHANISM; AMP; PDE7A; IDENTIFICATION; LYMPHOCYTES; COMPLEX	Phosphodiesterase (PDE) inhibitors have been widely studied as therapeutics for treatment of human diseases. However, the mechanism by which each PDE family recognizes selectively a category of inhibitors remains a puzzle. Here we report the crystal structure of PDE7A1 catalytic domain in complex with non-selective inhibitor 3-isobutyl-1-methylxanthine and kinetic analysis on the mutants of PDE7A1 and PDE4D2. Our studies suggest at least three elements play critical roles in inhibitor selectivity: 1) the conformation and position of an invariant glutamine, 2) the natures of scaffolding residues, and 3) residues that alter shape and size of the binding pocket. Kinetic analysis shows that single PDE7 to PDE4 mutations increase the sensitivity of PDE7 to PDE4 inhibitors but are not sufficient to render the engineered enzymes comparable with the wild types. The triple S373Y/S377T/I412S mutation of PDE7A1 produces a PDE4-like enzyme, implying that multiple elements must work together to determine inhibitor selectivity.	Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA; Cent S Univ, Sch Biosci & Technol, Changsha 410008, Peoples R China	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; United States Department of Energy (DOE); Brookhaven National Laboratory; Central South University	Ke, HM (corresponding author), Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA.	hke@med.unc.edu		Wang, Huanchen/0000-0003-2701-7155	NIGMS NIH HHS [GM59791] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059791] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Antoni FA, 2000, FRONT NEUROENDOCRIN, V21, P103, DOI 10.1006/frne.1999.0193; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bloom TJ, 1996, P NATL ACAD SCI USA, V93, P14188, DOI 10.1073/pnas.93.24.14188; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Card GL, 2004, STRUCTURE, V12, P2233, DOI 10.1016/j.str.2004.10.004; Carvajal JA, 2000, J CELL PHYSIOL, V184, P409, DOI 10.1002/1097-4652(200009)184:3<409::AID-JCP16>3.3.CO;2-B; Castro A, 2005, MED RES REV, V25, P229, DOI 10.1002/med.20020; Corbin JD, 2002, INT J CLIN PRACT, V56, P453; Gardner C, 2000, BIOCHEM BIOPH RES CO, V272, P186, DOI 10.1006/bbrc.2000.2743; Giembycz M A, 2002, Monaldi Arch Chest Dis, V57, P48; Giembycz MA, 1996, BRIT J PHARMACOL, V118, P1945, DOI 10.1111/j.1476-5381.1996.tb15629.x; Han P, 1997, J BIOL CHEM, V272, P16152, DOI 10.1074/jbc.272.26.16152; Hetman JM, 2000, P NATL ACAD SCI USA, V97, P472, DOI 10.1073/pnas.97.1.472; Huai Q, 2004, P NATL ACAD SCI USA, V101, P9624, DOI 10.1073/pnas.0401120101; Huai Q, 2004, J BIOL CHEM, V279, P13095, DOI 10.1074/jbc.M311556200; Huai Q, 2003, BIOCHEMISTRY-US, V42, P13220, DOI 10.1021/bi034653e; Huai Q, 2003, STRUCTURE, V11, P865, DOI 10.1016/S0969-2126(03)00123-0; Huang Z, 2001, CURR OPIN CHEM BIOL, V5, P432, DOI 10.1016/S1367-5931(00)00224-6; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Lee ME, 2002, FEBS LETT, V530, P53, DOI 10.1016/S0014-5793(02)03396-3; Lee R, 2002, CELL SIGNAL, V14, P277, DOI 10.1016/S0898-6568(01)00250-9; Li LS, 1999, SCIENCE, V283, P848, DOI 10.1126/science.283.5403.848; Lipworth BJ, 2005, LANCET, V365, P167, DOI 10.1016/S0140-6736(05)17708-3; Liu YG, 2001, CARDIOVASC DRUG REV, V19, P369, DOI 10.1111/j.1527-3466.2001.tb00076.x; Mehats C, 2002, TRENDS ENDOCRIN MET, V13, P29, DOI 10.1016/S1043-2760(01)00523-9; MICHAELI T, 1993, J BIOL CHEM, V268, P12925; Miro X, 2001, SYNAPSE, V40, P201, DOI 10.1002/syn.1043; Navaza J, 1997, METHOD ENZYMOL, V276, P581, DOI 10.1016/S0076-6879(97)76079-8; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Richter W, 2002, PROTEIN EXPRES PURIF, V25, P138, DOI 10.1006/prep.2002.1620; Rotella DP, 2002, NAT REV DRUG DISCOV, V1, P674, DOI 10.1038/nrd893; Scapin G, 2004, BIOCHEMISTRY-US, V43, P6091, DOI 10.1021/bi049868i; Soderling SH, 2000, CURR OPIN CELL BIOL, V12, P174, DOI 10.1016/S0955-0674(99)00073-3; Sung BJ, 2003, NATURE, V425, P98, DOI 10.1038/nature01914; Torphy TJ, 1998, AM J RESP CRIT CARE, V157, P351, DOI 10.1164/ajrccm.157.2.9708012; Truss MC, 2001, WORLD J UROL, V19, P344, DOI 10.1007/s003450100221; Xu RX, 2004, J MOL BIOL, V337, P355, DOI 10.1016/j.jmb.2004.01.040; Xu RX, 2000, SCIENCE, V288, P1822, DOI 10.1126/science.288.5472.1822; Yang GC, 2003, J IMMUNOL, V171, P6414, DOI 10.4049/jimmunol.171.12.6414; Zhang KYJ, 2004, MOL CELL, V15, P279, DOI 10.1016/j.molcel.2004.07.005	40	64	72	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	2005	280	35					30949	30955		10.1074/jbc.M504398200	http://dx.doi.org/10.1074/jbc.M504398200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	958ZX	15994308	hybrid			2022-12-25	WOS:000231487800037
J	Echizenya, M; Kondo, S; Takahashi, R; Oh, J; Kawashima, S; Kitayama, H; Takahashi, C; Noda, M				Echizenya, M; Kondo, S; Takahashi, R; Oh, J; Kawashima, S; Kitayama, H; Takahashi, C; Noda, M			The membrane-anchored MMP-regulator RECK is a target of myogenic regulatory factors	ONCOGENE			English	Article						RECK; MyoD; MRF4; myogenesis	SKELETAL-MUSCLE; MYOTENDINOUS JUNCTIONS; MRF4; CELL; EXPRESSION; GENE; DIFFERENTIATION; MEMBER; SP1; MATRIX-METALLOPROTEINASE-9	The membrane-anchored MMP-regulator RECK is down regulated in many solid tumors; the extent of RECK down regulation correlates with poor prognosis. Forced expression of RECK in tumor cells results in suppression of angiogenesis, invasion, and metastasis. Studies on the roles and the mechanisms of regulation of the RECK gene during normal development may therefore yield important insights into how the malignant behaviors of tumor cells arise and how they can be controlled. Our previous studies indicate that mice lacking RECK die around E10.5 with reduced tissue integrity. In the present study, we have found that in later stage wild-type embryos, RECK is abundantly expressed in skeletal muscles, especially in the areas where the myoblast differentiation factor MRF4 is expressed. Consistent with this finding, the RECK-promoter is activated by MRF4 in cultured cells. In contrast, a myoblast determination factor MyoD suppresses the RECK-promoter. Myoblastic cells lacking RECK expression give rise to myotubes at higher efficiency than the cells expressing RECK, indicating that RECK suppresses myotube formation. These findings suggest that MyoD down regulates RECK to facilitate myotube formation, whereas MRF4 up regulates RECK to promote other aspects of myogenesis that require extracellular matrix integrity.	Kyoto Univ, Grad Sch Med, Dept Mol Oncol, Sakyo Ku, Kyoto 6068501, Japan; Kyoto Univ, Dept Cellular Differentiat, Inst Frontier Med Sci, Sakyo Ku, Kyoto 6068501, Japan; Kyoto Univ, Grad Sch Med, Dept Pathol & Tumor Biol, Sakyo Ku, Kyoto 6068501, Japan; Korea Univ, Grad Sch Med, Ansan, South Korea; Kyoto Univ, Grad Sch Med, COE Program, Sakyo Ku, Kyoto 6068501, Japan	Kyoto University; Kyoto University; Kyoto University; Korea University; Korea University Medicine (KU Medicine); Kyoto University	Noda, M (corresponding author), Kyoto Univ, Grad Sch Med, Dept Mol Oncol, Sakyo Ku, Yoshida Konoe Cho, Kyoto 6068501, Japan.	mnoda@virus.kyoto-u.ac.jp		Oh, Junseo/0000-0002-0754-4946				Biesiada E, 1999, MOL CELL BIOL, V19, P2577; Birk DE, 1997, EUR J CELL BIOL, V72, P352; BLAU HM, 1985, SCIENCE, V230, P758, DOI 10.1126/science.2414846; BRAUN T, 1990, EMBO J, V9, P821, DOI 10.1002/j.1460-2075.1990.tb08179.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; Buckingham M, 2003, J ANAT, V202, P59, DOI 10.1046/j.1469-7580.2003.00139.x; Caron NJ, 1999, CELL TRANSPLANT, V8, P465, DOI 10.1177/096368979900800502; Chang THT, 2004, DEV BIOL, V269, P595, DOI 10.1016/j.ydbio.2004.02.013; Chen EH, 2004, TRENDS CELL BIOL, V14, P452, DOI 10.1016/j.tcb.2004.07.008; Chin JR, 1997, DEVELOPMENT, V124, P1519; COUCH CB, 1983, CELL, V32, P257, DOI 10.1016/0092-8674(83)90516-0; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; El Fahime E, 2000, EXP CELL RES, V258, P279, DOI 10.1006/excr.2000.4962; Ferguson JW, 2003, CELL TISSUE RES, V313, P93, DOI 10.1007/s00441-003-0743-z; Fomin M, 2004, DEV BIOL, V272, P498, DOI 10.1016/j.ydbio.2004.04.017; Horsley V, 2004, CELLS TISSUES ORGANS, V176, P67, DOI 10.1159/000075028; Kassar-Duchossoy L, 2004, NATURE, V431, P466, DOI 10.1038/nature02876; Lewis MP, 2000, J MUSCLE RES CELL M, V21, P223, DOI 10.1023/A:1005670507906; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; Novitch BG, 1996, J CELL BIOL, V135, P441, DOI 10.1083/jcb.135.2.441; Oh J, 2001, CELL, V107, P789, DOI 10.1016/S0092-8674(01)00597-9; Oh J, 2004, ONCOGENE, V23, P5041, DOI 10.1038/sj.onc.1207688; Osses N, 2002, AM J PHYSIOL-CELL PH, V282, pC383, DOI 10.1152/ajpcell.00322.2001; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; Sasahara RM, 1999, BIOCHEM BIOPH RES CO, V264, P668, DOI 10.1006/bbrc.1999.1552; SCHOLLMEYER JE, 1986, EXP CELL RES, V162, P411, DOI 10.1016/0014-4827(86)90346-0; Takahashi C, 1998, P NATL ACAD SCI USA, V95, P13221, DOI 10.1073/pnas.95.22.13221; TIDBALL JG, 1994, DEV BIOL, V163, P447, DOI 10.1006/dbio.1994.1161; Vinals F, 1997, J BIOL CHEM, V272, P12913, DOI 10.1074/jbc.272.20.12913; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; YAGAMIHIROMASA T, 1995, NATURE, V377, P652, DOI 10.1038/377652a0; Zhu ZM, 1997, DEV DYNAM, V209, P233, DOI 10.1002/(SICI)1097-0177(199706)209:2<233::AID-AJA9>3.3.CO;2-D	33	42	44	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	38					5850	5857		10.1038/sj.onc.1208733	http://dx.doi.org/10.1038/sj.onc.1208733			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960KW	16007210	Green Submitted, Bronze			2022-12-25	WOS:000231590400007
J	Bradbury, D; Clarke, D; Seedhouse, C; Corbett, L; Stocks, J; Knox, A				Bradbury, D; Clarke, D; Seedhouse, C; Corbett, L; Stocks, J; Knox, A			Vascular endothelial growth factor induction by prostaglandin E-2 in human airway smooth muscle cells is mediated by E prostanoid EP2/EP4 receptors and SP-1 transcription factor binding sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR GENE-TRANSCRIPTION; NECROSIS-FACTOR-ALPHA; PROSTANOID RECEPTORS; TUMOR ANGIOGENESIS; PROTEIN-KINASE; SP1 PHOSPHORYLATION; EXPRESSION; INHIBITION; DISEASE; DNA	Prostaglandin E-2 (PGE(2)) can increase vascular endothelial growth factor A (VEGF-A) production but the mechanisms involved are unclear. Here we characterized the transcriptional mechanisms involved in human airway smooth muscle cells (HASMC). PGE(2) increased VEGF-A mRNA and protein but not mRNA stability. PGE(2) stimulated the activity of a transiently transfected 2068- bp (- 2018 to + 50) VEGF-A promoter-driven luciferase construct. Functional 5' deletional analysis mapped the PGE(2) response element to the 135-bp sequence ( - 85/ + 50) of the human VEGF-A promoter. PGE(2)-induced luciferase activity was reduced in cells transfected with a 135-bp VEGF promoter fragment containing mutated Sp-1 binding sites but not in cells transfected with a construct containing mutated EGR-1 binding sites. Electrophoretic mobility shift assay and chromatin immuno-precipitation assay confirmed binding of Sp-1 to the VEGF promoter. PGE(2) increased phosphorylation of Sp-1 and luciferase activity of a transfected Sp-1 reporter construct. PGE(2) receptor agonists EP2 (ONO- AE1 259) and EP4 (ONO- AE1 329) mimicked the effect of PGE(2), and reverse transcription-PCR, Western blotting, and flow cytometry confirmed the presence of EP2 and EP4 receptors. VEGF protein release and Sp-1 reporter activity were increased by forskolin and isoproterenol, which increase cytosolic cAMP, and the cAMP analogue, 8-bromoadenosine-3', 5'-cyclophosphoric acid. These studies suggest that PGE(2) increases VEGF transcriptionally and involves the Sp-1 binding site via a cAMPdependent mechanism involving EP2 and EP4 receptors.	Univ Nottingham, Div Resp Med, City Hosp, Nottingham NG5 1PB, England	Nottingham University Hospital NHS Trust; Nottingham City Hospital; University of Nottingham	Knox, A (corresponding author), Univ Nottingham, Div Resp Med, City Hosp, Clin Sci Bldg,Hucknall Rd, Nottingham NG5 1PB, England.	alan.knox@nottingham.ac.uk	Stocks, Joanne/A-3307-2017; Stocks, Joanne/K-4403-2019; SEEDHOUSE, CLAIRE/B-3570-2009	Stocks, Joanne/0000-0002-7800-6002; Stocks, Joanne/0000-0002-7800-6002; Seedhouse, Claire/0000-0003-2280-4045; Knox, Alan/0000-0002-5906-4143				Achen MG, 1998, INT J EXP PATHOL, V79, P255, DOI 10.1046/j.1365-2613.1998.700404.x; Ballara SC, 1999, INT J EXP PATHOL, V80, P235, DOI 10.1046/j.1365-2613.1999.00129.x; Beck PL, 1999, INFLAMM BOWEL DIS, V5, P44, DOI 10.1097/00054725-199902000-00007; BEN AVP, 1995, FEBS LETT, V372, P83; Benckert C, 2003, CANCER RES, V63, P1083; BERSE B, 1992, MOL BIOL CELL, V3, P211, DOI 10.1091/mbc.3.2.211; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; Burgess JK, 2004, J ALLERGY CLIN IMMUN, V113, P876, DOI 10.1016/j.jaci.2004.02.029; Chakrabarti R, 2002, BIOTECHNIQUES, V32, P866, DOI 10.2144/02324rr04; Clarke DL, 2005, MOL PHARMACOL, V67, P383, DOI 10.1124/mol.104.006486; CLARKE DL, 2005, AM J PHYSIOL, V288, pL228; Clavel G, 2003, JOINT BONE SPINE, V70, P321, DOI 10.1016/S1297-319X(03)00088-5; COLEMAN RA, 1994, PHARMACOL REV, V46, P205; Daniel TO, 1999, CANCER RES, V59, P4574; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; Ferrara N, 2000, RECENT PROG HORM RES, V55, P15; FINKENZELLER G, 1995, BIOCHEM BIOPH RES CO, V208, P432, DOI 10.1006/bbrc.1995.1356; Gately S, 2000, CANCER METAST REV, V19, P19, DOI 10.1023/A:1026575610124; Gately S, 2004, SEMIN ONCOL, V31, P2, DOI 10.1053/j.seminoncol.2004.03.040; Gille J, 1997, EMBO J, V16, P750, DOI 10.1093/emboj/16.4.750; HARADA S, 1995, CLIN ORTHOP RELAT R, P76; HARADA S, 1994, J CLIN INVEST, V93, P2490, DOI 10.1172/JCI117258; Henke W, 1997, NUCLEIC ACIDS RES, V25, P3957, DOI 10.1093/nar/25.19.3957; Hoshino M, 2001, J ALLERGY CLIN IMMUN, V107, P295, DOI 10.1067/mai.2001.111928; Inoue H, 2002, BRIT J PHARMACOL, V136, P287, DOI 10.1038/sj.bjp.0704705; Jones MK, 1999, NAT MED, V5, P1418; Kanazawa H, 2003, AM J MED, V114, P354, DOI 10.1016/S0002-9343(02)01562-0; Kanazawa H, 2002, THORAX, V57, P885, DOI 10.1136/thorax.57.10.885; Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788; Knox AJ, 2001, FASEB J, V15, P2480, DOI 10.1096/fj.01-0256com; Maruyama T, 2001, BIOORG MED CHEM LETT, V11, P2029, DOI 10.1016/S0960-894X(01)00364-X; Mezquita P, 2005, ONCOGENE, V24, P889, DOI 10.1038/sj.onc.1208251; Milanini J, 1998, J BIOL CHEM, V273, P18165, DOI 10.1074/jbc.273.29.18165; Milanini-Mongiat J, 2002, J BIOL CHEM, V277, P20631, DOI 10.1074/jbc.M201753200; MILLER DM, 1987, AM J MED SCI, V294, P388, DOI 10.1097/00000441-198711000-00015; Narumiya S, 1999, PHYSIOL REV, V79, P1193, DOI 10.1152/physrev.1999.79.4.1193; Pallisgaard N, 1999, GENE CHROMOSOME CANC, V26, P355, DOI 10.1002/(SICI)1098-2264(199912)26:4<355::AID-GCC10>3.0.CO;2-3; Pang L, 1998, CLIN EXP ALLERGY, V28, P1050; Pang LH, 1997, BRIT J PHARMACOL, V121, P579, DOI 10.1038/sj.bjp.0701152; Pang LH, 1997, AM J PHYSIOL-LUNG C, V273, pL1132, DOI 10.1152/ajplung.1997.273.6.L1132; PETERSON HI, 1986, ANTICANCER RES, V6, P251; Ryuto M, 1996, J BIOL CHEM, V271, P28220, DOI 10.1074/jbc.271.45.28220; Schafer G, 2003, J BIOL CHEM, V278, P8190, DOI 10.1074/jbc.M211999200; Segura JA, 2005, CANCER LETT, V218, P91, DOI 10.1016/j.canlet.2004.06.054; Stoner M, 2004, ONCOGENE, V23, P1052, DOI 10.1038/sj.onc.1207201; Tanaka T, 2000, J MOL CELL CARDIOL, V32, P1955, DOI 10.1006/jmcc.2000.1228; Tani K, 2001, BIOORG MED CHEM LETT, V11, P2025, DOI 10.1016/S0960-894X(01)00359-6; TISCHER E, 1991, J BIOL CHEM, V266, P11947; Wen FQ, 2003, J ALLERGY CLIN IMMUN, V111, P1307, DOI 10.1067/mai.2003.1455	50	78	82	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	2005	280	34					29993	30000		10.1074/jbc.M414530200	http://dx.doi.org/10.1074/jbc.M414530200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	957IC	15970595	Green Published, hybrid			2022-12-25	WOS:000231362500003
J	Ding, HG; Harrison, K; Lu, JX				Ding, HG; Harrison, K; Lu, JX			Thioredoxin reductase system mediates iron binding in IscA and iron delivery for the iron-sulfur cluster assembly in IscU	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FE-S CLUSTER; ESCHERICHIA-COLI; AZOTOBACTER-VINELANDII; CYSTEINE DESULFURASE; TRANSCRIPTION FACTOR; SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURE; SCAFFOLD PROTEIN; 2FE-2S CLUSTERS; MARITIMA ISCU	IscA is a key member of the iron-sulfur cluster assembly machinery found in bacteria and eukaryotes. Previously, IscA was characterized as an alternative iron-sulfur cluster assembly scaffold, as purified IscA can host transient iron-sulfur clusters. However, recent studies indicated that IscA is an iron-binding protein that can provide iron for the iron-sulfur cluster assembly in a proposed scaffold IscU ( Ding H., Clark, R. J., and Ding, B. ( 2004) J. Biol. Chem. 279, 37499 - 37504). To further elucidate the roles of IscA in the biogenesis of iron-sulfur clusters, we reevaluate the iron binding activity of IscA under physiologically relevant conditions. The results indicate that in the presence of the thioredoxin reductase system, Escherichia coli IscA binds iron with an iron association constant of 2.0 x 10(19) M-1 in vitro. Whereas all three components (thioredoxin 1, thioredoxin reductase and NADPH) in the thioredoxin reductase system are essential for mediating the iron binding in IscA, only catalytic amounts of thioredoxin 1 and thioredoxin reductase are required. In contrast, IscU fails to bind iron in the presence of the thioredoxin reductase system, suggesting that the iron binding in IscA is specific. Nevertheless, the thioredoxin reductase system can promote the iron-sulfur cluster assembly in IscU in the presence of the iron-loaded IscA, cysteine desulfurase ( IscS), and L-cysteine, demonstrating a physiologically relevant system for the biogenesis of iron-sulfur clusters. The results provide additional evidence for the hypothesis that IscA is capable of recruiting intracellular "free" iron and delivering the iron for the iron-sulfur cluster assembly in IscU.	Louisiana State Univ, Dept Biol Sci, Baton Rouge, LA 70803 USA; Wenzhou Med Coll, Inst Cellular & Mol Med, Wenzhou 325035, Zhejiang, Peoples R China	Louisiana State University System; Louisiana State University; Wenzhou Medical University	Ding, HG (corresponding author), Louisiana State Univ, Dept Biol Sci, Baton Rouge, LA 70803 USA.	hding@lsu.edu	Ding, Huangen/AAJ-8550-2020	Ding, Huangen/0000-0002-4815-7336				Achebach S, 2004, FEBS LETT, V565, P203, DOI 10.1016/j.febslet.2004.04.007; Agar JN, 2000, BIOCHEMISTRY-US, V39, P7856, DOI 10.1021/bi000931n; Aslund F, 1999, J BACTERIOL, V181, P1375; Beinert H, 2000, EUR J BIOCHEM, V267, P5657, DOI 10.1046/j.1432-1327.2000.01637.x; Beinert H, 1997, SCIENCE, V277, P653, DOI 10.1126/science.277.5326.653; BEINERT H, 1983, ANAL BIOCHEM, V131, P373, DOI 10.1016/0003-2697(83)90186-0; Bertini I, 2003, J MOL BIOL, V331, P907, DOI 10.1016/S0022-2836(03)00768-X; Bilder PW, 2004, BIOCHEMISTRY-US, V43, P133, DOI 10.1021/bi035440s; Cozar-Castellano I, 2004, BBA-PROTEINS PROTEOM, V1700, P179, DOI 10.1016/j.bbapap.2004.05.004; Crichton R R, 1990, Adv Protein Chem, V40, P281, DOI 10.1016/S0065-3233(08)60288-0; Cupp-Vickery JR, 2004, J MOL BIOL, V338, P127, DOI 10.1016/j.jmb.2004.02.027; Ding BJ, 2005, BIOCHEM J, V389, P797, DOI 10.1042/BJ20050405; Ding H, 2004, J BIOL CHEM, V279, P37499, DOI 10.1074/jbc.M404533200; Ding HG, 2004, BIOCHEM J, V379, P433, DOI 10.1042/BJ20031702; Ding HG, 1998, BIOCHEMISTRY-US, V37, P17280, DOI 10.1021/bi980532g; Duby G, 2002, HUM MOL GENET, V11, P2635, DOI 10.1093/hmg/11.21.2635; Flint DH, 1996, J BIOL CHEM, V271, P16068; Hoff KG, 2003, J BIOL CHEM, V278, P37582, DOI 10.1074/jbc.M305292200; Jensen LT, 2000, MOL CELL BIOL, V20, P3918, DOI 10.1128/MCB.20.11.3918-3927.2000; Johnson DC, 2005, BIOCHEM SOC T, V33, P90, DOI 10.1042/BST0330090; Kato S, 2002, P NATL ACAD SCI USA, V99, P5948, DOI 10.1073/pnas.082123599; Kaut A, 2000, J BIOL CHEM, V275, P15955, DOI 10.1074/jbc.M909502199; KEYER K, 1995, J BACTERIOL, V177, P6782, DOI 10.1128/jb.177.23.6782-6790.1995; Krebs C, 2001, BIOCHEMISTRY-US, V40, P14069, DOI 10.1021/bi015656z; Li DS, 1999, FEBS LETT, V456, P13, DOI 10.1016/S0014-5793(99)00896-0; Mansy SS, 2002, J BIOL CHEM, V277, P21397, DOI 10.1074/jbc.M201439200; Morimoto K, 2003, J BIOCHEM, V134, P211, DOI 10.1093/jb/mvg131; Morimoto K, 2002, FEBS LETT, V519, P123, DOI 10.1016/S0014-5793(02)02736-9; Muhlenhoff U, 2003, EMBO J, V22, P4815, DOI 10.1093/emboj/cdg446; Mulrooney SB, 1997, PROTEIN EXPRES PURIF, V9, P372, DOI 10.1006/prep.1996.0698; Ollagnier-de-Choudens S, 2004, J BIOL INORG CHEM, V9, P828, DOI 10.1007/s00775-004-0581-9; Ollagnier-de-Choudens S, 2001, J BIOL CHEM, V276, P22604, DOI 10.1074/jbc.M102902200; Puccio H, 2002, CURR OPIN GENET DEV, V12, P272, DOI 10.1016/S0959-437X(02)00298-8; Ramazzotti A, 2004, FEBS LETT, V557, P215, DOI 10.1016/S0014-5793(03)01498-4; Ramelot TA, 2004, J MOL BIOL, V344, P567, DOI 10.1016/j.jmb.2004.08.038; Rodriguez-Manzaneque MT, 2002, MOL BIOL CELL, V13, P1109, DOI 10.1091/mbc.01-10-0517; Schwartz CJ, 2000, P NATL ACAD SCI USA, V97, P9009, DOI 10.1073/pnas.160261497; Schwartz CJ, 2001, P NATL ACAD SCI USA, V98, P14895, DOI 10.1073/pnas.251550898; Silberg JJ, 2004, J BIOL CHEM, V279, P53924, DOI 10.1074/jbc.M410117200; Smith AD, 2001, J AM CHEM SOC, V123, P11103, DOI 10.1021/ja016757n; Takahashi Y, 1999, J BIOCHEM, V126, P917, DOI 10.1093/oxfordjournals.jbchem.a022535; Urbina HD, 2001, J BIOL CHEM, V276, P44521, DOI 10.1074/jbc.M106907200; Veine DM, 1998, PROTEIN SCI, V7, P1441, DOI 10.1002/pro.5560070621; Wollenberg M, 2003, EUR J BIOCHEM, V270, P1662, DOI 10.1046/j.1432-1033.2003.03522.x; Wu G, 2002, J BIOL INORG CHEM, V7, P526, DOI 10.1007/s00775-001-0330-2; Wu SP, 2003, BIOCHEMISTRY-US, V42, P5784, DOI 10.1021/bi026939+; Yang WY, 2002, J BIOL CHEM, V277, P12868, DOI 10.1074/jbc.M109485200; Yoon T, 2004, J BIOL CHEM, V279, P25943, DOI 10.1074/jbc.C400107200; Yoon T, 2003, J AM CHEM SOC, V125, P6078, DOI 10.1021/ja027967i; Zhang Y, 2005, J BIOL CHEM, V280, P19794, DOI 10.1074/jbc.M500397200; ZHENG LM, 1993, P NATL ACAD SCI USA, V90, P2754, DOI 10.1073/pnas.90.7.2754; ZHENG LM, 1994, J BIOL CHEM, V269, P18723; Zheng LM, 1998, J BIOL CHEM, V273, P13264, DOI 10.1074/jbc.273.21.13264; Zheng M, 1998, SCIENCE, V279, P1718, DOI 10.1126/science.279.5357.1718	54	65	69	3	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	2005	280	34					30432	30437		10.1074/jbc.M504638200	http://dx.doi.org/10.1074/jbc.M504638200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	957IC	15985427	Green Published, hybrid			2022-12-25	WOS:000231362500056
J	Lu, XB; Zhang, F; McNew, JA; Shin, YK				Lu, XB; Zhang, F; McNew, JA; Shin, YK			Membrane fusion induced by neuronal SNAREs transits through hemifusion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLUENZA HEMAGGLUTININ; TRANSMEMBRANE DOMAIN; BIOLOGICAL-MEMBRANES; COMPLEX; PROTEIN; EXOCYTOSIS; PATHWAY; PORE	Synaptic transmission requires the controlled release of neurotransmitter from synaptic vesicles by membrane fusion with the presynaptic plasma membrane. SNAREs are the core constituents of the protein machinery responsible for synaptic membrane fusion. The mechanism by which SNAREs drive membrane fusion is thought to involve a hemifusion intermediate, a condition in which the outer leaflets of two bilayers are combined and the inner leaflets remain intact; however, hemifusion has been observed only as an end point rather than as an intermediate. Here, we examined the kinetics of membrane fusion of liposomes mediated by recombinant neuronal SNAREs using fluorescence assays that monitor both total lipid mixing and inner leaflet mixing. Our results demonstrate that hemifusion is dominant at the early stage of the fusion reaction. Over time, hemifusion transitioned to complete fusion, showing that hemifusion is a true intermediate. We also show that hemifusion intermediates can be trapped, likely as unproductive outcomes, by modulating the surface concentration of the SNARE proteins.	Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA; Rice Univ, Dept Biochem & Cell Biol, Houston, TX 77251 USA	Iowa State University; Rice University	Shin, YK (corresponding author), Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA.	colishin@iastate.edu	McNew, James/AAV-4911-2020; Zhang, Fan/A-3477-2011; McNew, James/ABD-8081-2020	McNew, James/0000-0001-8459-3664; 				Armstrong RT, 2000, J CELL BIOL, V151, P425, DOI 10.1083/jcb.151.2.425; Chen YA, 1999, CELL, V97, P165, DOI 10.1016/S0092-8674(00)80727-8; Chernomordik LV, 2003, ANNU REV BIOCHEM, V72, P175, DOI 10.1146/annurev.biochem.72.121801.161504; Chernomordik LV, 1998, J CELL BIOL, V140, P1369, DOI 10.1083/jcb.140.6.1369; CHERNOMORDIK LV, 1993, FEBS LETT, V318, P71, DOI 10.1016/0014-5793(93)81330-3; Han X, 2004, SCIENCE, V304, P289, DOI 10.1126/science.1095801; Hanson PI, 1997, CURR OPIN NEUROBIOL, V7, P310, DOI 10.1016/S0959-4388(97)80057-8; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; KEMBLE GW, 1994, CELL, V76, P383, DOI 10.1016/0092-8674(94)90344-1; Kuzmic P, 1996, ANAL BIOCHEM, V237, P260, DOI 10.1006/abio.1996.0238; Kweon DH, 2003, NAT STRUCT BIOL, V10, P440, DOI 10.1038/nsb928; Lin RC, 2000, ANNU REV CELL DEV BI, V16, P19, DOI 10.1146/annurev.cellbio.16.1.19; McNew JA, 2000, NATURE, V407, P153, DOI 10.1038/35025000; Meers P, 2000, BBA-BIOMEMBRANES, V1467, P227, DOI 10.1016/S0005-2736(00)00224-8; Melikyan GB, 2000, MOL BIOL CELL, V11, P3765, DOI 10.1091/mbc.11.11.3765; Parlati F, 1999, P NATL ACAD SCI USA, V96, P12565, DOI 10.1073/pnas.96.22.12565; Poirier MA, 1998, NAT STRUCT BIOL, V5, P765, DOI 10.1038/1799; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Xu YB, 2005, NAT STRUCT MOL BIOL, V12, P417, DOI 10.1038/nsmb921; Zaitseva E, 2005, J CELL BIOL, V169, P167, DOI 10.1083/jcb.200412059	23	90	93	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	2005	280	34					30538	30541		10.1074/jbc.M506862200	http://dx.doi.org/10.1074/jbc.M506862200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	957IC	15980065	hybrid			2022-12-25	WOS:000231362500068
J	McIntosh, JM; Plazas, PV; Watkins, M; Gomez-Casati, ME; Olivera, BM; Elgoyhen, AB				McIntosh, JM; Plazas, PV; Watkins, M; Gomez-Casati, ME; Olivera, BM; Elgoyhen, AB			A novel alpha-conotoxin, PeIA, cloned from Conus pergrandis, discriminates between rat alpha 9 alpha 10 and alpha 7 nicotinic cholinergic receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROOT GANGLION NEURONS; INNER HAIR-CELLS; LATERAL-LINE ORGAN; CHICK OPTIC LOBE; ACETYLCHOLINE-RECEPTOR; PHARMACOLOGICAL-PROPERTIES; SUBUNIT COMPOSITION; MOLECULAR-CLONING; GENE FAMILY; BETA 2	The alpha 9 and alpha 10 nicotinic cholinergic subunits assemble to form the receptor believed to mediate synaptic transmission between efferent olivocochlear fibers and hair cells of the cochlea, one of the few examples of postsynaptic function for a non-muscle nicotinic acetylcholine receptor ( nAChR). However, it has been suggested that the expression profile of alpha 9 and alpha 10 overlaps with that of alpha 7 in the cochlea and in sites such as dorsal root ganglion neurons, peripheral blood lymphocytes, developing thymocytes, and skin. We now report the cloning, total synthesis, and characterization of a novel toxin alpha-conotoxin PeIA that discriminates between alpha 9 alpha 10 and alpha 7 nAChRs. This is the first toxin to be identified from Conus pergrandis, a species found in deep waters of the Western Pacific. alpha-Conotoxin PeIA displayed a 260-fold higher selectivity for alpha-bungarotoxin-sensitive alpha 9 alpha 10 nAChRs compared with alpha-bungarotoxin-sensitive alpha 7 receptors. The IC50 of the toxin was 6.9 +/- 0.5 nM and 4.4 +/- 0.5 nM for recombinant alpha 9 alpha 10 and wild-type hair cell nAChRs, respectively. alpha-Conotoxin PeIA bears high resemblance to alpha-conotoxins MII and GIC isolated from Conus magus and Conus geographus, respectively. However, neither alpha-conotoxin MII nor alpha-conotoxin GIC at concentrations of 10 mu M blocked acetylcholine responses elicited in Xenopus oocytes injected with the alpha 9 and alpha 10 subunits. Among neuronal non-alpha-bungarotoxin-sensitive receptors, alpha-conotoxin PeIA was also active at alpha 3 beta 2 receptors and chimeric alpha 6/alpha 3 beta 2 beta 3 receptors. alpha-Conotoxin PeIA represents a novel probe to differentiate responses mediated either through alpha 9 alpha 10 or alpha 7 nAChRs in those tissues where both receptors are expressed.	Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA; Univ Utah, Dept Psychiat, Salt Lake City, UT 84112 USA; Univ Utah, Dept Pathol, Salt Lake City, UT 84112 USA; Univ Buenos Aires, Consejo Nacl Invest Cient & Tecn, Inst Invest Ingn Genet & Biol Mol, RA-1428 Buenos Aires, DF, Argentina	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires	McIntosh, JM (corresponding author), Univ Utah, Dept Biol, 257 S 1400 E, Salt Lake City, UT 84112 USA.	mcintosh.mike@gmail.com		Gomez-Casati, Maria/0000-0003-4923-8274; Plazas, Paola/0000-0001-8195-484X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM048677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R29MH053631, R01MH053631] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM48677] Funding Source: Medline; NIMH NIH HHS [MH53631] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Arredondo J, 2002, J CELL BIOL, V159, P325, DOI 10.1083/jcb.200206096; Azam L, 2005, J BIOL CHEM, V280, P80, DOI 10.1074/jbc.M406281200; Baker ER, 2004, MOL PHARMACOL, V65, P453, DOI 10.1124/mol.65.2.453; Balestra B, 2000, MOL PHARMACOL, V58, P300, DOI 10.1124/mol.58.2.300; Bleckmann H., 1993, BEHAV TELEOST FISHES, P201; BOBBIN RP, 1978, ANN OTO RHINOL LARYN, V87, P185; BOULTER J, 1987, P NATL ACAD SCI USA, V84, P7763, DOI 10.1073/pnas.84.21.7763; Cartier GE, 1996, J BIOL CHEM, V271, P7522, DOI 10.1074/jbc.271.13.7522; Champtiaux N, 2003, J NEUROSCI, V23, P7820; Chernyavsky AI, 2004, J CELL SCI, V117, P5665, DOI 10.1242/jcs.01492; Colquhoun LM, 1997, J NEUROCHEM, V69, P2355; Conroy WG, 1998, MOL PHARMACOL, V53, P392, DOI 10.1124/mol.53.3.392; COUTURIER S, 1990, NEURON, V5, P847, DOI 10.1016/0896-6273(90)90344-F; Dawkins R, 2005, J NEUROPHYSIOL, V93, P2541, DOI 10.1152/jn.01283.2004; DENERIS ES, 1988, NEURON, V1, P45, DOI 10.1016/0896-6273(88)90208-5; Drescher DG, 2004, NEUROSCIENCE, V127, P737, DOI 10.1016/j.neuroscience.2004.05.037; DUVOISIN RM, 1989, NEURON, V3, P487, DOI 10.1016/0896-6273(89)90207-9; ELGOYHEN AB, 1994, CELL, V79, P705, DOI 10.1016/0092-8674(94)90555-X; Elgoyhen AB, 2001, P NATL ACAD SCI USA, V98, P3501, DOI 10.1073/pnas.051622798; FLOCK A, 1962, J CELL BIOL, V15, P19, DOI 10.1083/jcb.15.1.19; Fuchs PA, 1996, CURR OPIN NEUROBIOL, V6, P514, DOI 10.1016/S0959-4388(96)80058-4; Genzen JR, 2001, J NEUROPHYSIOL, V86, P1773, DOI 10.1152/jn.2001.86.4.1773; Gerzanich V, 1998, J PHARMACOL EXP THER, V286, P311; Gerzanich V, 1997, MOL PHARMACOL, V51, P320, DOI 10.1124/mol.51.2.320; Glowatzki E, 2000, SCIENCE, V288, P2366, DOI 10.1126/science.288.5475.2366; GOLDMAN D, 1987, CELL, V48, P965, DOI 10.1016/0092-8674(87)90705-7; Gotti C, 2005, MOL PHARMACOL, V67, P2007, DOI 10.1124/mol.105.011940; GOTTI C, 1994, EUR J NEUROSCI, V6, P1281, DOI 10.1111/j.1460-9568.1994.tb00318.x; Groot-Kormelink PJ, 1998, J BIOL CHEM, V273, P15317, DOI 10.1074/jbc.273.25.15317; Guinan J.J., 1996, COCHLEA EDITED, P435; Haberberger RV, 2004, AUTON NEUROSCI-BASIC, V113, P32, DOI 10.1016/j.autneu.2004.05.008; Jones AK, 2003, GENOMICS, V82, P441, DOI 10.1016/S0888-7543(03)00153-8; Karlin A, 2002, NAT REV NEUROSCI, V3, P102, DOI 10.1038/nrn731; Katz E, 2000, HEARING RES, V141, P117, DOI 10.1016/S0378-5955(99)00214-2; Katz E, 2004, J NEUROSCI, V24, P7814, DOI 10.1523/JNEUROSCI.2102-04.2004; Kros CJ, 1998, NATURE, V394, P281, DOI 10.1038/28401; Kurzen H, 2005, EXP DERMATOL, V14, P155, DOI 10.1111/j.0906-6705.2005.0266i.x; Le Novere N, 2002, J NEUROBIOL, V53, P447, DOI 10.1002/neu.10153; Lips KS, 2002, NEUROSCIENCE, V115, P1, DOI 10.1016/S0306-4522(02)00274-9; LUEBKE AE, 1995, ABS ASS RES OTOLARYN, V18, P193; Lustig LR, 2001, GENOMICS, V73, P272, DOI 10.1006/geno.2000.6503; McIntosh JM, 2002, J BIOL CHEM, V277, P33610, DOI 10.1074/jbc.M205102200; McIntosh JM, 1999, ANNU REV BIOCHEM, V68, P59, DOI 10.1146/annurev.biochem.68.1.59; MIHOVILOVIC M, 1993, J IMMUNOL, V151, P6517; Morley BJ, 1998, MOL BRAIN RES, V53, P78, DOI 10.1016/S0169-328X(97)00272-6; Nguyen VT, 2000, AM J PATHOL, V157, P1377, DOI 10.1016/S0002-9440(10)64651-2; Nicke A, 2004, EUR J BIOCHEM, V271, P2305, DOI 10.1111/j.1432-1033.2004.04145.x; Peng HS, 2004, LIFE SCI, V76, P263, DOI 10.1016/j.lfs.2004.05.031; Pohlmann K, 2004, J EXP BIOL, V207, P2971, DOI 10.1242/jeb.01129; Rothlin CV, 2003, MOL PHARMACOL, V63, P1067, DOI 10.1124/mol.63.5.1067; RUSSELL IJ, 1971, J EXP BIOL, V54, P643; Santos AD, 2004, J BIOL CHEM, V279, P17596, DOI 10.1074/jbc.M309654200; Sato KZ, 1999, NEUROSCI LETT, V266, P17, DOI 10.1016/S0304-3940(99)00259-1; SEGUELA P, 1993, J NEUROSCI, V13, P596; Sgard F, 2002, MOL PHARMACOL, V61, P150, DOI 10.1124/mol.61.1.150; Terlau H, 2004, PHYSIOL REV, V84, P41, DOI 10.1152/physrev.00020.2003; Walker CS, 1999, J BIOL CHEM, V274, P30664, DOI 10.1074/jbc.274.43.30664; WALS JG, 1979, CONE SHELLS SYNOPSIS, P790; Weisstaub N, 2002, HEARING RES, V167, P122, DOI 10.1016/S0378-5955(02)00380-5	60	107	116	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	2005	280	34					30107	30112		10.1074/jbc.M504102200	http://dx.doi.org/10.1074/jbc.M504102200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	957IC	15983035	hybrid, Green Published			2022-12-25	WOS:000231362500016
J	Ohnishi, T; Hishida, T; Harada, Y; Iwasaki, H; Shinagawa, H				Ohnishi, T; Hishida, T; Harada, Y; Iwasaki, H; Shinagawa, H			Structure-function analysis of the three domains of RuvB DNA motor protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RUVA; JUNCTION-SPECIFIC ENDONUCLEASE; PROMOTES BRANCH MIGRATION; THERMUS-THERMOPHILUS HB8; HOLLIDAY JUNCTION; CRYSTAL-STRUCTURE; ATPASE ACTIVITY; HOMOLOGOUS RECOMBINATION; RECOGNITION PROTEIN; MUTATIONAL ANALYSIS	RuvB protein forms two hexameric rings that bind to the RuvA tetramer at DNA Holliday junctions. The RuvAB complex utilizes the energy of ATP hydrolysis to promote branch migration of Holliday junctions. The crystal structure of RuvB from Thermus thermophilus (Tth) HB8 showed that each RuvB monomer has three domains (N, M, and C). This study is a structure-function analysis of the three domains of RuvB. The results show that domain N is involved in RuvA-RuvB and RuvB-RuvB subunit interactions, domains N and M are required for ATP hydrolysis and ATP binding-induced hexamer formation, and domain C plays an essential role in DNA binding. The side chain of Arg-318 is essential for DNA binding and may directly interact with DNA. The data also provide evidence that coordinated ATP-dependent interactions between domains N, M, and C play an essential role during formation of the RuvAB Holliday junction ternary complex.	Osaka Univ, Dept Mol Microbiol, Microbial Dis Res Inst, Suita, Osaka 5650871, Japan; CREST, Japan Sci & Technol Agcy, Kawaguchi, Saitama 3320012, Japan; Yokohama City Univ, Div Mol & Cellular biol, Grad Sch Integrated Sci, Yokohama, Kanagawa 2300045, Japan; Tokyo Metropolitan Inst Med Sci, Dept Mol Physiol, Tokyo 1138613, Japan	Osaka University; Japan Science & Technology Agency (JST); Yokohama City University; Tokyo Metropolitan Institute of Medical Science	Shinagawa, H (corresponding author), Osaka Univ, Dept Mol Microbiol, Microbial Dis Res Inst, 3-1 Yamadaoka, Suita, Osaka 5650871, Japan.	shinagaw@biken.osaka-u.ac.jp	Iwasaki, Hiroshi/Y-7946-2018	Iwasaki, Hiroshi/0000-0002-0153-6873; Hishida, Takashi/0000-0002-9752-6599				ARIYOSHI M, 1994, CELL, V78, P1063, DOI 10.1016/0092-8674(94)90280-1; BACHMANN BJ, 1972, BACTERIOL REV, V36, P525, DOI 10.1128/MMBR.36.4.525-557.1972; DUNDERDALE HJ, 1991, NATURE, V354, P506, DOI 10.1038/354506a0; Han YW, 2001, J BIOL CHEM, V276, P35024, DOI 10.1074/jbc.M103611200; Hishida T, 1996, GENE, V182, P63, DOI 10.1016/S0378-1119(96)00474-X; Hishida T, 1999, J BIOL CHEM, V274, P25335, DOI 10.1074/jbc.274.36.25335; Hishida T, 2004, GENE DEV, V18, P1886, DOI 10.1101/gad.1223804; Hishida T, 2004, P NATL ACAD SCI USA, V101, P9573, DOI 10.1073/pnas.0403584101; Hishida T, 2003, GENES CELLS, V8, P721, DOI 10.1046/j.1365-2443.2003.00670.x; HOLLIDAY R, 1964, GENET RES, V5, P282, DOI 10.1017/S0016672300001233; Ichiyanagi K, 1998, GENES CELLS, V3, P575, DOI 10.1046/j.1365-2443.1998.00213.x; Iwasaki H, 2000, MOL MICROBIOL, V36, P528, DOI 10.1046/j.1365-2958.2000.01842.x; IWASAKI H, 1991, EMBO J, V10, P4381, DOI 10.1002/j.1460-2075.1991.tb05016.x; IWASAKI H, 1992, GENE DEV, V6, P2214, DOI 10.1101/gad.6.11.2214; MITCHELL AH, 1994, J MOL BIOL, V243, P208, DOI 10.1006/jmbi.1994.1648; MULLER B, 1993, J BIOL CHEM, V268, P17185; Neuwald AF, 1999, GENOME RES, V9, P27; Nishino T, 1998, STRUCTURE, V6, P11, DOI 10.1016/S0969-2126(98)00003-3; Nishino T, 2000, J MOL BIOL, V298, P407, DOI 10.1006/jmbi.2000.3675; Ohnishi T, 2000, GENES GENET SYST, V75, P233, DOI 10.1266/ggs.75.233; PARSONS CA, 1993, J MOL BIOL, V232, P397, DOI 10.1006/jmbi.1993.1399; Privezentzev CV, 2005, J BIOL CHEM, V280, P3365, DOI 10.1074/jbc.M409256200; Putnam CD, 2001, J MOL BIOL, V311, P297, DOI 10.1006/jmbi.2001.4852; Roe SM, 1998, MOL CELL, V2, P361, DOI 10.1016/S1097-2765(00)80280-4; SHIBA T, 1993, MOL GEN GENET, V237, P395, DOI 10.1007/BF00279443; SHIBA T, 1991, P NATL ACAD SCI USA, V88, P8445, DOI 10.1073/pnas.88.19.8445; Shinagawa H, 1996, TRENDS BIOCHEM SCI, V21, P107, DOI 10.1016/0968-0004(96)10014-1; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; STASIAK A, 1994, P NATL ACAD SCI USA, V91, P7618, DOI 10.1073/pnas.91.16.7618; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TSANEVA IR, 1992, MOL GEN GENET, V235, P1, DOI 10.1007/BF00286175; TSANEVA IR, 1992, CELL, V69, P1171, DOI 10.1016/0092-8674(92)90638-S; West SC, 1997, ANNU REV GENET, V31, P213, DOI 10.1146/annurev.genet.31.1.213; Yamada K, 1999, MOL GEN GENET, V261, P1001, DOI 10.1007/s004380051049; Yamada K, 2002, MOL CELL, V10, P671, DOI 10.1016/S1097-2765(02)00641-X; Yamada K, 2001, P NATL ACAD SCI USA, V98, P1442, DOI 10.1073/pnas.031470598	36	13	14	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	2005	280	34					30504	30510		10.1074/jbc.M502400200	http://dx.doi.org/10.1074/jbc.M502400200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	957IC	15972826	hybrid			2022-12-25	WOS:000231362500064
J	Wang, PJ; Wang, JJ; Xiao, YS; Murray, JW; Novikoff, PM; Angeletti, RH; Orr, GA; Lan, DD; Silver, DL; Wolkoff, AW				Wang, PJ; Wang, JJ; Xiao, YS; Murray, JW; Novikoff, PM; Angeletti, RH; Orr, GA; Lan, DD; Silver, DL; Wolkoff, AW			Interaction with PDZK1 is required for expression of organic anion transporting protein 1A1 on the hepatocyte surface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCAVENGER RECEPTOR-B; RAT-LIVER; TARGETED DISRUPTION; SULFOBROMOPHTHALEIN; IDENTIFICATION; BILIRUBIN; DOMAIN; SUPERFAMILY; COMPLEX; CLONING	Although many organic anion transport protein (Oatp) family members have PDZ consensus binding sites at their C termini, the functional significance is unknown. In the present study, we utilized rat Oatp1a1 (NM_017111) as a prototypical member of this family to examine the mechanism governing its subcellular trafficking. A peptide corresponding to the C-terminal 16 amino acids of rat Oatp1a1 was used to affinity-isolate interacting proteins from rat liver cytosol. Protein mass fingerprinting identified PDZK1 as the major interacting protein. This was confirmed by immunoprecipitation of an Oatp1a1-PDZK1 complex from cotransfected 293T cells as well as from native rat liver membrane extracts. Oatp1a1 bound predominantly to the first and third PDZ binding domains of PDZK1, whereas the high density lipoprotein receptor, scavenger receptor B type I binds to the first domain. Although it is possible that PDZK1 forms a complex with these two integral membrane proteins, this did not occur, suggesting that as yet undescribed factors lead to selectivity in the interaction of these protein ligands with PDZK1. Oatp1a1 protein expression was near normal in PDZK1 knock-out mouse liver. However, it was located predominantly in intracellular structures, in contrast to its normal basolateral plasma membrane distribution. Plasma disappearance of the Oatp1a1 ligand [S-35] sulfobromophthalein was correspondingly delayed in knock-out mice. These studies show a critical role for oligomerization of Oatp1a1 with PDZK1 for its proper subcellular localization and function. Because its ability to transport substances into the cell requires surface expression, this must be considered in any assessment of physiologic function.	Albert Einstein Coll Med, Liver Res Ctr, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Anat & Struct Biol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Columbia Univ, Div Mol Med, Dept Med, New York, NY 10032 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Columbia University	Wolkoff, AW (corresponding author), Albert Einstein Coll Med, Marion Bessin Liver Res Ctr, 625 Ullmann Bldg,1300 Morris Pk Ave, Bronx, NY 10461 USA.	wolkoff@aecom.yu.edu		Silver, David/0000-0002-7289-9890	NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR019352] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK023026, P30DK041296] Funding Source: NIH RePORTER; NCI NIH HHS [CA06576] Funding Source: Medline; NCRR NIH HHS [S10 RR019352, S10 RR019352-01] Funding Source: Medline; NIDDK NIH HHS [DK23026, DK41296] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ADDONA T, 2005, CURRENT PROTOCOLS PR; Angeletti RH, 1998, AM J PHYSIOL-CELL PH, V275, pC882, DOI 10.1152/ajpcell.1998.275.3.C882; Angeletti RH, 1997, P NATL ACAD SCI USA, V94, P283, DOI 10.1073/pnas.94.1.283; Bao Y, 2002, AM J PHYSIOL-RENAL, V282, pF1103, DOI 10.1152/ajprenal.00152.2001; Bergwerk AJ, 1996, AM J PHYSIOL-GASTR L, V271, pG231, DOI 10.1152/ajpgi.1996.271.2.G231; Capuano P, 2005, PFLUG ARCH EUR J PHY, V449, P392, DOI 10.1007/s00424-004-1351-9; Cvetkovic M, 1999, DRUG METAB DISPOS, V27, P866; Gao B, 2004, J HEPATOL, V41, P201, DOI 10.1016/j.jhep.2004.04.029; GARTNER U, 1982, GASTROENTEROLOGY, V83, P1163; Gartner U, 1997, GASTROENTEROLOGY, V113, P1707, DOI 10.1053/gast.1997.v113.pm9352876; Gisler SM, 2003, KIDNEY INT, V64, P1746, DOI 10.1046/j.1523-1755.2003.00267.x; Glavy JS, 2000, J BIOL CHEM, V275, P1479, DOI 10.1074/jbc.275.2.1479; Hagenbuch B, 2003, BBA-BIOMEMBRANES, V1609, P1, DOI 10.1016/S0005-2736(02)00633-8; Hagenbuch B, 2004, PFLUG ARCH EUR J PHY, V447, P653, DOI 10.1007/s00424-003-1168-y; Hagenbuch B, 1996, BIOCHEM J, V316, P901, DOI 10.1042/bj3160901; Hata S, 2003, AM J PHYSIOL-GASTR L, V285, pG829, DOI 10.1152/ajpgi.00352.2002; Hung AY, 2002, J BIOL CHEM, V277, P5699, DOI 10.1074/jbc.R100065200; Ikemoto M, 2000, P NATL ACAD SCI USA, V97, P6538, DOI 10.1073/pnas.100114397; JACQUEMIN E, 1994, P NATL ACAD SCI USA, V91, P133, DOI 10.1073/pnas.91.1.133; JACQUEMIN E, 1991, J CLIN INVEST, V88, P2146, DOI 10.1172/JCI115546; KANAI N, 1995, SCIENCE, V268, P866, DOI 10.1126/science.7754369; Kato Y, 2004, PHARM RES-DORDR, V21, P1886, DOI 10.1023/B:PHAM.0000045244.83999.43; Kim EJ, 2004, NAT REV NEUROSCI, V5, P771, DOI 10.1038/nrn1517; Kocher O, 2003, J BIOL CHEM, V278, P52820, DOI 10.1074/jbc.M310482200; Kocher O, 2003, MOL CELL BIOL, V23, P1175, DOI 10.1128/MCB.23.4.1175-1180.2003; KURISU H, 1989, ANAL BIOCHEM, V179, P72, DOI 10.1016/0003-2697(89)90202-9; Lan DB, 2005, J BIOL CHEM, V280, P23390, DOI 10.1074/jbc.M502777200; Lu R, 1996, J CLIN INVEST, V98, P1142, DOI 10.1172/JCI118897; Mohan S, 2003, ONCOGENE, V22, P5270, DOI 10.1038/sj.onc.1206592; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; SHI XY, 1995, J BIOL CHEM, V270, P25591, DOI 10.1074/jbc.270.43.25591; Silver DL, 2002, J BIOL CHEM, V277, P34042, DOI 10.1074/jbc.M206584200; STOLLMAN YR, 1983, J CLIN INVEST, V72, P718, DOI 10.1172/JCI111021; van Montfoort JE, 2002, BBA-BIOMEMBRANES, V1564, P183, DOI 10.1016/S0005-2736(02)00445-5	35	61	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	2005	280	34					30143	30149		10.1074/jbc.M503969200	http://dx.doi.org/10.1074/jbc.M503969200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	957IC	15994332	hybrid			2022-12-25	WOS:000231362500021
J	Sukezane, T; Oneyama, C; Kakumoto, K; Shibutani, K; Hanafusa, H; Akagi, T				Sukezane, T; Oneyama, C; Kakumoto, K; Shibutani, K; Hanafusa, H; Akagi, T			Human diploid fibroblasts are resistant to MEK/ERK-mediated disruption of the actin cytoskeleton and invasiveness stimulated by Ras	ONCOGENE			English	Article						ras; ROCK/LIMK/Cofilin pathway; tropomyosin; morphological change; MEK/ERK pathway	ONCOGENIC RAS; DIFFERENTIAL EXPRESSION; TRANSFORMED FIBROBLASTS; TUMOR-SUPPRESSOR; DOWN-REGULATION; CANCER-CELLS; RHO GTPASES; LIM-KINASE; TROPOMYOSIN; PATHWAY	Ras-induced transformation is characterized not only by uncontrolled proliferation but also by drastic morphological changes accompanied by the disruption of the actin cytoskeleton. Previously, we reported that human fibroblasts are more resistant than rodent fibroblasts to Ras-induced transformation. To explore the molecular basis for the difference in susceptibility to Ras-induced transformation, we investigated the effect of activated H-Ras on the actin cytoskeleton in human diploid fibroblasts and in rat embryo fibroblasts, both of which are immortalized by SV40 early region. We demonstrate here that Ras-induced morphological changes, decreased expression of tropomyosin isoforms, and suppression of the ROCK/LIMK/Cofilin pathway observed in the rat fibroblasts were not detected in the human fibroblasts even with high expression levels of Ras. We also show that activation of the MEK/ERK pathway sufficed to induce all of these alterations in the rat fibroblasts, whereas the human fibroblasts were refractory to these MEK/ERKmediated changes. In addition to morphological changes, we demonstrated that the expression of activated Ras induced an invasive phenotype in the rat, but not in the human fibroblasts. These studies provide evidence for the existence of human-specific mechanisms that resist Ras/MEK/ERK-mediated transformation.	Osaka Biosci Inst, Mol Oncol Lab, Suita, Osaka 5650874, Japan; Osaka Univ, Grad Sch Med, Dept Mol Oncol, Suita, Osaka 5650871, Japan	Osaka University	Akagi, T (corresponding author), Osaka Biosci Inst, Mol Oncol Lab, 6-2-4 Furuedai, Suita, Osaka 5650874, Japan.	takagi@obi.or.jp						Akagi T, 2000, P NATL ACAD SCI USA, V97, P7290, DOI 10.1073/pnas.140210297; Akagi T, 2003, P NATL ACAD SCI USA, V100, P13567, DOI 10.1073/pnas.1834876100; Alaiya AA, 1997, INT J CANCER, V73, P678, DOI 10.1002/(SICI)1097-0215(19971127)73:5<678::AID-IJC11>3.0.CO;2-2; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Bakin AV, 2004, MOL BIOL CELL, V15, P4682, DOI 10.1091/mbc.E04-04-0353; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Campbell PM, 2004, SEMIN CANCER BIOL, V14, P105, DOI 10.1016/j.semcancer.2003.09.015; FERNANDEZ JLR, 1992, J CELL BIOL, V119, P427, DOI 10.1083/jcb.119.2.427; Fukuda M, 1997, J BIOL CHEM, V272, P32642, DOI 10.1074/jbc.272.51.32642; GABBIANI G, 1976, AM J PATHOL, V83, P457; Gimona M, 1996, P NATL ACAD SCI USA, V93, P9618, DOI 10.1073/pnas.93.18.9618; GIMONA M, 1995, P NATL ACAD SCI USA, V92, P9776, DOI 10.1073/pnas.92.21.9776; GLUCK U, 1993, P NATL ACAD SCI USA, V90, P383, DOI 10.1073/pnas.90.2.383; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hashimoto Y, 1996, CANCER RES, V56, P5266; HENDRICKS M, 1981, P NATL ACAD SCI-BIOL, V78, P5633, DOI 10.1073/pnas.78.9.5633; Jaffe AB, 2002, ADV CANCER RES, V84, P57, DOI 10.1016/S0065-230X(02)84003-9; Janke J, 2000, J EXP MED, V191, P1675, DOI 10.1084/jem.191.10.1675; Janssen RAJ, 1998, J BIOL CHEM, V273, P32182, DOI 10.1074/jbc.273.48.32182; Janssen RAJ, 2003, MOL CELL BIOL, V23, P1786, DOI 10.1128/MCB.23.5.1786-1797.2003; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Lee S, 2004, J BIOL CHEM, V279, P1885, DOI 10.1074/jbc.M306968200; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; MATSUMURA F, 1983, J BIOL CHEM, V258, P3954; Pawlak G, 2002, MOL BIOL CELL, V13, P336, DOI 10.1091/mbc.01-02-0302; Pawlak G, 2001, CURR OPIN GENET DEV, V11, P41, DOI 10.1016/S0959-437X(00)00154-4; Raval GN, 2003, ONCOGENE, V22, P6194, DOI 10.1038/sj.onc.1206719; Saha D, 2001, J BIOL CHEM, V276, P29531, DOI 10.1074/jbc.M100069200; Sahai E, 2001, EMBO J, V20, P755, DOI 10.1093/emboj/20.4.755; Shah V, 2001, ONCOGENE, V20, P2112, DOI 10.1038/sj.onc.1204291; Shields JM, 2002, MOL CELL BIOL, V22, P2304, DOI 10.1128/MCB.22.7.2304-2317.2002; Takahashi C, 1998, P NATL ACAD SCI USA, V95, P13221, DOI 10.1073/pnas.95.22.13221; TAKENAGA K, 1988, MOL CELL BIOL, V8, P3934, DOI 10.1128/MCB.8.9.3934; TANAKA M, 1995, CANCER RES, V55, P3228; Wang FL, 1996, CANCER RES, V56, P3634; Watanabe N, 1999, NAT CELL BIOL, V1, P136, DOI 10.1038/11056; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735	37	9	11	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 25	2005	24	36					5648	5655		10.1038/sj.onc.1208724	http://dx.doi.org/10.1038/sj.onc.1208724			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	956JN	16007212				2022-12-25	WOS:000231296100011
J	Papaconstantinou, ME; Carrell, CJ; Pineda, AO; Bobofchak, KM; Mathews, FS; Flordellis, CS; Maragoudakis, ME; Tsopanoglou, NE; Di Cera, E				Papaconstantinou, ME; Carrell, CJ; Pineda, AO; Bobofchak, KM; Mathews, FS; Flordellis, CS; Maragoudakis, ME; Tsopanoglou, NE; Di Cera, E			Thrombin functions through its RGD sequence in a non-canonical conformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOVALENT CATION SPECIFICITY; INDUCED ANGIOGENESIS; ADHESIVE PROPERTIES; CRYSTAL-STRUCTURE; ALPHA(V)BETA(3)-INTEGRIN; HIRUDIN; BINDING; CELLS; INVOLVEMENT	Previous studies have suggested that thrombin interacts with integrins in endothelial cells through its RGD (Arg-187, Gly-188, Asp-189) sequence. All existing crystal structures of thrombin show that most of this sequence is buried under the 220-loop and therefore interaction via RGD implies either partial unfolding of the enzyme or its proteolytic digestion. Here, we demonstrate that surface-absorbed thrombin promotes attachment and migration of endothelial cells through interaction with alpha(v)beta(3) and alpha(5)beta(1) integrins. Using site-directed mutants of thrombin we prove that this effect is mediated by the RGD sequence and does not require catalytic activity. The effect is abrogated when residues of the RGD sequence are mutated to Ala and is not observed with proteases like trypsin and tissue-type plasminogen activator, unless the RGD sequence is introduced at position 187-189. The potent inhibitor hirudin does not abrogate the effect, suggesting that thrombin functions through its RGD sequence in a non-canonical conformation. A 1.9-angstrom resolution crystal structure of free thrombin grown in the presence of high salt (400 mM KCl) shows two molecules in the asymmetric unit, one of which assumes an unprecedented conformation with the autolysis loop shifted 20 angstrom away from its canonical position, the 220-loop entirely disordered, and the RGD sequence exposed to the solvent.	Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA; Univ Patras, Sch Med, Dept Pharmacol, Patras 26500, Greece	Washington University (WUSTL); University of Patras	Tsopanoglou, NE (corresponding author), Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA.	ntsopan@med.upatras.gr; enrico@wustl.edu			NHLBI NIH HHS [HL49413, HL58141, HL73813] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL049413, R01HL058141, R01HL049413, R01HL073813] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ayala YM, 2001, PROTEINS, V45, P107, DOI 10.1002/prot.1130; BANFIELD DK, 1992, P NATL ACAD SCI USA, V89, P2779, DOI 10.1073/pnas.89.7.2779; BarShavit R, 1996, J CELL BIOCHEM, V61, P278, DOI 10.1002/(SICI)1097-4644(19960501)61:2<278::AID-JCB11>3.0.CO;2-I; BARSHAVIT R, 1983, SCIENCE, V220, P728, DOI 10.1126/science.6836310; BARSHAVIT R, 1993, J CELL BIOL, V123, P1279, DOI 10.1083/jcb.123.5.1279; BARSHAVIT R, 1991, J CELL BIOL, V112, P335, DOI 10.1083/jcb.112.2.335; Bobofchak KM, 2005, J BIOL CHEM, V280, P25644, DOI 10.1074/jbc.M503499200; BODE W, 1992, PROTEIN SCI, V1, P426; Brass LF, 2003, CHEST, V124, p18S, DOI 10.1378/chest.124.3_suppl.18S; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Di Cera E, 2004, CR BIOL, V327, P1065, DOI 10.1016/j.crvi.2004.07.011; Di Cera E, 2003, CHEST, V124, p11S, DOI 10.1378/chest.124.3_suppl.11S; Esmon CT, 2003, CHEST, V124, p26S, DOI 10.1378/chest.124.3_suppl.26S; Frenette PS, 1996, NEW ENGL J MED, V334, P1526, DOI 10.1056/NEJM199606063342308; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Mengwasser KE, 2005, J BIOL CHEM, V280, P26997, DOI 10.1074/jbc.M502678200; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; Pineda AO, 2004, BIOPHYS CHEM, V112, P253, DOI 10.1016/j.bpc.2004.07.027; Pineda AO, 2002, J BIOL CHEM, V277, P32015, DOI 10.1074/jbc.M205009200; Pineda AO, 2004, J BIOL CHEM, V279, P31842, DOI 10.1074/jbc.M401756200; Prasad S, 2003, P NATL ACAD SCI USA, V100, P13785, DOI 10.1073/pnas.2333109100; Prasad S, 2004, J BIOL CHEM, V279, P10103, DOI 10.1074/jbc.M312614200; RYDEL TJ, 1991, J MOL BIOL, V221, P583, DOI 10.1016/0022-2836(91)80074-5; Sajid M, 2003, AM J PHYSIOL-CELL PH, V285, pC1330, DOI 10.1152/ajpcell.00475.2002; STONE SR, 1986, BIOCHEMISTRY-US, V25, P4622, DOI 10.1021/bi00364a025; Stouffer GA, 2003, ARTERIOSCL THROM VAS, V23, P1971, DOI 10.1161/01.ATV.0000093470.51580.0F; Tsopanoglou NE, 2004, THROMB HAEMOSTASIS, V92, P846, DOI 10.1160/TH04-04-0208; Tsopanoglou NE, 2002, AM J PHYSIOL-CELL PH, V283, pC1501, DOI 10.1152/ajpcell.00162.2002; Vindigni A, 1998, PROTEIN SCI, V7, P1728, DOI 10.1002/pro.5560070807	30	31	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	2005	280	33					29393	29396		10.1074/jbc.C500248200	http://dx.doi.org/10.1074/jbc.C500248200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	954SX	15998637	hybrid			2022-12-25	WOS:000231176200002
J	Bhattacharya, R; SenBanerjee, S; Lin, ZY; Mir, S; Hamik, A; Wang, P; Mukherjee, P; Mukhopadhyay, D; Jain, MK				Bhattacharya, R; SenBanerjee, S; Lin, ZY; Mir, S; Hamik, A; Wang, P; Mukherjee, P; Mukhopadhyay, D; Jain, MK			Inhibition of vascular permeability factor/vascular endothelial growth factor-mediated angiogenesis by the Kruppel-like factor KLF2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR RECEPTOR-2; EXPRESSION; PROMOTER; PROLIFERATION; SP1; IDENTIFICATION; ACTIVATION; REGULATOR; MIGRATION; KDR/FLK-1	The Kruppel-like factor KLF2 was recently identified as a novel regulator of endothelial pro-inflammatory and pro-thrombotic function. Here it is shown that overexpression of KLF2 potently inhibits vascular permeability factor/vascular endothelial growth factor (VEGFA)mediated angiogenesis and tissue edema in the nude ear mouse model of angiogenesis. In vitro, KLF2 expression retards VEGF-mediated calcium flux, proliferation and induction of pro-inflammatory factors in endothelial cells. This effect is due to a potent inhibition of VEGFR2/KDR expression and promoter activity. These observations identify KLF2 as a regulator of VEGFR2/KDR and provide a foundation for novel approaches to regulate angiogenesis.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Program Cardiovasc Transcriptional Biol, Boston, MA 02115 USA; Mayo Clin & Mayo Fdn, Mayo Clin Canc Ctr, Rochester, MN 55905 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Mayo Clinic	Jain, MK (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Program Cardiovasc Transcriptional Biol, Boston, MA 02115 USA.	mjain@rics.bwh.harvard.edu			NATIONAL CANCER INSTITUTE [R29CA078383, R01CA078383] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL075427, R01HL072178, R01HL070567, R01HL076754, R01HL072952, R01HL069477] Funding Source: NIH RePORTER; NCI NIH HHS [CA78383] Funding Source: Medline; NHLBI NIH HHS [HL70567, HL69477, HL072178, HL-76754, HL-72952, HL75427] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON KP, 1995, MOL CELL BIOL, V15, P5957; Banerjee SS, 2003, J BIOL CHEM, V278, P2581, DOI 10.1074/jbc.M210859200; Basu S, 2001, NAT MED, V7, P569, DOI 10.1038/87895; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; BOOCOCK CA, 1995, JNCI-J NATL CANCER I, V87, P506, DOI 10.1093/jnci/87.7.506; BROWN LF, 1993, AM J PATHOL, V143, P1255; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; Dang DT, 2002, NUCLEIC ACIDS RES, V30, P2736, DOI 10.1093/nar/gkf400; Feinberg MW, 2004, TRENDS CARDIOVAS MED, V14, P241, DOI 10.1016/j.tcm.2004.06.005; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; GALLAND F, 1993, ONCOGENE, V8, P1233; Giraudo E, 1998, J BIOL CHEM, V273, P22128, DOI 10.1074/jbc.273.34.22128; HATVA E, 1995, AM J PATHOL, V146, P368; Higaki Y, 2002, NUCLEIC ACIDS RES, V30, P2270, DOI 10.1093/nar/30.11.2270; Illi B, 2000, CIRC RES, V86, pE110; Jain RK, 2003, NAT MED, V9, P685, DOI 10.1038/nm0603-685; Kim I, 2001, FASEB J, V15, P126, DOI 10.1096/fj.01-0556fje; Kim I, 2001, J BIOL CHEM, V276, P7614, DOI 10.1074/jbc.M009705200; Kuo CT, 1997, GENE DEV, V11, P2996, DOI 10.1101/gad.11.22.2996; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Lin ZY, 2005, CIRC RES, V96, pE48, DOI 10.1161/01.RES.0000159707.05637.a1; Matsumoto T, 2001, Sci STKE, V2001, pre21, DOI 10.1126/stke.2001.112.re21; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; Mukhopadhyay D, 2004, MOL CELL BIOCHEM, V264, P51, DOI 10.1023/B:MCBI.0000044374.85095.df; PAJUSOLA K, 1992, CANCER RES, V52, P5738; PATTERSON C, 1995, J BIOL CHEM, V270, P23111, DOI 10.1074/jbc.270.39.23111; Patterson C, 1997, J BIOL CHEM, V272, P8410, DOI 10.1074/jbc.272.13.8410; Pettersson A, 2000, LAB INVEST, V80, P99, DOI 10.1038/labinvest.3780013; PLATE KH, 1993, CANCER RES, V53, P5822; Ruminy P, 2003, GENE, V315, P133, DOI 10.1016/S0378-1119(03)00727-3; SenBanerjee S, 2004, J EXP MED, V199, P1305, DOI 10.1084/jem.20031132; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SHIBUYA M, 1990, ONCOGENE, V5, P519; Sundberg C, 2001, AM J PATHOL, V158, P1145, DOI 10.1016/S0002-9440(10)64062-X; TERMAN BI, 1991, ONCOGENE, V6, P1677; Wang F, 2005, ONCOGENE, V24, P3875, DOI 10.1038/sj.onc.1208546; Yoshiji H, 1996, CANCER RES, V56, P2013; Zeng HY, 2001, J BIOL CHEM, V276, P26969, DOI 10.1074/jbc.M103213200; Zeng HY, 2001, J BIOL CHEM, V276, P32714, DOI 10.1074/jbc.M103130200; Zhang WQ, 1998, J BIOL CHEM, V273, P17917, DOI 10.1074/jbc.273.28.17917	41	122	132	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	2005	280	32					28848	28851		10.1074/jbc.C500200200	http://dx.doi.org/10.1074/jbc.C500200200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	952QT	15980434	hybrid			2022-12-25	WOS:000231021300003
J	Zer, C; Chanfreau, G				Zer, C; Chanfreau, G			Regulation and surveillance of normal and 3 '-extended forms of the yeast aci-reductone dioxygenase mRNA by RNase III cleavage and exonucleolytic degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL NUCLEOLAR RNAS; METHIONINE SALVAGE PATHWAY; SACCHAROMYCES-CEREVISIAE; KLEBSIELLA-PNEUMONIAE; BINDING DOMAIN; RECOGNITION; TETRALOOP; IDENTIFICATION; EXPRESSION; PREDICTION	Aci-reductone dioxygenases are key enzymes in the methionine salvage pathway. The mechanisms by which the expression of this important class of enzymes is regulated are poorly understood. Here we show that the expression of the mRNA encoding the yeast aci-reductone dioxygenase ADI1 is controlled post-transcriptionally by RNase III cleavage. Cleavage occurs in a large bipartite stem loop structure present in the open reading frame region of the ADI1 mRNA. The ADI1 mRNA is up-regulated in the absence of the yeast orthologue of RNase III Rnt1p or of the 5' -> 3' exonucleases Xrn1p and Rat1p. 3'-Extended forms of this mRNA, including a polycistronic mRNA ADI1-YMR010W mRNA, also accumulate in cells lacking Rnt1p, Xrn1p, and Rat1p or the nuclear exosome component Rrp6p, suggesting that these 3'-extended forms are subject to nuclear surveillance. We show that the ADI1 mRNA is up-regulated under heat shock conditions in a Rnt1p-independent manner. We propose that Rnt1p cleavage targets degradation of the ADI1 mRNA to prevent its expression prior to heat shock conditions and that RNA surveillance by multiple ribonucleases helps prevent accumulation of aberrant 3'-extended forms of this mRNA that arise from intrinsically inefficient 3'-processing signals.	Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Chanfreau, G (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, Box 951569, Los Angeles, CA 90095 USA.	guillom@chem.ucla.edu	Chanfreau, Guillaume/S-7421-2019		NIGMS NIH HHS [GM61518] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061518] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AbouElela S, 1996, CELL, V85, P115, DOI 10.1016/S0092-8674(00)81087-9; Allmang C, 1999, EMBO J, V18, P5399, DOI 10.1093/emboj/18.19.5399; Chanfreau C, 2000, P NATL ACAD SCI USA, V97, P3142, DOI 10.1073/pnas.070043997; Chanfreau G, 2003, EUKARYOT CELL, V2, P901, DOI 10.1128/EC.2.5.901-909.2003; Chanfreau G, 1997, GENE DEV, V11, P2741, DOI 10.1101/gad.11.20.2741; Chanfreau G, 1998, J MOL BIOL, V284, P975, DOI 10.1006/jmbi.1998.2237; Chanfreau G, 1998, EMBO J, V17, P3726, DOI 10.1093/emboj/17.13.3726; Dai Y, 2001, BIOCHEMISTRY-US, V40, P6379, DOI 10.1021/bi010110y; Danin-Kreiselman M, 2003, MOL CELL, V11, P1279, DOI 10.1016/S1097-2765(03)00137-0; Franch T, 1999, J BIOL CHEM, V274, P26572, DOI 10.1074/jbc.274.37.26572; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Ge DL, 2005, CURR BIOL, V15, P140, DOI 10.1016/j.cub.2004.12.001; HOFFMAN JL, 1986, BIOCHEMISTRY-US, V25, P4444, DOI 10.1021/bi00363a041; Johnson AW, 1997, MOL CELL BIOL, V17, P6122, DOI 10.1128/MCB.17.10.6122; Lee A, 2005, MOL CELL, V19, P39, DOI 10.1016/j.molcel.2005.05.021; Lee CY, 2003, RNA, V9, P1362, DOI 10.1261/rna.5126203; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; Nagel R, 2000, RNA, V6, P1142, DOI 10.1017/S1355838200000431; Oram S, 2004, ENDOCRINOLOGY, V145, P1933, DOI 10.1210/en.2003-0947; Petfalski E, 1998, MOL CELL BIOL, V18, P1181, DOI 10.1128/MCB.18.3.1181; Pochapsky TC, 2002, NAT STRUCT BIOL, V9, P966, DOI 10.1038/nsb863; Qu LH, 1999, MOL CELL BIOL, V19, P1144; Storici F, 2001, NAT BIOTECHNOL, V19, P773, DOI 10.1038/90837; Subhi AL, 2003, J BIOL CHEM, V278, P49868, DOI 10.1074/jbc.M308451200; Van Hoof A, 2000, MOL CELL BIOL, V20, P441, DOI 10.1128/MCB.20.2.441-452.2000; van Hoof A, 2000, EMBO J, V19, P1357, DOI 10.1093/emboj/19.6.1357; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; WRAY JW, 1995, J BIOL CHEM, V270, P3147, DOI 10.1074/jbc.270.7.3147; Wu HH, 2004, P NATL ACAD SCI USA, V101, P8307, DOI 10.1073/pnas.0402627101; Wu HH, 2001, EMBO J, V20, P7240, DOI 10.1093/emboj/20.24.7240; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	31	10	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	2005	280	32					28997	29003		10.1074/jbc.M505913200	http://dx.doi.org/10.1074/jbc.M505913200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	952QT	15967792	hybrid			2022-12-25	WOS:000231021300022
J	Mazieres, J; You, L; He, B; Xu, ZD; Lee, AY; Mikami, I; McCormick, F; Jablons, DM				Mazieres, J; You, L; He, B; Xu, ZD; Lee, AY; Mikami, I; McCormick, F; Jablons, DM			Inhibition of Wnt16 in human acute lymphoblastoid leukemia cells containing the t(1;19) translocation induces apoptosis	ONCOGENE			English	Article						Wnt; Wnt16; leukemia; apoptosis; human antibody; RNA interference	PRE-B; SIGNALING PATHWAY; E2A-PBX1; GENE; ACTIVATION; EXPRESSION; CLASSIFICATION; CANCER	The Wnt family of secreted glycoproteins is widely involved in cell proliferation, differentiation and oncogenesis. Many Wnt signaling genes are upregulated and activated in chronic lymphocytic leukemia. Less is known concerning acute leukemia. One subtype of acute lymphoblastoid leukemia (ALL) is characterized by a t(1;19) chromosomal translocation resulting in a fusion protein E2A-Pbx1 that promotes transformation and leukemogenesis. Wnt16 has been shown to be targeted by E2A-Pbx1. We performed a differential gene expression array in acute leukemia cell lines displaying or not displaying the t(1;19) translocation. We found that Wnt16 and many Wnt signaling-related genes were upregulated in the translocation-containing cells. As two isoforms of Wnt16, Wnt16a and Wnt16b, have been recently identified, we demonstrated by using RT-PCR and Western blot that Wnt16b (and not Wnt16a) is overexpressed in t(1;19)-containing cell lines. We then directly addressed the role played by both isoforms in this type of leukemia. Using specific short interfering RNA (siRNA) and an anti-Wnt16 antibody, we showed that targeted-Wnt16b inhibition leads to apoptotic cell death. We also demonstrated that Wnt16b mediates its effect through the canonical Wnt pathway involving dishevelled-2, beta-catenin and survivin. We thus propose that Wnt16 plays an important role in leukemogenesis, raising its therapeutic interest.	Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94115 USA; Inst Claudius Regaud, INSERM, U563, Dept Innovat Therapeut & Oncol Mol, F-31052 Toulouse, France	University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; UNICANCER; Institut Claudius Regaud; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)	Jablons, DM (corresponding author), Ctr Canc, Dept Surg, 1600 Divisadero St,C322C,Box 1674, San Francisco, CA 94115 USA.	jablonsd@surgery.ucsf.edu	MAZIERES, JULIEN/M-3986-2014	MAZIERES, JULIEN/0000-0002-5921-7613	NATIONAL CANCER INSTITUTE [R01CA093708] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA093708, R01 CA093708-01A3] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aspland SE, 2001, ONCOGENE, V20, P5708, DOI 10.1038/sj.onc.1204592; Carroll William L, 2003, Hematology Am Soc Hematol Educ Program, P102; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Fear MW, 2000, BIOCHEM BIOPH RES CO, V278, P814, DOI 10.1006/bbrc.2000.3852; Fu XY, 1999, ONCOGENE, V18, P4920, DOI 10.1038/sj.onc.1202874; Fu XY, 1997, MOL CELL BIOL, V17, P1503, DOI 10.1128/MCB.17.3.1503; KAMPS MP, 1991, GENE DEV, V5, P358, DOI 10.1101/gad.5.3.358; Kamps MP, 1996, ONCOGENE, V12, P19; Lu DS, 2004, P NATL ACAD SCI USA, V101, P3118, DOI 10.1073/pnas.0308648100; McWhirter JR, 1999, P NATL ACAD SCI USA, V96, P11464, DOI 10.1073/pnas.96.20.11464; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Muller-Tidow C, 2004, MOL CELL BIOL, V24, P2890, DOI 10.1128/MCB.24.7.2890-2904.2004; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Reya T, 2000, IMMUNITY, V13, P15, DOI 10.1016/S1074-7613(00)00004-2; Rhee CS, 2002, ONCOGENE, V21, P6598, DOI 10.1038/sj.onc.1205920; Ross ME, 2003, BLOOD, V102, P2951, DOI 10.1182/blood-2003-01-0338; Smith KS, 2003, MOL CELL, V12, P393, DOI 10.1016/S1097-2765(03)00277-6; Uematsu K, 2003, ONCOGENE, V22, P7218, DOI 10.1038/sj.onc.1206817; Uematsu K, 2003, CANCER RES, V63, P4547; Weeraratna AT, 2002, CANCER CELL, V1, P279, DOI 10.1016/S1535-6108(02)00045-4; Yeoh EJ, 2002, CANCER CELL, V1, P133, DOI 10.1016/S1535-6108(02)00032-6	22	89	92	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 11	2005	24	34					5396	5400		10.1038/sj.onc.1208568	http://dx.doi.org/10.1038/sj.onc.1208568			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	954MF	16007226				2022-12-25	WOS:000231158500014
J	Mackenzie, AB; Young, MT; Adinolfi, E; Surprenant, A				Mackenzie, AB; Young, MT; Adinolfi, E; Surprenant, A			Pseudoapoptosis induced by brief activation of ATP-gated P2X(7) receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL PERMEABILITY TRANSITION; INDEPENDENT CELL-DEATH; CYTOCHROME-C RELEASE; NUCLEOTIDE RECEPTOR; ROCK-I; BLEB FORMATION; APOPTOSIS; CASPASES; PROLIFERATION; PROTEINS	P2X(7) receptors are ATP-gated ion channels primarily expressed on antigen-presenting immune cells where they play a role in the acute inflammatory response. These ion channels couple not only to influx of cations, including calcium, but also to rapid alterations in cell morphology ( membrane blebbing, phosphatidylserine exposure, microvesicle shedding). These features resemble the extranuclear events associated with end stages of apoptosis but cell death does not occur if receptor activation is brief. Here we delineate two signaling pathways underlying these apoptotic-like processes. Loss of membrane asymmetry occurs within seconds, which directly triggers cytoskeletal disruption and zeiotic membrane blebbing; this is readily reversible and requires both calcium influx through P2X7 channels and mitochondrial calcium increase but is not associated with cytochrome c release. A slower, calcium-independent, ROCK-1-dependent cascade that does not involve rapid loss of membrane asymmetry but is associated with cytochrome c release is secondarily activated. The ROCK-1 pathway appears largely responsible for cell death, which occurs after prolonged stimulation of P2X(7) receptors. We suggest that the former mechanism underlies the reversible pseudoapoptotic events induced by brief activation of P2X(7) receptors.	Univ Sheffield, Inst Mol Physiol, Dept Biomed Sci, Sheffield S10 2TN, S Yorkshire, England	University of Sheffield	Surprenant, A (corresponding author), Univ Sheffield, Inst Mol Physiol, Dept Biomed Sci, Addison Bldg,Western Bank, Sheffield S10 2TN, S Yorkshire, England.	a.surprenant@sheffield.ac.uk	Adinolfi, Elena/F-9169-2010; Young, Mark T/E-8928-2010	Adinolfi, Elena/0000-0001-8129-9929; Young, Mark T/0000-0002-9615-9002; /0000-0002-9935-4188	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Baricordi OR, 1999, J BIOL CHEM, V274, P33206, DOI 10.1074/jbc.274.47.33206; Barros LF, 2003, CELL DEATH DIFFER, V10, P687, DOI 10.1038/sj.cdd.4401236; Bernardi P, 1999, EUR J BIOCHEM, V264, P687, DOI 10.1046/j.1432-1327.1999.00725.x; Bohm Ingrid, 2003, Mol Imaging Biol, V5, P2, DOI 10.1016/S1536-1632(03)00024-6; Burnstock G, 2002, ARTERIOSCL THROM VAS, V22, P364, DOI 10.1161/hq0302.105360; Camilleri-Broet S, 1998, EXP CELL RES, V239, P277, DOI 10.1006/excr.1997.3899; Chiozzi P, 1997, J CELL BIOL, V138, P697, DOI 10.1083/jcb.138.3.697; Chipuk JE, 2005, NAT REV MOL CELL BIO, V6, P268, DOI [10.1038/nrm1573, 10.1038/nrm2239]; Coleman ML, 2001, NAT CELL BIOL, V3, P339, DOI 10.1038/35070009; Coutinho-Silva R, 1999, AM J PHYSIOL-CELL PH, V276, pC1139, DOI 10.1152/ajpcell.1999.276.5.C1139; Critchley DR, 2000, CURR OPIN CELL BIOL, V12, P133, DOI 10.1016/S0955-0674(99)00067-8; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Di Virgilio F, 1998, CELL DEATH DIFFER, V5, P191; Di Virgilio F, 1999, J LEUKOCYTE BIOL, V66, P723, DOI 10.1002/jlb.66.5.723; Falzoni S, 2000, MOL BIOL CELL, V11, P3169, DOI 10.1091/mbc.11.9.3169; Ferrari D, 1999, FEBS LETT, V447, P71, DOI 10.1016/S0014-5793(99)00270-7; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Green DR, 2000, METHOD ENZYMOL, V322, P15; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Guimaraes CA, 2004, EUR J BIOCHEM, V271, P1638, DOI 10.1111/j.1432-1033.2004.04084.x; Hogg N, 2003, J CELL SCI, V116, P4695, DOI 10.1242/jcs.00876; Humphreys BD, 2000, J BIOL CHEM, V275, P26792; Ke HZ, 2003, MOL ENDOCRINOL, V17, P1356, DOI 10.1210/me.2003-0021; Kim M, 2001, EMBO J, V20, P6347, DOI 10.1093/emboj/20.22.6347; Lemasters JJ, 1998, BBA-BIOENERGETICS, V1366, P177, DOI 10.1016/S0005-2728(98)00112-1; Leverrier Y, 2001, NAT CELL BIOL, V3, pE91, DOI 10.1038/35070151; Lim MLR, 2001, FEBS LETT, V503, P69, DOI 10.1016/S0014-5793(01)02693-X; Lockshin RA, 2004, ONCOGENE, V23, P2766, DOI 10.1038/sj.onc.1207514; Lum MG, 2003, J CELL SCI, V116, P1437, DOI 10.1242/jcs.00320; MacKenzie A, 2001, IMMUNITY, V15, P825, DOI 10.1016/S1074-7613(01)00229-1; MacKenzie AB, 1999, ANN NY ACAD SCI, V868, P716, DOI 10.1111/j.1749-6632.1999.tb11351.x; MAJNO G, 1995, AM J PATHOL, V146, P3; Mayer B, 2003, NEWS PHYSIOL SCI, V18, P89, DOI 10.1152/nips.01433.2002; Mills JC, 1999, J CELL BIOL, V146, P703, DOI 10.1083/jcb.146.4.703; Minamikawa T, 1999, EXP CELL RES, V246, P26, DOI 10.1006/excr.1998.4290; Morelli A, 2003, MOL BIOL CELL, V14, P2655, DOI 10.1091/mbc.02-04-0061; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Orrenius S, 2003, NAT REV MOL CELL BIO, V4, P552, DOI 10.1038/nrm1150; Pfeiffer ZA, 2004, J LEUKOCYTE BIOL, V75, P1173, DOI 10.1189/jlb.1203648; Sebbagh M, 2001, NAT CELL BIOL, V3, P346, DOI 10.1038/35070019; Segundo C, 1999, BLOOD, V94, P1012, DOI 10.1182/blood.V94.3.1012.415k05_1012_1020; Seman M, 2003, IMMUNITY, V19, P571, DOI 10.1016/S1074-7613(03)00266-8; Single B, 2001, EXP CELL RES, V262, P8, DOI 10.1006/excr.2000.5059; Sloviter RS, 2002, TRENDS PHARMACOL SCI, V23, P19, DOI 10.1016/S0165-6147(00)01867-8; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; Verhoef PA, 2003, J IMMUNOL, V170, P5728, DOI 10.4049/jimmunol.170.11.5728; Virginio C, 1999, J PHYSIOL-LONDON, V519, P335, DOI 10.1111/j.1469-7793.1999.0335m.x; Wen LT, 2003, MOL PHARMACOL, V63, P706, DOI 10.1124/mol.63.3.706; Wilson HL, 2002, J BIOL CHEM, V277, P34017, DOI 10.1074/jbc.M205120200; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Zeuner A, 1999, CELL DEATH DIFFER, V6, P1075, DOI 10.1038/sj.cdd.4400596	51	129	130	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					33968	33976		10.1074/jbc.M502705200	http://dx.doi.org/10.1074/jbc.M502705200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	15994333	hybrid			2022-12-25	WOS:000232229700034
J	Marschall, M; Marzi, A; Siepen, PAD; Jochmann, R; Kalmer, M; Auerochs, S; Lischka, P; Leis, M; Stamminger, T				Marschall, M; Marzi, A; Siepen, PAD; Jochmann, R; Kalmer, M; Auerochs, S; Lischka, P; Leis, M; Stamminger, T			Cellular p32 recruits cytomegalovirus kinase pUL97 to redistribute the nuclear lamina	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL ARTIFICIAL CHROMOSOME; PROTEIN-KINASE; B-RECEPTOR; MEMBRANE PROTEIN; TRANSCRIPTIONAL ACTIVATION; HUMAN-FIBROBLASTS; ESCHERICHIA-COLI; LOCALIZATION; REPLICATION; EGRESS	Replication of human cytomegalovirus is limited at the level of nucleocytoplasmic transport of viral capsids, a process that requires the disassembly of the nuclear lamina. Deletion of the protein kinase gene UL97 from the viral genome showed that the activity of pUL97 plays an important role for viral capsid egress. Here, we report that p32, a novel cellular interactor of the viral kinase pUL97, promotes the accumulation of pUL97 at the nuclear membrane by recruiting the p32-pUL97 complex to the lamin B receptor. Transfection of active pUL97, but not a catalytically inactive mutant, induced a redistribution of lamina components as demonstrated for recombinant lamin B receptor-green fluorescent protein and endogenous lamins A and C. Consistent with this, p32 itself and lamins were phosphorylated by pUL97. Importantly, overexpression of p32 in human cytomegalovirus-infected cells resulted in increased efficiency of viral replication and release of viral particles. Thus, it is highly suggestive that the cellular protein p32 recruits pUL97 to induce a dissolution of the nuclear lamina thereby facilitating the nuclear export of viral capsids.	Univ Erlangen Nurnberg, Inst Clin & Mol Virol, D-91054 Erlangen, Germany	University of Erlangen Nuremberg	Marschall, M (corresponding author), Univ Erlangen Nurnberg, Inst Clin & Mol Virol, Schlossgarten 4, D-91054 Erlangen, Germany.	manfred.marschall@viro.med.uni-erlangen.de	Marzi, Andrea/AAF-4617-2020	Marzi, Andrea/0000-0003-0186-9587; Stamminger, Thomas/0000-0001-9878-3119				Borst EM, 1999, J VIROL, V73, P8320, DOI 10.1128/JVI.73.10.8320-8329.1999; Bryant HE, 2000, J VIROL, V74, P11322, DOI 10.1128/JVI.74.23.11322-11328.2000; Coen DM, 2003, NAT REV DRUG DISCOV, V2, P278, DOI 10.1038/nrd1065; Collas P, 1997, J BIOL CHEM, V272, P21274, DOI 10.1074/jbc.272.34.21274; Curran M, 2001, DRUGS, V61, P1145, DOI 10.2165/00003495-200161080-00013; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Ellenberg J, 1997, J CELL BIOL, V138, P1193, DOI 10.1083/jcb.138.6.1193; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Goldman RD, 2002, GENE DEV, V16, P533, DOI 10.1101/gad.960502; Herget T, 2004, ANTIMICROB AGENTS CH, V48, P4154, DOI 10.1128/AAC.48.11.4154-4162.2004; Hoffmann K, 2002, NAT GENET, V31, P410, DOI 10.1038/ng925; Jha BK, 2002, EUR J BIOCHEM, V269, P298, DOI 10.1046/j.0014-2956.2001.02654.x; Jiang JZ, 1999, P NATL ACAD SCI USA, V96, P3572, DOI 10.1073/pnas.96.7.3572; Klupp BG, 2001, J GEN VIROL, V82, P2363, DOI 10.1099/0022-1317-82-10-2363; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; Krosky PM, 2003, J VIROL, V77, P905, DOI 10.1128/JVI.77.2.905-914.2003; Majumdar M, 2002, BIOCHEM BIOPH RES CO, V291, P829, DOI 10.1006/bbrc.2002.6491; Marschall M, 2000, ANTIMICROB AGENTS CH, V44, P1588, DOI 10.1128/AAC.44.6.1588-1597.2000; Marschall M, 2003, VIROLOGY, V311, P60, DOI 10.1016/S0042-6822(03)00147-8; Marschall M, 2001, J GEN VIROL, V82, P1439, DOI 10.1099/0022-1317-82-6-1439; Messerle M, 1997, P NATL ACAD SCI USA, V94, P14759, DOI 10.1073/pnas.94.26.14759; Mettenleiter TC, 2002, J VIROL, V76, P1537, DOI 10.1128/JVI.76.4.1537-1547.2002; Michel D, 1996, J VIROL, V70, P6340, DOI 10.1128/JVI.70.9.6340-6346.1996; Mohan KVK, 2002, VIRUS RES, V85, P151, DOI 10.1016/S0168-1702(02)00030-8; Muranyi W, 2002, SCIENCE, V297, P854, DOI 10.1126/science.1071506; Mylonis I, 2004, J BIOL CHEM, V279, P11626, DOI 10.1074/jbc.M311949200; Nikolakaki E, 1996, J BIOL CHEM, V271, P8365, DOI 10.1074/jbc.271.14.8365; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; Prichard MN, 1999, J VIROL, V73, P5663, DOI 10.1128/JVI.73.7.5663-5670.1999; RADSAK K, 1989, ARCH VIROL, V105, P103, DOI 10.1007/BF01311120; Reynolds AE, 2004, J VIROL, V78, P5564, DOI 10.1128/JVI.78.11.5564-5575.2004; Reynolds AE, 2002, J VIROL, V76, P8939, DOI 10.1128/JVI.76.17.8939-8952.2002; Robles-Flores M, 2002, J BIOL CHEM, V277, P5247, DOI 10.1074/jbc.M109333200; Sanchez V, 1998, J VIROL, V72, P3321, DOI 10.1128/JVI.72.4.3321-3329.1998; Scott ES, 2001, J VIROL, V75, P8818, DOI 10.1128/JVI.75.18.8818-8830.2001; SIMOS G, 1992, EMBO J, V11, P4027, DOI 10.1002/j.1460-2075.1992.tb05496.x; SIMOS G, 1994, FEBS LETT, V346, P225, DOI 10.1016/0014-5793(94)00479-X; Storz P, 2000, J BIOL CHEM, V275, P24601, DOI 10.1074/jbc.M002964200; Tange TO, 1996, J BIOL CHEM, V271, P10066, DOI 10.1074/jbc.271.17.10066; van Leeuwen HC, 2001, J CELL SCI, V114, P2115; Van Scoy S, 2000, VIROLOGY, V275, P145, DOI 10.1006/viro.2000.0508; Wolf DG, 2001, P NATL ACAD SCI USA, V98, P1895, DOI 10.1073/pnas.98.4.1895; YU L, 1995, J VIROL, V69, P3007, DOI 10.1128/JVI.69.5.3007-3016.1995; Zheng YH, 2003, NAT CELL BIOL, V5, P611, DOI 10.1038/ncb1000	45	150	152	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	2005	280	39					33357	33367		10.1074/jbc.M502672200	http://dx.doi.org/10.1074/jbc.M502672200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	966YG	15975922	hybrid			2022-12-25	WOS:000232058100033
J	Wente, W; Stroh, T; Beaudet, A; Richter, D; Kreienkamp, HJ				Wente, W; Stroh, T; Beaudet, A; Richter, D; Kreienkamp, HJ			Interactions with PDZ domain proteins PIST/GOPC and PDZK1 regulate intracellular sorting of the somatostatin receptor subtype 5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; ETHYLMALEIMIDE-SENSITIVE FACTOR; COUPLED RECEPTORS; BINDING PHOSPHOPROTEIN-50; FUNCTIONAL EXPRESSION; PLASMA-MEMBRANE; GTPASE TC10; RAT-BRAIN; FAMILY; CELLS	By yeast two-hybrid screening we have identified interaction partners for the intracellular C-terminal tail of the human and rodent somatostatin receptor subtype 5 (SSTR5). Interactions with the PDZ domain-containing proteins PIST and PDZK1 are mediated by the PDZ ligand motif at the C terminus of the receptor; in case of the human and mouse ( but not the rat) receptors, a slight sequence variation of this motif also allows for binding of the peroxisomal receptor PEX5. PIST is Golgi-associated and retains SSTR5 in the Golgi apparatus when coexpressed with the receptor; PDZK1 on the other hand associates with the SSTR5 at the plasma membrane. Endogenous SSTR5 in the neuroendocrine AtT-20 tumor cell line is colocalized with PIST in the Golgi apparatus. On a functional level, removal of the PDZ ligand motif of the receptor does not interfere with agonist-dependent internalization of the receptor or its targeting to a Golgi-associated compartment; however, recycling of the receptor to the plasma membrane after washout of the agonist is inhibited, suggesting that the PDZ-mediated interaction of SSTR5 is required for postendocytic sorting.	Univ Krankenhaus Hamburg Eppendorf, Inst Human Genet, D-20246 Hamburg, Germany; Univ Krankenhaus Hamburg Eppendorf, Inst Zellbiochem & Klin Neurobiol, D-20246 Hamburg, Germany; McGill Univ, Montreal Neurol Inst, Montreal, PQ H3A 2B4, Canada	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf; McGill University	Richter, D (corresponding author), Univ Krankenhaus Hamburg Eppendorf, Inst Human Genet, Martinistr 52, D-20246 Hamburg, Germany.	Richter@uke.uni_hamburg.de; Kreienkamp@uke.uni-hamburg.de						Benharouga M, 2003, J BIOL CHEM, V278, P22079, DOI 10.1074/jbc.M301030200; Bockaert J, 2004, PHARMACOL THERAPEUT, V103, P203, DOI 10.1016/j.pharmthera.2004.06.004; BRUNS C, 1995, CIBA F SYMP, V190, P89; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Charest A, 2001, J BIOL CHEM, V276, P29456, DOI 10.1074/jbc.M104137200; Cheng J, 2005, J BIOL CHEM, V280, P3731, DOI 10.1074/jbc.M410026200; Cheng J, 2004, J BIOL CHEM, V279, P1892, DOI 10.1074/jbc.M308640200; Cheng J, 2002, J BIOL CHEM, V277, P3520, DOI 10.1074/jbc.M110177200; Cuadra AE, 2004, J NEUROSCI, V24, P7491, DOI 10.1523/JNEUROSCI.1255-04.2004; DODT G, 1995, NAT GENET, V9, P115, DOI 10.1038/ng0295-115; Gage RM, 2005, J BIOL CHEM, V280, P3305, DOI 10.1074/jbc.M406934200; Gentzsch M, 2003, J BIOL CHEM, V278, P6440, DOI 10.1074/jbc.M211050200; Gisler SM, 2003, KIDNEY INT, V64, P1733, DOI 10.1046/j.1523-1755.2003.00266.x; Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496; Handel M, 1999, NEUROSCIENCE, V89, P909, DOI 10.1016/S0306-4522(98)00354-6; Hassel B, 2003, J BIOL CHEM, V278, P40136, DOI 10.1074/jbc.M305577200; He JQ, 2004, J BIOL CHEM, V279, P50190, DOI 10.1074/jbc.M404876200; Helboe L, 1998, J NEUROSCI, V18, P4938; Heydorn A, 2004, J BIOL CHEM, V279, P54291, DOI 10.1074/jbc.M406169200; Hu LYA, 2000, J BIOL CHEM, V275, P38659, DOI 10.1074/jbc.M005938200; Kocher O, 1998, LAB INVEST, V78, P117; Kreienkamp HJ, 1997, FEBS LETT, V419, P92, DOI 10.1016/S0014-5793(97)01437-3; Kreienkamp HJ, 2002, J BIOL CHEM, V277, P39937, DOI 10.1074/jbc.M206931200; Kreienkamp HJ, 2002, CURR OPIN PHARMACOL, V2, P581, DOI 10.1016/S1471-4892(02)00203-5; Kuliawat R, 2004, MOL BIOL CELL, V15, P1690, DOI 10.1091/mbc.E03-08-0554; Mahon MJ, 2002, NATURE, V417, P858, DOI 10.1038/nature00816; Moyer BD, 2000, J BIOL CHEM, V275, P27069; Naren AP, 2003, P NATL ACAD SCI USA, V100, P342, DOI 10.1073/pnas.0135434100; Neuberger G, 2003, J MOL BIOL, V328, P581, DOI 10.1016/S0022-2836(03)00319-X; Neudauer CL, 2001, BIOCHEM BIOPH RES CO, V280, P541, DOI 10.1006/bbrc.2000.4160; PATEL YC, 1994, BIOCHEM BIOPH RES CO, V198, P605, DOI 10.1006/bbrc.1994.1088; Roth A, 1997, J BIOL CHEM, V272, P23769, DOI 10.1074/jbc.272.38.23769; Roth A, 1997, DNA CELL BIOL, V16, P111, DOI 10.1089/dna.1997.16.111; Sarret P, 2004, J BIOL CHEM, V279, P8029, DOI 10.1074/jbc.M310792200; Schreff M, 2000, J NEUROSCI, V20, P3785, DOI 10.1523/JNEUROSCI.20-10-03785.2000; Schwarzler A, 2000, J BIOL CHEM, V275, P9557, DOI 10.1074/jbc.275.13.9557; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Simonin F, 2004, J NEUROCHEM, V89, P766, DOI 10.1111/j.1471-4159.2004.02411.x; Simonsen A, 1999, J BIOL CHEM, V274, P28857, DOI 10.1074/jbc.274.41.28857; Stroh T, 2000, ENDOCRINOLOGY, V141, P354, DOI 10.1210/en.141.1.354; Stroh T, 1999, J COMP NEUROL, V412, P69, DOI 10.1002/(SICI)1096-9861(19990913)412:1<69::AID-CNE5>3.0.CO;2-V; Strowski MZ, 2000, ENDOCRINOLOGY, V141, P111, DOI 10.1210/en.141.1.111; Swiatecka-Urban A, 2002, J BIOL CHEM, V277, P40099, DOI 10.1074/jbc.M206964200; VANETTI M, 1992, FEBS LETT, V311, P290, DOI 10.1016/0014-5793(92)81122-3; Wang SS, 1998, FEBS LETT, V427, P103, DOI 10.1016/S0014-5793(98)00402-5; Whistler JL, 2002, SCIENCE, V297, P615, DOI 10.1126/science.1073308; Zitzer H, 1999, J BIOL CHEM, V274, P32997, DOI 10.1074/jbc.274.46.32997	47	60	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	2005	280	37					32419	32425		10.1074/jbc.M507198200	http://dx.doi.org/10.1074/jbc.M507198200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	963HM	16012170	hybrid			2022-12-25	WOS:000231794800048
J	Aldridge, C; Moller, SG				Aldridge, C; Moller, SG			The plastid division protein AtMinD1 is a Ca2+-ATPase stimulated by AtMinE1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL-CELL DIVISION; ESCHERICHIA-COLI; CHLOROPLAST DIVISION; FTSZ RING; TOPOLOGICAL REGULATION; PROPER PLACEMENT; POLE OSCILLATION; SITE PLACEMENT; MIND ATPASE; RAPID POLE	Bacteria and plastids divide symmetrically through binary fission by accurately placing the division site at midpoint, a process initiated by FtsZ polymerization, which forms a Z-ring. In Escherichia coli precise Z-ring placement at midcell depends on controlled oscillatory behavior of MinD and MinE: In the presence of ATP MinD interacts with the FtsZ inhibitor MinC and migrates to the membrane where the MinD-MinC complex recruits MinE, followed by MinD-mediated ATP hydrolysis and membrane release. Although correct Z-ring placement during Arabidopsis plastid division depends on the precise localization of the bacterial homologs AtMinD1 and AtMinE1, the underlying mechanism of this process remains unknown. Here we have shown that AtMinD1 is a Ca2+ -dependent ATPase and through mutation analysis demonstrated the physiological importance of this activity where loss of ATP hydrolysis results in protein mislocalization within plastids. The observed mislocalization is not due to disrupted AtMinD1 dimerization, however; the active siteAtMinD1(K72A) mutant is unable to interact with the topological specificity factor AtMinE1. We have shown that AtMinE1, but not E. coli MinE, stimulates AtMinD1-mediated ATP hydrolysis, but in contrast to prokaryotes stimulation occurs in the absence of membrane lipids. Although AtMinD1 appears highly evolutionarily conserved, we found that important biochemical and cell biological properties have diverged. We propose that correct intraplastidic AtMinD1 localization is dependent on AtMinE1-stimulated, Ca2+-dependent AtMinD1 ATP hydrolysis, ultimately ensuring precise Z-ring placement and symmetric plastid division.	Univ Leicester, Dept Biol, Leicester LE1 7RH, Leics, England; Univ Stavanger, Dept Sci & Technol, N-4036 Stavanger, Norway	University of Leicester; Universitetet i Stavanger	Moller, SG (corresponding author), Univ Leicester, Dept Biol, Leicester LE1 7RH, Leics, England.	sgm5@le.ac.uk		Aldridge, Cassie/0000-0002-9162-3478; Moller, Simon/0000-0002-0460-3592				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Berger G, 2001, J BIOENERG BIOMEMBR, V33, P93, DOI 10.1023/A:1010792213254; BI E, 1993, J BACTERIOL, V175, P1118, DOI 10.1128/JB.175.4.1118-1125.1993; BI E, 1991, NATURE, V354, P161, DOI 10.1038/354161a0; BOASSON R, 1972, AM J BOT, V59, P217, DOI 10.2307/2441420; Bouet JY, 1999, EMBO J, V18, P1415, DOI 10.1093/emboj/18.5.1415; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; Colletti KS, 2000, CURR BIOL, V10, P507, DOI 10.1016/S0960-9822(00)00466-8; DEBOER PAJ, 1989, CELL, V56, P641, DOI 10.1016/0092-8674(89)90586-2; DEBOER PAJ, 1991, EMBO J, V10, P4371, DOI 10.1002/j.1460-2075.1991.tb05015.x; Dinkins R, 2001, PLANTA, V214, P180, DOI 10.1007/s004250100605; Fu XL, 2001, P NATL ACAD SCI USA, V98, P980, DOI 10.1073/pnas.031549298; Fujiwara M, 2001, BIOCHEM BIOPH RES CO, V287, P462, DOI 10.1006/bbrc.2001.5588; Fujiwara MT, 2004, J CELL SCI, V117, P2399, DOI 10.1242/jcs.01092; Hale CA, 2001, EMBO J, V20, P1563, DOI 10.1093/emboj/20.7.1563; Hayashi I, 2001, EMBO J, V20, P1819, DOI 10.1093/emboj/20.8.1819; Hu ZL, 2003, MOL MICROBIOL, V47, P345, DOI 10.1046/j.1365-2958.2003.03321.x; Hu ZL, 2002, P NATL ACAD SCI USA, V99, P6761, DOI 10.1073/pnas.102059099; Hu ZL, 1999, MOL MICROBIOL, V34, P82, DOI 10.1046/j.1365-2958.1999.01575.x; Hu ZL, 2001, MOL CELL, V7, P1337, DOI 10.1016/S1097-2765(01)00273-8; Itoh R, 2001, PLANT PHYSIOL, V127, P1644, DOI 10.1104/pp.010386; Kost B, 1998, PLANT J, V16, P393, DOI 10.1046/j.1365-313x.1998.00304.x; Lutkenhaus J, 1997, ANNU REV BIOCHEM, V66, P93, DOI 10.1146/annurev.biochem.66.1.93; Ma LY, 2004, MOL MICROBIOL, V54, P99, DOI 10.1111/j.1365-2958.2004.04265.x; Ma LY, 2003, J BACTERIOL, V185, P4948, DOI 10.1128/JB.185.16.4948-4955.2003; Maple J, 2002, PLANT J, V31, P269, DOI 10.1046/j.1365-313X.2002.01358.x; MAPLE J, 2005, IN PRESS PLANT J; McAndrew RS, 2001, PLANT PHYSIOL, V127, P1656, DOI 10.1104/pp.010542; Meinhardt H, 2001, P NATL ACAD SCI USA, V98, P14202, DOI 10.1073/pnas.251216598; OSTERYOUNG KW, 1995, NATURE, V376, P473, DOI 10.1038/376473b0; Pichoff S, 2001, J BACTERIOL, V183, P6630, DOI 10.1128/JB.183.22.6630-6635.2001; PLATTALOIA KA, 1977, NEW PHYTOL, V78, P599, DOI 10.1111/j.1469-8137.1977.tb02163.x; POSSINGH.JV, 1969, PLANTA, V86, P186, DOI 10.1007/BF00379826; Raskin DM, 1999, P NATL ACAD SCI USA, V96, P4971, DOI 10.1073/pnas.96.9.4971; Sai JQ, 2002, PLANT CELL, V14, P1279, DOI 10.1105/tpc.000653; Szeto TH, 2002, P NATL ACAD SCI USA, V99, P15693, DOI 10.1073/pnas.232590599; Vitha S, 2001, J CELL BIOL, V153, P111, DOI 10.1083/jcb.153.1.111; Zhou HJ, 2004, J BACTERIOL, V186, P1546, DOI 10.1128/JB.186.5.1546-1555.2004	38	34	37	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	2005	280	36					31673	31678		10.1074/jbc.M505126200	http://dx.doi.org/10.1074/jbc.M505126200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	961LZ	16014621	hybrid			2022-12-25	WOS:000231665200043
J	Willoughby, D; Masada, N; Crossthwaite, AJ; Ciruela, A; Cooper, DMF				Willoughby, D; Masada, N; Crossthwaite, AJ; Ciruela, A; Cooper, DMF			Localized Na+/H+ exchanger 1 expression protects Ca2+-regulated adenylyl cyclases from changes in intracellular pH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CA2+ ENTRY; CLAMPED SNAIL NEURONS; C6-2B GLIOMA-CELLS; VACUOLAR H+-ATPASE; PLASMA-MEMBRANE; NCB-20 CELLS; LIPID RAFTS; CALCIUM; CAMP; RECEPTORS	The Ca2+-sensitive adenylyl cyclases (ACs) are exclusively regulated by capacitative Ca2+ entry (CCE) in nonexcitable cells. The present study investigates whether this Ca2+-dependent modulation of AC activity is further regulated by local pH changes that can arise beneath the plasma membrane as a consequence of cellular activity. Ca2+ stimulation of AC8 expressed in HEK 293 cells and inhibition of endogenous AC6 in C6-2B glioma cells exhibited clear sensitivity to modest pH changes in vitro. Acid pH (pH 7.14) reduced the Ca2+ sensitivity of both ACs, whereas alkaline pH (pH 7.85) enhanced the responsiveness of the enzymes to Ca2+, compared with controls (pH 7.50). Surprisingly, in the intact cell, the response of AC8 and AC6 to CCE was largely unperturbed by similar changes in intracellular pH (pH(i)), imposed using a weak acid (propionate) or weak base (trimethylamine). A range of hypotheses were tested to identify the mechanism(s) that could underlie this lack of pH effect in the intact cell. The pH sensitivity of CCE in HEK 293 cells is likely to dampen the effects of pHi on Ca2+-regulated ACs and may partly explain the discrepancy between in vitro and in vivo data. However, we have found that the Na+/H+ exchanger (NHE), NHE1, is functionally active in these cells, and like AC8 (and AC6) it resides in lipid rafts or caveolae, which may create cellular microdomains where pHi is tightly regulated. An abundance of NHE1 in these cellular subdomains may generate a privileged environment that protects the Ca2+-sensitive ACs and other caveolar proteins from local acid shifts.	Univ Cambridge, Dept Pharmacol, Cambridge CB2 1PD, England	University of Cambridge	Cooper, DMF (corresponding author), Univ Cambridge, Dept Pharmacol, Tennis Court Rd, Cambridge CB2 1PD, England.	dmfc2@cam.ac.uk			NIGMS NIH HHS [GM32483] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032483] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amos BJ, 1998, J NEUROPHYSIOL, V79, P695, DOI 10.1152/jn.1998.79.2.695; Bachmann O, 2003, AM J PHYSIOL-GASTR L, V284, pG37, DOI 10.1152/ajpgi.00209.2002; BIEMESDERFER D, 1992, AM J PHYSIOL, V263, pF833, DOI 10.1152/ajprenal.1992.263.5.F833; BIRNBAUMER L, 1974, J BIOL CHEM, V249, P7848; BOYAJIAN CL, 1991, J BIOL CHEM, V266, P4995; Breton S, 1998, J HISTOCHEM CYTOCHEM, V46, P205, DOI 10.1177/002215549804600209; Bullis BL, 2002, EUR J BIOCHEM, V269, P4887, DOI 10.1046/j.1432-1033.2002.03202.x; Busa W. B., 1984, AM J PHYSIOL, V246, P409; Carey KD, 2003, J BIOL CHEM, V278, P3185, DOI 10.1074/jbc.M207014200; CHIONO M, 1995, J BIOL CHEM, V270, P1149, DOI 10.1074/jbc.270.3.1149; Cooper DMF, 2003, BIOCHEM J, V375, P517, DOI 10.1042/BJ20031061; Crossthwaite AJ, 2005, J BIOL CHEM, V280, P6380, DOI 10.1074/jbc.M411987200; DEBERNARDI MA, 1993, BIOCHEM J, V293, P325, DOI 10.1042/bj2930325; DEITMER JW, 1995, J PHYSIOL-LONDON, V485, P157, DOI 10.1113/jphysiol.1995.sp020720; EVANS T, 1984, MOL PHARMACOL, V26, P395; Fagan KA, 2000, J BIOL CHEM, V275, P26530, DOI 10.1074/jbc.M001369200; Fagan KA, 1998, J BIOL CHEM, V273, P9297, DOI 10.1074/jbc.273.15.9297; Fagan KA, 1996, J BIOL CHEM, V271, P12438, DOI 10.1074/jbc.271.21.12438; Fagan KA, 2000, J BIOL CHEM, V275, P40187, DOI 10.1074/jbc.M006606200; FUJIMOTO T, 1993, J CELL BIOL, V120, P1147, DOI 10.1083/jcb.120.5.1147; GANZ MB, 1990, J BIOL CHEM, V265, P8989; GARRITSEN A, 1992, J NEUROCHEM, V59, P190, DOI 10.1111/j.1471-4159.1992.tb08890.x; Gende OA, 2003, PLATELETS, V14, P9, DOI 10.1080/0953710021000034465; GRINSTEIN S, 1993, EMBO J, V12, P5209, DOI 10.1002/j.1460-2075.1993.tb06216.x; Hu BA, 2002, J BIOL CHEM, V277, P33139, DOI 10.1074/jbc.M112373200; HUANG SL, 1994, J BIOL CHEM, V269, P7631; JOHNSON RA, 1982, ARCH BIOCHEM BIOPHYS, V218, P68, DOI 10.1016/0003-9861(82)90322-8; KAILA K, 1987, NATURE, V330, P163, DOI 10.1038/330163a0; KANDASAMY RK, 1995, J BIOL CHEM, V270, P29209, DOI 10.1074/jbc.270.49.29209; KLEE CB, 1980, ANNU REV BIOCHEM, V49, P489, DOI 10.1146/annurev.bi.49.070180.002421; Lang KS, 2003, CELL PHYSIOL BIOCHEM, V13, P257, DOI 10.1159/000074540; Li XH, 2001, J PHYSIOL-LONDON, V537, P537, DOI 10.1111/j.1469-7793.2001.00537.x; LIN MC, 1975, J BIOL CHEM, V250, P4246; Masereel B, 2003, EUR J MED CHEM, V38, P547, DOI 10.1016/S0223-5234(03)00100-4; McLean LA, 2000, AM J PHYSIOL-CELL PH, V278, pC676, DOI 10.1152/ajpcell.2000.278.4.C676; Mineo C, 1996, EXP CELL RES, V224, P237, DOI 10.1006/excr.1996.0133; Nakhoul NK, 2002, J NEPHROL, V15, pS22; Nitschke R, 1996, PFLUG ARCH EUR J PHY, V433, P98, DOI 10.1007/s004240050254; Ogi M, 2000, J GASTROENTEROL, V35, P912, DOI 10.1007/s005350070005; Ostrom RS, 2002, MOL PHARMACOL, V62, P983, DOI 10.1124/mol.62.5.983; Petrecca K, 1999, AM J PHYSIOL-HEART C, V276, pH709, DOI 10.1152/ajpheart.1999.276.2.H709; Putney James W. Jr, 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P143; Ro HA, 2004, J BIOL CHEM, V279, P37115, DOI 10.1074/jbc.M403099200; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SCHNITZER JE, 1995, P NATL ACAD SCI USA, V92, P1759, DOI 10.1073/pnas.92.5.1759; SCHWIENING CJ, 1993, P ROY SOC B-BIOL SCI, V253, P285, DOI 10.1098/rspb.1993.0115; Schwiening CJ, 2002, J PHYSIOL-LONDON, V538, P371, DOI 10.1113/jphysiol.2001.013055; Smith GAM, 1998, J PHYSIOL-LONDON, V512, P487, DOI 10.1111/j.1469-7793.1998.487be.x; Smith KE, 2002, J BIOL CHEM, V277, P6025, DOI 10.1074/jbc.M109615200; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; THOMAS RC, 1982, NATURE, V299, P826, DOI 10.1038/299826a0; TKACHUK V A, 1981, Biokhimiya, V46, P963; Trapp S, 1996, NEUROREPORT, V7, P2000, DOI 10.1097/00001756-199608120-00029; Trapp S, 1996, J PHYSIOL-LONDON, V496, P695, DOI 10.1113/jphysiol.1996.sp021720; Volk C, 1998, BBA-BIOMEMBRANES, V1372, P28, DOI 10.1016/S0005-2736(98)00044-3; Willoughby D, 2002, J PHYSIOL-LONDON, V544, P487, DOI 10.1113/jphysiol.2002.027508; Yamamoto M, 1998, J BIOL CHEM, V273, P26962, DOI 10.1074/jbc.273.41.26962	57	37	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	2005	280	35					30864	30872		10.1074/jbc.M414355200	http://dx.doi.org/10.1074/jbc.M414355200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	958ZX	16002403	hybrid			2022-12-25	WOS:000231487800027
J	Zakharov, SI; Morrow, JP; Liu, GX; Yang, L; Marx, SO				Zakharov, SI; Morrow, JP; Liu, GX; Yang, L; Marx, SO			Activation of the BK (SLO1) potassium channel by mallotoxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CA2+-DEPENDENT K+ CHANNELS; LARGE-CONDUCTANCE; VOLTAGE SENSOR; BETA-SUBUNIT; SMOOTH-MUSCLE; ROTTLERIN; DOMAIN; CELLS; PHOSPHORYLATION	Pharmacologic approaches to activate K+ channels represent an emerging strategy to regulate membrane excitability. Here we report the identification and characterization of a lipid soluble toxin, mallotoxin (rottlerin), which potently activates the large conductance voltage and Ca2+-activated K+ channel (BK) expressed in a heterologous expression system and human vascular smooth muscle cells, shifting the conductance/voltage relationship by >100 mV. Probing the mechanism of action, we discover that the BK channel can be activated in the absence of divalent cations (Ca2+, Mg2+), suggesting that the mallotoxin mechanism of action involves the voltage-dependent gating of the channel. Mallo-toxin-activated channels remain incrementally sensitive to Ca2+ and beta subunits. In comparison to other small hydrophobic poisons, anesthetic agents, and protein toxins that inhibit ion channel activity, mallotoxin potently activates channel activity. In certain respects, mallotoxin acts as a BK channel beta 1 subunit mimetic, preserving BK channel Ca2+ sensitivity yet adjusting the set-point for BK channel activation to a more hyperpolarized membrane potential.	Columbia Univ, Coll Phys & Surg, New York, NY 10032 USA; Dept Med, Div Cardiol, New York, NY 10029 USA; Ctr Mol Cardiol, New York, NY 10029 USA	Columbia University	Marx, SO (corresponding author), Columbia Univ, Coll Phys & Surg, 630 W 168th St, New York, NY 10032 USA.	sm460@columbia.edu		Morrow, John/0000-0002-9264-5273				ADELMAN JP, 1992, NEURON, V9, P209, DOI 10.1016/0896-6273(92)90160-F; Amberg GC, 2003, J CLIN INVEST, V112, P717, DOI 10.1172/JC1200318684; ANDERSON A, 1855, EDINBURGH NEW PHILOS, V1, P296; ATKINSON NS, 1991, SCIENCE, V253, P551, DOI 10.1126/science.1857984; Brenner R, 2000, J BIOL CHEM, V275, P6453, DOI 10.1074/jbc.275.9.6453; BUTLER A, 1993, SCIENCE, V261, P221, DOI 10.1126/science.7687074; Cestele S, 1998, NEURON, V21, P919, DOI 10.1016/S0896-6273(00)80606-6; Davies AG, 2003, CELL, V115, P655, DOI 10.1016/S0092-8674(03)00979-6; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Dworetzky SI, 1996, J NEUROSCI, V16, P4543; Golding NL, 1999, J NEUROSCI, V19, P8789, DOI 10.1523/JNEUROSCI.19-20-08789.1999; Gribkoff VK, 2001, NAT MED, V7, P471, DOI 10.1038/86546; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; Horrigan FT, 2002, J GEN PHYSIOL, V120, P267, DOI 10.1085/jgp.20028605; Hu H, 2001, J NEUROSCI, V21, P9585, DOI 10.1523/JNEUROSCI.21-24-09585.2001; Hu L, 2003, P NATL ACAD SCI USA, V100, P10488, DOI 10.1073/pnas.1834300100; Jiang YX, 2001, NEURON, V29, P593, DOI 10.1016/S0896-6273(01)00236-7; Kayali AG, 2002, ENDOCRINOLOGY, V143, P3884, DOI 10.1210/en.2002-220259; KHORANA M. L., 1949, INDIAN JOUR PHARM, V11, P37; KNAUS HG, 1994, J BIOL CHEM, V269, P17274; MCMANUS OB, 1995, NEURON, V14, P645, DOI 10.1016/0896-6273(95)90321-6; Nardi A, 2003, PLANTA MED, V69, P885, DOI 10.1055/s-2003-45095; Nelson MT, 2004, J CLIN INVEST, V113, P955, DOI 10.1172/JCI200421388; Nishimaru K, 2004, J PHYSIOL-LONDON, V559, P849, DOI 10.1113/jphysiol.2004.068676; Nishizawa S, 2003, J VASC RES, V40, P169, DOI 10.1159/000070714; OLESEN SP, 1994, EUR J PHARMACOL, V251, P53, DOI 10.1016/0014-2999(94)90442-1; Saito M, 1997, J BIOL CHEM, V272, P11710, DOI 10.1074/jbc.272.18.11710; Schreiber M, 1997, BIOPHYS J, V73, P1355, DOI 10.1016/S0006-3495(97)78168-2; Schubert R, 2001, TRENDS PHARMACOL SCI, V22, P505, DOI 10.1016/S0165-6147(00)01775-2; Semper A, 1910, ARCH EXP PATHOL PHAR, V63, P10, DOI 10.1007/BF01840850; Shao LR, 1999, J PHYSIOL-LONDON, V521, P135, DOI 10.1111/j.1469-7793.1999.00135.x; Shi JY, 2002, NATURE, V418, P876, DOI 10.1038/nature00941; Soltoff SP, 2001, J BIOL CHEM, V276, P37986; Susarla BTS, 2003, J NEUROCHEM, V86, P635, DOI 10.1046/j.1471-4159.2003.01886.x; Tang XD, 2004, ANNU REV PHYSIOL, V66, P131, DOI 10.1146/annurev.physiol.66.041002.142720; Tillman DM, 2003, CANCER RES, V63, P5118; Xia XM, 2002, NATURE, V418, P880, DOI 10.1038/nature00956; Xie JY, 1998, SCIENCE, V280, P443, DOI 10.1126/science.280.5362.443	40	57	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	2005	280	35					30882	30887		10.1074/jbc.M505302200	http://dx.doi.org/10.1074/jbc.M505302200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	958ZX	15998639	hybrid			2022-12-25	WOS:000231487800029
J	Christensen, C; Guldberg, P				Christensen, C; Guldberg, P			Growth factors rescue cutaneous melanoma cells from apoptosis induced by knockdown of mutated (V600E) B-RAF	ONCOGENE			English	Article						malignant melanoma; B-RAF; RNA interference; apoptosis; senescence; growth factors	POLYMERASE-III TRANSCRIPTION; ACTIVATED PROTEIN-KINASE; SHORT-INTERFERING RNAS; MALIGNANT-MELANOMA; HUMAN MELANOCYTES; METASTATIC MELANOMA; BRAF MUTATIONS; ONCOGENIC MUTATIONS; THERAPEUTIC TARGET; A-RAF	Constitutive activation of the RAS-RAF-MEK-ERK signaling cascade is a hallmark of cutaneous malignant melanoma. A single activating mutation (c. 1799T > A; p. V600E) in the gene encoding the serine/threonine kinase B-RAF occurs in > 60% of the tumors. Previous work has shown that knockdown of B-V600E-RAFby RNA interference induces a variety of phenotypic changes in cultured melanoma cells, including lower proliferation rates, reduced anchorage-independent growth and apoptosis. Here, we show that the majority of melanomas harboring the B-V600E-RAF mutation have retained the wild-type (WT) B-RAF allele, and that these cells can be rescued from the effects of B-V600E-RAF knockdown by stimulation with growth factors. Ectopic expression of short hairpin RNAs specifically suppressing B-V600E-RAF in melanoma cell lines reduced colony formation by similar to 80%. This response could be rescued by basic fibroblast growth factor, hepatocyte growth factor or, to a lesser extent, endothelin-1. Rescue with growth factors was not possible in cell lines lacking B-WT-RAF. Single-cell clones with efficient knockdown of B-V600E-RAF could be propagated in the presence of basic fibroblast growth factor but underwent apoptosis or senescence-like growth arrest upon withdrawal of this growth factor. The ability of growth factors to modulate the response of B-V600E-RAF knockdown in melanoma cells may have both experimental and therapeutic implications.	Danish Canc Soc, Inst Canc Biol, DK-2100 Copenhagen, Denmark	Danish Cancer Society	Guldberg, P (corresponding author), Danish Canc Soc, Inst Canc Biol, Strandboulevarden 49, DK-2100 Copenhagen, Denmark.	perg@cancer.dk						ALBINO AP, 1991, CANCER RES, V51, P4815; Bastian BC, 1998, CANCER RES, V58, P2170; Berking C, 2001, AM J PATHOL, V158, P943, DOI 10.1016/S0002-9440(10)64041-2; Bielenberg DR, 1998, J INVEST DERMATOL, V111, P864, DOI 10.1046/j.1523-1747.1998.00378.x; Bridge AJ, 2003, NAT GENET, V34, P263, DOI 10.1038/ng1173; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Collisson EA, 2003, CANCER RES, V63, P5669; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dong JL, 2003, CANCER RES, V63, P3883; Easty DJ, 2000, MELANOMA RES, V10, P401, DOI 10.1097/00008390-200010000-00001; EISINGER M, 1985, SCIENCE, V229, P984, DOI 10.1126/science.4023718; Garnett MJ, 2004, CANCER CELL, V6, P313, DOI 10.1016/j.ccr.2004.09.022; Gorden A, 2003, CANCER RES, V63, P3955; Guldberg P, 1997, CANCER RES, V57, P3660; Halaban R, 2000, PIGM CELL RES, V13, P4, DOI 10.1034/j.1600-0749.2000.130103.x; Halaban R, 1996, SEMIN ONCOL, V23, P673; Hingorani SR, 2003, CANCER RES, V63, P5198; Huang SY, 1996, ONCOGENE, V13, P2339; Huser M, 2001, EMBO J, V20, P1940, DOI 10.1093/emboj/20.8.1940; Imokawa G, 2000, J BIOL CHEM, V275, P33321, DOI 10.1074/jbc.M004346200; IMOKAWA G, 1992, J BIOL CHEM, V267, P24675; Karasarides M, 2004, ONCOGENE, V23, P6292, DOI 10.1038/sj.onc.1207785; Kumar R, 2003, CLIN CANCER RES, V9, P3362; Li G, 2003, ONCOGENE, V22, P3162, DOI 10.1038/sj.onc.1206455; Li G, 2001, ONCOGENE, V20, P8125, DOI 10.1038/sj.onc.1205034; Meier F, 2000, AM J PATHOL, V156, P193, DOI 10.1016/S0002-9440(10)64719-0; Mercer K, 2002, ONCOGENE, V21, P347, DOI 10.1038/sj.onc.1205101; Nesbit M, 1999, ONCOGENE, V18, P6469, DOI 10.1038/sj.onc.1203066; Otsuka T, 1998, CANCER RES, V58, P5157; Peyssonnaux C, 2001, BIOL CELL, V93, P53, DOI 10.1016/S0248-4900(01)01125-X; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; PRITCHARD CA, 1995, MOL CELL BIOL, V15, P6430; Satyamoorthy K, 2003, CANCER RES, V63, P756; Satyamoorthy K, 2001, CANCER RES, V61, P7318; Scott PH, 2001, J BIOL CHEM, V276, P1005, DOI 10.1074/jbc.M005417200; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; Smalley KSM, 2003, INT J CANCER, V104, P527, DOI 10.1002/ijc.10978; STORM SM, 1990, ONCOGENE, V5, P345; Sumimoto H, 2004, ONCOGENE, V23, P6031, DOI 10.1038/sj.onc.1207812; Sutcliffe JE, 2000, MOL CELL BIOL, V20, P9192, DOI 10.1128/MCB.20.24.9192-9202.2000; Tuveson DA, 2003, CANCER CELL, V4, P95, DOI 10.1016/S1535-6108(03)00189-2; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Wellbrock C, 2004, CANCER RES, V64, P2338, DOI 10.1158/0008-5472.CAN-03-3433; Wellbrock C, 2004, NAT REV MOL CELL BIO, V5, P875, DOI 10.1038/nrm1498; Zhang XD, 2003, ONCOGENE, V22, P2869, DOI 10.1038/sj.onc.1206427	46	42	44	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	41					6292	6302		10.1038/sj.onc.1208758	http://dx.doi.org/10.1038/sj.onc.1208758			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	964JM	16007203				2022-12-25	WOS:000231877100010
J	Vaughan, AM; Oram, JF				Vaughan, AM; Oram, JF			ABCG1 redistributes cell cholesterol to domains removable by high density lipoprotein but not by lipid-depleted apolipoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORONARY-HEART-DISEASE; HDL CHOLESTEROL; P-GLYCOPROTEIN; EFFLUX; RECEPTOR; ABCA1; GENE; TRANSPORTER; EXPRESSION; MACROPHAGES	ATP binding cassette transporter G1 (ABCG1) mediates the transport of cholesterol from cells to high density lipoprotein (HDL) but not to lipid-depleted apolipoprotein A-I. Here we show that human ABCG1 overexpressed in baby hamster kidney cells in the absence of lipoproteins traffics to the plasma membrane and redistributes membrane cholesterol to cell-surface domains accessible to treatment with the enzyme cholesterol oxidase. Cholesterol removed by HDL was largely derived from these domains in ABCG1 transfectants but not in cells lacking ABCG1. Overexpression of ABCG1 also increased cholesterol esterification, which was decreased by the addition of HDL, suggesting that a proportion of the cell-surface cholesterol not removed by HDL is transported to the intracellular esterifying enzyme acyl-CoA:cholesterol acyltransferase. A 638-amino acid ABCG1, which lacked the 40 N-terminal amino acids of the predicted full-length protein, was fully functional and of a similar size to ABCG1 expressed by cholesterol-loaded human monocyte-derived macrophages. Mutating an essential glycine residue in the Walker A motif abolished ABCG1-dependent cholesterol efflux and esterification and prevented localization of ABCG1 to the cell surface, indicating that the ATP binding domain in ABCG1 is essential for both lipid transport activity and protein trafficking. These studies show that ABCG1 redistributes cholesterol to cell-surface domains where it becomes accessible for removal by HDL, consistent with a direct role of ABCG1 in cellular cholesterol transport.	Univ Washington, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Vaughan, AM (corresponding author), Univ Washington, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA.	smashie@u.washington.edu			NHLBI NIH HHS [HL-18645, HL-55362] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055362, P01HL018645] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aiello RJ, 2003, ARTERIOSCL THROM VAS, V23, P972, DOI 10.1161/01.ATV.0000054661.21499.FB; Annilo T, 2001, CYTOGENET CELL GENET, V94, P196, DOI 10.1159/000048816; Berge KE, 2000, SCIENCE, V290, P1771, DOI 10.1126/science.290.5497.1771; CASTELLI WP, 1986, JAMA-J AM MED ASSOC, V256, P2835, DOI 10.1001/jama.256.20.2835; Chawla A, 2001, MOL CELL, V7, P161, DOI 10.1016/S1097-2765(01)00164-2; CORTI MC, 1995, JAMA-J AM MED ASSOC, V274, P539, DOI 10.1001/jama.274.7.539; Costet P, 2000, J BIOL CHEM, V275, P28240; Croop JM, 1997, GENE, V185, P77, DOI 10.1016/S0378-1119(96)00633-6; Cserepes J, 2004, BIOCHEM BIOPH RES CO, V320, P860, DOI 10.1016/j.bbrc.2004.06.037; Engel T, 2001, BIOCHEM BIOPH RES CO, V288, P483, DOI 10.1006/bbrc.2001.5756; Escher G, 2003, J BIOL CHEM, V278, P11015, DOI 10.1074/jbc.M212780200; Fitzgerald ML, 2002, J BIOL CHEM, V277, P33178, DOI 10.1074/jbc.M204996200; Garrigues A, 2002, P NATL ACAD SCI USA, V99, P10347, DOI 10.1073/pnas.162366399; Glomset J A, 1980, Adv Intern Med, V25, P91; Goldbourt U, 1997, ARTERIOSCL THROM VAS, V17, P107, DOI 10.1161/01.ATV.17.1.107; GORDON DJ, 1989, CIRCULATION, V79, P8, DOI 10.1161/01.CIR.79.1.8; GORDON T, 1977, AM J MED, V62, P707, DOI 10.1016/0002-9343(77)90874-9; Graf GA, 2004, J BIOL CHEM, V279, P24881, DOI 10.1074/jbc.M402634200; Graf GA, 2003, J BIOL CHEM, V278, P48275, DOI 10.1074/jbc.M310223200; Kennedy MA, 2001, J BIOL CHEM, V276, P39438, DOI 10.1074/jbc.M105863200; Kennedy MA, 2005, CELL METAB, V1, P121, DOI 10.1016/j.cmet.2005.01.002; Klucken J, 2000, P NATL ACAD SCI USA, V97, P817, DOI 10.1073/pnas.97.2.817; LANGE Y, 1993, J BIOL CHEM, V268, P13838; Langmann T, 2000, BBA-GENE STRUCT EXPR, V1494, P175, DOI 10.1016/S0167-4781(00)00215-3; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; Li AC, 2004, J CLIN INVEST, V114, P1564, DOI 10.1172/JCI200418730; Lorkowski S, 2001, BIOCHEM BIOPH RES CO, V280, P121, DOI 10.1006/bbrc.2000.4089; Marchler-Bauer A, 2005, NUCLEIC ACIDS RES, V33, pD192, DOI 10.1093/nar/gki069; MENDEZ AJ, 1994, J CLIN INVEST, V94, P1698, DOI 10.1172/JCI117515; MENDEZ AJ, 1991, J BIOL CHEM, V266, P10104; MILLER NE, 1977, LANCET, V1, P965, DOI 10.1016/S0140-6736(77)92274-7; Nakamura K, 2004, J BIOL CHEM, V279, P45980, DOI 10.1074/jbc.M408652200; Neufeld EB, 2001, J BIOL CHEM, V276, P27584, DOI 10.1074/jbc.M103264200; O'Connell BJ, 2004, CIRCULATION, V110, P2881, DOI 10.1161/01.CIR.0000146333.20727.2B; Oldfield S, 2002, BBA-MOL CELL RES, V1591, P175, DOI 10.1016/S0167-4889(02)00269-0; Oram JF, 2000, CURR OPIN LIPIDOL, V11, P253, DOI 10.1097/00041433-200006000-00005; Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200; Repa JJ, 2002, J BIOL CHEM, V277, P18793, DOI 10.1074/jbc.M109927200; Schwartz K, 2000, BIOCHEM BIOPH RES CO, V274, P794, DOI 10.1006/bbrc.2000.3243; Vaisman BL, 2001, J CLIN INVEST, V108, P303; vanHelvoort A, 1996, CELL, V87, P507, DOI 10.1016/S0092-8674(00)81370-7; Vaughan AM, 2003, J LIPID RES, V44, P1373, DOI 10.1194/jlr.M300078-JLR200; Venkateswaran A, 2000, J BIOL CHEM, V275, P14700, DOI 10.1074/jbc.275.19.14700; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Wang N, 2004, P NATL ACAD SCI USA, V101, P9774, DOI 10.1073/pnas.0403506101; Wang N, 2003, ARTERIOSCL THROM VAS, V23, P1178, DOI 10.1161/01.ATV.0000075912.83860.26; WILSON PWF, 1988, ARTERIOSCLEROSIS, V8, P737, DOI 10.1161/01.ATV.8.6.737; XU XX, 1991, J BIOL CHEM, V266, P17040; Yancey PG, 2003, ARTERIOSCL THROM VAS, V23, P712, DOI 10.1161/01.ATV.0000057572.97137.DD	50	212	223	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	2005	280	34					30150	30157		10.1074/jbc.M505368200	http://dx.doi.org/10.1074/jbc.M505368200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	957IC	15994327	hybrid			2022-12-25	WOS:000231362500022
J	Sluis-Cremer, N; Arion, D; Parikh, U; Koontz, D; Schinazi, RF; Mellors, JW; Parniak, MA				Sluis-Cremer, N; Arion, D; Parikh, U; Koontz, D; Schinazi, RF; Mellors, JW; Parniak, MA			The 3 '-azido group is not the primary determinant of 3 '-azido-3 '-deoxythymidine (AZT) responsible for the excision phenotype of AZT-resistant HIV-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; NUCLEOSIDE REVERSE-TRANSCRIPTASE; ANTIVIRAL ACTIVITY; PRIMER UNBLOCKING; WILD-TYPE; MECHANISM; INHIBITORS; SENSITIVITY; ZIDOVUDINE; POLYMERIZATION	The mechanism of human immunodeficiency virus (HIV) 1 resistance to 3'-azido-3'-deoxythymidine (AZT) involves reverse transcriptase (RT)-catalyzed phosphorolytic excision of the chain-terminating AZT-5'-monophosphate ( AZTMP). Primers terminated with AZTMP are generally better substrates for this reaction than those terminated with 2',3'-dideoxynucleoside-5'-monophosphate (2', 3'-ddNMP) analogs that lack a 3'-azido moiety. This led to the hypothesis that the 3'-azido group is a major structural determinant for maintaining the primer terminus in the appropriate site for phosphorolytic excision of AZTMP by AZT-resistant (AZTR) RT. To test this hypothesis, we evaluated the incorporation, phosphorolytic excision, and antiviral activity of a panel of 3'-azido-2', 3'-ddN including 3'-azido-2', 3'-ddA (AZddA), 3'-azido-2',3'-ddC (AZddC), 3'-azido-2',3'-ddG(AZddG), AZT, and 3'-azido-2', 3'-ddU ( AZddU). The results indicate that mutations correlated with resistance to AZT (D67N/K70R/T215F/K219Q) confer resistance to the 3'-azidopyrimidine nucleosides (AZddC, AZT, and AZddU) but not to the 3'-azidopurine nucleosides ( AZddA and AZddG). The data suggest that the presence of a 3'-azido group on the 3'-terminal nucleotide of the primer does not confer increased phosphorolytic excision by AZTR RT for all 3'-azido-ddNMP analogs. Thus, the 3'-azido group cannot be the only structural determinant important for the enhanced phosphorolytic excision of AZTMP associated with HIV resistance to AZT. Other structural components, such as the base, must play a role in defining the specificity of the excision phenotype arising from AZT resistance mutations.	Univ Pittsburgh, Sch Med, Dept Med, Div Infect Dis, Pittsburgh, PA 15261 USA; Emory Univ, Vet Affairs Med Ctr, Lab Biochem Pharmacol, Atlanta, GA 30033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Emory University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Atlanta VA Health Care System	Parniak, MA (corresponding author), Univ Pittsburgh, Sch Med, Dept Med, Div Infect Dis, Scaife Hall S817,3550 Terrace St, Pittsburgh, PA 15261 USA.	parniakm@msx.dept-med.pitt.edu	Schinazi, Raymond F/B-6777-2017		NIAID NIH HHS [AI052010] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052010] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arion D, 1998, BIOCHEMISTRY-US, V37, P15908, DOI 10.1021/bi981200e; Arion D, 2000, J BIOL CHEM, V275, P9251, DOI 10.1074/jbc.275.13.9251; ARTS EJ, 1994, J BIOL CHEM, V269, P14672; Boyer PL, 2001, J VIROL, V75, P4832, DOI 10.1128/JVI.75.10.4832-4842.2001; Coakley EP, 2000, AIDS, V14, pF9, DOI 10.1097/00002030-200001280-00002; Fletcher RS, 1996, PROTEIN EXPRES PURIF, V7, P27, DOI 10.1006/prep.1996.0004; GOODY RS, 1991, FEBS LETT, V291, P1, DOI 10.1016/0014-5793(91)81089-Q; Harrigan PR, 2000, J INFECT DIS, V181, P912, DOI 10.1086/315317; KATI WM, 1992, J BIOL CHEM, V267, P25988; Kerr SG, 1997, BIOCHEMISTRY-US, V36, P14064, DOI 10.1021/bi9713862; Krebs R, 1997, BIOCHEMISTRY-US, V36, P10292, DOI 10.1021/bi970512z; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LIGHTFOOTE MM, 1986, J VIROL, V60, P771, DOI 10.1128/JVI.60.2.771-775.1986; LIN PF, 1994, J INFECT DIS, V170, P1157, DOI 10.1093/infdis/170.5.1157; LIN TS, 1988, J MED CHEM, V31, P336, DOI 10.1021/jm00397a011; Marchand B, 2003, J BIOL CHEM, V278, P35362, DOI 10.1074/jbc.M304262200; MAYERS DL, 1994, ANTIMICROB AGENTS CH, V38, P307, DOI 10.1128/AAC.38.2.307; Meyer PR, 1999, MOL CELL, V4, P35, DOI 10.1016/S1097-2765(00)80185-9; Meyer PR, 2000, ANTIMICROB AGENTS CH, V44, P3465, DOI 10.1128/AAC.44.12.3465-3472.2000; Meyer PR, 1998, P NATL ACAD SCI USA, V95, P13471, DOI 10.1073/pnas.95.23.13471; Miller MD, 2001, NUCLEOS NUCLEOT NUCL, V20, P1025, DOI 10.1081/NCN-100002483; Miller V, 2000, AIDS, V14, P163, DOI 10.1097/00002030-200001280-00012; Naeger LK, 2002, ANTIMICROB AGENTS CH, V46, P2179, DOI 10.1128/AAC.46.7.2179-2184.2002; NGUYEN MH, 1994, ANTIMICROB AGENTS CH, V38, P2409, DOI 10.1128/AAC.38.10.2409; Parniak M A, 2000, Adv Pharmacol, V49, P67; PEDEN K, 1991, VIROLOGY, V185, P661, DOI 10.1016/0042-6822(91)90537-L; Ray AS, 2003, BIOCHEMISTRY-US, V42, P8831, DOI 10.1021/bi034435l; REED L. J., 1938, AMER JOUR HYG, V27, P493; Rothwell PJ, 2003, P NATL ACAD SCI USA, V100, P1655, DOI 10.1073/pnas.0434003100; Sarafianos SG, 2002, EMBO J, V21, P6614, DOI 10.1093/emboj/cdf637; Schinazi R.F., 2000, INT ANTIVIRAL NEWS, V8, P65; Selmi B, 2003, ANTIVIR THER, V8, P143; Sluis-Cremer N, 2000, CELL MOL LIFE SCI, V57, P1408, DOI 10.1007/PL00000626; TRAUT TW, 1994, MOL CELL BIOCHEM, V140, P1, DOI 10.1007/BF00928361; WILLIAMS GJ, 1990, ANN NY ACAD SCI, V616, P620	35	36	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	2005	280	32					29047	29052		10.1074/jbc.M503166200	http://dx.doi.org/10.1074/jbc.M503166200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	952QT	15970587	hybrid			2022-12-25	WOS:000231021300029
J	Bartl, FJ; Fritze, O; Ritter, E; Herrmann, R; Kuksa, V; Palczewski, K; Hofmann, KP; Ernst, OP				Bartl, FJ; Fritze, O; Ritter, E; Herrmann, R; Kuksa, V; Palczewski, K; Hofmann, KP; Ernst, OP			Partial agonism in a g protein-coupled receptor - Role of the retinal ring structure in rhodopsin activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-IONONE RING; METARHODOPSIN-II; FTIR SPECTROSCOPY; SIGNALING STATES; BOVINE RHODOPSIN; VISUAL PIGMENTS; BINDING-SITES; PROTON UPTAKE; GROUND-STATE; OPSIN	The visual process in rod cells is initiated by absorption of a photon in the rhodopsin retinal chromophore and consequent retinal cis/trans-isomerization. The ring structure of retinal is thought to be needed to transmit the photonic energy into conformational changes culminating in the active metarhodopsin II ( Meta II) intermediate. Here, we demonstrate that cis-acyclic retinals, lacking four carbon atoms of the ring, can activate rhodopsin. Detailed analysis of the activation pathway showed that, although the photoproduct pathway is more complex, Meta II formed with almost normal kinetics. However, lack of the ring structure resulted in a low amount of Meta II and a fast decay of activity. We conclude that the main role of the ring structure is to maintain the active state, thus specifying a mechanism of activation by a partial agonist of the G protein-coupled receptor rhodopsin.	Charite Univ Med Berlin, Inst Med Phys & Biophys, D-10098 Berlin, Germany; Humboldt Univ, Zentrum Biophys & Bioinformat, D-10015 Berlin, Germany; Univ Washington, Dept Ophthalmol, Seattle, WA 98195 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Dept Chem, Seattle, WA 98195 USA	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Humboldt University of Berlin; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Bartl, FJ (corresponding author), Charite Univ Med Berlin, Inst Med Phys & Biophys, Schumannstr 20-21, D-10098 Berlin, Germany.	franz.bartl@charite.de; oliver.ernst@charite.de						ARNIS S, 1993, P NATL ACAD SCI USA, V90, P7849, DOI 10.1073/pnas.90.16.7849; ARNIS S, 1994, J BIOL CHEM, V269, P23879; Bartl F, 2000, FEBS LETT, V473, P259, DOI 10.1016/S0014-5793(00)01544-1; Bartl FJ, 2001, J BIOL CHEM, V276, P30161, DOI 10.1074/jbc.M101506200; Borhan B, 2000, SCIENCE, V288, P2209, DOI 10.1126/science.288.5474.2209; Buczylko J, 1996, J BIOL CHEM, V271, P20621, DOI 10.1074/jbc.271.34.20621; COHEN GB, 1992, BIOCHEMISTRY-US, V31, P12592, DOI 10.1021/bi00165a008; CROUCH R, 1983, FEBS LETT, V158, P139, DOI 10.1016/0014-5793(83)80694-2; CROUCH RK, 1982, J AM CHEM SOC, V104, P4946, DOI 10.1021/ja00382a035; DeGrip W. J., 2000, HDB BIOL PHYS, P1, DOI 10.1016/s1383- 8121(00)80004- 4; FARAHBAKHSH ZT, 1993, SCIENCE, V262, P1416, DOI 10.1126/science.8248781; FARRENS DL, 1995, J BIOL CHEM, V270, P5073, DOI 10.1074/jbc.270.10.5073; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Filipek S, 2003, ANNU REV PHYSIOL, V65, P851, DOI 10.1146/annurev.physiol.65.092101.142611; Fritze O, 2003, P NATL ACAD SCI USA, V100, P2290, DOI 10.1073/pnas.0435715100; Heck M, 2003, VISION RES, V43, P3003, DOI 10.1016/j.visres.2003.08.011; Herrmann R, 2004, J BIOL CHEM, V279, P24283, DOI 10.1074/jbc.M311166200; Hofmann K. P., 2000, HDB BIOL PHYSICS, P91, DOI 10.1016/s1383-8121(00)80006-8; Hubbell WL, 2003, ADV PROTEIN CHEM, V63, P243; JAGER F, 1994, BIOCHEMISTRY-US, V33, P7389; JAGER F, 1994, BIOCHEMISTRY-US, V33, P10878; Karnaukhova E, 1999, BIOORG CHEM, V27, P372, DOI 10.1006/bioo.1999.1146; KIBELBEK J, 1991, BIOCHEMISTRY-US, V30, P6761, DOI 10.1021/bi00241a019; Kuksa V, 2002, J BIOL CHEM, V277, P42315, DOI 10.1074/jbc.M206014200; Li J, 2004, J MOL BIOL, V343, P1409, DOI 10.1016/j.jmb.2004.08.090; Lou JH, 2000, METHOD ENZYMOL, V315, P219; Martin EL, 1996, J BIOL CHEM, V271, P361, DOI 10.1074/jbc.271.1.361; Meyer CK, 2000, J BIOL CHEM, V275, P19713, DOI 10.1074/jbc.M000603200; Okada T, 2004, J MOL BIOL, V342, P571, DOI 10.1016/j.jmb.2004.07.044; Okada T, 2001, TRENDS BIOCHEM SCI, V26, P318, DOI 10.1016/S0968-0004(01)01799-6; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PARKES JH, 1984, BIOCHEMISTRY-US, V23, P5054, DOI 10.1021/bi00316a035; Patel AB, 2004, P NATL ACAD SCI USA, V101, P10048, DOI 10.1073/pnas.0402848101; Ritter E, 2004, J BIOL CHEM, V279, P48102, DOI 10.1074/jbc.M406857200; Scheer A, 1997, P NATL ACAD SCI USA, V94, P808, DOI 10.1073/pnas.94.3.808; Sheikh SP, 1996, NATURE, V383, P347, DOI 10.1038/383347a0; Siebert F, 1995, ISRAEL J CHEM, V35, P309; Spooner PJR, 2004, J MOL BIOL, V343, P719, DOI 10.1016/j.jmb.2004.08.049; Spooner PJR, 2003, BIOCHEMISTRY-US, V42, P13371, DOI 10.1021/bi0354029; Vogel R, 2001, J BIOL CHEM, V276, P38487, DOI 10.1074/jbc.M105423200; Vogel R, 2000, BIOCHEMISTRY-US, V39, P8895, DOI 10.1021/bi000852b; Vogel R, 2001, BIOCHEMISTRY-US, V40, P13342, DOI 10.1021/bi0113667	42	42	43	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					34259	34267		10.1074/jbc.M505260200	http://dx.doi.org/10.1074/jbc.M505260200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16027155	hybrid			2022-12-25	WOS:000232229700068
J	Taylor, EJ; Goyal, A; Guerreiro, CIPD; Prates, JAM; Money, VA; Ferry, N; Morland, C; Planas, A; Macdonald, JA; Stick, RV; Gilbert, HJ; Fontes, CMGA; Davies, GJ				Taylor, EJ; Goyal, A; Guerreiro, CIPD; Prates, JAM; Money, VA; Ferry, N; Morland, C; Planas, A; Macdonald, JA; Stick, RV; Gilbert, HJ; Fontes, CMGA; Davies, GJ			How family 26 glycoside hydrolases orchestrate catalysis on different polysaccharides - Structure and activity of a clostridium thermocellum lichenase, CtLic26A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE-BINDING MODULE; CRYSTAL-STRUCTURE; MARINE BACTERIUM; ISOFAGOMINE; HYDROLYSIS; MANNANASE; CELLULOSA; INSIGHTS; ENZYMES; BETA-1,3-XYLANASE	One of the most intriguing features of the 90 glycoside hydrolase families (GHs) is the range of specificities displayed by different members of the same family, whereas the catalytic apparatus and mechanism are often invariant. Family GH26 predominantly comprises beta-1,4 mannanases; however, a bifunctional Clostridium thermocellum GH26 member (hereafter CtLic26A) displays a markedly different specificity. We show that CtLic26A is a lichenase, specific for mixed (Glc beta 1,4Glc beta 1,4Glc beta 1,3)(n) oligo- and polysaccharides, and displays no activity on manno-configured substrates or beta-1,4-linked homopolymers of glucose or xylose. The three-dimensional structure of the native form of CtLic26A has been solved at 1.50-angstrom resolution, revealing a characteristic (beta/alpha)s barrel with Glu-109 and Glu-222 acting as the catalytic acid/base and nucleophile in a double-displacement mechanism. The complex with the competitive inhibitor, Glc-beta-1,3-isofagomine (K-i 1 mu M), at 1.60 angstrom sheds light on substrate recognition in the -2 and -1 subsites and illuminates why the enzyme is specific for lichenan-based substrates. Hydrolysis of beta-mannosides by GH26 members is thought to proceed through transition states in the B2+5 (boat) conformation in which structural distinction of glucosides versus mannosides reflects not the configuration at C2 but the recognition of the pseudoaxial O3 of the B2+5 conformation. We suggest a different conformational itinerary for the GH26 enzymes active on gluco-configured substrates.	Univ York, Dept Chem, York Struct Biol Lab, York YO10 5YW, N Yorkshire, England; Univ Tecn Lisboa, CIISA, Fac Med Vet, P-1300477 Lisbon, Portugal; Newcastle Univ, Inst Cell & Mol Biosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ Ramon Llull, Inst Quim Sarria, Biochem Lab, Barcelona 08017, Spain; Univ Western Australia, Sch Biomed & Chem Sci, Crawley, WA 6009, Australia	University of York - UK; Universidade de Lisboa; Newcastle University - UK; Universitat Ramon Llull; Institut Quimic de Sarria; University of Western Australia	Taylor, EJ (corresponding author), Univ York, Dept Chem, York Struct Biol Lab, York YO10 5YW, N Yorkshire, England.	davies@ysbl.york.ac.uk	Davies, Gideon J/A-9042-2011; PLANAS, ANTONI/I-4803-2015; Money, Victoria/E-8851-2013; Macdonald, James M/H-4209-2013; Prates, José A M/K-9934-2013	Davies, Gideon J/0000-0002-7343-776X; PLANAS, ANTONI/0000-0001-7073-3320; Prates, José A M/0000-0003-1032-5987; Ferry, Natalie/0000-0003-3728-4302; Taylor, Edward/0000-0003-4024-0976; Fontes, Carlos/0000-0002-1219-9753	Biotechnology and Biological Sciences Research Council [BBS/B/05974] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Araki T, 2000, APPL ENVIRON MICROB, V66, P1741, DOI 10.1128/AEM.66.4.1741-1743.2000; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bolam DN, 1996, BIOCHEMISTRY-US, V35, P16195, DOI 10.1021/bi961866d; Boraston AB, 2003, J BIOL CHEM, V278, P6120, DOI 10.1074/jbc.M209554200; Boraston AB, 2004, BIOCHEM J, V382, P769, DOI 10.1042/BJ20040892; Brett CT, 1996, PHYSL BIOCH PLANT CE; Burmeister WP, 1997, STRUCTURE, V5, P663, DOI 10.1016/S0969-2126(97)00221-9; Carvalho AL, 2004, J BIOL CHEM, V279, P34785, DOI 10.1074/jbc.M405867200; Coutinho PM, 1999, ROY SOC CH, P3; DAVIES G, 1997, COMPREHENSIVE BIOL C, V1, P119; Davies GJ, 1998, BIOCHEMISTRY-US, V37, P11707, DOI 10.1021/bi981315i; Davies GJ, 2003, BIOCHEM SOC T, V31, P523, DOI 10.1042/BST0310523; Dias FMV, 2004, J BIOL CHEM, V279, P25517, DOI 10.1074/jbc.M401647200; Ducros VMA, 2002, ANGEW CHEM INT EDIT, V41, P2824, DOI 10.1002/1521-3773(20020802)41:15<2824::AID-ANIE2824>3.0.CO;2-G; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FONTES CMGA, 1995, BIOCHEM J, V307, P151, DOI 10.1042/bj3070151; HALL J, 1995, BIOCHEM J, V309, P749, DOI 10.1042/bj3090749; Henrissat B, 1998, FEBS LETT, V425, P352, DOI 10.1016/S0014-5793(98)00265-8; HENRISSAT B, 1995, P NATL ACAD SCI USA, V92, P7090, DOI 10.1073/pnas.92.15.7090; Hogg D, 2001, J BIOL CHEM, V276, P31186, DOI 10.1074/jbc.M010290200; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JENKINS J, 1995, FEBS LETT, V362, P281, DOI 10.1016/0014-5793(95)00252-5; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESLIE AGW, 1992, JOINT CCP4 ESF EACMB, V26; Lillelund VH, 2003, ORG BIOMOL CHEM, V1, P282, DOI 10.1039/b208784g; Macdonald JM, 2004, AUST J CHEM, V57, P187, DOI 10.1071/CH03227; Macdonald JM, 2002, AUST J CHEM, V55, P747, DOI 10.1071/CH02165; Malet C, 1997, BIOCHEMISTRY-US, V36, P13838, DOI 10.1021/bi9711341; Mark BL, 2001, J BIOL CHEM, V276, P42131, DOI 10.1074/jbc.M107154200; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Navaza J, 1997, METHOD ENZYMOL, V276, P581, DOI 10.1016/S0076-6879(97)76079-8; Notenboom V, 2000, BIOCHEMISTRY-US, V39, P11553, DOI 10.1021/bi0010625; Numao S, 2003, J BIOL CHEM, V278, P48074, DOI 10.1074/jbc.M309249200; Okazaki F, 2002, J BACTERIOL, V184, P2399, DOI 10.1128/JB.184.9.2399-2403.2002; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Sabini E, 1999, CHEM BIOL, V6, P483, DOI 10.1016/S1074-5521(99)80066-0; SOMOGYI M, 1952, J BIOL CHEM, V195, P19; TOMME P, 1988, EUR J BIOCHEM, V170, P575, DOI 10.1111/j.1432-1033.1988.tb13736.x; Vallee F, 2000, J BIOL CHEM, V275, P41287, DOI 10.1074/jbc.M006927200; Varrot A, 2003, J AM CHEM SOC, V125, P7496, DOI 10.1021/ja034917k; Varroto A, 2005, J BIOL CHEM, V280, P20181, DOI 10.1074/jbc.C500142200; Vasella A, 2002, CURR OPIN CHEM BIOL, V6, P619, DOI 10.1016/S1367-5931(02)00380-0; Vincent F, 2004, CHEMBIOCHEM, V5, P1596, DOI 10.1002/cbic.200400169; Zechel DL, 2003, J AM CHEM SOC, V125, P14313, DOI 10.1021/ja036833h	46	54	58	1	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	2005	280	38					32761	32767		10.1074/jbc.M506580200	http://dx.doi.org/10.1074/jbc.M506580200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	964ZU	15987675	hybrid			2022-12-25	WOS:000231920300027
J	Ball, HL; Cortez, D				Ball, HL; Cortez, D			ATRIP oligomerization is required for ATR-dependent checkpoint signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION PROTEIN-A; SINGLE-STRANDED-DNA; SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; IONIZING-RADIATION; SECKEL-SYNDROME; DAMAGE; BINDING; COMPLEX; MEC1	The ATM and ATR kinases signal cell cycle checkpoint responses to DNA damage. Inactive ATM is an oligomer that is disrupted to form active monomers in response to ionizing radiation. We examined whether ATR is activated by a similar mechanism. We found that the ATRIP subunit of the ATR kinase and ATR itself exist as homo-oligomers in cells. We did not detect regulation of ATR or ATRIP oligomerization after DNA damage. The predicted coiled-coil domain of ATRIP is essential for ATRIP oligomerization, stable ATR binding, and accumulation of ATRIP at DNA lesions. Additionally, the ATRIP coiled-coil is also required for ATRIP to support ATR-dependent checkpoint signaling to Chk1. Replacing the ATRIP coiled-coil domain with a heterologous dimerization domain restored stable binding to ATR and localization to damage-induced intranuclear foci. Thus, the ATR-ATRIP complex exists in higher order oligomeric states within cells and ATRIP oligomerization is essential for its function.	Vanderbilt Univ, Dept Biochem, Nashville, TN 37232 USA	Vanderbilt University	Cortez, D (corresponding author), Vanderbilt Univ, Dept Biochem, 221 Kirkland Hall, Nashville, TN 37232 USA.	david.cortez@vanderbilt.edu			NATIONAL CANCER INSTITUTE [K01CA093701, R01CA102729, T32CA078136] Funding Source: NIH RePORTER; NCI NIH HHS [K01 CA093701, T32 CA078136, R01 CA102729, K01CA93701, R01CA102729, T32 CA78136] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Alderton GK, 2004, HUM MOL GENET, V13, P3127, DOI 10.1093/hmg/ddh335; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bakkenist CJ, 2004, CELL, V118, P9, DOI 10.1016/j.cell.2004.06.023; Ball HL, 2005, MOL BIOL CELL, V16, P2372, DOI 10.1091/mbc.e04-11-1006; Barr SM, 2003, CURR BIOL, V13, P1047, DOI 10.1016/S0960-9822(03)00376-2; Bentley NJ, 1996, EMBO J, V15, P6641, DOI 10.1002/j.1460-2075.1996.tb01054.x; Bomgarden RD, 2004, J BIOL CHEM, V279, P13346, DOI 10.1074/jbc.M311098200; Brown EJ, 2000, GENE DEV, V14, P397; Byun TS, 2005, GENE DEV, V19, P1040, DOI 10.1101/gad.1301205; Cortez D, 2001, SCIENCE, V294, P1713, DOI 10.1126/science.1065521; Cortez D, 2005, GENE DEV, V19, P1007, DOI 10.1101/gad.1316905; Edwards RJ, 1999, NAT CELL BIOL, V1, P393, DOI 10.1038/15623; Falck J, 2005, NATURE, V434, P605, DOI 10.1038/nature03442; Lee JH, 2005, SCIENCE, V308, P551, DOI 10.1126/science.1108297; Lindsay HD, 1998, GENE DEV, V12, P382, DOI 10.1101/gad.12.3.382; Lisby M, 2004, CURR OPIN CELL BIOL, V16, P328, DOI 10.1016/j.ceb.2004.03.011; Liu QH, 1998, CURR BIOL, V8, P1300, DOI 10.1016/S0960-9822(07)00560-X; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; O'Driscoll M, 2003, NAT GENET, V33, P497, DOI 10.1038/ng1129; Paciotti V, 2000, GENE DEV, V14, P2046; Paciotti V, 2001, MOL CELL BIOL, V21, P3913, DOI 10.1128/MCB.21.12.3913-3925.2001; Parrilla-Castellar E, 2003, J BIOL CHEM, V278, P45507, DOI 10.1074/jbc.C300418200; Rouse J, 2000, EMBO J, V19, P5801, DOI 10.1093/emboj/19.21.5801; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; Stauffer ME, 2004, J BIOL CHEM, V279, P25638, DOI 10.1074/jbc.M400029200; Unsal-Kacmaz K, 2004, MOL CELL BIOL, V24, P1292, DOI 10.1128/MCB.24.3.1292-1300.2003; Unsal-Kacmaz K, 2002, P NATL ACAD SCI USA, V99, P6673, DOI 10.1073/pnas.102167799; Wakayama T, 2001, MOL CELL BIOL, V21, P755, DOI 10.1128/MCB.21.3.755-764.2001; Wang Y, 2000, GENE DEV, V14, P927; Wright JA, 1998, P NATL ACAD SCI USA, V95, P7445, DOI 10.1073/pnas.95.13.7445; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	32	62	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	2005	280	36					31390	31396		10.1074/jbc.M504961200	http://dx.doi.org/10.1074/jbc.M504961200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	961LZ	16027118	hybrid, Green Accepted			2022-12-25	WOS:000231665200008
J	Bevilacqua, MA; Iovine, B; Zambrano, N; D'Ambrosio, C; Scaloni, A; Russo, T; Cimino, F				Bevilacqua, MA; Iovine, B; Zambrano, N; D'Ambrosio, C; Scaloni, A; Russo, T; Cimino, F			Fibromodulin gene transcription is induced by ultraviolet irradiation, and its regulation is impaired in senescent human fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEIN; CELLULAR SENESCENCE; NUCLEAR FACTOR; HUMAN-CELLS; REPAIR; INDUCTION; EFFICIENT; MICE; FE65; DDB	Cells undergoing replicative senescence display an altered pattern of gene expression. Senescent fibroblasts show significant changes in the expression of mRNAs encoding extracellular matrix-remodeling proteins; among these mRNAs, the mRNA encoding fibromodulin is highly decreased in these cells. To understand the molecular basis of this phenomenon, we explored the regulatory mechanisms of the human fibromodulin gene. We found that fibromodulin gene promoter contains a cis-element, crucial for its basal expression, that forms a DNA-protein complex when exposed to nuclear extracts from exponentially growing human fibroblasts and not to extracts from cells undergoing senescence by repeated in vitro passages or by mild oxidative stress. The purification of this complex showed that it contains the damage-specific DNA-binding protein DDB-1. The latter is known to be induced by UV irradiation; therefore we checked whether fibromodulin gene promoter is regulated upon the exposure of the cells to UV rays. The results showed that, in exponentially growing fibroblasts, the promoter efficiency is increased by UV irradiation and the DDB-1-containing complex is robustly enriched in cells exposed to UV light. Accordingly, in these experimental conditions the endogenous fibromodulin mRNA accumulates to very high levels. On the contrary, senescent cells did not show any activation of the fibromodulin gene promoter, any induction of the DDB-1-containing complex, or any accumulation of fibromodulin mRNA. These phenomena are accompanied in senescent cells by a decrease of the UV-damaged DNA binding activity.	Univ Naples Federico II, Dipartimento Biochim & Biotecnol Med, CEINGE Biotecnol Avanazate, I-80145 Naples, Italy; CNR, ISPAAM, Proteom & Mass Spectrometry Lab, I-80147 Naples, Italy	CEINGE Biotecnologie Avanzate; University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto Per Il Sistema Produzione Animale In Ambiente Mediterraneo (ISPAAM-CNR)	Cimino, F (corresponding author), Univ Naples Federico II, Dipartimento Biochim & Biotecnol Med, CEINGE Biotecnol Avanazate, Via Comunale Margherita 482, I-80145 Naples, Italy.	cimino@dbbm.unina.it	Russo, Tommaso/K-1331-2016; D'Ambrosio, Chiara/C-2753-2012; Zambrano, Nicola/B-9352-2014	Russo, Tommaso/0000-0003-4426-0106; D'Ambrosio, Chiara/0000-0003-2810-9270; Zambrano, Nicola/0000-0001-9395-3481; Scaloni, Andrea/0000-0001-9362-8515				Benanti JA, 2002, MOL CELL BIOL, V22, P7385, DOI 10.1128/MCB.22.21.7385-7397.2002; Bevilacqua MA, 1997, J BIOL CHEM, V272, P20736, DOI 10.1074/jbc.272.33.20736; BEVILACQUA MA, 1995, BIOCHEM J, V311, P769, DOI 10.1042/bj3110769; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Brenneisen P, 2002, ANN NY ACAD SCI, V973, P31, DOI 10.1111/j.1749-6632.2002.tb04602.x; Campisi J, 2001, TRENDS CELL BIOL, V11, pS27, DOI 10.1016/S0962-8924(01)02151-1; CHEN Q, 1994, P NATL ACAD SCI USA, V91, P4130, DOI 10.1073/pnas.91.10.4130; CHU G, 1988, SCIENCE, V242, P564, DOI 10.1126/science.3175673; Das S, 2004, J BIOL CHEM, V279, P7313, DOI 10.1074/jbc.M312585200; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Faraonio R, 2002, CELL DEATH DIFFER, V9, P862, DOI 10.1038/sj.cdd.4401053; FELDBERG RS, 1980, NUCLEIC ACIDS RES, V8, P1133, DOI 10.1093/nar/8.5.1133; Gianni D, 2003, J BIOL CHEM, V278, P9290, DOI 10.1074/jbc.M211899200; Groisman R, 2003, CELL, V113, P357, DOI 10.1016/S0092-8674(03)00316-7; Hayes S, 1998, MOL CELL BIOL, V18, P240, DOI 10.1128/MCB.18.1.240; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HEDBOM E, 1993, J BIOL CHEM, V268, P27307; Itahana K, 2004, BIOGERONTOLOGY, V5, P1, DOI 10.1023/B:BGEN.0000017682.96395.10; Jepsen KJ, 2002, J BIOL CHEM, V277, P35532, DOI 10.1074/jbc.M205398200; KEENEY S, 1993, J BIOL CHEM, V268, P21293; Liu W, 2000, J BIOL CHEM, V275, P21429, DOI 10.1074/jbc.M000961200; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Martinez E, 2001, MOL CELL BIOL, V21, P6782, DOI 10.1128/MCB.21.20.6782-6795.2001; Nouspikel T, 2000, MOL CELL BIOL, V20, P1562, DOI 10.1128/MCB.20.5.1562-1570.2000; Petri J B, 1999, Mol Cell Biol Res Commun, V1, P59, DOI 10.1006/mcbr.1999.0113; Sedelnikova OA, 2004, NAT CELL BIOL, V6, P168, DOI 10.1038/ncb1095; Seluanov A, 2004, P NATL ACAD SCI USA, V101, P7624, DOI 10.1073/pnas.0400726101; Shelton DN, 1999, CURR BIOL, V9, P939, DOI 10.1016/S0960-9822(99)80420-5; Sitterlin D, 2000, ONCOGENE, V19, P4427, DOI 10.1038/sj.onc.1203770; Svensson L, 1999, J BIOL CHEM, V274, P9636, DOI 10.1074/jbc.274.14.9636; SZTROLOVICS R, 1994, GENOMICS, V23, P715, DOI 10.1006/geno.1994.1567; Takata K, 2004, GENETICS, V168, P855, DOI 10.1534/genetics.103.025965; Telese F, 2005, EMBO REP, V6, P77, DOI 10.1038/sj.embor.7400309; Xu GG, 2000, MUTAT RES-DNA REPAIR, V459, P195, DOI 10.1016/S0921-8777(99)00069-5; Zambrano N, 1997, BIOCHEM J, V328, P293, DOI 10.1042/bj3280293	35	18	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	2005	280	36					31809	31817		10.1074/jbc.M414677200	http://dx.doi.org/10.1074/jbc.M414677200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	961LZ	16002407	hybrid			2022-12-25	WOS:000231665200060
J	Braithwaite, EK; Kedar, PS; Lan, L; Polosina, YY; Asagoshi, K; Poltoratsky, VP; Horton, JK; Miller, H; Teebor, GW; Yasui, A; Wilson, SH				Braithwaite, EK; Kedar, PS; Lan, L; Polosina, YY; Asagoshi, K; Poltoratsky, VP; Horton, JK; Miller, H; Teebor, GW; Yasui, A; Wilson, SH			DNA polymerase lambda protects mouse fibroblasts against oxidative DNA damage and is recruited to sites of DNA damage/repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE EXCISION-REPAIR; LYASE ACTIVITY; BETA; GENE; IDENTIFICATION; GLYCOSYLASE; REQUIREMENT; INVOLVEMENT; DEFICIENT	DNA polymerase lambda ( pol lambda) is a member of the X family of DNA polymerases that has been implicated in both base excision repair and non-homologous end joining through in vitro studies. However, to date, no phenotype has been associated with cells deficient in this DNA polymerase. Here we show that pol lambda null mouse fibroblasts are hypersensitive to oxidative DNA damaging agents, suggesting a role of pol lambda in protection of cells against the cytotoxic effects of oxidized DNA. Additionally, pol lambda co-immunoprecipitates with an oxidized base DNA glycosylase, single-strand-selective monofunctional uracil-DNA glycosylase (SMUG1), and localizes to oxidative DNA lesions in situ. From these data, we conclude that pol lambda protects cells against oxidative stress and suggest that it participates in oxidative DNA damage base excision repair.	NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA; Tohoku Univ, Inst Dev Aging & Canc, Dept Mol Genet, Sendai, Miyagi 9808575, Japan; SUNY Stony Brook, Dept Pharmacol Sci, Biol Chem Lab, Stony Brook, NY 11794 USA; NYU, Dept Pathol, New York, NY 10016 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Tohoku University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; New York University	Wilson, SH (corresponding author), NIEHS, Struct Biol Lab, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.	wilson5@niehs.nih.gov	Miller, Holly/I-6942-2015; Wilson, Samuel H/E-6644-2019	Miller, Holly/0000-0002-9076-5335; Wilson, Samuel H/0000-0002-1702-5293; Teebor, George/0000-0002-7397-2500	Intramural NIH HHS Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Aoufouchi S, 2000, NUCLEIC ACIDS RES, V28, P3684, DOI 10.1093/nar/28.18.3684; Bebenek K, 2004, ADV PROTEIN CHEM, V69, P137; Bertocci B, 2002, J IMMUNOL, V168, P3702, DOI 10.4049/jimmunol.168.8.3702; BOORSTEIN RJ, 1992, MOL CELL BIOL, V12, P5536, DOI 10.1128/MCB.12.12.5536; Boorstein RJ, 2001, J BIOL CHEM, V276, P41991, DOI 10.1074/jbc.M106953200; Braithwaite EK, 2005, J BIOL CHEM, V280, P18469, DOI 10.1074/jbc.M411864200; BUTLER WB, 1984, ANAL BIOCHEM, V141, P70, DOI 10.1016/0003-2697(84)90426-3; Dizdaroglu M, 2002, FREE RADICAL BIO MED, V32, P1102, DOI 10.1016/S0891-5849(02)00826-2; Fortini P, 2000, NUCLEIC ACIDS RES, V28, P3040, DOI 10.1093/nar/28.16.3040; Garcia-Diaz M, 2001, J BIOL CHEM, V276, P34659, DOI 10.1074/jbc.M106336200; Garcia-Diaz M, 2000, J MOL BIOL, V301, P851, DOI 10.1006/jmbi.2000.4005; Horton JK, 2003, DNA REPAIR, V2, P27, DOI 10.1016/S1568-7864(02)00184-2; Horton JK, 2002, DNA REPAIR, V1, P317, DOI 10.1016/S1568-7864(02)00008-3; Hubscher U, 2002, ANNU REV BIOCHEM, V71, P133, DOI 10.1146/annurev.biochem.71.090501.150041; KAUFMAN ER, 1986, SOMAT CELL MOLEC GEN, V12, P501, DOI 10.1007/BF01539921; Kedar PS, 2002, J BIOL CHEM, V277, P31115, DOI 10.1074/jbc.M201497200; Kobayashi Y, 2002, MOL CELL BIOL, V22, P2769, DOI 10.1128/MCB.22.8.2769-2776.2002; Lan L, 2004, P NATL ACAD SCI USA, V101, P13738, DOI 10.1073/pnas.0406048101; Lee JW, 2004, J BIOL CHEM, V279, P805, DOI 10.1074/jbc.M307913200; LEEM SH, 1994, NUCLEIC ACIDS RES, V22, P3011, DOI 10.1093/nar/22.15.3011; LIMOLI CL, 1993, RADIAT RES, V134, P160, DOI 10.2307/3578455; McInnis M, 2002, DNA REPAIR, V1, P311, DOI 10.1016/S1568-7864(02)00007-1; Nakamura J, 2003, NUCLEIC ACIDS RES, V31, P1790, DOI 10.1093/nar/gkg263; Polosina YY, 2004, DNA REPAIR, V3, P1469, DOI 10.1016/j.dnarep.2004.05.011; Prasad R, 1998, J BIOL CHEM, V273, P15263, DOI 10.1074/jbc.273.24.15263; Ramadan K, 2004, NAT REV MOL CELL BIO, V5, P1038, DOI 10.1038/nrm1530; ROBERTSON EJ, 1987, TERATOCARCINOMAS EMB, P7; SHCHERBAKOVA PV, 2003, SCI AGING KNOWL ENV, V26, pRE3; SINGHAL RK, 1995, J BIOL CHEM, V270, P949, DOI 10.1074/jbc.270.2.949; Sobol RW, 2000, NATURE, V405, P807, DOI 10.1038/35015598; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; Tebbs RS, 1999, DEV BIOL, V208, P513, DOI 10.1006/dbio.1999.9232; Wilson TE, 1999, J BIOL CHEM, V274, P23599, DOI 10.1074/jbc.274.33.23599	33	96	97	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	2005	280	36					31641	31647		10.1074/jbc.C500256200	http://dx.doi.org/10.1074/jbc.C500256200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	961LZ	16002405	hybrid			2022-12-25	WOS:000231665200039
J	Kang, DE; Yoon, IS; Repetto, E; Busse, T; Yermian, N; Ie, L; Koo, EH				Kang, DE; Yoon, IS; Repetto, E; Busse, T; Yermian, N; Ie, L; Koo, EH			Presenilins mediate phosphatidylinositol 3-kinase/AKT and ERK activation via select signaling receptors - Selectivity of PS2 in platelet-derived growth factor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; AMYLOID PRECURSOR PROTEIN; GAMMA-SECRETASE; INTRACELLULAR TRAFFICKING; HIPPOCAMPAL-NEURONS; MISSENSE MUTATIONS; BETA-CATENIN; 2 INTERACTS; FHL2; TURNOVER	The Alzheimer's disease-linked genes, PS1 and PS2, are required for intramembrane proteolysis of multiple type I proteins, including Notch and amyloid precursor protein. In addition, it has been documented that PS1 positively regulates, whereas PS1 familial Alzheimer disease mutations suppress, phosphatidylinositol 3-kinase (PI3K)/Akt activation, a pathway known to inactivate glycogen synthase kinase-3 and reduce tau phosphorylation. In this study, we show that the loss of presenilins not only inhibits PI3K/Akt signaling and increases tau phosphorylation but also suppresses the MEK/ERK pathway. The deficits in Akt and ERK activation in cells deficient in both PS1 and PS2 (PS-/-) are evident after serum withdrawal and stimulation with fetal bovine serum or ligands of select receptor tyrosine kinases, platelet-derived growth factor receptor beta (PDGFR beta) and PDGFR alpha, but not insulin-like growth factor-1R and epidermal growth factor receptor. The defects in PDGF signaling in PS-/- cells are due to reduced expression of PDGF receptors. Whereas fetal bovine serum-induced Akt activation is reconstituted by both PS1 and PS2 in PS-/- cells, PDGF signaling is selectively restored by PS2 but not PS1 and is dependent on the N-terminal fragment of PS2 but not gamma-secretase activity or the hydrophilic loop of PS2. The rescue of PDGF receptor expression and activation by PS2 is facilitated by FHL2, a PS2-interacting transcriptional co-activator. Finally, we present evidence that PS1 mutations interfere with this PS2-mediated activity by reducing PS2 fragments. These findings highlight important roles of both presenilins in Akt and ERK signaling via select signaling receptors.	Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Kang, DE (corresponding author), Univ Calif San Diego, Dept Neurosci, Leichtg Biomed Res 380, La Jolla, CA 92093 USA.	dekang@ucsd.edu	Kang, David E./E-5234-2012	REPETTO, EMANUELA/0000-0002-6270-3540; Kang, David E./0000-0002-7132-821X				Baki L, 2004, EMBO J, V23, P2586, DOI 10.1038/sj.emboj.7600251; Baki L, 2001, P NATL ACAD SCI USA, V98, P2381, DOI 10.1073/pnas.041603398; Beffert U, 2002, J BIOL CHEM, V277, P49958, DOI 10.1074/jbc.M209205200; Beher D, 2001, J BIOL CHEM, V276, P45394, DOI 10.1074/jbc.M103075200; Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7; Cai DM, 2003, J BIOL CHEM, V278, P3446, DOI 10.1074/jbc.M209065200; CHENG B, 1995, J NEUROSCI, V15, P7095; Dermaut B, 2004, ANN NEUROL, V55, P617, DOI 10.1002/ana.20083; Esselens C, 2004, J CELL BIOL, V166, P1041, DOI 10.1083/jcb.200406060; Feng RB, 2004, P NATL ACAD SCI USA, V101, P8162, DOI 10.1073/pnas.0402733101; Fimia GM, 2000, MOL CELL BIOL, V20, P8613, DOI 10.1128/MCB.20.22.8613-8622.2000; Hiesberger T, 1999, NEURON, V24, P481, DOI 10.1016/S0896-6273(00)80861-2; Kang DE, 2004, NEUROBIOL AGING, V25, pS559, DOI 10.1016/S0197-4580(04)81853-0; Kang DE, 1999, J NEUROSCI, V19, P4229; Kang DE, 2002, CELL, V110, P751, DOI 10.1016/S0092-8674(02)00970-4; Kaplan DR, 1997, CURR OPIN CELL BIOL, V9, P213, DOI 10.1016/S0955-0674(97)80065-8; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; Kashour T, 2003, BIOCHEM J, V370, P1063, DOI 10.1042/BJ20021197; Kawabe T, 1997, NEUROSCI RES, V29, P335, DOI 10.1016/S0168-0102(97)00105-3; Labalette C, 2004, MOL CELL BIOL, V24, P10689, DOI 10.1128/MCB.24.24.10689-10702.2004; Laffont I, 2002, BIOCHEM BIOPH RES CO, V292, P83, DOI 10.1006/bbrc.2002.6586; Lee MK, 1997, NAT MED, V3, P756, DOI 10.1038/nm0797-756; LEVITAN D, 1995, NATURE, V377, P351, DOI 10.1038/377351a0; MORI S, 1993, J BIOL CHEM, V268, P577; Morlon A, 2003, P NATL ACAD SCI USA, V100, P3977, DOI 10.1073/pnas.0735923100; Muller JM, 2000, EMBO J, V19, P359, DOI 10.1093/emboj/19.3.359; Naruse S, 1998, NEURON, V21, P1213, DOI 10.1016/S0896-6273(00)80637-6; Pack-Chung E, 2000, J BIOL CHEM, V275, P14440, DOI 10.1074/jbc.M909882199; Pearl LH, 2002, CURR OPIN STRUC BIOL, V12, P761, DOI 10.1016/S0959-440X(02)00386-X; Periz G, 2004, J NEUROSCI RES, V77, P309, DOI 10.1002/jnr.20203; Pigino G, 2003, J NEUROSCI, V23, P4499; Raux G, 2000, NEUROLOGY, V55, P1577, DOI 10.1212/WNL.55.10.1577; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Ryder J, 2004, CELL SIGNAL, V16, P187, DOI 10.1016/j.cellsig.2003.07.004; Saura CA, 2000, J BIOL CHEM, V275, P17136, DOI 10.1074/jbc.M909624199; Saura CA, 2004, NEURON, V42, P23, DOI 10.1016/S0896-6273(04)00182-5; Saura CA, 1999, J BIOL CHEM, V274, P13818, DOI 10.1074/jbc.274.20.13818; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Simakajornboon N, 2001, BRAIN RES, V895, P111, DOI 10.1016/S0006-8993(01)02054-6; Soriano S, 2001, J CELL BIOL, V152, P785, DOI 10.1083/jcb.152.4.785; Stabler SM, 1999, J CELL BIOL, V145, P1277, DOI 10.1083/jcb.145.6.1277; Steiner H, 1999, J BIOL CHEM, V274, P28669, DOI 10.1074/jbc.274.40.28669; Tanahashi H, 2000, HUM MOL GENET, V9, P2281, DOI 10.1093/oxfordjournals.hmg.a018919; Tang-Wai D, 2002, DEMENT GERIATR COGN, V14, P13, DOI 10.1159/000058328; Thinakaran G, 1997, J BIOL CHEM, V272, P28415, DOI 10.1074/jbc.272.45.28415; Uemura K, 2003, J NEUROSCI RES, V74, P184, DOI 10.1002/jnr.10753; Uramoto H, 2004, J CELL SCI, V117, P5323, DOI 10.1242/jcs.01384; Wang H, 2004, J BIOL CHEM, V279, P40560, DOI 10.1074/jbc.M404345200; Weihl CC, 1999, J NEUROSCI, V19, P5360; Wilson CA, 2004, J CELL BIOL, V165, P335, DOI 10.1083/jcb.200403061; Yang YH, 2005, EMBO J, V24, P1021, DOI 10.1038/sj.emboj.7600570; Ye YH, 1999, NATURE, V398, P525, DOI 10.1038/19096; Zhang JM, 1998, J BIOL CHEM, V273, P12436, DOI 10.1074/jbc.273.20.12436	53	91	93	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	2005	280	36					31537	31547		10.1074/jbc.M500833200	http://dx.doi.org/10.1074/jbc.M500833200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	961LZ	16014629	hybrid			2022-12-25	WOS:000231665200026
J	Hibino, T				Hibino, T			Nonfixed relationship of the Michaelis constant and maximum velocity with their corresponding rate constants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; COLI ADENYLATE KINASE; INDUCED-FIT MOVEMENTS; ESCHERICHIA-COLI; 3-DIMENSIONAL STRUCTURE; BINDING-SITE; X-RAY; PHENOTYPIC SELECTION; AMP; ENZYME	The Michaelis constant ( K-m) and V-max ( E(0)k(cat)) values for two mutant sets of enzymes were studied from the viewpoint of their definition in a rapid equilibrium reaction model and in a steady state reaction model. The " AMP set enzyme" had a mutation at the AMP- binding site ( Y95F, V67I, and V67I/ L76V), and the " ATP set enzyme" had a mutation at a possible ATP- binding region ( Y32F, Y34F, and Y32A/ Y34A). Reaction rate constants obtained using steady state model analysis explained discrepancies found by the rapid equilibrium model analysis. ( i) The unchanged number of bound AMPs for Y95F and the wild type despite the markedly increased Km values for AMP of the AMP set of enzymes was explained by alteration of the rate constants of the AMP step ( k (+2), k (-2)) to retain the ratio k (+2)/ k (-2). ( ii) A 100 times weakened selectivity of ATP for Y34F in contrast to no marked changes in Km values for both ATP and AMP for the ATP set of enzymes was explained by the alteration of the rate constants of the ATP steps. A similar alteration of the K-m and k(cat) values of these enzymes resulted from distinctive alterations of their rate constants. The pattern of alteration was highly suggestive. The most interesting finding was that the rate constants that decided the Km and kcat values were replaced by the mutation, and the simple relationships between Km, kcat, and the rate constants of K-m(1) = k (+1)/ k (-1) and k(cat) = k(f) were not valid. The nature of the Km and kcat alterations was discussed.	Osaka Prefecture Univ, Grad Sch Agr & Biol Sci, Biophys Chem Lab, Sakai, Osaka 5998531, Japan; Univ Tokyo, Fac Technol, Dept Ind Chem, Bunkyo Ku, Tokyo 113, Japan	Osaka Metropolitan University; University of Tokyo	Hibino, T (corresponding author), Osaka Prefecture Univ, Grad Sch Agr & Biol Sci, Biophys Chem Lab, Sakai, Osaka 5998531, Japan.							ABELE U, 1995, PROTEIN SCI, V4, P1262, DOI 10.1002/pro.5560040702; Agarwal K C, 1978, Methods Enzymol, V51, P483; AUGUSTIN J, 1973, EUR J BIOCHEM, V39, P75, DOI 10.1111/j.1432-1033.1973.tb03105.x; Ayabe T, 1998, BIOCHEM MOL BIOL INT, V46, P673; Ayabe T, 2000, J BIOCHEM-TOKYO, V128, P181, DOI 10.1093/oxfordjournals.jbchem.a022739; BARZU O, 1983, FEBS LETT, V153, P280, DOI 10.1016/0014-5793(83)80624-3; BEDOUELLE H, 1985, BIOCHIMIE, V67, P737, DOI 10.1016/S0300-9084(85)80161-9; BERRY MB, 1994, PROTEINS, V19, P183, DOI 10.1002/prot.340190304; Bilderback T, 1996, BIOCHEMISTRY-US, V35, P6100, DOI 10.1021/bi951833i; Briggs GE, 1925, BIOCHEM J, V19, P338, DOI 10.1042/bj0190338; DIEDERICHS K, 1990, BIOCHEMISTRY-US, V29, P8138, DOI 10.1021/bi00487a022; DREUSICKE D, 1988, J MOL BIOL, V199, P359, DOI 10.1016/0022-2836(88)90319-1; EINARSSON R, 1974, EUR J BIOCHEM, V49, P41, DOI 10.1111/j.1432-1033.1974.tb03809.x; FERSHT AR, 1988, BIOCHEMISTRY-US, V27, P1577, DOI 10.1021/bi00405a027; FERSHT AR, 1987, BIOCHEMISTRY-US, V26, P6030, DOI 10.1021/bi00393a013; FERSHT AR, 1986, PROTEIN ENG, P269; FRY DC, 1986, P NATL ACAD SCI USA, V83, P907, DOI 10.1073/pnas.83.4.907; FRY DC, 1985, BIOCHEMISTRY-US, V24, P4680, DOI 10.1021/bi00338a030; GERSTEIN M, 1993, J MOL BIOL, V229, P494, DOI 10.1006/jmbi.1993.1048; HAMADA M, 1978, ARCH BIOCHEM BIOPHYS, V190, P772, DOI 10.1016/0003-9861(78)90338-7; HIBINO T, 1994, J BIOTECHNOL, V32, P139, DOI 10.1016/0168-1656(94)90176-7; KIM HJ, 1990, BIOCHEMISTRY-US, V29, P1107, DOI 10.1021/bi00457a002; KING EL, 1956, J PHYS CHEM-US, V60, P1378, DOI 10.1021/j150544a011; KING EL, 1956, J PHYS CHEM-US, V60, P1375, DOI 10.1021/j150544a010; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LIANG P, 1991, PROTEINS, V9, P28, DOI 10.1002/prot.340090105; MULLER CW, 1992, J MOL BIOL, V224, P159, DOI 10.1016/0022-2836(92)90582-5; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; OKAJIMA T, 1993, J BIOCHEM-TOKYO, V114, P627, DOI 10.1093/oxfordjournals.jbchem.a124228; PAI EF, 1977, J MOL BIOL, V114, P37, DOI 10.1016/0022-2836(77)90281-9; Powell M.J.D., 1970, HYBRID METHOD NONLIN, P87; POWELL MJD, 1964, COMPUT J, V7, P155, DOI 10.1093/comjnl/7.2.155; RADDA GK, 1971, CURR TOP BIOENERG, V4, P81; SACHSENHEIMER W, 1977, J MOL BIOL, V114, P34; SCHULZ GE, 1992, FARADAY DISCUSS, V93, P85, DOI 10.1039/fd9929300085; SCHULZ GE, 1990, J MOL BIOL, V213, P627, DOI 10.1016/S0022-2836(05)80250-5; SCHULZ GE, 1974, NATURE, V250, P120, DOI 10.1038/250120a0; STEHLE T, 1990, J MOL BIOL, V211, P249, DOI 10.1016/0022-2836(90)90024-G; TIAN G, 1990, BIOCHEMISTRY-US, V29, P4296, DOI 10.1021/bi00470a006; TSAI MD, 1991, BIOCHEMISTRY-US, V30, P6806, DOI 10.1021/bi00242a002; VONRHEIN C, 1995, STRUCTURE, V3, P483, DOI 10.1016/S0969-2126(01)00181-2; WATZ MW, 2004, NAT STRUCT MOL BIOL, V11, P945; YAN HG, 1990, BIOCHEMISTRY-US, V29, P10956, DOI 10.1021/bi00501a013	44	2	3	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	2005	280	35					30671	30680		10.1074/jbc.M412601200	http://dx.doi.org/10.1074/jbc.M412601200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	958ZX	15972825	hybrid			2022-12-25	WOS:000231487800005
J	Ye, M; Shima, F; Muraoka, S; Liao, JL; Okamoto, H; Yamamoto, M; Tamura, A; Yagi, N; Ueki, T; Kataoka, T				Ye, M; Shima, F; Muraoka, S; Liao, JL; Okamoto, H; Yamamoto, M; Tamura, A; Yagi, N; Ueki, T; Kataoka, T			Crystal structure of M-Ras reveals a GTP-bound "off" state conformation of Ras family small GTPases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING DOMAIN; ACTIVATING PROTEIN; P21; IDENTIFICATION; SPECTROSCOPY; SWITCH; GDP	Although some members of Ras family small GTPases, including M-Ras, share the primary structure of their effector regions with Ras, they exhibit vastly different binding properties to Ras effectors such as c-Raf-1. We have solved the crystal structure of M-Ras in the GDP-bound and guanosine 5'-(beta, gamma-imido) triphosphate (Gpp(NH) p)-bound forms. The overall structure of M-Ras resembles those of H-Ras and Rap2A, except that M-Ras-Gpp( NH) p exhibits a distinctive switch I conformation, which is caused by impaired intramolecular interactions between Thr-45 (corresponding to Thr-35 of H-Ras) of the effector region and the gamma-phosphate of Gpp(NH) p. Previous P-31 NMR studies showed that H-Ras-Gpp( NH) p exists in two interconverting conformations, states 1 and 2. Whereas state 2 is a predominant form of H-Ras and corresponds to the "on" conformation found in the complex with effectors, state 1 is thought to represent the "off" conformation, whose tertiary structure remains unknown. P-31 NMR analysis shows that free M-Ras-Gpp(NH)p predominantly assumes the state 1 conformation, which undergoes conformational transition to state 2 upon association with c-Raf-1. These results indicate that the solved structure of M-Ras-Gpp(NH) p corresponds to the state 1 conformation. The predominance of state 1 in M-Ras is likely to account for its weak binding ability to the Ras effectors, suggesting the importance of the tertiary structure factor in small GTPase-effector interaction. Further, the first determination of the state 1 structure provides a molecular basis for developing novel anti-cancer drugs as compounds that hold Ras in the state 1 "off" conformation.	Kobe Univ, Div Mol Biol, Dept Mol & Cellular Biol, Grad Sch Med,Chuo Ku, Kobe, Hyogo 6500017, Japan; JASRI SPring 8, Mikazuki, Hyogo 6795198, Japan; Kobe Univ, Grad Sch Sci & Technol, Nada Ku, Kobe, Hyogo 6578501, Japan; RIKEN, SPring 8, Mikazuki, Hyogo 6795148, Japan	Kobe University; Japan Synchrotron Radiation Research Institute; Kobe University; Japan Synchrotron Radiation Research Institute; RIKEN	Kataoka, T (corresponding author), Kobe Univ, Div Mol Biol, Dept Mol & Cellular Biol, Grad Sch Med,Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.	kataoka@kobe-u.ac.jp	Yamamoto, Masaki/B-7844-2015	Yamamoto, Masaki/0000-0002-1311-1768; Tamura, Atsuo/0000-0001-8238-8851				BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Bellew BF, 1996, BIOCHEMISTRY-US, V35, P12186, DOI 10.1021/bi960594b; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cherfils J, 1997, EMBO J, V16, P5582, DOI 10.1093/emboj/16.18.5582; Corbett KD, 2001, TRENDS BIOCHEM SCI, V26, P710, DOI 10.1016/S0968-0004(01)01974-0; Gao XL, 2001, J BIOL CHEM, V276, P42219, DOI 10.1074/jbc.M105760200; Geyer M, 1997, NAT STRUCT BIOL, V4, P694, DOI 10.1038/nsb0997-694; Geyer M, 1996, BIOCHEMISTRY-US, V35, P10308, DOI 10.1021/bi952858k; Halkides CJ, 1996, BIOCHEMISTRY-US, V35, P12194, DOI 10.1021/bi9605954; Huang L, 1998, NAT STRUCT BIOL, V5, P422, DOI 10.1038/nsb0698-422; Iuga A, 2004, J MOL BIOL, V342, P1033, DOI 10.1016/j.jmb.2004.07.077; Kimmelman A, 1997, ONCOGENE, V15, P2675, DOI 10.1038/sj.onc.1201674; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LESLIE AGW, 1992, JOINT CCP4 PLUS ESF, V26; Linnemann T, 1999, J BIOL CHEM, V274, P13556, DOI 10.1074/jbc.274.19.13556; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; McRee D.E., 1999, PRACTICAL PROTEIN CR, V2nd ed., P91; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Pacold ME, 2000, CELL, V103, P931, DOI 10.1016/S0092-8674(00)00196-3; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; Quilliam LA, 1999, J BIOL CHEM, V274, P23850, DOI 10.1074/jbc.274.34.23850; Rebhun JF, 2000, J BIOL CHEM, V275, P34901, DOI 10.1074/jbc.M005327200; Rodriguez-Viciana P, 2004, MOL CELL BIOL, V24, P4943, DOI 10.1128/MCB.24.11.4943-4954.2004; Spoerner M, 2001, P NATL ACAD SCI USA, V98, P4944, DOI 10.1073/pnas.081441398; Vetter IR, 2001, SCIENCE, V294, P1299, DOI 10.1126/science.1062023; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925	31	51	53	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	2005	280	35					31267	31275		10.1074/jbc.M505503200	http://dx.doi.org/10.1074/jbc.M505503200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	958ZX	15994326	hybrid			2022-12-25	WOS:000231487800074
J	Kuns, R; Kissil, JL; Newsham, IF; Jacks, T; Gutmann, DH; Sherman, LS				Kuns, R; Kissil, JL; Newsham, IF; Jacks, T; Gutmann, DH; Sherman, LS			Protein 4.1B expression is induced in mammary epithelial cells during pregnancy and regulates their proliferation	ONCOGENE			English	Article						protein 4.1B; erbB2; mammary epithelial cells; pregnancy; mammary carcinoma	BREAST-CANCER CELLS; NEUROFIBROMATOSIS-2 TUMOR-SUPPRESSOR; EPIDERMAL-GROWTH-FACTOR; FUNCTIONAL-CHARACTERIZATION; CARCINOMA-CELLS; FAMILY MEMBERS; LUNG-CANCER; FERM DOMAIN; EZRIN; GENE	4.1B is a member of the protein 4.1 superfamily of proteins that link transmembrane proteins to the actin cytoskeleton. The 4.1B gene localizes to chromosome 18p11.3, which undergoes loss of heterozygosity in mammary tumors. Here, we examine the expression of 4.1B in murine mammary epithelium and find that 4.1B is dramatically upregulated in mammary epithelial cells during pregnancy when there is extensive cell proliferation. In contrast, 4.1B is not expressed in virgin, lactating, or involuting mammary epithelium. To examine the consequence of 4.1B loss on mammary epithelial cell proliferation, we analysed mammary glands in 4.1B-null mice. 4.1B loss results in a significant increase in mammary epithelial cell proliferation during pregnancy, but has no effect on mammary epithelial cell proliferation, in virgin or involuting mice. Furthermore, we show that 4.1B inhibits the proliferation of mammary epithelial cell lines by inducing a G(1) cell cycle arrest, characterized by decreased cyclin A expression and reduced Rb phosphorylation, and accompanied by reduced erbB2 phosphorylation. This cell cycle arrest does not involve alterations in the activities of MAPK, JNK, or Akt. Collectively, our findings demonstrate that 4.1B regulates mammary epithelial cell proliferation during pregnancy and suggest that its loss may influence mammary carcinoma pathogenesis in multiparous women.	Oregon Hlth Sci Univ, Oregon Natl Primate Res Ctr, Div Neurosci, Beaverton, OR 97006 USA; Univ Cincinnati, Sch Med, Dept Cell Biol Neurobiol & Anat, Cincinnati, OH 45267 USA; Wistar Inst Anat & Biol, Mol & Cellular Oncogenom Program, Philadelphia, PA 19104 USA; Henry Ford Hosp, Hermelin Brain Tumor Ctr, Dept Neurosurg, David & Hermelin Lab Mol Oncogenet, Detroit, MI 48202 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; MIT, Canc Res Ctr, Cambridge, MA 02139 USA; MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA; Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA	Oregon Health & Science University; Oregon National Primate Research Center; University System of Ohio; University of Cincinnati; The Wistar Institute; Henry Ford Health System; Henry Ford Hospital; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Washington University (WUSTL)	Sherman, LS (corresponding author), Oregon Hlth Sci Univ, Oregon Natl Primate Res Ctr, Div Neurosci, 505 NW 185th Ave, Beaverton, OR 97006 USA.	shermanl@ohsu.edu		Gutmann, David/0000-0002-3127-5045	NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000163] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041520, R01NS039550] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00163] Funding Source: Medline; NINDS NIH HHS [NS41520, NS39550] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Akisawa N, 1999, BIOCHEM BIOPH RES CO, V258, P395, DOI 10.1006/bbrc.1999.0653; Allred DC, 2000, J MAMMARY GLAND BIOL, V5, P351, DOI 10.1023/A:1009573710675; Batchelor CL, 2004, EXP CELL RES, V296, P208, DOI 10.1016/j.yexcr.2004.02.010; Charboneau AL, 2002, INT J CANCER, V100, P181, DOI 10.1002/ijc.10470; Chau BN, 2003, NAT REV CANCER, V3, P130, DOI 10.1038/nrc993; Chishti AH, 1998, TRENDS BIOCHEM SCI, V23, P281, DOI 10.1016/S0968-0004(98)01237-7; Chu I, 2005, CANCER RES, V65, P18; Cuppen E, 1999, J CELL SCI, V112, P3299; Daniel CW, 1999, J MAMMARY GLAND BIOL, V4, P3, DOI 10.1023/A:1018796301609; Faltus T, 2004, NEOPLASIA, V6, P786, DOI 10.1593/neo.04313; Fraenzer JT, 2003, INT J ONCOL, V23, P1493; Gascard P, 2004, BBA-GENE STRUCT EXPR, V1680, P71, DOI 10.1016/j.bbaexp.2004.08.006; Gautreau A, 1999, P NATL ACAD SCI USA, V96, P7300, DOI 10.1073/pnas.96.13.7300; GERDES J, 1984, J IMMUNOL, V133, P1710; Ghatak S, 2005, J BIOL CHEM, V280, P8875, DOI 10.1074/jbc.M410882200; Gimm JA, 2002, BIOCHEMISTRY-US, V41, P7275, DOI 10.1021/bi0256330; Gutmann DH, 2001, NEUROBIOL DIS, V8, P266, DOI 10.1006/nbdi.2000.0376; Gutmann DH, 2000, HUM MOL GENET, V9, P1495, DOI 10.1093/hmg/9.10.1495; Hall IJ, 2005, AM J EPIDEMIOL, V161, P40, DOI 10.1093/aje/kwh331; Hunter KW, 2004, TRENDS MOL MED, V10, P201, DOI 10.1016/j.molmed.2004.03.001; Jhabvala-Romero F, 2003, ONCOGENE, V22, P8178, DOI 10.1038/sj.onc.1206912; Khanna C, 2004, NAT MED, V10, P182, DOI 10.1038/nm982; Kittiniyom K, 2004, GENE CHROMOSOME CANC, V40, P190, DOI 10.1002/gcc.20034; Kittiniyom K, 2001, BREAST CANCER RES, V3, P192, DOI 10.1186/bcr294; LUTCHMAN M, 1995, CANCER RES, V55, P2270; Mattagajasingh SN, 1999, J CELL BIOL, V145, P29, DOI 10.1083/jcb.145.1.29; McClatchey AI, 1998, GENE DEV, V12, P1121, DOI 10.1101/gad.12.8.1121; Muranen T, 2005, ONCOGENE, V24, P1150, DOI 10.1038/sj.onc.1208283; Parra M, 2000, J BIOL CHEM, V275, P3247, DOI 10.1074/jbc.275.5.3247; Peters LL, 1998, GENOMICS, V54, P348, DOI 10.1006/geno.1998.5537; Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004; Richert MM, 2000, J MAMMARY GLAND BIOL, V5, P227, DOI 10.1023/A:1026499523505; Robb VA, 2003, NEUROBIOL DIS, V13, P191, DOI 10.1016/S0969-9961(03)00071-8; Robb VA, 2005, ONCOGENE, V24, P1946, DOI 10.1038/sj.onc.1208335; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; Scholzen T, 2000, J CELL PHYSIOL, V182, P311, DOI 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9; Sebastian J, 1998, CELL GROWTH DIFFER, V9, P777; Singh PK, 2002, MODERN PATHOL, V15, P526, DOI 10.1038/modpathol.3880558; Singh V, 2004, ONCOGENE, V23, P7761, DOI 10.1038/sj.onc.1208057; Stern DF, 2003, EXP CELL RES, V284, P89, DOI 10.1016/S0014-4827(02)00103-9; Stull MA, 2004, J MAMMARY GLAND BIOL, V9, P15, DOI 10.1023/B:JOMG.0000023585.95430.f4; Surace EI, 2004, J NEUROPATH EXP NEUR, V63, P1015, DOI 10.1093/jnen/63.10.1015; Tran Y, 1998, ONCOGENE, V17, P3499, DOI 10.1038/sj.onc.1202258; Tran YK, 1999, CANCER RES, V59, P35; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; TYLER JM, 1979, P NATL ACAD SCI USA, V76, P5192, DOI 10.1073/pnas.76.10.5192; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Whiteman MK, 2004, OBSTET GYNECOL, V104, P146, DOI 10.1097/01.AOG.0000128173.01611.ff; Wobus M, 2002, APPL IMMUNOHISTO M M, V10, P34, DOI 10.1097/00022744-200203000-00006; Yageta M, 2002, CANCER RES, V62, P5129; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yu YL, 2004, NAT MED, V10, P175, DOI 10.1038/nm966	53	15	16	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	43					6502	6515		10.1038/sj.onc.1208813	http://dx.doi.org/10.1038/sj.onc.1208813			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	968ZV	16007173	Bronze			2022-12-25	WOS:000232204100004
J	Yuen, EY; Jiang, Q; Feng, J; Yan, Z				Yuen, EY; Jiang, Q; Feng, J; Yan, Z			Microtubule regulation of N-methyl-D-aspartate receptor channels in neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ER RETENTION SIGNAL; PROTEIN-KINASE-C; NMDA-RECEPTOR; SYNAPTIC TRANSMISSION; PHOSPHORYLATION; TUBULIN; MAP2; TRAFFICKING; MECHANISMS; DYNAMICS	N-Methyl-D-aspartate (NMDA) receptors (NMDARs), which play a key role in synaptic plasticity, are dynamically regulated by many signaling molecules and scaffolding proteins. Although actin cytoskeleton has been implicated in regulating NMDAR stability in synaptic membrane, the role of microtubules in regulating NMDAR trafficking and function is largely unclear. Here we show that microtubule-depolymerizing agents inhibited NMDA receptor-mediated ionic and synaptic currents in cortical pyramidal neurons. This effect was Ca2+-independent, required GTP, and was more prominent in the presence of high NMDA concentrations. The NR2B subunit-containing NMDA receptor was the primary target of microtubules. The effect of microtubule depolymerizers on NMDAR currents was blocked by cellular knockdown of the kinesin motor protein KIF17, which transports NR2B-containing vesicles along microtubule in neuronal dendrites. Neuromodulators that can stabilize microtubules, such as brain-derived neurotrophic factor, significantly attenuated the microtubule depolymerizer-induced reduction of NMDAR currents. Moreover, immunocytochemical studies show that microtubule depolymerizers decreased the number of surface NR2B subunits on dendrites, which was prevented by the microtubule stabilizer. Taken together, these results suggest that interfering with microtubule assembly suppresses NMDAR function through a mechanism dependent on kinesin-based dendritic transport of NMDA receptors.	SUNY Buffalo, Sch Med & Biomed Sci, Dept Physiol & Biophys, Buffalo, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Yan, Z (corresponding author), SUNY Buffalo, Sch Med & Biomed Sci, Dept Physiol & Biophys, 124 Sherman Hall, Buffalo, NY 14214 USA.	zhenyan@buffalo.edu						BERNHARDT R, 1984, J COMP NEUROL, V226, P203, DOI 10.1002/cne.902260205; BRUGG B, 1991, J CELL BIOL, V114, P735, DOI 10.1083/jcb.114.4.735; CACERES A, 1984, J NEUROSCI, V4, P394; Carroll RC, 2002, TRENDS NEUROSCI, V25, P571, DOI 10.1016/S0166-2236(02)02272-5; Chen GJ, 2004, P NATL ACAD SCI USA, V101, P2596, DOI 10.1073/pnas.0308618100; CLEVELAND DW, 1982, CELL, V28, P689, DOI 10.1016/0092-8674(82)90048-4; Cull-Candy S, 2001, CURR OPIN NEUROBIOL, V11, P327, DOI 10.1016/S0959-4388(00)00215-4; DHAMODHARAN R, 1995, J CELL SCI, V108, P1679; Feng J, 2001, J NEUROSCI, V21, P6502, DOI 10.1523/JNEUROSCI.21-17-06502.2001; Goldstein LSB, 2000, ANNU REV NEUROSCI, V23, P39, DOI 10.1146/annurev.neuro.23.1.39; Goldstein LSB, 2003, NEURON, V40, P415, DOI 10.1016/S0896-6273(03)00630-5; Guillaud L, 2003, J NEUROSCI, V23, P131; HIROKAWA N, 1994, CURR OPIN CELL BIOL, V6, P74, DOI 10.1016/0955-0674(94)90119-8; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; Hirokawa N, 2005, NAT REV NEUROSCI, V6, P201, DOI 10.1038/nrn1624; Itoh TJ, 1997, BIOCHEMISTRY-US, V36, P12574, DOI 10.1021/bi962606z; JOSHI HC, 1989, J CELL BIOL, V109, P663, DOI 10.1083/jcb.109.2.663; Kim CH, 2001, J NEUROSCI, V21, P4188, DOI 10.1523/JNEUROSCI.21-12-04188.2001; KOWALSKI RJ, 1993, J BIOL CHEM, V268, P9847; Lavezzari G, 2004, J NEUROSCI, V24, P6383, DOI 10.1523/JNEUROSCI.1890-04.2004; Li JH, 1998, EUR J NEUROSCI, V10, P1704, DOI 10.1046/j.1460-9568.1998.00169.x; Lin Y, 2004, J NEUROSCI, V24, P10138, DOI 10.1523/JNEUROSCI.3159-04.2004; Luo JH, 2002, NEUROPHARMACOLOGY, V42, P306, DOI 10.1016/S0028-3908(01)00188-5; MANDELKOW E, 1995, CURR OPIN CELL BIOL, V7, P72, DOI 10.1016/0955-0674(95)80047-6; MITCHISON T, 1988, NEURON, V1, P761, DOI 10.1016/0896-6273(88)90124-9; PETRALIA RS, 1994, J NEUROSCI, V14, P667; Roche KW, 2001, NAT NEUROSCI, V4, P794, DOI 10.1038/90498; ROSENMUND C, 1993, NEURON, V10, P805, DOI 10.1016/0896-6273(93)90197-Y; Sanchez C, 2000, PROG NEUROBIOL, V61, P133, DOI 10.1016/S0301-0082(99)00046-5; Scott DB, 2001, J NEUROSCI, V21, P3063, DOI 10.1523/JNEUROSCI.21-09-03063.2001; Setou M, 2002, NATURE, V417, P83, DOI 10.1038/nature743; Setou M, 2000, SCIENCE, V288, P1796, DOI 10.1126/science.288.5472.1796; Standley S, 2000, NEURON, V28, P887, DOI 10.1016/S0896-6273(00)00161-6; Tovar KR, 1999, J NEUROSCI, V19, P4180; Tovar KR, 2002, NEURON, V34, P253; Tyszkiewicz JP, 2004, J PHYSIOL-LONDON, V554, P765, DOI 10.1113/jphysiol.2003.056812; Vaillant AR, 2002, NEURON, V34, P985, DOI 10.1016/S0896-6273(02)00717-1; van Rossum D, 1999, J NEUROCHEM, V72, P962, DOI 10.1046/j.1471-4159.1999.0720962.x; Vicini S, 1998, J NEUROPHYSIOL, V79, P555, DOI 10.1152/jn.1998.79.2.555; Vissel B, 2001, NAT NEUROSCI, V4, P587, DOI 10.1038/88404; Wang X, 2003, J NEUROSCI, V23, P9852; Washbourne P, 2002, NAT NEUROSCI, V5, P751, DOI 10.1038/nn883; Wenthold RJ, 2003, ANNU REV PHARMACOL, V43, P335, DOI 10.1146/annurev.pharmtox.43.100901.135803; WILLIAMS K, 1993, MOL PHARMACOL, V44, P851; Zhang S, 1998, NEURON, V21, P443, DOI 10.1016/S0896-6273(00)80553-X	45	42	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	2005	280	33					29420	29427		10.1074/jbc.M504499200	http://dx.doi.org/10.1074/jbc.M504499200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	954SX	15975919	hybrid			2022-12-25	WOS:000231176200006
J	Zagranichnaya, TK; Wu, XY; Villereal, ML				Zagranichnaya, TK; Wu, XY; Villereal, ML			Endogenous TRPC1, TRPC3, and TRPC7 proteins combine to form native store-operated channels in HEK-293 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-PERMEABLE CATION CHANNEL; CAPACITATIVE CA2+ ENTRY; SMOOTH-MUSCLE CELLS; TRANSIENT RECEPTOR; CALCIUM-ENTRY; FUNCTIONAL EXPRESSION; ENDOTHELIAL-CELLS; CANDIDATE PROTEIN; TRPC3 CHANNELS; HTRP3 CHANNELS	Endogenously expressed canonical transient receptor potential (TRPC) homologs were investigated for their role in forming store-operated, 1-oleoyl-2-acetyl-sn-glycerolstimulated, or carbachol (CCh)-stimulated calcium entry pathways in HEK-293 cells. Measurement of thapsigargin-stimulated Ba2+ entry indicated that the individual suppression of TRPC1, TRPC3, or TRPC7 protein levels, by small interfering RNA ( siRNA) techniques, dramatically inhibited (52-68%) store-operated calcium entry (SOCE), whereas suppression of TRPC4 or TRPC6 had no effect. Combined suppression of TRPC1-TRPC3, TRPC1-TRPC7, TRPC3-TRPC7, or TRPC1-TRPC3-TRPC7 gave only slightly more inhibition of SOCE (74-78%) than seen with suppression of TRPC1 alone (68%), suggesting that these three TRPC homologs work in tandem to mediate a large component of SOCE. Evidence from co-immunoprecipitation experiments indicates that a TRPC1-TRPC3-TRPC7 complex, predicted from siRNA results, does exist. The suppression of either TRPC3 or TRPC7, but not TRPC1, induced a high Ba2+ leak flux that was inhibited by 2-APB and SKF96365, suggesting that the influx is via leaky store-operated channels. The high Ba2+ leak flux is eliminated by co-suppression of TRPC1-TRPC3 or TRPC1-TRPC7. For 1-oleoyl-2-acetyl-sn-glycerolstimulated cells, siRNA data indicate that TRPC1 plays no role in mediating Ba2+ entry, which appears to be mediated by the participation of TRPC3, TRPC4, TRPC6, and TRPC7. CCh-stimulated Ba2+ entry, on the other hand, could be inhibited by suppression of any of the five endogenously expressed TRPC homologs, with the degree of inhibition being consistent with CCh stimulation of both store-operated and receptor-operated channels. In summary, endogenous TRPC1, TRPC3, and TRPC7 participate in forming heteromeric store-operated channels, whereas TRPC3 and TRPC7 can also participate in forming heteromeric receptor-operated channels.	Univ Chicago, Dept Neurobiol Pharmacol & Physiol, Chicago, IL 60637 USA	University of Chicago	Villereal, ML (corresponding author), Univ Chicago, Dept Neurobiol Pharmacol & Physiol, 947 E 58th St, Chicago, IL 60637 USA.	mitch@bsd.uchicago.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054500] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM54500] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Babnigg G, 2000, CELL CALCIUM, V27, P61, DOI 10.1054/ceca.1999.0093; Barritt GJ, 1999, BIOCHEM J, V337, P153, DOI 10.1042/0264-6021:3370153; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Boulay G, 1999, P NATL ACAD SCI USA, V96, P14955, DOI 10.1073/pnas.96.26.14955; Boulay G, 1997, J BIOL CHEM, V272, P29672, DOI 10.1074/jbc.272.47.29672; Brough GH, 2001, FASEB J, V15, P1727, DOI 10.1096/fj.01-0108com; Bugaj V, 2005, J BIOL CHEM, V280, P16790, DOI 10.1074/jbc.M500192200; Dietrich A, 2003, J BIOL CHEM, V278, P47842, DOI 10.1074/jbc.M302983200; Estacion M, 2004, J BIOL CHEM, V279, P22047, DOI 10.1074/jbc.M402320200; Freichel Marc, 2004, Novartis Found Symp, V258, P189; Garcia RL, 1997, BIOCHEM BIOPH RES CO, V239, P279, DOI 10.1006/bbrc.1997.7458; Goel M, 2002, J BIOL CHEM, V277, P48303, DOI 10.1074/jbc.M207882200; Hofmann T, 2002, P NATL ACAD SCI USA, V99, P7461, DOI 10.1073/pnas.102596199; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; Hurst RS, 1998, FEBS LETT, V422, P333, DOI 10.1016/S0014-5793(98)00035-0; Inoue R, 2001, CIRC RES, V88, P325, DOI 10.1161/01.RES.88.3.325; Jung S, 2002, AM J PHYSIOL-CELL PH, V282, pC347, DOI 10.1152/ajpcell.00283.2001; Kamouchi M, 1999, J PHYSIOL-LONDON, V518, P345, DOI 10.1111/j.1469-7793.1999.0345p.x; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; KWAN CY, 1990, J BIOL CHEM, V265, P678; Lievremont JP, 2004, AM J PHYSIOL-CELL PH, V287, pC1709, DOI 10.1152/ajpcell.00350.2004; Lintschinger B, 2000, J BIOL CHEM, V275, P27799; Liu XB, 2005, J BIOL CHEM, V280, P21600, DOI 10.1074/jbc.c400492200; Liu XB, 2000, J BIOL CHEM, V275, P3403, DOI 10.1074/jbc.275.5.3403; Liu XB, 2003, J BIOL CHEM, V278, P11337, DOI 10.1074/jbc.M213271200; Luo D, 2001, J BIOL CHEM, V276, P5613, DOI 10.1074/jbc.M007524200; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; McKay RR, 2000, BIOCHEM J, V351, P735, DOI 10.1042/0264-6021:3510735; Okada T, 1999, J BIOL CHEM, V274, P27359, DOI 10.1074/jbc.274.39.27359; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; Putney JW, 1999, BIOESSAYS, V21, P38; Putney JW, 2004, TRENDS CELL BIOL, V14, P282, DOI 10.1016/j.tcb.2004.04.002; Riccio A, 2002, MOL BRAIN RES, V109, P95, DOI 10.1016/S0169-328X(02)00527-2; Riccio A, 2002, J BIOL CHEM, V277, P12302, DOI 10.1074/jbc.M112313200; SCHILLING WP, 1989, J BIOL CHEM, V264, P12838; Shuttleworth TJ, 1999, CELL CALCIUM, V25, P237, DOI 10.1054/ceca.1999.0022; Sinkins WG, 1998, BIOCHEM J, V331, P331, DOI 10.1042/bj3310331; Strubing C, 2003, J BIOL CHEM, V278, P39014, DOI 10.1074/jbc.M306705200; Sweeney M, 2002, AM J PHYSIOL-LUNG C, V283, pL144, DOI 10.1152/ajplung.00412.2001; Trebak M, 2003, CELL CALCIUM, V33, P451, DOI 10.1016/S0143-4160(03)00056-3; Trebak M, 2003, J BIOL CHEM, V278, P16244, DOI 10.1074/jbc.M300544200; Vazquez G, 2003, J BIOL CHEM, V278, P21649, DOI 10.1074/jbc.M302162200; Venkatachalam K, 2003, J BIOL CHEM, V278, P29031, DOI 10.1074/jbc.M302751200; Wu XY, 2004, J BIOL CHEM, V279, P43392, DOI 10.1074/jbc.M408959200; Wu XY, 2000, AM J PHYSIOL-CELL PH, V278, pC526, DOI 10.1152/ajpcell.2000.278.3.C526; Wu XY, 2002, J BIOL CHEM, V277, P13597, DOI 10.1074/jbc.M110881200; Xu SZ, 2001, CIRC RES, V88, P84, DOI 10.1161/01.RES.88.1.84; Xu XZS, 1997, CELL, V89, P1155, DOI 10.1016/S0092-8674(00)80302-5; Yu Y, 2003, AM J PHYSIOL-CELL PH, V284, pC316, DOI 10.1152/ajpcell.00125.2002; Yuan JP, 2003, CELL, V114, P777, DOI 10.1016/S0092-8674(03)00716-5; Zhu X, 1998, J BIOL CHEM, V273, P133, DOI 10.1074/jbc.273.1.133; Zitt C, 1996, NEURON, V16, P1189, DOI 10.1016/S0896-6273(00)80145-2; Zitt C, 1997, J CELL BIOL, V138, P1333, DOI 10.1083/jcb.138.6.1333	53	166	177	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	2005	280	33					29559	29569		10.1074/jbc.M505842200	http://dx.doi.org/10.1074/jbc.M505842200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	954SX	15972814	hybrid			2022-12-25	WOS:000231176200023
J	Conde, R; Xavier, J; McLoughlin, C; Chinkers, M; Ovsenek, N				Conde, R; Xavier, J; McLoughlin, C; Chinkers, M; Ovsenek, N			Protein phosphatase 5 is a negative modulator of heat shock factor 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK FACTOR-1; PROTEIN PHOSPHATASE 5; TETRATRICOPEPTIDE REPEAT DOMAIN; TRANSCRIPTION FACTOR HSF1; DNA-BINDING; FACTOR-I; CHAPERONE INTERACTIONS; NUCLEAR-LOCALIZATION; ESTROGEN-RECEPTOR; ACTIVATION	The major stress protein transcription factor, heat shock factor (HSF1), is tightly regulated through a multilayered activation-deactivation process involving oligomerization, post-translational modification, and interaction with the heat shock protein (Hsp90)-containing multichaperone complex. Conditions of proteotoxic stress, such as heat shock, trigger reversible assembly of latent HSF1 monomers into DNA-binding homotrimers that bind with high affinity to cognate heat shock elements. Transactivation is a second and independently regulated function of HSF1 that is accompanied by hyperphosphorylation and appears to involve a number of signaling events. Association of HSF1 with Hsp90 chaperone complexes provides additional regulatory complexity, however, not all the co-chaperones have been identified, and the specific molecular interactions throughout the activation/deactivation pathway remain to be determined. Here we demonstrate that protein phosphatase 5 (PP5), a tetratricopeptide domain-containing component of Hsp90-steroid receptor complexes, functions as a negative modulator of HSF1 activity. Physical interactions between PP5 and HSF1-Hsp90 complexes were observed in co-immunoprecipitation and gel mobility supershift experiments. Overexpression of PP5 or activation of endogenous phosphatase activity resulted in diminished HSF1 DNA binding and transcriptional activities, and accelerated recovery. Conversely, microinjection of PP5 antibodies, or inhibition of its phosphatase activity in vivo, significantly delayed trimer disassembly after heat shock. Inhibition of PP5 activity did not activate HSF1 in unstressed cells. These results indicate that PP5 is a negative modulator of HSF1 activity.	Univ Saskatchewan, Coll Med, Dept Anat & Cell Biol, Saskatoon, SK S7N 5E5, Canada; Univ S Alabama, Dept Pharmacol, Mobile, AL 36688 USA	University of Saskatchewan; University of South Alabama	Ovsenek, N (corresponding author), Univ Saskatchewan, Coll Med, Dept Anat & Cell Biol, 107 Wiggins Rd, Saskatoon, SK S7N 5E5, Canada.	ovsenekn@duke.usask.ca		Conde, Renaud/0000-0001-9928-8937				Ali A, 1998, MOL CELL BIOL, V18, P4949, DOI 10.1128/MCB.18.9.4949; BALER R, 1993, MOL CELL BIOL, V13, P2486, DOI 10.1128/MCB.13.4.2486; Bharadwaj S, 1999, MOL CELL BIOL, V19, P8033; Borthwick EB, 2001, FEBS LETT, V491, P279, DOI 10.1016/S0014-5793(01)02177-9; Chen MS, 1996, J BIOL CHEM, V271, P32315, DOI 10.1074/jbc.271.50.32315; Chen MX, 1997, FEBS LETT, V400, P136, DOI 10.1016/S0014-5793(96)01427-5; Chinkers M, 2004, TOP CURR GENET, V5, P107; CHINKERS M, 1994, P NATL ACAD SCI USA, V91, P11075, DOI 10.1073/pnas.91.23.11075; Chinkers M, 2001, TRENDS ENDOCRIN MET, V12, P28, DOI 10.1016/S1043-2760(00)00335-0; Christians ES, 2002, CRIT CARE MED, V30, pS43, DOI 10.1097/00003246-200201001-00006; Chu BY, 1998, J BIOL CHEM, V273, P18640, DOI 10.1074/jbc.273.29.18640; Chu BY, 1996, J BIOL CHEM, V271, P30847, DOI 10.1074/jbc.271.48.30847; Duina AA, 1998, J BIOL CHEM, V273, P18974, DOI 10.1074/jbc.273.30.18974; FIRESTONE GL, 1990, METHOD ENZYMOL, V182, P688; Guo YL, 2001, J BIOL CHEM, V276, P45791, DOI 10.1074/jbc.M105931200; HENSOLD JO, 1990, MOL CELL BIOL, V10, P1600, DOI 10.1128/MCB.10.4.1600; Holmberg CI, 2001, EMBO J, V20, P3800, DOI 10.1093/emboj/20.14.3800; Ikeda K, 2004, MOL ENDOCRINOL, V18, P1131, DOI 10.1210/me.2003-0308; JURIVICH DA, 1992, SCIENCE, V255, P1243, DOI 10.1126/science.1546322; Kang H, 2001, BIOCHEMISTRY-US, V40, P10485, DOI 10.1021/bi010999i; Mercier PA, 1997, J BIOL CHEM, V272, P14147, DOI 10.1074/jbc.272.22.14147; Morimoto RI, 1990, STRESS PROTEINS BIOL; Nair SC, 1996, CELL STRESS CHAPERON, V1, P237, DOI 10.1379/1466-1268(1996)001<0237:APOMCI>2.3.CO;2; OVSENEK N, 1990, DEV GENET, V11, P97, DOI 10.1002/dvg.1020110111; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Ramsey AJ, 2000, J BIOL CHEM, V275, P17857, DOI 10.1074/jbc.M001625200; Ramsey AJ, 2002, BIOCHEMISTRY-US, V41, P5625, DOI 10.1021/bi016090h; Riggs DL, 2004, CRIT REV BIOCHEM MOL, V39, P279, DOI 10.1080/10409230490892513; Russell LC, 1999, J BIOL CHEM, V274, P20060, DOI 10.1074/jbc.274.29.20060; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; Silverstein AM, 1997, J BIOL CHEM, V272, P16224, DOI 10.1074/jbc.272.26.16224; Skinner J, 1997, J BIOL CHEM, V272, P22464, DOI 10.1074/jbc.272.36.22464; Soncin F, 2003, BIOCHEM BIOPH RES CO, V303, P700, DOI 10.1016/S0006-291X(03)00398-X; Voellmy R, 2004, CELL STRESS CHAPERON, V9, P122, DOI 10.1379/CSC-14R.1; Wang XZ, 2004, J BIOL CHEM, V279, P49460, DOI 10.1074/jbc.M406059200; WESTWOOD JT, 1993, MOL CELL BIOL, V13, P3481, DOI 10.1128/MCB.13.6.3481; WESTWOOD JT, 1991, NATURE, V353, P822, DOI 10.1038/353822a0; Xavier IJ, 2000, J BIOL CHEM, V275, P29147, DOI 10.1074/jbc.M002169200; Xia WL, 1997, J BIOL CHEM, V272, P4094, DOI 10.1074/jbc.272.7.4094; Yang J, 2005, EMBO J, V24, P1, DOI 10.1038/sj.emboj.7600496; Yang RC, 2004, EXP CELL RES, V296, P276, DOI 10.1016/j.yexcr.2004.01.027; Zou JY, 1998, CELL, V94, P471, DOI 10.1016/S0092-8674(00)81588-3; ZUO JR, 1994, MOL CELL BIOL, V14, P7557, DOI 10.1128/MCB.14.11.7557; ZUO JR, 1995, MOL CELL BIOL, V15, P4319; Zuo Z, 1999, BIOCHEMISTRY-US, V38, P8849, DOI 10.1021/bi990842e	45	42	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	2005	280	32					28989	28996		10.1074/jbc.M503594200	http://dx.doi.org/10.1074/jbc.M503594200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	952QT	15967796	hybrid			2022-12-25	WOS:000231021300021
J	Kawai, C; Prado, FM; Nunes, GLC; Di Mascio, P; Carmona-Ribeiro, AM; Nantes, IL				Kawai, C; Prado, FM; Nunes, GLC; Di Mascio, P; Carmona-Ribeiro, AM; Nantes, IL			pH-dependent interaction of cytochrome c with mitochondrial mimetic membranes - The role of an array of positively charged amino acids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILITY TRANSITION PORE; BINDING; FUSION; CONFORMATION; ASSOCIATION; APOPTOSIS; BILAYERS; RELEASE	The interaction of cytochrome c (cyt c) with mitochondrial mimetic vesicles of 1,2-dipalmitoyl-sn-glycero-3-phosphocholine, 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine, and heart cardiolipin (PCPECL) was investigated over the 7.4 - 6.2 pH range by means of turbidimetry and photon correlation spectroscopy. In the presence of cyt c, the decrease of pH induced an increase in vesicle turbidity and mean diameter resulting from vesicle fusion as determined by a rapid decrease in the excimer/monomer ratio of 2-(10-(1-pyrene)-decanoyl)-phosphatidylcholine (PyPC). N-acetylated cyt c and protamine, a positively charged protein, increased vesicle turbidity in a pH-independent manner, whereas albumin did not affect PCPECL vesicle turbidity. pH-dependent turbidity kinetics revealed a role for cyt c-ionizable groups with a pK(a(app)) of similar to 7.0. The carbethoxylation of these groups by diethylpyrocarbonate prevented cyt c-induced vesicle fusion, although cyt c association to vesicles remained unaffected. Matrix-assisted laser desorption ionization time-of-flight analysis revealed that Lys-22, Lys-27, His-33, and Lys-87 cyt c residues were the main targets for carbethoxylation performed at low pH values (< 7.5). In fact, these amino acid residues belong to clusters of positively charged amino acids that lower the pKa. Thus, at low pH, protonation of these invariant and highly conserved amino acid residues produced a second positively charged region opposite to the Lys-72 and Lys-73 region in the cyt c structure. These two opposing sites allowed two vesicles to be brought together by the same cyt c molecule for fusion. Therefore, a novel pH-dependent site associating cyt c to mitochondrial mimetic membranes was established in this study.	Univ Mogi das Cruzes, Ctr Interdisciplinar Invest Bioquim, BR-08780911 Sao Paulo, Brazil; Univ Sao Paulo, Inst Quim, Dept Bioquim, BR-05508970 Sao Paulo, Brazil	Universidade de Mogi das Cruzes; Universidade de Sao Paulo	Nantes, IL (corresponding author), Univ Mogi das Cruzes, Ctr Interdisciplinar Invest Bioquim, Predio 1,Sala 1S-15, BR-08780911 Sao Paulo, Brazil.	ilnantes@umc.br	Nantes, Iseli Lourenço/B-9517-2012; Carmona-Ribeiro, Ana M./B-4768-2016; Kawai, Cintia/H-2979-2013; Di Mascio, Paolo/D-1264-2014; Carmona-Ribeiro, Ana M/A-6235-2008	Nantes, Iseli Lourenço/0000-0003-1434-3154; Carmona-Ribeiro, Ana M./0000-0001-8500-2707; Di Mascio, Paolo/0000-0003-4125-8350; Carmona-Ribeiro, Ana M/0000-0001-8500-2707				ANTALIK M, 1999, BIOCHIM BIOPHYS ACTA, V1434, P347; Banci L, 1997, BIOCHEMISTRY-US, V36, P9867, DOI 10.1021/bi970724w; Barros MH, 2003, FREE RADICAL BIO MED, V35, P179, DOI 10.1016/S0891-5849(03)00307-1; CARMONARIBEIRO AM, 1985, J PHYS CHEM-US, V89, P2928, DOI 10.1021/j100259a045; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; De Giorgi F, 2002, FASEB J, V16, P607, DOI 10.1096/fj.01-0269fje; DEKRUIJFF B, 1980, BIOCHIM BIOPHYS ACTA, V602, P477, DOI 10.1016/0005-2736(80)90327-2; Dickerson R. E., 1979, PORPHYRINS, P397; Ernster L., 1992, MOL MECH BIOENERGETI; Grabowski E., 1983, MEASUREMENT SUSPENDE, P199; KINNUNEN PKJ, 1992, CHEM PHYS LIPIDS, V63, P251, DOI 10.1016/0009-3084(92)90041-M; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kostrzewa A, 2000, BIOCHEMISTRY-US, V39, P6066, DOI 10.1021/bi992559l; Kowaltowski A, 2000, CELL DEATH DIFFER, V7, P903, DOI 10.1038/sj.cdd.4400722; Kowaltowski AJ, 1999, J BIOENERG BIOMEMBR, V31, P581, DOI 10.1023/A:1005421112345; Kowaltowski AJ, 2001, FEBS LETT, V495, P12, DOI 10.1016/S0014-5793(01)02316-X; Kowaltowski AJ, 1999, FREE RADICAL BIO MED, V26, P463, DOI 10.1016/S0891-5849(98)00216-0; LEE S, 1989, ARCH BIOCHEM BIOPHYS, V271, P188, DOI 10.1016/0003-9861(89)90269-5; Lenaz G, 1998, BBA-BIOENERGETICS, V1366, P53, DOI 10.1016/S0005-2728(98)00120-0; Matroule JY, 2001, ONCOGENE, V20, P4070, DOI 10.1038/sj.onc.1204546; Nantes IL, 2001, J BIOL CHEM, V276, P153, DOI 10.1074/jbc.M006338200; Nicholls D.G., 1992, BIOENERGETICS, V2, P22; NICHOLLS P, 1974, BIOCHIM BIOPHYS ACTA, V346, P261, DOI 10.1016/0304-4173(74)90003-2; PELLETIER H, 1992, SCIENCE, V258, P1748, DOI 10.1126/science.1334573; PINHEIRO TJT, 1994, BIOCHIMIE, V76, P489, DOI 10.1016/0300-9084(94)90173-2; RYTOMAA M, 1995, J BIOL CHEM, V270, P3197, DOI 10.1074/jbc.270.7.3197; RYTOMAA M, 1992, J BIOL CHEM, V267, P22243; RYTOMAA M, 1994, J BIOL CHEM, V269, P1770; SCHENKMAN S, 1981, BIOCHIM BIOPHYS ACTA, V649, P633, DOI 10.1016/0005-2736(81)90168-1; Sugawara T, 2002, FASEB J, V16, P1997, DOI 10.1096/fj.02-0251fje; TAKANO T, 1981, J MOL BIOL, V153, P79, DOI 10.1016/0022-2836(81)90528-3; Tuominen EKJ, 2002, J BIOL CHEM, V277, P8822, DOI 10.1074/jbc.M200056200; WUTHRICH K, 1971, BIOCHIM BIOPHYS ACTA, V253, P98, DOI 10.1016/0005-2728(71)90237-4; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zhao HX, 2004, BIOCHEMISTRY-US, V43, P10302, DOI 10.1021/bi049002c; Zucchi MR, 2003, BIOCHEM J, V370, P671, DOI 10.1042/BJ20021521	36	94	95	0	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34709	34717		10.1074/jbc.M412532200	http://dx.doi.org/10.1074/jbc.M412532200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16012169	hybrid			2022-12-25	WOS:000232403900041
J	Rokhlin, OW; Taghiyev, AF; Guseva, NV; Glover, RA; Chumakov, PM; Kravchenko, JE; Cohen, MB				Rokhlin, OW; Taghiyev, AF; Guseva, NV; Glover, RA; Chumakov, PM; Kravchenko, JE; Cohen, MB			Androgen regulates apoptosis induced by TNFR family ligands via multiple signaling pathways in LNCaP	ONCOGENE			English	Article						androgen; androgen receptor; Akt; p53; caspase-2; apoptosis	PROSTATE-CANCER-CELLS; FAS-MEDIATED APOPTOSIS; LINE LNCAP; RECEPTOR; ACTIVATION; CASPASE-2; PROTEIN; DEATH; MITOCHONDRIA; P53	It has been suggested in many studies that combined treatment with chemotherapeutic agents and apoptosis-inducing ligands belonging to TNFR family is a more effective strategy for cancer treatment. However, the role of androgen regulation of TNFR family-induced apoptosis in prostate cancer is poorly understood. In this study, we investigated the dose-dependent effects of androgen on TNF-alpha and TRAIL-mediated apoptosis in LNCaP. To investigate the interaction between the androgen receptor (AR) and the caspase-2 gene, chromatin immunoprecipitation analysis was used, and we are the first to identify that AR interacts in vivo with an androgen-responsive elements in intron 8 of caspase-2 gene. We have found that DHT inhibited apoptosis in dose-dependent manner. There is a direct, androgen-dependent correlation between the levels of activated Akt and caspase activation after treatment with TNF-alpha and TRAIL. W e have also found that there are at least two different regulatory mechanisms of p53 expression by androgen: at the gene and protein levels. At the same time, the level of AR was found to be higher in LNCaP-si-p53 compared to LNCaP-mock cells. The se data indicate that there is a mutual regulation of expression between p53 and AR. Our study suggests that androgen-dependent outcome of apoptotic treatment can occur, at least in part, via the caspase-2, Akt and p53-mediated pathways.	Univ Iowa, Dept Pathol, Iowa City, IA 52242 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Biol, Cleveland, OH 44195 USA	University of Iowa; Cleveland Clinic Foundation	Rokhlin, OW (corresponding author), Univ Iowa, Dept Pathol, 1163 ML, Iowa City, IA 52242 USA.	oskar-rokhlin@uiowa.edu	Chumakov, Peter M/E-7731-2014	Chumakov, Peter/0000-0002-8078-2908	NATIONAL CANCER INSTITUTE [R01CA104903] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG025278] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA104903, R01 CA104903-01A1, CA 87717] Funding Source: Medline; NIA NIH HHS [R01 AG025278, R01 AG025278-01A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; Budanov AV, 2004, SCIENCE, V304, P596, DOI 10.1126/science.1095569; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Coffey RNT, 2002, PROSTATE, V53, P300, DOI 10.1002/pros.10159; Degterev A, 2003, ONCOGENE, V22, P8543, DOI 10.1038/sj.onc.1207107; Gnanapragasam V, 2003, BRIT J CANCER, V88, P1432, DOI 10.1038/sj.bjc.6600875; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Guseva NV, 2004, J CELL BIOCHEM, V91, P70, DOI 10.1002/jcb.10707; Heisler LE, 1997, MOL CELL ENDOCRINOL, V126, P59, DOI 10.1016/S0303-7207(96)03970-6; Hill MM, 2002, PHARMACOL THERAPEUT, V93, P243, DOI 10.1016/S0163-7258(02)00193-6; Huang HJ, 2004, ONCOGENE, V23, P2161, DOI 10.1038/sj.onc.1207326; Huang HJ, 2004, J BIOL CHEM, V279, P13866, DOI 10.1074/jbc.M314143200; Isaacs JT, 2004, NAT MED, V10, P26, DOI 10.1038/nm0104-26; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Linja MJ, 2001, CANCER RES, V61, P3550; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; Mayo LD, 2002, TRENDS BIOCHEM SCI, V27, P462, DOI 10.1016/S0968-0004(02)02166-7; Murillo H, 2001, ENDOCRINOLOGY, V142, P4795, DOI 10.1210/en.142.11.4795; NANTERMET PV, 2004, SCIENCE, V304, P843; Nelson WG, 2003, NEW ENGL J MED, V349, P366, DOI 10.1056/NEJMra021562; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Paroni G, 2002, J BIOL CHEM, V277, P15147, DOI 10.1074/jbc.M112338200; Pinski J, 2001, CANCER RES, V61, P6372; Reed JC, 2003, CANCER CELL, V3, P17, DOI 10.1016/S1535-6108(02)00241-6; Robertson JD, 2004, EMBO REP, V5, P643, DOI 10.1038/sj.embor.7400153; Rokhlin OW, 1998, CANCER RES, V58, P5870; Rokhlin OW, 2000, ONCOGENE, V19, P1959, DOI 10.1038/sj.onc.1203453; Rokhlin OW, 2002, CANCER BIOL THER, V1, P631, DOI 10.4161/cbt.311; Rokhlin OW, 2002, J BIOL CHEM, V277, P33213, DOI 10.1074/jbc.M204612200; Rokhlin OW, 2004, CANCER BIOL THER, V3, P761, DOI 10.4161/cbt.3.8.970; Rokhlin OW, 2001, ONCOGENE, V20, P2836, DOI 10.1038/sj.onc.1204410; Rokhlin OW, 1997, CANCER RES, V57, P1758; SONNENSCHEIN C, 1989, CANCER RES, V49, P3474; Sun M, 2003, J BIOL CHEM, V278, P42992, DOI 10.1074/jbc.M306295200; THALMANN GN, 1994, CANCER RES, V54, P2577; Tinel A, 2004, SCIENCE, V304, P843, DOI 10.1126/science.1095432; Zornig M., 2001, BIOCHIM BIOPHYS ACTA, V1551, P1	40	67	69	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 13	2005	24	45					6773	6784		10.1038/sj.onc.1208833	http://dx.doi.org/10.1038/sj.onc.1208833			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	973MV	16007156	Green Accepted			2022-12-25	WOS:000232527800005
J	Marin, F; Amons, R; Guichard, N; Stigter, M; Hecker, A; Luquet, G; Layrolle, P; Alcaraz, G; Riondet, C; Westbroek, P				Marin, F; Amons, R; Guichard, N; Stigter, M; Hecker, A; Luquet, G; Layrolle, P; Alcaraz, G; Riondet, C; Westbroek, P			Caspartin and calprismin, two proteins of the shell calcitic prisms of the Mediterranean fan mussel Pinna nobilis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							AMINO-ACID-SEQUENCE; SNAIL BIOMPHALARIA-GLABRATA; NACREOUS LAYER FORMATION; O-GLYCOSYLATION SITES; MATRIX PROTEIN; ORGANIC MATRIX; SOLUBLE MATRIX; MOLLUSK SHELLS; POLYACRYLAMIDE GELS; HALIOTIS-LAEVIGATA	We used the combination of preparative electrophoresis and immunological detection to isolate two new proteins from the shell calcitic prisms of Pinna nobilis, the Mediterranean fan mussel. The amino acid composition of these proteins was determined. Both proteins are soluble, intracrystalline, and acidic. The 38-kDa protein is glycosylated; the 17-kDa one is not. Ala, Asx, Thr, and Pro represent the dominant residues of the 38-kDa protein, named calprismin. An N-terminal sequence was obtained from calprismin. This sequence, which comprises a pattern of 4 cysteine residues, is not related to any known protein. The second protein, named caspartin, exhibits an unusual amino acid composition, since Asx constitutes by far the main amino acid residue. Preliminary sequencing surprisingly suggests that the first 75 N-terminal residues are all Asp. Caspartin self-aggregates spontaneously into multimers. In vitro tests show that it inhibits the precipitation of calcium carbonate. Furthermore, it strongly interferes with the growth of calcite crystals. A polyclonal antiserum raised against caspartin was used to localize this protein in the shell by immunogold. The immunolocalization demonstrates that caspartin is distributed within the prisms and makes a continuous film at the interface between the prisms and the surrounding insoluble sheets. Our finding emphasizes the prominent role of aspartic acid-rich proteins for the building of calcitic prisms among molluscs.	Univ Bourgogne, CNRS, UMR Biogeosci 5561, F-21000 Dijon, France; IsoTis NV, NL-3723 MB Bilthoven, Netherlands; Leiden Univ, Sylvius Labs, NL-2300 RA Leiden, Netherlands; Univ Paris 11, CNRS, UMR 8621, Inst Genet Mol,Equipe BMGE, F-91405 Orsay, France; ENESAD, INRA, UMR Biochim Interact Cellulaires 692, F-21079 Dijon, France; Leiden Univ, Leiden Inst Chem, Gorlaeus Labs, NL-2300 RA Leiden, Netherlands	Centre National de la Recherche Scientifique (CNRS); Universite de Bourgogne; Leiden University; Leiden University - Excl LUMC; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; INRAE; Leiden University; Leiden University - Excl LUMC	Marin, F (corresponding author), Univ Bourgogne, CNRS, UMR Biogeosci 5561, 6 Bd Gabriel, F-21000 Dijon, France.	frederic.marin@u-bourgogne.fr	HECKER, Arnaud/AAA-4853-2019; Layrolle, Pierre/K-9257-2015	HECKER, Arnaud/0000-0003-4511-5410; Layrolle, Pierre/0000-0001-9800-5210				ADDADI L, 1987, P NATL ACAD SCI USA, V84, P2732, DOI 10.1073/pnas.84.9.2732; Albeck S, 1996, CHEM-EUR J, V2, P278, DOI 10.1002/chem.19960020308; ALBECK S, 1993, J AM CHEM SOC, V115, P11691, DOI 10.1021/ja00078a005; Almeida MJ, 2000, J EXP ZOOL, V288, P327, DOI 10.1002/1097-010X(20001215)288:4<327::AID-JEZ5>3.0.CO;2-#; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ARMSTRONG DJ, 1993, BIOCHEM BIOPH RES CO, V192, P1380, DOI 10.1006/bbrc.1993.1569; Bateman A, 1998, J ENDOCRINOL, V158, P145, DOI 10.1677/joe.0.1580145; Bedouet L, 2001, COMP BIOCHEM PHYS B, V128, P389, DOI 10.1016/S1096-4959(00)00337-7; Belcher Angela M., 2000, P221; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; CAMPBELL KP, 1983, J BIOL CHEM, V258, P1267; Carter J.G., 1990, SKELETAL BIOMINERALI; Checa A, 2000, TISSUE CELL, V32, P405, DOI 10.1054/tice.2000.0129; Checa AG, 2001, P ROY SOC B-BIOL SCI, V268, P771, DOI 10.1098/rspb.2000.1415; Christlet THT, 2001, BIOPHYS J, V80, P952, DOI 10.1016/S0006-3495(01)76074-2; CLARK MF, 1977, J GEN VIROL, V34, P475, DOI 10.1099/0022-1317-34-3-475; CLEGG DO, 1988, J CELL BIOL, V107, P699, DOI 10.1083/jcb.107.2.699; Cuif J.P., 1983, Haliotis, V13, P131; Cuif J.P., 1991, P391; CUIF JP, 1987, CR ACAD SCI II, V304, P475; Currey JD, 1999, J EXP BIOL, V202, P3285; Dauphin Y, 2003, J STRUCT BIOL, V142, P272, DOI 10.1016/S1047-8477(03)00054-6; Dauphin Y, 2003, J BIOL CHEM, V278, P15168, DOI 10.1074/jbc.M204375200; Dauphin Y, 2002, COMP BIOCHEM PHYS A, V132, P577, DOI 10.1016/S1095-6433(02)00099-5; DEVINE PL, 1990, BIOTECHNIQUES, V8, P492; *DION CORP, 1998, 40 DION CORP, P1; DONACHY JE, 1992, MAR BIOL, V114, P423, DOI 10.1007/BF00350033; EDGE ASB, 1981, ANAL BIOCHEM, V118, P131, DOI 10.1016/0003-2697(81)90168-8; GASPARD D, 1978, Annales de Paleontologie Invertebres, V64, P1; Gattiker Alexandre, 2002, Appl Bioinformatics, V1, P107; Gotliv BA, 2005, CHEMBIOCHEM, V6, P304, DOI 10.1002/cbic.200400221; HALLORAN BA, 1995, COMP BIOCHEM PHYS B, V111, P221, DOI 10.1016/0305-0491(94)00245-P; Hansen JE, 1998, GLYCOCONJUGATE J, V15, P115, DOI 10.1023/A:1006960004440; HARDY MR, 1989, METHOD ENZYMOL, V179, P76; Hattan SJ, 2001, J BIOL CHEM, V276, P4461, DOI 10.1074/jbc.M006803200; HEYWOOD BR, 1994, ADV MATER, V6, P9, DOI 10.1002/adma.19940060103; HUTTNER WB, 1987, TRENDS BIOCHEM SCI, V12, P361, DOI 10.1016/0968-0004(87)90166-6; Iozzo RV, 1997, CRIT REV BIOCHEM MOL, V32, P141, DOI 10.3109/10409239709108551; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; Kaplan DL, 1998, CURR OPIN SOLID ST M, V3, P232, DOI 10.1016/S1359-0286(98)80096-X; KEITH J, 1993, COMP BIOCHEM PHYS B, V105, P487, DOI 10.1016/0305-0491(93)90078-J; Kono M, 2000, BIOCHEM BIOPH RES CO, V269, P213, DOI 10.1006/bbrc.2000.2274; Kouchinsky A, 2000, ACTA PALAEONTOL POL, V45, P119; KRAMPITZ G, 1983, BIOMINERALIZATION BI, P231; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEONG MML, 1986, J HISTOCHEM CYTOCHEM, V34, P1645, DOI 10.1177/34.12.3537113; Lopez Evelyne, 1995, Bulletin de l'Institut Oceanographique Numero Special (Monaco), V14, P49; Lowenstam HA, 1989, BIOMINERALIZATION; Mann K, 2000, EUR J BIOCHEM, V267, P5257, DOI 10.1046/j.1432-1327.2000.01602.x; MANN S, 1988, NATURE, V332, P119, DOI 10.1038/332119a0; Mann S., 2001, BIOMINERALIZATION PR; Marin F, 2004, CR PALEVOL, V3, P469, DOI 10.1016/j.crpv.2004.07.009; Marin F, 2003, PROTEIN EXPRES PURIF, V30, P246, DOI 10.1016/S1046-5928(03)00105-0; Marin F, 2001, PROTEIN EXPRES PURIF, V23, P175, DOI 10.1006/prep.2001.1487; MARIN F, 1994, CR ACAD SCI II, V318, P1653; Marin F, 2000, J BIOL CHEM, V275, P20667, DOI 10.1074/jbc.M003006200; Marin Frederic, 2003, ScientificWorldJournal, V3, P342; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; Marxen JC, 2003, BBA-PROTEINS PROTEOM, V1650, P92, DOI 10.1016/S1570-9639(03)00203-6; Marxen JC, 1997, COMP BIOCHEM PHYS B, V118, P23, DOI 10.1016/S0305-0491(97)00010-2; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCCALDON P, 1988, PROTEINS, V4, P99, DOI 10.1002/prot.340040204; Michenfelder M, 2003, BIOPOLYMERS, V70, P522, DOI 10.1002/bip.10536; Miyamoto H, 1996, P NATL ACAD SCI USA, V93, P9657, DOI 10.1073/pnas.93.18.9657; Miyashita T, 2000, MAR BIOTECHNOL, V2, P409; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; Nakahara H., 1980, JPN J MALACOL, V39, P167; Reddi AH, 2000, BIOCHEM SOC T, V28, P345, DOI 10.1042/0300-5127:0280345; Ritchie HH, 1996, J BIOL CHEM, V271, P21695, DOI 10.1074/jbc.271.36.21695; RUNNEGAR B, 1985, ALCHERINGA, V9, P245, DOI 10.1080/03115518508618971; RUSENKO KW, 1991, ACS SYM SER, V444, P107; SALEUDDIN ASM, 1983, MOLLUSCA, V4, P199; Samata T, 1999, FEBS LETT, V462, P225, DOI 10.1016/S0014-5793(99)01387-3; Sarashina I, 1998, AM MINERAL, V83, P1510, DOI 10.2138/am-1998-11-1239; Sarashina I, 2001, MAR BIOTECHNOL, V3, P362, DOI 10.1007/s10126-001-0013-6; SCHUSTER R, 1988, J CHROMATOGR-BIOMED, V431, P271, DOI 10.1016/S0378-4347(00)83096-0; Shen XY, 1997, J BIOL CHEM, V272, P32472, DOI 10.1074/jbc.272.51.32472; Simkiss K., 1968, EGG QUALITY STUDY HE, P3; Simkiss K, 1989, BIOMINERALIZATION CE; STETLERSTEVENSON WG, 1983, BIOCHEMISTRY-US, V22, P4326, DOI 10.1021/bi00287a025; Sudo S, 1997, NATURE, V387, P563, DOI 10.1038/42391; Suzuki M, 2004, BIOCHEM J, V382, P205, DOI 10.1042/BJ20040319; Takeuchi K, 2003, J BIOL CHEM, V278, P47416, DOI 10.1074/jbc.M309415200; TAYLOR JD, 1969, B BRIT MUSEUM NATU S, V3, P1; TISDELL CA, 2000, SPC PEARL OYSTER INF, V14, P21; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tsukamoto D, 2004, BIOCHEM BIOPH RES CO, V320, P1175, DOI 10.1016/j.bbrc.2004.06.072; UBUKATA T, 1994, PALAEONTOLOGY, V37, P241; Ubukata T, 1997, VELIGER, V40, P165; VEIS A, 1991, ACS SYM SER, V444, P1; Vitt UA, 2001, MOL ENDOCRINOL, V15, P681, DOI 10.1210/me.15.5.681; WALL RS, 1988, ANAL BIOCHEM, V175, P298, DOI 10.1016/0003-2697(88)90392-2; WEINER S, 1979, CALCIFIED TISSUE INT, V29, P163, DOI 10.1007/BF02408072; WEINER S, 1984, PHILOS T ROY SOC B, V304, P425, DOI 10.1098/rstb.1984.0036; WEINER S, 1983, BIOCHEMISTRY-US, V22, P4139, DOI 10.1021/bi00286a023; WEINER S, 1975, SCIENCE, V190, P987, DOI 10.1126/science.1188379; Weiner S., 1983, BIOMINER BIOL MET AC, P205, DOI [10.1007/978-94-009-7944-4_18, DOI 10.1007/978-94-009-7944-4_18]; Weiss IM, 2000, BIOCHEM BIOPH RES CO, V267, P17, DOI 10.1006/bbrc.1999.1907; Weiss IM, 2001, BIOCHEM BIOPH RES CO, V285, P244, DOI 10.1006/bbrc.2001.5170; Westbroek P, 1998, NATURE, V392, P861, DOI 10.1038/31798; WHEELER AP, 1987, COMP BIOCHEM PHYS B, V87, P953, DOI 10.1016/0305-0491(87)90418-4; WHEELER AP, 1981, SCIENCE, V212, P1397, DOI 10.1126/science.212.4501.1397; Wilkins MR, 1996, BIOCHEM BIOPH RES CO, V221, P609, DOI 10.1006/bbrc.1996.0643; Wilt FH, 2003, DIFFERENTIATION, V71, P237, DOI 10.1046/j.1432-0436.2003.7104501.x; YAZAKI PJ, 1990, BIOCHEM BIOPH RES CO, V170, P1089, DOI 10.1016/0006-291X(90)90504-G; Zhang Y, 2003, COMP BIOCHEM PHYS B, V135, P565, DOI 10.1016/S1096-4959(03)00138-6	106	110	112	4	51	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					33895	33908		10.1074/jbc.M506526200	http://dx.doi.org/10.1074/jbc.M506526200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	15994301	Green Published, hybrid			2022-12-25	WOS:000232229700026
J	Wang, YH; Zhou, XB; Zhu, HX; Liu, S; Zhou, CQ; Zhang, G; Xue, LY; Lu, N; Quan, LP; Bai, JF; Zhan, QM; Xu, NZ				Wang, YH; Zhou, XB; Zhu, HX; Liu, S; Zhou, CQ; Zhang, G; Xue, LY; Lu, N; Quan, LP; Bai, JF; Zhan, QM; Xu, NZ			Overexpression of EB1 in human esophageal squamous cell carcinoma (ESCC) may promote cellular growth by activating beta-catenin/TCF pathway	ONCOGENE			English	Article						esophageal cancer; overexpression; EB1; APC; beta-catenin	ADENOMATOUS POLYPOSIS-COLI; C-MYC; EXPRESSION; GENE; APC; TARGET	Esophageal squamous cell carcinoma (ESCC) has a multifactorial etiology involving environmental and/or genetic factors. End-binding protein 1 (EB1), which was cloned as an interacting partner of the adenomatous polyposis coli (APC) tumor suppressor protein, was previously found overexpressed in ESCC. However, the precise role of EB1 in the development of this malignancy has not yet been elucidated. In this study, we analysed freshly resected ESCC specimens and demonstrated that EB1 was overexpressed in approximately 63% of tumor samples compared to matched normal tissue. We report that overexpression of EB1 in the ESCC line EC9706 significantly promotes cell growth, whereas suppression of EB1 protein level by RNA interference significantly inhibited growth of esophageal tumor cells. In addition, EB1 overexpression induced nuclear accumulation of beta-catenin and promoted the transcriptional activity of beta-catenin/T-cell factor (TCF). These effects were partially or completely abolished by coexpression of APC or Delta N TCF4, respectively. Also, we found that EB1 affected the interaction between beta-catenin and APC. Furthermore, EB1 overexpression was correlated with cytoplasmic/nuclear accumulation of beta-catenin in primary human ESCC. Taken together, these results support the novel hypothesis that EB1 overexpression may play a role in the development of ESCC by affecting APC function and activating the beta-catenin/TCF pathway.	Chinese Acad Med Sci, Canc Inst & Canc Hosp, Lab Cell & Mol Biol, Beijing 100021, Peoples R China; Peking Union Med Coll, New York, NY 10021 USA; Chinese Acad Med Sci, Canc Inst & Canc Hosp, Dept Pathol, Beijing 100037, Peoples R China; Chinese Acad Med Sci, Canc Inst & Canc Hosp, Natl Lab Mol Oncol, Beijing, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College	Xu, NZ (corresponding author), Chinese Acad Med Sci, Canc Inst & Canc Hosp, Lab Cell & Mol Biol, Beijing 100021, Peoples R China.	xningzhi@public.bta.net.cn	Zhou, Cuiqi/B-1568-2010; Liu, Shuang/J-1798-2012; Zhang, Guo/Q-8513-2016	Wang, Yihua/0000-0001-5561-0648				Berrueta L, 1998, P NATL ACAD SCI USA, V95, P10596, DOI 10.1073/pnas.95.18.10596; Fodde R, 2001, NAT REV CANCER, V1, P55, DOI 10.1038/35094067; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Louie RK, 2004, J CELL SCI, V117, P1117, DOI 10.1242/jcs.00939; Polakis P, 2000, GENE DEV, V14, P1837; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Stoner GD, 2001, CARCINOGENESIS, V22, P1737, DOI 10.1093/carcin/22.11.1737; Struski S, 2002, CANCER GENET CYTOGEN, V135, P63, DOI 10.1016/S0165-4608(01)00624-0; SU LK, 1995, CANCER RES, V55, P2972; Tirnauer JS, 2000, J CELL BIOL, V149, P761, DOI 10.1083/jcb.149.4.761; Uys P, 2003, MOL CARCINOGEN, V36, P82, DOI 10.1002/mc.10100; Wang YH, 2005, BREAST CANCER RES, V7, pR220, DOI 10.1186/bcr975; Willert Jennifer, 2002, BMC Dev Biol, V2, P8, DOI 10.1186/1471-213X-2-8; Yen CC, 2001, CANCER, V92, P2769, DOI 10.1002/1097-0142(20011201)92:11<2769::AID-CNCR10118>3.0.CO;2-M; Zhang G, 2005, PATHOL INT, V55, P310, DOI 10.1111/j.1440-1827.2005.01840.x; Zhou CQ, 2005, INT J CANCER, V113, P891, DOI 10.1002/ijc.20642; ZHOU J, 1999, CHINESE J MED GENET, V16, P303; Zhou Xiao-bo, 2002, Ai Zheng, V21, P877; ZOU XN, 2002, B CHIN CANC, V11, P446	24	68	74	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 6	2005	24	44					6637	6645		10.1038/sj.onc.1208819	http://dx.doi.org/10.1038/sj.onc.1208819			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	971FL	16007168				2022-12-25	WOS:000232367800005
J	Markova, M; Koratkar, RA; Silverman, KA; Sollars, VE; Mac-Phee-Pellini, M; Walters, R; Palazzo, JP; Buchberg, AM; Siracusa, LD; Farber, SA				Markova, M; Koratkar, RA; Silverman, KA; Sollars, VE; Mac-Phee-Pellini, M; Walters, R; Palazzo, JP; Buchberg, AM; Siracusa, LD; Farber, SA			Diversity in secreted PLA(2)-IIA activity among inbred mouse strains that are resistant or susceptible to Apc(Min/+) tumorigenesis	ONCOGENE			English	Article						APC; PLA2; phospholipase; Mom1; intestine; cancer; mouse; BODIPY	PHOSPHOLIPASE A(2); INTESTINAL NEOPLASIA; GROUP-II; GROUP-V; MAJOR MODIFIER; LOCUS; GENE; ENZYMES; IDENTIFICATION; BIOSYNTHESIS	The secreted phospholipase A(2) type IIA (Pla2g2a) gene was previously identified as a modifier of intestinal adenoma multiplicity in Apc(Min/+) mice. To determine if intestinal secreted phospholipase A(2) (sPLA(2)) activity was also attenuated in susceptible strains, we developed a sensitive assay to directly quantitate sPL2 activity in the murine intestinal tract utilizing a fluorescent BODIPY-labeled phospholipid substrate. Here, we report assay conditions that distinguish between secreted and cytosolic PLA(2) enzyme activities in extracts of intestinal tissue. The small intestine exhibited higher activity levels than the large intestine. Consistent with predictions from the sPLA(2)-IIA gene sequence in inbred strains, we detected low levels of enzyme activity in inbred strains containing sPLA(2)-IIA mutations; these strains were also associated with greater numbers of intestinal polyps. Additionally, the assay was able to distinguish differences in levels of sPLA(2) activity between neoplasia-resistant strains, which were then shown by sequencing to carry variant wild-type sPLA(2)-IIA alleles. Immunohistochemical analyses of intestinal tissues were consistent with sPLA(2)-IIA activity levels. This approach enables further studies of the mechanisms of sPLA(2) action influencing the development and tumorigenesis of the small intestine and colon in both mice and humans.	Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Dept Surg Pathol, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University	Siracusa, LD (corresponding author), Carnegie Inst Washington, Dept Embryol, 115 W Univ Pkwy, Baltimore, MD 21210 USA.	siracusa@mail.jci.tju.edu; farber@ciwemb.edu	Sollars, Vincent/R-3769-2019; Farber, Steven A/G-5851-2012	Farber, Steven A/0000-0002-8037-7312; Sollars, Vincent/0000-0002-5602-3610; Buchberg, Arthur/0000-0002-0543-5631	NCI NIH HHS [P01CA72027, R01 CA89560] Funding Source: Medline; NIDDK NIH HHS [R01 DK060369] Funding Source: Medline; NINDS NIH HHS [F32 NS010326] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA089560, P01CA072027] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060369] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS010326] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Balsinde J, 1996, J BIOL CHEM, V271, P31937, DOI 10.1074/jbc.271.50.31937; Balsinde J, 2002, FEBS LETT, V531, P2, DOI 10.1016/S0014-5793(02)03413-0; Cormier RT, 1997, NAT GENET, V17, P88, DOI 10.1038/ng0997-88; Cormier RT, 2000, ONCOGENE, V19, P3182, DOI 10.1038/sj.onc.1203646; Dahim M, 2002, BIOPHYS J, V83, P1511, DOI 10.1016/S0006-3495(02)73921-0; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; Farber SA, 1999, J BIOL CHEM, V274, P19338, DOI 10.1074/jbc.274.27.19338; Farber SA, 2001, SCIENCE, V292, P1385, DOI 10.1126/science.1060418; GELB MH, 1994, FASEB J, V8, P916, DOI 10.1096/fasebj.8.12.8088457; GELB MH, 1995, ANNU REV BIOCHEM, V64, P653; Gould KA, 1997, P NATL ACAD SCI USA, V94, P5848, DOI 10.1073/pnas.94.11.5848; Gould KA, 1996, GENETICS, V144, P1769; HARA S, 1989, J BIOCHEM-TOKYO, V105, P395, DOI 10.1093/oxfordjournals.jbchem.a122675; Hendrickson HS, 1999, ANAL BIOCHEM, V276, P27, DOI 10.1006/abio.1999.4280; Ho IC, 2001, J BIOL CHEM, V276, P18321, DOI 10.1074/jbc.M008837200; Huang Z, 1996, BIOCHEMISTRY-US, V35, P3712, DOI 10.1021/bi952541k; KENNEDY BP, 1995, J BIOL CHEM, V270, P22378, DOI 10.1074/jbc.270.38.22378; Kim YJ, 2002, J BIOL CHEM, V277, P36479, DOI 10.1074/jbc.M205399200; Kim YJ, 2002, J BIOL CHEM, V277, P9358, DOI 10.1074/jbc.M110987200; Kirtane BM, 2002, J BIOSCIENCES, V27, P489, DOI 10.1007/BF02705045; Koduri RS, 2002, J BIOL CHEM, V277, P5849, DOI 10.1074/jbc.M109699200; Koratkar R, 2004, GENOMICS, V84, P844, DOI 10.1016/j.ygeno.2004.07.010; Koratkar R, 2002, CANCER RES, V62, P5413; Lio YC, 1996, BBA-LIPID LIPID MET, V1302, P55, DOI 10.1016/0005-2760(96)00002-1; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; MULHERKAR R, 1991, HISTOCHEMISTRY, V96, P367, DOI 10.1007/BF00271358; MULHERKAR R, 1993, FEBS LETT, V317, P263, DOI 10.1016/0014-5793(93)81289-C; Murakami M, 2002, J BIOCHEM, V131, P285, DOI 10.1093/oxfordjournals.jbchem.a003101; Murakami M, 1996, J BIOL CHEM, V271, P30041, DOI 10.1074/jbc.271.47.30041; Rouault M, 2003, BIOCHEMISTRY-US, V42, P11494, DOI 10.1021/bi0349930; SCOTT DL, 1990, SCIENCE, V250, P1563, DOI 10.1126/science.2274788; Silver L.M., 1995, MOUSE GENETICS CONCE; Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0; Valentin E, 1999, J BIOL CHEM, V274, P31195, DOI 10.1074/jbc.274.44.31195; Valentin E, 2000, BBA-MOL CELL BIOL L, V1488, P59, DOI 10.1016/S1388-1981(00)00110-4	36	18	19	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 22	2005	24	42					6450	6458		10.1038/sj.onc.1208791	http://dx.doi.org/10.1038/sj.onc.1208791			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	966RI	16007193	Green Accepted			2022-12-25	WOS:000232038200012
J	Grech, AP; Gardam, S; Chan, TN; Quinn, R; Gonzales, R; Basten, A; Brink, R				Grech, AP; Gardam, S; Chan, TN; Quinn, R; Gonzales, R; Basten, A; Brink, R			Tumor necrosis factor receptor 2 (TNFR2) signaling is negatively regulated by a novel, carboxyl-terminal TNFR-associated factor 2 (TRAF2)-binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; RECEPTOR-ASSOCIATED FACTOR-2; CELL-DEATH; CYTOPLASMIC DOMAIN; ADAPTER PROTEINS; STRUCTURAL BASIS; HUMAN TRAF2; ACTIVATION; CD40	Tumor necrosis factor (TNF) superfamily receptors typically induce both NF-kappa B and JNK activation by recruiting the TRAF2 signal transduction protein to their cytoplasmic domain. The type 2 TNF receptor (TNFR2), however, is a poor activator of these signaling pathways despite its high TRAF2 binding capability. This apparent paradox is resolved here by the demonstration that TNFR2 carries a novel carboxyl-terminal TRAF2-binding site (T2bs-C) that prevents the delivery of activation signals from its conventional TRAF2-binding site (T2bsN). T2bs-C does not conform to canonical TRAF2 binding motifs and appears to bind TRAF2 indirectly via an as yet unidentified intermediary. Specific inactivation of T2bs-N by site-directed mutagenesis eliminated most of the TRAF2 recruited to the TNFR2 cytoplasmic domain but had no effect on ligand-dependent activation of the NF-kappa B or JNK pathways. By contrast, inactivation of T2bs-C had little effect on the amount of TRAF2 recruited but greatly enhanced ligand-dependent NF-kappa B and JNK activation. In wild-type TNFR2 therefore, T2bs-C acts in a dominant fashion to attenuate signaling by the intrinsically more active T2bs-N but not by preventing TRAF2 recruitment. This unique uncoupling of TRAF2 recruitment and signaling at T2bs-N may be important in the modulation by TNFR2 of signaling through coexpressed TNFR1.	Centenary Inst Canc Med & Cell Biol, Newtown, NSW 4042, Australia	University of Sydney; Centenary Institute	Brink, R (corresponding author), Centenary Inst Canc Med & Cell Biol, Locked Bag 6, Newtown, NSW 4042, Australia.	r.brink@centenary.usyd.edu.au	Brink, Robert/B-7910-2010	Brink, Robert/0000-0002-9586-3655; Chan, Tyani/0000-0001-9276-8479				Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BAENS M, 1993, GENOMICS, V16, P214, DOI 10.1006/geno.1993.1161; Baud V, 1999, GENE DEV, V13, P1297, DOI 10.1101/gad.13.10.1297; BEG AA, 1996, SCIENCE, V274, P784; Bonnard M, 2000, EMBO J, V19, P4976, DOI 10.1093/emboj/19.18.4976; Brink R, 1998, J BIOL CHEM, V273, P4129, DOI 10.1074/jbc.273.7.4129; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Chainy GBN, 1996, J IMMUNOL, V157, P2410; Chan FKM, 2000, EUR J IMMUNOL, V30, P652; CLEMENT MV, 1994, J EXP MED, V180, P557, DOI 10.1084/jem.180.2.557; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Duckett CS, 1997, GENE DEV, V11, P2810, DOI 10.1101/gad.11.21.2810; Grech A, 2000, MOL IMMUNOL, V37, P721, DOI 10.1016/S0161-5890(00)00098-5; Grech AP, 2004, IMMUNITY, V21, P629, DOI 10.1016/j.immuni.2004.09.011; Grell M, 1999, EMBO J, V18, P3034, DOI 10.1093/emboj/18.11.3034; GRELL M, 1995, CELL, V83, P793, DOI 10.1016/0092-8674(95)90192-2; Grell M, 1998, EUR J IMMUNOL, V28, P257, DOI 10.1002/(SICI)1521-4141(199801)28:01<257::AID-IMMU257>3.0.CO;2-G; Haridas V, 1998, J IMMUNOL, V160, P3152; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Inoue J, 2000, EXP CELL RES, V254, P14, DOI 10.1006/excr.1999.4733; Ishida T, 1996, J BIOL CHEM, V271, P28745, DOI 10.1074/jbc.271.46.28745; Ishida T, 1996, P NATL ACAD SCI USA, V93, P9437, DOI 10.1073/pnas.93.18.9437; LAEGREID A, 1994, J BIOL CHEM, V269, P7785; Lee SY, 1996, J EXP MED, V183, P669, DOI 10.1084/jem.183.2.669; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Lucas R, 1998, EUR J IMMUNOL, V28, P3577, DOI 10.1002/(SICI)1521-4141(199811)28:11<3577::AID-IMMU3577>3.0.CO;2-#; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; McWhirter SM, 1999, P NATL ACAD SCI USA, V96, P8408, DOI 10.1073/pnas.96.15.8408; MUNROE ME, 2004, J BIOL CHEM; Pan S, 2002, MOL CELL BIOL, V22, P7512, DOI 10.1128/MCB.22.21.7512-7523.2002; Park YC, 2000, CELL, V101, P777, DOI 10.1016/S0092-8674(00)80889-2; Park YC, 1999, NATURE, V398, P533, DOI 10.1038/19110; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SCHINDLER U, 1994, MOL CELL BIOL, V14, P5820, DOI 10.1128/MCB.14.9.5820; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TORRES RM, 1992, J IMMUNOL, V148, P620; VAN AD, 1996, SCIENCE, V274, P787; Wajant H, 2001, INT J BIOCHEM CELL B, V33, P19, DOI 10.1016/S1357-2725(00)00064-9; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Weiss T, 1997, J IMMUNOL, V158, P2398; Ye H, 1999, MOL CELL, V4, P321, DOI 10.1016/S1097-2765(00)80334-2; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X	47	37	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	2005	280	36					31572	31581		10.1074/jbc.M504849200	http://dx.doi.org/10.1074/jbc.M504849200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	961LZ	16020544	hybrid			2022-12-25	WOS:000231665200030
J	Johnson, A; Gin, P; Marbois, BN; Hsieh, EJ; Wu, M; Barros, MH; Clarke, CF; Tzagoloff, A				Johnson, A; Gin, P; Marbois, BN; Hsieh, EJ; Wu, M; Barros, MH; Clarke, CF; Tzagoloff, A			COQ9, a new gene required for the biosynthesis of coenzyme Q in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							O-METHYLTRANSFERASE STEPS; UBIQUINONE BIOSYNTHESIS; MITOCHONDRIAL PROTEIN; MULTISUBUNIT COMPLEX; C-METHYLTRANSFERASE; YEAST; DEFECT; TRANSLATION; SUPPRESSION; MUTANTS	Currently, eight genes are known to be involved in coenzyme Q(6) biosynthesis in Saccharomyces cerevisiae. Here, we report a new gene designated COQ9 that is also required for the biosynthesis of this lipoid quinone. The respiratory-deficient pet mutant C92 was found to be deficient in coenzyme Q and to have low mitochondrial NADH-cytochrome c reductase activity, which could be restored by addition of coenzyme Q(2). The mutant was used to clone COQ9, corresponding to reading frame YLR201c on chromosome XII. The respiratory defect of C92 is complemented by COQ9 and suppressed by COQ8/ABC1. The latter gene has been shown to be required for coenzyme Q biosynthesis in yeast and bacteria. Suppression by COQ8/ABC1 of C92, but not other coq9 mutants tested, has been related to an increase in the mitochondrial concentration of several enzymes of the pathway. Coq9p may either catalyze a reaction in the coenzyme Q biosynthetic pathway or have a regulatory role similar to that proposed for Coq8p.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA; Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA	Columbia University; University of California System; University of California Los Angeles	Tzagoloff, A (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.	spud@cubpet2.bio.columbia.edu	Barros, Mario/Q-6358-2019; Barros, Mario H/B-8118-2012	Barros, Mario/0000-0003-2977-9815; Wu, Mian/0000-0002-2714-0500	NHLBI NIH HHS [R01 HL022174, HL2274] Funding Source: Medline; NIGMS NIH HHS [GM45952] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL022174] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045952] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baba SW, 2004, J BIOL CHEM, V279, P10052, DOI 10.1074/jbc.M313712200; Barkovich RJ, 1997, J BIOL CHEM, V272, P9182; Barrientos A, 2002, EMBO J, V21, P43, DOI 10.1093/emboj/21.1.43; Belogrudov GI, 2001, ARCH BIOCHEM BIOPHYS, V392, P48, DOI 10.1006/abbi.2001.2448; Benko AL, 2000, P NATL ACAD SCI USA, V97, P61, DOI 10.1073/pnas.97.1.61; BOTSTEIN D, 1982, MOL BIOL YEAST SACCH, P607; BOUSQUET I, 1991, EMBO J, V10, P2023, DOI 10.1002/j.1460-2075.1991.tb07732.x; CASEY J, 1978, BIOCHIM BIOPHYS ACTA, V530, P487, DOI 10.1016/0005-2760(78)90168-6; Do TQ, 2001, J BIOL CHEM, V276, P18161, DOI 10.1074/jbc.M100952200; FAYE G, 1974, J MOL BIOL, V88, P105, DOI 10.1016/0022-2836(74)90304-0; GIBSON F, 1973, Biochemical Society Transactions, V1, P317; Gin P, 2005, J BIOL CHEM, V280, P2676, DOI 10.1074/jbc.M411527200; Gin P, 2003, J BIOL CHEM, V278, P25308, DOI 10.1074/jbc.M303234200; Glerum DM, 1996, J BIOL CHEM, V271, P20531, DOI 10.1074/jbc.271.34.20531; Glick BS, 1995, METHOD ENZYMOL, V260, P224, DOI 10.1016/0076-6879(95)60140-6; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; Hsieh EJ, 2004, BIOCHEM BIOPH RES CO, V317, P648, DOI 10.1016/j.bbrc.2004.03.096; Hsu AY, 2000, BBA-MOL CELL BIOL L, V1484, P287, DOI 10.1016/S1388-1981(00)00019-6; Jiang N, 2001, J BIOL CHEM, V276, P29218, DOI 10.1074/jbc.M103686200; Jonassen T, 1998, J BIOL CHEM, V273, P3351, DOI 10.1074/jbc.273.6.3351; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leonard CJ, 1998, GENOME RES, V8, P1038, DOI 10.1101/gr.8.10.1038; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING LAB MANU; Marbois B, 2005, J BIOL CHEM, V280, P20231, DOI 10.1074/jbc.M501315200; MARTIN NC, 1980, NATURE, V285, P579, DOI 10.1038/285579a0; Meganathan R, 2001, FEMS MICROBIOL LETT, V203, P131, DOI 10.1016/S0378-1097(01)00330-5; Ohara K, 2004, PLANT J, V40, P734, DOI 10.1111/j.1365-313X.2004.02246.x; OLSON RE, 1983, VITAM HORM, V40, P1, DOI 10.1016/S0083-6729(08)60431-8; Poon WW, 2000, J BACTERIOL, V182, P5139, DOI 10.1128/JB.182.18.5139-5146.2000; Poon WW, 1999, J BIOL CHEM, V274, P21665, DOI 10.1074/jbc.274.31.21665; POON WW, 1995, ARCH BIOCHEM BIOPHYS, V320, P305, DOI 10.1016/0003-9861(95)90014-4; Poon WW, 1997, MOL ASPECTS MED, V18, pS121; RODEL G, 1986, CURR GENET, V11, P41, DOI 10.1007/BF00389424; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Soutourina J, 2000, J BIOL CHEM, V275, P11626, DOI 10.1074/jbc.275.16.11626; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; TZAGOLOFF A, 1975, J BIOL CHEM, V250, P8228	41	74	75	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	2005	280	36					31397	31404		10.1074/jbc.M503277200	http://dx.doi.org/10.1074/jbc.M503277200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	961LZ	16027161	hybrid			2022-12-25	WOS:000231665200009
J	Enyeart, JJ; Danthi, SJ; Liu, HY; Enyeart, JA				Enyeart, JJ; Danthi, SJ; Liu, HY; Enyeart, JA			Angiotensin II inhibits bTREK-1 K+ channels in adrenocortical cells by separate Ca2(+)- and ATP hydrolysis-dependent mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL GLOMERULOSA CELLS; GATED TRANSIENT CURRENTS; ZONA-FASCICULATA CELLS; T-TYPE; CORTICAL CELLS; POTASSIUM CHANNELS; ADENOSINE-TRIPHOSPHATE; ALDOSTERONE PRODUCTION; PHOSPHOLIPASE-C; CA2+ CHANNELS	Bovine adrenocortical cells express bTREK-1 K+ channels that set the resting membrane potential (V-m) and couple angiotensin II (AngII) and adrenocorticotropic hormone (ACTH) receptors to membrane depolarization and corticosteroid secretion. In this study, it was discovered that AngII inhibits bTREK-1 by separate Ca2+- and ATP hydrolysis-dependent signaling pathways. When whole cell patch clamp recordings were made with pipette solutions that support activation of both Ca2+- and ATP-dependent pathways, AngII was significantly more potent and effective at inhibiting bTREK-1 and depolarizing adrenal zona fasciculata cells, than when either pathway is activated separately. External ATP also inhibited bTREK-1 through these two pathways, but ACTH displayed no Ca2+-dependent inhibition. AngII-mediated inhibition of bTREK-1 through the novel Ca2+-dependent pathway was blocked by the AT(1) receptor antagonist losartan, or by including guanosine-5 '-O-(2-thiodiphosphate) in the pipette solution. The Ca2+- dependent inhibition of bTREK-1 by AngII was blunted in the absence of external Ca2+ or by including the phospholipase C antagonist U73122, the inositol 1,4,5-trisphosphate receptor antagonist 2-amino-ethoxydiphenyl borate, or a calmodulin inhibitory peptide in the pipette solution. The activity of unitary bTREK-1 channels in inside-out patches from adrenal zona fasciculata cells was inhibited by application of Ca2+ ( 5 or 10 mu M) to the cytoplasmic membrane surface. The Ca2+ ionophore ionomycin also inhibited bTREK-1 currents through channels expressed in CHO-K1 cells. These results demonstrate that AngII and selected paracrine factors that act through phospholipase C inhibit bTREK-1 in adrenocortical cells through simultaneous activation of separate Ca2+- and ATP hydrolysis-dependent signaling pathways, providing for efficient membrane depolarization. The novel Ca2+- dependent pathway is distinctive in its lack of ATP dependence, and is clearly different from the calmodulin kinase-dependent mechanism by which AngII modulates T-type Ca2+ channels in these cells.	Ohio State Univ, Coll Med & Publ Hlth, Dept Neurosci, Columbus, OH 43210 USA; Ohio State Univ, Math Biosci Inst, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Enyeart, JJ (corresponding author), Ohio State Univ, Coll Med & Publ Hlth, Dept Neurosci, 5196 Graves Hall,333 W 10th Ave, Columbus, OH 43210 USA.	enyeart.1@osu.edu			NIDDK NIH HHS [R01-DK47875] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047875] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bang H, 2000, J BIOL CHEM, V275, P17412, DOI 10.1074/jbc.M000445200; Bradley J, 2004, NAT NEUROSCI, V7, P705, DOI 10.1038/nn1266; BROOKS SPJ, 1992, ANAL BIOCHEM, V201, P119, DOI 10.1016/0003-2697(92)90183-8; BURNAY MM, 1994, ENDOCRINOLOGY, V135, P751, DOI 10.1210/en.135.2.751; CAPPONI AM, 1984, J BIOL CHEM, V259, P8863; Chemin J, 2003, EMBO J, V22, P5403, DOI 10.1093/emboj/cdg528; Chen XL, 1999, AM J PHYSIOL-RENAL, V276, pF674, DOI 10.1152/ajprenal.1999.276.5.F674; de Gasparo M, 2000, PHARMACOL REV, V52, P415; Doronin SV, 2004, J BIOL CHEM, V279, P48231, DOI 10.1074/jbc.M405789200; DUDLEY DT, 1990, MOL PHARMACOL, V38, P370; Ellis MV, 1998, J BIOL CHEM, V273, P11650, DOI 10.1074/jbc.273.19.11650; Enyeart JA, 2000, J BIOL CHEM, V275, P34640, DOI 10.1074/jbc.M004214200; Enyeart JA, 2004, AM J PHYSIOL-ENDOC M, V287, pE1154, DOI 10.1152/ajpendo.00223.2004; Enyeart JJ, 1997, J GEN PHYSIOL, V110, P679, DOI 10.1085/jgp.110.6.679; Enyeart JJ, 2002, J BIOL CHEM, V277, P49186, DOI 10.1074/jbc.M207233200; ENYEART JJ, 1993, MOL ENDOCRINOL, V7, P1031, DOI 10.1210/me.7.8.1031; Enyeart JJ, 1996, J GEN PHYSIOL, V108, P251, DOI 10.1085/jgp.108.4.251; Fink M, 1996, EMBO J, V15, P6854, DOI 10.1002/j.1460-2075.1996.tb01077.x; FRANKENHAEUSER B, 1957, J PHYSIOL-LONDON, V137, P218, DOI 10.1113/jphysiol.1957.sp005808; Goldstein SAN, 2001, NAT REV NEUROSCI, V2, P175, DOI 10.1038/35058574; Gomora JC, 1998, AM J PHYSIOL-CELL PH, V275, pC1526, DOI 10.1152/ajpcell.1998.275.6.C1526; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HOEY ED, 1994, ENDOCRINOLOGY, V134, P1553, DOI 10.1210/en.134.3.1553; Jiang YX, 2002, NATURE, V417, P515, DOI 10.1038/417515a; JURMAN ME, 1994, BIOTECHNIQUES, V17, P876; Kang D, 2005, J PHYSIOL-LONDON, V564, P103, DOI 10.1113/jphysiol.2004.081059; Kim D, 2003, TRENDS PHARMACOL SCI, V24, P648, DOI 10.1016/j.tips.2003.10.008; LU HK, 1994, AM J PHYSIOL, V267, pF183, DOI 10.1152/ajprenal.1994.267.1.F183; LYMANGROVER JR, 1982, ENDOCRINOLOGY, V110, P462, DOI 10.1210/endo-110-2-462; Maingret F, 2000, EMBO J, V19, P2483, DOI 10.1093/emboj/19.11.2483; Maingret F, 2000, J BIOL CHEM, V275, P10128, DOI 10.1074/jbc.275.14.10128; Maruyama T, 1997, J BIOCHEM-TOKYO, V122, P498; MATTHEWS EK, 1967, J PHYSIOL-LONDON, V189, P139, DOI 10.1113/jphysiol.1967.sp008159; MATTHEWS EK, 1973, J PHYSIOL-LONDON, V234, P43, DOI 10.1113/jphysiol.1973.sp010333; MLINAR B, 1993, J BIOL CHEM, V268, P8640; MLINAR B, 1993, J GEN PHYSIOL, V102, P239, DOI 10.1085/jgp.102.2.239; MLINAR B, 1993, J GEN PHYSIOL, V102, P217, DOI 10.1085/jgp.102.2.217; MLINAR B, 1995, J BIOL CHEM, V270, P20942, DOI 10.1074/jbc.270.36.20942; NADLER JL, 1987, J CLIN INVEST, V80, P1763, DOI 10.1172/JCI113269; Niu XW, 2004, NEURON, V42, P745, DOI 10.1016/j.neuron.2004.05.001; Patel AJ, 2001, TRENDS NEUROSCI, V24, P339, DOI 10.1016/S0166-2236(00)01810-5; Philipp S, 2000, J BIOL CHEM, V275, P23965, DOI 10.1074/jbc.M003408200; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Rossier M F, 2000, Vitam Horm, V60, P229, DOI 10.1016/S0083-6729(00)60021-3; Saimi Y, 2002, ANNU REV PHYSIOL, V64, P289, DOI 10.1146/annurev.physiol.64.100301.111649; Schonherr R, 2000, EMBO J, V19, P3263, DOI 10.1093/emboj/19.13.3263; Smith RD, 1999, ENDOCRINOLOGY, V140, P1385, DOI 10.1210/en.140.3.1385; SMITH RD, 1992, ANNU REV PHARMACOL, V32, P135; Spat A, 2004, PHYSIOL REV, V84, P489, DOI 10.1152/physrev.00030.2003; Suh BC, 2002, NEURON, V35, P507, DOI 10.1016/S0896-6273(02)00790-0; THOMPSON AK, 1991, J BIOL CHEM, V266, P23856; TOKOK K, 1994, BIOCHEMISTRY-US, V33, P12807; Venema RC, 1998, J BIOL CHEM, V273, P7703, DOI 10.1074/jbc.273.13.7703; Webb TE, 1996, MOL PHARMACOL, V50, P258; Welsby PJ, 2003, J NEUROSCI, V23, P10116, DOI 10.1523/jneurosci.23-31-10116.2003; Wen H, 2002, J NEUROSCI, V22, P7991, DOI 10.1523/jneurosci.22-18-07991.2002; Williams MC, 1997, ELEC SOC S, V97, P3; Wolfe JT, 2002, J PHYSIOL-LONDON, V538, P343, DOI 10.1113/jphysiol.2001.012839; Xia XM, 1998, NATURE, V395, P503, DOI 10.1038/26758; Xu L, 1999, J PHYSIOL-LONDON, V521, P81, DOI 10.1111/j.1469-7793.1999.00081.x; Xu L, 2001, AM J PHYSIOL-CELL PH, V280, pC199, DOI 10.1152/ajpcell.2001.280.1.C199; Xu L, 1999, MOL PHARMACOL, V55, P364, DOI 10.1124/mol.55.2.364	62	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	2005	280	35					30814	30828		10.1074/jbc.M504283200	http://dx.doi.org/10.1074/jbc.M504283200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	958ZX	15994319	hybrid			2022-12-25	WOS:000231487800022
J	Martinez-Vicente, M; Yim, L; Villarroya, M; Mellado, M; Perez-Paya, E; Bjork, GR; Armengod, ME				Martinez-Vicente, M; Yim, L; Villarroya, M; Mellado, M; Perez-Paya, E; Bjork, GR; Armengod, ME			Effects of mutagenesis in the switch I region and conserved arginines of Escherichia coli MnmE protein, a GTPase involved in tRNA modification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELONGATION-FACTOR G; WOBBLE MODIFICATION DEFICIENCY; GUANYLATE-BINDING PROTEIN-1; GUANINE-NUCLEOTIDE-BINDING; HUMAN MITOCHONDRIAL DISEASE; MUTANT TRANSFER-RNAS; RIBOSOMAL-RNA; TRANSLATION INITIATION; CONFORMATIONAL-CHANGES; MODIFICATION DEFECT	MnmE is an evolutionarily conserved, three domain GTPase involved in tRNA modification. In contrast to Ras proteins, MnmE exhibits a high intrinsic GTPase activity and requires GTP hydrolysis to be functionally active. Its G domain conserves the GTPase activity of the full protein, and thus, it should contain the catalytic residues responsible for this activity. In this work, mutational analysis of all conserved arginine residues of the MnmE G- domain indicates that MnmE, unlike other GTPases, does not use an arginine finger to drive catalysis. In addition, we show that residues in the G2 motif ( (249)GTTRD(253)), which resides in the switch I region, are not important for GTP binding but play some role in stabilizing the transition state, specially Gly(249) and Thr(251). On the other hand, G2 mutations leading to a minor loss of the GTPase activity result in a non- functional MnmE protein. This indicates that GTP hydrolysis is a required but non- sufficient condition so that MnmE can mediate modification of tRNA. The conformational change of the switch I region associated with GTP hydrolysis seems to be crucial for the function of MnmE, and the invariant threonine ( Thr251) of the G2 motif would be essential for such a change, because it cannot be substituted by serine. MnmE defects result in impaired growth, a condition that is exacerbated when defects in other genes involved in the decoding process are simultaneously present. This behavior is reminiscent to that found in yeast and stresses the importance of tRNA modification for gene expression.	Ctr Invest Principe Felipe, Genet Mol Lab, Valencia 46013, Spain; Ctr Invest Principe Felipe, Lab Peptidos & Desarrollo Ensayos, Valencia 46013, Spain; Umea Univ, Dept Mol Biol, S-90187 Umea, Sweden	Prince Felipe Research Center; Prince Felipe Research Center; Umea University	Armengod, ME (corresponding author), Ctr Invest Principe Felipe, Genet Mol Lab, Avda Autopista Saler 16, Valencia 46013, Spain.	armengod@ochoa.fib.es	Martinez-Vicente, Marta/K-4312-2014; Villarroya, M Magdalena/K-7621-2014; Björk, Glenn/AAE-8219-2022; Armengod, Maria Eugenia/K-6030-2014; Armengod, M. Eugenia/A-9609-2014	Martinez-Vicente, Marta/0000-0001-7053-2625; Villarroya, M Magdalena/0000-0003-4542-7430; Armengod, Maria Eugenia/0000-0003-1512-2687; Mellado, Maravillas/0000-0002-6025-8383				Agrawal RK, 1999, NAT STRUCT BIOL, V6, P643, DOI 10.1038/10695; Ahmadian MR, 1997, NAT STRUCT BIOL, V4, P686, DOI 10.1038/nsb0997-686; Andersen GR, 2003, TRENDS BIOCHEM SCI, V28, P434, DOI 10.1016/S0968-0004(03)00162-2; BACHMANN BJ, 1996, ESCHERICHIA COLI SAL, P2460; Bourne HR, 1997, NATURE, V389, P673, DOI 10.1038/39470; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; Bregeon D, 2001, GENE DEV, V15, P2295, DOI 10.1101/gad.207701; Bujnicki JM, 2004, RNA, V10, P1236, DOI 10.1261/rna.7470904; Cabedo H, 1999, EMBO J, V18, P7063, DOI 10.1093/emboj/18.24.7063; CHING WM, 1985, CURR TOP CELL REGUL, V27, P497; CHING WM, 1982, P NATL ACAD SCI-BIOL, V79, P374, DOI 10.1073/pnas.79.2.374; Curran J. F., 1998, MODIFICATION EDITING, P493; Daumke O, 2004, NATURE, V429, P197, DOI 10.1038/nature02505; DECOSTER E, 1993, J MOL BIOL, V232, P79, DOI 10.1006/jmbi.1993.1371; ELSEVIERS D, 1984, NUCLEIC ACIDS RES, V12, P3521, DOI 10.1093/nar/12.8.3521; EMILSSON V, 1990, EMBO J, V9, P4359, DOI 10.1002/j.1460-2075.1990.tb07885.x; Fourmy D, 1998, J MOL BIOL, V277, P333, DOI 10.1006/jmbi.1997.1551; GEHRKE CW, 1989, J CHROMATOGR, V471, P3, DOI 10.1016/S0021-9673(00)94152-9; Geyer M, 1997, CURR OPIN STRUC BIOL, V7, P786, DOI 10.1016/S0959-440X(97)80147-9; Hagervall TG, 1998, J MOL BIOL, V284, P33, DOI 10.1006/jmbi.1998.2162; HAGERVALL TG, 1987, J BIOL CHEM, V262, P8488; JOHN J, 1993, J BIOL CHEM, V268, P923; Kambampati R, 2003, BIOCHEMISTRY-US, V42, P1109, DOI 10.1021/bi026536+; Kirino Y, 2005, P NATL ACAD SCI USA, V102, P7127, DOI 10.1073/pnas.0500563102; Kirino Y, 2004, P NATL ACAD SCI USA, V101, P15070, DOI 10.1073/pnas.0405173101; Krab IM, 1999, BIOCHEMISTRY-US, V38, P13035, DOI 10.1021/bi9909748; KRAMER GF, 1988, J BACTERIOL, V170, P736, DOI 10.1128/jb.170.2.736-743.1988; Kruger MK, 1998, J MOL BIOL, V284, P609, DOI 10.1006/jmbi.1998.2197; Leipe DD, 2002, J MOL BIOL, V317, P41, DOI 10.1006/jmbi.2001.5378; Li GP, 2004, J MOL BIOL, V340, P921, DOI 10.1016/j.jmb.2004.06.007; Li XM, 2002, MOL CELL BIOL, V22, P7701, DOI 10.1128/MCB.22.21.7701-7711.2002; Li XM, 2002, J BIOL CHEM, V277, P27256, DOI 10.1074/jbc.M203267200; Lin B, 1999, J BACTERIOL, V181, P5825, DOI 10.1128/JB.181.18.5825-5832.1999; Lin B, 2001, MOL MICROBIOL, V39, P924, DOI 10.1046/j.1365-2958.2001.02285.x; Marks B, 2001, NATURE, V410, P231, DOI 10.1038/35065645; Miller J.H., 1992, SHORT COURSE BACTERI, P150; Mohr D, 2000, EMBO J, V19, P3458, DOI 10.1093/emboj/19.13.3458; Ogle JM, 2003, TRENDS BIOCHEM SCI, V28, P259, DOI 10.1016/S0968-0004(03)00066-5; Praefcke GJK, 1999, J MOL BIOL, V292, P321, DOI 10.1006/jmbi.1999.3062; Prakash B, 2000, EMBO J, V19, P4555, DOI 10.1093/emboj/19.17.4555; Prakash B, 2000, NATURE, V403, P567, DOI 10.1038/35000617; RICHTER MF, 1995, J BIOL CHEM, V270, P13512, DOI 10.1074/jbc.270.22.13512; Rodnina MV, 1997, NATURE, V385, P37, DOI 10.1038/385037a0; Rodnina MV, 1999, P NATL ACAD SCI USA, V96, P9586, DOI 10.1073/pnas.96.17.9586; Roll-Mecak A, 2000, CELL, V103, P781, DOI 10.1016/S0092-8674(00)00181-1; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Scrima A, 2005, EMBO J, V24, P23, DOI 10.1038/sj.emboj.7600507; Seewald MJ, 2002, NATURE, V415, P662, DOI 10.1038/415662a; Shimamoto T, 1996, FEMS MICROBIOL LETT, V136, P57, DOI 10.1016/0378-1097(95)00493-9; Spoerner M, 2001, P NATL ACAD SCI USA, V98, P4944, DOI 10.1073/pnas.081441398; Stark H, 2000, CELL, V100, P301, DOI 10.1016/S0092-8674(00)80666-2; Tomsic J, 2000, EMBO J, V19, P2127, DOI 10.1093/emboj/19.9.2127; Umeda N, 2005, J BIOL CHEM, V280, P1613, DOI 10.1074/jbc.M409306200; Urbonavicius J, 2001, EMBO J, V20, P4863, DOI 10.1093/emboj/20.17.4863; Uthaiah RC, 2003, J BIOL CHEM, V278, P29336, DOI 10.1074/jbc.M211973200; Vetter IR, 2001, SCIENCE, V294, P1299, DOI 10.1126/science.1062023; WITTWER AJ, 1986, ARCH BIOCHEM BIOPHYS, V248, P540, DOI 10.1016/0003-9861(86)90507-2; Wolfe MD, 2004, J BIOL CHEM, V279, P1801, DOI 10.1074/jbc.M310442200; Yamanaka K, 2000, J BACTERIOL, V182, P7078, DOI 10.1128/JB.182.24.7078-7082.2000; Yarian C, 2002, J BIOL CHEM, V277, P16391, DOI 10.1074/jbc.M200253200; Yasukawa T, 2005, FEBS LETT, V579, P2948, DOI 10.1016/j.febslet.2005.04.038; Yasukawa T, 2002, MITOCHONDRION, V2, P129, DOI 10.1016/S1567-7249(02)00033-8; Yasukawa T, 2001, EMBO J, V20, P4794, DOI 10.1093/emboj/20.17.4794; Yim L, 2003, J BIOL CHEM, V278, P28378, DOI 10.1074/jbc.M301381200; Zavialov AV, 2003, CELL, V114, P113, DOI 10.1016/S0092-8674(03)00478-1; Zhang BL, 1999, J BIOL CHEM, V274, P2609, DOI 10.1074/jbc.274.5.2609	66	30	31	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	2005	280	35					30660	30670		10.1074/jbc.M503223200	http://dx.doi.org/10.1074/jbc.M503223200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	958ZX	15983041	hybrid			2022-12-25	WOS:000231487800004
J	Lung, HL; Bangarusamy, DK; Xie, D; Cheung, AKL; Cheng, Y; Kumaran, MK; Miller, L; Liu, ETB; Guan, XY; Sham, JS; Fang, Y; Li, LQ; Wang, N; Protopopov, AI; Zabarovsky, ER; Tsao, SW; Stanbridge, EJ; Lung, ML				Lung, HL; Bangarusamy, DK; Xie, D; Cheung, AKL; Cheng, Y; Kumaran, MK; Miller, L; Liu, ETB; Guan, XY; Sham, JS; Fang, Y; Li, LQ; Wang, N; Protopopov, AI; Zabarovsky, ER; Tsao, SW; Stanbridge, EJ; Lung, ML			THY1 is a candidate tumour suppressor gene with decreased expression in metastatic nasopharyngeal carcinoma	ONCOGENE			English	Article						chromosome 11; THY1; nasopharyngeal carcinoma; microcell hybrid; oligo-microarray	HUMAN OVARIAN-CANCER; CELL-LINE; REGION; ADHESION	Using oligonucleotide microarray analysis, THY1, mapping close to a previously defined 11q22-23 nasopharyngeal carcinoma (NPC) critical region was identified as showing consistent downregulated expression in the tumour segregants, as compared to their parental tumour-suppressing microcell hybrids (MCHs). Gene expression and protein analyses show that THY1 was not expressed in the NPC HONE1 recipient cells, tumour segregants, and other NPC cell lines; THY1 was exclusively expressed in the non-tumourigenic MCHs. The mechanism of THY1 gene inactivation in these cell lines was attributed to hypermethylation. Clinical study showed that in 65% of NPC specimens there was either downregulation or loss of THY1 gene expression. Using a tissue microarray and immunohistochemical staining, 44% of the NPC cases showed downregulated expression of THY1 and 9% lost THY1 expression. The frequency of THY1 downregulated expression in lymph node metastatic NPC was 63%, which was significantly higher than in the primary tumour (33%). After transfection of THY1 gene into HONE1 cells, a dramatic reduction of colony formation ability was observed. These findings suggest that THY1 is a good candidate tumour suppressor gene in NPC, which is significantly associated with lymph node metastases.	Hong Kong Univ Sci & Technol, Dept Biol, Kowloon, Hong Kong, Peoples R China; Genome Inst Singapore, Inst Biomed Sci, Singapore, Singapore; Univ Hong Kong, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China; Sun Yat Sen Univ, Inst Canc, Guangzhou, Peoples R China; Univ Rochester, Sch Med & Dent, Dept Pathol & Lab Med, Rochester, NY 14642 USA; Karolinska Inst, Ctr Genom & Bioinformat, Ctr Microbiol & Tumor Biol, Stockholm, Sweden; Univ Hong Kong, Dept Anat, Hong Kong, Hong Kong, Peoples R China; Univ Calif Irvine, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA	Hong Kong University of Science & Technology; Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS); University of Hong Kong; Sun Yat Sen University; University of Rochester; Karolinska Institutet; University of Hong Kong; University of California System; University of California Irvine	Lung, ML (corresponding author), Hong Kong Univ Sci & Technol, Dept Biol, Kowloon, Hong Kong, Peoples R China.	bomaria@ust.hk	Miller, Lance/A-5633-2009; Cheung, Arthur Kwok Leung/H-8940-2013; Cheng, Yue/E-9853-2010; Lung, Hong Lok/C-4494-2009; Zabarovsky, Eugene R/A-6645-2010; Guan, Xin-Yuan/A-3639-2009; Lung, Maria Li/C-4495-2009	Cheng, Yue/0000-0002-2472-1879; Guan, Xin-Yuan/0000-0002-4485-6017; Miller, Lance/0000-0003-3799-2528; Lung, Maria Li/0000-0003-2559-3626				Abeysinghe HR, 2004, CANCER GENET CYTOGEN, V149, P1, DOI 10.1016/S0165-4608(03)00234-6; Abeysinghe HR, 2003, CANCER GENET CYTOGEN, V143, P125, DOI 10.1016/S0165-4608(02)00855-5; Barda-Saad M, 1999, EXP HEMATOL, V27, P834, DOI 10.1016/S0301-472X(99)00010-7; Barker TH, 2004, EXP CELL RES, V295, P488, DOI 10.1016/j.yexcr.2004.01.026; BONEWALD L, 1984, J IMMUNOGENET, V11, P283; Cavallaro U, 2001, BBA-REV CANCER, V1552, P39, DOI 10.1016/S0304-419X(01)00038-5; Chan KT, 2004, CANCER CHEMOTH PHARM, V53, P519, DOI 10.1007/s00280-004-0767-4; Cheng Y, 2002, GENE CHROMOSOME CANC, V34, P97, DOI 10.1002/gcc.10048; Cheng Y, 2000, GENE CHROMOSOME CANC, V28, P82, DOI 10.1002/(SICI)1098-2264(200005)28:1<82::AID-GCC10>3.0.CO;2-8; CRAWFORD JM, 1986, LAB INVEST, V54, P122; Diaz-Romero J, 2005, J CELL PHYSIOL, V202, P731, DOI 10.1002/jcp.20164; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Lin CY, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-9-r66; Lung HL, 2004, INT J CANCER, V112, P628, DOI 10.1002/ijc.20454; Protopopov AI, 2002, J GENE MED, V4, P397, DOI 10.1002/jgm.283; Qiu GH, 2004, ONCOGENE, V23, P4793, DOI 10.1038/sj.onc.1207632; Robertson G P, 1999, Mol Cell Biol Res Commun, V2, P1, DOI 10.1006/mcbr.1999.0141; Tang BW, 1998, NAT MED, V4, P802, DOI 10.1038/nm0798-802; Xie D, 2003, INT J CANCER, V107, P896, DOI 10.1002/ijc.11514	20	105	118	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	43					6525	6532		10.1038/sj.onc.1208812	http://dx.doi.org/10.1038/sj.onc.1208812			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	968ZV	16007174				2022-12-25	WOS:000232204100006
J	Yu, YL; Chiang, YJ; Chen, YC; Papetti, M; Juo, CG; Skoultchi, AI; Yen, JJY				Yu, YL; Chiang, YJ; Chen, YC; Papetti, M; Juo, CG; Skoultchi, AI; Yen, JJY			MAPK-mediated phosphorylation of GATA-1 promotes Bcl-X-L expression and cell survival	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GATA-1; ACTIVATED PROTEIN-KINASE; HEMATOPOIETIC-CELLS; ERYTHROLEUKEMIA-CELLS; SUBSTRATE RECOGNITION; SIGNALING PATHWAY; GENE; DIFFERENTIATION; INTERLEUKIN-3; APOPTOSIS	In the interleukin 3-dependent hematopoietic cell line Ba/F3, inhibition of mitogen-activated protein kinase, a member of the MAPK/c-Jun N-terminal kinase/stress-activated protein kinase kinase family that plays an important role in cell growth and death control, rapidly leads to severe apoptosis. However, most of the antiapoptotic substrates of MAPK remain to be identified. Here we report that, upon interleukin-3 stimulation of Ba/F3 cells, the transcription factor GATA-1 is strongly phosphorylated at residue serine 26 by a MAPK-dependent pathway. Phosphorylation of GATA-1 increases GATA-1-mediated transcription of the E4bp4 survival gene without significantly changing the DNA-binding affinity of GATA-1. Further characterization of GATA-1 phosphorylation site mutants revealed that the antiapoptotic function of GATA-1 is strongly dependent upon its phosphorylation at the Ser-26 position and is probably mediated through its up-regulation of Bcl-X-L expression. Taken together, our data demonstrate that MAPK-dependent GATA-1 phosphorylation is important for its transactivation of the E4bp4 gene, Bcl-X-L expression and cell survival. Therefore, GATA-1 may represent a novel MAPK substrate that plays an essential role in a cytokine-mediated antiapoptotic response.	Acad Sinica, Inst Biomed Sci, Taipei 11529, Taiwan; Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA	Academia Sinica - Taiwan; Yeshiva University; Albert Einstein College of Medicine	Yen, JJY (corresponding author), Acad Sinica, Inst Biomed Sci, 128,Sec 2,Yen Jiou Yuan Rd, Taipei 11529, Taiwan.	bmjyen@ibms.sinica.edu.tw	Yen, Jeffrey Jong-Young/Q-5134-2018	Yen, Jeffrey Jong-Young/0000-0001-6299-1995	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL078381, F32HL077242] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL78381-30, HL077242-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Anguita E, 2004, EMBO J, V23, P2841, DOI 10.1038/sj.emboj.7600274; Chen CH, 2000, J IMMUNOL, V165, P5597, DOI 10.4049/jimmunol.165.10.5597; Choe KS, 2003, CANCER RES, V63, P6363; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; CROSSLEY M, 1994, J BIOL CHEM, V269, P16589; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; Ferby IM, 1996, J BIOL CHEM, V271, P11684, DOI 10.1074/jbc.271.20.11684; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; Gregory T, 1999, BLOOD, V94, P87, DOI 10.1182/blood.V94.1.87.413k41_87_96; Grillot DAM, 1997, J IMMUNOL, V158, P4750; Huang HM, 1999, BLOOD, V93, P2569, DOI 10.1182/blood.V93.8.2569.408k08_2569_2577; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; Kamakura S, 1999, J BIOL CHEM, V274, P26563, DOI 10.1074/jbc.274.37.26563; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; Keinanen R, 1999, GENE, V234, P297, DOI 10.1016/S0378-1119(99)00196-1; Kitta K, 2003, J BIOL CHEM, V278, P4705, DOI 10.1074/jbc.M211616200; Lee SF, 1999, MOL CELL BIOL, V19, P7399; Liang QR, 2001, MOL CELL BIOL, V21, P7460, DOI 10.1128/MCB.21.21.7460-7469.2001; Lin DY, 2002, J BIOL CHEM, V277, P25446, DOI 10.1074/jbc.M200633200; OPREY J, 1993, MOL CELL BIOL, V13, P6290, DOI 10.1128/MCB.13.10.6290; ORKIN SH, 1992, BLOOD, V80, P575; Partington GA, 1999, NUCLEIC ACIDS RES, V27, P1168, DOI 10.1093/nar/27.4.1168; PEVNY L, 1995, DEVELOPMENT, V121, P163; Rao G, 1997, ONCOGENE, V14, P123, DOI 10.1038/sj.onc.1200807; Rekhtman N, 2003, MOL CELL BIOL, V23, P7460, DOI 10.1128/MCB.23.21.7460-7474.2003; RODRIGUEZTARDUCHY G, 1990, EMBO J, V9, P2997, DOI 10.1002/j.1460-2075.1990.tb07492.x; Shivdasani RA, 1997, EMBO J, V16, P3965, DOI 10.1093/emboj/16.13.3965; Smale ST, 2001, GENE DEV, V15, P2503, DOI 10.1101/gad.937701; Tanaka H, 2000, BLOOD, V95, P1264, DOI 10.1182/blood.V95.4.1264.004k09_1264_1273; TAXMAN DJ, 1994, PROTEIN EXPRES PURIF, V5, P587, DOI 10.1006/prep.1994.1081; Towatari M, 2004, HEMATOL J, V5, P262, DOI 10.1038/sj.thj.6200345; TOWATARI M, 1995, J BIOL CHEM, V270, P4101, DOI 10.1074/jbc.270.8.4101; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; Wang JM, 2003, MOL CELL BIOL, V23, P1896, DOI 10.1128/MCB.23.6.1896-1909.2003; Wang JM, 1999, MOL CELL BIOL, V19, P6195; WEISS MJ, 1995, P NATL ACAD SCI USA, V92, P9623, DOI 10.1073/pnas.92.21.9623; Yu YL, 2002, J BIOL CHEM, V277, P27144, DOI 10.1074/jbc.M200924200; ZHANG R, 1995, J BIOL CHEM, V270, P15320, DOI 10.1074/jbc.270.25.15320	40	41	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	2005	280	33					29533	29542		10.1074/jbc.M506514200	http://dx.doi.org/10.1074/jbc.M506514200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	954SX	15967790	Green Accepted, hybrid			2022-12-25	WOS:000231176200020
J	Han, SH; Han, GS; Iwanyshyn, WM; Carman, GM				Han, SH; Han, GS; Iwanyshyn, WM; Carman, GM			Regulation of the PIS1-encoded phosphatidylinositol synthase in Saccharomyces cerevisiae by zinc	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZAP1 TRANSCRIPTIONAL ACTIVATOR; PHOSPHOLIPID BIOSYNTHESIS; SPHINGOLIPID FUNCTIONS; COORDINATE REGULATION; TRANSPORTER PROTEIN; GENETIC-REGULATION; ANCHOR SYNTHESIS; DNA-BINDING; 1ST STEP; YEAST	In the yeast Saccharomyces cerevisiae, the mineral zinc is essential for growth and metabolism. Depletion of zinc from the growth medium of wild type cells results in changes in phospholipid metabolism, including an increase in phosphatidylinositol content (Iwanyshyn, W. M., Han, G.-S., and Carman, G. M. ( 2004) J. Biol. Chem. 279, 21976 - 21983). We examined the effects of zinc depletion on the regulation of the PIS1-encoded phosphatidylinositol synthase, the enzyme that catalyzes the formation of phosphatidylinositol from CDP-diacylglycerol and inositol. Phosphatidylinositol synthase activity increased when zinc was depleted from the growth medium. Analysis of a zrt1 Delta zrt2 Delta mutant defective in plasma membrane zinc transport indicated that the cytoplasmic levels of zinc were responsible for the regulation of phosphatidylinositol synthase. PIS1 mRNA, its encoded protein Pis1p, and the beta-galactosidase activity driven by the P-PIS1-lacZ reporter gene were elevated in zinc-depleted cells. This indicated that the increase in phosphatidylinositol synthase activity was the result of a transcriptional mechanism. The zinc-mediated induction of the P-PIS1-lacZ reporter gene, Pis1p, and phosphatidylinositol synthase activity was lost in zap1 Delta mutant cells. These data indicated that the regulation of PIS1 gene expression by zinc depletion was mediated by the zinc-regulated transcription factor Zap1p. Direct interaction between glutathione S-transferase (GST)-Zap1p(687-880) and a putative upstream activating sequence (UAS) zinc-responsive element in the PIS1 promoter was demonstrated by electrophoretic mobility shift assays. Mutations in the UAS zinc-responsive element in the PIS1 promoter abolished the GST-Zap1p(687-880)-DNA interaction in vitro and abolished the zinc- mediated regulation of the PIS1 gene in vivo. This work advances understanding of phospholipid synthesis regulation by zinc and the transcription control of the PIS1 gene.	Rutgers State Univ, Dept Food Sci, Cook Coll, New Jersey Agr Expt Stn, New Brunswick, NJ 08901 USA	Rutgers State University New Brunswick	Carman, GM (corresponding author), Rutgers State Univ, Dept Food Sci, Cook Coll, New Jersey Agr Expt Stn, New Brunswick, NJ 08901 USA.	carman@aesop.rutgers.edu			NIGMS NIH HHS [R01 GM028140, R37 GM028140, GM-28140] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028140, R37GM028140] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson MS, 1996, J BIOL CHEM, V271, P26596, DOI 10.1074/jbc.271.43.26596; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; Balla T, 1998, BBA-MOL CELL BIOL L, V1436, P69, DOI 10.1016/S0005-2760(98)00134-9; BECKER GW, 1977, J BIOL CHEM, V252, P8684; Bird A, 2000, J BIOL CHEM, V275, P16160, DOI 10.1074/jbc.M000664200; Bird AJ, 2004, EMBO J, V23, P1123, DOI 10.1038/sj.emboj.7600122; Bird AJ, 2000, EMBO J, V19, P3704, DOI 10.1093/emboj/19.14.3704; Bird AJ, 2003, EMBO J, V22, P5137, DOI 10.1093/emboj/cdg484; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carman GM, 1999, PROG LIPID RES, V38, P361, DOI 10.1016/S0163-7827(99)00010-7; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; Carman GM, 1996, J BIOL CHEM, V271, P13293, DOI 10.1074/jbc.271.23.13293; CARMAN GM, 1992, METHOD ENZYMOL, V209, P305; CRAVEN GR, 1965, J BIOL CHEM, V240, P2468; Daum G, 1998, YEAST, V14, P1471, DOI 10.1002/(SICI)1097-0061(199812)14:16<1471::AID-YEA353>3.0.CO;2-Y; Dickson RC, 2002, BBA-MOL CELL BIOL L, V1583, P13, DOI 10.1016/S1388-1981(02)00210-X; Dickson RC, 1998, ANNU REV BIOCHEM, V67, P27, DOI 10.1146/annurev.biochem.67.1.27; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; Dove SK, 1997, NATURE, V390, P187, DOI 10.1038/36613; DOWNES CP, 1990, EUR J BIOCHEM, V193, P1, DOI 10.1111/j.1432-1033.1990.tb19297.x; Eide DJ, 2003, J NUTR, V133, p1532S, DOI 10.1093/jn/133.5.1532S; Ellis CD, 2004, J CELL BIOL, V166, P325, DOI 10.1083/jcb.200401157; FISCHL AS, 1986, J BIOL CHEM, V261, P3178; FISCHL AS, 1983, J BACTERIOL, V154, P304, DOI 10.1128/JB.154.1.304-311.1983; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Gardocki ME, 2003, J BIOL CHEM, V278, P38646, DOI 10.1074/jbc.M305251200; GAYNOR PM, 1991, BIOCHIM BIOPHYS ACTA, V1090, P326, DOI 10.1016/0167-4781(91)90197-T; Gehrmann T, 1998, EUR J BIOCHEM, V253, P357, DOI 10.1046/j.1432-1327.1998.2530357.x; Greenberg ML, 1996, MICROBIOL REV, V60, P1; Griac P, 1999, NUCLEIC ACIDS RES, V27, P2043, DOI 10.1093/nar/27.9.2043; Habeler G, 2002, NUCLEIC ACIDS RES, V30, P80, DOI 10.1093/nar/30.1.80; HAID A, 1983, METHOD ENZYMOL, V96, P192; Han GS, 2001, J BIOL CHEM, V276, P10126, DOI 10.1074/jbc.M011421200; Harlow E., 1988, ANTIBODIES LAB MANUA; Henry S. A., 1982, MOL BIOL YEAST SACCH, P101; Henry SA, 1998, PROG NUCLEIC ACID RE, V61, P133, DOI 10.1016/S0079-6603(08)60826-0; HENRY SA, 1977, J BACTERIOL, V130, P472, DOI 10.1128/JB.130.1.472-484.1977; HERRICK D, 1990, MOL CELL BIOL, V10, P2269, DOI 10.1128/MCB.10.5.2269; HOMANN MJ, 1987, J BACTERIOL, V169, P533, DOI 10.1128/jb.169.2.533-539.1987; Innis MA, 1990, PCR PROTOCOLS GUIDE, P3; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Iwanyshyn WM, 2004, J BIOL CHEM, V279, P21976, DOI 10.1074/jbc.M402047200; KELLEY MJ, 1988, J BIOL CHEM, V263, P18078; Kersting MC, 2004, J BIOL CHEM, V279, P35353, DOI 10.1074/jbc.M405704200; KLIG LS, 1985, J BACTERIOL, V162, P1135, DOI 10.1128/JB.162.3.1135-1141.1985; KODAKI T, 1991, J BIOCHEM-TOKYO, V109, P276; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEIDICH SD, 1994, J BIOL CHEM, V269, P10193; Leidich SD, 1996, J BIOL CHEM, V271, P27829, DOI 10.1074/jbc.271.44.27829; LESTER RL, 1993, ADV LIPID RES, V26, P253; Loewen CJR, 2004, SCIENCE, V304, P1644, DOI 10.1126/science.1096083; Lyons TJ, 2000, P NATL ACAD SCI USA, V97, P7957, DOI 10.1073/pnas.97.14.7957; MacDiarmid CW, 2003, J BIOL CHEM, V278, P15065, DOI 10.1074/jbc.M300568200; MacDiarmid CW, 2000, EMBO J, V19, P2845, DOI 10.1093/emboj/19.12.2845; Miyabe S, 2000, BIOCHEM BIOPH RES CO, V276, P879, DOI 10.1006/bbrc.2000.3580; MORASH SC, 1994, J BIOL CHEM, V269, P28769; Nikawa J, 1997, BBA-LIPID LIPID MET, V1348, P173, DOI 10.1016/S0005-2760(97)00103-3; NIKAWA J, 1984, EUR J BIOCHEM, V143, P251, DOI 10.1111/j.1432-1033.1984.tb08366.x; NIKAWA J, 1987, J BIOL CHEM, V262, P4876; Odom AR, 2000, SCIENCE, V287, P2026, DOI 10.1126/science.287.5460.2026; Odorizzi G, 2000, TRENDS BIOCHEM SCI, V25, P229, DOI 10.1016/S0968-0004(00)01543-7; Oteiza PL, 1996, P SOC EXP BIOL MED, V213, P85, DOI 10.3181/00379727-213-44040; PALTAUF F, 1992, MOL CELLULAR BIOL YE, P415; PAULUS H, 1960, J BIOL CHEM, V235, P1303; RATTRAY JBM, 1975, BACTERIOL REV, V39, P197, DOI 10.1128/MMBR.39.3.197-231.1975; Rose MD., 1990, METHODS YEAST GENETI; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SCHWABE JWR, 1994, NAT STRUCT BIOL, V1, P345, DOI 10.1038/nsb0694-345; SIKORSKI RS, 1989, GENETICS, V122, P19; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; VALLEE BL, 1993, PHYSIOL REV, V73, P79, DOI 10.2466/pr0.1993.73.1.79; WALSH CT, 1994, ENVIRON HEALTH PERSP, V102, P5, DOI 10.2307/3431820; Waters BM, 2002, J BIOL CHEM, V277, P33749, DOI 10.1074/jbc.M206214200; WHITE MJ, 1991, ADV MICROB PHYSIOL, V32, P1, DOI 10.1016/S0065-2911(08)60004-1; Zhao H, 1998, J BIOL CHEM, V273, P28713, DOI 10.1074/jbc.273.44.28713; Zhao H, 1997, MOL CELL BIOL, V17, P5044, DOI 10.1128/MCB.17.9.5044; Zhao H, 1996, J BIOL CHEM, V271, P23203, DOI 10.1074/jbc.271.38.23203; Zhao H, 1996, P NATL ACAD SCI USA, V93, P2454, DOI 10.1073/pnas.93.6.2454	79	35	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	2005	280	32					29017	29024		10.1074/jbc.M505881200	http://dx.doi.org/10.1074/jbc.M505881200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	952QT	15980062	hybrid, Green Accepted			2022-12-25	WOS:000231021300025
J	Himes, SR; Cronau, S; Mulford, C; Hume, DA				Himes, SR; Cronau, S; Mulford, C; Hume, DA			The Runx1 transcription factor controls CSF-1-dependent and -independent growth and survival of macrophages	ONCOGENE			English	Article						Runx1; macrophage; CSF-1; survival	CORE-BINDING-FACTOR; ACUTE MYELOMONOCYTIC LEUKEMIA; AML1/ETO FUSION TRANSCRIPT; ACUTE MYELOGENOUS LEUKEMIA; FETAL LIVER HEMATOPOIESIS; ACUTE MYELOID-LEUKEMIA; MYOSIN HEAVY-CHAIN; C-FMS; FACTOR BETA; DEFINITIVE HEMATOPOIESIS	Gene translocations that repress the function of the Runx1 transcription factor play a critical role in the development of myeloid leukemia. In this report, we demonstrate that Runx1 precisely regulates c-fms (CSF-1 receptor) gene expression. Runx1 controlled expression by binding to multiple sites within the mouse c-fms gene, allowing interaction between promoter and downstream enhancer elements. The runx1 and c-fms genes showed an identical pattern of expression in mature macrophages. Runx1 expression was repressed in CSF-1 stimulated, proliferating bone marrow-derived macrophages (BMM) and significantly increased in quiescent, CSF-1 starved cells. The RAW264.7 and Mono-Mac-6, macrophage-like cell lines expressed low levels of Runx1 and both showed growth arrest and cell death with ectopic expression of Runx1. The EM-3 cell line, which represents an early myeloid progenitor cell line, showed growth arrest with Runx1 expression in the absence of any detectable changes in cell differentiation. These findings suggest that Runx1 regulates growth and survival of myeloid cells and provide a novel insight into the role of Runx family gene translocations in leukemogenesis.	Univ Queensland, Inst Mol Biosci, CRC Chron Inflammatory Dis, Queensland Biosci Precint, Brisbane, Qld 4072, Australia	University of Queensland	Hume, DA (corresponding author), Univ Queensland, Inst Mol Biosci, CRC Chron Inflammatory Dis, Queensland Biosci Precint, Bldg 80,Serv Rd, Brisbane, Qld 4072, Australia.	d.hume@imb.uq.edu.au	Hume, David A/C-7695-2013	Hume, David/0000-0002-2615-1478				Adya N, 1998, MOL CELL BIOL, V18, P7432, DOI 10.1128/MCB.18.12.7432; Castilla LH, 1999, NAT GENET, V23, P144, DOI 10.1038/13776; Cecchini MG, 1997, MOL REPROD DEV, V46, P75; Cochet O, 1998, MOL IMMUNOL, V35, P1097, DOI 10.1016/S0161-5890(98)00105-9; Dai XM, 2002, BLOOD, V99, P111, DOI 10.1182/blood.V99.1.111; DOWNING JR, 1993, BLOOD, V81, P2860; Follows GA, 2003, EMBO J, V22, P2798, DOI 10.1093/emboj/cdg250; Fukamachi H, 2004, ONCOGENE, V23, P4330, DOI 10.1038/sj.onc.1207121; Hiebert SW, 2001, CANCER CHEMOTH PHARM, V48, pS31, DOI 10.1007/s002800100302; Himes SR, 2001, J LEUKOCYTE BIOL, V70, P812; Hume DA, 1997, MOL REPROD DEV, V46, P46; Ichikawa M, 2004, NAT MED, V10, P299, DOI 10.1038/nm997; Levanon D, 2003, BLOOD CELL MOL DIS, V30, P161, DOI 10.1016/S1079-9796(03)00023-8; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Linggi B, 2002, NAT MED, V8, P743, DOI 10.1038/nm726; Lutterbach B, 2000, GENE, V245, P223, DOI 10.1016/S0378-1119(00)00014-7; MARUYAMA F, 1993, CANCER RES, V53, P4449; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; Mulloy JC, 2002, BLOOD, V99, P15, DOI 10.1182/blood.V99.1.15; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Okuda T, 1998, BLOOD, V91, P3134, DOI 10.1182/blood.V91.9.3134.3134_3134_3143; Petrovick HS, 1998, MOL CELL BIOL, V18, P3915, DOI 10.1128/MCB.18.7.3915; Sasaki K, 1996, P NATL ACAD SCI USA, V93, P12359, DOI 10.1073/pnas.93.22.12359; Sasmono RT, 2003, BLOOD, V101, P1155, DOI 10.1182/blood-2002-02-0569; SATAKE M, 1992, JPN J CANCER RES, V83, P714, DOI 10.1111/j.1349-7006.1992.tb01971.x; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; Sudo T, 1995, ONCOGENE, V11, P2469; Tagoh H, 2002, GENE DEV, V16, P1721, DOI 10.1101/gad.222002; THOMPSON PW, 1991, CANCER GENET CYTOGEN, V55, P269, DOI 10.1016/0165-4608(91)90089-D; Tracey WD, 2000, SEMIN CELL DEV BIOL, V11, P337, DOI 10.1006/scdb.2000.0186; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG SW, 1992, MOL CELL BIOL, V12, P89, DOI 10.1128/MCB.12.1.89; Yang YD, 2002, CANCER RES, V62, P2232; Zhang DE, 1996, CURR TOP MICROBIOL, V211, P137; Zhang DE, 1996, MOL CELL BIOL, V16, P1231	36	36	37	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 11	2005	24	34					5278	5286		10.1038/sj.onc.1208657	http://dx.doi.org/10.1038/sj.onc.1208657			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	954MF	16007221	Bronze			2022-12-25	WOS:000231158500002
J	Gombart, AF; Borregaard, N; Koeffler, HP				Gombart, AF; Borregaard, N; Koeffler, HP			Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin D-3	FASEB JOURNAL			English	Article						sepsis; wound healing; monocytes; VDRE	C/EBP-EPSILON; ANTIBACTERIAL PEPTIDES; HUMAN KERATINOCYTES; GRANULE DEFICIENCY; SEMINAL PLASMA; GENOME BROWSER; CUTTING EDGE; HOST-DEFENSE; HUMAN CAP18; EXPRESSION	The innate immune system of mammals provides a rapid response to repel assaults from numerous infectious agents including bacteria, viruses, fungi, and parasites. A major component of this system is a diverse combination of cationic antimicrobial peptides that include the alpha- and beta-defensins and cathelicidins. In this study, we show that 1,25-dihydroxyvitamin D-3 and three of its analogs induced expression of the human cathelicidin antimicrobial peptide (CAMP) gene. This induction was observed in acute myeloid leukemia (AML), immortalized keratinocyte, and colon cancer cell lines, as well as normal human bone marrow (BM)-derived macrophages and fresh BM cells from two normal individuals and one AML patient. The induction occurred via a consensus vitamin D response element (VDRE) in the CAMP promoter that was bound by the vitamin D receptor (VDR). Induction of CAMP in murine cells was not observed and expression of CAMP mRNA in murine VDR-deficient bone marrow was similar to wild-type levels. Comparison of mammalian genomes revealed evolutionary conservation of the VDRE in a short interspersed nuclear element or SINE in the CAMP promoter of primates that was absent in the mouse, rat, and canine genomes. Our findings reveal a novel activity of 1,25-dihydroxyvitamin D3 and the VDR in regulation of primate innate immunity.	Univ Calif Los Angeles, Div Hematol Oncol, David Geffen Sch Med, Dept Med,Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA; Univ Copenhagen, Rigshosp, Dept Hematol, DK-2100 Copenhagen, Denmark	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Rigshospitalet; University of Copenhagen	Gombart, AF (corresponding author), Univ Calif Los Angeles, Div Hematol Oncol, David Geffen Sch Med, Dept Med,Cedars Sinai Med Ctr, Davis Bldg 5019,8700 Beverly Blvd, Los Angeles, CA 90048 USA.	gombarta@csmc.edu	Gombart, Adrian/AAV-4738-2020	Gombart, Adrian/0000-0001-7830-0693	NCI NIH HHS [CA26038-20] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA026038] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agerberth B, 2000, BLOOD, V96, P3086, DOI 10.1182/blood.V96.9.3086.h8003086_3086_3093; Anderson E, 2002, HUM REPROD, V17, P2529, DOI 10.1093/humrep/17.10.2529; Andreu D, 1998, BIOPOLYMERS, V47, P415, DOI 10.1002/(SICI)1097-0282(1998)47:6<415::AID-BIP2>3.0.CO;2-D; Armogida SA, 2004, ALLERGY ASTHMA PROC, V25, P297; Bals R, 1999, J CLIN INVEST, V103, P1113, DOI 10.1172/JCI6570; Bals R, 1998, P NATL ACAD SCI USA, V95, P9541, DOI 10.1073/pnas.95.16.9541; Bals R, 1999, INFECT IMMUN, V67, P6084, DOI 10.1128/IAI.67.11.6084-6089.1999; Boman HG, 2003, J INTERN MED, V254, P197, DOI 10.1046/j.1365-2796.2003.01228.x; Carlberg C, 1998, CRIT REV EUKAR GENE, V8, P19, DOI 10.1615/CritRevEukarGeneExpr.v8.i1.20; Chumakov AM, 1997, MOL CELL BIOL, V17, P1375, DOI 10.1128/MCB.17.3.1375; Di Nardo A, 2003, J IMMUNOL, V170, P2274, DOI 10.4049/jimmunol.170.5.2274; Dorschner RA, 2001, J INVEST DERMATOL, V117, P91, DOI 10.1046/j.1523-1747.2001.01340.x; Erdag G, 2002, ANN SURG, V235, P113, DOI 10.1097/00000658-200201000-00015; Frohm M, 1997, J BIOL CHEM, V272, P15258, DOI 10.1074/jbc.272.24.15258; Frohm M, 1996, EUR J BIOCHEM, V237, P86, DOI 10.1111/j.1432-1033.1996.0086n.x; Gombart AF, 2002, BLOOD, V99, P1332, DOI 10.1182/blood.V99.4.1332; Gombart AF, 2002, CURR OPIN HEMATOL, V9, P36, DOI 10.1097/00062752-200201000-00007; Gombart AF, 2001, BLOOD, V97, P2561, DOI 10.1182/blood.V97.9.2561; Hammami-Hamza S, 2001, MOL HUM REPROD, V7, P625, DOI 10.1093/molehr/7.7.625; Hancock R. E. W., 2002, Current Drug Targets - Infectious Disorders, V2, P79, DOI 10.2174/1568005024605855; Hancock REW, 2000, P NATL ACAD SCI USA, V97, P8856, DOI 10.1073/pnas.97.16.8856; Hancock REW, 1998, TRENDS BIOTECHNOL, V16, P82, DOI 10.1016/S0167-7799(97)01156-6; Hancock REW, 2000, TRENDS MICROBIOL, V8, P402, DOI 10.1016/S0966-842X(00)01823-0; Hase K, 2003, GASTROENTEROLOGY, V125, P1613, DOI 10.1053/j.gastro.2003.08.028; Hase K, 2002, INFECT IMMUN, V70, P953, DOI 10.1128/IAI.70.2.953-963.2002; Hayes CE, 2003, CELL MOL BIOL, V49, P277; Islam D, 2001, NAT MED, V7, P180, DOI 10.1038/84627; Karolchik D, 2003, NUCLEIC ACIDS RES, V31, P51, DOI 10.1093/nar/gkg129; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; KHANNAGUPTA A, 1994, BLOOD, V84, P294; Kirikae T, 1998, INFECT IMMUN, V66, P1861, DOI 10.1128/IAI.66.5.1861-1868.1998; KOEFFLER HP, 1983, BLOOD, V62, P709; Larrick JW, 1996, FEBS LETT, V398, P74, DOI 10.1016/S0014-5793(96)01199-4; LARRICK JW, 1995, INFECT IMMUN, V63, P1291, DOI 10.1128/IAI.63.4.1291-1297.1995; Lehrer RI, 2002, CURR OPIN HEMATOL, V9, P18, DOI 10.1097/00062752-200201000-00004; Lehrer RI, 1999, CURR OPIN IMMUNOL, V11, P23, DOI 10.1016/S0952-7915(99)80005-3; Malm J, 2000, INFECT IMMUN, V68, P4297, DOI 10.1128/IAI.68.7.4297-4302.2000; Martin GS, 2003, NEW ENGL J MED, V348, P1546, DOI 10.1056/NEJMoa022139; Murakami M, 2005, PEDIATR RES, V57, P10, DOI 10.1203/01.PDR.0000148068.32201.50; Murakami M, 2002, J DENT RES, V81, P845, DOI 10.1177/154405910208101210; Murakami M, 2002, J INVEST DERMATOL, V119, P1090, DOI 10.1046/j.1523-1747.2002.19507.x; Nilsson MF, 1999, INFECT IMMUN, V67, P2561, DOI 10.1128/IAI.67.5.2561-2566.1999; Nizet V, 2001, NATURE, V414, P454, DOI 10.1038/35106587; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; PERL TM, 1995, JAMA-J AM MED ASSOC, V274, P338, DOI 10.1001/jama.274.4.338; Putsep K, 2002, LANCET, V360, P1144, DOI 10.1016/S0140-6736(02)11201-3; Quartin AA, 1997, JAMA-J AM MED ASSOC, V277, P1058, DOI 10.1001/jama.277.13.1058; Schauber J, 2003, GUT, V52, P735, DOI 10.1136/gut.52.5.735; Scott MG, 2002, J IMMUNOL, V169, P3883, DOI 10.4049/jimmunol.169.7.3883; Seow WK, 2003, AUST DENT J, V48, P156, DOI 10.1111/j.1834-7819.2003.tb00026.x; Sorensen O, 1997, BLOOD, V90, P2796; Sorensen O, 1997, J IMMUNOL METHODS, V206, P53, DOI 10.1016/S0022-1759(97)00084-7; Sorensen OE, 2003, J IMMUNOL, V170, P5583, DOI 10.4049/jimmunol.170.11.5583; Tavor S, 2002, BLOOD, V99, P1794, DOI 10.1182/blood.V99.5.1794; Toell A, 2000, BIOCHEM J, V352, P301, DOI 10.1042/0264-6021:3520301; Tsukasaki K, 2004, INT J CANCER, V109, P875, DOI 10.1002/ijc.20028; Turner J, 1998, ANTIMICROB AGENTS CH, V42, P2206, DOI 10.1128/AAC.42.9.2206; VANDERMEER TJ, 1995, SURGERY, V117, P656, DOI 10.1016/S0039-6060(95)80009-3; Verbeek W, 1999, BLOOD, V94, P3141, DOI 10.1182/blood.V94.9.3141.421k41_3141_3150; Wang TT, 2004, J IMMUNOL, V173, P2909, DOI 10.4049/jimmunol.173.5.2909; White JH, 2004, J STEROID BIOCHEM, V89-90, P239, DOI 10.1016/j.jsbmb.2004.03.074; Yoshizawa T, 1997, NAT GENET, V16, P391, DOI 10.1038/ng0897-391; Zasloff M, 2002, LANCET, V360, P1116, DOI 10.1016/S0140-6736(02)11239-6; Zasloff M, 2002, NEW ENGL J MED, V347, P1199, DOI 10.1056/NEJMe020106	65	779	812	1	50	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2005	19	9					1067	1077		10.1096/fj.04-3284com	http://dx.doi.org/10.1096/fj.04-3284com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	951IO	15985530				2022-12-25	WOS:000230923000035
J	Ghosh, MK; Sharma, P; Harbor, PC; O Rahaman, S; Haque, SJ				Ghosh, MK; Sharma, P; Harbor, PC; O Rahaman, S; Haque, SJ			PI3K-AKT pathway negatively controls EGFR-dependent DNA-binding activity of Stat3 in glioblastoma multiforme cells	ONCOGENE			English	Article						glioblastoma multiforme; apoptosis; Stat3; AKT; EGFR	EPIDERMAL-GROWTH-FACTOR; PROTEIN-KINASE-B; FACTOR RECEPTOR GENE; CONSTITUTIVE ACTIVATION; MOLECULAR-MECHANISMS; MALIGNANT GLIOMA; PHOSPHATASE 2A; EXPRESSION; APOPTOSIS; TYROSINE	Glioblastoma multiforme (GBM) cells frequently harbor amplification and/or gain-of-function mutation of the EGFR gene leading to the activation of mul tiple signaling pathways. Blockade of EGFR activation inhibited the activation of both AKT and Stat3 in U87 and D54 GBM cells and induced spontaneous apoptosis, which were associated with reduction in the steady-state level of Mcl-1. Surprisingly, inhibition of PI3 kinase (PI3K) activity, which in turn inhibited AKT activation, significantly increased the DNA-binding activity of Stat3 in U87 and D54 cells. This was not due to an increase in the level of tyrosine-phosphorylated Stat3. Conversely, ectopic expression of constitutively activated AKT significantly decreased the DNA-binding activity of Stat3 in 293T cells. Interestingly, blockade of protein phosphatase 2A activity in GBM or 293T cells by calyculin A, which activated AKT, stabilized the phosphorylation of mul tiple Ser/Thr residues that were located in the transactivation domain (TAD) of Stat3 and this in turn completely ablated the DNA-binding activity of Stat3. Collectively, these results suggest that both Stat3 and AKT provide survival signals in U87 and D54 cells, and Ser/Thr phosphorylation of Stat3-TAD by the PI3K-AKT pathway negatively controls the DNA-binding function of Stat3.	Cleveland Clin Fdn, Dept Canc Biol, Lerner Res Inst, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Brain Tumor Inst, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Pulm & Crit Care Med, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Haque, SJ (corresponding author), Cleveland Clin Fdn, Dept Canc Biol, Lerner Res Inst, NB4-85,9500 Euclid Ave, Cleveland, OH 44195 USA.	haquej@ccf.org	Sharma, Pankaj/AAH-7468-2019; sharma, pankaj/HGE-4423-2022	Sharma, Pankaj/0000-0001-7405-1706; 	NATIONAL CANCER INSTITUTE [R01CA095006] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060533] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA095006] Funding Source: Medline; NIGMS NIH HHS [R01-GM60533] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aldape KD, 2004, J NEUROPATH EXP NEUR, V63, P700, DOI 10.1093/jnen/63.7.700; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; Ballif BA, 2001, CELL GROWTH DIFFER, V12, P397; Brivanlou AH, 2002, SCIENCE, V295, P813, DOI 10.1126/science.1066355; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chen XM, 1998, CELL, V93, P827, DOI 10.1016/S0092-8674(00)81443-9; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; DiDonato JA, 2000, METHOD ENZYMOL, V322, P393; EKSTRAND AJ, 1991, CANCER RES, V51, P2164; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; Fukuchi K, 2000, BBA-MOL CELL RES, V1496, P207, DOI 10.1016/S0167-4889(00)00018-5; Ghosh MK, 2003, MOL CELL, V12, P255, DOI 10.1016/S1097-2765(03)00225-9; Goswami S, 1998, J NEUROCHEM, V71, P1837; Grandis JR, 2000, P NATL ACAD SCI USA, V97, P4227, DOI 10.1073/pnas.97.8.4227; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Haque SJ, 1997, P NATL ACAD SCI USA, V94, P8563, DOI 10.1073/pnas.94.16.8563; Haque SJ, 2000, J BIOL CHEM, V275, P26500, DOI 10.1074/jbc.275.34.26500; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Holland EC, 2000, P NATL ACAD SCI USA, V97, P6242, DOI 10.1073/pnas.97.12.6242; Kaptein A, 1996, J BIOL CHEM, V271, P5961, DOI 10.1074/jbc.271.11.5961; Kortylewski M, 2003, J BIOL CHEM, V278, P5242, DOI 10.1074/jbc.M205403200; Maher EA, 2001, GENE DEV, V15, P1311, DOI 10.1101/gad.891601; MAITI NR, 2005, IN PRESS J INTERFERO; Meier R, 1998, EMBO J, V17, P7294, DOI 10.1093/emboj/17.24.7294; Pieper AA, 1999, TRENDS PHARMACOL SCI, V20, P171, DOI 10.1016/S0165-6147(99)01292-4; Rahaman SO, 2002, ONCOGENE, V21, P8404, DOI 10.1038/sj.onc.1206047; Rahaman SO, 2005, CANCER RES, V65, P2956, DOI 10.1158/0008-5472.CAN-04-3592; Rao JS, 2003, NAT REV CANCER, V3, P489, DOI 10.1038/nrc1121; Rasheed B K, 1999, Curr Opin Oncol, V11, P162; Resjo S, 2002, CELL SIGNAL, V14, P231, DOI 10.1016/S0898-6568(01)00238-8; Rolhion C, 2001, J NEUROSURG, V94, P97, DOI 10.3171/jns.2001.94.1.0097; Singh SK, 2004, ONCOGENE, V23, P7267, DOI 10.1038/sj.onc.1207946; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Sonoda Y, 1999, J BIOL CHEM, V274, P10566, DOI 10.1074/jbc.274.15.10566; Tchirkov A, 2001, BRIT J CANCER, V85, P518, DOI 10.1054/bjoc.2001.1942; VAN MEIR E, 1990, CANCER RES, V50, P6683; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; Wechsler-Reya R, 2001, ANNU REV NEUROSCI, V24, P385, DOI 10.1146/annurev.neuro.24.1.385; Weissenberger J, 2004, ONCOGENE, V23, P3308, DOI 10.1038/sj.onc.1207455; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Woetmann A, 1999, P NATL ACAD SCI USA, V96, P10620, DOI 10.1073/pnas.96.19.10620; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899; Wu YJ, 2004, J CELL SCI, V117, P2227, DOI 10.1242/jcs.01057; Yonezawa K, 2003, CURR TOP MICROBIOL, V279, P271; ZHONG Z, 1994, P NATL ACAD SCI USA, V91, P4806, DOI 10.1073/pnas.91.11.4806; Zhu YA, 2002, NAT REV CANCER, V2, P616, DOI 10.1038/nrc866	52	46	52	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2005	24	49					7290	7300		10.1038/sj.onc.1208894	http://dx.doi.org/10.1038/sj.onc.1208894			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	982FA	16007122				2022-12-25	WOS:000233142100005
J	Diao, JY; Asghar, Z; Chan, CB; Wheeler, MB				Diao, JY; Asghar, Z; Chan, CB; Wheeler, MB			Glucose-regulated glucagon secretion requires insulin receptor expression in pancreatic alpha-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; ACTIVATED PROTEIN-KINASE; SWITCH-OFF HYPOTHESIS; ISLET BETA-CELL; DIABETES-MELLITUS; ENDOCRINE PANCREAS; SIGNAL-TRANSDUCTION; MAMMALIAN TARGET; GENE-EXPRESSION; TRANSGENIC MICE	The insulin receptor (IR) and its signaling appear to be essential for insulin secretion from pancreatic beta-cells. However, much less is known about the role of the IR in alpha-cells. To assess the role of the IR in glucagon and insulin secretion, we engineered adenoviruses for high efficiency small interference RNA ( siRNA)-IR expression in isolated mouse pancreatic islets and lentiviruses for siRNA-IR expression in pancreatic alpha- and beta-cell lines (alpha-TC6 and MIN6) with specific, long term stable IR knockdown. Western blot analysis showed that these strategies resulted in 60 - 80% reduction of IR protein in islets and alpha- and beta-cell lines. Cell growth was reduced by 35 - 50% in alpha-TC and MIN6 cells stably expressing siRNA-IR, respectively. Importantly, glucagon secretion, in response to glucose ( 25 to 2.8 mM), was completely abolished in islets expressing siRNA-IR, whereas secretion increased 1.7-fold in islets expressing control siRNA. In contrast, there was no difference in glucose-stimulated insulin secretion when comparing siRNA-IR and siRNA control, with both groups showing a 1.7-fold increase. Islet glucagon and insulin content were also unaffected by IR knockdown. To further explore the role of the IR, siRNA-IR was stably expressed in pancreatic cell lines, which dramatically suppressed glucose-regulated glucagon secretion in alpha-TC6 cells (3.4-fold) but did not affect GSIS in MIN6 cells. Defects in siRNA-IR-expressing alpha-cells were associated with an alteration in the activity of Akt and p70(S6K) where insulin-induced phosphorylation of protein kinase B/AKt was greatly reduced while p70(S6K) activation was enhanced, suggesting that the related pathways play important roles in alpha cell function. This study provides direct evidence that appropriate expression of the IR in alpha-cells is required for glucose-dependent glucagon secretion.	Univ Toronto, Dept Physiol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Med, Toronto, ON M5S 1A8, Canada; Univ Prince Edward Isl, Atlantic Vet Coll, Dept Biomed Sci, Charlottetown, PE C1A 4P3, Canada	University of Toronto; University of Toronto; University of Prince Edward Island	Wheeler, MB (corresponding author), Univ Toronto, Dept Physiol, 1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.	michael.wheeler@utoronto.ca	Chan, Catherine/C-1162-2011	Chan, Catherine/0000-0003-3882-0592; Wheeler, Michael B./0000-0002-7480-7267; Asghar Shyr, Zeenat/0000-0001-8710-9938				Aguirre V, 2000, J BIOL CHEM, V275, P9047, DOI 10.1074/jbc.275.12.9047; Antinozzi PA, 1999, ANNU REV NUTR, V19, P511, DOI 10.1146/annurev.nutr.19.1.511; Ashcroft F, 2004, HUM MOL GENET, V13, pR21, DOI 10.1093/hmg/ddh066; ASPLIN CM, 1981, J CLIN INVEST, V68, P314, DOI 10.1172/JCI110251; Ayuso E, 2004, HUM GENE THER, V15, P805, DOI 10.1089/1043034041648426; BAETENS D, 1979, SCIENCE, V206, P1323, DOI 10.1126/science.390711; Bain JR, 2004, DIABETES, V53, P2190, DOI 10.2337/diabetes.53.9.2190; Bell GI, 2001, NATURE, V414, P788, DOI 10.1038/414788a; Bhanot S, 1999, AM J PHYSIOL-ENDOC M, V277, pE299, DOI 10.1152/ajpendo.1999.277.2.E299; BOLLI G, 1983, DIABETES, V32, P134, DOI 10.2337/diabetes.32.2.134; BRUBAKER PL, 1992, J BIOL CHEM, V267, P20728; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; CAPRIO S, 1993, DIABETES, V42, P550, DOI 10.2337/diabetes.42.4.550; Chan CB, 1999, DIABETES, V48, P1482, DOI 10.2337/diabetes.48.7.1482; Cline GW, 2002, DIABETES, V51, P2903, DOI 10.2337/diabetes.51.10.2903; Coghlan MP, 2000, CHEM BIOL, V7, P793, DOI 10.1016/S1074-5521(00)00025-9; Cohen P, 1999, PHILOS T R SOC B, V354, P485, DOI 10.1098/rstb.1999.0399; Coutant A, 2002, HEPATOLOGY, V36, P1079, DOI 10.1053/jhep.2002.36160; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DA S, 2004, BIOCHEM J, V377, P149; Del Prato S, 2004, HORM METAB RES, V36, P775, DOI 10.1055/s-2004-826163; Dennis PB, 2001, SCIENCE, V294, P1102, DOI 10.1126/science.1063518; Dickson LM, 2004, AM J PHYSIOL-ENDOC M, V287, pE192, DOI 10.1152/ajpendo.00031.2004; Edlund H, 1999, CURR OPIN CELL BIOL, V11, P663, DOI 10.1016/S0955-0674(99)00033-2; Fingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542; Fisher TL, 2004, CURR BIOL, V14, pR1005, DOI 10.1016/j.cub.2004.11.024; FRIESEN SR, 1982, NEW ENGL J MED, V306, P580, DOI 10.1056/NEJM198203113061005; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; GERICH J, 1980, METABOLISM, V29, P1164, DOI 10.1016/0026-0495(80)90026-8; GERICH JE, 1973, SCIENCE, V182, P171, DOI 10.1126/science.182.4108.171; GREENBAUM CJ, 1991, J CLIN INVEST, V88, P767, DOI 10.1172/JCI115375; Gromada J, 2004, DIABETES, V53, pS181, DOI 10.2337/diabetes.53.suppl_3.S181; HAMAGUCHI K, 1990, DIABETES, V39, P415, DOI 10.2337/diabetes.39.4.415; Hara M, 2003, AM J PHYSIOL-ENDOC M, V284, pE177, DOI 10.1152/ajpendo.00321.2002; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; Harrington LS, 2004, J CELL BIOL, V166, P213, DOI 10.1083/jcb.200403069; Hayashi M, 2003, DIABETES, V52, P2066, DOI 10.2337/diabetes.52.8.2066; Hirosumi J, 2002, NATURE, V420, P333, DOI 10.1038/nature01137; Hope KM, 2004, DIABETES, V53, P1488, DOI 10.2337/diabetes.53.6.1488; Ishihara H, 2003, NAT CELL BIOL, V5, P330, DOI 10.1038/ncb951; Joseph JW, 2004, J BIOL CHEM, V279, P51049, DOI 10.1074/jbc.M409189200; Kemp BE, 1999, TRENDS BIOCHEM SCI, V24, P22, DOI 10.1016/S0968-0004(98)01340-1; Kimura N, 2003, GENES CELLS, V8, P65, DOI 10.1046/j.1365-2443.2003.00615.x; Kitamura T, 2003, ANNU REV PHYSIOL, V65, P313, DOI 10.1146/annurev.physiol.65.092101.142540; Lee YH, 2003, J BIOL CHEM, V278, P2896, DOI 10.1074/jbc.M208359200; Lim HK, 2003, J BIOL CHEM, V278, P45117, DOI 10.1074/jbc.M303789200; MacDonald PE, 2002, J BIOL CHEM, V277, P44938, DOI 10.1074/jbc.M205532200; MacDonald PE, 2001, MOL ENDOCRINOL, V15, P1423, DOI 10.1210/me.15.8.1423; MARUYAMA H, 1984, J CLIN INVEST, V74, P2296, DOI 10.1172/JCI111658; Mizusawa N, 2004, GENE, V331, P53, DOI 10.1016/j.gene.2004.01.016; MORRICE NA, 1994, J BIOL CHEM, V269, P20040; Nandi A, 2004, PHYSIOL REV, V84, P623, DOI 10.1152/physrev.00032.2003; Narushima M, 2004, ASAIO J, V50, P586, DOI 10.1097/01.MAT.0000142877.18621.BC; Neshat MS, 2001, P NATL ACAD SCI USA, V98, P10314, DOI 10.1073/pnas.171076798; Ohsugi M, 2005, J BIOL CHEM, V280, P4992, DOI 10.1074/jbc.M411727200; PALMER RH, 1995, J BIOL CHEM, V270, P22412, DOI 10.1074/jbc.270.38.22412; Pende M, 2000, NATURE, V408, P994, DOI 10.1038/35050135; PORTE D, 1995, CLIN INVEST MED, V18, P247; Radimerski T, 2002, GENE DEV, V16, P2627, DOI 10.1101/gad.239102; Raju B, 2005, DIABETES, V54, P757, DOI 10.2337/diabetes.54.3.757; RASKIN P, 1975, J CLIN INVEST, V56, P1132, DOI 10.1172/JCI108188; Ravier MA, 2005, DIABETES, V54, P1789, DOI 10.2337/diabetes.54.6.1789; Rhodes CJ, 2002, EUR J CLIN INVEST, V32, P3, DOI 10.1046/j.1365-2362.32.s3.2.x; RORSMAN P, 1989, NATURE, V341, P233, DOI 10.1038/341233a0; SAMOLS E, 1988, J CLIN INVEST, V82, P350, DOI 10.1172/JCI113593; Segel SA, 2002, DIABETES, V51, P724, DOI 10.2337/diabetes.51.3.724; Shah OJ, 2004, CURR BIOL, V14, P1650, DOI 10.1016/j.cub.2004.08.026; Shamji AF, 2003, MOL CELL, V12, P271, DOI 10.1016/j.molcel.2003.08.016; Shaw RJ, 2004, CANCER CELL, V6, P91, DOI 10.1016/j.ccr.2004.06.007; TEITELMAN G, 1993, DEVELOPMENT, V118, P1031; Thomas G, 2002, BIOL RES, V35, P305, DOI 10.4067/S0716-97602002000200022; Ueno M, 2005, DIABETOLOGIA, V48, P506, DOI 10.1007/s00125-004-1662-6; Um SH, 2004, NATURE, V431, P200, DOI 10.1038/nature02866; Volarevic S, 2000, SCIENCE, V288, P2045, DOI 10.1126/science.288.5473.2045; Wendt A, 2004, DIABETES, V53, P1038, DOI 10.2337/diabetes.53.4.1038; Yoshimitsu M, 2004, P NATL ACAD SCI USA, V101, P16909, DOI 10.1073/pnas.0407572101; Zhou HR, 2004, DIABETES, V53, P1482, DOI 10.2337/diabetes.53.6.1482	78	68	75	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	2005	280	39					33487	33496		10.1074/jbc.M506276200	http://dx.doi.org/10.1074/jbc.M506276200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	966YG	16027126	hybrid			2022-12-25	WOS:000232058100048
J	Kofler, M; Motzny, K; Beyermann, M; Freund, C				Kofler, M; Motzny, K; Beyermann, M; Freund, C			Novel interaction partners of the CD2BP2-GYF domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH3 DOMAIN; GYF DOMAIN; PROTEIN; PROLINE; BINDING; MOTIF; CD2; IDENTIFICATION; ACTIVATION; PROTEASOME	The GYF domain of CD2BP2 serves as an adapter that recognizes proline-rich sequences in intracellular proteins. Although the T cell adhesion molecule CD2 and the core splicing protein SmB/B' were previously shown to interact with CD2BP2-GYF, we are now using a general approach to identify putative GYF domain target sites within the human proteome. The phage display-derived recognition motif for CD2BP2-GYF is PPG(W/F/Y/M/L). SPOT analysis confirmed that the GYF domain interacts with peptides from human proteins containing the consensus site. Epitope mapping by NMR spectroscopy performed for several peptides revealed a conserved binding surface. A direct interaction of the CD2BP2-GYF domain with the novel protein interaction partners PI31 and NPWBP was verified by yeast two-hybrid analysis.	Forschungsinst Mol Pharmakol, Prot Engn Grp, D-13125 Berlin, Germany; Free Univ Berlin, D-13125 Berlin, Germany	Free University of Berlin	Freund, C (corresponding author), Forschungsinst Mol Pharmakol, Prot Engn Grp, Robert Rossle Str 10, D-13125 Berlin, Germany.	freund@fmp-berlin.de						Beyermann M, 1996, J MED CHEM, V39, P3324, DOI 10.1021/jm960116z; Bialkowska A, 2002, YEAST, V19, P1323, DOI 10.1002/yea.919; CHANG HC, 1990, J EXP MED, V172, P351, DOI 10.1084/jem.172.1.351; Craggs G, 2001, J BIOL CHEM, V276, P30552, DOI 10.1074/jbc.M103142200; FELICI F, 1991, J MOL BIOL, V222, P301, DOI 10.1016/0022-2836(91)90213-P; Freund C, 2002, EMBO J, V21, P5985, DOI 10.1093/emboj/cdf602; Freund C, 1999, NAT STRUCT BIOL, V6, P656, DOI 10.1038/10712; HAHN WC, 1993, J EXP MED, V178, P1831, DOI 10.1084/jem.178.5.1831; Hartmuth K, 2002, P NATL ACAD SCI USA, V99, P16719, DOI 10.1073/pnas.262483899; Heuer K, 2004, STRUCTURE, V12, P603, DOI 10.1016/j.str.2004.02.021; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Kofler M, 2004, J BIOL CHEM, V279, P28292, DOI 10.1074/jbc.M402008200; Komuro A, 1999, J BIOL CHEM, V274, P36513, DOI 10.1074/jbc.274.51.36513; Kramer A, 1998, METH MOL B, V87, P25; Kramer A, 1999, J PEPT RES, V54, P319, DOI 10.1034/j.1399-3011.1999.00108.x; Laggerbauer B, 2005, RNA, V11, P598, DOI 10.1261/rna.2300805; Makarova OV, 2004, EMBO J, V23, P2381, DOI 10.1038/sj.emboj.7600241; McCutchen-Maloney SL, 2000, J BIOL CHEM, V275, P18557, DOI 10.1074/jbc.M001697200; Nishizawa K, 1998, P NATL ACAD SCI USA, V95, P14897, DOI 10.1073/pnas.95.25.14897; Reuter K, 1999, J MOL BIOL, V294, P515, DOI 10.1006/jmbi.1999.3258; Waragai M, 2000, BIOCHEM BIOPH RES CO, V273, P592, DOI 10.1006/bbrc.2000.2992; YAMAMOTO KR, 1970, VIROLOGY, V40, P734, DOI 10.1016/0042-6822(70)90218-7; Zaiss DMW, 2002, P NATL ACAD SCI USA, V99, P14344, DOI 10.1073/pnas.212257299; Zhang YZ, 2000, GENE, V257, P33, DOI 10.1016/S0378-1119(00)00372-3; Zhou ZL, 2002, NATURE, V419, P182, DOI 10.1038/nature01031	25	18	19	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	2005	280	39					33397	33402		10.1074/jbc.M503989200	http://dx.doi.org/10.1074/jbc.M503989200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	966YG	16000308	hybrid			2022-12-25	WOS:000232058100037
J	Levitin, F; Stern, O; Weiss, M; Gil-Henn, C; Ziv, R; Prokocimer, Z; Smorodinsky, NI; Rubinstein, DB; Wreschner, DH				Levitin, F; Stern, O; Weiss, M; Gil-Henn, C; Ziv, R; Prokocimer, Z; Smorodinsky, NI; Rubinstein, DB; Wreschner, DH			The MUC1 SEA module is a self-cleaving domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARCINOMA-ASSOCIATED ANTIGEN; N-TERMINAL THREONINE; CANCER CELL-LINES; BREAST-CANCER; MONOCLONAL-ANTIBODY; SPLICE VARIANTS; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; BETA-CATENIN; TYROSINE PHOSPHORYLATION	MUC1, a glycoprotein overexpressed by a variety of human adenocarcinomas, is a type I transmembrane protein (MUC1/TM) that soon after its synthesis undergoes proteolytic cleavage in its extracellular domain. This cleavage generates two subunits, alpha and beta, that specifically recognize each other and bind together in a strong noncovalent interaction. Proteolysis occurs within the SEA module, a 120-amino acid domain that is highly conserved in a number of heavily glycosylated mucin-like proteins. Post-translational cleavage of the SEA module occurs at a site similar to that in MUC1 in the glycoproteins IgHepta and MUC3. However, as in the case of other proteins containing the cleaved SEA module, the mechanism of MUC1 proteolysis has not been elucidated. Alternative splicing generates two transmembrane MUC1 isoforms, designated MUC1/Y and MUC1/X. We demonstrated here that MUC1/X, whose extracellular domain is comprised solely of the SEA module in addition to 30 MUC1N-terminal amino acids, undergoes proteolytic cleavage at the same site as the MUC1/TM protein. In contrast, the MUC1/Y isoform, composed of an N-terminally truncated SEA module, is not cleaved. Cysteine or threonine mutations of the MUC1/X serine residue (Ser-63) immediately C-terminal to the cleavage site generated cleaved proteins, whereas mutation of the Ser-63 residue of MUC1/X to any other of 17 amino acids did not result in cleavage. In vitro incubation of highly purified precursor MUC1/X protein resulted in self-cleavage. Furthermore, addition of hydroxylamine, a strong nucleophile, markedly enhanced cleavage. Both these features are signature characteristics of self-cleaving proteins, and we concluded that MUC1 undergoes autoproteolysis mediated by an N-->O-acyl rearrangement at the cleavage site followed by hydrolytic resolution of the unstable ester and concomitant cleavage. It is likely that all cleaved SEA module-containing proteins follow a similar route.	Tel Aviv Univ, Dept Cell Res & Immunol, IL-69978 Ramat Aviv, Israel; Tel Aviv Univ, Akec & Myra Marmot Hybridoma Lab, IL-69978 Ramat Aviv, Israel; Assaf Harofeh Med Ctr, Dept Endocrinol, IL-70300 Zerifin, Israel; US FDA, Ctr Biol Evaluat & Res, Bethesda, MD 20851 USA	Tel Aviv University; Tel Aviv University; Shamir Medical Center (Assaf Harofeh); Tel Aviv University; US Food & Drug Administration (FDA)	Wreschner, DH (corresponding author), Tel Aviv Univ, Dept Cell Res & Immunol, IL-69978 Ramat Aviv, Israel.	danielhw@post.tau.ac.il		Wreschner, Daniel/0000-0003-2102-2164				Abe J, 2002, J BIOL CHEM, V277, P23391, DOI 10.1074/jbc.M110877200; Albert A, 1998, NAT STRUCT BIOL, V5, P289, DOI 10.1038/nsb0498-289; Aronson NN, 1996, GLYCOBIOLOGY, V6, P669, DOI 10.1093/glycob/6.7.669; Baldus SE, 2004, CLIN CANCER RES, V10, P2790, DOI 10.1158/1078-0432.CCR-03-0163; Baruch A, 1999, CANCER RES, V59, P1552; Baruch A, 1997, INT J CANCER, V71, P741; BORK P, 1995, PROTEIN SCI, V4, P1421, DOI 10.1002/pro.5560040716; BRANNIGAN JA, 1995, NATURE, V378, P416, DOI 10.1038/378416a0; Burton J, 1999, CLIN CANCER RES, V5, p3065S; CHOI KS, 1992, J BACTERIOL, V174, P6270, DOI 10.1128/JB.174.19.6270-6276.1992; Coughlin Sr, 2002, COLD SPRING HARB SYM, V67, P197, DOI 10.1101/sqb.2002.67.197; Croce MV, 2003, J HISTOCHEM CYTOCHEM, V51, P781, DOI 10.1177/002215540305100609; DUGGLEBY HJ, 1995, NATURE, V373, P264, DOI 10.1038/373264a0; Fujita K, 1999, BRIT J CANCER, V80, P301, DOI 10.1038/sj.bjc.6690355; Gasque P, 2004, MOL IMMUNOL, V41, P1089, DOI 10.1016/j.molimm.2004.06.011; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; GIRLING A, 1989, INT J CANCER, V43, P1072, DOI 10.1002/ijc.2910430620; Guan CD, 1996, J BIOL CHEM, V271, P1732, DOI 10.1074/jbc.271.3.1732; Hadden JW, 1999, INT J IMMUNOPHARMACO, V21, P79, DOI 10.1016/S0192-0561(98)00077-0; Hall TMT, 1997, CELL, V91, P85, DOI 10.1016/S0092-8674(01)80011-8; Hamann PR, 2005, BIOCONJUGATE CHEM, V16, P354, DOI 10.1021/bc049794n; Hartman ML, 1999, INT J CANCER, V82, P256, DOI 10.1002/(SICI)1097-0215(19990719)82:2<256::AID-IJC17>3.0.CO;2-C; HILKENS J, 1984, INT J CANCER, V34, P197, DOI 10.1002/ijc.2910340210; Hinojosa-Kurtzberg AM, 2003, AM J PHYSIOL-GASTR L, V284, pG853, DOI 10.1152/ajpgi.00326.2002; Howard MR, 2002, BIOTECHNIQUES, V32, P1282, DOI 10.2144/02326st03; Hsieh JJD, 2003, CELL, V115, P293, DOI 10.1016/S0092-8674(03)00816-X; Isupov MN, 1996, STRUCTURE, V4, P801, DOI 10.1016/S0969-2126(96)00087-1; Kawamoto T, 2001, CLIN CANCER RES, V7, P1333; Khatri IA, 2003, BIOCHEM J, V372, P263, DOI 10.1042/BJ20021333; Kisselev AF, 2000, J BIOL CHEM, V275, P14831, DOI 10.1074/jbc.275.20.14831; Kontani K, 2001, BRIT J CANCER, V84, P1258, DOI 10.1054/bjoc.2000.1744; Koumarianou AA, 1999, BRIT J CANCER, V81, P431, DOI 10.1038/sj.bjc.6690712; Krem MM, 2002, TRENDS BIOCHEM SCI, V27, P67, DOI 10.1016/S0968-0004(01)02007-2; Larsen TM, 1999, BIOCHEMISTRY-US, V38, P16146, DOI 10.1021/bi9915768; LEE JJ, 1994, SCIENCE, V266, P1528, DOI 10.1126/science.7985023; Levitin F, 2005, J BIOL CHEM, V280, P10655, DOI 10.1074/jbc.M406943200; Li YQ, 1998, MOL CELL BIOL, V18, P7216, DOI 10.1128/MCB.18.12.7216; LIGTENBERG MJL, 1992, J BIOL CHEM, V267, P6171; LIGTENBERG MJL, 1990, J BIOL CHEM, V265, P5573; Lillehoj EP, 2003, BIOCHEM BIOPH RES CO, V307, P743, DOI 10.1016/S0006-291X(03)01260-9; Lin HH, 2004, J BIOL CHEM, V279, P31823, DOI 10.1074/jbc.M402974200; Maeda T, 2004, J BIOL CHEM, V279, P13174, DOI 10.1074/jbc.M309417200; Mott JD, 2004, CURR OPIN CELL BIOL, V16, P558, DOI 10.1016/j.ceb.2004.07.010; Mukherjee P, 2005, J LEUKOCYTE BIOL, V77, P90, DOI 10.1189/jlb.0604333; O'Connor JC, 2005, PROSTATE CANCER P D, V8, P36, DOI 10.1038/sj.pcan.4500762; Obermair A, 2002, INT J CANCER, V100, P166, DOI 10.1002/ijc.10456; Obermair A, 2001, GYNECOL ONCOL, V83, P343, DOI 10.1006/gyno.2001.6396; Ohgami A, 1999, ANN THORAC SURG, V67, P810, DOI 10.1016/S0003-4975(99)00041-7; OINONEN C, 1995, NAT STRUCT BIOL, V2, P1102, DOI 10.1038/nsb1295-1102; Oosterkamp HM, 1997, INT J CANCER, V72, P87, DOI 10.1002/(SICI)1097-0215(19970703)72:1<87::AID-IJC13>3.0.CO;2-7; PANDEY P, 1995, CANCER RES, V55, P4000; Parry S, 2001, BIOCHEM BIOPH RES CO, V283, P715, DOI 10.1006/bbrc.2001.4775; Paulus H, 2000, ANNU REV BIOCHEM, V69, P447, DOI 10.1146/annurev.biochem.69.1.447; Perler FB, 2002, NUCLEIC ACIDS RES, V30, P383, DOI 10.1093/nar/30.1.383; Perler FB, 1998, CELL, V92, P1, DOI 10.1016/S0092-8674(00)80892-2; PORTER JA, 1995, NATURE, V374, P363, DOI 10.1038/374363a0; Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255; Qian F, 2002, P NATL ACAD SCI USA, V99, P16981, DOI 10.1073/pnas.252484899; Quin RJ, 2000, INT J CANCER, V87, P499, DOI 10.1002/1097-0215(20000815)87:4<499::AID-IJC6>3.0.CO;2-9; Saarela J, 1998, J BIOL CHEM, V273, P25320, DOI 10.1074/jbc.273.39.25320; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Schmidtke G, 1996, EMBO J, V15, P6887, DOI 10.1002/j.1460-2075.1996.tb01081.x; Schneider P, 2000, METHOD ENZYMOL, V322, P325; Schroeder JA, 2003, ONCOGENE, V22, P1324, DOI 10.1038/sj.onc.1206291; Selkoe D, 2003, ANNU REV NEUROSCI, V26, P565, DOI 10.1146/annurev.neuro.26.041002.131334; Shao Y, 1996, BIOCHEMISTRY-US, V35, P3810, DOI 10.1021/bi952592h; Snijdewint FGM, 2001, INT J CANCER, V93, P97, DOI 10.1002/ijc.1286; Stamenkovic I, 2003, J PATHOL, V200, P448, DOI 10.1002/path.1400; Suzuki H, 2002, J BIOL CHEM, V277, P43536, DOI 10.1074/jbc.M207680200; TAKAHASHI T, 1994, J IMMUNOL, V153, P2102; Tikkanen R, 1996, EMBO J, V15, P2954, DOI 10.1002/j.1460-2075.1996.tb00658.x; Treon SP, 2000, BLOOD, V96, P3147, DOI 10.1182/blood.V96.9.3147.h8003147_3147_3153; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; Wei XL, 2005, CANCER CELL, V7, P167, DOI 10.1016/j.ccr.2005.01.008; Wreesmann VB, 2004, CANCER RES, V64, P3780, DOI 10.1158/0008-5472.CAN-03-1460; Wreschner DH, 2002, PROTEIN SCI, V11, P698, DOI 10.1110/ps.16502; WRESCHNER DH, 1990, EUR J BIOCHEM, V189, P463, DOI 10.1111/j.1432-1033.1990.tb15511.x; XU MQ, 1993, CELL, V75, P1371, DOI 10.1016/0092-8674(93)90623-X; XU MQ, 1994, EMBO J, V13, P5517, DOI 10.1002/j.1460-2075.1994.tb06888.x; Xu QA, 1999, CELL, V98, P651, DOI 10.1016/S0092-8674(00)80052-5; Yamamoto M, 1997, J BIOL CHEM, V272, P12492, DOI 10.1074/jbc.272.19.12492; YONEZAWA S, 1991, BIOCHEM J, V276, P599, DOI 10.1042/bj2760599; ZARETSKY JZ, 1990, FEBS LETT, V265, P46, DOI 10.1016/0014-5793(90)80880-R; ZRIHANLICHT S, 1994, EUR J BIOCHEM, V224, P787, DOI 10.1111/j.1432-1033.1994.00787.x; ZRIHANLICHT S, 1994, FEBS LETT, V356, P130, DOI 10.1016/0014-5793(94)01251-2	86	153	175	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	2005	280	39					33374	33386		10.1074/jbc.M506047200	http://dx.doi.org/10.1074/jbc.M506047200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	966YG	15987679	hybrid			2022-12-25	WOS:000232058100035
J	Naoe, Y; Arita, K; Hashimoto, H; Kanazawa, H; Sato, M; Shimizu, T				Naoe, Y; Arita, K; Hashimoto, H; Kanazawa, H; Sato, M; Shimizu, T			Structural characterization of calcineurin B homologous protein 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR EXPORT SIGNALS; CA2+-BINDING PROTEIN; CRYSTAL-STRUCTURE; BINDING PROTEIN; NA+/H+ EXCHANGERS; DEPENDENT MANNER; LAMM EQUATION; CELL-DEATH; P22; LOCALIZATION	Calcineurin B homologous protein 1( CHP1), also known as p22, is a calcium-binding EF-hand protein that plays a role in membrane trafficking. It binds to multiple effector proteins, including Na+/H+ exchangers, a serine/threonine kinase, and calcineurin, potentially modulating their function. The crystal structure of calcium-bound CHP1 from rat has been determined at 2.2 angstrom of resolution. The molecule has a compact alpha-helical structure containing four EF-hands. The overall folding topology of the protein is similar to that of the regulatory B subunit of calcineurin and to that of calcium-and integrin-binding protein. The calcium ion is coordinated in typical fashion in the third and fourth EF-hands, but the first and second EF-hands contain no calcium ion. The first EF-hand is maintained by internal interactions, and the second EF- hand is stabilized by hydrophobic interactions. CHP1 contains a hydrophobic pocket on the opposite side of the protein to the EF- hands that has been implicated in ligand binding.	Yokohama City Univ, Int Grad Sch Arts & Sci, Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan; Osaka Univ, Grad Sch Sci, Dept Biol Sci, Toyonaka, Osaka 5600043, Japan	Yokohama City University; Osaka University	Shimizu, T (corresponding author), Yokohama City Univ, Int Grad Sch Arts & Sci, Tsurumi Ku, 1-7-29 Suehiro Cho, Yokohama, Kanagawa 2300045, Japan.	shimizu@tsurumi.yokohama-cu.ac.jp	Arita, Kyohei/AAJ-6402-2020	Arita, Kyohei/0000-0002-9762-8405; Hashimoto, Hiroshi/0000-0003-1503-6789				Ames JB, 1997, NATURE, V389, P198, DOI 10.1038/38310; An WF, 2000, NATURE, V403, P553, DOI 10.1038/35000592; Andrade J, 2004, MOL BIOL CELL, V15, P481, DOI 10.1091/mbc.E03-07-0500; Barroso MR, 1996, J BIOL CHEM, V271, P10183, DOI 10.1074/jbc.271.17.10183; Baumgartner M, 2004, AM J PHYSIOL-CELL PH, V287, pC844, DOI 10.1152/ajpcell.00094.2004; Bourne Y, 2001, J BIOL CHEM, V276, P11949, DOI 10.1074/jbc.M009373200; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Dam J, 2004, METHOD ENZYMOL, V384, P185; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; FLAHERTY KM, 1993, CELL, V75, P709, DOI 10.1016/0092-8674(93)90491-8; Gentry HR, 2005, J BIOL CHEM, V280, P8407, DOI 10.1074/jbc.M411515200; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; Inoue H, 2003, BIOL PHARM BULL, V26, P148, DOI 10.1248/bpb.26.148; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KISSINGER CR, 1995, NATURE, V378, P641, DOI 10.1038/378641a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krissinel E, 2004, ACTA CRYSTALLOGR D, V60, P2256, DOI 10.1107/S0907444904026460; Kuwahara H, 2003, J BIOCHEM, V134, P245, DOI 10.1093/jb/mvg137; la Cour T, 2004, PROTEIN ENG DES SEL, V17, P527, DOI 10.1093/protein/gzh062; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Lin X, 1996, P NATL ACAD SCI USA, V93, P12631, DOI 10.1073/pnas.93.22.12631; Lin X, 1999, J BIOL CHEM, V274, P36125, DOI 10.1074/jbc.274.51.36125; Matsumoto M, 2001, J BIOCHEM, V130, P217, DOI 10.1093/oxfordjournals.jbchem.a002975; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nagae M, 2003, J BIOL CHEM, V278, P42240, DOI 10.1074/jbc.M303630200; Nagita M, 2003, J BIOCHEM, V134, P919, DOI 10.1093/jb/mvg223; Nakamura N, 2002, J BIOCHEM, V132, P483, DOI 10.1093/oxfordjournals.jbchem.a003246; Naoe Y, 2005, ACTA CRYSTALLOGR F, V61, P612, DOI 10.1107/S1744309105016325; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Pang TX, 2004, BIOCHEMISTRY-US, V43, P3628, DOI 10.1021/bi0360004; Pang TX, 2002, J BIOL CHEM, V277, P43771, DOI 10.1074/jbc.M208313200; Pang TX, 2001, J BIOL CHEM, V276, P17367, DOI 10.1074/jbc.M100296200; Peshenko IV, 2004, BIOCHEMISTRY-US, V43, P13796, DOI 10.1021/bi048943m; Schuck P, 1998, BIOPHYS J, V75, P1503, DOI 10.1016/S0006-3495(98)74069-X; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; Shock DD, 1999, BIOCHEM J, V342, P729, DOI 10.1042/0264-6021:3420729; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Timm S, 1999, MOL BIOL CELL, V10, P3473, DOI 10.1091/mbc.10.10.3473; Vijay-Kumar S, 1999, NAT STRUCT BIOL, V6, P80; Yap Kyoko L, 2002, Methods Mol Biol, V173, P317; Zhou W, 2004, NEURON, V41, P573, DOI 10.1016/S0896-6273(04)00045-5	44	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	2005	280	37					32372	32378		10.1074/jbc.M503390200	http://dx.doi.org/10.1074/jbc.M503390200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	963HM	15987692	hybrid			2022-12-25	WOS:000231794800042
J	Kawahara, T; Ritsick, D; Cheng, GJ; Lambeth, JD				Kawahara, T; Ritsick, D; Cheng, GJ; Lambeth, JD			Point mutations in the proline-rich region of p22(phox) are dominant inhibitors of Nox1- and Nox2-dependent reactive oxygen generation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY BURST OXIDASE; PHAGOCYTE NADPH OXIDASE; SRC HOMOLOGY-3 DOMAINS; NAD(P)H OXIDASE; ACTIVATION DOMAIN; MOLECULAR-BASIS; CYTOCHROME-B; SUPEROXIDE; P47(PHOX); PROTEINS	The integral membrane protein p22(phox) is an indispensable component of the superoxide-generating phagocyte NADPH oxidase, whose catalytic core is the membrane-associated gp91(phox) ( also known as Nox2). p22(phox) associates with gp91(phox) and, through its proline-rich C terminus, provides a binding site for the tandem Src homology 3 domains of the activating subunit p47(phox). Whereas p22(phox) is expressed ubiquitously, its participation in regulating the activity of other Nox enzymes is less clear. This study investigates the requirement of p22phox for Nox enzyme activity and explores the role of its proline-rich region ( PRR) for regulating activity. Co-expression of specific Nox catalytic subunits ( Nox1, Nox2, Nox3, Nox4, or Nox5) along with their corresponding regulatory subunits ( NOXO1/NOXA1 for Nox1; p47(phox)/p67(phox)/Rac for Nox2; NOXO1 for Nox3; no subunits for Nox4 or Nox5) resulted in marked production of reactive oxygen. Small interfering RNAs decreased endogenous p22(phox) expression and inhibited reactive oxygen generation from Nox1, Nox2, Nox3, and Nox4 but not Nox5. Truncated forms of p22(phox) that disrupted the PRR-inhibited reactive oxygen generation from Nox1, Nox2, and Nox3 but not from Nox4 and Nox5. Similarly, p22(phox) ( P156Q), a mutation that disrupts Src homology 3 binding by the PRR, potently inhibited reactive oxygen production from Nox1 and Nox2 but not from Nox4 and Nox5. Expression of p22(phox) ( P156Q) inhibited NOXO1-stimulated Nox3 activity, but co-expression of NOXA1 overcame the inhibitory effect. The P157Q and P160Q mutations of p22(phox) showed selective inhibition of Nox2/p47(phox)/p67(phox), and selectivity was specific for the organizing subunit ( p47(phox) or NOXO1) rather than the Nox catalytic subunit. These studies stress the importance of p22(phox) for the function of Nox1, Nox2, Nox3, and Nox4, and emphasize the key role of the PRR for regulating Nox proteins whose activity is dependent upon p47phox or NOXO1.	Emory Univ, Sch Med, Dept Pathol & Expt Med, Atlanta, GA 30322 USA; Emory Univ, Grad Program Biochem Cell & Dev Biol, Atlanta, GA 30322 USA	Emory University; Emory University	Lambeth, JD (corresponding author), Emory Univ, Sch Med, Dept Pathol & Expt Med, 148 Whitehead Bldg,615 Michael St, Atlanta, GA 30322 USA.	noxdoc@mac.com		Cheng, Guangjie/0000-0002-9368-379X	NCI NIH HHS [CA84138, CA105116] Funding Source: Medline; NIGMS NIH HHS [GM067717] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R56CA105116, R01CA105116, R01CA084138] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067717] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ambasta RK, 2004, J BIOL CHEM, V279, P45935, DOI 10.1074/jbc.M406486200; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Babior BM, 2002, ARCH BIOCHEM BIOPHYS, V397, P342, DOI 10.1006/abbi.2001.2642; Baker MA, 2004, MOL CELL ENDOCRINOL, V216, P47, DOI 10.1016/j.mce.2003.10.068; Banfi B, 2004, J BIOL CHEM, V279, P46065, DOI 10.1074/jbc.M403046200; Banfi B, 2004, J BIOL CHEM, V279, P18583, DOI 10.1074/jbc.M310268200; Banfi B, 2003, J BIOL CHEM, V278, P3510, DOI 10.1074/jbc.C200613200; Banfi B, 2000, SCIENCE, V287, P138, DOI 10.1126/science.287.5450.138; Banfi B, 2001, J BIOL CHEM, V276, P37594, DOI 10.1074/jbc.M103034200; Bokoch GM, 2002, BLOOD, V100, P2692, DOI 10.1182/blood-2002-04-1149; Boonstra J, 2004, GENE, V337, P1, DOI 10.1016/j.gene.2004.04.032; Cheng GJ, 2004, J BIOL CHEM, V279, P34250, DOI 10.1074/jbc.M400660200; Cheng GJ, 2004, J BIOL CHEM, V279, P4737, DOI 10.1074/jbc.M305968200; Cheng GJ, 2001, GENE, V269, P131, DOI 10.1016/S0378-1119(01)00449-8; CORVILAIN B, 1991, ENDOCRINOLOGY, V128, P779, DOI 10.1210/endo-128-2-779; De Deken X, 2000, J BIOL CHEM, V275, P23227, DOI 10.1074/jbc.M000916200; De Deken X, 2002, EXP CELL RES, V273, P187, DOI 10.1006/excr.2001.5444; DELAMIRANDE E, 1995, FREE RADICAL BIO MED, V18, P487, DOI 10.1016/0891-5849(94)00169-K; Diebold BA, 2001, NAT IMMUNOL, V2, P211, DOI 10.1038/85259; DINAUER MC, 1991, P NATL ACAD SCI USA, V88, P11231, DOI 10.1073/pnas.88.24.11231; DINAUER MC, 1993, CRIT REV CL LAB SCI, V30, P329, DOI 10.3109/10408369309082591; Ebert BL, 1999, BLOOD, V94, P1864; Gao XP, 2002, J IMMUNOL, V168, P3974, DOI 10.4049/jimmunol.168.8.3974; Geiszt M, 2003, J BIOL CHEM, V278, P20006, DOI 10.1074/jbc.M301289200; Geiszt M, 2000, P NATL ACAD SCI USA, V97, P8010, DOI 10.1073/pnas.130135897; Gelbart WM, 2002, NUCLEIC ACIDS RES, V30, P106; Groemping Y, 2003, CELL, V113, P343, DOI 10.1016/S0092-8674(03)00314-3; Han CH, 1998, J BIOL CHEM, V273, P16663, DOI 10.1074/jbc.273.27.16663; HEYWORTH PG, 1994, J BIOL CHEM, V269, P30749; JESAITIS AJ, 1990, J CLIN INVEST, V85, P821, DOI 10.1172/JCI114509; Kawahara T, 2005, AM J PHYSIOL-CELL PH, V288, pC450, DOI 10.1152/ajpcell.00319.2004; Kawahara T, 2004, J IMMUNOL, V172, P3051, DOI 10.4049/jimmunol.172.5.3051; Keller T, 1998, PLANT CELL, V10, P255, DOI 10.1105/tpc.10.2.255; KEY LL, 1994, BONE, V15, P431, DOI 10.1016/8756-3282(94)90821-4; Kuribayashi F, 2002, EMBO J, V21, P6312, DOI 10.1093/emboj/cdf642; Lambeth JD, 2002, CURR OPIN HEMATOL, V9, P11, DOI 10.1097/00062752-200201000-00003; Lambeth JD, 2004, NAT REV IMMUNOL, V4, P181, DOI 10.1038/nri1312; Lassegue B, 2003, AM J PHYSIOL-REG I, V285, pR277, DOI 10.1152/ajpregu.00758.2002; LETO TL, 1994, P NATL ACAD SCI USA, V91, P10650, DOI 10.1073/pnas.91.22.10650; LEUSEN JHW, 1994, J EXP MED, V180, P2329, DOI 10.1084/jem.180.6.2329; Liu JH, 2004, CIRC RES, V95, P587, DOI 10.1161/01.RES.0000142317.88591.e6; Mahadev K, 2004, MOL CELL BIOL, V24, P1844, DOI 10.1128/MCB.24.5.1844-1854.2004; Mitsushita J, 2004, CANCER RES, V64, P3580, DOI 10.1158/0008-5472.CAN-03-3909; Nisimoto Y, 1999, J BIOL CHEM, V274, P22999, DOI 10.1074/jbc.274.33.22999; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; Paffenholz R, 2004, GENE DEV, V18, P486, DOI 10.1101/gad.1172504; Park HS, 2004, J IMMUNOL, V173, P3589, DOI 10.4049/jimmunol.173.6.3589; Quinn MT, 2004, J LEUKOCYTE BIOL, V76, P760, DOI 10.1189/jlb.0404216; Ritsick DR, 2004, BIOCHEM SOC SYMP, V71, P85; Shiose A, 2001, J BIOL CHEM, V276, P1417, DOI 10.1074/jbc.M007597200; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; Sumimoto H, 1996, J BIOL CHEM, V271, P22152, DOI 10.1074/jbc.271.36.22152; Takeya R, 2003, J BIOL CHEM, V278, P25234, DOI 10.1074/jbc.M212856200; Taniyama Y, 2003, HYPERTENSION, V42, P1075, DOI 10.1161/01.HYP.0000100443.09293.4F; Touyz RM, 2002, CIRC RES, V90, P1205, DOI 10.1161/01.RES.0000020404.01971.2F; Tsunawaki S, 2004, INFECT IMMUN, V72, P3373, DOI 10.1128/IAI.72.6.3373-3382.2004; Ueno N, 2005, J BIOL CHEM, V280, P23328, DOI 10.1074/jbc.M414548200; van de Loo FAJ, 2003, AM J PATHOL, V163, P1525, DOI 10.1016/S0002-9440(10)63509-2; Williams MS, 2004, FREE RADICAL BIO MED, V37, P1144, DOI 10.1016/j.freeradbiomed.2004.05.029; Yoshioka H, 2003, PLANT CELL, V15, P706, DOI 10.1105/tpc.008680	61	184	191	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	2005	280	36					31859	31869		10.1074/jbc.M501882200	http://dx.doi.org/10.1074/jbc.M501882200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	961LZ	15994299	hybrid			2022-12-25	WOS:000231665200065
J	Sebollela, A; Cagliari, TC; Limaverde, GSCS; Chapeaurouge, A; Sorgine, MHF; Coelho-Sampaio, T; Ramos, CHI; Ferreira, ST				Sebollela, A; Cagliari, TC; Limaverde, GSCS; Chapeaurouge, A; Sorgine, MHF; Coelho-Sampaio, T; Ramos, CHI; Ferreira, ST			Heparin-binding sites in granulocyte-macrophage colony-stimulating factor - Localization and regulation by histidine ionization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR GM-CSF; GROWTH-FACTOR; SULFATE PROTEOGLYCANS; NERVE REGENERATION; MITOGENIC ACTIVITY; ESCHERICHIA-COLI; CELL-LINES; RECEPTOR; ACTIVATION; GLYCOSAMINOGLYCANS	The biological activity of granulocyte-macrophage colony-stimulating factor (GM-CSF) is modulated by the sulfated glycosaminoglycans (GAGs) heparan sulfate and heparin. However, the molecular mechanisms involved in such interactions are still not completely understood. We have proposed previously that helix C, one of the four alpha-helices of human GM-CSF (hGM-CSF), contains a GAG-binding site in which positively charged residues are spatially positioned for interaction with the sulfate moieties of the GAGs (Wettreich, A., Sebollela, A., Carvalho, M. A., Azevedo, S. P., Borojevic, R., Ferreira, S. T., and Coelho-Sampaio, T. (1999) J. Biol. Chem. 274, 31468-31475). Protonation of two histidine residues ( His(83) and His(87)) in helix C of hGM-CSF appears to act as a pH-dependent molecular switch to control the interaction with GAGs. Based on these findings, we have now generated a triple mutant form of murine GM-CSF (mGM-CSF) in which three noncharged residues in helix C of the murine factor (Tyr(83), Gln(85), and Tyr(87)) were replaced by the corresponding basic residues present in hGM-CSF (His(83), Lys(85), and His87). Binding assays on heparin-Sepharose showed that, at acidic pH, the triple mutant mGM-CSF binds to immobilized heparin with significantly higher affinity than wild type (WT) mGM-CSF and that neither protein binds to the column at neutral pH. The fact that even WT mGM-CSF binds to heparin at acidic pH indicates the existence of a distinct, lower affinity heparin-binding site in the protein. Chemical modification of the single histidine residue (His(15)) located in helix A of WT mGM-CSF with diethyl pyrocarbonate totally abolished binding to immobilized heparin. Moreover, replacement of His(15) for an alanine residue significantly reduced the affinity of mGM-CSF for heparin at pH 5.0 and completely blocked heparin binding to a synthetic peptide corresponding to helix A of GM-CSF. These results indicate a major role of histidine residues in the regulation of the binding of GM-CSF to GAGs, supporting the notion that an acidic microenvironment is required for GM-CSF-dependent regulation of target cells. In addition, our results provide insight into the molecular basis of the strict species specificity of the biological activity of GM-CSF.	Univ Fed Rio de Janeiro, Programa Bioquim & Biofis Celular, Inst Bioquim Med, BR-21940590 Rio De Janeiro, Brazil; Univ Fed Rio de Janeiro, Lab Modelagem & Dinam Mol, Inst Biofis Carlos Chagas Filho, BR-21940590 Rio De Janeiro, Brazil; Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Dept Histol & Embriol, BR-21940590 Rio De Janeiro, Brazil; UNICAMP, Dept Bioquim, Inst Biol, BR-13084971 Campinas, SP, Brazil; Fiocruz MS, Dept Fisiol & Farmacodinam, BR-21045900 Rio De Janeiro, Brazil	Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro; Universidade de Sao Paulo; Universidade Estadual de Campinas; Fundacao Oswaldo Cruz	Ferreira, ST (corresponding author), Univ Fed Rio de Janeiro, Programa Bioquim & Biofis Celular, Inst Bioquim Med, BR-21940590 Rio De Janeiro, Brazil.	ferreira@bioqmed.ufrj.br	Sebollela, Adriano/O-4385-2014; Ferreira, Sergio/AAZ-1576-2020; Ramos, CH/C-1571-2012	Sebollela, Adriano/0000-0002-7444-9156; Ferreira, Sergio/0000-0001-7160-9866; Ramos, CH/0000-0002-7246-9081				AlvarezSilva M, 1996, J LEUKOCYTE BIOL, V59, P435, DOI 10.1002/jlb.59.3.435; ALVAREZSILVA M, 1993, J CELL SCI, V104, P477; Arcanjo K, 2002, J CELL BIOCHEM, V87, P160, DOI 10.1002/jcb.10293; Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; Borojevic R, 2003, CELL TISSUE RES, V313, P55, DOI 10.1007/s00441-003-0726-0; BURGESS AW, 1987, BLOOD, V69, P43; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; Carneiro FA, 2003, J BIOL CHEM, V278, P13789, DOI 10.1074/jbc.M210615200; Carvalho MA, 2000, BIOL CELL, V92, P605, DOI 10.1016/S0248-4900(01)01113-3; D'Andrea RJ, 2000, EXP HEMATOL, V28, P231, DOI 10.1016/S0301-472X(99)00159-9; DECRISTAN G, 1990, J CELL PHYSIOL, V144, P505; DELAMARTER JF, 1985, EMBO J, V4, P2575, DOI 10.1002/j.1460-2075.1985.tb03973.x; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; Freire E, 2004, J CELL SCI, V117, P4067, DOI 10.1242/jcs.01276; Freire E, 2002, J CELL SCI, V115, P4867, DOI 10.1242/jcs.00173; Gallagher JT, 2001, J CLIN INVEST, V108, P357, DOI 10.1172/JCI13713; Hallgren J, 2004, J IMMUNOL, V173, P1868, DOI 10.4049/jimmunol.173.3.1868; Harmer NJ, 2004, J MOL BIOL, V339, P821, DOI 10.1016/j.jmb.2004.04.031; Harmer NJ, 2003, BIOPHYS CHEM, V100, P545, DOI 10.1016/S0301-4622(02)00305-8; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; Hileman RE, 1998, BIOESSAYS, V20, P156, DOI 10.1002/(SICI)1521-1878(199802)20:2<156::AID-BIES8>3.3.CO;2-#; KAUSHANSKY K, 1988, J CLIN INVEST, V81, P92, DOI 10.1172/JCI113316; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; LUNDBLAD RL, 1984, CHEM REAGENTS PROTEI, P105; MARGALIT H, 1993, J BIOL CHEM, V268, P19228; MATSUMOTO R, 1995, J BIOL CHEM, V270, P19524, DOI 10.1074/jbc.270.33.19524; MEOTNER M, 1991, J AM CHEM SOC, V113, P4448, DOI 10.1021/ja00012a012; METCALF D, 1991, SCIENCE, V254, P529, DOI 10.1126/science.1948028; Miles E W, 1977, Methods Enzymol, V47, P431; Modrowski D, 1998, J CELL PHYSIOL, V177, P187, DOI 10.1002/(SICI)1097-4652(199810)177:1<187::AID-JCP19>3.0.CO;2-A; Modrowski D, 2000, J BIOL CHEM, V275, P9178, DOI 10.1074/jbc.275.13.9178; Monfardini C, 2002, CURR PHARM DESIGN, V8, P2185, DOI 10.2174/1381612023393198; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Mulloy B, 2001, CURR OPIN STRUC BIOL, V11, P623, DOI 10.1016/S0959-440X(00)00257-8; Sasaki T, 1999, EMBO J, V18, P6240, DOI 10.1093/emboj/18.22.6240; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; Schnaar RL, 2004, ARCH BIOCHEM BIOPHYS, V426, P163, DOI 10.1016/j.abb.2004.02.019; SCHRIMSHER JL, 1987, BIOCHEM J, V247, P195, DOI 10.1042/bj2470195; THOMPSON LD, 1994, BIOCHEMISTRY-US, V33, P3831, DOI 10.1021/bi00179a006; Tumova S, 2000, INT J BIOCHEM CELL B, V32, P269, DOI 10.1016/S1357-2725(99)00116-8; Vyas AA, 2002, P NATL ACAD SCI USA, V99, P8412, DOI 10.1073/pnas.072211699; WALTER MR, 1992, J MOL BIOL, V224, P1075, DOI 10.1016/0022-2836(92)90470-5; WANG HM, 1991, BIOCHEM J, V278, P689, DOI 10.1042/bj2780689; Wettreich A, 1999, J BIOL CHEM, V274, P31468, DOI 10.1074/jbc.274.44.31468; WINGFIELD P, 1988, EUR J BIOCHEM, V173, P65, DOI 10.1111/j.1432-1033.1988.tb13967.x	47	37	39	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	2005	280	36					31949	31956		10.1074/jbc.M505314200	http://dx.doi.org/10.1074/jbc.M505314200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	961LZ	16027123	hybrid			2022-12-25	WOS:000231665200074
J	Seth, R; Yang, C; Kaushal, V; Shah, SV; Kaushal, GP				Seth, R; Yang, C; Kaushal, V; Shah, SV; Kaushal, GP			p53-dependent caspase-2 activation in mitochondrial release of apoptosis-inducing factor and its role in renal tubular epithelial cell injury	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CISPLATIN-INDUCED APOPTOSIS; CYTOCHROME-C RELEASE; SUPEROXIDE-DISMUTASE; FACTOR AIF; IN-VITRO; DEATH; P53; DYSFUNCTION; INHIBITION; UPSTREAM	We activation in the mitochondrial release of apoptosis-inducing factor (AIF) in cisplatin-treated renal tubular epithelial cells. Gene silencing of AIF with its small interfering RNA ( siRNA) suppressed cisplatin-induced AIF expression and provided a marked protection against cell death. Subcellular fractionation and immunofluorescence studies revealed cisplatin-induced translocation of AIF from the mitochondria to the nuclei. Pancaspase inhibitor benzyloxycarbonyl-Val-Ala-Asp- fluoromethylketone or p53 inhibitor pifithrin-alpha markedly prevented mitochondrial release of AIF, suggesting that caspases and p53 are involved in this release. Caspase-2 and -3 that were predominantly activated in response to cisplatin provided a unique model to study the role of these caspases in AIF release. Cisplatin-treated caspase-3 (+/+) and caspase-3 (-/-) cells exhibited similar AIF translocation to the nuclei, suggesting that caspase- 3 does not affect AIF translocation, and thus, caspase- 2 may be involved in the translocation. Caspase-2 inhibitor benzyloxycarbonyl-Val-Asp-Val- Ala-Asp-fluoromethylketone or down-regulation of caspase- 2 by its siRNA significantly prevented translocation of AIF. Caspase-2 activation was a critical response from p53, which was markedly induced and phosphorylated in cisplatin-treated cells. Overexpression of p53 not only resulted in caspase- 2 activation but also mitochondrial release of AIF. The p53 inhibitor pifithrin-alpha or p53 siRNA prevented both cisplatin-induced caspase- 2 activation and mitochondrial release of AIF. Caspase-2 activation was dependent on the p53-responsive gene, PIDD, a death domain-containing protein that was induced by cisplatin in a p53-dependent manner. These results suggest that caspase- 2 activation mediated by p53 is an important pathway involved in the mitochondrial release of AIF in response to cisplatin injury.	Univ Arkansas Med Sci Hosp, Dept Med, Little Rock, AR 72205 USA; Univ Arkansas Med Sci Hosp, Dept Biochem, Little Rock, AR 72205 USA; Cent Arkansas Vet Healthcare Syst, Little Rock, AR 72205 USA	University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; US Department of Veterans Affairs; Veterans Health Administration (VHA); Central Arkansas Veterans Healthcare System	Kaushal, GP (corresponding author), Univ Arkansas Med Sci Hosp, Dept Med, 4301 W Markham St,Slot 501, Little Rock, AR 72205 USA.	kaushalgurp@uams.edu			NIDDK NIH HHS [DK-58324] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK058324] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arnoult D, 2002, J CELL BIOL, V159, P923, DOI 10.1083/jcb.200207071; Arnoult D, 2001, MOL BIOL CELL, V12, P3016, DOI 10.1091/mbc.12.10.3016; Baek SM, 2003, J LAB CLIN MED, V142, P178, DOI 10.1016/S0022-2143(03)00111-2; Bergin E, 2000, AM J PHYSIOL-RENAL, V278, pF758, DOI 10.1152/ajprenal.2000.278.5.F758; BRADY HR, 1990, AM J PHYSIOL, V258, pF1181, DOI 10.1152/ajprenal.1990.258.5.F1181; Cande C, 2004, CELL DEATH DIFFER, V11, P591, DOI 10.1038/sj.cdd.4401400; Cande C, 2004, ONCOGENE, V23, P1514, DOI 10.1038/sj.onc.1207279; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Cilenti L, 2005, AM J PHYSIOL-RENAL, V288, pF371, DOI 10.1152/ajprenal.00154.2004; Cregan SP, 2002, J CELL BIOL, V158, P507, DOI 10.1083/jcb.200202130; Cregan SP, 2000, GENE THER, V7, P1200, DOI 10.1038/sj.gt.3301208; Cregan SP, 2004, ONCOGENE, V23, P2785, DOI 10.1038/sj.onc.1207517; Cummings BS, 2002, J PHARMACOL EXP THER, V302, P8, DOI 10.1124/jpet.302.1.8; Daugas E, 2000, FEBS LETT, V476, P118, DOI 10.1016/S0014-5793(00)01731-2; Davis CA, 2001, J AM SOC NEPHROL, V12, P2683, DOI 10.1681/ASN.V12122683; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; El-Deiry WS, 2003, ONCOGENE, V22, P7486, DOI 10.1038/sj.onc.1206949; Enoksson M, 2004, J BIOL CHEM, V279, P49575, DOI 10.1074/jbc.C400374200; Fukuoka K, 1998, LIFE SCI, V62, P1125, DOI 10.1016/S0024-3205(98)00036-8; Gabriel B, 2003, EXP CELL RES, V289, P195, DOI 10.1016/S0014-4827(03)00255-6; GORDON JA, 1986, AM J PHYSIOL, V250, pF991, DOI 10.1152/ajprenal.1986.250.6.F991; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; JAGJIT S, 1998, J CLIN INVEST, V101, P2842; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Justo P, 2003, KIDNEY INT, V64, pS52, DOI 10.1046/j.1523-1755.64.s86.10.x; Kaushal GP, 1998, AM J PHYSIOL-RENAL, V274, pF587, DOI 10.1152/ajprenal.1998.274.3.F587; Kaushal GP, 2001, KIDNEY INT, V60, P1726, DOI 10.1046/j.1523-1755.2001.00026.x; Kim JS, 2004, BIOCHEM PHARMACOL, V67, P1459, DOI 10.1016/j.bcp.2003.12.013; Kruidering M, 1997, J PHARMACOL EXP THER, V280, P638; Kuwana T, 2003, CURR OPIN CELL BIOL, V15, P691, DOI 10.1016/j.ceb.2003.10.004; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Lin CF, 2004, J BIOL CHEM, V279, P40755, DOI 10.1074/jbc.M404726200; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nishikawa M, 2001, ARCH BIOCHEM BIOPHYS, V387, P78, DOI 10.1006/abbi.2000.2237; Nowak G, 2003, AM J PHYSIOL-RENAL, V285, pF440, DOI 10.1152/ajprenal.00233.2002; Nowak G, 2002, J BIOL CHEM, V277, P43377, DOI 10.1074/jbc.M206373200; Park MS, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V134858; Penninger JM, 2003, NAT CELL BIOL, V5, P97, DOI 10.1038/ncb0203-97; Robertson JD, 2002, J BIOL CHEM, V277, P29803, DOI 10.1074/jbc.M204185200; ROZENCWEIG M, 1977, ANN INTERN MED, V86, P803, DOI 10.7326/0003-4819-86-6-803; SAFIRSTEIN R, 1987, INT J ANDROL, V10, P325, DOI 10.1111/j.1365-2605.1987.tb00200.x; Satoh M, 2003, J PHARMACOL EXP THER, V305, P1183, DOI 10.1124/jpet.102.047522; Sauerwald TM, 2002, BIOTECHNOL BIOENG, V77, P704, DOI 10.1002/bit.10154; Sax JK, 2003, CELL DEATH DIFFER, V10, P413, DOI 10.1038/sj.cdd.4401227; Schuler M, 2001, BIOCHEM SOC T, V29, P684, DOI 10.1042/0300-5127:0290684; Schwerdt G, 2003, KIDNEY INT, V63, P1725, DOI 10.1046/j.1523-1755.2003.00934.x; SHERIDAN AM, 1993, AM J PHYSIOL, V265, pF342, DOI 10.1152/ajprenal.1993.265.3.F342; Slee EA, 2004, ONCOGENE, V23, P2809, DOI 10.1038/sj.onc.1207516; Stennicke HR, 2000, METHOD ENZYMOL, V322, P91; SUGIYAMA S, 1989, BIOCHEM BIOPH RES CO, V159, P1121, DOI 10.1016/0006-291X(89)92225-0; Susin SA, 2000, J EXP MED, V192, P571, DOI 10.1084/jem.192.4.571; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Takeda M, 1997, ARCH TOXICOL, V71, P612, DOI 10.1007/s002040050434; Tinel A, 2004, SCIENCE, V304, P843, DOI 10.1126/science.1095432; Uren RT, 2005, J BIOL CHEM, V280, P2266, DOI 10.1074/jbc.M411106200; Vahsen N, 2004, EMBO J, V23, P4679, DOI 10.1038/sj.emboj.7600461; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wagner KW, 2004, J BIOL CHEM, V279, P35047, DOI 10.1074/jbc.M400708200; Wang XC, 2002, SCIENCE, V298, P1587, DOI 10.1126/science.1076194; WOOD ER, 1990, J CELL BIOL, V111, P2839, DOI 10.1083/jcb.111.6.2839; Yakovlev AG, 2004, J BIOL CHEM, V279, P28367, DOI 10.1074/jbc.M313526200; Ye H, 2002, NAT STRUCT BIOL, V9, P680, DOI 10.1038/nsb836; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; Zhan Y, 1999, ONCOGENE, V18, P6505, DOI 10.1038/sj.onc.1203060; ZHANG JG, 1993, BIOCHEM PHARMACOL, V45, P2215	68	145	157	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	2005	280	35					31230	31239		10.1074/jbc.M503305200	http://dx.doi.org/10.1074/jbc.M503305200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	958ZX	15983031	hybrid			2022-12-25	WOS:000231487800070
J	Alarcon, R; Fuenzalida, C; Santibanez, M; von Bernhardi, R				Alarcon, R; Fuenzalida, C; Santibanez, M; von Bernhardi, R			Expression of scavenger receptors in glial cells - Comparing the adhesion of astrocytes and microglia from neonatal rats to surface-bound beta-amyloid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; ALZHEIMERS-DISEASE BRAIN; PLAQUE CORE PROTEIN; CLASS-B; NERVOUS-SYSTEM; SENILE PLAQUES; HOST-DEFENSE; IN-VITRO; INFLAMMATORY RESPONSE; CULTURED ASTROCYTES	Astrocytes and microglia associate to amyloid plaques, a pathological hallmark of Alzheimer disease. Microglia are activated by and can phagocytose beta-amyloid ( A beta). Scavenger receptors ( SRs) are among the receptors mediating the uptake of fibrillar A beta in vitro. However, little is known about the function of the astrocytes surrounding the plaques or the nature of their interaction with A beta. It is unknown whether glial cells bind to nonfibrillar A beta and if binding of astrocytes to A beta depends on the same Scavenger receptors described for microglia. We determined the binding of glia to A beta by an adhesion assay and evaluated the presence of scavenger receptors in glial cells by immunocytochemistry, immunohistochemistry of brain sections, and immunoblot. We found that astrocytes and microglia from neonatal rats adhered in a concentration-dependent manner to surfaces coated with fibrillar A beta or nonfibrillar A beta. Fucoidan and poly( I), known ligands for SR-type A, inhibited adhesion of microglia and astrocytes to A beta and also inhibited A beta phagocytosis. In contrast, a ligand for SR-type B like low density lipoprotein, did not compete glial adhesion to A beta. Microglia presented immunodetectable SR-BI, SR-AI/AII, RAGE, and SR-MARCO ( macrophage receptor with collagenous structure, a member of the SR-A family). Astrocytes presented SR-BI and SR-MARCO. To our knowledge, this is the first description of the presence of SR-MARCO in astrocytes. Our results indicate that both microglia and astrocytes adhere to fibrillar and nonfibrillar A beta. Adhesion was mediated by a fucoidan-sensitive receptor. We propose that SR-MARCO could be the Scavenger receptor responsible for the adhesion of astrocytes and microglia to A beta.	Pontificia Univ Catolica Chile, Dept Neurol, Fac Med, Santiago, Chile	Pontificia Universidad Catolica de Chile	von Bernhardi, R (corresponding author), Pontificia Univ Catolica Chile, Dept Neurol, Fac Med, Marcoleta 391, Santiago, Chile.	rvonb@med.puc.cl	von Bernhardi, Rommy/F-7232-2013	von Bernhardi, Rommy/0000-0002-9022-7676				ACTON SL, 1994, J BIOL CHEM, V269, P21003; Alvarez A, 1997, J MOL BIOL, V272, P348, DOI 10.1006/jmbi.1997.1245; Bechmann I, 1997, HISTOCHEM CELL BIOL, V107, P391, DOI 10.1007/s004180050125; BELL MD, 1994, J NEUROCYTOL, V23, P605, DOI 10.1007/BF01191555; Burudi EME, 1999, GLIA, V25, P44, DOI 10.1002/(SICI)1098-1136(19990101)25:1<44::AID-GLIA5>3.0.CO;2-C; Christie RH, 1996, AM J PATHOL, V148, P399; Chung HY, 1999, J BIOL CHEM, V274, P32301, DOI 10.1074/jbc.274.45.32301; Coraci IS, 2002, AM J PATHOL, V160, P101, DOI 10.1016/S0002-9440(10)64354-4; DeWitt DA, 1998, EXP NEUROL, V149, P329, DOI 10.1006/exnr.1997.6738; Dickson DW, 1997, J NEUROPATH EXP NEUR, V56, P321, DOI 10.1097/00005072-199704000-00001; ElKhoury J, 1996, NATURE, V382, P716; ELOMAA O, 1995, CELL, V80, P603, DOI 10.1016/0092-8674(95)90514-6; Gough PJ, 2000, MICROBES INFECT, V2, P305, DOI 10.1016/S1286-4579(00)00297-5; Granucci F, 2003, BLOOD, V102, P2940, DOI 10.1182/blood-2002-12-3651; Greaves DR, 1998, CURR OPIN LIPIDOL, V9, P425, DOI 10.1097/00041433-199810000-00006; Gu XJ, 2000, J BIOL CHEM, V275, P9120, DOI 10.1074/jbc.275.13.9120; HAASS C, 1992, NATURE, V359, P325; HAYES GM, 1988, J NEUROIMMUNOL, V19, P177, DOI 10.1016/0165-5728(88)90001-X; Herrera-Molina R, 2005, NEUROBIOL DIS, V19, P229, DOI 10.1016/j.nbd.2005.01.003; Honda M, 1998, BIOCHEM BIOPH RES CO, V245, P734, DOI 10.1006/bbrc.1998.8120; Hsu HY, 2001, J BIOL CHEM, V276, P28719, DOI 10.1074/jbc.M011117200; Hu JG, 1998, BRAIN RES, V785, P195, DOI 10.1016/S0006-8993(97)01318-8; Hu JR, 1999, BRAIN RES, V842, P46, DOI 10.1016/S0006-8993(99)01804-1; Husemann J, 2001, J NEUROIMMUNOL, V114, P142, DOI 10.1016/S0165-5728(01)00239-9; Husemann J, 2002, GLIA, V40, P195, DOI 10.1002/glia.10148; Husemann J, 2001, AM J PATHOL, V158, P825, DOI 10.1016/S0002-9440(10)64030-8; Inestrosa N., 1997, ALZHEIMERS DIS BIOL, P501; ITAGAKI S, 1989, J NEUROIMMUNOL, V24, P173, DOI 10.1016/0165-5728(89)90115-X; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; Johnstone M, 1999, J NEUROIMMUNOL, V93, P182, DOI 10.1016/S0165-5728(98)00226-4; Kim WS, 2003, BIOCHEM BIOPH RES CO, V310, P542, DOI 10.1016/j.bbrc.2003.09.049; Kraal G, 2000, MICROBES INFECT, V2, P313, DOI 10.1016/S1286-4579(00)00296-3; Krieger M, 1997, CURR OPIN LIPIDOL, V8, P275, DOI 10.1097/00041433-199710000-00006; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; Kurt MA, 1999, EXP NEUROL, V158, P221, DOI 10.1006/exnr.1999.7096; LENZ ML, 1990, J LIPID RES, V31, P1043; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Makranz C, 2004, NEUROBIOL DIS, V15, P279, DOI 10.1016/j.nbd.2003.11.007; Marzolo MP, 1999, J NEUROSCI RES, V58, P387, DOI 10.1002/(SICI)1097-4547(19991101)58:3<387::AID-JNR4>3.3.CO;2-C; McGeer PL, 1995, BRAIN RES REV, V21, P195, DOI 10.1016/0165-0173(95)00011-9; Nilsson KPR, 2005, BIOCHEMISTRY-US, V44, P3718, DOI 10.1021/bi047402u; Paresce DM, 1996, NEURON, V17, P553, DOI 10.1016/S0896-6273(00)80187-7; PIKE CJ, 1995, EXP NEUROL, V132, P172, DOI 10.1016/0014-4886(95)90022-5; Ramirez G, 2005, NEUROBIOL DIS, V19, P243, DOI 10.1016/j.nbd.2005.01.007; Re FB, 2002, J IMMUNOL, V169, P2264, DOI 10.4049/jimmunol.169.5.2264; Rezaie P, 2002, GLIA, V37, P64, DOI 10.1002/glia.1128; ROHER A, 1986, P NATL ACAD SCI USA, V83, P2662, DOI 10.1073/pnas.83.8.2662; ROHER AE, 1988, J CELL BIOL, V107, P2703, DOI 10.1083/jcb.107.6.2703; ROZEMULLER JM, 1989, NEUROSCI LETT, V101, P288, DOI 10.1016/0304-3940(89)90547-8; Sasaki A, 1997, ACTA NEUROPATHOL, V94, P316, DOI 10.1007/s004010050713; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHENG JG, 1995, NEUROPATH APPL NEURO, V21, P290, DOI 10.1111/j.1365-2990.1995.tb01063.x; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SOTO C, 1994, J NEUROCHEM, V63, P1191; SOTO C, 1995, J BIOL CHEM, V270, P3063, DOI 10.1074/jbc.270.7.3063; Tezel G, 2001, GLIA, V34, P178, DOI 10.1002/glia.1052; van der Laan LJW, 1999, J IMMUNOL, V162, P939; VINORES SA, 1993, J NEUROIMMUNOL, V43, P169, DOI 10.1016/0165-5728(93)90088-G; von Bernhardi R, 2004, BRAIN RES, V1025, P186, DOI 10.1016/j.brainres.2004.07.084; Von Bernhardi R, 2001, BIOL RES, V34, P123; von Bernhardi R, 2001, EUR J NEUROSCI, V14, P946, DOI 10.1046/j.0953-816x.2001.01715.x; Wallace MN, 1997, EXP NEUROL, V144, P266, DOI 10.1006/exnr.1996.6373; Wegiel J, 2000, ACTA NEUROPATHOL, V100, P356, DOI 10.1007/s004010000199; WOLF BB, 1992, AM J PATHOL, V141, P37; Wyss-Coray T, 2002, NEURON, V35, P419, DOI 10.1016/S0896-6273(02)00794-8; Wyss-Coray T, 2003, NAT MED, V9, P453, DOI 10.1038/nm838; Yamada Y, 1998, CELL MOL LIFE SCI, V54, P628, DOI 10.1007/s000180050191; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0	71	135	138	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	2005	280	34					30406	30415		10.1074/jbc.M414686200	http://dx.doi.org/10.1074/jbc.M414686200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	957IC	15987691	hybrid			2022-12-25	WOS:000231362500053
J	Hinckley, MB; Reynolds, CM; Ribeiro, AA; McGrath, SC; Cotter, RJ; Lauw, FN; Golenbock, DT; Raetz, CRH				Hinckley, MB; Reynolds, CM; Ribeiro, AA; McGrath, SC; Cotter, RJ; Lauw, FN; Golenbock, DT; Raetz, CRH			A Leptospira interrogans enzyme with similarity to yeast Ste14p that methylates the 1-phosphate group of lipid A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UDP-N-ACETYLGLUCOSAMINE; LINKED ACYL CHAINS; ESCHERICHIA-COLI; RHIZOBIUM-LEGUMINOSARUM; EXPRESSION CLONING; 3-DEOXY-D-MANNO-OCTULOSONIC ACID; LIPOPOLYSACCHARIDE BIOSYNTHESIS; NMR-SPECTROSCOPY; INNER MEMBRANE; MSBA	Distinct from other spirochetes, cells of Leptospira interrogans contain orthologues of all the Escherichia coli lpx genes required for lipid A biosynthesis, but they synthesize a modified form of lipopolysaccharide that supposedly activates toll-like receptor 2 ( TLR2) instead of TLR4. The recent determination of the L. interrogans lipid A structure revealed an unprecedented O-methylation of its 1-phosphate group ( Que-Gewirth, N. L. S., Ribeiro, A. A., Kalb, S. R., Cotter, R. J., Bulach, D. M., Adler, B., Saint Girons, I., Werts, C., and Raetz, C. R. H. ( 2004) J. Biol. Chem. 279, 25420 - 25429). The enzymatic activity responsible for selective 1-phosphate methylation has not been previously explored. A membrane enzyme that catalyzes the transfer of a methyl group from S-adenosylmethionine ( SAM) to the 1-phosphate moiety of E. coli Kdo(2)-[4'-P-32] lipid A has now been discovered. The gene encoding this enzyme was identified based on the hypothesis that methylation of a phosphate group is chemically analogous to methylation of a carboxylate moiety at a membrane-water interface. Database searching revealed a candidate gene ( renamed lmtA) in L. interrogans showing distant homology to the yeast isoprenylcysteine carboxyl methyltransferase, encoded by sterile-14, which methylates the a-type mating factor. Orthologues of lmtA were not present in E. coli, the lipid A of which normally lacks the 1-phosphomethyl group, or in other spirochetes, which do not synthesize lipid A. Expression of the lmtA gene behind the lac promoter on a low copy plasmid resulted in the appearance of SAM-dependent methyltransferase activity in E. coli inner membranes and methylation of about 30% of the endogenous E. coli lipid A. Inactivation of the ABC transporter MsbA did not inhibit methylation of newly synthesized lipid A. Methylated E. coli lipid A was analyzed by mass spectrometry and NMR spectroscopy to confirm the location of the phosphomethyl group at the 1-position. In human cells, engineered to express the individual TLR subtypes, 1-phosphomethyl-lipid A purified from lmtA-expressing E. coli potently activated TLR4 but not TLR2.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Duke Univ, Med Ctr, Duke NMR Spect Ctr, Durham, NC 27710 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Middle Atlantic Mass Spect Lab, Baltimore, MD 21205 USA; Univ Massachusetts, Sch Med, Dept Med, Worcester, MA 01605 USA	Duke University; Duke University; Johns Hopkins University; University of Massachusetts System; University of Massachusetts Worcester	Raetz, CRH (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.	raetz@biochem.duke.edu			NATIONAL CANCER INSTITUTE [P30CA014236] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI057784] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054882, R01GM051796, R01GM054060, R01GM051310, R37GM054060, F32GM073251, R37GM051796] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA014236] Funding Source: Medline; NIAID NIH HHS [AI057784, P01 AI057784] Funding Source: Medline; NIGMS NIH HHS [R37 GM054060, GM-54882, R37 GM051796-09, R01 GM054060, R37 GM051796, 1-F32-GM073251-01, F32 GM073251, GM-54060, R01 GM051796, GM-51796, GM-51310, R01 GM051310] Funding Source: Medline; PHS HHS [P30-AC-14236] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Anderson JL, 2005, J BIOL CHEM, V280, P7336, DOI 10.1074/jbc.M410292200; Basu SS, 1999, J BIOL CHEM, V274, P11139, DOI 10.1074/jbc.274.16.11139; Basu SS, 2002, J BIOL CHEM, V277, P28959, DOI 10.1074/jbc.M204525200; Beutler B, 2003, J LEUKOCYTE BIOL, V74, P479, DOI 10.1189/jlb.0203082; Bishop RE, 2000, EMBO J, V19, P5071, DOI 10.1093/emboj/19.19.5071; Brozek KA, 1996, J BIOL CHEM, V271, P32112, DOI 10.1074/jbc.271.50.32119; BROZEK KA, 1989, J BIOL CHEM, V264, P6956; Bulach DM, 2000, J MOL MICROB BIOTECH, V2, P375; Coggins BE, 2003, NAT STRUCT BIOL, V10, P645, DOI 10.1038/nsb948; Doerrler WT, 2004, J BIOL CHEM, V279, P45102, DOI 10.1074/jbc.M408106200; Doerrler WT, 2002, J BIOL CHEM, V277, P36697, DOI 10.1074/jbc.M205857200; Doerrler WT, 2001, J BIOL CHEM, V276, P11461, DOI 10.1074/jbc.C100091200; Fahy E, 2005, J LIPID RES, V46, P839, DOI 10.1194/jlr.E400004-JLR200; FREEZE HH, 1992, J BIOL CHEM, V267, P4431; Gioannini TL, 2004, P NATL ACAD SCI USA, V101, P4186, DOI 10.1073/pnas.0306906101; GONZALEZROMO P, 1992, ANAL BIOCHEM, V200, P235, DOI 10.1016/0003-2697(92)90458-J; GUYCAFFEY JK, 1992, J BACTERIOL, V174, P2460, DOI 10.1128/jb.174.8.2460-2465.1992; Hirschfeld M, 2000, J IMMUNOL, V165, P618, DOI 10.4049/jimmunol.165.2.618; INOUE H, 1990, GENE, V96, P23, DOI 10.1016/0378-1119(90)90336-P; KAGAN RM, 1994, ARCH BIOCHEM BIOPHYS, V310, P417, DOI 10.1006/abbi.1994.1187; Karbarz MJ, 2003, J BIOL CHEM, V278, P39269, DOI 10.1074/jbc.M305830200; KARBARZ MJ, 2004, THESIS DUKE U MED CT; KATES M, 1993, BIOCHIM BIOPHYS ACTA, V1169, P46, DOI 10.1016/0005-2760(93)90080-S; Latz E, 2002, J BIOL CHEM, V277, P47834, DOI 10.1074/jbc.M207873200; Lee H, 2004, J BACTERIOL, V186, P4124, DOI 10.1128/JB.186.13.4124-4133.2004; Levett PN, 2001, CLIN MICROBIOL REV, V14, P296, DOI 10.1128/CMR.14.2.296-326.2001; Miller J.H., 1972, EXPT MOL GENTICS; Miller SI, 2005, NAT REV MICROBIOL, V3, P36, DOI 10.1038/nrmicro1068; Onishi HR, 1996, SCIENCE, V274, P980, DOI 10.1126/science.274.5289.980; Osborn M J, 1974, Methods Enzymol, V31, P642; Pereira MM, 2000, J CLIN MICROBIOL, V38, P450; Que NLS, 2000, J BIOL CHEM, V275, P28017; Que-Gewirth NLS, 2004, J BIOL CHEM, V279, P25420, DOI 10.1074/jbc.M400598200; Que-Gewirth NLS, 2003, J BIOL CHEM, V278, P12120, DOI 10.1074/jbc.M300379200; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; Ren SX, 2003, NATURE, V422, P888, DOI 10.1038/nature01597; Reynolds CM, 2005, J BIOL CHEM, V280, P21202, DOI 10.1074/jbc.M500964200; Ribeiro AA, 1999, MAGN RESON CHEM, V37, P620, DOI 10.1002/(SICI)1097-458X(199909)37:9<620::AID-MRC517>3.0.CO;2-Q; Romano JD, 2001, MOL BIOL CELL, V12, P1957, DOI 10.1091/mbc.12.7.1957; Sweet CR, 2004, J BIOL CHEM, V279, P25400, DOI 10.1074/jbc.M400596200; Sweet CR, 2004, J BIOL CHEM, V279, P25411, DOI 10.1074/jbc.M400597200; Tran AX, 2004, J BIOL CHEM, V279, P55780, DOI 10.1074/jbc.M406480200; WANG RF, 1991, GENE, V100, P195, DOI 10.1016/0378-1119(91)90366-J; Wang XY, 2004, J BIOL CHEM, V279, P49470, DOI 10.1074/jbc.M409078200; Werts C, 2001, NAT IMMUNOL, V2, P346, DOI 10.1038/86354; Zhou ZM, 1998, J BIOL CHEM, V273, P12466, DOI 10.1074/jbc.273.20.12466; Zhou ZM, 2000, J BIOL CHEM, V275, P13542, DOI 10.1074/jbc.275.18.13542	47	17	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	2005	280	34					30214	30224		10.1074/jbc.M506103200	http://dx.doi.org/10.1074/jbc.M506103200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	957IC	15994324	Green Accepted, hybrid			2022-12-25	WOS:000231362500030
J	Regoes, A; Zourmpanou, D; Leon-Avila, G; van der Giezen, M; Tovar, J; Hehl, AB				Regoes, A; Zourmpanou, D; Leon-Avila, G; van der Giezen, M; Tovar, J; Hehl, AB			Protein import, replication, and inheritance of a vestigial mitochondrion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GIARDIA-LAMBLIA; TRICHOMONAS-VAGINALIS; ENTAMOEBA-HISTOLYTICA; REMNANT ORGANELLES; GENOME; GENES; HYDROGENOSOMES; INTESTINALIS; EUKARYOTES; MACHINERY	Mitochondrial remnant organelles ( mitosomes) that exist in a range of "amitochondrial" eukaryotic organisms represent ideal models for the study of mitochondrial evolution and for the establishment of the minimal set of proteins required for the biogenesis of an endosymbiosis-derived organelle. Giardia intestinalis, often described as the earliest branching eukaryote, contains double membrane-bounded structures involved in iron-sulfur cluster biosynthesis, an essential function of mitochondria. Here we present evidence that Giardia mitosomes also harbor Cpn60, mtHsp70, and ferredoxin and that despite their advanced state of reductive evolution they have retained vestiges of presequence-dependent and -independent protein import pathways akin to those that operate in mammalian mitochondria. Although import of IscU and ferredoxin is still reliant on their amino-terminal presequences, targeting of Giardia Cpn60, IscS, or mtHsp70 into mitosomes no longer requires cleavable presequences, a derived feature from their mitochondrial homologues. In addition, we found that division and segregation of a single centrally positioned mitosome tightly associated with the microtubular cytoskeleton is coordinated with the cell cycle, whereas peripherally located mitosomes are inherited into daughter cells stochastically.	Univ London Royal Holloway & Bedford New Coll, Sch Biol Sci, Egham TW20 0EX, Surrey, England; Univ Zurich, Inst Parasitol, CH-8057 Zurich, Switzerland	University of London; Royal Holloway University London; University of Zurich	Tovar, J (corresponding author), Univ London Royal Holloway & Bedford New Coll, Sch Biol Sci, Egham TW20 0EX, Surrey, England.	j.tovar@rhul.ac.uk	van der Giezen, Mark/J-9550-2019	van der Giezen, Mark/0000-0002-1033-1335; Hehl, Adrian/0000-0002-2110-4445	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Adam RD, 2001, CLIN MICROBIOL REV, V14, P447, DOI 10.1128/CMR.14.3.447-475.2001; AMAYA Y, 1988, J BIOL CHEM, V263, P14463; ARAKAWA H, 1990, J BIOCHEM-TOKYO, V107, P160, DOI 10.1093/oxfordjournals.jbchem.a123001; Arisue N, 2002, PARASITOL INT, V51, P9, DOI 10.1016/S1383-5769(01)00093-9; Bakatselou C, 2000, ARCH MED RES, V31, pS176, DOI 10.1016/S0188-4409(00)00211-3; Benchimol M, 1996, BIOL CELL, V87, P197, DOI 10.1016/S0248-4900(97)89276-3; Benchimol M, 2004, BIOL CELL, V96, P291, DOI 10.1016/j.biolcel.2004.01.007; BEREITERHAHN J, 1994, MICROSC RES TECHNIQ, V27, P198, DOI 10.1002/jemt.1070270303; Best AA, 2004, GENOME RES, V14, P1537, DOI 10.1101/gr.2256604; Boxma B, 2005, NATURE, V434, P74, DOI 10.1038/nature03343; Bradley PJ, 1997, EMBO J, V16, P3484, DOI 10.1093/emboj/16.12.3484; Bui ETN, 1996, P NATL ACAD SCI USA, V93, P9651, DOI 10.1073/pnas.93.18.9651; CLARK CG, 1995, P NATL ACAD SCI USA, V92, P6518, DOI 10.1073/pnas.92.14.6518; Dyall SD, 2003, J BIOL CHEM, V278, P30548, DOI 10.1074/jbc.M304032200; Emelyanov VV, 2003, FEMS MICROBIOL LETT, V226, P257, DOI 10.1016/S0378-1097(03)00598-6; FILICE FRANCIS P., 1952, UNIV CALIFORNIA PUBL ZOOL, V57, P53; Gray MW, 2005, NATURE, V434, P29, DOI 10.1038/434029a; Gribaldo S, 2002, THEOR POPUL BIOL, V61, P391, DOI 10.1006/tpbi.2002.1593; Hehl AB, 2000, MOL BIOL CELL, V11, P1789, DOI 10.1091/mbc.11.5.1789; Hehl AB, 2004, MOL MICROBIOL, V53, P19, DOI 10.1111/j.1365-2958.2004.04115.x; Inagaki Y, 2003, NUCLEIC ACIDS RES, V31, P4227, DOI 10.1093/nar/gkg440; JARVIS JA, 1995, J BIOL CHEM, V270, P1323, DOI 10.1074/jbc.270.3.1323; Katinka MD, 2001, NATURE, V414, P450, DOI 10.1038/35106579; Knight J, 2004, NATURE, V429, P236, DOI 10.1038/429236a; Koonin EV, 2003, NAT REV MICROBIOL, V1, P127, DOI 10.1038/nrmicro751; LaGier MJ, 2003, MICROBIOL-SGM, V149, P3519, DOI 10.1099/mic.0.26365-0; Leon-Avila G, 2004, MICROBIOL-SGM, V150, P1245, DOI 10.1099/mic.0.26923-0; Lill R, 2000, TRENDS BIOCHEM SCI, V25, P352, DOI 10.1016/S0968-0004(00)01589-9; Loftus B, 2005, NATURE, V433, P865, DOI 10.1038/nature03291; Lucattini R, 2004, MOL BIOL EVOL, V21, P652, DOI 10.1093/molbev/msh058; Marti M, 2003, J BIOL CHEM, V278, P24837, DOI 10.1074/jbc.M302082200; Martin W, 1998, NATURE, V392, P37, DOI 10.1038/32096; McArthur AG, 2000, FEMS MICROBIOL LETT, V189, P271, DOI 10.1111/j.1574-6968.2000.tb09242.x; Morgan GW, 2004, J BIOL CHEM, V279, P10692, DOI 10.1074/jbc.M312178200; Morrison HG, 2001, MOL BIOL EVOL, V18, P530, DOI 10.1093/oxfordjournals.molbev.a003832; Muhlenhoff U, 2004, J BIOL CHEM, V279, P36906, DOI 10.1074/jbc.M406516200; Muller M., 2003, MOL MED PARASITOLOGY, P125, DOI DOI 10.1016/B978-012473346-6/50008-9; Nasirudeen AMA, 2004, J MICROBIOL METH, V58, P101, DOI 10.1016/j.mimet.2004.03.008; Nixon JEJ, 2002, EUKARYOT CELL, V1, P181, DOI 10.1128/EC.1.2.181-190.2002; Ogbadoyi EO, 2003, MOL BIOL CELL, V14, P1769, DOI 10.1091/mbc.E02-08-0525; Plumper E, 2000, MOL BIOCHEM PARASIT, V106, P11, DOI 10.1016/S0166-6851(99)00196-6; Riordan CE, 2003, CURR GENET, V44, P138, DOI 10.1007/s00294-003-0432-1; Roger AJ, 2002, NATURE, V418, P827, DOI 10.1038/418827a; Roger AJ, 1998, P NATL ACAD SCI USA, V95, P229, DOI 10.1073/pnas.95.1.229; Singer SM, 1998, MOL BIOCHEM PARASIT, V92, P59, DOI 10.1016/S0166-6851(97)00225-9; SINGH B, 1990, BIOCHEM BIOPH RES CO, V169, P391, DOI 10.1016/0006-291X(90)90344-M; Slapeta J, 2004, EUKARYOT CELL, V3, P483, DOI 10.1128/EC.3.2.483-494.2004; Smirnova E, 2001, MOL BIOL CELL, V12, P2245, DOI 10.1091/mbc.12.8.2245; SOGIN ML, 1989, SCIENCE, V243, P75, DOI 10.1126/science.2911720; SOLTYS BJ, 1994, J PARASITOL, V80, P580, DOI 10.2307/3283195; Sutak R, 2004, P NATL ACAD SCI USA, V101, P10368, DOI 10.1073/pnas.0401319101; Tachezy J, 2001, MOL BIOL EVOL, V18, P1919, DOI 10.1093/oxfordjournals.molbev.a003732; Tielens AGM, 2002, TRENDS BIOCHEM SCI, V27, P564, DOI 10.1016/S0968-0004(02)02193-X; Tovar J, 1999, MOL MICROBIOL, V32, P1013, DOI 10.1046/j.1365-2958.1999.01414.x; Tovar J, 2003, NATURE, V426, P172, DOI 10.1038/nature01945; WEBSTER TJ, 1994, DNA CELL BIOL, V13, P1213, DOI 10.1089/dna.1994.13.1213; Wiedemann N, 2004, J BIOL CHEM, V279, P14473, DOI 10.1074/jbc.R400003200; Williams BAP, 2002, NATURE, V418, P865, DOI 10.1038/nature00949; Xu P, 2004, NATURE, V431, P1107, DOI 10.1038/nature02977; Yu LZ, 2002, EUKARYOT CELL, V1, P191, DOI 10.1128/EC.1.2.191-199.2002	60	82	86	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	2005	280	34					30557	30563		10.1074/jbc.M500787200	http://dx.doi.org/10.1074/jbc.M500787200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	957IC	15985435	hybrid			2022-12-25	WOS:000231362500071
J	Adlam, VJ; Harrison, JC; Porteous, CM; James, AM; Smith, RAJ; Murphy, MP; Sammut, IA				Adlam, VJ; Harrison, JC; Porteous, CM; James, AM; Smith, RAJ; Murphy, MP; Sammut, IA			Targeting an antioxidant to mitochondria decreases cardiac ischemia-reperfusion injury	FASEB JOURNAL			English	Article						TPP; oxidative damage; MitoQ	COMPLEX-I ACTIVITY; PERMEABILITY TRANSITION; OXIDATIVE DAMAGE; CYTOCHROME-C; HEART; ISCHEMIA/REPERFUSION; FIBROBLASTS; DYSFUNCTION; ACTIVATION; DELIVERY	Mitochondrial oxidative damage contributes to a wide range of pathologies, including cardiovascular disorders and neurodegenerative diseases. Therefore, protecting mitochondria from oxidative damage should be an effective therapeutic strategy. However, conventional antioxidants have limited efficacy due to the difficulty of delivering them to mitochondria in situ. To overcome this problem, we developed mitochondria-targeted antioxidants, typified by MitoQ, which comprises a lipophilic triphenylphosphonium (TPP) cation covalently attached to a ubiquinol antioxidant. Driven by the large mitochondrial membrane potential, the TPP cation concentrates MitoQ several hundred-fold within mitochondria, selectively preventing mitochondrial oxidative damage. To test whether MitoQ was active in vivo, we chose a clinically relevant form of mitochondrial oxidative damage: cardiac ischemia-reperfusion injury. Feeding MitoQ to rats significantly decreased heart dysfunction, cell death, and mitochondrial damage after ischemia-reperfusion. This protection was due to the antioxidant activity of MitoQ within mitochondria, as an untargeted antioxidant was ineffective and accumulation of the TPP cation alone gave no protection. Therefore, targeting antioxidants to mitochondria in vivo is a promising new therapeutic strategy in the wide range of human diseases such as Parkinson's disease, diabetes, and Friedreich's ataxia where mitochondrial oxidative damage underlies the pathology.	MRC, Dunn Human Nutr Unit, Cambridge CB2 2XY, England; Univ Otago, Dept Chem, Dunedin, New Zealand; Univ Otago, Dept Pharmacol & Toxicol, Dunedin, New Zealand; Univ Otago, Dept Biochem, Dunedin, New Zealand	UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research; University of Otago; University of Otago; University of Otago	Murphy, MP (corresponding author), MRC, Dunn Human Nutr Unit, Wellcome Trust MRC Bldg,Hills Rd, Cambridge CB2 2XY, England.	mpm@mrc-dunn.cam.ac.uk	James, Andrew M/A-2639-2015; Murphy, Michael P/C-2120-2009	James, Andrew M/0000-0002-0515-9649; Murphy, Michael P/0000-0003-1115-9618; Sammut, Ivan/0000-0002-9217-9452; Harrison, Joanne/0000-0002-2431-4480				Aliev MK, 2002, CARDIOVASC RES, V53, P48, DOI 10.1016/S0008-6363(01)00474-6; Asimakis GK, 2002, CIRCULATION, V105, P981, DOI 10.1161/hc0802.104502; Asin-Cayuela J, 2004, FEBS LETT, V571, P9, DOI 10.1016/j.febslet.2004.06.045; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Bergmeyer HU., 1974, METHODS ENZYMATIC AN, P574, DOI [10.1016/B978-0-12-091302-2.50010-4, DOI 10.1016/B978-0-12-091302-2.50010-4]; Berkich DA, 2003, ARCH BIOCHEM BIOPHYS, V420, P279, DOI 10.1016/j.abb.2003.09.021; Borutaite V, 2001, BBA-MOL BASIS DIS, V1537, P101, DOI 10.1016/S0925-4439(01)00062-X; Chen ZY, 1998, J MOL CELL CARDIOL, V30, P2281, DOI 10.1006/jmcc.1998.0789; Clarkson AN, 2004, FASEB J, V18, P1114, DOI 10.1096/fj.03-1203fje; Dhanasekaran A, 2004, J BIOL CHEM, V279, P37575, DOI 10.1074/jbc.M404003200; GRINIUS LL, 1970, BIOCHIM BIOPHYS ACTA, V216, P1, DOI 10.1016/0005-2728(70)90153-2; HARDY L, 1991, BIOCHEM J, V274, P133, DOI 10.1042/bj2740133; James AM, 1996, BIOCHEM J, V318, P401, DOI 10.1042/bj3180401; Jauslin ML, 2003, FASEB J, V17, P1972, DOI 10.1096/fj.03-0240fje; Kelso GF, 2001, J BIOL CHEM, V276, P4588, DOI 10.1074/jbc.M009093200; Kelso GF, 2002, ANN NY ACAD SCI, V959, P263, DOI 10.1111/j.1749-6632.2002.tb02098.x; KENNEDY MC, 1983, J BIOL CHEM, V258, P1098; Lesnefsky EJ, 2003, ARCH BIOCHEM BIOPHYS, V420, P287, DOI 10.1016/j.abb.2003.09.046; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Marczin N, 2003, ARCH BIOCHEM BIOPHYS, V420, P222, DOI 10.1016/j.abb.2003.08.037; Murphy MP, 2000, ADV DRUG DELIVER REV, V41, P235, DOI 10.1016/S0169-409X(99)00069-1; Murphy MP, 1997, TRENDS BIOTECHNOL, V15, P326, DOI 10.1016/S0167-7799(97)01068-8; Murphy MP, 2001, BBA-BIOENERGETICS, V1504, P1, DOI 10.1016/S0005-2728(00)00234-6; OKAMOTO K, 1985, CHEM PHARM BULL, V33, P3745; Paradies G, 2004, CIRC RES, V94, P53, DOI 10.1161/01.RES.0000109416.56608.64; Ragan MT, 1987, MITOCHONDRIA PRACTIC, P79; Raha S, 2000, TRENDS BIOCHEM SCI, V25, P502, DOI 10.1016/S0968-0004(00)01674-1; Sadek HA, 2003, ARCH BIOCHEM BIOPHYS, V420, P201, DOI 10.1016/j.abb.2003.09.029; Sammut IA, 2001, AM J PATHOL, V158, P1821, DOI 10.1016/S0002-9440(10)64138-7; Smith RAJ, 2003, P NATL ACAD SCI USA, V100, P5407, DOI 10.1073/pnas.0931245100; Suzuki K, 2002, CIRCULATION, V106, pI270, DOI 10.1161/01.cir.0000032880.55215.92; Vasquez-Vivar J, 2000, J BIOL CHEM, V275, P14064, DOI 10.1074/jbc.275.19.14064; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; Weiss JN, 2003, CIRC RES, V93, P292, DOI 10.1161/01.RES.0000087542.26971.D4; Wright AF, 2004, NAT GENET, V36, P1153, DOI 10.1038/ng1448; ZWEIER JL, 1987, P NATL ACAD SCI USA, V84, P1404, DOI 10.1073/pnas.84.5.1404	37	501	532	1	64	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2005	19	9					1088	1095		10.1096/fj.05-3718com	http://dx.doi.org/10.1096/fj.05-3718com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	951IO	15985532				2022-12-25	WOS:000230923000037
J	Chan, SW; Egan, PA				Chan, SW; Egan, PA			Hepatitis C virus envelope proteins regulate CHOP via induction of the unfolded protein response	FASEB JOURNAL			English	Article						ER-associated degradation; UPR	ENDOPLASMIC-RETICULUM STRESS; ER STRESS; TRANSCRIPTION FACTOR; MESSENGER-RNA; CELL-DEATH; GLYCOPROTEIN COMPLEXES; TRANSLATIONAL CONTROL; POSSIBLE INVOLVEMENT; MEDIATED APOPTOSIS; MAMMALIAN-CELLS	Unfolded protein response (UPR) is a cellular adaptive response that functions to reduce stress caused by malfolded proteins in the endoplasmic reticulum ( ER). UPR can be induced under physiological or pathological conditions and is responsible for the pathogenesis of many human diseases. Hepatitis C virus (HCV) is a single-stranded, positive-sense RNA virus causing chronic diseases. Its genome encodes two envelope proteins E1 and E2, which mature in the ER to form a noncovalently bound, native complex and disulfide aggregates and have previously been shown to induce expression of the molecular chaperone immunoglobulin heavy chain binding protein. In this study, we show that HCV envelope protein expression regulates another stress indicator CCAAT/enhancer-binding protein-homologous protein (CHOP). The ER-stress element and the activating transcription factor 4 element in the CHOP promoter were activated to a similar extent by HCV envelope protein expression. Using mouse embryonic fibroblasts deficient in the ER stress kinase RNA-activated protein kinase-like ER-resident kinase (PERK), we showed that PERK was necessary and sufficient for activating the CHOP promoter. Expression of HCV E1 and/or E2 also induced splicing of X-box binding protein 1 and transactivation of the unfolded protein response element, leading to the speculation that HCV E1 and E2 not only regulate the UPR but also ER-associated degradation.	UMIST, Fac Life Sci, Manchester M60 1QD, Lancs, England; Manchester Royal Infirm, Manchester M13 9WL, Lancs, England	University of Manchester; University of Manchester	Chan, SW (corresponding author), UMIST, Fac Life Sci, Jacksons Mill,POB 88,Sackerville St, Manchester M60 1QD, Lancs, England.	wan.chan@manchester.ac.uk		Chan, Shiu-Wan/0000-0002-4018-9309	Medical Research Council [G0000092] Funding Source: Medline; MRC [G0000092] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		BARONE MV, 1994, GENE DEV, V8, P453, DOI 10.1101/gad.8.4.453; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Bitko V, 2001, J CELL BIOCHEM, V80, P441, DOI 10.1002/1097-4644(20010301)80:3<441::AID-JCB170>3.0.CO;2-C; Brewer JW, 1999, P NATL ACAD SCI USA, V96, P8505, DOI 10.1073/pnas.96.15.8505; Bruhat A, 2000, MOL CELL BIOL, V20, P7192, DOI 10.1128/MCB.20.19.7192-7204.2000; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; CHEN JJ, 1995, TRENDS BIOCHEM SCI, V20, P105, DOI 10.1016/S0968-0004(00)88975-6; Choukhi A, 1998, J VIROL, V72, P3851, DOI 10.1128/JVI.72.5.3851-3858.1998; Ciccaglione AR, 2004, VIRUS RES, V104, P1, DOI 10.1016/j.virusres.2004.02.002; Deleersnyder V, 1997, J VIROL, V71, P697, DOI 10.1128/JVI.71.1.697-704.1997; Dimcheff DE, 2004, J BIOL CHEM, V279, P33782, DOI 10.1074/jbc.M403304200; Dubuisson J, 1996, J VIROL, V70, P778, DOI 10.1128/JVI.70.2.778-786.1996; DUBUISSON J, 1994, J VIROL, V68, P6147, DOI 10.1128/JVI.68.10.6147-6160.1994; Fernandez PM, 2000, BREAST CANCER RES TR, V59, P15, DOI 10.1023/A:1006332011207; Friedlander R, 2000, NAT CELL BIOL, V2, P379, DOI 10.1038/35017001; HARADA S, 1995, J GEN VIROL, V76, P1223, DOI 10.1099/0022-1317-76-5-1223; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Iwawaki T, 2001, NAT CELL BIOL, V3, P158, DOI 10.1038/35055065; Jordan R, 2002, J VIROL, V76, P9588, DOI 10.1128/JVI.76.19.9588-9599.2002; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kishimoto T, 1998, CELL GROWTH DIFFER, V9, P337; Liberman E, 1999, J VIROL, V73, P3718, DOI 10.1128/JVI.73.5.3718-3722.1999; Liu N, 2004, J NEUROVIROL, V10, P189, DOI 10.1080/13550280490448043; Ma YJ, 2002, J MOL BIOL, V318, P1351, DOI 10.1016/S0022-2836(02)00234-6; Marusawa H, 1999, J VIROL, V73, P4713, DOI 10.1128/JVI.73.6.4713-4720.1999; MATSUURA Y, 1992, J VIROL, V66, P1425, DOI 10.1128/JVI.66.3.1425-1431.1992; Maytin EV, 2001, EXP CELL RES, V267, P193, DOI 10.1006/excr.2001.5248; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; Merola M, 2001, J VIROL, V75, P11205, DOI 10.1128/JVI.75.22.11205-11217.2001; Michalak JP, 1997, J GEN VIROL, V78, P2299, DOI 10.1099/0022-1317-78-9-2299; Moradpour D, 2002, TRENDS MOL MED, V8, P476, DOI 10.1016/S1471-4914(02)02395-X; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; Reimold AM, 2000, GENE DEV, V14, P152; Roderick HL, 1997, FEBS LETT, V405, P181, DOI 10.1016/S0014-5793(97)00183-X; Sansonno D, 2004, J VIRAL HEPATITIS, V11, P27, DOI 10.1046/j.1365-2893.2003.00474.x; Schroder M, 2003, MOL MICROBIOL, V49, P591, DOI 10.1046/j.1365-2958.2003.03585.x; Selby M, 1999, J IMMUNOL, V162, P669; Shen JS, 2002, DEV CELL, V3, P99, DOI 10.1016/S1534-5807(02)00203-4; Shuda M, 2003, J HEPATOL, V38, P605, DOI 10.1016/S0168-8278(03)00029-1; Sidrauski C, 1997, CELL, V90, P1031, DOI 10.1016/S0092-8674(00)80369-4; Sood R, 2000, GENETICS, V154, P787; Su HL, 2002, J VIROL, V76, P4162, DOI 10.1128/JVI.76.9.4162-4171.2002; Tardif KD, 2002, J VIROL, V76, P7453, DOI 10.1128/JVI.76.15.7453-7459.2002; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; Wang Y, 2000, J BIOL CHEM, V275, P27013; Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127; Xu ZC, 1997, J VIROL, V71, P7387, DOI 10.1128/JVI.71.10.7387-7392.1997; Yoneda T, 2001, J BIOL CHEM, V276, P13935, DOI 10.1074/jbc.M010677200; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Yoshida H, 2000, MOL CELL BIOL, V20, P6755, DOI 10.1128/MCB.20.18.6755-6767.2000; Yoshida H, 2003, DEV CELL, V4, P265, DOI 10.1016/S1534-5807(03)00022-4; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; Zhou X J, 1993, Zhonghua Bing Li Xue Za Zhi, V22, P157; Zhu LX, 2004, WORLD J GASTROENTERO, V10, P2972; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	58	117	120	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2005	19	9					1510	+		10.1096/fj.04-3455fje	http://dx.doi.org/10.1096/fj.04-3455fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	951IO	16006626				2022-12-25	WOS:000230923000030
J	Hasaneen, NA; Zucker, S; Cao, J; Chiarelli, C; Panettieri, RA; Foda, HD				Hasaneen, NA; Zucker, S; Cao, J; Chiarelli, C; Panettieri, RA; Foda, HD			Cyclic mechanical strain-induced proliferation and migration of human airway smooth muscle cells: role of EMMPRIN and MMPs	FASEB JOURNAL			English	Article						matrix metalloproteinase; asthma	MEMBRANE-TYPE-1 MATRIX-METALLOPROTEINASE; EPIDERMAL-GROWTH-FACTOR; TENASCIN-C; TYROSINE PHOSPHORYLATION; EPITHELIAL-CELLS; GENE-EXPRESSION; LUNG INJURY; ACTIVATION; INHIBITOR; INDUCTION	Airway smooth muscle (ASM) proliferation and migration are major components of airway remodeling in asthma. Asthmatic airways are exposed to mechanical strain, which contributes to their remodeling. Matrix metalloproteinase (MMP) plays an important role in remodeling. In the present study, we examined if the mechanical strain of human ASM (HASM) cells contributes to their proliferation and migration and the role of MMPs in this process. HASM were exposed to mechanical strain using the FlexCell system. HASM cell proliferation, migration and MMP release, activation, and expression were assessed. Our results show that cyclic strain increased the proliferation and migration of HASM; cyclic strain increased release and activation of MMP-1, -2, and -3 and membrane type 1-MMP; MMP release was preceded by an increase in extracellular MMP inducer; Prinomastat [ a MMP inhibitor ( MMPI)] significantly decreased cyclic strain-induced proliferation and migration of HASM; and the strain-induced increase in the release of MMPs was accompanied by an increase in tenascin-C release. In conclusion, cyclic mechanical strain plays an important role in HASM cell proliferation and migration. This increase in proliferation and migration is through an increase in MMP release and activation. Pharmacological MMPIs should be considered in the pursuit of therapeutic options for airway remodeling in asthma.	SUNY Stony Brook, Hlth Sci Ctr, Stony Brook, NY 11794 USA; Vet Adm Med Ctr, Dept Med & Res, Northport, NY 11768 USA; Univ Penn, Med Ctr, Pulm Allergy & Crit Care Div, Philadelphia, PA 19104 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Pennsylvania	Foda, HD (corresponding author), SUNY Stony Brook, Hlth Sci Ctr, Stony Brook, NY 11794 USA.	Hussein.Foda@med.va.gov	panettieri, reynold/AAG-9485-2019		NATIONAL CANCER INSTITUTE [R01CA079866] Funding Source: NIH RePORTER; NCI NIH HHS [CA79866, R01 CA079866] Funding Source: Medline; NHLBI NIH HHS [R01 HL064634, HL-646340] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Belien ATJ, 1999, J CELL BIOL, V144, P373, DOI 10.1083/jcb.144.2.373; Black JL, 2003, RESP PHYSIOL NEUROBI, V137, P339, DOI 10.1016/S1569-9048(03)00157-5; Black JL, 2001, AM J RESP CRIT CARE, V164, pS63, DOI 10.1164/ajrccm.164.supplement_2.2106059; Buckley S, 2001, AM J PHYSIOL-LUNG C, V281, pL427; Cao JA, 1996, J BIOL CHEM, V271, P30174, DOI 10.1074/jbc.271.47.30174; Chess PR, 2000, AM J PHYSIOL-LUNG C, V279, pL43; Cleek RL, 1997, J BIOMED MATER RES, V35, P525, DOI 10.1002/(SICI)1097-4636(19970615)35:4<525::AID-JBM12>3.0.CO;2-A; Corbel M, 2001, EUR J PHARMACOL, V426, P113, DOI 10.1016/S0014-2999(01)01209-2; Cowan KN, 2000, J CLIN INVEST, V105, P21, DOI 10.1172/JCI6539; Cowan KN, 1999, CIRC RES, V84, P1223, DOI 10.1161/01.RES.84.10.1223; CROWAN K, 1997, CIRCULATION S1, V96, P243; DeCastro R, 1996, J INVEST DERMATOL, V106, P1260, DOI 10.1111/1523-1747.ep12348959; Deryugina EI, 2003, INT J CANCER, V104, P533, DOI 10.1002/ijc.10977; Deryugina EI, 2002, J BIOL CHEM, V277, P9749, DOI 10.1074/jbc.M110269200; DEZELASNY ETS, 1993, AM J RESP CELL MOL B, V9, P645; Elias JA, 2000, AM J RESP CRIT CARE, V161, pS168, DOI 10.1164/ajrccm.161.supplement_2.a1q4-4; Foda HD, 1996, LAB INVEST, V74, P538; Foda HD, 1999, AM J PHYSIOL-LUNG C, V277, pL174, DOI 10.1152/ajplung.1999.277.1.L174; Foda HD, 2001, AM J RESP CELL MOL, V25, P717, DOI 10.1165/ajrcmb.25.6.4558f; Fowlkes JL, 1999, ANN NY ACAD SCI, V878, P696, DOI 10.1111/j.1749-6632.1999.tb07765.x; Fowlkes JL, 2002, CYTOKINE GROWTH F R, V13, P277, DOI 10.1016/S1359-6101(02)00005-9; Gabison EE, 2005, AM J PATHOL, V166, P209, DOI 10.1016/S0002-9440(10)62245-6; Galvez BG, 2001, J BIOL CHEM, V276, P37491, DOI 10.1074/jbc.M104094200; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; Gizycki MJ, 1997, AM J RESP CELL MOL, V16, P664, DOI 10.1165/ajrcmb.16.6.9191468; Guo HM, 2000, CANCER RES, V60, P888; Haseneen NA, 2003, AM J PHYSIOL-LUNG C, V284, pL541, DOI 10.1152/ajplung.00290.2002; Hedges JC, 1999, J BIOL CHEM, V274, P24211, DOI 10.1074/jbc.274.34.24211; HEDIN U, 1991, AM J PATHOL, V139, P649; Hirst SJ, 2000, AM J RESP CELL MOL, V23, P335, DOI 10.1165/ajrcmb.23.3.3990; HIRST SJ, 1992, AM J RESP CELL MOL, V7, P574, DOI 10.1165/ajrcmb/7.6.574; JAMES AL, 1989, AM REV RESPIR DIS, V139, P242, DOI 10.1164/ajrccm/139.1.242; Johnson S, 1999, AM J PHYSIOL-LUNG C, V277, pL1109, DOI 10.1152/ajplung.1999.277.6.L1109; Jones PL, 1996, CIRC RES, V79, P1131, DOI 10.1161/01.RES.79.6.1131; Jones PL, 1999, J CELL SCI, V112, P435; Jones PL, 1997, J CELL BIOL, V139, P279, DOI 10.1083/jcb.139.1.279; JONES PL, 1995, J CELL SCI, V108, P519; Kajita M, 2001, J CELL BIOL, V153, P893, DOI 10.1083/jcb.153.5.893; Koshikawa N, 2000, J CELL BIOL, V148, P615, DOI 10.1083/jcb.148.3.615; Latijnhouwers MA, 1996, J PATHOL, V178, P30, DOI 10.1002/(SICI)1096-9896(199601)178:1<30::AID-PATH442>3.0.CO;2-7; Li, 2000, Arterioscler Thromb Vasc Biol, V20, pE1; Li CH, 2003, FASEB J, V17, P2106, DOI 10.1096/fj.03-0150fje; Lim M, 1998, FEBS LETT, V441, P88, DOI 10.1016/S0014-5793(98)01474-4; LIU M, 1992, AM J PHYSIOL, V263, pL376; MIYAUCHI T, 1990, J BIOCHEM-TOKYO, V107, P316, DOI 10.1093/oxfordjournals.jbchem.a123045; Murphy G, 1999, CURR OPIN CELL BIOL, V11, P614, DOI 10.1016/S0955-0674(99)00022-8; NOVERAL JP, 1994, AM J PHYSIOL-LUNG C, V267, pL761, DOI 10.1152/ajplung.1994.267.6.L761; Okamoto I, 1999, ONCOGENE, V18, P1435, DOI 10.1038/sj.onc.1202447; Oudin S, 2002, AM J RESP CELL MOL, V27, P107, DOI 10.1165/ajrcmb.27.1.4766; PANETTIERI RA, 1995, AM J RESP CELL MOL, V13, P205, DOI 10.1165/ajrcmb.13.2.7626288; PANETTIERI RA, 1990, AM J PHYSIOL, V259, pL365, DOI 10.1152/ajplung.1990.259.6.L365; Pavlaki M, 2002, J BIOL CHEM, V277, P2740, DOI 10.1074/jbc.M108987200; Proceedings of the ATS workshop on refractory asthma, 2000, AM J RESP CRIT CARE, V162, P2341, DOI DOI 10.1164/AJRCCM.162.6.ATS9-00; Rajah R, 1996, AM J PHYSIOL-LUNG C, V271, pL1014, DOI 10.1152/ajplung.1996.271.6.L1014; Rajah R, 1999, AM J RESP CELL MOL, V20, P199, DOI 10.1165/ajrcmb.20.2.3148; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Sameshima T, 2000, CANCER LETT, V157, P177, DOI 10.1016/S0304-3835(00)00485-7; Schwartz SM, 1997, J CLIN INVEST, V100, pS87; Seiki M, 2003, CANCER LETT, V194, P1, DOI 10.1016/S0304-3835(02)00699-7; Seiki M, 2003, CANCER METAST REV, V22, P129, DOI 10.1023/A:1023087113214; Shalinsky DR, 1999, ANN NY ACAD SCI, V878, P236, DOI 10.1111/j.1749-6632.1999.tb07689.x; Smith PG, 2003, AM J RESP CELL MOL, V28, P436, DOI 10.1165/rcmb.4754; SMITH PG, 1994, AM J RESP CELL MOL, V10, P85, DOI 10.1165/ajrcmb.10.1.8292386; Spinale FG, 2000, CARDIOVASC RES, V46, P225, DOI 10.1016/S0008-6363(99)00431-9; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; STEWART AG, 1994, CLIN EXP PHARMACOL P, V21, P277, DOI 10.1111/j.1440-1681.1994.tb02513.x; Suzuki M, 1997, J BIOL CHEM, V272, P31730, DOI 10.1074/jbc.272.50.31730; Tschumperlin DJ, 2001, AM J RESP CRIT CARE, V164, pS90, DOI 10.1164/ajrccm.164.supplement_2.2106060; Uzui H, 2000, ATHEROSCLEROSIS, V149, P51, DOI 10.1016/S0021-9150(99)00295-6; Vaalamo M, 1996, BRIT J DERMATOL, V135, P52; Yamamoto K, 1999, J BIOL CHEM, V274, P21840, DOI 10.1074/jbc.274.31.21840; Zucker S, 2001, AM J PATHOL, V158, P1921, DOI 10.1016/S0002-9440(10)64660-3	72	71	76	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2005	19	9					1507	+		10.1096/fj.04-3350fje	http://dx.doi.org/10.1096/fj.04-3350fje			33	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	951IO	16014803				2022-12-25	WOS:000230923000020
J	Krawitz, P; Haffner, C; Fluhrer, R; Steiner, H; Schmid, B; Haass, C				Krawitz, P; Haffner, C; Fluhrer, R; Steiner, H; Schmid, B; Haass, C			Differential localization and identification of a critical aspartate suggest non-redundant proteolytic functions of the presenilin homologues SPPL2b and SPPL3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-SECRETASE ACTIVITY; AMYLOID-BETA-PEPTIDE; REGULATED INTRAMEMBRANE PROTEOLYSIS; TRANSMEMBRANE ASPARTATES; EMBRYONIC-DEVELOPMENT; PRECURSOR PROTEIN; COMPLEX; PROTEASES; NICASTRIN; ZEBRAFISH	Signal peptide peptidase (SPP) is an unusual aspartyl protease that mediates clearance of signal peptides by proteolysis within the endoplasmic reticulum ( ER). Like presenilins, which provide the proteolytically active subunit of the gamma-secretase complex, SPP contains a critical GXGD motif in its C-terminal catalytic center. Although SPP is known to be an aspartyl protease of the GXGD type, several presenilin homologues/SPP-like proteins (PSHs/SPPL) of unknown function have been identified by data base searches. We now investigated the subcellular localization and a putative proteolytic activity of PSHs/SPPLs in cultured cells and in an in vivo model. We demonstrate that SPPL2b is targeted through the secretory pathway to endosomes/lysosomes, whereas SPP and SPPL3 are restricted to the ER. As suggested by the differential subcellular localization of SPPL2b compared with SPP and SPPL3, we found distinct phenotypes upon antisense gripNA-mediated knockdown in zebrafish. spp and sppl3 knockdowns in zebrafish result in cell death within the central nervous system, whereas reduction of sppl2b expression causes erythrocyte accumulation in an enlarged caudal vein. Moreover, expression of D/A mutations of the putative C-terminal active sites of spp, sppl2, and sppl3 produced phenocopies of the respective knockdown phenotypes. Thus, our data suggest that all investigated PSHs/SPPLs are members of the novel family of GXGD aspartyl proteases. Furthermore, SPPL2b is shown to be the first member of the SPP/PSH/SPPL family that is not located within the ER but in endosomal/lysosomal vesicles.	Univ Munich, Adolf Butenandt Inst, Dept Biochem, Lab Alzheimers & Parkinsons Dis Res, D-80336 Munich, Germany	University of Munich	Schmid, B (corresponding author), Univ Munich, Adolf Butenandt Inst, Dept Biochem, Lab Alzheimers & Parkinsons Dis Res, Schillerstr 44, D-80336 Munich, Germany.	beschmid@med.uni-muenchen.de; Christian.Haass@med.uni-muenchen.de	Haffner, Christof/AAG-6676-2020; Fluhrer, Regina/F-2642-2011; Krawitz, Peter M/F-3142-2012	Krawitz, Peter M/0000-0002-3194-8625				Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; CHEN JW, 1985, J CELL BIOL, V101, P85, DOI 10.1083/jcb.101.1.85; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; Edbauer D, 2002, P NATL ACAD SCI USA, V99, P8666, DOI 10.1073/pnas.132277899; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Fluhrer R, 2002, J NEUROCHEM, V81, P1011, DOI 10.1046/j.1471-4159.2002.00908.x; Friedmann E, 2004, J BIOL CHEM, V279, P50790, DOI 10.1074/jbc.M407898200; FURUTANISEIKI M, 1996, DEVELOPMENT, V123, P223; Geling A, 2002, EMBO REP, V3, P688, DOI 10.1093/embo-reports/kvf124; GRIBORENKO AP, 2004, P NATL ACAD SCI USA, V101, P14955; Grigorenko AP, 2002, BIOCHEMISTRY-MOSCOW+, V67, P826, DOI 10.1023/A:1016365227942; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; Haass C, 2004, EMBO J, V23, P483, DOI 10.1038/sj.emboj.7600061; Haass C, 2002, TRENDS CELL BIOL, V12, P556, DOI 10.1016/S0962-8924(02)02394-2; Haffner C, 2004, EMBO J, V23, P3041, DOI 10.1038/sj.emboj.7600307; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; Herreman A, 2003, J CELL SCI, V116, P1127, DOI 10.1242/jcs.00292; Kim SH, 2005, J BIOL CHEM, V280, P1992, DOI 10.1074/jbc.M412404200; Kimberly WT, 2003, P NATL ACAD SCI USA, V100, P6382, DOI 10.1073/pnas.1037392100; Kimberly WT, 2000, J BIOL CHEM, V275, P3173, DOI 10.1074/jbc.275.5.3173; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; Kornilova AY, 2003, J BIOL CHEM, V278, P16470, DOI 10.1074/jbc.C300019200; LaPointe CF, 2000, J BIOL CHEM, V275, P1502, DOI 10.1074/jbc.275.2.1502; Lee JR, 2001, CELL, V107, P161, DOI 10.1016/S0092-8674(01)00526-8; Leem JY, 2002, J BIOL CHEM, V277, P19236, DOI 10.1074/jbc.C200148200; Leimer U, 1999, BIOCHEMISTRY-US, V38, P13602, DOI 10.1021/bi991453n; Ma GJ, 2005, J NEUROSCI, V25, P192, DOI 10.1523/JNEUROSCI.3814-04.2005; MARGOGLIO B, 2003, HUM MOL GENET, V12, P201; Martoglio B, 1998, TRENDS CELL BIOL, V8, P410, DOI 10.1016/S0962-8924(98)01360-9; MULLINS MC, 1994, CURR BIOL, V4, P189, DOI 10.1016/S0960-9822(00)00048-8; Nyborg AC, 2004, J BIOL CHEM, V279, P15153, DOI 10.1074/jbc.M309305200; Ponting CP, 2002, HUM MOL GENET, V11, P1037, DOI 10.1093/hmg/11.9.1037; SCHULTEMERKER S, 1992, DEVELOPMENT, V116, P1021; Selkoe D, 2003, ANNU REV NEUROSCI, V26, P565, DOI 10.1146/annurev.neuro.26.041002.131334; Serneels L, 2005, P NATL ACAD SCI USA, V102, P1719, DOI 10.1073/pnas.0408901102; Shirotani K, 2004, J BIOL CHEM, V279, P41340, DOI 10.1074/jbc.M405768200; Steiner H, 2000, NAT CELL BIOL, V2, P848, DOI 10.1038/35041097; Steiner H, 1999, J BIOL CHEM, V274, P28669, DOI 10.1074/jbc.274.40.28669; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Urban S, 2001, CELL, V107, P173, DOI 10.1016/S0092-8674(01)00525-6; Van Uden E, 2002, J NEUROSCI, V22, P9298; Weihofen A, 2000, J BIOL CHEM, V275, P30951, DOI 10.1074/jbc.M005980200; Weihofen A, 2003, J BIOL CHEM, V278, P16528, DOI 10.1074/jbc.M301372200; Weihofen A, 2003, TRENDS CELL BIOL, V13, P71, DOI 10.1016/S0962-8924(02)00041-7; Weihofen A, 2002, SCIENCE, V296, P2215, DOI 10.1126/science.1070925; Wolfe MS, 2004, SCIENCE, V305, P1119, DOI 10.1126/science.1096187; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Zhang ZH, 2000, NAT CELL BIOL, V2, P463, DOI 10.1038/35017108	49	72	80	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					39515	39523		10.1074/jbc.M501645200	http://dx.doi.org/10.1074/jbc.M501645200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	15998642	hybrid, Green Published			2022-12-25	WOS:000233362200074
J	Faust, D; Dolado, I; Cuadrado, A; Oesch, F; Weiss, C; Nebreda, AR; Dietrich, C				Faust, D; Dolado, I; Cuadrado, A; Oesch, F; Weiss, C; Nebreda, AR; Dietrich, C			P38 alpha MAPK is required for contact inhibition	ONCOGENE			English	Article						contact inhibition; p38 MAPK; fibroblasts	CELL-CYCLE ARREST; PLASMA-MEMBRANE GLYCOPROTEINS; DEPENDENT INHIBITION; PROTEIN-KINASE; HUMAN-FIBROBLASTS; GROWTH; ACTIVATION; PATHWAY; SIGNAL; D1	Proliferation of nontransformed cells is regulated by cell cell contacts, which are referred to as contact-inhibition. Despite its generally accepted importance for cell cycle control, knowledge about the intracellular signalling pathways involved in contact inhibition is scarce. In the present work we show that p38 alpha mitogen-activated protein kinase (MAPK) is involved in the growth-inhibitory signalling cascade of contact inhibition in fibroblasts. p38 alpha activity is increased in confluent cultures of human fibroblasts compared to proliferating cultures. Time course studies show a sustained activation of p38 alpha in response to cell-cell contacts in contrast to a transient activation after serum stimulation. The induction of contact inhibition by addition of glutaraldehyde-fixed cells is impaired by pharmacological inhibition of p38 as well as in p38 alpha-/- fibroblasts. Further evidence for a central role of p38a in contact inhibition comes from the observation that p38 alpha-/- fibroblasts show a higher saturation density compared to wild-type (wt) fibroblasts, which is reversed by reconstituted expression of p38 alpha. In agreement with a defect in contact inhibition, p27(Kip1) accumulation is impaired in p38 alpha-/- fibroblasts compared to wt fibroblasts. Hence, our work shows a new role for p38 alpha in contact inhibition and provides a mechanistic basis for the recently proposed tumour suppressive function of this MAPK pathway.	Johannes Gutenberg Univ Mainz, Inst Toxicol, D-55131 Mainz, Germany; CNIO, Spanish Natl Canc Ctr, Madrid 28029, Spain	Johannes Gutenberg University of Mainz; Centro Nacional de Investigaciones Oncologicas (CNIO)	Dietrich, C (corresponding author), Johannes Gutenberg Univ Mainz, Inst Toxicol, Obere Zahlbacherstr 67, D-55131 Mainz, Germany.	cdietric@uni-mainz.de	Weiss, Carsten/I-1811-2013; Nebreda, Angel Rodriguez/R-9594-2019; Cuadrado, Ana/AAA-9277-2019; Cuadrado, Ana/HGU-4777-2022; Oesch, Franz/AAA-8746-2020	Weiss, Carsten/0000-0002-5380-3208; Cuadrado, Ana/0000-0002-9752-5932; 				ABERCROMBIE M, 1979, NATURE, V281, P259, DOI 10.1038/281259a0; Ambrosino C, 2001, BIOL CELL, V93, P47, DOI 10.1016/S0248-4900(01)01124-8; Bulavin DV, 2004, NAT GENET, V36, P343, DOI 10.1038/ng1317; Bulavin DV, 2002, NAT GENET, V31, P210, DOI 10.1038/ng894; Casanovas O, 2000, J BIOL CHEM, V275, P35091, DOI 10.1074/jbc.M006324200; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; Conrad PW, 1999, J BIOL CHEM, V274, P23570, DOI 10.1074/jbc.274.33.23570; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Dietrich C, 1997, ONCOGENE, V15, P2743, DOI 10.1038/sj.onc.1201439; Dietrich C, 1996, P NATL ACAD SCI USA, V93, P10815, DOI 10.1073/pnas.93.20.10815; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; EAGLE H, 1967, NATURE, V213, P1102, DOI 10.1038/2131102a0; Ellinger-Ziegelbauer H, 1999, MOL CELL BIOL, V19, P3857; GRADL G, 1995, CURR BIOL, V5, P526, DOI 10.1016/S0960-9822(95)00105-9; Haq R, 2002, CANCER RES, V62, P5076; Heit I, 2001, ONCOGENE, V20, P5143, DOI 10.1038/sj.onc.1204657; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Molnar A, 1997, J BIOL CHEM, V272, P13229, DOI 10.1074/jbc.272.20.13229; Nakatsuji Y, 1998, GLIA, V22, P379, DOI 10.1002/(SICI)1098-1136(199804)22:4<379::AID-GLIA7>3.0.CO;2-Z; Nebreda AR, 2000, TRENDS BIOCHEM SCI, V25, P257, DOI 10.1016/S0968-0004(00)01595-4; OESCH F, 1987, EUR J CELL BIOL, V43, P403; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Shi Y, 2002, BIOL CHEM, V383, P1519, DOI 10.1515/BC.2002.173; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Wang WP, 2002, MOL CELL BIOL, V22, P3389, DOI 10.1128/MCB.22.10.3389-3403.2002; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; Wieser RJ, 1999, ONCOGENE, V18, P277, DOI 10.1038/sj.onc.1202270; WIESER RJ, 1990, J CELL BIOL, V111, P2681, DOI 10.1083/jcb.111.6.2681; WIESER RJ, 1986, J CELL BIOL, V103, P361, DOI 10.1083/jcb.103.2.361; WIESER RJ, 1985, EXP CELL RES, V158, P493, DOI 10.1016/0014-4827(85)90472-0; WIESER RJ, 1995, GLYCOCONJUGATE J, V12, P672, DOI 10.1007/BF00731264	33	59	62	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2005	24	53					7941	7945		10.1038/sj.onc.1208948	http://dx.doi.org/10.1038/sj.onc.1208948			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	986PU	16027723	Bronze			2022-12-25	WOS:000233463000013
J	Aurikko, JP; Ruotolo, BT; Grossmann, JG; Moncrieffe, MC; Stephens, E; Leppanen, VM; Robinson, CV; Saarma, M; Bradshaw, RA; Blundell, TL				Aurikko, JP; Ruotolo, BT; Grossmann, JG; Moncrieffe, MC; Stephens, E; Leppanen, VM; Robinson, CV; Saarma, M; Bradshaw, RA; Blundell, TL			Characterization of symmetric complexes of nerve growth factor and the ectodomain of the pan-neurotrophin receptor, p75(NTR)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CEREBROSPINAL-FLUID; RAY SOLUTION SCATTERING; NF-KAPPA-B; CELL-DEATH; FUNCTIONAL INTERACTIONS; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; GENE-TRANSFER; PC12 CELLS; P75	Nerve growth factor (NGF) is the ligand for two unrelated cellular receptors, TrkA and p75(NTR), and acts as a mediator in the development and maintenance of the mammalian nervous system. Signaling through TrkA kinase domains promotes neuronal survival, whereas activation of the p75(NTR) "death domains" induces apoptosis under correct physiological conditions. However, co-expression of these receptors leads to enhanced neuronal survival upon NGF stimulation, possibly through a ternary p75(NTR) center dot NGF center dot TrkA complex. We have expressed human p75NTR ligand binding domain as a secreted glycosylated protein in Trichoplusia ni cells. Following assembly and purification of soluble p75(NTR) center dot NGF complexes, mass spectrometry, analytical ultracentrifugation, and solution x-ray scattering measurements are indicative of 2: 2 stoichiometry, which implies a symmetric complex. Molecular models of the 2: 2 p75(NTR) center dot NGF complex based on these data are not consistent with the further assembly of either symmetric ( 2: 2: 2) or asymmetric (2: 2: 1) ternary p75(NTR) center dot NGF center dot TrkA complexes.	Univ Cambridge, Dept Biochem, Cambridge CB2 1GA, England; Univ Cambridge, Dept Chem, Cambridge CB2 1EW, England; CCLRC Daresbury Lab, Synchrotron Radiat Dept, Warrington WA4 AD, Cheshire, England; Univ Helsinki, Inst Biotechnol, FIN-00014 Helsinki, Finland; Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA	University of Cambridge; University of Cambridge; STFC Daresbury Laboratory; University of Helsinki; University of California System; University of California Irvine	Aurikko, JP (corresponding author), Univ Cambridge, Dept Biochem, 80 Tennis Ct Rd, Cambridge CB2 1GA, England.	jukka@cryst.bioc.cam.ac.uk	Bradshaw, Ralph A/K-1515-2013; Ruotolo, Brandon/F-2669-2013	Ruotolo, Brandon/0000-0002-6084-2328; Leppanen, Veli-Matti/0000-0001-7100-965X; robinson, carol/0000-0001-7829-5505	Wellcome Trust [064597] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARIBAULT TJ, 1985, J NEUROSCI RES, V14, P49, DOI 10.1002/jnr.490140105; Bibel M, 1999, EMBO J, V18, P616, DOI 10.1093/emboj/18.3.616; BOTHWELL M, 1995, ANNU REV NEUROSCI, V18, P223, DOI 10.1146/annurev.neuro.18.1.223; Butler M, 2003, GLYCOBIOLOGY, V13, P601, DOI 10.1093/glycob/cwg079; Carter BD, 1996, SCIENCE, V272, P542, DOI 10.1126/science.272.5261.542; Chao MV, 2003, NAT REV NEUROSCI, V4, P299, DOI 10.1038/nrn1078; CHAO MV, 1986, SCIENCE, V232, P518, DOI 10.1126/science.3008331; CHAO MV, 1994, J NEUROBIOL, V25, P1373, DOI 10.1002/neu.480251106; CHAO MV, 1995, TRENDS NEUROSCI, V18, P321, DOI 10.1016/0166-2236(95)93922-K; Coulson EJ, 2000, J BIOL CHEM, V275, P30537, DOI 10.1074/jbc.M005214200; Esposito D, 2001, J BIOL CHEM, V276, P32687, DOI 10.1074/jbc.M011674200; Falck S, 2004, EMBO J, V23, P3010, DOI 10.1038/sj.emboj.7600310; Foehr ED, 2000, J NEUROSCI, V20, P7556; GROB PM, 1985, J BIOL CHEM, V260, P8044; Grossmann JG, 2002, BIOCHEMISTRY-US, V41, P3613, DOI 10.1021/bi015955o; He XL, 2004, SCIENCE, V304, P870, DOI 10.1126/science.1095190; HOFFMANN A, 1994, J NEUROCHEM, V63, P2185; HOFFMANN A, 1995, FEBS LETT, V359, P164, DOI 10.1016/0014-5793(95)00034-7; Huang EJ, 2003, ANNU REV BIOCHEM, V72, P609, DOI 10.1146/annurev.biochem.72.121801.161629; Ibanez CF, 2002, TRENDS NEUROSCI, V25, P284, DOI 10.1016/S0166-2236(02)02169-0; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; Jurchen JC, 2003, J AM CHEM SOC, V125, P2817, DOI 10.1021/ja0211508; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Liepinsh E, 1997, EMBO J, V16, P4999, DOI 10.1093/emboj/16.16.4999; LIGHTWAHL KJ, 1994, J AM CHEM SOC, V116, P5271, DOI 10.1021/ja00091a035; MAHADEO D, 1994, J BIOL CHEM, V269, P6884; Mamidipudi V, 2002, J NEUROSCI RES, V68, P373, DOI 10.1002/jnr.10244; MCDONALD NQ, 1991, NATURE, V354, P411, DOI 10.1038/354411a0; Neet KE, 2001, CELL MOL LIFE SCI, V58, P1021, DOI 10.1007/PL00000917; NELSON N, 1987, ANAL BIOCHEM, V165, P287, DOI 10.1016/0003-2697(87)90271-5; Nykjaer A, 2005, CURR OPIN NEUROBIOL, V15, P49, DOI 10.1016/j.conb.2005.01.004; Rabizadeh S, 2003, CYTOKINE GROWTH F R, V14, P225, DOI 10.1016/S1359-6101(03)00018-2; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; Rudd PM, 2000, BIOCHEMISTRY-US, V39, P1596, DOI 10.1021/bi9918285; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; SEMENYUK A, 1991, J APPL CRYSTALLOGR, V22, P537; Shooter EM, 2001, ANNU REV NEUROSCI, V24, P601, DOI 10.1146/annurev.neuro.24.1.601; Sobott F, 2002, CURR OPIN STRUC BIOL, V12, P729, DOI 10.1016/S0959-440X(02)00400-1; Sofroniew MV, 2001, ANNU REV NEUROSCI, V24, P1217, DOI 10.1146/annurev.neuro.24.1.1217; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; Svergun D, 1995, J APPL CRYSTALLOGR, V28, P768, DOI 10.1107/S0021889895007047; Svergun DI, 2001, BIOPHYS J, V80, P2946, DOI 10.1016/S0006-3495(01)76260-1; TYSON DR, 2003, HDB CELL SIGNALING, V1, P361; Vistica J, 2004, ANAL BIOCHEM, V326, P234, DOI 10.1016/j.ab.2003.12.014; Weber ANR, 2005, J BIOL CHEM, V280, P22793, DOI 10.1074/jbc.M502074200; Ye X, 1999, J BIOL CHEM, V274, P30202, DOI 10.1074/jbc.274.42.30202; Yeiser EC, 2004, J NEUROSCI, V24, P10521, DOI 10.1523/JNEUROSCI.1390-04.2004	49	27	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	2005	280	39					33453	33460		10.1074/jbc.M503189200	http://dx.doi.org/10.1074/jbc.M503189200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	966YG	16009712	Green Accepted, hybrid			2022-12-25	WOS:000232058100044
J	Gagnon, E; Bergeron, MJ; Daigle, ND; Lefoll, MH; Isenring, P				Gagnon, E; Bergeron, MJ; Daigle, ND; Lefoll, MH; Isenring, P			Molecular mechanisms of cation transport by the renal Na+-K+-Cl(-)cotransporter - Structural insight into the operating characteristics of the ion transport sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K-CL COTRANSPORTER; NA+-K+-2CL(-) COTRANSPORTER; FUNCTIONAL EXPRESSION; BUMETANIDE BINDING; NA; LOCALIZATION; CLONING; FAMILY; CELLS; POTASSIUM	Two variants of the renal Na+- K+-Cl- cotransporter ( NKCC2), called NKCC2A and NKCC2F, display marked differences in Na+, Rb+, and Cl- affinities, yet are identical to one another except for a 23-residue membrane-associated domain that is derived from alternatively spliced exons. The proximal portion of these exons is predicted to encode the second transmembrane domain (tm2) in the form of an alpha-helix, and the distal portion, part of the following connecting segment (cs1a). In recent studies, we have taken advantage of the A-F differences in kinetic behavior to determine which regions in tm2-cs1a are involved in ion transport. Functional characterizations of chimeras in which tm2 or cs1a were interchanged between the variants showed that both regions are important in specifying ion affinities, but did not allow delineating the contribution of individual residues. Here, we have extended these structure-function analyses by studying additional mutants in which variant residues between A and F were interchanged individually in the tm2-cs1a region (amino acid number 216, 220, 223, 229, or 233 in NKCC2). None of the substitutions were found to affect K-m(C1 (-)), suggesting that the affinity difference for anion transport is conveyed by a combination of variant residues in this domain. However, 2 substitutions in the tm2 of F were found to affect cation constants specifically; interestingly, one of these mutations ( residue 216) only affected Km(Rb+) while the other (residue 220) only affected Km(Na+). We have thus identified two novel residues in NKCC2 that play a key role in cation transport. Because such residues should be adjacent to one another on the vertical axis of the tm2 alpha-helix, our results imply, furthermore, that the ion transport sites in NKCC2 could be physically linked.	Univ Laval, Fac Med, Dept Med, Nephrol Res Grp, Quebec City, PQ G1R 2J6, Canada	Laval University	Isenring, P (corresponding author), Hop Hotel Dieu, Quebec Res Ctr, 10 Rue McMahon Rm 3852, Quebec City, PQ G1R 2J6, Canada.	paul.isenring@crhdq.ulaval.ca						Benjamin BA, 1997, AM J PHYSIOL-RENAL, V273, pF473, DOI 10.1152/ajprenal.1997.273.3.F473; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; DELPIRE E, 1994, J BIOL CHEM, V269, P25677; Doyle DA, 2004, EUR BIOPHYS J BIOPHY, V33, P175, DOI 10.1007/s00249-003-0382-z; Flemmer AW, 2002, J BIOL CHEM, V277, P37551, DOI 10.1074/jbc.M206294200; Gagnon E, 2004, J BIOL CHEM, V279, P5648, DOI 10.1074/jbc.M311218200; Gagnon E, 2003, AM J PHYSIOL-CELL PH, V284, pC365, DOI 10.1152/ajpcell.00262.2002; Gagnon E, 2002, AM J PHYSIOL-RENAL, V283, pF1046, DOI 10.1152/ajprenal.00107.2002; GAMBA G, 1994, J BIOL CHEM, V269, P17713; Garon L, 2000, J BIOL CHEM, V275, P32027, DOI 10.1074/jbc.M000108200; GECK P, 1980, BIOCHIM BIOPHYS ACTA, V600, P432, DOI 10.1016/0005-2736(80)90446-0; Gerelsaikhan T, 2000, J BIOL CHEM, V275, P40471, DOI 10.1074/jbc.M007751200; Gimenez I, 2003, J BIOL CHEM, V278, P26946, DOI 10.1074/jbc.M303435200; Gimenez I, 2002, J BIOL CHEM, V277, P8767, DOI 10.1074/jbc.C200021200; GREGER R, 1985, PHYSIOL REV, V65, P760, DOI 10.1152/physrev.1985.65.3.760; Haas M, 2000, ANNU REV PHYSIOL, V62, P515, DOI 10.1146/annurev.physiol.62.1.515; Hebert SC, 2004, PFLUG ARCH EUR J PHY, V447, P580, DOI 10.1007/s00424-003-1066-3; IGARASHI P, 1995, AM J PHYSIOL-RENAL, V269, pF405, DOI 10.1152/ajprenal.1995.269.3.F405; Isenring P, 1998, J BIOL CHEM, V273, P11295, DOI 10.1074/jbc.273.18.11295; Isenring P, 1998, J GEN PHYSIOL, V112, P549, DOI 10.1085/jgp.112.5.549; Isenring P, 1998, P NATL ACAD SCI USA, V95, P7179, DOI 10.1073/pnas.95.12.7179; Isenring P, 1997, J BIOL CHEM, V272, P24556, DOI 10.1074/jbc.272.39.24556; Isenring P, 2001, COMP BIOCHEM PHYS A, V130, P487, DOI 10.1016/S1095-6433(01)00420-2; Kaplan MR, 1996, KIDNEY INT, V49, P40, DOI 10.1038/ki.1996.6; Lytle C, 1998, AM J PHYSIOL-CELL PH, V274, pC299, DOI 10.1152/ajpcell.1998.274.2.C299; Lytle C, 1995, AM J PHYSIOL-CELL PH, V269, pC1496, DOI 10.1152/ajpcell.1995.269.6.C1496; MIYAMOTO H, 1986, J MEMBRANE BIOL, V92, P135, DOI 10.1007/BF01870703; Park JH, 1996, J MEMBRANE BIOL, V149, P161, DOI 10.1007/s002329900016; PAYNE JA, 1995, J BIOL CHEM, V270, P17977, DOI 10.1074/jbc.270.30.17977; PAYNE JA, 1994, P NATL ACAD SCI USA, V91, P4544, DOI 10.1073/pnas.91.10.4544; Plata C, 2002, J BIOL CHEM, V277, P11004, DOI 10.1074/jbc.M110442200; RUSSELL JM, 1983, J GEN PHYSIOL, V81, P909, DOI 10.1085/jgp.81.6.909; Russell JM, 2000, PHYSIOL REV, V80, P211, DOI 10.1152/physrev.2000.80.1.211; Takahashi N, 2000, P NATL ACAD SCI USA, V97, P5434, DOI 10.1073/pnas.090091297; XU JC, 1994, P NATL ACAD SCI USA, V91, P2201, DOI 10.1073/pnas.91.6.2201; Yang TX, 1996, AM J PHYSIOL-RENAL, V271, pF931, DOI 10.1152/ajprenal.1996.271.4.F931	36	25	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	2005	280	37					32555	32563		10.1074/jbc.M505511200	http://dx.doi.org/10.1074/jbc.M505511200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	963HM	16027154	hybrid			2022-12-25	WOS:000231794800065
J	Sander, S; Bullinger, L; Karlsson, A; Giuriato, S; Hernandez-Boussard, T; Felsher, DW; Pollack, JR				Sander, S; Bullinger, L; Karlsson, A; Giuriato, S; Hernandez-Boussard, T; Felsher, DW; Pollack, JR			Comparative genomic hybridization on mouse cDNA microarrays and its application to a murine lymphoma model	ONCOGENE			English	Article						array CGH; microarray; mouse model; lymphoma; expression profiling	COPY-NUMBER CHANGES; CYTOGENETIC ANALYSIS; RESOLUTION; CANCER; TUMOR; EXPRESSION; ONCOGENES; SURVIVAL; REVEALS; MCL-1	Microarray-based formats offer a high-resolution alternative to conventional, chromosome-based comparative genomic hybridization (CGH) methods for assessing DNA copy number alteration (CNA) genome-wide in human cancer. For murine tumors, array CGH should provide even greater advantage, since murine chromosomes are more difficult to individually discern. We report here the adaptation and evaluation of a cDNA microarray-based CGH method for the routine characterization of CNAs in murine tumors, using mouse cDNA microarrays representing similar to 14 000 different genes, thereby providing an average mapping resolution of 109 kb. As a first application, we have characterized CNAs in a set of 10 primary and recurrent lymphomas derived from a Myc-induced murine lymphoma model. In primary lymphomas and more commonly in Myc- independent relapses, we identified a recurrent genomic DNA loss at chromosome 3G3-3H4, and recurrent amplifications at chromosome 3F2.1-3G3 and chromosome 15E1/ E2 - 15F3, the boundaries of which we defined with high resolution. Further, by pro. ling gene expression using the same microarray platform, we identifed within CNAs the relevant subset of candidate cancer genes displaying comparably altered expression, including Mcl1 ( myeloid cell leukemia sequence 1), a highly expressed antiapoptotic gene residing within the chr 3 amplicon peak. CGH on mouse cDNA microarrays therefore represents a reliable method for the high-resolution characterization of CNAs in murine tumors, and a powerful approach for elucidating the molecular events in tumor development and progression in murine models.	Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA; Stanford Univ, Dept Med Oncol, Stanford, CA 94305 USA; Stanford Univ, Dept Biochem, Stanford, CA 94305 USA; Univ Ulm, Dept Internal Med 3, D-89069 Ulm, Germany	Stanford University; Stanford University; Stanford University; Ulm University	Pollack, JR (corresponding author), Stanford Univ, Sch Med, Dept Pathol, CCSR Bldg,Room 3245Am 269 Campus Dr, Stanford, CA 94305 USA.	pollack1@stanford.edu	Bullinger, Lars/AAL-7965-2020; Giuriato, Sylvie/A-9113-2010	Giuriato, Sylvie/0000-0003-3274-3397; Bullinger, Lars/0000-0002-5890-5510; Sander, Sandrine/0000-0003-4645-3366	NCI NIH HHS [CA97139] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA097139] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albertson DG, 2003, HUM MOL GENET, V12, pR145, DOI 10.1093/hmg/ddg261; Artandi SE, 2000, NATURE, V406, P641, DOI 10.1038/35020592; Barrett MT, 2004, P NATL ACAD SCI USA, V101, P17765, DOI 10.1073/pnas.0407979101; Bullinger L, 2004, NEW ENGL J MED, V350, P1605, DOI 10.1056/NEJMoa031046; Cai WW, 2002, NAT BIOTECHNOL, V20, P393, DOI 10.1038/nbt0402-393; Cho-Vega JH, 2004, HUM PATHOL, V35, P1095, DOI 10.1016/j.humpath.2004.04.018; Chung YJ, 2004, GENOME RES, V14, P188, DOI 10.1101/gr.1878804; Coleman AE, 1999, LEUKEMIA, V13, P1592, DOI 10.1038/sj.leu.2401518; Collins C, 1998, P NATL ACAD SCI USA, V95, P8703, DOI 10.1073/pnas.95.15.8703; Felsher DW, 2003, NAT REV CANCER, V3, P375, DOI 10.1038/nrc1070; Felsher DW, 1999, MOL CELL, V4, P199, DOI 10.1016/S1097-2765(00)80367-6; Giuriato S, 2004, SEMIN CANCER BIOL, V14, P3, DOI 10.1016/j.semcancer.2003.11.002; Gollub J, 2003, NUCLEIC ACIDS RES, V31, P94, DOI 10.1093/nar/gkg078; Hackett CS, 2003, CANCER RES, V63, P5266; Hodgson G, 2001, NAT GENET, V29, P459, DOI 10.1038/ng771; Jackson-Grusby L, 2002, ONCOGENE, V21, P5504, DOI 10.1038/sj.onc.1205603; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; Karlsson A, 2003, BLOOD, V101, P2797, DOI 10.1182/blood-2002-10-3091; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Li JZ, 2004, NAT GENET, V36, P952, DOI 10.1038/ng1417; Lichter P, 2000, SEMIN HEMATOL, V37, P348, DOI 10.1053/shem.2000.16594; Lucito R, 2003, GENOME RES, V13, P2291, DOI 10.1101/gr.1349003; O'Hagan RC, 2003, CANCER RES, V63, P5352; O'Hagan RC, 2002, CANCER CELL, V2, P149, DOI 10.1016/S1535-6108(02)00094-6; Opferman JT, 2003, NATURE, V426, P671, DOI 10.1038/nature02067; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999; Pollack JR, 2002, NAT GENET, V32, P515, DOI 10.1038/ng1035; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; SolinasToldo S, 1997, GENE CHROMOSOME CANC, V20, P399, DOI 10.1002/(SICI)1098-2264(199712)20:4<399::AID-GCC12>3.0.CO;2-I; Vrana JA, 2002, CANCER RES, V62, P892; Wang P, 2005, BIOSTATISTICS, V6, P45, DOI 10.1093/biostatistics/kxh017; Xu QL, 1998, MOL CELL, V1, P337, DOI 10.1016/S1097-2765(00)80034-9; Zhou P, 1998, BLOOD, V92, P3226, DOI 10.1182/blood.V92.9.3226.421k49_3226_3239	36	8	8	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 8	2005	24	40					6101	6107		10.1038/sj.onc.1208751	http://dx.doi.org/10.1038/sj.onc.1208751			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	962GD	16007205				2022-12-25	WOS:000231718100004
J	Locher, M; Lehnert, B; Krauss, K; Heesemann, J; Groll, M; Wilharm, G				Locher, M; Lehnert, B; Krauss, K; Heesemann, J; Groll, M; Wilharm, G			Crystal structure of the Yersinia enterocolitica type III secretion chaperone SycT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL PATHOGENS; FUNCTIONAL CONSERVATION; 3-DIMENSIONAL STRUCTURE; EFFECTOR PROTEIN; SYSTEM; PESTIS; RECOGNITION; POLYPEPTIDE; REFINEMENT; MACHINERY	Several Gram-negative pathogens deploy type III secretion systems (TTSSs) as molecular syringes to inject effector proteins into host cells. Prior to secretion, some of these effectors are accompanied by specific type III secretion chaperones. The Yersinia enterocolitica TTSS chaperone SycT escorts the effector YopT, a cysteine protease that inactivates the small GTPase RhoA of targeted host cells. We solved the crystal structure of SycT at 2.5 angstrom resolution. Despite limited sequence similarity among TTSS chaperones, the SycT structure revealed a global fold similar to that exhibited by other structurally solved TTSS chaperones. The dimerization domain of SycT, however, differed from that of all other known TTSS chaperone structures. Thus, the dimerization domain of TTSS chaperones does not likely serve as a general recognition pattern for downstream processing of effector/chaperone complexes. Yersinia Yop effectors are bound to their specific Syc chaperones close to the Yop N termini, distinct from their catalytic domains. Here, we showed that the catalytically inactive YopT(C139S) is reduced in its ability to bind SycT, suggesting an ancillary interaction between YopT and SycT. This interaction could maintain the protease inactive prior to secretion or could influence the secretion competence and folding of YopT.	Univ Munich, Adolf Butenandt Inst, Lehrstuhl Physiol Chem, D-81377 Munich, Germany; Max Planck Inst Biochem, D-82152 Martinsried, Germany; Univ Munich, Leh Bakteriol, Max Von Pettenkofer Inst, D-80336 Munich, Germany	University of Munich; Max Planck Society; University of Munich	Wilharm, G (corresponding author), Univ Munich, Adolf Butenandt Inst, Lehrstuhl Physiol Chem, Butenandtstr 5, D-81377 Munich, Germany.	maier@m3401.mpk.med.unimuenchen.de	Groll, Michael/C-1174-2010; Groll, Michael/F-5572-2015	Wilharm, Gottfried/0000-0002-1771-6799				BALZER D, 1992, NUCLEIC ACIDS RES, V20, P1851, DOI 10.1093/nar/20.8.1851; Birtalan S, 2001, NAT STRUCT BIOL, V8, P974, DOI 10.1038/nsb1101-974; Birtalan SC, 2002, MOL CELL, V9, P971, DOI 10.1016/S1097-2765(02)00529-4; Boyd AP, 2000, J BACTERIOL, V182, P4811, DOI 10.1128/JB.182.17.4811-4821.2000; Bricogne G, 2003, ACTA CRYSTALLOGR D, V59, P2023, DOI 10.1107/S0907444903017694; Cornelis GR, 2003, MOL MICROBIOL, V50, P1091, DOI 10.1046/j.1365-2958.2003.03812.x; Cornelis GR, 2002, INT J MED MICROBIOL, V291, P455; Duchaud E, 2003, NAT BIOTECHNOL, V21, P1307, DOI 10.1038/nbt886; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Evdokimov AG, 2003, NAT STRUCT BIOL, V10, P789, DOI 10.1038/nsb982; Evdokimov AG, 2002, ACTA CRYSTALLOGR D, V58, P398, DOI 10.1107/S090744490200015X; Feldman MF, 2003, FEMS MICROBIOL LETT, V219, P151, DOI 10.1016/S0378-1097(03)00042-9; Gauthier A, 2003, J BACTERIOL, V185, P6747, DOI 10.1128/JB.185.23.6747-6755.2003; GINOCCHIO CC, 1995, INFECT IMMUN, V63, P729, DOI 10.1128/IAI.63.2.729-732.1995; Gophna U, 2003, GENE, V312, P151, DOI 10.1016/S0378-1119(03)00612-7; HEESEMANN J, 1983, J BACTERIOL, V155, P761, DOI 10.1128/JB.155.2.761-767.1983; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hueck CJ, 1998, MICROBIOL MOL BIOL R, V62, P379, DOI 10.1128/MMBR.62.2.379-433.1998; Iriarte M, 1998, MOL MICROBIOL, V29, P915, DOI 10.1046/j.1365-2958.1998.00992.x; Luo Y, 2001, NAT STRUCT BIOL, V8, P1031, DOI 10.1038/nsb717; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; Neumayer W, 2004, PROTEIN EXPRES PURIF, V35, P237, DOI 10.1016/j.pep.2004.02.017; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Page AL, 2002, MOL MICROBIOL, V46, P1, DOI 10.1046/j.1365-2958.2002.03138.x; Pallen MJ, 2003, FEMS MICROBIOL LETT, V223, P53, DOI 10.1016/S0378-1097(03)00344-6; Parsot C, 2003, CURR OPIN MICROBIOL, V6, P7, DOI 10.1016/S1369-5274(02)00002-4; Phan J, 2004, ACTA CRYSTALLOGR D, V60, P1591, DOI 10.1107/S0907444904017597; Potterton E, 2003, ACTA CRYSTALLOGR D, V59, P1131, DOI 10.1107/S0907444903008126; Ramamurthi KS, 2003, MOL MICROBIOL, V50, P1095, DOI 10.1046/j.1365-2958.2003.03777.x; ROSQVIST R, 1995, EMBO J, V14, P4187, DOI 10.1002/j.1460-2075.1995.tb00092.x; Rossier O, 1999, P NATL ACAD SCI USA, V96, P9368, DOI 10.1073/pnas.96.16.9368; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; SCHOMAKER V, 1968, ACTA CRYSTALL B-STRU, VB 24, P63, DOI 10.1107/S0567740868001718; Schubot FD, 2005, J MOL BIOL, V346, P1147, DOI 10.1016/j.jmb.2004.12.036; Shao F, 2002, CELL, V109, P575, DOI 10.1016/S0092-8674(02)00766-3; Singer AU, 2004, STRUCTURE, V12, P1669, DOI 10.1016/j.str.2004.06.023; Stebbins CE, 2001, NATURE, V414, P77, DOI 10.1038/35102073; Trame CB, 2003, ACTA CRYSTALLOGR D, V59, P389, DOI 10.1107/S0907444902020826; Turk D., 1992, THESIS TU MUENCHEN; van Eerde A, 2004, EMBO REP, V5, P477, DOI 10.1038/sj.embor.7400144; Wilharm G, 2004, BMC MICROBIOL, V4, DOI 10.1186/1471-2180-4-27; Wilharm G, 2004, INFECT IMMUN, V72, P4004, DOI 10.1128/IAI.72.7.4004-4009.2004; Wulff-Strobel CR, 2002, MOL MICROBIOL, V43, P411, DOI 10.1046/j.1365-2958.2002.02752.x; Yip CK, 2005, NAT STRUCT MOL BIOL, V12, P75, DOI 10.1038/nsmb879; Zhu MF, 2004, P NATL ACAD SCI USA, V101, P302, DOI 10.1073/pnas.2036536100	45	31	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	2005	280	35					31149	31155		10.1074/jbc.M500603200	http://dx.doi.org/10.1074/jbc.M500603200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	958ZX	16000312	hybrid			2022-12-25	WOS:000231487800061
J	Huang, YC; Colman, RF				Huang, YC; Colman, RF			Location of the coenzyme binding site in the porcine mitochondrial NADP-dependent isocitrate dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIG-HEART; DIRECTED MUTAGENESIS; MECHANISM; ENZYME; COMPLEX; MN2+	The structure of crystalline porcine mitochondrial NADP-dependent isocitrate dehydrogenase ( IDH) has been determined in complex with Mn2+-isocitrate. Based on structural alignment between this porcine enzyme and seven determined crystal structures of complexes of NADP with bacterial IDHs, Arg(83), Thr(311), and Asn(328) were chosen as targets for site-directed mutagenesis of porcine IDH. The circular dichroism spectra of purified wild-type and mutant enzymes are similar. The mutant enzymes exhibit little change in Km for isocitrate or Mn2+, showing that these residues are not involved in substrate binding. In contrast, the Arg(83) mutants, Asn(328) mutants, and T311A exhibit 3-20-fold increase in the Km NADP. We propose that Arg(83) enhances NADP affinity by hydrogen bonding with the 3'-OH of the nicotinamide ribose, whereas Asn(328) hydrogen bonds with N1 of adenine. The pH dependence of V-max for Arg(83) and Asn(328) mutants is similar to that of wild-type enzyme, but for all the Thr(311) mutants, pK(es) is increased from 5.2 in the wild type to similar to 6.0. We have previously attributed the pH dependence of Vmax to the deprotonation of the metal-bound hydroxyl of isocitrate in the enzyme-substrate complex, prior to the transfer of a hydride from isocitrate to NADP's nicotinamide moiety. Thr(311) interacts with the nicotinamide ribose and is the closest of the target amino acids to the nicotinamide ring. Distortion of the nicotinamide by Thr(31)1 mutation will likely be transmitted to Mn2+-isocitrate resulting in an altered pKes. Because porcine and human mitochondrial NADP-IDH have 95% sequence identity, these results should be applicable to the human enzyme.	Univ Delaware, Dept Chem & Biochem, Newark, DE 19716 USA	University of Delaware	Colman, RF (corresponding author), Univ Delaware, Dept Chem & Biochem, Newark, DE 19716 USA.	rfcolman@chem.udel.edu			NHLBI NIH HHS [R01 HL67774] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067774] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAILEY JM, 1985, BIOCHEMISTRY-US, V24, P5367, DOI 10.1021/bi00341a015; Benderdour M, 2003, J BIOL CHEM, V278, P45154, DOI 10.1074/jbc.M306285200; Ceccarelli C, 2002, J BIOL CHEM, V277, P43454, DOI 10.1074/jbc.M207306200; COLMAN RF, 1983, PEPTIDE PROTEIN REV, V1, P41; Grodsky NB, 2000, BIOCHEMISTRY-US, V39, P2193, DOI 10.1021/bi9919753; HASELBECK RJ, 1992, BIOCHEMISTRY-US, V31, P6219, DOI 10.1021/bi00142a007; Huang YC, 2004, BIOCHEMISTRY-US, V43, P2821, DOI 10.1021/bi030253f; Huang YC, 2002, BIOCHEMISTRY-US, V41, P5637, DOI 10.1021/bi0200716; HURLEY JH, 1991, BIOCHEMISTRY-US, V30, P8671, DOI 10.1021/bi00099a026; Jo SH, 2001, J BIOL CHEM, V276, P16168, DOI 10.1074/jbc.M010120200; JOHANSON RA, 1981, ARCH BIOCHEM BIOPHYS, V207, P9, DOI 10.1016/0003-9861(81)90002-3; Karlstrom M, 2005, J MOL BIOL, V345, P559, DOI 10.1016/j.jmb.2004.10.025; KELLY JH, 1981, J BIOL CHEM, V256, P330; Kim TK, 2005, PROTEIN SCI, V14, P140, DOI 10.1110/ps.041091805; Kim TK, 2003, J BIOL CHEM, V278, P49323, DOI 10.1074/jbc.M303781200; Lee P, 2002, ARCH BIOCHEM BIOPHYS, V401, P81, DOI 10.1016/S0003-9861(02)00041-3; Soundar S, 2000, J BIOL CHEM, V275, P5606, DOI 10.1074/jbc.275.8.5606; Soundar S, 1996, PROTEIN EXPRES PURIF, V8, P305, DOI 10.1006/prep.1996.0105; STODDARD BL, 1993, BIOCHEMISTRY-US, V32, P9310, DOI 10.1021/bi00087a008; Xu X, 2004, J BIOL CHEM, V279, P33946, DOI 10.1074/jbc.M404298200; Zhu GP, 2005, SCIENCE, V307, P1279, DOI 10.1126/science.1106974	21	9	10	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	2005	280	34					30349	30353		10.1074/jbc.M505828200	http://dx.doi.org/10.1074/jbc.M505828200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	957IC	15975917	hybrid			2022-12-25	WOS:000231362500045
J	Natochin, M; Campbell, TN; Barren, B; Miller, LC; Hameed, S; Artemyev, NO; Braun, JEA				Natochin, M; Campbell, TN; Barren, B; Miller, LC; Hameed, S; Artemyev, NO; Braun, JEA			Characterization of the G alpha(s) regulator cysteine string protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRESYNAPTIC CALCIUM-CHANNEL; SYNAPTIC VESICLES; SECRETORY GRANULES; MUTANT DROSOPHILA; ESCHERICHIA-COLI; CHROMAFFIN CELLS; DENSE-CORE; EXOCYTOSIS; CSP; ALPHA	Cysteine string protein ( CSP) is an abundant regulated secretory vesicle protein that is composed of a string of cysteine residues, a linker domain, and an N-terminal J domain characteristic of the DnaJ/Hsp40 cochaperone family. We have shown previously that CSP associates with heterotrimeric GTP-binding proteins ( G proteins) and promotes G protein inhibition of N-type Ca2+ channels. To elucidate the mechanisms by which CSP modulates G protein signaling, we examined the effects of CSP1-198 ( full-length), CSP1-112, and CSP1-82 on the kinetics of guanine nucleotide exchange and GTP hydrolysis. In this report, we demonstrate that CSP selectively interacts with G alpha(s) and increases steady-state GTP hydrolysis. CSP1-198 modulation of G alpha(s) was dependent on Hsc70 ( 70-kDa heat shock cognate protein) and SGT ( small glutamine-rich tetratricopeptide repeat domain protein), whereas modulation by CSP1-112 was Hsc70-SGT-independent. CSP1-112 preferentially associated with the inactive GDP-bound conformation of G alpha(s). Consistent with the stimulation of GTP hydrolysis, CSP1-112 increased guanine nucleotide exchange of G alpha(s). The interaction of native G alpha(s) and CSP was confirmed by coimmunoprecipitation and showed that G alpha(s) associates with CSP. Furthermore, transient expression of CSP in HEK cells increased cellular cAMP levels in the presence of the beta(2) adrenergic agonist isoproterenol. Together, these results demonstrate that CSP modulates G protein function by preferentially targeting the inactive GDP-bound form of G alpha(s) and promoting GDP/GTP exchange. Our results show that the guanine nucleotide exchange activity of full-length CSP is, in turn, regulated by Hsc70-SGT.	Univ Calgary, Hotchkiss Brain Inst, Calgary, AB T2N 4N1, Canada; Univ Iowa, Dept Physiol & Biophys, Iowa City, IA 52254 USA	University of Calgary; University of Iowa	Natochin, M (corresponding author), Univ Calgary, Hotchkiss Brain Inst, 3330 Hostp Dr NW, Calgary, AB T2N 4N1, Canada.			Dansereau, Linda/0000-0002-0522-8309; Artemyev, Nikolai/0000-0002-5266-6854	NATIONAL EYE INSTITUTE [R01EY012682] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY012682, R01 EY-12682] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Afshar K, 2004, CELL, V119, P219, DOI 10.1016/j.cell.2004.09.026; AHNERTHILGER G, 1994, EUR J CELL BIOL, V65, P26; ARONIN N, 1992, J NEUROSCI, V12, P3435; Barclay JW, 2002, J COMP PHYSIOL A, V188, P71, DOI 10.1007/s00359-002-0279-9; Boal F, 2004, BIOCHEMISTRY-US, V43, P16212, DOI 10.1021/bi048612+; BRAUN JEA, 1995, NEUROPHARMACOLOGY, V34, P1361, DOI 10.1016/0028-3908(95)00114-L; Braun JEA, 1996, J BIOL CHEM, V271, P25989, DOI 10.1074/jbc.271.42.25989; Bronk P, 2005, J NEUROSCI, V25, P2204, DOI 10.1523/JNEUROSCI.3610-04.2005; Brown H, 1998, EMBO J, V17, P5048, DOI 10.1093/emboj/17.17.5048; Chamberlain LH, 1998, BIOCHEM J, V335, P205, DOI 10.1042/bj3350205; Chamberlain LH, 1998, MOL BIOL CELL, V9, P2259, DOI 10.1091/mbc.9.8.2259; Chamberlain LH, 1997, BIOCHEM J, V322, P853, DOI 10.1042/bj3220853; Chamberlain LH, 1996, J BIOL CHEM, V271, P19514, DOI 10.1074/jbc.271.32.19514; Chen S, 2002, J PHYSIOL-LONDON, V538, P383, DOI 10.1113/jphysiol.2001.013397; Cismowski MJ, 2000, J BIOL CHEM, V275, P23421, DOI 10.1074/jbc.C000322200; Dawson-Scully K, 2000, J NEUROSCI, V20, P6039, DOI 10.1523/JNEUROSCI.20-16-06039.2000; Evans GJO, 2003, TRAFFIC, V4, P653, DOI 10.1034/j.1600-0854.2003.00127.x; Evans GJO, 2001, J BIOL CHEM, V276, P47877, DOI 10.1074/jbc.M108186200; Fernandez-Chacon R, 2004, NEURON, V42, P237, DOI 10.1016/S0896-6273(04)00190-4; Graham ME, 2000, J NEUROSCI, V20, P1281; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUNDERSEN CB, 1992, NEURON, V9, P527, DOI 10.1016/0896-6273(92)90190-O; GUNDERSEN CB, 1994, J BIOL CHEM, V269, P19197; Jarvis SE, 2000, J BIOL CHEM, V275, P6388, DOI 10.1074/jbc.275.9.6388; KLEUSS C, 1987, J CHROMATOGR, V407, P281, DOI 10.1016/S0021-9673(01)92625-1; KONRAD RJ, 1995, J BIOL CHEM, V270, P12869, DOI 10.1074/jbc.270.21.12869; Leveque C, 1998, J BIOL CHEM, V273, P13488, DOI 10.1074/jbc.273.22.13488; Magga JM, 2000, NEURON, V28, P195, DOI 10.1016/S0896-6273(00)00096-9; MASTROGIACOMO A, 1994, SCIENCE, V263, P981, DOI 10.1126/science.7906056; Miller KG, 2000, NEURON, V27, P289, DOI 10.1016/S0896-6273(00)00037-4; Miller LC, 2003, J BIOL CHEM, V278, P53072, DOI 10.1074/jbc.M306230200; Miller LC, 2003, J CELL SCI, V116, P2967, DOI 10.1242/jcs.00595; Morales M, 1999, EUR J NEUROSCI, V11, P1818, DOI 10.1046/j.1460-9568.1999.00604.x; Natochin M, 1998, BIOCHEMISTRY-US, V37, P13776, DOI 10.1021/bi981155a; NGSEE JK, 1990, J NEUROSCI, V10, P317; Pahner I, 2003, MOL CELL NEUROSCI, V23, P398, DOI 10.1016/S1044-7431(03)00059-9; Ranjan R, 1998, J NEUROSCI, V18, P956; Reynolds NK, 2005, GENETICS, V169, P651, DOI 10.1534/genetics.104.031286; SHCADE MA, 2005, GENETICS, V169, P631; Stahl B, 1999, EUR J CELL BIOL, V78, P375, DOI 10.1016/S0171-9335(99)80079-X; Swayne LA, 2003, BIOCHEM BIOPH RES CO, V300, P921, DOI 10.1016/S0006-291X(02)02964-9; Tall GG, 2003, J BIOL CHEM, V278, P8356, DOI 10.1074/jbc.M211862200; Tobaben S, 2001, NEURON, V31, P987, DOI 10.1016/S0896-6273(01)00427-5; Umbach JA, 1998, J NEUROSCI, V18, P3233; UMBACH JA, 1994, NEURON, V13, P899, DOI 10.1016/0896-6273(94)90255-0; Umbach JA, 1997, J NEUROSCI, V17, P7203; Vitale N, 1996, EUR J NEUROSCI, V8, P1275, DOI 10.1111/j.1460-9568.1996.tb01296.x; WATSON EL, 1992, BIOCHEM J, V285, P441, DOI 10.1042/bj2850441; WILSON BS, 1994, ENDOCRINOLOGY, V134, P233, DOI 10.1210/en.134.1.233; ZINSMAIER KE, 1994, SCIENCE, V263, P977, DOI 10.1126/science.8310297	51	57	57	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	2005	280	34					30236	30241		10.1074/jbc.M500722200	http://dx.doi.org/10.1074/jbc.M500722200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	957IC	15972823	hybrid			2022-12-25	WOS:000231362500032
J	Yusa, K; Maeda, Y; Fujioka, A; Monde, K; Harada, S				Yusa, K; Maeda, Y; Fujioka, A; Monde, K; Harada, S			Isolation of TAK-779-resistant HIV-1 from an R5 HIV-1 GP120 v3 loop library	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TYPE-1 ENVELOPE GLYCOPROTEIN; AMINO-ACID SUBSTITUTION; V3 LOOP; SMALL-MOLECULE; CELL TROPISM; CORECEPTOR USAGE; CCR5 UTILIZATION; ENTRY INHIBITOR; IDENTIFICATION	The human immunodeficiency virus (HIV-1) envelope glycoprotein (GP) 120 interacts with CD4 and the CCR5 coreceptor for viral entry. The V3 loop in GP120 is a crucial region for determining coreceptor usage during viral entry, and a variety of amino acid substitutions has been observed in clinical isolates. To construct an HIV-1 V3 loop library, we chose 10 amino acid positions in the V3 loop and incorporated random combinations (27,648 possibilities) of the amino acid substitutions derived from 31 R5 viruses into the V3 loop of HIV-1(JR-FL) proviral DNA. The constructed HIV-1 library contained 6.6 x 106 independent clones containing a set of 0 - 10 amino acid substitutions in the V3 loop. To address whether restricted steric alteration in the V3 loop could confer resistance to an entry inhibitor, TAK-779, we selected entry inhibitor-resistant HIV-1 by increasing the concentration of TAK-779 from 0.10 to 0.30 mu M in PM1-CCR5 cells with high expression of CCR5. The selected viruses at passage 8 contained five amino acid substitutions in the V3 loop without any other mutations in GP120 and showed 15-fold resistance compared with the parental virus. These results indicated that a certain structure of the V3 loop containing amino acid substitutions derived from 31 R5 viruses can contribute to the acquisition of resistance to entry inhibitors binding to CCR5. Taken together, this type of HIV-1 V3 loop library is useful for isolating and analyzing the specific biological features of HIV-1 with respect to alterations of the V3 loop structure.	Kumamoto Univ, Grad Sch Med Sci, Dept Med Virol, Kumamoto 8608556, Japan	Kumamoto University	Yusa, K (corresponding author), Kumamoto Univ, Grad Sch Med Sci, Dept Med Virol, 2-1-1 Honjo, Kumamoto 8608556, Japan.	yusak@kaiju.medic.kumamoto-u.ac.jp	Monde, Kazuaki/I-6493-2019	Monde, Kazuaki/0000-0002-8314-5306				Aarons EJ, 2001, VIROLOGY, V287, P382, DOI 10.1006/viro.2001.1046; Baba M, 1999, P NATL ACAD SCI USA, V96, P5698, DOI 10.1073/pnas.96.10.5698; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; BERKHOUT B, 1993, NUCLEIC ACIDS RES, V21, P5020, DOI 10.1093/nar/21.22.5020; BOYD MT, 1993, J VIROL, V67, P3649, DOI 10.1128/JVI.67.6.3649-3652.1993; Briggs DR, 2000, AIDS, V14, P2937, DOI 10.1097/00002030-200012220-00016; Carrillo A, 1996, J VIROL, V70, P1301, DOI 10.1128/JVI.70.2.1301-1309.1996; CATASTI P, 1995, J BIOL CHEM, V270, P2224, DOI 10.1074/jbc.270.5.2224; Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0; Chen ZW, 1997, J VIROL, V71, P2705, DOI 10.1128/JVI.71.4.2705-2714.1997; CHESEBRO B, 1992, J VIROL, V66, P6547, DOI 10.1128/JVI.66.11.6547-6554.1992; Cho MW, 1998, J VIROL, V72, P2509, DOI 10.1128/JVI.72.3.2509-2515.1998; Cocchi F, 1996, NAT MED, V2, P1244, DOI 10.1038/nm1196-1244; DEJONG JJ, 1992, J VIROL, V66, P6777, DOI 10.1128/JVI.66.11.6777-6780.1992; Derdeyn CA, 2001, J VIROL, V75, P8605, DOI 10.1128/JVI.75.18.8605-8614.2001; Dragic T, 2000, P NATL ACAD SCI USA, V97, P5639, DOI 10.1073/pnas.090576697; FOUCHIER RAM, 1995, J CLIN MICROBIOL, V33, P906, DOI 10.1128/JCM.33.4.906-911.1995; Hoffman TL, 1999, MOL MEMBR BIOL, V16, P57, DOI 10.1080/096876899294760; Hu QX, 2000, J MOL BIOL, V302, P359, DOI 10.1006/jmbi.2000.4076; Hung CS, 1999, J VIROL, V73, P8216, DOI 10.1128/JVI.73.10.8216-8226.1999; HWANG SS, 1991, SCIENCE, V253, P71, DOI 10.1126/science.1905842; KIMPTON J, 1992, J VIROL, V66, P2232, DOI 10.1128/JVI.66.4.2232-2239.1992; KOITO A, 1994, J VIROL, V68, P2253, DOI 10.1128/JVI.68.4.2253-2259.1994; Kuhmann SE, 2004, J VIROL, V78, P2790, DOI 10.1128/JVI.78.6.2790-2807.2004; Kwong PD, 2000, J VIROL, V74, P1961, DOI 10.1128/JVI.74.4.1961-1972.2000; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; LUSSO P, 1995, J VIROL, V69, P3712, DOI 10.1128/JVI.69.6.3712-3720.1995; Maeda Y, 2000, J VIROL, V74, P1787, DOI 10.1128/JVI.74.4.1787-1793.2000; Moulard M, 2000, J VIROL, V74, P1948, DOI 10.1128/JVI.74.4.1948-1960.2000; OBRIEN WA, 1990, NATURE, V348, P69, DOI 10.1038/348069a0; Platt EJ, 2001, J VIROL, V75, P12266, DOI 10.1128/JVI.75.24.12266-12278.2001; Pollakis G, 2001, J BIOL CHEM, V276, P13433, DOI 10.1074/jbc.M009779200; Reeves JD, 2005, J VIROL, V79, P4991, DOI 10.1128/JVI.79.8.4991-4999.2005; Ross TM, 1998, P NATL ACAD SCI USA, V95, P7682, DOI 10.1073/pnas.95.13.7682; SCHWENK HU, 1975, BLUT, V31, P299, DOI 10.1007/BF01634146; Shimizu N, 1999, VIROLOGY, V259, P324, DOI 10.1006/viro.1999.9764; SHIODA T, 1991, NATURE, V349, P167, DOI 10.1038/349167a0; Trkola A, 2002, P NATL ACAD SCI USA, V99, P395, DOI 10.1073/pnas.012519099; Trujillo JR, 1996, VIROLOGY, V217, P613, DOI 10.1006/viro.1996.0158; Tugarinov V, 2000, STRUCT FOLD DES, V8, P385, DOI 10.1016/S0969-2126(00)00119-2; Verrier F, 1999, AIDS RES HUM RETROV, V15, P731, DOI 10.1089/088922299310827; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; Yusa K, 2002, J VIROL, V76, P3031, DOI 10.1128/JVI.76.6.3031-3037.2002	44	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	2005	280	34					30083	30090		10.1074/jbc.M414360200	http://dx.doi.org/10.1074/jbc.M414360200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	957IC	15983047	hybrid			2022-12-25	WOS:000231362500013
J	Zhang, DD; Lo, SC; Sun, Z; Habib, GM; Lieberman, MW; Hannink, M				Zhang, DD; Lo, SC; Sun, Z; Habib, GM; Lieberman, MW; Hannink, M			Ubiquitination of Keap1, a BTB-Kelch substrate adaptor protein for Cul3, targets Keap1 for degradation by a proteasome-independent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR NRF2; CUL3-BASED E3 LIGASE; F-BOX PROTEIN; OXIDATIVE STRESS; GENE-EXPRESSION; GLUTATHIONE SYNTHESIS; DROSOPHILA KELCH; COP9 SIGNALOSOME; SCF; BINDING	Keap1 is a BTB-Kelch protein that functions as a substrate adaptor protein for a Cul3-dependent E3 ubiquitin ligase complex. Keap1 targets its substrate, the Nrf2 transcription factor, for ubiquitination and subsequent degradation by the 26 S proteasome. Inhibition of Keap1-dependent ubiquitination of Nrf2 increases steady-state levels of Nrf2 and enables activation of cytoprotective Nrf2-dependent genes. In this report, we demonstrate that Keap1 and three other BTB-Kelch proteins, including GAN1, ENC1, and Sarcosin, are ubiquitinated by a Cul3-dependent complex. Ubiquitination of Keap1 is markedly increased in cells exposed to quinone-induced oxidative stress, occurs in parallel with inhibition of Keap1-dependent ubiquitination of Nrf2, and results in decreased steady-state levels of Keap1, particularly in cells that are unable to synthesize glutathione. Degradation of Keap1 is independent of the 26 S proteasome, because inhibitors of the 26 S proteasome do not prevent loss of Keap1 following exposure of cells to quinone-induced oxidative stress. Our results suggest that a switch from substrate to substrate adaptor ubiquitination is a critical regulatory step that controls steady-state levels of both BTB-Kelch substrate adaptor proteins and their cognate substrates.	Univ Missouri, Life Sci Ctr, Dept Biochem, Columbia, MO 65212 USA; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA	University of Missouri System; University of Missouri Columbia; Baylor College of Medicine	Hannink, M (corresponding author), Univ Missouri, Life Sci Ctr, Dept Biochem, 1201 E Rollins St, Columbia, MO 65212 USA.	hanninkm@missouri.edu	Sun, Zheng/C-1146-2012; Zhang, Donna/B-1015-2012	Sun, Zheng/0000-0002-6858-0633; Lo, Shih-Ching/0000-0002-5187-0730	NATIONAL CANCER INSTITUTE [P50CA103130] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059213] Funding Source: NIH RePORTER; NCI NIH HHS [P50-CA103130] Funding Source: Medline; NIGMS NIH HHS [1-R01-GM59213] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alam J, 2000, J BIOL CHEM, V275, P27694; AMES BN, 1993, OXIDANTS ARE MAJOR C, P1; Andreassi MG, 2003, MUTAT RES-REV MUTAT, V543, P67, DOI 10.1016/S1383-5742(02)00089-3; Bashir T, 2004, NATURE, V428, P190, DOI 10.1038/nature02330; Bomont P, 2000, NAT GENET, V26, P370, DOI 10.1038/81701; Bomont P, 2003, HUM MOL GENET, V12, P813, DOI 10.1093/hmg/ddg092; Bruno C, 2004, NEUROLOGY, V62, P13, DOI 10.1212/01.WNL.0000101676.41505.A7; Butterfield DA, 2001, CURR MED CHEM, V8, P815, DOI 10.2174/0929867013373048; Conaway RC, 2002, SCIENCE, V296, P1254, DOI 10.1126/science.1067466; Cope GA, 2003, CELL, V114, P663, DOI 10.1016/S0092-8674(03)00722-0; Cullen VC, 2004, NEUROREPORT, V15, P873, DOI 10.1097/00001756-200404090-00028; Cullinan SB, 2004, MOL CELL BIOL, V24, P8477, DOI 10.1128/MCB.24.19.8477-8486.2004; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Dhakshinamoorthy S, 2001, ONCOGENE, V20, P3906, DOI 10.1038/sj.onc.1204506; Dinkova-Kostova AT, 2001, P NATL ACAD SCI USA, V98, P3404, DOI 10.1073/pnas.051632198; Fang DY, 2004, P NATL ACAD SCI USA, V101, P14782, DOI 10.1073/pnas.0404445101; Fujita M, 2001, CANCER RES, V61, P7722; Furukawa M, 2005, MOL CELL BIOL, V25, P162, DOI 10.1128/MCB.25.1.162-171.2005; Galan JM, 1999, P NATL ACAD SCI USA, V96, P9124, DOI 10.1073/pnas.96.16.9124; Golden TR, 2002, AGING CELL, V1, P117, DOI 10.1046/j.1474-9728.2002.00015.x; Ishii T, 2000, J BIOL CHEM, V275, P16023, DOI 10.1074/jbc.275.21.16023; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Jaiswal AK, 2004, FREE RADICAL BIO MED, V36, P1199, DOI 10.1016/j.freeradbiomed.2004.02.074; Kang MI, 2004, P NATL ACAD SCI USA, V101, P2046, DOI 10.1073/pnas.0308347100; Kelso RJ, 2002, J CELL BIOL, V156, P703, DOI 10.1083/jcb.200110063; Kobayashi A, 2004, MOL CELL BIOL, V24, P7130, DOI 10.1128/MCB.24.16.7130-7139.2004; Kwak MK, 2003, J BIOL CHEM, V278, P8135, DOI 10.1074/jbc.M211898200; Li XC, 2004, J BIOL CHEM, V279, P54750, DOI 10.1074/jbc.M410073200; Li Y, 2004, J BIOL CHEM, V279, P11074, DOI 10.1074/jbc.M312301200; Liang XQ, 2004, ONCOGENE, V23, P5890, DOI 10.1038/sj.onc.1207776; Liu JD, 2002, MOL CELL, V10, P1511, DOI 10.1016/S1097-2765(02)00783-9; Lu SJ, 2003, J CELL SCI, V116, P2169, DOI 10.1242/jcs.00425; Nguyen T, 2003, ANNU REV PHARMACOL, V43, P233, DOI 10.1146/annurev.pharmtox.43.100901.140229; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Pickart CM, 2001, MOL CELL, V8, P499, DOI 10.1016/S1097-2765(01)00347-1; Prag S, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-42; Ramos-Gomez M, 2001, P NATL ACAD SCI USA, V98, P3410, DOI 10.1073/pnas.051618798; Rao AV, 2002, NUTR NEUROSCI, V5, P291, DOI 10.1080/1028415021000033767; Robinson DN, 1997, J CELL BIOL, V138, P799, DOI 10.1083/jcb.138.4.799; Schnell JD, 2003, J BIOL CHEM, V278, P35857, DOI 10.1074/jbc.R300018200; Sekhar KR, 2003, CANCER RES, V63, P5636; Shi ZZ, 2000, P NATL ACAD SCI USA, V97, P5101, DOI 10.1073/pnas.97.10.5101; Spence HJ, 2000, ONCOGENE, V19, P1266, DOI 10.1038/sj.onc.1203433; Stogios PJ, 2004, TRENDS BIOCHEM SCI, V29, P634, DOI 10.1016/j.tibs.2004.10.003; Suh JH, 2004, P NATL ACAD SCI USA, V101, P3381, DOI 10.1073/pnas.0400282101; Talalay P, 2001, J NUTR, V131, p3027S, DOI 10.1093/jn/131.11.3027S; Thimmulappa RK, 2002, CANCER RES, V62, P5196; Wakabayashi N, 2003, NAT GENET, V35, P238, DOI 10.1038/ng1248; Wei W, 2004, NATURE, V428, P194, DOI 10.1038/nature02381; Wirbelauer C, 2000, EMBO J, V19, P5362, DOI 10.1093/emboj/19.20.5362; Wolf DA, 2003, NAT CELL BIOL, V5, P1029, DOI 10.1038/ncb1203-1029; Zhang DD, 2003, MOL CELL BIOL, V23, P8137, DOI 10.1128/MCB.23.22.8137-8151.2003; Zhang DD, 2004, MOL CELL BIOL, V24, P10941, DOI 10.1128/MCB.24.24.10941-10953.2004; Zheng JY, 2002, MOL CELL, V10, P1519, DOI 10.1016/S1097-2765(02)00784-0; Zhou PB, 1998, MOL CELL, V2, P571, DOI 10.1016/S1097-2765(00)80156-2	55	225	237	2	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	2005	280	34					30091	30099		10.1074/jbc.M501279200	http://dx.doi.org/10.1074/jbc.M501279200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	957IC	15983046	hybrid			2022-12-25	WOS:000231362500014
J	Friedrich, JK; Panov, KI; Cabart, P; Russell, J; Zomerdijk, JCBM				Friedrich, JK; Panov, KI; Cabart, P; Russell, J; Zomerdijk, JCBM			TBP-TAF complex SL1 directs RNA polymerase I pre-initiation complex formation and stabilizes upstream binding factor at the rDNA promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOMAL DNA PROMOTER; TRANSCRIPTION FACTOR; FACTOR UBF; SPECIES-SPECIFICITY; GENE PROMOTERS; PROTEIN; RECRUITMENT; XUBF; ACTIVATION; LIFE	Knowledge of the role of components of the RNA polymerase I transcription machinery is paramount to understanding regulation of rDNA expression. We describe key findings for the roles of essential transcription factor SL1 and activator upstream binding factor (UBF). We demonstrate that human SL1 can direct accurate Pol I transcription in the absence of UBF and can interact with the rDNA promoter independently and stably, consistent with studies of rodent SL1 but contrary to previous reports of human SL1. UBF itself does not bind stably to rDNA but rapidly associates and dissociates. We show that SL1 significantly reduces the rate of dissociation of UBF from the rDNA promoter. Our findings challenge the idea that UBF activates transcription through recruitment of SL1 at the rDNA promoter and suggest that the rate of pre-initiation complex (PIC) formation is primarily determined by the rate of association of SL1, rather than UBF, with the promoter. Therefore, we propose that SL1 directs PIC formation, functioning in core promoter binding, RNA polymerase I recruitment, and UBF stabilization and that SL1-promoter complex formation is a necessary prerequisite to the assembly of functional and stable PICs that include the UBF activator in mammalian cells.	Univ Dundee, Sch Life Sci, Wellcome Trust Bioctr, Div Gene Regulat & Express, Dundee DD1 5EH, Scotland	University of Dundee	Zomerdijk, JCBM (corresponding author), Univ Dundee, Sch Life Sci, Wellcome Trust Bioctr, Div Gene Regulat & Express, Dundee DD1 5EH, Scotland.	j.zomerdijk@dundee.ac.uk	Zomerdijk, Joost/A-5142-2008	Panov, Konstantin/0000-0003-1375-7814; Cabart, Pavel/0000-0003-0065-367X; Zomerdijk, Joost/0000-0003-1865-729X	Wellcome Trust [045160] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAZETTJONES DP, 1994, SCIENCE, V264, P1134, DOI 10.1126/science.8178172; BECKMANN H, 1995, SCIENCE, V270, P1506, DOI 10.1126/science.270.5241.1506; BELL SP, 1988, SCIENCE, V241, P1192, DOI 10.1126/science.3413483; BELL SP, 1990, GENE DEV, V4, P943, DOI 10.1101/gad.4.6.943; Bric A, 2004, J BIOL CHEM, V279, P31259, DOI 10.1074/jbc.M311828200; COLEMAN RA, 1995, J BIOL CHEM, V270, P13850, DOI 10.1074/jbc.270.23.13850; COMAI L, 1994, SCIENCE, V266, P1966, DOI 10.1126/science.7801123; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; COPENHAVER GP, 1994, NUCLEIC ACIDS RES, V22, P2651, DOI 10.1093/nar/22.13.2651; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; Dundr M, 2002, SCIENCE, V298, P1623, DOI 10.1126/science.1076164; Geiduschek EP, 2001, J MOL BIOL, V310, P1, DOI 10.1006/jmbi.2001.4732; Grummt I, 2003, GENE DEV, V17, P1691, DOI 10.1101/gad.1098503R; HALTINER MM, 1986, MOL CELL BIOL, V6, P227, DOI 10.1128/MCB.6.1.227; HEIX J, 1995, CURR OPIN GENET DEV, V5, P652, DOI 10.1016/0959-437X(95)80035-2; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HU CH, 1994, MOL CELL BIOL, V14, P2871, DOI 10.1128/MCB.14.5.2871; James MJ, 2004, J BIOL CHEM, V279, P8911, DOI 10.1074/jbc.M307735200; JANTZEN HM, 1992, GENE DEV, V6, P1950, DOI 10.1101/gad.6.10.1950; JANTZEN HM, 1990, NATURE, V344, P830, DOI 10.1038/344830a0; Jordan P, 1996, J CELL BIOL, V133, P225, DOI 10.1083/jcb.133.2.225; Kalodimos CG, 2004, SCIENCE, V305, P386, DOI 10.1126/science.1097064; Kihm AJ, 1998, P NATL ACAD SCI USA, V95, P14816, DOI 10.1073/pnas.95.25.14816; LEARNED R M, 1982, Journal of Molecular and Applied Genetics, V1, P575; LEARNED RM, 1986, CELL, V45, P847, DOI 10.1016/0092-8674(86)90559-3; LEARNED RM, 1985, MOL CELL BIOL, V5, P1358, DOI 10.1128/MCB.5.6.1358; LEARNED RM, 1983, P NATL ACAD SCI-BIOL, V80, P3558, DOI 10.1073/pnas.80.12.3558; LEBLANC B, 1993, EMBO J, V12, P513, DOI 10.1002/j.1460-2075.1993.tb05683.x; Leung AKL, 2004, J CELL BIOL, V166, P787, DOI 10.1083/jcb.200405013; Mais C, 2005, GENE DEV, V19, P50, DOI 10.1101/gad.310705; Marilley M, 1996, NUCLEIC ACIDS RES, V24, P2204, DOI 10.1093/nar/24.12.2204; Miller G, 2001, EMBO J, V20, P1373, DOI 10.1093/emboj/20.6.1373; Moss T, 2002, CELL, V109, P545, DOI 10.1016/S0092-8674(02)00761-4; MOSS T, 1995, PROG NUCLEIC ACID RE, V50, P25, DOI 10.1016/S0079-6603(08)60810-7; O'Sullivan AC, 2002, MOL CELL BIOL, V22, P657, DOI 10.1128/MCB.22.2.657-668.2002; Panov KI, 2001, MOL CELL BIOL, V21, P2641, DOI 10.1128/MCB.21.8.2641-2649.2001; PIKAARD CS, 1989, GENE DEV, V3, P1779, DOI 10.1101/gad.3.11.1779; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; PUTNAM CD, 1994, MOL CELL BIOL, V14, P6476, DOI 10.1128/MCB.14.10.6476; RUDLOFF U, 1994, EMBO J, V13, P2611, DOI 10.1002/j.1460-2075.1994.tb06551.x; Russell J, 2005, TRENDS BIOCHEM SCI, V30, P87, DOI 10.1016/j.tibs.2004.12.008; SCHNAPP A, 1991, J BIOL CHEM, V266, P24588; Schramm L, 2002, GENE DEV, V16, P2593, DOI 10.1101/gad.1018902; SMALE ST, 1985, MOL CELL BIOL, V5, P352, DOI 10.1128/MCB.5.2.352; Smith S. David, 1993, Gene Expression, V3, P229; SMITH SD, 1990, MOL CELL BIOL, V10, P3105, DOI 10.1128/MCB.10.6.3105; Stefanovsky VY, 2001, NUCLEIC ACIDS RES, V29, P3241, DOI 10.1093/nar/29.15.3241; Thomas JO, 2001, TRENDS BIOCHEM SCI, V26, P167, DOI 10.1016/S0968-0004(01)01801-1; Tuan JC, 1999, MOL CELL BIOL, V19, P2872; Verrijzer CP, 1996, TRENDS BIOCHEM SCI, V21, P338, DOI 10.1016/0968-0004(96)10044-X; ZOMERDIJK JCB, 1998, TRANSCRIPTION EUKARY, P67; ZOMERDIJK JCBM, 1994, SCIENCE, V266, P2015, DOI 10.1126/science.7801130	52	57	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	2005	280	33					29551	29558		10.1074/jbc.M501595200	http://dx.doi.org/10.1074/jbc.M501595200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	954SX	15970593	Green Accepted, hybrid			2022-12-25	WOS:000231176200022
J	Vitale, N; Mawet, J; Camonis, J; Regazzi, R; Bader, MF; Chasserot-Golaz, S				Vitale, N; Mawet, J; Camonis, J; Regazzi, R; Bader, MF; Chasserot-Golaz, S			The small GTPase RalA controls exocytosis of large dense core secretory granules by interacting with ARF6-dependent phospholipase D1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-REGULATED EXOCYTOSIS; PLASMA-MEMBRANE; CHROMAFFIN CELLS; BINDING PROTEINS; EXOCYST COMPLEX; SYNAPTIC VESICLES; SEC6/8 COMPLEX; NEUROTRANSMITTER RELEASE; PUTATIVE EFFECTOR; EPITHELIAL-CELLS	RalA and RalB constitute a family of highly similar Ras-related GTPases widely distributed in different tissues. Recently, active forms of Ral proteins have been shown to bind to the exocyst complex, implicating them in the regulation of cellular secretion. Since RalA is present on the plasma membrane in neuroendocrine chromaffin and PC12 cells, we investigated the potential role of RalA in calcium-regulated exocytotic secretion. We show here that endogenous RalA is activated during exocytosis. Expression of the constitutively active RalA (G23V) mutant enhances secretagogue-evoked secretion from PC12 cells. Conversely, expression of the constitutively inactive GDP-bound RalA (G26A) or silencing of the RalA gene by RNA interference led to a strong impairment of the exocytotic response. RalA was found to co-localize with phospholipase D1 ( PLD1) at the plasma membrane in PC12 cells. We demonstrate that cell stimulation triggers a direct interaction between RalA and ARF6-activated PLD1. Moreover, reduction of endogenous RalA expression level interfered with the activation of PLD1 observed in secretagogue-stimulated cells. Finally, using various RalA mutants selectively impaired in their ability to activate downstream effectors, we show that PLD1 activation is essential for the activation of secretion by GTP-loaded RalA. Together, these results provide evidence that RalA is a positive regulator of calcium-evoked exocytosis of large dense core secretory granules and suggest that stimulation of PLD1 and consequent changes in plasma membrane phospholipid composition is the major function RalA undertakes in calcium-regulated exocytosis.	CNRS, UPR 2356, F-67084 Strasbourg, France; INSERM, Inst Curie, U 528, F-75248 Paris, France; Univ Lausanne, Inst Biol Cellulaire & Morphol, CH-1005 Lausanne, Switzerland	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; University of Lausanne	Bader, MF (corresponding author), CNRS, UPR 2356, 5 Rue Blaise Pascal, F-67084 Strasbourg, France.	bader@neurochem.u-strasbg.fr	Bader, Marie-France/O-2098-2016; Chasserot-Golaz, Sylvette/K-7625-2017; Vitale, Nicolas/G-5967-2014	Vitale, Nicolas/0000-0002-4752-4907; Regazzi, Romano/0000-0002-9773-2915; Chasserot-Golaz, Sylvette/0000-0002-7437-2558				BADER MF, 1986, J BIOL CHEM, V261, P5777; Bhullar RP, 1998, MOL CELL BIOCHEM, V179, P49, DOI 10.1023/A:1006891815211; BIELINSKI DF, 1993, BIOCHIM BIOPHYS ACTA, V1151, P246, DOI 10.1016/0005-2736(93)90109-D; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Brymora A, 2001, J BIOL CHEM, V276, P29792, DOI 10.1074/jbc.C100320200; Burgoyne RD, 2003, BBA-MOL CELL RES, V1641, P137, DOI 10.1016/S0167-4889(03)00089-2; CANTOR SB, 1995, MOL CELL BIOL, V15, P4578; Caumon AS, 2000, J BIOL CHEM, V275, P15637, DOI 10.1074/jbc.M908347199; Caumont AS, 1998, J BIOL CHEM, V273, P1373, DOI 10.1074/jbc.273.3.1373; CHAMBERLAIN LH, 1995, J CELL BIOL, V130, P1063, DOI 10.1083/jcb.130.5.1063; CHARDIN P, 1989, NUCLEIC ACIDS RES, V17, P4380, DOI 10.1093/nar/17.11.4380; ChasserotGolaz S, 1996, J CELL BIOL, V133, P1217, DOI 10.1083/jcb.133.6.1217; Chen YA, 1999, J BIOL CHEM, V274, P26469, DOI 10.1074/jbc.274.37.26469; Clough RR, 2002, J BIOL CHEM, V277, P28972, DOI 10.1074/jbc.M201504200; EHRHART M, 1986, J HISTOCHEM CYTOCHEM, V34, P1673, DOI 10.1177/34.12.2878021; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Feig LA, 2003, TRENDS CELL BIOL, V13, P419, DOI 10.1016/S0962-8924(03)00152-1; Gasman S, 1999, J CELL SCI, V112, P4763; Grindstaff KK, 1998, CELL, V93, P731, DOI 10.1016/S0092-8674(00)81435-X; Hammond SM, 2001, NAT REV GENET, V2, P110, DOI 10.1038/35052556; Hazuka CD, 1999, J NEUROSCI, V19, P1324; Hsu SC, 1999, TRENDS CELL BIOL, V9, P150, DOI 10.1016/S0962-8924(99)01516-0; Hsu SC, 1996, NEURON, V17, P1209, DOI 10.1016/S0896-6273(00)80251-2; Humeau Y, 2001, P NATL ACAD SCI USA, V98, P15300, DOI 10.1073/pnas.261358698; Ikeda M, 1998, J BIOL CHEM, V273, P814, DOI 10.1074/jbc.273.2.814; Inoue M, 2003, NATURE, V422, P629, DOI 10.1038/nature01533; Jullien-Flores V, 2000, J CELL SCI, V113, P2837; JULLIENFLORES V, 1995, J BIOL CHEM, V270, P22473, DOI 10.1074/jbc.270.38.22473; Kee Y, 1997, P NATL ACAD SCI USA, V94, P14438, DOI 10.1073/pnas.94.26.14438; Kim JH, 1998, FEBS LETT, V430, P231, DOI 10.1016/S0014-5793(98)00661-9; Lipschutz JH, 2002, CURR BIOL, V12, pR212, DOI 10.1016/S0960-9822(02)00753-4; Luo JQ, 1998, P NATL ACAD SCI USA, V95, P3632, DOI 10.1073/pnas.95.7.3632; Mark BL, 1996, BIOCHEM BIOPH RES CO, V225, P40, DOI 10.1006/bbrc.1996.1128; Moskalenko S, 2003, J BIOL CHEM, V278, P51743, DOI 10.1074/jbc.M308702200; Moskalenko S, 2002, NAT CELL BIOL, V4, P66, DOI 10.1038/ncb728; Murthy M, 2003, NEURON, V37, P433, DOI 10.1016/S0896-6273(03)00031-X; Nakashima S, 1999, EMBO J, V18, P3629, DOI 10.1093/emboj/18.13.3629; NGSEE JK, 1991, J BIOL CHEM, V266, P2675; Ohta Y, 1999, P NATL ACAD SCI USA, V96, P2122, DOI 10.1073/pnas.96.5.2122; Park SH, 1995, ONCOGENE, V11, P2349; Polzin A, 2002, MOL CELL BIOL, V22, P1714, DOI 10.1128/MCB.22.6.1714-1722.2002; Reuther GW, 2000, CURR OPIN CELL BIOL, V12, P157, DOI 10.1016/S0955-0674(99)00071-X; Santolini E, 1999, EXP CELL RES, V253, P186, DOI 10.1006/excr.1999.4694; Shen YJ, 2001, MOL CELL BIOL, V21, P595, DOI 10.1128/MCB.21.2.595-602.2001; Shipitsin M, 2004, MOL CELL BIOL, V24, P5746, DOI 10.1128/MCB.24.13.5746-5756.2004; Sugihara K, 2002, NAT CELL BIOL, V4, P73, DOI 10.1038/ncb720; TerBush DR, 1996, EMBO J, V15, P6483, DOI 10.1002/j.1460-2075.1996.tb01039.x; Vik-Mo EO, 2003, NEUROSCIENCE, V119, P73, DOI 10.1016/S0306-4522(03)00065-4; Vitale N, 2002, J CELL BIOL, V159, P79, DOI 10.1083/jcb.200203027; Vitale N, 2001, EMBO J, V20, P2424, DOI 10.1093/emboj/20.10.2424; VOLKNANDT W, 1993, FEBS LETT, V317, P53, DOI 10.1016/0014-5793(93)81490-Q; Wang KL, 1999, J BIOL CHEM, V274, P14525, DOI 10.1074/jbc.274.21.14525; Wang L, 2004, J BIOL CHEM, V279, P19875, DOI 10.1074/jbc.M400522200; Waselle L, 2003, MOL BIOL CELL, V14, P4103, DOI 10.1091/mbc.E03-01-0022; Wolthuis RMF, 1998, MOL CELL BIOL, V18, P2486, DOI 10.1128/MCB.18.5.2486; Yamaguchi A, 1997, J BIOL CHEM, V272, P31230, DOI 10.1074/jbc.272.50.31230	57	59	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	2005	280	33					29921	29928		10.1074/jbc.M413748200	http://dx.doi.org/10.1074/jbc.M413748200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	954SX	15980073	hybrid			2022-12-25	WOS:000231176200064
J	Waxman, EA; Lynch, DR				Waxman, EA; Lynch, DR			N-methyl-D-aspartate receptor subtype mediated bidirectional control of p38 mitogen-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; CULTURED HIPPOCAMPAL-NEURONS; SYNAPTIC NMDA RECEPTORS; RAT CORTICAL-NEURONS; AMYLOID BETA-PEPTIDE; PHOSPHATIDYLINOSITOL 3-KINASE; SUBUNIT COMPOSITION; IN-VITRO; PHOSPHOINOSITIDE 3-KINASE; TYROSINE PHOSPHORYLATION	N-methyl-D-aspartate receptor ( NMDAR) stimulation activates many downstream mechanisms involved in both cell survival and cell death. The manner in which the NMDAR regulates one of these pathways, the p38 mitogen-activated protein kinase ( p38) pathway, is currently unknown. In the present study, we have defined a developmental-, concentration-, and time-dependent phosphorylation and subsequent dephosphorylation of p38. In cultured hippocampal neurons 7-8 days in vitro (DIV7-8), NMDAR stimulation leads to a concentration-dependent increase in p38 phosphorylation (phosphop-38). However, in more mature neurons (> DIV17) application of NMDA produces concentration- dependent effects, such that low concentrations result in sustained increases in phospho-p38 levels, and high concentrations dephosphorylate p38 within 5 min. Conantokin G, an antagonist of NR1/2A/2B and NR1/2B receptors, inhibits p38 phosphorylation, while NR1/2B-specific antagonists prevent the rapid dephosphorylation of p38 without affecting p38 activation. Furthermore, inhibition of calcineurin prevents the activation of p38, whereas inhibition of phosphoinositide 3-kinase (PI3K) prevents the rapid dephosphorylation of p38. Our results support the presence of subtype-dependent pathways regulating p38 activation and deactivation: one involves NR1/2A/2B receptors activating calcineurin and resulting in p38 phosphorylation, and the other utilizes NR1/2B receptors binding to and activating PI3K and leading to the dephosphorylation of p38 in a manner involving both NR1/2A/2B receptor activation and tyrosine phosphorylation of NR2B. The ability of NMDAR subtype-specific mechanisms to regulate p38 has implications for NMDAR-mediated synaptic plasticity, gene regulation, and excitotoxicity.	Childrens Hosp Philadelphia, Div Neurol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Neurol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Lynch, DR (corresponding author), Childrens Hosp Philadelphia, Div Neurol, 502 Abramson Bldg,3615 Civic Ctr Blvd, Philadelphia, PA 19104 USA.	lynch@pharm.med.upenn.edu		Waxman, Elisa/0000-0003-4562-7969	NATIONAL INSTITUTE OF MENTAL HEALTH [T32MH014654] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045986, R56NS045986] Funding Source: NIH RePORTER; NIMH NIH HHS [T32 MH 14654] Funding Source: Medline; NINDS NIH HHS [NS45986] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Barone FC, 2001, J PHARMACOL EXP THER, V296, P312; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; Brimecombe JC, 1997, P NATL ACAD SCI USA, V94, P11019, DOI 10.1073/pnas.94.20.11019; Brown TC, 2005, NEURON, V45, P81, DOI 10.1016/j.neuron.2004.12.023; Butler MP, 2004, NEUROSCIENCE, V124, P319, DOI 10.1016/j.neuroscience.2003.11.040; Cammarota M, 2000, MOL BRAIN RES, V76, P36, DOI 10.1016/S0169-328X(99)00329-0; Chandler LJ, 2001, J BIOL CHEM, V276, P2627, DOI 10.1074/jbc.M003390200; Charton JP, 1999, BRAIN RES, V816, P609, DOI 10.1016/S0006-8993(98)01243-8; Chen HJ, 1998, NEURON, V20, P895, DOI 10.1016/S0896-6273(00)80471-7; Chen NS, 1997, MOL PHARMACOL, V51, P1015, DOI 10.1124/mol.51.6.1015; Chen QS, 2002, NEUROBIOL LEARN MEM, V77, P354, DOI 10.1006/nlme.2001.4034; CHOI DW, 1987, J NEUROSCI, V7, P369; Cowan KJ, 2003, J EXP BIOL, V206, P1107, DOI 10.1242/jeb.00220; Dell'Acqua ML, 2002, J BIOL CHEM, V277, P48796, DOI 10.1074/jbc.M207833200; Dingledine R, 1999, PHARMACOL REV, V51, P7; Donevan SD, 2000, MOL PHARMACOL, V58, P614, DOI 10.1124/mol.58.3.614; Fischer G, 1997, J PHARMACOL EXP THER, V283, P1285; Fujisawa S, 2003, NEUROSCIENCE, V121, P51, DOI 10.1016/S0306-4522(03)00341-5; Gisabella B, 2003, NEUROSCIENCE, V121, P297, DOI 10.1016/S0306-4522(03)00440-8; Gomez LL, 2002, J NEUROSCI, V22, P7027; Guttmann RP, 2001, J NEUROCHEM, V78, P1083, DOI 10.1046/j.1471-4159.2001.00493.x; Hardingham GE, 2002, NAT NEUROSCI, V5, P405, DOI 10.1038/nn835; Hatton CJ, 2005, NEURON, V46, P261, DOI 10.1016/j.neuron.2005.03.005; Hisatsune C, 1999, GENES CELLS, V4, P657, DOI 10.1046/j.1365-2443.1999.00287.x; HOLT KH, 1994, MOL CELL BIOL, V14, P42, DOI 10.1128/MCB.14.1.42; Huang YY, 2004, P NATL ACAD SCI USA, V101, P859, DOI 10.1073/pnas.2237201100; Kawasaki H, 1997, J BIOL CHEM, V272, P18518, DOI 10.1074/jbc.272.30.18518; Kew JNC, 1996, J PHYSIOL-LONDON, V497, P761, DOI 10.1113/jphysiol.1996.sp021807; Kim JH, 1998, NEURON, V20, P683, DOI 10.1016/S0896-6273(00)81008-9; Klein RC, 2001, J BIOL CHEM, V276, P26860, DOI 10.1074/jbc.M102428200; Kohr G, 2003, J NEUROSCI, V23, P10791; Kojima N, 1997, P NATL ACAD SCI USA, V94, P4761, DOI 10.1073/pnas.94.9.4761; Komiyama NH, 2002, J NEUROSCI, V22, P9721; Krapivinsky G, 2003, NEURON, V40, P775, DOI 10.1016/S0896-6273(03)00645-7; Kurosu H, 1997, J BIOL CHEM, V272, P24252, DOI 10.1074/jbc.272.39.24252; Lau LF, 1996, J BIOL CHEM, V271, P21622, DOI 10.1074/jbc.271.35.21622; Laube B, 1998, J NEUROSCI, V18, P2954; LAURIE DJ, 1994, EUR J PHARM-MOLEC PH, V268, P335, DOI 10.1016/0922-4106(94)90058-2; Legos JJ, 2002, EUR J PHARMACOL, V447, P37, DOI 10.1016/S0014-2999(02)01890-3; Legos JJ, 2001, BRAIN RES, V892, P70, DOI 10.1016/S0006-8993(00)03228-5; Li B, 2002, NAT NEUROSCI, V5, P833, DOI 10.1038/nn912; Li JH, 1998, EUR J NEUROSCI, V10, P1704, DOI 10.1046/j.1460-9568.1998.00169.x; Luo JH, 1997, MOL PHARMACOL, V51, P79, DOI 10.1124/mol.51.1.79; Lynch DR, 2001, CURR DRUG TARGETS, V2, P215, DOI 10.2174/1389450013348434; Lynch DR, 2001, EUR J PHARMACOL, V416, P185, DOI 10.1016/S0014-2999(01)00868-8; Mallon AP, 2005, EXP BRAIN RES, V162, P374, DOI 10.1007/s00221-004-2193-6; Man HY, 2003, NEURON, V38, P611, DOI 10.1016/S0896-6273(03)00228-9; Mukherjee PK, 1999, J BIOL CHEM, V274, P6493, DOI 10.1074/jbc.274.10.6493; Muller BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; Nakazawa T, 2001, J BIOL CHEM, V276, P693, DOI 10.1074/jbc.M008085200; Namura S, 2001, P NATL ACAD SCI USA, V98, P11569, DOI 10.1073/pnas.181213498; Nozaki K, 2001, MOL NEUROBIOL, V23, P1, DOI 10.1385/MN:23:1:01; Opazo P, 2003, J NEUROSCI, V23, P3679; PRIESTLEY T, 1995, MOL PHARMACOL, V48, P841; Puig B, 2004, ACTA NEUROPATHOL, V107, P185, DOI 10.1007/s00401-003-0793-z; Quinlan EM, 1999, NAT NEUROSCI, V2, P352, DOI 10.1038/7263; Rivera-Cervantes MC, 2004, J NEUROSCI RES, V76, P678, DOI 10.1002/jnr.20103; Sala C, 2000, J NEUROSCI, V20, P3529, DOI 10.1523/JNEUROSCI.20-10-03529.2000; Saleshando G, 2000, NEUROSCI LETT, V288, P119, DOI 10.1016/S0304-3940(00)01210-6; Sans N, 2000, J NEUROSCI, V20, P1260, DOI 10.1523/JNEUROSCI.20-03-01260.2000; SHENG M, 1994, NATURE, V368, P144, DOI 10.1038/368144a0; Shimokawara T, 2002, NEUROPATHOLOGY, V22, P261, DOI 10.1046/j.1440-1789.2002.00463.x; Shiraishi Y, 2003, MOL CELL NEUROSCI, V22, P188, DOI 10.1016/S1044-7431(03)00037-X; SHOELSON SE, 1993, EMBO J, V12, P795, DOI 10.1002/j.1460-2075.1993.tb05714.x; SIHRA TS, 1995, BIOCHEM BIOPH RES CO, V212, P609, DOI 10.1006/bbrc.1995.2013; Sinor JD, 2000, J NEUROSCI, V20, P8831; Steigerwald F, 2000, J NEUROSCI, V20, P4573, DOI 10.1523/JNEUROSCI.20-12-04573.2000; Stocca G, 1998, J PHYSIOL-LONDON, V507, P13, DOI 10.1111/j.1469-7793.1998.013bu.x; Suenaga A, 2005, J BIOL CHEM, V280, P1321, DOI 10.1074/jbc.M410436200; Takagi N, 2003, J NEUROCHEM, V84, P67, DOI 10.1046/j.1471-4159.2003.01500.x; Tovar KR, 1999, J NEUROSCI, V19, P4180; Townsend M, 2003, P NATL ACAD SCI USA, V100, P1340, DOI 10.1073/pnas.0335786100; Walker EH, 2000, MOL CELL, V6, P909, DOI 10.1016/S1097-2765(05)00089-4; Wang QW, 2004, J NEUROSCI, V24, P3370, DOI 10.1523/JNEUROSCI.1633-03.2004; Wenzel A, 1997, J NEUROCHEM, V68, P469; WILCOX KS, 1994, SYNAPSE, V18, P128, DOI 10.1002/syn.890180206; Williams K, 1996, NEUROSCI LETT, V215, P9, DOI 10.1016/S0304-3940(96)12924-4; WONG EHF, 1986, P NATL ACAD SCI USA, V83, P7104, DOI 10.1073/pnas.83.18.7104; Yaka R, 2002, P NATL ACAD SCI USA, V99, P5710, DOI 10.1073/pnas.062046299; Zhu JJ, 2002, CELL, V110, P443, DOI 10.1016/S0092-8674(02)00897-8	80	63	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	2005	280	32					29322	29333		10.1074/jbc.M502080200	http://dx.doi.org/10.1074/jbc.M502080200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	952QT	15967799	hybrid			2022-12-25	WOS:000231021300063
J	Kupatt, C; Horstkotte, J; Vlastos, GA; Pfosser, A; Lebherz, C; Semisch, M; Thalgott, M; Buttner, K; Browarzyk, C; Mages, J; Hoffmann, R; Deten, A; Lamparter, M; Muller, F; Beck, H; Buning, H; Boekstegers, P; Hatzopoulos, AK				Kupatt, C; Horstkotte, J; Vlastos, GA; Pfosser, A; Lebherz, C; Semisch, M; Thalgott, M; Buttner, K; Browarzyk, C; Mages, J; Hoffmann, R; Deten, A; Lamparter, M; Muller, F; Beck, H; Buning, H; Boekstegers, P; Hatzopoulos, AK			Embryonic endothelial progenitor cells expressing a broad range of proangiogenic and remodeling factors enhance vascularization and tissue recovery in acute and chronic ischemia	FASEB JOURNAL			English	Article						myocardial infarction; angiogenesis; endothelium-derived factors	MARROW-DERIVED CELLS; STEM-CELLS; MYOCARDIAL-INFARCTION; IN-VITRO; GROWTH; VIVO; ANGIOGENESIS; NEOVASCULARIZATION; RETROINFUSION; RECRUITMENT	Clonal embryonic endothelial progenitor cells (eEPCs) isolated from embryonic day 7.5 mice home specifically to hypoxic areas in mouse tumor metastases but spare normal organs and do not form carcinomas. Based on these results, we assessed the potential of eEPCs to enhance vascularization and limit organ dysfunction after ischemia in syngenic and xenotypic organisms. The angiogenic potential of eEPCs was evaluated in chronic ischemic rabbit hindlimbs after regional application by retroinfusion. eEPC treatment improved limb perfusion, paralleled by an increase in capillary density and collateral blood vessel number. Systemic eEPC infusion into mice after ischemic cardiac insult increased postischemic heart output measured by a marked improvement in left ventricle developed pressure and both systolic and diastolic functions. In vitro, eEPCs strongly induced vascular outgrowths from aortic rings. To address the molecular basis of this intrinsic angiogenic potential, we investigated the eEPC transcriptome. Genome-wide Affymetrix GeneChip analysis revealed that the eEPCs express a wealth of secreted factors known to induce angiogenesis, tissue remodeling, and organogenesis that may contribute to the eEPC-mediated beneficial effects. Our findings show that eEPCs induce blood vessel growth and cardioprotection in severe ischemic conditions providing a readily available source to study the mechanisms of neovascularization and tissue recovery.	Vanderbilt Univ, Dept Med, Div Cardiovasc Med, Nashville, TN 37232 USA; GSF Munich, Res Ctr Environm & Hlth, Inst Clin Mol Biol & Tumor Genet, D-81377 Munich, Germany; Klinikum Grosshadern, D-81377 Munich, Germany; Tech Univ Munich, Inst Med Microbiol, D-81675 Munich, Germany; Max Von Pettenkofer Inst, Dept Bacteriol, D-80336 Munich, Germany; Univ Leipzig, Inst Physiol, D-04103 Leipzig, Germany; Univ Munich, Gene Ctr, D-81377 Munich, Germany	Vanderbilt University; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich; Technical University of Munich; University of Munich; Leipzig University; University of Munich	Hatzopoulos, AK (corresponding author), Vanderbilt Univ, Dept Med, Div Cardiovasc Med, 2220 Pierce Ave, Nashville, TN 37232 USA.	antonis.hatzopoulos@vanderbilt.edu	Hatzopoulos, Antonis/X-2043-2019; Hoffmann, Reinhard/I-8748-2018; Hatzopoulos, Antonis/D-2049-2010; Buening, Hildegard/AAJ-2352-2020; Buening, Hildegard/AAV-9928-2021	Hatzopoulos, Antonis/0000-0001-5610-0017; Hoffmann, Reinhard/0000-0003-1514-1183; Buening, Hildegard/0000-0002-3365-6933; Kupatt, Christian/0000-0002-3611-1218				Aicher A, 2003, CIRCULATION, V107, P2134, DOI 10.1161/01.CIR.0000062649.63838.C9; Amin MA, 2003, CIRC RES, V93, P321, DOI 10.1161/01.RES.0000087641.56024.DA; Barandon L, 2003, CIRCULATION, V108, P2282, DOI 10.1161/01.CIR.0000093186.22847.4C; Beck H, 2003, J CEREBR BLOOD F MET, V23, P709, DOI 10.1097/01.WCB.0000065940.18332.8D; Beckner ME, 2002, MICROVASC RES, V63, P259, DOI 10.1006/mvre.2001.2384; Bock-Marquette I, 2004, NATURE, V432, P466, DOI 10.1038/nature03000; Britten MB, 2003, CIRCULATION, V108, P2212, DOI 10.1161/01.CIR.0000095788.78169.AF; Byrd N, 2002, DEVELOPMENT, V129, P361; Corbel SY, 2003, NAT MED, V9, P1528, DOI 10.1038/nm959; Eisenberg LM, 2004, STEM CELLS DEV, V13, P614, DOI 10.1089/scd.2004.13.614; Hatzopoulos AK, 1998, DEVELOPMENT, V125, P1457; Heil M, 2004, CIRC RES, V94, P573, DOI 10.1161/01.RES.0000124603.46777.EB; Jackson KA, 2001, J CLIN INVEST, V107, P1395, DOI 10.1172/JCI12150; Kamihata H, 2001, CIRCULATION, V104, P1046, DOI 10.1161/hc3501.093817; Kawamoto A, 2001, CIRCULATION, V103, P634; Kinnaird T, 2004, CIRC RES, V94, P678, DOI 10.1161/01.RES.0000118601.37875.AC; Koczulla R, 2003, J CLIN INVEST, V111, P1665, DOI 10.1172/JCI200317545; Kryczek I, 2005, CANCER RES, V65, P465; Kupatt C, 2003, FASEB J, V17, P705, DOI 10.1096/fj.02-0673fje; Kupatt C, 2002, GENE THER, V9, P518, DOI 10.1038/sj.gt.3301673; Kupatt C, 2002, J LEUKOCYTE BIOL, V72, P455; Lebherz C, 2003, ENDOTHELIUM-J ENDOTH, V10, P257, DOI 10.1080/713715242; Masuda H, 2003, CARDIOVASC RES, V58, P390, DOI 10.1016/S0008-6363(02)00785-X; Sato N, 2003, DEV BIOL, V260, P404, DOI 10.1016/S0012-1606(03)00256-2; Shi Q, 1998, BLOOD, V92, P362, DOI 10.1182/blood.V92.2.362.414k38_362_367; Shintani S, 2001, CIRCULATION, V103, P897, DOI 10.1161/01.CIR.103.6.897; Strauer BE, 2002, CIRCULATION, V106, P1913, DOI 10.1161/01.CIR.0000034046.87607.1C; Takahashi T, 1999, NAT MED, V5, P434, DOI 10.1038/7434; Vajkoczy P, 2003, J EXP MED, V197, P1755, DOI 10.1084/jem.20021659; von Degenfeld G, 2003, J AM COLL CARDIOL, V42, P1120, DOI 10.1016/S0735-1097(03)00915-X; Wei JW, 2004, CANCER CELL, V5, P477, DOI 10.1016/S1535-6108(04)00116-3; Witzenbichler B, 1998, AM J PATHOL, V153, P381, DOI 10.1016/S0002-9440(10)65582-4; Wollert KC, 2004, LANCET, V364, P141, DOI 10.1016/S0140-6736(04)16626-9; Ziegelhoeffer T, 2004, CIRC RES, V94, P230, DOI 10.1161/01.RES.0000110419.50982.1C	34	96	101	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2005	19	9					1576	+		10.1096/fj.04-3282fje	http://dx.doi.org/10.1096/fj.04-3282fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	951IO	16009705				2022-12-25	WOS:000230923000026
J	Tonello, C; Vindigni, V; Zavan, B; Abatangelo, S; Abatangelo, G; Brun, P; Cortivo, R				Tonello, C; Vindigni, V; Zavan, B; Abatangelo, S; Abatangelo, G; Brun, P; Cortivo, R			In vitro reconstruction of an endothelialized skin substitute provided with a microcapillary network using biopolymer scaffolds	FASEB JOURNAL			English	Article						endothelial cells; skin substitute; angiogenesis; hyaluronic acid; tissue engineering	HYALURONIC-ACID; CELLS; KERATINOCYTES; EQUIVALENT; REPLACEMENT; DERMIS; ULCERS; WOUNDS	SSuccessful in vitro reconstruction of skin requires the inclusion of several cell types that give rise in coculture to the specific elements present in native skin, and the appropriate scaffolding structure to house and support these cells. In addition to the two main structural components, epidermis and dermis, one critical apparatus of the skin is a capillary network that guarantees adequate perfusion of nutrients and oxygen. The aim of the present study was to develop an in vitro coculture system that assumed the human dermal-epidermal architecture and included a microcapillary network in a three-dimensional biomaterial that guaranteed ease of handling in a clinical setting. Endothelialized skin (ES) was prepared by coculturing three human cell types: keratinocytes, fibroblasts, and endothelial cells, obtained from human full-thickness skin samples, in scaffolds produced from modified hyaluronic acid. Results were evaluated by histological and immunohistochemical analyses at different time points. In vitro, engineered skin obtained with this composite culture developed into a well-differentiated upper layer of stratified keratinocytes lining a dermal-like structure, in which fibroblasts, extracellular matrix and a microvascular network were present. Furthermore, the biodegradable fabric produced from hyaluronic acid and used as the scaffolding support for this in vitro constructed skin graft greatly facilitated handling in the perioperative period.	Univ Padua, Dept Histol Microbiol & Med Biotechnol, I-35100 Padua, Italy	University of Padua	Abatangelo, G (corresponding author), Univ Padua, Dept Histol Microbiol & Med Biotechnol, Via G Colombo 3, I-35100 Padua, Italy.	g.abatangelo@unipd.it	Vindigni, Vincenzo/K-5059-2016; Brun, Paola/K-5729-2016	Vindigni, Vincenzo/0000-0001-6638-9010; Brun, Paola/0000-0002-4204-3549				Balasubramani M, 2001, BURNS, V27, P534, DOI 10.1016/S0305-4179(01)00018-3; Black AF, 1999, CELL BIOL TOXICOL, V15, P81, DOI 10.1023/A:1007541713398; Black AF, 1998, FASEB J, V12, P1331, DOI 10.1096/fasebj.12.13.1331; BRIGGAMAN RA, 1968, J INVEST DERMATOL, V514, P54; Brun P, 2000, Ostomy Wound Manage, V46, P44; Caravaggi C, 2003, DIABETES CARE, V26, P2853, DOI 10.2337/diacare.26.10.2853; CUONO CB, 1987, PLAST RECONSTR SURG, V80, P626, DOI 10.1097/00006534-198710000-00029; EADY RAJ, 1994, J INVEST DERMATOL, V103, pS13, DOI 10.1111/1523-1747.ep12398895; Galassi G, 2000, BIOMATERIALS, V21, P2183, DOI 10.1016/S0142-9612(00)00147-2; GALLICO GG, 1984, NEW ENGL J MED, V311, P448, DOI 10.1056/NEJM198408163110706; GALLICO GG, 1989, PLAST RECONSTR SURG, V84, P1; Giuggioli D, 2003, RHEUMATOLOGY, V42, P694, DOI 10.1093/rheumatology/keg106; GREEN H, 1979, P NATL ACAD SCI USA, V76, P5665, DOI 10.1073/pnas.76.11.5665; Griffiths M, 2004, TISSUE ENG, V10, P1180, DOI 10.1089/ten.2004.10.1180; Grigolo B, 2003, Chir Organi Mov, V88, P351; Guerret S, 2003, WOUND REPAIR REGEN, V11, P35, DOI 10.1046/j.1524-475X.2003.11107.x; Halbleib M, 2003, BIOMATERIALS, V24, P3125, DOI 10.1016/S0142-9612(03)00156-X; HANSBROUGH JF, 1994, SURGERY, V115, P633; Hudon V, 2003, BRIT J DERMATOL, V148, P1094, DOI 10.1046/j.1365-2133.2003.05298.x; Jones I, 2002, BRIT J PLAST SURG, V55, P185, DOI 10.1054/bjps.2002.3800; Lam PK, 1999, J TRAUMA, V47, P918, DOI 10.1097/00005373-199911000-00017; Lisignoli G, 2003, Chir Organi Mov, V88, P363; Lobmann R, 2003, J DIABETES COMPLICAT, V17, P199, DOI 10.1016/S1056-8727(02)00218-0; MURPHY JF, 2005, FASEB J ONLINE  0107; Pavesio Alessandra, 2003, Novartis Found Symp, V249, P203; Remuzzi A, 2004, TISSUE ENG, V10, P699, DOI 10.1089/1076327041348347; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; ROUSSELLE P, 1994, J CELL BIOL, V125, P205, DOI 10.1083/jcb.125.1.205; SCALA C, 1992, J HISTOCHEM CYTOCHEM, V40, P1799, DOI 10.1177/40.11.1431065; Schechner JS, 2003, FASEB J, V17, P2250, DOI 10.1096/fj.03-0257com; Supp DM, 2002, FASEB J, V16, DOI 10.1096/fj.01-0868com; Tonello C, 2003, BIOMATERIALS, V24, P1205, DOI 10.1016/S0142-9612(02)00450-7; Trompezinski S, 2004, EXP DERMATOL, V13, P98, DOI 10.1111/j.0906-6705.2004.00137.x; Turner NJ, 2004, BIOMATERIALS, V25, P5955, DOI 10.1016/j.biomaterials.2004.02.002; Weber E, 2004, LYMPHOLOGY, V37, P15; Zacchi V, 1998, J BIOMED MATER RES, V40, P187, DOI 10.1002/(SICI)1097-4636(199805)40:2<187::AID-JBM3>3.0.CO;2-H	36	52	54	1	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2005	19	8					1546	+		10.1096/fj.05-3804fje	http://dx.doi.org/10.1096/fj.05-3804fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	15972294				2022-12-25	WOS:000230207800010
J	Lee, S; Privalsky, ML				Lee, S; Privalsky, ML			Multiple mutations contribute to repression by the v-Erb A oncoprotein	ONCOGENE			English	Article						v-Erb A; c-Erb A; thyroid hormone receptor; T3R; dominant negative; c-Jun	THYROID-HORMONE RECEPTOR; RETINOIC ACID RECEPTORS; DOMINANT-NEGATIVE ACTIVITY; AVIAN ERYTHROBLASTOSIS VIRUS; DNA-BINDING; X-RECEPTOR; C-ERBA; RESPONSE ELEMENTS; TRANSCRIPTIONAL REPRESSION; ERYTHROID-DIFFERENTIATION	The v-Erb A oncoprotein of avian erythroblastosis virus is derived from c-Erb A, a hormone-activated transcription factor. Notably, v-Erb A has sustained multiple mutations relative to c-Erb A and functions as a constitutive transcriptional repressor. We report here an analysis of the contributions of these different mutations to v-Erb A function. Our experiments demonstrate that two amino-acid differences between v-Erb A and c-Erb A, located in the 'I-box,' alter the dimerization properties of the viral protein, resulting in more stable homodimer formation, increased corepressor binding, and increased target gene repression. An additional amino-acid difference between v-and c-Erb A, located in helix 3 of the hormone binding domain, renders corepressor binding by the viral protein more resistant to release by thyroid hormone. Finally, we report that a C-terminal truncation in v-Erb A not only inhibits exchange of corepressor and coactivator, as previously noted, but also permits v-Erb A to recruit both SMRT and N-CoR corepressors, whereas c-Erb A is selective for N-CoR. The latter two mutations in v-Erb A also impair its ability to suppress c-Jun function in response to T3 hormone. We propose that the acquisition of oncogenic potential by the v-Erb A protein was a multistep process involving a series of mutations that alter the transcriptional repressive properties of the viral protein through multiple mechanisms.	Univ Calif Davis, Biol Sect, Div Biol Sci, Davis, CA 95616 USA	University of California System; University of California Davis	Privalsky, ML (corresponding author), Univ Calif Davis, Biol Sect, Div Biol Sci, 1 Shields Ave, Davis, CA 95616 USA.	mlprivalsky@ucdavis.edu		Lee, Sangho/0000-0003-3771-7761	NCI NIH HHS [R37-CA53394, R37 CA053394-10, R37 CA053394] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA053394] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUFLIEGNER M, 1993, MOL CELL BIOL, V13, P5725, DOI 10.1128/MCB.13.9.5725; BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; Bauer A, 1997, ONCOGENE, V15, P701, DOI 10.1038/sj.onc.1201208; Bauer A, 1998, EMBO J, V17, P4291, DOI 10.1093/emboj/17.15.4291; Beug H, 1996, BBA-REV CANCER, V1288, pM35, DOI 10.1016/S0304-419X(96)00032-7; Chatterjee VKK, 1997, HORM RES, V48, P43, DOI 10.1159/000191312; CHEN HW, 1993, MOL CELL BIOL, V13, P2366, DOI 10.1128/MCB.13.4.2366; CHEN HW, 1993, MOL CELL BIOL, V13, P5970, DOI 10.1128/MCB.13.10.5970; Cohen RN, 1998, MOL ENDOCRINOL, V12, P1567, DOI 10.1210/me.12.10.1567; Cohen RN, 2001, MOL ENDOCRINOL, V15, P1049, DOI 10.1210/me.15.7.1049; Cohen RN, 2000, MOL ENDOCRINOL, V14, P900, DOI 10.1210/me.14.6.900; DAMM K, 1987, EMBO J, V6, P375, DOI 10.1002/j.1460-2075.1987.tb04765.x; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DARLING DS, 1993, J BIOL CHEM, V268, P10221; DeGroot LJ, 1996, ANN INTERN MED, V125, P623, DOI 10.7326/0003-4819-125-7-199610010-00022; DESBOIS C, 1991, ONCOGENE, V6, P2129; DISELA C, 1991, GENE DEV, V5, P2033, DOI 10.1101/gad.5.11.2033; EVANS RM, 1989, INT J CANCER, P26; Farboud B, 2004, MOL ENDOCRINOL, V18, P2839, DOI 10.1210/me.2004-0236; FORMAN B M, 1990, New Biologist, V2, P587; FORMAN BM, 1989, MOL ENDOCRINOL, V3, P1610, DOI 10.1210/mend-3-10-1610; FORMAN BM, 1992, MOL ENDOCRINOL, V6, P429, DOI 10.1210/me.6.3.429; FORREST D, 1990, ONCOGENE, V5, P309; GANDRILLON O, 1994, ONCOGENE, V9, P749; GANDRILLON O, 1989, CELL, V58, P115, DOI 10.1016/0092-8674(89)90408-X; GANDRILLON O, 1987, CELL, V49, P687, DOI 10.1016/0092-8674(87)90545-9; GHYSDAEL J, 1992, CANCER SURV, V14, P169; Glass CK, 1996, J ENDOCRINOL, V150, P349, DOI 10.1677/joe.0.1500349; Glass CK, 2000, GENE DEV, V14, P121; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; Goodson ML, 2005, J BIOL CHEM, V280, P7493, DOI 10.1074/jbc.M411514200; GRAF T, 1983, CELL, V34, P7, DOI 10.1016/0092-8674(83)90130-7; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Harbers M, 1998, J STEROID BIOCHEM, V67, P181, DOI 10.1016/S0960-0760(98)00100-9; Hauksdottir H, 2001, CELL GROWTH DIFFER, V12, P85; Judelson C, 1996, J BIOL CHEM, V271, P10800, DOI 10.1074/jbc.271.18.10800; KATZ RW, 1994, J BIOL CHEM, V269, P18915; KEIDEL S, 1994, MOL CELL BIOL, V14, P287, DOI 10.1128/MCB.14.1.287; LAZAR MA, 1991, MOL CELL BIOL, V11, P5005, DOI 10.1128/MCB.11.10.5005; Lee S, 2005, MOL ENDOCRINOL, V19, P863, DOI 10.1210/me.2004-0210; LENG XH, 1993, J STEROID BIOCHEM, V46, P643, DOI 10.1016/0960-0760(93)90306-H; Makowski A, 2003, MOL ENDOCRINOL, V17, P273, DOI 10.1210/me.2002-0310; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MIYAMOTO T, 1993, MOL ENDOCRINOL, V7, P224, DOI 10.1210/me.7.2.224; MUNOZ A, 1988, EMBO J, V7, P155, DOI 10.1002/j.1460-2075.1988.tb02795.x; PAIN B, 1990, New Biologist, V2, P284; Perlmann T, 1996, MOL ENDOCRINOL, V10, P958, DOI 10.1210/me.10.8.958; PIEDRAFITA FJ, 1995, MOL ENDOCRINOL, V9, P563, DOI 10.1210/me.9.5.563; PINCUS MR, 1992, ANN CLIN LAB SCI, V22, P323; Privalsky ML, 2004, ANNU REV PHYSIOL, V66, P315, DOI 10.1146/annurev.physiol.66.032802.155556; PRIVALSKY ML, 1992, BIOCHIM BIOPHYS ACTA, V1114, P51, DOI 10.1016/0304-419X(92)90006-K; REFETOFF S, 1993, CLIN LAB MED, V13, P563, DOI 10.1016/S0272-2712(18)30426-8; Reginato MJ, 1996, J BIOL CHEM, V271, P28199, DOI 10.1074/jbc.271.45.28199; RIBEIRO RC, 1992, MOL ENDOCRINOL, V6, P1142, DOI 10.1210/me.6.7.1142; Ribeiro RCJ, 1998, RECENT PROG HORM RES, V53, P351; Ribeiro RCJ, 2001, J BIOL CHEM, V276, P14987, DOI 10.1074/jbc.M010195200; Rietveld LEG, 2001, ONCOGENE, V20, P3100, DOI 10.1038/sj.onc.1204335; Saatcioglu F, 1997, MOL CELL BIOL, V17, P4687, DOI 10.1128/MCB.17.8.4687; Samarut J, 1996, CURR TOP MICROBIOL, V212, P163; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHROEDER C, 1992, ONCOGENE, V7, P203; SCHROEDER C, 1992, ONCOGENE, V7, P217; SELMI S, 1991, J BIOL CHEM, V266, P11589; SHARIF M, 1992, ONCOGENE, V7, P953; Shen Q, 2000, J BIOL CHEM, V275, P41018, DOI 10.1074/jbc.M006111200; Soucek L, 2002, CANCER CELL, V1, P406, DOI 10.1016/S1535-6108(02)00077-6; Starr DB, 1996, GENE DEV, V10, P1271, DOI 10.1101/gad.10.10.1271; Stunnenberg HG, 1999, BBA-REV CANCER, V1423, pF15, DOI 10.1016/S0304-419X(98)00036-5; SUBAUSTE JS, 1995, J BIOL CHEM, V270, P7957, DOI 10.1074/jbc.270.14.7957; Subauste JS, 1998, MOL ENDOCRINOL, V12, P1380, DOI 10.1210/me.12.9.1380; Thormeyer D, 1999, INT J MOL MED, V4, P351; Tzagarakis-Foster C, 1998, J BIOL CHEM, V273, P10926, DOI 10.1074/jbc.273.18.10926; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; Urnov FD, 2000, EMBO J, V19, P4074, DOI 10.1093/emboj/19.15.4074; Usala S J, 1991, Thyroid, V1, P361, DOI 10.1089/thy.1991.1.361; Vennstrom B, 1987, Horm Metab Res Suppl, V17, P14; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; Wahlstrom GM, 1996, ONCOGENE, V13, P843; Webb P, 2000, MOL ENDOCRINOL, V14, P1976, DOI 10.1210/me.14.12.1976; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; Wondisford FE, 2003, J INVEST MED, V51, P215, DOI 10.1136/jim-51-04-22; YEN PM, 1994, J BIOL CHEM, V269, P903; YEN PM, 1992, J BIOL CHEM, V267, P23248; Yoh SM, 2001, J BIOL CHEM, V276, P16857, DOI 10.1074/jbc.M010022200; Yoh Sunnie M, 2002, Methods Mol Biol, V202, P129; Zamir I, 1997, GENE DEV, V11, P835, DOI 10.1101/gad.11.7.835; ZENKE M, 1988, CELL, V52, P107, DOI 10.1016/0092-8674(88)90535-1; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P; Zhang JS, 2000, ANNU REV PHYSIOL, V62, P439, DOI 10.1146/annurev.physiol.62.1.439; Zubkova I, 2004, MOL BIOL REP, V31, P131, DOI 10.1023/B:MOLE.0000031412.25988.30; Zubkova I, 2003, MOL CELL ENDOCRINOL, V199, P61, DOI 10.1016/S0303-7207(02)00299-X; Zubkova I, 2002, BIOCHEM BIOPH RES CO, V294, P35, DOI 10.1016/S0006-291X(02)00428-X	94	10	10	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 13	2005	24	45					6737	6752		10.1038/sj.onc.1208826	http://dx.doi.org/10.1038/sj.onc.1208826			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	973MV	16007162	Green Accepted			2022-12-25	WOS:000232527800002
J	Su, YP; Bakker, T; Harris, J; Tsang, C; Brown, GD; Wormald, MR; Gordon, S; Dwek, RA; Rudd, PM; Martinez-Pomares, L				Su, YP; Bakker, T; Harris, J; Tsang, C; Brown, GD; Wormald, MR; Gordon, S; Dwek, RA; Rudd, PM; Martinez-Pomares, L			Glycosylation influences the lectin activities of the macrophage mannose receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN DENDRITIC CELLS; CYSTEINE-RICH DOMAIN; CARBOHYDRATE-RECOGNITION DOMAINS; BETA 1,4GLCNAC BETA; SIALIC ACIDS; MURINE MACROPHAGES; PIGMENT-EPITHELIUM; ENDOTHELIAL-CELLS; INTERFERON-GAMMA; DOWN-REGULATION	The mannose receptor ( MR) is a heavily glycosylated endocytic receptor that recognizes both mannosylated and sulfated ligands through its C- type lectin domains and cysteine- rich ( CR) domain, respectively. Differential binding properties have been described for MR isolated from different sources, and we hypothesized that this could be due to altered glycosylation. Using MR transductants and purified MR, we demonstrate that glycosylation differentially affects both MR lectin activities. MR transductants generated in glycosylation mutant cell lines lacked most mannose internalization activity, but could internalize sulfated glycans. Accordingly, purified MR bearing truncated Man(5)-GlcNAc(2) glycans (Man(5)-MR) or non-sialylated complex glycans (SA(0)-MR) did not bind mannosylated glycans, but could recognize SO4-3-Gal in vitro. Additional studies showed that, although mannose recognition was largely independent of the oligomerization state of the protein, recognition of sulfated carbohydrates was mostly mediated by self-associated MR and that, in SA(0)-MR, there was a higher proportion of oligomeric MR. These results suggest that self-association could lead to multiple presentation of CR domains and enhanced avidity for sulfated sugars and that non-sialylated MR is predisposed to oligomerize. Therefore, the glycosylation of MR, terminal sialylation in particular, could influence its binding properties at two levels. (i) It is required for mannose recognition; and ( ii) it modulates the tendency of MR to self-associate, effectively regulating the avidity of the CR domain for sulfated sugar ligands.	Univ Oxford, Glycobiol Inst, Oxford OX1 3QU, England; Univ Oxford, Dept Biochem, Oxford OX1 3QU, England; Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England	University of Oxford; University of Oxford; University of Oxford	Martinez-Pomares, L (corresponding author), Univ Oxford, Glycobiol Inst, S Parks Rd, Oxford OX1 3QU, England.	pauline.rudd@bioch.ox.ac.uk	Wormald, Mark R/G-2785-2011; brown, gordon/B-4249-2012	Wormald, Mark R/0000-0002-4853-2773; Martinez-Pomares, Luisa/0000-0002-2331-127X; brown, gordon/0000-0002-0287-5383; Harris, James/0000-0002-5634-9637				AFROUN S, 1988, BIOCHIM BIOPHYS ACTA, V971, P137; Barnes YC, 1999, BLOOD, V93, P1245, DOI 10.1182/blood.V93.4.1245.404k09_1245_1252; Berney C, 1999, J EXP MED, V190, P851, DOI 10.1084/jem.190.6.851; BORN GVR, 1985, BRIT J EXP PATHOL, V66, P543; BRAESCHANDERSEN S, 1994, J BIOL CHEM, V269, P11783; BREWER GJ, 1992, BIOCHEMISTRY-US, V31, P1816, DOI 10.1021/bi00121a033; Crocker PR, 2001, TRENDS IMMUNOL, V22, P337, DOI 10.1016/S1471-4906(01)01930-5; da Silva RP, 1999, BIOCHEM J, V338, P687, DOI 10.1042/bj3380687; DEVILLIERS WJS, 1994, IMMUNOL LETT, V43, P73, DOI 10.1016/0165-2478(94)00148-0; DOYLE AG, 1994, EUR J IMMUNOL, V24, P1441, DOI 10.1002/eji.1830240630; East L, 2002, BBA-GEN SUBJECTS, V1572, P364, DOI 10.1016/S0304-4165(02)00319-7; Engering AJ, 1997, EUR J IMMUNOL, V27, P2417, DOI 10.1002/eji.1830270941; EZEKOWITZ RAB, 1991, NATURE, V351, P155, DOI 10.1038/351155a0; EZEKOWITZ RAB, 1990, J EXP MED, V172, P1785, DOI 10.1084/jem.172.6.1785; FERRO TJ, 1987, AM REV RESPIR DIS, V135, P1340; Fiete D, 1997, J BIOL CHEM, V272, P14629, DOI 10.1074/jbc.272.23.14629; Fiete D, 1997, P NATL ACAD SCI USA, V94, P11256, DOI 10.1073/pnas.94.21.11256; FIETE D, 1991, CELL, V67, P1103, DOI 10.1016/0092-8674(91)90287-9; Fiete DJ, 1998, P NATL ACAD SCI USA, V95, P2089, DOI 10.1073/pnas.95.5.2089; FREEMAN SD, 1995, BLOOD, V85, P2005, DOI 10.1182/blood.V85.8.2005.bloodjournal8582005; Guile GR, 1996, ANAL BIOCHEM, V240, P210, DOI 10.1006/abio.1996.0351; GUTHRIDGE JM, 1994, IMMUNOL INVEST, V23, P393, DOI 10.3109/08820139409066834; HARRIS N, 1992, BLOOD, V80, P2363; Irjala H, 2001, J EXP MED, V194, P1033, DOI 10.1084/jem.194.8.1033; Jordens R, 1999, INT IMMUNOL, V11, P1775, DOI 10.1093/intimm/11.11.1775; KELM S, 1994, GLYCOCONJUGATE J, V11, P576, DOI 10.1007/BF00731309; Kelm S, 1997, INT REV CYTOL, V175, P137, DOI 10.1016/S0074-7696(08)62127-0; KERY V, 1992, ARCH BIOCHEM BIOPHYS, V298, P49, DOI 10.1016/0003-9861(92)90092-B; Lambotte O, 2003, J RHEUMATOL, V30, P1027; Lee SJ, 2002, SCIENCE, V295, P1898, DOI 10.1126/science.1069540; Leteux C, 2000, J EXP MED, V191, P1117, DOI 10.1084/jem.191.7.1117; Linehan SA, 1999, J EXP MED, V189, P1961, DOI 10.1084/jem.189.12.1961; Linehan SA, 2001, EUR J IMMUNOL, V31, P1857, DOI 10.1002/1521-4141(200106)31:6<1857::AID-IMMU1857>3.0.CO;2-D; Mahnke K, 2000, J CELL BIOL, V151, P673, DOI 10.1083/jcb.151.3.673; MARODI L, 1991, J IMMUNOL, V146, P2783; Martinez-Pomares L, 1999, IMMUNOL LETT, V65, P9, DOI 10.1016/S0165-2478(98)00117-5; Martinez-Pomares L, 1998, J BIOL CHEM, V273, P23376, DOI 10.1074/jbc.273.36.23376; Martinez-Pomares L, 2003, J LEUKOCYTE BIOL, V73, P604, DOI 10.1189/jlb.0902450; MartinezPomares L, 1996, J EXP MED, V184, P1927, DOI 10.1084/jem.184.5.1927; Moody AM, 2001, CELL, V107, P501, DOI 10.1016/S0092-8674(01)00577-3; Nguyen DG, 2003, EUR J IMMUNOL, V33, P483, DOI 10.1002/immu.200310024; ORIORDAN DM, 1995, INFECT IMMUN, V63, P779, DOI 10.1128/IAI.63.3.779-784.1995; PONTOW SE, 1992, INT REV CYTOL, V137B, P221; Pontow SE, 1996, J BIOL CHEM, V271, P30736, DOI 10.1074/jbc.271.48.30736; Ramakrishna V, 2004, J IMMUNOL, V172, P2845, DOI 10.4049/jimmunol.172.5.2845; Roseman DS, 2000, P NATL ACAD SCI USA, V97, P9949, DOI 10.1073/pnas.170184597; Rudd PM, 1999, J MOL BIOL, V293, P351, DOI 10.1006/jmbi.1999.3104; SALLUSTO F, 1995, J EXP MED, V182, P389, DOI 10.1084/jem.182.2.389; SHEPHERD VL, 1991, INVEST OPHTH VIS SCI, V32, P1779; Skelton TP, 1998, J CELL BIOL, V140, P431, DOI 10.1083/jcb.140.2.431; STANLEY P, 1989, MOL CELL BIOL, V9, P377, DOI 10.1128/MCB.9.2.377; STEIN M, 1992, J EXP MED, V176, P287, DOI 10.1084/jem.176.1.287; TAYLOR ME, 1990, J BIOL CHEM, V265, P12156; TAYLOR ME, 1993, J BIOL CHEM, V268, P399; Taylor PR, 2004, P NATL ACAD SCI USA, V101, P1963, DOI 10.1073/pnas.0308490100; Turville SG, 2001, BLOOD, V98, P2482, DOI 10.1182/blood.V98.8.2482; Wilt SD, 1999, EXP EYE RES, V69, P405, DOI 10.1006/exer.1999.0714; Wollenberg A, 2002, J INVEST DERMATOL, V118, P327, DOI 10.1046/j.0022-202x.2001.01665.x; YANG PF, 1994, J BIOL CHEM, V269, P23039; Yu P, 2002, J IMMUNOL, V168, P5117, DOI 10.4049/jimmunol.168.10.5117; Zamze S, 2002, J BIOL CHEM, V277, P41613, DOI 10.1074/jbc.M207057200	61	56	58	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	2005	280	38					32811	32820		10.1074/jbc.M503457200	http://dx.doi.org/10.1074/jbc.M503457200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	964ZU	15983039	hybrid			2022-12-25	WOS:000231920300033
J	Ahmad, A; Kikuchi, H; Takami, Y; Nakayama, T				Ahmad, A; Kikuchi, H; Takami, Y; Nakayama, T			Different roles of N-terminal and C-terminal halves of HIRA in transcription regulation of cell cycle-related genes that contribute to control of vertebrate cell growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASSEMBLY FACTOR-I; SYNDROME CRITICAL REGION; DNA-REPLICATION INVITRO; WD DIPEPTIDE MOTIFS; SACCHAROMYCES-CEREVISIAE; DIGEORGE-SYNDROME; HUMAN HOMOLOG; CANDIDATE GENE; HISTONE GENES; CHICKEN HIRA	We reported previously that chicken HIRA, a homolog of Saccharomyces cerevisiae transcriptional co-repressors Hir1p and Hir2p, possesses seven WD dipeptide motifs and an LXXLL motif in its N-terminal and C-terminal halves, respectively, required for transcription regulations. Here, by using the gene targeting technique, we generated the homozygous HIRA-deficient DT40 mutant Delta HIRA. The HIRA deficiency caused slightly delayed cell growth and affected the opposite transcriptions of cell cycle-related genes, i.e. repressions for P18, CDC25B, and BCL-2, activations for P19 and cyclin A, and histones H2A, H2B, H3, and H4. These altered expressions were completely revived by the artificial stable expression of hemagglutinin-tagged HIRA in Delta HIRA. The ability to rescue the delayed growth rate was preferentially aided by the N-terminal half instead of the C-terminal half. We cloned the chicken P18 genomic DNA, and we established that its promoter was located surrounding the sequence GCGGGCGC at positions -1157 to -1150. Chromatin immunoprecipitation assay revealed that the N-terminal half interacted directly or indirectly with the putative promoter region of the p18 gene, resulting in up-regulation of the gene. These results indicated that the N-terminal half of HIRA should contribute positively to the growth rate via up-regulation of a set of cell cycle-related genes, whereas the C-terminal half down-regulated another set of them without exhibiting any effect on the cell growth.	Miyazaki Univ, Coll Med, Frontier Sci Res Ctr, Dept Life Sci, Miyazaki 8891692, Japan; Miyazaki Univ, Coll Med, Dept Med Sci, Sect Biochem & Mol Biol, Miyazaki 8891692, Japan; Japan Sci & Technol, CREST, Chiba 2920818, Japan; Hasanuddin Univ, Dept Chem, Makassar 90245, Indonesia	University of Miyazaki; University of Miyazaki; Japan Science & Technology Agency (JST); Universitas Hasanuddin	Nakayama, T (corresponding author), Miyazaki Univ, Coll Med, Frontier Sci Res Ctr, Dept Life Sci, 5200 Kihara, Miyazaki 8891692, Japan.	tnakayam@med.miyazaki-u.ac.jp						Ahmad A, 2004, GENE, V342, P125, DOI 10.1016/j.gene.2004.07.031; Ahmad A, 2003, BIOCHEM BIOPH RES CO, V312, P1266, DOI 10.1016/j.bbrc.2003.11.073; Blackwell C, 2004, MOL CELL BIOL, V24, P4309, DOI 10.1128/MCB.24.10.4309-4320.2004; BUERSTEDDE JM, 1991, CELL, V67, P179, DOI 10.1016/0092-8674(91)90581-I; De Lucia F, 2001, BIOCHEM J, V358, P447, DOI 10.1042/0264-6021:3580447; Dimova D, 1999, MOL CELL, V4, P75, DOI 10.1016/S1097-2765(00)80189-6; Eberhardy SR, 2000, J BIOL CHEM, V275, P33798, DOI 10.1074/jbc.M005154200; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Hall C, 2001, MOL CELL BIOL, V21, P1854, DOI 10.1128/MCB.21.5.1854-1865.2001; Ito T, 1996, J BIOL CHEM, V271, P25041, DOI 10.1074/jbc.271.40.25041; Kaufman PD, 1998, MOL CELL BIOL, V18, P4793, DOI 10.1128/MCB.18.8.4793; KAUFMAN PD, 1995, CELL, V81, P1105, DOI 10.1016/S0092-8674(05)80015-7; Kikuchi H, 2005, GENE, V347, P83, DOI 10.1016/j.gene.2004.12.007; Krawitz DC, 2002, MOL CELL BIOL, V22, P614, DOI 10.1128/MCB.22.2.614-625.2002; KRUDE T, 1995, CURR BIOL, V5, P1232, DOI 10.1016/S0960-9822(95)00245-4; LAMOUR V, 1995, HUM MOL GENET, V4, P791, DOI 10.1093/hmg/4.5.791; Lorain S, 1998, MOL CELL BIOL, V18, P5546, DOI 10.1128/MCB.18.9.5546; Lorain S, 1996, GENOME RES, V6, P43, DOI 10.1101/gr.6.1.43; Magnaghi P, 1998, NAT GENET, V20, P74, DOI 10.1038/1739; Mello JA, 2002, EMBO REP, V3, P329, DOI 10.1093/embo-reports/kvf068; Nelson DM, 2002, MOL CELL BIOL, V22, P7459, DOI 10.1128/MCB.22.21.7459-7472.2002; OSLEY MA, 1987, MOL CELL BIOL, V7, P4204, DOI 10.1128/MCB.7.12.4204; Ray-Gallet D, 2002, MOL CELL, V9, P1091, DOI 10.1016/S1097-2765(02)00526-9; Roberts C, 1997, HUM MOL GENET, V6, P237, DOI 10.1093/hmg/6.2.237; Roberts C, 2002, MOL CELL BIOL, V22, P2318, DOI 10.1128/MCB.22.7.2318-2328.2002; SAMBROOK J, 1989, MOL CLONING, V2, P9; Scamps C, 1996, BBA-GENE STRUCT EXPR, V1306, P5, DOI 10.1016/0167-4781(96)00010-3; Sharp JA, 2002, GENE DEV, V16, P85, DOI 10.1101/gad.925302; Sharp JA, 2001, CURR BIOL, V11, P463, DOI 10.1016/S0960-9822(01)00140-3; SHERWOOD PW, 1993, MOL CELL BIOL, V13, P28, DOI 10.1128/MCB.13.1.28; SMITH S, 1989, CELL, V58, P15, DOI 10.1016/0092-8674(89)90398-X; SMITH S, 1991, J BIOL CHEM, V266, P12041; Spector MS, 1997, MOL CELL BIOL, V17, P545, DOI 10.1128/MCB.17.2.545; STILLMAN B, 1986, CELL, V45, P555, DOI 10.1016/0092-8674(86)90287-4; Tagami H, 2004, CELL, V116, P51, DOI 10.1016/S0092-8674(03)01064-X; Takami Y, 2000, J BIOL CHEM, V275, P16191, DOI 10.1074/jbc.M908066199; Takami Y, 1999, J BIOL CHEM, V274, P23977, DOI 10.1074/jbc.274.34.23977; Takami Y, 1995, J BIOL CHEM, V270, P30664, DOI 10.1074/jbc.270.51.30664; Tyler JK, 2001, MOL CELL BIOL, V21, P6574, DOI 10.1128/MCB.21.19.6574-6584.2001; Verreault A, 1996, CELL, V87, P95, DOI 10.1016/S0092-8674(00)81326-4; Wilming LG, 1997, HUM MOL GENET, V6, P247, DOI 10.1093/hmg/6.2.247	41	19	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	2005	280	37					32090	32100		10.1074/jbc.M501426200	http://dx.doi.org/10.1074/jbc.M501426200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	963HM	16024922	hybrid			2022-12-25	WOS:000231794800008
J	Kimura, T; Hosoda, Y; Sato, Y; Kitamura, Y; Ikeda, T; Horibe, T; Kikuchi, M				Kimura, T; Hosoda, Y; Sato, Y; Kitamura, Y; Ikeda, T; Horibe, T; Kikuchi, M			Interactions among yeast protein-disulfide isomerase proteins and endoplasmic reticulum chaperone proteins influence their activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL DIFFERENCES; MEMBRANE-PROTEINS; IN-VITRO; ERP57; BIP; CALRETICULIN; THIOREDOXIN; SEQUENCE; ENCODES; FAMILY	We previously reported that the reductive activities of yeast protein-disulfide isomerase (PDI) family proteins did not completely explain their contribution to the viability of Saccharomyces cerevisiae (Kimura, T., Hosoda, Y., Kitamura, Y., Nakamura, H., Horibe, T., and Kikuchi, M. (2004) Biochem. Biophys. Res. Commun. 320, 359-365). In this study, we examined oxidative refolding activities and found that Mpd1p, Mpd2, and Eug1p exhibit activities of 13.8, 16.0, and 2.16%, respectively, compared with Pdi1p and that activity for Eps1p is undetectable. In analyses of interactions between yeast PDI proteins and endoplasmic reticulum molecular chaperones, we found that Mpd1p alone does not have chaperone activity but that it interacts with and inhibits the chaperone activity of Cne1p, a homologue of mammalian calnexin, and that Cne1p increases the reductive activity of Mpd1p. These results suggest that the interface between Mpd1p and Cne1p is near the peptide-binding site of Cne1p. In addition, Eps1p interacts with Pdi1p, Eug1p, Mpd1p, and Kar2p with dissociation constants (K-D) in the range of 10(-7) to 10(-6) M. Interestingly, co-chaperone activities were completely suppressed in Eps1p-Pdi1p and Eps1p-Mpd1p complexes, although only Eps1p and Pdi1p have chaperone activity. The in vivo consequences of these results are discussed.	Ritsumeikan Univ, Coll Informat Sci & Engn, Dept Biosci & Bioinformat, Shiga 5258577, Japan	Ritsumeikan University	Kikuchi, M (corresponding author), Ritsumeikan Univ, Coll Informat Sci & Engn, Dept Biosci & Bioinformat, 1-1-1 Nojihigashi, Shiga 5258577, Japan.	kikuchi@is.ritsumei.ac.jp						Anelli T, 2002, EMBO J, V21, P835, DOI 10.1093/emboj/21.4.835; EDMAN JC, 1985, NATURE, V317, P267, DOI 10.1038/317267a0; Elliott JG, 1997, J BIOL CHEM, V272, P13849, DOI 10.1074/jbc.272.21.13849; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; Frickel EM, 2002, P NATL ACAD SCI USA, V99, P1954, DOI 10.1073/pnas.042699099; GUNTHER R, 1991, J BIOL CHEM, V266, P24557; Hayano T, 1995, FEBS LETT, V377, P505, DOI 10.1016/0014-5793(95)01410-1; Horibe T, 2002, J BIOCHEM, V132, P401, DOI 10.1093/oxfordjournals.jbchem.a003236; Hosoda A, 2003, J BIOL CHEM, V278, P2669, DOI 10.1074/jbc.M208346200; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; IBBETSON AL, 1976, BIOCHEM J, V159, P377, DOI 10.1042/bj1590377; Katiyar S, 2001, BBA-PROTEIN STRUCT M, V1548, P47, DOI 10.1016/S0167-4838(01)00214-X; Kimura T, 2005, BIOCHEM BIOPH RES CO, V331, P224, DOI 10.1016/j.bbrc.2005.03.147; Kimura T, 2004, BIOCHEM BIOPH RES CO, V320, P359, DOI 10.1016/j.bbrc.2004.05.178; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; Matsuo Y, 2001, J BIOL CHEM, V276, P10032, DOI 10.1074/jbc.M011037200; Mayer M, 2000, J BIOL CHEM, V275, P29421, DOI 10.1074/jbc.M002655200; Norgaard P, 2001, J CELL BIOL, V152, P553, DOI 10.1083/jcb.152.3.553; Norgaard P, 2001, BIOCHEM J, V358, P269, DOI 10.1042/0264-6021:3580269; NORMINGTON K, 1989, CELL, V57, P1223, DOI 10.1016/0092-8674(89)90059-7; Ohlmeier S, 2004, J BIOL CHEM, V279, P3956, DOI 10.1074/jbc.M310160200; Oliver JD, 1999, MOL BIOL CELL, V10, P2573, DOI 10.1091/mbc.10.8.2573; OTSU M, 1995, J BIOL CHEM, V270, P14958, DOI 10.1074/jbc.270.25.14958; Primm TP, 1996, J BIOL CHEM, V271, P33664, DOI 10.1074/jbc.271.52.33664; PUIG A, 1994, J BIOL CHEM, V269, P25889; TACHIBANA C, 1992, MOL CELL BIOL, V12, P4601, DOI 10.1128/MCB.12.10.4601; Tachikawa H, 1997, BIOCHEM BIOPH RES CO, V239, P710, DOI 10.1006/bbrc.1997.7426; TACHIKAWA H, 1995, FEBS LETT, V369, P212, DOI 10.1016/0014-5793(95)00750-4; Tu BP, 2000, SCIENCE, V290, P1571, DOI 10.1126/science.290.5496.1571; Turano C, 2002, J CELL PHYSIOL, V193, P154, DOI 10.1002/jcp.10172; Veijola J, 1996, BIOCHEM J, V315, P613, DOI 10.1042/bj3150613; Wang QQ, 1999, EMBO J, V18, P5972, DOI 10.1093/emboj/18.21.5972; WILSON R, 1995, BIOCHEM J, V307, P679, DOI 10.1042/bj3070679; Zapun A, 1998, J BIOL CHEM, V273, P6009, DOI 10.1074/jbc.273.11.6009	34	33	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	2005	280	36					31438	31441		10.1074/jbc.M503377200	http://dx.doi.org/10.1074/jbc.M503377200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	961LZ	16002399	hybrid			2022-12-25	WOS:000231665200014
J	Moore, J; Bailey, SES; Benmechernene, Z; Tzitzilonis, C; Griffiths, NJE; Virji, M; Derrick, JP				Moore, J; Bailey, SES; Benmechernene, Z; Tzitzilonis, C; Griffiths, NJE; Virji, M; Derrick, JP			Recognition of saccharides by the OpcA, OpaD, and OpaB outer membrane proteins from Neisseria meningitidis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ENDOTHELIAL-CELLS; EPITHELIAL-CELLS; CRYSTAL-STRUCTURE; PROTEOGLYCAN RECEPTORS; TYROSINE FLUORESCENCE; PATHOGENIC NEISSERIA; COMMENSAL NEISSERIA; N-ACETYLGLUCOSAMINE; INTEGRIN RECEPTORS; STRUCTURAL BASIS	The adhesion of the pathogen Neisseria meningitidis to host cell surface proteoglycan, mediated by the integral outer membrane proteins OpcA and Opa, plays an important part in the processes of colonization and invasion by the bacterium. The precise specificities of the OpcA and Opa proteins are, however, unknown. Here we use a fluorescence-based binding assay to show that both proteins bind to mono- and disaccharides with high affinity. Binding of saccharides caused a quench in the intrinsic fluorescence emission of both proteins, and mutation of selected Tyr residues within the external loop regions caused a substantial decrease in fluorescence. We suggest that the intrinsic fluorescence arises from resonance energy transfer from Tyr to Trp residues in the beta-barrel portion of the structure. OpcA bound sialic acid with a K-d of 0.31 mu M and was shown to be specific for pyranose saccharides. The binding specificities of two different Opa proteins were compared; unlike OpcA, neither protein bound to monosaccharides, but both bound to maltose, lactose, and sialic acid-containing oligosaccharides, with K-d values in the micromolar range. OpaB had a 10-fold higher affinity for sialic acid-containing ligands than OpaD as a result of the mutation Y165V, which was shown to restore this specificity to OpaD. Finally, the OpcA- and Opa-dependent adhesion of meningococci to epithelial cells was shown to be partially inhibited by exogenously added sialic acid and maltose. The results show that OpcA and the Opa proteins can be thought of as outer membrane lectins and that simple saccharides can modulate their recognition of complex proteoglycan receptors.	Univ Manchester, Fac Life Sci, Manchester M60 1QD, Lancs, England; Univ Bristol, Dept Cellular & Mol Med, Bristol BS8 1TD, Avon, England	University of Manchester; University of Bristol	Derrick, JP (corresponding author), Univ Manchester, Fac Life Sci, Manchester M60 1QD, Lancs, England.	Jeremy.Derrick@manchester.ac.uk		Derrick, Jeremy/0000-0002-4350-5354	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ACHTMAN M, 1988, J EXP MED, V168, P507, DOI 10.1084/jem.168.2.507; APICELLA MA, 1990, PRINCIPLES PRACTICE; BHAT KS, 1991, MOL MICROBIOL, V5, P1889, DOI 10.1111/j.1365-2958.1991.tb00813.x; Billker O, 2000, TRENDS MICROBIOL, V8, P258, DOI 10.1016/S0966-842X(00)01771-6; Bos MP, 1998, P NATL ACAD SCI USA, V95, P9584, DOI 10.1073/pnas.95.16.9584; Buts L, 2003, MOL MICROBIOL, V49, P705, DOI 10.1046/j.1365-2958.2003.03600.x; Cartwright K, 1995, MENINGOCOCCAL DIS; Cesur N, 2002, J PHARMACEUT BIOMED, V28, P487, DOI 10.1016/S0731-7085(01)00675-6; CHEN T, 1995, J EXP MED, V182, P511, DOI 10.1084/jem.182.2.511; CHIPMAN DM, 1967, J BIOL CHEM, V242, P4388; de Vries FP, 1998, MOL MICROBIOL, V27, P1203, DOI 10.1046/j.1365-2958.1998.00763.x; Dehio C, 1998, EXP CELL RES, V242, P528, DOI 10.1006/excr.1998.4116; Dehio C, 1998, TRENDS MICROBIOL, V6, P489, DOI 10.1016/S0966-842X(98)01365-1; Dehio M, 1998, FEBS LETT, V424, P84, DOI 10.1016/S0014-5793(98)00144-6; Derrick JP, 1999, INFECT IMMUN, V67, P2406, DOI 10.1128/IAI.67.5.2406-2413.1999; Douliez JP, 2000, BBA-BIOMEMBRANES, V1467, P65, DOI 10.1016/S0005-2736(00)00197-8; Duensing TD, 1998, BIOCHEM J, V334, P133, DOI 10.1042/bj3340133; Duensing TD, 1997, INFECT IMMUN, V65, P964, DOI 10.1128/IAI.65.3.964-970.1997; Eisenhawer M, 2001, BIOCHEMISTRY-US, V40, P12321, DOI 10.1021/bi0107694; Fotinou C, 2001, J BIOL CHEM, V276, P32274, DOI 10.1074/jbc.M103285200; Freissler E, 2000, CELL MICROBIOL, V2, P69, DOI 10.1046/j.1462-5822.2000.00036.x; Grant CCR, 1999, MOL MICROBIOL, V32, P233, DOI 10.1046/j.1365-2958.1999.01293.x; Hobbs MM, 1998, MICROBIOL-UK, V144, P157, DOI 10.1099/00221287-144-1-157; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kuzmic P, 1996, ANAL BIOCHEM, V237, P260, DOI 10.1006/abio.1996.0238; le Maire M, 2000, BBA-BIOMEMBRANES, V1508, P86, DOI 10.1016/S0304-4157(00)00010-1; Malorny B, 1998, J BACTERIOL, V180, P1323, DOI 10.1128/JB.180.5.1323-1330.1998; Merker P, 1997, MOL MICROBIOL, V23, P281, DOI 10.1046/j.1365-2958.1997.2051567.x; Nassif X, 1999, MOL MICROBIOL, V32, P1124, DOI 10.1046/j.1365-2958.1999.01416.x; Nassif X, 1999, CURR OPIN MICROBIOL, V2, P71, DOI 10.1016/S1369-5274(99)80012-5; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Prince SM, 2002, P NATL ACAD SCI USA, V99, P3417, DOI 10.1073/pnas.062630899; Prince SM, 2001, ACTA CRYSTALLOGR D, V57, P1164, DOI 10.1107/S0907444901009416; ROSENQVIST E, 1993, J INFECT DIS, V167, P1065, DOI 10.1093/infdis/167.5.1065; Seller A, 1996, MOL MICROBIOL, V19, P841, DOI 10.1046/j.1365-2958.1996.437970.x; Toleman M, 2001, CELL MICROBIOL, V3, P33, DOI 10.1046/j.1462-5822.2001.00089.x; Urwin R, 2002, MOL BIOL EVOL, V19, P1686, DOI 10.1093/oxfordjournals.molbev.a003991; van Putten JPM, 1998, MOL MICROBIOL, V29, P369, DOI 10.1046/j.1365-2958.1998.00951.x; Vandeputte-Rutten L, 2003, J BIOL CHEM, V278, P24825, DOI 10.1074/jbc.M302803200; vanPutten JPM, 1997, INFECT IMMUN, V65, P5028, DOI 10.1128/IAI.65.12.5028-5034.1997; VANPUTTEN JPM, 1995, EMBO J, V14, P2144, DOI 10.1002/j.1460-2075.1995.tb07208.x; VanScyoc WS, 2002, BIOPHYS J, V83, P2767, DOI 10.1016/S0006-3495(02)75286-7; Virji M, 2000, TRENDS MICROBIOL, V8, P260, DOI 10.1016/S0966-842X(00)01772-8; VIRJI M, 1994, MOL MICROBIOL, V14, P173, DOI 10.1111/j.1365-2958.1994.tb01277.x; VIRJI M, 1992, MOL MICROBIOL, V6, P2785, DOI 10.1111/j.1365-2958.1992.tb01458.x; Virji M, 1999, MOL MICROBIOL, V34, P538, DOI 10.1046/j.1365-2958.1999.01620.x; Virji M, 1995, MOL MICROBIOL, V18, P741, DOI 10.1111/j.1365-2958.1995.mmi_18040741.x; VIRJI M, 1991, MOL MICROBIOL, V5, P1831, DOI 10.1111/j.1365-2958.1991.tb00807.x; VIRJI M, 1993, MOL MICROBIOL, V10, P499, DOI 10.1111/j.1365-2958.1993.tb00922.x; VIRJI M, 1981, INFECT IMMUN, V31, P965, DOI 10.1128/IAI.31.3.965-970.1981; WOLFF K, 1995, FEMS MICROBIOL LETT, V125, P255; Zhu PX, 2003, GENE, V307, P31, DOI 10.1016/S0378-1119(02)01208-8; Zhu PX, 1999, MOL MICROBIOL, V33, P635, DOI 10.1046/j.1365-2958.1999.01514.x	53	42	43	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	2005	280	36					31489	31497		10.1074/jbc.M506354200	http://dx.doi.org/10.1074/jbc.M506354200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	961LZ	16006553	hybrid			2022-12-25	WOS:000231665200020
J	Tosi, GM; Trimarchi, C; Macaluso, M; La Sala, D; Ciccodicola, A; Lazzi, S; Massaro-Giordano, M; Caporossi, A; Giordano, A; Cinti, C				Tosi, GM; Trimarchi, C; Macaluso, M; La Sala, D; Ciccodicola, A; Lazzi, S; Massaro-Giordano, M; Caporossi, A; Giordano, A; Cinti, C			Genetic and epigenetic alterations of RB2/p130 tumor suppressor gene in human sporadic retinoblastoma: implications for pathogenesis and therapeutic approach	ONCOGENE			English	Article						sporadic retinoblastoma; Rb2/p130 mutation; methylation; demethylating agent; 5-Aza-dC	DNA METHYLATION; P53; APOPTOSIS; RB; EXPRESSION; PROTEIN; P73; ACCUMULATION; PROMOTER; MUTATION	Human retinoblastoma occurs in two forms (familial and sporadic) both due to biallelic mutation of the RB1/p105 gene even if its loss is insufficient for malignancy. We have recently reported that loss of expression of the retinoblastoma-related protein pRb2/p130 correlates with low apoptotic index, suggesting that RB2/p130 gene could be involved in retinoblastoma. Mutational analysis of RB2/p130 in primary tumors showed a tight correlation between Exon 1 mutations and pRb2/p130 expression level in sporadic retinoblastoma. These mutations are located within a CpG-enriched region prone to de novo methylation. Analysis of RB2/p130 methylation status revealed that epigenetic events, most probably consequent to the Exon 1 mutations, determined the observed phenotype. Treatment of Weri-Rb1 cell line by 5-Aza-dC induced an increase in expression level of pRb2/p130, E2F1, p73 and p53. Overall, our results highlight a crucial role of epigenetic events in sporadic retinoblastoma, which opens a perspective for new therapeutic approaches.	Univ Siena, CNR, IFC,Pathol Anat Unit, Inst Clin Physiol,Dept Human Pathol & Oncol, I-53100 Siena, Italy; CNR, Inst Clin Physiol, Siena, Italy; CNR, Inst Genet & Biophys, Naples, Italy; Univ Penn, Scheie Eye Inst, Philadelphia, PA 19104 USA; Temple Univ, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA; CNR, Inst Neurosci, I-56100 Pisa, Italy; Univ Siena, Dept Ophthalmol & Neurosurg, I-53100 Siena, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Fisiologia Clinica (IFC-CNR); University of Siena; Consiglio Nazionale delle Ricerche (CNR); Istituto di Fisiologia Clinica (IFC-CNR); Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR); University of Pennsylvania; Pennsylvania Medicine; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Consiglio Nazionale delle Ricerche (CNR); Istituto di Neuroscienze (IN-CNR); University of Siena	Cinti, C (corresponding author), Univ Siena, CNR, IFC,Pathol Anat Unit, Inst Clin Physiol,Dept Human Pathol & Oncol, Via Scotte 6, I-53100 Siena, Italy.	cinti@area.bo.cnr.it	Giordano, Antonio/F-1927-2010; Lazzi, Stefano/P-8265-2018	Giordano, Antonio/0000-0002-5959-016X; Lazzi, Stefano/0000-0002-2218-3771; Ciccodicola, Alfredo/0000-0002-9924-1482; Cinti, Caterina/0000-0001-8049-0369; CAPOROSSI, Aldo/0000-0002-8680-3773				Baldi A, 1996, P NATL ACAD SCI USA, V93, P4629, DOI 10.1073/pnas.93.10.4629; Bellan C, 2002, INVEST OPHTH VIS SCI, V43, P3602; Bender CM, 1998, CANCER RES, V58, P95; Brown R, 2002, TRENDS MOL MED, V8, pS43, DOI 10.1016/S1471-4914(02)02314-6; Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062; Chen D, 2004, CANCER CELL, V5, P539, DOI 10.1016/j.ccr.2004.05.025; Choy KW, 2004, INVEST OPHTH VIS SCI, V45, P3404, DOI 10.1167/iovs.03-1273; CINTI C, 2003, REGULATION G1 PHASE, P200; CINTI C, 2000, EMERGING THER TARGET, V4, P765; DiCiommo D, 2000, SEMIN CANCER BIOL, V10, P255, DOI 10.1006/scbi.2000.0326; Douc-Rasy S, 2004, M S-MED SCI, V20, P317, DOI 10.1051/medsci/2004203317; ENG C, 1993, JNCI-J NATL CANCER I, V85, P1121, DOI 10.1093/jnci/85.14.1121; Gallie BL, 1999, CANCER RES, V59, p1731S; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HIEBERT SW, 1995, MOL CELL BIOL, V15, P6864; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Issa JP, 1999, CRIT REV ONCOL HEMAT, V32, P31, DOI 10.1016/S1040-8428(99)00019-0; Johnson David G., 1998, Frontiers in Bioscience, V3, pD447; JOHNSON DG, 1995, ONCOGENE, V11, P1685; KALIBIC T, 2003, ANN NY ACAD SCI, V983, P278; Kastner A, 1998, CELL GROWTH DIFFER, V9, P857; KNUDSON AG, 1975, P NATL ACAD SCI USA, V72, P5116, DOI 10.1073/pnas.72.12.5116; Knudson AG, 2002, AM J MED GENET, V111, P96, DOI 10.1002/ajmg.10320; Kondo Y, 1997, EXP CELL RES, V236, P51, DOI 10.1006/excr.1997.3693; Kowalik TF, 1998, CELL GROWTH DIFFER, V9, P113; Kusek JC, 2001, BRAIN RES BULL, V54, P187, DOI 10.1016/S0361-9230(00)00447-0; La Sala D, 2003, ONCOGENE, V22, P3518, DOI 10.1038/sj.onc.1206487; Lai H, 2003, J CELL BIOCHEM, V88, P121, DOI 10.1002/jcb.10283; MAANDAG ECR, 1994, EMBO J, V13, P4260, DOI 10.1002/j.1460-2075.1994.tb06746.x; MacPherson D, 2004, GENE DEV, V18, P1681, DOI 10.1101/gad.1203304; MAYOL X, 1993, ONCOGENE, V8, P2561; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Robanus-Maandag E, 1998, GENE DEV, V12, P1599, DOI 10.1101/gad.12.11.1599; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; Stirzaker C, 1997, CANCER RES, V57, P2229; Sugimura T, 2000, MUTAT RES-REV MUTAT, V462, P235, DOI 10.1016/S1383-5742(00)00005-3; Zheng L, 2002, ADV CANCER RES, V85, P13, DOI 10.1016/S0065-230X(02)85002-3	39	29	32	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	38					5827	5836		10.1038/sj.onc.1208630	http://dx.doi.org/10.1038/sj.onc.1208630			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960KW	16007224				2022-12-25	WOS:000231590400005
J	Hammar, EB; Irminger, JC; Rickenbach, K; Parnaud, G; Ribaux, P; Bosco, D; Rouiller, DG; Halban, PA				Hammar, EB; Irminger, JC; Rickenbach, K; Parnaud, G; Ribaux, P; Bosco, D; Rouiller, DG; Halban, PA			Activation of NF-kappa B by extracellular matrix is involved in spreading and glucose-stimulated insulin secretion of pancreatic beta cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVITY; SIGNAL-TRANSDUCTION; ADHESION RECEPTORS; SHORT-TERM; IN-VITRO; INTEGRIN; APOPTOSIS; ISLETS; EXPRESSION; ALPHA	Laminin-5-rich extracellular matrix derived from 804G cells ( 804G-ECM) engages beta 1 integrins to induce spreading, improve glucose-stimulated insulin secretion ( GSIS), and increase survival of pancreatic beta cells. The present study examines whether 804G-ECM activates the transcriptional activity of NF-kappa B and the involvement of NF-kappa B in those effects of 804G-ECM on pancreatic beta cells. 804G-ECM induces nuclear translocation and the DNA binding activity of the p65 subunit of NF-kappa B. 804G-ECM-induced nuclear translocation of NF-kappa B was weak as compared with that induced by interleukin-1 beta. Transient 804G-ECM-induced DNA binding activity of NF-kappa B ( peak at 2 h) and overexpression of NF-kappa B target genes I kappa B alpha and NF-kappa B1( p105) ( peak at 4 h) were observed. When NF-kappa B was inhibited by an inhibitor of I kappa B alpha phosphorylation ( Bay 11-7082) or by a recombinant adenovirus expressing the nonphosphorylatable form of I kappa B alpha, 804G-ECM-induced cell spreading and actin cytoskeleton organization were reduced. GSIS from cells on 804G-ECM was inhibited 5-fold, whereas cell survival was not affected. In summary, the results indicate that 804G-ECM induces a transient and moderate NF-kappa B activity. This study shows for the first time that ECM- induced NF-kappa B activity is necessary in maintaining GSIS, although it does not affect survival of pancreatic beta cells. The effects of ECM- induced NF-kappa B activity contrast with the deleterious effects of cytokine-induced NF-kappa B activity. It is proposed that transient and moderate NF-kappa B activity is essential for proper function of the pancreatic beta cell.	Univ Geneva, Med Ctr, Dept Genet Med & Dev, CH-1211 Geneva, Switzerland; Univ Hosp Geneva, Cell Isolat & Transplantat Ctr, CH-1211 Geneva, Switzerland	University of Geneva; University of Geneva	Hammar, EB (corresponding author), Univ Geneva, Med Ctr, Dept Genet Med & Dev, Rue Michel Servet 1, CH-1211 Geneva, Switzerland.	eva.hammar@medecine.unige.ch	Ferrante, Antonio/B-1927-2008	Ferrante, Antonio/0000-0001-7781-9784; Hammar, Eva/0000-0002-3267-2202; Bosco, Domenico/0000-0003-3453-9613				Alahari SK, 2002, INT REV CYTOL, V220, P145; Anrather J, 2005, J BIOL CHEM, V280, P244, DOI 10.1074/jbc.M409344200; BEATTIE GM, 1991, J CLIN ENDOCR METAB, V73, P93, DOI 10.1210/jcem-73-1-93; Bernal-Mizrachi E, 2002, DIABETES, V51, pS484, DOI 10.2337/diabetes.51.2007.S484; Bosco D, 2000, DIABETES, V49, P233, DOI 10.2337/diabetes.49.2.233; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; Cardozo AK, 2001, J BIOL CHEM, V276, P48879, DOI 10.1074/jbc.M108658200; Chen LF, 2004, NAT REV MOL CELL BIO, V5, P392, DOI 10.1038/nrm1368; de Fougerolles AR, 2000, IMMUNITY, V13, P749, DOI 10.1016/S1074-7613(00)00073-X; Donath MY, 2003, J MOL MED-JMM, V81, P455, DOI 10.1007/s00109-003-0450-y; Furukawa K, 1998, J NEUROCHEM, V70, P1876; GABBIANI G, 1974, ENDOCRINOLOGY, V95, P1630, DOI 10.1210/endo-95-6-1630; Giannoukakis N, 2000, J BIOL CHEM, V275, P36509, DOI 10.1074/jbc.M005943200; Hammar E, 2004, DIABETES, V53, P2034, DOI 10.2337/diabetes.53.8.2034; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Heimberg H, 2001, DIABETES, V50, P2219, DOI 10.2337/diabetes.50.10.2219; HERBERT V, 1965, J CLIN ENDOCR METAB, V25, P1375, DOI 10.1210/jcem-25-10-1375; Howe AK, 2002, CURR OPIN GENET DEV, V12, P30, DOI 10.1016/S0959-437X(01)00260-X; Juliano RL, 2002, ANNU REV PHARMACOL, V42, P283, DOI 10.1146/annurev.pharmtox.42.090401.151133; Kaido T, 2004, J BIOL CHEM, V279, P53762, DOI 10.1074/jbc.M411202200; KAISER N, 1988, ENDOCRINOLOGY, V123, P834, DOI 10.1210/endo-123-2-834; Klein S, 2002, MOL CELL BIOL, V22, P5912, DOI 10.1128/MCB.22.16.5912-5922.2002; LI GD, 1994, MOL BIOL CELL, V5, P1199, DOI 10.1091/mbc.5.11.1199; Malek S, 1998, J BIOL CHEM, V273, P25427, DOI 10.1074/jbc.273.39.25427; McGilvray ID, 1997, J BIOL CHEM, V272, P10287; Miranti CK, 2002, NAT CELL BIOL, V4, pE83, DOI 10.1038/ncb0402-e83; Nagata N, 2001, CELL TRANSPLANT, V10, P447; Nevins AK, 2003, AM J PHYSIOL-CELL PH, V285, pC698, DOI 10.1152/ajpcell.00093.2003; Norlin S, 2005, DIABETES, V54, P125, DOI 10.2337/diabetes.54.1.125; ORCI L, 1972, SCIENCE, V175, P1128, DOI 10.1126/science.175.4026.1128; Papaccio G, 2005, J CELL PHYSIOL, V204, P124, DOI 10.1002/jcp.20276; Parnaud G, 2005, AM J PHYSIOL-ENDOC M, V289, pE313, DOI 10.1152/ajpendo.00006.2005; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; QWARNSTROM EE, 1994, J BIOL CHEM, V269, P30765; Rehman KK, 2003, J BIOL CHEM, V278, P9862, DOI 10.1074/jbc.M207700200; Reyes-Reyes M, 2001, J CELL SCI, V114, P1579; Ris F, 2002, DIABETOLOGIA, V45, P841, DOI 10.1007/s00125-002-0840-7; Rosales C, 1996, CANCER RES, V56, P2302; Rosenberg L, 1999, SURGERY, V126, P393, DOI 10.1067/msy.1999.98783; ROUILLER DG, 1990, EXP CELL RES, V191, P305, DOI 10.1016/0014-4827(90)90019-7; Scatena M, 1998, J CELL BIOL, V141, P1083, DOI 10.1083/jcb.141.4.1083; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; Shishodia S, 2004, BIOCHEM PHARMACOL, V68, P1071, DOI 10.1016/j.bcp.2004.04.026; Thomas FT, 1999, SURGERY, V126, P299, DOI 10.1067/msy.1999.99164; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; Thurmond DC, 2003, MOL ENDOCRINOL, V17, P732, DOI 10.1210/me.2002-0333; Tian B, 2003, RECENT PROG HORM RES, V58, P95, DOI 10.1210/rp.58.1.95; Vermeulen L, 2002, BIOCHEM PHARMACOL, V64, P963, DOI 10.1016/S0006-2952(02)01161-9; Wang RN, 1999, J ENDOCRINOL, V163, P181, DOI 10.1677/joe.0.1630181; Yamamoto Y, 2004, TRENDS BIOCHEM SCI, V29, P72, DOI 10.1016/j.tibs.2003.12.003; Zahir N, 2003, J CELL BIOL, V163, P1397, DOI 10.1083/jcb.200302023; Zeender E, 2004, J CLIN ENDOCR METAB, V89, P5059, DOI 10.1210/jc.2004-0446	53	82	86	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	2005	280	34					30630	30637		10.1074/jbc.M502493200	http://dx.doi.org/10.1074/jbc.M502493200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	957IC	15994334	hybrid, Green Published			2022-12-25	WOS:000231362500080
J	Kinclova-Zimmermannova, O; Zavrel, M; Sychrova, H				Kinclova-Zimmermannova, O; Zavrel, M; Sychrova, H			Identification of conserved prolyl residue important for transport activity and the substrate specificity range of yeast plasma membrane Na+/H+ antiporters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; PROLINE RESIDUES; ESCHERICHIA-COLI; ZYGOSACCHAROMYCES-ROUXII; TRANSMEMBRANE HELICES; SALT-TOLERANCE; ALPHA-HELICES; NHA1 ANTIPORTER; CATION/H+ ANTIPORTERS; FUNCTIONAL-ANALYSIS	Yeast plasma membrane Na+/H+ antiporters are divided according to their substrate specificity in two distinct subfamilies. To identify amino acid residues responsible for substrate specificity determination ( recognition of K+), the Zygosaccharomyces rouxii Sod2-22 antiporter ( non-transporting K+) was mutagenized and a collection of ZrSod2-22 mutants that improved the KCl tolerance of a salt-sensitive Saccharomyces cerevisiae strain was isolated. Several independent ZrSod2-22 mutated alleles contained the replacement of a highly conserved proline 145 with a residue containing a hydroxyl group ( Ser, Thr). Site-directed mutagenesis of Pro(145) proved that an amino acid with a hydroxyl group at this position is enough to enable ZrSod2-22p to transport K+. Simultaneously, the P145( S/T) mutation decreased the antiporter transport activity for both Na+ and Li+. Replacement of Pro(145) with glycine resulted in a ZrSod2-22p with extremely low activity only for Na+, and the exchange of a charged residue ( Asp, Lys) for Pro(145) completely stopped the activity. Mutagenesis of the corresponding proline in the S. cerevisiae Nha1 antiporter ( Pro(146)) confirmed that this proline of the fifth transmembrane domain is a critical residue for antiporter function. This is the first evidence that a non-polar amino acid residue is important for the substrate specificity and activity of yeast Nha antiporters.	Acad Sci Czech Republ, Inst Physiol, Dept Membrane Transport, CR-14220 Prague, Czech Republic	Czech Academy of Sciences; Institute of Physiology of the Czech Academy of Sciences	Kinclova-Zimmermannova, O (corresponding author), Acad Sci Czech Republ, Inst Physiol, Dept Membrane Transport, Videnska 1083, CR-14220 Prague, Czech Republic.	kinclova@biomed.cas.cz	Sychrova, Hana/B-1350-2012; Zimmermannova, Olga/B-7925-2012; Zavrel, Martin/C-9918-2015	Sychrova, Hana/0000-0001-5967-5019; Zimmermannova, Olga/0000-0003-2538-4488; Zavrel, Martin/0000-0003-4740-876X				Ballesteros JA, 2000, BIOPHYS J, V79, P2754, DOI 10.1016/S0006-3495(00)76514-3; Banuelos MA, 1998, MICROBIOL-UK, V144, P2749, DOI 10.1099/00221287-144-10-2749; Banuelos MA, 2002, YEAST, V19, P1365, DOI 10.1002/yea.922; BRANDL CJ, 1986, P NATL ACAD SCI USA, V83, P917, DOI 10.1073/pnas.83.4.917; Brett CL, 2005, MOL BIOL CELL, V16, P1396, DOI 10.1091/mbc.E04-11-0999; Brett CL, 2005, AM J PHYSIOL-CELL PH, V288, pC223, DOI 10.1152/ajpcell.00360.2004; BROWN AJP, 1998, METHOD MICROBIOL, V26, P59; Chakrabarti P, 1998, J MOL BIOL, V284, P867, DOI 10.1006/jmbi.1998.2199; Cliften PF, 2001, GENOME RES, V11, P1175, DOI 10.1101/gr.182901; CONSLER TG, 1991, BIOCHEMISTRY-US, V30, P1291, DOI 10.1021/bi00219a019; Cordes FS, 2002, J MOL BIOL, V323, P951, DOI 10.1016/S0022-2836(02)01006-9; Dibrov P, 1998, FEBS LETT, V424, P1, DOI 10.1016/S0014-5793(98)00119-7; Dujon B, 2004, NATURE, V430, P35, DOI 10.1038/nature02579; Fliegel L, 2005, MOL CELL BIOCHEM, V268, P83; Fliegel L, 2002, ANN NY ACAD SCI, V976, P117; Galili L, 2004, J BIOL CHEM, V279, P23104, DOI 10.1074/jbc.M400288200; Galili L, 2002, BIOCHEMISTRY-US, V41, P609, DOI 10.1021/bi011655v; GRAY TM, 1984, J MOL BIOL, V175, P75, DOI 10.1016/0022-2836(84)90446-7; HARO R, 1991, FEBS LETT, V291, P189, DOI 10.1016/0014-5793(91)81280-L; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; Iwaki T, 1998, YEAST, V14, P1167, DOI 10.1002/(SICI)1097-0061(19980930)14:13<1167::AID-YEA318>3.0.CO;2-5; JIA ZP, 1992, EMBO J, V11, P1631, DOI 10.1002/j.1460-2075.1992.tb05209.x; Kamauchi S, 2002, J BIOCHEM, V131, P821, DOI 10.1093/oxfordjournals.jbchem.a003171; KAWAKAMI T, 1988, J BIOL CHEM, V263, P14276; Kellis M, 2003, NATURE, V423, P241, DOI 10.1038/nature01644; Kinclova O, 2001, MOL MICROBIOL, V40, P656, DOI 10.1046/j.1365-2958.2001.02412.x; Kinclova O, 2002, MICROBIOL-SGM, V148, P1225, DOI 10.1099/00221287-148-4-1225; Kinclova O, 2001, FEBS LETT, V504, P11, DOI 10.1016/S0014-5793(01)02755-7; Kinclova O, 2001, J BIOTECHNOL, V88, P151, DOI 10.1016/S0168-1656(01)00274-7; Koike K, 2004, J BIOL CHEM, V279, P12325, DOI 10.1074/jbc.M311435200; Kuwabara N, 2004, J BIOL CHEM, V279, P40567, DOI 10.1074/jbc.M401132200; Lin ZC, 2000, FASEB J, V14, P715, DOI 10.1096/fasebj.14.5.715; MACARTHUR MW, 1991, J MOL BIOL, V218, P397, DOI 10.1016/0022-2836(91)90721-H; Maresova L, 2005, MOL MICROBIOL, V55, P588, DOI 10.1111/j.1365-2958.2004.04410.x; MCGREGOR MJ, 1987, J MOL BIOL, V198, P295, DOI 10.1016/0022-2836(87)90314-7; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; NAKAMURA T, 1995, BBA-BIOENERGETICS, V1230, P170, DOI 10.1016/0005-2728(95)00053-L; Nass R, 1997, J BIOL CHEM, V272, P26145, DOI 10.1074/jbc.272.42.26145; Nass R, 1998, J BIOL CHEM, V273, P21054, DOI 10.1074/jbc.273.33.21054; NIU XM, 1995, PLANT PHYSIOL, V109, P735, DOI 10.1104/pp.109.3.735; Noumi T, 1997, J BIOCHEM-TOKYO, V121, P661; Olivella M, 2002, BIOPHYS J, V82, P3207, DOI 10.1016/S0006-3495(02)75663-4; Orlowski J, 2004, PFLUG ARCH EUR J PHY, V447, P549, DOI 10.1007/s00424-003-1110-3; Padan E, 2001, BBA-BIOENERGETICS, V1505, P144, DOI 10.1016/S0005-2728(00)00284-X; Prior C, 1996, FEBS LETT, V387, P89, DOI 10.1016/0014-5793(96)00470-X; Proft M, 2004, CELL, V118, P351, DOI 10.1016/j.cell.2004.07.016; Ramirez J, 1998, J BACTERIOL, V180, P5860; RAMOS J, 1986, EUR J BIOCHEM, V154, P307, DOI 10.1111/j.1432-1033.1986.tb09398.x; Regenberg B, 2001, YEAST, V18, P1429, DOI 10.1002/yea.792.abs; RODRIGUEZNAVARRO A, 1994, BBA-BIOENERGETICS, V1187, P203, DOI 10.1016/0005-2728(94)90111-2; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANSOM MSP, 1992, PROTEIN ENG, V5, P53, DOI 10.1093/protein/5.1.53; Senes A, 2000, J MOL BIOL, V296, P921, DOI 10.1006/jmbi.1999.3488; Shi HZ, 2000, P NATL ACAD SCI USA, V97, P6896, DOI 10.1073/pnas.120170197; Simon E, 2001, J BIOL CHEM, V276, P29740, DOI 10.1074/jbc.M101992200; Slepkov ER, 2004, BIOCHEM J, V379, P31, DOI 10.1042/BJ20030884; Soong TW, 2000, MICROBIOL-UK, V146, P1035, DOI 10.1099/00221287-146-5-1035; Sychrova H, 1999, FEMS MICROBIOL LETT, V171, P167, DOI 10.1111/j.1574-6968.1999.tb13428.x; Sychrova H, 2004, PHYSIOL RES, V53, pS91; Ulmschneider MB, 2005, PROTEINS, V59, P252, DOI 10.1002/prot.20334; Ulmschneider MB, 2001, BBA-BIOMEMBRANES, V1512, P1, DOI 10.1016/S0005-2736(01)00299-1; Visiers I, 2000, PROTEIN ENG, V13, P603, DOI 10.1093/protein/13.9.603; WATANABE Y, 1995, YEAST, V11, P829, DOI 10.1002/yea.320110905; Watanabe Y, 2002, FEMS MICROBIOL LETT, V209, P39, DOI 10.1111/j.1574-6968.2002.tb11106.x; Wiebe CA, 2003, MOL CELL BIOCHEM, V254, P117, DOI 10.1023/A:1027311916247; WILLIAMS KA, 1991, BIOCHEMISTRY-US, V30, P8919, DOI 10.1021/bi00101a001; WOOLFSON DN, 1990, FEBS LETT, V277, P185, DOI 10.1016/0014-5793(90)80839-B; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	68	42	42	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	2005	280	34					30638	30647		10.1074/jbc.M506341200	http://dx.doi.org/10.1074/jbc.M506341200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	957IC	15994323	hybrid			2022-12-25	WOS:000231362500081
J	Yamazaki, Y; Matsunaga, Y; Nakano, Y; Morita, T				Yamazaki, Y; Matsunaga, Y; Nakano, Y; Morita, T			Identification of vascular endothelial growth factor receptor-binding protein in the venom of eastern cottonmouth - A new role of snake venom myotoxic Lys(49)-phospholipase A(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN-CONTAINING RECEPTOR; LYS49 PHOSPHOLIPASE A(2); CRYSTAL-STRUCTURE; VEGF BINDING; KINASE; LIGAND; DISSOCIATION; APOPTOSIS; VEGF(165); PEPTIDES	Vascular endothelial growth factor (VEGF(165)) and its receptor KDR ( kinase insert domain-containing receptor) are central regulators of blood vessel formation. We herein report a KDR-binding protein we have isolated in the venom of eastern cottonmouth (Agkistrodon piscivorus piscivorus). Sequence analysis revealed the isolated KDR-binding protein (designated KDR- bp) is identical to Lys49-phosholipase A(2) (Lys(49)PLA(2)), an inactive PLA(2) homologue with strong myotoxicity, in which Lys(49) substitutes Asp(49), a key residue for binding the essential cofactor Ca2+. KDR-bp binds to the extracellular domain of KDR with subnanomolar affinity. KDR- bp also binds to a lesser extent with Flt-1 and IgG but not to other receptors with similar immunoglobulin-like domain structures such as platelet-derived growth factor receptor alpha. The interaction between KDR-bp and KDR was blocked by VEGF165, and KDR- bp specifically inhibited VEGF165-stimulated endothelial cell proliferation, indicating KDR-bp is an antagonistic ligand for KDR. Lys(49)PLA(2)s from another snake venom were found to exhibit similar receptor binding properties to KDR-bp. This is the first report to demonstrate that an exogenous factor antagonizes VEGF and its receptor system. Our observation offers further insight into the as yet unknown molecular mechanism of myotoxic activity of snake venom Lys49PLA2s. Furthermore, KDR- bp would make a valuable tool for studying the structure and function of KDR, such as that expressed on skeletal muscle cells.	Meiji Pharmaceut Univ, Dept Biochem, Tokyo 2048588, Japan	Meiji Pharmaceutical University	Morita, T (corresponding author), Meiji Pharmaceut Univ, Dept Biochem, 2-522-1 Noshio, Tokyo 2048588, Japan.	tmorita@my-pharm.ac.jp		Matsunaga, Yukiko/0000-0002-1392-5681; Yamazaki, Yasuo/0000-0001-5297-9837				Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; de Oliveira AHC, 2001, BIOCHEMISTRY-US, V40, P6912, DOI 10.1021/bi0026728; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; Dias S, 2000, J CLIN INVEST, V106, P511, DOI 10.1172/JCI8978; Dias S, 2002, BLOOD, V99, P2532, DOI 10.1182/blood.V99.7.2532; Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027; Ferrara N, 2004, ONCOLOGIST, V9, P2, DOI 10.1634/theoncologist.9-suppl_1-2; Fuh G, 1998, J BIOL CHEM, V273, P11197, DOI 10.1074/jbc.273.18.11197; Germani A, 2003, AM J PATHOL, V163, P1417, DOI 10.1016/S0002-9440(10)63499-2; Gutierrez JM, 2003, TOXICON, V42, P915, DOI 10.1016/j.toxicon.2003.11.005; HOLLAND DR, 1990, J BIOL CHEM, V265, P17649; Joukov V, 1996, EMBO J, V15, P290; Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788; Lomonte B, 2003, TOXICON, V42, P885, DOI 10.1016/j.toxicon.2003.11.008; Lomonte B, 2003, TOXICON, V42, P307, DOI 10.1016/S0041-0101(03)00149-1; Mizuno H, 2001, P NATL ACAD SCI USA, V98, P7230, DOI 10.1073/pnas.131179698; Mora R, 2005, TOXICON, V45, P651, DOI 10.1016/j.toxicon.2005.01.008; Nunez CE, 2001, TOXICON, V39, P1587, DOI 10.1016/S0041-0101(01)00141-6; Qi JH, 2003, NAT MED, V9, P407, DOI 10.1038/nm846; Rocha SLG, 2002, EUR J BIOCHEM, V269, P6052, DOI 10.1046/j.1432-1033.2002.03308.x; Shinkai A, 1998, J BIOL CHEM, V273, P31283, DOI 10.1074/jbc.273.47.31283; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Suto K, 2005, J BIOL CHEM, V280, P2126, DOI 10.1074/jbc.M411395200; Tans G, 2001, HAEMOSTASIS, V31, P225; TESSLER S, 1994, J BIOL CHEM, V269, P12456; Ward RJ, 2002, BIOCHEM J, V362, P89, DOI 10.1042/0264-6021:3620089; Wiesmann C, 1997, CELL, V91, P695, DOI 10.1016/S0092-8674(00)80456-0; Yamazaki Y, 2003, J BIOL CHEM, V278, P51985, DOI 10.1074/jbc.C300454200	28	45	46	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	2005	280	34					29989	29992		10.1074/jbc.C500236200	http://dx.doi.org/10.1074/jbc.C500236200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	957IC	16014630	hybrid			2022-12-25	WOS:000231362500002
J	Chen, S; Rani, S; Wu, YM; Unterbrink, A; Gu, TT; Gluhak-Heinrich, J; Chuang, HH; MacDougall, M				Chen, S; Rani, S; Wu, YM; Unterbrink, A; Gu, TT; Gluhak-Heinrich, J; Chuang, HH; MacDougall, M			Differential regulation of dentin sialophosphoprotein expression by Runx2 during odontoblast cytodifferentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEIN-2; OSTEOCALCIN GENE-EXPRESSION; GROWTH-FACTOR BETA-1; OSTEOBLAST DIFFERENTIATION; TRANSCRIPTION FACTOR; CLEIDOCRANIAL DYSPLASIA; DSPP GENE; TOOTH DEVELOPMENT; SEQUENCE DETERMINATION; CELL-DIFFERENTIATION	Dentin sialophosphoprotein (DSPP) consists of dentin sialoprotein (DSP) and dentin phosphoprotein (DPP). The spatial-temporal expression of DSPP is largely restricted during differentiational stages of dental cells. DSPP plays a vital role in tooth development. It is known that an osteoblast-specific transcription factor, Runx2, is essential for osteoblast differentiation. However, effects of Runx2 on DSPP transcription remain unknown. Here, we studied different roles of Runx2 in controlling DSPP expression in mouse preodontoblast (MD10-F2) and odontoblast (MO6-G3) cells. Two Runx2 isoforms were expressed in preodontoblast and odontoblast cells, and in situ hybridization assay showed that DSPP expression increased, whereas Runx2 was down-regulated during odontoblast differentiation and maturation. Three potential Runx2 sites are present in promoters of mouse and rat DSPP genes. Runx2 binds to these sites as demonstrated by electrophoretic mobility shift assay and supershift experiments. Mutations of Runx2 sites in mouse DSPP promoter resulted in a decline of promoter activity in MD10-F2 cells compared with an increase of its activity in MO6-G3 cells. Multiple Runx2 sites were more active than a single site in regulating the DSPP promoter. Furthermore, forced overexpression of Runx2 isoforms induced increases of endogenous DSPP protein levels in MD10-F2 cells but reduced its expression in MO6-G3 cells consistent with the DSPP promoter analysis. Thus, our results suggest that differential positive and negative regulation of DSPP by Runx2 is dependent on use of cytodifferentiation of dental ectomesenchymal-derived cells that may contribute to the spatial-temporal expression of DSPP during tooth development.	Univ Texas, Hlth Sci Ctr, Dept Pediat Dent, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Pharmacol, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Orthodont, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Chen, S (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Pediat Dent, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	chens0@uthscsa.edu	MacDougall, Mary/ABG-8212-2021		NIDCR NIH HHS [R03-DE01448401A2, P01-DE113221] Funding Source: Medline	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Aberg T, 1997, DEV DYNAM, V210, P383, DOI 10.1002/(SICI)1097-0177(199712)210:4<383::AID-AJA3>3.0.CO;2-C; Alliston T, 2001, EMBO J, V20, P2254, DOI 10.1093/emboj/20.9.2254; AUSUBEL FM, 1995, SHORT PROTOCOLS MOL, P15; Baba O, 2004, EUR J ORAL SCI, V112, P163, DOI 10.1111/j.0909-8836.2004.00110.x; Banerjee C, 1996, P NATL ACAD SCI USA, V93, P4968, DOI 10.1073/pnas.93.10.4968; Banerjee C, 2001, ENDOCRINOLOGY, V142, P4026, DOI 10.1210/en.142.9.4026; Barnes GL, 2003, CANCER RES, V63, P2631; Bidder M, 1998, J BONE MINER RES, V13, P609, DOI 10.1359/jbmr.1998.13.4.609; Bleicher F, 1999, MATRIX BIOL, V18, P133, DOI 10.1016/S0945-053X(99)00007-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen S, 2005, ARCH ORAL BIOL, V50, P227, DOI 10.1016/j.archoralbio.2004.10.014; Chen S, 2004, J BIOL CHEM, V279, P42182, DOI 10.1074/jbc.M402476200; Chen S, 2002, CONNECT TISSUE RES, V43, P338, DOI 10.1080/03008200290000691; CHEN S, 2001, J DENT RES, V80, P196; Couble ML, 2000, CALCIFIED TISSUE INT, V66, P129, DOI 10.1007/PL00005833; D'Souza RN, 1999, DEVELOPMENT, V126, P2911; Dhamija S, 2001, J BIOL CHEM, V276, P35159, DOI 10.1074/jbc.M010719200; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dong J, 2005, AM J MED GENET A, V132A, P305, DOI 10.1002/ajmg.a.30460; Drissi H, 2002, J CELL BIOCHEM, V86, P403, DOI 10.1002/jcb.10238; Drissi H, 2000, J CELL PHYSIOL, V184, P341, DOI 10.1002/1097-4652(200009)184:3<341::AID-JCP8>3.0.CO;2-Z; DSouza RN, 1997, J BONE MINER RES, V12, P2040, DOI 10.1359/jbmr.1997.12.12.2040; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Feng JQ, 1998, J BIOL CHEM, V273, P9457, DOI 10.1074/jbc.273.16.9457; Fisher LW, 2003, CONNECT TISSUE RES, V44, P33, DOI 10.1080/03008200390152061; Gaikwad J S, 2001, Adv Dent Res, V15, P19; Geoffroy V, 1995, J BIOL CHEM, V270, P30973, DOI 10.1074/jbc.270.52.30973; George A, 1996, J BIOL CHEM, V271, P32869, DOI 10.1074/jbc.271.51.32869; GOLDBERG M, 1995, J DENT, V23, P15, DOI 10.1016/0300-5712(95)90655-2; Harada H, 1999, J BIOL CHEM, V274, P6972, DOI 10.1074/jbc.274.11.6972; HARRIS SE, 1994, J BONE MINER RES, V9, P389; He WX, 2004, ARCH ORAL BIOL, V49, P911, DOI 10.1016/j.archoralbio.2004.05.005; Ito Y, 2001, J BIOL CHEM, V276, P44163, DOI 10.1074/jbc.M011424200; Javed A, 2001, MOL CELL BIOL, V21, P2891, DOI 10.1128/MCB.21.8.2891-2905.2001; Jimenez MJG, 1999, MOL CELL BIOL, V19, P4431; Karsenty G, 1999, GENE DEV, V13, P3037, DOI 10.1101/gad.13.23.3037; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; Kern B, 2001, J BIOL CHEM, V276, P7101, DOI 10.1074/jbc.M006215200; Kim JW, 2004, HUM GENET, V115, P248, DOI 10.1007/s00439-004-1143-5; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Lee B, 1997, NAT GENET, V16, P307, DOI 10.1038/ng0797-307; Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783-8792.2000; Lee MH, 1999, J CELL BIOCHEM, V73, P114, DOI 10.1002/(SICI)1097-4644(19990401)73:1<114::AID-JCB13>3.3.CO;2-D; Liu WG, 2001, J CELL BIOL, V155, P157, DOI 10.1083/jcb.200105052; MacDougall M, 1997, J BIOL CHEM, V272, P835, DOI 10.1074/jbc.272.2.835; MacDougall M, 1995, Connect Tissue Res, V33, P97, DOI 10.3109/03008209509016988; MacNeil R L, 1995, Connect Tissue Res, V33, P1, DOI 10.3109/03008209509016974; MERRIMAN HL, 1995, BIOCHEMISTRY-US, V34, P13125, DOI 10.1021/bi00040a025; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; Narayanan K, 2004, J BIOL CHEM, V279, P45423, DOI 10.1074/jbc.M405031200; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Petersen DN, 2000, J BIOL CHEM, V275, P36172, DOI 10.1074/jbc.M003622200; Qin C, 2002, J DENT RES, V81, P392, DOI 10.1177/154405910208100607; Rajpar MH, 2002, HUM MOL GENET, V11, P2559, DOI 10.1093/hmg/11.21.2559; REICHERT T, 1992, CALCIFIED TISSUE INT, V50, P468, DOI 10.1007/BF00296779; RITCHIE HH, 1994, J BIOL CHEM, V269, P3698; Ritchie HH, 2002, CONNECT TISSUE RES, V43, P331, DOI 10.1080/03008200290001041; Sommer B, 1996, BONE, V19, P371, DOI 10.1016/S8756-3282(96)00218-9; SUPAKAR PC, 1995, J BIOL CHEM, V270, P837, DOI 10.1074/jbc.270.2.837; Thesleff I, 1996, CURR OPIN CELL BIOL, V8, P844, DOI 10.1016/S0955-0674(96)80086-X; Thirunavukkarasu K, 2000, J BIOL CHEM, V275, P25163, DOI 10.1074/jbc.M000322200; Thyagarajan T, 2001, J BIOL CHEM, V276, P11016, DOI 10.1074/jbc.M010502200; Tsuji K, 1998, BONE, V22, P87, DOI 10.1016/S8756-3282(97)00267-6; VAINIO S, 1993, CELL, V75, P45, DOI 10.1016/S0092-8674(05)80083-2; Xiao SX, 2001, NAT GENET, V27, P201, DOI 10.1038/84848; Xiao ZS, 2001, J CELL BIOCHEM, V82, P647, DOI 10.1002/jcb.1192; Xiao ZS, 2004, J BIOL CHEM, V279, P20307, DOI 10.1074/jbc.M401109200; Xiong SB, 2000, P NATL ACAD SCI USA, V97, P3948, DOI 10.1073/pnas.040574197; Xu X, 2003, INT J DEV BIOL, V47, P31; YAMAGUCHI A, 1991, J CELL BIOL, V113, P681, DOI 10.1083/jcb.113.3.681; Yang SY, 2003, J BONE MINER RES, V18, P705, DOI 10.1359/jbmr.2003.18.4.705; Zaidi SK, 2002, P NATL ACAD SCI USA, V99, P8048, DOI 10.1073/pnas.112664499; ZEICHNERDAVID M, 1995, INT J DEV BIOL, V39, P69; Zhang XH, 2001, NAT GENET, V27, P151, DOI 10.1038/84765; Zhang YW, 2000, P NATL ACAD SCI USA, V97, P10549, DOI 10.1073/pnas.180309597	76	130	139	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	2005	280	33					29717	29727		10.1074/jbc.M502929200	http://dx.doi.org/10.1074/jbc.M502929200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	954SX	15980071	hybrid			2022-12-25	WOS:000231176200042
J	Dominguez, F; Yanez-Mo, M; Sanchez-Madrid, F; Simon, C				Dominguez, F; Yanez-Mo, M; Sanchez-Madrid, F; Simon, C			Embryonic implantation and leukocyte transendothelial migration: different processes with similar players?	FASEB JOURNAL			English	Article						implantation; leukocyte trafficking; integrins; chemokines; L-selectin	ENDOMETRIAL EPITHELIAL-CELLS; ADHESION MOLECULES; GENE-EXPRESSION; MUCIN MUC1; INTEGRINS; SELECTIN; CYTOSKELETON; BLASTOCYST; CHEMOKINES; APOPTOSIS	A clear parallelism between the different steps in human embryo-endometrial apposition/adhesion/invasion and leukocyte-endothelium rolling/adhesion/extravasation can be established. During human implantation and leukocyte trafficking, a first wave of soluble mediators regulates the expression and functional activity of adhesion molecules such as L-selectin and integrins, which mediate both processes. Apical surfaces of human endometrial epithelium and endothelium are key elements for the initiation of molecular interactions to capture the blastocyst or leukocyte, respectively. Subsequently, the blastocyst and the leukocyte migrate through the epithelium and endothelium toward their final destination, the endometrial stroma, to initiate placentation or the inflammatory foci as part of the immune response. Similarities between the intermediate molecular mechanisms of these two physiologically unrelated processes are discussed.	Univ Valencia, FIVI, Valencia 46015, Spain; Univ Valencia, Sch Med, Dept Pediat Obstet & Gynecol, Valencia, Spain; Univ Autonoma Madrid, Hosp Princesa, Serv Inmunol, Madrid, Spain	University of Valencia; University of Valencia; Autonomous University of Madrid; Hospital de La Princesa	Simon, C (corresponding author), Univ Valencia, FIVI, C Guadassuar 1, Valencia 46015, Spain.	csimon@ivi.es	Dominguez, Francisco/AAA-7260-2020; YÃÃez-MÃ, Maria/AAI-4544-2020; Simon, Carlos/G-2186-2014; Yáñez-Mó, María/K-8577-2014; Sanchez-Madrid, Francisco/M-7889-2016	Dominguez, Francisco/0000-0002-7620-8081; YÃÃez-MÃ, Maria/0000-0001-7484-2866; Simon, Carlos/0000-0003-0902-9531; Yáñez-Mó, María/0000-0001-7484-2866; Sanchez-Madrid, Francisco/0000-0001-5303-0762				Barreiro O, 2004, FRONT BIOSCI-LANDMRK, V9, P1849, DOI 10.2741/1285; Barreiro O, 2002, J CELL BIOL, V157, P1233, DOI 10.1083/jcb.200112126; BARREIRO O, IN PRESS BLOOD; Bentin-Ley U, 2000, HUM REPROD, V15, P67; Berditchevski F, 2001, J CELL SCI, V114, P4143; BERLIN C, 1995, CELL, V80, P413, DOI 10.1016/0092-8674(95)90491-3; Bischof P, 2002, J REPROD IMMUNOL, V55, P3, DOI 10.1016/S0165-0378(01)00142-5; Borthwick JM, 2003, MOL HUM REPROD, V9, P19, DOI 10.1093/molehr/gag004; Caballero-Campo P, 2002, MOL HUM REPROD, V8, P375, DOI 10.1093/molehr/8.4.375; Carson DD, 2002, MOL HUM REPROD, V8, P871, DOI 10.1093/molehr/8.9.871; Dominguez F, 2003, MOL HUM REPROD, V9, P189, DOI 10.1093/molehr/gag024; Galan A, 2000, HUM REPROD, V15, P74; Genbacev OD, 2003, SCIENCE, V299, P405, DOI 10.1126/science.1079546; Geng JG, 1997, J CELL BIOL, V137, P743, DOI 10.1083/jcb.137.3.743; Goldman-Wohl D, 2002, MOL CELL ENDOCRINOL, V187, P233, DOI 10.1016/S0303-7207(01)00687-6; Gonzalez-Amaro R, 1999, CRIT REV IMMUNOL, V19, P389; HEY NA, 1994, J CLIN ENDOCR METAB, V78, P337, DOI 10.1210/jc.78.2.337; Imhof BA, 2004, NAT REV IMMUNOL, V4, P432, DOI 10.1038/nri1375; IRVING JA, 1995, EXP CELL RES, V217, P419, DOI 10.1006/excr.1995.1105; Kamijo T, 1998, MOL HUM REPROD, V4, P990, DOI 10.1093/molehr/4.10.990; Kao LC, 2002, ENDOCRINOLOGY, V143, P2119, DOI 10.1210/en.143.6.2119; Kayisli UA, 2002, AM J REPROD IMMUNOL, V47, P213, DOI 10.1034/j.1600-0897.2002.01075.x; Le Naour F, 2000, SCIENCE, V287, P319, DOI 10.1126/science.287.5451.319; LESSEY BA, 1992, J CLIN INVEST, V90, P188, DOI 10.1172/JCI115835; Lessey BA, 2002, J REPROD IMMUNOL, V55, P101, DOI 10.1016/S0165-0378(01)00139-5; Ley K, 2004, NAT REV IMMUNOL, V4, P325, DOI 10.1038/nri1351; Luscinskas FW, 2002, IMMUNOL REV, V186, P57, DOI 10.1034/j.1600-065X.2002.18606.x; Martin JC, 2000, BIOL REPROD, V63, P1370, DOI 10.1095/biolreprod63.5.1370; Matsumoto H, 2004, BIOL REPROD, V70, P729, DOI 10.1095/biolreprod.103.022764; Meseguer M, 2001, BIOL REPROD, V64, P590, DOI 10.1095/biolreprod64.2.590; Milstone DS, 2000, DEV DYNAM, V219, P63, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1035>3.0.CO;2-D; Miyado K, 2000, SCIENCE, V287, P321, DOI 10.1126/science.287.5451.321; Moser B, 2001, NAT IMMUNOL, V2, P123, DOI 10.1038/84219; Nagaoka K, 2003, J BIOL CHEM, V278, P29048, DOI 10.1074/jbc.M300470200; Nardo LG, 2003, J REPROD MED, V48, P355; Paria BC, 2002, SCIENCE, V296, P2185, DOI 10.1126/science.1071601; Park KR, 2000, MOL HUM REPROD, V6, P252, DOI 10.1093/molehr/6.3.252; Riesewijk A, 2003, MOL HUM REPROD, V9, P253, DOI 10.1093/molehr/gag037; Sanchez-Madrid F, 1999, EMBO J, V18, P501, DOI 10.1093/emboj/18.3.501; Shufaro Y, 2001, FERTIL STERIL, V75, P1217, DOI 10.1016/S0015-0282(01)01795-2; Simon C, 1997, J CLIN ENDOCR METAB, V82, P2607, DOI 10.1210/jc.82.8.2607; STEPHENS LE, 1995, GENE DEV, V9, P1883, DOI 10.1101/gad.9.15.1883; TORTOSA CG, 1993, VIRCHOWS ARCH A, V423, P287, DOI 10.1007/BF01606892; Urzainqui A, 2002, IMMUNITY, V17, P401, DOI 10.1016/S1074-7613(02)00420-X; Vestweber D, 2002, CURR OPIN CELL BIOL, V14, P587, DOI 10.1016/S0955-0674(02)00372-1; Vicente-Manzanares M, 2004, NAT REV IMMUNOL, V4, P110, DOI 10.1038/nri1268; Vicente-Manzanares M, 2002, INT REV CYTOL, V216, P233; VONANDRIAN UH, 1995, CELL, V82, P989, DOI 10.1016/0092-8674(95)90278-3; ZHOU Y, 1993, J CLIN INVEST, V91, P950, DOI 10.1172/JCI116316	49	74	81	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2005	19	9					1056	1060		10.1096/fj.05-3781hyp	http://dx.doi.org/10.1096/fj.05-3781hyp			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	951IO	15985528				2022-12-25	WOS:000230923000033
J	Papoutsaki, M; Moretti, F; Lanza, M; Marinari, B; Sartorelli, V; Guerrini, L; Chimenti, S; Levrero, M; Costanzo, A				Papoutsaki, M; Moretti, F; Lanza, M; Marinari, B; Sartorelli, V; Guerrini, L; Chimenti, S; Levrero, M; Costanzo, A			A p38-dependent pathway regulates Delta Np63 DNA binding to p53-dependent promoters in UV-induced apoptosis of keratinocytes	ONCOGENE			English	Article						p53; p63; apoptosis; p38; keratinocytes	JUN NH2-TERMINAL KINASE; P53; P63; PHOSPHORYLATION; ACTIVATION; EXPRESSION; DAMAGE	The p53 protein plays a pivotal role in determining the quality of the response to DNA damage through its transcriptional activity. Upon DNA damage, p53 is activated by post-translational modi. cations, binds its cognate sequences on the promoters of its target genes and stimulates transcription. In proliferating keratinocytes, the activity of p53 is blunted by its inhibitor Delta Np63 alpha. Here, we describe a novel mechanism through which Delta Np63 functions in order to prevent the survival and propagation of ultraviolet (UV)-damaged keratinocytes. We found that UVB stimulation induces the rapid phosphorylation of DNp63, which precedes DNp63 transcriptional downregulation and protein degradation, which is mediated by the p38 MAPK. Phosphorylated Delta Np63 has a lower affinity for p53REs and detaches from cell cycle arrest and apoptotic promoters, thus allowing the rapid activation of p53-dependent transcriptional apoptotic program.	Univ Roma Tor Vergata, Dept Dermatol, Dermatol Clin, I-00133 Rome, Italy; CRS Regina Elena Canc Ctr, Fondaz A Cesalpino, I-00153 Rome, Italy; NIMAS, Muscle Biol Lab, Muscle Gene Express Grp, NIH, Bethesda, MD USA; Univ Milan, Dipartimento Genet & Biol Microorganismi, I-20122 Milan, Italy; Univ Roma La Sapienza, Dept Internal Med, Rome, Italy	University of Rome Tor Vergata; National Institutes of Health (NIH) - USA; University of Milan; Sapienza University Rome	Levrero, M (corresponding author), Univ Roma Tor Vergata, Dept Dermatol, Dermatol Clin, Viale Oxford 81, I-00133 Rome, Italy.	levmax@tin.it; antonio.costanzo@uniroma2.it	Costanzo, Antonio/D-3896-2012; Costanzo, Antonio/GZG-2433-2022; Levrero, Massimo/G-5680-2016	Costanzo, Antonio/0000-0001-9697-2557; Levrero, Massimo/0000-0002-4978-0875	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [ZIAAR041126, Z01AR041126] Funding Source: NIH RePORTER; Telethon [E.1325] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Telethon(Fondazione Telethon)		BODE AM, 2003, SCI STKE, pRE2; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Buschmann T, 2000, CANCER RES, V60, P896; Buschmann T, 2001, MOL CELL BIOL, V21, P2743, DOI 10.1128/MCB.21.8.2743-2754.2001; Cleaver JE, 2002, FRONT BIOSCI-LANDMRK, V7, pD1024, DOI 10.2741/cleaver; Crook T, 2000, ONCOGENE, V19, P3439, DOI 10.1038/sj.onc.1203656; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; Diepgen TL, 2002, BRIT J DERMATOL, V146, P1, DOI 10.1046/j.1365-2133.146.s61.2.x; Friedberg EC, 2003, NATURE, V421, P436, DOI 10.1038/nature01408; Ghioni P, 2002, MOL CELL BIOL, V22, P8659, DOI 10.1128/MCB.22.24.8659-8668.2002; Hibi K, 2000, P NATL ACAD SCI USA, V97, P5462, DOI 10.1073/pnas.97.10.5462; Hildesheim J, 2002, CANCER RES, V62, P7305; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; Liefer KM, 2000, CANCER RES, V60, P4016; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Park BJ, 2000, CANCER RES, V60, P3370; Qin JZ, 2002, ONCOGENE, V21, P2991, DOI 10.1038/sj.onc.1205404; Ratovitski EA, 2001, P NATL ACAD SCI USA, V98, P1817, DOI 10.1073/pnas.98.4.1817; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Sinha RP, 2002, PHOTOCH PHOTOBIO SCI, V1, P225, DOI 10.1039/b201230h; Westfall MD, 2003, MOL CELL BIOL, V23, P2264, DOI 10.1128/MCB.23.7.2264-2276.2003; Wu XW, 2002, FRONT BIOSCI, V7, pD151, DOI 10.2741/wu1; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0	27	39	41	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2005	24	46					6970	6975		10.1038/sj.onc.1208835	http://dx.doi.org/10.1038/sj.onc.1208835			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	975ZD	16007154				2022-12-25	WOS:000232701700011
J	Tsuzuki, K; Tricoire, L; Courjean, O; Gibelin, N; Rossier, J; Lambolez, B				Tsuzuki, K; Tricoire, L; Courjean, O; Gibelin, N; Rossier, J; Lambolez, B			Thermostable mutants of the photoprotein aequorin obtained by in vitro evolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIRECTED MOLECULAR EVOLUTION; C-TERMINAL PROLINE; FIREFLY LUCIFERASE; SEQUENCE-ANALYSIS; CALCIUM-BINDING; CA-2+-ACTIVATED PHOTOPROTEIN; CA2+-BINDING PHOTOPROTEIN; BACTERIAL LUCIFERASE; ANGSTROM RESOLUTION; RANDOM MUTAGENESIS	Aequorin is a photoprotein that emits light upon binding calcium. Aequorin mutants showing increased intensity or slow decay of bioluminescence were isolated by in vitro evolution combining DNA shuffling and functional screening in bacteria. Luminescence decay mutants were isolated at the first round of screening and carried mutations located in EF-hand calcium binding sites or their vicinity. During in vitro evolution, the luminescence intensity of the population of mutants increased with the frequency of effective mutations whereas the frequency of other amino acid substitutions remained roughly stable. Luminescence intensity mutations neighbored the His-16 or His-169 coelenterazine binding residues or were located in the first EF-hand. None of the selected mutants exhibited an increase in photon yield when examined in a cell-free assay. However, we observed that two mutants, Q168R and L170I, exhibited an increase of the photoprotein lifetime at 37 degrees C that may underlie their high luminescence intensity in bacteria. Further analysis of Q168R and L170I mutations showed that they increased aequorin thermostability. Conversely, examination of luminescence decay mutants revealed that the F149S substitution decreased aequorin thermostability. Finally, screening of a library of random Gln-168 and Leu-170 mutants confirmed the involvement of both positions in thermostability and indicated that optimal thermostability was conferred by Q168R and L170I mutations selected through in vitro evolution. Our results suggest that Phe-149 and Gln-168 residues participate in stabilization of the coelenterazine peroxide and the triggering of photon emission by linking the third EF-hand to Trp-129 and His-169 coelenterazine binding residues.	Ecole Super Phys & Chim Ind Ville Paris, CNRS, UMR 7637, Lab Neurobiol & Divers Cellulaire, F-75005 Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI)	Lambolez, B (corresponding author), Univ Paris 06, CNRS, UMR 7102, 9 Quai St Bernard, F-75005 Paris, France.	bertrand.lambolez@snv.jussieu.fr		lambolez, bertrand/0000-0002-0653-480X				Badminton MN, 1995, BIOCHEM BIOPH RES CO, V217, P950, DOI 10.1006/bbrc.1995.2862; Brini M, 1999, MICROSC RES TECHNIQ, V46, P380, DOI 10.1002/(SICI)1097-0029(19990915)46:6<380::AID-JEMT6>3.0.CO;2-Y; Christians FC, 1999, NAT BIOTECHNOL, V17, P259, DOI 10.1038/7003; CLINE T, 1971, P NATL ACAD SCI USA, V68, P500, DOI 10.1073/pnas.68.2.500; CLINE TW, 1972, BIOCHEMISTRY-US, V11, P3359, DOI 10.1021/bi00768a008; Combet C, 2002, BIOINFORMATICS, V18, P213, DOI 10.1093/bioinformatics/18.1.213; Crameri A, 1996, NAT BIOTECHNOL, V14, P315, DOI 10.1038/nbt0396-315; Deng L, 2005, PROTEIN SCI, V14, P663, DOI 10.1110/ps.041142905; FAGAN TF, 1993, FEBS LETT, V333, P301, DOI 10.1016/0014-5793(93)80675-K; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; Haddock SHD, 2001, P NATL ACAD SCI USA, V98, P11148, DOI 10.1073/pnas.201329798; HASTINGS JW, 1969, NATURE, V222, P1047, DOI 10.1038/2221047a0; HASTINGS JW, 1963, J BIOL CHEM, V238, P2537; Head JF, 2000, NATURE, V405, P372, DOI 10.1038/35012659; HERRERA JE, 1994, J MOL BIOL, V236, P405, DOI 10.1006/jmbi.1994.1152; Hirokawa K, 2002, BBA-PROTEIN STRUCT M, V1597, P271, DOI 10.1016/S0167-4838(02)00302-3; Hosseinkhani S, 2005, BIOCHEM J, V385, P575, DOI 10.1042/BJ20040863; Iffland A, 2000, BIOCHEMISTRY-US, V39, P10790, DOI 10.1021/bi001121e; ILLARIONOV BA, 1995, GENE, V153, P273, DOI 10.1016/0378-1119(94)00797-V; INOUYE S, 1985, P NATL ACAD SCI USA, V82, P3154, DOI 10.1073/pnas.82.10.3154; INOUYE S, 1993, FEBS LETT, V315, P343, DOI 10.1016/0014-5793(93)81191-2; KAJIYAMA N, 1991, PROTEIN ENG, V4, P691, DOI 10.1093/protein/4.6.691; KAJIYAMA N, 1993, BIOCHEMISTRY-US, V32, P13795, DOI 10.1021/bi00213a007; KENDALL JM, 1992, BIOCHEM BIOPH RES CO, V187, P1091, DOI 10.1016/0006-291X(92)91309-E; KEOHAVONG P, 1989, P NATL ACAD SCI USA, V86, P9253, DOI 10.1073/pnas.86.23.9253; Kolkman JA, 2001, NAT BIOTECHNOL, V19, P423, DOI 10.1038/88084; Kurtzman AL, 2001, CURR OPIN BIOTECH, V12, P361, DOI 10.1016/S0958-1669(00)00228-7; Leong SR, 2003, P NATL ACAD SCI USA, V100, P1163, DOI 10.1073/pnas.0237327100; Lewis JC, 2000, FRESEN J ANAL CHEM, V366, P760, DOI 10.1007/s002160051570; Liu ZJ, 2000, PROTEIN SCI, V9, P2085, DOI 10.1110/ps.9.11.2085; Markova SV, 2002, BIOCHEMISTRY-US, V41, P2227, DOI 10.1021/bi0117910; MOISESCU DG, 1977, BIOCHIM BIOPHYS ACTA, V460, P189, DOI 10.1016/0005-2728(77)90206-7; Moore JC, 1996, NAT BIOTECHNOL, V14, P458, DOI 10.1038/nbt0496-458; NOMURA M, 1991, FEBS LETT, V295, P63, DOI 10.1016/0014-5793(91)81385-L; OHMIYA Y, 1992, FEBS LETT, V301, P197, DOI 10.1016/0014-5793(92)81247-J; OHMIYA Y, 1993, FEBS LETT, V320, P267, DOI 10.1016/0014-5793(93)80600-Y; PRASHER D, 1985, BIOCHEM BIOPH RES CO, V126, P1259, DOI 10.1016/0006-291X(85)90321-3; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SHIMOMURA O, 1975, NATURE, V256, P236, DOI 10.1038/256236a0; SHIMOMURA O, 1974, BIOCHEMISTRY-US, V13, P3278, DOI 10.1021/bi00713a016; SHIMOMURA O, 1978, P NATL ACAD SCI USA, V75, P2611, DOI 10.1073/pnas.75.6.2611; SHIMOMURA O, 1970, NATURE, V227, P1356, DOI 10.1038/2271356a0; STEMMER WPC, 1994, P NATL ACAD SCI USA, V91, P10747, DOI 10.1073/pnas.91.22.10747; Toma S, 2005, PROTEIN SCI, V14, P409, DOI 10.1110/ps.041067805; TSUJI FI, 1986, P NATL ACAD SCI USA, V83, P8107, DOI 10.1073/pnas.83.21.8107; WATKINS NJ, 1993, BIOCHEM J, V293, P181, DOI 10.1042/bj2930181; White PJ, 1996, BIOCHEM J, V319, P343, DOI 10.1042/bj3190343; Wilson T, 1998, ANNU REV CELL DEV BI, V14, P197, DOI 10.1146/annurev.cellbio.14.1.197; Yano T, 1998, P NATL ACAD SCI USA, V95, P5511, DOI 10.1073/pnas.95.10.5511	49	27	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					34324	34331		10.1074/jbc.M505303200	http://dx.doi.org/10.1074/jbc.M505303200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	15972815	hybrid			2022-12-25	WOS:000232229700075
J	Jeong, SJ; Pise-Masison, CA; Radonovich, MF; Park, HU; Brady, JN				Jeong, SJ; Pise-Masison, CA; Radonovich, MF; Park, HU; Brady, JN			Activated AKT regulates NF-kappa B activation, p53 inhibition and cell survival in HTLV-1-transformed cells	ONCOGENE			English	Article						HTLV-1; p53; NF-kappa B; AKT; p65; IKK	VIRUS TYPE-I; SERINE-THREONINE KINASE; HTLV-I; PHOSPHATIDYLINOSITOL 3-KINASE; TRANSCRIPTIONAL ACTIVITY; CLINICAL ENTITY; HUMAN CANCER; IKK-BETA; PATHWAY; LEUKEMIA	AKT activation enhances resistance to apoptosis and induces cell survival signaling through multiple downstream pathways. We now present evidence that AKT is activated in HTLV-1-transformed cells and that Tax activation of AKT is linked to NF-kappa B activation, p53 inhibition and cell survival. Overexpression of AKT wild type (WT), but not a kinase dead (KD) mutant, resulted in increased Tax-mediated NF-kappa B activation. Blocking AKT with the PI3K/AKT inhibitor LY294002 or AKT SiRNA prevented NF-kappa B activation and inhibition of p53. Treatment of C81 cells with LY294002 resulted in an increase in the p53-responsive gene MDM2, suggesting a role for AKT in the Tax-mediated regulation of p53 transcriptional activity. Further, we show that LY294002 treatment of C81cells abrogates in vitro IKK beta phosphorylation of p65 and causes a reduction of p65 Ser-536 phosphorylation in vivo, steps critical to p53 inhibition. Interestingly, blockage of AKT function did not affect IKKb phosphorylation of I kappa Ba in vitro suggesting selective activity of AKT on the IKKb complex. Finally, AKT prosurvival function in HTLV-1-transformed cells is linked to expression of Bcl-xL. We suggest that AKT plays a role in the activation of prosurvival pathways in HTLV-1-transformed cells, possibly through NF-kappa B activation and inhibition of p53 transcription activity.	Natl Canc Inst, Virus Tumor Biol Sect, Cellular Oncol Lab, Ctr Canc Res,NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Brady, JN (corresponding author), Natl Canc Inst, Virus Tumor Biol Sect, Cellular Oncol Lab, Ctr Canc Res,NIH, Bldg 41-B201,9000 Rockville Pike, Bethesda, MD 20892 USA.	bradyj@exchange.nih.gov			NATIONAL CANCER INSTITUTE [ZIABC005691, Z01BC005691] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKAGI T, 1995, BLOOD, V86, P4243, DOI 10.1182/blood.V86.11.4243.bloodjournal86114243; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Downward J, 2004, SEMIN CELL DEV BIOL, V15, P177, DOI 10.1016/j.semcdb.2004.01.002; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; GESSAIN A, 1985, LANCET, V2, P407; Gills JJ, 2004, EXPERT OPIN INV DRUG, V13, P787, DOI 10.1517/13543784.13.7.787; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; Hovelmann S, 2004, BRIT J CANCER, V90, P2370, DOI 10.1038/sj.bjc.6601876; Jeong SJ, 2005, J BIOL CHEM, V280, P10326, DOI 10.1074/jbc.M412643200; Jeong SJ, 2004, BLOOD, V104, P1490, DOI 10.1182/blood-2003-12-4174; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liu Y, 2001, ONCOGENE, V20, P2514, DOI 10.1038/sj.onc.1204364; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Mayo LD, 2002, TRENDS BIOCHEM SCI, V27, P462, DOI 10.1016/S0968-0004(02)02166-7; MOCHIZUKI M, 1992, JPN J CANCER RES, V83, P236, DOI 10.1111/j.1349-7006.1992.tb00092.x; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; NISHIOKA K, 1989, LANCET, V1, P441; OSAME M, 1986, LANCET, V1, P1031; Ozes ON, 1999, NATURE, V401, P82; Parsons R, 2004, SEMIN CELL DEV BIOL, V15, P171, DOI 10.1016/j.semcdb.2003.12.021; Pise-Masison CA, 2000, MOL CELL BIOL, V20, P3377, DOI 10.1128/MCB.20.10.3377-3386.2000; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Raina D, 2004, J BIOL CHEM, V279, P20607, DOI 10.1074/jbc.M310538200; Ren S, 2003, BIOCHEM BIOPH RES CO, V308, P120, DOI 10.1016/S0006-291X(03)01309-3; Scheid MP, 2003, FEBS LETT, V546, P108, DOI 10.1016/S0014-5793(03)00562-3; Shan XC, 2000, MOL CELL BIOL, V20, P6945, DOI 10.1128/MCB.20.18.6945-6957.2000; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200; Slee EA, 2004, ONCOGENE, V23, P2809, DOI 10.1038/sj.onc.1207516; STAAL SP, 1977, P NATL ACAD SCI USA, V74, P3065, DOI 10.1073/pnas.74.7.3065; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; Thompson JE, 2004, J CLIN ONCOL, V22, P4217, DOI 10.1200/jco.2004.01.103; Vara JAF, 2004, CANCER TREAT REV, V30, P193, DOI 10.1016/j.ctrv.2003.07.007; VERNANT JC, 1988, LANCET, V1, P177; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Yang F, 2003, J IMMUNOL, V170, P5630, DOI 10.4049/jimmunol.170.11.5630; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345	44	159	168	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 6	2005	24	44					6719	6728		10.1038/sj.onc.1208825	http://dx.doi.org/10.1038/sj.onc.1208825			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	971FL	16007163				2022-12-25	WOS:000232367800013
J	Chellaiah, MA				Chellaiah, MA			Regulation of actin ring formation by Rho GTPases in Osteoclasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 4-PHOSPHATE 5-KINASE; ALDRICH-SYNDROME MACROPHAGES; SRC KINASE-ACTIVITY; N-WASP; ARP2/3 COMPLEX; BINDING-PROTEIN; ACTIVATION MECHANISMS; BONE-RESORPTION; PHOSPHOLIPASE-D; EXCHANGE FACTOR	Actin ring formation is a prerequisite for osteoclast bone resorption. Although gelsolin null osteoclasts failed to exhibit podosomes, actin ring was observed in these osteoclasts. Wiscott-Aldrich syndrome protein (WASP) was observed in the actin ring of gelsolin null osteoclast. Osteoclasts stimulated with osteopontin simulated the effects of Rho and Cdc42 in phosphatidylinositol 4,5-bisphosphate (PIP2) association with WASP as well as formation of podosomes, peripheral microfilopodia-like structures, and actin ring. To explore the potential functions of Rho and Cdc42, TAT-mediated delivery of Rho proteins into osteoclasts was performed. Although Rho and Cdc42 are required for actin ring formation, transduction of either one of the proteins alone is insufficient for this process. Addition of osteopontin to osteoclasts transduced with Cdc42(Val12) or transduction of osteoclasts with both Rho(Val14) and Cdc42(Val12) augments the formation of WASP-Arp2/3 complex and actin ring. Neomycin, an antibiotic, blocked the effects of osteopontin or TAT-Rho(Val14) on PIP2 interaction with WASP. WASP distribution was found to be cytosolic in these osteoclasts. Depletion of WASP by short interfering RNA-mediated gene silencing blocked actin polymerization as well as actin ring formation in osteoclasts. These results suggest that Rho-mediated PIP2 interaction with WASP may contribute to the activation and membrane targeting of WASP. Subsequent interaction of Cdc42 and Arp2/3 with WASP may enhance cortical actin polymerization in the process of actin ring formation in osteoclasts.	Univ Maryland, Sch Dent, Dept Biomed Sci, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Chellaiah, MA (corresponding author), Univ Maryland, Sch Dent, Dept Biomed Sci, Baltimore, MD 21201 USA.	mac001@dental.umaryland.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR046292] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01-AR46292] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aharonovitz O, 2000, J CELL BIOL, V150, P213, DOI 10.1083/jcb.150.1.213; Arbuzova A, 2000, BBA-BIOMEMBRANES, V1464, P35, DOI 10.1016/S0005-2736(99)00243-6; Aspenstrom P, 1996, CURR BIOL, V6, P70, DOI 10.1016/S0960-9822(02)00423-2; Benesch S, 2002, J BIOL CHEM, V277, P37771, DOI 10.1074/jbc.M204145200; Biswas RS, 2004, BMC CELL BIOL, V5, DOI 10.1186/1471-2121-5-19; BISWAS RS, 2003, J BONE MINER RES  S1, V18, P279; Burgess TL, 1999, J CELL BIOL, V145, P527, DOI 10.1083/jcb.145.3.527; Burns S, 2001, BLOOD, V98, P1142, DOI 10.1182/blood.V98.4.1142; Calle Y, 2004, BLOOD, V103, P3552, DOI 10.1182/blood-2003-04-1259; Carron CP, 2000, J ENDOCRINOL, V165, P587, DOI 10.1677/joe.0.1650587; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; Chellaiah M, 2000, J CELL BIOL, V148, P665, DOI 10.1083/jcb.148.4.665; Chellaiah M, 1996, MOL BIOL CELL, V7, P743, DOI 10.1091/mbc.7.5.743; Chellaiah M, 1998, J BIOL CHEM, V273, P11908, DOI 10.1074/jbc.273.19.11908; Chellaiah MA, 2000, J BIOL CHEM, V275, P11993, DOI 10.1074/jbc.275.16.11993; Chellaiah MA, 2001, J BIOL CHEM, V276, P47434, DOI 10.1074/jbc.M107494200; Chellaiah MA, 2003, J BIOL CHEM, V278, P29086, DOI 10.1074/jbc.M211074200; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; CHUANG TH, 1993, J BIOL CHEM, V268, P26206; Cooper JA, 2000, CURR OPIN CELL BIOL, V12, P97, DOI 10.1016/S0955-0674(99)00062-9; Cory GOC, 2003, MOL CELL, V11, P1229, DOI 10.1016/S1097-2765(03)00172-2; Cunningham CC, 2001, J BIOL CHEM, V276, P43390, DOI 10.1074/jbc.M105289200; Demeter J, 1998, J CELL BIOL, V143, P415, DOI 10.1083/jcb.143.2.415; Destaing O, 2003, MOL BIOL CELL, V14, P407, DOI 10.1091/mbc.E02-07-0389; DILLON ST, 1995, METHOD ENZYMOL, V256, P174; Duong LT, 2001, J BIOL CHEM, V276, P7484, DOI 10.1074/jbc.M008368200; Fukuoka M, 2001, J CELL BIOL, V152, P471, DOI 10.1083/jcb.152.3.471; Glogauer M, 2000, J CELL BIOL, V150, P785, DOI 10.1083/jcb.150.4.785; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; Higgs HN, 2000, J CELL BIOL, V150, P1311, DOI 10.1083/jcb.150.6.1311; Huang M, 1999, CURR BIOL, V9, P979, DOI 10.1016/S0960-9822(99)80428-X; Huang YA, 1999, MOL CELL BIOCHEM, V197, P195, DOI 10.1023/A:1006930706311; Hufner K, 2002, FEBS LETT, V514, P168, DOI 10.1016/S0014-5793(02)02358-X; Hurst IR, 2004, J BONE MINER RES, V19, P499, DOI 10.1359/JBMR.0301238; Insall RH, 2004, CELL, V118, P140, DOI 10.1016/j.cell.2004.07.005; JACKSON TR, 1992, J BIOL CHEM, V267, P16627; Janmey PA, 1998, CHEM BIOL, V5, pR81, DOI 10.1016/S1074-5521(98)90631-7; JANMEY PA, 1989, J BIOL CHEM, V264, P4825; Jones GE, 2002, INT J BIOCHEM CELL B, V34, P806, DOI 10.1016/S1357-2725(01)00162-5; Kim AS, 2000, NATURE, V404, P151, DOI 10.1038/35004513; Kurz T, 2004, J MOL CELL CARDIOL, V36, P225, DOI 10.1016/j.yjmcc.2003.11.008; Lakkakorpi PT, 2003, J BIOL CHEM, V278, P11502, DOI 10.1074/jbc.M206579200; Linder S, 2000, J IMMUNOL, V165, P221, DOI 10.4049/jimmunol.165.1.221; Linder S, 1999, P NATL ACAD SCI USA, V96, P9648, DOI 10.1073/pnas.96.17.9648; Ma L, 1998, P NATL ACAD SCI USA, V95, P15362, DOI 10.1073/pnas.95.26.15362; Machesky LM, 1999, P NATL ACAD SCI USA, V96, P3739, DOI 10.1073/pnas.96.7.3739; Machesky LM, 1999, CURR OPIN CELL BIOL, V11, P117, DOI 10.1016/S0955-0674(99)80014-3; McHugh KP, 2000, J CLIN INVEST, V105, P433, DOI 10.1172/JCI8905; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; Miyazaki T, 2004, J BIOL CHEM, V279, P17660, DOI 10.1074/jbc.M311032200; Moreau V, 2003, MOL CELL BIOL, V23, P6809, DOI 10.1128/MCB.23.19.6809-6822.2003; NAKAMURA I, 1995, FEBS LETT, V361, P79, DOI 10.1016/0014-5793(95)00153-Z; Nakamura I, 1996, J BONE MINER RES, V11, P1873; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Paris S, 1997, J BIOL CHEM, V272, P22221, DOI 10.1074/jbc.272.35.22221; Pelham RJ, 2002, NATURE, V419, P82, DOI 10.1038/nature00999; Peterson JR, 2004, NAT STRUCT MOL BIOL, V11, P747, DOI 10.1038/nsmb796; Pfaff M, 2001, J CELL SCI, V114, P2775; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Ren XD, 1996, MOL BIOL CELL, V7, P435, DOI 10.1091/mbc.7.3.435; Rohatgi R, 2000, J CELL BIOL, V150, P1299, DOI 10.1083/jcb.150.6.1299; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Rossman KL, 2003, J BIOL CHEM, V278, P18393, DOI 10.1074/jbc.M300127200; Rozelle AL, 2000, CURR BIOL, V10, P311, DOI 10.1016/S0960-9822(00)00384-5; Sanjay A, 2001, J CELL BIOL, V152, P181, DOI 10.1083/jcb.152.1.181; Sechi AS, 2000, J CELL SCI, V113, P3685; Takenawa T, 2001, J CELL SCI, V114, P1801; Takeshita S, 2002, NAT MED, V8, P943, DOI 10.1038/nm752; Violette SM, 2000, CHEM BIOL, V7, P225, DOI 10.1016/S1074-5521(00)00090-9; Vocero-Akbani A, 2001, METHOD ENZYMOL, V332, P36; Wang Q, 2003, J CELL BIOL, V160, P565, DOI 10.1083/jcb.200207036; Yamamoto M, 2001, J CELL BIOL, V152, P867, DOI 10.1083/jcb.152.5.867; Yonemura S, 2002, J CELL SCI, V115, P2569; ZHANG J, 1993, J BIOL CHEM, V268, P22251; Zhang Z, 2002, BONE, V31, P359, DOI 10.1016/S8756-3282(02)00834-7; Zigmond SH, 2000, J CELL BIOL, V150, pF117, DOI 10.1083/jcb.150.6.F117; Zigmond SH, 1997, J CELL BIOL, V138, P363, DOI 10.1083/jcb.138.2.363	77	53	54	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	2005	280	38					32930	32943		10.1074/jbc.M500154200	http://dx.doi.org/10.1074/jbc.M500154200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	964ZU	16006560	hybrid			2022-12-25	WOS:000231920300048
J	Jacob, C; Yang, PC; Darmoul, D; Amadesi, S; Saito, T; Cottrell, GS; Coelho, AM; Singh, P; Grady, EF; Perdue, M; Bunnett, NW				Jacob, C; Yang, PC; Darmoul, D; Amadesi, S; Saito, T; Cottrell, GS; Coelho, AM; Singh, P; Grady, EF; Perdue, M; Bunnett, NW			Mast cell tryptase controls paracellular permeability of the intestine - Role of protease-activated receptor 2 and beta-arrestins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL BARRIER FUNCTION; ACTIVATED RECEPTOR 2; TIGHT JUNCTION; DEPENDENT ENDOCYTOSIS; MOLECULAR-CLONING; INFLAMMATION; EXPRESSION; PROTEINASES; INHIBITORS; TRANSPORT	Tight junctions between intestinal epithelial cells prevent ingress of luminal macromolecules and bacteria and protect against inflammation and infection. During stress and inflammation, mast cells mediate increased mucosal permeability by unknown mechanisms. We hypothesized that mast cell tryptase cleaves protease-activated receptor 2 (PAR2) on colonocytes to increase paracellular permeability. Colonocytes expressed PAR(2) mRNA and responded to PAR(2) agonists with increased [Ca2+](i). Supernatant from degranulated mast cells increased [Ca2+](i) in colonocytes, which was prevented by a tryptase inhibitor, and desensitized responses to PAR2 agonist, suggesting PAR2 cleavage. When applied to the basolateral surface of colonocytes, PAR2 agonists and mast cell supernatant decreased transepithelial resistance, increased transepithelial flux of macromolecules, and induced redistribution of tight junction ZO-1 and occludin and perijunctional F-actin. When mast cells were co-cultured with colonocytes, mast cell degranulation increased paracellular permeability of colonocytes. This was prevented by a tryptase inhibitor. We determined the role of ERK1/2 and of beta-arrestins, which recruit ERK1/2 to PAR2 in endosomes and retain ERK1/2 in the cytosol, on PAR2-mediated alterations in permeability. An ERK1/2 inhibitor abolished the effects of PAR2 agonist on permeability and redistribution of F-actin. Downregulation of beta-arrestins with small interfering RNA inhibited PAR2-induced activation of ERK1/2 and suppressed PAR2-induced changes in permeability. Thus, mast cells signal to colonocytes in a paracrine manner by release of tryptase and activation of PAR2. PAR2 couples to beta-arrestin-dependent activation of ERK1/2, which regulates reorganization of perijunctional F-actin to increase epithelial permeability. These mechanisms may explain the increased epithelial permeability of the intestine during stress and inflammation.	Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; McMaster Univ, Intestinal Dis Res Program, Hamilton, ON L8S 4L8, Canada	University of California System; University of California San Francisco; University of California System; University of California San Francisco; McMaster University	Bunnett, NW (corresponding author), Univ Calif San Francisco, Dept Surg, 521 Parnassus Ave, San Francisco, CA 94143 USA.	nigelb@itsa.ucsf.edu	Darmoul, Dalila/M-5812-2018; Yang, Ping-Chang/K-4669-2019; Jacob, Claire/C-1485-2012	Darmoul, Dalila/0000-0002-1206-0655; Jacob, Claire/0000-0001-9567-3950; Bunnett, Nigel W./0000-0003-3367-0644; Cottrell, Graeme/0000-0001-9098-7627	NIDDK NIH HHS [DK39957, DK43207, DK57840, DK52388] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039957, R01DK052388, R56DK043207, R37DK039957, R01DK057840, R01DK043207] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Berin MC, 1999, AM J PHYSIOL-CELL PH, V276, pC1046, DOI 10.1152/ajpcell.1999.276.5.C1046; Bohm SK, 1996, J BIOL CHEM, V271, P22003; Bohm SK, 1996, BIOCHEM J, V314, P1009; Bruewer M, 2003, J IMMUNOL, V171, P6164, DOI 10.4049/jimmunol.171.11.6164; Bustos D, 1998, MEDICINA-BUENOS AIRE, V58, P262; BUTTERFIELD JH, 1990, J LEUKOCYTE BIOL, V47, P409, DOI 10.1002/jlb.47.5.409; Camerer E, 2000, P NATL ACAD SCI USA, V97, P5255, DOI 10.1073/pnas.97.10.5255; CAUGHEY GH, 1993, J PHARMACOL EXP THER, V264, P676; Cenac N, 2004, J PHYSIOL-LONDON, V558, P913, DOI 10.1113/jphysiol.2004.061721; Cenac N, 2003, J IMMUNOL, V170, P4296, DOI 10.4049/jimmunol.170.8.4296; Cenac N, 2002, AM J PATHOL, V161, P1903, DOI 10.1016/S0002-9440(10)64466-5; Chen ML, 2002, J BIOL CHEM, V277, P4247, DOI 10.1074/jbc.M109254200; Chin AC, 2003, P NATL ACAD SCI USA, V100, P11104, DOI 10.1073/pnas.1831452100; Corvera CU, 1999, J PHYSIOL-LONDON, V517, P741, DOI 10.1111/j.1469-7793.1999.0741s.x; Corvera CU, 1997, J CLIN INVEST, V100, P1383, DOI 10.1172/JCI119658; Costanzo MJ, 2003, J MED CHEM, V46, P3865, DOI 10.1021/jm030050p; Cottrell GS, 2004, J BIOL CHEM, V279, P13532, DOI 10.1074/jbc.M312090200; Cuffe JE, 2002, J PHYSIOL-LONDON, V539, P209, DOI 10.1113/jphysiol.2001.013159; Darmoul D, 2004, J BIOL CHEM, V279, P20927, DOI 10.1074/jbc.M401430200; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; Dery O, 1999, J BIOL CHEM, V274, P18524, DOI 10.1074/jbc.274.26.18524; Ge L, 2003, J BIOL CHEM, V278, P34418, DOI 10.1074/jbc.M300573200; Green BT, 2000, J PHARMACOL EXP THER, V295, P410; Kjeldsen J, 1998, SCAND J GASTROENTERO, V33, P637, DOI 10.1080/00365529850171927; Kong WY, 1997, P NATL ACAD SCI USA, V94, P8884, DOI 10.1073/pnas.94.16.8884; Ma TY, 2004, AM J PHYSIOL-GASTR L, V286, pG367, DOI 10.1152/ajpgi.00173.2003; MAY GR, 1993, GASTROENTEROLOGY, V104, P1627, DOI 10.1016/0016-5085(93)90638-S; McDermott JR, 2003, P NATL ACAD SCI USA, V100, P7761, DOI 10.1073/pnas.1231488100; Miller HRP, 2002, IMMUNOLOGY, V105, P375, DOI 10.1046/j.1365-2567.2002.01375.x; Molino M, 1997, J BIOL CHEM, V272, P4043, DOI 10.1074/jbc.272.7.4043; Moyer MP, 1996, IN VITRO CELL DEV-AN, V32, P315; Mule F, 2004, GUT, V53, P229, DOI 10.1136/gut.2003.021899; Nguyen C, 2003, CAN J PHYSIOL PHARM, V81, P920, DOI 10.1139/Y03-080; NYSTEDT S, 1994, P NATL ACAD SCI USA, V91, P9208, DOI 10.1073/pnas.91.20.9208; Ossovskaya VS, 2004, PHYSIOL REV, V84, P579, DOI 10.1152/physrev.00028.2003; PLAYFORD RJ, 1995, AM J PATHOL, V146, P310; Santos J, 1999, GUT, V45, P553, DOI 10.1136/gut.45.4.553; Santos J, 2001, GUT, V48, P630, DOI 10.1136/gut.48.5.630; Schmitz H, 1999, GASTROENTEROLOGY, V116, P301, DOI 10.1016/S0016-5085(99)70126-5; Schneeberger EE, 2004, AM J PHYSIOL-CELL PH, V286, pC1213, DOI 10.1152/ajpcell.00558.2003; SCUDAMORE CL, 1995, J EXP MED, V182, P1871, DOI 10.1084/jem.182.6.1871; Soderholm JD, 2002, GASTROENTEROLOGY, V123, P1099, DOI 10.1053/gast.2002.36019; Steinhoff M, 2000, NAT MED, V6, P151, DOI 10.1038/72247; Tarlton JF, 2000, AM J PATHOL, V157, P1927, DOI 10.1016/S0002-9440(10)64831-6; Vergnolle N, 1998, P NATL ACAD SCI USA, V95, P7766, DOI 10.1073/pnas.95.13.7766; Wang Y, 2004, EXP EYE RES, V78, P125, DOI 10.1016/j.exer.2003.09.002; Yang PC, 1999, J IMMUNOL, V163, P2769; Youakim A, 1999, AM J PHYSIOL-GASTR L, V276, pG1279, DOI 10.1152/ajpgi.1999.276.5.G1279	48	244	256	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	2005	280	36					31936	31948		10.1074/jbc.M506338200	http://dx.doi.org/10.1074/jbc.M506338200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	961LZ	16027150	hybrid			2022-12-25	WOS:000231665200073
J	Murakami, T; Takagi, H; Suzuma, K; Suzuma, I; Ohashi, H; Watanabe, D; Ojima, T; Suganami, E; Kurimoto, M; Kaneto, H; Honda, Y; Yoshimura, N				Murakami, T; Takagi, H; Suzuma, K; Suzuma, I; Ohashi, H; Watanabe, D; Ojima, T; Suganami, E; Kurimoto, M; Kaneto, H; Honda, Y; Yoshimura, N			Angiopoietin-1 attenuates H2O2-induced SEK1/JNK phosphorylation through the phosphatidylinositol 3-kinase/Akt pathway in vascular endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; N-TERMINAL KINASE; OXIDATIVE STRESS; INDUCED APOPTOSIS; DIABETIC-RETINOPATHY; BLOOD-VESSELS; TIE2 RECEPTOR; GROWTH-FACTOR; SURVIVAL; JNK	Oxidative stress activates various signal transduction pathways, including Jun N-terminal kinase ( JNK) and its substrates, that induce apoptosis. We reported here the role of angiopoietin-1 ( Ang1), which is a prosurvival factor in endothelial cells, during endothelial cell damage induced by oxidative stress. Hydrogen peroxide ( H2O2) increased apoptosis of endothelial cells through JNK activation, whereas Ang1 inhibited H2O2-induced apoptosis and concomitant JNK phosphorylation. The inhibition of H2O2-induced JNK phosphorylation was reversed by inhibitors of phosphatidylinositol ( PI) 3-kinase and dominant-negative Akt, and constitutively active-Akt attenuated JNK phosphorylation without Ang1. These data suggested that Ang1-dependent Akt phosphorylation through PI 3-kinase leads to the inhibition of JNK phosphorylation. H2O2-induced phosphorylation of SAPK/Erk kinase ( SEK1) at Thr(261), which is an upstream regulator of JNK, was also attenuated by Ang1-dependent activation of the PI 3-kinase/Akt pathway. In addition, Ang1 induced SEK1 phosphorylation at Ser(80), suggesting the existence of an additional signal transduction pathway through which Ang1 attenuates JNK phosphorylation. These results demonstrated that Ang1 attenuates H2O2-induced SEK1/JNK phosphorylation through the PI 3-kinase/Akt pathway and inhibits the apoptosis of endothelial cells to oxidative stress.	Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, Kyoto 6068507, Japan; Osaka Univ, Grad Sch Med, Dept Internal Med & Therapeut, Suita, Osaka 5650871, Japan	Kyoto University; Osaka University	Takagi, H (corresponding author), Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, 54 Shogoin Kawaharacho, Kyoto 6068507, Japan.	hitoshi@kuhp.kyoto-u.ac.jp		Murakami, Tomoaki/0000-0002-0314-8807				Audero E, 2004, J BIOL CHEM, V279, P13224, DOI 10.1074/jbc.M307456200; Barthwal MK, 2003, J BIOL CHEM, V278, P3897, DOI 10.1074/jbc.M211598200; Cuda G, 2002, CIRCULATION, V105, P968, DOI 10.1161/hc0802.104324; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; Dumont A, 1999, ONCOGENE, V18, P747, DOI 10.1038/sj.onc.1202325; DUMONT DJ, 1992, ONCOGENE, V7, P1471; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; Hammes HP, 2004, DIABETES, V53, P1104, DOI 10.2337/diabetes.53.4.1104; Harfouche R, 2003, FASEB J, V17, P1523, DOI 10.1096/fj.02-0698fje; Hirosumi J, 2002, NATURE, V420, P333, DOI 10.1038/nature01137; Hojo Y, 2002, CIRC RES, V91, P712, DOI 10.1161/01.RES.0000037981.97541.25; Inoshita S, 2002, J BIOL CHEM, V277, P43730, DOI 10.1074/jbc.M207951200; Jones N, 1999, J BIOL CHEM, V274, P30896, DOI 10.1074/jbc.274.43.30896; Joussen AM, 2002, AM J PATHOL, V160, P1683, DOI 10.1016/S0002-9440(10)61115-7; Kaneto H, 2002, J BIOL CHEM, V277, P3680, DOI 10.1074/jbc.M109647200; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; Kim AH, 2002, NEURON, V35, P697, DOI 10.1016/S0896-6273(02)00821-8; Kim I, 2000, CIRC RES, V86, P952, DOI 10.1161/01.RES.86.9.952; Kim I, 2000, CIRC RES, V86, P24, DOI 10.1161/01.RES.86.1.24; KING GL, 1985, J CLIN INVEST, V75, P1028, DOI 10.1172/JCI111764; Kishore R, 2003, CIRC RES, V93, P932, DOI 10.1161/01.RES.0000102400.22370.20; Kwak HJ, 1999, FEBS LETT, V448, P249, DOI 10.1016/S0014-5793(99)00378-6; Kwak HJ, 2000, CIRCULATION, V101, P2317, DOI 10.1161/01.CIR.101.19.2317; KYRIAKIS JM, 1990, J BIOL CHEM, V265, P17355; Lee SW, 2003, NAT MED, V9, P900, DOI 10.1038/nm889; Lee YH, 2003, J BIOL CHEM, V278, P2896, DOI 10.1074/jbc.M208359200; Lyon CJ, 2003, ENDOCRINOLOGY, V144, P2195, DOI 10.1210/en.2003-0285; Master Z, 2001, EMBO J, V20, P5919, DOI 10.1093/emboj/20.21.5919; Minamino T, 1999, P NATL ACAD SCI USA, V96, P15127, DOI 10.1073/pnas.96.26.15127; Morse D, 2003, J BIOL CHEM, V278, P36993, DOI 10.1074/jbc.M302942200; Nambu H, 2004, GENE THER, V11, P865, DOI 10.1038/sj.gt.3302230; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; Ohashi H, 2004, MOL VIS, V10, P608; Park HS, 2002, J BIOL CHEM, V277, P2573, DOI 10.1074/jbc.M110299200; Sudoh N, 2001, CIRCULATION, V103, P724; Suzuma K, 2000, J BIOL CHEM, V275, P40725, DOI 10.1074/jbc.M006509200; Tadros A, 2003, BLOOD, V102, P4407, DOI 10.1182/blood-2003-05-1602; Thurston G, 2003, CELL TISSUE RES, V314, P61, DOI 10.1007/s00441-003-0749-6; Thurston G, 1999, SCIENCE, V286, P2511, DOI 10.1126/science.286.5449.2511; Uemura A, 2002, J CLIN INVEST, V110, P1619, DOI 10.1172/JCI200215621; Ushio-Fukai M, 2002, CIRC RES, V91, P1160, DOI 10.1161/01.RES.0000046227.65158.F8; Wang NP, 1999, CIRC RES, V85, P387, DOI 10.1161/01.RES.85.5.387; YAN MH, 1994, NATURE, V372, P798; Yoshizumi M, 2004, EXP CELL RES, V292, P1, DOI 10.1016/j.yexcr.2003.08.003	44	29	33	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	2005	280	36					31841	31849		10.1074/jbc.M503108200	http://dx.doi.org/10.1074/jbc.M503108200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	961LZ	16000309	hybrid, Green Submitted			2022-12-25	WOS:000231665200063
J	Nagano, S; Poulos, TL				Nagano, S; Poulos, TL			Crystallographic study on the dioxygen complex of wild-type and mutant cytochrome P450cam - Implications for the dioxygen activation mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-PUTIDA CYTOCHROME-P-450; CRYSTAL-STRUCTURE; AMINO-ACID; OXYGEN ACTIVATION; HYDROXYLATION; MUTAGENESIS; SEQUENCE; MUTATION; ENDOR; EPR	Two key amino acids, Thr(252) and Asp(251), are known to be important for dioxygen activation by cytochrome P450cam. We have solved crystal structures of a critical intermediate, the ferrous dioxygen complex (Fe(II)-O-2), of the wild-type P450cam and its mutants, D251N and T252A. The wild-type dioxygen complex structure is very much the same as reported previously (Schlichting, I., Berendzen, J., Chu, K., Stock, A. M., Maves, S. A., Benson, D. E., Sweet, R. M., Ringe, D., Petsko, G. A., and Sligar, S. G. ( 2000) Science 287, 1615 - 1622) with the exception of higher occupancy and a more ordered structure of the iron-linked dioxygen and two "catalytic" water molecules that form part of a proton relay system to the iron-linked dioxygen. Due to of the altered conformation of the I helix groove these two waters are missing in the D251N dioxygen complex which explains its lower catalytic activity and slower proton transfer to the dioxygen ligand. Similarly, the T252A mutation was expected to disrupt the active site solvent structure leading to hydrogen peroxide formation rather than substrate hydroxylation. Unexpectedly, however, the two "catalytic" waters are retained in the T252A mutant. Based on these findings, we propose that the Thr252 accepts a hydrogen bond from the hydroperoxy (Fe(III)-OOH) intermediate that promotes the second protonation on the distal oxygen atom, leading to O-O bond cleavage and compound I formation.	Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Chem, Irvine, CA 92697 USA; Univ Calif Irvine, Ctr Chem & Struct Biol, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine	Nagano, S (corresponding author), RIKEN, Harima Inst SPring 8, 1-1-1 Koto, Sayo, Hyogo 6795148, Japan.	snagano@riken.jp; poulos@uci.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033688] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM33688] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Davydov R, 1999, J AM CHEM SOC, V121, P10654, DOI 10.1021/ja9918829; Davydov R, 2001, J AM CHEM SOC, V123, P1403, DOI 10.1021/ja003583l; de Montellano PR Ortiz, 1995, CYTOCHROME P450 STRU; GERBER NC, 1994, J BIOL CHEM, V269, P4260; GERBER NC, 1992, J AM CHEM SOC, V114, P8742, DOI 10.1021/ja00048a081; Gunsalus I C, 1978, Methods Enzymol, V52, P166; HANIU M, 1982, J BIOL CHEM, V257, P2664; HARRIS D, 1993, J AM CHEM SOC, V115, P8775, DOI 10.1021/ja00072a034; IMAI M, 1989, P NATL ACAD SCI USA, V86, P7823, DOI 10.1073/pnas.86.20.7823; INGRAHAM LL, 1985, BIOCH DIOXYGEN; ISHIMURA Y, 1971, BIOCHEM BIOPH RES CO, V42, P140, DOI 10.1016/0006-291X(71)90373-1; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KATAGIRI M, 1968, J BIOL CHEM, V243, P3543; KIMATA Y, 1995, BIOCHEM BIOPH RES CO, V208, P96, DOI 10.1006/bbrc.1995.1310; MARTINIS SA, 1989, J AM CHEM SOC, V111, P9252, DOI 10.1021/ja00208a031; Nagano S, 2005, J BIOL CHEM, V280, P22102, DOI 10.1074/jbc.M501732200; Nagano S, 2004, J BIOL CHEM, V279, P42844, DOI 10.1074/jbc.M404217200; OMURA T, 1962, J BIOL CHEM, V237, P1375; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; POULOS TL, 1985, J BIOL CHEM, V260, P6122; RAAG R, 1991, BIOCHEMISTRY-US, V30, P11420, DOI 10.1021/bi00112a008; Read RJ, 2001, ACTA CRYSTALLOGR D, V57, P1373, DOI 10.1107/S0907444901012471; Schlichting I, 2000, SCIENCE, V287, P1615, DOI 10.1126/science.287.5458.1615; SHIMADA H, 1991, INT S OXYGENASES OXY, P133; UNGER BP, 1986, J BIOL CHEM, V261, P1158; Vidakovic M, 1998, BIOCHEMISTRY-US, V37, P9211, DOI 10.1021/bi980189f	26	176	177	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	2005	280	36					31659	31663		10.1074/jbc.M505261200	http://dx.doi.org/10.1074/jbc.M505261200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	961LZ	15994329	hybrid			2022-12-25	WOS:000231665200041
J	Van Le, H; Minn, AJ; Massague, J				Van Le, H; Minn, AJ; Massague, J			Cyclin-dependent kinase inhibitors uncouple cell cycle progression from mitochondrial apoptotic functions in DNA-damaged cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLORECTAL-CANCER; MITOTIC CATASTROPHE; POTENTIAL MEDIATOR; CYTOCHROME-C; TUMOR-CELLS; S-PHASE; P53; PUMA; GENE; P21	DNA damage results in transcriptional induction of p53 target genes, including the cyclin-dependent kinase (CDK) inhibitor p21(Cip1) (CDKN1A) and the proapoptotic Bcl-2 family member p53 up-regulated modulator of apoptosis (PUMA). Depending on the cellular context, p21Cip1 and PUMA mediate cell cycle arrest and apoptosis, respectively. By imposing cell cycle arrest at the expense of apoptosis, p21Cip1 can sharply reduce the effectiveness of DNA-damaging anticancer agents in colorectal cancer cells. We investigated the link between cell cycle progression and the onset of apoptosis in DNA-damaged cells by analyzing the activation of the apoptotic cascade in p21(Cip1)-deficient HCT116 colorectal cancer cells. DNA damage induced a similar level of p53 activation and PUMA induction in p21(Cip1)-deficient cells compared with wild-type isogenic counterparts. p21Cip1 did not act as a direct blocker of PUMA. However, only p21(Cip1)-deficient cells showed extensive cytochrome c release, mitochondrial membrane depolarization, and caspase activation. An increase in caspase activation occurred as these cells reached M-phase and incurred polyploidy. When ectopically expressed in p21(Cip1)-deficient HCT116 cells, p21Cip1, its family member p27(Kip1), and the structurally unrelated CDK inhibitor p16(Ink4a) were similarly effective at causing cell cycle arrest and inhibiting DNA damage-induced apoptotic events such as cytochrome c release, mitochondrial membrane depolarization, and activation of the caspase cascade. These observations suggest that by blocking dysregulated cell cycle progression, CDK inhibitors can influence the sensitivity of the mitochondria to proapoptotic signals in DNA damage-induced cancer cells.	Mem Sloan Kettering Canc Ctr, Canc Biol & Genet Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Massague, J (corresponding author), Mem Sloan Kettering Canc Ctr, Canc Biol & Genet Program, 1275 York Ave,Box 116, New York, NY 10021 USA.	j-massague@mskcc.org		Minn, Andy/0000-0003-1418-0906; Massague, Joan/0000-0001-9324-8408				Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Brown M, 2003, CANCER BIOL THER, V2, P477, DOI 10.4161/cbt.2.5.450; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Castedo Maria, 2004, Journal de la Societe de Biologie, V198, P97; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Conklin Kenneth A, 2004, Integr Cancer Ther, V3, P294, DOI 10.1177/1534735404270335; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Fang M, 2000, ANTICANCER RES, V20, P103; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P21429, DOI 10.1074/jbc.270.37.21429; Gartel AL, 2002, MOL CANCER THER, V1, P639; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; Han JW, 2001, P NATL ACAD SCI USA, V98, P11318, DOI 10.1073/pnas.201208798; Hernando E, 2004, NATURE, V430, P797, DOI 10.1038/nature02820; Jayaraman S, 2003, CYTOM PART A, V56A, P104, DOI 10.1002/cyto.a.10094; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Lu YJ, 2000, MOL CARCINOGEN, V29, P1; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Nahle Z, 2002, NAT CELL BIOL, V4, P859, DOI 10.1038/ncb868; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Pediconi N, 2003, NAT CELL BIOL, V5, P552, DOI 10.1038/ncb998; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Prabhu NS, 1999, INT J ONCOL, V15, P209; Rajagopalan H, 2003, NAT REV CANCER, V3, P695, DOI 10.1038/nrc1165; Ricci JE, 2004, CELL, V117, P773, DOI 10.1016/j.cell.2004.05.008; Roninson IB, 2001, DRUG RESIST UPDATE, V4, P303, DOI 10.1054/drup.2001.0213; Rupnarain C, 2004, BIOL CHEM, V385, P449, DOI 10.1515/BC.2004.053; Sahara S, 1999, NATURE, V401, P168, DOI 10.1038/43678; Schmidt M, 2001, ONCOGENE, V20, P6164, DOI 10.1038/sj.onc.1204814; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Shao RG, 1997, CANCER RES, V57, P4029; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Stanelle J, 2002, NUCLEIC ACIDS RES, V30, P1859, DOI 10.1093/nar/30.8.1859; Suzuki A, 1998, ONCOGENE, V17, P931, DOI 10.1038/sj.onc.1202021; Tetsu O, 2003, CANCER CELL, V3, P233, DOI 10.1016/S1535-6108(03)00053-9; Tse AN, 2004, CANCER RES, V64, P6635, DOI 10.1158/0008-5472.CAN-04-0841; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Vogel C, 2005, J BIOL CHEM, V280, P4025, DOI 10.1074/jbc.C400545200; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Waldman T, 1997, NAT MED, V3, P1034, DOI 10.1038/nm0997-1034; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang XD, 2001, GENE DEV, V15, P2922; Waterhouse NJ, 2003, CELL DEATH DIFFER, V10, P853, DOI 10.1038/sj.cdd.4401263; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100	53	30	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	2005	280	36					32018	32025		10.1074/jbc.M504689200	http://dx.doi.org/10.1074/jbc.M504689200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	961LZ	16002406	hybrid			2022-12-25	WOS:000231665200082
J	Dittmann, K; Mayer, C; Fehrenbacher, B; Schaller, M; Raju, U; Milas, L; Chen, DJ; Kehlbach, R; Rodemann, HP				Dittmann, K; Mayer, C; Fehrenbacher, B; Schaller, M; Raju, U; Milas, L; Chen, DJ; Kehlbach, R; Rodemann, HP			Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAKS; LIGAND-INDEPENDENT ACTIVATION; IN-VIVO; CATALYTIC SUBUNIT; EGF RECEPTOR; ATAXIA-TELANGIECTASIA; IONIZING-RADIATION; TYROSINE KINASE; CELLS; PHOSPHORYLATION	Ionizing radiation, but not stimulation with epidermal growth factor (EGF), triggers EGF receptor ( EGFR) import into the nucleus in a probably karyopherin alpha-linked manner. An increase in nuclear EGFR is also observed after treatment with H2O2, heat, or cisplatin. During this process, the proteins Ku70/80 and the protein phosphatase 1 are transported into the nucleus. As a consequence, an increase in the nuclear kinase activity of DNA-dependent kinase (DNA-PK) and increased formation of the DNA end-binding protein complexes containing DNA-PK, essential for repair of DNA-strand breaks, occurred. Blockade of EGFR import by the anti-EGFR monoclonal antibody C225 abolished EGFR import into the nucleus and radiation-induced activation of DNA-PK, inhibited DNA repair, and increased radiosensitivity of treated cells. Our data implicate a novel function of the EGFR during DNA repair processes.	Univ Tubingen, Dept Radiat Oncol, Div Radiobiol & Mol Environm Res, D-72076 Tubingen, Germany; Univ Tubingen, Dept Dermatol, D-72076 Tubingen, Germany; Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA; Utah SW Med Ctr, Dept Radiat Oncol, Div Mol Radiat Biol, Dallas, TX 75390 USA; Univ Tubingen, Dept Radiol, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; University of Texas System; UTMD Anderson Cancer Center; Eberhard Karls University of Tubingen	Dittmann, K (corresponding author), Univ Tubingen, Dept Radiat Oncol, Div Radiobiol & Mol Environm Res, Rontgenweg 11, D-72076 Tubingen, Germany.	klaus.dittmann@uni-tuebingen.de			NCI NIH HHS [CA16672, CA06294] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA006294, P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Apte UM, 2002, TOXICOL SCI, V69, P448, DOI 10.1093/toxsci/69.2.448; Bandyopadhyay D, 1998, J BIOL CHEM, V273, P1568, DOI 10.1074/jbc.273.3.1568; Baselga J, 2002, ONCOLOGIST, V7, P2; Boerner JL, 2003, EXP CELL RES, V284, P111, DOI 10.1016/S0014-4827(02)00096-4; Burma S, 2001, J BIOL CHEM, V276, P42462, DOI 10.1074/jbc.C100466200; Chan DW, 2002, GENE DEV, V16, P2333, DOI 10.1101/gad.1015202; Chen BPC, 2005, J BIOL CHEM, V280, P14709, DOI 10.1074/jbc.M408827200; Chen X, 2002, J BIOL CHEM, V277, P49631, DOI 10.1074/jbc.M208327200; Citri A, 2003, EXP CELL RES, V284, P54, DOI 10.1016/S0014-4827(02)00101-5; DahmDaphi J, 1996, INT J RADIAT BIOL, V69, P615, DOI 10.1080/095530096145625; DeFazio LG, 2002, EMBO J, V21, P3192, DOI 10.1093/emboj/cdf299; Ding Q, 2003, MOL CELL BIOL, V23, P5836, DOI 10.1128/MCB.23.16.5836-5848.2003; Dittmann KH, 1998, RADIAT RES, V150, P648, DOI 10.2307/3579887; Douglas P, 2002, BIOCHEM J, V368, P243, DOI 10.1042/BJ20020973; Douglas P, 2001, J BIOL CHEM, V276, P18992, DOI 10.1074/jbc.M011703200; Gatei M, 2001, J BIOL CHEM, V276, P17276, DOI 10.1074/jbc.M011681200; Goldstein NI, 1995, CLIN CANCER RES, V1, P1311; Gu YS, 1997, P NATL ACAD SCI USA, V94, P8076, DOI 10.1073/pnas.94.15.8076; Gueven N, 2001, J BIOL CHEM, V276, P8884, DOI 10.1074/jbc.M006190200; Gupta AK, 2002, CLIN CANCER RES, V8, P885; Harari PM, 2001, SEMIN RADIAT ONCOL, V11, P281, DOI 10.1053/srao.2001.26027; Herrlich A, 1998, P NATL ACAD SCI USA, V95, P8985, DOI 10.1073/pnas.95.15.8985; Huang SM, 1999, CANCER RES, V59, P1935; Karmakar P, 2002, J BIOL CHEM, V277, P18291, DOI 10.1074/jbc.M111523200; KHAZAIE K, 1993, CANCER METAST REV, V12, P255, DOI 10.1007/BF00665957; Kimura T, 2004, J CELL SCI, V117, P2259, DOI 10.1242/jcs.01076; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; Komurasaki T, 2002, GROWTH FACTORS, V20, P61, DOI 10.1080/08977190290024192; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; Leuther KK, 1999, EMBO J, V18, P1114, DOI 10.1093/emboj/18.5.1114; Lin SY, 2001, NAT CELL BIOL, V3, P802, DOI 10.1038/ncb0901-802; Maggiorella L, 2003, CANCER RES, V63, P2513; Manna SK, 2000, ONCOGENE, V19, P2110, DOI 10.1038/sj.onc.1203547; Mendelsohn J, 2003, J CLIN ONCOL, V21, P2787, DOI 10.1200/JCO.2003.01.504; Milas L, 2003, HEAD NECK-J SCI SPEC, V25, P152, DOI 10.1002/hed.10232; Milas L, 2000, CLIN CANCER RES, V6, P701; Miyamoto Y, 2004, J CELL BIOL, V165, P617, DOI 10.1083/jcb.200312008; Mosammaparast N, 2004, TRENDS CELL BIOL, V14, P547, DOI 10.1016/j.tcb.2004.09.004; Oksvold M, 2002, NAT CELL BIOL, V4, pE22, DOI 10.1038/ncb0202-e22a; Peus D, 2000, PHOTOCHEM PHOTOBIOL, V72, P135, DOI 10.1562/0031-8655(2000)072<0135:UIEGFR>2.0.CO;2; Prewett M, 1996, J IMMUNOTHER, V19, P419, DOI 10.1097/00002371-199611000-00006; Ritter CA, 2003, SEMIN ONCOL, V30, P3, DOI 10.1053/sonc.2003.50027; Rothkamm K, 2003, P NATL ACAD SCI USA, V100, P5057, DOI 10.1073/pnas.0830918100; Rothkamm K, 2001, CANCER RES, V61, P3886; Shao RG, 1999, EMBO J, V18, P1397, DOI 10.1093/emboj/18.5.1397; Simeonova PP, 2002, J BIOL CHEM, V277, P2945, DOI 10.1074/jbc.M109136200; Soubeyrand S, 2003, CANCER RES, V63, P1198; Williams CC, 2004, J CELL BIOL, V167, P469, DOI 10.1083/jcb.200403155	48	426	457	3	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	2005	280	35					31182	31189		10.1074/jbc.M506591200	http://dx.doi.org/10.1074/jbc.M506591200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	958ZX	16000298	hybrid			2022-12-25	WOS:000231487800065
J	Milakovic, T; Johnson, GVW				Milakovic, T; Johnson, GVW			Mitochondrial respiration and ATP production are significantly impaired in striatal cells expressing mutant Huntingtin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; KNOCK-IN MICE; 3-NITROPROPIONIC ACID; OXIDATIVE-PHOSPHORYLATION; SUCCINATE-DEHYDROGENASE; BRAIN MITOCHONDRIA; TRANSGENIC MOUSE; DISEASE; TRANSPORT; MUTATION	There is significant evidence that energy production impairment and mitochondrial dysfunction play a role in the pathogenesis of Huntington disease. Nonetheless, the specific mitochondrial defects due to the presence of mutant huntingtin have not been fully elucidated. To determine the effects of mutant huntingtin on mitochondrial energy production, a thorough analysis of respiration, ATP production, and functioning of the respiratory complexes was carried out in clonal striatal cells established from Hdh(Q7) (wild-type) and Hdh(Q111) (mutant huntingtin knock-in) mouse embryos. Mitochondrial respiration and ATP production were significantly reduced in the mutant striatal cells compared with the wild-type cells when either glutamate/malate or succinate was used as the substrate. However, mitochondrial respiration was similar in the two cell lines when the artificial electron donor TMPD/ascorbate, which feeds into complex IV, was used as the substrate. The attenuation of mitochondrial respiration and ATP production when either glutamate/malate or succinate was used as the substrate was not due to impairment of the respiratory complexes, because their activities were equivalent in both cell lines. Intriguingly, in the striatum of presymptomatic and pathological grade 1 Huntington disease cases there is also no impairment of mitochondrial complexes I-IV (Guidetti, P., Charles, V., Chen, E. Y., Reddy, P. H., Kordower, J. H., Whetsell, W. O., Jr., Schwarcz, R., and Tagle, D. A. (2001) Exp. Neurol. 169, 340-350). To our knowledge, this is the first comprehensive analysis of the effects of physiological levels of mutant huntingtin on mitochondrial respiratory function within an appropriate cellular context. These findings demonstrate that the presence of mutant huntingtin impairs mitochondrial ATP production through one or more mechanisms that do not directly affect the function of the respiration complexes.	Univ Alabama, Dept Psychiat, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Johnson, GVW (corresponding author), Univ Alabama, Dept Psychiat, 1720 7th Ave S,SC1061, Birmingham, AL 35294 USA.	gvwj@uab.edu	Johnson, Gail V.W./K-4723-2012	Johnson, Gail V.W./0000-0003-3464-0404	NINDS NIH HHS [NS41744] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041744] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ardehali H, 2004, P NATL ACAD SCI USA, V101, P11880, DOI 10.1073/pnas.0401703101; BEAL MF, 1993, J NEUROSCI, V13, P4181; Bogdanov MB, 1998, J NEUROCHEM, V71, P2642; BROUILLET E, 1995, P NATL ACAD SCI USA, V92, P7105, DOI 10.1073/pnas.92.15.7105; Browne SE, 1997, ANN NEUROL, V41, P646, DOI 10.1002/ana.410410514; Browne SE, 2004, NEUROCHEM RES, V29, P531, DOI 10.1023/B:NERE.0000014824.04728.dd; CHRETIEN D, 1990, BIOCHEM BIOPH RES CO, V173, P26, DOI 10.1016/S0006-291X(05)81016-2; COLBEAU A, 1971, BIOCHIM BIOPHYS ACTA, V249, P462, DOI 10.1016/0005-2736(71)90123-4; COLES CJ, 1979, J BIOL CHEM, V254, P5161; DARLEYUSMAR VM, 1987, MITOCHONDRIA PRACTIC, P113; Davey GP, 1998, J BIOL CHEM, V273, P12753, DOI 10.1074/jbc.273.21.12753; Davey GP, 1997, J NEUROCHEM, V69, P2564; Davey GP, 1996, J NEUROCHEM, V66, P1617; DUBINSKY WP, 1975, FEBS LETT, V59, P39, DOI 10.1016/0014-5793(75)80336-X; Feigin A, 2001, J NUCL MED, V42, P1591; FISKUM G, 1980, P NATL ACAD SCI-BIOL, V77, P3430, DOI 10.1073/pnas.77.6.3430; Gines S, 2003, HUM MOL GENET, V12, P497, DOI 10.1093/hmg/ddg046; GRANGER DL, 1982, J CELL BIOL, V95, P527, DOI 10.1083/jcb.95.2.527; Gu M, 1996, ANN NEUROL, V39, P385, DOI 10.1002/ana.410390317; Guidetti P, 2001, EXP NEUROL, V169, P340, DOI 10.1006/exnr.2000.7626; Hansson O, 2001, J NEUROCHEM, V78, P694, DOI 10.1046/j.1471-4159.2001.00482.x; HARRIS SI, 1981, J BIOL CHEM, V256, P319; Hatefi Y, 1978, Methods Enzymol, V53, P21; Helmerhorst EJ, 2002, BBA-BIOENERGETICS, V1556, P73, DOI 10.1016/S0005-2728(02)00308-0; Hickey MA, 2000, J NEUROCHEM, V75, P2163, DOI 10.1046/j.1471-4159.2000.0752163.x; Higgins DS, 1999, ANN NY ACAD SCI, V893, P298, DOI 10.1111/j.1749-6632.1999.tb07841.x; Hofhaus G, 1996, Methods Enzymol, V264, P476, DOI 10.1016/S0076-6879(96)64043-9; Holmuhamedov EL, 1999, J PHYSIOL-LONDON, V519, P347, DOI 10.1111/j.1469-7793.1999.0347m.x; JENKINS BG, 1993, NEUROLOGY, V43, P2689, DOI 10.1212/WNL.43.12.2689; Kuhl D E, 1985, Res Publ Assoc Res Nerv Ment Dis, V63, P199; KUHL DE, 1982, ANN NEUROL, V12, P425, DOI 10.1002/ana.410120504; KUHL DE, 1984, ANN NEUROL S, V15, P119; Kun E, 1979, Methods Enzymol, V55, P115; Li SH, 1999, J NEUROSCI, V19, P5159; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; MALLAJOSYULA JK, 2004, 34 ANN M SOC NEUR SA; MANN VM, 1990, LANCET, V336, P749, DOI 10.1016/0140-6736(90)92242-A; MORENOSANCHEZ R, 1985, J BIOL CHEM, V260, P4028; Panov AV, 2002, NAT NEUROSCI, V5, P731, DOI 10.1038/nn884; Ragan MT, 1987, MITOCHONDRIA PRACTIC, P79; ROBINSON JB, 1987, MITOCHONDRIA PRACTIC, P160; Rossignol R, 1999, J BIOL CHEM, V274, P33426, DOI 10.1074/jbc.274.47.33426; Rossignol R, 2003, BIOCHEM J, V370, P751, DOI 10.1042/BJ20021594; Ruan QM, 2004, HUM MOL GENET, V13, P669, DOI 10.1093/hmg/ddh082; Trettel F, 2000, HUM MOL GENET, V9, P2799, DOI 10.1093/hmg/9.19.2799; Villani G, 1998, J BIOL CHEM, V273, P31829, DOI 10.1074/jbc.273.48.31829; Villani G, 1997, P NATL ACAD SCI USA, V94, P1166, DOI 10.1073/pnas.94.4.1166	47	190	196	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	2005	280	35					30773	30782		10.1074/jbc.M504749200	http://dx.doi.org/10.1074/jbc.M504749200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	958ZX	15983033	hybrid			2022-12-25	WOS:000231487800017
J	Fukui, T; Kondo, M; Ito, G; Maeda, O; Sato, N; Yoshioka, H; Yokoi, K; Ueda, Y; Shimokata, K; Sekido, Y				Fukui, T; Kondo, M; Ito, G; Maeda, O; Sato, N; Yoshioka, H; Yokoi, K; Ueda, Y; Shimokata, K; Sekido, Y			Transcriptional silencing of secreted frizzled related protein 1 (SFRP1) by promoter hypermethylation in non-small-cell lung cancer	ONCOGENE			English	Article						chromosome 8p; hypermethylation; non small-cell lung cancer; SFRP1; tumor suppressor gene	WNT ANTAGONIST SFRP1; COLORECTAL-CANCER; BREAST-CANCER; GENE; INACTIVATION; EXPRESSION; CATENIN; ADENOCARCINOMAS; HETEROZYGOSITY; MESOTHELIOMA	Secreted frizzled related protein 1 (SFRP1) is an antagonist of the transmembrane frizzled receptor, a component of the Wnt signaling pathway, and has been suggested to be a candidate tumor suppressor in several human malignancies. Since SFRP1 is located at chromosome 8p11, where lung cancers also exhibit frequent allelic loss, we hypothesized that the inactivation of SFRP1 is also involved in lung carcinogenesis. To substantiate this, we performed mutational analysis of SFRP1 for 29 nonsmall-cell lung cancer (NSCLC) and 25 small-cell lung cancer (SCLC) cell lines, and expression analysis for the same cell lines. Although somatic mutations were not detected in the coding sequence, downregulation of SFRP1 was observed in 14 (48%) NSCLC and nine (36%) SCLC cell lines. We analysed epigenetic alteration of the SFRP1 promoter region and detected hypermethylation in 15 (52%) of 29 NSCLC cell lines, two (8%) of 25 SCLC cell lines, and 44 (55%) of 80 primary lung tumors. By comparing the methylation status with SFRP1 expression, we found a significant correlation between them. We also performed loss of heterozygosity (LOH) analysis and found that 15 (38%) of 40 informative surgical specimens had LOH in the SFRP1 gene locus. Furthermore, we performed colony formation assay of two NSCLC cell lines (NCI-H460 and NCI-H2009) and found the reduction of colony formation with SFRP1 transfection. In addition, we also detected that SFRP1 inhibits the transcriptional activity of beta-catenin, which is thought to be a downstream molecule of SFRP1, with luciferase reporter assay. Our current studies demonstrated that the SFRP1 gene is frequently downregulated by promoter hypermethylation and suppresses tumor growth activity of lung cancer cells, which suggests that SFRP1 is a candidate tumor suppressor gene for lung cancer.	Nagoya Univ, Sch Med, Dept Clin Prevent Med, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Sch Med, Dept Thorac Surg, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Sch Med, Dept Resp Med, Nagoya, Aichi 4668550, Japan	Nagoya University; Nagoya University; Nagoya University	Sekido, Y (corresponding author), Aichi Canc Ctr, Res Inst, Div Mol Oncol, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.	ysekido@aichi-cc.jp	Kondo, Masashi/I-7378-2014; Yokoi, Kohei/I-7261-2014; Fukui, Takayuki/AAR-2292-2021; Sekido, Yoshitaka/P-9756-2015; FUKUI, Takayuki/I-7443-2014	Sekido, Yoshitaka/0000-0002-2428-3848				Caldwell GM, 2004, CANCER RES, V64, P883, DOI 10.1158/0008-5472.CAN-03-1346; EMI M, 1992, CANCER RES, V52, P5368; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Girard L, 2000, CANCER RES, V60, P4894; HORII A, 1992, CANCER RES, V52, P6696; Howe LR, 2004, CANCER BIOL THER, V3, P36, DOI 10.4161/cbt.3.1.561; Ito G, 2004, CANCER RES, V64, P3838, DOI 10.1158/0008-5472.CAN-04-0185; Ito M, 2005, CANCER LETT, V225, P131, DOI 10.1016/j.canlet.2004.10.041; Klopocki E, 2004, INT J ONCOL, V25, P641; Lee AY, 2004, ONCOGENE, V23, P6672, DOI 10.1038/sj.onc.1207881; Maeda O, 2004, ONCOGENE, V23, P964, DOI 10.1038/sj.onc.1207254; Minna JD, 2002, CANCER J, V8, pS41; Mori S, 2004, CANCER-AM CANCER SOC, V100, P1673, DOI 10.1002/cncr.20164; Morin Patrice J, 2003, Cancer Treat Res, V115, P169; Pei JM, 2001, GENE CHROMOSOME CANC, V31, P282, DOI 10.1002/gcc.1145; Polakis P, 2000, GENE DEV, V14, P1837; Sanchez-Cespedes M, 2002, CANCER RES, V62, P3659; Sekido Y, 2003, ANNU REV MED, V54, P73, DOI 10.1146/annurev.med.54.101601.152202; Sekido Y, 2002, CANCER GENET CYTOGEN, V137, P33, DOI 10.1016/S0165-4608(02)00536-8; Shigemitsu K, 2001, ONCOGENE, V20, P4249, DOI 10.1038/sj.onc.1204557; Stoehr R, 2004, LAB INVEST, V84, P465, DOI 10.1038/labinvest.3700068; Sunaga N, 2001, GENE CHROMOSOME CANC, V30, P316, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1097>3.0.CO;2-9; Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Takada T, 2004, CANCER SCI, V95, P741, DOI 10.1111/j.1349-7006.2004.tb03255.x; Toyooka S, 2002, CLIN CANCER RES, V8, P2292; Uchiyama M, 2003, INT J CANCER, V107, P962, DOI 10.1002/ijc.11493; Usami N, 2003, ONCOGENE, V22, P7922, DOI 10.1038/sj.onc.1206533; Wistuba II, 1999, CANCER RES, V59, P1973; Yuan BZ, 2004, ONCOGENE, V23, P1405, DOI 10.1038/sj.onc.1207291	30	148	153	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	41					6323	6327		10.1038/sj.onc.1208777	http://dx.doi.org/10.1038/sj.onc.1208777			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	964JM	16007200				2022-12-25	WOS:000231877100013
J	Clayton, AHA; Walker, F; Orchard, SG; Henderson, C; Fuchs, D; Rothacker, J; Nice, EC; Burgess, AW				Clayton, AHA; Walker, F; Orchard, SG; Henderson, C; Fuchs, D; Rothacker, J; Nice, EC; Burgess, AW			Ligand-induced dimer-tetramer transition during the activation of the cell surface epidermal growth factor receptor-A multidimensional microscopy analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIFETIME IMAGING MICROSCOPY; ERBB SIGNALING NETWORK; EXTRACELLULAR DOMAIN; CRYSTAL-STRUCTURE; EGF RECEPTOR; CORRELATION SPECTROSCOPY; FACTOR-ALPHA; DIMERIZATION; ECTODOMAIN; BINDING	The epidermal growth factor receptor ( EGFR) is a member of the erbB tyrosine kinase family of receptors. For many years it has been believed that receptor activation occurs via a monomer-dimer transition that is associated with a conformational change to activate the kinase. However, little is known about the quaternary state of the receptor at normal levels of expression (< 105 receptors/cell). We employed multidimensional microscopy techniques to gain insight into the state of association of the human EGFR, in the absence and presence of ligand, on the surface of intact BaF/3 cells ( 50,000 receptors/cell). Image correlation microscopy of an EGFR-enhanced green fluorescent protein chimera was used to establish an average degree of aggregation on the submicron scale of 2.2 receptors/cluster in the absence of ligand increasing to 3.7 receptors/cluster in the presence of ligand. Energy transfer measurements between mixtures of fluorescein isothiocyanate-EGF and Alexa 555-EGF were performed using fluorescence lifetime imaging microscopy as a function of the donor: acceptor labeling ratio to gain insight into the spatial disposition of EGFR ligand binding sites on the nanometer scale. In the context of a two-state Forster resonance energy transfer ( FRET)/non-FRET model, the data are consistent with a minimum transfer efficiency of 75% in the FRET population. The microscopy data are related to biophysical data on the EGFR in the A431 cell line and the three-dimensional structure of the ligated EGFR extracellular domain. In the context of a monomerdimer-oligomer model, the biophysical data are consistent with a significant fraction of ligated EGFR tetramers comprising two dimers juxtaposed in a side-by-side ( or slightly staggered) arrangement. Our data are consistent with a specific higher order association of the ligand-bound EGFR on the nanometer scale and indicate the existence of distinct signaling entities beyond the level of the EGFR dimer which could play an important role in receptor transactivation.	Royal Melbourne Hosp, Cell Biophys Lab, Melbourne Tumour Biol Branch, Ludwig Inst Canc Res, Melbourne, Vic 3050, Australia	Ludwig Institute for Cancer Research; Royal Melbourne Hospital	Clayton, AHA (corresponding author), Royal Melbourne Hosp, Cell Biophys Lab, Melbourne Tumour Biol Branch, Ludwig Inst Canc Res, POB 2008, Melbourne, Vic 3050, Australia.	andrew.clayton@ludwig.edu.au	Orchard, Suzanne/GXF-5346-2022; Nice, Edouard C/B-1026-2011	Orchard, Suzanne/0000-0003-0211-3183; Rothacker, Julie/0000-0001-7560-4982				Bastiaens PIH, 1999, TRENDS CELL BIOL, V9, P48, DOI 10.1016/S0962-8924(98)01410-X; Brock R, 2001, J CELL SCI, V114, P2437; BURGESS AW, 1983, EMBO J, V2, P2065, DOI 10.1002/j.1460-2075.1983.tb01701.x; CANALS F, 1992, BIOCHEMISTRY-US, V31, P4493, DOI 10.1021/bi00133a016; Carter RE, 1998, J BIOL CHEM, V273, P35000, DOI 10.1074/jbc.273.52.35000; CHATELIER RC, 1986, EMBO J, V5, P1181, DOI 10.1002/j.1460-2075.1986.tb04344.x; Chen Y, 1999, BIOPHYS J, V77, P553, DOI 10.1016/S0006-3495(99)76912-2; Cho HS, 2002, SCIENCE, V297, P1330, DOI 10.1126/science.1074611; Clayton AHA, 2004, J MICROSC-OXFORD, V213, P1, DOI 10.1111/j.1365-2818.2004.01265.x; DERYNCK R, 1987, CANCER RES, V47, P707; Domagala T, 2000, GROWTH FACTORS, V18, P11, DOI 10.3109/08977190009003231; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; Elleman TC, 2001, BIOCHEMISTRY-US, V40, P8930, DOI 10.1021/bi010037b; Ferguson KM, 2003, MOL CELL, V11, P507, DOI 10.1016/S1097-2765(03)00047-9; FORSTER T, 1948, ANN PHYS-BERLIN, V2, P55, DOI 10.1002/andp.19484370105; GADELLA TWJ, 1995, J CELL BIOL, V129, P1543, DOI 10.1083/jcb.129.6.1543; Gamett DC, 1997, J BIOL CHEM, V272, P12052, DOI 10.1074/jbc.272.18.12052; Garrett TPJ, 2003, MOL CELL, V11, P495, DOI 10.1016/S1097-2765(03)00048-0; Garrett TPJ, 2002, CELL, V110, P763, DOI 10.1016/S0092-8674(02)00940-6; Glauner KS, 1999, NATURE, V402, P813, DOI 10.1038/45561; GROENEN LC, 1994, GROWTH FACTORS, V11, P235, DOI 10.3109/08977199409010997; Hanley QS, 2005, J MICROSC-OXFORD, V218, P62, DOI 10.1111/j.1365-2818.2005.01463.x; Holbro T, 2003, EXP CELL RES, V284, P99, DOI 10.1016/S0014-4827(02)00099-X; Huang GC, 1998, BIOCHEM J, V331, P113, DOI 10.1042/bj3310113; Ichinose J, 2004, BIOCHEM BIOPH RES CO, V324, P1143, DOI 10.1016/j.bbrc.2004.09.173; Jorissen RN, 2003, EXP CELL RES, V284, P31, DOI 10.1016/S0014-4827(02)00098-8; KNUTSON VP, 1983, J BIOL CHEM, V258, P2139; LAKOWICZ JR, 1982, BIOPHYS CHEM, V16, P99, DOI 10.1016/0301-4622(82)85012-6; Magde D, 1999, PHOTOCHEM PHOTOBIOL, V70, P737, DOI 10.1111/j.1751-1097.1999.tb08277.x; Martin-Fernandez M, 2002, BIOPHYS J, V82, P2415, DOI 10.1016/S0006-3495(02)75585-9; Morris C F, 1990, Immunol Ser, V49, P177; Murali R, 1996, P NATL ACAD SCI USA, V93, P6252, DOI 10.1073/pnas.93.13.6252; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; Ogiso H, 2002, CELL, V110, P775, DOI 10.1016/S0092-8674(02)00963-7; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Petersen NO, 1998, FARADAY DISCUSS, V111, P289; PETERSEN NO, 1986, BIOPHYS J, V49, P809, DOI 10.1016/S0006-3495(86)83709-2; QIAN H, 1990, P NATL ACAD SCI USA, V87, P5479, DOI 10.1073/pnas.87.14.5479; Sako Y, 2000, NAT CELL BIOL, V2, P168, DOI 10.1038/35004044; Schlessinger J, 2002, CELL, V110, P669, DOI 10.1016/S0092-8674(02)00966-2; SOROKIN A, 1994, J BIOL CHEM, V269, P9752; Stamos J, 2002, J BIOL CHEM, V277, P46265, DOI 10.1074/jbc.M207135200; van Munster EB, 2004, CYTOM PART A, V58A, P185, DOI 10.1002/cyto.a.20013; Verveer PJ, 2000, SCIENCE, V290, P1567, DOI 10.1126/science.290.5496.1567; Walker F, 1998, GROWTH FACTORS, V16, P53, DOI 10.3109/08977199809017491; Walker F, 2004, J BIOL CHEM, V279, P22387, DOI 10.1074/jbc.M401244200; WHITEHEAD RH, 1985, JNCI-J NATL CANCER I, V74, P759; Whitson KB, 2004, ANAL BIOCHEM, V324, P227, DOI 10.1016/j.ab.2003.09.023; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034; Yu XC, 2002, MOL BIOL CELL, V13, P2547, DOI 10.1091/mbc.01-08-0411; Zhu HJ, 2003, GROWTH FACTORS, V21, P15, DOI 10.1080/0897719031000096424; ZIDOVETZKI R, 1981, P NATL ACAD SCI-BIOL, V78, P6981, DOI 10.1073/pnas.78.11.6981	53	204	215	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	2005	280	34					30392	30399		10.1074/jbc.M504770200	http://dx.doi.org/10.1074/jbc.M504770200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	957IC	15994331	hybrid			2022-12-25	WOS:000231362500051
J	Gauthier, E; Rahuel, C; Wautier, MP; El Nemer, W; Gane, P; Wautier, JL; Cartron, JP; Colin, Y; Le Van Kim, C				Gauthier, E; Rahuel, C; Wautier, MP; El Nemer, W; Gane, P; Wautier, JL; Cartron, JP; Colin, Y; Le Van Kim, C			Protein kinase A-dependent phosphorylation of lutheran/basal cell adhesion molecule glycoprotein regulates cell adhesion to laminin alpha 5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC AGONISTS; BLOOD-GROUP GLYCOPROTEIN; LAMININ ALPHA-5 CHAIN; CARCINOMA-CELLS; CYCLIC-AMP; HUMAN ERYTHROCYTES; ENDOTHELIAL-CELLS; EPITHELIAL-CELLS; INTEGRIN; BINDING	Lutheran (Lu) blood group and basal cell adhesion molecule (B-CAM) antigens reside on two glycoprotein (gp) isoforms Lu and Lu(v13) that belong to the Ig superfamily and differ only by the size of their cytoplasmic tail. Lu/B-CAM gps have been recognized as laminin alpha 5 receptors on red blood cells and epithelial cells in multiple tissues. It has been shown that sickle red cells exhibit enhanced adhesion to laminin alpha 5 when intracellular cAMP is up-regulated by physiological stimuli such as epinephrine and that this signaling pathway is protein kinase A- and Lu/B-CAM-dependent. In this study, we analyzed the relationship between the phosphorylation status of Lu/B-CAM gps and their adhesion function to laminin alpha 5. We showed that Lu isoform was phosphorylated in sickle red cells as well as in erythroleukemic K562 and epithelial Madin-Darby canine kidney cells and that this phosphorylation is enhanced by different stimuli of the PKA pathway. Lu gp is phosphorylated by glycogen synthase kinase 3 beta, casein kinase II, and PKA at serines 596, 598, and 621, respectively. Alanine substitutions of serines 596 and 598 abolished phosphorylation by glycogen synthase kinase 3 beta and casein kinase II, respectively, but had no effect on adhesion of K562 cells to laminin under flow conditions. Conversely, mutation of serine 621 prevented phosphorylation by PKA and dramatically reduced cell adhesion. Furthermore, stimulation of K562 cells by epinephrine increased Lu gp phosphorylation by PKA and enhanced adhesion to laminin. It is postulated that modulation of the phosphorylation state of Lu gp might be a critical factor for the sickle red cells adhesiveness to laminin alpha 5 in sickle cell disease.	INSERM, U665, INTS, F-75015 Paris, France; Univ Paris 07, F-75006 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Le Van Kim, C (corresponding author), INSERM, U665, INTS, 6 Rue Alexandre Cabanel, F-75015 Paris, France.	levankim@idf.inserm.fr	wautier, marie/ABC-4444-2020; Nemer, Wassim El/N-4247-2017; colin, yves/O-1910-2017; Wautier, Jean-Luc/T-9851-2019; le van kim, caroline/O-7030-2017	Nemer, Wassim El/0000-0001-8184-427X; colin, yves/0000-0001-5196-4254; le van kim, caroline/0000-0002-3251-1310; WAUTIER, Marie-Paule/0000-0002-9353-5180; WAUTIER, Jean-Luc/0000-0001-6826-2312				Aurbach G D, 1975, Adv Cyclic Nucleotide Res, V5, P117; Bolcato-Bellemin AL, 2003, DEV BIOL, V260, P376, DOI 10.1016/S0012-1606(03)00254-9; Brittain JE, 2001, J CLIN INVEST, V107, P1555, DOI 10.1172/JCI10817; Brunati AM, 2000, BLOOD, V96, P1550, DOI 10.1182/blood.V96.4.1550.h8001550_1550_1557; Colognato H, 2000, DEV DYNAM, V218, P213, DOI 10.1002/(SICI)1097-0177(200006)218:2<213::AID-DVDY1>3.0.CO;2-R; Cook A D, 1993, J Biomater Appl, V8, P72, DOI 10.1177/088532829300800105; de Bruyn KMT, 2002, J BIOL CHEM, V277, P29468, DOI 10.1074/jbc.M204990200; Doi M, 2002, J BIOL CHEM, V277, P12741, DOI 10.1074/jbc.M111228200; Drewniok C, 2004, ARCH DERMATOL RES, V296, P59, DOI 10.1007/s00403-004-0481-4; El Nemer W, 1998, J BIOL CHEM, V273, P16686; El Nemer W, 2001, J BIOL CHEM, V276, P23757, DOI 10.1074/jbc.M102978200; El Nemer W, 1999, J BIOL CHEM, V274, P31903, DOI 10.1074/jbc.274.45.31903; ElNemer W, 1997, BLOOD, V89, P4608, DOI 10.1182/blood.V89.12.4608; Enserink JM, 2004, J BIOL CHEM, V279, P44889, DOI 10.1074/jbc.M404599200; Gane P, 2001, BRIT J HAEMATOL, V113, P680, DOI 10.1046/j.1365-2141.2001.02757.x; Genersch E, 2003, EUR J CELL BIOL, V82, P105, DOI 10.1078/0171-9335-00297; Gu YC, 1999, BLOOD, V93, P2533, DOI 10.1182/blood.V93.8.2533.408k22_2533_2542; Han JW, 2003, J BIOL CHEM, V278, P34845, DOI 10.1074/jbc.M304691200; Hines PC, 2003, BLOOD, V101, P3281, DOI 10.1182/blood-2001-12-0289; Horga JF, 2000, BLOOD CELL MOL DIS, V26, P223, DOI 10.1006/bcmd.2000.0299; Inoue A, 2004, EXP HEMATOL, V32, P244, DOI 10.1016/j.exphem.2003.12.006; Kikkawa Y, 2003, J CELL BIOL, V161, P187, DOI 10.1083/jcb.200211121; Kikkawa Y, 1998, J BIOL CHEM, V273, P15854, DOI 10.1074/jbc.273.25.15854; Kikkawa Y, 2000, J CELL SCI, V113, P869; Kleinman H K, 2001, Surg Oncol Clin N Am, V10, P329; Kroviarski Y, 2004, BRIT J HAEMATOL, V126, P255, DOI 10.1111/j.1365-2141.2004.05010.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVITZKI A, 1988, SCIENCE, V241, P800, DOI 10.1126/science.2841758; Lickert H, 2000, J BIOL CHEM, V275, P5090, DOI 10.1074/jbc.275.7.5090; Lin L, 2000, EXP EYE RES, V70, P537, DOI 10.1006/exer.1999.0811; Marques F, 1997, BIOL SIGNAL, V6, P52; Miner JH, 2004, ANNU REV CELL DEV BI, V20, P255, DOI 10.1146/annurev.cellbio.20.010403.094555; Miner JH, 1998, J CELL BIOL, V143, P1713, DOI 10.1083/jcb.143.6.1713; Moulson CL, 2001, DEV DYNAM, V222, P101, DOI 10.1002/dvdy.1169; Murphy MM, 2005, BLOOD, V105, P3322, DOI 10.1182/blood-2004-07-2881; Nielsen PK, 2001, J BIOL CHEM, V276, P10906, DOI 10.1074/jbc.M008743200; Parsons SF, 2001, BLOOD, V97, P312, DOI 10.1182/blood.V97.1.312; Patarroyo M, 2002, SEMIN CANCER BIOL, V12, P197, DOI 10.1016/S1044-579X(02)00023-8; Pece S, 2000, J BIOL CHEM, V275, P41227, DOI 10.1074/jbc.M006578200; Perrault C, 2003, BLOOD, V101, P3477, DOI 10.1182/blood-2002-06-1847; Pouliot N, 2001, EXP CELL RES, V266, P1, DOI 10.1006/excr.2001.5197; RAINGER GE, 1995, AM J PHYSIOL-HEART C, V269, pH1398, DOI 10.1152/ajpheart.1995.269.4.H1398; Solovey A, 1997, NEW ENGL J MED, V337, P1584, DOI 10.1056/NEJM199711273372203; Tani T, 1999, EXP CELL RES, V248, P115, DOI 10.1006/excr.1999.4399; Telen MJ, 2000, SEMIN HEMATOL, V37, P130, DOI 10.1016/S0037-1963(00)90038-6; Tuvia S, 1999, J PHYSIOL-LONDON, V516, P781, DOI 10.1111/j.1469-7793.1999.0781u.x; Udani M., 1996, Blood, V88, p6A; Udani M, 1998, J CLIN INVEST, V101, P2550, DOI 10.1172/JCI1204; WEITZMANN MN, 1993, BIOCHEM BIOPH RES CO, V190, P564, DOI 10.1006/bbrc.1993.1085; Zamurs L, 2003, BIOMED CHROMATOGR, V17, P201, DOI 10.1002/bmc.248; Zen Q, 1999, J BIOL CHEM, V274, P728, DOI 10.1074/jbc.274.2.728; Zen Q, 2004, AM J HEMATOL, V75, P63, DOI 10.1002/ajh.10442; Zennadi R, 2004, BLOOD, V104, P3774, DOI 10.1182/blood-2004-01-0042	53	51	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	2005	280	34					30055	30062		10.1074/jbc.M503293200	http://dx.doi.org/10.1074/jbc.M503293200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	957IC	15975931	hybrid			2022-12-25	WOS:000231362500010
J	Shigaki, T; Barkla, BJ; Miranda-Vergara, MC; Zhao, J; Pantoja, O; Hirschi, KD				Shigaki, T; Barkla, BJ; Miranda-Vergara, MC; Zhao, J; Pantoja, O; Hirschi, KD			Identification of a crucial histidine involved in metal transport activity in the Arabidopsis cation/H+ exchanger CAX1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; H+/CA2+ ANTIPORTER; AMINO-ACID; RESIDUES; DETERMINANTS; EXPRESSION; CHANNEL; PH	In plants, yeast, and bacteria, cation/H+ exchangers (CAXs) have been shown to translocate Ca2+ and other metal ions utilizing the H+ gradient. The best characterized of these related transporters is the plant vacuolar localized CAX1. We have used site-directed mutagenesis to assess the impact of altering the seven histidine residues to alanine within Arabidopsis CAX1. The mutants were expressed in a Saccharomyces cerevisiae strain that is sensitive to Ca2+ and other metals. By utilizing a yeast growth assay, the H338A mutant was the only mutation that appeared to alter Ca2+ transport activity. The CAX1 His(338) residue is conserved among various CAX transporters and may be located within a filter for cation selection. We proceeded to mutate His338 to every other amino acid residue and utilized yeast growth assays to estimate the transport properties of the 19 CAX mutants. Expression of 16 of these His338 mutants could not rescue any of the metal sensitivities. However, expression of H338N, H338Q, and H338K allowed for some growth on media containing Ca2+. Most interestingly, H338N exhibited increased tolerance to Cd2+ and Zn2+. Endomembrane fractions from yeast cells were used to measure directly the transport of H338N. Although the H338N mutant demonstrated 25% of the wild type Ca2+/H+ transport, it showed an increase in transport for both Cd2+ and Zn2+ reflected in a decrease in the Km for these substrates. This study provides insights into the CAX cation filter and novel mechanisms by which metals may be partitioned across membranes.	Baylor Coll Med, USDA, ARS,Dept Pediat, Plant Physiol Labs,Childrens Nutr Res Ctr, Houston, TX 77030 USA; Univ Nacl Autonoma Mexico, Inst Biotechnol, Dept Plant Mol Biol, Cuernavaca 62250, Morelos, Mexico; Texas A&M Univ, Dept Hort, Vegetable & Fruit Improvement Ctr, College Stn, TX 77845 USA	Baylor College of Medicine; United States Department of Agriculture (USDA); Universidad Nacional Autonoma de Mexico; Texas A&M University System; Texas A&M University College Station	Hirschi, KD (corresponding author), Baylor Coll Med, USDA, ARS,Dept Pediat, Plant Physiol Labs,Childrens Nutr Res Ctr, 1100 Bates St, Houston, TX 77030 USA.	kendalh@bcm.tmc.edu	Zhao, Jian/Q-8591-2019; Zhao, Jian/A-2336-2008; Barkla, Bronwyn J/O-6301-2017; Pantoja, Omar/H-5981-2012; hirschi, kendal/GNP-0351-2022	Zhao, Jian/0000-0002-4416-7334; Barkla, Bronwyn J/0000-0002-4691-8023; Pantoja, Omar/0000-0002-6538-9059; 				Ausubel FM, 1998, CURRENT PROTOCOLS MO; Barkla BJ, 1999, PLANT PHYSIOL, V120, P811, DOI 10.1104/pp.120.3.811; BENNETT AB, 1983, J MEMBRANE BIOL, V71, P95, DOI 10.1007/BF01870678; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cai XJ, 2004, MOL BIOL EVOL, V21, P1692, DOI 10.1093/molbev/msh177; Chen XZ, 2000, BIOCHEM BIOPH RES CO, V272, P726, DOI 10.1006/bbrc.2000.2851; Cunningham KW, 1996, MOL CELL BIOL, V16, P2226; Fei YJ, 2000, J BIOL CHEM, V275, P23707, DOI 10.1074/jbc.M002282200; GABER R, 1999, J EXP BOT, V50, P1073; Gaxiola RA, 2002, PLANT PHYSIOL, V129, P967, DOI 10.1104/pp.020009; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; Hirschi KD, 1996, P NATL ACAD SCI USA, V93, P8782, DOI 10.1073/pnas.93.16.8782; Hirschi KD, 2004, PLANT PHYSIOL, V136, P2438, DOI 10.1104/pp.104.046490; Hoth S, 1997, P NATL ACAD SCI USA, V94, P4806, DOI 10.1073/pnas.94.9.4806; Kamiya T, 2004, J BIOL CHEM, V279, P812, DOI 10.1074/jbc.M309726200; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lu JMY, 1998, P NATL ACAD SCI USA, V95, P9025, DOI 10.1073/pnas.95.15.9025; Nathan DF, 1999, P NATL ACAD SCI USA, V96, P1409, DOI 10.1073/pnas.96.4.1409; Park S, 2004, MOL BREEDING, V14, P275, DOI 10.1023/B:MOLB.0000047773.20175.ae; Pittman JK, 2003, CURR OPIN PLANT BIOL, V6, P257, DOI 10.1016/S1369-5266(03)00036-0; Pittman JK, 2001, PLANT PHYSIOL, V127, P1020, DOI 10.1104/pp.010409; Rogers EE, 2000, P NATL ACAD SCI USA, V97, P12356, DOI 10.1073/pnas.210214197; Shigaki T, 2003, J BIOL CHEM, V278, P6610, DOI 10.1074/jbc.M209952200; Shigaki T, 2001, J BIOL CHEM, V276, P43152, DOI 10.1074/jbc.M106637200; Shigaki T, 2001, ANAL BIOCHEM, V298, P118, DOI 10.1006/abio.2001.5341; Uozumi N, 1998, P NATL ACAD SCI USA, V95, P9773, DOI 10.1073/pnas.95.17.9773; Wiebe CA, 2001, BIOCHEM J, V357, P1, DOI 10.1042/0264-6021:3570001; Zhou F, 2004, BIOCHEM J, V384, P87, DOI 10.1042/BJ20040751; Zong XG, 2001, J BIOL CHEM, V276, P6313, DOI 10.1074/jbc.M010326200	29	54	60	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	2005	280	34					30136	30142		10.1074/jbc.M503610200	http://dx.doi.org/10.1074/jbc.M503610200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	957IC	15994298	hybrid			2022-12-25	WOS:000231362500020
J	Thomson, AM; Cahill, CM; Cho, HH; Kassachau, KD; Epis, MR; Bridges, KR; Leedman, PJ; Rogers, JT				Thomson, AM; Cahill, CM; Cho, HH; Kassachau, KD; Epis, MR; Bridges, KR; Leedman, PJ; Rogers, JT			The acute box cis-element in human heavy ferritin mRNA 5 '-untranslated region is a unique translation enhancer that binds poly(C)-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-REGULATORY PROTEIN; 3' UNTRANSLATED REGION; 3'-UNTRANSLATED REGION; POSTTRANSCRIPTIONAL REGULATION; 3-UNTRANSLATED REGION; RESPONSIVE ELEMENTS; SECONDARY STRUCTURE; RIBOSOMAL-SUBUNIT; H-FERRITIN; SEQUENCE	Intracellular levels of the light (L) and heavy (H) ferritin subunits are regulated by iron at the level of message translation via a modulated interaction between the iron regulatory proteins (IRP1 and IRP2) and a 5'-untranslated region. Iron-responsive element (IRE). Here we show that iron and interleukin-1 beta (IL-1 beta) act synergistically to increase H- and L-ferritin expression in hepatoma cells. A GC-rich cis-element, the acute box (AB), located downstream of the IRE in the H- ferritin mRNA 5'-untranslated region, conferred a substantial increase in basal and IL-1 beta-stimulated translation over a similar time course to the induction of endogenous ferritin. A scrambled version of the AB was unresponsive to IL-1. Targeted mutation of the AB altered translation; reverse orientation and a deletion of the AB abolished the wild-type stem-loop structure and abrogated translational enhancement, whereas a conservative structural mutant had little effect. Labeled AB transcripts formed specific complexes with hepatoma cell extracts that contained the poly( C)binding proteins, iso-alpha CP1 and -alpha CP2, which have well defined roles as translation regulators. Iron influx increased the association of alpha CP1 with ferritin mRNA and decreased the alpha CP2-ferritin mRNA interaction, whereas IL-1 beta reduced the association of alpha CP1 and alpha CP2 with H-ferritin mRNA. In summary, the H-ferritin mRNA AB is a key cis-acting translation enhancer that augments H- subunit expression in Hep3B and HepG2 hepatoma cells, in concert with the IRE. The regulated association of H- ferritin mRNA with the poly(C)-binding proteins suggests a novel role for these proteins in ferritin translation and iron homeostasis in human liver.	Massachusetts Gen Hosp, Ctr Neurosci, Charlestown, MA 02129 USA; Massachusetts Gen Hosp, Genet & Aging Res Unit, Dept Psychiat, Charlestown, MA 02129 USA; Massachusetts Gen Hosp, Genet & Aging Res Unit, Dept Mol Biol, Charlestown, MA 02129 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Hematol,Dept Med, Boston, MA 02115 USA; Univ Western Australia, Lab Canc Med, Sch Med & Pharmacol, Med Res Ctr,Western Australian Inst Med Res, Perth, WA 6000, Australia; Univ Western Australia, Royal Perth Hosp, Perth, WA 6000, Australia	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Western Australia; Royal Perth Hospital; University of Western Australia	Rogers, JT (corresponding author), Massachusetts Gen Hosp, Ctr Neurosci, Rm 3580,Mass Gen E,Bldg 114 16th St 3850, Charlestown, MA 02129 USA.	jtrogers@rics.bwh.harvard.edu	Leedman, Peter J/O-4044-2014		NIA NIH HHS [AG20181] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Adams DJ, 2003, J BIOL CHEM, V278, P44894, DOI 10.1074/jbc.M307782200; Anwar A, 2000, J BIOL CHEM, V275, P34231, DOI 10.1074/jbc.M006343200; BALLA G, 1992, J BIOL CHEM, V267, P18148; BEAUMONT C, 1995, NAT GENET, V11, P444, DOI 10.1038/ng1295-444; Belsham GJ, 2000, TRENDS MICROBIOL, V8, P330, DOI 10.1016/S0966-842X(00)01788-1; Blyn LB, 1997, J VIROL, V71, P6243, DOI 10.1128/JVI.71.8.6243-6246.1997; Bonnah RA, 2004, CELL MICROBIOL, V6, P473, DOI 10.1111/j.1462-5822.2004.00376.x; Cazzola M, 2000, BLOOD, V95, P3280, DOI 10.1182/blood.V95.11.3280.011k41_3280_3288; CHEN CY, 1995, SCIENCE, V268, P415, DOI 10.1126/science.7536344; Chkheidze AN, 1999, MOL CELL BIOL, V19, P4572; CIGAN AM, 1991, MOL CELL BIOL, V11, P3217, DOI 10.1128/MCB.11.6.3217; COX LA, 1993, BIOCHEMISTRY-US, V32, P4738, DOI 10.1021/bi00069a007; COX LA, 1995, BIOCHEM BIOPH RES CO, V212, P925, DOI 10.1006/bbrc.1995.2058; Czyzyk-Krzeska MF, 1999, BLOOD, V93, P2111, DOI 10.1182/blood.V93.6.2111.406k24_2111_2120; CzyzykKrzeska MF, 1996, J BIOL CHEM, V271, P3293, DOI 10.1074/jbc.271.6.3293; DENTE L, 1985, NUCLEIC ACIDS RES, V13, P3941, DOI 10.1093/nar/13.11.3941; DICKEY LF, 1988, J BIOL CHEM, V263, P3071; DIX DJ, 1992, BIOCHEMISTRY-US, V31, P2818, DOI 10.1021/bi00125a024; Fillebeen C, 2005, BIOCHEM J, V388, P143, DOI 10.1042/BJ20041623; FU LN, 1991, SCIENCE, V251, P807, DOI 10.1126/science.1990443; Gamarnik AV, 1998, GENE DEV, V12, P2293, DOI 10.1101/gad.12.15.2293; Giles KM, 2003, J BIOL CHEM, V278, P2937, DOI 10.1074/jbc.M208439200; GILLIES SD, 1983, CELL, V33, P717, DOI 10.1016/0092-8674(83)90014-4; GOOSSEN B, 1992, MOL CELL BIOL, V12, P1959, DOI 10.1128/MCB.12.5.1959; Huez I, 1998, MOL CELL BIOL, V18, P6178, DOI 10.1128/MCB.18.11.6178; Huez I, 2001, MOL ENDOCRINOL, V15, P2197, DOI 10.1210/me.15.12.2197; KONIJN AM, 1977, BRIT J HAEMATOL, V37, P7, DOI 10.1111/j.1365-2141.1977.tb08806.x; Kozak M, 1997, EMBO J, V16, P2482, DOI 10.1093/emboj/16.9.2482; KOZAK M, 1989, MOL CELL BIOL, V9, P5134, DOI 10.1128/MCB.9.11.5134; LaVaute T, 2001, NAT GENET, V27, P209, DOI 10.1038/84859; Leedman PJ, 1996, J BIOL CHEM, V271, P12017, DOI 10.1074/jbc.271.20.12017; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; Makeyev AV, 2002, RNA, V8, P265, DOI 10.1017/S1355838202024627; Martelli A, 2004, J INORG BIOCHEM, V98, P1413, DOI 10.1016/j.jinorgbio.2004.04.011; McGary EC, 1997, J BIOL CHEM, V272, P8628, DOI 10.1074/jbc.272.13.8628; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MORRONE G, 1988, J BIOL CHEM, V263, P12554; Muckenthaler M, 1998, MOL CELL, V2, P383, DOI 10.1016/S1097-2765(00)80282-8; Ostareck DH, 2001, CELL, V104, P281, DOI 10.1016/S0092-8674(01)00212-4; Park YW, 1999, P NATL ACAD SCI USA, V96, P6694, DOI 10.1073/pnas.96.12.6694; Paulding WR, 1999, J BIOL CHEM, V274, P2532, DOI 10.1074/jbc.274.4.2532; Pinero DJ, 2000, BBA-MOL CELL RES, V1497, P279, DOI 10.1016/S0167-4889(00)00066-5; Preiss T, 1998, RNA, V4, P1321, DOI 10.1017/S1355838298980669; ROGERS JT, 1990, J BIOL CHEM, V265, P14572; ROGERS JT, 1994, NUCLEIC ACIDS RES, V22, P2678, DOI 10.1093/nar/22.13.2678; Rogers JT, 1996, BLOOD, V87, P2525, DOI 10.1182/blood.V87.6.2525.bloodjournal8762525; Rogers JT, 2002, J BIOL CHEM, V277, P45518, DOI 10.1074/jbc.M207435200; Rogers JT, 1999, J BIOL CHEM, V274, P6421, DOI 10.1074/jbc.274.10.6421; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; Sampath P, 2003, MOL CELL BIOL, V23, P1509, DOI 10.1128/MCB.23.5.1509-1519.2003; SHINE J, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1342, DOI 10.1073/pnas.71.4.1342; Thompson K, 2003, J NEUROSCI RES, V71, P46, DOI 10.1002/jnr.10463; Thomson AM, 2000, J BIOL CHEM, V275, P31609, DOI 10.1074/jbc.M002354200; Thomson AM, 1999, INT J BIOCHEM CELL B, V31, P1139, DOI 10.1016/S1357-2725(99)00080-1; Thomson AM, 1999, BIOTECHNIQUES, V27, P1032, DOI 10.2144/99275rr03; Tsuji Y, 2000, MOL CELL BIOL, V20, P5818, DOI 10.1128/MCB.20.16.5818-5827.2000; WANG XM, 1995, MOL CELL BIOL, V15, P1769; WULCZYN FG, 1991, CELL, V65, P259, DOI 10.1016/0092-8674(91)90160-Z; Yeap BB, 2002, J BIOL CHEM, V277, P27183, DOI 10.1074/jbc.M202883200	59	12	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	2005	280	34					30032	30045		10.1074/jbc.M502951200	http://dx.doi.org/10.1074/jbc.M502951200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	957IC	15967798	hybrid			2022-12-25	WOS:000231362500008
J	Zhou, H; Yu, K; McCoy, KL; Lee, A				Zhou, H; Yu, K; McCoy, KL; Lee, A			Molecular mechanism for divergent regulation of Ca(v)1.2 Ca2+ channels by calmodulin and Ca2+-binding protein-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE CALCIUM-CHANNEL; GATED CA2+ CHANNELS; PROTEIN-KINASE-C; ALPHA(1C) SUBUNIT; CA2+-DEPENDENT INACTIVATION; CA2+-SENSITIVE INACTIVATION; FUNCTIONAL EXPRESSION; VOLTAGE; FACILITATION; MODULATION	Ca2+-binding protein-1 (CaBP1) and calmodulin (CaM) are highly related Ca2+-binding proteins that directly interact with, and yet differentially regulate, voltagegated Ca2+ channels. Whereas CaM enhances inactivation of Ca2+ currents through Ca(v)1.2 (L-type) Ca2+ channels, CaBP1 completely prevents this process. How CaBP1 and CaM mediate such opposing effects on Ca(v)1.2 inactivation is unknown. Here, we identified molecular determinants in the alpha(1)-subunit of Ca(v)1.2 (alpha(1)1.2) that distinguish the effects of CaBP1 and CaM on inactivation. Although both proteins bind to a well characterized IQ-domain in the cytoplasmic C-terminal domain of alpha(1)1.2, mutations of the IQ-domain that significantly weakened CaM and CaBP1 binding abolished the functional effects of CaM, but not CaBP1. Pulldown binding assays revealed Ca2+-independent binding of CaBP1 to the N-terminal domain (NT) of alpha(1)1.2, which was in contrast to Ca2+-dependent binding of CaM to this region. Deletion of the NT abolished the effects of CaBP1 in prolonging Ca(v)1.2 Ca2+ currents, but spared Ca2+-dependent inactivation due to CaM. We conclude that the NT and IQ-domains of alpha(1)1.2 mediate functionally distinct interactions with CaBP1 and CaM that promote conformational alterations that either stabilize or inhibit inactivation of Ca(v)1.2.	Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Ctr Neurodegenerat Dis, Atlanta, GA 30322 USA	Emory University; Emory University	Lee, A (corresponding author), Emory Univ, Sch Med, Dept Pharmacol, 5123 Rollins Res Bldg,1510 Clifton Rd, Atlanta, GA 30322 USA.	alee@pharm.emory.edu		Lee, Amy/0000-0001-8021-0443	NIA NIH HHS [AG021723] Funding Source: Medline; NINDS NIH HHS [NS044922] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS044922] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R03AG021723] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BIEL M, 1990, FEBS LETT, V269, P409, DOI 10.1016/0014-5793(90)81205-3; Blumenstein Y, 2002, J BIOL CHEM, V277, P3419, DOI 10.1074/jbc.C100642200; Burgoyne RD, 2001, BIOCHEM J, V353, P1; Cens T, 1999, J BIOL CHEM, V274, P5483, DOI 10.1074/jbc.274.9.5483; Chakravarthy B, 1999, TRENDS NEUROSCI, V22, P12, DOI 10.1016/S0166-2236(98)01288-0; Dai BS, 2002, BIOCHEM BIOPH RES CO, V296, P429, DOI 10.1016/S0006-291X(02)00894-X; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; Erickson MG, 2001, NEURON, V31, P973, DOI 10.1016/S0896-6273(01)00438-X; Erickson MG, 2003, NEURON, V39, P97, DOI 10.1016/S0896-6273(03)00395-7; Haeseleer F, 2004, NAT NEUROSCI, V7, P1079, DOI 10.1038/nn1320; Haeseleer F, 2000, J BIOL CHEM, V275, P1247, DOI 10.1074/jbc.275.2.1247; Haeseleer F, 2002, BIOCHEM BIOPH RES CO, V290, P615, DOI 10.1006/bbrc.2001.6228; Haynes LP, 2004, J BIOL CHEM, V279, P547, DOI 10.1074/jbc.M309617200; Ivanina T, 2000, J BIOL CHEM, V275, P39846, DOI 10.1074/jbc.M005881200; Kasri NN, 2004, EMBO J, V23, P312, DOI 10.1038/sj.emboj.7600037; Kim J, 2004, NEURON, V41, P745, DOI 10.1016/S0896-6273(04)00081-9; KINOSHITAKAWADA NN, 2005, IN PRESS PFLUGERS AR; Kobrinsky E, 2005, J BIOL CHEM, V280, P12474, DOI 10.1074/jbc.M412140200; KOCH WJ, 1990, J BIOL CHEM, V265, P17786; Lee A, 2000, J NEUROSCI, V20, P6830, DOI 10.1523/JNEUROSCI.20-18-06830.2000; Lee A, 1999, NATURE, V399, P155, DOI 10.1038/20194; Lee A, 2002, NAT NEUROSCI, V5, P210, DOI 10.1038/nn805; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; NAIRN AC, 1994, SEMIN CANCER BIOL, V5, P295; O'Connor V, 1999, SCIENCE, V286, P1180, DOI 10.1126/science.286.5442.1180; Pang L, 2003, FEBS LETT, V546, P349, DOI 10.1016/S0014-5793(03)00629-X; PEREZREYES E, 1992, J BIOL CHEM, V267, P1792; Peterson BZ, 1999, NEURON, V22, P549, DOI 10.1016/S0896-6273(00)80709-6; Pitt GS, 2001, J BIOL CHEM, V276, P30794, DOI 10.1074/jbc.M104959200; Qin N, 1999, P NATL ACAD SCI USA, V96, P2435, DOI 10.1073/pnas.96.5.2435; Saimi Y, 2002, ANNU REV PHYSIOL, V64, P289, DOI 10.1146/annurev.physiol.64.100301.111649; Shistik E, 1998, J BIOL CHEM, V273, P17901, DOI 10.1074/jbc.273.28.17901; SNUTCH TP, 1991, NEURON, V7, P45, DOI 10.1016/0896-6273(91)90073-9; Soldatov MM, 2003, TRENDS PHARMACOL SCI, V24, P167, DOI 10.1016/S0165-6147(03)00065-8; Soldatov NM, 1998, J BIOL CHEM, V273, P957, DOI 10.1074/jbc.273.2.957; Stotz SC, 2000, J BIOL CHEM, V275, P24575, DOI 10.1074/jbc.M000399200; Tang W, 2003, BIOPHYS J, V85, P1538, DOI 10.1016/S0006-3495(03)74586-X; Tang ZZ, 2004, J BIOL CHEM, V279, P44335, DOI 10.1074/jbc.M407023200; Weiss JL, 2002, TRENDS NEUROSCI, V25, P489, DOI 10.1016/S0166-2236(02)02247-6; Xia XM, 1998, NATURE, V395, P503, DOI 10.1038/26758; Yang J, 2002, P NATL ACAD SCI USA, V99, P7711, DOI 10.1073/pnas.102006299; Zhou H, 2004, J NEUROSCI, V24, P4698, DOI 10.1523/JNEUROSCI.5523-03.2004; Zuhlke RD, 2000, J BIOL CHEM, V275, P21121, DOI 10.1074/jbc.M002986200; Zuhlke RD, 1998, P NATL ACAD SCI USA, V95, P3287, DOI 10.1073/pnas.95.6.3287; Zuhlke RD, 1999, NATURE, V399, P159, DOI 10.1038/20200	45	81	84	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	2005	280	33					29612	29619		10.1074/jbc.M504167200	http://dx.doi.org/10.1074/jbc.M504167200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	954SX	15980432	hybrid			2022-12-25	WOS:000231176200029
J	Simbulan-Rosenthal, CM; Trabosh, V; Velarde, A; Chou, FP; Daher, A; Tenzin, F; Tokino, T; Rosenthal, DS				Simbulan-Rosenthal, CM; Trabosh, V; Velarde, A; Chou, FP; Daher, A; Tenzin, F; Tokino, T; Rosenthal, DS			Id2 protein is selectively upregulated by UVB in primary, but not in immortalized human keratinocytes and inhibits differentiation	ONCOGENE			English	Article						Id2; keratinocyte; differentiation; promoter; ETS	LOOP-HELIX PROTEINS; HUMAN-PAPILLOMAVIRUS; ULTRAVIOLET-B; TRANSCRIPTIONAL ACTIVATION; EPIDERMAL DIFFERENTIATION; 5-FLANKING REGION; ENHANCER-BINDING; GENE-EXPRESSION; CELL-GROWTH; DNA-BINDING	Solar ultraviolet B (UVB) acts as both an initiator and promoter in models of multistage skin carcinogenesis. We found that, whereas UVB induces apoptosis in human papillomavirus-16 E6/7-immortalized keratinocytes, it inhibits markers of differentiation in human foreskin keratinocytes (HFK). Potential mechanisms for this differential response were examined by DNA microarray, which revealed that UVB alters the expression of three of the four human inhibitor of differentiation/DNA binding (Id) proteins that comprise a class of helix-loop-helix family of transcription factors involved in proliferation, differentiation, apoptosis, and carcinogenesis. These results were verified by RT-PCR and immunoblot analysis of control and UVB-irradiated primary and immortalized keratinocytes. Whereas Id1 was down-regulated in both cell types, Id2 expression was upregulated in primary HFK, but not immortalized cells. In contrast, Id3 expression was significantly increased only in immortalized cells. The differential expression pattern of Id2 in response to UVB was recapitulated in reporter constructs containing the 5' regulatory regions of this gene. Id2 promoter activity increased in response to UVB in HFK, but not in immortalized cells. To identify the regulatory elements in the Id2 promoter that mediate transcriptional activation by UVB in HFK, promoter deletion/mutation analysis was performed. Deletion analysis revealed that transactivation involves a 166 bp region immediately upstream to the Id2 transcriptional start site and is independent of c-Myc. The consensus E twenty-six (ETS) binding site at -120 appears to mediate UVB transcriptional activation of Id2 because point mutations at this site completely abrogated this response. Chromatin immunoprecipitation and electrophoretic mobility-shift assays verified that the Id2 promoter interacts with known Id2 promoter (ETS) binding factors Erg1/2 and Fli1, but not with c-Myc; and this interaction is enhanced after UVB exposure. Similar to the effects of UVB exposure, ectopic expression of Id2 protein in primary HFK resulted in inhibition of differentiation, as shown by decreased levels of the terminal differentiation marker keratin K1 and inhibition of involucrin crosslinking. Reduction of Id2 expression by small interfering RNAs attenuated the UVB-induced inhibition of differentiation in these cells. These results suggest that UVB-induced inhibition of differentiation of primary HFK is at least, in part, due to the upregulation of Id2, and that upregulation of Id2 by UVB might predispose keratinocytes to carcinogenesis by preventing their normal differentiation program.	Georgetown Univ, Sch Med, Dept Biochem & Mol Biol, Washington, DC 20007 USA; Sapporo Med Univ, Sch Med, Dept Mol Biol, Sapporo, Hokkaido 0608556, Japan	Georgetown University; Sapporo Medical University	Rosenthal, DS (corresponding author), Georgetown Univ, Sch Med, Dept Biochem & Mol Biol, 3900 Reservoir Rd NW, Washington, DC 20007 USA.	rosenthd@georgetown.edu	Feng-Pai, Chou/AGS-4250-2022; Simbulan-Rosenthal, Cynthia M./W-8429-2019; Rosenthal, Dean S/J-2360-2014; Tokino, Takashi/AAI-9887-2021	Simbulan-Rosenthal, Ph.D, Cynthia M./0000-0002-5070-0342; Rosenthal, Dean/0000-0002-7624-0209	NCI NIH HHS [R01 CA100443-04, R01 CA100443-02, R01 CA100443, R01 CA100443-03, R01 CA100443-05, 5R01 CA100443-02, R01 CA100443-01A1] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA100443] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKAZAWA C, 1992, J BIOL CHEM, V267, P21879; Alani RM, 1999, P NATL ACAD SCI USA, V96, P9637, DOI 10.1073/pnas.96.17.9637; Armstrong BK, 2001, J PHOTOCH PHOTOBIO B, V63, P8, DOI 10.1016/S1011-1344(01)00198-1; Atchley WR, 1997, P NATL ACAD SCI USA, V94, P5172, DOI 10.1073/pnas.94.10.5172; BAGHDOYAN S, 2005, J BIOL CHEM, V3, P3; BARONE MV, 1994, P NATL ACAD SCI USA, V91, P4985, DOI 10.1073/pnas.91.11.4985; Bavinck JNB, 2000, BRIT J DERMATOL, V142, P103, DOI 10.1046/j.1365-2133.2000.03248.x; Bernerd F, 1997, DEV BIOL, V183, P123, DOI 10.1006/dbio.1996.8465; Brellier F, 2004, CANCER RES, V64, P2699, DOI 10.1158/0008-5472.CAN-03-3477; BRENNAN TJ, 1990, GENE DEV, V4, P582, DOI 10.1101/gad.4.4.582; BROWN L, 1994, MOL CELL BIOL, V14, P1245, DOI 10.1128/MCB.14.2.1245; Brown VL, 2004, J INVEST DERMATOL, V122, P1284, DOI 10.1111/j.0022-202X.2004.22501.x; CHAKRABORTY T, 1991, J BIOL CHEM, V266, P2878; CHAKRABORTY T, 1991, MOL CELL BIOL, V11, P3633, DOI 10.1128/MCB.11.7.3633; CHEN BPC, 1994, J BIOL CHEM, V269, P15819; CHIARAMELLO A, 1995, MOL CELL BIOL, V15, P6036; Cleaver JE, 2002, FRONT BIOSCI-LANDMRK, V7, pD1024, DOI 10.2741/cleaver; D'Errico M, 2004, BRIT J DERMATOL, V150, P47, DOI 10.1111/j.1365-2133.2004.05714.x; Dazard JE, 2003, ONCOGENE, V22, P2993, DOI 10.1038/sj.onc.1206537; de Gruijl FR, 2001, J PHOTOCH PHOTOBIO B, V63, P19, DOI 10.1016/S1011-1344(01)00199-3; Del Bino S, 2004, BRIT J DERMATOL, V150, P658, DOI 10.1111/j.0007-0963.2004.05886.x; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; ELIEZRI YD, 1990, J AM ACAD DERMATOL, V23, P836, DOI 10.1016/0190-9622(90)70299-W; Ezura Y, 1997, J BIOL CHEM, V272, P29865, DOI 10.1074/jbc.272.47.29865; FRENCH BA, 1991, MOL CELL BIOL, V11, P2439, DOI 10.1128/MCB.11.5.2439; Fukuma M, 2003, ONCOGENE, V22, P1, DOI 10.1038/sj.onc.1206055; GUERINREVERCHON I, 1990, J CANCER RES CLIN, V116, P295, DOI 10.1007/BF01612906; Hacker C, 2003, NAT IMMUNOL, V4, P380, DOI 10.1038/ni903; Henson JD, 2002, ONCOGENE, V21, P598, DOI 10.1038/sj.onc.1205058; HSU HL, 1991, MOL CELL BIOL, V11, P3037, DOI 10.1128/MCB.11.6.3037; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; Jonason AS, 1996, P NATL ACAD SCI USA, V93, P14025, DOI 10.1073/pnas.93.24.14025; Kang YB, 2003, MOL CELL, V11, P915, DOI 10.1016/S1097-2765(03)00109-6; Karen J, 1999, CANCER RES, V59, P474; KAWAGUCHI N, 1992, P NATL ACAD SCI USA, V89, P4569, DOI 10.1073/pnas.89.10.4569; Kee BL, 2001, NAT IMMUNOL, V2, P242, DOI 10.1038/85303; KETTLER AH, 1990, ARCH DERMATOL, V126, P777, DOI 10.1001/archderm.126.6.777; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Kleeff J, 1998, CANCER RES, V58, P3769; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; KURABAYASHI M, 1995, GENE, V156, P311, DOI 10.1016/0378-1119(95)00017-Z; Kwiatkowski BA, 1998, J BIOL CHEM, V273, P17525, DOI 10.1074/jbc.273.28.17525; Langlands K, 2000, CANCER RES, V60, P5929; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; Lasorella A, 1996, MOL CELL BIOL, V16, P2570; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; Ling G, 2001, AM J PATHOL, V159, P1247, DOI 10.1016/S0002-9440(10)62511-4; Liu J, 2000, BIOCHEM BIOPH RES CO, V273, P1042, DOI 10.1006/bbrc.2000.3055; Maki K, 2004, MOL CELL BIOL, V24, P3227, DOI 10.1128/MCB.24.8.3227-3237.2004; Mammone T, 2000, CELL BIOL TOXICOL, V16, P293, DOI 10.1023/A:1026746330146; Maruyama H, 1999, AM J PATHOL, V155, P815, DOI 10.1016/S0002-9440(10)65180-2; MURAKAMI K, 1993, ONCOGENE, V8, P1559; Murphy DJ, 2004, MOL CELL BIOL, V24, P2083, DOI 10.1128/MCB.24.5.2083-2090.2004; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; Nickoloff BJ, 2000, J BIOL CHEM, V275, P27501; Nishimori H, 2002, ONCOGENE, V21, P8302, DOI 10.1038/sj.onc.1206025; Norton JD, 2000, J CELL SCI, V113, P3897; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; Opitz OG, 2001, J CLIN INVEST, V108, P725, DOI 10.1172/JCI11909; Perrem K, 1999, ONCOGENE, V18, P3383, DOI 10.1038/sj.onc.1202752; Poignee M, 2001, CANCER RES, V61, P7118; QUERTERMOUS EE, 1994, P NATL ACAD SCI USA, V91, P7066, DOI 10.1073/pnas.91.15.7066; Reddel RR, 2001, RADIAT RES, V155, P194, DOI 10.1667/0033-7587(2001)155[0194:ALOTIH]2.0.CO;2; Rizki A, 2001, NATURE, V411, P713, DOI 10.1038/35079641; Ruiz S, 2004, DEVELOPMENT, V131, P2737, DOI 10.1242/dev.01148; Rundhaug JE, 2005, MOL CARCINOGEN, V42, P40, DOI 10.1002/mc.20064; Sablitzky F, 1998, CELL GROWTH DIFFER, V9, P1015; Shamanin V, 1996, JNCI-J NATL CANCER I, V88, P802, DOI 10.1093/jnci/88.12.802; Sharrocks AD, 1997, INT J BIOCHEM CELL B, V29, P1371, DOI 10.1016/S1357-2725(97)00086-1; Sikder HA, 2003, CANCER CELL, V3, P525, DOI 10.1016/S1535-6108(03)00141-7; Simbulan-Rosenthal CM, 2002, J BIOL CHEM, V277, P24709, DOI 10.1074/jbc.M200281200; Steenbergen RDM, 1998, INT J CANCER, V76, P412, DOI 10.1002/(SICI)1097-0215(19980504)76:3<412::AID-IJC20>3.0.CO;2-B; Steenbergen RDM, 2001, JNCI-J NATL CANCER I, V93, P865, DOI 10.1093/jnci/93.11.865; Stratton S P, 2001, Curr Oncol Rep, V3, P295, DOI 10.1007/s11912-001-0080-x; Takao J, 2002, PHOTODERMATOL PHOTO, V18, P5, DOI 10.1034/j.1600-0781.2002.180102.x; Tootle TL, 2005, BIOESSAYS, V27, P285, DOI 10.1002/bies.20198; TORNALETTI S, 1993, ONCOGENE, V8, P2051; Tsai KY, 2004, AM J MED GENET C, V131C, P82, DOI 10.1002/ajmg.c.30037; Vandeputte DAA, 2002, GLIA, V38, P329, DOI 10.1002/glia.10076; Veldman T, 2003, P NATL ACAD SCI USA, V100, P8211, DOI 10.1073/pnas.1435900100; Veldman T, 2001, J VIROL, V75, P4467, DOI 10.1128/JVI.75.9.4467-4472.2001; Wikonkal NM, 1999, J INVEST DERM SYMP P, V4, P6, DOI 10.1038/sj.jidsp.5640173; Wilson JW, 2001, CANCER RES, V61, P8803; Wingender E, 2000, NUCLEIC ACIDS RES, V28, P316, DOI 10.1093/nar/28.1.316; Wingender Edgar, 2004, In Silico Biology, V4, P55; Xiao XD, 2003, EXP MOL PATHOL, V75, P238, DOI 10.1016/S0014-4800(03)00092-3; Yeh KC, 2000, GENE, V254, P163, DOI 10.1016/S0378-1119(00)00274-2; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	89	18	19	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 18	2005	24	35					5443	5458		10.1038/sj.onc.1208709	http://dx.doi.org/10.1038/sj.onc.1208709			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	955JN	16007217				2022-12-25	WOS:000231222300005
J	Prinzen, C; Muller, U; Endres, K; Fahrenholz, F; Postina, R				Prinzen, C; Muller, U; Endres, K; Fahrenholz, F; Postina, R			Genomic structure and functional characterization of the human ADAM10 promoter	FASEB JOURNAL			English	Article						Alzheimer disease; amyloid precursor protein; alpha-secretase; luciferase promoter assay; retinoic acid	AMYLOID PRECURSOR PROTEIN; TRANSCRIPTION FACTOR; ALZHEIMERS-DISEASE; BETA-PROTEIN; MEMBRANE-PROTEINS; POU DOMAIN; DISINTEGRIN; ALPHA; GENE; SEQUENCE	The ADAM10 gene encodes a membrane-bound disintegrin-metalloproteinase, which, after overexpression in an Alzheimer disease ( AD) mouse model, prevents amyloid pathology and improves long-term potentiation and memory. Because enhancing ADAM10 expression appears to be a reasonable approach for treatment of AD, we functionally analyzed the ADAM10 gene. Both human and mouse ADAM10 genes comprise similar to 160 kbp, are composed of 16 exons, and are evolutionarily highly conserved within 500 bp upstream of either translation initiation site. By using luciferase reporter assays, we demonstrate that nucleotides - 2179 to - 1 upstream of the human ADAM10 translation initiation site represent a functional TATA-less promoter. Within this region we identified and examined several single nucleotide polymorphisms, but did not detect significant differences in their appearance between AD and nondemented control subjects. By deletion analysis, site-directed mutagenesis, transcription factor overexpression and electrophoretic mobility shift assays, we identified nucleotides - 508 to - 300 as the core promoter and found Sp1, USF, and retinoic acid-responsive elements to modulate its activity. Finally, we identified vitamin A acid (RA) as an inducer of human ADAM10 promoter activity. This finding suggests that pharmacologic targeting of RA receptors may increase the expression of the alpha-secretase ADAM10 with beneficial effects on AD pathology.	Johannes Gutenberg Univ Mainz, Inst Biochem, D-55128 Mainz, Germany; Univ Giessen, Inst Human Genet, Giessen, Germany	Johannes Gutenberg University of Mainz; Justus Liebig University Giessen	Postina, R (corresponding author), Johannes Gutenberg Univ Mainz, Inst Biochem, Becherweg 30, D-55128 Mainz, Germany.	bio.chemie@uni-mainz.de	Endres, Kristina/K-4960-2015					ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Anders A, 2001, FASEB J, V15, P1837, DOI 10.1096/fj.01-0007fje; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; Chiang MY, 1998, NEURON, V21, P1353, DOI 10.1016/S0896-6273(00)80654-6; Citron M, 1996, P NATL ACAD SCI USA, V93, P13170, DOI 10.1073/pnas.93.23.13170; CITRON M, 1995, NEURON, V14, P661, DOI 10.1016/0896-6273(95)90323-2; Furukawa K, 1996, J NEUROCHEM, V67, P1882, DOI 10.1046/j.1471-4159.1996.67051882.x; Goodman AB, 2003, P NATL ACAD SCI USA, V100, P2901, DOI 10.1073/pnas.0437937100; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Howard L, 1996, BIOCHEM J, V317, P45, DOI 10.1042/bj3170045; Ishida A, 1997, NEUROREPORT, V8, P2133, DOI 10.1097/00001756-199707070-00009; IZUMI R, 1992, GENE, V112, P189, DOI 10.1016/0378-1119(92)90375-Y; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; KAUFMANN J, 1994, GENE DEV, V8, P821, DOI 10.1101/gad.8.7.821; KOVACS DM, 1995, HUM MOL GENET, V4, P1527, DOI 10.1093/hmg/4.9.1527; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; LANNFELT L, 1995, NAT MED, V1, P829, DOI 10.1038/nm0895-829; LANS MS, 1994, J BIOL CHEM, V269, P14170; LARSEN F, 1992, GENOMICS, V13, P1095, DOI 10.1016/0888-7543(92)90024-M; LI P, 1993, GENE DEV, V7, P2483, DOI 10.1101/gad.7.12b.2483; Loots GG, 2002, GENOME RES, V12, P832, DOI 10.1101/gr.225502; MARTINEZ E, 1994, EMBO J, V13, P3115, DOI 10.1002/j.1460-2075.1994.tb06610.x; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; Misner DL, 2001, P NATL ACAD SCI USA, V98, P11714, DOI 10.1073/pnas.191369798; Mitsuda N, 1997, J BIOL CHEM, V272, P23489, DOI 10.1074/jbc.272.38.23489; Muller U, 1996, NEUROLOGY, V47, P1575, DOI 10.1212/WNL.47.6.1575; Nunan J, 2000, FEBS LETT, V483, P6, DOI 10.1016/S0014-5793(00)02076-7; Penn I, 1998, Pediatr Transplant, V2, P56; Postina R, 2004, J CLIN INVEST, V113, P1456, DOI 10.1172/JCI200420864; POTTER JJ, 1991, J BIOL CHEM, V266, P15457; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Rietveld I, 2003, EUR J EPIDEMIOL, V18, P191; Rinaldi P, 2003, NEUROBIOL AGING, V24, P915, DOI 10.1016/S0197-4580(03)00031-9; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; Salbaum J M, 1989, Prog Clin Biol Res, V317, P277; Santamarina-Fojo S, 2000, P NATL ACAD SCI USA, V97, P7987, DOI 10.1073/pnas.97.14.7987; SAWADOGO M, 1988, J BIOL CHEM, V263, P11994; Schwartz S, 2003, NUCLEIC ACIDS RES, V31, P3518, DOI 10.1093/nar/gkg579; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Sennvik K, 2000, NEUROSCI LETT, V278, P169, DOI 10.1016/S0304-3940(99)00929-5; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; Suske G, 2000, Methods Mol Biol, V130, P175; Takahashi J, 1999, J NEUROBIOL, V38, P65, DOI 10.1002/(SICI)1097-4695(199901)38:1<65::AID-NEU5>3.3.CO;2-H; TAZI J, 1990, CELL, V60, P909, DOI 10.1016/0092-8674(90)90339-G; Weis L, 1997, MOL CELL BIOL, V17, P2973, DOI 10.1128/MCB.17.6.2973; Weskamp G, 1996, J CELL BIOL, V132, P717, DOI 10.1083/jcb.132.4.717; WOLFSBERG TG, 1995, J CELL BIOL, V131, P275, DOI 10.1083/jcb.131.2.275; WOLFSBERG TG, 1995, DEV BIOL, V169, P378, DOI 10.1006/dbio.1995.1152; WORKMAN JL, 1990, EMBO J, V9, P1299, DOI 10.1002/j.1460-2075.1990.tb08239.x; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0; YAMASHITA K, 1997, NEW CERAMICS, V10, P15; Yamazaki K, 1997, GENOMICS, V46, P528, DOI 10.1006/geno.1997.5043; Yavari R, 1998, HUM MOL GENET, V7, P1161, DOI 10.1093/hmg/7.7.1161; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9	56	106	110	1	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2005	19	8					1522	+		10.1096/fj.04-3619fje	http://dx.doi.org/10.1096/fj.04-3619fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	15972296				2022-12-25	WOS:000230207800011
J	Weber, A; Hengge, UR; Bardenheuer, W; Tischoff, I; Sommerer, F; Markwarth, A; Dietz, A; Wittekind, C; Tannapfel, A				Weber, A; Hengge, UR; Bardenheuer, W; Tischoff, I; Sommerer, F; Markwarth, A; Dietz, A; Wittekind, C; Tannapfel, A			SOCS-3 is frequently methylated in head and neck squamous cell carcinoma and its precursor lesions and causes growth inhibition	ONCOGENE			English	Article						SOCS; squamous cell carcinoma; head and neck; precursor lesions; methylation; tumor suppressor	TUMOR-SUPPRESSOR GENES; CPG ISLAND HYPERMETHYLATION; CONSTITUTIVE ACTIVATION; HEPATOCELLULAR-CARCINOMA; ABERRANT METHYLATION; NEGATIVE REGULATOR; SIGNAL TRANSDUCER; IN-VIVO; CANCER; STAT3	The suppressors of cytokine signaling ( SOCS) are inhibitors of cytokine signaling that function via the Janus kinase (JAK)/signal transducers and activators of transcription ( STAT) pathway. Recently, methylation of SOCS-1 and SOCS-3 has been implicated in the tumorigenesis of liver and lung cancer. This study was performed to elucidate the role of SOCS-1 and SOCS-3 in squamous cell carcinoma of the head and neck (HNSCC) and its precursor lesions. HNSCC of 94 patients and corresponding normal mucosa, lymph node metastases as well as 16 high- and 21 low-grade squamous cell dysplasias were studied by using methylation-specific PCR (MSP) for the SOCS-1 and SOCS-3 promoter after microdissection. The presence of SOCS-3 mRNA transcripts was confirmed by semiquantitative real-time PCR, and the SOCS-3 protein was analysed immunohistochemically. SOCS-3 hypermethylation was found in 85/94 HNSCC (90%) and in 10/16 high- grade and 9/21 low-grade dysplasias (63 and 43%, respectively). SOCS-1 promoter hypermethylation was detected in 10/94 HNSCC samples (11%) and in 2/16 high-grade and 1/21 low-grade dysplasias (13 and 5%, respectively). Lymph node metastases exhibited an identical methylation status as the primary tumors. Methylation of the SOCS-3 promoter correlated with downregulation of SOCS-3 transcripts and protein expression in these tumors and various cell lines. In the cell lines tested, SOCS-3 and SOCS-1 transcripts increased upon treatment with the demethylation compound 5-aza-2-deoxycytidine (5-AZA-DC). Overexpression of wild-type SOCS-3 in carcinoma cells with methylated SOCS-3 resulted in the induction of apoptosis and growth suppression as well as downregulation of STAT3, bcl-2 as well as bcl-xL. Our data suggest that promoter methylation and subsequent transcript downregulation of SOCS-3 transcripts and, to a much lesser extent, SOCS-1 are involved in the multistep carcinogenesis of HNSCC. During its involvement in tumor growth, restoration of SOCS-3 may hold treatment potential for HNSCC.	Univ Leipzig, Inst Pathol, D-04103 Leipzig, Germany; Univ Leipzig, Dept Otorhinolaryngol Head & Neck Surg, D-04103 Leipzig, Germany; Univ Dusseldorf, Dept Dermatol, D-40225 Dusseldorf, Germany	Leipzig University; Leipzig University; Heinrich Heine University Dusseldorf	Tannapfel, A (corresponding author), Univ Leipzig, Inst Pathol, D-04103 Leipzig, Germany.	tana@medizin.uni-leipzig.de						Ali S, 2003, J BIOL CHEM, V278, P52021, DOI 10.1074/jbc.M306758200; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Cacalano NA, 2001, NAT CELL BIOL, V3, P460, DOI 10.1038/35074525; De Vos J, 2000, BRIT J HAEMATOL, V109, P823, DOI 10.1046/j.1365-2141.2000.02127.x; Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600; Forastiere A, 2001, NEW ENGL J MED, V345, P1890, DOI 10.1056/NEJMra001375; Fukushima N, 2003, BRIT J CANCER, V89, P338, DOI 10.1038/sj.bjc.6601039; Galm O, 2003, BLOOD, V101, P2784, DOI 10.1182/blood-2002-06-1735; Grandis JR, 2000, P NATL ACAD SCI USA, V97, P4227, DOI 10.1073/pnas.97.8.4227; He B, 2003, P NATL ACAD SCI USA, V100, P14133, DOI 10.1073/pnas.2232790100; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Larsen L, 2002, APMIS, V110, P833, DOI 10.1034/j.1600-0463.2002.1101201.x; Levy DE, 2000, ONCOGENE, V19, P2505, DOI 10.1038/sj.onc.1203480; Lin SY, 2004, ONCOL REP, V11, P341; Melzner I, 2003, BLOOD, V102, P1554, DOI 10.1182/blood-2003-04-1083; Mora LB, 2002, CANCER RES, V62, P6659; Nagai H, 2003, J HUM GENET, V48, P65, DOI 10.1007/s100380300008; Nagai H, 2002, CANCER LETT, V186, P59, DOI 10.1016/S0304-3835(02)00244-6; Niu GL, 1999, CANCER RES, V59, P5059; Niu GL, 2001, CANCER RES, V61, P3276; Oshimo Y, 2004, INT J CANCER, V112, P1003, DOI 10.1002/ijc.20521; Sengupta TK, 1998, P NATL ACAD SCI USA, V95, P11107, DOI 10.1073/pnas.95.19.11107; Shelburne CP, 2003, BLOOD, V102, P1290, DOI 10.1182/blood-2002-11-3490; Song JI, 2000, ONCOGENE, V19, P2489, DOI 10.1038/sj.onc.1203483; Sriuranpong V, 2003, CANCER RES, V63, P2948; Tannapfel A, 2001, EUR ARCH OTO-RHINO-L, V258, P83, DOI 10.1007/s004050000303; Tannapfel A, 2001, VIRCHOWS ARCH, V439, P1, DOI 10.1007/s004280100401; Uehara E, 2003, INT J ONCOL, V23, P693; Union for International Cancer Control, 2017, TNM CLASSIFICATION M; Wang TH, 2004, NAT MED, V10, P48, DOI 10.1038/nm976; Weber A, 2003, ONCOGENE, V22, P4757, DOI 10.1038/sj.onc.1206705; Yang B, 2003, AM J PATHOL, V163, P1101, DOI 10.1016/S0002-9440(10)63469-4; Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/88225	34	154	167	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 6	2005	24	44					6699	6708		10.1038/sj.onc.1208818	http://dx.doi.org/10.1038/sj.onc.1208818			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	971FL	16007169				2022-12-25	WOS:000232367800011
J	Arasada, RR; Carpenter, G				Arasada, RR; Carpenter, G			Secretase-dependent tyrosine phosphorylation of Mdm2 by the ErbB-4 intracellular domain fragment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; NUCLEAR EXPRESSION; CELL CARCINOMA; MAMMARY-GLAND; CLEAVAGE; P53; PROTEIN; DIFFERENTIATION; TRANSCRIPTION; PROTEOLYSIS	Heregulin activation of the endogenous receptor tyrosine kinase ErbB-4 in ZR-75-1 breast cancer cells provokes tyrosine phosphorylation of Hdm2 in a manner that is sensitive to inhibition of alpha- or gamma-secretase activity, indicating that liberation of the tyrosine kinase intracellular domain (ICD) fragment is required. Similar results are obtained when Erbb-4 is exogenously expressed in 32D cells, which do not otherwise express any ErbB family members. Expression of the ErbB-4 ICD fragment leads to its constitutive association with Mdm2 and tyrosine phosphorylation of Mdm2, a protein that is predominantly localized in the nucleus and that regulates p53 levels. When the ErbB-4 ICD fragment was expressed in H1299 cells, it promoted Hdm2 ubiquitination and increased the levels of p53 and p21, a transcriptional target of p53. In addition, expression of the ICD fragment increased p53 activity toward the p21 promoter in a luciferase reporter assay.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA	Vanderbilt University	Carpenter, G (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA.	graham.carpenter@vanderbilt.edu			NCI NIH HHS [CA97456] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA097456] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bei R, 2004, J PATHOL, V204, P317, DOI 10.1002/path.1642; Carpenter G, 2003, EXP CELL RES, V284, P66, DOI 10.1016/S0014-4827(02)00100-3; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Cheng QC, 2003, J BIOL CHEM, V278, P38421, DOI 10.1074/jbc.M302111200; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Flatt PM, 2000, MOL CELL BIOL, V20, P4210, DOI 10.1128/MCB.20.12.4210-4223.2000; Fortini ME, 2002, NAT REV MOL CELL BIO, V3, P673, DOI 10.1038/nrm910; GASSMANN M, 1995, NATURE, V378, P390, DOI 10.1038/378390a0; Goldberg Z, 2002, EMBO J, V21, P3715, DOI 10.1093/emboj/cdf384; Haas IG, 2005, J BIOL CHEM, V280, P9313, DOI 10.1074/jbc.M412909200; Hughes DPM, 2004, CANCER RES, V64, P2047, DOI 10.1158/0008-5472.CAN-03-3096; Jones FE, 1999, J CELL BIOL, V147, P77, DOI 10.1083/jcb.147.1.77; Junttila TT, 2005, CANCER RES, V65, P1384, DOI 10.1158/0008-5472.CAN-04-3150; Junttila TT, 2003, CLIN CANCER RES, V9, P5346; Kainulainen V, 2000, J BIOL CHEM, V275, P8641, DOI 10.1074/jbc.275.12.8641; Kim DY, 2002, J BIOL CHEM, V277, P49976, DOI 10.1074/jbc.M210179200; Komuro A, 2003, J BIOL CHEM, V278, P33334, DOI 10.1074/jbc.M305597200; Lee HJ, 2002, J BIOL CHEM, V277, P6318, DOI 10.1074/jbc.M110371200; Long WW, 2003, DEVELOPMENT, V130, P5257, DOI 10.1242/dev.00715; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; Marambaud P, 2003, CELL, V114, P635, DOI 10.1016/j.cell.2003.08.008; Michael D, 2003, SEMIN CANCER BIOL, V13, P49, DOI 10.1016/S1044-579X(02)00099-8; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Okamoto I, 2001, J CELL BIOL, V155, P755, DOI 10.1083/jcb.200108159; Omerovic J, 2004, EXP CELL RES, V294, P469, DOI 10.1016/j.yexcr.2003.12.002; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; Rio C, 2000, J BIOL CHEM, V275, P10379, DOI 10.1074/jbc.275.14.10379; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Sartor CI, 2001, MOL CELL BIOL, V21, P4265, DOI 10.1128/MCB.21.13.4265-4275.2001; Schulz JG, 2003, J BIOL CHEM, V278, P48651, DOI 10.1074/jbc.M308424200; Srinivasan R, 2000, CANCER RES, V60, P1483; Taniguchi Y, 2003, J BIOL CHEM, V278, P30425, DOI 10.1074/jbc.C300239200; Tidcombe H, 2003, P NATL ACAD SCI USA, V100, P8281, DOI 10.1073/pnas.1436402100; Vaskovsky A, 2000, J NEUROCHEM, V74, P979, DOI 10.1046/j.1471-4159.2000.0740979.x; Vecchi M, 1996, J BIOL CHEM, V271, P18989, DOI 10.1074/jbc.271.31.18989; Wang JYJ, 2000, ONCOGENE, V19, P5643, DOI 10.1038/sj.onc.1203878; Wilhelmsen K, 2004, MOL CELL BIOL, V24, P454, DOI 10.1128/MCB.24.1.454-464.2004; Williams CC, 2004, J CELL BIOL, V167, P469, DOI 10.1083/jcb.200403155; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973; Zhou WL, 2000, J BIOL CHEM, V275, P34737, DOI 10.1074/jbc.M003756200	40	46	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	2005	280	35					30783	30787		10.1074/jbc.M506057200	http://dx.doi.org/10.1074/jbc.M506057200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	958ZX	15985438	hybrid			2022-12-25	WOS:000231487800018
J	Tanaka, K; Tomisato, W; Hoshino, T; Ishihara, T; Namba, T; Aburaya, M; Katsu, T; Suzuki, K; Tsutsumi, S; Mizushima, T				Tanaka, K; Tomisato, W; Hoshino, T; Ishihara, T; Namba, T; Aburaya, M; Katsu, T; Suzuki, K; Tsutsumi, S; Mizushima, T			Involvement of intracellular Ca2+ levels in nonsteroidal anti-inflammatory drug-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GASTRIC-MUCOSAL CELLS; CELECOXIB-INDUCED APOPTOSIS; ENDOPLASMIC-RETICULUM; SULINDAC SULFONE; CANCER CELLS; ASPIRIN USE; CALCIUM; CALPAIN; CYCLOOXYGENASE-2; INHIBITOR	We recently reported that nonsteroidal anti- inflammatory drug ( NSAID)- induced gastric lesions involve NSAID- induced apoptosis of gastric mucosal cells, which in turn involves the endoplasmic reticulum stress response, in particular the up- regulation of CCAAT/ enhancerbinding protein homologous transcription factor ( CHOP). In this study, we have examined the molecular mechanism governing this NSAID- induced apoptosis in primary cultures of gastric mucosal cells. Various NSAIDs showed membrane permeabilization activity that correlated with their apoptosis- inducing activity. Various NSAIDs, particularly celecoxib, also increased intracellular Ca2+ levels. This increase was accompanied by K+ efflux from cells and was virtually absent when extracellular Ca2+ had been depleted. These data indicate that the increase in intracellular Ca2+ levels that is observed in the presence of NSAIDs is due to the stimulation of Ca2+ influx across the cytoplasmic membrane, which results from their membrane permeabilization activity. An intracellular Ca2+ chelator partially inhibited celecoxib- induced release of cytochrome c from mitochondria, reduced the magnitude of the celecoxib- induced decrease in mitochondrial membrane potential and inhibited celecoxib- induced apoptotic cell death. It is therefore likely that an increase in intracellular Ca2+ levels is involved in celecoxib- induced mitochondrial dysfunction and the resulting apoptosis. An inhibitor of calpain, a Ca2+ dependent cysteine protease, partially suppressed mitochondrial dysfunction and apoptosis in the presence of celecoxib. Celecoxib- dependent CHOP- induction was partially inhibited by the intracellular Ca2+ chelator but not by the calpain inhibitor. These results suggest that Ca2+- stimulated calpain activity and CHOP expression play important roles in celecoxib- induced apoptosis in gastric mucosal cells.	Kumamoto Univ, Grad Sch Med & Pharmaceut Sci, Kumamoto 8620973, Japan; Okayama Univ, Fac Pharmaceut Sci, Okayama 7008530, Japan	Kumamoto University; Okayama University	Mizushima, T (corresponding author), Kumamoto Univ, Grad Sch Med & Pharmaceut Sci, Kumamoto 8620973, Japan.	mizu@gpo.kumamoto-u.ac.jp	KATSU, Takashi/B-1640-2011					Baron JA, 2003, PROG EXP TUMOR RES, V37, P1; BARRIER CH, 1989, ARTHRITIS RHEUM, V32, P926; Belton O, 2000, CIRCULATION, V102, P840; Chan TA, 2002, LANCET ONCOL, V3, P166, DOI 10.1016/S1470-2045(02)00680-0; Ding HM, 2005, INT J CANCER, V113, P803, DOI 10.1002/ijc.20639; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; FRIES JF, 1989, GASTROENTEROLOGY, V96, P647, DOI 10.1016/S0016-5085(89)80061-7; GABRIEL SE, 1991, ANN INTERN MED, V115, P787, DOI 10.7326/0003-4819-115-10-787; Gil-Parrado S, 2002, J BIOL CHEM, V277, P27217, DOI 10.1074/jbc.M202945200; GIOVANNUCCI E, 1994, ANN INTERN MED, V121, P241, DOI 10.7326/0003-4819-121-4-199408150-00001; Gwag BJ, 1999, NEUROSCIENCE, V90, P1339, DOI 10.1016/S0306-4522(98)00508-9; Hajnoczky G, 2003, BIOCHEM BIOPH RES CO, V304, P445, DOI 10.1016/S0006-291X(03)00616-8; Hanif R, 1996, BIOCHEM PHARMACOL, V52, P237, DOI 10.1016/0006-2952(96)00181-5; Hawkey CJ, 2000, GASTROENTEROLOGY, V119, P521, DOI 10.1053/gast.2000.9561; Hoshino T, 2003, J BIOL CHEM, V278, P12752, DOI 10.1074/jbc.M212097200; Hsu AL, 2000, J BIOL CHEM, V275, P11397, DOI 10.1074/jbc.275.15.11397; JIANG S, 1994, EXP CELL RES, V212, P84, DOI 10.1006/excr.1994.1121; Johnson AJ, 2002, BIOCHEM J, V366, P831, DOI 10.1042/BJ20020279; KAO JPY, 1989, J BIOL CHEM, V264, P8179; KATSU T, 1987, BIOCHIM BIOPHYS ACTA, V899, P159, DOI 10.1016/0005-2736(87)90396-8; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; KURATA JH, 1990, J CLIN GASTROENTEROL, V12, P260, DOI 10.1097/00004836-199006000-00005; LIGUMSKY M, 1983, GASTROENTEROLOGY, V84, P756; Liu H, 1997, J BIOL CHEM, V272, P21751, DOI 10.1074/jbc.272.35.21751; Liu XG, 2004, JNCI-J NATL CANCER I, V96, P1769, DOI 10.1093/jnci/djh322; LUGIMSKY M, 1990, GASTROENTEROLOGY, V5, P1245; Majumder PK, 2000, J BIOL CHEM, V275, P21793, DOI 10.1074/jbc.C000048200; Mandic A, 2002, MOL CELL BIOL, V22, P3003, DOI 10.1128/MCB.22.9.3003-3013.2002; McAdam BF, 1999, P NATL ACAD SCI USA, V96, P272, DOI 10.1073/pnas.96.1.272; MILLER TA, 1983, AM J PHYSIOL, V245, pG601, DOI 10.1152/ajpgi.1983.245.5.G601; Mori K, 2000, CELL, V101, P451, DOI 10.1016/S0092-8674(00)80855-7; Mukherjee D, 2002, BIOCHEM PHARMACOL, V63, P817, DOI 10.1016/S0006-2952(02)00842-0; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; Nozaki S, 2001, ONCOGENE, V20, P2178, DOI 10.1038/sj.onc.1204292; Orrenius S, 2003, NAT REV MOL CELL BIO, V4, P552, DOI 10.1038/nrm1150; Piazza GA, 1997, CANCER RES, V57, P2909; Polster BM, 2005, J BIOL CHEM, V280, P6447, DOI 10.1074/jbc.M413269200; Ray WA, 2004, NEW ENGL J MED, V351, P2767, DOI 10.1056/NEJMc045711; Reddy BS, 1999, CANCER RES, V59, P3387; Reddy RK, 1999, J BIOL CHEM, V274, P28476, DOI 10.1074/jbc.274.40.28476; Ristimaki A, 1997, CANCER RES, V57, P1276; Rizzuto R, 2003, ONCOGENE, V22, P8619, DOI 10.1038/sj.onc.1207105; Singh D, 2004, BRIT MED J, V329, P816, DOI 10.1136/bmj.329.7470.816-a; SMALLEY WE, 1995, AM J EPIDEMIOL, V141, P539, DOI 10.1093/oxfordjournals.aje.a117469; Szabadkai G, 2004, FEBS LETT, V567, P111, DOI 10.1016/j.febslet.2004.04.059; Tomisato W, 2004, BIOCHEM BIOPH RES CO, V323, P1032, DOI 10.1016/j.bbrc.2004.08.205; Tomisato W, 2004, BIOCHEM PHARMACOL, V67, P575, DOI 10.1016/j.bcp.2003.09.020; Tomisato W, 2002, DIGEST DIS SCI, V47, P2125, DOI 10.1023/A:1019653719397; Tomisato W, 2001, AM J PHYSIOL-GASTR L, V281, pG1092, DOI 10.1152/ajpgi.2001.281.4.G1092; Tsutsumi S, 2004, CELL DEATH DIFFER, V11, P1009, DOI 10.1038/sj.cdd.4401436; Tsutsumi S, 2002, BBA-MOL CELL RES, V1589, P168, DOI 10.1016/S0167-4889(02)00171-4; VANE J, 1994, NATURE, V367, P215, DOI 10.1038/367215a0; Vane JR, 1996, SCAND J RHEUMATOL, P9; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Wang JL, 2004, BIOCHEM PHARMACOL, V67, P1123, DOI 10.1016/j.bcp.2003.11.004; Wood DE, 1998, ONCOGENE, V17, P1069, DOI 10.1038/sj.onc.1202034; Zhang XP, 1999, J EXP MED, V190, P451, DOI 10.1084/jem.190.4.451; Zhang ZC, 2004, HEPATOLOGY, V39, P1028, DOI 10.1002/hep.20143; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	59	100	106	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	2005	280	35					31059	31067		10.1074/jbc.M502956200	http://dx.doi.org/10.1074/jbc.M502956200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	958ZX	15987693	hybrid			2022-12-25	WOS:000231487800050
J	Tang, L; Li, MH; Cao, P; Wang, F; Chang, WR; Bach, S; Reinhardt, J; Ferandin, Y; Galons, H; Wan, YQ; Gray, N; Meijer, L; Jiang, T; Liang, DC				Tang, L; Li, MH; Cao, P; Wang, F; Chang, WR; Bach, S; Reinhardt, J; Ferandin, Y; Galons, H; Wan, YQ; Gray, N; Meijer, L; Jiang, T; Liang, DC			Crystal structure of pyridoxal kinase in complex with roscovitine and derivatives	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; CDK INHIBITORS; R-ROSCOVITINE; PROTEIN; CANCER; PROGRAM; BRAIN; IDENTIFICATION; DEREGULATION; DISEASE	Pyridoxal kinase (PDXK) catalyzes the phosphorylation of pyridoxal, pyridoxamine, and pyridoxine in the presence of ATP and Zn2+. This constitutes an essential step in the synthesis of pyridoxal 5'- phosphate (PLP), the active form of vitamin B-6, a cofactor for over 140 enzymes. (R)- Roscovitine (CYC202, Seliciclib) is a relatively selective inhibitor of cyclin-dependent kinases (CDKs), currently evaluated for the treatment of cancers, neurodegenerative disorders, renal diseases, and several viral infections. Affinity chromatography investigations have shown that ( R)- roscovitine also interacts with PDXK. To understand this interaction, we determined the crystal structure of PDXK in complex with (R)- roscovitine, N-6-methyl-(R)- roscovitine, and O-6-(R)roscovitine, the two latter derivatives being designed to bind to PDXK but not to CDKs. Structural analysis revealed that these three roscovitines bind similarly in the pyridoxal-binding site of PDXK rather than in the anticipated ATP-binding site. The pyridoxal pocket has thus an unexpected ability to accommodate molecules different from and larger than pyridoxal. This work provides detailed structural information on the interactions between PDXK and roscovitine and analogs. It could also aid in the design of roscovitine derivatives displaying strict selectivity for either PDXK or CDKs.	Chinese Acad Sci, Natl Lab Biomacromol, Inst Biophys, Beijing 100101, Peoples R China; CNRS, Cell Cycle Grp, UPS 2682, F-29682 Roscoff, Bretagne, France; UMR Mer & Sante 7150, Biol Stn, F-29682 Roscoff, Bretagne, France; Univ Paris 05, Lab Chim Organ 2, F-75270 Paris, France; Novartis Res Fdn, Genomics Inst, Dept Chem, San Diego, CA 92121 USA; Chinese Acad Sci, Grad Sch, Beijing 100039, Peoples R China	Chinese Academy of Sciences; Institute of Biophysics, CAS; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Novartis; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS	Jiang, T (corresponding author), Chinese Acad Sci, Natl Lab Biomacromol, Inst Biophys, 15 Datun Rd, Beijing 100101, Peoples R China.	x-ray@sun5.ibp.ac.cn	MEIJER, Laurent/ABE-7465-2021	, laurent/0000-0003-3511-4916; , Peng/0000-0002-2044-3074				Bach S, 2005, J BIOL CHEM, V280, P31208, DOI 10.1074/jbc.M500806200; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chang YT, 1999, CHEM BIOL, V6, P361, DOI 10.1016/S1074-5521(99)80048-9; Cruz JC, 2004, TRENDS MOL MED, V10, P452, DOI 10.1016/j.molmed.2004.07.001; DAKSHINAMURTI K, 1990, ANN NY ACAD SCI, V585, P128, DOI 10.1111/j.1749-6632.1990.tb28049.x; de la Motte S, 2004, INT J CLIN PHARM TH, V42, P232; DeAzevedo WF, 1997, EUR J BIOCHEM, V243, P518, DOI 10.1111/j.1432-1033.1997.0518a.x; Eliot AC, 2004, ANNU REV BIOCHEM, V73, P383, DOI 10.1146/annurev.biochem.73.011303.074021; Fabian MA, 2005, NAT BIOTECHNOL, V23, P329, DOI 10.1038/nbt1068; FISCHER PM, 2003, CELL CYCLE REGULATOR, V5, P235; Harper JW, 2001, CHEM REV, V101, P2511, DOI 10.1021/cr0001030; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KERRY JA, 1986, EUR J BIOCHEM, V158, P581, DOI 10.1111/j.1432-1033.1986.tb09794.x; Knockaert M, 2000, CHEM BIOL, V7, P411, DOI 10.1016/S1074-5521(00)00124-1; Knockaert M, 2002, TRENDS PHARMACOL SCI, V23, P417, DOI 10.1016/S0165-6147(02)02071-0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LaineCessac P, 1997, BIOCHEM PHARMACOL, V54, P863, DOI 10.1016/S0006-2952(97)00252-9; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li MH, 2004, J BIOL CHEM, V279, P17459, DOI 10.1074/jbc.M312380200; Li MH, 2002, J BIOL CHEM, V277, P46385, DOI 10.1074/jbc.M208600200; Malumbres M, 2000, BIOL CHEM, V381, P827, DOI 10.1515/BC.2000.105; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Mapelli M, 2005, J MED CHEM, V48, P671, DOI 10.1021/jm049323m; McClue SJ, 2002, INT J CANCER, V102, P463, DOI 10.1002/ijc.10738; MCCORMICK DB, 1959, P NATL ACAD SCI USA, V45, P1371, DOI 10.1073/pnas.45.9.1371; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Meijer L, 2003, ACCOUNTS CHEM RES, V36, P417, DOI 10.1021/ar0201198; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Monaco EA, 2003, CURR MED CHEM, V10, P367, DOI 10.2174/0929867033368277; Navaza J, 1997, METHOD ENZYMOL, V276, P581, DOI 10.1016/S0076-6879(97)76079-8; OTWINOWSKI Z, 1993, OSCILLATION DATA RED, P56; Percudani R, 2003, EMBO REP, V4, P850, DOI 10.1038/sj.embor.embor914; Rosania GR, 1999, P NATL ACAD SCI USA, V96, P4797, DOI 10.1073/pnas.96.9.4797; Safo MK, 2004, J BACTERIOL, V186, P8074, DOI 10.1128/JB.186.23.8074-8082.2004; Smith PD, 2004, TRENDS MOL MED, V10, P445, DOI 10.1016/j.molmed.2004.07.003; Vermeulen K, 2003, CELL PROLIFERAT, V36, P131, DOI 10.1046/j.1365-2184.2003.00266.x; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Wang J, 2003, NAT NEUROSCI, V6, P1039, DOI 10.1038/nn1119; Wang SD, 2001, TETRAHEDRON-ASYMMETR, V12, P2891, DOI 10.1016/S0957-4166(01)00471-2; Zhang M, 2004, AM J PATHOL, V165, P843, DOI 10.1016/S0002-9440(10)63347-0	40	60	68	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	2005	280	35					31220	31229		10.1074/jbc.M500805200	http://dx.doi.org/10.1074/jbc.M500805200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	958ZX	15985434	hybrid			2022-12-25	WOS:000231487800069
J	Forget, G; Gregory, DJ; Olivier, M				Forget, G; Gregory, DJ; Olivier, M			Proteasome-mediated degradation of STAT1 alpha following infection of macrophages with Leishmania donovani	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NITRIC-OXIDE SYNTHASE; JAK-STAT PATHWAYS; ERYTHROPOIETIN RECEPTOR; TRANSCRIPTIONAL ACTIVATION; TYROSINE PHOSPHORYLATION; IMMUNE-RESPONSE; INHIBITION; EXPRESSION; PHOSPHATASE	Activation of the Janus-activated kinase 2 (JAK2)/ STAT1 alpha signaling pathway is repressed in Leishmania-infected macrophages. This represents an important mechanism by which this parasite subverts the microbicidal functions of the cell to promote its own survival and propagation. We recently provided evidence that the protein tyrosine phosphatase (PTP) SHP-1 was responsible for JAK2 inactivation. However, STAT1 translocation to the nucleus was not restored in the absence of SHP-1. In the present study, we have used B10R macrophages to study the mechanism by which this Leishmania-induced STAT1 inactivation occurs. STAT1 alpha nuclear localization was shown to be rapidly reduced by the infection. Western blot analysis revealed that cellular STAT1 alpha, but not STAT3, was degraded. Using PTP inhibitors and an immortalized bone marrow-derived macrophage cell line from SHP-1-deficient mice, we showed that STAT1 inactivation was independent of PTP activity. However, inhibition of macrophage proteasome activity significantly rescued Leishmania-induced STAT1 alpha degradation. We further demonstrated that degradation was receptor-mediated and involved protein kinase C alpha. All Leishmania species tested ( L. major, L. donovani, L. mexicana, L. braziliensis), but not the related parasite Trypanosoma cruzi, caused STAT1 alpha degradation. Collectively, results from this study revealed a new mechanism for STAT1 regulation by a microbial pathogen, which favors its establishment and propagation within the host.	McGill Univ, Dept Microbiol & Immunol, Ctr Hlth, Montreal, PQ H3A 2B4, Canada; McGill Univ, Ctr Study Host Resistance Inst, Ctr Hlth, Montreal, PQ H3A 2B4, Canada; McGill Univ, Div Expt Med, Montreal, PQ H3A 2B4, Canada; Univ Laval, Ctr Hosp, Ctr Rech Infectiol, Univ Quebec, Quebec City, PQ G1V 4G2, Canada; Univ Laval, Ctr Hosp, Dept Med Biol, Univ Quebec, Quebec City, PQ G1V 4G2, Canada	McGill University; McGill University; McGill University; Laval University; University of Quebec; Laval University; University of Quebec	Forget, G (corresponding author), McGill Univ, Dept Microbiol & Immunol, Ctr Hlth, 3775 Univ St, Montreal, PQ H3A 2B4, Canada.	martin.olivier@mcgill.ca	Gregory, David/P-2582-2015	Gregory, David/0000-0001-6534-7150				Alvarez GR, 2003, J IMMUNOL, V171, P6766, DOI 10.4049/jimmunol.171.12.6766; Bertholet S, 2003, INFECT IMMUN, V71, P2095, DOI 10.1128/IAI.71.4.2095-2101.2003; BIONDI A, 1984, J IMMUNOL, V132, P1237; Blanchette J, 1999, EUR J IMMUNOL, V29, P3737, DOI 10.1002/(SICI)1521-4141(199911)29:11&lt;3737::AID-IMMU3737&gt;3.0.CO;2-S; Bogdan C, 1998, INT J PARASITOL, V28, P121, DOI 10.1016/S0020-7519(97)00169-0; Brittingham A, 1999, INFECT IMMUN, V67, P4477, DOI 10.1128/IAI.67.9.4477-4484.1999; Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673; Callus BA, 1998, BLOOD, V91, P3182, DOI 10.1182/blood.V91.9.3182.3182_3182_3192; Carrera L, 1996, J EXP MED, V183, P515, DOI 10.1084/jem.183.2.515; Croker BA, 2003, NAT IMMUNOL, V4, P540, DOI 10.1038/ni931; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; De Sepulveda P, 2000, J BIOL CHEM, V275, P14005, DOI 10.1074/jbc.C000106200; Didcock L, 1999, J VIROL, V73, P9928, DOI 10.1128/JVI.73.12.9928-9933.1999; Duthie MS, 2002, J IMMUNOL, V168, P5778, DOI 10.4049/jimmunol.168.11.5778; EGAN TJ, 1994, FEBS LETT, V352, P54, DOI 10.1016/0014-5793(94)00921-X; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Forget G, 2001, EUR J IMMUNOL, V31, P3185, DOI 10.1002/1521-4141(200111)31:11&lt;3185::AID-IMMU3185&gt;3.0.CO;2-J; Frantsve J, 2001, MOL CELL BIOL, V21, P3547, DOI 10.1128/MCB.21.10.3547-3557.2001; Garcin D, 2004, J VIROL, V78, P8799, DOI 10.1128/JVI.78.16.8799-8811.2004; Gotoh B, 2002, REV MED VIROL, V12, P337, DOI 10.1002/rmv.357; Haspel RL, 1999, P NATL ACAD SCI USA, V96, P10188, DOI 10.1073/pnas.96.18.10188; Haspel RL, 1996, EMBO J, V15, P6262, DOI 10.1002/j.1460-2075.1996.tb01016.x; Herwaldt BL, 1999, LANCET, V354, P1191, DOI 10.1016/S0140-6736(98)10178-2; Jaramillo M, 2005, J IMMUNOL, V174, P475, DOI 10.4049/jimmunol.174.1.475; Johnston JA, 2004, J LEUKOCYTE BIOL, V75, P743, DOI 10.1189/jlb.1003507; Kile BT, 2001, CELL MOL LIFE SCI, V58, P1627, DOI 10.1007/PL00000801; Kim TK, 1996, SCIENCE, V273, P1717, DOI 10.1126/science.273.5282.1717; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; Knutson KL, 1998, J BIOL CHEM, V273, P645, DOI 10.1074/jbc.273.1.645; Komatsu T, 2000, J VIROL, V74, P2477, DOI 10.1128/JVI.74.5.2477-2480.2000; KWAN WC, 1992, INFECT IMMUN, V60, P2115, DOI 10.1128/IAI.60.5.2115-2120.1992; Lang R, 2003, NAT IMMUNOL, V4, P546, DOI 10.1038/ni932; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; Malek RL, 1999, CYTOKINE, V11, P192, DOI 10.1006/cyto.1998.0421; Mansfield John M., 2002, P379; Martiny A, 1999, MOL BIOCHEM PARASIT, V102, P1, DOI 10.1016/S0166-6851(99)00067-5; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; Mosser David M., 1993, Seminars in Cell Biology, V4, P315, DOI 10.1006/scel.1993.1038; MOSSER DM, 1987, J EXP MED, V165, P140, DOI 10.1084/jem.165.1.140; MOSSER DM, 1985, J IMMUNOL, V135, P2785; NANDAN D, 1995, INFECT IMMUN, V63, P4495, DOI 10.1128/IAI.63.11.4495-4500.1995; Nandan D, 1999, INFECT IMMUN, V67, P4055, DOI 10.1128/IAI.67.8.4055-4063.1999; NEWMAN SL, 1991, J IMMUNOL, V146, P967; Olivier M, 1996, PARASITOL TODAY, V12, P145, DOI 10.1016/0169-4758(96)10006-5; Olivier M, 2005, CLIN MICROBIOL REV, V18, P293, DOI 10.1128/CMR.18.2.293-305.2005; Olivier M, 1998, J BIOL CHEM, V273, P13944, DOI 10.1074/jbc.273.22.13944; OLIVIER M, 1992, P NATL ACAD SCI USA, V89, P7481, DOI 10.1073/pnas.89.16.7481; OLIVIER M, 1992, J IMMUNOL, V148, P1188; POSNER BI, 1994, J BIOL CHEM, V269, P4596; Proudfoot L, 1996, P NATL ACAD SCI USA, V93, P10984, DOI 10.1073/pnas.93.20.10984; RADZIOCH D, 1991, J LEUKOCYTE BIOL, V50, P263, DOI 10.1002/jlb.50.3.263; Rogers RS, 2003, J BIOL CHEM, V278, P30091, DOI 10.1074/jbc.M301344200; Turco SJ, 1999, PARASITE IMMUNOL, V21, P597, DOI 10.1046/j.1365-3024.1999.00266.x; Ulane CM, 2002, VIROLOGY, V304, P160, DOI 10.1006/viro.2002.1773; Ungureanu D, 2003, BLOOD, V102, P3311, DOI 10.1182/blood-2002-12-3816; Verdier F, 2000, J BIOL CHEM, V275, P18375, DOI 10.1074/jbc.275.24.18375; Verdier F, 1998, J BIOL CHEM, V273, P28185, DOI 10.1074/jbc.273.43.28185; Wormald S, 2004, J BIOL CHEM, V279, P821, DOI 10.1074/jbc.R300030200; Yang WT, 2002, BLOOD CELL MOL DIS, V28, P63, DOI 10.1006/bcmd.2002.0485; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; Yu CL, 1997, J BIOL CHEM, V272, P14017, DOI 10.1074/jbc.272.22.14017; Zakharova N, 2003, J BIOL CHEM, V278, P43067, DOI 10.1074/jbc.M308166200	62	55	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	2005	280	34					30542	30549		10.1074/jbc.M414126200	http://dx.doi.org/10.1074/jbc.M414126200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	957IC	15983048	hybrid			2022-12-25	WOS:000231362500069
J	Tahmatzopoulos, A; Sheng, SJ; Kyprianou, N				Tahmatzopoulos, A; Sheng, SJ; Kyprianou, N			Maspin sensitizes prostate cancer cells to doxazosin-induced apoptosis	ONCOGENE			English	Article						prostate cancer; alpha-blockers; apoptosis	ALPHA-1-ADRENOCEPTOR ANTAGONISTS; GROWTH-FACTOR; TUMOR-SUPPRESSOR; CARCINOMA CELLS; INDUCTION; ANGIOGENESIS; METASTASIS; EXPRESSION; INVASION; TERAZOSIN	Maspin is a mammary serine protease inhibitor or serpin with tumor suppressive and antiangiogenic activity that inhibits tumor motility, invasion and metastasis, at least by its actions on cell membrane and extracellular matrix (ECM) proteins. Previous studies documented that the quinazoline-derived alpha 1-adrenoceptor antagonist doxazosin affects the attachment and migration of prostate cancer cells. In this study, we investigated the effect of maspin overexpression on the apoptotic/antiadhesion response of prostate cancer cells to doxazosin. The response of maspin-overexpressing clones of human prostate cancer cells DU-145 to doxazosin was evaluated by determining cell viability, apoptosis and cell proliferation on the basis of the trypan blue exclusion assay/methylthiazolyldiphenyl-tetrazolium bromide (MTT) assay, Hoechst staining and caspase-3 activation, and [H-3] thymidine incorporation assay. Vascular endothelial growth factor (VEGF), transforming growth factor beta RII (TGF beta RII), Smad4 (a TGF beta intracellular effector) and bax expression was evaluated at the mRNA and protein level using reverse transcriptase-polymerase chain reaction and Western blotting, respectively. The effect of doxazosin on cell attachment of maspin-expressing prostate cancer cells was evaluated on collagen- and fibronectin-coated plates. Cell migration was assessed using the wounding assay. In response to tumor necrosis factor-related apoptosis-inducing ligand, DU-145-maspin expressing cells undergo apoptosis, via poly(ADP-ribose) polymerasecleavage and caspase-3 activation. DU-145-maspin cells exhibited higher sensitivity to doxazosin and an earlier temporal activation of caspase-3. The number of apoptotic cells detected in response to doxazosin was significantly higher compared to the neo control (P < 0.0001). Doxazosin resulted in dramatic downregulation of the 189 isoform of VEGF in maspin transfectants, while a fivefold induction of Smad4 mRNA expression was detected in those cells after 24 h of treatment. Maspin overexpression in prostate cancer cells resulted in an increased ability to attach to ECM-coated plates, and doxazosin treatment considerably antagonized this effect by decreasing the attachment potential to collagen and fibronectin. The present study supports the ability of maspin to enhance the apoptotic threshold of prostate cancer cells to the quinazoline-based alpha 1-adrenoceptor antagonist doxazosin. These findings may have therapeutic significance in the development of antiangiogenic targeting by doxazosin and derivative agents for advanced prostate cancer.	Univ Kentucky, Med Ctr, Dept Surg, Div Oncol, Lexington, KY 40536 USA; Univ Kentucky, Med Ctr, Dept Mol & Cellular Biochem, Lexington, KY USA; Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA; Univ Kentucky, Coll Med, Dept Pathol, Lexington, KY USA	University of Kentucky; University of Kentucky; Wayne State University; University of Kentucky	Kyprianou, N (corresponding author), Univ Kentucky, Med Ctr, Dept Surg, Div Oncol, 800 Rose St,MS-283, Lexington, KY 40536 USA.	nkypr2@uky.edu			NATIONAL CANCER INSTITUTE [R01CA107575] Funding Source: NIH RePORTER; NCI NIH HHS [CA10757-01, R01 CA107575, R01 CA107575-02, R01 CA107575-03, R01 CA107575-04] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham S, 2003, J UROLOGY, V169, P1157, DOI 10.1097/01.ju.0000040245.70349.37; Bare R L, 1998, Cancer Treat Res, V94, P69; Benning CM, 2002, CANCER RES, V62, P597; BILIRAN JH, 2001, CANCER RES, V61, P676; Blacque OE, 2002, J BIOL CHEM, V277, P10783, DOI 10.1074/jbc.M110992200; Bruckheimer EM, 2000, CELL TISSUE RES, V301, P153, DOI 10.1007/s004410000196; Burchardt M, 1999, BIOL REPROD, V60, P398, DOI 10.1095/biolreprod60.2.398; Cher ML, 2003, P NATL ACAD SCI USA, V100, P7847, DOI 10.1073/pnas.1331360100; Domann FE, 2000, INT J CANCER, V85, P805, DOI 10.1002/(SICI)1097-0215(20000315)85:6<805::AID-IJC12>3.0.CO;2-5; Guo YP, 1998, CELL GROWTH DIFFER, V9, P185; Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8; Jiang N, 2002, ONCOGENE, V21, P4089, DOI 10.1038/sj.onc.1205507; Keledjian K, 2005, J CELL BIOCHEM, V94, P374, DOI 10.1002/jcb.20240; Keledjian K, 2003, J UROLOGY, V169, P1150, DOI 10.1097/01.ju.0000042453.12079.77; Keledjian K, 2001, PROSTATE, V48, P71, DOI 10.1002/pros.1083; Kyprianou N, 2000, CANCER RES, V60, P4550; Liu JY, 2004, CANCER RES, V64, P1703, DOI 10.1158/0008-5472.CAN-03-2568; Oades G M, 2000, Curr Urol Rep, V1, P97, DOI 10.1007/s11934-000-0043-z; Partin JV, 2003, BRIT J CANCER, V88, P1615, DOI 10.1038/sj.bjc.6600961; Raghavan D, 1997, EUR J CANCER, V33, P566, DOI 10.1016/S0959-8049(96)00510-2; Schaefer JS, 2003, CURR MOL MED, V3, P653, DOI 10.2174/1566524033479519; Sheng S, 1996, P NATL ACAD SCI USA, V93, P11669, DOI 10.1073/pnas.93.21.11669; SHENG SJ, 1994, J BIOL CHEM, V269, P30988; Shi HY, 2001, CANCER RES, V61, P6945; Sternberg CN, 2003, EUR J CANCER, V39, P136, DOI 10.1016/S0959-8049(02)00665-2; WANG J, 1995, J BIOL CHEM, V270, P22044, DOI 10.1074/jbc.270.37.22044; Yang G, 1997, PROSTATE, V33, P157; Zhang M, 2000, NAT MED, V6, P196, DOI 10.1038/72303; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	29	34	38	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 11	2005	24	34					5375	5383		10.1038/sj.onc.1208684	http://dx.doi.org/10.1038/sj.onc.1208684			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	954MF	16007219	Green Accepted			2022-12-25	WOS:000231158500011
J	Hilberg, T; Deigner, HP; Moller, E; Claus, RA; Ruryk, A; Glaser, D; Landre, JBP; Brunkhorst, FM; Reinhart, K; Gabriel, HHW; Russwurm, S				Hilberg, T; Deigner, HP; Moller, E; Claus, RA; Ruryk, A; Glaser, D; Landre, JBP; Brunkhorst, FM; Reinhart, K; Gabriel, HHW; Russwurm, S			Transcription in response to physical stress - clues to the molecular mechanisms of exercise-induced asthma	FASEB JOURNAL			English	Article						microarray; leukotriene; acute-phase response; gene expression	INDIVIDUAL ANAEROBIC THRESHOLD; INTERLEUKIN-6 PRODUCTION; CYTOKINE RESPONSE; SKELETAL-MUSCLE; IMMUNE-SYSTEM; MESSENGER-RNA; RECEPTOR; EXPRESSION; CELLS; IL-6	To clarify stress-induced immunological reactions and molecular events during exercise and the potential relevance to exercise-induced bronchoconstriction, transcriptional responses to standardized physical stress were determined. Six healthy, young volunteers underwent an endurance exercise of 90% of their individual anaerobic threshold for 90 min. Time-dependent alterations in the expression pattern of leukocytes from healthy, trained subjects were analyzed by DNA microarrays before and 2 h and 6 h after exercise. Starting out from a large collection of cDNA library clones comprising more than 70,000 human expressed sequence tags, we selected, designed, and immobilized oligonucleotide probes (60-70mers) for transcripts of 5000 stress and inflammation-relevant genes. Exercise-induced stress provoked changes in the expression of 433 gene activities 2 h and/or 6 h after exercise, which could be grouped into six clusters. The most prominent feature was an enhanced transcription of two genes, coding for 5-lipoxygenase (ALOX5) and ALOX5-activating protein. Moreover, enhanced levels of leukotriene B-4 (LTB4) and LTC4 (P < 0.05) were detected in plasma after exercise. Our data demonstrate that exercise alters the activities of a distinct number of genes. In particular, they possibly provide novel insights into the molecular mechanisms of exercise-induced bronchoconstriction and suggest that enhanced transcription of ALOX5 and its activating protein together with a present predisposition of the subject critically contribute to exercise-induced asthma.	Univ Jena, Sch Chem Sci, D-07749 Jena, Germany; Univ Jena, Dept Sports Med, Wollnitzerstr 42, D-07749 Jena, Germany; SIRS Lab GmbH, Jena, Germany; Univ Hosp Jena, Dept Anesthesiol & Intens Care Med, Jena, Germany	Friedrich Schiller University of Jena; Friedrich Schiller University of Jena; Friedrich Schiller University of Jena	Hilberg, T (corresponding author), Univ Jena, Sch Chem Sci, Wollnitzerstr 42, D-07749 Jena, Germany.	thomas.hilberg@uni-jena.de; h-p.deigner@uea.ac.uk	Claus, Ralf A./Q-4035-2016	Claus, Ralf A./0000-0001-7232-4088; Brunkhorst, Frank Martin/0000-0002-8132-8651				ARM JP, 1988, AM REV RESPIR DIS, V138, P47, DOI 10.1164/ajrccm/138.1.47; Ball CA, 2002, SCIENCE, V298, P539; Bethin KE, 2000, P NATL ACAD SCI USA, V97, P9317, DOI 10.1073/pnas.97.16.9317; Caillaud C, 2003, CAN J APPL PHYSIOL, V28, P793, DOI 10.1139/h03-059; Ericson SG, 1998, BLOOD, V91, P2099, DOI 10.1182/blood.V91.6.2099.2099_2099_2107; Febbraio MA, 2003, EXERC IMMUNOL REV, V9, P34; Fehrenbach E, 2003, EXERC IMMUNOL REV, V9, P58; FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B; Fried SK, 1998, J CLIN ENDOCR METAB, V83, P847, DOI 10.1210/jc.83.3.847; GABRIEL H, 1992, INT J SPORTS MED, V13, P359, DOI 10.1055/s-2007-1021281; Gadient RA, 1999, STEM CELLS, V17, P127, DOI 10.1002/stem.170127; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Helgadottir A, 2004, NAT GENET, V36, P233, DOI 10.1038/ng1311; Hilberg T, 2003, EUR J APPL PHYSIOL, V90, P639, DOI 10.1007/s00421-003-0907-2; Hoshino M, 1989, Arerugi, V38, P1302; Huber W, 2003, STAT APPL GENET MOL, P2; Keller C, 2001, FASEB J, V15, P2748, DOI 10.1096/fj.01-0507fje; KESTLER DP, 1995, BLOOD, V86, P4559, DOI 10.1182/blood.V86.12.4559.bloodjournal86124559; Kippelen P, 2004, INT J SPORTS MED, V25, P130; Lacy P, 1998, BLOOD, V91, P2508, DOI 10.1182/blood.V91.7.2508.2508_2508_2516; Lauter J, 1996, BIOMETRICS, V52, P964, DOI 10.2307/2533057; MELANI C, 1993, BLOOD, V81, P2744; Moldoveanu AI, 2001, SPORTS MED, V31, P115, DOI 10.2165/00007256-200131020-00004; MONTEROJULIAN FA, 1994, J IMMUNOL METHODS, V169, P111, DOI 10.1016/0022-1759(94)90130-9; Nieman DC, 2003, J APPL PHYSIOL, V94, P1917, DOI 10.1152/japplphysiol.01130.2002; Ostrowski K, 1998, J PHYSIOL-LONDON, V508, P949, DOI 10.1111/j.1469-7793.1998.949bp.x; Pedersen BK, 2000, PHYSIOL REV, V80, P1055, DOI 10.1152/physrev.2000.80.3.1055; Prucha M, 2004, SHOCK, V22, P29, DOI 10.1097/01.shk.0000129199.30965.02; Rao GN, 1996, J BIOL CHEM, V271, P27760, DOI 10.1074/jbc.271.44.27760; Rundell KW, 2002, SPORTS MED, V32, P583, DOI 10.2165/00007256-200232090-00004; SAD S, 1995, IMMUNITY, V2, P271, DOI 10.1016/1074-7613(95)90051-9; Sayers I, 2003, CLIN EXP ALLERGY, V33, P1103, DOI 10.1046/j.1365-2222.2003.01733.x; Shephard RJ, 2001, BRIT J SPORT MED, V35, P223, DOI 10.1136/bjsm.35.4.223; SIMON R, 2003, DESIGN ANAL DNA MICR; Starkie R, 2003, FASEB J, V17, P884, DOI 10.1096/fj.02-0670fje; Steensberg A, 2003, AM J PHYSIOL-ENDOC M, V285, pE433, DOI 10.1152/ajpendo.00074.2003; Steensberg A, 2003, EXERC IMMUNOL REV, V9, P40; STEGMANN H, 1981, INT J SPORTS MED, V2, P160, DOI 10.1055/s-2008-1034604; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; Storms WW, 2003, MED SCI SPORT EXER, V35, P1464, DOI 10.1249/01.MSS.0000084533.75912.B4; STOUTHARD JML, 1995, AM J PHYSIOL-ENDOC M, V268, pE813, DOI 10.1152/ajpendo.1995.268.5.E813; van der Meijden M, 1998, CELL IMMUNOL, V190, P156, DOI 10.1006/cimm.1998.1387; Weinstock C, 1997, MED SCI SPORT EXER, V29, P345, DOI 10.1097/00005768-199703000-00009; XIN XN, 1995, ENDOCRINOLOGY, V136, P132, DOI 10.1210/en.136.1.132; Xing Z, 1998, J CLIN INVEST, V101, P311, DOI 10.1172/JCI1368; Zhao L, 2004, NAT MED, V10, P966, DOI 10.1038/nm1099	46	36	37	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2005	19	9					1492	+		10.1096/fj.04-3063fje	http://dx.doi.org/10.1096/fj.04-3063fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	951IO	16027142				2022-12-25	WOS:000230923000019
J	Mauri, P; Scarpa, A; Nascimbeni, AC; Benazzi, L; Parmagnani, E; Mafficini, A; Della Peruta, M; Bassi, C; Miyazaki, K; Sorio, C				Mauri, P; Scarpa, A; Nascimbeni, AC; Benazzi, L; Parmagnani, E; Mafficini, A; Della Peruta, M; Bassi, C; Miyazaki, K; Sorio, C			Identification of proteins released by pancreatic cancer cells by multidimensional protein identification technology: a strategy for identification of novel cancer markers	FASEB JOURNAL			English	Article						secreted proteins; proteomics; MudPIT	UROKINASE PLASMINOGEN-ACTIVATOR; IN-VIVO; MOLECULAR CLASSIFICATION; EXTRACELLULAR-MATRIX; SHOTGUN PROTEOMICS; MASS-SPECTROMETRY; HEPARAN-SULFATE; TUMOR-GROWTH; EXPRESSION; CARCINOMA	The purpose of this study is to identify novel proteins released by cancer cells that are involved in extracellular matrix (ECM) remodeling using small-volume samples and automated technology. We applied multidimensional protein identification technology (MudPIT), which incorporates two-dimensional capillary chromatography coupled to tandem mass spectrometry to small quantities of serum-free supernatants of resting or phorbol ester-activated Suit-2 pancreatic cancer cells. Selected markers were validated in additional pancreatic cancer cell lines, primary cancers, and xenografted cancer cells. MudPIT analysis of 10 mu l of supernatants identified 46 proteins, 21 of which are classified as secreted, and 10 have never been associated with pancreatic cancer. These include CSPG2/versican, Mac25/angiomodulin, IGFBP-1, HSPG2/perlecan, syndecan 4, FAM3C, APLP2, cyclophilin B, beta 2 microglobulin, and ICA69. Evidence that cancer cells release these proteins in vivo was obtained for CSPG2/versican and Mac25/angiomodulin by immunohistochemistry on both primary pancreatic cancers and in a model consisting of Suit-2 cells embedded in an amorphous matrix and implanted in athymic mice. MudPIT allowed efficient and rapid identification of proteins released by cancer cells, including molecules previously undescribed in the type of cancer analyzed. Our finding that pancreatic cancer cells secrete a series of proteoglycans, including versican, perlecan, syndecan I and 4, challenges the common view that fibroblasts of tumor stroma are the sole source of these molecules.	Univ Verona, Dipartimento Patol, Sez Patol Gen, I-37134 Verona, Italy; CNR, Ist Tecnol Biomed, I-20133 Milan, Italy; Univ Verona, Dipartimento Sci Chirurg & Gastroenterol, I-37100 Verona, Italy; Yokohama City Univ, Kihara Inst Biol Res, Yokohama, Kanagawa 232, Japan	University of Verona; Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of Verona; Yokohama City University	Sorio, C (corresponding author), Univ Verona, Dipartimento Patol, Sez Patol Gen, Strada Grazie, I-37134 Verona, Italy.	claudio.sorio@univr.it	benazzi, louise/AAW-2684-2020; scarpa, aldo/K-6832-2016; Mauri, Pietro Luigi/AAC-3095-2019; della peruta, marco/H-8704-2016; Paulo, Joao A/C-7781-2011; Nascimbeni, Anna Chiara/AAG-4782-2021; Mafficini, Andrea/AAK-8158-2020; Sorio, Claudio/F-2764-2018	scarpa, aldo/0000-0003-1678-739X; Mauri, Pietro Luigi/0000-0003-4364-0393; Paulo, Joao A/0000-0002-4291-413X; Mafficini, Andrea/0000-0002-7471-3121; Sorio, Claudio/0000-0003-2739-4014; Della Peruta, Marco/0000-0002-5580-1847; SALVIA, Roberto/0000-0002-3514-8473				Adachi Y, 2001, INT J CANCER, V95, P216, DOI 10.1002/1097-0215(20010720)95:4<216::AID-IJC1037>3.0.CO;2-O; Akaogi K, 1996, P NATL ACAD SCI USA, V93, P8384, DOI 10.1073/pnas.93.16.8384; Albo D, 1998, J SURG RES, V76, P86, DOI 10.1006/jsre.1998.5299; Aspberg A, 1999, J BIOL CHEM, V274, P20444, DOI 10.1074/jbc.274.29.20444; BARNARD JA, 2003, GASTROINTESTINAL CAN, P33; Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115; Bramhall SR, 1997, J PATHOL, V182, P347, DOI 10.1002/(SICI)1096-9896(199707)182:3<347::AID-PATH848>3.0.CO;2-J; Buchholz M, 2003, CANCER RES, V63, P4945; Cantero D, 1997, BRIT J CANCER, V75, P388, DOI 10.1038/bjc.1997.63; Carr S, 2004, MOL CELL PROTEOMICS, V3, P531, DOI 10.1074/mcp.T400006-MCP200; Cattaneo M, 2003, ONCOGENE, V22, P6359, DOI 10.1038/sj.onc.1206665; Cattaruzza S, 2002, J BIOL CHEM, V277, P47626, DOI 10.1074/jbc.M206521200; Conejo JR, 2000, INT J CANCER, V88, P12, DOI 10.1002/1097-0215(20001001)88:1<12::AID-IJC3>3.0.CO;2-T; Corthals GL, 2000, ELECTROPHORESIS, V21, P1104, DOI 10.1002/(SICI)1522-2683(20000401)21:6<1104::AID-ELPS1104>3.3.CO;2-3; Cravatt BF, 2000, CURR OPIN CHEM BIOL, V4, P663, DOI 10.1016/S1367-5931(00)00147-2; Crnogorac-Jurcevic T, 2001, ONCOGENE, V20, P7437, DOI 10.1038/sj.onc.1204935; Diehn M, 2000, NAT GENET, V25, P58, DOI 10.1038/75603; Durr E, 2004, NAT BIOTECHNOL, V22, P985, DOI 10.1038/nbt993; Ellenrieder V, 2000, INT J CANCER, V85, P14, DOI 10.1002/(SICI)1097-0215(20000101)85:1<14::AID-IJC3>3.3.CO;2-F; Gao J, 2003, J PROTEOME RES, V2, P643, DOI 10.1021/pr034038x; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Gordon J, 2003, INT J CANCER, V103, P316, DOI 10.1002/ijc.10828; Griffin TJ, 2001, J BIOL CHEM, V276, P45497, DOI 10.1074/jbc.R100014200; Gygi SP, 2000, P NATL ACAD SCI USA, V97, P9390, DOI 10.1073/pnas.160270797; Gygi SP, 1999, NAT BIOTECHNOL, V17, P994, DOI 10.1038/13690; Hansel DE, 2003, CANCER RES, V63, P7032; Hill AS, 2003, GENE CHROMOSOME CANC, V38, P260, DOI 10.1002/gcc.10277; HUANG CJ, 1994, ANAL CELL PATHOL, V6, P93; Isogai Z, 2002, J BIOL CHEM, V277, P4565, DOI 10.1074/jbc.M110583200; Kasper HU, 2001, VIRCHOWS ARCH, V438, P116; Kishibe J, 2000, J BIOL CHEM, V275, P15321, DOI 10.1074/jbc.275.20.15321; Kitamura N, 2001, CLIN EXP METASTAS, V18, P561, DOI 10.1023/A:1011900818419; Kratchmarova I, 2002, MOL CELL PROTEOMICS, V1, P213, DOI 10.1074/mcp.M200006-MCP200; Kunzli BM, 2002, CANCER-AM CANCER SOC, V94, P228, DOI 10.1002/cncr.10162; LIOTTA LA, 2002, CANC HDB, V1, P225; Liu HB, 2004, ANAL CHEM, V76, P4193, DOI 10.1021/ac0498563; Liu W, 1998, J BIOL CHEM, V273, P22825, DOI 10.1074/jbc.273.35.22825; Martin DB, 2004, CANCER RES, V64, P347, DOI 10.1158/0008-5472.CAN-03-2062; MAURI PL, 2003, 16 INT MASS SPECTR C; Moore PS, 2001, VIRCHOWS ARCH, V439, P798, DOI 10.1007/s004280100474; Mor-Vaknin N, 2003, NAT CELL BIOL, V5, P59, DOI 10.1038/ncb898; Nagakubo D, 2003, J IMMUNOL, V171, P553, DOI 10.4049/jimmunol.171.2.553; Pejler G, 2003, EUR J BIOCHEM, V270, P3971, DOI 10.1046/j.1432-1033.2003.03785.x; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pilon M, 2000, MOL BIOL CELL, V11, P3277, DOI 10.1091/mbc.11.10.3277; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; Rustgi A. K., 2003, GASTROINTESTINAL CAN, P69; Sato J, 1999, J CELL BIOCHEM, V75, P187, DOI 10.1002/(SICI)1097-4644(19991101)75:2<187::AID-JCB1>3.0.CO;2-R; Schneider D, 2002, BBA-MOL BASIS DIS, V1588, P1, DOI 10.1016/S0925-4439(02)00052-2; Sharma B, 1998, J CLIN INVEST, V102, P1599, DOI 10.1172/JCI3793; Sorio C, 2001, VIRCHOWS ARCH, V438, P154, DOI 10.1007/s004280000343; Tamura M, 2001, JPN J CANCER RES, V92, P762, DOI 10.1111/j.1349-7006.2001.tb01159.x; Tinari N, 1997, BIOCHEM BIOPH RES CO, V232, P367, DOI 10.1006/bbrc.1997.6258; Washburn MP, 2001, NAT BIOTECHNOL, V19, P242, DOI 10.1038/85686; Wight TN, 1997, AM J PATHOL, V151, P963; Wolters DA, 2001, ANAL CHEM, V73, P5683, DOI 10.1021/ac010617e; Wu CC, 2003, NAT BIOTECHNOL, V21, P262, DOI 10.1038/nbt0303-262; Xie MJ, 2002, PANCREAS, V25, P234, DOI 10.1097/00006676-200210000-00004; Zhu Y, 2002, GENOMICS, V80, P144, DOI 10.1006/geno.2002.6816	59	98	110	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2005	19	7					1125	+		10.1096/fj.04-3000fje	http://dx.doi.org/10.1096/fj.04-3000fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	933CU	15985535				2022-12-25	WOS:000229602600020
J	Javelaud, D; Delmas, V; Moller, M; Sextius, P; Andre, J; Menashi, S; Larue, L; Mauviel, A				Javelaud, D; Delmas, V; Moller, M; Sextius, P; Andre, J; Menashi, S; Larue, L; Mauviel, A			Stable overexpression of Smad7 in human melanoma cells inhibits their tumorigenicity in vitro and in vivo	ONCOGENE			English	Article						TGF-ss; Smad; melanoma; tumor progression; metalloproteinases; angiogenesis	GROWTH-FACTOR-BETA; TGF-BETA; MATRIX METALLOPROTEINASES	We previously identified constitutive Smad signaling in human melanoma cells despite resistance to transforming growth factor-beta (TGF-beta) control of cell proliferation. This led us to investigate the effect of inhibitory Smad7 overexpression on melanoma cell behavior. Using the highly metastatic cell line, 1205-Lu, we thus generated melanoma cell clones constitutively expressing Smad7, and their mock-transfected counterparts. Stable expression of Smad7 resulted in an inhibition of constitutive Smad2/3 phosphorylation, and in a reduced TGF-beta response of Smad3/Smad4- driven gene transactivation, as measured using transfected Smad3/4-specific reporter gene constructs. Smad7 overexpression, however, did not alter their proliferative capacity and resistance to TGF-beta-driven growth inhibition. On the other hand, expression of Smad7 efficiently reduced the capacity of human melanoma cells to invade Matrigel in Boyden migration chambers, while not affecting their motility and adhesion to collagen and laminin. Gelatin zymography identified reduced MMP-2 and MMP-9 secretion by Smad7-expressing melanoma cells as compared with their control counterparts. Smad7-expressing melanoma cells exhibited a dramatically reduced capacity to form colonies under anchorage-independent culture conditions, and, when injected subcutaneously into nude mice, were largely delayed in their ability to form tumors. These results suggest that TGF-beta production by melanoma cells not only affects the tumor environment but also directly contributes to tumor cell aggressiveness through autocrine activation of Smad signaling.	Hop St Louis, INSERM, U697, F-75010 Paris, France; Inst Curie, CNRS, UMR 146, F-91405 Orsay, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Mauviel, A (corresponding author), Hop St Louis, INSERM, U697, Pavillon Bazin,1 Ave Claude Vellefaux, F-75010 Paris, France.	alain.mauviel@stlouis.inserm.fr	; javelaud, delphine/B-1129-2019	Delmas, veronique/0000-0001-7368-3664; SEXTIUS, PEGGY/0000-0002-8710-6582; Mauviel, Alain/0000-0002-0438-2793; javelaud, delphine/0000-0002-7674-7739				Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Berking C, 2001, CANCER RES, V61, P8306; Daniels CE, 2004, J CLIN INVEST, V114, P1308, DOI 10.1175/JCI200419603; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Gold LI, 1999, CRIT REV ONCOGENESIS, V10, P303; Hofmann UB, 2000, J INVEST DERMATOL, V115, P337, DOI 10.1046/j.1523-1747.2000.00068.x; Javelaud D, 2004, INT J BIOCHEM CELL B, V36, P1161, DOI 10.1016/S1357-2725(03)00255-3; Javelaud D, 2003, J BIOL CHEM, V278, P24624, DOI 10.1074/jbc.M301942200; Komuro A, 2004, ONCOGENE, V23, P6914, DOI 10.1038/sj.onc.1207885; Ludwig T, 2002, AM J PHYSIOL-RENAL, V283, pF319, DOI 10.1152/ajprenal.00327.2001; MacDougall John R., 1993, Molecular and Cellular Differentiation, V1, P21; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nakao A, 2002, TRENDS MOL MED, V8, P361, DOI 10.1016/S1471-4914(02)02376-6; Reed JA, 2001, CANCER RES, V61, P8074; Rodeck U, 1999, CANCER RES, V59, P547; RODECK U, 1994, CANCER RES, V54, P575; Shi WB, 2004, J CELL BIOL, V164, P291, DOI 10.1083/jcb.200307151; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Stamenkovic I, 2000, SEMIN CANCER BIOL, V10, P415, DOI 10.1006/scbi.2000.0379; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Xavier S, 2004, J BIOL CHEM, V279, P15167, DOI 10.1074/jbc.M309798200	23	85	94	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 17	2005	24	51					7624	7629		10.1038/sj.onc.1208900	http://dx.doi.org/10.1038/sj.onc.1208900			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	984VQ	16007121	Green Submitted			2022-12-25	WOS:000233333800012
J	Feyt, C; Kienlen-Campard, P; Leroy, K; N'Kuli, F; Courtoy, PJ; Brion, JP; Octave, JN				Feyt, C; Kienlen-Campard, P; Leroy, K; N'Kuli, F; Courtoy, PJ; Brion, JP; Octave, JN			Lithium chloride increases the production of amyloid-beta peptide independently from its inhibition of glycogen synthase kinase 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENTS; DISEASE-LIKE PHOSPHORYLATION; REDUCES TAU-PHOSPHORYLATION; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; SECRETASE CLEAVAGE; NEUROFIBRILLARY TANGLES; CYTOPLASMIC DOMAIN; INTACT-CELLS; IN-VITRO	Glycogen synthase kinase 3 (GSK3) is able to phosphorylate tau at many sites that are found to be phosphorylated in paired helical filaments in Alzheimer disease. Lithium chloride (LiCl) efficiently inhibits GSK3 and was recently reported to also decrease the production of amyloid-beta peptide (A beta) from its precursor, the amyloid precursor protein. Therefore, lithium has been proposed as a combined therapeutic agent, inhibiting both the hyperphosphorylation of tau and the production of A beta. Here, we demonstrate that the inhibition of GSK3 by LiCl induced the nuclear translocation of beta-catenin in Chinese hamster ovary cells and rat cultured neurons, in which a decrease in tau phosphorylation was observed. In both cellular models, a nontoxic concentration of LiCl increased the production of A beta by increasing the beta-cleavage of amyloid precursor protein, generating more substrate for an unmodified gamma-secretase activity. SB415286, another GSK3 inhibitor, induced the nuclear translocation of beta-catenin and slightly decreased A beta production. It is concluded that the LiCl-mediated increase in A beta production is not related to GSK3 inhibition.	Catholic Univ Louvain, Lab Expt Pharmacol, B-1200 Brussels, Belgium; Catholic Univ Louvain, Cell Unit, B-1200 Brussels, Belgium; Univ Libre Bruxelles, Lab Histol Neuroanat & Neuropathol, B-1070 Brussels, Belgium	Universite Catholique Louvain; Universite Catholique Louvain; Universite Libre de Bruxelles	Octave, JN (corresponding author), Catholic Univ Louvain, Lab Pharmacol Expt 54 10, Av Hippocrate 54, B-1200 Brussels, Belgium.	octave@nchm.ucl.ac.be	Brion, Jean-Pierre/C-6467-2009	Brion, Jean-Pierre/0000-0002-1917-775X; Leroy, Karelle/0000-0002-8661-5262; Kienlen-Campard, Pascal/0000-0003-1086-2942				Abbenante G, 2000, BIOCHEM BIOPH RES CO, V268, P133, DOI 10.1006/bbrc.2000.2098; Aplin AE, 1996, J NEUROCHEM, V67, P699; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; BREWER GJ, 1995, J NEUROSCI RES, V42, P674, DOI 10.1002/jnr.490420510; BRION JP, 1991, BIOCHEM J, V279, P831, DOI 10.1042/bj2790831; BRION JP, 1991, BIOCHEM J, V273, P127, DOI 10.1042/bj2730127; BRION JP, 1985, J SUBMICR CYTOL PATH, V17, P89; CITRON M, 1995, NEURON, V14, P661, DOI 10.1016/0896-6273(95)90323-2; Coghlan MP, 2000, CHEM BIOL, V7, P793, DOI 10.1016/S1074-5521(00)00025-9; Cupers P, 1997, BIOCHEM BIOPH RES CO, V236, P661, DOI 10.1006/bbrc.1997.7033; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; DELACOURTE A, 1986, J NEUROL SCI, V76, P173, DOI 10.1016/0022-510X(86)90167-X; Dovey HF, 2001, J NEUROCHEM, V76, P173, DOI 10.1046/j.1471-4159.2001.00012.x; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Ermolieff J, 2000, BIOCHEMISTRY-US, V39, P12450, DOI 10.1021/bi001494f; Essalmani R, 1996, BIOCHEM BIOPH RES CO, V218, P89, DOI 10.1006/bbrc.1996.0017; GRUNDKEIQBAL I, 1986, J BIOL CHEM, V261, P6084; HANGER DP, 1992, NEUROSCI LETT, V147, P58, DOI 10.1016/0304-3940(92)90774-2; Hong M, 1997, J BIOL CHEM, V272, P25326, DOI 10.1074/jbc.272.40.25326; Ida N, 1996, J BIOL CHEM, V271, P22908, DOI 10.1074/jbc.271.37.22908; Iijima K, 2000, J NEUROCHEM, V75, P1085, DOI 10.1046/j.1471-4159.2000.0751085.x; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kienlen-Campard P, 2002, J BIOL CHEM, V277, P15666, DOI 10.1074/jbc.M200887200; Kienlen-Campard P, 2002, PEPTIDES, V23, P1199, DOI 10.1016/S0196-9781(02)00055-4; Kumaraswamy S, 2004, P NATL ACAD SCI USA, V101, P7511, DOI 10.1073/pnas.0402367101; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; LEIGHTON F, 1968, J CELL BIOL, V37, P482, DOI 10.1083/jcb.37.2.482; LEMARCHAND P, 1992, P NATL ACAD SCI USA, V89, P6482, DOI 10.1073/pnas.89.14.6482; LOVESTONE S, 1994, CURR BIOL, V4, P1077, DOI 10.1016/S0960-9822(00)00246-3; Lovestone S, 1999, BIOL PSYCHIAT, V45, P995, DOI 10.1016/S0006-3223(98)00183-8; Macq AF, 1998, J BIOL CHEM, V273, P28931, DOI 10.1074/jbc.273.44.28931; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MunozMontano JR, 1997, FEBS LETT, V411, P183, DOI 10.1016/S0014-5793(97)00688-1; Octave JN, 1995, ACTA NEUROL BELG, V95, P197; Octave JN, 1995, REV NEUROSCIENCE, V6, P287; Phiel CJ, 2003, NATURE, V423, P435, DOI 10.1038/nature01640; Reynolds CH, 2000, J NEUROCHEM, V74, P1587, DOI 10.1046/j.1471-4159.2000.0741587.x; Ryder J, 2003, BIOCHEM BIOPH RES CO, V312, P922, DOI 10.1016/j.bbrc.2003.11.014; SARASTE J, 1987, J CELL BIOL, V105, P2021, DOI 10.1083/jcb.105.5.2021; SPERBER BR, 1995, NEUROSCI LETT, V197, P149, DOI 10.1016/0304-3940(95)11902-9; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; Standen CL, 2001, J NEUROCHEM, V76, P316, DOI 10.1046/j.1471-4159.2001.00102.x; STRATFORDPERRICAUDET LD, 1992, J CLIN INVEST, V90, P626, DOI 10.1172/JCI115902; Su Y, 2004, BIOCHEMISTRY-US, V43, P6899, DOI 10.1021/bi035627j; Sun X, 2002, NEUROSCI LETT, V321, P61, DOI 10.1016/S0304-3940(01)02583-6; van Noort M, 2002, J BIOL CHEM, V277, P17901, DOI 10.1074/jbc.M111635200; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735	47	38	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	2005	280	39					33220	33227		10.1074/jbc.M501610200	http://dx.doi.org/10.1074/jbc.M501610200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	966YG	16014628	hybrid			2022-12-25	WOS:000232058100017
J	Yamada, T; Sakisaka, T; Hisata, S; Baba, T; Takai, Y				Yamada, T; Sakisaka, T; Hisata, S; Baba, T; Takai, Y			RA-RhoGAP, Rap-activated Rho GTPase-activating protein implicated in neurite outgrowth through Rho	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN; ACTIN CYTOSKELETON; NEURONAL POLARITY; SIGNALING PATHWAY; EXCHANGE FACTOR; INVOLVEMENT; ADHERENS; CDC42; KINASE; NECTIN	Rap1 and Rho small G proteins have been implicated in the neurite outgrowth, but the functional relationship between Rap1 and Rho in the neurite outgrowth remains to be established. Here we identified a potent Rho GTPase-activating protein ( GAP), RA-RhoGAP, as a direct downstream target of Rap1 in the neurite outgrowth. RA-RhoGAP has the RA and GAP domains and showed GAP activity specific for Rho, which was enhanced by the binding of the GTP-bound active form of Rap1 to the RA domain. Overexpression of RA-RhoGAP induced inactivation of Rho for promoting the neurite outgrowth in a Rap1-dependent manner. Knockdown of RA-RhoGAP reduced the Rap1-induced neurite outgrowth. These results indicate that RA-RhoGAP transduces a signal from Rap1 to Rho and regulates the neurite outgrowth.	Osaka Univ, Dept Mol Biol & Biochem, Grad Sch Med, Fac Med, Suita, Osaka 5650871, Japan	Osaka University	Takai, Y (corresponding author), Osaka Univ, Dept Mol Biol & Biochem, Grad Sch Med, Fac Med, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	ytakai@molbio.med.osaka-u.ac.jp						Aoki K, 2005, MOL BIOL CELL, V16, P2207, DOI 10.1091/mbc.e04-10-0904; Bito H, 2000, NEURON, V26, P431, DOI 10.1016/S0896-6273(00)81175-7; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; Bradke F, 2000, CURR BIOL, V10, P1467, DOI 10.1016/S0960-9822(00)00807-1; Caron E, 2003, J CELL SCI, V116, P435, DOI 10.1242/jcs.00238; Christopoulos A, 2003, J BIOL CHEM, V278, P3293, DOI 10.1074/jbc.C200629200; CRAIG AM, 1995, NATURE, V375, P592, DOI 10.1038/375592a0; Cullere X, 2005, BLOOD, V105, P1950, DOI 10.1182/blood-2004-05-1987; Curry BJ, 2004, GENOMICS, V84, P406, DOI 10.1016/j.ygeno.2004.03.004; Da Silva JS, 2003, J CELL BIOL, V162, P1267, DOI 10.1083/jcb.200304021; Da Silva JS, 2002, NAT REV NEUROSCI, V3, P694, DOI 10.1038/nrn918; Dickson BJ, 2001, CURR OPIN NEUROBIOL, V11, P103, DOI 10.1016/S0959-4388(00)00180-X; Fukuhara A, 2003, J BIOL CHEM, V278, P51885, DOI 10.1074/jbc.M308015200; Fukui K, 1997, J BIOL CHEM, V272, P4655, DOI 10.1074/jbc.272.8.4655; Fukuyama T, 2005, J BIOL CHEM, V280, P815, DOI 10.1074/jbc.M411099200; Gendron L, 2003, J BIOL CHEM, V278, P3606, DOI 10.1074/jbc.M202446200; GOSLIN K, 1989, J CELL BIOL, V108, P1507, DOI 10.1083/jcb.108.4.1507; Hirose M, 1998, J CELL BIOL, V141, P1625, DOI 10.1083/jcb.141.7.1625; Horton AC, 2003, NEURON, V40, P277, DOI 10.1016/S0896-6273(03)00629-9; Hoshino T, 2004, MOL BIOL CELL, V15, P1077, DOI 10.1091/mbc.E03-05-0321; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; JALINK K, 1993, CELL GROWTH DIFFER, V4, P247; Jordan JD, 2005, J BIOL CHEM, V280, P11413, DOI 10.1074/jbc.M411521200; Kalla C, 2005, GENE CHROMOSOME CANC, V42, P128, DOI 10.1002/gcc.20131; Katoh M, 2003, INT J ONCOL, V23, P1471; KATOH M, 2005, IN PRESS GENES CHROM; Kinashi T, 2004, IMMUNOL LETT, V93, P1, DOI 10.1016/j.imlet.2004.02.008; Kohno H, 1996, EMBO J, V15, P6060, DOI 10.1002/j.1460-2075.1996.tb00994.x; Komuro R, 1996, GENES CELLS, V1, P943, DOI 10.1046/j.1365-2443.1996.760276.x; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; Liao YH, 2001, J BIOL CHEM, V276, P28478, DOI 10.1074/jbc.M101737200; Luo LQ, 2000, NAT REV NEUROSCI, V1, P173, DOI 10.1038/35044547; Machida N, 2004, J BIOL CHEM, V279, P15711, DOI 10.1074/jbc.C300542200; MITCHISON T, 1988, NEURON, V1, P761, DOI 10.1016/0896-6273(88)90124-9; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; NIRENBERG M, 1983, SCIENCE, V222, P794, DOI 10.1126/science.6314503; Price LS, 2004, NAT IMMUNOL, V5, P1007, DOI 10.1038/ni1004-1007; Sakisaka T, 2004, J CELL BIOL, V166, P17, DOI 10.1083/jcb.200405002; Sasaki T, 1998, BIOCHEM BIOPH RES CO, V245, P641, DOI 10.1006/bbrc.1998.8253; Schwamborn JC, 2004, NAT NEUROSCI, V7, P923, DOI 10.1038/nn1295; SEKINE A, 1989, J BIOL CHEM, V264, P8602; Shi SH, 2003, CELL, V112, P63, DOI 10.1016/S0092-8674(02)01249-7; Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Takai Y, 2003, J CELL SCI, V116, P17, DOI 10.1242/jcs.00167; Umikawa M, 1999, J BIOL CHEM, V274, P25197, DOI 10.1074/jbc.274.36.25197; Yamada A, 2005, J BIOL CHEM, V280, P6016, DOI 10.1074/jbc.M408215200	47	57	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	2005	280	38					33026	33034		10.1074/jbc.M504587200	http://dx.doi.org/10.1074/jbc.M504587200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	964ZU	16014623	hybrid			2022-12-25	WOS:000231920300057
J	Einav, U; Tabach, Y; Getz, G; Yitzhaky, A; Ozbek, U; Amariglio, N; Izraeli, S; Rechavi, G; Domany, E				Einav, U; Tabach, Y; Getz, G; Yitzhaky, A; Ozbek, U; Amariglio, N; Izraeli, S; Rechavi, G; Domany, E			Gene expression analysis reveals a strong signature of an interferon-induced pathway in childhood lymphoblastic leukemia as well as in breast and ovarian cancer	ONCOGENE			English	Article						gene expression; ALL; class discovery; interferon pathway; viral infection	T-CELLS; CLASSIFICATION; VIRUS; PREDICTION; SEQUENCES; DISCOVERY; HYPERMUTATION; INFLAMMATION; PATHOGENESIS; CHROMOSOMES	On the basis of epidemiological studies, infection was suggested to play a role in the etiology of human cancer. While for some cancers such a role was indeed demonstrated, there is no direct biological support for the role of viral pathogens in the pathogenesis of childhood leukemia. Using a novel bioinformatic tool that alternates between clustering and standard statistical methods of analysis, we performed a 'double-blind' search of published gene expression data of subjects with different childhood acute lymphoblastic leukemia (ALL) subtypes, looking for unanticipated partitions of patients, induced by unexpected groups of genes with correlated expression. We discovered a group of about 30 genes, related to the interferon response pathway, whose expression levels divide the ALL samples into two subgroups; high in 50, low in 285 patients. Leukemic subclasses prevalent in early childhood (the age most susceptible to infection) are over-represented in the high-expression subgroup. Similar partitions, induced by the same genes, were found also in breast and ovarian cancer but not in lung cancer, prostate cancer and lymphoma. About 40% of breast cancer samples expressed the 'interferon-related' signature. It is of interest that several studies demonstrated mouse mammary tumor virus-like sequences in about 40% of breast cancer samples. Our discovery of an unanticipated strong signature of an interferon-induced pathway provides molecular support for a role for either inflammation or viral infection in the pathogenesis of childhood leukemia as well as breast and ovarian cancer.	Safa Childrens Hosp, Sheba Med Ctr, Dept Pediat Hematol & Oncol, IL-52621 Tel Hashomer, Israel; Weizmann Inst Sci, Dept Phys, IL-76100 Rehovot, Israel; Istanbul Univ, DETAE, Dept Genet, Expt Med Res Inst, Istanbul, Turkey; Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel	Chaim Sheba Medical Center; Weizmann Institute of Science; Istanbul University; Tel Aviv University; Sackler Faculty of Medicine	Rechavi, G (corresponding author), Safa Childrens Hosp, Sheba Med Ctr, Dept Pediat Hematol & Oncol, IL-52621 Tel Hashomer, Israel.	gidi.rechavi@sheba.health.gov.il; eytan.domany@weizmann.ac.il	Ozbek, Ugur/C-9513-2017; DOMANY, EYTAN/K-1560-2012; Tabach, Yuval/Q-8488-2019	Ozbek, Ugur/0000-0001-5319-0547; 				Akyerli CB, 2005, LEUKEMIA RES, V29, P283, DOI 10.1016/j.leukres.2004.07.007; Armstrong SA, 2002, NAT GENET, V30, P41, DOI 10.1038/ng765; Ben-Dor A, 2000, J COMPUT BIOL, V7, P559, DOI 10.1089/106652700750050943; Benekli M, 2003, BLOOD, V101, P2940, DOI 10.1182/blood-2002-04-1204; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Blatt M, 1997, NEURAL COMPUT, V9, P1805, DOI 10.1162/neco.1997.9.8.1805; Blatt M, 1996, PHYS REV LETT, V76, P3251, DOI 10.1103/PhysRevLett.76.3251; Califano A, 2000, Proc Int Conf Intell Syst Mol Biol, V8, P75; Chawla-Sarkar M, 2003, APOPTOSIS, V8, P237, DOI 10.1023/A:1023668705040; Cheng Y., 2000, P 8 INT C INT SYST M, P93; Colonna M, 2002, CURR OPIN IMMUNOL, V14, P373, DOI 10.1016/S0952-7915(02)00349-7; Dalgleish AG, 2002, ADV CANCER RES, V84, P231, DOI 10.1016/S0065-230X(02)84008-8; Ernst P, 1999, ALIMENT PHARM THER, V13, P13, DOI 10.1046/j.1365-2036.1999.00003.x; Ford AM, 1998, P NATL ACAD SCI USA, V95, P4584, DOI 10.1073/pnas.95.8.4584; Ford CE, 2003, CLIN CANCER RES, V9, P1118; Gale KB, 1997, P NATL ACAD SCI USA, V94, P13950, DOI 10.1073/pnas.94.25.13950; Georgiannos SN, 2003, SURGERY, V134, P827, DOI 10.1016/S0039-6060(03)00292-7; Getz G, 2000, P NATL ACAD SCI USA, V97, P12079, DOI 10.1073/pnas.210134797; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Greaves MF, 1997, LANCET, V349, P344, DOI 10.1016/S0140-6736(96)09412-3; GREAVES MF, 1988, LEUKEMIA, V2, P120; GREAVES MF, 1993, LEUKEMIA, V7, P349; HASLE H, 1995, LEUKEMIA, V9, P605; Heerema NA, 2000, J CLIN ONCOL, V18, P1876, DOI 10.1200/JCO.2000.18.9.1876; HENLE G, 1966, J BACTERIOL, V91, P1248, DOI 10.1128/JB.91.3.1248-1256.1966; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; Ihmels J, 2002, NAT GENET, V31, P370, DOI 10.1038/ng941; Ito C, 1999, BLOOD, V93, P315, DOI 10.1182/blood.V93.1.315.401k35_315_320; KEYDAR I, 1984, P NATL ACAD SCI-BIOL, V81, P4188, DOI 10.1073/pnas.81.13.4188; KINLEN LJ, 1995, BRIT J CANCER, V71, P1, DOI 10.1038/bjc.1995.1; Kinlen LJ, 2001, LANCET, V357, P858, DOI 10.1016/S0140-6736(00)04208-2; Koushik A, 2001, CANCER CAUSE CONTROL, V12, P483, DOI 10.1023/A:1011266413087; Liyanage UK, 2002, J IMMUNOL, V169, P2756, DOI 10.4049/jimmunol.169.5.2756; MacKenzie J, 1999, BRIT J CANCER, V81, P898, DOI 10.1038/sj.bjc.6690783; MacKenzie J, 2001, LEUKEMIA, V15, P415, DOI 10.1038/sj.leu.2402049; Mangeat B, 2003, NATURE, V424, P99, DOI 10.1038/nature01709; Mele A, 2003, BLOOD, V102, P996, DOI 10.1182/blood-2002-10-3230; Ness RB, 2003, J INFECT DIS, V187, P1147, DOI 10.1086/368380; Nzula S, 2003, CANCER RES, V63, P3275; Peek RM, 2002, NAT REV CANCER, V2, P28, DOI 10.1038/nrc703; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Pui C, 2004, NEW ENGL J MED, V350, P1535, DOI 10.1056/NEJMra023001; Ramaswamy S, 2001, P NATL ACAD SCI USA, V98, P15149, DOI 10.1073/pnas.211566398; Reome JB, 2004, CLIN IMMUNOL, V111, P69, DOI 10.1016/j.clim.2003.11.013; Ross ME, 2003, BLOOD, V102, P2951, DOI 10.1182/blood-2003-01-0338; Rozovskaia T, 2003, P NATL ACAD SCI USA, V100, P7853, DOI 10.1073/pnas.1132115100; Sangfelt O, 2001, MED ONCOL, V18, P3, DOI 10.1385/MO:18:1:3; Shipp MA, 2002, NAT MED, V8, P68, DOI 10.1038/nm0102-68; Singh D, 2002, CANCER CELL, V1, P203, DOI 10.1016/S1535-6108(02)00030-2; Staunton JE, 2001, P NATL ACAD SCI USA, V98, P10787, DOI 10.1073/pnas.191368598; Tabori U, 2001, LEUKEMIA, V15, P866, DOI 10.1038/sj.leu.2402102; Tanay Amos, 2002, Bioinformatics, V18 Suppl 1, pS136; Troyanskaya O, 2001, BIOINFORMATICS, V17, P520, DOI 10.1093/bioinformatics/17.6.520; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Wall L, 2003, GYNECOL ONCOL, V88, pS149, DOI 10.1006/gyno.2002.6707; WANG Y, 1995, CANCER RES, V55, P5173; Welsh JB, 2001, CANCER RES, V61, P5974; Welsh JB, 2001, P NATL ACAD SCI USA, V98, P1176, DOI 10.1073/pnas.98.3.1176; Wiemels JL, 1999, BLOOD, V94, P1057, DOI 10.1182/blood.V94.3.1057.415k10_1057_1062; Wiemels JL, 1999, LANCET, V354, P1499, DOI 10.1016/S0140-6736(99)09403-9; Yeoh EJ, 2002, CANCER CELL, V1, P133, DOI 10.1016/S1535-6108(02)00032-6; Yu M, 1997, P NATL ACAD SCI USA, V94, P7406, DOI 10.1073/pnas.94.14.7406; Zhang H, 2003, NATURE, V424, P94, DOI 10.1038/nature01707; Zhang L, 2003, NEW ENGL J MED, V348, P203, DOI 10.1056/NEJMoa020177	65	56	56	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 22	2005	24	42					6367	6375		10.1038/sj.onc.1208797	http://dx.doi.org/10.1038/sj.onc.1208797			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	966RI	16007187	Green Submitted			2022-12-25	WOS:000232038200004
J	Niwa, Y; Kanda, H; Shikauchi, Y; Saiura, A; Matsubara, K; Kitagawa, T; Yamamoto, J; Kubo, T; Yoshikawa, H				Niwa, Y; Kanda, H; Shikauchi, Y; Saiura, A; Matsubara, K; Kitagawa, T; Yamamoto, J; Kubo, T; Yoshikawa, H			Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma	ONCOGENE			English	Article						SOCS-3; FAK; JAK/ STAT; HCC	PROTEIN-TYROSINE KINASE; FOCAL ADHESION KINASE; CONSTITUTIVE ACTIVATION; LIVER; OVEREXPRESSION; INACTIVATION; ASSOCIATION; PP125(FAK); ASSIGNMENT; FRAGMENTS	We identified that suppressor of cytokine signaling-3 (SOCS-3) gene was aberrantly methylated in its CpG island in three of 10 human hepatocellular carcinoma ( HCC) cell lines. SOCS-3 RNA was undetectable in five of the 10 HCC cell lines including the three methylated cell lines, and a demethylating agent, 5-aza-2'-deoxycytidine, reactivated SOCS-3 expression in three cell lines tested. The DNA region where we found aberrant DNA methylation includes a signal transducers and activators of transcription ( STAT) binding consensus sequence. When the DNA region was used as a promoter, DNA methylation markedly reduced promoter activity. SOCS-3 was also aberrantly methylated in six of 18 primary HCC samples. SOCS-3 expression was reduced in three of the three methylated and one of the three unmethylated primary samples examined. Restoration of SOCS-3 in cells lacking SOCS-3 expression suppressed STAT3 phosphorylation and cell growth. We found that IL-6 acted as a growth factor in HCC cells. Inhibition of SOCS-3 expression in cells whose growth was induced by IL-6 enhanced STAT3 phosphorylation and cell growth. In addition, AG490, a chemical JAK2 inhibitor, suppressed cell growth and downregulated STAT3 phosphorylation, but not FAK phosphorylation. We also found that SOCS-3 physically interacted with phosphorylated FAK and Elongin B in HCC cells. Restoration of SOCS-3 decreased FAK phosphorylation as well as FAK protein level. Inhibition of SOCS-3 expression increased FAK phosphorylation, resulting in enhancement of cell migration. These data indicate that SOCS-3 negatively regulates cell growth and cell motility by inhibiting Janus kinase (JAK)/STAT and FAK signalings in HCC cells. Thus, loss of SOCS-3 by the associated DNA methylation confers cells advantage in growth and migration.	Japanese Fdn Canc Res, Inst Canc, Dept Epigenet Carcinogenesis, Koto Ku, Tokyo 1358550, Japan; Japanese Fdn Canc Res, Inst Canc, Dept Pathol, Koto Ku, Tokyo 1358550, Japan; Japanese Fdn Canc Res, Inst Canc, Dept Surg, Koto Ku, Tokyo 1358550, Japan; DNA Chip Res Inc, Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan	Japanese Foundation for Cancer Research; Japanese Foundation for Cancer Research; Japanese Foundation for Cancer Research; DNA Chip Research Inc.	Yoshikawa, H (corresponding author), Japanese Fdn Canc Res, Inst Canc, Dept Epigenet Carcinogenesis, Koto Ku, 3-10-6 Ariake, Tokyo 1358550, Japan.	hirohide.yoshikawa@jfcr.or.jp						Auernhammer CJ, 1999, P NATL ACAD SCI USA, V96, P6964, DOI 10.1073/pnas.96.12.6964; BEDOSSA P, 1994, HEPATOLOGY, V20, P15; Cary LA, 1996, J CELL SCI, V109, P1787; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; EDMONDSON HA, 1954, CANCER-AM CANCER SOC, V7, P462, DOI 10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; He B, 2003, P NATL ACAD SCI USA, V100, P14133, DOI 10.1073/pnas.2232790100; Herman JG, 1997, CANCER RES, V57, P837; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; ILLC D, 1995, NATURE, V377, P539; Kamizono S, 2001, J BIOL CHEM, V276, P12530, DOI 10.1074/jbc.M010074200; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; Kubo T, 2004, CANCER RES, V64, P5172, DOI 10.1158/0008-5472.CAN-03-3314; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; Liu E, 2003, EMBO J, V22, P5036, DOI 10.1093/emboj/cdg503; LUO H, 1995, EMBO J, V14, P1412, DOI 10.1002/j.1460-2075.1995.tb07127.x; MIKI S, 1989, FEBS LETT, V250, P607, DOI 10.1016/0014-5793(89)80805-1; Nagamori S, 2000, J GASTROENTEROL, V35, P493, DOI 10.1007/s005350070071; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; OWENS LV, 1995, CANCER RES, V55, P2752; Sasaki A, 2003, J BIOL CHEM, V278, P2432, DOI 10.1074/jbc.C200608200; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; WeberNordt RM, 1996, BLOOD, V88, P809; Yoshida T, 2004, J EXP MED, V199, P1701, DOI 10.1084/jem.20031675; Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/88225; Yoshikawa H, 1996, GENOMICS, V31, P28, DOI 10.1006/geno.1996.0005; Yoshikawa H, 1997, GENE, V197, P129, DOI 10.1016/S0378-1119(97)00251-5; Yoshikawa H, 1998, GENOMICS, V49, P237, DOI 10.1006/geno.1998.5246; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071; Zimmers TA, 2003, HEPATOLOGY, V38, P326, DOI 10.1053/jhep.2003.50318	39	273	310	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 22	2005	24	42					6406	6417		10.1038/sj.onc.1208788	http://dx.doi.org/10.1038/sj.onc.1208788			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	966RI	16007195				2022-12-25	WOS:000232038200008
J	Kobayashi, Y; Shibusawa, A; Saito, H; Ohshiro, N; Ohbayashi, M; Kohyama, N; Yamamoto, T				Kobayashi, Y; Shibusawa, A; Saito, H; Ohshiro, N; Ohbayashi, M; Kohyama, N; Yamamoto, T			Isolation and functional characterization of a novel organic solute carrier protein, hOSCP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION CLONING; ANION TRANSPORTER; MOLECULAR-CLONING; HUMAN-PLACENTA; LIVER; IDENTIFICATION; SYSTEM; ACID	We succeeded in isolating a novel organic solute carrier from a human placenta cDNA library. The isolated cDNA consisted of 1137 base pairs that encoded a 379-amino acid protein, hOSCP1. Northern blot and reverse transcription PCR analyses revealed that the hOSCP1 mRNA is expressed in the placenta and testis and weakly expressed in the thymus and small intestine. When expressed in Xenopus laevis oocytes, hOSCP1 mediated the high affinity transport of p-aminohippurate ( PAH) (K-m = 35.0 +/- 7.5 mu M) and tetraethylammonium ( K-m = 62.3 +/- 12.2 mu M) in a sodium-independent manner. However, the hOSCP1-expressing oocyte did not mediate the transport of L-carnitine. The transport of PAH by hOSCP1 was sensitive to pH, but the tetraethylammonium was not transported at the high pH examined. hOSCP1 transported prostaglandin E-2, prostaglandin F-2 alpha, estrone sulfate, glutarate, L-leucine, L-ascorbic acid, and tetracycline. Thus, hOSCP1 also showed broad substrate specificity. A wide range of structurally unrelated organic compounds inhibited the hOSCP1-mediated PAH uptake. Immunohistochemical analysis revealed that the hOSCP1 protein is localized in the basal membrane of the syncytiotrophoblast in the human placenta. Our results suggest that hOSCP1 is a novel polyspecific organic solute carrier protein responsible for drug clearance from the human placenta.	Showa Univ, Sch Pharmaceut Sci, Dept Clin Pharm, Tokyo 1428555, Japan	Showa University	Yamamoto, T (corresponding author), Showa Univ, Sch Pharmaceut Sci, Dept Clin Pharm, 1-5-8 Hatanodai, Tokyo 1428555, Japan.	yamagen@pharm.showa-u.ac.jp		Kohyama, Noriko/0000-0002-4681-5833				Cha SH, 2000, J BIOL CHEM, V275, P4507, DOI 10.1074/jbc.275.6.4507; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Griffiths M, 1997, BIOCHEM J, V328, P739, DOI 10.1042/bj3280739; HAGENBUCH B, 1991, P NATL ACAD SCI USA, V88, P10629, DOI 10.1073/pnas.88.23.10629; Hediger MA, 2004, PFLUG ARCH EUR J PHY, V447, P465, DOI 10.1007/s00424-003-1192-y; JACQUEMIN E, 1994, P NATL ACAD SCI USA, V91, P133, DOI 10.1073/pnas.91.1.133; Kanai Y, 1998, J BIOL CHEM, V273, P23629, DOI 10.1074/jbc.273.37.23629; Kekuda R, 1998, J BIOL CHEM, V273, P15971, DOI 10.1074/jbc.273.26.15971; Kobayashi Y, 2002, MOL PHARMACOL, V62, P7, DOI 10.1124/mol.62.1.7; Li LQ, 1998, J BIOL CHEM, V273, P16184, DOI 10.1074/jbc.273.26.16184; Matthews JC, 1998, AM J PHYSIOL-CELL PH, V274, pC603, DOI 10.1152/ajpcell.1998.274.3.C603; Meier PJ, 1995, AM J PHYSIOL-GASTR L, V269, pG801, DOI 10.1152/ajpgi.1995.269.6.G801; MOLLER JV, 1982, PHARMACOL REV, V34, P315; PAJOR AM, 1995, J BIOL CHEM, V270, P5779, DOI 10.1074/jbc.270.11.5779; PETZINGER E, 1994, REV PHYSIOL BIOCH P, V123, P47, DOI 10.1007/BFb0030903; Prasad PD, 1998, J BIOL CHEM, V273, P7501, DOI 10.1074/jbc.273.13.7501; PRITCHARD JB, 1993, PHYSIOL REV, V73, P765, DOI 10.1152/physrev.1993.73.4.765; SAIGO K, 1990, REPROD TOXICOL, V4, P29, DOI 10.1016/0890-6238(90)90076-8; Sekine T, 1997, J BIOL CHEM, V272, P18526, DOI 10.1074/jbc.272.30.18526; Seward DJ, 2003, J BIOL CHEM, V278, P27473, DOI 10.1074/jbc.M301106200; SHIN BC, 1997, ENDOCRINOLOGY, V138, P3397; Tamai I, 1998, J BIOL CHEM, V273, P20378, DOI 10.1074/jbc.273.32.20378; Ullrich KJ, 1997, PFLUG ARCH EUR J PHY, V433, P735, DOI 10.1007/s004240050339; VANDERAA EM, 1994, PLACENTA, V15, P279, DOI 10.1016/0143-4004(94)90019-1; Wang W, 2001, P NATL ACAD SCI USA, V98, P9431, DOI 10.1073/pnas.161099898; WHITSETT JA, 1980, J PEDIATR-US, V96, P600, DOI 10.1016/S0022-3476(80)80873-0	27	31	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	2005	280	37					32332	32339		10.1074/jbc.M504246200	http://dx.doi.org/10.1074/jbc.M504246200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	963HM	16006562	hybrid			2022-12-25	WOS:000231794800037
J	Rampal, R; Arboleda-Velasquez, JF; Nita-Lazar, A; Kosik, KS; Haltiwanger, RS				Rampal, R; Arboleda-Velasquez, JF; Nita-Lazar, A; Kosik, KS; Haltiwanger, RS			Highly conserved O-fucose sites have distinct effects on Notch1 function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING; PROTEIN O-FUCOSYL-TRANSFERASE-1; DELTA INTERACTIONS; LINKED FUCOSE; FRINGE; GLYCOSYLATION; RECEPTOR; GENE; GLYCOSYLTRANSFERASE; MODULATION	The extracellular domain of mouse Notch1 contains 36 tandem epidermal growth factor-like (EGF) repeats, many of which are modified with O-fucose. Previous work from several laboratories has indicated that O-fucosylation plays an important role in ligand mediated Notch activation. Nonetheless, it is not clear whether all, or a subset, of the EGF repeats need to be O-fucosylated. Three O-fucose sites are invariantly conserved in all Notch homologues with 36 EGF repeats ( within EGF repeats 12, 26, and 27). To investigate which O-fucose sites on Notch1 are important for ligand-mediated signaling, we mutated the three invariant O-fucose sites in mouse Notch1, along with several less highly conserved sites, and evaluated their ability to transduce Jagged1- and Delta1-mediated signaling in a cell-based assay. Our analysis revealed that mutation of any of the three invariant O-fucose sites resulted in significant changes in both Delta1 and Jagged1 mediated signaling, but mutations in less highly conserved sites had no detectable effect. Interestingly, mutation of each invariant site gave a distinct effect on Notch function. Mutation of the O-fucose site in EGF repeat 12 resulted in loss of Delta1 and Jagged1 signaling, while mutation of the O-fucose site in EGF repeat 26 resulted in hyperactivation of both Delta1 and Jagged1 signaling. Mutation of the O-fucose site in EGF repeat 27 resulted in faulty trafficking of the Notch receptor to the cell surface and a decreased S1 processing of the receptor. These results indicate that the most highly conserved O-fucose sites in Notch1 are important for both processing and ligand-mediated signaling in the context of a cell-based signaling assay.	SUNY Stony Brook, Inst Cell & Dev Biol, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA; Brigham & Womens Hosp, Dept Neurol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Haltiwanger, RS (corresponding author), SUNY Stony Brook, Inst Cell & Dev Biol, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA.	rhaltiwanger@ms.cc.sunysb.edu	Nita-Lazar, Aleksandra/N-3740-2018	Nita-Lazar, Aleksandra/0000-0002-8523-605X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061126, T32GM008444] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 61126, R01 GM061126, T32 GM008444] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arboleda-Velasquez JF, 2005, HUM MOL GENET, V14, P1631, DOI 10.1093/hmg/ddi171; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Blaumueller CM, 1997, CELL, V90, P281, DOI 10.1016/S0092-8674(00)80336-0; Bruckner K, 2000, NATURE, V406, P411, DOI 10.1038/35019075; Chen JH, 2001, P NATL ACAD SCI USA, V98, P13716, DOI 10.1073/pnas.241398098; de Celis JF, 2000, DEVELOPMENT, V127, P1291; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Fleming RJ, 1997, DEVELOPMENT, V124, P2973; Haines N, 2003, NAT REV MOL CELL BIO, V4, P786, DOI 10.1038/nrm1228; Hambleton S, 2004, STRUCTURE, V12, P2173, DOI 10.1016/j.str.2004.09.012; Hicks C, 2000, NAT CELL BIOL, V2, P515, DOI 10.1038/35019553; John GR, 2002, NAT MED, V8, P1115, DOI 10.1038/nm781; Joutel A, 1996, NATURE, V383, P707, DOI 10.1038/383707a0; Lei L, 2003, DEVELOPMENT, V130, P6411, DOI 10.1242/dev.00883; Luo Y, 2005, J BIOL CHEM, V280, P11289, DOI 10.1074/jbc.M414574200; May P, 2003, J BIOL CHEM, V278, P37386, DOI 10.1074/jbc.M305858200; Moloney DJ, 1997, J BIOL CHEM, V272, P19046, DOI 10.1074/jbc.272.30.19046; Moloney DJ, 2000, J BIOL CHEM, V275, P9604, DOI 10.1074/jbc.275.13.9604; Moloney DJ, 2000, NATURE, V406, P369, DOI 10.1038/35019000; Mumm JS, 2000, DEV BIOL, V228, P151, DOI 10.1006/dbio.2000.9960; Nofziger D, 1999, DEVELOPMENT, V126, P1689; Okajima T, 2003, J BIOL CHEM, V278, P42340, DOI 10.1074/jbc.M308687200; Okajima T, 2005, SCIENCE, V307, P1599, DOI 10.1126/science.1108995; Okajima T, 2002, CELL, V111, P893, DOI 10.1016/S0092-8674(02)01114-5; Panin VM, 1997, NATURE, V387, P908, DOI 10.1038/43191; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; Sasamura T, 2003, DEVELOPMENT, V130, P4785, DOI 10.1242/dev.00679; Shao L, 2003, J BIOL CHEM, V278, P7775, DOI 10.1074/jbc.M212221200; Shi SL, 2003, P NATL ACAD SCI USA, V100, P5234, DOI 10.1073/pnas.0831126100; Yang LT, 2005, MOL BIOL CELL, V16, P927, DOI 10.1091/mbc.e04-07-0614	30	82	82	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	2005	280	37					32133	32140		10.1074/jbc.M506104200	http://dx.doi.org/10.1074/jbc.M506104200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	963HM	15994302	hybrid, Green Accepted			2022-12-25	WOS:000231794800013
J	Cui, SJ; Guo, XQ; Chang, F; Cui, YW; Ma, LG; Sun, Y; Sun, D				Cui, SJ; Guo, XQ; Chang, F; Cui, YW; Ma, LG; Sun, Y; Sun, D			Apoplastic calmodulin receptor-like binding proteins in suspension-cultured cells of Arabidopsis thaliana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEIN; EXTRACELLULAR CALMODULIN; SIGNAL-TRANSDUCTION; POLLEN GERMINATION; ENDOTHELIAL-CELLS; TUBE GROWTH; PLANTS; PROLIFERATION; RELEASE; SURFACE	Calmodulin, a highly conserved protein family that has long been well known as an intracellular calcium sensor, was identified in the culture medium and cell walls of Arabidopsis thaliana suspension-cultured cells by immunoblotting assay. A promotion effect by applying exogenous purified calmodulin and an inhibition effect by the addition of anti-calmodulin anti-serum or calmodulin antagonist to the medium on proliferation of suspension cells were found by monitoring incorporation of [methyl-H-3]thymidine into nuclear DNA. Radioligand binding analysis with S-35-labeled calmodulin indicated the presence of specific, reversible, and saturable calmodulin binding sites on the surface of both A. thaliana suspension-cultured cells and its protoplasts; among them at least one is on the surface of Arabidopsis protoplasts, with the K-d similar to 9.2 nM, and two are on the out-surface of Arabidopsis suspension-cultured cells, with K-d values of similar to 47.5 and 830 nM. Chemical cross-linking of S-35-labeled calmodulin to protoplasts revealed 117- and 41-kDa plasma membrane proteins specifically bound to calmodulin, whereas cross-linking with intact suspension-cultured cells verified more calmodulin binding proteins which might be cell wall-associated in addition to membrane-localized. Taking together, our data provide first evidence for the presence of apoplastic calmodulin receptor-like binding proteins on the cell surface of Arabidopsis suspension-cultured cells, which strongly supports our previous idea that apoplastic calmodulin functions as a peptide signal involved in regulation of cell growth and development.	Hebei Normal Univ, Inst Mol Cell Biol, Shijiazhuang 050016, Peoples R China	Hebei Normal University	Sun, D (corresponding author), Hebei Normal Univ, Inst Mol Cell Biol, 265 Yuhua Rd, Shijiazhuang 050016, Peoples R China.	cell@mail.hebtu.edu.cn						BANTING FG, 1922, J LAB CLIN MED, V7, P256; BIRO RL, 1984, PLANT PHYSIOL, V75, P382, DOI 10.1104/pp.75.2.382; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen YL, 2004, PLANT PHYSIOL, V136, P4096, DOI 10.1104/pp.104.047837; Clark GB, 2001, CURR SCI INDIA, V80, P170; CROCKER C, 1988, BIOCHEM J, V25, P877; CUI SJ, 2002, PROG BIOCHEM BIOPHYS, V29, P801; DAWSON RA, 1992, BRIT J HAEMATOL, V82, P151, DOI 10.1111/j.1365-2141.1992.tb04607.x; EDWARD EF, 1984, ANAL BIOCHEM, V141, P79; Endl I, 1996, MOL BIOL CELL, V7, P17, DOI 10.1091/mbc.7.1.17; Fromm H, 1992, PLANT MOL BIOL REP, V10, P199, DOI 10.1007/BF02668347; Han SC, 2003, NATURE, V425, P196, DOI 10.1038/nature01932; Houston DS, 1997, J BIOL CHEM, V272, P11778, DOI 10.1074/jbc.272.18.11778; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; LI JX, 1993, CELL RES, V3, P11; Lindsey K, 2002, TRENDS PLANT SCI, V7, P78, DOI 10.1016/S1360-1385(01)02194-X; LOURDES GG, 2002, TRENDS PLANT SCI, V7, P251; Ma LG, 1997, PLANTA, V202, P336, DOI 10.1007/s004250050135; Ma LG, 1999, PLANT CELL, V11, P1351, DOI 10.1105/tpc.11.7.1351; Ma LG, 2001, CHINESE SCI BULL, V46, P622, DOI 10.1007/BF03182819; Ma Li-Geng, 1998, Acta Phytophysiologica Sinica, V24, P196; MACNEIL S, 1988, J ENDOCRINOL, V118, P501, DOI 10.1677/joe.0.1180501; MACNEIL S, 1984, J INVEST DERMATOL, V83, P15, DOI 10.1111/1523-1747.ep12261637; Mao GH, 2005, PLANTA, V222, P428, DOI 10.1007/s00425-005-1558-9; Mao Guo-Hong, 1999, Acta Phytophysiologica Sinica, V25, P165; Marx J, 1996, SCIENCE, V273, P1338, DOI 10.1126/science.273.5280.1338; Matsubayashi Y, 2003, J CELL SCI, V116, P3863, DOI 10.1242/jcs.00733; Matsubayashi Y, 1997, P NATL ACAD SCI USA, V94, P13357, DOI 10.1073/pnas.94.24.13357; PERSHADSINGH HA, 1980, J BIOL CHEM, V255, P4087; POLLAK MR, 1993, CELL, V75, P1297, DOI 10.1016/0092-8674(93)90617-Y; REMGARD P, 1995, EUR J NEUROSCI, V7, P1386, DOI 10.1111/j.1460-9568.1995.tb01130.x; Ryan CA, 2002, PLANT CELL, V14, pS251, DOI 10.1105/tpc.010484; Scheer JM, 1999, PLANT CELL, V11, P1525, DOI 10.1105/tpc.11.8.1525; Shang ZL, 2005, PLANT CELL PHYSIOL, V46, P598, DOI 10.1093/pcp/pci063; SUN DY, 1995, PLANT CELL PHYSIOL, V36, P133; SUN DY, 1994, PLANT SCI, V99, P1, DOI 10.1016/0168-9452(94)90114-7; Sun DY, 2001, SCI CHINA SER C, V44, P449, DOI 10.1007/BF02882387; Tang J, 1996, PLANTA, V198, P510, DOI 10.1007/BF00262636; TANG WQ, 1997, J ENDOCRINOL, V155, P13; Thomas C, 2000, PLANT CELL, V12, P519, DOI 10.1105/tpc.12.4.519; Thomas C, 1999, PLANT PHYSIOL, V119, P543, DOI 10.1104/pp.119.2.543; Yang TB, 2003, TRENDS PLANT SCI, V8, P505, DOI 10.1016/j.tplants.2003.09.004; YE ZH, 1988, CHINESE SCI BULL, V33, P624; Zielinski RE, 1998, ANNU REV PLANT PHYS, V49, P697, DOI 10.1146/annurev.arplant.49.1.697; ZIELINSKI RE, 2000, METHOD MOL BIOL, V172, P1; 孙大业, 1995, 科学通报, V40, P1153	46	20	22	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	2005	280	36					31420	31427		10.1074/jbc.M501349200	http://dx.doi.org/10.1074/jbc.M501349200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	961LZ	16000297	hybrid			2022-12-25	WOS:000231665200012
J	Hong, F; Sekhar, KR; Freeman, ML; Liebler, DC				Hong, F; Sekhar, KR; Freeman, ML; Liebler, DC			Specific patterns of electrophile adduction trigger Keap1 ubiquitination and Nrf2 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CUL3-BASED E3 LIGASE; TRANSCRIPTION FACTOR; COP9 SIGNALOSOME; GENE-EXPRESSION; SUBUNIT GENE; INDUCTION; PROTEIN; DEGRADATION; INDUCERS; ADAPTER	Activation of the transcription factor Nrf2 regulates expression of phase II enzymes and other adaptive responses to electrophile and oxidant stress. Nrf2 concentrations are regulated by the thiol-rich sensor protein Keap1, which is an adaptor protein for Cul3-dependent ubiquitination and degradation of Nrf2. However, the links between site specificity of Keap1 modification by electrophiles and mechanisms of Nrf2 activation are poorly understood. We studied the actions of the prototypical Nrf2 inducer tert-butylhydroquinone ( tBHQ) and two biotin-tagged, thiol-reactive electrophiles, Niodoacetyl-N-biotinylhexylenediamine ( IAB) and 1-biotinamido-4-( 4'-[ maleimidoethyl-cyclohexane]-carboxamido) butane ( BMCC). Both IAB and tBHQ induced antioxidant response element ( ARE)-directed green fluorescent protein ( GFP) expression in ARE/thymidine kinase GFP HepG2 cells, and both initiated nuclear Nrf2 accumulation and induction of heme oxygenase 1 in HEK293 cells. In contrast, BMCC produced none of these effects. Liquid chromatography tandem mass spectrometry ( MS-MS) analysis of human Keap1 modified by IAB or BMCC in vitro indicated that IAB adduction occurred primarily in the central linker domain, whereas BMCC modified other Keap1 domains. Treatment of FLAG-Keap1-transfected HEK293 with the Nrf2-activating compounds IAB and tBHQ generated high molecular weight Keap1 forms, which were identified as K-48linked polyubiquitin conjugates by immunoblotting and liquid chromatography MS-MS. Keap1 polyubiquitination coincided with Nrf2 stabilization and nuclear accumulation. In contrast, BMCC did not induce Keap1 polyubiquitination. Our results suggest that Nrf2 activation is regulated through the polyubiquitination of Keap1, which in turn is triggered by specific patterns of electrophile modification of the Keap1 central linker domain. These results suggest that Keap1 adduction triggers a switching of Cul3-dependent ubiquitination from Nrf2 to Keap1, leading to Nrf2 activation.	Vanderbilt Univ, Sch Med, Mass Spectrometry Res Ctr, Nashville, TN 37232 USA; Univ Arizona, Coll Pharm, Dept Pharmacol & Toxicol, Tucson, AZ 85721 USA; Vanderbilt Univ, Sch Med, Dept Radiat Oncol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA	Vanderbilt University; University of Arizona; Vanderbilt University; Vanderbilt University; Vanderbilt University	Liebler, DC (corresponding author), Vanderbilt Univ, Sch Med, Mass Spectrometry Res Ctr, 9110A Med Res Bldg 3,465 21st Ave S, Nashville, TN 37232 USA.	daniel.liebler@vanderbilt.edu		Freeman, Michael/0000-0003-1881-366X; Konjeti, Sekhar/0000-0003-2930-0739; Liebler, Daniel/0000-0002-7873-3031	NATIONAL CANCER INSTITUTE [R01CA104590] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES010056, P30ES000267] Funding Source: NIH RePORTER; NCI NIH HHS [CA104590, R01 CA104590] Funding Source: Medline; NIEHS NIH HHS [ES010056, ES000267] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Alam J, 1999, J BIOL CHEM, V274, P26071, DOI 10.1074/jbc.274.37.26071; BARRAL Y, 1995, GENE DEV, V9, P399, DOI 10.1101/gad.9.4.399; Cope GA, 2003, CELL, V114, P663, DOI 10.1016/S0092-8674(03)00722-0; Cullinan SB, 2004, MOL CELL BIOL, V24, P8477, DOI 10.1128/MCB.24.19.8477-8486.2004; Dinkova-Kostova AT, 2002, P NATL ACAD SCI USA, V99, P11908, DOI 10.1073/pnas.172398899; Dinkova-Kostova AT, 2001, P NATL ACAD SCI USA, V98, P3404, DOI 10.1073/pnas.051632198; Furukawa M, 2005, MOL CELL BIOL, V25, P162, DOI 10.1128/MCB.25.1.162-171.2005; Galan JM, 1999, P NATL ACAD SCI USA, V96, P9124, DOI 10.1073/pnas.96.16.9124; Geyer R, 2003, MOL CELL, V12, P783, DOI 10.1016/S1097-2765(03)00341-1; Hayes JD, 2001, CANCER LETT, V174, P103, DOI 10.1016/S0304-3835(01)00695-4; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Itoh K, 2003, GENES CELLS, V8, P379, DOI 10.1046/j.1365-2443.2003.00640.x; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; ITOH K, 1995, MOL CELL BIOL, V15, P4184, DOI 10.1128/mcb.15.8.4184; Kang MI, 2004, P NATL ACAD SCI USA, V101, P2046, DOI 10.1073/pnas.0308347100; Kensler TW, 1997, ENVIRON HEALTH PERSP, V105, P965, DOI 10.2307/3433311; Kobayashi A, 2004, MOL CELL BIOL, V24, P7130, DOI 10.1128/MCB.24.16.7130-7139.2004; Kwak MK, 2003, J BIOL CHEM, V278, P8135, DOI 10.1074/jbc.M211898200; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; Moinova HR, 1999, BIOCHEM BIOPH RES CO, V261, P661, DOI 10.1006/bbrc.1999.1109; Nguyen T, 2003, ANNU REV PHARMACOL, V43, P233, DOI 10.1146/annurev.pharmtox.43.100901.140229; Peng JM, 2003, NAT BIOTECHNOL, V21, P921, DOI 10.1038/nbt849; Ramos-Gomez M, 2001, P NATL ACAD SCI USA, V98, P3410, DOI 10.1073/pnas.051618798; Talalay P, 2003, ADV ENZYME REGUL, V43, P121, DOI 10.1016/S0065-2571(02)00038-9; Talalay P, 2000, BIOFACTORS, V12, P5, DOI 10.1002/biof.5520120102; Wakabayashi N, 2004, P NATL ACAD SCI USA, V101, P2040, DOI 10.1073/pnas.0307301101; Wild AC, 1999, J BIOL CHEM, V274, P33627, DOI 10.1074/jbc.274.47.33627; Wirbelauer C, 2000, EMBO J, V19, P5362, DOI 10.1093/emboj/19.20.5362; Wolf DA, 2003, NAT CELL BIOL, V5, P1029, DOI 10.1038/ncb1203-1029; Zhang DD, 2003, MOL CELL BIOL, V23, P8137, DOI 10.1128/MCB.23.22.8137-8151.2003; Zhang DD, 2004, MOL CELL BIOL, V24, P10941, DOI 10.1128/MCB.24.24.10941-10953.2004	31	257	267	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	2005	280	36					31768	31775		10.1074/jbc.M503346200	http://dx.doi.org/10.1074/jbc.M503346200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	961LZ	15985429	hybrid			2022-12-25	WOS:000231665200055
J	Ordaz, B; Tang, J; Xiao, R; Salgado, A; Sampieri, A; Zhu, MX; Vaca, L				Ordaz, B; Tang, J; Xiao, R; Salgado, A; Sampieri, A; Zhu, MX; Vaca, L			Calmodulin and calcium interplay in the modulation of TRPC5 channel activity - Identification of a novel C-terminal domain for calcium/calmodulin-mediated facilitation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTORS; NONSELECTIVE CATION CHANNELS; SF9 INSECT CELLS; TRANSIENT-RECEPTOR; BINDING-SITES; CA2+ INFLUX; PROTEIN; ACTIVATION; DROSOPHILA; GENE	TRPC5 forms Ca2+-permeable nonselective cation channels important for neurite outgrowth and growth cone morphology of hippocampal neurons. Here we studied the activation of mouse TRPC5 expressed in Chinese hamster ovary and human embryonic kidney 293 cells by agonist stimulation of several receptors that couple to the phosphoinositide signaling cascade and the role of calmodulin (CaM) on the activation. We showed that exogenous application of 10 mu m CaM through patch pipette accelerated the agonist-induced channel activation by 2.8-fold, with the time constant for half-activation reduced from 4.25 +/- 0.4 to 1.56 +/- 0.85 min. We identified a novel CaM-binding site located at the C terminus of TRPC5, 95 amino acids downstream from the previously determined common CaM/IP3R-binding (CIRB) domain for all TRPC proteins. Deletion of the novel CaM-binding site attenuated the acceleration in channel activation induced by CaM. However, disruption of the CIRB domain from TRPC5 rendered the channel irresponsive to agonist stimulation without affecting the cell surface expression of the channel protein. Furthermore, we showed that high (>5 mu m) intracellular free Ca2+ inhibited the current density without affecting the time course of TRPC5 activation by receptor agonists. These results demonstrated that intracellular Ca2+ has dual and opposite effects on the activation of TRPC5. The novel CaM-binding site is important for the Ca2+/CaM-mediated facilitation, whereas the CIRB domain is critical for the overall response of receptor-induced TRPC5 channel activation.	Ohio State Univ, Dept Neurosci, Columbus, OH 43210 USA; Ohio State Univ, Ctr Mol Neurobiol, Columbus, OH 43210 USA; Univ Nacl Autonoma Mexico, Dept Biol Celular, Inst Fisiol Celular, Mexico City 04510, DF, Mexico	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Universidad Nacional Autonoma de Mexico	Zhu, MX (corresponding author), Ohio State Univ, Dept Neurosci, Columbus, OH 43210 USA.	zhu.55@osu.edu; lvaca@ifc.unam.mxn	Xiao, Rui/G-1193-2011; Sampieri, Alicia/L-3896-2019	Xiao, Rui/0000-0001-5541-6685; Vaca, Luis/0000-0003-2266-4847; Salgado, Alfonso/0000-0001-8102-3690	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS042183] Funding Source: NIH RePORTER; NINDS NIH HHS [NS42183] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bezzerides VJ, 2004, NAT CELL BIOL, V6, P709, DOI 10.1038/ncb1150; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; Greka A, 2003, NAT NEUROSCI, V6, P837, DOI 10.1038/nn1092; Hu HZ, 2004, J BIOL CHEM, V279, P35741, DOI 10.1074/jbc.M404164200; HU YF, 1994, BIOCHEM BIOPH RES CO, V201, P1050, DOI 10.1006/bbrc.1994.1808; Jung S, 2003, J BIOL CHEM, V278, P3562, DOI 10.1074/jbc.M211484200; Kanki H, 2001, MOL PHARMACOL, V60, P989, DOI 10.1124/mol.60.5.989; Kunze DL, 1997, AM J PHYSIOL-CELL PH, V272, pC27, DOI 10.1152/ajpcell.1997.272.1.C27; LIU YC, 1990, TRENDS PHARMACOL SCI, V11, P107; Obukhov AG, 2004, J CELL PHYSIOL, V201, P227, DOI 10.1002/jcp.20057; Obukhov AG, 1998, NEUROSCIENCE, V85, P487, DOI 10.1016/S0306-4522(97)00616-7; Okada T, 1999, J BIOL CHEM, V274, P27359, DOI 10.1074/jbc.274.39.27359; PHILLIPS AM, 1992, NEURON, V8, P631, DOI 10.1016/0896-6273(92)90085-R; Plant TD, 2003, CELL CALCIUM, V33, P441, DOI 10.1016/S0143-4160(03)00055-1; Schaefer M, 2000, J BIOL CHEM, V275, P17517, DOI 10.1074/jbc.275.23.17517; Singh BB, 2002, MOL CELL, V9, P739, DOI 10.1016/S1097-2765(02)00506-3; Tang J, 2001, J BIOL CHEM, V276, P21303, DOI 10.1074/jbc.M102316200; Vaca L, 2002, J BIOL CHEM, V277, P42178, DOI 10.1074/jbc.M204531200; VACA L, 1994, AM J PHYSIOL-CELL PH, V267, pC1501, DOI 10.1152/ajpcell.1994.267.5.C1501; Wang CB, 2004, J BIOL CHEM, V279, P37423, DOI 10.1074/jbc.M407205200; Warr CG, 1996, BIOCHEM J, V314, P497, DOI 10.1042/bj3140497; Wedel BJ, 2003, J BIOL CHEM, V278, P25758, DOI 10.1074/jbc.M303890200; Zeng FN, 2004, J PHYSIOL-LONDON, V559, P739, DOI 10.1113/jphysiol.2004.065391; Zhang ZM, 2001, P NATL ACAD SCI USA, V98, P3168, DOI 10.1073/pnas.051632698; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7; Zimmer S, 2000, PFLUG ARCH EUR J PHY, V440, P409, DOI 10.1007/s004240000292	26	73	79	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	2005	280	35					30788	30796		10.1074/jbc.M504745200	http://dx.doi.org/10.1074/jbc.M504745200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	958ZX	15987684	hybrid			2022-12-25	WOS:000231487800019
J	Pei, XH; An, XL; Guo, XH; Tarnawski, M; Coppel, R; Mohandas, N				Pei, XH; An, XL; Guo, XH; Tarnawski, M; Coppel, R; Mohandas, N			Structural and functional studies of interaction between Plasmodium falciparum knob-associated histidine-rich protein (KAHRP) and erythrocyte spectrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RED-CELL MEMBRANE; SURFACE-ANTIGEN; BINDING DOMAIN; BETA-SPECTRIN; BLOOD-CELL; MALARIA; ACTIN; THROMBOSPONDIN; IDENTIFICATION; VIRULENCE	Plasmodium falciparum dramatically modifies the structure and function of the membrane of the parasitized host erythrocyte. Altered membrane properties are the consequence of the interaction of a group of exported malaria proteins with host cell membrane proteins. KAHRP (the knob-associated histidine-rich protein), a member of this group, has been shown to interact with erythrocyte membrane skeletal protein spectrin. However, the molecular basis for this interaction has yet to be defined. In the present study, we defined the binding motifs in both KAHRP and spectrin and identified a functional role for this interaction. We showed that spectrin bound to a 72-amino-acid KAHRP fragment (residues 370-441). Among nine-spectrin fragments, which encompass the entire alpha and beta spectrin molecules (four alpha spectrin and five beta spectrin fragments), KAHRP bound only to one, the alpha N-5 fragment. The KAHRP-binding site within the alpha N-5 fragment was localized uniquely to repeat 4. The interaction of full-length spectrin dimer to KAHRP was inhibited by repeat 4 of alpha spectrin. Importantly, resealing of this repeat peptide into erythrocytes mislocalized KAHRP in the parasitized cells. We concluded that the interaction of KAHRP with spectrin is critical for appropriate membrane localization of KAHRP in parasitized erythrocytes. As the presence of KAHRP at the erythrocyte membrane is necessary for cytoadherence in vivo, our findings have implications for the development of new therapies for mitigating the severity of malaria infection.	New York Blood Ctr, Red Cell Physiol Lab, New York, NY 10021 USA; Monash Univ, Dept Microbiol, Clayton, Vic 3800, Australia	New York Blood Center; Monash University	Mohandas, N (corresponding author), New York Blood Ctr, Red Cell Physiol Lab, New York, NY 10021 USA.	mnarla@nybloodcenter.org	Coppel, Ross L/A-6626-2008	Coppel, Ross L/0000-0002-4476-9124	NIDDK NIH HHS [DK 32094, DK 26263] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026263, P01DK032094, R37DK026263] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALEY SB, 1984, J EXP MED, V160, P1585, DOI 10.1084/jem.160.5.1585; ALEY SB, 1986, PARASITOLOGY, V92, P511, DOI 10.1017/S0031182000065410; ANDERS RF, 1987, UCLA S MOL CELL BIOL, V42, P333; Baruch DI, 1996, P NATL ACAD SCI USA, V93, P3497, DOI 10.1073/pnas.93.8.3497; BECKER PS, 1993, J CLIN INVEST, V92, P612, DOI 10.1172/JCI116628; Bennett BJ, 1997, J BIOL CHEM, V272, P15299, DOI 10.1074/jbc.272.24.15299; Bennett V, 2001, PHYSIOL REV, V81, P1353, DOI 10.1152/physrev.2001.81.3.1353; BERENDT AR, 1994, PARASITOLOGY, V108, pS19, DOI 10.1017/S0031182000075685; Campanella ME, 2005, P NATL ACAD SCI USA, V102, P2402, DOI 10.1073/pnas.0409741102; CERAMI C, 1992, CELL, V70, P1021, DOI 10.1016/0092-8674(92)90251-7; Cherry L, 1999, J BIOL CHEM, V274, P2077, DOI 10.1074/jbc.274.4.2077; Cooke BM, 2000, PARASITOL TODAY, V16, P416, DOI 10.1016/S0169-4758(00)01753-1; Cooke BM, 2004, SEMIN HEMATOL, V41, P173, DOI 10.1053/j.seminhematol.2004.01.004; Cooke BM, 2001, ADV PARASIT, V50, P1, DOI 10.1016/S0065-308X(01)50029-9; Crabb BS, 1997, CELL, V89, P287, DOI 10.1016/S0092-8674(00)80207-X; DASILVA E, 1994, MOL BIOCHEM PARASIT, V66, P59, DOI 10.1016/0166-6851(94)90036-1; DE M, 2000, J CELL SCI, V113, P2331; DLUZEWSKI AR, 1983, PARASITOLOGY, V87, P429, DOI 10.1017/S0031182000082950; FOLEY M, 1991, MOL BIOCHEM PARASIT, V46, P137, DOI 10.1016/0166-6851(91)90207-M; FOLEY M, 1994, EXP PARASITOL, V79, P340, DOI 10.1006/expr.1994.1096; HERRERA S, 1993, EMBO J, V12, P1607, DOI 10.1002/j.1460-2075.1993.tb05805.x; Hiller NL, 2004, SCIENCE, V306, P1934, DOI 10.1126/science.1102737; KARINCH AM, 1990, J BIOL CHEM, V265, P11833; KILEJIAN A, 1991, MOL BIOCHEM PARASIT, V44, P175, DOI 10.1016/0166-6851(91)90003-O; KILEJIAN A, 1979, P NATL ACAD SCI USA, V76, P4650, DOI 10.1073/pnas.76.9.4650; MACPHERSON GG, 1985, AM J PATHOL, V119, P385; MAGOWAN C, 1995, BLOOD, V86, P3196; Magowan C, 2000, BBA-MOL BASIS DIS, V1502, P461, DOI 10.1016/S0925-4439(00)00069-7; Marti M, 2004, SCIENCE, V306, P1930, DOI 10.1126/science.1102452; MOHANDAS N, 1994, ANNU REV BIOPH BIOM, V23, P787, DOI 10.1146/annurev.bb.23.060194.004035; MULLER HM, 1993, EMBO J, V12, P2881, DOI 10.1002/j.1460-2075.1993.tb05950.x; Nicolas G, 1998, BIOCHEM J, V332, P81, DOI 10.1042/bj3320081; Oh SS, 2000, MOL BIOCHEM PARASIT, V108, P237, DOI 10.1016/S0166-6851(00)00227-9; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x; TAYLOR DW, 1987, MOL BIOCHEM PARASIT, V25, P165, DOI 10.1016/0166-6851(87)90005-3; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; TYLER JM, 1979, P NATL ACAD SCI USA, V76, P5192, DOI 10.1073/pnas.76.10.5192; VERNOTHERNANDEZ JP, 1984, MOL BIOCHEM PARASIT, V12, P337, DOI 10.1016/0166-6851(84)90090-2; Waller KL, 1999, J BIOL CHEM, V274, P23808, DOI 10.1074/jbc.274.34.23808; Waller KL, 2003, BLOOD, V102, P1911, DOI 10.1182/blood-2002-11-3513	40	83	85	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	2005	280	35					31166	31171		10.1074/jbc.M505298200	http://dx.doi.org/10.1074/jbc.M505298200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	958ZX	16006556	hybrid			2022-12-25	WOS:000231487800063
J	Rhee, DK; Marcelino, J; Al-Mayouf, S; Schelling, DK; Bartels, CF; Cui, YJ; Laxer, R; Goldbach-Mansky, R; Warman, ML				Rhee, DK; Marcelino, J; Al-Mayouf, S; Schelling, DK; Bartels, CF; Cui, YJ; Laxer, R; Goldbach-Mansky, R; Warman, ML			Consequences of disease-causing mutations on lubricin protein synthesis, secretion, and post-translational processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPERFICIAL ZONE PROTEIN; BOVINE SYNOVIAL-FLUID; ARTICULAR-CARTILAGE; LUBRICATING FACTOR; GENE-EXPRESSION; GROWTH-FACTOR; 2-CHAIN FORM; VITRONECTIN; DOMAIN; BINDING	Lubricin, a protein product of the gene PRG4, is a secreted mucin-like proteoglycan that is a major lubricant in articulating joints. Mutations in PRG4 cause the autosomal recessive, human disorder camptodactyly-arthropathycoxa vara-pericarditis syndrome. We developed rabbit polyclonal antibodies against human lubricin to determine the consequence of disease-causing mutations at the protein level and to study the protein's normal post-translational processing. Antiserum generated against an epitope in the amino-terminal portion of lubricin detected protein in wild-type synovial fluid and in conditioned media from wild-type cultured synoviocytes. However, the antiserum did not detect lubricin in synovial fluid or cultured synoviocytes from several patients with frameshift or nonsense mutations in PRG4. Antiserum generated against an epitope in the protein's carboxyl-terminal, hemopexin-like domain identified a post-translational cleavage event in wild-type lubricin, mediated by a subtilisin-like proprotein convertase (SPC). Interestingly, in contrast to wild-type lubricin, one disease-causing mutation that removes the last 8 amino acids of the protein, including a conserved cysteine residue, was not cleaved within the hemopexin-like domain when expressed in COS-7 cells. This suggests that formation of an intrachain disulfide bond is required for SPC-mediated cleavage and that SPC-mediated cleavage is essential to protein function.	Case Western Reserve Univ, Dept Genet, Sch Med, Cleveland, OH 44106 USA; Case Western Reserve Univ, Ctr Human Genet, Sch Med, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA; King Faisal Specialist Hosp & Res Ctr, Dept Pediat, Riyadh 11211, Saudi Arabia; Hosp Sick Children, Dept Pediat, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Div Rheumatol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Toronto, ON M5G 1X8, Canada; NIAMS, NIH, Bethesda, MD 20892 USA	Case Western Reserve University; Case Western Reserve University; University Hospitals of Cleveland; King Faisal Specialist Hospital & Research Center; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	Warman, ML (corresponding author), Case Western Reserve Univ, Dept Genet, Sch Med, Rm BRB-719,2109 Adelbert Rd, Cleveland, OH 44106 USA.	mlw14@case.edu	Goldbach-Mansky, Raphaela/N-5917-2017	Al-Mayouf, Sulaiman/0000-0003-0142-6698	NIAMS NIH HHS [AR050180] Funding Source: Medline; NICHD NIH HHS [HD07104, HD07518] Funding Source: Medline; NIGMS NIH HHS [GM08613, GM07250] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR050180] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Bahabri SA, 1998, ARTHRITIS RHEUM, V41, P730, DOI 10.1002/1529-0131(199804)41:4<730::AID-ART22>3.0.CO;2-Y; Blanchette F, 1997, J CLIN INVEST, V99, P1974, DOI 10.1172/JCI119365; CHAIN D, 1990, FEBS LETT, V269, P221, DOI 10.1016/0014-5793(90)81159-L; Constam DB, 1999, J CELL BIOL, V144, P139, DOI 10.1083/jcb.144.1.139; Deng G, 2001, J CELL PHYSIOL, V189, P23, DOI 10.1002/jcp.1133; Elsaid KA, 2005, ARTHRITIS RHEUM-US, V52, P1746, DOI 10.1002/art.21038; Flannery CR, 1999, BIOCHEM BIOPH RES CO, V254, P535, DOI 10.1006/bbrc.1998.0104; GomisRuth FX, 1996, J MOL BIOL, V264, P556, DOI 10.1006/jmbi.1996.0661; Hentze MW, 1999, CELL, V96, P307, DOI 10.1016/S0092-8674(00)80542-5; Ikegawa S, 2000, CYTOGENET CELL GENET, V90, P291, DOI 10.1159/000056791; Jay GD, 2001, J ORTHOPAED RES, V19, P677, DOI 10.1016/S0736-0266(00)00040-1; JAY GD, 1992, CONNECT TISSUE RES, V28, P71, DOI 10.3109/03008209209014228; JAY GD, 1992, CONNECT TISSUE RES, V28, P245, DOI 10.3109/03008209209016818; Liu YJ, 2004, BLOOD, V103, P4449, DOI 10.1182/blood-2003-06-1825; Marcelino J, 1999, NAT GENET, V23, P319, DOI 10.1038/15496; Matsuda A, 2003, J BIOL CHEM, V278, P36350, DOI 10.1074/jbc.M301509200; MERBERG DM, 1993, INT CONGR SER, V1042, P45; Murphy G, 1997, MATRIX BIOL, V15, P511, DOI 10.1016/S0945-053X(97)90025-1; Perez-Vilar J, 1999, J BIOL CHEM, V274, P31751, DOI 10.1074/jbc.274.45.31751; Rees SG, 2002, MATRIX BIOL, V21, P593, DOI 10.1016/S0945-053X(02)00056-2; Rhee DK, 2005, J CLIN INVEST, V115, P622, DOI 10.1172/JCI200522263; Sancho D, 2003, J CLIN INVEST, V112, P872, DOI 10.1172/JCI200319112; Schroeck F, 2002, BIOL CHEM, V383, P1143, DOI 10.1515/BC.2002.125; Schumacher BL, 1999, J ORTHOP RES, V17, P110, DOI 10.1002/jor.1100170117; SCHUMACHER BL, 1994, ARCH BIOCHEM BIOPHYS, V311, P144, DOI 10.1006/abbi.1994.1219; Schvartz I, 1999, INT J BIOCHEM CELL B, V31, P539, DOI 10.1016/S1357-2725(99)00005-9; Seger D, 2000, FEBS LETT, V480, P169, DOI 10.1016/S0014-5793(00)01917-7; Sidenius N, 2000, FEBS LETT, V470, P40, DOI 10.1016/S0014-5793(00)01282-5; Su JL, 2001, HYBRIDOMA, V20, P149, DOI 10.1089/027245701750293475; SWANN DA, 1985, BIOCHEM J, V225, P195, DOI 10.1042/bj2250195; SWANN DA, 1977, BIOCHEM J, V161, P473, DOI 10.1042/bj1610473	31	51	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	2005	280	35					31325	31332		10.1074/jbc.M505401200	http://dx.doi.org/10.1074/jbc.M505401200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	958ZX	16000300	hybrid			2022-12-25	WOS:000231487800080
J	Zhou, XH; Li, F; Kong, L; Tomita, H; Li, C; Cao, W				Zhou, XH; Li, F; Kong, L; Tomita, H; Li, C; Cao, W			Involvement of inflammation, degradation, and apoptosis in a mouse model of glaucoma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; MATRIX METALLOPROTEINASES; INTRAOCULAR-PRESSURE; PIGMENTARY GLAUCOMA; SIGNALING PATHWAYS; DBA/2J MICE; P38 MAPK; EXTRACELLULAR-MATRIX; INCREASED EXPRESSION; PHOTORECEPTOR CELLS	Glaucoma is a common cause of blindness affecting at least 66 million people worldwide. Pigmentary glaucoma is one of the most common forms of secondary glaucoma, and its pathogenesis remains unclear. Interleukin-18 (IL-18) is an important regulator of innate and acquired immune responses and plays an important role in inflammatory/autoimmunity diseases. Using the DBA/2J mouse as an animal model of human pigmentary glaucoma, we demonstrated for the first time that the expression of the IL-18 protein and gene in the iris/ciliary body and level of IL-18 protein in the aqueous humor of DBA/2J mice are dramatically increased with age. This increase precedes the onset of clinical evidence of pigmentary glaucoma, implying a pathogenic role of inflammation/immunity in this disease. We also observed that activated NF-kappa B and phosphorylated MAPK are increased in the iris/ciliary body of DBA/2J mice, suggesting that both signaling pathways may be involved in IL-18 mediated pathogenesis of pigmentary glaucoma in the eyes of DBA/2J mice. In addition, matrix metalloproteinase-2 (MMP-2) expression in the iris/ciliary body and the activity of MMP-2 in the aqueous humor are increased whereas tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) expression in the iris/ciliary body is decreased, indicating that the degradation process is involved in this mouse model of pigmentary glaucoma. Furthermore, the expressions of apoptosis-related genes, caspase-8, Fas, FADD, FAP, and FAF, and the activity of caspase- 3 are increased in the iris/ciliary body of DBA/2J mice. Elucidation of biochemical and molecular mechanisms of IL-18 participation in the pathogenesis of pigmentary glaucoma should provide approaches for developing improved and targeted treatments to ameliorate this blinding disease. The possibility that altered IL-18 expression in the eye of DBA/2J mice initiates and/or amplifies the pathogenesis of pigmentary glaucoma requires further investigation.	Univ Oklahoma, Hlth Sci Ctr, Dept Ophthalmol, Dean A McGee Eye Inst, Oklahoma City, OK 73104 USA; Tohoku Univ, Biofunct Sci Biomed Engn Res Org, Sendai, Miyagi 9808575, Japan; Sichuan Univ, W China Hosp, Chengdu 610041, Sichuan, Peoples R China	University of Oklahoma System; University of Oklahoma Health Sciences Center; Tohoku University; Sichuan University	Cao, W (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Ophthalmol, Dean A McGee Eye Inst, 608 Stanton L Young Blvd, Oklahoma City, OK 73104 USA.	wei-cao@ouhsc.edu	Tomita, Hiroshi/O-2135-2018	Tomita, Hiroshi/0000-0003-1051-2301	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017703] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R03EY014427, P30EY012190] Funding Source: NIH RePORTER; NCRR NIH HHS [P20 RR17703] Funding Source: Medline; NEI NIH HHS [EY014427, EY12190] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Abraham M, 2002, INT IMMUNOL, V14, P1449, DOI 10.1093/intimm/dxf108; Ahn JH, 2002, BLOOD, V100, P1742, DOI 10.1182/blood.V100.5.1742.h81702001742_1742_1754; Anderson MG, 2002, NAT GENET, V30, P81, DOI 10.1038/ng794; Bachner Dietmar, 2002, Brain Res Gene Expr Patterns, V1, P159; Beaudeux JL, 2004, CLIN CHEM LAB MED, V42, P121, DOI 10.1515/CCLM.2004.024; Bora NS, 1997, INVEST OPHTH VIS SCI, V38, P2171; Burbach GJ, 2001, CURR EYE RES, V23, P64, DOI 10.1076/ceyr.23.1.64.5425; Campbell J, 2004, J IMMUNOL, V173, P6928, DOI 10.4049/jimmunol.173.11.6928; Cao W, 2003, ADV EXP MED BIOL, V533, P395; Cao W, 2000, J NEUROSCI RES, V60, P195, DOI 10.1002/(SICI)1097-4547(20000415)60:2<195::AID-JNR8>3.0.CO;2-7; Chandrasekar B, 2004, J BIOL CHEM, V279, P20221, DOI 10.1074/jbc.M313980200; Chang B, 1999, NAT GENET, V21, P405, DOI 10.1038/7741; Chen L, 2003, CURR EYE RES, V26, P291, DOI 10.1076/ceyr.26.4.291.15432; Chintala SK, 2002, J BIOL CHEM, V277, P47461, DOI 10.1074/jbc.M204824200; Creagh EM, 2003, IMMUNOL REV, V193, P10, DOI 10.1034/j.1600-065X.2003.00048.x; Danias J, 2003, INVEST OPHTH VIS SCI, V44, P1138, DOI 10.1167/iovs.02-0553; Delaleu N, 2004, PERIODONTOL 2000, V35, P42, DOI 10.1111/j.0906-6713.2004.003569.x; DiGirolamo N, 1996, CURR EYE RES, V15, P1060; DiGirolamo N, 1997, AM J PATHOL, V150, P653; FARRAR SM, 1993, SURV OPHTHALMOL, V37, P233, DOI 10.1016/0039-6257(93)90008-U; Goldblum D, 2002, GRAEF ARCH CLIN EXP, V240, P942, DOI 10.1007/s00417-002-0571-y; Gracie JA, 2004, CLIN EXP IMMUNOL, V136, P402, DOI 10.1111/j.1365-2249.2004.02475.x; Gracie JA, 2003, J LEUKOCYTE BIOL, V73, P213, DOI 10.1189/jlb.0602313; Guo L, 2005, INVEST OPHTH VIS SCI, V46, P175, DOI 10.1167/iovs.04-0832; Herlaar E, 1999, MOL MED TODAY, V5, P439, DOI 10.1016/S1357-4310(99)01544-0; Huang WX, 2004, MULT SCLER J, V10, P482, DOI 10.1191/1352458504ms1071oa; Hue J, 2005, IMMUNOL LETT, V96, P211, DOI 10.1016/j.imlet.2004.08.008; Ishida Y, 2004, FEBS LETT, V569, P156, DOI 10.1016/j.febslet.2004.05.039; Jiang HR, 2001, INVEST OPHTH VIS SCI, V42, P177; John SWM, 1998, INVEST OPHTH VIS SCI, V39, P951; Kalina U, 2000, J IMMUNOL, V165, P1307, DOI 10.4049/jimmunol.165.3.1307; KAYA M, 1992, INVEST OPHTH VIS SCI, V33, P522; Kee C, 1999, J GLAUCOMA, V8, P51; Kermer P, 2000, J NEUROSCI, V20, P722, DOI 10.1523/JNEUROSCI.20-02-00722.2000; Kimura-Shimmyo A, 2002, J IMMUNOTHER, V25, pS42, DOI 10.1097/00002371-200203001-00007; Kirwan RP, 2004, J GLAUCOMA, V13, P327, DOI 10.1097/00061198-200408000-00011; Kontiola AI, 2001, EXP EYE RES, V73, P781, DOI 10.1006/exer.2001.1088; Lan J, 2003, BRIT J OPHTHALMOL, V87, P208, DOI 10.1136/bjo.87.2.208; Lee JK, 2004, P NATL ACAD SCI USA, V101, P8815, DOI 10.1073/pnas.0402800101; Luo LH, 2004, INVEST OPHTH VIS SCI, V45, P4293, DOI 10.1167/iovs.03-1145; Mahmoud Randa Abdel Kader, 2004, Ital J Biochem, V53, P73; Martinon F, 2004, CELL, V117, P561, DOI 10.1016/j.cell.2004.05.004; McGinnis JF, 2002, J NEUROSCI RES, V67, P290, DOI 10.1002/jnr.10120; Mo JS, 2003, J EXP MED, V197, P1335, DOI 10.1084/jem.20022041; Mook ORF, 2004, BBA-REV CANCER, V1705, P69, DOI 10.1016/j.bbcan.2004.09.006; Naib-Majani W, 2004, GRAEF ARCH CLIN EXP, V242, P332, DOI 10.1007/s00417-003-0846-y; Nakamura H, 1999, ANN RHEUM DIS, V58, P382, DOI 10.1136/ard.58.6.382; Nakazawa T, 2002, CURR EYE RES, V24, P114, DOI 10.1076/ceyr.24.2.114.8162; Narins CR, 2004, AM J CARDIOL, V94, P1285, DOI 10.1016/j.amjcard.2004.07.114; Nicoletti F, 2001, DIABETOLOGIA, V44, P309, DOI 10.1007/s001250051619; Noel A, 2004, J CLIN PATHOL, V57, P577, DOI 10.1136/jcp.2003.014472; Novak N, 2003, TRENDS IMMUNOL, V24, P570, DOI 10.1016/j.it.2003.09.009; Quiding-Jarbrink M, 2001, INFECT IMMUN, V69, P5661, DOI 10.1128/IAI.69.9.5661-5670.2001; Reddy P, 2004, CURR OPIN HEMATOL, V11, P405, DOI 10.1097/01.moh.0000141926.95319.42; Ruland J, 2003, SEMIN IMMUNOL, V15, P177, DOI 10.1016/S1044-5323(03)00034-4; Schuettauf F, 2002, VISION RES, V42, P2333, DOI 10.1016/S0042-6989(02)00188-8; Sergi B, 2004, J BIOL REG HOMEOS AG, V18, P55; Sivak JM, 2002, PROG RETIN EYE RES, V21, P1, DOI 10.1016/S1350-9462(01)00015-5; Sowka Joseph, 2004, Optometry, V75, P115, DOI 10.1016/S1529-1839(04)70023-8; Xue ML, 2003, INVEST OPHTH VIS SCI, V44, P2020, DOI 10.1167/iovs.02-0565; Yamaki K, 2000, J IMMUNOL, V165, P7323, DOI 10.4049/jimmunol.165.12.7323; Yu XR, 2004, J BIOL CHEM, V279, P13086, DOI 10.1074/jbc.M313283200; Zhang X, 2004, INVEST OPHTH VIS SCI, V45, P2374, DOI 10.1167/iovs.03-1239	63	115	123	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	2005	280	35					31240	31248		10.1074/jbc.M502641200	http://dx.doi.org/10.1074/jbc.M502641200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	958ZX	15985430	hybrid			2022-12-25	WOS:000231487800071
J	Nemoda, Z; Sahin-Toth, M				Nemoda, Z; Sahin-Toth, M			The tetra-aspartate motif in the activation peptide of human cationic trypsinogen is essential for autoactivation control but not for enteropeptidase recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEREDITARY PANCREATITIS; ANIONIC TRYPSINOGEN; BOVINE ENTEROKINASE; ZYMOGEN ACTIVATION; CRYSTAL-STRUCTURE; CATHEPSIN-B; HEAVY-CHAIN; SPECIFICITY; MUTATIONS; PROTEIN	The activation peptide of vertebrate trypsinogens contains a highly conserved tetra-aspartate sequence (Asp(19-22) in humans) preceding the Lys-Ile scissile bond. A large body of research has defined the primary role of this acidic motif as a specific recognition site for enteropeptidase, the physiological activator of trypsinogen. In addition, the acidic stretch was shown to contribute to the suppression of autoactivation. In the present study, we determined the relative importance of these two activation peptide functions in human cationic trypsinogen. Individual Ala replacements of Asp(19-22) had minimal or no effect on trypsinogen activation catalyzed by human enteropeptidase. Strikingly, a tetra-Ala(19-22) trypsinogen mutant devoid of acidic residues in the activation peptide was still a highly specific substrate for human, but not for bovine, enteropeptidase. In contrast, an intact Asp(19-22) motif was critical for autoactivation control. Thus, single Ala mutations of Asp19, Asp(20) and Asp(21) resulted in 2-3-fold increased autoactivation, whereas the Asp(22) -> Ala mutant autoactivated at a 66-fold increased rate. These effects were multiplicative in the tri-Ala(19-21) and tetra-Ala(19)-22 mutants. Structural modeling revealed that the conserved hydrophobic S2 subsite of trypsin and the unique Asp(218), which forms part of the S3-S4 subsite, participate in distinct inhibitory interactions with the activation peptide. Finally, mutagenesis studies confirmed the significance of the negative charge of Asp(218) in autoactivation control. The results demonstrate that in human cationic trypsinogen the Asp(19-22) motif per se is not required for enteropeptidase recognition, whereas it is essential for maximal suppression of autoactivation. The evolutionary selection of Asp(218), which is absent in the large majority of vertebrate trypsins, provides an additional mechanism of autoactivation control in the human pancreas.	Boston Univ, Goldman Sch Dent Med, Dept Mol & Cell Biol, Boston, MA 02118 USA	Boston University	Sahin-Toth, M (corresponding author), 715 Albany St,Evans-433, Boston, MA 02118 USA.	miklos@bu.edu		Sahin-Toth, Miklos/0000-0003-4513-9922; Nemoda, Zsofia/0000-0002-9550-7730	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058088] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK058088, R01 DK058088] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABITA JP, 1969, EUR J BIOCHEM, V8, P314, DOI 10.1111/j.1432-1033.1969.tb00530.x; ANDERSON LE, 1977, BIOCHEMISTRY-US, V16, P3354, DOI 10.1021/bi00634a011; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; BRODRICK JW, 1978, J BIOL CHEM, V253, P2737; Chen JM, 2003, MOL BIOL EVOL, V20, P1767, DOI 10.1093/molbev/msg183; Chen JM, 1999, SCAND J GASTROENTERO, V34, P831; CHEN JM, 2003, NATURE ENCY HUMAN GE, P645; DELAAGE M, 1967, BIOCHEM BIOPH RES CO, V29, P235, DOI 10.1016/0006-291X(67)90593-1; FIGARELLA C, 1988, BIOL CHEM H-S, V369, P293; Gaboriaud C, 1996, J MOL BIOL, V259, P995, DOI 10.1006/jmbi.1996.0376; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hedstrom L, 2002, CHEM REV, V102, P4501, DOI 10.1021/cr000033x; Howes N, 2004, CLIN GASTROENTEROL H, V2, P252, DOI 10.1016/S1542-3565(04)00013-8; Idris MM, 2005, GUT, V54, P728, DOI 10.1136/gut.2004.055335; Kukor Z, 2003, EUR J BIOCHEM, V270, P2047, DOI 10.1046/j.1432-1033.2003.03581.x; Kunitz M, 1939, J GEN PHYSIOL, V22, P293, DOI 10.1085/jgp.22.3.293; LIGHT A, 1989, TRENDS BIOCHEM SCI, V14, P110, DOI 10.1016/0968-0004(89)90133-3; LIGHT A, 1980, ANAL BIOCHEM, V106, P199, DOI 10.1016/0003-2697(80)90138-4; LU D, 2000, HDB PROTEOLYTIC ENZY, P50; Lu DS, 1997, J BIOL CHEM, V272, P31293, DOI 10.1074/jbc.272.50.31293; Lu DS, 1999, J MOL BIOL, V292, P361, DOI 10.1006/jmbi.1999.3089; MAROUX S, 1971, J BIOL CHEM, V246, P5031; Mikhailova AG, 2004, BIOCHEMISTRY-MOSCOW+, V69, P909, DOI 10.1023/B:BIRY.0000040224.47278.3b; Mikhailova AG, 1999, FEBS LETT, V442, P226, DOI 10.1016/S0014-5793(98)01656-1; RADHAKRI.TM, 1969, BIOCHEMISTRY-US, V8, P4020, DOI 10.1021/bi00838a019; Roach JC, 1997, J MOL EVOL, V45, P640, DOI 10.1007/PL00006268; Sahin-Toth M, 2000, BIOCHEM BIOPH RES CO, V278, P286, DOI 10.1006/bbrc.2000.3797; Sahin-Toth M, 2000, J BIOL CHEM, V275, P22750, DOI 10.1074/jbc.M002943200; Szilagyi L, 2001, J BIOL CHEM, V276, P24574, DOI 10.1074/jbc.M011374200; Teich N, 2000, GASTROENTEROLOGY, V119, P461, DOI 10.1053/gast.2000.9312; Whitcomb DC, 1996, NAT GENET, V14, P141, DOI 10.1038/ng1096-141; Wu JW, 2001, EUR J BIOCHEM, V268, P1547, DOI 10.1046/j.1432-1033.2001.01914.x; ZIMMERLE CT, 1989, BIOCHEM J, V258, P381, DOI 10.1042/bj2580381	33	44	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	2005	280	33					29645	29652		10.1074/jbc.M505661200	http://dx.doi.org/10.1074/jbc.M505661200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	954SX	15970597	Green Accepted, hybrid			2022-12-25	WOS:000231176200033
J	Nikoshkov, A; Hurd, YL; Yakovleva, T; Bazov, I; Marinova, Z; Cebers, G; Pasikova, N; Gharibyan, A; Terenius, L; Bakalkin, G				Nikoshkov, A; Hurd, YL; Yakovleva, T; Bazov, I; Marinova, Z; Cebers, G; Pasikova, N; Gharibyan, A; Terenius, L; Bakalkin, G			Prodynorphin transcripts and proteins differentially expressed and regulated in the adult human brain	FASEB JOURNAL			English	Article						preprodynorphin; opioid peptides; kappa-opioid receptor; alternative transcripts	MESSENGER-RNA EXPRESSION; FUNCTIONAL POLYMORPHISM; OPIOID RECEPTOR; BINDING PROTEIN; LEU-ENKEPHALIN; UP-REGULATION; SPINAL-CORD; DYNORPHIN; GENE; RAT	Transcription from multiple promoters along with alternative mRNA splicing constitutes the basis for cell-specific gene expression and mRNA and protein diversity. The prodynorphin gene (PDYN) gives rise to prodynorphin (PDYN), precursor to dynorphin opioid peptides that regulate diverse physiological functions and are implicated in various neuropsychiatric disorders. Here, we characterized PDYN transcripts and proteins in the adult human brain and studied PDYN processing and intracellular localization in model cell lines. Seven PDYN mRNAs were identified in the human brain; two of the transcripts, FL1 and FL2, encode the full-length PDYN. The dominant, FL1 transcript shows high expression in limbic-related structures such as the nucleus accumbens and amygdala. The second, FL2 transcript is only expressed in few brain structures such as the claustrum and hypothalamus. FL-PDYN was identified for the first time in the brain as the dominant PDYN protein product. Three novel PDYNs expressed from spliced or truncated PDYN transcripts either lack a central segment but are still processed into dynorphins, or are translated into N-terminally truncated proteins. One truncated PDYN is located in the cell nucleus, suggesting a novel nonopioid function for this protein. The complexity of PDYN expression and diversity of its protein products may be relevant for diverse levels of plasticity in adaptive responses for the dynorphin system.	Karolinska Inst, Sect Psychiat, Dept Clin Neurosci, S-17176 Stockholm, Sweden; Karolinska Inst, Sect Alcohol & Drug Dependence Res, Dept Clin Neurosci, S-17176 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet	Hurd, YL (corresponding author), Karolinska Hosp, Psychiat Sect, Dept Clin Neurosci R500, S-17176 Stockholm, Sweden.	Yasmin.hurd@cns.ki.se	Pasikova, Natalia/K-2056-2018; Gharibyan, Anna L./B-3401-2010	Gharibyan, Anna L./0000-0001-9070-6215; Bakalkin, Georgy/0000-0002-8074-9833; Bazov, Igor/0000-0003-4388-1656	NIDA NIH HHS [DA-313312] Funding Source: Medline	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		BAKALKIN G, 1994, MOL BRAIN RES, V24, P301, DOI 10.1016/0169-328X(94)90143-0; BAKALKIN G, 1995, P NATL ACAD SCI USA, V92, P9024, DOI 10.1073/pnas.92.20.9024; Bakalkin G, 1997, BIOCHEM BIOPH RES CO, V231, P135, DOI 10.1006/bbrc.1997.6062; BAKALKIN GY, 1991, FEBS LETT, V282, P175, DOI 10.1016/0014-5793(91)80471-E; Bigey P, 2000, GENE, V242, P407, DOI 10.1016/S0378-1119(99)00501-6; BOTTGER A, 1995, J CELL BIOL, V130, P1251, DOI 10.1083/jcb.130.6.1251; Brown CH, 1998, J NEUROSCI, V18, P9480, DOI 10.1523/jneurosci.18-22-09480.1998; Campos D, 2003, MOL CELL NEUROSCI, V22, P135, DOI 10.1016/S1044-7431(03)00040-X; Carrion AM, 1999, NATURE, V398, P80, DOI 10.1038/18044; Cenci MA, 1998, EUR J NEUROSCI, V10, P2694, DOI 10.1046/j.1460-9568.1998.t01-1-00285.x; Chen ACH, 2002, AM J MED GENET, V114, P429, DOI 10.1002/ajmg.10362; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTENSSONNYLANDER I, 1985, REGUL PEPTIDES, V11, P65, DOI 10.1016/0167-0115(85)90032-1; CLARK AJL, 1990, MOL ENDOCRINOL, V4, P1737, DOI 10.1210/mend-4-11-1737; De Vries TJ, 2002, J NEUROSCI, V22, P3321; Dores RM, 2000, NEUROENDOCRINOLOGY, V72, P224, DOI 10.1159/000054591; DOUGLASS J, 1994, MOL ENDOCRINOL, V8, P333, DOI 10.1210/me.8.3.333; Fagergren P, 2003, EUR J NEUROSCI, V17, P2212, DOI 10.1046/j.1460-9568.2003.02636.x; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GRAMSCH C, 1982, BRAIN RES, V233, P65, DOI 10.1016/0006-8993(82)90930-1; HORIKAWA S, 1983, NATURE, V306, P611, DOI 10.1038/306611a0; Horvath GC, 2003, BBA-GENE STRUCT EXPR, V1625, P165, DOI 10.1016/S0167-4781(02)00604-8; Hurd YL, 2002, MOL PSYCHIATR, V7, P75, DOI 10.1038/sj/mp/4000930; HURD YL, 1993, SYNAPSE, V13, P357, DOI 10.1002/syn.890130408; Ji RR, 2002, J NEUROSCI, V22, P478, DOI 10.1523/JNEUROSCI.22-02-00478.2002; KHACHATURIAN H, 1993, HDB EXPT PHARM, P471; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Kreek MJ, 2002, NAT REV DRUG DISCOV, V1, P710, DOI 10.1038/nrd897; Kuzmin A, 2000, J PHARMACOL EXP THER, V295, P1031; MANSOUR A, 1994, MOL CELL NEUROSCI, V5, P124, DOI 10.1006/mcne.1994.1015; McLaughlin JP, 2003, J NEUROSCI, V23, P5674, DOI 10.1523/jneurosci.23-13-05674.2003; Modrek B, 2003, NAT GENET, V34, P177, DOI 10.1038/ng1159; NARANJO JR, 1991, NEURON, V6, P607, DOI 10.1016/0896-6273(91)90063-6; Newton SS, 2002, J NEUROSCI, V22, P10883; NYBERG F, 1987, REGUL PEPTIDES, V17, P159, DOI 10.1016/0167-0115(87)90025-5; Palko L, 2004, J CELL SCI, V117, P465, DOI 10.1242/jcs.00870; Pattee P, 2003, J BIOL CHEM, V278, P53098, DOI 10.1074/jbc.M306724200; Sharifi N, 1999, NEUROPEPTIDES, V33, P236, DOI 10.1054/npep.1999.0023; Sheffler DJ, 2003, TRENDS PHARMACOL SCI, V24, P107, DOI 10.1016/S0165-6147(03)00027-0; Shirayama Y, 2004, J NEUROCHEM, V90, P1258, DOI 10.1111/j.1471-4159.2004.02589.x; Shuster SJ, 2000, NEUROSCIENCE, V96, P373, DOI 10.1016/S0306-4522(99)00472-8; Stogmann E, 2002, ANN NEUROL, V51, P260, DOI 10.1002/ana.10108; Tan-No K, 2005, PAIN, V113, P301, DOI 10.1016/j.pain.2004.11.004; Tanne-Gariepy J, 2002, J COMP NEUROL, V454, P140, DOI 10.1002/cne.10425; Telkov M, 1998, BRAIN RES, V804, P284, DOI 10.1016/S0006-8993(98)00706-9; USHEVA A, 1994, CELL, V76, P1115, DOI 10.1016/0092-8674(94)90387-5; Wang X, 2003, NEUROSCIENCE, V118, P681, DOI 10.1016/S0306-4522(03)00020-4; Wang ZJ, 2001, J NEUROSCI, V21, P1779, DOI 10.1523/JNEUROSCI.21-05-01779.2001; Xu M, 2004, J NEUROSCI, V24, P4576, DOI 10.1523/JNEUROSCI.5552-03.2004; Yuferov V, 2001, BRAIN RES BULL, V55, P65, DOI 10.1016/S0361-9230(01)00496-8; Zimmer A, 2001, J NEUROSCI, V21, P9499, DOI 10.1523/JNEUROSCI.21-23-09499.2001	51	35	35	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2005	19	9					1543	+		10.1096/fj.05-3743fje	http://dx.doi.org/10.1096/fj.05-3743fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	951IO	16014400				2022-12-25	WOS:000230923000023
J	Hurskainen, M; Eklund, L; Hagg, PO; Fruttiger, M; Sormunen, R; Ilves, M; Pihlajaniemi, T				Hurskainen, M; Eklund, L; Hagg, PO; Fruttiger, M; Sormunen, R; Ilves, M; Pihlajaniemi, T			Abnormal maturation of the retinal vasculature in type XVIII collagen/endostatin deficient mice and changes in retinal glial cells due to lack of collagen types XV and XVIII	FASEB JOURNAL			English	Article						Col18a1(-/-) mice; VEGF	ENDOTHELIAL GROWTH-FACTOR; FACTOR VEGF; BILATERAL PSEUDOTUMOR; ENDOGENOUS INHIBITOR; NORRIES-DISEASE; ASTROCYTES; EXPRESSION; ANGIOGENESIS; HETEROGENEITY; RETINOPATHY	Type XVIII collagen is important in the early phase of retinal vascular development and for the regression of the primary vasculature in the vitreous body after birth. We show here that the retina in Col18a1(-/-) mice becomes densely vascularized by anomalous anastomoses from the persistent hyaloid vasculature by day 10 after birth. In situ hybridizations revealed normal VEGF mRNA expression, but the phenotype of collagen XVIII deficient mice closely resembled that of mice expressing VEGF(120) and VEGF(188) isoforms only, suggesting that type XVIII collagen may be involved in VEGF function. Type XVIII collagen was found to be indispensable for angiogenesis in the eye, as also oxygen-induced neovascularization was less intense than normal in the Col18a1(-/-) mice. We observed a marked increase in the amount of retinal astrocytes in the Col18a1(-/-) mice. Whereas the retinal vessels of wild-type mice are covered by astrocytes and the regressing, thin hyaloid vessels are devoid of astrocytes, the retinal vessels in the Col18a1(-/-) mice were similarly covered by astrocytes but not the persistent hyaloid vessels in the vitreous body. Interestingly, double null mice lacking type XVIII collagen and its homologue type XV collagen had the persistent hyaloid vessels covered by astrocytes, including the parts located in the vitreous body. We thus hypothesize that type XV collagen is a regulator of glial cell recruitment around vessels and that type XVIII collagen regulates their proliferation.	Univ Oulu, Collagen Res Unit, Bioctr Oulu, FIN-90014 Oulu, Finland; Univ Oulu, Dept Med Biochem & Mol Biol, FIN-90014 Oulu, Finland; Univ Oulu, Dept Ophthalmol, SF-90220 Oulu, Finland; UCL, Wolfson Inst Biomed Res, London, England; Univ Oulu, Dept Pathol, Oulu, Finland; Univ Oulu, Bioctr Oulu, Oulu, Finland; Univ Oulu, Dept Physiol, Oulu, Finland	University of Oulu; University of Oulu; University of Oulu; University of London; University College London; University of Oulu; University of Oulu; University of Oulu	Pihlajaniemi, T (corresponding author), Univ Oulu, Collagen Res Unit, Bioctr Oulu, POB 5000, FIN-90014 Oulu, Finland.	taina.pihlajaniemi@oulu.fi		Hurskainen, Merja/0000-0001-8270-8974; Fruttiger, Marcus/0000-0002-6962-5485; Pihlajaniemi, Taina/0000-0002-1664-9045				Abbott NJ, 2002, J ANAT, V200, P629, DOI 10.1046/j.1469-7580.2002.00064.x; ANDERSEN SR, 1961, ARCH OPHTHALMOL-CHIC, V66, P614, DOI 10.1001/archopht.1961.00960010616003; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; COHEN T, 1995, J BIOL CHEM, V270, P11322, DOI 10.1074/jbc.270.19.11322; Eklund L, 2001, P NATL ACAD SCI USA, V98, P1194, DOI 10.1073/pnas.031444798; Fruttiger M, 1996, NEURON, V17, P1117, DOI 10.1016/S0896-6273(00)80244-5; Fruttiger M, 2002, INVEST OPHTH VIS SCI, V43, P522; Fukai N, 2002, EMBO J, V21, P1535, DOI 10.1093/emboj/21.7.1535; Hackett SF, 2002, J CELL PHYSIOL, V192, P182, DOI 10.1002/jcp.10128; Haddad A, 2001, J NEUROSCI METH, V106, P131, DOI 10.1016/S0165-0270(01)00335-1; Halfter W, 1998, J BIOL CHEM, V273, P25404, DOI 10.1074/jbc.273.39.25404; KIVIRIKKO S, 1995, AM J PATHOL, V147, P1500; LEVINE RA, 1983, OPHTHALMOLOGY, V90, P1600; LING TL, 1989, J COMP NEUROL, V286, P345, DOI 10.1002/cne.902860305; Luo J, 1999, J NEUROSCI, V19, P10014, DOI 10.1523/jneurosci.19-22-10014.1999; Majalahti-Palviainen T, 2000, ENDOCRINOLOGY, V141, P731, DOI 10.1210/en.141.2.731; Marneros AG, 2003, INVEST OPHTH VIS SCI, V44, P2367, DOI 10.1167/iovs.02-1180; McKeller RN, 2002, P NATL ACAD SCI USA, V99, P3848, DOI 10.1073/pnas.052484199; Muona A, 2002, MATRIX BIOL, V21, P89, DOI 10.1016/S0945-053X(01)00187-1; MURAGAKI Y, 1995, P NATL ACAD SCI USA, V92, P8763, DOI 10.1073/pnas.92.19.8763; Myers JC, 1996, CELL TISSUE RES, V286, P493, DOI 10.1007/s004410050719; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317; Provis JM, 1997, EXP EYE RES, V65, P555, DOI 10.1006/exer.1997.0365; Ramchandran R, 1999, BIOCHEM BIOPH RES CO, V255, P735, DOI 10.1006/bbrc.1999.0248; REHN M, 1995, J BIOL CHEM, V270, P4705, DOI 10.1074/jbc.270.9.4705; Reichel MB, 1998, CELL DEATH DIFFER, V5, P156, DOI 10.1038/sj.cdd.4400326; Saarela J, 1998, AM J PATHOL, V153, P611, DOI 10.1016/S0002-9440(10)65603-9; SCHNITZER J, 1988, J NEUROCYTOL, V17, P433, DOI 10.1007/BF01189801; Sertie AL, 2000, HUM MOL GENET, V9, P2051, DOI 10.1093/hmg/9.13.2051; SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101; Stalmans I, 2002, J CLIN INVEST, V109, P327, DOI 10.1172/jci0214362; Stone J, 1996, INVEST OPHTH VIS SCI, V37, P290; STONE J, 1987, J COMP NEUROL, V255, P35, DOI 10.1002/cne.902550104; STONE J, 1995, J NEUROSCI, V15, P4738, DOI 10.1523/jneurosci.15-07-04738.1995; Suzuki OT, 2002, AM J HUM GENET, V71, P1320, DOI 10.1086/344695; Walker E, 1942, ARCH NEURO PSYCHIATR, V48, P13, DOI 10.1001/archneurpsyc.1942.02290070023002; WARBURG M, 1963, ACTA OPHTHALMOL, V41, P134; WARBURG M, 1979, T OPHTHAL SOC UK, V99, P272; Yamada H, 2000, AM J PATHOL, V156, P477, DOI 10.1016/S0002-9440(10)64752-9; Ylikarppa R, 2003, FASEB J, V17, P2257, DOI 10.1096/fj.02-1001fje; Ylikarppa R, 2003, MATRIX BIOL, V22, P443, DOI 10.1016/S0945-053X(03)00074-X; Zhang Y, 1999, DEV BRAIN RES, V118, P135, DOI 10.1016/S0165-3806(99)00140-6; Zhang YF, 1997, INVEST OPHTH VIS SCI, V38, P1653; Zhuo L, 1997, DEV BIOL, V187, P36, DOI 10.1006/dbio.1997.8601	46	44	44	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2005	19	8					1564	+		10.1096/fj.04-3101fje	http://dx.doi.org/10.1096/fj.04-3101fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	15976268				2022-12-25	WOS:000230207800006
J	Kasperczyk, H; La Ferla-Bruhl, K; Westhoff, MA; Behrend, L; Zwacka, RM; Debatin, KM; Fulda, S				Kasperczyk, H; La Ferla-Bruhl, K; Westhoff, MA; Behrend, L; Zwacka, RM; Debatin, KM; Fulda, S			Betulinic acid as new activator of NF-kappa B: molecular mechanisms and implications for cancer therapy	ONCOGENE			English	Article						apoptosis; betulinic acid; cancer; NF-kappa B	MELANOMA-CELLS; TUMOR-CELLS; APOPTOSIS; EXPRESSION; PATHWAY; KINASE; CHEMOTHERAPY; INHIBITION; GROWTH; POTENT	Recent evidence demonstrates that the anticancer activity of betulinic acid (BetA) can be markedly increased by combination protocols, for example with chemotherapy, ionizing radiation or TRAIL. Since nuclear factor kappaB (NF-kappa B), a key regulator of stress-induced transcriptional activation, has been implicated in mediating apoptosis resistance, we investigated the role of NF-kappa B in BetA-induced apoptosis. Here, we provide for the first time evidence that BetA activates NF-kappa B in a variety of tumor cell lines. NF-kappa B DNA-binding complexes induced by BetA consisted of p50 and p65 subunits. Nuclear translocation of p65 was also confirmed by immunofluoresence microscopy. BetA-induced NF-kappa B activation involved increased IKK activity and phosphorylation of I kappa B-alpha at serine 32/36 followed by degradation of I kappa B-alpha. Reporter assays revealed that NF-kappa B activated by BetA is transcriptionally active. Interestingly, inhibition of BetA-induced NF-kappa B activation by different chemical inhibitors ( proteasome inhibitor, antioxidant, IKK inhibitor) attenuated BetA-induced apoptosis. Importantly, specific NF-kappa B inhibition by transient or stable expression of I kappa B-alpha super-repressor inhibited BetA-induced apoptosis in SHEP neuroblastoma cells, while transient expression of I kappa B-alpha super-repressor had no influence on BetA-induced apoptosis in two other cell lines. Thus, our. ndings that activation of NF-kappa B by BetA promotes BetA-induced apoptosis in a cell type-specific fashion indicate that NF-kappa B inhibitors in combination with BetA would have no therapeutic benefit or could even be contraproductive in certain tumors, which has important implications for the design of BetA-based combination protocols.	Univ Ulm, Childrens Hosp, Dept Hematol Oncol, D-89075 Ulm, Germany; Univ Ulm, Div Gene Therapy, D-89081 Ulm, Germany	Ulm University; Ulm University	Fulda, S (corresponding author), Univ Ulm, Childrens Hosp, Dept Hematol Oncol, Prittwitzstr 43, D-89075 Ulm, Germany.	simone.fulda@medizin.uni-ulm.de	Ibrahim, Essam Hassan/G-1960-2018; Westhoff, Mike-Andrew/ABA-9272-2021; Debatin, Klaus-Michael/J-9704-2014; Fulda, Simone/D-5864-2011	Ibrahim, Essam Hassan/0000-0003-0130-2257; Westhoff, Mike-Andrew/0000-0003-3256-7100; Debatin, Klaus-Michael/0000-0002-8397-1886; Fulda, Simone/0000-0002-0459-6417; Zwacka, Ralf/0000-0003-2821-0387				Algul H, 2002, J GASTROINTEST CANC, V31, P71, DOI 10.1385/IJGC:31:1-3:71; Baetu TM, 2001, J IMMUNOL, V167, P3164, DOI 10.4049/jimmunol.167.6.3164; Baumann B, 2002, J BIOL CHEM, V277, P44791, DOI 10.1074/jbc.M208003200; Campbell KJ, 2004, MOL CELL, V13, P853, DOI 10.1016/S1097-2765(04)00131-5; Debatin KM, 2002, ONCOGENE, V21, P8786, DOI 10.1038/sj.onc.1206039; Fulda S, 1999, INT J CANCER, V82, P435, DOI 10.1002/(SICI)1097-0215(19990730)82:3<435::AID-IJC18>3.0.CO;2-1; Fulda S, 2004, ONCOGENE, V23, P7611, DOI 10.1038/sj.onc.1207970; Fulda S, 1997, CANCER RES, V57, P4956; Fulda S, 1998, CANCER RES, V58, P4453; Fulda S, 2002, ONCOGENE, V21, P2295, DOI 10.1038/sj.onc.1205255; Fulda S, 1998, J BIOL CHEM, V273, P33942, DOI 10.1074/jbc.273.51.33942; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Herr I, 2001, BLOOD, V98, P2603, DOI 10.1182/blood.V98.9.2603; Jeremias I, 1998, BLOOD, V91, P4624, DOI 10.1182/blood.V91.12.4624.412k19_4624_4631; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279; Kim B, 2002, J BIOL CHEM, V277, P27393, DOI 10.1074/jbc.M201963200; PISHA E, 1995, NAT MED, V1, P1046, DOI 10.1038/nm1095-1046; Ravi R, 2001, NAT CELL BIOL, V3, P409, DOI 10.1038/35070096; Sawada N, 2004, BRIT J CANCER, V90, P1672, DOI 10.1038/sj.bjc.6601746; Selzer E, 2000, J INVEST DERMATOL, V114, P935, DOI 10.1046/j.1523-1747.2000.00972.x; Takada Y, 2003, J IMMUNOL, V171, P3278, DOI 10.4049/jimmunol.171.6.3278; van Loo G, 2002, CELL DEATH DIFFER, V9, P1031, DOI 10.1038/sj.cdd.4401088; Wahl C, 1998, J CLIN INVEST, V101, P1163, DOI 10.1172/JCI992; Weaver KD, 2003, J NEURO-ONCOL, V61, P187, DOI 10.1023/A:1022554824129; Younes A, 2003, LEUKEMIA LYMPHOMA, V44, P929, DOI 10.1080/1042819031000067558; Zhang YD, 2004, CANCER RES, V64, P1902, DOI 10.1158/0008-5472.CAN-03-3361; Zuco V, 2002, CANCER LETT, V175, P17, DOI 10.1016/S0304-3835(01)00718-2; Zwacka RM, 2000, J GENE MED, V2, P334, DOI 10.1002/1521-2254(200009/10)2:5<334::AID-JGM129>3.0.CO;2-Q	31	121	125	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2005	24	46					6945	6956		10.1038/sj.onc.1208842	http://dx.doi.org/10.1038/sj.onc.1208842			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	975ZD	16007147				2022-12-25	WOS:000232701700009
J	Giordano, TJ; Kuick, R; Thomas, DG; Misek, DE; Vinco, M; Sanders, D; Zhu, ZW; Ciampi, R; Roh, M; Shedden, K; Gauger, P; Doherty, G; Thompson, NW; Hanash, S; Koenig, RJ; Nikiforov, YE				Giordano, TJ; Kuick, R; Thomas, DG; Misek, DE; Vinco, M; Sanders, D; Zhu, ZW; Ciampi, R; Roh, M; Shedden, K; Gauger, P; Doherty, G; Thompson, NW; Hanash, S; Koenig, RJ; Nikiforov, YE			Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis	ONCOGENE			English	Article						thyroid cancer; molecular profiling; DNA microarray; activating mutation; RET/RAS/RAF/MAPK signaling pathway	GROWTH-FACTOR-RECEPTOR; TALL-CELL VARIANT; FOLLICULAR VARIANT; HIGH PREVALENCE; CLINICAL-IMPLICATIONS; ONCOGENE ACTIVATION; ANTITUMOR-ACTIVITY; IMMUNE-RESPONSE; LUNG-CANCER; EARLY EVENT	Thyroid cancer poses a significant clinical challenge, and our understanding of its pathogenesis is incomplete. To gain insight into the pathogenesis of papillary thyroid carcinoma, transcriptional profiles of four normal thyroids and 51 papillary carcinomas (PCs) were generated using DNA microarrays. The tumors were genotyped for their common activating mutations: BRAF V600E point mutation, RET/PTC1 and 3 rearrangement and point mutations of KRAS, HRAS and NRAS. Principal component analysis based on the entire expression data set separated the PCs into three groups that were found to reflect tumor morphology and mutational status. By combining expression profiles with mutational status, we defined distinct expression profiles for the BRAF, RET/PTC1 and RAS mutation groups. Using small numbers of genes, a simple classifier was able to classify correctly the mutational status of all 40 tumors with known mutations. One tumor without a detectable mutation was predicted by the classifier to have a RET/PTC rearrangement and was shown to contain one by fluorescence in situ hybridization analysis. Among the mutation-specific expression signatures were genes whose differential expression was a direct consequence of the mutation, as well as genes involved in a variety of biological processes including immune response and signal transduction. Expression of one mutation-specific differentially expressed gene, TPO, was validated at the protein level using immunohistochemistry and tissue arrays containing an independent set of tumors. The results demonstrate that mutational status is the primary determinant of gene expression variation within these tumors, a finding that may have clinical and diagnostic significance and predicts success for therapies designed to prevent the consequences of these mutations.	Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Pediat, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Cincinnati, Sch Med, Dept Pathol, Cincinnati, OH USA; Univ Michigan, Sch Med, Dept Stat, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Surg, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University System of Ohio; University of Cincinnati; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Giordano, TJ (corresponding author), Univ Michigan, Sch Med, Dept Pathol, UH 2G3320054, Ann Arbor, MI 48109 USA.	Giordano@umich.edu	Gauger, Paul/W-8176-2019; Ciampi, Raffaele/E-5350-2015	Giordano, Thomas/0000-0003-0641-8873; Ciampi, Raffaele/0000-0001-6345-9343; Doherty, Gerard/0000-0002-1685-9552	NATIONAL CANCER INSTITUTE [P30CA046592] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK020572, P60DK020572] Funding Source: NIH RePORTER; NCI NIH HHS [5 P30 CA46592, CA84952] Funding Source: Medline; NIDDK NIH HHS [DK58771, DK20572] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aldred MA, 2004, J CLIN ONCOL, V22, P3531, DOI 10.1200/JCO.2004.08.127; Allander SV, 2001, CANCER RES, V61, P8624; BAKER JR, 1995, J CLIN ENDOCR METAB, V80, P3419, DOI 10.1210/jc.80.12.3419; Balmain A, 2003, NAT GENET, V33, P238, DOI 10.1038/ng1107; Barden CB, 2003, CLIN CANCER RES, V9, P1792; Batistatou A, 2002, ENDOCR PATHOL, V13, P111, DOI 10.1385/EP:13:2:111; Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733; Begum S, 2004, MODERN PATHOL, V17, P1359, DOI 10.1038/modpathol.3800198; Bertucci F, 2004, ONCOGENE, V23, P2564, DOI 10.1038/sj.onc.1207361; BONGARZONE I, 1989, ONCOGENE, V4, P1457; Bongarzone I, 2003, TUMORI, V89, P514, DOI 10.1177/030089160308900510; Bounacer A, 1997, ONCOGENE, V15, P1263, DOI 10.1038/sj.onc.1200206; Capella G, 1996, DIAGN MOL PATHOL, V5, P45, DOI 10.1097/00019606-199603000-00008; Carlomagno F, 2002, CANCER RES, V62, P7284; Carlomagno F, 2003, J CLIN ENDOCR METAB, V88, P1897, DOI 10.1210/jc.2002-021278; Chevillard S, 2004, CLIN CANCER RES, V10, P6586, DOI 10.1158/1078-0432.CCR-04-0053; Ciampi R, 2005, J CLIN INVEST, V115, P94, DOI 10.1172/JCI200523237; Ciro M, 2003, CURR OPIN CELL BIOL, V15, P213, DOI 10.1016/S0955-0674(03)00007-3; Cohen J, 2003, J NATL CANCER I, V95, P625, DOI 10.1093/jnci/95.8.625; Cuccuru G, 2004, JNCI-J NATL CANCER I, V96, P1006, DOI 10.1093/jnci/djh184; Dancey JE, 2004, CANCER CELL, V5, P411, DOI 10.1016/S1535-6108(04)00122-9; De Micco C, 2003, AM J CLIN PATHOL, V120, P803; DEGROOT LJ, 1990, J CLIN ENDOCR METAB, V71, P414, DOI 10.1210/jcem-71-2-414; DeLellis RA., 2004, TUMOURS ENDOCRINE OR; DOBASHI Y, 1994, DIAGN MOL PATHOL, V3, P9, DOI 10.1097/00019606-199403010-00003; DONGHI R, 1993, J CLIN INVEST, V91, P1753, DOI 10.1172/JCI116385; Ezzat S, 1996, THYROID, V6, P409, DOI 10.1089/thy.1996.6.409; Fagin JA, 2002, ENDOCRINOLOGY, V143, P2025, DOI 10.1210/en.143.6.2025; Finley DJ, 2004, J CLIN ENDOCR METAB, V89, P3214, DOI 10.1210/jc.2003-031811; Frattini M, 2004, ONCOGENE, V23, P7436, DOI 10.1038/sj.onc.1207980; Frisk T, 2002, GENE CHROMOSOME CANC, V35, P74, DOI 10.1002/gcc.10098; Giordano TJ, 2003, AM J PATHOL, V162, P521, DOI 10.1016/S0002-9440(10)63846-1; Giordano TJ, 2001, AM J PATHOL, V159, P1231, DOI 10.1016/S0002-9440(10)62509-6; Giuffrida D, 2000, ANN ONCOL, V11, P1083, DOI 10.1023/A:1008322002520; Hanash S, 2004, NAT REV CANCER, V4, P638, DOI 10.1038/nrc1414; Hawthorn L, 2004, HEAD NECK-J SCI SPEC, V26, P1069, DOI 10.1002/hed.20099; Hedenfalk I, 2001, NEW ENGL J MED, V344, P539, DOI 10.1056/NEJM200102223440801; Ho CL, 2004, CANCER RES, V64, P6915, DOI 10.1158/0008-5472.CAN-04-2067; Huang Y, 2001, P NATL ACAD SCI USA, V98, P15044, DOI 10.1073/pnas.251547398; Hundahl SA, 1998, CANCER-AM CANCER SOC, V83, P2638, DOI 10.1002/(SICI)1097-0142(19981215)83:12<2638::AID-CNCR31>3.0.CO;2-1; Jazaeri AA, 2002, JNCI-J NATL CANCER I, V94, P990, DOI 10.1093/jnci/94.13.990; Juhasz F, 1996, J CLIN ENDOCR METAB, V81, P4175, DOI 10.1210/jcem.81.11.8923882; Karasarides M, 2004, ONCOGENE, V23, P6292, DOI 10.1038/sj.onc.1207785; KARGA H, 1991, J CLIN ENDOCR METAB, V73, P832, DOI 10.1210/jcem-73-4-832; Kimura ET, 2003, CANCER RES, V63, P1454; LiVolsi V A, 1996, Clin Oncol (R Coll Radiol), V8, P281, DOI 10.1016/S0936-6555(05)80712-5; Lloyd RV, 2004, AM J SURG PATHOL, V28, P1336, DOI 10.1097/01.pas.0000135519.34847.f6; Lowinger TB, 2002, CURR PHARM DESIGN, V8, P2269, DOI 10.2174/1381612023393125; Luo J, 2003, CANCER INVEST, V21, P937, DOI 10.1081/CNV-120025096; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Lyons JF, 2001, ENDOCR-RELAT CANCER, V8, P219, DOI 10.1677/erc.0.0080219; Machens A, 2004, LANGENBECK ARCH SURG, V389, P278, DOI 10.1007/s00423-004-0485-8; Mazzanti C, 2004, CANCER RES, V64, P2898, DOI 10.1158/0008-5472.CAN-03-3811; Miyagi E, 2004, MOL CARCINOGEN, V41, P98, DOI 10.1002/mc.20042; Moretti F, 2000, BEST PRACT RES CL EN, V14, P517, DOI 10.1053/beem.2000.0101; NAMBA H, 1990, MOL ENDOCRINOL, V4, P1474, DOI 10.1210/mend-4-10-1474; Nardone HC, 2003, CANCER, V98, P1386, DOI 10.1002/cncr.11638; Nikiforov YE, 2002, ENDOCR PATHOL, V13, P3, DOI 10.1385/EP:13:1:03; Nikiforova MN, 2002, INT J SURG PATHOL, V10, P15, DOI 10.1177/106689690201000104; Nikiforova MN, 2003, J CLIN ENDOCR METAB, V88, P5399, DOI 10.1210/jc.2003-030838; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pavey S, 2004, ONCOGENE, V23, P4060, DOI 10.1038/sj.onc.1207563; Prendiville S, 2000, OTOLARYNG HEAD NECK, V122, P352, DOI 10.1016/S0194-5998(00)70047-7; Rabes HM, 2000, CLIN CANCER RES, V6, P1093; Ruco LP, 2001, J PATHOL, V194, P4, DOI 10.1002/path.847; SANTORO M, 1992, J CLIN INVEST, V89, P1517, DOI 10.1172/JCI115743; Sawyers CL, 2003, GENE DEV, V17, P2998, DOI 10.1101/gad.1152403; Schaefer KL, 2004, CANCER RES, V64, P3395, DOI 10.1158/0008-5472.CAN-03-0809; Schwartz DR, 2002, CANCER RES, V62, P4722; Segev DL, 2003, SURG ONCOL, V12, P69, DOI 10.1016/S0960-7404(03)00037-9; Singer G, 2003, J NATL CANCER I, V95, P484, DOI 10.1093/jnci/95.6.484; SMANIK PA, 1994, BIOCHEM BIOPH RES CO, V198, P948, DOI 10.1006/bbrc.1994.1135; Soares P, 2003, ONCOGENE, V22, P4578, DOI 10.1038/sj.onc.1206706; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; STONE M, 1977, BIOMETRIKA, V64, P29; SUAREZ HG, 1988, ONCOGENE, V2, P403; Sweet-Cordero A, 2005, NAT GENET, V37, P48, DOI 10.1038/ng1490; Tanaka T, 1996, J PATHOL, V179, P89; VIGLIETTO G, 1995, ONCOGENE, V11, P1207; Wasenius VM, 2003, CLIN CANCER RES, V9, P68; Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443; Wreesmann VB, 2004, CANCER RES, V64, P3780, DOI 10.1158/0008-5472.CAN-03-1460; Zhu ZW, 2003, AM J CLIN PATHOL, V120, P71, DOI 10.1309/ND8D9LAJTRCTG6QD	83	289	309	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 6	2005	24	44					6646	6656		10.1038/sj.onc.1208822	http://dx.doi.org/10.1038/sj.onc.1208822			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	971FL	16007166				2022-12-25	WOS:000232367800006
J	Minagawa, N; Kruglov, EA; Dranoff, JA; Robert, ME; Gores, GJ; Nathanson, MH				Minagawa, N; Kruglov, EA; Dranoff, JA; Robert, ME; Gores, GJ; Nathanson, MH			The anti-apoptotic protein Mcl-1 inhibits mitochondrial Ca2+ signals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; BILE-DUCT EPITHELIA; CYTOCHROME-C; CALCIUM SIGNALS; BCL-2 FAMILY; PERMEABILITY TRANSITION; ENDOPLASMIC-RETICULUM; CELL-DIFFERENTIATION; DEATH RECEPTORS; BAX	Apoptosis contributes to the regulation of cell growth and regeneration and to the development of neoplasia. Mcl-1 is an anti-apoptotic protein that is particularly important for the development of hematological and biliary malignancies, but the mechanism of action of Mcl-1 is unknown. A number of pro- and anti-apoptotic proteins exhibit their effects by modulating Ca2+ signals, so we examined the effects of Mcl-1 on components of the Ca2+ signaling pathway that are known to regulate apoptosis. Expression of Mcl-1 did not affect expression of the inositol 1,4,5-trisphosphate receptor or the size of endoplasmic reticulum Ca2+ stores. However, mitochondrial Ca2+ signals induced by either Ca2+ agonists or apoptotic stimuli were decreased in cells overexpressing Mcl-1 and increased in cells in which Mcl-1 expression was inhibited. These findings provide evidence that Mcl-1 directly inhibits Ca2+ signals within mitochondria, which may provide a novel mechanism to inhibit apoptosis and thereby promote neoplasia.	Yale Univ, Sch Med, Sect Digest Dis, Dept Med, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA; Mayo Clin & Mayo Grad Sch Med, Dept Med, Rochester, MN 55905 USA	Yale University; Yale University; Mayo Clinic	Nathanson, MH (corresponding author), Yale Univ, Sch Med, Sect Digest Dis, Dept Med, 1 Gilbert St,Rm TAC S241D, New Haven, CT 06520 USA.	michael.nathanson@yale.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061747, P30DK034989, R29DK045710, R01DK045710] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK61747, DK45710, DK34989] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Baines CP, 2005, NATURE, V434, P658, DOI 10.1038/nature03434; Bassik MC, 2004, EMBO J, V23, P1207, DOI 10.1038/sj.emboj.7600104; Boehning D, 2003, NAT CELL BIOL, V5, P1051, DOI 10.1038/ncb1063; Chami M, 2004, J BIOL CHEM, V279, P54581, DOI 10.1074/jbc.M409663200; Csordas G, 1999, EMBO J, V18, P96, DOI 10.1093/emboj/18.1.96; Echevarria W, 2003, NAT CELL BIOL, V5, P440, DOI 10.1038/ncb980; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; GUNTER TE, 1990, AM J PHYSIOL, V258, P755; Hagar RE, 1998, NATURE, V396, P81, DOI 10.1038/23954; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; Hirata K, 1998, P NATL ACAD SCI USA, V95, P8381, DOI 10.1073/pnas.95.14.8381; Hirata K, 2002, HEPATOLOGY, V36, P284, DOI 10.1053/jhep.2002.34432; Ichas F, 1997, CELL, V89, P1145, DOI 10.1016/S0092-8674(00)80301-3; Jayaraman T, 1997, MOL CELL BIOL, V17, P3005, DOI 10.1128/MCB.17.6.3005; JOUAVILLE IS, 1995, NATURE, V377, P438; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kaufmann SH, 1998, BLOOD, V91, P991, DOI 10.1182/blood.V91.3.991.991_991_1000; Khan AA, 1996, SCIENCE, V273, P503, DOI 10.1126/science.273.5274.503; KNUTH A, 1985, J HEPATOL, V1, P579, DOI 10.1016/S0168-8278(85)80002-7; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; LeSage G, 1999, GASTROENTEROLOGY, V117, P191, DOI 10.1016/S0016-5085(99)70567-6; Leu JIJ, 2004, NAT CELL BIOL, V6, P443, DOI 10.1038/ncb1123; Li C, 2002, P NATL ACAD SCI USA, V99, P9830, DOI 10.1073/pnas.152571899; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MCGILL JM, 1994, GASTROENTEROLOGY, V107, P236, DOI 10.1016/0016-5085(94)90082-5; Nakagawa T, 2005, NATURE, V434, P652, DOI 10.1038/nature03317; Nathanson MH, 1996, AM J PHYSIOL-GASTR L, V271, pG86, DOI 10.1152/ajpgi.1996.271.1.G86; Pacher P, 2001, EMBO J, V20, P4107, DOI 10.1093/emboj/20.15.4107; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; Salvioli S, 1997, FEBS LETT, V411, P77, DOI 10.1016/S0014-5793(97)00669-8; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Shibao K, 2003, GASTROENTEROLOGY, V125, P1175, DOI 10.1016/S0016-5085(03)01201-0; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Szalai G, 1999, EMBO J, V18, P6349, DOI 10.1093/emboj/18.22.6349; Taniai M, 2004, CANCER RES, V64, P3517, DOI 10.1158/0008-5472.CAN-03-2770; Vrana JA, 2002, CANCER RES, V62, P892; Yang T, 1996, J CELL PHYSIOL, V166, P523, DOI 10.1002/(SICI)1097-4652(199603)166:3<523::AID-JCP7>3.0.CO;2-R	43	59	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	2005	280	39					33637	33644		10.1074/jbc.M503210200	http://dx.doi.org/10.1074/jbc.M503210200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	966YG	16027162	hybrid			2022-12-25	WOS:000232058100065
J	Bergefall, K; Trybala, E; Johansson, M; Uyama, T; Naito, S; Yamada, S; Kitagawa, H; Sugahara, K; Bergstrom, T				Bergefall, K; Trybala, E; Johansson, M; Uyama, T; Naito, S; Yamada, S; Kitagawa, H; Sugahara, K; Bergstrom, T			Chondroitin sulfate characterized by the E-disaccharide unit is a potent inhibitor of herpes simplex virus infectivity and provides the virus binding sites on gro2C cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; GLAND EPITHELIAL-CELLS; PROTEIN LINKAGE REGION; TYPE-1 GLYCOPROTEIN-C; HEPARAN-SULFATE; STRUCTURAL DETERMINATION; ENVELOPED VIRUSES; DERMATAN SULFATE; GLUCURONIC-ACID; GROWTH-FACTORS	Although cell surface chondroitin sulfate ( CS) is regarded as an auxiliary receptor for binding of herpes simplex virus to cells, and purified CS chain types A, B, and C are known to interfere poorly or not at all with the virus infection of cells, we have found that CS type E (CS-E), derived from squid cartilage, exhibited potent antiviral activity. The IC50 values ranged from 0.06 to 0.2 mu g/ml and substantially exceeded the antiviral potency of heparin, the known inhibitor of virus binding to cells. Furthermore, in mutant gro2C cells that express CS but not heparan sulfate, CS-E showed unusually high anti-herpes virus activity with IC50 values of < 1 ng/ml. Enzymatic degradation of CS-E with chondroitinase ABC abolished its antiviral activity. CS-E inhibited the binding to cells of the purified virus attachment protein gC. A direct interaction of gC with immobilized CS-E and inhibition of this binding by CS-E oligosaccharide fragments greater than octasaccharide were demonstrated. Likewise, the gro2C-specific CS chains interfered with the binding of viral gC to these cells and were found to contain a considerable proportion (13%) of the E-disaccharide unit, suggesting that this unit is an essential component of the CS receptor for herpes simplex virus on gro2C cells and that the antiviral activity of CS-E was due to interference with the binding of viral gC to a CS-E-like receptor on the cell surface. Knowledge of the determinants of antiviral properties of CS-E will help in the development of inhibitors of herpes simplex virus infections in humans.	Gothenburg Univ, Dept Clin Virol, S-41346 Gothenburg, Sweden; Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, Kobe, Hyogo 6588558, Japan	University of Gothenburg; Kobe Pharmaceutical University	Bergstrom, T (corresponding author), Gothenburg Univ, Dept Clin Virol, Guldhedsgatan 10B, S-41346 Gothenburg, Sweden.	tomas.bergstrom@microbio.gu.se	Kitagawa, Hiroshi/AAJ-1344-2020	Kitagawa, Hiroshi/0000-0002-9307-7079; Trybala, Edward/0000-0003-2384-2123; Bergstrom, Tomas/0000-0002-9257-6757				BABA M, 1988, ANTIMICROB AGENTS CH, V32, P1742, DOI 10.1128/AAC.32.11.1742; BANFIELD BW, 1995, VIROLOGY, V208, P531, DOI 10.1006/viro.1995.1184; BLUMENKR.N, 1973, ANAL BIOCHEM, V54, P484, DOI 10.1016/0003-2697(73)90377-1; Damonte EB, 1996, CHEMOTHERAPY, V42, P57, DOI 10.1159/000239422; Deepa SS, 2002, J BIOL CHEM, V277, P43707, DOI 10.1074/jbc.M207105200; Deepa SS, 2004, J BIOL CHEM, V279, P37368, DOI 10.1074/jbc.M403031200; Di Caro A, 1999, ANTIVIR CHEM CHEMOTH, V10, P33, DOI 10.1177/095632029901000104; Duarte MER, 2001, PHYTOMEDICINE, V8, P53, DOI 10.1078/0944-7113-00007; DUFF R, 1971, NATURE-NEW BIOL, V233, P48, DOI 10.1038/newbio233048a0; GRUENHEID S, 1993, J VIROL, V67, P93, DOI 10.1128/JVI.67.1.93-100.1993; Gunalp A., 1965, P SOC EXP BIOL MED, V118, P185; HOLLAND TC, 1983, J VIROL, V45, P672, DOI 10.1128/JVI.45.2.672-682.1983; HOLLAND TC, 1984, J VIROL, V52, P566, DOI 10.1128/JVI.52.2.566-574.1984; KARGER A, 1993, VIROLOGY, V194, P654, DOI 10.1006/viro.1993.1305; Kawashima H, 2002, J BIOL CHEM, V277, P12921, DOI 10.1074/jbc.M200396200; Kinoshita A, 1997, J BIOL CHEM, V272, P19656, DOI 10.1074/jbc.272.32.19656; Kinoshita A, 1999, ANAL BIOCHEM, V269, P367, DOI 10.1006/abio.1999.4027; Kinoshita A, 2001, BIOCHEMISTRY-US, V40, P12654, DOI 10.1021/bi015577n; Kinoshita-Toyoda A, 2004, BIOCHEMISTRY-US, V43, P11063, DOI 10.1021/bi049622d; LYCKE E, 1991, J GEN VIROL, V72, P1131, DOI 10.1099/0022-1317-72-5-1131; LYON M, 1994, J BIOL CHEM, V269, P11216; Marchetti M, 2004, VIROLOGY, V318, P405, DOI 10.1016/j.virol.2003.09.029; Mardberg K, 2002, J GEN VIROL, V83, P291, DOI 10.1099/0022-1317-83-2-291; Nyberg K, 2004, ANTIVIR RES, V63, P15, DOI 10.1016/j.antiviral.2004.01.001; SHIEH MT, 1992, J CELL BIOL, V116, P1273, DOI 10.1083/jcb.116.5.1273; Sinha S, 2003, ANTIMICROB AGENTS CH, V47, P494, DOI 10.1128/AAC.47.2.494-500.2003; SUGAHARA K, 1995, J BIOL CHEM, V270, P7204, DOI 10.1074/jbc.270.13.7204; Sugahara K, 1996, J BIOL CHEM, V271, P26745, DOI 10.1074/jbc.271.43.26745; Sugahara K, 2003, CURR OPIN STRUC BIOL, V13, P612, DOI 10.1016/j.sbi.2003.09.011; Trybala E, 2000, J VIROL, V74, P9106, DOI 10.1128/JVI.74.19.9106-9114.2000; Tsuchida K, 2001, J BIOL CHEM, V276, P37155, DOI 10.1074/jbc.M105818200; Ueno M, 2001, J BIOL CHEM, V276, P29134, DOI 10.1074/jbc.M102089200; Ueoka C, 2000, J BIOL CHEM, V275, P37407, DOI 10.1074/jbc.M002538200; VAHERI A, 1964, ACTA PATHOL MIC SC, P7; Witvrouw M, 1997, GEN PHARMACOL-VASC S, V29, P497, DOI 10.1016/S0306-3623(96)00563-0	35	96	102	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	2005	280	37					32193	32199		10.1074/jbc.M503645200	http://dx.doi.org/10.1074/jbc.M503645200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	963HM	16027159	hybrid			2022-12-25	WOS:000231794800020
J	Mendiratta, SS; Sekulic, N; Lavie, A; Colley, KJ				Mendiratta, SS; Sekulic, N; Lavie, A; Colley, KJ			Specific amino acids in the first fibronectin type III repeat of the neural cell adhesion molecule play a role in its recognition and polysialylation by the polysialyltransferase ST8Sia IV/PST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYSIALIC ACID; N-CAM; LUNG-CARCINOMA; IN-VIVO; 3-DIMENSIONAL STRUCTURE; NEURITE OUTGROWTH; NERVOUS-SYSTEM; PROCATHEPSIN-D; NCAM; PROTEIN	Polysialic acid is an anti-adhesive protein modification that promotes cell migration and the plasticity of cell interactions. Because so few proteins carry polysialic acid, we hypothesized that polysialylation is a protein-specific event and that a specific polysialyltransferase-substrate interaction is the basis of this specificity. The major substrate for the polysialyltransferases is the neural cell adhesion molecule, NCAM. Previous work demonstrates that the first fibronectin type III repeat of NCAM (FN1) was necessary for the polysialylation of the N-glycans on the adjacent immunoglobulin domain (Ig5) ( Close, B. E., Mendiratta, S. S., Geiger, K. M., Broom, L. J., Ho, L. L., and Colley, K. J. ( 2003) J. Biol. Chem. 278, 30796 30805). This suggested that FN1 may be a recognition site for the polysialyltransferases. In this study, we showed that the second fibronectin type III repeat (FN2) of NCAM cannot replace FN1. Arg substitution of three unique acidic amino acids on the surface of FN1 eliminated polysialylation not only of a minimal Ig5-FN1 substrate but also of full-length NCAM. Ala substitution of these residues eliminated Ig5-FN1 polysialylation but not that of full-length NCAM, suggesting that the two proteins are interacting differently with the enzymes and that multiple residues are involved in the enzyme-NCAM interaction. By using another truncated protein, Ig5-FN1-FN2, we confirmed the importance of enzyme-substrate positioning for optimal recognition and polysialylation. In sum, we have found that acidic residues on the surface of FN1 are part of a larger protein interaction region that is critical for NCAM recognition and polysialylation by the polysialyltransferases.	Univ Illinois, Coll Med, Dept Biochem & Mol Genet, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Colley, KJ (corresponding author), Univ Illinois, Coll Med, Dept Biochem & Mol Genet, 900 S Ashland Ave,M-C 669, Chicago, IL 60607 USA.	karenc@uic.edu	Lavie, Arnon/H-4927-2012; Sekulic, Nikolina/N-5550-2016; Sekulic, Nikolina/F-8911-2013	Sekulic, Nikolina/0000-0001-7555-3222; Lavie, Arnon/0000-0001-5591-8722	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM063483, R01GM063843] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM63483] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Angata K, 2003, BIOCHIMIE, V85, P195, DOI 10.1016/S0300-9084(03)00051-8; Angata K, 2004, J BIOL CHEM, V279, P32603, DOI 10.1074/jbc.M403429200; Angata K, 2000, J BIOL CHEM, V275, P18594, DOI 10.1074/jbc.M910204199; BAENZIGER JU, 1994, FASEB J, V8, P1019, DOI 10.1096/fasebj.8.13.7926366; BARANSKI TJ, 1991, J BIOL CHEM, V266, P23365; BARANSKI TJ, 1992, J BIOL CHEM, V267, P23342; BARANSKI TJ, 1990, CELL, V63, P281, DOI 10.1016/0092-8674(90)90161-7; Becker CG, 1996, J NEUROSCI RES, V45, P143, DOI 10.1002/(SICI)1097-4547(19960715)45:2<143::AID-JNR6>3.0.CO;2-A; BORK P, 1992, P NATL ACAD SCI USA, V89, P8990, DOI 10.1073/pnas.89.19.8990; Bruses JL, 2001, BIOCHIMIE, V83, P635, DOI 10.1016/S0300-9084(01)01293-7; Close BE, 2003, J BIOL CHEM, V278, P30796, DOI 10.1074/jbc.M305390200; Close BE, 2000, J BIOL CHEM, V275, P4484, DOI 10.1074/jbc.275.6.4484; Close BE, 1998, J BIOL CHEM, V273, P34586, DOI 10.1074/jbc.273.51.34586; CREMER H, 1994, NATURE, V367, P455, DOI 10.1038/367455a0; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; Durbec P, 2001, MOL NEUROBIOL, V24, P53; DUSTIN ML, 1995, J BIOL CHEM, V270, P170, DOI 10.1074/jbc.270.1.170; DZHANDZHUGAZYAN K, 1993, FEBS LETT, V336, P279, DOI 10.1016/0014-5793(93)80820-K; Dzhandzhugazyan K, 1997, BIOCHEMISTRY-US, V36, P15381, DOI 10.1021/bi9709351; Eckhardt M, 2000, J NEUROSCI, V20, P5234, DOI 10.1523/JNEUROSCI.20-14-05234.2000; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; FIETE D, 1991, CELL, V67, P1103, DOI 10.1016/0092-8674(91)90287-9; FINNE J, 1983, BIOCHEM BIOPH RES CO, V112, P482, DOI 10.1016/0006-291X(83)91490-0; FINNE J, 1987, J IMMUNOL, V138, P4402; HALL AK, 1987, J CELL BIOL, V104, P1579, DOI 10.1083/jcb.104.6.1579; Hamlin JA, 2004, J COMP NEUROL, V474, P438, DOI 10.1002/cne.20133; Hildebrandt H, 1998, CANCER RES, V58, P779; HOFFMAN S, 1983, P NATL ACAD SCI-BIOL, V80, P5762, DOI 10.1073/pnas.80.18.5762; HUBER AH, 1994, NEURON, V12, P717, DOI 10.1016/0896-6273(94)90326-3; Inoue S, 2001, J BIOL CHEM, V276, P31863, DOI 10.1074/jbc.M103336200; JAMES WM, 1987, BIOCHEM BIOPH RES CO, V148, P817, DOI 10.1016/0006-291X(87)90949-1; JAMES WM, 1989, BIOCHEMISTRY-US, V28, P6001, DOI 10.1021/bi00440a042; Johnson CP, 2005, J BIOL CHEM, V280, P137, DOI 10.1074/jbc.M410216200; Johnson CP, 2004, P NATL ACAD SCI USA, V101, P6963, DOI 10.1073/pnas.0307567100; KIBBELAAR RE, 1989, J PATHOL, V159, P23, DOI 10.1002/path.1711590108; Kiselyov VV, 2003, STRUCTURE, V11, P691, DOI 10.1016/S0969-2126(03)00096-0; Kiss JZ, 2001, BRAIN RES REV, V36, P175, DOI 10.1016/S0165-0173(01)00093-5; KOMMINOTH P, 1991, AM J PATHOL, V139, P297; KRIEG PA, 1989, NUCLEIC ACIDS RES, V17, P10321, DOI 10.1093/nar/17.24.10321; LANDMESSER L, 1990, NEURON, V4, P655, DOI 10.1016/0896-6273(90)90193-J; LEAHY DJ, 1992, SCIENCE, V258, P987, DOI 10.1126/science.1279805; LIVINGSTON BD, 1988, J BIOL CHEM, V263, P9443; MAIN AL, 1992, CELL, V71, P671, DOI 10.1016/0092-8674(92)90600-H; MENGELING BJ, 1995, P NATL ACAD SCI USA, V92, P502, DOI 10.1073/pnas.92.2.502; Muhlenhoff M, 1996, EMBO J, V15, P6943, DOI 10.1002/j.1460-2075.1996.tb01086.x; Muhlenhoff M, 1998, CURR OPIN STRUC BIOL, V8, P558, DOI 10.1016/S0959-440X(98)80144-9; NELSON RW, 1995, J BIOL CHEM, V270, P17171, DOI 10.1074/jbc.270.29.17171; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; PETERSEN TE, 1983, P NATL ACAD SCI-BIOL, V80, P137, DOI 10.1073/pnas.80.1.137; ROTH J, 1988, AM J PATHOL, V133, P227; ROTH J, 1987, P NATL ACAD SCI USA, V84, P1969, DOI 10.1073/pnas.84.7.1969; ROTHBARD JB, 1982, J BIOL CHEM, V257, P1064; ROUGON G, 1993, EUR J CELL BIOL, V61, P197; Rutishauser U, 1996, TRENDS NEUROSCI, V19, P422; RUTISHAUSER U, 1985, J CELL BIOL, V101, P1842, DOI 10.1083/jcb.101.5.1842; SADOUL R, 1983, NATURE, V304, P347, DOI 10.1038/304347a0; Saffell JL, 1997, NEURON, V18, P231, DOI 10.1016/S0896-6273(00)80264-0; SCHEIDEGGER EP, 1994, LAB INVEST, V70, P95; Schmitt-Ulms G, 2001, J MOL BIOL, V314, P1209, DOI 10.1006/jmbi.2000.5183; Seidenfaden R, 2003, MOL CELL BIOL, V23, P5908, DOI 10.1128/MCB.23.16.5908-5918.2003; Skladchikova G, 1999, J NEUROSCI RES, V57, P207; SMALL SJ, 1990, J CELL BIOL, V111, P2089, DOI 10.1083/jcb.111.5.2089; SMITH PL, 1992, P NATL ACAD SCI USA, V89, P329, DOI 10.1073/pnas.89.1.329; TROY FA, 1992, GLYCOBIOLOGY, V2, P5, DOI 10.1093/glycob/2.1.5; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; Walmod PS, 2004, NEUROCHEM RES, V29, P2015, DOI 10.1007/s11064-004-6875-z; WILLIAMS EJ, 1994, NEURON, V13, P583, DOI 10.1016/0896-6273(94)90027-2; Yabe U, 2003, J BIOL CHEM, V278, P13875, DOI 10.1074/jbc.M300458200; ZUBER C, 1992, J BIOL CHEM, V267, P9965	69	35	35	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	2005	280	37					32340	32348		10.1074/jbc.M506217200	http://dx.doi.org/10.1074/jbc.M506217200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	963HM	16027151	hybrid			2022-12-25	WOS:000231794800038
J	Kelly, BL; Vassar, R; Ferreira, A				Kelly, BL; Vassar, R; Ferreira, A			beta-Amyloid-induced dynamin 1 depletion in hippocampal neurons - A potential mechanism for early cognitive decline in Alzheimer disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED NEUTRAL PROTEINASE; SYNAPTIC VESICLE TRAFFICKING; A-BETA; MEMORY DEFICITS; TRANSGENIC MICE; FRONTAL-CORTEX; CALPAIN; EXPRESSION; MEMBRANE; CULTURE	Synaptic dysfunction is one of the earliest events in the pathogenesis of Alzheimer disease ( AD). However, the molecular mechanisms underlying synaptic defects in AD are largely unknown. We report here that beta-amyloid ( A beta), the main component of senile plaques, induced a significant decrease in dynamin 1, a protein that is essential for synaptic vesicle recycling and, hence, for memory formation and information processing. The A beta-induced dynamin 1 decrease occurred in the absence of overt synaptic loss and was also observed in the Tg2576 mouse model of AD. In addition, our results provided evidence that the A beta-induced decrease in dynamin 1 was likely the result of a calpain-mediated cleavage of dynamin 1 protein and possibly the down-regulation of dynamin 1 gene expression. These data suggest a mechanism to explain the early cognitive loss without a major decline in synapse number observed in AD and propose a novel therapeutic target for AD intervention.	Northwestern Univ, Feinberg Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Inst Neurosci, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine	Ferreira, A (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA.	a-ferreira@northwestern.edu		Ferreira, Adriana/0000-0003-3705-3918	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039080] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG022560, T32AG020506] Funding Source: NIH RePORTER; NIA NIH HHS [AG20506, T32 AG020506, R01 AG022560, R01AG022560] Funding Source: Medline; NINDS NIH HHS [R01 NS039080, NS39080] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAHR BA, 1995, J PHARMACOL EXP THER, V273, P902; BARTLETT WP, 1984, J NEUROSCI, V4, P1954; BARTLETT WP, 1984, J NEUROSCI, V4, P1944; Battaglia F, 2003, J MOL NEUROSCI, V20, P357, DOI 10.1385/JMN:20:3:357; BERTONIFREDDARI C, 1992, PATHOL RES PRACT, V188, P612, DOI 10.1016/S0344-0338(11)80066-X; BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; Clark SG, 1997, P NATL ACAD SCI USA, V94, P10438, DOI 10.1073/pnas.94.19.10438; Cleary JP, 2005, NAT NEUROSCI, V8, P79, DOI 10.1038/nn1372; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; Dawson HN, 2001, J CELL SCI, V114, P1179; DEKOSKY ST, 1990, ANN NEUROL, V27, P457, DOI 10.1002/ana.410270502; Demuro A, 2005, J BIOL CHEM, V280, P17294, DOI 10.1074/jbc.M500997200; Dodart JC, 2002, NAT NEUROSCI, V5, P452, DOI 10.1038/nn842; FERREIRA A, 1992, J NEUROSCI RES, V32, P516, DOI 10.1002/jnr.490320407; Ferreira A, 1997, MOL CELL NEUROSCI, V9, P220, DOI 10.1006/mcne.1997.0615; Ferreira A, 1996, MOL CELL NEUROSCI, V8, P286, DOI 10.1006/mcne.1996.0064; Friedrich P, 2004, BIOCHEM BIOPH RES CO, V323, P1131, DOI 10.1016/j.bbrc.2004.08.194; Gastard MC, 2003, ANN NEUROL, V54, P393, DOI 10.1002/ana.10680; Gervais FG, 1999, CELL, V97, P395, DOI 10.1016/S0092-8674(00)80748-5; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V122, P1131, DOI 10.1016/0006-291X(84)91209-9; GRUNDKEIQBAL I, 1986, J BIOL CHEM, V261, P6084; Honer WG, 2003, NEUROBIOL AGING, V24, P1047, DOI 10.1016/j.neurobiolaging.2003.04.005; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; King DL, 2002, BRAIN RES, V926, P58, DOI 10.1016/S0006-8993(01)03294-2; KOENIG JH, 1989, J NEUROSCI, V9, P3844; Lee MS, 2000, NATURE, V405, P360, DOI 10.1038/35012636; Lue LF, 1999, AM J PATHOL, V155, P853, DOI 10.1016/S0002-9440(10)65184-X; MALENKA RC, 1994, CELL, V78, P535, DOI 10.1016/0092-8674(94)90517-7; MATTSON MP, 1992, J NEUROSCI, V12, P376, DOI 10.1523/jneurosci.12-02-00376.1992; Ohno M, 2004, NEURON, V41, P27, DOI 10.1016/S0896-6273(03)00810-9; Rohlff C, 1997, J BIOL CHEM, V272, P21137, DOI 10.1074/jbc.272.34.21137; Ryan TA, 1996, NEURON, V17, P125, DOI 10.1016/S0896-6273(00)80286-X; Sabbagh MN, 1999, ARCH NEUROL-CHICAGO, V56, P1458, DOI 10.1001/archneur.56.12.1458; SAITO KI, 1993, P NATL ACAD SCI USA, V90, P2628, DOI 10.1073/pnas.90.7.2628; Savage MJ, 2002, J NEUROSCI, V22, P3376; SCHEFF SW, 1990, NEUROBIOL AGING, V11, P29, DOI 10.1016/0197-4580(90)90059-9; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; SIMAN R, 1984, P NATL ACAD SCI-BIOL, V81, P3572, DOI 10.1073/pnas.81.11.3572; Suen KC, 2003, J NEUROCHEM, V87, P1413, DOI 10.1111/j.1471-4159.2003.02259.x; TERRY RD, 1991, ANN NEUROL, V30, P572, DOI 10.1002/ana.410300410; Tiraboschi P, 2000, NEUROLOGY, V55, P1278, DOI 10.1212/WNL.55.9.1278; Tsuji T, 1998, NEUROSCI LETT, V248, P109, DOI 10.1016/S0304-3940(98)00348-6; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; Veeranna, 2004, AM J PATHOL, V165, P795, DOI 10.1016/S0002-9440(10)63342-1; Vitolo OV, 2002, P NATL ACAD SCI USA, V99, P13217, DOI 10.1073/pnas.172504199; WIEDENMANN B, 1985, CELL, V41, P1017, DOI 10.1016/S0092-8674(85)80082-9; Yao PJ, 2004, TRENDS NEUROSCI, V27, P24, DOI 10.1016/j.tins.2003.10.012; Yao PJ, 2003, NEUROBIOL DIS, V12, P97, DOI 10.1016/S0969-9961(02)00009-8; Yoo J, 2002, J BIOL CHEM, V277, P11904, DOI 10.1074/jbc.M111788200	49	112	121	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	2005	280	36					31746	31753		10.1074/jbc.M503259200	http://dx.doi.org/10.1074/jbc.M503259200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	961LZ	16002400	Green Accepted, hybrid			2022-12-25	WOS:000231665200052
J	Nony, PA; Kennett, SB; Glasgow, WC; Olden, K; Roberts, JD				Nony, PA; Kennett, SB; Glasgow, WC; Olden, K; Roberts, JD			15(S)-lipoxygenase-2 mediates arachidonic acid-stimulated adhesion of human breast carcinoma cells through the activation of TAK1, MKK6, and p38 MAPK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIETARY FATTY-ACIDS; PROSTATE ADENOCARCINOMA; KINASE ISOFORMS; CANCER INVASION; IV COLLAGEN; LIPOXYGENASE; EXPRESSION; 15-LIPOXYGENASE-1; EICOSANOIDS; INDUCTION	The dietary cis-polyunsaturated fatty acid, arachidonic acid, stimulates adhesion of metastatic human breast carcinoma cells (MDA-MB-435) to the extracellular matrix, but the molecular mechanisms by which fatty acids modify the behavior of these cells are unclear. Exposure to arachidonic acid activates multiple signaling pathways. Activation of p38 mitogen-activated protein kinase (p38 MAPK) is required for increased cell adhesion to type IV collagen, and this activation is sensitive to inhibitors of lipoxygenases, suggesting a requirement for arachidonic acid metabolism. The goals of the current study were to identify the one or more key metabolites of arachidonic acid that are responsible for activation of p38 MAPK and to elucidate the upstream kinases that lead to p38 MAPK activation. High performance liquid chromatographic analysis revealed that MDA-MB-435 cells metabolize exogenous arachidonic acid predominantly to 15(S)-hydroxyeicosatetraenoic acid (15(S)-HETE). Immunoblot analysis with antibodies specific to 15(S)-lipoxygenase-1 (LOX-1) and 15(S)-lipoxygenase-2 (LOX-2) demonstrated the expression of 15-LOX-2, but not 15-LOX-1, in these tumor cells. A LOX inhibitor, nordihydroguaiaretic acid, attenuated production of 15(S)HETE and inhibited the phosphorylation of p38 MAPK following exposure to arachidonic acid. In contrast, overexpression of LOX-2 sensitized the cells to the addition of arachidonic acid, leading to increased activation of p38 MAPK. Addition of exogenous 15(S)-HETE to MDA-MB-435 cells stimulated cell adhesion to type IV collagen and activated the p38 MAPK pathway, including the upstream kinases transforming growth factor-beta(1)-activated protein kinase-1 (TAK1) and MAPK kinase 6. Transfection of these cells with a dominant negative form of TAK1 blocked arachidonic acid-stimulated p38 MAPK phosphorylation. These data demonstrate that 15(S)-LOX-2 generation of 15(S)HETE activates specific growth factor receptor-related signaling pathways, thereby initiating signal transduction events leading to increased cell adhesion to the extracellular matrix.	NIEHS, Lab Mol Carcinogenesis, NIH, Res Triangle Pk, NC 27709 USA; Mercer Univ, Sch Med, Div Bas Med Sci, Macon, GA 31207 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Mercer University	Roberts, JD (corresponding author), NIEHS, Lab Mol Carcinogenesis, NIH, POB 12233,Mail Drop D2-05, Res Triangle Pk, NC 27709 USA.	roberts1@niehs.nih.gov			NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES023018] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Alonso G, 2000, J BIOL CHEM, V275, P40641, DOI 10.1074/jbc.M007835200; Arsura M, 2003, ONCOGENE, V22, P412, DOI 10.1038/sj.onc.1206132; Brash AR, 1997, P NATL ACAD SCI USA, V94, P6148, DOI 10.1073/pnas.94.12.6148; BRYANT RW, 1982, J BIOL CHEM, V257, P6050; Cavallaro U, 2001, BBA-REV CANCER, V1552, P39, DOI 10.1016/S0304-419X(01)00038-5; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Engers R, 2000, J CANCER RES CLIN, V126, P682, DOI 10.1007/s004320000148; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; FAN XT, 1990, BIOCHEM BIOPH RES CO, V169, P933, DOI 10.1016/0006-291X(90)91983-Y; Funk CD, 1996, BBA-LIPID LIPID MET, V1304, P65, DOI 10.1016/S0005-2760(96)00107-5; Ge BX, 2002, SCIENCE, V295, P1291, DOI 10.1126/science.1067289; HONN KV, 1994, CANCER METAST REV, V13, P365, DOI 10.1007/BF00666105; Hsi LC, 2002, J BIOL CHEM, V277, P40549, DOI 10.1074/jbc.M203522200; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Ikawa H, 1999, CANCER RES, V59, P360; Jack GS, 2000, HUM PATHOL, V31, P1146, DOI 10.1053/hupa.2000.16670; Kelavkar UP, 2000, CARCINOGENESIS, V21, P1777; Kennett SB, 2004, J BIOL CHEM, V279, P3300, DOI 10.1074/jbc.M305734200; Kilty I, 1999, EUR J BIOCHEM, V266, P83, DOI 10.1046/j.1432-1327.1999.00818.x; KOHN EC, 1995, CANCER RES, V55, P1856; Kuhn H, 2002, PROSTAG OTH LIPID M, V68-9, P263, DOI 10.1016/S0090-6980(02)00035-7; Leaver HA, 2002, PROSTAG LEUKOTR ESS, V66, P1, DOI 10.1054/plef.2001.0333; LIU B, 1991, CELL REGUL, V2, P1045, DOI 10.1091/mbc.2.12.1045; Liu XH, 1996, CLIN EXP METASTAS, V14, P145, DOI 10.1007/BF00121211; Monjazeb AM, 2002, PROSTAG LEUKOTR ESS, V66, P5, DOI 10.1054/plef.2001.0334; Natarajan R, 1997, J CLIN ENDOCR METAB, V82, P1790, DOI 10.1210/jc.82.6.1790; NATARAJAN R, 1998, FRONT BIOSCI, V3, P81; Nie D, 2000, E SCHERING RES FDN W, V31, P201; NOGUCHI M, 1995, ONCOLOGY-BASEL, V52, P265; Paine E, 2000, J BIOL CHEM, V275, P11284, DOI 10.1074/jbc.275.15.11284; Palmantier R, 1996, CANCER RES, V56, P2206; Palmantier R, 2001, CANCER RES, V61, P2445; Pidgeon GP, 2002, CANCER RES, V62, P2721; Piomelli D, 1993, CURR OPIN CELL BIOL, V5, P274, DOI 10.1016/0955-0674(93)90116-8; Raso E, 2001, THROMB HAEMOSTASIS, V85, P1037, DOI 10.1055/s-0037-1615960; Reddy N, 1997, BIOCHEM BIOPH RES CO, V231, P111, DOI 10.1006/bbrc.1997.6048; ROSE DP, 1994, NUTR CANCER, V21, P103, DOI 10.1080/01635589409514309; Rose DP, 1997, AM J CLIN NUTR, V66, P1513; Rose DP, 2000, NUTR CANCER, V37, P119, DOI 10.1207/S15327914NC372_1; ROSE DP, 1997, BREAST CANC, V4, P7; Sakurai H, 2000, FEBS LETT, V474, P141, DOI 10.1016/S0014-5793(00)01588-X; Shappell SB, 1999, AM J PATHOL, V155, P235, DOI 10.1016/S0002-9440(10)65117-6; Shappell SB, 2001, J INVEST DERMATOL, V117, P36, DOI 10.1046/j.1523-1747.2001.01378.x; Shappell SB, 2001, CANCER RES, V61, P497; Shureiqi I, 2001, CANCER RES, V61, P6307; TANG DG, 1995, J CELL SCI, V108, P2629; Tang DG, 1996, P NATL ACAD SCI USA, V93, P5241, DOI 10.1073/pnas.93.11.5241; TIMAR J, 1992, INT J CANCER, V52, P594, DOI 10.1002/ijc.2910520418; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; YOUNG MRI, 1994, CANCER METAST REV, V13, P337, DOI 10.1007/BF00666103	50	49	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	2005	280	36					31413	31419		10.1074/jbc.M500418200	http://dx.doi.org/10.1074/jbc.M500418200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	961LZ	16000313	hybrid			2022-12-25	WOS:000231665200011
J	Sommer, U; Schmid, C; Sobota, RM; Lehmann, U; Stevenson, NJ; Johnston, JA; Schaper, F; Heinrich, PC; Haan, S				Sommer, U; Schmid, C; Sobota, RM; Lehmann, U; Stevenson, NJ; Johnston, JA; Schaper, F; Heinrich, PC; Haan, S			Mechanisms of SOCS3 phosphorylation upon interleukin-6 stimulation - Contributions of Src- and receptor-tyrosine kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; IL-6 SIGNAL-TRANSDUCTION; ONCOSTATIN-M-RECEPTOR; CYTOKINE SIGNALING-3; JANUS KINASE; MEDIATED DEGRADATION; CELL-PROLIFERATION; UBIQUITIN LIGASE; GLYCOPROTEIN 130; SH2 DOMAIN	The suppressors of cytokine signaling (SOCS) are negative feedback inhibitors of cytokine signal transduction. SOCS3 is a key negative regulator of interleuking-6 (IL-6) signal transduction. Furthermore, SOCS3 was shown to be phosphorylated upon treatment of cells with IL-2, and this has been reported to regulate its function and half-life. We set out to investigate whether SOCS3 phosphorylation may play a role in IL-6 signaling. Tyrosine-phosphorylated SOCS3 was detected upon treatment of mouse embryonic fibroblasts with IL-6. Interestingly, the observed SOCS3 phosphorylation does not require SOCS3 recruitment to phosphotyrosine (Tyr(P)) 759 of gp130, and the kinetics of SOCS3 phosphorylation do not match the activation kinetics of the Janus kinases. This suggests that other kinases may be involved in SOCS3 phosphorylation. Using Src and Janus kinase inhibitors as well as Src kinase-deficient mouse embryonic fibroblasts, we provide evidence that Src kinases, which we found to be constitutively active in these cells, are involved in the phosphorylation of IL-6-induced SOCS3. In addition, we found that receptor-tyrosine kinases such as platelet-derived growth factor receptor or epidermal growth factor receptor can very potently phosphorylate IL-6-induced SOCS3. Taken together, these results suggest that SOCS3 phosphorylation is not a JAK-mediated phenomenon but is dependent on the activity of other kinases such as Src kinases or receptor-tyrosine kinases, which can either be constitutively active or activated by an additional stimulus.	Rhein Westfal TH Aachen, Inst Biochem, D-52074 Aachen, Germany; Queens Univ Belfast, Dept Immunol, Belfast BT9 7BL, Antrim, North Ireland	RWTH Aachen University; Queens University Belfast	Haan, S (corresponding author), Rhein Westfal TH Aachen, Inst Biochem, Paulwelsstsr 30, D-52074 Aachen, Germany.	serge.haan@rwth-aachen.de	Stevenson, Nigel/X-5412-2018; Schaper, Fred/F-1403-2013	Stevenson, Nigel/0000-0002-6966-9314; Schaper, Fred/0000-0002-8899-5414				AKIRA S, 1993, ADV IMMUNOL, V54, P1, DOI 10.1016/S0065-2776(08)60532-5; ANDUS T, 1987, FEBS LETT, V221, P18, DOI 10.1016/0014-5793(87)80344-7; ARCONE R, 1991, EUR J BIOCHEM, V198, P541, DOI 10.1111/j.1432-1033.1991.tb16048.x; Behrmann I, 2004, J BIOL CHEM, V279, P35486, DOI 10.1074/jbc.M404202200; Cacalano NA, 2001, NAT CELL BIOL, V3, P460, DOI 10.1038/35074525; CARTWRIGHT CA, 1989, J CLIN INVEST, V83, P2025, DOI 10.1172/JCI114113; CASTELL JV, 1988, FEBS LETT, V232, P347, DOI 10.1016/0014-5793(88)80766-X; Cohney SJ, 1999, MOL CELL BIOL, V19, P4980; Croker BA, 2003, NAT IMMUNOL, V4, P540, DOI 10.1038/ni931; De Sepulveda P, 2000, J BIOL CHEM, V275, P14005, DOI 10.1074/jbc.C000106200; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Frantsve J, 2001, MOL CELL BIOL, V21, P3547, DOI 10.1128/MCB.21.10.3547-3557.2001; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; GAULDIE J, 1987, P NATL ACAD SCI USA, V84, P7251, DOI 10.1073/pnas.84.20.7251; Gerhartz C, 1996, J BIOL CHEM, V271, P12991, DOI 10.1074/jbc.271.22.12991; Giese B, 2003, J BIOL CHEM, V278, P39205, DOI 10.1074/jbc.M303347200; Gnarra JR, 1996, BBA-REV CANCER, V1242, P201, DOI 10.1016/0304-419X(95)00012-5; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; Haan C, 2001, J BIOL CHEM, V276, P37451, DOI 10.1074/jbc.M106135200; Haan S, 2003, J BIOL CHEM, V278, P31972, DOI 10.1074/jbc.M303170200; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Hermanns HM, 1999, J IMMUNOL, V163, P6651; HIRANO T, 1986, NATURE, V324, P73, DOI 10.1038/324073a0; Hortner M, 2002, EUR J BIOCHEM, V269, P2516, DOI 10.1046/j.1432-1033.2002.02916.x; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; Kamizono S, 2001, J BIOL CHEM, V276, P12530, DOI 10.1074/jbc.M010074200; Kamura T, 2002, J BIOL CHEM, V277, P30388, DOI 10.1074/jbc.M203344200; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Kamura T, 2001, J BIOL CHEM, V276, P29748, DOI 10.1074/jbc.M103093200; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; Kile BT, 2002, TRENDS BIOCHEM SCI, V27, P235, DOI 10.1016/S0968-0004(02)02085-6; Kim HK, 1998, MOL CELL BIOL, V18, P1525, DOI 10.1128/MCB.18.3.1525; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; Lang R, 2003, NAT IMMUNOL, V4, P546, DOI 10.1038/ni932; Lehmann U, 2003, J BIOL CHEM, V278, P661, DOI 10.1074/jbc.M210552200; Limnander A, 2004, MOL CELL, V15, P329, DOI 10.1016/j.molcel.2004.06.041; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; Maher ER, 1997, MEDICINE, V76, P381, DOI 10.1097/00005792-199711000-00001; Mao WG, 1997, ONCOGENE, V15, P3083, DOI 10.1038/sj.onc.1201496; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Nicholson SE, 2000, P NATL ACAD SCI USA, V97, P6493, DOI 10.1073/pnas.100135197; Nicholson SE, 1999, EMBO J, V18, P375, DOI 10.1093/emboj/18.2.375; Pause A, 1997, P NATL ACAD SCI USA, V94, P2156, DOI 10.1073/pnas.94.6.2156; Peraldi P, 2001, J BIOL CHEM, V276, P24614, DOI 10.1074/jbc.M102209200; Radtke S, 2002, J BIOL CHEM, V277, P11297, DOI 10.1074/jbc.M100822200; Rodig SJ, 1998, CELL, V93, P373, DOI 10.1016/S0092-8674(00)81166-6; Rui LY, 2002, J BIOL CHEM, V277, P42394, DOI 10.1074/jbc.C200444200; Saharinen P, 2000, MOL CELL BIOL, V20, P3387, DOI 10.1128/MCB.20.10.3387-3395.2000; Sasaki A, 1999, GENES CELLS, V4, P339, DOI 10.1046/j.1365-2443.1999.00263.x; Sasaki A, 2003, J BIOL CHEM, V278, P2432, DOI 10.1074/jbc.C200608200; Schaeffer M, 2001, MOL CELL BIOL, V21, P8068, DOI 10.1128/MCB.21.23.8068-8081.2001; Schaper F, 1998, BIOCHEM J, V335, P557, DOI 10.1042/bj3350557; Schmitz J, 2000, J BIOL CHEM, V275, P12848, DOI 10.1074/jbc.275.17.12848; Schmitz J, 2000, J IMMUNOL, V164, P848, DOI 10.4049/jimmunol.164.2.848; Schoenfeld AR, 2000, P NATL ACAD SCI USA, V97, P8507, DOI 10.1073/pnas.97.15.8507; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Ungureanu D, 2002, MOL CELL BIOL, V22, P3316, DOI 10.1128/MCB.22.10.3316-3326.2002; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WEIERGRABER O, 1995, EUR J BIOCHEM, V234, P661, DOI 10.1111/j.1432-1033.1995.661_b.x; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; Yasukawa H, 2003, NAT IMMUNOL, V4, P551, DOI 10.1038/ni938; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071	68	31	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	2005	280	36					31478	31488		10.1074/jbc.M506008200	http://dx.doi.org/10.1074/jbc.M506008200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	961LZ	16000307	Green Published, hybrid			2022-12-25	WOS:000231665200019
J	Basso, AD; Mirza, A; Liu, GJ; Long, BJ; Bishop, WR; Kirschmeier, P				Basso, AD; Mirza, A; Liu, GJ; Long, BJ; Bishop, WR; Kirschmeier, P			The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling - Role in FTI enhancement of taxane and tamoxifen anti-tumor activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUBEROUS SCLEROSIS GENE; BREAST-CANCER CELLS; RAS-RELATED PROTEIN; TSC2 GAP ACTIVITY; FARNESYLTRANSFERASE INHIBITOR; TRANSGENIC MICE; IN-VITRO; SACCHAROMYCES-CEREVISIAE; MAMMALIAN TARGET; EGFR MUTATIONS	Lonafarnib (SCH66336) is a farnesyl transferase inhibitor (FTI) that inhibits the post-translational lipid modification of H-Ras and other farnesylated proteins. K- and N-Ras are also substrates of farnesyl transferase; however, upon treatment with FTIs, they are alternatively prenylated by geranylgeranyl transferase-1. Despite the failure to abrogate prenylation of K- and N-Ras, growth of many tumors in preclinical models is inhibited by FTIs. This suggests that the anti-proliferative action of FTIs is dependent on blocking the farnesylation of other proteins. Rheb (Ras homologue enriched in brain) is a farnesylated small GTPase that positively regulates mTOR ( mammalian target of rapamycin) signaling. We found that Rheb and Rheb2 mRNA were elevated in various tumor cell lines relative to normal cells. Peptides derived from the carboxyl termini of human Rheb and Rheb2 are in vitro substrates for farnesyl transferase but not geranylgeranyl transferase-1. Rheb prenylation in cell culture was completely inhibited by SCH66336, indicating a lack of alternative prenylation. SCH66336 treatment also inhibited the phosphorylation of S6 ribosomal protein, a downstream target of Rheb and mTOR signaling. SCH66336 did not inhibit S6 phosphorylation in cells expressing Rheb-CSVL, a mutant construct of Rheb designed to be geranylgeranylated. Importantly, expression of Rheb-CSVL also abrogated SCH66336 enhancement of tamoxifen-and docetaxel-induced apoptosis in MCF-7 breast cancer cells and ES-2 ovarian cancer cells, respectively. Further, inhibition of Rheb signaling by rapamycin treatment, small interfering RNA, or dominant negative Rheb enhanced tamoxifen- and docetaxel-induced apoptosis, similar to FTI treatment. These studies demonstrated that Rheb is modified by farnesylation, is not a substrate for alternative prenylation, and plays a role in SCH66336 enhancement of the antitumor response to other chemotherapeutics.	Schering Plough Res Inst, Dept Tumor Biol, Kenilworth, NJ 07033 USA	Merck & Company; Schering-Plough Research Institute	Kirschmeier, P (corresponding author), Schering Plough Res Inst, Dept Tumor Biol, 2015 Galloping Hill Rd,K-15-4950, Kenilworth, NJ 07033 USA.	paul.kirschmeier@spcorp.com						Alsina M, 2004, BLOOD, V103, P3271, DOI 10.1182/blood-2003-08-2764; Ashar HR, 2000, J BIOL CHEM, V275, P30451, DOI 10.1074/jbc.M003469200; Ashar HR, 2001, EXP CELL RES, V262, P17, DOI 10.1006/excr.2000.5076; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; Bose S, 1998, ONCOGENE, V17, P123, DOI 10.1038/sj.onc.1201940; CAPLAN AJ, 1992, J BIOL CHEM, V267, P18890; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; Castro AF, 2003, J BIOL CHEM, V278, P32493, DOI 10.1074/jbc.C300226200; Clark GJ, 1997, J BIOL CHEM, V272, P10608; DeGraffenried LA, 2004, CLIN CANCER RES, V10, P8059, DOI 10.1158/1078-0432.CCR-04-0035; Feilotter HE, 1998, ONCOGENE, V16, P1743, DOI 10.1038/sj.onc.1200205; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; Gromov PS, 1995, FEBS LETT, V377, P221, DOI 10.1016/0014-5793(95)01349-0; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HANCOCK JF, 1991, EMBO J, V10, P641, DOI 10.1002/j.1460-2075.1991.tb07992.x; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; James G, 1996, P NATL ACAD SCI USA, V93, P4454, DOI 10.1073/pnas.93.9.4454; JAMES GL, 1995, J BIOL CHEM, V270, P6221, DOI 10.1074/jbc.270.11.6221; Jenne DE, 1998, NAT GENET, V18, P38, DOI 10.1038/ng0198-38; KIM CM, 1992, J BIOL CHEM, V267, P23113; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; Law BK, 2000, J BIOL CHEM, V275, P10796, DOI 10.1074/jbc.275.15.10796; Lebowitz PF, 1997, J BIOL CHEM, V272, P15591, DOI 10.1074/jbc.272.25.15591; Li Y, 2002, J BIOL CHEM, V277, P44593, DOI 10.1074/jbc.C200510200; Li Y, 2004, MOL CELL BIOL, V24, P7965, DOI 10.1128/MCB.24.18.7965-7975.2004; Liu M, 1998, CANCER RES, V58, P4947; Liu MY, 2002, CANCER RES, V62, P6475; Long X, 2005, CURR BIOL, V15, P702, DOI 10.1016/j.cub.2005.02.053; Mangues R, 1998, CANCER RES, V58, P1253; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Moasser MM, 1998, P NATL ACAD SCI USA, V95, P1369, DOI 10.1073/pnas.95.4.1369; Mondesire WH, 2004, CLIN CANCER RES, V10, P7031, DOI 10.1158/1078-0432.CCR-04-0361; NELLIST M, 1993, CELL, V75, P1305; Nielsen LL, 1999, CANCER RES, V59, P5896; Njoroge FG, 1998, J MED CHEM, V41, P4890, DOI 10.1021/jm980462b; Omer CA, 2000, CANCER RES, V60, P2680; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Patel PH, 2003, J CELL SCI, V116, P3601, DOI 10.1242/jcs.00661; Pesche S, 1998, ONCOGENE, V16, P2879, DOI 10.1038/sj.onc.1202081; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; Saucedo LJ, 2003, NAT CELL BIOL, V5, P566, DOI 10.1038/ncb996; Shaw RJ, 2004, CANCER CELL, V6, P91, DOI 10.1016/j.ccr.2004.06.007; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Shi B, 2000, CANCER CHEMOTH PHARM, V46, P387, DOI 10.1007/s002800000170; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Smith EM, 2005, J BIOL CHEM, V280, P18717, DOI 10.1074/jbc.M414499200; Sordella R, 2004, SCIENCE, V305, P1163, DOI 10.1126/science.1101637; Stocker H, 2003, NAT CELL BIOL, V5, P559, DOI 10.1038/ncb995; Tabancay AP, 2003, J BIOL CHEM, V278, P39921, DOI 10.1074/jbc.M306553200; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Urano J, 2000, J BIOL CHEM, V275, P11198, DOI 10.1074/jbc.275.15.11198; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; Wang J, 2002, J BIOL CHEM, V277, P46659, DOI 10.1074/jbc.M206407200; WOLDA SL, 1988, J BIOL CHEM, V263, P5997; YAMAGATA K, 1994, J BIOL CHEM, V269, P16333; YOKOYAMA K, 1991, P NATL ACAD SCI USA, V88, P5302, DOI 10.1073/pnas.88.12.5302; Zhang FL, 1997, J BIOL CHEM, V272, P10232; Zhang Y, 2003, NAT CELL BIOL, V5, P578, DOI 10.1038/ncb999	62	137	147	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	2005	280	35					31101	31108		10.1074/jbc.M503763200	http://dx.doi.org/10.1074/jbc.M503763200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	958ZX	16006564	hybrid			2022-12-25	WOS:000231487800055
J	Kassim, SY; Fu, XY; Liles, WC; Shapiro, SD; Parks, WC; Heinecke, JW				Kassim, SY; Fu, XY; Liles, WC; Shapiro, SD; Parks, WC; Heinecke, JW			NADPH oxidase restrains the matrix metalloproteinase activity of macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; LOW-DENSITY-LIPOPROTEIN; HYPOCHLOROUS ACID; SUPEROXIDE PRODUCTION; PROTEIN OXIDATION; TISSUE INHIBITOR; HOST-DEFENSE; ACTIVATION; MYELOPEROXIDASE; INFLAMMATION	Matrix metalloproteinases ( MMPs) regulate numerous functions in normal and disease processes; thus, irreversibly blocking their activity is a key step in regulating MMP catalysis. We previously showed in vitro that oxidizing intermediates generated by phagocytes inactivate MMPs by modifying specific amino acids. To assess whether this mechanism operates in vivo, we focused on MMP-12, a macrophage-specific MMP known to mediate emphysema in mouse models. We found that mice lacking gp91(phox), a phagocyte-specific component of the NADPH oxidase, developed extensive, spontaneous emphysematous destruction of their peripheral air spaces, whereas mice deficient in both NADPH oxidase and MMP-12 were protected from spontaneous emphysema. Although gp91(phox)-null and wild-type macrophages produced equivalent levels of MMP-12 protein, the oxidant-deficient cells had greater MMP-12 activity than wild-type macrophages. These findings indicate that reactive intermediates provide a physiological mechanism to protect tissues from excessive macrophage-mediated damage during inflammation.	Univ Washington, Div Metab Endocrinol & Nutr, Dept Med, Seattle, WA 98195 USA; Washington Univ, Dept Med, St Louis, MO 63110 USA; Washington Univ, Dept Pediat, St Louis, MO 63110 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA	University of Washington; University of Washington Seattle; Washington University (WUSTL); Washington University (WUSTL); Harvard University; Brigham & Women's Hospital	Heinecke, JW (corresponding author), Univ Washington, Div Metab Endocrinol & Nutr, Dept Med, Box 356426, Seattle, WA 98195 USA.	heinecke@u.washington.edu	Parks, William C./AAH-6786-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL075381, R01HL064344, R01HL078527, R01HL062995, P50HL073996, P01HL029594, R01HL077555] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007033] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG021191] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL77555, HL64344, HL075381, P01-HL29594, HL62995, HL078527, P50-HL073996] Funding Source: Medline; NIA NIH HHS [AG021191] Funding Source: Medline; NIEHS NIH HHS [P30-ES07033] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Babior BM, 2002, ARCH BIOCHEM BIOPHYS, V397, P342, DOI 10.1006/abbi.2001.2642; Baker AH, 2002, J CELL SCI, V115, P3719, DOI 10.1242/jcs.00063; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; Berliner JA, 1996, FREE RADICAL BIO MED, V20, P707, DOI 10.1016/0891-5849(95)02173-6; Campbell EJ, 1999, J CLIN INVEST, V104, P337, DOI 10.1172/JCI6092; Caterina JJ, 2000, J BIOL CHEM, V275, P26416, DOI 10.1074/jbc.M001271200; Corry DB, 2004, FASEB J, V18, P995, DOI 10.1096/fj.03-1412fje; Corry DB, 2002, NAT IMMUNOL, V3, P347, DOI 10.1038/ni773; CURNUTTE JT, 1975, NEW ENGL J MED, V293, P628, DOI 10.1056/NEJM197509252931303; de Jager W, 2003, CLIN DIAGN LAB IMMUN, V10, P133, DOI 10.1128/CDLI.10.1.133-139.2003; DUNNILL M. S., 1962, THORAX, V17, P320, DOI 10.1136/thx.17.4.320; Filippov S, 2003, J EXP MED, V198, P925, DOI 10.1084/jem.20030626; Foster CB, 1998, J CLIN INVEST, V102, P2146, DOI 10.1172/JCI5084; Fu XY, 2003, J BIOL CHEM, V278, P28403, DOI 10.1074/jbc.M304739200; Fu XY, 2004, J BIOL CHEM, V279, P6209, DOI 10.1074/jbc.C300506200; Fu XY, 2001, J BIOL CHEM, V276, P41279, DOI 10.1074/jbc.M106958200; Galis ZS, 2002, CIRC RES, V90, P251, DOI 10.1161/res.90.3.251; Hautamaki RD, 1997, SCIENCE, V277, P2002, DOI 10.1126/science.277.5334.2002; Heinecke JW, 2002, FREE RADICAL BIO MED, V32, P1090, DOI 10.1016/S0891-5849(02)00792-X; Heinecke JW, 1998, ATHEROSCLEROSIS, V141, P1, DOI 10.1016/S0021-9150(98)00173-7; HEINONEN OP, 1994, NEW ENGL J MED, V330, P1029; Henderson JP, 2003, J BIOL CHEM, V278, P23522, DOI 10.1074/jbc.M303928200; Lambert E, 2004, CRIT REV ONCOL HEMAT, V49, P187, DOI 10.1016/j.critrevonc.2003.09.008; Li QL, 2002, CELL, V111, P635, DOI 10.1016/S0092-8674(02)01079-6; Marnett LJ, 2003, J CLIN INVEST, V111, P583, DOI 10.1172/JCI200318022; McCawley LJ, 2001, CURR OPIN CELL BIOL, V13, P534, DOI 10.1016/S0955-0674(00)00248-9; McQuibban GA, 2000, SCIENCE, V289, P1202, DOI 10.1126/science.289.5482.1202; MICHAELIS J, 1992, ARCH BIOCHEM BIOPHYS, V292, P555, DOI 10.1016/0003-9861(92)90030-Z; Mohammed FF, 2003, ANN RHEUM DIS, V62, P43; Morgenstern DE, 1997, J EXP MED, V185, P207, DOI 10.1084/jem.185.2.207; Morris DG, 2003, NATURE, V422, P169, DOI 10.1038/nature01413; Oh J, 2001, CELL, V107, P789, DOI 10.1016/S0092-8674(01)00597-9; Parks WC, 2001, RESP RES, V2, P10, DOI 10.1186/rr33; Parks WC, 2004, NAT REV IMMUNOL, V4, P617, DOI 10.1038/nri1418; POLLOCK JD, 1995, NAT GENET, V9, P202, DOI 10.1038/ng0295-202; Qi JH, 2003, NAT MED, V9, P407, DOI 10.1038/nm846; Rajagopalan S, 1996, J CLIN INVEST, V98, P2572, DOI 10.1172/JCI119076; SAVENKOVA MI, 1994, J BIOL CHEM, V269, P20394; Seo DW, 2003, CELL, V114, P171, DOI 10.1016/S0092-8674(03)00551-8; SHAPIRO SD, 1991, J CLIN INVEST, V87, P1828, DOI 10.1172/JCI115204; Shipley JM, 1996, P NATL ACAD SCI USA, V93, P3942, DOI 10.1073/pnas.93.9.3942; van de Loo FAJ, 2003, AM J PATHOL, V163, P1525, DOI 10.1016/S0002-9440(10)63509-2; Vivekananthan DP, 2003, LANCET, V361, P2017, DOI 10.1016/S0140-6736(03)13637-9; Wang ZP, 2000, J BIOL CHEM, V275, P26411, DOI 10.1074/jbc.M001270200; Wert SE, 2000, P NATL ACAD SCI USA, V97, P5972, DOI 10.1073/pnas.100448997	45	49	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	2005	280	34					30201	30205		10.1074/jbc.M503292200	http://dx.doi.org/10.1074/jbc.M503292200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	957IC	15983040	hybrid			2022-12-25	WOS:000231362500028
J	Toogood, HS; van Thiel, A; Scrutton, NS; Leys, D				Toogood, HS; van Thiel, A; Scrutton, NS; Leys, D			Stabilization of non-productive conformations underpins rapid electron transfer to electron-transferring flavoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEHYDROGENASE; PRINCIPLES; COMPLEXES	Crystal structures of protein complexes with electron-transferring flavoprotein ( ETF) have revealed a dual protein-protein interface with one region serving as anchor while the ETF FAD domain samples available space within the complex. We show that mutation of the conserved Glu-165 beta in human ETF leads to drastically modulated rates of interprotein electron transfer with both medium chain acyl-CoA dehydrogenase and dimethylglycine dehydrogenase. The crystal structure of free E165 beta A ETF is essentially identical to that of wild-type ETF, but the crystal structure of the E165 beta A ETF(.)medium chain acyl-CoA dehydrogenase complex reveals clear electron density for the FAD domain in a position optimal for fast interprotein electron transfer. Based on our observations, we present a dynamic multistate model for conformational sampling that for the wild-type ETF(.)medium chain acyl-CoA dehydrogenase complex involves random motion between three distinct positions for the ETF FAD domain. ETF Glu-165 beta plays a key role in stabilizing positions incompatible with fast interprotein electron transfer, thus ensuring high rates of complex dissociation.	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England	University of Leicester	Leys, D (corresponding author), Univ Leicester, Dept Biochem, Henry Wellcome Bldg,Lancaster Rd, Leicester LE1 7RH, Leics, England.	david.leys@manchester.ac.uk		Toogood, Helen/0000-0003-4797-0293	Biotechnology and Biological Sciences Research Council [BBS/B/03572/2] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Binzak BA, 2000, MOL GENET METAB, V69, P181, DOI 10.1006/mgme.2000.2980; Cane DE, 1999, CHEM BIOL, V6, pR319, DOI 10.1016/S1074-5521(00)80001-0; Challis GL, 2004, CURR OPIN STRUC BIOL, V14, P748, DOI 10.1016/j.sbi.2004.10.005; Chohan KK, 2001, J BIOL CHEM, V276, P34142, DOI 10.1074/jbc.M101341200; Cowtan K, 1998, ACTA CRYSTALLOGR D, V54, P750, DOI 10.1107/S0907444997016247; Crowley PB, 2004, PROTEINS, V55, P603, DOI 10.1002/prot.20043; Darrouzet E, 2001, TRENDS BIOCHEM SCI, V26, P445, DOI 10.1016/S0968-0004(01)01897-7; Garcin ED, 2004, J BIOL CHEM, V279, P37918, DOI 10.1074/jbc.M406204200; Gruez A, 2000, J MOL BIOL, V299, P199, DOI 10.1006/jmbi.2000.3748; GUTTIERREZ A, 2000, BIOCHEMISTRY-US, V41, P4626; Hoard-Fruchey HM, 2004, J BIOL CHEM, V279, P13786, DOI 10.1074/jbc.M313914200; Jones M, 2002, J BIOL CHEM, V277, P8457, DOI 10.1074/jbc.M111105200; LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648; Lee HJ, 1996, BIOCHEMISTRY-US, V35, P12412, DOI 10.1021/bi9607867; Leys D, 2003, NAT STRUCT BIOL, V10, P219, DOI 10.1038/nsb894; Leys D, 2004, CURR OPIN STRUC BIOL, V14, P642, DOI 10.1016/j.sbi.2004.10.002; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; OKUMARAIKEDA K, 1908, J BIOL CHEM, V260, P1338; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Page CC, 1999, NATURE, V402, P47, DOI 10.1038/46972; Page CC, 2003, CURR OPIN CHEM BIOL, V7, P551, DOI 10.1016/j.cbpa.2003.08.005; Roberts DL, 1996, P NATL ACAD SCI USA, V93, P14355, DOI 10.1073/pnas.93.25.14355; Sato K, 2003, J BIOCHEM, V134, P719, DOI 10.1093/jb/mvg199; Thorpe C, 1991, CHEM BIOCH FLAVOENZY, P471; Toogood HS, 2004, J BIOL CHEM, V279, P32904, DOI 10.1074/jbc.M404884200	26	30	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	2005	280	34					30361	30366		10.1074/jbc.M505562200	http://dx.doi.org/10.1074/jbc.M505562200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	957IC	15975918	hybrid			2022-12-25	WOS:000231362500047
J	Wallick, CJ; Gamper, I; Thorne, M; Feith, DJ; Takasaki, KY; Wilson, SM; Seki, JA; Pegg, AE; Byus, CV; Bachmann, AS				Wallick, CJ; Gamper, I; Thorne, M; Feith, DJ; Takasaki, KY; Wilson, SM; Seki, JA; Pegg, AE; Byus, CV; Bachmann, AS			Key role for p27(Kip1), retinoblastoma protein Rb, and MYCN in polyamine inhibitor-induced G(1) cell cycle arrest in MYCN-amplified human neuroblastoma cells	ONCOGENE			English	Article						DFMO; SAM486A; MYCN-amplified neuroblastoma; p27(Kip1); Rb; cell cycle	S-ADENOSYLMETHIONINE DECARBOXYLASE; ALPHA-DIFLUOROMETHYLORNITHINE; N-MYC; ORNITHINE DECARBOXYLASE; PHASE-I; BIOSYNTHESIS INHIBITOR; RETINOIC ACID; POSTRADIOTHERAPY CHEMOTHERAPY; NEURO-BLASTOMA; BREAST-CANCER	Alpha-difluoromethylornithine (DFMO) inhibits the protooncogene ornithine decarboxylase (ODC) and is known to induce cell cycle arrest. However, the effect of DFMO on human neuroblastoma (NB) cells and the exact mechanism of DFMO-induced cell death are largely unknown. Treatment with DFMO in combination with SAM486A, an S-adenosylmethionine decarboxylase (AdoMetDC) inhibitor, has been shown to enhance polyamine pool depletion. Therefore, we analysed the mechanism of action of DFMO and/or SAM486A in two established MYCN-amplified human NB cell lines. DFMO and SAM486A caused rapid cell growth inhibition, polyamine depletion, and G(1) cell cycle arrest without apoptosis in cell lines LAN-1 and NMB-7. These effects were enhanced with combined inhibitors and largely prevented by cotreatment with exogenous polyamines. The G(1) cell cycle arrest was concomitant with an increase in cyclin-dependent kinase inhibitor p27(Kip1). In a similar fashion, DFMO and DFMO/SAM486A inhibited the phosphorylation of the G(1)/S transition-regulating retinoblastoma protein Rb at residues Ser795 and Ser807/811. Moreover, we observed a dramatic decrease in MYCN protein levels. Overexpression of MYCN induces an aggressive NB phenotype with malignant behavior. We show for the first time that DFMO and SAM486A induce G(1) cell cycle arrest in NB cells through p27(Kip1) and Rb hypophosphorylation.	Univ Hawaii, Canc Res Ctr Hawaii, Honolulu, HI 96813 USA; Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA; Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA	Cancer Research Center of Hawaii; University of Hawaii System; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; University of California System; University of California Riverside	Bachmann, AS (corresponding author), Univ Hawaii, Canc Res Ctr Hawaii, 1236 Lauhala St, Honolulu, HI 96813 USA.	abachmann@crch.hawaii.edu			NCI NIH HHS [R01CA18138, R01 CA018138, R01CA79909] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA079909, R01CA018138] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bachmann Andre S, 2004, Hawaii Med J, V63, P371; Ben-Yosef T, 1998, ONCOGENE, V17, P165, DOI 10.1038/sj.onc.1201939; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Carbone PP, 2001, CANCER EPIDEM BIOMAR, V10, P657; CHAPMAN SK, 1980, LIFE SCI, V26, P1359, DOI 10.1016/0024-3205(80)90097-1; Coleman C S, 1998, Methods Mol Biol, V79, P41; DAVIDOFF AM, 1992, ONCOGENE, V7, P127; Davidson NE, 1999, ENDOCR-RELAT CANCER, V6, P69, DOI 10.1677/erc.0.0060069; DORHOUT B, 1995, INT J CANCER, V62, P738, DOI 10.1002/ijc.2910620615; Eskens FALM, 2000, CLIN CANCER RES, V6, P1736; Fabian CJ, 2002, CLIN CANCER RES, V8, P3105; Galderisi U, 2003, ONCOGENE, V22, P5208, DOI 10.1038/sj.onc.1206558; Galderisi U, 1999, J CELL BIOCHEM, V73, P97, DOI 10.1002/(SICI)1097-4644(19990401)73:1<97::AID-JCB11>3.0.CO;2-M; GILBERT RS, 1991, ANAL BIOCHEM, V199, P86, DOI 10.1016/0003-2697(91)90273-V; Goldman SC, 1996, AM J PATHOL, V148, P1381; Hopkins-Donaldson S, 2002, ONCOGENE, V21, P6132, DOI 10.1038/sj.onc.1205879; Kramer DL, 2001, CANCER RES, V61, P7754; KRAMER DL, 1989, BIOCHEM J, V259, P325, DOI 10.1042/bj2590325; KRISHAN A, 1975, J CELL BIOL, V66, P188, DOI 10.1083/jcb.66.1.188; Levin VA, 2000, CLIN CANCER RES, V6, P3878; Levin VA, 2003, CLIN CANCER RES, V9, P981; Lu XH, 2003, CANCER LETT, V197, P125, DOI 10.1016/S0304-3835(03)00096-X; Lutz W, 1996, ONCOGENE, V13, P803; Matsuo T, 1998, ONCOGENE, V16, P3337, DOI 10.1038/sj.onc.1201830; MCCANN PP, 1992, PHARMACOL THERAPEUT, V54, P195, DOI 10.1016/0163-7258(92)90032-U; McKenzie PP, 2003, CANCER RES, V63, P3840; MELINO G, 1991, PROG CLIN BIOL RES, V366, P283; MELINO G, 1988, EXP CELL RES, V179, P429, DOI 10.1016/0014-4827(88)90281-9; METCALF BW, 1978, J AM CHEM SOC, V100, P2551, DOI 10.1021/ja00476a050; Meyskens FL, 1999, CLIN CANCER RES, V5, P945; Nakamura M, 2003, CELL DEATH DIFFER, V10, P230, DOI 10.1038/sj.cdd.4401125; Paridaens R, 2000, BRIT J CANCER, V83, P594, DOI 10.1054/bjoc.2000.1305; PEGG AE, 1988, CANCER RES, V48, P759; Pless M, 2004, CLIN CANCER RES, V10, P1299, DOI 10.1158/1078-0432.CCR-0977-03; Porter C. W., 1992, V62, P301; Ray RM, 1999, AM J PHYSIOL-CELL PH, V276, pC684, DOI 10.1152/ajpcell.1999.276.3.C684; REGENASS U, 1994, CANCER RES, V54, P3210; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; Shantz L M, 1998, Methods Mol Biol, V79, P45; SHANTZ LM, 1994, BIOCHEM J, V302, P765, DOI 10.1042/bj3020765; Singh R, 2001, CARCINOGENESIS, V22, P1863, DOI 10.1093/carcin/22.11.1863; Siu LL, 2002, CLIN CANCER RES, V8, P2157; Svensson F, 1997, BIOCHEM J, V322, P297, DOI 10.1042/bj3220297; TABIB A, 1994, BIOCHEM BIOPH RES CO, V202, P720, DOI 10.1006/bbrc.1994.1990; Takahashi Y, 2000, INT J CANCER, V85, P243, DOI 10.1002/(SICI)1097-0215(20000115)85:2<243::AID-IJC15>3.0.CO;2-2; Tweddle DA, 2003, CANCER LETT, V197, P93, DOI 10.1016/S0304-3835(03)00088-0; Tweddle DA, 2001, CANCER RES, V61, P8; van Zuylen L, 2004, CLIN CANCER RES, V10, P1949, DOI 10.1158/1078-0432.CCR-02-0995; Wallace HM, 2003, BIOCHEM J, V376, P1, DOI 10.1042/BJ20031327	50	71	76	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 25	2005	24	36					5606	5618		10.1038/sj.onc.1208808	http://dx.doi.org/10.1038/sj.onc.1208808			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	956JN	16007177				2022-12-25	WOS:000231296100007
J	Bausch, SL; Poliakova, E; Draper, DE				Bausch, SL; Poliakova, E; Draper, DE			Interactions of the N-terminal domain of ribosomal protein L11 with thiostrepton and rRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELONGATION-FACTOR-G; CONSERVED GTPASE CENTER; ESCHERICHIA-COLI; PROTEIN L11; TERTIARY STRUCTURE; BINDING DOMAIN; EF-G; CRYSTAL-STRUCTURE; SUBUNIT; RECOGNITION	Ribosomal protein L11 has two domains: the C-terminal domain (L11-C76) binds rRNA, whereas the N-terminal domain (L11-NTD) may variously interact with elongation factor G, the antibiotic thiostrepton, and rRNA. To begin to quantitate these interactions, L11 from Bacillus stearothermophilus has been overexpressed and its properties compared with those of L11-C76 alone in a fluorescence assay for protein- rRNA binding. The assay relies on 2'-amino-butyryl-pyrene-uridine incorporated in a 58-nucleotide rRNA fragment, which gives similar to 15-fold enhancement when L11 or L11-C76 is bound. Although the pyrene tag weakens protein binding, unbiased protein-RNA association constants were obtained in competition experiments with untagged RNA. It was found that (i) intact B. stearothermophilus L11 binds rRNA with K approximate to 1.2 x 10(9) m(-1) in buffers with 0.2 M KCl, about 100-fold tighter than Escherichia coli L11; (ii) the N-terminal domain makes a small, salt-dependent contribution to the overall L11-RNA binding affinity (similar to 8- fold enhancement at 0.2 M KCl), (iii) L11 stimulates thiostrepton binding by 2.3 +/- 0.6 x 10(3)-fold, predicting an overall thiostrepton affinity for the ribosome of similar to 10(9) M-1, and (iv) the yeast homolog of L11 shows no stimulation of thiostrepton binding. The latter observation resolves the question of why eukaryotes are insensitive to the antibiotic. These measurements also show that it is plausible for thiostrepton to compete directly with EFG G(.)GDP for binding to the L11-RNA complex, and provide a quantitative basis for further studies of L11 function and thiostrepton mechanism.	Johns Hopkins Univ, Dept Chem, Baltimore, MD 21210 USA	Johns Hopkins University	Draper, DE (corresponding author), Johns Hopkins Univ, Dept Chem, Baltimore, MD 21210 USA.	draper@jhu.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM029048, R01GM029048] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM29048] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agrawal RK, 2001, J MOL BIOL, V311, P777, DOI 10.1006/jmbi.2001.4907; BACA OG, 1976, BIOCHEMISTRY-US, V15, P4570, DOI 10.1021/bi00666a004; Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; Blyn LB, 2000, NUCLEIC ACIDS RES, V28, P1778, DOI 10.1093/nar/28.8.1778; Bowen WS, 2005, J BIOL CHEM, V280, P2934, DOI 10.1074/jbc.M407008200; Brandi L, 2004, J MOL BIOL, V335, P881, DOI 10.1016/j.jmb.2003.10.067; Brodersen DE, 2002, J MOL BIOL, V316, P725, DOI 10.1006/jmbi.2001.5359; Cameron DM, 2002, J MOL BIOL, V319, P27, DOI 10.1016/S0022-2836(02)00235-8; Chen JF, 1999, PROTEIN EXPRES PURIF, V15, P115, DOI 10.1006/prep.1998.0999; Conn GL, 1998, BIOCHEMISTRY-US, V37, P11980, DOI 10.1021/bi980825+; Conn GL, 1999, SCIENCE, V284, P1171, DOI 10.1126/science.284.5417.1171; Draper DE, 1995, METHOD ENZYMOL, V259, P281; DRAPER DE, 1995, J MOL BIOL, V249, P231, DOI 10.1006/jmbi.1995.0291; DRAPER DE, 1988, METHOD ENZYMOL, V164, P203; EGEBJERG J, 1989, EMBO J, V8, P607, DOI 10.1002/j.1460-2075.1989.tb03415.x; Garcia-Garcia C, 2003, J MOL BIOL, V331, P75, DOI 10.1016/S0022-2836(03)00615-6; Gerstner RB, 2001, BIOCHEMISTRY-US, V40, P7165, DOI 10.1021/bi010026i; Gruber T, 2003, FEBS LETT, V549, P123, DOI 10.1016/S0014-5793(03)00760-9; GuhaThakurta D, 2000, J MOL BIOL, V295, P569, DOI 10.1006/jmbi.1999.3372; HIGHLAND JH, 1975, EUR J BIOCHEM, V53, P313, DOI 10.1111/j.1432-1033.1975.tb04070.x; HIGHLAND JH, 1971, BIOCHEMISTRY-US, V10, P4404, DOI 10.1021/bi00800a009; JENSEN DE, 1976, J BIOL CHEM, V251, P7198; Klein DJ, 2004, J MOL BIOL, V340, P141, DOI 10.1016/j.jmb.2004.03.076; LAING LG, 1994, J MOL BIOL, V237, P560, DOI 10.1006/jmbi.1994.1255; Lentzen G, 2003, CHEM BIOL, V10, P769, DOI 10.1016/S1074-5521(03)00173-X; LILJAS A, 1991, INT REV CYTOL, V124, P103; LOHMAN TM, 1992, METHOD ENZYMOL, V212, P400; LU M, 1994, J MOL BIOL, V244, P572, DOI 10.1006/jmbi.1994.1753; Markus MA, 2001, J BIOMOL NMR, V20, P293, DOI 10.1023/A:1011275602138; MOAZED D, 1988, NATURE, V334, P362, DOI 10.1038/334362a0; NOMURA M, 1973, SCIENCE, V179, P864, DOI 10.1126/science.179.4076.864; Pan J, 1997, J MOL BIOL, V273, P7, DOI 10.1006/jmbi.1997.1311; PARKER J, 1976, MOL GEN GENET, V144, P111, DOI 10.1007/BF00277313; Rawat UBS, 2003, NATURE, V421, P87, DOI 10.1038/nature01224; Rodnina MV, 1999, P NATL ACAD SCI USA, V96, P9586, DOI 10.1073/pnas.96.17.9586; RYAN PC, 1991, P NATL ACAD SCI USA, V88, P6308, DOI 10.1073/pnas.88.14.6308; RYAN PC, 1989, BIOCHEMISTRY-US, V28, P9949, DOI 10.1021/bi00452a012; RYAN PC, 1991, J MOL BIOL, V221, P1257, DOI 10.1016/0022-2836(91)80125-E; SCHMIDT FJ, 1981, J BIOL CHEM, V256, P2301; Silverman SK, 1999, BIOCHEMISTRY-US, V38, P14224, DOI 10.1021/bi991333f; Stark H, 2000, CELL, V100, P301, DOI 10.1016/S0092-8674(00)80666-2; TATE WP, 1986, J BIOL CHEM, V261, P2289; THOMPSON J, 1979, EUR J BIOCHEM, V98, P261, DOI 10.1111/j.1432-1033.1979.tb13184.x; THOMPSON J, 1982, J BIOL CHEM, V257, P7915; THOMPSON J, 1993, EMBO J, V12, P1499, DOI 10.1002/j.1460-2075.1993.tb05793.x; UCHIUMI T, 1995, J BIOL CHEM, V270, P29889; Uchiumi T, 2002, J BIOL CHEM, V277, P3857, DOI 10.1074/jbc.M107730200; Van Dyke N, 2003, J MOL BIOL, V330, P9, DOI 10.1016/S0022-2836(03)00537-0; Wilson KS, 2004, J MOL BIOL, V337, P15, DOI 10.1016/j.jmb.2004.01.013; Wimberly BT, 1999, CELL, V97, P491, DOI 10.1016/S0092-8674(00)80759-X; Xing YY, 1997, NAT STRUCT BIOL, V4, P24, DOI 10.1038/nsb0197-24; Xing YY, 1996, BIOCHEMISTRY-US, V35, P1581, DOI 10.1021/bi952132o; Yamana K, 1999, NUCLEIC ACIDS RES, V27, P2387, DOI 10.1093/nar/27.11.2387	53	27	27	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	2005	280	33					29956	29963		10.1074/jbc.M504182200	http://dx.doi.org/10.1074/jbc.M504182200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	954SX	15972821	hybrid			2022-12-25	WOS:000231176200068
J	Chen, J; Wu, A; Sun, HZ; Drakas, R; Garofalo, C; Cascio, S; Surmacz, E; Baserga, R				Chen, J; Wu, A; Sun, HZ; Drakas, R; Garofalo, C; Cascio, S; Surmacz, E; Baserga, R			Functional significance of type 1 insulin-like growth factor-mediated nuclear translocation of the insulin receptor substrate-1 and beta-catenin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-RECEPTOR SUBSTRATE-1; POLYMERASE-I TRANSCRIPTION; RIBOSOMAL GENE-TRANSCRIPTION; GROWTH-FACTOR; IGF-I; UPSTREAM BINDING-FACTOR-1; T-ANTIGEN; CYCLIN D1; CELL-SIZE; C-MYC	Previous work has shown that the transcriptional regulator beta-catenin can translocate to the nuclei when cells are stimulated with the type 1 insulin-like growth factor (IGF-1). We show by immunocoprecipitation and by confocal microscopy that beta-catenin binds to and co-localizes with the insulin receptor substrate-1 (IRS-1), a docking protein for both the insulin and the IGF-1 receptors. IRS-1 is required for IGF-1-mediated nuclear translocation of beta-catenin, resulting in the activation of the beta-catenin target genes. IGF-1-mediated nuclear translocation of beta-catenin is facilitated by the nuclear translocation of IRS-1. Both IRS-1 and beta-catenin are recruited to the cyclin D1 promoter, an established target for beta-catenin, but only IRF-1 is recruited to the ribosomal DNA ( rDNA) promoter. UBF proteins ( known to interact with both IRS-1 and beta-catenin) are also detectable in the cyclin D1 and rDNA promoters. These results indicate that IRS-1 ( activated by the IGF-1 receptor) is one of several proteins that regulate the subcellular localization and activity of beta-catenin. The ability of IRS-1 to localize to both RNA polymerase II ( with beta-catenin) and RNA polymerase I-regulated promoters suggest an explanation for the effect of IRS-1 on both cell growth in size and cell proliferation. This possibility is supported by the demonstration that enforced nuclear localization of IRS-1 causes nuclear translocation of beta-catenin and transformation of normal mouse embryo fibroblasts ( colony formation in soft agar).	Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Temple Univ, Ctr Biotechnol, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA	Jefferson University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Baserga, R (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, 233 S 1oth St,624 Bluemle Life Sci Bldg, Philadelphia, PA 19107 USA.	B_lupo@mail.jci.tju.edu	Garofalo, Cecilia/B-3834-2017	Garofalo, Cecilia/0000-0001-5334-8930; Cascio, Sandra/0000-0003-4234-0508	NCI NIH HHS [CA089640] Funding Source: Medline; NIA NIH HHS [AG20956] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA089640] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG020956] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Baserga Renato, 2004, VVolume 42, P235; CASTLES CG, 1993, CANCER RES, V53, P5934; CROCE CM, 1977, P NATL ACAD SCI USA, V74, P694, DOI 10.1073/pnas.74.2.694; Desbois-Mouthon C, 2001, ONCOGENE, V20, P252, DOI 10.1038/sj.onc.1204064; Drakas R, 2005, PROTEOMICS, V5, P132, DOI 10.1002/pmic.200400919; Drakas R, 2004, P NATL ACAD SCI USA, V101, P9272, DOI 10.1073/pnas.0403328101; Eastman Q, 1999, CURR OPIN CELL BIOL, V11, P233, DOI 10.1016/S0955-0674(99)80031-3; Gan DD, 2004, ONCOGENE, V23, P483, DOI 10.1038/sj.onc.1207018; Gao ZH, 2002, P NATL ACAD SCI USA, V99, P1182, DOI 10.1073/pnas.032468199; Grueneberg DA, 2003, MOL CELL BIOL, V23, P3936, DOI 10.1128/MCB.23.11.3936-3950.2003; Grummt I, 2003, GENE DEV, V17, P1691, DOI 10.1101/gad.1098503R; Grummt I, 1999, PROG NUCLEIC ACID RE, V62, P109; Hall MN, 2004, CELL GROWTH CONTROL; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Henderson BR, 2002, EMBO REP, V3, P834, DOI 10.1093/embo-reports/kvf181; James MJ, 2004, J BIOL CHEM, V279, P8911, DOI 10.1074/jbc.M307735200; JANTZEN HM, 1990, NATURE, V344, P830, DOI 10.1038/344830a0; Kirmizis A, 2003, MOL CANCER THER, V2, P113; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Lassak A, 2002, J BIOL CHEM, V277, P17231, DOI 10.1074/jbc.M110885200; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; Lu ZM, 2004, CELL CYCLE, V3, P571; Maiorana A, 2004, ONCOGENE, V23, P7116, DOI 10.1038/sj.onc.1207916; Morali OG, 2001, ONCOGENE, V20, P4942, DOI 10.1038/sj.onc.1204660; Morelli C, 2004, ONCOGENE, V23, P7517, DOI 10.1038/sj.onc.1208014; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; O'Sullivan AC, 2002, MOL CELL BIOL, V22, P657, DOI 10.1128/MCB.22.2.657-668.2002; OMAHONY DJ, 1991, P NATL ACAD SCI USA, V88, P3180, DOI 10.1073/pnas.88.8.3180; Oskarsson T, 2005, NAT CELL BIOL, V7, P215, DOI 10.1038/ncb0305-215; Persad S, 2001, J CELL BIOL, V153, P1161, DOI 10.1083/jcb.153.6.1161; Playford MP, 2000, P NATL ACAD SCI USA, V97, P12103, DOI 10.1073/pnas.210394297; Polakis P, 2000, GENE DEV, V14, P1837; Poortinga G, 2004, EMBO J, V23, P3325, DOI 10.1038/sj.emboj.7600335; Prisco M, 2002, J BIOL CHEM, V277, P32078, DOI 10.1074/jbc.M204658200; Reiss K, 1998, EXP CELL RES, V242, P361, DOI 10.1006/excr.1998.4113; Rowlands TM, 2003, P NATL ACAD SCI USA, V100, P11400, DOI 10.1073/pnas.1534601100; Rubini M, 1997, EXP CELL RES, V230, P284, DOI 10.1006/excr.1996.3430; Satyamoorthy K, 2001, CANCER RES, V61, P7318; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; Service RF, 2005, SCIENCE, V309, P548, DOI 10.1126/science.309.5734.548; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Sharpe C, 2001, BIOESSAYS, V23, P311, DOI 10.1002/bies.1045; Sun HZ, 2003, MOL ENDOCRINOL, V17, P472, DOI 10.1210/me.2002-0276; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SURMACZ E, 1992, CANCER RES, V52, P4522; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tu X, 2002, J BIOL CHEM, V277, P44357, DOI 10.1074/jbc.M208001200; Valentinis B, 2000, J BIOL CHEM, V275, P25451, DOI 10.1074/jbc.M002271200; van Noort M, 2002, DEV BIOL, V244, P1, DOI 10.1006/dbio.2001.0566; Veeman MT, 2003, DEV CELL, V5, P367, DOI 10.1016/S1534-5807(03)00266-1; VOIT R, 1995, NUCLEIC ACIDS RES, V23, P2593, DOI 10.1093/nar/23.14.2593; Wang ZH, 2003, CANCER RES, V63, P5234; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; Wu A, 2005, J BIOL CHEM, V280, P2863, DOI 10.1074/jbc.M406138200; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173	56	131	134	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	2005	280	33					29912	29920		10.1074/jbc.M504516200	http://dx.doi.org/10.1074/jbc.M504516200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	954SX	15967802	hybrid			2022-12-25	WOS:000231176200063
J	Yee, M; Fas, SC; Stohlmeyer, MM; Wandless, TJ; Cimprich, KA				Yee, M; Fas, SC; Stohlmeyer, MM; Wandless, TJ; Cimprich, KA			A cell-permeable, activity-based probe for protein and lipid kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE HYDROLASE ACTIVITIES; PHOSPHOINOSITIDE 3-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; CATALYTIC SUBUNIT; COMPLEX PROTEOMES; ATM KINASE; IN-VITRO; WORTMANNIN; INHIBITION; ENZYME	Protein and lipid kinases are two important classes of biomedically relevant enzymes. The expression and activity of many kinases are known to be dysregulated in a variety of diseases, and proteomic tools that can assess the presence and activity of these enzymes are likely to be useful for their evaluation. Because many of the mechanisms by which protein kinases can become unregulated involve post-translational modifications or changes in protein localization, they can only be detected by examining protein activity, sometimes within the context of the living cell. Wortmannin is a steroid-derived fungal metabolite that covalently inhibits both protein and lipid kinases. Here we describe the synthesis of three wortmannin derivatives, biotin-wortmannin, BODIPY-wortmannin, and tetramethylrhodamine-wortmannin. We demonstrate that these reagents exhibit reactivity similarly as wortmannin and react with members of the phosphatidylinositol 3-kinase and PI3-kinase related kinase families in cellular lysates. Moreover, in some cases these reagents can differentiate between the active and inactive forms of the enzyme, indicating that they are activity-based probes. The reagents also exhibit complementary properties. The biotin-wortmannin reagent is effective in the isolation of labeled proteins; all three can be used for protein labeling, and BODIPY-wortmannin is cell-permeable and can be used to label proteins within cells.	Stanford Univ, Clark Ctr, Dept Mol Pharmacol, Stanford, CA 94305 USA	Stanford University	Cimprich, KA (corresponding author), Stanford Univ, Clark Ctr, Dept Mol Pharmacol, 318 Campus Dr, Stanford, CA 94305 USA.	cimprich@stanford.edu			NIGMS NIH HHS [GM062193, GM068589] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062193, R01GM068589] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abraham RT, 2004, DNA REPAIR, V3, P883, DOI 10.1016/j.dnarep.2004.04.002; Adam GC, 2004, J AM CHEM SOC, V126, P1363, DOI 10.1021/ja038441g; Adam GC, 2002, NAT BIOTECHNOL, V20, P805, DOI 10.1038/nbt714; Adam GC, 2001, CHEM BIOL, V8, P81, DOI 10.1016/S1074-5521(00)90060-7; Anderson KE, 2003, INT J BIOCHEM CELL B, V35, P1028, DOI 10.1016/S1357-2725(02)00270-4; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; Bakkenist CJ, 2004, CELL, V118, P9, DOI 10.1016/j.cell.2004.06.023; Bomgarden RD, 2004, J BIOL CHEM, V279, P13346, DOI 10.1074/jbc.M311098200; Borodovsky A, 2002, CHEM BIOL, V9, P1149, DOI 10.1016/S1074-5521(02)00248-X; BRIAN P. W., 1957, TRANS BRIT MYCOL SOC, V40, P365; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chan DW, 2002, GENE DEV, V16, P2333, DOI 10.1101/gad.1015202; Creemer LC, 1996, J MED CHEM, V39, P5021, DOI 10.1021/jm960283z; Douglas P, 2002, BIOCHEM J, V368, P243, DOI 10.1042/BJ20020973; Faleiro L, 1997, EMBO J, V16, P2271, DOI 10.1093/emboj/16.9.2271; Greenbaum D, 2000, CHEM BIOL, V7, P569, DOI 10.1016/S1074-5521(00)00014-4; Jeffery DA, 2003, CURR OPIN BIOTECH, V14, P87, DOI 10.1016/S0958-1669(02)00010-1; Jessani N, 2004, P NATL ACAD SCI USA, V101, P13756, DOI 10.1073/pnas.0404727101; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Kidd D, 2001, BIOCHEMISTRY-US, V40, P4005, DOI 10.1021/bi002579j; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Kumar S, 2004, P NATL ACAD SCI USA, V101, P7943, DOI 10.1073/pnas.0402323101; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; Liu YS, 1999, P NATL ACAD SCI USA, V96, P14694, DOI 10.1073/pnas.96.26.14694; Liu YS, 2005, CHEM BIOL, V12, P99, DOI 10.1016/j.chembiol.2004.11.009; Noble MEM, 2004, SCIENCE, V303, P1800, DOI 10.1126/science.1095920; Patricelli MP, 2001, PROTEOMICS, V1, P1067, DOI 10.1002/1615-9861(200109)1:9<1067::AID-PROT1067>3.0.CO;2-4; Saghatelian A, 2004, P NATL ACAD SCI USA, V101, P10000, DOI 10.1073/pnas.0402784101; Sarkaria JN, 1998, CANCER RES, V58, P4375; Schmidt DR, 1999, BIOCHEMISTRY-US, V38, P14711, DOI 10.1021/bi991614n; Sherr CJ, 2004, CELL, V116, P235, DOI 10.1016/S0092-8674(03)01075-4; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Walker EH, 2000, MOL CELL, V6, P909, DOI 10.1016/S1097-2765(05)00089-4; Wymann MP, 2005, CURR OPIN CELL BIOL, V17, P141, DOI 10.1016/j.ceb.2005.02.011; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; YANO H, 1993, J BIOL CHEM, V268, P25846; Yu JH, 1998, MOL CELL BIOL, V18, P1379, DOI 10.1128/MCB.18.3.1379; Ziv Y, 1997, ONCOGENE, V15, P159, DOI 10.1038/sj.onc.1201319	38	147	149	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	2005	280	32					29053	29059		10.1074/jbc.M504730200	http://dx.doi.org/10.1074/jbc.M504730200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	952QT	15975929	hybrid			2022-12-25	WOS:000231021300030
J	Tang, PCY; Yakimov, AO; Teesdale, MA; Coady, MA; Dardik, A; Elefteriades, JA; Tellides, G				Tang, PCY; Yakimov, AO; Teesdale, MA; Coady, MA; Dardik, A; Elefteriades, JA; Tellides, G			Transmural inflammation by interferon-gamma-producing T cells correlates with outward vascular remodeling and intimal expansion of ascending thoracic aortic aneurysms	FASEB JOURNAL			English	Article						aortic diseases; cytokines; leukocytes	IFN-GAMMA; ELASTIN DEGRADATION; LYMPHOID-TISSUE; ATHEROSCLEROSIS; DISEASE; LESIONS; ARTERIOSCLEROSIS; DETERMINANTS; LYMPHOCYTES; EXPRESSION	Arterial pathology manifests as aneurysmal or obstructive disease depending on changes in lumen size due to vascular remodeling ( change in vessel external diameter) and/or intimal expansion. Recent clinical and experimental observations in abdominal aortic aneurysms have led to the emerging dogma that Th2-dominant immune responses result in expansive vascular remodeling and luminal ectasia, whereas Th1 immune responses cause intimal hyperplasia and luminal stenosis. We tested this hypothesis by descriptive analyses of 31 non-aneurysmal and 29 aneurysmal ascending thoracic aortic specimens. Approximately half the aneurysms were distinguished by transmural inflammation. The remaining aneurysms and all the non-aneurysmal aortas had a similar leukocytic infiltrate that spared the inner media. Aneurysm tissue had increased expression of the prototypical Th1 cytokine, interferon (IFN)-gamma, and undetectable Th2 cytokines. Specimens with inner media infiltration displayed robust production of IFN-gamma, induction of the IFN-gamma- inducible chemokines IP-10 and Mig, and recruitment of lymphocytes bearing their cognate receptor CXCR3. Transmural inflammation and IFN-gamma production were associated with increased aortic external diameter, intimal thickening, preserved vascular smooth muscle cell density, and decreased matrix proteins. Th1, but not Th2, immune responses have a positive correlation with both outward vascular remodeling and intimal expansion of ascending thoracic aortic aneurysms.	Yale Univ, Sch Med, Dept Surg, New Haven, CT 06510 USA; Yale Univ, Sch Med, Interdept Program Vasc Biol & Transplantat, New Haven, CT 06510 USA	Yale University; Yale University	Tellides, G (corresponding author), Boyer Ctr Mol Med 454, 295 Congress Ave, New Haven, CT 06510 USA.	george.tellides@yale.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL070295] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL70295-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Absi TS, 2003, J THORAC CARDIOV SUR, V126, P344, DOI 10.1016/S0022-5223(02)73576-9; Bobryshev YV, 2001, ATHEROSCLEROSIS, V154, P15, DOI 10.1016/S0021-9150(00)00441-X; BOBRYSHEV YV, 1995, CARDIOVASC RES, V29, P689, DOI 10.1016/0008-6363(96)88642-1; CENACCHI G, 1995, J SUBMICR CYTOL PATH, V27, P75; Dal Canto AJ, 2001, J CLIN INVEST, V107, pR15, DOI 10.1172/JCI11540; Davis VA, 2001, J SURG RES, V101, P152, DOI 10.1006/jsre.2001.6281; EMESON EE, 1988, AM J PATHOL, V130, P369; FREESTONE T, 1995, ARTERIOSCL THROM VAS, V15, P1145, DOI 10.1161/01.ATV.15.8.1145; Ghorpade A, 1996, ANN NY ACAD SCI, V800, P138, DOI 10.1111/j.1749-6632.1996.tb33305.x; Gupta S, 1997, J CLIN INVEST, V99, P2752, DOI 10.1172/JCI119465; HALLORAN BG, 1995, J SURG RES, V59, P17, DOI 10.1006/jsre.1995.1126; Hance KA, 2002, J VASC SURG, V35, P254, DOI 10.1067/mva.2002.120382; Juvonen J, 1997, ARTERIOSCL THROM VAS, V17, P2843, DOI 10.1161/01.ATV.17.11.2843; KATSUDA S, 1992, AM J PATHOL, V140, P907; KOCH AE, 1990, AM J PATHOL, V137, P1199; LopezCandales A, 1997, AM J PATHOL, V150, P993; Millonig G, 2002, ATHEROSCLEROSIS, V160, P441, DOI 10.1016/S0021-9150(01)00596-2; Nagano H, 1997, J CLIN INVEST, V100, P550, DOI 10.1172/JCI119564; Ocana E, 2003, ATHEROSCLEROSIS, V170, P39, DOI 10.1016/S0021-9150(03)00282-X; Ruddle NH, 1999, IMMUNOL RES, V19, P119, DOI 10.1007/BF02786481; SALGAME P, 1991, SCIENCE, V254, P279, DOI 10.1126/science.1681588; Satta J, 1998, EUR J VASC ENDOVASC, V15, P313, DOI 10.1016/S1078-5884(98)80034-8; Schonbeck U, 2002, AM J PATHOL, V161, P499, DOI 10.1016/S0002-9440(10)64206-X; Shimizu K, 2004, J CLIN INVEST, V114, P300, DOI 10.1172/JCI200419855; SZEKANECZ Z, 1994, AGENTS ACTIONS, V42, P159, DOI 10.1007/BF01983484; Tellides G, 2000, NATURE, V403, P207, DOI 10.1038/35003221; Thompson RW, 2002, CARDIOVASC SURG, V10, P389, DOI 10.1016/S0967-2109(02)00042-X; Topouzis S, 1996, DEV BIOL, V178, P430, DOI 10.1006/dbio.1996.0229; VASAN RS, 1995, CIRCULATION, V91, P734, DOI 10.1161/01.CIR.91.3.734; Wang YN, 2004, FASEB J, V18, P606, DOI 10.1096/fj.03-0840fje; Ward MR, 2000, CIRCULATION, V102, P1186, DOI 10.1161/01.CIR.102.10.1186; Wick G, 1997, FASEB J, V11, P1199, DOI 10.1096/fasebj.11.13.9367355; WOLINSKY H, 1967, CIRC RES, V20, P409, DOI 10.1161/01.RES.20.4.409; Xiong WF, 2004, J IMMUNOL, V172, P2607, DOI 10.4049/jimmunol.172.4.2607; XU QB, 1990, CLIN IMMUNOL IMMUNOP, V56, P344, DOI 10.1016/0090-1229(90)90155-J	36	64	69	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2005	19	9					1528	+		10.1096/fj.05-3671fje	http://dx.doi.org/10.1096/fj.05-3671fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	951IO	16014397				2022-12-25	WOS:000230923000025
J	Siegfried, G; Basak, A; Prichett-Pejic, W; Scamuffa, N; Ma, LM; Benjannet, S; Veinot, JP; Calvo, F; Seidah, N; Khatib, AM				Siegfried, G; Basak, A; Prichett-Pejic, W; Scamuffa, N; Ma, LM; Benjannet, S; Veinot, JP; Calvo, F; Seidah, N; Khatib, AM			Regulation of the stepwise proteolytic cleavage and secretion of PDGF-B by the proprotein convertases	ONCOGENE			English	Article						PDGF-B; proprotein convertases; prosegments; secretion; processing	GROWTH-FACTOR-A; PROTEASE-ACTIVATED LIGAND; CONNECTIVE-TISSUE; HUMAN-PLATELETS; ALPHA-RECEPTOR; BETA-RECEPTOR; FURIN; CELL; CHAIN; EXPRESSION	Platelet-derived growth factor-B (PDGF-B) is important for normal tissue growth and maintenance and its overexpression has been linked to several diseases, including cancer, fibrotic disease and atherosclerosis. Here, we show that synthesized as a precursor, proPDGF-B is converted to a mature form by proteolytic cleavage at two sites and its N-terminal cleavage is a prerequisite for processing at its C-terminus. The first cleavage occurs at residues RGRR(81)down arrow, and the second cleavage close to residues ARPVT(190), just before the C-terminal amino-acid sequence crucial for PDGF-B retention to cell surface. Cotransfection of a Furin-deficient cell line LoVo-C5 with proPDGF-B and different PC members revealed that Furin, PACE4, PC5, and PC7 are candidate proPDGF-B convertases. This finding is consistent with the in vitro digestions of a synthetic peptide mimicking the cleavage site of proPDGF-B. The processing of proPDGF-B is blocked by site-directed mutagenesis of the RGRR(81)down arrow sequence and by various PC inhibitors. Mutation of the PDGF-A and/or PDGF-B convertase sites, revealed that processing of both A and B chains is required for the formation of mature PDGF-B dimers and that the processing of the B chain controls the level of secreted and matrix-bound PDGF-BB forms. Our findings emphasize the importance of the convertase-directed processing of proPDGF-B at the RGRR(81)down arrow sequence for PDGF-B maturation and secretion.	INSERM, Inst Genet Mol, U716, Lab Pharmacol Expt & Clin, F-75010 Paris, France; Clin Res Inst Montreal, Biochem Neuroendocrinol Lab, Montreal, PQ H2W 1R7, Canada; Ottawa Hlth Res Inst, Dis Ageing Unit, Reg Prot Chem Ctr, Ottawa, ON K1Y 4E9, Canada	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; University of Ottawa; Ottawa Hospital Research Institute	Khatib, AM (corresponding author), INSERM, Inst Genet Mol, U716, Lab Pharmacol Expt & Clin, 27 Rue Juliette Dodu, F-75010 Paris, France.	majid.khatib@stlouis.inserm.fr	KHATIB, Abdel-Majid/A-9948-2015; Siegfried, Géraldine/N-6017-2018; Seidah, Nabil/I-3596-2013	KHATIB, Abdel-Majid/0000-0001-6957-0384; Seidah, Nabil/0000-0001-6503-9342; calvo, fabien/0000-0002-0298-7633; siegfried, geraldine/0000-0002-6346-5206				ANDERSON ED, 1993, J BIOL CHEM, V268, P24887; ANDERSSON M, 1994, J BIOL CHEM, V269, P926; Ataliotis P, 1997, INT REV CYTOL, V172, P95, DOI 10.1016/S0074-7696(08)62359-1; Basak A, 2001, BIOCHEM J, V353, P537, DOI 10.1042/0264-6021:3530537; Bassi DE, 2003, AM J PATHOL, V162, P439, DOI 10.1016/S0002-9440(10)63838-2; BECKMANN MP, 1988, SCIENCE, V241, P1346, DOI 10.1126/science.2842868; Benjannet S, 2004, J BIOL CHEM, V279, P48865, DOI 10.1074/jbc.M409699200; Benjannet S, 1997, J BIOL CHEM, V272, P26210, DOI 10.1074/jbc.272.42.26210; Benjannet S, 2001, J BIOL CHEM, V276, P10879, DOI 10.1074/jbc.M009899200; Bergsten E, 2001, NAT CELL BIOL, V3, P512, DOI 10.1038/35074588; Bostrom H, 1996, CELL, V85, P863, DOI 10.1016/S0092-8674(00)81270-2; BYWATER M, 1988, MOL CELL BIOL, V8, P2753, DOI 10.1128/MCB.8.7.2753; Eming SA, 1999, AM J PATHOL, V154, P281, DOI 10.1016/S0002-9440(10)65274-1; HAMMACHER A, 1988, J BIOL CHEM, V263, P16493; HAMMACHER A, 1988, EUR J BIOCHEM, V176, P179, DOI 10.1111/j.1432-1033.1988.tb14266.x; HART CE, 1990, BIOCHEMISTRY-US, V29, P166, DOI 10.1021/bi00453a022; HELDIN CH, 1986, NATURE, V319, P511, DOI 10.1038/319511a0; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; HOPPE J, 1990, EUR J BIOCHEM, V187, P207, DOI 10.1111/j.1432-1033.1990.tb15296.x; Hoyle GW, 1999, AM J PATHOL, V154, P1763, DOI 10.1016/S0002-9440(10)65432-6; Kaetzel DM, 1996, BBA-PROTEIN STRUCT M, V1298, P250, DOI 10.1016/S0167-4838(96)00136-7; Khatib AM, 2002, AM J PATHOL, V160, P1921, DOI 10.1016/S0002-9440(10)61140-6; LAROCHELLE WJ, 1991, GENE DEV, V5, P1191, DOI 10.1101/gad.5.7.1191; Li XR, 2000, NAT CELL BIOL, V2, P302, DOI 10.1038/35010579; MERCOLA M, 1990, DEV BIOL, V138, P114, DOI 10.1016/0012-1606(90)90181-H; NABEL EG, 1993, P NATL ACAD SCI USA, V90, P10759, DOI 10.1073/pnas.90.22.10759; Nour N, 2003, J BIOL CHEM, V278, P2886, DOI 10.1074/jbc.M208009200; ORRURTREGER A, 1992, DEVELOPMENT, V115, P1045; OSTMAN A, 1988, J BIOL CHEM, V263, P16202; OSTMAN A, 1992, J CELL BIOL, V118, P509, DOI 10.1083/jcb.118.3.509; Pullikotil P, 2004, J BIOL CHEM, V279, P17338, DOI 10.1074/jbc.M313764200; ROBBINS KC, 1983, NATURE, V305, P605, DOI 10.1038/305605a0; Roebroek AJM, 1998, DEVELOPMENT, V125, P4863; Rolny C, 2002, J BIOL CHEM, V277, P19315, DOI 10.1074/jbc.M111805200; Seidah NG, 2002, ESSAYS BIOCHEM, V38, P79, DOI 10.1042/bse0380079; Seidah NG, 1999, BRAIN RES, V848, P45, DOI 10.1016/S0006-8993(99)01909-5; Seidah NG, 2003, P NATL ACAD SCI USA, V100, P928, DOI 10.1073/pnas.0335507100; Siegfried G, 2003, J CLIN INVEST, V111, P1723, DOI 10.1172/JCI200317220; Siegfried G, 2003, CANCER RES, V63, P1458; Sundberg C, 1997, AM J PATHOL, V151, P479; ZHENG M, 1994, J NEUROSCI, V14, P4656; Zhong M, 1999, J BIOL CHEM, V274, P33913, DOI 10.1074/jbc.274.48.33913	42	59	64	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2005	24	46					6925	6935		10.1038/sj.onc.1208838	http://dx.doi.org/10.1038/sj.onc.1208838			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	975ZD	16007151				2022-12-25	WOS:000232701700007
J	Bruysters, M; Jongejan, A; Akdemir, A; Bakker, RA; Leurs, R				Bruysters, M; Jongejan, A; Akdemir, A; Bakker, RA; Leurs, R			AG(q/11)-coupled mutant histamine H-1 receptor F435A activated solely by synthetic ligands (RASSL)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DESIGNED G(I)-COUPLED RECEPTOR; CONDITIONAL EXPRESSION; H-1-RECEPTOR AGONISTS; MUTATIONAL ANALYSIS; MOLECULAR-DYNAMICS; G-PROTEINS; CARDIOMYOPATHY; SIMULATION; ALGORITHM; GENE	Recently, G protein-coupled receptors activated solely by synthetic ligands (RASSLs) have been introduced as new tools to study G alpha(i) signaling in vivo ( 1, 2). Also, G alpha(s)-coupled G protein-coupled receptors have been engineered to generate G alpha(s)-coupled RASSLs ( 3, 4). In this study, we exploited the differences in binding pockets between different classes of H-1 receptor agonists and identified the first G alpha(q/11)-coupled RASSL. The mutant human H-1 receptor F435A (6.55) combines a strongly decreased affinity (25-fold) and potency for the endogenous ligand histamine (200-fold) with improved affinities (54-fold) and potencies (2600-fold) for 2-phenylhistamines, a synthetic class of H-1 receptor agonists. Molecular dynamics simulations provided a mechanism for distinct agonist binding to both wild-type and F435A mutant H-1 receptors.	Vrije Univ Amsterdam, Dept Med Chem, Fac Sci, Leiden Amsterdam Ctr Drug Res, NL-1081 HV Amsterdam, Netherlands	Leiden University; Leiden University - Excl LUMC; Vrije Universiteit Amsterdam	Leurs, R (corresponding author), Vrije Univ Amsterdam, Dept Med Chem, Fac Sci, Leiden Amsterdam Ctr Drug Res, De Boelelaan 1083, NL-1081 HV Amsterdam, Netherlands.	r.leurs@few.vu.nl	Leurs, Rob/ABB-4299-2021; Akdemir, Atilla/G-2595-2015; Leurs, Rob/AAC-8508-2022	Akdemir, Atilla/0000-0001-8416-0471; Leurs, Rob/0000-0003-1354-2848				Baker AJ, 2001, AM J PHYSIOL-HEART C, V280, pH1653, DOI 10.1152/ajpheart.2001.280.4.H1653; Bakker RA, 2001, MOL PHARMACOL, V60, P1133, DOI 10.1124/mol.60.5.1133; BERENDSEN HJC, 1995, COMPUT PHYS COMMUN, V91, P43, DOI 10.1016/0010-4655(95)00042-E; BRACKETT DJ, 1990, AGENTS ACTIONS, V31, P263, DOI 10.1007/BF01997618; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bruysters M, 2004, EUR J PHARMACOL, V487, P55, DOI 10.1016/j.ejphar.2004.01.028; Canutescu AA, 2003, PROTEIN SCI, V12, P2001, DOI 10.1110/ps.03154503; Claeysen S, 2003, J BIOL CHEM, V278, P699, DOI 10.1074/jbc.C200588200; Coward P, 1998, P NATL ACAD SCI USA, V95, P352, DOI 10.1073/pnas.95.1.352; Enwonwu CO, 2000, J NEURAL TRANSM, V107, P1273, DOI 10.1007/s007020070017; FUKUI H, 1994, BIOCHEM BIOPH RES CO, V201, P894, DOI 10.1006/bbrc.1994.1786; Goldman LA, 1996, BIOTECHNIQUES, V21, P1013; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H; Horn F, 2001, NUCLEIC ACIDS RES, V29, P346, DOI 10.1093/nar/29.1.346; Leopoldt D, 1997, N-S ARCH PHARMACOL, V356, P216, DOI 10.1007/PL00005044; LESCHKE C, 1995, J MED CHEM, V38, P1287, DOI 10.1021/jm00008a007; LEURS R, 1994, BIOCHEM BIOPH RES CO, V201, P295, DOI 10.1006/bbrc.1994.1701; Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045; Lutz S, 2005, J BIOL CHEM, V280, P11134, DOI 10.1074/jbc.M411322200; Matsuda N, 2002, N-S ARCH PHARMACOL, V366, P513, DOI 10.1007/s00210-002-0651-x; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; Okada T, 2002, P NATL ACAD SCI USA, V99, P5982, DOI 10.1073/pnas.082666399; Pertz HH, 2004, MINI-REV MED CHEM, V4, P935, DOI 10.2174/1389557043403198; Redfern CH, 2000, P NATL ACAD SCI USA, V97, P4826, DOI 10.1073/pnas.97.9.4826; Redfern CH, 1999, NAT BIOTECHNOL, V17, P165, DOI 10.1038/6165; Riobo NA, 2005, TRENDS PHARMACOL SCI, V26, P146, DOI 10.1016/j.tips.2005.01.007; Scearce-Levie K, 2001, TRENDS PHARMACOL SCI, V22, P414, DOI 10.1016/S0165-6147(00)01743-0; SCHMIDT MW, 1993, J COMPUT CHEM, V14, P1347, DOI 10.1002/jcc.540141112; Seifert R, 2003, J PHARMACOL EXP THER, V305, P1104, DOI 10.1124/jpet.103.049619; Srinivasan S, 2003, ANN NY ACAD SCI, V994, P225, DOI 10.1111/j.1749-6632.2003.tb03184.x; TIMONEY AG, 1989, GUT, V30, P65, DOI 10.1136/gut.30.1.65; VANGUNSTEREN WF, 1990, ANGEW CHEM INT EDIT, V29, P992, DOI 10.1002/anie.199009921; Wieland K, 1999, J BIOL CHEM, V274, P29994, DOI 10.1074/jbc.274.42.29994	35	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34741	34746		10.1074/jbc.M504165200	http://dx.doi.org/10.1074/jbc.M504165200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16027157	Green Published, hybrid			2022-12-25	WOS:000232403900045
J	Ropke, A; Buhtz, P; Bohm, M; Seger, J; Wieland, I; Allhoff, EP; Wieacker, PF				Ropke, A; Buhtz, P; Bohm, M; Seger, J; Wieland, I; Allhoff, EP; Wieacker, PF			Promoter CpG hypermethylation and downregulation of DICE1 expression in prostate cancer	ONCOGENE			English	Article						DICE1 (DDX26); promoter; hypermethylation; downregulation; prostate cancer	TUMOR-SUPPRESSOR GENE; CARCINOMA CELL-LINE; LASER MICRODISSECTION; CHROMOSOME 13Q14.3; DNA METHYLATION; HIGH-RESOLUTION; BREAST-CANCER; ALLELIC LOSS; LUNG; INACTIVATION	A critical region of loss of heterozygosity on human chromosome 13q14 harbors the tumor suppressor gene DICE1 (DDX26). To elucidate the reduced DICE1 expression in tumor cells, the putative promoter sequence upstream of the DICE1 gene was analysed. This sequence shows a high GC content and is rich in CpG sites and binding sites of transcriptional factors. Promoter activity was identified within three overlapping fragments of the 800 bp sequence upstream of the DICE1 gene. A 13 bp deletion polymorphism detected in the DICE1 promoter region showed a decreased activity compared with the undeleted variant. However, this 13 bp deletion was seen in male control samples and patients with prostate cancer or benign prostatic hyperplasia at similar rates. A reduced DICE1 expression was observed in prostate cancer cell lines DU145 and LNCaP. This downregulation is associated with hypermethylation of the DICE1 promoter. Treatment of both prostate cancer cell lines with 5-azacytidine leads to upregulation of DICE1 expression. Hypermethylation of CpG sites of the DICE1 promoter was observed in four of eight analysed prostate cancers. This study suggests that transcriptional repression of DICE1 is caused by hypermethylation of the DICE1 promoter region in prostate cancer cells.	Univ Magdeburg, Inst Human Genet, D-39120 Magdeburg, Germany; Univ Magdeburg, Inst Pathol, D-39120 Magdeburg, Germany; Univ Magdeburg, Dept Urol, D-39120 Magdeburg, Germany	Otto von Guericke University; Otto von Guericke University; Otto von Guericke University	Wieacker, PF (corresponding author), Univ Magdeburg, Inst Human Genet, Leipziger Str 44, D-39120 Magdeburg, Germany.	peter.wieacker@medizin.uni-magdeburg.de		Wieland, Ilse/0000-0002-8017-3029				Ausubel F.M., 1989, CURRENT PROTOCOLS MO, V2; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Bohm M, 1997, AM J PATHOL, V151, P63; Bohm M, 1999, ONKOLOGIE, V22, P296, DOI 10.1159/000026978; Deng GR, 2001, ONCOGENE, V20, P7120, DOI 10.1038/sj.onc.1204891; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; DiNardo DNM, 2001, ONCOGENE, V20, P5331, DOI 10.1038/sj.onc.1204697; Esteller M, 2002, J PATHOL, V196, P1, DOI 10.1002/path.1024; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GIBAS Z, 1984, CANCER GENET CYTOGEN, V11, P399, DOI 10.1016/0165-4608(84)90020-7; GLEASON DF, 1974, J UROLOGY, V111, P58, DOI 10.1016/S0022-5347(17)59889-4; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; JUTTERMANN R, 1994, P NATL ACAD SCI USA, V91, P11797, DOI 10.1073/pnas.91.25.11797; Klein G, 2002, SEMIN CANCER BIOL, V12, P327, DOI 10.1016/S1044-579X(02)00052-4; Kuroki T, 2003, CANCER RES, V63, P3724; Li WJ, 2003, ONCOGENE, V22, P314, DOI 10.1038/sj.onc.1206098; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Ogawara K, 1998, INT J CANCER, V79, P312, DOI 10.1002/(SICI)1097-0215(19980821)79:4<312::AID-IJC2>3.0.CO;2-Y; REHFUSS RP, 1991, J BIOL CHEM, V266, P18431; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SOBIN LH, 1997, CLASSIFICATION MALIG, P170; STONE KR, 1978, INT J CANCER, V21, P274, DOI 10.1002/ijc.2910210305; Strathdee G, 2002, SEMIN CANCER BIOL, V12, P373, DOI 10.1016/S1044-579X(02)00057-3; Tamura K, 1997, INT J CANCER, V74, P45, DOI 10.1002/(SICI)1097-0215(19970220)74:1<45::AID-IJC8>3.0.CO;2-0; Ueda T, 1999, GENE CHROMOSOME CANC, V24, P183, DOI 10.1002/(SICI)1098-2264(199903)24:3<183::AID-GCC2>3.3.CO;2-A; Watanabe T, 2001, J NEUROPATH EXP NEUR, V60, P1181, DOI 10.1093/jnen/60.12.1181; Wieland I, 2004, ONCOL REP, V12, P207; Wieland I, 1999, ONCOGENE, V18, P4530, DOI 10.1038/sj.onc.1202806; Wieland I, 2001, ONCOL RES, V12, P491, DOI 10.3727/096504001108747503; Yang QF, 2002, CLIN CANCER RES, V8, P2890; Yin ZN, 1999, ONCOGENE, V18, P7576, DOI 10.1038/sj.onc.1203203; Zochbauer-Muller S, 2001, CANCER RES, V61, P3581	35	22	23	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 6	2005	24	44					6667	6675		10.1038/sj.onc.1208824	http://dx.doi.org/10.1038/sj.onc.1208824			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	971FL	16007164				2022-12-25	WOS:000232367800008
J	Imtiyaz, HZ; Zhang, YH; Zhang, JK				Imtiyaz, HZ; Zhang, YH; Zhang, JK			Structural requirements for signal-induced target binding of FADD determined by functional reconstitution of FADD deficiency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR RECEPTOR; DEATH DOMAIN; TNF RECEPTOR; CELL-DEATH; INDUCED APOPTOSIS; MICE LACKING; MEDIATED APOPTOSIS; CD95 FAS/APO-1; FAS; PROTEIN	FADD is a key adaptor modulating several signaling pathways such as apoptosis induced by Fas (CD95) and tumor necrosis factor receptor 1, and cell proliferation induced by mitogens. Whereas mutations in Fas disrupt its binding to FADD and cause autoimmune lymphoproliferative (lpr) syndromes, a FADD deficiency blocks embryonic development in mice. To delineate the multifunction of FADD in vivo, we performed functional reconstitution analysis by introducing wild type and mutant FADD into FADD(-/-) cells or FADD(-/-) mice lacking the endogenous FADD. An lpr-like FADD mutant, V121N, was reported previously as being defective in Fas binding in vitro. However, we found that in mice V121N can bind to Fas and is functional in signaling apoptosis. Unexpectedly, this lpr-like mutant FADD failed to support mouse development, indicating that the death domain of FADD has an additional function required for embryogenesis, which is independent of that required for receptor-induced apoptosis. Further mutagenesis was targeted at charged residues in the FADD death domain, presumably mediating electrostatic interactions with Fas. We showed that the target binding and apoptosis signaling functions of FADD were not affected when mutations were introduced to a majority of the charged residues. In one exception, replacing arginine 117 with an uncharged residue disrupted target binding and apoptosis signaling, but restoring the positive charge at position 117 failed to reconstitute the FADD function. Therefore, in vivo target binding of FADD involves an additional mechanism distinct from electrostatic interaction.	Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University	Zhang, JK (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, 233 S 10th St,Rm 731 BLSB, Philadelphia, PA 19107 USA.	jzhang@mail.jci.tju.edu		Zhang, Yuhang/0000-0002-9738-5343; Zhang, Jianke/0000-0002-5822-2226	NATIONAL CANCER INSTITUTE [R01CA095454] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA95454] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADACHI M, 1995, NAT GENET, V11, P294, DOI 10.1038/ng1195-294; BARTEL PL, 1995, METHOD ENZYMOL, V254, P241; Berglund H, 2000, J MOL BIOL, V302, P171, DOI 10.1006/jmbi.2000.4011; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; CHINNAIYAN AM, 1995, CELL, V81, P512; COHEN PL, 1991, ANNU REV IMMUNOL, V9, P243, DOI 10.1146/annurev.iy.09.040191.001331; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Diehl GE, 2004, IMMUNITY, V21, P877, DOI 10.1016/j.immuni.2004.11.008; Eberstadt M, 1997, NAT STRUCT BIOL, V4, P983, DOI 10.1038/nsb1297-983; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; FEINSTEIN E, 1995, TRENDS BIOCHEM SCI, V20, P342, DOI 10.1016/S0968-0004(00)89070-2; Hill JM, 2004, J BIOL CHEM, V279, P1474, DOI 10.1074/jbc.M304996200; HOFMANN K, 1995, FEBS LETT, V371, P321, DOI 10.1016/0014-5793(95)00931-X; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Huang BH, 1996, NATURE, V384, P638, DOI 10.1038/384638a0; ITOH N, 1993, J BIOL CHEM, V268, P10932; Jeong EJ, 1999, J BIOL CHEM, V274, P16337, DOI 10.1074/jbc.274.23.16337; Juo P, 1999, CELL GROWTH DIFFER, V10, P797; Kabra NH, 2001, P NATL ACAD SCI USA, V98, P6307, DOI 10.1073/pnas.111158698; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Kuang AA, 2000, J BIOL CHEM, V275, P25065, DOI 10.1074/jbc.C000284200; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Marsden VS, 2003, ANNU REV IMMUNOL, V21, P71, DOI 10.1146/annurev.immunol.21.120601.141029; Matsumura H, 2000, J CELL BIOL, V151, P1247, DOI 10.1083/jcb.151.6.1247; Meier P, 2000, NATURE, V407, P796, DOI 10.1038/35037734; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; RATHMELL JC, 2002, CELL S, V109, P97; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Sprick MR, 2004, BBA-MOL CELL RES, V1644, P125, DOI 10.1016/j.bbamcr.2003.11.002; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; WATANABEFUKUNAG.R, 1992, NATURE, V356, P317; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; Xiao T, 1999, CELL, V99, P545, DOI 10.1016/S0092-8674(00)81542-1; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Zhang J, 1996, MOL CELL BIOL, V16, P2756; Zhang JK, 1998, NATURE, V392, P296, DOI 10.1038/32681; Zhou T, 1996, J IMMUNOL, V156, P2661	47	19	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	2005	280	36					31360	31367		10.1074/jbc.M504138200	http://dx.doi.org/10.1074/jbc.M504138200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	961LZ	16009710	hybrid			2022-12-25	WOS:000231665200005
J	McBride, AE; Cook, JT; Stemmler, EA; Rutledge, KL; McGrath, KA; Rubens, JA				McBride, AE; Cook, JT; Stemmler, EA; Rutledge, KL; McGrath, KA; Rubens, JA			Arginine methylation of yeast mRNA-binding protein Npl3 directly affects its function, nuclear export, and intranuclear protein interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORM MASS-SPECTROMETRY; SACCHAROMYCES-CEREVISIAE; POLYMERASE-II; 3'-END FORMATION; METHYLTRANSFERASE; RESIDUES; COMPLEX; TRANSCRIPTION; PEPTIDES; IDENTIFICATION	Arginine methylation can affect both nucleocytoplasmic transport and protein-protein interactions of RNA-binding proteins. These effects are seen in cells that lack the yeast hnRNP methyltransferase (HMT1), raising the question of whether effects on specific proteins are direct or indirect. The presence of multiple arginines in individual methylated proteins also raises the question of whether overall methylation or methylation of a subset of arginines affects protein function. We have used the yeast mRNA-binding protein Npl3 to address these questions in vivo. Matrix-assisted laser desorption/ionization Fourier transform mass spectrometry was used to identify 17 methylated arginines in Npl3 purified from yeast: whereas 10 Arg-Gly-Gly (RGG) tripeptides were exclusively dimethylated, variable levels of methylation were found for 5 RGG and 2 RG motif arginines. We constructed a set of Npl3 proteins in which subsets of the RGG arginines were mutated to lysine. Expression of these mutant proteins as the sole form of Npl3 specifically affected growth of a strain that requires Hmt1. Although decreased growth generally correlated with increased numbers of Arg-to-Lys mutations, lysine substitutions in the N terminus of the RGG domain showed more severe effects. Npl3 with all 15 RGG arginines mutated to lysine exited the nucleus independent of Hmt1, indicating a direct effect of methylation on Npl3 transport. These mutations also resulted in a decreased, methylation-independent interaction of Npl3 with transcription elongation factor Tho2 and inhibited Npl3 self-association. These results support a model in which arginine methylation facilitates Npl3 export directly by weakening contacts with nuclear proteins.	Bowdoin Coll, Dept Biol, Brunswick, ME 04011 USA; Bowdoin Coll, Dept Chem, Brunswick, ME 04011 USA	Bowdoin College; Bowdoin College	McBride, AE (corresponding author), Bowdoin Coll, Dept Biol, 6500 Coll Stn, Brunswick, ME 04011 USA.	amcbride@bowdoin.edu						Bedford MT, 2005, MOL CELL, V18, P263, DOI 10.1016/j.molcel.2005.04.003; BOFFA LC, 1977, BIOCHEM BIOPH RES CO, V74, P969, DOI 10.1016/0006-291X(77)91613-8; Boisvert FM, 2005, GENE DEV, V19, P671, DOI 10.1101/gad.1279805; BOISVERT FM, 2005, SCI STKE, pRE2, DOI DOI 10.1126/STKE.2712005RE2; BOSSIE MA, 1992, MOL BIOL CELL, V3, P875, DOI 10.1091/mbc.3.8.875; Brame CJ, 2004, RAPID COMMUN MASS SP, V18, P877, DOI 10.1002/rcm.1421; Bucheli ME, 2005, EMBO J, V24, P2150, DOI 10.1038/sj.emboj.7600687; CALNAN BJ, 1991, SCIENCE, V252, P1167, DOI 10.1126/science.252.5009.1167; Chavez S, 2000, EMBO J, V19, P5824, DOI 10.1093/emboj/19.21.5824; Clauser KR, 1999, ANAL CHEM, V71, P2871, DOI 10.1021/ac9810516; Cuthbert GL, 2004, CELL, V118, P545, DOI 10.1016/j.cell.2004.08.020; Denman RB, 2002, CELL MOL BIOL LETT, V7, P877; DOYE V, 1994, EMBO J, V13, P6062, DOI 10.1002/j.1460-2075.1994.tb06953.x; Dreyfuss G, 2002, NAT REV MOL CELL BIO, V3, P195, DOI 10.1038/nrm760; FLACH J, 1994, MOL CELL BIOL, V14, P8399, DOI 10.1128/MCB.14.12.8399; Gary JD, 1998, PROG NUCLEIC ACID RE, V61, P65, DOI 10.1016/S0079-6603(08)60825-9; Gehrig PM, 2004, J AM SOC MASS SPECTR, V15, P142, DOI 10.1016/j.jasms.2003.10.002; Gilbert W, 2001, RNA, V7, P302, DOI 10.1017/S1355838201002369; Green DM, 2002, J BIOL CHEM, V277, P7752, DOI 10.1074/jbc.M110053200; Hellmuth K, 1998, MOL CELL BIOL, V18, P6374, DOI 10.1128/MCB.18.11.6374; Henry M, 1996, GENETICS, V142, P103; Henry MF, 1996, MOL CELL BIOL, V16, P3668; Hurt E, 2004, P NATL ACAD SCI USA, V101, P1858, DOI 10.1073/pnas.0308663100; Kim M, 2004, EMBO J, V23, P354, DOI 10.1038/sj.emboj.7600053; Kwak YT, 2003, MOL CELL, V11, P1055, DOI 10.1016/S1097-2765(03)00101-1; Lee DY, 2005, ENDOCR REV, V26, P147, DOI 10.1210/er.2004-0008; Lee JH, 2000, BIOCHEM BIOPH RES CO, V274, P105, DOI 10.1006/bbrc.2000.3049; Lee MS, 1996, GENE DEV, V10, P1233, DOI 10.1101/gad.10.10.1233; Lee YH, 2005, P NATL ACAD SCI USA, V102, P3611, DOI 10.1073/pnas.0407159102; Lei EP, 2001, GENE DEV, V15, P1771, DOI 10.1101/gad.892401; Marfatia KA, 2003, J BIOL CHEM, V278, P6731, DOI 10.1074/jbc.M207571200; Marshall AG, 1998, MASS SPECTROM REV, V17, P1, DOI 10.1002/(SICI)1098-2787(1998)17:1<1::AID-MAS1>3.0.CO;2-K; McBride AE, 2001, CELL, V106, P5, DOI 10.1016/S0092-8674(01)00423-8; McBride AE, 2000, J BIOL CHEM, V275, P3128, DOI 10.1074/jbc.275.5.3128; NAJBAUER J, 1993, J BIOL CHEM, V268, P10501; Nichols RC, 2000, EXP CELL RES, V256, P522, DOI 10.1006/excr.2000.4827; Niewmierzycka A, 1999, J BIOL CHEM, V274, P814, DOI 10.1074/jbc.274.2.814; O'Connor PB, 2000, ANAL CHEM, V72, P5881, DOI 10.1021/ac000770t; Olsen JV, 2004, MOL CELL PROTEOMICS, V3, P608, DOI 10.1074/mcp.T400003-MCP200; Pellar GJ, 2003, CHROMOSOMA, V111, P461, DOI 10.1007/s00412-003-0231-y; Pritzker LB, 2000, BIOCHEMISTRY-US, V39, P5382, DOI 10.1021/bi9925571; QIN J, 1995, J AM CHEM SOC, V117, P5411, DOI 10.1021/ja00124a045; RAJPUROHIT R, 1994, BIOCHEM J, V304, P903, DOI 10.1042/bj3040903; Raman B, 2001, NUCLEIC ACIDS RES, V29, P3377, DOI 10.1093/nar/29.16.3377; Rappsilber J, 2003, ANAL CHEM, V75, P3107, DOI 10.1021/ac026283q; Rose MD., 1990, METHODS YEAST GENETI; Senger B, 1998, EMBO J, V17, P2196, DOI 10.1093/emboj/17.8.2196; Shen EC, 2000, J BIOL CHEM, V275, P23718, DOI 10.1074/jbc.M002312200; Shen EC, 1998, GENE DEV, V12, P679, DOI 10.1101/gad.12.5.679; Siebel CW, 1996, P NATL ACAD SCI USA, V93, P13641, DOI 10.1073/pnas.93.24.13641; SIKORSKI RS, 1989, GENETICS, V122, P19; Siniossoglou S, 1998, CELL BIOLOGY - A LABORATORY HANDBOOK, 2ND EDITION, VOL 2, P159; Smith JJ, 1999, J BIOL CHEM, V274, P13229, DOI 10.1074/jbc.274.19.13229; Stemmler EA, 2005, ANAL CHEM, V77, P3594, DOI 10.1021/ac0502347; Strasser K, 2002, NATURE, V417, P304, DOI 10.1038/nature746; Tsaprailis G, 2000, INT J MASS SPECTROM, V195, P467, DOI 10.1016/S1387-3806(99)00221-3; Valentini SR, 1999, RNA, V5, P272, DOI 10.1017/S1355838299981633; Wang Y, 2004, SCIENCE, V306, P279, DOI 10.1126/science.1101400; WILSON SM, 1994, J CELL BIOL, V127, P1173, DOI 10.1083/jcb.127.5.1173; Windgassen M, 2004, MOL CELL BIOL, V24, P10479, DOI 10.1128/MCB.24.23.10479-10491.2004; Xu C, 2004, MOL CELL BIOL, V24, P10742, DOI 10.1128/MCB.24.24.10742-10756.2004; Yu MC, 2004, GENE DEV, V18, P2024, DOI 10.1101/gad.1223204; Yun CY, 2000, J CELL BIOL, V150, P707, DOI 10.1083/jcb.150.4.707	63	87	87	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	2005	280	35					30888	30898		10.1074/jbc.M505831200	http://dx.doi.org/10.1074/jbc.M505831200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	958ZX	15998636	hybrid			2022-12-25	WOS:000231487800030
J	Morosinotto, T; Ballottari, M; Klimmek, F; Jansson, S; Bassi, R				Morosinotto, T; Ballottari, M; Klimmek, F; Jansson, S; Bassi, R			The association of the antenna system to photosystem I in higher plants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-HARVESTING COMPLEX; CHLAMYDOMONAS-REINHARDTII; PHOTOSYNTHETIC APPARATUS; ARABIDOPSIS-THALIANA; ANGSTROM RESOLUTION; PROTEIN-COMPOSITION; LHCA PROTEINS; PS II; ORGANIZATION; SUPERCOMPLEX	We report on the association of the antenna system to the reaction center in Photosystem I. Biochemical analysis of mutants depleted in antenna polypeptides showed that the binding of the antenna moiety is strongly cooperative. The minimal building block for the antenna system was shown to be a dimer. Specific protein- protein interactions play an important role in antenna association, and the gap pigments, bound at the interface between core and antenna, are proposed to mediate these interactions Gap pigments have been characterized by comparing the spectra of the Photosystem I to those of the isolated antenna and core components. CD spectroscopy showed that they are involved in pigment- pigment interactions, supporting their relevance in energy transfer from antenna to the reaction center. Moreover, gap pigments contribute to the redshifted emission forms of Photosystem I antenna. When compared with Photosystem II, the association of peripheral antenna complexes in PSI appears to be more stable, but far less flexible and functional implications are discussed.	Univ Verona, Dipartimento Sci & Tecnol, I-37134 Verona, Italy; Univ Aix Marseille 2, LGBP, Fac Sci Luminy, Dept Biol, F-13288 Marseille, France; Umea Univ, Dept Plant Physiol, Umea Plant Sci Ctr, S-90187 Umea, Sweden	University of Verona; UDICE-French Research Universities; Aix-Marseille Universite; Umea University	Bassi, R (corresponding author), Univ Verona, Dipartimento Sci & Tecnol, Str Grazie 15, I-37134 Verona, Italy.	bassi@sci.univr.it	Morosinotto, Tomas/AAC-3188-2019; Jansson, Stefan/A-1119-2009; Ballottari, Matteo/N-1916-2019	Morosinotto, Tomas/0000-0002-0803-7591; Jansson, Stefan/0000-0002-7906-6891; Ballottari, Matteo/0000-0001-8410-3397; bassi, roberto/0000-0002-4140-8446				BALL EH, 1986, ANAL BIOCHEM, V155, P23, DOI 10.1016/0003-2697(86)90218-6; Ballottari M, 2004, EUR J BIOCHEM, V271, P4659, DOI 10.1111/j.1432-1033.2004.04426.x; BASSI R, 1992, J BIOL CHEM, V267, P25714; BASSI R, 1987, EUR J BIOCHEM, V163, P221, DOI 10.1111/j.1432-1033.1987.tb10791.x; Ben-Shem A, 2004, PHOTOSYNTH RES, V81, P239, DOI 10.1023/B:PRES.0000036881.23512.42; Ben-Shem A, 2004, FEBS LETT, V564, P274, DOI 10.1016/S0014-5793(04)00360-6; Ben-Shem A, 2003, NATURE, V426, P630, DOI 10.1038/nature02200; Boekema EJ, 2001, BIOCHEMISTRY-US, V40, P1029, DOI 10.1021/bi0015358; Bossmann B, 1997, PHOTOSYNTH RES, V52, P127, DOI 10.1023/A:1005823711838; Castelletti S, 2003, BIOCHEMISTRY-US, V42, P4226, DOI 10.1021/bi027398r; Croce R, 1996, BIOCHEMISTRY-US, V35, P8572, DOI 10.1021/bi960214m; Croce R, 1998, BIOCHEMISTRY-US, V37, P17355, DOI 10.1021/bi9813227; Croce R, 2002, BBA-BIOENERGETICS, V1556, P29, DOI 10.1016/S0005-2728(02)00304-3; Croce R, 2002, BIOCHEMISTRY-US, V41, P7334, DOI 10.1021/bi0257437; Dall'Osto L, 2005, PLANT CELL, V17, P1217, DOI 10.1105/tpc.104.030601; Elrad D, 2004, CURR GENET, V45, P61, DOI 10.1007/s00294-003-0460-x; Ganeteg U, 2004, PLANT MOL BIOL, V54, P641, DOI 10.1023/B:PLAN.0000040813.05224.94; Ganeteg U, 2004, PLANT PHYSIOL, V134, P502, DOI 10.1104/pp.103.033324; Ganeteg U, 2001, PLANT PHYSIOL, V127, P150, DOI 10.1104/pp.127.1.150; Germano M, 2002, FEBS LETT, V525, P121, DOI 10.1016/S0014-5793(02)03100-9; GILMORE AM, 1991, PLANT PHYSIOL, V96, P635, DOI 10.1104/pp.96.2.635; Haldrup A, 1999, PLANT J, V17, P689, DOI 10.1046/j.1365-313X.1999.00419.x; HAWORTH P, 1983, BIOCHIM BIOPHYS ACTA, V724, P151, DOI 10.1016/0005-2728(83)90036-1; Ihalainen JA, 2000, BIOCHEMISTRY-US, V39, P8625, DOI 10.1021/bi0007369; Jansson S, 1996, PLANT PHYSIOL, V112, P409, DOI 10.1104/pp.112.1.409; Jansson S, 1997, BBA-BIOENERGETICS, V1320, P297, DOI 10.1016/S0005-2728(97)00033-9; Jansson S, 1999, TRENDS PLANT SCI, V4, P236, DOI 10.1016/S1360-1385(99)01419-3; Jordan P, 2001, NATURE, V411, P909, DOI 10.1038/35082000; Kargul J, 2003, J BIOL CHEM, V278, P16135, DOI 10.1074/jbc.M300262200; Klimmek F, 2005, BIOCHEMISTRY-US, V44, P3065, DOI 10.1021/bi047873g; Knoetzel H, 2002, FEBS LETT, V510, P145, DOI 10.1016/S0014-5793(01)03253-7; Krauss N, 1996, NAT STRUCT BIOL, V3, P965, DOI 10.1038/nsb1196-965; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAM E, 1984, FEBS LETT, V168, P10, DOI 10.1016/0014-5793(84)80197-0; MALKIN R, 1985, PHYSIOL VEG, V23, P619; Morosinotto T, 2003, J BIOL CHEM, V278, P49223, DOI 10.1074/jbc.M309203200; Moya I, 2001, BIOCHEMISTRY-US, V40, P12552, DOI 10.1021/bi010342x; NAGAI K, 1987, METHOD ENZYMOL, V153, P461; PAULSEN H, 1993, EUR J BIOCHEM, V215, P809, DOI 10.1111/j.1432-1033.1993.tb18096.x; PETER GF, 1991, J BIOL CHEM, V266, P16745; Ruban AV, 2003, NATURE, V421, P648, DOI 10.1038/nature01344; Scheller HV, 2001, BBA-BIOENERGETICS, V1507, P41, DOI 10.1016/S0005-2728(01)00196-7; Schmid VHR, 1997, P NATL ACAD SCI USA, V94, P7667, DOI 10.1073/pnas.94.14.7667; Stauber EJ, 2003, EUKARYOT CELL, V2, P978, DOI 10.1128/EC.2.5.978-994.2003; Storf S, 2004, BIOCHEMISTRY-US, V43, P9214, DOI 10.1021/bi0498196; Takahashi Y, 2004, BIOCHEMISTRY-US, V43, P7816, DOI 10.1021/bi035988z; Tokutsu R, 2004, PLANT CELL PHYSIOL, V45, P138, DOI 10.1093/pcp/pch013; Van Amerongen H, 2000, PHOTOSYNTHERIC EXCIT; WALTERS RG, 1994, PLANTA, V195, P248, DOI 10.1007/BF00199685; Wollman FA, 2001, EMBO J, V20, P3623, DOI 10.1093/emboj/20.14.3623; Zhang H, 1997, PLANT PHYSIOL, V115, P1525, DOI 10.1104/pp.115.4.1525	51	38	40	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	2005	280	35					31050	31058		10.1074/jbc.M502935200	http://dx.doi.org/10.1074/jbc.M502935200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	958ZX	15983042	hybrid			2022-12-25	WOS:000231487800049
J	Berteaux, N; Lottin, V; Monte, D; Pinte, S; Quatannens, B; Coll, J; Hondermarck, H; Curgy, JJ; Dugimont, T; Adriaenssens, E				Berteaux, N; Lottin, V; Monte, D; Pinte, S; Quatannens, B; Coll, J; Hondermarck, H; Curgy, JJ; Dugimont, T; Adriaenssens, E			H19 mRNA-like noncoding RNA promotes breast cancer cell proliferation through positive control by E2F1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; IMPRINTED H19; TRANSCRIPTION FACTOR; THIOREDOXIN; OVEREXPRESSION; ACTIVATION; FAMILY; IGF2; TUMORIGENICITY; IDENTIFICATION	The imprinted H19 gene has riboregulatory functions. We show here that H19 transcription is up-regulated during the S-phase of growth-stimulated cells and that the H19 promoter is activated by E2F1 in breast cancer cells. H19 repression by pRb and E2F6 confirms the E2F1-dependent control of the H19 promoter. Consistently, we demonstrate by chromatin immunoprecipitation assays that endogenous E2F1 is recruited to the H19 promoter in vivo. The functionality of E2F promoter sites was further confirmed by gel shift and mutagenesis experiments, revealing that these sites are required for binding and promoter response to E2F1 exogenous expression and serum stimulation. Furthermore, we show that H19 overexpression confers a growth advantage on breast cancer cells released from growth arrest as well as in asynchronously growing cells. The H19 knockdown by small interfering RNA duplexes impedes S-phase entry in both wild-type and stably H19-transfected cells. Based on these findings, we conclude that the H19 RNA is actively linked to E2F1 to promote cell cycle progression of breast cancer cells. This clearly supports the H19 oncogenic function in breast tumor genesis.	USTL, INSERM, ERI8, UPRES EA 1033,IFR 118, F-59655 Villeneuve Dascq, France; Inst Pasteur, CNRS, UMR 8117, F-59019 Lille, France; Inst Pasteur, CNRS, UMR 8526, F-59019 Lille, France; Inst Pasteur, CNRS, UMR 8527, IBL, F-59019 Lille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille	Curgy, JJ (corresponding author), USTL, INSERM, ERI8, UPRES EA 1033,IFR 118, SN3, F-59655 Villeneuve Dascq, France.	curgy@univ-lille1.fr		monte, didier/0000-0002-0613-6203				Adriaenssens E, 1998, AM J PATHOL, V153, P1597, DOI 10.1016/S0002-9440(10)65748-3; Adriaenssens E, 2002, EXP CELL RES, V275, P215, DOI 10.1006/excr.2002.5500; Adriaenssens E, 1999, ONCOGENE, V18, P4460, DOI 10.1038/sj.onc.1202819; ARIEL I, 1995, UROLOGY, V45, P335, DOI 10.1016/0090-4295(95)80030-1; Ariel I, 2000, AM J MED GENET, V91, P46, DOI 10.1002/(SICI)1096-8628(20000306)91:1<46::AID-AJMG8>3.0.CO;2-I; Ayesh S, 2002, MOL CARCINOGEN, V35, P63, DOI 10.1002/mc.10075; Berggren M, 1996, ANTICANCER RES, V16, P3459; Blais A, 2002, J BIOL CHEM, V277, P31679, DOI 10.1074/jbc.M204554200; BRANNAN CI, 1990, MOL CELL BIOL, V10, P28, DOI 10.1128/MCB.10.1.28; Cartwright P, 1998, ONCOGENE, V17, P611, DOI 10.1038/sj.onc.1201975; Conner EA, 2000, ONCOGENE, V19, P5054, DOI 10.1038/sj.onc.1203885; Cooper MJ, 1996, J UROLOGY, V155, P2120, DOI 10.1016/S0022-5347(01)66120-2; DOUCRASY S, 1993, INT J ONCOL, V2, P753; Dugimont T, 1998, ONCOGENE, V16, P2395, DOI 10.1038/sj.onc.1201742; Dugimont T, 1995, BIOL CELL, V85, P117, DOI 10.1016/0248-4900(96)85272-5; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; DYSON N, 1994, J CELL SCI, P81; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; ELKIN M, 1995, FEBS LETT, V374, P57, DOI 10.1016/0014-5793(95)01074-O; Fry CJ, 1999, J BIOL CHEM, V274, P15883, DOI 10.1074/jbc.274.22.15883; Gallegos A, 1996, CANCER RES, V56, P5765; GASDASKA JR, 1995, CELL GROWTH DIFFER, V6, P1643; GELMANN EP, 1992, INT J CANCER, V50, P665, DOI 10.1002/ijc.2910500431; GIANNOUKAKIS N, 1993, NAT GENET, V4, P98, DOI 10.1038/ng0593-98; Ginsberg D, 2002, FEBS LETT, V529, P122, DOI 10.1016/S0014-5793(02)03270-2; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Hateboer G, 1998, MOL CELL BIOL, V18, P6679, DOI 10.1128/MCB.18.11.6679; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; Hibi K, 1996, CANCER RES, V56, P480; IKEDA MA, 1993, MOL CELL BIOL, V13, P7029, DOI 10.1128/MCB.13.11.7029; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Joubel A, 1996, CELL MOL BIOL, V42, P1159; Juan V, 2000, NUCLEIC ACIDS RES, V28, P1221, DOI 10.1093/nar/28.5.1221; KASID A, 1987, CANCER RES, V47, P5733; KONDO M, 1995, ONCOGENE, V10, P1193; Kopf E, 1998, FEBS LETT, V432, P123, DOI 10.1016/S0014-5793(98)00841-2; Li YM, 1998, J BIOL CHEM, V273, P28247, DOI 10.1074/jbc.273.43.28247; Lottin S, 2003, RRD HUM PAT, V1, P9; Lottin S, 2002, ONCOGENE, V21, P1625, DOI 10.1038/sj.onc.1205233; Lottin S, 2002, CARCINOGENESIS, V23, P1885, DOI 10.1093/carcin/23.11.1885; Ma YH, 2003, MOL CANCER THER, V2, P73; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Okamoto K, 1997, P NATL ACAD SCI USA, V94, P5367, DOI 10.1073/pnas.94.10.5367; OTHANI K, 1999, FRONT BIOSCI, V4, P793; PACHNIS V, 1988, EMBO J, V7, P673, DOI 10.1002/j.1460-2075.1988.tb02862.x; PACHNIS V, 1984, P NATL ACAD SCI-BIOL, V81, P5523, DOI 10.1073/pnas.81.17.5523; PEEPER DS, 1993, MOL BIOL REP, V17, P197, DOI 10.1007/BF00986728; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pierce AM, 1998, ONCOGENE, V16, P1267, DOI 10.1038/sj.onc.1201666; RACHMILEWITZ J, 1995, ONCOGENE, V11, P863; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Scrable H J, 1990, Adv Cancer Res, V54, P25, DOI 10.1016/S0065-230X(08)60807-6; Sears R, 1997, MOL CELL BIOL, V17, P5227, DOI 10.1128/MCB.17.9.5227; Sorensen TS, 1996, MOL CELL BIOL, V16, P5888; STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433; Takahashi Y, 2000, GENE DEV, V14, P804; Takaishi S, 2003, DIGEST DIS SCI, V48, P379, DOI 10.1023/A:1021952132241; Tevosian SG, 1996, CELL GROWTH DIFFER, V7, P43; Trimarchi JM, 1998, P NATL ACAD SCI USA, V95, P2850, DOI 10.1073/pnas.95.6.2850; Vigo E, 1999, MOL CELL BIOL, V19, P6379; VOUTILAINEN R, 1994, ENDOCRINOLOGY, V134, P2051, DOI 10.1210/en.134.5.2051; Wang A, 2000, J BIOL CHEM, V275, P4532, DOI 10.1074/jbc.275.6.4532; Wilkin F, 2000, EUR J BIOCHEM, V267, P4020, DOI 10.1046/j.1432-1327.2000.01438.x; ZEMEL S, 1992, NAT GENET, V2, P61, DOI 10.1038/ng0992-61; ZHANG YH, 1992, NAT GENET, V1, P40, DOI 10.1038/ng0492-40; Zwicker J, 1997, TRENDS GENET, V13, P3, DOI 10.1016/S0168-9525(96)30112-1	67	293	320	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	2005	280	33					29625	29636		10.1074/jbc.M504033200	http://dx.doi.org/10.1074/jbc.M504033200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	954SX	15985428	hybrid			2022-12-25	WOS:000231176200031
J	Bourges, I; Horan, S; Meunier, B				Bourges, I; Horan, S; Meunier, B			Effect of inhibition of the bc(1) complex on gene expression profile in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL CYTOCHROME-B; SACCHAROMYCES-CEREVISIAE; ENVIRONMENTAL-CHANGES; NUCLEAR-LOCALIZATION; ALTERNATIVE OXIDASE; Q(O) SITE; INDUCTION; STRESS; DEHYDROGENASE; DEFICIENCY	Because the respiratory chain is the major site of oxidation of the reduced equivalents and of energy production in aerobic cells, its inhibition has severe impact on the cells. Communication pathways from the respiratory chain are required to allow the cell to sense the defect and respond to it. In this work, we studied changes in gene expression induced by the treatment of yeast cells with myxothiazol, an inhibitor of the bc(1) complex, an enzyme of the respiratory chain. The pattern and time-course expression of the genes resemble those of the environmental stress response, a common gene expression program induced by sudden changes in the environment. In addition, the changes were, for most of the genes, mediated through the transcription factors Msn2/4, which play a central role in the cellular response to these stresses. By using a mutant with a myxothiazol-resistant bc(1) complex, we showed that the changes of expression of the majority of the genes was caused by the inhibition of the bc(1) complex but that other stresses might be involved. The expression pattern of CTT1, coding for a cytoplasmic catalase, was further studied. The expression of this gene was largely dependent on Msn2/4 and the inhibition of the cytochrome bc(1). Addition of oxidants of NADH was found to decrease the expression of CTT1 induced by myxothiazol treatment, suggesting that the accumulation of NADH caused by the inhibition of the respiratory chain may be involved in the signaling pathway from the mitochondria to the transcription factor.	UCL, Wolfson Inst Biomed Res, London WC1E 6BT, England	University of London; University College London	Meunier, B (corresponding author), UCL, Wolfson Inst Biomed Res, Gower St, London WC1E 6BT, England.	b.meunier@ucl.ac.uk		Meunier, Brigitte/0000-0002-6988-4663				Ansell R, 1997, EMBO J, V16, P2179, DOI 10.1093/emboj/16.9.2179; Bakker BM, 2001, FEMS MICROBIOL REV, V25, P15, DOI 10.1016/S0168-6445(00)00039-5; Bouzidi MF, 1996, BBA-MOL BASIS DIS, V1317, P199, DOI 10.1016/S0925-4439(96)00055-5; Butow RA, 2004, MOL CELL, V14, P1, DOI 10.1016/S1097-2765(04)00179-0; Causton HC, 2001, MOL BIOL CELL, V12, P323, DOI 10.1091/mbc.12.2.323; DAY DA, 1991, PLANT PHYSIOL, V95, P948, DOI 10.1104/pp.95.3.948; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Dumoulin R, 1996, MOL CELL PROBE, V10, P389, DOI 10.1006/mcpr.1996.0053; ESTRUCH F, 1993, MOL CELL BIOL, V13, P3872, DOI 10.1128/MCB.13.7.3872; Fisher N, 2004, J BIOL CHEM, V279, P12951, DOI 10.1074/jbc.M313866200; Fisher N, 2004, EUR J BIOCHEM, V271, P2264, DOI 10.1111/j.1432-1033.2004.04169.x; Fisher N, 2001, EUR J BIOCHEM, V268, P1155, DOI 10.1046/j.1432-1327.2001.02010.x; FISHER N, 2005, IN PRESS PEST MANAG; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Gisi U, 2002, PEST MANAG SCI, V58, P859, DOI 10.1002/ps.565; Gorner W, 1998, GENE DEV, V12, P586, DOI 10.1101/gad.12.4.586; Kirchman PA, 1999, GENETICS, V152, P179; Kuge S, 1997, EMBO J, V16, P1710, DOI 10.1093/emboj/16.7.1710; MartinezPastor MT, 1996, EMBO J, V15, P2227, DOI 10.1002/j.1460-2075.1996.tb00576.x; MINAGAWA N, 1992, FEBS LETT, V302, P217, DOI 10.1016/0014-5793(92)80444-L; Palkova Z, 2002, MOL BIOL CELL, V13, P3901, DOI 10.1091/mbc.E01-12-0149; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; Tai SL, 2005, J BIOL CHEM, V280, P437, DOI 10.1074/jbc.M410573200; Ter Linde JJM, 2002, YEAST, V19, P825, DOI 10.1002/yea.879; Valadi A, 2004, J BIOL CHEM, V279, P39677, DOI 10.1074/jbc.M403310200; Veal EA, 2003, J BIOL CHEM, V278, P30896, DOI 10.1074/jbc.M303542200; WAGNER AM, 1995, FEBS LETT, V368, P339, DOI 10.1016/0014-5793(95)00688-6; Wood PM, 2003, PEST MANAG SCI, V59, P499, DOI 10.1002/ps.655	28	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	2005	280	33					29743	29749		10.1074/jbc.M505915200	http://dx.doi.org/10.1074/jbc.M505915200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	954SX	15967791	hybrid			2022-12-25	WOS:000231176200044
J	Nejmeddine, M; Barnard, AL; Tanaka, Y; Taylor, GP; Bangham, CRM				Nejmeddine, M; Barnard, AL; Tanaka, Y; Taylor, GP; Bangham, CRM			Human T-lymphotropic virus, type 1, tax protein triggers microtubule reorientation in the virological synapse	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I HTLV-I; TRANSACTIVATOR PROTEIN; CELL POLARITY; MONOCLONAL-ANTIBODIES; ORGANIZING CENTERS; SURFACE MOLECULES; GOLGI-APPARATUS; LYMPHOCYTES-T; GENE-PRODUCTS; TARGET-CELLS	We showed recently that the human T-lymphotropic virus, type 1 (HTLV-1), spreads directly from cell to cell via a virological synapse. The HTLV-1 virological synapse resembles the immunological synapse; each is a specialized contact between a lymphocyte and another cell that contains organized protein microdomains, and each involves repolarization of the T-cell microtubule cytoskeleton. However, formation of the virological synapse is not triggered by T-cell receptor-mediated antigen recognition. On the basis of our previous data, we postulated that formation of the viral synapse was triggered by a conjunction of two signals, one from HTLV-1 infection of the T-cell and one from cell-cell contact. We have recently identified ICAM-1 engagement as a cell-contact signal that causes the microtubule polarization associated with the virological synapse. Here we used confocal microscopy of T-lymphocytes naturally infected with HTLV-1 or transfected with individual HTLV-1 genes to investigate the role of the viral transcriptional transactivator protein Tax. Polarization of the microtubules was induced by cell-cell contact or by cross-linking T-cell surface molecules with monoclonal antibodies adsorbed to latex beads. We show that Tax, which is mainly found in the nucleus, is also present at two specific extranuclear sites as follows: around the microtubule organizing center in association with the cis-Golgi and in the cell-cell contact region. We show that expression of Tax provides an intracellular signal that synergizes with ICAM-1 engagement to cause the T-cell microtubule polarization observed at the virological synapse.	Univ London Imperial Coll Sci & Technol, Wright Fleming Inst, Dept Immunol, London W2 1PG, England; Univ London Imperial Coll Sci & Technol, Wright Fleming Inst, Dept Infect Dis, London W2 1PG, England; Univ Ryukyus, Dept Immunol, Grad Sch, Nishihara, Okinawa 9030215, Japan; Univ Ryukyus, Fac Med, Nishihara, Okinawa 9030215, Japan	Imperial College London; Imperial College London; University of the Ryukyus; University of the Ryukyus	Bangham, CRM (corresponding author), Univ London Imperial Coll Sci & Technol, Wright Fleming Inst, Dept Immunol, St Marys Campus,Norfolk Pl, London W2 1PG, England.	c.bangham@imperial.ac.uk		Bangham, Charles/0000-0003-2624-3599; Nejmeddine, Mohamed/0000-0003-0160-2727	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Alefantis T, 2003, J BIOL CHEM, V278, P21814, DOI 10.1074/jbc.M211576200; ALEXANDRE C, 1991, ONCOGENE, V6, P543; Allen WE, 1998, J CELL BIOL, V141, P1147, DOI 10.1083/jcb.141.5.1147; Armitage P., 2002, STAT METHODS MED RES, P215; BARNARD AL, 2005, IN PRESS BLOOD, V106; Bex F, 1997, J VIROL, V71, P3484, DOI 10.1128/JVI.71.5.3484-3497.1997; Burton M, 2000, J VIROL, V74, P2351, DOI 10.1128/JVI.74.5.2351-2364.2000; Carlier MF, 1999, CHEM BIOL, V6, pR235, DOI 10.1016/S1074-5521(99)80107-0; Chiari E, 2004, J VIROL, V78, P11823, DOI 10.1128/JVI.78.21.11823-11832.2004; Daub H, 2001, J BIOL CHEM, V276, P1677, DOI 10.1074/jbc.C000635200; Etienne-Manneville S, 2003, NATURE, V421, P753, DOI 10.1038/nature01423; Etienne-Manneville S, 2001, CELL, V106, P489, DOI 10.1016/S0092-8674(01)00471-8; GEIGER B, 1982, J CELL BIOL, V95, P137, DOI 10.1083/jcb.95.1.137; Goon PKC, 2004, J INFECT DIS, V189, P2294, DOI 10.1086/420832; GOTLIEB AI, 1983, J CELL BIOL, V96, P1266, DOI 10.1083/jcb.96.5.1266; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; GUNDERSEN GG, 1988, P NATL ACAD SCI USA, V85, P5946, DOI 10.1073/pnas.85.16.5946; Hanon E, 2000, BLOOD, V95, P1386, DOI 10.1182/blood.V95.4.1386.004k22_1386_1392; Igakura T, 2003, SCIENCE, V299, P1713, DOI 10.1126/science.1080115; JACOBSON S, 1990, NATURE, V348, P245, DOI 10.1038/348245a0; Jeang KT, 2004, J BIOL CHEM, V279, P31991, DOI 10.1074/jbc.R400009200; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; KANNAGI M, 1991, INT IMMUNOL, V3, P761, DOI 10.1093/intimm/3.8.761; Kroschewski R, 1999, NAT CELL BIOL, V1, P8, DOI 10.1038/8977; KUPFER A, 1983, P NATL ACAD SCI-BIOL, V80, P7224, DOI 10.1073/pnas.80.23.7224; KUPFER A, 1987, J EXP MED, V165, P1565, DOI 10.1084/jem.165.6.1565; Lebedeva T, 2005, CURR OPIN IMMUNOL, V17, P251, DOI 10.1016/j.coi.2005.04.008; Lomas M, 2002, J GEN VIROL, V83, P641, DOI 10.1099/0022-1317-83-3-641; Lowin-Kropf B, 1998, J CELL BIOL, V140, P861, DOI 10.1083/jcb.140.4.861; Maruta H, 1999, MICROSC RES TECHNIQ, V47, P61; Meertens L, 2004, J BIOL CHEM, V279, P43307, DOI 10.1074/jbc.M400497200; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Palazzo AF, 2001, CURR BIOL, V11, P1536, DOI 10.1016/S0960-9822(01)00475-4; Peloponese JM, 2004, J VIROL, V78, P11686, DOI 10.1128/JVI.78.21.11686-11695.2004; Reddy TR, 1998, P NATL ACAD SCI USA, V95, P702, DOI 10.1073/pnas.95.2.702; Robek MD, 1999, J VIROL, V73, P4856, DOI 10.1128/JVI.73.6.4856-4865.1999; Rubbi CP, 1996, J IMMUNOL METHODS, V192, P157, DOI 10.1016/0022-1759(96)00046-4; Schmitz AAP, 2000, EXP CELL RES, V261, P1, DOI 10.1006/excr.2000.5049; SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643; Sedwick CE, 1999, J IMMUNOL, V162, P1367; Semmes OJ, 1996, J VIROL, V70, P6347, DOI 10.1128/JVI.70.9.6347-6357.1996; Shuh M, 1999, VIROLOGY, V262, P442, DOI 10.1006/viro.1999.9909; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; SMITH MR, 1992, VIROLOGY, V187, P316, DOI 10.1016/0042-6822(92)90320-O; SOKAL RR, 2004, BIOMETRY, P794; STOWERS L, 1995, P NATL ACAD SCI USA, V92, P5027, DOI 10.1073/pnas.92.11.5027; TANAKA Y, 1986, INT J CANCER, V37, P35, DOI 10.1002/ijc.2910370107; TANAKA Y, 1992, AIDS RES HUM RETROV, V8, P227, DOI 10.1089/aid.1992.8.227; Thyberg J, 1999, EXP CELL RES, V246, P263, DOI 10.1006/excr.1998.4326; Trihn D, 1997, J BIOMED SCI, V4, P47, DOI 10.1007/BF02255593; Wang AH, 2001, MOL CELL BIOL, V21, P5992, DOI 10.1128/MCB.21.17.5992-6005.2001; WEISS A, 1984, J IMMUNOL, V133, P123; Wu KL, 2004, J BIOL CHEM, V279, P495, DOI 10.1074/jbc.M310069200; Yamamoto A, 1997, J NEUROL SCI, V151, P121, DOI 10.1016/S0022-510X(97)00121-4; Yoshida M, 2001, ANNU REV IMMUNOL, V19, P475, DOI 10.1146/annurev.immunol.19.1.475; Yusuf-Makagiansar H, 2001, PEPTIDES, V22, P1955, DOI 10.1016/S0196-9781(01)00546-0	57	110	114	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	2005	280	33					29653	29660		10.1074/jbc.M502639200	http://dx.doi.org/10.1074/jbc.M502639200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	954SX	15975923	hybrid			2022-12-25	WOS:000231176200034
J	Lanni, A; Moreno, M; Lombardi, A; de Lange, P; Silvestri, E; Ragni, M; Farina, P; Baccari, GC; Fallahi, P; Antonelli, A; Goglia, F				Lanni, A; Moreno, M; Lombardi, A; de Lange, P; Silvestri, E; Ragni, M; Farina, P; Baccari, GC; Fallahi, P; Antonelli, A; Goglia, F			3,5-Diiodo-L-thyronine powerfully reduces adiposity in rats by increasing the burning of fats	FASEB JOURNAL			English	Article						thyroid hormone; mitochondria; liver; energy metabolism	ACETYL-COA CARBOXYLASE; CARNITINE PALMITOYLTRANSFERASE-I; THYROID-HORMONE ACTION; RESTING METABOLIC-RATE; UNCOUPLING PROTEIN-3; MALONYL-COA; ENERGY-METABOLISM; OXYGEN-CONSUMPTION; RAPID STIMULATION; SKELETAL-MUSCLE	The effect of thyroid hormones on metabolism has long supported their potential as drugs to stimulate fat reduction, but the concomitant induction of a thyrotoxic state has greatly limited their use. Recent evidence suggests that 3,5-diiodo-L-thyronine (T-2), a naturally occurring iodothyronine, stimulates metabolic rate via mechanisms involving the mitochondrial apparatus. We examined whether this effect would result in reduced energy storage. Here, we show that T-2 administration to rats receiving a high-fat diet (HFD) reduces both adiposity and body weight gain without inducing thyrotoxicity. Rats receiving HFD + T-2 showed ( when compared with rats receiving HFD alone) a 13% lower body weight, a 42% higher liver fatty acid oxidation rate, similar to 50% less fat mass, a complete disappearance of fat from the liver, and significant reductions in the serum triglyceride and cholesterol levels (-52% and -18%, respectively). Thyroid hormones and thyroid-stimulating hormone (TSH) serum levels were not influenced by T-2 administration. The biochemical mechanism underlying the effects of T-2 on liver metabolism involves the carnitine palmitoyl-transferase system and mitochondrial uncoupling. If the results hold true for humans, pharmacological administration of T-2 might serve to counteract the problems associated with overweight, such as accumulation of lipids in liver and serum, without inducing thyrotoxicity. However, the results reported here do not exclude deleterious effects of T-2 on a longer time scale as well as do not show that T-2 acts in the same way in humans.	Univ Sannio, Dipartimento Sci Biol & Ambientali, I-82100 Benevento, Italy; Univ Naples 2, Dipartimento Sci Vita, I-81100 Caserta, Italy; Univ Naples Federico II, Dipartimento Sci Biol, Sez Igiene & Fisiol, I-80134 Naples, Italy; Univ Pisa, Dipartimento Med Interna, I-56126 Pisa, Italy	University of Sannio; Universita della Campania Vanvitelli; University of Naples Federico II; University of Pisa	Goglia, F (corresponding author), Univ Sannio, Dipartimento Sci Biol & Ambientali, Via Port Arsa 11, I-82100 Benevento, Italy.	goglia@unisannio.it	Ragni, Maurizio/AAB-1527-2020; de Lange, Pieter/GXA-3052-2022	Ragni, Maurizio/0000-0001-6548-741X; MORENO, Maria/0000-0002-6218-5501; Silvestri, Elena/0000-0002-0592-9033; GOGLIA, Fernando/0000-0003-0468-9645				Abu-Elheiga L, 2000, P NATL ACAD SCI USA, V97, P1444, DOI 10.1073/pnas.97.4.1444; Acin A, 1999, BIOCHEM BIOPH RES CO, V258, P278, DOI 10.1006/bbrc.1999.0530; ALEXSON SEH, 1988, J BIOL CHEM, V263, P13564; Angulo P, 2002, NEW ENGL J MED, V346, P1221, DOI 10.1038/nrdp.2015.80; Arnold S, 1998, EUR J BIOCHEM, V252, P325, DOI 10.1046/j.1432-1327.1998.2520325.x; Ball SG, 1997, J MOL ENDOCRINOL, V19, P137, DOI 10.1677/jme.0.0190137; BRAVERMAN LE, 2000, THYROID, P515; BROWN GC, 1985, BIOCHEM J, V225, P399, DOI 10.1042/bj2250399; Brown SB, 1997, J BIOL CHEM, V272, P2163, DOI 10.1074/jbc.272.4.2163; CASTELLANI LW, 1991, BIOCHIM BIOPHYS ACTA, V1086, P197, DOI 10.1016/0005-2760(91)90008-6; Cimmino M, 1996, J ENDOCRINOL, V149, P319, DOI 10.1677/joe.0.1490319; Davis PJ, 2002, J ENDOCRINOL INVEST, V25, P377, DOI 10.1007/BF03344022; de Lange P, 2003, FASEB J, V17, P350, DOI 10.1096/fj.03-0342fje; de Lange P, 2001, ENDOCRINOLOGY, V142, P3414, DOI 10.1210/en.142.8.3414; Fail PA, 1999, TOXICOL SCI, V52, P107, DOI 10.1093/toxsci/52.1.107; FREAKE HC, 1995, ANNU REV NUTR, V15, P263, DOI 10.1146/annurev.nu.15.070195.001403; Gilat T, 2003, HEPATOLOGY, V38, P436, DOI 10.1053/jhep.2003.50348; Goglia F, 1999, FEBS LETT, V452, P115, DOI 10.1016/S0014-5793(99)00642-0; GOGLIA F, 1994, FEBS LETT, V346, P295, DOI 10.1016/0014-5793(94)00476-5; Goglia F, 2005, BIOCHEMISTRY-MOSCOW+, V70, P164, DOI 10.1007/s10541-005-0097-0; HARTREE EF, 1972, ANAL BIOCHEM, V48, P422, DOI 10.1016/0003-2697(72)90094-2; HOLLENBERG AN, 1995, MOL ENDOCRINOL, V9, P540, DOI 10.1210/me.9.5.540; HORST C, 1989, BIOCHEM J, V261, P945, DOI 10.1042/bj2610945; HORST C, 1995, J ENDOCRINOL, V145, P291, DOI 10.1677/joe.0.1450291; Hulbert AJ, 2000, BIOL REV, V75, P519, DOI 10.1017/S146479310000556X; Jansen MS, 2000, J BIOL CHEM, V275, P34989, DOI 10.1074/jbc.M001752200; Kadenbach B, 2000, FREE RADICAL BIO MED, V29, P211, DOI 10.1016/S0891-5849(00)00305-1; Kadenbach B, 2003, BBA-BIOENERGETICS, V1604, P77, DOI 10.1016/S0005-2728(03)00027-6; Kerner J, 2001, AM J PHYSIOL-ENDOC M, V281, pE1054; KIM KH, 1989, FASEB J, V3, P2250, DOI 10.1096/fasebj.3.11.2570725; Krauss S, 2005, NAT REV MOL CELL BIO, V6, P248, DOI 10.1038/nrm1592; Lanni A, 2003, FEBS LETT, V543, P5, DOI 10.1016/S0014-5793(03)00320-X; Lanni A, 2001, J ENDOCRINOL INVEST, V24, P897, DOI 10.1007/BF03343949; LANNI A, 1992, MOL CELL ENDOCRINOL, V86, P143, DOI 10.1016/0303-7207(92)90138-V; Lanni A, 1999, FEBS LETT, V444, P250, DOI 10.1016/S0014-5793(99)00061-7; Lanni A, 1996, J PHYSIOL-LONDON, V494, P831, DOI 10.1113/jphysiol.1996.sp021536; LAZAR MA, 1990, J CLIN INVEST, V86, P1777, DOI 10.1172/JCI114906; Lazar MA, 2003, J CLIN INVEST, V112, P497, DOI 10.1172/JCI200319479; Lombardi A, 1998, BIOCHEM J, V330, P521, DOI 10.1042/bj3300521; MCGARRY JD, 1983, BIOCHEM J, V214, P21, DOI 10.1042/bj2140021; Moreno M, 1997, J PHYSIOL-LONDON, V505, P529, DOI 10.1111/j.1469-7793.1997.529bb.x; Moreno M, 2002, ENDOCRINOLOGY, V143, P504, DOI 10.1210/en.143.2.504; MUNDAY MR, 1991, BIOCHEM J, V280, P733, DOI 10.1042/bj2800733; OH SS, 1994, P SOC EXP BIOL MED, V207, P260, DOI 10.3181/00379727-207-43814; OREILLY I, 1992, ACTA ENDOCRINOL-COP, V127, P542, DOI 10.1530/acta.0.1270542; Pearse AGE., 1980, HISTOCHEMISTRY THEOR; Pinna G, 1997, J CLIN ENDOCR METAB, V82, P1535, DOI 10.1210/jc.82.5.1535; PORTER RK, 1993, NATURE, V362, P628, DOI 10.1038/362628a0; Ramsey JJ, 2000, FREE RADICAL BIO MED, V29, P946, DOI 10.1016/S0891-5849(00)00417-2; Rousset S, 2004, DIABETES, V53, pS130, DOI 10.2337/diabetes.53.2007.S130; SADDIK M, 1993, J BIOL CHEM, V268, P25836; Shibusawa N, 2003, J CLIN INVEST, V112, P588, DOI 10.1172/JCI200318377; SOBOLL S, 1993, BIOCHIM BIOPHYS ACTA, V1144, P1, DOI 10.1016/0005-2728(93)90024-A; Tanabe T, 1981, Methods Enzymol, V71 Pt C, P5; Velasco G, 1998, J BIOL CHEM, V273, P21497, DOI 10.1074/jbc.273.34.21497; Velasco G, 1997, ARCH BIOCHEM BIOPHYS, V337, P169, DOI 10.1006/abbi.1996.9784; Young ME, 1996, FEBS LETT, V382, P43, DOI 10.1016/0014-5793(96)00129-9; Zammit VA, 1999, BIOCHEM J, V343, P505, DOI 10.1042/0264-6021:3430505; Zhang JS, 2000, ANNU REV PHYSIOL, V62, P439, DOI 10.1146/annurev.physiol.62.1.439	59	118	123	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2005	19	9								10.1096/fj.05.3977fje	http://dx.doi.org/10.1096/fj.05.3977fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	951IO	16014396				2022-12-25	WOS:000230923000024
J	Ellis, S; Mouihate, A; Pittman, QJ				Ellis, S; Mouihate, A; Pittman, QJ			Early life immune challenge alters innate immune responses to lipopolysaccharide: implications for host defense as adults	FASEB JOURNAL			English	Article						fever; cytokine; hypothalamic-pituitary-adrenal axis; neonate	PITUITARY-ADRENAL AXIS; FACTOR-KAPPA-B; MESSENGER-RNA; MATERNAL-CARE; LOCALIZED INFLAMMATION; FEVER; GLUCOCORTICOIDS; EXPRESSION; ENDOTOXIN; RECEPTOR	Fever is the most common manifestation of the innate immune response to invading pathogens. Animals prevented from developing fever have increased morbidity and mortality to infection. We now show that early life events can program this innate immune response, in that rats that have been challenged neonatally with the immune stimulant lipopolysaccharide (LPS) have both suppressed febrile responses to LPS as adults and significantly reduced nuclear factor (NF)-kappa B activation in peripheral immune organs. This was associated with reduced levels of proinflammatory cytokines tumor necrosis factor (TNF)-alpha, and interleukin-6 (IL- 6) in the plasma after adult LPS challenge, compared with animals that have received saline neonatally. In contrast, adult LPS challenge elicited higher corticosterone levels in the animals that had been treated neonatally with LPS. When this increased corticosterone response was negated by adrenalectomy or by administration of the glucocorticoid receptor antagonist RU-486, both the cytokine and febrile responses were normalized. This study indicates that the innate immune response can be programmed by a neonatal LPS challenge, whereby an amplified hypothalamic-pituitary-adrenal response causes reduced cytokine synthesis and an attenuated febrile response to an adult immune challenge. In light of the importance of fever in the host defense response, these alterations may have deleterious consequences on an individual's ability to combat disease later in life.	Univ Calgary, Fac Med, Hotchkiss Brain Inst, Dept Physiol & Biophys, Calgary, AB T2N 4N1, Canada	University of Calgary	Pittman, QJ (corresponding author), Univ Calgary, Fac Med, Hotchkiss Brain Inst, Dept Physiol & Biophys, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	pittman@ucalgary.ca		Pittman, Quentin/0000-0003-0984-7665				Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Almawi WY, 2002, J MOL ENDOCRINOL, V28, P69, DOI 10.1677/jme.0.0280069; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; BESEDOVSKY H, 1986, SCIENCE, V233, P652, DOI 10.1126/science.3014662; Bethin KE, 2000, P NATL ACAD SCI USA, V97, P9317, DOI 10.1073/pnas.97.16.9317; Blackwell TS, 1997, AM J RESP CELL MOL, V17, P3, DOI 10.1165/ajrcmb.17.1.f132; Blatteis CM, 2000, J PHYSIOL-LONDON, V526, P470; Blatteis CM, 1998, ANN NY ACAD SCI, V840, P608, DOI 10.1111/j.1749-6632.1998.tb09600.x; Boisse L, 2004, J NEUROSCI, V24, P4928, DOI 10.1523/JNEUROSCI.1077-04.2004; Bowie A, 2000, J LEUKOCYTE BIOL, V67, P508, DOI 10.1002/jlb.67.4.508; Caldji C, 2000, BIOL PSYCHIAT, V48, P1164, DOI 10.1016/S0006-3223(00)01084-2; Cartmell T, 2000, J PHYSIOL-LONDON, V526, P653, DOI 10.1111/j.1469-7793.2000.00653.x; Cartmell T, 2003, J PHYSIOL-LONDON, V549, P653, DOI 10.1113/jphysiol.2002.037291; Cartmell T, 2001, J PHYSIOL-LONDON, V531, P171, DOI 10.1111/j.1469-7793.2001.0171j.x; Chai Z, 1996, J EXP MED, V183, P311, DOI 10.1084/jem.183.1.311; CHROUSOS GP, 1995, NEW ENGL J MED, V332, P1351, DOI 10.1056/NEJM199505183322008; COELHO MM, 1995, AM J PHYSIOL-REG I, V269, pR527, DOI 10.1152/ajpregu.1995.269.3.R527; De Bosscher K, 2000, J NEUROIMMUNOL, V109, P16, DOI 10.1016/S0165-5728(00)00297-6; Hawiger J, 2001, IMMUNOL RES, V23, P99, DOI 10.1385/IR:23:2-3:099; JACOBSON L, 1988, ENDOCRINOLOGY, V122, P1343, DOI 10.1210/endo-122-4-1343; Jiang QQ, 2000, INFECT IMMUN, V68, P1265, DOI 10.1128/IAI.68.3.1265-1270.2000; Kakizaki Y, 1999, ENDOCR J, V46, P487, DOI 10.1507/endocrj.46.487; Kapcala LP, 1995, ANN NY ACAD SCI, V771, P419, DOI 10.1111/j.1749-6632.1995.tb44699.x; Kluger MJ, 1998, ANN NY ACAD SCI, V856, P224, DOI 10.1111/j.1749-6632.1998.tb08329.x; Kozak W, 1998, ANN NY ACAD SCI, V856, P33, DOI 10.1111/j.1749-6632.1998.tb08310.x; Ledeboer A, 2002, AM J PHYSIOL-REG I, V282, pR1762, DOI 10.1152/ajpregu.00766.2001; Leon LR, 1998, AM J PHYSIOL-REG I, V275, pR269, DOI 10.1152/ajpregu.1998.275.1.R269; Li ZH, 2004, J ENDOTOXIN RES, V10, P39, DOI 10.1179/096805104225003825; Liu D, 1997, SCIENCE, V277, P1659, DOI 10.1126/science.277.5332.1659; Macri S, 2004, EUR J NEUROSCI, V20, P1017, DOI 10.1111/j.1460-9568.2004.03541.x; MASFERRER JL, 1994, J PHARMACOL EXP THER, V270, P1340; MATHISON JC, 1979, J IMMUNOL, V123, P2133; McKay LI, 1999, ENDOCR REV, V20, P435, DOI 10.1210/er.20.4.435; McKay LI, 1998, MOL ENDOCRINOL, V12, P45, DOI 10.1210/mend.12.1.0044; MEANEY MJ, 1985, DEV BRAIN RES, V22, P301, DOI 10.1016/0165-3806(85)90183-X; Meltzer JC, 2003, BRAIN BEHAV IMMUN, V17, P482, DOI 10.1016/S0889-1591(03)00084-9; Mouihate A, 2003, ENDOCRINOLOGY, V144, P2454, DOI 10.1210/en.2002-0093; Nadeau S, 2003, J NEUROSCI, V23, P5536, DOI 10.1523/jneurosci.23-13-05536.2003; NEWMAN SP, 1994, BIOCHEM BIOPH RES CO, V202, P931, DOI 10.1006/bbrc.1994.2019; Nilsson C, 2002, EUR J ENDOCRINOL, V146, P251, DOI 10.1530/eje.0.1460251; PLOTSKY PM, 1993, MOL BRAIN RES, V18, P195, DOI 10.1016/0169-328X(93)90189-V; Quan N, 2000, J NEUROSCI, V20, P6473, DOI 10.1523/JNEUROSCI.20-17-06473.2000; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; RIVIER C, 1989, ENDOCRINOLOGY, V125, P2800, DOI 10.1210/endo-125-6-2800; ROTH J, 1993, AM J PHYSIOL, V265, pR653, DOI 10.1152/ajpregu.1993.265.3.R653; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; Scotte M, 1996, CYTOKINE, V8, P115, DOI 10.1006/cyto.1996.0016; SHANKS N, 1995, J NEUROSCI, V15, P376, DOI 10.1523/jneurosci.15-01-00376.1995; Shanks N, 2000, P NATL ACAD SCI USA, V97, P5645, DOI 10.1073/pnas.090571897; Tatro JB, 2000, CLIN INFECT DIS, V31, pS190, DOI 10.1086/317519; Turnbull AV, 1995, BRAIN BEHAV IMMUN, V9, P253, DOI 10.1006/brbi.1995.1026; Turrin NP, 2001, BRAIN RES BULL, V54, P443, DOI 10.1016/S0361-9230(01)00445-2; Weaver ICG, 2004, NAT NEUROSCI, V7, P847, DOI 10.1038/nn1276	53	89	90	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2005	19	8					1519	+		10.1096/fj.04-3569fje	http://dx.doi.org/10.1096/fj.04-3569fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	15972802				2022-12-25	WOS:000230207800009
J	Steinman, HA; Hoover, KM; Keeler, ML; Sands, AT; Jones, SN				Steinman, HA; Hoover, KM; Keeler, ML; Sands, AT; Jones, SN			Rescue of Mdm4-deficient mice by Mdm2 reveals functional overlap of Mdm2 and Mdm4 in development	ONCOGENE			English	Article						Mdm4; Mdm2; development; tumorigenesis	EMBRYONIC LETHALITY; GROWTH-CHARACTERISTICS; MDM2-DEFICIENT MICE; MDM4-NULL MICE; CELL-GROWTH; P53; APOPTOSIS; DELETION; ABSENCE; DEATH	The Mdm2 and Mdm4 genes are amplified and overexpressed in a variety of human cancers and encode structurally related oncoproteins that bind to the p53 tumor suppressor protein and inhibit p53 activity. Mice deleted for either Mdm2 or Mdm4 die during embryogenesis, and the developmental lethality of either mouse model can be rescued by concomitant deletion of p53. However, the phenotypes of Mdm2 and Mdm4-deficient mice suggest that Mdm2 and Mdm4 play nonoverlapping roles in regulating p53 activity during development, with Mdm2 regulating p53-mediated cell death and Mdm4 regulating p53-mediated inhibition of cell growth. Here, we describe complete rescue of Mdm4-deficient mice by expression of an Mdm2 transgene, and demonstrate that Mdm2 can regulate both p53-mediated apoptosis and inhibition of cell growth in the absence of Mdm4 in primary cells. Furthermore, deletion of Mdm4 enhances the ability of Mdm2 to promote cell growth and tumor formation, indicating that Mdm4 has antioncogenic properties when Mdm2 is overexpressed.	Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA; Univ Massachusetts, Sch Med, Dept Canc Biol, Worcester, MA 01655 USA; Lexicon Genet, The Woodlands, TX 77381 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; Lexicon Pharmaceuticals	Jones, SN (corresponding author), Univ Massachusetts, Sch Med, Dept Cell Biol, S3-123,55 Lake Ave N, Worcester, MA 01655 USA.	Stephen.jones@umassmed.edu			NATIONAL CANCER INSTITUTE [R56CA077735, R01CA077735] Funding Source: NIH RePORTER; NCI NIH HHS [CA77735] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Attardi LD, 2000, GENE DEV, V14, P704; Chavez-Reyes A, 2003, CANCER RES, V63, P8664; Danovi D, 2004, MOL CELL BIOL, V24, P5835, DOI 10.1128/MCB.24.13.5835-5843.2004; de Rozieres S, 2000, ONCOGENE, V19, P1691, DOI 10.1038/sj.onc.1203468; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Finch RA, 2002, CANCER RES, V62, P3221; Gu JJ, 2002, J BIOL CHEM, V277, P19251, DOI 10.1074/jbc.C200150200; HARVEY M, 1993, ONCOGENE, V8, P2457; Jackson MW, 2000, MOL CELL BIOL, V20, P1001, DOI 10.1128/MCB.20.3.1001-1007.2000; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Jones SN, 1996, P NATL ACAD SCI USA, V93, P14106, DOI 10.1073/pnas.93.24.14106; Jones SN, 1998, P NATL ACAD SCI USA, V95, P15608, DOI 10.1073/pnas.95.26.15608; LUNA RMD, 1995, NATURE, V378, P203; Luna RMD, 1997, NAT GENET, V16, P336; Mancini F, 2004, J BIOL CHEM, V279, P8169, DOI 10.1074/jbc.M311793200; Michael D, 2002, CURR OPIN GENET DEV, V12, P53, DOI 10.1016/S0959-437X(01)00264-7; Migliorini D, 2002, MOL CELL BIOL, V22, P5527, DOI 10.1128/MCB.22.15.5527-5538.2002; OLINER JD, 1992, NATURE, V358, P15; Parant J, 2001, NAT GENET, V29, P92, DOI 10.1038/ng714; Sharp DA, 1999, J BIOL CHEM, V274, P38189, DOI 10.1074/jbc.274.53.38189; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; Stad R, 2000, J BIOL CHEM, V275, P28039; Stad R, 2001, EMBO REP, V2, P1029, DOI 10.1093/embo-reports/kve227; Steinman HA, 2004, ONCOGENE, V23, P303, DOI 10.1038/sj.onc.1206925; Steinman HA, 2002, GENESIS, V32, P142, DOI 10.1002/gene.10035; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Woods DB, 2001, EXP CELL RES, V264, P56, DOI 10.1006/excr.2000.5141	27	32	32	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2005	24	53					7935	7940		10.1038/sj.onc.1208930	http://dx.doi.org/10.1038/sj.onc.1208930			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	986PU	16027727				2022-12-25	WOS:000233463000012
J	Ito, H; Iwamoto, I; Morishita, R; Nozawa, Y; Narumiya, S; Asano, T; Nagata, KI				Ito, H; Iwamoto, I; Morishita, R; Nozawa, Y; Narumiya, S; Asano, T; Nagata, KI			Possible role of Rho/Rhotekin signaling in mammalian septin organization	ONCOGENE			English	Article						septin; Sept9; Rho; Rhotekin; actin	NUCLEOTIDE EXCHANGE FACTOR; RHO-GTPASES; FAMILY; PROTEINS; CELLS	There is growing evidence for crosstalk between septin. laments and actin cytoskeleton which is regulated by Rho family of GTPases. Here we show that active Rho disrupts septin filament structures in rat embryonic fibroblast REF52 cells. Among Rho effector molecules tested, Rhotekin induced morphological changes of septin. laments similar to those by activated Rho. The center region of Rhotekin was sufficient for the septin reorganization in the cells, and likely to interact indirectly with the C-terminal half of a septin Sept9b, where a GTPase domain is located. Rhotekin and Sept9b are colocalized mainly in perinuclear regions in serum-starved REF52 cells. Upon stimulation with lysophosphatidic acid, they translocated to actin stress fibers in 10 min and then redistributed again to cytoplasm after 90 min treatment. In neuroblastoma Neuro2a cells, Rhotekin and Sept9b were enriched in the tip of neurites, a location where cortical actin reorganization is induced upon stimulation with lysophosphatidic acid. Taken together, we propose that Rhotekin is a novel regulator organizing mammalian septin structures and provide a new link between the septin and Rho-signaling.	Aichi Human Serv Ctr, Dept Mol Neurobiol, Inst Dev Res, Kamiya, Kasugai 4800392, Japan; Gifu Int Inst Biotechnol, Gifu 5040838, Japan; Kyoto Univ, Fac Med, Dept Pharmacol, Sakyo Ku, Kyoto 6068501, Japan	Kyoto University	Nagata, KI (corresponding author), Aichi Human Serv Ctr, Dept Mol Neurobiol, Inst Dev Res, Kamiya, Kasugai 4800392, Japan.	knagata@inst-hsc.jp		Ito, Hidenori/0000-0002-6527-477X				Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Faty M, 2002, CURR GENET, V41, P123, DOI 10.1007/s00294-002-0304-0; Goetzl EJ, 1998, FASEB J, V12, P1589, DOI 10.1096/fasebj.12.15.1589; Govek EE, 2005, GENE DEV, V19, P1, DOI 10.1101/gad.1256405; Hall PA, 2004, J PATHOL, V204, P489, DOI 10.1002/path.1654; Jaffe AB, 2002, ADV CANCER RES, V84, P57, DOI 10.1016/S0065-230X(02)84003-9; Joberty G, 1999, MOL CELL BIOL, V19, P6585; Joberty G, 2001, NAT CELL BIOL, V3, P861, DOI 10.1038/ncb1001-861; Kartmann B, 2001, J CELL SCI, V114, P839; Kinoshita M, 2003, J BIOCHEM, V134, P491, DOI 10.1093/jb/mvg182; Kinoshita M, 2002, DEV CELL, V3, P791, DOI 10.1016/S1534-5807(02)00366-0; Nagata K, 2004, J BIOL CHEM, V279, P55895, DOI 10.1074/jbc.M406153200; Nagata K, 2003, J BIOL CHEM, V278, P18538, DOI 10.1074/jbc.M205246200; Nagata KI, 2005, ONCOGENE, V24, P65, DOI 10.1038/sj.onc.1208101; Nakano K, 1999, MOL BIOL CELL, V10, P2481, DOI 10.1091/mbc.10.8.2481; Reid T, 1996, J BIOL CHEM, V271, P13556, DOI 10.1074/jbc.271.23.13556; Sheffield PJ, 2003, J BIOL CHEM, V278, P3483, DOI 10.1074/jbc.M209701200; Togashi H, 2000, J BIOL CHEM, V275, P29570, DOI 10.1074/jbc.M003726200; Trimble WS, 1999, J MEMBRANE BIOL, V169, P75, DOI 10.1007/s002329900519	19	49	54	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 27	2005	24	47					7064	7072		10.1038/sj.onc.1208862	http://dx.doi.org/10.1038/sj.onc.1208862			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	977WC	16007136				2022-12-25	WOS:000232833200008
J	Malchinkhuu, E; Sato, K; Horiuchi, Y; Mogi, C; Ohwada, S; Ishiuchi, S; Saito, N; Kurose, H; Tomura, H; Okajima, F				Malchinkhuu, E; Sato, K; Horiuchi, Y; Mogi, C; Ohwada, S; Ishiuchi, S; Saito, N; Kurose, H; Tomura, H; Okajima, F			Role of p38 mitogen-activated kinase and c-Jun terminal kinase in migration response to lysophosphatidic acid and sphingosine-1-phosphate in glioma cells	ONCOGENE			English	Article						glioma; cell migration; lysophosphatidic acid; sphingosine-1-phosphate; MAP kinase	GROWTH-FACTOR RECEPTOR; PROTEIN-COUPLED RECEPTOR; SPHINGOSINE 1-PHOSPHATE; CANCER CELLS; ACTIN REORGANIZATION; STIMULATES MOTILITY; LYSOPHOSPHOLIPASE-D; GLIOBLASTOMA CELLS; RAC ACTIVATION; MAP KINASE	A potential role for 1-oleoyl-sn-glycero-3-phosphate or lysophosphatidic acid (LPA) and sphingosine-1-phosphate (S1P) in the regulation of malignant diseases has been widely considered. In this study, we found that in transformed astroglial cells, the expression pro. le of lysophospholipid receptor mRNA and the action modes of LPA and S1P on cell motility were changed: there was a change in the acquisition of the ability of LPA to stimulate cell migration and a change in the migratory response to S1P from stimulation through S1P(1) to inhibition through S1P(2). LPA-induced cell migration was almost completely inhibited by either pertussis toxin, LPA(1) receptor antagonists including Ki16425(3(4[4([1(2chlorophenyl)ethoxy]carbonyl amino)-3-methyl-5-isoxazolyl] benzylsulfonyl) propanoic acid) or an inhibitor of phosphatidylinositol 3- kinase (PI3K) wortmannin. The LPA-induced action was also suppressed, although incompletely, by several specific inhibitors for intracellular signaling pathways including Rac1, Cdc42, p38 mitogen-activated protein kinase (p38MAPK) and c-Jun terminal kinase (JNK), but not extracellular signal-regulated kinase. Nearly complete inhibition of migration response to LPA, however, required simultaneous inhibition of both the p38MAPK and JNK pathways. Inhibition of Rac1 suppressed JNK but not p38MAPK, while the activity of p38MAPK was abolished by a dominant-negative form of Cdc42. These findings suggest that, in glioma cells, the PI3K/Cdc42/p38MAPK and PI3K/Rac1/JNK pathways are equally important for LPA1 receptor-mediated migration.	Gunma Univ, Inst Mol & Cellular Regulat, Lab Signal Transduct, Maebashi, Gumma 3718512, Japan; Gunma Univ, Grad Sch Med, Maebashi, Gumma 3718511, Japan; Gunma Univ, Grad Sch Med, Dept Neurosurg, Maebashi, Gumma 3718511, Japan; Kyushu Univ, Grad Sch Pharmaceut Sci, Dept Pharmacol & Toxicol, Fukuoka 8128582, Japan	Gunma University; Gunma University; Gunma University; Kyushu University	Sato, K (corresponding author), Gunma Univ, Inst Mol & Cellular Regulat, Lab Signal Transduct, 3-39-15 Showa Machi, Maebashi, Gumma 3718512, Japan.	kosato@showa.gunma-u.ac.jp	Malchinkhuu, Enkhzol/AAH-4600-2019	Sato, Koichi/0000-0001-7694-4014; Malchinkhuu, Enkhzol/0000-0003-0744-079X				Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bian DF, 2004, CANCER RES, V64, P4209, DOI 10.1158/0008-5472.CAN-04-0060; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Cara DC, 2001, J IMMUNOL, V167, P6552, DOI 10.4049/jimmunol.167.11.6552; Chandrasekar N, 2003, ONCOGENE, V22, P392, DOI 10.1038/sj.onc.1206164; Cunnick JM, 1998, J BIOL CHEM, V273, P14468, DOI 10.1074/jbc.273.23.14468; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Edlund S, 2002, MOL BIOL CELL, V13, P902, DOI 10.1091/mbc.01-08-0398; Fischer DJ, 2001, MOL PHARMACOL, V60, P776; Gschwind A, 2002, CANCER RES, V62, P6329; Hama K, 2004, J BIOL CHEM, V279, P17634, DOI 10.1074/jbc.M313927200; Heise CE, 2001, MOL PHARMACOL, V60, P1173, DOI 10.1124/mol.60.6.1173; Hsia DA, 2003, J CELL BIOL, V160, P753, DOI 10.1083/jcb.200212114; Huang C, 2003, NATURE, V424, P219, DOI 10.1038/nature01745; IMAMURA F, 1993, BIOCHEM BIOPH RES CO, V193, P497, DOI 10.1006/bbrc.1993.1651; Ishiuchi S, 2002, NAT MED, V8, P971, DOI 10.1038/nm746; Ishizuka T, 2001, J IMMUNOL, V167, P2298, DOI 10.4049/jimmunol.167.4.2298; Kawauchi T, 2003, EMBO J, V22, P4190, DOI 10.1093/emboj/cdg413; Kimura T, 2003, ARTERIOSCL THROM VAS, V23, P1283, DOI 10.1161/01.ATV.0000079011.67194.5A; Kon J, 1999, J BIOL CHEM, V274, P23940, DOI 10.1074/jbc.274.34.23940; Lamalice L, 2004, ONCOGENE, V23, P434, DOI 10.1038/sj.onc.1207034; Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905; Malchinkhuu E, 2003, BIOCHEM J, V370, P817, DOI 10.1042/BJ20020867; Manning TJ, 2000, CELL MOTIL CYTOSKEL, V45, P185, DOI 10.1002/(SICI)1097-0169(200003)45:3<185::AID-CM2>3.0.CO;2-G; Maruyama Y, 2002, CIRC RES, V91, P961, DOI 10.1161/01.RES.0000043282.39776.7C; Matsumoto T, 1999, J BIOL CHEM, V274, P13954, DOI 10.1074/jbc.274.20.13954; Mills GB, 2003, NAT REV CANCER, V3, P582, DOI 10.1038/nrc1143; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Ohta H, 2003, MOL PHARMACOL, V64, P994, DOI 10.1124/mol.64.4.994; Okamoto H, 2000, MOL CELL BIOL, V20, P9247, DOI 10.1128/MCB.20.24.9247-9261.2000; Pebay A, 2001, EUR J NEUROSCI, V13, P2067, DOI 10.1046/j.0953-816x.2001.01585.x; Pichon S, 2004, J CELL SCI, V117, P2569, DOI 10.1242/jcs.01110; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Rao TS, 2003, BRAIN RES, V990, P182, DOI 10.1016/S0006-8993(03)03527-3; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; Sato K, 1999, MOL PHARMACOL, V55, P126, DOI 10.1124/mol.55.1.126; Sato K, 2000, MOL BRAIN RES, V85, P151, DOI 10.1016/S0169-328X(00)00262-X; Sato K, 1999, MOL BRAIN RES, V74, P182, DOI 10.1016/S0169-328X(99)00279-X; Schafer B, 2004, ONCOGENE, V23, P991, DOI 10.1038/sj.onc.1207278; Schulte KM, 2001, INT J CANCER, V92, P249, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1166>3.0.CO;2-D; Shi GX, 2003, J IMMUNOL, V171, P3407, DOI 10.4049/jimmunol.171.7.3407; Stahle M, 2003, J CELL SCI, V116, P3835, DOI 10.1242/jcs.00679; Stam JC, 1998, EMBO J, V17, P4066, DOI 10.1093/emboj/17.14.4066; Steiner MR, 2002, BBA-MOL CELL BIOL L, V1582, P154, DOI 10.1016/S1388-1981(02)00150-6; Tokumura A, 2002, J BIOL CHEM, V277, P39436, DOI 10.1074/jbc.M205623200; Umezu-Goto M, 2002, J CELL BIOL, V158, P227, DOI 10.1083/jcb.200204026; Van Brocklyn JR, 2003, CANCER LETT, V199, P53, DOI 10.1016/S0304-3835(03)00334-3; van Leeuwen FN, 2003, J BIOL CHEM, V278, P400, DOI 10.1074/jbc.M210151200; VANDENBERG SR, 1992, J NEUROPATH EXP NEUR, V51, P644, DOI 10.1097/00005072-199211000-00008; Wang F, 1999, J BIOL CHEM, V274, P35343, DOI 10.1074/jbc.274.50.35343; Westermann AM, 1998, ANN ONCOL, V9, P437, DOI 10.1023/A:1008217129273; Xia Y, 2000, P NATL ACAD SCI USA, V97, P5243, DOI 10.1073/pnas.97.10.5243; Xie YH, 2002, J BIOL CHEM, V277, P32516, DOI 10.1074/jbc.M203864200; XU Y, 1995, BIOCHEM J, V309, P933, DOI 10.1042/bj3090933; Yamada T, 2004, J BIOL CHEM, V279, P6595, DOI 10.1074/jbc.M308133200	55	68	79	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 6	2005	24	44					6676	6688		10.1038/sj.onc.1208805	http://dx.doi.org/10.1038/sj.onc.1208805			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	971FL	16007180				2022-12-25	WOS:000232367800009
J	Dentelli, P; Rosso, A; Garbarino, G; Calvi, C; Lombard, E; Di Stefano, P; Defilippi, P; Pegoraro, L; Brizzi, MF				Dentelli, P; Rosso, A; Garbarino, G; Calvi, C; Lombard, E; Di Stefano, P; Defilippi, P; Pegoraro, L; Brizzi, MF			The interaction between KDR and interleukin-3 receptor (IL-3R) beta common modulates tumor neovascularization	ONCOGENE			English	Article						interleukin-3; vascular endothelial growth factor; endothelial cells; cancer; angiogenesis	ENDOTHELIAL GROWTH-FACTOR; COLONY-STIMULATING FACTOR; GM-CSF; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; VESSEL FORMATION; POTENTIAL ROLE; BREAST-CANCER; CELL MOTILITY; RHO GTPASES	As vascular endothelial growth factor (VEGF), interleukin-3 (IL-3), released into the tumor microenvironment stimulates motogenic and mitogenic activity of normal and transformed cells. In the present study, we investigate the effects of IL-3 and VEGF on neoplastic vascular growth. Engagement of IL-3 receptor beta common (IL-3R beta c) contributes to both IL-3- and VEGF-induced Rac1 activation, cell migration and in vitro tube-like structure formation as shown by the expression of the dominant-negative IL-3R beta c construct (Delta 455). In normal and transformed endothelial cells (EC) as well as in HEK 293 cells expressing KDR and IL-3R, VEGF and IL-3 treatment induces the formation of a KDR/IL-3R beta c complex. Moreover, as shown by the IL-3R Delta 455 mutant or by the kinase dead KDR, functional receptors are required for this interaction. Consistent with the contribution of IL-3R beta c in both IL-3- and VEGF-mediated angiogenic signal, a reduced number of vessels inside tumors are found in mice injected with cells expressing the IL-3R Delta 455 mutant. Thus, these findings provide a novel mechanism through which IL-3 and VEGF support cell survival and tumor neovascularization.	Univ Turin, Dept Internal Med, I-10126 Turin, Italy; Univ Turin, Dept Genet Biol & Biochem, I-10126 Turin, Italy	University of Turin; University of Turin	Brizzi, MF (corresponding author), Univ Turin, Dept Internal Med, Corso Dogliotti 14, I-10126 Turin, Italy.	mariafelice.brizzi@unito.it	DEFILIPPI, Paola/L-2232-2014; Brizzi, Maria Felice/J-7882-2016	Defilippi, Paola/0000-0001-6427-4906				Aronica MG, 1996, ONCOGENE, V13, P1017; Bachelder RE, 2001, CANCER RES, V61, P5736; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Bartoli M, 2000, J BIOL CHEM, V275, P33189, DOI 10.1074/jbc.C000318200; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Benitah SA, 2003, MOL BIOL CELL, V14, P40, DOI 10.1091/mbc.E02-08-0454; Biancone L, 1999, J IMMUNOL, V162, P5263; BOWMAN S, 1990, Technique (Philadelphia), V2, P254; BRIZZI MF, 1994, J BIOL CHEM, V269, P31680; BRIZZI MF, 1993, J CLIN INVEST, V91, P2887, DOI 10.1172/JCI116534; Brizzi MF, 2001, CIRCULATION, V103, P549, DOI 10.1161/01.CIR.103.4.549; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Bussolati B, 2003, FASEB J, V17, P1159, DOI 10.1096/fj.02-0557fje; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; Dentelli P, 2004, ONCOGENE, V23, P1681, DOI 10.1038/sj.onc.1207290; Dentelli P, 1999, J IMMUNOL, V163, P2151; Deregibus MC, 2002, J BIOL CHEM, V277, P25195, DOI 10.1074/jbc.M200921200; Dougher M, 1999, ONCOGENE, V18, P1619, DOI 10.1038/sj.onc.1202478; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Groner B, 2000, GROWTH HORM IGF RES, V10, P15, DOI 10.1016/S1096-6374(00)80004-0; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; Huang JZ, 2003, P NATL ACAD SCI USA, V100, P7785, DOI 10.1073/pnas.1432908100; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Kerbel RS, 2001, CANCER METAST REV, V20, P79, DOI 10.1023/A:1013172910858; Kerbel RS, 2001, J CLIN ONCOL, V19, p45S; KIBBEY MC, 1992, J NATL CANCER I, V84, P1633, DOI 10.1093/jnci/84.21.1633; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; Konecny G, 2001, CLIN CANCER RES, V7, P2448; Korpelainen EI, 1999, ONCOGENE, V18, P1, DOI 10.1038/sj.onc.1202288; Liu W, 2000, APOPTOSIS, V5, P323, DOI 10.1023/A:1009679307513; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; Rafii S, 2002, NAT REV CANCER, V2, P826, DOI 10.1038/nrc925; Reddy EP, 2000, ONCOGENE, V19, P2532, DOI 10.1038/sj.onc.1203594; Ridley AJ, 2001, J CELL SCI, V114, P2713; Rofstad EK, 2000, CANCER RES, V60, P4932; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; Tanimoto T, 2002, J BIOL CHEM, V277, P42997, DOI 10.1074/jbc.M204764200; TERMAN BI, 1991, ONCOGENE, V6, P1677; Thuringer D, 2002, J BIOL CHEM, V277, P2028, DOI 10.1074/jbc.M109493200; van Golen KL, 2003, BREAST CANCER RES, V5, P174, DOI 10.1186/bcr598; WIMPERIS JZ, 1989, BLOOD, V74, P1525; Yamashita H, 1998, J BIOL CHEM, V273, P30218, DOI 10.1074/jbc.273.46.30218; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; Zachary I, 2001, CARDIOVASC RES, V49, P568, DOI 10.1016/S0008-6363(00)00268-6	53	11	11	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 22	2005	24	42					6394	6405		10.1038/sj.onc.1208786	http://dx.doi.org/10.1038/sj.onc.1208786			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	966RI	16007196				2022-12-25	WOS:000232038200007
J	Isabel, MPV; Hume, RI; Krejci, E; Akaaboune, M				Isabel, MPV; Hume, RI; Krejci, E; Akaaboune, M			In vivo regulation of acetylcholinesterase insertion at the neuromuscular junction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN SKELETAL-MUSCLE; CRYSTAL-STRUCTURE; METABOLIC STABILIZATION; CIRCULATORY RESIDENCE; ALPHA-BUNGAROTOXIN; PERIPHERAL SITE; TAIL SUBUNIT; FASCICULIN 2; LIVING MICE; RECEPTOR	The efficiency of synaptic transmission between nerve and muscle depends on the number and density of acetylcholinesterase molecules ( AChE) at the neuromuscular junction. However, little is known about the way this density is maintained and regulated in vivo. By using time lapse and quantitative fluorescence imaging assays in living mice, we demonstrated that insertion of new AChEs occurs within hours of saturating pre-existing AChEs with fasciculin2, a snake toxin that selectively labels AChE. In the absence of muscle postsynaptic activity or evoked nerve presynaptic neurotransmitter release, AChE insertion was decreased significantly, whereas direct stimulation of the muscle completely restored AChE insertion to control levels. This activity-dependent AChE insertion is mediated by intracellular calcium. In muscle stimulated in the presence of a Ca2+ channel blocker or calcium-permeable Ca2+ chelator, AChE insertion into synapses was significantly decreased, whereas ryanodine or ionophore A12387 treatment of blocked and unstimulated synapses significantly increased AChE insertion. These results demonstrated that synaptic activity is critical for AChE insertion and indicated that a rise in intracellular calcium either through voltage-gated calcium channels or from intracellular stores is critical for proper AChE insertion into the adult synapse.	Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA; Univ Paris 05, UFR Biomed, INSERM U686 Biol Jonct Neuromusculaires, F-75006 Paris, France	University of Michigan System; University of Michigan; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Akaaboune, M (corresponding author), Univ Michigan, Dept Mol Cellular & Dev Biol, 830 N Univ Ave, Ann Arbor, MI 48109 USA.	makaabou@umich.edu	Martinez-Pena y Valenzuela, Isabel/AAI-9845-2020; , Richard/AAI-5000-2020	Hume, Richard/0000-0001-9807-112X; , Isabel/0000-0002-2196-9297	NINDS NIH HHS [NS047332] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS047332] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Akaaboune M, 1999, SCIENCE, V286, P503, DOI 10.1126/science.286.5439.503; ANDREOSE JS, 1993, J NEUROSCI, V13, P3433; Anglister L, 1998, J NEUROSCI METH, V81, P63, DOI 10.1016/S0165-0270(98)00015-6; ANGLISTER L, 1994, NEURON, V12, P783, DOI 10.1016/0896-6273(94)90331-X; Arikawa-Hirasawa E, 2002, NAT NEUROSCI, V5, P119, DOI 10.1038/nn801; BARNARD EA, 1971, NATURE, V234, P207, DOI 10.1038/234207a0; BEAM KG, 1988, J GEN PHYSIOL, V91, P781, DOI 10.1085/jgp.91.6.781; BETZ H, 1981, EUR J BIOCHEM, V117, P131; Borges LS, 2002, J NEUROBIOL, V50, P69, DOI 10.1002/neu.10020; BOURNE Y, 1995, CELL, V83, P503, DOI 10.1016/0092-8674(95)90128-0; CARONI P, 1993, J NEUROSCI, V13, P1315; Cartaud A, 2004, J CELL BIOL, V165, P505, DOI 10.1083/jcb.200307164; Chitlaru T, 2002, BIOCHEM J, V363, P619, DOI 10.1042/0264-6021:3630619; Chitlaru T, 2001, BIOCHEM J, V354, P613, DOI 10.1042/0264-6021:3540613; COGNARD C, 1986, P NATL ACAD SCI USA, V83, P517, DOI 10.1073/pnas.83.2.517; CRUZ LJ, 1985, J BIOL CHEM, V260, P9280; DARVENIZA P, 1979, BIOCHEM J, V181, P545, DOI 10.1042/bj1810545; DELAPORTE S, 1984, DEV BIOL, V106, P450, DOI 10.1016/0012-1606(84)90244-6; Deprez P, 2003, J BIOL CHEM, V278, P23233, DOI 10.1074/jbc.M301384200; DMYTRENKO GM, 1993, EXP CELL RES, V206, P323, DOI 10.1006/excr.1993.1153; EASTMAN J, 1995, J BIOL CHEM, V270, P19694, DOI 10.1074/jbc.270.34.19694; FAIRHURST AS, 1973, BIOCHEM PHARMACOL, V22, P2815, DOI 10.1016/0006-2952(73)90148-2; FAIRHURST AS, 1974, AM J PHYSIOL, V227, P1124, DOI 10.1152/ajplegacy.1974.227.5.1124; Feng GP, 1999, J CELL BIOL, V144, P1349, DOI 10.1083/jcb.144.6.1349; Harel M, 1995, STRUCTURE, V3, P1355, DOI 10.1016/S0969-2126(01)00273-8; JENDEN DJ, 1969, PHARMACOL REV, V21, P1; KARLSSON E, 1984, J PHYSIOLOGY PARIS, V79, P232; KASPRZAK H, 1985, J NEUROSCI, V5, P951; KATZ B, 1973, J PHYSIOL-LONDON, V231, P549, DOI 10.1113/jphysiol.1973.sp010248; LEONARD JP, 1979, J CELL BIOL, V82, P811, DOI 10.1083/jcb.82.3.811; LICHTMAN JW, 1987, J NEUROSCI, V7, P1215; LOMO T, 1980, J PHYSIOL-LONDON, V303, P173, DOI 10.1113/jphysiol.1980.sp013279; Marchot P, 1998, TOXICON, V36, P1613, DOI 10.1016/S0041-0101(98)00154-8; MARCHOT P, 1993, J BIOL CHEM, V268, P12458; MCCLESKEY EW, 1985, J PHYSIOL-LONDON, V361, P231, DOI 10.1113/jphysiol.1985.sp015643; MCMANAMAN JL, 1981, J NEUROSCI, V1, P771, DOI 10.1523/JNEUROSCI.01-07-00771.1981; Megeath LJ, 1998, J NEUROSCI, V18, P672; MEISSNER G, 1986, J BIOL CHEM, V261, P6300; Ohno K, 1998, P NATL ACAD SCI USA, V95, P9654, DOI 10.1073/pnas.95.16.9654; OMalley JP, 1997, J CELL BIOL, V138, P159, DOI 10.1083/jcb.138.1.159; Peng HB, 1999, J CELL BIOL, V145, P911, DOI 10.1083/jcb.145.4.911; RADIC Z, 1994, J BIOL CHEM, V269, P11233; RADIC Z, 1995, J BIOL CHEM, V270, P20391, DOI 10.1074/jbc.270.35.20391; Radic Z, 1997, J BIOL CHEM, V272, P23265, DOI 10.1074/jbc.272.37.23265; Radic Z, 2001, J BIOL CHEM, V276, P4622, DOI 10.1074/jbc.M006855200; ROGERS AW, 1969, J CELL BIOL, V41, P665, DOI 10.1083/jcb.41.3.665; Rosenberry TL, 1996, BIOCHEMISTRY-US, V35, P685, DOI 10.1021/bi952431d; Rotundo RL, 1997, J CELL BIOL, V136, P367, DOI 10.1083/jcb.136.2.367; ROTZLER S, 1991, NATURE, V349, P337, DOI 10.1038/349337a0; RUBIN LL, 1980, NATURE, V283, P264, DOI 10.1038/283264a0; SALPETER MM, 1972, J HISTOCHEM CYTOCHEM, V20, P1059, DOI 10.1177/20.12.1059; SALPETER MM, 1979, J NEUROCYTOL, V8, P95, DOI 10.1007/BF01206461; Sanes JR, 2001, NAT REV NEUROSCI, V2, P791, DOI 10.1038/35097557; Sanes JR, 1999, ANNU REV NEUROSCI, V22, P389, DOI 10.1146/annurev.neuro.22.1.389; Soreq H, 2001, NAT REV NEUROSCI, V2, P294, DOI 10.1038/35067589; Turney SG, 1996, J NEUROSCI METH, V64, P199, DOI 10.1016/0165-0270(95)00135-2; VANMIER P, 1994, J NEUROSCI, V14, P5672; WALLACE BG, 1988, J CELL BIOL, V107, P267, DOI 10.1083/jcb.107.1.267; WECKER L, 1986, FUND APPL TOXICOL, V6, P172, DOI 10.1016/0272-0590(86)90273-3; WEINBERG CB, 1979, DEV BIOL, V68, P631, DOI 10.1016/0012-1606(79)90233-1	60	5	6	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	2005	280	36					31801	31808		10.1074/jbc.M502874200	http://dx.doi.org/10.1074/jbc.M502874200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	961LZ	15998641	hybrid			2022-12-25	WOS:000231665200059
J	Bergeron, S; Madathiparambil, T; Swanson, PC				Bergeron, S; Madathiparambil, T; Swanson, PC			Both high mobility group (HMG)-boxes and the acidic tail of HMGB1 regulate recombination-activating gene (RAG)-mediated recombination signal synapsis and cleavage in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROPERTIES; V(D)J RECOMBINATION; PROTEIN HMGB1; BOX DOMAINS; COMPLEXES; RAG-1; HMG-1; TRANSPOSITION; TRANSCRIPTION; RECOGNITION	RAG-1 and RAG-2 initiate V(D) J recombination through synapsis and cleavage of a 12/23 pair of V( D) J recombination signal sequences (RSS). RAG-RSS complex assembly and activity in vitro is promoted by high mobility group proteins of the "HMG-box" family, exemplified by HMGB1. How HMGB1 stimulates the DNA binding and cleavage activity of the RAG complex remains unclear. HMGB1 contains two homologous HMG-box DNA binding domains, termed A and B, linked by a stretch of basic residues to a highly acidic C-terminal tail. To identify determinants of HMGB1 required for stimulation of RAG-mediated RSS binding and cleavage, we prepared an extensive panel of mutant HMGB1 proteins and tested their ability to augment RAG-mediated RSS binding and cleavage activity. Using a combination of mobility shift and in-gel cleavage assays, we find that HMGB1 promotes RAG-mediated cleavage largely through the activity of box B, but optimal stimulation requires a functional A box tethered in the correct orientation. Box A or B mutants fail to promote RAG synaptic complex formation, but this defect is alleviated when the acidic tail is removed from these mutants.	Creighton Univ, Med Ctr, Dept Med Microbiol & Immunol, Omaha, NE 68178 USA	Creighton University	Swanson, PC (corresponding author), Creighton Univ, Med Ctr, Dept Med Microbiol & Immunol, 2500 Calif Plaza, Omaha, NE 68178 USA.	pswanson@creighton.edu			NCRR NIH HHS [P20 RR016469, C06 RR017417] Funding Source: Medline; NIAID NIH HHS [R01 AI055599-01, R01 AI055599] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [C06RR017417, P20RR016469] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI055599] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aidinis V, 1999, MOL CELL BIOL, V19, P6532; Bassing CH, 2002, CELL, V109, pS45, DOI 10.1016/S0092-8674(02)00675-X; Baumann M, 2003, EMBO J, V22, P5197, DOI 10.1093/emboj/cdg487; Bonaldi T, 2002, EMBO J, V21, P6865, DOI 10.1093/emboj/cdf692; Boonyaratanakornkit V, 1998, MOL CELL BIOL, V18, P4471, DOI 10.1128/MCB.18.8.4471; Bustin M, 1999, MOL CELL BIOL, V19, P5237; Costello E, 1997, EMBO J, V16, P5943, DOI 10.1093/emboj/16.19.5943; Ellwood KB, 2000, MOL CELL BIOL, V20, P4359, DOI 10.1128/MCB.20.12.4359-4370.2000; GE H, 1994, J BIOL CHEM, V269, P17136; Jayaraman L, 1998, GENE DEV, V12, P462, DOI 10.1101/gad.12.4.462; Kasparkova J, 2003, BIOCHEMISTRY-US, V42, P1234, DOI 10.1021/bi026695t; Knapp S, 2004, BIOCHEMISTRY-US, V43, P11992, DOI 10.1021/bi049364k; Kwon J, 1998, MOL CELL, V2, P829, DOI 10.1016/S1097-2765(00)80297-X; Lee KB, 2000, J MOL BIOL, V304, P135, DOI 10.1006/jmbi.2000.4206; Li WH, 1997, MOL CELL BIOL, V17, P6932, DOI 10.1128/MCB.17.12.6932; Ma YM, 2002, CELL, V108, P781, DOI 10.1016/S0092-8674(02)00671-2; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; Mitsouras K, 2002, MOL CELL BIOL, V22, P4390, DOI 10.1128/MCB.22.12.4390-4401.2002; Mo XM, 2000, NUCLEIC ACIDS RES, V28, P1228, DOI 10.1093/nar/28.5.1228; ONATE SA, 1994, MOL CELL BIOL, V14, P3376, DOI 10.1128/MCB.14.5.3376; Ramstein J, 1999, EUR J BIOCHEM, V260, P692, DOI 10.1046/j.1432-1327.1999.00185.x; ROTH DB, 1992, CELL, V70, P983, DOI 10.1016/0092-8674(92)90248-B; ROTH DB, 1993, P NATL ACAD SCI USA, V90, P10788, DOI 10.1073/pnas.90.22.10788; SCHLISSEL M, 1993, GENE DEV, V7, P2520, DOI 10.1101/gad.7.12b.2520; Stros M, 1998, J BIOL CHEM, V273, P10355; Stros M, 2000, J BIOL CHEM, V275, P35699, DOI 10.1074/jbc.M007167200; Swanson PC, 2004, IMMUNOL REV, V200, P90, DOI 10.1111/j.0105-2896.2004.00159.x; Swanson PC, 2004, J BIOL CHEM, V279, P4034, DOI 10.1074/jbc.M311100200; Swanson PC, 2002, MOL CELL BIOL, V22, P7790, DOI 10.1128/MCB.22.22.7790-7801.2002; Swanson PC, 2002, MOL CELL BIOL, V22, P1340, DOI 10.1128/MCB.22.5.1340-1351.2002; Swanson PC, 1999, MOL CELL BIOL, V19, P3674; Swanson PC, 1998, IMMUNITY, V9, P115, DOI 10.1016/S1074-7613(00)80593-2; Swanson PC, 2001, MOL CELL BIOL, V21, P449, DOI 10.1128/MCB.21.2.449-458.2001; TEO SH, 1995, EUR J BIOCHEM, V230, P943, DOI 10.1111/j.1432-1033.1995.tb20640.x; Thomas JO, 2001, TRENDS BIOCHEM SCI, V26, P167, DOI 10.1016/S0968-0004(01)01801-1; Ueda T, 2004, BIOCHEMISTRY-US, V43, P9901, DOI 10.1021/bi035975l; vanGent DC, 1997, EMBO J, V16, P2665, DOI 10.1093/emboj/16.10.2665; vanGent DC, 1996, SCIENCE, V271, P1592, DOI 10.1126/science.271.5255.1592; Webb M, 1999, J MOL BIOL, V294, P373, DOI 10.1006/jmbi.1999.3150; Zayed H, 2003, NUCLEIC ACIDS RES, V31, P2313, DOI 10.1093/nar/gkg341	40	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	2005	280	35					31314	31324		10.1074/jbc.M503063200	http://dx.doi.org/10.1074/jbc.M503063200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	958ZX	15994314	Green Accepted, hybrid			2022-12-25	WOS:000231487800079
J	Yang, L; Carlson, SG; McBurney, D; Horton, WE				Yang, L; Carlson, SG; McBurney, D; Horton, WE			Multiple signals induce endoplasmic reticulum stress in both primary and immortalized chondrocytes resulting in loss of differentiation, impaired cell growth, and apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OLIGOMERIC MATRIX PROTEIN; ARTICULAR-CARTILAGE; RAT CHONDROCYTES; EXPRESSION; GADD153; DEATH; CHOP; PROTEOGLYCAN; ACTIVATION; MUTATIONS	The endoplasmic reticulum is the site of synthesis and folding of secretory proteins and is sensitive to changes in the internal and external environment of the cell. Both physiological and pathological conditions may perturb the function of the endoplasmic reticulum, resulting in endoplasmic reticulum stress. The chondrocyte is the only resident cell found in cartilage and is responsible for synthesis and turnover of the abundant extracellular matrix and may be sensitive to endoplasmic reticulum stress. Here we report that glucose withdrawal, tunicamycin, and thapsigargin induce up-regulation of GADD153 and caspase-12, two markers of endoplasmic reticulum stress, in both primary chondrocytes and a chondrocyte cell line. Other agents such as interleukin-1 beta or tumor necrosis factor alpha induced a minimal or no induction of GADD153, respectively. The endoplasmic reticulum stress resulted in decreased chondrocyte growth based on cell counts, up-regulation of p21, and decreased PCNA expression. In addition, perturbation of endoplasmic reticulum function resulted in decreased accumulation of an Alcian Blue positive matrix by chondrocytes and decreased expression of type II collagen at the protein level. Further, quantitative realtime PCR was used to demonstrate a down-regulation of steady state mRNA levels coding for aggrecan, collagen II, and link protein in chondrocytes exposed to endoplasmic reticulum stress-inducing conditions. Ultimately, endoplasmic reticulum stress resulted in chondrocyte apoptosis, as evidenced by DNA fragmentation and annexin V staining. These findings have potentially important implications regarding consequences of endoplasmic reticulum stress in cartilage biology.	Northeastern Ohio Univ Coll Med & Pharm, Coll Med, Dept Anat, Rootstown, OH 44272 USA; Cleveland Clin Fdn, Lerner Res Inst, Cleveland, OH 44195 USA	Northeast Ohio Medical University (NEOMED); Cleveland Clinic Foundation	Horton, WE (corresponding author), Northeastern Ohio Univ Coll Med & Pharm, Coll Med, Dept Anat, 4209 State Route 44, Rootstown, OH 44272 USA.	wehj@neoucom.edu	Yang, Ling/C-8000-2011	Yang, Ling/0000-0002-3105-3063				Adams CS, 1998, ANAT RECORD, V250, P418; Archer CW, 2003, INT J BIOCHEM CELL B, V35, P401, DOI 10.1016/S1357-2725(02)00301-1; Aridor M, 1999, NAT MED, V5, P745, DOI 10.1038/10466; BARONE MV, 1994, GENE DEV, V8, P453, DOI 10.1101/gad.8.4.453; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Breckenridge DG, 2003, ONCOGENE, V22, P8608, DOI 10.1038/sj.onc.1207108; Brewer JW, 2000, P NATL ACAD SCI USA, V97, P12625, DOI 10.1073/pnas.220247197; BRIGGS MD, 1995, NAT GENET, V10, P330, DOI 10.1038/ng0795-330; CARLSON SG, 1993, MOL CELL BIOL, V13, P4736, DOI 10.1128/MCB.13.8.4736; Delot E, 1998, J BIOL CHEM, V273, P26692, DOI 10.1074/jbc.273.41.26692; Erickson GR, 2003, OSTEOARTHR CARTILAGE, V11, P187, DOI 10.1053/S1063-4584(02)00347-3; EYRE DR, 1991, SEMIN ARTHRITIS RHEU, V21, P2, DOI 10.1016/0049-0172(91)90035-X; Gartel AL, 2002, MOL CANCER THER, V1, P639; Goggs R, 2003, VET J, V166, P140, DOI 10.1016/S1090-0233(02)00331-3; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; Harris TE, 2001, J BIOL CHEM, V276, P29200, DOI 10.1074/jbc.M011587200; HECHT JT, 1995, NAT GENET, V10, P325, DOI 10.1038/ng0795-325; Horton WE, 1998, IN VITRO CELL DEV-AN, V34, P378; HORTON WE, 1988, EXP CELL RES, V178, P457, DOI 10.1016/0014-4827(88)90414-4; HORTON WE, 1991, J BIOL CHEM, V266, P24804; Iwawaki T, 2004, NAT MED, V10, P98, DOI 10.1038/nm970; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kinkel MD, 2004, ANAT REC PART A, V279A, P720, DOI 10.1002/ar.a.20063; Kinkel MD, 2003, J CELL BIOCHEM, V88, P941, DOI 10.1002/jcb.10442; Kronenberg HM, 2003, NATURE, V423, P332, DOI 10.1038/nature01657; Lee RB, 2002, BIORHEOLOGY, V39, P133; Lefebvre V, 1997, MOL CELL BIOL, V17, P2336, DOI 10.1128/MCB.17.4.2336; LOESER RF, 2004, SCI AGING KNOWLEDGE, V29, pE31; Luo W, 1996, J BIOL CHEM, V271, P16447, DOI 10.1074/jbc.271.28.16447; Maddox BK, 1997, J BIOL CHEM, V272, P30993, DOI 10.1074/jbc.272.49.30993; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; McLaughlin SH, 1998, MATRIX BIOL, V16, P369, DOI 10.1016/S0945-053X(98)90010-5; Morishima N, 2002, J BIOL CHEM, V277, P34287, DOI 10.1074/jbc.M204973200; Mroz PJ, 2003, BIOCHEM J, V376, P511, DOI 10.1042/BJ20030982; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Oliver BL, 2005, J CELL PHYSIOL, V204, P45, DOI 10.1002/jcp.20261; Olsen BR, 2000, ANNU REV CELL DEV BI, V16, P191, DOI 10.1146/annurev.cellbio.16.1.191; Oyadomari S, 2004, CELL DEATH DIFFER, V11, P381, DOI 10.1038/sj.cdd.4401373; Patil C, 2001, CURR OPIN CELL BIOL, V13, P349, DOI 10.1016/S0955-0674(00)00219-2; Pelletier JP, 2000, ARTHRITIS RHEUM-US, V43, P1290, DOI 10.1002/1529-0131(200006)43:6<1290::AID-ANR11>3.0.CO;2-R; Rao RV, 2004, CELL DEATH DIFFER, V11, P372, DOI 10.1038/sj.cdd.4401378; Rao RV, 2002, FEBS LETT, V514, P122, DOI 10.1016/S0014-5793(02)02289-5; Rutishauser J, 2002, SWISS MED WKLY, V132, P211; Shen XH, 2001, CELL, V107, P893, DOI 10.1016/S0092-8674(01)00612-2; Shikhman AR, 2001, J IMMUNOL, V166, P5155, DOI 10.4049/jimmunol.166.8.5155; Smith RL, 2004, CLIN ORTHOP RELAT R, pS89, DOI 10.1097/01.blo.0000143938.30681.9d; Ubeda M, 1999, MOL CELL BIOL, V19, P7589; VERTEL BM, 1989, J CELL BIOL, V109, P1827, DOI 10.1083/jcb.109.4.1827; VERTEL BM, 1993, J CELL SCI, V104, P939; Vranka J, 2001, MATRIX BIOL, V20, P439, DOI 10.1016/S0945-053X(01)00148-2; Wildey GM, 2003, J BIOL CHEM, V278, P18069, DOI 10.1074/jbc.M211958200; Yagi A, 2003, J CELL BIOCHEM, V90, P1242, DOI 10.1002/jcb.10711; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	53	85	93	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	2005	280	35					31156	31165		10.1074/jbc.M501069200	http://dx.doi.org/10.1074/jbc.M501069200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	958ZX	16000304	hybrid			2022-12-25	WOS:000231487800062
J	Yatsula, B; Lin, S; Read, AJ; Poholek, A; Yates, K; Yue, DX; Hui, P; Perkins, AS				Yatsula, B; Lin, S; Read, AJ; Poholek, A; Yates, K; Yue, DX; Hui, P; Perkins, AS			Identification of binding sites of EVI1 in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE MYELOGENOUS LEUKEMIAS; MYELOID-TRANSFORMING GENE; ZINC-FINGER PROTEIN; HEMATOPOIETIC-CELLS; CONSENSUS SEQUENCE; CO-REPRESSOR; EXPRESSION; TRANSCRIPTION; ACTIVATION; GATA-2	The leukemia- associated protein EVI1 possesses seven zinc fingers within an N- terminal domain ( amino acids 1 - 250) that binds to GACAAGATA. Single amino acid missense mutants of EVI1 were developed that failed to bind DNA either in vitro, as assessed by gel shift assay, or in vivo, as shown by transactivation studies. Specifically, mutation R205N lacks high affinity binding to the GACAAGATA motif. Putative EVI1 target genes were identified by using an EVI1-( 1 - 250)VP16 fusion protein that acts as a transcriptional activator with the binding specificity of EVI1. Sixteen genes induced in NIH 3T3 cells by wild type EVI1- VP16 but not by mutant forms were identified. Sequence analysis revealed evolutionarily conserved GACAA-GATA-like motifs within 10 kb of their transcription start sites, and by chromatin immunoprecipitation in fibroblasts, we showed occupancy of many of these sites by EVI1- VP16. To assess whether native EVI1 binds to these sites in EVI1- transformed myeloid cells, we performed chromatin immunoprecipitation in 32Dcl3 and NFS58 cells, using anti- EVI1 antisera, and we showed that the majority of these sites is bound by wild type EVI1. These putative target genes include Gadd45g, Gata2, Zfpm2/ Fog2, Skil ( SnoN), Klf5 ( BTEB2), Dcn, and Map3k14 ( Nik). In this study we demonstrated for the first time that the N- terminal DNA binding domain of EVI1 has the capacity to bind to endogenous genes. We hypothesized that these genes play a critical role in EVI1- induced transformation.	Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA	Yale University	Perkins, AS (corresponding author), POB 208023, New Haven, CT 06520 USA.	archibald.perkins@yale.edu		Read, Andrew/0000-0001-7336-8496	PHS HHS [R01 81216] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Bartholomew C, 1997, ONCOGENE, V14, P569, DOI 10.1038/sj.onc.1200864; BARTHOLOMEW C, 1989, ONCOGENE, V4, P529; BARTHOLOMEW C, 1994, ONCOGENE, V9, P939; BERG JM, 1988, P NATL ACAD SCI USA, V85, P99, DOI 10.1073/pnas.85.1.99; BORDEREAUX D, 1990, ONCOGENE, V5, P925; BOYER PL, 1993, ONCOGENE, V8, P457; Cheng T, 1996, P NATL ACAD SCI USA, V93, P13158, DOI 10.1073/pnas.93.23.13158; Chi YQ, 2003, J BIOL CHEM, V278, P49806, DOI 10.1074/jbc.M309645200; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DELWEL R, 1993, MOL CELL BIOL, V13, P4291, DOI 10.1128/MCB.13.7.4291; Ezoe S, 2002, BLOOD, V100, P3512, DOI 10.1182/blood-2002-04-1177; Fears S, 1996, P NATL ACAD SCI USA, V93, P1642, DOI 10.1073/pnas.93.4.1642; Feng XH, 2000, EMBO J, V19, P5178, DOI 10.1093/emboj/19.19.5178; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; FICHELSON S, 1992, LEUKEMIA, V6, P93; FUNABIKI T, 1994, ONCOGENE, V9, P1575; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; He J, 2003, J BIOL CHEM, V278, P30540, DOI 10.1074/jbc.M304016200; HOCHULI E, 1990, GENETIC ENG PRINCIPL, V2, P87; Ikonomi P, 2000, EXP HEMATOL, V28, P1423, DOI 10.1016/S0301-472X(00)00553-1; Izutsu K, 2001, BLOOD, V97, P2815, DOI 10.1182/blood.V97.9.2815; KELLER JR, 1988, J EXP MED, V168, P737, DOI 10.1084/jem.168.2.737; KhannaGupta A, 1996, ONCOGENE, V12, P563; Kilbey A, 1998, ONCOGENE, V16, P2287, DOI 10.1038/sj.onc.1201732; Kilbey A, 1999, CELL GROWTH DIFFER, V10, P601; Kim JH, 1998, ONCOGENE, V17, P1527, DOI 10.1038/sj.onc.1202331; KLEVIT RE, 1991, SCIENCE, V253, P1367, DOI 10.1126/science.1896847; KREIDER BL, 1993, P NATL ACAD SCI USA, V90, P6454, DOI 10.1073/pnas.90.14.6454; Kumano K, 2001, BLOOD, V98, P3283, DOI 10.1182/blood.V98.12.3283; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; KUROKAWA M, 1995, ONCOGENE, V11, P833; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MORISHITA K, 1990, ONCOGENE, V5, P963; MORISHITA K, 1992, MOL CELL BIOL, V12, P183, DOI 10.1128/MCB.12.1.183; MORISHITA K, 1995, ONCOGENE, V10, P1961; MORISHITA K, 1992, P NATL ACAD SCI USA, V89, P3937, DOI 10.1073/pnas.89.9.3937; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; NUCIFORA G, 1994, P NATL ACAD SCI USA, V91, P4004, DOI 10.1073/pnas.91.9.4004; Palmer S, 2001, J BIOL CHEM, V276, P25834, DOI 10.1074/jbc.M102343200; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PERKINS AS, 1991, MOL CELL BIOL, V11, P2665, DOI 10.1128/MCB.11.5.2665; PERKINS AS, 1991, DEVELOPMENT, V111, P479; Perkins AS, 1996, J BIOL CHEM, V271, P1104, DOI 10.1074/jbc.271.2.1104; Phillips RL, 2000, SCIENCE, V288, P1635, DOI 10.1126/science.288.5471.1635; RIGGS AD, 1970, J MOL BIOL, V48, P67, DOI 10.1016/0022-2836(70)90219-6; SHIMAMOTO T, 1994, LEUKEMIA, V8, P1176; Shinagawa T, 2000, EMBO J, V19, P2280, DOI 10.1093/emboj/19.10.2280; SHOCKETT P, 1995, P NATL ACAD SCI USA, V92, P6522, DOI 10.1073/pnas.92.14.6522; Sitailo S, 1999, LEUKEMIA, V13, P1639, DOI 10.1038/sj.leu.2401585; Stroschein SL, 1999, SCIENCE, V286, P771, DOI 10.1126/science.286.5440.771; SUZUKAWA K, 1994, BLOOD, V84, P2681; TANAKA T, 1994, J BIOL CHEM, V269, P24020; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; Turner J, 1998, EMBO J, V17, P5129, DOI 10.1093/emboj/17.17.5129; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; Yuasa H, 2005, EMBO J, V24, P1976, DOI 10.1038/sj.emboj.7600679	61	48	51	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	2005	280	35					30712	30722		10.1074/jbc.M504293200	http://dx.doi.org/10.1074/jbc.M504293200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	958ZX	16006653	hybrid			2022-12-25	WOS:000231487800010
J	Caron, L; Bost, F; Prot, M; Hofman, P; Binetruy, B				Caron, L; Bost, F; Prot, M; Hofman, P; Binetruy, B			A new role for the oncogenic high-mobility group A2 transcription factor in myogenesis of embryonic stem cells	ONCOGENE			English	Article						HMGA2 transcription factor; ES cells; myogenesis	HMGI-C GENE; EXPRESSION; PATHWAY; DIFFERENTIATION; PROTEINS; LIPOMAS	The high mobility group type A-2 (HMGA2) transcription factor is involved in proliferation and differentiation, mainly during embryogenesis. Its activated form (HMGA2/T) presents oncogenic activities both in vivo and in vitro. However, its precise role during embryogenesis is unknown. We investigated its role during the commitment of mouse embryonic stem (ES) cells by constructing cell lines expressing either wild type (wt) or HMGA2/T forms of the gene. Following differentiation, control and wt HMGA2 ES cells did not display myotubes; whereas HMGA2/T ES cell lines massively formed contractile myotubes. Furthermore, as opposed to control cells, HMGA2/T ES cells highly expressed the muscle myosin heavy chain (MHC) marker. Interestingly, in experimental conditions inhibitory for myogenesis, we observed a strong expression of MyoD and myogenin in HMGA2/T cells. By contrast, commitment into adipocyte, neuron, and cardiomyocyte lineages was not affected. Teratocarcinomas induced by HMGA2/T ES cell lines presented numerous skeletal muscle-differentiated tissues that were not observed in wt HMGA2 or control tumours. Finally, rapamycin, an inhibitor of the mTOR kinase, downregulated endogenous HMGA-2 expression and inhibited myogenesis. This effect was prevented by overexpression of exogenous HMGA-2. Our results reveal a novel function of HMGA-2 in skeletal muscle differentiation.	Univ Nice Sophia Antipolis, INSERM, U568, Fac Med, F-06107 Nice, France; Univ Nice Sophia Antipolis, INSERM E0215, Fac Med, F-06107 Nice, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Binetruy, B (corresponding author), Univ Nice Sophia Antipolis, INSERM, U568, Fac Med, Ave Valombrose, F-06107 Nice, France.	binetruy@unice.fr	Binetruy, Bernard/AFL-7188-2022; Hofman, Paul/P-7654-2018; Binetruy, Bernard/S-2062-2019; BOST, Frederic/AAN-4691-2020; Binetruy, Bernard/AAG-7139-2022; Binetruy, Bernard/A-6465-2009; Caron, Leslie/AAE-3511-2022	Hofman, Paul/0000-0003-0431-9353; Binetruy, Bernard/0000-0001-8012-7092; BOST, Frederic/0000-0003-4509-4701; Caron, Leslie/0000-0003-4118-2974				Anand A, 2000, NAT GENET, V24, P377, DOI 10.1038/74207; Anisimov SV, 2002, MECH DEVELOP, V117, P25, DOI 10.1016/S0925-4773(02)00177-6; ASHAR HR, 1995, CELL, V82, P57; Baldassarre G, 2001, P NATL ACAD SCI USA, V98, P7970, DOI 10.1073/pnas.141224998; Battista S, 1999, CANCER RES, V59, P4793; Bost F, 2002, BIOCHEM J, V361, P621, DOI 10.1042/0264-6021:3610621; Chieffi P, 2002, ONCOGENE, V21, P3644, DOI 10.1038/sj/onc/1205501; COLMENARES C, 1989, CELL, V59, P293, DOI 10.1016/0092-8674(89)90291-2; Fedele M, 1998, ONCOGENE, V17, P413, DOI 10.1038/sj.onc.1201952; Gao XS, 2002, NAT CELL BIOL, V4, P699, DOI 10.1038/ncb847; Hirning-Folz U, 1998, GENE CHROMOSOME CANC, V23, P350, DOI 10.1002/(SICI)1098-2264(199812)23:4<350::AID-GCC10>3.0.CO;2-E; Hunter DS, 2002, CANCER RES, V62, P3766; Molkentin JD, 1996, CURR OPIN GENET DEV, V6, P445, DOI 10.1016/S0959-437X(96)80066-9; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Noro B, 2003, BIOCHEMISTRY-US, V42, P4569, DOI 10.1021/bi026605k; Pende M, 2004, MOL CELL BIOL, V24, P3112, DOI 10.1128/MCB.24.8.3112-3124.2004; Reeves R, 2001, BBA-GENE STRUCT EXPR, V1519, P13, DOI 10.1016/S0167-4781(01)00215-9; Reeves R, 1999, METHOD ENZYMOL, V304, P155; Tallini G, 2000, LAB INVEST, V80, P359, DOI 10.1038/labinvest.3780040; Vernochet C, 2002, FEBS LETT, V510, P94, DOI 10.1016/S0014-5793(01)03235-5; Wobus Anna M., 2001, Molecular Aspects of Medicine, V22, P149, DOI 10.1016/S0098-2997(01)00006-1; ZHOU XJ, 1995, NATURE, V376, P771, DOI 10.1038/376771a0; Zhou XJ, 1996, NUCLEIC ACIDS RES, V24, P4071, DOI 10.1093/nar/24.20.4071	23	32	33	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	41					6281	6291		10.1038/sj.onc.1208781	http://dx.doi.org/10.1038/sj.onc.1208781			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	964JM	16007198				2022-12-25	WOS:000231877100009
J	Kirk, GD; Lesi, OA; Mendy, M; Szymanska, K; Whittle, H; Goedert, JJ; Hainaut, P; Montesano, R				Kirk, GD; Lesi, OA; Mendy, M; Szymanska, K; Whittle, H; Goedert, JJ; Hainaut, P; Montesano, R			249(ser) TP53 mutation in plasma DNA, hepatitis B viral infection, and risk of hepatocellular carcinoma	ONCOGENE			English	Article						hepatocellular carcinoma; aflatoxin; hepatitis B virus; TP53 gene; plasma DNA	AFLATOXIN-ALBUMIN ADDUCTS; CIRCULATING NUCLEIC-ACIDS; LIVER-CANCER RISK; REPUBLIC-OF-CHINA; WEST-AFRICA; P53 GENE; MOLECULAR PATHOGENESIS; VIRUS-INFECTION; STEM-CELLS; E-ANTIGEN	Hepatocellular carcinoma (HCC) from regions with high dietary exposure to aflatoxins and endemic for hepatitis B virus (HBV) often contain a specific mutation at codon 249 in TP53 (249(ser); AGG to AGT, Arg to Ser). This mutation is also detectable in circulating cell-free DNA from the plasma of HCC patients and healthy subjects in these regions. We have examined the joint effect of plasma 249(ser) and HBV infection in a case-control study design involving 348 control, 98 cirrhotic, and 186 HCC participants from The Gambia, West Africa, an area of high HCC incidence. The 249(ser) mutation was detected in 3.5% of controls, 15.3% of cirrhotics, and 39.8% of HCC cases (adjusted odds ratios (OR): 4.83, (95% confidence interval (CI): 1.71-13.7) for cirrhosis and 20.3 (8.19-50.0) for HCC). HBsAg positivity along with plasma 249(ser) was observed in 45/183 (24.6%) HCC cases compared to only one (0.3%) control. Risk for HCC was associated with markers of HBV alone (OR: 10.0, 95% CI: 5.16-19.6), 249(ser) alone (OR: 13.2, 95% CI: 4.99-35.0), and both markers present (OR: 399, 95% CI: 48.6-3270). These results suggest a multiplicative effect on HCC risk resulting from the mutational effect of aflatoxin on TP53, as monitored by detection of plasma 249(ser), with concomitant chronic infection with HBV.	Johns Hopkins Bloomberg Sch Publ Hlth, Infect Dis Epidemiol Program, Dept Epidemiol, Baltimore, MD 21205 USA; Gambia Hepatitis Intervent Study, Banjul, Gambia; NCI, Viral Epidemiol Branch, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA; MRC Labs, Banjul, Gambia; Int Agcy Res Canc, F-69372 Lyon, France	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); MRC Laboratory Molecular Biology; World Health Organization; International Agency for Research on Cancer (IARC)	Kirk, GD (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Infect Dis Epidemiol Program, Dept Epidemiol, 615 N Wolfe St,E-6533, Baltimore, MD 21205 USA.	gkirk@jhsph.edu	Kirk, Gregory/A-8484-2009; Hainaut, Pierre/B-6018-2012; Mendy, Maimuna/ABD-5038-2021	Hainaut, Pierre/0000-0002-1303-1610; LESI, Olufunmilayo/0000-0002-6958-1531	NATIONAL CANCER INSTITUTE [Z01CP010176, ZIACP010176] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGUILAR F, 1994, SCIENCE, V264, P1317, DOI 10.1126/science.8191284; Anker P, 2003, INT J CANCER, V103, P149, DOI 10.1002/ijc.10791; AUTRUP H, 1987, CANCER RES, V47, P3430; Bah E, 2001, BRIT J CANCER, V84, P1207, DOI 10.1054/bjoc.2001.1730; BANNASCH P, 1995, CANCER RES, V55, P3318; Brechot C, 2000, SEMIN CANCER BIOL, V10, P211, DOI 10.1006/scbi.2000.0321; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; Chen CJ, 1996, HEPATOLOGY, V24, P38, DOI 10.1002/hep.510240108; COURSAGET P, 1993, BRIT J CANCER, V67, P1395, DOI 10.1038/bjc.1993.258; Friedler A, 2003, J BIOL CHEM, V278, P24108, DOI 10.1074/jbc.M302458200; Ghebranious N, 1998, HEPATOLOGY, V27, P967, DOI 10.1002/hep.510270411; Groopman JD, 1996, PROG CLIN BIOL RES, V395, P211; HAGEN TM, 1994, P NATL ACAD SCI USA, V91, P12808, DOI 10.1073/pnas.91.26.12808; Hainaut P, 2000, ADV CANCER RES, V77, P81; Hudson Geoffrey J., 1992, Natural Toxins, V1, P100, DOI 10.1002/nt.2620010208; Hussain SP, 2000, MUTAT RES-REV MUTAT, V462, P311, DOI 10.1016/S1383-5742(00)00015-6; IARC, 2002, MON EV CARC RISKS HU, V82; IARC, 1994, MON EV CARC RISKS HU; Jackson PE, 2003, CARCINOGENESIS, V24, P1657, DOI 10.1093/carcin/bgg101; Jackson PE, 1999, BEST PRACT RES CL GA, V13, P545, DOI 10.1053/bega.1999.0047; Jackson PE, 2001, CANCER RES, V61, P33; Kirk GD, 2004, HEPATOLOGY, V39, P211, DOI 10.1002/hep.20027; Kirk GD, 2000, JNCI-J NATL CANCER I, V92, P148, DOI 10.1093/jnci/92.2.148; Liang TJ, 2002, NEW ENGL J MED, V347, P208, DOI 10.1056/NEJMe020060; LIN DY, 1993, J CLIN ULTRASOUND, V21, P303, DOI 10.1002/jcu.1870210502; Liu MC, 2002, SEMIN ONCOL, V29, P246, DOI 10.1053/sonc.2002.32900; Mandishona E, 1998, HEPATOLOGY, V27, P1563, DOI 10.1002/hep.510270614; Mendy ME, 1999, BRIT J BIOMED SCI, V56, P34; MENDY ME, 1998, BRIT J BIOMED SCI, V55, P92; Montesano R, 1997, JNCI-J NATL CANCER I, V89, P1844, DOI 10.1093/jnci/89.24.1844; Olubuyide I O, 1993, Afr J Med Med Sci, V22, P89; Omer RE, 2001, CANCER CAUSE CONTROL, V12, P23, DOI 10.1023/A:1008943200826; Omer RE, 1998, NUTR CANCER, V32, P174, DOI 10.1080/01635589809514737; OZTURK M, 1991, LANCET, V338, P1356, DOI 10.1016/0140-6736(91)92236-U; Payne RJH, 1996, P NATL ACAD SCI USA, V93, P6542, DOI 10.1073/pnas.93.13.6542; Pisani P, 1997, CANCER EPIDEM BIOMAR, V6, P387; PONCHEL F, 1994, CANCER RES, V54, P2064; QIAN GS, 1994, CANCER EPIDEM BIOMAR, V3, P3; SELL S, 1993, INT J DEV BIOL, V37, P189; Smela ME, 2002, P NATL ACAD SCI USA, V99, P6655, DOI 10.1073/pnas.102167699; Smela ME, 2001, CARCINOGENESIS, V22, P535, DOI 10.1093/carcin/22.4.535; Stern MC, 2001, CANCER EPIDEM BIOMAR, V10, P617; Strain AJ, 2000, GUT, V46, P743, DOI 10.1136/gut.46.6.743; Sun ZT, 1999, HEPATOLOGY, V30, P379, DOI 10.1002/hep.510300204; Szymanska K, 2004, INT J CANCER, V110, P374, DOI 10.1002/ijc.20103; Taback B, 2004, CURR OPIN MOL THER, V6, P273; Thorgeirsson S S, 1995, Princess Takamatsu Symp, V25, P163; Thorgeirsson SS, 2002, NAT GENET, V31, P339, DOI 10.1038/ng0802-339; Turner PC, 2000, TROP MED INT HEALTH, V5, P837, DOI 10.1046/j.1365-3156.2000.00664.x; Vall Mayans M., 1990, Lancet, V336, P1107; van Rensburg S J, 1990, J Environ Pathol Toxicol Oncol, V10, P11; Wang LY, 1996, INT J CANCER, V67, P620, DOI 10.1002/(SICI)1097-0215(19960904)67:5&lt;620::AID-IJC5&gt;3.0.CO;2-W; Wang XW, 2002, TOXICOLOGY, V181, P43, DOI 10.1016/S0300-483X(02)00253-6; WHITTLE H, 1990, J INFECT DIS, V161, P1112, DOI 10.1093/infdis/161.6.1112; Wild CP, 1996, CANCER EPIDEM BIOMAR, V5, P179; Wild CP, 2000, INT J CANCER, V86, P1, DOI 10.1002/(SICI)1097-0215(20000401)86:1&lt;1::AID-IJC1&gt;3.0.CO;2-I; WILD CP, 1990, CARCINOGENESIS, V11, P2271, DOI 10.1093/carcin/11.12.2271; WILD CP, 1992, CANCER EPIDEM BIOMAR, V1, P229; WILD CP, 1987, INT J CANCER, V40, P328, DOI 10.1002/ijc.2910400308; WILD CP, 1992, TOXICOL LETT, V64-5, P455, DOI 10.1016/0378-4274(92)90219-A; Wogan GN, 2000, SEMIN CANCER BIOL, V10, P201, DOI 10.1006/scbi.2000.0320; Wu TL, 2002, CLIN CHIM ACTA, V321, P77, DOI 10.1016/S0009-8981(02)00091-8; Yan R Q, 1989, Zhonghua Bing Li Xue Za Zhi, V18, P19; Yang HI, 2002, NEW ENGL J MED, V347, P168, DOI 10.1056/NEJMoa013215	64	111	118	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2005	24	38					5858	5867		10.1038/sj.onc.1208732	http://dx.doi.org/10.1038/sj.onc.1208732			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960KW	16007211				2022-12-25	WOS:000231590400008
J	Bomati, EK; Austin, MB; Bowman, ME; Dixon, RA; Noel, JP				Bomati, EK; Austin, MB; Bowman, ME; Dixon, RA; Noel, JP			Structural elucidation of chalcone reductase and implications for deoxychalcone biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALDO-KETO REDUCTASES; POLYKETIDE BIOSYNTHESIS; PHYTOALEXIN SYNTHESIS; SESBANIA-ROSTRATA; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; SYNTHASE; SUPERFAMILY; PROTEIN; EXPRESSION	4,2', 4', 6'-tetrahydroxychalcone (chalcone) and 4,2', 4'-trihydroxychalcone ( deoxychalcone) serve as precursors of ecologically important flavonoids and isoflavonoids. Deoxychalcone formation depends on chalcone synthase and chalcone reductase; however, the identity of the chalcone reductase substrate out of the possible substrates formed during the multistep reaction catalyzed by chalcone synthase remains experimentally elusive. We report here the three-dimensional structure of alfalfa chalcone reductase bound to the NADP(+) cofactor and propose the identity and binding mode of its substrate, namely the non-aromatized coumaryl-trione intermediate of the chalcone synthase-catalyzed cyclization of the fully extended coumaryl-tetraketide thioester intermediate. In the absence of a ternary complex, the quality of the refined NADP(+)-bound chalcone reductase structure serves as a template for computer-assisted docking to evaluate the likelihood of possible substrates. Interestingly, chalcone reductase adopts the three-dimensional structure of the aldo/keto reductase superfamily. The aldo/keto reductase fold is structurally distinct from all known ketoreductases of fatty acid biosynthesis, which instead belong to the short-chain dehydrogenase/reductase superfamily. The results presented here provide structural support for convergent functional evolution of these two ketoreductases that share similar roles in the biosynthesis of fatty acids/polyketides. In addition, the chalcone reductase structure represents the first protein structure of a member of the aldo/ketoreductase 4 family. Therefore, the chalcone reductase structure serves as a template for the homology modeling of other aldo/ketoreductase 4 family members, including the reductase involved in morphine biosynthesis, namely codeinone reductase.	Salk Inst Biol Studies, Jack Skirball Chem Biol, La Jolla, CA 92037 USA; Salk Inst Biol Studies, Prote Lab, La Jolla, CA 92037 USA; Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92037 USA; Samuel Roberts Noble Fdn Inc, Div Plant Biol, Ardmore, OK 73401 USA	Salk Institute; Salk Institute; University of California System; University of California San Diego; Noble Research Institute	Noel, JP (corresponding author), Salk Inst Biol Studies, Jack Skirball Chem Biol, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	noel@salk.edu	Noel, Joseph P/A-9459-2009		Howard Hughes Medical Institute Funding Source: Medline	Howard Hughes Medical Institute(Howard Hughes Medical Institute)		Akashi T, 1997, PHYTOCHEMISTRY, V46, P283, DOI 10.1016/S0031-9422(97)00298-7; Austin MB, 2003, NAT PROD REP, V20, P79, DOI 10.1039/b100917f; AYABE SI, 1988, ARCH BIOCHEM BIOPHYS, V261, P458, DOI 10.1016/0003-9861(88)90362-1; BALLANCE GM, 1995, PLANT PHYSIOL, V107, P1027, DOI 10.1104/pp.107.3.1027; BANNER DW, 1976, BIOCHEM BIOPH RES CO, V72, P146, DOI 10.1016/0006-291X(76)90972-4; BOHREN KM, 1989, J BIOL CHEM, V264, P9547; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burbulis IE, 1999, P NATL ACAD SCI USA, V96, P12929, DOI 10.1073/pnas.96.22.12929; Cohen-Gonsaud M, 2002, J MOL BIOL, V320, P249, DOI 10.1016/S0022-2836(02)00463-1; DIXON RA, 1995, PLANT CELL, V7, P1085, DOI 10.1105/tpc.7.7.1085; Ehrensberger AH, 2004, J MOL BIOL, V337, P661, DOI 10.1016/j.jmb.2004.01.059; ELKABBANI O, 1995, NAT STRUCT BIOL, V2, P687, DOI 10.1038/nsb0895-687; Ferrer JL, 1999, NAT STRUCT BIOL, V6, P775, DOI 10.1038/11553; Fisher M, 2000, STRUCTURE, V8, P339, DOI 10.1016/S0969-2126(00)00115-5; Gavidia I, 2002, EUR J BIOCHEM, V269, P2842, DOI 10.1046/j.1432-1033.2002.02931.x; Goormachtig S, 1995, MOL PLANT MICROBE IN, V8, P816, DOI 10.1094/MPMI-8-0816; Goormachtig S, 1999, PLANTA, V209, P45, DOI 10.1007/s004250050605; GRAHAM TL, 1991, PLANT PHYSIOL, V95, P594, DOI 10.1104/pp.95.2.594; Hadfield AT, 2004, STRUCTURE, V12, P1865, DOI 10.1016/j.str.2004.08.002; Hara A, 1996, BIOCHEM J, V313, P373, DOI 10.1042/bj3130373; Hyndman D, 2003, CHEM-BIOL INTERACT, V143, P621, DOI 10.1016/S0009-2797(02)00193-X; Jez JM, 1997, BIOCHEM J, V326, P625, DOI 10.1042/bj3260625; Jez JM, 2001, CHEM-BIOL INTERACT, V130, P499, DOI 10.1016/S0009-2797(00)00295-7; Jez JM, 2000, BIOCHEMISTRY-US, V39, P890, DOI 10.1021/bi991489f; Jones G, 1997, J MOL BIOL, V267, P727, DOI 10.1006/jmbi.1996.0897; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kenrick P, 1997, NATURE, V389, P33, DOI 10.1038/37918; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE SP, 1993, PLANT PHYSIOL, V101, P1089, DOI 10.1104/pp.101.3.1089; Manning K, 1998, PLANTA, V205, P622, DOI 10.1007/s004250050365; Nahoum V, 2001, J BIOL CHEM, V276, P42091, DOI 10.1074/jbc.M105610200; Oguro S, 2004, BIOCHEM BIOPH RES CO, V325, P561, DOI 10.1016/j.bbrc.2004.10.057; Oka M, 2000, J MED CHEM, V43, P2479, DOI 10.1021/jm990502r; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Price AC, 2001, BIOCHEMISTRY-US, V40, P12772, DOI 10.1021/bi010737g; Price AC, 2004, STRUCTURE, V12, P417, DOI 10.1016/j.str.2004.02.008; RONCARATI R, 1995, PLANT J, V7, P809, DOI 10.1046/j.1365-313X.1995.07050809.x; SALI A, 1995, PROTEINS, V23, P318, DOI 10.1002/prot.340230306; SALLAUD C, 1995, PLANT PHYSIOL, V108, P869, DOI 10.1104/pp.108.2.869; Schroder J, 2000, RECENT ADV PHYTOCHEM, V34, P55, DOI 10.1016/S0079-9920(00)80004-0; Staunton J, 2001, NAT PROD REP, V18, P380, DOI 10.1039/a909079g; TARTOFF KD, 1987, FOCUS, V2, P12; Unterlinner B, 1999, PLANT J, V18, P465, DOI 10.1046/j.1365-313X.1999.00470.x; WELLE R, 1991, EUR J BIOCHEM, V196, P423, DOI 10.1111/j.1432-1033.1991.tb15833.x; WELLE R, 1989, ARCH BIOCHEM BIOPHYS, V272, P97, DOI 10.1016/0003-9861(89)90199-9; WELLE R, 1988, ARCH BIOCHEM BIOPHYS, V263, P191, DOI 10.1016/0003-9861(88)90627-3; WILSON DK, 1992, SCIENCE, V257, P81, DOI 10.1126/science.1621098; WOJTASZEK P, 1993, J PLANT PHYSIOL, V142, P689, DOI 10.1016/S0176-1617(11)80903-X	48	74	84	5	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	2005	280	34					30496	30503		10.1074/jbc.M502239200	http://dx.doi.org/10.1074/jbc.M502239200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	957IC	15970585	hybrid, Green Accepted			2022-12-25	WOS:000231362500063
J	Xu, AG; Lei, L; Irvine, KD				Xu, AG; Lei, L; Irvine, KD			Regions of Drosophila Notch that contribute to ligand binding and the modulatory influence of fringe	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							O-FUCOSYL-TRANSFERASE; FACTOR-LIKE REPEATS; PROTEIN O-FUCOSYL-TRANSFERASE-1; ABRUPTEX MUTATIONS; DELTA INTERACTIONS; SERRATE; RECEPTOR; JAGGED1; DOMAIN; PAIR	Two glycosyltransferases that transfer sugars to epidermal growth factor (EGF) domains, OFUT1 and Fringe, regulate Notch signaling. To characterize the impact of glycosylation at the 23 consensus O-fucose sites in Drosophila Notch, we conducted deletion mapping and site-specific mutagenesis and then assayed the binding of soluble forms of Notch to cell-surface ligands. Our results support the conclusion that EGF11 and EGF12 are essential for ligand binding, but indicate that other EGF domains also make substantial contributions to ligand binding. Characterization of Notch deletion constructs and O-fucose site mutants further revealed that no single site or region can account for the influence of Fringe on Notch-ligand binding. Additionally, we observed an influence of Fringe on a Notch fragment including only 4 of its 36 EGF domains (EGF10 - 13). Together, our observations imply that glycosylation influences Notch-ligand interactions through a distributive mechanism that involves local interactions with multiple EGF domains and led us to suggest a structural model for how Notch interacts with its ligands.	Rutgers State Univ, Waksman Inst, Howard Hughes Med Inst, Piscataway, NJ 08854 USA; Rutgers State Univ, Dept Mol Biol & Biochem, Piscataway, NJ 08854 USA	Howard Hughes Medical Institute; Rutgers State University New Brunswick; Rutgers State University New Brunswick	Lei, L (corresponding author), Rutgers State Univ, Waksman Inst, Howard Hughes Med Inst, 190 Frellinghuysen Rd, Piscataway, NJ 08854 USA.	irvine@waksman.rutgers.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054594] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM54594] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brennan K, 1999, DEV BIOL, V216, P230, DOI 10.1006/dbio.1999.9501; Bruckner K, 2000, NATURE, V406, P411, DOI 10.1038/35019075; Chen JH, 2001, P NATL ACAD SCI USA, V98, P13716, DOI 10.1073/pnas.241398098; de Celis JF, 2000, DEVELOPMENT, V127, P1291; DECELIS JF, 1993, P NATL ACAD SCI USA, V90, P4037, DOI 10.1073/pnas.90.9.4037; DECELIS JF, 1994, GENETICS, V136, P183; Downing AK, 1996, CELL, V85, P597, DOI 10.1016/S0092-8674(00)81259-3; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; Fleming RJ, 1997, DEVELOPMENT, V124, P2973; Fleming RJ, 1998, SEMIN CELL DEV BIOL, V9, P599, DOI 10.1006/scdb.1998.0260; Haines N, 2003, NAT REV MOL CELL BIO, V4, P786, DOI 10.1038/nrm1228; Haltiwanger RS, 2002, BBA-GEN SUBJECTS, V1573, P328, DOI 10.1016/S0304-4165(02)00400-2; Hambleton S, 2004, STRUCTURE, V12, P2173, DOI 10.1016/j.str.2004.09.012; Hicks C, 2000, NAT CELL BIOL, V2, P515, DOI 10.1038/35019553; KELLEY MR, 1987, CELL, V51, P539, DOI 10.1016/0092-8674(87)90123-1; Klein T, 1998, DEVELOPMENT, V125, P2951; Klueg KM, 1999, J CELL SCI, V112, P3289; Lai EC, 2004, DEVELOPMENT, V131, P965, DOI 10.1242/dev.01074; Lawrence N, 2000, DEVELOPMENT, V127, P3185; Lei L, 2003, DEVELOPMENT, V130, P6411, DOI 10.1242/dev.00883; Moloney DJ, 2000, NATURE, V406, P369, DOI 10.1038/35019000; Morgan WD, 1999, J MOL BIOL, V289, P113, DOI 10.1006/jmbi.1999.2753; Okajima T, 2003, J BIOL CHEM, V278, P42340, DOI 10.1074/jbc.M308687200; Okajima T, 2005, SCIENCE, V307, P1599, DOI 10.1126/science.1108995; Okajima T, 2002, CELL, V111, P893, DOI 10.1016/S0092-8674(02)01114-5; Panin VM, 2002, J BIOL CHEM, V277, P29945, DOI 10.1074/jbc.M204445200; Panin VM, 1997, NATURE, V387, P908, DOI 10.1038/43191; Papayannopoulos V, 1998, SCIENCE, V281, P2031, DOI 10.1126/science.281.5385.2031; Perez L, 2005, MECH DEVELOP, V122, P479, DOI 10.1016/j.mod.2004.12.007; Powell PA, 2001, NATURE, V409, P626, DOI 10.1038/35054566; Ramain P, 2001, CURR BIOL, V11, P1729, DOI 10.1016/S0960-9822(01)00562-0; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; Saha S, 2001, STRUCTURE, V9, P451, DOI 10.1016/S0969-2126(01)00606-2; Sasamura T, 2003, DEVELOPMENT, V130, P4785, DOI 10.1242/dev.00679; Schweisguth F, 2004, CURR BIOL, V14, pR129, DOI 10.1016/j.cub.2004.01.023; Shao L, 2003, J BIOL CHEM, V278, P7775, DOI 10.1074/jbc.M212221200; Shi SL, 2003, P NATL ACAD SCI USA, V100, P5234, DOI 10.1073/pnas.0831126100; Shimizu K, 1999, J BIOL CHEM, V274, P32961, DOI 10.1074/jbc.274.46.32961; Wang Y, 1998, J BIOL CHEM, V273, P8112, DOI 10.1074/jbc.273.14.8112; Wang Y, 2001, J BIOL CHEM, V276, P40338, DOI 10.1074/jbc.M107849200; Yang LT, 2005, MOL BIOL CELL, V16, P927, DOI 10.1091/mbc.e04-07-0614	41	61	81	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	2005	280	34					30158	30165		10.1074/jbc.M505569200	http://dx.doi.org/10.1074/jbc.M505569200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	957IC	15994325	hybrid			2022-12-25	WOS:000231362500023
J	Sala, A; Capaldi, S; Campagnoli, M; Faggion, B; Labo, S; Perduca, M; Romano, A; Carrizo, ME; Valli, M; Visai, L; Minchiotti, L; Galliano, M; Monaco, HL				Sala, A; Capaldi, S; Campagnoli, M; Faggion, B; Labo, S; Perduca, M; Romano, A; Carrizo, ME; Valli, M; Visai, L; Minchiotti, L; Galliano, M; Monaco, HL			Structure and properties of the C-terminal domain of insulin-like growth factor-binding protein-1 isolated from human amniotic fluid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IGF-BINDING; CELL-MIGRATION; ALPHA-5-BETA-1 INTEGRIN; THYROGLOBULIN; PROGRAM; PHOSPHORYLATION; IDENTIFICATION; SUBSTRATE; SEQUENCE; FRAGMENT	Insulin-like growth factor (IGF)-binding protein-1 (IGFBP1) regulates the activity of the insulin-like growth factors in early pregnancy and is, thus, thought to play a key role at the fetal-maternal interface. The C-terminal domain of IGFBP-1 and three isoforms of the intact protein were isolated from human amniotic fluid, and sequencing of the four N-terminal polypeptide chains showed them to be highly pure. The addition of both intact IGFBP-1 and its C-terminal fragment to cultured fibroblasts has a similar stimulating effect on cell migration, and therefore, the domain has a biological activity on its own. The three-dimensional structure of the C-terminal domain was determined by x-ray crystallography to 1.8 angstrom resolution. The fragment folds as a thyroglobulin type I domain and was found to bind the Fe2+ ion in the crystals through the only histidine residue present in the polypeptide chain. Iron (II) decreases the binding of intact IGFBP-1 and the C-terminal domain to IGF-II, suggesting that the metal binding site is close to or part of the surface of interaction of the two molecules.	Univ Pavia, Dept Biochem A Castellani, I-27100 Pavia, Italy; Univ Verona, Dept Sci & Technol, Biocrystallog Lab, I-37134 Verona, Italy	University of Pavia; University of Verona	Galliano, M (corresponding author), Univ Pavia, Dept Biochem A Castellani, Viaa Taramelli 3B, I-27100 Pavia, Italy.	galliano@unipv.it	Perduca, Massimiliano/AAS-2666-2020; Visai, Livia/R-7397-2017	Perduca, Massimiliano/0000-0001-8291-0523; Visai, Livia/0000-0003-1181-3632; Monaco, Hugo L./0000-0002-2067-0365; capaldi, stefano/0000-0003-4632-8100; Carrizo, Maria Elena/0000-0003-0501-8894				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baumrucker CR, 2003, DOMEST ANIM ENDOCRIN, V24, P287, DOI 10.1016/S0739-7240(03)00014-6; Baxter RC, 2000, AM J PHYSIOL-ENDOC M, V278, pE967, DOI 10.1152/ajpendo.2000.278.6.E967; Bricogne G, 2003, ACTA CRYSTALLOGR D, V59, P2023, DOI 10.1107/S0907444903017694; Bunn RC, 2003, TRENDS ENDOCRIN MET, V14, P176, DOI 10.1016/S1043-2760(03)00049-3; CHEN P, 1994, J CELL BIOL, V124, P547, DOI 10.1083/jcb.124.4.547; Coppock HA, 2004, BIOL REPROD, V71, P438, DOI 10.1095/biolreprod.103.023101; DAVIES SC, 1991, CLIN ENDOCRINOL, V34, P501, DOI 10.1111/j.1365-2265.1991.tb00331.x; DROP SLS, 1984, J CLIN ENDOCR METAB, V59, P899, DOI 10.1210/jcem-59-5-899; Fernandez-Tornero C, 2005, J BIOL CHEM, V280, P18899, DOI 10.1074/jbc.M500587200; Firth SM, 2002, ENDOCR REV, V23, P824, DOI 10.1210/er.2001-0033; Forbes BE, 1998, J BIOL CHEM, V273, P4647, DOI 10.1074/jbc.273.8.4647; Galesa K, 2003, FEBS LETT, V539, P120, DOI 10.1016/S0014-5793(03)00215-1; GIANAZZA E, 1985, ELECTROPHORESIS, V6, P53, DOI 10.1002/elps.1150060113; Gibson JM, 2001, MOL HUM REPROD, V7, P79, DOI 10.1093/molehr/7.1.79; Gleeson LM, 2001, J CLIN ENDOCR METAB, V86, P2484, DOI 10.1210/jc.86.6.2484; GOCKERMAN A, 1995, ENDOCRINOLOGY, V136, P4168, DOI 10.1210/en.136.10.4168; Guncar G, 1999, EMBO J, V18, P793, DOI 10.1093/emboj/18.4.793; Han VKM, 1996, J CLIN ENDOCR METAB, V81, P2680, DOI 10.1210/jc.81.7.2680; Headey SJ, 2004, MOL ENDOCRINOL, V18, P2740, DOI 10.1210/me.2004-0248; Horney MJ, 2001, J BIOL CHEM, V276, P2880, DOI 10.1074/jbc.M007526200; IRVING JA, 1995, EXP CELL RES, V217, P419, DOI 10.1006/excr.1995.1105; JONES JI, 1993, J BIOL CHEM, V268, P1125; JONES JI, 1993, P NATL ACAD SCI USA, V90, P10553, DOI 10.1073/pnas.90.22.10553; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1976, ACTA CRYSTALLOGR A, V32, P922, DOI 10.1107/S0567739476001873; Kajimura S, 2005, P NATL ACAD SCI USA, V102, P1240, DOI 10.1073/pnas.0407443102; Kalus W, 1998, EMBO J, V17, P6558, DOI 10.1093/emboj/17.22.6558; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee PDK, 1997, P SOC EXP BIOL MED, V216, P319; LESLIE AGW, 1992, JNT CCP4 ESF EAMCB N, V26, P27; MALTHIERY Y, 1987, EUR J BIOCHEM, V165, P491, DOI 10.1111/j.1432-1033.1987.tb11466.x; Manes S, 1997, J BIOL CHEM, V272, P25706, DOI 10.1074/jbc.272.41.25706; Mark S, 2005, BIOCHEMISTRY-US, V44, P3644, DOI 10.1021/bi0478401; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Molina F, 1996, EUR J BIOCHEM, V240, P125, DOI 10.1111/j.1432-1033.1996.0125h.x; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Park HI, 2002, J BIOL CHEM, V277, P35168, DOI 10.1074/jbc.M205071200; PEKONEN F, 1992, CANCER RES, V52, P5204; SHELDRICK GM, 1991, P CCP4 STUDY WEEKEND, P23; Singh B, 2004, J BIOL CHEM, V279, P477, DOI 10.1074/jbc.M307322200; Siwanowicz I, 2005, STRUCTURE, V13, P155, DOI 10.1016/j.str.2004.11.009; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Weinzimer SA, 2001, J CLIN ENDOCR METAB, V86, P1806, DOI 10.1210/jc.86.4.1806; WESTWOOD M, 1994, J CLIN ENDOCR METAB, V79, P1735, DOI 10.1210/jc.79.6.1735; Yao SG, 2004, BIOCHEMISTRY-US, V43, P11187, DOI 10.1021/bi049456+; Zeslawski W, 2001, EMBO J, V20, P3638, DOI 10.1093/emboj/20.14.3638	51	34	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	2005	280	33					29812	29819		10.1074/jbc.M504304200	http://dx.doi.org/10.1074/jbc.M504304200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	954SX	15972819	hybrid			2022-12-25	WOS:000231176200052
J	Park, SW; Sung, MW; Heo, DS; Inoue, H; Shim, SH; Kim, KH				Park, SW; Sung, MW; Heo, DS; Inoue, H; Shim, SH; Kim, KH			Nitric oxide upregulates the cyclooxygenase-2 expression through the cAMP-response element in its promoter in several cancer cell lines	ONCOGENE			English	Article						nitric oxide; NO; cyclooxygenase-2; COX-2; cAMP-response element; CRE	TRANSCRIPTION FACTOR; PROSTAGLANDIN E-2; KAPPA-B; EPITHELIAL-CELLS; CARCINOMA CELLS; NECK-CANCER; HEAD; SYNTHASE; GROWTH; COX-2	We previously showed that nitric oxide (NO) induces overexpression of cyclooxygenase-2 (COX-2) and production of prostaglandin E-2 in cancer cells. Here, we investigated the mechanisms by which NO induces COX-2 expression in cancer cells. We found that the cAMP-response element (CRE) is a critical factor in NO-induced COX-2 expression in all cells tested. We found that in cancer cells, three transcription factors (TFs) cAMP response element-binding protein (CREB), activating transcription factor-2 (ATF-2) and c-jun, bound the CRE in the COX-2 promoter, and their activities were increased by addition of the NO donor, S-nitroso-N-acetyl-D, L-penicillamine (SNAP). NO-induced activation of soluble guanylate cyclase (sGC), p38 and c-Jun NH2 terminal kinase (JNK) upregulated the three TFs, leading to COX-2 overexpression. Addition of dibutyryl-cGMP (db-cGMP) induced COX-2 expression in a manner similar to SNAP; this induction was blocked by a p38 inhibitor (SB202190), but not by a JNK inhibitor (SP600125). NO-induced cGMP was found to activate CREB and ATF-2 in a p38, but not c-jun- dependent manner,while NO induced JNK in a cGMP-independent manner, leading to subsequent activation of c-jun and ATF-2. These results suggest that the low concentrations of endogenous NO present in cancer cell may induce the expression of many genes, including COX-2, which promotes the growth and survival of tumor cells.	Seoul Natl Univ, Coll Med, Dept Otorhinolaryngol Head & Neck Surg, Seoul 110744, South Korea; Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul 110744, South Korea; Seoul Natl Univ, Coll Med, Dept Tumor Biol, Seoul 110744, South Korea; Seoul Natl Univ, Coll Med, Clin Res Inst, Seoul 110744, South Korea; Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul 110744, South Korea; Nara Womens Univ, Dept Food Sci & Nutr, Nara 630, Japan	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Nara Womens University	Sung, MW (corresponding author), Seoul Natl Univ, Coll Med, Dept Otorhinolaryngol Head & Neck Surg, 28 Yongon Dong, Seoul 110744, South Korea.	mwsung@snu.ac.kr	Kim, Kwang Hyun/J-5385-2012; Heo, Dae/J-2184-2012	Heo, Dae/0000-0001-5221-173X				Bogdan C, 2001, TRENDS CELL BIOL, V11, P66, DOI 10.1016/S0962-8924(00)01900-0; Browning DD, 2000, J BIOL CHEM, V275, P2811, DOI 10.1074/jbc.275.4.2811; Chabot-Fletcher M., 1996, PHARM REV COMMUN, V8, P317; Chan G, 1999, CANCER RES, V59, P991; Chung PS, 2000, LARYNGOSCOPE, V110, P1312, DOI 10.1097/00005537-200008000-00016; Coffey RJ, 1997, P NATL ACAD SCI USA, V94, P657, DOI 10.1073/pnas.94.2.657; Gallo O, 1998, J NATL CANCER I, V90, P587, DOI 10.1093/jnci/90.8.587; Guo YS, 2001, J BIOL CHEM, V276, P22941, DOI 10.1074/jbc.M101801200; Habib A, 1997, J IMMUNOL, V158, P3845; Han JA, 2002, EMBO J, V21, P5635, DOI 10.1093/emboj/cdf591; HEO DS, 1989, CANCER RES, V49, P5167; Howe LR, 2001, J BIOL CHEM, V276, P20108, DOI 10.1074/jbc.M010692200; Inoue H, 2000, J BIOL CHEM, V275, P28028; Lee DW, 2002, ANTICANCER RES, V22, P2089; Liaudet L, 2000, CRIT CARE MED, V28, pN37, DOI 10.1097/00003246-200004001-00005; Liu YM, 2004, J BIOL CHEM, V279, P18694, DOI 10.1074/jbc.M308136200; Luque I, 1997, SEMIN CANCER BIOL, V8, P103, DOI 10.1006/scbi.1997.0061; Nose F, 2002, AM J CLIN PATHOL, V117, P546; Pai R, 2002, NAT MED, V8, P289, DOI 10.1038/nm0302-289; Park SW, 2003, INT J CANCER, V107, P729, DOI 10.1002/ijc.11498; Park YG, 1999, J BIOL CHEM, V274, P1573, DOI 10.1074/jbc.274.3.1573; Posadas I, 2000, N-S ARCH PHARMACOL, V361, P98, DOI 10.1007/s002109900150; SALVEMINI D, 1993, P NATL ACAD SCI USA, V90, P7240, DOI 10.1073/pnas.90.15.7240; Sheng HM, 2001, J BIOL CHEM, V276, P18075, DOI 10.1074/jbc.M009689200; Slice LW, 2000, BIOCHEM BIOPH RES CO, V276, P406, DOI 10.1006/bbrc.2000.3487; Son HJ, 2001, J CLIN GASTROENTEROL, V33, P383, DOI 10.1097/00004836-200111000-00008; Song SH, 2001, CANCER RES, V61, P4628; STADLER J, 1993, J LEUKOCYTE BIOL, V53, P165, DOI 10.1002/jlb.53.2.165; Subbaramaiah K, 2002, J BIOL CHEM, V277, P18649, DOI 10.1074/jbc.M111415200; Sun YJ, 2002, CANCER RES, V62, P6323; Surh YJ, 2001, MUTAT RES-FUND MOL M, V480, P243, DOI 10.1016/S0027-5107(01)00183-X; Tamura M, 2002, J BIOL CHEM, V277, P26208, DOI 10.1074/jbc.M201347200; Tanabe T, 2002, PROSTAG OTH LIPID M, V68-9, P95, DOI 10.1016/S0090-6980(02)00024-2; Tang QB, 2001, ONCOGENE, V20, P5164, DOI 10.1038/sj.onc.1204667; TSAI AL, 1994, ARCH BIOCHEM BIOPHYS, V313, P367, DOI 10.1006/abbi.1994.1400; Vadlamudi R, 1999, ONCOGENE, V18, P305, DOI 10.1038/sj.onc.1202307; Wink DA, 1998, CARCINOGENESIS, V19, P711, DOI 10.1093/carcin/19.5.711; Xu XM, 1997, J BIOL CHEM, V272, P6943, DOI 10.1074/jbc.272.11.6943	38	46	53	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 6	2005	24	44					6689	6698		10.1038/sj.onc.1208816	http://dx.doi.org/10.1038/sj.onc.1208816			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	971FL	16007171				2022-12-25	WOS:000232367800010
J	Roque, A; Iloro, I; Ponte, I; Arrondo, JLR; Suau, P				Roque, A; Iloro, I; Ponte, I; Arrondo, JLR; Suau, P			DNA-induced secondary structure of the carboxyl-terminal domain of histone H1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; ALPHA-HELICES; H-1; CHROMATIN; PROTEINS; BINDING; SUBFRACTIONS; 3(10)-HELICES; TRANSCRIPTION; CONDENSATION	We have studied the secondary structure of the carboxyl-terminal domains of linker histone H1 subtypes H1 degrees (C-H1 degrees) and H1t (C-H1t), free in solution and bound to DNA, by IR spectroscopy. The carboxyl-terminal domain has little structure in aqueous solution but becomes extensively folded upon interaction with DNA. The secondary structure elements present in the bound carboxyl-terminal domain include the alpha-helix, beta-structure, turns, and open loops. The structure of the bound domain shows a significant dependence on salt concentration. In low salt (10 mM NaCl), there is a residual amount of random coil, 7% in C-H1 degrees and 12% in C-H1t. In physiological salt concentrations ( 140 mM NaCl), the carboxyl termini become fully structured. Under these conditions, C-H1 degrees contained 24% alpha-helix, 25% alpha-structure, 17% open loops, and 33% turns. The latter component could include a substantial proportion of the 310 helix. Despite their low sequence identity (similar to 30%), the representation of the different structural motifs in C-H1t was similar to that in C-H1 degrees. Examination of the changes in the amide I components in the 20-80 degrees C temperature interval showed that the secondary structure of the DNA-bound C-H1t is for the most part extremely stable. The H1 carboxyl-terminal domain appears to belong to the so-called disordered proteins, undergoing coupled binding and folding.	Univ Autonoma Barcelona, Fac Ciencias, Dept Bioquim & Biol Mol, Bellaterra 08193, Barcelona, Spain; Univ Basque Country, Dept Bioquim, E-48080 Bilbao, Spain	Autonomous University of Barcelona; University of Basque Country	Suau, P (corresponding author), Univ Autonoma Barcelona, Fac Ciencias, Dept Bioquim & Biol Mol, Bellaterra 08193, Barcelona, Spain.	pere.suau@uab.es	Ponte, Inma/AGN-5337-2022; Iloro, Ibon/L-6022-2014; Suau, Pedro/D-2695-2009; Córdova, Alicia Roque/W-5229-2019; Roque, Alicia/H-7756-2015; Ponte, Inma/E-6848-2015	Iloro, Ibon/0000-0002-9537-1714; Suau, Pedro/0000-0001-6673-8209; Córdova, Alicia Roque/0000-0002-6206-6481; Roque, Alicia/0000-0002-6206-6481; Ponte, Inma/0000-0002-9448-6915				ALLAN J, 1986, J MOL BIOL, V187, P591, DOI 10.1016/0022-2836(86)90337-2; ALLAN J, 1980, NATURE, V288, P675, DOI 10.1038/288675a0; Arrondo JLR, 1999, PROG BIOPHYS MOL BIO, V72, P367, DOI 10.1016/S0079-6107(99)00007-3; ARRONDO JLR, 1994, BIOCHEMISTRY-US, V33, P11650, DOI 10.1021/bi00204a029; Arrondo JR, 2003, J BACTERIOL, V185, P4226, DOI 10.1128/JB.185.14.4226-4232.2003; Bharath MMS, 2002, PROTEINS, V49, P71, DOI 10.1002/prot.10204; BOUVET P, 1994, GENE DEV, V8, P1147, DOI 10.1101/gad.8.10.1147; Bracken C, 2004, CURR OPIN STRUC BIOL, V14, P570, DOI 10.1016/j.sbi.2004.08.003; BUCCI LR, 1982, EXP CELL RES, V140, P111, DOI 10.1016/0014-4827(82)90162-8; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; CHURCHILL MEA, 1991, TRENDS BIOCHEM SCI, V16, P92, DOI 10.1016/0968-0004(91)90040-3; CLARK DJ, 1988, EMBO J, V7, P69, DOI 10.1002/j.1460-2075.1988.tb02784.x; DOMINGUEZ V, 1992, DEVELOPMENT, V115, P181; Dou YL, 1999, MOL CELL, V4, P641, DOI 10.1016/S1097-2765(00)80215-4; DYSON HJ, 1988, J MOL BIOL, V201, P201, DOI 10.1016/0022-2836(88)90447-0; Dyson HJ, 2005, NAT REV MOL CELL BIO, V6, P197, DOI 10.1038/nrm1589; Fink AL, 2005, CURR OPIN STRUC BIOL, V15, P35, DOI 10.1016/j.sbi.2005.01.002; HALL JM, 1985, BIOCHEMISTRY-US, V24, P7765, DOI 10.1021/bi00347a040; HARTMAN PG, 1977, EUR J BIOCHEM, V77, P45, DOI 10.1111/j.1432-1033.1977.tb11639.x; Hendzel MJ, 2004, J BIOL CHEM, V279, P20028, DOI 10.1074/jbc.M400070200; Iakoucheva LM, 2004, NUCLEIC ACIDS RES, V32, P1037, DOI 10.1093/nar/gkh253; IZAURRALDE E, 1989, J MOL BIOL, V210, P573, DOI 10.1016/0022-2836(89)90133-2; KENNEDY DF, 1991, BIOCHEMISTRY-US, V30, P6541, DOI 10.1021/bi00240a026; KHADAKE JR, 1995, BIOCHEMISTRY-US, V34, P15792, DOI 10.1021/bi00048a025; KHOCHBIN S, 1994, EUR J BIOCHEM, V225, P501, DOI 10.1111/j.1432-1033.1994.00501.x; Khochbin S, 2001, GENE, V271, P1, DOI 10.1016/S0378-1119(01)00495-4; Lee HL, 1998, EMBO J, V17, P1454, DOI 10.1093/emboj/17.5.1454; LENNOX RW, 1982, J BIOL CHEM, V257, P5183; LENNOX RW, 1984, J BIOL CHEM, V259, P669; LIAO LW, 1981, J BIOL CHEM, V256, P124; Lu X, 2004, J BIOL CHEM, V279, P8701, DOI 10.1074/jbc.M311348200; MANNING GS, 1979, BIOPOLYMERS, V18, P2929, DOI 10.1002/bip.1979.360181203; MIICK SM, 1992, NATURE, V359, P653, DOI 10.1038/359653a0; PANYIM S, 1969, BIOCHEM BIOPH RES CO, V37, P1042, DOI 10.1016/0006-291X(69)90237-X; PENNINGS S, 1994, P NATL ACAD SCI USA, V91, P10275, DOI 10.1073/pnas.91.22.10275; Ponte I, 1998, MOL BIOL EVOL, V15, P702, DOI 10.1093/oxfordjournals.molbev.a025973; Ponte I, 2003, MOL BIOL EVOL, V20, P371, DOI 10.1093/molbev/msg041; Reisdorf WC, 1996, BIOCHEMISTRY-US, V35, P1383, DOI 10.1021/bi951589v; RODRIGUEZ AT, 1991, BIOPHYS CHEM, V39, P145, DOI 10.1016/0301-4622(91)85016-J; Roque A, 2004, NUCLEIC ACIDS RES, V32, P6111, DOI 10.1093/nar/gkh945; Shen XT, 1996, CELL, V86, P475, DOI 10.1016/S0092-8674(00)80120-8; SUBIRANA JA, 1990, BIOPOLYMERS, V29, P1351, DOI 10.1002/bip.360291003; Talasz H, 1998, J BIOL CHEM, V273, P32236, DOI 10.1074/jbc.273.48.32236; Tanaka M, 2001, DEVELOPMENT, V128, P655; Th'ng JPH, 2005, J BIOL CHEM, V280, P27809, DOI 10.1074/jbc.M501627200; Vermaak D, 1998, CURR BIOL, V8, P533, DOI 10.1016/S0960-9822(98)70206-4; Vila R, 2000, PROTEIN SCI, V9, P627; Vila R, 2002, PROTEIN SCI, V11, P214, DOI 10.1110/ps.29602; Vila R, 2001, J BIOL CHEM, V276, P46429, DOI 10.1074/jbc.M106952200; Vila R, 2001, J BIOL CHEM, V276, P30898, DOI 10.1074/jbc.M104189200; Widlak P, 2005, BIOCHEMISTRY-US, V44, P7871, DOI 10.1021/bi050100n; WILSON RW, 1979, BIOCHEMISTRY-US, V18, P2192, DOI 10.1021/bi00578a009; Wolffe AP, 1997, BIOESSAYS, V19, P249, DOI 10.1002/bies.950190311; ZLATANOVA J, 1992, J CELL SCI, V103, P889	54	76	80	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	2005	280	37					32141	32147		10.1074/jbc.M505636200	http://dx.doi.org/10.1074/jbc.M505636200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	963HM	16006555	hybrid			2022-12-25	WOS:000231794800014
J	Inagaki, K; Kobayashi, H; Yoshida, R; Kanada, Y; Fukuda, Y; Yagyu, T; Kondo, T; Kurita, N; Kitanaka, T; Yamada, Y; Sakamoto, Y; Suzuki, M; Kanayama, N; Terao, T				Inagaki, K; Kobayashi, H; Yoshida, R; Kanada, Y; Fukuda, Y; Yagyu, T; Kondo, T; Kurita, N; Kitanaka, T; Yamada, Y; Sakamoto, Y; Suzuki, M; Kanayama, N; Terao, T			Suppression of urokinase expression and invasion by a soybean Kunitz trypsin inhibitor are mediated through inhibition of Src-dependent signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANCER CELL INVASION; PROTEASE INHIBITOR; BINDING-SITES; UP-REGULATION; KINASE; BIKUNIN; ACTIVATION; TRANSDUCTION; PROMOTION; PROTEINS	A soybean Kunitz trypsin inhibitor (KTI) interacts with cells as a negative modulator of the invasive cells. Using complementary pharmacological and genetic approaches, we provide novel findings regarding mechanisms by which KTI inhibits signaling pathways in ovarian cancer cells leading to invasion. Transforming growth factor-beta 1 (TGF-beta 1) directly activates Src kinase, which in turn activates ERK-phosphatidylinositol 3-kinase/Akt, the downstream targets of Src, for urokinase-type plasminogen activator (uPA) up-regulation in human ovarian cancer HRA cells. Preincubation of the HRA cells with KTI reduced the ability of TGF-beta 1 to trigger the uPA expression at the gene level and at the protein level. To further elucidate the mechanism of the KTI-dependent suppressive effect of TGF-beta 1-induced uPA expression and invasion, we investigated which signaling pathway transduced by KTI is responsible for this inhibitory effect. Here, we show that 1) KTI suppressed TGF-beta 1-induced phosphorylation of Src, ERK1/2, and Akt by 40-60%; 2) KTI was insensitive to suppress the phosphorylation of ERK1/2 and Akt in the constitutively active (CA)-c-Src (Y529F) cells; 3) uPA expression was up-regulated in TGF-beta 1-stimulated HRA cells and in unstimulated Y529F cells; 4) the addition of KTI reduced the TGF-beta 1-induced increase of uPA gene and protein expression in the wild-type c-Src-transfected cells (in contrast, KTI could not inhibit uPA expression in the Y529F cells); and 5) CA-c-Src transfection resulted in a 2-fold increase in invasiveness, whereas KTI did not reduce invasion of the Y529F cells. Using additional complementary genetic approaches (CA-MEK1, CA-Akt, or kinase-dead-Akt), we conclude that KTI may suppress uPA expression and promotion of invasion possibly through one or more upstream targets of Src.	NetForce Co Ltd, Nagoya, Aichi 4530801, Japan; Hamamatsu Univ Sch Med, Dept Obstet & Gynecol, Hamamatsu, Shizuoka 4313192, Japan; Fuji Oil Co Ltd, Tsukuba R&D Ctr, Food Sci Res Inst, Tsukuba, Ibaraki 3002497, Japan; Comp Technol Integrat Co Ltd, Izumisano, Osaka, Japan; Toyohashi Univ Technol, Dept Knowledge Based Informat Engn, Toyohashi, Aichi 4418580, Japan; Nara Med Univ, Dept Obstet & Gynecol, Kashihara, Nara 6348522, Japan	Hamamatsu University School of Medicine; Fuji Oil Co., Ltd.; Toyohashi University of Technology; Nara Medical University	Kobayashi, H (corresponding author), NetForce Co Ltd, Taiko 3-1-18, Nagoya, Aichi 4530801, Japan.	hirokoba@hama-med.ac.jp						Abram CL, 2000, EXP CELL RES, V254, P1, DOI 10.1006/excr.1999.4732; Derrien A, 2003, J BIOL CHEM, V278, P16107, DOI 10.1074/jbc.M210371200; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; Friedman M, 2001, J AGR FOOD CHEM, V49, P1069, DOI 10.1021/jf0009246; Fukuda K, 1998, ONCOGENE, V16, P3349, DOI 10.1038/sj.onc.1201896; Hirashima Y, 2001, J BIOL CHEM, V276, P13650, DOI 10.1074/jbc.M009906200; Jacob A, 2002, J BIOL CHEM, V277, P23420, DOI 10.1074/jbc.M202485200; KOBAYASHI H, 1994, J BIOL CHEM, V269, P20642; KOBAYASHI H, 1995, BRIT J CANCER, V72, P1131, DOI 10.1038/bjc.1995.476; Kobayashi H, 2004, CLIN EXP METASTAS, V21, P159, DOI 10.1023/B:CLIN.0000024751.73174.c2; Kobayashi H, 2004, INT J CANCER, V112, P519, DOI 10.1002/ijc.20430; Kobayashi H, 2003, BIOL CHEM, V384, P749, DOI 10.1515/BC.2003.083; Kobayashi H, 2003, J BIOL CHEM, V278, P7790, DOI 10.1074/jbc.M210407200; Kobayashi H, 2002, EUR J BIOCHEM, V269, P3945, DOI 10.1046/j.1432-1033.2002.03068.x; Kobayashi H, 2001, J BIOL CHEM, V276, P2015, DOI 10.1074/jbc.M007650200; Kobayashi H, 2000, J BIOL CHEM, V275, P21185, DOI 10.1074/jbc.M907862199; Kobayashi H, 2000, MOL HUM REPROD, V6, P735, DOI 10.1093/molehr/6.8.735; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Liu Q, 1998, J IMMUNOL, V160, P1393; Morel JCM, 2002, J BIOL CHEM, V277, P34679, DOI 10.1074/jbc.M206337200; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Saxena M, 1999, J BIOL CHEM, V274, P11693, DOI 10.1074/jbc.274.17.11693; Servitja JM, 2003, J BIOL CHEM, V278, P34339, DOI 10.1074/jbc.M302960200; Sutor SL, 1999, J BIOL CHEM, V274, P7002, DOI 10.1074/jbc.274.11.7002; Suzuki M, 2003, INT J CANCER, V104, P289, DOI 10.1002/ijc.10950; Suzuki M, 2003, J BIOL CHEM, V278, P14640, DOI 10.1074/jbc.M300239200; Suzuki M, 2002, J BIOL CHEM, V277, P8022, DOI 10.1074/jbc.M108545200; Suzuki M, 2001, BBA-PROTEIN STRUCT M, V1547, P26, DOI 10.1016/S0167-4838(01)00167-4; Tanaka Y, 2004, J BIOL CHEM, V279, P8567, DOI 10.1074/jbc.M309131200; Xi SC, 2003, J BIOL CHEM, V278, P31574, DOI 10.1074/jbc.M303499200	30	13	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	2005	280	36					31428	31437		10.1074/jbc.M501406200	http://dx.doi.org/10.1074/jbc.M501406200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	961LZ	16002410	hybrid			2022-12-25	WOS:000231665200013
J	Jalil, MA; Begum, L; Contreras, L; Pardo, B; Iijima, M; Li, MX; Ramos, M; Marmol, P; Horiuchi, M; Shimotsu, K; Nakagawa, S; Okubo, A; Sameshima, M; Isashiki, Y; del Arco, A; Kobayashi, K; Satrustegui, J; Saheki, T				Jalil, MA; Begum, L; Contreras, L; Pardo, B; Iijima, M; Li, MX; Ramos, M; Marmol, P; Horiuchi, M; Shimotsu, K; Nakagawa, S; Okubo, A; Sameshima, M; Isashiki, Y; del Arco, A; Kobayashi, K; Satrustegui, J; Saheki, T			Reduced N-acetylaspartate levels in mice lacking aralar, a brain- and muscle-type mitochondrial aspartate-glutamate carrier	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELIN LIPID-SYNTHESIS; ACETYL-L-ASPARTATE; NERVOUS-SYSTEM; GENE; CALCIUM; METABOLISM; EXPRESSION; CITRIN; MOUSE; GALACTOCEREBROSIDE	Aralar is a mitochondrial calcium-regulated aspartate-glutamate carrier mainly distributed in brain and skeletal muscle, involved in the transport of aspartate from mitochondria to cytosol, and in the transfer of cytosolic reducing equivalents into mitochondria as a member of the malate-aspartate NADH shuttle. In the present study, we describe the characteristics of aralar-deficient (Aralar(-/-)) mice, generated by a gene-trap method, showing no aralar mRNA and protein, and no detectable malate-aspartate shuttle activity in skeletal muscle and brain mitochondria. Aralar-/- mice were growth-retarded, exhibited generalized tremoring, and had pronounced motor coordination defects along with an impaired myelination in the central nervous system. Analysis of lipid components showed a marked decrease in the myelin lipid galactosyl cerebroside. The content of the myelin lipid precursor, N-acetylaspartate, and that of aspartate are drastically decreased in the brain of Aralar(-/-) mice. The defect in N-acetylaspartate production was also observed in cell extracts from primary neuronal cultures derived from Aralar(-/-) mouse embryos. These results show that aralar plays an important role in myelin formation by providing aspartate for the synthesis of N-acetylaspartate in neuronal cells.	Kagoshima Univ, Dept Mol Metab & Biochem Genet, Grad Sch Med & Dent Sci, Kagoshima 8908544, Japan; Kagoshima Univ, Lab Neuroanat, Grad Sch Med & Dent Sci, Kagoshima 8908544, Japan; Kagoshima Univ, Dept Ophthalmol, Grad Sch Med & Dent Sci, Kagoshima 8908544, Japan; Univ Autonoma Madrid, Dept Biol Mol, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain; Univ Castilla La Mancha, Fac Ciencias Med Ambiente, Toledo 45071, Spain	Kagoshima University; Kagoshima University; Kagoshima University; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); Universidad de Castilla-La Mancha	Saheki, T (corresponding author), Kagoshima Univ, Dept Mol Metab & Biochem Genet, Grad Sch Med & Dent Sci, 8-35-1 Sakuragaoka, Kagoshima 8908544, Japan.	takesah@m.kufm.kagoshima-u.ac.jp	Satrustegui, Jorgina/R-6732-2019; Contreras, Laura/ABG-7620-2021; Contreras, Laura/A-2296-2015; del Arco, Araceli/R-5653-2019	Contreras, Laura/0000-0003-1157-4942; Satrustegui Gil Delgado, Jorgina/0000-0003-3377-2667; RAMOS GOMEZ, MILAGROS/0000-0001-5798-9508; del Arco, Araceli/0000-0002-6839-542X				Barker PB, 2001, ANN NEUROL, V49, P423, DOI 10.1002/ana.90; Baslow MH, 2003, NEUROCHEM RES, V28, P941, DOI 10.1023/A:1023250721185; BAUMANN NA, 1968, EUR J BIOCHEM, V4, P340, DOI 10.1111/j.1432-1033.1968.tb00216.x; BEAUDET AL, 1995, METABOLIC MOL BASIS, P4599; Begum L, 2002, BBA-GENE STRUCT EXPR, V1574, P283, DOI 10.1016/S0167-4781(01)00376-1; Bhakoo KK, 2001, J NEUROCHEM, V79, P211, DOI 10.1046/j.1471-4159.2001.00561.x; BIRD TD, 1978, J NEUROCHEM, V31, P387, DOI 10.1111/j.1471-4159.1978.tb12479.x; Bjartmar C, 2002, ANN NEUROL, V51, P51, DOI 10.1002/ana.10052; Bosio A, 1996, P NATL ACAD SCI USA, V93, P13280, DOI 10.1073/pnas.93.23.13280; BURRI R, 1991, DEV NEUROSCI-BASEL, V13, P403, DOI 10.1159/000112191; CAMMER W, 1984, J NEUROCHEM, V42, P1372, DOI 10.1111/j.1471-4159.1984.tb02797.x; Chakraborty G, 2001, J NEUROCHEM, V78, P736, DOI 10.1046/j.1471-4159.2001.00456.x; CHEESEMAN AJ, 1988, J NEUROCHEM, V50, P1559, DOI 10.1111/j.1471-4159.1988.tb03044.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Coetzee T, 1996, CELL, V86, P209, DOI 10.1016/S0092-8674(00)80093-8; DADAMO AF, 1966, J NEUROCHEM, V13, P961, DOI 10.1111/j.1471-4159.1966.tb10292.x; del Arco A, 2000, BIOCHEM J, V345, P725, DOI 10.1042/0264-6021:3450725; del Arco A, 2002, EUR J BIOCHEM, V269, P3313, DOI 10.1046/j.1432-1033.2002.03018.x; del Arco A, 1998, J BIOL CHEM, V273, P23327, DOI 10.1074/jbc.273.36.23327; Demougeot C, 2001, J NEUROCHEM, V77, P408, DOI 10.1046/j.1471-4159.2001.00285.x; Heidenhain M., 1896, Z WISS MIKROSK, V13, P186; Hisaoka S, 2001, NEURORADIOLOGY, V43, P496, DOI 10.1007/s002340000520; Honke K, 2002, P NATL ACAD SCI USA, V99, P4227, DOI 10.1073/pnas.032068299; Kirmani BF, 2003, DEV BRAIN RES, V140, P105, DOI 10.1016/S0165-3806(02)00592-8; Kobayashi K, 1999, NAT GENET, V22, P159, DOI 10.1038/9667; Levitt JG, 2003, BIOL PSYCHIAT, V54, P1355, DOI 10.1016/S0006-3223(03)00688-7; Lu ZH, 2004, MOL BRAIN RES, V122, P71, DOI 10.1016/j.molbrainres.2003.12.002; MACALA LJ, 1983, J LIPID RES, V24, P1243; Madhavarao CN, 2005, P NATL ACAD SCI USA, V102, P5221, DOI 10.1073/pnas.0409184102; Madhavarao CN, 2003, J NEUROCHEM, V86, P824, DOI 10.1046/j.1471-4159.2003.01905.x; Marcus J, 2002, BBA-GEN SUBJECTS, V1573, P406, DOI 10.1016/S0304-4165(02)00410-5; Martin E, 2001, ANN NEUROL, V49, P518, DOI 10.1002/ana.102; MARTINEZSERRANO A, 1992, MOL BIOL CELL, V3, P235, DOI 10.1091/mbc.3.2.235; Matalon R, 2000, J GENE MED, V2, P165; MEHTA V, 1995, MOL BRAIN RES, V31, P151, DOI 10.1016/0169-328X(95)00044-S; Otsuka H, 1999, NEURORADIOLOGY, V41, P517, DOI 10.1007/s002340050795; Palmieri L, 2001, EMBO J, V20, P5060, DOI 10.1093/emboj/20.18.5060; PATEL TB, 1979, BIOCHEM J, V184, P539, DOI 10.1042/bj1840539; Ramos M, 2003, DEV BRAIN RES, V143, P33, DOI 10.1016/S0165-3806(03)00097-X; Ramoz N, 2004, AM J PSYCHIAT, V161, P662, DOI 10.1176/appi.ajp.161.4.662; ROLFE DFS, 1994, BBA-BIOENERGETICS, V1188, P405, DOI 10.1016/0005-2728(94)90062-0; Ruiz F, 1998, NEUROREPORT, V9, P1277; Saheki T, 2002, J HUM GENET, V47, P333, DOI 10.1007/s100380200046; Saher G, 2005, NAT NEUROSCI, V8, P468, DOI 10.1038/nn1426; Sanchez-Abarca LI, 2001, GLIA, V36, P321, DOI 10.1002/glia.1119; Sanz R, 2000, CYTOGENET CELL GENET, V89, P143, DOI 10.1159/000015595; Scherer SS, 1997, NEURON, V18, P13, DOI 10.1016/S0896-6273(01)80042-8; Sereda M, 1996, NEURON, V16, P1049, DOI 10.1016/S0896-6273(00)80128-2; Sinasac DS, 2004, MOL CELL BIOL, V24, P527, DOI 10.1128/MCB.24.2.527-536.2004; SVENNERHOLM L, 1956, J NEUROCHEM, V1, P42, DOI 10.1111/j.1471-4159.1956.tb12053.x; Takeda Y, 2003, J NEUROBIOL, V56, P252, DOI 10.1002/neu.10222; URENJAK J, 1992, J NEUROCHEM, V59, P55, DOI 10.1111/j.1471-4159.1992.tb08875.x; URENJAK J, 1993, J NEUROSCI, V13, P981, DOI 10.1523/jneurosci.13-03-00981.1993; Yasuda T, 2000, HUM GENET, V107, P537, DOI 10.1007/s004390000430; Zambrowicz BP, 1998, NATURE, V392, P608, DOI 10.1038/33423	55	123	126	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	2005	280	35					31333	31339		10.1074/jbc.M505286200	http://dx.doi.org/10.1074/jbc.M505286200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	958ZX	15987682	hybrid			2022-12-25	WOS:000231487800081
J	Rompler, M; Schulz, A; Pitra, C; Coop, G; Przeworski, M; Paabo, S; Schoneberg, T				Rompler, M; Schulz, A; Pitra, C; Coop, G; Przeworski, M; Paabo, S; Schoneberg, T			The rise and fall of the chemoattractant receptor GPR33	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; CHEMOKINE RECEPTOR; STATISTICAL-METHOD; HIV-1 INFECTION; HUMAN-DISEASES; GENE; RESISTANCE; EVOLUTION; RECOMBINATION; INDIVIDUALS	Chemokine and chemoattractant receptors are members of the large superfamily of G protein- coupled receptors ( GPCR), which control leukocyte chemotaxis. In addition to their physiological role, several chemokine and chemoattractant receptors, such as CCR5 and Duffy, have been directly associated with pathogen entry. GPR33 is an orphan chemoattractant GPCR that was previously identified as a pseudogene in humans. GPR33 evolved in mammals about 125 - 190 million years ago. The cloning and analysis of more than 120 mammalian GPR33 orthologs from 16 of 18 eutherian orders revealed an inactivation of this chemoattractant GPCR not only in humans, but also in several great ape and rodent species. Intriguingly, in all ape and some rodent species where the inactivation occurred, samples harbored both pseudogene and intact gene variants. The analysis of over 1200 human individuals representing all major linguistic groups revealed that the intact allele of GPR33 is still present in the human population. Estimates of the age of the human alleles suggest inactivation in the past 1 million years. Similarly, analysis of more than 120 wild- caught gray rats ( Rattus norvegicus), revealed that inactivation of gpr33 is worldwide fixed and occurred in less than 0.7 million years ago. The coincidental inactivation and its fixation in several species of distantly related mammalian orders suggest a selective pressure on this chemoattractant receptor gene.	Univ Leipzig, Fac Med, Inst Biochem, Max Planck Inst Interin, D-04103 Leipzig, Germany; Inst Zoo & Wildlife Res, Dept Evolut Genet, D-10315 Berlin, Germany; Univ Oxford, Dept Stat, Oxford OX1 3TG, England; Brown Univ, Dept Ecol & Evolutionary Biol, Providence, RI 02912 USA; Max Planck Inst Evolutionary Anthropol, D-04103 Leipzig, Germany	Leipzig University; Max Planck Society; Leibniz Institut fur Zoo und Wildtierforschung; University of Oxford; Brown University; Max Planck Society	Schoneberg, T (corresponding author), Univ Leipzig, Fac Med, Inst Biochem, Max Planck Inst Interin, Deutscher Pl 6, D-04103 Leipzig, Germany.	schoberg@medizin.uni-leipzig.de		Coop, Graham/0000-0001-8431-0302				Akey JM, 2004, PLOS BIOL, V2, P1591, DOI 10.1371/journal.pbio.0020286; [Anonymous], PHYLIP PHYLOGENY INF; Bamshad M, 2003, NAT REV GENET, V4, P99, DOI 10.1038/nrg999; BERRIDGE MJ, 1983, BIOCHEM J, V212, P849, DOI 10.1042/bj2120849; COOPER DN, 1989, HUM GENET, V83, P181, DOI 10.1007/BF00286715; Dubois JYF, 2002, J MOL EVOL, V55, P522, DOI 10.1007/s00239-002-2347-8; Fischer A, 2004, MOL BIOL EVOL, V21, P799, DOI 10.1093/molbev/msh083; FU YX, 1993, GENETICS, V133, P693; Galvani AP, 2003, P NATL ACAD SCI USA, V100, P15276, DOI 10.1073/pnas.2435085100; Gilad Y, 2003, P NATL ACAD SCI USA, V100, P3324, DOI 10.1073/pnas.0535697100; Griffiths RC, 2003, THEOR POPUL BIOL, V64, P241, DOI 10.1016/S0040-5809(03)00075-3; GRIFFITHS RC, 1997, PROGR POPULATION GEN, P165; Hadley TJ, 1997, BLOOD, V89, P3077, DOI 10.1182/blood.V89.9.3077; Helgason A, 2003, AM J HUM GENET, V72, P1370, DOI 10.1086/375453; Ji Q, 2002, NATURE, V416, P816, DOI 10.1038/416816a; Kaessmann H, 2002, J INTERN MED, V251, P1, DOI 10.1046/j.1365-2796.2002.00907.x; Kaessmann H, 1999, NAT GENET, V22, P78, DOI 10.1038/8785; Kostenis E, 2001, TRENDS PHARMACOL SCI, V22, P560, DOI 10.1016/S0165-6147(00)01810-1; Kumar S, 1998, NATURE, V392, P917, DOI 10.1038/31927; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; Marchese A, 1998, GENOMICS, V50, P281, DOI 10.1006/geno.1998.5297; Migeotte I, 2002, EUR J IMMUNOL, V32, P494, DOI 10.1002/1521-4141(200202)32:2<494::AID-IMMU494>3.0.CO;2-Y; Mighell AJ, 2000, FEBS LETT, V468, P109, DOI 10.1016/S0014-5793(00)01199-6; Mombaerts P, 2001, ANNU REV GENOM HUM G, V2, P493, DOI 10.1146/annurev.genom.2.1.493; Musser G G, 1993, MAMMAL SPECIES WORLD; Okada T, 2001, TRENDS BIOCHEM SCI, V26, P318, DOI 10.1016/S0968-0004(01)01799-6; Przeworski M, 2000, TRENDS GENET, V16, P296, DOI 10.1016/S0168-9525(00)02030-8; Przeworski M, 2002, GENETICS, V160, P1179; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Samson M, 1998, EUR J IMMUNOL, V28, P1689, DOI 10.1002/(SICI)1521-4141(199805)28:05<1689::AID-IMMU1689>3.0.CO;2-I; Schoneberg T, 2002, REV PHYSIOL BIOCH P, V144, P143; Schoneberg T, 1997, J CLIN INVEST, V100, P1547, DOI 10.1172/JCI119678; Schoneberg T, 2004, PHARMACOL THERAPEUT, V104, P173, DOI 10.1016/j.pharmthera.2004.08.008; Schulz A, 2003, J BIOL CHEM, V278, P35531, DOI 10.1074/jbc.M303346200; Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501; TAJIMA F, 1989, GENETICS, V123, P585; Thelen M, 2001, NAT IMMUNOL, V2, P129, DOI 10.1038/84224; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Vaughn MW, 2002, J IMMUNOL, V169, P3363, DOI 10.4049/jimmunol.169.6.3363; WATTERSON GA, 1975, THEOR POPUL BIOL, V7, P256, DOI 10.1016/0040-5809(75)90020-9; Wittamer V, 2003, J EXP MED, V198, P977, DOI 10.1084/jem.20030382; Woodburne MO, 2003, MOL PHYLOGENET EVOL, V28, P360, DOI 10.1016/S1055-7903(03)00113-1	43	24	24	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	2005	280	35					31068	31075		10.1074/jbc.M503586200	http://dx.doi.org/10.1074/jbc.M503586200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	958ZX	15987686	Green Published, hybrid			2022-12-25	WOS:000231487800051
J	Suzuki, T; Ishihara, K; Migaki, H; Ishihara, K; Nagao, M; Yamaguchi-Iwai, Y; Kambe, T				Suzuki, T; Ishihara, K; Migaki, H; Ishihara, K; Nagao, M; Yamaguchi-Iwai, Y; Kambe, T			Two different zinc transport complexes of cation diffusion facilitator proteins localized in the secretory pathway operate to activate alkaline phosphatases in vertebrate cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL-CHARACTERIZATION; CONFERS RESISTANCE; CRYSTAL-STRUCTURE; CLONING; EXPRESSION; SPECIFICITY; TRANSITION; EFFLUX; ZNT7	Zinc is an essential component for the catalytic activity of numerous zinc- requiring enzymes. However, until recently little has been known about the molecules involved in the pathways required for supplying zinc to these enzymes. We showed recently ( Suzuki, T., Ishihara, K., Migaki, H., Matsuura, W., Kohda, A., Okumura, K., Nagao, M., Yamaguchi- Iwai, Y., and Kambe, T. ( 2005) J. Biol. Chem. 280, 637 - 643) that zinc transporters, ZnT5 and ZnT7, are required for the activation of zinc- requiring enzymes, alkaline phosphatases ( ALPs), by transporting zinc into the lumens of the Golgi apparatus and the vesicular compartments where ALPs locate and converting apoALPs to holoALPs. ZnT6 is also located in the vesicular compartments like ZnT5 and ZnT7. However, the functions of ZnT6 and relationships among these three transporters have not been characterized yet. Here, we characterized the cellular function of ZnT6 together with ZnT5 and ZnT7 by gene- targeting studies using DT40 cells. ZnT6- deficient DT40 cells showed low ALP activity, suggesting that ZnT6 is required for the activation of zinc-requiring enzymes like ZnT5 and ZnT7. Combined disruptions of three transporter genes and re- expressions of transgenes revealed that ZnT5 and ZnT6 work in the same pathway, whereas ZnT7 acts alone. Furthermore, co- immunoprecipitation studies revealed that ZnT5 and ZnT6 formed hetero- oligomers, whereas ZnT7 formed homo- oligomers. Interestingly, the Ser- rich loop in ZnT6, a potential zinc- binding site, was dispensable for the zinc- supplying function of ZnT5/ ZnT6 hetero- oligomers, suggesting that the His- rich loop in ZnT5 may be important for zinc binding and that the loop in ZnT6 may acquire another function in the hetero- oligomer formation. These results suggest that two different zinc transport complexes operate to activate ALPs.	Kyoto Univ, Grad Sch Biostudies, Div Life Sci, Kyoto 6068502, Japan; Sugiyama Jogakuen Univ, Sch Life Studies, Dept Food & Nutr, Nagoya, Aichi 4648662, Japan	Kyoto University	Kambe, T (corresponding author), Kyoto Univ, Grad Sch Biostudies, Div Life Sci, Kyoto 6068502, Japan.	kambe1@kais.kyoto-u.ac.jp	Ishihara, Kengo/J-7913-2019	Ishihara, Kengo/0000-0001-9374-5033				Arakawa H, 2001, BMC Biotechnol, V1, P7, DOI 10.1186/1472-6750-1-7; Blaudez D, 2003, PLANT CELL, V15, P2911, DOI 10.1105/tpc.017541; Bloss T, 2002, PLANTA, V214, P783, DOI 10.1007/s00425-001-0677-1; Chimienti F, 2003, CURR DRUG TARGETS, V4, P323, DOI 10.2174/1389450033491082; Chimienti F, 2004, DIABETES, V53, P2330, DOI 10.2337/diabetes.53.9.2330; Ellis CD, 2005, J BIOL CHEM, V280, P28811, DOI 10.1074/jbc.M505500200; Ellis CD, 2004, J CELL BIOL, V166, P325, DOI 10.1083/jcb.200401157; Gaither LA, 2001, BIOMETALS, V14, P251, DOI 10.1023/A:1012988914300; Graf GA, 2003, J BIOL CHEM, V278, P48275, DOI 10.1074/jbc.M310223200; Huang LP, 2002, J BIOL CHEM, V277, P26389, DOI 10.1074/jbc.M200462200; Huang LP, 1997, NAT GENET, V17, P292, DOI 10.1038/ng1197-292; Kambe T, 2004, CELL MOL LIFE SCI, V61, P49, DOI 10.1007/s00018-003-3148-y; Kambe T, 2002, J BIOL CHEM, V277, P19049, DOI 10.1074/jbc.M200910200; Kirschke CP, 2003, J BIOL CHEM, V278, P4096, DOI 10.1074/jbc.M207644200; Kobayashi T, 1999, NAT CELL BIOL, V1, P113, DOI 10.1038/10084; Le Du MH, 2001, J BIOL CHEM, V276, P9158, DOI 10.1074/jbc.M009250200; Li LT, 1998, J BIOL CHEM, V273, P22181, DOI 10.1074/jbc.273.35.22181; Liuzzi JP, 2004, ANNU REV NUTR, V24, P151, DOI 10.1146/annurev.nutr.24.012003.132402; Murgia C, 1999, AM J PHYSIOL-GASTR L, V277, pG1231, DOI 10.1152/ajpgi.1999.277.6.G1231; Natesh R, 2003, NATURE, V421, P551, DOI 10.1038/nature01370; NIES DH, 1995, J IND MICROBIOL, V14, P186, DOI 10.1007/BF01569902; Overall CM, 2002, NAT REV CANCER, V2, P657, DOI 10.1038/nrc884; Palmiter RD, 2004, PFLUG ARCH EUR J PHY, V447, P744, DOI 10.1007/s00424-003-1070-7; Palmiter RD, 1996, P NATL ACAD SCI USA, V93, P14934, DOI 10.1073/pnas.93.25.14934; PALMITER RD, 1995, EMBO J, V14, P639, DOI 10.1002/j.1460-2075.1995.tb07042.x; Palmiter RD, 1996, EMBO J, V15, P1784, DOI 10.1002/j.1460-2075.1996.tb00527.x; PAULSEN LT, 1997, J MEMBRANE BIOL, V156, P99; Suzuki T, 2005, J BIOL CHEM, V280, P637, DOI 10.1074/jbc.M411247200; Wei YN, 2004, J BIOL CHEM, V279, P39251, DOI 10.1074/jbc.M407044200; Yamashita S, 2004, NATURE, V429, P298, DOI 10.1038/nature02545; Zhang Y, 1998, EMBO J, V17, P7304, DOI 10.1093/emboj/17.24.7304	31	129	137	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	2005	280	35					30956	30962		10.1074/jbc.M506902200	http://dx.doi.org/10.1074/jbc.M506902200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	958ZX	15994300	hybrid			2022-12-25	WOS:000231487800038
J	Tsuge, H; Kawakami, R; Sakuraba, H; Ago, H; Miyano, M; Aki, K; Katunuma, N; Ohshima, T				Tsuge, H; Kawakami, R; Sakuraba, H; Ago, H; Miyano, M; Aki, K; Katunuma, N; Ohshima, T			Crystal structure of a novel FAD-, FMN-, and ATP-containing L-proline dehydrogenase complex from Pyrococcus horikoshii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID DEHYDROGENASE; HYPERTHERMOPHILIC ARCHAEON; SALMONELLA-TYPHIMURIUM; 3-DIMENSIONAL STRUCTURE; THERMOCOCCUS-PROFUNDUS; ANGSTROM RESOLUTION; SARCOSINE OXIDASE; PROTEIN; REDUCTASE; FLAVOPROTEIN	Two novel types of dye- linked (L)- proline dehydrogenase complex ( PDH1 and PDH2) were found in a hyperthermophilic archaeon, Pyrococcus horikoshii OT3. Here we report the first crystal structure of PDH1, which is a heterooctameric complex (alpha beta) (4) containing three different cofactors: FAD, FMN, and ATP. The structure was determined by x- ray crystallography to a resolution of 2.86 angstrom. The structure of the beta subunit, which is an L- proline dehydrogenase catalytic component containing FAD as a cofactor, was similar to that of monomeric sarcosine oxidase. On the other hand, the alpha subunit possessed a unique structure composed of a classical dinucleotide fold domain with ATP, a central domain, an N- terminal domain, and a Cys- clustered domain. Serving as a third cofactor, FMN was located at the interface between the alpha and beta subunits in a novel configuration. The observed structure suggests that FAD and FMN are incorporated into an electron transfer system, with electrons passing from the former to the latter. The function of ATP is unknown, but it may play a regulatory role. Although the structure of the alpha subunit differs from that of the beta subunit, except for the presence of an analogous dinucleotide domain with a different cofactor, the structural characteristics of PDH1 suggest that each represents a divergent enzyme that arose from a common ancestral flavoenzyme and that they eventually formed a complex to gain a new function. The structural characteristics described here reveal the PDH1 complex to be a unique diflavin dehydrogenase containing a novel electron transfer system.	Tokushima Bunri Univ, Inst Hlth Sci, Yamashiro, Tokushima 7708514, Japan; Univ Tokushima, Fac Engn, Dept Biol Sci & Technol, Tokushima 7708506, Japan; RIKEN, Harima SPring 8, Struct Biophys Lab, Sayo, Hyogo 6795148, Japan; Univ Tokushima, Inst Enzyme Res, Tokushima, Tokushima 7708503, Japan	Tokushima Bunri University; Tokushima University; RIKEN; Tokushima University	Tsuge, H (corresponding author), Tokushima Bunri Univ, Inst Hlth Sci, 180 Nishihamabouji, Yamashiro, Tokushima 7708514, Japan.	tsuge@tokushima.bunri-u.ac.jp; ohshima@bio.tokushima-u.ac.jp	Tsuge, Hideaki/ABF-6424-2021; Miyano, Masashi/R-2785-2016	Miyano, Masashi/0000-0003-2253-6175; Ago, Hideo/0000-0002-9040-488X; Tsuge, Hideaki/0000-0003-0166-9163				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkt1223, 10.1093/nar/gkp985, 10.1093/nar/gkr1065]; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BRUNS CM, 1995, J MOL BIOL, V247, P125, DOI 10.1006/jmbi.1994.0127; Dym O, 2001, PROTEIN SCI, V10, P1712, DOI 10.1110/ps.12801; Eschenbrenner M, 2001, BIOCHEMISTRY-US, V40, P5352, DOI 10.1021/bi010101p; GRAHAM SB, 1984, J BIOL CHEM, V259, P2656; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; KARPLUS PA, 1987, J MOL BIOL, V195, P701, DOI 10.1016/0022-2836(87)90191-4; Kawakami R, 2004, EXTREMOPHILES, V8, P99, DOI 10.1007/s00792-003-0368-x; KAWAKAMI R, 2005, IN PRESS EUR J BIOCH; Lee YH, 2003, NAT STRUCT BIOL, V10, P109, DOI 10.1038/nsb885; LIM LW, 1988, J BIOL CHEM, V263, P3075; MALOY SR, 1983, J BACTERIOL, V154, P561, DOI 10.1128/JB.154.2.561-568.1983; Mattevi A, 1996, P NATL ACAD SCI USA, V93, P7496, DOI 10.1073/pnas.93.15.7496; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; MENZEL R, 1981, J BIOL CHEM, V256, P9755; MENZEL R, 1981, J BIOL CHEM, V256, P9762; Mizutani H, 1996, J BIOCHEM-TOKYO, V120, P14; MOSER CC, 1992, NATURE, V355, P796, DOI 10.1038/355796a0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Potterton E, 2003, ACTA CRYSTALLOGR D, V59, P1131, DOI 10.1107/S0907444903008126; Sakuraba H, 2001, APPL ENVIRON MICROB, V67, P1470, DOI 10.1128/AEM.67.4.1470-1475.2001; Satomura T, 2002, J BIOL CHEM, V277, P12861, DOI 10.1074/jbc.M112272200; Terwilliger T, 2004, J SYNCHROTRON RADIAT, V11, P49, DOI 10.1107/S0909049503023938; Trickey P, 1999, STRUCTURE, V7, P331, DOI 10.1016/S0969-2126(99)80043-4; Wang M, 1997, P NATL ACAD SCI USA, V94, P8411, DOI 10.1073/pnas.94.16.8411	27	36	39	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	2005	280	35					31045	31049		10.1074/jbc.C500234200	http://dx.doi.org/10.1074/jbc.C500234200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	958ZX	16027125	hybrid			2022-12-25	WOS:000231487800048
J	Vial, C; Evans, RJ				Vial, C; Evans, RJ			Disruption of lipid rafts inhibits P2X(1) receptor-mediated currents and arterial vasoconstriction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; CHAIN KINASE ACTIVATION; CA2+ TRANSIENTS; MESENTERIC-ARTERY; ADENYLYL-CYCLASE; VAS-DEFERENS; ION CHANNELS; MEMBRANE MICRODOMAINS; POTASSIUM CHANNELS; NERVE-STIMULATION	P2X(1) receptors for ATP are ligand- gated cation channels expressed on a range of smooth muscle preparations and blood platelets. The receptors appear to be clustered close to sympathetic nerve varicosities and mediate the underlying membrane potential changes and constriction following nerve stimulation in a range of arteries and resistance arterioles. In this study we have used discontinuous sucrose density gradients, Western blot analysis, and cholesterol measurements to show that recombinant and smooth muscle ( rat tail artery, vas deferens, and bladder) P2X(1) receptors are present in cholesterol- rich lipid rafts and co- localize with the lipid raft markers flotillin- 1 and - 2. Lipid rafts are specialized lipid membrane microdomains involved in signaling and trafficking. To determine whether lipid raft association was essential for P2X(1) receptor channel function we used the cholesterol- depleting agent methyl-beta cyclodextrin ( 10 mM for 1 h). This led to a redistribution of the P2X(1) receptor throughout the sucrose gradient and reduced P2X(1) receptor- mediated ( alpha, beta-methylene ATP, 10 mu M) currents in HEK293 cells by > 90% and contractions of the rat tail artery by similar to 50%. However contractions evoked by potassium chloride ( 60 mM) were unaffected by methyl- beta- cyclodextrin and the inactive analogue alpha- cyclodextrin had no effect on P2X(1) receptor- mediated currents or contractions. P2X(1) receptors are subject to ongoing regulation by receptors and kinases, and the present results suggest that lipid rafts are an essential component in the maintenance of these localized signaling domains and play an important role in P2X(1) receptor- mediated control of arteries.	Univ Leicester, Dept Cell Physiol & Pharmacol, Leicester LE1 9HN, Leics, England	University of Leicester	Evans, RJ (corresponding author), Univ Leicester, Dept Cell Physiol & Pharmacol, Leicester LE1 9HN, Leics, England.	rje6@le.ac.uk			Wellcome Trust [065573] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Bang B, 2005, EXP DERMATOL, V14, P266, DOI 10.1111/j.0906-6705.2005.00283.x; BENHAM CD, 1989, J PHYSIOL-LONDON, V419, P689, DOI 10.1113/jphysiol.1989.sp017893; BENHAM CD, 1987, NATURE, V328, P275, DOI 10.1038/328275a0; Berry DA, 1999, ELECTROPHORESIS, V20, P2059, DOI 10.1002/(SICI)1522-2683(19990701)20:10<2059::AID-ELPS2059>3.0.CO;2-T; Bickel PE, 1997, J BIOL CHEM, V272, P13793, DOI 10.1074/jbc.272.21.13793; Brady JD, 2004, MOL PHARMACOL, V65, P503, DOI 10.1124/mol.65.3.503; Brain KL, 2002, J PHYSIOL-LONDON, V541, P849, DOI 10.1113/jphysiol.2002.019612; Drab M, 2001, SCIENCE, V293, P2449, DOI 10.1126/science.1062688; Dreja K, 2002, ARTERIOSCL THROM VAS, V22, P1267, DOI 10.1161/01.ATV.0000023438.32585.A1; Ennion SJ, 2001, FEBS LETT, V489, P154, DOI 10.1016/S0014-5793(01)02102-0; EVANS RJ, 1992, N-S ARCH PHARMACOL, V345, P424; EVANS RJ, 1992, BRIT J PHARMACOL, V106, P242, DOI 10.1111/j.1476-5381.1992.tb14323.x; Foster LJ, 2003, P NATL ACAD SCI USA, V100, P5813, DOI 10.1073/pnas.0631608100; Galbiati F, 1999, J BIOL CHEM, V274, P5843, DOI 10.1074/jbc.274.9.5843; Gitterman DP, 2001, BRIT J PHARMACOL, V132, P1201, DOI 10.1038/sj.bjp.0703925; Grassme H, 2001, J BIOL CHEM, V276, P20589, DOI 10.1074/jbc.M101207200; Hansen MA, 1999, J AUTONOM NERV SYST, V75, P147, DOI 10.1016/S0165-1838(98)00189-1; Hechler B, 2003, J EXP MED, V198, P661, DOI 10.1084/jem.20030144; Heppner TJ, 2005, J PHYSIOL-LONDON, V564, P201, DOI 10.1113/jphysiol.2004.077826; Hering H, 2003, J NEUROSCI, V23, P3262; IINO M, 1994, EMBO J, V13, P5026, DOI 10.1002/j.1460-2075.1994.tb06831.x; Inscho EW, 2004, ACTA PHYSIOL SCAND, V181, P445, DOI 10.1111/j.1365-201X.2004.01317.x; Inscho EW, 2003, J CLIN INVEST, V112, P1895, DOI 10.1172/JCI200318499; Janes PW, 1999, J CELL BIOL, V147, P447, DOI 10.1083/jcb.147.2.447; Lai EC, 2003, J CELL BIOL, V162, P365, DOI 10.1083/jcb.200307087; Lamont C, 2003, J PHYSIOL-LONDON, V549, P801, DOI 10.1113/jphysiol.2003.043380; Lamont C, 2002, CIRC RES, V91, P454, DOI 10.1161/01.RES.0000035060.98415.4B; Lee H, 2001, J BIOL CHEM, V276, P35150, DOI 10.1074/jbc.M104530200; Lewis CJ, 2000, BRIT J PHARMACOL, V129, P124, DOI 10.1038/sj.bjp.0702993; Lewis CJ, 2001, DRUG DEVELOP RES, V52, P164, DOI 10.1002/ddr.1111; Lewis CJ, 2000, BRIT J PHARMACOL, V131, P1659, DOI 10.1038/sj.bjp.0703744; Lewis CJ, 2000, J PHYSIOL-LONDON, V527, P315, DOI 10.1111/j.1469-7793.2000.00315.x; Li JH, 2004, CIRCULATION, V110, P3049, DOI 10.1161/01.CIR.0000147188.46287.1B; Lohn M, 2000, CIRC RES, V87, P1034, DOI 10.1161/01.RES.87.11.1034; Malmsjo M, 1999, CARDIOVASC RES, V43, P219, DOI 10.1016/S0008-6363(99)00060-7; Martens JR, 2000, J BIOL CHEM, V275, P7443, DOI 10.1074/jbc.275.11.7443; Martens JR, 2004, TRENDS PHARMACOL SCI, V25, P16, DOI 10.1016/j.tips.2003.11.007; Mulryan K, 2000, NATURE, V403, P86, DOI 10.1038/47495; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Ostrom RS, 2002, MOL PHARMACOL, V62, P983, DOI 10.1124/mol.62.5.983; Ostrom RS, 2002, MOL PHARMACOL, V61, P473, DOI 10.1124/mol.61.3.473; Ostrom RS, 2001, J BIOL CHEM, V276, P42063, DOI 10.1074/jbc.M105348200; Oury C, 2004, J BIOL CHEM, V279, P26266, DOI 10.1074/jbc.M402032200; Oury C, 2003, BLOOD, V101, P3969, DOI 10.1182/blood-2002-10-3215; Pike LJ, 2004, BIOCHEM J, V378, P281, DOI 10.1042/BJ20031672; Ralevic V, 1998, PHARMACOL REV, V50, P413; RAMME D, 1987, N-S ARCH PHARMACOL, V336, P267; Reungpatthanaphong P, 2004, J BIOENERG BIOMEMBR, V36, P533, DOI 10.1007/s10863-004-9000-8; Rybin VO, 2000, J BIOL CHEM, V275, P41447, DOI 10.1074/jbc.M006951200; Sampson LJ, 2004, CIRC RES, V95, P1012, DOI 10.1161/01.RES.0000148634.47095.ab; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Toth-Zsamboki E, 2003, J BIOL CHEM, V278, P46661, DOI 10.1074/jbc.M308452200; Vacca F, 2004, J NEUROSCI RES, V76, P653, DOI 10.1002/jnr.20069; Vial C, 2004, BIOCHEM J, V382, P101, DOI 10.1042/BJ20031910; Vial C, 2002, MOL PHARMACOL, V62, P1438, DOI 10.1124/mol.62.6.1438; Vial C, 2002, BRIT J PHARMACOL, V135, P363, DOI 10.1038/sj.bjp.0704486; Wang LW, 2003, ARTERIOSCL THROM VAS, V23, P1370, DOI 10.1161/01.ATV.0000080350.37408.5A; Xia FZ, 2004, J BIOL CHEM, V279, P24685, DOI 10.1074/jbc.M314314200	58	82	82	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	2005	280	35					30705	30711		10.1074/jbc.M504256200	http://dx.doi.org/10.1074/jbc.M504256200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	958ZX	16006561	Green Accepted, hybrid			2022-12-25	WOS:000231487800009
J	Croonquist, PA; Van Ness, B				Croonquist, PA; Van Ness, B			The polycomb group protein enhancer of zeste homolog 2 (EZH2) is an oncogene that influences myeloma cell growth and the mutant ras phenotype	ONCOGENE			English	Article						myeloma; ras; EZH2	HISTONE METHYLTRANSFERASE ACTIVITY; THERAPEUTIC RESPONSE; H3 METHYLTRANSFERASE; ACTIVATING MUTATIONS; DROSOPHILA ENHANCER; MULTIPLE-MYELOMA; PROSTATE-CANCER; LINE ANBL6; GENE; DIFFERENTIATION	Three distinct proliferative signals for multiple myeloma (MM) cell lines induce enhancer of zeste homolog 2 (ezh2) transcript expression. EZH2 is a polycomb group protein that mediates repression of gene transcription at the chromatin level through its methyltransferase activity. Normal bone marrow plasma cells do not express ezh2; however, gene expression is induced and correlates with tumor burden during progression of this disease. We therefore investigated how EZH2 expression is deregulated in MM cell lines and determined the consequence of this activity on proliferation and transformation. We found that EZH2 protein expression is induced by interleukin 6 (IL-6) in growth factor-dependent cell lines and is constitutive in IL-6-independent cell lines. Furthermore, EZH2 expression correlates with proliferation and B-cell terminal differentiation. Significantly, EZH2 protein inhibition by short interference RNA treatment results in MM cell growth arrest. Conversely, EZH2 ectopic overexpression induces growth factor independence. We found that the growth factor-independent proliferative phenotype in MM cell lines harboring a mutant N- or K-ras gene requires EZH2 activity. Finally, this is the first report to demonstrate that EZH2 has oncogenic activity in vivo, and that cell transformation and tumor formation require histone methyltransferase activity.	Univ Minnesota, Dept Genet Cell Biol & Dev, Minneapolis, MN 55455 USA; Univ Minnesota, Grad Program Mol Cellular Dev Biol & Genet, Minneapolis, MN 55455 USA; Univ Minnesota, Ctr Canc, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Van Ness, B (corresponding author), Univ Minnesota, Dept Genet Cell Biol & Dev, Canc Ctr Res Bldg,MMC 806,6-160 Jackson Hall,321, Minneapolis, MN 55455 USA.	vanne001@umn.edu			NATIONAL CANCER INSTITUTE [P01CA062242, T32CA009138] Funding Source: NIH RePORTER; NCI NIH HHS [CA09138, CA62242] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Acs P, 1997, J BIOL CHEM, V272, P28793, DOI 10.1074/jbc.272.45.28793; Bajusz I, 2001, GENETICS, V159, P1135; Billadeau D, 1997, CANCER RES, V57, P2268; BILLADEAU D, 1995, CANCER RES, V55, P3640; Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Carrington EA, 1996, DEVELOPMENT, V122, P4073; Chen-Kiang S, 1995, Curr Top Microbiol Immunol, V194, P189; Chesi M, 1998, BLOOD, V92, P3025, DOI 10.1182/blood.V92.9.3025.421k53_3025_3034; Cheung WC, 2002, LEUKEMIA, V16, P1182, DOI 10.1038/sj.leu.2402481; Cheung WC, 2001, LEUKEMIA, V15, P264, DOI 10.1038/sj.leu.2402022; Croonquist PA, 2003, BLOOD, V102, P2581, DOI 10.1182/blood-2003-04-1227; Czermin B, 2002, CELL, V111, P185, DOI 10.1016/S0092-8674(02)00975-3; Denisenko O, 1998, MOL CELL BIOL, V18, P5634, DOI 10.1128/MCB.18.10.5634; Fukuyama T, 2000, BRIT J HAEMATOL, V108, P842, DOI 10.1046/j.1365-2141.2000.01914.x; JELINEK DF, 1993, CANCER RES, V53, P5320; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; Kuzmichev A, 2002, GENE DEV, V16, P2893, DOI 10.1101/gad.1035902; Muller J, 2002, CELL, V111, P197, DOI 10.1016/S0092-8674(02)00976-5; Nishioka K, 2002, GENE DEV, V16, P479, DOI 10.1101/gad.967202; Novina CD, 2002, NAT MED, V8, P681, DOI 10.1038/nm725; Raaphorst FM, 2001, J IMMUNOL, V166, P5925, DOI 10.4049/jimmunol.166.10.5925; Raaphorst FM, 2000, AM J PATHOL, V157, P709, DOI 10.1016/S0002-9440(10)64583-X; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Rowley M, 2000, BLOOD, V96, P3175, DOI 10.1182/blood.V96.9.3175.h8003175_3175_3180; Sears RC, 2002, J BIOL CHEM, V277, P11617, DOI 10.1074/jbc.R100063200; Tachibana M, 2001, J BIOL CHEM, V276, P25309, DOI 10.1074/jbc.M101914200; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Visser HPJ, 2001, BRIT J HAEMATOL, V112, P950, DOI 10.1046/j.1365-2141.2001.02641.x; Wang X, 2001, J BIOL CHEM, V276, P40417, DOI 10.1074/jbc.M104765200; Westendorf JJ, 1996, LEUKEMIA, V10, P866; Zhan FH, 2003, BLOOD, V101, P1128, DOI 10.1182/blood-2002-06-1737; Zhan FH, 2002, BLOOD, V99, P1745, DOI 10.1182/blood.V99.5.1745	33	124	134	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	41					6269	6280		10.1038/sj.onc.1208771	http://dx.doi.org/10.1038/sj.onc.1208771			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	964JM	16007202				2022-12-25	WOS:000231877100008
J	Yan, SR; Joseph, RR; Rosen, K; Reginato, MJ; Jackson, A; Allaire, N; Brugge, JS; Jobin, C; Stadnyk, AW				Yan, SR; Joseph, RR; Rosen, K; Reginato, MJ; Jackson, A; Allaire, N; Brugge, JS; Jobin, C; Stadnyk, AW			Activation of NF-kappa B following detachment delays apoptosis in intestinal epithelial cells	ONCOGENE			English	Article						anoikis; intestinal epithelial cell; apoptosis; NF-kappa B; detachment	INDUCED NEUTROPHIL APOPTOSIS; ULCERATIVE-COLITIS; GENE-EXPRESSION; KINASE; ALPHA; RECEPTOR; ANOIKIS; PHOSPHORYLATION; INHIBITION; CANCER	We reported earlier that IL-1 beta, an NF-kappa B-regulated cytokine, was made by intestinal epithelial cells during detachment-induced apoptosis (anoikis) and that IL-1 was antiapoptotic for detached cells. Since surviving anoikis is a prerequisite for cancer progression and metastases, we are further exploring the link between anoikis and cytokines. Here we determined that multiple genes are expressed following detachment including a number of NF-kappa B- regulated products and therefore aimed to determine whether NF-kappa B signalling plays any role in regulating apoptosis. Using Western blotting, we detected that I kappa B alpha becomes phosphorylated immediately following detachment and that levels of phospho-I kappa B alpha peaked within 20 min. Phosphorylation of I kappa B alpha was followed by Rel A (p65) nuclear translocation. Increased NF-kappa B activity following detachment was confirmed using the detection of NF-kappa B-promoted luciferase gene expression delivered by adenovirus infection. Infection of cells with adenovirus expressing a super-repressor I kappa B alpha protein and pharmacological inhibitors of NF-kappa B resulted in the failure to phosphorylate I kappa B alpha, a more rapid activation of caspases and earlier apoptosis. We also detected that I kappa B kinase alpha (IKK alpha) and not IKK beta became phosphorylated following detachment. Since IKK alpha is activated by NF-kappa B-inducing kinase (NIK), we overexpressed native NIK using an adenovirus vector that resulted in enhanced phospho-I kappa B alpha and nuclear p65 in detached cells compared to control detached cells but did not result in a significantly greater number of cells surviving to 24 h. We conclude that detachment directly activates NF-kappa B, which, in addition to launching an inflammatory cytokine wave, contributes to a delay in apoptosis in intestinal epithelial cells.	Dalhousie Univ, Dept Pediat, Halifax, NS B3H 4R2, Canada; Dalhousie Univ, Dept Microbiol & Immunol, Halifax, NS B3H 4R2, Canada; Dalhousie Univ, Dept Biochem & Mol Biol, Halifax, NS B3H 4R2, Canada; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Aventis Pharmaceut, Cambridge, MA USA; Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA	Dalhousie University; Dalhousie University; Dalhousie University; Harvard University; Harvard Medical School; Sanofi-Aventis; University of North Carolina; University of North Carolina Chapel Hill	Stadnyk, AW (corresponding author), IWK Hlth Ctr, Mucosal Immunol Res, 5850 Univ Ave, Halifax, NS B3K 6R8, Canada.	astadnyk@dal.ca	Reginato, Mauricio/I-6155-2013	Reginato, Mauricio/0000-0002-7541-4094	NCI NIH HHS [R01 CA105134] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA105134] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Bader T, 1996, J IMMUNOL, V157, P3089; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Beinke S, 2004, BIOCHEM J, V382, P393, DOI 10.1042/BJ20040544; BETT AJ, 1994, P NATL ACAD SCI USA, V91, P8802, DOI 10.1073/pnas.91.19.8802; Biswas DK, 2003, CANCER RES, V63, P290; Bonner S, 2001, INFECT IMMUN, V69, P3143, DOI 10.1128/IAI.69.5.3143-3149.2001; Chen YH, 2000, BIOCHEM BIOPH RES CO, V274, P576, DOI 10.1006/bbrc.2000.3176; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; Clevers H, 2004, CELL, V118, P671, DOI 10.1016/j.cell.2004.09.005; Colell A, 2002, FEBS LETT, V526, P15, DOI 10.1016/S0014-5793(02)03106-X; Douma S, 2004, NATURE, V430, P1034, DOI 10.1038/nature02765; Elewaut D, 1999, J IMMUNOL, V163, P1457; Evertsson S, 2002, INT J MOL MED, V10, P547; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Gill JS, 2000, NEUROBIOL DIS, V7, P448, DOI 10.1006/nbdi.2000.0312; GILLEN CD, 1994, GUT, V35, P1590, DOI 10.1136/gut.35.11.1590; Hochstrasser M, 1996, CELL, V84, P813, DOI 10.1016/S0092-8674(00)81058-2; Jijon H, 2004, CELL SIGNAL, V16, P1023, DOI 10.1016/j.cellsig.2004.02.005; Jobin C, 1997, J IMMUNOL, V158, P226; Jobin C, 1998, J IMMUNOL, V160, P410; Jobin C, 1998, GUT, V42, P779, DOI 10.1136/gut.42.6.779; Karlen P, 1999, AM J GASTROENTEROL, V94, P1047; Kuhnel F, 2000, J BIOL CHEM, V275, P6421, DOI 10.1074/jbc.275.9.6421; Lin Y, 2000, MOL CELL BIOL, V20, P6638, DOI 10.1128/MCB.20.18.6638-6645.2000; Ma A, 2001, MOL BIOL CELL, V12, P1; MAHER PA, 1993, P NATL ACAD SCI USA, V90, P11177, DOI 10.1073/pnas.90.23.11177; Miller TL, 2002, IMMUNOLOGY, V105, P101, DOI 10.1046/j.0019-2805.2001.01352.x; Niwa M, 1999, EUR J PHARMACOL, V371, P59, DOI 10.1016/S0014-2999(99)00145-4; Pahl HL, 1996, J EXP MED, V183, P1829, DOI 10.1084/jem.183.4.1829; Ramakrishnan P, 2004, IMMUNITY, V21, P477, DOI 10.1016/j.immuni.2004.08.009; Rosen K, 2002, J BIOL CHEM, V277, P46123, DOI 10.1074/jbc.M207883200; Russo MP, 2004, CELL SIGNAL, V16, P741, DOI 10.1016/j.cellsig.2003.11.007; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Savkovic SD, 1997, AM J PHYSIOL-CELL PH, V273, pC1160, DOI 10.1152/ajpcell.1997.273.4.C1160; Scaife CL, 2002, CANCER RES, V62, P6870; Shanmugathasan M, 2000, PATHOL INT, V50, P273, DOI 10.1046/j.1440-1827.2000.01047.x; Shibata Y, 1996, J IMMUNOL, V156, P772; STADNYK AW, 1995, EXP CELL RES, V220, P298, DOI 10.1006/excr.1995.1319; Strater J, 1996, GASTROENTEROLOGY, V110, P1776, DOI 10.1053/gast.1996.v110.pm8964403; Theilhaber J, 2001, J COMPUT BIOL, V8, P585, DOI 10.1089/106652701753307502; Vachon PH, 2002, GASTROENTEROLOGY, V123, P1980, DOI 10.1053/gast.2002.37072; van der Woude CJ, 2004, APOPTOSIS, V9, P123, DOI 10.1023/B:APPT.0000018794.26438.22; Ward C, 1999, J BIOL CHEM, V274, P4309, DOI 10.1074/jbc.274.7.4309; Waterhouse CCM, 1999, CELL IMMUNOL, V193, P1, DOI 10.1006/cimm.1999.1468; Waterhouse CCM, 2001, EXP CELL RES, V269, P109, DOI 10.1006/excr.2001.5303; Weaver VM, 2002, CANCER CELL, V2, P205, DOI 10.1016/S1535-6108(02)00125-3; Yamashita K, 1999, BLOOD, V93, P674, DOI 10.1182/blood.V93.2.674.402k26_674_685; Yang CL, 2001, J BIOL CHEM, V276, P47277, DOI 10.1074/jbc.M105396200; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533	50	43	45	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	43					6482	6491		10.1038/sj.onc.1208810	http://dx.doi.org/10.1038/sj.onc.1208810			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	968ZV	16007176	Green Accepted			2022-12-25	WOS:000232204100002
J	Ameziane-El-Hassani, R; Morand, S; Boucher, JL; Frapart, YM; Apostolou, D; Agnandji, D; Gnidehou, S; Ohayon, R; Noel-Hudson, MS; Francon, J; Lalaoui, K; Virion, A; Dupuy, C				Ameziane-El-Hassani, R; Morand, S; Boucher, JL; Frapart, YM; Apostolou, D; Agnandji, D; Gnidehou, S; Ohayon, R; Noel-Hudson, MS; Francon, J; Lalaoui, K; Virion, A; Dupuy, C			Dual oxidase-2 has an intrinsic Ca2+-dependent H2O2-generating activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AIRWAY EPITHELIAL-CELLS; THYROID PARTICULATE FRACTION; NADPH-OXIDASE; HYDROGEN-PEROXIDE; PLASMA-MEMBRANE; NAD(P)H OXIDASE; REACTIVE OXYGEN; SUPEROXIDE ANION; ACTIVATION; PORCINE	Duox2 ( and probably Duox1) is a glycoflavoprotein involved in thyroid hormone biosynthesis, as the thyroid H2O2 generator functionally associated with Tpo (thyroperoxidase). So far, because of the impairment of maturation and of the targeting process, transfecting DUOX into nonthyroid cell lines has not led to the expression of a functional H2O2-generating system at the plasma membrane. For the first time, we investigated the H2O2-generating activity in the particulate fractions from DUOX2- and DUOX1-transfected HEK293 and Chinese hamster ovary cells. The particulate fractions of these cells stably or transiently transfected with human or porcine DUOX cDNA demonstrate a functional NADPH/Ca2+-dependent H2O2-generating activity. The immature Duox proteins had less activity than pig thyrocyte particulate fractions, and their activity depended on their primary structures. Human Duox2 seemed to be more active than human Duox1 but only half as active as its porcine counterpart. TPO co-transfection produced a slight increase in the enzymatic activity, whereas p22(phox), the 22-kDa subunit of the leukocyte NADPH oxidase, had no effect. In previous studies on the mechanism of H2O2 formation, it was shown that mature thyroid NADPH oxidase does not release O-2. but H2O2. Using a spin-trapping technique combined with electron paramagnetic resonance spectroscopy, we confirmed this result but also demonstrated that the partially glycosylated form of Duox2, located in the endoplasmic reticulum, generates superoxide in a calcium-dependent manner. These results suggest that post-translational modifications during the maturation process of Duox2 could be implicated in the mechanism of H2O2 formation by favoring intramolecular superoxide dismutation.	Univ Paris 11, INSERM, Unite 486, Fac Pharm, F-92296 Chatenay Malabry, France; Univ Paris 05, CNRS, UMR 8601, F-75270 Paris, France; Ctr Natl Energie Sci & Tech Nucl, Dept Sci Vivant, Rabat 10000, Morocco	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; Universite Paris Cite	Dupuy, C (corresponding author), Univ Paris 11, INSERM, Unite 486, Fac Pharm, 5,Rue JB Clement, F-92296 Chatenay Malabry, France.	corinne.dupuy@cep.u-psud.fr		Yves-Michel, FRAPART/0000-0003-3854-3580				Ambasta RK, 2004, J BIOL CHEM, V279, P45935, DOI 10.1074/jbc.M406486200; Arbiser JL, 2002, P NATL ACAD SCI USA, V99, P715, DOI 10.1073/pnas.022630199; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Banfi B, 2004, J BIOL CHEM, V279, P18583, DOI 10.1074/jbc.M310268200; Banfi B, 2001, J BIOL CHEM, V276, P37594, DOI 10.1074/jbc.M103034200; BJORKMAN U, 1984, ENDOCRINOLOGY, V115, P392; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brar SS, 2003, AM J PHYSIOL-CELL PH, V285, pC353, DOI 10.1152/ajpcell.00525.2002; BURDON RH, 1995, FREE RADICAL BIO MED, V18, P775, DOI 10.1016/0891-5849(94)00198-S; Caillou B, 2001, J CLIN ENDOCR METAB, V86, P3351, DOI 10.1210/jc.86.7.3351; Chamulitrat W, 2003, ONCOGENE, V22, P6045, DOI 10.1038/sj.onc.1206654; CORVILAIN B, 1994, J CLIN ENDOCR METAB, V79, P152, DOI 10.1210/jc.79.1.152; CORVILAIN B, 1991, ENDOCRINOLOGY, V128, P779, DOI 10.1210/endo-128-2-779; De Deken X, 2000, J BIOL CHEM, V275, P23227, DOI 10.1074/jbc.M000916200; De Deken X, 2002, EXP CELL RES, V273, P187, DOI 10.1006/excr.2001.5444; DEME D, 1985, FEBS LETT, V186, P107, DOI 10.1016/0014-5793(85)81349-1; Dupuy C, 2000, BIOCHEM BIOPH RES CO, V277, P287, DOI 10.1006/bbrc.2000.3671; DUPUY C, 1989, EUR J BIOCHEM, V185, P597, DOI 10.1111/j.1432-1033.1989.tb15155.x; DUPUY C, 1992, BIOCHEM J, V283, P591, DOI 10.1042/bj2830591; Dupuy C, 1999, J BIOL CHEM, V274, P37265, DOI 10.1074/jbc.274.52.37265; DUPUY C, 1991, J BIOL CHEM, V266, P3739; Edens WA, 2001, J CELL BIOL, V154, P879, DOI 10.1083/jcb.200103132; EKHOLM R, 1981, MOL CELL ENDOCRINOL, V24, P141, DOI 10.1016/0303-7207(81)90056-3; El Hassani RA, 2005, AM J PHYSIOL-GASTR L, V288, pG933, DOI 10.1152/ajpgi.00198.2004; Fayadat L, 1998, ENDOCRINOLOGY, V139, P4277, DOI 10.1210/en.139.10.4277; Forteza R, 2005, AM J RESP CELL MOL, V32, P462, DOI 10.1165/rcmb.2004-0302OC; Geiszt M, 2003, FASEB J, V17, P1502, DOI 10.1096/fj.02-1104fje; Geiszt M, 2000, P NATL ACAD SCI USA, V97, P8010, DOI 10.1073/pnas.130135897; HEINECKE JW, 1989, P NATL ACAD SCI USA, V86, P1259, DOI 10.1073/pnas.86.4.1259; Kikuchi H, 2000, GENE, V254, P237, DOI 10.1016/S0378-1119(00)00258-4; Lambeth JD, 2004, NAT REV IMMUNOL, V4, P181, DOI 10.1038/nri1312; Leseney AM, 1999, BIOCHIMIE, V81, P373, DOI 10.1016/S0300-9084(99)80084-4; Mitsushita J, 2004, CANCER RES, V64, P3580, DOI 10.1158/0008-5472.CAN-03-3909; Morand S, 2003, ENDOCRINOLOGY, V144, P1241, DOI 10.1210/en.2002-220981; Morand S, 2004, J BIOL CHEM, V279, P30244, DOI 10.1074/jbc.M405406200; Moreno JC, 2002, NEW ENGL J MED, V347, P95, DOI 10.1056/NEJMoa012752; NAKAMURA Y, 1989, J BIOL CHEM, V264, P4759; NAKAMURA Y, 1987, J BIOCHEM-TOKYO, V102, P1121, DOI 10.1093/oxfordjournals.jbchem.a122150; NAKAMURA Y, 1991, BIOCHEMISTRY-US, V30, P4880, DOI 10.1021/bi00234a007; Schwarzer C, 2004, J BIOL CHEM, V279, P36454, DOI 10.1074/jbc.M404983200; Shao MXG, 2005, P NATL ACAD SCI USA, V102, P767, DOI 10.1073/pnas.0408932102; Shi HL, 2005, ARCH BIOCHEM BIOPHYS, V437, P59, DOI 10.1016/j.abb.2005.02.028; Shiose A, 2001, J BIOL CHEM, V276, P1417, DOI 10.1074/jbc.M007597200; Sugawara M, 2002, EXP BIOL MED, V227, P141, DOI 10.1177/153537020222700209; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; Takeya R, 2003, J BIOL CHEM, V278, P25234, DOI 10.1074/jbc.M212856200; VIRION A, 1985, ARCH BIOCHEM BIOPHYS, V242, P41, DOI 10.1016/0003-9861(85)90477-1; Wang DT, 2005, J BIOL CHEM, V280, P3096, DOI 10.1074/jbc.M407709200; Wong JL, 2004, DEV CELL, V7, P801, DOI 10.1016/j.devcel.2004.10.014; Zhao HT, 2001, FREE RADICAL BIO MED, V31, P599, DOI 10.1016/S0891-5849(01)00619-0	50	166	173	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	2005	280	34					30046	30054		10.1074/jbc.M500516200	http://dx.doi.org/10.1074/jbc.M500516200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	957IC	15972824	hybrid			2022-12-25	WOS:000231362500009
J	Cuthbertson, L; Powers, J; Whitfield, C				Cuthbertson, L; Powers, J; Whitfield, C			The C-terminal domain of the nucleotide-binding domain protein Wzt determines substrate specificity in the ATP-binding cassette transporter for the lipopolysaccharide O-antigens in Escherichia coli serotypes O8 and O9a	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEAROTHERMOPHILUS NRS 2004/3A; CAPSULAR POLYSIALIC ACID; S-LAYER GLYCOPROTEIN; ABC-TRANSPORTER; GENE-CLUSTER; SALMONELLA-TYPHIMURIUM; KLEBSIELLA-PNEUMONIAE; MALTOSE TRANSPORT; NEISSERIA-MENINGITIDIS; CYTOPLASMIC MEMBRANE	The polymannan O-antigenic polysaccharides ( O-PSs) of Escherichia coli O8 and O9a are synthesized via an ATP-binding cassette ( ABC) transporter-dependent pathway. The group 2 capsular polysaccharides of E. coli serve as prototypes for polysaccharide synthesis and export via this pathway. Here, we show that there are some fundamental differences between the ABC transporter-dependent pathway for O-PS biosynthesis and the capsular polysaccharide paradigm. In the capsule system, mutants lacking the ABC transporter are viable, and membranes isolated from these strains are no longer able to synthesize polymer using an endogenous acceptor. In contrast, E. coli strains carrying mutations in the membrane component ( Wzm) and/or the nucleotide-binding component ( Wzt) of the O8 and O9a polymannan transporters are nonviable under conditions permissive to O-PS biosynthesis and take on an aberrant elongated cell morphology. Whereas the ABC transporters for capsular polysaccharides with different structures are functionally interchangeable, the O8 and O9a exporters are specific for their cognate polymannan substrates. The E. coli O8 and O9a Wzt proteins contain a C-terminal domain not present in the corresponding nucleotide-binding protein ( KpsT) from the capsule exporter. Whereas the Wzm components are functionally interchangeable, albeit with reduced efficiency, the Wzt components are not, indicating a specific role for Wzt in substrate specificity. Chimeric Wzt proteins were constructed in order to localize the region involved in substrate specificity to the C-terminal domain.	Univ Guelph, Dept Mol & Cellular Biol, Guelph, ON N1G 2W1, Canada	University of Guelph	Whitfield, C (corresponding author), Univ Guelph, Dept Mol & Cellular Biol, Guelph, ON N1G 2W1, Canada.	cwhitfie@uoguelph.ca						ALEXANDER DC, 1994, J BACTERIOL, V176, P7079, DOI 10.1128/JB.176.22.7079-7084.1994; Altenberg GA, 2003, NEWS PHYSIOL SCI, V18, P191, DOI 10.1152/nips.01445.2003; Amor PA, 1997, MOL MICROBIOL, V26, P145, DOI 10.1046/j.1365-2958.1997.5631930.x; Bacon DJ, 2001, MOL MICROBIOL, V40, P769, DOI 10.1046/j.1365-2958.2001.02431.x; Benabdelhak H, 2003, J MOL BIOL, V327, P1169, DOI 10.1016/S0022-2836(03)00204-3; Bliss JM, 1996, MOL MICROBIOL, V21, P221, DOI 10.1046/j.1365-2958.1996.6461357.x; Bliss JM, 1996, GLYCOBIOLOGY, V6, P445, DOI 10.1093/glycob/6.4.445; BRONNER D, 1993, FEMS MICROBIOL LETT, V113, P279, DOI 10.1016/0378-1097(93)90218-Q; BRONNER D, 1993, J BACTERIOL, V175, P5984, DOI 10.1128/JB.175.18.5984-5992.1993; Cieslewicz M, 1996, J BACTERIOL, V178, P3212, DOI 10.1128/jb.178.11.3212-3220.1996; Clarke BR, 2004, J BIOL CHEM, V279, P35709, DOI 10.1074/jbc.M404738200; Davidson AL, 2004, ANNU REV BIOCHEM, V73, P241, DOI 10.1146/annurev.biochem.73.011303.073626; DAVIDSON AL, 1992, P NATL ACAD SCI USA, V89, P2360, DOI 10.1073/pnas.89.6.2360; Diederichs K, 2000, EMBO J, V19, P5951, DOI 10.1093/emboj/19.22.5951; Edwards RA, 1998, GENE, V207, P149, DOI 10.1016/S0378-1119(97)00619-7; Frirdich E, 2004, J BIOL CHEM, V279, P27928, DOI 10.1074/jbc.M402549200; GOTSCHLICH EC, 1981, J BIOL CHEM, V256, P8915; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; HITCHCOCK PJ, 1983, J BACTERIOL, V154, P269, DOI 10.1128/JB.154.1.269-277.1983; Holland IB, 1999, J MOL BIOL, V293, P381, DOI 10.1006/jmbi.1999.2993; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; Izquierdo L, 2003, J BACTERIOL, V185, P1634, DOI 10.1128/JB.185.5.1634-1641.2003; JANN K, 1982, EUR J BIOCHEM, V127, P157, DOI 10.1111/j.1432-1033.1982.tb06850.x; Joly N, 2004, J BIOL CHEM, V279, P33123, DOI 10.1074/jbc.M403615200; Jones PM, 1999, FEMS MICROBIOL LETT, V179, P187, DOI 10.1111/j.1574-6968.1999.tb08727.x; Kahlig H, 2005, J BIOL CHEM, V280, P20292, DOI 10.1074/jbc.M501724200; KIDO N, 1995, J BACTERIOL, V177, P2178, DOI 10.1128/jb.177.8.2178-2187.1995; Kobayashi M, 1997, J BIOL CHEM, V272, P27197, DOI 10.1074/jbc.272.43.27197; KOPMANN HJ, 1975, EUR J BIOCHEM, V60, P587, DOI 10.1111/j.1432-1033.1975.tb21037.x; KRONCKE KD, 1990, J BACTERIOL, V172, P3469; KUHNAU S, 1991, J BACTERIOL, V173, P2180; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Lee HM, 1998, FEBS LETT, V427, P291, DOI 10.1016/S0014-5793(98)00451-7; LEFEBVRE B, 1995, BIOTECHNIQUES, V19, P186; Linton KJ, 1998, MOL MICROBIOL, V28, P5, DOI 10.1046/j.1365-2958.1998.00764.x; Lo RYC, 2001, INFECT IMMUN, V69, P4458, DOI 10.1128/IAI.69.7.4458-4464.2001; Locher KP, 2004, CURR OPIN STRUC BIOL, V14, P426, DOI 10.1016/j.sbi.2004.06.005; MACLACHLAN PR, 1991, J BACTERIOL, V173, P7151, DOI 10.1128/jb.173.22.7151-7163.1991; MCGRATH BC, 1991, J BACTERIOL, V173, P649, DOI 10.1128/jb.173.2.649-654.1991; NELSON SO, 1984, J BACTERIOL, V160, P360, DOI 10.1128/JB.160.1.360-364.1984; Novotny R, 2004, MICROBIOL-SGM, V150, P953, DOI 10.1099/mic.0.26672-0; PAVELKA MS, 1991, J BACTERIOL, V173, P4603, DOI 10.1128/jb.173.15.4603-4610.1991; PAVELKA MS, 1994, J BIOL CHEM, V269, P20149; PEARCE R, 1995, J BACTERIOL, V177, P3992, DOI 10.1128/jb.177.14.3992-3997.1995; Persson K, 2001, NAT STRUCT BIOL, V8, P166, DOI 10.1038/84168; PETRONILLI V, 1991, J BIOL CHEM, V266, P16293; PIGEON RP, 1994, MOL MICROBIOL, V14, P871, DOI 10.1111/j.1365-2958.1994.tb01323.x; QUIOCHO FA, 1990, PHILOS T R SOC B, V326, P341, DOI 10.1098/rstb.1990.0016; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; Rahn A, 2003, MOL MICROBIOL, V47, P1045, DOI 10.1046/j.1365-2958.2003.03354.x; Reyes CL, 2005, SCIENCE, V308, P1028, DOI 10.1126/science.1107733; REYES M, 1988, J BACTERIOL, V170, P4598, DOI 10.1128/jb.170.10.4598-4602.1988; Rigg GP, 1998, MICROBIOL-SGM, V144, P2905, DOI 10.1099/00221287-144-10-2905; ROBERTS I, 1986, J BACTERIOL, V168, P1228, DOI 10.1128/jb.168.3.1228-1233.1986; ROBERTS IS, 1988, J BACTERIOL, V170, P1305, DOI 10.1128/jb.170.3.1305-1310.1988; Safa Ahmad R., 2004, Current Medicinal Chemistry - Anti-Cancer Agents, V4, P1, DOI 10.2174/1568011043482142; Saigi F, 1999, J BACTERIOL, V181, P1883; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schaffer C, 2002, J BIOL CHEM, V277, P6230, DOI 10.1074/jbc.M108873200; Scheffel F, 2005, FEBS LETT, V579, P2953, DOI 10.1016/j.febslet.2005.04.017; Sharom FJ, 1999, BBA-BIOMEMBRANES, V1461, P327, DOI 10.1016/S0005-2736(99)00166-2; SHUMAN HA, 1982, J BIOL CHEM, V257, P5455; SMITH AN, 1990, MOL MICROBIOL, V4, P1863, DOI 10.1111/j.1365-2958.1990.tb02035.x; SPEISER DM, 1991, J BACTERIOL, V173, P1444, DOI 10.1128/jb.173.4.1444-1451.1991; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TREPTOW NA, 1985, J BACTERIOL, V163, P654, DOI 10.1128/JB.163.2.654-660.1985; TSAI CM, 1982, ANAL BIOCHEM, V119, P115, DOI 10.1016/0003-2697(82)90673-X; Tzeng YL, 2005, INFECT IMMUN, V73, P1491, DOI 10.1128/IAI.73.3.1491-1505.2005; Verdon G, 2003, J MOL BIOL, V330, P343, DOI 10.1016/S0022-2836(03)00575-8; VIMR ER, 1985, J BACTERIOL, V164, P845, DOI 10.1128/JB.164.2.845-853.1985; VIMR ER, 1985, J BACTERIOL, V164, P854, DOI 10.1128/JB.164.2.854-860.1985; VIMR ER, 1989, J BACTERIOL, V171, P1106, DOI 10.1128/jb.171.2.1106-1117.1989; Vinogradov E, 2002, J BIOL CHEM, V277, P25070, DOI 10.1074/jbc.M202683200; Ward CK, 1997, INFECT IMMUN, V65, P2491, DOI 10.1128/IAI.65.6.2491-2496.1997; Whitfield C, 1999, MOL MICROBIOL, V31, P1307, DOI 10.1046/j.1365-2958.1999.01276.x; Whitfield C, 2003, CARBOHYD RES, V338, P2491, DOI 10.1016/j.carres.2003.08.010; WHITFIELD C, 1989, J GEN MICROBIOL, V135, P2589; Whitfield C., 1994, P437; Zaitseva J, 2005, EMBO J, V24, P1901, DOI 10.1038/sj.emboj.7600657	79	71	72	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	2005	280	34					30310	30319		10.1074/jbc.M504371200	http://dx.doi.org/10.1074/jbc.M504371200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	957IC	15980069	hybrid			2022-12-25	WOS:000231362500040
J	Jia, ZJ; Barbier, L; Stuart, H; Amraei, M; Pelech, S; Dennis, JW; Metalnikov, P; O'Donnell, P; Nabi, IR				Jia, ZJ; Barbier, L; Stuart, H; Amraei, M; Pelech, S; Dennis, JW; Metalnikov, P; O'Donnell, P; Nabi, IR			Tumor cell pseudopodial protrusions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN MESSENGER-RNA; BETA-ACTIN; TYROSINE KINASE; C-MET; POLY(A)-BINDING PROTEIN-1; CARCINOMA CELLS; POTENTIAL ROLE; LUNG-CANCER; RHO-KINASE; MDCK CELLS	The pseudopodial protrusions of Moloney sarcoma virus ( MSV)-Madin-Darby canine kidney ( MDCK)-invasive ( INV) variant cells were purified on 1-mu m pore polycarbonate filters that selectively allow passage of the pseudopodial domains but not the cell body. The purified pseudopodial fraction contains phosphotyrosinated proteins, including Met and FAK, and various signaling proteins, including Raf1, MEK1, ERK2, PKB alpha ( Akt1), GSK3 alpha, GSK3 beta, Rb, and Stat3. Pseudopodial proteins identified by liquid chromatography tandem mass spectrometry included actin and actin-regulatory proteins ( ERM, calpain, filamin, myosin, Sra-1, and IQGAP1), tubulin, vimentin, adhesion proteins ( vinculin, talin, and beta 1 integrin), glycolytic enzymes, proteins associated with protein translation, RNA translocation, and ubiquitin-mediated protein degradation, as well as protein chaperones ( HSP90 and HSC70) and signaling proteins ( RhoGDI and ROCK). Inhibitors of MEK1 ( U0126) and HSP90 ( geldanamycin) significantly reduced MSV-MDCK-INV cell motility and pseudopod expression, and geldanamycin treatment inhibited Met phosphorylation and induced the expression of actin stress fibers. ROCK inhibition did not inhibit cell motility but transformed the pseudopodial protrusions of MSV-MDCK-INV cells into extended lamellipodia. Dominant negative Rho disrupted pseudopod expression and, in serum-starved cells, L-alpha-lysophosphatidic acid ( oleoyl) activation of Rho induced pseudopodial protrusions or, in the presence of the ROCK inhibitor, extended lamellipodia. RNA was localized to the actin-rich pseudopodial domains of MSV-MDCK-INV cells, but the extent of colocalization with dense actin ruffles was reduced in the extended lamellipodia formed upon ROCK inhibition. Rho/ROCK activation in epithelial tumor cells therefore regulates RNA translocation to a pseudopodial domain that contains proteins involved in signaling, cytoskeleton remodeling, cell adhesion, glycolysis, and protein translation and degradation.	Univ British Columbia, Dept Cellular & Physiol Sci, Vancouver, BC V6T 1Z3, Canada; Univ Montreal, Dept Pathol & Cell Biol, Montreal, PQ H3C 3J7, Canada; Kinexus Bioinformat Corp, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Med, Vancouver, BC V6T 1Z3, Canada; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada	University of British Columbia; Universite de Montreal; University of British Columbia; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Nabi, IR (corresponding author), Univ British Columbia, Dept Cellular & Physiol Sci, 2177 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada.	irnabi@interchange.ubc.ca	Nabi, Ivan R/C-5493-2009; Dennis, James/E-7268-2013; Nabi, Ivan/GWZ-5144-2022	Nabi, Ivan/0000-0002-0670-0513; Metalnikov, Pavel/0000-0003-3261-4421				Arap MA, 2004, CANCER CELL, V6, P275, DOI 10.1016/j.ccr.2004.08.018; Beckner ME, 2005, LAB INVEST, V85, P316, DOI 10.1038/labinvest.3700239; BECKNER ME, 1990, JNCI-J NATL CANCER I, V82, P1836, DOI 10.1093/jnci/82.23.1836; Beviglia L, 1999, INT J CANCER, V83, P640, DOI 10.1002/(SICI)1097-0215(19991126)83:5<640::AID-IJC13>3.0.CO;2-D; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; Cardone RA, 2005, MOL BIOL CELL, V16, P3117, DOI 10.1091/mbc.e04-10-0945; Chen HC, 1998, J BIOL CHEM, V273, P25777, DOI 10.1074/jbc.273.40.25777; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Croft DR, 2004, CANCER RES, V64, P8994, DOI 10.1158/0008-5472.CAN-04-2052; Cullen BR, 2003, J CELL SCI, V116, P587, DOI 10.1242/jcs.00268; Day RM, 1999, ONCOGENE, V18, P3399, DOI 10.1038/sj.onc.1202683; de Hoog CL, 2004, CELL, V117, P649, DOI 10.1016/S0092-8674(04)00456-8; Delpino A, 2002, BIOSCIENCE REP, V22, P407, DOI 10.1023/A:1020966008615; DERMAN MP, 1995, AM J PHYSIOL-RENAL, V268, pF1211, DOI 10.1152/ajprenal.1995.268.6.F1211; Fukata Y, 1999, J CELL BIOL, V145, P347, DOI 10.1083/jcb.145.2.347; Gregson HC, 2001, J BIOL CHEM, V276, P47575, DOI 10.1074/jbc.M103364200; HILL MA, 1994, J CELL BIOL, V126, P1221, DOI 10.1083/jcb.126.5.1221; HOOCK TC, 1991, J CELL BIOL, V112, P653, DOI 10.1083/jcb.112.4.653; HOUTHAEVE T, 1995, FEBS LETT, V376, P91, DOI 10.1016/0014-5793(95)01242-7; Hung W, 2001, J BIOL CHEM, V276, P12395, DOI 10.1074/jbc.M010715200; Izawa T, 2000, BIOCHEM BIOPH RES CO, V278, P72, DOI 10.1006/bbrc.2000.3772; Jeffers M, 1997, MOL CELL BIOL, V17, P799, DOI 10.1128/MCB.17.2.799; Kamei T, 1999, ONCOGENE, V18, P6776, DOI 10.1038/sj.onc.1203114; Kanai Y, 2004, NEURON, V43, P513, DOI 10.1016/j.neuron.2004.07.022; Kislauskis EH, 1997, J CELL BIOL, V136, P1263, DOI 10.1083/jcb.136.6.1263; Kodama A, 2000, MOL BIOL CELL, V11, P2565, DOI 10.1091/mbc.11.8.2565; Lagana A, 2000, J CELL SCI, V113, P3649; Latham VM, 2001, CURR BIOL, V11, P1010, DOI 10.1016/S0960-9822(01)00291-3; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Le PU, 1998, CANCER RES, V58, P1631; Lin YH, 2004, J CELL BIOL, V165, P421, DOI 10.1083/jcb.200311045; Liu F, 2002, FASEB J, V16, P950, DOI 10.1096/fj.01-0870com; Liu G, 2002, MOL BIOL CELL, V13, P579, DOI 10.1091/mbc.01-03-0140; Liu ZX, 2002, J BIOL CHEM, V277, P10452, DOI 10.1074/jbc.M107551200; Mackay DJG, 1997, J CELL BIOL, V138, P927, DOI 10.1083/jcb.138.4.927; Maulik G, 2002, CLIN CANCER RES, V8, P620; Maulik G, 2002, J CELL MOL MED, V6, P539, DOI 10.1111/j.1582-4934.2002.tb00453.x; Moriyama K, 2002, J CELL SCI, V115, P1591; Nabi IR, 1999, J CELL SCI, V112, P1803; Nguyen TN, 2000, EXP CELL RES, V258, P171, DOI 10.1006/excr.2000.4929; Peschard P, 2001, MOL CELL, V8, P995, DOI 10.1016/S1097-2765(01)00378-1; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; Rodal AA, 1999, J CELL BIOL, V145, P1251, DOI 10.1083/jcb.145.6.1251; Rogers SL, 2003, J CELL BIOL, V162, P1079, DOI 10.1083/jcb.200303023; Rottner K, 1999, CURR BIOL, V9, P640, DOI 10.1016/S0960-9822(99)80286-3; Royal I, 2000, MOL BIOL CELL, V11, P1709, DOI 10.1091/mbc.11.5.1709; Royal I, 1997, J CELL PHYSIOL, V173, P196, DOI 10.1002/(SICI)1097-4652(199711)173:2<196::AID-JCP20>3.0.CO;2-D; Sahai E, 2003, NAT CELL BIOL, V5, P711, DOI 10.1038/ncb1019; Steffen A, 2004, EMBO J, V23, P749, DOI 10.1038/sj.emboj.7600084; Stossel TP, 2001, NAT REV MOL CELL BIO, V2, P138, DOI 10.1038/35052082; Vadlamudi RK, 2002, NAT CELL BIOL, V4, P681, DOI 10.1038/ncb838; Vadnais J, 2002, J BIOL CHEM, V277, P48342, DOI 10.1074/jbc.M209481200; Wang HR, 2003, SCIENCE, V302, P1775, DOI 10.1126/science.1090772; Webb CP, 2000, CANCER RES, V60, P342; Woodman PG, 2003, J CELL SCI, V116, P4283, DOI 10.1242/jcs.00817; Woods AJ, 2002, J BIOL CHEM, V277, P6428, DOI 10.1074/jbc.M109446200; Woods AJ, 2005, MOL CELL BIOL, V25, P3763, DOI 10.1128/MCB.25.9.3763-3773.2005; Xiao GH, 2001, P NATL ACAD SCI USA, V98, P247, DOI 10.1073/pnas.011532898; Zondag GCM, 2000, J CELL BIOL, V149, P775, DOI 10.1083/jcb.149.4.775	60	60	61	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	2005	280	34					30564	30573		10.1074/jbc.M501754200	http://dx.doi.org/10.1074/jbc.M501754200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	957IC	15985431	hybrid			2022-12-25	WOS:000231362500072
J	Larson, HN; Weiner, H; Hurley, TD				Larson, HN; Weiner, H; Hurley, TD			Disruption of the coenzyme binding site and dimer interface revealed in the crystal structure of mitochondrial aldehyde dehydrogenase "Asian" variant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURIFICATION; INVOLVEMENT; MECHANISM; CATALYSIS; DISORDER; LYSINE; ORDER; GENE; RAT	Mitochondrial aldehyde dehydrogenase ( ALDH2) is the major enzyme that oxidizes ethanol-derived acetaldehyde. A nearly inactive form of the enzyme, ALDH2*2, is found in about 40% of the East Asian population. This variant enzyme is defined by a glutamate to lysine substitution at residue 487 located within the oligomerization domain. ALDH2*2 has an increased Km for its coenzyme, NAD(+), and a decreased k(cat), which lead to low activity in vivo. Here we report the 2.1 angstrom crystal structure of ALDH2*2. The structure shows a large disordered region located at the dimer interface that includes much of the coenzyme binding cleft and a loop of residues that form the base of the active site. As a consequence of these structural changes, the variant enzyme exhibits rigid body rotations of its catalytic and coenzyme-binding domains relative to the oligomerization domain. These structural perturbations are the direct result of the inability of lysine 487 to form important stabilizing hydrogen bonds with arginines 264 and 475. Thus, the elevated K-m for coenzyme exhibited by this variant probably reflects the energetic penalty for reestablishing this site for productive coenzyme binding, whereas the structural alterations near the active site are consistent with the lowered V-max.	Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Purdue Univ, Dept Biochem, W Lafayette, IN 47907 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Hurley, TD (corresponding author), Indiana Univ, Sch Med, Dept Biochem & Mol Biol, 635 Barnhill Dr, Indianapolis, IN 46202 USA.	thurley@iupui.edu		HURLEY, THOMAS/0000-0002-5942-1163	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA011982] Funding Source: NIH RePORTER; NIAAA NIH HHS [R01 AA011982, R01 AA 11982] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		AMBROZIAK W, 1989, BIOCHEMISTRY-US, V28, P5367, DOI 10.1021/bi00439a008; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bordelon T, 2004, J BIOL CHEM, V279, P43085, DOI 10.1074/jbc.M406139200; BROSS P, 1995, J BIOL CHEM, V270, P10284, DOI 10.1074/jbc.270.17.10284; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chen ZQ, 2002, P NATL ACAD SCI USA, V99, P8306, DOI 10.1073/pnas.122225199; ENOMOTO N, 1991, HEPATOLOGY, V13, P1071, DOI 10.1002/hep.1840130611; FARRES J, 1994, J BIOL CHEM, V269, P13854; GHENBOT G, 1992, PROTEIN EXPRES PURIF, V3, P470, DOI 10.1016/1046-5928(92)90064-4; GREENBAUM AL, 1971, ARCH BIOCHEM BIOPHYS, V143, P617, DOI 10.1016/0003-9861(71)90247-5; Hammen PK, 2002, BIOCHEMISTRY-US, V41, P7156, DOI 10.1021/bi012197t; Hayward S, 1998, PROTEINS, V30, P144, DOI 10.1002/(SICI)1097-0134(19980201)30:2<144::AID-PROT4>3.0.CO;2-N; Hurley TD, 2001, CHEM-BIOL INTERACT, V130, P3, DOI 10.1016/S0009-2797(00)00217-9; Hurley TD, 2002, PHARMACOGENOMICS SEA, P417, DOI DOI 10.1002/3527600752; JENG JJ, 1991, ARCH BIOCHEM BIOPHYS, V289, P214, DOI 10.1016/0003-9861(91)90464-T; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1976, ACTA CRYSTALLOGR A, V32, P922, DOI 10.1107/S0567739476001873; KIM JJP, 1988, P NATL ACAD SCI USA, V85, P6677, DOI 10.1073/pnas.85.18.6677; Lamb AL, 1999, BIOCHEMISTRY-US, V38, P6003, DOI 10.1021/bi9900471; Moore SA, 1998, STRUCTURE, V6, P1541, DOI 10.1016/S0969-2126(98)00152-X; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Ni L, 1997, J BIOL CHEM, V272, P18823, DOI 10.1074/jbc.272.30.18823; Ni L, 1999, PROTEIN SCI, V8, P2784; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Peng GS, 1999, PHARMACOGENETICS, V9, P463; Perez-Miller SJ, 2003, BIOCHEMISTRY-US, V42, P7100, DOI 10.1021/bi034182w; Seitz HK, 2001, ALCOHOL CLIN EXP RES, V25, p137S, DOI 10.1097/00000374-200105051-00024; Steinmetz CG, 1997, STRUCTURE, V5, P701, DOI 10.1016/S0969-2126(97)00224-4; TAKAHASHI K, 1980, ARCH BIOCHEM BIOPHYS, V205, P571, DOI 10.1016/0003-9861(80)90140-X; WEINER H, 1976, J BIOL CHEM, V251, P3853; Yokoyama A, 1999, ALCOHOL CLIN EXP RES, V23, P1705, DOI 10.1097/00000374-199911000-00001; ZHENG CF, 1993, ALCOHOL CLIN EXP RES, V17, P828, DOI 10.1111/j.1530-0277.1993.tb00849.x; Zhou JZ, 2000, BIOCHEMISTRY-US, V39, P12019, DOI 10.1021/bi001221k	33	79	88	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	2005	280	34					30550	30556		10.1074/jbc.M502345200	http://dx.doi.org/10.1074/jbc.M502345200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	957IC	15983043	hybrid, Green Accepted			2022-12-25	WOS:000231362500070
J	Ai, JH; Smith, P; Wang, SW; Zhang, P; Zheng, XL				Ai, JH; Smith, P; Wang, SW; Zhang, P; Zheng, XL			The proximal carboxyl-terminal domains of ADAMTS13 determine substrate specificity and are all required for cleavage of von Willebrand factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THROMBOTIC THROMBOCYTOPENIC PURPURA; FACTOR-CLEAVING PROTEASE; FACTOR MULTIMERS; SPACER DOMAIN; CUB DOMAIN; MUTATIONS; DEFICIENCY; BINDING; FAMILY; PURIFICATION	ADAMTS13 limits platelet-rich thrombosis by cleaving von Willebrand factor at the Tyr(1605)-Met(1606) bond. Previous studies showed that ADAMTS13 truncated after spacer domain remains proteolytically active or hyperactive. However, the relative contribution of each domain within the proximal carboxyl terminus of ADAMTS13 in substrate recognition and specificity is not known. We showed that a metalloprotease domain alone was unable to cleave the Tyr-Met bond of glutathione S-transferase (GST)-VWF73-H substrate in 3 h, but it did cleave the substrate at a site other than the Tyr-Met bond after 16-24 h of incubation. Remarkably, the addition of even one or several proximal carboxyl-terminal domains of ADAMTS13 restored substrate specificity. Full proteolytic activity, however, was not achieved until all of the proximal carboxyl-terminal domains were added. The addition of TSP1 2-8 repeats and two CUB domains did not further increase proteolytic activity. Furthermore, ADAMTS13 truncated after the spacer domain with or without metalloprotease domain bound GST-VWF73-H with a K-d of approximate to 7.0 or 13 nM, comparable with full-length ADAMTS13 (K-d = 4.6 nM). Metalloprotease domain did not bind GST-VWF73-H detectably, but the disintegrin domain, first TSP1 repeat, Cys-rich domain, and spacer domain bound GST-VWF73-H with Kd values of 489, 136, 121, and 108 nM, respectively. These proximal carboxyl-terminal domains dose-dependently inhibited cleavage of fluorescent resonance energy transfer (FRETS)-VWF73 by full-length ADAMTS13 and ADAMTS13 truncated after the spacer domain. These data demonstrated that the proximal carboxyl-terminal domains of ADAMTS13 determine substrate specificity and are all required for recognition and cleavage of von Willebrand factor between amino acid residues Asp(1595) and Arg(1668).	Childrens Hosp Philadelphia, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania	Zheng, XL (corresponding author), Childrens Hosp Philadelphia, Dept Pathol & Lab Med, 34th St & Civic Ctr Blvd,Abramson Bldg 816G, Philadelphia, PA 19104 USA.	zheng@email.chop.edu	Zheng, X. Long/ABD-7362-2021	Zheng, X. Long/0000-0003-1680-5295	NHLBI NIH HHS [R01 HL079027-03, R01 HL079027-01, R01 HL079027, HL079027, R01 HL079027-02] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL079027] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Assink K, 2003, KIDNEY INT, V63, P1995, DOI 10.1046/j.1523-1755.63.6s.1.x; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; Cal S, 2002, GENE, V283, P49, DOI 10.1016/S0378-1119(01)00861-7; Dong JF, 2003, J BIOL CHEM, V278, P29633, DOI 10.1074/jbc.M301385200; Dong JF, 2002, BLOOD, V100, P4033, DOI 10.1182/blood-2002-05-1401; Fujikawa K, 2001, BLOOD, V98, P1662, DOI 10.1182/blood.V98.6.1662; Furlan M, 1998, BLOOD, V91, P2839, DOI 10.1182/blood.V91.8.2839.2839_2839_2846; Furlan M, 1996, BLOOD, V87, P4223, DOI 10.1182/blood.V87.10.4223.bloodjournal87104223; Furlan M, 1998, BAILLIERE CLIN HAEM, V11, P509, DOI 10.1016/S0950-3536(98)80064-4; Gerritsen HE, 2001, BLOOD, V98, P1654, DOI 10.1182/blood.V98.6.1654; Klaus C, 2004, BLOOD, V103, P4514, DOI 10.1182/blood-2003-12-4165; Kokame K, 2005, BRIT J HAEMATOL, V129, P93, DOI 10.1111/j.1365-2141.2005.05420.x; Kokame K, 2004, SEMIN HEMATOL, V41, P34, DOI 10.1053/j.seminhematol.2003.10.002; Kokame K, 2002, P NATL ACAD SCI USA, V99, P11902, DOI 10.1073/pnas.172277399; Kokame K, 2004, BLOOD, V103, P607, DOI 10.1182/blood-2003-08-2861; Levy GG, 2001, NATURE, V413, P488, DOI 10.1038/35097008; Luken BM, 2005, THROMB HAEMOSTASIS, V93, P267, DOI 10.1160/TH04-05-0301; Majerus EM, 2003, J BIOL CHEM, V278, P46643, DOI 10.1074/jbc.M309872200; Majerus EM, 2005, J BIOL CHEM, V280, P21773, DOI 10.1074/jbc.M502529200; Matsumoto M, 2004, BLOOD, V103, P1305, DOI 10.1182/blood-2003-06-1796; MOAKE JL, 1982, NEW ENGL J MED, V307, P1432, DOI 10.1056/NEJM198212023072306; Nishio K, 2004, P NATL ACAD SCI USA, V101, P10578, DOI 10.1073/pnas.0402041101; Pimanda JE, 2004, BLOOD, V103, P627, DOI 10.1182/blood-2003-04-1346; Plaimauer B, 2002, BLOOD, V100, P3626, DOI 10.1182/blood-2002-05-1397; Schneppenheim R, 2003, BLOOD, V101, P1845, DOI 10.1182/blood-2002-08-2399; Soejima K, 2001, J BIOCHEM-TOKYO, V130, P475, DOI 10.1093/oxfordjournals.jbchem.a003009; Soejima K, 2003, BLOOD, V102, P3232, DOI 10.1182/blood-2003-03-0908; Tao ZY, 2005, BLOOD, V106, P141, DOI 10.1182/blood-2004-11-4188; Tsai HM, 1996, BLOOD, V87, P4235, DOI 10.1182/blood.V87.10.4235.bloodjournal87104235; Veyradier A, 2001, BLOOD, V98, P1765, DOI 10.1182/blood.V98.6.1765; Zheng XL, 2001, J BIOL CHEM, V276, P41059, DOI 10.1074/jbc.C100515200; Zheng XL, 2004, BLOOD, V103, P4043, DOI 10.1182/blood-2003-11-4035; Zheng XL, 2003, J BIOL CHEM, V278, P30136, DOI 10.1074/jbc.M305331200; Zhou WH, 2004, THROMB HAEMOSTASIS, V91, P806, DOI 10.1160/TH03-11-0675	34	88	97	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	2005	280	33					29428	29434		10.1074/jbc.M505513200	http://dx.doi.org/10.1074/jbc.M505513200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	954SX	15975930	hybrid, Green Accepted			2022-12-25	WOS:000231176200007
J	Handa, V; Yeh, HJC; McPhie, P; Usdin, K				Handa, V; Yeh, HJC; McPhie, P; Usdin, K			The AUUCU repeats responsible for spinocerebellar ataxia type 10 form unusual RNA hairpins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOTONIC-DYSTROPHY; HUNTINGTONS-DISEASE; PROTEIN-KINASE; CUG REPEATS; EXPANSION; MISMATCHES; APOPTOSIS; SCA10; PKR	Spinocerebellar ataxia type 10 is an autosomal dominant disorder caused by expansion of a pentameric repeat tract (ATTCT center dot AGAAT)(n) in intron 9 of the gene that encodes ataxin-10. We have analyzed duplex DNA containing the repeat, the individual DNA strands, and the RNA that would be generated by transcription of the repeat. Circular dichroism and UV absorbance measurements suggest that the previously reported tendency of the repeat to unpair when supercoiled is probably related simply to GC content rather than reflecting any unusual property of the duplex. DNA containing d(AT-TCT) 9 forms a folded structure at relatively low temperatures, whereas the antisense strand, d(AGAAT)(9), does not form a structure even at 0 degrees C. In contrast r(AUUCU)(9) forms a folded structure under physiologically reasonable conditions. S1 nuclease analysis reveals a single region of hypersensitivity in the middle of the repeat tract, whereas V1 digestion is consistent with a hydrogen bonded or well stacked structure. CD spectroscopy shows that the structure is unimolecular and hydrogen bonded and has a significant amount of A-form helix. NMR spectroscopy demonstrates that these hydrogen bonds comprise an equal number of A center dot U and U center dot U base pairs. Our data thus suggest that the repeat forms an unusual RNA hairpin. Thus the ability to form an RNA hairpin seems to be a common property of those Repeat Expansion Diseases that are not recessively inherited and are caused by repeats that are transcribed but not translated.	NIDDK, Mol & Cellular Biol Lab, NIH, Bethesda, MD 20892 USA; NIDDK, Lab Biochem & Genet, NIH, Bethesda, MD 20892 USA; NIDDK, Bioorgan Chem Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Usdin, K (corresponding author), NIDDK, Mol & Cellular Biol Lab, NIH, Bethesda, MD 20892 USA.	ku@helix.nih.gov			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK057602, ZIADK032101, ZIADK057602, Z01DK032101, Z01DK024942] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARNDT KM, 1990, J MOL BIOL, V213, P79, DOI 10.1016/S0022-2836(05)80123-8; Breslauer K.J., 1986, THERMODYNAMIC DATA B, P402; Buratti E, 2004, MOL CELL BIOL, V24, P10505, DOI 10.1128/MCB.24.24.10505-10514.2004; Burkard M. E., 1999, RNA WORLD, P675; CANTOR CR, 1980, BIOPHYSICAL CHEM, P1147; GUSELLA JF, 1995, SEMIN CELL BIOL, V6, P21, DOI 10.1016/1043-4682(95)90011-X; Handa V, 2003, NUCLEIC ACIDS RES, V31, P6243, DOI 10.1093/nar/gkg818; Heidenfelder BL, 2003, J BIOL CHEM, V278, P2425, DOI 10.1074/jbc.M210643200; HWANG TL, 1995, J MAGN RESON SER A, V112, P275, DOI 10.1006/jmra.1995.1047; Jin P, 2003, NEURON, V39, P739, DOI 10.1016/S0896-6273(03)00533-6; Kierzek R, 1999, BIOCHEMISTRY-US, V38, P14214, DOI 10.1021/bi991186l; Koch KS, 1998, J THEOR BIOL, V192, P505, DOI 10.1006/jtbi.1998.0679; Lin X, 2003, CYTOGENET GENOME RES, V100, P184, DOI 10.1159/000072853; LOCKARD RE, 1981, NUCLEIC ACIDS RES, V9, P5125, DOI 10.1093/nar/9.19.5125; Mankodi A, 2003, ANN NEUROL, V54, P760, DOI 10.1002/ana.10763; MARZ P, 2004, J BIOL CHEM; Matsuura T, 2000, NAT GENET, V26, P191, DOI 10.1038/79911; Matzke MA, 2005, NAT REV GENET, V6, P24, DOI 10.1038/nrg1500; Miller JW, 2000, EMBO J, V19, P4439, DOI 10.1093/emboj/19.17.4439; Mitas M, 1997, NUCLEIC ACIDS RES, V25, P2245, DOI 10.1093/nar/25.12.2245; Napierala M, 1997, J BIOL CHEM, V272, P31079, DOI 10.1074/jbc.272.49.31079; Potaman VN, 2003, J MOL BIOL, V326, P1095, DOI 10.1016/S0022-2836(03)00037-8; Ranum LPW, 2004, AM J HUM GENET, V74, P793, DOI 10.1086/383590; Ranum LPW, 2002, CURR OPIN GENET DEV, V12, P266, DOI 10.1016/S0959-437X(02)00297-6; SANTALUCIA J, 1991, BIOCHEMISTRY-US, V30, P8242, DOI 10.1021/bi00247a021; SHEN LX, 1995, FASEB J, V9, P1023, DOI 10.1096/fasebj.9.11.7544309; Shi PY, 1996, BIOCHEMISTRY-US, V35, P4222, DOI 10.1021/bi952398v; Sobczak K, 2003, NUCLEIC ACIDS RES, V31, P5469, DOI 10.1093/nar/gkg766; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; Usdin K, 2000, CELL MOL LIFE SCI, V57, P914, DOI 10.1007/PL00000734; Yeung MC, 1996, P NATL ACAD SCI USA, V93, P12451, DOI 10.1073/pnas.93.22.12451; ZEITLIN S, 1995, NAT GENET, V11, P155, DOI 10.1038/ng1095-155; Zu L, 1999, AM J HUM GENET, V64, P594, DOI 10.1086/302247	33	26	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	2005	280	32					29340	29345		10.1074/jbc.M503495200	http://dx.doi.org/10.1074/jbc.M503495200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	952QT	15970586	hybrid			2022-12-25	WOS:000231021300065
J	Hurley, RL; Anderson, KA; Franzone, JM; Kemp, BE; Means, AR; Witters, LA				Hurley, RL; Anderson, KA; Franzone, JM; Kemp, BE; Means, AR; Witters, LA			The Ca2+/calmodulin-dependent protein kinase kinases are AMP-activated protein kinase kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SNF1-ACTIVATING KINASES; UPSTREAM KINASES; CASCADE; BETA; SNF1; LKB1; ENERGY; YEAST; MECHANISMS; COMPONENTS	The AMP-activated protein kinase ( AMPK) is an important regulator of cellular metabolism in response to metabolic stress and to other regulatory signals. AMPK activity is absolutely dependent upon phosphorylation of AMPK alpha Thr-172 in its activation loop by one or more AMPK kinases (AMPKKs). The tumor suppressor kinase, LKB1, is a major AMPKK present in a variety of tissues and cells, but several lines of evidence point to the existence of other AMPKKs. We have employed three cell lines deficient in LKB1 to study AMPK regulation and phosphorylation, HeLa, A549, and murine embryo fibroblasts derived from LKB-/- mice. In HeLa and A549 cells, mannitol, 2-deoxyglucose, and ionomycin, but not 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR), treatment activates AMPK by alpha Thr-172 phosphorylation. These responses, as well as the downstream effects of AMPK on the phosphorylation of acetyl-CoA carboxylase, are largely inhibited by the Ca2+/calmodulin-dependent protein kinase kinase (CaMKK) inhibitor, STO-609. AMPKK activity in HeLa cell lysates measured in vitro is totally inhibited by STO-609 with an IC50 comparable with that of the known CaMKK isoforms, CaMKK alpha and CaMKK beta. Furthermore, 2-deoxyglucose and ionomycin-stimulated AMPK activity, alpha Thr-172 phosphorylation, and acetyl-CoA carboxylase phosphorylation are substantially reduced in HeLa cells transfected with small interfering RNAs specific for CaMKK alpha and CaMKK beta. Lastly, the activation of AMPK in response to ionomycin and 2-deoxyglucose is not impaired in LKB1(-/-) murine embryo fibroblasts. These data indicate that the CaMKKs function in intact cells as AMPKKs, predicting wider roles for these kinases in regulating AMPK activity in vivo.	Dartmouth Coll Sch Med, Dept Med, Hanover, NH 03755 USA; Dartmouth Coll Sch Med, Dept Biochem, Hanover, NH 03755 USA; Dartmouth Coll, Dept Sci Biol, Hanover, NH 03755 USA; St Vincents Inst, Fitzroy, Vic 3065, Australia; CSIRO, Hlth Sci & Nutr, Fitzroy, Vic 3065, Australia; Duke Univ, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Dartmouth College; Dartmouth College; Dartmouth College; St. Vincent's Institute of Medical Research; Commonwealth Scientific & Industrial Research Organisation (CSIRO); Duke University	Witters, LA (corresponding author), Dartmouth Coll Sch Med, Dept Med, Remsen 322,N Coll St, Hanover, NH 03755 USA.	lee.a.witters@dartmouth.edu	Kemp, Bruce/G-9602-2019; Kemp, Bruce E/L-2633-2014	Kemp, Bruce/0000-0001-6735-5082; Kemp, Bruce E/0000-0001-6735-5082	NICHD NIH HHS [HD07503] Funding Source: Medline; NIDDK NIH HHS [DK35712] Funding Source: Medline; NIGMS NIH HHS [GM33976] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035712] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033976] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altarejos JY, 2005, J BIOL CHEM, V280, P183, DOI 10.1074/jbc.M411810200; Anderson KA, 1998, J BIOL CHEM, V273, P31880, DOI 10.1074/jbc.273.48.31880; Baron SJ, 2005, CIRC RES, V96, P337, DOI 10.1161/01.RES.0000155723.53868.d2; Carling D, 2004, TRENDS BIOCHEM SCI, V29, P18, DOI 10.1016/j.tibs.2003.11.005; Chen ZP, 2003, DIABETES, V52, P2205, DOI 10.2337/diabetes.52.9.2205; Corcoran EE, 2001, J BIOL CHEM, V276, P2975, DOI 10.1074/jbc.R000027200; Edelman AM, 1996, J BIOL CHEM, V271, P10806, DOI 10.1074/jbc.271.18.10806; Hamilton SR, 2002, BIOCHEM BIOPH RES CO, V293, P892, DOI 10.1016/S0006-291X(02)00312-1; Hamilton SR, 2001, FEBS LETT, V500, P163, DOI 10.1016/S0014-5793(01)02602-3; Hardie DG, 2003, FEBS LETT, V546, P113, DOI 10.1016/S0014-5793(03)00560-X; HAWLEY SA, 1995, J BIOL CHEM, V270, P27186, DOI 10.1074/jbc.270.45.27186; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Hong SP, 2005, J BIOL CHEM, V280, P21804, DOI 10.1074/jbc.M501887200; Hong SP, 2003, P NATL ACAD SCI USA, V100, P8839, DOI 10.1073/pnas.1533136100; Hsu LS, 2001, J BIOL CHEM, V276, P31113, DOI 10.1074/jbc.M011720200; Ishikawa Y, 2003, FEBS LETT, V550, P57, DOI 10.1016/S0014-5793(03)00817-2; McCartney R, 2005, CURR GENET, V47, P335, DOI 10.1007/s00294-005-0576-2; MORGAN AJ, 1994, BIOCHEM J, V300, P665, DOI 10.1042/bj3000665; Nath N, 2003, MOL CELL BIOL, V23, P3909, DOI 10.1128/MCB.23.11.3909-3917.2003; Qanungo S, 2003, NEOPLASIA, V5, P367, DOI 10.1016/S1476-5586(03)80030-1; SELBERT MA, 1995, J BIOL CHEM, V270, P17616, DOI 10.1074/jbc.270.29.17616; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Soderling TR, 1999, TRENDS BIOCHEM SCI, V24, P232, DOI 10.1016/S0968-0004(99)01383-3; Soderling TR, 2001, CHEM REV, V101, P2341, DOI 10.1021/cr0002386; Sutherland CM, 2003, CURR BIOL, V13, P1299, DOI 10.1016/S0960-9822(03)00459-7; Tokumitsu H, 2003, J BIOL CHEM, V278, P10908, DOI 10.1074/jbc.M213183200; Tokumitsu H, 2002, J BIOL CHEM, V277, P15813, DOI 10.1074/jbc.M201075200; Vinet J, 2003, MOL BRAIN RES, V111, P216, DOI 10.1016/S0169-328X(02)00698-8; WITTERS LA, 1992, J BIOL CHEM, V267, P2864	29	787	809	1	48	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	2005	280	32					29060	29066		10.1074/jbc.M503824200	http://dx.doi.org/10.1074/jbc.M503824200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	952QT	15980064	hybrid			2022-12-25	WOS:000231021300031
J	Wicks, SJ; Haros, K; Maillard, M; Song, L; Cohen, RE; ten Dijke, P; Chantry, A				Wicks, SJ; Haros, K; Maillard, M; Song, L; Cohen, RE; ten Dijke, P; Chantry, A			The deubiquitinating enzyme UCH37 interacts with Smads and regulates TGF-beta signalling	ONCOGENE			English	Article						transforming growth factor-beta; Smads; ubiquitin	UBIQUITIN LIGASE; PATHWAY; DEGRADATION; MEMBRANE; RECEPTOR; TARGETS; BINDS	Disruption of components in the transforming growth factor-beta (TGF-beta) signalling cascade is a common occurrence in human cancers. TGF-beta pathway activation is accomplished via serine/threonine kinase receptors and intracellular Smad transcription factors. A key regulatory step involves specific ubiquitination by Smurfs that mediate the proteasomal degradation of Smads and/or receptors. Here, we report a novel interaction between Smads and ubiquitin C-terminal hydrolase UCH37, a deubiquitinating enzyme that could potentially reverse Smurf-mediated ubiquitination. In GST pull down experiments, UCH37 bound weakly to Smad2 and Smad3, and bound very strongly to Smad7 in a region that is distinct from the -PY- motif in Smad7 that interacts with Smurf ubiquitin ligases. Endogenous Smad7 and UCH37 formed a stable complex in U4A/JAK1 cells, and FLAG-Smad7 co- immunoprecipitated with HA-UCH37 in transfected HEK-293 cells. In addition, we show that UCH37 can deubiquitinate and stabilize the type I TGF-beta receptor. Furthermore, overexpression of UCH37 upregulates TGF-beta-dependent transcription, and this effect is reversed in cells subject to RNAi-mediated knockdown of endogenous UCH37. These findings support a new role for deubiquitinating enzymes in the control of the TGF-beta signalling pathway, and provide a novel molecular target for the design of inhibitors with therapeutic potential in cancer.	Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England; Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA; Leiden Univ, Med Ctr, Dept Mol Cell Biol, NL-2333 AL Leiden, Netherlands	University of East Anglia; University of Iowa; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Chantry, A (corresponding author), Univ E Anglia, Sch Biol Sci, Earlham Rd, Norwich NR4 7TJ, Norfolk, England.	a.chantry@uea.ac.uk	Song, Ling/HGA-5011-2022; 高, 雨莉/HGU-8187-2022; Dijke, Peter ten/AAG-4660-2021	Dijke, Peter ten/0000-0002-7234-342X	NIGMS NIH HHS [R01 GM37666] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037666] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHANTRY A, 1995, J BIOL CHEM, V270, P3068; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Jensen DE, 1998, ONCOGENE, V16, P1097, DOI 10.1038/sj.onc.1201861; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Lam YA, 1997, J BIOL CHEM, V272, P28438, DOI 10.1074/jbc.272.45.28438; Lam YA, 1997, NATURE, V385, P737, DOI 10.1038/385737a0; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; Lo RS, 1999, NAT CELL BIOL, V1, P472, DOI 10.1038/70258; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Suzuki C, 2002, J BIOL CHEM, V277, P39919, DOI 10.1074/jbc.M201901200; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; Wicks SJ, 2000, MOL CELL BIOL, V20, P8103, DOI 10.1128/MCB.20.21.8103-8111.2000; Wing SS, 2003, INT J BIOCHEM CELL B, V35, P590, DOI 10.1016/S1357-2725(02)00392-8; Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293	15	139	149	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 1	2005	24	54					8080	8084		10.1038/sj.onc.1208944	http://dx.doi.org/10.1038/sj.onc.1208944			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	989EV	16027725				2022-12-25	WOS:000233656600014
J	Taniguchi, H; Yamamoto, H; Hirata, T; Miyamoto, N; Oki, M; Nosho, K; Adachi, Y; Endo, T; Imai, K; Shinomura, Y				Taniguchi, H; Yamamoto, H; Hirata, T; Miyamoto, N; Oki, M; Nosho, K; Adachi, Y; Endo, T; Imai, K; Shinomura, Y			Frequent epigenetic inactivation of Wnt inhibitory factor-1 in human gastrointestinal cancers	ONCOGENE			English	Article						WIF-1; Wnt; methylation; gastrointestinal cancers	HUMAN COLORECTAL-CANCER; HISTONE DEACETYLASE INHIBITION; PRIMARY GASTRIC-CANCER; UP-REGULATION; SIGNALING PATHWAY; CELLS; TUMORIGENESIS; EXPRESSION; DEMETHYLATION; CARCINOMA	Aberrant activation and upregulation of the Wnt pathway is a key feature of many cancers. Wnt antagonists have recently attracted wide attention. Wnt inhibitory factor-1 (WIF-1) is a secreted antagonist that can bind to Wnt proteins directly and inhibit Wnt signaling pathway. It has been reported that WIF-1 expression is down regulated in several solid tumors and that WIF-1 is silenced by promoter hypermethylation in lung and colorectal cancer. By using RT-PCR, bisulfite sequence analysis, and methylation-specific PCR, we analysed expression and methylation of WIF-1 in cancer cell lines and freshly resected cancer tissues of the esophagus, stomach, colorectum, and pancreas. Downregulation of WIF-1 mRNA expression was observed in 61 (91.0%) of 67 cancer cell lines, 16 (80.0%) of 20 esophageal, 23 (74.2%) of 31 gastric, 41 (82.0%) of 50 colorectal, and six (75.0%) of eight pancreatic cancer tissues. Downregulation of WIF-1 expression was also observed at protein level. No significant association between WIF-1 downregulation and clinicopathological characteristics was found, suggesting that downregulation of WIF-1 expression is an early event in carcinogenesis of these cancers. Indeed, downregulation of WIF-1 expression was observed in 32 (72.7%) of 44 colorectal adenoma tissues and 18 (78.2%) of 23 early mucosal or submucosal colorectal carcinoma tissues. CpG island hypermethylation in the WIF-1 promoter region correlated with downregulation of WIF-1 expression in cancer cell lines and tissues. Treatment with demethylating agent, 5-aza-2'-deoxycytidine (5-aza-dC), restored WIF-1 expression in cancer cell lines. A combined treatment of 5-aza-dC and a histone deacetylase inhibitor, trichostatinA, restored WIF-1 expression synergistically, indicating the role of cytosine methylation and histone deacetylation in the silencing of the WIF-1 gene. Transfection of the WIF-1 gene construct into TE-1 esophageal cancer cell lines or SW48 colon cancer cell lines lacking WIF-1 expression resulted in a significant inhibition on colony formation, cell proliferation, anchorage-independent growth in soft agar. TOP. ash assay showed WIF-1 inhibits Wnt canonical signaling in these cell lines.These results suggest tumor suppressive function of WIF-1, due to its ability to inhibit Wnt signaling. Our results suggest that WIF-1 silencing due to promoter hypermethylation is an important mechanism underlying aberrant activation of the Wnt signaling pathway in carcinogenesis of the digestive organs. Modulation of the Wnt pathway, through reversal of WIF-1 silencing by demethylating agents, is a potential target for treatment and/or prevention of gastrointestinal cancers.	Sapporo Med Univ, Dept Internal Med 1, Chuo Ku, Sapporo, Hokkaido 0608543, Japan	Sapporo Medical University	Yamamoto, H (corresponding author), Sapporo Med Univ, Dept Internal Med 1, Chuo Ku, South 1,West 16, Sapporo, Hokkaido 0608543, Japan.	h-yama@sapmed.ac.jp	Peng, Bo/A-6920-2009; Taniguchi, Hiroaki/AGB-3012-2022	Peng, Bo/0000-0001-8225-2284; Taniguchi, Hiroaki/0000-0003-0494-5290				Caldwell GM, 2004, CANCER RES, V64, P883, DOI 10.1158/0008-5472.CAN-03-1346; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Cebrat M, 2004, CANCER LETT, V206, P107, DOI 10.1016/j.canlet.2003.10.024; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; He BA, 2005, ONCOGENE, V24, P3054, DOI 10.1038/sj.onc.1208511; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Holcombe RF, 2002, J CLIN PATHOL-MOL PA, V55, P220, DOI 10.1136/mp.55.4.220; Hsieh JC, 1999, NATURE, V398, P431, DOI 10.1038/18899; Ikenoue T, 2002, JPN J CANCER RES, V93, P1213, DOI 10.1111/j.1349-7006.2002.tb01226.x; Katoh M, 2001, INT J ONCOL, V19, P1003; Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623; Kirikoshi H, 2001, INT J ONCOL, V19, P1221; Kolligs FT, 2002, DIGESTION, V66, P131, DOI 10.1159/000066755; Lustig B, 2003, J CANCER RES CLIN, V129, P199, DOI 10.1007/s00432-003-0431-0; Mazieres J, 2004, CANCER RES, V64, P4717, DOI 10.1158/0008-5472.CAN-04-1389; Mizushima T, 2002, CANCER RES, V62, P277; Reguart N, 2004, BIOCHEM BIOPH RES CO, V323, P229, DOI 10.1016/j.bbrc.2004.08.075; Saitoh T, 2002, INT J MOL MED, V9, P515; Smith K, 1999, BRIT J CANCER, V81, P496, DOI 10.1038/sj.bjc.6690721; Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Wissmann C, 2003, J PATHOL, V201, P204, DOI 10.1002/path.1449	22	154	168	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2005	24	53					7946	7952		10.1038/sj.onc.1208910	http://dx.doi.org/10.1038/sj.onc.1208910			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	986PU	16007117				2022-12-25	WOS:000233463000014
J	Tsuji, Y				Tsuji, Y			JunD activates transcription of the human ferritin H gene through an antioxidant response element during oxidative stress	ONCOGENE			English	Article						ferritin; oxidative stress; JunD; AP1; ARE; iron	TUMOR-NECROSIS-FACTOR; YA-SUBUNIT GENE; CONTROLLING INDUCIBLE EXPRESSION; NF-KAPPA-B; HEAVY-CHAIN; FACTOR-ALPHA; C-JUN; PHENOLIC ANTIOXIDANTS; TISSUE ISOFERRITINS; MEDIATED EXPRESSION	Ferritin is the major intracellular iron storage protein that sequesters excess free iron to minimize generation of iron-catalysed reactive oxygen species. We previously demonstrated that expression of ferritin heavy chain (ferritin H) was induced by pro-oxidants, which is a part of cellular antioxidant response to protect cells from oxidative damage. In this study, we have identified that the antioxidant/electrophile response element (ARE) located 4.5 kb upstream to the human ferritin H transcription initiation site is responsible for the oxidant response. The human ferritin H ARE comprises two copies of bidirectional AP1 motifs. Mutations in each AP1 motif significantly impaired protein binding and the function of the ARE, indicating that both of the AP1 motifs are required for pro-oxidant-mediated activation of the ferritin H gene. We identified that JunD, an AP1 family basic-leucine zipper (bZip) trans cription factor, is one of the ferritin H ARE binding proteins and activates ferritin H transcription in HepG2 hepatocarcinoma cells. Gel retardation assay demonstrated that H2O2 (hydrogen peroxide) or t-BHQ (tert-butylhydroquinone) treatment increased total protein binding as well as JunD binding to the ferritin H ARE. Chromatin immunoprecipitation assay showed that H2O2 treatment induced JunD binding to the ferritin H ARE. Both H2O2 and t-BHQ induced phosphorylation of JunD at Ser-100, an activated form of JunD. Furthermore, overexpression of JunD induced endogenous ferritin H protein synthesis. Since JunD has recently been demonstrated to protect cells from several stress stimuli including oxidative stress, these results suggest that, in addition to NFE2-related factor 2 (Nrf2) as a major ARE regulatory protein, JunD is another ARE regulatory protein for transcriptional activation of the human ferritin H gene and probably other antioxidant genes containing the conserved ARE sequences by which JunD may confer cytoprotection during oxidative stress.	N Carolina State Univ, Dept Environm & Mol Toxicol, Raleigh, NC 27695 USA	University of North Carolina; North Carolina State University	Tsuji, Y (corresponding author), N Carolina State Univ, Dept Environm & Mol Toxicol, Campus Box 7633, Raleigh, NC 27695 USA.	yoshiaki_tsuji@ncsu.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060007] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-60007, R01 DK060007, R01 DK060007-01A1, R01 DK060007-02] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ainbinder E, 1997, EUR J BIOCHEM, V243, P49, DOI 10.1111/j.1432-1033.1997.0049a.x; Arosio P, 2002, FREE RADICAL BIO MED, V33, P457, DOI 10.1016/S0891-5849(02)00842-0; BEAUMONT C, 1994, J BIOL CHEM, V269, P20281; BEAUMONT C, 1987, J BIOL CHEM, V262, P10619; Bevilacqua MA, 1998, BIOCHEM J, V335, P521, DOI 10.1042/bj3350521; Bevilacqua MA, 1997, J BIOL CHEM, V272, P20736, DOI 10.1074/jbc.272.33.20736; BOMFORD A, 1981, J BIOL CHEM, V256, P948; CAIRO G, 1995, J BIOL CHEM, V270, P700, DOI 10.1074/jbc.270.2.700; CHOI HS, 1993, MOL ENDOCRINOL, V7, P1596, DOI 10.1210/me.7.12.1596; CHOU CC, 1986, MOL CELL BIOL, V6, P566, DOI 10.1128/MCB.6.2.566; Cozzi A, 2000, J BIOL CHEM, V275, P25122, DOI 10.1074/jbc.M003797200; Dhakshinamoorthy S, 2000, J BIOL CHEM, V275, P40134, DOI 10.1074/jbc.M003531200; Epsztejn S, 1999, BLOOD, V94, P3593, DOI 10.1182/blood.V94.10.3593.422k26_3593_3603; Faniello MC, 1999, J BIOL CHEM, V274, P7623, DOI 10.1074/jbc.274.12.7623; FRILING RS, 1990, P NATL ACAD SCI USA, V87, P6258, DOI 10.1073/pnas.87.16.6258; Gallo A, 2002, ONCOGENE, V21, P6434, DOI 10.1038/sj.onc.1205822; Gerald D, 2004, CELL, V118, P781, DOI 10.1016/j.cell.2004.08.025; Harrison PM, 1996, BBA-BIOENERGETICS, V1275, P161, DOI 10.1016/0005-2728(96)00022-9; Hayes JD, 2001, CANCER LETT, V174, P103, DOI 10.1016/S0304-3835(01)00695-4; Hentze MW, 2004, CELL, V117, P285, DOI 10.1016/S0092-8674(04)00343-5; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; Inamdar NM, 1996, BIOCHEM BIOPH RES CO, V221, P570, DOI 10.1006/bbrc.1996.0637; Jaiswal AK, 2004, METHOD ENZYMOL, V378, P221; JAISWAL AK, 1994, BIOCHEM PHARMACOL, V48, P439, DOI 10.1016/0006-2952(94)90272-0; Jindra M, 2004, EMBO J, V23, P3538, DOI 10.1038/sj.emboj.7600356; KWAK EL, 1995, J BIOL CHEM, V270, P15285, DOI 10.1074/jbc.270.25.15285; Kwak MK, 2001, MOL MED, V7, P135, DOI 10.1007/BF03401947; Lamb JA, 2003, MOL CELL, V11, P1479, DOI 10.1016/S1097-2765(03)00203-X; LEVI S, 1994, J MOL BIOL, V238, P649, DOI 10.1006/jmbi.1994.1325; LEVI S, 1988, J BIOL CHEM, V263, P18086; LEVI S, 1992, BIOCHEM J, V288, P591, DOI 10.1042/bj2880591; LI Y, 1992, J BIOL CHEM, V267, P15097; Liu SX, 1996, BIOCHEMISTRY-US, V35, P11517, DOI 10.1021/bi960572p; Marziali G, 1997, MOL CELL BIOL, V17, P1387, DOI 10.1128/MCB.17.3.1387; Meneghini R, 1997, FREE RADICAL BIO MED, V23, P783, DOI 10.1016/S0891-5849(97)00016-6; MILLER LL, 1991, P NATL ACAD SCI USA, V88, P4946, DOI 10.1073/pnas.88.11.4946; Motohashi H, 2002, GENE, V294, P1, DOI 10.1016/S0378-1119(02)00788-6; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; Nguyen T, 2003, ANNU REV PHARMACOL, V43, P233, DOI 10.1146/annurev.pharmtox.43.100901.140229; Nioi P, 2003, BIOCHEM J, V374, P337, DOI 10.1042/BJ20030754; Orino K, 2001, BIOCHEM J, V357, P241, DOI 10.1042/0264-6021:3570241; Orino K, 1999, FEBS LETT, V461, P334, DOI 10.1016/S0014-5793(99)01443-X; Pham CG, 2004, CELL, V119, P529, DOI 10.1016/j.cell.2004.10.017; Pietsch EC, 2003, J BIOL CHEM, V278, P2361, DOI 10.1074/jbc.M210664200; Richardson DR, 1997, BBA-REV BIOMEMBRANES, V1331, P1, DOI 10.1016/S0304-4157(96)00014-7; Rouault TA, 1996, TRENDS BIOCHEM SCI, V21, P174, DOI 10.1016/0968-0004(96)10024-4; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; RUSHMORE TH, 1990, J BIOL CHEM, V265, P14648; RUSHMORE TH, 1990, P NATL ACAD SCI USA, V87, P3826, DOI 10.1073/pnas.87.10.3826; SANTAMBROGIO P, 1992, J BIOL CHEM, V267, P14077; Theil EC, 2003, J NUTR, V133, p1549S, DOI 10.1093/jn/133.5.1549S; Theil EC, 2000, BIOCHEM PHARMACOL, V59, P87, DOI 10.1016/S0006-2952(99)00300-7; Torti FM, 2002, BLOOD, V99, P3505, DOI 10.1182/blood.V99.10.3505; TORTI SV, 1988, J BIOL CHEM, V263, P12638; TSUJI Y, 1991, J BIOL CHEM, V266, P7257; Tsuji Y, 2000, MOL CELL BIOL, V20, P5818, DOI 10.1128/MCB.20.16.5818-5827.2000; TSUJI Y, 1993, J IMMUNOL, V150, P1897; TSUJI Y, 1995, MOL CELL BIOL, V15, P5152; Tsuji Y, 1999, J BIOL CHEM, V274, P7501, DOI 10.1074/jbc.274.11.7501; Vasiliou V, 1995, BIOCHEM PHARMACOL, V50, P2057, DOI 10.1016/0006-2952(95)02108-6; Venugopal R, 1998, ONCOGENE, V17, P3145, DOI 10.1038/sj.onc.1202237; Vinciguerra M, 2004, J BIOL CHEM, V279, P9634, DOI 10.1074/jbc.M308721200; WAGSTAFF M, 1978, BIOCHEM J, V173, P969, DOI 10.1042/bj1730969; Wasserman WW, 1997, ARCH BIOCHEM BIOPHYS, V344, P387, DOI 10.1006/abbi.1997.0215; Wasserman WW, 1997, P NATL ACAD SCI USA, V94, P5361, DOI 10.1073/pnas.94.10.5361; Weitzman JB, 2000, MOL CELL, V6, P1109, DOI 10.1016/S1097-2765(00)00109-X; Wild AC, 1999, J BIOL CHEM, V274, P33627, DOI 10.1074/jbc.274.47.33627; Xanthoudakis S, 1996, ADV EXP MED BIOL, V387, P69; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x; Yazgan O, 2002, J BIOL CHEM, V277, P29710, DOI 10.1074/jbc.M204552200	71	104	111	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 17	2005	24	51					7567	7578		10.1038/sj.onc.1208901	http://dx.doi.org/10.1038/sj.onc.1208901			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	984VQ	16007120	Green Accepted			2022-12-25	WOS:000233333800006
J	Melnikova, VO; Pacifico, A; Chimenti, S; Peris, K; Ananthaswamy, HN				Melnikova, VO; Pacifico, A; Chimenti, S; Peris, K; Ananthaswamy, HN			Fate of UVB-induced p53 mutations in SKH-hr1 mouse skin after discontinuation of irradiation: relationship to skin cancer development	ONCOGENE			English	Article						UVB carcinogenesis; p53; tumor progression; differentiation; skin tumor	ULTRAVIOLET-B IRRADIATION; GROWTH-FACTOR; MUTANT P53; SIGNAL-TRANSDUCTION; HUMAN KERATINOCYTES; HAIRLESS MICE; FAS-LIGAND; DNA-REPAIR; RECEPTOR; ACTIVATION	Chronic exposure to ultraviolet (UV) radiation causes skin cancer in humans and mice. We have previously shown that in hairless SKH-hr1 mice, UVB-induced p53 mutations arise very early, well before tumor development. In this study, we investigated whether discontinuation of UVB exposure before the onset of skin tumors results in the disappearance of p53 mutations in the skin of hairless SKH-hr1 mice. Irradiation of mice at a dose of 2.5 kJ/m(2) three times a week for 8 weeks induced p53 mutations in the epidermal keratinocytes of 100% of the mice. UVB irradiation was discontinued after 8 weeks, but p53 mutations at most hotspot codons were still present even 22 weeks later. During that period, the percent of mice carrying p53(V154A/R155C), p53(H175H/H176Y), and p53(R275C) mutant alleles remained at or near 100%, whereas the percentage of mice with p53(R270C) mutation decreased by 45%. As expected, discontinuation of UVB after 8 weeks resulted in a delay in tumor development. A 100% of tumors carried p53(V154A/R155C) mutant alleles, 76% carried p53(H175H/H176Y) mutants, and 24 and 19% carried p53(R270C) and p53(R275C) mutants, respectively. These results suggest that different UVB-induced p53 mutants may provide different survival advantages to keratinocytes in the absence of further UVB exposure and that skin cancer development can be delayed but not prevented by avoidance of further exposure to UVB radiation.	Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA; Univ Roma Tor Vergata, Dept Dermatol, Rome, Italy; Univ Aquila, Dept Dermatol, I-67100 Laquila, Italy	University of Texas System; UTMD Anderson Cancer Center; University of Rome Tor Vergata; University of L'Aquila	Ananthaswamy, HN (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Immunol, POB 301402, Houston, TX 77030 USA.	hanantha@mdanderson.org	Pacifico, Alessia/AAE-9908-2019; Pacifico, Alessia/J-3525-2018	Pacifico, Alessia/0000-0003-0348-0620; Pacifico, Alessia/0000-0003-0348-0620; Peris, Ketty/0000-0002-5237-0463	NCI NIH HHS [CA 16672, CA 46523, U01 CA105345] Funding Source: Medline; NIEHS NIH HHS [ES07784] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, U01CA105345, R01CA046523] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ananthaswamy HN, 1997, NAT MED, V3, P510, DOI 10.1038/nm0597-510; Bender K, 1997, J PHOTOCH PHOTOBIO B, V37, P1, DOI 10.1016/S1011-1344(96)07459-3; Berg RJW, 1996, P NATL ACAD SCI USA, V93, P274, DOI 10.1073/pnas.93.1.274; Blum HF, 1969, BIOL EFFECTS ULTRAVI, P543; Brash DE, 1996, NAT MED, V2, P525, DOI 10.1038/nm0596-525; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; Brash DE, 1996, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 1, NO 2, APRIL 1996, P136; CHUNG KY, 1993, CANCER RES, V53, P1676; COFFER PJ, 1995, ONCOGENE, V11, P561; DEGRUIJL FR, 1991, CANCER RES, V51, P979; DEGRUIJL FR, 1995, BIOESSAYS, V17, P651, DOI 10.1002/bies.950170711; DeMeyts P, 1995, ANN NY ACAD SCI, V766, P388, DOI 10.1111/j.1749-6632.1995.tb26688.x; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; EPSTEIN JH, 1962, J INVEST DERMATOL, V39, P455, DOI 10.1038/jid.1962.142; GILCHREST BA, 1990, ANNU REV MED, V41, P199; Hill LL, 1999, SCIENCE, V285, P898, DOI 10.1126/science.285.5429.898; Jonason AS, 1996, P NATL ACAD SCI USA, V93, P14025, DOI 10.1073/pnas.93.24.14025; Jost M, 2000, EUR J DERMATOL, V10, P505; KANJILAL S, 1995, CANCER RES, V55, P3604; KANJILAL S, 1993, CANCER RES, V53, P2961; KIESER A, 1994, ONCOGENE, V9, P963; KRIPKE M L, 1991, Journal of Dermatology (Tokyo), V18, P429; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; Kuhn C, 1999, INT J CANCER, V80, P431, DOI 10.1002/(SICI)1097-0215(19990129)80:3<431::AID-IJC16>3.3.CO;2-X; Lanyi A, 1998, ONCOGENE, V16, P3169, DOI 10.1038/sj.onc.1201857; Leffell DJ, 1996, SCI AM, V275, P52, DOI 10.1038/scientificamerican0796-52; Li G, 1996, AM J PATHOL, V148, P1113; LIN JY, 1995, ONCOGENE, V10, P2387; LudesMeyers JH, 1996, MOL CELL BIOL, V16, P6009; Marconi A, 1999, J INVEST DERMATOL, V113, P920, DOI 10.1046/j.1523-1747.1999.00773.x; Matas D, 2001, EMBO J, V20, P4163, DOI 10.1093/emboj/20.15.4163; Melnikova VO, 2003, ONCOGENE, V22, P5958, DOI 10.1038/sj.onc.1206595; MILLER DL, 1994, J AM ACAD DERMATOL, V30, P774, DOI 10.1016/S0190-9622(08)81509-5; Mudgil AV, 2003, J INVEST DERMATOL, V121, P191, DOI 10.1046/j.1523-1747.2003.12320.x; Ouhtit A, 2000, AM J PATHOL, V157, P1975, DOI 10.1016/S0002-9440(10)64836-5; Ouhtit A, 2000, AM J PATHOL, V156, P201, DOI 10.1016/S0002-9440(10)64720-7; Peus D, 2000, PHOTOCHEM PHOTOBIOL, V72, P135, DOI 10.1562/0031-8655(2000)072<0135:UIEGFR>2.0.CO;2; Rebel H, 2001, CANCER RES, V61, P977; Remenyik E, 2003, ONCOGENE, V22, P6369, DOI 10.1038/sj.onc.1206657; Ren ZP, 1996, ONCOGENE, V12, P765; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Sigal A, 2000, CANCER RES, V60, P6788; Smith ML, 1997, P NATL ACAD SCI USA, V94, P12255, DOI 10.1073/pnas.94.23.12255; Tron VA, 1998, AM J PATHOL, V153, P579, DOI 10.1016/S0002-9440(10)65600-3; UEBA T, 1994, P NATL ACAD SCI USA, V91, P9009, DOI 10.1073/pnas.91.19.9009; Ullrich SE, 2000, BIOCHEMICAL MODULATION OF SKIN REACTIONS, P281; URBACH F, 1991, DERMATOL CLIN, V9, P751; Urbach F, 1997, J PHOTOCH PHOTOBIO B, V40, P3, DOI 10.1016/S1011-1344(97)00029-8; van Hogerlinden M, 1999, CANCER RES, V59, P3299; Walterscheid JP, 2002, J EXP MED, V195, P171, DOI 10.1084/jem.20011450; YOUNG AR, 1990, SEMIN DERMATOL, V9, P25; Zhang WG, 2001, P NATL ACAD SCI USA, V98, P13948, DOI 10.1073/pnas.241353198; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	53	33	33	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 27	2005	24	47					7055	7063		10.1038/sj.onc.1208863	http://dx.doi.org/10.1038/sj.onc.1208863			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	977WC	16007135				2022-12-25	WOS:000232833200007
J	Lomonosova, E; Subramanian, T; Chinnadurai, G				Lomonosova, E; Subramanian, T; Chinnadurai, G			Mitochondrial localization of p53 during adenovirus infection and regulation of its activity by E1B-19K	ONCOGENE			English	Article						adenovirus; apoptosis; mitochondria; p53; E1B-19K	WILD-TYPE P53; COLORECTAL-CANCER CELLS; TUMOR-SUPPRESSOR P53; BCL-2 PROTEINS; E1B 19K; TRANSCRIPTIONAL ACTIVATION; E4ORF6 PROTEIN; P53-DEPENDENT APOPTOSIS; SV40-TRANSFORMED CELLS; HOST PROTEIN	Recent results have revealed that the p53 tumor suppressor protein possesses a direct transcription-independent apoptotic activity. During apoptosis induced by genotoxic stress, a small fraction of p53 is targeted to mitochondria where it initiates apoptosis by causing mitochondrial dysfunction. In adenovirus-infected cells, the expression of E1A protein enhances the accumulation of p53 during early phases of infection and during late times after infection, it is targeted for degradation by the combined action of E1B-55K and E4-orf6 proteins. The functional significance of E1A-mediated accumulation of p53 during early phases of viral replication is not known. Our studies with isogenic epithelial cell lines that differ only on the status of p53 indicate that Ad infection induces apoptosis by p53-dependent and -independent pathways and both pathways are suppressed by E1B-19K. We show that during early phase of Ad infection, a fraction of p53 is targeted to the mitochondria. In virus infected cells, a large fraction of the viral antiapoptosis protein E1B-19K is also localized in mitochondria during early and late phases of infection. Coimmunoprecipitation analysis has revealed that p53 and E1B-19K form a complex in mitochondria. The interaction of 19K involves two noncontiguous regions located around amino-acid residues 14-15 and 123-124. On p53, the mutations within the DNA-binding domain reduce interaction with E1B-19K. Our studies also suggest that 19K may additionally complex with the multidomain mitochondrial proapoptotic protein BAK, thereby reducing the level of p53 interaction with BAK. We suggest that p53-induced apoptosis may be important for efficient cell lysis and viral spread and that E1B-19K may neutralize the apoptotic activity of p53 at multiple levels.	St Louis Univ, Sch Med, Inst Mol Virol, St Louis, MO 63110 USA	Saint Louis University	Chinnadurai, G (corresponding author), St Louis Univ, Sch Med, Inst Mol Virol, 3681 Pk Ave, St Louis, MO 63110 USA.	chinnag@slu.edu			NATIONAL CANCER INSTITUTE [R01CA033616] Funding Source: NIH RePORTER; NCI NIH HHS [CA-33616, R01 CA033616] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BABISS LE, 1984, J VIROL, V49, P731, DOI 10.1128/JVI.49.3.731-740.1984; BABISS LE, 1984, J VIROL, V50, P202, DOI 10.1128/JVI.50.1.202-212.1984; BACCHETTI S, 1993, INT J ONCOL, V3, P781; Balint E, 2001, BRIT J CANCER, V85, P1813, DOI 10.1054/bjoc.2001.2128; BECK GR, 1998, HUMAN TUMOR VIRUSES, P51; Benard J, 2003, HUM MUTAT, V21, P182, DOI 10.1002/humu.10172; BETT AJ, 1995, VIRUS RES, V39, P75; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; BOYD JM, 1995, ONCOGENE, V11, P1921; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Chen G, 1996, J BIOL CHEM, V271, P24221, DOI 10.1074/jbc.271.39.24221; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Chinnadurai G, 1998, SEMIN VIROL, V8, P399, DOI 10.1006/smvy.1997.0139; Chiou SK, 1997, J VIROL, V71, P3515, DOI 10.1128/JVI.71.5.3515-3525.1997; CHIOU SK, 1994, J VIROL, V68, P6553, DOI 10.1128/JVI.68.10.6553-6566.1994; Chipuk JE, 2003, CANCER CELL, V4, P371, DOI 10.1016/S1535-6108(03)00272-1; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Chipuk JE, 2003, J CLIN IMMUNOL, V23, P355, DOI 10.1023/A:1025365432325; Collett D, 2003, MODELLING SURVIVAL D; Collot-Teixeira S, 2004, REV MED VIROL, V14, P301, DOI 10.1002/rmv.431; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; Cuconati A, 2002, GENE DEV, V16, P2465, DOI 10.1101/gad.1012702; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; Degenhardt K, 2000, Symp Soc Exp Biol, V52, P241; Dix BR, 2000, CANCER RES, V60, P2666; Dobner T, 1996, SCIENCE, V272, P1470, DOI 10.1126/science.272.5267.1470; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; Erster S, 2004, CELL CYCLE, V3, P1492, DOI 10.4161/cc.3.12.1318; Erster S, 2004, MOL CELL BIOL, V24, P6728, DOI 10.1128/MCB.24.15.6728-6741.2004; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; Fu LN, 1996, EMBO J, V15, P4392, DOI 10.1002/j.1460-2075.1996.tb00812.x; Gallimore PH, 2001, ONCOGENE, V20, P7824, DOI 10.1038/sj.onc.1204913; GRAND RJA, 1994, VIROLOGY, V203, P229, DOI 10.1006/viro.1994.1480; Grossman SR, 2003, SCIENCE, V300, P342, DOI 10.1126/science.1080386; Hale TK, 1999, J BIOL CHEM, V274, P23777, DOI 10.1074/jbc.274.34.23777; Hall AR, 1998, NAT MED, V4, P1068, DOI 10.1038/2057; Han J, 1996, MOL CELL BIOL, V16, P5857; HAN J, 1996, WANG, V10, P461; Harada JN, 2002, J VIROL, V76, P9194, DOI 10.1128/JVI.76.18.9194-9206.2002; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Henry H, 2002, ONCOGENE, V21, P748, DOI 10.1038/sj.onc.1205125; Hobom U, 2004, J VIROL, V78, P7685, DOI 10.1128/JVI.78.14.7685-7697.2004; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Koch P, 2001, CANCER RES, V61, P5941; Kokontis JM, 2001, ONCOGENE, V20, P659, DOI 10.1038/sj.onc.1204139; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; Leu JIJ, 2004, NAT CELL BIOL, V6, P443, DOI 10.1038/ncb1123; Liang SH, 2001, EUR J BIOCHEM, V268, P2779, DOI 10.1046/j.1432-1327.2001.02227.x; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; Lomonosova E, 2002, J VIROL, V76, P11283, DOI 10.1128/JVI.76.22.11283-11290.2002; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; Mahyar-Roemer M, 2004, ONCOGENE, V23, P6226, DOI 10.1038/sj.onc.1207637; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; Mathai JP, 2002, ONCOGENE, V21, P2534, DOI 10.1038/sj.onc.1205340; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Mirza A, 2002, ONCOGENE, V21, P2613, DOI 10.1038/sj.onc.1205353; MIYASHITA T, 1995, CELL, V80, P293; Moll UM, 2003, MOL CANCER RES, V1, P1001; Moore M, 1996, P NATL ACAD SCI USA, V93, P11295, DOI 10.1073/pnas.93.21.11295; MORAN E, 1993, FASEB J, V7, P880, DOI 10.1096/fasebj.7.10.8344487; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Perfettini JL, 2004, NAT CELL BIOL, V6, P386, DOI 10.1038/ncb0504-386; Petros AM, 2004, FEBS LETT, V559, P171, DOI 10.1016/s0014-5793(04)00059-6; Querido E, 1997, J VIROL, V71, P3526, DOI 10.1128/JVI.71.5.3526-3533.1997; Querido E, 2001, GENE DEV, V15, P3104, DOI 10.1101/gad.926401; Querido E, 1997, J VIROL, V71, P3788, DOI 10.1128/JVI.71.5.3788-3798.1997; Querido E, 2001, J VIROL, V75, P699, DOI 10.1128/JVI.75.2.699-709.2001; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; Shen YQ, 2001, J VIROL, V75, P4297, DOI 10.1128/JVI.75.9.4297-4307.2001; Steegenga WT, 1998, ONCOGENE, V16, P349, DOI 10.1038/sj.onc.1201540; Subramanian T, 1995, ONCOGENE, V11, P2403; Subramanian T, 2003, J CELL BIOCHEM, V89, P1102, DOI 10.1002/jcb.10573; SUBRAMANIAN T, 1993, GENE, V124, P173, DOI 10.1016/0378-1119(93)90391-F; SUBRAMANIAN T, 1984, J VIROL, V52, P336, DOI 10.1128/JVI.52.2.336-343.1984; SUBRAMANIAN T, 1995, CELL GROWTH DIFFER, V6, P131; TARODI B, 1993, INT J ONCOL, V3, P467; Teodoro JG, 1997, J VIROL, V71, P3620, DOI 10.1128/JVI.71.5.3620-3627.1997; Theodorakis P, 2002, CANCER RES, V62, P3373; Theodorakis P, 1996, ONCOGENE, V12, P1707; Tollefson AE, 1996, J VIROL, V70, P2296, DOI 10.1128/JVI.70.4.2296-2306.1996; Turnell AS, 2000, EMBO J, V19, P4759, DOI 10.1093/emboj/19.17.4759; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wang GD, 2004, ONCOL REP, V12, P955; Webster GA, 1999, MOL CELL BIOL, V19, P3485; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHITE E, 1984, MOL CELL BIOL, V4, P2865, DOI 10.1128/MCB.4.12.2865; Wu YL, 2001, ONCOGENE, V20, P240, DOI 10.1038/sj.onc.1204067; Xu Y, 2003, CELL DEATH DIFFER, V10, P1213, DOI 10.1038/sj.cdd.4401292; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100	99	36	37	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 13	2005	24	45					6796	6808		10.1038/sj.onc.1208836	http://dx.doi.org/10.1038/sj.onc.1208836			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	973MV	16007153				2022-12-25	WOS:000232527800007
J	Kotaja, N; Macho, B; Sassone-Corsi, P				Kotaja, N; Macho, B; Sassone-Corsi, P			Microtubule-independent and protein kinase A-mediated function of kinesin KIF17b controls the intracellular transport of activator of CREM in testis (ACT)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GERM-CELL DIFFERENTIATION; SOLUBLE ADENYLYL-CYCLASE; SEMINIFEROUS EPITHELIUM; SPERMATOGENIC CELLS; CATALYTIC SUBUNIT; EXPRESSION; SPERM; MICE; SPERMIOGENESIS; MODULATION	Kinesins are motor proteins that transport their cargos along microtubules in an ATP- dependent manner. The testis-specific kinesin KIF17b was shown to directly regulate cAMP-response element modulator (CREM)-dependent transcription by determining the subcellular localization of the activator of CREM in testis ( ACT), the testis-specific coactivator of CREM in postmeiotic male germ cells. CREM is a crucial transcriptional regulator of many important genes required for spermatid maturation, as demonstrated by the complete block of sperm development at the first steps of spermiogenesis in crem-null mice. To better understand the complex regulation of postmeiotic germ cell differentiation, we further characterized the ACT-KIF17b interaction, the function of KIF17b, and the signaling pathways governing its action. In this study, we demonstrated that the abilities of KIF17b to shuttle between the nuclear and the cytoplasmic compartments and to transport ACT are neither dependent on its motor domain nor on microtubules, thus revealing a novel microtubule-independent function for kinesins. We also showed that the cyclic AMP-dependent protein kinase A mediates the phosphorylation of KIF17b, and this modification is important for its subcellular localization. These results indicate that cyclic AMP signaling controls CREM-mediated transcription in male germ cells through modification of KIF17b function.	Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Sassone-Corsi, P (corresponding author), Inst Genet & Biol Mol & Cellulaire, BP 10142, F-67404 Illkirch Graffenstaden, France.	paolosc@igbmc.u-strasbg.fr	Sassone-Corsi, Paolo/H-6182-2011	Kotaja, Noora/0000-0003-1503-9170				Bach I, 2000, MECH DEVELOP, V91, P5, DOI 10.1016/S0925-4773(99)00314-7; Blendy JA, 1996, NATURE, V380, P162, DOI 10.1038/380162a0; Chen YQ, 2000, SCIENCE, V289, P625, DOI 10.1126/science.289.5479.625; DELMAS V, 1993, MOL ENDOCRINOL, V7, P1502, DOI 10.1210/me.7.11.1502; Fimia GM, 1999, NATURE, V398, P165, DOI 10.1038/18237; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; Griswold MD, 1998, SEMIN CELL DEV BIOL, V9, P411, DOI 10.1006/scdb.1998.0203; Kamal A, 2002, CURR OPIN CELL BIOL, V14, P63, DOI 10.1016/S0955-0674(01)00295-2; KANGASNIEMI M, 1990, ANAT RECORD, V227, P62, DOI 10.1002/ar.1092270108; Kierszenbaum AL, 2004, ARCH HISTOL CYTOL, V67, P271, DOI 10.1679/aohc.67.271; Kimmins S, 2005, NATURE, V434, P583, DOI 10.1038/nature03368; Kotaja N, 2004, NAT METHODS, V1, P249, DOI 10.1038/nmeth1204-249; Kotaja N, 2004, P NATL ACAD SCI USA, V101, P10620, DOI 10.1073/pnas.0401947101; LONNERBERG P, 1992, BIOL REPROD, V46, P1057, DOI 10.1095/biolreprod46.6.1057; Macho B, 2002, SCIENCE, V298, P2388, DOI 10.1126/science.1077265; Miki H, 2001, P NATL ACAD SCI USA, V98, P7004, DOI 10.1073/pnas.111145398; Nantel F, 1996, NATURE, V380, P159, DOI 10.1038/380159a0; OAKBERG EF, 1956, AM J ANAT, V99, P391, DOI 10.1002/aja.1000990303; PARVINEN M, 1982, ENDOCR REV, V3, P404, DOI 10.1210/edrv-3-4-404; RUPP RAW, 1994, GENE DEV, V8, P1311, DOI 10.1101/gad.8.11.1311; Russell LD, 1990, HISTOLOGICAL HISTOPA, P1; San Agustin JT, 2001, BIOL REPROD, V65, P151, DOI 10.1095/biolreprod65.1.151; San Agustin JT, 2000, MOL BIOL CELL, V11, P3031, DOI 10.1091/mbc.11.9.3031; Sassone-Corsi P, 1998, SEMIN CELL DEV BIOL, V9, P475, DOI 10.1006/scdb.1998.0200; Sassone-Corsi P, 2002, SCIENCE, V296, P2176, DOI 10.1126/science.1070963; Skalhegg B.S., 1997, FRONT BIOSCI, V2, P331; Ullas KS, 2003, J BIOL CHEM, V278, P52673, DOI 10.1074/jbc.M308365200; Weinbauer GF, 1999, ANDROLOGIA, V31, P249, DOI 10.1046/j.1439-0272.1999.00295.x; Woehlke G, 2000, NAT REV MOL CELL BIO, V1, P50, DOI 10.1038/35036069; Xie F, 2004, DEV BIOL, V265, P196, DOI 10.1016/j.ydbio.2003.09.020	30	35	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	2005	280	36					31739	31745		10.1074/jbc.M505971200	http://dx.doi.org/10.1074/jbc.M505971200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	961LZ	16002395	hybrid			2022-12-25	WOS:000231665200051
J	Robinson, FL; Dixon, JE				Robinson, FL; Dixon, JE			The phosphoinositide-3-phosphatase MTMR2 associates with MTMR13, a membrane-associated pseudophosphatase also mutated in type 4B Charcot-Marie-Tooth disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOTUBULARIN-RELATED PROTEIN-2; PHOSPHATIDYLINOSITOL 3-PHOSPHATE; PHOSPHATASE MYOTUBULARIN; IMPAIRED SPERMATOGENESIS; CAENORHABDITIS-ELEGANS; SENSORY NEUROPATHY; MAMMALIAN-CELLS; ONSET GLAUCOMA; SBF2 MUTATION; GRAM DOMAIN	Charcot-Marie- Tooth disease type 4B (CMT4B) is a severe, demyelinating peripheral neuropathy characterized by distinctive, focally folded myelin sheaths. CMT4B is caused by recessively inherited mutations in either myotubularin-related 2 (MTMR2) or MTMR13 ( also called SET-binding factor 2). MTMR2 encodes a member of the myotubularin family of phosphoinositide-3- phosphatases, which dephosphorylate phosphatidylinositol 3-phosphate ( PI( 3) P) and bisphosphate PI( 3,5) P-2. MTMR13 encodes a large, uncharacterized member of the myotubularin family. The MTMR13 phosphatase domain is catalytically inactive because the essential Cys and Arg residues are absent. Given the genetic association of both MTMR2 and MTMR13 with CMT4B, we investigated the biochemical relationship between these two proteins. We found that the endogenous MTMR2 and MTMR13 proteins are associated in human embryonic kidney 293 cells. MTMR2-MTMR13 association is mediated by coiled-coil sequences present in each protein. We also examined the cellular localization of MTMR2 and MTMR13 using fluorescence microscopy and subcellular fractionation. We found that (i) MTMR13 is a predominantly membrane-associated protein; (ii) MTMR2 and MTMR13 cofractionate in both a light membrane fraction and a cytosolic fraction; and (iii) MTMR13 membrane association is mediated by the segment of the protein which contains the pseudophosphatase domain. This work, which describes the first cellular or biochemical investigation of the MTMR13 pseudophosphatase protein, suggests that MTMR13 functions in association with MTMR2. Loss of MTMR13 function in CMT4B2 patients may lead to alterations in MTMR2 function and subsequent alterations in 3-phosphoinositide signaling. Such a mechanism would explain the strikingly similar phenotypes of patients with recessive mutations in either MTMR2 or MTMR13.	Univ Calif San Diego, Dept Pharmacol, Sch Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Dixon, JE (corresponding author), Univ Calif San Diego, Dept Pharmacol, Sch Med, Leichtag Bldg,Rm 284,9500 Gilman Dr, La Jolla, CA 92093 USA.	jedixon@ucsd.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD007203] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018024] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS047846] Funding Source: NIH RePORTER; NICHD NIH HHS [5 T32 HD07203-20] Funding Source: Medline; NIDDK NIH HHS [2R01 DK018024-31] Funding Source: Medline; NINDS NIH HHS [1 F32 NS047846-01A1] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Azzedine H, 2003, AM J HUM GENET, V72, P1141, DOI 10.1086/375034; Begley MJ, 2003, MOL CELL, V12, P1391, DOI 10.1016/S1097-2765(03)00486-6; Ben Othmane K, 1999, GENOMICS, V62, P344, DOI 10.1006/geno.1999.6028; Benstead TJ, 2001, CAN J NEUROL SCI, V28, P199, DOI 10.1017/S0317167100001347; Berger P, 2003, P NATL ACAD SCI USA, V100, P12177, DOI 10.1073/pnas.2132732100; Berger P, 2002, HUM MOL GENET, V11, P1569, DOI 10.1093/hmg/11.13.1569; Blondeau F, 2000, HUM MOL GENET, V9, P2223, DOI 10.1093/oxfordjournals.hmg.a018913; Bolino A, 2004, J CELL BIOL, V167, P711, DOI 10.1083/jcb.200407010; Bolino A, 2000, NAT GENET, V25, P17, DOI 10.1038/75542; Buj-Bello A, 2002, P NATL ACAD SCI USA, V99, P15060, DOI 10.1073/pnas.212498399; Buj-Bello A, 2002, HUM MOL GENET, V11, P2297, DOI 10.1093/hmg/11.19.2297; Burd CG, 1998, MOL CELL, V2, P157, DOI 10.1016/S1097-2765(00)80125-2; Chaussade C, 2003, MOL ENDOCRINOL, V17, P2448, DOI 10.1210/me.2003-0261; Conforti FL, 2004, NEUROLOGY, V63, P1327, DOI 10.1212/01.WNL.0000140617.02312.80; Cooke FT, 2002, ARCH BIOCHEM BIOPHYS, V407, P143, DOI 10.1016/S0003-9861(02)00487-3; Cooke FT, 1998, CURR BIOL, V8, P1219, DOI 10.1016/S0960-9822(07)00513-1; Dang H, 2004, MOL BIOL CELL, V15, P189, DOI 10.1091/mbc.E03-08-0605; Doerks T, 2000, TRENDS BIOCHEM SCI, V25, P483, DOI 10.1016/S0968-0004(00)01664-9; Dove SK, 1997, NATURE, V390, P187, DOI 10.1038/36613; Efe JA, 2005, CURR OPIN CELL BIOL, V17, P402, DOI 10.1016/j.ceb.2005.06.002; Firestein R, 2002, J CLIN INVEST, V109, P1165, DOI [10.1172/JCI200212589, 10.1172/JCI0212589]; Firestein R, 2001, J CELL SCI, V114, P2921; Gary JD, 1998, J CELL BIOL, V143, P65, DOI 10.1083/jcb.143.1.65; Gillooly DJ, 2000, EMBO J, V19, P4577, DOI 10.1093/emboj/19.17.4577; Gruenberg J, 2004, NAT REV MOL CELL BIO, V5, P317, DOI 10.1038/nrm1360; Hirano R, 2004, NEUROLOGY, V63, P577, DOI 10.1212/01.WNL.0000133211.40288.9A; Howard TL, 2001, J CELL SCI, V114, P2395; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Ikonomov OC, 2003, MOL BIOL CELL, V14, P4581, DOI 10.1091/mbc.E03-04-0222; Ikonomov OC, 2001, J BIOL CHEM, V276, P26141, DOI 10.1074/jbc.M101722200; Isakoff SJ, 1998, EMBO J, V17, P5374, DOI 10.1093/emboj/17.18.5374; Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973; Kim SA, 2003, P NATL ACAD SCI USA, V100, P4492, DOI 10.1073/pnas.0431052100; Kim SA, 2002, J BIOL CHEM, V277, P4526, DOI 10.1074/jbc.M111087200; Laporte J, 2003, HUM MOL GENET, V12, pR285, DOI 10.1093/hmg/ddg273; Laporte J, 2002, J CELL SCI, V115, P3105; Laporte J, 2002, BIOCHEM BIOPH RES CO, V291, P305, DOI 10.1006/bbrc.2002.6445; Laporte J, 1996, NAT GENET, V13, P175, DOI 10.1038/ng0696-175; Levivier E, 2001, BIOCHEM BIOPH RES CO, V287, P688, DOI 10.1006/bbrc.2001.5652; Li JCH, 2000, J CELL PHYSIOL, V185, P366, DOI 10.1002/1097-4652(200012)185:3<366::AID-JCP7>3.0.CO;2-1; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Maquat LE, 2004, NAT REV MOL CELL BIO, V5, P89, DOI 10.1038/nrm1310; Mochizuki Y, 2003, P NATL ACAD SCI USA, V100, P9768, DOI 10.1073/pnas.1333958100; Nandurkar HH, 2003, P NATL ACAD SCI USA, V100, P8660, DOI 10.1073/pnas.1033097100; Odorizzi G, 2000, TRENDS BIOCHEM SCI, V25, P229, DOI 10.1016/S0968-0004(00)01543-7; OHNISHI A, 1989, MUSCLE NERVE, V12, P568, DOI 10.1002/mus.880120707; Parrish WR, 2004, MOL BIOL CELL, V15, P3567, DOI 10.1091/mbc.E04-03-0209; Press B, 1998, J CELL BIOL, V140, P1075, DOI 10.1083/jcb.140.5.1075; Quattrone A, 1996, NEUROLOGY, V46, P1318, DOI 10.1212/WNL.46.5.1318; Roth MG, 2004, PHYSIOL REV, V84, P699, DOI 10.1152/physrev.00033.2003; Saifi GM, 2003, J INVEST MED, V51, P261, DOI 10.1136/jim-51-05-14; Sato TK, 2001, SCIENCE, V294, P1881, DOI 10.1126/science.1065763; Sbrissa D, 1999, J BIOL CHEM, V274, P21589, DOI 10.1074/jbc.274.31.21589; Schaletzky J, 2003, CURR BIOL, V13, P504, DOI 10.1016/S0960-9822(03)00132-5; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; Senderek J, 2003, HUM MOL GENET, V12, P349, DOI 10.1093/hmg/ddg030; Shisheva A, 2001, CELL BIOL INT, V25, P1201, DOI 10.1006/cbir.2001.0803; Suter U, 2003, NAT REV NEUROSCI, V4, P714, DOI 10.1038/nrn1196; Taylor GS, 2000, P NATL ACAD SCI USA, V97, P8910, DOI 10.1073/pnas.160255697; Taylor GS, 2003, METHOD ENZYMOL, V366, P43; Tronchere H, 2004, J BIOL CHEM, V279, P7304, DOI 10.1074/jbc.M311071200; Tsujita K, 2004, J BIOL CHEM, V279, P13817, DOI 10.1074/jbc.M312294200; VOLINIA S, 1995, EMBO J, V14, P3339, DOI 10.1002/j.1460-2075.1995.tb07340.x; Walker DM, 2001, CURR BIOL, V11, P1600, DOI 10.1016/S0960-9822(01)00501-2; Whiteford CC, 1997, BIOCHEM J, V323, P597, DOI 10.1042/bj3230597; Wishart MJ, 2002, TRENDS CELL BIOL, V12, P579, DOI 10.1016/S0962-8924(02)02412-1; Xue YZ, 2003, J BIOL CHEM, V278, P34380, DOI 10.1074/jbc.M303259200	67	81	88	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	2005	280	36					31699	31707		10.1074/jbc.M505159200	http://dx.doi.org/10.1074/jbc.M505159200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	961LZ	15998640	hybrid			2022-12-25	WOS:000231665200046
J	Sakaue, F; Saito, T; Sato, Y; Asada, A; Ishiguro, K; Hasegawa, M; Hisanaga, S				Sakaue, F; Saito, T; Sato, Y; Asada, A; Ishiguro, K; Hasegawa, M; Hisanaga, S			Phosphorylation of FTDP-17 mutant tau by cyclin-dependent kinase 5 complexed with p35, p25, or p39	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CDK5 ACTIVATOR P35; IN-VITRO PHOSPHORYLATION; PAIRED HELICAL FILAMENTS; FRONTOTEMPORAL DEMENTIA; ALZHEIMERS-DISEASE; MASS-SPECTROMETRY; NEUROFIBRILLARY TANGLES; WILD-TYPE; MUTATIONS; PROTEIN	One of the major pathological hallmarks of Alzheimer disease is neurofibrillary tangles. Neurofibrillary tangles are bundles of paired helical filaments composed of hyperphosphorylated tau. Cyclin-dependent kinase 5 (Cdk5) is one of the tau protein kinases that increase paired helical filament epitopes in tau by phosphorylation. Recently, various mutations of tau have been identified in frontotemporal dementia and Parkinsonism linked to chromosome 17 (FTDP-17). Here, we investigated the phosphorylation of FTDP-17 mutant tau proteins, K257T, P301L, P301S, and R406W, by Cdk5 complexed with p35, p25, or p39 in vitro and in cultured cells. The extent of phosphorylation by all Cdk5 species was slightly lower in mutant tau than in wild-type tau. Major phosphorylation sites, including Ser(202), Ser(235), and Ser(404), were the same among the wild-type, K257T, P301L, and P301S tau proteins phosphorylated by any Cdk5. On the other hand, R406W tau was less phosphorylated at Ser(404) than were the other variants. This was not due to the simple replacement of amino acid Arg(406) with Trp close to the phosphorylation site, because Ser(404) in a R406W peptide was equally phosphorylated in a wild-type peptide. The decreased phosphorylation of mutant tau by Cdk5s was canceled when tau protein bound to microtubules was phosphorylated. These results indicate that FTDP-17 mutations do not affect the phosphorylatability of tau by Cdk5 complexed with p35, p25, or p39 and may explain part of the discrepancy reported previously between in vivo and in vitro phosphorylation of FTDP-17 tau mutants.	Tokyo Metropolitan Univ, Grad Sch Sci, Dept Biol Sci, Hachioji, Tokyo 1920397, Japan; Mitsubishi Kagaku Inst Life Sci, Machida, Tokyo 1948511, Japan; Tokyo Inst Psychiat, Dept Mol Neurobiol, Tokyo 1568585, Japan	Tokyo Metropolitan University; Mitsubishi Kagaku Institute of Life Sciences (MITILS); Tokyo Institute of Psychiatry	Hisanaga, S (corresponding author), Tokyo Metropolitan Univ, Grad Sch Sci, Dept Biol Sci, 1-1 Minami Osawa, Hachioji, Tokyo 1920397, Japan.	hisanaga-shinichi@c.metro-u.ac.jp		Sakaue, Fumika/0000-0003-1364-8730				Alonso AD, 2004, J BIOL CHEM, V279, P34873, DOI 10.1074/jbc.M405131200; Barghorn S, 2000, BIOCHEMISTRY-US, V39, P11714, DOI 10.1021/bi000850r; Connell JW, 2001, FEBS LETT, V493, P40, DOI 10.1016/S0014-5793(01)02267-0; Cruz JC, 2003, NEURON, V40, P471, DOI 10.1016/S0896-6273(03)00627-5; DeTure M, 2002, AM J PATHOL, V161, P1711, DOI 10.1016/S0002-9440(10)64448-3; Dhavan R, 2001, NAT REV MOL CELL BIO, V2, P749, DOI 10.1038/35096019; Goedert M, 2001, CURR OPIN GENET DEV, V11, P343, DOI 10.1016/S0959-437X(00)00200-8; Hanger DP, 1998, J NEUROCHEM, V71, P2465; Hasegawa M, 1998, FEBS LETT, V437, P207, DOI 10.1016/S0014-5793(98)01217-4; Hashiguchi M, 2002, J BIOL CHEM, V277, P44525, DOI 10.1074/jbc.M207426200; Hisanaga S, 2003, NEUROSIGNALS, V12, P221, DOI 10.1159/000074624; Hong M, 1998, SCIENCE, V282, P1914, DOI 10.1126/science.282.5395.1914; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; ILLENBERGER S, 1998, MOL BIOL CELL, V9, P195; Imahori K, 1997, J BIOCHEM, V121, P179; Iqbal K, 2005, BBA-MOL BASIS DIS, V1739, P198, DOI 10.1016/j.bbadis.2004.09.008; ISHIGURO K, 1992, J BIOL CHEM, V267, P10897; Ishiguro K, 1995, NEUROSCI LETT, V202, P81, DOI 10.1016/0304-3940(95)12206-0; Johnson Gail V. W., 1998, Alzheimer's Disease Review, V3, P125; Krishnamurthy PK, 2004, J BIOL CHEM, V279, P7893, DOI 10.1074/jbc.M311203200; Kusakawa G, 2000, J BIOL CHEM, V275, P17166, DOI 10.1074/jbc.M907757199; Lee MS, 2000, NATURE, V405, P360, DOI 10.1038/35012636; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; Liu F, 2002, FEBS LETT, V530, P209, DOI 10.1016/S0014-5793(02)03487-7; Lund ET, 2001, J NEUROCHEM, V76, P1221, DOI 10.1046/j.1471-4159.2001.00130.x; Mack TGA, 2001, NEUROSCIENCE, V108, P701, DOI 10.1016/S0306-4522(01)00434-1; Matsumura N, 1999, AM J PATHOL, V154, P1649, DOI 10.1016/S0002-9440(10)65420-X; Miyasaka T, 2001, AM J PATHOL, V158, P373, DOI 10.1016/S0002-9440(10)63979-X; MORISHIMAKAWASHIMA M, 1995, J BIOL CHEM, V270, P823, DOI 10.1074/jbc.270.2.823; Nath R, 2000, BIOCHEM BIOPH RES CO, V274, P16, DOI 10.1006/bbrc.2000.3070; Nguyen MD, 2001, NEURON, V30, P135, DOI 10.1016/S0896-6273(01)00268-9; Noble W, 2003, NEURON, V38, P555, DOI 10.1016/S0896-6273(03)00259-9; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; PAUDEL HK, 1993, J BIOL CHEM, V268, P23512; Perez M, 2000, J NEUROCHEM, V74, P2583, DOI 10.1046/j.1471-4159.2000.0742583.x; Poorkaj P, 1998, ANN NEUROL, V43, P815, DOI 10.1002/ana.410430617; Reed LA, 1997, ANN NEUROL, V42, P564, DOI 10.1002/ana.410420406; Saito T, 2003, J NEUROSCI, V23, P1189, DOI 10.1523/JNEUROSCI.23-04-01189.2003; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P7737, DOI 10.1073/pnas.95.13.7737; Stoothoff WH, 2005, BBA-MOL BASIS DIS, V1739, P280, DOI 10.1016/j.bbadis.2004.06.017; Takahashi S, 2003, J BIOL CHEM, V278, P10506, DOI 10.1074/jbc.M211964200; Tang D, 1996, Prog Cell Cycle Res, V2, P205; Taniguchi S, 2001, FEBS LETT, V489, P46, DOI 10.1016/S0014-5793(00)02431-5; Tseng HC, 2002, FEBS LETT, V523, P58, DOI 10.1016/S0014-5793(02)02934-4; Wada Y, 1998, J BIOCHEM-TOKYO, V124, P738, DOI 10.1093/oxfordjournals.jbchem.a022174; Yoo BC, 2001, NATURE, V411, P763, DOI 10.1038/35081146	47	33	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	2005	280	36					31522	31529		10.1074/jbc.M504792200	http://dx.doi.org/10.1074/jbc.M504792200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	961LZ	15994305	hybrid			2022-12-25	WOS:000231665200024
J	Yang, CH; Murti, A; Pfeffer, LM				Yang, CH; Murti, A; Pfeffer, LM			Interferon induces NF-kappa B-inducing kinase/tumor necrosis factor receptor-associated factor-dependent NF-kappa B activation to promote cell survival	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOTOXIN-BETA-RECEPTOR; GLUTATHIONE-S-TRANSFERASE; PROTEIN-TYROSINE KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; SPLENIC MICROARCHITECTURE; INDUCED TRANSCRIPTION; SIGNAL-TRANSDUCTION; COMPLEMENTS DEFECTS; ESCHERICHIA-COLI; IMMUNE-RESPONSES	Type I interferons (IFNs) play critical roles in the host defense by modulating the expression of various genes via the IFN-dependent activation of signal transducers and activators of transcription and NF-kappa B (nuclear factor kappa B) transcription factors. Previous studies established that IFN alpha/beta activates NF-kappa B to promote cell survival through a phosphatidylinositol 3-kinase (PI3K)/Akt pathway, which involves serine phosphorylation and degradation of I kappa B alpha. We now describe a second pathway by which IFNs activate NF-kappa B that is independent of I kappa B degradation. This pathway involves NF-kappa B-inducing kinase (NIK) and the tumor necrosis factor receptor-associated factor-2 (TRAF2) and results in IFN alpha/beta-induced processing of the p100/NF-kappa B2 precursor into p52. IFN alpha/beta stimulates NF-kappa B DNA binding and NF-kappa B-dependent transcription. Whereas expression of NIK and TRAF2 constructs causes NF-kappa B activation, expression of dominant negative NIK and TRAF2 constructs blocks IFN-promoted NF-kappa B activation and IFN-stimulated kappa B-dependent transcription and IFN alpha/beta-induced processing of the p100/NF-kappa B2 precursor into p52. In contrast, PI3K does not mediate IFN alpha/beta-induced p100 processing, although PI3K is involved in the pathway resulting in I kappa B alpha degradation. Moreover, whereas IFN promotes cell survival in lymphoblastoid cells, expression of dominant negative NIK and TRAF2 constructs enhances IFN-induced apoptosis. Our results for the first time place NIK and TRAF2, previously shown to function in TNF signaling, within the IFN signal transduction pathway. Thus, IFN induces NF-kappa B activation to mediate IFN-dependent cell survival signals through a "canonical" pathway of I kappa B alpha proteolysis mediated by PI3K/Akt and a "noncanonical" pathway of p100 processing mediated by NIK/TRAF.	Univ Tennessee, Hlth Sci Ctr, Dept Pathol & Lab Med, Memphis, TN 38163 USA; Univ Tennessee, Canc Inst, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	Pfeffer, LM (corresponding author), Univ Tennessee, Hlth Sci Ctr, Dept Pathol & Lab Med, 930 Madison Ave,Rm 530, Memphis, TN 38163 USA.	lpfeffer@utmem.edu		Pfeffer, Lawrence/0000-0003-2809-1234	NATIONAL CANCER INSTITUTE [R01CA073753] Funding Source: NIH RePORTER; NCI NIH HHS [CA73753, R01 CA073753] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Blanco FL, 1998, BIOTECHNIQUES, V24, P354, DOI 10.2144/98243bm04; Caamano JH, 1998, J EXP MED, V187, P185, DOI 10.1084/jem.187.2.185; Chawla-Sarkar M, 2002, J IMMUNOL, V169, P847, DOI 10.4049/jimmunol.169.2.847; Claudio E, 2002, NAT IMMUNOL, V3, P958, DOI 10.1038/ni842; Coope HJ, 2002, EMBO J, V21, P5375, DOI 10.1093/emboj/cdf542; Cremer I, 1999, VIROLOGY, V253, P241, DOI 10.1006/viro.1998.9470; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; DETOGNI P, 1994, SCIENCE, V264, P703, DOI 10.1126/science.8171322; Einhorn S, 1996, J INTERF CYTOK RES, V16, P275, DOI 10.1089/jir.1996.16.275; Franzoso G, 1998, J EXP MED, V187, P147, DOI 10.1084/jem.187.2.147; FRIEDMAN RL, 1985, NATURE, V314, P637, DOI 10.1038/314637a0; Futterer A, 1998, IMMUNITY, V9, P59, DOI 10.1016/S1074-7613(00)80588-9; Gil MP, 2001, P NATL ACAD SCI USA, V98, P6680, DOI 10.1073/pnas.111163898; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; Grumont RJ, 1998, J EXP MED, V187, P663, DOI 10.1084/jem.187.5.663; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; LARNER AC, 1986, J BIOL CHEM, V261, P453; Luftig M, 2004, P NATL ACAD SCI USA, V101, P141, DOI 10.1073/pnas.2237183100; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Marinari B, 2004, P NATL ACAD SCI USA, V101, P6098, DOI 10.1073/pnas.0308688101; Marrack P, 1999, J EXP MED, V189, P521, DOI 10.1084/jem.189.3.521; Matsushima A, 2001, J EXP MED, V193, P631, DOI 10.1084/jem.193.5.631; MIYAWAKI S, 1994, EUR J IMMUNOL, V24, P429, DOI 10.1002/eji.1830240224; Muller JR, 2003, J BIOL CHEM, V278, P12006, DOI 10.1074/jbc.M210768200; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; OLIVEIRA IC, 1994, MOL CELL BIOL, V14, P5300, DOI 10.1128/MCB.14.8.5300; Ozes ON, 1999, NATURE, V401, P82; Park C, 2000, IMMUNITY, V13, P795, DOI 10.1016/S1074-7613(00)00077-7; Pfeffer LM, 2004, J BIOL CHEM, V279, P31304, DOI 10.1074/jbc.M308975200; Pfeffer LM, 1997, SCIENCE, V276, P1418, DOI 10.1126/science.276.5317.1418; Pomerantz JL, 2002, MOL CELL, V10, P693, DOI 10.1016/S1097-2765(02)00697-4; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; REICH N, 1987, P NATL ACAD SCI USA, V84, P6394, DOI 10.1073/pnas.84.18.6394; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; Schiemann B, 2001, SCIENCE, V293, P2111, DOI 10.1126/science.1061964; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Snapper CM, 1996, J EXP MED, V184, P1537, DOI 10.1084/jem.184.4.1537; Takeda K, 2004, SEMIN IMMUNOL, V16, P3, DOI 10.1016/j.smim.2003.10.003; Thompson JS, 2001, SCIENCE, V293, P2108, DOI 10.1126/science.1061965; VAN AD, 1996, SCIENCE, V274, P787; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Xiao GT, 2004, J BIOL CHEM, V279, P30099, DOI 10.1074/jbc.M401428200; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3; YAN CH, 1996, J BIOL CHEM, V271, P8057; Yang CH, 2004, EXP CELL RES, V298, P197, DOI 10.1016/j.yexcr.2004.04.008; Yang CH, 1998, P NATL ACAD SCI USA, V95, P5568, DOI 10.1073/pnas.95.10.5568; Yang CH, 2000, P NATL ACAD SCI USA, V97, P13631, DOI 10.1073/pnas.250477397; Yang CL, 2001, J BIOL CHEM, V276, P47277, DOI 10.1074/jbc.M105396200; Ye H, 2000, P NATL ACAD SCI USA, V97, P8961, DOI 10.1073/pnas.160241997; Yilmaz ZB, 2003, EMBO J, V22, P121, DOI 10.1093/emboj/cdg004	63	62	63	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	2005	280	36					31530	31536		10.1074/jbc.M503120200	http://dx.doi.org/10.1074/jbc.M503120200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	961LZ	16009713	hybrid, Green Accepted			2022-12-25	WOS:000231665200025
J	Bach, S; Knockaert, M; Reinhardt, J; Lozach, O; Schmitt, S; Baratte, B; Koken, M; Coburn, SP; Tang, L; Jiang, T; Liang, DC; Galons, H; Dierick, JF; Pinna, LA; Meggio, F; Totzke, F; Schachtele, C; Lerman, AS; Carnero, A; Wan, YQ; Gray, N; Meijer, L				Bach, S; Knockaert, M; Reinhardt, J; Lozach, O; Schmitt, S; Baratte, B; Koken, M; Coburn, SP; Tang, L; Jiang, T; Liang, DC; Galons, H; Dierick, JF; Pinna, LA; Meggio, F; Totzke, F; Schachtele, C; Lerman, AS; Carnero, A; Wan, YQ; Gray, N; Meijer, L			Roscovitine targets, protein kinases and pyridoxal kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; INHIBITOR AFFINITY-CHROMATOGRAPHY; INTRACELLULAR TARGETS; IN-VIVO; PARKINSONS-DISEASE; CDK INHIBITORS; R-ROSCOVITINE; CELL-CYCLE; IDENTIFICATION; PURIFICATION	(R)-Roscovitine (CYC202) is often referred to as a "selective inhibitor of cyclin-dependent kinases." Besides its use as a biological tool in cell cycle, neuronal functions, and apoptosis studies, it is currently evaluated as a potential drug to treat cancers, neurodegenerative diseases, viral infections, and glomerulonephritis. We have investigated the selectivity of (R)-roscovitine using three different methods: 1) testing on a wide panel of purified kinases that, along with previously published data, now reaches 151 kinases; 2) identifying roscovitine-binding proteins from various tissue and cell types following their affinity chromatography purification on immobilized roscovitine; 3) investigating the effects of roscovitine on cells deprived of one of its targets, CDK2. Altogether, the results show that (R)-roscovitine is rather selective for CDKs, in fact most kinases are not affected. However, it binds an unexpected, non-protein kinase target, pyridoxal kinase, the enzyme responsible for phosphorylation and activation of vitamin B-6. These results could help in interpreting the cellular actions of (R)-roscovitine but also in guiding the synthesis of more selective roscovitine analogs.	CNRS, Biol Stn, Cell Cycle Grp, UPS 2682, F-29682 Roscoff, France; Biol Stn, UMR 2775, F-29682 Roscoff, France; Indiana Univ Purdue Univ, Dept Chem, Ft Wayne, IN 46805 USA; Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China; Univ Paris 05, Lab Chim Organ 2, F-75270 Paris, France; BioVallee, Proteom Unit, B-6041 Gosselies, Belgium; Univ Padua, Dipartimento Chim Biol, I-35121 Padua, Italy; ProQinase GmbH, D-79106 Freiburg, Germany; CNIO, Programa Terapias Expt, E-28029 Madrid, Spain; Genom Inst, Novartis Res Fdn, Dept Chem, San Diego, CA 92121 USA	Centre National de la Recherche Scientifique (CNRS); Purdue University System; Indiana University Purdue University Fort Wayne; Chinese Academy of Sciences; Institute of Biophysics, CAS; UDICE-French Research Universities; Universite Paris Cite; University of Padua; ProQinase; Centro Nacional de Investigaciones Oncologicas (CNIO); Novartis	Meijer, L (corresponding author), CNRS, Biol Stn, Cell Cycle Grp, UPS 2682, BP 74, F-29682 Roscoff, France.	meijer@sb-roscoff.fr	koken, marcel/J-8154-2012; BACH, Stéphane/ABD-5865-2020; koken, marcel/N-1349-2019; IBIS, CANCER/P-3323-2015	koken, marcel/0000-0002-0839-0125; Totzke, Frank/0000-0002-7261-8155; Olivier, Lozach/0000-0003-0568-4387; Carnero, Amancio/0000-0003-4357-3979; , laurent/0000-0003-3511-4916; Dierick, Jean-Francois/0000-0002-2291-8635				Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Becker F, 2004, CHEM BIOL, V11, P211, DOI 10.1016/j.chembiol.2004.02.001; BORGNE A, 2003, PROGR CELL CYCLE RES, P453; Brehmer D, 2004, MOL CELL PROTEOMICS, V3, P490, DOI 10.1074/mcp.M300139-MCP200; Chang YT, 1999, CHEM BIOL, V6, P361, DOI 10.1016/S1074-5521(99)80048-9; Clough J, 2002, DRUG DISCOV TODAY, V7, P789, DOI 10.1016/S1359-6446(02)02392-9; Coburn SP, 2001, FASEB J, V15, pA963; Cohen P, 2002, NAT REV DRUG DISCOV, V1, P309, DOI 10.1038/nrd773; Cruz JC, 2004, CURR OPIN NEUROBIOL, V14, P390, DOI 10.1016/j.conb.2004.05.002; Daub H, 2004, ASSAY DRUG DEV TECHN, V2, P215, DOI 10.1089/154065804323056558; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; de la Motte S, 2004, INT J CLIN PHARM TH, V42, P232; DeAzevedo WF, 1997, EUR J BIOCHEM, V243, P518, DOI 10.1111/j.1432-1033.1997.0518a.x; Eliot AC, 2004, ANNU REV BIOCHEM, V73, P383, DOI 10.1146/annurev.biochem.73.011303.074021; Fabian MA, 2005, NAT BIOTECHNOL, V23, P329, DOI 10.1038/nbt1068; Fischer PM, 2004, CURR MED CHEM, V11, P1563, DOI 10.2174/0929867043365062; Gachon F, 2004, GENE DEV, V18, P1397, DOI 10.1101/gad.301404; Garriga J, 2004, GENE, V337, P15, DOI 10.1016/j.gene.2004.05.007; Gherardi D, 2004, J AM SOC NEPHROL, V15, P1212, DOI 10.1097/01.ASN.0000124672.41036.F4; Gobom J, 1999, J MASS SPECTROM, V34, P105, DOI 10.1002/(SICI)1096-9888(199902)34:2<105::AID-JMS768>3.0.CO;2-4; Godl K, 2003, P NATL ACAD SCI USA, V100, P15434, DOI 10.1073/pnas.2535024100; Gray NS, 1998, SCIENCE, V281, P533, DOI 10.1126/science.281.5376.533; HAESSLEIN JL, 2002, CURR TOP MED CHEM, V2, P1035; KERRY JA, 1986, EUR J BIOCHEM, V158, P581, DOI 10.1111/j.1432-1033.1986.tb09794.x; Knockaert M, 2002, BIOCHEM PHARMACOL, V64, P819, DOI 10.1016/S0006-2952(02)01144-9; Knockaert M, 2000, CHEM BIOL, V7, P411, DOI 10.1016/S1074-5521(00)00124-1; Knockaert M, 2002, TRENDS PHARMACOL SCI, V23, P417, DOI 10.1016/S0165-6147(02)02071-0; Knockaert M, 2002, J BIOL CHEM, V277, P25493, DOI 10.1074/jbc.M202651200; Knockaert M, 2002, ONCOGENE, V21, P6413, DOI 10.1038/sj.onc.1205908; Kung C, 2005, P NATL ACAD SCI USA, V102, P3587, DOI 10.1073/pnas.0407170102; Li MH, 2004, J BIOL CHEM, V279, P17459, DOI 10.1074/jbc.M312380200; Li MH, 2002, J BIOL CHEM, V277, P46385, DOI 10.1074/jbc.M208600200; Lolli G, 2003, PROTEOMICS, V3, P1287, DOI 10.1002/pmic.200300431; Malumbres M, 2000, BIOL CHEM, V381, P827, DOI 10.1515/BC.2000.105; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Mapelli M, 2005, J MED CHEM, V48, P671, DOI 10.1021/jm049323m; McClue SJ, 2002, INT J CANCER, V102, P463, DOI 10.1002/ijc.10738; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Meijer L, 2003, CHEM BIOL, V10, P1255, DOI 10.1016/j.chembiol.2003.11.010; Meijer L, 2003, ACCOUNTS CHEM RES, V36, P417, DOI 10.1021/ar0201198; Mills PB, 2005, HUM MOL GENET, V14, P1077, DOI 10.1093/hmg/ddi120; Noble MEM, 2004, SCIENCE, V303, P1800, DOI 10.1126/science.1095920; Ortega S, 2003, NAT GENET, V35, P25, DOI 10.1038/ng1232; Percudani R, 2003, EMBO REP, V4, P850, DOI 10.1038/sj.embor.embor914; Pippin JW, 1997, J CLIN INVEST, V100, P2512, DOI 10.1172/JCI119793; Raynaud FI, 2004, MOL CANCER THER, V3, P353; Schang LM, 2004, BBA-PROTEINS PROTEOM, V1697, P197, DOI 10.1016/j.bbapap.2003.11.024; Sche PP, 1999, CHEM BIOL, V6, P707, DOI 10.1016/S1074-5521(00)80018-6; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shima D, 2003, GENES CELLS, V8, P215, DOI 10.1046/j.1365-2443.2003.00627.x; Smith PD, 2004, TRENDS MOL MED, V10, P445, DOI 10.1016/j.molmed.2004.07.003; Smith PD, 2003, P NATL ACAD SCI USA, V100, P13650, DOI 10.1073/pnas.2232515100; Tang L, 2005, J BIOL CHEM, V280, P31220, DOI 10.1074/jbc.M500805200; Tsai LH, 2004, BBA-PROTEINS PROTEOM, V1697, P137, DOI 10.1016/j.bbapap.2003.11.019; Valsasina B, 2004, EXPERT REV PROTEOMIC, V1, P303, DOI 10.1586/14789450.1.3.303; Vermeulen K, 2003, CELL PROLIFERAT, V36, P131, DOI 10.1046/j.1365-2184.2003.00266.x; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; Wan YQ, 2004, CHEM BIOL, V11, P247, DOI 10.1016/j.chembiol.2004.01.015; Wang J, 2003, NAT NEUROSCI, V6, P1039, DOI 10.1038/nn1119; Wang SD, 2001, TETRAHEDRON-ASYMMETR, V12, P2891, DOI 10.1016/S0957-4166(01)00471-2; Zhang GJ, 2004, NAT MED, V10, P643, DOI 10.1038/nm1047; Zhang M, 2004, AM J PATHOL, V165, P843, DOI 10.1016/S0002-9440(10)63347-0	62	289	304	0	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	2005	280	35					31208	31219		10.1074/jbc.M500806200	http://dx.doi.org/10.1074/jbc.M500806200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	958ZX	15975926	Green Published, hybrid			2022-12-25	WOS:000231487800068
J	Deaton, RA; Su, C; Valencia, TG; Grant, SR				Deaton, RA; Su, C; Valencia, TG; Grant, SR			Transforming growth factor-beta 1-induced expression of smooth muscle marker genes involves activation of PKN and p38 MAPK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE FACTOR; PROTEIN-KINASE; IN-VIVO; TRANSCRIPTION FACTOR; ALPHA-ACTIN; CARG ELEMENTS; CELLS; DIFFERENTIATION; RHO; PROMOTER	Differentiated vascular smooth muscle cells (SMCs) exhibit a work phenotype characterized by expression of several well documented contractile apparatus-associated proteins. However, SMCs retain the ability to de-differentiate into a proliferative phenotype, which is involved in the progression of vascular diseases such as atherosclerosis and restenosis. Understanding the mechanisms involved in maintaining SMC differentiation is critical for preventing proliferation associated with vascular disease. In this study, the molecular mechanisms through which transforming growth factor-beta 1 (TGF-beta 1) induces differentiation of SMCs were examined. TGF-beta 1 stimulated actin re-organization, inhibited cell proliferation, and up-regulated SMC marker gene expression in PAC-1 SMCs. These effects were blocked by pretreatment of cells with either HA1077 or Y-27632, which inhibit the kinases downstream of RhoA. Moreover, TGF-beta 1 activated RhoA and its downstream target PKN. Overexpression of active PKN alone was sufficient to increase the transcriptional activity of the promoters that control expression of smooth muscle (SM) alpha-actin, SM-myosin heavy chain, and SM22 alpha. In addition, PKN increased the activities of serum-response factor (SRF), GATA, and MEF2-dependent enhancer-reporters. RNA interference-mediated inhibition of PKN abolished TGF-beta 1-induced activation of SMC marker gene promoters. Finally, examination of MAPK signaling demonstrated that TGF-beta 1 increased the activity of p38 MAPK, which was required for activation of the SMC marker gene promoters. Co-expression of dominant negative p38 MAPK was sufficient to block PKN-mediated activation of the SMC marker gene promoters as well as the serum-response factor, GATA, and MEF2 enhancers. Taken together, these results identify components of an important intracellular signaling pathway through which TGF-beta 1 activates PKN to promote differentiation of SMCs.	Univ Texas, Hlth Sci Ctr, Dept Integrat Physiol, Inst Cardiovasc Res, Ft Worth, TX 76107 USA; Univ Texas, Hlth Sci Ctr, Dept Biomed Sci, Ft Worth, TX 76107 USA	University of Texas System; University of Texas Arlington; University of Texas System; University of Texas Arlington	Grant, SR (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Integrat Physiol, Inst Cardiovasc Res, 3500 Camp Bowie Blvd, Ft Worth, TX 76107 USA.	sgrant@hsc.unt.edu	Su, Chang/A-2158-2010; Deaton, Rebecca A/HGU-5484-2022	Deaton, Rebecca A/0000-0001-7569-1924; Su, Chang/0000-0001-5428-0878	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067152] Funding Source: NIH RePORTER; NHLBI NIH HHS [R0-1 HL67152] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adam PJ, 2000, J BIOL CHEM, V275, P37798, DOI 10.1074/jbc.M006323200; Amano M, 1999, J BIOL CHEM, V274, P32418, DOI 10.1074/jbc.274.45.32418; BARBEE RW, 1993, BIOCHEM BIOPH RES CO, V190, P70, DOI 10.1006/bbrc.1993.1012; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; BJORKERUD S, 1991, ARTERIOSCLER THROMB, V11, P892, DOI 10.1161/01.ATV.11.4.892; Boehm Manfred, 2003, Prog Cell Cycle Res, V5, P19; Charron F, 2001, GENE DEV, V15, P2702, DOI 10.1101/gad.915701; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Edlund S, 2002, MOL BIOL CELL, V13, P902, DOI 10.1091/mbc.01-08-0398; Garat C, 2000, J BIOL CHEM, V275, P22537, DOI 10.1074/jbc.M003000200; Glass CK, 2001, CELL, V104, P503, DOI 10.1016/S0092-8674(01)00238-0; Grainger DJ, 1998, J CELL SCI, V111, P2977; Halayko AJ, 2001, J APPL PHYSIOL, V90, P358, DOI 10.1152/jappl.2001.90.1.358; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; Han JH, 1997, FEBS LETT, V403, P19, DOI 10.1016/S0014-5793(97)00021-5; Hautmann MB, 1997, J BIOL CHEM, V272, P10948; Hirschi KK, 2002, J BIOL CHEM, V277, P6287, DOI 10.1074/jbc.M106649200; Hu YH, 1997, ARTERIOSCL THROM VAS, V17, P2808, DOI 10.1161/01.ATV.17.11.2808; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; Ishizaki T, 2000, MOL PHARMACOL, V57, P976; Izumi Y, 2001, CIRC RES, V88, P1120, DOI 10.1161/hh1101.091267; Katoh Y, 1998, J BIOL CHEM, V273, P1511, DOI 10.1074/jbc.273.3.1511; Kim S, 1998, CIRCULATION, V97, P1731, DOI 10.1161/01.CIR.97.17.1731; Kintscher U, 2003, BIOCHEM BIOPH RES CO, V305, P552, DOI 10.1016/S0006-291X(03)00802-7; Kumar MS, 2003, ARTERIOSCL THROM VAS, V23, P737, DOI 10.1161/01.ATV.0000065197.07635.BA; Li L, 1997, DEV BIOL, V187, P311, DOI 10.1006/dbio.1997.8621; Li ZJ, 1996, BIOCHEM BIOPH RES CO, V228, P334, DOI 10.1006/bbrc.1996.1662; Lin Q, 1998, DEVELOPMENT, V125, P4565; Lu JR, 2000, P NATL ACAD SCI USA, V97, P4070, DOI 10.1073/pnas.080064097; Mack CP, 2001, J BIOL CHEM, V276, P341, DOI 10.1074/jbc.M005505200; Mack CP, 1999, CIRC RES, V84, P852; Manabe I, 2001, J CLIN INVEST, V107, P823, DOI 10.1172/JCI11385; Mano T, 1999, CIRC RES, V84, P647, DOI 10.1161/01.RES.84.6.647; Marinissen MT, 2001, GENE DEV, V15, P535, DOI 10.1101/gad.855801; Masszi A, 2003, AM J PHYSIOL-RENAL, V284, pF911, DOI 10.1152/ajprenal.00183.2002; Miyazawa K, 2002, GENES CELLS, V7, P1191, DOI 10.1046/j.1365-2443.2002.00599.x; OWENS GK, 1995, PHYSIOL REV, V75, P487; OWENS GK, 1988, J CELL BIOL, V107, P771, DOI 10.1083/jcb.107.2.771; Page K, 2001, AM J PHYSIOL-LUNG C, V280, pL955, DOI 10.1152/ajplung.2001.280.5.L955; Parmacek MS, 2001, CURR TOP DEV BIOL, V51, P69, DOI 10.1016/S0070-2153(01)51002-9; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; ROTHMAN A, 1992, CIRCULATION, V86, P1977, DOI 10.1161/01.CIR.86.6.1977; Sahai E, 1998, EMBO J, V17, P1350, DOI 10.1093/emboj/17.5.1350; SHANAHAN CM, 1993, CIRC RES, V73, P193, DOI 10.1161/01.RES.73.1.193; Shen X, 2001, J BIOL CHEM, V276, P15362, DOI 10.1074/jbc.M009534200; SHIMIZU RT, 1995, J BIOL CHEM, V270, P7631, DOI 10.1074/jbc.270.13.7631; SOLWAY J, 1995, J BIOL CHEM, V270, P13460, DOI 10.1074/jbc.270.22.13460; Suzuki E, 1996, GENOMICS, V38, P283, DOI 10.1006/geno.1996.0630; Takahashi M, 1998, P NATL ACAD SCI USA, V95, P11566, DOI 10.1073/pnas.95.20.11566; Takahashi M, 2003, J BIOCHEM, V133, P181, DOI 10.1093/jb/mvg022; Takano H, 1998, MOL CELL BIOL, V18, P1580, DOI 10.1128/MCB.18.3.1580; Wang DZ, 2001, CELL, V105, P851, DOI 10.1016/S0092-8674(01)00404-4; White SL, 1996, J BIOL CHEM, V271, P15008, DOI 10.1074/jbc.271.25.15008; YAMAGATA T, 1995, MOL CELL BIOL, V15, P3830; Zetser A, 1999, J BIOL CHEM, V274, P5193, DOI 10.1074/jbc.274.8.5193; Zilberman A, 1998, CIRC RES, V82, P566, DOI 10.1161/01.RES.82.5.566	57	105	115	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	2005	280	35					31172	31181		10.1074/jbc.M504774200	http://dx.doi.org/10.1074/jbc.M504774200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	958ZX	15980430	hybrid			2022-12-25	WOS:000231487800064
J	Fotinopoulou, A; Tsachaki, M; Vlavaki, M; Poulopoulos, A; Rostagno, A; Frangione, B; Ghiso, J; Efthimiopoulos, S				Fotinopoulou, A; Tsachaki, M; Vlavaki, M; Poulopoulos, A; Rostagno, A; Frangione, B; Ghiso, J; Efthimiopoulos, S			BRI2 interacts with amyloid precursor protein (APP) and regulates amyloid beta (A beta) production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL BRITISH DEMENTIA; ALZHEIMERS-DISEASE; MOLECULAR-CLONING; GENE; EXPRESSION; BRAIN; CDNA; PEPTIDES; SEQUENCE; DOMAIN	Transmembrane proteins BRI2 and amyloid precursor protein (APP) co-localize with amyloid beta(A beta) lesions in sporadic Alzheimer disease and mutations in both precursor proteins are linked to early-onset familial cases of cerebral amyloidosis associated with dementia and/or cerebral hemorrhage. A specific interaction between BRI2 and APP was unveiled by immunoprecipitation experiments using transfected and non-transfected cells. The use of deletion mutants further revealed that stretches 648-719 of APP751 and 46-106 of BRI2, both inclusive of the full transmembrane domains, are sufficient for the interaction. Removal of most of the APP and BRI2 extracellular domains without affecting the interaction implies that both proteins interact when are expressed on the same cell membrane (cis) rather than on adjacent cells (trans). The presence of BRI2 had a modulatory effect on APP processing, specifically increasing the levels of cellular APP as well as beta-secretase-generated COOH-terminal fragments while decreasing the levels of alpha-secretase-generated COOH-terminal fragments as well as the secretion of total APP and A beta peptides. Determining the precise molecular pathways affected by the specific binding between APP and BRI2 could result in the identification of common therapeutic targets for these sporadic and familial neurodegenerative disorders.	Univ Athens, Dept Biol, Div Anim & Human Physiol, Athens 15784, Greece; NYU, Sch Med, Dept Pathol, New York, NY 10016 USA; NYU, Sch Med, Dept Psychiat, New York, NY 10016 USA	National & Kapodistrian University of Athens; New York University; New York University	Efthimiopoulos, S (corresponding author), Univ Athens, Dept Biol, Div Anim & Human Physiol, Athens 15784, Greece.	efthis@biol.uoa.gr	Rostagno, Agueda/A-5801-2008; Poulopoulos, Alexandros/C-3659-2008; Efthimiopoulos, Spiros/H-3956-2013	Poulopoulos, Alexandros/0000-0002-5318-7388; Efthimiopoulos, Spiros/0000-0001-9244-4570; Rostagno, Agueda/0000-0002-6817-2074	NIA NIH HHS [AG05891, AG08721, AG10491] Funding Source: Medline; NINDS NIH HHS [NS38777] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038777] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG005891, R01AG008721, P01AG010491, R01AG005891] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ABRAHAM CR, 1988, CELL, V52, P487, DOI 10.1016/0092-8674(88)90462-X; Akiyama H, 2004, ACTA NEUROPATHOL, V107, P53, DOI 10.1007/s00401-003-0783-1; ANDERSON JP, 1989, EMBO J, V8, P3627, DOI 10.1002/j.1460-2075.1989.tb08536.x; Cam JA, 2004, J BIOL CHEM, V279, P29639, DOI 10.1074/jbc.M313893200; Choi SI, 2003, FASEB J, V17, P373, DOI 10.1096/fj.03-0730fje; CHOIMIURA NH, 1992, ACTA NEUROPATHOL, V83, P260, DOI 10.1007/BF00296787; CORIA F, 1988, LAB INVEST, V58, P454; Deleersnijder W, 1996, J BIOL CHEM, V271, P19475, DOI 10.1074/jbc.271.32.19475; EFTHIMIOPOULOS S, 1994, J NEUROSCI RES, V38, P81, DOI 10.1002/jnr.490380111; EIKELENBOOM P, 1994, VIRCHOWS ARCH, V424, P421, DOI 10.1007/BF00190565; Gandy S, 2005, J CLIN INVEST, V115, P1121, DOI 10.1172/JCI200525100; Ghiso J, 2002, ADV DRUG DELIVER REV, V54, P1539, DOI 10.1016/S0169-409X(02)00149-7; Jacobsen TL, 1998, DEVELOPMENT, V125, P4531; Kim SH, 1999, NAT NEUROSCI, V2, P984, DOI 10.1038/14783; Kinoshita A, 2003, J BIOL CHEM, V278, P41182, DOI 10.1074/jbc.M306403200; MCGEER PL, 1992, BRAIN RES, V579, P337, DOI 10.1016/0006-8993(92)90071-G; Perret E, 2004, P NATL ACAD SCI USA, V101, P16472, DOI 10.1073/pnas.0402085101; Pietrzik CU, 2002, EMBO J, V21, P5691, DOI 10.1093/emboj/cdf568; Pittois K, 1998, GENE, V217, P141, DOI 10.1016/S0378-1119(98)00354-0; ROBAKIS NK, 1987, P NATL ACAD SCI USA, V84, P4190, DOI 10.1073/pnas.84.12.4190; Sanchez-Pulido L, 2002, TRENDS BIOCHEM SCI, V27, P329, DOI 10.1016/S0968-0004(02)02134-5; Sato T, 2004, GENES CELLS, V9, P791, DOI 10.1111/j.1365-2443.2004.00763.x; SNOW AD, 1987, LAB INVEST, V56, P120; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; Ulery PG, 2000, J BIOL CHEM, V275, P7410, DOI 10.1074/jbc.275.10.7410; Vidal R, 2000, P NATL ACAD SCI USA, V97, P4920, DOI 10.1073/pnas.080076097; Vidal R, 1999, NATURE, V399, P776; Vidal R, 2001, GENE, V266, P95, DOI 10.1016/S0378-1119(01)00374-2	28	90	98	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	2005	280	35					30768	30772		10.1074/jbc.C500231200	http://dx.doi.org/10.1074/jbc.C500231200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	958ZX	16027166	hybrid			2022-12-25	WOS:000231487800016
J	Heo, J; Campbell, SL				Heo, J; Campbell, SL			Mechanism of redox-mediated guanine nucleotide exchange on redox-active rho GTPases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYGEN-SPECIES GENERATION; NITRIC-OXIDE SYNTHASES; SMOOTH-MUSCLE-CELLS; XANTHINE OXIDOREDUCTASE; SUPEROXIDE-DISMUTASE; PROTEIN INTERACTIONS; SIGNAL-TRANSDUCTION; ACTIVATION; RAS; P21(RAS)	Rho GTPases regulate multiple cellular processes including actin cytoskeletal rearrangements, transcriptional regulation, and oxidant production. The studies described herein demonstrate that small molecule redox agents, in addition to protein regulatory factors, can regulate the activity of redox- active Rho GTPases. A novel ( GXXXXGK( S/ T) C) motif, conserved in a number of Rho GTPases, appears critical for redox- mediated guanine nucleotide dissociation in vitro. A detailed molecular mechanism for redox regulation of GXXXXGK( S/ T) C motif- containing Rho GTPases is proposed.	Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Campbell, SL (corresponding author), Univ N Carolina, Dept Biochem & Biophys, 530 Mary Ellen Jones Bldg, Chapel Hill, NC 27599 USA.	campbesl@med.unc.edu	, Proteomics Core UNC/AFQ-7201-2022	campbell, sharon/0000-0003-0311-409X	NCI NIH HHS [R01CA89614-O1A1] Funding Source: Medline; NHLBI NIH HHS [P01 HL45100] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA089614] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL045100] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adachi T, 2004, J BIOL CHEM, V279, P29857, DOI 10.1074/jbc.M313320200; Adams PD, 2004, BIOCHEMISTRY-US, V43, P9968, DOI 10.1021/bi0490901; Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593; Augusto O, 2002, FREE RADICAL BIO MED, V32, P841, DOI 10.1016/S0891-5849(02)00786-4; Bae GU, 2004, EXP CELL RES, V300, P476, DOI 10.1016/j.yexcr.2004.07.013; Bokoch GM, 2003, TRENDS BIOCHEM SCI, V28, P502, DOI 10.1016/S0968-0004(03)00194-4; Bonini MG, 2004, BIOCHEMISTRY-US, V43, P344, DOI 10.1021/bi035606p; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brennan LA, 2003, DNA CELL BIOL, V22, P317, DOI 10.1089/104454903322216662; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Chang YZ, 2002, CIRC RES, V91, P390, DOI 10.1161/01.RES.0000033524.92083.64; Delarue FL, 2001, ONCOGENE, V20, P6531, DOI 10.1038/sj.onc.1204801; Dougherty CJ, 2004, FASEB J, V18, P1060, DOI 10.1096/fj.04-1505com; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Feltham JL, 1997, BIOCHEMISTRY-US, V36, P8755, DOI 10.1021/bi970694x; Godber BLJ, 2000, J BIOL CHEM, V275, P7757, DOI 10.1074/jbc.275.11.7757; Harrison R, 2002, FREE RADICAL BIO MED, V33, P774, DOI 10.1016/S0891-5849(02)00956-5; Heo J, 2005, BIOCHEMISTRY-US, V44, P6573, DOI 10.1021/bi047443q; Heo J, 2005, J MOL BIOL, V346, P1423, DOI 10.1016/j.jmb.2004.12.050; Heo J, 2005, J BIOL CHEM, V280, P12438, DOI 10.1074/jbc.M414282200; Heo JY, 2004, BIOCHEMISTRY-US, V43, P2314, DOI 10.1021/bi035275g; Hirshberg M, 1997, NAT STRUCT BIOL, V4, P147, DOI 10.1038/nsb0297-147; Hodges GR, 2000, FREE RADICAL BIO MED, V29, P434, DOI 10.1016/S0891-5849(00)00298-7; Jourd'heuil D, 2003, J BIOL CHEM, V278, P15720, DOI 10.1074/jbc.M300203200; KHAN AU, 1994, P NATL ACAD SCI USA, V91, P12365, DOI 10.1073/pnas.91.26.12365; Kone BC, 2000, ACTA PHYSIOL SCAND, V168, P27; Kone BC, 2003, AM J PHYSIOL-RENAL, V285, pF178, DOI 10.1152/ajprenal.00048.2003; Lander HM, 1997, FASEB J, V11, P118, DOI 10.1096/fasebj.11.2.9039953; Lander HM, 1996, NATURE, V381, P380, DOI 10.1038/381380a0; MCCORD JM, 1969, J BIOL CHEM, V244, P6056; Mori K, 2004, CANCER RES, V64, P7464, DOI 10.1158/0008-5472.CAN-04-1725; Nimnual AS, 2003, NAT CELL BIOL, V5, P236, DOI 10.1038/ncb938; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; Park HS, 2004, MOL CELL BIOL, V24, P4384, DOI 10.1128/MCB.24.10.4384-4394.2004; POU S, 1992, J BIOL CHEM, V267, P24173; REINSTEIN J, 1991, J BIOL CHEM, V266, P17700; STEINMAN HM, 1974, J BIOL CHEM, V249, P7326; Stenmark H, 2001, GENOME BIOL, V2; Sundaresan M, 1996, BIOCHEM J, V318, P379, DOI 10.1042/bj3180379; Turcotte S, 2003, J CELL SCI, V116, P2247, DOI 10.1242/jcs.00427; Vetter IR, 2001, SCIENCE, V294, P1299, DOI 10.1126/science.1062023; Wainwright MS, 2003, DEV BRAIN RES, V146, P79, DOI 10.1016/j.devbrainres.2003.09.012; Wardman P, 1996, RADIAT RES, V145, P523, DOI 10.2307/3579270; Wennerberg K, 2004, J CELL SCI, V117, P1301, DOI 10.1242/jcs.01118; Werner E, 2004, J CELL SCI, V117, P143, DOI 10.1242/jcs.00937; Wojciak-Stothard B, 2005, AM J PHYSIOL-LUNG C, V288, pL749, DOI 10.1152/ajplung.00361.2004; Yun HY, 1998, P NATL ACAD SCI USA, V95, P5773, DOI 10.1073/pnas.95.10.5773; Zhao TM, 2003, J CLIN INVEST, V112, P1732, DOI 10.1172/JCI200319108	48	93	95	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	2005	280	35					31003	31010		10.1074/jbc.M504768200	http://dx.doi.org/10.1074/jbc.M504768200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	958ZX	15994296	Green Published, hybrid			2022-12-25	WOS:000231487800043
J	Nieto, N; Cederbaum, AI				Nieto, N; Cederbaum, AI			S-adenosylmethionine blocks collagen I production by preventing transforming growth factor-beta induction of the COL1A2 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATIC STELLATE CELLS; ADENOSYL-L-METHIONINE; FAR-UPSTREAM ENHANCER; HISTONE DEACETYLASE INHIBITOR; NECROSIS-FACTOR-ALPHA; RAT-LIVER FIBROSIS; GENE-EXPRESSION; LIPID-PEROXIDATION; OXIDATIVE STRESS; TRANSGENIC MICE	To study the antifibrogenic mechanisms of S- adenosylmethionine ( AdoMet), transgenic mice harboring the - 17 kb to + 54 bp of the collagen alpha 2 ( I) promoter ( COL1A2) cloned upstream from the beta- gal reporter gene were injected with carbon tetrachloride ( CCl4) to induce fibrosis and coadministered either AdoMet or saline. Control groups received AdoMet or mineral oil. AdoMet lowered the pathology in CCl4- treated mice as shown by transaminase levels, hematoxylin and eosin, Masson's trichrome staining, and collagen I expression. beta- Galactosidase activity indicated activation of the COL1A2 promoter in stellate cells from CCl4- treated mice and repression of such activation by AdoMet. Lipid peroxidation, transforming growth factor- beta ( TGF beta) expression, and decreases in glutathione levels were prevented by AdoMet. Incubation of primary stellate cells with AdoMet down- regulated basal and TGF beta- induced collagen I and alpha- smooth muscle actin proteins. AdoMet metabolites down- regulated collagen I protein and mRNA levels. AdoMet repressed basal and TGF beta- induced reporter activity in stellate cells transfected with COL1A2 promoter deletion constructs. AdoMet blocked TGF beta induction of the - 378 bp region of the COL1A2 promoter and prevented the phosphorylation of extracellular signal-regulated kinase 1/ 2 and the binding of Sp1 to the TGF beta- responsive element. These observations unveil a novel mechanism by which AdoMet could ameliorate liver fibrosis.	Mt Sinai Sch Med, Dept Pharmacol & Biol Chem, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Nieto, N (corresponding author), Mt Sinai Sch Med, Dept Pharmacol & Biol Chem, 1 Gustave L Levy Pl,Box 1603, New York, NY 10029 USA.	natalia.nieto@mssm.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK069286, R01DK069286] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA014132, R56AA003312, R01AA003312] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA 03312, AA 14132] Funding Source: Medline; NIDDK NIH HHS [DK69286] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Antoniv TT, 2001, J BIOL CHEM, V276, P21754, DOI 10.1074/jbc.M101397200; BARAK AJ, 1993, ALCOHOL CLIN EXP RES, V17, P552, DOI 10.1111/j.1530-0277.1993.tb00798.x; BEDOSSA P, 1994, HEPATOLOGY, V19, P1262, DOI 10.1016/0270-9139(94)90876-1; BOAST S, 1990, J BIOL CHEM, V265, P13351; BouGharios G, 1996, J CELL BIOL, V134, P1333, DOI 10.1083/jcb.134.5.1333; Carmiel-Haggai M, 2004, FASEB J, V18, P136, DOI 10.1096/fj.04-2291fje; Chawla RK, 1998, AM J PHYSIOL-GASTR L, V275, pG125, DOI 10.1152/ajpgi.1998.275.1.G125; Colell A, 1997, HEPATOLOGY, V26, P699, DOI 10.1053/jhep.1997.v26.pm0009303501; CORRALES F, 1992, HEPATOLOGY, V16, P1022, DOI 10.1002/hep.1840160427; De Val S, 2002, J BIOL CHEM, V277, P9286, DOI 10.1074/jbc.M111040200; Deulofeu R, 2000, CLIN SCI, V99, P315, DOI 10.1042/CS20000127; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Duffield JS, 2005, J CLIN INVEST, V115, P56, DOI 10.1172/JCI200522675; Finkelstein JD, 2003, AM J CLIN NUTR, V77, P1094, DOI 10.1093/ajcn/77.5.1094; Gasso M, 1996, J HEPATOL, V25, P200, DOI 10.1016/S0168-8278(96)80074-2; Greenwel P, 1997, J BIOL CHEM, V272, P19738, DOI 10.1074/jbc.272.32.19738; GREENWEL P, 1995, MOL CELL BIOL, V15, P6813; Greenwel P, 2000, MOL CELL BIOL, V20, P912, DOI 10.1128/MCB.20.3.912-918.2000; Greenwel P, 2000, HEPATOLOGY, V31, P109, DOI 10.1002/hep.510310118; Huang ZZ, 1998, AM J PHYSIOL-GASTR L, V275, pG14, DOI 10.1152/ajpgi.1998.275.1.G14; Inagaki Y, 2003, HEPATOLOGY, V38, P890, DOI 10.1053/jhep.2003.50408; INAGAKI Y, 1995, J BIOL CHEM, V270, P3353, DOI 10.1074/jbc.270.7.3353; INAGAKI Y, 1995, HEPATOLOGY, V22, P573, DOI 10.1016/0270-9139(95)90582-0; INAGAKI Y, 1994, J BIOL CHEM, V269, P14828; Kinbara T, 2002, J CELL PHYSIOL, V190, P375, DOI 10.1002/jcp.10046; LIEBER CS, 1990, HEPATOLOGY, V11, P165, DOI 10.1002/hep.1840110203; Lieber CS, 2002, ALCOHOL, V27, P173, DOI 10.1016/S0741-8329(02)00230-6; LOPEZDELEON A, 1985, J HISTOCHEM CYTOCHEM, V33, P737, DOI 10.1177/33.8.2410480; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lu SC, 2002, ALCOHOL, V27, P155, DOI 10.1016/S0741-8329(02)00226-4; Mato JM, 1997, PHARMACOL THERAPEUT, V73, P265, DOI 10.1016/S0163-7258(96)00197-0; Mato JM, 1999, J HEPATOL, V30, P1081, DOI 10.1016/S0168-8278(99)80263-3; NAKATSUKASA H, 1990, J CLIN INVEST, V85, P1833, DOI 10.1172/JCI114643; NIEDERREITHER K, 1992, J CELL BIOL, V119, P1361, DOI 10.1083/jcb.119.5.1361; Nieto N, 1999, HEPATOLOGY, V30, P987, DOI 10.1002/hep.510300433; Nieto N, 2002, HEPATOLOGY, V35, P62, DOI 10.1053/jhep.2002.30362; Nieto N, 2001, HEPATOLOGY, V33, P597, DOI 10.1053/jhep.2001.22520; Nieto N, 2000, J BIOL CHEM, V275, P20136, DOI 10.1074/jbc.M001422200; Niki T, 1999, HEPATOLOGY, V29, P858, DOI 10.1002/hep.510290328; Oakley F, 2005, GASTROENTEROLOGY, V128, P108, DOI 10.1053/j.gastro.2004.10.003; Parola M, 1998, J CLIN INVEST, V102, P1942, DOI 10.1172/JCI1413; PASCALE RM, 1992, CANCER RES, V52, P4979; REINKE LA, 1985, DRUG METAB DISPOS, V13, P548; Rombouts K, 2002, EXP CELL RES, V278, P184, DOI 10.1006/excr.2002.5577; Shimizu I, 1999, HEPATOLOGY, V29, P149, DOI 10.1002/hep.510290108; ShimizuSaito K, 1997, HEPATOLOGY, V26, P424, DOI 10.1002/hep.510260224; Simile MM, 2001, J HEPATOL, V34, P386, DOI 10.1016/S0168-8278(00)00078-7; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; SOHN DH, 1991, BIOCHEM BIOPH RES CO, V179, P449, DOI 10.1016/0006-291X(91)91391-O; Song ZY, 2003, J NUTR BIOCHEM, V14, P591, DOI 10.1016/S0955-2863(03)00116-5; TIERNEY DJ, 1992, ARCH BIOCHEM BIOPHYS, V293, P9, DOI 10.1016/0003-9861(92)90358-4; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; Tsukada S, 2005, J BIOL CHEM, V280, P10055, DOI 10.1074/jbc.M409381200; TSUKAMOTO H, 1993, ALCOHOL, V10, P465, DOI 10.1016/0741-8329(93)90066-W; VENDEMIALE G, 1989, SCAND J GASTROENTERO, V24, P407, DOI 10.3109/00365528909093067; Zhang W, 2000, J BIOL CHEM, V275, P39237, DOI 10.1074/jbc.M003339200	56	44	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	2005	280	35					30963	30974		10.1074/jbc.M503569200	http://dx.doi.org/10.1074/jbc.M503569200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	958ZX	15983038	hybrid			2022-12-25	WOS:000231487800039
J	Rapedius, M; Soom, M; Shumilina, E; Schulze, D; Schonherr, R; Kirsch, C; Lang, F; Tucker, SJ; Baukrowitz, T				Rapedius, M; Soom, M; Shumilina, E; Schulze, D; Schonherr, R; Kirsch, C; Lang, F; Tucker, SJ; Baukrowitz, T			Long chain CoA esters as competitive antagonists of phosphatidylinositol 4,5-bisphosphate activation in Kir channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K-ATP CHANNELS; RECTIFIER POTASSIUM CHANNELS; ACYL-COA; INWARD RECTIFICATION; PIP2; METABOLISM; SENSITIVITY; INHIBITION; MECHANISM; PHOSPHOINOSITIDES	Long chain fatty acid esters of coenzyme A (LC-CoA) are potent activators of ATP-sensitive (K-ATP) channels, and elevated levels have been implicated in the pathophysiology of type 2 diabetes. This stimulatory effect is thought to involve a mechanism similar to phosphatidylinositol 4,5-bisphosphate (PIP2), which activates all known inwardly rectifying potassium (Kir) channels. However, the effect of LC-CoA on other Kir channels has not been well characterized. In this study, we show that in contrast to their stimulatory effect on K-ATP channels, LC-CoA ( e. g. oleoyl-CoA) potently and reversibly inhibits all other Kir channels tested (Kir1.1, Kir2.1, Kir3.4, Kir7.1). We also demonstrate that the inhibitory potency of the LC-CoA increases with the chain length of the fatty acid chain, while both its activatory and inhibitory effects critically depend on the presence of the 3 '-ribose phosphate on the CoA group. Biochemical studies also demonstrate that PIP2 and LC-CoA bind with similar affinity to the C-terminal domains of Kir2.1 and Kir6.2 and that PIP2 binding can be competitively antagonized by LC-CoA, suggesting that the mechanism of LC-CoA inhibition involves displacement of PIP2. Furthermore, we demonstrate that in contrast to its stimulatory effect on K-ATP channels, phosphatidylinositol 3,4-bisphosphate has an inhibitory effect on Kir1.1 and Kir2.1. These results demonstrate a bi-directional modulation of Kir channel activity by LC-CoA and phosphoinositides and suggest that changes in fatty acid metabolism ( e. g. LC-CoA production) could have profound and widespread effects on cellular electrical activity.	Univ Jena, Inst Physiol 2, D-07743 Jena, Germany; Univ Tubingen, Dept Physiol 1, D-72076 Tubingen, Germany; Univ Jena, D-07747 Jena, Germany; Univ Jena, Inst Biochem, D-07743 Jena, Germany; Univ Oxford, Physiol Lab, Oxford Ctr Gene Funct, Oxford OX1 3PT, England	Friedrich Schiller University of Jena; Eberhard Karls University of Tubingen; Friedrich Schiller University of Jena; Friedrich Schiller University of Jena; University of Oxford	Baukrowitz, T (corresponding author), Univ Jena, Inst Physiol 2, Teichgraben 8, D-07743 Jena, Germany.	thbau@mti.uni-jena.de	Tucker, Stephen J./ABE-6741-2020; Schönherr, Roland/K-8713-2013; Tucker, Stephen J./ABE-7468-2020	Tucker, Stephen J./0000-0001-8996-2000; Schönherr, Roland/0000-0003-0633-0775; Tucker, Stephen J./0000-0001-8996-2000; Baukrowitz, Thomas/0000-0003-4562-0505				BARRY PH, 1991, J MEMBRANE BIOL, V121, P101, DOI 10.1007/BF01870526; Baukrowitz T, 1998, SCIENCE, V282, P1141, DOI 10.1126/science.282.5391.1141; Baukrowitz T, 2000, BIOCHEM PHARMACOL, V60, P735, DOI 10.1016/S0006-2952(00)00267-7; Baukrowitz T, 1999, EMBO J, V18, P847, DOI 10.1093/emboj/18.4.847; Branstrom R, 2004, DIABETOLOGIA, V47, P277, DOI 10.1007/s00125-003-1299-x; Faergeman NJ, 1997, BIOCHEM J, V323, P1; FAKLER B, 1995, CELL, V80, P149, DOI 10.1016/0092-8674(95)90459-X; FULCERI R, 1994, CELL CALCIUM, V15, P109, DOI 10.1016/0143-4160(94)90049-3; Gamper N, 2002, PFLUG ARCH EUR J PHY, V443, P625, DOI 10.1007/s00424-001-0741-5; Gribble FM, 1998, J BIOL CHEM, V273, P26383, DOI 10.1074/jbc.273.41.26383; HEBERT SC, 2002, PHYSIOL REV, V85, P319; Huang CL, 1998, NATURE, V391, P803, DOI 10.1038/35882; Kobrinsky E, 2000, NAT CELL BIOL, V2, P507, DOI 10.1038/35019544; Larsson O, 1996, J BIOL CHEM, V271, P10623, DOI 10.1074/jbc.271.18.10623; Liu GX, 2001, CIRC RES, V88, P918, DOI 10.1161/hh0901.089881; Lopes CMB, 2002, NEURON, V34, P933, DOI 10.1016/S0896-6273(02)00725-0; Nichols CG, 1997, ANNU REV PHYSIOL, V59, P171, DOI 10.1146/annurev.physiol.59.1.171; Plaster NM, 2001, CELL, V105, P511, DOI 10.1016/S0092-8674(01)00342-7; Reimann F, 1999, J PHYSIOL-LONDON, V520, P661, DOI 10.1111/j.1469-7793.1999.00661.x; Riedel MJ, 2003, DIABETES, V52, P2630, DOI 10.2337/diabetes.52.10.2630; Rohacs T, 2003, P NATL ACAD SCI USA, V100, P745, DOI 10.1073/pnas.0236364100; Rohacs T, 1999, J BIOL CHEM, V274, P36065, DOI 10.1074/jbc.274.51.36065; Schulze D, 2003, J BIOL CHEM, V278, P10500, DOI 10.1074/jbc.M208413200; Schulze D, 2003, J PHYSIOL-LONDON, V552, P357, DOI 10.1113/jphysiol.2003.047035; Shyng SL, 2000, J GEN PHYSIOL, V116, P599, DOI 10.1085/jgp.116.5.599; Shyng SL, 1998, SCIENCE, V282, P1138, DOI 10.1126/science.282.5391.1138; Soom M, 2001, FEBS LETT, V490, P49, DOI 10.1016/S0014-5793(01)02136-6; Tarasov A, 2004, DIABETES, V53, pS113, DOI 10.2337/diabetes.53.suppl_3.S113; VANDERVUSSE GJ, 1992, PHYSIOL REV, V72, P881, DOI 10.1152/physrev.1992.72.4.881; Xie LH, 1999, P NATL ACAD SCI USA, V96, P15292, DOI 10.1073/pnas.96.26.15292	30	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	2005	280	35					30760	30767		10.1074/jbc.M503503200	http://dx.doi.org/10.1074/jbc.M503503200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	958ZX	15980413	hybrid			2022-12-25	WOS:000231487800015
J	Takagi, Y; Chadick, JZ; Davis, JA; Asturias, FJ				Takagi, Y; Chadick, JZ; Davis, JA; Asturias, FJ			Preponderance of free mediator in the yeast Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TRANSCRIPTIONAL ACTIVATION; PROTEIN IDENTIFICATIONS; PREINITIATION COMPLEX; INITIATION COMPLEX; NUCLEAR RECEPTORS; REPEAT DOMAIN; CELL-CYCLE; IN-VITRO; HOLOENZYME	Biochemical evidence suggesting that the predominant form of Mediator in the yeast Saccharomyces cerevisiae might be one in which the complex is associated with RNA polymerase II to form a holoenzyme has led to the proposition of a holoenzyme-based model for transcription initiation. We report that polymerase-free Mediator, isolated early on during a whole-cell extract fractionation protocol, is in fact the most abundant form of the Mediator complex. The existence of free Mediator would make possible independent recruitment of Mediator and RNA polymerase II to the preinitiation complex. This is in agreement with reports from in vivo studies of time and spatial independence of Mediator and RNA polymerase II promoter interaction, with current models of preinitiation complex structure in which promoter DNA upstream of the transcription start site is positioned between Mediator and polymerase, and with the proposed role of Mediator as the major component of the Scaffold complex involved in transcription reinitiation.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94035 USA	Scripps Research Institute; Stanford University	Asturias, FJ (corresponding author), Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA.	asturias@scripps.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR011823] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036659, R01GM067167] Funding Source: NIH RePORTER; NCRR NIH HHS [RR11823] Funding Source: Medline; NIGMS NIH HHS [R01 GM36659, R01 GM67167] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Asturias FJ, 2004, CURR OPIN STRUC BIOL, V14, P121, DOI 10.1016/j.sbi.2004.03.007; Asturias FJ, 1999, SCIENCE, V283, P985, DOI 10.1126/science.283.5404.985; Borggrefe T, 2001, J BIOL CHEM, V276, P47150, DOI 10.1074/jbc.M109581200; Boube M, 2002, CELL, V110, P143, DOI 10.1016/S0092-8674(02)00830-9; BURATOWSKI S, 1991, P NATL ACAD SCI USA, V88, P7509, DOI 10.1073/pnas.88.17.7509; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; Bushnell DA, 2004, SCIENCE, V303, P983, DOI 10.1126/science.1090838; Chadick JZ, 2005, TRENDS BIOCHEM SCI, V30, P264, DOI 10.1016/j.tibs.2005.03.001; Chen HT, 2004, CELL, V119, P169, DOI 10.1016/j.cell.2004.09.028; Chung WH, 2003, MOL CELL, V12, P1003, DOI 10.1016/S1097-2765(03)00387-3; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; Cosma MP, 2001, MOL CELL, V7, P1213, DOI 10.1016/S1097-2765(01)00266-0; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; Davis JA, 2002, MOL CELL, V10, P409, DOI 10.1016/S1097-2765(02)00598-1; De Antoni A, 2000, GENE, V246, P179, DOI 10.1016/S0378-1119(00)00083-4; Dotson MR, 2000, P NATL ACAD SCI USA, V97, P14307, DOI 10.1073/pnas.260489497; Farrell S, 1996, GENE DEV, V10, P2359, DOI 10.1101/gad.10.18.2359; FLANAGAN PM, 1991, NATURE, V350, P436, DOI 10.1038/350436a0; Fondell JD, 1999, P NATL ACAD SCI USA, V96, P1959, DOI 10.1073/pnas.96.5.1959; Gaudreau L, 1998, MOL CELL, V1, P913, DOI 10.1016/S1097-2765(00)80090-8; Gaudreau L, 1997, CELL, V89, P55, DOI 10.1016/S0092-8674(00)80182-8; Griesenbeck J, 2004, METHOD ENZYMOL, V375, P170; Guglielmi B, 2004, NUCLEIC ACIDS RES, V32, P5379, DOI 10.1093/nar/gkh878; Ito M, 1999, MOL CELL, V3, P361, DOI 10.1016/S1097-2765(00)80463-3; JAZWINSKI SM, 1990, METHOD ENZYMOL, V182, P154; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; Kellogg DR, 2002, METHOD ENZYMOL, V351, P172; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; Koleske AJ, 1996, METHOD ENZYMOL, V273, P176; KOLESKE AJ, 1995, TRENDS BIOCHEM SCI, V20, P113, DOI 10.1016/S0968-0004(00)88977-X; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; Kuras L, 2003, P NATL ACAD SCI USA, V100, P13887, DOI 10.1073/pnas.2036346100; Lee YC, 1999, MOL CELL BIOL, V19, P2967; Lee YC, 1997, MOL CELL BIOL, V17, P4622, DOI 10.1128/MCB.17.8.4622; LI Y, 1995, P NATL ACAD SCI USA, V92, P10864, DOI 10.1073/pnas.92.24.10864; Linder T, 2004, J BIOL CHEM, V279, P49455, DOI 10.1074/jbc.M409046200; Liu Y, 2001, J BIOL CHEM, V276, P7169, DOI 10.1074/jbc.M009586200; MacCoss MJ, 2002, ANAL CHEM, V74, P5593, DOI 10.1021/ac025826t; Maldonado E, 1996, NATURE, V381, P86, DOI 10.1038/381086a0; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Myers LC, 1997, METHODS, V12, P212, DOI 10.1006/meth.1997.0473; Myers LC, 1999, P NATL ACAD SCI USA, V96, P67, DOI 10.1073/pnas.96.1.67; Myers LC, 1998, GENE DEV, V12, P45, DOI 10.1101/gad.12.1.45; Naar AM, 1999, NATURE, V398, P828, DOI 10.1038/19789; NONET ML, 1989, GENETICS, V123, P715; PONTICELLI AS, 1990, MOL CELL BIOL, V10, P2832, DOI 10.1128/MCB.10.6.2832; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Sato S, 2004, MOL CELL, V14, P685, DOI 10.1016/j.molcel.2004.05.006; SAYRE MH, 1992, J BIOL CHEM, V267, P23383; STOFFLER G, 1983, MODERN METHODS PROTE, P409; Taatjes DJ, 2004, MOL CELL, V14, P675, DOI 10.1016/j.molcel.2004.05.014; Tabb DL, 2002, J PROTEOME RES, V1, P21, DOI 10.1021/pr015504q; Takagi Y, 2003, J BIOL CHEM, V278, P43897, DOI 10.1074/jbc.C300417200; THOMPSON CM, 1995, P NATL ACAD SCI USA, V92, P4587, DOI 10.1073/pnas.92.10.4587; TISCHENDORF GW, 1974, MOL GEN GENET, V134, P187, DOI 10.1007/BF00267715	56	13	33	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	2005	280	35					31200	31207		10.1074/jbc.C500150200	http://dx.doi.org/10.1074/jbc.C500150200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	958ZX	16002404	hybrid			2022-12-25	WOS:000231487800067
J	Wu, JH; Goswami, R; Kim, LK; Miller, WE; Peppel, K; Freedman, NJ				Wu, JH; Goswami, R; Kim, LK; Miller, WE; Peppel, K; Freedman, NJ			The platelet-derived growth factor receptor-beta phosphorylates and activates g protein-coupled receptor kinase-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; SRC TYROSINE KINASE; AGONIST-DEPENDENT PHOSPHORYLATION; EXCHANGER REGULATORY FACTOR; C-SRC; G(BETA-GAMMA) SUBUNITS; PDGF RECEPTOR; 2 GRK2; DESENSITIZATION; DEGRADATION	G protein- coupled receptor kinase- 2 ( GRK2) serinephosphorylates the platelet- derived growth factor receptor-beta ( PDGFR beta), and thereby diminishes signaling by the receptor. Because activation of GRK2 may involve phosphorylation of its N- terminal tyrosines by cSrc, we tested whether the PDGFR beta itself could tyrosine-phosphorylate and activate GRK2. To do so, we used wild type ( WT) and Y857F mutant PDGFR beta s in HEK cells, which lack endogenous PDGFRs. The Y857F PDGFR beta autophosphorylates normally but does not phosphorylate exogenous substrates. Although PDGF-stimulated Y857F and WT PDGFR beta s activated c- Src equivalently, the WT PDGFR beta tyrosine- phosphorylated GKR2 60- fold more than the Y857F PDGFR beta in intact cells. With purified GRK2 and either WT or Y857F PDGFR beta s immunoprecipitated from HEK cells, GRK2 tyrosyl phosphorylation was PDGF- dependent and required the WT PDGFR beta, even though the WT and Y857F PDGFR beta s autophosphorylated equivalently. This PDGFR beta- mediated GRK2 tyrosyl phosphorylation enhanced GRK2 activity: GRK2- mediated seryl phosphorylation of the PDGFR beta was 9- fold greater for the WT than for the Y857F in response to PDGF, but equivalent when GRK2 was activated by sequential stimulation of beta(2)- adrenergic and PDGF- beta receptors. Furthermore, both PDGFR beta- mediated GRK2 tyrosyl phosphorylation and GRK2- mediated PDGFR beta seryl phosphorylation were reduced similar to 50% in intact cells by mutation to phenylalanine of three tyrosines in the N- terminal domain of GRK2. We conclude that the activated PDGFR beta itself phosphorylates GRK2 tyrosyl residues and thereby activates GRK2, which then serine- phosphorylates and desensitizes the PDGFR beta.	Duke Univ, Ctr Med, Dept Med Cardiol, Durham, NC 27710 USA	Duke University	Freedman, NJ (corresponding author), Duke Univ, Ctr Med, Dept Med Cardiol, Box 3187, Durham, NC 27710 USA.	neil.freedman@duke.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063288, R01HL064744, R01HL077185] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL64744, HL77185, HL63288] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARAK LS, 1994, J BIOL CHEM, V269, P2790; Baxter RM, 1998, J BIOL CHEM, V273, P17050, DOI 10.1074/jbc.273.27.17050; BENOVIC JL, 1986, NATURE, V321, P869, DOI 10.1038/321869a0; BENOVIC JL, 1987, J BIOL CHEM, V262, P17251; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BENOVIC JL, 1986, P NATL ACAD SCI USA, V83, P2797, DOI 10.1073/pnas.83.9.2797; Bergers G, 2003, J CLIN INVEST, V111, P1287, DOI 10.1172/JCI200317929; Bioukar EB, 1999, J BIOL CHEM, V274, P21457, DOI 10.1074/jbc.274.30.21457; Boucher P, 2003, SCIENCE, V300, P329, DOI 10.1126/science.1082095; BUTT E, 1994, J BIOL CHEM, V269, P14509; Carman CV, 1999, J BIOL CHEM, V274, P8858, DOI 10.1074/jbc.274.13.8858; CHIARUGI P, 1995, FEBS LETT, V372, P49, DOI 10.1016/0014-5793(95)00947-8; Collins SP, 1999, J BIOL CHEM, V274, P8391, DOI 10.1074/jbc.274.13.8391; Elorza A, 2003, J BIOL CHEM, V278, P29164, DOI 10.1074/jbc.M304314200; Fan GF, 2001, J BIOL CHEM, V276, P13240, DOI 10.1074/jbc.M011578200; Freedman NJ, 2002, J BIOL CHEM, V277, P48261, DOI 10.1074/jbc.M204431200; Freedman NJ, 1997, J BIOL CHEM, V272, P17734, DOI 10.1074/jbc.272.28.17734; FREEDMAN NJ, 1995, J BIOL CHEM, V270, P17953, DOI 10.1074/jbc.270.30.17953; George D, 2001, SEMIN ONCOL, V28, P27, DOI 10.1053/sonc.2001.29185; Heldin CH, 1998, BIOCHIM BIOPHYS ACTA, V1378, P79; Hildreth KL, 2004, J BIOL CHEM, V279, P41775, DOI 10.1074/jbc.M403274200; Hubbard SR, 2000, ANNU REV BIOCHEM, V69, P373, DOI 10.1146/annurev.biochem.69.1.373; INGLESE J, 1993, J BIOL CHEM, V268, P23735; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KLINGHOFFER RA, 1995, J BIOL CHEM, V270, P22208, DOI 10.1074/jbc.270.38.22208; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; LUTTRELL LM, 1995, J BIOL CHEM, V270, P16495, DOI 10.1074/jbc.270.28.16495; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Matveev SV, 2002, AM J PHYSIOL-CELL PH, V282, pC935, DOI 10.1152/ajpcell.00349.2001; Maudsley S, 2000, MOL CELL BIOL, V20, P8352, DOI 10.1128/MCB.20.22.8352-8363.2000; Miller WE, 2000, J BIOL CHEM, V275, P11312, DOI 10.1074/jbc.275.15.11312; MORI S, 1992, J BIOL CHEM, V267, P6429; Oak JN, 2001, MOL PHARMACOL, V60, P92, DOI 10.1124/mol.60.1.92; ONORATO JJ, 1995, J BIOL CHEM, V270, P21346, DOI 10.1074/jbc.270.36.21346; Oppermann M, 1996, P NATL ACAD SCI USA, V93, P7649, DOI 10.1073/pnas.93.15.7649; Penela P, 1998, J BIOL CHEM, V273, P35238, DOI 10.1074/jbc.273.52.35238; Penela P, 2001, EMBO J, V20, P5129, DOI 10.1093/emboj/20.18.5129; Peppel K, 2002, J MOL CELL CARDIOL, V34, P1399, DOI 10.1006/jmcc.2002.2092; Peppel K, 2000, CIRCULATION, V102, P793, DOI 10.1161/01.CIR.102.7.793; Pitcher JA, 1999, J BIOL CHEM, V274, P34531, DOI 10.1074/jbc.274.49.34531; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Prasad SVN, 2001, J BIOL CHEM, V276, P18953, DOI 10.1074/jbc.M102376200; Ren XR, 2005, P NATL ACAD SCI USA, V102, P1448, DOI 10.1073/pnas.0409534102; RICHARDSON RM, 1993, J BIOL CHEM, V268, P13650; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Sano H, 2001, CIRCULATION, V103, P2955, DOI 10.1161/01.CIR.103.24.2955; Sarnago S, 1999, J BIOL CHEM, V274, P34411, DOI 10.1074/jbc.274.48.34411; Sarnago S, 2003, MOL PHARMACOL, V64, P629, DOI 10.1124/mol.64.3.629; SHIH ML, 1994, P NATL ACAD SCI USA, V91, P12193, DOI 10.1073/pnas.91.25.12193; SORKIN A, 1991, J CELL BIOL, V112, P469, DOI 10.1083/jcb.112.3.469; Walter AO, 1999, ONCOGENE, V18, P1911, DOI 10.1038/sj.onc.1202513; Yamamoto M, 1999, EXP CELL RES, V247, P380, DOI 10.1006/excr.1998.4379; Zhou Songyang, 1995, Nature (London), V373, P536	54	22	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	2005	280	35					31027	31035		10.1074/jbc.M501473200	http://dx.doi.org/10.1074/jbc.M501473200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	958ZX	15994317	hybrid			2022-12-25	WOS:000231487800046
J	Porstmann, T; Griffiths, B; Chung, YL; Delpuech, O; Griffiths, JR; Downward, J; Schulze, A				Porstmann, T; Griffiths, B; Chung, YL; Delpuech, O; Griffiths, JR; Downward, J; Schulze, A			PKB/Akt induces transcription of enzymes involved in cholesterol and fatty acid biosynthesis via activation of SREBP	ONCOGENE			English	Article						PKB/Akt; SREBP; cholesterol and fatty acid biosynthesis; transcription; microarray	STEROL-REGULATORY-ELEMENT; PROTEIN-KINASE-B; NF-KAPPA-B; LIVER-X-RECEPTOR; BINDING-PROTEIN; PROSTATE-CANCER; SYNTHASE PROMOTER; GENE-EXPRESSION; DIFFERENTIAL REGULATION; TARGET PROMOTERS	Protein kinase B (PKB/Akt) has been shown to play a role in protection from apoptosis, cell proliferation and cell growth. It is also involved in mediating the effects of insulin, such as lipogenesis, glucose uptake and conversion of glucose into fatty acids and cholesterol. Sterol-regulatory element binding proteins (SREBPs) are the major transcription factors that regulate genes involved in fatty acid and cholesterol synthesis. It has been postulated that constitutive activation of the phosphatidylinositol 3 kinase/Akt pathway may be involved in fatty acid and cholesterol accumulation that has been described in several tumour types. In this study, we have analysed changes in gene expression in response to Akt activation using DNA microarrays. We identied several enzymes involved in fatty acid and cholesterol synthesis as targets for Akt-regulated transcription. Expression of these enzymes has previously been shown to be regulated by the SREBP family of transcription factors. Activation of Akt induces synthesis of full-length SREBP-1 and SREBP-2 proteins as well as expression of fatty acid synthase (FAS), the key regulatory enzyme in lipid biosynthesis. We also show that Akt leads to the accumulation of nuclear SREBP-1 but not SREBP-2, and that activation of SREBP is required for Akt-induced activation of the FAS promoter. Finally, activation of Akt induces an increase in the concentration of cellular fatty acids as well as phosphoglycerides, the components of cellular membranes. Our data indicate that activation of SREBP by Akt leads to the induction of key enzymes of the cholesterol and fatty acid biosynthesis pathways, and thus membrane lipid biosynthesis.	Canc Res UK, London Res Inst, Gene Express Anal Lab, London WC2A 3PX, England; Univ London St Georges Hosp, Sch Med, Dept Basic Med Sci, Canc Res UK Biomed Magnet Resonance Res Grp, London SW17 0RE, England; Canc Res UK, London Res Inst, Signal Transduct Lab, London WC2A 3PX, England	Cancer Research UK; St Georges University London; Cancer Research UK	Schulze, A (corresponding author), Canc Res UK, London Res Inst, Gene Express Anal Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.	almut.schulze@cancer.org.uk	Schulze, Almut/E-1496-2013; Schulze, Almut/AAX-8257-2020; Griffiths, John R/F-2853-2010; Chung, Yuen-Li/K-2269-2019; Downward, Julian/A-3251-2012	Schulze, Almut/0000-0002-8199-6422; Chung, Yuen-Li/0000-0003-0807-1658; Downward, Julian/0000-0002-2331-4729				Alo PL, 1996, CANCER, V77, P474, DOI 10.1002/(SICI)1097-0142(19960201)77:3<474::AID-CNCR8>3.0.CO;2-K; Amemiya-Kudo M, 2002, J LIPID RES, V43, P1220, DOI 10.1194/jlr.M100417-JLR200; Amemiya-Kudo M, 2000, J BIOL CHEM, V275, P31078, DOI 10.1074/jbc.M005353200; Baron A, 2004, J CELL BIOCHEM, V91, P47, DOI 10.1002/jcb.10708; Barthel A, 2001, BIOCHEM BIOPH RES CO, V285, P897, DOI 10.1006/bbrc.2001.5261; Bennett MK, 2004, J BIOL CHEM, V279, P37360, DOI 10.1074/jbc.M404693200; BENNETT MK, 1995, J BIOL CHEM, V270, P25578, DOI 10.1074/jbc.270.43.25578; Bobard A, 2005, J BIOL CHEM, V280, P199, DOI 10.1074/jbc.M406522200; Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006; Brower V, 2003, J NATL CANCER I, V95, P844, DOI 10.1093/jnci/95.12.844; Brown AJ, 2002, MOL CELL, V10, P237, DOI 10.1016/S1097-2765(02)00591-9; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7; BURERING BM, 2002, TRENDS BIOCHEM SCI, V27, P352; Cagen LM, 2005, BIOCHEM J, V385, P207, DOI 10.1042/BJ20040162; Cook SA, 2002, J BIOL CHEM, V277, P22528, DOI 10.1074/jbc.M201462200; Datta S, 2005, J BIOL CHEM, V280, P3338, DOI 10.1074/jbc.M411222200; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; del Peso L, 1999, ONCOGENE, V18, P7328, DOI 10.1038/sj.onc.1203159; DEL PL, 1997, SCIENCE, V278, P687; Deng X, 2002, BIOCHEM BIOPH RES CO, V290, P256, DOI 10.1006/bbrc.2001.6148; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Eberle D, 2004, BIOCHIMIE, V86, P839, DOI 10.1016/j.biochi.2004.09.018; Fleischmann M, 2000, BIOCHEM J, V349, P13, DOI 10.1042/bj3490013; Freeman MR, 2004, J CELL BIOCHEM, V91, P54, DOI 10.1002/jcb.10724; Gera JF, 2004, J BIOL CHEM, V279, P2737, DOI 10.1074/jbc.M309999200; Hegarty BD, 2005, P NATL ACAD SCI USA, V102, P791, DOI 10.1073/pnas.0405067102; Horton JD, 2003, P NATL ACAD SCI USA, V100, P12027, DOI 10.1073/pnas.1534923100; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; KIM JB, 1995, MOL CELL BIOL, V15, P2582; Kim KH, 2004, J BIOL CHEM, V279, P51999, DOI 10.1074/jbc.M405522200; Kohn AD, 1998, J BIOL CHEM, V273, P11937, DOI 10.1074/jbc.273.19.11937; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Kops GJPL, 2002, MOL CELL BIOL, V22, P2025, DOI 10.1128/MCB.22.7.2025-2036.2002; Kotzka J, 2000, J LIPID RES, V41, P99; Kozma SC, 2002, BIOESSAYS, V24, P65, DOI 10.1002/bies.10031; Latasa MJ, 2000, P NATL ACAD SCI USA, V97, P10619, DOI 10.1073/pnas.180306597; Leevers SJ, 1996, EMBO J, V15, P6584, DOI 10.1002/j.1460-2075.1996.tb01049.x; Magana MM, 1996, J BIOL CHEM, V271, P32689, DOI 10.1074/jbc.271.51.32689; Nakae J, 2001, J CLIN INVEST, V108, P1359, DOI 10.1172/JCI200112876; Peng XD, 2003, GENE DEV, V17, P1352, DOI 10.1101/gad.1089403; Pizer ES, 1998, CANCER-AM CANCER SOC, V83, P528, DOI 10.1002/(SICI)1097-0142(19980801)83:3<528::AID-CNCR22>3.0.CO;2-X; Pore N, 2004, MOL BIOL CELL, V15, P4841, DOI 10.1091/mbc.E04-05-0374; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Pugazhenthi S, 1999, J BIOL CHEM, V274, P2829, DOI 10.1074/jbc.274.5.2829; Rashid A, 1997, AM J PATHOL, V150, P201; Rawson RB, 2003, BIOCHEM SOC SYMP, V70, P221, DOI 10.1042/bss0700221; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; Roth G, 2000, J BIOL CHEM, V275, P33302, DOI 10.1074/jbc.M005425200; Sato R, 1996, J BIOL CHEM, V271, P26461, DOI 10.1074/jbc.271.43.26461; SATO R, 1994, J BIOL CHEM, V269, P17267; Shimomura I, 1997, J CLIN INVEST, V99, P838, DOI 10.1172/JCI119247; Shimomura L, 1999, P NATL ACAD SCI USA, V96, P13656, DOI 10.1073/pnas.96.24.13656; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Su HS, 2000, J NUTR, V130, p315S, DOI 10.1093/jn/130.2.315S; Swinnen JV, 2000, ONCOGENE, V19, P5173, DOI 10.1038/sj.onc.1203889; Swinnen JV, 2004, J STEROID BIOCHEM, V92, P273, DOI 10.1016/j.jsbmb.2004.10.013; SZE DY, 1990, BIOCHIM BIOPHYS ACTA, V1054, P198, DOI 10.1016/0167-4889(90)90241-5; Takaishi H, 1999, P NATL ACAD SCI USA, V96, P11836, DOI 10.1073/pnas.96.21.11836; Tiwari G, 2003, MOL CANCER RES, V1, P475; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; Toth JI, 2004, MOL CELL BIOL, V24, P8288, DOI 10.1128/MCB.24.18.8288-8300.2004; Verdu J, 1999, NAT CELL BIOL, V1, P500, DOI 10.1038/70293; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; Whiteman EL, 2002, TRENDS ENDOCRIN MET, V13, P444, DOI 10.1016/S1043-2760(02)00662-8; Yabe D, 2003, P NATL ACAD SCI USA, V100, P3155, DOI 10.1073/pnas.0130116100; Yang T, 2002, CELL, V110, P489, DOI 10.1016/S0092-8674(02)00872-3; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9; Zeng LF, 2004, EMBO J, V23, P950, DOI 10.1038/sj.emboj.7600106; Zhang CK, 2005, BIOCHEM J, V386, P161, DOI 10.1042/BJ20041514; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	76	320	338	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	43					6465	6481		10.1038/sj.onc.1208802	http://dx.doi.org/10.1038/sj.onc.1208802			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	968ZV	16007182	Bronze			2022-12-25	WOS:000232204100001
J	Alberghini, A; Recalcati, S; Tacchini, L; Santambrogio, P; Campanella, A; Cairo, G				Alberghini, A; Recalcati, S; Tacchini, L; Santambrogio, P; Campanella, A; Cairo, G			Loss of the von Hippel Lindau tumor suppressor disrupts iron homeostasis in renal carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCIBLE FACTOR-I; TRANSFERRIN RECEPTOR GENE; REGULATORY PROTEIN-2; FERRITIN SYNTHESIS; NEOPLASTIC-CELLS; HELA-CELLS; POSTTRANSCRIPTIONAL REGULATION; MOLECULAR CONTROL; OXIDATIVE STRESS; NITRIC-OXIDE	Given the modulation of iron metabolism by hypoxia and the high iron requirement of neoplastic cells, we investigated iron metabolism in a human renal cancer cell line with a mutated von Hippel Lindau (VHL) tumor suppressor gene (RCC10) and in a transfectant clone with wild-type VHL (RCC63). The loss of VHL strongly up-regulated transferrin receptor expression in RCC10 cells as a result of hypoxia inducible factor-1 (HIF-1)-mediated transcriptional activation, leading to an increased uptake of transferrin-bound Fe-55. Increased iron availability did not compromise the resistance of VHL-defective cells to oxidative stress or promote faster cell multiplication. Surprisingly, the content of ferritin H and L subunits and ferritin mRNA levels were considerably lower in the RCC10 than in the RCC63 cells. Despite the similarities between HIF-1 and iron regulatory protein 2 (IRP2), we found no evidence of specific regulation of IRP2 by VHL. However, both IRP2 and IRP1 were slightly activated in RCC10 cells, thus indicating that this cell line has a somewhat reduced labile iron pool (LIP). The finding that RCC10 cells had a lower ferritin content but more ferritin-associated 55Fe than RCC63 explains why VHL-lacking cells may have a smaller LIP despite increased iron uptake. We also found a correlation between cytoprotection from iron-mediated damage and efficient incorporation into ferritin of both transferrin and non-transferrin-bound 55Fe. This study shows that, like oncogene activation, the loss of an oncosuppressor rearranges the expression pattern of the genes of iron metabolism to increase iron availability. However, in the case of VHL loss, mechanisms affecting iron handling by ferritin somehow counteract the effects that the reduced content of this protective protein may have on proliferation and oxidant sensitivity.	Univ Milan, Inst Gen Pathol, I-20133 Milan, Italy; Hosp San Raffaele, Prot Engn Unit, Dibit Sci Inst Recovery & Care, I-20132 Milan, Italy; Osped Maggiore Policlin, Milan, Italy	University of Milan; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; IRCCS Ca Granda Ospedale Maggiore Policlinico	Cairo, G (corresponding author), Univ Milan, Inst Gen Pathol, Via Mangiagalli 31, I-20133 Milan, Italy.	gaetano.cairo@unimi.it	Tacchini, Lorenza/L-1418-2016; recalcati, stefania/M-5045-2016; Campanella, Alessandro/N-8315-2015; Santambrogio, Paolo/AAN-3837-2020; Cairo, Gaetano/M-5104-2016	Tacchini, Lorenza/0000-0002-4863-178X; recalcati, stefania/0000-0002-2115-8283; Campanella, Alessandro/0000-0002-3463-1199; Santambrogio, Paolo/0000-0002-5481-2130; Cairo, Gaetano/0000-0002-8147-4720				Baba M, 2001, ONCOGENE, V20, P2727, DOI 10.1038/sj.onc.1204397; Bianchi L, 1999, NUCLEIC ACIDS RES, V27, P4223, DOI 10.1093/nar/27.21.4223; Bluyssen HAR, 2004, FEBS LETT, V556, P137, DOI 10.1016/S0014-5793(03)01392-9; Bonnah RA, 2004, CELL MICROBIOL, V6, P473, DOI 10.1111/j.1462-5822.2004.00376.x; Bradley SJ, 1997, BRIT J HAEMATOL, V99, P337, DOI 10.1046/j.1365-2141.1997.4143221.x; CAIRO G, 1985, BIOCHEM BIOPH RES CO, V133, P314, DOI 10.1016/0006-291X(85)91877-7; Cairo G, 2002, FREE RADICAL BIO MED, V32, P1237, DOI 10.1016/S0891-5849(02)00825-0; CAIRO G, 1993, EXP CELL RES, V206, P255, DOI 10.1006/excr.1993.1145; Cairo G, 2000, BIOCHEM J, V352, P241, DOI 10.1042/0264-6021:3520241; CAIRO G, 1995, J BIOL CHEM, V270, P700, DOI 10.1074/jbc.270.2.700; Caltagirone A, 2001, J BIOL CHEM, V276, P19738, DOI 10.1074/jbc.M100245200; Campanella A, 2004, BIOCHEMISTRY-US, V43, P195, DOI 10.1021/bi035386f; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Corna G, 2004, J BIOL CHEM, V279, P13738, DOI 10.1074/jbc.M310106200; Corsi B, 2002, J BIOL CHEM, V277, P22430, DOI 10.1074/jbc.M105372200; Cozzi A, 2004, BLOOD, V103, P2377, DOI 10.1182/blood-2003-06-1842; Cuevas Y, 2003, CANCER RES, V63, P6877; Denko NC, 2003, ONCOGENE, V22, P5907, DOI 10.1038/sj.onc.1206703; GUO B, 1995, J BIOL CHEM, V270, P16529, DOI 10.1074/jbc.270.28.16529; Hanson ES, 2003, J BIOL CHEM, V278, P40337, DOI 10.1074/jbc.M302798200; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Harrison PM, 1996, BBA-BIOENERGETICS, V1275, P161, DOI 10.1016/0005-2728(96)00022-9; Hentze MW, 2004, CELL, V117, P285, DOI 10.1016/S0092-8674(04)00343-5; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; Jiang YD, 2003, MOL CANCER RES, V1, P453; Kim W, 2003, CURR OPIN GENET DEV, V13, P55, DOI 10.1016/S0959-437X(02)00010-2; Krieg M, 2000, ONCOGENE, V19, P5435, DOI 10.1038/sj.onc.1203938; Kwok JC, 2004, MOL PHARMACOL, V65, P181, DOI 10.1124/mol.65.1.181; Kwok JC, 2002, CRIT REV ONCOL HEMAT, V42, P65, DOI 10.1016/S1040-8428(01)00213-X; Kwok JC, 2003, MOL PHARMACOL, V63, P849, DOI 10.1124/mol.63.4.849; Le NTV, 2002, BBA-REV CANCER, V1603, P31, DOI 10.1016/S0304-419X(02)00068-9; Lok CN, 1999, J BIOL CHEM, V274, P24147, DOI 10.1074/jbc.274.34.24147; Meyron-Holtz EG, 2004, EMBO J, V23, P386, DOI 10.1038/sj.emboj.7600041; Minotti G, 2001, CANCER RES, V61, P8422; PIETRANGELO A, 1992, GASTROENTEROLOGY, V102, P802, DOI 10.1016/0016-5085(92)90161-Q; PIETRANGELO A, 1995, GASTROENTEROLOGY, V108, P208, DOI 10.1016/0016-5085(95)90026-8; Pugh CW, 2003, SEMIN CANCER BIOL, V13, P83, DOI 10.1016/S1044-579X(02)00103-7; Ratcliffe PJ, 2003, NAT CELL BIOL, V5, P7, DOI 10.1038/ncb0103-7; Recalcati S, 1998, BLOOD, V91, P1059, DOI 10.1182/blood.V91.3.1059.1059_1059_1066; Recalcati S, 1999, EUR J BIOCHEM, V259, P304, DOI 10.1046/j.1432-1327.1999.00038.x; Semenza GL, 2001, CURR OPIN CELL BIOL, V13, P167, DOI 10.1016/S0955-0674(00)00194-0; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Tacchini L, 2003, EXP CELL RES, V290, P391, DOI 10.1016/S0014-4827(03)00348-3; Tacchini L, 1999, J BIOL CHEM, V274, P24142, DOI 10.1074/jbc.274.34.24142; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; Wang J, 2005, BBA-MOL CELL RES, V1743, P79, DOI 10.1016/j.bbamcr.2004.08.011; Wang J, 2004, MOL CELL BIOL, V24, P954, DOI 10.1128/MCB.24.3.954-965.2004; WHITE K, 1988, J BIOL CHEM, V263, P8938; Wu KJ, 1999, SCIENCE, V283, P676, DOI 10.1126/science.283.5402.676; Wykoff CC, 2004, BRIT J CANCER, V90, P1235, DOI 10.1038/sj.bjc.6601657; Yamanaka K, 2003, NAT CELL BIOL, V5, P336, DOI 10.1038/ncb952; Zatyka M, 2002, CANCER RES, V62, P3803	52	32	35	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	2005	280	34					30120	30128		10.1074/jbc.M500971200	http://dx.doi.org/10.1074/jbc.M500971200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	957IC	15985433	hybrid			2022-12-25	WOS:000231362500018
J	Hornberg, JJ; Binder, B; Bruggeman, FJ; Schoeberl, B; Heinrich, R; Westerhoff, HV				Hornberg, JJ; Binder, B; Bruggeman, FJ; Schoeberl, B; Heinrich, R; Westerhoff, HV			Control of MAPK signalling: from complexity to what really matters	ONCOGENE			English	Article						MAPK signalling; control analysis; kinetic model; systems biology	EPIDERMAL-GROWTH-FACTOR; METABOLIC CONTROL ANALYSIS; PROTEIN-KINASE CASCADES; FACTOR RECEPTOR; MATHEMATICAL-MODELS; DNA-SYNTHESIS; HUMAN CANCER; ACTIVATION; PATHWAY; PHOSPHORYLATION	Oncogenesis results from changes in kinetics or in abundance of proteins in signal transduction networks. Recently, it was shown that control of signalling cannot reside in a single gene product, and might well be dispersed over many components. Which of the reactions in these complex networks are most important, and how can the existing molecular information be used to understand why particular genes are oncogenes whereas others are not? We implement a new method to help address such questions. We apply control analysis to a detailed kinetic model of the epidermal growth factor-induced mitogen-activated protein kinase network. We determine the control of each reaction with respect to three biologically relevant characteristics of the output of this network: the amplitude, duration and integrated output of the transient phosphorylation of extracellular signal-regulated kinase (ERK). We confirm that control is distributed, but far from randomly: a small proportion of reactions substantially control signalling. In particular, the activity of Raf is in control of all characteristics of the transient profile of ERK phosphorylation, which may clarify why Raf is an oncogene. Most reactions that really matter for one signalling characteristic are also important for the other characteristics. Our analysis also predicts the effects of mutations and changes in gene expression.	Vrije Univ Amsterdam, Fac Earth & Life Sci, Dept Mol Cell Physiol, Inst Mol Cell Biol, NL-1085 HV Amsterdam, Netherlands; Merrimack Pharmaceut, Cambridge, England; Humboldt Univ, Dept Theoret Biophys, Berlin, Germany; Univ Amsterdam, Swammerdan Inst Life Sci, NL-1012 WX Amsterdam, Netherlands	Vrije Universiteit Amsterdam; Humboldt University of Berlin; University of Amsterdam	Westerhoff, HV (corresponding author), Vrije Univ Amsterdam, Fac Earth & Life Sci, Dept Mol Cell Physiol, Inst Mol Cell Biol, Boelelaan 1085, NL-1085 HV Amsterdam, Netherlands.	hw@bio.vu.nl	damiani, chiara/R-4256-2016; Westerhoff, Hans V/I-5762-2012; Bruggeman, Frank/C-4356-2015; Bruggeman, Frank/AAS-8371-2020	Westerhoff, Hans V/0000-0002-0443-6114; Bruggeman, Frank/0000-0002-0255-4766; Bruggeman, Frank/0000-0002-0255-4766	Biotechnology and Biological Sciences Research Council [BB/C008219/1] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Asthagiri AR, 2001, BIOTECHNOL PROGR, V17, P227, DOI 10.1021/bp010009k; Asthagiri AR, 2000, J CELL SCI, V113, P4499; Bakker BM, 1999, J BIOL CHEM, V274, P14551, DOI 10.1074/jbc.274.21.14551; Bhalla US, 1999, SCIENCE, V283, P381, DOI 10.1126/science.283.5400.381; BOS JL, 1989, CANCER RES, V49, P4682; Bruggeman FJ, 2000, BIOL CHEM, V381, P965, DOI 10.1515/BC.2000.119; Bruggeman FJ, 2002, J THEOR BIOL, V218, P507, DOI 10.1006/jtbi.2002.3096; BUDAY L, 1995, ONCOGENE, V11, P1327; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Carpenter G, 2000, BIOESSAYS, V22, P697, DOI 10.1002/1521-1878(200008)22:8<697::AID-BIES3>3.3.CO;2-T; Cascante M, 2002, NAT BIOTECHNOL, V20, P243, DOI 10.1038/nbt0302-243; Chen D, 1996, J BIOL CHEM, V271, P6328, DOI 10.1074/jbc.271.11.6328; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; Cook SJ, 1999, MOL CELL BIOL, V19, P330; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; FELL DA, 1992, BIOCHEM J, V286, P313, DOI 10.1042/bj2860313; GROEN AK, 1982, J BIOL CHEM, V257, P2754; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Haugh JM, 1999, J BIOL CHEM, V274, P34350, DOI 10.1074/jbc.274.48.34350; HEINRICH R, 1974, EUR J BIOCHEM, V42, P89, DOI 10.1111/j.1432-1033.1974.tb03318.x; Heinrich R, 2002, MOL CELL, V9, P957, DOI 10.1016/S1097-2765(02)00528-2; Hornberg JJ, 2005, FEBS J, V272, P244, DOI 10.1111/j.1432-1033.2004.04404.x; Hornberg JJ, 2004, EUR J BIOCHEM, V271, P3905, DOI 10.1111/j.1432-1033.2004.04327.x; Hoshino R, 1999, ONCOGENE, V18, P813, DOI 10.1038/sj.onc.1202367; Huang CYF, 1996, P NATL ACAD SCI USA, V93, P10078, DOI 10.1073/pnas.93.19.10078; Kacser H, 1973, Symp Soc Exp Biol, V27, P65; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; Kholodenko BN, 2000, TRENDS CELL BIOL, V10, P173, DOI 10.1016/S0962-8924(00)01741-4; Kholodenko BN, 1999, J BIOL CHEM, V274, P30169, DOI 10.1074/jbc.274.42.30169; Kholodenko BN, 2000, EUR J BIOCHEM, V267, P1583, DOI 10.1046/j.1432-1327.2000.01197.x; KHOLODENKO BN, 1993, FEBS LETT, V320, P71, DOI 10.1016/0014-5793(93)81660-R; Lee E, 2003, PLOS BIOL, V1, P116, DOI 10.1371/journal.pbio.0000010; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; MAGNUSON NS, 1994, SEMIN CANCER BIOL, V5, P247; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; Oksvold MP, 2001, EUR J CELL BIOL, V80, P285, DOI 10.1078/0171-9335-00160; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; Pedersen MW, 2001, ANN ONCOL, V12, P745, DOI 10.1023/A:1011177318162; Periwal V, 2002, NAT BIOTECHNOL, V20, P345, DOI 10.1038/nbt0402-345; Porfiri E, 1996, J BIOL CHEM, V271, P5871, DOI 10.1074/jbc.271.10.5871; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; Schoeberl B, 2002, NAT BIOTECHNOL, V20, P370, DOI 10.1038/nbt0402-370; SCHUSTER R, 1995, EUR J BIOCHEM, V229, P403, DOI 10.1111/j.1432-1033.1995.0403k.x; Sebolt-Leopold JS, 2000, ONCOGENE, V19, P6594, DOI 10.1038/sj.onc.1204083; Snoep JL, 2004, CURR GENOMICS, V5, P687, DOI 10.2174/1389202043348553; Teusink B, 2000, EUR J BIOCHEM, V267, P5313, DOI 10.1046/j.1432-1327.2000.01527.x; Todd JL, 1999, J BIOL CHEM, V274, P13271, DOI 10.1074/jbc.274.19.13271; Tombes RM, 1998, BIOCHEM J, V330, P1451; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Westerhoff H., 1987, THERMODYNAMICS CONTR	54	141	140	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 25	2005	24	36					5533	5542		10.1038/sj.onc.1208817	http://dx.doi.org/10.1038/sj.onc.1208817			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	956JN	16007170				2022-12-25	WOS:000231296100001
J	Verbsky, J; Majerus, PW				Verbsky, J; Majerus, PW			Increased levels of inositol hexakisphosphate (InsP(6)) protect HEK293 cells from tumor necrosis factor alpha- and Fas-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN KINASE RIP; 1,3,4-TRISPHOSPHATE 5/6-KINASE; C-JUN; PATHWAY; SIGNAL	The overexpression of inositol 1,3,4-trisphosphate 5/6-kinase has recently been shown to protect HEK293 cells from tumor necrosis factor alpha( TNF alpha)-induced apoptosis. This overexpression leads to an increase in the levels of both inositol 1,3,4,5,6- pentakisphosphate (InsP(5)) and inositol 1,2,3,4,5,6-hexakisphosphate ( InsP(6)). Cells that overexpress InsP(5) 2-kinase have increased levels of InsP(6) and are also protected from TNF alpha-induced apoptosis; furthermore, cells that express an RNA interference construct to the 2-kinase are deficient in InsP(6) and are sensitized to TNF alpha-induced apoptosis. Therefore the protective effect of 5/6-kinase on TNF alpha-mediated apoptosis is due to an increase of InsP(6) or to a metabolite derived from InsP(6). Furthermore, we find that the InsP(6) also protects from Fas-mediated apoptosis. No effect was seen in the endocytic rate of transferrin receptor, caspase 8 activity, or TNF receptor number at the cell surface. Cells that overexpress 2-kinase do show an increase in the amount of receptor-interacting protein (RIP), while cells with reduced InsP(6) levels show relatively less RIP, providing a possible mechanism for the effect on apoptosis.	Washington Univ, Sch Med, Dept Internal Med, Div Hematol, St Louis, MO 63110 USA	Washington University (WUSTL)	Majerus, PW (corresponding author), Washington Univ, Sch Med, Dept Internal Med, Div Hematol, Box 8125,660 S Euclid St, St Louis, MO 63110 USA.	phil@im.wustl.edu			NHLBI NIH HHS [HL 16634, HL 55272] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016634, R01HL016634] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bech-Otschir D, 2001, EMBO J, V20, P1630, DOI 10.1093/emboj/20.7.1630; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; CHANDA VB, 1997, CURRENT PROTOCOLS MO; Chang SC, 2002, J BIOL CHEM, V277, P43836, DOI 10.1074/jbc.M206134200; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Fujii M, 2005, J BIOL CHEM, V280, P1156, DOI 10.1074/jbc.M412006200; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Lin Y, 1999, GENE DEV, V13, P2514, DOI 10.1101/gad.13.19.2514; MAJERUS PW, 1992, ANNU REV BIOCHEM, V61, P225, DOI 10.1146/annurev.bi.61.070192.001301; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Morrison BH, 2001, J BIOL CHEM, V276, P24965, DOI 10.1074/jbc.M101161200; Naumann M, 1999, J BIOL CHEM, V274, P35297, DOI 10.1074/jbc.274.50.35297; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schneider-Brachert W, 2004, IMMUNITY, V21, P415, DOI 10.1016/j.immuni.2004.08.017; Seeger M, 1998, FASEB J, V12, P469, DOI 10.1096/fasebj.12.6.469; Sun Y, 2003, J BIOL CHEM, V278, P43645, DOI 10.1074/jbc.M300674200; Verbsky JW, 2005, J BIOL CHEM, V280, P1911, DOI 10.1074/jbc.M411528200; Verbsky JW, 2002, J BIOL CHEM, V277, P31857, DOI 10.1074/jbc.M205682200; Wilson MP, 2001, J BIOL CHEM, V276, P40998, DOI 10.1074/jbc.M106605200; Wilson MP, 1996, J BIOL CHEM, V271, P11904, DOI 10.1074/jbc.271.20.11904	20	28	30	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	2005	280	32					29263	29268		10.1074/jbc.M503366200	http://dx.doi.org/10.1074/jbc.M503366200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	952QT	15967797	hybrid			2022-12-25	WOS:000231021300056
J	Lelliott, CJ; Lopez, M; Curtis, RK; Parker, N; Laudes, M; Yeo, G; Jimenez-Linan, M; Grosse, J; Saha, AK; Wiggins, D; Hauton, D; Brand, MD; O'Rahilly, S; Griffin, JL; Gibbons, GF; Vidal-Puig, A				Lelliott, CJ; Lopez, M; Curtis, RK; Parker, N; Laudes, M; Yeo, G; Jimenez-Linan, M; Grosse, J; Saha, AK; Wiggins, D; Hauton, D; Brand, MD; O'Rahilly, S; Griffin, JL; Gibbons, GF; Vidal-Puig, A			Transcript and metabolite analysis of the effects of tamoxifen in rat liver reveals inhibition of fatty acid synthesis in the presence of hepatic steatosis	FASEB JOURNAL			English	Article						fatty acid synthase; malonyl-CoA; metabolomics; metabolic pathways	DENSITY LIPOPROTEIN SECRETION; BREAST-CANCER; NONALCOHOLIC STEATOHEPATITIS; MITOCHONDRIAL DYSFUNCTION; INSULIN-RESISTANCE; GENE-EXPRESSION; MICROARRAY DATA; DISEASE; HEPATOTOXICITY; SPECTROSCOPY	Nonalcoholic steatohepatitis (NASH) is a common feature of the metabolic syndrome and toxic reactions to pharmacological drugs. Tamoxifen, (TMX) a widely used anti-breast cancer drug, can induce NASH and changes in plasma cholesterol levels through mechanisms that are unclear. We studied primary actions of TMX using a short-term treatment ( 5 days) that induces microvesicular hepatic steatosis and marked hypercholesterolemia in male rats. Using a combined approach of gene expression profiling and NMR-based metabolite analysis, we found that TMX-treated livers have increased saturated fatty acid content despite changes in gene expression, indicating decreased de novo lipogenesis and increased fatty acid oxidation. Our results show that TMX predominantly down-regulates FAS expression and activity as indicated by the accumulation of malonyl-CoA, a known inhibitor of mitochondrial beta-oxidation. In the face of a continued supply of exogenous free fatty acids, the blockade of fatty acid oxidation produced by elevated malonyl-CoA is likely to be the major factor leading to steatosis. Use of a combination of metabolomic and transcriptomic analysis has allowed us to identify mechanisms underlying important metabolic side effects of a widely prescribed drug. Given the broader importance of hepatic steatosis, the novel molecular mechanism revealed in this study should be examined in other forms of steatosis and nonalcoholic steatohepatitis.	Univ Cambridge, Addenbrookes Hosp, Dept Clin Biochem, Cambridge CB2 2QR, England; Ingenium Pharmaceut AG, Martinsried, Germany; Boston Med Ctr, Diabet Res Unit, Boston, MA USA; Univ Oxford, Nuffield Dept Clin Med, Metab Res Lab, Oxford Ctr Diabet Endocrinol & Metab, Oxford, England; Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England; MRC, Dunn Human Nutr Unit, Cambridge, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Boston Medical Center; University of Oxford; University of Cambridge; UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research	Vidal-Puig, A (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Clin Biochem, Hills Rd,Box 232, Cambridge CB2 2QR, England.	ajv22@cam.ac.uk	O'Rahilly, Stephen/ABF-6509-2020; López, Miguel/ABF-4844-2021; Parker, Nadeene/C-1562-2008; Brand, Martin D/A-9423-2012; Lelliott, Christopher J/G-4620-2011; Laudes, Matthias/C-8885-2011	O'Rahilly, Stephen/0000-0003-2199-4449; López, Miguel/0000-0002-7823-1648; Brand, Martin D/0000-0003-4418-6153; Lelliott, Christopher J/0000-0001-8087-4530; Yeo, Giles See How/0000-0001-8823-3615; Vidal-Puig, Antonio/0000-0003-4220-9577; Saha, Asish/0000-0003-1001-5110	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019514] Funding Source: NIH RePORTER; MRC [G0400192] Funding Source: UKRI; Medical Research Council [G0400192] Funding Source: Medline; NIDDK NIH HHS [DK 19514] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Wellcome Trust(Wellcome Trust)		BARTLETT SM, 1988, BIOCHEM J, V249, P37, DOI 10.1042/bj2490037; Berson A, 1998, GASTROENTEROLOGY, V114, P764, DOI 10.1016/S0016-5085(98)70590-6; Bollard ME, 2000, MAGNET RESON MED, V44, P201, DOI 10.1002/1522-2594(200008)44:2<201::AID-MRM6>3.0.CO;2-5; Cardoso CMP, 2001, TOXICOL APPL PHARM, V176, P145, DOI 10.1006/taap.2001.9265; Carthew P, 2000, CARCINOGENESIS, V21, P793, DOI 10.1093/carcin/21.4.793; Chitturi S, 2001, SEMIN LIVER DIS, V21, P27, DOI 10.1055/s-2001-12927; Dahlquist KD, 2002, NAT GENET, V31, P19, DOI 10.1038/ng0502-19; Day CP, 1998, GASTROENTEROLOGY, V114, P842, DOI 10.1016/S0016-5085(98)70599-2; Doniger SW, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-1-r7; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Fromenty B, 2004, DIABETES METAB, V30, P121, DOI 10.1016/S1262-3636(07)70098-8; FROMENTY B, 1995, PHARMACOL THERAPEUT, V67, P101, DOI 10.1016/0163-7258(95)00012-6; Griffin JL, 2004, PHYSIOL GENOMICS, V17, P140, DOI 10.1152/physiolgenomics.00158.2003; Harris MA, 2004, NUCLEIC ACIDS RES, V32, pD258, DOI 10.1093/nar/gkh036; Jaeschke H, 2002, TOXICOL SCI, V65, P166, DOI 10.1093/toxsci/65.2.166; JORDAN VC, 1977, J ENDOCRINOL, V75, P305, DOI 10.1677/joe.0.0750305; Jordan VC, 2001, ANN NY ACAD SCI, V952, P60, DOI 10.1111/j.1749-6632.2001.tb02728.x; Lelliott CJ, 2002, J CLIN ENDOCR METAB, V87, P728, DOI 10.1210/jc.87.2.728; LUDWIG J, 1980, MAYO CLIN PROC, V55, P434; Marchesini G, 2001, DIABETES, V50, P1844, DOI 10.2337/diabetes.50.8.1844; Matteoni CA, 1999, GASTROENTEROLOGY, V116, P1413, DOI 10.1016/S0016-5085(99)70506-8; MCGARRY JD, 1978, J BIOL CHEM, V253, P8291; Mensenkamp AR, 2001, J HEPATOL, V35, P816, DOI 10.1016/S0168-8278(01)00249-5; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Murata Y, 2003, ONCOL REP, V10, P97; Nebert DW, 2002, LANCET, V360, P1155, DOI 10.1016/S0140-6736(02)11203-7; Nguyen MC, 2001, INT J OBESITY, V25, P296, DOI 10.1038/sj.ijo.0801488; Nishino M, 2003, AM J ROENTGENOL, V180, P129, DOI 10.2214/ajr.180.1.1800129; Noga AA, 2002, J BIOL CHEM, V277, P42358, DOI 10.1074/jbc.M204542200; Patti ME, 2003, P NATL ACAD SCI USA, V100, P8466, DOI 10.1073/pnas.1032913100; Pessayre D, 2002, AM J PHYSIOL-GASTR L, V282, pG193, DOI 10.1152/ajpgi.00426.2001; Rooney OM, 2003, MAGN RESON MED, V50, P925, DOI 10.1002/mrm.10620; SAHA AK, 1995, AM J PHYSIOL, V269, P283; Sanyal AJ, 2001, GASTROENTEROLOGY, V120, P1183, DOI 10.1053/gast.2001.23256; Sekiya M, 2003, HEPATOLOGY, V38, P1529, DOI 10.1016/j.hep.2003.09.028; Tuquet C, 2000, CELL BIOL TOXICOL, V16, P207, DOI 10.1023/A:1007695308257; VidalPuig AJ, 1997, J CLIN INVEST, V99, P2416, DOI 10.1172/JCI119424; WADE GN, 1993, AM J PHYSIOL, V264, pR1219, DOI 10.1152/ajpregu.1993.264.6.R1219; Yahagi N, 2002, J BIOL CHEM, V277, P19353, DOI 10.1074/jbc.M201584200; Younossi ZM, 2002, HEPATOLOGY, V35, P746, DOI 10.1053/jhep.2002.32483; Zhang W, 2000, CANCER RES, V60, P5395	41	69	77	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2005	19	9					1108	1119		10.1096/fj.04-3196com	http://dx.doi.org/10.1096/fj.04-3196com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	951IO	15985534				2022-12-25	WOS:000230923000039
J	Taleb, S; Lacasa, D; Bastard, JP; Poitou, C; Cancello, R; Pelloux, V; Viguerie, N; Benis, A; Zucker, JD; Bouillot, JL; Coussieu, C; Basdevant, A; Langin, D; Clement, K				Taleb, S; Lacasa, D; Bastard, JP; Poitou, C; Cancello, R; Pelloux, V; Viguerie, N; Benis, A; Zucker, JD; Bouillot, JL; Coussieu, C; Basdevant, A; Langin, D; Clement, K			Cathepsin S, a novel biomarker of adiposity: relevance to atherogenesis	FASEB JOURNAL			English	Article						obesity; atherosclerosis and gene profiling	RECEPTOR ANTAGONIST; CYSTEINE PROTEASES; TISSUE; EXPRESSION; OBESITY; INFLAMMATION; ATHEROSCLEROSIS; DEFICIENCY; ADIPONECTIN; ADIPOCYTES	The molecular mechanisms by which obesity increases the risk of cardiovascular diseases are poorly understood. The purpose of this study was to identify candidate biomarkers overexpressed in adipose tissue of obese subjects that could link expanded fat mass to atherosclerosis. We compared gene expression profile in subcutaneous adipose tissue (scWAT) of 28 obese and 11 lean subjects using microarray technology. This analysis identified 240 genes significantly overexpressed in scWAT of obese subjects. The genes were then ranked according to the correlation between gene expression and body mass index (BMI). In this list, the elastolytic cysteine protease cathepsin S was among the highly correlated genes. RT-PCR and Western blotting confirmed the increase in cathepsin S mRNA ( P= 0.006) and protein ( P < 0.05) in obese scWAT. The circulating concentrations of cathepsin S were also significantly higher in obese than in nonobese subjects ( P < 0.0001). Both cathepsin S mRNA in scWAT and circulating levels were positively correlated with BMI, body fat, and plasma triglyceride levels. In addition, we show that the proinflammatory factors, lipopolysaccharide, interleukin-1 beta, and tumor necrosis factor-alpha increase cathepsin S secretion in human scWAT explants. This study identifies cathepsin S as a novel marker of adiposity. Since this enzyme has been implicated in the development of atherosclerotic lesions, we propose that cathepsin S represents a molecular link between obesity and atherosclerosis.	Hop Hotel Dieu, INSERM Avenir, Dept Nutr, CHRU Pitie Salpetriere,Ctr Rech & Nutr Humaine, F-75004 Paris, France; INSERM Avenir Team, F-75004 Paris, France; INSERM, U680, F-75970 Paris, France; CHRU Tenon Hosp, Dept Biochem, F-75970 Paris, France; Univ Toulouse 3, INSERM, U586, Louis Bugnard Inst, F-31059 Toulouse, France; CHRU Toulouse, F-31059 Toulouse, France; Hop Hotel Dieu, Dept Surg, F-75004 Paris, France; Univ Paris 13, LIM & BIO, F-93000 Bobigny, France; CHRU Pitie Salpetriere, Hop Hotel Dieu, Hormonol Dept, F-75004 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP; Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; CHU de Toulouse; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP; UDICE-French Research Universities; Universite Paris Cite; Universite Paris 13; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP; Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite	Clement, K (corresponding author), Hop Hotel Dieu, INSERM Avenir, Dept Nutr, CHRU Pitie Salpetriere,Ctr Rech & Nutr Humaine, Pl Parvis Notre Dame, F-75004 Paris, France.	karine.clement@htd.ap-hopparis.fr	ZUCKER, Jean-Daniel/K-3008-2016; Benis, Arriel/M-6262-2016; Taleb, Soraya/K-8176-2017; Clément, karine/R-1120-2017; Viguerie, Nathalie/M-2422-2017	ZUCKER, Jean-Daniel/0000-0002-5597-7922; Benis, Arriel/0000-0002-9125-8300; Taleb, Soraya/0000-0002-6650-619X; Langin, Dominique/0000-0002-2669-7825; Viguerie, Nathalie/0000-0002-1730-9915				Abate N, 2000, J DIABETES COMPLICAT, V14, P154, DOI 10.1016/S1056-8727(00)00067-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chapman HA, 1997, ANNU REV PHYSIOL, V59, P63, DOI 10.1146/annurev.physiol.59.1.63; Chiellini C, 2003, J CELL PHYSIOL, V195, P309, DOI 10.1002/jcp.10253; Clement K, 2004, FASEB J, V18, P1657, DOI 10.1096/fj.04-2204com; Curat CA, 2004, DIABETES, V53, P1285, DOI 10.2337/diabetes.53.5.1285; Ferroni Patrizia, 2004, Curr Atheroscler Rep, V6, P424, DOI 10.1007/s11883-004-0082-x; Fruchart JC, 2004, CIRCULATION, V109, P15, DOI 10.1161/01.CIR.0000131513.33892.5b; Goldstein BJ, 2004, J CLIN ENDOCR METAB, V89, P2563, DOI 10.1210/jc.2004-0518; Grundy SM, 2004, J CLIN ENDOCR METAB, V89, P2595, DOI 10.1210/jc.2004-0372; HOTAMISLIGIL GS, 1995, J CLIN INVEST, V95, P2409, DOI 10.1172/JCI117936; Jormsjo S, 2002, AM J PATHOL, V161, P939, DOI 10.1016/S0002-9440(10)64254-X; Juge-Aubry CE, 2004, J CLIN ENDOCR METAB, V89, P2652, DOI 10.1210/jc.2003-031219; Juge-Aubry CE, 2003, DIABETES, V52, P1104, DOI 10.2337/diabetes.52.5.1104; Katsuda Shogo, 2003, J Atheroscler Thromb, V10, P267; Katz A, 2000, J CLIN ENDOCR METAB, V85, P2402, DOI 10.1210/jc.85.7.2402; Kos J, 2001, BRIT J CANCER, V85, P1193, DOI 10.1054/bjoc.2001.2057; Lafontan M, 2003, TRENDS PHARMACOL SCI, V24, P276, DOI 10.1016/S0165-6147(03)00132-9; Liu JA, 2004, ARTERIOSCL THROM VAS, V24, P1359, DOI 10.1161/01.ATV.0000134530.27208.41; Liu YM, 2004, J CLIN ENDOCR METAB, V89, P2684, DOI 10.1210/jc.2003-031978; Lyon CJ, 2003, ENDOCRINOLOGY, V144, P2195, DOI 10.1210/en.2003-0285; Meier U, 2004, CLIN CHEM, V50, P1511, DOI 10.1373/clinchem.2004.032482; Muoio DM, 2002, BEST PRACT RES CL EN, V16, P653, DOI 10.1053/beem.2002.0223; Nakajima I, 2002, BIOL CELL, V94, P197, DOI 10.1016/S0248-4900(02)01189-9; Petanceska S, 1996, J BIOL CHEM, V271, P4403; REDDY VY, 1995, P NATL ACAD SCI USA, V92, P3849, DOI 10.1073/pnas.92.9.3849; SHI GP, 1992, J BIOL CHEM, V267, P7258; Shi GP, 2003, CIRC RES, V92, P493, DOI 10.1161/01.RES.0000060485.20318.96; SHI GP, 1994, J BIOL CHEM, V269, P11530; Shi GP, 1999, J CLIN INVEST, V104, P1191, DOI 10.1172/JCI7709; Singhal A, 2002, CIRCULATION, V106, P1919, DOI 10.1161/01.CIR.0000033219.24717.52; Sukhova GK, 2003, J CLIN INVEST, V111, P897, DOI 10.1172/JCI200314915; Sukhova GK, 1998, J CLIN INVEST, V102, P576, DOI 10.1172/JCI181; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Vanhala MJ, 1998, INT J OBESITY, V22, P369, DOI 10.1038/sj.ijo.0800597; Watari M, 2000, J SOC GYNECOL INVEST, V7, P190, DOI 10.1016/S1071-5576(00)00054-X; Willerson JT, 2004, CIRCULATION, V109, P2, DOI 10.1161/01.CIR.0000129535.04194.38; Xu HY, 2002, ENDOCRINOLOGY, V143, P1502, DOI 10.1210/en.143.4.1502; Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451	39	115	122	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2005	19	8					1540	+		10.1096/fj.05-3673fje	http://dx.doi.org/10.1096/fj.05-3673fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	15985526				2022-12-25	WOS:000230207800005
J	Chan, AY; Coniglio, SJ; Chuang, YY; Michaelson, D; Knaus, UG; Philips, MR; Symons, M				Chan, AY; Coniglio, SJ; Chuang, YY; Michaelson, D; Knaus, UG; Philips, MR; Symons, M			Roles of the Rac1 and Rac3 GTPases in human tumor cell invasion	ONCOGENE			English	Article						Rac1; Rac3; glioma; invasion; migration; RNA interference	GUANINE-NUCLEOTIDE EXCHANGE; RHO-FAMILY GTPASES; ALPHA-6-BETA-4 INTEGRIN; GROWTH-FACTOR; MIGRATION; ACTIVATION; KINASE; RNAS; CDC42; LOCALIZATION	Members of the Rho family of small GTPases have been shown to be involved in tumorigenesis and metastasis. Currently, most of the available information on the function of Rho proteins in malignant transformation is based on the use of dominant-negative mutants of these GTPases. The specificity of these dominant-negative mutants is limited however. In this study, we used small interfering RNA directed against either Rac1 or Rac3 to reduce their expression specifically. In line with observations using dominant-negative Rac1 in other cell types, we show that RNA interference-mediated depletion of Rac1 strongly inhibits lamellipodia formation, cell migration and invasion in SNB19 glioblastoma cells. Surprisingly however, Rac1 depletion has a much smaller inhibitory effect on SNB19 cell proliferation and survival. Interestingly, whereas depletion of Rac3 strongly inhibits SNB19 cell invasion, it does not affect lamellipodia formation and has only minor effects on cell migration and proliferation. Similar results were obtained in BT549 breast carcinoma cells. Thus, functional analysis of Rac1 and Rac3 using RNA interference reveals a critical role for these GTPases in the invasive behavior of glioma and breast carcinoma cells.	N Shore Long Isl Jewish Res Inst, Ctr Oncol & Cell Biol, Dept Surg, Manhasset, NY 11030 USA; N Shore LIJ, Med Res Inst, Manhasset, NY 11030 USA; Albert Einstein Coll Med, Dept Anat & Struct Biol, Bronx, NY 10461 USA; NYU, Dept Med, Sch Med, New York, NY 10016 USA; NYU, Dept Cell Biol, Sch Med, New York, NY 10016 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Northwell Health; Northwell Health; Yeshiva University; Albert Einstein College of Medicine; New York University; New York University; Scripps Research Institute	Symons, M (corresponding author), N Shore Long Isl Jewish Res Inst, Ctr Oncol & Cell Biol, Dept Surg, 350 Community Dr, Manhasset, NY 11030 USA.	msymons@nshs.edu		Mark, Philips/0000-0002-1179-8156; Chan, yan fan (Amanda)/0000-0001-5720-7270	NATIONAL CANCER INSTITUTE [R01CA087567] Funding Source: NIH RePORTER; NCI NIH HHS [CA87567] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allen WE, 1998, J CELL BIOL, V141, P1147, DOI 10.1083/jcb.141.5.1147; Anand-Apte B, 1997, J BIOL CHEM, V272, P30688, DOI 10.1074/jbc.272.49.30688; Bokoch GM, 2003, ANNU REV BIOCHEM, V72, P743, DOI 10.1146/annurev.biochem.72.121801.161742; Bouzahzah B, 2001, MOL MED, V7, P816, DOI 10.1007/BF03401974; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Chuang YY, 2004, CANCER RES, V64, P8271, DOI 10.1158/0008-5472.CAN-04-2097; Coniglio SJ, 2001, J BIOL CHEM, V276, P28113, DOI 10.1074/jbc.M102299200; Debreceni B, 2004, J BIOL CHEM, V279, P3777, DOI 10.1074/jbc.M308282200; Denli AM, 2003, TRENDS BIOCHEM SCI, V28, P196, DOI 10.1016/S0968-0004(03)00058-6; Dykxhoorn DM, 2003, NAT REV MOL CELL BIO, V4, P457, DOI 10.1038/nrm1129; Eden S, 2002, NATURE, V418, P790, DOI 10.1038/nature00859; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Feig LA, 1999, NAT CELL BIOL, V1, pE25, DOI 10.1038/10018; Filippi MD, 2004, NAT IMMUNOL, V5, P744, DOI 10.1038/ni1081; Gu Y, 2003, SCIENCE, V302, P445, DOI 10.1126/science.1088485; Gulli MP, 2001, GENE DEV, V15, P365, DOI 10.1101/gad.876901; Haataja L, 2002, J BIOL CHEM, V277, P8321, DOI 10.1074/jbc.M105363200; Haataja L, 1997, J BIOL CHEM, V272, P20384, DOI 10.1074/jbc.272.33.20384; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; Joyce PL, 2003, CANCER RES, V63, P7959; Karnoub AE, 2001, NAT STRUCT BIOL, V8, P1037, DOI 10.1038/nsb719; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Kheradmand F, 1998, SCIENCE, V280, P898, DOI 10.1126/science.280.5365.898; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Lin R, 1997, CURR BIOL, V7, P794, DOI 10.1016/S0960-9822(06)00338-1; Michaelson D, 2001, J CELL BIOL, V152, P111, DOI 10.1083/jcb.152.1.111; Mira JP, 2000, P NATL ACAD SCI USA, V97, P185, DOI 10.1073/pnas.97.1.185; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; O'Connor KL, 2000, J CELL BIOL, V148, P253, DOI 10.1083/jcb.148.2.253; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003; REPESH LA, 1989, INVAS METAST, V9, P192; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Ruggieri R, 2001, MOL MED, V7, P293, DOI 10.1007/BF03402212; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Saxena S, 2003, J BIOL CHEM, V278, P44312, DOI 10.1074/jbc.M307089200; Scacheri PC, 2004, P NATL ACAD SCI USA, V101, P1892, DOI 10.1073/pnas.0308698100; Senger DL, 2002, CANCER RES, V62, P2131; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Small JV, 2002, TRENDS CELL BIOL, V12, P112, DOI 10.1016/S0962-8924(01)02237-1; Symons M, 2000, TRENDS CELL BIOL, V10, P415, DOI 10.1016/S0962-8924(00)01832-8; VAN AL, 1997, GENE DEV, V11, P2295; Wells CM, 2004, J CELL SCI, V117, P1259, DOI 10.1242/jcs.00997; Zheng Y, 2001, TRENDS BIOCHEM SCI, V26, P724, DOI 10.1016/S0968-0004(01)01973-9; Zhuge Y, 2001, J BIOL CHEM, V276, P16248, DOI 10.1074/jbc.M010190200	50	197	207	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2005	24	53					7821	7829		10.1038/sj.onc.1208909	http://dx.doi.org/10.1038/sj.onc.1208909			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	986PU	16027728				2022-12-25	WOS:000233463000001
J	Passioura, T; Shen, S; Symonds, G; Dolnikov, A				Passioura, T; Shen, S; Symonds, G; Dolnikov, A			A retroviral library genetic screen identifies IRF-2 as an inhibitor of N-ras-induced growth suppression in leukemic cells	ONCOGENE			English	Article						N-ras; IRF-2; leukemia	FULL-LENGTH HUMAN; MESSENGER-RNA; ONCOGENIC RAS; P53; EXPRESSION; PML; DIFFERENTIATION; PROLIFERATION; PROTOONCOGENES; ACTIVATION	Activating mutations of the N- ras gene occur at relatively high frequency in acute myeloid leukemia and myelodysplastic syndrome. Somewhat paradoxically, ectopic expression of activated N-ras in primary hematopoietic cells and myeloid cell lines (in some cases) can lead to inhibition of proliferation. Expression of mutant N-ras in murine hematopoietic stem/progenitor cells is sufficient to induce myeloid malignancies, but these pathologies occur with long latency. This suggests that mutations that disable the growth suppressive properties of N-ras in hematopoietic cells are required for the development of frank malignancy. In the present work, the growth suppression induced by a mutant N- ras gene in U937 myeloid cells was used as the basis to screen a retroviral cDNA library for genes that prevent mutant N-ras-induced growth suppression (i.e., putative cooperating oncogenes). This screen identifi. ed the gene for the transcription factor interferon regulatory factor-2 ( IRF-2), and as con. firmation of the screen, overexpression of this gene in U937 cells was shown to inhibit mutant N-ras-induced growth suppression. Also recovered from the screen were two truncated clones of an uncharacterized gene ( interim of. ficial symbol: PP2135). Overexpression of this truncated PP2135 gene in U937 cells did not appear to abrogate mutant N-ras-induced growth suppression, but rather appeared to confer an increased sensitivity of U937 cells to retroviral infection, accounting for the recovery of this gene from the genetic screen.	Univ New S Wales, Sch Med Sci, Sydney, NSW, Australia; Johnson & Johnson Res, Childrens Canc Inst Australia, Sydney, NSW 2012, Australia	University of New South Wales Sydney; Children's Cancer Institute; Johnson & Johnson	Symonds, G (corresponding author), Univ New S Wales, Sch Med Sci, Sydney, NSW, Australia.	gsymonds@medau.jnj.com		Passioura, Toby/0000-0002-6089-5067				Appelbaum F R, 2001, Hematology Am Soc Hematol Educ Program, P62; Chan IT, 2004, J CLIN INVEST, V113, P528, DOI 10.1172/JCI200420476; Clark HF, 2003, GENOME RES, V13, P2265, DOI 10.1101/gr.1293003; Coccia EM, 1999, ONCOGENE, V18, P2129, DOI 10.1038/sj.onc.1202536; Darley RL, 1997, J EXP MED, V185, P1337, DOI 10.1084/jem.185.7.1337; de Stanchina E, 2004, MOL CELL, V13, P523, DOI 10.1016/S1097-2765(04)00062-0; Delgado MD, 2000, ONCOGENE, V19, P783, DOI 10.1038/sj.onc.1203384; Dolnikov A, 2000, CANCER GENE THER, V7, P1491, DOI 10.1038/sj.cgt.7700229; Dolnikov A, 2003, J GEN VIROL, V84, P3131, DOI 10.1099/vir.0.19099-0; Dolnikov A, 2003, CANCER GENE THER, V10, P745, DOI 10.1038/sj.cgt.7700603; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Ferbeyre G, 2000, GENE DEV, V14, P2015; HARADA H, 1994, ONCOGENE, V9, P3313; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; Lallemand C, 2002, EMBO REP, V3, P153, DOI 10.1093/embo-reports/kvf032; Lallemand C, 1997, J BIOL CHEM, V272, P29801, DOI 10.1074/jbc.272.47.29801; MacKenzie KL, 1999, BLOOD, V93, P2043, DOI 10.1182/blood.V93.6.2043.406k17_2043_2056; Maher J, 1996, LEUKEMIA, V10, P83; Matsumura I, 2000, BLOOD, V96, P2440; MILLER DG, 1990, MOL CELL BIOL, V10, P4239, DOI 10.1128/MCB.10.8.4239; NEUBAUER A, 1994, LEUKEMIA, V8, P638; NEUBAUER A, 1994, BLOOD, V83, P1603; Ota T, 2004, NAT GENET, V36, P40, DOI 10.1038/ng1285; Passioura T, 2005, CANCER RES, V65, P797; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Preisler HD, 2001, AM J HEMATOL, V68, P23, DOI 10.1002/ajh.1144; Rubinstein YR, 2000, ONCOGENE, V19, P1411, DOI 10.1038/sj.onc.1203435; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shen SW, 2004, EXP HEMATOL, V32, P852, DOI 10.1016/j.exphem.2004.06.001; Shiohara M, 1996, J CELL PHYSIOL, V166, P568, DOI 10.1002/(SICI)1097-4652(199603)166:3<568::AID-JCP11>3.0.CO;2-3; Stadler M, 1995, ONCOGENE, V11, P2565; Strausberg RL, 2002, P NATL ACAD SCI USA, V99, P16899, DOI 10.1073/pnas.242603899; Tanaka N, 1996, NATURE, V382, P816, DOI 10.1038/382816a0; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; Xi HK, 2003, MOL IMMUNOL, V39, P677, DOI 10.1016/S0161-5890(02)00214-6; Xie RL, 2002, CANCER RES, V62, P2510	39	15	15	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2005	24	49					7327	7336		10.1038/sj.onc.1208877	http://dx.doi.org/10.1038/sj.onc.1208877			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	982FA	16007130				2022-12-25	WOS:000233142100009
J	Rasschaert, J; Ladriere, L; Urbain, M; Dogusan, Z; Katabua, B; Sato, S; Akira, S; Gysemans, C; Mathieu, C; Eizirik, DL				Rasschaert, J; Ladriere, L; Urbain, M; Dogusan, Z; Katabua, B; Sato, S; Akira, S; Gysemans, C; Mathieu, C; Eizirik, DL			Toll-like receptor 3 and STAT-1 contribute to double-stranded RNA plus interferon-gamma-induced apoptosis in primary pancreatic beta-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; DEPENDENT DIABETES-MELLITUS; ISLET CELLS; IFN-BETA; ENTEROVIRUS INFECTION; TRANSGENIC MICE; INNATE IMMUNITY; INDUCED GENES; NITRIC-OXIDE; PRONE BB	Viral infections and local production of cytokines probably contribute to the pathogenesis of Type 1 diabetes. The viral replicative intermediate double-stranded RNA ( dsRNA, tested in the form of polyinosinic-polycytidylic acid, PIC), in combination with the cytokine interferon-gamma (IFN-gamma), triggers beta-cell apoptosis. We have previously observed by microarray analysis that PIC induces expression of several mRNAs encoding for genes downstream of Toll-like receptor 3 (TLR3) signaling pathway. In this report, we show that exposure of beta-cells to dsRNA in combination with IFN-alpha, -beta, or -gamma significantly increases apoptosis. Moreover, dsRNA induces TLR3 mRNA expression and activates NF-kappa B and the IFN-beta promoter in a TRIF-dependent manner. dsRNA also induces an early ( 1 h) and sustained increase in IFN-beta mRNA expression, and blocking IFN-beta with a specific antibody partially prevents PIC plus IFN-gamma-induced beta-cell death. On the other hand, dsRNA plus IFN-gamma does not induce apoptosis in INS-1E cells, and expression of TLR3 and type I IFNs mRNAs is not detected in these cells. Of note, disruption of the STAT-1 signaling pathway protects beta-cells against dsRNA plus IFN-gamma-induced beta-cell apoptosis. This study suggests that dsRNA plus IFN-gamma triggers beta-cell apoptosis by two complementary pathways, namely TLR3-TRIF-NF-kappa B and STAT-1.	Univ Libre Bruxelles, Expt Med Lab, B-1070 Brussels, Belgium; Osaka Univ, Res Inst Microbial Dis, Dept Host Def, Suita, Osaka 5650871, Japan; Katholieke Univ Leuven, Lab Expt Med & Endocrinol, B-3000 Louvain, Belgium	Universite Libre de Bruxelles; Osaka University; KU Leuven	Rasschaert, J (corresponding author), Univ Libre Bruxelles, Expt Med Lab, Route de Lennik 808,CP 618, B-1070 Brussels, Belgium.	jrasscha@ulb.ac.be	mathieu, chantal/ABD-5505-2021; Akira, Shizuo/C-3134-2009	mathieu, chantal/0000-0002-4055-5233; Sato, Shintaro/0000-0001-5156-3354; gysemans, conny/0000-0003-3559-6089; Rasschaert, Joanne/0000-0002-9388-7995; DOGUSAN, ZEYNEP/0000-0002-1506-669X				Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Alba A, 2004, J IMMUNOL, V173, P6667, DOI 10.4049/jimmunol.173.11.6667; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; Besser D, 1999, MOL CELL BIOL, V19, P1401; Beutler B, 2004, NATURE, V430, P257, DOI 10.1038/nature02761; Bonny C, 2001, DIABETES, V50, P77, DOI 10.2337/diabetes.50.1.77; Cardozo AK, 2003, DIABETOLOGIA, V46, P255, DOI 10.1007/s00125-002-1017-0; Cardozo AK, 2001, DIABETES, V50, P909, DOI 10.2337/diabetes.50.5.909; Delaney CA, 1997, ENDOCRINOLOGY, V138, P2610, DOI 10.1210/en.138.6.2610; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; Doyle SE, 2003, J IMMUNOL, V170, P3565, DOI 10.4049/jimmunol.170.7.3565; Doyle SE, 2002, IMMUNITY, V17, P251, DOI 10.1016/S1074-7613(02)00390-4; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; EWEL CH, 1992, DIABETES, V41, P1016, DOI 10.2337/diabetes.41.8.1016; Giannoukakis N, 2000, J BIOL CHEM, V275, P36509, DOI 10.1074/jbc.M005943200; Guidotti LG, 2001, ANNU REV IMMUNOL, V19, P65, DOI 10.1146/annurev.immunol.19.1.65; Han KJ, 2004, J BIOL CHEM, V279, P15652, DOI 10.1074/jbc.M311629200; Haverkos HW, 2003, BIOMED PHARMACOTHER, V57, P379, DOI 10.1016/j.biopha.2003.03.001; Heimberg H, 2001, DIABETES, V50, P2219, DOI 10.2337/diabetes.50.10.2219; Heitmeier MR, 1999, J BIOL CHEM, V274, P12531, DOI 10.1074/jbc.274.18.12531; Hertzog PJ, 2003, TRENDS IMMUNOL, V24, P534, DOI 10.1016/j.it.2003.08.006; Hoorens A, 1996, J CLIN INVEST, V98, P1568, DOI 10.1172/JCI118950; HUANG XJ, 1995, DIABETES, V44, P658, DOI 10.2337/diabetes.44.6.658; Hyoty H, 2002, DIABETOLOGIA, V45, P1353, DOI 10.1007/s00125-002-0852-3; Jacobs BL, 1996, VIROLOGY, V219, P339, DOI 10.1006/viro.1996.0259; Jun HS, 2003, DIABETES-METAB RES, V19, P8, DOI 10.1002/dmrr.337; Jun HS, 2001, DIABETOLOGIA, V44, P271, DOI 10.1007/s001250051614; Jung DY, 2005, J IMMUNOL, V174, P6467, DOI 10.4049/jimmunol.174.10.6467; Kharroubi I, 2003, BIOCHEM BIOPH RES CO, V312, P1118, DOI 10.1016/j.bbrc.2003.11.042; Kobayashi M, 2003, J CLIN INVEST, V111, P1297, DOI 10.1172/JCI200317085; Lang KS, 2005, NAT MED, V11, P138, DOI 10.1038/nm1176; LERNMARK A, 1997, TXB DIABETES; LING Z, 1994, DIABETOLOGIA, V37, P15; Ling ZD, 1998, ENDOCRINOLOGY, V139, P1540, DOI 10.1210/en.139.4.1540; Ling ZD, 2000, DIABETES, V49, P340, DOI 10.2337/diabetes.49.3.340; Liu DB, 2000, DIABETES, V49, P1116, DOI 10.2337/diabetes.49.7.1116; Liu DB, 2002, ENDOCRINOLOGY, V143, P1225, DOI 10.1210/en.143.4.1225; Liu DB, 2001, ENDOCRINOLOGY, V142, P2593, DOI 10.1210/en.142.6.2593; Lonnrot M, 2000, DIABETES, V49, P1314, DOI 10.2337/diabetes.49.8.1314; Matsumoto M, 2004, MICROBIOL IMMUNOL, V48, P147, DOI 10.1111/j.1348-0421.2004.tb03500.x; Matsumoto S, 2005, J BIOL CHEM, V280, P25687, DOI 10.1074/jbc.M412784200; O'Neill LAJ, 2003, TRENDS IMMUNOL, V24, P287, DOI 10.1016/S1471-4906(03)00115-7; Oshiumi H, 2003, NAT IMMUNOL, V4, P161, DOI 10.1038/ni886; Pavlovic D, 1999, EUR CYTOKINE NETW, V10, P403; Pelegrin M, 1998, J BIOL CHEM, V273, P12332, DOI 10.1074/jbc.273.20.12332; PIPELEERS DG, 1985, ENDOCRINOLOGY, V117, P806, DOI 10.1210/endo-117-3-806; Rasschaert J, 2003, DIABETOLOGIA, V46, P1641, DOI 10.1007/s00125-003-1245-y; RHODES CJ, 1985, BIOCHEM J, V228, P87, DOI 10.1042/bj2280087; Ruckdeschel K, 2004, J IMMUNOL, V173, P3320, DOI 10.4049/jimmunol.173.5.3320; Sen GC, 2005, CYTOKINE GROWTH F R, V16, P1, DOI 10.1016/j.cytogfr.2005.01.006; SOBEL DO, 1994, DIABETES, V43, P518, DOI 10.2337/diabetes.43.4.518; SOBEL DO, 1992, DIABETES, V41, P515, DOI 10.2337/diabetes.41.4.515; SOMOZA N, 1994, J IMMUNOL, V153, P1360; Stephanou A, 2003, INT J EXP PATHOL, V84, P239, DOI 10.1111/j.0959-9673.2003.00363.x; Stephanou A, 2000, J BIOL CHEM, V275, P10002, DOI 10.1074/jbc.275.14.10002; STEWART TA, 1993, SCIENCE, V260, P1942, DOI 10.1126/science.8100367; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Tisch R, 1996, CELL, V85, P291, DOI 10.1016/S0092-8674(00)81106-X; Triantafilou K, 2004, J VIROL, V78, P11313, DOI 10.1128/JVI.78.20.11313-11320.2004; Vassileva G, 2003, J IMMUNOL, V170, P5748, DOI 10.4049/jimmunol.170.11.5748; Vives-Pi M, 2003, CLIN EXP IMMUNOL, V133, P208, DOI 10.1046/j.1365-2249.2003.02211.x; Wang T, 2004, NAT MED, V10, P1366, DOI 10.1038/nm1140; Wen L, 2004, J IMMUNOL, V172, P3173, DOI 10.4049/jimmunol.172.5.3173; Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127; Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262; Ylipaasto P, 2004, DIABETOLOGIA, V47, P225, DOI 10.1007/s00125-003-1297-z; YOON JW, 1997, TXB DIABETES; Zipris D, 2005, J IMMUNOL, V174, P131, DOI 10.4049/jimmunol.174.1.131	69	138	141	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					33984	33991		10.1074/jbc.M502213200	http://dx.doi.org/10.1074/jbc.M502213200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16027122	hybrid			2022-12-25	WOS:000232229700036
J	Helguero, LA; Faulds, MH; Gustafsson, JA; Haldosen, LA				Helguero, LA; Faulds, MH; Gustafsson, JA; Haldosen, LA			Estrogen receptors alfa (ER alpha) and beta (ER beta) differentially regulate proliferation and apoptosis of the normal murine mammary epithelial cell line HC11	ONCOGENE			English	Article						estrogen receptors; mammary epithelial cells; estradiol; estrogen receptor-selective ligands; proliferation; apoptosis	HUMAN BREAST-CANCER; MESSENGER-RNA EXPRESSION; GENE-EXPRESSION; IN-VIVO; QUANTITATIVE-ANALYSIS; MOLECULAR MECHANISMS; BCL-2; PROTEIN; LIGANDS; PHENOTYPE	The mitogenic effect of 17 beta-estradiol (E2) on the breast is mediated by estrogen receptor alfa (ER alpha), hence ER alpha antagonists are effective in the treatment of breast cancer. The possible use of estrogen receptor beta (ER beta) as a target in treatment of breast cancer is under investigation. The mouse mammary cell line HC11 expresses both ERs and was used to study the role of the two receptors in proliferation. E2 had no effect on proliferation. The ER alpha-selective agonist 4,4',4''-(4- propyl-(1H)- pyrazole- 1,3,5-triyl) trisphenol (PPT) stimulated proliferation. The ER beta-selective agonist 2,3-bis(4-hydroxy-phenyl)- propionitrile (DPN) inhibited cell growth and induced apoptosis. PPT upregulated while DPN downregulated cyclin D1 and proliferating cell nuclear antigen (PCNA). Upon inhibition of ER alpha expression with RNA interference, E2 caused a decrease in cyclin D1 and PCNA, and increased apoptosis. When ER beta expression was blocked, E2 induced proliferation and cells gained the capacity to grow in soft agar. In summary, in HC11 mammary epithelial cells, ER alpha drives proliferation in response to E2 while ER beta is growth inhibitory. The lack of effect of E2 on HC11 cell growth is the result of the combined actions of ER alpha (proliferation) and ER beta (apoptosis). We suggest that use of ER beta agonists will be a useful addition in treatment of breast cancer, which, at present, is only aimed at inhibition of ER alpha.	Karolinska Inst, Dept Med Nutr, Novum, SE-14186 Huddinge, Sweden	Karolinska Institutet	Haldosen, LA (corresponding author), Karolinska Inst, Dept Med Nutr, Novum, SE-14186 Huddinge, Sweden.	lars-arne.haldosen@mednut.ki.se	Cruz e Silva, Odete/AAH-5595-2020; Helguero, Luisa/B-1221-2013	Helguero, Luisa/0000-0001-8237-2390				BALL RK, 1988, EMBO J, V7, P2089, DOI 10.1002/j.1460-2075.1988.tb03048.x; Bocchinfuso WP, 2000, ENDOCRINOLOGY, V141, P2982, DOI 10.1210/en.141.8.2982; Clarke R, 1996, Cancer Treat Res, V87, P263; Deugnier MA, 1999, J CELL SCI, V112, P1035; Dotzlaw H, 1997, J CLIN ENDOCR METAB, V82, P2371, DOI 10.1210/jc.82.7.2371; Elledge RM, 1997, J CLIN ONCOL, V15, P1916, DOI 10.1200/JCO.1997.15.5.1916; Faulds MH, 2004, MOL ENDOCRINOL, V18, P412, DOI 10.1210/me.2003-0290; Forster C, 2002, P NATL ACAD SCI USA, V99, P15578, DOI 10.1073/pnas.192561299; Frasor J, 2003, ENDOCRINOLOGY, V144, P4562, DOI 10.1210/en.2003-0567; Fuqua SAW, 2003, CANCER RES, V63, P2434; GASPARINI G, 1995, CLIN CANCER RES, V1, P189; GREENE GL, 1986, SCIENCE, V231, P1150, DOI 10.1126/science.3753802; Hall JM, 2002, J BIOL CHEM, V277, P44455, DOI 10.1074/jbc.M200849200; Humphreys RC, 1997, CELL GROWTH DIFFER, V8, P839; Imamov O, 2004, P NATL ACAD SCI USA, V101, P9375, DOI 10.1073/pnas.0403041101; Iwao K, 2000, CANCER, V89, P1732, DOI 10.1002/1097-0142(20001015)89:8<1732::AID-CNCR13>3.0.CO;2-2; Iwao K, 2000, INT J CANCER, V88, P733, DOI 10.1002/1097-0215(20001201)88:5<733::AID-IJC8>3.0.CO;2-M; Kraichely DM, 2000, ENDOCRINOLOGY, V141, P3534, DOI 10.1210/en.141.10.3534; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Kushner PJ, 2000, J STEROID BIOCHEM, V74, P311, DOI 10.1016/S0960-0760(00)00108-4; Lamb CA, 2003, BREAST CANCER RES TR, V79, P25, DOI 10.1023/A:1023324827225; Leung LK, 1999, BRIT J CANCER, V81, P387, DOI 10.1038/sj.bjc.6690706; Leygue E, 1998, CANCER RES, V58, P3197; Liu MM, 2002, J BIOL CHEM, V277, P24353, DOI 10.1074/jbc.M201829200; Margeat E, 2003, J MOL BIOL, V326, P77, DOI 10.1016/S0022-2836(02)01355-4; Meyers MJ, 2001, J MED CHEM, V44, P4230, DOI 10.1021/jm010254a; MOLINOLO AA, 1987, J NATL CANCER I, V79, P1341; Omoto Y, 2003, ONCOGENE, V22, P5011, DOI 10.1038/sj.onc.1206787; Petersen H, 1998, EXP CELL RES, V243, P347, DOI 10.1006/excr.1998.4160; Saville B, 2000, J BIOL CHEM, V275, P5379, DOI 10.1074/jbc.275.8.5379; Schorr K, 1999, CANCER RES, V59, P2541; Schorr K, 1999, J MAMMARY GLAND BIOL, V4, P153, DOI 10.1023/A:1018773123899; Shaaban AM, 2003, AM J SURG PATHOL, V27, P1502, DOI 10.1097/00000478-200312000-00002; SHYAMALA G, 1982, ENDOCRINOLOGY, V110, P1249, DOI 10.1210/endo-110-4-1249; Speirs V, 1999, CANCER RES, V59, P525; Speirs V, 2004, LANCET ONCOL, V5, P174, DOI 10.1016/S1470-2045(04)01413-5; Stauffer SR, 2000, J MED CHEM, V43, P4934, DOI 10.1021/jm000170m; Strom A, 2004, P NATL ACAD SCI USA, V101, P1566, DOI 10.1073/pnas.0308319100; Vanzulli S, 2002, CARCINOGENESIS, V23, P749, DOI 10.1093/carcin/23.5.749; VisserWisselaar HA, 1997, ENDOCRINOLOGY, V138, P1180, DOI 10.1210/en.138.3.1180; Zhang GJ, 1999, CLIN CANCER RES, V5, P2971; Zhang WH, 2003, FEBS LETT, V546, P17, DOI 10.1016/S0014-5793(03)00436-8	42	207	217	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 6	2005	24	44					6605	6616		10.1038/sj.onc.1208807	http://dx.doi.org/10.1038/sj.onc.1208807			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	971FL	16007178				2022-12-25	WOS:000232367800002
J	Zhang, XY; Fan, SJ; Meng, QH; Ma, YX; Katiyar, P; Schlegel, R; Rosen, EM				Zhang, XY; Fan, SJ; Meng, QH; Ma, YX; Katiyar, P; Schlegel, R; Rosen, EM			BRCA1 interaction with human papillomavirus oncoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER; PROMOTER HYPERMETHYLATION; SPORADIC BREAST; IN-VIVO; PROTEINS; GENE; P53; E6; INHIBITION; CARCINOMA	Previously, we reported that BRCA1 strongly represses the transcriptional activity of estrogen receptor-alpha(ER-alpha) in human breast and prostate cancer cells but only weakly inhibits ER-alpha in cervical cancer cells. We now report that introduction of the human papillomavirus E7 or E6 oncogenes into human papillomavirus- negative cells rescues the BRCA1 repression of ER-alpha activity and that the E7 and E6 oncoproteins interact directly with BRCA1 in vitro and associate with BRCA1 in vivo in cultured cells. This interaction involves at least two contact points on BRCA1, one within an N-terminal site shown previously to interact with ER-alpha and the other in a C-terminal region of BRCA1 containing the first BRCA1 C-terminal domain. Point mutations within the zinc finger domains of E7 and E6 inactivated the binding to the N terminus of BRCA1 and reduced their ability to rescue BRCA1 inhibition of ER-alpha. E6 and E7 also antagonized the ability of BRCA1 to inhibit c-MycE-box-mediated transactivation and human telomerase reverse transcriptase promoter activity, in a manner dependent upon the zinc finger domains. Finally, the ability of E6 and E7 to antagonize BRCA1 did not involve proteolytic degradation of BRCA1. These findings suggest functional interactions of BRCA1 with E7 and E6. The potential significance of these findings is discussed.	Georgetown Univ, Lombardi Comprehens Canc Ctr, Dept Oncol, Washington, DC 20057 USA; Georgetown Univ, Lombardi Comprehens Canc Ctr, Dept Pathol, Washington, DC 20057 USA	Georgetown University; Georgetown University	Rosen, EM (corresponding author), Georgetown Univ, Lombardi Comprehens Canc Ctr, Dept Oncol, Preclin Sci Bldg,Rm GM12B,3970 Reservoir Rd NW,Bo, Washington, DC 20057 USA.	emr36@georgetown.edu			NATIONAL CANCER INSTITUTE [R01CA082599] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009169] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aprelikova ON, 1999, P NATL ACAD SCI USA, V96, P11866, DOI 10.1073/pnas.96.21.11866; Arbeit JM, 1996, P NATL ACAD SCI USA, V93, P2930, DOI 10.1073/pnas.93.7.2930; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Brehm A, 1999, EMBO J, V18, P2449, DOI 10.1093/emboj/18.9.2449; CASEY G, 1991, ONCOGENE, V6, P1791; Chai YL, 1999, ONCOGENE, V18, P263, DOI 10.1038/sj.onc.1202323; de Villiers EM, 2005, BREAST CANCER RES, V7, pR1, DOI 10.1186/bcr940; de Villiers EM, 2003, INT J CANCER, V103, P705, DOI 10.1002/ijc.10868; Einstein MH, 2002, CANCER INVEST, V20, P1080, DOI 10.1081/CNV-120005927; Elson DA, 2000, CANCER RES, V60, P1267; Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Fan SJ, 2002, CANCER RES, V62, P141; Fan SJ, 2001, ONCOGENE, V20, P77, DOI 10.1038/sj.onc.1204073; Fan SJ, 2001, ONCOGENE, V20, P4827, DOI 10.1038/sj.onc.1204666; Fan SJ, 2001, ONCOGENE, V20, P8215, DOI 10.1038/sj.onc.1205033; Fan SJ, 1998, ONCOGENE, V16, P3069, DOI 10.1038/sj.onc.1202116; FOSTER SA, 1994, J VIROL, V68, P5698, DOI 10.1128/JVI.68.9.5698-5705.1994; Franco EL, 2003, CANCER J, V9, P348, DOI 10.1097/00130404-200309000-00004; Henttu PMA, 1997, MOL CELL BIOL, V17, P1832, DOI 10.1128/MCB.17.4.1832; HURWITZ DR, 1985, P NATL ACAD SCI USA, V82, P163, DOI 10.1073/pnas.82.1.163; Johannsson O, 1999, EUR J CANCER, V35, P1248, DOI 10.1016/S0959-8049(99)00135-5; JONES L, 2005, ONCOGENE, V93; LIANG XH, 1995, J CELL BIOCHEM, V57, P509, DOI 10.1002/jcb.240570316; Liu XF, 2005, J BIOL CHEM, V280, P10807, DOI 10.1074/jbc.M410343200; Ma YX, 2005, ONCOGENE, V24, P1831, DOI 10.1038/sj.onc.1208190; Maclean J, 2005, EXPERT REV ANTICANC, V5, P97, DOI 10.1586/14737140.5.1.97; Meissner JD, 1999, J GEN VIROL, V80, P1725, DOI 10.1099/0022-1317-80-7-1725; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Miyai K, 2004, GYNECOL ONCOL, V94, P115, DOI 10.1016/j.ygyno.2004.04.013; Munger K, 2004, J VIROL, V78, P11451, DOI 10.1128/JVI.78.21.11451-11460.2004; Narayan G, 2004, CANCER RES, V64, P2994, DOI 10.1158/0008-5472.CAN-04-0245; Narayan Gopeshwar, 2003, Mol Cancer, V2, P24, DOI 10.1186/1476-4598-2-24; Narod SA, 2001, ANN NY ACAD SCI, V952, P36, DOI 10.1111/j.1749-6632.2001.tb02726.x; Ouchi T, 2000, P NATL ACAD SCI USA, V97, P5208, DOI 10.1073/pnas.080469697; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Peng SW, 2004, J VIROL, V78, P8468, DOI 10.1128/JVI.78.16.8468-8476.2004; Pestell RG, 1996, CELL GROWTH DIFFER, V7, P1337; Rebbeck TR, 2002, NEW ENGL J MED, V346, P1616, DOI 10.1056/NEJMoa012158; Robson ME, 2004, BREAST CANCER RES, V6, pR8, DOI 10.1186/bcr658; Rosen EM, 2003, J CELL PHYSIOL, V196, P19, DOI 10.1002/jcp.10257; ROSEN EM, 2005, IN PRESS ENDOCR RELA; ROWELL S, 1994, AM J HUM GENET, V55, P861; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Scheffner M, 2003, SEMIN CANCER BIOL, V13, P59, DOI 10.1016/S1044-579X(02)00100-1; SEEDORF K, 1987, EMBO J, V6, P139, DOI 10.1002/j.1460-2075.1987.tb04731.x; Staff S, 2003, CANCER RES, V63, P4978; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; Thompson D, 2002, JNCI-J NATL CANCER I, V94, P1358, DOI 10.1093/jnci/94.18.1358; Veldman T, 2003, P NATL ACAD SCI USA, V100, P8211, DOI 10.1073/pnas.1435900100; Wang Q, 1998, ONCOGENE, V17, P1939, DOI 10.1038/sj.onc.1202403; Williams RS, 2004, NAT STRUCT MOL BIOL, V11, P519, DOI 10.1038/nsmb776; Xiong JB, 2003, MOL CELL BIOL, V23, P8668, DOI 10.1128/MCB.23.23.8668-8690.2003; Xu JW, 2005, ENDOCRINOLOGY, V146, P2031, DOI 10.1210/en.2004-0409; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; ZHU JY, 1992, J VIROL, V66, P2780, DOI 10.1128/JVI.66.5.2780-2791.1992; Zimmermann H, 1999, J VIROL, V73, P6209, DOI 10.1128/JVI.73.8.6209-6219.1999	58	62	68	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	2005	280	39					33165	33177		10.1074/jbc.M505124200	http://dx.doi.org/10.1074/jbc.M505124200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	966YG	15983032	hybrid			2022-12-25	WOS:000232058100011
J	Bennetts, B; Rychkov, GY; Ng, HL; Morton, CJ; Stapleton, D; Parker, MW; Cromer, BA				Bennetts, B; Rychkov, GY; Ng, HL; Morton, CJ; Stapleton, D; Parker, MW; Cromer, BA			Cytoplasmic ATP-sensing domains regulate gating of skeletal muscle ClC-1 chloride channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IDIOPATHIC GENERALIZED EPILEPSIES; NEPHROLITHIASIS KIDNEY-STONES; TEMPERATURE-DEPENDENCE; CBS DOMAINS; K+-CHANNEL; FORCE PRODUCTION; MOLECULAR-BASIS; MUTATIONS; PROTEIN; FIBERS	ClC proteins are a family of chloride channels and transporters that are found in a wide variety of prokaryotic and eukaryotic cell types. The mammalian voltage-gated chloride channel ClC-1 is important for controlling the electrical excitability of skeletal muscle. Reduced excitability of muscle cells during metabolic stress can protect cells from metabolic exhaustion and is thought to be a major factor in fatigue. Here we identify a novel mechanism linking excitability to metabolic state by showing that ClC-1 channels are modulated by ATP. The high concentration of ATP in resting muscle effectively inhibits ClC-1 activity by shifting the voltage gating to more positive potentials. ADP and AMP had similar effects to ATP, but IMP had no effect, indicating that the inhibition of ClC-1 would only be relieved under anaerobic conditions such as intense muscle activity or ischemia, when depleted ATP accumulates as IMP. The resulting increase in ClC-1 activity under these conditions would reduce muscle excitability, thus contributing to fatigue. We show further that the modulation by ATP is mediated by cystathionine beta-synthase-related domains in the cytoplasmic C terminus of ClC-1. This defines a function for these domains as gating-modulatory domains sensitive to intracellular ligands, such as nucleotides, a function that is likely to be conserved in other ClC proteins.	St Vincents Inst, Fitzroy, Vic 3065, Australia; Univ Adelaide, Adelaide, SA 5005, Australia; Univ Melbourne, Mol Sci & Biotechnol Inst Bio21, Parkville, Vic 3010, Australia	St. Vincent's Institute of Medical Research; University of Adelaide; University of Melbourne	Cromer, BA (corresponding author), St Vincents Inst, 9 Princes St, Fitzroy, Vic 3065, Australia.	bcromer@svi.edu.au	Cromer, Brett/AAQ-6533-2020; Morton, Craig/GON-8638-2022; Parker, Michael W/F-9069-2013	Morton, Craig/0000-0001-5452-5193; Parker, Michael W/0000-0002-3101-1138; Cromer, Brett/0000-0003-0743-1535; Rychkov, Grigori/0000-0002-2788-2977				Accardi A, 2004, NATURE, V427, P803, DOI 10.1038/nature02314; Aromataris EC, 2001, MOL PHARMACOL, V60, P200, DOI 10.1124/mol.60.1.200; Bateman A, 1997, TRENDS BIOCHEM SCI, V22, P12, DOI 10.1016/S0968-0004(96)30046-7; Bennetts B, 2001, J PHYSIOL-LONDON, V535, P83, DOI 10.1111/j.1469-7793.2001.t01-1-00083.x; Charlet-B N, 2002, MOL CELL, V10, P45, DOI 10.1016/S1097-2765(02)00572-5; Cuppoletti J, 2004, J BIOL CHEM, V279, P21849, DOI 10.1074/jbc.M312567200; Debold EP, 2004, AM J PHYSIOL-CELL PH, V287, pC673, DOI 10.1152/ajpcell.00044.2004; Deymeer F, 1998, MUSCLE NERVE, V21, P1334, DOI 10.1002/(SICI)1097-4598(199810)21:10<1334::AID-MUS16>3.0.CO;2-1; Duffield M, 2003, J GEN PHYSIOL, V121, P149, DOI 10.1085/jgp.20028741; Dutka TL, 2004, J PHYSIOL-LONDON, V560, P451, DOI 10.1113/jphysiol.2004.069112; Dutzler R, 2002, NATURE, V415, P287, DOI 10.1038/415287a; Eisenberg D, 1997, METHOD ENZYMOL, V277, P396, DOI 10.1016/S0076-6879(97)77022-8; Estevez R, 2004, J PHYSIOL-LONDON, V557, P363, DOI 10.1113/jphysiol.2003.058453; Fong PY, 1998, AM J PHYSIOL-CELL PH, V274, pC966, DOI 10.1152/ajpcell.1998.274.4.C966; Gong B, 2000, AM J PHYSIOL-CELL PH, V279, pC1351, DOI 10.1152/ajpcell.2000.279.5.C1351; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; GURNETT CA, 1995, J BIOL CHEM, V270, P9035, DOI 10.1074/jbc.270.16.9035; Haug K, 2003, NAT GENET, V33, P527, DOI 10.1038/ng1121; Hebeisen S, 2004, J BIOL CHEM, V279, P13140, DOI 10.1074/jbc.M312649200; Hellsten Y, 1999, J PHYSIOL-LONDON, V520, P909, DOI 10.1111/j.1469-7793.1999.00909.x; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; IDSTROM JP, 1990, AM J PHYSIOL, V258, pH1668, DOI 10.1152/ajpheart.1990.258.6.H1668; Jentsch TJ, 2002, PHYSIOL REV, V82, P503, DOI 10.1152/physrev.00029.2001; Karatzaferi C, 2001, PFLUG ARCH EUR J PHY, V442, P467, DOI 10.1007/s004240100552; Konrad M, 2000, J AM SOC NEPHROL, V11, P1449, DOI 10.1681/ASN.V1181449; Kornak U, 2001, CELL, V104, P205, DOI 10.1016/S0092-8674(01)00206-9; Lamb GD, 1995, J PHYSIOL-LONDON, V489, P349, DOI 10.1113/jphysiol.1995.sp021056; Lloyd SE, 1997, HUM MOL GENET, V6, P1233, DOI 10.1093/hmg/6.8.1233; Maduke M, 1998, BIOCHEMISTRY-US, V37, P1315, DOI 10.1021/bi972418o; Mankodi A, 2002, MOL CELL, V10, P35, DOI 10.1016/S1097-2765(02)00563-4; MORISAKI T, 1992, P NATL ACAD SCI USA, V89, P6457, DOI 10.1073/pnas.89.14.6457; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; Nielsen OB, 2001, J PHYSIOL-LONDON, V536, P161, DOI 10.1111/j.1469-7793.2001.t01-1-00161.x; Niemeyer MI, 2004, PHYSIOL GENOMICS, V19, P74, DOI 10.1152/physiolgenomics.00070.2004; NOMA A, 1983, NATURE, V305, P147, DOI 10.1038/305147a0; PALADE PT, 1977, J GEN PHYSIOL, V69, P325, DOI 10.1085/jgp.69.3.325; Papponen H, 2005, EXP NEUROL, V191, P163, DOI 10.1016/j.expneurol.2004.07.018; Pedersen TH, 2005, J GEN PHYSIOL, V125, P237, DOI 10.1085/jgp.200409173; Pedersen TH, 2004, SCIENCE, V305, P1144, DOI 10.1126/science.1101141; Ponting CP, 1997, J MOL MED-JMM, V75, P160; Pusch M, 1997, J GEN PHYSIOL, V109, P105, DOI 10.1085/jgp.109.1.105; Pusch M, 2002, HUM MUTAT, V19, P423, DOI 10.1002/humu.10063; Roosild TP, 2004, TRENDS BIOCHEM SCI, V29, P39, DOI 10.1016/j.tibs.2003.11.008; Rychkov GY, 1996, J PHYSIOL-LONDON, V497, P423, DOI 10.1113/jphysiol.1996.sp021778; Saviane C, 1999, J GEN PHYSIOL, V113, P457, DOI 10.1085/jgp.113.3.457; Scott JW, 2004, J CLIN INVEST, V113, P274, DOI 10.1172/JCI200419874; Sejersted OM, 2000, PHYSIOL REV, V80, P1411, DOI 10.1152/physrev.2000.80.4.1411; Simpson Bronwyn J, 2004, Hum Mutat, V24, P185, DOI 10.1002/humu.9260; Stapleton D, 1996, J BIOL CHEM, V271, P611, DOI 10.1074/jbc.271.2.611; Suzuki M, 2002, J CLIN INVEST, V109, P509, DOI 10.1172/JC1200214270; Szentesi P, 2001, J PHYSIOL-LONDON, V531, P393, DOI 10.1111/j.1469-7793.2001.0393i.x; Tucker SJ, 1998, CURR OPIN NEUROBIOL, V8, P316, DOI 10.1016/S0959-4388(98)80055-X; Tullson P C, 1991, Exerc Sport Sci Rev, V19, P507; Vanoye CG, 2002, J PHYSIOL-LONDON, V539, P373, DOI 10.1113/jphysiol.2001.013115; Westerblad H, 1998, ACTA PHYSIOL SCAND, V162, P253, DOI 10.1046/j.1365-201X.1998.0301f.x; Wollnik B, 1997, HUM MOL GENET, V6, P1943, DOI 10.1093/hmg/6.11.1943; Zarembinski TI, 1998, P NATL ACAD SCI USA, V95, P15189, DOI 10.1073/pnas.95.26.15189; Zhang RG, 1999, BIOCHEMISTRY-US, V38, P4691, DOI 10.1021/bi982858v	58	97	98	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	2005	280	37					32452	32458		10.1074/jbc.M502890200	http://dx.doi.org/10.1074/jbc.M502890200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	963HM	16027167	Green Accepted, hybrid			2022-12-25	WOS:000231794800052
J	Ferreiro, DU; Dellarole, M; Nadra, AD; de Prat-Gay, G				Ferreiro, DU; Dellarole, M; Nadra, AD; de Prat-Gay, G			Free energy contributions to direct readout of a DNA sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAPILLOMAVIRUS E2 PROTEINS; BINDING DOMAIN; RECOGNITION; SPECIFICITY; FLEXIBILITY; INTERFACES; CODE; DISCRIMINATION; ENDONUCLEASE; CONSERVATION	The energetic contributions of individual DNA-contacting side chains to specific DNA recognition in the human papillomavirus 16 E2C-DNA complex is small (less than 1.0 kcal mol(-1)), independent of the physical and chemical nature of the interaction, and is strictly additive. The sum of the individual contributions differs 1.0 kcal mol(-1) from the binding energy of the wild- type protein. This difference corresponds to the contribution from the deformability of the DNA, known as "indirect readout." Thus, we can dissect the energetic contribution to DNA binding into 90% direct and 10% indirect readout components. The lack of high energy interactions indicates the absence of "hot spots," such as those found in protein-protein interfaces. These results are compatible with a highly dynamic and " wet" protein-DNA interface, yet highly specific and tight, where individual interactions are constantly being formed and broken.	Univ Buenos Aires, Consejo Nacl Invest Cient & Tecn, Inst Leloir, RA-1405 Buenos Aires, DF, Argentina; Univ Buenos Aires, Fac Ciencias Exactas & Nat, RA-1405 Buenos Aires, DF, Argentina	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Leloir Institute; University of Buenos Aires; University of Buenos Aires	de Prat-Gay, G (corresponding author), Univ Buenos Aires, Consejo Nacl Invest Cient & Tecn, Inst Leloir, Patricias Argentinas 435, RA-1405 Buenos Aires, DF, Argentina.	gpratgay@leloir.org.ar	Nadra, Alejandro/A-5668-2009	Nadra, Alejandro/0000-0002-7860-3245; Prat Gay, Gonzalo/0000-0001-5748-6863; Ferreiro, Diego/0000-0002-7869-4247	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Alexander KA, 1996, BIOCHEMISTRY-US, V35, P9864, DOI 10.1021/bi960447d; Anderson EM, 2003, BIOCHEMISTRY-US, V42, P3751, DOI 10.1021/bi027047c; Bogan AA, 1998, J MOL BIOL, V280, P1, DOI 10.1006/jmbi.1998.1843; Dell G, 2003, J MOL BIOL, V334, P979, DOI 10.1016/j.jmb.2003.10.009; Engler LE, 2001, J MOL BIOL, V307, P619, DOI 10.1006/jmbi.2000.4428; Ferreiro DU, 2000, BIOCHEMISTRY-US, V39, P14692, DOI 10.1021/bi001694r; Ferreiro DU, 2003, J MOL BIOL, V331, P89, DOI 10.1016/S0022-2836(03)00720-4; FERSHT A, 1999, STRUCTURE MECH PROTE, P129; Gromiha MM, 2004, J MOL BIOL, V337, P285, DOI 10.1016/j.jmb.2004.01.033; HAM J, 1991, TRENDS BIOCHEM SCI, V16, P440, DOI 10.1016/0968-0004(91)90172-R; HARRINGTON RE, 1994, PROG NUCLEIC ACID RE, V47, P195, DOI 10.1016/S0079-6603(08)60253-6; HEGDE RS, 1992, NATURE, V359, P505, DOI 10.1038/359505a0; Hegde RS, 2002, ANNU REV BIOPH BIOM, V31, P343, DOI 10.1146/annurev.biophys.31.100901.142129; Hines CS, 1998, J MOL BIOL, V276, P809, DOI 10.1006/jmbi.1997.1578; Janin J, 1999, STRUCT FOLD DES, V7, pR277, DOI 10.1016/S0969-2126(00)88333-1; Jen-Jacobson L, 2000, STRUCTURE, V8, P1015, DOI 10.1016/S0969-2126(00)00501-3; JenJacobson L, 1997, BIOPOLYMERS, V44, P153; Kim SS, 2000, J BIOL CHEM, V275, P31245, DOI 10.1074/jbc.M004541200; Kurpiewski MR, 2004, STRUCTURE, V12, P1775, DOI 10.1016/j.str.2004.07.016; Levy Y, 2004, P NATL ACAD SCI USA, V101, P3325, DOI 10.1073/pnas.0400157101; Liang H, 1996, BIOCHEMISTRY-US, V35, P2095, DOI 10.1021/bi951932w; Lima LMTR, 2004, J BIOL CHEM, V279, P47968, DOI 10.1074/jbc.M407696200; Luscombe NM, 2002, J MOL BIOL, V320, P991, DOI 10.1016/S0022-2836(02)00571-5; MATTHEWS BW, 1988, NATURE, V335, P294, DOI 10.1038/335294a0; Mauricio L, 1997, J BIOL CHEM, V272, P19295, DOI 10.1074/jbc.272.31.19295; MCBRIDE AA, 1991, J BIOL CHEM, V266, P18411; Mok YK, 2000, PROTEIN SCI, V9, P799; Mok YK, 1996, NAT STRUCT BIOL, V3, P711, DOI 10.1038/nsb0896-711; Mok YK, 1996, PROTEIN SCI, V5, P310; Nadra AD, 2004, J BIOMOL NMR, V30, P211, DOI 10.1023/B:JNMR.0000048942.96866.76; Oobatake M, 2003, PROTEINS, V53, P33, DOI 10.1002/prot.10438; Pabo CO, 2000, J MOL BIOL, V301, P597, DOI 10.1006/jmbi.2000.3918; Rozenberg H, 1998, P NATL ACAD SCI USA, V95, P15194, DOI 10.1073/pnas.95.26.15194; RUIZSANZ J, 1995, BIOCHEMISTRY-US, V34, P1695, DOI 10.1021/bi00005a026; SANDERS CM, 1994, NUCLEIC ACIDS RES, V22, P4890, DOI 10.1093/nar/22.23.4890; SARAI A, 1989, BIOCHEMISTRY-US, V28, P7842, DOI 10.1021/bi00445a046; Selvaraj S, 2002, J MOL BIOL, V322, P907, DOI 10.1016/S0022-2836(02)00846-X; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; VONHIPPEL PH, 1986, P NATL ACAD SCI USA, V83, P1608; WELLS JA, 1991, METHOD ENZYMOL, V202, P390; Zhang YL, 2004, P NATL ACAD SCI USA, V101, P8337, DOI 10.1073/pnas.0402319101	41	30	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	2005	280	37					32480	32484		10.1074/jbc.M505706200	http://dx.doi.org/10.1074/jbc.M505706200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	963HM	16000299	hybrid, Green Published			2022-12-25	WOS:000231794800055
J	Harada, Y; Sakai, M; Kurabayashi, N; Hirota, T; Fukada, Y				Harada, Y; Sakai, M; Kurabayashi, N; Hirota, T; Fukada, Y			Ser-557-phosphorylated mCRY2 is degraded upon synergistic phosphorylation by glycogen synthase kinase-3 beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; DROSOPHILA CLOCK GENE; CIRCADIAN ACTIVATION; NUCLEAR-LOCALIZATION; GROWTH-FACTOR; BETA-CATENIN; DOUBLE-TIME; PERIOD; LIGHT; RHYTHMS	Cryptochrome 1 and 2 act as essential components of the central and peripheral circadian clocks for generation of circadian rhythms in mammals. Here we show that mouse cryptochrome 2 (mCRY2) is phosphorylated at Ser-557 in the liver, a well characterized peripheral clock tissue. The Ser-557- phosphorylated form accumulates in the liver during the night in parallel with mCRY2 protein, and the phosphorylated form reaches its maximal level at late night, preceding the peak-time of the protein abundance by similar to 4 h in both light-dark cycle and constant dark conditions. The Ser-557- phosphorylated form of mCRY2 is localized in the nucleus, whereas mCRY2 protein is located in both the cytoplasm and nucleus. Importantly, phosphorylation of mCRY2 at Ser-557 allows subsequent phosphorylation at Ser-553 by glycogen synthase kinase-3 beta (GSK-3 beta), resulting in efficient degradation of mCRY2 by a proteasome pathway. As assessed by phosphorylation of GSK-3 beta at Ser-9, which negatively regulates the kinase activity, GSK-3 beta exhibits a circadian rhythm in its activity with a peak from late night to early morning when Ser-557 of mCRY2 is highly phosphorylated. Altogether, the present study demonstrates an important role of sequential phosphorylation at Ser-557/Ser-553 for destabilization of mCRY2 and illustrates a model that the circadian regulation of mCRY2 phosphorylation contributes to rhythmic degradation of mCRY2 protein.	Univ Tokyo, Dept Biochem & Biophys, Grad Sch Sci, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo	Fukada, Y (corresponding author), Univ Tokyo, Dept Biochem & Biophys, Grad Sch Sci, Bunkyo Ku, Hongo 7-3-1, Tokyo 1130033, Japan.	sfukada@mail.ecc.u-tokyo.ac.jp	吉孝, 深田/G-5090-2014; Hirota, Tsuyoshi/D-8158-2015; KURABAYASHI, NOBUHIRO/G-4891-2014	Hirota, Tsuyoshi/0000-0003-4876-3608; Kurabayashi, Nobuhiro/0000-0003-3097-8539				Akashi M, 2000, GENE DEV, V14, P645; Boucher N, 2002, J BIOL CHEM, V277, P19511, DOI 10.1074/jbc.M200500200; Butcher GQ, 2004, EUR J NEUROSCI, V19, P907, DOI 10.1111/j.0953-816X.2004.03155.x; Cashmore AR, 1999, SCIENCE, V284, P760, DOI 10.1126/science.284.5415.760; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Eide EJ, 2005, MOL CELL BIOL, V25, P2795, DOI 10.1128/MCB.25.7.2795-2807.2005; Eide EJ, 2002, J BIOL CHEM, V277, P17248, DOI 10.1074/jbc.M111466200; ELDARFINKELMAN H, 1995, J BIOL CHEM, V270, P987, DOI 10.1074/jbc.270.3.987; FIOL CJ, 1987, J BIOL CHEM, V262, P14042; FIOL CJ, 1994, J BIOL CHEM, V269, P32187; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; Grima B, 2002, NATURE, V420, P178, DOI 10.1038/nature01122; Harada Y, 2000, J BIOL CHEM, V275, P37078, DOI 10.1074/jbc.M004706200; Iwahana E, 2004, EUR J NEUROSCI, V19, P2281, DOI 10.1111/j.0953-816X.2004.03322.x; Keesler GA, 2000, NEUROREPORT, V11, P951, DOI 10.1097/00001756-200004070-00011; Kloss B, 1998, CELL, V94, P97, DOI 10.1016/S0092-8674(00)81225-8; Ko HW, 2002, NATURE, V420, P673, DOI 10.1038/nature01272; Kume K, 1999, CELL, V98, P193, DOI 10.1016/S0092-8674(00)81014-4; Lee C, 2001, CELL, V107, P855, DOI 10.1016/S0092-8674(01)00610-9; Lee CG, 1998, NEURON, V21, P857, DOI 10.1016/S0896-6273(00)80601-7; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Lowrey PL, 2000, SCIENCE, V288, P483, DOI 10.1126/science.288.5465.483; Martinek S, 2001, CELL, V105, P769, DOI 10.1016/S0092-8674(01)00383-X; Obrietan K, 1998, NAT NEUROSCI, V1, P693, DOI 10.1038/3695; Price JL, 1998, CELL, V94, P83, DOI 10.1016/S0092-8674(00)81224-6; RALPH MR, 1990, SCIENCE, V247, P975, DOI 10.1126/science.2305266; RUSAK B, 1977, PHYSIOL REV, V59, P449; Sakakida Y, 2005, J BIOL CHEM, V280, P13272, DOI 10.1074/jbc.M413236200; Sanada K, 2004, GENES CELLS, V9, P697, DOI 10.1111/j.1356-9597.2004.00758.x; Sanada K, 2002, J BIOL CHEM, V277, P267, DOI 10.1074/jbc.M107850200; Sanada K, 2000, J NEUROSCI, V20, P986, DOI 10.1523/JNEUROSCI.20-03-00986.2000; Schibler U, 2002, CELL, V111, P919, DOI 10.1016/S0092-8674(02)01225-4; Shearman LP, 2000, SCIENCE, V288, P1013, DOI 10.1126/science.288.5468.1013; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; TAKAHASHI JS, 1995, ANNU REV NEUROSCI, V18, P531, DOI 10.1146/annurev.neuro.18.1.531; van der Horst GTJ, 1999, NATURE, V398, P627, DOI 10.1038/19323; WELSH DK, 1995, NEURON, V14, P697, DOI 10.1016/0896-6273(95)90214-7; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Yagita K, 2002, EMBO J, V21, P1301, DOI 10.1093/emboj/21.6.1301; Yagita K, 2001, SCIENCE, V292, P278, DOI 10.1126/science.1059542; Yamazaki S, 2000, SCIENCE, V288, P682, DOI 10.1126/science.288.5466.682; Zeng HK, 1996, NATURE, V380, P129, DOI 10.1038/380129a0; Zhu HS, 2003, CURR BIOL, V13, P1653, DOI 10.1016/j.cub.2003.08.033	47	142	147	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	2005	280	36					31714	31721		10.1074/jbc.M506225200	http://dx.doi.org/10.1074/jbc.M506225200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	961LZ	15980066	hybrid			2022-12-25	WOS:000231665200048
J	Potter, MD; Barbero, S; Cheresh, DA				Potter, MD; Barbero, S; Cheresh, DA			Tyrosine phosphorylation of VE-cadherin prevents binding of p120- and beta-catenin and maintains the cellular mesenchymal state	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROVASCULAR ENDOTHELIAL-CELLS; N-CADHERIN; ADHERENS JUNCTIONS; MOLECULAR-BASIS; ADHESION; MORPHOGENESIS; ANGIOGENESIS; ASSOCIATION; GROWTH; PERMEABILITY	In several pathological conditions, epithelial cells demonstrate a breakdown of barrier function and acquire an invasive phenotype. Endothelial cells in particular are maintained in a mesenchymal state during the cell invasion phase of angiogenesis. We show here that tyrosine phosphorylation of the adherens junction protein VE-cadherin at two critical tyrosines, Tyr-658 and Tyr-731, via tyrosine kinase activation or phosphatase inactivation was sufficient to prevent the binding of p120- and beta-catenin, respectively, to the cytoplasmic tail of VE-cadherin. In fact, phosphorylation at either site led to the inhibition of cell barrier function. Cells expressing wild-type VE-cadherin showed decreased cell migration compared with cells lacking VE-cadherin, whereas expression of VE-cadherin with a simple phosphomimetic tyrosine-to-glutamic acid mutation of Y658E or Y731E was sufficient to restore the migratory response. These findings demonstrate that a single phosphorylation event within the VE-cadherin cytoplasmic tail is sufficient to maintain cells in a mesenchymal state.	Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Cheresh, DA (corresponding author), Univ Calif San Diego, Moores Canc Ctr, 3855 Hlth Sci Dr 0803, La Jolla, CA 92093 USA.	dcheresh@ucsd.edu			NCI NIH HHS [CA45726, CA95262, CA78045, 5F32CA097885, CA50286] Funding Source: Medline; NEI NIH HHS [EY14174] Funding Source: Medline; NHLBI NIH HHS [HL57900] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA045726, F32CA097885, P01CA078045, R37CA050286, R01CA050286, R01CA095262] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R24EY014174] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL057900] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andriopoulou P, 1999, ARTERIOSCL THROM VAS, V19, P2286, DOI 10.1161/01.ATV.19.10.2286; Balsamo J, 1996, J CELL BIOL, V134, P801, DOI 10.1083/jcb.134.3.801; Berx G, 1995, EMBO J, V14, P6107, DOI 10.1002/j.1460-2075.1995.tb00301.x; Brunton VG, 2004, BBA-MOL CELL RES, V1692, P121, DOI 10.1016/j.bbamcr.2004.04.010; Burden-Gulley SM, 1999, J CELL BIOL, V144, P1323, DOI 10.1083/jcb.144.6.1323; Carmeliet P, 2000, ANN NY ACAD SCI, V902, P249; Cavallaro U, 2004, NAT REV CANCER, V4, P118, DOI 10.1038/nrc1276; Dejana E, 2000, INT J DEV BIOL, V44, P743; Dejana E, 1999, EXP CELL RES, V252, P13, DOI 10.1006/excr.1999.4601; Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X; Eliceiri BP, 2002, J CELL BIOL, V157, P149, DOI 10.1083/jcb.200109079; Esser S, 1998, J CELL SCI, V111, P1853; Ferber A, 2002, EXP CELL RES, V274, P35, DOI 10.1006/excr.2001.5436; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Handschuh G, 1999, ONCOGENE, V18, P4301, DOI 10.1038/sj.onc.1202790; Hazan RB, 2004, ANN NY ACAD SCI, V1014, P155, DOI 10.1196/annals.1294.016; Hicklin DJ, 2005, J CLIN ONCOL, V23, P1011, DOI 10.1200/JCO.2005.06.081; Iyer S, 2004, AM J PHYSIOL-LUNG C, V286, pL1143, DOI 10.1152/ajplung.00305.2003; Lambeng N, 2005, CIRC RES, V96, P384, DOI 10.1161/01.RES.0000156652.99586.9f; Lampugnani MG, 2002, MOL BIOL CELL, V13, P1175, DOI 10.1091/mbc.01-07-0368; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; Navarro P, 1998, J CELL BIOL, V140, P1475, DOI 10.1083/jcb.140.6.1475; Nawroth R, 2002, EMBO J, V21, P4885, DOI 10.1093/emboj/cdf497; Peinado HC, 2004, INT J DEV BIOL, V48, P365, DOI 10.1387/ijdb.041794hp; Perez-Moreno M, 2003, CELL, V112, P535, DOI 10.1016/S0092-8674(03)00108-9; Reynolds AB, 2004, ONCOGENE, V23, P7947, DOI 10.1038/sj.onc.1208161; Roura S, 1999, J BIOL CHEM, V274, P36734, DOI 10.1074/jbc.274.51.36734; Takeda H, 1995, J CELL BIOL, V131, P1839, DOI 10.1083/jcb.131.6.1839; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; Ukropec JA, 2000, J BIOL CHEM, V275, P5983, DOI 10.1074/jbc.275.8.5983; Verin AD, 2005, AM J PATHOL, V166, P955, DOI 10.1016/S0002-9440(10)62316-4; Vincent PA, 2004, AM J PHYSIOL-CELL PH, V286, pC987, DOI 10.1152/ajpcell.00522.2003; Weis S, 2004, J CELL BIOL, V167, P223, DOI 10.1083/jcb.200408130; Weis S, 2004, J CLIN INVEST, V113, P885, DOI 10.1172/JCI200420702; Wheelock MJ, 2003, CURR OPIN CELL BIOL, V15, P509, DOI 10.1016/S0955-0674(03)00101-7; Xiao KY, 2003, J CELL BIOL, V163, P535, DOI 10.1083/jcb.200306001; Xiao KY, 2003, J BIOL CHEM, V278, P19199, DOI 10.1074/jbc.M211746200; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Young BA, 2003, AM J PHYSIOL-LUNG C, V285, pL63, DOI 10.1152/ajplung.00423.2002	39	260	264	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	2005	280	36					31906	31912		10.1074/jbc.M505568200	http://dx.doi.org/10.1074/jbc.M505568200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	961LZ	16027153	hybrid			2022-12-25	WOS:000231665200070
J	Winayanuwattikun, P; Ketterman, AJ				Winayanuwattikun, P; Ketterman, AJ			An electron-sharing network involved in the catalytic mechanism is functionally conserved in different glutathione transferase classes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-CAPPING BOX; S-TRANSFERASE; ACTIVE-SITE; EVOLUTIONARY STRATEGIES; SUBSTRATE GLUTATHIONE; DIRECTED MUTAGENESIS; ENZYMATIC-PROPERTIES; CRYSTAL-STRUCTURE; PROTON RELEASE; T2-2 DISCLOSES	In Anopheles dirus glutathione transferase D3-3, there are electrostatic interactions between the negatively charged glutamyl alpha-carboxylate group of glutathione, the positively charged Arg-66, and the negatively charged Asp-100. This ionic interaction is stabilized by a network of hydrogen bonds from Ser-65, Thr-158, Thr-162, and a conserved water-mediated contact. This alternating ionic bridge interaction between negatively and positively charged residues stabilized by a network of hydrogen bonding we have named an electron-sharing network. We show that the electron- sharing network assists the glutamyl alpha-carboxylate of glutathione to function as a catalytic base accepting the proton from the thiol group forming an anionic glutathione, which is a crucial step in the glutathione transferase ( GST) catalysis. Kinetic studies demonstrate that the mutation of electron- sharing network residues results in a decreased ability to lower the pK(a) of the thiol group of glutathione. Although the residues that contribute to the electron- sharing network are not conserved in the primary sequence, structural characterizations indicate that the presence of the network can be mapped to the same region in all GST classes. A structural diversification but functional conservation suggests a significant role for the electron- sharing network in catalysis as the purpose was maintained during the divergent evolution of GSTs. This network appears to be a functionally conserved motif that contributes to the "base-assisted deprotonation" model suggested to be essential for the glutathione ionization step of the catalytic mechanism.	Mahidol Univ, Inst Mol Biol & Genet, Salaya 73170, Nakhon Pathom, Thailand	Mahidol University	Winayanuwattikun, P (corresponding author), Mahidol Univ, Inst Mol Biol & Genet, Salaya Campus,25-25 Putthamonthol,Rd 4, Salaya 73170, Nakhon Pathom, Thailand.	frakt@mahidol.ac.th						Aceto A, 1997, BIOCHEM J, V322, P229, DOI 10.1042/bj3220229; AHMAD H, 1990, ARCH BIOCHEM BIOPHYS, V278, P398, DOI 10.1016/0003-9861(90)90277-6; Allardyce CS, 1999, BIOCHEM J, V343, P525, DOI 10.1042/0264-6021:3430525; Armstrong RN, 1997, CHEM RES TOXICOL, V10, P2, DOI 10.1021/tx960072x; Armstrong RN, 2001, CHEM-BIOL INTERACT, V133, P167; BJORNESTEDT R, 1995, J MOL BIOL, V247, P765; Board PG, 1997, BIOCHEM J, V328, P929; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CACCURI AM, 1994, BIOCHEM BIOPH RES CO, V200, P1428, DOI 10.1006/bbrc.1994.1610; Caccuri AM, 2001, J BIOL CHEM, V276, P5427, DOI 10.1074/jbc.M002819200; Caccuri AM, 2001, J BIOL CHEM, V276, P5432, DOI 10.1074/jbc.M002818200; Caccuri AM, 1998, BIOCHEMISTRY-US, V37, P3028, DOI 10.1021/bi971903g; Caccuri AM, 1999, BIOCHEM J, V344, P419, DOI 10.1042/0264-6021:3440419; Caccuri AM, 1996, J BIOL CHEM, V271, P16193, DOI 10.1074/jbc.271.27.16193; Caccuri AM, 1997, J BIOL CHEM, V272, P29681, DOI 10.1074/jbc.272.47.29681; CHEN WJ, 1988, BIOCHEMISTRY-US, V27, P647, DOI 10.1021/bi00402a023; Dragani B, 1997, J BIOL CHEM, V272, P25518, DOI 10.1074/jbc.272.41.25518; Eaton DL, 1999, TOXICOL SCI, V49, P156, DOI 10.1093/toxsci/49.2.156; Gustafsson A, 2001, BIOCHEMISTRY-US, V40, P15835, DOI 10.1021/bi010429i; HABIG WH, 1974, J BIOL CHEM, V249, P7130; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; JAKOBY WB, 1980, ENZYMATIC BASIS DETO, V2, P63; Jirajaroenrat K, 2001, INSECT BIOCHEM MOLEC, V31, P867, DOI 10.1016/S0965-1748(01)00032-7; JOHNSON WW, 1993, J BIOL CHEM, V268, P11508; Ketterer B, 2001, CHEM-BIOL INTERACT, V138, P27, DOI 10.1016/S0009-2797(01)00277-0; KOLM RH, 1992, BIOCHEM J, V285, P537, DOI 10.1042/bj2850537; Kong GKW, 2003, J BIOL CHEM, V278, P1291, DOI 10.1074/jbc.M209581200; KONG KH, 1993, PROTEIN ENG, V6, P93, DOI 10.1093/protein/6.1.93; LIU SX, 1992, J BIOL CHEM, V267, P4296; MANNERVIK B, 1985, P NATL ACAD SCI USA, V82, P7202, DOI 10.1073/pnas.82.21.7202; MANNERVIK B, 1992, BIOCHEM J, V282, P305, DOI 10.1042/bj2820305; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; MANOHARAN TH, 1992, J BIOL CHEM, V267, P18940; MANOHARAN TH, 1992, J MOL BIOL, V226, P319, DOI 10.1016/0022-2836(92)90949-K; MEYER DJ, 1991, BIOCHEM J, V274, P409, DOI 10.1042/bj2740409; MOTOYAMA N, 1978, INSECT BIOCHEM, V8, P337, DOI 10.1016/0020-1790(78)90019-7; Nilsson LO, 2002, BBA-PROTEIN STRUCT M, V1597, P157; Oakley AJ, 2001, PROTEIN SCI, V10, P2176, DOI 10.1110/ps.21201; Pemble SE, 1996, BIOCHEM J, V319, P749, DOI 10.1042/bj3190749; PEMBLE SE, 1992, BIOCHEM J, V287, P957, DOI 10.1042/bj2870957; Rossjohn J, 2000, J MOL BIOL, V302, P295, DOI 10.1006/jmbi.2000.4054; Rossjohn J, 1998, STRUCTURE, V6, P309, DOI 10.1016/S0969-2126(98)00034-3; Sheehan D, 2001, BIOCHEM J, V360, P1, DOI 10.1042/0264-6021:3600001; Stenberg G, 2001, CHEM-BIOL INTERACT, V133, P49; STENBERG G, 1991, BIOCHEM J, V274, P549, DOI 10.1042/bj2740549; Tan KL, 1996, BIOCHEM J, V319, P315, DOI 10.1042/bj3190315; WIDERSTEIN M, 1992, BIOCHEM J, V285, P377, DOI 10.1042/bj2850377; Widersten M, 1996, BIOCHEMISTRY-US, V35, P7731, DOI 10.1021/bi9601619; WILCE MCJ, 1994, BBA-PROTEIN STRUCT M, V1205, P1, DOI 10.1016/0167-4838(94)90086-8; Winayanuwattikun P, 2004, BIOCHEM J, V382, P751, DOI 10.1042/BJ20040697; Wolf AV, 1985, HDB CHEM PHYSICS, pD; Wongtrakul J, 2003, INSECT BIOCHEM MOLEC, V33, P971, DOI 10.1016/S0965-1748(03)00103-6	52	52	52	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	2005	280	36					31776	31782		10.1074/jbc.M502612200	http://dx.doi.org/10.1074/jbc.M502612200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	961LZ	16012173	hybrid			2022-12-25	WOS:000231665200056
J	Landa, LR; Harbeck, M; Kaihara, K; Chepurny, O; Kitiphongspattana, K; Graf, O; Nikolaev, VO; Lohse, MJ; Holz, GG; Roe, MW				Landa, LR; Harbeck, M; Kaihara, K; Chepurny, O; Kitiphongspattana, K; Graf, O; Nikolaev, VO; Lohse, MJ; Holz, GG; Roe, MW			Interplay of Ca2+ and cAMP signaling in the insulin-secreting MIN6 beta-cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES; CA2+-INHIBITABLE ADENYLYL-CYCLASE; PLASMA-MEMBRANE CA2+-ATPASE; C6-2B GLIOMA-CELLS; PANCREATIC-ISLETS; NONEXCITABLE CELLS; EPAC ACTIVATION; CALCIUM; EXPRESSION; RELEASE	Ca2+ and cAMP are important second messengers that regulate multiple cellular processes. Although previous studies have suggested direct interactions between Ca2+ and cAMP signaling pathways, the underlying mechanisms remain unresolved. In particular, direct evidence for Ca2+-regulated cAMP production in living cells is incomplete. Genetically encoded fluorescence resonance energy transfer-based biosensors have made possible real-time imaging of spatial and temporal gradients of intracellular cAMP concentration in single living cells. Here, we used confocal microscopy, fluorescence resonance energy transfer, and insulin-secreting MIN6 cells expressing Epac1-camps, a biosynthetic unimolecular cAMP indicator, to better understand the role of intracellular Ca2+ in cAMP production. We report that depolarization with high external K+, tolbutamide, or glucose caused a rapid increase in cAMP that was dependent on extracellular Ca2+ and inhibited by nitrendipine, a Ca2+ channel blocker, or 2', 5'-dideoxyadenosine, a P-site antagonist of transmembrane adenylate cyclases. Stimulation of MIN6 cells with glucose in the presence of tetraethylammonium chloride generated concomitant Ca2+ and cAMP oscillations that were abolished in the absence of extracellular Ca2+ and blocked by 2', 5'-dideoxyadenosine or 3- isobutyl-1-methylxanthine, an inhibitor of phosphodiesterase. Simultaneous measurements of Ca2+ and cAMP concentrations with Fura-2 and Epac1-camps, respectively, revealed a close temporal and causal interrelationship between the increases in cytoplasmic Ca2+ and cAMP levels following membrane depolarization. These findings indicate highly coordinated interplay between Ca2+ and cAMP signaling in electrically excitable endocrine cells and suggest that Ca2+-dependent cAMP oscillations are derived from an increase in adenylate cyclase activity and periodic activation and inactivation of cAMP-hydrolyzing phosphodiesterase.	Univ Chicago, Dept Med, Chicago, IL 60637 USA; NYU, Sch Med, Dept Physiol & Neurosci, New York, NY 10016 USA; Univ Wurzburg, Inst Pharmacol & Toxicol, D-97078 Wurzburg, Germany	University of Chicago; New York University; University of Wurzburg	Roe, MW (corresponding author), Univ Chicago, Dept Med, MC-1027,5841 S Maryland Ave, Chicago, IL 60637 USA.	mroe@medicine.bsd.uchicago.edu	Holz, George G/A-3386-2012; Lohse, Martin J/A-7160-2012; Nikolaev, Vyacheslav/AAT-7746-2020	Lohse, Martin J/0000-0002-0599-3510; Holz, George/0000-0002-1781-3580; Kaihara, Kelly/0000-0002-1277-6418	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK064162, R01DK063493, R29DK045817, R21DK068822, R01DK045817] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK045817, R21 DK068822, DK63493, DK45817, DK68822, DK64162, R01 DK063493, R21 DK064162] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agnihotri N, 1997, J NEUROSCI RES, V47, P555, DOI 10.1002/(SICI)1097-4547(19970301)47:5<555::AID-JNR11>3.0.CO;2-X; Ang KL, 2002, J NEUROCHEM, V81, P422, DOI 10.1046/j.1471-4159.2002.00903.x; Antoni FA, 1997, TRENDS ENDOCRIN MET, V8, P7, DOI 10.1016/S1043-2760(96)00206-8; Beltran C, 1996, BIOCHEMISTRY-US, V35, P7591, DOI 10.1021/bi952806v; BOOKER G, 1973, SCIENCE, V182, P933; Bruce JIE, 2003, CELL CALCIUM, V34, P431, DOI 10.1016/S0143-4160(03)00150-7; Bruce JIE, 2002, J BIOL CHEM, V277, P48172, DOI 10.1074/jbc.M208393200; CHIONO M, 1995, J BIOL CHEM, V270, P1149, DOI 10.1074/jbc.270.3.1149; Cooper DMF, 2003, BIOCHEM J, V375, P517, DOI 10.1042/BJ20031061; COOPER DMF, 1995, NATURE, V374, P421, DOI 10.1038/374421a0; Cooper DMF, 1998, J BIOL CHEM, V273, P27703, DOI 10.1074/jbc.273.42.27703; Dean WL, 1997, J BIOL CHEM, V272, P15113, DOI 10.1074/jbc.272.24.15113; DeBernardi MA, 1996, P NATL ACAD SCI USA, V93, P4577, DOI 10.1073/pnas.93.10.4577; Delmeire D, 2003, DIABETOLOGIA, V46, P1383, DOI 10.1007/s00125-003-1203-8; DiPilato LM, 2004, P NATL ACAD SCI USA, V101, P16513, DOI 10.1073/pnas.0405973101; Dyer JL, 2005, J BIOL CHEM, V280, P8936, DOI 10.1074/jbc.M410045200; Fagan KA, 1998, J BIOL CHEM, V273, P9297, DOI 10.1074/jbc.273.15.9297; Fagan KA, 1996, J BIOL CHEM, V271, P12438, DOI 10.1074/jbc.271.21.12438; Goaillard JM, 2001, J PHYSIOL-LONDON, V530, P79, DOI 10.1111/j.1469-7793.2001.0079m.x; Goraya TA, 2004, J BIOL CHEM, V279, P40494, DOI 10.1074/jbc.M313441200; Gorbunova YV, 2002, NATURE, V418, P93, DOI 10.1038/nature00835; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Guenifi A, 2000, HISTOCHEM CELL BIOL, V113, P81, DOI 10.1007/s004180050010; Guillou JL, 1999, J BIOL CHEM, V274, P35539, DOI 10.1074/jbc.274.50.35539; Holz GG, 1999, J BIOL CHEM, V274, P14147, DOI 10.1074/jbc.274.20.14147; Houslay MD, 1997, TRENDS BIOCHEM SCI, V22, P217, DOI 10.1016/S0968-0004(97)01050-5; Hurley JH, 1999, J BIOL CHEM, V274, P7599, DOI 10.1074/jbc.274.12.7599; Kang GX, 2001, J PHYSIOL-LONDON, V536, P375, DOI 10.1111/j.1469-7793.2001.0375c.xd; KARL RC, 1975, J BIOL CHEM, V250, P4575; Leech CA, 1999, BIOCHEM BIOPH RES CO, V254, P703, DOI 10.1006/bbrc.1998.9906; Maeda M, 2004, SCIENCE, V304, P875, DOI 10.1126/science.1094647; Maurice DH, 2003, MOL PHARMACOL, V64, P533, DOI 10.1124/mol.64.3.533; Mehats C, 2002, TRENDS ENDOCRIN MET, V13, P29, DOI 10.1016/S1043-2760(01)00523-9; NAKADE S, 1994, J BIOL CHEM, V269, P6735; Nikolaev VO, 2004, J BIOL CHEM, V279, P37215, DOI 10.1074/jbc.C400302200; Palmer AE, 2004, P NATL ACAD SCI USA, V101, P17404, DOI 10.1073/pnas.0408030101; Ponsioen B, 2004, EMBO REP, V5, P1176, DOI 10.1038/sj.embor.7400290; Pyne NJ, 2003, DIABETOLOGIA, V46, P1179, DOI 10.1007/s00125-003-1176-7; RAPP PE, 1977, J THEOR BIOL, V66, P497, DOI 10.1016/0022-5193(77)90299-5; RASMUSSEN H, 1981, CALCIUM CAMP SYNARCH; Roe MW, 1996, J BIOL CHEM, V271, P32241, DOI 10.1074/jbc.271.50.32241; Roe MW, 1998, J BIOL CHEM, V273, P10402, DOI 10.1074/jbc.273.17.10402; ROOS W, 1977, NATURE, V266, P259, DOI 10.1038/266259a0; SCHULTZ JE, 1992, SCIENCE, V255, P600, DOI 10.1126/science.1371017; Tian YR, 2003, MOL CELL ENDOCRINOL, V204, P75, DOI 10.1016/S0303-7207(03)00126-6; VALVERDE I, 1979, SCIENCE, V206, P225, DOI 10.1126/science.225798; Zaccolo M, 2003, TRENDS NEUROSCI, V26, P53, DOI 10.1016/S0166-2236(02)00017-6	47	162	166	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	2005	280	35					31294	31302		10.1074/jbc.M505657200	http://dx.doi.org/10.1074/jbc.M505657200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	958ZX	15987680	Green Accepted, hybrid			2022-12-25	WOS:000231487800077
J	Wullschleger, S; Loewith, R; Oppliger, W; Hall, MN				Wullschleger, S; Loewith, R; Oppliger, W; Hall, MN			Molecular organization of target of rapamycin complex 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; CELL-GROWTH; ACTIN CYTOSKELETON; TRYPTOPHAN PERMEASE; BINDING PARTNER; MAMMALIAN TOR; YEAST; PATHWAY; NUTRIENT; RAPTOR	The target of rapamycin ( TOR), a highly conserved serine/ threonine kinase, plays a central role in the control of eukaryotic cell growth. TOR exists in two functionally and structurally distinct complexes, TOR complex 1 ( TORC1) and TOR complex 2 ( TORC2). TORC1 controls cell growth via a rapamycin- sensitive signaling branch regulating translation, transcription, nutrient uptake, ribosome biogenesis, and autophagy. TORC2 controls the organization of the actin cytoskeleton through a rapamycin- insensitive signaling branch and in yeast consists of the six proteins AVO1, AVO2, AVO3, BIT61, LST8, and TOR2. Here we have focused on the characterization of TORC2. Our studies suggest that TORC2 is oligomeric, likely a TORC2- TORC2 dimer. AVO1 and AVO3 bind cooperatively to the N- terminal HEAT repeat region in TOR2 and are required for TORC2 integrity. AVO2 is a nonessential peripheral protein associated with AVO1 and AVO3. LST8 binds separately to the C- terminal kinase domain region in TOR2 and appears to modulate both the integrity and kinase activity of TORC2. TORC2 autophosphorylates sites in AVO1 and AVO3, but TORC2 kinase activity is not required for TORC2 integrity. We have demonstrated that mammalian TOR is also oligomeric. The architecture of TORC2 is discussed in the context of TORC2 assembly and regulation.	Univ Basel, Biozentrum, Div Biochem, CH-4056 Basel, Switzerland	University of Basel	Hall, MN (corresponding author), Univ Basel, Biozentrum, Div Biochem, Klingelbergstr 70, CH-4056 Basel, Switzerland.	M.Hall@unibas.ch	Loewith, Robbie J/S-6289-2016	Loewith, Robbie J/0000-0002-2482-603X; Wullschleger, Stephan/0000-0002-5521-2276; Hall, Michael N/0000-0002-2998-0757				Alarcon CM, 1999, MOL BIOL CELL, V10, P2531, DOI 10.1091/mbc.10.8.2531; Audhya A, 2004, EMBO J, V23, P3747, DOI 10.1038/sj.emboj.7600384; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Beck T, 1999, J CELL BIOL, V146, P1227, DOI 10.1083/jcb.146.6.1227; Beeler T, 1998, J BIOL CHEM, V273, P30688, DOI 10.1074/jbc.273.46.30688; Bosotti R, 2000, TRENDS BIOCHEM SCI, V25, P225, DOI 10.1016/S0968-0004(00)01563-2; Butow RA, 2004, MOL CELL, V14, P1, DOI 10.1016/S1097-2765(04)00179-0; Chen EJ, 2003, J CELL BIOL, V161, P333, DOI 10.1083/jcb.200210141; Dennis PB, 2001, SCIENCE, V294, P1102, DOI 10.1126/science.1063518; Fingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Harris Thurl E, 2003, Sci STKE, V2003, pre15; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Heinisch JJ, 1999, MOL MICROBIOL, V32, P671, DOI 10.1046/j.1365-2958.1999.01375.x; Helliwell SB, 1998, CURR BIOL, V8, P1211, DOI 10.1016/S0960-9822(07)00511-8; HELLIWELL SB, 1994, MOL BIOL CELL, V5, P105, DOI 10.1091/mbc.5.1.105; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183; Jiang Y, 1999, EMBO J, V18, P2782, DOI 10.1093/emboj/18.10.2782; Kim DH, 2003, MOL CELL, V11, P895, DOI 10.1016/S1097-2765(03)00114-X; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Kunz J, 2000, J BIOL CHEM, V275, P37011, DOI 10.1074/jbc.M007296200; Liu ZC, 2001, EMBO J, V20, P7209, DOI 10.1093/emboj/20.24.7209; Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6; Loewith Robbie, 2004, VVolume 42, P139; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Martin DE, 2005, CURR OPIN CELL BIOL, V17, P158, DOI 10.1016/j.ceb.2005.02.008; Perry J, 2003, CELL, V112, P151, DOI 10.1016/S0092-8674(03)00033-3; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Reinke A, 2004, J BIOL CHEM, V279, P14752, DOI 10.1074/jbc.M313062200; Roberg KJ, 1997, GENETICS, V147, P1569; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Schmidt A, 1997, CELL, V88, P531, DOI 10.1016/S0092-8674(00)81893-0; Schmidt A, 1998, EMBO J, V17, P6924, DOI 10.1093/emboj/17.23.6924; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Wedaman KP, 2003, MOL BIOL CELL, V14, P1204, DOI 10.1091/mbc.E02-09-0609	36	182	192	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	2005	280	35					30697	30704		10.1074/jbc.M505553200	http://dx.doi.org/10.1074/jbc.M505553200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	958ZX	16002396	Green Accepted, hybrid			2022-12-25	WOS:000231487800008
J	Hastie, C; Saxton, M; Akpan, A; Cramer, R; Masters, JR; Naaby-Hansen, S				Hastie, C; Saxton, M; Akpan, A; Cramer, R; Masters, JR; Naaby-Hansen, S			Combined affinity labelling and mass spectrometry analysis of differential cell surface protein expression in normal and prostate cancer cells	ONCOGENE			English	Article						affinity labelling; mass spectrometry; cell surface proteins; prostate cancer; interferons; CD9	MEMBRANE PROTEINS; IDENTIFICATION; PROTEOMICS; ELECTROPHORESIS; MAP	Differences in the expression of cell surface proteins between a normal prostate epithelial (1542-NP2TX) and a prostate cancer cell line (1542-CP3TX) derived from the same patient were investigated. A combination of affinity chromatographic purification of biotin-tagged surface proteins with mass spectrometry analysis identified 26 integral membrane proteins and 14 peripheral surface proteins. The findings confirm earlier reports of altered expression in prostate cancer for several cell surface proteins, including ALCAM/CD166, the Ephrin type A receptor, EGFR and the prostaglandin F2 receptor regulatory protein. In addition, several novel findings of differential expression were made, including the voltage-dependent anion selective channel proteins Porin 1 and 2, ecto-5'-nucleotidase (CD73) and Scavenger receptor B1. Cell surface protein expression changed both qualitatively and quantitatively when the cells were grown in the presence of either or both interferon INF alpha and INF gamma. Costimulation with type I and II interferons had additive or synergistic effects on the membrane density of several, mainly peripherally attached surface proteins. Concerted upregulation of surface exposed antigens may be of benefit in immuno-adjuvant-based treatment of interferon-responsive prostate cancer. In conclusion, this study demonstrates that differences in the expression of membrane proteins between normal and prostate cancer cells are reproducibly detectable following vectorial labelling with biotin, and that detailed analysis of extracellular-induced surface changes can be achieved by combining surface-specific labelling with high-resolution two-dimensional gel electrophoresis and mass spectrometry.	Royal Free & UCL, Sch Med, Ludwig Inst Canc Res, London W1W 7BS, England; Royal Free & UCL, Sch Med, Prostate Canc Res Ctr, London W1W 7BS, England	Ludwig Institute for Cancer Research; University of London; University College London; UCL Medical School; University of London; University College London; UCL Medical School	Naaby-Hansen, S (corresponding author), Royal Free & UCL, Sch Med, Ludwig Inst Canc Res, 91 Riding House St, London W1W 7BS, England.	soren@ludwig.ucl.ac.uk	aukim-hastie, claire/A-7485-2011; Masters, John R/C-5694-2011	Cramer, Rainer/0000-0002-8037-2511	MRC [G0100116] Funding Source: UKRI; Medical Research Council [G0100116] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Bright RK, 1997, CANCER RES, V57, P995; Clauser KR, 1999, ANAL CHEM, V71, P2871, DOI 10.1021/ac9810516; Coonrod SA, 1999, DEV BIOL, V207, P334, DOI 10.1006/dbio.1998.9161; Gygi SP, 1999, NAT BIOTECHNOL, V17, P994, DOI 10.1038/13690; Hippler M, 2001, PLANT J, V28, P595, DOI 10.1046/j.1365-313X.2001.01175.x; HOCHSTRASSER DF, 1988, ANAL BIOCHEM, V173, P424, DOI 10.1016/0003-2697(88)90209-6; Jans R, 2004, ARCH DERMATOL RES, V296, P30, DOI 10.1007/s00403-004-0469-0; NaabyHansen S, 1997, BIOL REPROD, V56, P771, DOI 10.1095/biolreprod56.3.771; NAABYHANSEN S, 1990, J REPROD IMMUNOL, V17, P167, DOI 10.1016/0165-0378(90)90001-M; NAABYHANSEN S, 2003, PROSTATE CANC METHOD, V81, P277; Nagano K, 2004, ONCOGENE, V23, P1693, DOI 10.1038/sj.onc.1207297; Nouwens AS, 2000, ELECTROPHORESIS, V21, P3797, DOI 10.1002/1522-2683(200011)21:17<3797::AID-ELPS3797>3.0.CO;2-P; Ong SE, 2003, METHODS, V29, P124, DOI 10.1016/S1046-2023(02)00303-1; Page MJ, 1999, P NATL ACAD SCI USA, V96, P12589, DOI 10.1073/pnas.96.22.12589; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Quaranta S, 2001, ELECTROPHORESIS, V22, P1810, DOI 10.1002/1522-2683(200105)22:9&lt;1810::AID-ELPS1810&gt;3.0.CO;2-M; Righetti PG, 1997, J CHROMATOGR B, V699, P77, DOI 10.1016/S0378-4347(96)00151-X; Scadden ADJ, 2001, METHOD ENZYMOL, V341, P126, DOI 10.1016/S0076-6879(01)41149-9; Shetty J, 2001, ELECTROPHORESIS, V22, P3053, DOI 10.1002/1522-2683(200108)22:14<3053::AID-ELPS3053>3.0.CO;2-K; Zhao YX, 2004, ANAL CHEM, V76, P1817, DOI 10.1021/ac0354037	20	42	46	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	38					5905	5913		10.1038/sj.onc.1208747	http://dx.doi.org/10.1038/sj.onc.1208747			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960KW	16007208				2022-12-25	WOS:000231590400013
J	Hsieh, SY; Chen, WY; Yeh, TS; Sheen, IS; Huang, SF				Hsieh, SY; Chen, WY; Yeh, TS; Sheen, IS; Huang, SF			High-frequency Alu-mediated genomic recombination/deletion within the caspase-activated DNase gene in human hepatoma	ONCOGENE			English	Article						DNA fragmentation factor B; CAPN; caspase-activated Dnase; CAD; Alu repetitive elements; hepatoma	CHROMATIN CONDENSATION; REPEATS; INHIBITOR; REARRANGEMENTS; FRAGMENTATION; NEUROBLASTOMA; SEQUENCES; ELEMENTS; HETEROZYGOSITY; TUMORIGENICITY	The Alu repetitive elements, which constitute 10% of human genome, may serve as bridges for genomic recombination. However, their roles in tumorigenesis remain to be elucidated. Caspase-activated DNase (CAD), whose gene (hCAD) is mapped at chromosome 1p36, a region frequently displaying hemizygote deletion in many human cancers, is the key enzyme for nucleosome fragmentation during apoptosis. Recently, we detected many aberrant mRNAs for hCAD in many human hepatoma cells. To elucidate the genetic basis leading to the mRNA aberration, we used PCR-based chromosome walking to clone the corresponding genomic DNA identifying a novel Alu/Alu homologous recombination/ deletion within hCAD in HepG2 and Hep3B cells. We then detected similar recombination events in 13 out of the 20 hepatoma tissues and in eight of the para-cancerous cirrhotic livers. The recombination was inclined to occur in males (P = 0.031) and had marginal association with high-grade hepatoma (P = 0.070) and tumor recurrence (P = 0.070). The recombination caused exon-3 deletion, which in turn led to exon-3 skipping or replacement with a partial Alu-sequence, and consequential C-truncation of CAD. Our findings of high frequency of Alu-mediated hCAD deletion in human hepatoma not only underscore the implication of hCAD in hepatocarcinogenesis, but also highlight the potential roles of human repetitive sequences in mediating genome instability in human cancers.	Chang Gung Mem Hosp, Liver Res Unit, Taoyuan 333, Taiwan; Chang Gung Mem Hosp, Clin Proteom Ctr, Taoyuan 333, Taiwan; Chang Gung Mem Hosp, Sch Med, Dept Microbiol & Immunol, Taoyuan 333, Taiwan; Chang Gung Mem Hosp, Dept Gen Surg, Taoyuan 333, Taiwan; Natl Hlth Res Inst, Div Mol & Genom Med, Taipei 115, Taiwan	Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; National Health Research Institutes - Taiwan	Hsieh, SY (corresponding author), Chang Gung Mem Hosp, Liver Res Unit, 5 Fu Hsin Rd, Taoyuan 333, Taiwan.	siming@adm.cgmh.org.tw	Huang, Shiu-Feng Kathy/E-3977-2010					BADER SA, 1991, CELL GROWTH DIFFER, V2, P245; Batzer MA, 2002, NAT REV GENET, V3, P370, DOI 10.1038/nrg798; CHEN SJ, 1989, NUCLEIC ACIDS RES, V17, P7631, DOI 10.1093/nar/17.19.7631; CHENG NC, 1995, ONCOGENE, V10, P291; Deininger PL, 1999, MOL GENET METAB, V67, P183, DOI 10.1006/mgme.1999.2864; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Halenbeck R, 1998, CURR BIOL, V8, P537, DOI 10.1016/S0960-9822(98)79298-X; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hsieh SY, 1997, P NATL ACAD SCI USA, V94, P3206, DOI 10.1073/pnas.94.7.3206; Hsieh SY, 2003, BRIT J CANCER, V88, P210, DOI 10.1038/sj.bjc.6600695; Jeffs AR, 1998, HUM MOL GENET, V7, P767, DOI 10.1093/hmg/7.5.767; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kolomietz E, 2001, BLOOD, V97, P3581, DOI 10.1182/blood.V97.11.3581; KUROKI T, 1995, GENE CHROMOSOME CANC, V13, P163, DOI 10.1002/gcc.2870130305; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LEHRMAN MA, 1987, J BIOL CHEM, V262, P3354; Lin CH, 2001, CANCER RES, V61, P4238; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Lobachev KS, 2000, EMBO J, V19, P3822, DOI 10.1093/emboj/19.14.3822; Mighell AJ, 1997, FEBS LETT, V417, P1, DOI 10.1016/S0014-5793(97)01259-3; Mukae N, 1998, P NATL ACAD SCI USA, V95, P9123, DOI 10.1073/pnas.95.16.9123; Nagai H, 1997, ONCOGENE, V14, P2927, DOI 10.1038/sj.onc.1201136; Nagase H, 2003, CELL DEATH DIFFER, V10, P142, DOI 10.1038/sj.cdd.4401139; Nagata S, 2003, CELL DEATH DIFFER, V10, P108, DOI 10.1038/sj.cdd.4401161; Rohlfs EM, 2000, GENE CHROMOSOME CANC, V28, P300, DOI 10.1002/1098-2264(200007)28:3<300::AID-GCC8>3.0.CO;2-1; Rowold DJ, 2000, GENETICA, V108, P57, DOI 10.1023/A:1004099605261; RUDIGER NS, 1995, NUCLEIC ACIDS RES, V23, P256, DOI 10.1093/nar/23.2.256; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Schmid CW, 1996, PROG NUCLEIC ACID RE, V53, P283, DOI 10.1016/S0079-6603(08)60148-8; SIMON D, 1991, ONCOGENE, V6, P765; Smit AFA, 1999, CURR OPIN GENET DEV, V9, P657, DOI 10.1016/S0959-437X(99)00031-3; Stenger JE, 2001, GENOME RES, V11, P12, DOI 10.1101/gr.158801; STOPPALYONNET D, 1990, P NATL ACAD SCI USA, V87, P1551, DOI 10.1073/pnas.87.4.1551; TANAKA K, 1993, ONCOGENE, V8, P2253; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Yeh SH, 2001, GASTROENTEROLOGY, V121, P699, DOI 10.1053/gast.2001.27211; Zhang JH, 1998, P NATL ACAD SCI USA, V95, P12480, DOI 10.1073/pnas.95.21.12480	38	28	30	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	43					6584	6589		10.1038/sj.onc.1208803	http://dx.doi.org/10.1038/sj.onc.1208803			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	968ZV	16007181				2022-12-25	WOS:000232204100012
J	Zhu, YH; Denhardt, DT; Cao, HB; Sutphin, PD; Koong, AC; Giaccia, AJ; Le, QT				Zhu, YH; Denhardt, DT; Cao, HB; Sutphin, PD; Koong, AC; Giaccia, AJ; Le, QT			Hypoxia upregulates osteopontin expression in NIH-3T3 cells via a ras-activated enhancer	ONCOGENE			English	Article						Akt; hypoxia; osteopontin; ras; regulation	ENDOTHELIAL GROWTH-FACTOR; SOLID TUMORS; GENE-EXPRESSION; MESSENGER-RNA; SECRETED PHOSPHOPROTEIN; TRANSCRIPTION FACTOR; TRANSFORMED-CELLS; SIGNALING PATHWAY; CANCER-THERAPY; PROTEIN	Osteopontin (OPN) is a secreted phosphoglycoprotein that has been linked to tumor progression and survival in several solid tumors, including head and neck cancers. Previous studies showed that OPN expression is induced by tumor hypoxia, and its plasma levels can serve as a surrogate marker for tumor hypoxia and treatment outcome in head and neck cancer patients. In this study, we investigate the transcriptional mechanism by which hypoxia enhances OPN expression. We found that OPN is induced in head and neck squamous cell carcinoma (HNSCC) cell lines and in NIH3T3 cells by hypoxia at both mRNA and protein levels in a time-dependent manner. Actinomycin D chase experiments showed that hypoxic induction of OPN was not due to increased mRNA stability. Deletion analyses of the mouse OPN promoter regions indicated that a ras-activated enhancer (RAE) located at -731 to -712 relative to the transcription start site was essential for hypoxia-enhanced OPN transcription. Using electrophoretic mobility shift assays with the RAE DNA sequence, we found that hypoxia induced sequence-specific DNA-binding complexes. Furthermore, hypoxia and ras exposure resulted in an additive induction of OPN protein and mRNA levels that appeared to be mediated by the RAE. Induction of OPN through the RAE element by hypoxia is mediated by an Akt-kinase signaled pathway as decreasing Akt levels with dominant negative constructs resulted in inhibition of OPN induction by hypoxia. Taken together, these results have identified a new hypoxia responsive transcriptional enhancer that is regulated by Akt signaling.	Stanford Univ, Dept Radiat Oncol, Stanford, CA 94305 USA; Rutgers State Univ, Dept Cell Biol & Neurosci, Piscataway, NJ 08855 USA	Stanford University; Rutgers State University New Brunswick	Le, QT (corresponding author), Stanford Univ, Dept Radiat Oncol, 875 Blake Wilbur Dr,R CC-G228, Stanford, CA 94305 USA.	qle@stanford.edu		Le, Quynh Thu/0000-0002-3682-1439; Koong, Albert/0000-0001-9824-1643	NATIONAL CANCER INSTITUTE [P01CA067166] Funding Source: NIH RePORTER; NCI NIH HHS [CA 67166] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUSSERER WA, 1994, MOL CELL BIOL, V14, P5032, DOI 10.1128/MCB.14.8.5032; Bedogni B, 2004, CANCER RES, V64, P2552, DOI 10.1158/0008-5472.CAN-03-3327; Brizel DM, 1996, CANCER RES, V56, P5347; Brown JM, 1998, CANCER RES, V58, P1408; CHAMBERS AF, 1992, ANTICANCER RES, V12, P43; Chan DA, 2002, J BIOL CHEM, V277, P40112, DOI 10.1074/jbc.M206922200; CHOI HS, 1990, J BIOL CHEM, V265, P18005; CRAIG AM, 1990, INT J CANCER, V46, P133, DOI 10.1002/ijc.2910460124; CRAIG AM, 1989, J BIOL CHEM, V264, P9682; DENHARDT DT, 1993, FASEB J, V7, P1475, DOI 10.1096/fasebj.7.15.8262332; Denhardt DT, 2003, CLIN EXP METASTAS, V20, P77, DOI 10.1023/A:1022550721404; Denhardt DT, 2001, ANNU REV PHARMACOL, V41, P723, DOI 10.1146/annurev.pharmtox.41.1.723; Denhardt DT, 2001, J CLIN INVEST, V107, P1055, DOI 10.1172/JCI12980; DENHARDT DT, 1995, ANN NY ACAD SCI, V760, P27142; Denko NC, 2003, ONCOGENE, V22, P5907, DOI 10.1038/sj.onc.1206703; Ebert BL, 1998, MOL CELL BIOL, V18, P4089, DOI 10.1128/MCB.18.7.4089; Furger Kara A., 2001, Current Molecular Medicine (Hilversum), V1, P621, DOI 10.2174/1566524013363339; Giaccia A, 2003, NAT REV DRUG DISCOV, V2, P803, DOI 10.1038/nrd1199; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GUO XJ, 1995, MOL CELL BIOL, V15, P476, DOI 10.1128/MCB.15.1.476; Hammond EM, 2002, MOL CELL BIOL, V22, P1834, DOI 10.1128/MCB.22.6.1834-1843.2002; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; HARROLD S, 1991, ANAL BIOCHEM, V198, P19, DOI 10.1016/0003-2697(91)90500-S; HIJIYA N, 1994, BIOCHEM J, V303, P255, DOI 10.1042/bj3030255; Hockel M, 1996, CANCER RES, V56, P4509; HUANG LE, 1994, J BIOL CHEM, V269, P30718; HWANG SM, 1994, J CELL PHYSIOL, V160, P61, DOI 10.1002/jcp.1041600108; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Koong AC, 2000, CANCER RES, V60, P883; Koszewski NJ, 1996, J STEROID BIOCHEM, V59, P377, DOI 10.1016/S0960-0760(96)00127-6; Le QT, 2003, CLIN CANCER RES, V9, P59; Le QT, 2004, CANCER METAST REV, V23, P293, DOI 10.1023/B:CANC.0000031768.89246.d7; Liaw L, 1998, J CLIN INVEST, V101, P1468; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Mazure NM, 1997, BLOOD, V90, P3322, DOI 10.1182/blood.V90.9.3322; NODA M, 1990, P NATL ACAD SCI USA, V87, P9995, DOI 10.1073/pnas.87.24.9995; Noiri E, 1999, KIDNEY INT, V56, P74, DOI 10.1046/j.1523-1755.1999.00526.x; Pollmann C, 2001, CANCER RES, V61, P8416; Sodhi CP, 2001, DIABETES, V50, P1482, DOI 10.2337/diabetes.50.6.1482; Sodhi CP, 2000, KIDNEY INT, V58, P691, DOI 10.1046/j.1523-1755.2000.00215.x; TEICHER BA, 1990, CANCER RES, V50, P3339; Teramoto H, 2003, ONCOGENE, V22, P2689, DOI 10.1038/sj.onc.1206364; Vaupel P, 2001, MED ONCOL, V18, P243, DOI 10.1385/MO:18:4:243; Weber Georg F., 1996, Cytokine and Growth Factor Reviews, V7, P241, DOI 10.1016/S1359-6101(96)00030-5; Weber GF, 2001, BBA-REV CANCER, V1552, P61, DOI 10.1016/S0304-419X(01)00037-3; Xie YS, 2001, KIDNEY INT, V60, P1645, DOI 10.1046/j.1523-1755.2001.00032.x; YOUNG SD, 1990, JNCI-J NATL CANCER I, V82, P371, DOI 10.1093/jnci/82.5.371; Zhang GX, 2003, MOL CELL BIOL, V23, P6507, DOI 10.1128/MCB.23.18.6507-6519.2003; Zhu Y, 2002, NEUROSCIENCE, V110, P191, DOI 10.1016/S0306-4522(01)00522-X; Zhu YH, 2002, CELL GROWTH DIFFER, V13, P431; Zhu YH, 1999, BIOCHEM BIOPH RES CO, V258, P87, DOI 10.1006/bbrc.1999.0586; Zhu YH, 2003, STROKE, V34, P2483, DOI 10.1161/01.STR.0000088644.60368.ED	52	58	61	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	43					6555	6563		10.1038/sj.onc.1208800	http://dx.doi.org/10.1038/sj.onc.1208800			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	968ZV	16007184				2022-12-25	WOS:000232204100009
J	Eisenhauer, HA; Shames, S; Pawelek, PD; Coulton, JW				Eisenhauer, HA; Shames, S; Pawelek, PD; Coulton, JW			Siderophore transport through Escherichia coli outer membrane receptor FhuA with disulfide-tethered cork and barrel domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FERRICHROME-IRON RECEPTOR; HUMAN P-GLYCOPROTEIN; CROSS-LINKING; IN-VIVO; OXALOBACTER-FORMIGENES; COBALAMIN TRANSPORTER; CONFORMATIONAL-CHANGE; CRYSTAL-STRUCTURE; BOUND-STATES; PROTEIN	The hydroxamate siderophore receptor FhuA is a TonB-dependent outer membrane protein of Escherichia coli composed of a C-terminal 22-stranded beta-barrel occluded by an N-terminal globular cork domain. During siderophore transport into the periplasm, the FhuA cork domain has been proposed to undergo conformational changes that allow transport through the barrel lumen; alternatively, the cork may be completely displaced from the barrel. To probe such changes, site-directed cysteine mutants in the cork domain ( L109C and Q112C) and in the barrel domain ( S356C and M383C) were created within the putative siderophore transport pathway. Molecular modeling predicted that the double cysteine mutants L109C/S356C and Q112C/M383C would form disulfide bonds, thereby tethering the cork and barrel domains. The double cysteine FhuA mutants were denatured under nonreducing conditions and fluorescently labeled with thiol-specific Oregon Green maleimide. Subsequent SDS-PAGE analysis revealed two distinct species: FhuA containing a disulfide bond and FhuA with free sulfhydryl groups. To address the role of the putative siderophore transport pathway and to evaluate possible rearrangements of the cork domain during ferricrocin transport, disulfide bond formation was enhanced by an oxidative catalyst. Cells containing double cysteine FhuA mutants that were subjected to oxidation during ferricrocin transport exhibited disulfide bond formation to near completion. After disulfide tethering of the cork to the barrel, ferricrocin transport was equivalent to transport by untreated cells. These results demonstrate that blocking the putative siderophore transport pathway does not abrogate ferricrocin uptake. We propose that, during siderophore transport through FhuA, the cork domain remains within the barrel rather than being displaced.	McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3A 2B4, Canada	McGill University	Coulton, JW (corresponding author), McGill Univ, Dept Microbiol & Immunol, Rm 403,3775 Univ St, Montreal, PQ H3A 2B4, Canada.	james.coulton@mcgill.ca	Pawelek, Peter/E-7950-2014	Pawelek, Peter/0000-0002-8361-6593				Aziz QH, 2002, J BIOL CHEM, V277, P42719, DOI 10.1074/jbc.M207258200; Bonhivers M, 2001, BIOCHEMISTRY-US, V40, P2606, DOI 10.1021/bi001725i; Bos C, 1997, FEMS MICROBIOL LETT, V153, P311; Braun M, 1999, MOL MICROBIOL, V33, P1037, DOI 10.1046/j.1365-2958.1999.01546.x; Braun V, 2002, FEBS LETT, V529, P78, DOI 10.1016/S0014-5793(02)03185-X; Buchanan SK, 1999, NAT STRUCT BIOL, V6, P56; Cadieux N, 1999, P NATL ACAD SCI USA, V96, P10673, DOI 10.1073/pnas.96.19.10673; CHERVITZ SA, 1995, J BIOL CHEM, V270, P24043, DOI 10.1074/jbc.270.41.24043; Chimento DP, 2003, NAT STRUCT BIOL, V10, P394, DOI 10.1038/nsb914; COULTON JW, 1983, J BACTERIOL, V156, P1315, DOI 10.1128/JB.156.3.1315-1321.1983; Endriss F, 2003, J BACTERIOL, V185, P4683, DOI 10.1128/JB.185.16.4683-4692.2003; FADRUS H, 1975, ANALYST, V100, P549, DOI 10.1039/an9750000549; Faraldo-Gomez JD, 2003, BIOPHYS J, V85, P1406, DOI 10.1016/S0006-3495(03)74573-1; Ferguson AD, 2004, CELL, V116, P15, DOI 10.1016/S0092-8674(03)01030-4; Ferguson AD, 1998, SCIENCE, V282, P2215, DOI 10.1126/science.282.5397.2215; Fu DX, 2001, J BIOL CHEM, V276, P8753, DOI 10.1074/jbc.M008417200; HANTKE K, 1981, MOL GEN GENET, V182, P288, DOI 10.1007/BF00269672; HAZES B, 1988, PROTEIN ENG, V2, P119, DOI 10.1093/protein/2.2.119; Hughson AG, 1996, P NATL ACAD SCI USA, V93, P11546, DOI 10.1073/pnas.93.21.11546; Klebba PE, 2003, FRONT BIOSCI, V8, pS1422, DOI 10.2741/1233; Larsen RA, 2003, MOL MICROBIOL, V49, P211, DOI 10.1046/j.1365-2958.2003.03579.x; Locher KP, 1998, CELL, V95, P771, DOI 10.1016/S0092-8674(00)81700-6; Loo TW, 2004, J BIOL CHEM, V279, P18232, DOI 10.1074/jbc.M400229200; Loo TW, 2004, J BIOL CHEM, V279, P7692, DOI 10.1074/jbc.M311825200; MOECK GS, 1995, J BACTERIOL, V177, P6118, DOI 10.1128/jb.177.21.6118-6125.1995; Moeck GS, 1996, MOL MICROBIOL, V22, P459, DOI 10.1046/j.1365-2958.1996.00112.x; Postle K, 2003, MOL MICROBIOL, V49, P869, DOI 10.1046/j.1365-2958.2003.03629.x; Scott DC, 2001, J BIOL CHEM, V276, P13025, DOI 10.1074/jbc.M011282200; Usher KC, 2001, P NATL ACAD SCI USA, V98, P10676, DOI 10.1073/pnas.181353398; Van Gelder P, 2002, J BACTERIOL, V184, P2994, DOI 10.1128/JB.184.11.2994-2999.2002; Ye LW, 2001, J BACTERIOL, V183, P2490, DOI 10.1128/JB.183.8.2490-2496.2001	31	45	45	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	2005	280	34					30574	30580		10.1074/jbc.M506708200	http://dx.doi.org/10.1074/jbc.M506708200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	957IC	15994322	Green Accepted, hybrid			2022-12-25	WOS:000231362500073
J	Galkin, A; Brandt, U				Galkin, A; Brandt, U			Superoxide radical formation by pure complex I (NADH : Ubiquinone oxidoreductase) from Yarrowia lipolytica	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEART SUBMITOCHONDRIAL PARTICLES; IRON-SULFUR CENTERS; ADENINE-DINUCLEOTIDE; HYDROGEN-PEROXIDE; CYTOCHROME-C; CONFORMATIONAL-CHANGE; OXIDATION-REDUCTION; RESPIRATORY-CHAIN; ELECTRON-TRANSFER; REDUCED FLAVINS	Generation of reactive oxygen species (ROS) is increasingly recognized as an important cellular process involved in numerous physiological and pathophysiological processes. Complex I ( NADH: ubiquinone oxidoreductase) is considered as one of the major sources of ROS within mitochondria. Yet, the exact site and mechanism of superoxide production by this large membrane-bound multiprotein complex has remained controversial. Here we show that isolated complex 1 from Yarrowia lipolytica forms superoxide at a rate of 0.15% of the rate measured for catalytic turnover. Superoxide production is not inhibited by ubiquinone analogous inhibitors. Because mutant complex I lacking a detectable iron-sulfur cluster N2 exhibited the same rate of ROS production, this terminal redox center could be excluded as a source of electrons. From the effect of different ubiquinone derivatives and pH on this side reaction of complex I we concluded that oxygen accepts electrons from FMNH2 or FMN semiquinone either directly or via more hydrophilic ubiquinone derivatives.	Goethe Univ Frankfurt, Zentrum Biol Chem, Fac Med, D-60590 Frankfurt, Germany	Goethe University Frankfurt	Brandt, U (corresponding author), Goethe Univ Frankfurt, Zentrum Biol Chem, Fac Med, Theodor Stern Kai 7,Haus 26, D-60590 Frankfurt, Germany.	brandt@zbc.kgu.de	Brandt, Ulrich/GLV-1242-2022; Brandt, Ulrich/C-4406-2008	Brandt, Ulrich/0000-0003-1869-6811; Brandt, Ulrich/0000-0003-1869-6811				Ahlers PM, 2000, J BIOL CHEM, V275, P23577, DOI 10.1074/jbc.M002074200; BALLOU D, 1969, BIOCHEM BIOPH RES CO, V36, P898, DOI 10.1016/0006-291X(69)90288-5; BEHAR D, 1970, J PHYS CHEM-US, V74, P3209, DOI 10.1021/j100711a009; Bottcher B, 2002, J BIOL CHEM, V277, P17970, DOI 10.1074/jbc.M112357200; BOVERIS A, 1975, FEBS LETT, V54, P311, DOI 10.1016/0014-5793(75)80928-8; BOVERIS A, 1984, METHOD ENZYMOL, V105, P429; Brandt U, 2003, FEBS LETT, V545, P9, DOI 10.1016/S0014-5793(03)00387-9; BUNIK V, 1995, FEBS LETT, V371, P167, DOI 10.1016/0014-5793(95)00904-N; CADENAS E, 1977, ARCH BIOCHEM BIOPHYS, V180, P248, DOI 10.1016/0003-9861(77)90035-2; Drose S, 2002, BBA-BIOENERGETICS, V1556, P65, DOI 10.1016/S0005-2728(02)00307-9; Eschemann A, 2005, J BIOL CHEM, V280, P3138, DOI 10.1074/jbc.M411217200; Faig M, 2000, P NATL ACAD SCI USA, V97, P3177, DOI 10.1073/pnas.050585797; FORMAN HJ, 1973, ARCH BIOCHEM BIOPHYS, V158, P396, DOI 10.1016/0003-9861(73)90636-X; Galkin AS, 1999, FEBS LETT, V451, P157, DOI 10.1016/S0014-5793(99)00575-X; Genova ML, 2001, FEBS LETT, V505, P364, DOI 10.1016/S0014-5793(01)02850-2; Grgic L, 2004, J BIOL CHEM, V279, P21193, DOI 10.1074/jbc.M313180200; Hasegawa T, 2004, BBA-GEN SUBJECTS, V1670, P19, DOI 10.1016/j.bbagen.2003.10.008; Hatefi Y, 1967, METHOD ENZYMOL, V10, P235; Herrero A, 2000, J BIOENERG BIOMEMBR, V32, P609, DOI 10.1023/A:1005626712319; HINKLE PC, 1967, J BIOL CHEM, V242, P5169; Hirst J, 2003, BBA-BIOENERGETICS, V1604, P135, DOI 10.1016/S0005-2728(03)00059-8; INGLEDEW WJ, 1980, BIOCHEM J, V186, P111, DOI 10.1042/bj1860111; KAKINUMA K, 1978, BIOCHIM BIOPHYS ACTA, V538, P50, DOI 10.1016/0304-4165(78)90251-9; Kashani-Poor N, 2001, BBA-BIOENERGETICS, V1504, P363, DOI 10.1016/S0005-2728(00)00266-8; Kerscher SJ, 1999, J CELL SCI, V112, P2347; Korshunov SS, 1997, FEBS LETT, V416, P15, DOI 10.1016/S0014-5793(97)01159-9; KOTLYAR AB, 1990, BIOCHIM BIOPHYS ACTA, V1019, P151, DOI 10.1016/0005-2728(90)90137-S; KRISHNAMOORTHY G, 1988, J BIOL CHEM, V263, P17566; Kushnareva Y, 2002, BIOCHEM J, V368, P545, DOI 10.1042/BJ20021121; Kwong LK, 1998, ARCH BIOCHEM BIOPHYS, V350, P118, DOI 10.1006/abbi.1997.0489; Lambert AJ, 2004, J BIOL CHEM, V279, P39414, DOI 10.1074/jbc.M406576200; Liu YB, 2002, J NEUROCHEM, V80, P780, DOI 10.1046/j.0022-3042.2002.00744.x; LOWE HJ, 1956, J BIOL CHEM, V221, P983; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Magnitsky S, 2002, J BIOENERG BIOMEMBR, V34, P193, DOI 10.1023/A:1016083419979; MAJANDER A, 1994, J BIOL CHEM, V269, P21037; Mamedova AA, 2004, J BIOL CHEM, V279, P23830, DOI 10.1074/jbc.M401539200; MASSEY V, 1969, BIOCHEM BIOPH RES CO, V36, P891, DOI 10.1016/0006-291X(69)90287-3; MCCORD JM, 1968, J BIOL CHEM, V243, P5753; McLennan HR, 2000, J BIOENERG BIOMEMBR, V32, P153, DOI 10.1023/A:1005507913372; MISRA HP, 1972, J BIOL CHEM, V247, P188; Muller FL, 2004, J BIOL CHEM, V279, P49064, DOI 10.1074/jbc.M407715200; Ohnishi ST, 2005, J BIOENERG BIOMEMBR, V37, P1, DOI 10.1007/s10863-005-4117-y; Ohnishi T, 2005, FEBS LETT, V579, P500, DOI 10.1016/j.febslet.2004.11.107; Okun JG, 1999, J BIOL CHEM, V274, P2625, DOI 10.1074/jbc.274.5.2625; RAGAN CI, 1977, BIOCHEM J, V163, P605, DOI 10.1042/bj1630605; RAGAN CI, 1975, J BIOL CHEM, V250, P8472; Raha S, 2000, FREE RADICAL BIO MED, V29, P170, DOI 10.1016/S0891-5849(00)00338-5; Raha S, 2000, TRENDS BIOCHEM SCI, V25, P502, DOI 10.1016/S0968-0004(00)01674-1; Sun H, 2003, ARCH BIOCHEM BIOPHYS, V419, P198, DOI 10.1016/j.abb.2003.08.028; Taille C, 2005, J BIOL CHEM, V280, P25350, DOI 10.1074/jbc.M503512200; TAKESHIGE K, 1979, BIOCHEM J, V180, P129, DOI 10.1042/bj1800129; Trimmer BA, 2001, SCIENCE, V292, P2486, DOI 10.1126/science.1059833; TURRENS JF, 1980, BIOCHEM J, V191, P421, DOI 10.1042/bj1910421; VALLIN I, 1964, BIOCHIM BIOPHYS ACTA, V92, P446, DOI 10.1016/0926-6569(64)90004-5; WIKSTROM M, 1984, FEBS LETT, V169, P300, DOI 10.1016/0014-5793(84)80338-5; Yamaguchi M, 1998, J BIOL CHEM, V273, P8094, DOI 10.1074/jbc.273.14.8094	57	131	134	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	2005	280	34					30129	30135		10.1074/jbc.M504709200	http://dx.doi.org/10.1074/jbc.M504709200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	957IC	15985426	hybrid			2022-12-25	WOS:000231362500019
J	Guo, JJ; Chu, M; Abbeyquaye, T; Chen, CY				Guo, JJ; Chu, M; Abbeyquaye, T; Chen, CY			Persistent nicotine treatment potentiates amplification of the dihydrofolate reductase gene in rat lung epithelial cells as a consequence of Ras activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENOMIC INSTABILITY; P53 FUNCTION; RECEPTOR EXPRESSION; CYCLE CONTROL; PROTEIN; CANCER; APOPTOSIS; GROWTH; PATHWAY; INDUCE	Although nicotine has been suggested to promote lung carcinogenesis, the mechanism of its action in this process remains unknown. The present investigation demonstrates that the treatment of rat lung epithelial cells with nicotine for various periods differentially mobilizes multiple intracellular pathways. Protein kinase C and phosphoinositide 3-OH-kinase are transiently activated after the treatment. Also, Ras and its downstream effector ERK1/2 are activated after long term exposure to nicotine. The activation of Ras by nicotine treatment is responsible for the subsequent perturbation of the methotrexate ( MTX)-mediated G(1) cell cycle restriction as well as an increase in production of reactive oxygen species. When p53 expression is suppressed by introducing E6, persistent exposure to nicotine enables dihydrofolate reductase gene amplification in the presence of methotrexate ( MTX) and the formation of the MTX-resistant colonies. Altering the activity of phosphoinositide 3-OH-kinase has no effect on dihydrofolate reductase amplification. However, the suppression of protein kinase C dramatically affects the colony formation in soft agar. Thus, our data suggest that persistent exposure to nicotine perturbs the G1 checkpoint and causes DNA damage through the increase of the production of reactive oxygen species. However, a third element rendered by loss of p53 is required for the initiation of the process of gene amplification. Under p53-deficient conditions, the establishment of a full oncogenic transformation, in response to long term nicotine exposure, is achieved through the cooperation of multiple signaling pathways.	Boston Univ, Sch Med, Dept Pathol, Canc Res Ctr, Boston, MA 02118 USA	Boston University	Chen, CY (corresponding author), Boston Univ, Sch Med, Dept Pathol, Canc Res Ctr, K522,80 E Concord St, Boston, MA 02118 USA.	yanyan@bu.edu			NATIONAL CANCER INSTITUTE [R01CA100498] Funding Source: NIH RePORTER; NCI NIH HHS [1R01CA100498] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Azzoli CG, 1998, MOL CARCINOGEN, V21, P50, DOI 10.1002/(SICI)1098-2744(199801)21:1<50::AID-MC7>3.0.CO;2-T; BOS JL, 1989, CANCER RES, V49, P4682; Brognard J, 2001, CANCER RES, V61, P3986; BROWN PC, 1983, MOL CELL BIOL, V3, P1097, DOI 10.1128/MCB.3.6.1097; Chen CY, 1998, CELL DEATH DIFFER, V5, P984, DOI 10.1038/sj.cdd.4400448; Chu M, 2005, J BIOL CHEM, V280, P6369, DOI 10.1074/jbc.M408947200; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; DENKO NC, 1994, P NATL ACAD SCI USA, V91, P5124, DOI 10.1073/pnas.91.11.5124; Downward J, 1997, CURR BIOL, V7, pR258, DOI 10.1016/S0960-9822(06)00116-3; Fukasawa K, 1997, MOL CELL BIOL, V17, P506, DOI 10.1128/MCB.17.1.506; GARBONE DP, 1992, ADV INTERNAL MED, V37, P153; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Heeschen C, 2001, NAT MED, V7, P833, DOI 10.1038/89961; Heusch WL, 1998, CARCINOGENESIS, V19, P551, DOI 10.1093/carcin/19.4.551; Hsu SL, 1998, BIOCHEM J, V333, P57, DOI 10.1042/bj3330057; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Joneson T, 1997, J MOL MED-JMM, V75, P587, DOI 10.1007/s001090050143; KAHN S, 1987, ANTICANCER RES, V7, P639; Kampfer S, 2001, J BIOL CHEM, V276, P42834, DOI 10.1074/jbc.M102047200; Kawakami Y, 2003, P NATL ACAD SCI USA, V100, P9470, DOI 10.1073/pnas.1633695100; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; Lee AC, 1999, J BIOL CHEM, V274, P7936, DOI 10.1074/jbc.274.12.7936; Liou JS, 2000, J BIOL CHEM, V275, P39001, DOI 10.1074/jbc.M007154200; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; Ma PH, 2002, MOL CELL BIOL, V22, P2928, DOI 10.1128/MCB.22.9.2928-2938.2002; Macklin KD, 1998, J PHARMACOL EXP THER, V287, P435; Mai HQ, 2003, J BIOL CHEM, V278, P1886, DOI 10.1074/jbc.M209044200; MANECKJEE R, 1990, P NATL ACAD SCI USA, V87, P3294, DOI 10.1073/pnas.87.9.3294; MANECKJEE R, 1994, CELL GROWTH DIFFER, V5, P1033; Maus ADJ, 1998, MOL PHARMACOL, V54, P779, DOI 10.1124/mol.54.5.779; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Minna JD, 2003, J CLIN INVEST, V111, P31, DOI 10.1172/JCI200317492; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; Paulson TG, 1998, MOL CELL BIOL, V18, P3089, DOI 10.1128/MCB.18.5.3089; Pontieri FE, 1996, NATURE, V382, P255, DOI 10.1038/382255a0; Prives C, 1993, CURR OPIN CELL BIOL, V5, P214, DOI 10.1016/0955-0674(93)90105-Y; RAKESH KJ, 1988, NEW ENGL J MED, V319, P1318; RILEY DJ, 1994, ANNU REV CELL BIOL, V10, P1, DOI 10.1146/annurev.cb.10.110194.000245; Rusanescu G, 2001, MOL CELL BIOL, V21, P2650, DOI 10.1128/MCB.21.8.2650-2658.2001; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SMITH KA, 1995, PHILOS T ROY SOC B, V347, P49, DOI 10.1098/rstb.1995.0008; Sweet-Cordero A, 2005, NAT GENET, V37, P48, DOI 10.1038/ng1490; Vafa O, 2002, MOL CELL, V9, P1031, DOI 10.1016/S1097-2765(02)00520-8; Vaziri C, 1996, J BIOL CHEM, V271, P13642, DOI 10.1074/jbc.271.23.13642; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; Wani MA, 1997, SOMAT CELL MOLEC GEN, V23, P123, DOI 10.1007/BF02679971; West KA, 2003, J CLIN INVEST, V111, P81, DOI 10.1172/JCI200316147; WRIGHT SC, 1993, FASEB J, V7, P1045, DOI 10.1096/fasebj.7.11.8370474; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	51	37	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	2005	280	34					30422	30431		10.1074/jbc.M504688200	http://dx.doi.org/10.1074/jbc.M504688200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	957IC	15983034	hybrid			2022-12-25	WOS:000231362500055
J	Ryu, CH; Kim, SW; Lee, KH; Lee, JY; Kim, H; Lee, WK; Choi, BH; Lim, Y; Kim, YH; Lee, KH; Hwang, TK; Jun, TY; Rha, HK				Ryu, CH; Kim, SW; Lee, KH; Lee, JY; Kim, H; Lee, WK; Choi, BH; Lim, Y; Kim, YH; Lee, KH; Hwang, TK; Jun, TY; Rha, HK			The merlin tumor suppressor interacts with Ral guanine nucleotide dissociation stimulator and inhibits its activity	ONCOGENE			English	Article						NF2; merlin; tumor suppressor; RalGDS; oncogenic signals	GROWTH-FACTOR RECEPTOR; NEUROFIBROMATOSIS TYPE-2; GENE-PRODUCT; CELLULAR-TRANSFORMATION; BINDING PROTEIN-1; SIGNALING PATHWAY; SPLICED ISOFORMS; FERM DOMAIN; SCHWANNOMIN; ACTIVATION	Neurofibromatosis type 2 (NF2) is the most commonly mutated gene in benign tumors of the human nervous system such as schwannomas and meningiomas. The NF2 gene encodes a protein called schwannomin or merlin, which is involved in regulating cell growth and proliferation through protein-protein interactions with various cellular proteins. In order to better understand the mechanism by which merlin exerts its function, yeast two-hybrid screening was performed and Ral guanine nucleotide dissociation stimulator (RalGDS), a downstream molecule of Ras, was identified as a merlin-binding protein. The direct interaction between merlin and RalGDS was confirmed both in vitro and in the NIH3T3 cells. The domain analyses revealed that the broad C-terminal region of merlin (aa 141-595) is necessary for the interaction with the C-terminal Ras-binding domain (RBD) of RalGDS. Functional studies showed that merlin inhibits the RalGDS-induced RalA activation, the colony formation and the cell migration in mammalian cells. These results suggest that merlin can function as a tumor suppressor by inhibiting the RalGDS-mediated oncogenic signals.	Catholic Univ Korea, Catholic Neurosci Ctr, Dept Psychiat, Seoul 137701, South Korea; Catholic Univ, Dept Urol, Seoul 137701, South Korea; Catholic Univ, Dept Pharmacol, Seoul 137701, South Korea; Catholic Univ, Dept Occupat & Environm Med, Seoul 137701, South Korea; Catholic Univ, Dept Psychiat, Seoul 137701, South Korea	Catholic University of Korea; Catholic University of Korea; Catholic University of Korea; Catholic University of Korea; Catholic University of Korea	Jun, TY (corresponding author), Catholic Univ Korea, Catholic Neurosci Ctr, Dept Psychiat, 505 Banpo Dong, Seoul 137701, South Korea.	ngrc@catholic.ac.kr						Arvelo Francisco, 2001, Acta Cientifica Venezolana, V52, P304; CANTOR SB, 1995, MOL CELL BIOL, V15, P4578; Chishti AH, 1998, TRENDS BIOCHEM SCI, V23, P281, DOI 10.1016/S0968-0004(98)01237-7; Feig LA, 1996, TRENDS BIOCHEM SCI, V21, P438, DOI 10.1016/S0968-0004(96)10058-X; Fernandez-Valle C, 2002, NAT GENET, V31, P354, DOI 10.1038/ng930; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Gildea JJ, 2002, CANCER RES, V62, P982; Goutebroze L, 2000, MOL CELL BIOL, V20, P1699, DOI 10.1128/MCB.20.5.1699-1712.2000; Hirokawa Y, 2004, CANCER J, V10, P20, DOI 10.1097/00130404-200401000-00006; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; Ikeda K, 1999, J NEUROSURG, V91, P85, DOI 10.3171/jns.1999.91.1.0085; Ikeda M, 1998, J BIOL CHEM, V273, P814, DOI 10.1074/jbc.273.2.814; Jannatipour M, 2001, J BIOL CHEM, V276, P33093, DOI 10.1074/jbc.M105792200; Joffe E B, 2001, Medicina (B Aires), V61, P658; Johnson KC, 2002, ONCOGENE, V21, P5990, DOI 10.1038/sj.onc.1205693; Joneson T, 1997, J MOL MED-JMM, V75, P587, DOI 10.1007/s001090050143; Kim H, 2002, MOL CELLS, V14, P108; Kim JY, 2002, BIOCHEM BIOPH RES CO, V296, P1295, DOI 10.1016/S0006-291X(02)02077-6; Koga H, 1998, ONCOGENE, V17, P801, DOI 10.1038/sj.onc.1202010; Kressel M, 2002, HUM MOL GENET, V11, P2269, DOI 10.1093/hmg/11.19.2269; Lee IK, 2004, BIOCHEM BIOPH RES CO, V325, P774, DOI 10.1016/j.bbrc.2004.10.095; Lee JY, 2004, J BIOL CHEM, V279, P30265, DOI 10.1074/jbc.M312083200; Lee T, 1996, DEVELOPMENT, V122, P409; Lim JY, 2003, BIOCHEM BIOPH RES CO, V302, P238, DOI 10.1016/S0006-291X(03)00124-4; LOUIS DN, 1995, BRAIN PATHOL, V5, P163, DOI 10.1111/j.1750-3639.1995.tb00590.x; Lu ZM, 2000, MOL CELL BIOL, V20, P462, DOI 10.1128/MCB.20.2.462-467.2000; Matthews J N S, 2002, Dev Biol (Basel), V107, P87; McClatchey AI, 1998, GENE DEV, V12, P1121, DOI 10.1101/gad.12.8.1121; McCormick F, 1996, CURR OPIN BIOTECH, V7, P449, DOI 10.1016/S0958-1669(96)80123-6; MELCHIORI A, 1990, ANTICANCER RES, V10, P37; Morrison H, 2001, GENE DEV, V15, P968, DOI 10.1101/gad.189601; Murthy A, 1998, J BIOL CHEM, V273, P1273, DOI 10.1074/jbc.273.3.1273; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; Rusanescu G, 2001, MOL CELL BIOL, V21, P2650, DOI 10.1128/MCB.21.8.2650-2658.2001; Sainio M, 1997, J CELL SCI, V110, P2249; Schmucker B, 1999, HUM MOL GENET, V8, P1561, DOI 10.1093/hmg/8.8.1561; Scoles DR, 2000, HUM MOL GENET, V9, P1567, DOI 10.1093/hmg/9.11.1567; Scoles DR, 1998, NAT GENET, V18, P354, DOI 10.1038/ng0498-354; Scoles DR, 2002, BIOCHEM BIOPH RES CO, V290, P366, DOI 10.1006/bbrc.2001.6178; Sherman L, 1997, ONCOGENE, V15, P2505, DOI 10.1038/sj.onc.1201418; Sun CX, 2002, J CELL SCI, V115, P3991, DOI 10.1242/jcs.00094; Suzuki J, 2000, MOL CELL BIOL, V20, P4658, DOI 10.1128/MCB.20.13.4658-4665.2000; Takaya A, 2004, MOL BIOL CELL, V15, P2549, DOI 10.1091/mbc.E03-11-0857; THOMAS G, 1994, EUR J CANCER, V30A, P1981, DOI 10.1016/0959-8049(94)00390-Q; TIKOO A, 1994, J BIOL CHEM, V269, P23387; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; Tsukita S, 1997, TRENDS BIOCHEM SCI, V22, P53, DOI 10.1016/S0968-0004(96)10071-2; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; Wolthuis RMF, 1998, CURR BIOL, V8, P471, DOI 10.1016/S0960-9822(98)70183-6; Yamaguchi A, 1997, J BIOL CHEM, V272, P31230, DOI 10.1074/jbc.272.50.31230	52	19	20	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 11	2005	24	34					5355	5364		10.1038/sj.onc.1208633	http://dx.doi.org/10.1038/sj.onc.1208633			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	954MF	16007223				2022-12-25	WOS:000231158500009
J	Sun, YP; Lowther, W; Kato, K; Bianco, C; Kenney, N; Strizzi, L; Raafat, D; Hirota, M; Khan, NI; Bargo, S; Jones, B; Salomon, D; Callahan, R				Sun, YP; Lowther, W; Kato, K; Bianco, C; Kenney, N; Strizzi, L; Raafat, D; Hirota, M; Khan, NI; Bargo, S; Jones, B; Salomon, D; Callahan, R			Notch4 intracellular domain binding to Smad3 and inhibition of the TGF-beta signaling	ONCOGENE			English	Article						Notch4ICD; Smad3; TGF-beta	GROWTH-FACTOR-BETA; MAMMARY EPITHELIAL-CELLS; TRUNCATED INT3 GENE; NEOPLASTIC TRANSFORMATION; BRANCHING MORPHOGENESIS; TUMOR-SUPPRESSOR; MAMMALIAN NOTCH; CROSS-TALK; EXPRESSION; RECEPTORS	We present evidence that Notch4ICD attenuates TGF-beta signaling. Cells expressing the activated form of the Notch4 receptor (ICD4) were resistant to the growth-inhibitory effects of TGF-beta. Notch4ICD was found to bind to Smad2, Smad3 and Smad4 but with higher affinity to Smad3. Deletion analysis showed that binding of Smad3 to ICD4 was mediated by its MH2 domain and was not dependent on the presence of the RAM23 region in ICD4. Using two TGF-beta/Activin reporter luciferase assays, RT-PCR and Western blot analysis, we demonstrate that ICD4 and ICD4 delta RAM23 inhibit Smad-binding element and 3TP luciferase reporter activity and PAI-1 gene expression. MCF-7 human breast cancer cells express Notch4ICD (ICD4) and are resistant to the growth-inhibitory effects of TGF-beta. Blockage of Notch4 processing to ICD4 by gamma-secretase inhibitor renders MCF-7 cells sensitive to growth inhibition by TGF-beta. The interplay between these two signaling pathways may be a significant determinant during mammary tumorigenesis.	NCI, Tumor Growth Factor Sect, Mammary Biol & Tumorigenesis Lab, Canc Res Ctr,NIH, Bethesda, MD 20892 USA; NCI, Oncogenesis Sect, Mammary Biol & Tumorigenesis Lab, Ctr Canc Res,NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Salomon, D (corresponding author), NCI, Tumor Growth Factor Sect, Mammary Biol & Tumorigenesis Lab, Canc Res Ctr,NIH, Bethesda, MD 20892 USA.	salomond@mail.nih.gov; Callahro@mail.nih.gov		Hirota, Morihisa/0000-0001-5682-0911	NATIONAL CANCER INSTITUTE [ZIABC009003, Z01BC009003] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akiyoshi S, 1999, J BIOL CHEM, V274, P35269, DOI 10.1074/jbc.274.49.35269; Allenspach EJ, 2002, CANCER BIOL THER, V1, P466, DOI 10.4161/cbt.1.5.159; Baron M, 2002, MOL MEMBR BIOL, V19, P27, DOI 10.1080/09687680110112929; Bianco C, 2002, MOL CELL BIOL, V22, P2586, DOI 10.1128/MCB.22.8.2586-2597.2002; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Blokzijl A, 2003, J CELL BIOL, V163, P723, DOI 10.1083/jcb.200305112; Callahan R, 2004, J MAMMARY GLAND BIOL, V9, P145, DOI 10.1023/B:JOMG.0000037159.63644.81; Capobianco AJ, 1997, MOL CELL BIOL, V17, P6265, DOI 10.1128/MCB.17.11.6265; Cordenonsi M, 2003, CELL, V113, P301, DOI 10.1016/S0092-8674(03)00308-8; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Fan X, 2004, CANCER RES, V64, P7787, DOI 10.1158/0008-5472.CAN-04-1446; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Fujii M, 1999, MOL BIOL CELL, V10, P3801, DOI 10.1091/mbc.10.11.3801; Gallahan D, 1996, CANCER RES, V56, P1775; Hocevar BA, 2001, EMBO J, V20, P2789, DOI 10.1093/emboj/20.11.2789; Imatani A, 2000, ONCOGENE, V19, P223, DOI 10.1038/sj.onc.1203295; Iso T, 2001, MOL CELL BIOL, V21, P6071, DOI 10.1128/MCB.21.17.6071-6079.2001; Itoh F, 2004, EMBO J, V23, P541, DOI 10.1038/sj.emboj.7600065; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Jeffries S, 2000, MOL CELL BIOL, V20, P3928, DOI 10.1128/MCB.20.11.3928-3941.2000; JHAPPAN C, 1992, GENE DEV, V6, P345, DOI 10.1101/gad.6.3.345; Kawabata M, 1998, EMBO J, V17, P4056, DOI 10.1093/emboj/17.14.4056; Kiaris H, 2004, AM J PATHOL, V165, P695, DOI 10.1016/S0002-9440(10)63333-0; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; Korchynskyi O, 2002, J BIOL CHEM, V277, P4883, DOI 10.1074/jbc.M111023200; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; Labbe E, 2000, P NATL ACAD SCI USA, V97, P8358, DOI 10.1073/pnas.150152697; Liu XH, 2000, EMBO J, V19, P6759, DOI 10.1093/emboj/19.24.6759; Maier MM, 2000, BIOCHEM BIOPH RES CO, V275, P652, DOI 10.1006/bbrc.2000.3354; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Miyazono K, 2000, J CELL SCI, V113, P1101; Moustakas A, 2001, J CELL SCI, V114, P4359; Nicolas M, 2003, NAT GENET, V33, P416, DOI 10.1038/ng1099; Rao P, 2003, MOL CELL BIOL, V23, P6694, DOI 10.1128/MCB.23.18.6694-6701.2003; Shimizu K, 2002, BIOCHEM BIOPH RES CO, V291, P775, DOI 10.1006/bbrc.2002.6528; SMITH GH, 1995, CELL GROWTH DIFFER, V6, P563; Sun Y, 2001, MOL CELL ENDOCRINOL, V172, P177, DOI 10.1016/S0303-7207(00)00370-1; Sun YP, 2002, J BIOL CHEM, V277, P19080, DOI 10.1074/jbc.M200936200; Takizawa T, 2003, NUCLEIC ACIDS RES, V31, P5723, DOI 10.1093/nar/gkg778; Tamura K, 1995, CURR BIOL, V5, P1416, DOI 10.1016/S0960-9822(95)00279-X; Uyttendaele H, 1998, DEV BIOL, V196, P204, DOI 10.1006/dbio.1998.8863; Uyttendaele H, 1996, DEVELOPMENT, V122, P2251; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Wechselberger C, 2001, EXP CELL RES, V266, P95, DOI 10.1006/excr.2001.5195; Weijzen S, 2002, NAT MED, V8, P979, DOI 10.1038/nm754; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Wu GY, 2001, MOL CELL BIOL, V21, P7403, DOI 10.1128/MCB.21.21.7403-7415.2001; Wu LY, 2003, J BIOL CHEM, V278, P15192, DOI 10.1074/jbc.M212332200; Xie W, 2002, CANCER RES, V62, P497; ZAGOURAS P, 1995, P NATL ACAD SCI USA, V92, P6414, DOI 10.1073/pnas.92.14.6414; Zavadil J, 2004, EMBO J, V23, P1155, DOI 10.1038/sj.emboj.7600069; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhou YL, 2000, MOL ENDOCRINOL, V14, P2066, DOI 10.1210/me.14.12.2066	54	72	78	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 11	2005	24	34					5365	5374		10.1038/sj.onc.1208528	http://dx.doi.org/10.1038/sj.onc.1208528			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	954MF	16007227				2022-12-25	WOS:000231158500010
J	Perna, AM; Masini, E; Nistri, S; Briganti, V; Chiappini, L; Stefano, P; Bigazzi, M; Pieroni, C; Sacchi, TB; Bani, D				Perna, AM; Masini, E; Nistri, S; Briganti, V; Chiappini, L; Stefano, P; Bigazzi, M; Pieroni, C; Sacchi, TB; Bani, D			Novel drug development opportunity for relaxin in acute myocardial infarction: evidences from a swine model	FASEB JOURNAL			English	Article						cardiac ischemia/reperfusion; adjunctive therapy; cardioprotection	RECOMBINANT HUMAN RELAXIN; REPERFUSION INJURY; ISCHEMIA-REPERFUSION; PREGNANCY HORMONE; NITRIC-OXIDE; PIG HEARTS; IN-VITRO; INVOLVEMENT; NEUTROPHILS; ACTIVATION	The hormone relaxin has been shown to cause coronary vasodilation and to prevent ischemia/reperfusion-induced cardiac injury in rodents. This study provides evidence that relaxin, used as an adjunctive drug to coronary reperfusion, reduces the functional, biochemical, and histopathological signs of myocardial injury in an in vivo swine model of heart ischemia/reperfusion, currently used to test cardiotropic drugs for myocardial infarction. Human recombinant relaxin, given at reperfusion at doses of 1.25, 2.5, and 5 mu g/kg b. wt. after a 30-min ischemia, caused a dose-related reduction of key markers of myocardial damage (serum myoglobin, CK-MB, troponin T) and cardiomyocyte apoptosis (caspase 3, TUNEL assay), as well as of cardiomyocyte contractile dysfunction (myofibril hypercontraction). Compared with the controls, relaxin also increased the uptake of the viability tracer (201)Thallium and improved ventricular performance (cardiac index). Relaxin likely acts by reducing oxygen free radical-induced myocardial injury (malondialdehyde, tissue calcium overload) and inflammatory leukocyte recruitment (myeloperoxidase). The present findings show that human relaxin, given as a drug to counteract reperfusion-induced cardiac injury, affords a clear-cut protection to the heart of swine with induced myocardial infarction. The findings also provide background to future clinical trials with relaxin as adjunctive therapy to catheter-based coronary angioplasty in patients with acute myocardial infarction.	Univ Florence, Dept Anat Histol & Forens Med, I-50139 Florence, Italy; Careggi Hosp, Unit Nucl Med, Florence, Italy; Prosperius Inst, Florence, Italy; Careggi Hosp, Unit Cardiac & Expt Surg, Florence, Italy; Univ Florence, Dept Preclin & Clin Pharmacol, Florence, Italy	University of Florence; University of Florence; Azienda Ospedaliero Universitaria Careggi; University of Florence; Azienda Ospedaliero Universitaria Careggi; University of Florence	Bani, D (corresponding author), Univ Florence, Dept Anat Histol & Forens Med, Viale G Pieraccini 6, I-50139 Florence, Italy.	daniele.bani@unifi.it		Bani, Daniele/0000-0001-6302-901X				Bani D, 1997, GEN PHARMACOL-VASC S, V28, P13, DOI 10.1016/S0306-3623(96)00171-1; BANI D, 1995, LAB INVEST, V73, P709; Bani D, 1998, AM J PATHOL, V152, P1367; Becker LB, 2004, CARDIOVASC RES, V61, P461, DOI 10.1016/j.cardiores.2003.10.025; BERMAN DS, 2000, REV PORT CARDIOL S1, V19, P31; Bertini Giovanni, 1993, Journal of Emergency Medicine, V11, P667, DOI 10.1016/0736-4679(93)90624-G; Bigazzi M, 2001, Climacteric, V4, P137, DOI 10.1080/713605086; Claeys MJ, 2004, AM J CARDIOL, V94, P9, DOI 10.1016/j.amjcard.2004.03.021; Dschietzig T, 2003, CELL MOL LIFE SCI, V60, P688, DOI 10.1007/s00018-003-2169-x; Dschietzig T, 2001, FASEB J, V15, P2187, DOI 10.1096/fj.01-0070com; Dschietzig T, 2004, FASEB J, V18, P1536, DOI 10.1096/fj.03-1120fje; EDDIE LW, 1986, LANCET, V1, P1344; Eltzschig HK, 2004, BRIT MED BULL, V70, P71, DOI 10.1093/bmb/ldh025; HALE SL, 1993, CARDIOVASC RES, V27, P2140, DOI 10.1093/cvr/27.12.2140; Hsu SY, 2002, SCIENCE, V295, P671, DOI 10.1126/science.1065654; Hu FB, 2000, NEW ENGL J MED, V343, P530, DOI 10.1056/NEJM200008243430802; Keeley EC, 2003, LANCET, V361, P13, DOI 10.1016/S0140-6736(03)12113-7; Masini E, 1997, ENDOCRINOLOGY, V138, P4713, DOI 10.1210/en.138.11.4713; Masini E, 2004, ENDOCRINOLOGY, V145, P1106, DOI 10.1210/en.2003-0833; MASINI E, 1994, J CLIN INVEST, V94, P1974, DOI 10.1172/JCI117549; Nediani C, 1997, J MOL CELL CARDIOL, V29, P2825, DOI 10.1006/jmcc.1997.0516; Nistri S, 2003, FASEB J, V17, P2109, DOI 10.1096/fj.03-0216fje; O'Neill WW, 2004, J AM COLL CARDIOL, V43, P875, DOI 10.1016/j.jacc.2003.12.024; OBYRNE EM, 1978, J CLIN ENDOCR METAB, V47, P1106, DOI 10.1210/jcem-47-5-1106; OSHEROFF PL, 1993, J BIOL CHEM, V268, P15193; SACCHI TB, 1995, BRIT J PHARMACOL, V116, P1589; Samuel CS, 2003, CURR OPIN PHARMACOL, V3, P152, DOI 10.1016/S1471-4892(03)00011-0; Seibold JR, 2000, ANN INTERN MED, V132, P871, DOI 10.7326/0003-4819-132-11-200006060-00004; Seibold JR, 1998, J RHEUMATOL, V25, P302; Sherwood OD, 2004, ENDOCR REV, V25, P205, DOI 10.1210/er.2003-0013; Stennicke HR, 1997, J BIOL CHEM, V272, P25719, DOI 10.1074/jbc.272.41.25719; STULTS JT, 1990, BIOMED ENVIRON MASS, V19, P655, DOI 10.1002/bms.1200191105; TAYLOR D, 1994, INTERNET WORLD, V5, P8; THORNTON JD, 1992, CIRCULATION, V85, P659, DOI 10.1161/01.CIR.85.2.659; Vinten-Johansen J, 2004, CARDIOVASC RES, V61, P481, DOI 10.1016/j.cardiores.2003.10.011	35	81	87	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2005	19	9					1525	+		10.1096/fj.04-3664fje	http://dx.doi.org/10.1096/fj.04-3664fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	951IO	16009702				2022-12-25	WOS:000230923000027
J	Suliman, HB; Welty-Wolf, KE; Carraway, MS; Schwartz, DA; Hollingsworth, JW; Piantadosi, CA				Suliman, HB; Welty-Wolf, KE; Carraway, MS; Schwartz, DA; Hollingsworth, JW; Piantadosi, CA			Toll-like receptor 4 mediates mitochondrial DNA damage and biogenic responses after heat-inactivated E. coli	FASEB JOURNAL			English	Article						bacterial infection; inflammation; endotoxin shock; knockout mice; signal transduction; nitric oxide; mitochondrial biogenesis	NF-KAPPA-B; NITRIC-OXIDE SYNTHASE; TOLL-LIKE RECEPTORS; TRANSCRIPTION FACTOR; ENDOTHELIAL-CELLS; MOUSE HEPATOCYTES; OXIDATIVE DAMAGE; RELA/P65 SUBUNIT; ADAPTER PROTEIN; GENE-EXPRESSION	An important site of cellular damage in bacterial sepsis is mitochondrial DNA (mtDNA), which we proposed is caused by reactive oxygen and nitrogen species generated by activation of signaling through specific toll-like receptors (TLR). In wild-type (Wt) mice injected with heat-inactivated E. coli, hepatic TLR4 and TLR2 proteins were up-regulated with TLR-dependent increases in transcript levels for tumor necrosis factor (TNF-alpha), interleukin 6, nitric oxide synthase-II (iNOS), and NADPH oxidase 2 (Nox2). The accompanying stress significantly depleted hepatic mtDNA despite eight- and fourfold increases in manganese superoxide dismutase (MnSOD) and mitochondrial transcription factor A (Tfam) expression, respectively. The identical E. coli dose generated significantly less TNF-alpha, NO, and Nox2 in TLR4(-/-) and TLR2/4(-/-) but not in TLR2(-/-) mice. TLR4(-/-) and TLR2/4(-/-) compared with Wt mice were protected from mtDNA oxidation but showed no Tfam up-regulation and little copy number restoration. A critical role in the mtDNA damage was determined for TLR4-mediated iNOS transcription through the MyD88 pathway. In Wt mice, mtDNA depletion was avoided by selective iNOS blockade, and residual mtDNA loss was linked to NF-kappa B-dependent TNF-alpha expression. These data disclose the dual role of TLR4 in mtDNA damage and compensatory mitochondrial biogenic responses after innate immune activation.	Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA	Duke University	Piantadosi, CA (corresponding author), Duke Univ, Med Ctr, Dept Med, Box 3315,Room 0590,CR2 Bldg, Durham, NC 27710 USA.	piant001@mc.duke.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL042444] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES101945, Z01ES101946] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL-42444] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arbour NC, 2000, NAT GENET, V25, P187, DOI 10.1038/76048; Azevedo-Martins AK, 2003, DIABETES, V52, P93, DOI 10.2337/diabetes.52.1.93; Ballinger SW, 2000, CIRC RES, V86, P960, DOI 10.1161/01.RES.86.9.960; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Begbie M, 2000, THROMB HAEMOSTASIS, V84, P216; Brealey David, 2002, Lancet (North American Edition), V360, P219, DOI 10.1016/S0140-6736(02)09459-X; Brookes PS, 2002, FREE RADICAL BIO MED, V33, P755, DOI 10.1016/S0891-5849(02)00901-2; Burns K, 1998, J BIOL CHEM, V273, P12203, DOI 10.1074/jbc.273.20.12203; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Chen BC, 2002, J BIOL CHEM, V277, P24169, DOI 10.1074/jbc.M106014200; CLANCY RM, 1992, J CLIN INVEST, V90, P1116, DOI 10.1172/JCI115929; CLAYTON DA, 1984, ANNU REV BIOCHEM, V53, P573; CROSS A, 1995, J CLIN INVEST, V96, P676, DOI 10.1172/JCI118110; DIJKSTRA CD, 1985, IMMUNOLOGY, V54, P589; Dishart MK, 1998, J APPL PHYSIOL, V84, P791; Ekstrand MI, 2004, HUM MOL GENET, V13, P935, DOI 10.1093/hmg/ddh109; Essani NA, 1996, J IMMUNOL, V156, P2956; Fan J, 2003, J CLIN INVEST, V112, P1234, DOI 10.1172/JCI200318696; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; GU GL, 2002, AM J PHYSIOL-GASTR L, V283, pG256; Hatano E, 2001, GASTROENTEROLOGY, V120, P1251, DOI 10.1053/gast.2001.23239; Henneke P, 2002, J IMMUNOL, V169, P3970, DOI 10.4049/jimmunol.169.7.3970; Hornef MW, 2003, J EXP MED, V198, P1225, DOI 10.1084/jem.20022194; Hoshino K, 1999, J IMMUNOL, V162, P3749; Janssen-Heininger YMW, 2000, FREE RADICAL BIO MED, V28, P1317, DOI 10.1016/S0891-5849(00)00218-5; Josse C, 1998, FREE RADICAL BIO MED, V25, P104, DOI 10.1016/S0891-5849(98)00057-4; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kurose I, 1996, HEPATOLOGY, V24, P1185; Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/ng0398-231; Lavon I, 2000, NAT MED, V6, P573, DOI 10.1038/75057; Lemasters JJ, 1999, J BIOENERG BIOMEMBR, V31, P305, DOI 10.1023/A:1005419617371; Lin PH, 2003, FREE RADICAL BIO MED, V35, P1310, DOI 10.1016/j.freeradbiomed.2003.07.002; Liu SB, 2002, INFECT IMMUN, V70, P3433, DOI 10.1128/IAI.70.7.3433-3442.2002; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; Matsumura T, 2000, J INTERF CYTOK RES, V20, P915, DOI 10.1089/10799900050163299; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; Muir A, 2004, AM J RESP CELL MOL, V30, P777, DOI 10.1165/rcmb.2003-0329OC; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Radi R, 2004, P NATL ACAD SCI USA, V101, P4003, DOI 10.1073/pnas.0307446101; Rogers RJ, 2001, J BIOL CHEM, V276, P20419, DOI 10.1074/jbc.M008915200; Schmidt HHHW, 1996, P NATL ACAD SCI USA, V93, P14492, DOI 10.1073/pnas.93.25.14492; SIMONSON SG, 1994, CIRC SHOCK, V43, P34; Suliman HB, 2004, CARDIOVASC RES, V64, P279, DOI 10.1016/j.cardiores.2004.07.005; Suliman HB, 2004, BLOOD, V104, P43, DOI 10.1182/blood-2003-07-2240; Suliman HB, 2003, J BIOL CHEM, V278, P41510, DOI 10.1074/jbc.M304719200; Suliman HB, 2002, FREE RADICAL BIO MED, V32, P246, DOI 10.1016/S0891-5849(01)00797-3; Suliman HB, 2003, AM J RESP CRIT CARE, V167, P570, DOI 10.1164/rccm.200206-518OC; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; TRACEY KJ, 1986, SCIENCE, V234, P470, DOI 10.1126/science.3764421; Tsan MF, 2001, AM J PHYSIOL-CELL PH, V280, pC1422; Uchikura K, 2004, AM J PHYSIOL-GASTR L, V287, pG620, DOI 10.1152/ajpgi.00314.2003; Vodovotz Y, 2001, J ENDOTOXIN RES, V7, P365, DOI 10.1179/096805101101532936; VOLPES R, 1992, J HEPATOL, V16, P228, DOI 10.1016/S0168-8278(05)80121-7; Welty-Wolf KE, 1998, AM J RESP CRIT CARE, V158, P610, DOI 10.1164/ajrccm.158.2.9704064; Yang H, 2000, J BIOL CHEM, V275, P20861, DOI 10.1074/jbc.M002896200	58	83	84	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2005	19	9					1531	+		10.1096/fj.04-3500fje	http://dx.doi.org/10.1096/fj.04-3500fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	951IO	15994412				2022-12-25	WOS:000230923000031
J	D'Alessio, M; De Nicola, M; Coppola, S; Gualandi, G; Pugliese, L; Cerella, C; Cristofanon, S; Civitareale, P; Ciriolo, MR; Bergamaschi, A; Magrini, A; Ghibelli, L				D'Alessio, M; De Nicola, M; Coppola, S; Gualandi, G; Pugliese, L; Cerella, C; Cristofanon, S; Civitareale, P; Ciriolo, MR; Bergamaschi, A; Magrini, A; Ghibelli, L			Oxidative Bax dimerization promotes its translocation to mitochondria independently of apoptosis	FASEB JOURNAL			English	Article						oxidative stress; glutathione; disulfide	CYTOCHROME-C RELEASE; PERMEABILITY TRANSITION PORE; ENDOPLASMIC-RETICULUM; CONFORMATIONAL-CHANGE; CASPASE ACTIVATION; PROAPOPTOTIC BAX; GSH EXTRUSION; CELL-DEATH; GLUTATHIONE; BCL-2	Bax is a cytosolic protein, which in response to stressing apoptotic stimuli, is activated and translocates to mitochondria, thus initiating the intrinsic apoptotic pathway. In spite of many studies and the importance of the issue, the molecular mechanisms that trigger Bax translocation are still obscure. We show by computer simulation that the two cysteine residues of Bax may form disulfide bridges, producing conformational changes that favor Bax translocation. Oxidative, nonapoptogenic treatments produce an up-shift of Bax migration compatible with homodimerization, which is reverted by reducing agents; this is accompanied by translocation to mitochondria. Dimers also appear in pure cytosolic fractions of cell lysates treated with H2O2, showing that Bax dimerization may take place in the cytosol. Bax dimer-enriched lysates support Bax translocation to isolated mitochondria much more efficiently than untreated lysates, indicating that dimerization may promote Bax translocation. The absence of apoptosis in our system allows the demonstration that Bax moves because of oxidations, even in the absence of apoptosis. This provides the first evidence that Bax dimerization and translocation respond to oxidative stimuli, suggesting a novel role for Bax as a sensor of redox imbalance.	Univ Roma Tor Vergata, Dipartimento Biol, I-00133 Rome, Italy; Univ Roma Tor Vergata, Cattedra Med Lavoro, Rome, Italy; Univ Tuscia, Turin, Italy	University of Rome Tor Vergata; University of Rome Tor Vergata; Tuscia University	Ghibelli, L (corresponding author), Univ Roma Tor Vergata, Dipartimento Biol, Via Ric Sci 1, I-00133 Rome, Italy.	ghibelli@uniroma2.it	Coppola, Simona/A-6638-2015; Ciriolo, Maria Rosa/K-6572-2016	Coppola, Simona/0000-0001-7851-9409; Cerella, Claudia/0000-0001-9308-8176; Ciriolo, Maria Rosa/0000-0002-7863-9029				Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Colussi C, 2000, FASEB J, V14, P2266, DOI 10.1096/fj.00-0074com; COOPERSTEIN SJ, 1951, J BIOL CHEM, V189, P665; COPPOLA S, 1995, EXP CELL RES, V221, P462, DOI 10.1006/excr.1995.1397; Coppola S, 2000, BIOCHEM SOC T, V28, P56, DOI 10.1042/bst0280056; D'Alessio M, 2004, FASEB J, V18, P1609, DOI 10.1096/fj.04-1813fje; D'Alessio M, 2003, ANN NY ACAD SCI, V1010, P449, DOI 10.1196/annals.1299.082; De Giorgi F, 2002, FASEB J, V16, P607, DOI 10.1096/fj.01-0269fje; Devadas S, 2003, FREE RADICAL BIO MED, V35, P648, DOI 10.1016/S0891-5849(03)00391-5; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Dini L, 1996, EXP CELL RES, V223, P340, DOI 10.1006/excr.1996.0089; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; Filomeni G, 2005, ANTIOXID REDOX SIGN, V7, P446, DOI 10.1089/ars.2005.7.446; Filomeni G, 2002, BIOCHEM PHARMACOL, V64, P1057, DOI 10.1016/S0006-2952(02)01176-0; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; Gajkowska B, 2004, J MOL HISTOL, V35, P11; Ghibelli L, 1999, FASEB J, V13, P2031, DOI 10.1096/fasebj.13.14.2031; GHIBELLI L, 1995, BIOCHEM BIOPH RES CO, V216, P313, DOI 10.1006/bbrc.1995.2626; Ghibelli L, 1998, FASEB J, V12, P479, DOI 10.1096/fasebj.12.6.479; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Griffiths GJ, 1999, J CELL BIOL, V144, P903, DOI 10.1083/jcb.144.5.903; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Hampton MB, 1998, ANN NY ACAD SCI, V854, P328, DOI 10.1111/j.1749-6632.1998.tb09913.x; Hampton MB, 1997, FEBS LETT, V414, P552, DOI 10.1016/S0014-5793(97)01068-5; Hentze H, 2002, J BIOL CHEM, V277, P5588, DOI 10.1074/jbc.M110766200; Hentze H, 1999, HEPATOLOGY, V30, P177, DOI 10.1002/hep.510300111; Hentze H, 2000, AM J PATHOL, V156, P2045, DOI 10.1016/S0002-9440(10)65076-6; Honda T, 2004, CANCER GENE THER, V11, P249, DOI 10.1038/sj.cgt.7700684; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; Jungas T, 2002, J BIOL CHEM, V277, P27912, DOI 10.1074/jbc.M110288200; Khaled AR, 1999, P NATL ACAD SCI USA, V96, P14476, DOI 10.1073/pnas.96.25.14476; Krieger E, 2002, PROTEINS, V47, P393, DOI 10.1002/prot.10104; Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Makin GWJ, 2001, EMBO J, V20, P6306, DOI 10.1093/emboj/20.22.6306; Murphy KM, 1999, ONCOGENE, V18, P5991, DOI 10.1038/sj.onc.1203001; Murphy KM, 2000, J BIOL CHEM, V275, P17225, DOI 10.1074/jbc.C900590199; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Nechushtan A, 2001, J CELL BIOL, V153, P1265, DOI 10.1083/jcb.153.6.1265; Nomura M, 2003, J BIOL CHEM, V278, P2058, DOI 10.1074/jbc.M207880200; NOSSERI C, 1994, EXP CELL RES, V212, P367, DOI 10.1006/excr.1994.1156; Nouraini S, 2000, MOL CELL BIOL, V20, P1604, DOI 10.1128/MCB.20.5.1604-1615.2000; Oakes SA, 2005, P NATL ACAD SCI USA, V102, P105, DOI 10.1073/pnas.0408352102; Pan Z, 2001, J BIOL CHEM, V276, P32257, DOI 10.1074/jbc.M100178200; Peter ME, 1998, CURR OPIN IMMUNOL, V10, P545, DOI 10.1016/S0952-7915(98)80222-7; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; REED DJ, 1980, ANAL BIOCHEM, V106, P55, DOI 10.1016/0003-2697(80)90118-9; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Schlesinger PH, 1997, P NATL ACAD SCI USA, V94, P11357, DOI 10.1073/pnas.94.21.11357; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Sen CK, 1999, CELL DEATH DIFFER, V6, P481, DOI 10.1038/sj.cdd.4400514; Shangary S, 2002, BIOCHEMISTRY-US, V41, P9485, DOI 10.1021/bi025605h; Single B, 1998, CELL DEATH DIFFER, V5, P1001, DOI 10.1038/sj.cdd.4400462; Stefan C, 1997, CHEM RES TOXICOL, V10, P636, DOI 10.1021/tx970006a; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Thomas A, 1996, ONCOGENE, V12, P1055; Wang K, 1998, MOL CELL BIOL, V18, P6083, DOI 10.1128/MCB.18.10.6083; WIEDER ED, 1993, CYTOMETRY, V14, P916, DOI 10.1002/cyto.990140810; WILLIAMS CH, 1962, J BIOL CHEM, V237, P587; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Wood DE, 1998, ONCOGENE, V17, P1069, DOI 10.1038/sj.onc.1202034; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Yamaguchi H, 2001, ONCOGENE, V20, P7779, DOI 10.1038/sj.onc.1204984; Yamaguchi H, 2004, J BIOL CHEM, V279, P45495, DOI 10.1074/jbc.M406933200; Yamaguchi H, 2003, CANCER RES, V63, P1483; Yethon JA, 2003, J BIOL CHEM, V278, P48935, DOI 10.1074/jbc.M306289200; Zha HB, 1997, J BIOL CHEM, V272, P31482, DOI 10.1074/jbc.272.50.31482; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440; Zong WX, 2003, J CELL BIOL, V162, P59, DOI 10.1083/jcb.200302084	72	102	104	1	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2005	19	8					1504	+		10.1096/fj.04-3329fje	http://dx.doi.org/10.1096/fj.04-3329fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	15972297				2022-12-25	WOS:000230207800012
J	Starczynowski, DT; Reynolds, JG; Gilmore, TD				Starczynowski, DT; Reynolds, JG; Gilmore, TD			Mutations of tumor necrosis factor alpha-responsive serine residues within the C-terminal transactivation domain of human transcription factor REL enhance its in vitro transforming ability	ONCOGENE			English	Article						c-Rel; Rel; NF-kappa B; malignant transformation; lymphoma; tumor necrosis factor	NF-KAPPA-B; MANGANESE SUPEROXIDE-DISMUTASE; CHICKEN SPLEEN-CELLS; V-REL; UP-REGULATION; DNA-BINDING; LINE RC-K8; LYMPHOMA; PROTEIN; ACTIVATION	The human c-rel gene (REL), encoding an NF-KB transcription factor, is amplifi. ed or mutated in several human B-cell lymphomas and can transform chicken lymphoid cells in vitro. We have previously shown that certain deletions of C-terminal transactivation sequences enhance REL's transforming ability in chicken spleen cells. In this report, we have analysed the effect of single amino-acid changes at select serine residues in the C-terminal transactivation domain on REL's transforming ability. Mutation of either of two TNF alpha-inducible serine residues (Ser460 and Ser471) to nonphosphorylatable residues (alanine, asparagine, phenylalanine) made REL more effi. cient at transforming chicken spleen cells in vitro. In contrast, mutation of Ser471 to a phosphorylation mimetic aspartate residue impaired REL's transforming ability, even though it increased REL's inherent transactivation ability as a GAL4-fusion protein. Alanine mutations of several other serine residues within the transactivation domain did not substantially affect REL's transforming ability. Transactivation by GAL4-REL fusion proteins containing either transformation enhancing or nonenhancing mutations at serine residues was generally similar to wild-type GAL4-REL. However, more transforming mutants with mutations at either Ser460 or Ser471 differed from wild-type REL in their ability to transactivate certain KB-site reporter genes. In particular, the SOD2 promoter, encoding manganese superoxide dismutase, was activated less strongly by the more transforming REL mutant REL-S471N transient assays, but REL-S471N-transformed chicken spleen cells had increased levels of MnSOD protein as compared to wild- type REL-transformed cells. Taken together, our results show that mutations of certain serine residues can enhance REL's transforming ability in vitro and suggest that these mutations increase REL-mediated transformation by altering REL's ability to modulate the expression of select target genes. Furthermore, phosphorylation of Ser471 may be involved in REL-mediated modulation of transformation-specific target gene expression. Lastly, these results suggest that similar mutations in the REL transactivation domain contribute to the development of certain human B-cell lymphomas.	Boston Univ, Dept Biol, Boston, MA 02215 USA	Boston University	Gilmore, TD (corresponding author), Boston Univ, Dept Biol, 5 Cummington St, Boston, MA 02215 USA.	gilmore@bu.edu			NATIONAL CANCER INSTITUTE [R01CA047763, R29CA047763] Funding Source: NIH RePORTER; NCI NIH HHS [CA47763] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABBADIE C, 1993, CELL, V75, P899, DOI 10.1016/0092-8674(93)90534-W; Abid MR, 2004, J BIOL CHEM, V279, P44030, DOI 10.1074/jbc.M408285200; Barth TFE, 2003, BLOOD, V101, P3681, DOI 10.1182/blood-2002-08-2577; Bash J, 1997, MOL CELL BIOL, V17, P6526, DOI 10.1128/MCB.17.11.6526; Bernard D, 2002, ONCOGENE, V21, P4392, DOI 10.1038/sj.onc.1205536; Bernard D, 2001, CANCER RES, V61, P2656; Chen EY, 1998, BIOCHEM BIOPH RES CO, V249, P728, DOI 10.1006/bbrc.1998.9224; Epinat JC, 2000, ONCOGENE, V19, P599, DOI 10.1038/sj.onc.1203376; Fan YJ, 2004, ONCOGENE, V23, P1030, DOI 10.1038/sj.onc.1207221; FEUERHAKE F, 2005, IN PRESS BLOOD; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; Gilmore TD, 1999, ONCOGENE, V18, P6925, DOI 10.1038/sj.onc.1203222; Gilmore TD, 2004, ONCOGENE, V23, P2275, DOI 10.1038/sj.onc.1207410; GILMORE TD, 1995, DNA PROVIRUS, P109; Gilmore TD, 2001, ONCOGENE, V20, P7098, DOI 10.1038/sj.onc.1204898; Hansen GM, 2000, GENOME RES, V10, P237, DOI 10.1101/gr.10.2.237; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hrdlickova R, 2001, MOL CELL BIOL, V21, P6369; HRDLICKOVA R, 1994, J VIROL, V68, P2371; Huguet C, 1999, APOPTOSIS, V4, P31, DOI 10.1023/A:1009678015249; Iwai K, 2005, FEBS LETT, V579, P141, DOI 10.1016/j.febslet.2004.11.060; KABRUN N, 1990, MOL CELL BIOL, V10, P4788, DOI 10.1128/MCB.10.9.4788; Kalaitzidis D, 2002, ONCOGENE, V21, P8759, DOI 10.1038/sj.onc.1206033; Kalaitzidis D, 2002, GENE CHROMOSOME CANC, V34, P129, DOI 10.1002/gcc.10051; Kralova J, 1998, MOL CELL BIOL, V18, P2997, DOI 10.1128/MCB.18.5.2997; Kralova J, 2002, J VIROL, V76, P11960, DOI 10.1128/JVI.76.23.11960-11970.2002; Lawrence T, 2005, NATURE, V434, P1138, DOI 10.1038/nature03491; Leung TH, 2004, CELL, V118, P453, DOI 10.1016/j.cell.2004.08.007; LU D, 1991, ONCOGENE, V6, P1235; Martin AG, 2000, J BIOL CHEM, V275, P24383, DOI 10.1074/jbc.M909396199; Martin AG, 2001, J BIOL CHEM, V276, P15840, DOI 10.1074/jbc.M011313200; MITCHELL T, 1995, J VIROL, V69, P2968, DOI 10.1128/JVI.69.5.2968-2976.1995; MOSIALOS G, 1991, MOL CELL BIOL, V11, P5867, DOI 10.1128/MCB.11.12.5867; Rayet B, 2003, MOL CELL BIOL, V23, P1520, DOI 10.1128/MCB.23.5.1520-1533.2003; Sachdev S, 1998, MOL CELL BIOL, V18, P5445, DOI 10.1128/MCB.18.9.5445; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHATZLE JD, 1995, J VIROL, V69, P5383, DOI 10.1128/JVI.69.9.5383-5390.1995; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SmithSorensen B, 1996, J BIOL CHEM, V271, P5513, DOI 10.1074/jbc.271.10.5513; Starczynowski DT, 2003, ONCOGENE, V22, P6928, DOI 10.1038/sj.onc.1206801; Wang Y, 2001, BBA-MOL CELL RES, V1538, P260, DOI 10.1016/S0167-4889(01)00077-5; Yu SH, 2004, J MOL MED, V82, P621, DOI 10.1007/s00109-004-0559-7	42	25	25	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2005	24	49					7355	7368		10.1038/sj.onc.1208902	http://dx.doi.org/10.1038/sj.onc.1208902			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	982FA	16027730				2022-12-25	WOS:000233142100012
J	Xue, LY; Chiu, SM; Oleinick, NL				Xue, LY; Chiu, SM; Oleinick, NL			Differential responses of Mcl-1 in photosensitized epithelial vs lymphoid-derived human cancer cells	ONCOGENE			English	Article						Mcl-1; Bcl-2; apoptosis; photodynamic therapy	THERAPY-INDUCED APOPTOSIS; BCL-2 FAMILY-MEMBERS; PHOTODYNAMIC THERAPY; ENDOPLASMIC-RETICULUM; MEDIATED APOPTOSIS; INDUCED DEATH; CYTOCHROME-C; CLEAVAGE; PROTEIN; STAUROSPORINE	The antiapoptotic Bcl-2-family proteins, Bcl-2 and BclxL, are recognized phototargets of photodynamic therapy (PDT) with the mitochondrion-targeting phthalocyanine photosensitizer Pc 4. In the present study, we found that myeloid cell leukemia 1 (Mcl-1), another antiapoptotic member of the Bcl-2 family, was not photodamaged in Pc 4-PDT-treated human carcinoma cells MCF-7c3, MDA-MB468, DU145, and A431, although Mcl-1 turnover was observed after exposure of HeLa or MCF-7c3 cells to a supralethal dose of UVC. In contrast, when human lymphoma U937 and Jurkat cells were treated with Pc 4-PDT, staurosporine (STS) or UVC, Mcl-1 was cleaved to generate a 28-kDa fragment over a 2 - 4 h period. The cleavage of Mcl-1 was accompanied by the activation of caspases-3, - 9, and - 8. The broad-specificity caspase inhibitor z-VAD-fmk completely blocked Mcl-1 cleavage induced by PDT, STS or UVC, providing evidence for Mcl-1 as a substrate for caspases. Western blot analysis localized Mcl-1 to mitochondria, ER, and cytosol of both MCF-7c3 and U937 cells, suggesting that Mcl-1 protein, unlike Bcl-2 and Bcl-xL, is not a target for Pc 4-PDT, probably due to its localization to sites removed from those of Pc 4 binding. The 28-kDa cleaved fragment of Mcl-1, which has proapoptotic activity, was produced in PDT-treated lymphoid-derived cells, but not in cells of epithelial origin, suggesting that PDT-induced rapid and extensive apoptosis in lymphoma cells may result in part from the sensitivity of their Mcl-1 to caspase cleavage, removing an important negative control on apoptosis.	Case Western Reserve Univ, Sch Med, Dept Radiat Oncol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Oleinick, NL (corresponding author), Case Western Reserve Univ, Sch Med, Dept Radiat Oncol, 10900 Euclid Ave, Cleveland, OH 44106 USA.	nlo@po.cwru.edu			NCI NIH HHS [R01 CA83917, P30 CA43703, P01 CA48735] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA043703, R01CA083917, P01CA048735] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bae J, 2000, J BIOL CHEM, V275, P25255, DOI 10.1074/jbc.M909826199; BOHR VA, 1986, P NATL ACAD SCI USA, V83, P3830, DOI 10.1073/pnas.83.11.3830; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; CHAO DT, 1995, J EXP MED, V182, P821, DOI 10.1084/jem.182.3.821; Chiu SM, 2001, CANCER LETT, V165, P51, DOI 10.1016/S0304-3835(01)00422-0; Clohessy JG, 2004, BRIT J HAEMATOL, V125, P655, DOI 10.1111/j.1365-2141.2004.04949.x; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Craig RW, 2002, LEUKEMIA, V16, P444, DOI 10.1038/sj.leu.2402416; Cuconati A, 2003, GENE DEV, V17, P2922, DOI 10.1101/gad.1156903; Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889; Fujita N, 1998, BIOCHEM BIOPH RES CO, V246, P484, DOI 10.1006/bbrc.1998.8587; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Herrant M, 2004, ONCOGENE, V23, P7863, DOI 10.1038/sj.onc.1208069; Herrant M, 2002, ONCOGENE, V21, P4957, DOI 10.1038/sj.onc.1205689; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Iglesias-Serret D, 2003, ARCH BIOCHEM BIOPHYS, V417, P141, DOI 10.1016/S0003-9861(03)00345-X; Kessel D, 1999, CELL DEATH DIFFER, V6, P28, DOI 10.1038/sj.cdd.4400446; Kessel D, 2001, PHOTOCHEM PHOTOBIOL, V74, P318, DOI 10.1562/0031-8655(2001)074<0318:ETBITT>2.0.CO;2; Kim HRC, 1999, CANCER RES, V59, P3429; Kitada S, 2000, BLOOD, V96, P393; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Lam M, 2001, J BIOL CHEM, V276, P47379, DOI 10.1074/jbc.M107678200; Leu CM, 2000, ONCOGENE, V19, P1665, DOI 10.1038/sj.onc.1203452; Leu JIJ, 2004, NAT CELL BIOL, V6, P443, DOI 10.1038/ncb1123; Michels J, 2004, ONCOGENE, V23, P4818, DOI 10.1038/sj.onc.1207648; Nijhawan D, 2003, GENE DEV, V17, P1475, DOI 10.1101/gad.1093903; Oleinick NL, 1998, RADIAT RES, V150, pS146, DOI 10.2307/3579816; OLEINICK NL, 1993, PHOTOCHEM PHOTOBIOL, V57, P242, DOI 10.1111/j.1751-1097.1993.tb02282.x; Oleinick NL, 2002, PHOTOCH PHOTOBIO SCI, V1, P1, DOI 10.1039/b108586g; REED JC, 1995, HEMATOL ONCOL CLIN N, V9, P451, DOI 10.1016/S0889-8588(18)30104-7; REYNOLDS JE, 1994, CANCER RES, V54, P6348; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; Separovic D, 1998, PHOTOCHEM PHOTOBIOL, V68, P101, DOI 10.1111/j.1751-1097.1998.tb03259.x; Snowden RT, 2003, LEUKEMIA, V17, P1981, DOI 10.1038/sj.leu.2403088; Trivedi NS, 2000, PHOTOCHEM PHOTOBIOL, V71, P634, DOI 10.1562/0031-8655(2000)071<0634:QAOPLI>2.0.CO;2; Usuda J, 2003, J BIOL CHEM, V278, P2021, DOI 10.1074/jbc.M205219200; Varela N, 2001, J BIOL CHEM, V276, P17779, DOI 10.1074/jbc.M100815200; Varnes ME, 1999, BIOCHEM BIOPH RES CO, V255, P673, DOI 10.1006/bbrc.1999.0261; Vrana JA, 2002, CANCER RES, V62, P892; Wang NS, 2001, J BIOL CHEM, V276, P44117, DOI 10.1074/jbc.M101958200; Xue LY, 2003, ONCOGENE, V22, P9197, DOI 10.1038/sj.onc.1207019; Xue LY, 2003, EXP CELL RES, V283, P135, DOI 10.1016/S0014-4827(02)00032-0; Xue LY, 2001, EXP CELL RES, V263, P145, DOI 10.1006/excr.2000.5108; Xue LY, 2001, ONCOGENE, V20, P3420, DOI 10.1038/sj.onc.1204441; YANG T, 1995, J CELL BIOL, V128, P1173, DOI 10.1083/jcb.128.6.1173; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zha JP, 1997, J BIOL CHEM, V272, P24101, DOI 10.1074/jbc.272.39.24101; Zhou P, 1997, BLOOD, V89, P630, DOI 10.1182/blood.V89.2.630	49	14	14	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2005	24	46					6987	6992		10.1038/sj.onc.1208837	http://dx.doi.org/10.1038/sj.onc.1208837			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	975ZD	16007152				2022-12-25	WOS:000232701700014
J	Baldassarre, G; Belletti, B; Battista, S; Nicoloso, MS; Pentimalli, F; Fedele, M; Croce, CM; Fusco, A				Baldassarre, G; Belletti, B; Battista, S; Nicoloso, MS; Pentimalli, F; Fedele, M; Croce, CM; Fusco, A			HMGA1 protein expression sensitizes cells to cisplatin-induced cell death	ONCOGENE			English	Article						HMGA1; BRCA1; knockout; ES cells; apoptosis; DNA damage	NUCLEOTIDE EXCISION-REPAIR; HMGI(Y) PROTEIN; GENE-EXPRESSION; PROSTATE-CANCER; DNA-DAMAGE; BRCA1; CARCINOMA; TRANSFORMATION; CHEMOTHERAPY; APOPTOSIS	HMGA1 proteins belong to a family of nonhistone chromatin proteins able to bind DNA in AT-rich regions and to interact with various transcription factors thus enhancing or inhibiting gene transcription by acting as architectural proteins. Although their expression is very low or absent in many adult tissues, HMGA1 proteins have been frequently found to be upregulated in human cancers and are expressed at high levels during embryogenesis, suggesting they could have a role in highly proliferating cells. We have previously demonstrated that HMGA1 expression in primary breast cancer and mammary carcinoma derived cell lines inversely correlated with BRCA1 expression and that HMGA1 is able to downregulate the expression of BRCA1 gene by binding directly to its promoter region. Being BRCA1 protein expression strictly linked to the DNA repair activity of the cell, we investigated whether HMGA1 expression was able to influence cellular responses to DNA damage. Here, we report that high expression levels of HMGA1 proteins in MCF-7 or mouse embryonic stem cells results in diminished BRCA1 expression and enhanced sensitivity to Cisplatin and Bleomycin. The increased DNA damage-induced cell death in HMGA1-expressing cells is likely due to a diminished cellular DNA repair activity. Therefore, we propose that high expression of HMGA1 protein in human malignant neoplasias, acting on BRCA1 expression, could contribute to the progression of malignant transformation influencing the response of the cells to the damaged DNA.	Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, Ctr Endocrinol & Oncol Sperimentale, CNR,Fac Med & Chirurg, I-80131 Naples, Italy; Ctr Riferimento Oncol, Div Oncol Sperimentale 2, I-33081 Aviano, Italy; New Jersey Med Coll, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Ohio State Univ, Ctr Comprehens Canc, Div Human Canc Genet, Columbus, OH 43210 USA; NOGEC Naple Oncogenom Ctr, CEINGE, Ctr Biotecnol Avanzate, I-80145 Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; IRCCS Aviano (CRO); Jefferson University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; CEINGE Biotecnologie Avanzate	Fusco, A (corresponding author), Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, Ctr Endocrinol & Oncol Sperimentale, CNR,Fac Med & Chirurg, Via Pansini 5, I-80131 Naples, Italy.	afusco@napoli.com	Fedele, Monica/C-1417-2015; Belletti, Barbara/J-2028-2018; Nicoloso, Milena S/K-6411-2012; Battista, Sabrina/AAY-2981-2020; Baldassarre, Gustavo/K-1350-2016; Young, Richard A/F-6495-2012; Pentimalli, Francesca/K-4936-2014	Fedele, Monica/0000-0002-9171-1312; Belletti, Barbara/0000-0003-2249-0285; Nicoloso, Milena S/0000-0003-4231-9303; Battista, Sabrina/0000-0001-5899-9759; Baldassarre, Gustavo/0000-0002-9750-8825; Young, Richard A/0000-0001-8855-8647; Pentimalli, Francesca/0000-0003-4740-6801; Fusco, Alfredo/0000-0003-3332-5197	NATIONAL CANCER INSTITUTE [P30CA056036, P01CA076259] Funding Source: NIH RePORTER; NCI NIH HHS [P01CA76259, P30CA56036] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andres JL, 1998, ONCOGENE, V16, P2229, DOI 10.1038/sj.onc.1201752; Baldassarre G, 1999, ONCOGENE, V18, P6241, DOI 10.1038/sj.onc.1203031; Baldassarre G, 2003, MOL CELL BIOL, V23, P2225, DOI 10.1128/MCB.23.7.2225-2238.2003; Battista S, 2003, FASEB J, V17, P1496, DOI 10.1096/fj.02-0977fje; BERLINGIERI MT, 1995, MOL CELL BIOL, V15, P1545; Bhattacharyya A, 2000, J BIOL CHEM, V275, P23899, DOI 10.1074/jbc.C000276200; Buschfort-Papewalis C, 2002, BLOOD, V100, P845, DOI 10.1182/blood-2002-01-0022; Chiappetta G, 1998, CANCER RES, V58, P4193; Chiappetta G, 1996, ONCOGENE, V13, P2439; Fabbro M, 2004, J BIOL CHEM, V279, P31251, DOI 10.1074/jbc.M405372200; Hartman AR, 2002, NAT GENET, V32, P180, DOI 10.1038/ng953; Husain A, 1998, CANCER RES, V58, P1120; ITO M, 2005, J GENE MED, V8; Liu WM, 1999, CANCER RES, V59, P5695; Masciullo V, 2003, CARCINOGENESIS, V24, P1191, DOI 10.1093/carcin/bgg075; Quinn JE, 2003, CANCER RES, V63, P6221; RAM TG, 1993, CANCER RES, V53, P2655; Reed E, 1998, CANCER TREAT REV, V24, P331, DOI 10.1016/S0305-7372(98)90056-1; Reeves R, 2001, BBA-GENE STRUCT EXPR, V1519, P13, DOI 10.1016/S0167-4781(01)00215-9; Rosen EM, 2001, CANCER INVEST, V19, P396, DOI 10.1081/CNV-100103134; Scala S, 2000, P NATL ACAD SCI USA, V97, P4256, DOI 10.1073/pnas.070029997; Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000; Soldani C, 2002, APOPTOSIS, V7, P321, DOI 10.1023/A:1016119328968; Takaha N, 2002, CANCER RES, V62, P647; TAMIMI Y, 1993, CANCER RES, V53, P5512; Taniguchi T, 2003, NAT MED, V9, P568, DOI 10.1038/nm852	26	22	23	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 13	2005	24	45					6809	6819		10.1038/sj.onc.1208831	http://dx.doi.org/10.1038/sj.onc.1208831			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	973MV	16007157				2022-12-25	WOS:000232527800008
J	Ensenauer, R; He, M; Willard, JM; Goetzman, ES; Corydon, TJ; Vandahl, BB; Mohsen, AW; Isaya, G; Vockley, J				Ensenauer, R; He, M; Willard, JM; Goetzman, ES; Corydon, TJ; Vandahl, BB; Mohsen, AW; Isaya, G; Vockley, J			Human acyl-CoA dehydrogenase-9 plays a novel role in the mitochondrial beta-oxidation of unsaturated fatty acids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; COENZYME-A DEHYDROGENASE; LONG-CHAIN; INTERMEDIATE PEPTIDASE; SUBSTRATE-SPECIFICITY; CRYSTAL-STRUCTURES; CHROMOSOMAL ASSIGNMENT; ISOVALERIC ACIDEMIA; MOLECULAR-CLONING; HUMAN-FIBROBLASTS	Unsaturated fatty acids play an important role in the prevention of human diseases such as diabetes, obesity, cancer, and neurodegeneration. However, their oxidation in vivo by acyl-CoA dehydrogenases (ACADs) that catalyze the first step of each cycle of mitochondrial fatty acid beta-oxidation is not entirely understood. Recently, a novel ACAD (ACAD-9) of unknown function that is highly homologous to human very-long-chain acyl-CoA dehydrogenase was identified by large-scale random sequencing. To characterize its enzymatic role, we have expressed ACAD-9 in Escherichia coli, purified it, and determined its pattern of substrate utilization. The N terminus of the mature form of the enzyme was identified by in vitro mitochondrial import studies of precursor protein. A 37-amino acid leader peptide was cleaved sequentially by two mitochondrial peptidases to yield a predicted molecular mass of 65 kDa for the mature subunit. Submitochondrial fractionation studies found native ACAD-9 to be associated with the mitochondrial membrane. Gel filtration analysis indicated that, like very-long-chain acyl-CoA dehydrogenase, ACAD-9 is a dimer, in contrast to the other known ACADs, which are tetramers. Purified mature ACAD-9 had maximal activity with long-chain unsaturated acyl-CoAs as substrates (C16:1-, C18:1-, C18:2-, C22:6-CoA). These results suggest a previously unrecognized role for ACAD-9 in the mitochondrial beta-oxidation of long-chain unsaturated fatty acids. Because of the substrate specificity and abundance of ACAD-9 in brain, we speculate that it may play a role in the turnover of lipid membrane unsaturated fatty acids that are essential for membrane integrity and structure.	Univ Pittsburgh, Childrens Hosp Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15213 USA; Mayo Clin & Mayo Fdn, Coll Med, Dept Med Genet, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Coll Med, Dept Pediat & Adolescent Med, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Coll Med, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Univ Munich, Dr Von Haunerschen Kinderspital, Childrens Res Ctr, D-80337 Munich, Germany; Univ Pittsburgh, Grad Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA 15213 USA; Univ Aarhus, Dept Human Genet, DK-8000 Aarhus, Denmark; Univ Aarhus, Inst Med Microbiol & Immunol, DK-8000 Aarhus, Denmark	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Mayo Clinic; Mayo Clinic; Mayo Clinic; University of Munich; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Aarhus University; Aarhus University	Vockley, J (corresponding author), Univ Pittsburgh, Childrens Hosp Pittsburgh, Sch Med, Dept Pediat, 3705 5th Ave, Pittsburgh, PA 15213 USA.	gerard.vockley@chp.edu	Vockley, Jerry/B-5210-2016; Vockley, Jerry/AAF-8523-2020; Mohsen, Al-Walid/D-6577-2018	Vockley, Jerry/0000-0002-8180-6457; Vockley, Jerry/0000-0002-8180-6457; Mohsen, Al-Walid/0000-0002-0096-5959; Corydon, Thomas Juhl/0000-0003-3588-6350	NATIONAL INSTITUTE ON AGING [R01AG015709] Funding Source: NIH RePORTER; NIA NIH HHS [R01-AG15709] Funding Source: Medline; NIDDK NIH HHS [R01-DK4548] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andresen BS, 1996, HUM MOL GENET, V5, P461, DOI 10.1093/hmg/5.4.461; Andresen BS, 1999, AM J HUM GENET, V64, P479, DOI 10.1086/302261; AOYAMA T, 1994, J BIOL CHEM, V269, P19088; AOYAMA T, 1995, AM J HUM GENET, V57, P273; Arechaga I, 2000, FEBS LETT, V482, P215, DOI 10.1016/S0014-5793(00)02054-8; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; Battaile KP, 1998, BBA-LIPID LIPID MET, V1390, P333, DOI 10.1016/S0005-2760(97)00185-9; Battaile KP, 2004, J BIOL CHEM, V279, P16526, DOI 10.1074/jbc.M400034200; Battaile KP, 2002, J BIOL CHEM, V277, P12200, DOI 10.1074/jbc.M111296200; Belury MA, 2002, ANNU REV NUTR, V22, P505, DOI 10.1146/annurev.nutr.22.021302.121842; Benatti P, 2004, J AM COLL NUTR, V23, P281, DOI 10.1080/07315724.2004.10719371; BRANDA SS, 1995, J BIOL CHEM, V270, P27366, DOI 10.1074/jbc.270.45.27366; Calon F, 2004, NEURON, V43, P633, DOI 10.1016/j.neuron.2004.08.013; Cavadini P, 2002, METHODS, V26, P298, DOI 10.1016/S1046-2023(02)00035-X; Chew A, 1997, GENOMICS, V40, P493, DOI 10.1006/geno.1996.4586; Corydon Thomas Juhl, 2003, Methods Mol Biol, V232, P183; Corydon TJ, 1998, J BIOL CHEM, V273, P13065, DOI 10.1074/jbc.273.21.13065; Cox KB, 2001, HUM MOL GENET, V10, P2069, DOI 10.1093/hmg/10.19.2069; de Boer HA., 1986, MAXIMIZING GENE EXPR, P225; DeLany JP, 2000, AM J CLIN NUTR, V72, P905; DJORDJEVIC S, 1995, BIOCHEMISTRY-US, V34, P2163, DOI 10.1021/bi00007a009; Edman P, 1975, PROTEIN SEQUENCE DET, P232; FRERMAN FE, 1985, BIOCHEM MED METAB B, V33, P38, DOI 10.1016/0006-2944(85)90124-3; Fu ZJ, 2004, BIOCHEMISTRY-US, V43, P9674, DOI 10.1021/bi049290c; Fusconi E, 2003, TUMORI J, V89, P624, DOI 10.1177/030089160308900606; Gakh E, 2002, BBA-MOL CELL RES, V1592, P63, DOI 10.1016/S0167-4889(02)00265-3; GAVEL Y, 1990, PROTEIN ENG, V4, P33, DOI 10.1093/protein/4.1.33; Gobom J, 1999, J MASS SPECTROM, V34, P105, DOI 10.1002/(SICI)1096-9888(199902)34:2<105::AID-JMS768>3.0.CO;2-4; Hiltunen JK, 2000, BBA-MOL CELL BIOL L, V1484, P117, DOI 10.1016/S1388-1981(00)00013-5; HOCHSTRASSER DF, 1988, ANAL BIOCHEM, V173, P412, DOI 10.1016/0003-2697(88)90208-4; IKEDA Y, 1987, ARCH BIOCHEM BIOPHYS, V252, P662, DOI 10.1016/0003-9861(87)90072-5; IKEDA Y, 1985, J BIOL CHEM, V260, P1311; ISAYA G, 1995, METHOD ENZYMOL, V248, P556; IZAI K, 1992, J BIOL CHEM, V267, P1027; KELLY DP, 1989, J BIOL CHEM, V264, P18921; Kim JJP, 2004, EUR J BIOCHEM, V271, P483, DOI 10.1046/j.1432-1033.2003.03948.x; KIM JJP, 1993, P NATL ACAD SCI USA, V90, P7523, DOI 10.1073/pnas.90.16.7523; Kurtz DM, 1998, P NATL ACAD SCI USA, V95, P15592, DOI 10.1073/pnas.95.26.15592; Le WP, 2000, BBA-MOL CELL BIOL L, V1485, P121, DOI 10.1016/S1388-1981(00)00034-2; Lee HJ, 1996, BIOCHEMISTRY-US, V35, P12412, DOI 10.1021/bi9607867; LEHMAN TC, 1990, ANAL BIOCHEM, V186, P280, DOI 10.1016/0003-2697(90)90080-S; Liang X, 2001, BIOCHEM SOC T, V29, P279, DOI 10.1042/BST0290279; MAO LF, 1995, ARCH BIOCHEM BIOPHYS, V321, P221, DOI 10.1006/abbi.1995.1389; MATSUBARA Y, 1989, J BIOL CHEM, V264, P16321; Mohsen AA, 1998, BIOCHEMISTRY-US, V37, P10325, DOI 10.1021/bi973096r; MOHSEN AWA, 1995, GENE, V160, P263, DOI 10.1016/0378-1119(95)00256-6; Montine KS, 2004, CHEM PHYS LIPIDS, V128, P117, DOI 10.1016/j.chemphyslip.2003.10.010; ROE CR, 2001, METABOLIC MOL BASES, P2297; Roe DS, 2001, CLIN CHIM ACTA, V312, P55, DOI 10.1016/S0009-8981(01)00594-0; Souri M, 1998, FEBS LETT, V426, P187, DOI 10.1016/S0014-5793(98)00343-3; Sweetman L., 2001, METABOLIC MOL BASES, P2125; Tiffany KA, 1997, BIOCHEMISTRY-US, V36, P8455, DOI 10.1021/bi970422u; Toogood HS, 2004, J BIOL CHEM, V279, P32904, DOI 10.1074/jbc.M404884200; Vockley J, 2000, METHOD ENZYMOL, V324, P241; VOCKLEY J, 1992, J BIOL CHEM, V267, P2494; Vockley J, 2002, NEUROMUSCULAR DISORD, V12, P235, DOI 10.1016/S0960-8966(01)00308-X; Wahrburg U, 2004, EUR J NUTR, V43, P6, DOI 10.1007/s00394-004-1103-9; Wanders RJA, 1998, BBA-LIPID LIPID MET, V1393, P35, DOI 10.1016/S0005-2760(98)00053-8; Zhang J, 2002, BIOCHEM BIOPH RES CO, V297, P1033, DOI 10.1016/S0006-291X(02)02336-7	59	74	77	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	2005	280	37					32309	32316		10.1074/jbc.M504460200	http://dx.doi.org/10.1074/jbc.M504460200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	963HM	16020546	hybrid			2022-12-25	WOS:000231794800034
J	Giraud, E; Zappa, S; Vuillet, L; Adriano, JM; Hannibal, L; Fardoux, J; Berthomieu, C; Bouyer, P; Pignol, D; Vermeglio, A				Giraud, E; Zappa, S; Vuillet, L; Adriano, JM; Hannibal, L; Fardoux, J; Berthomieu, C; Bouyer, P; Pignol, D; Vermeglio, A			A new type of bacteriophytochrome acts in tandem with a classical bacteriophytochrome to control the antennae synthesis in Rhodopseudomonas palustris	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOACTIVE YELLOW PROTEIN; CHROMATIC ADAPTATION; AGROBACTERIUM-TUMEFACIENS; HISTIDINE KINASES; LOW-LIGHT; PHYTOCHROME; PHOTORECEPTOR; CHROMOPHORE; PERCEPTION; SIMILARITY	Phytochromes are chromoproteins found in plants and bacteria that switch between two photointerconvertible forms via the photoisomerization of their chromophore. These two forms, Pr and Pfr, absorb red and far- red light, respectively. We have characterized the biophysical and biochemical properties of two bacteriophytochromes, RpBphP2 and RpBphP3, from the photosynthetic bacterium Rhodopseudomonas palustris. Their genes are contiguous and localized near the pucBAd genes encoding the polypeptides of the light harvesting complexes LH4, whose synthesis depends on the light intensity. At variance with all ( bacterio) phytochromes studied so far, the light-induced isomerization of the chromophore of RpBphP3 converts the Pr form to a form absorbing at shorter wavelength around 645 nm, designated as Pnr for near red. The quantum yield for the transformation of Pr into Pnr is about 6-fold smaller than for the reverse reaction. Both RpBphP2 and RpBphP3 auto-phosphorylate in their dark-adapted Pr forms and transfer their phosphate to a common response regulator Rpa3017. Under semi-aerobic conditions, LH4 complexes replace specifically the LH2 complexes in wild-type cells illuminated by wavelengths comprised between 680 and 730 nm. In contrast, mutants deleted in each of these two bacteriophytochromes display no variation in the composition of their light harvesting complexes whatever the light intensity. From both the peculiar properties of these bacteriophytochromes and the phenotypes of their deletion mutants, we propose that they operate in tandem to control the synthesis of LH4 complexes by measuring the relative intensities of 645 and 710 nm lights.	Univ Aix Marseille 2, CEA,CNRS, Cadarache DEVM, Lab Bioenerget Cellulaire,UMR 6191, F-13108 St Paul Les Durance, France; INRA, Lab Symbioses Trop & Mediterraneennes, IRD, CIRAD,AGROM,UM2, F-34398 Montpellier, France	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; CIRAD; INRAE; Institut Agro; Montpellier SupAgro; Institut de Recherche pour le Developpement (IRD); Universite de Montpellier	Vermeglio, A (corresponding author), Univ Aix Marseille 2, CEA,CNRS, Cadarache DEVM, Lab Bioenerget Cellulaire,UMR 6191, F-13108 St Paul Les Durance, France.	avermeglio@cea.fr	Giraud, Eric/GLS-1036-2022; Berthomieu, Catherine/AAX-9559-2021	PIGNOL, David/0000-0002-8070-0319; Berthomieu, Catherine/0000-0001-8784-5396				Bhoo SH, 2001, NATURE, V414, P776, DOI 10.1038/414776a; BOGORAD L, 1975, ANNU REV PLANT PHYS, V26, P369, DOI 10.1146/annurev.pp.26.060175.002101; Davis SJ, 1999, SCIENCE, V286, P2517, DOI 10.1126/science.286.5449.2517; DEMARSAC NT, 1977, J BACTERIOL, V130, P82, DOI 10.1128/JB.130.1.82-91.1977; EVANS MB, 1990, BIOCHIM BIOPHYS ACTA, V1016, P71, DOI 10.1016/0005-2728(90)90008-R; Foerstendorf H, 1996, BIOCHEMISTRY-US, V35, P10793, DOI 10.1021/bi960960r; Foerstendorf H, 2001, BIOCHEMISTRY-US, V40, P14952, DOI 10.1021/bi0156916; Giraud E, 2004, PHOTOCH PHOTOBIO SCI, V3, P587, DOI 10.1039/b315770a; Giraud E, 2004, J BIOL CHEM, V279, P15076, DOI 10.1074/jbc.M312113200; Giraud E, 2002, NATURE, V417, P202, DOI 10.1038/417202a; Hartigan N, 2002, BIOPHYS J, V82, P963, DOI 10.1016/S0006-3495(02)75456-8; Hughes J, 1997, NATURE, V386, P663, DOI 10.1038/386663a0; Jiang ZY, 1999, SCIENCE, V285, P406, DOI 10.1126/science.285.5426.406; JOLIOT P, 1980, J CHIM PHYS PCB, V77, P209, DOI 10.1051/jcp/1980770209; Karniol B, 2003, P NATL ACAD SCI USA, V100, P2807, DOI 10.1073/pnas.0437914100; Kehoe DM, 1996, SCIENCE, V273, P1409, DOI 10.1126/science.273.5280.1409; KOKOTEK W, 1989, GENE, V84, P467, DOI 10.1016/0378-1119(89)90522-2; Kyndt JA, 2004, PHOTOCH PHOTOBIO SCI, V3, P519, DOI 10.1039/b315731h; Lamparter T, 2002, P NATL ACAD SCI USA, V99, P11628, DOI 10.1073/pnas.152263999; Larimer FW, 2004, NAT BIOTECHNOL, V22, P55, DOI 10.1038/nbt923; LINSCHITZ H, 1966, J BIOL CHEM, V241, P3395; QUAIL PH, 1995, SCIENCE, V268, P675, DOI 10.1126/science.7732376; QUANDT J, 1993, GENE, V127, P15, DOI 10.1016/0378-1119(93)90611-6; SINESHCHEKOV VA, 1995, BBA-BIOENERGETICS, V1228, P125, DOI 10.1016/0005-2728(94)00173-3; Smith H, 2000, NATURE, V407, P585, DOI 10.1038/35036500; TADROS MH, 1989, EMBO J, V8, P1303, DOI 10.1002/j.1460-2075.1989.tb03509.x; Terauchi K, 2004, MOL MICROBIOL, V51, P567, DOI 10.1046/j.1365-2958.2003.03853.x; Vila X, 1996, ECOL MODEL, V87, P59, DOI 10.1016/0304-3800(94)00205-3; Yeh KC, 1997, SCIENCE, V277, P1505, DOI 10.1126/science.277.5331.1505; Yoshihara S, 2004, PLANT CELL PHYSIOL, V45, P1729, DOI 10.1093/pcp/pch214; Yoshihara S, 2000, PLANT CELL PHYSIOL, V41, P1299, DOI 10.1093/pcp/pce010	31	116	124	0	15	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	2005	280	37					32389	32397		10.1074/jbc.M506890200	http://dx.doi.org/10.1074/jbc.M506890200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	963HM	16009707	hybrid			2022-12-25	WOS:000231794800044
J	Dulac, C; Michels, AA; Fraldi, A; Bonnet, F; Van Nguyen, T; Napolitano, G; Lania, L; Bensaude, O				Dulac, C; Michels, AA; Fraldi, A; Bonnet, F; Van Nguyen, T; Napolitano, G; Lania, L; Bensaude, O			Transcription-dependent association of multiple positive transcription elongation factor units to a HEXIM multimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; RNA-POLYMERASE-II; P-TEFB; FACTOR-B; GENE-EXPRESSION; CLP-1 GENE; HIV-1 TAT; 7SK SNRNA; KINASE; PROTEIN	The positive transcription elongation factor ( P-TEFb) comprises a kinase, CDK9, and a Cyclin T1 or T2. Its activity is inhibited by association with the HEXIM1 or HEXIM2 protein bound to 7SK small nuclear RNA. HEXIM1 and HEXIM2 were found to form stable homo- and hetero-oligomers. Using yeast two-hybrid and transfection assays, we have now shown that the C-terminal domains of HEXIM proteins directly interact with each other. Hydrodynamic parameters measured by glycerol gradient ultracentrifugation and gel-permeation chromatography demonstrate that both purified recombinant and cellular HEXIM1 proteins form highly anisotropic particles. Chemical cross-links suggest that HEXIM1 proteins form dimers. The multimeric nature of HEXIM1 is maintained in P-TEFb(.)HEXIM1(.)7SK RNA complexes. Multiple P-TEFb modules are found in the inactive P-TEFb(.)HEXIM1(.)7SK complexes. It is proposed that 7SK RNA binding to a HEXIM1 multimer promotes the simultaneous recruitment and hence inactivation of multiple P-TEFb units.	CNRS, UMR 8541, Ecole Normale Super, Lab Regulat Express Genet, F-75230 Paris, France; Univ Naples Federico II, Dipartimento Biol Strutt & Funz, I-80134 Naples, Italy	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); University of Naples Federico II	Bensaude, O (corresponding author), CNRS, UMR 8541, Ecole Normale Super, Lab Regulat Express Genet, 46 Rue Ulm, F-75230 Paris, France.	bensaude@biologie.ens.fr	Fraldi, Alessandro/AAB-2243-2021	Bensaude, Olivier/0000-0002-0259-6608; Napolitano, Giuliana/0000-0002-1637-6016; Michels, Annemieke/0000-0002-1735-1697; Fraldi, Alessandro/0000-0002-7795-0720	Telethon [TGM06S01] Funding Source: Medline	Telethon(Fondazione Telethon)		BARTEL PL, 1995, METHOD ENZYMOL, V254, P241; Byers SA, 2005, J BIOL CHEM, V280, P16360, DOI 10.1074/jbc.M500424200; Fraldi A, 2001, J CELL BIOCHEM, P247; Garber ME, 1998, GENE DEV, V12, P3512, DOI 10.1101/gad.12.22.3512; Garriga J, 2004, GENE, V337, P15, DOI 10.1016/j.gene.2004.05.007; Giudicelli F, 2001, GENE DEV, V15, P567, DOI 10.1101/gad.189801; Huang F, 2004, MECH DEVELOP, V121, P559, DOI 10.1016/j.mod.2004.04.012; Huang FC, 2002, GENE, V292, P245, DOI 10.1016/S0378-1119(02)00596-6; Kusuhara M, 1999, BIOMED RES-TOKYO, V20, P273, DOI 10.2220/biomedres.20.273; Li QT, 2005, J BIOL CHEM, V280, P28819, DOI 10.1074/jbc.M502712200; Licciardo P, 2001, AIDS, V15, P301, DOI 10.1097/00002030-200102160-00002; Medlin JE, 2003, EMBO J, V22, P925, DOI 10.1093/emboj/cdg077; Michels AA, 2004, EMBO J, V23, P2608, DOI 10.1038/sj.emboj.7600275; Michels AA, 2003, MOL CELL BIOL, V23, P4859, DOI 10.1128/MCB.23.14.4859-4869.2003; Nguyen VT, 2001, NATURE, V414, P322, DOI 10.1038/35104581; Ni ZY, 2004, MOL CELL, V13, P55, DOI 10.1016/S1097-2765(03)00526-4; O'Keeffe B, 2000, J BIOL CHEM, V275, P279, DOI 10.1074/jbc.275.1.279; Ouchida R, 2003, GENES CELLS, V8, P95, DOI 10.1046/j.1365-2443.2003.00618.x; Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; Sano M, 2004, EMBO J, V23, P3559, DOI 10.1038/sj.emboj.7600351; Sano M, 2002, NAT MED, V8, P1310, DOI 10.1038/nm778; Schulte A, 2005, J BIOL CHEM, V280, P24968, DOI 10.1074/jbc.M501431200; Shimizu N, 2005, P NATL ACAD SCI USA, V102, P8555, DOI 10.1073/pnas.0409863102; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; Wittmann BM, 2003, CANCER RES, V63, P5151; WITTMANN BM, 2005, IN PRESS ONCOGENE, V24; Yang ZY, 2001, NATURE, V414, P317, DOI 10.1038/35104575; Yik JHN, 2005, J BIOL CHEM, V280, P16368, DOI 10.1074/jbc.M500912200; Yik JHN, 2003, MOL CELL, V12, P971, DOI 10.1016/S1097-2765(03)00388-5; ZIEVE G, 1976, CELL, V8, P19, DOI 10.1016/0092-8674(76)90181-1	31	49	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	2005	280	34					30619	30629		10.1074/jbc.M502471200	http://dx.doi.org/10.1074/jbc.M502471200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	957IC	15994294	hybrid			2022-12-25	WOS:000231362500079
J	Nguyen, Q; Lee, CM; Le, A; Reddy, EP				Nguyen, Q; Lee, CM; Le, A; Reddy, EP			JLP associates with kinesin light chain 1 through a novel leucine zipper-like domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAST AXONAL-TRANSPORT; KINESIN HEAVY-CHAIN; SCAFFOLD PROTEIN; KINASE; IDENTIFICATION; ACTIVATION; APOPTOSIS; NEURONS; COMPLEX; FAMILY	Scaffolding proteins exist in eukaryotes to properly assemble signaling proteins into specific multimeric functional complexes. JLP is a novel leucine zipper protein belonging to a family of scaffolding proteins that assemble JNK signaling modules. JLP is a proline-rich protein that contains two leucine zipper domains and a highly conserved C-terminal domain. We have identified kinesin light chain 1 ( KLC1) as a binding partner for the second leucine zipper domain of JLP using yeast two-hybrid screening. The interaction domain of KLC1 was mapped to its tetratripeptide repeat, which contains a novel leucine zipper-like domain that is crucial for the interaction with JLP. Mutations of Leu-280, Leu-287, Val-294, and Leu-301 within this domain of KLC1 disrupted its ability to associate with JLP. Immunofluorescence studies showed that JLP and KLC1 co-localized in the cytoplasm and that the localization of JLP was dependent on its second leucine zipper. Ectopic expression of a dominant negative form of KLC1 resulted in the mislocalization of endogenous JLP. Moreover, the association between JLP and KLC1 occurred in vivo and was important in the formation of ternary complex with JNK1. These results identify a novel protein-protein interaction between KLC1 and JLP that involves leucine zipper-like domains and support the role of motor proteins in the spatial regulation of signaling modules.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Reddy, EP (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, 3307 N Broad St,AHP Rm 154, Philadelphia, PA 19140 USA.	reddy@temple.edu	Lee, Clement M./E-7104-2012; Reddy, E. Premkumar/F-6233-2011	Lee, Clement M./0000-0003-3486-8492; 	NATIONAL CANCER INSTITUTE [R24CA088261] Funding Source: NIH RePORTER; NCI NIH HHS [R24 CA88261] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUSUBEL EM, 1989, CURRENT PROTOCOLS MO; Blatch GL, 1999, BIOESSAYS, V21, P932, DOI 10.1002/(SICI)1521-1878(199911)21:11<932::AID-BIES5>3.0.CO;2-N; Bowman AB, 2000, CELL, V103, P583, DOI 10.1016/S0092-8674(00)00162-8; Bowman AB, 1999, J CELL BIOL, V146, P165; BRADY ST, 1985, NATURE, V317, P73, DOI 10.1038/317073a0; Cross R, 1999, NAT CELL BIOL, V1, pE119, DOI 10.1038/12947; Diefenbach RJ, 1998, BIOCHEMISTRY-US, V37, P16663, DOI 10.1021/bi981163r; Gatto GJ, 2000, NAT STRUCT BIOL, V7, P1091; Gindhart JG, 1996, TRENDS BIOCHEM SCI, V21, P52, DOI 10.1016/0968-0004(96)80865-6; Goldstein LSB, 2000, ANNU REV NEUROSCI, V23, P39, DOI 10.1146/annurev.neuro.23.1.39; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hollenbeck PJ, 2001, J CELL BIOL, V152, pF25, DOI 10.1083/jcb.152.5.F25; Hurd DD, 1996, GENETICS, V144, P1075; Inomata H, 2003, J BIOL CHEM, V278, P22946, DOI 10.1074/jbc.M212160200; Ito M, 1999, MOL CELL BIOL, V19, P7539; Kelkar N, 2005, MOL CELL BIOL, V25, P2733, DOI 10.1128/MCB.25.7.2733-2743.2005; Kelkar N, 2000, MOL CELL BIOL, V20, P1030, DOI 10.1128/MCB.20.3.1030-1043.2000; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; Lee CM, 2002, P NATL ACAD SCI USA, V99, P14189, DOI 10.1073/pnas.232310199; Liu YS, 1996, FREE RADICAL BIO MED, V21, P771, DOI 10.1016/0891-5849(96)00176-1; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Martin M, 1999, MOL BIOL CELL, V10, P3717, DOI 10.1091/mbc.10.11.3717; Namgung U, 2001, TOXICOL APPL PHARM, V174, P130, DOI 10.1006/taap.2001.9200; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Rahman A, 1998, J BIOL CHEM, V273, P15395, DOI 10.1074/jbc.273.25.15395; SKOUFIAS DA, 1994, J BIOL CHEM, V269, P1477; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; Verhey KJ, 1998, J CELL BIOL, V143, P1053, DOI 10.1083/jcb.143.4.1053; Verhey KJ, 2001, J CELL BIOL, V152, P959, DOI 10.1083/jcb.152.5.959; WARREN TG, 1984, CELL, V39, P547, DOI 10.1016/0092-8674(84)90461-6; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Yasuda J, 1999, MOL CELL BIOL, V19, P7245	32	48	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	2005	280	34					30185	30191		10.1074/jbc.M505499200	http://dx.doi.org/10.1074/jbc.M505499200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	957IC	15987681	hybrid			2022-12-25	WOS:000231362500026
J	Ridge, KM; Linz, L; Flitney, FW; Kuczmarski, ER; Chou, YH; Omary, MB; Sznajder, JI; Goldman, RD				Ridge, KM; Linz, L; Flitney, FW; Kuczmarski, ER; Chou, YH; Omary, MB; Sznajder, JI; Goldman, RD			Keratin 8 phosphorylation by protein kinase C delta regulates shear stress-mediated disassembly of keratin intermediate filaments in alveolar epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELLS; PKC-EPSILON; ACTIVATION; VIMENTIN; EXPRESSION; DISPLACEMENT; NA,K-ATPASE; MODULATION; BINDING; INJURY	Phosphorylation of keratin intermediate filaments ( IF) is known to affect their assembly state and organization; however, little is known about the mechanisms regulating keratin phosphorylation. In this study, we demonstrate that shear stress, but not stretch, causes disassembly of keratin IF in lung alveolar epithelial cells ( AEC) and that this disassembly is regulated by protein kinase C delta-mediated phosphorylation of keratin 8 ( K8) Ser-73. Specifically, in AEC subjected to shear stress, keratin IF are disassembled, as reflected by their increased solubility. In contrast, AEC subjected to stretch showed no changes in the state of assembly of IF. Pretreatment with the protein kinase C ( PKC) inhibitor, bisindolymaleimide, prevents the increase in solubility of either K8 or its assembly partner K18 in shear-stressed AEC. Phosphoserine-specific antibodies demonstrate that K8 Ser-73 is phosphorylated in a time-dependent manner in shear-stressed AEC. Furthermore, we showed that shear stress activates PKC delta and that the PKC delta peptide antagonist, delta V1-1, significantly attenuates the shear stress-induced increase in keratin phosphorylation and solubility. These data suggested that shear stress mediates the phosphorylation of serine residues in K8, leading to the disassembly of IF in alveolar epithelial cells. Importantly, these data provided clues regarding a molecular link between mechanically induced signal transduction and alterations in cytoskeletal IF.	Northwestern Univ, Sch Med, Div Pulm & Crit Care Med, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Dept Mol Cell Biol, Chicago, IL 60611 USA; Vet Affairs Chicago Hlth Care Syst, Med Serv, Chicago, IL 60611 USA	Northwestern University; Northwestern University	Ridge, KM (corresponding author), Northwestern Univ, Sch Med, Div Pulm & Crit Care Med, 240 E Huron,McGaw 2328, Chicago, IL 60611 USA.	kridge@northwestern.edu		Omary, Bishr/0000-0002-8624-2347	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL071643] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE012328] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01-HL71643] Funding Source: Medline; NIDCR NIH HHS [P01-DE12328] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Bilek AM, 2003, J APPL PHYSIOL, V94, P770, DOI 10.1152/japplphysiol.00764.2002; Cheng JJ, 2001, J BIOL CHEM, V276, P31368, DOI 10.1074/jbc.M011317200; Coulombe PA, 2002, CURR OPIN CELL BIOL, V14, P110, DOI 10.1016/S0955-0674(01)00301-5; Dada LA, 2003, J CLIN INVEST, V111, P1057, DOI 10.1172/JCI200316826; DREYFUSS D, 1988, AM REV RESPIR DIS, V137, P1159, DOI 10.1164/ajrccm/137.5.1159; ERIKSSON JE, 1992, P NATL ACAD SCI USA, V89, P11093, DOI 10.1073/pnas.89.22.11093; Ghadiali SN, 2000, J APPL PHYSIOL, V88, P493, DOI 10.1152/jappl.2000.88.2.493; Goldman RD, 1999, FASEB J, V13, pS261, DOI 10.1096/fasebj.13.9002.S261; Guerrero C, 2002, AM J PHYSIOL-LUNG C, V282, pL1099, DOI 10.1152/ajplung.00178.2001; He T, 2002, J BIOL CHEM, V277, P10767, DOI 10.1074/jbc.M111436200; Helmke BP, 2001, BIOPHYS J, V80, P184, DOI 10.1016/S0006-3495(01)76006-7; Helmke BP, 2000, CIRC RES, V86, P745, DOI 10.1161/01.RES.86.7.745; Herrmann H, 2000, CURR OPIN CELL BIOL, V12, P79, DOI 10.1016/S0955-0674(99)00060-5; JANMEY PA, 1991, J CELL BIOL, V113, P155, DOI 10.1083/jcb.113.1.155; Johnson JA, 1996, CIRC RES, V79, P1086, DOI 10.1161/01.RES.79.6.1086; Ku NO, 1996, CANCER METAST REV, V15, P429, DOI 10.1007/BF00054011; Ku NO, 1998, EMBO J, V17, P1892, DOI 10.1093/emboj/17.7.1892; Ku NO, 1997, J BIOL CHEM, V272, P7556, DOI 10.1074/jbc.272.11.7556; Ku NO, 1999, AM J PHYSIOL-GASTR L, V277, pG1108, DOI 10.1152/ajpgi.1999.277.6.G1108; Ku NO, 1996, J CLIN INVEST, V98, P1034, DOI 10.1172/JCI118864; Ku NO, 1998, J CELL BIOL, V143, P2023, DOI 10.1083/jcb.143.7.2023; Ku NO, 2002, J BIOL CHEM, V277, P10775, DOI 10.1074/jbc.M107623200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lecuona E, 1999, AM J RESP CRIT CARE, V159, P603, DOI 10.1164/ajrccm.159.2.9805050; LIAO J, 1995, EXP CELL RES, V219, P348, DOI 10.1006/excr.1995.1238; Liao J, 1996, J CELL BIOL, V133, P345, DOI 10.1083/jcb.133.2.345; Liu MY, 1999, AM J PHYSIOL-LUNG C, V277, pL667, DOI 10.1152/ajplung.1999.277.4.L667; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; NOLLERT MU, 1990, BIOCHEM BIOPH RES CO, V170, P281, DOI 10.1016/0006-291X(90)91271-S; Omary M B, 1998, Subcell Biochem, V31, P105; PAINE R, 1988, DEV BIOL, V129, P505, DOI 10.1016/0012-1606(88)90396-X; Prahlad V, 1998, J CELL BIOL, V143, P159, DOI 10.1083/jcb.143.1.159; Prekeris R, 1996, J CELL BIOL, V132, P77, DOI 10.1083/jcb.132.1.77; Ridge KM, 2002, MOL BIOL CELL, V13, P1381, DOI 10.1091/mbc.01-07-0323; SHOJI M, 1986, BIOCHEM BIOPH RES CO, V135, P1144, DOI 10.1016/0006-291X(86)91047-8; Soh JW, 1999, MOL CELL BIOL, V19, P1313; Stebbins EG, 2001, J BIOL CHEM, V276, P29644, DOI 10.1074/jbc.M101044200; Suzuma I, 2002, J BIOL CHEM, V277, P1047, DOI 10.1074/jbc.M105336200; Sznajder JI, 1998, LUNG BIOL HEALTH DIS, V116, P413; Toivola DM, 1997, J CELL SCI, V110, P23; Traub O, 1997, J BIOL CHEM, V272, P31251, DOI 10.1074/jbc.272.50.31251; Waters CM, 1999, J APPL PHYSIOL, V87, P715, DOI 10.1152/jappl.1999.87.2.715; Wedgwood S, 2001, AM J PHYSIOL-LUNG C, V281, pL490, DOI 10.1152/ajplung.2001.281.2.L490; WOODCOCKMITCHELL J, 1989, AM REV RESPIR DIS, V139, P343, DOI 10.1164/ajrccm/139.2.343; Yoon KH, 2001, J CELL BIOL, V153, P503, DOI 10.1083/jcb.153.3.503; Yoon M, 1998, J CELL BIOL, V143, P147, DOI 10.1083/jcb.143.1.147	46	106	108	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	2005	280	34					30400	30405		10.1074/jbc.M504239200	http://dx.doi.org/10.1074/jbc.M504239200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	957IC	15972820	hybrid			2022-12-25	WOS:000231362500052
J	Zandy, AJ; Lakhani, S; Zheng, T; Flavell, RA; Bassnett, S				Zandy, AJ; Lakhani, S; Zheng, T; Flavell, RA; Bassnett, S			Role of the executioner caspases during lens development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBER CELL-DIFFERENTIATION; ORGANELLE DEGRADATION; MEMBRANE SKELETON; DNA-DEGRADATION; TRANSGENIC MICE; EYE LENS; TGF-BETA; APOPTOSIS; CATARACT; ACTIVATION	The notion that the cell death machinery is utilized during lens organelle degradation is supported by the observation that well characterized apoptotic substrates are cleaved during this process. Here, we test directly the role of executioner caspases ( caspase-3, -6, and -7) in fiber cell differentiation. The distribution of mRNA, protein, and enzymatic activity for each caspase was determined in the mouse lens. Transcripts for all three executioner caspases were identified in lens fiber cells by real time RT-PCR, although only caspase- 6 and -7 proteins were detected subsequently by Western blot analysis. Endogenous proteolytic activity was noted for caspase-3 but not caspase- 6 or -7. We tested the role of executioner caspases in organelle degradation by examining lenses from mice deficient in each caspase. Knock-out lenses appeared grossly normal with the exception of caspase-3(-/-) lenses, which exhibited marked cataracts at the anterior lens pole. The distribution of lens organelles was mapped by confocal microscopy. There was no significant difference in the size of the lens organelle-free zone ( OFZ)(1) between wild-type and knock-out lenses. In response to treatment with staurosporine, caspase- 3 and -6 ( but not caspase-7) enzymatic activities were induced. We generated double knock-out animals to examine the phenotype of lenses deficient in both caspase-3 and -6. Histological examination of such lenses indicated the presence of a properly formed OFZ. Thus, no single executioner caspase ( nor a combination of caspase-3 and -6) is required for organelle loss, although caspase-3 activity may be required for other aspects of lens transparency.	Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Yale Univ, Sch Med, Immunobiol Sect, New Haven, CT 06520 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06520 USA; Biogen Idec Inc, Cambridge, MA USA	Washington University (WUSTL); Washington University (WUSTL); Yale University; Howard Hughes Medical Institute; Yale University; Biogen	Zandy, AJ (corresponding author), Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, 660 S Euclid Ave,Campus Box 8096, St Louis, MO 63110 USA.	ajzandy@artsci.wustl.edu	Lakhani, Sunil R/I-1970-2018	Lakhani, Sunil R/0000-0003-4067-2760; Lakhani, Saquib/0000-0003-3235-3460; Bassnett, Steven/0000-0002-8337-2760	NATIONAL EYE INSTITUTE [R01EY012260, P30EY002687, R01EY009852] Funding Source: NIH RePORTER; NEI NIH HHS [R01EY012260, R01EY009852, EY02687, P30 EY002687] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		APPLEBY DW, 1977, P NATL ACAD SCI USA, V74, P5579, DOI 10.1073/pnas.74.12.5579; Bassnett S, 2003, J EXP BIOL, V206, P4353, DOI 10.1242/jeb.00670; Bassnett S, 1997, J CELL BIOL, V137, P37, DOI 10.1083/jcb.137.1.37; Bassnett S, 2002, EXP EYE RES, V74, P1, DOI 10.1006/exer.2001.1111; BASSNETT S, 1995, INVEST OPHTH VIS SCI, V36, P1793; BASSNETT S, 1992, DEV DYNAM, V194, P85, DOI 10.1002/aja.1001940202; BASSNETT S, 1992, CURR EYE RES, V11, P1227, DOI 10.3109/02713689208999548; Buki KG, 1997, BBA-PROTEIN STRUCT M, V1338, P100, DOI 10.1016/S0167-4838(96)00189-6; CAPETANAKI Y, 1989, J CELL BIOL, V109, P1653, DOI 10.1083/jcb.109.4.1653; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Dahm R, 1998, EUR J CELL BIOL, V75, P237, DOI 10.1016/S0171-9335(98)80118-0; Dahm R, 1999, OPHTHALMIC RES, V31, P163, DOI 10.1159/000055530; Denault JB, 2003, J BIOL CHEM, V278, P34042, DOI 10.1074/jbc.M305110200; Duan HJ, 1996, J BIOL CHEM, V271, P16720, DOI 10.1074/jbc.271.28.16720; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Faulkner-Jones B, 2003, EXP EYE RES, V77, P463, DOI 10.1016/S0014-4835(03)00172-6; Fernando P, 2002, P NATL ACAD SCI USA, V99, P11025, DOI 10.1073/pnas.162172899; Foley JD, 2004, J BIOL CHEM, V279, P32142, DOI 10.1074/jbc.M313683200; FONT RL, 1966, ARCH OPHTHALMOL-CHIC, V75, P475, DOI 10.1001/archopht.1966.00970050477006; Fromm L, 1997, DEV GENET, V20, P276, DOI 10.1002/(SICI)1520-6408(1997)20:3<276::AID-DVG10>3.0.CO;2-6; HAMAI Y, 1975, INVEST OPHTH VISUAL, V14, P517; HAMAI Y, 1974, EXP EYE RES, V18, P537, DOI 10.1016/0014-4835(74)90060-8; Ishizaki Y, 1998, J CELL BIOL, V140, P153, DOI 10.1083/jcb.140.1.153; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Lee A, 2000, DEV DYNAM, V217, P257, DOI 10.1002/(SICI)1097-0177(200003)217:3<257::AID-DVDY4>3.0.CO;2-5; Lee A, 2001, J BIOL CHEM, V276, P20735, DOI 10.1074/jbc.M009723200; Lee EH, 2002, MOL VIS, V8, P235; Leonard JR, 2002, J NEUROPATH EXP NEUR, V61, P673, DOI 10.1093/jnen/61.8.673; Lockshin RA, 2004, ONCOGENE, V23, P2766, DOI 10.1038/sj.onc.1207514; Lovicu FJ, 2002, BRIT J OPHTHALMOL, V86, P220, DOI 10.1136/bjo.86.2.220; Majima K, 2003, OPHTHALMOLOGICA, V217, P215, DOI 10.1159/000068971; Maruno Kevin A, 2002, Clin Exp Optom, V85, P76; McAvoy JW, 2000, CLIN EXP OPHTHALMOL, V28, P133, DOI 10.1046/j.1442-9071.2000.00310.x; Nishimoto S, 2003, NATURE, V424, P1071, DOI 10.1038/nature01895; Sanders EJ, 2003, DIFFERENTIATION, V71, P425, DOI 10.1046/j.1432-0436.2003.7107005.x; Schwerk C, 2003, BIOCHEM PHARMACOL, V66, P1453, DOI 10.1016/S0006-2952(03)00497-0; Shiokawa D, 1999, NUCLEIC ACIDS RES, V27, P4083, DOI 10.1093/nar/27.20.4083; Slee EA, 1999, CELL DEATH DIFFER, V6, P1067, DOI 10.1038/sj.cdd.4400601; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Weil M, 1999, CURR BIOL, V9, P361, DOI 10.1016/S0960-9822(99)80162-6; Wride MA, 1999, DEV BIOL, V213, P142, DOI 10.1006/dbio.1999.9375; Yin XY, 2001, CELL COMMUN ADHES, V8, P373, DOI 10.3109/15419060109080756; Yin XY, 2001, J BIOL CHEM, V276, P34567, DOI 10.1074/jbc.M106073200; Zermati Y, 2001, J EXP MED, V193, P247, DOI 10.1084/jem.193.2.247; Zheng TS, 2000, NAT MED, V6, P1241, DOI 10.1038/81343; Zheng TS, 1999, CELL DEATH DIFFER, V6, P1043, DOI 10.1038/sj.cdd.4400593	47	89	90	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	2005	280	34					30263	30272		10.1074/jbc.M504007200	http://dx.doi.org/10.1074/jbc.M504007200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	957IC	15994297	hybrid			2022-12-25	WOS:000231362500035
J	Babitt, JL; Zhang, Y; Samad, TA; Xia, Y; Tang, J; Campagna, JA; Schneyer, AL; Woolf, CJ; Lin, HY				Babitt, JL; Zhang, Y; Samad, TA; Xia, Y; Tang, J; Campagna, JA; Schneyer, AL; Woolf, CJ; Lin, HY			Repulsive guidance molecule (RGMa), a DRAGON homologue, is a bone morphogenetic protein co-receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E3 UBIQUITIN LIGASE; GROWTH-FACTOR-BETA; VERTEBRATE DEVELOPMENT; EXPRESSION PATTERN; SIGNALING PATHWAYS; DIRECT BINDING; I RECEPTOR; MOUSE; GENE; MEMBRANE	Bone morphogenetic proteins (BMPs) are members of the transforming growth factor beta( TGF-beta) superfamily of ligands, which regulate many mammalian physiologic and pathophysiologic processes. BMPs exert their effects through type I and type II serine/threonine kinase receptors and the Smad intracellular signaling pathway. Recently, the glycosylphosphatidylinositol (GPI)anchored protein DRAGON was identified as a co-receptor for BMP signaling. Here, we investigate whether a homologue of DRAGON, repulsive guidance molecule (RGMa), is similarly involved in the BMP signaling pathway. We show that RGMa enhances BMP, but not TGF-beta, signals in a ligand-dependent manner in cell culture. The soluble extracellular domain of RGMa fused to human Fc ( RGMa. Fc) forms a complex with BMP type I receptors and binds directly and selectively to radiolabeled BMP-2 and BMP-4. RGMa mediates BMP signaling through the classical BMP signaling pathway involving Smad1, 5, and 8, and it up-regulates endogenous inhibitor of differentiation (Id1) protein, an important downstream target of BMP signals. Finally, we demonstrate that BMP signaling occurs in neurons that express RGMa in vivo. These data are consistent with a role for RGMa as a BMP co-receptor.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, Program Membrane Biol, Boston, MA 02129 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Nephrol,Dept Med, Boston, MA 02129 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Anesthesia & Crit Care,Neural Plastic Res Gr, Boston, MA 02129 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Med,Reprod Endocrine Unit, Boston, MA 02129 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital	Lin, HY (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Program Membrane Biol, Boston, MA 02129 USA.	hlin@partners.org	Xia, Yin/M-5440-2018; Woolf, Clifford/A-9784-2010	Xia, Yin/0000-0003-0315-7532; 	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK071837, P30DK057521, F32DK068997] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-071837, DK-57521, F32 DK068997-02, F32 DK068997-01, F32 DK-068997, F32 DK068997] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Balemans W, 2002, DEV BIOL, V250, P231, DOI 10.1006/dbio.2002.0779; Brinks H, 2004, J NEUROSCI, V24, P3862, DOI 10.1523/JNEUROSCI.5296-03.2004; Chen D, 1998, J CELL BIOL, V142, P295, DOI 10.1083/jcb.142.1.295; Cheng SK, 2003, GENE DEV, V17, P31, DOI 10.1101/gad.1041203; Clarke TR, 2001, MOL ENDOCRINOL, V15, P946, DOI 10.1210/me.15.6.946; Costigan M, 1998, J NEUROSCI, V18, P5891; del Re E, 2004, J BIOL CHEM, V279, P22765, DOI 10.1074/jbc.M401350200; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; FROLIK CA, 1984, J BIOL CHEM, V259, P995; Gray PC, 2003, P NATL ACAD SCI USA, V100, P5193, DOI 10.1073/pnas.0531290100; Groppe J, 2002, NATURE, V420, P636, DOI 10.1038/nature01245; Hata A, 1998, GENE DEV, V12, P186, DOI 10.1101/gad.12.2.186; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Hollnagel A, 1999, J BIOL CHEM, V274, P19838, DOI 10.1074/jbc.274.28.19838; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Korchynskyi O, 2002, J BIOL CHEM, V277, P4883, DOI 10.1074/jbc.M111023200; Lin JM, 2005, NAT MED, V11, P387, DOI 10.1038/nm1217; Lopez-Rovira T, 2002, J BIOL CHEM, V277, P3176, DOI 10.1074/jbc.M106826200; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; Macias-Silva M, 1998, J BIOL CHEM, V273, P25628, DOI 10.1074/jbc.273.40.25628; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Matsunaga E, 2004, NAT CELL BIOL, V6, P749, DOI 10.1038/ncb1157; Merino R, 1999, DEV BIOL, V206, P33, DOI 10.1006/dbio.1998.9129; MIYAZONO K, 2002, SCI STKE PE40; Monnier PP, 2002, NATURE, V419, P392, DOI 10.1038/nature01041; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Niederkofler V, 2004, J NEUROSCI, V24, P808, DOI 10.1523/JNEUROSCI.4610-03.2004; Oldekamp J, 2004, GENE EXPR PATTERNS, V4, P283, DOI 10.1016/j.modgep.2003.11.008; Onichtchouk D, 1999, NATURE, V401, P480, DOI 10.1038/46794; Papanikolaou G, 2004, NAT GENET, V36, P77, DOI 10.1038/ng1274; Piscione TD, 2001, AM J PHYSIOL-RENAL, V280, pF19, DOI 10.1152/ajprenal.2001.280.1.F19; Rajagopalan S, 2004, NAT CELL BIOL, V6, P756, DOI 10.1038/ncb1156; RODRIGUEZ MA, 2004, HAEMATOLOGICA, V89, P1441; Samad TA, 2005, J BIOL CHEM, V280, P14122, DOI 10.1074/jbc.M410034200; Samad TA, 2004, J NEUROSCI, V24, P2027, DOI 10.1523/JNEUROSCI.4115-03.2004; Schmidtmer J, 2004, GENE EXPR PATTERNS, V4, P105, DOI 10.1016/S1567-133X(03)00144-3; Shen MM, 2000, TRENDS GENET, V16, P303, DOI 10.1016/S0168-9525(00)02006-0; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Souchelnytskyi S, 1998, J BIOL CHEM, V273, P25364, DOI 10.1074/jbc.273.39.25364; ten Dijke P, 2003, MOL CELL ENDOCRINOL, V211, P105, DOI 10.1016/j.mce.2003.09.016; von Bubnoff A, 2001, DEV BIOL, V239, P1, DOI 10.1006/dbio.2001.0388; Wiater E, 2003, J BIOL CHEM, V278, P7934, DOI 10.1074/jbc.M209710200; XIA Y, 2005, IN PRESS ENDOCRINOLO; Zhang Y, 2001, P NATL ACAD SCI USA, V98, P974, DOI 10.1073/pnas.98.3.974; Zhao GQ, 2003, GENESIS, V35, P43, DOI 10.1002/gene.10167; Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6	49	159	182	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	2005	280	33					29820	29827		10.1074/jbc.M503511200	http://dx.doi.org/10.1074/jbc.M503511200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	954SX	15975920	hybrid			2022-12-25	WOS:000231176200053
J	Ragolia, L; Palaia, T; Hall, CE; Maesaka, JK; Eguchi, N; Urade, Y				Ragolia, L; Palaia, T; Hall, CE; Maesaka, JK; Eguchi, N; Urade, Y			Accelerated glucose intolerance, nephropathy, and atherosclerosis in prostaglandin D-2 synthase knock-out mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; FOCAL ADHESION KINASE; POTENTIAL ROLE; SKELETAL-MUSCLE; EARLY-STAGE; BETA-TRACE; INSULIN; EXPRESSION; GROWTH; MOUSE	Type 2 diabetics have an increased risk of developing atherosclerosis, suggesting the mechanisms that cause this disease are enhanced by insulin resistance. In this study we examined the effects of gene knock-out ( KO) of lipocalin-type prostaglandin D-2 synthase (L-PGDS), a protein found at elevated levels in type 2 diabetics, on diet-induced glucose tolerance and atherosclerosis. Our results show that L-PGDS KO mice become glucose-intolerant and insulin-resistant at an accelerated rate when compared with the C57BL/6 control strain. Adipocytes were significantly larger in the L-PGDS KO mice compared with controls on the same diets. Cell culture data revealed significant differences between insulin-stimulated mitogen-activated protein kinase phosphatase-2, protein-tyrosine phosphatase-1D, and phosphorylated focal adhesion kinase expression levels in L-PGDS KO vascular smooth muscle cells and controls. In addition, only the L-PGDS KO mice developed nephropathy and an aortic thickening reminiscent to the early stages of atherosclerosis when fed a "diabetogenic" high fat diet. We conclude that L-PGDS plays an important role regulating insulin sensitivity and atherosclerosis in type 2 diabetes and may represent a novel model of insulin resistance, atherosclerosis, and diabetic nephropathy.	Winthrop Univ Hosp, Vasc Biol Inst, Mineola, NY 11501 USA; SUNY Stony Brook, Sch Med, Stony Brook, NY 11794 USA; Osaka Biosci Inst, Osaka, Japan	Winthrop University Hospital; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Ragolia, L (corresponding author), Winthrop Univ Hosp, Vasc Biol Inst, 222 Stn Plaza N,Suite 505 B, Mineola, NY 11501 USA.	lragolia@winthrop.org	Ragolia, Louis/AAW-2383-2021	Ragolia, Louis/0000-0002-8292-5159	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067953] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01HL06 7953-01A2] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Awazu M, 1999, J AM SOC NEPHROL, V10, P738; Baron V, 1998, J BIOL CHEM, V273, P7162, DOI 10.1074/jbc.273.12.7162; Breyer MD, 2005, J AM SOC NEPHROL, V16, P27, DOI [10.1681/ASN.2009070721, 10.1681/ASN.2004080648]; Campbell M, 2005, CIRC RES, V96, P197, DOI 10.1161/01.RES.0000152966.88353.9d; Cheng A, 2002, EUR J BIOCHEM, V269, P1050, DOI 10.1046/j.0014-2956.2002.02756.x; Cipollone F, 2004, ARTERIOSCL THROM VAS, V24, P1259, DOI 10.1161/01.ATV.0000133192.39901.be; Claudel T, 2001, P NATL ACAD SCI USA, V98, P2610, DOI 10.1073/pnas.041609298; Eguchi N, 1999, P NATL ACAD SCI USA, V96, P726, DOI 10.1073/pnas.96.2.726; Eguchi Y, 1997, P NATL ACAD SCI USA, V94, P14689, DOI 10.1073/pnas.94.26.14689; Fallow GD, 2004, MOL CELL BIOCHEM, V261, P263, DOI 10.1023/B:MCBI.0000028764.01670.30; Fisher FM, 2005, DIABETOLOGIA, V48, P1084, DOI 10.1007/s00125-005-1758-7; Ganfornina MD, 2005, DEV DYNAM, V232, P191, DOI 10.1002/dvdy.20193; Goel HL, 2002, J MUSCLE RES CELL M, V23, P269, DOI 10.1023/A:1022028808806; Hirawa N, 2001, NEPHRON, V87, P321, DOI 10.1159/000045937; Hsueh WA, 2001, ARTERIOSCL THROM VAS, V21, P1891, DOI 10.1161/hq1201.100261; Huang DS, 2002, J BIOL CHEM, V277, P18151, DOI 10.1074/jbc.M104252200; Imai T, 2001, P NATL ACAD SCI USA, V98, P224, DOI 10.1073/pnas.011528898; Inoue T, 2001, THROMB HAEMOSTASIS, V85, P165; KHARITONENKOV A, 1995, J BIOL CHEM, V270, P29189, DOI 10.1074/jbc.270.49.29189; Law RE, 1996, J CLIN INVEST, V98, P1897, DOI 10.1172/JCI118991; Maier VH, 2000, DIABETES, V49, P618, DOI 10.2337/diabetes.49.4.618; Marks JB, 2000, J DIABETES COMPLICAT, V14, P108, DOI 10.1016/S1056-8727(00)00065-9; MIKHAIL N, 1993, J CARDIOVASC PHARM, V22, pS64; Miwa Y, 2004, BIOCHEM BIOPH RES CO, V322, P428, DOI 10.1016/j.bbrc.2004.07.143; Muhammad Shahid, 2004, Compend Contin Educ Dent, V25, P195; Ortmeyer H K, 2000, Int J Exp Diabetes Res, V1, P195, DOI 10.1155/EDR.2000.195; Ragolia L, 2004, AM J PHYSIOL-CELL PH, V287, pC1273, DOI 10.1152/ajpcell.00230.2004; Ragolia L, 2003, J BIOL CHEM, V278, P22175, DOI 10.1074/jbc.M302769200; Ragolia L, 2003, AM J PHYSIOL-CELL PH, V284, pC119, DOI 10.1152/ajpcell.00247.2002; Reddy ST, 2004, ARTERIOSCL THROM VAS, V24, P1676, DOI 10.1161/01.ATV.0000138342.94314.64; Schreyer SA, 1998, ATHEROSCLEROSIS, V136, P17, DOI 10.1016/S0021-9150(97)00165-2; Schulze MB, 2005, DIABETES, V54, P534, DOI 10.2337/diabetes.54.2.534; Srivastava AK, 2002, INT J MOL MED, V9, P85; Taba Y, 2000, CIRC RES, V86, P967, DOI 10.1161/01.RES.86.9.967; Toriumi Y, 2003, FEBS LETT, V553, P419, DOI 10.1016/S0014-5793(03)01040-8; Wakino S, 2001, ARTERIOSCL THROM VAS, V21, P746, DOI 10.1161/01.ATV.21.5.746; Watson Karol E., 2003, Journal of Cardiovascular Pharmacology and Therapeutics, V8, P253, DOI 10.1177/107424840300800402; Wei P, 2004, DIABETOLOGIA, V47, P1541, DOI 10.1007/s00125-004-1489-1; Wolf G, 2004, EUR J CLIN INVEST, V34, P785, DOI 10.1111/j.1365-2362.2004.01429.x; Xu HY, 2003, J BIOL CHEM, V278, P30187, DOI 10.1074/jbc.M302010200	40	91	91	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	2005	280	33					29946	29955		10.1074/jbc.M502927200	http://dx.doi.org/10.1074/jbc.M502927200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	954SX	15970590	hybrid			2022-12-25	WOS:000231176200067
J	Yuan, HJ; Erreger, K; Dravid, SM; Traynelis, SF				Yuan, HJ; Erreger, K; Dravid, SM; Traynelis, SF			Conserved structural and functional control of N-methyl-D-aspartate receptor Gating by transmembrane domain M3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NMDA RECEPTORS; GLUTAMATE-RECEPTOR; MOLECULAR DETERMINANTS; LURCHER MUTATION; ZINC INHIBITION; CHANNEL; BINDING; SELECTIVITY; ANTAGONIST; ACTIVATION	The molecular events controlling glutamate receptor ion channel gating are complex. The movement of transmembrane domain M3 within N-methyl-D-aspartate ( NMDA) receptor subunits has been suggested to be one structural determinant linking agonist binding to channel gating. Here we report that covalent modification of NR1-A652C or the analogous mutation in NR2A, -2B, -2C, or -2D by methanethiosulfonate ethylammonium ( MTSEA) occurs only in the presence of glutamate and glycine, and that modification potentiates recombinant NMDA receptor currents. The modified channels remain open even after removing glutamate and glycine from the external solution. The degree of potentiation depends on the identity of the NR2 subunit ( NR2A < NR2B < NR2C, D) inversely correlating with previous measurements of channel open probability. MTSEA-induced modification of channels is associated with increased glutamate potency, increased mean single-channel open time, and slightly decreased channel conductance. Modified channels are insensitive to the competitive antagonists D-2-amino-5-phosphonovaleric acid (APV) and 7-Cl-kynurenic acid, as well as allosteric modulators of gating ( extracellular protons and Zn2+). However, channels remain fully sensitive to Mg2+ blockade and partially sensitive to pore block by (+) MK-801, (-) MK-801, ketamine, memantine, amantadine, and dextrorphan. The partial sensitivity to (+) MK-801 may reflect its ability to stimulate agonist unbinding from MTSEA-modified receptors. In summary, these data suggest that the SYTANLAAF motif within M3 is a conserved and critical determinant of channel gating in all NMDA receptors.	Emory Univ, Sch Med, Dept Pharmacol, Rollins Res Ctr, Atlanta, GA 30322 USA	Emory University	Yuan, HJ (corresponding author), Emory Univ, Sch Med, Dept Pharmacol, Rollins Res Ctr, 1510 Clifton Rd, Atlanta, GA 30322 USA.	hyuan@emory.edu		Yuan, Hongjie/0000-0002-8127-7145				Antonov SM, 1996, J PHYSIOL-LONDON, V493, P425, DOI 10.1113/jphysiol.1996.sp021394; Antonov SM, 1998, NAT NEUROSCI, V1, P451, DOI 10.1038/2167; Banke TG, 2005, J NEUROSCI, V25, P42, DOI 10.1523/JNEUROSCI.3154-04.2005; Banke TG, 2003, NAT NEUROSCI, V6, P144, DOI 10.1038/nn1000; BEHE P, 1995, P ROY SOC B-BIOL SCI, V262, P205, DOI 10.1098/rspb.1995.0197; Blanpied TA, 2005, J NEUROSCI, V25, P3312, DOI 10.1523/JNEUROSCI.4262-04.2005; Blanpied TA, 1997, J NEUROPHYSIOL, V77, P309, DOI 10.1152/jn.1997.77.1.309; Bolshakov KV, 2003, J NEUROCHEM, V87, P56, DOI 10.1046/j.1471-4159.2003.01956.x; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Choi YB, 1999, NEURON, V23, P171, DOI 10.1016/S0896-6273(00)80763-1; Colquhoun D, 1998, BRIT J PHARMACOL, V125, P924; Colquhoun D, 1995, FITTING STAT ANAL SI, P483; Dingledine R, 1999, PHARMACOL REV, V51, P7; Erreger K, 2005, J PHYSIOL-LONDON, V563, P345, DOI 10.1113/jphysiol.2004.080028; Erreger Kevin, 2004, Critical Reviews in Neurobiology, V16, P187; Grosman C, 2001, P NATL ACAD SCI USA, V98, P14102, DOI 10.1073/pnas.251402498; Jones KS, 2002, J NEUROSCI, V22, P2044, DOI 10.1523/JNEUROSCI.22-06-02044.2002; KLECKNER NW, 1989, MOL PHARMACOL, V36, P430; Klein RM, 2004, J NEUROSCI, V24, P4941, DOI 10.1523/JNEUROSCI.0660-04.2004; Kohda K, 2000, NAT NEUROSCI, V3, P315, DOI 10.1038/73877; Kuner T, 1996, NEURON, V17, P343, DOI 10.1016/S0896-6273(00)80165-8; Laube B, 1998, J NEUROSCI, V18, P2954; LePage KT, 2005, NEUROPHARMACOLOGY, V49, P1, DOI 10.1016/j.neuropharm.2005.01.029; Low CM, 2003, MOL PHARMACOL, V63, P1212, DOI 10.1124/mol.63.6.1212; Low CM, 2000, P NATL ACAD SCI USA, V97, P11062, DOI 10.1073/pnas.180307497; Premkumar LS, 1997, J GEN PHYSIOL, V109, P181, DOI 10.1085/jgp.109.2.181; Qin F, 2004, BIOPHYS J, V86, P1488, DOI 10.1016/S0006-3495(04)74217-4; Schorge S, 2003, J NEUROSCI, V23, P1151, DOI 10.1523/JNEUROSCI.23-04-01151.2003; Sobolevsky A, 1998, BIOPHYS J, V74, P1305, DOI 10.1016/S0006-3495(98)77844-0; Sobolevsky AI, 2002, NEURON, V33, P75, DOI 10.1016/S0896-6273(01)00560-8; Taverna F, 2000, J BIOL CHEM, V275, P8475, DOI 10.1074/jbc.275.12.8475; Traynelis SF, 1998, J NEUROSCI, V18, P6163; VERDOORN TA, 1989, MOL PHARMACOL, V35, P360; Wollmuth LP, 2004, TRENDS NEUROSCI, V27, P321, DOI 10.1016/j.tins.2004.04.005; Wollmuth LP, 1996, J PHYSIOL-LONDON, V491, P779, DOI 10.1113/jphysiol.1996.sp021257; WOOD MW, 1995, P NATL ACAD SCI USA, V92, P4882, DOI 10.1073/pnas.92.11.4882; Wyllie DJA, 1998, J PHYSIOL-LONDON, V510, P1, DOI 10.1111/j.1469-7793.1998.001bz.x; Yuzaki M, 2003, NEUROSCI RES, V46, P11, DOI 10.1016/S0168-0102(03)00036-1	38	83	87	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	2005	280	33					29708	29716		10.1074/jbc.M414215200	http://dx.doi.org/10.1074/jbc.M414215200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	954SX	15970596	hybrid			2022-12-25	WOS:000231176200041
J	Bhatt, AS; Erdjument-Bromage, H; Tempst, P; Craik, CS; Moasser, MM				Bhatt, AS; Erdjument-Bromage, H; Tempst, P; Craik, CS; Moasser, MM			Adhesion signaling by a novel mitotic substrate of src kinases	ONCOGENE			English	Article						src; Trask; MT-SP1; matriptase; yes; CDCP1	PROTEIN-TYROSINE KINASES; HUMAN-COLON-CARCINOMA; HUMAN COLORECTAL-CANCER; C-SRC; SERINE-PROTEASE; TRANSGENIC MICE; MAMMARY-TUMORS; CELLS; ACTIVATION; MITOSIS	Src kinases are activated and relocalize to the cytoplasm during mitosis, but their mitotic function has remained elusive. We describe here a novel mitotic substrate of src kinases. Trask (transmembrane and associated with src kinases) is a 140 kDa type I transmembrane glycoprotein unrelated to currently known protein families. Src kinases phosphorylate Trask in vitro and mediate its mitotic hyperphosphorylation in vivo. Trask associates with both yes and src, is localized to the cell membrane during interphase, and undergoes cytoplasmic relocalization during mitosis. Overexpression of Trask leads to cell rounding and a loss of adhesion phenotype. Consistent with a function in cell adhesion, Trask interacts with a number of adhesion and matrix proteins including cadherins, syndecans, and the membrane-type serine protease 1 (MT-SP1), and is proteolytically cleaved by MT-SP1. Trask is unique among cell adhesion molecules in that it is under cell cycle regulation and thus links src kinases with the mitotic regulation of cell adhesion. This suggests a potential pathway by which hyperactive src kinases in tumors can deregulate adhesion signaling and mediate the metastatic phenotype.	Univ Calif San Francisco, Sch Med, Dept Med, San Francisco, CA 94143 USA; Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; Memorial Sloan Kettering Cancer Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Moasser, MM (corresponding author), Univ Calif San Francisco, Sch Med, Dept Med, UCSF Box 0875,2340 Sutter St,Rm 144, San Francisco, CA 94143 USA.	mmoasser@medicine.ucsf.edu		Tempst, Paul/0000-0002-6680-3987; Bhatt, Ami/0000-0001-8099-2975; Erdjument-Bromage, Hediye/0000-0003-0224-3594	NCI NIH HHS [R01 CA113952-02, CA 72006, P01 CA072006, R01 CA113952, R01 CA113952-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA113952, P01CA072006] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAGRODIA S, 1991, NATURE, V349, P172, DOI 10.1038/349172a0; BAGRODIA S, 1994, J BIOL CHEM, V269, P10247; Bhatt AS, 2003, BIOL CHEM, V384, P257, DOI 10.1515/BC.2003.029; Boyer B, 2002, ONCOGENE, V21, P2347, DOI 10.1038/sj.onc.1205298; Brown TA, 2004, J BIOL CHEM, V279, P14772, DOI 10.1074/jbc.M309678200; CARTWRIGHT CA, 1989, J CLIN INVEST, V83, P2025, DOI 10.1172/JCI114113; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; DAVIDPFEUTY T, 1990, J CELL BIOL, V111, P3097, DOI 10.1083/jcb.111.6.3097; Erdjument-Bromage H, 1998, J CHROMATOGR A, V826, P167, DOI 10.1016/S0021-9673(98)00705-5; ERPEL T, 1995, CURR OPIN CELL BIOL, V7, P176, DOI 10.1016/0955-0674(95)80025-5; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; Geromanos S, 2000, ANAL CHEM, V72, P777, DOI 10.1021/ac991071n; GUY CT, 1994, GENE DEV, V8, P23, DOI 10.1101/gad.8.1.23; Hooper JD, 2003, ONCOGENE, V22, P1783, DOI 10.1038/sj.onc.1206220; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; Jones RJ, 2002, BRIT J CANCER, V87, P1128, DOI 10.1038/sj.bjc.6600594; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KAPLAN KB, 1992, J CELL BIOL, V118, P321, DOI 10.1083/jcb.118.2.321; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Kraker AJ, 2000, BIOCHEM PHARMACOL, V60, P885, DOI 10.1016/S0006-2952(00)00405-6; Lee SL, 2000, J BIOL CHEM, V275, P36720, DOI 10.1074/jbc.M007802200; Lukong KE, 2003, BBA-REV CANCER, V1653, P73, DOI 10.1016/j.bbcan.2003.09.001; Mamidipudi V, 2004, MOL CELL BIOL, V24, P6788, DOI 10.1128/MCB.24.15.6788-6798.2004; Mao WG, 1997, ONCOGENE, V15, P3083, DOI 10.1038/sj.onc.1201496; Mizenina OA, 2004, CELL CYCLE, V3, P796; Moasser MM, 1999, CANCER RES, V59, P6145; MUSTELIN T, 2002, SCI STKE, V115, pPE3; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; PARK J, 1995, MOL CELL BIOL, V15, P2374; PARK JS, 1993, ONCOGENE, V8, P2627; PENA SV, 1995, GASTROENTEROLOGY, V108, P117, DOI 10.1016/0016-5085(95)90015-2; ROCHE S, 1995, SCIENCE, V269, P1567, DOI 10.1126/science.7545311; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; ROSEN N, 1986, J BIOL CHEM, V261, P3754; Santin AD, 2004, INT J CANCER, V112, P14, DOI 10.1002/ijc.20408; Scherl-Mostageer M, 2001, ONCOGENE, V20, P4402, DOI 10.1038/sj.onc.1204566; Sugimura M, 2000, JPN J CANCER RES, V91, P395, DOI 10.1111/j.1349-7006.2000.tb00958.x; Takeuchi T, 2000, J BIOL CHEM, V275, P26333, DOI 10.1074/jbc.M002941200; Tatsuka M, 1996, MOL CARCINOGEN, V15, P300, DOI 10.1002/(SICI)1098-2744(199604)15:4<300::AID-MC7>3.0.CO;2-J; TAYLOR SJ, 1995, J BIOL CHEM, V270, P10120, DOI 10.1074/jbc.270.17.10120; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; WANG LL, 1995, J BIOL CHEM, V270, P2010, DOI 10.1074/jbc.270.5.2010; WEBSTER MA, 1995, P NATL ACAD SCI USA, V92, P7849, DOI 10.1073/pnas.92.17.7849	44	106	117	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 11	2005	24	34					5333	5343		10.1038/sj.onc.1208582	http://dx.doi.org/10.1038/sj.onc.1208582			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	954MF	16007225	Green Accepted			2022-12-25	WOS:000231158500007
J	Messina, A; Bortolotto, SK; Cassell, OCS; Kelly, J; Abberton, KM; Morrison, WA				Messina, A; Bortolotto, SK; Cassell, OCS; Kelly, J; Abberton, KM; Morrison, WA			Generation of a vascularized organoid using skeletal muscle as the inductive source	FASEB JOURNAL			English	Article						tissue engineering; rat; adipogenesis; myogenesis; angiogenesis	MESENCHYMAL STEM-CELLS; FIBROBLAST-GROWTH-FACTOR; IN-VIVO; ARTERIOVENOUS SHUNT; BASEMENT-MEMBRANE; BLOOD-VESSELS; BONE-MARROW; TISSUE; TRANSPLANTATION; SKIN	The technology required for creating an in vivo microenvironment and a neovasculature that can grow with and service new tissue is lacking, precluding the possibility of engineering complex three-dimensional organs. We have shown that when an arterio-venous ( AV) loop is constructed in vivo in the rat groin, and placed inside a semisealed chamber, an extensive functional vasculature is generated. To test whether this unusually angiogenic environment supports the survival and growth of implanted tissue or cells, we inserted various preparations of rat and human skeletal muscle. We show that after 6 weeks incubation of muscle tissue, the chamber filled with predominantly well-vascularized recipient-derived adipose tissue, but some new donor-derived skeletal muscle and connective tissue were also evident. When primary cultured myoblasts were inserted into the chamber with the AV loop, they converted to mature striated muscle fibers. Furthermore, we identify novel adipogenesis-inducing properties of skeletal muscle. This represents the first report of a specific three-dimensional tissue grown on its own vascular supply.	Univ Melbourne, Dept Surg, Parkville, Vic 3052, Australia; St Vincents Hosp, Bernard O Brien Inst Microsurg, Fitzroy, Vic 3065, Australia	University of Melbourne; St Vincent's Hospital Melbourne	Messina, A (corresponding author), Bernard O Brien Inst Microsurg, 42 Fitzory St, Fitzroy, Vic 3065, Australia.	messinaa@svhm.org.au		Abberton, Keren/0000-0001-6009-9725				Alsberg E, 2002, P NATL ACAD SCI USA, V99, P12025, DOI 10.1073/pnas.192291499; Auger FA, 2004, BIOTECHNOL APPL BIOC, V39, P263; Barbero A, 2001, J CELL PHYSIOL, V186, P183, DOI 10.1002/1097-4652(200102)186:2<183::AID-JCP1020>3.3.CO;2-H; CARLSON BM, 1968, J MORPHOL, V125, P447, DOI 10.1002/jmor.1051250405; Cassell OCS, 2001, ANN NY ACAD SCI, V944, P429; Chaikof EL, 2002, ANN NY ACAD SCI, V961, P96, DOI 10.1111/j.1749-6632.2002.tb03057.x; CINTI S, 1989, ANAT REC, V224, P466, DOI 10.1002/ar.1092240403; Coraux C, 2003, CURR BIOL, V13, P849, DOI 10.1016/S0960-9822(03)00296-3; Cronin KJ, 2004, PLAST RECONSTR SURG, V113, P260, DOI 10.1097/01.PRS.0000095942.71618.9D; Crosby HA, 2001, GUT, V48, P153, DOI 10.1136/gut.48.2.153; Csete M, 2001, J CELL PHYSIOL, V189, P189, DOI 10.1002/jcp.10016; Cunha G R, 1992, Epithelial Cell Biol, V1, P105; Devine SM, 2001, EXP HEMATOL, V29, P244, DOI 10.1016/S0301-472X(00)00635-4; Eastlick HL, 1943, J EXP ZOOL, V93, P27, DOI 10.1002/jez.1400930103; FONTAINE M, 1995, J PEDIATR SURG, V30, P56, DOI 10.1016/0022-3468(95)90610-X; Germain L, 2000, MED BIOL ENG COMPUT, V38, P232, DOI 10.1007/BF02344782; Griffith LG, 2002, ANN NY ACAD SCI, V961, P83, DOI 10.1111/j.1749-6632.2002.tb03056.x; Gu Y, 2001, CELL TRANSPLANT, V10, P453; Guan JY, 1998, DIABETES, V47, P1020, DOI 10.2337/diabetes.47.7.1020; GUSSONI E, 1992, NATURE, V356, P435, DOI 10.1038/356435a0; Hunt EA, 1932, J EXP ZOOL, V62, P57, DOI 10.1002/jez.1400620103; Irintchev A, 1998, J CELL SCI, V111, P3287; Kaihara S, 2000, TISSUE ENG, V6, P105, DOI 10.1089/107632700320739; Kawaguchi N, 1998, P NATL ACAD SCI USA, V95, P1062, DOI 10.1073/pnas.95.3.1062; Kimura Y, 2003, BIOMATERIALS, V24, P2513, DOI 10.1016/S0142-9612(03)00049-8; KLEINMAN HK, 1986, BIOCHEMISTRY-US, V25, P312, DOI 10.1021/bi00350a005; Koike N, 2004, NATURE, V428, P138, DOI 10.1038/428138a; Liechty KW, 2000, NAT MED, V6, P1282, DOI 10.1038/81395; LOKMIC Z, 2004, ENCY BIOMATERIALS BI; Lucas Paul A., 1995, Wound Repair and Regeneration, V3, P449, DOI 10.1046/j.1524-475X.1995.30409.x; Marler JJ, 1998, ADV DRUG DELIVER REV, V33, P165, DOI 10.1016/S0169-409X(98)00025-8; MATHIEU O, 1981, J MICROSC-OXFORD, V121, P75, DOI 10.1111/j.1365-2818.1981.tb01200.x; Mattioli-Belmonte M, 2003, INT J ARTIF ORGANS, V26, P1077, DOI 10.1177/039139880302601205; Mian RA, 2001, TISSUE ENG, V7, P73, DOI 10.1089/107632700300003305; Ochoa ER, 2002, ANN NY ACAD SCI, V979, P10, DOI 10.1111/j.1749-6632.2002.tb04863.x; Peng HR, 2004, TRANSPL IMMUNOL, V12, P311, DOI 10.1016/j.trim.2003.12.009; Sachlos E., 2003, European Cells & Materials, V5, P29; Smythe GM, 2000, CELL TRANSPLANT, V9, P379, DOI 10.1177/096368970000900309; Soker S, 2000, WORLD J UROL, V18, P10, DOI 10.1007/PL00007070; Tanaka Y, 2000, BRIT J PLAST SURG, V53, P51, DOI 10.1054/bjps.1999.3186; WAKE MC, 1994, CELL TRANSPLANT, V3, P339, DOI 10.1177/096368979400300411; Warejcka DJ, 1996, J SURG RES, V62, P233, DOI 10.1006/jsre.1996.0201; Whitaker MJ, 2001, J PHARM PHARMACOL, V53, P1427, DOI 10.1211/0022357011777963; WILLIAMS D, 2004, MED DEVICE TECHNOL, V15, P8; Xaymardan M, 2002, ANAT RECORD, V267, P28, DOI 10.1002/ar.10072; YOUNG HE, 1995, DEV DYNAM, V202, P137, DOI 10.1002/aja.1002020205; ZACKS SI, 1977, LAB INVEST, V36, P303	47	73	74	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2005	19	9					1570	+		10.1096/fj.04-3241fje	http://dx.doi.org/10.1096/fj.04-3241fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	951IO	16014398				2022-12-25	WOS:000230923000021
J	Lee, WC; Courtenay, A; Troendle, FJ; Stallings- Mann, ML; Dickey, CA; DeLucia, MW; Dickson, DW; Eckman, CB				Lee, WC; Courtenay, A; Troendle, FJ; Stallings- Mann, ML; Dickey, CA; DeLucia, MW; Dickson, DW; Eckman, CB			Enzyme replacement therapy results in substantial improvements in early clinical phenotype in a mouse model of globoid cell leukodystrophy	FASEB JOURNAL			English	Article						Krabbe disease; lysosomal storage disorder; protein therapy; twitcher; blood brain barrier	CENTRAL-NERVOUS-SYSTEM; TWITCHER MOUSE; KRABBE-DISEASE; PSYCHOSINE CYTOTOXICITY; PHORBOL ESTER; MURINE MODEL; TRANSPLANTATION; PATHOLOGY; GALACTOSYLSPHINGOSINE; LEUCODYSTROPHY	Globoid cell leukodystrophy (GLD) or Krabbe disease is a devastating, degenerative neurological disorder caused by mutations in the galactosylceramidase (GALC) gene that severely affect enzyme activity. Currently, treatment options for this disorder are very limited. Enzyme replacement therapy (ERT) has been shown to be effective in lysosomal storage disorders with predominantly peripheral manifestations such as type I Gaucher's and Fabry's disease. Little however is known about the possible benefit of ERT in GLD, which has a substantial central nervous system component. In this study, we examined the effect of peripheral GALC injections in the twitcher mouse model of the disease. Although we were unable to block the precipitous decline that normally occurs just before death, we did observe significant early improvements in motor performance, a substantial attenuation in the initial failure to thrive, and an increase in life span. Immunohistochemical and activity analyses demonstrated GALC uptake in multiple tissues, including the brain. This was associated with a decrease in the abnormal accumulation of the GALC substrate psychosine, which is thought to play a pivotal role in disease pathology. These results indicate that peripheral ERT is likely to be beneficial in GLD.	Mayo Clin, Coll Med, Dept Pharmacol, Jacksonville, FL 32224 USA; Mayo Clin, Coll Med, Dept Neurosci, Jacksonville, FL 32224 USA	Mayo Clinic; Mayo Clinic	Eckman, CB (corresponding author), Mayo Clin, Coll Med, Dept Pharmacol, Birdsall Bldg,Room 327,4500 San Pablo Rd, Jacksonville, FL 32224 USA.	Eckman@mayo.edu	Dickey, Chad A/H-4441-2011	Dickson, Dennis W/0000-0001-7189-7917; Stallings-Mann, Melody/0000-0003-3227-6063; Lee, Chris/0000-0001-9068-5274	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS044230] Funding Source: NIH RePORTER; NINDS NIH HHS [NS44230] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BEMBI B, 1994, LANCET, V344, P1679, DOI 10.1016/S0140-6736(94)90462-6; Cohen IJ, 1998, BLOOD CELL MOL DIS, V24, P296, DOI 10.1006/bcmd.1998.0195; De Gasperi R, 2004, GENE THER, V11, P1188, DOI 10.1038/sj.gt.3302282; Desnick RJ, 2002, NAT REV GENET, V3, P954, DOI 10.1038/nrg963; DUCHEN LW, 1980, BRAIN, V103, P695, DOI 10.1093/brain/103.3.695; Dunder U, 2000, FASEB J, V14, P361, DOI 10.1096/fasebj.14.2.361; Eng CM, 2001, NEW ENGL J MED, V345, P9, DOI 10.1056/NEJM200107053450102; GAL AE, 1977, CLIN CHIM ACTA, V77, P53, DOI 10.1016/0009-8981(77)90401-6; HOOGERBRUGGE PM, 1988, J CLIN INVEST, V81, P1790, DOI 10.1172/JCI113521; HOOGERBRUGGE PM, 1988, SCIENCE, V239, P1035, DOI 10.1126/science.3278379; JACOBS JM, 1982, J NEUROL SCI, V55, P285, DOI 10.1016/0022-510X(82)90127-7; Kaye Edward M., 1995, Current Opinion in Pediatrics, V7, P650; KOBAYASHI T, 1980, BRAIN RES, V202, P479, DOI 10.1016/0006-8993(80)90159-6; KOLODNY EH, 1996, HDB CLIN NEUROLOGY, V22, P187; KONDO A, 1987, BRAIN RES, V425, P186, DOI 10.1016/0006-8993(87)90499-9; Krivit W, 2004, SPRINGER SEMIN IMMUN, V26, P119, DOI 10.1007/s00281-004-0166-2; Krivit W, 1998, NEW ENGL J MED, V338, P1119, DOI 10.1056/NEJM199804163381605; Matsuda J, 2001, HUM MOL GENET, V10, P2709, DOI 10.1093/hmg/10.23.2709; Matsumoto A, 1997, DEV BRAIN DYSFUNCT, V10, P142; MIYATAKE T, 1972, BIOCHEM BIOPH RES CO, V48, P538, DOI 10.1016/0006-291X(72)90381-6; NEUFELD EF, 2004, LYSOSOMAL DISORDERS, P327; OLMSTEAD CE, 1987, BEHAV BRAIN RES, V25, P143, DOI 10.1016/0166-4328(87)90007-6; Pedchenko TV, 1999, EXP NEUROL, V158, P459, DOI 10.1006/exnr.1999.7125; Roces DP, 2004, HUM MOL GENET, V13, P1979, DOI 10.1093/hmg/ddh220; Sakai N, 1996, J NEUROCHEM, V66, P1118, DOI 10.1046/j.1471-4159.1996.66031118.x; Schiffmann R, 2001, JAMA-J AM MED ASSOC, V285, P2743, DOI 10.1001/jama.285.21.2743; Scriver C.R., 2001, METABOLIC MOL BASES, P3669; SHAPIRO E, 1991, TREATMENT GENETIC DI, P223; Shen JS, 2001, GENE THER, V8, P1081, DOI 10.1038/sj.gt.3301495; Sly W S, 1978, Prog Clin Biol Res, V23, P547; SUGAMA S, 1990, PEDIATR RES, V28, P473, DOI 10.1203/00006450-199011000-00011; SUGAMA S, 1991, BRAIN DEV-JPN, V13, P104, DOI 10.1016/S0387-7604(12)80116-1; SUZUKI K, 1983, AM J PATHOL, V111, P394; SUZUKI K, 1970, P NATL ACAD SCI USA, V66, P302, DOI 10.1073/pnas.66.2.302; SUZUKI K, 1988, LAB INVEST, V58, P302; SUZUKI K, 1995, MICROSC RES TECHNIQ, V32, P204, DOI 10.1002/jemt.1070320304; SUZUKI K, 1995, BRAIN PATHOL, V5, P249, DOI 10.1111/j.1750-3639.1995.tb00601.x; SUZUKI K, 1989, METABOLIC BASIS INHE, P1699; TANAKA K, 1993, J NEUROPATH EXP NEUR, V52, P490, DOI 10.1097/00005072-199309000-00007; TANAKA K, 1989, BRAIN RES, V482, P347, DOI 10.1016/0006-8993(89)91198-0; Taniike M, 1999, J NEUROPATH EXP NEUR, V58, P644, DOI 10.1097/00005072-199906000-00009; Tohyama J, 2001, NEUROCHEM RES, V26, P667, DOI 10.1023/A:1010991420942; Vanier M, 1976, Adv Exp Med Biol, V68, P115; Wenger D.A., 1997, MOL GENETIC BASIS NE, P421; Wenger DA, 2000, MOL GENET METAB, V70, P1, DOI 10.1006/mgme.2000.2990; Wu YP, 2000, J NEUROPATH EXP NEUR, V59, P628, DOI 10.1093/jnen/59.7.628; YEAGER AM, 1984, SCIENCE, V225, P1052, DOI 10.1126/science.6382609; [No title captured]	48	73	76	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2005	19	8					1549	+		10.1096/fj.05-3826fje	http://dx.doi.org/10.1096/fj.05-3826fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	15987783				2022-12-25	WOS:000230207800002
J	Ren-Patterson, RF; Kim, DK; Zheng, X; Sherrill, S; Huang, SJ; Tolliver, T; Murphy, DL				Ren-Patterson, RF; Kim, DK; Zheng, X; Sherrill, S; Huang, SJ; Tolliver, T; Murphy, DL			Serotonergic-like progenitor cells propagated from neural stem cells in vitro: survival with SERT protein expression following implantation into brains of mice lacking SERT	FASEB JOURNAL			English	Article						precursor; differentiation; serotonin transporter; uptake	DOPAMINERGIC PHENOTYPE; NEUROTROPHIC FACTOR; NEURONS; DIFFERENTIATION; CNS; MOUSE; TRANSPLANTATION; INDUCTION; MIDBRAIN; THERAPY	Neural stem cells (NSCs) obtained from the midbrain region of embryonic (E14) mice were initially cultured with basic fibroblast growth factor ( bFGF), Sonic hedgehog, and FGF-8 in a serum-free N-2 culture medium to foster differentiation into a serotonergic-like phenotype. During the initial differentiating phase, these progenitor cells expressed En1, Pax3, and Pax5 mRNA. Subsequently, a single serotonin [5- hydroxytryptamine (5-HT)] and tryptophan hydroxylase-positive clone was isolated, which gave rise to cells that developed serotonergic properties. Sixty percent of these progenitor cells expressed the serotonin transporter (SERT), as indicated by specific ligand binding of [I-125]-RTI-55. To further evaluate SERT functionality, we showed that these progenitor cells possessed specific [H-3]-5-HT uptake activity. Implantation of the serotonergic-like progenitors into the hippocampus of adult mice genetically lacking SERT was followed by migration of these cells into adjacent brain regions, and survival of the cells at 8 weeks was accompanied by a gradual increase in density of SERT protein expression, which was not found in vehicle-injected, control mice. These findings suggest that this serotonergic-like NSC model will be a useful contribution to the development of cell biotechnology in regard to the expression of missing genes such as SERT in the adult brain.	NIMH, Clin Sci Lab, NIH, Bethesda, MD 20892 USA; Natl Inst Neurol Disorders & Stroke, NIH, Bethesda, MD USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Ren-Patterson, RF (corresponding author), NIMH, Clin Sci Lab, NIH, Bldg 10 Room 3D41, Bethesda, MD 20892 USA.	renpatr@intra.nimh.nih.gov			Intramural NIH HHS Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [Z01MH000332, ZIAMH000332] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Alvarez-Buylla A, 2001, NAT REV NEUROSCI, V2, P287, DOI 10.1038/35067582; Barberi T, 2003, NAT BIOTECHNOL, V21, P1200, DOI 10.1038/nbt870; Bengel D, 1998, MOL PHARMACOL, V53, P649, DOI 10.1124/mol.53.4.649; Brezun JM, 2000, EUR J NEUROSCI, V12, P391, DOI 10.1046/j.1460-9568.2000.00932.x; Chiba S, 2003, CELL TRANSPLANT, V12, P457, DOI 10.3727/000000003108747019; Dziewczapolski G, 2003, EXP NEUROL, V183, P653, DOI 10.1016/S0014-4886(03)00212-7; Eaton M, 1996, EXP NEUROL, V140, P105, DOI 10.1006/exnr.1996.0121; Flax JD, 1998, NAT BIOTECHNOL, V16, P1033, DOI 10.1038/3473; GAGE FH, 1995, P NATL ACAD SCI USA, V92, P11879, DOI 10.1073/pnas.92.25.11879; GAGE FH, 1995, ANNU REV NEUROSCI, V18, P159, DOI 10.1146/annurev.neuro.18.1.159; Gage FH, 1998, NATURE, V392, P18; Galter D, 2000, J NEUROSCI RES, V61, P295, DOI 10.1002/1097-4547(20000801)61:3<295::AID-JNR7>3.0.CO;2-4; Hochedlinger K, 2003, NEW ENGL J MED, V349, P275, DOI 10.1056/NEJMra035397; Hynes M, 1999, CURR OPIN NEUROBIOL, V9, P26, DOI 10.1016/S0959-4388(99)80004-X; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Kawasaki H, 2000, NEURON, V28, P31, DOI 10.1016/S0896-6273(00)00083-0; Kondo T, 2000, SCIENCE, V289, P1754, DOI 10.1126/science.289.5485.1754; LaBarge MA, 2002, CELL, V111, P589, DOI 10.1016/S0092-8674(02)01078-4; Lai ZN, 2002, P NATL ACAD SCI USA, V99, P3651, DOI 10.1073/pnas.062032499; Lee SH, 2000, NAT BIOTECHNOL, V18, P675, DOI 10.1038/76536; Lun K, 1998, DEVELOPMENT, V125, P3049; MartinezSerrano A, 1997, TRENDS NEUROSCI, V20, P530, DOI 10.1016/S0166-2236(97)01119-3; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; McKay R, 2002, ANN NY ACAD SCI, V961, P44, DOI 10.1111/j.1749-6632.2002.tb03045.x; Mochizuki H, 1998, J VIROL, V72, P8873, DOI 10.1128/JVI.72.11.8873-8883.1998; Mossner R, 2000, NEUROCHEM INT, V36, P197, DOI 10.1016/S0197-0186(99)00122-9; Ourednik J, 2002, NAT BIOTECHNOL, V20, P1103, DOI 10.1038/nbt750; Ourednik V, 2001, SCIENCE, V293, P1820, DOI 10.1126/science.1060580; Pfeffer PL, 1998, DEVELOPMENT, V125, P3063; Rosenthal A, 1998, NEURON, V20, P169, DOI 10.1016/S0896-6273(00)80445-6; ROWITCH DH, 1995, MECH DEVELOP, V52, P3, DOI 10.1016/0925-4773(95)00380-J; Rumajogee P, 2002, J NEUROCHEM, V83, P1525, DOI 10.1046/j.1471-4159.2002.01264.x; Salli U, 2004, EXP NEUROL, V188, P351, DOI 10.1016/j.expneurol.2004.04.015; Saucedo-Cardenas O, 1998, P NATL ACAD SCI USA, V95, P4013, DOI 10.1073/pnas.95.7.4013; Shihabuddin LS, 2004, J NEUROSCI, V24, P10642, DOI 10.1523/JNEUROSCI.3584-04.2004; SILVERTHORN ML, 1995, J PHARMACOL EXP THER, V273, P213; Smidt MP, 1997, P NATL ACAD SCI USA, V94, P13305, DOI 10.1073/pnas.94.24.13305; Snyder EY, 1997, P NATL ACAD SCI USA, V94, P11663, DOI 10.1073/pnas.94.21.11663; Studer L, 1998, NAT NEUROSCI, V1, P290, DOI 10.1038/1105; Stull ND, 2001, EXP NEUROL, V169, P36, DOI 10.1006/exnr.2001.7640; Sugaya K, 2003, CELL MOL LIFE SCI, V60, P1891, DOI 10.1007/s00018-002-3014-y; Svendsen C N, 2000, Prog Brain Res, V127, P13; Tao R, 2000, J PSYCHOPHARMACOL, V14, P100, DOI 10.1177/026988110001400201; Temple S, 2001, NAT REV NEUROSCI, V2, P513, DOI 10.1038/35081577; Verma IM, 1997, NATURE, V389, P239, DOI 10.1038/38410; Vogel G, 2000, SCIENCE, V290, P1672, DOI 10.1126/science.290.5497.1672; Wagner J, 1999, NAT BIOTECHNOL, V17, P653, DOI 10.1038/10862; Yang M, 2003, CELL MOL NEUROBIOL, V23, P851, DOI 10.1023/A:1025017423102; Ye WL, 1998, CELL, V93, P755, DOI 10.1016/S0092-8674(00)81437-3; Zetterstrom RH, 1997, SCIENCE, V276, P248, DOI 10.1126/science.276.5310.248; Zhou JW, 2000, BRAIN RES, V877, P37, DOI 10.1016/S0006-8993(00)02624-X	51	6	6	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2005	19	8					1537	+		10.1096/fj.04-3657fje	http://dx.doi.org/10.1096/fj.04-3657fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	15972295				2022-12-25	WOS:000230207800013
J	Stoter, M; Bamberger, AM; Aslan, B; Kurth, M; Speidel, D; Loning, T; Frank, HG; Kaufmann, P; Lohler, J; Henne-Bruns, D; Deppert, W; Knippschild, U				Stoter, M; Bamberger, AM; Aslan, B; Kurth, M; Speidel, D; Loning, T; Frank, HG; Kaufmann, P; Lohler, J; Henne-Bruns, D; Deppert, W; Knippschild, U			Inhibition of casein kinase I delta alters mitotic spindle formation and induces apoptosis in trophoblast cells	ONCOGENE			English	Article						casein kinase I delta; trophoblast; choriocarcinoma; apoptosis; IC261	WILD-TYPE P53; POLYMORPHIC VARIANTS; PROTEIN-KINASES; MOLECULAR-CLONING; CENTROSOME; PHOSPHORYLATION; EXPRESSION; EPSILON; LOCALIZATION; INSTABILITY	The serine/threonine-specific casein kinase I delta (CKI delta) is ubiquitously expressed in all tissues, is p53 dependently induced in stress situations and plays an important role in various cellular processes. Our immunohistochemical analysis of the human placenta revealed strongest expression of CKId in extravillous trophoblast cells and in choriocarcinomas. Investigation of the functional role of CKId in an extravillous trophoblast hybrid cell line revealed that CKId was constitutively localized at the centrosomes and the mitotic spindle. Inhibition of CKId with the CKI-specific inhibitor IC261 led to structural alterations of the centrosomes, the formation of multipolar spindles, the inhibition of mitosis and, in contrast to other cell lines, the induction of apoptosis. Our findings indicate that CKId plays an important role in the mitotic progression and in the survival of cells of trophoblast origin. Therefore, IC261 could provide a new tool in treating choriocarcinomas.	Univ Ulm, Dept Visceral & Transplantat Surg, Ulm, Germany; Univ Hosp Eppendorf, Inst Pathol, Dept Gynecopathol, Hamburg, Germany; Heinrich Pette Inst Expt Virol & Immunol, Hamburg, Germany; Rhein Westfal TH Aachen, Dept Anat 2, Aachen, Germany	Ulm University; University of Hamburg; University Medical Center Hamburg-Eppendorf; Heinrich Pette Institute; RWTH Aachen University	Knippschild, U (corresponding author), Univ Ulm Klinikum, Steinhovelstr 9, D-89075 Ulm, Germany.	uwe.knippschild@medizin.uni-ulm.de	Frank, Hans-Georg/G-6038-2012; Speidel, Daniel/I-4244-2012	Frank, Hans-Georg/0000-0002-3562-138X; 				Bamberger AM, 1997, ENDOCRINE, V6, P111, DOI 10.1007/BF02738953; Behrend L, 2000, ONCOGENE, V19, P5303, DOI 10.1038/sj.onc.1203939; Behrend L, 2000, EUR J CELL BIOL, V79, P240, DOI 10.1078/S0171-9335(04)70027-8; BEYAERT R, 1995, J BIOL CHEM, V270, P23293, DOI 10.1074/jbc.270.40.23293; Bischof P, 2000, HUM REPROD, V15, P51; Bornens M, 1999, METHOD CELL BIOL, V61, P13; BROCKMAN JL, 1992, P NATL ACAD SCI USA, V89, P9454, DOI 10.1073/pnas.89.20.9454; Chakraborty C, 2002, CAN J PHYSIOL PHARM, V80, P116, DOI 10.1139/Y02-016; Desagher S, 2001, MOL CELL, V8, P601, DOI 10.1016/S1097-2765(01)00335-5; DHILLON N, 1994, EMBO J, V13, P2777, DOI 10.1002/j.1460-2075.1994.tb06571.x; Dumaz N, 1999, FEBS LETT, V463, P312, DOI 10.1016/S0014-5793(99)01647-6; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; FISH KJ, 1995, J BIOL CHEM, V270, P14875, DOI 10.1074/jbc.270.25.14875; Frank HG, 2000, CANCER GENET CYTOGEN, V116, P16, DOI 10.1016/S0165-4608(99)00107-7; Funayama H., 1997, PLACENTA, V18, P191; Ghadimi BM, 2000, GENE CHROMOSOME CANC, V27, P183, DOI 10.1002/(SICI)1098-2264(200002)27:2<183::AID-GCC10>3.0.CO;2-P; GRAVES PR, 1993, J BIOL CHEM, V268, P6394; Gross SD, 1998, CELL SIGNAL, V10, P699, DOI 10.1016/S0898-6568(98)00042-4; Izeradjene K, 2004, CANCER RES, V64, P8036, DOI 10.1158/0008-5472.CAN-04-0762; Kalderon D, 2002, TRENDS CELL BIOL, V12, P523, DOI 10.1016/S0962-8924(02)02388-7; Knippschild U, 2005, CELL SIGNAL, V17, P675, DOI 10.1016/j.cellsig.2004.12.011; Knippschild U, 1996, ONCOGENE, V13, P1387; Knippschild U, 1997, ONCOGENE, V15, P1727, DOI 10.1038/sj.onc.1201541; Ling YH, 1998, J BIOL CHEM, V273, P18984, DOI 10.1074/jbc.273.30.18984; Lingle WL, 1998, P NATL ACAD SCI USA, V95, P2950, DOI 10.1073/pnas.95.6.2950; Marchal C, 2002, J CELL SCI, V115, P217; Maritzen T, 2003, EUR J CELL BIOL, V82, P369, DOI 10.1078/0171-9335-00323; Martin-Subero JI, 2003, LEUKEMIA, V17, P2214, DOI 10.1038/sj.leu.2403129; Mashhoon N, 2000, J BIOL CHEM, V275, P20052, DOI 10.1074/jbc.M001713200; McKay RM, 2001, DEV BIOL, V235, P388, DOI 10.1006/dbio.2001.0308; Milne DM, 2001, EXP CELL RES, V263, P43, DOI 10.1006/excr.2000.5100; Murakami A, 1999, J BIOL CHEM, V274, P3804, DOI 10.1074/jbc.274.6.3804; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Okamura A, 2004, BLOOD, V103, P2997, DOI 10.1182/blood-2003-08-2768; Panek HR, 2000, J CELL SCI, V113, P4545; Pihan GA, 1998, CANCER RES, V58, P3974; Pim D, 2004, INT J CANCER, V108, P196, DOI 10.1002/ijc.11548; ROWLES J, 1991, P NATL ACAD SCI USA, V88, P9548, DOI 10.1073/pnas.88.21.9548; Sakaguchi K, 2000, J BIOL CHEM, V275, P9278, DOI 10.1074/jbc.275.13.9278; Thomas M, 1999, MOL CELL BIOL, V19, P1092; TUAZON PT, 1991, ADV 2 MESSENGER PHOS, V23, P123; Urbani L, 1999, CURR BIOL, V9, pR315, DOI 10.1016/S0960-9822(99)80201-2; Vielhaber E, 2001, IUBMB LIFE, V51, P73, DOI 10.1080/15216540152122049; Winter M, 2004, BIOCHEMISTRY-US, V43, P16356, DOI 10.1021/bi0489255; YAGEL S, 1988, J CELL PHYSIOL, V136, P455, DOI 10.1002/jcp.1041360309; ZHAI LM, 1995, J BIOL CHEM, V270, P12717, DOI 10.1074/jbc.270.21.12717; Zhang JR, 1996, BIOCHEMISTRY-US, V35, P16319, DOI 10.1021/bi9614444; Zhao Y, 2004, J BIOL CHEM, V279, P30844, DOI 10.1074/jbc.M404651200; Zimmerman W, 1999, CURR OPIN CELL BIOL, V11, P122, DOI 10.1016/S0955-0674(99)80015-5	50	49	50	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 1	2005	24	54					7964	7975		10.1038/sj.onc.1208941	http://dx.doi.org/10.1038/sj.onc.1208941			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	989EV	16027726				2022-12-25	WOS:000233656600003
J	Sulton, D; Pagan-Rodriguez, D; Zhou, X; Liu, YD; Hujer, AM; Bethel, CR; Helfand, MS; Thomson, JM; Anderson, VE; Buynak, JD; Ng, LM; Bonomo, RA				Sulton, D; Pagan-Rodriguez, D; Zhou, X; Liu, YD; Hujer, AM; Bethel, CR; Helfand, MS; Thomson, JM; Anderson, VE; Buynak, JD; Ng, LM; Bonomo, RA			Clavulanic acid inactivation of SHV-1 and the inhibitor-resistant S130G SHV-1 beta-lactamase - Insights into the mechanism of inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RTEM BETA-LACTAMASE; IONIZATION MASS-SPECTROMETRY; ESCHERICHIA-COLI; CLASS-A; TAZOBACTAM; MUTAGENESIS; TEM-1; VARIANT; INTERMEDIATE; PENICILLIN	Clavulanic acid is a potent mechanism-based inhibitor of TEM-1 and SHV-1 beta-lactamases, enzymes that confer resistance to beta-lactams in many Gram-negative pathogens. This compound has enjoyed widespread clinical use as part of beta-lactam beta-lactamase inhibitor therapy directed against penicillin-resistant pathogens. Unfortunately, the emergence of clavulanic acid-resistant variants of TEM-1 and SHV-1 beta-lactamase significantly compromise the efficacy of this combination. A single amino acid change at Ambler position Ser(130) (Ser -> Gly) results in resistance to inactivation by clavulanate in the SHV1 and TEM-1 beta-lactamases. Herein, we investigated the inactivation of SHV-1 and the inhibitor-resistant S130G variant beta-lactamases by clavulanate. Using liquid chromatography electrospray ionization mass spectrometry, we detected multiple modified proteins when SHV-1 beta-lactamase is inactivated by clavulanate. Matrix-assisted laser desorption ionization-time of flight mass spectrometry was used to study tryptic digests of SHV-1 and S130G beta-lactamases (+/- inactivation with clavulanate) and identified peptides modified at the active site Ser(70). Ultraviolet (UV) difference spectral studies comparing SHV-1 and S130G beta-lactamases inactivated by clavulanate showed that the formation of reaction intermediates with absorption maxima at 227 and 280nm are diminished and delayed when S130G beta-lactamase is inactivated. We conclude that the clavulanic acid inhibition of the S130G variant beta-lactamase must follow a branch of the normal inactivation pathway. These findings highlight the importance of understanding the intermediates formed in the inactivation process of inhibitor-resistant beta-lactamases and suggest how strategic chemical design can lead to novel ways to inhibit beta-lactamases.	Cleveland State Univ, Dept Chem, Cleveland, OH 44115 USA; Mass Spectrometry Facil, Cleveland, OH 44115 USA; Louis Stokes Cleveland Vet Affairs Med Ctr, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA; So Methodist Univ, Dept Chem, Dallas, TX 75275 USA	University System of Ohio; Cleveland State University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; Case Western Reserve University; Case Western Reserve University; Southern Methodist University	Bonomo, RA (corresponding author), Cleveland State Univ, Dept Chem, 2121 Euclid Ave, Cleveland, OH 44115 USA.	Robert.Bonomo@med.va.gov	Anderson, Vernon/W-2673-2019	Anderson, Vernon Emmett/0000-0002-1699-7621	NIGMS NIH HHS [T32 GM07250] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007250] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brown RPA, 1996, BIOCHEMISTRY-US, V35, P12421, DOI 10.1021/bi961044g; BUSH K, 1993, ANTIMICROB AGENTS CH, V37, P851, DOI 10.1128/AAC.37.4.851; CARTWRIGHT SJ, 1979, NATURE, V278, P360, DOI 10.1038/278360a0; CHARNAS RL, 1981, BIOCHEMISTRY-US, V20, P3214, DOI 10.1021/bi00514a035; CHARNAS RL, 1978, BIOCHEMISTRY-US, V17, P2185, DOI 10.1021/bi00604a025; CHEN CCH, 1992, J MOL BIOL, V224, P1103, DOI 10.1016/0022-2836(92)90472-V; DELAIRE M, 1992, J BIOL CHEM, V267, P20600; FISHER J, 1978, BIOCHEMISTRY-US, V17, P2180, DOI 10.1021/bi00604a024; FISHER J, 1981, BIOCHEMISTRY-US, V20, P2726, DOI 10.1021/bi00513a004; GORBACH SL, 1994, INTENS CARE MED, V20, P27; Helfand Marion S., 2003, Current Drug Targets - Infectious Disorders, V3, P9, DOI 10.2174/1568005033342181; Helfand MS, 2003, J BIOL CHEM, V278, P52724, DOI 10.1074/jbc.M306059200; Helfand MS, 2003, BIOCHEMISTRY-US, V42, P13386, DOI 10.1021/bi035716w; Hujer AM, 2001, BBA-PROTEIN STRUCT M, V1547, P37, DOI 10.1016/S0167-4838(01)00164-9; KNOX JR, 1995, ANTIMICROB AGENTS CH, V39, P2593, DOI 10.1128/AAC.39.12.2593; Kuzin AP, 2001, BIOCHEMISTRY-US, V40, P1861, DOI 10.1021/bi0022745; Massova I, 1999, CURR PHARM DESIGN, V5, P929; Meroueh SO, 2002, J AM CHEM SOC, V124, P9422, DOI 10.1021/ja026547q; Nukaga M, 2003, BIOCHEMISTRY-US, V42, P13152, DOI 10.1021/bi034986b; Padayatti PS, 2004, BIOCHEMISTRY-US, V43, P843, DOI 10.1021/bi035985m; Pagan-Rodriguez D, 2004, J BIOL CHEM, V279, P19494, DOI 10.1074/jbc.M311669200; SAVES I, 1995, J BIOL CHEM, V270, P18240, DOI 10.1074/jbc.270.31.18240; Sun T, 2004, BIOCHEMISTRY-US, V43, P14111, DOI 10.1021/bi0487903; Swaren P, 1999, BIOCHEMISTRY-US, V38, P9570, DOI 10.1021/bi990758z; Vakulenko SB, 1998, ANTIMICROB AGENTS CH, V42, P1542, DOI 10.1128/AAC.42.7.1542; Wang XJ, 2002, J BIOL CHEM, V277, P32149, DOI 10.1074/jbc.M204212200; Yang Y, 2000, J BIOL CHEM, V275, P26674	27	59	60	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35528	35536		10.1074/jbc.M501251200	http://dx.doi.org/10.1074/jbc.M501251200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	15987690	hybrid			2022-12-25	WOS:000232561200054
J	Ogishima, T; Shiina, H; Breault, JE; Terashima, M; Honda, S; Enokida, H; Urakami, S; Tokizane, T; Kawakami, T; Ribeiro, LA; Fujime, M; Kane, CJ; Carroll, PR; Igawa, M; Dahiya, R				Ogishima, T; Shiina, H; Breault, JE; Terashima, M; Honda, S; Enokida, H; Urakami, S; Tokizane, T; Kawakami, T; Ribeiro, LA; Fujime, M; Kane, CJ; Carroll, PR; Igawa, M; Dahiya, R			Promoter CpG hypomethylation and transcription factor EGR1 hyperactivate heparanase expression in bladder cancer	ONCOGENE			English	Article						heparanase; methylation; epigenetics; bladder cancer	HUMAN BREAST-CANCER; MAMMALIAN HEPARANASE; PANCREATIC-CANCER; DNA METHYLATION; PROSTATE-CANCER; TUMOR INVASION; GENE; CELLS; HYPERMETHYLATION; METASTASIS	Heparanase plays a critical role in the degradation of extracellular matrix and cell membrane and is frequently upregulated in malignant tumors. Transcription factor, early growth response 1 (EGR1), is closely associated with inducible transcription of the heparanase gene. We hypothesized that promoter CpG hypomethylation with increased EGR1 expression could determine heparanase expression during the pathogenesis of bladder cancer. Bladder cancer cell lines (J82, T24 and transitional cell carcinoma) significantly restored heparanase expression after 5-Aza-dC treatment. Transfection of EGR1 siRNA with T24 bladder cancer cell line significantly downregulated heparanase expression compared to the control siRNA transfection. In 54 bladder cancer and paired normal bladder samples, heparanase expression was significantly higher in bladder cancer than in normal bladder (P < 0.01). We performed methylation-specific PCR targeting the CpG sites within the core-binding consensus motifs of EGR1 (GGCG) and Sp1 (GGGCGG). Methylation prevalence was significantly higher in normal bladder than in bladder cancer (P < 0.05) and inversely correlated with heparanase expression (P = 0.055). In the total series of bladder cancer and normal bladder samples, the combination of promoter CpG methylation and EGR1 expression regulated heparanase expression in a stepwise manner, where heparanase expression was the lowest in methylation-positive and EGR1-negative samples and the highest in methylation-negative and EGR1-positive samples. To our knowledge, this is the first study demonstrating that increased heparanase expression during the pathogenesis of bladder cancer is due to promoter hypomethylation and transcription factor EGR1.	Vet Affairs Med Ctr, Dept Urol, San Francisco, CA 94121 USA; Univ Calif San Francisco, San Francisco, CA 94121 USA; Shimane Univ, Sch Med, Dept Urol, Izumo, Shimane 6930085, Japan; Univ Sao Paulo, Sch Med, Dept Urol, Sao Paulo, Brazil; Juntendo Univ, Sch Med, Dept Urol, Tokyo 1130082, Japan	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; Shimane University; Universidade de Sao Paulo; Juntendo University	Dahiya, R (corresponding author), Vet Affairs Med Ctr, Dept Urol, 4150 Clement St, San Francisco, CA 94121 USA.	rdahiya@urol.ucsf.edu			FIC NIH HHS [R01TW006215] Funding Source: Medline; NCI NIH HHS [R01CA1018447] Funding Source: Medline; NIA NIH HHS [R01AG21418] Funding Source: Medline; NIDDK NIH HHS [T32DK07790] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [R01TW006215] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007790] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG021418] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abdulkadir SA, 2001, NAT MED, V7, P101, DOI 10.1038/83231; Adamson E, 2003, CANCER BIOL THER, V2, P617; Akiyama Y, 2003, AM J PATHOL, V163, P1911, DOI 10.1016/S0002-9440(10)63549-3; Dahiya R, 1997, INT J CANCER, V72, P762, DOI 10.1002/(SICI)1097-0215(19970904)72:5<762::AID-IJC10>3.0.CO;2-B; de Mestre AM, 2003, J BIOL CHEM, V278, P50377, DOI 10.1074/jbc.M310154200; Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651; Fujii H, 1998, ONCOGENE, V16, P2159, DOI 10.1038/sj.onc.1201976; Gohji K, 2001, INT J CANCER, V95, P295, DOI 10.1002/1097-0215(20010920)95:5<295::AID-IJC1051>3.0.CO;2-A; Guo YJ, 2002, J BIOL CHEM, V277, P41571, DOI 10.1074/jbc.M201864200; Hulett MD, 1999, NAT MED, V5, P803, DOI 10.1038/10525; Hurst CD, 2004, ONCOGENE, V23, P2250, DOI 10.1038/sj.onc.1207260; Jiang P, 2002, J BIOL CHEM, V277, P8989, DOI 10.1074/jbc.M105682200; Kanaya T, 2003, ONCOGENE, V22, P2352, DOI 10.1038/sj.onc.1206365; Kaneda A, 2004, CANCER SCI, V95, P58, DOI 10.1111/j.1349-7006.2004.tb03171.x; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; Koliopanos A, 2001, CANCER RES, V61, P4655; Kosir MA, 1997, J SURG RES, V67, P98, DOI 10.1006/jsre.1996.4976; Marchetti D, 1996, CANCER RES, V56, P2856; Ogishima T, 2005, CLIN CANCER RES, V11, P1028; Sasaki M, 2003, BIOCHEM BIOPH RES CO, V309, P305, DOI 10.1016/j.bbrc.2003.08.005; Sato N, 2003, JNCI-J NATL CANCER I, V95, P327, DOI 10.1093/jnci/95.4.327; Shteper PJ, 2003, ONCOGENE, V22, P7737, DOI 10.1038/sj.onc.1207056; Silverman ES, 1997, AM J PHYSIOL-HEART C, V273, pH1415, DOI 10.1152/ajpheart.1997.273.3.H1415; Simon R, 1998, J PATHOL, V185, P345; Sobin, 2009, UICC TNM CLASSIFICAT; Takaoka M, 2003, LAB INVEST, V83, P613, DOI 10.1097/01.LAB.0000067482.84946.BD; Vlodavsky I, 2001, J CLIN INVEST, V108, P341, DOI 10.1172/JCI200113662	27	74	77	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 13	2005	24	45					6765	6772		10.1038/sj.onc.1208811	http://dx.doi.org/10.1038/sj.onc.1208811			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	973MV	16007175				2022-12-25	WOS:000232527800004
J	Inaba, K; Takahashi, YH; Ito, K				Inaba, K; Takahashi, YH; Ito, K			Reactivities of quinone-free DsbB from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE BOND FORMATION; MEMBRANE-PROTEIN DSBB; RESPIRATORY-CHAIN; ELECTRON-TRANSPORT; CYSTEINE RESIDUES; FORMATION PATHWAY; REDOX PROPERTIES; UBIQUINONE; MECHANISM; CATALYSIS	DsbB is a disulfide oxidoreductase present in the Escherichia coli plasma membrane. Its cysteine pairs, Cys(41)-Cys(44) and Cys(104)-Cys(130), facing the periplasm, as well as the bound quinone molecules play crucial roles in oxidizing DsbA, the protein dithiol oxidant in the periplasm. In this study, we characterized quinone-free forms of DsbB prepared from mutant cells unable to synthesize ubiquinone and menaquinone. While such preparations lacked detectable quinones, previously reported lauroylsarcosine treatment was ineffective in removing DsbB-associated quinones. Moreover, DsbB-bound quinone was shown to contribute to the redox-dependent fluorescence changes observed with DsbB. Now we reconfirmed that redox potentials of cysteine pairs of quinone-free DsbB are lower than that of DsbA, as far as determined in dithiothreitol redox buffer. Nevertheless, the quinone-free DsbB was able to oxidize similar to 40% of DsbA in a 1:1 stoichiometric reaction, in which hemi-oxidized forms of DsbB having either disulfide are generated. It was suggested that the DsbB-DsbA system is designed in such a way that specific interaction of the two components enables the thiol-disulfide exchanges in the "forward" direction. In addition, a minor fraction of quinone-free DsbB formed the DsbA-DsbB disulfide complex stably. Our results show that the rapid and the slow pathways of DsbA oxidation can proceed up to significant points, after which these reactions must be completed and recycled by quinones under physiological conditions. We discuss the significance of having such multiple reaction pathways for the DsbB-dependent DsbA oxidation.	Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan; Japan Sci & Technol Agcy, CREST, Kyoto 6068507, Japan	Kyoto University; Japan Science & Technology Agency (JST)	Ito, K (corresponding author), Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan.	kito@virus.kyoto-u.ac.jp		Inaba, Kenji/0000-0001-8229-0467				Bader M, 1999, CELL, V98, P217, DOI 10.1016/S0092-8674(00)81016-8; Bader MW, 2000, J BIOL CHEM, V275, P26082, DOI 10.1074/jbc.M003850200; Bunoust O, 2005, J BIOL CHEM, V280, P3407, DOI 10.1074/jbc.M407746200; GILBERT HF, 1995, METHOD ENZYMOL, V251, P8, DOI 10.1016/0076-6879(95)51107-5; Grauschopf U, 2003, EMBO J, V22, P3503, DOI 10.1093/emboj/cdg356; GUILHOT C, 1995, P NATL ACAD SCI USA, V92, P9895, DOI 10.1073/pnas.92.21.9895; Huber-Wunderlich M, 1998, FOLD DES, V3, P161, DOI 10.1016/S1359-0278(98)00024-8; Inaba K, 2004, J BIOL CHEM, V279, P6761, DOI 10.1074/jbc.M310765200; Inaba K, 2002, EMBO J, V21, P2646, DOI 10.1093/emboj/21.11.2646; JANDER G, 1994, EMBO J, V13, P5121, DOI 10.1002/j.1460-2075.1994.tb06841.x; Kadokura H, 2003, ANNU REV BIOCHEM, V72, P111, DOI 10.1146/annurev.biochem.72.121801.161459; Kadokura H, 2002, EMBO J, V21, P2354, DOI 10.1093/emboj/21.10.2354; KISHIGAMI S, 1995, J BIOL CHEM, V270, P17072, DOI 10.1074/jbc.270.29.17072; Kishigami S, 1996, GENES CELLS, V1, P201, DOI 10.1046/j.1365-2443.1996.d01-233.x; Kobayashi T, 1997, P NATL ACAD SCI USA, V94, P11857, DOI 10.1073/pnas.94.22.11857; Kobayashi T, 1999, EMBO J, V18, P1192, DOI 10.1093/emboj/18.5.1192; MAJIMA E, 1995, BBA-GEN SUBJECTS, V1243, P336, DOI 10.1016/0304-4165(94)00159-U; Nakamoto H, 2004, BBA-MOL CELL RES, V1694, P111, DOI 10.1016/j.bbamcr.2004.02.012; NELSON JW, 1994, BIOCHEMISTRY-US, V33, P5974, DOI 10.1021/bi00185a039; Regeimbal J, 2002, J BIOL CHEM, V277, P32706, DOI 10.1074/jbc.M205433200; Sevier CS, 2005, PROTEIN SCI, V14, P1630, DOI 10.1110/ps.051355705; Takahashi YH, 2004, J BIOL CHEM, V279, P47057, DOI 10.1074/jbc.M407153200; Tie JK, 2003, J BIOL CHEM, V278, P45468, DOI 10.1074/jbc.M309164200; WALLACE BJ, 1977, BIOCHIM BIOPHYS ACTA, V461, P84, DOI 10.1016/0005-2728(77)90071-8; WATMOUGH NJ, 1991, BIOCHEMISTRY-US, V30, P1317, DOI 10.1021/bi00219a023	25	36	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	2005	280	38					33035	33044		10.1074/jbc.M506189200	http://dx.doi.org/10.1074/jbc.M506189200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	964ZU	16027117	hybrid			2022-12-25	WOS:000231920300058
J	Iram, SH; Cronan, JE				Iram, SH; Cronan, JE			Unexpected functional diversity among FadR fatty acid transcriptional regulatory proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ACYL-COENZYME; INDUCIBLE SYSTEM; GENE FADR; METABOLISM; BINDING; DEGRADATION; CONSTRUCTION; POLYMERASE; EXPRESSION	The FadR protein of Escherichia coli has been shown to play a dual role in transcription of the genes of bacterial fatty acid metabolism. The protein acts as a repressor of beta-oxidation and an activator of unsaturated fatty acid synthesis. FadR DNA binding is antagonized by long chain acyl-CoAs, and thus FadR acts as a sensor of fatty acid availability in the environment. When viewed from a genomic viewpoint, FadR proteins are unusual in that the DNA binding domain is very highly conserved among FadR-containing bacteria, whereas the C-terminal acyl-CoA binding domain shows only weak conservation. To further our understanding of the role of FadR in bacterial lipid metabolism we have examined the in vivo and in vitro properties of a diverse set of FadR proteins expressed in E. coli. In addition to E. coli FadR the proteins examined were those of Salmonella enterica, Vibrio cholerae, Pasteurella multocida, and Haemophilus influenzae. These FadR proteins were found to differ markedly in their effects on repression and induction of beta-oxidation in E. coli and in their acyl-CoA binding abilities as measured by isothermal titration calorimetry. The E. coli and S. enterica proteins were the most similar, although they differed in their effects on utilization of oleic acid and acyl-CoA binding affinities, whereas the P. multocida and H. influenzae proteins showed only weak repression and poor acyl-CoA binding affinities. The V. cholerae FadR was strikingly superior to the other proteins in the amplitude of its regulatory response, and it bound long chain acyl-CoAs appreciably more strongly than the E. coli and S. enterica proteins. The significance of these findings is discussed in view of the protein sequences and the physiological niches occupied by these organisms.	Univ Illinois, Dept Microbiol, Chem & Life Sci Lab B103, Urbana, IL 61801 USA; Univ Illinois, Dept Biochem, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Cronan, JE (corresponding author), Univ Illinois, Dept Microbiol, Chem & Life Sci Lab B103, 601 S Goodwin Ave, Urbana, IL 61801 USA.	j-cronan@life.uiuc.edu	Iram, Surtaj Hussain/T-5510-2019; Cronan, John/V-6626-2019	Iram, Surtaj/0000-0002-0672-0936	NIAID NIH HHS [AI15650] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI015650, R01AI015650] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BLACK PN, 1994, BBA-LIPID LIPID MET, V1210, P123, DOI 10.1016/0005-2760(94)90113-9; BRENNAN RG, 1993, CELL, V74, P773, DOI 10.1016/0092-8674(93)90456-Z; Campbell JW, 2003, MOL MICROBIOL, V47, P793, DOI 10.1046/j.1365-2958.2003.03341.x; Campbell JW, 2001, J BACTERIOL, V183, P5982, DOI 10.1128/JB.183.20.5982-5990.2001; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CHEREPANOV PP, 1995, GENE, V158, P9, DOI 10.1016/0378-1119(95)00193-A; CLARK D, 1981, J BACTERIOL, V148, P521, DOI 10.1128/JB.148.2.521-526.1981; Clark D. P., 1996, ESCHERICHIA COLI SAL, P343; Cronan JE, 1998, MOL MICROBIOL, V29, P937, DOI 10.1046/j.1365-2958.1998.00917.x; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; DiRusso CC, 1998, J BIOL CHEM, V273, P33652, DOI 10.1074/jbc.273.50.33652; DIRUSSO CC, 1992, J BIOL CHEM, V267, P8685; DIRUSSO CC, 1985, J BACTERIOL, V161, P583, DOI 10.1128/JB.161.2.583-588.1985; Ellermeier CD, 2002, GENE, V290, P153, DOI 10.1016/S0378-1119(02)00551-6; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Gui LZ, 1996, J BACTERIOL, V178, P4704, DOI 10.1128/jb.178.15.4704-4709.1996; HAYDON DJ, 1991, FEMS MICROBIOL LETT, V79, P291, DOI 10.1016/0378-1097(91)90101-F; HENRY MF, 1992, CELL, V70, P671, DOI 10.1016/0092-8674(92)90435-F; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KLEIN K, 1971, EUR J BIOCHEM, V19, P442, DOI 10.1111/j.1432-1033.1971.tb01334.x; MILLER JH, 1992, SHORT COURSE BACTERI, P268; Miller JH, 1972, EXPT MOL GENETICS, P201; NUNN WD, 1983, J BACTERIOL, V154, P554, DOI 10.1128/JB.154.2.554-560.1983; NUNN WD, 1986, J BIOL CHEM, V261, P167; OVERATH P, 1969, EUR J BIOCHEM, V7, P559; PAULI G, 1972, EUR J BIOCHEM, V29, P553, DOI 10.1111/j.1432-1033.1972.tb02021.x; Raman N, 1997, J BIOL CHEM, V272, P30645, DOI 10.1074/jbc.272.49.30645; RAMAN N, 1995, J BIOL CHEM, V270, P1092, DOI 10.1074/jbc.270.3.1092; Sadovskaya NS, 2001, MOL BIOL+, V35, P862, DOI 10.1023/A:1013238318852; SIMONS RW, 1980, J BACTERIOL, V143, P726, DOI 10.1128/JB.143.2.726-730.1980; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; van Aalten DMF, 2000, EMBO J, V19, P5167, DOI 10.1093/emboj/19.19.5167; van Aalten DMF, 2001, EMBO J, V20, P2041, DOI 10.1093/emboj/20.8.2041; Wang HH, 2003, J BACTERIOL, V185, P4930, DOI 10.1128/JB.185.16.4930-4937.2003; WEEKS G, 1970, J BIOL CHEM, V245, P1913; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Xu YB, 2001, J BIOL CHEM, V276, P17373, DOI 10.1074/jbc.M100195200	37	40	42	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	2005	280	37					32148	32156		10.1074/jbc.M504054200	http://dx.doi.org/10.1074/jbc.M504054200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	963HM	16027119	hybrid			2022-12-25	WOS:000231794800015
J	Mizuarai, S; Miki, S; Araki, H; Takahashi, K; Kotani, H				Mizuarai, S; Miki, S; Araki, H; Takahashi, K; Kotani, H			Identification of dicarboxylate carrier Slc25a10 as malate transporter in de novo fatty acid synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; ACETYL-COA CARBOXYLASE; WHITE ADIPOSE-TISSUE; CAENORHABDITIS-ELEGANS; MICROARRAY ANALYSIS; GENE-EXPRESSION; TRICARBOXYLATE; CITRATE; MICE; CELLS	Mitochondrial solute carrier family 25 member 10 (Slc25a10) transports dicarboxylates such as malate or succinate across the mitochondrial inner membrane. Although fatty acid synthesis in adipose tissue or the liver is initiated by citrate transport in exchange for malate across the mitochondrial membrane, the transporter responsible for supplying malate during citrate transport has not been identified. In the present study, we clarified the role of Slc25a10 in supplying malate for citrate transport and examined the effect of Slc25a10 suppression on the lipogenic pathway and lipid accumulation. We have reported an Slc25a10 increase in white adipose tissue in obese mouse models and a decrease in a fasted mouse model using expression profiles. Next, we examined the effect of Slc25a10 suppression by small interfering RNA on citrate transport in the lipogenic cell lines HepG2 and 3T3-L1. We observed that inhibition of malate transport by Slc25a10 suppression significantly reduced the citrate transport from the mitochondria to the cytosol. We also found that suppression of Slc25a10 down-regulated the lipogenic pathway, indicated by decreases in ACC1 expression and malonyl-CoA level. Furthermore, suppression of Slc25a10 decreased triglyceride lipid accumulation in adipose-differentiated 3T3-L1 cells. These results suggested that Slc25a10 plays an important role in supplying malate for citrate transport required for fatty acid synthesis and indicated that inhibition of Slc25a10 might effectively reduce lipid accumulation in adipose tissues.	Banyu Pharmaceut Co Ltd, Tsukuba Res Inst, Tsukuba, Ibaraki 3002611, Japan	Merck & Company; Novartis	Kotani, H (corresponding author), Banyu Pharmaceut Co Ltd, Tsukuba Res Inst, Okubo 3, Tsukuba, Ibaraki 3002611, Japan.	hidehito_kotani@merck.com						Ashrafi K, 2003, NATURE, V421, P268, DOI 10.1038/nature01279; Das K, 1999, BIOCHEM J, V344, P313, DOI 10.1042/0264-6021:3440313; Deng X, 2004, ENDOCRINOLOGY, V145, P5847, DOI 10.1210/en.2004-0371; Fei YJ, 2004, BIOCHEM J, V379, P191, DOI 10.1042/BJ20031807; Fiermonte G, 1998, J BIOL CHEM, V273, P24754, DOI 10.1074/jbc.273.38.24754; GUO KY, 2004, AM J PHYSIOL, V28, pR122; Hannah VC, 2001, J BIOL CHEM, V276, P4365, DOI 10.1074/jbc.M007273200; Harwood HJ, 2003, J BIOL CHEM, V278, P37099, DOI 10.1074/jbc.M304481200; INDIVERI C, 1993, BIOCHIM BIOPHYS ACTA, V1143, P310, DOI 10.1016/0005-2728(93)90202-Q; Inoue K, 2002, BIOCHEM J, V367, P313, DOI 10.1042/BJ20021132; Kajimoto K, 2005, MOL GENET METAB, V85, P46, DOI 10.1016/j.ymgme.2005.01.006; KAPLAN RS, 1990, J BIOL CHEM, V265, P13379; KEAY S, 1980, P NATL ACAD SCI-BIOL, V77, P4099, DOI 10.1073/pnas.77.7.4099; Lin Y, 2005, J BIOL CHEM, V280, P4617, DOI 10.1074/jbc.M411863200; Lopez IP, 2003, OBES RES, V11, P188, DOI 10.1038/oby.2003.30; LOWRY OH, 1972, FLEXIBLE SYSTEM ENZY, P149; Majima E, 2001, J BIOL CHEM, V276, P9792, DOI 10.1074/jbc.M007222200; Mao JQ, 2003, P NATL ACAD SCI USA, V100, P7515, DOI 10.1073/pnas.1332670100; Mashiko S, 2003, ENDOCRINOLOGY, V144, P1793, DOI 10.1210/en.2002-0119; Matsuzaka T, 2002, J LIPID RES, V43, P911; Munday MR, 2002, BIOCHEM SOC T, V30, P1059, DOI 10.1042/bst0301059; Ntambi JM, 2002, P NATL ACAD SCI USA, V99, P11482, DOI 10.1073/pnas.132384699; ROBINSON BH, 1970, EUR J BIOCHEM, V15, P263, DOI 10.1111/j.1432-1033.1970.tb01003.x; ROBINSON BH, 1971, EUR J BIOCHEM, V20, P65, DOI 10.1111/j.1432-1033.1971.tb01363.x; Rogina B, 2000, SCIENCE, V290, P2137, DOI 10.1126/science.290.5499.2137; Smith SJ, 2000, NAT GENET, V25, P87, DOI 10.1038/75651; Takahashi K, 2003, J BIOL CHEM, V278, P46654, DOI 10.1074/jbc.M309895200; Tang QQ, 2003, P NATL ACAD SCI USA, V100, P850, DOI 10.1073/pnas.0337434100; Unami A, 2004, BIOCHEM PHARMACOL, V67, P555, DOI 10.1016/j.bcp.2003.09.010; WAKIL SJ, 1983, ANNU REV BIOCHEM, V52, P537, DOI 10.1146/annurev.bi.52.070183.002541; WATSON JA, 1970, J BIOL CHEM, V245, P5993; ZARA V, 1995, BBA-BIOMEMBRANES, V1239, P33, DOI 10.1016/0005-2736(95)00125-M	32	58	59	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	2005	280	37					32434	32441		10.1074/jbc.M503152200	http://dx.doi.org/10.1074/jbc.M503152200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	963HM	16027120	hybrid			2022-12-25	WOS:000231794800050
J	Graveleau, C; Zaha, VG; Mohajer, A; Banerjee, RR; Dudley-Rucker, N; Steppan, CM; Rajala, MW; Scherer, PE; Ahima, RS; Lazar, MA; Abel, ED				Graveleau, C; Zaha, VG; Mohajer, A; Banerjee, RR; Dudley-Rucker, N; Steppan, CM; Rajala, MW; Scherer, PE; Ahima, RS; Lazar, MA; Abel, ED			Mouse and human resistins impair glucose transport in primary mouse cardiomyocytes, and oligomerization is required for this biological action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID OXIDATION; INSULIN-RESISTANCE; SKELETAL-MUSCLE; ADIPOSE-TISSUE; EXPRESSION; OBESITY; GENE; ASSOCIATION; CELLS; ACRP30/ADIPONECTIN	The adipocytokine resistin impairs glucose tolerance and insulin sensitivity in rodents. Here, we examined the effect of resistin on glucose uptake in isolated adult mouse cardiomyocytes. Murine resistin reduced insulin-stimulated glucose uptake, establishing the heart as a resistin target tissue. Notably, human resistin also impaired insulin action in mouse cardiomyocytes, providing the first evidence that human and mouse resistin homologs have similar functions. Resistin is a cysteine-rich molecule that circulates as a multimer of a dimeric form dependent upon a single intermolecular disulfide bond, which, in the mouse, involves Cys(26); mutation of this residue to alanine (C26A) produces a monomeric molecule that appears to be bioactive in the liver. Remarkably, unlike native resistin, monomeric C26A resistin had no effect on basal or insulin-stimulated glucose uptake in mouse cardiomyocytes. Resistin impairs glucose uptake in cardiomyocytes by mechanisms that involve altered vesicle trafficking. Thus, in cardiomyocytes, both mouse and human resistins directly impair glucose transport; and in contrast to effects on the liver, these actions of resistin require oligomerization.	Univ Utah, Sch Med, Div Endocrinol Diabet & Metab, Salt Lake City, UT 84112 USA; Univ Utah, Program Human Mol Biol & Genet, Salt Lake City, UT 84112 USA; Univ Penn, Sch Med, Div Endocrinol Diabet & Metab, Philadelphia, PA 19104 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; University of Pennsylvania; Yeshiva University; Albert Einstein College of Medicine	Abel, ED (corresponding author), Univ Utah, Sch Med, Div Endocrinol Diabet & Metab, 15 North 2030 East,Bldg 533,Rm 3410B, Salt Lake City, UT 84112 USA.	dale.abel@hmbg.utah.edu	Scherer, Philipp E/K-7819-2012; Banerjee, Ronadip/U-6649-2019; Ahima, Rexford/W-1394-2019; Lazar, Mitchell A/AAF-3738-2019	Scherer, Philipp E/0000-0003-0680-3392; Zaha, Vlad/0000-0003-4878-891X; Abel, E. Dale/0000-0001-5290-0738	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R03DK058073, R01DK049780, P01DK049210, R01DK055758, R01DK092065] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007288] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK55758, DK49210, DK49780, DK58073, R01 DK092065] Funding Source: Medline; NIGMS NIH HHS [T32-GM07288] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abel ED, 2004, MOL ENDOCRINOL, V18, P2491, DOI 10.1210/me.2004-0175; Banerjee RR, 2004, SCIENCE, V303, P1195, DOI 10.1126/science.1092341; Banerjee RR, 2003, J MOL MED, V81, P218, DOI 10.1007/s00109-003-0428-9; Banerjee RR, 2001, J BIOL CHEM, V276, P25970, DOI 10.1074/jbc.M103109200; Belke DD, 2002, J CLIN INVEST, V109, P629, DOI 10.1172/JCI200213946; Chen J, 2002, J ENDOCRINOL, V175, P499, DOI 10.1677/joe.0.1750499; ECKEL J, 1985, BASIC RES CARDIOL, V80, P103; Engert JC, 2002, DIABETES, V51, P1629, DOI 10.2337/diabetes.51.5.1629; Fain JN, 2003, BIOCHEM BIOPH RES CO, V300, P674, DOI 10.1016/S0006-291X(02)02864-4; Fruebis J, 2001, P NATL ACAD SCI USA, V98, P2005, DOI 10.1073/pnas.041591798; Jonke J, 2002, OBES RES, V10, P1; Kamin D, 2005, J CLIN ENDOCR METAB, V90, P3423, DOI 10.1210/jc.2005-0287; Lehrke M, 2004, PLOS MED, V1, P161, DOI 10.1371/journal.pmed.0010045; Ma XW, 2002, J CLIN ENDOCR METAB, V87, P4407, DOI 10.1210/jc.2002-020109; Mazumder PK, 2004, DIABETES, V53, P2366, DOI 10.2337/diabetes.53.9.2366; McTernan CL, 2002, LANCET, V359, P46, DOI 10.1016/S0140-6736(02)07281-1; McTernan PG, 2002, J CLIN ENDOCR METAB, V87, P2407, DOI 10.1210/jc.87.5.2407; Moon B, 2003, AM J PHYSIOL-ENDOC M, V285, pE106, DOI 10.1152/ajpendo.00457.2002; Muse ED, 2004, J CLIN INVEST, V114, P232, DOI 10.1172/JCI200421270; Nagaev I, 2001, BIOCHEM BIOPH RES CO, V285, P561, DOI 10.1006/bbrc.2001.5173; Osawa H, 2004, AM J HUM GENET, V75, P678, DOI 10.1086/424761; Pajvani UB, 2003, J BIOL CHEM, V278, P9073, DOI 10.1074/jbc.M207198200; Patel L, 2003, BIOCHEM BIOPH RES CO, V300, P472, DOI 10.1016/S0006-291X(02)02841-3; Patel SD, 2004, SCIENCE, V304, P1154, DOI 10.1126/science.1093466; Pravenec M, 2003, J BIOL CHEM, V278, P45209, DOI 10.1074/jbc.M304869200; Rajala MW, 2003, J CLIN INVEST, V111, P225, DOI 10.1172/JCI200316521; Rangwala SM, 2004, DIABETES, V53, P1937, DOI 10.2337/diabetes.53.8.1937; Reilly MP, 2005, CIRCULATION, V111, P932, DOI 10.1161/01.CIR.0000155620.10387.43; Satoh H, 2004, J CLIN INVEST, V114, P224, DOI 10.1172/JCI200420785; Savage DB, 2001, DIABETES, V50, P2199, DOI 10.2337/diabetes.50.10.2199; Sentinelli F, 2002, DIABETES, V51, P860, DOI 10.2337/diabetes.51.3.860; Steppan CM, 2005, MOL CELL BIOL, V25, P1569, DOI 10.1128/MCB.25.4.1569-1575.2005; Steppan CM, 2001, NATURE, V409, P307, DOI 10.1038/35053000; TAEGTMEYER H, 1994, CURR PROB CARDIOLOGY, V19, P61, DOI 10.1016/0146-2806(94)90008-6; Tan MS, 2003, J CLIN ENDOCR METAB, V88, P1258, DOI 10.1210/jc.2002-021453; Tsao TS, 2003, J BIOL CHEM, V278, P50810, DOI 10.1074/jbc.M309469200; Wang H, 2002, J CLIN ENDOCR METAB, V87, P2520, DOI 10.1210/jc.87.6.2520; Yang RZ, 2003, BIOCHEM BIOPH RES CO, V310, P927, DOI 10.1016/j.bbrc.2003.09.093	38	86	87	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	2005	280	36					31679	31685		10.1074/jbc.M504008200	http://dx.doi.org/10.1074/jbc.M504008200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	961LZ	15983036	hybrid			2022-12-25	WOS:000231665200044
J	Klein, JB; Barati, MT; Wu, R; Gozal, D; Sachleben, LR; Kausar, H; Trent, JO; Gozal, E; Rane, MJ				Klein, JB; Barati, MT; Wu, R; Gozal, D; Sachleben, LR; Kausar, H; Trent, JO; Gozal, E; Rane, MJ			Akt-mediated valosin-containing protein 97 phosphorylation regulates its association with ubiquitinated proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM STRESS; RAT HIPPOCAMPAL SLICES; INTERMITTENT HYPOXIA; MEMBRANE-FUSION; CELL-DEATH; IN-VITRO; ACTIVATED PROTEIN-KINASE-2; TYROSINE PHOSPHORYLATION; PROTEOMIC IDENTIFICATION; GENOMIC CONSEQUENCES	Hypoxia is a common environmental stress that influences signaling pathways and cell function. Previous studies from our laboratory have identified significant differences in cellular responses to sustained or intermittent hypoxia with the latter proving more cytotoxic. We hypothesized that differences in susceptibility of neurons to intermittent ( IH) and sustained hypoxia ( SH) are mediated by altered Akt signaling. SH, but not IH, induced a significant increase in Akt activation in rat CA1 hippocampal region extracts compared with room air controls. Akt immunoprecipitations followed by proteomic analysis identified valosin-containing protein ( VCP) as an Akt-binding protein. In addition, VCP expression and association with Akt was enhanced during SH, and this association was decreased upon phosphoinositide 3-kinase/Akt pathway blockade with LY294002. Active recombinant Akt phosphorylated recombinant VCP in vitro. Site-directed mutagenesis studies identified Ser(352), Ser(746), and Ser(748) as Akt phosphorylation sites on VCP. In addition, rat CA1 hippocampal tissue exposed to SH exhibited an acidic pI shift of VCP. Protein phosphatase 2A treatment inhibited this acidic shift consistent with SH-induced phosphorylation of VCP in vivo. PC-12 cells transfected with active Akt, but not dominant negative Akt or vector, induced VCP expression and an acidic shift in VCP pI, which was inhibited by protein phosphatase 2A treatment. Furthermore, VCP association with ubiquitinated proteins was demonstrated in vector-transfected PC-12 cell lysates, whereas active Akt-transfected cells demonstrated a marked decrease in association of VCP with ubiquitinated proteins. We concluded that Akt phosphorylates VCP in vitro and in vivo, and VCP phosphorylation releases it from ubiquitinated substrate protein( s) possibly allowing ubiquitinated protein( s) to be degraded by the proteosome.	Univ Louisville, Core Proteom Lab, Louisville, KY 40202 USA; Univ Louisville, Dept Biochem & Mol Biol, Louisville, KY 40202 USA; Univ Louisville, Dept Med, Louisville, KY 40202 USA; Vet Affairs Med Ctr, Louisville, KY 40206 USA; Univ Louisville, Dept Pediat, Louisville, KY 40202 USA; Univ Louisville, Dept Pharmacol, Louisville, KY 40202 USA; Univ Louisville, James Graham Brown Canc Ctr, Louisville, KY 40202 USA	University of Louisville; University of Louisville; University of Louisville; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Louisville; University of Louisville; University of Louisville	Rane, MJ (corresponding author), Univ Louisville, Core Proteom Lab, 570 S Preston St,Baxter 1 Bldg South 102C, Louisville, KY 40202 USA.	mrane@louisville.edu	Klein, Jon/B-9833-2013; Gozal, David/M-9492-2017; Gozal, David/ABH-3805-2020	trent, John/0000-0002-7346-4231	NHLBI NIH HHS [HL69932, HL66358, HL074296] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066358, R01HL074296, R01HL069932] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACHARYA U, 1995, CELL, V82, P895, DOI 10.1016/0092-8674(95)90269-4; Asai T, 2002, JPN J CANCER RES, V93, P296, DOI 10.1111/j.1349-7006.2002.tb02172.x; Basu S, 2003, MOL CELL, V11, P11, DOI 10.1016/S1097-2765(02)00776-1; Bernaudin M, 1998, EXP NEUROL, V150, P30, DOI 10.1006/exnr.1997.6728; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Braun S, 2002, EMBO J, V21, P615, DOI 10.1093/emboj/21.4.615; CONFALONIERI F, 1995, BIOESSAYS, V17, P639, DOI 10.1002/bies.950170710; Dai RM, 2001, NAT CELL BIOL, V3, P740, DOI 10.1038/35087056; Dai RM, 1998, J BIOL CHEM, V273, P3562, DOI 10.1074/jbc.273.6.3562; DAVOLIO C, 1995, NEUROSCI LETT, V192, P29, DOI 10.1016/0304-3940(95)11600-2; Doss-Pepe EW, 2003, MOL CELL BIOL, V23, P6469, DOI 10.1128/MCB.23.18.6469-6483.2003; FLETCHER EC, 1995, AM J MED, V98, P118, DOI 10.1016/S0002-9343(99)80395-7; Geussova G, 2002, MOL REPROD DEV, V63, P366, DOI 10.1002/mrd.10156; Gozal D, 1998, PEDIATRICS, V102, P616, DOI 10.1542/peds.102.3.616; Gozal D, 2001, J NEUROSCI, V21, P2442, DOI 10.1523/JNEUROSCI.21-07-02442.2001; Gozal E, 2002, J NEUROCHEM, V83, P331, DOI 10.1046/j.1471-4159.2002.01134.x; Gozal E, 2001, NEUROSCI LETT, V305, P197, DOI 10.1016/S0304-3940(01)01853-5; Gozal E, 2001, J APPL PHYSIOL, V90, P1995, DOI 10.1152/jappl.2001.90.5.1995; GOZAL E, 2004, AM J PHYSIOL, V288, pC535; Hatakeyama S, 2004, GENES CELLS, V9, P533, DOI 10.1111/j.1356-9597.2004.00742.x; Hetzer M, 2001, NAT CELL BIOL, V3, P1086, DOI 10.1038/ncb1201-1086; Hirai K, 2004, MOL BRAIN RES, V124, P51, DOI 10.1016/j.molbrainres.2004.02.009; Hui AS, 2003, HYPERTENSION, V42, P1130, DOI 10.1161/01.HYP.0000101691.12358.26; Imamura S, 2003, FEBS LETT, V549, P14, DOI 10.1016/S0014-5793(03)00723-3; Ishigaki S, 2004, J BIOL CHEM, V279, P51376, DOI 10.1074/jbc.M406683200; Kadar T, 1998, J NEURAL TRANSM, V105, P987, DOI 10.1007/s007020050107; Klein JB, 2003, RESP PHYSIOL NEUROBI, V136, P91, DOI 10.1016/S1569-9048(03)00074-0; Kobayashi T, 2002, J BIOL CHEM, V277, P47358, DOI 10.1074/jbc.M207783200; Kostova Z, 2003, EMBO J, V22, P2309, DOI 10.1093/emboj/cdg227; Kreisman NR, 2000, J NEUROPHYSIOL, V83, P1031, DOI 10.1152/jn.2000.83.2.1031; Kreisman NR, 1999, J NEUROPHYSIOL, V82, P320, DOI 10.1152/jn.1999.82.1.320; LATTERICH M, 1995, CELL, V82, P885, DOI 10.1016/0092-8674(95)90268-6; Lavoie C, 2000, P NATL ACAD SCI USA, V97, P13637, DOI 10.1073/pnas.240278097; Lawlor MA, 2001, J CELL SCI, V114, P2903; Madeo F, 1998, MOL BIOL CELL, V9, P131, DOI 10.1091/mbc.9.1.131; Maurizi Michael R., 2001, EMBO Reports, V2, P980, DOI 10.1093/embo-reports/kve229; Mayr PSM, 1999, EUR J CELL BIOL, V78, P224, DOI 10.1016/S0171-9335(99)80055-7; NABETANI M, 1994, DEV NEUROSCI-BASEL, V16, P301, DOI 10.1159/000112123; Nagahama M, 2003, MOL BIOL CELL, V14, P262, DOI 10.1091/mbc.02-07-0115; Neubauer JA, 2001, J APPL PHYSIOL, V90, P1593, DOI 10.1152/jappl.2001.90.4.1593; Obata T, 2000, J BIOL CHEM, V275, P36108, DOI 10.1074/jbc.M005497200; Ogura T, 2001, GENES CELLS, V6, P575, DOI 10.1046/j.1365-2443.2001.00447.x; Partridge JJ, 2003, MOL BIOL CELL, V14, P4221, DOI 10.1091/mbc.E03-02-0111; Patel S, 1998, TRENDS CELL BIOL, V8, P65, DOI 10.1016/S0962-8924(97)01212-9; PLEASURE IT, 1993, NATURE, V365, P459, DOI 10.1038/365459a0; Powell DW, 2003, MOL CELL BIOL, V23, P5376, DOI 10.1128/MCB.23.15.5376-5387.2003; Powell DW, 2002, J BIOL CHEM, V277, P21639, DOI 10.1074/jbc.M203167200; Rabinovich E, 2002, MOL CELL BIOL, V22, P626, DOI 10.1128/MCB.22.2.626-634.2002; RABOUILLE C, 1995, CELL, V82, P905, DOI 10.1016/0092-8674(95)90270-8; Rane MJ, 2003, J BIOL CHEM, V278, P27828, DOI 10.1074/jbc.M303417200; Rao RV, 2004, J BIOL CHEM, V279, P177, DOI 10.1074/jbc.M304490200; Reddy RK, 2003, J BIOL CHEM, V278, P20915, DOI 10.1074/jbc.M212328200; Saito A, 2004, J NEUROSCI, V24, P1584, DOI 10.1523/JNEUROSCI.5209-03.2004; Singh S, 2003, J BIOL CHEM, V278, P36410, DOI 10.1074/jbc.M306428200; STRASSER U, 1995, BRAIN RES, V687, P167, DOI 10.1016/0006-8993(95)00519-V; Tanaka S, 2000, J BIOL CHEM, V275, P10388, DOI 10.1074/jbc.275.14.10388; Taxis C, 2003, J BIOL CHEM, V278, P35903, DOI 10.1074/jbc.M301080200; Thongboonkerd V, 2002, J BIOL CHEM, V277, P16599, DOI 10.1074/jbc.M200746200; Uchiyama K, 2002, J CELL BIOL, V159, P855, DOI 10.1083/jcb.200208112; Vakser IA, 1996, BIOPOLYMERS, V39, P455, DOI 10.1002/(SICI)1097-0282(199609)39:3<455::AID-BIP16>3.3.CO;2-8; Vakser IA, 1997, PROTEINS, P226; Vakser IA, 1996, PROTEIN ENG, V9, P741, DOI 10.1093/protein/9.9.741; Vale RD, 2000, J CELL BIOL, V150, pF13, DOI 10.1083/jcb.150.1.F13; Waugh MG, 2003, BIOCHEM J, V373, P57, DOI 10.1042/BJ20030089; Wilde GJC, 1997, J NEUROCHEM, V69, P883; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737; Yamada T, 2000, FEBS LETT, V466, P287, DOI 10.1016/S0014-5793(99)01673-7; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147; Ye YH, 2001, NATURE, V414, P652, DOI 10.1038/414652a; Yu ZF, 1999, EXP NEUROL, V155, P302, DOI 10.1006/exnr.1998.7002; Zhang SH, 1999, J BIOL CHEM, V274, P17806, DOI 10.1074/jbc.274.25.17806; Zhang SXL, 2003, FASEB J, V17, P1709, DOI 10.1096/fj.02-1111fje; Zhong XY, 2004, J BIOL CHEM, V279, P45676, DOI 10.1074/jbc.M409034200; Zwickl P, 1999, NAT CELL BIOL, V1, pE97, DOI 10.1038/12097	74	52	53	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	2005	280	36					31870	31881		10.1074/jbc.M501802200	http://dx.doi.org/10.1074/jbc.M501802200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	961LZ	16027165	hybrid			2022-12-25	WOS:000231665200066
J	Sobotka, R; Komenda, J; Bumba, L; Tichy, M				Sobotka, R; Komenda, J; Bumba, L; Tichy, M			Photosystem II assembly in CP47 mutant of Synechocystis sp PCC 6803 is dependent on the level of chlorophyll precursors regulated by ferrochelatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OLIGONUCLEOTIDE-DIRECTED MUTAGENESIS; TETRAPYRROLE BIOSYNTHETIC-PATHWAY; DNA MICROARRAY ANALYSIS; GENE-EXPRESSION; PCC 6803; HISTIDINE-RESIDUES; HEME-BIOSYNTHESIS; BINDING PROTEIN; DIMETHYL ESTER; D1 PRECURSOR	Accumulation of chlorophyll and expression of the chlorophyll (Chl)-binding CP47 protein that serves as the core antenna of photosystem II are indispensable for the assembly of a functional photosystem II. We have characterized the CP47 mutant with an impaired photosystem II assembly and its two spontaneous pseudorevertants with their much improved photoautotrophic growth. The complementing mutations in these pseudorevertants were previously mapped to the ferrochelatase gene ( 1). We demonstrated that complementing mutations dramatically decrease ferrochelatase activity in pseudorevertants and that this decrease is responsible for their improved photoautotrophic growth. Photo-autotrophic growth of the CP47 mutant was also restored by in vivo inhibition of ferrochelatase by a specific inhibitor. The decrease in ferrochelatase activity in pseudorevertants was followed by increased steady-state levels of Chl precursors and Chl, leading to CP47 accumulation and photosystem II assembly. Similarly, supplementation of the CP47 mutant with the Chl precursor Mg-protoporphyrin IX increased the number of active photosystem-II centers, suggesting that synthesis of the mutated CP47 protein is enhanced by an increased Chl availability in the cell. The probable role of ferrochelatase in the regulation of Chl biosynthesis is discussed.	Univ S Bohemia, Inst Phys Biol, Nove Hrady 37333, Czech Republic; Inst Microbiol, Dept Autotroph Microorganisms, Trebon 37971, Czech Republic; Acad Sci Czech Republ, Inst Plant Mol Biol, CR-37005 Ceske Budejovice, Czech Republic	University of South Bohemia Ceske Budejovice; Czech Academy of Sciences; Institute of Microbiology of the Czech Academy of Sciences; Czech Academy of Sciences; Biology Centre of the Czech Academy of Sciences	Sobotka, R (corresponding author), Univ S Bohemia, Inst Phys Biol, Nove Hrady 37333, Czech Republic.	sobotka@alga.cz	Bumba, Ladislav/ABC-9943-2020; Bumba, Ladislav/H-2494-2014; Tichy, Martin/B-6545-2008; Komenda, Josef/H-4083-2014; Sobotka, Roman/J-3077-2014	Bumba, Ladislav/0000-0001-6659-5447; Tichy, Martin/0000-0003-2814-1959; Komenda, Josef/0000-0003-4588-0382; Sobotka, Roman/0000-0001-5909-3879				Bricker TM, 2002, PHOTOSYNTH RES, V72, P131, DOI 10.1023/A:1016128715865; CAMADRO JM, 1988, J BIOL CHEM, V263, P11675; Cornah JE, 2003, TRENDS PLANT SCI, V8, P224, DOI 10.1016/S1360-1385(03)00064-5; DEMATTEIS F, 1980, BIOCHEM J, V189, P645, DOI 10.1042/bj1890645; EATONRYE JJ, 1991, PLANT MOL BIOL, V17, P1165, DOI 10.1007/BF00028733; Eichacker LA, 1996, J BIOL CHEM, V271, P32174, DOI 10.1074/jbc.271.50.32174; Funk C, 1999, BIOCHEMISTRY-US, V38, P9397, DOI 10.1021/bi990545+; HAAG E, 1993, BIOCHEMISTRY-US, V32, P4444, DOI 10.1021/bi00067a037; He QF, 1998, P NATL ACAD SCI USA, V95, P5830, DOI 10.1073/pnas.95.10.5830; Hihara Y, 2003, J BACTERIOL, V185, P1719, DOI 10.1128/JB.185.5.1719-1725.2003; Hihara Y, 2001, PLANT CELL, V13, P793, DOI 10.1105/tpc.13.4.793; HOUGHTON JD, 1982, BIOCHEM J, V208, P479, DOI 10.1042/bj2080479; Jung S, 2004, PLANT SCI, V167, P789, DOI 10.1016/j.plantsci.2004.05.038; KANAZIREVA E, 1995, J BACTERIOL, V177, P6693, DOI 10.1128/jb.177.22.6693-6694.1995; Komenda J, 2004, J BIOL CHEM, V279, P48620, DOI 10.1074/jbc.M405725200; Manna P, 1997, EUR J BIOCHEM, V247, P666, DOI 10.1111/j.1432-1033.1997.00666.x; Matsumoto F, 2004, PLANT PHYSIOL, V135, P2379, DOI 10.1104/pp.104.042408; Muller B, 1999, PLANT CELL, V11, P2365, DOI 10.1105/tpc.11.12.2365; Olsson U, 2002, J BACTERIOL, V184, P4018, DOI 10.1128/JB.184.14.4018-4024.2002; PAKRASI HB, 1989, PLANT CELL, V1, P591, DOI 10.2307/3868946; Papenbrock J, 1999, PLANTA, V208, P264, DOI 10.1007/s004250050558; Papenbrock J, 2001, PLANT J, V28, P41, DOI 10.1046/j.1365-313X.2001.01126.x; PAULSEN H, 1993, EUR J BIOCHEM, V215, P809, DOI 10.1111/j.1432-1033.1993.tb18096.x; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; SHEN GZ, 1993, BIOCHEMISTRY-US, V32, P5109, DOI 10.1021/bi00070a019; SHEN GZ, 1994, BIOCHEMISTRY-US, V33, P7379, DOI 10.1021/bi00189a044; SHIBA T, 1992, J GEN APPL MICROBIOL, V38, P439, DOI 10.2323/jgam.38.439; Singh DP, 2002, PLANT MOL BIOL, V50, P773, DOI 10.1023/A:1019959224271; Steiger S, 1999, J PHOTOCH PHOTOBIO B, V52, P14, DOI 10.1016/S1011-1344(99)00094-9; STILLMAN LC, 1978, ANAL BIOCHEM, V91, P166, DOI 10.1016/0003-2697(78)90827-8; Suzuki T, 2002, J BIOL CHEM, V277, P4731, DOI 10.1074/jbc.M105613200; Thomas H, 1997, NEW PHYTOL, V136, P163, DOI 10.1046/j.1469-8137.1997.00737.x; Tichy M, 2000, EUR J BIOCHEM, V267, P6296, DOI 10.1046/j.1432-1327.2000.01718.x; Vavilin DV, 2002, PHYSIOL PLANTARUM, V115, P9, DOI 10.1034/j.1399-3054.2002.1150102.x; Xu H, 2002, J BIOL CHEM, V277, P42726, DOI 10.1074/jbc.M205237200; Yaronskaya E, 2003, PLANT J, V35, P512, DOI 10.1046/j.1365-313X.2003.01825.x; YU JJ, 1990, PLANT CELL, V2, P315; Zavgorodnyaya A, 1997, PLANT J, V12, P169, DOI 10.1046/j.1365-313X.1997.12010169.x	40	22	22	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	2005	280	36					31595	31602		10.1074/jbc.M505976200	http://dx.doi.org/10.1074/jbc.M505976200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	961LZ	16027152	hybrid			2022-12-25	WOS:000231665200033
J	Steegborn, C; Litvin, TN; Hess, KC; Capper, AB; Taussig, R; Buck, J; Levin, LR; Wu, H				Steegborn, C; Litvin, TN; Hess, KC; Capper, AB; Taussig, R; Buck, J; Levin, LR; Wu, H			A novel mechanism for adenylyl cyclase inhibition from the crystal structure of its complex with catechol estrogen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC MECHANISM; PURIFICATION; BICARBONATE; PROGRAM; PERSPECTIVES; RECEPTORS; DOMAINS; BINDING; TISSUES; CELLS	Catechol estrogens are steroid metabolites that elicit physiological responses through binding to a variety of cellular targets. We show here that catechol estrogens directly inhibit soluble adenylyl cyclases and the abundant trans-membrane adenylyl cyclases. Catechol estrogen inhibition is non-competitive with respect to the substrate ATP, and we solved the crystal structure of a catechol estrogen bound to a soluble adenylyl cyclase from Spirulina platensis in complex with a substrate analog. The catechol estrogen is bound to a newly identified, conserved hydrophobic patch near the active center but distinct from the ATP-binding cleft. Inhibitor binding leads to a chelating interaction between the catechol estrogen hydroxyl groups and the catalytic magnesium ion, distorting the active site and trapping the enzyme substrate complex in a non-productive conformation. This novel inhibition mechanism likely applies to other adenylyl cyclase inhibitors, and the identified ligand-binding site has important implications for the development of specific adenylyl cyclase inhibitors.	Cornell Univ, Weill Med Coll, Dept Biochem, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Pharmacol, New York, NY 10021 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	Cornell University; Cornell University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Wu, H (corresponding author), Cornell Univ, Weill Med Coll, Dept Biochem, W206,1300 York Ave, New York, NY 10021 USA.	haowu@med.cornell.edu	Hess, Kenneth/K-6546-2019	Hess, Kenneth/0000-0003-1377-6070; Levin, Lonny/0000-0002-5204-6356	NICHD NIH HHS [R01 HD038722] Funding Source: Medline; NIGMS NIH HHS [R01 GM053645, GM53645] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD038722] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053645] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alanko J, 1998, BIOCHEM PHARMACOL, V55, P101, DOI 10.1016/S0006-2952(97)00398-5; Bertini R, 2004, P NATL ACAD SCI USA, V101, P11791, DOI 10.1073/pnas.0402090101; Bieger B, 2001, EMBO J, V20, P433, DOI 10.1093/emboj/20.3.433; BRAUN T, 1990, P SOC EXP BIOL MED, V194, P58; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buck J, 1999, P NATL ACAD SCI USA, V96, P79, DOI 10.1073/pnas.96.1.79; Buck J, 2002, METHOD ENZYMOL, V345, P95; Chen YQ, 2000, SCIENCE, V289, P625, DOI 10.1126/science.289.5479.625; Das SK, 1997, P NATL ACAD SCI USA, V94, P12786, DOI 10.1073/pnas.94.24.12786; Dessauer CW, 1999, TRENDS PHARMACOL SCI, V20, P205, DOI 10.1016/S0165-6147(99)01310-3; Dessauer CW, 1997, J BIOL CHEM, V272, P22272, DOI 10.1074/jbc.272.35.22272; Dubey RK, 2004, J PHARMACOL EXP THER, V308, P403, DOI 10.1124/jpet.103.058057; Ebina T, 1997, J MOL CELL CARDIOL, V29, P1247, DOI 10.1006/jmcc.1996.0362; ENGLUND PT, 1969, J BIOL CHEM, V244, P3038; ESNOUF R, 1995, NAT STRUCT BIOL, V2, P303, DOI 10.1038/nsb0495-303; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Hanoune J, 2001, ANNU REV PHARMACOL, V41, P145, DOI 10.1146/annurev.pharmtox.41.1.145; Haunso A, 2003, MOL PHARMACOL, V63, P624, DOI 10.1124/mol.63.3.624; Jaleel M, 2004, BIOCHEMISTRY-US, V43, P8247, DOI 10.1021/bi036234n; JONES TA, 1991, O MANUAL; KLEYWEGT GJ, 1994, ESF CCP4 NEWSLETTER, V31, P9; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Levy DE, 2003, J MED CHEM, V46, P2177, DOI 10.1021/jm0205604; Liehr JG, 1996, P NATL ACAD SCI USA, V93, P3294, DOI 10.1073/pnas.93.8.3294; Linder JU, 2003, CELL SIGNAL, V15, P1081, DOI 10.1016/S0898-6568(03)00130-X; Litvin TN, 2003, J BIOL CHEM, V278, P15922, DOI 10.1074/jbc.M212475200; LLOYD T, 1978, J BIOL CHEM, V253, P4841; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Otwinowski Z, 1993, DENZO FILM PROCESSIN; PAUL SM, 1977, NATURE, V266, P559, DOI 10.1038/266559a0; PAUL SM, 1977, SCIENCE, V197, P657, DOI 10.1126/science.877577; Philips BJ, 2004, BIOCHEMISTRY-US, V43, P6698, DOI 10.1021/bi036154j; Salomon Y, 1979, Adv Cyclic Nucleotide Res, V10, P35; SMIGEL MD, 1986, J BIOL CHEM, V261, P1976; Soudijn W, 2004, DRUG DISCOV TODAY, V9, P752, DOI 10.1016/S1359-6446(04)03220-9; Steegborn C, 2005, NAT STRUCT MOL BIOL, V12, P32, DOI 10.1038/nsmb880; Tang WJ, 1998, MOL PHARMACOL, V54, P231, DOI 10.1124/mol.54.2.231; TAUSSIG R, 1994, METHOD ENZYMOL, V238, P95; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; Tesmer JJG, 1999, SCIENCE, V285, P756, DOI 10.1126/science.285.5428.756; Tesmer JJG, 1998, CURR OPIN STRUC BIOL, V8, P713, DOI 10.1016/S0959-440X(98)80090-0; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Wiesmann C, 2004, NAT STRUCT MOL BIOL, V11, P730, DOI 10.1038/nsmb803; Yan SZ, 2002, METHOD ENZYMOL, V345, P231; Zhang GY, 1997, NATURE, V386, P247, DOI 10.1038/386247a0; Zhu BT, 1998, CARCINOGENESIS, V19, P1, DOI 10.1093/carcin/19.1.1; Zippin JH, 2001, TRENDS ENDOCRIN MET, V12, P366, DOI 10.1016/S1043-2760(01)00454-4; [No title captured]	48	65	69	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	2005	280	36					31754	31759		10.1074/jbc.M507144200	http://dx.doi.org/10.1074/jbc.M507144200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	961LZ	16002394	hybrid, Green Accepted			2022-12-25	WOS:000231665200053
J	Suzuki, A; Kusakai, G; Shimojo, Y; Chen, J; Ogura, T; Kobayashi, M; Esumi, H				Suzuki, A; Kusakai, G; Shimojo, Y; Chen, J; Ogura, T; Kobayashi, M; Esumi, H			Involvement of transforming growth factor-beta 1 signaling in hypoxia-induced tolerance to glucose starvation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; GROWTH-FACTOR-BETA; TGF-BETA; NUTRIENT DEPRIVATION; CELL-PROLIFERATION; TUMOR HYPOXIA; NITRIC-OXIDE; CANCER-CELLS; YEAST SNF1; AKT	Because survival and growth of human hepatoma cells are maintained by nutrient, especially glucose, glucose starvation induces acute cell death. The cell death is markedly suppressed by hypoxia, and we have reported involvement of AMP-activated protein kinase-alpha (AMPK-alpha), Akt, and ARK5 in hypoxia-induced tolerance. In the current study we investigated the mechanism of hypoxia-induced tolerance in human hepatoma cell line HepG2. ARK5 expression was induced in HepG2 cells when they were subjected to glucose starvation, and we found that glucose starvation transiently induced Akt and AMPK-alpha phosphorylation and that hypoxia prolonged phosphorylation of both protein kinases. We also found that hypoxia-induced tolerance was partially abrogated by blocking the Akt/ARK5 system or by suppressing AMPK-alpha expression and that suppression of both completely abolished the tolerance, suggesting that AMPK-alpha activation signaling and the Akt/ARK5 system play independent essential roles in hypoxia-induced tolerance. By using chemical compounds that specifically inhibit kinase activity of type I-transforming growth factor-beta (TGF-beta) receptor, we showed an involvement of TGF-beta in hypoxia-induced tolerance. TGF-beta 1 mRNA expression was induced by hypoxia in an hypoxia-inducible factor-1 alpha-independent manner, and addition of recombinant TGF-beta suppressed cell death during glucose starvation even under normoxic condition. AMPK-alpha, Akt, and ARK5 were activated by TGF-beta 1, and Akt and AMPK-alpha phosphorylation, which was prolonged by hypoxia, was suppressed by an inhibitor of type I TGF-beta receptor. Based on these findings, we propose that hypoxia-induced tumor cell tolerance to glucose starvation is caused by hypoxia-induced TGF-beta 1 through AMPK-alpha activation and the Akt/ARK5 system.	Natl Canc Ctr, Res Inst E, Canc Physiol Project, Kashiwa, Chiba 2778577, Japan; Natl Canc Ctr, Res Inst E, Investigat Treatment Div, Kashiwa, Chiba 2778577, Japan; Univ Tokyo, Grad Sch Frontier Sci, Dept Integrated Biosci, Kashiwa, Chiba 2778562, Japan; Hokkaido Univ, Inst Med Genet, Div Canc Pathobiol, Kita Ku, Sapporo, Hokkaido 0600815, Japan	National Cancer Center - Japan; National Cancer Center - Japan; University of Tokyo; Hokkaido University	Esumi, H (corresponding author), Natl Canc Ctr, Res Inst E, Canc Physiol Project, 6-5-1 Kashiwanoha, Kashiwa, Chiba 2778577, Japan.	hesumi@east.ncc.go.jp						Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; Benson JR, 2004, LANCET ONCOL, V5, P229, DOI 10.1016/S1470-2045(04)01426-3; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; CARLING D, 1994, J BIOL CHEM, V269, P11442; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Charames GS, 2003, CURR MOL MED, V3, P589, DOI 10.2174/1566524033479456; Chen J, 2003, AM J PATHOL, V162, P1283, DOI 10.1016/S0002-9440(10)63924-7; Cutroneo KR, 2003, J CELL BIOCHEM, V90, P1, DOI 10.1002/jcb.10599; Denko NC, 2001, CANCER RES, V61, P795; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Duff SE, 2003, FASEB J, V17, P984, DOI 10.1096/fj.02-0634rev; El-Rifai W, 2002, SEMIN RADIAT ONCOL, V12, P128, DOI 10.1053/srao.2002.30815; Esumi H, 2002, J BIOL CHEM, V277, P32791, DOI 10.1074/jbc.M112270200; Folkman J, 2001, P NATL ACAD SCI USA, V98, P398, DOI 10.1073/pnas.98.2.398; Folkman J, 1974, Adv Cancer Res, V19, P331, DOI 10.1016/S0065-230X(08)60058-5; Gold LI, 1999, CRIT REV ONCOGENESIS, V10, P303; Goto D, 1998, FEBS LETT, V430, P201, DOI 10.1016/S0014-5793(98)00658-9; Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901; Hardie DG, 1997, EUR J BIOCHEM, V246, P259, DOI 10.1111/j.1432-1033.1997.00259.x; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Heyer BS, 1997, MOL REPROD DEV, V47, P148, DOI 10.1002/(SICI)1098-2795(199706)47:2&lt;148::AID-MRD4&gt;3.0.CO;2-M; Hockel M, 2001, JNCI-J NATL CANCER I, V93, P266, DOI 10.1093/jnci/93.4.266; Hong SP, 2003, P NATL ACAD SCI USA, V100, P8839, DOI 10.1073/pnas.1533136100; Inman GJ, 2002, MOL PHARMACOL, V62, P65, DOI 10.1124/mol.62.1.65; Izuishi K, 2000, CANCER RES, V60, P6201; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Kato K, 2002, ONCOGENE, V21, P6082, DOI 10.1038/sj.onc.1205737; Kawabata M, 1999, ANN NY ACAD SCI, V886, P73, DOI 10.1111/j.1749-6632.1999.tb09402.x; Kemp BE, 2003, BIOCHEM SOC T, V31, P162; Kemp BE, 1999, TRENDS BIOCHEM SCI, V24, P22, DOI 10.1016/S0968-0004(98)01340-1; Kimura H, 2000, BLOOD, V95, P189, DOI 10.1182/blood.V95.1.189.001k05_189_197; Laping NJ, 2002, MOL PHARMACOL, V62, P58, DOI 10.1124/mol.62.1.58; Leask A, 2004, FASEB J, V18, P816, DOI 10.1096/fj.03-1273rev; Lebrin F, 2004, EMBO J, V23, P4018, DOI 10.1038/sj.emboj.7600386; Lefebvre DL, 2001, BIOCHEM J, V355, P297, DOI 10.1042/0264-6021:3550297; Lynch HT, 1999, J MED GENET, V36, P801; Majewski N, 2004, MOL CELL BIOL, V24, P730, DOI 10.1128/MCB.24.2.730-740.2004; MASSAGUE J, 1992, CANCER SURV, V12, P81; Matsuyama S, 2003, CANCER RES, V63, P7791; MITCHELHILL KI, 1994, J BIOL CHEM, V269, P2361; Muraoka RS, 2002, J CLIN INVEST, V109, P1551, DOI 10.1172/JCI200215234; Nam SY, 2002, ONCOGENE, V21, P337, DOI 10.1038/sj.onc.1205068; Norman JT, 2000, KIDNEY INT, V58, P2351, DOI 10.1046/j.1523-1755.2000.00419.x; Plas DR, 2001, J BIOL CHEM, V276, P12041, DOI 10.1074/jbc.M010551200; Rathmell JC, 2003, MOL CELL BIOL, V23, P7315, DOI 10.1128/MCB.23.20.7315-7328.2003; Roman C, 2001, MICROSC RES TECHNIQ, V52, P450, DOI 10.1002/1097-0029(20010215)52:4<450::AID-JEMT1030>3.0.CO;2-O; Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Srinivasan S, 2002, AM J PHYSIOL-ENDOC M, V283, pE784, DOI 10.1152/ajpendo.00177.2002; Suzuki A, 2004, BIOCHEM BIOPH RES CO, V324, P986, DOI 10.1016/j.bbrc.2004.09.145; Suzuki A, 2004, ONCOGENE, V23, P7067, DOI 10.1038/sj.onc.1207963; Suzuki A, 2003, BIOCHEM BIOPH RES CO, V311, P156, DOI 10.1016/j.bbrc.2003.09.184; Suzuki A, 2003, ONCOGENE, V22, P6177, DOI 10.1038/sj.onc.1206899; Suzuki A, 2003, J BIOL CHEM, V278, P48, DOI 10.1074/jbc.M206025200; Vaupel P, 2001, SEMIN ONCOL, V28, P29, DOI 10.1016/S0093-7754(01)90210-6; Wahl SM, 2004, J LEUKOCYTE BIOL, V76, P15, DOI 10.1189/jlb.1103539; Warren SM, 2001, J SURG RES, V99, P147, DOI 10.1006/jsre.2001.6128; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Yan ZF, 2002, J BIOL CHEM, V277, P9870, DOI 10.1074/jbc.M107646200; Zhang H, 2003, BLOOD, V101, P2253, DOI 10.1182/blood-2002-02-0629; Zhou SH, 2005, J BIOL CHEM, V280, P22688, DOI 10.1074/jbc.M412953200	64	45	54	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	2005	280	36					31557	31563		10.1074/jbc.M503714200	http://dx.doi.org/10.1074/jbc.M503714200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	961LZ	16014625	hybrid			2022-12-25	WOS:000231665200028
J	Bledsoe, RK; Madauss, KP; Holt, JA; Apolito, CJ; Lambert, MH; Pearce, KH; Stanley, TB; Stewart, EL; Trump, RP; Willson, TM; Williams, SP				Bledsoe, RK; Madauss, KP; Holt, JA; Apolito, CJ; Lambert, MH; Pearce, KH; Stanley, TB; Stewart, EL; Trump, RP; Willson, TM; Williams, SP			A ligand-mediated hydrogen bond network required for the activation of the mineralocorticoid receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOCORTICOID-RECEPTOR; BINDING DOMAIN; HUMAN KIDNEY; I PSEUDOHYPOALDOSTERONISM; INACTIVATING MUTATIONS; ANDROGEN RECEPTOR; NORMAL-PREGNANCY; S810L MUTATION; SEVERE FORM; PROGESTERONE	Ligand binding is the first step in hormone regulation of mineralocorticoid receptor (MR) activity. Here, wereport multiple crystal structures of MR (NR3C2) bound to both agonist and antagonists. These structures combined with mutagenesis studies reveal that maximal receptor activation involves an intricate ligand-mediated hydrogen bond network with Asn(770) which serves dual roles: stabilization of the loop preceding the C-terminal activation function-2 helix and direct contact with the hormone ligand. In addition, most activating ligands hydrogen bond to Thr(945) on helix 10. Structural characterization of the naturally occurring S810L mutant explains how stabilization of a helix 3/helix 5 interaction can circumvent the requirement for this hydrogen bond network. Taken together, these results explain the potency of MR activation by aldosterone, the weak activation induced by progesterone and the antihypertensive agent spironolactone, and the binding selectivity of cortisol over cortisone.	GlaxoSmithKline Inc, Dept Gene Express & Prot Biochem, Res Triangle Pk, NC 27709 USA; GlaxoSmithKline Inc, Dept Computat Analyt & Struct Sci, Res Triangle Pk, NC 27709 USA; GlaxoSmithKline Inc, Dept High Throughput Biol, Res Triangle Pk, NC 27709 USA; GlaxoSmithKline Inc, Dept High Throughput Chem, Discovery Res, Res Triangle Pk, NC 27709 USA	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline	Bledsoe, RK (corresponding author), GlaxoSmithKline Inc, Dept Gene Express & Prot Biochem, 5 Moore Dr, Res Triangle Pk, NC 27709 USA.	randy.k.bledsoe@gsk.com	feinstein, doug/M-9414-2019	Williams, Shawn/0000-0001-8311-2638				Agarwal MK, 1999, PHARMACOL THERAPEUT, V84, P273, DOI 10.1016/S0163-7258(99)00038-8; ALNEMRI ES, 1991, J BIOL CHEM, V266, P18072; ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703; Auwerx J, 1999, CELL, V97, P161; Auzou G, 2000, MOL PHARMACOL, V58, P684, DOI 10.1124/mol.58.4.684; Bledsoe RK, 2002, CELL, V110, P93, DOI 10.1016/S0092-8674(02)00817-6; BRILLA CG, 1992, J LAB CLIN MED, V120, P893; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Bumke-Vogt C, 2002, J ENDOCRINOL, V175, P349, DOI 10.1677/joe.0.1750349; CORVOL P, 1981, KIDNEY INT, V20, P1, DOI 10.1038/ki.1981.97; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Fagart J, 1998, EMBO J, V17, P3317, DOI 10.1093/emboj/17.12.3317; Farman N, 2001, AM J PHYSIOL-RENAL, V280, pF181, DOI 10.1152/ajprenal.2001.280.2.F181; FUNDER JW, 1988, SCIENCE, V242, P583, DOI 10.1126/science.2845584; FUNDER JW, 1974, BIOCHEM PHARMACOL, V23, P1493, DOI 10.1016/0006-2952(74)90386-4; Geller DS, 2000, SCIENCE, V289, P119, DOI 10.1126/science.289.5476.119; Hellal-Levy C, 2000, MOL ENDOCRINOL, V14, P1210, DOI 10.1210/me.14.8.1210; Hellal-Levy C, 2000, KIDNEY INT, V57, P1250, DOI 10.1046/j.1523-1755.2000.00958.x; JOHANSSON EB, 1971, ACTA OBSTET GYN SCAN, V50, P339, DOI 10.3109/00016347109157335; Kauppi B, 2003, J BIOL CHEM, V278, P22748, DOI 10.1074/jbc.M212711200; LOMBES M, 1995, CIRCULATION, V92, P175, DOI 10.1161/01.CIR.92.2.175; Matias PM, 2000, J BIOL CHEM, V275, P26164, DOI 10.1074/jbc.M004571200; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; NOLTEN WE, 1978, AM J OBSTET GYNECOL, V132, P414, DOI 10.1016/0002-9378(78)90777-9; PETERFALVI M, 1980, BIOCHEM PHARMACOL, V29, P353, DOI 10.1016/0006-2952(80)90513-4; Pinon GM, 2004, MOL CELL ENDOCRINOL, V217, P181, DOI 10.1016/j.mce.2003.10.053; Pitt B, 1999, NEW ENGL J MED, V341, P709, DOI 10.1056/NEJM199909023411001; Quinkler M, 2003, J CLIN ENDOCR METAB, V88, P2803, DOI 10.1210/jc.2002-021970; Quinkler M, 2001, MOL CELL ENDOCRINOL, V171, P21, DOI 10.1016/S0303-7207(00)00429-9; Rafestin-Oblin ME, 2003, ENDOCRINOLOGY, V144, P528, DOI 10.1210/en.2002-220708; Rafestin-Oblin ME, 2002, MOL PHARMACOL, V62, P1306, DOI 10.1124/mol.62.6.1306; Rogerson FM, 2000, STEROIDS, V65, P61, DOI 10.1016/S0039-128X(99)00087-2; RUPPRECHT R, 1993, MOL ENDOCRINOL, V7, P597, DOI 10.1210/me.7.4.597; RUPPRECHT R, 1993, EUR J PHARM-MOLEC PH, V247, P145, DOI 10.1016/0922-4106(93)90072-H; Sack JS, 2001, P NATL ACAD SCI USA, V98, P4904, DOI 10.1073/pnas.081565498; Sartorato P, 2004, MOL ENDOCRINOL, V18, P2151, DOI 10.1210/me.2003-0408; Sartorato P, 2004, MOL CELL ENDOCRINOL, V217, P119, DOI 10.1016/j.mce.2003.10.017; Sartorato P, 2003, J CLIN ENDOCR METAB, V88, P2508, DOI 10.1210/jc.2002-021932; SOUQUE A, 1995, ENDOCRINOLOGY, V136, P5651, DOI 10.1210/en.136.12.5651; STEWART PM, 1991, J STEROID BIOCHEM, V40, P501, DOI 10.1016/0960-0760(91)90269-B; SUTANTO W, 1991, MED RES REV, V11, P617, DOI 10.1002/med.2610110604; Tajima T, 2000, J CLIN ENDOCR METAB, V85, P4690, DOI 10.1210/jc.85.12.4690; Williams SP, 1998, NATURE, V393, P392, DOI 10.1038/30775; Young MJ, 2002, J HYPERTENS, V20, P1465, DOI 10.1097/00004872-200208000-00002; Zennaro MC, 2004, TRENDS ENDOCRIN MET, V15, P264, DOI 10.1016/j.tem.2004.06.003; Zhang JH, 2005, P NATL ACAD SCI USA, V102, P2707, DOI 10.1073/pnas.0409663102	48	159	164	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	2005	280	35					31283	31293		10.1074/jbc.M504098200	http://dx.doi.org/10.1074/jbc.M504098200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	958ZX	15967794	hybrid			2022-12-25	WOS:000231487800076
J	Dominguez, D; Tournoy, J; Hartmann, D; Huth, T; Cryns, K; Deforce, S; Serneels, L; Camacho, IE; Marjaux, E; Craessaerts, K; Roebroek, AJM; Schwake, M; D'Hooge, R; Bach, P; Kalinke, U; Moechars, D; Alzheimer, C; Reiss, K; Saftig, P; De Strooper, B				Dominguez, D; Tournoy, J; Hartmann, D; Huth, T; Cryns, K; Deforce, S; Serneels, L; Camacho, IE; Marjaux, E; Craessaerts, K; Roebroek, AJM; Schwake, M; D'Hooge, R; Bach, P; Kalinke, U; Moechars, D; Alzheimer, C; Reiss, K; Saftig, P; De Strooper, B			Phenotypic and biochemical analyses of BACE1- and BACE2-deficient mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; BETA-SECRETASE; KNOCKOUT MICE; HIPPOCAMPAL-NEURONS; PEPTIDE PRODUCTION; ASPARTYL PROTEASE; ALZHEIMER-DISEASE; SODIUM-CHANNELS; E-SELECTIN; BACE1	beta-Secretase (BACE1) is the rate-limiting protease for the generation of the amyloid beta-peptide (A beta) in Alzheimer disease. Mice in which the bace1 gene is inactivated are reported to be healthy. However, the presence of a homologous gene encoding BACE2 raises the possibility of compensatory mechanisms. Therefore, we have generated bace1, bace2, and double knockout mice. We report here that BACE1 mice display a complex phenotype. A variable but significant number of BACE1 offspring died in the first weeks after birth. The surviving mice remained smaller than their littermate controls and presented a hyperactive behavior. Electrophysiologically, subtle alterations in the steady-state inactivation of voltage-gated sodium channels in BACE1-deficient neurons were observed. In contrast, bace2 knockout mice displayed an overall healthy phenotype. However, a combined deficiency of BACE2 and BACE1 enhanced the bace1(-/-) lethality phenotype. At the biochemical level, we have confirmed that BACE1 deficiency results in an almost complete block of A beta generation in neurons, but not in glia. As glia are 10 times more abundant in brain compared with neurons, our data indicate that BACE2 could indeed contribute to A beta generation in the brains of Alzheimer disease and, in particular, Down syndrome patients. In conclusion, our data challenge the general idea of BACE1 as a safe drug target and call for some caution when claiming that no major side effects should be expected from blocking BACE1 activity.	Univ Kiel, Inst Biochem, Dept Physiol, D-24098 Kiel, Germany; Katholieke Univ Leuven, Ctr Human Genet, B-3000 Louvain, Belgium; Flanders Interuniv Inst Biotechnol VIB4, B-3000 Louvain, Belgium; Univ Kiel, Dept Biochem, D-24118 Kiel, Germany; Johnson & Johnson Pharmaceut Res & Dev, B-2340 Beerse, Belgium; Katholieke Univ Leuven, Lab Biol Psychol, B-3000 Louvain, Belgium; Paul Ehrlich Inst, Div Immunol, D-63225 Langen, Germany	University of Kiel; KU Leuven; University of Kiel; Johnson & Johnson; Janssen Pharmaceuticals; KU Leuven; Paul Ehrlich Institute	Saftig, P (corresponding author), Univ Kiel, Inst Biochem, Dept Physiol, Olshausenstr 40, D-24098 Kiel, Germany.	psaftig@biochem.uni-kiel.de; bart.destrooper@med.kuleuven.ac.be	Espuny, Ira/AAM-1991-2021; Reiss, Karina/B-3175-2010; De Strooper, Bart/F-6507-2012; tournoy, jos/AAR-1965-2020; Saftig, Paul/A-7966-2010; Bach, Patrick/AAF-5716-2019; de+Strooper, Bart/Z-1638-2019; Schwake, Michael/F-5381-2010	Espuny, Ira/0000-0002-2356-2159; De Strooper, Bart/0000-0001-5455-5819; tournoy, jos/0000-0002-0265-9154; Bach, Patrick/0000-0001-5962-019X; Schwake, Michael/0000-0002-4173-2166; Kalinke, Ulrich/0000-0003-0503-9564; Serneels, Lutgarde/0000-0002-5463-4231; Huth, Tobias/0000-0002-6414-8923				Acquati F, 2000, FEBS LETT, V468, P59, DOI 10.1016/S0014-5793(00)01192-3; ALZHEIMER C, 1994, J PHYSIOL-LONDON, V479, P199, DOI 10.1113/jphysiol.1994.sp020288; Basi G, 2003, J BIOL CHEM, V278, P31512, DOI 10.1074/jbc.M300169200; Bennett BD, 2000, J BIOL CHEM, V275, P20647, DOI 10.1074/jbc.M002688200; Cai HB, 2001, NAT NEUROSCI, V4, P233, DOI 10.1038/85064; Crawley Jacqueline N., 2007, WHATS WRONG MY MOUSE; DESTROOPER B, 1995, EMBO J, V14, P4932, DOI 10.1002/j.1460-2075.1995.tb00176.x; Esselens C, 2004, J CELL BIOL, V166, P1041, DOI 10.1083/jcb.200406060; Farzan M, 2000, P NATL ACAD SCI USA, V97, P9712, DOI 10.1073/pnas.160115697; Fluhrer R, 2002, J NEUROCHEM, V81, P1011, DOI 10.1046/j.1471-4159.2002.00908.x; Harrison SM, 2003, MOL CELL NEUROSCI, V24, P646, DOI 10.1016/S1044-7431(03)00227-6; Hennet T, 1998, P NATL ACAD SCI USA, V95, P4504, DOI 10.1073/pnas.95.8.4504; Hussain I, 2000, MOL CELL NEUROSCI, V16, P609, DOI 10.1006/mcne.2000.0884; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; Isom LL, 2002, NOVART FDN SYMP, V241, P124; Isom LL, 2002, FRONT BIOSCI, V7, P12; Kamenetz F, 2003, NEURON, V37, P925, DOI 10.1016/S0896-6273(03)00124-7; Lin XL, 2000, P NATL ACAD SCI USA, V97, P1456, DOI 10.1073/pnas.97.4.1456; Luo Y, 2003, NEUROBIOL DIS, V14, P81, DOI 10.1016/S0969-9961(03)00104-9; Luo Y, 2001, NAT NEUROSCI, V4, P231, DOI 10.1038/85059; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; Motonaga K, 2002, NEUROSCI LETT, V326, P64, DOI 10.1016/S0304-3940(02)00287-2; NASLUND J, 1994, P NATL ACAD SCI USA, V91, P8378, DOI 10.1073/pnas.91.18.8378; Ohno M, 2004, NEURON, V41, P27, DOI 10.1016/S0896-6273(03)00810-9; PIKE CJ, 1995, J BIOL CHEM, V270, P23895, DOI 10.1074/jbc.270.41.23895; Qi-Takahara Y, 2005, J NEUROSCI, V25, P436, DOI 10.1523/JNEUROSCI.1575-04.2005; Roberds SL, 2001, HUM MOL GENET, V10, P1317, DOI 10.1093/hmg/10.12.1317; Simons M, 1996, J NEUROSCI, V16, P899; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Solans A, 2000, CYTOGENET CELL GENET, V89, P177, DOI 10.1159/000015608; TEDDER TF, 1995, J EXP MED, V181, P2259, DOI 10.1084/jem.181.6.2259; Tienari PJ, 1996, COLD SPRING HARB SYM, V61, P575; Tournoy J, 2004, HUM MOL GENET, V13, P1321, DOI 10.1093/hmg/ddh151; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; WATSON SR, 1991, NATURE, V349, P164, DOI 10.1038/349164a0; Wong GT, 2004, J BIOL CHEM, V279, P12876, DOI 10.1074/jbc.M311652200; Wong HK, 2005, J BIOL CHEM, V280, P23009, DOI 10.1074/jbc.M414648200; Wong PC, 2001, SCIENCE, V293, P1434; Xia LJ, 2002, J CLIN INVEST, V109, P939; Yan RQ, 2001, J BIOL CHEM, V276, P34019, DOI 10.1074/jbc.M105583200; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Yang J, 1999, J EXP MED, V190, P1769, DOI 10.1084/jem.190.12.1769	42	281	293	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	2005	280	35					30797	30806		10.1074/jbc.M505249200	http://dx.doi.org/10.1074/jbc.M505249200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	958ZX	15987683	hybrid, Green Published			2022-12-25	WOS:000231487800020
J	Zang, Z; Fang, QM; Pegg, AE; Guengerich, FP				Zang, Z; Fang, QM; Pegg, AE; Guengerich, FP			Kinetic analysis of steps in the repair of damaged DNA by human O-6-alkylguanine-DNA alkyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							O-6-METHYLGUANINE-DNA METHYLTRANSFERASE; STEADY-STATE; BINDING; ALKYLATION; MECHANISM; OLIGODEOXYNUCLEOTIDES; O-6-BENZYLGUANINE; INACTIVATION; RECOGNITION; SPECIFICITY	Rates of individual steps in the removal of alkyl groups from O-6-methyl (Me) and -benzyl (Bz) guanine in oligonucleotides by human O-6-alkylguanine DNA alkyltransferase (AGT) were estimated using rapid reaction kinetic methods. The overall reaction yields hyperbolic plots of rate versus AGT concentration for O-6-MeG but linear plots for the O-6-BzG reaction, which is similar to 100-fold faster. The binding of AGT and DNA (double-stranded 30-mer/36-mer complex) appears to be diffusion-limited. The rate of dissociation of the complex is similar to 25-fold slower (similar to 1 s(-1)) for DNA containing O-6-MeG or O-6-BzG than unmodified DNA. The fluorescent dC-analog 6-methylpyrrolo[2,3-d]pyrimidine-2(3H) one deoxyribonucleoside (pyrrolo dC), which pairs with G, was positioned opposite G, O-6-MeG, or O-6-BzG and used as a probe of the rate of base flipping. A rapid increase of fluorescence (k similar to 200 s(-1)) was observed with O-6-MeG and O-6-BzG and AGT but not with a Gly mutation at Arg(128), which has been implicated in base flipping with crystal structures. Only weak and slower fluorescence changes were observed with G: pyrrolo dC or T: 2-aminopurine pairs. These rate estimates were used in a kinetic model in which AGT binds and scans DNA rapidly, flips O-6-alkylG residues, transfers the alkyl group in a chemical step that is rate-limiting in the case of O-6-MeG but not O-6-BzG, and releases the dealkylated DNA. The results explain the overall patterns of rates of alkyl group removal versus AGT concentration and the effects of the mutations, as well as the greater affinity of AGT for DNA with O-6-alkylG lesions.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Ctr Mol Toxicol, Nashville, TN 37232 USA; Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA	Vanderbilt University; Vanderbilt University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Guengerich, FP (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 638 Robinson Res Bldg,23rd & Pierce Ave, Nashville, TN 37232 USA.	f.guengerich@vanderbilt.edu	Fang, Qingming/B-6839-2008	Fang, Qingming/0000-0002-4006-0636	NCI NIH HHS [R01 CA18137] Funding Source: Medline; NIEHS NIH HHS [P30 ES00267, R01 ES10546] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA018137] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES010546, P30ES000267] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BECKETT D, 2003, KINETIC ANAL MACROMO, V267, P171; Bender K, 1996, NUCLEIC ACIDS RES, V24, P2087, DOI 10.1093/nar/24.11.2087; BHATTACHARYYA D, 1990, EUR J BIOCHEM, V193, P337, DOI 10.1111/j.1432-1033.1990.tb19343.x; CHAN CL, 1993, ARCH BIOCHEM BIOPHYS, V300, P193, DOI 10.1006/abbi.1993.1027; Christmann M, 2003, TOXICOLOGY, V193, P3, DOI 10.1016/S0300-483X(03)00287-7; Crone TM, 1996, MUTAT RES-DNA REPAIR, V363, P15, DOI 10.1016/0921-8777(95)00058-5; Daniels DS, 2004, NAT STRUCT MOL BIOL, V11, P714, DOI 10.1038/nsmb791; DOLAN ME, 1991, CARCINOGENESIS, V12, P2305, DOI 10.1093/carcin/12.12.2305; DOLAN ME, 1988, CARCINOGENESIS, V9, P2139, DOI 10.1093/carcin/9.11.2139; Duguid EM, 2003, CHEM BIOL, V10, P827, DOI 10.1016/j.chembiol.2003.08.007; FERSHT A, 1999, STRUCTURE MECH PROTE, P158; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Furge LL, 1997, BIOCHEMISTRY-US, V36, P6475, DOI 10.1021/bi9627267; Goodtzova K, 1998, BIOCHEMISTRY-US, V37, P12489, DOI 10.1021/bi9811718; Goodtzova K, 1997, J BIOL CHEM, V272, P8332, DOI 10.1074/jbc.272.13.8332; Guengerich FP, 2003, BIOCHEMISTRY-US, V42, P10965, DOI 10.1021/bi034937z; Hazra TK, 1997, BIOCHEMISTRY-US, V36, P5769, DOI 10.1021/bi963085i; Krosky DJ, 2005, BIOCHEMISTRY-US, V44, P5949, DOI 10.1021/bi050084u; Krosky DJ, 2004, BIOCHEMISTRY-US, V43, P4188, DOI 10.1021/bi036303y; Kuzmic P, 1996, ANAL BIOCHEM, V237, P260, DOI 10.1006/abio.1996.0238; LIEM LK, 1993, J MOL BIOL, V231, P950, DOI 10.1006/jmbi.1993.1344; Liu LP, 2004, J BIOL CHEM, V279, P4250, DOI 10.1074/jbc.M311105200; Meyer AS, 2003, CHEM RES TOXICOL, V16, P1405, DOI 10.1021/tx0341254; Mijal RS, 2004, CHEM RES TOXICOL, V17, P424, DOI 10.1021/tx0342417; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; PEGG AE, 1993, BIOCHEMISTRY-US, V32, P11998, DOI 10.1021/bi00096a009; PEGG AE, 1995, PROG NUCLEIC ACID RE, V51, P167, DOI 10.1016/S0079-6603(08)60879-X; Pegg AE, 1998, J BIOL CHEM, V273, P10863, DOI 10.1074/jbc.273.18.10863; Rasimas JJ, 2004, PROTEIN SCI, V13, P301, DOI 10.1110/ps.03319404; Rasimas JJ, 2003, BIOCHEMISTRY-US, V42, P980, DOI 10.1021/bi026970b; Rasimas JJ, 2003, J BIOL CHEM, V278, P7973, DOI 10.1074/jbc.M211854200; Spratt TE, 1999, BIOCHEMISTRY-US, V38, P6801, DOI 10.1021/bi982908w; Stivers JT, 1999, BIOCHEMISTRY-US, V38, P952, DOI 10.1021/bi9818669; Terashima I, 1997, CHEM RES TOXICOL, V10, P1234, DOI 10.1021/tx9700580; Vora RA, 1998, PROTEINS, V32, P3; Woodside AM, 2002, BIOCHEMISTRY-US, V41, P1027, DOI 10.1021/bi011495n; Zang H, 2005, J BIOL CHEM, V280, P1165, DOI 10.1074/jbc.M405996200	37	59	60	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	2005	280	35					30873	30881		10.1074/jbc.M505283200	http://dx.doi.org/10.1074/jbc.M505283200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	958ZX	16000301	hybrid			2022-12-25	WOS:000231487800028
J	Lu, YJ; White, SW; Rock, CO				Lu, YJ; White, SW; Rock, CO			Domain swapping between Enterococcus faecalis FabN and FabZ proteins localizes the structural determinants for isomerase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL CARRIER PROTEIN; FATTY-ACID BIOSYNTHESIS; SYNTHASE III FABH; ESCHERICHIA-COLI; STREPTOCOCCUS-PNEUMONIAE; GENE; INHIBITION; RESISTANCE; REGULATOR; DEHYDRASE	Anaerobic unsaturated fatty acid synthesis in bacteria occurs through the introduction of a double bond into the growing acyl chain. In the Escherichia coli model system, FabA catalyzes both the dehydration of beta-hydroxydecanoyl-ACP and the isomerization of trans-2-decenoyl-ACP to cis-3-decenoyl-ACP as the essential step. A second dehydratase, FabZ, functions in acyl chain elongation but cannot carry out the isomerization reaction. Enterococcus faecalis has two highly related FabZ homologs. One of these, termed EfFabN, carries out the isomerization reaction in vivo, whereas the other, EfFabZ, does not ( Wang, H., and Cronan, J. E. ( 2004) J. Biol. Chem. 279, 34489 - 34495). We carried out a series of domain swapping and mutagenesis experiments coupled with in vitro biochemical analyses to define the structural feature( s) that specify the catalytic properties of these two enzymes. Substitution of the beta 3 and beta 4 strands of EfFabZ with the corresponding strands from EfFabN was necessary and sufficient to convert EfFabZ into an isomerase. These data are consistent with the hypothesis that the isomerase potential of beta-hydroxyacyl-ACP dehydratases is determined by the properties of the beta-sheets that dictate the orientation of the central alpha-helix and thus the shape of the substrate binding tunnel rather than the catalytic machinery at the active site.	St Jude Childrens Res Hosp, Dept Infect Dis, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Biol Struct, Memphis, TN 38105 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital	Rock, CO (corresponding author), St Jude Childrens Res Hosp, Dept Infect Dis, 332 N Lauderdale, Memphis, TN 38105 USA.	charles.rock@stjude.org	White, Stephen W/N-8164-2018		NCI NIH HHS [CA 21765] Funding Source: Medline; NIGMS NIH HHS [GM 34496] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034496, R37GM034496] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alekshun MN, 2001, NAT STRUCT BIOL, V8, P710, DOI 10.1038/90429; Alekshun MN, 2000, MOL MICROBIOL, V35, P1394, DOI 10.1046/j.1365-2958.2000.01802.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Campbell JW, 2001, J BACTERIOL, V183, P5982, DOI 10.1128/JB.183.20.5982-5990.2001; Choi KH, 2000, J BIOL CHEM, V275, P28201; Choi KH, 2000, J BACTERIOL, V182, P365, DOI 10.1128/JB.182.2.365-370.2000; Clark D P, 1981, Methods Enzymol, V72, P693; CLARK DP, 1983, BIOCHEMISTRY-US, V22, P5897, DOI 10.1021/bi00294a032; Cronan JE, 1996, ESCHERICHIA COLI SAL, V1, P612; DAGNOLO G, 1975, J BIOL CHEM, V250, P5289; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Fozo EM, 2004, J BACTERIOL, V186, P4152, DOI 10.1128/JB.186.13.4152-4158.2004; GARWIN JL, 1980, J BIOL CHEM, V255, P1949; HEATH RJ, 1995, J BIOL CHEM, V270, P26538, DOI 10.1074/jbc.270.44.26538; Heath RJ, 1996, J BIOL CHEM, V271, P10996, DOI 10.1074/jbc.271.18.10996; Heath RJ, 1996, J BIOL CHEM, V271, P27795, DOI 10.1074/jbc.271.44.27795; KASS LR, 1967, P NATL ACAD SCI USA, V58, P1168, DOI 10.1073/pnas.58.3.1168; Kimber MS, 2004, J BIOL CHEM, V279, P52593, DOI 10.1074/jbc.M408105200; Leesong M, 1996, STRUCTURE, V4, P253, DOI 10.1016/S0969-2126(96)00030-5; Lu YJ, 2004, BIOCHEM CELL BIOL, V82, P145, DOI 10.1139/o03-076; Marrakchi H, 2002, J BIOL CHEM, V277, P44809, DOI 10.1074/jbc.M208920200; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MOHAN S, 1994, J BIOL CHEM, V269, P32896; Rock CO, 1996, BBA-LIPID LIPID MET, V1302, P1, DOI 10.1016/0005-2760(96)00056-2; Schujman GE, 2001, J BACTERIOL, V183, P3032, DOI 10.1128/JB.183.10.3032-3040.2001; TROMBE MC, 1979, BIOCHIM BIOPHYS ACTA, V574, P290, DOI 10.1016/0005-2760(79)90010-9; Wang HH, 2004, J BIOL CHEM, V279, P34489, DOI 10.1074/jbc.M403874200	27	32	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	2005	280	34					30342	30348		10.1074/jbc.M504637200	http://dx.doi.org/10.1074/jbc.M504637200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	957IC	15980063	hybrid			2022-12-25	WOS:000231362500044
J	Xu, Q; Briggs, J; Park, S; Niu, GL; Kortylewski, M; Zhang, SM; Gritsko, T; Turkson, J; Kay, H; Semenza, GL; Cheng, JQ; Jove, R; Yu, H				Xu, Q; Briggs, J; Park, S; Niu, GL; Kortylewski, M; Zhang, SM; Gritsko, T; Turkson, J; Kay, H; Semenza, GL; Cheng, JQ; Jove, R; Yu, H			Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways	ONCOGENE			English	Article						stat3; HIF-1; VEGF; Akt; angiogenesis	DNA-BINDING ACTIVITY; PHOSPHATIDYLINOSITOL 3-KINASE; CONSTITUTIVE ACTIVATION; TUMOR ANGIOGENESIS; V-SRC; CANCER; INTERLEUKIN-6; TRANSCRIPTION; CELLS; PHOSPHORYLATION	Vascular endothelial growth factor (VEGF) upregulation is induced by many receptor and intracellular oncogenic proteins commonly activated in cancer, rendering molecular targeting of VEGF expression a complex challenge. While VEGF inducers abound, only two major transcription activators have been identified for its promoter: hypoxia inducible factor-1 (HIF-1) and signal transducer and activator of transcription (Stat3). Both HIF-1 expression and Stat3 activity are upregulated in diverse cancers. Here, we provide evidence that Stat3 is required for both basal and growth signal-induced expression of HIF-1. Moreover, induction of VEGF by diverse oncogenic growth stimuli, including IL-6R, c-Src, Her2/Neu, is attenuated in cells without Stat3 signaling. We further demonstrate that Stat3 regulates expression of Akt, which is required for growth signal-induced HIF-1 upregulation. Targeting Stat3 with a small-molecule inhibitor blocks HIF-1 and VEGF expression in vitro and inhibits tumor growth and angiogenesis in vivo. Furthermore, tumor cells' in vivo angiogenic capacity induced by IL-6R, which simultaneously activates Jak/TAT and PI3K/Akt pathways, is abrogated when Stat3 is inhibited. Activation of Stat3 signaling by various growth signaling is prevalent in diverse cancers. Results presented here demonstrate that Stat3 is an effective target for inhibiting tumor VEGF expression and angiogenesis.	Univ S Florida, H Lee Moffitt Canc Ctr, Program Immunol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Res Inst, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA; Univ S Florida, Dept Pathol, Coll Med, Tampa, FL 33612 USA; Univ S Florida, Coll Publ Hlth, Tampa, FL 33612 USA; Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21218 USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21218 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; Johns Hopkins University; Johns Hopkins University	Yu, H (corresponding author), Univ S Florida, H Lee Moffitt Canc Ctr, Program Immunol, 12902 Magnolia Dr, Tampa, FL 33612 USA.	chengjq@moffitt.usf.edu; huayu@moffitt.usf.edu	Kortylewski, Marcin/H-8052-2019	Kortylewski, Marcin/0000-0002-6003-1816; XU, QING/0000-0002-4785-2994; YU, Hua/0000-0003-0931-1000	NATIONAL CANCER INSTITUTE [R01CA089693, P01CA082533, P01CA078038, R29CA075243] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R43MH096663, R43MH090939] Funding Source: NIH RePORTER; NCI NIH HHS [CA82533, CA78038, CA89693, CA75243] Funding Source: Medline; NIMH NIH HHS [R43 MH090939, R43 MH096663] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Bartoli M, 2003, FASEB J, V17, P1562, DOI 10.1096/fj.02-1084fje; Benjamin LE, 1999, J CLIN INVEST, V103, P159, DOI 10.1172/JCI5028; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Dankbar B, 2000, BLOOD, V95, P2630, DOI 10.1182/blood.V95.8.2630; Darnell JE, 2002, NAT REV CANCER, V2, P740, DOI 10.1038/nrc906; Deo DD, 2002, J BIOL CHEM, V277, P21237, DOI 10.1074/jbc.M110955200; Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; Gray MJ, 2005, ONCOGENE, V24, P3110, DOI 10.1038/sj.onc.1208513; Hideshima T, 2004, BLOOD, V104, P607, DOI 10.1182/blood-2004-01-0037; Hideshima T, 2001, ONCOGENE, V20, P5991, DOI 10.1038/sj.onc.1204833; Huss WJ, 2003, MOL CANCER THER, V2, P611; Inoue M, 2002, CANCER CELL, V1, P193, DOI 10.1016/S1535-6108(02)00031-4; Jiang BH, 2001, CELL GROWTH DIFFER, V12, P363; Jiang BH, 2000, P NATL ACAD SCI USA, V97, P1749, DOI 10.1073/pnas.040560897; Jiang BH, 1997, CANCER RES, V57, P5328; Karni R, 2002, J BIOL CHEM, V277, P42919, DOI 10.1074/jbc.M206141200; Klement G, 2000, J CLIN INVEST, V105, pR15, DOI 10.1172/JCI8829; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Liu AX, 1998, CANCER RES, V58, P2973; Mora LB, 2002, CANCER RES, V62, P6659; Niu G, 2002, ONCOGENE, V21, P7001, DOI 10.1038/sj.onc.1205859; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Podar K, 2005, BLOOD, V105, P1383, DOI 10.1182/blood-2004-07-2909; Porter AC, 1998, ONCOGENE, V17, P1343, DOI 10.1038/sj.onc.1202171; Rak J, 1995, CANCER METAST REV, V14, P263, DOI 10.1007/BF00690598; Rane SG, 2002, ONCOGENE, V21, P3334, DOI 10.1038/sj.onc.1205398; Repovic P, 2003, ONCOGENE, V22, P8117, DOI 10.1038/sj.onc.1206922; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Tan C, 2004, CANCER CELL, V5, P79, DOI 10.1016/S1535-6108(03)00281-2; Turkson J, 2004, MOL CANCER THER, V3, P261; Turkson J, 2001, J BIOL CHEM, V276, P45443, DOI 10.1074/jbc.M107527200; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wang TH, 2004, NAT MED, V10, P48, DOI 10.1038/nm976; Wei DY, 2003, ONCOGENE, V22, P319, DOI 10.1038/sj.onc.1206122; Wei LH, 2003, ONCOGENE, V22, P1517, DOI 10.1038/sj.onc.1206226; Wen Y, 2000, CANCER RES, V60, P6841; Xie KP, 2004, CYTOKINE GROWTH F R, V15, P297, DOI 10.1016/j.cytogfr.2004.04.003; Yahata Y, 2003, J BIOL CHEM, V278, P40026, DOI 10.1074/jbc.M301866200; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	44	445	492	0	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 25	2005	24	36					5552	5560		10.1038/sj.onc.1208719	http://dx.doi.org/10.1038/sj.onc.1208719			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	956JN	16007214				2022-12-25	WOS:000231296100003
J	Ma, K; Zhang, Y; Elam, MB; Cook, GA; Park, EA				Ma, K; Zhang, Y; Elam, MB; Cook, GA; Park, EA			Cloning of the rat pyruvate dehydrogenase kinase 4 gene promoter - Activation of pyruvate dehydrogenase kinase 4 by the peroxisome proliferator-activated receptor gamma coactivator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CPT-I-ALPHA; TRANSCRIPTIONAL COACTIVATOR; HEPATIC GLUCONEOGENESIS; PROTEIN EXPRESSION; SKELETAL-MUSCLE; PGC-1-ALPHA; LIVER; INDUCTION; PGC-1; STARVATION	The pyruvate dehydrogenase complex catalyzes the conversion of pyruvate to acetyl-CoA in mitochondria and is a key regulatory enzyme in the metabolism of glucose to acetyl-CoA. Phosphorylation of pyruvate dehydrogenase by the pyruvate dehydrogenase kinases (PDK) inhibits pyruvate dehydrogenase complex activity. There are four PDK isoforms, and expression of PDK4 and PDK2 genes is elevated in starvation and diabetes, allowing glucose to be conserved while fatty acid oxidation is increased. In these studies we have investigated the transcriptional mechanisms by which the expression of the PDK4 gene is increased. The peroxisome proliferator-activated receptor gamma coactivator (PGC-1 alpha) stimulates the expression of genes involved in hepatic gluconeogenesis and mitochondrial fatty acid oxidation. We have found that PGC-1 alpha will induce the expression of both the PDK2 and PDK4 genes in primary rat hepatocytes and ventricular myocytes. We cloned the promoter for the rat PDK4 gene. Hepatic nuclear factor 4 (HNF4), which activates many genes in the liver, will induce PDK4 expression. Although HNF4 and PGC-1 alpha interact to stimulate several genes encoding gluconeogenic enzymes, the induction of PDK4 does not involve interactions of PGC-1 alpha with HNF4. Using the chromatin immunoprecipitation assay, we have demonstrated that HNF4 and PGC-1 alpha are associated with the PDK4 gene in vivo. Our data suggest that by inducing PDK genes PGC-1 alpha will direct pyruvate away from metabolism into acetyl-CoA and toward the formation of oxaloacetate and into the gluconeogenic pathway.	Univ Tennessee, Coll Med, Dept Pharmacol, Memphis, TN 38163 USA; Vet Affairs Med Ctr, Dept Med, Memphis, TN 38104 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center	Park, EA (corresponding author), Univ Tennessee, Coll Med, Dept Pharmacol, 874 Union Ave, Memphis, TN 38163 USA.	epark@utmem.edu			NHLBI NIH HHS [HL-66924] Funding Source: Medline; NIDDK NIH HHS [DK-059368] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066924] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059368] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Boustead JN, 2003, BIOCHEM J, V369, P17, DOI 10.1042/BJ20021382; Cook GA, 2001, J MOL CELL CARDIOL, V33, P317, DOI 10.1006/jmcc.2000.1304; Deng X, 2002, BIOCHEM BIOPH RES CO, V290, P256, DOI 10.1006/bbrc.2001.6148; Furuyama T, 2003, BIOCHEM J, V375, P365, DOI 10.1042/BJ20030022; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; Gupta RK, 2004, TRENDS MOL MED, V10, P521, DOI 10.1016/j.molmed.2004.09.004; Harris RA, 2002, ADV ENZYME REGUL, V42, P249, DOI 10.1016/S0065-2571(01)00061-9; Harris RA, 2001, ADV ENZYME REGUL, V41, P269, DOI 10.1016/S0065-2571(00)00020-0; Holness MJ, 2000, DIABETES, V49, P775, DOI 10.2337/diabetes.49.5.775; Holness MJ, 2003, BIOCHEM J, V369, P687, DOI 10.1042/BJ20021509; Holness MJ, 2002, BIOCHEM J, V364, P687, DOI 10.1042/bj20011841; Huang BL, 2003, DIABETES, V52, P1371, DOI 10.2337/diabetes.52.6.1371; Huang BL, 2002, DIABETES, V51, P276, DOI 10.2337/diabetes.51.2.276; Jurado LA, 2002, J BIOL CHEM, V277, P27606, DOI 10.1074/jbc.M201429200; Koo SH, 2004, NAT MED, V10, P530, DOI 10.1038/nm1044; Kwon HS, 2004, DIABETES, V53, P899, DOI 10.2337/diabetes.53.4.899; Lehman JJ, 2000, J CLIN INVEST, V106, P847, DOI 10.1172/JCI10268; Lin JD, 2004, CELL, V119, P121, DOI 10.1016/j.cell.2004.09.013; Louet JF, 2002, J BIOL CHEM, V277, P37991, DOI 10.1074/jbc.M205087200; Odom DT, 2004, SCIENCE, V303, P1378, DOI 10.1126/science.1089769; PARK EA, 1995, BIOCHEM J, V310, P853, DOI 10.1042/bj3100853; Park EA, 1998, BIOCHEM J, V330, P217; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Puigserver P, 2003, ENDOCR REV, V24, P78, DOI 10.1210/er.2002-0012; Puigserver P, 2003, NATURE, V423, P550, DOI 10.1038/nature01667; Rhee J, 2003, P NATL ACAD SCI USA, V100, P4012, DOI 10.1073/pnas.0730870100; Ryffel GU, 2001, J MOL ENDOCRINOL, V27, P11, DOI 10.1677/jme.0.0270011; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; Song SL, 2004, BBA-GENE STRUCT EXPR, V1679, P164, DOI 10.1016/j.bbaexp.2004.06.006; Steffen ML, 1999, BIOCHEM J, V340, P425, DOI 10.1042/0264-6021:3400425; Sugden MC, 2003, AM J PHYSIOL-ENDOC M, V284, pE855, DOI 10.1152/ajpendo.00526.2002; Vega RB, 2000, MOL CELL BIOL, V20, P1868, DOI 10.1128/MCB.20.5.1868-1876.2000; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050; Zhang Y, 2004, J BIOL CHEM, V279, P53963, DOI 10.1074/jbc.M406028200	34	37	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	2005	280	33					29525	29532		10.1074/jbc.M502236200	http://dx.doi.org/10.1074/jbc.M502236200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	954SX	15967803	hybrid			2022-12-25	WOS:000231176200019
J	Jay, PY; Rozhitskaya, O; Tarnavski, O; Sherwood, MC; Dorfman, AL; Lu, YL; Ueyama, T; Izumo, S				Jay, PY; Rozhitskaya, O; Tarnavski, O; Sherwood, MC; Dorfman, AL; Lu, YL; Ueyama, T; Izumo, S			Haploinsufficiency of the cardiac transcription factor Nkx2-5 variably affects the expression of putative target genes	FASEB JOURNAL			English	Article						gene regulation; cardiac development; heart failure; heterozygosity	CONGENITAL HEART-DISEASE; HOMEOBOX GENE; NATRIURETIC PEPTIDE; MICE; PROMOTER; TBX5; ARRHYTHMIAS; CSX/NKX2.5; MUTATIONS; LACKING	Heterozygous mutations of the cardiac transcription factor Nkx2-5 cause congenital heart disease. To elucidate the molecular pathways of transcription factor mutant phenotypes or diseases, direct targets are commonly sought in studies of homozygous null mutant animals and by heterologous promoter-reporter gene transactivation assays. The expression of putative target genes in a physiologic range of transcription factor concentration, however, is often not examined. Heterozygous Nkx2-5 knockout (Nkx2-5(+/-)) mice have no more than half-normal levels of Nkx2- 5 protein. We therefore measured the mRNA expression of four putative targets of the cardiac transcription factor Nkx2-5 in wild-type and Nkx2-5(+/-) animals in a variety of developmental and pathologic states. Wild-type and Nkx2-5(+/-) embryonic hearts expressed similar levels of atrial natriuretic factor (ANF), brain natriuretic peptide (BNP), the RNA helicase Csm, and homeodomain only protein HOP. In the failing adult ventricle, ANF and BNP were up-regulated to the same extent in wild- type and Nkx2-5(+/-) myocardium. Csm and HOP were down-regulated in heart failure, and Nkx2-5(+/-) hearts expressed about half-normal levels in healthy and failing states. No consistent relationship existed between the expression of putative transcriptional targets and Nkx2- 5 gene dosage in the physiologically relevant range. Any dependence of gene expression on Nkx2-5(+/-) gene dosage is affected by factors specific to the individual gene and the physiologic context.	Washington Univ, Sch Med, Dept Pediat & Genet, St Louis, MO 63110 USA; Childrens Hosp, Dept Cardiol, Boston, MA 02115 USA	Washington University (WUSTL); Harvard University; Boston Children's Hospital	Jay, PY (corresponding author), Washington Univ, Sch Med, Dept Pediat, 660 S Euclid Ave,Box 8208, St Louis, MO 63110 USA.	jay_p@kids.wustl.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K12HD001487] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32 HL007572] Funding Source: Medline; NICHD NIH HHS [K12-HD001487] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Biben C, 2000, CIRC RES, V87, P888, DOI 10.1161/01.RES.87.10.888; Bruneau BG, 2001, CELL, V106, P709, DOI 10.1016/S0092-8674(01)00493-7; Chen F, 2002, CELL, V110, P713, DOI 10.1016/S0092-8674(02)00932-7; Durocher D, 1996, MOL CELL BIOL, V16, P4648, DOI 10.1128/mcb.16.9.4648; Durocher D, 1997, EMBO J, V16, P5687, DOI 10.1093/emboj/16.18.5687; Hiroi Y, 2001, NAT GENET, V28, P276, DOI 10.1038/90123; Jay PY, 2004, J CLIN INVEST, V113, P1130, DOI 10.1172/JCI200419846; Kirchhoff S, 1998, CURR BIOL, V8, P299, DOI 10.1016/S0960-9822(98)70114-9; Knowles JW, 2001, J CLIN INVEST, V107, P975, DOI 10.1172/JCI11273; Linhares VLF, 2004, CARDIOVASC RES, V64, P402, DOI 10.1016/j.cardiores.2004.09.021; LYONS I, 1995, GENE DEV, V9, P1654, DOI 10.1101/gad.9.13.1654; Magee JA, 2003, CANCER CELL, V3, P273, DOI 10.1016/S1535-6108(03)00047-3; Pashmforoush M, 2004, CELL, V117, P373, DOI 10.1016/S0092-8674(04)00405-2; Quon KC, 2001, GENE DEV, V15, P2917, DOI 10.1101/gad.949001; Sadoshima J, 1997, ANNU REV PHYSIOL, V59, P551, DOI 10.1146/annurev.physiol.59.1.551; Schott JJ, 1998, SCIENCE, V281, P108, DOI 10.1126/science.281.5373.108; Seidman JG, 2002, J CLIN INVEST, V109, P451, DOI 10.1172/JC1200215043; Shin CH, 2002, CELL, V110, P725, DOI 10.1016/S0092-8674(02)00933-9; Small EA, 2003, DEV BIOL, V261, P116, DOI 10.1016/S0012-1606(03)00306-3; Tamura N, 2000, P NATL ACAD SCI USA, V97, P4239, DOI 10.1073/pnas.070371497; Tanaka M, 2002, COLD SPRING HARB SYM, V67, P317, DOI 10.1101/sqb.2002.67.317; Tanaka M, 1999, DEVELOPMENT, V126, P1269; Tarnavski O, 2004, PHYSIOL GENOMICS, V16, P349, DOI 10.1152/physiolgenomics.00041.2003; Ueyama T, 2003, J BIOL CHEM, V278, P28750, DOI 10.1074/jbc.M300014200; Veitia RA, 2002, BIOESSAYS, V24, P175, DOI 10.1002/bies.10023	25	19	20	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2005	19	8					1495	+		10.1096/fj.04-3064fje	http://dx.doi.org/10.1096/fj.04-3064fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	15972800				2022-12-25	WOS:000230207800007
J	Zhou, XW; Kafsack, BFC; Cole, RN; Beckett, P; Shen, RF; Carruthers, VB				Zhou, XW; Kafsack, BFC; Cole, RN; Beckett, P; Shen, RF; Carruthers, VB			The opportunistic pathogen Toxoplasma gondii deploys a diverse legion of invasion and survival proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							NUCLEOSIDE TRIPHOSPHATE HYDROLASE; DENSE GRANULE PROTEIN; PARASITOPHOROUS VACUOLE MEMBRANE; HOST-CELL INVASION; MASS-SPECTROMETRY; MOLECULAR CHARACTERIZATION; MICRONEME PROTEIN; APICOMPLEXAN PARASITES; PLASMODIUM-FALCIPARUM; SURFACE-ANTIGEN	Host cell invasion is an essential step during infection by Toxoplasma gondii, an intracellular protozoan that causes the severe opportunistic disease toxoplasmosis in humans. Recent evidence strongly suggests that proteins discharged from Toxoplasma apical secretory organelles (micronemes, dense granules, and rhoptries) play key roles in host cell invasion and survival during infection. However, to date, only a limited number of secretory proteins have been discovered, and the full spectrum of effector molecules involved in parasite invasion and survival remains unknown. To address these issues, we analyzed a large cohort of freely released Toxoplasma secretory proteins by using two complementary methodologies, two-dimensional electrophoresis/mass spectrometry and liquid chromatography/electrospray ionization-tandem mass spectrometry (MudPIT, shotgun proteomics). Visualization of Toxoplasma secretory products by two-dimensional electrophoresis revealed similar to 100 spots, most of which were successfully identified by protein microsequencing or matrix-assisted laser desorption ionization-mass spectrometry analysis. Many proteins were present in multiple species suggesting they are subjected to substantial posttranslational modification. Shotgun proteomic analysis of the secretory fraction revealed several additional products, including novel putative adhesive proteins, proteases, and hypothetical secretory proteins similar to products expressed by other related parasites including Plasmodium, the etiologic agent of malaria. A subset of novel proteins were re-expressed as fusions to yellow fluorescent protein, and this initial screen revealed shared and distinct localizations within secretory compartments of T. gondii tachyzoites. These findings provided a uniquely broad view of Toxoplasma secretory proteins that participate in parasite survival and pathogenesis during infection.	Johns Hopkins Bloomberg Sch Publ Hlth, W Harry Feinstone Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA; Johns Hopkins Sch Med, Baltimore, MD 21205 USA; NHLBI, NIH, Bethesda, MD 20892 USA; GE Healthcare, Piscataway, NJ 08855 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Medicine; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); General Electric	Carruthers, VB (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, W Harry Feinstone Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA.	vcarruth@jhsph.edu		Kafsack, Bjorn F.C./0000-0003-0089-1096; Carruthers, Vern/0000-0001-6859-8895	NCRR NIH HHS [1S10-RR14702] Funding Source: Medline; NIAID NIH HHS [R21AI053797, R01 AI046675, R21 AI053797] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR014702] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI046675, R21AI053797] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aebersold R, 2003, NATURE, V422, P198, DOI 10.1038/nature01511; Alberti J, 2003, NAT IMMUNOL, V4, P485, DOI 10.1038/ni915; Aliberti J, 2000, NAT IMMUNOL, V1, P83, DOI 10.1038/76957; Aramini JJ, 1999, EPIDEMIOL INFECT, V122, P305, DOI 10.1017/S0950268899002113; ASAI T, 1995, J BIOL CHEM, V270, P11391, DOI 10.1074/jbc.270.19.11391; Bahia-Oliveira LMG, 2003, EMERG INFECT DIS, V9, P55; Bahl A, 2003, NUCLEIC ACIDS RES, V31, P212, DOI 10.1093/nar/gkg081; Barta JR, 1997, METHODS, V13, P81, DOI 10.1006/meth.1997.0501; Bender A, 2003, MOL BIOCHEM PARASIT, V132, P59, DOI 10.1016/j.molbiopara.2003.07.001; Bendtsen JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028; BERMUDES D, 1994, MOL BIOCHEM PARASIT, V68, P247, DOI 10.1016/0166-6851(94)90169-4; Blader IJ, 2001, J BIOL CHEM, V276, P24223, DOI 10.1074/jbc.M100951200; Boothroyd JC, 1998, INT J PARASITOL, V28, P3, DOI 10.1016/S0020-7519(97)00182-3; Bradley PJ, 2005, J BIOL CHEM, V280, P34245, DOI 10.1074/jbc.M504158200; Brecht S, 2001, J BIOL CHEM, V276, P4119, DOI 10.1074/jbc.M008294200; Bromley E, 2003, PROTEOMICS, V3, P1553, DOI 10.1002/pmic.200300479; Brossier F, 2003, J BIOL CHEM, V278, P6229, DOI 10.1074/jbc.M209837200; Brown PJ, 2000, MOL BIOCHEM PARASIT, V107, P91, DOI 10.1016/S0166-6851(00)00179-1; Brydges SD, 2000, MOL BIOCHEM PARASIT, V111, P51, DOI 10.1016/S0166-6851(00)00296-6; BURG JL, 1988, J IMMUNOL, V141, P3584; Carey KL, 2000, MOL BIOCHEM PARASIT, V105, P25, DOI 10.1016/S0166-6851(99)00160-7; Carruthers VB, 1999, BIOCHEM J, V342, P379, DOI 10.1042/0264-6021:3420379; Carruthers VB, 2000, J BIOL CHEM, V275, P14346, DOI 10.1074/jbc.275.19.14346; Carruthers VB, 1999, MOL MICROBIOL, V31, P421, DOI 10.1046/j.1365-2958.1999.01174.x; Carruthers VB, 2002, ACTA TROP, V81, P111, DOI 10.1016/S0001-706X(01)00201-7; Carruthers VB, 1997, EUR J CELL BIOL, V73, P114; Carruthers Vern B., 1999, Parasitology International, V48, P1; CESBRON JY, 1985, J IMMUNOL METHODS, V83, P151, DOI 10.1016/0022-1759(85)90068-7; CESBRONDELAUW MF, 1989, P NATL ACAD SCI USA, V86, P7537, DOI 10.1073/pnas.86.19.7537; Chen HF, 2003, CHINESE MED J-PEKING, V116, P1561; Clauser KR, 1999, ANAL CHEM, V71, P2871, DOI 10.1021/ac9810516; Cohen AM, 2002, INT J PARASITOL, V32, P39, DOI 10.1016/S0020-7519(01)00308-3; Cokol M, 2000, EMBO REP, V1, P411, DOI 10.1093/embo-reports/kvd092; Delorme V, 2003, MOL BIOL CELL, V14, P1900, DOI 10.1091/mbc.E02-08-0462; Delorme V, 2002, MICROBES INFECT, V4, P271, DOI 10.1016/S1286-4579(02)01538-1; Dlugonska H, 2001, PARASITOL RES, V87, P634, DOI 10.1007/s004360000367; Donahue CG, 2000, MOL BIOCHEM PARASIT, V111, P15, DOI 10.1016/S0166-6851(00)00289-9; Dowse T, 2004, CURR OPIN MICROBIOL, V7, P388, DOI 10.1016/j.mib.2004.06.013; Drummelsmith J, 2003, MOL CELL PROTEOMICS, V2, P146, DOI 10.1074/mcp.M200085-MCP200; DUBEY JP, 1994, J AM VET MED ASSOC, V205, P1593; Dubey JP, 1998, INT J PARASITOL, V28, P1019, DOI 10.1016/S0020-7519(98)00023-X; Ducret A, 1998, PROTEIN SCI, V7, P706, DOI 10.1002/pro.5560070320; Dzierszinski F, 2001, J MOL BIOL, V309, P1017, DOI 10.1006/jmbi.2001.4730; Dzierszinski F, 2000, MOL MICROBIOL, V37, P574, DOI 10.1046/j.1365-2958.2000.02014.x; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Ersfeld Klaus, 2003, Current Issues in Molecular Biology, V5, P61; Fast NM, 2001, MOL BIOL EVOL, V18, P418, DOI 10.1093/oxfordjournals.molbev.a003818; Florens L, 2002, NATURE, V419, P520, DOI 10.1038/nature01107; Fourmaux MN, 1996, MOL BIOCHEM PARASIT, V83, P201, DOI 10.1016/S0166-6851(96)02773-9; Garcia-Reguet N, 2000, CELL MICROBIOL, V2, P353, DOI 10.1046/j.1462-5822.2000.00064.x; Graves PR, 2002, MICROBIOL MOL BIOL R, V66, P39, DOI 10.1128/MMBR.66.1.39-63.2002; Gubbels MJ, 2004, MOL BIOCHEM PARASIT, V137, P99, DOI 10.1016/j.molbiopara.2004.05.007; Harper JM, 2004, INT J PARASITOL, V34, P1047, DOI 10.1016/j.ijpara.2004.05.006; Harper JM, 2004, MOL BIOCHEM PARASIT, V134, P201, DOI 10.1016/j.molbiopara.2003.12.001; Hehl A, 1997, MOL BIOCHEM PARASIT, V89, P271, DOI 10.1016/S0166-6851(97)00126-6; Hehl AB, 2000, INFECT IMMUN, V68, P7078, DOI 10.1128/IAI.68.12.7078-7086.2000; HIGH KP, 1994, J BIOL CHEM, V269, P9105; Hoff EF, 2001, EXP PARASITOL, V97, P77, DOI 10.1006/expr.2000.4585; Huynh MH, 2004, CELL MICROBIOL, V6, P771, DOI 10.1111/j.1462-5822.2004.00403.x; Huynh MH, 2003, EMBO J, V22, P2082, DOI 10.1093/emboj/cdg217; Ishino T, 2005, CELL MICROBIOL, V7, P199, DOI 10.1111/j.1462-5822.2004.00447.x; Jacobs D, 1998, MOL BIOCHEM PARASIT, V91, P237, DOI 10.1016/S0166-6851(97)00204-1; Jacobs D, 1999, CLIN DIAGN LAB IMMUN, V6, P24, DOI 10.1128/CDLI.6.1.24-29.1999; Jewett TJ, 2003, MOL CELL, V11, P885, DOI 10.1016/S1097-2765(03)00113-8; Jewett TJ, 2004, J BIOL CHEM, V279, P9362, DOI 10.1074/jbc.M312590200; Kaasch AJ, 2000, J BIOL CHEM, V275, P1112, DOI 10.1074/jbc.275.2.1112; Kadota K, 2004, P NATL ACAD SCI USA, V101, P16310, DOI 10.1073/pnas.0406187101; Koyama T, 2001, VET PARASITOL, V96, P65, DOI 10.1016/S0304-4017(00)00424-6; Lasonder E, 2002, NATURE, V419, P537, DOI 10.1038/nature01111; LECORDIER L, 1993, MOL BIOCHEM PARASIT, V59, P143, DOI 10.1016/0166-6851(93)90015-P; Lee Y, 2002, GENOME RES, V12, P493, DOI 10.1101/gr.212002; LERICHE MA, 1990, PARASITOL RES, V76, P559, DOI 10.1007/BF00932560; Li L, 2004, NUCLEIC ACIDS RES, V32, pD326, DOI 10.1093/nar/gkh112; Li L, 2003, GENOME RES, V13, P2178, DOI 10.1101/gr.1224503; Lingelbach K, 1998, J CELL SCI, V111, P1467; Lourenco EV, 2001, GLYCOBIOLOGY, V11, P541, DOI 10.1093/glycob/11.7.541; Lyons RE, 1998, INT J PARASITOL, V28, P1041, DOI 10.1016/S0020-7519(98)00074-5; LYONS RE, 1995, PARASITE IMMUNOL, V17, P353, DOI 10.1111/j.1365-3024.1995.tb00902.x; Manger ID, 1998, INFECT IMMUN, V66, P2237, DOI 10.1128/IAI.66.5.2237-2244.1998; Meek B, 2002, FEBS LETT, V522, P104, DOI 10.1016/S0014-5793(02)02911-3; Meek B, 2002, INT IMMUNOL, V14, P1291, DOI 10.1093/intimm/dxf091; Meissner M, 2002, J CELL SCI, V115, P563; Mercier C, 2002, MOL BIOL CELL, V13, P2397, DOI 10.1091/mbc.E02-01-0021; Miller SA, 2001, J BIOL CHEM, V276, P45341, DOI 10.1074/jbc.M106665200; Monteiro VG, 2001, J STRUCT BIOL, V136, P181, DOI 10.1006/jsbi.2002.4444; Morris MT, 2002, J BIOL CHEM, V277, P45259, DOI 10.1074/jbc.M205517200; Nakaar V, 1998, MOL BIOCHEM PARASIT, V92, P229, DOI 10.1016/S0166-6851(97)00220-X; Nakaar V, 2003, J CELL SCI, V116, P2311, DOI 10.1242/jcs.00382; Nakaar V, 1999, J BIOL CHEM, V274, P5083, DOI 10.1074/jbc.274.8.5083; Neudeck A, 2002, MICROBES INFECT, V4, P581, DOI 10.1016/S1286-4579(02)01576-9; NEUHOFF V, 1988, ELECTROPHORESIS, V9, P255, DOI 10.1002/elps.1150090603; Ngo HM, 2003, J BIOL CHEM, V278, P5343, DOI 10.1074/jbc.M208291200; Odberg-Ferragut C, 2000, MOL BIOCHEM PARASIT, V106, P121, DOI 10.1016/S0166-6851(99)00211-X; Onnerfjord P, 1999, RAPID COMMUN MASS SP, V13, P315; Paba J, 2004, PROTEOMICS, V4, P1052, DOI 10.1002/pmic.200300637; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; PRINCE JB, 1989, MOL BIOCHEM PARASIT, V34, P3, DOI 10.1016/0166-6851(89)90014-5; PRINCE JB, 1990, MOL BIOCHEM PARASIT, V43, P97, DOI 10.1016/0166-6851(90)90134-8; Pszenny V, 2002, MOL BIOCHEM PARASIT, V121, P283, DOI 10.1016/S0166-6851(02)00045-2; Quackenbush J, 2001, NUCLEIC ACIDS RES, V29, P159, DOI 10.1093/nar/29.1.159; Rabenau KE, 2001, MOL MICROBIOL, V41, P537, DOI 10.1046/j.1365-2958.2001.02513.x; Reichmann G, 2002, MOL BIOCHEM PARASIT, V119, P43, DOI 10.1016/S0166-6851(01)00397-8; Reiss M, 2001, J CELL BIOL, V152, P563, DOI 10.1083/jcb.152.3.563; SANTORO F, 1985, CLIN EXP IMMUNOL, V62, P262; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Silverman JA, 1998, J BIOL CHEM, V273, P12352, DOI 10.1074/jbc.273.20.12352; Sinai AP, 1997, J CELL SCI, V110, P2117; Sinai AP, 1997, ANNU REV MICROBIOL, V51, P415, DOI 10.1146/annurev.micro.51.1.415; Soldati D, 2004, CURR OPIN CELL BIOL, V16, P32, DOI 10.1016/j.ceb.2003.11.013; Son Eui-Sun, 2001, Korean Journal of Parasitology, V39, P133, DOI 10.3347/kjp.2001.39.2.133; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; Sullivan WJ, 2004, BIOCHEM J, V380, P523, DOI 10.1042/BJ20040262; Suzuki Y, 2000, J CLIN MICROBIOL, V38, P3967, DOI 10.1128/JCM.38.11.3967-3970.2000; Tomley FM, 2001, TRENDS PARASITOL, V17, P81, DOI 10.1016/S1471-4922(00)01761-X; TONEY DM, 1994, J IMMUNOL, V152, P2952; Vollmer M, 2001, J BIOL CHEM, V276, P5483, DOI 10.1074/jbc.M009452200; Wan KL, 1997, MOL BIOCHEM PARASIT, V84, P203, DOI 10.1016/S0166-6851(96)02796-X; Yang SM, 1997, GENE, V184, P1, DOI 10.1016/S0378-1119(96)00566-5; Zuegge J, 2001, GENE, V280, P19, DOI 10.1016/S0378-1119(01)00776-4	119	97	113	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					34233	34244		10.1074/jbc.M504160200	http://dx.doi.org/10.1074/jbc.M504160200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16002397	hybrid, Green Accepted			2022-12-25	WOS:000232229700066
J	Lee, JO; Kwun, HJ; Jung, JK; Choi, KH; Min, DS; Jang, KL				Lee, JO; Kwun, HJ; Jung, JK; Choi, KH; Min, DS; Jang, KL			Hepatitis B virus X protein represses E-cadherin expression via activation of DNA methyltransferase 1	ONCOGENE			English	Article						DNA methyltransferase 1; E-cadherin; hepatitis B virus X; hepatocellular carcinoma; metastasis; tumor invasion	CELL-CELL-ADHESION; HEPATOCELLULAR-CARCINOMA; CPG METHYLATION; HBX PROTEIN; TRANSCRIPTIONAL ACTIVITY; DOWN-REGULATION; GENE; CANCER; INVASION; SYSTEM	E-cadherin is a key cell adhesion molecule implicated as a tumor suppressor, which is frequently altered in hepatocellular carcinoma, especially in hepatitis B virus (HBV)-related tumors. Here, we report that HBV X protein (HBx) represses E-cadherin expression at the transcription level. Based on the differential effects of HBx natural variants, we determined that Lys-130 in the transactivation domain of HBx is critical for the E-cadherin repression. The repression effect of HBx was abolished after treatment with DNA methyltransferase inhibitor, 5'-Aza-2'dC. In addition, methylation-specific PCR analysis revealed that the CpG island 1 of E-cadherin promoter is hypermethylated by HBx. Furthermore, HBx induces DNA methyltransferase 1 expression by stimulating its transcription. Therefore, we conclude that HBx represses E-cadherin expression by inducing methylation-mediated promoter inactivation. The reduced E-cadherin expression results in dramatic morphological changes of the HBx-expressing cells. In addition, HBx-expressing cells aggregate poorly in suspension culture, reflecting their altered intercellular interactions. The biological significance was further demonstrated by the increased collagen invasion ability of HBx-expressing cells. Therefore, the present study suggests that HBx plays a role during hepatocellular carcinogenesis by favoring cell detachment from the surrounding cells and migration outside of the primary tumor site.	Pusan Natl Univ, Coll Nat Sci, Div Biol Sci, Pusan 609735, South Korea	Pusan National University	Jang, KL (corresponding author), Pusan Natl Univ, Coll Nat Sci, Div Biol Sci, Pusan 609735, South Korea.	kljang@pusan.ac.kr	Kwun, Hyun jin/AAJ-3365-2020; Kwun, Hyun Jin/F-5511-2011; Kwun, Hyun Jin/AAH-2706-2020	Kwun, Hyun jin/0000-0002-8926-746X; Kwun, Hyun Jin/0000-0002-8926-746X; 				Anzola M, 2004, J VIRAL HEPATITIS, V11, P383, DOI 10.1111/j.1365-2893.2004.00521.x; Baptista M, 1999, HEPATOLOGY, V29, P946, DOI 10.1002/hep.510290336; Benn J, 1996, J VIROL, V70, P4978, DOI 10.1128/JVI.70.8.4978-4985.1996; Berx G, 1996, ONCOGENE, V13, P1919; Bigey P, 2000, GENE, V242, P407, DOI 10.1016/S0378-1119(99)00501-6; Block TM, 2003, ONCOGENE, V22, P5093, DOI 10.1038/sj.onc.1206557; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Chan CF, 2004, CLIN CANCER RES, V10, P4140, DOI 10.1158/1078-0432.CCR-03-0574; Chu CHC, 1996, LANCET, V348, P625, DOI 10.1016/S0140-6736(05)64851-9; Chung TW, 2004, FASEB J, V18, P1123, DOI 10.1096/fj.03-1429fje; Diao JY, 2001, CYTOKINE GROWTH F R, V12, P189, DOI 10.1016/S1359-6101(00)00034-4; Feitelson MA, 1997, AM J PATHOL, V150, P1141; Foty RA, 2004, INT J DEV BIOL, V48, P397, DOI 10.1387/ijdb.041810rf; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hirohashi S, 2003, CANCER SCI, V94, P575, DOI 10.1111/j.1349-7006.2003.tb01485.x; Hirohashi S, 1998, AM J PATHOL, V153, P333, DOI 10.1016/S0002-9440(10)65575-7; Jia L, 1999, INT J CANCER, V80, P875, DOI 10.1002/(SICI)1097-0215(19990315)80:6<875::AID-IJC13>3.3.CO;2-Q; Kanai Y, 1997, INT J CANCER, V71, P355; KAWANISHI J, 1995, MOL CELL BIOL, V15, P1175; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Kwun HJ, 2004, NUCLEIC ACIDS RES, V32, P2202, DOI 10.1093/nar/gkh553; Lara-Pezzi E, 2002, J CLIN INVEST, V110, P1831, DOI 10.1172/JCI200215887; Lara-Pezzi E, 2001, HEPATOLOGY, V33, P1270, DOI 10.1053/jhep.2001.1270; Lara-Pezzi E, 2001, J HEPATOL, V34, P409, DOI 10.1016/S0168-8278(00)00090-8; Lara-Pezzi E, 2001, ONCOGENE, V20, P3323, DOI 10.1038/sj.onc.1204451; Lee CW, 1998, ONCOGENE, V16, P2695, DOI 10.1038/sj.onc.1201818; Matsumura T, 2001, CLIN CANCER RES, V7, P594; Melki JR, 2000, BLOOD, V95, P3208; MIYASAKA M, 1995, CLIN ORTHOP RELAT R, V312, P10; Nabi IR, 1999, J CELL SCI, V112, P1803; Rhee I, 2000, NATURE, V404, P1003, DOI 10.1038/35010000; Sanders DSA, 1999, J CLIN PATHOL-MOL PA, V52, P151, DOI 10.1136/mp.52.3.151; SANTI DV, 1984, P NATL ACAD SCI-BIOL, V81, P6993, DOI 10.1073/pnas.81.22.6993; Shih WL, 2000, J BIOL CHEM, V275, P25858, DOI 10.1074/jbc.M003578200; Silye R, 1998, J PATHOL, V186, P350, DOI 10.1002/(SICI)1096-9896(199812)186:4<350::AID-PATH181>3.0.CO;2-K; Takahashi K, 1998, ARCH VIROL, V143, P2313, DOI 10.1007/s007050050463; Terradillos O, 1997, ONCOGENE, V14, P395, DOI 10.1038/sj.onc.1200850; Tsai CN, 2002, P NATL ACAD SCI USA, V99, P10084, DOI 10.1073/pnas.152059399; Venard V, 2000, J MED VIROL, V62, P177, DOI 10.1002/1096-9071(200010)62:2&lt;177::AID-JMV8&gt;3.0.CO;2-V; WANG XW, 1995, CANCER RES, V55, P6012; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WATABE M, 1994, J CELL BIOL, V127, P247, DOI 10.1083/jcb.127.1.247; Wei Y, 2002, HEPATOLOGY, V36, P692, DOI 10.1053/jhep.2002.35342; Wheelock MJ, 2003, ANNU REV CELL DEV BI, V19, P207, DOI 10.1146/annurev.cellbio.19.011102.111135; Yoo YG, 2003, J BIOL CHEM, V278, P39076, DOI 10.1074/jbc.M305101200; YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416	48	157	174	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 6	2005	24	44					6617	6625		10.1038/sj.onc.1208827	http://dx.doi.org/10.1038/sj.onc.1208827			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	971FL	16007161				2022-12-25	WOS:000232367800003
J	Bachhuber, T; Konig, J; Voelcker, T; Murle, B; Schreiber, R; Kunzelmann, K				Bachhuber, T; Konig, J; Voelcker, T; Murle, B; Schreiber, R; Kunzelmann, K			Cl- interference with the epithelial Na+ channel ENaC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; PDZ-INTERACTING DOMAIN; COLLECTING DUCT CELLS; CYSTIC-FIBROSIS; SODIUM-CHANNEL; XENOPUS OOCYTES; CHLORIDE CHANNEL; FUNCTIONAL INTERACTIONS; PURINERGIC STIMULATION; SURFACE EXPRESSION	The cystic fibrosis transmembrane conductance regulator (CFTR) is a protein kinase A and ATP-regulated Cl- channel that also controls the activity of other membrane transport proteins, such as the epithelial Na+ channel ENaC. Previous studies demonstrated that cytosolic domains of ENaC are critical for down-regulation of ENaC by CFTR, whereas others suggested a role of cytosolic Cl- ions. We therefore examined in detail the anion dependence of ENaC and the role of its cytosolic domains for the inhibition by CFTR and the Cl- channel CLC-0. Coexpression of rat ENaC with human CFTR or the human Cl- channel CLC-0 caused inhibition of amiloride-sensitive Na+ currents after cAMP-dependent stimulation and in the presence of a 100 mM bath Cl- concentration. After activation of CFTR by 3-isobutyl-1-methylxanthine and forskolin or expression of CLC-0, the intracellular Cl- concentration was increased in Xenopus oocytes in the presence of a high bath Cl- concentration, which inhibited ENaC without changing surface expression of alpha beta gamma ENaC. In contrast, a 5 mM bath Cl- concentration reduced the cytosolic Cl- concentration and enhanced ENaC activity. ENaC was also inhibited by injection of Cl- into oocytes and in inside/out macropatches by exposure to high cytosolic Cl- concentrations. The effect of Cl- was mimicked by Br-, NO3-, and I-. Inhibition by Cl- was reduced in trimeric channels with a truncated COOH terminus of beta ENaC and gamma ENaC, and it was no longer detected in dimeric alpha beta gamma ENaC channels. Deletion of the NH2 terminus of alpha-, beta-, or gamma ENaC, mutations in the NH2-terminal phosphatidylinositol bisphosphate-binding domain of beta ENaC and gamma EnaC, and activation of phospholipase C, all reduced ENaC activity but allowed for Cl--dependent inhibition of the remaining ENaC current. The results confirm a role of the carboxyl terminus of beta ENaC for Cl-- dependent inhibition of the Na+ channel, which, however, may only be part of a complex regulation of ENaC by CFTR.	Univ Regensburg, Inst Physiol, Univ Str 31, D-93053 Regensburg, Germany	University of Regensburg	Kunzelmann, K (corresponding author), Univ Regensburg, Inst Physiol, Univ Str 31, D-93053 Regensburg, Germany.	uqkkunze@mailbox.uq.edu.au	Schreiber, Robert/Q-7550-2019	Kunzelmann, Karl/0000-0002-4583-7037				Adam G, 2005, PFLUG ARCH EUR J PHY, V449, P470, DOI 10.1007/s00424-004-1356-4; Berdiev BK, 2000, BIOPHYS J, V78, P1881, DOI 10.1016/S0006-3495(00)76737-3; BOUCHER RC, 1986, J CLIN INVEST, V78, P1245, DOI 10.1172/JCI112708; Boucher RC, 1999, J PHYSIOL-LONDON, V516, P631, DOI 10.1111/j.1469-7793.1999.0631u.x; BOUCHER RC, 1988, J PHYSIOL-LONDON, V405, P77, DOI 10.1113/jphysiol.1988.sp017322; Boucherot A, 2001, BBA-BIOMEMBRANES, V1515, P64, DOI 10.1016/S0005-2736(01)00396-0; Briel M, 1998, J PHYSIOL-LONDON, V508, P825, DOI 10.1111/j.1469-7793.1998.825bp.x; Carattino MD, 2005, J BIOL CHEM, V280, P17608, DOI 10.1074/jbc.M501770200; Chabot H, 1999, J MEMBRANE BIOL, V169, P175, DOI 10.1007/s002329900529; Chalfant ML, 1999, J BIOL CHEM, V274, P32889, DOI 10.1074/jbc.274.46.32889; Chen TY, 1998, J GEN PHYSIOL, V112, P715, DOI 10.1085/jgp.112.6.715; Cuffe JE, 2000, J PHYSIOL-LONDON, V524, P77, DOI 10.1111/j.1469-7793.2000.00077.x; DINUDOM A, 1995, J PHYSIOL-LONDON, V487, P549, DOI 10.1113/jphysiol.1995.sp020899; DINUDOM A, 1993, J MEMBRANE BIOL, V135, P289; Firsov D, 1996, P NATL ACAD SCI USA, V93, P15370, DOI 10.1073/pnas.93.26.15370; Grubb Barbara R., 1999, Physiological Reviews, V79, pS193; GRUBB BR, 1994, AM J PHYSIOL, V266, pC1478, DOI 10.1152/ajpcell.1994.266.5.C1478; Hill WG, 2002, J BIOL CHEM, V277, P33541, DOI 10.1074/jbc.C200309200; Hopf A, 1999, J BIOL CHEM, V274, P13894, DOI 10.1074/jbc.274.20.13894; Hubner M, 1999, FEBS LETT, V459, P443, DOI 10.1016/S0014-5793(99)01291-0; Ismailov II, 1996, J BIOL CHEM, V271, P4725; Ji HL, 2000, J BIOL CHEM, V275, P27947; Jiang QS, 2000, J BIOL CHEM, V275, P13266, DOI 10.1074/jbc.275.18.13266; KIEFERLE S, 1994, P NATL ACAD SCI USA, V91, P6943, DOI 10.1073/pnas.91.15.6943; Komwatana P, 1998, J MEMBRANE BIOL, V162, P225, DOI 10.1007/s002329900360; Konig J, 2002, BBA-BIOMEMBRANES, V1565, P17, DOI 10.1016/S0005-2736(02)00502-3; Konig J, 2001, EMBO REP, V2, P1047, DOI 10.1093/embo-reports/kve232; Konstas AA, 2003, PFLUG ARCH EUR J PHY, V445, P513, DOI 10.1007/s00424-002-0957-z; Konstas AA, 2002, J BIOL CHEM, V277, P25377, DOI 10.1074/jbc.M201925200; Kowalski MP, 2004, J IMMUNOL, V172, P418, DOI 10.4049/jimmunol.172.1.418; Kreda SM, 2005, MOL BIOL CELL, V16, P2154, DOI 10.1091/mbc.E04-11-1010; Kunzelmann K, 1999, Rev Physiol Biochem Pharmacol, V137, P1; Kunzelmann K, 1997, KIDNEY BLOOD PRESS R, V20, P151, DOI 10.1159/000174129; Kunzelmann K, 2004, FASEB J, V18, P142, DOI 10.1096/fj.04-2314fje; KUNZELMANN K, 1995, PFLUG ARCH EUR J PHY, V431, P1, DOI 10.1007/BF00374371; Kunzelmann K, 2001, KIDNEY INT, V60, P455, DOI 10.1046/j.1523-1755.2001.060002455.x; Kunzelmann K, 1997, FEBS LETT, V400, P341, DOI 10.1016/S0014-5793(96)01414-7; KUNZELMANN K, 2003, PFLUGERS ARCH, V445, P505; Ma HP, 2002, J BIOL CHEM, V277, P7641, DOI 10.1074/jbc.C100737200; Mall M, 1999, AM J PHYSIOL-GASTR L, V277, pG709, DOI 10.1152/ajpgi.1999.277.3.G709; Mall M, 1996, FEBS LETT, V381, P47, DOI 10.1016/0014-5793(96)00079-8; Mall M, 2004, NAT MED, V10, P487, DOI 10.1038/nm1028; Mall M, 1998, J CLIN INVEST, V102, P15, DOI 10.1172/JCI2729; Matsui H, 2000, J CLIN INVEST, V105, P1419, DOI 10.1172/JCI4546; Mehta A, 2005, PEDIATR PULM, V39, P292, DOI 10.1002/ppul.20147; Moyer BD, 1999, J CLIN INVEST, V104, P1353, DOI 10.1172/JCI7453; Moyer BD, 2000, J BIOL CHEM, V275, P27069; Nagel G, 2005, J PHYSIOL-LONDON, V564, P671, DOI 10.1113/jphysiol.2004.079046; Nagel G, 2001, EMBO REP, V2, P249, DOI 10.1093/embo-reports/kve045; Niisato N, 2004, AM J PHYSIOL-RENAL, V287, pF932, DOI 10.1152/ajprenal.00131.2004; Oceandy D, 2002, HUM MOL GENET, V11, P1059, DOI 10.1093/hmg/11.9.1059; Reddy MM, 1999, NATURE, V402, P301, DOI 10.1038/46297; Rochelle LG, 2000, AM J PHYSIOL-LUNG C, V279, pL14, DOI 10.1152/ajplung.2000.279.1.L14; Schreiber R, 1999, P NATL ACAD SCI USA, V96, P5310, DOI 10.1073/pnas.96.9.5310; Schreiber R, 2004, J MEMBRANE BIOL, V199, P85, DOI 10.1007/s00232-004-0679-6; Schreiber R, 2003, J MEMBRANE BIOL, V192, P101, DOI 10.1007/s00232-002-1067-8; SCHWIEBERT EM, 1999, PHYSL REV S, V79, P145; STUTTS MJ, 1995, SCIENCE, V269, P847, DOI 10.1126/science.7543698; Suaud L, 2002, J BIOL CHEM, V277, P50341, DOI 10.1074/jbc.M209641200; Suaud L, 2002, J BIOL CHEM, V277, P8928, DOI 10.1074/jbc.M111482200; Wang SS, 1998, FEBS LETT, V427, P103, DOI 10.1016/S0014-5793(98)00402-5; Xie Y, 2004, AM J PHYSIOL-RENAL, V287, pF722, DOI 10.1152/ajprenal.00135.2004; Yan WS, 2004, J BIOL CHEM, V279, P23183, DOI 10.1074/jbc.M402373200; Yue G, 2002, J BIOL CHEM, V277, P11965, DOI 10.1074/jbc.M108951200	64	46	49	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	2005	280	36					31587	31594		10.1074/jbc.M504347200	http://dx.doi.org/10.1074/jbc.M504347200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	961LZ	16027156	hybrid			2022-12-25	WOS:000231665200032
J	Cai, L; Holoweckyj, N; Schaller, MD; Bear, JE				Cai, L; Holoweckyj, N; Schaller, MD; Bear, JE			Phosphorylation of coronin 1B by protein kinase C regulates interaction with Arp2/3 and cell motility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN-BINDING-PROTEIN; GROWTH-FACTOR; MICROTUBULE CYTOSKELETONS; PHORBOL ESTER; DICTYOSTELIUM; ASSOCIATION; FAMILY; REGION	Coronins are a conserved family of WD repeat-containing, actin-binding proteins that regulate cell motility in a variety of model organisms. Our results show that Coronin 1B is a ubiquitously expressed member of the mammalian Coronin gene family that co-localizes with the Arp2/3 complex at the leading edge of fibroblasts, and co-immunoprecipitates with this complex. Pharmacological experiments show that the interaction between Coronin 1B and the Arp2/3 complex is regulated by protein kinase C (PKC) phosphorylation. Coronin 1B is phosphorylated by PKC both in vitro and in vivo. Using tryptic peptide mapping and mutagenesis, we have identified serine 2 (Ser-2) on Coronin 1B as the major residue phosphorylated by PKC in vivo. Rat2 fibroblasts expressing the Coronin 1B S2A mutant show enhanced ruffling in response to phorbol 12-myristate 13-acetate (PMA) and increased speed in single cell tracking assays. Cells expressing the Coronin 1B S2D mutant have attenuated PMA-induced ruffling and slower cell speed. Expression of the S2A mutant partially protects cells from the inhibitory effects of PMA on cell speed, whereas expression of the S2D mutant renders cells hypersensitive to its effects. These data demonstrate that Coronin 1B regulates leading edge dynamics and cell motility in fibroblasts, and that its ability to control motility and interactions with the Arp2/3 complex are regulated by PKC phosphorylation at Ser-2. Furthermore, Coronin 1B phosphorylation is responsible for a significant fraction of the effects of PMA on fibroblast motility.	Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Bear, JE (corresponding author), Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, CB 7295, Chapel Hill, NC 27599 USA.	jbear@email.unc.edu			NATIONAL CANCER INSTITUTE [R01CA090901] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL045100] Funding Source: NIH RePORTER; NCI NIH HHS [CA90901] Funding Source: Medline; NHLBI NIH HHS [HL45100] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Asano S, 2001, GENES CELLS, V6, P225, DOI 10.1046/j.1365-2443.2001.00416.x; Bear JE, 2000, CELL, V101, P717, DOI 10.1016/S0092-8674(00)80884-3; Bharathi V, 2004, J CELL SCI, V117, P1911, DOI 10.1242/jcs.01034; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; de Hostos EL, 1999, TRENDS CELL BIOL, V9, P345, DOI 10.1016/S0962-8924(99)01620-7; DEHOSTOS EL, 1991, EMBO J, V10, P4097, DOI 10.1002/j.1460-2075.1991.tb04986.x; DEHOSTOS EL, 1993, J CELL BIOL, V120, P163, DOI 10.1083/jcb.120.1.163; Di Giovanni S, 2005, J BIOL CHEM, V280, P2084, DOI 10.1074/jbc.M411975200; DUGINA VB, 1987, P NATL ACAD SCI USA, V84, P4122, DOI 10.1073/pnas.84.12.4122; FRIDMAN R, 1990, J CELL PHYSIOL, V142, P55, DOI 10.1002/jcp.1041420108; GLOWACKA D, 1992, J NEUROSCI RES, V31, P263, DOI 10.1002/jnr.490310207; Goode BL, 1999, J CELL BIOL, V144, P83, DOI 10.1083/jcb.144.1.83; Hacker U, 1997, J CELL SCI, V110, P105; Heil-Chapdelaine RA, 1998, CURR BIOL, V8, P1281, DOI 10.1016/S0960-9822(07)00539-8; Humphries CL, 2002, J CELL BIOL, V159, P993, DOI 10.1083/jcb.200206113; Itoh S, 2002, BIOL PHARM BULL, V25, P837, DOI 10.1248/bpb.25.837; Jackson D, 2005, ONCOGENE, V24, P3067, DOI 10.1038/sj.onc.1208465; KELLER HU, 1989, INT J CANCER, V44, P934, DOI 10.1002/ijc.2910440531; Kurokawa K, 2004, MOL BIOL CELL, V15, P1003, DOI 10.1091/mbc.E03-08-0609; LUO KX, 1991, METHOD ENZYMOL, V201, P149; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Mishima M, 1999, J CELL SCI, V112, P2833; Nal B, 2004, INT IMMUNOL, V16, P231, DOI 10.1093/intimm/dxh022; Ng T, 1999, EMBO J, V18, P3909, DOI 10.1093/emboj/18.14.3909; Oku T, 2005, BIOCHEM J, V387, P325, DOI 10.1042/BJ20041020; Overbergh L, 2003, J Biomol Tech, V14, P33; Parente JA, 1999, J BIOL CHEM, V274, P3017, DOI 10.1074/jbc.274.5.3017; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Rodal AA, 2005, NAT STRUCT MOL BIOL, V12, P26, DOI 10.1038/nsmb870; Spoerl Z, 2002, J BIOL CHEM, V277, P48858, DOI 10.1074/jbc.M205136200; Taunton J, 2000, J CELL BIOL, V148, P519, DOI 10.1083/jcb.148.3.519; WILKINSON SE, 1993, BIOCHEM J, V294, P335, DOI 10.1042/bj2940335; Ziegler WH, 2002, J BIOL CHEM, V277, P7396, DOI 10.1074/jbc.M110008200	33	76	85	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	2005	280	36					31913	31923		10.1074/jbc.M504146200	http://dx.doi.org/10.1074/jbc.M504146200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	961LZ	16027158	Green Published, hybrid			2022-12-25	WOS:000231665200071
J	Lee, FY; Kast-Woelbern, HR; Chang, J; Luo, GZ; Jones, SA; Fishbein, MC; Edwards, PA				Lee, FY; Kast-Woelbern, HR; Chang, J; Luo, GZ; Jones, SA; Fishbein, MC; Edwards, PA			alpha-Crystallin is a target gene of the farnesoid X-activated receptor in human livers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; SALT EXPORT PUMP; B-CRYSTALLIN; NUCLEAR RECEPTOR; A-CRYSTALLIN; BILE-ACIDS; CHOLESTEROL 7-ALPHA-HYDROXYLASE; MOLECULAR CHAPERONE; MISSENSE MUTATION; ABC TRANSPORTER	alpha-Crystallins comprise 35% of soluble proteins in the ocular lens and possess chaperone-like functions. Furthermore, the alpha A subunit ( alpha A-crystallin) of alpha crystallin is thought to be "lens-specific" as only very low levels of expression were detected in a few non-lenticular tissues. Here we report that human alpha A-crystallin is expressed in human livers and is regulated by farnesoid X-activated receptor ( FXR) in response to FXR agonists. alpha A-Crystallin was identified in a microarray screen as one of the most highly induced genes after treatment of HepG2 cells with the synthetic FXR ligand GW4064. Northern blot and quantitative realtime PCR analyses confirmed that alpha A-crystallin expression was induced in HepG2-derived cell lines and human primary hepatocytes and hepatic stellate cells in response to either natural or synthetic FXR ligands. Transient transfection studies and electrophoretic mobility shift assays revealed a functional FXR response element located in intron 1 of the human alpha A-crystallin gene. Importantly, immunohistochemical staining of human liver sections showed increased alpha A-crystallin expression in cholangiocytes and hepatocytes. As a member of the small heat shock protein family possessing chaperone-like activity, alpha A-crystallin may be involved in protection of hepatocytes from the toxic effects of high concentrations of bile acids, as would occur in disease states such as cholestasis.	Univ Calif Los Angeles, David Geffen Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; GlaxoSmithKline Inc, Res & Dev, Res Triangle Pk, NC 27709 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; GlaxoSmithKline	Edwards, PA (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Biol Chem, 10833 Le Conte Ave,33-257 CHS, Los Angeles, CA 90095 USA.	pedwards@mednet.ucla.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068445, P01HL030568] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL30568, HL68445] Funding Source: Medline; NIGMS NIH HHS [GM07185] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alison M, 1998, PHILOS T R SOC B, V353, P877, DOI 10.1098/rstb.1998.0252; Ananthanarayanan M, 2001, J BIOL CHEM, V276, P28857, DOI 10.1074/jbc.M011610200; Anisfeld AM, 2005, J LIPID RES, V46, P458, DOI 10.1194/jlr.M400292-JLR200; Anisfeld AM, 2003, J BIOL CHEM, V278, P20420, DOI 10.1074/jbc.M302505200; Barbier O, 2003, GASTROENTEROLOGY, V124, P1926, DOI 10.1016/S0016-5085(03)00388-3; Bataller R, 2005, J CLIN INVEST, V115, P209, DOI 10.1172/JCI200524282; Berry V, 2001, AM J HUM GENET, V69, P1141, DOI 10.1086/324158; BHAT SP, 1989, BIOCHEM BIOPH RES CO, V158, P319, DOI 10.1016/S0006-291X(89)80215-3; BHAT SP, 1991, EUR J BIOCHEM, V202, P775, DOI 10.1111/j.1432-1033.1991.tb16432.x; Brady JP, 1997, P NATL ACAD SCI USA, V94, P884, DOI 10.1073/pnas.94.3.884; Brady JP, 2001, INVEST OPHTH VIS SCI, V42, P2924; Chiang JYL, 2001, GENE, V262, P257, DOI 10.1016/S0378-1119(00)00518-7; Claudel T, 2004, EXPERT OPIN INV DRUG, V13, P1135, DOI 10.1517/13543784.13.9.1135; Deleuze JF, 1996, HEPATOLOGY, V23, P904, DOI 10.1002/hep.510230435; Derham BK, 1999, PROG RETIN EYE RES, V18, P463, DOI 10.1016/S1350-9462(98)00030-5; DUBIN RA, 1989, MOL CELL BIOL, V9, P1083, DOI 10.1128/MCB.9.3.1083; DUELAND S, 1993, J LIPID RES, V34, P923; Edwards PA, 2002, J LIPID RES, V43, P2; Fitzgerald ML, 2002, J MOL MED, V80, P271, DOI 10.1007/s00109-001-0318-y; FITZGERALD PG, 1991, CURR EYE RES, V10, P417, DOI 10.3109/02713689109001750; FORMAN BM, 1995, CELL, V81, P687, DOI 10.1016/0092-8674(95)90530-8; Francis GA, 2003, ANNU REV PHYSIOL, V65, P261, DOI 10.1146/annurev.physiol.65.092101.142528; Ganea E, 2000, BIOCHEM J, V345, P467, DOI 10.1042/0264-6021:3450467; Gangalum RK, 2004, J BIOL CHEM, V279, P43374, DOI 10.1074/jbc.C400371200; Gerloff T, 1998, J BIOL CHEM, V273, P10046, DOI 10.1074/jbc.273.16.10046; Goenka S, 2001, BIOCHEM J, V359, P547, DOI 10.1042/0264-6021:3590547; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Goodwin B, 2003, MOL ENDOCRINOL, V17, P386, DOI 10.1210/me.2002-0246; Gupta S, 2001, J BIOL CHEM, V276, P15816, DOI 10.1074/jbc.M010878200; Hatters DM, 2001, J BIOL CHEM, V276, P33755, DOI 10.1074/jbc.M105285200; Hofmann AF, 1999, ARCH INTERN MED, V159, P2647, DOI 10.1001/archinte.159.22.2647; Holt JA, 2003, GENE DEV, V17, P1581, DOI 10.1101/gad.1083503; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; Horwitz J, 2003, EXP EYE RES, V76, P145, DOI 10.1016/S0014-4835(02)00278-6; Huang L, 2003, J BIOL CHEM, V278, P51085, DOI 10.1074/jbc.M308321200; Huber RM, 2002, GENE, V290, P35, DOI 10.1016/S0378-1119(02)00557-7; JAWORSKI CJ, 1989, NATURE, V337, P752, DOI 10.1038/337752a0; JELINEK DF, 1990, J BIOL CHEM, V265, P8190; KANTOROW M, 1995, J BIOL CHEM, V270, P17215, DOI 10.1074/jbc.270.29.17215; KANTOROW M, 1994, P NATL ACAD SCI USA, V91, P3112, DOI 10.1073/pnas.91.8.3112; Kast HR, 2002, J BIOL CHEM, V277, P2908, DOI 10.1074/jbc.M109326200; Kast HR, 2001, MOL ENDOCRINOL, V15, P1720, DOI 10.1210/me.15.10.1720; KATO K, 1991, BIOCHIM BIOPHYS ACTA, V1080, P173, DOI 10.1016/0167-4838(91)90146-Q; Kida M, 2003, HEPATOL RES, V27, P151, DOI 10.1016/S1386-6346(03)00201-8; KING CR, 1983, CELL, V32, P707, DOI 10.1016/0092-8674(83)90056-9; Kliewer SA, 2002, J LIPID RES, V43, P359; Kullak-Ublick GA, 2004, GASTROENTEROLOGY, V126, P322, DOI 10.1053/j.gastro.2003.06.005; Kullak-Ublick GA, 2003, J HEPATOL, V39, P628, DOI 10.1016/S0168-8278(03)00397-0; Laffitte BA, 2000, J BIOL CHEM, V275, P10638, DOI 10.1074/jbc.275.14.10638; Laffitte BA, 2001, MOL CELL BIOL, V21, P7558, DOI 10.1128/MCB.21.22.7558-7568.2001; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; Lehmann JM, 1998, J CLIN INVEST, V102, P1016, DOI 10.1172/JCI3703; Li MK, 2004, SEMIN LIVER DIS, V24, P21; LI YC, 1990, J BIOL CHEM, V265, P12012; Litt M, 1998, HUM MOL GENET, V7, P471, DOI 10.1093/hmg/7.3.471; Liu YP, 2003, J CLIN INVEST, V112, P1678, DOI 10.1172/JCI200318945; Mackay DS, 2003, EUR J HUM GENET, V11, P784, DOI 10.1038/sj.ejhg.5201046; Mak PA, 2002, J LIPID RES, V43, P2037, DOI 10.1194/jlr.C200014-JLR200; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; Maloney PR, 2000, J MED CHEM, V43, P2971, DOI 10.1021/jm0002127; MERCK KB, 1993, J BIOL CHEM, V268, P1046; Moschetta A, 2004, NAT MED, V10, P1352, DOI 10.1038/nm1138; Muchowski PJ, 1999, INVEST OPHTH VIS SCI, V40, P951; Narberhaus F, 2002, MICROBIOL MOL BIOL R, V66, P64, DOI 10.1128/MMBR.66.1.64-93.2002; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; Pauli-Magnus C, 2005, J CLIN GASTROENTEROL, V39, pS103, DOI 10.1097/01.mcg.0000155550.29643.7b; Paulusma CC, 1996, SCIENCE, V271, P1126, DOI 10.1126/science.271.5252.1126; Pinzani M, 2004, DIGEST LIVER DIS, V36, P231, DOI 10.1016/j.dld.2004.01.003; Pras E, 2000, INVEST OPHTH VIS SCI, V41, P3511; Quinlan RA, 1996, TRENDS CELL BIOL, V6, P123, DOI 10.1016/0962-8924(96)20001-7; Reddy GB, 2002, FEBS LETT, V522, P59, DOI 10.1016/S0014-5793(02)02884-3; Reddy GB, 2001, BIOCHEM BIOPH RES CO, V282, P712, DOI 10.1006/bbrc.2001.4642; Rekas A, 2004, J MOL BIOL, V340, P1167, DOI 10.1016/j.jmb.2004.05.054; Roskams TA, 2003, SEMIN LIVER DIS, V23, P385; RUETZ S, 1994, CELL, V77, P1071, DOI 10.1016/0092-8674(94)90446-4; Selcen D, 2003, ANN NEUROL, V54, P804, DOI 10.1002/ana.10767; SEOL WG, 1995, MOL ENDOCRINOL, V9, P72, DOI 10.1210/me.9.1.72; Sherlock S, 1998, Clin Liver Dis, V2, P217, DOI 10.1016/S1089-3261(05)70004-0; Sinal CJ, 2000, CELL, V102, P731, DOI 10.1016/S0092-8674(00)00062-3; SRINIVASAN AN, 1992, J BIOL CHEM, V267, P23337; Staudinger JL, 2001, P NATL ACAD SCI USA, V98, P3369, DOI 10.1073/pnas.051551698; Strautnieks SS, 1998, NAT GENET, V20, P233, DOI 10.1038/3034; TAKEMOTO L, 1993, BIOCHEM J, V294, P435, DOI 10.1042/bj2940435; Toh S, 1999, AM J HUM GENET, V64, P739, DOI 10.1086/302292; Torra IP, 2003, MOL ENDOCRINOL, V17, P259, DOI 10.1210/me.2002-0120; Vicart P, 1998, NAT GENET, V20, P92, DOI 10.1038/1765; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; Xie W, 2001, P NATL ACAD SCI USA, V98, P3375, DOI 10.1073/pnas.051014398; Zhang Y, 2001, J BIOL CHEM, V276, P43018, DOI 10.1074/jbc.M107823200; Zhang YQ, 2003, J BIOL CHEM, V278, P104, DOI 10.1074/jbc.M209505200	90	28	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	2005	280	36					31792	31800		10.1074/jbc.M503182200	http://dx.doi.org/10.1074/jbc.M503182200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	961LZ	16012168	hybrid			2022-12-25	WOS:000231665200058
J	Sato, M; Sasaki, H; Kazui, T; Yokota, J; Kohno, T				Sato, M; Sasaki, H; Kazui, T; Yokota, J; Kohno, T			Probing the chromosome 9p21 region susceptible to DNA double-strand breaks in human cells in vivo by restriction enzyme transfer	ONCOGENE			English	Article						DNA double-strand break; chromosome deletion; p16; tumor suppressor gene; restriction enzyme	BREAKPOINT-CLUSTER REGION; ALTERED CHROMATIN-STRUCTURE; HUMAN LUNG-CANCER; ALTERNATIVE MECHANISMS; MLL GENE; METHYLATION; DELETIONS; CLEAVAGE; LEUKEMIA; TRANSLOCATIONS	A restriction enzyme, MspI, was introduced into cultured human cells as a probe to detect genomic regions susceptible to DNA double-strand breaks ( DSBs). A 2 h exposure to MspI at a concentration of 8U/mu l produced DSBs at MspI sites in more than 80% of HeLa cells. The sensitivity to digestion was examined on chromosomal DNAs for the region containing the p16 tumor suppressor gene and two other related genes, p14ARF and p15, by Southern blot hybridization analysis and linker-mediated capture of DNA fragments digested in vivo. DNAs for the promoter regions of the three genes, respectively, were sensitive to MspI digestion in HeLa cells, while DNA for the p16 promoter region was less sensitive in lung cancer cells with hypermethylation of the region. Breakpoints for interstitial 9p21 deletions removing the p16/p14ARF/p15 locus in a variety of human cancers were significantly over-represented in the three sensitive regions. The results suggest that the MspI sensitivity in vivo of each genomic region reflects its susceptibility to DSBs that trigger chromosome aberrations in human cells. This method could help us understand the pathogenic significance of differential susceptibility to DSBs among genomic regions in human carcinogenesis.	Natl Canc Ctr, Div Biol, Chuo Ku, Tokyo 1040045, Japan; Hamamatsu Univ Sch Med, Dept Surg 1, Hamamatsu, Shizuoka 4313192, Japan; Natl Canc Ctr, Div Genet, Tokyo 1040045, Japan	National Cancer Center - Japan; Hamamatsu University School of Medicine; National Cancer Center - Japan	Yokota, J (corresponding author), Natl Canc Ctr, Div Biol, Chuo Ku, 1-1 Tsukiji 5-Chome,, Tokyo 1040045, Japan.	jyokota@gan2.ncc.go.jp						Albertson DG, 2003, NAT GENET, V34, P369, DOI 10.1038/ng1215; ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; Broeker PLS, 1996, BLOOD, V87, P1912, DOI 10.1182/blood.V87.5.1912.bloodjournal8751912; Cayuela JM, 1997, BLOOD, V90, P3720, DOI 10.1182/blood.V90.9.3720; Costello JF, 1996, CANCER RES, V56, P2405; Daser A, 2004, GENE DEV, V18, P965, DOI 10.1101/gad.1195504; Elliott B, 2002, CELL MOL LIFE SCI, V59, P373, DOI 10.1007/s00018-002-8429-3; Florl AR, 2003, GENE CHROMOSOME CANC, V37, P141, DOI 10.1002/gcc.10192; Folle GA, 1998, MUTAT RES-FUND MOL M, V404, P17, DOI 10.1016/S0027-5107(98)00090-6; Furuta T, 2003, J BIOL CHEM, V278, P20303, DOI 10.1074/jbc.M300198200; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; Hamada K, 2000, GENE CHROMOSOME CANC, V27, P308, DOI 10.1002/(SICI)1098-2264(200003)27:3<308::AID-GCC12>3.3.CO;2-N; Inoue H, 1997, P NATL ACAD SCI USA, V94, P14584, DOI 10.1073/pnas.94.26.14584; KAMB A, 1994, SCIENCE, V264, P440; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Khobta A, 2004, CANCER RES, V64, P2656, DOI 10.1158/0008-5472.CAN-03-1126; Kitagawa Y, 2002, J BIOL CHEM, V277, P46289, DOI 10.1074/jbc.M208353200; Kuwahara Y, 2004, GENE CHROMOSOME CANC, V41, P125, DOI 10.1002/gcc.20075; LAZARIDES E, 1974, P NATL ACAD SCI USA, V71, P4742, DOI 10.1073/pnas.71.12.4742; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Mills KD, 2003, IMMUNOL REV, V194, P77, DOI 10.1034/j.1600-065X.2003.00060.x; Moiseenko VV, 1998, INT J RADIAT BIOL, V74, P533, DOI 10.1080/095530098141113; Nguyen CT, 2001, NUCLEIC ACIDS RES, V29, P4598, DOI 10.1093/nar/29.22.4598; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; Obe G, 2002, MUTAT RES-FUND MOL M, V504, P17, DOI 10.1016/S0027-5107(02)00076-3; Park MJ, 2003, CANCER GENET CYTOGEN, V141, P5, DOI 10.1016/S0165-4608(02)00645-3; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Raschke S, 2005, GENE CHROMOSOME CANC, V42, P58, DOI 10.1002/gcc.20119; Rogakou EP, 2000, J BIOL CHEM, V275, P9390, DOI 10.1074/jbc.275.13.9390; Rowley JD, 2001, NAT REV CANCER, V1, P245, DOI 10.1038/35106108; Sasaki S, 2003, ONCOGENE, V22, P3792, DOI 10.1038/sj.onc.1206589; Sato M, 2002, ONCOGENE, V21, P4822, DOI 10.1038/sj.onc.1205581; Sim SP, 2001, J BIOL CHEM, V276, P31590, DOI 10.1074/jbc.M103962200; Stanulla M, 2001, HUM MOL GENET, V10, P2481, DOI 10.1093/hmg/10.22.2481; Strissel PL, 1998, BLOOD, V92, P3793, DOI 10.1182/blood.V92.10.3793.422a24_3793_3803; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; WINEGAR RA, 1990, SOMAT CELL MOLEC GEN, V16, P251, DOI 10.1007/BF01233361; Xing EP, 1999, CLIN CANCER RES, V5, P2704	38	4	4	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 8	2005	24	40					6108	6118		10.1038/sj.onc.1208750	http://dx.doi.org/10.1038/sj.onc.1208750			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	962GD	16007206	Green Submitted			2022-12-25	WOS:000231718100005
J	Bae, E; Phillips, GN				Bae, E; Phillips, GN			Identifying and engineering ion pairs in adenylate kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-DYNAMICS SIMULATIONS; CHARGE-CHARGE INTERACTIONS; COLD SHOCK PROTEIN; THERMOPHILIC HOMOLOG; EXTREME ENVIRONMENTS; SALT BRIDGES; STABILITY; ENZYMES; THERMOSTABILITY; SURFACE	Molecular dynamics simulations were performed to study thermal stabilization of proteins via electrostatic interactions of ion pairs. Dynamic motions of four ion pairs previously proposed to be important in thermal stability of adenylate kinase from the thermophile Bacillus stearothermophilus were monitored during the simulation. One of the four ion pairs identified in the crystal structure, Lys(180)-Asp(114), was not maintained in close contact suggesting that the ion pair does not contribute to thermal stability. Among the other three ion pairs, the ion pair Arg(116)-Glu(198) was proposed to be the most important for stability. To predict behaviors of the ion pairs when engineered into a mesophilic homologue to increase stability, in silico mutants of adenylate kinase from the mesophile Bacillus subtilis were generated, and their molecular dynamics simulations were carried out. The ion pairs in the mutant simulations displayed similar behaviors to those in the simulation of the thermophilic protein. To validate the results of the simulations experimentally, the same mutants were produced in vitro and their thermal stabilities were measured using differential scanning calorimetry. In agreement with the simulations, the Lys(180)-Asp(114) did not result in any increase in stability by itself or additive effect with other ion pairs, whereas a mutant with the Arg(116)-Glu(198) exhibited the highest stability among the mutants having one of the four ion pairs. These results provide specific knowledge about stability in adenylate kinases and more generally suggest that molecular dynamics simulations can provide valuable information for identifying and engineering ion pairs.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Phillips, GN (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.	phillips@biochem.wisc.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR013790] Funding Source: NIH RePORTER; NCRR NIH HHS [S10 RR13790] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Bae E, 2004, J BIOL CHEM, V279, P28202, DOI 10.1074/jbc.M401865200; Berry MB, 1998, PROTEIN-STRUCT FUNCT, V32, P275; Bruins ME, 2001, APPL BIOCHEM BIOTECH, V90, P155, DOI 10.1385/ABAB:90:2:155; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; Butterwick JA, 2004, J MOL BIOL, V339, P855, DOI 10.1016/j.jmb.2004.03.055; Colombo G, 1999, J AM CHEM SOC, V121, P6895, DOI 10.1021/ja990420s; Criswell AR, 2003, J MOL BIOL, V330, P1087, DOI 10.1016/S0022-2836(03)00655-7; D'Amico S, 2003, J BIOL CHEM, V278, P7891, DOI 10.1074/jbc.M212508200; DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397; de Bakker PIW, 1999, J MOL BIOL, V285, P1811, DOI 10.1006/jmbi.1998.2397; ERIKSSON MAL, 1995, BIOPHYS J, V68, P402, DOI 10.1016/S0006-3495(95)80203-1; FELLER SE, 1995, J CHEM PHYS, V103, P4613, DOI 10.1063/1.470648; Fields PA, 2001, COMP BIOCHEM PHYS A, V129, P417, DOI 10.1016/S1095-6433(00)00359-7; GLASER P, 1992, BIOCHEMISTRY-US, V31, P3038, DOI 10.1021/bi00127a002; Grimsley GR, 1999, PROTEIN SCI, V8, P1843, DOI 10.1110/ps.8.9.1843; Grottesi A, 2002, PROTEINS, V46, P287, DOI 10.1002/prot.10045; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Ibarra-Molero B, 1999, BIOCHEMISTRY-US, V38, P8138, DOI 10.1021/bi9905819; JAENICKE R, 1991, EUR J BIOCHEM, V202, P715, DOI 10.1111/j.1432-1033.1991.tb16426.x; Jaenicke R, 1998, CURR OPIN STRUC BIOL, V8, P738, DOI 10.1016/S0959-440X(98)80094-8; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; Kale L, 1999, J COMPUT PHYS, V151, P283, DOI 10.1006/jcph.1999.6201; Liang ZX, 2004, BIOCHEMISTRY-US, V43, P14676, DOI 10.1021/bi049004x; Loladze VV, 1999, BIOCHEMISTRY-US, V38, P16419, DOI 10.1021/bi992271w; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; Makhatadze GI, 2004, J MOL BIOL, V336, P929, DOI 10.1016/j.jmb.2003.12.058; Makhatadze GI, 2003, J MOL BIOL, V327, P1135, DOI 10.1016/S0022-2836(03)00233-X; MARTYNA GJ, 1994, J CHEM PHYS, V101, P4177, DOI 10.1063/1.467468; Perl D, 2000, NAT STRUCT BIOL, V7, P380; PERRIER V, 1994, BIOCHEMISTRY-US, V33, P9960, DOI 10.1021/bi00199a019; Rothschild LJ, 2001, NATURE, V409, P1092, DOI 10.1038/35059215; Sanchez-Ruiz JM, 2001, TRENDS BIOTECHNOL, V19, P132, DOI 10.1016/S0167-7799(00)01548-1; SOMERO GN, 1978, ANNU REV ECOL SYST, V9, P1, DOI 10.1146/annurev.es.09.110178.000245; Spector S, 2000, BIOCHEMISTRY-US, V39, P872, DOI 10.1021/bi992091m; Szilagyi A, 2000, STRUCTURE, V8, P493, DOI 10.1016/S0969-2126(00)00133-7; Tanner JJ, 1996, BIOCHEMISTRY-US, V35, P2597, DOI 10.1021/bi951988q; Vieille C, 2001, MICROBIOL MOL BIOL R, V65, P1, DOI 10.1128/MMBR.65.1.1-43.2001; Wintrode PL, 2003, J MOL BIOL, V327, P745, DOI 10.1016/S0022-2836(03)00147-5	38	54	54	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	2005	280	35					30943	30948		10.1074/jbc.M504216200	http://dx.doi.org/10.1074/jbc.M504216200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	958ZX	15995248	hybrid			2022-12-25	WOS:000231487800036
J	Cheshenko, N; Liu, W; Satlin, LM; Herold, BC				Cheshenko, N; Liu, W; Satlin, LM; Herold, BC			Focal adhesion kinase plays a pivotal role in herpes simplex virus entry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYPE-1 GLYCOPROTEIN-H; TOPICAL MICROBICIDES; CELLS; ACTIVATION; INFECTION; TRANSPORT; FAK; PHOSPHORYLATION; PATHWAYS; PROTEINS	Development of strategies to prevent herpes simplex virus (HSV) infection requires knowledge of cellular pathways harnessed by the virus for invasion. This study demonstrates that HSV induces rapid phosphorylation of focal adhesion kinase (FAK) in several human target cells and that phosphorylation is important for entry post-binding. Nuclear transport of the viral tegument protein VP16, transport of viral capsids to the nuclear pore, and downstream events ( including expression of immediate-early genes and viral plaque formation) were substantially reduced in cells transfected with dominant-negative mutants of FAK or small interfering RNA designed to inhibit FAK expression. These observations were substantiated using mouse embryonic fibroblast cells derived from embryonic FAK-deficient mice. Infection was reduced by > 90 % in knockout cells relative to control cells and was further reduced if the knockout cells were transfected with small interfering RNA targeting proline-rich tyrosine kinase-2, which was also phosphorylated in response to HSV. The knockout cells were permissive for viral binding, and virus triggered an intracellular calcium response, but nuclear transport was inhibited. Together, these results support a novel model for invasion that implicates FAK phosphorylation as important for delivery of viral capsids to the nuclear pore.	Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA; Mt Sinai Sch Med, Dept Microbiol, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Herold, BC (corresponding author), Mt Sinai Sch Med, Dept Pediat, 1 Gustave L Levy Pl,POB 1657, New York, NY 10029 USA.	betsy.herold@mssm.edu	Cheshenko, Natalia/ABF-5896-2021	Herold, Betsy/0000-0001-9974-0786	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI061679, R56AI061679] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK064104, R29DK038470, R01DK038470] Funding Source: NIH RePORTER; NIAID NIH HHS [AI061679] Funding Source: Medline; NICHD NIH HHS [HD43733] Funding Source: Medline; NIDDK NIH HHS [DK38470, DK64104] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Cheshenko N, 2003, J CELL BIOL, V163, P283, DOI 10.1083/jcb.200301084; Cheshenko N, 2002, J GEN VIROL, V83, P2247, DOI 10.1099/0022-1317-83-9-2247; Cicala C, 2000, P NATL ACAD SCI USA, V97, P1178, DOI 10.1073/pnas.97.3.1178; CICALA C, 1999, J VIROL, V72, P9992; Desai P, 1998, J VIROL, V72, P7563, DOI 10.1128/JVI.72.9.7563-7568.1998; Dohner K, 2002, MOL BIOL CELL, V13, P2795, DOI 10.1091/mbc.01-07-0348; Fichorova RN, 1997, BIOL REPROD, V57, P847, DOI 10.1095/biolreprod57.4.847; Foster TP, 2004, J VIROL, V78, P13262, DOI 10.1128/JVI.78.23.13262-13277.2004; Galdiero M, 1997, J VIROL, V71, P2163, DOI 10.1128/JVI.71.3.2163-2170.1997; Gelman IH, 2003, CELL BIOL INT, V27, P507, DOI 10.1016/S1065-6995(03)00078-7; HEROLD BC, 1994, J GEN VIROL, V75, P1211, DOI 10.1099/0022-1317-75-6-1211; HEROLD BC, 1991, J VIROL, V65, P1090, DOI 10.1128/JVI.65.3.1090-1098.1991; ILLC D, 1995, NATURE, V377, P539; Keller MJ, 2005, J ANTIMICROB CHEMOTH, V55, P420, DOI 10.1093/jac/dki056; Keller MJ, 2003, J ANTIMICROB CHEMOTH, V51, P1099, DOI 10.1093/jac/dkg214; KRISTENSSON K, 1986, J GEN VIROL, V67, P2023, DOI 10.1099/0022-1317-67-9-2023; Naranatt PP, 2003, J VIROL, V77, P1524, DOI 10.1128/JVI.77.2.1524-1539.2003; Naranatt PP, 2005, J VIROL, V79, P1191, DOI 10.1128/JVI.79.2.1191-1206.2005; Natarajan K, 2002, INVEST OPHTH VIS SCI, V43, P2685; Palazzo AF, 2004, SCIENCE, V303, P836, DOI 10.1126/science.1091325; Parry C, 2005, J GEN VIROL, V86, P7, DOI 10.1099/vir.0.80567-0; Qie LX, 1999, VIROLOGY, V256, P220, DOI 10.1006/viro.1999.9673; Sharma-Walia N, 2004, J VIROL, V78, P4207, DOI 10.1128/JVI.78.8.4207-4223.2004; Smith GA, 2002, ANNU REV CELL DEV BI, V18, P135, DOI 10.1146/annurev.cellbio.18.012502.105920; Sodeik B, 1997, J CELL BIOL, V136, P1007, DOI 10.1083/jcb.136.5.1007; Topp KS, 1997, EXP EYE RES, V64, P343, DOI 10.1006/exer.1996.0209; Wang FZ, 2003, J VIROL, V77, P3131, DOI 10.1128/JVI.77.5.3131-3147.2003; Xie ZG, 2003, CELL, V114, P469, DOI 10.1016/S0092-8674(03)00605-6; Zhao J, 2001, MOL BIOL CELL, V12, P4066, DOI 10.1091/mbc.12.12.4066	29	47	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	2005	280	35					31116	31125		10.1074/jbc.M503518200	http://dx.doi.org/10.1074/jbc.M503518200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	958ZX	15994312	hybrid			2022-12-25	WOS:000231487800057
J	Ray, RM; Bhattacharya, S; Johnson, LR				Ray, RM; Bhattacharya, S; Johnson, LR			Protein phosphatase 2A regulates apoptosis in intestinal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORNITHINE-DECARBOXYLASE; BAD PHOSPHORYLATION; POLYAMINES; BCL-2; DEPHOSPHORYLATION; INHIBITORS; KINASE; DEATH; PP2A; MITOCHONDRIA	Polyamine depletion prevents apoptosis by increasing serine/threonine phosphorylation leading to either inactivation or activation of pro- and anti-apoptotic proteins, respectively. Despite evidence that protein kinases are regulators of apoptosis, a specific role for protein phosphatases in regulating cell survival has not been established. In this study, we show that polyamine depletion inhibits serine/threonine phosphatase 2A (PP2A). Inhibition of PP2A in cells depleted of polyamines correlated well with increased phosphorylation of Bad at Ser(112). Bad Ser(112) phosphorylation in response to tumor necrosis factor (TNF)-alpha treatment decreased with time in cells grown in control as well as those grown in the presence of alpha-difluoromethylornithine plus putrescine. However, a sustained increase in the levels of Bad Ser112 phosphorylation was maintained in response to TNF-alpha treatment in cells grown in the presence of alpha-difluoromethylornithine. Inhibition of PP2A by okadaic acid and fostriecin or PP2A small interfering RNA transfection significantly decreased TNF-alpha-induced apoptosis in control and polyamine-depleted cells. Inhibition of PP2A by okadaic acid: 1) increased Bad and Bcl-2 phosphorylation at Ser(112) and Ser(70), respectively; 2) increased ERK activity; 3) prevented JNK activation; 4) prevented cytochrome c release, and activation of caspases-9 and -3 in response to TNF-alpha. Inhibition of MEK1 by U0126 prevented phosphorylation of Bad at Ser(112). These results indicate that polyamines regulate PP2A activity, and inhibition of PP2A in response to polyamine depletion increases steady state levels of Bad and Bcl-2 proteins and their phosphorylation and thereby prevents cytochrome c release, caspase-9, and caspase-3 activation.	Univ Tennessee, Ctr Hlth Sci, Dept Physiol, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Ray, RM (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Physiol, 894 Union Ave, Memphis, TN 38163 USA.	rray@physio1.utmem.edu	Bhattacharya, Sujoy/AAD-2253-2022	Bhattacharya, Sujoy/0000-0003-4443-9691	NIDDK NIH HHS [DK-16505] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK016505, R37DK016505] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; Ayllon V, 2000, EMBO J, V19, P2237, DOI 10.1093/emboj/19.10.2237; Bernstein HG, 1999, PROG NEUROBIOL, V57, P485, DOI 10.1016/S0301-0082(98)00065-3; Bhattacharya S, 2005, APOPTOSIS, V10, P759, DOI 10.1007/s10495-005-2943-3; Bhattacharya S, 2003, AM J PHYSIOL-GASTR L, V285, pG980, DOI 10.1152/ajpgi.00206.2003; Chatfield K, 2004, BIOCHEM BIOPH RES CO, V323, P1313, DOI 10.1016/j.bbrc.2004.09.003; Chiang CW, 2003, MOL CELL BIOL, V23, P6350, DOI 10.1128/MCB.23.18.6350-6362.2003; CORNWELL T, 1986, J CYCLIC NUCL PROT, V11, P373; Deng WL, 2005, AM J PHYSIOL-GASTR L, V289, pG599, DOI 10.1152/ajpgi.00564.2004; Fang XJ, 1999, ONCOGENE, V18, P6635, DOI 10.1038/sj.onc.1203076; Favre B, 1997, J BIOL CHEM, V272, P13856, DOI 10.1074/jbc.272.21.13856; Garcia A, 2003, BIOCHIMIE, V85, P721, DOI 10.1016/j.biochi.2003.09.004; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Kramer DL, 1997, CANCER RES, V57, P5521; Lewy DS, 2002, CURR MED CHEM, V9, P2005, DOI 10.2174/0929867023368809; Lin CKE, 1997, EXP CELL RES, V237, P231, DOI 10.1006/excr.1997.3794; MARTON LJ, 1995, ANNU REV PHARMACOL, V35, P55, DOI 10.1146/annurev.pa.35.040195.000415; MAY WS, 1994, J BIOL CHEM, V269, P26865; MCCORMACK SA, 1993, AM J PHYSIOL, V264, pG367, DOI 10.1152/ajpgi.1993.264.2.G367; MCCORMACK SA, 1992, AM J PHYSIOL, V263, pG426, DOI 10.1152/ajpgi.1992.263.3.G426; Monti MG, 1998, LIFE SCI, V62, P799, DOI 10.1016/S0024-3205(97)01181-8; Noda T, 1998, AM J PHYSIOL-GASTR L, V274, pG270, DOI 10.1152/ajpgi.1998.274.2.G270; Penning LC, 1998, CYTOKINE, V10, P423, DOI 10.1006/cyto.1997.0310; PERSSON L, 1996, POLYAMINES CANC BASI, P19; QUARONI A, 1979, J CELL BIOL, V80, P248, DOI 10.1083/jcb.80.2.248; Ray RM, 2003, J BIOL CHEM, V278, P13039, DOI 10.1074/jbc.M208741200; Ray RM, 1999, AM J PHYSIOL-CELL PH, V276, pC684, DOI 10.1152/ajpcell.1999.276.3.C684; Ray RM, 2000, AM J PHYSIOL-CELL PH, V278, pC480, DOI 10.1152/ajpcell.2000.278.3.C480; Ruvolo PP, 1999, J BIOL CHEM, V274, P20296, DOI 10.1074/jbc.274.29.20296; Ruvolo PP, 2001, LEUKEMIA, V15, P515, DOI 10.1038/sj.leu.2402090; Scheid MP, 1999, J BIOL CHEM, V274, P31108, DOI 10.1074/jbc.274.43.31108; Schipper RG, 2000, SEMIN CANCER BIOL, V10, P55, DOI 10.1006/scbi.2000.0308; Seiler N, 1996, INT J BIOCHEM CELL B, V28, P843, DOI 10.1016/1357-2725(96)00021-0; Sim ATR, 1999, CELL CALCIUM, V26, P209, DOI 10.1054/ceca.1999.0072; Tan Y, 2000, J BIOL CHEM, V275, P25865, DOI 10.1074/jbc.M004199200; Tewari M, 1998, ORAL ONCOL, V34, P538, DOI 10.1016/S1368-8375(98)00044-X; TUNG HYL, 1985, EUR J BIOCHEM, V149, P305, DOI 10.1111/j.1432-1033.1985.tb08927.x; Van Hoof C, 2003, BBA-MOL CELL RES, V1640, P97, DOI 10.1016/S0167-4889(03)00029-6; Walsh AH, 1997, FEBS LETT, V416, P230, DOI 10.1016/S0014-5793(97)01210-6; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; WANG JY, 1991, GASTROENTEROLOGY, V100, P333, DOI 10.1016/0016-5085(91)90200-5; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yuan Q, 2002, AM J PHYSIOL-CELL PH, V282, pC1290, DOI 10.1152/ajpcell.00351.2001; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zolnierowicz S, 2000, BIOCHEM PHARMACOL, V60, P1225, DOI 10.1016/S0006-2952(00)00424-X	49	63	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	2005	280	35					31091	31100		10.1074/jbc.M503041200	http://dx.doi.org/10.1074/jbc.M503041200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	958ZX	15994315	hybrid			2022-12-25	WOS:000231487800054
J	Khaleque, MA; Bharti, A; Sawyer, D; Gong, JL; Benjamin, IJ; Stevenson, MA; Calderwood, SK				Khaleque, MA; Bharti, A; Sawyer, D; Gong, JL; Benjamin, IJ; Stevenson, MA; Calderwood, SK			Induction of heat shock proteins by heregulin beta 1 leads to protection from apoptosis and anchorage-independent growth	ONCOGENE			English	Article						heregulin; heat shock protein; HSF1; anchorage independent growth; signal transduction	BREAST-CANCER; GENE-EXPRESSION; FACTOR-I; TRANSCRIPTIONAL ACTIVATION; TARGETED DISRUPTION; ESTROGEN-RECEPTOR; CELL-SURVIVAL; PHOSPHORYLATION; FACTOR-1; STRESS	Elevation of heat shock protein (HSP) levels is widespread in cancer and predicts a poor prognosis and resistance to therapy. We show that HSP elevation in tumor cells can be induced by the highly malignant factor heregulin beta 1 (HRG beta 1), which induces HSP expression through heat shock transcription factor 1 (HSF1). Inactivation of the hsf1 gene prevents HSP induction by HRG beta 1. HSP expression is induced through a cascade response initiated by HRG beta 1 binding to c-erbB receptors on the cell surface and which leads to the inhibition of intracellular HSF1 antagonist glycogen synthase kinase 3. HSF1 activated by this pathway plays a key role in the protection of cells from apoptosis and the mediation of anchorage independent growth by HRGb1, indicating a role for HSF1 in this tumorigenic pathway.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Radiat Oncol, Boston, MA 02215 USA; Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA; Univ Utah, Ctr Hlth Sci, Dept Internal Med, Salt Lake City, UT 84132 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Boston University; Utah System of Higher Education; University of Utah	Calderwood, SK (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Radiat Oncol, 21-27 Burlington Ave, Boston, MA 02215 USA.	scalderw@bidmc.harvard.edu		Bharti, Ajit/0000-0001-7972-6688; Gong, Jianlin/0000-0003-0910-014X; Khaleque, Md Abdul/0000-0002-6873-9165	NATIONAL CANCER INSTITUTE [R01CA047407, R01CA050642, P01CA031303] Funding Source: NIH RePORTER; NCI NIH HHS [CA31303, CA47407, CA50642] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aguilar Z, 1999, ONCOGENE, V18, P6050, DOI 10.1038/sj.onc.1202993; Beere HM, 2004, J CELL SCI, V117, P2641, DOI 10.1242/jcs.01284; Bhat-Nakshatri P, 2002, ONCOGENE, V21, P2066, DOI 10.1038/sj.onc.1205243; Blagosklonny MV, 2001, J NATL CANCER I, V93, P239, DOI 10.1093/jnci/93.3.239-a; Cardozo T, 2004, NAT REV MOL CELL BIO, V5, P739, DOI 10.1038/nrm1471; Chen CM, 1997, J BIOL CHEM, V272, P26803, DOI 10.1074/jbc.272.43.26803; Chen XM, 1996, J BIOL CHEM, V271, P7620, DOI 10.1074/jbc.271.13.7620; Chu BY, 1998, J BIOL CHEM, V273, P18640, DOI 10.1074/jbc.273.29.18640; Chu BY, 1996, J BIOL CHEM, V271, P30847, DOI 10.1074/jbc.271.48.30847; CIOCCA DR, 1993, J NATL CANCER I, V85, P570, DOI 10.1093/jnci/85.7.570; Cornford PA, 2000, CANCER RES, V60, P7099; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; deFazio A, 2000, INT J CANCER, V87, P487, DOI 10.1002/1097-0215(20000815)87:4<487::AID-IJC5>3.0.CO;2-J; Downward J, 2004, SEMIN CELL DEV BIOL, V15, P177, DOI 10.1016/j.semcdb.2004.01.002; FADOK VA, 1992, J IMMUNOL, V148, P2207; Gabai VL, 1997, J BIOL CHEM, V272, P18033, DOI 10.1074/jbc.272.29.18033; Gottlieb TM, 2002, ONCOGENE, V21, P1299, DOI 10.1038/sj.onc.1205181; GREEN M, 1995, MOL CELL BIOL, V15, P3354; Ha NC, 2004, MOL CELL, V15, P511, DOI 10.1016/j.molcel.2004.08.010; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hoang AT, 2000, AM J PATHOL, V156, P857, DOI 10.1016/S0002-9440(10)64954-1; Jackson JG, 2004, CANCER RES, V64, P2601, DOI 10.1158/0008-5472.CAN-03-3106; Karim RZ, 2004, PATHOLOGY, V36, P120, DOI 10.1080/00313020410001671957; Kim SO, 1999, J BIOL CHEM, V274, P36015, DOI 10.1074/jbc.274.50.36015; Klapper LN, 1997, ONCOGENE, V14, P2099, DOI 10.1038/sj.onc.1201029; Li YW, 2001, MOL CELL NEUROSCI, V17, P761, DOI 10.1006/mcne.2000.0967; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LUPU R, 1990, SCIENCE, V249, P1552, DOI 10.1126/science.2218496; McMillan DR, 1998, J BIOL CHEM, V273, P7523, DOI 10.1074/jbc.273.13.7523; Newton EM, 1996, MOL CELL BIOL, V16, P839; Nylandsted J, 2000, ANN NY ACAD SCI, V926, P122; Nylandsted J, 2000, P NATL ACAD SCI USA, V97, P7871, DOI 10.1073/pnas.97.14.7871; Rubin I, 2001, ANN ONCOL, V12, P3, DOI 10.1023/A:1011195320446; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SCHILLER P, 1988, J MOL BIOL, V203, P97, DOI 10.1016/0022-2836(88)90094-0; Schulze-Bergkamen H, 2004, SEMIN ONCOL, V31, P90, DOI 10.1053/j.seminoncol.2003.11.006; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Siddik ZH, 2003, ONCOGENE, V22, P7265, DOI 10.1038/sj.onc.1206933; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; Stoica GE, 2003, ONCOGENE, V22, P2073, DOI 10.1038/sj.onc.1206311; Tang D, 2005, CELL STRESS CHAPERON, V10, P46, DOI 10.1379/CSC-44R.1; Tsai MS, 2003, ONCOGENE, V22, P761, DOI 10.1038/sj.onc.1206130; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Venkateswarlu S, 2002, ONCOGENE, V21, P78, DOI 10.1038/sj.onc.1205011; Viatour P, 2004, MOL CELL, V16, P35, DOI 10.1016/j.molcel.2004.09.004; Volloch VZ, 1999, ONCOGENE, V18, P3648, DOI 10.1038/sj.onc.1202525; Wang L, 2004, J BIOL CHEM, V279, P32444, DOI 10.1074/jbc.M313963200; Wang XZ, 2004, J BIOL CHEM, V279, P49460, DOI 10.1074/jbc.M406059200; Wang XZ, 2003, MOL CELL BIOL, V23, P6013, DOI 10.1128/MCB.23.17.6013-6026.2003; Wang YQ, 2004, J BIOL CHEM, V279, P32651, DOI 10.1074/jbc.M401475200; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zhang Y, 2002, J CELL BIOCHEM, V86, P376, DOI 10.1002/jcb.10232	54	86	94	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	43					6564	6573		10.1038/sj.onc.1208798	http://dx.doi.org/10.1038/sj.onc.1208798			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	968ZV	16007186				2022-12-25	WOS:000232204100010
J	Beernink, PT; Hwang, M; Ramirez, M; Murphy, MB; Doyle, SA; Thelen, MP				Beernink, PT; Hwang, M; Ramirez, M; Murphy, MB; Doyle, SA; Thelen, MP			Specificity of protein interactions mediated by BRCT domains of the XRCC1 DNA repair protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE EXCISION-REPAIR; STRAND BREAK REPAIR; LIGASE III-ALPHA; ABASIC SITE REPAIR; POLYMERASE-BETA; POLY(ADP-RIBOSE) POLYMERASE; PHYSICALLY INTERACTS; AP-ENDONUCLEASE; GLYCOSYLASE; DAMAGE	Protein interactions critical to DNA repair and cell cycle control systems are often coordinated by modules that belong to a superfamily of structurally conserved BRCT domains. Because the mechanisms of BRCT interactions and their significance are not well understood, we sought to define the affinity and specificity of those BRCT modules that orchestrate base excision repair and single-strand break repair. Common to these pathways is the essential XRCC1 DNA repair protein, which interacts with at least nine other proteins and DNA. Here, we characterized the interactions of four purified BRCT domains, two from XRCC1 and their two partners from DNA ligase III alpha and poly( ADP-ribosyl) polymerase 1. A monoclonal antibody was selected that recognizes the ligase III alpha BRCT domain, but not the other BRCT domains, and was used to capture the relevant ligase III alpha BRCT complex. To examine the assembly states of isolated BRCT domains and pairwise domain complexes, we used size-exclusion chromatography coupled with on-line light scattering. This analysis indicated that isolated BRCT domains form homo-oligomers and that the BRCT complex between the C-terminal XRCC1 domain and the ligase III alpha domain is a heterotetramer with 2: 2 stoichiometry. Using affinity capture and surface plasmon resonance methods, we determined that specific heteromeric interactions with high nanomolar dissociation constants occur between pairs of cognate BRCT domains. A structural model for a XRCC1(.)DNA ligase III alpha heterotetramer is proposed as a core base excision repair complex, which constitutes a scaffold for higher order complexes to which other repair proteins and DNA are brought into proximity.	Lawrence Livermore Natl Lab, Biosci Directorate, Livermore, CA 94551 USA; Joint Genome Inst, Dept Energy, Walnut Creek, CA 94598 USA	United States Department of Energy (DOE); Lawrence Livermore National Laboratory; United States Department of Energy (DOE); Joint BioEnergy Institute - JBEI; Joint Genome Institute - JGI	Beernink, PT (corresponding author), Childrens Hosp Oakland, Res Inst, 5700 Martin Luther King Jr Way, Oakland, CA 94609 USA.	pbeernink@chori.org	Thelen, Michael/C-6834-2008; Thelen, Michael P/G-2032-2014	Thelen, Michael/0000-0002-2479-5480; Thelen, Michael P/0000-0002-2479-5480				BEERNINK PT, 1994, PROTEIN SCI, V3, P1383, DOI 10.1002/pro.5560030904; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Caldecott KW, 1996, NUCLEIC ACIDS RES, V24, P4387, DOI 10.1093/nar/24.22.4387; CALDECOTT KW, 1994, MOL CELL BIOL, V14, P68, DOI 10.1128/MCB.14.1.68; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Clements PM, 2004, DNA REPAIR, V3, P1493, DOI 10.1016/j.dnarep.2004.06.017; Du LL, 2004, J BIOL CHEM, V279, P38409, DOI 10.1074/jbc.M403326200; Dulic A, 2001, BIOCHEMISTRY-US, V40, P5906, DOI 10.1021/bi002701e; Fan JS, 2004, NUCLEIC ACIDS RES, V32, P2193, DOI 10.1093/nar/gkh556; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; Glover JNM, 2004, TRENDS BIOCHEM SCI, V29, P579, DOI 10.1016/j.tibs.2004.09.010; GOODHEAD DT, 1994, INT J RADIAT BIOL, V65, P7, DOI 10.1080/09553009414550021; Hazra TK, 2001, PROG NUCLEIC ACID RE, V68, P193; Hill JW, 2001, NUCLEIC ACIDS RES, V29, P430, DOI 10.1093/nar/29.2.430; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; Krishnan VV, 2001, BIOCHEMISTRY-US, V40, P13158, DOI 10.1021/bi010979g; Kubota Y, 2003, DNA REPAIR, V2, P407, DOI 10.1016/S1568-7864(02)00242-2; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; Kumaresan KR, 2002, BIOCHEMISTRY-US, V41, P890, DOI 10.1021/bi011614z; Loizou JI, 2004, CELL, V117, P17, DOI 10.1016/S0092-8674(04)00206-5; Lomax ME, 2004, DNA REPAIR, V3, P289, DOI 10.1016/j.dnarep.2003.11.006; Luo H, 2004, MOL CELL BIOL, V24, P8356, DOI 10.1128/MCB.24.19.8356-8365.2004; Maiti R, 2004, NUCLEIC ACIDS RES, V32, pW590, DOI 10.1093/nar/gkh477; Manke IA, 2003, SCIENCE, V302, P636, DOI 10.1126/science.1088877; Marintchev A, 1999, NAT STRUCT BIOL, V6, P884; Marintchev A, 2000, NUCLEIC ACIDS RES, V28, P2049, DOI 10.1093/nar/28.10.2049; Marsin S, 2003, J BIOL CHEM, V278, P44068, DOI 10.1074/jbc.M306160200; Masson M, 1998, MOL CELL BIOL, V18, P3563, DOI 10.1128/MCB.18.6.3563; MATSUMOTO Y, 1994, MOL CELL BIOL, V14, P6187, DOI 10.1128/MCB.14.9.6187; Nash RA, 1997, BIOCHEMISTRY-US, V36, P5207, DOI 10.1021/bi962281m; PANAYOTOU G, 1993, MOL CELL BIOL, V13, P3567, DOI 10.1128/MCB.13.6.3567; Parikh SS, 1998, EMBO J, V17, P5214, DOI 10.1093/emboj/17.17.5214; Parker A, 2001, J BIOL CHEM, V276, P5547, DOI 10.1074/jbc.M008463200; PARSELL DA, 1989, J BIOL CHEM, V264, P7590; PETERSON CB, 1994, PROTEIN SCI, V3, P960; Plo I, 2003, DNA REPAIR, V2, P1087, DOI 10.1016/S1568-7864(03)00116-2; Privezentzev CV, 2001, MUTAT RES-FUND MOL M, V480, P277, DOI 10.1016/S0027-5107(01)00186-5; Shen NR, 1998, NUCLEIC ACIDS RES, V26, P1032, DOI 10.1093/nar/26.4.1032; Taylor RM, 1998, CURR BIOL, V8, P877, DOI 10.1016/S0960-9822(07)00350-8; Thornton K, 1999, PROTEIN EXPRES PURIF, V16, P236, DOI 10.1006/prep.1999.1070; Thornton KH, 2001, PROTEIN EXPRES PURIF, V21, P401, DOI 10.1006/prep.2001.1391; Vidal AE, 2001, EMBO J, V20, P6530, DOI 10.1093/emboj/20.22.6530; Vidal AE, 2001, NUCLEIC ACIDS RES, V29, P1285, DOI 10.1093/nar/29.6.1285; Whitehouse CJ, 2001, CELL, V104, P107, DOI 10.1016/S0092-8674(01)00195-7; Williams RS, 2001, NAT STRUCT BIOL, V8, P838, DOI 10.1038/nsb1001-838; Yamane K, 2000, BIOCHEM BIOPH RES CO, V279, P678, DOI 10.1006/bbrc.2000.3983; Yang HJ, 2001, NUCLEIC ACIDS RES, V29, P743, DOI 10.1093/nar/29.3.743; Yu XC, 2003, SCIENCE, V302, P639, DOI 10.1126/science.1088753; Zhang XD, 1998, EMBO J, V17, P6404, DOI 10.1093/emboj/17.21.6404	49	43	46	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	2005	280	34					30206	30213		10.1074/jbc.M502155200	http://dx.doi.org/10.1074/jbc.M502155200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	957IC	15987676	hybrid			2022-12-25	WOS:000231362500029
J	Yamamoto, K; Uchida, E; Urushino, N; Sakaki, T; Kagawa, N; Sawada, N; Kamakura, M; Kato, S; Inouye, K; Yamada, S				Yamamoto, K; Uchida, E; Urushino, N; Sakaki, T; Kagawa, N; Sawada, N; Kamakura, M; Kato, S; Inouye, K; Yamada, S			Identification of the amino acid residue of CYP27B1 responsible for binding of 25-hydroxyvitamin D-3 whose mutation causes vitamin D-dependent rickets type 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-DEFICIENCY RICKETS; D-3 1-ALPHA-HYDROXYLASE GENE; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; CLONING; D-1-ALPHA-HYDROXYLASE; CYTOCHROME-P450; PURIFICATION; EXPRESSION; REDUCTASE	We previously reported the three-dimensional structure of human CYP27B1 (25-hydroxyvitamin D-3 1 alpha-hydroxylase) constructed by homology modeling. Using the three-dimensional model we studied the docking of the substrate, 25-hydroxyvitamin D-3, into the substrate binding pocket of CYP27B1. In this study, we focused on the amino acid residues whose point mutations cause vitamin D-dependent rickets type 1, especially unconserved residues among mitochondrial CYPs such as Gln(65) and Thr(409). Recently, we successfully overexpressed mouse CYP27B1 by using a GroEL/ES co-expression system. In a mutation study of mouse CYP27B1 that included spectroscopic analysis, we concluded that in a 1 alpha-hydroxylation process, Ser(408) of mouse CYP27B1 corresponding to Thr409 of human CYP27B1 forms a hydrogen bond with the 25-hydroxyl group of 25-hydroxyvitamin D-3. This is the first report that shows a critical amino acid residue recognizing the 25-hydroxyl group of the vitamin D-3.	Toyama Prefectural Univ, Biotechnol Res Ctr, Fac Engn, Toyama 9390398, Japan; Tokyo Med & Dent Univ, Inst Biomat & Bioengn, Chiyoda Ku, Tokyo 1010062, Japan; Tokyo Med & Dent Univ, Sch Biomed Sci, Chiyoda Ku, Tokyo 1010062, Japan; Kyoto Univ, Div Food Sci & Biotechnol, Grad Sch Agr, Sakyo Ku, Kyoto 6068502, Japan; Vanderbilt Univ, Dept Biochem, Sch Med, Nashville, TN 37232 USA; Univ Shizuoka, Lab Endocrinol & Mol Metab, Grad Sch Nutr Sci, Shizuoka 4228526, Japan; Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan	Toyama Prefectural University; Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Kyoto University; Vanderbilt University; University of Shizuoka; University of Tokyo	Sakaki, T (corresponding author), Toyama Prefectural Univ, Biotechnol Res Ctr, Fac Engn, 5180 Kurokawa, Toyama 9390398, Japan.	tsakaki@pu-toyama.ac.jp; yamada.mr@tmd.ac.jp	Kamakura, Masaki/E-7954-2011	Yamamoto, Keiko/0000-0001-6642-7961				Cupp-Vickery J, 2000, P NATL ACAD SCI USA, V97, P3050, DOI 10.1073/pnas.050406897; Feldman D, 1997, VITAMIN D; Fu GK, 1997, MOL ENDOCRINOL, V11, P1961, DOI 10.1210/me.11.13.1961; HIWATASHI A, 1982, BIOCHEM BIOPH RES CO, V105, P320, DOI 10.1016/S0006-291X(82)80047-8; Kitanaka S, 1999, J CLIN ENDOCR METAB, V84, P4111, DOI 10.1210/jc.84.11.4111; Kitanaka S, 1998, NEW ENGL J MED, V338, P653, DOI 10.1056/NEJM199803053381004; Kondo S, 1999, BIOCHEM BIOPH RES CO, V257, P273, DOI 10.1006/bbrc.1999.0455; Omdahl JL, 2001, STEROIDS, V66, P381, DOI 10.1016/S0039-128X(00)00157-4; OMURA T, 1964, J BIOL CHEM, V118, P397; Portale AA, 2000, PEDIATR NEPHROL, V14, P620; Sawada N, 1999, EUR J BIOCHEM, V265, P950, DOI 10.1046/j.1432-1327.1999.00794.x; Sawada N, 2001, EUR J BIOCHEM, V268, P6607, DOI 10.1046/j.0014-2956.2001.02615.x; Schlichting I, 1997, FEBS LETT, V415, P253, DOI 10.1016/S0014-5793(97)01135-6; Schlichting I, 2000, SCIENCE, V287, P1615, DOI 10.1126/science.287.5458.1615; Shinki T, 1997, P NATL ACAD SCI USA, V94, P12920, DOI 10.1073/pnas.94.24.12920; StArnaud R, 1997, J BONE MINER RES, V12, P1552, DOI 10.1359/jbmr.1997.12.10.1552; Takeyama K, 1997, SCIENCE, V277, P1827, DOI 10.1126/science.277.5333.1827; Uchida E, 2004, BIOCHEM BIOPH RES CO, V323, P505, DOI 10.1016/j.bbrc.2004.08.110; Williams D, 2000, PERFORM RES, V5, P131; Yamamoto K, 2004, J STEROID BIOCHEM, V89-90, P167, DOI 10.1016/j.jsbmb.2004.03.098; Yoshida T, 1998, KIDNEY INT, V54, P1437, DOI 10.1046/j.1523-1755.1998.00133.x	21	40	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	2005	280	34					30511	30516		10.1074/jbc.M505244200	http://dx.doi.org/10.1074/jbc.M505244200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	957IC	15972816	hybrid			2022-12-25	WOS:000231362500065
J	Layer, G; Grage, K; Teschner, T; Schunemann, V; Breckau, D; Masoumi, A; Jahn, M; Heathcote, P; Trautwein, AX; Jahn, D				Layer, G; Grage, K; Teschner, T; Schunemann, V; Breckau, D; Masoumi, A; Jahn, M; Heathcote, P; Trautwein, AX; Jahn, D			Radical S-adenosylmethionine enzyme coproporphyrinogen III oxidase HemN - Functional features of the [4Fe-4S] cluster and the two bound S-adenosyl-L-methionines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRUVATE FORMATE-LYASE; IRON-SULFUR CENTER; ANAEROBIC RIBONUCLEOTIDE REDUCTASE; BIOTIN SYNTHASE; ESCHERICHIA-COLI; LYSINE 2,3-AMINOMUTASE; ACTIVATING ENZYME; CRYSTAL-STRUCTURE; SUBSTRATE-BINDING; ELECTRON-TRANSFER	The S-adenosylmethionine (AdoMet) radical enzyme oxygen-independent coproporphyrinogen III oxidase HemN catalyzes the oxidative decarboxylation of coproporphyrinogen III to protoporphyrinogen IX during bacterial heme biosynthesis. The recently solved crystal structure of Escherichia coli HemN revealed the presence of an unusually coordinated iron-sulfur cluster and two molecules of AdoMet. EPR spectroscopy of the reduced iron-sulfur center in anaerobically purified HemN in the absence of AdoMet has revealed a [4Fe4S](1+) cluster in two slightly different conformations. Mossbauer spectroscopy of anaerobically purified HemN has identified a predominantly [4Fe-4S](2+) cluster in which only three iron atoms were coordinated by cysteine residues (isomer shift of delta = 0.43 (1) mm/s). The fourth non-cysteine-ligated iron exhibited a delta=0.57 (3) mm/s, which shifted to a delta=0.68 (3) mm/s upon addition of AdoMet. Substrate binding by HemN did not alter AdoMet coordination to the cluster. Multiple rounds of AdoMet cleavage with the formation of the reaction product methionine indicated AdoMet consumption during catalysis and identified AdoMet as a co- substrate for HemN catalysis. AdoMet cleavage was found to be dependent on the presence of the substrate coproporphyrinogen III. Two molecules of AdoMet were cleaved during one catalytic cycle for the formation of one molecule of protoporphyrinogen IX. Finally, the binding site for the unusual second, non iron-sulfur cluster coordinating AdoMet molecule (AdoMet2) was targeted using site-directed mutagenesis. All AdoMet2 binding site mutants still contained an iron-sulfur cluster and most still exhibited AdoMet cleavage, albeit reduced compared with the wild-type enzyme. However, all mutants lost their overall catalytic ability indicating a functional role for AdoMet2 in HemN catalysis. The reported significant correlation of structural and functional biophysical and biochemical data identifies HemN as a useful model system for the elucidation of general AdoMet radical enzyme features.	Tech Univ Braunschweig, Inst Microbiol, D-38106 Braunschweig, Germany; Med Univ Lubeck, Inst Phys, D-23538 Lubeck, Germany; Univ London, Sch Biol Sci, London E1 4NS, England	Braunschweig University of Technology; University of Lubeck; University of London	Jahn, D (corresponding author), Tech Univ Braunschweig, Inst Microbiol, Spielmannstr 7, D-38106 Braunschweig, Germany.	d.jahn@tu-bs.de	Heathcote, Peter/B-3749-2011; Schünemann, Volker/C-6603-2016	Jahn, Dieter/0000-0002-4064-9205	Biotechnology and Biological Sciences Research Council [BB/C504686/1] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Benda R, 2002, BIOCHEMISTRY-US, V41, P15000, DOI 10.1021/bi026590q; BENDA R, 2002, MOSSBAUERSPEKTROSKOP, P80; Berkovitch F, 2004, SCIENCE, V303, P76, DOI 10.1126/science.1088493; BIRCH OM, 1995, J BIOL CHEM, V270, P19158, DOI 10.1074/jbc.270.32.19158; Breckau D, 2003, J BIOL CHEM, V278, P46625, DOI 10.1074/jbc.M308553200; Bui BTS, 2003, BIOCHEMISTRY-US, V42, P8791, DOI 10.1021/bi034426c; Cheek J, 2002, J AM CHEM SOC, V124, P2860, DOI 10.1021/ja017784g; Chen DW, 2003, J AM CHEM SOC, V125, P11788, DOI 10.1021/ja036120z; Cosper MM, 2002, J AM CHEM SOC, V124, P14006, DOI 10.1021/ja0283044; Cosper MM, 2004, BIOCHEMISTRY-US, V43, P2007, DOI 10.1021/bi0356653; Dailey HA, 2002, BIOCHEM SOC T, V30, P590, DOI 10.1042/bst0300590; Escalettes F, 1999, J AM CHEM SOC, V121, P3571, DOI 10.1021/ja9811748; Fontecave M, 2001, CURR OPIN CHEM BIOL, V5, P506, DOI 10.1016/S1367-5931(00)00237-4; Frankenberg N, 2003, APPL MICROBIOL BIOT, V63, P115, DOI 10.1007/s00253-003-1432-2; FREY M, 1994, J BIOL CHEM, V269, P12432; Frey PA, 2003, CHEM REV, V103, P2129, DOI 10.1021/cr020422m; Guianvarc'h D, 1997, BIOCHEM BIOPH RES CO, V236, P402, DOI 10.1006/bbrc.1997.6952; Hanzelmann P, 2004, P NATL ACAD SCI USA, V101, P12870, DOI 10.1073/pnas.0404624101; HARWOOD CR, 1990, MODERN MICROBIOLOGIC, P584; Henshaw TF, 2000, J AM CHEM SOC, V122, P8331, DOI 10.1021/ja002012q; Hewitson KS, 2002, J BIOL INORG CHEM, V7, P83, DOI 10.1007/s007750100268; Hinckley GT, 2003, ARCH BIOCHEM BIOPHYS, V414, P34, DOI 10.1016/S0003-9861(03)00160-7; Jarrett JT, 2003, CURR OPIN CHEM BIOL, V7, P174, DOI 10.1016/S1367-5931(03)00022-X; Krebs C, 2002, J AM CHEM SOC, V124, P912, DOI 10.1021/ja017562i; Krebs C, 2000, J AM CHEM SOC, V122, P12497, DOI 10.1021/ja003335p; Layer G, 2002, J BIOL CHEM, V277, P34136, DOI 10.1074/jbc.M205247200; Layer G, 2003, EMBO J, V22, P6214, DOI 10.1093/emboj/cdg598; Lieder KW, 1998, BIOCHEMISTRY-US, V37, P2578, DOI 10.1021/bi972417w; Magnusson OT, 2001, BIOCHEMISTRY-US, V40, P7773, DOI 10.1021/bi0104569; Martins BM, 2001, J BIOL CHEM, V276, P44108, DOI 10.1074/jbc.M104759200; MOSS ML, 1990, J BIOL CHEM, V265, P18112; Mulliez E, 2001, BIOCHEMISTRY-US, V40, P3730, DOI 10.1021/bi001746c; Ollagnier S, 1997, J BIOL CHEM, V272, P24216, DOI 10.1074/jbc.272.39.24216; Ollagnier-de Choudens S, 2002, J BIOL CHEM, V277, P13449, DOI 10.1074/jbc.M111324200; Padovani D, 2001, BIOCHEMISTRY-US, V40, P6713, DOI 10.1021/bi002936q; PETROVICH RM, 1992, BIOCHEMISTRY-US, V31, P10774, DOI 10.1021/bi00159a019; Phillips JD, 2003, EMBO J, V22, P6225, DOI 10.1093/emboj/cdg606; Pierrel F, 2004, J BIOL CHEM, V279, P47555, DOI 10.1074/jbc.M408562200; Rebeil R, 2001, P NATL ACAD SCI USA, V98, P9038, DOI 10.1073/pnas.161278998; SEEHRA JS, 1983, BIOCHEM J, V209, P709, DOI 10.1042/bj2090709; Sofia HJ, 2001, NUCLEIC ACIDS RES, V29, P1097, DOI 10.1093/nar/29.5.1097; Tamarit J, 1999, J BIOL CHEM, V274, P31291, DOI 10.1074/jbc.274.44.31291; Tamarit J, 2000, J BIOL CHEM, V275, P15669, DOI 10.1074/jbc.275.21.15669; Ugulava NB, 2003, BIOCHEMISTRY-US, V42, P2708, DOI 10.1021/bi0261084; Walsby CJ, 2002, J AM CHEM SOC, V124, P11270, DOI 10.1021/ja027078v; Walsby CJ, 2002, J AM CHEM SOC, V124, P3143, DOI 10.1021/ja012034s; Wu WM, 2000, BIOCHEMISTRY-US, V39, P9561, DOI 10.1021/bi000658p	47	65	68	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	2005	280	32					29038	29046		10.1074/jbc.M501275200	http://dx.doi.org/10.1074/jbc.M501275200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	952QT	15967800	hybrid			2022-12-25	WOS:000231021300028
J	Narita, K; Choudhury, A; Dobrenis, K; Sharma, DK; Holicky, EL; Marks, DL; Walkley, SU; Pagano, RE				Narita, K; Choudhury, A; Dobrenis, K; Sharma, DK; Holicky, EL; Marks, DL; Walkley, SU; Pagano, RE			Protein transduction of Rab9 in Niemann-Pick C cells reduces cholesterol storage	FASEB JOURNAL			English	Article						Rab proteins; sphingolipid storage diseases; lipid transport; late endosomes and lysosomes	LOW-DENSITY-LIPOPROTEIN; IN-VIVO; GENE-TRANSFER; DISEASE; ACCUMULATION; TRANSPORT; GLYCOSPHINGOLIPIDS; TRAFFICKING; FIBROBLASTS; ENDOCYTOSIS	Niemann-Pick disease type C ( NPC) is a genetic disorder in which patient cells exhibit lysosomal accumulation of cholesterol and sphingolipids (SLs) caused by defects in either NPC1 or NPC2 proteins. We previously demonstrated that NPC1 human skin fibroblasts overexpressing endosomal Rab proteins (Rab7 or Rab9) showed a correction in the storage disease phenotype. In the current study, we used protein transduction to further investigate Rab9-mediated reduction of stored lipids in NPC cells. Recombinant human Rab9 fused with the herpes simplex virus VP22 protein fragment was overexpressed, purified, and added to culture medium to induce protein transduction. When VP22-Rab9 was transduced into NPC1 fibroblasts, nearly all cells showed significant reduction in cellular free cholesterol levels, with no cytotoxicity up to 5 mu M. A fraction of the VP22-Rab9 that was transduced into the cells was shown to bind to rab GDP dissociation inhibitor, suggesting that this pool of VP22-Rab9 had become prenylated. The reduction in cellular free cholesterol was associated with correction of abnormal intracellular trafficking of BODIPY-lactosylceramide and an increase of sterols in the culture media. The clearance of lysosomal free cholesterol was also associated with a decrease in LDL-receptor levels. In addition, we demonstrated reduction of intracellular cholesterol by VP22-Rab9 transduction in NPC2 fibroblasts and in cultured mouse NPC1 neurons. These observations provide important new information about the correction of membrane traffic in NPC cells by Rab9 overexpression and may lead to new therapeutic approaches for treatment of this disease.	Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Albert Einstein Coll Med, Dept Neurosci, Bronx, NY 10461 USA; Mayo Clin & Mayo Fdn, Mol Neurosci Program, Rochester, MN 55905 USA	Mayo Clinic; Yeshiva University; Albert Einstein College of Medicine; Mayo Clinic	Pagano, RE (corresponding author), Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, 200 1st St SW,Stabile 8, Rochester, MN 55905 USA.	pagano.richard@mayo.edu	Narita, Keishi/E-3539-2010	Narita, Keishi/0000-0002-7602-8523	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060934] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-60934] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Boenicke L, 2003, J MOL MED-JMM, V81, P205, DOI 10.1007/s00109-003-0421-3; Chen CS, 1999, LANCET, V354, P901, DOI 10.1016/S0140-6736(98)10034-X; Chen CS, 1997, BIOPHYS J, V72, P37, DOI 10.1016/S0006-3495(97)78645-4; Choudhury A, 2004, MOL BIOL CELL, V15, P4500, DOI 10.1091/mbc.E04-05-0432; Choudhury A, 2002, J CLIN INVEST, V109, P1541, DOI 10.1172/JCI200215420; Day GJ, 1998, MOL CELL BIOL, V18, P7444, DOI 10.1128/MCB.18.12.7444; Dolo V, 2000, BBA-MOL CELL BIOL L, V1486, P265, DOI 10.1016/S1388-1981(00)00063-9; Ford KG, 2001, GENE THER, V8, P1, DOI 10.1038/sj.gt.3301383; Frolov A, 2003, J BIOL CHEM, V278, P25517, DOI 10.1074/jbc.M302588200; Gondre M., 1999, Society for Neuroscience Abstracts, V25, P1118; JOHNSON WJ, 1991, BIOCHIM BIOPHYS ACTA, V1085, P273, DOI 10.1016/0005-2760(91)90132-2; Kretz A, 2003, MOL THER, V7, P659, DOI 10.1016/S1525-0016(03)00062-5; KRUTH HS, 1986, J BIOL CHEM, V261, P6769; Lai Z, 2002, J NEUROSCI RES, V67, P363, DOI 10.1002/jnr.10137; Lebrand C, 2002, EMBO J, V21, P1289, DOI 10.1093/emboj/21.6.1289; Marks DL, 2002, TRENDS CELL BIOL, V12, P605, DOI 10.1016/S0962-8924(02)02399-1; MARTIN OC, 1994, J CELL BIOL, V125, P769, DOI 10.1083/jcb.125.4.769; Ostermeyer AG, 2001, J CELL BIOL, V152, P1071, DOI 10.1083/jcb.152.5.1071; Pagano RE, 2000, TRAFFIC, V1, P807, DOI 10.1034/j.1600-0854.2000.011101.x; PATTERSON MC, 2001, NIEMANN PICK DIS TYP, V3; PFEFFER SR, 1995, J BIOL CHEM, V270, P17057, DOI 10.1074/jbc.270.29.17057; Puri V, 1999, NAT CELL BIOL, V1, P386, DOI 10.1038/14084; Puri V, 2003, J BIOL CHEM, V278, P20961, DOI 10.1074/jbc.M300304200; RIEDERER MA, 1994, J CELL BIOL, V125, P573, DOI 10.1083/jcb.125.3.573; RIEDERER MA, 1995, METHOD ENZYMOL, V257, P15; Schwartz JJ, 2000, CURR OPIN MOL THER, V2, P162; SOKOL J, 1988, J BIOL CHEM, V263, P3411; SOLDATI T, 1993, MOL BIOL CELL, V4, P425, DOI 10.1091/mbc.4.4.425; Sun XF, 2001, AM J HUM GENET, V68, P1361, DOI 10.1086/320599; VANIER MT, 1991, DEV NEUROSCI-BASEL, V13, P307, DOI 10.1159/000112178; Wadia JS, 2002, CURR OPIN BIOTECH, V13, P52, DOI 10.1016/S0958-1669(02)00284-7; Walter M, 2003, J LIPID RES, V44, P243, DOI 10.1194/jlr.M200230-JLR200; Wang Y, 2005, J BIOL CHEM, V280, P11876, DOI 10.1074/jbc.M414676200; Zavaglia D, 2003, MOL THER, V8, P840, DOI 10.1016/j.ymthe.2003.08.001; Zervas M, 2001, J NEUROPATH EXP NEUR, V60, P49, DOI 10.1093/jnen/60.1.49	35	63	63	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2005	19	8					1558	+		10.1096/fj.04-2714fje	http://dx.doi.org/10.1096/fj.04-2714fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	15972801				2022-12-25	WOS:000230207800008
J	Zalfa, F; Adinolfi, S; Napoli, I; Kuhn-Holsken, E; Urlaub, H; Achsel, T; Pastore, A; Bagni, C				Zalfa, F; Adinolfi, S; Napoli, I; Kuhn-Holsken, E; Urlaub, H; Achsel, T; Pastore, A; Bagni, C			Fragile X mental retardation protein (FMRP) binds specifically to the brain cytoplasmic RNAs BC1/BC200 via a novel RNA-binding motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; NEURONAL BC1; TRANSLATION; LOCALIZATION; PRODUCT; DOMAIN; GENE; RIBONUCLEOPROTEIN; IDENTIFICATION; RECOGNITION	Fragile X mental retardation protein (FMRP), the protein responsible for the fragile X syndrome, is an RNA-binding protein involved in localization and translation of neuronal mRNAs. One of the RNAs known to interact with FMRP is the dendritic non-translatable brain cytoplasmic RNA 1 BC1 RNA that works as an adaptor molecule linking FMRP and some of its regulated mRNAs. Here, we showed that the N terminus of FMRP binds strongly and specifically to BC1 and to its potential human analog BC200. This region does not contain a motif known to specifically recognize RNA and thus constitutes a new RNA-binding motif. We further demonstrated that FMRP recognition involves the 5' stem loop of BC1 and that this is the region that exhibits complementarity to FMRP target mRNAs, raising the possibility that FMRP plays a direct role in BC1/ mRNA annealing.	Univ Roma Tor Vergata, Dipartimento Biol, I-00133 Rome, Italy; Natl Inst Med Res, Mol Struct Div, London NW7 1AA, England; Fdn Santa Lucia, Ist Ric & Cura Carattere Sci, Ist Neurosci Sperimentali, I-00179 Rome, Italy; Max Planck Inst Biophys Chem, Mass Spectrometry Grp, Dept Cellular Biochem, D-37077 Gottingen, Germany	University of Rome Tor Vergata; MRC National Institute for Medical Research; IRCCS Santa Lucia; Max Planck Society	Bagni, C (corresponding author), Univ Roma Tor Vergata, Dipartimento Biol, Via Ric Sci 1, I-00133 Rome, Italy.	claudia.bagni@uniroma2.it	Zalfa, Francesca/J-7759-2018	Zalfa, Francesca/0000-0002-1922-9468; Bagni, Claudia/0000-0002-4419-210X; Napoli, Ilaria/0000-0002-0649-1950; ADINOLFI, Salvatore/0000-0003-1319-5516	Telethon [GGP02357] Funding Source: Medline	Telethon(Fondazione Telethon)		Adinolfi S, 1999, RNA, V5, P1248, DOI 10.1017/S1355838299990647; Adinolfi S, 2003, BIOCHEMISTRY-US, V42, P10437, DOI 10.1021/bi034909g; Antar LN, 2004, J NEUROSCI, V24, P2648, DOI 10.1523/JNEUROSCI.0099-04.2004; Bagni C, 2005, NAT REV NEUROSCI, V6, P376, DOI 10.1038/nrn1667; Bovia F, 1997, NUCLEIC ACIDS RES, V25, P318, DOI 10.1093/nar/25.2.318; Brown V, 2001, CELL, V107, P477, DOI 10.1016/S0092-8674(01)00568-2; Caudy AA, 2002, GENE DEV, V16, P2491, DOI 10.1101/gad.1025202; Chen L, 2003, NEUROSCIENCE, V120, P1005, DOI 10.1016/S0306-4522(03)00406-8; Cheng JG, 1996, DNA CELL BIOL, V15, P549, DOI 10.1089/dna.1996.15.549; Darnell JC, 2005, GENE DEV, V19, P903, DOI 10.1101/gad.1276805; Darnell JC, 2001, CELL, V107, P489, DOI 10.1016/S0092-8674(01)00566-9; Eberhart DE, 1996, HUM MOL GENET, V5, P1083, DOI 10.1093/hmg/5.8.1083; Feng Y, 1997, J NEUROSCI, V17, P1539; Gabus C, 2004, NUCLEIC ACIDS RES, V32, P2129, DOI 10.1093/nar/gkh535; Huang YS, 2003, GENE DEV, V17, P638, DOI 10.1101/gad.1053003; Ishizuka A, 2002, GENE DEV, V16, P2497, DOI 10.1101/gad.1022002; Jin P, 2004, NAT NEUROSCI, V7, P113, DOI 10.1038/nn1174; Kanai Y, 2004, NEURON, V43, P513, DOI 10.1016/j.neuron.2004.07.022; Khandjian EW, 1999, BIOCHEM CELL BIOL, V77, P331, DOI 10.1139/bcb-77-4-331; Laggerbauer B, 2001, HUM MOL GENET, V10, P329, DOI 10.1093/hmg/10.4.329; Li ZZ, 2001, NUCLEIC ACIDS RES, V29, P2276, DOI 10.1093/nar/29.11.2276; Lu R, 2004, P NATL ACAD SCI USA, V101, P15201, DOI 10.1073/pnas.0404995101; MARTIGNETTI JA, 1993, P NATL ACAD SCI USA, V90, P11563, DOI 10.1073/pnas.90.24.11563; Martin KC, 2000, CURR OPIN NEUROBIOL, V10, P587, DOI 10.1016/S0959-4388(00)00128-8; Maurer-Stroh S, 2003, TRENDS BIOCHEM SCI, V28, P69, DOI 10.1016/S0968-0004(03)00004-5; Mazroui R, 2002, HUM MOL GENET, V11, P3007, DOI 10.1093/hmg/11.24.3007; Miyashiro KY, 2003, NEURON, V37, P417, DOI 10.1016/S0896-6273(03)00034-5; Muddashetty RS, 2002, J MOL BIOL, V321, P433, DOI 10.1016/S0022-2836(02)00655-1; Muslimov IA, 1997, J NEUROSCI, V17, P4722; Nottrott S, 1999, EMBO J, V18, P6119, DOI 10.1093/emboj/18.21.6119; Ramos A, 2003, RNA, V9, P1198, DOI 10.1261/rna.5960503; Reis SA, 2004, J MOL HISTOL, V35, P389; Schaeffer C, 2001, EMBO J, V20, P4803, DOI 10.1093/emboj/20.17.4803; SIOMI H, 1993, CELL, V74, P291, DOI 10.1016/0092-8674(93)90420-U; Stefani G, 2004, J NEUROSCI, V24, P7272, DOI 10.1523/JNEUROSCI.2306-04.2004; Steiner T, 2002, EMBO J, V21, P4641, DOI 10.1093/emboj/cdf455; Steward O, 2003, NEURON, V40, P347, DOI 10.1016/S0896-6273(03)00635-4; Tamanini F, 1999, HUM MOL GENET, V8, P863, DOI 10.1093/hmg/8.5.863; TIEDGE H, 1993, J NEUROSCI, V13, P2382, DOI 10.1523/JNEUROSCI.13-06-02382.1993; VERHEIJ C, 1993, NATURE, V363, P722, DOI 10.1038/363722a0; Wang HD, 2002, J NEUROSCI, V22, P10232; West NC, 2002, J MOL BIOL, V321, P423, DOI 10.1016/S0022-2836(02)00542-9; Zalfa F, 2003, CELL, V112, P317, DOI 10.1016/S0092-8674(03)00079-5; Zhang YQ, 2001, CELL, V107, P591, DOI 10.1016/S0092-8674(01)00589-X	44	103	105	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	2005	280	39					33403	33410		10.1074/jbc.M504286200	http://dx.doi.org/10.1074/jbc.M504286200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	966YG	16006558	Green Published, hybrid			2022-12-25	WOS:000232058100038
J	Kim, YE; Isas, JM; Haigler, HT; Langen, R				Kim, YE; Isas, JM; Haigler, HT; Langen, R			A helical hairpin region of soluble annexin B12 refolds and forms a continuous transmembrane helix at mildly acidic pH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-BINDING; LIPID-BILAYERS; PROTEINS; DYNAMICS; MICROSCOPY; INSERTION; CRYSTALS; VESICLES	Annexins are soluble proteins that are best known for their ability to undergo reversible Ca2+-dependent binding to the surface of phospholipid bilayers. Recent studies, however, have shown that annexins also reversibly bind to membranes in a Ca2+-independent manner at mildly acidic pH. We investigated the structural changes that occur upon pH-dependent membrane binding by performing a nitroxide scan on the helical hairpin encompassing helices A and B in the fourth repeat of annexin B12. Residues 251-273 of annexin B12 were replaced, one at a time, with cysteine and then labeled with a nitroxide spin label. Electron paramagnetic resonance (EPR) mobility and accessibility analyses of soluble annexin B12 derivatives were in excellent agreement with the known crystal structure of annexin B12. However, EPR studies of annexin B12 derivatives bound to membranes at pH 4.0 indicated major structural changes in the scanned region. The helix-loop-helix structure present in the soluble protein was converted into a continuous transmembrane alpha-helix that was exposed to the hydrophobic core of the bilayer on one side and exposed to an aqueous pore on the other side. Asp-264 was on the hydrophobic membrane-exposed face of the amphipathic transmembrane helix, thereby suggesting that protonation of its carboxylate group stabilized the transmembrane form. Inspection of the amino acid sequence of annexin B12 revealed several other helical hairpin regions that might refold and form continuous amphipathic transmembrane helices in response to protonation of Asp or Glu switch residues on or near the hydrophobic face of the helix.	Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA; Univ So Calif, Keck Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA	University of California System; University of California Irvine; University of Southern California	Haigler, HT (corresponding author), Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA.	hhaigler@uci.edu; langen@usc.edu	Kim, Yujin/P-4270-2014; Haigler, Harry/C-3788-2011	Kim, Yujin/0000-0003-4290-0974; 	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055651, R01GM063915] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 55651, GM 63915] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTENBACH C, 1994, P NATL ACAD SCI USA, V91, P1667, DOI 10.1073/pnas.91.5.1667; Faure AV, 2002, EXP CELL RES, V276, P79, DOI 10.1006/excr.2002.5512; GENGE BR, 1991, J BIOL CHEM, V266, P10678; Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001; Golczak Marcin, 2001, FASEB Journal, V15, P1083; Gross A, 1999, BIOCHEMISTRY-US, V38, P10324, DOI 10.1021/bi990856k; Hayes MJ, 2004, BIOCHEM BIOPH RES CO, V322, P1166, DOI 10.1016/j.bbrc.2004.07.124; Hubbell WL, 2000, NAT STRUCT BIOL, V7, P735, DOI 10.1038/78956; Hubbell WL, 1998, CURR OPIN STRUC BIOL, V8, P649, DOI 10.1016/S0959-440X(98)80158-9; Isas JM, 2004, J BIOL CHEM, V279, P32492, DOI 10.1074/jbc.M402568200; Isas JM, 2003, J BIOL CHEM, V278, P30227, DOI 10.1074/jbc.M301228200; Isas JM, 2000, BIOCHEMISTRY-US, V39, P3015, DOI 10.1021/bi9922401; Isas JM, 2002, BIOCHEMISTRY-US, V41, P1464, DOI 10.1021/bi011856z; Jao CC, 2004, P NATL ACAD SCI USA, V101, P8331, DOI 10.1073/pnas.0400553101; Kohler G, 1997, BIOCHEMISTRY-US, V36, P8189, DOI 10.1021/bi9703960; Ladokhin AS, 2005, BIOCHEMISTRY-US, V44, P3402, DOI 10.1021/bi047805u; Ladokhin AS, 2002, BIOCHEMISTRY-US, V41, P13617, DOI 10.1021/bi0264418; Langen R, 1998, J BIOL CHEM, V273, P22453, DOI 10.1074/jbc.273.35.22453; Langen R, 1998, P NATL ACAD SCI USA, V95, P14060, DOI 10.1073/pnas.95.24.14060; LUECKE H, 1995, NATURE, V378, P512, DOI 10.1038/378512a0; Mailliard WS, 1997, BIOCHEMISTRY-US, V36, P9045, DOI 10.1021/bi970749v; Mchaourab HS, 1996, BIOCHEMISTRY-US, V35, P7692, DOI 10.1021/bi960482k; Moss SE, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-4-219; Oling F, 2001, J STRUCT BIOL, V133, P55, DOI 10.1006/jsbi.2000.4337; Rand JH, 1999, NEW ENGL J MED, V340, P1035, DOI 10.1056/NEJM199904013401310; REEVES JP, 1969, J CELL PHYSIOL, V73, P49, DOI 10.1002/jcp.1040730108; Rescher U, 2004, J CELL SCI, V117, P2631, DOI 10.1242/jcs.01245; Reviakine I, 2000, J STRUCT BIOL, V131, P234, DOI 10.1006/jsbi.2000.4286; Reviakine I, 1998, J STRUCT BIOL, V121, P356, DOI 10.1006/jsbi.1998.4003; Rosengarth A, 1998, FEBS LETT, V438, P279, DOI 10.1016/S0014-5793(98)01318-0; Seaton B. A., 1996, ANNEXINS MOL STRUCTU; Torok M, 2002, J BIOL CHEM, V277, P40810, DOI 10.1074/jbc.M205659200; VOGES D, 1994, J MOL BIOL, V238, P199, DOI 10.1006/jmbi.1994.1281; Wimley WC, 1996, NAT STRUCT BIOL, V3, P842, DOI 10.1038/nsb1096-842; Zeuschner D, 2001, EUR J CELL BIOL, V80, P499, DOI 10.1078/0171-9335-00184	35	22	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	2005	280	37					32398	32404		10.1074/jbc.M505017200	http://dx.doi.org/10.1074/jbc.M505017200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	963HM	15975928	hybrid			2022-12-25	WOS:000231794800045
J	Nguyen, T; Sherratt, PJ; Nioi, P; Yang, CS; Pickett, CB				Nguyen, T; Sherratt, PJ; Nioi, P; Yang, CS; Pickett, CB			Nrf2 controls constitutive and inducible expression of ARE-driven genes through a dynamic pathway involving nucleocytoplasmic shuttling by Keap1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIOXIDANT RESPONSE ELEMENT; TRANSCRIPTION FACTOR NRF2; PROTEIN-KINASE-C; CUL3-BASED E3 LIGASE; OXIDATIVE STRESS; NF-E2-RELATED FACTOR-2; PROTEASOMAL DEGRADATION; OXIDOREDUCTASE-1 GENE; SULFHYDRYL-GROUPS; FEMALE MICE	Nrf2 regulates the expression of genes encoding antioxidant proteins involved in cellular redox homeostasis. Previous studies have suggested that activation of Nrf2 is mediated by mechanisms promoting its dissociation from Keap1, a cytosolic repressor that acts to sequester the transcription factor in the cytoplasm. As a short-lived protein, Nrf2 is also activated by mechanisms leading to its stabilization in cells under stress, and recent evidence indicates that Keap1 has an active role in the control of its stability. In this report, using immunocytochemistry, cell fractionation, and chromatin immunoprecipitation analyses, we found that Nrf2 is primarily a nuclear protein and that it is expressed and recruited to the chromatin constitutively to drive basal gene expression. Furthermore, we found evidence indicating that Keap1 may repress Nrf2 activity by transiently shuttling into the nucleus to promote its ubiquitylation. The data suggested that the steady-state level of Nrf2 is maintained by a dynamic pathway that balances its constitutive expression with a Keap1-regulated degradation process downstream of its role as a transcriptional activator. We suggest that the stabilization of Nrf2 in cells under stress represents the central regulatory response mediated by mechanisms that interfere with its interaction with Keap1, leading to the induction of antioxidant enzymes important to maintain cellular redox homeostasis.	Schering Plough Res Inst, Kenilworth, NJ 07033 USA; Rutgers State Univ, Ernest Mario Sch Pharm, Dept Biol Chem, Piscataway, NJ 08854 USA	Merck & Company; Schering-Plough Research Institute; Rutgers State University New Brunswick	Pickett, CB (corresponding author), Schering Plough Res Inst, 2015 Galloping Hill Rd, Kenilworth, NJ 07033 USA.	cecil.pickett@spcorp.com						Alberts AS, 1998, CELL, V92, P475, DOI 10.1016/S0092-8674(00)80941-1; Bloom DA, 2003, J BIOL CHEM, V278, P44675, DOI 10.1074/jbc.M307633200; Boyd KE, 1999, MOL CELL BIOL, V19, P8393; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; Chan KM, 1999, P NATL ACAD SCI USA, V96, P12731, DOI 10.1073/pnas.96.22.12731; Chan KM, 2001, P NATL ACAD SCI USA, V98, P4611, DOI 10.1073/pnas.081082098; Chanas SA, 2002, BIOCHEM J, V365, P405, DOI 10.1042/BJ20020320; Cullinan SB, 2003, MOL CELL BIOL, V23, P7198, DOI 10.1128/MCB.23.20.7198-7209.2003; Cullinan SB, 2004, MOL CELL BIOL, V24, P8477, DOI 10.1128/MCB.24.19.8477-8486.2004; Dhakshinamoorthy S, 2001, ONCOGENE, V20, P3906, DOI 10.1038/sj.onc.1204506; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dinkova-Kostova AT, 2002, P NATL ACAD SCI USA, V99, P11908, DOI 10.1073/pnas.172398899; Dinkova-Kostova AT, 2001, P NATL ACAD SCI USA, V98, P3404, DOI 10.1073/pnas.051632198; Enomoto A, 2001, TOXICOL SCI, V59, P169, DOI 10.1093/toxsci/59.1.169; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Furukawa M, 2005, MOL CELL BIOL, V25, P162, DOI 10.1128/MCB.25.1.162-171.2005; Hayashi A, 2003, BIOCHEM BIOPH RES CO, V310, P824, DOI 10.1016/j.bbrc.2003.09.086; Huang HC, 2000, P NATL ACAD SCI USA, V97, P12475, DOI 10.1073/pnas.220418997; Huang HC, 2002, J BIOL CHEM, V277, P42769, DOI 10.1074/jbc.M206911200; Ishii T, 2000, J BIOL CHEM, V275, P16023, DOI 10.1074/jbc.275.21.16023; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Itoh K, 2003, GENES CELLS, V8, P379, DOI 10.1046/j.1365-2443.2003.00640.x; Karapetian RN, 2005, MOL CELL BIOL, V25, P1089, DOI 10.1128/MCB.25.3.1089-1099.2005; Kobayashi A, 2004, MOL CELL BIOL, V24, P7130, DOI 10.1128/MCB.24.16.7130-7139.2004; Levonen AL, 2004, BIOCHEM J, V378, P373, DOI 10.1042/BJ20031049; Li J, 2002, J BIOL CHEM, V277, P388, DOI 10.1074/jbc.M109380200; McMahon M, 2001, CANCER RES, V61, P3299; McMahon M, 2003, J BIOL CHEM, V278, P21592, DOI 10.1074/jbc.M300931200; McMahon M, 2004, J BIOL CHEM, V279, P31556, DOI 10.1074/jbc.M403061200; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; Morimitsu Y, 2002, J BIOL CHEM, V277, P3456, DOI 10.1074/jbc.M110244200; Nguyen T, 2004, FREE RADICAL BIO MED, V37, P433, DOI 10.1016/j.freeradbiomed.2004.04.033; Nguyen T, 2003, J BIOL CHEM, V278, P4536, DOI 10.1074/jbc.M207293200; Nguyen T, 2003, ANNU REV PHARMACOL, V43, P233, DOI 10.1146/annurev.pharmtox.43.100901.140229; Numazawa S, 2003, AM J PHYSIOL-CELL PH, V285, pC334, DOI 10.1152/ajpcell.00043.2003; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Ramos-Gomez M, 2001, P NATL ACAD SCI USA, V98, P3410, DOI 10.1073/pnas.051618798; Rangasamy T, 2004, J CLIN INVEST, V114, P1248, DOI 10.1172/JCI200421146; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; Singer JD, 1999, GENE DEV, V13, P2375, DOI 10.1101/gad.13.18.2375; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Stewart D, 2003, J BIOL CHEM, V278, P2396, DOI 10.1074/jbc.M209195200; Wakabayashi N, 2004, P NATL ACAD SCI USA, V101, P2040, DOI 10.1073/pnas.0307301101; Wakabayashi N, 2003, NAT GENET, V35, P238, DOI 10.1038/ng1248; Wild AC, 1999, J BIOL CHEM, V274, P33627, DOI 10.1074/jbc.274.47.33627; Yoh K, 2001, KIDNEY INT, V60, P1343, DOI 10.1046/j.1523-1755.2001.00939.x; Zhang DD, 2003, MOL CELL BIOL, V23, P8137, DOI 10.1128/MCB.23.22.8137-8151.2003; Zhang DD, 2004, MOL CELL BIOL, V24, P10941, DOI 10.1128/MCB.24.24.10941-10953.2004	50	287	300	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	2005	280	37					32485	32492		10.1074/jbc.M503074200	http://dx.doi.org/10.1074/jbc.M503074200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	963HM	16000310	hybrid			2022-12-25	WOS:000231794800056
J	Yew, KH; Hembree, M; Prasadan, K; Preuett, B; McFall, C; Benjes, C; Crowley, A; Sharp, S; Tulachan, S; Mehta, S; Tei, E; Gittes, G				Yew, KH; Hembree, M; Prasadan, K; Preuett, B; McFall, C; Benjes, C; Crowley, A; Sharp, S; Tulachan, S; Mehta, S; Tei, E; Gittes, G			Cross-talk between bone morphogenetic protein and transforming growth factor-beta signaling is essential for exendin-4-induced insulin-positive differentiation of AR42J cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSDUCTION; EXPRESSION; ENDODERM; SMAD1	A key goal of cellular engineering is to manipulate progenitor cells to become beta-cells, allowing cell replacement therapy to cure diabetes mellitus. As a paradigm for cell engineering, we have studied the molecular mechanisms by which AR42J cells become beta-cells. Bone morphogenetic proteins (BMPs), implicated in a myriad of developmental pathways, have not been well studied in insulin-positive differentiation. We found that the canonical intracellular mediators of BMP signaling, Smad-1 and Smad-8, were significantly elevated in AR42J cells undergoing insulin-positive differentiation in response to exendin-4 treatment, suggesting a role for BMP signaling in beta-cell formation. Similarly, endogenous BMP-2 ligand and ALK-1 receptor ( activin receptor-like kinase-1; known to activate Smads 1 and 8) mRNAs were specifically up-regulated in exendin-4-treated AR42J cells. Surprisingly, Smad-1 and Smad-8 levels were suppressed by the addition of BMP-soluble receptor inhibition of BMP ligand binding to its receptor. Here, insulin-positive differentiation was also ablated. BMP-2 ligand antisense also strongly inhibited Smad-1 and Smad-8 expression, again with the abolition of insulin-positive differentiation. These results demonstrate a previously unrecognized key role for BMP signaling in mediating insulin- positive differentiation through the intracellular Smad signaling pathway. In short, BMP signaling may represent a novel downstream target of exendin-4 (glucagon-like peptide 1) signaling and potentially serve as an upstream regulator of transforming growth factor-beta isoform signaling to differentiate the acinar-like AR42J cells into insulin- secreting cells.	Childrens Hosp Pittsburgh, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Gittes, G (corresponding author), Childrens Hosp Pittsburgh, 3705 5th Ave, Pittsburgh, PA 15213 USA.	george.gittes@chp.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK064952, R01DK058400] Funding Source: NIH RePORTER; NIDDK NIH HHS [1 R01 DK064952-01, 1 R01 DK58400-01] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aoki H, 2001, J CELL SCI, V114, P1483; Arora K, 1996, ANN NY ACAD SCI, V785, P80, DOI 10.1111/j.1749-6632.1996.tb56246.x; Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; Brorson M, 2001, HISTOCHEM CELL BIOL, V116, P263, DOI 10.1007/s004180100316; Dick A, 1999, DEV DYNAM, V216, P285, DOI 10.1002/(SICI)1097-0177(199911)216:3<285::AID-DVDY7>3.0.CO;2-L; Hogan BLM, 1996, CURR OPIN GENET DEV, V6, P432, DOI 10.1016/S0959-437X(96)80064-5; Jiang FX, 2002, J CELL SCI, V115, P753; Miyazawa K, 2002, GENES CELLS, V7, P1191, DOI 10.1046/j.1365-2443.2002.00599.x; MonsoroBurq AH, 1996, DEVELOPMENT, V122, P3607; Nishimura R, 2003, FRONT BIOSCI, V8, pS275, DOI 10.2741/1049; Oh SP, 2000, P NATL ACAD SCI USA, V97, P2626, DOI 10.1073/pnas.97.6.2626; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Tiso N, 2002, MECH DEVELOP, V118, P29, DOI 10.1016/S0925-4773(02)00252-6; Tremblay KD, 2001, DEVELOPMENT, V128, P3609; Vrljicak P, 2004, AM J PHYSIOL-RENAL, V286, pF625, DOI 10.1152/ajprenal.00152.2003; Weaver M, 1999, DEVELOPMENT, V126, P4005; Yamashita H, 1996, BONE, V19, P569, DOI 10.1016/S8756-3282(96)00259-1; Yew KH, 2004, DIABETES, V53, P2824, DOI 10.2337/diabetes.53.11.2824	18	32	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	2005	280	37					32209	32217		10.1074/jbc.M505465200	http://dx.doi.org/10.1074/jbc.M505465200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	963HM	16020542	hybrid			2022-12-25	WOS:000231794800022
J	Chen, L; Kurokawa, J; Kass, RS				Chen, L; Kurokawa, J; Kass, RS			Phosphorylation of the A-kinase-anchoring protein Yotiao contributes to protein kinase A regulation of a heart potassium channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AKAP SIGNALING COMPLEXES; LONG-QT SYNDROME; PKA PHOSPHORYLATION; NA+ CHANNEL; RECEPTOR; SUBUNIT; COMPARTMENTATION; REQUIREMENT; SCAFFOLD; BINDING	Regulation of the heart by the sympathetic nervous system, fundamental to the physiological response to stress and exercise, requires coordinated phosphorylation of multiple downstream molecular targets, including the I-Ks (slowly activating potassium current) channel. Sympathetic nervous system stimulation increases intracellular cAMP for which targeted regulation is directed in large part by distinct scaffold or anchoring proteins. Yotiao is an A-kinase-anchoring protein (AKAP) that recruits the cyclic AMP-dependent protein kinase (protein kinase A (PKA)) and protein phosphatase 1 to the carboxyl terminus of the I-Ks channel to form a molecular complex and control its phosphorylation state, crucial to the cardiac cellular response to sympathetic nervous system stimulation. Here we report that Yotiao itself is a substrate for PKA phosphorylation, and we identify a Yotiao amino-terminal (N-T) residue (Ser-43) that is PKA-phosphorylated in response to beta-adrenergic receptor stimulation. The replacement of Ser-43 by Ala ablates the PKA phosphorylation of N-T Yotiao and markedly diminishes the functional response of the wild type and pseudo-phosphorylated I-Ks channel to cAMP but neither prevents the PKA phosphorylation of KCNQ1 nor its binding to Yotiao. These results suggest, for the first time, a critical role for the PKA phosphorylation of an AKAP in the functional regulation of an ion channel protein and postphosphorylation allosteric modulation of the I-Ks channel by Yotiao.	Columbia Univ, Coll Phys & Surg, Dept Pharmacol, New York, NY 10032 USA; Tokyo Med & Dent Univ, Dept Bioinformat Pharmacol, Tokyo 1010062, Japan	Columbia University; Tokyo Medical & Dental University (TMDU)	Kass, RS (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Pharmacol, 630 W 168th St, New York, NY 10032 USA.	rsk20@columbia.edu	Kurokawa, Junko/ABF-7557-2021; Kurokawa, Junko/Q-6287-2017	Kurokawa, Junko/0000-0002-9098-0908; Kurokawa, Junko/0000-0002-9098-0908	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044365] Funding Source: NIH RePORTER; NHLBI NIH HHS [1R01-HL 44365, R01 HL044365-13, R01 HL044365] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abriel H, 2001, CIRC RES, V88, P740, DOI 10.1161/hh0701.089668; Angelo R, 1998, J BIOL CHEM, V273, P14633, DOI 10.1074/jbc.273.23.14633; Bauman AL, 2004, NEUROPHARMACOLOGY, V46, P299, DOI 10.1016/j.neuropharm.2003.09.016; Carnegie GK, 2004, MOL CELL, V15, P889, DOI 10.1016/j.molcel.2004.09.015; Colledge M, 1999, TRENDS CELL BIOL, V9, P216, DOI 10.1016/S0962-8924(99)01558-5; Gray PC, 1997, J BIOL CHEM, V272, P6297, DOI 10.1074/jbc.272.10.6297; Herberg FW, 2000, J MOL BIOL, V298, P329, DOI 10.1006/jmbi.2000.3662; Hoshi N, 2003, NAT NEUROSCI, V6, P564, DOI 10.1038/nn1062; Hulme JT, 2003, P NATL ACAD SCI USA, V100, P13093, DOI 10.1073/pnas.2135335100; Jin J, 2004, CURR BIOL, V14, P1436, DOI 10.1016/j.cub.2004.07.051; Kapiloff MS, 2002, MOL PHARMACOL, V62, P193, DOI 10.1124/mol.62.2.193; Kass RS, 2003, TRENDS CARDIOVAS MED, V13, P52, DOI 10.1016/S1050-1738(02)00211-6; KASS RS, 1982, J PHYSIOL-LONDON, V322, P541, DOI 10.1113/jphysiol.1982.sp014054; Kurokawa J, 2004, P NATL ACAD SCI USA, V101, P16374, DOI 10.1073/pnas.0405583101; Kurokawa J, 2003, P NATL ACAD SCI USA, V100, P2122, DOI 10.1073/pnas.0434935100; Marx SO, 2000, CELL, V101, P365, DOI 10.1016/S0092-8674(00)80847-8; Marx SO, 2002, SCIENCE, V295, P496, DOI 10.1126/science.1066843; Marx SO, 2001, J CELL BIOL, V153, P699, DOI 10.1083/jcb.153.4.699; Michel JJC, 2002, ANNU REV PHARMACOL, V42, P235, DOI 10.1146/annurev.pharmtox.42.083101.135801; Motoike HK, 2004, J GEN PHYSIOL, V123, P155, DOI 10.1085/jgp.200308929; Paavonen KJ, 2001, HEART, V86, P39, DOI 10.1136/heart.86.1.39; Reinitz CA, 1997, ARCH BIOCHEM BIOPHYS, V348, P391, DOI 10.1006/abbi.1997.0401; Tao JC, 2003, EMBO J, V22, P6419, DOI 10.1093/emboj/cdg628; Tasken K, 2004, PHYSIOL REV, V84, P137, DOI 10.1152/physrev.00021.2003; Terrenoire C, 2005, CIRC RES, V96, pE25, DOI 10.1161/01.RES.0000160555.58046.9a; WALSH KB, 1988, SCIENCE, V242, P67, DOI 10.1126/science.2845575; Wong W, 2004, NAT REV MOL CELL BIO, V5, P959, DOI 10.1038/nrm1527	27	66	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	2005	280	36					31347	31352		10.1074/jbc.M505191200	http://dx.doi.org/10.1074/jbc.M505191200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	961LZ	16002409	hybrid			2022-12-25	WOS:000231665200003
J	Gsandtner, I; Charalambous, C; Stefan, E; Ogris, E; Freissmuth, M; Zezula, J				Gsandtner, I; Charalambous, C; Stefan, E; Ogris, E; Freissmuth, M; Zezula, J			Heterotrimeric G protein-independent signaling of a G protein-coupled receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUTEINIZING HORMONE/CHORIOGONADOTROPIN RECEPTOR; MAP KINASE STIMULATION; A(2A)-ADENOSINE RECEPTOR; EXCHANGE FACTOR; BREFELDIN-A; DOWNSTREAM ACTIVATION; ARF6; ARNO; DESENSITIZATION; ENDOCYTOSIS	The A(2A) adenosine receptor is a prototypical G(s)-coupled receptor, but it also signals, e. g. to mitogen-activated protein ( MAP) kinase, via a pathway that is independent of heterotrimeric G proteins. Truncation of the carboxyl terminus affects the strength of the signal through these alternative pathways. In a yeast two-hybrid interaction hunt, we screened a human brain library for proteins that bound to the juxtamembrane portion of the carboxyl terminus of the A(2A) receptor. This approach identified ARNO/cytohesin-2, a nucleotide exchange factor for the small ( monomeric) G proteins of the Arf ( ADP-ribosylation factor) family, as a potential interaction partner. We confirmed a direct interaction by mutual pull down ( of fusion proteins expressed in bacteria) and by immunoprecipitation of the proteins expressed in mammalian cells. To circumvent the long term toxicity associated with overexpression of ARNO/cytohesin-2, we created stable cell lines that stably expressed the A(2A) receptor and where ARNO/cytohesin-2 or the dominant negative version E156K-ARNO/cytohesin-2 was inducible by mifepristone. Cyclic AMP accumulation induced by an A(2A)-specific agonist was neither altered by ARNO/ cytohesin-2 nor by the dominant negative version. This was also true for agonist-induced desensitization. In contrast, expression of dominant negative E156K-ARNO/cytohesin-2 and of dominant negative T27N-Arf6 abrogated the sustained phase of MAP kinase stimulation induced by the A(2A) receptor. We therefore conclude that ARNO/ cytohesin-2 is required to support the alternative, heterotrimeric G protein-independent, signaling pathway of A(2A) receptor, which is stimulation of MAP kinase.	Med Univ Vienna, Inst Pharmacol, Ctr Biomol Med & Pharmacol, A-1090 Vienna, Austria; Med Univ Vienna, Dept Biochem Med, Vienna Bioctr, A-1090 Vienna, Austria	Medical University of Vienna; Medical University of Vienna; Vienna Biocenter (VBC)	Zezula, J (corresponding author), Med Univ Vienna, Inst Pharmacol, Ctr Biomol Med & Pharmacol, Wahringer Str 13A, A-1090 Vienna, Austria.	juergen.zezula@meduniwien.ac.at		Stefan, Eduard/0000-0003-3650-4713; Freissmuth, Michael/0000-0001-9398-1765; Ogris, Egon/0000-0001-5950-9264				Beraud-Dufour S, 1998, EMBO J, V17, P3651, DOI 10.1093/emboj/17.13.3651; Bivona TG, 2003, NATURE, V424, P694, DOI 10.1038/nature01806; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; Claing A, 2001, J BIOL CHEM, V276, P42509, DOI 10.1074/jbc.M108399200; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; Di Fiore PP, 2003, NATURE, V424, P624, DOI 10.1038/424624a; Hernandez-Deviez DJ, 2004, MOL BIOL CELL, V15, P111, DOI 10.1091/mbc.E03-06-0410; Heuss C, 2000, TRENDS NEUROSCI, V23, P469, DOI 10.1016/S0166-2236(00)01643-X; Honda A, 1999, CELL, V99, P521, DOI 10.1016/S0092-8674(00)81540-8; Hunzicker-Dunn M, 2003, J BIOL CHEM, V278, P42744, DOI 10.1074/jbc.M306133200; Klinger M, 2002, CELL SIGNAL, V14, P99, DOI 10.1016/S0898-6568(01)00235-2; Klinger M, 2002, J BIOL CHEM, V277, P32490, DOI 10.1074/jbc.M200556200; Klinger M, 2002, N-S ARCH PHARMACOL, V366, P287, DOI 10.1007/s00210-002-0617-z; Korkhov VM, 2004, J BIOL CHEM, V279, P55728, DOI 10.1074/jbc.M409449200; Kudlacek O, 2001, J BIOL CHEM, V276, P3010, DOI 10.1074/jbc.M007910200; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MASSENBURG D, 1994, P NATL ACAD SCI USA, V91, P11718, DOI 10.1073/pnas.91.24.11718; Miller WE, 2001, CURR OPIN CELL BIOL, V13, P139, DOI 10.1016/S0955-0674(00)00190-3; Mukherjee S, 2001, J BIOL CHEM, V276, P6524, DOI 10.1074/jbc.C000725200; Mukherjee S, 2000, P NATL ACAD SCI USA, V97, P5901, DOI 10.1073/pnas.100127097; NANOFF C, 1993, J RECEPTOR RES, V13, P961, DOI 10.3109/10799899309073703; NANOFF C, 1991, MOL PHARMACOL, V39, P130; Nordstrom JL, 2003, STEROIDS, V68, P1085, DOI 10.1016/j.steroids.2003.07.008; O'Connor V, 1999, SCIENCE, V286, P1180, DOI 10.1126/science.286.5442.1180; Peyroche A, 1999, MOL CELL, V3, P275, DOI 10.1016/S1097-2765(00)80455-4; Premont RT, 1998, P NATL ACAD SCI USA, V95, P14082, DOI 10.1073/pnas.95.24.14082; Radhakrishna H, 1997, J CELL BIOL, V139, P49, DOI 10.1083/jcb.139.1.49; RAMKUMAR V, 1991, MOL PHARMACOL, V40, P639; Santy LC, 2001, J CELL BIOL, V154, P599, DOI 10.1083/jcb.200104019; Sata M, 1999, P NATL ACAD SCI USA, V96, P2752, DOI 10.1073/pnas.96.6.2752; Scholze P, 2002, J BIOL CHEM, V277, P43682, DOI 10.1074/jbc.M205602200; Seidel MG, 1999, J BIOL CHEM, V274, P25833, DOI 10.1074/jbc.274.36.25833; Sexl V, 1997, J BIOL CHEM, V272, P5792, DOI 10.1074/jbc.272.9.5792; Someya A, 2001, P NATL ACAD SCI USA, V98, P2413, DOI 10.1073/pnas.051634798; Song J, 1998, J CELL SCI, V111, P2257; Theis MG, 2004, P NATL ACAD SCI USA, V101, P11221, DOI 10.1073/pnas.0402901101; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Yeong FM, 2003, CURR BIOL, V13, P2058, DOI 10.1016/j.cub.2003.10.032	38	54	55	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	2005	280	36					31898	31905		10.1074/jbc.M506515200	http://dx.doi.org/10.1074/jbc.M506515200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	961LZ	16027149	hybrid			2022-12-25	WOS:000231665200069
J	Suvarna, N; Borgland, SL; Wang, J; Phamluong, K; Auberson, YP; Bonci, A; Ron, D				Suvarna, N; Borgland, SL; Wang, J; Phamluong, K; Auberson, YP; Bonci, A; Ron, D			Ethanol alters trafficking and functional N-methyl-D-aspartate receptor NR2 subunit ratio via H-Ras	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; CELL-SURFACE EXPRESSION; SRC TYROSINE KINASE; NMDA-RECEPTOR; GLUTAMATE RECEPTORS; ACUTE TOLERANCE; FYN-KINASE; C0 DOMAIN; SENSITIVITY; INHIBITION	The N-methyl-D-aspartate receptor (NMDAR) plays a critical role in synaptic plasticity and is one of the main targets for alcohol (ethanol) in the brain. Trafficking of the NMDAR is emerging as a key regulatory mechanism that underlies channel activity and synaptic plasticity. Here we show that exposure of hippocampal neurons to ethanol increases the internalization of the NR2A but not NR2B subunit of the NMDAR via the endocytic pathway. We further observed that ethanol exposure results in NR2A endocytosis through the activation of H-Ras and the inhibition of the tyrosine kinase Src. Importantly, ethanol treatment alters functional subunit composition from NR2A/NR2B- to mainly NR2B-containing NMDARs. Our results suggest that addictive drugs such as ethanol alter NMDAR trafficking and subunit composition. This may be an important mechanism by which ethanol exerts its effects on NMDARs to produce alcohol-induced aberrant plasticity.	Ernest Gallo Clin & Res Ctr, Dept Neurol, Emeryville, CA 94608 USA; Novartis Inst BioMed Res, CH-4002 Basel, Switzerland; Ernest Gallo Res Ctr, Emeryville, CA 94608 USA	University of California System; University of California San Francisco; Ernest Gallo Clinic & Research Center; Novartis; University of California System; University of California San Francisco; Ernest Gallo Clinic & Research Center	Ron, D (corresponding author), Ernest Gallo Clin & Res Ctr, Dept Neurol, 5858 Horton St,Suite 200, Emeryville, CA 94608 USA.	dorit@itsa.ucsf.edu	Wang, Jun/M-2337-2016; Borgland, Stephanie/GPC-5260-2022; Auberson, Yves/AAF-6538-2019; Borgland, Stephanie/M-2936-2016; Wang, Jun/N-8472-2015	Wang, Jun/0000-0002-0085-4722; Borgland, Stephanie/0000-0001-7546-5687; Auberson, Yves/0000-0001-5800-4811; Borgland, Stephanie/0000-0001-7546-5687; Wang, Jun/0000-0002-0085-4722	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA013438] Funding Source: NIH RePORTER; NIAAA NIH HHS [R01AA013438-03] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Allgaier C, 2002, NEUROCHEM INT, V41, P377, DOI 10.1016/S0197-0186(02)00046-3; Alvestad RM, 2003, J BIOL CHEM, V278, P11020, DOI 10.1074/jbc.M210167200; Ambrosini A, 2000, MOL BRAIN RES, V75, P54, DOI 10.1016/S0169-328X(99)00294-6; Anders DL, 1999, ALCOHOL CLIN EXP RES, V23, P357, DOI 10.1111/j.1530-0277.1999.tb04122.x; Anders DL, 2000, J BIOL CHEM, V275, P15019, DOI 10.1074/jbc.275.20.15019; Barria A, 2002, NEURON, V35, P345, DOI 10.1016/S0896-6273(02)00776-6; Blevins T, 1997, J NEUROCHEM, V69, P2345; Brambilla R, 1997, NATURE, V390, P281, DOI 10.1038/36849; CHU B, 1995, J NEUROCHEM, V65, P140; Coyle JT, 2003, ANN NY ACAD SCI, V1003, P318, DOI 10.1196/annals.1300.020; Cull-Candy S, 2001, CURR OPIN NEUROBIOL, V11, P327, DOI 10.1016/S0959-4388(00)00215-4; Diamond I, 1997, PHYSIOL REV, V77, P1, DOI 10.1152/physrev.1997.77.1.1; Dumaz N, 2003, J BIOL CHEM, V278, P29819, DOI 10.1074/jbc.C300182200; Dunah AW, 2004, MOL PHARMACOL, V65, P121, DOI 10.1124/mol.65.1.121; EHLERS MD, 1995, SCIENCE, V269, P1734, DOI 10.1126/science.7569904; Fang M, 2003, J BIOL CHEM, V278, P36669, DOI 10.1074/jbc.M303520200; FARRANT M, 1994, NATURE, V368, P335, DOI 10.1038/368335a0; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Grimwood S, 1996, J NEUROCHEM, V66, P2239; Grosshans DR, 2002, NAT NEUROSCI, V5, P27, DOI 10.1038/nn779; GROSSHANS DR, 2002, SCI STKE, V137, pPL8; GROVER CA, 1994, BRAIN RES, V642, P70, DOI 10.1016/0006-8993(94)90906-7; Hendricson AW, 2002, J PHARMACOL EXP THER, V301, P938, DOI 10.1124/jpet.301.3.938; Honse Y, 2003, NEUROSCIENCE, V122, P689, DOI 10.1016/S0306-4522(03)00603-1; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Krystal JH, 2003, PHARMACOL THERAPEUT, V99, P79, DOI 10.1016/S0163-7258(03)00054-8; Krystal JH, 2003, ANN NY ACAD SCI, V1003, P176, DOI 10.1196/annals.1300.010; Kumari M, 2000, PROG DRUG RES, V54, P152; KUNER T, 1993, NEUROREPORT, V5, P297, DOI 10.1097/00001756-199312000-00029; Lavezzari G, 2003, NEUROPHARMACOLOGY, V45, P729, DOI 10.1016/S0028-3908(03)00308-3; LEON J, 1987, MOL CELL BIOL, V7, P1535, DOI 10.1128/MCB.7.4.1535; Li HF, 2003, BRIT J PHARMACOL, V139, P73, DOI 10.1038/sj.bjp.0705198; Liu LD, 2004, SCIENCE, V304, P1021, DOI 10.1126/science.1096615; LOVINGER DM, 1995, J PHARMACOL EXP THER, V274, P164; LOVINGER DM, 1989, SCIENCE, V243, P1721, DOI 10.1126/science.2467382; LOVINGER DM, 1990, J NEUROSCI, V10, P1372; Ludvig N, 2001, BRAIN RES, V900, P252, DOI 10.1016/S0006-8993(01)02319-8; MALENKA RC, 1993, TRENDS NEUROSCI, V16, P521, DOI 10.1016/0166-2236(93)90197-T; Manabe T, 2000, J NEUROSCI, V20, P2504; MASOOD K, 1994, MOL PHARMACOL, V45, P324; McGough NNH, 2004, J NEUROSCI, V24, P10542, DOI 10.1523/JNEUROSCI.3714-04.2004; MIRSHAHI T, 1995, NEUROPHARMACOLOGY, V34, P347, DOI 10.1016/0028-3908(94)00155-L; Mirshahi T, 1998, J NEUROCHEM, V71, P1095; Miyakawa T, 1997, SCIENCE, V278, P698, DOI 10.1126/science.278.5338.698; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; MORRISETT RA, 1991, NEUROPHARMACOLOGY, V30, P1173, DOI 10.1016/0028-3908(91)90162-5; MORRISETT RA, 1993, J NEUROSCI, V13, P2264; Mu YY, 2003, NEURON, V40, P581, DOI 10.1016/S0896-6273(03)00676-7; Nagy J, 2004, CNS NEUROL DISORD-DR, V3, P169, DOI 10.2174/1568007043337409; Nong Y, 2004, CURR OPIN NEUROBIOL, V14, P353, DOI 10.1016/j.conb.2004.05.001; Nong Y, 2003, NATURE, V422, P302, DOI 10.1038/nature01497; Okabe S, 1999, J NEUROSCI, V19, P7781; Popp RL, 1998, NEUROPHARMACOLOGY, V37, P45, DOI 10.1016/S0028-3908(97)00186-X; Popp RL, 1999, J PHARMACOL EXP THER, V289, P1564; Prybylowski K, 2004, J BIOL CHEM, V279, P9673, DOI 10.1074/jbc.R300029200; Roche KW, 2001, NAT NEUROSCI, V4, P794, DOI 10.1038/90498; Ron D, 2004, NEUROSCIENTIST, V10, P325, DOI 10.1177/1073858404263516; Ronald KM, 2001, J BIOL CHEM, V276, P44729, DOI 10.1074/jbc.M102800200; Salter MW, 2004, NAT REV NEUROSCI, V5, P317, DOI 10.1038/nrn1368; Scott DB, 2003, NEUROPHARMACOLOGY, V45, P755, DOI 10.1016/S0028-3908(03)00250-8; Siggins GR, 2003, ANN NY ACAD SCI, V1003, P196, DOI 10.1196/annals.1300.012; Smothers CT, 2001, NEUROCHEM INT, V38, P333, DOI 10.1016/S0197-0186(00)00094-2; Thornton C, 2003, J BIOL CHEM, V278, P23823, DOI 10.1074/jbc.M302389200; Tovar KR, 2002, NEURON, V34, P253; Ungless MA, 2001, NATURE, V411, P583, DOI 10.1038/35079077; Vissel B, 2001, NAT NEUROSCI, V4, P587, DOI 10.1038/88404; Wadia JS, 2003, CURR PROTEIN PEPT SC, V4, P97, DOI 10.2174/1389203033487289; WANG YT, 1994, NATURE, V369, P233, DOI 10.1038/369233a0; Yaka R, 2003, J NEUROSCI, V23, P3623	70	61	63	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	2005	280	36					31450	31459		10.1074/jbc.M504120200	http://dx.doi.org/10.1074/jbc.M504120200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	961LZ	16009711	hybrid			2022-12-25	WOS:000231665200016
J	Yadav, A; Kalita, A; Dhillon, S; Banerjee, K				Yadav, A; Kalita, A; Dhillon, S; Banerjee, K			JAK/STAT3 pathway is involved in survival of neurons in response to insulin-like growth factor and negatively regulated by suppressor of cytokine signaling-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CILIARY NEUROTROPHIC FACTOR; NECROSIS-FACTOR-ALPHA; FACTOR-I; GENE-EXPRESSION; MAMMALIAN LENS; STAT-PATHWAY; IGF-I; BRAIN; RECEPTOR; ACTIVATION	Janus kinases ( JAK) and signal transducers and activator of transcription ( STAT) proteins are activated in response to many cytokines and growth factors and are well studied in the immune system. This study was conducted to examine the role of the JAK/STAT pathway in neurons in response to tumor necrosis factor-alpha ( TNF alpha) and insulin-like growth factor-1 ( IGF-1), which play a major role during neurodegeneration, and to study their effect on expression of suppressors of cytokine signaling 3 ( SOCS-3), belonging to the novel family of feedback regulators of cytokine and growth factor activities. In this report, we showed that TNF alpha is inhibitory to the survival of primary cortical neurons at higher doses and that IGF-1 can rescue TNF alpha-stimulated cell death. We showed that the JAK/STAT pathway is involved in this rescue as tyrphostin AG490, a specific inhibitor of JAK/STAT, completely inhibits cell survival in response to IGF-1. STAT3 gets tyrosine-phosphorylated and translocated to the nucleus in response to IGF-1. Northern blot, semi-quantitative reverse transcription-PCR, and real time PCR experiments demonstrated that the JAK/STAT pathway also up-regulated SOCS-3 mainly in response to IGF-1. SOCS-3 associated with the IGF receptor and blocked further STAT3 activation. To our knowledge, this is the first report that demonstrated the importance of the JAK/STAT pathway and the role of SOCS-3 in the survival of neurons in response to IGF-1. We have subsequently shown that SOCS-3 overexpression, on one hand, leads to neuroblastoma cell death and on the other hand leads to primary cell differentiation, indicating the involvement of SOCS-3 in cell survival and differentiation.	Natl Inst Immunol, Eukaryot Gene Express Lab, New Delhi 110067, India	Department of Biotechnology (DBT) India; National Institute of Immunology (NII)	Banerjee, K (corresponding author), Natl Inst Immunol, Eukaryot Gene Express Lab, Aruna Asaf Ali Marg, New Delhi 110067, India.	kakoli@nii.res.in		Yadav, Ajay/0000-0003-3321-4198				Bartoe JL, 2002, MOL BRAIN RES, V107, P108, DOI 10.1016/S0169-328X(02)00452-7; Botchkina GI, 1997, MOL MED, V3, P765, DOI 10.1007/BF03401714; Carmichael ST, 2003, CURR OPIN NEUROL, V16, P699, DOI 10.1097/00019052-200312000-00009; CHENG B, 1994, NEURON, V12, P139, DOI 10.1016/0896-6273(94)90159-7; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; De-Fraja C, 2000, INT J DEV NEUROSCI, V18, P439, DOI 10.1016/S0736-5748(00)00007-1; Dey BR, 1998, J BIOL CHEM, V273, P24095, DOI 10.1074/jbc.273.37.24095; Dore S, 1997, TRENDS NEUROSCI, V20, P326; Dunn SL, 2005, MOL ENDOCRINOL, V19, P925, DOI 10.1210/me.2004-0353; Ebong S, 2004, MOL VIS, V10, P122; Ebong S, 2004, INVEST OPHTH VIS SCI, V45, P872, DOI 10.1167/iovs.03-0311; Emanuelli B, 2000, J BIOL CHEM, V275, P15985, DOI 10.1074/jbc.275.21.15985; Emanuelli B, 2001, J BIOL CHEM, V276, P47944, DOI 10.1074/jbc.M104602200; Fujitani Y, 1997, ONCOGENE, V14, P751, DOI 10.1038/sj.onc.1200907; Goldshmit Y, 2004, J BIOL CHEM, V279, P16349, DOI 10.1074/jbc.M312873200; Guan J, 2003, PROG NEUROBIOL, V70, P443, DOI 10.1016/j.pneurobio.2003.08.002; Guan J, 1996, NEUROREPORT, V7, P632, DOI 10.1097/00001756-199601310-00061; HATTTEN MB, 2002, CULTURING NERVE CELL, P419; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Kaur N, 2005, J NEUROCHEM, V92, P1521, DOI 10.1111/j.1471-4159.2004.02990.x; Kaur N, 2002, CELL SIGNAL, V14, P419, DOI 10.1016/S0898-6568(01)00280-7; Kenchappa P, 2004, J NEUROSCI RES, V76, P466, DOI 10.1002/jnr.20081; Kim OS, 2002, J BIOL CHEM, V277, P40594, DOI 10.1074/jbc.M203885200; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Li XX, 1997, MOL CELL BIOL, V17, P2048, DOI 10.1128/MCB.17.4.2048; Mori H, 2004, NAT MED, V10, P739, DOI 10.1038/nm1071; Nicholson SE, 2000, P NATL ACAD SCI USA, V97, P6493, DOI 10.1073/pnas.100135197; Park K, 2004, J NEUROSCI, V24, P10806, DOI 10.1523/JNEUROSCI.3532-04.2004; Peterson WM, 2000, J NEUROSCI, V20, P4081; Rao VLR, 2003, J NEUROSCI RES, V71, P208, DOI 10.1002/jnr.10486; Rui LY, 2002, J BIOL CHEM, V277, P42394, DOI 10.1074/jbc.C200444200; Russo VC, 2004, ENDOCRINOLOGY, V145, P4103, DOI 10.1210/en.2003-1767; Sass G, 2005, BIOCHEM J, V385, P537, DOI 10.1042/BJ20040279; Starr R, 1999, BIOESSAYS, V21, P47, DOI 10.1002/(SICI)1521-1878(199901)21:1<47::AID-BIES6>3.0.CO;2-N; TALLEY AK, 1995, MOL CELL BIOL, V15, P2359; Uddin S, 1997, BLOOD, V90, P2574; Venters HD, 1999, P NATL ACAD SCI USA, V96, P9879, DOI 10.1073/pnas.96.17.9879; Vinkemeier U, 2004, J CELL BIOL, V167, P197, DOI 10.1083/jcb.200407163; Vitkovic L, 2000, J NEUROCHEM, V74, P457, DOI 10.1046/j.1471-4159.2000.740457.x; Wang JP, 2002, J NEUROSCI RES, V67, P423, DOI 10.1002/jnr.10145; Zong CS, 2000, J BIOL CHEM, V275, P15099, DOI 10.1074/jbc.M000089200; Zong CS, 1998, J BIOL CHEM, V273, P28065, DOI 10.1074/jbc.273.43.28065	43	108	117	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	2005	280	36					31830	31840		10.1074/jbc.M501316200	http://dx.doi.org/10.1074/jbc.M501316200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	961LZ	15998644	hybrid			2022-12-25	WOS:000231665200062
J	Anderson, LL; Marshall, GR; Crocker, E; Smith, SO; Baranski, TJ				Anderson, LL; Marshall, GR; Crocker, E; Smith, SO; Baranski, TJ			Motion of carboxyl terminus of G alpha is restricted upon G protein activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYZED NUCLEOTIDE EXCHANGE; HETEROTRIMERIC G-PROTEIN; CRYSTAL-STRUCTURE; BETA-GAMMA; SYNTHETIC PEPTIDES; GTP HYDROLYSIS; BINDING-SITES; RECEPTOR; TRANSDUCIN; SUBUNIT	The carboxyl terminus of the G protein alpha subunit plays a key role in interactions with G protein- coupled receptors. Previous studies that have incorporated co-valently attached probes have demonstrated that the carboxyl terminus undergoes conformational changes upon G protein activation. To examine the conformational changes that occur at the carboxyl terminus of G alpha subunits upon G protein activation in a more native system, we generated a semisynthetic G alpha subunit, site-specifically labeled in its carboxyl terminus with C-13 amino acids. Using expressed protein ligation, 9- mer peptides were ligated to recombinant G alpha(i1) subunits lacking the corresponding carboxyl- terminal residues. In a receptor- G protein reconstitution assay, the truncated G alpha(i1) subunit could not be activated by receptor; whereas the semisynthetic protein demonstrated functionality that was comparable with recombinant G alpha(i1). To study the conformation of the carboxyl terminus of the semisynthetic G protein, we applied high resolution solution NMR to G alpha subunits containing 13C labels at the corresponding sites in G alpha(i1): Leu- 348 ( uniform), Gly-352 ( alpha carbon), and Phe- 354 ( ring). In the GDP- bound state, the spectra of the ligated carboxyl terminus appeared similar to the spectra obtained for C-13- labeled free peptide. Upon titration with increasing concentrations of AlF4-, the C-13 resonances demonstrated a marked loss of signal intensity in the semisynthetic G alpha subunit but not in free peptide subjected to the same conditions. Because AlF4- complexes with GDP to stabilize an activated state of the G alpha subunit, these results suggest that the G alpha carboxyl terminus is highly mobile in its GDP- bound state but adopts an ordered conformation upon activation by AlF4-.	Washington Univ, Dept Med, St Louis, MO 63110 USA; Washington Univ, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA; Washington Univ, Dept Mol Biol, St Louis, MO 63110 USA; Washington Univ, Dept Pharmacol, St Louis, MO 63110 USA; SUNY Stony Brook, Dept Phys & Astron, Stony Brook, NY 11794 USA; SUNY Stony Brook, Ctr Struct Biol, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Baranski, TJ (corresponding author), Washington Univ, Dept Med, 660 S Euclid Ave,Campus Box 8127, St Louis, MO 63110 USA.	baranski@wustl.edu		Marshall, Garland/0000-0002-3098-0332	NATIONAL EYE INSTITUTE [R01EY012113] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063720, R01GM041412] Funding Source: NIH RePORTER; NEI NIH HHS [EY12113] Funding Source: Medline; NIGMS NIH HHS [R01 GM041412, R01 GM063720, T32GM0878, GM63720-01] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ayers B, 1999, BIOPOLYMERS, V51, P343, DOI 10.1002/(SICI)1097-0282(1999)51:5<343::AID-BIP4>3.0.CO;2-W; Conklin BR, 1996, MOL PHARMACOL, V50, P885; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; DAWSON PE, 1994, SCIENCE, V266, P776, DOI 10.1126/science.7973629; DENKER BM, 1992, J BIOL CHEM, V267, P9998; DHANASEKARAN N, 1988, J BIOL CHEM, V263, P17942; DRATZ EA, 1993, NATURE, V363, P276, DOI 10.1038/363276a0; FAWZI AB, 1991, J BIOL CHEM, V266, P12194; HAGA K, 1986, J BIOL CHEM, V261, P133; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; Hamm HE, 2001, P NATL ACAD SCI USA, V98, P4819, DOI 10.1073/pnas.011099798; Hansen JL, 2000, CIRC RES, V87, P753, DOI 10.1161/01.RES.87.9.753; Hellmich MR, 1997, P NATL ACAD SCI USA, V94, P751, DOI 10.1073/pnas.94.2.751; Kisselev OG, 1998, P NATL ACAD SCI USA, V95, P4270, DOI 10.1073/pnas.95.8.4270; Klco JM, 2003, J BIOL CHEM, V278, P35345, DOI 10.1074/jbc.M305606200; Koenig BW, 2002, J MOL BIOL, V322, P441, DOI 10.1016/S0022-2836(02)00745-3; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Marin EP, 2002, BIOCHEMISTRY-US, V41, P6988, DOI 10.1021/bi025514k; Marin EP, 2001, J BIOL CHEM, V276, P27400, DOI 10.1074/jbc.C100198200; Martin EL, 1996, J BIOL CHEM, V271, P361, DOI 10.1074/jbc.271.1.361; MIXON MB, 1995, SCIENCE, V270, P954, DOI 10.1126/science.270.5238.954; Natochin M, 2001, J NEUROCHEM, V77, P202, DOI 10.1046/j.1471-4159.2001.00221.x; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; Onrust R, 1997, SCIENCE, V275, P381, DOI 10.1126/science.275.5298.381; Perler FB, 1998, CELL, V92, P1, DOI 10.1016/S0092-8674(00)80892-2; RASENICK MM, 1994, J BIOL CHEM, V269, P21519; Sheikh SP, 1999, J BIOL CHEM, V274, P17033, DOI 10.1074/jbc.274.24.17033; Skiba NP, 1996, J BIOL CHEM, V271, P413, DOI 10.1074/jbc.271.1.413; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Yang CS, 1999, J BIOL CHEM, V274, P2379, DOI 10.1074/jbc.274.4.2379; Yu B, 1998, J BIOL CHEM, V273, P30183, DOI 10.1074/jbc.273.46.30183	34	20	21	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	2005	280	35					31019	31026		10.1074/jbc.M503690200	http://dx.doi.org/10.1074/jbc.M503690200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	958ZX	15983037	Green Accepted, hybrid			2022-12-25	WOS:000231487800045
J	Chan, SP; Cheng, SC				Chan, SP; Cheng, SC			The Prp19-associated complex is required for specifying interactions of U5 and U6 with pre-mRNA during spliceosome activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE-PAIRING INTERACTION; SMALL NUCLEAR-RNA; PRP19P-ASSOCIATED COMPLEX; FUNCTIONAL-ANALYSIS; SITE SELECTION; CROSS-LINKING; U1 SNRNA; YEAST; PROTEIN; ASSOCIATION	Activation of the spliceosome involves a major structural change in the spliceosome, including release of U1 and U4 small nuclear ribonucleoprotein particles and the addition of a large protein complex, the Prp19-associated complex. We previously showed that the Prp19-associated complex is required for stable association of U5 and U6 with the spliceosome after U4 is released. Changes within the spliceosome upon binding of the Prp19-associated complex include remodeling of the U6/5' splice site interaction and destabilization of Lsm proteins to allow further interaction of U6 with the intron sequence. Here, we further analyzed interactions of U5 and U6 with pre-mRNA at various stages of spliceosome assembly from initial binding of tri- small nuclear ribonucleoprotein complex to the activated spliceosome to reveal stepwise changes of interactions. We demonstrate that both U5 and U6 interacted with pre-mRNA in dynamic manners spanning over a large region of U6 and the 5' exon sequences prior to the activation of the spliceosome. During spliceosome activation, interactions were locked down to small regions, and the Prp19-associated complex was required for defining the specificity of interaction of U5 and U6 with the 5' splice site to stabilize their association with the spliceosome after U4 is dissociated.	Acad Sinica, Inst Mol Biol, Nankang 115, Taiwan	Academia Sinica - Taiwan	Cheng, SC (corresponding author), Acad Sinica, Inst Mol Biol, Nankang 115, Taiwan.	mbscc@ccvax.sinica.edu.tw	Cheng, Soo-Chen/AAZ-7956-2021	Cheng, Soo-Chen/0000-0002-7570-9415; Chan, Shih-Peng/0000-0001-6322-2821				Alvi RK, 2001, RNA, V7, P1013, DOI 10.1017/S135583820101041X; Awasthi S, 2001, J BIOL CHEM, V276, P31004, DOI 10.1074/jbc.M100022200; Brow DA, 2002, ANNU REV GENET, V36, P333, DOI 10.1146/annurev.genet.36.043002.091635; Burge CB, 1999, RNA WORLD, P525; Chan SP, 2003, SCIENCE, V302, P279, DOI 10.1126/science.1086602; Chen CH, 2002, NUCLEIC ACIDS RES, V30, P1029, DOI 10.1093/nar/30.4.1029; Chen CH, 2001, J BIOL CHEM, V276, P488, DOI 10.1074/jbc.M006958200; Chen HR, 1998, MOL CELL BIOL, V18, P2196, DOI 10.1128/MCB.18.4.2196; Chen JYF, 2001, MOL CELL, V7, P227, DOI 10.1016/S1097-2765(01)00170-8; CHENG SC, 1994, NUCLEIC ACIDS RES, V22, P1548, DOI 10.1093/nar/22.9.1548; CHENG SC, 1990, METHOD ENZYMOL, V181, P89; FromontRacine M, 1997, NAT GENET, V16, P277, DOI 10.1038/ng0797-277; Johnson TL, 2001, GENE DEV, V15, P1957, DOI 10.1101/gad.895601; Kuhn AN, 1999, MOL CELL, V3, P65, DOI 10.1016/S1097-2765(00)80175-6; LESSER CF, 1993, SCIENCE, V262, P1982, DOI 10.1126/science.8266093; Li ZR, 1996, RNA, V2, P879; LIN RJ, 1985, J BIOL CHEM, V260, P4780; MADHANI HD, 1992, CELL, V71, P803, DOI 10.1016/0092-8674(92)90556-R; Maroney PA, 2000, MOL CELL, V6, P317, DOI 10.1016/S1097-2765(00)00032-0; Newman AJ, 1995, RNA, V1, P968; Newman AJ, 1997, EMBO J, V16, P5797, DOI 10.1093/emboj/16.19.5797; NEWMAN AJ, 1992, CELL, V68, P743, DOI 10.1016/0092-8674(92)90149-7; O'Keefe RT, 1998, EMBO J, V17, P565, DOI 10.1093/emboj/17.2.565; Raghunathan PL, 1998, CURR BIOL, V8, P847, DOI 10.1016/S0960-9822(07)00345-4; SAWA H, 1992, P NATL ACAD SCI USA, V89, P11269, DOI 10.1073/pnas.89.23.11269; SAWA H, 1992, GENE DEV, V6, P244, DOI 10.1101/gad.6.2.244; SERAPHIN B, 1988, EMBO J, V7, P2533, DOI 10.1002/j.1460-2075.1988.tb03101.x; SILICIANO PG, 1988, GENE DEV, V2, P1258, DOI 10.1101/gad.2.10.1258; SONTHEIMER EJ, 1993, SCIENCE, V262, P1989, DOI 10.1126/science.8266094; Staley JP, 1998, CELL, V92, P315, DOI 10.1016/S0092-8674(00)80925-3; TARN WY, 1993, P NATL ACAD SCI USA, V90, P10821, DOI 10.1073/pnas.90.22.10821; TARN WY, 1994, EMBO J, V13, P2421, DOI 10.1002/j.1460-2075.1994.tb06527.x; Tsai WY, 1999, J BIOL CHEM, V274, P9455, DOI 10.1074/jbc.274.14.9455; van Nues RW, 2001, GENETICS, V157, P1451; Will CL, 1997, CURR OPIN CELL BIOL, V9, P320, DOI 10.1016/S0955-0674(97)80003-8; WU J, 1989, GENE DEV, V3, P1553, DOI 10.1101/gad.3.10.1553; WYATT JR, 1992, GENE DEV, V6, P2542, DOI 10.1101/gad.6.12b.2542; ZHUANG Y, 1986, CELL, V46, P827, DOI 10.1016/0092-8674(86)90064-4; ZHUANG Y, 1989, GENE DEV, V3, P1545, DOI 10.1101/gad.3.10.1545	39	87	88	2	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	2005	280	35					31190	31199		10.1074/jbc.M505060200	http://dx.doi.org/10.1074/jbc.M505060200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	958ZX	15994330	hybrid			2022-12-25	WOS:000231487800066
J	Magdesian, MH; Nery, AA; Martins, AHB; Juliano, MA; Juliano, L; Ulrich, H; Ferreira, ST				Magdesian, MH; Nery, AA; Martins, AHB; Juliano, MA; Juliano, L; Ulrich, H; Ferreira, ST			Peptide blockers of the inhibition of neuronal nicotinic acetylcholine receptors by amyloid beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; PROTEIN; IDENTIFICATION; BETA-AMYLOID(1-42); NEUROTOXICITY; GENERATION; BINDING	Alzheimer disease ( AD) is characterized by accumulation of the neurotoxic amyloid beta peptide ( A beta) and by the loss of cholinergic neurons and nicotinic acetylcholine receptors ( nAChRs) throughout the brain. Direct inhibition of nAChRs by A beta has also been suggested to contribute to cholinergic dysfunction in AD. In an effort to find ligands capable of blocking A beta- induced inhibition of nAChRs, we have screened a phage display library to identify peptides that bind to A beta. Using this approach, we identified a heptapeptide denoted IQ, which binds with nanomolar affinity to A beta and is homologous to the acetylcholine- binding protein and to most subtypes of nAChRs. Rapid kinetic whole- cell current- recording measurements showed that A beta inhibits nAChR function in a dose- dependent manner in neuronal differentiated PC12 cells and that nanomolar concentrations of IQ completely block the inhibition by A beta. These results indicate that the A beta binding site in nAChRs is homologous to the IQ peptide and that this is a relevant target for A beta neurotoxicity in AD and, more generally, for the regulation of nAChR function by soluble A beta in a physiological context. Furthermore, the results suggest that the IQ peptide may be a lead for the development of novel drugs to block the inhibition of nAChRs in AD.	Univ Fed Rio de Janeiro, Inst Bioquim Med, Programa Bioquim & Biofis Celular, BR-21944590 Rio De Janeiro, RJ, Brazil; Univ Sao Paulo, Inst Quim, Dept Bioquim, BR-05513970 Sao Paulo, Brazil; Univ Fed Sao Paulo, Dept Biofis, BR-04044020 Sao Paulo, Brazil	Universidade Federal do Rio de Janeiro; Universidade de Sao Paulo; Universidade Federal de Sao Paulo (UNIFESP)	Ferreira, ST (corresponding author), Univ Fed Rio de Janeiro, Inst Bioquim Med, Programa Bioquim & Biofis Celular, Av Brigadeiro Trompowsky S-N,Bloco H Sala 19,CCS, BR-21944590 Rio De Janeiro, RJ, Brazil.	ferreira@bioqmed.ufrj.br	Ulrich, Henning/C-5245-2013; Ferreira, Sergio/AAZ-1576-2020; Juliano, Luiz/D-7204-2012	Ulrich, Henning/0000-0002-2114-3815; Ferreira, Sergio/0000-0001-7160-9866; Juliano, Luiz/0000-0002-5589-2822				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Azzazy HME, 2002, CLIN BIOCHEM, V35, P425, DOI 10.1016/S0009-9120(02)00343-0; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; Celie PHN, 2004, NEURON, V41, P907, DOI 10.1016/S0896-6273(04)00115-1; CORRINGER PJ, 1995, J BIOL CHEM, V270, P11749, DOI 10.1074/jbc.270.20.11749; De Felice FG, 2002, CELL MOL NEUROBIOL, V22, P545, DOI 10.1023/A:1021832302524; Dineley KT, 2002, J BIOL CHEM, V277, P25056, DOI 10.1074/jbc.M200066200; Espinoza-Fonseca LM, 2004, BIOCHEM BIOPH RES CO, V320, P587, DOI 10.1016/j.bbrc.2004.05.207; Grassi F, 2003, J PHYSIOL-LONDON, V547, P147, DOI 10.1113/jphysiol.2002.035436; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hartley DM, 1999, J NEUROSCI, V19, P8876, DOI 10.1523/JNEUROSCI.19-20-08876.1999; Hess GP, 2003, BIOCHEMISTRY-US, V42, P6106, DOI 10.1021/bi020677u; HO PL, 1992, J CELL PHYSIOL, V150, P647, DOI 10.1002/jcp.1041500326; JARRETT JT, 1993, ANN NY ACAD SCI, V695, P144, DOI 10.1111/j.1749-6632.1993.tb23043.x; Kang CK, 2003, NEUROBIOL DIS, V14, P146, DOI 10.1016/S0969-9961(03)00105-0; Klein WL, 2001, TRENDS NEUROSCI, V24, P219, DOI 10.1016/S0166-2236(00)01749-5; Lewczuk P, 2004, NEUROBIOL AGING, V25, P273, DOI 10.1016/S0197-4580(03)00086-1; Liu QS, 2001, P NATL ACAD SCI USA, V98, P4734, DOI 10.1073/pnas.081553598; Louzada PR, 2004, FASEB J, V18, P511, DOI 10.1096/fj.03-0739com; Magdesian MH, 2001, J BIOL CHEM, V276, P19382, DOI 10.1074/jbc.M011474200; Martin SE, 2004, BRAIN RES, V1022, P254, DOI 10.1016/j.brainres.2004.07.016; MIRZABEKOV T, 1994, BIOCHEM BIOPH RES CO, V202, P1142, DOI 10.1006/bbrc.1994.2047; Nagele RG, 2002, NEUROSCIENCE, V110, P199, DOI 10.1016/S0306-4522(01)00460-2; Nishiki T, 1997, BIOCHEM BIOPH RES CO, V239, P57, DOI 10.1006/bbrc.1997.7427; Nordberg A, 2001, BIOL PSYCHIAT, V49, P200, DOI 10.1016/S0006-3223(00)01125-2; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Stephan A, 2001, J NEUROSCI, V21, P5703, DOI 10.1523/JNEUROSCI.21-15-05703.2001; TERRY RD, 1991, ANN NEUROL, V30, P572, DOI 10.1002/ana.410300410; Tozaki H, 2002, BIOCHEM BIOPH RES CO, V294, P42, DOI 10.1016/S0006-291X(02)00429-1; UDGAONKAR JB, 1987, P NATL ACAD SCI USA, V84, P8758, DOI 10.1073/pnas.84.24.8758; Wang HY, 2000, J BIOL CHEM, V275, P5626, DOI 10.1074/jbc.275.8.5626; Wiesehan K, 2003, CHEMBIOCHEM, V4, P748, DOI 10.1002/cbic.200300631; Wu J, 2004, J BIOL CHEM, V279, P37842, DOI 10.1074/jbc.M400335200; Ye CP, 2004, NEUROSCI LETT, V366, P320, DOI 10.1016/j.neulet.2004.05.060	34	46	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	2005	280	35					31085	31090		10.1074/jbc.M502406200	http://dx.doi.org/10.1074/jbc.M502406200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	958ZX	15987688	hybrid			2022-12-25	WOS:000231487800053
J	Carrotta, R; Manno, M; Bulone, D; Martorana, V; San Biagio, PL				Carrotta, R; Manno, M; Bulone, D; Martorana, V; San Biagio, PL			Protofibril formation of amyloid beta-protein at low pH via a non-cooperative elongation mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALTERNATE AGGREGATION PATHWAYS; ATOMIC-FORCE MICROSCOPY; IN-VITRO MODEL; ALZHEIMERS-DISEASE; FIBRIL GROWTH; KINETICS; FIBRILLOGENESIS; PEPTIDE; OLIGOMERS; ASSOCIATION	Deposition of the amyloid beta-protein (A beta) in senile or diffuse plaques is a distinctive feature of Alzheimer's disease. The role of A beta aggregates in the etiology of the disease is still controversial. The formation of linear aggregates, known as amyloid fibrils, has been proposed as the onset and the cause of pathological deposition. Yet, recent findings suggest that a more crucial role is played by prefibrillar oligomeric assemblies of A beta that are highly toxic in the extracellular environment. In the present work, the mechanism of protofibril formation is studied at pH 3.1, starting from a solution of oligomeric precursors. By combining static light scattering and photon correlation spectroscopy, the growth of the mass and the size of aggregates are determined at different temperatures. Analysis and scaling of kinetic data reveal that under the studied conditions protofibrils are formed via a single non-cooperative elongation mechanism, not prompted by nucleation. This process is well described as a linear colloidal aggregation due to diffusion and coalescence of growing aggregates. The rate of elongation follows an Arrhenius law with an activation enthalpy of 15 kcal mol(-1). Such a value points to a conformational change of peptides or oligomers being involved in binding to protofibrils or in general to a local reorganization of each aggregate. These results contribute to establishing a clearer relation at the molecular level between the fibrillation mechanism and fibrillar precursors. The observation of a non-cooperative aggregation pathway supports the hypothesis that amyloid formation may represent an escape route from a dangerous condition, induced by the presence of toxic oligomeric species.	Italian Natl Res Council, Inst Biophys, I-90146 Palermo, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biofisica (IBF-CNR)	Manno, M (corresponding author), Italian Natl Res Council, Inst Biophys, Via U La Malfa 153, I-90146 Palermo, Italy.	mauro.manno@pa.ibf.cnr.it	Manno, Mauro/F-1385-2010; bulone, donatella/AAB-6116-2022	Manno, Mauro/0000-0001-9843-0428; bulone, donatella/0000-0002-5841-9133; Martorana, Vincenzo/0000-0001-7092-6077; Carrotta, Rita/0000-0003-4628-2819; SAN BIAGIO, PIER LUIGI/0000-0002-4622-7361				Ban T, 2004, J MOL BIOL, V344, P757, DOI 10.1016/j.jmb.2004.09.078; Bauer R, 2000, BIOPHYS J, V79, P1030, DOI 10.1016/S0006-3495(00)76357-0; BERNE B. J., 1976, DYNAMIC LIGHT SCATTE; Bitan G, 2003, P NATL ACAD SCI USA, V100, P330, DOI 10.1073/pnas.222681699; Bitan G, 2001, J BIOL CHEM, V276, P35176, DOI 10.1074/jbc.M102223200; Blackley HKL, 2000, J MOL BIOL, V298, P833, DOI 10.1006/jmbi.2000.3711; Blackley HKL, 1999, EXP NEUROL, V158, P437, DOI 10.1006/exnr.1999.7114; Bulone D, 2001, BIOPHYS CHEM, V91, P61, DOI 10.1016/S0301-4622(01)00155-7; Carrotta R, 2001, PROTEIN SCI, V10, P1312, DOI 10.1110/ps.42501; Chandrasekhar S, 1943, REV MOD PHYS, V15, P0001, DOI 10.1103/RevModPhys.15.1; Chiti F, 1999, P NATL ACAD SCI USA, V96, P3590, DOI 10.1073/pnas.96.7.3590; Crescenzi O, 2002, EUR J BIOCHEM, V269, P5642, DOI 10.1046/j.1432-1033.2002.03271.x; DEGENNES PG, 1979, SCALING CONCEPTS POL, P38; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; Family F., 1984, KINETICS AGGREGATION; Fezoui Y, 2002, J BIOL CHEM, V277, P36948, DOI 10.1074/jbc.M204168200; Flyvbjerg H, 1996, P NATL ACAD SCI USA, V93, P5975, DOI 10.1073/pnas.93.12.5975; Gorman PM, 2003, J MOL BIOL, V325, P743, DOI 10.1016/S0022-2836(02)01279-2; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Harper JD, 1999, BIOCHEMISTRY-US, V38, P8972, DOI 10.1021/bi9904149; Harper JD, 1997, ANNU REV BIOCHEM, V66, P385, DOI 10.1146/annurev.biochem.66.1.385; HILL TL, 1983, BIOPHYS J, V44, P285, DOI 10.1016/S0006-3495(83)84301-X; Hoshi M, 2003, P NATL ACAD SCI USA, V100, P6370, DOI 10.1073/pnas.1237107100; Huang THJ, 2000, J MOL BIOL, V297, P73, DOI 10.1006/jmbi.2000.3559; Huang THJ, 2000, J BIOL CHEM, V275, P36436, DOI 10.1074/jbc.M005698200; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; Kelly JW, 1996, CURR OPIN STRUC BIOL, V6, P11, DOI 10.1016/S0959-440X(96)80089-3; Kheterpal I, 2003, BIOCHEMISTRY-US, V42, P14092, DOI 10.1021/bi0357816; Khurana R, 2003, BIOPHYS J, V85, P1135, DOI 10.1016/S0006-3495(03)74550-0; Kirkitadze MD, 2001, J MOL BIOL, V312, P1103, DOI 10.1006/jmbi.2001.4970; Kirkitadze MD, 2002, J NEUROSCI RES, V69, P567, DOI 10.1002/jnr.10328; Klein WL, 2004, NEUROBIOL AGING, V25, P569, DOI 10.1016/j.neurobiolaging.2004.02.010; Klug GMJA, 2003, EUR J BIOCHEM, V270, P4282, DOI 10.1046/j.1432-1033.2003.03815.x; Krapivsky PL, 1996, PHYS REV E, V54, P3553, DOI 10.1103/PhysRevE.54.3553; Kuo YM, 1996, J BIOL CHEM, V271, P4077; Kusumoto Y, 1998, P NATL ACAD SCI USA, V95, P12277, DOI 10.1073/pnas.95.21.12277; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Lansbury PT, 1999, P NATL ACAD SCI USA, V96, P3342, DOI 10.1073/pnas.96.7.3342; Lashuel HA, 2002, NATURE, V418, P291, DOI 10.1038/418291a; Lomakin A, 1997, P NATL ACAD SCI USA, V94, P7942, DOI 10.1073/pnas.94.15.7942; Lomakin A, 1996, P NATL ACAD SCI USA, V93, P1125, DOI 10.1073/pnas.93.3.1125; MAGID L, 1993, DYNAMIC LIGHT SCATTE, P554; McLaurin J, 1996, J BIOL CHEM, V271, P26482, DOI 10.1074/jbc.271.43.26482; Modler AJ, 2003, J MOL BIOL, V325, P135, DOI 10.1016/S0022-2836(02)01175-0; Murphy RM, 2000, J STRUCT BIOL, V130, P109, DOI 10.1006/jsbi.2000.4253; Naiki H, 1999, METHOD ENZYMOL, V309, P305; Nichols MR, 2002, BIOCHEMISTRY-US, V41, P6115, DOI 10.1021/bi015985r; NICOLAI T, 1993, LIGHT SCATTERING PRI, P201; OLIVIER BJ, 1990, PHYS REV A, V41, P2093, DOI 10.1103/PhysRevA.41.2093; Oosawa F., 1975, THERMODYNAMICS POLYM; Pallitto MM, 2001, BIOPHYS J, V81, P1805, DOI 10.1016/S0006-3495(01)75831-6; PORTE G, 1981, J PHYS CHEM-US, V85, P2511, DOI 10.1021/j150617a020; Relini A, 2004, J MOL BIOL, V338, P943, DOI 10.1016/j.jmb.2004.03.054; Rochet JC, 2000, CURR OPIN STRUC BIOL, V10, P60, DOI 10.1016/S0959-440X(99)00049-4; Roher AE, 1996, J BIOL CHEM, V271, P20631, DOI 10.1074/jbc.271.34.20631; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; Selkoe DJ, 2002, ANNU REV GENOM HUM G, V3, P67, DOI 10.1146/annurev.genom.3.022502.103022; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; SHEN CL, 1994, BIOPHYS J, V67, P1238, DOI 10.1016/S0006-3495(94)80593-4; Stefani M, 2003, J MOL MED, V81, P678, DOI 10.1007/s00109-003-0464-5; Stepanek P., 1993, DYNAMIC LIGHT SCATTE, P177; Stine WB, 2003, J BIOL CHEM, V278, P11612, DOI 10.1074/jbc.M210207200; TAYLOR TW, 1987, PHYS REV A, V36, P5415, DOI 10.1103/PhysRevA.36.5415; TERRY RD, 1991, ANN NEUROL, V30, P572, DOI 10.1002/ana.410300410; Thunecke M, 1998, J PEPT RES, V52, P509; TIRADO MM, 1984, J CHEM PHYS, V81, P2047, DOI 10.1063/1.447827; TOMSKI SJ, 1992, ARCH BIOCHEM BIOPHYS, V294, P630, DOI 10.1016/0003-9861(92)90735-F; VANDONGEN PGJ, 1985, PHYS REV LETT, V54, P1396, DOI 10.1103/PhysRevLett.54.1396; VICSEK T, 1984, PHYS REV LETT, V52, P1669, DOI 10.1103/PhysRevLett.52.1669; Walsh DM, 1997, J BIOL CHEM, V272, P22364, DOI 10.1074/jbc.272.35.22364; Walsh DM, 1999, J BIOL CHEM, V274, P25945, DOI 10.1074/jbc.274.36.25945; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; WEITZ DA, 1986, PHYS REV LETT, V57, P2037, DOI 10.1103/PhysRevLett.57.2037; WEITZ DA, 1984, PHYS REV LETT, V53, P1657, DOI 10.1103/PhysRevLett.53.1657; Westlind-Danielsson A, 2001, BIOCHEMISTRY-US, V40, P14736, DOI 10.1021/bi010375c; Xu SH, 2001, BIOPHYS J, V81, P446, DOI 10.1016/S0006-3495(01)75712-8; YAMAKAWA H, 1973, MACROMOLECULES, V6, P407, DOI 10.1021/ma60033a018; Yip CM, 2001, BIOPHYS J, V80, P1359, DOI 10.1016/S0006-3495(01)76109-7; Yong W, 2002, P NATL ACAD SCI USA, V99, P150, DOI 10.1073/pnas.012584899	79	103	106	0	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	2005	280	34					30001	30008		10.1074/jbc.M500052200	http://dx.doi.org/10.1074/jbc.M500052200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	957IC	15985437	hybrid			2022-12-25	WOS:000231362500004
J	Singh, D; Solan, JL; Taffet, SM; Javier, R; Lampe, PD				Singh, D; Solan, JL; Taffet, SM; Javier, R; Lampe, PD			Connexin 43 interacts with zona occludens-1 and-2 proteins in a cell cycle stage-specific manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAP-JUNCTION PROTEIN; TUMOR-SUPPRESSOR PROTEIN; TIGHT JUNCTION; C-SRC; TISSUE DISTRIBUTION; ZONULA OCCLUDENS-1; POSSIBLE MECHANISM; MOLECULAR-CLONING; CARDIAC MYOCYTES; PDZ DOMAINS	Gap junction channels play an important role in cell growth control, secretion and embryonic development. Gap junctional communication and channel assembly can be regulated by protein-protein interaction with kinases and phosphatases. We have utilized tandem mass spectrometry ( MS/MS) sequence analysis as a screen to identify proteins from cell lysates that interact with the C-terminal cytoplasmic region of connexin 43 ( Cx43). MS/MS analysis of tryptic fragments yielded several proteins including zona occludens-1 ( ZO-1), a structural protein previously identified to interact with Cx43, and ZO-2, a potential novel interacting partner. We confirmed the interaction of ZO-2 with Cx43 by using a combination of fusion protein "pull down," co-immunoprecipitation, and co-localization experiments. We show that the C-terminal region of Cx43 is necessary for interaction with the PDZ2 domain of ZO-2. Far Western analysis revealed that ZO-2 can directly bind to Cx43 independent of other interacting partners. Immunofluorescence studies indicate that both ZO-1 and ZO-2 can co-localize with Cx43 within the plasma membrane at apparent gap junctional structures. We examined Cx43 interaction with ZO-1 and ZO-2 at different stages of the cell cycle and found that Cx43 had a strong preference for interaction with ZO-1 during G(0), whereas ZO-2 interaction occurred approximately equally during G(0) and S phases. Since essentially all of the Cx43 in G(0) cells is assembled into Triton X-100-resistant junctions, Cx43ZO-1 interaction may contribute to their stability.	Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98109 USA; Univ Washington, Dept Pathobiol, Seattle, WA 98195 USA; SUNY Upstate Med Univ, Dept Microbiol, Syracuse, NY 13210 USA; Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; Baylor College of Medicine	Lampe, PD (corresponding author), Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, POB 19024,Mailstop M5C800,1100 Fairview Ave N, Seattle, WA 98109 USA.	plampe@fhcrc.org			NCI NIH HHS [R01 CA058541] Funding Source: Medline; NIAMS NIH HHS [AR47963, R01 AR047963] Funding Source: Medline; NIGMS NIH HHS [R01 GM055632, GM55632] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058541] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047963] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055632] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON JM, 1995, AM J PHYSIOL-GASTR L, V269, pG467, DOI 10.1152/ajpgi.1995.269.4.G467; Barker RJ, 2002, CIRC RES, V90, P317, DOI 10.1161/hh0302.104471; Bowling N, 2001, J MOL CELL CARDIOL, V33, P789, DOI 10.1006/jmcc.2000.1349; Butkevich E, 2004, CURR BIOL, V14, P650, DOI 10.1016/j.cub.2004.03.063; Cooper CD, 2002, J BIOL CHEM, V277, P44962, DOI 10.1074/jbc.M209427200; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; Fu CT, 2004, J BIOL CHEM, V279, P36943, DOI 10.1074/jbc.M403952200; Gellhaus A, 2004, J BIOL CHEM, V279, P36931, DOI 10.1074/jbc.M404073200; Giepmans BNG, 2004, CARDIOVASC RES, V62, P233, DOI 10.1016/j.cardiores.2003.12.009; Giepmans BNG, 2001, CELL COMMUN ADHES, V8, P219, DOI 10.3109/15419060109080727; Giepmans BNG, 2001, J BIOL CHEM, V276, P8544, DOI 10.1074/jbc.M005847200; Giepmans BNG, 1998, CURR BIOL, V8, P931, DOI 10.1016/S0960-9822(07)00375-2; Glaunsinger BA, 2001, EMBO J, V20, P5578, DOI 10.1093/emboj/20.20.5578; Goldberg GS, 2002, J BIOL CHEM, V277, P36725, DOI 10.1074/jbc.M109797200; GUMBINER B, 1991, P NATL ACAD SCI USA, V88, P3460, DOI 10.1073/pnas.88.8.3460; Haskins J, 1998, J CELL BIOL, V141, P199, DOI 10.1083/jcb.141.1.199; JESAITIS LA, 1994, J CELL BIOL, V124, P949, DOI 10.1083/jcb.124.6.949; Kamberov E, 2000, J BIOL CHEM, V275, P11425, DOI 10.1074/jbc.275.15.11425; Kausalya PJ, 2001, FEBS LETT, V505, P92, DOI 10.1016/S0014-5793(01)02786-7; Khokhlatchev A, 1997, J BIOL CHEM, V272, P11057; Laing JG, 2001, J BIOL CHEM, V276, P23051, DOI 10.1074/jbc.M100303200; Lampe PD, 1998, J CELL SCI, V111, P833; Link AJ, 1999, NAT BIOTECHNOL, V17, P676, DOI 10.1038/10890; MUSIL LS, 1991, J CELL BIOL, V115, P1357, DOI 10.1083/jcb.115.5.1357; MUSIL LS, 1990, J CELL BIOL, V111, P2077, DOI 10.1083/jcb.111.5.2077; Nielsen PA, 2002, J BIOL CHEM, V277, P38272, DOI 10.1074/jbc.M205348200; Segretain D, 2004, BIOCHIMIE, V86, P241, DOI 10.1016/j.biochi.2004.05.003; Seki A, 2004, CIRC RES, V95, P22, DOI 10.1161/01.RES.0000140737.62245.c5; Singh D, 2003, CELL COMMUN ADHES, V10, P215, DOI 10.1080/714040430; Sohl G, 2004, CARDIOVASC RES, V62, P228, DOI 10.1016/j.cardiores.2003.11.013; Solan JL, 2003, J CELL SCI, V116, P2203, DOI 10.1242/jcs.00428; Solan JL, 2005, BBA-BIOMEMBRANES, V1711, P154, DOI 10.1016/j.bbamem.2004.09.013; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Sorgen PL, 2004, J BIOL CHEM, V279, P54695, DOI 10.1074/jbc.M409552200; Toyofuku T, 1998, J BIOL CHEM, V273, P12725, DOI 10.1074/jbc.273.21.12725; Toyofuku T, 2001, J BIOL CHEM, V276, P1780, DOI 10.1074/jbc.M005826200; Umeda K, 2004, J BIOL CHEM, V279, P44785, DOI 10.1074/jbc.M406563200; Wei CJ, 2004, ANNU REV CELL DEV BI, V20, P811, DOI 10.1146/annurev.cellbio.19.111301.144309; White TW, 1999, ANNU REV PHYSIOL, V61, P283, DOI 10.1146/annurev.physiol.61.1.283; Wittchen ES, 1999, J BIOL CHEM, V274, P35179, DOI 10.1074/jbc.274.49.35179; Wu JC, 2003, J CELL BIOCHEM, V88, P823, DOI 10.1002/jcb.10390; YATES JR, 1995, ANAL CHEM, V67, P1426, DOI 10.1021/ac00104a020	43	106	111	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	2005	280	34					30416	30421		10.1074/jbc.M506799200	http://dx.doi.org/10.1074/jbc.M506799200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	957IC	15980428	hybrid, Green Accepted			2022-12-25	WOS:000231362500054
J	Cano, E; Canellada, A; Minami, T; Iglesias, T; Redondo, JM				Cano, E; Canellada, A; Minami, T; Iglesias, T; Redondo, JM			Depolarization of neural cells induces transcription of the down syndrome critical region 1 isoform 4 via a calcineurin/nuclear factor of activated T cells-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNDROME CRITICAL REGION; DOWN-SYNDROME; GENE-EXPRESSION; INHIBITS CALCINEURIN; CYCLOSPORINE-A; NUCLEAR FACTOR; MESSENGER-RNA; ENDOGENOUS INHIBITOR; ENDOTHELIAL-CELLS; DSCR1 ADAPT78	In this study we showed that the transcriptional regulation of Down syndrome critical region isoform 4 (DSCR1.4) is mediated by the calcineurin/nuclear factor of activated T cells (NFAT) pathway in neural cells. Stimuli that elicit an increase in the intracellular concentrations of calcium, such as membrane depolarization, induced de novo transcription of DSCR1.4, with mRNA expression peaking after 4 h and then declining. Action via the physiologically relevant L-type calcium channel was confirmed by blockade with nifedipine and verapamil. This calcium-dependent transcription of DSCR1.4 was inhibited by the calcineurin inhibitors cyclosporin A and FK506. Deletional analysis showed that the calcium- and calcineurin-dependent activation is mediated by the promoter region between nucleotides -350 and -166, a region that contains putative NFAT-binding motifs. Exogenous NFATc2 potently augmented the DSCR1.4 promoter transcriptional activity, and the involvement of endogenous NFAT signaling pathway in DSCR1.4 transcription was confirmed by the suppression of depolarization-inducible promoter activity with the NFAT inhibitor peptide VIVIT. Exogenous overexpression of DSCR1 protein (calcipressin 1) resulted in the inhibition of the transcription of DSCR1.4 and NFAT-dependent signaling. These findings suggest that calcineurin-dependent induction of DSCR1.4 product may represent an important auto-regulatory mechanism for the homeostatic control of NFAT signaling in neural cells.	Ctr Nacl Invest Cardiovasc, E-28029 Madrid, Spain; Univ Autonoma Madrid, Fac Ciencias, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain; Univ Tokyo, Res Ctr Adv Sci & Technol, Tokyo 1538904, Japan; Inst Invest Biomed Alberto Sols, Madrid 28029, Spain	Centro Nacional de Investigaciones Cardiovasculares (CNIC); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); University of Tokyo; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)	Redondo, JM (corresponding author), Ctr Nacl Invest Cardiovasc, Melchor Fernandez Almagro 3, E-28029 Madrid, Spain.	jmredondo@cnic.es	Vacas, Teresa Iglesias/ABF-8663-2020; Redondo, Juan Miguel/H-6351-2015; Cano, Eva/A-2049-2010	Vacas, Teresa Iglesias/0000-0002-4326-9005; Redondo, Juan Miguel/0000-0001-5779-9122; Cano, Eva/0000-0003-2750-6135				Aramburu J, 1999, SCIENCE, V285, P2129, DOI 10.1126/science.285.5436.2129; Armesilla AL, 1999, MOL CELL BIOL, V19, P2032; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Cao X, 2002, BIOCHEM J, V367, P459, DOI 10.1042/BJ20011797; Casas C, 2001, MECH DEVELOP, V101, P289, DOI 10.1016/S0925-4773(00)00583-9; Chen L, 1999, COLD SPRING HARB SYM, V64, P527, DOI 10.1101/sqb.1999.64.527; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; Crawford DR, 1997, ARCH BIOCHEM BIOPHYS, V342, P6, DOI 10.1006/abbi.1997.0109; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; Ermak G, 2002, FASEB J, V16, DOI 10.1096/fj.01-0846com; Ermak G, 2002, DRUG TODAY, V38, P509, DOI 10.1358/dot.2002.38.7.704681; Ermak G, 2001, J BIOL CHEM, V276, P38787, DOI 10.1074/jbc.M102829200; Fenyvesi R, 2004, BIOCHEM BIOPH RES CO, V320, P599, DOI 10.1016/j.bbrc.2004.06.005; FRANKLIN JL, 1994, ANN NY ACAD SCI, V747, P195; FRANKLIN JL, 1995, J NEUROSCI, V15, P643; FUENTES JJ, 1995, HUM MOL GENET, V4, P1935, DOI 10.1093/hmg/4.10.1935; Fuentes JJ, 2000, HUM MOL GENET, V9, P1681, DOI 10.1093/hmg/9.11.1681; Fuentes JJ, 1997, GENOMICS, V44, P358, DOI 10.1006/geno.1997.4866; Genazzani AA, 1999, P NATL ACAD SCI USA, V96, P5797, DOI 10.1073/pnas.96.10.5797; Genesca L, 2003, BIOCHEM J, V374, P567, DOI 10.1042/BJ20030267; GOMEZ DA, 2000, J BIOL CHEM, V275, P13872; Gorlach J, 2000, EMBO J, V19, P3618, DOI 10.1093/emboj/19.14.3618; Graef IA, 2003, CELL, V113, P657, DOI 10.1016/S0092-8674(03)00390-8; Graef IA, 1999, NATURE, V401, P703, DOI 10.1038/44378; Groth RD, 2003, J NEUROSCI, V23, P8125; HACK N, 1993, NEUROSCIENCE, V57, P9, DOI 10.1016/0306-4522(93)90108-R; Hernandez GL, 2001, J EXP MED, V193, P607, DOI 10.1084/jem.193.5.607; Hesser BA, 2004, BLOOD, V104, P149, DOI 10.1182/blood-2004-01-0273; Hilioti Z, 2004, GENE DEV, V18, P35, DOI 10.1101/gad.1159204; Hill JA, 2002, J BIOL CHEM, V277, P10251, DOI 10.1074/jbc.M110722200; HO AM, 1994, J BIOL CHEM, V269, P28181; Kashishian A, 1998, J BIOL CHEM, V273, P27412, DOI 10.1074/jbc.273.42.27412; Kingsbury TJ, 2000, GENE DEV, V14, P1595; KLEE CB, 1979, BIOCHEMISTRY-US, V18, P722, DOI 10.1021/bi00571a026; KUNO T, 1992, J NEUROCHEM, V58, P1643, DOI 10.1111/j.1471-4159.1992.tb10036.x; Lai MM, 1998, J BIOL CHEM, V273, P18325, DOI 10.1074/jbc.273.29.18325; Lange AW, 2004, DEV BIOL, V266, P346, DOI 10.1016/j.ydbio.2003.10.036; Lara-Pezzi E, 1998, EMBO J, V17, P7066, DOI 10.1093/emboj/17.23.7066; Leahy KP, 2000, ARCH BIOCHEM BIOPHYS, V379, P221, DOI 10.1006/abbi.2000.1897; Leahy KP, 1999, ARCH BIOCHEM BIOPHYS, V368, P67, DOI 10.1006/abbi.1998.1059; Lin X, 1999, J BIOL CHEM, V274, P36125, DOI 10.1074/jbc.274.51.36125; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Ma H, 2004, J NEUROCHEM, V88, P1485, DOI 10.1046/j.1471-4159.2003.02294.x; Macian F, 2001, ONCOGENE, V20, P2476, DOI 10.1038/sj.onc.1204386; Mammucari C, 2005, DEV CELL, V8, P665, DOI 10.1016/j.devcel.2005.02.016; Mansuy IM, 2003, BIOCHEM BIOPH RES CO, V311, P1195, DOI 10.1016/j.bbrc.2003.10.046; Martinez-Martinez S, 2004, CURR MED CHEM, V11, P997, DOI 10.2174/0929867043455576; Minami T, 2004, J BIOL CHEM, V279, P50537, DOI 10.1074/jbc.M406454200; Miyazaki T, 1996, J BIOL CHEM, V271, P14567, DOI 10.1074/jbc.271.24.14567; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Okamura H, 2000, MOL CELL, V6, P539, DOI 10.1016/S1097-2765(00)00053-8; Olson EN, 2000, BIOESSAYS, V22, P510, DOI 10.1002/(SICI)1521-1878(200006)22:6<510::AID-BIES4>3.3.CO;2-T; Rodriguez A, 2005, J BIOL CHEM, V280, P9980, DOI 10.1074/jbc.C400401200; Rothermel B, 2000, J BIOL CHEM, V275, P8719, DOI 10.1074/jbc.275.12.8719; Rothermel BA, 2003, TRENDS CARDIOVAS MED, V13, P15, DOI 10.1016/S1050-1738(02)00188-3; Ryeom S, 2003, NAT IMMUNOL, V4, P874, DOI 10.1038/ni966; Shibasaki F, 2002, J BIOCHEM, V131, P1, DOI 10.1093/oxfordjournals.jbchem.a003063; Sola C, 1999, PROG NEUROBIOL, V58, P207, DOI 10.1016/S0301-0082(98)00082-3; Strippoli P, 2000, GENOMICS, V64, P252, DOI 10.1006/geno.2000.6127; Sun L, 1998, IMMUNITY, V8, P703, DOI 10.1016/S1074-7613(00)80575-0; Vega RB, 2003, J BIOL CHEM, V278, P36981, DOI 10.1074/jbc.R300023200; Vega RB, 2002, J BIOL CHEM, V277, P30401, DOI 10.1074/jbc.M200123200; Wang YL, 2002, AM J PHYSIOL-HEART C, V283, pH533, DOI 10.1152/ajpheart.00002.2002; Yang J, 2000, CIRC RES, V87, pE61, DOI 10.1161/01.RES.87.12.e61; Yang TTC, 2003, J BIOL CHEM, V278, P15874, DOI 10.1074/jbc.M211560200; Yao YG, 2004, BIOCHEM BIOPH RES CO, V321, P648, DOI 10.1016/j.bbrc.2004.06.176	68	54	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	2005	280	33					29435	29443		10.1074/jbc.M506205200	http://dx.doi.org/10.1074/jbc.M506205200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	954SX	15975916	hybrid			2022-12-25	WOS:000231176200008
J	Doherty, KM; Sommers, JA; Gray, MD; Lee, JW; von Kobbe, C; Thoma, NH; Kureekattil, RP; Kenny, MK; Brosh, RM				Doherty, KM; Sommers, JA; Gray, MD; Lee, JW; von Kobbe, C; Thoma, NH; Kureekattil, RP; Kenny, MK; Brosh, RM			Physical and functional mapping of the replication protein A interaction domain of the Werner and Bloom syndrome helicases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNDROME GENE-PRODUCT; DNA-REPLICATION; RECQ HELICASES; HUMAN-DISEASES; WRN HELICASE; S-PHASE; SUBUNIT; COMPLEX; ARREST; GENOME	The single-stranded DNA-binding protein replication protein A (RPA) interacts with several human RecQ DNA helicases that have important roles in maintaining genomic stability; however, the mechanism for RPA stimulation of DNA unwinding is not well understood. To map regions of Werner syndrome helicase (WRN) that interact with RPA, yeast two-hybrid studies, WRN affinity pull-down experiments and enzyme-linked immunosorbent assays with purified recombinant WRN protein fragments were performed. The results indicated that WRN has two RPA binding sites, a high affinity N-terminal site, and a lower affinity C-terminal site. Based on results from mapping studies, we sought to determine if the WRN N-terminal region harboring the high affinity RPA interaction site was important for RPA stimulation of WRN helicase activity. To accomplish this, we tested a catalytically active WRN helicase domain fragment (WRNH-R) that lacked the N-terminal RPA interaction site for its ability to unwind long DNA duplex substrates, which the wild-type enzyme can efficiently unwind only in the presence of RPA. WRNH-R helicase activity was significantly reduced on RPA-dependent partial duplex substrates compared with full-length WRN despite the presence of RPA. These results clearly demonstrate that, although WRNH-R had comparable helicase activity to full-length WRN on short duplex substrates, its ability to unwind RPA-dependent WRN helicase substrates was significantly impaired. Similarly, a Bloom syndrome helicase (BLM) domain fragment, BLM642-1290, that lacked its N-terminal RPA interaction site also unwound short DNA duplex substrates similar to wild-type BLM, but was severely compromised in its ability to unwind long DNA substrates that full-length BLM helicase could unwind in the presence of RPA. These results suggest that the physical interaction between RPA and WRN or BLM helicases plays an important role in the mechanism for RPA stimulation of helicase-catalyzed DNA unwinding.	NIA, Lab Mol Gerontol, NIH, Baltimore, MD 21224 USA; MDG Assoicates, Seattle, WA 98126 USA; Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, Struct Biol Program, New York, NY 10021 USA; Montefiore Med Ctr, Albert Einstein Coll Med, Dept Emergency Med, Bronx, NY 10467 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine	Brosh, RM (corresponding author), NIA, Lab Mol Gerontol, NIH, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	BroshR@grc.nia.nih.gov		von Kobbe, Cayetano/0000-0003-3895-3790	NATIONAL INSTITUTE ON AGING [Z01AG000741, ZIAAG000741] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bachrati CZ, 2003, BIOCHEM J, V374, P577, DOI 10.1042/BJ20030491; Balajee AS, 1999, MOL BIOL CELL, V10, P2655, DOI 10.1091/mbc.10.8.2655; Bochkareva E, 2002, EMBO J, V21, P1855, DOI 10.1093/emboj/21.7.1855; Brosh RM, 2000, J BIOL CHEM, V275, P23500, DOI 10.1074/jbc.M001557200; Brosh RM, 2002, J BIOL CHEM, V277, P23236, DOI 10.1074/jbc.M111446200; Brosh RM, 2001, EMBO J, V20, P5791; Brosh RM, 2002, EXP GERONTOL, V37, P491, DOI 10.1016/S0531-5565(01)00227-3; Brosh RM, 1999, J BIOL CHEM, V274, P18341, DOI 10.1074/jbc.274.26.18341; Chen CY, 2001, J CELL BIOL, V152, P985, DOI 10.1083/jcb.152.5.985; Cobb JA, 2003, EMBO J, V22, P4325, DOI 10.1093/emboj/cdg391; Constantinou A, 2000, EMBO REP, V1, P80, DOI 10.1093/embo-reports/kvd004; Cui S, 2004, NUCLEIC ACIDS RES, V32, P2158, DOI 10.1093/nar/gkh540; Ellis NA, 1996, HUM MOL GENET, V5, P1457, DOI 10.1093/hmg/5.Supplement_1.1457; ERDILE LF, 1991, J BIOL CHEM, V266, P12090; Garcia PL, 2004, EMBO J, V23, P2882, DOI 10.1038/sj.emboj.7600301; GERMAN J, 1993, MEDICINE, V72, P393, DOI 10.1097/00005792-199311000-00003; GIANNELLI F, 1977, NATURE, V265, P466, DOI 10.1038/265466a0; GOMES XV, 1995, J BIOL CHEM, V270, P4534, DOI 10.1074/jbc.270.9.4534; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; Harrigan JA, 2003, BIOCHIMIE, V85, P1185, DOI 10.1016/j.biochi.2003.10.006; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; Hickson ID, 2003, NAT REV CANCER, V3, P169, DOI 10.1038/nrc1012; Jacobs DM, 1999, J BIOMOL NMR, V14, P321, DOI 10.1023/A:1008373009786; Janscak P, 2003, J MOL BIOL, V330, P29, DOI 10.1016/S0022-2836(03)00534-5; Karow JK, 1999, CURR BIOL, V9, P597, DOI 10.1016/S0960-9822(99)80264-4; KENNY M K, 1990, Journal of Biological Chemistry, V265, P7693; LANGLOIS RG, 1989, P NATL ACAD SCI USA, V86, P670, DOI 10.1073/pnas.86.2.670; Lin YL, 1996, J BIOL CHEM, V271, P17190, DOI 10.1074/jbc.271.29.17190; LONN U, 1990, CANCER RES, V50, P3141; Morozov V, 1997, TRENDS BIOCHEM SCI, V22, P417, DOI 10.1016/S0968-0004(97)01128-6; Myung K, 2001, NATURE, V411, P1073, DOI 10.1038/35082608; Opresko PL, 2003, CARCINOGENESIS, V24, P791, DOI 10.1093/carcin/bgg034; Opresko PL, 2001, J BIOL CHEM, V276, P44677, DOI 10.1074/jbc.M107548200; Pichierri P, 2001, MOL BIOL CELL, V12, P2412, DOI 10.1091/mbc.12.8.2412; POOT M, 1992, EXP CELL RES, V202, P267, DOI 10.1016/0014-4827(92)90074-I; Rodriguez-Lopez AM, 2002, AGING CELL, V1, P30, DOI 10.1046/j.1474-9728.2002.00002.x; Sakamoto S, 2001, GENES CELLS, V6, P421, DOI 10.1046/j.1365-2443.2001.00433.x; Sharma S, 2004, MOL BIOL CELL, V15, P734, DOI 10.1091/mbc.E03-08-0567; Shen JC, 2003, MECH AGEING DEV, V124, P921, DOI 10.1016/S0047-6374(03)00164-7; Shen JC, 1998, NUCLEIC ACIDS RES, V26, P2879, DOI 10.1093/nar/26.12.2879; Sinclair DA, 1997, CELL, V91, P1033, DOI 10.1016/S0092-8674(00)80493-6; Suzuki N, 1997, NUCLEIC ACIDS RES, V25, P2973, DOI 10.1093/nar/25.15.2973; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; von Kobbe C, 2003, J BIOL CHEM, V278, P52997, DOI 10.1074/jbc.M308338200; von Kobbe C, 2002, J CELL SCI, V115, P3901, DOI 10.1242/jcs.00076; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; Wu L, 2000, J BIOL CHEM, V275, P9636, DOI 10.1074/jbc.275.13.9636; Yamagata K, 1998, P NATL ACAD SCI USA, V95, P8733, DOI 10.1073/pnas.95.15.8733; Yan H, 1998, NAT GENET, V19, P375, DOI 10.1038/1263; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	50	102	103	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	2005	280	33					29494	29505		10.1074/jbc.M500653200	http://dx.doi.org/10.1074/jbc.M500653200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	954SX	15965237	hybrid			2022-12-25	WOS:000231176200015
J	Golding, H; Khurana, S; Yarovinsky, F; King, LR; Abdoulaeva, G; Antonsson, L; Owman, C; Platt, EJ; Kabat, D; Andersen, JF; Sher, A				Golding, H; Khurana, S; Yarovinsky, F; King, LR; Abdoulaeva, G; Antonsson, L; Owman, C; Platt, EJ; Kabat, D; Andersen, JF; Sher, A			CCR5 N-terminal region plays a critical role in HIV-1 inhibition by Toxoplasma gondii-derived cyclophilin-18	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; ENVELOPE GLYCOPROTEIN; AMINO-TERMINUS; GASTROINTESTINAL-TRACT; CHEMOKINE RECEPTORS; ENTRY INHIBITORS; GP120 BINDING; CELL-LINE; INFECTION; DOMAIN	Molecular mimicry of chemokine ligands has been described for several pathogens. Toxoplasma gondii produces a protein, cyclophilin-18 (C-18), which binds to the human immunodeficiency virus (HIV) co-receptor CCR5 and inhibits fusion and infection of T cells and macrophages by R5 viruses but not by X4 viruses. We recently identified structural determinants of C-18 required for anti-HIV activity (Yarovinsky, F., Andersen, J. F., King, L. R., Caspar, P., Aliberti, J., Golding, H., and Sher, A. ( 2004) J. Biol. Chem. 279, 53635 - 53642). Here we have elucidated the fine specificity of CCR5 residues involved in binding and HIV inhibitory potential of C-18. To delineate the regions of CCR5 involved in C-18 binding, we analyzed C-18 inhibition of cells expressing CXCR4/CCR5 chimeric receptors and CCR5 with a truncated N terminus (Delta 2-19). These experiments identified a critical role for the N terminus of CCR5 in C-18 binding and anti-HIV activity. Studies with a large panel of CCR5 N-terminal peptides, including Tyr-sulfated analogues, truncated peptides, and alanine-scanning mutants, suggested that each of the 12 - 17 amino acids in the N terminus of CCR5 are essential for C-18 binding and inhibitory activity. Tyr sulfation did not improve C-18 reactivity. This finding is of interest because the same CCR5 N-terminal region was shown previously to play a key role in binding of HIV-1 envelope glycoproteins. The elucidation of the functional C-18-binding mechanism may help in the rational design of novel antiviral agents against HIV.	US FDA, Div Viral Prodat & Res, Bethesda, MD 20892 USA; US FDA, Core Facil, Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA; NIAID, Parasit Dis Lab, NIH, Bethesda, MD 20892 USA; NIAID, Lab Malaria & Vector Res, NIH, Bethesda, MD 20892 USA; Div Mol Neurobiol, SE-22184 Lund, Sweden; Oregon Hlth & Sci Univ, Portland, OR 97239 USA	US Food & Drug Administration (FDA); US Food & Drug Administration (FDA); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Oregon Health & Science University	Golding, H (corresponding author), US FDA, Div Viral Prodat & Res, Bethesda, MD 20892 USA.	goldingh@cber.FDA.gov		Yarovinsky, Felix/0000-0001-5825-8002	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000579, Z01AI000579] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alberti J, 2003, NAT IMMUNOL, V4, P485, DOI 10.1038/ni915; Aliberti J, 2000, NAT IMMUNOL, V1, P83, DOI 10.1038/76957; Aliberti J, 2002, MICROBES INFECT, V4, P991, DOI 10.1016/S1286-4579(02)01618-0; Antonsson L, 2003, AIDS, V17, P2571, DOI 10.1097/00002030-200312050-00004; Balotta C, 1997, AIDS, V11, pF67, DOI 10.1097/00002030-199710000-00001; Blanpain C, 2003, J BIOL CHEM, V278, P5179, DOI 10.1074/jbc.M205684200; Blanpain C, 1999, J BIOL CHEM, V274, P18902, DOI 10.1074/jbc.274.27.18902; Blanpain C, 1999, J BIOL CHEM, V274, P34719, DOI 10.1074/jbc.274.49.34719; Brenchley JM, 2004, J EXP MED, V200, P749, DOI 10.1084/jem.20040874; BRODER CC, 1995, P NATL ACAD SCI USA, V92, P9004, DOI 10.1073/pnas.92.19.9004; Cooley LA, 2003, J CLIN VIROL, V26, P121, DOI 10.1016/S1386-6532(02)00111-7; Cormier EG, 2000, P NATL ACAD SCI USA, V97, P5762, DOI 10.1073/pnas.97.11.5762; Cormier EG, 2001, J VIROL, V75, P5541, DOI 10.1128/JVI.75.12.5541-5549.2001; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Farzan M, 2000, J BIOL CHEM, V275, P33516, DOI 10.1074/jbc.M007228200; Farzan M, 1999, CELL, V96, P667, DOI 10.1016/S0092-8674(00)80577-2; Farzan M, 1998, J VIROL, V72, P1160, DOI 10.1128/JVI.72.2.1160-1164.1998; Golding H, 2003, BLOOD, V102, P3280, DOI 10.1182/blood-2003-04-1096; HILLMAN K, 1990, J IMMUNOL, V144, P2131; Holst PJ, 2003, MICROBES INFECT, V5, P179, DOI 10.1016/S1286-4579(02)00081-3; Karlsson I, 2003, AIDS, V17, P2561, DOI 10.1097/00002030-200312050-00003; Lee B, 1999, J BIOL CHEM, V274, P9617, DOI 10.1074/jbc.274.14.9617; Ling BH, 2004, J VIROL, V78, P8902, DOI 10.1128/JVI.78.16.8902-8908.2004; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; LUSSO P, 1995, J VIROL, V69, P3712, DOI 10.1128/JVI.69.6.3712-3720.1995; Mehandru S, 2004, J EXP MED, V200, P761, DOI 10.1084/jem.20041196; Nguyen GT, 1999, J ACQ IMMUN DEF SYND, V22, P75, DOI 10.1097/00042560-199909010-00010; O'Brien TR, 1998, JAMA-J AM MED ASSOC, V279, P317, DOI 10.1001/jama.279.4.317; Olson WC, 1999, J VIROL, V73, P4145, DOI 10.1128/JVI.73.5.4145-4155.1999; Paxton WA, 1996, AIDS RES HUM RETROV, V12, P1203, DOI 10.1089/aid.1996.12.1203; Platt EJ, 2005, J VIROL, V79, P4357, DOI 10.1128/JVI.79.7.4357-4368.2005; Platt EJ, 1998, J VIROL, V72, P2855, DOI 10.1128/JVI.72.4.2855-2864.1998; Rosenkilde MM, 2001, ONCOGENE, V20, P1582, DOI 10.1038/sj.onc.1204191; Shaheen F, 2004, CURR OPIN INFECT DIS, V17, P7, DOI 10.1097/00001432-200402000-00003; Siciliano SJ, 1999, J BIOL CHEM, V274, P1905, DOI 10.1074/jbc.274.4.1905; Veazey RS, 2004, J EXP MED, V200, P697, DOI 10.1084/jem.20041464; Wolinsky SM, 2004, VIROLOGY, V328, P19, DOI 10.1016/j.virol.2004.07.021; Wu LJ, 1997, J EXP MED, V186, P1373, DOI 10.1084/jem.186.8.1373; Yarovinsky F, 2004, J BIOL CHEM, V279, P53635, DOI 10.1074/jbc.M410550200; Zaitseva M, 2003, BBA-BIOMEMBRANES, V1614, P51, DOI 10.1016/S0005-2736(03)00162-7	40	8	11	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	2005	280	33					29570	29577		10.1074/jbc.M500236200	http://dx.doi.org/10.1074/jbc.M500236200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	954SX	15975927	hybrid			2022-12-25	WOS:000231176200024
J	Qu, XX; Hao, P; Song, XJ; Jiang, SM; Liu, YX; Wang, PG; Rao, X; Song, HD; Wang, SY; Zuo, Y; Zheng, AH; Luo, M; Wang, HL; Deng, F; Wang, HZ; Hu, ZH; Ding, MX; Zhao, GP; Deng, HK				Qu, XX; Hao, P; Song, XJ; Jiang, SM; Liu, YX; Wang, PG; Rao, X; Song, HD; Wang, SY; Zuo, Y; Zheng, AH; Luo, M; Wang, HL; Deng, F; Wang, HZ; Hu, ZH; Ding, MX; Zhao, GP; Deng, HK			Identification of two critical amino acid residues of the severe acute respiratory syndrome coronavirus spike protein for its variation in zoonotic tropism transition via a double substitution strategy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGIOTENSIN-CONVERTING ENZYME-2; SARS-CORONAVIRUS; AMINOPEPTIDASE-N; FUNCTIONAL-CHARACTERIZATION; NEUTRALIZING ANTIBODIES; EFFICIENT REPLICATION; VIRUS TYPE-1; RECEPTOR; GLYCOPROTEIN; EXPRESSION	Severe acute respiratory syndrome coronavirus (SARS-CoV) is a recently identified human coronavirus. The extremely high homology of the viral genomic sequences between the viruses isolated from human (huSARS-CoV) and those of palm civet origin (pcSARSCoV) suggested possible palm civet-to-human transmission. Genetic analysis revealed that the spike ( S) protein of pcSARS-CoV and huSARS-CoV was subjected to the strongest positive selection pressure during transmission, and there were six amino acid residues within the receptor-binding domain of the S protein being potentially important for SARS progression and tropism. Using the single-round infection assay, we found that a two-amino acid substitution (N479K/T487S) of a huSARS-CoV for those of pcSARSCoV almost abolished its infection of human cells expressing the SARS-CoV receptor ACE2 but no effect upon the infection of mouse ACE2 cells. Although single substitution of these two residues had no effects on the infectivity of huSARS-CoV, these recombinant S proteins bound to human ACE2 with different levels of reduced affinity, and the two-amino acid-substituted S protein showed extremely low affinity. On the contrary, substitution of these two amino acid residues of pcSARS-CoV for those of huSRAS-CoV made pcSARS-CoV capable of infecting human ACE2-expressing cells. These results suggest that amino acid residues at position 479 and 487 of the S protein are important determinants for SARS-CoV tropism and animal-to-human transmission.	Chinese Acad Sci, Shanghai Inst Biol Sci, Ctr Hlth Sci, Bioinformat Ctr,Inst Plant Physiol & Ecol, Shanghai 200031, Peoples R China; Peking Univ, Coll Life Sci, Dept Cell Biol & Genet, Beijing 100871, Peoples R China; Shanghai Med Univ 2, Ruijin Hosp, Pole Sinfrancais Rech Sci Vivant & Genom, State Key Lab Med Genom, Shanghai 200025, Peoples R China; Chinese Natl Human Genome Ctr, Shanghai 201203, Peoples R China; Chinese Acad Sci, Wuhan Inst Virol, State Key Lab Virol, Wuhan 430071, Peoples R China; Fudan Univ, Sch Life Sci, Dept Microbiol, State Key lab Genet Engn, Shanghai 200433, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Peking University; Chinese Academy of Sciences; Shanghai Jiao Tong University; Chinese Academy of Sciences; Wuhan Institute of Virology, CAS; Fudan University	Zhao, GP (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Ctr Hlth Sci, Bioinformat Ctr,Inst Plant Physiol & Ecol, Shanghai 200031, Peoples R China.	gpzhao@sibs.ac.cn; hongkui_deng@pku.edu.cn	Liu, Yanxia/T-1338-2019; zheng, aihua/E-5153-2011; Hu, Zhihong/AAS-2215-2020; Song, Huai-Dong/G-8961-2011	Hu, Zhihong/0000-0002-1560-0928; Zuo, Yu/0000-0002-9303-7480; Zhao, Guo-Ping/0000-0002-7621-6620; Hao, Pei/0000-0002-1498-7059; Wang, Peigang/0000-0001-6045-2007				Babcock GJ, 2004, J VIROL, V78, P4552, DOI 10.1128/JVI.78.9.4552-4560.2004; Bernini A, 2004, BIOCHEM BIOPH RES CO, V325, P1210, DOI 10.1016/j.bbrc.2004.10.156; Bosch BJ, 2003, J VIROL, V77, P8801, DOI 10.1128/JVI.77.16.8801-8811.2003; CONNOR RI, 1995, VIROLOGY, V206, P935, DOI 10.1006/viro.1995.1016; DELMAS B, 1992, NATURE, V357, P417, DOI 10.1038/357417a0; Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747; DUBIN G, 1994, J VIROL, V68, P2478, DOI 10.1128/JVI.68.4.2478-2485.1994; DVEKSLER GS, 1993, J VIROL, V67, P1; Fouchier RAM, 2003, NATURE, V423, P240, DOI 10.1038/423240a; Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139; He JF, 2004, SCIENCE, V303, P1666, DOI 10.1126/science.1092002; HOLMES KV, 1993, ADV EXP MED BIOL, V342, P261; Jeffers SA, 2004, P NATL ACAD SCI USA, V101, P15748, DOI 10.1073/pnas.0403812101; Jordan M, 1996, NUCLEIC ACIDS RES, V24, P596, DOI 10.1093/nar/24.4.596; Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781; Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145; Li WH, 2005, EMBO J, V24, P1634, DOI 10.1038/sj.emboj.7600640; Li WH, 2004, J VIROL, V78, P11429, DOI 10.1128/JVI.78.20.11429-11433.2004; Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953; Nie YC, 2004, J INFECT DIS, V190, P1119, DOI 10.1086/423286; Nie YC, 2004, BIOCHEM BIOPH RES CO, V321, P994, DOI 10.1016/j.bbrc.2004.07.060; Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2; Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952; Schickli JH, 2004, J VIROL, V78, P9073, DOI 10.1128/JVI.78.17.9073-9083.2004; Song HD, 2005, P NATL ACAD SCI USA, V102, P2430, DOI 10.1073/pnas.0409608102; Subbarao K, 2004, J VIROL, V78, P3572, DOI 10.1128/JVI.78.7.3572-3577.2004; Tresnan DB, 1998, ADV EXP MED BIOL, V440, P69; Wang PG, 2004, BIOCHEM BIOPH RES CO, V315, P439, DOI 10.1016/j.bbrc.2004.01.076; Wang Z, 2004, VIROLOGY, V330, P332, DOI 10.1016/j.virol.2004.09.023; Wong SK, 2004, J BIOL CHEM, V279, P3197, DOI 10.1074/jbc.C300520200; Xiao XD, 2003, BIOCHEM BIOPH RES CO, V312, P1159, DOI 10.1016/j.bbrc.2003.11.054; Yang ZY, 2005, P NATL ACAD SCI USA, V102, P797, DOI 10.1073/pnas.0409065102; YEAGER CL, 1992, NATURE, V357, P420, DOI 10.1038/357420a0; Zhang H, 2004, J VIROL, V78, P6938, DOI 10.1128/JVI.78.13.6938-6945.2004	34	118	130	0	38	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	2005	280	33					29588	29595		10.1074/jbc.M500662200	http://dx.doi.org/10.1074/jbc.M500662200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	954SX	15980414	hybrid, Green Published			2022-12-25	WOS:000231176200026
J	Yamashita, M; Shinnakasu, R; Asou, H; Kimura, M; Hasegawa, A; Hashimoto, K; Hatano, N; Ogata, M; Nakayama, T				Yamashita, M; Shinnakasu, R; Asou, H; Kimura, M; Hasegawa, A; Hashimoto, K; Hatano, N; Ogata, M; Nakayama, T			Ras-ERK MAPK cascade regulates GATA3 stability and Th2 differentiation through ubiquitin-proteasome pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; TRANSCRIPTION FACTOR GATA-3; CYTOKINE GENE-EXPRESSION; T-CELL DIFFERENTIATION; MEDIATED ACTIVATION; HISTONE HYPERACETYLATION; INTERLEUKIN-5 GENE; P53; PHOSPHORYLATION; LIGASE	Differentiation of naive CD4 T cells into Th2 cells requires protein expression of GATA3. Interleukin-4 induces STAT6 activation and subsequent GATA3 transcription. Little is known, however, on how T cell receptor-mediated signaling regulates GATA3 and Th2 cell differentiation. Here we demonstrated that T cell receptor-mediated activation of the Ras-ERK MAPK cascade stabilizes GATA3 protein in developing Th2 cells through the inhibition of the ubiquitin-proteasome pathway. Mdm2 was associated with GATA3 and induced ubiquitination on GATA3, suggesting its role as a ubiquitin-protein isopeptide ligase for GATA3 ubiquitination. Thus, the Ras-ERK MAPK cascade controls GATA3 protein stability by a post-transcriptional mechanism and facilitates GATA3-mediated chromatin remodeling at Th2 cytokine gene loci leading to successful Th2 cell differentiation.	Chiba Univ, Grad Sch Med, Dept Immunol, Chuo Ku, Chiba 2608670, Japan; Chiba Inst Technol, Dept Life & Environm Sci, Tsudanuma, Chiba 2750016, Japan; Chiba Inst Technol, High Technol Res Ctr, Tsudanuma, Chiba 2750016, Japan; Mie Univ, Sch Med, Dept Biochem, Tsu, Mie 5148507, Japan	Chiba University; Chiba Institute of Technology; Chiba Institute of Technology; Mie University	Nakayama, T (corresponding author), Chiba Univ, Grad Sch Med, Dept Immunol, Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan.	tnakayama@faculty.chiba-u.jp	Nakayama, Toshinori/E-1067-2017	Nakayama, Toshinori/0000-0002-1434-2007; K Asou, Hikari/0000-0002-2701-5953				Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Avni O, 2002, NAT IMMUNOL, V3, P643, DOI 10.1038/ni808; Ben-Neriah Y, 2002, NAT IMMUNOL, V3, P20, DOI 10.1038/ni0102-20; Brondello JM, 1999, SCIENCE, V286, P2514, DOI 10.1126/science.286.5449.2514; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Chen CH, 2000, J IMMUNOL, V165, P5597, DOI 10.4049/jimmunol.165.10.5597; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Constant SL, 1997, ANNU REV IMMUNOL, V15, P297, DOI 10.1146/annurev.immunol.15.1.297; Dong C, 1998, SCIENCE, V282, P2092, DOI 10.1126/science.282.5396.2092; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fields PE, 2002, J IMMUNOL, V169, P647, DOI 10.4049/jimmunol.169.2.647; Fuchs SY, 2000, J BIOL CHEM, V275, P12560, DOI 10.1074/jbc.275.17.12560; Gately MK, 1998, ANNU REV IMMUNOL, V16, P495, DOI 10.1146/annurev.immunol.16.1.495; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; Inami M, 2004, J BIOL CHEM, V279, P23123, DOI 10.1074/jbc.M401248200; Iritani BM, 1997, EMBO J, V16, P7019, DOI 10.1093/emboj/16.23.7019; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kimura M, 2001, IMMUNITY, V15, P275, DOI 10.1016/S1074-7613(01)00182-0; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Lee HJ, 2000, J EXP MED, V192, P105, DOI 10.1084/jem.192.1.105; Leon RP, 1998, P NATL ACAD SCI USA, V95, P13159, DOI 10.1073/pnas.95.22.13159; Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362; Li YQ, 1999, IMMUNOLOGY, V96, P524; Liu YC, 2004, ANNU REV IMMUNOL, V22, P81, DOI 10.1146/annurev.immunol.22.012703.104813; Lovett-Racke AE, 2004, IMMUNITY, V21, P719, DOI 10.1016/j.immuni.2004.09.010; Michael D, 2003, SEMIN CANCER BIOL, V13, P49, DOI 10.1016/S1044-579X(02)00099-8; Morimoto T, 2000, J BIOL CHEM, V275, P13721, DOI 10.1074/jbc.275.18.13721; MOSMANN TR, 1989, ADV IMMUNOL, V46, P111, DOI 10.1016/S0065-2776(08)60652-5; Murphy KM, 2000, ANNU REV IMMUNOL, V18, P451, DOI 10.1146/annurev.immunol.18.1.451; Nelms K, 1999, ANNU REV IMMUNOL, V17, P701, DOI 10.1146/annurev.immunol.17.1.701; O'Garra A, 1998, IMMUNITY, V8, P275, DOI 10.1016/S1074-7613(00)80533-6; Oh-hora M, 1999, J IMMUNOL, V163, P1282; Omori M, 2003, IMMUNITY, V19, P281, DOI 10.1016/S1074-7613(03)00210-3; Ouyang W, 1998, IMMUNITY, V9, P745, DOI 10.1016/S1074-7613(00)80671-8; Ouyang WJ, 2000, IMMUNITY, V12, P27, DOI 10.1016/S1074-7613(00)80156-9; Pai SY, 2004, P NATL ACAD SCI USA, V101, P1993, DOI 10.1073/pnas.0308697100; Persons DL, 2000, J BIOL CHEM, V275, P35778, DOI 10.1074/jbc.M004267200; Pickart CM, 2004, CELL, V116, P181, DOI 10.1016/S0092-8674(03)01074-2; Prives C, 2001, CELL, V107, P815, DOI 10.1016/S0092-8674(01)00619-5; REINER SL, 1995, ANNU REV IMMUNOL, V13, P151, DOI 10.1146/annurev.iy.13.040195.001055; Rengarajan J, 2000, IMMUNOL TODAY, V21, P479, DOI 10.1016/S0167-5699(00)01712-6; Rock KL, 1999, ANNU REV IMMUNOL, V17, P739, DOI 10.1146/annurev.immunol.17.1.739; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Sears R, 1999, MOL CELL, V3, P169, DOI 10.1016/S1097-2765(00)80308-1; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.iy.12.040194.003223; She QB, 2000, J BIOL CHEM, V275, P20444, DOI 10.1074/jbc.M001020200; Shibata Y, 2002, J IMMUNOL, V169, P2134, DOI 10.4049/jimmunol.169.4.2134; Suzuki H, 1999, BIOCHEM BIOPH RES CO, V256, P121, DOI 10.1006/bbrc.1999.0296; SWAN KA, 1995, EMBO J, V14, P276, DOI 10.1002/j.1460-2075.1995.tb07001.x; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; Tanaka K, 1998, GENES CELLS, V3, P499, DOI 10.1046/j.1365-2443.1998.00207.x; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; TOWATARI M, 1995, J BIOL CHEM, V270, P4101, DOI 10.1074/jbc.270.8.4101; Yamashita M, 2004, J BIOL CHEM, V279, P26983, DOI 10.1074/jbc.M403688200; Yamashita M, 1998, INT IMMUNOL, V10, P577, DOI 10.1093/intimm/10.5.577; Yamashita M, 1999, P NATL ACAD SCI USA, V96, P1024, DOI 10.1073/pnas.96.3.1024; Yamashita M, 2002, J BIOL CHEM, V277, P42399, DOI 10.1074/jbc.M205876200; Yamashita M, 2000, J EXP MED, V191, P1869, DOI 10.1084/jem.191.11.1869; Yang DD, 1998, IMMUNITY, V9, P575, DOI 10.1016/S1074-7613(00)80640-8; Zhang DH, 1997, J BIOL CHEM, V272, P21597, DOI 10.1074/jbc.272.34.21597; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8	64	133	139	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	2005	280	33					29409	29419		10.1074/jbc.M502333200	http://dx.doi.org/10.1074/jbc.M502333200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	954SX	15975924	hybrid			2022-12-25	WOS:000231176200005
J	Pons, M; Cigudosa, JC; Rodriguez-Perales, S; Bella, JL; Gonzalez, C; Gamallo, C; Quintanilla, M				Pons, M; Cigudosa, JC; Rodriguez-Perales, S; Bella, JL; Gonzalez, C; Gamallo, C; Quintanilla, M			Chromosomal instability and phenotypic plasticity during the squamous-spindle carcinoma transition: association of a specific T(14;15) with malignant progression	ONCOGENE			English	Article						malignant progression; H-Ras; INK4a; chromosomal instability; T(14;15)	SKIN TUMOR PROGRESSION; MOUSE SKIN; GENETIC INSTABILITY; EPIDERMAL CARCINOGENESIS; CELL CARCINOMAS; RAS GENE; IN-VIVO; HA-RAS; CANCER; ANEUPLOIDY	In mouse epidermal carcinogenesis, the latest stage of malignant progression involves the transition from squamous cell carcinoma to a highly aggressive type of tumor with spindle morphology. In this work, we have isolated a minor epithelial cell subpopulation (CarC-R) contained in the highly malignant spindle carcinoma cell line CarC. CarC-R exhibited a drastic reduction in tumorigenicity when compared with CarC, but CarC-R-induced tumors were mainly sarcomatoid, although they subsequently reverted to the epithelial phenotype when tumor explants were recultured in vitro. Several single-cell clones with either stable epithelial or fibroblastic phenotypes were isolated from an explanted CarC-R tumor (CarC-RT). All these cell lines contained the same specific point mutation in H-Ras codon 61, but while CarC spindle cells had lost the normal H-Ras allele, it was retained in CarC-R- and CarC-RT-derived cell lines. Furthermore, CarC cells have inactivated p161NK4a and p191NK4a/ARF transcription, while CarC-R and CarC-RT clones expressed p19 mRNA and protein but not p16. Altogether, these results suggest that CarC-R represents a precursor stage to CarC in malignant progression. Spectral karyotyping analysis revealed that CarC-R was highly aneuploid and contained many chromosomal abnormalities. In contrast, CarC had a diploid or tetraploid modal chromosome number and contained a specific T(14;15) translocation in all of the analysed metaphases. The T(14;15) translocation was present in only a minority (1.9%) of CarC-R cells, but it was widely spread in CarC-RT and its derived cell clones, regardless of their epithelial or fibroblastic phenotype, indicating that T(14;15) segregates with malignancy.	Univ Autonoma Madrid, CSIC, Inst Invest Biomed, E-28029 Madrid, Spain; Univ Autonoma Madrid, Fac Ciencias, Dept Biol, E-28029 Madrid, Spain; Univ Autonoma Madrid, Fac Med, Hosp Univ Princesa, Ctr Nacl Inves Ocol,Cytogenet Unit, E-28029 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Autonomous University of Madrid; Autonomous University of Madrid; Hospital de La Princesa	Quintanilla, M (corresponding author), Univ Autonoma Madrid, CSIC, Inst Invest Biomed, Arturo Duperier 4, E-28029 Madrid, Spain.	mquintanilla@iib.uam.es	pons, marisa/AAA-7983-2019; Cigudosa, Juan C/E-4105-2016; Rodriguez-Perales, Sandra/T-7667-2017; Quintanilla, Miguel/K-9293-2017	Rodriguez-Perales, Sandra/0000-0001-7221-3636; Quintanilla, Miguel/0000-0002-2124-7657				Akhurst RJ, 1999, J PATHOL, V187, P82, DOI 10.1002/(SICI)1096-9896(199901)187:1<82::AID-PATH248>3.0.CO;2-8; ALDAZ CM, 1989, MOL CARCINOGEN, V2, P22, DOI 10.1002/mc.2940020104; ALDAZ CM, 1987, P NATL ACAD SCI USA, V84, P2029, DOI 10.1073/pnas.84.7.2029; Beheshti B, 2001, NEOPLASIA, V3, P62, DOI 10.1038/sj.neo.7900125; BELLA JL, 1995, GENOME, V38, P864, DOI 10.1139/g95-114; BIANCHI AB, 1990, P NATL ACAD SCI USA, V87, P6902, DOI 10.1073/pnas.87.17.6902; BREMNER R, 1990, CELL, V61, P407, DOI 10.1016/0092-8674(90)90523-H; BUCHMANN A, 1991, CANCER RES, V51, P4097; BURNS PA, 1991, ONCOGENE, V6, P2363; Celeste A, 2003, CELL, V114, P371, DOI 10.1016/S0092-8674(03)00567-1; CONTI CJ, 1986, CARCINOGENESIS, V7, P1845, DOI 10.1093/carcin/7.11.1845; DIAZGUERRA M, 1992, CANCER RES, V52, P680; Difilippantonio MJ, 2002, J EXP MED, V196, P469, DOI 10.1084/jem.20020851; Duesberg P, 1999, ANTICANCER RES, V19, P4887; Duesberg P, 1998, P NATL ACAD SCI USA, V95, P13692, DOI 10.1073/pnas.95.23.13692; DURO D, 1995, ONCOGENE, V11, P21; Frame S, 1998, PHILOS T ROY SOC B, V353, P839, DOI 10.1098/rstb.1998.0248; Frame S, 2000, CURR OPIN GENET DEV, V10, P106, DOI 10.1016/S0959-437X(99)00052-0; FUSENIG NE, 1978, B CANCER, V65, P271; Gotzmann J, 2004, MUTAT RES-REV MUTAT, V566, P9, DOI 10.1016/S1383-5742(03)00033-4; Grady WM, 2004, CANCER METAST REV, V23, P11, DOI 10.1023/A:1025861527711; Kelly-Spratt KS, 2004, PLOS BIOL, V2, P1138, DOI 10.1371/journal.pbio.0020242; KLEINSZANTO AJP, 1989, CARCINOGENESIS, V10, P2169, DOI 10.1093/carcin/10.11.2169; KULESZMARTIN M, 1983, CARCINOGENESIS, V4, P1367, DOI 10.1093/carcin/4.11.1367; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; LINARDOPOULOS S, 1995, CANCER RES, V55, P5168; MAO L, 1995, CANCER RES, V55, P2995; Miyoshi Y, 2000, CANCER LETT, V159, P211, DOI 10.1016/S0304-3835(00)00558-9; NAVARRO P, 1991, J CELL BIOL, V115, P517, DOI 10.1083/jcb.115.2.517; Pihan GA, 1999, SEMIN CANCER BIOL, V9, P289, DOI 10.1006/scbi.1999.0131; Portella G, 1998, CELL GROWTH DIFFER, V9, P393; QUELLE DE, 1995, CELL, V83, P993; QUINTANILLA M, 1991, CARCINOGENESIS, V12, P1875, DOI 10.1093/carcin/12.10.1875; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; Rajagopalan H, 2003, NAT REV CANCER, V3, P695, DOI 10.1038/nrc1165; Rodriguez-Puebla ML, 1999, MOL CARCINOGEN, V26, P150, DOI 10.1002/(SICI)1098-2744(199911)26:3<150::AID-MC3>3.0.CO;2-P; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; RUGGERI B, 1992, AM J PATHOL, V140, P1179; Serrano M, 2000, CARCINOGENESIS, V21, P865, DOI 10.1093/carcin/21.5.865; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Shih IM, 2001, CANCER RES, V61, P818; STOLER AB, 1993, J CELL BIOL, V122, P1103, DOI 10.1083/jcb.122.5.1103; STONE S, 1995, CANCER RES, V55, P2988; Takahashi T, 1999, ONCOGENE, V18, P4295, DOI 10.1038/sj.onc.1202807; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; YUSPA SH, 1994, J INVEST DERMATOL, V103, pS90, DOI 10.1111/1523-1747.ep12399255	49	11	11	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 17	2005	24	51					7608	7618		10.1038/sj.onc.1208903	http://dx.doi.org/10.1038/sj.onc.1208903			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	984VQ	16007119	Green Submitted			2022-12-25	WOS:000233333800010
J	Yang, TX; Zhang, AH; Honeggar, M; Kohan, DE; Mizel, D; Sanders, K; Hoidal, JR; Briggs, JP; Schnermann, JB				Yang, TX; Zhang, AH; Honeggar, M; Kohan, DE; Mizel, D; Sanders, K; Hoidal, JR; Briggs, JP; Schnermann, JB			Hypertonic induction of COX-2 in collecting duct cells by reactive oxygen species of mitochondrial origin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSMOTIC RESPONSE ELEMENT; CYCLOOXYGENASE-2 EXPRESSION; NADPH OXIDASE; TYROSINE PHOSPHORYLATION; PROSTAGLANDIN SYNTHESIS; P38 KINASE; IN-VIVO; STRESS; KIDNEY; RAT	Our previous studies have documented MAPK mediation of the hypertonicity-induced stimulation of COX-2 expression in cultured renal medullary epithelial cells (Yang, T., Huang, Y., Heasley, L. E., Berl, T., Schnermann, J. B., and Briggs, J. P. (2000) J. Biol. Chem. 275, 23281-23286). The present study extends this observation by examining the role of reactive oxygen species (ROSs). ROS levels, determined using dichlorodihydrofluorescence diacetate and cytochrome c, were rapidly and significantly increased following exposure of mIMCD-K2 cells to media made hypertonic by adding NaCl. Hypertonic treatment (550 mosmol/kg) for 16 h induced a 5.6-fold increase in COX-2 protein levels and comparable increases in prostaglandin E-2 release, both of which were completely abolished by the NADPH oxidase inhibitor diphenyleneiodonium (25-50 mu M). The general antioxidant N-acetyl-L-cysteine (6 mM), and the superoxide dismutase mimetic TEMPO (2.0 mM) reduced COX-2 levels by 75.6 and 79.8%, respectively. Exposure of mIMCD-K2 cells to exogenous O-2(-center dot) generated by the xanthine/xanthine oxidase system mimicked the effect of hypertonicity on COX-2 expression and prostaglandin E2 release. The increases in phosphorylation of ERK1/2 and p38 were detected 20 min following the hypertonic treatment and were both prevented by N-acetyl-L-cysteine. The increases in ROSs in response to hypertonic treatment were completely blocked by any one of the mitochondrial inhibitors tested, such as rotenone, thenoyltrifluoroacetone, or carbonyl cyanide m-chlorophenylhydrazone, associated with remarkable inhibition of COX-2 expression. In contrast, the increases in ROSs were not significantly altered in IMCD cells deficient in either gp91(phox) or p47(phox), nor were the increases in COX-2 expression. We conclude that ROSs derived from mitochondria, but not NADPH oxidase, mediate the hypertonicity-induced phosphorylation of MAPK and the stimulation of COX-2 expression.	Univ Utah, Res Serv 151 E, Dept Internal Med, Salt Lake City, UT 84148 USA; Vet Affairs Med Ctr, Res Serv 151 E, Salt Lake City, UT 84148 USA; NIDDK, NIH, Bethesda, MD 20892 USA	Utah System of Higher Education; University of Utah; US Department of Veterans Affairs; Veterans Health Administration (VHA); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Yang, TX (corresponding author), Univ Utah, Res Serv 151 E, Dept Internal Med, Bldg 2,500 Foothill Dr, Salt Lake City, UT 84148 USA.	tianxin.yang@hsc.utah.edu	Briggs, Josephine P/B-9394-2009	Briggs, Josephine P/0000-0003-0798-1190	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL079453] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK043408, R01DK066592, R21DK069490, K01DK064981] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL079453] Funding Source: Medline; NIDDK NIH HHS [R21 DK069490, K01 DK064981, R01 DK066592] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adegboyega PA, 2004, APPL IMMUNOHISTO M M, V12, P71; ALBERTYN J, 1994, MOL CELL BIOL, V14, P4135, DOI 10.1128/MCB.14.6.4135; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Berl T, 1997, AM J PHYSIOL-RENAL, V272, pF305, DOI 10.1152/ajprenal.1997.272.3.F305; Burg MB, 1997, ANNU REV PHYSIOL, V59, P437, DOI 10.1146/annurev.physiol.59.1.437; BURG MB, 1995, AM J PHYSIOL-RENAL, V268, pF983, DOI 10.1152/ajprenal.1995.268.6.F983; Campean V, 2003, AM J PHYSIOL-RENAL, V285, pF19, DOI 10.1152/ajprenal.00443.2002; Denkert C, 1998, ARCH BIOCHEM BIOPHYS, V354, P172, DOI 10.1006/abbi.1998.0661; Ferguson S, 1999, J AM SOC NEPHROL, V10, P2261; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Handler JS, 2001, KIDNEY INT, V60, P408, DOI 10.1046/j.1523-1755.2001.060002408.x; Hao CM, 2000, J CLIN INVEST, V106, P973, DOI 10.1172/JCI9956; HARRIS RC, 1994, J CLIN INVEST, V94, P2504, DOI 10.1172/JCI117620; JACKSON SH, 1995, J EXP MED, V182, P751, DOI 10.1084/jem.182.3.751; Kapus A, 1999, J BIOL CHEM, V274, P8093, DOI 10.1074/jbc.274.12.8093; KING CR, 1989, ONCOGENE, V4, P13; Kitiyakara C, 2003, J AM SOC NEPHROL, V14, P2775, DOI 10.1097/01.ASN.0000092145.90389.65; Ko BCB, 2002, J BIOL CHEM, V277, P46085, DOI 10.1074/jbc.M208138200; Kultz D, 2005, ANNU REV PHYSIOL, V67, P225, DOI 10.1146/annurev.physiol.67.040403.103635; Kultz D, 1997, J BIOL CHEM, V272, P13165, DOI 10.1074/jbc.272.20.13165; Lunn JA, 2004, J BIOL CHEM, V279, P45266, DOI 10.1074/jbc.M314132200; Moeckel GW, 2003, J BIOL CHEM, V278, P19352, DOI 10.1074/jbc.M302209200; Nadkarni V, 1999, J BIOL CHEM, V274, P20185, DOI 10.1074/jbc.274.29.20185; Neuhofer W, 2004, KIDNEY INT, V65, P431, DOI 10.1111/j.1523-1755.2004.00387.x; POLLOCK JD, 1995, NAT GENET, V9, P202, DOI 10.1038/ng0295-202; RUIS H, 1995, BIOESSAYS, V17, P959, DOI 10.1002/bies.950171109; Schumacher K, 2002, CELL PHYSIOL BIOCHEM, V12, P63, DOI 10.1159/000063782; Sheikh-Hamad D, 1998, J BIOL CHEM, V273, P1832, DOI 10.1074/jbc.273.3.1832; SIMMONS DL, 1989, P NATL ACAD SCI USA, V86, P1178, DOI 10.1073/pnas.86.4.1178; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Teufelhofer O, 2003, TOXICOL SCI, V76, P376, DOI 10.1093/toxsci/kfg234; Wojtaszek PA, 1998, J BIOL CHEM, V273, P800, DOI 10.1074/jbc.273.2.800; WU JM, 1993, SCI CHINA SER B, V36, P948; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; Yang TX, 2000, J BIOL CHEM, V275, P23281, DOI 10.1074/jbc.M910237199; Yang TX, 1999, AM J PHYSIOL-RENAL, V277, pF1, DOI 10.1152/ajprenal.1999.277.1.F1; YANG TX, 1993, AM J PHYSIOL, V264, pF684, DOI 10.1152/ajprenal.1993.264.4.F684; Yang TX, 1998, AM J PHYSIOL-RENAL, V274, pF481, DOI 10.1152/ajprenal.1998.274.3.F481; ZHANG F, 1995, BIOCHEM J, V312, P135, DOI 10.1042/bj3120135; Zhang Z, 2004, P NATL ACAD SCI USA, V101, P9491, DOI 10.1073/pnas.0402961101; Zhao HY, 2003, AM J PHYSIOL-RENAL, V285, pF281, DOI 10.1152/ajprenal.00030.2003	42	63	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34966	34973		10.1074/jbc.M502430200	http://dx.doi.org/10.1074/jbc.M502430200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16024921	hybrid			2022-12-25	WOS:000232403900070
J	Casanovas, O; Hager, JH; Chun, MGH; Hanahan, D				Casanovas, O; Hager, JH; Chun, MGH; Hanahan, D			Incomplete inhibition of the Rb tumor suppressor pathway in the context of inactivated p53 is sufficient for pancreatic islet tumorigenesis	ONCOGENE			English	Article						oncogenesis; retinoblastoma protein ( Rb); tumor suppressor genes; transgenic mice; RIP-Tag2	CERVICAL CARCINOMAS; INSULIN; INTERMEDIATE; EXPRESSION; MUTATION; CELLS; MICE	Here, we describe the surprising residual capability of the Rb pathway to negatively regulate proliferation and tumorigenesis in a SV40 large T antigen (Tag)-driven mouse model of pancreatic islet carcinogenesis. Heterogeneous Tag expression during all progression stages suggested that a threshold level of the T antigen oncoprotein might be deterministic for beta-cell hyperproliferation and led us to hypothesize that Tag might not be fully inhibiting the tumor suppressor activity of Rb. Moreover, genomic pro. ling of these tumors by array CGH pointed to regions of loss on chromosomes 6 and 14, where the Rb pathway inhibitor p27 and Rb itself, respectively, reside. Indeed, genetic ablation of the p27(Kip1) or Rb genes accentuated Tag-induced tumorigenesis, with loss of Rb in particular broadly enhancing multiple parameters of tumorigenesis including the frequency and growth rates of premalignant lesions, of nascent solid tumors, and of invasive carcinomas. The data indicate that attenuation rather than complete inactivation of Rb tumor suppressor gene function, in the context of p53 inhibition, is sufficient to initiate tumorigenesis in this model of islet cell cancer, with the demonstrable possibility that subsequent losses of Rb or its regulators can enhance malignant progression. The results may be relevant to human papillomavirus (HPV)-induced cervical neoplasias where E7 oncogene expression levels or activity (in the case of intermediate/low-risk HPV subtypes) incompletely inhibits Rb tumor suppressor functions, as well as to other neoplasias where initiating oncogenic or tumor suppressor events reduce but do not abrogate Rb function.	Univ Calif San Francisco, Ctr Diabet, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center	Hanahan, D (corresponding author), Univ Calif San Francisco, Ctr Diabet, Dept Biochem & Biophys, 513 Parnassus Ave,HSW-1090, San Francisco, CA 94143 USA.	dh@biochem.ucsf.edu	Casanovas, Oriol/L-5210-2014	Casanovas, Oriol/0000-0002-4298-3995				BADER JL, 1980, LANCET, V2, P582; Bergers G, 2003, J CLIN INVEST, V111, P1287, DOI 10.1172/JCI200317929; BROWNSTEIN S, 1984, ARCH OPHTHALMOL-CHIC, V102, P257, DOI 10.1001/archopht.1984.01040030207028; CHRISTOFORI G, 1994, NATURE, V369, P414, DOI 10.1038/369414a0; EFRAT S, 1987, EMBO J, V6, P2699, DOI 10.1002/j.1460-2075.1987.tb02562.x; Ferguson KL, 2002, EMBO J, V21, P3337, DOI 10.1093/emboj/cdf338; Gannon M, 2000, GENESIS, V26, P139, DOI 10.1002/(SICI)1526-968X(200002)26:2<139::AID-GENE12>3.0.CO;2-7; Giannoudis A, 2000, CANCER, V89, P1300, DOI 10.1002/1097-0142(20000915)89:6<1300::AID-CNCR15>3.0.CO;2-U; Hager JH, 2004, CANCER RES, V64, P2406, DOI 10.1158/0008-5472.CAN-03-3522; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; Hashizume H, 2000, AM J PATHOL, V156, P1363, DOI 10.1016/S0002-9440(10)65006-7; Herzig M, 1999, BIOL CHEM, V380, P203, DOI 10.1515/BC.1999.028; Hodgson G, 2001, NAT GENET, V29, P459, DOI 10.1038/ng771; Inoue M, 2002, CANCER CELL, V1, P193, DOI 10.1016/S1535-6108(02)00031-4; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Kim HJ, 2001, EUR J OBSTET GYN R B, V98, P213, DOI 10.1016/S0301-2115(01)00309-8; LO KW, 1992, ANTICANCER RES, V12, P1989; Lopez T, 2002, CANCER CELL, V1, P339, DOI 10.1016/S1535-6108(02)00055-7; Marino S, 2000, GENE DEV, V14, P994; Nakagawa S, 1999, BRIT J CANCER, V79, P1139, DOI 10.1038/sj.bjc.6690181; Peters MG, 2004, ONCOL REP, V12, P1143; Pipas JM, 2001, SEMIN CANCER BIOL, V11, P23, DOI 10.1006/scbi.2000.0343; PIPELEERS DG, 1992, DIABETES, V41, P777, DOI 10.2337/diabetes.41.7.777; Saenz-Robles MT, 2001, ONCOGENE, V20, P7899, DOI 10.1038/sj.onc.1204936; SANG BC, 1992, P NATL ACAD SCI USA, V89, P8063, DOI 10.1073/pnas.89.17.8063; Weir GC, 2001, DIABETES, V50, pS154, DOI 10.2337/diabetes.50.2007.S154	26	25	26	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 6	2005	24	44					6597	6604		10.1038/sj.onc.1208823	http://dx.doi.org/10.1038/sj.onc.1208823			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	971FL	16007165				2022-12-25	WOS:000232367800001
J	Bhat, S; Sorci-Thomas, MG; Alexander, ET; Samuel, MP; Thomas, MJ				Bhat, S; Sorci-Thomas, MG; Alexander, ET; Samuel, MP; Thomas, MJ			Intermolecular contact between globular N-terminal fold and C-terminal domain of ApoA-I stabilizes its lipid-bound conformation - Studies employing chemical cross-linking and mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-I; HIGH-DENSITY-LIPOPROTEINS; RESONANCE ENERGY-TRANSFER; ALPHA-CRYSTALLIN; WILD-TYPE; SR-BI; PROTEIN; RECEPTOR; MODEL; IDENTIFICATION	The structure of apoA-I on discoidal high density lipoprotein (HDL) was studied using a combination of chemical cross-linking and mass spectrometry. RecombinantHDLparticles containing 145 molecules of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine and two molecules of apoA-I with a 96-angstrom diameter were treated with the lysine-specific cross-linker, dithiobis( succinimidylpropionate) at varying molar ratios from 2: 1 to 200:1. At low molar ratios of dithiobis( succinimidylpropionate) to apoA-I, two products were obtained corresponding to similar to 53 and similar to 80 kDa. At high molar ratios, these two products merged, yielding a product of similar to 59 kDa, close to the theoretical molecular mass of dimeric apoA-I. To identify the intermolecular cross-links giving rise to the two different sized products, bands were excised from the gel, digested with trypsin, and then analyzed by liquid chromatography-electrospray-tandem mass spectrometry. In addition, tandem mass spectrometry of unique cross-links found in the 53- and 80-kDa products suggested that a distinct conformation exists for lipid-bound apoA-I on 96-angstrom recombinant HDL, emphasizing the inherent flexibility and malleability of the N termini and its interaction with its C-terminal domain.	Wake Forest Univ Hlth Sci, Dept Pathol, Winston Salem, NC 27157 USA; Wake Forest Univ Hlth Sci, Dept Biochem, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest University School of Medicine; Wake Forest University; Wake Forest University School of Medicine	Sorci-Thomas, MG (corresponding author), Wake Forest Univ Hlth Sci, Dept Pathol, Med Ctr Blvd, Winston Salem, NC 27157 USA.	msthomas@wfubmc.edu		Sorci-Thomas, Mary/0000-0002-6464-5006	NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR017846] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL049373, R01HL064163] Funding Source: NIH RePORTER; NCRR NIH HHS [1 S10 RR17846] Funding Source: Medline; NHLBI NIH HHS [HL-49373, HL-64163, HL-07115] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Agree AKB, 2002, BBA-PROTEIN STRUCT M, V1594, P286, DOI 10.1016/S0167-4838(01)00317-X; Alexander ET, 2005, BIOCHEMISTRY-US, V44, P5409, DOI 10.1021/bi047412v; Back JW, 2003, J MOL BIOL, V331, P303, DOI 10.1016/S0022-2836(03)00721-6; Beckstead JA, 2005, BIOCHEMISTRY-US, V44, P4591, DOI 10.1021/bi0477135; Bennett KL, 2000, PROTEIN SCI, V9, P1503, DOI 10.1110/ps.9.8.1503; BODEN WE, 2000, AM J CARDIOL, V86, P19, DOI DOI 10.1016/S0002-9149(00)01464-8; Borhani DW, 1997, P NATL ACAD SCI USA, V94, P12291, DOI 10.1073/pnas.94.23.12291; Chait A, 2005, J LIPID RES, V46, P389, DOI 10.1194/jlr.R400017-JLR200; Corsico B, 2001, J BIOL CHEM, V276, P16978, DOI 10.1074/jbc.M011533200; Davidson WS, 1999, BIOCHEMISTRY-US, V38, P14387, DOI 10.1021/bi991428h; Davidson WS, 2003, J BIOL CHEM, V278, P27199, DOI 10.1074/jbc.M302764200; Davidson WS, 1996, P NATL ACAD SCI USA, V93, P13605, DOI 10.1073/pnas.93.24.13605; Dong LM, 1996, NAT STRUCT BIOL, V3, P718, DOI 10.1038/nsb0896-718; Fang YL, 2003, BIOCHEMISTRY-US, V42, P13260, DOI 10.1021/bi0354031; Fang YL, 2003, BIOCHEMISTRY-US, V42, P6881, DOI 10.1021/bi034152t; Gorshkova IN, 2002, BIOCHEMISTRY-US, V41, P10529, DOI 10.1021/bi025807d; Green NS, 2001, PROTEIN SCI, V10, P1293, DOI 10.1110/ps.51201; Harper CR, 1999, ARCH INTERN MED, V159, P1049, DOI 10.1001/archinte.159.10.1049; Huang BX, 2005, BIOCHEM J, V387, P695, DOI 10.1042/BJ20041624; Kinter M, 2000, PROTEIN SEQUENCING I, V1st, P152; Klon AE, 2002, J MOL BIOL, V324, P703, DOI 10.1016/S0022-2836(02)01143-9; Koppaka V, 1999, J BIOL CHEM, V274, P14541, DOI 10.1074/jbc.274.21.14541; Krishna MMG, 2005, P NATL ACAD SCI USA, V102, P1053, DOI 10.1073/pnas.0409114102; Li HH, 2000, J BIOL CHEM, V275, P37048, DOI 10.1074/jbc.M005336200; Li HH, 2002, J BIOL CHEM, V277, P39093, DOI 10.1074/jbc.M206770200; Li HH, 2001, J LIPID RES, V42, P2084; Li L, 2004, J MOL BIOL, V343, P1293, DOI 10.1016/j.jmb.2004.09.017; Libby P, 2001, AM J CARDIOL, V88, p3J, DOI [DOI 10.1016/S0002-9149(01)02145-2, 10.1016/S0002-9149(01)02145-2]; Maiorano JN, 2000, J BIOL CHEM, V275, P17374, DOI 10.1074/jbc.M000044200; Maiorano JN, 2004, BIOCHEMISTRY-US, V43, P11717, DOI 10.1021/bi0496642; Manning M, 2004, BIOCHEMISTRY-US, V43, P11248, DOI 10.1021/bi0491898; Marcel YL, 2003, CURR OPIN LIPIDOL, V14, P151, DOI 10.1097/00041433-200304000-00006; Navab M, 2000, J LIPID RES, V41, P1481; NICHOLS AV, 1976, BIOCHIM BIOPHYS ACTA, V446, P226, DOI 10.1016/0005-2795(76)90113-6; Oda MN, 2003, NAT STRUCT BIOL, V10, P455, DOI 10.1038/nsb931; Panagotopulos SE, 2001, J BIOL CHEM, V276, P42965, DOI 10.1074/jbc.M106462200; Pennathur S, 2004, J BIOL CHEM, V279, P42977, DOI 10.1074/jbc.M406762200; Peterson JJ, 2004, MOL VIS, V10, P857; Reschly EJ, 2002, J BIOL CHEM, V277, P9645, DOI 10.1074/jbc.M107883200; Rogers DP, 1998, BIOCHEMISTRY-US, V37, P11714, DOI 10.1021/bi973112k; SAITO Y, 1982, SCIENCE, V217, P1151, DOI 10.1126/science.7112121; Segrest JP, 1999, J BIOL CHEM, V274, P31755, DOI 10.1074/jbc.274.45.31755; SEGREST JP, 1994, ADV PROTEIN CHEM, V45, P303; Silva RAGD, 2005, BIOCHEMISTRY-US, V44, P8600, DOI 10.1021/bi050421z; Silva RAGD, 2005, BIOCHEMISTRY-US, V44, P2759, DOI 10.1021/bi047717+; Sinz A, 2003, J MASS SPECTROM, V38, P1225, DOI 10.1002/JMS.559; Sorci-Thomas MG, 2002, TRENDS CARDIOVAS MED, V12, P121, DOI 10.1016/S1050-1738(01)00163-3; Sorci-Thomas MG, 2000, J BIOL CHEM, V275, P12156, DOI 10.1074/jbc.275.16.12156; SorciThomas MG, 1996, J LIPID RES, V37, P673; Steinberg D, 2002, NAT MED, V8, P1211, DOI 10.1038/nm1102-1211; Swaim CL, 2004, PROTEIN SCI, V13, P2832, DOI 10.1110/ps.04910004; Tian SM, 2002, BBA-PROTEINS PROTEOM, V1599, P56, DOI 10.1016/S1570-9639(02)00377-1; Tricerri MA, 2001, BIOCHEMISTRY-US, V40, P5065, DOI 10.1021/bi002815q; Trigatti B, 2000, CURR OPIN LIPIDOL, V11, P123, DOI 10.1097/00041433-200004000-00004; Trigatti BL, 2000, BBA-MOL CELL BIOL L, V1529, P276, DOI 10.1016/S1388-1981(00)00154-2; Wang GS, 2002, FEBS LETT, V529, P157, DOI 10.1016/S0014-5793(02)03354-9; WATERS MG, 1988, J BIOL CHEM, V263, P6209; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194; Yancey PG, 2003, ARTERIOSCL THROM VAS, V23, P712, DOI 10.1161/01.ATV.0000057572.97137.DD; Young MM, 2000, P NATL ACAD SCI USA, V97, P5802, DOI 10.1073/pnas.090099097; Zheng L, 2005, J BIOL CHEM, V280, P38, DOI 10.1074/jbc.M407019200	61	85	87	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	2005	280	38					33015	33025		10.1074/jbc.M505081200	http://dx.doi.org/10.1074/jbc.M505081200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	964ZU	15972827	hybrid			2022-12-25	WOS:000231920300056
J	Thoden, JB; Holden, HM				Thoden, JB; Holden, HM			The molecular architecture of human N-acetylgalactosamine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOSIN MOTOR DOMAIN; HUMAN GALACTOKINASE; PHOSPHOMEVALONATE KINASE; SUBSTRATE-SPECIFICITY; MEVALONATE KINASE; CRYSTAL-STRUCTURE; II GALACTOSEMIA; MECHANISM; SUPERFAMILY; ACTIVATION	Galactokinase plays a key role in normal galactose metabolism by catalyzing the conversion of alpha-(D)-galactose to galactose 1-phosphate. Within recent years, the three-dimensional structures of human galactokinase and two bacterial forms of the enzyme have been determined. Originally, the gene encoding galactokinase in humans was mapped to chromosome 17. An additional gene, encoding a protein with sequence similarity to galactokinase, was subsequently mapped to chromosome 15. Recent reports have shown that this second gene (GALK2) encodes an enzyme with greater activity against GalNAc than galactose. This enzyme, GalNAc kinase, has been implicated in a salvage pathway for the reutilization of free GalNAc derived from the degradation of complex carbohydrates. Here we report the first structural analysis of a GalNAc kinase. The structure of the human enzyme was solved in the presence of MnAMPPNP and GalNAc or MgATP and GalNAc ( which resulted in bound products in the active site). The enzyme displays a distinctly bilobal appearance with its active site wedged between the two domains. The N- terminal region is dominated by a seven-stranded mixed beta-sheet, whereas the C-terminal motif contains two layers of anti-parallel beta-sheet. The overall topology displayed by GalNAc kinase places it into the GHMP superfamily of enzymes, which generally function as small molecule kinases. From this investigation, the geometry of the GalNAc kinase active site before and after catalysis has been revealed, and the determinants of substrate specificity have been defined on a molecular level.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Holden, HM (corresponding author), Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA.	Hazel_Holden@biochem.wisc.edu			NIDDK NIH HHS [DK47814] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047814, R56DK047814] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADMIRAAL SJ, 1995, CHEM BIOL, V2, P729, DOI 10.1016/1074-5521(95)90101-9; ELSEVIER SM, 1974, NATURE, V251, P633, DOI 10.1038/251633a0; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; Fu ZJ, 2002, J BIOL CHEM, V277, P18134, DOI 10.1074/jbc.M200912200; Hartley A, 2004, J MOL BIOL, V337, P387, DOI 10.1016/j.jmb.2004.01.043; Hoffmeister D, 2003, P NATL ACAD SCI USA, V100, P13184, DOI 10.1073/pnas.2235011100; Holden HM, 2004, CELL MOL LIFE SCI, V61, P2471, DOI 10.1007/s00018-004-4160-6; Holden HM, 2003, J BIOL CHEM, V278, P43885, DOI 10.1074/jbc.R300025200; Krishna SS, 2001, BIOCHEMISTRY-US, V40, P10810, DOI 10.1021/bi010851z; LEE RT, 1992, P NATL ACAD SCI USA, V89, P10887, DOI 10.1073/pnas.89.22.10887; NAKAMAYE KL, 1985, BIOCHEMISTRY-US, V24, P5226, DOI 10.1021/bi00340a041; NAVAZA J, 1987, ACTA CRYSTALLOGR A, V43, P645, DOI 10.1107/S0108767387098787; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pastuszak I, 1996, J BIOL CHEM, V271, P23653, DOI 10.1074/jbc.271.39.23653; Pastuszak I, 1996, J BIOL CHEM, V271, P20776, DOI 10.1074/jbc.271.34.20776; Pilloff D, 2003, J BIOL CHEM, V278, P4510, DOI 10.1074/jbc.M210551200; Platt A, 2000, P NATL ACAD SCI USA, V97, P3154, DOI 10.1073/pnas.97.7.3154; Platt A, 1998, EMBO J, V17, P4086, DOI 10.1093/emboj/17.14.4086; Reece RJ, 2000, CELL MOL LIFE SCI, V57, P1161, DOI 10.1007/PL00000756; Romanowski MJ, 2002, PROTEINS, V47, P568, DOI 10.1002/prot.10118; SCHWEINS T, 1994, NAT STRUCT BIOL, V1, P476, DOI 10.1038/nsb0794-476; SCHWEINS T, 1995, NAT STRUCT BIOL, V2, P36, DOI 10.1038/nsb0195-36; Smith CA, 1996, BIOCHEMISTRY-US, V35, P5404, DOI 10.1021/bi952633+; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; STAMBOLIAN D, 1995, NAT GENET, V10, P307, DOI 10.1038/ng0795-307; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Thoden JB, 2005, J BIOL CHEM, V280, P9662, DOI 10.1074/jbc.M412916200; Thoden JB, 2003, J BIOL CHEM, V278, P33305, DOI 10.1074/jbc.M304789200; Thorson JS, 2004, CHEMBIOCHEM, V5, P16, DOI 10.1002/cbic.200300620; THORSON JS, 2002, GLYCOSYLATED NATURAL; Timson David J, 2003, BMC Biochem, V4, P16, DOI 10.1186/1471-2091-4-16; Timson DJ, 2003, EUR J BIOCHEM, V270, P1767, DOI 10.1046/j.1432-1033.2003.03538.x; Timson DJ, 2002, BIOCHIMIE, V84, P265, DOI 10.1016/S0300-9084(02)01399-8; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; Yang D, 2002, J BIOL CHEM, V277, P9462, DOI 10.1074/jbc.M110787200; Yang J, 2004, CHEMBIOCHEM, V5, P992, DOI 10.1002/cbic.200400041; Zenke FT, 1996, SCIENCE, V272, P1662, DOI 10.1126/science.272.5268.1662; Zhou T, 2000, STRUCTURE, V8, P1247, DOI 10.1016/S0969-2126(00)00533-5	39	64	67	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	2005	280	38					32784	32791		10.1074/jbc.M505730200	http://dx.doi.org/10.1074/jbc.M505730200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	964ZU	16006554	hybrid			2022-12-25	WOS:000231920300030
J	Grasemann, C; Gratias, S; Stephan, H; Schuler, A; Schramm, A; Klein-Hitpass, L; Rieder, H; Schneider, S; Kappes, F; Eggert, A; Lohmann, DR				Grasemann, C; Gratias, S; Stephan, H; Schuler, A; Schramm, A; Klein-Hitpass, L; Rieder, H; Schneider, S; Kappes, F; Eggert, A; Lohmann, DR			Gains and overexpression identify DEK and E2F3 as targets of chromosome 6p gains in retinoblastoma	ONCOGENE			English	Article						retinoblastoma; tumour progression; chromosome 6p; oncogene; microarray analysis; quantitative PCR	COMPARATIVE GENOMIC HYBRIDIZATION; ACUTE MYELOID-LEUKEMIA; CHROMATIN PROTEIN DEK; TUMOR-SUPPRESSOR; BLADDER-CANCER; AMPLIFICATION; GENE; EXPRESSION; OSTEOSARCOMA; INVOLVEMENT	The paediatric eye tumour retinoblastoma is initiated by inactivation of RB1, a tumour suppressor on chromosome 13q. In addition to RB1 loss, many retinoblastomas show other genetic alterations including gains on chromosomes 6p21-pter and 1q31-q32. Recently, the minimal region of gains on chromosome 6 was narrowed to band p22. We examined genomic gains and expression changes in primary retinoblastomas to identify potential target genes in 6p22. Quantitative multiplex PCR detected copy numbers >= 3 in 25 (33%) tumours and no gains in 31 of 76 (40%) tumours. The remaining 20 (26%) samples showed gains only at some loci, most often including E2F3 and DEK in 6p22.3. Analysis of RNA from 21 primary retinoblastomas showed that expression levels of these and some other genes in 6p22 correspond to DNA gains. However, KIF 13A, a reported candidate oncogene on 6p, was expressed at low levels or absent. Clinical manifestation of tumours with gains at all 6p22 loci was distinct in that distribution of age at diagnosis was markedly shifted to older age compared to tumours with no or partial gains. In summary, our results suggest that DEK and E2F3 are potential targets of 6p gains in retinoblastoma.	Univ Klinikum Essen, Inst Humangenet, D-45122 Essen, Germany; Univ Childrens Hosp Essen, Univ Klinikum Essen, D-45122 Essen, Germany; Univ Klinikum Essen, Augenklin, D-45122 Essen, Germany; Univ Klinikum Essen, Inst Zellbiol, D-45122 Essen, Germany; Univ Dusseldorf, Inst Human Genet & Anthropol, D-40225 Dusseldorf, Germany; Univ Klinikum Marburg, Inst Klin Genet, D-35033 Marburg, Germany; Univ Konstanz, Dept Biol, D-78457 Constance, Germany	University of Duisburg Essen; University of Duisburg Essen; University of Duisburg Essen; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Duisburg Essen; Heinrich Heine University Dusseldorf; University of Konstanz	Lohmann, DR (corresponding author), Univ Klinikum Essen, Inst Humangenet, D-45122 Essen, Germany.	dietmar.lohmann@uni-essen.de	Ferdinand, Kappes/H-4445-2014; Schramm, Alexander/G-5688-2010; Lohmann, Dietmar R/B-4041-2013; Eggert, Angelika/AAE-6907-2022; Grasemann, Corinna/AAG-3861-2021; Stephan, Harald/AAT-6802-2021; Lohmann, Dietmar R./X-4895-2019	Ferdinand, Kappes/0000-0002-0369-0065; Schramm, Alexander/0000-0001-7670-7529; Lohmann, Dietmar R/0000-0002-2624-9889; Eggert, Angelika/0000-0003-3476-8184; Lohmann, Dietmar R./0000-0002-2624-9889; Grasemann, Corinna/0000-0003-1793-4603				Baugh LR, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.5.e29; Boonstra R, 2003, VIRCHOWS ARCH, V443, P164, DOI 10.1007/s00428-003-0836-9; CANO J, 1994, CANCER GENET CYTOGEN, V76, P112, DOI 10.1016/0165-4608(94)90459-6; Casas S, 2003, LEUKEMIA LYMPHOMA, V44, P1935, DOI 10.1080/1042819031000119299; Chen D, 2002, CANCER RES, V62, P967; Chen DN, 2001, CANCER GENET CYTOGEN, V129, P57, DOI 10.1016/S0165-4608(01)00427-7; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; Feber A, 2004, ONCOGENE, V23, P1627, DOI 10.1038/sj.onc.1207274; Fletcher O, 2004, JNCI-J NATL CANCER I, V96, P357, DOI 10.1093/jnci/djh058; Foster CS, 2004, ONCOGENE, V23, P5871, DOI 10.1038/sj.onc.1207800; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; Gallie BL, 1999, CANCER RES, V59, p1731S; Ginsberg D, 2004, DEV CELL, V6, P742, DOI 10.1016/j.devcel.2004.05.012; Herzog S, 2001, HUM GENET, V108, P98, DOI 10.1007/s004390000450; Hoglund M, 2004, INT J CANCER, V108, P57, DOI 10.1002/ijc.11558; HORSTHEMKE B, 1992, CANCER GENET CYTOGEN, V63, P1, DOI 10.1016/0165-4608(92)90055-D; Hui R, 1997, ONCOGENE, V15, P1617, DOI 10.1038/sj.onc.1201311; Kappes F, 2004, MOL CELL BIOL, V24, P6011, DOI 10.1128/MCB.24.13.6011-6020.2004; Kappes F, 2004, MOL CELL BIOL, V24, P6000, DOI 10.1128/MCB.24.13.6000-6010.2004; Koon N, 2004, NEOPLASIA, V6, P143, DOI 10.1593/neo.03385; Lau CC, 2004, GENE CHROMOSOME CANC, V39, P11, DOI 10.1002/gcc.10291; Mairal A, 2000, GENE CHROMOSOME CANC, V28, P370, DOI 10.1002/1098-2264(200008)28:4<370::AID-GCC2>3.0.CO;2-8; Micci F, 2003, CANCER GENET CYTOGEN, V144, P119, DOI 10.1016/S0165-4608(03)00025-6; Mittnacht S, 2005, EUR J CELL BIOL, V84, P97, DOI 10.1016/j.ejcb.2004.12.012; Nakagawa T, 1997, P NATL ACAD SCI USA, V94, P9654, DOI 10.1073/pnas.94.18.9654; Oeggerli M, 2004, ONCOGENE, V23, P5616, DOI 10.1038/sj.onc.1207749; Parisi T, 2002, BIOCHEM BIOPH RES CO, V291, P1138, DOI 10.1006/bbrc.2002.6591; Partheen K, 2004, GENE CHROMOSOME CANC, V40, P342, DOI 10.1002/gcc.20053; REIFENBERGER G, 1994, CANCER RES, V54, P4299; Saavedra HI, 2002, CELL GROWTH DIFFER, V13, P215; Sakowicz R, 2004, CANCER RES, V64, P3276, DOI 10.1158/0008-5472.CAN-03-3839; Sitwala KV, 2003, ANTICANCER RES, V23, P2155; SQUIRE J, 1985, HUM GENET, V70, P291, DOI 10.1007/BF00295364; SQUIRE J, 1984, HUM GENET, V66, P46, DOI 10.1007/BF00275185; van der Wal JE, 2003, J CLIN PATHOL, V56, P26, DOI 10.1136/jcp.56.1.26; VOGEL F, 1979, HUM GENET, V52, P1; VONLINDERN M, 1992, MOL CELL BIOL, V12, P1687, DOI 10.1128/MCB.12.4.1687	37	81	83	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 22	2005	24	42					6441	6449		10.1038/sj.onc.1208792	http://dx.doi.org/10.1038/sj.onc.1208792			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	966RI	16007192				2022-12-25	WOS:000232038200011
J	Zhu, JX; Goldoni, S; Bix, G; Owens, RT; McQuillan, DJ; Reed, CC; Iozzo, RV				Zhu, JX; Goldoni, S; Bix, G; Owens, RT; McQuillan, DJ; Reed, CC; Iozzo, RV			Decorin evokes protracted internalization and degradation of the epidermal growth factor receptor via caveolar endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE-RICH PROTEOGLYCANS; CHICK-EMBRYO FIBROBLASTS; DOWN-REGULATION; EGF RECEPTOR; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; UP-REGULATION; CELL-GROWTH; SUPPRESSION; KINASE	Decorin inhibits the epidermal growth factor receptor ( EGFR) by down-regulating its tyrosine kinase activity, thereby blocking the growth of a variety of transformed cells and tumor xenografts. In this study we provide evidence that decorin directly binds to the EGFR causing its dimerization, internalization, and ultimately its degradation. Using various pharmacological agents to disrupt clathrin-dependent and -independent endocytosis, we demonstrate that decorin evokes a protracted internalization of the EGFR primarily via caveolar-mediated endocytosis. In contrast to EGF, decorin targets the EGFR to caveolae, but not to early or recycling endosomes. Ultimately, however, both EGF- and decorin-induced pathways converge into late endosomes/lysosomes for final degradation. Thus, we have discovered a novel biological mechanism for decorin that could explain its anti-proliferative and anti-oncogenic mode of action.	Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; LifeCell Corp, Branchburg, NJ 08876 USA; Thomas Jefferson Univ, Kimmel Canc Ctr, Cell Biol & Signaling Program, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University	Iozzo, RV (corresponding author), Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Rm 249 Jefferson Alumni Hall,1020 Locust St, Philadelphia, PA 19107 USA.	iozzo@mail.jci.tju.edu	Iozzo, Renato/AAS-1980-2020	Iozzo, Renato/0000-0002-5908-5112	NCI NIH HHS [R01 CA39481, R01 CA47282] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047282, R01CA039481] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abulrob A, 2004, ONCOGENE, V23, P6967, DOI 10.1038/sj.onc.1207911; Bailly M, 2000, MOL BIOL CELL, V11, P3873, DOI 10.1091/mbc.11.11.3873; Biglari A, 2004, CANCER GENE THER, V11, P721, DOI 10.1038/sj.cgt.7700783; Carpenter G, 2000, BIOESSAYS, V22, P697, DOI 10.1002/1521-1878(200008)22:8<697::AID-BIES3>3.3.CO;2-T; Carpenter G, 1999, J CELL BIOL, V146, P697, DOI 10.1083/jcb.146.4.697; Carter RE, 1998, J BIOL CHEM, V273, P35000, DOI 10.1074/jbc.273.52.35000; Chen X, 2002, J BIOL CHEM, V277, P49631, DOI 10.1074/jbc.M208327200; Cohen AW, 2004, PHYSIOL REV, V84, P1341, DOI 10.1152/physrev.00046.2003; Csordas G, 2000, J BIOL CHEM, V275, P32879, DOI 10.1074/jbc.M005609200; De Renzis S, 2002, NAT CELL BIOL, V4, P124, DOI 10.1038/ncb744; DeLuca A, 1996, J BIOL CHEM, V271, P18961, DOI 10.1074/jbc.271.31.18961; Di Guglielmo GM, 2003, NAT CELL BIOL, V5, P410, DOI 10.1038/ncb975; Escola JM, 1998, J BIOL CHEM, V273, P20121, DOI 10.1074/jbc.273.32.20121; FAN Z, 1995, J CELL BIOL, V131, P235, DOI 10.1083/jcb.131.1.235; Fisher LW, 1995, ACTA ORTHOP SCAND, V66, P61, DOI 10.3109/17453679509157649; Goldoni S, 2004, J BIOL CHEM, V279, P6606, DOI 10.1074/jbc.M310342200; Gulli LF, 1996, CELL GROWTH DIFFER, V7, P173; Hausser H, 1998, ARCH BIOCHEM BIOPHYS, V349, P363, DOI 10.1006/abbi.1997.0471; HAUSSER H, 1991, J CELL BIOL, V114, P45, DOI 10.1083/jcb.114.1.45; Iozzo RV, 1999, PROG NUCLEIC ACID RE, V62, P19; Iozzo RV, 1999, P NATL ACAD SCI USA, V96, P3092, DOI 10.1073/pnas.96.6.3092; Iozzo RV, 1999, J BIOL CHEM, V274, P18843, DOI 10.1074/jbc.274.27.18843; Iozzo RV, 1999, J BIOL CHEM, V274, P4489, DOI 10.1074/jbc.274.8.4489; Iozzo RV, 1997, CRIT REV BIOCHEM MOL, V32, P141, DOI 10.3109/10409239709108551; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; Kjer-Nielsen L, 1999, J CELL SCI, V112, P1645; Kolettas E, 1998, EUR J BIOCHEM, V254, P266, DOI 10.1046/j.1432-1327.1998.2540266.x; LAMAZE C, 1995, J CELL BIOL, V129, P47, DOI 10.1083/jcb.129.1.47; Le PU, 2003, J CELL SCI, V116, P1059, DOI 10.1242/jcs.00327; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Lu ZM, 2003, CANCER CELL, V4, P499, DOI 10.1016/S1535-6108(03)00304-0; McDoniels-Silvers AL, 2002, CLIN CANCER RES, V8, P1127; Mineo C, 1999, J BIOL CHEM, V274, P30636, DOI 10.1074/jbc.274.43.30636; Miyasaka Y, 2001, BRIT J CANCER, V85, P228, DOI 10.1054/bjoc.2001.1901; Moghal N, 1999, CURR OPIN CELL BIOL, V11, P190, DOI 10.1016/S0955-0674(99)80025-8; Mongiat M, 2003, J BIOL CHEM, V278, P17491, DOI 10.1074/jbc.M210529200; Mongiat M, 2003, J BIOL CHEM, V278, P4238, DOI 10.1074/jbc.M210445200; Moscatello DK, 1998, J CLIN INVEST, V101, P406, DOI 10.1172/JCI846; Nash MA, 2002, CLIN CANCER RES, V8, P1754; Nash MA, 1999, CANCER RES, V59, P6192; Nichols B, 2003, J CELL SCI, V116, P4707, DOI 10.1242/jcs.00840; NORTHWOOD IC, 1988, J BIOL CHEM, V263, P7450; Pelkmans L, 2002, TRAFFIC, V3, P311, DOI 10.1034/j.1600-0854.2002.30501.x; Perez S, 2001, ONCOGENE, V20, P1135, DOI 10.1038/sj.onc.1204200; Pike LJ, 2004, BIOCHEM J, V378, P281, DOI 10.1042/BJ20031672; Ramamurthy P, 1996, J BIOL CHEM, V271, P19578, DOI 10.1074/jbc.271.32.19578; Reed CC, 2005, ONCOGENE, V24, P1104, DOI 10.1038/sj.onc.1208329; Reed CC, 2002, GLYCOCONJUGATE J, V19, P249, DOI 10.1023/A:1025383913444; Reed CC, 2002, ONCOGENE, V21, P3688, DOI 10.1038/sj.onc.1205470; Ringerike T, 2002, J CELL SCI, V115, P1331; Rubino M, 2000, J BIOL CHEM, V275, P3745, DOI 10.1074/jbc.275.6.3745; Santiago-Garcia J, 2003, J BIOL CHEM, V278, P6942, DOI 10.1074/jbc.M208358200; Santra M, 1997, J CLIN INVEST, V100, P149, DOI 10.1172/JCI119507; Santra M, 2002, J BIOL CHEM, V277, P35671, DOI 10.1074/jbc.M205317200; SANTRA M, 1995, P NATL ACAD SCI USA, V92, P7016, DOI 10.1073/pnas.92.15.7016; Santra M, 2000, J BIOL CHEM, V275, P35153, DOI 10.1074/jbc.M006821200; Schlessinger J, 2002, CELL, V110, P669, DOI 10.1016/S0092-8674(02)00966-2; Schmidt MHH, 2003, P NATL ACAD SCI USA, V100, P6505, DOI 10.1073/pnas.1031790100; Schonherr E, 2005, J BIOL CHEM, V280, P15767, DOI 10.1074/jbc.M500451200; Schonherr E, 2001, J BIOL CHEM, V276, P40687, DOI 10.1074/jbc.M105426200; Shridhar V, 2001, CANCER RES, V61, P5895; Sigismund S, 2005, P NATL ACAD SCI USA, V102, P2760, DOI 10.1073/pnas.0409817102; Tran KT, 2004, WOUND REPAIR REGEN, V12, P262, DOI 10.1111/j.1067-1927.2004.012302.x; Troup S, 2003, CLIN CANCER RES, V9, P207; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Vial E, 2000, ONCOGENE, V19, P1772, DOI 10.1038/sj.onc.1203493; WANG LH, 1993, J CELL BIOL, V123, P1107, DOI 10.1083/jcb.123.5.1107; Wang XQ, 2002, J BIOL CHEM, V277, P47028, DOI 10.1074/jbc.M208257200; Xaus J, 2001, BLOOD, V98, P2124, DOI 10.1182/blood.V98.7.2124; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0	70	159	163	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	2005	280	37					32468	32479		10.1074/jbc.M503833200	http://dx.doi.org/10.1074/jbc.M503833200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	963HM	15994311	hybrid			2022-12-25	WOS:000231794800054
J	Kim, JY; Saffen, D				Kim, JY; Saffen, D			Activation of M1 muscarinic acetylcholine receptors stimulates the formation of a multiprotein complex centered on TRPC6 channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; TRANSIENT RECEPTOR; CALCIUM-RELEASE; CA2+ CHANNEL; PHEOCHROMOCYTOMA CELLS; SIGNALING COMPLEX; CRYSTAL-STRUCTURE; PROTEIN; CALCINEURIN; IMMUNOPHILIN	In this study we showed that stimulation of M1 muscarinic acetylcholine receptors (mAChRs) activates endogenous transient receptor potential-canonical, subtype 6 (TRPC6), channels in neuronal PC12D cells. Activation of TRPC6 channels is correlated with the formation of a multiprotein complex containing M1 mAChRs, TRPC6 channels, and protein kinase C (PKC). Formation of the M1 mAChR-TRPC6-PKC complex is transient, with highest levels reached similar to 2 min after stimulation of M1 mAChRs. PKC in the complex phosphorylates TRPC6 on a conserved serine residue in the carboxyl-terminal domain (Ser(768) in the TRPC6A isoform and Ser(714) in the TRPC6B isoform). The immunophilin FKBP12, the phosphatase calcineurin, and Ca2+-binding protein calmodulin are also recruited to the M1 mAChR-TRPC6-PKC complex following activation of M1 mAChRs and remain stably associated with the TRPC6 channels after M1 mAChRs and PKC have disassociated. Binding of FKBP12, calcineurin, and calmodulin to TRPC6 channels is blocked by the following: 1) inhibition of PKC; 2) mutation of the PKC phosphorylation site (Ser(7168/714)) in the channels; or 3) pretreatment with FK506 or rapamycin, immunosuppressants that directly bind FKBP12. Inhibition of FKBP12 binding blocks the dephosphorylation of TRPC6 channels and the disassociation of M1 mAChRs, without affecting disassociation of PKC. The calcineurin inhibitor cyclosporin A also blocks the dephosphorylation of TRPC6 and prevents the disassociation of M1 mAChRs. Together, these results show that activated TRPC6 channels form the center of a dynamic multiprotein complex that includes PKC and calcineurin, which respectively phosphorylate and dephosphorylate the channels. Phosphorylation of the TRPC6 channels by PKC is required for the binding of FKBP12, which in turn is required for the binding of calcineurin and calmodulin. Subsequent dephosphorylation of the channels by calcineurin is required for the disassociation of M1 mAChRs.	Ohio State Univ, Coll Med & Publ Hlth, Dept Pharmacol, Columbus, OH 43210 USA; Ohio State Univ, Coll Med & Publ Hlth, Dept Psychiat, Columbus, OH 43210 USA; Ohio State Univ, Coll Med & Publ Hlth, Grad Program Mol Cellular & Dev Biol, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Saffen, D (corresponding author), Ohio State Univ, Coll Med & Publ Hlth, Dept Pharmacol, 5072C Graves Hall,333 W 10th Ave, Columbus, OH 43210 USA.	saffen.1@osu.edu						ALDAPE RA, 1992, J BIOL CHEM, V267, P16029; Balzer M, 1999, CARDIOVASC RES, V42, P543, DOI 10.1016/S0008-6363(99)00025-5; Beech DJ, 2003, CELL CALCIUM, V33, P433, DOI 10.1016/S0143-4160(03)00054-X; Berridge MJ, 2001, NOVART FDN SYMP, V239, P52; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; Bultynck G, 2003, BIOCHEM BIOPH RES CO, V311, P1181, DOI 10.1016/j.bbrc.2003.08.084; Cameron AM, 1997, J BIOL CHEM, V272, P27582, DOI 10.1074/jbc.272.44.27582; CAMERON AM, 1995, P NATL ACAD SCI USA, V92, P1784, DOI 10.1073/pnas.92.5.1784; CAMERON AM, 1995, CELL, V83, P463, DOI 10.1016/0092-8674(95)90124-8; Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; Falquet L, 2002, NUCLEIC ACIDS RES, V30, P235, DOI 10.1093/nar/30.1.235; Goel M, 2002, J BIOL CHEM, V277, P48303, DOI 10.1074/jbc.M207882200; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; Groschner K, 1998, FEBS LETT, V437, P101, DOI 10.1016/S0014-5793(98)01212-5; Hofmann T, 2002, P NATL ACAD SCI USA, V99, P7461, DOI 10.1073/pnas.102596199; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; Huai Q, 2002, P NATL ACAD SCI USA, V99, P12037, DOI 10.1073/pnas.192206699; Huber A, 1996, EMBO J, V15, P7036, DOI 10.1002/j.1460-2075.1996.tb01095.x; JAYARAMAN T, 1992, J BIOL CHEM, V267, P9474; Jin L, 2002, P NATL ACAD SCI USA, V99, P13522, DOI 10.1073/pnas.212504399; Jungnickel MK, 2001, NAT CELL BIOL, V3, P499, DOI 10.1038/35074570; KATOHSEMBA R, 1987, J NEUROSCI RES, V17, P36, DOI 10.1002/jnr.490170106; Leypold BG, 2002, P NATL ACAD SCI USA, V99, P6376, DOI 10.1073/pnas.082127599; Liman ER, 1999, P NATL ACAD SCI USA, V96, P5791, DOI 10.1073/pnas.96.10.5791; Liu XB, 2003, J BIOL CHEM, V278, P11337, DOI 10.1074/jbc.M213271200; Lockwich TP, 2000, J BIOL CHEM, V275, P11934, DOI 10.1074/jbc.275.16.11934; Marks AR, 1996, PHYSIOL REV, V76, P631, DOI 10.1152/physrev.1996.76.3.631; Minke B, 2002, PHYSIOL REV, V82, P429, DOI 10.1152/physrev.00001.2002; Montell C, 2002, MOL CELL, V9, P229, DOI 10.1016/S1097-2765(02)00448-3; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Okada T, 1999, J BIOL CHEM, V274, P27359, DOI 10.1074/jbc.274.39.27359; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Plant TD, 2003, CELL CALCIUM, V33, P441, DOI 10.1016/S0143-4160(03)00055-1; Putney JW, 2004, TRENDS CELL BIOL, V14, P282, DOI 10.1016/j.tcb.2004.04.002; Putney JW, 2001, J CELL SCI, V114, P2223; Rosado JA, 2002, J BIOL CHEM, V277, P42157, DOI 10.1074/jbc.M207320200; Rosado JA, 2001, BIOCHEM J, V356, P191, DOI 10.1042/0264-6021:3560191; SCHILLING WP, 1989, J BIOL CHEM, V264, P12838; Shieh BH, 1996, NEURON, V16, P991, DOI 10.1016/S0896-6273(00)80122-1; Singh BB, 2002, MOL CELL, V9, P739, DOI 10.1016/S1097-2765(02)00506-3; Sinkins WG, 2004, J BIOL CHEM, V279, P34521, DOI 10.1074/jbc.M401156200; Stowers L, 2002, SCIENCE, V295, P1493, DOI 10.1126/science.1069259; Strubing C, 2003, J BIOL CHEM, V278, P39014, DOI 10.1074/jbc.M306705200; Tang J, 2001, J BIOL CHEM, V276, P21303, DOI 10.1074/jbc.M102316200; Tang Y, 2000, J BIOL CHEM, V275, P37559, DOI 10.1074/jbc.M006635200; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Trebak M, 2005, MOL PHARMACOL, V67, P558, DOI 10.1124/mol.104.007252; Trebak M, 2003, CELL CALCIUM, V33, P451, DOI 10.1016/S0143-4160(03)00056-3; Venkatachalam K, 2003, J BIOL CHEM, V278, P29031, DOI 10.1074/jbc.M302751200; Venkatachalam K, 2002, NAT CELL BIOL, V4, pE263, DOI 10.1038/ncb1102-e263; Wehrens XHT, 2005, ANNU REV PHYSIOL, V67, P69, DOI 10.1146/annurev.physiol.67.040403.114521; YAMAGUCHI DT, 1989, J BIOL CHEM, V264, P197; Yuan JP, 2003, CELL, V114, P777, DOI 10.1016/S0092-8674(03)00716-5; Zhang L, 2001, J BIOL CHEM, V276, P13331, DOI 10.1074/jbc.M008914200; Zhang ZM, 2001, P NATL ACAD SCI USA, V98, P3168, DOI 10.1073/pnas.051632698	61	73	79	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	2005	280	36					32035	32047		10.1074/jbc.M500429200	http://dx.doi.org/10.1074/jbc.M500429200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	961LZ	15994335	hybrid			2022-12-25	WOS:000231665200084
J	Koga, S; Yogo, K; Yoshikawa, K; Samori, H; Goto, M; Uchida, T; Ishida, N; Takeya, T				Koga, S; Yogo, K; Yoshikawa, K; Samori, H; Goto, M; Uchida, T; Ishida, N; Takeya, T			Physical and functional association of c-Src and adhesion and degranulation promoting adaptor protein (ADAP) in osteoclastogenesis in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FYN-BINDING PROTEIN; SIGNAL-TRANSDUCTION PATHWAYS; NECROSIS-FACTOR RECEPTOR; ALPHA(V)BETA(3) INTEGRIN; TYROSINE-PHOSPHATASE; KINASE-ACTIVITY; DEFICIENT MICE; CELL-ADHESION; DIFFERENTIATION; TCR	c-Src plays a crucial role in osteoclastogenesis. In this study, we searched for c-Src-binding proteins using a combination of pull-down assays and mass spectrometric analysis, and identified the association of adhesion and degranulation promoting adaptor protein ( ADAP) with c-Src in RAW264 cells and osteoclast precursors prepared from bone marrow cells. The kinase activity and the SH2 domain of c-Src were required for this association and Tyr(807) in the extreme carboxyl terminus of ADAP was identified as a major recognition site. ADAP was found to be expressed in cells at the pre-fusion stage and localized mainly in the leading edge of lamellipodia and in pseudopodia. Tyrosine phosphorylation of ADAP was induced in an integrin-dependent manner, and the level was Src kinase-dependent. ADAP-knockdown RAW264 cells showed retarded migration and formed few multinucleated cells. Cas, known to be phosphorylated by c-Src, was identified as a major tyrosine-phosphorylated protein in differentiating RAW264 cells and the phosphorylation appeared to be decreased in ADAP-knockdown cells. ADAP thus may play an important role as a partner of c-Src for cell migration and progression to the multinucleated cell stage in osteoclastogenesis in vitro.	Nara Inst Sci & Technol, Grad Sch Biol Sci, Nara 6300101, Japan	Nara Institute of Science & Technology	Takeya, T (corresponding author), Nara Inst Sci & Technol, Grad Sch Biol Sci, Nara 6300101, Japan.	ttakeya@bs.naist.jp		Yogo, Keiichiro/0000-0003-2051-6891				Akagi T, 2003, P NATL ACAD SCI USA, V100, P13567, DOI 10.1073/pnas.1834876100; Banin S, 1996, CURR BIOL, V6, P981, DOI 10.1016/S0960-9822(02)00642-5; Black DS, 1997, EMBO J, V16, P2730, DOI 10.1093/emboj/16.10.2730; BOYCE BF, 1992, J CLIN INVEST, V90, P1622, DOI 10.1172/JCI116032; Brown MT, 1998, MOL CELL BIOL, V18, P7038, DOI 10.1128/MCB.18.12.7038; Chambers TJ, 2000, J PATHOL, V192, P4; Chodniewicz D, 2004, BBA-MOL CELL RES, V1692, P63, DOI 10.1016/j.bbamcr.2004.03.006; DaSilva AJ, 1997, P NATL ACAD SCI USA, V94, P7493, DOI 10.1073/pnas.94.14.7493; Deleuil F, 2003, CELL MICROBIOL, V5, P53, DOI 10.1046/j.1462-5822.2003.00236.x; Frame MC, 2004, J CELL SCI, V117, P989, DOI 10.1242/jcs.01111; Galan JE, 1996, ANNU REV CELL DEV BI, V12, P221, DOI 10.1146/annurev.cellbio.12.1.221; Geng LP, 1999, J IMMUNOL, V163, P5753; Geng LP, 2001, P NATL ACAD SCI USA, V98, P11527, DOI 10.1073/pnas.191378198; Giuriato S, 2000, BIOCHEM J, V348, P107, DOI 10.1042/0264-6021:3480107; Griffiths EK, 2002, CURR OPIN IMMUNOL, V14, P317, DOI 10.1016/S0952-7915(02)00334-5; Griffiths EK, 2001, SCIENCE, V293, P2260, DOI 10.1126/science.1063397; Hamid N, 1999, MICROB PATHOGENESIS, V27, P231, DOI 10.1006/mpat.1999.0301; Heuer K, 2004, STRUCTURE, V12, P603, DOI 10.1016/j.str.2004.02.021; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; HORNE WC, 1992, J CELL BIOL, V119, P1003, DOI 10.1083/jcb.119.4.1003; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540; Ishida N, 2002, J BIOL CHEM, V277, P41147, DOI 10.1074/jbc.M205063200; Krause M, 2000, J CELL BIOL, V149, P181, DOI 10.1083/jcb.149.1.181; Kumagai N, 2004, BIOCHEM BIOPH RES CO, V325, P758, DOI 10.1016/j.bbrc.2004.10.094; Kuwana R, 2002, MICROBIOL-SGM, V148, P3971, DOI 10.1099/00221287-148-12-3971; LOWE C, 1993, P NATL ACAD SCI USA, V90, P4485, DOI 10.1073/pnas.90.10.4485; Meiyanto E, 2001, BIOCHEM BIOPH RES CO, V282, P278, DOI 10.1006/bbrc.2001.4564; Miyazaki T, 2004, J BIOL CHEM, V279, P17660, DOI 10.1074/jbc.M311032200; Musci MA, 1997, J BIOL CHEM, V272, P11674, DOI 10.1074/jbc.272.18.11674; Nakamura I, 1999, J CELL SCI, V112, P3985; Nakamura I, 1998, ENDOCRINOLOGY, V139, P5182, DOI 10.1210/en.139.12.5182; Peterson EJ, 2003, IMMUNOL REV, V192, P113, DOI 10.1034/j.1600-065X.2003.00026.x; Peterson EJ, 2001, SCIENCE, V293, P2263, DOI 10.1126/science.1063486; Raab M, 1999, J BIOL CHEM, V274, P21170, DOI 10.1074/jbc.274.30.21170; Rohrschneider LR, 2000, GENE DEV, V14, P505; Roodman GD, 1996, ENDOCR REV, V17, P308, DOI 10.1210/er.17.4.308; ROSENSHINE I, 1993, BIOESSAYS, V15, P17, DOI 10.1002/bies.950150104; SAKAI N, 2004, PRECLINICA, V2, P57; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Sanjay A, 2001, J CELL BIOL, V152, P181, DOI 10.1083/jcb.152.1.181; Schwartzberg PL, 1997, GENE DEV, V11, P2835, DOI 10.1101/gad.11.21.2835; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STEHELIN D, 1976, NATURE, V260, P170, DOI 10.1038/260170a0; Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345; Takeshita S, 2002, NAT MED, V8, P943, DOI 10.1038/nm752; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; Tanaka S, 2003, J BONE MINER METAB, V21, P123, DOI 10.1007/s007740300021; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; Thomas M, 2002, P NATL ACAD SCI USA, V99, P14640, DOI 10.1073/pnas.192581499; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Troen BR, 2003, EXP GERONTOL, V38, P605, DOI 10.1016/S0531-5565(03)00069-X; Veale M, 1999, J BIOL CHEM, V274, P28427, DOI 10.1074/jbc.274.40.28427; Vuori K, 1996, MOL CELL BIOL, V16, P2606; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366	55	11	13	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	2005	280	36					31564	31571		10.1074/jbc.M502703200	http://dx.doi.org/10.1074/jbc.M502703200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	961LZ	16020549	hybrid			2022-12-25	WOS:000231665200029
J	Fernandez-Garcia, NI; Palmer, HG; Garcia, M; Gonzalez-Martin, A; del Rio, M; Barettino, D; Volpert, O; Munoz, A; Jimenez, B				Fernandez-Garcia, NI; Palmer, HG; Garcia, M; Gonzalez-Martin, A; del Rio, M; Barettino, D; Volpert, O; Munoz, A; Jimenez, B			1 alpha, 25-Dihydroxyvitamin D-3 regulates the expression of Id1 and Id2 genes and the angiogenic phenotype of human colon carcinoma cells	ONCOGENE			English	Article						Id; 1 alpha, 25( OH)(2)D-3; colon carcinoma; angiogenesis; E-cadherin	LOOP-HELIX PROTEINS; VITAMIN-D ANALOGS; 1-ALPHA,25-DIHYDROXYVITAMIN D-3; CYCLE CONTROL; PHASE-I; DIFFERENTIATION; CANCER; PROLIFERATION; INHIBITION; 1,25-DIHYDROXYVITAMIN-D3	1 alpha,25-Dihydroxyvitamin D-3 (1 alpha,25(OH)(2)D-3) has antitumor activity in addition to its classical action on calcium metabolism and bone tissue biology. It is thought to regulate the expression of multiple target genes and thus modulate processes critical for tumor growth and metastases. Here we show that 1 alpha, 25(OH)(2)D-3 differentially regulates the expression of Id1 and Id2 genes, members of a family of transcriptional regulators of cell proliferation and differentiation. 1 alpha,25(OH)(2)D-3 induced epithelial differentiation in SW480-ADH human colon carcinoma cell line by promoting expression of the proteins implicated in adherent junction formation, including E-cadherin, and by inhibiting beta-catenin transcriptional activity. 1 alpha,25(OH)(2)D-3 activated the human Id1 gene promoter and rapidly induced Id1 RNA and protein. E-cadherin, overexpression of Id1 was not sufficient to induce E-cadherin, which was critical for the morphological changes induced by 1 alpha,25(OH)(2)D-3 in SW480-ADH cells. Conversely, Id2 transcription rate, RNA and protein levels were decreased by 1 alpha,25(OH)(2)D-3. Id2 downregulation by 1 alpha,25(OH)(2)D-3 mediated the antiproliferative effect of 1 alpha,25(OH)(2)D-3 on SW480-ADH cells. In addition, we showed that 1 alpha,25(OH)(2)D-3 changed the levels of the inducer of angiogenesis, vascular endothelial growth factor and the potent antiangiogenic factor thrombospondin-1, leading to a balanced change in the angiogenic potential of SW480-ADH human colon carcinoma cells.	Univ Autonoma Madrid, CSIC, Inst Invest Biomed, Madrid 28029, Spain; Univ Autonoma Madrid, Dept Biochem, Madrid 28029, Spain; Canc Res, London WC2A 3PX, England; CIEMAT, Project Damage, Repair & Tissue Engn, E-28040 Madrid, Spain; CSIC, Inst Biomed Valencia, E-46010 Valencia, Spain; Northwestern Univ, Sch Med, Dept Urol, Chicago, IL 60611 USA	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Autonomous University of Madrid; Centro de Investigaciones Energeticas, Medioambientales Tecnologicas; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biomedicina de Valencia (IBV); Northwestern University	Jimenez, B (corresponding author), Univ Autonoma Madrid, CSIC, Inst Invest Biomed, Artuto Duperier 4, Madrid 28029, Spain.	bjimenez@iib.uam.es	Gonzalez-Martin, Alicia/B-1702-2017; DEL RIO, MARCELA/H-2796-2015; Palmer, Héctor G./AAG-8332-2019; Cuenca, Benilde Jimenez/K-9959-2014; Munoz, Alberto/O-6393-2014	Gonzalez-Martin, Alicia/0000-0002-6179-089X; DEL RIO, MARCELA/0000-0003-2910-7189; Munoz, Alberto/0000-0003-3890-4251; Jimenez Cuenca, Benilde/0000-0002-1806-6636; Palmer, Hector/0000-0002-9823-5638				Behrens J, 2000, ANN NY ACAD SCI, V910, P21; Benezra R, 2001, ONCOGENE, V20, P8334, DOI 10.1038/sj.onc.1205160; Bernardi RJ, 2002, ENDOCRINOLOGY, V143, P2508, DOI 10.1210/en.143.7.2508; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Dalhoff K, 2003, BRIT J CANCER, V89, P252, DOI 10.1038/sj.bjc.6601104; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; Diaz GD, 2000, CANCER RES, V60, P2304; Evans SRT, 2000, INT J ONCOL, V16, P1249; Ezura Y, 1997, J BIOL CHEM, V272, P29865, DOI 10.1074/jbc.272.47.29865; Gross C, 1998, J UROLOGY, V159, P2035, DOI 10.1016/S0022-5347(01)63236-1; Gulliford T, 1998, BRIT J CANCER, V78, P6, DOI 10.1038/bjc.1998.434; Gumireddy K, 2003, BIOCHEM PHARMACOL, V65, P1943, DOI 10.1016/S0006-2952(03)00205-3; Guyton KZ, 2001, ANNU REV PHARMACOL, V41, P421, DOI 10.1146/annurev.pharmtox.41.1.421; HALLINE AG, 1994, ENDOCRINOLOGY, V134, P1710, DOI 10.1210/en.134.4.1710; Hewitt RE, 2000, J PATHOL, V192, P446; Iseki K, 1999, INT J CANCER, V81, P730, DOI 10.1002/(SICI)1097-0215(19990531)81:5&lt;730::AID-IJC11&gt;3.0.CO;2-Q; Israel MA, 1999, CANCER RES, V59, p1726S; Jensen SS, 2001, MOL ENDOCRINOL, V15, P1370, DOI 10.1210/me.15.8.1370; Koli K, 2000, CELL GROWTH DIFFER, V11, P221; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; Lasorella A, 2002, CANCER RES, V62, P301; Lasorella A, 2001, ONCOGENE, V20, P8326, DOI 10.1038/sj.onc.1205093; Lasorella A, 1996, MOL CELL BIOL, V16, P2570; LEIBOVITZ A, 1976, CANCER RES, V36, P4562; Liu YH, 2004, MOL CELL BIOL, V24, P2662, DOI 10.1128/MCB.24.7.2662-2672.2004; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; Mantell DJ, 2000, CIRC RES, V87, P214, DOI 10.1161/01.RES.87.3.214; Matsumura ME, 2002, J BIOL CHEM, V277, P7293, DOI 10.1074/jbc.M108986200; Nehlin JO, 1997, BIOCHEM BIOPH RES CO, V231, P628, DOI 10.1006/bbrc.1997.6152; Nishii Y, 2001, STEROIDS, V66, P137, DOI 10.1016/S0039-128X(00)00227-0; Palmer HG, 2003, CANCER RES, V63, P7799; Palmer HG, 2001, J CELL BIOL, V154, P369, DOI 10.1083/jcb.200102028; Ramsauer M, 2002, J CLIN INVEST, V110, P1615, DOI 10.1172/JCI200217326; Rockman SP, 2001, J BIOL CHEM, V276, P45113, DOI 10.1074/jbc.M107742200; Ruzinova MB, 2003, CANCER CELL, V4, P277, DOI 10.1016/S1535-6108(03)00240-X; Scaglione-Sewell BA, 2000, ENDOCRINOLOGY, V141, P3931, DOI 10.1210/en.141.11.3931; Schlaeppi JM, 1997, ENDOCR RES, V23, P213, DOI 10.3109/07435809709031855; Sikder HA, 2003, CANCER CELL, V3, P525, DOI 10.1016/S1535-6108(03)00141-7; Smith DC, 1999, CLIN CANCER RES, V5, P1339; VENNSTROM B, 1982, CELL, V28, P135, DOI 10.1016/0092-8674(82)90383-X; Verlinden L, 1998, MOL CELL ENDOCRINOL, V142, P57, DOI 10.1016/S0303-7207(98)00117-8; Volpert OV, 2002, CANCER CELL, V2, P473, DOI 10.1016/S1535-6108(02)00209-X; Wilson JW, 2001, CANCER RES, V61, P8803; Woo PL, 2000, J BIOL CHEM, V275, P28649, DOI 10.1074/jbc.M910373199; Yam CH, 2002, CELL MOL LIFE SCI, V59, P1317, DOI 10.1007/s00018-002-8510-y; Yokota Y, 2001, ONCOGENE, V20, P8290, DOI 10.1038/sj.onc.1205090; Zebedee Z, 2001, ONCOGENE, V20, P8317, DOI 10.1038/sj.onc.1205092	48	81	88	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	43					6533	6544		10.1038/sj.onc.1208801	http://dx.doi.org/10.1038/sj.onc.1208801			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	968ZV	16007183				2022-12-25	WOS:000232204100007
J	Lu, CH; Shen, Q; DuPre, E; Kim, H; Hilsenbeck, S; Brown, PH				Lu, CH; Shen, Q; DuPre, E; Kim, H; Hilsenbeck, S; Brown, PH			cFos is critical for MCF-7 breast cancer cell growth	ONCOGENE			English	Article						cFos; cJun; AP-1; breast cancer; cell proliferation	DOMINANT-NEGATIVE MUTANT; C-FOS; AP-1 ACTIVITY; MATRIX-METALLOPROTEINASE; ESTROGEN-RECEPTOR; GENE-EXPRESSION; KINASE-ACTIVITY; RETINOIC ACID; ANTISENSE RNA; JUN	The activating protein-1 (AP-1) transcription factor is a converging point of multiple signal transduction pathways in many cells. We have previously demonstrated that overexpressing Tam67, a dominant-negative (DN) form of cJun, blocks AP-1 activity and inhibits breast cancer cell growth. We hypothesized that Tam67 forms dimers with other AP-1 proteins to suppress the growth of breast cancer cells. In the present study, we used immunoprecipitation-Western blotting to demonstrate that Tam67 binds all Jun and Fos proteins in breast cancer cells. In addition, we used two variants of the Tam67 mutant to investigate whether Jun or Fos protein was required for breast cancer cell growth. We created a Tam/Fos mutant in which the cJun dimerization domain was replaced by the cFos dimerization domain, and a Tam/Squelcher mutant in which the cJun dimerization domain was deleted. We then isolated MCF-7 cell lines that stably expressed these cJun-DN mutants under the control of an inducible promoter. Using AP-1-dependent reporter assays, we observed that Tam67 and Tam/Fos mutants inhibited AP-1 transcriptional activity, while the Tam/Squelcher mutant did not. We then determined whether Tam/Fos or Tam/Squelcher inhibited breast cell growth as well as Tam67. We found that while Tam67 repressed cell growth, neither Tam/Fos nor Tam/Squelcher mutant affected cell growth. These results indicate that Tam67 likely inactivates Fos family member proteins to suppress breast cancer cell growth. Finally, we performed antisense experiments to knock down the expression of individual family members (cJun or cFos). Our results demonstrated that antisense cFos inhibited breast cancer cell proliferation and colony formation, while antisense cJun did not. These results suggest that Tam67 suppresses breast cancer cell growth by interacting with Fos family members, specifically with cFos, to produce an inactive AP-1 complex.	Baylor Coll Med, Breast Ctr, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Breast Ctr, Dept Biol Celular, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Brown, PH (corresponding author), Baylor Coll Med, Breast Ctr, Dept Med, 1 Baylor Pl,MS600, Houston, TX 77030 USA.	pbrown@breastcenter.tmc.edu		Brown, Powel/0000-0002-3398-163X; Shen, Qiang/0000-0002-1491-5434				ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; Aronheim A, 1997, MOL CELL BIOL, V17, P3094, DOI 10.1128/MCB.17.6.3094; Arteaga CL, 1996, CANCER RES, V56, P1098; Bamberger AM, 1999, INT J CANCER, V84, P533, DOI 10.1002/(SICI)1097-0215(19991022)84:5<533::AID-IJC16>3.0.CO;2-J; BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; BLAND KI, 1995, ANN SURG, V221, P706, DOI 10.1097/00000658-199506000-00010; Brown PH, 1996, CELL GROWTH DIFFER, V7, P1013; BROWN PH, 1994, ONCOGENE, V9, P791; BROWN PH, 1993, ONCOGENE, V8, P877; Chen TK, 1996, MOL CARCINOGEN, V15, P215, DOI 10.1002/(SICI)1098-2744(199603)15:3<215::AID-MC7>3.0.CO;2-G; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; Daschner PJ, 1999, BREAST CANCER RES TR, V53, P229, DOI 10.1023/A:1006138803392; DeNardo DG, 2005, MOL ENDOCRINOL, V19, P362, DOI 10.1210/me.2004-0267; Gajate C, 1996, BIOCHEM BIOPH RES CO, V218, P267, DOI 10.1006/bbrc.1996.0047; GEE JMW, 1995, INT J CANCER, V64, P269, DOI 10.1002/ijc.2910640410; Gee JMW, 2000, INT J CANCER, V89, P177, DOI 10.1002/(SICI)1097-0215(20000320)89:2<177::AID-IJC13>3.0.CO;2-0; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; Hennigan RF, 2001, MOL BIOL CELL, V12, P2352, DOI 10.1091/mbc.12.8.2352; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4794, DOI 10.1073/pnas.83.13.4794; Johnston SRD, 1999, CLIN CANCER RES, V5, P251; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Lin F, 2000, CANCER RES, V60, P3271; Liu YM, 2004, ONCOGENE, V23, P8238, DOI 10.1038/sj.onc.1207889; Liu YM, 2002, ONCOGENE, V21, P7680, DOI 10.1038/sj.onc.1205883; Ludes-Meyers JH, 2001, ONCOGENE, V20, P2771, DOI 10.1038/sj.onc.1204377; MACKAY AR, 1992, INVAS METAST, V12, P168; MATRISIAN LM, 1994, ANN NY ACAD SCI, V732, P42, DOI 10.1111/j.1749-6632.1994.tb24723.x; MCDONNELL SE, 1990, MOL CELL BIOL, V10, P4284, DOI 10.1128/MCB.10.8.4284; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; PIECHACZYK M, 1994, CRIT REV ONCOL HEMAT, V17, P93, DOI 10.1016/1040-8428(94)90021-3; Piu F, 2001, MOL CELL BIOL, V21, P3012, DOI 10.1128/MCB.21.9.3012-3024.2001; Preston GA, 1996, MOL CELL BIOL, V16, P211; RIABOWOL KT, 1988, MOL CELL BIOL, V8, P1670, DOI 10.1128/MCB.8.4.1670; ROBINSONBENION C, 1994, LEUKEMIA, V8, pS152; RODGERS WH, 1994, J CLIN INVEST, V94, P946, DOI 10.1172/JCI117461; RofflerTarlov S, 1996, DEVELOPMENT, V122, P1; Schiff R, 2000, J NATL CANCER I, V92, P1926, DOI 10.1093/jnci/92.23.1926; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; Smith LM, 1999, ONCOGENE, V18, P6063, DOI 10.1038/sj.onc.1202989; SZABO E, 1991, CELL GROWTH DIFFER, V2, P475; Tang ZQ, 1997, MOL CELL BIOL, V17, P1274, DOI 10.1128/MCB.17.3.1274; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; Webb P, 1999, MOL ENDOCRINOL, V13, P1672, DOI 10.1210/me.13.10.1672; YOSHIOKA K, 1995, P NATL ACAD SCI USA, V92, P4972, DOI 10.1073/pnas.92.11.4972	47	58	63	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	43					6516	6524		10.1038/sj.onc.1208905	http://dx.doi.org/10.1038/sj.onc.1208905			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	968ZV	16027729				2022-12-25	WOS:000232204100005
J	Andreeva, AV; Kutuzov, MA; Vaiskunaite, R; Profirovic, J; Meigs, TE; Predescu, S; Malik, AB; Voyno-Yasenetskaya, T				Andreeva, AV; Kutuzov, MA; Vaiskunaite, R; Profirovic, J; Meigs, TE; Predescu, S; Malik, AB; Voyno-Yasenetskaya, T			G alpha(12) interaction with alpha SNAP induces VE-cadherin localization endothelial junctions and regulates barrier function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G-PROTEIN G(13); SIGNALING PATHWAYS; MAMMALIAN-CELLS; MEMBRANE-FUSION; P115 RHOGEF; SUBUNIT; RECEPTOR; TRANSFORMATION; ACTIVATION; EXPRESSION	The involvement of heterotrimeric G proteins in the regulation of adherens junction function is unclear. We identified alpha SNAP as an interactive partner of G alpha(12) using yeast two-hybrid screening. glutathione S-transferase pull-down assays showed the selective interaction of alpha SNAP with G alpha(12) in COS- 7 as well as in human umbilical vein endothelial cells. Using domain swapping experiments, we demonstrated that the N-terminal region of G alpha(12) ( 1-37 amino acids) was necessary and sufficient for its interaction with alpha SNAP. G alpha(13) with its N-terminal extension replaced by that of G alpha(12) acquired the ability to bind to alpha SNAP, whereas G alpha(12) with its N terminus replaced by that of G alpha(13) lost this ability. Using four point mutants of alpha SNAP, which alter its ability to bind to the SNARE complex, we determined that the convex rather than the concave surface of alpha SNAP was involved in its interaction with G alpha(12). Co-transfection of human umbilical vein endothelial cells with G alpha(12) and alpha SNAP stabilized VE-cadherin at the plasma membrane, whereas down-regulation of alpha SNAP with siRNA resulted in the loss of VE-cadherin from the cell surface and, when used in conjunction with G alpha 12 overexpression, decreased endothelial barrier function. Our results demonstrate a direct link between the alpha subunit of G(12) and alpha SNAP, an essential component of the membrane fusion machinery, and implicate a role for this interaction in regulating the membrane localization of VE-cadherin and endothelial barrier function.	Univ Illinois, Dept Pharmacol, Coll Med, Chicago, IL 60612 USA; Univ N Carolina, Asheville, NC 28804 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of North Carolina; University of North Carolina - Asheville	Voyno-Yasenetskaya, T (corresponding author), Univ Illinois, Dept Pharmacol, Coll Med, MC 868,835 S Wolcott Ave, Chicago, IL 60612 USA.	tvy@uic.edu	voyno-yasenetskaya, tatyana/A-3171-2008	Kutuzov, Mikhail/0000-0003-3386-4350; Predescu, Sanda/0000-0002-9386-6756; Malik, Asrar/0000-0002-8205-7128	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056159, R01GM065160, R55GM056159] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL06078] Funding Source: Medline; NIGMS NIH HHS [GM65160, GM56159] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmadian MR, 1997, FEBS LETT, V408, P315, DOI 10.1016/S0014-5793(97)00422-5; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Chae TH, 2004, NAT GENET, V36, P264, DOI 10.1038/ng1302; Chen XY, 2003, J CELL BIOL, V163, P547, DOI 10.1083/jcb.200305137; Echard A, 2004, CURR BIOL, V14, P1685, DOI 10.1016/j.cub.2004.08.063; Ellis CA, 1999, AM J PHYSIOL-CELL PH, V276, pC38, DOI 10.1152/ajpcell.1999.276.1.C38; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; GIAEVER I, 1991, P NATL ACAD SCI USA, V88, P7896, DOI 10.1073/pnas.88.17.7896; Gohla A, 1998, J BIOL CHEM, V273, P4653, DOI 10.1074/jbc.273.8.4653; Gu JL, 2002, P NATL ACAD SCI USA, V99, P9352, DOI 10.1073/pnas.102291599; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Izumi G, 2004, J CELL BIOL, V166, P237, DOI 10.1083/jcb.200401078; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; Katoh H, 1998, J BIOL CHEM, V273, P28700, DOI 10.1074/jbc.273.44.28700; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Krakstad BF, 2004, P NATL ACAD SCI USA, V101, P10314, DOI 10.1073/pnas.0401366101; Kurose H, 2003, LIFE SCI, V74, P155, DOI 10.1016/j.lfs.2003.09.003; Le TL, 1999, J CELL BIOL, V146, P219, DOI 10.1083/jcb.146.1.219; Marz KE, 2003, J BIOL CHEM, V278, P27000, DOI 10.1074/jbc.M302003200; Meigs TE, 2002, J BIOL CHEM, V277, P24594, DOI 10.1074/jbc.M201984200; Meigs TE, 2001, P NATL ACAD SCI USA, V98, P519, DOI 10.1073/pnas.021350998; Meyer TN, 2003, AM J PHYSIOL-CELL PH, V285, pC1281, DOI 10.1152/ajpcell.00548.2002; Morita K, 2001, EMBO J, V20, P6028, DOI 10.1093/emboj/20.21.6028; Nagao M, 1999, ONCOGENE, V18, P4425, DOI 10.1038/sj.onc.1202832; Offermanns S, 2003, PROG BIOPHYS MOL BIO, V83, P101, DOI 10.1016/S0079-6107(03)00052-X; Offermanns S, 1997, SCIENCE, V275, P533, DOI 10.1126/science.275.5299.533; Peifer M, 2003, J CELL BIOL, V163, P437, DOI 10.1083/jcb.200310090; Plonk SG, 1998, J BIOL CHEM, V273, P4823, DOI 10.1074/jbc.273.9.4823; Ponimaskin EG, 2002, J BIOL CHEM, V277, P20812, DOI 10.1074/jbc.M112216200; Rice LM, 1999, MOL CELL, V4, P85, DOI 10.1016/S1097-2765(00)80190-2; Schuck S, 2003, P NATL ACAD SCI USA, V100, P5795, DOI 10.1073/pnas.0631579100; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; TIRUPPATHI C, 1992, P NATL ACAD SCI USA, V89, P7919, DOI 10.1073/pnas.89.17.7919; Vaiskunaite R, 2000, J BIOL CHEM, V275, P26206, DOI 10.1074/jbc.M001863200; Vaiskunaite R, 2001, FASEB J, V15, pA206; Vincent PA, 2004, AM J PHYSIOL-CELL PH, V286, pC987, DOI 10.1152/ajpcell.00522.2003; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; Wall MA, 1998, STRUCTURE, V6, P1169, DOI 10.1016/S0969-2126(98)00117-8; WILSON DW, 1992, J CELL BIOL, V117, P531, DOI 10.1083/jcb.117.3.531; Xiao KY, 2003, J CELL BIOL, V163, P535, DOI 10.1083/jcb.200306001; Xiao KY, 2003, J BIOL CHEM, V278, P19199, DOI 10.1074/jbc.M211746200; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; Yamaguchi Y, 2003, J BIOL CHEM, V278, P14936, DOI 10.1074/jbc.M301409200; Zhu DG, 2004, J BIOL CHEM, V279, P54983, DOI 10.1074/jbc.C400508200	46	24	24	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	2005	280	34					30376	30383		10.1074/jbc.M502844200	http://dx.doi.org/10.1074/jbc.M502844200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	957IC	15980433	hybrid			2022-12-25	WOS:000231362500049
J	Lambert, DW; Yarski, M; Warner, FJ; Thornhill, P; Parkin, ET; Smith, AI; Hooper, NM; Turner, AJ				Lambert, DW; Yarski, M; Warner, FJ; Thornhill, P; Parkin, ET; Smith, AI; Hooper, NM; Turner, AJ			Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL RECEPTOR; PROTEOLYTIC RELEASE; ENZYME; CLEAVAGE; PROTEIN; EXPRESSION; DISINTEGRIN; IDENTIFICATION; JUXTAMEMBRANE; INHIBITORS	Angiotensin-converting enzyme-2 (ACE2) is a critical regulator of heart function and a cellular receptor for the causative agent of severe-acute respiratory syndrome (SARS), SARS- CoV (coronavirus). ACE2 is a type I transmembrane protein, with an extracellular N-terminal domain containing the active site and a short intracellular C-terminal tail. A soluble form of ACE2, lacking its cytosolic and transmembrane domains, has been shown to block binding of the SARS- CoV spike protein to its receptor. In this study, we examined the ability of ACE2 to undergo proteolytic shedding and investigated the mechanisms responsible for this shedding event. We demonstrated that ACE2, heterologously expressed in HEK293 cells and endogenously expressed in Huh7 cells, undergoes metalloproteinase-mediated, phorbol ester-inducible ectodomain shedding. By using inhibitors with differing potency toward different members of the ADAM (a disintegrin and metalloproteinase) family of proteases, we identified ADAM17 as a candidate mediator of stimulated ACE2 shedding. Furthermore, ablation of ADAM17 expression using specific small interfering RNA duplexes reduced regulated ACE2 shedding, whereas overexpression of ADAM17 significantly increased shedding. Taken together, these data provided direct evidence for the involvement of ADAM17 in the regulated ectodomain shedding of ACE2. The identification of ADAM17 as the protease responsible for ACE2 shedding may provide new insight into the physiological roles of ACE2.	Univ Leeds, Sch Biochem & Microbiol, Proteolysis Res Grp, Leeds LS2 9JT, W Yorkshire, England; Monash Univ, Dept Biochem & Mol Biol, Melbourne, Vic 3800, Australia	University of Leeds; Monash University	Lambert, DW (corresponding author), Univ Leeds, Sch Biochem & Microbiol, Proteolysis Res Grp, Leeds LS2 9JT, W Yorkshire, England.	d.w.lambert@leeds.ac.uk		Smith, Ian/0000-0002-4143-2892; Hooper, Nigel/0000-0002-5811-3484; Parkin, Edward/0000-0003-3270-3184				Allinson TMJ, 2004, EUR J BIOCHEM, V271, P2539, DOI 10.1111/j.1432-1033.2004.04184.x; Amour A, 2000, FEBS LETT, V473, P275, DOI 10.1016/S0014-5793(00)01528-3; Amour A, 2002, FEBS LETT, V524, P154, DOI 10.1016/S0014-5793(02)03047-8; Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; Arribas J, 2002, CHEM REV, V102, P4627, DOI 10.1021/cr010202t; ARRIBAS J, 1995, J CELL BIOL, V128, P433, DOI 10.1083/jcb.128.3.433; Asakura M, 2002, NAT MED, V8, P35, DOI 10.1038/nm0102-35; BELDENT V, 1993, J BIOL CHEM, V268, P26428; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; BOSENBERG MW, 1993, J CELL BIOL, V122, P95, DOI 10.1083/jcb.122.1.95; Brosnihan KB, 2003, HYPERTENSION, V42, P749, DOI 10.1161/01.HYP.0000085220.53285.11; Crackower MA, 2002, NATURE, V417, P822, DOI 10.1038/nature00786; Donoghue M, 2000, CIRC RES, V87, pE1, DOI 10.1161/01.res.87.5.e1; Donoghue M, 2003, J MOL CELL CARDIOL, V35, P1043, DOI 10.1016/S0022-2828(03)00177-9; Ehlers MRW, 1996, BIOCHEMISTRY-US, V35, P9549, DOI 10.1021/bi9602425; EHLERS MRW, 1989, BIOCHEMISTRY-US, V28, P5311, DOI 10.1021/bi00439a001; ERDOS EG, 1975, CIRC RES, V36, P247, DOI 10.1161/01.RES.36.2.247; Eriksson U, 2002, CURR BIOL, V12, pR745, DOI 10.1016/S0960-9822(02)01255-1; Garton KJ, 2003, J BIOL CHEM, V278, P37459, DOI 10.1074/jbc.M305877200; Gillim-Ross L, 2004, J CLIN MICROBIOL, V42, P3196, DOI 10.1128/JCM.42.7.3196-3206.2004; Gough PJ, 2004, J IMMUNOL, V172, P3678, DOI 10.4049/jimmunol.172.6.3678; Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570; Hirata M, 2001, BIOCHEM BIOPH RES CO, V283, P915, DOI 10.1006/bbrc.2001.4879; Hundhausen C, 2003, BLOOD, V102, P1186, DOI 10.1182/blood-2002-12-3775; Hussain I, 2003, J BIOL CHEM, V278, P36264, DOI 10.1074/jbc.M304186200; Koike H, 1999, BIOCHEM J, V343, P371, DOI 10.1042/0264-6021:3430371; Lee MH, 2002, BIOCHEM J, V364, P227, DOI 10.1042/bj3640227; Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145; PALECANDA A, 1992, EUR J IMMUNOL, V22, P1279, DOI 10.1002/eji.1830220524; Pang S, 2001, BIOCHEM J, V358, P185, DOI 10.1042/0264-6021:3580185; Parkin ET, 2004, J BIOL CHEM, V279, P11170, DOI 10.1074/jbc.M312105200; Parvathy S, 1998, BIOCHEMISTRY-US, V37, P1680, DOI 10.1021/bi972034y; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Rosendahl MS, 1997, J BIOL CHEM, V272, P24588, DOI 10.1074/jbc.272.39.24588; Sadhukhan R, 1999, J BIOL CHEM, V274, P10511, DOI 10.1074/jbc.274.15.10511; Tipnis SR, 2000, J BIOL CHEM, V275, P33238, DOI 10.1074/jbc.M002615200; Wang PG, 2004, BIOCHEM BIOPH RES CO, V315, P439, DOI 10.1016/j.bbrc.2004.01.076; Wang XD, 2002, J BIOL CHEM, V277, P50510, DOI 10.1074/jbc.M208738200; WOODMAN ZL, 2005, IN PRESS BIOCH J; Zisman LS, 2003, CIRCULATION, V108, P1707, DOI 10.1161/01.CIR.0000094734.67990.99	40	462	480	3	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	2005	280	34					30113	30119		10.1074/jbc.M505111200	http://dx.doi.org/10.1074/jbc.M505111200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	957IC	15983030	Green Published, hybrid			2022-12-25	WOS:000231362500017
J	Zhang, M; Mileykovskaya, E; Dowhan, W				Zhang, M; Mileykovskaya, E; Dowhan, W			Cardiolipin is essential for organization of complexes III and IV into a supercomplex in intact yeast mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY-CHAIN SUPERCOMPLEXES; SACCHAROMYCES-CEREVISIAE; CYTOCHROME BC(1); OXIDATIVE-PHOSPHORYLATION; ANTIMYCIN; MEMBRANE; OXIDOREDUCTASE; BIOSYNTHESIS; UBIQUINONE; MECHANISM	Digitonin extracts of mitochondria from cardiolipin-containing (wild type) and cardiolipin-lacking (crd1 Delta mutant) Saccharomyces cerevisiae subjected to colorless native polyacrylamide gel electrophoresis in the presence of 0.003% digitonin displayed a supercomplex composed of homodimers of complexes III and IV in the former case but only the individual homodimers in the latter case. To avoid treatment with any detergent or dye, we compared organization of the respiratory chain in intact mitochondria from wild type and cardiolipin-lacking cells by using a functional analysis developed previously for the study of the organization of the respiratory chain of S. cerevisiae (Boumans, H., Grivell, L. A., and Berden, J. A. (1998) J. Biol. Chem. 273, 4872 4877). Dependence of the kinetics of NADH oxidation via complexes III, IV, and cytochrome c on the concentration of the complex III-specific inhibitor antimycin A was studied. A linear relationship between respiratory activity and saturation of complex III with antimycin A was obtained for wild type mitochondria consistent with single functional unit kinetics of the respiratory chain. Under the same conditions, cardiolipin-lacking mitochondria displayed a hyperbolic relationship indicating cytochrome c pool behavior. No release of cytochrome c from cardiolipin-lacking mitochondria or mitoplasts under our standard experimental conditions was detected. Identical cytochrome c pool behavior was observed for both wild type and cardiolipin-lacking mitochondria in the presence of a chaotropic agent, which disrupts the interaction between respiratory complexes. The results demonstrate that cardiolipin is essential for association of complexes III and IV into a supercomplex in intact yeast mitochondria.	Univ Texas, Sch Med, Dept Biochem & Mol Biol, Houston, TX 77225 USA; Grad Sch Biomed Sci, Houston, TX 77225 USA	University of Texas System	Mileykovskaya, E (corresponding author), Univ Texas, Sch Med, Dept Biochem & Mol Biol, POB 20708, Houston, TX 77225 USA.	Eugenia.Mileykovskaya@uth.tmc.edu; William.Dowhan@uth.tmc.edu	Zhang, Mei/G-8690-2014	Mileykovskaya, Eugenia/0000-0002-8775-4467	NIGMS NIH HHS [GM56389, R01 GM056389] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056389] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERDEN JA, 1970, BIOCHIM BIOPHYS ACTA, V216, P237, DOI 10.1016/0005-2728(70)90215-X; Boumans H, 1998, J BIOL CHEM, V273, P4872, DOI 10.1074/jbc.273.9.4872; CHANCE B, 1955, NATURE, V176, P250, DOI 10.1038/176250a0; Cruciat CM, 2000, J BIOL CHEM, V275, P18093, DOI 10.1074/jbc.M001901200; DEVRIES S, 1987, BIOCHIM BIOPHYS ACTA, V895, P205, DOI 10.1016/S0304-4173(87)80003-4; Dowhan W, 2004, BBA-BIOMEMBRANES, V1666, P19, DOI 10.1016/j.bbamem.2004.04.010; Genova Maria Luisa, 2003, Ital J Biochem, V52, P58; Glick BS, 1995, METHOD ENZYMOL, V260, P224, DOI 10.1016/0076-6879(95)60140-6; GLICK BS, 1992, CELL, V69, P809, DOI 10.1016/0092-8674(92)90292-K; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; Gomez B, 1999, BIOCHEMISTRY-US, V38, P9031, DOI 10.1021/bi990603r; Iverson SL, 2004, J BIOL CHEM, V279, P1100, DOI 10.1074/jbc.M305020200; Krause F, 2004, J BIOL CHEM, V279, P48369, DOI 10.1074/jbc.M406085200; KROGER A, 1973, EUR J BIOCHEM, V39, P313, DOI 10.1111/j.1432-1033.1973.tb03129.x; KUBOTA T, 1992, J BIOCHEM-TOKYO, V111, P91, DOI 10.1093/oxfordjournals.jbchem.a123725; Lange C, 2001, EMBO J, V20, P6591, DOI 10.1093/emboj/20.23.6591; MARRES CAM, 1991, EUR J BIOCHEM, V195, P857, DOI 10.1111/j.1432-1033.1991.tb15775.x; Mileykovskaya E, 2005, BIOCHEMISTRY-MOSCOW+, V70, P154, DOI 10.1007/s10541-005-0095-2; Palsdottir H, 2004, BBA-BIOMEMBRANES, V1666, P2, DOI 10.1016/j.bbamem.2004.06.012; Pfeiffer K, 2003, J BIOL CHEM, V278, P52873, DOI 10.1074/jbc.M308366200; Schagger H, 2002, BBA-BIOENERGETICS, V1555, P154, DOI 10.1016/S0005-2728(02)00271-2; Schagger H, 2000, EMBO J, V19, P1777, DOI 10.1093/emboj/19.8.1777; Schagger H, 2001, J BIOL CHEM, V276, P37861; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Schlame M, 2000, PROG LIPID RES, V39, P257, DOI 10.1016/S0163-7827(00)00005-9; Sedlak E, 1999, BIOCHEMISTRY-US, V38, P14966, DOI 10.1021/bi9914053; TSAI A, 1986, BIOCHIM BIOPHYS ACTA, V852, P100, DOI 10.1016/0005-2728(86)90061-7; TSAI AL, 1982, BIOCHIM BIOPHYS ACTA, V681, P484, DOI 10.1016/0005-2728(82)90191-8; Zhang M, 2003, J BIOL CHEM, V278, P35204, DOI 10.1074/jbc.M306729200; Zhang M, 2002, J BIOL CHEM, V277, P43553, DOI 10.1074/jbc.C200551200	30	248	255	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	2005	280	33					29403	29408		10.1074/jbc.M504955200	http://dx.doi.org/10.1074/jbc.M504955200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	954SX	15972817	Green Accepted, hybrid			2022-12-25	WOS:000231176200004
J	Yamamichi, N; Yamamichi-Nishina, M; Mizutani, T; Watanabe, H; Minoguchi, S; Kobayashi, N; Kimura, S; Ito, T; Yahagi, N; Ichinose, M; Omata, M; Iba, H				Yamamichi, N; Yamamichi-Nishina, M; Mizutani, T; Watanabe, H; Minoguchi, S; Kobayashi, N; Kimura, S; Ito, T; Yahagi, N; Ichinose, M; Omata, M; Iba, H			The Brm gene suppressed at the post-transcriptional level in various human cell lines is inducible by transient HDAC inhibitor treatment, which exhibits antioncogenic potential	ONCOGENE			English	Article						Brm; SWI/SNF complex; HDAC inhibitors; post-transcriptional regulation; retroviral gene silencing	HISTONE DEACETYLASE INHIBITOR; MAMMALIAN SWI/SNF COMPLEXES; CHROMATIN REMODELING FACTOR; TUMOR-SUPPRESSOR; RHABDOID TUMORS; CYCLE ARREST; LUNG-CANCER; SNF COMPLEX; EXPRESSION; PROTEIN	The mammalian SWI/SNF chromatin remodeling complex is composed of more than 10 protein subunits, and plays important roles in epigenetic regulation. Each complex includes a single BRG1 or Brm molecule as the catalytic subunit. We previously reported that loss of Brm, but not BRG1, causes transcriptional gene silencing of murine leukemia virus-based retrovirus vectors. To understand the biological function and biogenesis of Brm protein, we examined seven cell lines derived from various human tumors that do not produce Brm protein. We show here that these Brm-deficient cell lines transcribe the Brm genes efficiently as detected by nuclear run-on transcription assay, whereas Brm mRNA and Brm hnRNA were undetectable by reverse transcription-polymerase c am reaction analysis. These results indicate that expression of Brm is strongly and promptly suppressed at the posttranscriptional level, through processing and transport of the primary transcript or through stability of mature Brm mRNA. This suppression was attenuated by transient treatment of these cell tines with HDAC inhibitors probably through indirect mechanism. Importantly, all of the treated cells showed prolonged induction of Brm expression after the removal of HDAC inhibitors, and acquired the ability to maintain retroviral gene expression. These results indicate that these Brm-deficient human tumor cell tines carry a functional Brm gene. Treatment with HDAC inhibitors or introduction of exogenous Brm into Brm-deficient cell lines significantly reduced the oncogenic potential as assessed by colony-forming activity in soft agar or invasion into collagen gel, indicating that, like BRG1, Brm is involved in tumor suppression.	Univ Tokyo, Inst Med Sci, Div Host Parasite Interact, Dept Microbiol & Immunol,Minato Ku, Tokyo 1088639, Japan; Univ Tokyo, Fac Med, Dept Gastroenterol, Tokyo 113, Japan; Wakayama Med Coll, Dept Internal Med, Wakayama 640, Japan	University of Tokyo; University of Tokyo; Wakayama Medical University	Iba, H (corresponding author), Univ Tokyo, Inst Med Sci, Div Host Parasite Interact, Dept Microbiol & Immunol,Minato Ku, 4-6-1,Shirokanedai, Tokyo 1088639, Japan.	iba@ims.u-tokyo.ac.jp	Ichinose, Masao/HAB-1645-2022					Arai T, 1998, J VIROL, V72, P1115, DOI 10.1128/JVI.72.2.1115-1121.1998; Barker N, 2001, EMBO J, V20, P4935, DOI 10.1093/emboj/20.17.4935; Betz BL, 2002, ONCOGENE, V21, P5193, DOI 10.1038/sj.onc.1205706; Biegel JA, 1999, CANCER RES, V59, P74; Bourachot B, 2003, EMBO J, V22, P6505, DOI 10.1093/emboj/cdg621; Bultman S, 2000, MOL CELL, V6, P1287, DOI 10.1016/S1097-2765(00)00127-1; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; DeCristofaro MF, 1999, ONCOGENE, V18, P7559, DOI 10.1038/sj.onc.1203168; DeCristofaro MF, 2001, J CELL PHYSIOL, V186, P136; Doan DN, 2004, ONCOGENE, V23, P3462, DOI 10.1038/sj.onc.1207472; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600; Furumai R, 2002, CANCER RES, V62, P4916; Geng FQ, 2001, MOL CELL BIOL, V21, P4311, DOI 10.1128/MCB.21.13.4311-4320.2001; Guidi CJ, 2001, MOL CELL BIOL, V21, P3598, DOI 10.1128/MCB.21.10.3598-3603.2001; Iba H, 2003, REV MED VIROL, V13, P99, DOI 10.1002/rmv.378; Ito T, 2001, J BIOL CHEM, V276, P2852, DOI 10.1074/jbc.M009633200; Jia LQ, 1997, MOL CARCINOGEN, V19, P243, DOI 10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D; Klochendler-Yeivin A, 2000, EMBO REP, V1, P500, DOI 10.1093/embo-reports/kvd129; Komatsu Y, 2001, CANCER RES, V61, P4459; LAURENT BC, 1993, GENE DEV, V7, P583, DOI 10.1101/gad.7.4.583; Lee D, 2002, J BIOL CHEM, V277, P22330, DOI 10.1074/jbc.M111987200; LeGouy E, 1998, DEV DYNAM, V212, P38, DOI 10.1002/(SICI)1097-0177(199805)212:1<38::AID-AJA4>3.0.CO;2-3; Mizutani T, 2002, J BIOL CHEM, V277, P15859, DOI 10.1074/jbc.M112421200; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Nakajima H, 1998, EXP CELL RES, V241, P126, DOI 10.1006/excr.1998.4027; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Reisman DN, 2003, CANCER RES, V63, P560; Reisman DN, 2002, ONCOGENE, V21, P1196, DOI 10.1038/sj.onc.1205188; Reyes JC, 1998, EMBO J, V17, P6979, DOI 10.1093/emboj/17.23.6979; Roberts CWM, 2000, P NATL ACAD SCI USA, V97, P13796, DOI 10.1073/pnas.250492697; SHIMIZU E, 1994, ONCOGENE, V9, P2441; Strobeck MW, 2000, P NATL ACAD SCI USA, V97, P7748, DOI 10.1073/pnas.97.14.7748; Trouche D, 1997, P NATL ACAD SCI USA, V94, P11268, DOI 10.1073/pnas.94.21.11268; Ui M, 2000, BIOCHEM BIOPH RES CO, V278, P97, DOI 10.1006/bbrc.2000.3777; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117; Wong AKC, 2000, CANCER RES, V60, P6171; Yamamichi-Nishina M, 2003, J BIOL CHEM, V278, P7422, DOI 10.1074/jbc.M208458200; Yu JY, 2002, P NATL ACAD SCI USA, V99, P6047, DOI 10.1073/pnas.092143499	40	86	86	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 18	2005	24	35					5471	5481		10.1038/sj.onc.1208716	http://dx.doi.org/10.1038/sj.onc.1208716			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	955JN	16007216				2022-12-25	WOS:000231222300007
J	Shao, BH; Belaaouaj, A; Verlinde, CLMJ; Fu, XY; Heinecke, JW				Shao, BH; Belaaouaj, A; Verlinde, CLMJ; Fu, XY; Heinecke, JW			Methionine sulfoxide and proteolytic cleavage contribute to the inactivation of cathepsin G by hypochlorous acid - An oxidative mechanism for regulation of serine proteinases by myeloperoxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; HUMAN-NEUTROPHILS; HYDROGEN-PEROXIDE; LYSINE RESIDUES; CROSS-LINKING; HOST-DEFENSE; PROTEASES; SUPEROXIDE; DEFICIENT; OXIDANTS	Using myeloperoxidase and hydrogen peroxide, activated neutrophils produce high local concentrations of hypochlorous acid (HOCl). They also secrete cathepsin G, a serine protease implicated in cytokine release, receptor activation, and degradation of tissue proteins. Isolated cathepsin G was inactivated by HOCl but not by hydrogen peroxide in vitro. We found that activated neutrophils lost cathepsin G activity by a pathway requiring myeloperoxidase, suggesting that oxidants generated by myeloperoxidase might regulate cathepsin G activity in vivo. Tandem mass spectrometric analysis of oxidized cathepsin G revealed that loss of a peptide containing Asp(108), which lies in the active site, associated quantitatively with loss of enzymatic activity. Catalytic domain peptides containing Asp108 were lost from the oxidized protein in concert with the conversion of Met(110) to the sulfoxide. Release of this peptide was blocked by pretreating cathepsin G with phenylmethylsulfonyl fluoride, strongly implying that oxidation introduced proteolytic cleavage sites into cathepsin G. Model system studies demonstrated that methionine oxidation can direct the regiospecific proteolysis of peptides by cathepsin G. Thus, oxidation of Met110 may contribute to cathepsin G inactivation by at least two distinct mechanisms. One involves direct oxidation of the thioether residue adjacent to the aspartic acid in the catalytic domain. The other involves the generation of new sites that are susceptible to proteolysis by cathepsin G. These observations raise the possibility that oxidants derived from neutrophils restrain pericellular proteolysis by inactivating cathepsin G. They also suggest that methionine oxidation could render cathepsin G susceptible to autolytic cleavage. Myeloperoxidase may thus play a previously unsuspected role in regulating tissue injury by serine proteases during inflammation.	Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Washington, Dept Biol Struct, Seattle, WA 98195 USA; Washington Univ, Dept Med, St Louis, MO 63110 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Washington University (WUSTL)	Heinecke, JW (corresponding author), Div Metab Endocrinol & Nutr, Campus Box 356246,1959 NE Pacific St, Seattle, WA 98195 USA.	heinecke@u.washington.edu	Bentaher, Abderrazzaq/M-4424-2017; VERLINDE, CHRISTOPHE LMJ/J-5796-2013; A, Bentaher/F-6531-2018	VERLINDE, CHRISTOPHE LMJ/0000-0002-7790-3203; A, Bentaher/0000-0001-6001-5456; Shao, Baohai/0000-0001-8832-2845	NHLBI NIH HHS [P01HL030086, P01HL60886, HL078527, HL075381, HL030086, P50HL073996] Funding Source: Medline; NIA NIH HHS [AG021191] Funding Source: Medline; NIDDK NIH HHS [DK02456] Funding Source: Medline; NIEHS NIH HHS [P30 ES007033] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL078527, P01HL030086, R01HL075381, P01HL060886, P50HL073996] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007033] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG021191] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Adkison AM, 2002, J CLIN INVEST, V109, P363, DOI 10.1172/JCI13462; Aratani Y, 1999, INFECT IMMUN, V67, P1828; BABIOR BM, 1973, J CLIN INVEST, V52, P741, DOI 10.1172/JCI107236; Bank U, 1999, FEBS LETT, V461, P235, DOI 10.1016/S0014-5793(99)01466-0; Belaaouaj A, 1998, NAT MED, V4, P615, DOI 10.1038/nm0598-615; BOTT R, 1988, J BIOL CHEM, V263, P7895; Brennan ML, 2001, J CLIN INVEST, V107, P419, DOI 10.1172/JCI8797; Campbell EJ, 1999, J CLIN INVEST, V104, P337, DOI 10.1172/JCI6092; CLARK RA, 1985, BLOOD, V65, P375; Czapinska H, 1999, EUR J BIOCHEM, V260, P571, DOI 10.1046/j.1432-1327.1999.00160.x; DELMAR EG, 1979, ANAL BIOCHEM, V99, P316, DOI 10.1016/S0003-2697(79)80013-5; DePaz RA, 2000, ARCH BIOCHEM BIOPHYS, V384, P123, DOI 10.1006/abbi.2000.2106; Fu XY, 2003, J BIOL CHEM, V278, P28403, DOI 10.1074/jbc.M304739200; Fu XY, 2004, J BIOL CHEM, V279, P6209, DOI 10.1074/jbc.C300506200; Fu XY, 2001, J BIOL CHEM, V276, P41279, DOI 10.1074/jbc.M106958200; Gaut JP, 2002, J CLIN INVEST, V109, P1311, DOI 10.1172/JCI200215021; Gaut JP, 2001, P NATL ACAD SCI USA, V98, P11961, DOI 10.1073/pnas.211190298; Hampton MB, 1998, BLOOD, V92, P3007, DOI 10.1182/blood.V92.9.3007.421k47_3007_3017; HARRISON JE, 1976, J BIOL CHEM, V251, P1371; Hawkins CL, 1998, BIOCHEM J, V332, P617, DOI 10.1042/bj3320617; HAZELL LJ, 1994, BIOCHEM J, V302, P297, DOI 10.1042/bj3020297; Hazen SL, 1997, J CLIN INVEST, V99, P2075, DOI 10.1172/JCI119379; Hazen SL, 1996, J CLIN INVEST, V98, P1283, DOI 10.1172/JCI118914; HEINECKE JW, 1986, J CLIN INVEST, V77, P757, DOI 10.1172/JCI112371; HEINECKE JW, 1993, J CLIN INVEST, V91, P2866, DOI 10.1172/JCI116531; Heinecke JW, 1999, J LAB CLIN MED, V133, P321, DOI 10.1016/S0022-2143(99)90061-6; Heller JI, 2000, J BIOL CHEM, V275, P9957, DOI 10.1074/jbc.275.14.9957; Henderson JP, 2003, J BIOL CHEM, V278, P23522, DOI 10.1074/jbc.M303928200; Hirche TO, 2005, J IMMUNOL, V174, P1557, DOI 10.4049/jimmunol.174.3.1557; Hof P, 1996, EMBO J, V15, P5481, DOI 10.1002/j.1460-2075.1996.tb00933.x; KLEBANOFF SJ, 1975, SEMIN HEMATOL, V12, P117; KLEBANOFF SJ, 1980, ANN INTERN MED, V93, P480, DOI 10.7326/0003-4819-93-3-480; KOBAYASHI M, 1982, J LAB CLIN MED, V100, P896; Leeuwenburgh C, 1997, J BIOL CHEM, V272, P3520, DOI 10.1074/jbc.272.6.3520; MacIvor DM, 1999, BLOOD, V94, P4282, DOI 10.1182/blood.V94.12.4282.424k45_4282_4293; MAISON CM, 1991, J IMMUNOL, V147, P921; MOLINO M, 1995, J BIOL CHEM, V270, P11168, DOI 10.1074/jbc.270.19.11168; MORRIS JC, 1966, J PHYS CHEM-US, V70, P3798, DOI 10.1021/j100884a007; NELSON DP, 1972, ANAL BIOCHEM, V49, P474, DOI 10.1016/0003-2697(72)90451-4; OWEN CA, 1995, J CELL BIOL, V131, P775, DOI 10.1083/jcb.131.3.775; Pattison DI, 2001, CHEM RES TOXICOL, V14, P1453, DOI 10.1021/tx0155451; Reeves EP, 2002, NATURE, V416, P291, DOI 10.1038/416291a; SCHECHTER I, 1968, BIOCHEM BIOPH RES CO, V32, P898, DOI 10.1016/0006-291X(68)90326-4; TANAKA T, 1985, BIOCHEMISTRY-US, V24, P2040, DOI 10.1021/bi00329a036; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; TRAVIS J, 1988, AM J MED, V84, P37; TURKINGTON PT, 1992, THROMB RES, V67, P147, DOI 10.1016/0049-3848(92)90134-V; Vivekananthan DP, 2003, LANCET, V361, P2017, DOI 10.1016/S0140-6736(03)13637-9; VOETMAN AA, 1981, J CLIN INVEST, V67, P1541, DOI 10.1172/JCI110185; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; Winterbourn CC, 1999, FREE RADICAL BIO MED, V27, P322, DOI 10.1016/S0891-5849(99)00051-9; WINTERBOURN CC, 1985, BIOCHIM BIOPHYS ACTA, V840, P204, DOI 10.1016/0304-4165(85)90120-5	52	28	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	2005	280	32					29311	29321		10.1074/jbc.M504040200	http://dx.doi.org/10.1074/jbc.M504040200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	952QT	15967795	hybrid			2022-12-25	WOS:000231021300062
J	Bernhard, D; Csordas, A; Henderson, B; Rossmann, A; Kind, M; Wick, G				Bernhard, D; Csordas, A; Henderson, B; Rossmann, A; Kind, M; Wick, G			Cigarette smoke metal-catalyzed protein oxidation leads to vascular endothelial cell contraction by depolymerization of microtubules	FASEB JOURNAL			English	Article						cigarette smoke extract; endothelial; atherosclerosis; microtubules; oxidative stress; cytokines/chemokines	SOLUBLE P-SELECTIN; HYDROGEN-PEROXIDE; CARDIOVASCULAR-DISEASE; RISK-FACTORS; ATHEROSCLEROSIS; APOPTOSIS; ASSOCIATION; MECHANISMS; INFLAMMATION; DYSFUNCTION	Smoking is a significant risk factor for development of atherosclerosis. However, the pathophysiology of smoking-mediated vessel wall damage is not understood. With tools ranging from analytical chemistry to cell biology, we show that cigarette smoke contains metals that catalyze the direct oxidation of cellular proteins by smoke oxidants. Oxidation of cellular proteins causes a loss of microtubule function, culminating in microtubule depolymerization and proteasome-dependent degradation of alpha-tubulin. As a consequence of the microtubule collapse, cytoskeletal structures as well as intermediate filaments break down, leading finally to a contraction of vascular endothelial cells. We observed a smoke extract-induced, calpain-dependent degradation of the intracellular form of platelet-endothelial cell adhesion molecule 1/CD31, as well as a release of P-selectin/ CD62P, IL-6, and IL-8 from endothelial cells into the supernatant. Increased levels of soluble CD62P and IL-6 are well known to be associated with smoking in humans. Increased permeability of the vascular endothelium is a crucial event in atherogenesis. This work highlights the compounds and mechanisms by which cigarette smoke induces leakiness of the vascular endothelium.	Innsbruck Med Univ, Vasc Biol Grp, Div Expt Pathophysiol & Immunol, Dept Bioctr, A-6020 Innsbruck, Austria	Medical University of Innsbruck	Bernhard, D (corresponding author), Innsbruck Med Univ, Vasc Biol Grp, Div Expt Pathophysiol & Immunol, Dept Bioctr, Fritz Pregl Str 3-4 OG, A-6020 Innsbruck, Austria.	David.Bernhard@uibk.ac.at		Bernhard, David/0000-0002-2383-6607				Ahmad KA, 2003, ANN NY ACAD SCI, V1010, P365, DOI 10.1196/annals.1299.067; Amberger A, 1997, CELL STRESS CHAPERON, V2, P94, DOI 10.1379/1466-1268(1997)002<0094:CEOIVE>2.3.CO;2; Ambrose JA, 2004, J AM COLL CARDIOL, V43, P1731, DOI 10.1016/j.jacc.2003.12.047; Barbaux SC, 2001, ARTERIOSCL THROM VAS, V21, P1668, DOI 10.1161/hq1001.097022; Bermudez EA, 2002, AM J CARDIOL, V89, P1117, DOI 10.1016/S0002-9149(02)02284-1; Bernhard D, 2003, FASEB J, V17, P2302, DOI 10.1096/fj.03-0312fje; Bernhard D, 2001, CELL DEATH DIFFER, V8, P1014, DOI 10.1038/sj.cdd.4400914; Bernhard David, 2004, Journal of Pharmacological and Toxicological Methods, V50, P45, DOI 10.1016/j.vascn.2004.01.003; Blankenberg S, 2003, ATHEROSCLEROSIS, V170, P191, DOI 10.1016/S0021-9150(03)00097-2; Cai H, 2000, CIRC RES, V87, P840, DOI 10.1161/01.RES.87.10.840; Conway DSG, 2002, CIRCULATION, V106, P1962, DOI 10.1161/01.CIR.0000033220.97592.9A; CRAIG WY, 1989, BMJ-BRIT MED J, V298, P784, DOI 10.1136/bmj.298.6676.784; de Maat MPM, 2002, VASC PHARMACOL, V39, P137, DOI 10.1016/S1537-1891(02)00301-4; Durand E, 2004, CIRCULATION, V109, P2503, DOI 10.1161/01.CIR.0000130172.62481.90; Feghali CA, 1997, FRONT BIOSCI, V2, P12; Fernandez-Real JM, 2001, J CLIN ENDOCR METAB, V86, P1154, DOI 10.1210/jc.86.3.1154; FREI B, 1991, BIOCHEM J, V277, P133, DOI 10.1042/bj2770133; GALVEZ BG, 2004, J BIOL CHEM; Heitzer T, 1996, CIRCULATION, V93, P1346, DOI 10.1161/01.CIR.93.7.1346; Herrington DM, 2000, CONTROL CLIN TRIALS, V21, P257, DOI 10.1016/S0197-2456(00)00054-4; HINSHAW DB, 1989, J SURG RES, V46, P339, DOI 10.1016/0022-4804(89)90199-6; HOLDEN WE, 1989, J APPL PHYSIOL, V66, P443, DOI 10.1152/jappl.1989.66.1.443; Kashyap R, 2002, J INVEST MED, V50, P46, DOI 10.2310/6650.2002.33517; KUTTI J, 1990, ADV EXP MED BIOL, V273, P129; LASSILA R, 1992, PROSTAG LEUKOTR ESS, V46, P81, DOI 10.1016/0952-3278(92)90212-2; Lopez-Ongil S, 1999, FREE RADICAL BIO MED, V26, P501, DOI 10.1016/S0891-5849(98)00223-8; MARCY TW, 1987, CLIN CHEST MED, V8, P381; MICHNOVICZ JJ, 1989, METABOLISM, V38, P537, DOI 10.1016/0026-0495(89)90213-8; Mortada WI, 2004, MED SCI MONITOR, V10, pCR112; NIIMI Y, 1994, AM J PHYSIOL, V266, pH1348, DOI 10.1152/ajpheart.1994.266.4.H1348; Penn A, 1996, ENVIRON HEALTH PERSP, V104, P1108, DOI 10.2307/3433125; Podmore ID, 1998, NATURE, V392, P559, DOI 10.1038/33308; RENAUD S, 1990, ADV EXP MED BIOL, V273, P161; Ridker PM, 2001, CIRCULATION, V103, P491, DOI 10.1161/01.CIR.103.4.491; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Selman M, 2003, CHEST, V124, P1185, DOI 10.1378/chest.124.4.1185; Semenov AV, 1999, BIOCHEMISTRY-MOSCOW+, V64, P1326; Stone PCW, 2002, BIOCHEM BIOPH RES CO, V295, P1150, DOI 10.1016/S0006-291X(02)00800-8; Tracy RP, 1997, ARTERIOSCL THROM VAS, V17, P2167, DOI 10.1161/01.ATV.17.10.2167; Valen G, 1999, FREE RADICAL BIO MED, V26, P1480, DOI 10.1016/S0891-5849(99)00009-X; VANHINSBERGH VWM, 1992, ANN NY ACAD SCI, V673, P321; Vayssier-Taussat M, 2001, AM J PHYSIOL-HEART C, V280, pH1293, DOI 10.1152/ajpheart.2001.280.3.H1293; VOEKEL NF, 2000, CHEST, V117, pS241; Weber C, 2004, ARTERIOSCL THROM VAS, V24, P1997, DOI 10.1161/01.ATV.0000142812.03840.6f; Wickenden JA, 2003, AM J RESP CELL MOL, V29, P562, DOI 10.1165/rcmb.2002-0235OC; Wohlfrom M, 2001, CARDIOVASC RES, V49, P169, DOI 10.1016/S0008-6363(00)00245-5; Wong MX, 2004, FEBS LETT, V568, P70, DOI 10.1016/j.febslet.2004.04.094; Zevin S, 2001, J AM COLL CARDIOL, V38, P1633, DOI 10.1016/S0735-1097(01)01616-3	48	88	93	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2005	19	9					1096	1107		10.1096/fj.04-3192com	http://dx.doi.org/10.1096/fj.04-3192com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	951IO	15985533				2022-12-25	WOS:000230923000038
J	Mahoney, DJ; Parise, G; Melov, S; Safdar, A; Tarnopolsky, MA				Mahoney, DJ; Parise, G; Melov, S; Safdar, A; Tarnopolsky, MA			Analysis of global mRNA expression in human skeletal muscle during recovery from endurance exercise	FASEB JOURNAL			English	Article						ATP; cDNA microarrays	ACTIVATED RECEPTOR-GAMMA; NA+-K+-ATPASE; PYRUVATE-DEHYDROGENASE KINASE-4; LIPID-BINDING PROTEINS; GENE-EXPRESSION; PEROXISOME PROLIFERATOR; SARCOPLASMIC-RETICULUM; OXIDATIVE STRESS; TRANSCRIPTIONAL ACTIVATION; MICROARRAY TECHNOLOGY	To search for novel transcriptional pathways that are activated in skeletal muscle after endurance exercise, we used cDNA microarrays to measure global mRNA expression after an exhaustive bout of high-intensity cycling (similar to 75 min). Healthy, young, sedentary males performed the cycling bout, and skeletal muscle biopsies were taken from the vastus lateralis before, and at 3 and 48 h after exercise. We examined mRNA expression in individual muscle samples from four subjects using cDNA microarrays, used repeated-measures significance analysis of microarray (SAM) to determine statistically significant expression changes, and confirmed selected results using real-time RT-PCR. In total, the expression of 118 genes significantly increased 3 h postcycling and 8 decreased. At 48 h, the expression of 29 genes significantly increased and 5 decreased. Many of these are potentially important novel genes involved in exercise recovery and adaptation, including several involved in 1) metabolism and mitochondrial biogenesis ( FOXO1, PPAR delta, PPAR gamma, nuclear receptor binding protein 2, IL- 6 receptor, ribosomal protein L2, aminolevulinate delta-synthase 2); 2) the oxidant stress response (metalothioneins 1B, 1F, 1G, 1H, 1L, 2A, 3, interferon regulatory factor 1); and 3) electrolyte transport across membranes [Na+- K+- ATPase (beta 3), SERCA3, chloride channel 4]. Others include genes involved in cell stress, proteolysis, apoptosis, growth, differentiation, and transcriptional activation, as well as all three nuclear receptor subfamily 4A family members (Nur77, Nurr1, and Nor1). This study is the first to characterize global mRNA expression during recovery from endurance exercise, and the results provide potential insight into 1) the transcriptional contributions to homeostatic recovery in human skeletal muscle after endurance exercise, and 2) the transcriptional contributions from a single bout of endurance exercise to the adaptive processes that occur after a period of endurance exercise training.	McMaster Univ, Med Ctr, Dept Med Sci, Hamilton, ON, Canada; McMaster Univ, Med Ctr, Dept Kinesiol, Hamilton, ON, Canada; McMaster Univ, Med Ctr, Dept Pediat & Med, Hamilton, ON, Canada; Buck Inst Age Res, Novato, CA 94945 USA	McMaster University; McMaster University; McMaster University; Buck Institute for Research on Aging	Tarnopolsky, MA (corresponding author), McMaster Univ, Med Ctr, Dept Pediat, Rm 4U4,1200 Main St W, Hamilton, ON L8N 3Z5, Canada.	tarnopol@mcmaster.ca	Melov, Simon/AAC-9469-2020	Melov, Simon/0000-0001-8554-2834; Safdar, Adeel/0000-0002-7453-7770; Safdar, Adeel/0000-0003-2469-0467	NATIONAL INSTITUTE ON AGING [R01AG018679] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Accili D, 2004, CELL, V117, P421, DOI 10.1016/S0092-8674(04)00452-0; Adhihetty PJ, 2003, EXP PHYSIOL, V88, P99, DOI 10.1113/eph8802505; Ahtikoski AM, 2004, PFLUG ARCH EUR J PHY, V448, P123, DOI 10.1007/s00424-003-1226-5; Aschenbach WG, 2004, SPORTS MED, V34, P91, DOI 10.2165/00007256-200434020-00003; Bakay M, 2002, BMC BIOINFORMATICS, V3, DOI 10.1186/1471-2105-3-4; Barash IA, 2004, AM J PHYSIOL-CELL PH, V286, pC355, DOI 10.1152/ajpcell.00211.2003; BAUMAN JW, 1991, TOXICOL APPL PHARM, V110, P347, DOI 10.1016/S0041-008X(05)80017-1; Beckman KB, 2004, MITOCHONDRION, V4, P453, DOI 10.1016/j.mito.2004.07.029; Bonen A, 1999, AM J PHYSIOL-ENDOC M, V276, pE642, DOI 10.1152/ajpendo.1999.276.4.E642; Cairns SP, 2004, AM J PHYSIOL-CELL PH, V287, pC762, DOI 10.1152/ajpcell.00589.2003; Carson JA, 2001, FASEB J, V15, P207, DOI 10.1096/fj.01-0544fje; Carter SL, 2001, AM J PHYSIOL-ENDOC M, V280, pE898, DOI 10.1152/ajpendo.2001.280.6.E898; Chen YW, 2003, J APPL PHYSIOL, V95, P2485, DOI 10.1152/japplphysiol.01161.2002; Chen YW, 2002, J PHYSIOL-LONDON, V545, P27, DOI 10.1113/jphysiol.2002.021220; Dalton TP, 1996, J BIOL CHEM, V271, P26233, DOI 10.1074/jbc.271.42.26233; DOHM GL, 1987, MED SCI SPORT EXER, V19, pS166; Dowell P, 2003, J BIOL CHEM, V278, P45485, DOI 10.1074/jbc.M309069200; Febbraio MA, 2004, DIABETES, V53, P1643, DOI 10.2337/diabetes.53.7.1643; Fehrenbach E, 2003, EXERC IMMUNOL REV, V9, P58; Ferre P, 2004, DIABETES, V53, pS43, DOI 10.2337/diabetes.53.2007.S43; Fischer CP, 2004, AM J PHYSIOL-ENDOC M, V287, pE1189, DOI 10.1152/ajpendo.00206.2004; Fowles JR, 2002, J APPL PHYSIOL, V93, P1703, DOI 10.1152/japplphysiol.00708.2001; Furuyama T, 2003, BIOCHEM J, V375, P365, DOI 10.1042/BJ20030022; Gorla-Bajszczak A, 2000, EUR J ENDOCRINOL, V142, P71, DOI 10.1530/eje.0.1420071; Green HJ, 2004, J APPL PHYSIOL, V97, P143, DOI 10.1152/japplphysiol.00559.2003; Green HJ, 2004, CAN J APPL PHYSIOL, V29, P291, DOI 10.1139/h04-020; Green HJ, 2003, J APPL PHYSIOL, V94, P2034, DOI 10.1152/japplphysiol.00244.2002; Haq F, 2003, MUTAT RES-FUND MOL M, V533, P211, DOI 10.1016/j.mrfmmm.2003.07.014; Heller MJ, 2002, ANNU REV BIOMED ENG, V4, P129, DOI 10.1146/annurev.bioeng.4.020702.153438; Hollander J, 2001, PFLUG ARCH EUR J PHY, V442, P426, DOI 10.1007/s004240100539; Jeukendrup AE, 2003, BIOCHEM SOC T, V31, P1270, DOI 10.1042/BST0311270; Ji LL, 2002, ANN NY ACAD SCI, V959, P82, DOI 10.1111/j.1749-6632.2002.tb02085.x; Johnson NA, 2004, SPORTS MED, V34, P151, DOI 10.2165/00007256-200434030-00002; Kamei Y, 2004, J BIOL CHEM, V279, P41114, DOI 10.1074/jbc.M400674200; Kamei Y, 2003, FEBS LETT, V536, P232, DOI 10.1016/S0014-5793(03)00062-0; Kawamura T, 2004, HYPERTENS RES, V27, P61, DOI 10.1291/hypres.27.61; Kawasaki Masanobu, 1999, American Journal of Physiology, V277, pC948; Keller C, 2001, FASEB J, V15, P2748, DOI 10.1096/fj.01-0507fje; Keller P, 2003, BIOCHEM BIOPH RES CO, V310, P550, DOI 10.1016/j.bbrc.2003.09.048; Kiens B, 2004, J APPL PHYSIOL, V97, P1209, DOI 10.1152/japplphysiol.01278.2003; Kondoh M, 2001, LIFE SCI, V69, P2137, DOI 10.1016/S0024-3205(01)01294-2; Kuo C.-H., 1999, Acta Physiologica Scandinavica, V165, P193, DOI 10.1046/j.1365-201x.1999.00489.x; Kwon HS, 2004, DIABETES, V53, P899, DOI 10.2337/diabetes.53.4.899; Lapsys NM, 2000, J CLIN ENDOCR METAB, V85, P4293, DOI 10.1210/jc.85.11.4293; LAZO JS, 1995, J BIOL CHEM, V270, P5506, DOI 10.1074/jbc.270.10.5506; Leppik JA, 2004, J APPL PHYSIOL, V97, P1414, DOI 10.1152/japplphysiol.00964.2003; Li Y, 2004, J BIOTECHNOL, V107, P19, DOI 10.1016/j.jbiotec.2003.09.008; LINDINGER MI, 1988, AM J PHYSIOL, V254, pR117, DOI 10.1152/ajpregu.1988.254.1.R117; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Luquet S, 2003, FASEB J, V17, P2299, DOI 10.1096/fj.03-0269fje; Mahoney DJ, 2004, PHYSIOL GENOMICS, V18, P226, DOI 10.1152/physiolgenomics.00067.2004; Maret W, 1998, P NATL ACAD SCI USA, V95, P3478, DOI 10.1073/pnas.95.7.3478; MURAKAMI S, 1998, J PLASMA FUSION RES, V1, P122; Murphy KT, 2004, J PHYSIOL-LONDON, V556, P507, DOI 10.1113/jphysiol.2003.054981; NehlsenCannarella SL, 1997, J APPL PHYSIOL, V82, P1662, DOI 10.1152/jappl.1997.82.5.1662; Neufer PD, 1996, AM J PHYSIOL-CELL PH, V271, pC1828; Norrbom J, 2004, J APPL PHYSIOL, V96, P189, DOI 10.1152/japplphysiol.00765.2003; Norris AW, 2003, J CLIN INVEST, V112, P608, DOI 10.1172/JCI200317305; Ohlendieck K, 1999, PFLUG ARCH EUR J PHY, V438, P700, DOI 10.1007/s004240051096; PENKOVA M, 2005, IN PRESS EXP PH 0107; Pilegaard H, 2003, J PHYSIOL-LONDON, V546, P851, DOI 10.1113/jphysiol.2002.034850; Pilegaard H, 2004, P NUTR SOC, V63, P221, DOI 10.1079/PNS2004345; Pilegaard H, 2000, AM J PHYSIOL-ENDOC M, V279, pE806; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Puigserver P, 2003, ENDOCR REV, V24, P78, DOI 10.1210/er.2002-0012; Quesada AR, 1996, ARCH BIOCHEM BIOPHYS, V334, P241, DOI 10.1006/abbi.1996.0452; REN JM, 1994, J BIOL CHEM, V269, P14396; Richter EA, 2001, J PHYSIOL-LONDON, V535, P313, DOI 10.1111/j.1469-7793.2001.t01-2-00313.x; Roepstorff C, 2004, P NUTR SOC, V63, P239, DOI 10.1079/PNS2004332; Rome S, 2003, J BIOL CHEM, V278, P18063, DOI 10.1074/jbc.M300293200; Roth SM, 2002, PHYSIOL GENOMICS, V10, P181, DOI 10.1152/physiolgenomics.00028.2002; Ruel M, 2003, J THORAC CARDIOV SUR, V126, P1521, DOI 10.1016/S0022-5223(03)00969-3; Russell AP, 2003, DIABETES, V52, P2874, DOI 10.2337/diabetes.52.12.2874; Stavinoha MA, 2004, AM J PHYSIOL-ENDOC M, V287, pE878, DOI 10.1152/ajpendo.00189.2004; THORNALLEY PJ, 1985, BIOCHIM BIOPHYS ACTA, V827, P36, DOI 10.1016/0167-4838(85)90098-6; Tunstall RJ, 2002, AM J PHYSIOL-ENDOC M, V283, pE66, DOI 10.1152/ajpendo.00475.2001; Tupling AR, 2003, J APPL PHYSIOL, V95, P138, DOI 10.1152/japplphysiol.00483.2002; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Vissing K, 2004, FASEB J, V18, P94, DOI 10.1096/fj.04-2084fje; WAHLI W, 1995, CHEM BIOL, V2, P261, DOI 10.1016/1074-5521(95)90045-4; Wang YX, 2004, PLOS BIOL, V2, P1532, DOI 10.1371/journal.pbio.0020294; Winoto A, 2002, CELL, V109, pS57, DOI 10.1016/S0092-8674(02)00710-9; Wittwer M, 2004, ACTA PHYSIOL SCAND, V180, P217, DOI 10.1046/j.0001-6772.2003.01242.x; Wu Q, 1997, EMBO J, V16, P1656, DOI 10.1093/emboj/16.7.1656; Yasumo H, 2000, BBA-GENE STRUCT EXPR, V1490, P189, DOI 10.1016/S0167-4781(99)00244-4; You HJ, 2002, BBA-GEN SUBJECTS, V1573, P33, DOI 10.1016/S0304-4165(02)00325-2; Zambon AC, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r61	87	312	323	2	34	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2005	19	8					1498	+		10.1096/fj.04-3149fje	http://dx.doi.org/10.1096/fj.04-3149fje			28	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	15985525				2022-12-25	WOS:000230207800004
J	Jeanblanc, M; Mousli, M; Hopfner, R; Bathami, K; Martinet, N; Abbady, AQ; Siffert, JC; Mathieu, E; Muller, CD; Bronner, C				Jeanblanc, M; Mousli, M; Hopfner, R; Bathami, K; Martinet, N; Abbady, AQ; Siffert, JC; Mathieu, E; Muller, CD; Bronner, C			The retinoblastoma gene and its product are targeted by ICBP90: a key mechanism in the G1/S transition during the cell cycle	ONCOGENE			English	Article						cell cycle; ICBP90; methylated promoter; retinoblastoma protein	II-ALPHA EXPRESSION; CCAAT-BINDING-PROTEIN; S-PHASE ENTRY; TRANSCRIPTIONAL REPRESSION; CONTACT INHIBITION; DOWN-REGULATION; CPG ISLAND; RB; CANCER; ARREST	The retinoblastoma protein (pRB) is encoded by the RB1 gene whose promoter contains several putative binding sites for ICBP90 (Inverted CCAAT box Binding Protein of 90 kDa), a transcriptional regulator of the topoisomerase II alpha gene. ICBP90 has two consensus binding sites for pRB in its primary sequence. Here, we show that pRB and ICBP90 co-immunoprecipitate in cell extracts of proliferating human lung fibroblasts and of proliferating or confluent Jurkat cells. GST pull-down assays and immunocytochemistry, after cell synchronization in late G1 phase, con. firmed this interaction. Overexpression of ICBP90 induces downregulation of pRB expression in lung. fibroblasts as a result of mRNA decrease. DNA chromatin immunoprecipitation experiment shows that ICBP90 binds to the RB1 gene promoter under its methylated status. Overexpression of ICBP90 increases the S and G2/M phase cell fractions of serum-starved lung fibroblasts as assessed by. flow cytometry analysis and increases topoisomerase IIa expression. Together, these results show that ICBP90 regulates pRB at the protein and gene transcription levels, thus favoring the entry into the S phase of the cells. We propose that ICBP90 overexpression, found in cancer cells, is involved in the altered checkpoint controls occurring in cancerogenesis.	INSERM, UMR S392, Fac Pharm, F-60024 Illkirch Graffenstaden, France; CNRS, UMR 7034, Fac Pharm, F-67401 Illkirch Graffenstaden, France; INSERM, EMI 0014, Fac Med, F-54511 Vandoeuvre Les Nancy, France; Ctr Hosp Belfort Montbeliard, Lab Biochim Immunochim, F-90016 Belfort, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lorraine	Bronner, C (corresponding author), INSERM, UMR S392, Fac Pharm, 74 Route Rhin,BP 60024, F-60024 Illkirch Graffenstaden, France.	bronner@pharma.u-strasbg.fr	Mousli, Marc/Q-1722-2017; Bronner, Christian/R-8488-2016; Abbady, Abdul Qader/O-2761-2015; MULLER, Christian D./F-8399-2010	Mousli, Marc/0000-0001-9759-6864; Bronner, Christian/0000-0002-3101-9279; Abbady, Abdul Qader/0000-0002-3898-5269; MULLER, Christian D./0000-0002-3463-1025				ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; Angus SP, 2002, EXP CELL RES, V276, P201, DOI 10.1006/excr.2002.5510; Arima Y, 2004, GENES CELLS, V9, P131, DOI 10.1111/j.1356-9597.2004.00710.x; Betticher DC, 1997, INT J CANCER, V74, P556, DOI 10.1002/(SICI)1097-0215(19971021)74:5<556::AID-IJC14>3.0.CO;2-4; Bhattacharya S, 2003, ONCOGENE, V22, P2443, DOI 10.1038/sj.onc.1206339; Bonapace IM, 2002, J CELL BIOL, V157, P909, DOI 10.1083/jcb.200201025; Bronner C, 2002, ANTICANCER RES, V22, P605; Chan HM, 2001, ONCOGENE, V20, P6152, DOI 10.1038/sj.onc.1204793; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; CHENG CH, 1993, BIOCHEMISTRY-US, V32, P8568, DOI 10.1021/bi00084a025; Christman JK, 2002, ONCOGENE, V21, P5483, DOI 10.1038/sj.onc.1205699; Citterio E, 2004, MOL CELL BIOL, V24, P2526, DOI 10.1128/MCB.24.6.2526-2535.2004; COPPOLA JA, 1990, ONCOGENE, V5, P1731; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; ENDO T, 1992, J BIOCHEM-TOKYO, V112, P427, DOI 10.1093/oxfordjournals.jbchem.a123916; Fan SJ, 2001, ONCOGENE, V20, P4827, DOI 10.1038/sj.onc.1204666; Fang XJ, 1998, ONCOGENE, V16, P1, DOI 10.1038/sj.onc.1201525; Gonzalez-Gomez P, 2003, BRIT J CANCER, V88, P109, DOI 10.1038/sj.bjc.6600737; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; Hickman ES, 2002, CURR OPIN GENET DEV, V12, P60, DOI 10.1016/S0959-437X(01)00265-9; HONG FD, 1989, P NATL ACAD SCI USA, V86, P5502, DOI 10.1073/pnas.86.14.5502; Hopfner R, 2002, ANTICANCER RES, V22, P3165; Hopfner R, 2000, CANCER RES, V60, P121; Kaelin WG, 1997, CANCER INVEST, V15, P243, DOI 10.3109/07357909709039722; Kaelin WG, 1999, BIOESSAYS, V21, P950, DOI 10.1002/(SICI)1521-1878(199911)21:11<950::AID-BIES7>3.0.CO;2-D; Macaluso M, 2003, ONCOGENE, V22, P3511, DOI 10.1038/sj.onc.1206578; Meerson A, 2004, FEBS LETT, V559, P152, DOI 10.1016/S0014-5793(04)00027-4; Momparler RL, 2003, ONCOGENE, V22, P6479, DOI 10.1038/sj.onc.1206774; Mousli M, 2003, BRIT J CANCER, V89, P120, DOI 10.1038/sj.bjc.6601068; Muto M, 2002, J BIOL CHEM, V277, P34549, DOI 10.1074/jbc.M205189200; Nakamura M, 2001, LAB INVEST, V81, P77, DOI 10.1038/labinvest.3780213; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Pradhan S, 2002, EMBO J, V21, P779, DOI 10.1093/emboj/21.4.779; RICHON VM, 1992, CELL GROWTH DIFFER, V3, P413; Roncalli M, 1998, LAB INVEST, V78, P1049; Simpson DJ, 2001, CARCINOGENESIS, V22, P1149, DOI 10.1093/carcin/22.8.1149; Simpson DJ, 2000, CANCER RES, V60, P1211; SLACK RS, 1993, ONCOGENE, V8, P1585; Strobeck MW, 2000, ONCOGENE, V19, P1857, DOI 10.1038/sj.onc.1203510; Strobeck MW, 2000, P NATL ACAD SCI USA, V97, P7748, DOI 10.1073/pnas.97.14.7748; Trotzier MA, 2004, BIOCHEM BIOPH RES CO, V319, P590, DOI 10.1016/j.bbrc.2004.05.028; Unoki M, 2004, ONCOGENE, V23, P7601, DOI 10.1038/sj.onc.1208053; Vasquez RJ, 1997, MOL BIOL CELL, V8, P973, DOI 10.1091/mbc.8.6.973; Wade PA, 2001, HUM MOL GENET, V10, P693, DOI 10.1093/hmg/10.7.693; Walker GJ, 1998, GENE CHROMOSOME CANC, V22, P157, DOI 10.1002/(SICI)1098-2264(199806)22:2<157::AID-GCC11>3.0.CO;2-N; Wang G, 2000, EXP CELL RES, V254, P64, DOI 10.1006/excr.1999.4743; Wood A, 2003, MOL CELL, V11, P267, DOI 10.1016/S1097-2765(02)00802-X; Young AP, 2004, ONCOGENE, V23, P2587, DOI 10.1038/sj.onc.1207330; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X; Zhang HS, 2001, ONCOGENE, V20, P3134, DOI 10.1038/sj.onc.1204338; Zhang Y, 2003, GENE DEV, V17, P2733, DOI 10.1101/gad.1156403	51	100	111	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2005	24	49					7337	7345		10.1038/sj.onc.1208878	http://dx.doi.org/10.1038/sj.onc.1208878			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	982FA	16007129				2022-12-25	WOS:000233142100010
J	Kawaguchi, T; Kato, S; Otsuka, K; Watanabe, G; Kumabe, T; Tominaga, T; Yoshimoto, T; Ishioka, C				Kawaguchi, T; Kato, S; Otsuka, K; Watanabe, G; Kumabe, T; Tominaga, T; Yoshimoto, T; Ishioka, C			The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	ONCOGENE			English	Article						p53; oligomerization; transactivation	PROLYL ISOMERASE PIN1; TUMOR-SUPPRESSOR P53; LI-FRAUMENI SYNDROME; TETRAMERIZATION DOMAIN; DNA-BINDING; WILD-TYPE; P53-INDUCED APOPTOSIS; TRANSFORMING DOMAIN; CRYSTAL-STRUCTURE; MUTANTS	Tumor suppressor p53 forms a homo-tetramer through its COOH-terminal oligomerization domain and acts as a sequence-specific transcription factor. We have analysed the interrelation among the transcriptional activities, the structure and the cancer-related mutations in the oligomerization domain by using a comprehensive missense mutation library. Here, we examined the ability of 184 mutant p53s in the domain to form an oligomer by expressing these mutant p53s in yeast, and compared the data with the previous information. We showed that specific residues in the alpha-helix and the beta-strand of the oligomerization domain were critical for both oligomer formation and sequence-specific transactivation, and the activities were closely related. In particular, the alpha-helix was more sensitive to amino-acid substitutions than the beta-strand. We found identity in the interrelation between the two activities, that is, monomer mutants were transcriptionally inactive whereas dimer and tetramer mutants retained their transcriptional activities. In TP53 mutation databases, a small number of mutations have been reported in this domain. Surprisingly, most do not encode p53s defective in functional properties. These results indicate that, although oligomer formation is essential for p53 transactivation function, the inactivation of oligomer formation and therefore the inactivation of transactivation may not be essential for tumor suppression by p53 because they do not lead to oncogenic proteins.	Inst Dev Aging & Canc, Dept Clin Oncol, Aoba Ku, Sendai, Miyagi 9808575, Japan; Tohoku Univ Hosp, Aoba Ku, Sendai, Miyagi 9808575, Japan; Tohoku Univ, Grad Sch Med, Dept Neurosurg, Sendai, Miyagi 8908574, Japan	Tohoku University; Tohoku University	Ishioka, C (corresponding author), Inst Dev Aging & Canc, Dept Clin Oncol, Aoba Ku, 4-1 Seiryo Machi, Sendai, Miyagi 9808575, Japan.	chikashi@idac.tohoku.ac.jp	Kato, Shunsuke/F-7607-2014	Ishioka, Chikashi/0000-0002-3023-1227				Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Brachmann RK, 1996, P NATL ACAD SCI USA, V93, P4091, DOI 10.1073/pnas.93.9.4091; Chene P, 1999, J MOL BIOL, V288, P891, DOI 10.1006/jmbi.1999.2738; Chene P, 1997, J MOL BIOL, V273, P873, DOI 10.1006/jmbi.1997.1360; CLORE GM, 1995, SCIENCE, V267, P1515, DOI 10.1126/science.7878474; Davison TS, 1998, ONCOGENE, V17, P651, DOI 10.1038/sj.onc.1202062; DiGiammarino EL, 2002, NAT STRUCT BIOL, V9, P12, DOI 10.1038/nsb730; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; ISHIOKA C, 1995, ONCOGENE, V10, P1485; Ishioka C, 1997, BIOCHEM BIOPH RES CO, V232, P54, DOI 10.1006/bbrc.1997.6216; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; Kakudo Y, 2005, CANCER RES, V65, P2108, DOI 10.1158/0008-5472.CAN-04-2935; Kato S, 2003, P NATL ACAD SCI USA, V100, P8424, DOI 10.1073/pnas.1431692100; LEE WT, 1994, NAT STRUCT BIOL, V1, P877, DOI 10.1038/nsb1294-877; Lomax ME, 1998, ONCOGENE, V17, P643, DOI 10.1038/sj.onc.1201974; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; Mateu MG, 1998, EMBO J, V17, P2748, DOI 10.1093/emboj/17.10.2748; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Miller M, 1996, FEBS LETT, V399, P166, DOI 10.1016/S0014-5793(96)01231-8; Mittl PRE, 1998, ACTA CRYSTALLOGR D, V54, P86, DOI 10.1107/S0907444997006550; MIYASHITA T, 1995, CELL, V80, P293; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHAULIAN E, 1993, EMBO J, V12, P2789, DOI 10.1002/j.1460-2075.1993.tb05940.x; SLINGERLAND JM, 1991, J CELL PHYSIOL, V148, P391, DOI 10.1002/jcp.1041480309; Soussi T, 2005, HUM MUTAT, V25, P6, DOI 10.1002/humu.20114; SRIVASTAVA S, 1993, ONCOGENE, V8, P2449; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; UNGER T, 1993, MOL CELL BIOL, V13, P5186, DOI 10.1128/MCB.13.9.5186; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; Varley JM, 1996, ONCOGENE, V12, P2437; Zacchi P, 2002, NATURE, V419, P853, DOI 10.1038/nature01120; Zheng HW, 2002, NATURE, V419, P849, DOI 10.1038/nature01116	41	70	71	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2005	24	46					6976	6981		10.1038/sj.onc.1208839	http://dx.doi.org/10.1038/sj.onc.1208839			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	975ZD	16007150				2022-12-25	WOS:000232701700012
J	Martin, NL; Saba-El-Leil, MK; Sadekova, S; Meloche, S; Sauvageau, G				Martin, NL; Saba-El-Leil, MK; Sadekova, S; Meloche, S; Sauvageau, G			EN2 is a candidate oncogene in human breast cancer	ONCOGENE			English	Article						Engrailed-2; homeobox; breast cancer; RNAi; transplantation	DIFFERENTIAL EXPRESSION; GENE-EXPRESSION; HOMEOBOX GENES; IN-VIVO; C-MYC; MOUSE; CELLS; MICE; TRANSFORMATION; PHENOTYPE	Only a few critical oncogenes have been identified in the more commonly occurring cases of sporadic breast cancer. We provide evidence that EN2 is ectopically expressed in a subset of human breast cancer and may have a causal role in mammary tumorigenesis. Nontumorigenic mammary cell lines engineered to ectopically express En-2 have a marked reduction in their cycling time, lose cell contact inhibition, become sensitive to 17-AAG treatment, fail to differentiate when exposed to lactogenic hormones and induce mammary tumors when transplanted into cleared mammary glands of syngeneic hosts. RNA interference studies suggest that EN2 expression is required for the maintenance of the transformed phenotype of a human breast tumor cell line.	Inst Rech Immunol & Cancerol, Lab Mol Genet Hematopoiet Stem Cells, Montreal, PQ H3C 3J7, Canada; Inst Rech Immunol & Cancerol, Lab Signaling & Cell Growth, Montreal, PQ H3C 3J7, Canada; McGill Univ, Dept Oncol, Montreal, PQ H3A 2B4, Canada; Hop Maison Neuve Rosemont, Dept Med, Montreal, PQ H1T 2M4, Canada; Hop Maison Neuve Rosemont, Div Hematol, Montreal, PQ H1T 2M4, Canada; Hop Maison Neuve Rosemont, Leukemia Cell Bank Quebec, Montreal, PQ H1T 2M4, Canada	Universite de Montreal; Universite de Montreal; McGill University; Universite de Montreal; Universite de Montreal; Universite de Montreal	Meloche, S (corresponding author), Inst Rech Immunol & Cancerol, Lab Mol Genet Hematopoiet Stem Cells, CP 6128,Succursale Ctr Ville, Montreal, PQ H3C 3J7, Canada.	sylvain.meloche@umontreal.ca; guy.sauvageau@umontreal.ca		Sauvageau, Guy/0000-0002-4333-7266				Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; BALL RK, 1988, EMBO J, V7, P2089, DOI 10.1002/j.1460-2075.1988.tb03048.x; Baselga J, 2002, CANCER CELL, V1, P319, DOI 10.1016/S1535-6108(02)00066-1; Bieche I, 1999, CANCER RES, V59, P2759; BROWN AMC, 1986, CELL, V46, P1001, DOI 10.1016/0092-8674(86)90699-9; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Cella N, 1998, MOL CELL BIOL, V18, P1783, DOI 10.1128/MCB.18.4.1783; DANIELSON KG, 1984, P NATL ACAD SCI-BIOL, V81, P3756, DOI 10.1073/pnas.81.12.3756; DAVIS CA, 1988, GENE DEV, V2, P1736, DOI 10.1101/gad.2.12b.1736; DAVIS CA, 1991, DEVELOPMENT, V111, P287; DEOME K.B., 1959, JNCI-J NATL CANCER I, V78, P751; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HUGUET EL, 1994, CANCER RES, V54, P2615; Humphreys RC, 1997, CELL GROWTH DIFFER, V8, P839; Hutchinson JN, 2000, ONCOGENE, V19, P6130, DOI 10.1038/sj.onc.1203970; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Ingvarsson S, 1999, SEMIN CANCER BIOL, V9, P277, DOI 10.1006/scbi.1999.0124; JOYNER AL, 1991, SCIENCE, V251, P1239, DOI 10.1126/science.1672471; Kroon E, 1998, EMBO J, V17, P3714, DOI 10.1093/emboj/17.13.3714; Krosl J, 1998, ONCOGENE, V16, P3403, DOI 10.1038/sj.onc.1201883; LAWRENCE HJ, 1995, EXP HEMATOL, V23, P1160; Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572; Lewis MT, 2000, BREAST CANCER RES, V2, P158, DOI 10.1186/bcr49; Liao DJ, 2000, ENDOCR-RELAT CANCER, V7, P143, DOI 10.1677/erc.0.0070143; LIZARDNACOL S, 1995, CANCER RES, V55, P4416; MCMAHON AP, 1992, CELL, V69, P581, DOI 10.1016/0092-8674(92)90222-X; Neckers L, 2003, NATURE, V425, P357, DOI 10.1038/425357a; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; PAWLIUK R, 1994, BLOOD, V84, P2868, DOI 10.1182/blood.V84.9.2868.bloodjournal8492868; Peltenburg LTC, 1996, EMBO J, V15, P3385, DOI 10.1002/j.1460-2075.1996.tb00704.x; Peltenburg LTC, 1997, DEVELOPMENT, V124, P1089; Ross JS, 2003, EXPERT REV MOL DIAGN, V3, P573, DOI 10.1586/14737159.3.5.573; SAUVAGEAU G, 1994, P NATL ACAD SCI USA, V91, P12223, DOI 10.1073/pnas.91.25.12223; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Thorsteinsdottir U, 1999, MOL CELL BIOL, V19, P6355; Tognon C, 2002, CANCER CELL, V2, P367, DOI 10.1016/S1535-6108(02)00180-0; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; VAIDYA AB, 1978, VIROLOGY, V90, P12, DOI 10.1016/0042-6822(78)90328-8	39	44	56	2	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2005	24	46					6890	6901		10.1038/sj.onc.1208840	http://dx.doi.org/10.1038/sj.onc.1208840			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	975ZD	16007149				2022-12-25	WOS:000232701700004
J	Banas, A; Carlsson, AS; Huang, B; Lenman, M; Banas, W; Lee, M; Noiriel, A; Benveniste, P; Schaller, H; Bouvier-Nave, P; Stymne, S				Banas, A; Carlsson, AS; Huang, B; Lenman, M; Banas, W; Lee, M; Noiriel, A; Benveniste, P; Schaller, H; Bouvier-Nave, P; Stymne, S			Cellular sterol ester synthesis in plants is performed by an enzyme (phospholipid : sterol acyltransferase) different from the yeast and mammalian acyl-CoA : sterol acyltransferases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LECITHIN-CHOLESTEROL ACYLTRANSFERASE; DIACYLGLYCEROL ACYLTRANSFERASE; ARABIDOPSIS-THALIANA; TOBACCO MUTANT; OVERPRODUCES STEROLS; SPINACH LEAVES; SINAPIS-ALBA; KEY ENZYME; TRIACYLGLYCEROL; ESTERIFICATION	A gene encoding a sterol ester-synthesizing enzyme was identified in Arabidopsis. The cDNA of the Arabidopsis gene At1g04010 (AtPSAT) was overexpressed in Arabidopsis behind the cauliflower mosaic virus 35S promoter. Microsomal membranes from the leaves of overexpresser lines catalyzed the transacylation of acyl groups from phosphatidylethanolamine to sterols. This activity correlated with the expression level of the AtPSAT gene, thus demonstrating that this gene encodes a phospholipid: sterol acyltransferase (PSAT). Properties of the AtPSAT were examined in microsomal fractions from the tissues of an overexpresser. The enzyme did not utilize neutral lipids, had the highest activity with phosphatidylethanolamine, had a 5-fold preference for the sn-2 position, and utilized both saturated and unsaturated fatty acids. Various sterols and sterol intermediates, including triterpenic precursors, were acylated by the PSAT, whereas other triterpenes were not. Sterol selectivity studies showed that the enzyme is activated by end product sterols and that sterol intermediates are preferentially acylated by the activated enzyme. This indicates that PSAT both regulates the pool of free sterols as well as limits the amount of free sterol intermediates in the membranes. Two T-DNA insertion mutants in the AtPSAT gene, with strongly reduced ( but still measurable) levels of sterol esters in their tissues, had no detectable PSAT activity in the microsomal fractions, suggesting that Arabidopsis possess other enzyme(s) capable of acylating sterols. The AtPSAT is the only intracellular enzyme found so far that catalyzes an acyl-CoA-independent sterol ester formation. Thus, PSAT has a similar physiological function in plant cells as the unrelated acyl-CoA: sterol acyltransferase has in animal cells.	Swedish Univ Agr Sci, Dept Crop Sci, SE-23053 Alnarp, Sweden; Hubei Univ, Coll Life Sci, Wuhan 430062, Peoples R China; ScanBi AB, S-23052 Alnarp, Sweden; Univ Podlasie, Inst Biol, PL-08110 Siedlce, Poland; CNRS, Dept Isoprenoides, Inst Bot, Inst Biol Mol Plantes, F-67083 Strasbourg, France	Swedish University of Agricultural Sciences; Hubei University; Scania; University of Podlasie; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Carlsson, AS (corresponding author), Swedish Univ Agr Sci, Dept Crop Sci, POB 44, SE-23053 Alnarp, Sweden.	anders.carlsson@vv.slu.se		Carlsson, Anders/0000-0002-8525-9753; Lee, Michael/0000-0002-6643-1984; Banas, Antoni/0000-0001-9397-7627; Schaller, Hubert/0000-0002-4099-4447				Alonso JM, 2003, SCIENCE, V301, P653, DOI 10.1126/science.1086391; BACH TJ, 1986, LIPIDS, V21, P82, DOI 10.1007/BF02534307; BECKER D, 1992, PLANT MOL BIOL, V20, P1195, DOI 10.1007/BF00028908; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BLOCH KE, 1983, CRC CR REV BIOCH MOL, V14, P47, DOI 10.3109/10409238309102790; BOUVIERNAVE P, 1995, PLANT SCI, V110, P11, DOI 10.1016/0168-9452(95)04181-S; Cases S, 1998, P NATL ACAD SCI USA, V95, P13018, DOI 10.1073/pnas.95.22.13018; Chang TY, 1997, ANNU REV BIOCHEM, V66, P613, DOI 10.1146/annurev.biochem.66.1.613; Chenchik A, 1996, BIOTECHNIQUES, V21, P526; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; Dahlqvist A, 2000, P NATL ACAD SCI USA, V97, P6487, DOI 10.1073/pnas.120067297; DEMEL RA, 1976, BIOCHIM BIOPHYS ACTA, V457, P109, DOI 10.1016/0304-4157(76)90008-3; DYAS L, 1993, PHYTOCHEMISTRY, V34, P17, DOI 10.1016/S0031-9422(00)90777-5; GARCIA RE, 1978, PLANT PHYSIOL, V62, P348, DOI 10.1104/pp.62.3.348; GARCIA RE, 1978, ARCH BIOCHEM BIOPHYS, V190, P315, DOI 10.1016/0003-9861(78)90281-3; GONDET L, 1994, PLANT PHYSIOL, V105, P509, DOI 10.1104/pp.105.2.509; Hobbs DH, 1999, FEBS LETT, V452, P145, DOI 10.1016/S0014-5793(99)00646-8; Jonas A, 2000, BBA-MOL CELL BIOL L, V1529, P245, DOI 10.1016/S1388-1981(00)00153-0; KANDA P, 1981, J LIPID RES, V22, P877; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; LEWIS TA, 1987, BIOCHIM BIOPHYS ACTA, V921, P205, DOI 10.1016/0005-2760(87)90020-8; MAILLOTVERNIER P, 1991, MOL GEN GENET, V231, P33, DOI 10.1007/BF00293818; Noiriel A, 2004, EUR J BIOCHEM, V271, P3752, DOI 10.1111/j.1432-1033.2004.04317.x; NOIRIEL A, 2004, THESIS U L PASTEUR S; Peelman F, 1998, PROTEIN SCI, V7, P587, DOI 10.1002/pro.5560070307; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schaeffer A, 2001, PLANT J, V25, P605, DOI 10.1046/j.1365-313x.2001.00994.x; SCHALLER H, 1995, PLANT PHYSIOL, V109, P761, DOI 10.1104/pp.109.3.761; Stahl U, 2004, PLANT PHYSIOL, V135, P1324, DOI 10.1104/pp.104.044354; STOBART AK, 1985, BIOCHEM J, V232, P217, DOI 10.1042/bj2320217; Sturley SL, 1997, CURR OPIN LIPIDOL, V8, P167, DOI 10.1097/00041433-199706000-00007; THORNTON J, 1988, BIOCHIM BIOPHYS ACTA, V959, P153, DOI 10.1016/0005-2760(88)90026-4; Wang JC, 2003, BIOCHEMISTRY-US, V42, P13941, DOI 10.1021/biO35460u; Yang HY, 1996, SCIENCE, V272, P1353, DOI 10.1126/science.272.5266.1353; ZIMOWSKI J, 1981, PHYTOCHEMISTRY, V20, P1795, DOI 10.1016/0031-9422(81)84006-X; ZIMOWSKI J, 1981, PHYTOCHEMISTRY, V20, P1799, DOI 10.1016/0031-9422(81)84007-1	36	46	53	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34626	34634		10.1074/jbc.M504459200	http://dx.doi.org/10.1074/jbc.M504459200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16020547	hybrid			2022-12-25	WOS:000232403900031
J	Dolloff, NG; Shulby, SS; Nelson, AV; Stearns, ME; Johannes, GJ; Thomas, JD; Meucci, O; Fatatis, A				Dolloff, NG; Shulby, SS; Nelson, AV; Stearns, ME; Johannes, GJ; Thomas, JD; Meucci, O; Fatatis, A			Bone-metastatic potential of human prostate cancer cells correlates with Akt/PKB activation by alpha platelet-derived growth factor receptor	ONCOGENE			English	Article						prostate cancer; metastasis; PDGF; EGF; Akt	IN-VIVO; EXPRESSION; INVOLVEMENT; PROGRESSION; MIGRATION; SURVIVAL; AKT	Prostate adenocarcinoma metastasizes to the skeleton more frequently than any other organ. An underlying cause of this phenomenon may be the ability of bone-produced factors to specifically select disseminated prostate cancer cells that are susceptible to their trophic effects. Platelet-derived growth factor ( PDGF), a potent mitogen for both normal and tumor cells, is produced in several tissues including bone, where it is synthesized by both osteoblasts and osteoclasts. Here, we show that PDGF causes a significantly stronger activation of the Akt/PKB survival pathway in bone-metastatic prostate cancer cells compared to nonmetastatic cells. Normal prostate epithelial cells and DU-145 prostate cells, originally derived from a brain metastasis, are not responsive to PDGF. In contrast, epidermal growth factor stimulates Akt to the same extent in all prostate cells tested. This difference in PDGF responsiveness depends on the higher expression of alpha-PDGFR in bone-metastatic compared to nonmetastatic prostate cells and the lack of alpha-PDGFR expression in normal and metastatic prostate cells derived from tissues other than bone. Thus, alpha-PDGFR expression might identify prostate cancer cells with the highest propensity to metastasize to the skeleton.	Drexel Univ, Coll Med, Dept Physiol & Pharmacol, Philadelphia, PA 19102 USA; Drexel Univ, Coll Med, Dept Pathol, Philadelphia, PA 19102 USA	Drexel University; Drexel University	Fatatis, A (corresponding author), Drexel Univ, Coll Med, Dept Physiol & Pharmacol, 245 N 15th St,New Coll Bldg MS488, Philadelphia, PA 19102 USA.	af39@drexel.edu			NCI NIH HHS [CA076639, R01 CA076639, CA112096] Funding Source: Medline; NIDA NIH HHS [R01 DA015014-01, R01 DA019808-03, R01 DA015014-04, DA19808, R01 DA019808-02, R01 DA019808, R01 DA019808-01, R01 DA015014-02, R01 DA015014-03, R01 DA015014, DA15014] Funding Source: Medline; NIGMS NIH HHS [GM067892, R01 GM067892] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076639] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067892] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA019808, R01DA015014] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Chang F, 2003, LEUKEMIA, V17, P590, DOI 10.1038/sj.leu.2402824; Chott A, 1999, AM J PATHOL, V155, P1271, DOI 10.1016/S0002-9440(10)65229-7; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; FUDGE K, 1994, MODERN PATHOL, V7, P549; Graff Jeremy R, 2002, Expert Opin Ther Targets, V6, P103, DOI 10.1517/14728222.6.1.103; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; Kubota K, 2002, J BONE MINER RES, V17, P257, DOI 10.1359/jbmr.2002.17.2.257; Majumder PK, 2003, P NATL ACAD SCI USA, V100, P7841, DOI 10.1073/pnas.1232229100; Mundy GR, 2000, CANCER AND THE SKELETON, P1; Raftopoulou M, 2004, SCIENCE, V303, P1179, DOI 10.1126/science.1092089; Ruijter E, 1999, ENDOCR REV, V20, P22, DOI 10.1210/er.20.1.22; Russell PJ, 1998, CLIN CHEM, V44, P705; Shulby SA, 2004, CANCER RES, V64, P4693, DOI 10.1158/0008-5472.CAN-03-3437; STONE KR, 1978, INT J CANCER, V21, P274, DOI 10.1002/ijc.2910210305; WANG M, 1991, DIFFERENTIATION, V48, P115, DOI 10.1111/j.1432-0436.1991.tb00250.x; Watson PH, 1996, J MOL ENDOCRINOL, V17, P45, DOI 10.1677/jme.0.0170045; Xu WP, 2003, CANCER RES, V63, P7777; Yang DH, 2000, CYTOKINE, V12, P1271, DOI 10.1006/cyto.2000.0707	19	52	56	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 13	2005	24	45					6848	6854		10.1038/sj.onc.1208815	http://dx.doi.org/10.1038/sj.onc.1208815			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	973MV	16007172	Green Accepted			2022-12-25	WOS:000232527800013
J	Wong, C; Jin, ZG				Wong, C; Jin, ZG			Protein kinase C-dependent protein kinase D activation modulates ERK signal pathway and endothelial cell proliferation by vascular endothelial growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; TRANS-GOLGI NETWORK; FACTOR RECEPTORS; DNA-SYNTHESIS; AUTOPHOSPHORYLATION SITE; TRANSDUCTION PATHWAY; PKC-MU; VEGF; STRESS; PHOSPHORYLATION	Vascular endothelial growth factor ( VEGF) is essential for many angiogenic processes both in normal conditions and in pathological conditions. However, the signaling pathways involved in VEGF-induced angiogenesis are not well defined. Protein kinase D (PKD), a newly described serine/threonine protein kinase, has been implicated in many signal transduction pathways and in cell proliferation. We hypothesized that PKD would mediate VEGF signaling and function in endothelial cells. Here we found that VEGF rapidly and strongly stimulated PKD phosphorylation and activation in endothelial cells via VEGF receptor 2 (VEGFR2). The pharmacological inhibitors for phospholipase C gamma (PLC gamma) and protein kinase C(PKC) significantly inhibited VEGF-induced PKD activation, suggesting the involvement of the PLC gamma/PKC pathway. In particular, PKC alpha was critical for VEGF-induced PKD activation since both overexpression of adenovirus PKC alpha dominant negative mutant and reduction of PKC alpha expression by small interfering RNA markedly inhibited VEGF-induced PKD activation. Importantly, we found that small interfering RNA knockdown of PKD and PKC alpha expression significantly attenuated ERK activation and DNA synthesis in endothelial cells by VEGF. Taken together, our results demonstrated for the first time that VEGF activates PKD via the VEGFR2/PLC gamma/ PKC alpha pathway and revealed a critical role of PKD in VEGF-induced ERK signaling and endothelial cell proliferation.	Univ Rochester, Med Ctr, Dept Med, Cardiovasc Res Inst, Rochester, NY 14642 USA	University of Rochester	Jin, ZG (corresponding author), Univ Rochester, Med Ctr, Dept Med, Cardiovasc Res Inst, 601 Elmwood Ave,Box 679, Rochester, NY 14642 USA.	zheng-gen_jin@urmc.rochester.edu			NHLBI NIH HHS [R01 HL080611, HL080611, R01 HL080611-05] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL080611] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baron CL, 2002, SCIENCE, V295, P325, DOI 10.1126/science.1066759; Brandlin I, 2002, J BIOL CHEM, V277, P6490, DOI 10.1074/jbc.M106083200; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; Carpenter L, 2001, J BIOL CHEM, V276, P5368, DOI 10.1074/jbc.M010036200; Claesson-Welsh L, 2003, BIOCHEM SOC T, V31, P20, DOI 10.1042/bst0310020; Endo K, 2000, J BIOL CHEM, V275, P18476, DOI 10.1074/jbc.M002266200; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Hausser A, 2002, J CELL BIOL, V156, P65, DOI 10.1083/jcb.200110047; Hausser A, 2001, FEBS LETT, V492, P39, DOI 10.1016/S0014-5793(01)02219-0; Iglesias T, 1998, J BIOL CHEM, V273, P27662, DOI 10.1074/jbc.273.42.27662; Jamora C, 1999, CELL, V98, P59, DOI 10.1016/S0092-8674(00)80606-6; Jin ZG, 2000, CIRC RES, V87, P789, DOI 10.1161/01.RES.87.9.789; Jin ZG, 2005, J BIOL CHEM, V280, P12305, DOI 10.1074/jbc.M500294200; Jin ZG, 2004, ARTERIOSCL THROM VAS, V24, P1186, DOI 10.1161/01.ATV.0000130664.51010.28; Jin ZG, 2003, CIRC RES, V93, P354, DOI 10.1161/01.RES.0000089257.94002.96; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; Karkkainen MJ, 2000, ONCOGENE, V19, P5598, DOI 10.1038/sj.onc.1203855; Lawson ND, 2003, GENE DEV, V17, P1346, DOI 10.1101/gad.1072203; Liljedahl M, 2001, CELL, V104, P409, DOI 10.1016/S0092-8674(01)00228-8; Lungu AO, 2004, J BIOL CHEM, V279, P48794, DOI 10.1074/jbc.M313897200; Matthews SA, 1999, J BIOL CHEM, V274, P26543, DOI 10.1074/jbc.274.37.26543; Petrova TV, 1999, EXP CELL RES, V253, P117, DOI 10.1006/excr.1999.4707; ROSALES OR, 1992, BIOCHEM BIOPH RES CO, V189, P40, DOI 10.1016/0006-291X(92)91522-R; Rozengurt E, 2005, J BIOL CHEM, V280, P13205, DOI 10.1074/jbc.R500002200; Sakurai Y, 2005, P NATL ACAD SCI USA, V102, P1076, DOI 10.1073/pnas.0404984102; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Sinnett-Smith J, 2004, J BIOL CHEM, V279, P16883, DOI 10.1074/jbc.M313225200; Storz P, 2003, EMBO J, V22, P109, DOI 10.1093/emboj/cdg009; Takahashi T, 1999, ONCOGENE, V18, P2221, DOI 10.1038/sj.onc.1202527; Takahashi T, 2001, EMBO J, V20, P2768, DOI 10.1093/emboj/20.11.2768; Tan MQ, 2003, J BIOL CHEM, V278, P2824, DOI 10.1074/jbc.M211523200; Traub O, 1997, J BIOL CHEM, V272, P31251, DOI 10.1074/jbc.272.50.31251; VALVERDE AM, 1994, P NATL ACAD SCI USA, V91, P8572, DOI 10.1073/pnas.91.18.8572; Van Lint J, 2002, INT J BIOCHEM CELL B, V34, P577, DOI 10.1016/S1357-2725(01)00163-7; Xia P, 1996, J CLIN INVEST, V98, P2018, DOI 10.1172/JCI119006; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; Yeaman C, 2004, NAT CELL BIOL, V6, P106, DOI 10.1038/ncb1090; Zachary I, 2003, BIOCHEM SOC T, V31, P1171; Zugaza JL, 1996, EMBO J, V15, P6220, DOI 10.1002/j.1460-2075.1996.tb01012.x; Zugaza JL, 1997, J BIOL CHEM, V272, P23952, DOI 10.1074/jbc.272.38.23952	44	142	145	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	2005	280	39					33262	33269		10.1074/jbc.M503198200	http://dx.doi.org/10.1074/jbc.M503198200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	966YG	16006559	hybrid, Green Accepted			2022-12-25	WOS:000232058100021
J	Han, JH; Tsukada, Y; Hara, E; Kitamura, N; Tanaka, T				Han, JH; Tsukada, Y; Hara, E; Kitamura, N; Tanaka, T			Hepatocyte growth factor induces redistribution of p21(CIP1) and p27(KIP1) through ERK-dependent p16(INK4a) up-regulation, leading to cell cycle arrest at G(1) in HepG2 hepatoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-MET RECEPTOR; TYROSINE KINASE; SCATTER FACTOR; INDUCED PROLIFERATION; TRANSCRIPTION FACTOR; MOLECULAR-CLONING; CDK INHIBITORS; EXPRESSION; PROTEINS; LIVER	Hepatocyte growth factor (HGF) has an anti-proliferative effect on many types of tumor cell lines and tumors in vivo. We found previously that inhibition of HGF-induced proliferation in HepG2 hepatoma cells is caused by cell cycle arrest at G(1) through a high intensity ERK signal, which represses Cdk2 activity. To examine further the mechanisms of G(1) arrest by HGF, we analyzed the Cdk inhibitor p16(INK4a), which has an anti-proliferative function through cell cycle arrest at G1. We found that HGF treatment drastically increased endogenous p16 levels. Knockdown of p16 with small interfering RNA reversed the arrest, indicating that the induction of p16 is required for G(1) arrest by HGF. Analysis of the promoter of the human p16 gene identified the proximal Ets-binding site as a responsive element for HGF, and this responded to the high intensity ERK signal. HGF treatment of the cells led to a redistribution of p21(CIP1) and p27(KIP1) from Cdk4 to Cdk2. The redistribution was blocked by the knockdown of p16 with small interfering RNA, which restored the Cdk2 activity repressed by HGF, demonstrating the requirement of p16 induction for the redistribution and eventual repression of Cdk2 activity. Our results reveal a signaling pathway for G(1) arrest induced by HGF.	Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Dept Biol Sci, Midori Ku, Yokohama, Kanagawa 2268501, Japan; Univ Tokushima, Inst Genome Res, Div Prot Informat, Tokushima 7708503, Japan	Tokyo Institute of Technology; Tokushima University	Tanaka, T (corresponding author), Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Dept Biol Sci, Midori Ku, 4259 Nagatsuta, Yokohama, Kanagawa 2268501, Japan.	ttanaka@bio.titech.ac.jp	Han, Junhong/L-5264-2013; Tanaka, Toshiaki/C-5567-2013	Tanaka, Toshiaki/0000-0002-9448-1452; Han, Junhong/0000-0002-3371-8698				BIRCHMEIER C, 1993, ANNU REV CELL BIOL, V9, P511, DOI 10.1146/annurev.cb.09.110193.002455; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; Bond J, 2004, EXP CELL RES, V292, P151, DOI 10.1016/j.yexcr.2003.09.021; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Calbo J, 2004, CELL DEATH DIFFER, V11, P1055, DOI 10.1038/sj.cdd.4401481; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; DEAN M, 1985, NATURE, V318, P385, DOI 10.1038/318385a0; DURO D, 1995, ONCOGENE, V11, P21; Foulds CE, 2004, MOL CELL BIOL, V24, P10954, DOI 10.1128/MCB.24.24.10954-10964.2004; Furge KA, 2000, ONCOGENE, V19, P5582, DOI 10.1038/sj.onc.1203859; HALABAN R, 1992, ONCOGENE, V7, P2195; Hara E, 1996, MOL CELL BIOL, V16, P859; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; Jiang H, 1998, MOL CELL BIOL, V18, P5284, DOI 10.1128/MCB.18.9.5284; KAN M, 1991, BIOCHEM BIOPH RES CO, V174, P331, DOI 10.1016/0006-291X(91)90524-B; KOMADA M, 1992, EUR J BIOCHEM, V204, P857, DOI 10.1111/j.1432-1033.1992.tb16705.x; Krishnamurthty J, 2004, J CLIN INVEST, V114, P1299, DOI 10.1172/JCI200422475; LIU ML, 1995, CARCINOGENESIS, V16, P841, DOI 10.1093/carcin/16.4.841; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; MAO L, 1995, CANCER RES, V55, P2995; MATSUMOTO K, 1992, Critical Reviews in Oncogenesis, V3, P27; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; McConnell BB, 1999, MOL CELL BIOL, V19, P1981; Mitra J, 1999, MOL CELL BIOL, V19, P3916; MIYAZAKI M, 1992, CELL BIOL INT REP, V16, P145, DOI 10.1016/S0309-1651(06)80108-6; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; NAGNASS AU, 1994, BIOCHEM BIOPH RES CO, V202, P701; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NALDINI L, 1991, ONCOGENE, V6, P501; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; Oikawa T, 2004, CANCER SCI, V95, P626, DOI 10.1111/j.1349-7006.2004.tb03320.x; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; Paumelle R, 2002, ONCOGENE, V21, P2309, DOI 10.1038/sj.onc.1205297; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; QUELLE DE, 1995, CELL, V83, P993; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; ROSEN EM, 1994, J CELL BIOL, V127, P1783, DOI 10.1083/jcb.127.6.1783; Rottinger E, 2004, DEVELOPMENT, V131, P1075, DOI 10.1242/dev.01000; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; SantoniRugiu E, 1996, P NATL ACAD SCI USA, V93, P9577, DOI 10.1073/pnas.93.18.9577; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shima N, 1998, J CELL PHYSIOL, V177, P130, DOI 10.1002/(SICI)1097-4652(199810)177:1<130::AID-JCP14>3.3.CO;2-O; SHIMA N, 1991, CELL BIOL INT REP, V15, P397, DOI 10.1016/0309-1651(91)90128-6; SHIMA N, 1991, BIOCHEM BIOPH RES CO, V180, P1151, DOI 10.1016/S0006-291X(05)81187-8; SHIOTA G, 1992, P NATL ACAD SCI USA, V89, P373, DOI 10.1073/pnas.89.1.373; STONE S, 1995, CANCER RES, V55, P2988; Swarbrick A, 2000, MOL CELL BIOL, V20, P2581, DOI 10.1128/MCB.20.7.2581-2591.2000; TAJIMA H, 1992, EXP CELL RES, V202, P423, DOI 10.1016/0014-4827(92)90095-P; TAJIMA H, 1991, FEBS LETT, V291, P229, DOI 10.1016/0014-5793(91)81291-F; Tsukada Y, 2004, J BIOCHEM, V136, P701, DOI 10.1093/jb/mvh177; Tsukada Y, 2001, J BIOL CHEM, V276, P40968, DOI 10.1074/jbc.M010890200; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; Vaque JP, 2005, J BIOL CHEM, V280, P1112, DOI 10.1074/jbc.M409503200; VIGNA E, 1994, CELL MOL BIOL, V40, P597; WEIDNER KM, 1993, AM J RESP CELL MOL, V8, P229, DOI 10.1165/ajrcmb/8.3.229; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; ZARNEGAR R, 1995, J CELL BIOL, V129, P1177, DOI 10.1083/jcb.129.5.1177; Zhang YW, 2003, J CELL BIOCHEM, V88, P408, DOI 10.1002/jcb.10358	69	49	52	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	2005	280	36					31548	31556		10.1074/jbc.M503431200	http://dx.doi.org/10.1074/jbc.M503431200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	961LZ	16014626	hybrid			2022-12-25	WOS:000231665200027
J	Sergiev, PV; Lesnyak, DV; Burakovsky, DE; Kiparisov, SV; Leonov, AA; Bogdanov, AA; Brimacombe, R; Dontsova, OA				Sergiev, PV; Lesnyak, DV; Burakovsky, DE; Kiparisov, SV; Leonov, AA; Bogdanov, AA; Brimacombe, R; Dontsova, OA			Alteration in location of a conserved GTPase-associated center of the ribosome induced by mutagenesis influences the structure of peptidyltransferase center and activity of elongation factor G	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; TRANSFER-RNA; CRYOELECTRON MICROSCOPY; EF-G; MUTATIONS; TRANSLOCATION; PROTEIN; LOOP; SUBUNIT; MODEL	Translocation catalyzed by elongation factor G occurs after the peptidyltransferase reaction on the large ribosomal subunit. Deacylated tRNA in the P-site stimulates multiple turnover GTPase activity of EF-G. We suggest that the allosteric signal from the peptidyltransferase center that activates EF-G may involve the alteration in the conformation of elongation factor binding center of the ribosome. The latter consists of the moveable GTPase-associated center and the sarcin-ricin loop that keeps its position on the ribosome during translation elongation. The position of the GTPase-associated center was altered by mutagenesis. An insertion of additional base pair at positions C1030/G1124 was lethal and affected function of EF-G, but not that of EF-Tu. Structure probing revealed a putative allosteric signal pathway connecting the P-site with the binding site of the elongation factors. The results are consistent with the different structural requirements for EF-G and EF-Tu function, where the integrity of the path between the peptidyltransferase center and both GTPase-associated center and sarcin-ricin loop is important for EF-G binding.	Moscow MV Lomonosov State Univ, AN Belozersky Inst Physicochem Biol, Moscow 119992, Russia; Moscow MV Lomonosov State Univ, Dept Chem, Moscow 119992, Russia; Moscow MV Lomonosov State Univ, Dept Bioinformat & Bioengn, Moscow 119992, Russia; Max Planck Inst Mol Genet, D-14195 Berlin, Germany	Lomonosov Moscow State University; Lomonosov Moscow State University; Lomonosov Moscow State University; Max Planck Society	Dontsova, OA (corresponding author), Moscow MV Lomonosov State Univ, AN Belozersky Inst Physicochem Biol, Bldg A, Moscow 119992, Russia.	dontsova@genebee.msu.su	Sergiev, Petr V/D-7493-2012; Dontsova, Olga/T-6072-2019; Bogdanov, Alexey A/L-1407-2013	Sergiev, Petr V/0000-0001-8866-1863; 				Agrawal RK, 2001, J MOL BIOL, V311, P777, DOI 10.1006/jmbi.2001.4907; Asai T, 1999, P NATL ACAD SCI USA, V96, P1971, DOI 10.1073/pnas.96.5.1971; BARTETZKO A, 1988, METHOD ENZYMOL, V164, P650; Belova L, 2001, P NATL ACAD SCI USA, V98, P3726, DOI 10.1073/pnas.071527498; BERGEMANN K, 1983, J BIOL CHEM, V258, P5105; Blaha G, 2000, METHOD ENZYMOL, V317, P292; CUNDLIFFE E, 1981, EUR J BIOCHEM, V118, P47, DOI 10.1111/j.1432-1033.1981.tb05484.x; CUPPLES CG, 1989, P NATL ACAD SCI USA, V86, P5345, DOI 10.1073/pnas.86.14.5345; EGEBJERG J, 1989, EMBO J, V8, P607, DOI 10.1002/j.1460-2075.1989.tb03415.x; Ehrenberg M, 1990, RIBOSOMES PROTEIN SY, P101; Gao HX, 2003, CELL, V113, P789, DOI 10.1016/S0092-8674(03)00427-6; Gregory ST, 1999, J MOL BIOL, V285, P1475, DOI 10.1006/jmbi.1998.2410; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Harger JW, 2002, TRENDS BIOCHEM SCI, V27, P448, DOI 10.1016/S0968-0004(02)02149-7; Harms J, 2001, CELL, V107, P679, DOI 10.1016/S0092-8674(01)00546-3; HARTZ D, 1988, METHOD ENZYMOL, V164, P419; Klein DJ, 2001, EMBO J, V20, P4214, DOI 10.1093/emboj/20.15.4214; Leonov AA, 2003, J BIOL CHEM, V278, P25664, DOI 10.1074/jbc.M302873200; LILL R, 1989, EMBO J, V8, P3933, DOI 10.1002/j.1460-2075.1989.tb08574.x; MOAZED D, 1989, NATURE, V342, P142, DOI 10.1038/342142a0; MOAZED D, 1989, CELL, V57, P585, DOI 10.1016/0092-8674(89)90128-1; MOAZED D, 1988, NATURE, V334, P362, DOI 10.1038/334362a0; MOINE H, 1994, J MOL BIOL, V243, P402, DOI 10.1006/jmbi.1994.1668; OCONNOR M, 1993, P NATL ACAD SCI USA, V90, P9214, DOI 10.1073/pnas.90.19.9214; POWERS T, 1990, P NATL ACAD SCI USA, V87, P1042, DOI 10.1073/pnas.87.3.1042; Sergiev PV, 2000, J MOL BIOL, V299, P379, DOI 10.1006/jmbi.2000.3739; Shimizu Y, 2001, NAT BIOTECHNOL, V19, P751, DOI 10.1038/90802; Valle M, 2003, NAT STRUCT BIOL, V10, P899, DOI 10.1038/nsb1003; Zavialov AV, 2003, CELL, V114, P113, DOI 10.1016/S0092-8674(03)00478-1	29	19	23	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	2005	280	36					31882	31889		10.1074/jbc.M505670200	http://dx.doi.org/10.1074/jbc.M505670200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	961LZ	16014631	hybrid			2022-12-25	WOS:000231665200067
J	Bertoncini, CW; Fernandez, CO; Griesinger, C; Jovin, TM; Zweckstetter, M				Bertoncini, CW; Fernandez, CO; Griesinger, C; Jovin, TM; Zweckstetter, M			Familial mutants of alpha-synuclein with increased neurotoxicity have a destabilized conformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISEASE-LINKED MUTATIONS; PARKINSONS-DISEASE; STRUCTURAL-CHARACTERIZATION; NEURODEGENERATIVE DISEASE; UNFOLDED PROTEINS; DIPOLAR COUPLINGS; NMR; AGGREGATION; SYSTEM; DEGRADATION	A30P and A53T mutations of the presynaptic protein alpha- synuclein are associated with familial forms of Parkinson disease. NMR spectroscopy demonstrates that Parkinsonism- linked mutations greatly perturb specific tertiary interactions essential for the native state of alpha- synuclein. However, alpha- synuclein is not completely unfolded but exhibits structural fluctuations on the time scale of secondary structure formation and loses its native conformation gradually when protein stability decreases. The redistribution of the ensemble of alpha- synuclein conformers may underlie toxic gain- of- function by fostering self- association and altered binding affinity to ligands and receptors.	Max Planck Inst Biophys Chem, Dept NMR Based Struct Biol, D-37077 Gottingen, Germany; Max Planck Inst Biophys Chem, Dept Mol Biol, D-37077 Gottingen, Germany; Univ Nacl Rosario, Inst Biol Mol & Celular Rosario, Consejo Nacl Invest Cient & Tecn, RA-2000 Rosario, Argentina	Max Planck Society; Max Planck Society; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); National University of Rosario	Zweckstetter, M (corresponding author), Max Planck Inst Biophys Chem, Dept NMR Based Struct Biol, Fassberg 11, D-37077 Gottingen, Germany.	cfernan@gwdg.de; mzwecks@gwdg.de		Fernandez, Claudio Oscar/0000-0003-0454-7735; Bertoncini, Carlos/0000-0001-7695-2882; Zweckstetter, Markus/0000-0002-2536-6581				Abeliovich A, 2000, NEURON, V25, P239, DOI 10.1016/S0896-6273(00)80886-7; BAX A, 1993, ACCOUNTS CHEM RES, V26, P131, DOI 10.1021/ar00028a001; Bertoncini CW, 2005, P NATL ACAD SCI USA, V102, P1430, DOI 10.1073/pnas.0407146102; Bussell R, 2001, J BIOL CHEM, V276, P45996, DOI 10.1074/jbc.M106777200; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Cuervo AM, 2004, SCIENCE, V305, P1292, DOI 10.1126/science.1101738; Dedmon MM, 2005, J AM CHEM SOC, V127, P476, DOI 10.1021/ja044834j; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Dev KK, 2003, NEUROPHARMACOLOGY, V45, P14, DOI 10.1016/S0028-3908(03)00140-0; Dyson HJ, 2004, CHEM REV, V104, P3607, DOI 10.1021/cr030403s; Goedert M, 2001, NAT REV NEUROSCI, V2, P492, DOI 10.1038/35081564; Hansen MR, 1998, NAT STRUCT BIOL, V5, P1065, DOI 10.1038/4176; Hoyer W, 2004, BIOCHEMISTRY-US, V43, P16233, DOI 10.1021/bi048453u; Hoyer W, 2002, J MOL BIOL, V322, P383, DOI 10.1016/S0022-2836(02)00775-1; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Krishnan S, 2003, BIOCHEMISTRY-US, V42, P829, DOI 10.1021/bi026528t; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Kubelka J, 2004, CURR OPIN STRUC BIOL, V14, P76, DOI 10.1016/j.sbi.2004.01.013; Lashuel HA, 2002, NATURE, V418, P291, DOI 10.1038/418291a; Lee JC, 2004, P NATL ACAD SCI USA, V101, P16466, DOI 10.1073/pnas.0407307101; Li J, 2002, NEUROTOXICOLOGY, V23, P553, DOI 10.1016/S0161-813X(02)00066-9; Li WX, 2005, P NATL ACAD SCI USA, V102, P2162, DOI 10.1073/pnas.0406976102; Mohana-Borges R, 2004, J MOL BIOL, V340, P1131, DOI 10.1016/j.jmb.2004.05.022; Morar AS, 2001, PROTEIN SCI, V10, P2195, DOI 10.1110/ps.24301; Ottiger M, 1998, J MAGN RESON, V131, P373, DOI 10.1006/jmre.1998.1361; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Rasia RM, 2005, P NATL ACAD SCI USA, V102, P4294, DOI 10.1073/pnas.0407881102; Singleton AB, 2003, SCIENCE, V302, P841, DOI 10.1126/science.1090278; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Stefanis L, 2001, J NEUROSCI, V21, P9549, DOI 10.1523/JNEUROSCI.21-24-09549.2001; Syme CD, 2002, EUR J BIOCHEM, V269, P148, DOI 10.1046/j.0014-2956.2001.02633.x; Tanaka Y, 2001, HUM MOL GENET, V10, P919, DOI 10.1093/hmg/10.9.919; Volles MJ, 2002, BIOCHEMISTRY-US, V41, P4595, DOI 10.1021/bi0121353; Volles MJ, 2003, BIOCHEMISTRY-US, V42, P7871, DOI 10.1021/bi030086j; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n	35	142	144	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	2005	280	35					30649	30652		10.1074/jbc.C500288200	http://dx.doi.org/10.1074/jbc.C500288200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	958ZX	16020550	Green Published, hybrid			2022-12-25	WOS:000231487800002
J	Friedemann, J; Grosse, F; Zhang, SS				Friedemann, J; Grosse, F; Zhang, SS			Nuclear DNA helicase II (RNA helicase A) interacts with Werner syndrome helicase and stimulates its exonuclease activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNDROME PROTEIN; FUNCTIONAL INTERACTION; POLYMERASE-DELTA; NUCLEOLAR LOCALIZATION; MALELESS PROTEIN; GENE-EXPRESSION; RECQ HELICASES; COMPLEX; REPLICATION; CELLS	Nuclear DNA helicase II (NDH II), alternatively named RNA helicase A, is involved in transcription and RNA processing. Here, we report that NDH II interacts with the Werner syndrome helicase WRN, an enzyme associated with premature aging and predisposition to tumorigenesis. NDH II was co-purified with WRN, DNA polymerase delta, and replication protein A (70 kDa) during several steps of conventional column chromatography. Co-immunoprecipitations revealed an association between NDH II, WRN, and polymerase delta. We demonstrate a direct protein-protein interaction between WRN and NDH II that is mediated by the N-terminal double-strand RNA-binding domain II and C-terminal RGG box of NDH II and the N-terminal exonuclease domain of WRN. WRN inhibited the DNA-dependent NTPase and DNA helicase activities of NDH II. On the other hand, the 3' -> 5' exonuclease activity of WRN was increased by the presence of NDH II. NDH II directly stimulated the exonuclease domain of WRN, whereas the exonuclease domain of WRN suppressed the DNA-dependent (but not RNA-dependent) ATPase activity of NDH II. These results suggest that the double-strand RNA-binding domain II and RGG box of NDH II together form a protein-protein interaction surface that contacts the exonuclease domain of WRN. Furthermore, NDH II enhanced the degradation of D-loop DNA by the WRN exonuclease. Taken together, these results suggest that NDH II plays a role in promoting the DNA processing function of WRN, which in turn might be necessary for maintaining genomic stability.	Inst Mol Biotechnol, Dept Biochem, D-07708 Jena, Germany		Grosse, F (corresponding author), Inst Mol Biotechnol, Dept Biochem, Beutenbergstr 11,Postfach 100 813, D-07745 Jena, Germany.	fgrosse@imb-jena.de						Abdelhaleem M, 2004, BBA-REV CANCER, V1704, P37, DOI 10.1016/j.bbcan.2004.05.001; Aguilera A, 2002, EMBO J, V21, P195, DOI 10.1093/emboj/21.3.195; Bachrati CZ, 2003, BIOCHEM J, V374, P577, DOI 10.1042/BJ20030491; Balajee AS, 1999, MOL BIOL CELL, V10, P2655, DOI 10.1091/mbc.10.8.2655; Brosh RM, 2001, J BIOL CHEM, V276, P35093, DOI 10.1074/jbc.M103332200; Chang S, 2004, NAT GENET, V36, P877, DOI 10.1038/ng1389; Constantinou A, 2000, EMBO REP, V1, P80, DOI 10.1093/embo-reports/kvd004; Cooper MP, 2000, GENE DEV, V14, P907; Crabbe L, 2004, SCIENCE, V306, P1951, DOI 10.1126/science.1103619; Du XB, 2004, MOL CELL BIOL, V24, P8437, DOI 10.1128/MCB.24.19.8437-8446.2004; Heyer WD, 2004, CURR BIOL, V14, pR895, DOI 10.1016/j.cub.2004.09.073; Hieronymus H, 2004, GENE DEV, V18, P2652, DOI 10.1101/gad.1241204; Hishida T, 2004, GENE DEV, V18, P1886, DOI 10.1101/gad.1223804; Kamath-Loeb AS, 2000, P NATL ACAD SCI USA, V97, P4603, DOI 10.1073/pnas.97.9.4603; Kamath-Loeb AS, 2001, J BIOL CHEM, V276, P16439, DOI 10.1074/jbc.M100253200; Khakhar RR, 2003, TRENDS CELL BIOL, V13, P493, DOI 10.1016/S0962-8924(03)00171-5; KURODA MI, 1991, CELL, V66, P935, DOI 10.1016/0092-8674(91)90439-6; Kyng KJ, 2003, P NATL ACAD SCI USA, V100, P12259, DOI 10.1073/pnas.2130723100; Lebel M, 1999, J BIOL CHEM, V274, P37795, DOI 10.1074/jbc.274.53.37795; LEE CG, 1993, J BIOL CHEM, V268, P16822; LEE CG, 1992, J BIOL CHEM, V267, P4398; Machwe A, 2004, ONCOGENE, V23, P149, DOI 10.1038/sj.onc.1206906; Marciniak RA, 1998, P NATL ACAD SCI USA, V95, P6887, DOI 10.1073/pnas.95.12.6887; Mischo HE, 2005, J BIOL CHEM, V280, P9586, DOI 10.1074/jbc.M411444200; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Opresko PL, 2004, MOL CELL, V14, P763, DOI 10.1016/j.molcel.2004.05.023; Pellizzoni L, 2001, J CELL BIOL, V152, P75, DOI 10.1083/jcb.152.1.75; Reichman TW, 2003, J MOL BIOL, V332, P85, DOI 10.1016/S0022-2836(03)00885-4; Schlegel BP, 2003, ONCOGENE, V22, P983, DOI 10.1038/sj.onc.1206195; Shen JC, 2000, TRENDS GENET, V16, P213, DOI 10.1016/S0168-9525(99)01970-8; Shen JC, 1998, J BIOL CHEM, V273, P34139, DOI 10.1074/jbc.273.51.34139; Shiratori M, 2002, ONCOGENE, V21, P2447, DOI 10.1038/sj.onc.1205334; Stauffer ME, 2004, J BIOL CHEM, V279, P30915, DOI 10.1074/jbc.R400015200; Szekely AM, 2000, P NATL ACAD SCI USA, V97, P11365, DOI 10.1073/pnas.97.21.11365; Tang HL, 1997, SCIENCE, V276, P1412, DOI 10.1126/science.276.5317.1412; Terns MP, 2001, CURR BIOL, V11, pR862, DOI 10.1016/S0960-9822(01)00517-6; Vijg J, 2004, TRENDS GENET, V20, P221, DOI 10.1016/j.tig.2004.04.007; von Kobbe C, 2002, J BIOL CHEM, V277, P22035, DOI 10.1074/jbc.M200914200; ZHANG SS, 1994, BIOCHEMISTRY-US, V33, P3906, DOI 10.1021/bi00179a016; ZHANG SS, 1995, J BIOL CHEM, V270, P16422, DOI 10.1074/jbc.270.27.16422; Zhang SS, 1997, J BIOL CHEM, V272, P11487; Zhang SS, 2004, NUCLEIC ACIDS RES, V32, P1, DOI 10.1093/nar/gkg933; ZHANG SS, 1991, J BIOL CHEM, V266, P20483; Zhang SS, 1999, J CELL SCI, V112, P2693	44	32	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	2005	280	35					31303	31313		10.1074/jbc.M503882200	http://dx.doi.org/10.1074/jbc.M503882200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	958ZX	15995249	hybrid			2022-12-25	WOS:000231487800078
J	Reddig, PJ; Xu, D; Juliano, RL				Reddig, PJ; Xu, D; Juliano, RL			Regulation of p21-activated kinase-independent Rac1 signal transduction by nischarin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; RHO-GTPASES; PROTEIN-KINASE; CELL-CYCLE; NUCLEAR-LOCALIZATION; DEPENDENT PATHWAY; POLYBASIC REGION; ACTIVATION; EXPRESSION; RAS	Nischarin regulates Rac1- dependent cell motility by interaction with and inhibition of the p21- activated kinase ( PAK1). In addition to regulating the activation of PAK1, Rac1 controls multiple downstream pathways to regulate cell growth and differentiation, as well as cell motility. Signaling by a constitutively activated Rac1 mutant deficient in PAK binding ( Rac1Q61L- 40C) was examined to determine whether Nischarin impinges on these other Rac1 effector pathways. Nischarin formed immunoprecipitatable complexes with Rac1Q61L and Rac1Q61L- 40C when the proteins were co- expressed. In NIH3T3 cells, Rac1Q61L and Rac1Q61L- 40C stimulation of a minimal NF- kappa B response element or the cyclin D1 promoter, a downstream target of NF- kappa B, was inhibited by co- expression of Nischarin. Additionally, suppression of endogenous Nischarin protein with small interfering RNA in PC12 cells enhanced Rac1Q61L and Rac1Q61L- 40C activation of NF- kappa B. In further support of Nischarin suppressing PAK independent Rac signaling, foci formation in monolayers of NIH3T3 cells by Rac1Q61L- 40C in cooperation with c- Raf/ CAAX was inhibited by the presence of Nischarin. Nischarin alters the cellular localization of Rac1Q61L and Rac1Q61L- 40C to vesicles and this positively correlates with the repression of the Rac1 signal. Thus, Nischarin, in addition to regulating the PAK strand of Rac1 signaling, can also regulate other links in the web of Rac1 signaling pathways.	Univ N Carolina, Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Juliano, RL (corresponding author), Univ N Carolina, Sch Med, Dept Pharmacol, 1017 Mary Eleen Jones Bldg,CB 7365, Chapel Hill, NC 27599 USA.	arjay@med.unc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026165] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01-HL4500] Funding Source: Medline; NIGMS NIH HHS [GM26165] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alahari SK, 2004, EMBO J, V23, P2777, DOI 10.1038/sj.emboj.7600291; Alahari SK, 2004, BIOCHEM J, V377, P449, DOI 10.1042/BJ20030411; Alahari SK, 2003, EXP CELL RES, V288, P415, DOI 10.1016/S0014-4827(03)00233-7; Alahari SK, 2000, J CELL BIOL, V151, P1141, DOI 10.1083/jcb.151.6.1141; Balasenthil S, 2004, J BIOL CHEM, V279, P1422, DOI 10.1074/jbc.M309937200; Bokoch GM, 2003, ANNU REV BIOCHEM, V72, P743, DOI 10.1146/annurev.biochem.72.121801.161742; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; Boyer L, 2004, MOL BIOL CELL, V15, P1124, DOI 10.1091/mbc.E03-05-0301; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Cammarano MS, 2001, J BIOL CHEM, V276, P25876, DOI 10.1074/jbc.M011345200; Coleman ML, 2004, NAT REV MOL CELL BIO, V5, P355, DOI 10.1038/nrm1365; del Pozo MA, 2004, SCIENCE, V303, P839, DOI 10.1126/science.1092571; Del Pozo MA, 2002, NAT CELL BIOL, V4, P232, DOI 10.1038/ncb759; Eden S, 2002, NATURE, V418, P790, DOI 10.1038/nature00859; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fernandez-Zapico ME, 2005, CANCER CELL, V7, P39, DOI 10.1016/j.ccr.2004.11.024; Frost JA, 2000, J BIOL CHEM, V275, P19693, DOI 10.1074/jbc.M909860199; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Howe AK, 2002, CURR OPIN GENET DEV, V12, P30, DOI 10.1016/S0959-437X(01)00260-X; Joneson T, 1999, MOL CELL BIOL, V19, P5892; Joneson T, 1998, J BIOL CHEM, V273, P17991, DOI 10.1074/jbc.273.29.17991; Joyce D, 1999, J BIOL CHEM, V274, P25245, DOI 10.1074/jbc.274.36.25245; Karnoub AE, 2004, BREAST CANCER RES TR, V84, P61, DOI 10.1023/B:BREA.0000018427.84929.5c; Kheradmand F, 1998, SCIENCE, V280, P898, DOI 10.1126/science.280.5365.898; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Lanning CC, 2004, J BIOL CHEM, V279, P44197, DOI 10.1074/jbc.M404977200; Letunic I, 2002, NUCLEIC ACIDS RES, V30, P242, DOI 10.1093/nar/30.1.242; Lim KP, 2004, J BIOL CHEM, V279, P54770, DOI 10.1074/jbc.M411315200; Matos P, 2003, J BIOL CHEM, V278, P50442, DOI 10.1074/jbc.M308215200; Mettouchi A, 2001, MOL CELL, V8, P115, DOI 10.1016/S1097-2765(01)00285-4; Miki H, 2000, NATURE, V408, P732, DOI 10.1038/35047107; Montaner S, 1998, J BIOL CHEM, V273, P12779, DOI 10.1074/jbc.273.21.12779; Page K, 1999, J BIOL CHEM, V274, P22065, DOI 10.1074/jbc.274.31.22065; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Qualmann B, 2003, BIOCHEM J, V371, P233, DOI 10.1042/bj20030139; Radhakrishna H, 1999, J CELL SCI, V112, P855; Reyes-Reyes M, 2001, J CELL SCI, V114, P1579; Ridley AJ, 2001, DEV CELL, V1, P160, DOI 10.1016/S1534-5807(01)00029-6; Schlunck G, 2004, MOL BIOL CELL, V15, P256, DOI 10.1091/mbc.E03-01-0019; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Schwartz M, 2004, J CELL SCI, V117, P5457, DOI 10.1242/jcs.01582; Singh A, 2004, ONCOGENE, V23, P9369, DOI 10.1038/sj.onc.1208182; Storz P, 2004, MOL CELL BIOL, V24, P2614, DOI 10.1128/MCB.24.7.2614-2626.2004; Storz P, 2003, EMBO J, V22, P109, DOI 10.1093/emboj/cdg009; Sulciner DJ, 1996, MOL CELL BIOL, V16, P7115; Tang Y, 1999, MOL CELL BIOL, V19, P1881; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Williams CL, 2003, CELL SIGNAL, V15, P1071, DOI 10.1016/S0898-6568(03)00098-6	49	24	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	2005	280	35					30994	31002		10.1074/jbc.M502546200	http://dx.doi.org/10.1074/jbc.M502546200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	958ZX	16002401	hybrid, Green Published			2022-12-25	WOS:000231487800042
J	O'Keefe, LV; Liu, YH; Perkins, A; Dayan, S; Saint, R; Richards, RI				O'Keefe, LV; Liu, YH; Perkins, A; Dayan, S; Saint, R; Richards, RI			FRA16D common chromosomal fragile site oxido-reductase (FOR/WWOX) protects against the effects of ionizing radiation in Drosophila	ONCOGENE			English	Article						chromosomal fragile site; oxidoreductase; radiation sensitivity; gene rescue	TUMOR-SUPPRESSOR GENE; DOMAIN-CONTAINING OXIDOREDUCTASE; CELL LUNG-CANCER; HOMOZYGOUS DELETIONS; DNA-DAMAGE; WWOX; EXPRESSION; CARCINOMA; PARKIN; IDENTIFICATION	Fragile sites are chromosomal structures that have been proposed to have a determining role in cancer-associated DNA instability. The human WWOX gene spans the FRA16D chromosomal fragile site, the common minimal region of homozygous deletion found in adenocarcinomas and three out of five translocation breakpoints in multiple myeloma. Transcripts from the alternatively spliced WWOX gene encode proteins with common N-terminal WW domains and variable homology to the oxidoreductase family of proteins. In this study, the Drosophila orthologue of the WWOX gene was identified and subjected to mutagenesis via homologous recombination. The resultant DmWWOX(1) mutants were viable but exhibited an increased sensitivity to ionizing radiation. This radiation sensitivity was rescued by reintroduction and expression of either the wild-type Drosophila or human WWOX genes. Thus, the protective function of DmWWOX in response to irradiation in Drosophila is conserved with human WWOX (hWWOX). This is consistent with a protective role for hWWOX where aberrant expression, as a result of breakage at the associated fragile site, could contribute directly to cancer progression.	Univ Adelaide, Sch Mol & Biomed Sci, Res Network Genes & Environm Dev, ARC,NHMRC, Adelaide, SA 5005, Australia; Univ Adelaide, ARC, Special Res Ctr Mol Genet Dev, Adelaide, SA 5005, Australia; Australian Natl Univ, Res Sch Biol Sci, Canberra, ACT 2601, Australia	University of Adelaide; University of Adelaide; Australian National University	Richards, RI (corresponding author), Univ Adelaide, Sch Mol & Biomed Sci, Res Network Genes & Environm Dev, ARC,NHMRC, Mol Life Sci Bldg,Gate 8,Victoria Dr, Adelaide, SA 5005, Australia.	robert.richards@adelaide.edu.au	O'Keefe, Louise V/B-9856-2008; Saint, Robert/A-4190-2008; Dayan, Sonia/D-7960-2013; Dayan, Sonia/U-9400-2017; Richards, Robert/ABE-6423-2020	Saint, Robert/0000-0002-7989-6043; Dayan, Sonia/0000-0002-5616-7542; Dayan, Sonia/0000-0002-5616-7542; Richards, Robert Ian/0000-0002-5978-6453				Aqeilan RI, 2004, P NATL ACAD SCI USA, V101, P4401, DOI 10.1073/pnas.0400805101; Aqeilan RI, 2004, CLIN CANCER RES, V10, P3053, DOI 10.1158/1078-0432.CCR-03-0594; Aqeilan RI, 2004, CANCER RES, V64, P8256, DOI 10.1158/0008-5472.CAN-04-2055; Bednarek AK, 2000, CANCER RES, V60, P2140; Bednarek AK, 2001, CANCER RES, V61, P8068; Bluteau O, 2002, ONCOGENE, V21, P1225, DOI 10.1038/sj.onc.1205197; BRAND AH, 1993, DEVELOPMENT, V118, P401; Cesari R, 2003, P NATL ACAD SCI USA, V100, P5956, DOI 10.1073/pnas.0931262100; Chang NS, 2003, J BIOL CHEM, V278, P9195, DOI 10.1074/jbc.M208373200; Chang NS, 2001, J BIOL CHEM, V276, P3361, DOI 10.1074/jbc.M007140200; Denison SR, 2003, ONCOGENE, V22, P8370, DOI 10.1038/sj.onc.1207072; Driouch K, 2002, ONCOGENE, V21, P1832, DOI 10.1038/sj.onc.1205273; Finnis M, 2005, HUM MOL GENET, V14, P1341, DOI 10.1093/hmg/ddi144; Glover TW, 1998, CANCER RES, V58, P3409; Guler G, 2004, CANCER, V100, P1605, DOI 10.1002/cncr.20137; Ishii H, 2003, MOL CANCER RES, V1, P940; Jaklevic BR, 2004, CURR BIOL, V14, P23, DOI 10.1016/j.cub.2003.12.032; Krummel KA, 2002, GENE CHROMOSOME CANC, V34, P154, DOI 10.1002/gcc.10047; Kuroki T, 2004, CLIN CANCER RES, V10, P2459, DOI 10.1158/1078-0432.CCR-03-0096; Kuroki T, 2002, CANCER RES, V62, P2258; Lee JH, 2003, FEBS LETT, V550, P5, DOI 10.1016/S0014-5793(03)00771-3; Ludes-Meyers JH, 2004, ONCOGENE, V23, P5049, DOI 10.1038/sj.onc.1207680; Mangelsdorf M, 2000, CANCER RES, V60, P1683; Nioi P, 2004, MUTAT RES-FUND MOL M, V555, P149, DOI 10.1016/j.mrfmmm.2004.05.023; Paige AJW, 2001, P NATL ACAD SCI USA, V98, P11417, DOI 10.1073/pnas.191175898; Pekarsky Y, 2002, LANCET ONCOL, V3, P748, DOI 10.1016/S1470-2045(02)00931-2; Picchio MC, 2004, CLIN CANCER RES, V10, P2720, DOI 10.1158/1078-0432.CCR-03-0086; Richards RI, 2001, TRENDS GENET, V17, P339, DOI 10.1016/S0168-9525(01)02303-4; Ried K, 2000, HUM MOL GENET, V9, P1651, DOI 10.1093/hmg/9.11.1651; Rong YKS, 2002, GENE DEV, V16, P1568, DOI 10.1101/gad.986602; Rozier L, 2004, ONCOGENE, V23, P6872, DOI 10.1038/sj.onc.1207809; Sogame N, 2003, P NATL ACAD SCI USA, V100, P4696, DOI 10.1073/pnas.0736384100; Sze CI, 2004, J BIOL CHEM, V279, P30498, DOI 10.1074/jbc.M401399200; Wang F, 2004, GENE CHROMOSOME CANC, V40, P85, DOI 10.1002/gcc.20020; Watanabe A, 2003, CANCER RES, V63, P8629; Wiesner S, 2002, J MOL BIOL, V324, P807, DOI 10.1016/S0022-2836(02)01145-2; Yakicier MC, 2001, ONCOGENE, V20, P5232, DOI 10.1038/sj.onc.1204674; Yendamuri S, 2003, CANCER RES, V63, P878; Zanesi N, 2001, P NATL ACAD SCI USA, V98, P10250, DOI 10.1073/pnas.191345898	39	19	22	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	43					6590	6596		10.1038/sj.onc.1208806	http://dx.doi.org/10.1038/sj.onc.1208806			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	968ZV	16007179				2022-12-25	WOS:000232204100013
J	Lu, ZL; Gallagher, R; Sellar, R; Coetsee, M; Millar, RP				Lu, ZL; Gallagher, R; Sellar, R; Coetsee, M; Millar, RP			Mutations remote from the human gonadotropin-releasing hormone (GnRH) receptor-binding sites specifically increase binding affinity for GnRH II but not GnRH I - Evidence for ligand-selective, receptor-active conformations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCARINIC ACETYLCHOLINE-RECEPTOR; PROTEIN-COUPLED RECEPTORS; DELTA-OPIOID RECEPTOR; 7-TRANSMEMBRANE RECEPTORS; CONSTITUTIVE ACTIVATION; AMINO-ACIDS; IDENTIFICATION; SWITCH; EXPRESSION; AGONISTS	The human gonadotropin-releasing hormone ( GnRH) receptor is evolutionarily configured for high affinity binding of GnRH I ([Tyr(5), Leu(7), Arg(8)]GnRH) but at lower affinity for GnRH II ([His(5), Trp(7), Tyr(8)]GnRH). GnRH I is more potent in the activation of the G(q/11) protein in the gonadotrope; however, GnRH II is more potent in the stimulation of apoptosis and antiproliferative effects through activating G(i) protein-mediated signaling, implying that GnRH I and II selectively stabilize different receptor-active conformations that preferentially couple to different signaling pathways. Receptor activation involves ligand induction or conformational selection, but the molecular basis of the communication between ligand-binding sites and receptor allosteric sites remains unclear. We have sought conformational coupling between receptor-ligand intermolecular interactions and intramolecular interaction networks in the human GnRH receptor by mutating remote residues that induce differential ligand binding affinity shifts for GnRH I and II. We have demonstrated that certain Ala mutations in the intracellular segments of transmembrane domains 3 (Met(132)), 5 (Met(227)), 6 (Phe(272) and Phe(276)), and 7 (Ile(322) and Tyr(323)) of the human GnRH receptor allosterically increased ligand binding affinity for GnRH II but had little effect on GnRH I binding affinity. We examined the role of the three amino acids that differ in these two ligands, and we found that Tyr8 in GnRH II plays a dominant role for the increased affinity of the receptor mutants for GnRH II. We propose that creation of a high affinity binding site for GnRH II accompanies receptor conformational changes, i.e." induced fit" or "conformational selection," mainly determined by the intermolecular interactions between Tyr8 and the receptor contact residues, which can be facilitated by disruption of particular sets of receptor-stabilizing intramolecular interactions. The findings suggest that GnRH I and II binding may selectively stabilize different receptor-active conformations and therefore different ligand-induced selective signaling described previously for these ligands.	MRC, Human Reprod Sci Unit, Ctr Reprod Biol, Edinburgh EH16 4SB, Midlothian, Scotland		Lu, ZL (corresponding author), MRC, Human Reprod Sci Unit, Ctr Reprod Biol, Chancellors Bldg,49 Little France Crescent, Edinburgh EH16 4SB, Midlothian, Scotland.	z.lu@hrsu.mrc.ac.uk	Millar, Robert P/A-4853-2012	Millar, Robert P/0000-0003-3606-2708; Lu, Zhiliang/0000-0002-3442-1415	Medical Research Council [U.1276.00.005.00001.01 (85846), MC_U127685846] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Alves ID, 2004, J BIOL CHEM, V279, P44673, DOI 10.1074/jbc.M404713200; Alves ID, 2004, MOL PHARMACOL, V65, P1248, DOI 10.1124/mol.65.5.1248; Arora KK, 1997, MOL ENDOCRINOL, V11, P1203, DOI 10.1210/me.11.9.1203; Arora KK, 1996, MOL ENDOCRINOL, V10, P979, DOI 10.1210/me.10.8.979; Baranski TJ, 1999, J BIOL CHEM, V274, P15757, DOI 10.1074/jbc.274.22.15757; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Caunt CJ, 2004, ENDOCRINOLOGY, V145, P3594, DOI 10.1210/en.2004-0092; Chen SH, 2000, EMBO J, V19, P4265, DOI 10.1093/emboj/19.16.4265; Chen SH, 2002, BIOCHEMISTRY-US, V41, P6045, DOI 10.1021/bi012189c; Cordeaux Y, 2001, J BIOL CHEM, V276, P28667, DOI 10.1074/jbc.M008644200; Davidson JS, 1997, BIOCHEMISTRY-US, V36, P12881, DOI 10.1021/bi971377t; Eisenberg D, 1997, METHOD ENZYMOL, V277, P396, DOI 10.1016/S0076-6879(97)77022-8; Fiser A, 2003, METHOD ENZYMOL, V374, P461, DOI 10.1016/S0076-6879(03)74020-8; Flanagan CA, 1998, ENDOCRINOLOGY, V139, P4115, DOI 10.1210/en.139.10.4115; Fromme BJ, 2001, MOL PHARMACOL, V60, P1280, DOI 10.1124/mol.60.6.1280; Gbahou F, 2003, P NATL ACAD SCI USA, V100, P11086, DOI 10.1073/pnas.1932276100; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; Ghanouni P, 2001, J BIOL CHEM, V276, P24433, DOI 10.1074/jbc.C100162200; Han M, 1998, BIOCHEMISTRY-US, V37, P8253, DOI 10.1021/bi980147r; Hermans E, 2003, PHARMACOL THERAPEUT, V99, P25, DOI 10.1016/S0163-7258(03)00051-2; Hubbell WL, 2003, ADV PROTEIN CHEM, V63, P243; Hulme EC, 1999, EUR J PHARMACOL, V375, P247, DOI 10.1016/S0014-2999(99)00297-6; Hulme EC, 2003, RECEPTOR CHANNEL, V9, P215, DOI 10.1080/10606820308261; Hunyady L, 2003, TRENDS PHARMACOL SCI, V24, P81, DOI 10.1016/S0165-6147(02)00050-0; Janovick JA, 2002, J CLIN ENDOCR METAB, V87, P3255, DOI 10.1210/jc.87.7.3255; Kenakin T, 2002, ANNU REV PHARMACOL, V42, P349, DOI 10.1146/annurev.pharmtox.42.091401.113012; KENAKIN T, 1995, TRENDS PHARMACOL SCI, V16, P232, DOI 10.1016/S0165-6147(00)89032-X; Kenakin T, 2001, FASEB J, V15, P598, DOI 10.1096/fj.00-0438rev; Kenakin T, 2003, TRENDS PHARMACOL SCI, V24, P346, DOI 10.1016/S0165-6147(03)00167-6; Krsmanovic LZ, 2003, P NATL ACAD SCI USA, V100, P2969, DOI 10.1073/pnas.0535708100; Lee TW, 1997, BIOCHEM J, V325, P733, DOI 10.1042/bj3250733; Limonta P, 2003, FRONT NEUROENDOCRIN, V24, P279, DOI 10.1016/j.yfrne.2003.10.003; Lu ZL, 2001, J BIOL CHEM, V276, P34098, DOI 10.1074/jbc.M104217200; Lu ZL, 1999, J BIOL CHEM, V274, P7309, DOI 10.1074/jbc.274.11.7309; Lu ZL, 2000, J BIOL CHEM, V275, P5682, DOI 10.1074/jbc.275.8.5682; Lu ZL, 2002, TRENDS PHARMACOL SCI, V23, P140, DOI 10.1016/S0165-6147(00)01973-8; Lu ZL, 1997, MOL PHARMACOL, V51, P234, DOI 10.1124/mol.51.2.234; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; Ma BY, 2002, PROTEIN SCI, V11, P184, DOI 10.1110/ps.21302; Marvin JS, 2001, NAT STRUCT BIOL, V8, P795, DOI 10.1038/nsb0901-795; Maudsley S, 2004, CANCER RES, V64, P7533, DOI 10.1158/0008-5472.CAN-04-1360; Millar R, 1995, METH NEUROSCI, P145; Millar RP, 2004, ENDOCR REV, V25, P235, DOI 10.1210/er.2003-0002; MILLAR RP, 1989, J BIOL CHEM, V264, P21007; Millar RP, 2004, ENDOCRINOLOGY, V145, P3590, DOI 10.1210/en.2004-0461; Mirzadegan T, 2003, BIOCHEMISTRY-US, V42, P2759, DOI 10.1021/bi027224+; Myburgh DB, 1998, EUR J ENDOCRINOL, V139, P438, DOI 10.1530/eje.0.1390438; Okada T, 2001, TRENDS BIOCHEM SCI, V26, P318, DOI 10.1016/S0968-0004(01)01799-6; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Prioleau C, 2002, J BIOL CHEM, V277, P36577, DOI 10.1074/jbc.M206223200; Rader AJ, 2004, P NATL ACAD SCI USA, V101, P7246, DOI 10.1073/pnas.0401429101; Seifert R, 2001, J PHARMACOL EXP THER, V297, P1218; Spalding TA, 1998, J BIOL CHEM, V273, P21563, DOI 10.1074/jbc.273.34.21563; Suel GM, 2003, NAT STRUCT BIOL, V10, P59, DOI 10.1038/nsb881; Sun YM, 2001, J BIOL CHEM, V276, P7754, DOI 10.1074/jbc.M009020200; Swaminath G, 2004, J BIOL CHEM, V279, P686, DOI 10.1074/jbc.M310888200; Tao YX, 2000, MOL ENDOCRINOL, V14, P1272, DOI 10.1210/me.14.8.1272; Teague SJ, 2003, NAT REV DRUG DISCOV, V2, P527, DOI 10.1038/nrd1129; WARD WHJ, 1990, TRENDS PHARMACOL SCI, V11, P280, DOI 10.1016/0165-6147(90)90009-W; White RB, 1998, P NATL ACAD SCI USA, V95, P305, DOI 10.1073/pnas.95.1.305; Wu TJ, 2005, ENDOCRINOLOGY, V146, P280, DOI 10.1210/en.2004-0560	61	50	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	2005	280	33					29796	29803		10.1074/jbc.M413520200	http://dx.doi.org/10.1074/jbc.M413520200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	954SX	15967801	hybrid			2022-12-25	WOS:000231176200050
J	Perez-Losada, J; Wu, D; DelRosario, R; Balmain, A; Mao, JH				Perez-Losada, J; Wu, D; DelRosario, R; Balmain, A; Mao, JH			p63 and p73 do not contribute to p53-mediated lymphoma suppressor activity in vivo	ONCOGENE			English	Article						p53; p63; p73; tumor suppressor; radiation; lymphoma	LI-FRAUMENI-SYNDROME; KINASE C-ABL; P53 HOMOLOG; DNA-DAMAGE; P53-DEPENDENT APOPTOSIS; INDUCE APOPTOSIS; TUMOR-SUPPRESSOR; TUMORIGENESIS; CARCINOMA; ONCOGENE	p53 is one of the most important tumor suppressor genes in human cancer, but the roles of its homologues p63 and p73 in tumor suppression, alone or in collaboration with p53, remains controversial. Both p63 and p73 can be deregulated after DNA damage, and induce cell cycle arrest and apoptosis, but mice carrying inactive alleles of these genes do not develop spontaneous tumors. Since heterozygous loss of p53 confers strong sensitization to radiation-induced lymphoma development, we investigated the possibility that radiation exposure may reveal previously undetected tumor suppressor properties in p63 or p73, alone or in combination with p53. Animals heterozygous for p63 or p73, as well as both double heterozygous p53/p63 or p53/p73 mice, showed no significant differences in tumor latency, spectrum or frequency after gamma-radiation, compared to their control counterparts. Deletions were found near the p63 locus on chromosome 16 in radiation-induced tumors, but these frequently included the knockout allele. No deletions or LOH involving the p73 gene were detected, and expression of both genes was maintained in the tumors. We conclude that P53 homologues do not contribute to p53 tumor suppressor activity in lymphoma development.	Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Balmain, A (corresponding author), Univ Calif San Francisco, Canc Res Inst, 2340 Sutter St, San Francisco, CA 94143 USA.	abalmain@cc.ucsf.edu; jmao@cc.ucsf.edu	Pérez-Losada, Jesús/A-5883-2019; Mao, Jian-Hua/EIZ-8595-2022	Pérez-Losada, Jesús/0000-0003-2400-624X; Mao, Jian-Hua/0000-0001-9320-6021	NATIONAL CANCER INSTITUTE [U01CA084244] Funding Source: NIH RePORTER; NCI NIH HHS [U01 CA84244] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agami R, 1999, NATURE, V399, P809; Cai WW, 2002, NAT BIOTECHNOL, V20, P393, DOI 10.1038/nbt0402-393; Crook T, 2000, ONCOGENE, V19, P3439, DOI 10.1038/sj.onc.1203656; Dohn M, 2001, ONCOGENE, V20, P3193, DOI 10.1038/sj.onc.1204427; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Gong JG, 1999, NATURE, V399, P806; Hibi K, 2000, P NATL ACAD SCI USA, V97, P5462, DOI 10.1073/pnas.97.10.5462; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; KEMP CJ, 1994, NAT GENET, V8, P66, DOI 10.1038/ng0994-66; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; Liefer KM, 2000, CANCER RES, V60, P4016; Mao JH, 2004, NATURE, V432, P775, DOI 10.1038/nature03155; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Park JJ, 2000, AM J SURG PATHOL, V24, P1414, DOI 10.1097/00000478-200010000-00012; Senoo M, 2004, CANCER CELL, V6, P85, DOI 10.1016/j.ccr.2004.06.005; Stiewe T, 2002, J BIOL CHEM, V277, P14177, DOI 10.1074/jbc.M200480200; Stiewe T, 2002, CELL DEATH DIFFER, V9, P237, DOI 10.1038/sj.cdd.4400995; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zaika AI, 1999, CANCER RES, V59, P3257	25	27	28	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 18	2005	24	35					5521	5524		10.1038/sj.onc.1208799	http://dx.doi.org/10.1038/sj.onc.1208799			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	955JN	16007185				2022-12-25	WOS:000231222300012
J	Jbilo, O; Ravinet-Trillou, C; Arnone, M; Buisson, I; Bribes, E; Peleraux, A; Penarier, G; Soubrie, P; Le Fur, G; Galiegue, S; Casellas, P				Jbilo, O; Ravinet-Trillou, C; Arnone, M; Buisson, I; Bribes, E; Peleraux, A; Penarier, G; Soubrie, P; Le Fur, G; Galiegue, S; Casellas, P			The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance	FASEB JOURNAL			English	Article						SR141716; dietary obesity; energy expenditure; DNA chips	ADIPOSE-TISSUE; EXPRESSION; INSULIN; LEPTIN; ADIPOGENESIS; ACTIVATION; FAT	We investigated the molecular events involved in the long-lasting reduction of adipose mass by the selective CB1 antagonist, SR141716. Its effects were assessed at the transcriptional level both in white (WAT) and brown (BAT) adipose tissues in a diet-induced obesity model in mice. Our data clearly indicated that SR141716 reversed the phenotype of obese adipocytes at both macroscopic and genomic levels. First, oral treatment with SR141716 at 10 mg/kg/d for 40 days induced a robust reduction of obesity, as shown by the 50% decrease in adipose mass together with a major restoration of white adipocyte morphology similar to lean animals. Second, we found that the major alterations in gene expression levels induced by obesity in WAT and BAT were mostly reversed in SR141716-treated obese mice. Importantly, the transcriptional patterns of treated obese mice were similar to those obtained in the CB1 receptor knockout mice fed a high-fat regimen and which are resistant to obesity, supporting a CB1 receptor-mediated process. Functional analysis of these modulations indicated that the reduction of adipose mass by the molecule resulted from an enhanced lipolysis through the induction of enzymes of the beta-oxidation and TCA cycle, increased energy expenditure, mainly through futile cycling (calcium and substrate), and a tight regulation of glucose homeostasis. These changes accompanied a significant cellular remodeling and contributed to a reduction of the obesity-related inflammatory status. In addition to a transient reduction of food consumption, increases of both fatty acid oxidation and energy expenditure induced by the molecule summate leading to a sustained weight loss. Altogether, these data strongly indicate that the endocannabinoid system has a major role in the regulation of energy metabolism.	Sanofi Synthelabo Rech, Cent Nervous Syst Res Dept, F-34184 Montpellier, France; Sanofi Synthelabo Rech, Paris, France; Sanofi Synthelabo Rech, Oncol Res Dept, F-34184 Montpellier, France; Sanofi Synthelabo Rech, Cent Nervous Syst Res Dept, Toulouse, France	Sanofi-Aventis; Sanofi France; Sanofi-Aventis; Sanofi France; Sanofi-Aventis; Sanofi France; Sanofi-Aventis; Sanofi France	Casellas, P (corresponding author), Sanofi Synthelabo Rech, Cent Nervous Syst Res Dept, 371 Rue Prof Joseph Blayac, F-34184 Montpellier, France.	pierre.casellas@sanofi-aventis.com						Beattie JH, 2000, AM J PHYSIOL-REG I, V278, pR1082; Bensaid M, 2003, MOL PHARMACOL, V63, P908, DOI 10.1124/mol.63.4.908; Bernardis LL, 1996, NEUROSCI BIOBEHAV R, V20, P189, DOI 10.1016/0149-7634(95)00015-1; Bouaboula M, 1997, J BIOL CHEM, V272, P22330, DOI 10.1074/jbc.272.35.22330; Breivogel CS, 1997, J PHARMACOL EXP THER, V282, P1632; Cota D, 2003, J CLIN INVEST, V112, P423, DOI 10.1172/JCI17725; Croci T, 1998, BRIT J PHARMACOL, V125, P1393, DOI 10.1038/sj.bjp.0702190; Di Marzo V, 2001, NATURE, V410, P822, DOI 10.1038/35071088; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Gomez R, 2002, J NEUROSCI, V22, P9612; Hilairet S, 2003, J BIOL CHEM, V278, P23731, DOI 10.1074/jbc.M212369200; Imamura M, 2002, AM J PHYSIOL-ENDOC M, V283, pE775, DOI 10.1152/ajpendo.00040.2002; Kim KH, 2004, P NATL ACAD SCI USA, V101, P6780, DOI 10.1073/pnas.0305905101; Li JP, 2002, AM J PHYSIOL-ENDOC M, V282, pE1334, DOI 10.1152/ajpendo.00516.2001; Lowell BB, 2000, NATURE, V404, P652, DOI 10.1038/35007527; Matias I, 2004, RECENT ADVANCES IN PHARMACOLOGY AND PHYSIOLOGY OF CANNABINOIDS, P217; Mukhopadhyay S, 2000, MOL PHARMACOL, V57, P162; Nadler ST, 2000, P NATL ACAD SCI USA, V97, P11371, DOI 10.1073/pnas.97.21.11371; RAVINET TC, 2003, AM J PHYSIOL-REG I, V284, pR345, DOI DOI 10.1152/AJPREGU.00545.2002; RINALDICARMONA M, 1995, LIFE SCI, V56, P1941, DOI 10.1016/0024-3205(95)00174-5; Rolfe DFS, 1997, PHYSIOL REV, V77, P731, DOI 10.1152/physrev.1997.77.3.731; Ross SE, 2002, MOL CELL BIOL, V22, P5989, DOI 10.1128/MCB.22.16.5989-5999.2002; SACKS N, 1990, J AM COLL NUTR, V9, P630; Soukas A, 2000, GENE DEV, V14, P963; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; Tartare-Deckert S, 2001, J BIOL CHEM, V276, P22231, DOI 10.1074/jbc.M010634200; Trayhurn P, 2001, P NUTR SOC, V60, P329, DOI 10.1079/PNS200194; Trillou CR, 2004, INT J OBESITY, V28, P640, DOI 10.1038/sj.ijo.0802583; Tsou K, 1998, NEUROSCIENCE, V83, P393, DOI 10.1016/S0306-4522(97)00436-3; WILLIAMS SK, 1999, TIS ENGN INTELL UNIT, V1, P143; Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451; Zhou YT, 1999, P NATL ACAD SCI USA, V96, P2391, DOI 10.1073/pnas.96.5.2391	32	290	303	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2005	19	9					1567	+		10.1096/fj.04-3177fje	http://dx.doi.org/10.1096/fj.04-3177fje			27	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	951IO	16009704				2022-12-25	WOS:000230923000029
J	Opalenik, SR; Davidson, JM				Opalenik, SR; Davidson, JM			Fibroblast differentiation of bone marrow-derived cells during wound repair	FASEB JOURNAL			English	Article; Proceedings Paper	Annual Meeting of the Wound-Healing-Society	2003	SEATTLE, WA	Wound Healing Soc		wound fibroblast; collagen I; tissue remodeling; stem cells	HEMATOPOIETIC STEM-CELLS; TRANSGENIC MICE; ENGRAFTMENT; PLASTICITY; MOUSE; IDENTIFICATION; PLURIPOTENCY; FIBROCYTES	To examine the ontogeny of the wound fibroblast, bone marrow transplantation was performed to wild-type recipients from transgenic donors that express both the luciferase and beta-galactosidase reporter genes under transcriptional control of the promoter/enhancer for the alpha 2 chain of type I collagen. Polyvinyl alcohol sponges were implanted to elicit a naive granulation tissue response, removed at defined time points, and processed for nucleic acids and histochemistry. Quantitative PCR for the luciferase transgene demonstrated that donor-derived cells were present during inflammation, declined, and rebounded during later stages of tissue remodeling. Furthermore, quantitative RT-PCR revealed that bone marrow-derived collagen transcripts contributed significantly to the total collagen I alpha 2 promoter activation during later stages of repair. beta-galactosidase staining revealed that indeed those cells which expressed the transgene exhibited a fibroblastic phenotype, co-localized with sites of active collagen deposition, and expressed fibroblast specific protein-1. These data strongly support the concept that the adult bone marrow compartment houses progenitors with the potential to migrate to sites of tissue damage, and participate in repair beyond inflammation as fibroblasts. Moreover, that bone marrow-derived fibroblasts make a substantial contribution to the formation of new connective tissue, including type I collagen, during wound repair.	Vanderbilt Univ, Dept Pathol, Nashville, TN 37232 USA; Dept Vet Affairs Med Ctr, Nashville, TN 37212 USA	Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Davidson, JM (corresponding author), Vanderbilt Univ, Dept Pathol, C3321 Med Ctr N, Nashville, TN 37232 USA.	jeff.davidson@vanderbilt.edu			NIA NIH HHS [R01-AG06528, R01 AG006528] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG006528] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abe R, 2001, J IMMUNOL, V166, P7556, DOI 10.4049/jimmunol.166.12.7556; Awad HA, 1999, TISSUE ENG, V5, P267, DOI 10.1089/ten.1999.5.267; Badiavas EV, 2003, J CELL PHYSIOL, V196, P245, DOI 10.1002/jcp.10260; BouGharios G, 1996, J CELL BIOL, V134, P1333, DOI 10.1083/jcb.134.5.1333; BUCALA R, 1994, MOL MED, V1, P71, DOI 10.1007/bf03403533; CAPLAN AI, 1991, J ORTHOP RES, V9, P641, DOI 10.1002/jor.1100090504; Chesney J, 1997, P NATL ACAD SCI USA, V94, P6307, DOI 10.1073/pnas.94.12.6307; Clark R., 1996, Mezhdunarodnyi Sel'skokhozyaistvennyi Zhurnal, P3; Davidson JM, 1998, ARCH DERMATOL RES, V290, pS1, DOI 10.1007/PL00007448; DAVIDSON JM, 1992, INFLAMMATION BASIC P, P809; Dennis JE, 1999, J BONE MINER RES, V14, P700, DOI 10.1359/jbmr.1999.14.5.700; Direkze NC, 2003, STEM CELLS, V21, P514, DOI 10.1634/stemcells.21-5-514; DOWN JD, 1993, EXP HEMATOL, V21, P913; Eckes B., 1996, MOL CELLULAR BIOL WO, P493; Fathke C, 2004, STEM CELLS, V22, P812, DOI 10.1634/stemcells.22-5-812; FRIEDENSTEIN AJ, 1976, EXP HEMATOL, V4, P267; Herzog EL, 2003, BLOOD, V102, P3483, DOI 10.1182/blood-2003-05-1664; Iwano M, 2002, J CLIN INVEST, V110, P341, DOI 10.1172/JCI200215518; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Krause DS, 2002, GENE THER, V9, P754, DOI 10.1038/sj.gt.3301760; OKADA H, 1997, AM J PHYSIOL, V273, P563; PEREIRA RF, 1995, P NATL ACAD SCI USA, V92, P4857, DOI 10.1073/pnas.92.11.4857; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Reyes M, 2001, BLOOD, V98, P2615, DOI 10.1182/blood.V98.9.2615; Schwartz RE, 2002, J CLIN INVEST, V109, P1291, DOI 10.1172/JCI200215182; STRUTZ F, 1995, J CELL BIOL, V130, P393, DOI 10.1083/jcb.130.2.393; Tao H, 2003, PATHOLOGY, V35, P6, DOI 10.1080/003130202201471; Verfaillie CM, 2002, TRENDS CELL BIOL, V12, P502, DOI 10.1016/S0962-8924(02)02386-3; Wagers AJ, 2002, SCIENCE, V297, P2256, DOI 10.1126/science.1074807; Wu NJ, 2002, MATRIX BIOL, V21, P149, DOI 10.1016/S0945-053X(01)00192-5; ZIJLMANS JMJM, 1995, P NATL ACAD SCI USA, V92, P8901, DOI 10.1073/pnas.92.19.8901; Zijlmans JMJM, 1998, P NATL ACAD SCI USA, V95, P725, DOI 10.1073/pnas.95.2.725	33	94	98	2	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2005	19	9					1561	+		10.1096/fj.04-2978fje	http://dx.doi.org/10.1096/fj.04-2978fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	951IO	16014399				2022-12-25	WOS:000230923000022
J	Tilkin-Mariame, AF; Cormary, C; Ferro, N; Sarrabayrouse, G; Lajoie-Mazenc, I; Faye, JC; Favre, G				Tilkin-Mariame, AF; Cormary, C; Ferro, N; Sarrabayrouse, G; Lajoie-Mazenc, I; Faye, JC; Favre, G			Geranylgeranyl transferase inhibition stimulates antimelanoma immune response through MHC class I and costimulatory molecule expression	FASEB JOURNAL			English	Article						cancer; immunity; antigen presentation; costimulation; Rho proteins	HUMAN-MELANOMA CELLS; ANTIGEN PRESENTATION; TUMOR-CELLS; IFN-GAMMA; CD80; INDUCTION; IDENTIFICATION; TRANSFORMATION; SURVEILLANCE; DEFICIENCIES	Defective antitumor immune responses are frequent consequences of defects in the expression of major histocompatibility complex (MHC) class I and costimulatory molecules. We demonstrated that statins, inhibitors of HMGCoA reductase, enhance mIFN-gamma induced expression of MHC class I antigens on murine B16F10 melanoma. GGTI-298, a geranylgeranyl transferase I inhibitor, but not FTI-277, a farnesyl transferase inhibitor, mimics this effect of statins. This effect is related to peptide transporter protein TAP1 up-regulation. Simultaneously, GGTI-298 induces the expression of CD80 and CD86 costimulatory molecules. C3 exoenzyme, which selectively inactivates Rho proteins, phenocopies the effects of GGTI-298, indicating a role for Rho proteins in these events. Furthermore, the treatment of B16F10 cells with GGTI-298 or C3 exoenzyme associated with mIFN-gamma induces in vivo tumor growth slowing down in immunocompetent but not in nu/nu syngeneic mice. Both in vivo injections and in vitro restimulation of splenocytes with GGTI-298- and mIFN-gamma- treated B16F10 cells induces an enhancement of specific CD8 T lymphocytes labeled by TRP-2/H-2K(b) tetramers. Finally, these effects are not limited to mouse models since they were also reproduced in two human melanoma cell lines. These observations indicate that protein geranylgeranylation as well as Rho protein are critical for costimulatory and IFN-gamma- dependent MHC class I molecule expression in melanoma.	Inst Claudius Regaud, Dept Innovat Therapeut & Oncol Mol, INSERM, U563,CPTP, F-31052 Toulouse, France; Univ Toulouse 3, F-31062 Toulouse, France	UNICANCER; Institut Claudius Regaud; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Tilkin-Mariame, AF (corresponding author), Inst Claudius Regaud, Dept Innovat Therapeut & Oncol Mol, INSERM, U563,CPTP, 20-24 Rue Pt St Pierre, F-31052 Toulouse, France.	tilkin@icr.fnclcc.fr	FAVRE, Gilles/K-9189-2014; Lajoie-Mazenc, Isabelle/M-4636-2014	FAVRE, Gilles/0000-0002-2344-1883; 				AKTORIES K, 1989, TRENDS PHARMACOL SCI, V10, P415, DOI 10.1016/0165-6147(89)90191-0; Allal C, 2000, J BIOL CHEM, V275, P31001, DOI 10.1074/jbc.M005264200; Bernsen MR, 2003, BRIT J CANCER, V88, P424, DOI 10.1038/sj.bjc.6600703; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Bloom MB, 1997, J EXP MED, V185, P453, DOI 10.1084/jem.185.3.453; Bohm W, 1998, J IMMUNOL, V161, P897; Botti C, 1998, INT J BIOL MARKER, V13, P51; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Cramer LA, 2000, J IMMUNOL, V165, P3190, DOI 10.4049/jimmunol.165.6.3190; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; Douin-Echinard V, 2000, CANCER GENE THER, V7, P1543, DOI 10.1038/sj.cgt.7700268; Dunn GP, 2002, NAT IMMUNOL, V3, P991, DOI 10.1038/ni1102-991; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; FERRONE S, 1995, IMMUNOL TODAY, V16, P487, DOI 10.1016/0167-5699(95)80033-6; Fong L, 2000, ANNU REV IMMUNOL, V18, P245, DOI 10.1146/annurev.immunol.18.1.245; Garcia-Lora A, 2003, J CELL PHYSIOL, V195, P346, DOI 10.1002/jcp.10290; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Grangeon C, 2002, CANCER GENE THER, V9, P282, DOI 10.1038/sj.cgt.7700439; Guilloux Y, 2001, CANCER RES, V61, P1107; Johnsen AK, 1999, J IMMUNOL, V163, P4224; Johnson BD, 2003, CELL IMMUNOL, V222, P15, DOI 10.1016/S0008-8749(03)00079-0; Khong HT, 2002, NAT IMMUNOL, V3, P999, DOI 10.1038/ni1102-999; Kwak B, 2000, NAT MED, V6, P1399, DOI 10.1038/82219; Lejeune FJ, 1998, CURR OPIN IMMUNOL, V10, P573, DOI 10.1016/S0952-7915(98)80226-4; Lens SMA, 1998, SEMIN IMMUNOL, V10, P491, DOI 10.1006/smim.1998.0154; Li J, 1996, CANCER IMMUNOL IMMUN, V43, P213, DOI 10.1007/s002620050324; Mazieres J, 2004, CLIN CANCER RES, V10, P2742, DOI 10.1158/1078-0432.CCR-03-0149; McCarthy DO, 2000, CANCER IMMUNOL IMMUN, V49, P85, DOI 10.1007/s002620050606; Miquel K, 1997, CANCER RES, V57, P1846; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Renkvist N, 2001, CANCER IMMUNOL IMMUN, V50, P3, DOI 10.1007/s002620000169; RIVOLTINI L, 1995, CANCER RES, V55, P3149; ROBEY E, 1995, IMMUNOL TODAY, V16, P306, DOI 10.1016/0167-5699(95)80140-5; Rudy W, 1997, INT IMMUNOL, V9, P853, DOI 10.1093/intimm/9.6.853; Sebbagh M, 2001, NAT CELL BIOL, V3, P346, DOI 10.1038/35070019; Seliger B, 1996, CANCER RES, V56, P1756; Seliger B, 1997, IMMUNOL TODAY, V18, P292, DOI 10.1016/S0167-5699(97)01052-9; Seliger B, 2001, CANCER RES, V61, P1095; Trentin L, 2000, CANCER, V89, P1259, DOI 10.1002/1097-0142(20000915)89:6<1259::AID-CNCR10>3.3.CO;2-7; Tsukada N, 1997, J EXP CLIN CANC RES, V16, P171; Vindelov L, 1990, Methods Cell Biol, V33, P127; Youssef S, 2002, NATURE, V420, P78, DOI 10.1038/nature01158; Zaks TZ, 1999, J IMMUNOL, V162, P3273; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	44	28	29	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2005	19	8					1513	+		10.1096/fj.04-3482fje	http://dx.doi.org/10.1096/fj.04-3482fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	15990392				2022-12-25	WOS:000230207800003
J	Mei, YD; Du, WJ; Yang, YH; Wu, MA				Mei, YD; Du, WJ; Yang, YH; Wu, MA			Puma* Mcl-1 interaction is not sufficient to prevent rapid degradation of Mcl-1	ONCOGENE			English	Article						apoptosis; colocalization; protein stabilization; Puma; Mcl-1	COLORECTAL-CANCER CELLS; HAMSTER OVARY CELLS; BCL-2 FAMILY; CYTOCHROME-C; DNA-DAMAGE; IN-VIVO; APOPTOSIS; P53; PROTEIN; DEATH	Although Puma (p53 upregulated modulator of apoptosis) was known as a principal mediator of cell death in response to diverse apoptotic signals, the molecular mechanism underlying its proapoptotic regulation remains largely uncharacterized. Here we reported that myeloid cell leukemia-1 (Mcl-1), an antiapoptotic member of the Bcl-2 family with a rapid turnover rate, interacts with Puma. The Puma/Mcl-1 interaction was verified by both yeast two-hybrid assay and co-immunoprecipation studies. Their binding sites were mapped to BH3 (Bcl-2 homology) domain of Puma and BH1 domain of Mcl-1, respectively. Mcl-1 and Puma was shown to colocalize at the mitochondria by immunostaining. The level of Mcl-1 was increased when coexpressed with Puma, indicating Puma is able to stabilize Mcl-1. Puma binding to Mcl-1 via its BH3 domain is the prerequisite for this effect, which is further supported by the finding that Puma mutant lacking BH3 domain no longer promotes Mcl-1 protein stability. This Puma-enhanced Mcl-1 stabilization was validated in vivo under nonoverexpression conditions. We also showed that BH1 domain is essential for Mcl-1 to inhibit Puma-induced apoptosis, since Mcl-1 mutant lacking BH1 domain completely abrogates its protective function. In addition, we concluded that binding of Puma to BH1 domain of Mcl-1 is necessary, but not sufficient to prevent rapid degradation of Mcl-1. In addition to PEST (proline, glutamic acid, serine, and threonine) and BH1 domain, some additional degradation signal is expected to reside in the C-terminal region of Mcl-1. In conclusion, our results provide the first evidence that the interaction between Mcl-1 and Puma may represent a novel mechanism by which Mcl-1 prevents apoptosis by increasing its stability through binding to Puma.	Univ Sci & Technol China, Hefei Natl Lab Phys Sci Microscale, Hefei 230027, Anhui, Peoples R China; Univ Sci & Technol China, Sch Life Sci, Hefei 230027, Anhui, Peoples R China; Nanyang Technol Univ, Sch Biol Sci, Singapore 637551, Singapore	Chinese Academy of Sciences; University of Science & Technology of China, CAS; Chinese Academy of Sciences; University of Science & Technology of China, CAS; Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University	Wu, MA (corresponding author), Univ Sci & Technol China, Hefei Natl Lab Phys Sci Microscale, Hefei 230027, Anhui, Peoples R China.	wumian88@yahoo.com	Wu, Mian/H-2494-2018; du, wenjing/A-2530-2013; Mei, Yide/M-4468-2013	du, wenjing/0000-0002-3967-9984; Wu, Mian/0000-0002-2714-0500				Akgul C, 2000, FEBS LETT, V478, P72, DOI 10.1016/S0014-5793(00)01809-3; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Derenne S, 2002, BLOOD, V100, P194, DOI 10.1182/blood.V100.1.194; Fujise K, 2000, J BIOL CHEM, V275, P39458, DOI 10.1074/jbc.M006626200; Han JH, 1996, GENE DEV, V10, P461, DOI 10.1101/gad.10.4.461; Han JW, 2001, P NATL ACAD SCI USA, V98, P11318, DOI 10.1073/pnas.201208798; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Moulding DA, 2000, BLOOD, V96, P1756, DOI 10.1182/blood.V96.5.1756.h8001756_1756_1763; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nijhawan D, 2003, GENE DEV, V17, P1475, DOI 10.1101/gad.1093903; Opferman JT, 2003, NATURE, V426, P671, DOI 10.1038/nature02067; Prives C, 1999, J PATHOL, V187, P112; Reynolds JE, 1996, EXP CELL RES, V225, P430, DOI 10.1006/excr.1996.0194; REYNOLDS JE, 1994, CANCER RES, V54, P6348; Rich T, 2000, NATURE, V407, P777, DOI 10.1038/35037717; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SAMBROOK J, 2000, MOL CLONING LAB MANU; Schmitt CA, 2002, CANCER CELL, V1, P289, DOI 10.1016/S1535-6108(02)00047-8; Unkila M, 2001, J BIOL CHEM, V276, P39132, DOI 10.1074/jbc.M104986200; VILLUNGER A, 2003, SCIENCE         0918; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Yang T, 1996, J CELL PHYSIOL, V166, P523, DOI 10.1002/(SICI)1097-4652(199603)166:3<523::AID-JCP7>3.0.CO;2-R; YANG T, 1995, J CELL BIOL, V128, P1173, DOI 10.1083/jcb.128.6.1173; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Yoon JH, 2002, CANCER RES, V62, P6500; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100; Zhan QM, 1997, ONCOGENE, V14, P1031, DOI 10.1038/sj.onc.1200927; Zhou P, 1997, BLOOD, V89, P630, DOI 10.1182/blood.V89.2.630; Zhou P, 1998, BLOOD, V92, P3226, DOI 10.1182/blood.V92.9.3226.421k49_3226_3239	37	54	55	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 3	2005	24	48					7224	7237		10.1038/sj.onc.1208873	http://dx.doi.org/10.1038/sj.onc.1208873			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	980BY	16007132				2022-12-25	WOS:000232990100011
J	Scholz, C; Richter, A; Lehmann, M; Schulze-Osthoff, K; Dorken, B; Daniel, PT				Scholz, C; Richter, A; Lehmann, M; Schulze-Osthoff, K; Dorken, B; Daniel, PT			Arsenic trioxide induces regulated, death receptor-independent cell death through a Bcl-2-controlled pathway	ONCOGENE			English	Article						arsenic trioxide; apoptosis; caspase-8; FADD; death receptor; CD95/Fas	ACUTE PROMYELOCYTIC LEUKEMIA; DRUG-INDUCED APOPTOSIS; CD95/FAS RECEPTOR; CYCLE ARREST; ACTIVATION; CASPASE-8; INDUCTION; BCL-2; MANNER; LINES	Arsenic trioxide (As2O3, arsenite) efficiently kills cells from various hematologic malignancies and has successfully been employed especially for the treatment of acute promyelocytic leukemia. There and in lymphoid cells, we demonstrated that As2O3 induces cell death in a caspase-2- and -9-independent fashion. Here, we address a potential role of death receptor signaling through the FADD/caspase-8 death-inducing signaling complex in As2O3-induced cell death. In detail, we demonstrate that As2O3 induces cell death independently of caspase-8 or FADD and cannot be blocked by disruption of CD95/Fas receptor ligand interaction. Unlike in death receptor ligation-induced apoptosis, As2O3-induced cell death was not blocked by the broad-spectrum caspase inhibitor z-VAD-fmk or the caspase-8-specific inhibitor z- IETD-fmk. Nevertheless, As2O3-induced cell death occurred in a regulated manner and was abrogated upon Bcl-2 overexpression. In contrast, As2O3-induced cell demise was neither blocked by the caspase-9 inhibitor z-LEHD-fmk nor substantially inhibited through the expression of a dominant negative caspase-9 mutant. Altogether our data demonstrate that As2O3-induced cell death occurs independently of the extrinsic death receptor pathway of apoptosis. Cell death proceeds entirely via an intrinsic, Bcl-2-controlled mitochondrial pathway that does, however, not rely on caspase-9.	Humboldt Univ, Med Ctr, Dept Hematol Oncol & Tumor Immunol, Berlin, Germany; Univ Dusseldorf, Inst Mol Med, D-4000 Dusseldorf, Germany; Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany	Humboldt University of Berlin; Heinrich Heine University Dusseldorf; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Daniel, PT (corresponding author), Charite Univ, Campus Virchow Klinikum, Med Ctr, Augustenburger Platz 1, D-13353 Berlin, Germany.	pdaniel@mdc-berlin.de	Scholz, Christian W/Q-2778-2017; Lehmann, Mario/G-6090-2016; Schulze-Osthoff, Klaus/N-9025-2013	Scholz, Christian W/0000-0001-6260-4086; Lehmann, Mario/0000-0001-8284-5071; Schulze-Osthoff, Klaus/0000-0003-1443-2720				Akao Y, 1998, BRIT J HAEMATOL, V102, P1055, DOI 10.1046/j.1365-2141.1998.00869.x; Belka C, 2003, ONCOGENE, V22, P176, DOI 10.1038/sj.onc.1206103; Belka C, 2000, ONCOGENE, V19, P1181, DOI 10.1038/sj.onc.1203401; Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0; Chandra D, 2004, MOL CELL BIOL, V24, P6592, DOI 10.1128/mcb.24.15.6592-6607.2004; Daniel PT, 2003, ESSAYS BIOCHEM, V39, P73, DOI 10.1042/bse0390073; Daniel PT, 1998, BLOOD, V92, P4750, DOI 10.1182/blood.V92.12.4750.424k34_4750_4757; Daniel PT, 2001, LEUKEMIA, V15, P1022, DOI 10.1038/sj.leu.2402169; DHEIN J, 1992, J IMMUNOL, V149, P3166; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; Hemmati PG, 2002, ONCOGENE, V21, P3149, DOI 10.1038/sj.onc.1205458; Hossain K, 2000, J IMMUNOL, V165, P4290, DOI 10.4049/jimmunol.165.8.4290; Jendrossek V, 2003, FASEB J, V17, P1547, DOI 10.1096/fj.02-0947fje; Jendrossek V, 2003, ONCOGENE, V22, P2621, DOI 10.1038/sj.onc.1206355; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Kitamura K, 2000, LEUKEMIA, V14, P1743, DOI 10.1038/sj.leu.2401900; Klopfer A, 2004, ONCOGENE, V23, P9408, DOI 10.1038/sj.onc.1207975; Larochette N, 1999, EXP CELL RES, V249, P413, DOI 10.1006/excr.1999.4519; Liu Q, 2003, BLOOD, V101, P4078, DOI 10.1182/blood-2002-10-3231; Niu C, 1999, BLOOD, V94, P3315, DOI 10.1182/blood.V94.10.3315.422k16_3315_3324; Perkins C, 2000, BLOOD, V95, P1014, DOI 10.1182/blood.V95.3.1014.003k04_1014_1022; Peter ME, 2003, CELL DEATH DIFFER, V10, P26, DOI 10.1038/sj.cdd.4401186; Rudner J, 2005, ONCOGENE, V24, P130, DOI 10.1038/sj.onc.1208191; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scholz C, 2005, ONCOGENE, V24, P1904, DOI 10.1038/sj.onc.1208233; Shen ZX, 1997, BLOOD, V89, P3354, DOI 10.1182/blood.V89.9.3354; Sohn D, 2005, J BIOL CHEM, V280, P5267, DOI 10.1074/jbc.M408585200; Soignet SL, 1998, NEW ENGL J MED, V339, P1341, DOI 10.1056/NEJM199811053391901; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; von Haefen C, 2003, ONCOGENE, V22, P2236, DOI 10.1038/sj.onc.1206280; von Haefen C, 2004, ONCOGENE, V23, P8320, DOI 10.1038/sj.onc.1207971; Wang ZG, 1998, BLOOD, V92, P1497, DOI 10.1182/blood.V92.5.1497.417k41_1497_1504; Weinmann M, 2004, ONCOGENE, V23, P3757, DOI 10.1038/sj.onc.1207481; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378; Woo SH, 2004, INT J CANCER, V112, P596, DOI 10.1002/ijc.20433; Zhang W, 1998, LEUKEMIA, V12, P1383, DOI 10.1038/sj.leu.2401112; Zhu JB, 2003, ONCOL REP, V10, P705; Zhu XH, 1999, J NATL CANCER I, V91, P772, DOI 10.1093/jnci/91.9.772	40	31	36	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 27	2005	24	47					7031	7042		10.1038/sj.onc.1208868	http://dx.doi.org/10.1038/sj.onc.1208868			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	977WC	16007134				2022-12-25	WOS:000232833200005
J	Morales, C; Ribas, M; Aiza, G; Peinado, MA				Morales, C; Ribas, M; Aiza, G; Peinado, MA			Genetic determinants of methotrexate responsiveness and resistance in colon cancer cells	ONCOGENE			English	Article						drug resistance; colorectal cancer; genetic instability; tumor classification	COMPARATIVE GENOMIC HYBRIDIZATION; DIHYDROFOLATE-REDUCTASE; FRAGILE SITES; CHROMOSOME; AMPLIFICATION; PATHWAYS; TUMOR; INSTABILITY; EXPRESSION; HYDROLASE	Alternative genetic pathways characterized by specific genetic profiles and exhibiting distinctive biological and clinical features have been proposed in colorectal carcinogenesis. Methotrexate (MTX) is a potent inhibitor of the dihydrofolate reductase (DHFR) enzyme, which is essential for DNA synthesis and cell growth. We have evaluated the association between different genetic features and the capacity to develop MTX resistance in colon cancer cell lines representative of alternative genetic pathways. Three aneuploid cell lines (HT-29, SW480, and SK-CO-1) showed pre-existing amplifications, but only one (HT-29) developed MTX resistance, showing amplification of the DHFR gene at 5q12-14 (> 20-fold amplification and presence of extrachromosomal double minutes). Failure to develop resistance was attributed to the absence of two complete chromosomes 5 in SW480 and SK-CO-1 cells. Four near-diploid cell lines (LoVo, HCT116, DLD-1 and KM12C) and two aneuploid KM12C-derived metastases (KM12SM and KM12L4A) developed MTX resistance but none exhibited DHFR amplification. All resistant cells without DHFR gene amplification showed microsatellite instability. We conclude that chemoresistance capacity and the mechanism of chemoresistance are related with the genetic pathway and the karyotypic features of colon cancer cells.	Inst Recerca Oncol, IDIBELL, Barcelona 08907, Spain	Institut d'Investigacio Biomedica de Bellvitge (IDIBELL)	Peinado, MA (corresponding author), Inst Recerca Oncol, IDIBELL, Granvia Km 2-7,Hosp, Barcelona 08907, Spain.	mpeinado@iro.es	Peinado, Miguel A./A-5591-2008	Peinado, Miguel A./0000-0002-4090-793X				Abdel-Rahman WM, 2001, P NATL ACAD SCI USA, V98, P2538, DOI 10.1073/pnas.041603298; Albertson DG, 2003, NAT GENET, V34, P369, DOI 10.1038/ng1215; Banerjee D, 2002, BBA-MOL BASIS DIS, V1587, P164, DOI 10.1016/S0925-4439(02)00079-0; Blakley RL, 1998, HUM MUTAT, V11, P259, DOI 10.1002/(SICI)1098-1004(1998)11:4<259::AID-HUMU1>3.3.CO;2-N; Bosson G, 2003, BRIT J BIOMED SCI, V60, P117, DOI 10.1080/09674845.2003.11783687; Camps J, 2004, INT J CANCER, V110, P869, DOI 10.1002/ijc.20195; CHEN MJ, 1984, J BIOL CHEM, V259, P3933; Chu E, 1996, STEM CELLS, V14, P41, DOI 10.1002/stem.140041; Cole PD, 2001, CANCER RES, V61, P4599; Coquelle A, 1997, CELL, V89, P215, DOI 10.1016/S0092-8674(00)80201-9; DICKER AP, 1993, P NATL ACAD SCI USA, V90, P11797, DOI 10.1073/pnas.90.24.11797; Dutrillaux B, 1995, ADV CANCER RES, V67, P59, DOI 10.1016/S0065-230X(08)60710-1; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Frattini M, 2004, CLIN CANCER RES, V10, P4015, DOI 10.1158/1078-0432.CCR-04-0031; Gayet J, 2001, ONCOGENE, V20, P5025, DOI 10.1038/sj.onc.1204611; Goel A, 2003, CANCER RES, V63, P1608; Gorlick R, 1996, NEW ENGL J MED, V335, P1041, DOI 10.1056/NEJM199610033351408; Grady WM, 2002, ANNU REV GENOM HUM G, V3, P101, DOI 10.1146/annurev.genom.3.022502.103043; Heppner GH, 1998, INT REV CYTOL, V177, P1; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Loeb LA, 2001, CANCER RES, V61, P3230; Masramon L, 2000, CANCER GENET CYTOGEN, V121, P17, DOI 10.1016/S0165-4608(00)00219-3; Masramon L, 1998, BRIT J CANCER, V77, P2349, DOI 10.1038/bjc.1998.390; Matherly LH, 2001, PROG NUCLEIC ACID RE, V67, P131, DOI 10.1016/S0079-6603(01)67027-2; Meyerhardt JA, 2005, NEW ENGL J MED, V352, P476, DOI 10.1056/NEJMra040958; Mitelman F, 1997, CANCER GENET CYTOGEN, V95, P1, DOI 10.1016/S0165-4608(96)00252-X; MORIKAWA K, 1988, CANCER RES, V48, P1943; MORIKAWA K, 1988, CANCER RES, V48, P6863; NUNBERG JH, 1978, P NATL ACAD SCI USA, V75, P5553, DOI 10.1073/pnas.75.11.5553; Olschwang S, 1997, P NATL ACAD SCI USA, V94, P12122, DOI 10.1073/pnas.94.22.12122; PERUCHO M, 1994, COLD SPRING HARB SYM, V59, P339, DOI 10.1101/SQB.1994.059.01.038; Poupon MF, 1996, MOL BIOL CELL, V7, P345, DOI 10.1091/mbc.7.3.345; Rajagopalan H, 2004, NATURE, V432, P338, DOI 10.1038/nature03099; Ribas M, 2002, FASEB J, V16, P289, DOI 10.1096/fj.02-0425fje; Risques RA, 2003, CANCER RES, V63, P7206; Rots MG, 2000, BRIT J HAEMATOL, V110, P791, DOI 10.1046/j.1365-2141.2000.02070.x; Rots MG, 1999, BLOOD, V93, P1677, DOI 10.1182/blood.V93.5.1677.405a16_1677_1683; Ruggiero T, 2003, NUCLEIC ACIDS RES, V31, P6561, DOI 10.1093/nar/gkg858; Singer MJ, 2000, P NATL ACAD SCI USA, V97, P7921, DOI 10.1073/pnas.130194897; Snijders AM, 2003, ONCOGENE, V22, P4370, DOI 10.1038/sj.onc.1206482; Tanaka H, 2002, P NATL ACAD SCI USA, V99, P8772, DOI 10.1073/pnas.132275999; Tsushimi T, 2001, CANCER GENET CYTOGEN, V126, P34, DOI 10.1016/S0165-4608(00)00391-5; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; YUNIS JJ, 1984, SCIENCE, V226, P1199, DOI 10.1126/science.6239375; [No title captured]	45	29	33	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 13	2005	24	45					6842	6847		10.1038/sj.onc.1208834	http://dx.doi.org/10.1038/sj.onc.1208834			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	973MV	16007155				2022-12-25	WOS:000232527800012
J	Slawson, C; Zachara, NE; Vosseller, K; Cheung, WD; Lane, MD; Hart, GW				Slawson, C; Zachara, NE; Vosseller, K; Cheung, WD; Lane, MD; Hart, GW			Perturbations in O-linked beta-N-acetylglucosamine protein modification cause severe defects in mitotic progression and cytokinesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; GLCNAC TRANSFERASE; CELL-CYCLE; NUCLEOCYTOPLASMIC PROTEINS; CYTOPLASMIC PROTEINS; INSULIN-RESISTANCE; CLONAL EXPANSION; BINDING PROTEIN; POTENTIAL ROLE; X-CHROMOSOME	The dynamic modification of nuclear and cytoplasmic proteins with O-linked beta-N-acetylglucosamine (O-GlcNAc) is a regulatory post-translational modification that is rapidly responsive to morphogens, hormones, nutrients, and cellular stress. Here we show that O-GlcNAc is an important regulator of the cell cycle. Increased O-GlcNAc (pharmacologically or genetically) results in growth defects linked to delays in G(2)/M progression, altered mitotic phosphorylation, and cyclin expression. Overexpression of O-GlcNAcase, the enzyme that removes O-GlcNAc, induces amitotic exit phenotype accompanied by a delay in mitotic phosphorylation, altered cyclin expression, and pronounced disruption in nuclear organization. Overexpression of the O-GlcNAc transferase, the enzyme that adds O-GlcNAc, results in a polyploid phenotype with faulty cytokinesis. Notably, O-GlcNAc transferase is concentrated at the mitotic spindle and midbody at M phase. These data suggest that dynamic O-GlcNAc processing is a pivotal regulatory component of the cell cycle, controlling cell cycle progression by regulating mitotic phosphorylation, cyclin expression, and cell division.	Johns Hopkins Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA	Johns Hopkins University; Johns Hopkins Medicine; University of California System; University of California San Francisco	Hart, GW (corresponding author), Johns Hopkins Sch Med, Dept Biol Chem, 725 N Wolfe St, Baltimore, MD 21205 USA.	gwhart@jhmi.edu		Hart, Gerald/0000-0001-7812-4351	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD013563, R37HD013563] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA042486] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061671] Funding Source: NIH RePORTER; NCI NIH HHS [CA42486] Funding Source: Medline; NICHD NIH HHS [HD13563] Funding Source: Medline; NIDDK NIH HHS [DK61671] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams PD, 2001, BBA-REV CANCER, V1471, pM123, DOI 10.1016/S0304-419X(01)00019-1; Arnold CS, 1996, J BIOL CHEM, V271, P28741, DOI 10.1074/jbc.271.46.28741; Austen M, 1997, J BIOL CHEM, V272, P1709, DOI 10.1074/jbc.272.3.1709; Bailis JM, 2003, CELL CYCLE, V2, P303, DOI 10.4161/cc.2.4.434; Bettencourt-Dias M, 2004, NATURE, V432, P980, DOI 10.1038/nature03160; Boehmelt G, 2000, EMBO J, V19, P5092, DOI 10.1093/emboj/19.19.5092; Cheng XG, 2000, BIOCHEMISTRY-US, V39, P11609, DOI 10.1021/bi000755i; CHOU CF, 1993, J BIOL CHEM, V268, P4465; CHOU TY, 1995, J BIOL CHEM, V270, P18961, DOI 10.1074/jbc.270.32.18961; Clark RJ, 2003, J BIOL CHEM, V278, P44230, DOI 10.1074/jbc.M303810200; Comer FI, 2001, ANAL BIOCHEM, V293, P169, DOI 10.1006/abio.2001.5132; Comtesse N, 2001, BIOCHEM BIOPH RES CO, V283, P634, DOI 10.1006/bbrc.2001.4815; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; Ditchfield C, 2003, J CELL BIOL, V161, P267, DOI 10.1083/jcb.200208091; Dudognon P, 2004, FEBS LETT, V561, P44, DOI 10.1016/S0014-5793(04)00109-7; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; Fang B, 2001, EXP CELL RES, V263, P243, DOI 10.1006/excr.2000.5110; Gao Y, 2001, J BIOL CHEM, V276, P9838, DOI 10.1074/jbc.M010420200; Geng Y, 1999, CELL, V97, P767, DOI 10.1016/S0092-8674(00)80788-6; Geng Y, 2003, CELL, V114, P431, DOI 10.1016/S0092-8674(03)00645-7; Gray CH, 2003, EMBO J, V22, P3524, DOI 10.1093/emboj/cdg348; Haltiwanger RS, 1997, J BIOL CHEM, V272, P8752, DOI 10.1074/jbc.272.13.8752; Haltiwanger RS, 1998, J BIOL CHEM, V273, P3611, DOI 10.1074/jbc.273.6.3611; HALTIWANGER RS, 1992, J BIOL CHEM, V267, P9005; Hiromura M, 2003, J BIOL CHEM, V278, P14046, DOI 10.1074/jbc.M300789200; HOLT GD, 1987, J CELL BIOL, V104, P1157, DOI 10.1083/jcb.104.5.1157; HUBER KR, 1987, BRIT J CANCER, V55, P653, DOI 10.1038/bjc.1987.133; JACKSON SP, 1989, P NATL ACAD SCI USA, V86, P1781, DOI 10.1073/pnas.86.6.1781; Jinek M, 2004, NAT STRUCT MOL BIOL, V11, P1001, DOI 10.1038/nsmb833; KEARSE KP, 1991, P NATL ACAD SCI USA, V88, P1701, DOI 10.1073/pnas.88.5.1701; KELLY WG, 1989, CELL, V57, P243, DOI 10.1016/0092-8674(89)90962-8; KELLY WG, 1993, J BIOL CHEM, V268, P10416; Kreppel LK, 1999, J BIOL CHEM, V274, P32015, DOI 10.1074/jbc.274.45.32015; LEVENBERG B, 1957, J BIOL CHEM, V225, P163; Logarinho E, 1998, J CELL SCI, V111, P2897; Lubas WA, 2000, J BIOL CHEM, V275, P10983, DOI 10.1074/jbc.275.15.10983; MARSHALL S, 1991, J BIOL CHEM, V266, P4706; McClain DA, 2002, P NATL ACAD SCI USA, V99, P10695, DOI 10.1073/pnas.152346899; Miller MW, 1999, ARCH BIOCHEM BIOPHYS, V367, P51, DOI 10.1006/abbi.1999.1237; Mishima M, 2004, NATURE, V430, P908, DOI 10.1038/nature02767; Murray AW, 2004, CELL, V116, P221, DOI 10.1016/S0092-8674(03)01080-8; O'Donnell N, 2004, MOL CELL BIOL, V24, P1680, DOI 10.1128/MCB.24.4.1680-1690.2004; Ortega S, 2003, NAT GENET, V35, P25, DOI 10.1038/ng1232; Rane SG, 1999, NAT GENET, V22, P44, DOI 10.1038/8751; Robertson LA, 2004, J ALZHEIMERS DIS, V6, P489; Schultz J, 2002, FEBS LETT, V529, P179, DOI 10.1016/S0014-5793(02)03322-7; Shafi R, 2000, P NATL ACAD SCI USA, V97, P5735, DOI 10.1073/pnas.100471497; Slawson C, 2003, CURR OPIN STRUC BIOL, V13, P631, DOI 10.1016/j.sbi.2003.08.003; Slawson C, 2002, BBA-GEN SUBJECTS, V1573, P121, DOI 10.1016/S0304-4165(02)00369-0; Slawson C, 2001, BBA-MOL BASIS DIS, V1537, P147, DOI 10.1016/S0925-4439(01)00067-9; STUDENT AK, 1980, J BIOL CHEM, V255, P4745; Sumegi M, 2003, BIOCHEM BIOPH RES CO, V312, P1284, DOI 10.1016/j.bbrc.2003.11.074; Tang QQ, 2003, P NATL ACAD SCI USA, V100, P850, DOI 10.1073/pnas.0337434100; Tang QQ, 1999, GENE DEV, V13, P2231, DOI 10.1101/gad.13.17.2231; Toleman C, 2004, J BIOL CHEM, V279, P53665, DOI 10.1074/jbc.M410406200; Vosseller K, 2002, P NATL ACAD SCI USA, V99, P5313, DOI 10.1073/pnas.072072399; Walgren JLE, 2003, AM J PHYSIOL-ENDOC M, V284, pE424, DOI 10.1152/ajpendo.00382.2002; Wells L, 2004, J BIOL CHEM, V279, P38466, DOI 10.1074/jbc.M406481200; Wells L, 2001, SCIENCE, V291, P2376, DOI 10.1126/science.1058714; WICE BM, 1985, J BIOL CHEM, V260, P139; Yang XY, 2002, CELL, V110, P69, DOI 10.1016/S0092-8674(02)00810-3; Yao YL, 2001, MOL CELL BIOL, V21, P5979, DOI 10.1128/MCB.21.17.5979-5991.2001; Zachara NE, 2004, J BIOL CHEM, V279, P30133, DOI 10.1074/jbc.M403773200; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738; Zhang FX, 2003, CELL, V115, P715, DOI 10.1016/S0092-8674(03)00974-7	65	216	226	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	2005	280	38					32944	32956		10.1074/jbc.M503396200	http://dx.doi.org/10.1074/jbc.M503396200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	964ZU	16027160	hybrid			2022-12-25	WOS:000231920300049
J	Gesty-Palmer, D; El Shewy, H; Kohout, TA; Luttrell, LM				Gesty-Palmer, D; El Shewy, H; Kohout, TA; Luttrell, LM			beta-arrestin 2 expression determines the transcriptional response to lysophosphatidic acid stimulation in murine embryo fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; SIGNAL-REGULATED KINASE-1; BETA-ARRESTIN; ANGIOTENSIN-II; EGF RECEPTOR; MAP KINASE; ERK ACTIVATION; TRANSACTIVATION; ENDOCYTOSIS; PATHWAYS	G protein-coupled receptors often employ novel signaling mechanisms, such as transactivation of epidermal growth factor (EGF) receptors or G protein-independent signals transmitted by beta-arrestins, to control the activity of extracellular signal-regulated kinases 1 and 2 (ERK1/2). In this study we investigated the role of beta-arrestins in lysophosphatidic acid (LPA) receptor-stimulated ERK1/ 2 activation using fibroblast lines derived from wild type, beta-arrestin 1, beta-arrestin 2, and beta-arrestin 1/2 knock-out mice. LPA stimulation produced robust ERK1/ 2 phosphorylation in all four backgrounds. In cells lacking beta-arrestin 2, > 80% of LPA-stimulated ERK1/ 2 phosphorylation was mediated by transactivated EGF receptors. In contrast, ERK1/ 2 activation in cells expressing beta-arrestin 2 was predominantly EGF receptor-independent. Introducing FLAG epitope-tagged beta-arrestin 2 into the beta-arrestin 1/2 null background restored EGF receptor-independent ERK1/ 2 activation, indicating that beta-arrestin 2 expression confers ERK1/ 2 activation via a distinct mechanism. To determine the contributions of beta-arrestin 2, transactivated EGF receptors, and ERK1/ 2 to LPA-stimulated transcriptional responses, we employed gene expression arrays containing cDNA markers for G protein-coupled receptor-mediated signaling. In the beta-arrestin 1/2 null background, 1 h of exposure to LPA significantly increased transcription of seven marker genes. Six of these responses were EGF receptor-dependent, and two required ERK1/ 2 activation. In beta-arrestin 2 expressing cells, three of the seven LPA-stimulated transcriptional responses observed in the beta-arrestin 1/2 null background were lost. The four residual responses were independent of EGF receptor transactivation, but all were ERK1/2-dependent. These data indicate that beta-arrestin 2 functions both to attenuate EGF receptor transactivation-dependent signaling and to promote a distinct subset of ERK1/2-mediated responses to LPA receptor activation.	Med Univ S Carolina, Dept Med, Div Endocrinol Diabet & Med Genet, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Durham Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Durham, NC 27705 USA; Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA; Neurocrine Biosci Inc, Dept Exploratory Discovery, San Diego, CA 92121 USA; Neurocrine Biosci Inc, Dept Mol Biol, San Diego, CA 92121 USA	Medical University of South Carolina; Medical University of South Carolina; Duke University; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Durham VA Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center; Neurocrine Biosciences; Neurocrine Biosciences	Luttrell, LM (corresponding author), Med Univ S Carolina, Dept Med, Div Endocrinol Diabet & Med Genet, 96 Jonathan Lucas St,816 CSB,POB 250624, Charleston, SC 29425 USA.	luttrell@musc.edu		Luttrell, Louis/0000-0003-2805-6949	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK064353, R01DK055524, R56DK055524] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK55524, DK64353] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahmed I, 2003, MOL ENDOCRINOL, V17, P1607, DOI 10.1210/me.2002-0040; Ahn S, 2004, J BIOL CHEM, V279, P7807, DOI 10.1074/jbc.C300443200; Ahn SK, 2004, J BIOL CHEM, V279, P35518, DOI 10.1074/jbc.M405878200; Azzi M, 2003, P NATL ACAD SCI USA, V100, P11406, DOI 10.1073/pnas.1936664100; Brady AE, 2002, CELL SIGNAL, V14, P297, DOI 10.1016/S0898-6568(01)00239-X; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; DeFea KA, 2000, P NATL ACAD SCI USA, V97, P11086, DOI 10.1073/pnas.190276697; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; Gaborik Z, 2003, ENDOCRINOLOGY, V144, P2220, DOI 10.1210/en.2002-0135; Grewal SS, 2000, J BIOL CHEM, V275, P34433, DOI 10.1074/jbc.M004728200; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Hackel PO, 1999, CURR OPIN CELL BIOL, V11, P184, DOI 10.1016/S0955-0674(99)80024-6; Hall RA, 2002, CIRC RES, V91, P672, DOI 10.1161/01.RES.0000037000.74258.03; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; Heeneman S, 2000, J BIOL CHEM, V275, P15926, DOI 10.1074/jbc.M909616199; Hobson JP, 2001, SCIENCE, V291, P1800, DOI 10.1126/science.1057559; Holloway AC, 2002, MOL PHARMACOL, V61, P768, DOI 10.1124/mol.61.4.768; Kohout TA, 2001, P NATL ACAD SCI USA, V98, P1601, DOI 10.1073/pnas.041608198; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LINSEMAN DA, 1995, J BIOL CHEM, V270, P12563, DOI 10.1074/jbc.270.21.12563; Luttrell LM, 2002, J CELL SCI, V115, P455; Luttrell LM, 2003, J MOL ENDOCRINOL, V30, P117, DOI 10.1677/jme.0.0300117; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; Oakley RH, 2000, J BIOL CHEM, V275, P17201, DOI 10.1074/jbc.M910348199; Perry SJ, 2002, TRENDS CELL BIOL, V12, P130, DOI 10.1016/S0962-8924(01)02239-5; Pierce KL, 2001, J BIOL CHEM, V276, P23155, DOI 10.1074/jbc.M101303200; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Shenoy SK, 2003, BIOCHEM J, V375, P503, DOI 10.1042/BJ20031076; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Terrillon S, 2004, EMBO J, V23, P3950, DOI 10.1038/sj.emboj.7600387; Tohgo A, 2003, J BIOL CHEM, V278, P6258, DOI 10.1074/jbc.M212231200; Tohgo AK, 2002, J BIOL CHEM, V277, P9429, DOI 10.1074/jbc.M106457200; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Wei HJ, 2004, J BIOL CHEM, V279, P48255, DOI 10.1074/jbc.M406205200; Wei HJ, 2003, P NATL ACAD SCI USA, V100, P10782, DOI 10.1073/pnas.1834556100; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zwick E, 1999, TRENDS PHARMACOL SCI, V20, P408, DOI 10.1016/S0165-6147(99)01373-5	43	38	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	2005	280	37					32157	32167		10.1074/jbc.M507460200	http://dx.doi.org/10.1074/jbc.M507460200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	963HM	16027114	hybrid			2022-12-25	WOS:000231794800016
J	Huang, CJ; Chang, JG; Wu, SC; Choo, KB				Huang, CJ; Chang, JG; Wu, SC; Choo, KB			Negative transcriptional modulation and silencing of the Bi-exonic Rnf35 gene in the preimplantation embryo - Binding of the CCAAT-displacement protein/Cux to the untranslated exon 1 sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE EMBRYO; CUT REPEATS; EXPRESSION PATTERNS; DIFFERENT MODES; DNA-BINDING; PROMOTER; ACTIVATION; REPRESSION; ELEMENT; REGION	Previous works have indicated promiscuous transcription from the zygotic genome immediately after fertilization. The mouse Rnf35 gene is bi- exonic in structure and is transcribed in the preimplantation embryo until it is permanently silenced at the blastocyst stage of development. We have previously shown that Rnf35 transcription is positively regulated by the nuclear factor Y. Using the uniquely permissive Chinese hamster ovary- K1 cell line in transient transfection assays, we demonstrate in this work that the Rnf35 promoter was negatively modulated by a cis- cognate repressor element, designated as the downstream exon 1 repressor, or DER, residing between + 72 and + 95 in the untranslated exon 1 of the Rnf35 gene. Simultaneous mutagenesis of the two half- sections, DER1 and DER2, of the DER sequence was required for derepression suggesting participation of multiple proteins in the DER- dependent transcriptional repression. Electrophoretic mobility shift assays demonstrated that the 3 '- half of DER ( DER2) was targeted by the repressor CCAAT- displacement protein ( CDP)/ Cux. Chromatin immunoprecipitation experiments further demonstrated in vivo CDP- DER association in the blastocyst and the 8.5day embryo. Furthermore, the DER- dependent repression was partially relieved in vivo in co- transfection with an antisense CDP construct. Transcription of the Cdp gene was shown to first occur between the eight- cell and the blastocyst stages, correlating and possibly explaining the onset of Rnf35 silencing at the blastocyst stage. Taken together, our results suggest that the evolutionarily acquired exon 1 of Rnf35, and possibly exon 1 of other similarly structured bi- exonic early embryonic genes, contributes to transcriptional modulation and silencing in the developing mouse embryo.	Vet Gen Hosp, Dept Med Res & Educ, Taipei 11217, Taiwan; Chinese Culture Univ, Coll Agr, Dept Anim Sci, Taipei 111, Taiwan; Chinese Culture Univ, Coll Agr, Grad Inst Biotechnol, Taipei 111, Taiwan; China Med Univ Hosp, Dept Mol Med, Taichung 404, Taiwan; Natl Taiwan Univ, Coll BioResources & Agr, Dept Anim Sci, Taipei 106, Taiwan	Chinese Culture University; Chinese Culture University; China Medical University Taiwan; China Medical University Hospital - Taiwan; National Taiwan University	Choo, KB (corresponding author), Vet Gen Hosp, Dept Med Res & Educ, Taipei 11217, Taiwan.	kbchu@vghtpe.gov.tw	Chang, Jan-Gowth/C-9544-2009	Wu, Shinn-Chih/0000-0001-8881-1550				AUFIERO B, 1994, P NATL ACAD SCI USA, V91, P7757, DOI 10.1073/pnas.91.16.7757; Banan M, 1997, J BIOL CHEM, V272, P18440, DOI 10.1074/jbc.272.29.18440; Barbaric S, 1998, MOL CELL BIOL, V18, P2629, DOI 10.1128/MCB.18.5.2629; Bevilacqua A, 2000, DEVELOPMENT, V127, P1541; Bevilacqua A, 1997, NUCLEIC ACIDS RES, V25, P1333, DOI 10.1093/nar/25.7.1333; Bhoite LT, 2002, J BIOL CHEM, V277, P37612, DOI 10.1074/jbc.M206125200; Boudreau F, 2002, MOL CELL BIOL, V22, P5467, DOI 10.1128/MCB.22.15.5467-5478.2002; Chen HH, 2002, GENOMICS, V79, P18, DOI 10.1006/geno.2001.6664; Chen HH, 2002, GENOMICS, V80, P140, DOI 10.1006/geno.2002.6808; Choo KB, 2002, NUCLEIC ACIDS RES, V30, P4836, DOI 10.1093/nar/gkf623; Choo KB, 2001, MOL REPROD DEV, V59, P249, DOI 10.1002/mrd.1029; CHRISTIANS E, 1995, DEVELOPMENT, V121, P113; di Silvio A, 1999, NUCLEIC ACIDS RES, V27, P2578; Ellis T, 2001, GENE DEV, V15, P2307, DOI 10.1101/gad.200101; EMAMI KH, 1995, MOL CELL BIOL, V15, P5906; Glusman G, 2001, GENOME RES, V11, P685, DOI 10.1101/gr.171001; Goebel P, 2002, J IMMUNOL, V169, P2477, DOI 10.4049/jimmunol.169.5.2477; HARADA R, 1995, MOL CELL BIOL, V15, P129, DOI 10.1128/MCB.15.1.129; Huang CJ, 2005, BIOCHEM J, V387, P367, DOI 10.1042/BJ20041364; Huang CJ, 2004, GENE, V324, P117, DOI 10.1016/j.gene.2003.09.022; Kaffman A, 1998, GENE DEV, V12, P2673, DOI 10.1101/gad.12.17.2673; Kim EC, 1997, CELL GROWTH DIFFER, V8, P1329; Ko MSH, 2000, DEVELOPMENT, V127, P1737; Last TJ, 1998, GENE, V221, P267, DOI 10.1016/S0378-1119(98)00415-6; Li S, 1999, J BIOL CHEM, V274, P7803, DOI 10.1074/jbc.274.12.7803; Liu TYC, 2003, MOL REPROD DEV, V64, P52, DOI 10.1002/mrd.10218; Ma J, 2001, BIOL REPROD, V64, P1713, DOI 10.1095/biolreprod64.6.1713; Mailly F, 1996, MOL CELL BIOL, V16, P5346; MANEJWALA FM, 1991, DEV BIOL, V144, P301, DOI 10.1016/0012-1606(91)90423-Z; Matsumoto K, 1998, EMBO J, V17, P2107, DOI 10.1093/emboj/17.7.2107; Matsumoto K, 1998, TRENDS CELL BIOL, V8, P318, DOI 10.1016/S0962-8924(98)01300-2; Moon NS, 2000, J BIOL CHEM, V275, P31325, DOI 10.1074/jbc.M002912200; Nepveu A, 2001, GENE, V270, P1, DOI 10.1016/S0378-1119(01)00485-1; Nirodi C, 2001, J BIOL CHEM, V276, P26122, DOI 10.1074/jbc.M102872200; Proudfoot N, 2000, TRENDS BIOCHEM SCI, V25, P290, DOI 10.1016/S0968-0004(00)01591-7; ROTHSTEIN JL, 1992, GENE DEV, V6, P1190, DOI 10.1101/gad.6.7.1190; Schultz RM, 1999, J EXP ZOOL, V285, P276, DOI 10.1002/(SICI)1097-010X(19991015)285:3&lt;276::AID-JEZ11&gt;3.0.CO;2-K; Schultz RM, 2002, HUM REPROD UPDATE, V8, P323, DOI 10.1093/humupd/8.4.323; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; Smale ST, 1998, COLD SPRING HARB SYM, V63, P21, DOI 10.1101/sqb.1998.63.21; Smale ST, 2001, GENE DEV, V15, P2503, DOI 10.1101/gad.937701; STATON JAL, 2003, REPRODUCION, V125, P457; Truscott M, 2003, MOL CELL BIOL, V23, P3013, DOI 10.1128/MCB.23.8.3013-3028.2003; Worrad DM, 1997, MOL REPROD DEV, V46, P268, DOI 10.1002/(SICI)1098-2795(199703)46:3&lt;268::AID-MRD5&gt;3.0.CO;2-N; Young JM, 2002, HUM MOL GENET, V11, P1153, DOI 10.1093/hmg/11.10.1153; Zhang XM, 2002, NAT NEUROSCI, V5, P124, DOI 10.1038/nn800; Zhou TY, 2002, NUCLEIC ACIDS RES, V30, P4145, DOI 10.1093/nar/gkf537	47	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	2005	280	35					30681	30688		10.1074/jbc.M413144200	http://dx.doi.org/10.1074/jbc.M413144200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	958ZX	15994318	Green Published, hybrid			2022-12-25	WOS:000231487800006
J	Jaeger, T; Arsic, M; Mayer, C				Jaeger, T; Arsic, M; Mayer, C			Scission of the lactyl ether bond of N-acetylmuramic acid by Escherichia coli "etherase"	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-WALL MUREIN; BETA-ARYL ETHER; IDENTIFICATION; MECHANISM; HYDROLYSIS; CLEAVAGE; PATHWAY; GENES; ELIMINATION; SPECIFICITY	The ubiquitous bacterial cell wall sugar N-acetylmuramic acid (MurNAc) carries a unique (D)-lactyl ether substituent at the C3 position. Recently, we proposed an etherase capable of cleaving this lactyl ether to be part of the novel bacterial MurNAc dissimilation pathway ( Dahl, U., Jaeger, T., Nguyen, B. T., Sattler, J.M., Mayer, C. (2004) J. Bacteriol. 186, 2385 - 2392). Here, we report the identification of the first known MurNAc etherase. The encoding gene murQ is located at 55 min on the Escherichia coli chromosome adjacent to murP, the MurNAc-specific phosphotransferase system. A murQ deletion mutant could not grow on MurNAc as the sole source of carbon and energy but could be complemented by expressing murQ from a plasmid. The mutant had no obvious phenotype when grown on different carbon sources but accumulated MurNAc 6-phosphate at millimolar concentrations from externally supplied MurNAc. Purified MurQ-His(6) fusion protein and extracts of cells expressing murQ both catalyze the cleavage of MurNAc 6-phosphate, with GlcNAc 6-phosphate and D-lactate being the primary products. The O-18 label from enriched water is incorporated into the sugar molecule, showing that the C3-O bond is cleaved and reformed by the enzyme. Moreover, an intermediate was detected and identified as an unsaturated sugar molecule. Based on this observation, we suggested a lyase-type mechanism (beta-elimination/ hydration) for the cleavage of the lactyl ether bond of MurNAc 6-phosphate. Close homologs of murQ were found on the chromosome of several bacteria, and amino acid sequence similarity with the N-terminal domain of human glucokinase-regulatory protein (GckR or GKRP) was recognized.	Univ Konstanz, Fachbereich Biol, D-78457 Constance, Germany	University of Konstanz	Mayer, C (corresponding author), Univ Konstanz, Fachbereich Biol, D-78459 Constance, Germany.	ch.mayer@uni-konstanz.de	Mayer, Christoph/S-8666-2017	Mayer, Christoph/0000-0003-4731-4851				BADET B, 1987, BIOCHEMISTRY-US, V26, P1940, DOI 10.1021/bi00381a023; Bateman A, 1999, TRENDS BIOCHEM SCI, V24, P94, DOI 10.1016/S0968-0004(99)01357-2; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; Dahl U, 2004, J BACTERIOL, V186, P2385, DOI 10.1128/JB.186.8.2385-2392.2004; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; FRINGS J, 1994, ARCH MICROBIOL, V162, P199, DOI 10.1007/s002030050125; Holtje JV, 1998, MICROBIOL MOL BIOL R, V62, P181; ISHIBASHI T, 1983, EUR J BIOCHEM, V132, P23, DOI 10.1111/j.1432-1033.1983.tb07320.x; JOLLES P, 1969, ANGEW CHEM INT EDIT, V8, P227, DOI 10.1002/anie.196902271; Masai E, 2003, J BACTERIOL, V185, P1768, DOI 10.1128/JB.185.6.1768-1775.2003; MASAI E, 1991, J BACTERIOL, V173, P7950, DOI 10.1128/jb.173.24.7950-7955.1991; Masai E, 1999, J IND MICROBIOL BIOT, V23, P364, DOI 10.1038/sj.jim.2900747; MAYER C, 2005, CELLULAR MOL BIOL; Miller J.H., 1992, SHORT COURSE BACTERI, P150; Park JT, 2001, J BACTERIOL, V183, P3842, DOI 10.1128/JB.183.13.3842-3847.2001; PARQUET C, 1983, EUR J BIOCHEM, V133, P371, DOI 10.1111/j.1432-1033.1983.tb07472.x; Parsons JF, 2003, BIOCHEMISTRY-US, V42, P5684, DOI 10.1021/bi027385d; PETERSON D, 1974, ARCH BIOCHEM BIOPHYS, V162, P135, DOI 10.1016/0003-9861(74)90112-X; Rajan SS, 2004, STRUCTURE, V12, P1619, DOI 10.1016/j.str.2004.06.020; REISSIG JL, 1955, J BIOL CHEM, V217, P959; ROLLS JP, 1972, J BACTERIOL, V112, P894, DOI 10.1128/JB.112.2.894-902.1972; SELTMANN G, 2002, BACTERIAL CELL WALL, P105; SNYDER F, 1973, BIOCHIM BIOPHYS ACTA, V316, P259, DOI 10.1016/0005-2760(73)90018-0; Speranza G, 2002, J BIOL CHEM, V277, P11684, DOI 10.1074/jbc.M111059200; SPIER JL, 1964, CHEMISTRY, V37, P6; TIPPER DJ, 1968, BIOCHEMISTRY-US, V7, P1441, DOI 10.1021/bi00844a029; Uehara T, 2005, J BACTERIOL, V187, P3643, DOI 10.1128/JB.187.11.3643-3649.2005; van Heijenoort J, 2001, NAT PROD REP, V18, P503, DOI 10.1039/a804532a; VanSchaftingen E, 1997, BIOCHEM SOC T, V25, P136, DOI 10.1042/bst0250136; Varrot A, 2005, J MOL BIOL, V346, P423, DOI 10.1016/j.jmb.2004.11.058; White GF, 1996, MICROBIOL REV, V60, P216, DOI 10.1128/MMBR.60.1.216-232.1996; Wiame E, 2002, J BIOL CHEM, V277, P42523, DOI 10.1074/jbc.M200863200; Yip VLY, 2004, J AM CHEM SOC, V126, P8354, DOI 10.1021/ja047632w; YOUNG IG, 1969, BIOCHIM BIOPHYS ACTA, V177, P401, DOI 10.1016/0304-4165(69)90302-X; Yu DG, 2000, P NATL ACAD SCI USA, V97, P5978, DOI 10.1073/pnas.100127597	35	43	44	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	2005	280	34					30100	30106		10.1074/jbc.M502208200	http://dx.doi.org/10.1074/jbc.M502208200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	957IC	15983044	hybrid			2022-12-25	WOS:000231362500015
J	Fukunaga, R; Yokoyama, S				Fukunaga, R; Yokoyama, S			Structural basis for non-cognate amino acid discrimination by the valyl-tRNA synthetase editing domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; CP1 DOMAIN; L-VALINE; AMINOACYLATION; COMPLEX; SIEVE; RECOGNITION; THREONINE; REJECTION; PATHWAYS	The editing domain of valyl-tRNA synthetase (ValRS) is known to deacylate, or edit, misformed Thr-tRNA(Val) (post-transfer editing). Here, we determined the 1.7-angstrom-resolution crystal structure of the Thermus thermophilus ValRS editing domain. A comparison of the structure with the previously reported tRNA complex structure revealed conformational changes of the editing domain upon accommodation of the terminal A76; the "GTG loop" moves to expand the pocket, and the side chain of Phe-264 on the GTG loop rotates to interact with the A76 adenine ring. If these conformational changes did not occur, then C75 and A76 of the tRNA would clash with Phe-264. To elucidate the mechanism of the threonine side-chain recognition, we determined the crystal structure of the editing domain bound with [N-( L- threonyl)sulfamoyl] adenosine at 1.7-angstrom resolution. The gamma-OH of the threonyl moiety is recognized by the Lys-270, Thr-272, and Asp-279 side chains, which may reject the cognate valyl moiety. Accordingly, ValRS mutants with an Ala substitution for Lys-270 or Asp-279 synthesized significant amounts of Thr-tRNA(Val). The misproduced ThrtRNAVal was hydrolyzed efficiently by the wild-type ValRS, but this post-transfer editing activity was drastically impaired by the Ala substitutions for Lys-270 and Asp-279 and was also decreased by those for Arg-216, Phe-264, and Thr-272. These results indicate that the threonyl moiety and A76 of Thr-tRNA(Val) are recognized by the Lys-270, Thr- 272, and Asp-279 side chains and by the Phe-264 side chain, respectively, of the ValRS editing domain.	Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Bunkyo Ku, Tokyo 1130033, Japan; RIKEN, Genom Sci Ctr, Yokohama, Kanagawa 2300045, Japan; RIKEN, Harima Inst SPring 8, Sayo, Hyogo 6795148, Japan	University of Tokyo; RIKEN; RIKEN	Yokoyama, S (corresponding author), Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	yokoyama@biochem.s.u-tokyo.ac.jp	Yokoyama, Shigeyuki/N-6911-2015; Fukunaga, Ryuya/AAK-8609-2020	Yokoyama, Shigeyuki/0000-0003-3133-7338; Fukunaga, Ryuya/0000-0002-5814-8206				Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chen JF, 2000, BIOCHEMISTRY-US, V39, P6726, DOI 10.1021/bi000108r; Cusack S, 2000, EMBO J, V19, P2351, DOI 10.1093/emboj/19.10.2351; FERSHT AR, 1977, BIOCHEMISTRY-US, V16, P1025, DOI 10.1021/bi00624a034; FERSHT AR, 1976, BIOCHEMISTRY-US, V15, P3342, DOI 10.1021/bi00660a026; FREIST W, 1988, EUR J BIOCHEM, V173, P27, DOI 10.1111/j.1432-1033.1988.tb13962.x; Fukai S, 2000, CELL, V103, P793, DOI 10.1016/S0092-8674(00)00182-3; Fukunaga R, 2005, J MOL BIOL, V346, P57, DOI 10.1016/j.jmb.2004.11.060; Fukunaga R, 2004, J BIOL CHEM, V279, P8396, DOI 10.1074/jbc.M312830200; GIEGE R, 1974, EUR J BIOCHEM, V45, P351, DOI 10.1111/j.1432-1033.1974.tb03560.x; Hendrickson TL, 2002, MOL CELL, V9, P353, DOI 10.1016/S1097-2765(02)00449-5; Hountondji C, 2002, BIOCHEMISTRY-US, V41, P14856, DOI 10.1021/bi0205101; JAKUBOWSKI H, 1981, NUCLEIC ACIDS RES, V9, P3105, DOI 10.1093/nar/9.13.3105; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lin L, 1996, BIOCHEMISTRY-US, V35, P5596, DOI 10.1021/bi960011y; Lin L, 1996, NATURE, V384, P33, DOI 10.1038/384033b0; Lincecum TL, 2003, MOL CELL, V11, P951, DOI 10.1016/S1097-2765(03)00098-4; Martinis SA, 1999, BIOCHIMIE, V81, P683, DOI 10.1016/S0300-9084(99)80126-6; Nordin BE, 2002, J BIOL CHEM, V277, P20510, DOI 10.1074/jbc.M202023200; Nureki O, 1998, SCIENCE, V280, P578, DOI 10.1126/science.280.5363.578; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; SCHMIDT E, 1994, SCIENCE, V264, P265, DOI 10.1126/science.8146659; Silvian LF, 1999, SCIENCE, V285, P1074, DOI 10.1126/science.285.5430.1074; Tardif KD, 2004, RNA, V10, P493, DOI 10.1261/rna.5166704; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766	26	30	34	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	2005	280	33					29937	29945		10.1074/jbc.M502668200	http://dx.doi.org/10.1074/jbc.M502668200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	954SX	15970591	hybrid			2022-12-25	WOS:000231176200066
J	Welbourn, S; Green, R; Gamache, I; Dandache, S; Lohmann, V; Bartenschlager, R; Meerovitch, K; Pause, A				Welbourn, S; Green, R; Gamache, I; Dandache, S; Lohmann, V; Bartenschlager, R; Meerovitch, K; Pause, A			Hepatitis C virus NS2/3 processing is required for NS3 stability and viral RNA replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONTRANSLATED REGION; ENZYMATIC-ACTIVITIES; NS2-3 PROTEASE; BOVINE VIRUS; IN-VITRO; CLEAVAGE; HELICASE; NS4A; PROTEINASE; TRANS	The hepatitis C virus NS2/3 protease is responsible for cleavage of the viral polyprotein between nonstructural proteins NS2 and NS3. We show here that mutation of three highly conserved residues in NS2 (His(952), Glu(972), and Cys(993)) abrogates NS2/3 protease activity and that introduction of any of these mutations into subgenomic NS2-5B replicons results in complete inactivation of NS2/3 processing and RNA replication in both stable and transient replication assays. The effect of uncleaved NS2 on the various activities of NS3 was therefore explored. Unprocessed NS2 had no significant effect on the in vitro ATPase and helicase activities of NS3, whereas immunoprecipitation experiments demonstrated a decreased affinity of NS4A for uncleaved NS2/3 as compared with NS3. This subsequently resulted in reduced kinetics in an in vitro NS3 protease assay with the unprocessed NS2/3 protein. Interestingly, NS3 was still capable of efficient processing of the polyprotein expressed from a subgenomic replicon in Huh-7 cells in the presence of uncleaved NS2. Notably, we show that fusion with NS2 leads to the rapid degradation of NS3, whose activity is essential for RNA replication. Finally, we demonstrate that uncleaved NS2/3 degradation can be prevented by the addition of a proteasome inhibitor. We therefore propose that NS2/3 processing is a critical step in the viral life cycle and is required to permit the accumulation of sufficient NS3 for RNA replication to occur. The regulation of NS2/3 cleavage could constitute a novel mechanism of switching between viral RNA replication and other processes of the hepatitis C virus life cycle.	McGill Univ, McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; Heidelberg Univ, Dept Mol Virol, D-69120 Heidelberg, Germany	McGill University; McGill University; Ruprecht Karls University Heidelberg	Pause, A (corresponding author), McGill Univ, McGill Canc Ctr, McIntyre Bldg,Rm 716,3655 Sir William Osler Prome, Montreal, PQ H3G 1Y6, Canada.	arnim.pause@mcgill.ca	Lohmann, Volker/H-4211-2019; Welbourn, Sarah/AAU-5645-2020; Bartenschlager, Ralf/L-2582-2015	Lohmann, Volker/0000-0001-8719-7608; Welbourn, Sarah/0000-0002-2932-1436; Bartenschlager, Ralf/0000-0001-5601-9307				Agapov EV, 2004, J VIROL, V78, P2414, DOI 10.1128/JVI.78.5.2414-2425.2004; BARTENSCHLAGER R, 1993, J VIROL, V67, P3835, DOI 10.1128/JVI.67.7.3835-3844.1993; BARTENSCHLAGER R, 1995, J VIROL, V69, P198, DOI 10.1128/JVI.69.1.198-205.1995; BARTENSCHLAGER R, 1994, J VIROL, V68, P5045, DOI 10.1128/JVI.68.8.5045-5055.1994; Breiman A, 2005, J VIROL, V79, P3969, DOI 10.1128/JVI.79.7.3969-3978.2005; Buckwold VE, 2003, ANTIVIR RES, V60, P1, DOI 10.1016/S0166-3542(03)00174-8; CHAN KM, 1986, ANAL BIOCHEM, V157, P375, DOI 10.1016/0003-2697(86)90640-8; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; CHOO QL, 1991, P NATL ACAD SCI USA, V88, P2451, DOI 10.1073/pnas.88.6.2451; Darke PL, 1999, J BIOL CHEM, V274, P34511, DOI 10.1074/jbc.274.49.34511; DONIS RO, 1987, VIROLOGY, V158, P168, DOI 10.1016/0042-6822(87)90250-9; Dumoulin FL, 2003, VIROLOGY, V305, P260, DOI 10.1006/viro.2002.1701; Erdtmann L, 2003, J BIOL CHEM, V278, P18256, DOI 10.1074/jbc.M209732200; FAILLA C, 1994, J VIROL, V68, P3753, DOI 10.1128/JVI.68.6.3753-3760.1994; Foy E, 2005, P NATL ACAD SCI USA, V102, P2986, DOI 10.1073/pnas.0408707102; Foy E, 2003, SCIENCE, V300, P1145, DOI 10.1126/science.1082604; Franck N, 2005, J VIROL, V79, P2700, DOI 10.1128/JVI.79.5.2700-2708.2005; Friebe P, 2005, J VIROL, V79, P380, DOI 10.1128/JVI.79.1.380-392.2005; Friebe P, 2001, J VIROL, V75, P12047, DOI 10.1128/JVI.75.24.12047-12057.2001; Gallinari P, 1999, BIOCHEMISTRY-US, V38, P5620, DOI 10.1021/bi982892+; Gallinari P, 1998, J VIROL, V72, P6758, DOI 10.1128/JVI.72.8.6758-6769.1998; Gao L, 2003, J VIROL, V77, P4149, DOI 10.1128/JVI.77.7.4149-4159.2003; GRAKOUI A, 1993, P NATL ACAD SCI USA, V90, P10583, DOI 10.1073/pnas.90.22.10583; HIJIKATA M, 1993, P NATL ACAD SCI USA, V90, P10773, DOI 10.1073/pnas.90.22.10773; HIJIKATA M, 1993, J VIROL, V67, P4665, DOI 10.1128/JVI.67.8.4665-4675.1993; Hoofnagle JH, 1997, HEPATOLOGY, V26, pS15, DOI 10.1002/hep.510260703; Howe AYM, 1999, PROTEIN SCI, V8, P1332, DOI 10.1110/ps.8.6.1332; Kim JL, 1996, CELL, V87, P343, DOI 10.1016/S0092-8674(00)81351-3; Kolykhalov AA, 2000, J VIROL, V74, P2046, DOI 10.1128/JVI.74.4.2046-2051.2000; Krieger N, 2001, J VIROL, V75, P4614, DOI 10.1128/JVI.75.10.4614-4624.2001; Kuang WF, 2004, BIOCHEM BIOPH RES CO, V317, P211, DOI 10.1016/j.bbrc.2004.03.032; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; Kyono K, 2003, J BIOCHEM, V134, P505, DOI 10.1093/jb/mvg167; Lackner T, 2004, J VIROL, V78, P10765, DOI 10.1128/JVI.78.19.10765-10775.2004; Li K, 2005, P NATL ACAD SCI USA, V102, P2992, DOI 10.1073/pnas.0408824102; LIN C, 1994, J VIROL, V68, P8147, DOI 10.1128/JVI.68.12.8147-8157.1994; Lohmann V, 2001, J VIROL, V75, P1437, DOI 10.1128/JVI.75.3.1437-1449.2001; Lohmann V, 2003, J VIROL, V77, P3007, DOI 10.1128/JVI.77.5.3007-3019.2003; Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110; MILLER RH, 1990, P NATL ACAD SCI USA, V87, P2057, DOI 10.1073/pnas.87.6.2057; Neddermann P, 1999, J VIROL, V73, P9984, DOI 10.1128/JVI.73.12.9984-9991.1999; Pallaoro M, 2001, J VIROL, V75, P9939, DOI 10.1128/JVI.75.20.9939-9946.2001; Pang PS, 2002, EMBO J, V21, P1168, DOI 10.1093/emboj/21.5.1168; Pieroni L, 1997, J VIROL, V71, P6373, DOI 10.1128/JVI.71.9.6373-6380.1997; POCOCK DH, 1987, ARCH VIROL, V94, P43, DOI 10.1007/BF01313724; Reed KE, 2000, CURR TOP MICROBIOL, V242, P55; REED KE, 1995, J VIROL, V69, P4127, DOI 10.1128/JVI.69.7.4127-4136.1995; SANTOLINI E, 1995, J VIROL, V69, P7461, DOI 10.1128/JVI.69.12.7461-7471.1995; TANJI Y, 1995, J VIROL, V69, P1575, DOI 10.1128/JVI.69.3.1575-1581.1995; Thibeault D, 2001, J BIOL CHEM, V276, P46678, DOI 10.1074/jbc.M108266200; TOMEI L, 1993, J VIROL, V67, P4017, DOI 10.1128/JVI.67.7.4017-4026.1993; VANDENHOFF MJB, 1992, NUCLEIC ACIDS RES, V20, P2902, DOI 10.1093/nar/20.11.2902; Waxman L, 2001, P NATL ACAD SCI USA, V98, P13931, DOI 10.1073/pnas.241510898; Wolk B, 2000, J VIROL, V74, P2293, DOI 10.1128/JVI.74.5.2293-2304.2000; Yan YW, 1998, PROTEIN SCI, V7, P837	55	52	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	2005	280	33					29604	29611		10.1074/jbc.M505019200	http://dx.doi.org/10.1074/jbc.M505019200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	954SX	15980068	hybrid			2022-12-25	WOS:000231176200028
J	Bustos, DM; Velours, J				Bustos, DM; Velours, J			The modification of the conserved GXXXG motif of the membrane-spanning segment of subunit g destabilizes the supramolecular species of yeast ATP synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYACRYLAMIDE-GEL ELECTROPHORESIS; MITOCHONDRIAL CRISTAE MORPHOLOGY; BOVINE HEART-MITOCHONDRIA; SACCHAROMYCES-CEREVISIAE; F1F0-ATP SYNTHASE; TRANSMEMBRANE DOMAIN; HELIX INTERACTIONS; CELL-MEMBRANES; COMPLEXES; RESOLUTION	The supernumerary subunit g is found in all mitochondrial ATP synthases. Most of the conserved amino acid residues are present in the membrane C-terminal part of the protein that contains a dimerization motif GXXXG. In yeast, alteration of this motif leads to the loss of subunit g and of supramolecular structures of the ATP synthase with concomitant appearance of anomalous mitochondrial morphologies. Disulfide bond formation involving an engineered cysteine in position 109 of subunit g and the endogenous cysteine 28 of subunit e promoted g + g, e + g, and e + e adducts, thus revealing the proximity in the mitochondrial membrane of several subunits e and g. Disulfide bond formation between two subunits g in mitochondria increased the stability of an oligomeric structure of the ATP synthase in digitonin extracts. These data suggest the participation of the dimerization motif of subunit g in the formation of supramolecular structures and is in favor of the existence of ATP synthase associations, in the inner mitochondrial membrane, whose masses are higher than those of ATP synthase dimers.	Univ Victor Segalen, CNRS, Inst Biochim & Genet Cellulaires, F-33077 Bordeaux, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux	Bustos, DM (corresponding author), Univ Victor Segalen, CNRS, Inst Biochim & Genet Cellulaires, 1 Rue Camille St Saens, F-33077 Bordeaux, France.	diego.bustos@ibgc.u-bordeaux2.fr						ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Arnold I, 1998, EMBO J, V17, P7170, DOI 10.1093/emboj/17.24.7170; Arnold I, 1997, FEBS LETT, V411, P195, DOI 10.1016/S0014-5793(97)00691-1; Arselin G, 2004, J BIOL CHEM, V279, P40392, DOI 10.1074/jbc.M404316200; Arselin G, 2003, EUR J BIOCHEM, V270, P1875, DOI 10.1046/j.1432-1033.2003.03557.x; Arselin G, 1996, J BIOL CHEM, V271, P20284, DOI 10.1074/jbc.271.34.20284; Belogrudov GI, 1996, J BIOL CHEM, V271, P20340, DOI 10.1074/jbc.271.34.20340; Bianchet MA, 1998, P NATL ACAD SCI USA, V95, P11065, DOI 10.1073/pnas.95.19.11065; Brunner S, 2002, J BIOL CHEM, V277, P48484, DOI 10.1074/jbc.M209382200; COLLINSON IR, 1994, BIOCHEMISTRY-US, V33, P7971, DOI 10.1021/bi00191a026; Dawson JP, 2003, J MOL BIOL, V331, P255, DOI 10.1016/S0022-2836(03)00714-9; Everard-Gigot V, 2005, EUKARYOT CELL, V4, P346, DOI 10.1128/EC.4.2.346-355.2005; Fillingame RH, 1999, SCIENCE, V286, P1687, DOI 10.1126/science.286.5445.1687; Fleming KG, 2001, PROTEINS, V45, P313, DOI 10.1002/prot.1151; Fraser HB, 2002, SCIENCE, V296, P750, DOI 10.1126/science.1068696; Fronzes R, 2003, BIOCHEMISTRY-US, V42, P12038, DOI 10.1021/bi035270j; Gavin PD, 2004, J CELL SCI, V117, P2333, DOI 10.1242/jcs.01074; Gibbons C, 2000, NAT STRUCT BIOL, V7, P1055; Giraud MF, 2002, BBA-BIOENERGETICS, V1555, P174, DOI 10.1016/S0005-2728(02)00274-8; GrandierVazeille X, 1996, ANAL BIOCHEM, V242, P248, DOI 10.1006/abio.1996.0460; Hausrath AC, 1999, P NATL ACAD SCI USA, V96, P13697, DOI 10.1073/pnas.96.24.13697; Li RH, 2004, J BIOL CHEM, V279, P26666, DOI 10.1074/jbc.M314168200; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Melnyk RA, 2004, J BIOL CHEM, V279, P16591, DOI 10.1074/jbc.M313936200; Mendrola JM, 2002, J BIOL CHEM, V277, P4704, DOI 10.1074/jbc.M108681200; Paumard P, 2002, EMBO J, V21, P221, DOI 10.1093/emboj/21.3.221; Paumard P, 2002, BIOCHEMISTRY-US, V41, P10390, DOI 10.1021/bi025923g; Pedersen PL, 2000, J BIOENERG BIOMEMBR, V32, P423, DOI 10.1023/A:1005652605340; Rexroth S, 2004, BBA-BIOENERGETICS, V1658, P202, DOI 10.1016/j.bbabio.2004.05.014; Russ WP, 2000, J MOL BIOL, V296, P911, DOI 10.1006/jmbi.1999.3489; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Senes A, 2001, P NATL ACAD SCI USA, V98, P9056, DOI 10.1073/pnas.161280798; Senior AE, 2002, BBA-BIOENERGETICS, V1553, P188, DOI 10.1016/S0005-2728(02)00185-8; Soubannier V, 2002, J BIOL CHEM, V277, P10739, DOI 10.1074/jbc.M111882200; Spannagel C, 1998, BBA-BIOMEMBRANES, V1414, P260, DOI 10.1016/S0005-2736(98)00174-6; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; Stock D, 2000, CURR OPIN STRUC BIOL, V10, P672, DOI 10.1016/S0959-440X(00)00147-0; Velours J, 2001, J BIOL CHEM, V276, P8602, DOI 10.1074/jbc.M008123200; Velours J, 2000, J BIOENERG BIOMEMBR, V32, P383, DOI 10.1023/A:1005580020547	40	59	60	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	2005	280	32					29004	29010		10.1074/jbc.M502140200	http://dx.doi.org/10.1074/jbc.M502140200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	952QT	15970598	hybrid			2022-12-25	WOS:000231021300023
J	Chen, YY; Deng, YQ; Bao, XY; Reuss, L; Altenberg, GA				Chen, YY; Deng, YQ; Bao, XY; Reuss, L; Altenberg, GA			Mechanism of the defect in gap-junctional communication by expression of a connexin 26 mutant associated with dominant deafness	FASEB JOURNAL			English	Article						channel; genetic disease	NONJUNCTIONAL PLASMA-MEMBRANE; HEMICHANNELS; CHANNELS; INHIBITION; MUTATIONS; CALCIUM; ORGAN; PERMEABILITY; UNDERLIES; CURRENTS	Gap-junctional channels ( connexin oligomers) are large-diameter aqueous pores formed by head-to-head association of two gap-junctional hemichannels, one from each of the adjacent cells. Profound hearing loss of genetic origin is common, and mutations of connexin 26 (Cx26) are the most frequent cause of this disorder. The Cx26 R75W mutant has been associated with disruption of cell-to-cell communication and profound hearing loss, but the mechanism of the gap-junctional defect is unknown. Here, we show that Cx26 R75W forms gap-junctional hemichannels that display altered voltage dependency and reduced permeability, and which cannot form functional gap-junctional channels between neighboring cells. The R75W phenotype is dominant at the gap-junction channel but not at the hemichannel level. Therefore, the absence of gap-junctional communication caused by R75W expression is due to defective gap-junction formation by functional hemichannels.	Univ Texas, Med Branch, Dept Neurosci & Cell Biol, Galveston, TX 77550 USA; Univ Texas, Med Branch, Membrane Prot Lab, Sealy Ctr Struct Biol, Galveston, TX 77550 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Altenberg, GA (corresponding author), Univ Texas, Med Branch, Dept Neurosci & Cell Biol, Galveston, TX 77550 USA.	galtenbe@utmb.edu		Altenberg, Guillermo/0000-0002-8932-740X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068586] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM068586] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmad S, 2003, BIOCHEM BIOPH RES CO, V307, P362, DOI 10.1016/S0006-291X(03)01166-5; Bao XY, 2004, J BIOL CHEM, V279, P9689, DOI 10.1074/jbc.M311438200; Bao XY, 2004, AM J PHYSIOL-CELL PH, V286, pC647, DOI 10.1152/ajpcell.00295.2003; Beltramello M, 2005, NAT CELL BIOL, V7, P63, DOI 10.1038/ncb1205; Beltramello M, 2003, BIOCHEM BIOPH RES CO, V305, P1024, DOI 10.1016/S0006-291X(03)00868-4; Bruzzone R, 2003, FEBS LETT, V533, P79, DOI 10.1016/S0014-5793(02)03755-9; CALVO J, X CONNEXINS DEAFNESS; Cohen-Salmon M, 2002, CURR BIOL, V12, P1106, DOI 10.1016/S0960-9822(02)00904-1; Contreras JE, 2002, P NATL ACAD SCI USA, V99, P495, DOI 10.1073/pnas.012589799; Corey DP, 2004, NATURE, V432, P723, DOI 10.1038/nature03066; Ebihara L, 1996, BIOPHYS J, V71, P742, DOI 10.1016/S0006-3495(96)79273-1; Eskandari S, 2002, J MEMBRANE BIOL, V185, P93, DOI 10.1007/s00232-001-0115-0; Foote CI, 1998, J CELL BIOL, V140, P1187, DOI 10.1083/jcb.140.5.1187; Forge A, 2003, J COMP NEUROL, V467, P207, DOI 10.1002/cne.10916; Forge A, 2003, CELL COMMUN ADHES, V10, P341, DOI 10.1080/cac.10.4-6.341.346; Forge A, 2002, AUDIOL NEURO-OTOL, V7, P141, DOI 10.1159/000058299; Forge A, 2002, BRIT MED BULL, V63, P5, DOI 10.1093/bmb/63.1.5; Gomez-Hernandez JM, 2003, P NATL ACAD SCI USA, V100, P16030, DOI 10.1073/pnas.2530348100; Harris AL, 2001, Q REV BIOPHYS, V34, P325, DOI 10.1017/S0033583501003705; Jentsch TJ, 2000, NAT REV NEUROSCI, V1, P21, DOI 10.1038/35036198; John SA, 1999, J BIOL CHEM, V274, P236, DOI 10.1074/jbc.274.1.236; JOHNSTONE BM, 1989, J PHYSIOL-LONDON, V408, P77, DOI 10.1113/jphysiol.1989.sp017448; Kikuchi Toshihiko, 2000, Medical Electron Microscopy, V33, P51, DOI 10.1007/s007950070001; Kudo T, 2003, HUM MOL GENET, V12, P995, DOI 10.1093/hmg/ddg116; Lautermann J, 1998, CELL TISSUE RES, V294, P415, DOI 10.1007/s004410051192; Marziano NK, 2003, HUM MOL GENET, V12, P805, DOI 10.1093/hmg/ddg076; METHFESSEL C, 1986, PFLUG ARCH EUR J PHY, V407, P577, DOI 10.1007/BF00582635; Mo L, 1999, J MEMBRANE BIOL, V168, P253, DOI 10.1007/s002329900514; Oh S, 1999, J GEN PHYSIOL, V114, P339, DOI 10.1085/jgp.114.3.339; Oshima A, 2003, J BIOL CHEM, V278, P1807, DOI 10.1074/jbc.M207713200; PAUL DL, 1991, J CELL BIOL, V115, P1077, DOI 10.1083/jcb.115.4.1077; Pfahnl A, 1999, PFLUG ARCH EUR J PHY, V437, P345, DOI 10.1007/s004240050788; Richard G, 1998, HUM GENET, V103, P393, DOI 10.1007/s004390050839; Rizzuto R, 2003, ONCOGENE, V22, P8619, DOI 10.1038/sj.onc.1207105; SANTOS-SACCHI J, 1986, HEARING RES, V21, P205, DOI 10.1016/0378-5955(86)90219-4; Skerrett IM, 2004, FASEB J, V18, P860, DOI 10.1096/fj.03-0763fje; SPRAY DC, 1981, J GEN PHYSIOL, V77, P77, DOI 10.1085/jgp.77.1.77; Steel KP, 1999, SCIENCE, V285, P1363, DOI 10.1126/science.285.5432.1363; Suchyna TM, 1999, BIOPHYS J, V77, P2968, DOI 10.1016/S0006-3495(99)77129-8; Thomson SC, 2003, KIDNEY BLOOD PRESS R, V26, P10, DOI 10.1159/000069766; Vergara L, 2003, J MEMBRANE BIOL, V196, P173, DOI 10.1007/s00232-003-0636-9; Zhao HB, 2000, J MEMBRANE BIOL, V175, P17, DOI 10.1007/s002320001051	42	36	37	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2005	19	9					1516	+		10.1096/fj.04-3491fje	http://dx.doi.org/10.1096/fj.04-3491fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	951IO	16009703				2022-12-25	WOS:000230923000028
J	Avivi, A; Shams, I; Joel, A; Lache, O; Levy, AP; Nevo, E				Avivi, A; Shams, I; Joel, A; Lache, O; Levy, AP; Nevo, E			Increased blood vessel density provides the mole rat physiological tolerance to its hypoxic subterranean habitat	FASEB JOURNAL			English	Article						subterranean Spalax; VEGF; hypoxia-inducible factor; HuR; hypoxia tolerance	ENDOTHELIAL GROWTH-FACTOR; FACTOR MESSENGER-RNA; INDUCIBLE FACTOR-I; LACTATE-DEHYDROGENASE; SPALAX-EHRENBERGI; EXPRESSION; BINDING; ELEMENT; ELAV; GENE	The blind subterranean mole rat superspecies Spalax ehrenbergi has evolved adaptations that allow it to survive and carry out intensive activities in its highly hypoxic underground sealed burrows. A key component of this adaptation is a higher capillary density in some Spalax tissues, primarily in muscles used in digging and in other energetic activities, resulting in a shorter diffusion distance for oxygen. Vascular endothelial growth factor ( VEGF) is an angiogenic factor that is critical for angiogenesis during development and is found in response to tissue ischemia. We demonstrate here that due to physiological differences, the Spalax muscle regulatory mechanism for VEGF is different than in Rattus muscle. In vivo, the constitutive level of the VEGF mRNA and the mRNA levels of its transcriptional regulator HIF-1 alpha and its mRNA stabilizer HuR are significantly higher in Spalax muscle than in Rattus muscle. Furthermore, as opposed to Rattus, the mRNA levels of HIF-1 alpha, HuR, VEGF, as well as that of LDH-A, the enzyme that catalyzes the production of lactate, an accepted marker of anaerobic metabolism, are not increased in Spalax after hypoxia. However, ex vivo, when oxygenation by blood vessels is no longer relevant, the expression pattern of all these genes is similar in the two rodents under both normoxic and hypoxic conditions. Our studies provide evidence that the highly vascularized muscle in Spalax, the most energy consuming tissue during digging, is resistant to the effects of oxygen deprivation. The significance of these results with respect to ischemic vascular disease is abundantly clear.	Univ Haifa, Inst Evolut, Lab Anim Mol Evolut, IL-31905 Haifa, Israel; Technion Fac Med, Haifa, Israel	University of Haifa; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Avivi, A (corresponding author), Univ Haifa, Inst Evolut, Lab Anim Mol Evolut, IL-31905 Haifa, Israel.	aaron@esti.haifa.ac.il		Shams, Imad/0000-0001-6496-2928				AR A, 1977, RESP PHYSIOL, V30, P201, DOI 10.1016/0034-5687(77)90031-7; ARIELI R, 1991, COMP BIOCHEM PHYS A, V100, P543, DOI 10.1016/0300-9629(91)90367-L; ARIELI R, 1977, PHYSIOL ZOOL, V50, P61, DOI 10.1086/physzool.50.1.30155716; ARIELI R, 1989, EVOLUTION SUBTERRANE, P251; Ashur-Fabian C, 2004, P NATL ACAD SCI USA, V101, P12236, DOI 10.1073/pnas.0404998101; Avivi A, 1999, FEBS LETT, V452, P133, DOI 10.1016/S0014-5793(99)00584-0; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; BURLINGTON RF, 1968, NATURE, V219, P1370, DOI 10.1038/2191370a0; Bustin SA, 2002, J MOL ENDOCRINOL, V29, DOI 10.1677/jme.0.0290023; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Ferrara N, 1999, NAT MED, V5, P1359, DOI 10.1038/70928; FIRTH JD, 1995, J BIOL CHEM, V270, P21021, DOI 10.1074/jbc.270.36.21021; Goldberg-Cohen I, 2002, J BIOL CHEM, V277, P13635, DOI 10.1074/jbc.M108703200; Hochachka PW, 1996, P NATL ACAD SCI USA, V93, P9493, DOI 10.1073/pnas.93.18.9493; Hochachka PW, 1996, J APPL PHYSIOL, V81, P1355, DOI 10.1152/jappl.1996.81.3.1355; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; Iyer NV, 1998, GENOMICS, V52, P159, DOI 10.1006/geno.1998.5416; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jewell UR, 2001, FASEB J, V15, P1312, DOI 10.1096/fj.00-0732fje; Jubb AM, 2004, J CLIN PATHOL, V57, P504, DOI 10.1136/jcp.2003.012963; Jubb AM, 2003, J PATHOL, V200, P577, DOI 10.1002/path.1371; KEREM D, 1973, COMP BIOCHEM PHYSIOL, V45, P731, DOI 10.1016/0300-9629(73)90076-5; Koshikawa N, 2003, ONCOGENE, V22, P6717, DOI 10.1038/sj.onc.1206765; Lai WS, 2001, J BIOL CHEM, V276, P23144, DOI 10.1074/jbc.M100680200; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417; Ma WJ, 1996, J BIOL CHEM, V271, P8144, DOI 10.1074/jbc.271.14.8144; MARKERT CL, 1975, SCIENCE, V189, P102, DOI 10.1126/science.1138367; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Nevo, 1999, MOSAIC EVOLUTION SUB; Nevo E., 1961, Mammalia Paris, V25, P127, DOI 10.1515/mamm.1961.25.2.127; NEVO E., 2001, ADAPTIVE RAD BLIND S; PETERS KG, 1993, P NATL ACAD SCI USA, V90, P8915, DOI 10.1073/pnas.90.19.8915; PLOUET J, 1989, EMBO J, V8, P3801, DOI 10.1002/j.1460-2075.1989.tb08557.x; Powell FL, 2003, ANNU REV PHYSIOL, V65, P203, DOI 10.1146/annurev.physiol.65.092101.142711; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; ROBINOW S, 1988, SCIENCE, V242, P1570, DOI 10.1126/science.3144044; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; Shams I, 2004, FASEB J, V18, P307, DOI 10.1096/fj.04-2758fje; Shams I, 2004, P NATL ACAD SCI USA, V101, P9698, DOI 10.1073/pnas.0403540101; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SZABO A, 1991, CELL, V67, P325, DOI 10.1016/0092-8674(91)90184-Z; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; Wenger RH, 1996, BIOCHEM BIOPH RES CO, V223, P54, DOI 10.1006/bbrc.1996.0845; Widmer HR, 1997, P NATL ACAD SCI USA, V94, P2062, DOI 10.1073/pnas.94.5.2062; Wiener CM, 1996, BIOCHEM BIOPH RES CO, V225, P485, DOI 10.1006/bbrc.1996.1199	47	58	64	0	15	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2005	19	8					1314	+		10.1096/fj.04-3414fje	http://dx.doi.org/10.1096/fj.04-3414fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	16000366				2022-12-25	WOS:000230207800018
J	Dias-Gunasekara, S; Gubbens, J; van Lith, M; Dunne, C; Williams, JAG; Kataky, R; Scoones, D; Lapthorn, A; Bulleid, NJ; Benham, AM				Dias-Gunasekara, S; Gubbens, J; van Lith, M; Dunne, C; Williams, JAG; Kataky, R; Scoones, D; Lapthorn, A; Bulleid, NJ; Benham, AM			Tissue-specific expression and dimerization of the endoplasmic reticulum oxidoreductase Ero1 beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DISULFIDE-ISOMERASE; BOND FORMATION; SECRETORY PATHWAY; STRESS; ERO1P; ERO1-L-ALPHA; DOMAIN; GLUTATHIONE; OXIDATION; CHAPERONE	Endoplasmic reticulum oxidoreductases (Eros) are essential for the formation of disulfide bonds. Understanding disulfide bond catalysis in mammals is important because of the involvement of protein misfolding in conditions such as diabetes, arthritis, cancer, and aging. Mammals express two related Ero proteins, Ero1 alpha and Ero1 beta. Ero1 beta is incompletely characterized but is of physiological interest because it is induced by the unfolded protein response. Here, we show that Ero1 beta can form homodimers and mixed heterodimers with Ero1 alpha, in addition to Ero-PDI dimers. Ero-Ero dimers require the Ero active site, occur in vivo, and can be modeled onto the Ero1p crystal structure. Our data indicate that the Ero1 beta protein is constitutively strongly expressed in the stomach and the pancreas, but in a cell-specific fashion. In the stomach, selective expression of Ero1 beta occurs in the enzyme-producing chief cells. In pancreatic islets, Ero1 beta expression is high, but is inversely correlated with PDI and PDIp levels, demonstrating that cell-specific differences exist in the regulation of oxidative protein folding in vivo.	Univ Durham, Sch Biol & Biomed Sci, Durham DH1 3LE, England; Univ Durham, Dept Chem, Durham DH1 3LE, England; James Cook Univ Hosp, Dept Pathol, Middlesbrough TS4 3BW, Cleveland, England; Univ Glasgow, Dept Chem, Glasgow G12 8QQ, Lanark, Scotland; Univ Manchester, Fac Life Sci, Manchester M13 9PT, Lancs, England	Durham University; Durham University; James Cook University Hospital; University of Glasgow; University of Manchester	Benham, AM (corresponding author), Univ Durham, Sch Biol & Biomed Sci, South Rd, Durham DH1 3LE, England.	Adam.benham@durham.ac.uk	Williams, J A Gareth/F-6618-2012; Kataky, Ritu/B-1800-2009; Benham, Adam/AAC-6606-2019; Gubbens, Jacob/C-8448-2013	Williams, J A Gareth/0000-0002-4688-3000; Kataky, Ritu/0000-0002-6386-9606; Lapthorn, Adrian/0000-0002-2197-8134; Benham, Adam/0000-0002-0919-7431; Van Lith, Marcel/0000-0003-0225-5501; Bulleid, Neil/0000-0002-9839-5279	Wellcome Trust [074081] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Alanen HI, 2003, ANTIOXID REDOX SIGN, V5, P367, DOI 10.1089/152308603768295096; Anelli T, 2002, EMBO J, V21, P835, DOI 10.1093/emboj/21.4.835; Bader MW, 2001, EMBO J, V20, P1555, DOI 10.1093/emboj/20.7.1555; Benham AM, 2000, EMBO J, V19, P4493, DOI 10.1093/emboj/19.17.4493; Bertoli G, 2004, J BIOL CHEM, V279, P30047, DOI 10.1074/jbc.M403192200; Cabibbo A, 2000, J BIOL CHEM, V275, P4827, DOI 10.1074/jbc.275.7.4827; Chakravarthi S, 2004, J BIOL CHEM, V279, P39872, DOI 10.1074/jbc.M406912200; DeSilva MG, 1997, DNA CELL BIOL, V16, P269, DOI 10.1089/dna.1997.16.269; Dobson CM, 2003, NATURE, V426, P884, DOI 10.1038/nature02261; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Frand AR, 1999, MOL CELL, V4, P469, DOI 10.1016/S1097-2765(00)80198-7; Frand AR, 1998, MOL CELL, V1, P161, DOI 10.1016/S1097-2765(00)80017-9; Frand AR, 2000, MOL BIOL CELL, V11, P2833, DOI 10.1091/mbc.11.9.2833; Gess B, 2003, EUR J BIOCHEM, V270, P2228, DOI 10.1046/j.1432-1033.2003.03590.x; Gross E, 2004, CELL, V117, P601, DOI 10.1016/S0092-8674(04)00418-0; Kaufman RJ, 2002, NAT REV MOL CELL BIO, V3, P411, DOI 10.1038/nrm829; Klappa P, 2001, BIOCHEM J, V354, P553, DOI 10.1042/0264-6021:3540553; Lawless MW, 2004, J IMMUNOL, V172, P5722, DOI 10.4049/jimmunol.172.9.5722; May D, 2005, ONCOGENE, V24, P1011, DOI 10.1038/sj.onc.1208325; Mezghrani A, 2001, EMBO J, V20, P6288, DOI 10.1093/emboj/20.22.6288; Molteni SN, 2004, J BIOL CHEM, V279, P32667, DOI 10.1074/jbc.M404992200; Nakatani Y, 2005, J BIOL CHEM, V280, P847, DOI 10.1074/jbc.M411860200; Norgaard P, 2001, J CELL BIOL, V152, P553, DOI 10.1083/jcb.152.3.553; Ozcan U, 2004, SCIENCE, V306, P457, DOI 10.1126/science.1103160; Pagani M, 2000, J BIOL CHEM, V275, P23685, DOI 10.1074/jbc.M003061200; Pollard MG, 1998, MOL CELL, V1, P171, DOI 10.1016/S1097-2765(00)80018-0; Russell SJ, 2004, J BIOL CHEM, V279, P18861, DOI 10.1074/jbc.M400575200; Schebesta M, 2002, CURR OPIN IMMUNOL, V14, P216, DOI 10.1016/S0952-7915(02)00324-2; Thorpe C, 2002, ARCH BIOCHEM BIOPHYS, V405, P1, DOI 10.1016/S0003-9861(02)00337-5; Tsai M, 2002, J CELL BIOL, V159, P207, DOI 10.1083/jcb.200207120; Tu BP, 2000, SCIENCE, V290, P1571, DOI 10.1126/science.290.5496.1571; Tu BP, 2002, MOL CELL, V10, P983, DOI 10.1016/S1097-2765(02)00696-2; van Lith M, 2005, J BIOL CHEM, V280, P1376, DOI 10.1074/jbc.M408651200; Wilkinson B, 2004, BBA-PROTEINS PROTEOM, V1699, P35, DOI 10.1016/j.bbapap.2004.02.017; Wilson R, 1998, J BIOL CHEM, V273, P9637, DOI 10.1074/jbc.273.16.9637; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Zhao Z, 2003, J BIOL CHEM, V278, P43292, DOI 10.1074/jbc.M306945200	37	70	73	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	2005	280	38					33066	33075		10.1074/jbc.M505023200	http://dx.doi.org/10.1074/jbc.M505023200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	964ZU	16012172	hybrid			2022-12-25	WOS:000231920300061
J	Barnes, DJ; Schultheis, B; Adedeji, S; Melo, JV				Barnes, DJ; Schultheis, B; Adedeji, S; Melo, JV			Dose-dependent effects of Bcr-Abl in cell line models of different stages of chronic myeloid leukemia	ONCOGENE			English	Article						chronic myeloid leukemia; Bcr-Abl; growth factor dependence; tumorigenicity; adhesion	CHRONIC MYELOGENOUS LEUKEMIA; MURINE HEMATOPOIETIC-CELLS; INTEGRIN-MEDIATED ADHESION; TYROSINE KINASE-ACTIVITY; BONE-MARROW; PROGENITOR CELLS; NOD/SCID MICE; CD34(+) CELLS; CHRONIC-PHASE; EXPRESSION	Chronic myeloid leukemia (CML) is caused by Bcr-Abl, an activated tyrosine kinase. The amounts of Bcr-Abl mRNA and protein in cells from patients in blast crisis (BC) are higher than in those chronic phase (CP), indicating that their expression rises with disease progression. In order to study this phenomenon on cells with the same genetic background, we transfected the 32D cell line with the BCR-ABL transgene and selected clones with graded expression of Bcr-Abl within the range found in cells from CP to BC. In vitro, we found that Bcr-Abl exerted dose-dependent effects upon growth factor dependence, clonogenicity and migration. How ever, the relationship between Bcr-Abl expression and cellular adhesion to fibronectin was more complex: rather than a direct positive correlation, clones that expressed low, but not high, levels of Bcr-Abl were less adhesive than growth factor stimulated, parental BCR-ABL-negative 32D cells. This finding parallels the situation with normal and CML-CP progenitors where the latter exhibit defective adhesion to fibronectin. Treatment with the tyrosine kinase inhibitor imatinib mesylate reversed the adhesion deficient phenotype of clones expressing low levels of Bcr-Abl. When injected subcutaneously into syngeneic mice, cell lines expressing high levels of Bcr-Abl rapidly induced tumors, whereas low-expressing clones led to tumor formation only after a prolonged latency. These findings suggest that the level of Bcr-Abl may be essential in determining the phenotype of the leukemic clone at different stages of the disease.	Hammersmith Hosp, Imperial Coll London, Fac Med, Dept Haematol, London W12 0NN, England	Imperial College London	Melo, JV (corresponding author), Hammersmith Hosp, Imperial Coll London, Fac Med, Dept Haematol, Du Cane Rd, London W12 0NN, England.	j.melo@imperial.ac.uk	Schultheis, Beate/M-5889-2017	Barnes, David/0000-0002-7937-2004				AMOS TAS, 1995, BRIT J HAEMATOL, V91, P387, DOI 10.1111/j.1365-2141.1995.tb05308.x; Bazzoni G, 1996, J CLIN INVEST, V98, P521, DOI 10.1172/JCI118820; Bhatia R, 1998, BLOOD, V91, P3414, DOI 10.1182/blood.V91.9.3414.3414_3414_3422; Bhatia R, 1998, LEUKEMIA, V12, P1708, DOI 10.1038/sj.leu.2401193; Bhatia R, 2001, BRIT J HAEMATOL, V115, P845, DOI 10.1046/j.1365-2141.2001.03192.x; Cambier N, 1998, ONCOGENE, V16, P335, DOI 10.1038/sj.onc.1201490; Dazzi F, 1998, BLOOD, V92, P1390, DOI 10.1182/blood.V92.4.1390.416k09_1390_1396; Deininger MWN, 2000, BLOOD, V96, P3343, DOI 10.1182/blood.V96.10.3343; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Elmaagacli AH, 2000, ANN HEMATOL, V79, P424, DOI 10.1007/s002770000169; GAIGER A, 1995, BLOOD, V86, P2371, DOI 10.1182/blood.V86.6.2371.bloodjournal8662371; GORDON MY, 1987, NATURE, V328, P342, DOI 10.1038/328342a0; GUO JQ, 1991, CANCER RES, V51, P3048; HURLEY RW, 1995, J CLIN INVEST, V96, P511, DOI 10.1172/JCI118063; Issaad C, 2000, LEUKEMIA, V14, P662, DOI 10.1038/sj.leu.2401730; KABAROWSKI JHS, 1994, EMBO J, V13, P5887, DOI 10.1002/j.1460-2075.1994.tb06934.x; Kramer A, 1999, P NATL ACAD SCI USA, V96, P2087, DOI 10.1073/pnas.96.5.2087; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANEUVILLE P, 1991, ONCOGENE, V6, P275; LEVESQUE JP, 1995, J EXP MED, V181, P1805, DOI 10.1084/jem.181.5.1805; Lewis ID, 1998, BLOOD, V91, P630, DOI 10.1182/blood.V91.2.630.630_630_640; Lin F, 1996, BLOOD, V87, P4473, DOI 10.1182/blood.V87.10.4473.bloodjournal87104473; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; Ramaraj P, 2004, CANCER RES, V64, P5322, DOI 10.1158/0008-5472.CAN-03-3656; Salgia R, 1997, J CLIN INVEST, V100, P46, DOI 10.1172/JCI119520; Schleuning M, 1999, EUR J HAEMATOL, V62, P149; VERFAILLIE CM, 1992, J CLIN INVEST, V90, P1232, DOI 10.1172/JCI115985; Wang JCY, 1998, BLOOD, V91, P2406, DOI 10.1182/blood.V91.7.2406.2406_2406_2414; Wertheim JA, 2003, BLOOD, V102, P2220, DOI 10.1182/blood-2003-01-0062; Wertheim JA, 2002, BLOOD, V99, P4122, DOI 10.1182/blood.V99.11.4122; Zhao RC, 2001, BLOOD, V97, P2406, DOI 10.1182/blood.V97.8.2406	32	53	57	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 22	2005	24	42					6432	6440		10.1038/sj.onc.1208796	http://dx.doi.org/10.1038/sj.onc.1208796			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	966RI	16007188				2022-12-25	WOS:000232038200010
J	Cleary, J; Sitwala, KV; Khodadoust, MS; Kwok, RPS; Mor-Vaknin, N; Cebrat, M; Cole, PA; Markovitz, DM				Cleary, J; Sitwala, KV; Khodadoust, MS; Kwok, RPS; Mor-Vaknin, N; Cebrat, M; Cole, PA; Markovitz, DM			p300/CBP-associated factor drives DEK into interchromatin granule clusters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE MYELOID-LEUKEMIA; POSTTRANSLATIONAL PROTEIN MODIFICATIONS; SCAFFOLD ATTACHMENT FACTOR; EXON JUNCTION COMPLEX; BREAST-CANCER CELLS; MESSENGER-RNA; REVERSIBLE ACETYLATION; GENE-EXPRESSION; HUMAN SPLICEOSOME; NUCLEAR SPECKLES	DEK is a mammalian protein that has been implicated in the pathogenesis of autoimmune diseases and cancer, including acute myeloid leukemia, melanoma, glioblastoma, hepatocellular carcinoma, and bladder cancer. In addition, DEK appears to participate in multiple cellular processes, including transcriptional repression, mRNA processing, and chromatin remodeling. Sub-nuclear distribution of this protein, with the attendant functional ramifications, has remained a controversial topic. Here we report that DEK undergoes acetylation in vivo at lysine residues within the first 70 N-terminal amino acids. Acetylation of DEK decreases its affinity for DNA elements within the promoter, which is consistent with the involvement of DEK in transcriptional repression. Furthermore, deacetylase inhibition results in accumulation of DEK within interchromatin granule clusters ( IGCs), sub-nuclear structures that contain RNA processing factors. Overexpression of P/CAF acetylase drives DEK into IGCs, and addition of a newly developed, synthetic, cell-permeable P/CAF inhibitor blocks this movement. To our knowledge, this is the first reported example of acetylation playing a direct role in relocation of a protein to IGCs, and this may explain how DEK can function in multiple pathways that take place in distinct sub-nuclear compartments. These findings also suggest that DEK-associated malignancies and autoimmune diseases might be amenable to treatment with agents that alter acetylation.	Univ Michigan, Dept Internal Med, Div Infect Dis, Ann Arbor, MI 48109 USA; Johns Hopkins Univ, Cell & Mol Biol Program, Baltimore, MD 21205 USA; Johns Hopkins Univ, Program Immunol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Dept Obstet & Gynecol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Dept Biol Chem, Baltimore, MD 21205 USA; Johns Hopkins Univ, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; Univ Wroclaw, Fac Chem, PL-50383 Wroclaw, Poland	University of Michigan System; University of Michigan; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; University of Wroclaw	Markovitz, DM (corresponding author), Univ Michigan, Dept Internal Med, Div Infect Dis, 5220 MSRB 3,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	dmarkov@umich.edu	Khodadoust, Michael/AAU-3936-2020; Cebrat, Marek A/G-9754-2011; Khodadoust, Michael/K-7764-2019	Khodadoust, Michael/0000-0001-9061-7351; Cebrat, Marek A/0000-0003-4975-4025; Khodadoust, Michael/0000-0001-9061-7351	NCI NIH HHS [T32 CA88784-03, T32 CA07863] Funding Source: Medline; NIDDK NIH HHS [5P-60-DK20572] Funding Source: Medline; NIGMS NIH HHS [GM62437] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA088784] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020572] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062437, R37GM062437] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alexiadis V, 2000, GENE DEV, V14, P1308; Aravind L, 2000, TRENDS BIOCHEM SCI, V25, P112, DOI 10.1016/S0968-0004(99)01537-6; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Casas S, 2003, LEUKEMIA LYMPHOMA, V44, P1935, DOI 10.1080/1042819031000119299; Chakraborty S, 2001, J BIOL CHEM, V276, P44936, DOI 10.1074/jbc.M106733200; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Chubb JR, 2003, CELL, V112, P403, DOI 10.1016/S0092-8674(03)00078-3; Daibata M, 2004, INT J CANCER, V108, P845, DOI 10.1002/ijc.11647; Dong XW, 2000, ARTHRITIS RHEUM-US, V43, P85, DOI 10.1002/1529-0131(200001)43:1<85::AID-ANR11>3.0.CO;2-D; Doyle HA, 2002, CURR OPIN RHEUMATOL, V14, P244, DOI 10.1097/00002281-200205000-00009; Doyle HA, 2001, TRENDS IMMUNOL, V22, P443, DOI 10.1016/S1471-4906(01)01976-7; Edmondson DG, 2002, J BIOL CHEM, V277, P29496, DOI 10.1074/jbc.M200651200; Evans AJ, 2004, AM J PATHOL, V164, P285, DOI 10.1016/S0002-9440(10)63118-5; Faulkner NE, 2001, J BIOL CHEM, V276, P25804, DOI 10.1074/jbc.M006454200; Fu GK, 1997, P NATL ACAD SCI USA, V94, P1811, DOI 10.1073/pnas.94.5.1811; Galasinski SC, 2002, J BIOL CHEM, V277, P2579, DOI 10.1074/jbc.M107894200; Gohring F, 1997, EMBO J, V16, P7361, DOI 10.1093/emboj/16.24.7361; Grottke C, 2000, INT J CANCER, V88, P535, DOI 10.1002/1097-0215(20001115)88:4<535::AID-IJC4>3.0.CO;2-V; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Guidez F, 2005, MOL CELL BIOL, V25, P5552, DOI 10.1128/MCB.25.13.5552-5566.2005; Hayakawa F, 2004, J LEUKOCYTE BIOL, V75, P529, DOI 10.1189/jlb.0603289; He Q, 2000, P NATL ACAD SCI USA, V97, P5768, DOI 10.1073/pnas.100108697; Hollenbach AD, 2002, J CELL SCI, V115, P3319; Jang ER, 2004, ONCOGENE, V23, P1724, DOI 10.1038/sj.onc.1207315; Kappes F, 2001, J BIOL CHEM, V276, P26317, DOI 10.1074/jbc.M100162200; Kashanchi F, 1998, J BIOL CHEM, V273, P34646, DOI 10.1074/jbc.273.51.34646; Kataoka N, 2004, J BIOL CHEM, V279, P7009, DOI 10.1074/jbc.M307692200; Kim MS, 2003, CANCER RES, V63, P7291; Kim VN, 2001, MOL CELLS, V12, P1; Kipp M, 2000, J BIOL CHEM, V275, P5031, DOI 10.1074/jbc.275.7.5031; Kondoh N, 1999, CANCER RES, V59, P4990; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Kroes RA, 2000, CANCER LETT, V156, P191, DOI 10.1016/S0304-3835(00)00462-6; Lamond AI, 1998, SCIENCE, V280, P547, DOI 10.1126/science.280.5363.547; Lamond AI, 2003, NAT REV MOL CELL BIO, V4, P605, DOI 10.1038/nrm1172; LaMorte VJ, 1998, P NATL ACAD SCI USA, V95, P4991, DOI 10.1073/pnas.95.9.4991; Larramendy ML, 2002, HAEMATOLOGICA, V87, P569; Lau OD, 2000, MOL CELL, V5, P589, DOI 10.1016/S1097-2765(00)80452-9; Le Hir H, 2000, EMBO J, V19, P6860, DOI 10.1093/emboj/19.24.6860; Maniatis T, 2002, NATURE, V416, P499, DOI 10.1038/416499a; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Marzio G, 2000, J BIOL CHEM, V275, P10887, DOI 10.1074/jbc.275.15.10887; McGarvey T, 2000, J CELL BIOL, V150, P309, DOI 10.1083/jcb.150.2.309; Mintz PJ, 1999, EMBO J, V18, P4308, DOI 10.1093/emboj/18.15.4308; Nagatani G, 2001, CANCER RES, V61, P1592; Neugebauer KM, 2000, ARTHRITIS RHEUM, V43, P1768, DOI 10.1002/1529-0131(200008)43:8<1768::AID-ANR13>3.0.CO;2-9; Polesskaya A, 2001, EMBO J, V20, P6816, DOI 10.1093/emboj/20.23.6816; Poux AN, 2002, P NATL ACAD SCI USA, V99, P14065, DOI 10.1073/pnas.222373899; Proudfoot NJ, 2002, CELL, V108, P501, DOI 10.1016/S0092-8674(02)00617-7; RECORD MT, 1978, Q REV BIOPHYS, V11, P103, DOI 10.1017/S003358350000202X; RECORD MT, 1976, J MOL BIOL, V107, P145, DOI 10.1016/S0022-2836(76)80023-X; Reichert VL, 2002, GENE DEV, V16, P2778, DOI 10.1101/gad.1030602; REVZIN A, 1990, CONCEPTS BIOCH, V67, P749; Sacco-Bubulya P, 2002, J CELL BIOL, V156, P425, DOI 10.1083/jcb.200107017; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Schubert S, 2004, ONCOGENE, V23, P1392, DOI 10.1038/sj.onc.1207255; SIERAKOWSKA H, 1993, CLIN EXP IMMUNOL, V94, P435; Soutoglou E, 2000, MOL CELL, V5, P745, DOI 10.1016/S1097-2765(00)80253-1; Spector DL, 1996, EXP CELL RES, V229, P189, DOI 10.1006/excr.1996.0358; Spilianakis C, 2000, MOL CELL BIOL, V20, P8489, DOI 10.1128/MCB.20.22.8489-8498.2000; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Tani M, 2004, GENE CHROMOSOME CANC, V40, P146, DOI 10.1002/gcc.20027; Tomita A, 2000, ONCOGENE, V19, P444, DOI 10.1038/sj.onc.1203329; Tong X, 2004, BIOCHEM BIOPH RES CO, V317, P463, DOI 10.1016/j.bbrc.2004.03.066; VONLINDERN M, 1992, MOL CELL BIOL, V12, P1687, DOI 10.1128/MCB.12.4.1687; Waldmann T, 2003, NUCLEIC ACIDS RES, V31, P7003, DOI 10.1093/nar/gkg864; Waldmann T, 2002, J BIOL CHEM, V277, P24988, DOI 10.1074/jbc.M204045200; WEEKS KM, 1992, BIOCHEMISTRY-US, V31, P10281, DOI 10.1021/bi00157a015; Zhou ZL, 2002, NATURE, V419, P182, DOI 10.1038/nature01031; Zirwes RF, 1997, MOL BIOL CELL, V8, P231, DOI 10.1091/mbc.8.2.231	71	48	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	2005	280	36					31760	31767		10.1074/jbc.M500884200	http://dx.doi.org/10.1074/jbc.M500884200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	961LZ	15987677	hybrid			2022-12-25	WOS:000231665200054
J	Hogestatt, ED; Jonsson, BAG; Ermund, A; Andersson, DA; Bjork, H; Alexander, JP; Cravatt, BF; Basbaum, AI; Zygmunt, PM				Hogestatt, ED; Jonsson, BAG; Ermund, A; Andersson, DA; Bjork, H; Alexander, JP; Cravatt, BF; Basbaum, AI; Zygmunt, PM			Conversion of acetaminophen to the bioactive N-acylphenolamine AM404 via fatty acid amide hydrolase-dependent arachidonic acid conjugation in the nervous system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VANILLOID RECEPTOR; CANNABINOID-RECEPTOR; IN-VIVO; ANANDAMIDE TRANSPORT; CAPSAICIN; VR1; PARACETAMOL; INHIBITION; PAIN; RAT	Acetaminophen ( paracetamol) is a popular domestic analgesic and antipyretic agent with a weak anti-inflammatory action and a low incidence of adverse effects as compared with aspirin and other non-steroidal anti-inflammatory drugs. Here we show that acetaminophen, following deacetylation to its primary amine, is conjugated with arachidonic acid in the brain and the spinal cord to form the potent TRPV1 agonist N-arachidonoyl-phenolamine (AM404). This conjugation is absent in mice lacking the enzyme fatty acid amide hydrolase. AM404 also inhibits purified cyclooxygenase (COX)-1 and COX-2 and prostaglandin synthesis in lipopolysaccharide-stimulated RAW264.7 macrophages. This novel metabolite of acetaminophen also acts on the endogenous cannabinoid system, which, together with TRPV1 and COX, is present in the pain and thermoregulatory pathways. These findings identify fatty acid conjugation as a novel pathway for drug metabolism and provide a molecular mechanism for the occurrence of the analgesic N-acylphenolamine AM404 in the nervous system following treatment with acetaminophen.	Lund Univ, Div Clin Chem, SE-22185 Lund, Sweden; Lund Univ, Div Pharmacol, SE-22185 Lund, Sweden; Lund Univ, Div Occupat & Environm Med & Psychiat Epidemiol, SE-22185 Lund, Sweden; Scripps Res Inst, Skaggs Inst Chem Biol, Dept Cell Biol & Chem, La Jolla, CA 92037 USA; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA	Lund University; Lund University; Lund University; Scripps Research Institute; University of California System; University of California San Francisco	Zygmunt, PM (corresponding author), Lund Univ, Div Clin Chem, SE-22185 Lund, Sweden.	peter.zygmunt@med.lu.se	Ermund, Anna/AAG-3160-2020; Andersson, David A/C-3435-2008	Andersson, David A/0000-0001-7451-8548; Zygmunt, Peter/0000-0002-5102-8199; Ermund, Anna/0000-0002-3233-043X; Jonsson, Bo/0000-0002-8767-0589	NIDCR NIH HHS [DE08377] Funding Source: Medline	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Abbott FV, 2000, BEHAV BRAIN RES, V112, P177, DOI 10.1016/S0166-4328(00)00179-0; Bae YC, 2004, J COMP NEUROL, V478, P62, DOI 10.1002/cne.20272; Beltramo M, 1997, SCIENCE, V277, P1094, DOI 10.1126/science.277.5329.1094; Bisogno T, 2000, BIOCHEM J, V351, P817, DOI 10.1042/0264-6021:3510817; Boutaud O, 2002, P NATL ACAD SCI USA, V99, P7130, DOI 10.1073/pnas.102588199; Burstein SH, 2000, PROSTAG OTH LIPID M, V61, P29, DOI 10.1016/S0090-6980(00)00053-8; CLISSOLD SP, 1986, DRUGS, V32, P46, DOI 10.2165/00003495-198600324-00005; Cravatt BF, 1996, NATURE, V384, P83, DOI 10.1038/384083a0; Cravatt BF, 2001, P NATL ACAD SCI USA, V98, P9371, DOI 10.1073/pnas.161191698; De Petrocellis L, 2000, FEBS LETT, V483, P52, DOI 10.1016/S0014-5793(00)02082-2; DEUTSCH DG, 1993, BIOCHEM PHARMACOL, V46, P791, DOI 10.1016/0006-2952(93)90486-G; Deutsch DG, 2002, PROSTAG LEUKOTR ESS, V66, P201, DOI 10.1054/plef.2001.0358; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Egertova M, 2003, NEUROSCIENCE, V119, P481, DOI 10.1016/S0306-4522(03)00145-3; Fegley D, 2004, P NATL ACAD SCI USA, V101, P8756, DOI 10.1073/pnas.0400997101; FERREIRA SH, 1978, EUR J PHARMACOL, V53, P39, DOI 10.1016/0014-2999(78)90265-0; FLOWER RJ, 1972, NATURE, V240, P410, DOI 10.1038/240410a0; Fowler CJ, 1997, PHARMACOL TOXICOL, V80, P103, DOI 10.1111/j.1600-0773.1997.tb00291.x; Garcia-Martinez C, 2002, P NATL ACAD SCI USA, V99, P2374, DOI 10.1073/pnas.022285899; GREEN K, 1989, PROSTAG OTH LIPID M, V37, P311, DOI 10.1016/0090-6980(89)90001-4; Guhring H, 2002, EUR J PHARMACOL, V454, P153, DOI 10.1016/S0014-2999(02)02485-8; HANEL AM, 1982, BIOCHEM PHARMACOL, V31, P3307, DOI 10.1016/0006-2952(82)90565-2; Hardman J.G., 1996, GOODMAN GILSMANS PHA, P617; Huang SM, 2001, J BIOL CHEM, V276, P42639, DOI 10.1074/jbc.M107351200; Huang SM, 2002, P NATL ACAD SCI USA, V99, P8400, DOI 10.1073/pnas.122196999; HUNSKAAR S, 1987, PAIN, V30, P103, DOI 10.1016/0304-3959(87)90088-1; JANUSZ JM, 1993, J MED CHEM, V36, P2595, DOI 10.1021/jm00070a002; Kalgutkar AS, 2000, P NATL ACAD SCI USA, V97, P925, DOI 10.1073/pnas.97.2.925; Karai L, 2004, J CLIN INVEST, V113, P1344, DOI 10.1172/JCI200420449; Melck D, 1999, BIOCHEM BIOPH RES CO, V262, P275, DOI 10.1006/bbrc.1999.1105; Mezey E, 2000, P NATL ACAD SCI USA, V97, P3655, DOI 10.1073/pnas.060496197; Morisset V, 2001, EUR J PHARMACOL, V429, P93, DOI 10.1016/S0014-2999(01)01309-7; NEWTON JF, 1982, TOXICOL APPL PHARM, V65, P336, DOI 10.1016/0041-008X(82)90017-5; OBRIEN WF, 1993, AM J OBSTET GYNECOL, V168, P1164, DOI 10.1016/0002-9378(93)90362-M; Ouellet M, 2001, ARCH BIOCHEM BIOPHYS, V387, P273, DOI 10.1006/abbi.2000.2232; Patricelli MP, 1998, BIOCHEMISTRY-US, V37, P15177, DOI 10.1021/bi981733n; Pelissier T, 1996, J PHARMACOL EXP THER, V278, P8; Piomelli D, 1999, P NATL ACAD SCI USA, V96, P5802, DOI 10.1073/pnas.96.10.5802; Piomelli D, 2000, TRENDS PHARMACOL SCI, V21, P218, DOI 10.1016/S0165-6147(00)01482-6; Pomonis JD, 2003, J PHARMACOL EXP THER, V306, P387, DOI 10.1124/jpet.102.046268; Price TJ, 2005, NEUROPHARMACOLOGY, V49, P25, DOI 10.1016/j.neuropharm.2005.01.031; Rodella LF, 2005, EUR J PHARMACOL, V508, P139, DOI 10.1016/j.ejphar.2004.12.031; Simmons DL, 2004, PHARMACOL REV, V56, P387, DOI 10.1124/pr.56.3.3; Suh YG, 2003, BIOORG MED CHEM LETT, V13, P4389, DOI 10.1016/j.bmcl.2003.09.024; Szallasi A, 2000, TRENDS NEUROSCI, V23, P491, DOI 10.1016/S0166-2236(00)01630-1; Szallasi A, 1999, PHARMACOL REV, V51, P159; Urban L, 2000, PAIN, V89, P65, DOI 10.1016/S0304-3959(00)00349-3; Vaz ZR, 1996, J PHARMACOL EXP THER, V278, P304; Wahl P, 2001, MOL PHARMACOL, V59, P9, DOI 10.1124/mol.59.1.9; Werner MU, 2002, EPIDEMIOLOGY, V13, P605, DOI 10.1097/00001648-200209000-00023; Zygmunt PM, 2000, EUR J PHARMACOL, V396, P39, DOI 10.1016/S0014-2999(00)00207-7; Zygmunt PM, 1999, NATURE, V400, P452, DOI 10.1038/22761	52	300	311	0	33	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	2005	280	36					31405	31412		10.1074/jbc.M501489200	http://dx.doi.org/10.1074/jbc.M501489200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	961LZ	15987694	hybrid			2022-12-25	WOS:000231665200010
J	Liang, L; Deng, L; Chen, YP; Li, GC; Shao, CS; Tischfield, JA				Liang, L; Deng, L; Chen, YP; Li, GC; Shao, CS; Tischfield, JA			Modulation of DNA end joining by nuclear proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAK; IN-VITRO; HOMOLOGOUS RECOMBINATION; KU80-DEFICIENT CELLS; MAMMALIAN-CELLS; REPAIR PROTEINS; BACKUP PATHWAYS; ERROR-PRONE; LIGASE-IV; KU	DNA double strand breaks in mammalian cells are primarily repaired by homologous recombination and non-homologous end joining (NHEJ). NHEJ may either be error-free or mutagenic with deletions or insertions at the joint. Recent studies showed that DNA ends can also be joined via microhomologous sequences flanking the break point especially when proteins responsible for NHEJ, such as Ku, are absent. Microhomology-mediated end joining (MHEJ) is always accompanied by a deletion that spans one of the two homologous sequences and the intervening sequence, if any. In this study we evaluated several factors affecting the relative contribution of MHEJ to DNA end joining using nuclear extracts and DNA substrates containing 10-bp repeats at the ends. We found that the occurrence of MHEJ is determined by the relative abundance of nuclear proteins. At low DNA/protein ratios, an error-free end-joining mechanism predominated over MHEJ. As the DNA/protein ratio increased, MHEJ became predominant. We show that the nuclear proteins that contribute to the inhibition of the error-prone MHEJ include Ku and histone H1. Treatment of extracts with flap endonuclease 1 antiserum significantly reduced MHEJ. Addition of a 17-bp intervening sequence between the microhomologous sequences significantly reduced the efficiency of MHEJ. Thus, this cell-free assay provides a platform for evaluating factors modulating end joining.	State Univ New Jersey, Nelson Biol Labs, Dept Genet, Piscataway, NJ 08854 USA; Mem Sloan Kettering Canc Ctr, Dept Med Phys, Dept Radiat Onocl, New York, NY 10021 USA	Rutgers State University New Brunswick; Memorial Sloan Kettering Cancer Center	Liang, L (corresponding author), State Univ New Jersey, Nelson Biol Labs, Dept Genet, 604 Allison Rd,Rm B211, Piscataway, NJ 08854 USA.	liang@biology.rutgers.edu	Shao, Changshun/AAD-8977-2022	Shao, Changshun/0000-0003-2618-9342; Tischfield, Jay/0000-0003-3217-8287	NCI NIH HHS [CA 78497, CA 56909] Funding Source: Medline; NIEHS NIH HHS [ES011633] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056909, R01CA078497] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES011633] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bentley J, 2004, NUCLEIC ACIDS RES, V32, P5249, DOI 10.1093/nar/gkh842; Blanco MG, 2004, J BIOL CHEM, V279, P26797, DOI 10.1074/jbc.M402832200; Boulton SJ, 1996, NUCLEIC ACIDS RES, V24, P4639, DOI 10.1093/nar/24.23.4639; Boulton SJ, 1996, EMBO J, V15, P5093, DOI 10.1002/j.1460-2075.1996.tb00890.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown DT, 2003, BIOCHEM CELL BIOL, V81, P221, DOI 10.1139/o03-049; Chen C, 1999, NAT GENET, V23, P81, DOI 10.1038/12687; Chen S, 2001, J BIOL CHEM, V276, P24323, DOI 10.1074/jbc.M010544200; Dibiase SJ, 2000, CANCER RES, V60, P1245; Difilippantonio MJ, 2000, NATURE, V404, P510, DOI 10.1038/35006670; Downs JA, 2004, NAT REV MOL CELL BIO, V5, P367, DOI 10.1038/nrm1367; Feldmann E, 2000, NUCLEIC ACIDS RES, V28, P2585, DOI 10.1093/nar/28.13.2585; Gottlich B, 1998, EUR J BIOCHEM, V258, P387, DOI 10.1046/j.1432-1327.1998.2580387.x; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; Jackson SP, 2002, CARCINOGENESIS, V23, P687, DOI 10.1093/carcin/23.5.687; JESSBERGER R, 1991, MOL CELL BIOL, V11, P445, DOI 10.1128/MCB.11.1.445; Kabotyanski EB, 1998, NUCLEIC ACIDS RES, V26, P5333, DOI 10.1093/nar/26.23.5333; Liang F, 1996, J BIOL CHEM, V271, P14405, DOI 10.1074/jbc.271.24.14405; Lieber MR, 2003, NAT REV MOL CELL BIO, V4, P712, DOI 10.1038/nrm1202; Liu Y, 2004, ANNU REV BIOCHEM, V73, P589, DOI 10.1146/annurev.biochem.73.012803.092453; MILES C, 1989, MUTAT RES, V227, P97, DOI 10.1016/0165-7992(89)90004-3; MORRIS T, 1993, P NATL ACAD SCI USA, V90, P1392, DOI 10.1073/pnas.90.4.1392; Nagaki S, 1998, BIOCHEM BIOPH RES CO, V246, P137, DOI 10.1006/bbrc.1998.8589; Ouyang H, 1997, J EXP MED, V186, P921, DOI 10.1084/jem.186.6.921; Perrault R, 2004, J CELL BIOCHEM, V92, P781, DOI 10.1002/jcb.20104; Prasad R, 2000, J BIOL CHEM, V275, P4460, DOI 10.1074/jbc.275.6.4460; Shao C, 1996, CYTOGENET CELL GENET, V75, P216, DOI 10.1159/000134486; Shao CS, 1999, P NATL ACAD SCI USA, V96, P9230, DOI 10.1073/pnas.96.16.9230; Smith J, 2003, NUCLEIC ACIDS RES, V31, P2157, DOI 10.1093/nar/gkg317; Stark JM, 2004, MOL CELL BIOL, V24, P9305, DOI 10.1128/MCB.24.21.9305-9316.2004; Sugawara N, 2004, P NATL ACAD SCI USA, V101, P9315, DOI 10.1073/pnas.0305749101; Sugawara N, 1997, P NATL ACAD SCI USA, V94, P9214, DOI 10.1073/pnas.94.17.9214; Sugawara N, 2000, MOL CELL BIOL, V20, P5300, DOI 10.1128/MCB.20.14.5300-5309.2000; Tauchi H, 2002, NATURE, V420, P93, DOI 10.1038/nature01125; Tseng HM, 2004, J BIOL CHEM, V279, P47580, DOI 10.1074/jbc.M404492200; Verkaik NS, 2002, EUR J IMMUNOL, V32, P701, DOI 10.1002/1521-4141(200203)32:3<701::AID-IMMU701>3.0.CO;2-T; Walker JR, 2001, NATURE, V412, P607, DOI 10.1038/35088000; Wang HC, 2001, NUCLEIC ACIDS RES, V29, P1653, DOI 10.1093/nar/29.8.1653; Wang HC, 2003, NUCLEIC ACIDS RES, V31, P5377, DOI 10.1093/nar/gkg728; Wilson TE, 1999, J BIOL CHEM, V274, P23599, DOI 10.1074/jbc.274.33.23599; Wu XT, 1999, P NATL ACAD SCI USA, V96, P1303, DOI 10.1073/pnas.96.4.1303; Yamanaka S, 2002, BIOCHEM BIOPH RES CO, V292, P268, DOI 10.1006/bbrc.2002.6647; Zhu CM, 2002, CELL, V109, P811, DOI 10.1016/S0092-8674(02)00770-5	43	51	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	2005	280	36					31442	31449		10.1074/jbc.M503776200	http://dx.doi.org/10.1074/jbc.M503776200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	961LZ	16012167	hybrid			2022-12-25	WOS:000231665200015
J	Onodera, J; Ohsumi, Y				Onodera, J; Ohsumi, Y			Autophagy is required for maintenance of amino acid levels and protein synthesis under nitrogen starvation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; DEFICIENT MUTANTS; YEAST-CELLS; MACROAUTOPHAGY; SPORULATION; DEGRADATION; MACHINERY; DELIVERY; VACUOLAR; MEIOSIS	Autophagy is a transport system of cytoplasmic components to the lysosome/vacuole for degradation well conserved in eukaryotes. Autophagy is strongly induced by nutrient starvation. Several specific proteins, including amino acid synthesis enzymes and vacuolar enzymes, are increased during nitrogen starvation in wildtype cells but not in autophagy-defective Delta atg7 cells despite similar mRNA levels. We further examined deficiencies in these cells. Bulk protein synthesis was substantially reduced in Delta atg7 cells under nitrogen starvation compared with wild-type cells. The total intracellular amino acid pool was reduced in Delta atg7 cells, and the levels of several amino acids fell below critical values. In contrast, wild-type cells maintained amino acid levels compatible with life. Autophagy-defective cells fail to maintain physiologic amino acid levels, and their inability to synthesize new proteins may explain most phenotypes associated with autophagy mutants at least partly.	Grad Univ Adv Studies, Div Mol Cell Biol, Natl Inst Basic Biol, Okazaki, Aichi 4448585, Japan; Grad Univ Adv Studies, Sch Life Sci, Dept Basic Biol, Okazaki, Aichi 4448585, Japan	Graduate University for Advanced Studies - Japan; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Graduate University for Advanced Studies - Japan	Ohsumi, Y (corresponding author), Grad Univ Adv Studies, Div Mol Cell Biol, Natl Inst Basic Biol, Nishigonaka 38, Okazaki, Aichi 4448585, Japan.	yohsumi@nibb.ac.jp	Ohsumi, Yoshinori/C-6449-2009	Ohsumi, Yoshinori/0000-0003-2384-2166				BABA M, 1994, J CELL BIOL, V124, P903, DOI 10.1083/jcb.124.6.903; Burke D, 2000, METHOD YEAST GENETIC; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Grabowska D, 2003, J BIOL CHEM, V278, P13984, DOI 10.1074/jbc.M210076200; Hamasaki M, 2005, TRAFFIC, V6, P56, DOI 10.1111/j.1600-0854.2004.00245.x; Hamasaki M, 2003, CELL STRUCT FUNCT, V28, P49; Kirisako T, 1999, J CELL BIOL, V147, P435, DOI 10.1083/jcb.147.2.435; KITAMOTO K, 1988, J BACTERIOL, V170, P2683, DOI 10.1128/jb.170.6.2683-2686.1988; Klionsky DJ, 2005, J CELL SCI, V118, P7, DOI 10.1242/jcs.01620; Komatsu M, 2005, J CELL BIOL, V169, P425, DOI 10.1083/jcb.200412022; Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029; Kupiec Martin, 1997, P889; Kuroda A, 2001, SCIENCE, V293, P705, DOI 10.1126/science.1061315; Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1; Melendez A, 2003, SCIENCE, V301, P1387, DOI 10.1126/science.1087782; NODA T, 1995, BIOCHEM BIOPH RES CO, V210, P126, DOI 10.1006/bbrc.1995.1636; OHSUMI Y, 1988, J BACTERIOL, V170, P2676, DOI 10.1128/jb.170.6.2676-2682.1988; Onodera J, 2004, J BIOL CHEM, V279, P16071, DOI 10.1074/jbc.M312706200; Otto GP, 2004, J BIOL CHEM, V279, P15621, DOI 10.1074/jbc.M311139200; Otto GP, 2003, J BIOL CHEM, V278, P17636, DOI 10.1074/jbc.M212467200; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Scott RC, 2004, DEV CELL, V7, P167, DOI 10.1016/j.devcel.2004.07.009; Scott SV, 1996, P NATL ACAD SCI USA, V93, P12304, DOI 10.1073/pnas.93.22.12304; SEGLEN PO, 1987, LYSOSOMES THEIR ROLE, P371; SIKORSKI RS, 1989, GENETICS, V122, P19; TAKESHIGE K, 1992, J CELL BIOL, V119, P301, DOI 10.1083/jcb.119.2.301; Thomas D, 1997, MICROBIOL MOL BIOL R, V61, P503, DOI 10.1128/.61.4.503-532.1997; TSUKADA M, 1993, FEBS LETT, V333, P169, DOI 10.1016/0014-5793(93)80398-E; ZUBENKO GS, 1981, GENETICS, V97, P45	30	326	337	0	48	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	2005	280	36					31582	31586		10.1074/jbc.M506736200	http://dx.doi.org/10.1074/jbc.M506736200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	961LZ	16027116	hybrid			2022-12-25	WOS:000231665200031
J	Tretyakova, I; Zolotukhin, AS; Tan, W; Bear, J; Propst, F; Ruthel, G; Felber, BK				Tretyakova, I; Zolotukhin, AS; Tan, W; Bear, J; Propst, F; Ruthel, G; Felber, BK			Nuclear export factor family protein participates in cytoplasmic mRNA trafficking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUGH ENDOPLASMIC-RETICULUM; CONTAINING RIBONUCLEOPROTEIN-PARTICLES; HUMAN-IMMUNODEFICIENCY-VIRUS; PERIPHERAL NERVOUS-SYSTEM; GREEN FLUORESCENT PROTEIN; BINDING PROTEIN; MOLECULAR-CLONING; HIPPOCAMPAL-NEURONS; MAMMALIAN STAUFEN; PORE COMPLEX	In eukaryotes, the nuclear export of mRNA is mediated by nuclear export factor 1 (NXF1) receptors. Metazoans encode additional NXF1-related proteins of unknown function, which share homology and domain organization with NXF1. Some mammalian NXF1-related genes are expressed preferentially in the brain and are thought to participate in neuronal mRNA metabolism. To address the roles of NXF1-related factors, we studied the two mouse NXF1 homologues, mNXF2 and mNXF7. In neuronal cells, mNXF2, but not mNXF7, exhibited mRNA export activity similar to that of Tip-associated protein/NXF1. Surprisingly, mNXF7 incorporated into mobile particles in the neurites that contained poly(A) and ribosomal RNA and colocalized with Staufen1-containing transport granules, indicating a role in neuronal mRNA trafficking. Yeast two-hybrid interaction, coimmunoprecipitation, and in vitro binding studies showed that NXF proteins bound to brain-specific microtubule-associated proteins (MAP) such as MAP1B and the WD repeat protein Unrip. Both in vitro and in vivo, MAP1B also bound to NXF export cofactor U2AF as well as to Staufen1 and Unrip. These findings revealed a network of interactions likely coupling the export and cytoplasmic trafficking of mRNA. We propose a model in which MAP1B tethers the NXF-associated mRNA to microtubules and facilitates their translocation along dendrites while Unrip provides a scaffold for the assembly of these transport intermediates.	NCI, Human Retrovirus Pathogenesis Sect, Vaccine Branch, Ctr Canc Res,NIH, Frederick, MD 21702 USA; Univ Vienna, Vienna Bioctr, Inst Biochem & Mol Cell Biol, A-1030 Vienna, Austria; Goldbelt Raven LLC, Ft Detrick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Vienna; Vienna Biocenter (VBC)	Felber, BK (corresponding author), NCI, Human Retrovirus Pathogenesis Sect, Vaccine Branch, Ctr Canc Res,NIH, Bldg 535,Rm 209, Frederick, MD 21702 USA.	felber@mail.ncifcrf.gov	Ruthel, Gordon/GYU-9133-2022	Ruthel, Gordon/0000-0001-9193-5589	NATIONAL CANCER INSTITUTE [ZIABC010334, Z01BC010334] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AINGER K, 1993, J CELL BIOL, V123, P431, DOI 10.1083/jcb.123.2.431; Barbarese E, 1999, J NEUROCYTOL, V28, P263, DOI 10.1023/A:1007097226688; BARBARESE E, 1995, J CELL SCI, V108, P2781; Bear J, 1999, MOL CELL BIOL, V19, P6306; Braun IC, 2001, J BIOL CHEM, V276, P20536, DOI 10.1074/jbc.M100400200; Carson J H, 2001, Results Probl Cell Differ, V34, P69; Carson JH, 2001, CURR OPIN NEUROBIOL, V11, P558, DOI 10.1016/S0959-4388(00)00249-X; Datta PK, 2000, MOL CELL BIOL, V20, P3157, DOI 10.1128/MCB.20.9.3157-3167.2000; Datta PK, 1998, J BIOL CHEM, V273, P34671, DOI 10.1074/jbc.273.52.34671; Dreyfuss G, 2002, NAT REV MOL CELL BIO, V3, P195, DOI 10.1038/nrm760; Forler D, 2004, MOL CELL BIOL, V24, P1155, DOI 10.1128/MCB.24.3.1155-1167.2004; GARNER CC, 1990, J NEUROCHEM, V55, P146, DOI 10.1111/j.1471-4159.1990.tb08832.x; Gonzalez-Billault C, 2004, J NEUROBIOL, V58, P48, DOI 10.1002/neu.10283; Grosset C, 2000, CELL, V103, P29, DOI 10.1016/S0092-8674(00)00102-1; Guzik BW, 2001, MOL CELL BIOL, V21, P2545, DOI 10.1128/MCB.21.7.2545-2554.2001; Hachet O, 2004, NATURE, V428, P959, DOI 10.1038/nature02521; Heidemann SR, 2003, METHOD CELL BIOL, V71, P51, DOI 10.1016/S0091-679X(03)01004-5; Herold A, 2001, RNA, V7, P1768; Herold A, 2000, MOL CELL BIOL, V20, P8996, DOI 10.1128/MCB.20.23.8996-9008.2000; HUANG XJ, 1991, J VIROL, V65, P2131, DOI 10.1128/JVI.65.4.2131-2134.1991; Huang YQ, 2004, P NATL ACAD SCI USA, V101, P9666, DOI 10.1073/pnas.0403533101; Huang YQ, 2001, MOL CELL, V7, P899, DOI 10.1016/S1097-2765(01)00233-7; Hunt SL, 1999, GENE DEV, V13, P437, DOI 10.1101/gad.13.4.437; Izaurralde E, 2004, NAT STRUCT MOL BIOL, V11, P210, DOI 10.1038/nsmb0304-210; Izaurralde Elisa, 2002, Results Probl Cell Differ, V35, P133; Jin L, 2003, GENE DEV, V17, P3075, DOI 10.1101/gad.1155703; Job C, 2001, NAT REV NEUROSCI, V2, P889, DOI 10.1038/35104069; Jun L, 2001, CURR BIOL, V11, P1381, DOI 10.1016/S0960-9822(01)00419-5; Kanai Y, 2004, NEURON, V43, P513, DOI 10.1016/j.neuron.2004.07.022; Kataoka N, 2001, EMBO J, V20, P6424, DOI 10.1093/emboj/20.22.6424; Kataoka N, 2000, MOL CELL, V6, P673, DOI 10.1016/S1097-2765(00)00065-4; Kiebler MA, 1999, J NEUROSCI, V19, P288, DOI 10.1523/JNEUROSCI.19-01-00288.1999; Knowles RB, 1996, J NEUROSCI, V16, P7812; Kohrmann M, 1999, MOL BIOL CELL, V10, P2945, DOI 10.1091/mbc.10.9.2945; KOSIK KS, 2002, SCI STKE, pPE16; Krichevsky AM, 2001, NEURON, V32, P683, DOI 10.1016/S0896-6273(01)00508-6; Kuersten S, 2004, MOL CELL, V14, P599, DOI 10.1016/j.molcel.2004.05.004; Lai MC, 2004, J BIOL CHEM, V279, P31745, DOI 10.1074/jbc.C400173200; Levesque L, 2001, J BIOL CHEM, V276, P44953, DOI 10.1074/jbc.M106558200; Macchi P, 2003, J NEUROSCI, V23, P5778; Macchi P, 2003, MOL BIOL CELL, V14, P1570, DOI 10.1091/mbc.E02-08-0505; Mallardo M, 2003, P NATL ACAD SCI USA, V100, P2100, DOI 10.1073/pnas.0334355100; Marion RM, 1999, MOL CELL BIOL, V19, P2212; Martinez CY, 2003, METHOD CELL BIOL, V71, P339, DOI 10.1016/S0091-679X(03)01016-1; Matsuda S, 2000, CANCER RES, V60, P13; MCDONALD D, 1992, J VIROL, V66, P7232, DOI 10.1128/JVI.66.12.7232-7238.1992; Mei X, 2000, BRAIN RES BULL, V53, P801, DOI 10.1016/S0361-9230(00)00416-0; Meixner A, 2000, J CELL BIOL, V151, P1169, DOI 10.1083/jcb.151.6.1169; Monshausen M, 2004, NEUROMOL MED, V6, P127, DOI 10.1385/NMM:6:2-3:127; Muslimov IA, 1997, J NEUROSCI, V17, P4722; Noiges R, 2002, J NEUROSCI, V22, P2106, DOI 10.1523/JNEUROSCI.22-06-02106.2002; Ohashi S, 2002, J BIOL CHEM, V277, P37804, DOI 10.1074/jbc.M203608200; Opal P, 2003, J BIOL CHEM, V278, P34691, DOI 10.1074/jbc.M302785200; Palacios IM, 2004, NATURE, V427, P753, DOI 10.1038/nature02351; Roegiers F, 2000, TRENDS CELL BIOL, V10, P220, DOI 10.1016/S0962-8924(00)01767-0; Sasaki M, 2005, GENOMICS, V85, P641, DOI 10.1016/j.ygeno.2005.01.003; Smith R, 2004, NEUROSCIENTIST, V10, P495, DOI 10.1177/1073858404266759; Smith TF, 1999, TRENDS BIOCHEM SCI, V24, P181, DOI 10.1016/S0968-0004(99)01384-5; Snee M, 2002, J CELL SCI, V115, P4661, DOI 10.1242/jcs.00137; Stauber RH, 1998, BIOTECHNIQUES, V24, P462, DOI 10.2144/98243rr01; Strasser K, 2000, EMBO J, V19, P410, DOI 10.1093/emboj/19.3.410; Stutz F, 2000, RNA, V6, P638, DOI 10.1017/S1355838200000078; Tan W, 2005, NUCLEIC ACIDS RES, V33, P3855, DOI 10.1093/nar/gki706; Tan W, 2000, RNA, V6, P1762, DOI 10.1017/S1355838200000832; Tang SJ, 2001, NEURON, V32, P463, DOI 10.1016/S0896-6273(01)00493-7; Togel M, 1998, J CELL BIOL, V143, P695, DOI 10.1083/jcb.143.3.695; Villace P, 2004, NUCLEIC ACIDS RES, V32, P2411, DOI 10.1093/nar/gkh552; Vinciguerra P, 2004, CURR OPIN CELL BIOL, V16, P285, DOI 10.1016/j.ceb.2004.03.013; Wickham L, 1999, MOL CELL BIOL, V19, P2220; Zolotukhin AS, 2002, J BIOL CHEM, V277, P3935, DOI 10.1074/jbc.M107598200	70	42	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	2005	280	36					31981	31990		10.1074/jbc.M502736200	http://dx.doi.org/10.1074/jbc.M502736200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	961LZ	16014633	hybrid			2022-12-25	WOS:000231665200078
J	Andrianifahanana, M; Agrawal, A; Singh, AP; Moniaux, N; van Seuningen, I; Aubert, JP; Meza, J; Batra, SK				Andrianifahanana, M; Agrawal, A; Singh, AP; Moniaux, N; van Seuningen, I; Aubert, JP; Meza, J; Batra, SK			Synergistic induction of the MUC4 mucin gene by interferon-gamma and retinoic acid in human pancreatic tumour cells involves a reprogramming of signalling pathways	ONCOGENE			English	Article						MUC4 mucin; IFN gamma; retinoic acid; synergism; gene regulation; pancreatic cancer	MEMBRANE-ASSOCIATED MUCIN; SIALOMUCIN COMPLEX; CANCER-CELLS; MOLECULAR-CLONING; EPISIALIN MUC1; EXPRESSION; GROWTH; LINES; INHIBITION; RECEPTOR	The transmembrane mucin, MUC4, is aberrantly expressed with a high incidence in human pancreatic adenocarcinomas and plays an important role in the pathogenesis of the disease. Our recent studies have shown that interferon-gamma ( IFN gamma) and retinoic acid ( RA) are important regulators of MUC4 in pancreatic tumour cells. Induction of MUC4 by IFN gamma occurs via a novel pathway involving upregulation of the signal transducer and activator of transcription 1 ( STAT-1), whereas its stimulation by RA requires mediation by the transforming growth factor beta-2 ( TGF beta-2). In this study, we have investigated the molecular mechanisms underlying the interaction of IFN gamma and RA in MUC4 regulation in pancreatic tumour cells. We demonstrate that these reagents exert a synergistic induction of MUC4. Interestingly, while the upregulation of STAT-1 by IFN gamma is partially inhibited by RA, IFN gamma is shown to repress RA-driven TGFb-2 induction, pointing to the involvement of alternative mechanism( s) in IFN gamma-RA synergism. Moreover, a dose-dependent and cooperative induction of MUC4 promoter activity suggests a regulation at the transcriptional level, most likely by STAT-1 and RAR/RXR ( RA receptor/retinoic X receptor) or other IFN gamma/RA-induced secondary intermediate effectors. Our findings provide potential mechanisms that may account for the aberrant expression of MUC4 in pancreatic tumour cells and expose a novel molecular mechanism of gene induction, whereby a reprogramming of signalling pathway through alternative route(s) operates during a synergistic interaction of biological modifiers.	Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Prevent & Societal Med, Omaha, NE 68198 USA; INSERM, F-59045 Lille, France	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; Institut National de la Sante et de la Recherche Medicale (Inserm)	Batra, SK (corresponding author), Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Dept Biochem & Mol Biol, 600 S 42nd St, Omaha, NE 68198 USA.	sbatra@unmc.edu	VAN SEUNINGEN, Isabelle/N-6176-2016; Moniaux, Nicolas/Y-3243-2018; Singh, Ajay/AAF-4414-2020	VAN SEUNINGEN, Isabelle/0000-0002-3131-2694; Moniaux, Nicolas/0000-0001-9718-1386; Singh, Ajay/0000-0003-3492-6330	NCI NIH HHS [CA 78590] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078590] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andrianifahanana M, 2001, CLIN CANCER RES, V7, P4033; Andrianifahanana Mahefatiana, 2002, Proceedings of the American Association for Cancer Research Annual Meeting, V43, P607; Andrianifahanana Mahefatiana, 2002, Proceedings of the American Association for Cancer Research Annual Meeting, V43, P1135; Bach EA, 1997, ANNU REV IMMUNOL, V15, P563, DOI 10.1146/annurev.immunol.15.1.563; Chelbi-Alix MK, 1999, LEUKEMIA, V13, P1167, DOI 10.1038/sj.leu.2401469; Choudhury A, 2000, J BIOL CHEM, V275, P33929, DOI 10.1074/jbc.M005115200; Detjen KM, 2001, GUT, V49, P251, DOI 10.1136/gut.49.2.251; GENDLER SJ, 1995, ANNU REV PHYSIOL, V57, P607, DOI 10.1146/annurev.ph.57.030195.003135; Gianni M, 1997, BLOOD, V89, P1001, DOI 10.1182/blood.V89.3.1001; Guzhova I, 2001, INT J CANCER, V94, P97, DOI 10.1002/ijc.1443; Hara I, 2001, INT J ONCOL, V19, P959; HO CK, 1985, CANCER RES, V45, P5348; Hollingsworth MA, 2004, NAT REV CANCER, V4, P45, DOI 10.1038/nrc1251; Hu W, 2002, INT J GYNECOL CANCER, V12, P202, DOI 10.1046/j.1525-1438.2002.01084.x; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Jesnowski R, 2002, PANCREATOLOGY, V2, P421, DOI 10.1159/000065091; Kolla V, 1996, J BIOL CHEM, V271, P10508, DOI 10.1074/jbc.271.18.10508; Komatsu M, 1999, CANCER RES, V59, P2229; Komatsu M, 2000, INT J CANCER, V87, P480, DOI 10.1002/1097-0215(20000815)87:4<480::AID-IJC4>3.0.CO;2-6; Kondo K, 1998, CANCER RES, V58, P2014; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; MATSUBARA N, 1991, INT J PANCREATOL, V8, P235; Moniaux N, 2004, J HISTOCHEM CYTOCHEM, V52, P253, DOI 10.1177/002215540405200213; Moniaux N, 1999, BIOCHEM J, V338, P325, DOI 10.1042/0264-6021:3380325; Moniaux N, 2001, FRONT BIOSCI-LANDMRK, V6, pD1192, DOI 10.2741/Moniaux; Niitsu N, 2002, LEUKEMIA RES, V26, P745, DOI 10.1016/S0145-2126(01)00202-8; Park C, 1998, METHODS, V15, P175, DOI 10.1006/meth.1998.0622; Perrais M, 2001, J BIOL CHEM, V276, P30923, DOI 10.1074/jbc.M104204200; Ramana CV, 2002, TRENDS IMMUNOL, V23, P96, DOI 10.1016/S1471-4906(01)02118-4; Reber H, 1998, PANCREATIC CANC PATH; SHENG ZQ, 1992, J BIOL CHEM, V267, P16341; Singh AP, 2004, CANCER RES, V64, P622, DOI 10.1158/0008-5472.CAN-03-2636; Sirivatanauksorn V, 1998, LANGENBECK ARCH SURG, V383, P105, DOI 10.1007/s004230050101; Soto P, 2003, J BIOL CHEM, V278, P20338, DOI 10.1074/jbc.M301886200; Swartz MJ, 2002, AM J CLIN PATHOL, V117, P791; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; VANDEWIELVANKEMENADE E, 1993, J IMMUNOL, V151, P767; WARSHAW AL, 1992, NEW ENGL J MED, V326, P455, DOI 10.1056/NEJM199202133260706; Wesseling J, 1996, MOL BIOL CELL, V7, P565, DOI 10.1091/mbc.7.4.565; Widschwendter M, 1997, INT J CANCER, V71, P497; Windbichler GH, 1996, GYNECOL ONCOL, V61, P387, DOI 10.1006/gyno.1996.0162; WU K, 1994, J BIOL CHEM, V269, P11950; Yang JB, 2001, J BIOL CHEM, V276, P20989, DOI 10.1074/jbc.M011488200	43	37	39	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 8	2005	24	40					6143	6154		10.1038/sj.onc.1208756	http://dx.doi.org/10.1038/sj.onc.1208756			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	962GD	16007204				2022-12-25	WOS:000231718100008
J	Nagayama, S; Fukukawa, C; Katagiri, T; Okamoto, T; Aoyama, T; Oyaizu, N; Imamura, M; Toguchida, J; Nakamura, Y				Nagayama, S; Fukukawa, C; Katagiri, T; Okamoto, T; Aoyama, T; Oyaizu, N; Imamura, M; Toguchida, J; Nakamura, Y			Therapeutic potential of antibodies against FZD10, a cell-surface protein, for synovial sarcomas	ONCOGENE			English	Article						synovial sarcoma; antibody-based therapy; FZD10; ADCC; xenograft	SOFT-TISSUE SARCOMAS; FRIZZLED GENE FAMILY; EPITHELIAL TRANSFORMATION; METANEPHRIC MESENCHYME; DEVELOPING KIDNEY; CHEMOTHERAPY; DOXORUBICIN; IFOSFAMIDE; SSX; SYT	Genome-wide expression pro. ling revealed overexpression of the gene encoding frizzled homologue 10 (FZD10), a cell-surface receptor for molecules in the Wnt pathway, as a potential contributor to synovial sarcomas (SS). Northern blotting and immunohistochemical staining confirmed that expression levels of FZD10 were very high in nearly all SS tumors and cell lines examined but absent in most normal organs or in some cancers arising in other tissues. Treatment of human SS cells with small-interfering RNA ( siRNA) to FZD10 decreased the amount of its product and suppressed growth of SS cells. Moreover, a polyclonal antibody specifically recognizing the extracellular domain (ECD) of FZD10 was markedly effective in mediating ADCC against FZD10-overexpressing synovial sarcoma cells in vitro. Injection of the antibody into SS xenografts in nude mice attenuated tumor growth, and TUNEL assays revealed clusters of apoptotic cells in antibody-treated xenografts. Taken together, these findings suggest that a humanized antibody against FZD10 might be a promising treatment for patients with tumors that over-express FZD10; minimal or no adverse reactions would be expected because FZD10 protein is not abundant in vital organs.	Univ Tokyo, Mol Med Lab, Human Genome Ctr, Inst Med Sci, Tokyo 1088639, Japan; Kyoto Univ, Dept Surg & Surg Basic Sci, Grad Sch Med, Kyoto 6068507, Japan; Kyoto Univ, Inst Frontier Med Sci, Kyoto 6068507, Japan; Kyoto Univ, Dept Orthopaed Surg, Grad Sch Med, Kyoto 6068507, Japan; Univ Tokyo, Dept Lab Med, Div Pathol, Hosp Inst Med Sci, Tokyo 1088639, Japan	University of Tokyo; Kyoto University; Kyoto University; Kyoto University; University of Tokyo	Nakamura, Y (corresponding author), Univ Tokyo, Mol Med Lab, Human Genome Ctr, Inst Med Sci, Tokyo 1088639, Japan.	yusuke@ims.u-tokyo.ac.jp	Katagiri, Toyomasa/I-7344-2012					Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; ANTMAN K, 1993, J CLIN ONCOL, V11, P1276, DOI 10.1200/JCO.1993.11.7.1276; CLARK J, 1994, NAT GENET, V7, P502, DOI 10.1038/ng0894-502; Crist WM, 2001, J CLIN ONCOL, V19, P3091, DOI 10.1200/JCO.2001.19.12.3091; dos Santos NR, 2001, GENE CHROMOSOME CANC, V30, P1, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1056>3.0.CO;2-G; Edmonson JH, 2002, CANCER, V94, P786, DOI 10.1002/cncr.10259; FENDLY BM, 1990, CANCER RES, V50, P1550; Ferguson WS, 2001, CANCER INVEST, V19, P292, DOI 10.1081/CNV-100102557; Frustaci S, 2001, J CLIN ONCOL, V19, P1238, DOI 10.1200/JCO.2001.19.5.1238; Kaykas A, 2004, NAT CELL BIOL, V6, P52, DOI 10.1038/ncb1081; Kirikoshi H, 2001, INT J ONCOL, V19, P767; Kispert A, 1998, DEVELOPMENT, V125, P4225; Koike J, 1999, BIOCHEM BIOPH RES CO, V262, P39, DOI 10.1006/bbrc.1999.1161; Maloney DG, 1997, BLOOD, V90, P2188; Nagai M, 2001, P NATL ACAD SCI USA, V98, P3843, DOI 10.1073/pnas.061036798; Nagayama S, 2002, CANCER RES, V62, P5859; Patel SR, 1998, AM J CLIN ONCOL-CANC, V21, P317, DOI 10.1097/00000421-199806000-00025; Sato Y, 2002, J IMMUNOL, V169, P1611, DOI 10.4049/jimmunol.169.3.1611; STARK K, 1994, NATURE, V372, P679, DOI 10.1038/372679a0; Terasaki H, 2002, INT J MOL MED, V9, P107; van de Rijn M, 1999, AM J CLIN PATHOL, V112, P43; Worley BS, 2001, CANCER RES, V61, P6868; Wunder JS, 1998, J BONE JOINT SURG AM, V80A, P1020, DOI 10.2106/00004623-199807000-00011	23	97	116	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	41					6201	6212		10.1038/sj.onc.1208780	http://dx.doi.org/10.1038/sj.onc.1208780			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	964JM	16007199				2022-12-25	WOS:000231877100001
J	Murbartian, J; Lei, QB; Sando, JJ; Bayliss, DA				Murbartian, J; Lei, QB; Sando, JJ; Bayliss, DA			Sequential phosphorylation mediates receptor- and kinase-induced inhibition of TREK-1 background potassium channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; K+; EXPRESSION; FAMILY	Background potassium channels determine membrane potential and input resistance and serve as prominent effectors for modulatory regulation of cellular excitability. TREK-1 is a two-pore domain background K+ channel ( KCNK2, K2P2.1) that is sensitive to a variety of physicochemical and humoral factors. In this work, we used a recombinant expression system to show that activation of G alpha(q)-coupled receptors leads to inhibition of TREK-1 channels via protein kinase C ( PKC), and we identified a critical phosphorylation site in a key regulatory domain that mediates inhibition of the channel. In HEK 293 cells co-expressing TREK-1 and either the thyrotropin-releasing hormone receptor ( TRHR1) or the Orexin receptor ( Orx1R), agonist stimulation induced robust channel inhibition that was suppressed by a bisindolylmaleimide PKC inhibitor but not by a protein kinase A blocker (( R-p)cAMP-S). Channel inhibition by agonists or by direct activators of PKC ( phorbol dibutyrate) and PKA ( forskolin) was disrupted not only by alanine or aspartate mutations at an identified PKA site ( Ser-333) in the C terminus, but also at a more proximal regulatory site in the cytoplasmic C terminus ( Ser-300); S333A and S300A mutations enhanced basal TREK-1 current, whereas S333D and S300D substitutions mimicked phosphorylation and strongly diminished currents. When studied in combination, TREK-1 current density was enhanced in S300A/S333D but reduced in S300D/S333A mutant channels. Channel mutants were expressed and appropriately targeted to cell membranes. Together, these data support a sequential phosphorylation model in which receptor-induced kinase activation drives modification at Ser-333 that enables subsequent phosphorylation at Ser-300 to inhibit TREK- 1 channel activity.	Univ Virginia, Hlth Syst, Dept Pharmacol, Charlottesville, VA 22908 USA; Univ Virginia, Dept Anesthesiol, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Bayliss, DA (corresponding author), Univ Virginia, Hlth Syst, Dept Pharmacol, POB 800735,1300 Jefferson Pk Ave, Charlottesville, VA 22908 USA.	dab3y@virginia.edu		Murbartian, Janet/0000-0001-5776-1167	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033583, R29NS033583] Funding Source: NIH RePORTER; NINDS NIH HHS [NS33583, R01 NS033583] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Chemin J, 2003, EMBO J, V22, P5403, DOI 10.1093/emboj/cdg528; Chemin J, 2005, EMBO J, V24, P44, DOI 10.1038/sj.emboj.7600494; Du XO, 2004, J BIOL CHEM, V279, P37271, DOI 10.1074/jbc.M403413200; Fink M, 1996, EMBO J, V15, P6854, DOI 10.1002/j.1460-2075.1996.tb01077.x; Gershengorn MC, 1996, PHYSIOL REV, V76, P175, DOI 10.1152/physrev.1996.76.1.175; Goldstein SAN, 2001, NAT REV NEUROSCI, V2, P175, DOI 10.1038/35058574; Hervieu GJ, 2001, NEUROSCIENCE, V103, P899, DOI 10.1016/S0306-4522(01)00030-6; Heurteaux C, 2004, EMBO J, V23, P2684, DOI 10.1038/sj.emboj.7600234; Hilgemann D W, 2001, Sci STKE, V2001, pre19, DOI 10.1126/stke.2001.111.re19; Hille B., 2001, ION CHANNELS EXCITAB, V3rd Edn; Honore E, 2002, EMBO J, V21, P2968, DOI 10.1093/emboj/cdf288; KIM GD, 1994, J BIOL CHEM, V269, P19933; Koh SD, 2001, J BIOL CHEM, V276, P44338, DOI 10.1074/jbc.M108125200; Lesage F, 2000, AM J PHYSIOL-RENAL, V279, pF793, DOI 10.1152/ajprenal.2000.279.5.F793; Lopes CMB, 2005, J PHYSIOL-LONDON, V564, P117, DOI 10.1113/jphysiol.2004.081935; Maingret F, 2000, EMBO J, V19, P2483, DOI 10.1093/emboj/19.11.2483; Maingret F, 2002, BIOCHEM BIOPH RES CO, V292, P339, DOI 10.1006/bbrc.2002.6674; Maingret F, 2000, J BIOL CHEM, V275, P10128, DOI 10.1074/jbc.275.14.10128; Maingret F, 1999, J BIOL CHEM, V274, P26691, DOI 10.1074/jbc.274.38.26691; Patel AJ, 1999, NAT NEUROSCI, V2, P422, DOI 10.1038/8084; Patel AJ, 1998, EMBO J, V17, P4283, DOI 10.1093/emboj/17.15.4283; Patel AJ, 2001, TRENDS NEUROSCI, V24, P339, DOI 10.1016/S0166-2236(00)01810-5; Patel AJ, 2001, CURR OPIN CELL BIOL, V13, P422, DOI 10.1016/S0955-0674(00)00231-3; Sakurai T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6; Talley EM, 2003, NEUROSCIENTIST, V9, P46, DOI 10.1177/1073858402239590; Vinton BB, 1998, BIOCHEM J, V330, P1433, DOI 10.1042/bj3301433; Zeng WZ, 2003, J BIOL CHEM, V278, P16852, DOI 10.1074/jbc.M300619200	27	118	119	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	2005	280	34					30175	30184		10.1074/jbc.M503862200	http://dx.doi.org/10.1074/jbc.M503862200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	957IC	16006563	hybrid			2022-12-25	WOS:000231362500025
J	Ohnuma, M; Terui, Y; Tamakoshi, M; Mitome, H; Niitsu, M; Samejima, K; Kawashima, E; Oshima, T				Ohnuma, M; Terui, Y; Tamakoshi, M; Mitome, H; Niitsu, M; Samejima, K; Kawashima, E; Oshima, T			N-1-aminopropylagmatine, a new polyamine produced as a key intermediate in polyamine biosynthesis of an extreme thermophile, Thermus thermophilus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; LYSINE DECARBOXYLASE; SPERMIDINE SYNTHASE; CLONING; GENE; TEMPERATURE; PUTRESCINE; BINDING; ENZYME; SITE	In the extreme thermophile Thermus thermophilus, a disruption mutant of a gene homologous to speB ( coding for agmatinase = agmatine ureohydrolase) accumulated N-1-aminopropylagmatine (N-8-amidino-1,8-diamino-4-azaoctane, N-8-amidinospermidine), a new compound, whereas all other polyamines produced by the wild-type strain were absent from the cells. Double disruption of speB and speE ( polyamine aminopropyltransferase) resulted in the disappearance of N-1-aminopropylagmatine and the accumulation of agmatine. These results suggested the following. 1) N-1-Aminopropylagmatine is produced from agmatine by the action of an enzyme coded by speE. 2) N-1-Aminopropylagmatine is a metabolic intermediate in the biosynthesis of unique polyamines found in the thermophile. 3) N-1-Aminopropylagmatine is a substrate of the SpeB homolog. They further suggest a new biosynthetic pathway in T. thermophilus, by which polyamines are formed from agmatine via N-1-aminopropylagmatine. To confirm our speculation, we purified the expression product of the speB homolog and confirmed that the enzyme hydrolyzes N-1-aminopropylagmatine to spermidine but does not act on agmatine.	Tokyo Univ Pharm & Life Sci, Dept Mol Biol, Hachioji, Tokyo 1920392, Japan; Tokyo Univ Pharm & Life Sci, Sch Pharm, Hachioji, Tokyo 1920392, Japan; Josai Univ, Fac Pharmaceut Sci, Sakado, Saitama 5300248, Japan	Tokyo University of Pharmacy & Life Sciences; Tokyo University of Pharmacy & Life Sciences; Josai University	Oshima, T (corresponding author), Tokyo Univ Pharm & Life Sci, Dept Mol Biol, 1432-1 Horinouchi, Hachioji, Tokyo 1920392, Japan.	toshima@ls.toyaku.ac.jp						BANNARD RAB, 1958, CAN J CHEM, V36, P1541, DOI 10.1139/v58-225; Carvajal N, 1999, BIOCHEM BIOPH RES CO, V264, P196, DOI 10.1006/bbrc.1999.1505; Glockner FO, 2003, P NATL ACAD SCI USA, V100, P8298, DOI 10.1073/pnas.1431443100; Henne A, 2004, NAT BIOTECHNOL, V22, P547, DOI 10.1038/nbt956; Igarashi K, 2000, BIOCHEM BIOPH RES CO, V271, P559, DOI 10.1006/bbrc.2000.2601; JAKUS J, 1993, J BIOL CHEM, V268, P13151; KAKEGAWA T, 1988, ARCH BIOCHEM BIOPHYS, V261, P250, DOI 10.1016/0003-9861(88)90339-6; KIRINO H, 1990, J BIOCHEM-TOKYO, V107, P661; Korolev S, 2002, NAT STRUCT BIOL, V9, P27, DOI 10.1038/nsb737; KOYAMA Y, 1986, J BACTERIOL, V166, P338, DOI 10.1128/jb.166.1.338-340.1986; LAWSON WB, 1968, H-S Z PHYSIOL CHEM, V349, P251, DOI 10.1515/bchm2.1968.349.1.251; NIITSU M, 1993, J CHROMATOGR, V641, P115, DOI 10.1016/0021-9673(93)83465-5; Nureki O, 2002, ACTA CRYSTALLOGR D, V58, P1129, DOI 10.1107/S0907444902006601; OHNOIWASHITA Y, 1975, ARCH BIOCHEM BIOPHYS, V171, P490, DOI 10.1016/0003-9861(75)90058-2; OSHIMA T, 1983, METHOD ENZYMOL, V94, P401; OSHIMA T, 1989, PHYSL POLYAMINES, V2, P36; Pantazaki AA, 1999, MOL CELL BIOCHEM, V195, P55, DOI 10.1023/A:1006984618465; PARK MH, 1993, BIOFACTORS, V4, P95; Perozich J, 1998, BBA-PROTEIN STRUCT M, V1382, P23, DOI 10.1016/S0167-4838(97)00131-3; RAINA A, 1983, METHOD ENZYMOL, V94, P257; RAY PH, 1971, J BACTERIOL, V108, P227, DOI 10.1128/JB.108.1.227-235.1971; ROBIN Y, 1967, COMP BIOCHEM PHYSIOL, V22, P787, DOI 10.1016/0010-406X(67)90771-2; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TAKADA T, 1993, APPL ENVIRON MICROB, V59, P2737, DOI 10.1128/AEM.59.8.2737-2739.1993; Takatsuka Y, 2000, J BACTERIOL, V182, P6732, DOI 10.1128/JB.182.23.6732-6741.2000; Tamakoshi M, 1999, FEMS MICROBIOL LETT, V173, P431, DOI 10.1016/S0378-1097(99)00101-9; Tamakoshi M, 1997, J BACTERIOL, V179, P4811, DOI 10.1128/jb.179.15.4811-4814.1997; TANAKA T, 1981, J BIOCHEM-TOKYO, V89, P677, DOI 10.1093/oxfordjournals.jbchem.a133245; Terui Y, 2005, BIOCHEM J, V388, P427, DOI 10.1042/BJ20041778; UZAWA T, 1993, J BIOCHEM-TOKYO, V114, P478, DOI 10.1093/oxfordjournals.jbchem.a124203; WERTHEIMER SJ, 1983, BIOCHEM BIOPH RES CO, V114, P882, DOI 10.1016/0006-291X(83)90863-X; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZAPPIA V, 1977, ANAL BIOCHEM, V79, P535, DOI 10.1016/0003-2697(77)90427-4	33	52	56	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	2005	280	34					30073	30082		10.1074/jbc.M413332200	http://dx.doi.org/10.1074/jbc.M413332200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	957IC	15983049	hybrid			2022-12-25	WOS:000231362500012
J	Quezada, CM; Hamel, DJ; Gradinaru, C; Bilwes, AM; Dahlquist, FW; Crane, BR; Simon, MI				Quezada, CM; Hamel, DJ; Gradinaru, C; Bilwes, AM; Dahlquist, FW; Crane, BR; Simon, MI			Structural and chemical requirements for histidine phosphorylation by the chemotaxis kinase CheA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; ASYMMETRIC PHOSPHORYLATION; PHOSPHOTRANSFER DOMAIN; RESONANCE ASSIGNMENTS; SERINE-PROTEASE; ACTIVE-SITE; SPECTROSCOPY; PHOSPHORELAY; BINDING; SENSOR	The CheA histidine kinase initiates the signal transduction pathway of bacterial chemotaxis by autophosphorylating a conserved histidine on its phosphotransferase domain ( P1). Site-directed mutations of neighboring conserved P1 residues ( Glu-67, Lys-48, and His-64) show that a hydrogen-bonding network controls the reactivity of the phospho-accepting His ( His-45) in Thermotoga maritima CheA. In particular, the conservative mutation E67Q dramatically reduces phospho-transfer to P1 without significantly affecting the affinity of P1 for the CheA ATP-binding domain. High resolution crystallographic studies revealed that although all mutants disrupt the hydrogen-bonding network to varying degrees, none affect the conformation of His-45. N-15-NMR chemical shift studies instead showed that Glu-67 functions to stabilize the unfavored (NH)-H-delta 1 tautomer of His-45, thereby rendering the N-epsilon 2 imidazole unprotonated and well positioned for accepting the ATP phosphoryl group.	CALTECH, Dept Biol 147 75, Pasadena, CA 91125 USA; Cornell Univ, Dept Chem & Chem Biol, Ithaca, NY 14853 USA; Univ Calif Santa Barbara, Dept Chem & Biochem, Santa Barbara, CA 93106 USA	California Institute of Technology; Cornell University; University of California System; University of California Santa Barbara	Simon, MI (corresponding author), CALTECH, Dept Biol 147 75, 1200 E Calif Blvd, Pasadena, CA 91125 USA.	simonm@caltech.edu		Bilwes Crane, Alexandrine/0000-0001-9922-0692	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019296] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066775, R01GM059544] Funding Source: NIH RePORTER; NIAID NIH HHS [R01-AI 19296] Funding Source: Medline; NIGMS NIH HHS [R01-GM066775, 5R01GM059544-25] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACHOVCHIN WW, 1986, BIOCHEMISTRY-US, V25, P7751, DOI 10.1021/bi00371a070; Bilwes AM, 1999, CELL, V96, P131, DOI 10.1016/S0092-8674(00)80966-6; Bilwes AM, 2001, NAT STRUCT BIOL, V8, P353, DOI 10.1038/86243; Hedstrom L, 2002, CHEM REV, V102, P4501, DOI 10.1021/cr000033x; Hirschman A, 2001, BIOCHEMISTRY-US, V40, P13876, DOI 10.1021/bi0113622; Ikegami T, 2001, BIOCHEMISTRY-US, V40, P375, DOI 10.1021/bi001619g; Inouye M, 2003, HISTIDINE KINASES SI; JACKSON AP, 1993, P NATL ACAD SCI USA, V90, P11232, DOI 10.1073/pnas.90.23.11232; Janiak-Spens F, 2000, MOL MICROBIOL, V37, P136, DOI 10.1046/j.1365-2958.2000.01973.x; Kato M, 1997, CELL, V88, P717, DOI 10.1016/S0092-8674(00)81914-5; MARION D, 1989, J MAGN RESON, V85, P393, DOI 10.1016/0022-2364(89)90152-2; Matsushika A, 1998, BIOSCI BIOTECH BIOCH, V62, P2236, DOI 10.1271/bbb.62.2236; MCEVOY MM, 1995, BIOCHEMISTRY-US, V34, P13871, DOI 10.1021/bi00042a019; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Mourey L, 2001, J BIOL CHEM, V276, P31074, DOI 10.1074/jbc.M101943200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Quezada CM, 2004, J MOL BIOL, V341, P1283, DOI 10.1016/j.jmb.2004.06.061; SCHUSTER II, 1979, J ORG CHEM, V44, P3864, DOI 10.1021/jo01336a025; Sculimbrene BR, 2002, J AM CHEM SOC, V124, P11653, DOI 10.1021/ja027402m; Sculimbrene BR, 2001, J AM CHEM SOC, V123, P10125, DOI 10.1021/ja016779+; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; Stock AM, 2000, ANNU REV BIOCHEM, V69, P183, DOI 10.1146/annurev.biochem.69.1.183; Xu QP, 1999, J MOL BIOL, V292, P1039, DOI 10.1006/jmbi.1999.3143; ZHANG OW, 1994, J BIOMOL NMR, V4, P845, DOI 10.1007/BF00398413; Zhou HJ, 1997, BIOCHEMISTRY-US, V36, P699, DOI 10.1021/bi961663p	28	29	30	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	2005	280	34					30581	30585		10.1074/jbc.M505316200	http://dx.doi.org/10.1074/jbc.M505316200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	957IC	15994328	hybrid, Green Accepted			2022-12-25	WOS:000231362500074
J	Yagi, R; McBurney, D; Horton, WE				Yagi, R; McBurney, D; Horton, WE			Bcl-2 positively regulates Sox9-dependent chondrocyte gene expression by suppressing the MEK-ERK1/2 signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PRO-ALPHA-1(II) COLLAGEN GENE; TUMOR-NECROSIS-FACTOR; ARTICULAR CHONDROCYTES; RETINOIC ACID; IN-VIVO; SELECTIVE-INHIBITION; MESENCHYMAL CELLS; INDUCED APOPTOSIS; INTERFERING RNAS	Bcl-2 is an anti-apoptotic protein that has recently been shown to regulate other cellular functions. We previously reported that Bcl-2 regulates chondrocyte matrix gene expression, independent of its anti-apoptotic function. Here, we further investigate this novel function of Bcl-2 and examine three intracellular signaling pathways likely to be associated with this function. The present study demonstrates that the activity of Sox9, a master transcription factor that regulates the gene expression of chondrocyte matrix proteins, is suppressed by Bcl-2 small interference RNA in the presence of caspase inhibitors. This effect was attenuated by prior exposure of chondrocytes to an adenoviral vector expressing sense Bcl-2. In addition, the down-regulation of Bcl-2, Sox9, and chondrocyte-specific gene expression by serum withdrawal in primary chondrocytes was reversed by expressing Bcl-2. Inhibition of the protein kinase C alpha and NF kappa B pathways had no effect on the maintenance of Sox9-dependent gene expression by Bcl-2. In contrast, whereas the MEK-ERK1/2 pathway negatively regulated the differentiated phenotype in wild type chondrocytes, inhibition of this pathway reversed the loss of differentiation markers and fibroblastic phenotype in Bcl-2-deficient chondrocytes. In conclusion, the present study identifies a specific signaling pathway, namely, MEK-ERK1/2, that is downstream of Bcl- 2 in the regulation of Sox9-dependent chondrocyte gene expression and phenotype.	NE Ohio Univ, Coll Med, Dept Anat, Rootstown, OH 44272 USA	Northeast Ohio Medical University (NEOMED)	Horton, WE (corresponding author), NE Ohio Univ, Coll Med, Dept Anat, 4209 State Route 44, Rootstown, OH 44272 USA.	wehj@neoucom.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR046459] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-046459] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Adams CS, 1998, ANAT RECORD, V250, P418; Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Akiyama H, 2002, GENE DEV, V16, P2813, DOI 10.1101/gad.1017802; Amling M, 1997, J CELL BIOL, V136, P205, DOI 10.1083/jcb.136.1.205; Bi WM, 1999, NAT GENET, V22, P85, DOI 10.1038/8792; Biroccio A, 2000, FASEB J, V14, P652, DOI 10.1096/fasebj.14.5.652; Bobick BE, 2004, J BIOL CHEM, V279, P4588, DOI 10.1074/jbc.M309805200; Bolton MC, 1999, BIOCHEM J, V337, P77, DOI 10.1042/0264-6021:3370077; Bridgewater LC, 1998, J BIOL CHEM, V273, P14998, DOI 10.1074/jbc.273.24.14998; Carrington JL, 2005, BIOCHEM BIOPH RES CO, V328, P700, DOI 10.1016/j.bbrc.2004.12.041; Chang SH, 1998, J BIOL CHEM, V273, P19213, DOI 10.1074/jbc.273.30.19213; Chen DF, 1997, NATURE, V385, P434, DOI 10.1038/385434a0; CHOI B, 1995, BIOCHEM BIOPH RES CO, V216, P1034, DOI 10.1006/bbrc.1995.2724; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; de Crombrugghe B, 2000, MATRIX BIOL, V19, P389, DOI 10.1016/S0945-053X(00)00094-9; Feng LX, 1999, J CELL BIOCHEM, V74, P576, DOI 10.1002/(SICI)1097-4644(19990915)74:4<576::AID-JCB7>3.0.CO;2-N; Feng LX, 1998, J CELL BIOCHEM, V71, P302, DOI 10.1002/(SICI)1097-4644(19981101)71:2<302::AID-JCB14>3.0.CO;2-M; Harada H, 1998, J ORAL PATHOL MED, V27, P11; HASSELL JR, 1982, TERATOGEN CARCIN MUT, V2, P325, DOI 10.1002/1520-6866(1990)2:3/4<325::AID-TCM1770020314>3.0.CO;2-1; Haughn L, 2003, J BIOL CHEM, V278, P25158, DOI 10.1074/jbc.M212849200; Hilton M, 1997, CURR BIOL, V7, P798, DOI 10.1016/S0960-9822(06)00339-3; HORTON WE, 1988, EXP CELL RES, V178, P457, DOI 10.1016/0014-4827(88)90414-4; Iervolino A, 2002, FASEB J, V16, P1453, DOI 10.1096/fj.02-0122fje; Kim SJ, 2002, J BIOL CHEM, V277, P30375, DOI 10.1074/jbc.M205193200; Kinkel MD, 2004, ANAT REC PART A, V279A, P720, DOI 10.1002/ar.a.20063; Kinkel MD, 2003, J CELL BIOCHEM, V88, P941, DOI 10.1002/jcb.10442; Lee L, 1998, MOL GENET METAB, V64, P19, DOI 10.1006/mgme.1998.2704; Lefebvre V, 1996, MOL CELL BIOL, V16, P4512; Lefebvre V, 1997, MOL CELL BIOL, V17, P2336, DOI 10.1128/MCB.17.4.2336; Li XX, 2002, EXP HEMATOL, V30, P285, DOI 10.1016/S0301-472X(02)00777-4; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Matsuzaki Y, 1997, BLOOD, V89, P853, DOI 10.1182/blood.V89.3.853; Middleton G, 1998, J NEUROSCI, V18, P3344; Murakami S, 2004, GENE DEV, V18, P290, DOI 10.1101/gad.1179104; Murakami S, 2000, P NATL ACAD SCI USA, V97, P1113, DOI 10.1073/pnas.97.3.1113; Murakami S, 2000, J BIOL CHEM, V275, P3687, DOI 10.1074/jbc.275.5.3687; NERLICH AG, 1992, HISTOCHEMISTRY, V98, P275, DOI 10.1007/BF00270010; Ng LJ, 1997, DEV BIOL, V183, P108, DOI 10.1006/dbio.1996.8487; Oh CD, 2000, J BIOL CHEM, V275, P5613, DOI 10.1074/jbc.275.8.5613; Oh CD, 2003, J BIOL CHEM, V278, P36563, DOI 10.1074/jbc.M304857200; Pardo OE, 2002, J BIOL CHEM, V277, P12040, DOI 10.1074/jbc.M109006200; Pelletier JP, 2003, ARTHRITIS RHEUM-US, V48, P1582, DOI 10.1002/art.11014; Persengiev SP, 2004, RNA, V10, P12, DOI 10.1261/rna5160904; Scacheri PC, 2004, P NATL ACAD SCI USA, V101, P1892, DOI 10.1073/pnas.0308698100; Seghatoleslami MR, 2003, J CELL BIOCHEM, V88, P1129, DOI 10.1002/jcb.10458; Sekiya I, 2000, J BIOL CHEM, V275, P10738, DOI 10.1074/jbc.275.15.10738; Sitcheran R, 2003, GENE DEV, V17, P2368, DOI 10.1101/gad.1114503; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Trisciuoglio D, 2004, J BIOL CHEM, V279, P6737, DOI 10.1074/jbc.M308938200; Varfolomeev EE, 2004, CELL, V116, P491, DOI 10.1016/S0092-8674(04)00166-7; Verbruggen G, 2000, OSTEOARTHR CARTILAGE, V8, P170, DOI 10.1053/joca.1999.0287; Vornehm SI, 1996, MATRIX BIOL, V15, P91, DOI 10.1016/S0945-053X(96)90150-X; Wang Y, 1997, HISTOCHEM CELL BIOL, V108, P45, DOI 10.1007/s004180050145; Watanabe H, 2001, J BIOL CHEM, V276, P14466, DOI 10.1074/jbc.M005724200; Xie WF, 1999, J BONE MINER RES, V14, P757, DOI 10.1359/jbmr.1999.14.5.757; YAGI R, 2005, IN PRESS J ORTHOP RE; YAMADA Y, 1991, J CRAN GENET DEV BIO, V11, P350; Yang MS, 1998, MOL CELLS, V8, P266; Yoon BS, 2004, J CELL BIOCHEM, V93, P93, DOI 10.1002/jcb.20211; Yoon YM, 2000, J BIOL CHEM, V275, P12353, DOI 10.1074/jbc.275.16.12353; Yoon YM, 2002, J BIOL CHEM, V277, P8412, DOI 10.1074/jbc.M110608200; Zhao Q, 1997, DEV DYNAM, V209, P377, DOI 10.1002/(SICI)1097-0177(199708)209:4<377::AID-AJA5>3.0.CO;2-F	62	25	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	2005	280	34					30517	30525		10.1074/jbc.M502751200	http://dx.doi.org/10.1074/jbc.M502751200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	957IC	15975921	hybrid			2022-12-25	WOS:000231362500066
J	Tveit, H; Dick, G; Skibeli, V; Prydz, K				Tveit, H; Dick, G; Skibeli, V; Prydz, K			A proteoglycan undergoes different modifications en route to the apical and basolateral surfaces of Madin-Darby canine kidney cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN LINKAGE REGION; POLARIZED EPITHELIAL-CELLS; HEPARAN-SULFATE; CHONDROITIN SULFATE; BREFELDIN-A; N-GLYCANS; GLYCOSAMINOGLYCAN BIOSYNTHESIS; DERMATAN SULFATE; SORTING SIGNALS; MDCK CELLS	We have grown polarized epithelial Madin-Darby canine kidney II (MDCK II) cells on filters in the presence of [S-35]sulfate, [H-3]glucosamine, or [S-35]cysteine/[S-35] methionine to study proteoglycan (PG) synthesis, sorting, and secretion to the apical and basolateral media. Whereas most of the [S-35] sulfate label was recovered in basolateral PGs, the [H-3] glucosamine label was predominantly incorporated into the glycosaminoglycan chains of apical PGs, indicating that basolateral PGs are more intensely sulfated than their apical counterparts. Expression of the PG serglycin with a green fluorescent protein tag (SG-GFP) in MDCK II cells produced a protein core secreted 85% apically, which was largely modified by chondroitin sulfate chains. Surprisingly, the 15% of secreted SG-GFP molecules recovered basolaterally were more heavily sulfated and displayed a different sulfation pattern than the apical counterpart. More detailed studies of the differential modification of apically and basolaterally secreted SG-GFP indicate that the protein cores have been designated to apical and basolateral transport platforms before pathway-specific, post-translational modifications have been completed.	Univ Oslo, Dept Mol Biosci, N-0316 Oslo, Norway	University of Oslo	Prydz, K (corresponding author), Univ Oslo, Dept Mol Biosci, Box 1041, N-0316 Oslo, Norway.	kristian.prydz@imbv.uio.no		Dick, Gunnar/0000-0003-4529-5239				Bagnat M, 2000, P NATL ACAD SCI USA, V97, P3254, DOI 10.1073/pnas.060034697; Benting JH, 1999, J CELL BIOL, V146, P313, DOI 10.1083/jcb.146.2.313; Chen RL, 2001, J BIOL CHEM, V276, P7507, DOI 10.1074/jbc.M008283200; CHENG PW, 1989, J CLIN INVEST, V84, P68, DOI 10.1172/JCI114171; Emery G, 2003, J CELL SCI, V116, P4821, DOI 10.1242/jcs.00802; Fjeldstad K, 2002, J BIOL CHEM, V277, P36272, DOI 10.1074/jbc.M206365200; FRANSSON LA, 1992, BIOCHIM BIOPHYS ACTA, V1137, P287, DOI 10.1016/0167-4889(92)90149-6; Gulberti S, 2005, J BIOL CHEM, V280, P1417, DOI 10.1074/jbc.M411552200; Gut A, 1998, EMBO J, V17, P1919, DOI 10.1093/emboj/17.7.1919; Kolset SO, 1999, J CELL SCI, V112, P1797; Kusche-Gullberg M, 2003, CURR OPIN STRUC BIOL, V13, P605, DOI 10.1016/j.sbi.2003.08.002; Ledin J, 2004, J BIOL CHEM, V279, P42732, DOI 10.1074/jbc.M405382200; LIDHOLT K, 1995, BIOCHEM J, V311, P233, DOI 10.1042/bj3110233; Mertens G, 1996, J CELL BIOL, V132, P487, DOI 10.1083/jcb.132.3.487; Moses J, 1997, EUR J BIOCHEM, V248, P521, DOI 10.1111/j.1432-1033.1997.00521.x; Mostov KE, 2000, CURR OPIN CELL BIOL, V12, P483, DOI 10.1016/S0955-0674(00)00120-4; Ohkura T, 2002, J BIOCHEM, V132, P891, DOI 10.1093/oxfordjournals.jbchem.a003302; Paladino S, 2004, J CELL BIOL, V167, P699, DOI 10.1083/jcb.200407094; Prydz K, 2000, J CELL SCI, V113, P193; Rodriguez-Boulan E, 1999, TRENDS CELL BIOL, V9, P291, DOI 10.1016/S0962-8924(99)01595-0; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; SELDIN DC, 1985, J BIOL CHEM, V260, P1131; SPIRO RC, 1991, J CELL BIOL, V115, P1463, DOI 10.1083/jcb.115.5.1463; SUGAHARA K, 1991, EUR J BIOCHEM, V202, P805, DOI 10.1111/j.1432-1033.1991.tb16436.x; Sugahara K, 2003, CURR OPIN STRUC BIOL, V13, P612, DOI 10.1016/j.sbi.2003.09.011; SUGUMARAN G, 1992, J BIOL CHEM, V267, P8802; SVENNEVIG K, 1995, BIOCHEM J, V311, P881, DOI 10.1042/bj3110881; Ueno M, 2001, J BIOL CHEM, V276, P29134, DOI 10.1074/jbc.M102089200; UHLINHANSEN L, 1993, J BIOL CHEM, V268, P17370; Yamada S, 2004, J BIOL CHEM, V279, P32134, DOI 10.1074/jbc.M312624200; ZHANG LJ, 1994, J BIOL CHEM, V269, P19295; ZHANG LJ, 1995, J BIOL CHEM, V270, P27127, DOI 10.1074/jbc.270.45.27127	33	39	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	2005	280	33					29596	29603		10.1074/jbc.M503691200	http://dx.doi.org/10.1074/jbc.M503691200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	954SX	15980070	hybrid			2022-12-25	WOS:000231176200027
J	Jin, J; Woodgett, JR				Jin, J; Woodgett, JR			Chronic activation of protein kinase B beta/Akt2 leads to multinucleation and cell fusion in human epithelial kidney cells: events associated with tumorigenesis	ONCOGENE			English	Article						PKB; Akt; cell fusion; tumorigenesis; tamoxifen-induced; cytokinesis; endomitosis/endoreplication; phagocytosis; pinocytosis; autophagy	HUMAN BREAST; HUMAN CANCER; PHOSPHOINOSITIDE 3-KINASE; CENTROSOME AMPLIFICATION; TRANSCRIPTION FACTOR; PATHWAY; AKT; PHOSPHORYLATION; OVEREXPRESSION; DICTYOSTELIUM	Most cancers arise from the stepwise accumulation of genetic changes. There is also evidence for defects in the machinery and checkpoints for maintenance of normal diploid chromosome complements, resulting in genetic instability that helps fuel the accumulation of mutations that contribute to the development of cancer. The protooncogene protein kinase B (PKB/Akt), and its regulators including phosphatidylinositol 3' kinase and PTEN, has been shown to play critical roles in the regulation of multiple cellular functions such as transcription, cell survival, cell cycle progression, angiogenesis and cell motility - all of which are important to the malignant process. Here, we report the use of a membrane targeted PKB beta, the activation of which is under the control of a 4-hydroxy-Tamoxifen-responsive estrogen-receptor (ER) ligand binding domain. Induction of PKB beta-ER activity in human kidney epithelial cells (HEK293) resulted in changes in cellular growth, size, and in the appearance of aneuploid cells. Over time, in a PKB beta-dependent manner, cells also underwent extensive multinucleation caused due to a combination of both endomitosis and cell fusion. These findings suggest that chronic activation of PKB beta may contribute to genetic instability and autophagy, properties commonly found in tumor cells.	Dept Med Biophys, Toronto, ON M5G 2M9, Canada; Ontario Canc Inst, Toronto, ON M5G 2M9, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto	Woodgett, JR (corresponding author), Dept Med Biophys, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.	jwoodget@uhnres.utoronto.ca	Woodgett, Jim/F-1087-2010	Woodgett, Jim/0000-0003-3731-5797				Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0; Arboleda MJ, 2003, CANCER RES, V63, P196; Bacus SS, 2002, ONCOGENE, V21, P3532, DOI 10.1038/sj.onc.1205438; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Bischoff JR, 1999, TRENDS CELL BIOL, V9, P454, DOI 10.1016/S0962-8924(99)01658-X; Botelho RJ, 2004, CURR TOP MICROBIOL, V282, P1; Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; Chung CY, 2001, MOL CELL, V7, P937, DOI 10.1016/S1097-2765(01)00247-7; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Ellson CD, 2001, CURR BIOL, V11, P1631, DOI 10.1016/S0960-9822(01)00447-X; Funakoshi E, 2003, BMC CELL BIOL, V4, DOI 10.1186/1471-2121-4-12; Funamoto S, 2001, J CELL BIOL, V153, P795, DOI 10.1083/jcb.153.4.795; Goepfert TM, 2000, CURR TOP DEV BIOL, V49, P331; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hannak E, 2001, J CELL BIOL, V155, P1109, DOI 10.1083/jcb.200108051; Hutchinson JN, 2004, CANCER RES, V64, P3171, DOI 10.1158/0008-5472.CAN-03-3465; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Jin J, 2001, DEV CELL, V1, P817, DOI 10.1016/S1534-5807(01)00090-9; Katayama H, 1999, J NATL CANCER I, V91, P1160, DOI 10.1093/jnci/91.13.1160; Kenerson HL, 2002, CANCER RES, V62, P5645; Kohn AD, 1998, J BIOL CHEM, V273, P11937, DOI 10.1074/jbc.273.19.11937; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Mirza AM, 2000, CELL GROWTH DIFFER, V11, P279; Miyoshi Y, 2001, INT J CANCER, V92, P370, DOI 10.1002/ijc.1200; Mora A, 2004, SEMIN CELL DEV BIOL, V15, P161, DOI 10.1016/j.semcdb.2003.12.022; Otto SP, 2000, ANNU REV GENET, V34, P401, DOI 10.1146/annurev.genet.34.1.401; Razzini G, 2000, FASEB J, V14, P1179, DOI 10.1096/fasebj.14.9.1179; Rupper A, 2001, MOL BIOL CELL, V12, P2813, DOI 10.1091/mbc.12.9.2813; Rupper AC, 2001, J CELL SCI, V114, P1283; Russell DG, 2001, NAT REV MOL CELL BIO, V2, P569, DOI 10.1038/35085034; Sakakura C, 2001, BRIT J CANCER, V84, P824, DOI 10.1054/bjoc.2000.1684; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Scheid MP, 2002, MOL CELL BIOL, V22, P6247, DOI 10.1128/MCB.22.17.6247-6260.2002; Sen S, 1997, ONCOGENE, V14, P2195, DOI 10.1038/sj.onc.1201065; Stephens L, 2002, CURR OPIN CELL BIOL, V14, P203, DOI 10.1016/S0955-0674(02)00311-3; Storchova Z, 2004, NAT REV MOL CELL BIO, V5, P45, DOI 10.1038/nrm1276; Sulis ML, 2003, TRENDS CELL BIOL, V13, P478, DOI 10.1016/S0962-8924(03)00175-2; Tee AR, 2003, J BIOL CHEM, V278, P37288, DOI 10.1074/jbc.M303257200; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Woods YL, 2001, BIOCHEM J, V355, P597, DOI 10.1042/bj3550597; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	50	26	26	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 18	2005	24	35					5459	5470		10.1038/sj.onc.1208704	http://dx.doi.org/10.1038/sj.onc.1208704			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	955JN	16007218				2022-12-25	WOS:000231222300006
J	Rossetti, S; Van Unen, L; Touw, IP; Hoogeveen, AT; Sacchi, N				Rossetti, S; Van Unen, L; Touw, IP; Hoogeveen, AT; Sacchi, N			Myeloid maturation block by AML1-MTG16 is associated with Csf1r epigenetic downregulation	ONCOGENE			English	Article						epigenetic regulation; AML1-MTG16; Csf1r; myelogenesis	STIMULATING FACTOR-RECEPTOR; GRANULOCYTIC DIFFERENTIATION; TRANSCRIPTION FACTOR; GENE-EXPRESSION; LEUKEMIC-CELLS; METHYLATION; AML1; IDENTIFICATION; PROMOTER; FUSION	De novo epigenetic changes at histone and DNA level that affect gene transcription in cancer may be less random than we originally thought. Leukemia fusion proteins associated with specific chromosome translocations could mechanistically determine the epigenetic fate of specific target genes critical for normal hematopoiesis. This seems to be the case with AML1-MTG16, a fusion protein resulting from the t(16;21) translocation, a hallmark of therapy-related leukemia and myelodysplastic syndrome. Here we show that AML1-MTG16 blocks both myeloid differentiation and proliferation in the 32D/WT1-mouse myeloid cell line. These biological effects can be traced to the AML1 and MTG16 moieties of the fusion protein, respectively. Further, we show that AML1-MTG16 can induce epigenetic repressive changes at the histone and DNA level of the AML1 target gene Csf1r (c-fms), encoding the macrophage colony stimulating factor receptor. We observed that, concomitant with Csf1r downregulation, 32D/WT1 cells lost the ability to undergo myeloid differentiation in response to the granulocyte macrophage colony-stimulating factor (GM-CSF). Thus, there seems to be an association between AML1-MTG16-induced myeloid maturation block and epigenetic changes of a myeloid master gene.	Erasmus Med Ctr, Dept Clin Genet, NL-3015 GE Rotterdam, Netherlands; Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA; Erasmus Med Ctr, Dept Hematol, NL-3015 GE Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Roswell Park Cancer Institute; Erasmus University Rotterdam; Erasmus MC	Hoogeveen, AT (corresponding author), Erasmus Med Ctr, Dept Clin Genet, Dr Molewaterplein 50, NL-3015 GE Rotterdam, Netherlands.	a.hoogeveen@erasmusmc.nl; nicoletta.sacchi@roswellpark.org						Ahn MY, 1998, P NATL ACAD SCI USA, V95, P1812, DOI 10.1073/pnas.95.4.1812; Baylin S, 2002, CANCER CELL, V1, P299, DOI 10.1016/S1535-6108(02)00061-2; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; de Koning JP, 1998, BLOOD, V91, P1924, DOI 10.1182/blood.V91.6.1924.1924_1924_1933; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; ERICKSON P, 1992, BLOOD, V80, P1825; Fazi F, 2005, ONCOGENE, V24, P1820, DOI 10.1038/sj.onc.1208286; FELGNER J, 1991, PATHOBIOLOGY, V59, P293; Follows GA, 2003, EMBO J, V22, P2798, DOI 10.1093/emboj/cdg250; Gamou T, 1998, BLOOD, V91, P4028, DOI 10.1182/blood.V91.11.4028.411a45_4028_4037; Heidenreich O, 2003, BLOOD, V101, P3157, DOI 10.1182/blood-2002-05-1589; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hoogeveen AT, 2002, ONCOGENE, V21, P6703, DOI 10.1038/sj.onc.1205882; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Kohzaki H, 1999, ONCOGENE, V18, P4055, DOI 10.1038/sj.onc.1202735; KOZU T, 1993, BLOOD, V82, P1270; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; NISSON PE, 1992, CANCER GENET CYTOGEN, V63, P81, DOI 10.1016/0165-4608(92)90384-K; Pabst T, 2001, NAT MED, V7, P444, DOI 10.1038/86515; Rossetti S, 2004, GENOMICS, V84, P1, DOI 10.1016/j.ygeno.2004.02.011; Shi HD, 2003, CANCER RES, V63, P2164; Tagoh H, 2002, GENE DEV, V16, P1721, DOI 10.1101/gad.222002; Zent CS, 1996, P NATL ACAD SCI USA, V93, P1044, DOI 10.1073/pnas.93.3.1044; Zhang DE, 1996, MOL CELL BIOL, V16, P1231; ZHANG DE, 1994, MOL CELL BIOL, V14, P8085, DOI 10.1128/MCB.14.12.8085	27	15	16	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 11	2005	24	34					5325	5332		10.1038/sj.onc.1208651	http://dx.doi.org/10.1038/sj.onc.1208651			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	954MF	16007222				2022-12-25	WOS:000231158500006
J	Lee, JM; Li, J; Johnson, DA; Stein, TD; Kraft, AD; Calkins, MJ; Jakel, RJ; Johnson, JA				Lee, JM; Li, J; Johnson, DA; Stein, TD; Kraft, AD; Calkins, MJ; Jakel, RJ; Johnson, JA			Nrf2, a multi-organ protector?	FASEB JOURNAL			English	Article						Nrf2; ARE; multi-organ protection	ANTIOXIDANT RESPONSE ELEMENT; PROTEIN-KINASE-C; YA-SUBUNIT GENE; INDUCIBLE EXPRESSION; TRANSCRIPTION FACTOR; OXIDATIVE STRESS; NF-E2-RELATED FACTOR-2; CONFERRING PROTECTION; REGULATORY ELEMENTS; MEDIATED EXPRESSION	NF-E2-related factor 2 (Nrf2) is a basic leucine zipper transcription factor that binds to the promoter sequence "antioxidant responsive element (ARE)" leading to coordinated up-regulation of ARE-driven detoxification and antioxidant genes. Since the expression of a wide array of antioxidant and detoxification genes are positively regulated by the ARE sequence, Nrf2 may serve as a master regulator of the ARE-driven cellular defense system against oxidative stress. In support of this, numerous studies have shown that Nrf2 protects many cell types and organ systems from a broad spectrum of toxic insults and disease pathogenesis. This Nrf2-conferred, multi-organ protection phenomenon raises an interesting question about how a single protein can protect many different organs from various toxic insults. A possible molecular mechanism explaining this phenomenon is that Nrf2 protects many different cell types by coordinately up-regulating classic ARE-driven genes as well as cell type-specific target genes that are required for the defense system of each cell type in its unique environment. This hypothesis is supported by microarray data indicating the protective role of Nrf2 is conveyed through both known ARE-driven genes and novel cell type-specific genes. The widespread nature of Nrf2 may have an important therapeutic potential, allowing prevention of carcinogenesis and neurodegenerative diseases.	Univ Wisconsin, Sch Pharm, Madison, WI 53705 USA; Univ Wisconsin, Mol & Environm Toxicol Ctr, Madison, WI 53705 USA; Univ Wisconsin, Neurosci Training Program, Madison, WI 53705 USA; Univ Wisconsin, Waisman Ctr, Madison, WI 53705 USA; Univ Wisconsin, Ctr Neurosci, Madison, WI 53705 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Mol Neurogenet Unit, Charlestown, MA USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Harvard University; Massachusetts General Hospital	Johnson, JA (corresponding author), Univ Wisconsin, Sch Pharm, 6125 Rennebohm Hall,777 Highland Ave, Madison, WI 53705 USA.	jajohnson@pharmacy.wisc.edu		Li, Jiang/0000-0002-7006-1285; Stein, Thor/0000-0001-6954-4477	VA [5I01CX001038-04] Funding Source: Federal RePORTER; NIGMS NIH HHS [T32 GM008692] Funding Source: Medline; CSRD VA [I01 CX001038] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008692] Funding Source: NIH RePORTER; Veterans Affairs [I01CX001038] Funding Source: NIH RePORTER	VA(US Department of Veterans Affairs); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); CSRD VA; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Veterans Affairs(US Department of Veterans Affairs)		Bloom DA, 2003, J BIOL CHEM, V278, P44675, DOI 10.1074/jbc.M307633200; Braun S, 2002, MOL CELL BIOL, V22, P5492, DOI 10.1128/MCB.22.15.5492-5505.2002; Calkins MJ, 2005, P NATL ACAD SCI USA, V102, P244, DOI 10.1073/pnas.0408487101; Chan KM, 1999, P NATL ACAD SCI USA, V96, P12731, DOI 10.1073/pnas.96.22.12731; Chan KM, 2001, P NATL ACAD SCI USA, V98, P4611, DOI 10.1073/pnas.081082098; Cho HY, 2004, FASEB J, V18, P1258, DOI 10.1096/fj.03-1127fje; Cho HY, 2002, AM J RESP CELL MOL, V26, P175, DOI 10.1165/ajrcmb.26.2.4501; Dhakshinamoorthy S, 2004, J BIOL CHEM, V279, P20096, DOI 10.1074/jbc.M312492200; Dhakshinamoorthy S, 2001, ONCOGENE, V20, P3906, DOI 10.1038/sj.onc.1204506; Dinkova-Kostova AT, 2002, P NATL ACAD SCI USA, V99, P11908, DOI 10.1073/pnas.172398899; Dyck PA, 2003, MAMM GENOME, V14, P601, DOI 10.1007/s00335-003-2269-9; Enomoto A, 2001, TOXICOL SCI, V59, P169, DOI 10.1093/toxsci/59.1.169; Fahey JW, 2002, P NATL ACAD SCI USA, V99, P7610, DOI 10.1073/pnas.112203099; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; FRILING RS, 1990, P NATL ACAD SCI USA, V87, P6258, DOI 10.1073/pnas.87.16.6258; Gao XQ, 2004, P NATL ACAD SCI USA, V101, P10446, DOI 10.1073/pnas.0403886101; Huang HC, 2000, P NATL ACAD SCI USA, V97, P12475, DOI 10.1073/pnas.220418997; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Kang KW, 2002, MOL PHARMACOL, V62, P1001, DOI 10.1124/mol.62.5.1001; Kobayashi A, 2004, METHOD ENZYMOL, V378, P273; Kraft AD, 2004, J NEUROSCI, V24, P1101, DOI 10.1523/JNEUROSCI.3817-03.2004; Kwak MK, 2003, J BIOL CHEM, V278, P8135, DOI 10.1074/jbc.M211898200; Lee JM, 2003, J BIOL CHEM, V278, P12029, DOI 10.1074/jbc.M211558200; Lee JM, 2004, P NATL ACAD SCI USA, V101, P9751, DOI 10.1073/pnas.0403620101; Lee JM, 2003, J BIOL CHEM, V278, P37948, DOI 10.1074/jbc.M305204200; Li J, 2002, J BIOL CHEM, V277, P388, DOI 10.1074/jbc.M109380200; Li J, 2004, PHYSIOL GENOMICS, V18, P261, DOI 10.1152/physiolgenomics.00209.2003; Li N, 2004, J IMMUNOL, V173, P3467, DOI 10.4049/jimmunol.173.5.3467; LI Y, 1992, J BIOL CHEM, V267, P15097; Motohashi H, 2004, P NATL ACAD SCI USA, V101, P6379, DOI 10.1073/pnas.0305902101; MURPHY TH, 1991, J NEUROCHEM, V56, P990, DOI 10.1111/j.1471-4159.1991.tb02019.x; Ramos-Gomez M, 2001, P NATL ACAD SCI USA, V98, P3410, DOI 10.1073/pnas.051618798; Ramos-Gomez M, 2003, CARCINOGENESIS, V24, P461, DOI 10.1093/carcin/24.3.461; Rangasamy T, 2004, J CLIN INVEST, V114, P1248, DOI 10.1172/JCI200421146; RUSHMORE TH, 1990, J BIOL CHEM, V265, P14648; SAKAI M, 1988, P NATL ACAD SCI USA, V85, P9456, DOI 10.1073/pnas.85.24.9456; Shih AY, 2003, J NEUROSCI, V23, P3394, DOI 10.1523/jneurosci.23-08-03394.2003; Thimmulappa RK, 2002, CANCER RES, V62, P5196; Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960; Wakabayashi N, 2004, P NATL ACAD SCI USA, V101, P2040, DOI 10.1073/pnas.0307301101; Yoh K, 2001, KIDNEY INT, V60, P1343, DOI 10.1046/j.1523-1755.2001.00939.x; Yu R, 2000, J BIOL CHEM, V275, P39907, DOI 10.1074/jbc.M004037200	43	374	392	0	17	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2005	19	9					1061	1066		10.1096/fj.04-2591hyp	http://dx.doi.org/10.1096/fj.04-2591hyp			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	951IO	15985529				2022-12-25	WOS:000230923000034
J	Rockenstein, E; Mante, M; Alford, M; Adame, A; Crews, L; Hashimoto, M; Esposito, L; Mucke, L; Masliah, E				Rockenstein, E; Mante, M; Alford, M; Adame, A; Crews, L; Hashimoto, M; Esposito, L; Mucke, L; Masliah, E			High beta-secretase activity elicits neurodegeneration in transgenic mice despite reductions in amyloid-beta levels - Implications for the treatment of Alzheimer disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-CLEAVING ENZYME; CARBOXYL-TERMINAL FRAGMENT; PRECURSOR PROTEIN; GAMMA-SECRETASE; MOUSE MODEL; IN-VIVO; PLAQUE PATHOLOGY; ALPHA-SYNUCLEIN; KNOCKOUT MICE; BACE	Amyloid-beta peptides (A beta) are widely presumed to play a causal role in Alzheimer disease. Release of A beta from the amyloid precursor protein (APP) requires proteolysis by the beta-site APP-cleaving enzyme (BACE1). Although increased BACE1 activity in Alzheimer disease brains and human ( h) BACE1 transgenic (tg) mice results in altered APP cleavage, the contribution of these molecular alterations to neurodegeneration is unclear. We therefore used the murine Thy1 promoter to express high levels of hBACE1, with or without hAPP, in neurons of tg mice. Compared with hAPP mice, hBACE1/hAPP doubly tg mice had increased levels of APP C-terminal fragments (C89, C83) and decreased levels of full-length APP and A beta. In contrast to non-tg controls and hAPP mice, hBACE1 mice and hBACE1/hAPP mice showed degeneration of neurons in the neocortex and hippocampus and degradation of myelin. Neurological deficits were also more severe in hBACE1 and hBACE1/hAPP mice than in hAPP mice. These results demonstrate that high levels of BACE1 activity are sufficient to elicit neurodegeneration and neurological decline in vivo. This pathogenic pathway involves the accumulation of APP C-terminal fragments but does not depend on increased production of human A beta. Thus, inhibiting BACE1 may block not only A beta-dependent but also A beta-independent pathogenic mechanisms.	Univ Calif San Diego, Dept Neurosci, Sch Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Pathol, Sch Med, La Jolla, CA 92093 USA; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94158 USA; Univ Calif San Francisco, Gladstone Inst Neurol Dis, San Francisco, CA 94158 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Francisco; University of California System; University of California San Francisco; The J David Gladstone Institutes	Masliah, E (corresponding author), Univ Calif San Diego, Dept Neurosci, Sch Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.	emasliah@ucsd.edu	Crews, Leslie/B-7584-2014	Crews, Leslie/0000-0003-0704-0067	NIA NIH HHS [AG10869, AG022074, AG18840, AG5131] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG022074, R29AG010869] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Anderson JJ, 2005, BIOCHEM PHARMACOL, V69, P689, DOI 10.1016/j.bcp.2004.11.015; Ando K, 1999, J NEUROSCI, V19, P4421; Asai M, 2003, BIOCHEM BIOPH RES CO, V301, P231, DOI 10.1016/S0006-291X(02)02999-6; Berger-Sweeney J, 1999, MOL BRAIN RES, V66, P150, DOI 10.1016/S0169-328X(99)00014-5; Bodendorf U, 2002, J NEUROCHEM, V80, P799, DOI 10.1046/j.0022-3042.2002.00770.x; Bredesen DE, 1995, ANN NEUROL, V38, P839, DOI 10.1002/ana.410380604; Cai HB, 2001, NAT NEUROSCI, V4, P233, DOI 10.1038/85064; Chiocco MJ, 2004, J BIOL CHEM, V279, P52535, DOI 10.1074/jbc.M409680200; Citron M, 2002, NEUROBIOL AGING, V23, P1017, DOI 10.1016/S0197-4580(02)00122-7; DeMattos RB, 2001, P NATL ACAD SCI USA, V98, P8850, DOI 10.1073/pnas.151261398; Durkin JT, 1999, J BIOL CHEM, V274, P20499, DOI 10.1074/jbc.274.29.20499; Fukumoto H, 2002, ARCH NEUROL-CHICAGO, V59, P1381, DOI 10.1001/archneur.59.9.1381; Harrison SM, 2003, MOL CELL NEUROSCI, V24, P646, DOI 10.1016/S1044-7431(03)00227-6; Holsinger RMD, 2002, ANN NEUROL, V51, P783, DOI 10.1002/ana.10208; Huse JT, 2000, J BIOL CHEM, V275, P33729, DOI 10.1074/jbc.M004175200; Huse JT, 2002, J BIOL CHEM, V277, P16278, DOI 10.1074/jbc.M111141200; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; Iijima K, 2000, J NEUROCHEM, V75, P1085, DOI 10.1046/j.1471-4159.2000.0751085.x; JohnsonWood K, 1997, P NATL ACAD SCI USA, V94, P1550, DOI 10.1073/pnas.94.4.1550; Jung SS, 1999, NEUROBIOL AGING, V20, P249, DOI 10.1016/S0197-4580(99)00051-2; Kamenetz F, 2003, NEURON, V37, P925, DOI 10.1016/S0896-6273(03)00124-7; Kim HS, 2000, FASEB J, V14, P1508, DOI 10.1096/fj.14.11.1508; Kim K., 1988, NEUROSCI RES COMMUN, V2, P121; KIM KS, 1990, NEUROSCI RES COMMUN, V7, P113; Kirschling CM, 2003, NEUROREPORT, V14, P1243, DOI 10.1097/00001756-200307010-00011; Kitazume S, 2005, J BIOL CHEM, V280, P8589, DOI 10.1074/jbc.M409417200; Kitazume S, 2001, P NATL ACAD SCI USA, V98, P13554, DOI 10.1073/pnas.241509198; Koo EH, 1999, P NATL ACAD SCI USA, V96, P9989, DOI 10.1073/pnas.96.18.9989; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; Lee EB, 2005, J CELL BIOL, V168, P291, DOI 10.1083/jcb.200407070; Li R, 2004, P NATL ACAD SCI USA, V101, P3632, DOI 10.1073/pnas.0205689101; Luo Y, 2001, NAT NEUROSCI, V4, P231, DOI 10.1038/85059; Masliah E, 2001, P NATL ACAD SCI USA, V98, P12245, DOI 10.1073/pnas.211412398; Masliah E, 2000, J NEURAL TRANSM-SUPP, P175; Mohajeri MH, 2004, J NEURAL TRANSM, V111, P413, DOI 10.1007/s00702-003-0057-z; Mucke L, 2000, J NEUROSCI, V20, P4050, DOI 10.1523/jneurosci.20-11-04050.2000; Mucke L, 2000, AM J PATHOL, V157, P2003, DOI 10.1016/S0002-9440(10)64839-0; Muresan Z, 2004, HUM MOL GENET, V13, P475, DOI 10.1093/hmg/ddh054; OLTERSDORF T, 1990, J BIOL CHEM, V265, P4492; OsterGranite ML, 1996, J NEUROSCI, V16, P6732; Roberds SL, 2001, HUM MOL GENET, V10, P1317, DOI 10.1093/hmg/10.12.1317; Rockenstein E, 2002, J NEUROSCI RES, V68, P568, DOI 10.1002/jnr.10231; Rockenstein E, 2001, J NEUROSCI RES, V66, P573, DOI 10.1002/jnr.1247; ROCKENSTEIN EM, 1995, J BIOL CHEM, V270, P28257; Rossner S, 2001, J NEUROSCI RES, V64, P437; Selkoe DJ, 2003, ANNU REV PHARMACOL, V43, P545, DOI 10.1146/annurev.pharmtox.43.100901.140248; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Sinha S, 2000, ANN NY ACAD SCI, V920, P206; SISODIA SS, 1993, J NEUROSCI, V13, P3136; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; Song DK, 1998, J NEUROCHEM, V71, P875; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; Willem M, 2004, AM J PATHOL, V165, P1621, DOI 10.1016/S0002-9440(10)63419-0; Wong HK, 2005, J BIOL CHEM, V280, P23009, DOI 10.1074/jbc.M414648200; Xia WM, 2003, J CELL SCI, V116, P2839, DOI 10.1242/jcs.00651; Zheng H, 1996, ANN NY ACAD SCI, V777, P421, DOI 10.1111/j.1749-6632.1996.tb34456.x	59	75	77	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	2005	280	38					32957	32967		10.1074/jbc.M507016200	http://dx.doi.org/10.1074/jbc.M507016200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	964ZU	16027115	hybrid			2022-12-25	WOS:000231920300050
J	Godon, C; Coullet, S; Baus, B; Alonso, B; Davin, AH; Delcuze, Y; Marchetti, C; Hainaut, P; Kazmaier, M; Quemeneur, E				Godon, C; Coullet, S; Baus, B; Alonso, B; Davin, AH; Delcuze, Y; Marchetti, C; Hainaut, P; Kazmaier, M; Quemeneur, E			Quantitation of p53 nuclear relocation in response to stress using a yeast functional assay: effects of irradiation and modulation by heavy metal ions	ONCOGENE			English	Article						p53; genotoxic stress; nuclear relocation	TUMOR-SUPPRESSOR PROTEIN; SACCHAROMYCES-CEREVISIAE; OXIDATIVE STRESS; EXPORT SIGNAL; DNA-DAMAGE; IN-VIVO; LOCALIZATION; ACTIVATION; GENE; YAP1	Many regulatory proteins undergo transient nuclear relocation under physical or chemical stress. This phenomenon is, however, difficult to assess due to the lack of sensitive and standardized biological assays. Here, we describe a new quantitative nuclear relocation assay (QNR), based on expression in yeasts of chimeric proteins in which an artificial transcription factor is fused to a target protein acting as driver for relocation. This assay combines the experimental versatility of yeast with quantitation of nuclear relocation at low levels of protein expression. We have assessed the nuclear relocation of yeast Yap1 and human p53, two transcription factors that relocate to the nucleus in response to oxidative-stress and DNA damage, respectively. We show that p53 efficiently drives the relocation of the chimeric reporter in response to irradiation and that this process requires the C-terminal nuclear export signal (NES). Cd2+ and Hg2+, two metal ions inducing DNA damage as well as conformational changes in p53, have opposite effects on p53 relocation in response to DNA damage. Whereas Hg2+ effects are synergistic to DNA damage, Cd2+ inhibits relocation and sequesters p53 into the cytoplasm. These results demonstrate the effectiveness of QNR to investigate the regulation of p53 shuttling in response to stress signals including suspected environmental carcinogens.	CEA Valrho, DSV, DIEP, SBTN, F-30207 Bagnols Sur Ceze, France; CEN Cadarache, DSV, DEVM, LBC, F-13108 St Paul Les Durance, France; IARC Lyon, Unit Mol Carcinogenesis, F-69372 Lyon, France	CEA; CEA; World Health Organization; International Agency for Research on Cancer (IARC)	Godon, C (corresponding author), CEA Valrho, DSV, DIEP, SBTN, F-30207 Bagnols Sur Ceze, France.	christian.godon@cea.fr	Hainaut, Pierre/B-6018-2012	Hainaut, Pierre/0000-0002-1303-1610				BISCHOFF JR, 1992, MOL CELL BIOL, V12, P1405, DOI 10.1128/MCB.12.4.1405; Candau R, 1997, ONCOGENE, V15, P807, DOI 10.1038/sj.onc.1201244; Cyert MS, 2001, J BIOL CHEM, V276, P20805, DOI 10.1074/jbc.R100012200; Delaunay A, 2000, EMBO J, V19, P5157, DOI 10.1093/emboj/19.19.5157; Delaunay A, 2002, CELL, V111, P471, DOI 10.1016/S0092-8674(02)01048-6; Fabbro M, 2003, EXP CELL RES, V282, P59, DOI 10.1016/S0014-4827(02)00019-8; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; FRITSCHE M, 1993, ONCOGENE, V8, P307; Hood JK, 1999, CURR OPIN CELL BIOL, V11, P241, DOI 10.1016/S0955-0674(99)80032-5; ISHIOKA C, 1993, NAT GENET, V5, P124, DOI 10.1038/ng1093-124; Jimenez GS, 1999, ONCOGENE, V18, P7656, DOI 10.1038/sj.onc.1203013; Kato S, 2003, P NATL ACAD SCI USA, V100, P8424, DOI 10.1073/pnas.1431692100; Kitagawa K, 2002, BIOTECHNIQUES, V33, P288, DOI 10.2144/02332bm07; Klibanov SA, 2001, J CELL SCI, V114, P1867; KUGE S, 1994, EMBO J, V13, P655, DOI 10.1002/j.1460-2075.1994.tb06304.x; Kuge S, 1997, EMBO J, V16, P1710, DOI 10.1093/emboj/16.7.1710; Kungolos A, 1999, ECOTOX ENVIRON SAFE, V43, P149, DOI 10.1006/eesa.1999.1767; Lee J, 1999, J BIOL CHEM, V274, P16040, DOI 10.1074/jbc.274.23.16040; Meplan C, 1999, J BIOL CHEM, V274, P31663, DOI 10.1074/jbc.274.44.31663; Merwin JR, 2002, CARCINOGENESIS, V23, P1609, DOI 10.1093/carcin/23.10.1609; O'Keefe K, 2003, MOL CELL BIOL, V23, P6396, DOI 10.1128/MCB.23.18.6396-6405.2003; Oldenburg KR, 1997, NUCLEIC ACIDS RES, V25, P451, DOI 10.1093/nar/25.2.451; SCHNELL N, 1992, CURR GENET, V21, P269, DOI 10.1007/BF00351681; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Sutton DJ, 2002, INT J MOL SCI, V3, P965, DOI 10.3390/i3090965; Waalkes MP, 2003, MUTAT RES-FUND MOL M, V533, P107, DOI 10.1016/j.mrfmmm.2003.07.011; WU AL, 1993, J BIOL CHEM, V268, P18850; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637	28	6	6	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 22	2005	24	42					6459	6464		10.1038/sj.onc.1208785	http://dx.doi.org/10.1038/sj.onc.1208785			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	966RI	16007197				2022-12-25	WOS:000232038200013
J	Pelz, A; Wieland, KP; Putzbach, K; Hentschel, P; Albert, K; Gotz, F				Pelz, A; Wieland, KP; Putzbach, K; Hentschel, P; Albert, K; Gotz, F			Structure and biosynthesis of staphyloxanthin from Staphylococcus aureus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAROTENOID BIOSYNTHESIS; INTERCELLULAR-ADHESION; MEVALONATE PATHWAY; GENOME SEQUENCE; EXPRESSION; GENES; EPIDERMIDIS; 4,4'-DIAPONEUROSPORENE; IDENTIFICATION; ESSENTIALITY	Most Staphylococcus aureus strains produce the orange carotenoid staphyloxanthin. The staphyloxanthin biosynthesis genes are organized in an operon, crtOPQMN, with sigma(B)-dependent promoter upstream of crtO and a termination region downstream of crtN. The functions of the five encoded enzymes were predicted on the basis of their sequence similarity to known enzymes and by product analysis of gene deletion mutants. The first step in staphyloxanthin biosynthesis is the head-to-head condensation of two molecules of farnesyl diphosphate to form dehydrosqualene (4,4'-diapophytoene), catalyzed by the dehydrosqualene synthase CrtM. The dehydrosqualene desaturase CrtN dehydrogenates dehydrosqualene to form the yellow, main intermediate 4,4'-diaponeurosporene. CrtP, very likely a mixed function oxidase, oxidizes the terminal methyl group of 4,4'-diaponeurosporene to form 4,4'-diaponeurosporenic acid. CrtQ, a glycosyltransferase, esterifies glucose at the C-1" position with the carboxyl group of 4,4'-diaponeurosporenic acid to yield glycosyl 4,4'-diaponeurosporenoate; this compound was the major product in the clone expressing crtPQMN. In the final step, the acyltransferase CrtO esterifies glucose at the C-6" position with the carboxyl group of 12-methyltetradecanoic acid to yield staphyloxanthin. Staphyloxanthin overexpressed in Staphylococcus carnosus (pTX-crtOPQMN) and purified was analyzed by high pressure liquid chromatography-mass spectroscopy and NMR spectroscopy. Staphyloxanthin was identified as beta-D-glucopyranosyl 1-O( 4,4'-diaponeurosporen-4-oate)-6-O-(12-methyltetradecanoate).	Univ Tubingen, Dept Microbial Genet, D-72076 Tubingen, Germany; Univ Tubingen, Inst Organ Chem, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen	Gotz, F (corresponding author), Univ Tubingen, Dept Microbial Genet, Waldhauser Str 70-8, D-72076 Tubingen, Germany.	friedrich.goetz@uni-tuebingen.de						Armstrong GA, 1997, ANNU REV MICROBIOL, V51, P629, DOI 10.1146/annurev.micro.51.1.629; ARMSTRONG GA, 1990, P NATL ACAD SCI USA, V87, P9975, DOI 10.1073/pnas.87.24.9975; BOTELLA JA, 1995, EUR J BIOCHEM, V233, P238, DOI 10.1111/j.1432-1033.1995.238_1.x; Campobasso N, 2004, J BIOL CHEM, V279, P44883, DOI 10.1074/jbc.M407882200; Cramton SE, 1999, INFECT IMMUN, V67, P5427, DOI 10.1128/IAI.67.10.5427-5433.1999; Eisen JA, 2002, P NATL ACAD SCI USA, V99, P9509, DOI 10.1073/pnas.132181499; Gerke C, 1998, J BIOL CHEM, V273, P18586, DOI 10.1074/jbc.273.29.18586; GOTZ F, 1987, FEMS MICROBIOL LETT, V40, P285, DOI 10.1016/0378-1097(87)90391-0; GOTZ F, 2004, PROCARYOTES; Heilmann C, 1996, MOL MICROBIOL, V20, P1083, DOI 10.1111/j.1365-2958.1996.tb02548.x; Kaneda K, 2001, P NATL ACAD SCI USA, V98, P932, DOI 10.1073/pnas.020472198; KREUTZ B, 1984, GENE, V31, P301, DOI 10.1016/0378-1119(84)90226-9; Kullik I, 1998, J BACTERIOL, V180, P4814, DOI 10.1128/JB.180.18.4814-4820.1998; Kuroda M, 2001, LANCET, V357, P1225, DOI 10.1016/S0140-6736(00)04403-2; Lang S, 2000, FEMS IMMUNOL MED MIC, V29, P213, DOI 10.1111/j.1574-695X.2000.tb01525.x; MARSHALL JH, 1981, J BACTERIOL, V147, P914, DOI 10.1128/JB.147.3.914-919.1981; MARSHALL JH, 1981, J BACTERIOL, V147, P900, DOI 10.1128/JB.147.3.900-913.1981; MARSHALL JH, 1972, 3RD INT S CAR CLUJ, P56; MOSS GP, 1979, PURE APPL CHEM, V51, P507, DOI 10.1351/pac197951030507; Peschel A, 1996, FEMS MICROBIOL LETT, V137, P279; PESCHEL A, 1993, MOL MICROBIOL, V9, P31, DOI 10.1111/j.1365-2958.1993.tb01666.x; Pinner M, 1932, J INFECT DIS, V50, P185, DOI 10.1093/infdis/50.3.185; Rocap G, 2003, NATURE, V424, P1042, DOI 10.1038/nature01947; ROSENSTEIN R, 1992, J BACTERIOL, V174, P3676, DOI 10.1128/JB.174.11.3676-3683.1992; SAXENA IM, 1995, J BACTERIOL, V177, P1419, DOI 10.1128/jb.177.6.1419-1424.1995; Schumann G, 1996, MOL GEN GENET, V252, P658, DOI 10.1007/s004380050274; Takaichi S, 1997, ARCH MICROBIOL, V168, P277, DOI 10.1007/s002030050499; Takami H, 2002, NUCLEIC ACIDS RES, V30, P3927, DOI 10.1093/nar/gkf526; Voynova NE, 2004, J BACTERIOL, V186, P61, DOI 10.1128/JB.186.1.61-67.2004; WIELAND B, 1994, J BACTERIOL, V176, P7719, DOI 10.1128/JB.176.24.7719-7726.1994; WIELAND KP, 1995, GENE, V158, P91, DOI 10.1016/0378-1119(95)00137-U; Wilding EI, 2000, J BACTERIOL, V182, P4319, DOI 10.1128/JB.182.15.4319-4327.2000; Wilding EI, 2000, J BACTERIOL, V182, P5147, DOI 10.1128/JB.182.18.5147-5152.2000	33	221	239	1	43	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	2005	280	37					32493	32498		10.1074/jbc.M505070200	http://dx.doi.org/10.1074/jbc.M505070200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	963HM	16020541	hybrid			2022-12-25	WOS:000231794800057
J	Clark, R; Ali Ansari, M; Dash, S; Geeves, MA; Coluccio, LM				Clark, R; Ali Ansari, M; Dash, S; Geeves, MA; Coluccio, LM			Loop 1 of transducer region in mammalian class I myosin, Myo1b, modulates actin affinity, ATPase activity, and nucleotide access	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSIENT KINETIC-ANALYSIS; SMOOTH-MUSCLE MYOSIN; SURFACE LOOPS; MOTOR DOMAIN; ADP RELEASE; RAT-LIVER; BINDING; ISOFORMS; PROTEIN; ALPHA	Loop 1, a flexible surface loop in the myosin motor domain, comprises in part the transducer region that lies near the nucleotide-binding site and is proposed from structural studies to be responsible for the kinetic tuning of product release following ATP hydrolysis ( 1). Biochemical studies have shown that loop 1 affects the affinity of actin-myosin-II for ADP, motility and the V-max of the actin-activated Mg2+-ATPase activity, possibly through P-i release (2-8). To test the influence of loop 1 on the mammalian class I myosin, Myo1b, chimeric molecules in which (i) loop 1 of a truncated form of Myo1b, Myo1b(1IQ), was replaced with either loop 1 from other myosins; (ii) loop 1 was replaced with glycine; or (iii) some amino acids in the loop were substituted with alanine and were expressed in baculovirus, and their interactions with actin and nucleotide were evaluated. The steady-state actin-activated ATPase activity; rate of ATP-induced dissociation of actin from Myo1b(1IQ); rate of ADP release from actin-Myo1b(1IQ); and the affinity of actin for Myo1b(1IQ) and Myo1b(1IQ)center dot ADP differed in the chimeras versus wild type, indicating that loop 1 has a much wider range of effects on the coupling between actin and nucleotide binding events than previously thought. In particular, the biphasic ATP-induced dissociation of actin from actin-Myo1b(1IQ) was significantly altered in the chimeras. This provided evidence that loop 1 contributes to the accessibility of the nucleotide pocket and is involved in the integration of information from the actin-, nucleotide-, gamma-P-i-, and calmodulin-binding sites and predicts that loop 1 modulates the load dependence of the motor.	Boston Biomed Res Inst, Watertown, MA 02472 USA; Univ Kent, Dept Biosci, Canterbury CT2 7NJ, Kent, England	Boston Biomedical Research Institute; University of Kent	Coluccio, LM (corresponding author), Boston Biomed Res Inst, 64 Grove St, Watertown, MA 02472 USA.	coluccio@bbri.org	Geeves, Michael/F-7583-2011	Geeves, Michael/0000-0002-9364-8898	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068080] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM068080] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Wellcome Trust(Wellcome TrustEuropean Commission)		ASHLEY CC, 1977, J PHYSIOL-LONDON, V270, P627, DOI 10.1113/jphysiol.1977.sp011972; Balish MF, 1999, ARCH BIOCHEM BIOPHYS, V370, P285, DOI 10.1006/abbi.1999.1409; COLUCCIO LM, 1993, CELL MOTIL CYTOSKEL, V24, P189, DOI 10.1002/cm.970240306; Coluccio LR, 1999, J BIOL CHEM, V274, P21575, DOI 10.1074/jbc.274.31.21575; Cordonnier MN, 2001, MOL BIOL CELL, V12, P4013, DOI 10.1091/mbc.12.12.4013; Coureux PD, 2004, EMBO J, V23, P4527, DOI 10.1038/sj.emboj.7600458; Cremo CR, 1998, BIOCHEMISTRY-US, V37, P1969, DOI 10.1021/bi9722406; Geeves MA, 2000, J BIOL CHEM, V275, P21624, DOI 10.1074/jbc.M000342200; Geeves MA, 1999, ANNU REV BIOCHEM, V68, P687, DOI 10.1146/annurev.biochem.68.1.687; Goodson HV, 1999, J MOL BIOL, V287, P173, DOI 10.1006/jmbi.1999.2565; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kollmar M, 2002, EMBO J, V21, P2517, DOI 10.1093/emboj/21.11.2517; Kurzawa SE, 1996, J MUSCLE RES CELL M, V17, P669, DOI 10.1007/BF00154061; Kurzawa-Goertz SE, 1998, BIOCHEMISTRY-US, V37, P7517, DOI 10.1021/bi972844+; Lauzon AM, 1998, J MUSCLE RES CELL M, V19, P825, DOI 10.1023/A:1005489501357; MOISESCU DG, 1978, J PHYSIOL-LONDON, V275, P241, DOI 10.1113/jphysiol.1978.sp012188; Murphy CT, 2000, J MUSCLE RES CELL M, V21, P139, DOI 10.1023/A:1005610007209; Murphy CT, 1998, BIOCHEMISTRY-US, V37, P6738, DOI 10.1021/bi972903j; Nyitrai M, 2004, PHILOS T R SOC B, V359, P1867, DOI 10.1098/rstb.2004.1560; Perreault-Micale C, 2000, J BIOL CHEM, V275, P21618, DOI 10.1074/jbc.M000363200; PerreaultMicale CL, 1996, J MUSCLE RES CELL M, V17, P543, DOI 10.1007/BF00124354; POLLARD TD, 1982, METHOD CELL BIOL, V24, P333; Raposo G, 1999, MOL BIOL CELL, V10, P1477, DOI 10.1091/mbc.10.5.1477; Rovner AS, 1997, J MUSCLE RES CELL M, V18, P103, DOI 10.1023/A:1018689102122; RUPPERT C, 1993, J CELL BIOL, V120, P1393, DOI 10.1083/jcb.120.6.1393; RUPPERT C, 1995, J CELL SCI, V108, P3775; Sellers J. R., 1999, MYOSINS; SHERR EH, 1993, J CELL BIOL, V120, P1405, DOI 10.1083/jcb.120.6.1405; SPUDICH JA, 1994, NATURE, V372, P515, DOI 10.1038/372515a0; Sweeney HL, 1998, J BIOL CHEM, V273, P6262, DOI 10.1074/jbc.273.11.6262; Veigel C, 1999, NATURE, V398, P530, DOI 10.1038/19104	31	26	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	2005	280	35					30935	30942		10.1074/jbc.M504698200	http://dx.doi.org/10.1074/jbc.M504698200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	958ZX	15980431	hybrid			2022-12-25	WOS:000231487800035
J	Regala, RP; Weems, C; Jamieson, L; Copland, JA; Thompson, EA; Fields, AP				Regala, RP; Weems, C; Jamieson, L; Copland, JA; Thompson, EA; Fields, AP			Atypical protein kinase C iota plays a critical role in human lung cancer cell growth and tumorigenicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B ACTIVATION; RAS-MEDIATED REORGANIZATION; DRUG-INDUCED APOPTOSIS; COLON CARCINOGENESIS; ACTIN CYTOSKELETON; BINDING PROTEIN; CYCLIN D1; IN-VIVO; ZETA; TRANSFORMATION	Atypical protein kinase C ( aPKC) isozymes function in epithelial cell polarity, proliferation, and survival and have been implicated in cellular transformation. However, the role of these enzymes in human cancer is largely unexplored. Here, we report that aPKC iota is highly expressed in human non-small cell lung cancer cell lines, whereas the closely related aPKC isozyme PKC iota is undetectable in these cells. Disruption of PKC iota signaling reveals that PKC iota is dispensable for adherent growth of non-small cell lung cancer cells but is required for transformed growth in soft agar in vitro and for tumorigenicity in vivo. Molecular dissection of signaling downstream of PKC iota demonstrates that Rac1 is a critical molecular target for PKC iota-dependent transformation, whereas PKC iota is not necessary for NF kappa B activation in vitro or in vivo. Expression of the PB1 domain of PKC iota (PKC iota- (1-113)) blocks PKC iota-dependent Rac1 activity and inhibits cellular transformation indicating a role for this domain in the transforming activity of PKC iota. Taken together, our data demonstrate that PKC iota is a critical lung cancer gene that activates a Rac1 -> Pak -> Mek1,2 -> Erk1,2 signaling pathway required for transformed growth. Our data indicate that PKC iota may be an attractive molecular target for mechanism-based therapies for treatment of lung cancer.	Mayo Clin, Ctr Comprehens Canc, Dept Canc Biol, Jacksonville, FL 32224 USA	Mayo Clinic	Fields, AP (corresponding author), Mayo Clin, Ctr Comprehens Canc, Dept Canc Biol, Griffin Canc Res Bldg,Rm 312,4500 San Pablo Rd, Jacksonville, FL 32224 USA.	fields.alan@mayo.edu			NATIONAL CANCER INSTITUTE [R01CA081436] Funding Source: NIH RePORTER; NCI NIH HHS [CA81436] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		*AM CANC SOC, 2004, SURV RES CANC STAT, P4; Bible KC, 1999, ANAL BIOCHEM, V267, P217, DOI 10.1006/abio.1998.2980; Bjorkoy G, 1997, J BIOL CHEM, V272, P11557; CARBONE D, 1992, AM J MED, V93, P13; Cheng QW, 2000, ONCOGENE, V19, P4936, DOI 10.1038/sj.onc.1203861; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; Coghlan MP, 2000, MOL CELL BIOL, V20, P2880, DOI 10.1128/MCB.20.8.2880-2889.2000; DIAZMECO MT, 1994, J BIOL CHEM, V269, P31706; Dong LQ, 1999, J BIOL CHEM, V274, P8117, DOI 10.1074/jbc.274.12.8117; Eblen ST, 2002, MOL CELL BIOL, V22, P6023, DOI 10.1128/MCB.22.17.6023-6033.2002; Etienne-Manneville S, 2003, CURR OPIN CELL BIOL, V15, P67, DOI 10.1016/S0955-0674(02)00005-4; Fields Alan P, 2003, Methods Mol Biol, V233, P519; Gazdar AF, 1999, JNCI-J NATL CANCER I, V91, P299, DOI 10.1093/jnci/91.4.299; Grunicke HH, 2003, ADV ENZYME REGUL, V43, P213, DOI 10.1016/S0065-2571(02)00032-8; Gustafson WC, 2004, J BIOL CHEM, V279, P9400, DOI 10.1074/jbc.M312840200; Hellbert K, 2000, ADV ENZYME REGUL, V40, P49, DOI 10.1016/S0065-2571(99)00038-2; Jamieson L, 1999, J BIOL CHEM, V274, P3927, DOI 10.1074/jbc.274.7.3927; Jiang YX, 2001, ONCOGENE, V20, P2254, DOI 10.1038/sj.onc.1204293; Joberty G, 2000, NAT CELL BIOL, V2, P531, DOI 10.1038/35019573; Kampfer S, 2001, J BIOL CHEM, V276, P42834, DOI 10.1074/jbc.M102047200; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Lallena MJ, 1999, MOL CELL BIOL, V19, P2180; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Leitges M, 2001, MOL CELL, V8, P771, DOI 10.1016/S1097-2765(01)00361-6; Lin D, 2000, NAT CELL BIOL, V2, P540, DOI 10.1038/35019582; Lu Y, 2001, ONCOGENE, V20, P4777, DOI 10.1038/sj.onc.1204607; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; MAYO MW, 2000, BIOCHIM BIOPHYS ACTA, V1470, P55; Minna JD, 1996, NAT MED, V2, P974, DOI 10.1038/nm0996-974; Moscat J, 2000, EMBO REP, V1, P399, DOI 10.1093/embo-reports/kvd098; Moscat J, 2001, ADV ENZYME REGUL, V41, P99, DOI 10.1016/S0065-2571(00)00009-1; Murray NR, 1997, J BIOL CHEM, V272, P27521, DOI 10.1074/jbc.272.44.27521; Murray NR, 2002, J CELL BIOL, V157, P915, DOI 10.1083/jcb.200201127; Murray NR, 2004, J CELL BIOL, V164, P797, DOI 10.1083/jcb.200311011; Mwanjewe J, 2001, BIOCHEM J, V359, P211, DOI 10.1042/0264-6021:3590211; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Noda Y, 2001, GENES CELLS, V6, P107, DOI 10.1046/j.1365-2443.2001.00404.x; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; Puls A, 1997, P NATL ACAD SCI USA, V94, P6191, DOI 10.1073/pnas.94.12.6191; Qiu RG, 2000, CURR BIOL, V10, P697, DOI 10.1016/S0960-9822(00)00535-2; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Salgia R, 1998, J CLIN ONCOL, V16, P1207, DOI 10.1200/JCO.1998.16.3.1207; Sanchez P, 1998, MOL CELL BIOL, V18, P3069, DOI 10.1128/MCB.18.5.3069; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Sanz L, 1999, EMBO J, V18, P3044, DOI 10.1093/emboj/18.11.3044; Schiller JH, 2001, ONCOLOGY-BASEL, V61, P1, DOI 10.1159/000055385; Soloff RS, 2004, J IMMUNOL, V173, P3250, DOI 10.4049/jimmunol.173.5.3250; Suzuki A, 2003, J BIOCHEM, V133, P9, DOI 10.1093/jb/mvg018; Suzuki A, 2001, J CELL BIOL, V152, P1183, DOI 10.1083/jcb.152.6.1183; Uberall F, 1999, J CELL BIOL, V144, P413, DOI 10.1083/jcb.144.3.413; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Webster JC, 2002, ENDOCRINOLOGY, V143, P3866, DOI 10.1210/en.2002-220188; Wooten MW, 2001, J BIOL CHEM, V276, P7709, DOI 10.1074/jbc.C000869200; Yu WS, 2003, J BIOL CHEM, V278, P11167, DOI 10.1074/jbc.M211424200; Zhang J, 2004, J BIOL CHEM, V279, P22118, DOI 10.1074/jbc.M400774200	57	160	174	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	2005	280	35					31109	31115		10.1074/jbc.M505402200	http://dx.doi.org/10.1074/jbc.M505402200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	958ZX	15994303	hybrid			2022-12-25	WOS:000231487800056
J	Bauer, DE; Hatzivassiliou, G; Zhao, FP; Andreadis, C; Thompson, CB				Bauer, DE; Hatzivassiliou, G; Zhao, FP; Andreadis, C; Thompson, CB			ATP citrate lyase is an important component of cell growth and transformation	ONCOGENE			English	Article						ATP citrate lyase; Akt; glucose metabolism; lipid synthesis; cell growth; transformation	FACTOR-INDEPENDENT SURVIVAL; DEPENDENT PROTEIN-KINASE; GLUCOSE-TRANSPORTER; CANCER-CELLS; AKT; PHOSPHORYLATION; METABOLISM; PURIFICATION; APOPTOSIS; ACTIVATION	Cell proliferation requires a constant supply of lipids and lipid precursors to fuel membrane biogenesis and protein modi. cation. Cytokine stimulation of hematopoietic cells directly stimulates glucose utilization in excess of bioenergetic demand, resulting in a shift from oxidative to glycolytic metabolism. A potential benefit of this form of metabolism is the channeling of glucose into biosynthetic pathways. Here we report that glucose supports de novo lipid synthesis in growing hematopoietic cells in a manner regulated by cytokine availability and the PI3K/Akt signaling pathway. The net conversion of glucose to lipid is dependent on the ability of cells to produce cytosolic acetyl CoA from mitochondria-derived citrate through the action of ATP citrate lyase (ACL). Stable knockdown of ACL leads to a significant impairment of glucose-dependent lipid synthesis and an elevation of mitochondrial membrane potential. Cells with ACL knockdown display decreased cytokine-stimulated cell proliferation. In contrast, these cells resist cell death induced by either cytokine or glucose withdrawal. However, ACL knockdown significantly impairs Akt-mediated tumorigenesis in vivo. These data suggest that enzymes involved in the conversion of glucose to lipid may be targets for the treatment of pathologic cell growth.	Univ Penn, Dept Canc Biol, Abramson Family Canc Res Inst, Sch Med, Philadelphia, PA 19104 USA; Univ Penn, Div Hematol Oncol, Dept Med, Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania	Thompson, CB (corresponding author), Univ Penn, Dept Canc Biol, Abramson Family Canc Res Inst, Sch Med, 450 BRB 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.	craig@mail.med.upenn.edu	Andreadis, Charalambos/A-1076-2007					Alli PM, 2005, ONCOGENE, V24, P39, DOI 10.1038/sj.onc.1208174; Bauer DE, 2004, FASEB J, V18, P1303, DOI 10.1096/fj.03-1001fje; Beigneux AP, 2004, J BIOL CHEM, V279, P9557, DOI 10.1074/jbc.M310512200; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Bentley J, 2003, J BIOL CHEM, V278, P39337, DOI 10.1074/jbc.M305689200; BERRIDGE MV, 1995, BIOCHEM J, V305, P843, DOI 10.1042/bj3050843; Berwick DC, 2002, J BIOL CHEM, V277, P33895, DOI 10.1074/jbc.M204681200; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Board M, 1996, BIOCHEM MOL BIOL INT, V40, P1047; Boudreau DM, 2004, CANCER-AM CANCER SOC, V100, P2308, DOI 10.1002/cncr.20271; Conlon I, 1999, CELL, V96, P235, DOI 10.1016/S0092-8674(00)80563-2; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; Deprez J, 1997, J BIOL CHEM, V272, P17269, DOI 10.1074/jbc.272.28.17269; Dimitroulakos J, 1999, BLOOD, V93, P1308, DOI 10.1182/blood.V93.4.1308.404k08_1308_1318; Edinger AL, 2003, DEV CELL, V5, P571, DOI 10.1016/S1534-5807(03)00291-0; Edinger AL, 2002, MOL BIOL CELL, V13, P2276, DOI 10.1091/mbc.01-12-0584; Elstrom RL, 2004, CANCER RES, V64, P3892, DOI 10.1158/0008-5472.CAN-03-2904; Fox CJ, 2003, GENE DEV, V17, P1841, DOI 10.1101/gad.1105003; Franke TF, 2003, ONCOGENE, V22, P8983, DOI 10.1038/sj.onc.1207115; Gonin-Giraud S, 2002, CELL DEATH DIFFER, V9, P1147, DOI 10.1038/sj.cdd.4401079; Gottlieb E, 2003, CELL DEATH DIFFER, V10, P709, DOI 10.1038/sj.cdd.4401231; Graaf MR, 2004, J CLIN ONCOL, V22, P2388, DOI 10.1200/JCO.2004.02.027; HEDESKOV CJ, 1968, BIOCHEM J, V110, P373, DOI 10.1042/bj1100373; IMESCH E, 1984, INT J BIOCHEM, V16, P875, DOI 10.1016/0020-711X(84)90146-0; Karnauskas R, 2003, ONCOGENE, V22, P688, DOI 10.1038/sj.onc.1206159; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; KUHAJDA FP, 1994, P NATL ACAD SCI USA, V91, P6379, DOI 10.1073/pnas.91.14.6379; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; MCKEARN JP, 1985, P NATL ACAD SCI USA, V82, P7414, DOI 10.1073/pnas.82.21.7414; NUNEZ G, 1990, J IMMUNOL, V144, P3602; Paddison PJ, 2002, CANCER CELL, V2, P17, DOI 10.1016/S1535-6108(02)00092-2; PIERCE MW, 1981, J BIOL CHEM, V256, P8867; Plas DR, 2001, J BIOL CHEM, V276, P12041, DOI 10.1074/jbc.M010551200; Potapova IA, 2000, BIOCHEMISTRY-US, V39, P1169, DOI 10.1021/bi992159y; PRICE DJ, 1989, J BIOL CHEM, V264, P13825; Russo Patrizia, 2004, Current Medicinal Chemistry - Anti-Cancer Agents, V4, P123, DOI 10.2174/1568011043482098; Srere P A, 1972, Curr Top Cell Regul, V5, P229; SRERE PA, 1959, J BIOL CHEM, V234, P2544; SULLIVAN AC, 1974, LIPIDS, V9, P121, DOI 10.1007/BF02532136; SUMI S, 1992, GASTROENTEROLOGY, V103, P982, DOI 10.1016/0016-5085(92)90032-T; Vander Heiden MG, 2001, MOL CELL BIOL, V21, P5899, DOI 10.1128/MCB.21.17.5899-5912.2001; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; WHETTON AD, 1985, J CELL PHYSIOL, V123, P73, DOI 10.1002/jcp.1041230112; YU KT, 1990, BIOCHEM J, V268, P539, DOI 10.1042/bj2680539	45	375	393	3	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	41					6314	6322		10.1038/sj.onc.1208773	http://dx.doi.org/10.1038/sj.onc.1208773			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	964JM	16007201				2022-12-25	WOS:000231877100012
J	Dublet, B; Ruello, A; Pederzoli, M; Hajjar, E; Courbebaisse, M; Canteloup, S; Reuter, N; Witko-Sarsat, V				Dublet, B; Ruello, A; Pederzoli, M; Hajjar, E; Courbebaisse, M; Canteloup, S; Reuter, N; Witko-Sarsat, V			Cleavage of p21/WAF1/CIP1 by proteinase 3 modulates differentiation of a monocytic cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; MOLECULAR-DYNAMICS; SERINE-PROTEASE; TRANSCRIPTIONAL ACTIVATION; NEUTROPHIL ELASTASE; CRYSTAL-STRUCTURE; CYSTIC-FIBROSIS; LEUKEMIA-CELLS; U937 CELLS; APOPTOSIS	Proteinase 3 ( PR3), also called myeloblastin, is involved in the control of myeloid cell growth, but the underlying molecular mechanisms have not been elucidated. In U937/PR3, stably transfected with PRCRSV/PR3 to overexpress PR3, PMA-induced p21 expression was significantly decreased as compared with control U937, and this phenomenon was reversed in the presence of the serine proteinase inhibitor, pefabloc. Conversely, when PR3 was inactivated by small interfering RNA, p21 protein was increased, and PMA-induced monocytic differentiation was potentiated. Mass spectrometry analysis identified Ala(45) as the primary cleavage site on p21, and the recombinant mutated p21A45R, generated by site-directed mutagenesis and expressed in Escherichia coli, was resistant to in vitro PR3 cleavage. The U937 cells were then stably transfected with either PRCRSV/p21 or PRCRSV/p21A45R, to ectopically express wild type p21 or PR3-resistant p21, respectively. In U937/p21A45R treated with PS-341, a selective proteasome inhibitor, a significant decrease in the S phase and a blockade in the G(0)-G(1) phase of cell cycle were observed when compared with U937/p21 or control U937. This suggested that both PR3 and the proteasome are efficiently involved in the proteolytic regulation of p21 expression in myeloid cells. Moreover, PMA-induced p21 expression was more pronounced in U937/p21A45R compared with U937/p21 and was concomitant with the morphological features of early differentiation. Our data demonstrated that p21 is one specific target of PR3 and that PR3-mediated p21 cleavage prevents monocytic differentiation.	Univ Paris 05, INSERM U507, Hop Necker Enfants Malad, F-75015 Paris, France; Univ Grenoble 1, Lab Spectrometrie Masse Prot, Inst Biol Struct Jean Pierre Ebel, CEA,CNRS, F-38000 Grenoble, France; Univ Bergen, Bergen Ctr Computat Sci, Computat Biol Unit, N-5020 Bergen, Norway	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); University of Bergen	Witko-Sarsat, V (corresponding author), Univ Paris 05, INSERM U507, Hop Necker Enfants Malad, 161 Rue Sevres, F-75015 Paris, France.	witko-sarsat@necker.fr	Witko-Sarsat, Veronique/L-9714-2017; Reuter, Nathalie/G-2037-2012	Witko-Sarsat, Veronique/0000-0002-5296-9601; Reuter, Nathalie/0000-0002-3649-7675				Adams J, 2002, ONCOLOGIST, V7, P9, DOI 10.1634/theoncologist.7-1-9; ANDERSEN HC, 1983, J COMPUT PHYS, V52, P24, DOI 10.1016/0021-9991(83)90014-1; Asada M, 1998, LEUKEMIA, V12, P1944, DOI 10.1038/sj.leu.2401228; Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; BAGGIOLINI M, 1978, AGENTS ACTIONS, V8, P3, DOI 10.1007/BF01972395; Bauvois B, 2002, LEUKEMIA, V16, P791, DOI 10.1038/sj.leu.2402472; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; BORIES D, 1989, CELL, V59, P959, DOI 10.1016/0092-8674(89)90752-6; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUBAKER MJ, 1992, BIOCHEM BIOPH RES CO, V188, P1318, DOI 10.1016/0006-291X(92)91375-Z; CAMPANELLI D, 1990, J EXP MED, V172, P1709, DOI 10.1084/jem.172.6.1709; Cayrol C, 1998, ONCOGENE, V17, P2437, DOI 10.1038/sj.onc.1202189; DARDEN TA, 1993, ENVIRON HEALTH PERSP, V101, P410, DOI 10.2307/3431897; DENGLER R, 1995, BRIT J HAEMATOL, V89, P250, DOI 10.1111/j.1365-2141.1995.tb03297.x; Dong C, 2005, BLOOD, V105, P1187, DOI 10.1182/blood-2004-06-2188; Dublet B, 1999, J BIOL CHEM, V274, P18909, DOI 10.1074/jbc.274.27.18909; Durant S, 2004, J LEUKOCYTE BIOL, V75, P87, DOI 10.1189/jlb.0203079; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117; Fujinaga M, 1996, J MOL BIOL, V261, P267, DOI 10.1006/jmbi.1996.0458; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Gervais JLM, 1998, J BIOL CHEM, V273, P19207, DOI 10.1074/jbc.273.30.19207; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; HARPER JW, 1993, CELL, V75, P805; Hedstrom L, 2002, CHEM REV, V102, P4501, DOI 10.1021/cr000033x; Izaguirre JA, 1999, J CHEM PHYS, V110, P9853, DOI 10.1063/1.478995; Just J, 1999, FEBS LETT, V457, P437, DOI 10.1016/S0014-5793(99)01098-4; Kale L, 1999, J COMPUT PHYS, V151, P283, DOI 10.1006/jcph.1999.6201; Korkmaz B, 2002, J BIOL CHEM, V277, P39074, DOI 10.1074/jbc.M202918200; Korkmaz B, 2004, AM J RESP CELL MOL, V30, P801, DOI 10.1165/rcmb.2003-0139OC; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723; Lutz PG, 2000, P NATL ACAD SCI USA, V97, P1601, DOI 10.1073/pnas.97.4.1601; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; Martyna GJ, 1996, MOL PHYS, V87, P1117, DOI 10.1080/00268979600100761; Molldrem JJ, 1997, BLOOD, V90, P2529, DOI 10.1182/blood.V90.7.2529.2529_2529_2534; Pederzoli M, 2005, J IMMUNOL, V174, P6381, DOI 10.4049/jimmunol.174.10.6381; Pendergraft WF, 2004, KIDNEY INT, V65, P75, DOI 10.1111/j.1523-1755.2004.00364.x; Rao J, 1998, J CELL PHYSIOL, V175, P121, DOI 10.1002/(SICI)1097-4652(199805)175:2<121::AID-JCP1>3.0.CO;2-Q; Rao NV, 1996, J BIOL CHEM, V271, P2972, DOI 10.1074/jbc.271.6.2972; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SPECTOR NL, 1995, J BIOL CHEM, V270, P1003, DOI 10.1074/jbc.270.3.1003; Steinman RA, 1998, BLOOD, V91, P4531, DOI 10.1182/blood.V91.12.4531.412k10_4531_4542; STEINMAN RA, 1994, ONCOGENE, V9, P3389; van der Geld YM, 2001, J LEUKOCYTE BIOL, V69, P177; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Witko-Sarsat V, 1999, AM J RESP CELL MOL, V20, P729, DOI 10.1165/ajrcmb.20.4.3371; Witko-Sarsat V, 2000, LAB INVEST, V80, P617, DOI 10.1038/labinvest.3780067; Witko-Sarsat V, 2002, J BIOL CHEM, V277, P47338, DOI 10.1074/jbc.M202789200; ZIMMER M, 1992, P NATL ACAD SCI USA, V89, P8215, DOI 10.1073/pnas.89.17.8215	55	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	2005	280	34					30242	30253		10.1074/jbc.M414609200	http://dx.doi.org/10.1074/jbc.M414609200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	957IC	15975933	hybrid			2022-12-25	WOS:000231362500033
J	Huan, CM; Sashital, D; Hailemariam, T; Kelly, ML; Roman, CAJ				Huan, CM; Sashital, D; Hailemariam, T; Kelly, ML; Roman, CAJ			Renal carcinoma-associated transcription factors TFE3 and TFEB are leukemia inhibitory factor-responsive transcription activators of E-cadherin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; MESENCHYMAL TRANSITIONS; MICROPHTHALMIA; EXPRESSION; MITF; GENE; DOMAINS; BINDING; FAMILY; CELLS	Translocations of the genes encoding the related transcription factors TFE3 and TFEB are almost exclusively associated with a rare juvenile subset of renal cell carcinoma and lead to overexpression of TFE3 or TFEB protein sequences. A better understanding of how deregulated TFE3 and TFEB contribute to the transformation process requires elucidating more of the normal cellular processes in which they participate. Here we identify TFE3 and TFEB as cell type-specific leukemia inhibitory factor-responsive activators of E-cadherin. Overexpression of TFE3 or TFEB in 3T3 cells activated endogenous and reporter E-cadherin expression. Conversely, endogenous TFE3 and/or TFEB was required for endogenous E-cadherin expression in primary mouse embryonic fibroblasts and human embryonic kidney cells. Chromatin precipitation analyses and E-cadherin promoter reporter gene assays revealed that E-cadherin induction by TFE3 or TFEB was primarily or exclusively direct and mitogen-activated protein kinase-dependent in those cell types. In mouse embryonic fibroblasts, TFE3 and TFEB activation of E-cadherin was responsive to leukemia inhibitory factor. In 3T3 cells, TFE3 and TFEB expression also induced expression of Wilms' tumor-1, another E-cadherin activator. In contrast, E-cadherin expression in model mouse and canine renal epithelial cell lines was indifferent to inhibition of endogenous TFE3 and/or TFEB and was reduced by TFE3 or TFEB overexpression. These results reveal new cell type-specific activities of TFE3 and TFEB which may be affected by their mutation.	Suny Downstate Med Ctr, Dept Microbiol & Immunol, Brooklyn, NY 11203 USA; Suny Downstate Med Ctr, Morse Inst Mol Genet, Brooklyn, NY 11203 USA; Suny Downstate Med Ctr, Mol & Cellular Biol Program, Sch Grad Studies, Brooklyn, NY 11203 USA; Suny Downstate Med Ctr, Dept Med, Div Hematol & Oncol, Brooklyn, NY 11203 USA	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	Roman, CAJ (corresponding author), Suny Downstate Med Ctr, Dept Microbiol & Immunol, 450 Clarkson Ave,Box 44, Brooklyn, NY 11203 USA.	Christopher.Roman@Downstate.edu			NIDDK NIH HHS [R21 DK065011-02] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK065011] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Argani P, 2003, ADV ANAT PATHOL, V10, P243, DOI 10.1097/00125480-200309000-00001; Aubert J, 1999, J BIOL CHEM, V274, P24965, DOI 10.1074/jbc.274.35.24965; Barasch J, 2001, CURR OPIN NEPHROL HY, V10, P429, DOI 10.1097/00041552-200105000-00021; Barasch J, 1999, CELL, V99, P377, DOI 10.1016/S0092-8674(00)81524-X; Batsche E, 1998, MOL CELL BIOL, V18, P3647, DOI 10.1128/MCB.18.7.3647; Bodmer D, 2002, HUM MOL GENET, V11, P2489, DOI 10.1093/hmg/11.20.2489; Bolos V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224; Boyd KE, 1999, MOL CELL BIOL, V19, P8393; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Davis IJ, 2003, P NATL ACAD SCI USA, V100, P6051, DOI 10.1073/pnas.0931430100; Du JY, 2004, CANCER CELL, V6, P565, DOI 10.1016/j.ccr.2004.10.014; Fisher DE, 2000, PIGM CELL RES, V13, P145, DOI 10.1034/j.1600-0749.13.s8.26.x; Giangrande PH, 2004, EMBO J, V23, P1336, DOI 10.1038/sj.emboj.7600134; Giroldi LA, 1997, BIOCHEM BIOPH RES CO, V241, P453, DOI 10.1006/bbrc.1997.7831; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Hemesath TJ, 1998, NATURE, V391, P298, DOI 10.1038/34681; Hershey CL, 2004, BONE, V34, P689, DOI 10.1016/j.bone.2003.08.014; Hosono S, 1999, ONCOGENE, V18, P417, DOI 10.1038/sj.onc.1202311; Hosono S, 2000, J BIOL CHEM, V275, P10943, DOI 10.1074/jbc.275.15.10943; Hua XX, 2000, J BIOL CHEM, V275, P33205, DOI 10.1074/jbc.C000568200; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Kawata Y, 2002, J BIOL CHEM, V277, P11375, DOI 10.1074/jbc.M111284200; Kuiper RP, 2003, HUM MOL GENET, V12, P1661, DOI 10.1093/hmg/ddg178; Mansky KC, 2002, J LEUKOCYTE BIOL, V71, P295; Mathur M, 2003, ONCOGENE, V22, P5031, DOI 10.1038/sj.onc.1206643; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; MBALAVIELE G, 1995, J CLIN INVEST, V95, P2757, DOI 10.1172/JCI117979; McGill GG, 2002, CELL, V109, P707, DOI 10.1016/S0092-8674(02)00762-6; Patil S, 2000, J BIOL CHEM, V275, P38363, DOI 10.1074/jbc.M004861200; Perez-Moreno MA, 2001, J BIOL CHEM, V276, P27424, DOI 10.1074/jbc.M100827200; Price ER, 1998, J BIOL CHEM, V273, P17983, DOI 10.1074/jbc.273.29.17983; Pui JC, 1999, IMMUNITY, V11, P299, DOI 10.1016/S1074-7613(00)80105-3; QURESHI SA, 1991, J BIOL CHEM, V266, P20594; Rehli M, 1999, GENOMICS, V56, P111, DOI 10.1006/geno.1998.5588; ROMAN C, 1991, SCIENCE, V254, P94, DOI 10.1126/science.1840705; ROMAN C, 1992, MOL CELL BIOL, V12, P817, DOI 10.1128/MCB.12.2.817; Rubinson DA, 2003, NAT GENET, V33, P401, DOI 10.1038/ng1117; RUEZINSKY D, 1991, GENE DEV, V5, P29, DOI 10.1101/gad.5.1.29; Sakurai H, 1997, AM J PHYSIOL-RENAL, V272, pF139, DOI 10.1152/ajprenal.1997.272.1.F139; Sato S, 1997, ONCOGENE, V14, P3083, DOI 10.1038/sj.onc.1201298; Stahl PJ, 2001, AM J PATHOL, V159, P1187, DOI 10.1016/S0002-9440(10)62503-5; Steingrimsson E, 2004, ANNU REV GENET, V38, P365, DOI 10.1146/annurev.genet.38.072902.092717; Steingrimsson E, 2002, P NATL ACAD SCI USA, V99, P4477, DOI 10.1073/pnas.072071099; Steingrimsson E, 1998, DEVELOPMENT, V125, P4607; Tachibana M, 1996, NAT GENET, V14, P50, DOI 10.1038/ng0996-50; Torban E, 1998, BBA-MOL CELL RES, V1401, P53, DOI 10.1016/S0167-4889(97)00119-5; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; Weilbaecher KN, 2001, MOL CELL, V8, P749, DOI 10.1016/S1097-2765(01)00360-4; Weilbaecher KN, 1998, J EXP MED, V187, P775, DOI 10.1084/jem.187.5.775; Weterman MAJ, 2001, P NATL ACAD SCI USA, V98, P13808, DOI 10.1073/pnas.241304198; Widlund HR, 2002, J CELL BIOL, V158, P1079, DOI 10.1083/jcb.200202049; Wu M, 2000, GENE DEV, V14, P301; Yasumoto K, 2002, EMBO J, V21, P2703, DOI 10.1093/emboj/21.11.2703	54	30	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	2005	280	34					30225	30235		10.1074/jbc.M502380200	http://dx.doi.org/10.1074/jbc.M502380200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	957IC	15994295	hybrid			2022-12-25	WOS:000231362500031
J	Merlo, P; Fulco, M; Costanzo, A; Mangiacasale, R; Strano, S; Blandino, G; Taya, Y; Lavia, P; Levrero, M				Merlo, P; Fulco, M; Costanzo, A; Mangiacasale, R; Strano, S; Blandino, G; Taya, Y; Lavia, P; Levrero, M			A role of p73 in mitotic exit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-ABL; PHOSPHATASE CDC14; TARGET GENES; DNA-DAMAGE; DIFFERENTIATION; IDENTIFICATION; MICROARRAY; EXPRESSION; INDUCTION; MITOSIS	The p53-related p73 proteins regulate developmental processes, cell growth, and DNA damage response. p73 function is regulated by post-translational modifications and protein-protein interactions. At the G(2)/M transition, p73 is phosphorylated at Thr-86 by the p34cdc2/cyclin B complex; this is associated with its exclusion from condensed chromosomes and loss of DNA binding and transcriptional activation ability. Here we showed that p73 hypo-phosphorylated species reappear during mitotic exit, concomitant with p73 relocalization to telophase nuclei and recovered ability to activate transcription. Functional knock-out of p73 gene expression by small interfering RNAs ( siRNAs) alters mitotic progression, yielding an increase of ana-telophase cells, the accumulation of aberrant late mitotic figures, and the appearance of abnormalities in the subsequent interphase. This p73 activity at the M-to-G(1) transition is mediated by its transactivating function because expression of the transcription dominant negative mutant p73DD induces the same mitotic exit phenotype. We also found that the cyclin-dependent kinase inhibitor Kip2/p57 gene is a specific target of p73 regulation during mitotic exit and re-entry into G(1). Both knock-out of p73 gene expression by siRNAs and abrogation of p73-dependent transcription by the p73DD mutant abrogate Kip2/p57 increase at the M-to-G(1) transition. Moreover, similar abnormalities ( e. g. delay in late mitotic stages with the accumulation of aberrant ana-telophase figures, and abnormalities in the following interphase) are observed in cultures in which the expression of Kip2/p57 is abrogated by siRNAs. These results identify a novel p73-Kip2/p57 pathway that coordinates mitotic exit and transition to G(1).	Fdn Andrea Cesapino, Lab Gene Express, I-00161 Rome, Italy; Univ Roma Tor Vergata, Dept Dermatol, I-00133 Rome, Italy; CNR, Inst Mol Biol & Pathol, Genet Sect, I-00185 Rome, Italy; Regina Elena Canc Ctr, Mol Oncogenesis Lab, I-00158 Rome, Italy; Natl Canc Ctr, Tokyo 1004, Japan; Univ Roma La Sapienza, Dept Internal Med, I-00161 Rome, Italy	University of Rome Tor Vergata; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR); National Cancer Center - Japan; Sapienza University Rome	Levrero, M (corresponding author), Fdn Andrea Cesapino, Lab Gene Express, I-00161 Rome, Italy.	levmax@tin.it	strano, sabrina/B-6743-2013; Costanzo, Antonio/D-3896-2012; Blandino, Giovanni/B-1137-2013; Lavia, Patrizia/AAL-3982-2021; Strano, Sabrina/K-9654-2016; Lavia, Patrizia/J-5793-2019; Merlo, Paola/K-5330-2014; Costanzo, Antonio/GZG-2433-2022; Levrero, Massimo/G-5680-2016	strano, sabrina/0000-0002-6341-4230; Blandino, Giovanni/0000-0002-6970-2241; Lavia, Patrizia/0000-0003-3310-6701; Merlo, Paola/0000-0003-0105-7044; Costanzo, Antonio/0000-0001-9697-2557; Levrero, Massimo/0000-0002-4978-0875	Telethon [E.1325] Funding Source: Medline	Telethon(Fondazione Telethon)		Agami R, 1999, NATURE, V399, P809; Balint E, 2002, P NATL ACAD SCI USA, V99, P3529, DOI 10.1073/pnas.062491899; Bergamaschi D, 2003, CANCER CELL, V3, P387, DOI 10.1016/S1535-6108(03)00079-5; Ciciarello M, 2001, J BIOL CHEM, V276, P19205, DOI 10.1074/jbc.M009528200; Costanzo A, 2002, MOL CELL, V9, P175, DOI 10.1016/S1097-2765(02)00431-8; De Laurenzi V, 2000, J BIOL CHEM, V275, P15226, DOI 10.1074/jbc.275.20.15226; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Fontemaggi G, 2002, J BIOL CHEM, V277, P43359, DOI 10.1074/jbc.M205573200; Fulco M, 2003, J BIOL CHEM, V278, P49196, DOI 10.1074/jbc.M304921200; Gaiddon C, 2003, J BIOL CHEM, V278, P27421, DOI 10.1074/jbc.M300251200; Gong JG, 1999, NATURE, V399, P806; Gorbsky GJ, 2001, CURR BIOL, V11, pR1001, DOI 10.1016/S0960-9822(01)00609-1; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Irwin MS, 2003, CANCER CELL, V3, P403, DOI 10.1016/S1535-6108(03)00078-3; Knapp D, 1996, MOL CELL BIOL, V16, P5701; Krebs JE, 2000, CELL, V102, P587, DOI 10.1016/S0092-8674(00)00081-7; Levrero M, 2000, J CELL SCI, V113, P1661; Lew DJ, 2003, ANNU REV GENET, V37, P251, DOI 10.1146/annurev.genet.37.042203.120656; Lissy NA, 2000, NATURE, V407, P642, DOI 10.1038/35036608; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Pediconi N, 2003, NAT CELL BIOL, V5, P552, DOI 10.1038/ncb998; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; Sanchez-Prieto R, 2002, ONCOGENE, V21, P974, DOI 10.1038/sj.onc.1205134; Sciortino S, 2001, EMBO REP, V2, P1018, DOI 10.1093/embo-reports/kve223; Shou WY, 1999, CELL, V97, P233, DOI 10.1016/S0092-8674(00)80733-3; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; Tritarelli A, 2004, MOL BIOL CELL, V15, P3751, DOI 10.1091/mbc.E03-12-0900; Tullo A, 2003, ONCOGENE, V22, P8738, DOI 10.1038/sj.onc.1206967; Visintin R, 1998, MOL CELL, V2, P709, DOI 10.1016/S1097-2765(00)80286-5; Vossio S, 2002, ONCOGENE, V21, P3796, DOI 10.1038/sj.onc.1205465; Wan YSY, 2003, IMMUNITY, V18, P331, DOI 10.1016/S1074-7613(03)00053-0; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Zhang PM, 1997, NATURE, V387, P151, DOI 10.1038/387151a0	34	33	35	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	2005	280	34					30354	30360		10.1074/jbc.M500635200	http://dx.doi.org/10.1074/jbc.M500635200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	957IC	15985436	hybrid			2022-12-25	WOS:000231362500046
J	Novotny, M; Datta, S; Biswas, R; Hamilton, T				Novotny, M; Datta, S; Biswas, R; Hamilton, T			Functionally independent AU-rich sequence motifs regulate KC (CXCL1) mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; ACTIVATED PROTEIN-KINASE; C-FOS; CODING REGION; ELEMENTS; STABILITY; HUR; DESTABILIZATION; STABILIZATION; TRISTETRAPROLIN	Certain pro-inflammatory chemokine mRNAs containing adenine/uridine-rich sequence elements (AREs) in their 3' untranslated regions (3'-UTRs) are known to exhibit constitutive instability and sensitivity to pro-inflammatory stimuli resulting in the stabilization of the message. Using tetR-regulated transcription we now show that the 3'-UTR of the mouse CXCL1 ( KC) mRNA contains at least two ARE motifs that are structurally and functionally distinct. A fragment of 77 nucleotides containing 4 clustered AUUUA pentamers located at the 5'-end of the KC 3'-UTR is only modestly unstable yet promotes markedly enhanced, post-transcriptional protein production in response to either interleukin-1 alpha(IL-1 alpha) or lipopolysaccharide (LPS), suggesting translational regulation. In contrast, a fragment containing 3 isolated AUUUA pentamers corresponding to the residual 3' 400 nucleotides of the KC 3'-UTR confers both instability and is stabilized in response to IL-1 alpha. Although the clustered AUUUA pentamers in the upstream region are required for stimulus sensitivity, mutation of all three pentamers in the downstream region has little or no effect on either instability or stimulus sensitivity. The upstream region is comparably stabilized in response to either IL-1 alpha or LPS, whereas the AUUUA-independent downstream determinant is differentially more sensitive to IL-1 alpha. Finally, using UV-induced RNA cross-linking, these functionally independent sequences exhibit different patterns of interaction with RNA-binding proteins. Collectively, these findings document the presence of multiple independent determinants of KC mRNA function and demonstrate that these operate via distinct mechanisms.	Cleveland Clin Fdn, Dept Immunol, Lerner Res Inst, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Hamilton, T (corresponding author), Cleveland Clin Fdn, Dept Immunol, Lerner Res Inst, NB30,9500 Euclid Ave, Cleveland, OH 44195 USA.	hamiltt@ccf.org	Biswas, Roopa/AAC-4928-2020	Hamilton, Thomas/0000-0002-9817-242X	NCI NIH HHS [CA39621] Funding Source: Medline; NIAID NIH HHS [AI50739] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039621] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050739] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baggiolini M, 2001, J INTERN MED, V250, P91, DOI 10.1046/j.1365-2796.2001.00867.x; Bakheet T, 2003, NUCLEIC ACIDS RES, V31, P421, DOI 10.1093/nar/gkg023; Biswas R, 2003, J IMMUNOL, V170, P6202, DOI 10.4049/jimmunol.170.12.6202; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brennan CM, 2001, CELL MOL LIFE SCI, V58, P266, DOI 10.1007/PL00000854; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; Carrick DM, 2004, ARTHRITIS RES THER, V6, P248, DOI 10.1186/ar1441; CHEN CYA, 1995, MOL CELL BIOL, V15, P5777; Chen CYA, 2002, MOL CELL BIOL, V22, P7268, DOI 10.1128/MCB.22.20.7268-7278.2002; CHEN CYA, 1992, MOL CELL BIOL, V12, P5748, DOI 10.1128/MCB.12.12.5748; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Datta S, 2004, J IMMUNOL, V173, P2755, DOI 10.4049/jimmunol.173.4.2755; Dean JLE, 2004, CELL SIGNAL, V16, P1113, DOI 10.1016/j.cellsig.2004.04.006; Dean JLE, 1999, J BIOL CHEM, V274, P264, DOI 10.1074/jbc.274.1.264; Ford LP, 1999, GENE DEV, V13, P188, DOI 10.1101/gad.13.2.188; Frevel MAE, 2003, MOL CELL BIOL, V23, P425, DOI 10.1128/MCB.23.2.425-436.2003; Gerard C, 2001, NAT IMMUNOL, V2, P108, DOI 10.1038/84209; Gueydan C, 1999, J BIOL CHEM, V274, P2322, DOI 10.1074/jbc.274.4.2322; Guhaniyogi J, 2001, GENE, V265, P11, DOI 10.1016/S0378-1119(01)00350-X; Hamilton TA, 2002, IMMUNOL RES, V25, P229, DOI 10.1385/IR:25:3:229; Han J, 1990, Eur Cytokine Netw, V1, P71; HAN J, 1990, J EXP MED, V171, P465, DOI 10.1084/jem.171.2.465; Holtmann H, 1999, MOL CELL BIOL, V19, P6742; Kishore R, 1999, J IMMUNOL, V162, P2457; Kontoyiannis D, 1999, IMMUNITY, V10, P387, DOI 10.1016/S1074-7613(00)80038-2; KRUYS V, 1989, SCIENCE, V245, P852, DOI 10.1126/science.2672333; Lai WS, 1999, MOL CELL BIOL, V19, P4311; Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417; Lewis T, 1998, J BIOL CHEM, V273, P13781, DOI 10.1074/jbc.273.22.13781; Li XX, 1999, MOL CELL BIOL, V19, P4643; Loflin P, 1999, GENE DEV, V13, P1884, DOI 10.1101/gad.13.14.1884; Mukherjee D, 2002, EMBO J, V21, P165, DOI 10.1093/emboj/21.1.165; OHMORI Y, 1994, BIOCHEM BIOPH RES CO, V198, P590, DOI 10.1006/bbrc.1994.1086; OQUENDO P, 1989, J BIOL CHEM, V264, P4133; Paste M, 2003, EUR J BIOCHEM, V270, P1590, DOI 10.1046/j.1432-1033.2003.03530.x; Phillips K, 2004, P NATL ACAD SCI USA, V101, P2011, DOI 10.1073/pnas.0400148101; Piecyk M, 2000, EMBO J, V19, P4154, DOI 10.1093/emboj/19.15.4154; RAJ NBK, 1993, FASEB J, V7, P702, DOI 10.1096/fasebj.7.8.8500695; Romagnani P, 2004, TRENDS IMMUNOL, V25, P201, DOI 10.1016/j.it.2004.02.006; Rot A, 2004, ANNU REV IMMUNOL, V22, P891, DOI 10.1146/annurev.immunol.22.012703.104543; Saklatvala J, 2003, BIOCHEM SOC SYMP, V70, P95, DOI 10.1042/bss0700095; Shim J, 2002, MOL CELLS, V14, P323; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; Stoecklin G, 2004, EMBO J, V23, P1313, DOI 10.1038/sj.emboj.7600163; Stoecklin G, 2003, MOL CELL BIOL, V23, P3506, DOI 10.1128/MCB.23.10.3506-3515.2003; Sully G, 2004, BIOCHEM J, V377, P629, DOI 10.1042/BJ20031484; Tebo J, 2003, J BIOL CHEM, V278, P12085, DOI 10.1074/jbc.M212992200; Tebo JM, 2000, J BIOL CHEM, V275, P12987, DOI 10.1074/jbc.275.17.12987; Wang WG, 2000, EMBO J, V19, P2340, DOI 10.1093/emboj/19.10.2340; Wang WG, 2000, MOL CELL BIOL, V20, P760, DOI 10.1128/MCB.20.3.760-769.2000; Wilson GM, 1999, PROG NUCLEIC ACID RE, V62, P257; Wilusz CJ, 2001, NAT REV MOL CELL BIO, V2, P237, DOI 10.1038/35067025; Winzen R, 2004, MOL CELL BIOL, V24, P4835, DOI 10.1128/MCB.24.11.4835-4847.2004; Zhang T, 2002, BIOCHEM SOC T, V30, P952, DOI 10.1042/BST0300952	54	22	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	2005	280	34					30166	30174		10.1074/jbc.M502280200	http://dx.doi.org/10.1074/jbc.M502280200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	957IC	15994316	hybrid			2022-12-25	WOS:000231362500024
J	Wang, JD; Kataoka, H; Suzuki, M; Sato, N; Nakamura, R; Tao, H; Maruyama, K; Isogaki, J; Kanaoka, S; Ihara, M; Tanaka, M; Kanamori, M; Nakamura, T; Shinmura, K; Sugimura, H				Wang, JD; Kataoka, H; Suzuki, M; Sato, N; Nakamura, R; Tao, H; Maruyama, K; Isogaki, J; Kanaoka, S; Ihara, M; Tanaka, M; Kanamori, M; Nakamura, T; Shinmura, K; Sugimura, H			Downregulation of EphA7 by hypermethylation in colorectal cancer	ONCOGENE			English	Article						EphA7; colorectal cancer; DNA methylation	RECEPTOR TYROSINE KINASES; MICROSATELLITE INSTABILITY; PROMOTER HYPERMETHYLATION; BREAST-CARCINOMA; COLON-CANCER; C-ELEGANS; OVEREXPRESSION; METHYLATION; EXPRESSION; LIGANDS	A significant reduction of EphA7 expression in human colorectal cancers was shown using semiquantitative reverse transcription-polymerase chain reaction analysis in 59 colorectal cancer tissues, compared to corresponding normal mucosas (P=0.008), and five colon cancer cell lines. To investigate the mechanism of EphA7 down-regulation in colorectal cancer, we examined the methylation status of the 5'CpG island around the translation start site in five colon cancer cell lines using restriction enzymes, methylation-specific PCR, and bisulfite sequencing and found evidence of aberrant methylation. The expression of EphA7 in colon cancer cell lines was restored after treatment with 5-aza-2'-deoxycytidine. Analysis of methylation status in totally 75 tumors compared to clinicopathological parameters revealed that hypermethylation of colorectal cancers was more frequent in male than in female (P=0.0078), and in moderately differentiated than in well-differentiated adenocarcinomas (P=0.0361). There was a tendency that hypermethylation in rectal cancers was more frequent than in colon cancers (P=0.0816). Hypermethylation was also observed in colorectal adenomas. This is the first report describing the downregulation of an Eph family gene in a solid tumor via aberrant 5'CpG island methylation. It provides the evidence that EphA7 gene is involved in human colorectal carcinogenesis.	Hamamatsu Univ Sch Med, Dept Pathol, Hamamatsu, Shizuoka 4313192, Japan; Hamamatsu Univ Sch Med, Dept Med, Hamamatsu, Shizuoka 4313192, Japan; Hamamatsu Univ Sch Med, Dept Clin Nursing, Hamamatsu, Shizuoka 4313192, Japan; Hamamatsu Univ Sch Med, Dept Surg, Hamamatsu, Shizuoka 4313192, Japan; Hamamatsu Univ Sch Med, Dept Publ Hlth, Hamamatsu, Shizuoka 4313192, Japan; Biwako Seikei Sport Coll, Dept Lifelong Sport, Shiga 5200503, Japan	Hamamatsu University School of Medicine; Hamamatsu University School of Medicine; Hamamatsu University School of Medicine; Hamamatsu University School of Medicine; Hamamatsu University School of Medicine	Sugimura, H (corresponding author), Hamamatsu Univ Sch Med, Dept Pathol, 1-20-1 Handayama, Hamamatsu, Shizuoka 4313192, Japan.	hsugimur@hama-med.ac.jp	Shinmura, Kazuya/K-8940-2012	Shinmura, Kazuya/0000-0003-4963-746X				Adams RH, 2002, SEMIN CELL DEV BIOL, V13, P55, DOI 10.1006/scdb.2001.0289; Aoki M, 2004, J BIOL CHEM, V279, P32643, DOI 10.1074/jbc.M313247200; Bardelli A, 2003, SCIENCE, V300, P949, DOI 10.1126/science.1082596; Brock MV, 2003, CLIN CANCER RES, V9, P2912; Chin-Sang ID, 2002, DEVELOPMENT, V129, P5499, DOI 10.1242/dev.00122; Chin-Sang ID, 1999, CELL, V99, P781, DOI 10.1016/S0092-8674(00)81675-X; CIOSSEK T, 1995, ONCOGENE, V10, P97; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Cunningham JM, 1998, CANCER RES, V58, P3455; Dottori M, 1999, BLOOD, V94, P2477, DOI 10.1182/blood.V94.7.2477.419k13_2477_2486; Easty DJ, 1999, INT J CANCER, V84, P494, DOI 10.1002/(SICI)1097-0215(19991022)84:5<494::AID-IJC8>3.3.CO;2-F; ENDO Y, 1995, PATHOL INT, V45, P602, DOI 10.1111/j.1440-1827.1995.tb03509.x; Favre CJ, 2003, AM J PHYSIOL-HEART C, V285, pH1917, DOI 10.1152/ajpheart.00983.2002; Fox BP, 2004, BIOCHEM BIOPH RES CO, V318, P882, DOI 10.1016/j.bbrc.2004.04.102; Friedman GC, 1996, CURR OPIN NEUROBIOL, V6, P127, DOI 10.1016/S0959-4388(96)80018-3; Frisen J, 1999, EMBO J, V18, P5159, DOI 10.1093/emboj/18.19.5159; Goel A, 2004, CANCER RES, V64, P3014, DOI 10.1158/0008-5472.CAN-2401-2; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; Hsieh CJ, 1998, CANCER RES, V58, P3942; Kataoka H, 2004, CANCER SCI, V95, P136, DOI 10.1111/j.1349-7006.2004.tb03194.x; Kataoka H, 2002, J CANCER RES CLIN, V128, P343, DOI 10.1007/s00432-002-0355-0; KIYOKAWA E, 1994, CANCER RES, V54, P3645; Liu W, 2004, BRIT J CANCER, V90, P1620, DOI 10.1038/sj.bjc.6601723; Liu WB, 2002, CANCER, V94, P934, DOI 10.1002/cncr.10122; Miyazaki T, 2003, INT J CANCER, V103, P657, DOI 10.1002/ijc.10860; Shen L, 2003, GASTROENTEROLOGY, V124, P626, DOI 10.1053/gast.2003.50102; Stephenson S A, 2001, BMC Mol Biol, V2, P15, DOI 10.1186/1471-2199-2-15; Sullivan DD, 2003, BRIT J CANCER, V89, P228, DOI 10.1038/sj.bjc.6601107; Tang XX, 1999, CLIN CANCER RES, V5, P455; Tao H, 2004, CARCINOGENESIS, V25, P1859, DOI 10.1093/carcin/bgh206; VALENZUELA DM, 1995, ONCOGENE, V10, P1573; Wiencke JK, 1999, CANCER EPIDEM BIOMAR, V8, P501; Wu QH, 2004, PATHOL ONCOL RES, V10, P26, DOI 10.1007/BF02893405	34	90	108	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 25	2005	24	36					5637	5647		10.1038/sj.onc.1208720	http://dx.doi.org/10.1038/sj.onc.1208720			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	956JN	16007213				2022-12-25	WOS:000231296100010
J	Tai, LK; Zheng, QL; Pan, S; Jin, ZG; Berk, BC				Tai, LK; Zheng, QL; Pan, S; Jin, ZG; Berk, BC			Flow activates ERK1/2 and endothelial nitric oxide synthase via a pathway involving PECAM1, SHP2, and Tie2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE-1; PROTEIN-TYROSINE PHOSPHATASES; SHEAR-STRESS; PLATELET; KINASE; RECEPTOR; PHOSPHORYLATION; TRANSDUCTION; ROLES; CD31	Blood flow modulates endothelial cell (EC) functions through specific signaling events. Previous data show that flow stimulates SHP2 translocation to cell membranes and binding to phosphotyrosine proteins. Flow-induced ERK1/2 phosphorylation depends on SHP2 phosphatase activity and SHP2 binding to phospho-PECAM1 ( platelet endothelial adhesion molecule 1), suggesting that SHP2 forms a signaling module with PECAM1. We hypothesized that flow induces assembly of the multi-protein complexes with SHP2 that are required for downstream signaling. ECs were exposed to flow for 10 min, and endogenous SHP2 was immunoprecipitated. SHP2-associated proteins were analyzed by SDS-PAGE and identified by mass spectrometry. Tie2 and several known SHP2-binding proteins were identified in flow-induced SHP2 complexes. Flow significantly increased tyrosine phosphorylation of both Tie2 and PECAM1 and their association with SHP2. To evaluate their functional roles, ECs were treated with Tie2 or PECAM1 small interfering RNA ( siRNA). Tie2 and PECAM1 expression decreased > 80% after siRNA treatment, and flow-stimulated phosphorylation of ERK1/2, Akt, and endothelial nitric oxide synthase was significantly inhibited by Tie2 and PECAM1 siRNA. Tie2 phosphorylation by flow was significantly inhibited by PECAM1 siRNA treatment. These results establish Tie2 transactivation via PECAM1 as an early event in flow-mediated mechanotransduction and suggest an important role for a PECAM1-SHP2-Tie2 pathway in flow-mediated signal transduction.	Univ Rochester, Inst Cardiovasc Res, Rochester, NY 14642 USA; Univ Rochester, Dept Med, Rochester, NY 14642 USA	University of Rochester; University of Rochester	Berk, BC (corresponding author), Univ Rochester, Inst Cardiovasc Res, Box 679,601 Elmwood Ave, Rochester, NY 14642 USA.	Bradford_Berk@urmc.rochester.edu		Berk, Bradford/0000-0002-2767-4115; Pan, Shi/0000-0002-8247-2110	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064839, R01HL080611] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Chen BB, 2000, NAT GENET, V24, P296, DOI 10.1038/73528; Chen BPC, 2001, PHYSIOL GENOMICS, V7, P55, DOI 10.1152/physiolgenomics.2001.7.1.55; Chen KD, 1999, J BIOL CHEM, V274, P18393, DOI 10.1074/jbc.274.26.18393; Davies PF, 1997, J VASC RES, V34, P208, DOI 10.1159/000159224; DAVIES PF, 1995, PHYSIOL REV, V75, P519, DOI 10.1152/physrev.1995.75.3.519; Dimmeler S, 1998, CIRC RES, V83, P334, DOI 10.1161/01.RES.83.3.334; Duncan GS, 1999, J IMMUNOL, V162, P3022; Dusserre N, 2004, ARTERIOSCL THROM VAS, V24, P1796, DOI 10.1161/01.ATV.0000141133.32496.41; FENG GS, 1994, ONCOGENE, V9, P1545; Fujikawa K, 1999, EXP CELL RES, V253, P663, DOI 10.1006/excr.1999.4693; Henshall TL, 2001, J IMMUNOL, V166, P3098, DOI 10.4049/jimmunol.166.5.3098; Hove JR, 2003, NATURE, V421, P172, DOI 10.1038/nature01282; Ichinose J, 2004, BIOCHEM BIOPH RES CO, V324, P1143, DOI 10.1016/j.bbrc.2004.09.173; Ilan N, 1999, J CELL SCI, V112, P3005; Jackson DE, 1997, J BIOL CHEM, V272, P6986, DOI 10.1074/jbc.272.11.6986; Jin ZG, 2003, CIRC RES, V93, P354, DOI 10.1161/01.RES.0000089257.94002.96; Jones N, 1999, J BIOL CHEM, V274, P30896, DOI 10.1074/jbc.274.43.30896; Kano Y, 2000, CIRC RES, V86, P425, DOI 10.1161/01.RES.86.4.425; Kim I, 2002, FASEB J, V16, P1126, DOI 10.1096/fj.01-0805fje; Kogata N, 2003, MOL BIOL CELL, V14, P3553, DOI 10.1091/mbc.E03-02-0080; Lee HJ, 2003, BIOCHEM BIOPH RES CO, V304, P399, DOI 10.1016/S0006-291X(03)00592-8; Meng TC, 2002, MOL CELL, V9, P387, DOI 10.1016/S1097-2765(02)00445-8; NEWMAN PJ, 1990, SCIENCE, V247, P1219, DOI 10.1126/science.1690453; Newman PJ, 2003, ARTERIOSCL THROM VAS, V23, P953, DOI 10.1161/01.ATV.0000071347.69358.D9; Okuda M, 1999, J BIOL CHEM, V274, P26803, DOI 10.1074/jbc.274.38.26803; Osawa M, 1997, EUR J CELL BIOL, V72, P229; Osawa M, 2002, J CELL BIOL, V158, P773, DOI 10.1083/jcb.200205049; Pi XC, 2004, CIRC RES, V94, P362, DOI 10.1161/01.RES.0000112406.27800.6F; Reynolds AR, 2003, NAT CELL BIOL, V5, P447, DOI 10.1038/ncb981; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; Schwachtgen JL, 1998, J CLIN INVEST, V101, P2540, DOI 10.1172/JCI1404; Shay-Salit A, 2002, P NATL ACAD SCI USA, V99, P9462, DOI 10.1073/pnas.142224299; Solowiej A, 2003, AM J PATHOL, V162, P953, DOI 10.1016/S0002-9440(10)63890-4; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Tai LK, 2002, ARTERIOSCL THROM VAS, V22, P1790, DOI 10.1161/01.ATV.0000034475.40227.40; Traub O, 1998, ARTERIOSCL THROM VAS, V18, P677, DOI 10.1161/01.ATV.18.5.677; Yan C, 1999, J BIOL CHEM, V274, P143, DOI 10.1074/jbc.274.1.143; Zhang SQ, 2004, MOL CELL, V13, P341, DOI 10.1016/S1097-2765(04)00050-4	38	34	34	0	6	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	2005	280	33					29620	29624		10.1074/jbc.M501243200	http://dx.doi.org/10.1074/jbc.M501243200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	954SX	15985432	hybrid			2022-12-25	WOS:000231176200030
